FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Sun, SB
   Sen, S
   Kim, NJ
   Magliery, TJ
   Schultz, PG
   Wang, F
AF Sun, Sophie B.
   Sen, Shiladitya
   Kim, Nam-Jung
   Magliery, Thomas J.
   Schultz, Peter G.
   Wang, Feng
TI RETRACTED: Mutational Analysis of 48G7 Reveals that Somatic
   Hypermutation Affects Both Antibody Stability and Binding Affinity
   (Retracted article. See vol. 140, pg. 1976, 2018)
SO JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Article; Retracted Publication
ID IMMUNOLOGICAL EVOLUTION; MATURATION; DIVERSITY
AB The monoclonal antibody 48G7 differs from its germline precursor by 10 somatic mutations, a number of which appear to be functionally silent. We analyzed the effects of individual somatic mutations and combinations thereof on both antibody binding affinity and thermal stability. Individual somatic mutations that enhance binding affinity to hapten decrease the stability of the germline antibody; combining these binding mutations produced a mutant with high affinity for hapten but exceptionally low stability. Adding back each of the remaining somatic mutations restored thermal stability. These results, in conjunction with recently published studies, suggest an expanded role for somatic hypermutation in which both binding affinity and stability are optimized during clonal selection.
C1 [Sun, Sophie B.; Kim, Nam-Jung; Schultz, Peter G.] Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA.
   [Sun, Sophie B.; Kim, Nam-Jung; Schultz, Peter G.] Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA.
   [Wang, Feng] Calif Inst Biomed Res, La Jolla, CA 92037 USA.
   [Sen, Shiladitya; Magliery, Thomas J.] Ohio State Univ, Dept Chem & Biochem, Columbus, OH 43210 USA.
RP Magliery, TJ (reprint author), Ohio State Univ, Dept Chem & Biochem, 100 West 18th Ave, Columbus, OH 43210 USA.
EM magliery.1@osu.edu; schultz@scripps.edu; fwang@calibr.org
RI Magliery, Thomas/B-6050-2009
OI Magliery, Thomas/0000-0003-0779-1477
FU NIH [R01 GM062159, R01 GM083114]; Skaggs Institute of Chemical Biology
FX We thank Peter Lee and the Ian Wilson lab for the use of their ForteBio
   Octet RED96 for binding affinity measurements, and we also thank
   Virginia Seely for assistance with manuscript preparation. This work was
   supported by NIH Grant R01 GM062159 (PGS), The Skaggs Institute of
   Chemical Biology (PGS), and NIH Grant R01 GM083114 (TJM). This is
   manuscript #23062 of The Scripps Research Institute.
CR Center for Biological Sequence Analysis, NETNGLYC 1 0 SERV
   Chong LT, 1999, P NATL ACAD SCI USA, V96, P14330, DOI 10.1073/pnas.96.25.14330
   Di Nola JM, 2007, ANNU REV BIOCHEM, V76, P1, DOI 10.1146/annurev.biochem.76.061705.090740
   Ekiert DC, 2011, SCIENCE, V333, P843, DOI 10.1126/science.1204839
   FRENCH DL, 1989, SCIENCE, V244, P1152, DOI 10.1126/science.2658060
   JACOBS J, 1987, J AM CHEM SOC, V109, P2174, DOI 10.1021/ja00241a042
   KIM S, 1981, CELL, V27, P573, DOI 10.1016/0092-8674(81)90399-8
   King AC, 2011, PROTEIN SCI, V20, P1546, DOI 10.1002/pro.680
   Lavinder JJ, 2009, J AM CHEM SOC, V131, P3794, DOI 10.1021/ja8049063
   Patten PA, 1996, SCIENCE, V271, P1086, DOI 10.1126/science.271.5252.1086
   Schultz PG, 2002, ANGEW CHEM INT EDIT, V41, P4427, DOI 10.1002/1521-3773(20021202)41:23<4427::AID-ANIE4427>3.0.CO;2-K
   Wang F, 2013, P NATL ACAD SCI USA, V110, P4261, DOI 10.1073/pnas.1301810110
   Wedemayer GJ, 1997, J MOL BIOL, V268, P390, DOI 10.1006/jmbi.1997.0974
   Wedemayer GJ, 1997, SCIENCE, V276, P1665, DOI 10.1126/science.276.5319.1665
   Yang PL, 1999, J MOL BIOL, V294, P1191, DOI 10.1006/jmbi.1999.3197
   Yin J, 2003, J MOL BIOL, V330, P651, DOI 10.1016/S0022-2836(03)00631-4
   Yin J, 2001, BIOCHEMISTRY-US, V40, P10764, DOI 10.1021/bi010536c
NR 17
TC 17
Z9 17
U1 2
U2 20
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0002-7863
J9 J AM CHEM SOC
JI J. Am. Chem. Soc.
PD JUL 10
PY 2013
VL 135
IS 27
BP 9980
EP 9983
DI 10.1021/ja402927u
PG 4
WC Chemistry, Multidisciplinary
SC Chemistry
GA 183JG
UT WOS:000321810400005
PM 23795814
OA Green Accepted
DA 2018-12-27
ER

PT J
AU Lin, LJ
   Lin, Y
   Jin, Y
   Zheng, CQ
AF Lin, Lianjie
   Lin, Yan
   Jin, Yu
   Zheng, Changqing
TI RETRACTED: Microarray analysis of microRNA expression in liver cancer
   tissues and normal control (Retracted article. See vol. 578, pg. 137,
   2016)
SO GENE
LA English
DT Article; Retracted Publication
DE Liver cancer; miRNA analysis; hsa-miR-421
ID HEPATOCELLULAR-CARCINOMA; CELL; PROLIFERATION; ASSOCIATION; METASTASIS;
   BIOMARKERS; ONCOGENE; PROFILES; FEATURES; TARGETS
AB Background: Recently, many studies have focused on microRNAs (miRNAs) expression profiling in liver cancer, due to the ability of these small RNAs to potently influence cellular behavior. In this study, to further investigate the relationship between them, the miRNA expression profiling of the cancer liver tissues and normal liver tissues were compared.
   Methods: The datasets of miRNAs microarray in liver cancer and normal control were downloaded from Gene Expression Omnibus. Then the SOAP analysis was performed to identify the differentially expressed miRNAs.
   Results: A total of 221 differentially expressed miRNAs were found. Five of them (including hsa-miR-15b, hsa-miR-1975, hsa-miR-199a-3p, hsa-miR-199b-3p and hsa-miR-421) were determined by t-test and may be involved in the pathogenesis of liver cancer.
   Conclusion: There differentially expressed miRNAs may be potential molecular markers for liver cancer screening. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Lin, Lianjie; Lin, Yan; Jin, Yu; Zheng, Changqing] China Med Univ, Shengjing Hosp, Dept Gastroenterol & Hepatol, Shenyang 110004, Peoples R China.
RP Lin, LJ (reprint author), China Med Univ, Shengjing Hosp, Dept Gastroenterol & Hepatol, 36 Sanhao, Shenyang 110004, Peoples R China.
EM audreylin73@hotmail.com
FU Science and Technology Program of Liaoning Province [2010225008]; Ph.D.
   Start-up Foundation of Liaoning Province [20081048]; Science and
   Technology Program of Shenyang [F10-205-1-17]
FX This work was supported partly by the Science and Technology Program of
   Liaoning Province (2010225008); the Ph.D. Start-up Foundation of
   Liaoning Province (20081048); and the Science and Technology Program of
   Shenyang (F10-205-1-17).
CR Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002
   Basyuk E, 2003, NUCLEIC ACIDS RES, V31, P6593, DOI 10.1093/nar/gkg855
   Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799
   Chan SK, 2008, CANCER EPIDEM BIOMAR, V17, P543, DOI 10.1158/1055-9965.EPI-07-2615
   Chen R, 2008, ONCOGENE, V27, P4712, DOI 10.1038/onc.2008.112
   Coulouarn C, 2009, ONCOGENE, V28, P3526, DOI 10.1038/onc.2009.211
   Eifert C, 2012, NAT REV CANCER, V12, P572, DOI 10.1038/nrc3299
   Fornari F, 2010, CANCER RES, V70, P5184, DOI 10.1158/0008-5472.CAN-10-0145
   Hao J, 2011, BIOCHEM BIOPH RES CO, V406, P552, DOI 10.1016/j.bbrc.2011.02.086
   HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2
   He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552
   Henry JC, 2010, BIOCHEM BIOPH RES CO, V403, P120, DOI 10.1016/j.bbrc.2010.10.130
   Hiroki E, 2010, CANCER SCI, V101, P241, DOI 10.1111/j.1349-7006.2009.01385.x
   Hou J, 2011, CANCER CELL, V19, P232, DOI 10.1016/j.ccr.2011.01.001
   Huang XH, 2011, J PATHOL, V225, P463, DOI 10.1002/path.2877
   Jiang Z, 2010, J GASTROENTEROL, V45, P17, DOI 10.1007/s00535-009-0135-6
   Kusenda Branislav, 2006, Biomedical Papers (Olomouc), V150, P205
   LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y
   Lee Y, 2002, EMBO J, V21, P4663, DOI 10.1093/emboj/cdf476
   Li RQ, 2008, BIOINFORMATICS, V24, P713, DOI 10.1093/bioinformatics/btn025
   Liang LH, 2010, HEPATOLOGY, V52, P1731, DOI 10.1002/hep.23904
   Sarver AL, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-401
   Wen J., 2012, J CLIN INVEST, P1
   Xia HP, 2009, BIOCHEM BIOPH RES CO, V380, P205, DOI 10.1016/j.bbrc.2008.12.169
   Yi X, 2008, MOL CELL PROTEOMICS, V7, P315, DOI 10.1074/mcp.M700116-MCP200
   Youssef YM, 2011, EUR UROL, V59, P721, DOI 10.1016/j.eururo.2011.01.004
   Yu S, 2012, J CLIN ENDOCR METAB, V97, P2084, DOI 10.1210/jc.2011-3059
   Zhang Y., 2012, MOL CANCER RES, V10, P546
NR 28
TC 20
Z9 21
U1 2
U2 35
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-1119
EI 1879-0038
J9 GENE
JI Gene
PD JUL 10
PY 2013
VL 523
IS 2
BP 158
EP 160
DI 10.1016/j.gene.2013.02.055
PG 3
WC Genetics & Heredity
SC Genetics & Heredity
GA 164QK
UT WOS:000320424400007
PM 23583794
DA 2018-12-27
ER

PT J
AU Carabellese, F
   La Tegola, D
   Alfarano, E
   Tamma, M
   Candelli, C
   Catanesi, R
AF Carabellese, F.
   La Tegola, D.
   Alfarano, E.
   Tamma, M.
   Candelli, C.
   Catanesi, R.
TI RETRACTED: Stalking by females (Retracted article. See vol. 54, pg. 181,
   2014)
SO MEDICINE SCIENCE AND THE LAW
LA English
DT Review; Retracted Publication
DE aggression; erotomanic delusional disorder; female stalking; same gender
   stalking; stalking
ID MENTAL-HEALTH PROFESSIONALS; OBSESSIONAL HARASSMENT; SYNDROME
   EROTOMANIA; PREVALENCE; STALKERS; CLIENTS; PSYCHOLOGISTS; POPULATION;
   DISORDERS; FOLLOWERS
AB The aim of this review was to study "female stalking'' in the sense of the specific traits characterizing the phenomenon of stalking behaviour committed by women. The main medical databases were searched (Medline, Social Science Research Network, Apa Psyc Net), and 67 articles were selected, reporting studies conducted in clinical populations, case series, reports, reviews, retrospective studies and original articles. We outline a variety of different tactics adopted by female stalkers and a lesser propensity to pass on to physical violence. Nevertheless, female stalkers are more frequently affected by erotomania, and this condition generally increases the risk of violence. If there have previously been intimate relations between the stalker and her victim, this will increase the risk of violence. In a significant proportion of female stalkers, the behavior is carried out in the occupational setting, especially in the field of psychotherapy, where the male-female ratio is reversed. No significant differences emerged between the motivations of heterosexual or homosexual stalkers. In the category of crimes of harassment committed by women, stalking, at least in Italy, seems to be among the most prominent.
C1 [Carabellese, F.; La Tegola, D.; Alfarano, E.; Tamma, M.; Candelli, C.; Catanesi, R.] Univ Bari, Dept Criminol & Forens Psychiat, I-70124 Bari, Italy.
RP La Tegola, D (reprint author), Univ Bari, Dept Criminol & Forens Psychiat, Pza G Cesare 11, I-70124 Bari, Italy.
EM donatella.lategola@libero.it
OI Catanesi, Roberto/0000-0003-1691-6366
CR Allnutt S, 2009, ANZ J SURG, V79, P533, DOI 10.1111/j.1445-2197.2009.04984.x
   Basile KC, 2006, AM J PREV MED, V31, P172, DOI 10.1016/j.amepre.2006.03.028
   Baum K, STALKING VICTIMIZATI
   Binder RL, 2006, J AM ACAD PSYCHIATRY, V34, P451
   Bjerregaard B, 2002, STALKING PERSPECTIVE, P112
   Brune M, 2003, BEHAV SCI LAW, V21, P83, DOI 10.1002/bsl.518
   Budd T., 2000, STALKING FINDINGS 19
   Budd T, 2000, EXTENT NATURE STALKI
   Carabellese F, 2008, J FORENSIC SCI, V53, P1450, DOI 10.1111/j.1556-4029.2008.00897.x
   Carabellese F, 2011, J FORENSIC SCI, V56, P256, DOI 10.1111/j.1556-4029.2010.01536.x
   Catanesi R, 2013, J FORENSIC SCI, V228, P6
   Catanesi R, 1998, ZACCHIA, V1, P37
   Catanesi R, 2010, INT J OFFENDER THER, V54, P441, DOI 10.1177/0306624X09334987
   DAVIES G., 2001, HOWARD J, V40, P215, DOI DOI 10.1111/1468-2311.00204
   Dressing H, 2005, PSYCHIAT PRAX, V32, P73, DOI 10.1055/s-2004-828345
   Dressing H, 2002, PSYCHOPATHOLOGY, V35, P313, DOI 10.1159/000067068
   Dressing H, 2005, BRIT J PSYCHIAT, V187, P168, DOI 10.1192/bjp.187.2.168
   Dressing H, 2006, BRIT J PSYCHIAT, V189, P566, DOI 10.1192/bjp.189.6.566
   Dressing H, 2006, CURR OPIN PSYCHIATR, V19, P395, DOI 10.1097/01.yco.0000228760.95237.f5
   Dunne FJ, 2000, HOSP MED, V61, P31, DOI 10.12968/hosp.2000.61.1.1269
   ELGADDAL YY, 1989, BRIT J PSYCHIAT, V154, P714, DOI 10.1192/bjp.154.5.714
   ENOCH MD, 1979, UNCOMMON PSYCHIAT SY
   Fox KA, 2009, AM J CRIM JUSTICE, V34, P181, DOI 10.1007/s12103-009-9064-4
   Fremouw WJ, 1997, J FORENSIC SCI, V42, P666
   Galeazzi GM, 2005, PSYCHIAT SERV, V56, P137, DOI 10.1176/appi.ps.56.2.137
   Gentile SR, 2002, PROF PSYCHOL-RES PR, V33, P490, DOI 10.1037//0735-7028.33.5.490
   Glass N, 2008, AM J PUBLIC HEALTH, V98, P1021, DOI 10.2105/AJPH.2007.117770
   Goldstein R L, 1987, Bull Am Acad Psychiatry Law, V15, P267
   Hall D., 1998, PSYCHOL STALKING CLI
   HARMON RB, 1995, J FORENSIC SCI, V40, P188
   James DV, 2009, PSYCHOL MED, V39, P1479, DOI 10.1017/S0033291709005443
   Kienlen KK, 1997, J AM ACAD PSYCHIATRY, V25, P317
   KURT JL, 1995, B AM ACAD PSYCH LAW, V23, P219
   Laskowski Cheryl, 2003, Clin Nurse Spec, V17, P298, DOI 10.1097/00002800-200311000-00011
   LeBlanc JJ, 2001, J FORENSIC SCI, V46, P367
   LEONG GB, 1994, J FORENSIC SCI, V39, P378
   Lion JR, 1998, PSYCHOL STALKING CLI
   McEwan T, 2007, INT J LAW PSYCHIAT, V30, P1, DOI 10.1016/j.ijlp.2006.03.005
   McIvor RJ, 2006, BRIT J PSYCHIAT, V188, P403, DOI 10.1192/bjp.bp.105.018523
   Meloy JR, 2011, BEHAV SCI LAW, V29, P240, DOI 10.1002/bsl.976
   MELOY JR, 1989, B MENNINGER CLIN, V53, P477
   Meloy JR, 2000, J FORENSIC SCI, V45, P147
   Meloy JR, 1996, AGGRESS VIOLENT BEH, V1, P147
   Meloy JR, 2003, J AM ACAD PSYCHIATRY, V31, P211
   MELOY JR, 1995, AM J PSYCHIAT, V152, P258
   Meloy JR, 1992, VIOLENT ATTACHMENTS
   Mohan N., 2003, PRINCIPLES PRACTICE
   Mohandie K, 2006, J FORENSIC SCI, V51, P147, DOI 10.1111/j.1556-4029.2005.00030.x
   Morgan JF, 1999, POSTGRAD MED J, V75, P410, DOI 10.1136/pgmj.75.885.410
   Morgan R., 2009, J SCHOLARSHIP TEACHI, V9, P98
   Morgan RK, 2010, SEX CULT, V14, P5, DOI 10.1007/s12119-009-9062-1
   Mullen P. E., 2000, STALKERS THEIR VICTI
   MULLEN PE, 1994, AUST NZ J PSYCHIAT, V28, P469, DOI 10.3109/00048679409075876
   Mullen PE, 1999, AM J PSYCHIAT, V156, P1244
   MUNRO A, 1988, CAN J PSYCHIAT, V33, P399, DOI 10.1177/070674378803300516
   Nicastro AM, 2000, J CRIM JUST, V28, P69, DOI 10.1016/S0047-2352(99)00038-0
   Pathe M, 1997, BRIT J PSYCHIAT, V170, P12, DOI 10.1192/bjp.170.1.12
   Pathe MT, 2000, J AM ACAD PSYCHIATRY, V28, P191
   Pathe MT, 2002, MED J AUSTRALIA, V176, P335
   Pierce SK, 2009, IMMUNOL RES, V43, P85, DOI 10.1007/s12026-008-8052-y
   Purcell R, 2002, AUST NZ J PSYCHIAT, V36, P114, DOI 10.1046/j.1440-1614.2002.00985.x
   Purcell R, 2001, AM J PSYCHIAT, V158, P2056, DOI 10.1176/appi.ajp.158.12.2056
   Purcell R, 2005, PROF PSYCHOL-RES PR, V36, P537, DOI 10.1037/0735-7028.36.5.537
   Purcell R, 2009, BRIT J PSYCHIAT, V194, P451, DOI 10.1192/bjp.bp.108.054833
   Romans JSC, 1996, PROF PSYCHOL-RES PR, V27, P595, DOI 10.1037/0735-7028.27.6.595
   Rosenfeld B, 2003, LAW HUMAN BEHAV, V27, P251, DOI 10.1023/A:1023479706822
   RUDDEN M, 1990, AM J PSYCHIAT, V147, P625
   Schwartz-Watts D, 1998, J AM ACAD PSYCHIATRY, V26, P241
   SEGAL JH, 1989, AM J PSYCHIAT, V146, P1261
   Slashinski Melody J, 2003, Violence Vict, V18, P595, DOI 10.1891/vivi.2003.18.6.595
   Spitzberg BH, 2007, AGGRESS VIOLENT BEH, V12, P64, DOI 10.1016/j.avb.2006.05.001
   Strand S, 2011, BEHAV SCI LAW, V29, P202, DOI 10.1002/bsl.981
   Thomas SDM, 2008, AUST NZ J PSYCHIAT, V42, P800, DOI 10.1080/00048670802277230
   Tjaden P., 1998, STALKING AM FINDINGS
   Vaida G, 2005, J CHILD ADOLESC MENT, V10, P23
   West Sara G, 2008, Psychiatry (Edgmont), V5, P37
   Westrup D, 1998, AGGRESS VIOLENT BEH, V3, P255, DOI 10.1016/S1359-1789(97)00023-2
   ZONA MA, 1993, J FORENSIC SCI, V38, P894
NR 78
TC 4
Z9 4
U1 2
U2 23
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0025-8024
EI 2042-1818
J9 MED SCI LAW
JI Med. Sci. Law
PD JUL
PY 2013
VL 53
IS 3
BP 123
EP 131
DI 10.1177/0025802413477397
PG 9
WC Law; Medicine, Legal; Pathology
SC Government & Law; Legal Medicine; Pathology
GA 297YN
UT WOS:000330291100001
PM 23761433
DA 2018-12-27
ER

PT J
AU Bashir, MF
   Xu, CS
   Zaman, K
   Akhmat, G
   Ikram, M
AF Bashir, Malik Fahim
   Xu, Changsheng
   Zaman, Khalid
   Akhmat, Ghulam
   Ikram, Muhammad
TI RETRACTED: Impact of foreign political instability on Chinese exports
   (Retracted article. See vol. 45, pg. 288, 2015)
SO ECONOMIC MODELLING
LA English
DT Article; Retracted Publication
DE International trade; Political instability; Exchange rate; Chinese
   exports; Dynamic panel model
ID SUB-SAHARAN AFRICA; ECONOMIC-GROWTH; CIVIL-WAR; DEVELOPING-COUNTRIES;
   BILATERAL TRADE; CAPITAL FLIGHT; PANEL DATA; REGRESSION; DETERMINANTS;
   EQUATIONS
AB International trade promotes economic development and leads to peace and stability in a country. Political instability affects trade through its direct effect on income and prices and indirectly through its influence on investment in physical capital. This study aims to examine the impact of foreign political instability on Chinese exports. A panel data set of 121 importing countries, covering time period from 1988 to 2011 is used to investigate the potential impact of foreign political instability on Chinese exports. The data was analyzed using the alternative dynamic panel and dynamic system generalized method of moments (SGMM). Three measures of political instability including political safety, revolutionary wars and adverse regime change have been used to analyze the impact of foreign political instability on Chinese exports. Results suggest that foreign political instability (adverse regime change) has negative and statistically significant impact on Chinese export. The results further show that income and real exchange rate have a positive and significant impact on Chinese exports. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Bashir, Malik Fahim; Xu, Changsheng] Huazhong Univ Sci & Technol, Sch Econ, Wuhan 430074, Peoples R China.
   [Zaman, Khalid] COMSATS Inst Informat Technol, Dept Management Sci, Abbottabad, Pakistan.
   [Akhmat, Ghulam] Huazhong Univ Sci & Technol, Coll Publ Adm, Wuhan 430074, Peoples R China.
   [Ikram, Muhammad] Int Islamic Univ, Sch Econ, Islamabad, Pakistan.
RP Bashir, MF (reprint author), Huazhong Univ Sci & Technol, Sch Econ, 1037 Luoyu Rd, Wuhan 430074, Peoples R China.
EM malik_fhm@hotmail.com; chshxu@hotmail.com; khalidzaman@ciit.net.pk;
   ahmad_choudary@hotmail.com; makram2341@gmail.com
CR ALESINA A, 1989, J INT ECON, V27, P199, DOI 10.1016/0022-1996(89)90052-4
   Anderson JE, 2002, REV ECON STAT, V84, P342, DOI 10.1162/003465302317411587
   ANDERSON TW, 1982, J ECONOMETRICS, V18, P47, DOI 10.1016/0304-4076(82)90095-1
   ARELLANO M, 1991, REV ECON STUD, V58, P277, DOI 10.2307/2297968
   ARELLANO M, 1995, J ECONOMETRICS, V68, P29, DOI 10.1016/0304-4076(94)01642-D
   Attri V.N., 2011, 2011 NEW ORL INT AC
   Awokuse T.O., 2005, EC B, V6, P1
   BALASSA B, 1985, J DEV ECON, V18, P23, DOI 10.1016/0304-3878(85)90004-5
   Baltagi B. H., 2008, ECONOMETRIC ANAL PAN
   Baum C. F, 2006, INTRO MODERN ECONOME
   Bergsten C.F., 2012, CHINA WORLD EC
   Blomberg SB, 2006, REV ECON STAT, V88, P599, DOI 10.1162/rest.88.4.599
   Bond S. R., 2002, PORT ECON J, V1, P141, DOI DOI 10.1007/S10258-002-0009-9
   Collier P, 1998, OXFORD ECON PAP, V50, P563, DOI 10.1093/oep/50.4.563
   Collins SM, 1996, J DEV ECON, V51, P117, DOI 10.1016/S0304-3878(96)00428-2
   CUKIERMAN A, 1992, AM ECON REV, V82, P537
   Davies VAB, 2008, J PEACE RES, V45, P519, DOI 10.1177/0022343308091359
   De Soysa I, 2002, J PEACE RES, V39, P395, DOI 10.1177/0022343302039004002
   DIXON WJ, 1993, POLIT RES QUART, V46, P5, DOI 10.2307/449053
   Easterly W, 1997, Q J ECON, V112, P1203, DOI 10.1162/003355300555466
   Fearon JD, 2003, AM POLIT SCI REV, V97, P75, DOI 10.1017/S0003055403000534
   FEDER G, 1983, J DEV ECON, V12, P59, DOI 10.1016/0304-3878(83)90031-7
   Fosu AK, 2003, J DEV STUD, V39, P68, DOI 10.1080/713869426
   Fosu AK, 2002, AM J ECON SOCIOL, V61, P329, DOI 10.1111/1536-7150.00162
   FOSU AK, 1992, ECON DEV CULT CHANGE, V40, P829, DOI 10.1086/451979
   Gempesaw C.M., 2003, ANN M AM AGR EC MONT, P21
   GHURA D, 1995, ECON DEV CULT CHANGE, V43, P759, DOI 10.1086/452185
   Greene W, 2008, ECONOMETRIC ANAL
   Gyimah-Brempong K, 1999, J AFR ECON, V8, P52, DOI 10.1093/jae/8.1.52
   Hsiao C., 2003, ANAL PANEL DATA
   Lussier M., 1993, J AFRICAN EC, V2, P106
   MARSHALL MONTY G., 2011, POLITY 4 PROJECT POL
   MICHAELY M, 1977, J DEV ECON, V4, P49, DOI 10.1016/0304-3878(77)90006-2
   Morrow JD, 1998, AM POLIT SCI REV, V92, P649, DOI 10.2307/2585487
   Nunn N, 2007, Q J ECON, V122, P569, DOI 10.1162/qjec.122.2.569
   Oh CH, 2010, GLOBAL ENVIRON CHANG, V20, P243, DOI 10.1016/j.gloenvcha.2009.11.005
   PARKS RW, 1967, J AM STAT ASSOC, V62, P500, DOI 10.2307/2283977
   POLLINS BM, 1989, AM J POLIT SCI, V33, P737, DOI 10.2307/2111070
   PRS, 2011, POL RISK SERV PRS IN
   RAM R, 1985, ECON DEV CULT CHANGE, V33, P415, DOI 10.1086/451468
   Roodman D, 2006, 103 CTR GLOB DEV
   Roodman D., 2007, 125 CTR GLOB DEV
   Ross ML, 2004, INT ORGAN, V58, P35, DOI 10.1017/S002081830458102X
   ROUBINI N, 1991, J INT MONEY FINANC, V10, pS49, DOI 10.1016/0261-5606(91)90046-M
   SACHS JD, 1995, BROOKINGS PAP ECO AC, P1
   Sambanis Nicholas, 2004, PERSPECTIVES POLITIC, V2, P259, DOI DOI 10.1017/S1537592704040149
   SIVERSON RM, 1991, J CONFLICT RESOLUT, V35, P285, DOI 10.1177/0022002791035002007
   SRIVASTAVA RK, 1986, J BUS, V59, P623, DOI 10.1086/296358
   Staiger D, 1997, ECONOMETRICA, V65, P557, DOI 10.2307/2171753
   STIMSON JA, 1985, AM J POLIT SCI, V29, P914, DOI 10.2307/2111187
   SUMMARY RM, 1989, REV ECON STAT, V71, P179, DOI 10.2307/1928068
   The Economist, 2012, ECONOMIST
   Thoenig M., 1998, J EUROPEAN EC ASS, V6, P541
   TYLER WG, 1981, J DEV ECON, V9, P121, DOI 10.1016/0304-3878(81)90007-9
   Wooldridge Jeffrey M., 2007, ECONOMETRIC ANAL CRO
NR 55
TC 3
Z9 3
U1 2
U2 27
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0264-9993
EI 1873-6122
J9 ECON MODEL
JI Econ. Model.
PD JUL
PY 2013
VL 33
BP 802
EP 807
DI 10.1016/j.econmod.2013.06.002
PG 6
WC Economics
SC Business & Economics
GA 209ZC
UT WOS:000323798100092
DA 2018-12-27
ER

PT J
AU Kaya, A
   Yoruk, MA
   Esenbuga, N
   Temelli, A
   Ekinci, O
AF Kaya, Adem
   Yoruk, Mehmet A.
   Esenbuga, Nurinisa
   Temelli, Aysel
   Ekinci, Ozlem
TI RETRACTED: The Effect of Raw and Processed Common Vetch Seed (Vicia
   sativa) Added to Diets of Laying Hens on Performance, Egg Quality, Blood
   Parameters and Liver Histopathology (Retracted article. See vol. 50, pg.
   228, 2014)
SO JOURNAL OF POULTRY SCIENCE
LA English
DT Article; Retracted Publication
DE blood parameters; common vetch; egg quality; performance; laying hens;
   liver histopathology
ID LUPINS LUPINUS-ALBUS; FIELD BEANS; ANTINUTRITIONAL FACTORS; FABA L;
   PROTEOLYTIC ACTIVITY; PROTEIN-QUALITY; BROILER CHICKS; LEGUME SEEDS;
   AMINO-ACIDS; FATTY LIVER
AB Abbreviation Key: C=control diet not containing common vetch seed, CV=common vetch seed.
   This study was carried out to determine the effects of raw and physical processed common vetch seed added to diets of laying hens on the laying performance, egg quality traits, blood parameters and liver histopathology. Lohman layers, 46 wk of age as 6 replicate cages each containing 4 hens, were allocated randomly to one of four dietary treatments. Treatment groups were fed diets containing a standard commercial layer diet (Control), basal diet plus 25% raw common vetch seed (CV), 25% autoclaved (at 120 degrees C for 30 minutes) common vetch seed (ACV) and 25% roasted (at 130 degrees C for 30 minutes) common vetch seed (RCV) for 12 weeks. Considering the findings of performance traits, differences among the groups were found significant (P<0,05); however the effects of treatments were not significant on egg quality and blood parameters. The diets containing raw and different physical processed vetchs reduced feed consumption and egg production.
   CV compared to the control caused lipid accumulation in hepatocytes, severe congestion of hepatic blood vessels, inflammation, the increased numbers of Kupffer cells and sinusoidal dilatations. Findings from present study pointed out the risk of increased hepatic damage due to use of raw vetch seed. It is also remarkable that increasing treatments of vetch seed lead to decrease of liver damages.
   The results of this experiment indicated that inclusion of CV and ACV in diet affected adversely performance parameters and hepatic damage in laying hens. Alleviation was observed on laying hens fed on diet including 25% RCV.
   As a conclusion, it has been determined that 25% RCV is more appropriate to use in diets of laying hens than 25% CV and ACV.
C1 [Kaya, Adem; Esenbuga, Nurinisa; Ekinci, Ozlem] Ataturk Univ, Dept Anim Sci, TR-25240 Erzurum, Turkey.
   [Yoruk, Mehmet A.] Ataturk Univ, TR-25240 Erzurum, Turkey.
   [Temelli, Aysel] Ataturk Univ, Kazim Karabekir Educ Fuculty, Dept Biol, TR-25240 Erzurum, Turkey.
RP Kaya, A (reprint author), Ataturk Univ, Fac Agr, Dept Anim Sci, TR-25240 Erzurum, Turkey.
EM akaya5858@hotmail.com
CR Abreu JMF, 1998, ANIM FEED SCI TECH, V70, P49, DOI 10.1016/S0377-8401(97)00071-0
   [Anonymous], 2000, AGR HDB, V75
   Association of Official Analytical Chemists, 1990, OFFICIAL METHODS ANA, VI
   Baier PK, 2005, EUR SURG RES, V37, P290, DOI 10.1159/000089239
   Bancroft SD, 1982, THEORY PRACTICE HIST, P150
   BEUVING G, 1977, J REPROD FERTIL, V51, P169
   BRENES A, 1993, POULTRY SCI, V72, P2281, DOI 10.3382/ps.0722281
   CASTANON JIR, 1990, BRIT POULTRY SCI, V31, P173, DOI 10.1080/00071669008417243
   Cheeke PR, 1985, NATURAL TOXICANTS FE
   Darre MJ, 1999, J AGR FOOD CHEM, V47, P352, DOI 10.1021/jf981226c
   Del Carmen J, 1999, POULTRY SCI, V78, P866, DOI 10.1093/ps/78.6.866
   Dilcicioglu T, 1996, J FACULTY VET MED U, V3, P349
   ERGUN A, 1987, J FAC VET MED U ANKA, V34, P449
   Farran MT, 2002, INT J TOXICOL, V21, P201, DOI 10.1080/10915810290096333
   Farran MT, 2001, POULTRY SCI, V80, P203, DOI 10.1093/ps/80.2.203
   FARRAN MT, 1995, POULTRY SCI, V74, P1630, DOI 10.3382/ps.0741630
   FERNANDEZ R, 1972, POULTRY SCI, V51, P1960, DOI 10.3382/ps.0511960
   FERNANDEZFIGARES I, 1993, ANIM PROD, V57, P309, DOI 10.1017/S0003356100006930
   GATEL F, 1994, ANIM FEED SCI TECH, V45, P317, DOI 10.1016/0377-8401(94)90036-1
   Gul M, 2005, J APPL POULTRY RES, V14, P217, DOI 10.1093/japr/14.2.217
   Hinton David E., 1990, P51
   Huisman J, 1992, RECENT ADV ANIMAL NU, P31
   Iyayi EA, 2003, TROPICAL SUBTROPICAL, V1, P239
   KADAM SS, 1987, J SCI FOOD AGR, V39, P267, DOI 10.1002/jsfa.2740390310
   Lalles JP, 1998, EAAP PUBLIC, P219
   LONGSTAFF M, 1991, BRIT J NUTR, V65, P199, DOI 10.1079/BJN19910081
   Lopez Bellido L, 1994, PLANT PRODUCTION PRO, V26, P273
   MAHMOOD S, 1993, BRIT J NUTR, V70, P701, DOI 10.1079/BJN19930165
   MARTINEZ JA, 1992, BRIT J NUTR, V68, P493, DOI 10.1079/BJN19920107
   Marzo F, 2002, POULTRY SCI, V81, P92, DOI 10.1093/ps/81.1.92
   MUDUULI DS, 1981, CAN J ANIM SCI, V61, P757, DOI 10.4141/cjas81-091
   National Research Council, 1994, NUTR REQ POULTR
   Ocio E., 1980, AVANCES ALIMENTACION, V21, P467
   Okamura N, 2005, PEDIATR DEVEL PATHOL, V8, P581, DOI 10.1007/s10024-005-0037-4
   OLOGHOBO AD, 1993, BRIT POULTRY SCI, V34, P323, DOI 10.1080/00071669308417588
   Onwuka GI, 2006, J FOOD PROCESS PRES, V30, P616, DOI 10.1111/j.1745-4549.2006.00092.x
   Ozcan MA, 2000, TARIM YE KOYISERI BA, V2, P36
   Ozturk H, 2006, HEPATOL RES, V34, P76, DOI 10.1016/j.hepres.2005.11.003
   RUBIO LA, 1989, BRIT POULTRY SCI, V30, P101, DOI 10.1080/00071668908417129
   RUBIO LA, 1990, BRIT J NUTR, V63, P419, DOI 10.1079/BJN19900130
   Sadeghi G., 2004, International Journal of Poultry Science, V3, P522
   Sadeghi G, 2009, TROP ANIM HEALTH PRO, V41, P85, DOI 10.1007/s11250-008-9159-9
   SANTIDRIAN S, 1987, ENZYME, V37, P150, DOI 10.1159/000469252
   SANTIDRIAN S, 1981, ENZYME, V26, P103, DOI 10.1159/000459156
   Santidrian S, 1994, J NUTR, V124, P249
   *SAS I INC, 1998, SAS US GUID STAT VER
   Takamura M, 2004, J GASTROENTEROL, V39, P681, DOI 10.1007/s535-004-1365-2
   Tolman KG, 1998, AM J MED, V105, P13
   Wang J, 2004, ENVIRON INT, V5, P605
   WHITEHEAD CC, 1979, TIJDSCHR DIERGENEESK, V104, P150
   WIGHT PAL, 1975, RES VET SCI, V19, P173, DOI 10.1016/S0034-5288(18)33528-8
   Wiryawan KG, 1999, ANIM FEED SCI TECH, V76, P185, DOI 10.1016/S0377-8401(98)00218-1
   WYBURN GM, 1965, J ANAT, V99, P469
   WYCKOFF S, 1983, POULTRY SCI, V62, P1576, DOI 10.3382/ps.0621576
   Yalcin S, 1998, TURK J VET ANIM SCI, V22, P37
   Yokouchi Y, 2005, DEV GROWTH DIFFER, V47, P357
NR 56
TC 2
Z9 2
U1 3
U2 51
PU JAPAN POULTRY SCIENCE ASSOC
PI TSUKUBA
PA C/O NATL INST LIVESTOCK & GLASSLAND SCIENCE, 2 IKENODAI, TSUKUBA,
   IBARAKI 305-0901, JAPAN
SN 1346-7395
J9 J POULT SCI
JI J. Poult. Sci.
PD JUL
PY 2013
VL 50
IS 3
BP 228
EP 236
DI 10.2141/jpsa.0120013
PG 9
WC Agriculture, Dairy & Animal Science
SC Agriculture
GA 190NV
UT WOS:000322348400007
OA Bronze
DA 2018-12-27
ER

PT J
AU Saleh, AI
AF Saleh, A. I.
TI RETRACTED: A new compaction strategy for enhancing the utilization of
   reconfigurable chips (Retracted article. See vol. 80, pg. 719, 2015)
SO INTERNATIONAL JOURNAL OF ADVANCED MANUFACTURING TECHNOLOGY
LA English
DT Article; Retracted Publication
DE Compaction; FPGA; Reconfiguration; Fragmentations; Chip utilization
ID PARTIAL DYNAMIC RECONFIGURATION; ARCHITECTURES; PLACEMENT; DEVICES;
   HARDWARE; OVERHEAD; SUPPORT; TASKS
AB Field programmable gate arrays (FPGAs) are designed to implement any logic circuit with the ability to host several independent tasks simultaneously. They inherit reconfigurability from their programmable architecture. However, designs are usually dynamic and the arrival times of tasks may be unknown in advance. Accordingly, FPGA should have the ability to: (1) place incoming tasks at run time, and (2) compact the chip whenever needed. Compaction is a proposed solution to alleviate external fragmentations. It tries to move running tasks closer to each others to free a sufficient area for hosting more tasks. Unfortunately, traditional compaction techniques suffer from internal and external fragmentations. This paper introduces a novel puzzle-based compaction (PBC) technique. PBC is a shape-aware technique that is the first to take the task shape into consideration. Hence, it succeeds not only to eliminate the internal fragmentations but also to minimize the external fragmentations. Moreover, the paper develops a novel formula, which is the first not to estimate, but to exactly calculate the amount of external fragmentations generated by hosting a set of tasks inside the reconfigurable chip. Experimental results have shown that PBC outperforms recent compaction techniques in which the chip utilization has reached 87 %.
C1 Mansoura Univ, Fac Engn, Dept Comp Eng & Syst, Mansoura, Egypt.
RP Saleh, AI (reprint author), Mansoura Univ, Fac Engn, Dept Comp Eng & Syst, Mansoura, Egypt.
EM aisaleh@yahoo.com
CR Aigner M, 2011, P INT S MEM MAN ISMM
   Banerjee S, 2005, ANN IEEE SYM FIELD P, P273
   Banerjee S, 2005, DES AUT CON, P335
   Banerjee S, 2006, IEEE T VLSI SYST, V14, P1189, DOI 10.1109/TVLSI.2006.886411
   Bazargan K, 2000, IEEE DES TEST COMPUT, V17, P68, DOI 10.1109/54.825678
   Chen Y, 2003, EUC, P489
   Diessel O, 2000, IEE P-COMPUT DIG T, V147, P181, DOI 10.1049/ip-cdt:20000485
   El Farag AA, 2007, J SUPERCOMPUT, V42, P235, DOI 10.1007/s11227-007-0134-4
   Fekete S, 2004, MATH OPER RES, V29, P591
   Fekete SP, 2001, DESIGN, AUTOMATION AND TEST IN EUROPE, CONFERENCE AND EXHIBITION 2001, PROCEEDINGS, P658, DOI 10.1109/DATE.2001.915093
   Giani Matteo, 2007, 2007 International Conference on Engineering of Reconfigurable Systems & Algorithms (ERSA'07), P78
   Handa M, 2004, DES AUT CON, P960, DOI 10.1145/996566.996820
   Jean JSN, 1999, IEEE T COMPUT, V48, P591, DOI 10.1109/12.773796
   Marconi Thomas, 2009, Proceedings of the 2009 International Conference on Field-Programmable Technology (FPT 2009), P296, DOI 10.1109/FPT.2009.5377661
   Marconi T., 2008, DESIGN AUTOMATION TE, P1346
   Marconi T, 2008, LECT NOTES COMPUT SC, V4943, P306, DOI 10.1007/978-3-540-78610-8_33
   Resano J, 2004, DES AUT CON, P119, DOI 10.1145/996566.996604
   Roberto C, 2009, IEEE T COMPUTER DESI, V28
   Steiger C, 2003, LECT NOTES COMPUT SC, V2778, P575
   Tabero J, 2003, EUR SYST DES C SEPT
   Thomas M, 2010, ARC 2010, P194
   Xilinx, 2008, VIRT 4 FPGA CONF US
   Xilinx, 2007, UG190 XIL
   Zhou XG, 2006, 2006 IEEE INTERNATIONAL CONFERENCE ON FIELD PROGRAMMABLE TECHNOLOGY, PROCEEDINGS, P57, DOI 10.1109/FPT.2006.270295
   Zhou XG, 2007, I C FIELD PROG LOGIC, P132, DOI 10.1109/FPL.2007.4380637
NR 25
TC 1
Z9 1
U1 4
U2 14
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0268-3768
EI 1433-3015
J9 INT J ADV MANUF TECH
JI Int. J. Adv. Manuf. Technol.
PD JUL
PY 2013
VL 67
IS 1-4
SI SI
BP 455
EP 473
DI 10.1007/s00170-012-4497-1
PG 19
WC Automation & Control Systems; Engineering, Manufacturing
SC Automation & Control Systems; Engineering
GA 173XX
UT WOS:000321117300037
DA 2018-12-27
ER

PT J
AU Hua, H
   Shang, LS
   Martinez, H
   Freeby, M
   Gallagher, MP
   Ludwig, T
   Deng, LY
   Greenberg, E
   LeDuc, C
   Chung, WK
   Goland, R
   Leibel, RL
   Egli, D
AF Hua, Haiqing
   Shang, Linshan
   Martinez, Hector
   Freeby, Matthew
   Gallagher, Mary Pat
   Ludwig, Thomas
   Deng, Liyong
   Greenberg, Ellen
   LeDuc, Charles
   Chung, Wendy K.
   Goland, Robin
   Leibel, Rudolph L.
   Egli, Dieter
TI RETRACTED: iPSC-derived beta cells model diabetes due to glucokinase
   deficiency (Retracted article. See vol. 127, pg. 1115, 2017)
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article; Retracted Publication
ID PLURIPOTENT STEM-CELLS; GLUCOSE; MUTATIONS; PROLIFERATION; YOUNG; RISK;
   GENE; EXPRESSION; GENERATION; DERIVATION
AB Diabetes is a disorder characterized by loss of beta cell mass and/or beta cell function, leading to deficiency of insulin relative to metabolic need. To determine whether stem cell-derived beta cells recapitulate molecular-physiological phenotypes of a diabetic subject, we generated induced pluripotent stem cells (iPSCs) from subjects with maturity-onset diabetes of the young type 2 (MODY2), which is characterized by heterozygous loss of function of the gene encoding glucokinase (GCK). These stem cells differentiated into beta cells with efficiency comparable to that of controls and expressed markers of mature beta cells, including urocortin-3 and zinc transporter 8, upon transplantation into mice. While insulin secretion in response to arginine or other secretagogues was identical to that in cells from healthy controls, GCK mutant beta cells required higher glucose levels to stimulate insulin secretion. Importantly, this glucose-specific phenotype was fully reverted upon gene sequence correction by homologous recombination. Our results demonstrate that iPSC-derived beta cells reflect beta cell-autonomous phenotypes of MODY2 subjects, providing a platform for mechanistic analysis of specific genotypes on beta cell function.
C1 [Hua, Haiqing; Shang, Linshan; Martinez, Hector; Egli, Dieter] New York Stem Cell Fdn Lab, New York, NY USA.
   [Hua, Haiqing; Freeby, Matthew; Gallagher, Mary Pat; Ludwig, Thomas; Deng, Liyong; Greenberg, Ellen; LeDuc, Charles; Chung, Wendy K.; Goland, Robin; Leibel, Rudolph L.] Columbia Univ, Dept Pediat, Div Mol Genet, New York, NY 10027 USA.
   [Hua, Haiqing; Freeby, Matthew; Gallagher, Mary Pat; Ludwig, Thomas; Deng, Liyong; Greenberg, Ellen; LeDuc, Charles; Chung, Wendy K.; Goland, Robin; Leibel, Rudolph L.] Columbia Univ, Naomi Berrie Diabet Ctr, New York, NY USA.
RP Leibel, RL (reprint author), 1150 St Nicholas Ave,Room 620A, New York, NY 10032 USA.
EM rl232@columbia.edu; d.egli@nyscf.org
RI Ludwig, Thomas/Q-6484-2016
OI Ludwig, Thomas/0000-0003-3461-2585
FU New York Stem Cell Foundation; Russell Berrie Foundation; Leona M. and
   Harry B. Helmsley Charitable Trust; Hunter Eastman Scholar Award in
   Translational Diabetes Research; James and Irene Hunter Charitable Fund;
   ADA-Mentored Fellowship; NIH [RO1 DK52431, P30DK063608]
FX We thank Andrew Sproul and Samson Jacob (The New York Stem Cell
   Foundation) for assistance in Southern blotting. This work was supported
   by The New York Stem Cell Foundation, The Russell Berrie Foundation, a
   grant from the Leona M. and Harry B. Helmsley Charitable Trust, The
   Hunter Eastman Scholar Award in Translational Diabetes Research, The
   James and Irene Hunter Charitable Fund, an ADA-Mentored Fellowship to H.
   Hua, and NIH grants RO1 DK52431 and P30DK063608.
CR Blum B, 2012, NAT BIOTECHNOL, V30, P261, DOI 10.1038/nbt.2141
   BYRNE MM, 1994, J CLIN INVEST, V93, P1120, DOI 10.1172/JCI117064
   Chen AE, 2009, CELL STEM CELL, V4, P103, DOI 10.1016/j.stem.2008.12.001
   Chimienti F, 2005, BIOMETALS, V18, P313, DOI 10.1007/s10534-005-3687-9
   D'Amour KA, 2006, NAT BIOTECHNOL, V24, P1392, DOI 10.1038/nbt1259
   Dean L, 2004, GENETIC LANDSCAPE DI
   DEKRIJGER RR, 1992, DEV BIOL, V153, P368, DOI 10.1016/0012-1606(92)90121-V
   Dupuis J, 2010, NAT GENET, V42, P105, DOI 10.1038/ng.520
   Ehtisham S, 2004, ARCH DIS CHILD, V89, P526, DOI 10.1136/adc.2003.027821
   Estalella I, 2007, CLIN ENDOCRINOL, V67, P538, DOI 10.1111/j.1365-2265.2007.02921.x
   Fajans SS, 2001, NEW ENGL J MED, V345, P971, DOI 10.1056/NEJMra002168
   Furuya F, 2010, J BIOL CHEM, V285, P24477, DOI 10.1074/jbc.M109.100222
   Fusaki N, 2009, P JPN ACAD B-PHYS, V85, P348, DOI 10.2183/pjab.85.348
   GIDHJAIN M, 1993, P NATL ACAD SCI USA, V90, P1932, DOI 10.1073/pnas.90.5.1932
   Kassem SA, 2000, DIABETES, V49, P1325, DOI 10.2337/diabetes.49.8.1325
   Kroon E, 2008, NAT BIOTECHNOL, V26, P443, DOI 10.1038/nbt1393
   Liu GH, 2011, CELL STEM CELL, V8, P688, DOI 10.1016/j.stem.2011.04.019
   Maehr R, 2009, P NATL ACAD SCI USA, V106, P15768, DOI 10.1073/pnas.0906894106
   MALLY MI, 1994, PEDIATR RES, V36, P537, DOI 10.1203/00006450-199410000-00022
   Naylor R, 2011, CLIN ENDOCRINOL, V75, P422, DOI 10.1111/j.1365-2265.2011.04049.x
   Njolstad PR, 2003, DIABETES, V52, P2854, DOI 10.2337/diabetes.52.11.2854
   Nostro MC, 2011, DEVELOPMENT, V138, P861, DOI 10.1242/dev.055236
   Ohmine S, 2012, AGING ALBANY NY, V4, P60
   Park IH, 2008, CELL, V134, P877, DOI 10.1016/j.cell.2008.07.041
   Porat S, 2011, CELL METAB, V13, P440, DOI 10.1016/j.cmet.2011.02.012
   Redmer T, 2011, EMBO REP, V12, P720, DOI 10.1038/embor.2011.88
   Sandhu MS, 2007, NAT GENET, V39, P951, DOI 10.1038/ng2067
   Scott LJ, 2007, SCIENCE, V316, P1341, DOI 10.1126/science.1142382
   Shultz LD, 2005, J IMMUNOL, V174, P6477, DOI 10.4049/jimmunol.174.10.6477
   Song WJ, 2008, DIABETES, V57, P2371, DOI 10.2337/db07-1541
   Szot Gregory L, 2007, J Vis Exp, P404, DOI 10.3791/404
   Teo AKK, 2013, J BIOL CHEM, V288, P5353, DOI 10.1074/jbc.C112.428979
   Terauchi Y, 1995, J BIOL CHEM, V270, P30253, DOI 10.1074/jbc.270.51.30253
   Terauchi Y, 2007, J CLIN INVEST, V117, P246
   Tu JA, 1999, ENDOCRINOLOGY, V140, P3762, DOI 10.1210/en.140.8.3762
   Vaxillaire M, 2008, DIABETES, V57, P244, DOI 10.2337/db07-0615
   VELHO G, 1992, LANCET, V340, P444, DOI 10.1016/0140-6736(92)91768-4
   Zhu H, 2011, NAT REV GENET, V12, P266, DOI 10.1038/nrg2951
NR 38
TC 58
Z9 61
U1 2
U2 28
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA
SN 0021-9738
EI 1558-8238
J9 J CLIN INVEST
JI J. Clin. Invest.
PD JUL
PY 2013
VL 123
IS 7
BP 3146
EP 3153
DI 10.1172/JCI67638
PG 8
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 176PN
UT WOS:000321316700041
PM 23778137
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Marques, CAF
   Bilro, LB
   Alberto, NJ
   Webb, DJ
   Nogueira, RN
AF Marques, Carlos A. F.
   Bilro, Lucia B.
   Alberto, Nelia J.
   Webb, David J.
   Nogueira, Rogerio N.
TI RETRACTED: Inscription of narrow bandwidth Bragg gratings in polymer
   optical fibers(Retracted article. See vol. 15, 129701, 2013)
SO JOURNAL OF OPTICS
LA English
DT Article; Retracted Publication
DE Bragg gratings; POF transmission devices; optical filters; polymer
   optical fiber
ID FIBER; SERVICES; CORE
AB We report on the inscription and characterization of narrow bandwidth fiber Bragg gratings (FBGs) in different spectral regions using polymer optical fibers (POFs). Narrow bandwidth FBGs are increasingly essential for optical filtering in POF transmission systems and photonic applications. Long FBGs with resonance wavelengths of around 600, 850 and 1550 nm were inscribed in several types of polymer optical fibers using a scanning technique with a short optical path. The technique allowed the inscription in relatively short periods of time. The achieved 3 dB bandwidth varied from 0.22 down to 0.045 nm considering FBG lengths of 10 and 25 mm, respectively.
C1 [Marques, Carlos A. F.; Bilro, Lucia B.; Alberto, Nelia J.; Nogueira, Rogerio N.] Polo Aveiro, Inst Telecomunicacoes, P-3810193 Aveiro, Portugal.
   [Webb, David J.] Aston Univ, Aston Inst Photon Technol, Birmingham B4 7ET, W Midlands, England.
RP Marques, CAF (reprint author), Polo Aveiro, Inst Telecomunicacoes, P-3810193 Aveiro, Portugal.
EM cmarques@av.it.pt
RI Division, Nanotechnology/O-2342-2013; Alberto, Nelia/K-6936-2015;
   Research Unit, TEMA/H-9264-2012; Bilro, Lucia/D-2667-2016
OI Alberto, Nelia/0000-0002-8176-7953; Bilro, Lucia/0000-0001-8804-593X;
   Marques, Carlos/0000-0002-8596-5092; Nogueira,
   Rogerio/0000-0002-4156-8984
FU Fundacao para a Ciencia e Tecnologia (FCT) [PTDC/EEA-TEL/122792/2010];
   FCT [SFRH/BD/70661/2010, SFRH/BPD/78205/2011, SFRH/BPD/78141/2011]
FX The Fundacao para a Ciencia e Tecnologia (FCT) Project
   PTDC/EEA-TEL/122792/2010 is acknowledged. Carlos A F Marques, Lucia B
   Bilro and Nelia J Alberto were supported by the FCT under the
   SFRH/BD/70661/2010, SFRH/BPD/78205/2011 and SFRH/BPD/78141/2011
   scholarships.
CR Atef M, 2012, IEEE PHOTONIC TECH L, V24, P1331, DOI 10.1109/LPT.2012.2203119
   Johnson IP, 2011, PROC SPIE, V7753, DOI 10.1117/12.885926
   Koike Y, 2009, NPG ASIA MATER, V1, P22, DOI 10.1038/asiamat.2009.2
   Kuhlmey BT, 2002, OPT LETT, V27, P1684, DOI 10.1364/OL.27.001684
   Large M C, 2011, OPT FIB COMM C NAT F
   Lethien C, 2005, IEEE PHOTONIC TECH L, V17, P2793, DOI 10.1109/LPT.2005.859533
   Lethien C, 2011, POLYMERS-BASEL, V3, P1006, DOI 10.3390/polym3031006
   Luo YH, 2011, OPT FIBER TECHNOL, V17, P201, DOI 10.1016/j.yofte.2011.02.005
   Lwin R, 2011, PROC SPIE, V7753, DOI 10.1117/12.885672
   Makino K, 2012, OPT EXPRESS, V20, P12893, DOI 10.1364/OE.20.012893
   Marshall GD, 2007, OPT EXPRESS, V15, P7876, DOI 10.1364/OE.15.007876
   Park KY, 2011, J SEMICOND TECH SCI, V11, P221, DOI 10.5573/JSTS.2011.11.3.221
   Polishuk P, 2006, IEEE COMMUN MAG, V44, P140, DOI 10.1109/MCOM.2006.1705991
   Shi Y, 2013, J LIGHTWAVE TECHNOL, V31, P874, DOI 10.1109/JLT.2013.2238888
   Stefani A, 2011, IEEE PHOTONIC TECH L, V23, P660, DOI 10.1109/LPT.2011.2125786
   van Eijkelenborg MA, 2001, OPT EXPRESS, V9, P319, DOI 10.1364/OE.9.000319
   Yuan W, 2012, IEEE PHOTONIC TECH L, V24, P401, DOI 10.1109/LPT.2011.2179927
   Yuan W, 2011, OPT EXPRESS, V19, P19731, DOI 10.1364/OE.19.019731
   Yuan W, 2011, OPT COMMUN, V284, P176, DOI 10.1016/j.optcom.2010.08.069
   Zhang W, 2012, J LIGHTWAVE TECHNOL, V30, P1090, DOI 10.1109/JLT.2011.2169941
   Ziemann O., 2008, POF HDB OPTICAL SHOR
NR 21
TC 6
Z9 6
U1 2
U2 18
PU IOP PUBLISHING LTD
PI BRISTOL
PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND
SN 2040-8978
EI 2040-8986
J9 J OPTICS-UK
JI J. Opt.
PD JUL
PY 2013
VL 15
IS 7
AR 075404
DI 10.1088/2040-8978/15/7/075404
PG 6
WC Optics
SC Optics
GA 177JR
UT WOS:000321371800019
OA Green Published
DA 2018-12-27
ER

PT J
AU Wu, MJ
   Lu, LH
   Passarotti, AM
   Wegbreit, E
   Fitzgerald, J
   Pavuluri, MN
AF Wu, Minjie
   Lu, Lisa H.
   Passarotti, Alessandra M.
   Wegbreit, Ezra
   Fitzgerald, Jacklynn
   Pavuluri, Mani N.
TI RETRACTED: Altered affective, executive and sensorimotor resting state
   networks in patients with pediatric mania (Retracted article. See vol.
   40, pg. 411, 2015)
SO JOURNAL OF PSYCHIATRY & NEUROSCIENCE
LA English
DT Article; Retracted Publication
ID INDEPENDENT COMPONENT ANALYSIS; VOXEL-BASED MORPHOMETRY; DEFAULT-MODE
   NETWORK; BIPOLAR DISORDER; FUNCTIONAL CONNECTIVITY; NEURAL CIRCUITRY;
   STRUCTURAL CONNECTIVITY; EUTHYMIC PATIENTS; TASK; ADOLESCENTS
AB Background: The aim of the present study was to map the pathophysiology of resting state functional connectivity accompanying structural and functional abnormalities in children with bipolar disorder. Methods: Children with bipolar disorder and demographically matched healthy controls underwent resting-state functional magnetic resonance imaging. A model-free independent component analysis was performed to identify intrinsically interconnected networks. Results: We included 34 children with bipolar disorder and 40 controls in our analysis. Three distinct resting state networks corresponding to affective, executive and sensorimotor functions emerged as being significantly different between the pediatric bipolar disorder (PBD) and control groups. All 3 networks showed hyperconnectivity in the PBD relative to the control group. Specifically, the connectivity of the dorsal anterior cingulate cortex (ACC) differentiated the PBD from the control group in both the affective and the executive networks. Exploratory analysis suggests that greater connectivity of the right amygdala within the affective network is associated with better executive function in children with bipolar disorder, but not in controls. Limitations: Unique clinical characteristics of the study sample allowed us to evaluate the pathophysiology of resting state connectivity at an early state of PBD, which led to the lack of generalizability in terms of comorbid disorders existing in a typical PBD population. Conclusion: Abnormally engaged resting state affective, executive and sensorimotor networks observed in children with bipolar disorder may reflect a biological context in which abnormal task-based brain activity can occur. Dual engagement of the dorsal ACC in affective and executive networks supports the neuroanatomical interface of these networks, and the amygdala's engagement in moderating executive function illustrates the intricate interplay of these neural operations at rest.
C1 [Wu, Minjie; Lu, Lisa H.; Passarotti, Alessandra M.; Wegbreit, Ezra; Fitzgerald, Jacklynn; Pavuluri, Mani N.] Univ Illinois, Inst Juvenile Res, Pediat Brain Res & Intervent Ctr, Chicago, IL 60608 USA.
   [Wu, Minjie; Lu, Lisa H.; Passarotti, Alessandra M.; Wegbreit, Ezra; Fitzgerald, Jacklynn; Pavuluri, Mani N.] Univ Illinois, Dept Psychiat, Colbeth Clin, Chicago, IL 60608 USA.
   [Lu, Lisa H.] Roosevelt Univ, Dept Psychol, Chicago, IL 60605 USA.
RP Wu, MJ (reprint author), Univ Illinois, Dept Psychiat, Pediat Brain Res & Intervent Ctr, 1747 Roosevelt Rd M-C 747, Chicago, IL 60608 USA.
EM mwu@psych.uic.edu
OI Wegbreit, Ezra/0000-0001-5887-1392
FU Berger-Colbeth Endowed funds;  [1R01MH085639];  [RC1MH088462]; 
   [1R01MH081019]
FX This research is supported by 1R01MH085639, RC1MH088462, 1R01MH081019
   and Berger-Colbeth Endowed funds (M.N. Pavuluri).
CR Adler CM, 2006, AM J PSYCHIAT, V163, P322, DOI 10.1176/appi.ajp.163.2.322
   Adler CM, 2004, BIPOLAR DISORD, V6, P540, DOI 10.1111/j.1399-5618.2004.00117.x
   ALEXANDER GE, 1986, ANNU REV NEUROSCI, V9, P357, DOI 10.1146/annurev.ne.09.030186.002041
   ALMEIDA JR, 2009, BIOL PSYCHIAT, V66, P451, DOI DOI 10.1016/J.BIOPSYCH.2009.03.024
   American Psychiatric Association, 1994, DIAGN STAT MAN MENT
   Barnea-Goraly N, 2009, BIOL PSYCHIAT, V66, P238, DOI 10.1016/j.biopsych.2009.02.025
   Beckmann C. F., 2009, NEUROIMAGE, V47, pS148, DOI [10.1016/S1053-8119(09)71511-3, DOI 10.1016/S1053-8119(09)71511-3]
   Beckmann CF, 2004, IEEE T MED IMAGING, V23, P137, DOI 10.1109/TMI.2003.822821
   Beckmann CF, 2005, PHILOS T ROY SOC B, V360, P1001, DOI 10.1098/rstb.2005.1634
   Birmaher B, 2010, AM J PSYCHIAT, V167, P321, DOI 10.1176/appi.ajp.2009.09070977
   Bora E, 2009, J AFFECT DISORDERS, V113, P1, DOI 10.1016/j.jad.2008.06.009
   Chen S, 2008, BRAIN RES, V1239, P141, DOI 10.1016/j.brainres.2008.08.028
   Chiu S, 2008, J AFFECT DISORDERS, V105, P93, DOI 10.1016/j.jad.2007.04.019
   Craig MC, 2009, MOL PSYCHIATR, V14, P946, DOI 10.1038/mp.2009.40
   Damoiseaux JS, 2006, P NATL ACAD SCI USA, V103, P13848, DOI 10.1073/pnas.0601417103
   Damoiseaux JS, 2009, BRAIN STRUCT FUNCT, V213, P525, DOI 10.1007/s00429-009-0208-6
   Deco G, 2011, NEUROSCIENTIST, V17, P107, DOI 10.1177/1073858409354384
   Dickstein DP, 2010, BIOL PSYCHIAT, V68, P839, DOI 10.1016/j.biopsych.2010.06.029
   Dickstein DP, 2005, ARCH GEN PSYCHIAT, V62, P734, DOI 10.1001/archpsyc.62.7.734
   Elliott R, 2003, BRIT MED BULL, V65, P49, DOI 10.1093/bmb/65.1.49
   Frazier JA, 2007, BIPOLAR DISORD, V9, P799, DOI 10.1111/j.1399-5618.2007.00482.x
   Geller B, 1998, J AFFECT DISORDERS, V51, P93, DOI 10.1016/S0165-0327(98)00176-1
   Gioia GA, 2002, CHILD NEUROPSYCHOL, V8, P249, DOI 10.1076/chin.8.4.249.13513
   Greicius MD, 2004, P NATL ACAD SCI USA, V101, P4637, DOI 10.1073/pnas.0308627101
   Greicius MD, 2009, CEREB CORTEX, V19, P72, DOI 10.1093/cercor/bhn059
   Kafantaris V, 2009, J AM ACAD CHILD PSY, V48, P79, DOI 10.1097/CHI.0b013e3181900421
   Kaufman J, 2000, J AM ACAD CHILD PSY, V39, P1208, DOI 10.1097/00004583-200010000-00002
   Leh SE, 2007, NEUROSCI LETT, V419, P113, DOI 10.1016/j.neulet.2007.04.049
   Lehericy S, 2004, ANN NEUROL, V55, P522, DOI 10.1002/ana.20030
   Leibenluft E, 2007, AM J PSYCHIAT, V164, P52, DOI 10.1176/appi.ajp.164.1.52
   Leung HC, 2000, CEREB CORTEX, V10, P552, DOI 10.1093/cercor/10.6.552
   Lie CH, 2006, NEUROIMAGE, V30, P1038, DOI 10.1016/j.neuroimage.200510031
   Lowe MJ, 1998, NEUROIMAGE, V7, P119, DOI 10.1006/nimg.1997.0315
   Monchi O, 2001, J NEUROSCI, V21, P7733
   Mur M, 2007, J CLIN PSYCHIAT, V68, P1078, DOI 10.4088/JCP.v68n0715
   Nichols TE, 2002, HUM BRAIN MAPP, V15, P1, DOI 10.1002/hbm.1058
   Passarotti AM, 2010, PSYCHIAT RES-NEUROIM, V181, P36, DOI 10.1016/j.pscychresns.2009.07.002
   Passarotti AM, 2009, SOC COGN AFFECT NEUR, V4, P387, DOI 10.1093/scan/nsp029
   Pavuluri MN, 2008, PSYCHIAT RES-NEUROIM, V162, P244, DOI 10.1016/j.pscychresns.2007.10.003
   Pavuluri MN, 2007, BIOL PSYCHIAT, V62, P158, DOI 10.1016/j.biopsych.2006.07.011
   Pavuluri MN, 2010, J CLIN PSYCHIAT, V71, P1526, DOI 10.4088/JCP.09m05504yel
   Pavuluri MN, 2010, J CHILD ADOL PSYCHOP, V20, P395, DOI 10.1089/cap.2009.0105
   Pavuluri MN, 2009, BIOL PSYCHIAT, V65, P586, DOI 10.1016/j.biopsych.2008.10.015
   Pavuluri MN, 2009, J AM ACAD CHILD PSY, V48, P308, DOI 10.1097/CHI.0b013e3181948fc7
   Pavuluri MN, 2009, J AM ACAD CHILD PSY, V48, P299, DOI 10.1097/CHI.0b013e318196b907
   Pizzagalli DA, 2008, BIOL PSYCHIAT, V64, P162, DOI 10.1016/j.biopsych.2007.12.001
   Rich BA, 2005, BIPOLAR DISORD, V7, P198, DOI 10.1111/j.1399-5618.2005.00183.x
   Rich BA, 2006, P NATL ACAD SCI USA, V103, P8900, DOI 10.1073/pnas.0603246103
   Shehzad Z, 2009, CEREB CORTEX, V19, P2209, DOI 10.1093/cercor/bhn256
   Sheline YI, 2010, P NATL ACAD SCI USA, V107, P11020, DOI 10.1073/pnas.1000446107
   Thomason ME, 2011, NEUROIMAGE, V55, P165, DOI 10.1016/j.neuroimage.2010.11.080
   Wakana S, 2004, RADIOLOGY, V230, P77, DOI 10.1148/radiol.2301021640
   Wegbreit E, 2011, BRAIN CONNECT, V1, P411, DOI 10.1089/brain.2011.0035
   Wilke M, 2004, PSYCHIAT RES-NEUROIM, V131, P57, DOI 10.1016/j.pscychresns.2004.01.004
   Zuo XN, 2010, NEUROIMAGE, V49, P2163, DOI 10.1016/j.neuroimage.2009.10.080
NR 55
TC 15
Z9 16
U1 4
U2 26
PU CMA-CANADIAN MEDICAL ASSOC
PI OTTAWA
PA 1867 ALTA VISTA DR, OTTAWA, ONTARIO K1G 5W8, CANADA
SN 1180-4882
EI 1488-2434
J9 J PSYCHIATR NEUROSCI
JI J. Psychiatry Neurosci.
PD JUL
PY 2013
VL 38
IS 4
BP 232
EP 240
DI 10.1503/jpn.120073
PG 9
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 180CR
UT WOS:000321571000008
PM 23735583
OA Bronze, Green Published
DA 2018-12-27
ER

PT J
AU Galloway, C
   Chattopadhyay, M
AF Galloway, Christina
   Chattopadhyay, Munmun
TI RETRACTED: Increases in inflammatory mediators in DRG implicate in the
   pathogenesis of painful neuropathy in Type 2 diabetes (Retracted
   article. See vol. 110, pg. 483, 2018)
SO CYTOKINE
LA English
DT Article; Retracted Publication
DE Diabetic neuropathy; Pain; Cytokines; DRG; Sodium channel
ID EXPRESSION; CYTOKINES; ACTIVATION
AB Background: Painful neuropathy is a common, difficult to treat complication of both Types I and 2 diabetes (T1D and T2D). Reports have shown that activation of inflammatory cascades play an important role in the development and persistence of neuropathic pain states, but it is not well established in painful diabetic neuropathy (PDN). Previously, studies have shown increased inflammatory cytokines in the serum of the diabetic patients with painful neuropathy. This study focuses on the changes in the levels of inflammatory mediators such as TNF alpha, interleukins, chemokines and cell adhesion molecules with the development of pain in the DRG of the Zucker diabetic fatty (ZDF) rat, an established model for T2D. This study also demonstrates an alteration in the levels of voltage gated sodium channel 1.7 (Na(v)1.7) with the development of pain in DRG of the ZDF rats.
   Results: Pre-diabetic ZDF animals at 8-9 weeks of age showed no thermal and mechanical hyperalgesia compared to their respective lean controls. Diabetic-ZDF animals tested for pain related behaviors showed significant thermal and mechanical hyperalgesia at 4 and 6 weeks after the onset of diabetes when compared with their age matched lean controls. These ZDF animals with PDN also showed changes in a large number of inflammatory mediators in the DRG as assessed by Western blot as well as by cytokine antibody array compared to their age matched lean controls. Further analysis by Rat cytokine antibody array of DRG of the ZDF animals with PDN at 6 weeks after diabetes when compared with ZDF animals with no pain revealed an elevation of a significant number of inflammatory mediators including, the pro-inflammatory cytokines such as TNF alpha, interleukin-1, 6, 13 and 17, chemokines such as MIP1 and 3, RANTES, Fractalkine and cell adhesion molecule sICAM that are associated with pain phenotype. The ZDF animals with PDN also demonstrated an increase in the protein levels of voltage gated sodium channel Na(v)1.7 in DRG compared to lean controls with no pain.
   Conclusions: The rise in inflammatory markers in the DRG of Type 2 diabetic animals and increases in voltage gated sodium channel Na(v)1.7 in DRG with the onset of pain in PDN suggest that inflammation in the DRG may play an important role in the development of pain in this model. Published by Elsevier Ltd.
C1 [Chattopadhyay, Munmun] Univ Michigan, Dept Neurol, Ann Arbor, MI 48109 USA.
   VA Ann Arbor Healthcare Syst, Ann Arbor, MI USA.
RP Chattopadhyay, M (reprint author), Univ Michigan, Dept Neurol, 5248 BSRB, Ann Arbor, MI 48109 USA.
EM munmunc@umich.edu
FU Pilot and Feasibility Grant from the Michigan Diabetes Research and
   Training Center [R000617]; NIDDK [5P60-DK020572]; American Diabetes
   Association [7-12-BS-021]
FX This work has funded by Pilot and Feasibility Grant from the Michigan
   Diabetes Research and Training Center (Award Number R000617 to MC, from
   the NIDDK Grant 5P60-DK020572) and American Diabetes Association (Grant
   #7-12-BS-021). We acknowledge Drs. David Fink and Marina Mata for the
   resources and guidance.
CR Bhangoo S, 2007, MOL PAIN, V3, DOI 10.1186/1744-8069-3-38
   Chattopadhyay M, 2008, J NEUROSCI, V28, P6652, DOI 10.1523/JNEUROSCI.5530-07.2008
   Chen X, 2011, EXP NEUROL, V227, P279, DOI 10.1016/j.expneurol.2010.11.017
   Doupis J, 2009, J CLIN ENDOCR METAB, V94, P2157, DOI 10.1210/jc.2008-2385
   Gonzalez-Clemente JM, 2005, CLIN ENDOCRINOL, V63, P525, DOI 10.1111/j.1365-2265.2005.02376.x
   Ji RR, 2004, SCI STKE, V2004
   Johnston IN, 2004, J NEUROSCI, V24, P7353, DOI 10.1523/JNEUROSCI.1850-04.2004
   Kiuchi H, 2009, BJU INT, V104, P826, DOI 10.1111/j.1464-410X.2009.08467.x
   Ramirez BU, 2003, BIOL RES, V36, P303, DOI 10.4067/S0716-97602003000300003
   Rothman SM, 2011, SPINE, V36, P197, DOI 10.1097/BRS.0b013e3181ce4f4d
   Schmader KE, 2002, CLIN J PAIN, V18, P350, DOI 10.1097/00002508-200211000-00002
   Tesfaye S, 2011, DIABETES METAB RES R
   Uceyler N, 2007, NEUROLOGY, V69, P42, DOI 10.1212/01.wnl.0000265062.92340.a5
   Vorobeychik Y, 2011, CNS DRUGS, V25, P1023, DOI 10.2165/11596280-000000000-00000
NR 14
TC 28
Z9 30
U1 2
U2 16
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1043-4666
EI 1096-0023
J9 CYTOKINE
JI Cytokine
PD JUL
PY 2013
VL 63
IS 1
BP 1
EP 5
DI 10.1016/j.cyto.2013.04.009
PG 5
WC Biochemistry & Molecular Biology; Cell Biology; Immunology
SC Biochemistry & Molecular Biology; Cell Biology; Immunology
GA 172CG
UT WOS:000320977000001
PM 23664770
DA 2018-12-27
ER

PT J
AU Chen, CW
   Yang, HC
   Chen, CH
   Tseng, CP
   Lee, KL
AF Chen, Cheng-Wu
   Yang, Han-Chung
   Chen, Chia-Hung
   Tseng, Chun-Pin
   Lee, King-Ling
TI RETRACTED: The Relationship between Personality Traits and Sales Force
   Automation Usage: A Review of Methodology (Retracted article. See vol.
   26, pg. 291, 2016)
SO HUMAN FACTORS AND ERGONOMICS IN MANUFACTURING & SERVICE INDUSTRIES
LA English
DT Article; Retracted Publication
DE Pharmaceutical industry; Personality trait; Human factor; Taiwanese
   enterprises; Sales force automation
ID INFORMATION-TECHNOLOGY; 5-FACTOR MODEL; JOB-PERFORMANCE; USER
   ACCEPTANCE; CONSENSUAL VALIDATION; LONGITUDINAL-FIELD; SELF-EFFICACY;
   BIG 5; ADOPTION; RATINGS
AB In recent decades, pharmaceutical companies have been facing increasing difficulties in sustaining sales growth due to tight market competition (off-patents, pricing erosion, and generics substitution). Pharmaceutical companies are desperately seeking ways to sustain and optimize their sales coverage and sales volume in the middle and long term. In such unpromising circumstances, one of the few options that comes to mind is customer relationship management (CRM). This study specifically looks at the utilization-individual impact link. In particular, this study aims to identify the personality type of sales representative most closely linked with individual usage of sales forces automation systems in the pharmaceutical industry in Taiwan. (c) 2012 Wiley Periodicals, Inc.
C1 [Chen, Cheng-Wu] Natl Kaohsiung Marine Univ, Inst Maritime Informat & Technol, Kaohsiung 80543, Taiwan.
   [Chen, Cheng-Wu] Natl Cheng Kung Univ, Global Earth Observat & Data Anal Ctr, Tinan, Taiwan.
   [Yang, Han-Chung] Shu Te Univ, Dept Leisure Recreat & Tourism Management, Kaohsiung, Taiwan.
   [Chen, Chia-Hung] Shu Te Univ, Dept Logist Management, Kaohsiung, Taiwan.
   [Tseng, Chun-Pin] Chung Shan Inst Sci & Technol, Armaments Bur, Tao Yuan, Taiwan.
   [Lee, King-Ling] Univ Maryland, Univ Coll, Adelphi, MD USA.
RP Chen, CW (reprint author), Natl Kaohsiung Marine Univ, Inst Maritime Informat & Technol, Kaohsiung 80543, Taiwan.
EM chengwu@mail.nkmu.edu.tw
FU National Science Council of Taiwan, ROC [NSC 98-2221-E-366-006-MY2]
FX We acknowledge the financial support received from the National Science
   Council of Taiwan, ROC, under Project No. NSC 98-2221-E-366-006-MY2. We
   are also most grateful for the kind assistance of Professor Waldemar
   Karwowski, chief editor of Human Factors and Ergonomics in Manufacturing
   & Service Industries, and the constructive suggestions of the anonymous
   reviewers, all of which has led to the making of several corrections and
   suggestions that have greatly aided us in the presentation of this
   article.
CR AJZEN I, 1991, ORGAN BEHAV HUM DEC, V50, P179, DOI 10.1016/0749-5978(91)90020-T
   Ajzen I, 1980, UNDERSTANDING ATTITU
   Ajzen I., 1985, INTTENTIONS ACTIONS
   Allport G. W., 1936, PSYCHOL MONOGR, V47, P211
   Allport G. W., 1961, PATTERN GROWTH PERSO
   Allport GW, 1937, PERSONALITY PSYCHOL
   Bandura A, 1986, SOCIAL FDN THOUGHT A
   Block J, 2001, J RES PERS, V35, P98, DOI 10.1006/jrpe.2000.2293
   Buttle F, 2006, INT J MANAG REV, V8, P213, DOI 10.1111/j.1468-23370.2006.00128.x
   Carson SH, 2005, CREATIVITY RES J, V17, P37, DOI 10.1207/s15326934crj1701_4
   Cattell HEP, 1996, EUR REV APPL PSYCHOL, V46, P5
   Cattell R. B., 1946, DESCRIPTION MEASUREM
   Costa P. T., 1992, REVISEDNEO PERSONALI
   DAVIS FD, 1993, INT J MAN MACH STUD, V38, P475, DOI 10.1006/imms.1993.1022
   DAVIS FD, 1989, MANAGE SCI, V35, P982, DOI 10.1287/mnsc.35.8.982
   DAVIS FD, 1989, MIS QUART, V13, P319, DOI 10.2307/249008
   DeLone WH, 1992, INFORM SYST RES, V3, P60, DOI 10.1287/isre.3.1.60
   DeYoung CG, 2005, J PERS, V73, P825, DOI 10.1111/j.1467-6494.2005.00330.x
   DIGMAN JM, 1981, MULTIVAR BEHAV RES, V16, P149, DOI 10.1207/s15327906mbr1602_2
   DIGMAN JM, 1990, ANNU REV PSYCHOL, V41, P417, DOI 10.1146/annurev.ps.41.020190.002221
   Duckworth AL, 2005, PSYCHOL SCI, V16, P939, DOI 10.1111/j.1467-9280.2005.01641.x
   Epstein W, 1977, STABILITY CONSTANCY
   EYSENCK HJ, 1995, INT HDB PERSONALITY
   FISKE DW, 1949, J ABNORM SOC PSYCH, V44, P329, DOI 10.1037/h0057198
   Ford N. M., 1997, SALES FORCE MANAGEME
   Galton F., 1884, FORTNIGHTLY REV, V36, P179
   Gellatly IR, 1996, J APPL PSYCHOL, V81, P474, DOI 10.1037/0021-9010.81.5.474
   GIST ME, 1992, ACAD MANAGE REV, V17, P183, DOI 10.2307/258770
   Goldberg J., 1990, J PERS SOC PSYCHOL, V59, P1216
   GOLDBERG LR, 1993, AM PSYCHOL, V48, P26, DOI 10.1037/0003-066X.48.1.26
   GOODHUE DL, 1995, MIS QUART, V19, P213, DOI 10.2307/249689
   Harrison DA, 1997, INFORM SYST RES, V8, P171, DOI 10.1287/isre.8.2.171
   Hartwick J., 1994, MANAGE SCI, V40, P460
   Hogan R., 1991, HDB IND ORG PSYCHOL, P327
   Hurtz GM, 2000, J APPL PSYCHOL, V85, P869, DOI 10.1037/0021-9010.85.6.869
   Jones E., 2002, J PERSONAL SELLING S, V22, P145, DOI DOI 10.1080/08853134.2002.10754303
   Judge TA, 1999, PERS PSYCHOL, V52, P621, DOI 10.1111/j.1744-6570.1999.tb00174.x
   Judge TA, 1998, HUM PERFORM, V11, P167, DOI 10.1207/s15327043hup1102&3_4
   Judge TA, 2000, J APPL PSYCHOL, V85, P751, DOI 10.1037/0021-9010.85.5.751
   Judge TA, 2002, J APPL PSYCHOL, V87, P765, DOI 10.1037/0021-9010.87.4.765
   Karahanna E, 1999, MIS QUART, V23, P183, DOI 10.2307/249751
   KRUG SE, 1986, PSYCHOL REP, V59, P683, DOI 10.2466/pr0.1986.59.2.683
   Mathieson K, 1991, INFORM SYST RES, V2, P173, DOI 10.1287/isre.2.3.173
   MCCRAE RR, 1982, J PERS SOC PSYCHOL, V43, P293, DOI 10.1037/0022-3514.43.2.293
   MCCRAE RR, 1992, J PERS, V60, P175, DOI 10.1111/j.1467-6494.1992.tb00970.x
   MCCRAE RR, 1987, J PERS SOC PSYCHOL, V52, P81, DOI 10.1037/0022-3514.52.1.81
   MERSHON B, 1988, J PERS SOC PSYCHOL, V55, P675, DOI 10.1037/0022-3514.55.4.675
   Morris MG, 2000, PERS PSYCHOL, V53, P375, DOI 10.1111/j.1744-6570.2000.tb00206.x
   Mount M. K., 1995, RES PERSONNEL HUMAN, P153
   NORMAN WT, 1963, J ABNORM PSYCHOL, V66, P574, DOI 10.1037/h0040291
   Parks L, 2007, ANN C SOC IND ORG PS
   Parks L, 2009, PERS INDIV DIFFER, V47, P675, DOI 10.1016/j.paid.2009.06.002
   Paunonen SV, 2001, J RES PERS, V35, P78, DOI 10.1006/jrpe.2000.2309
   PEABODY D, 1989, J PERS SOC PSYCHOL, V57, P552, DOI 10.1037/0022-3514.57.3.552
   Plank Richard E, 1994, J PERSONAL SELLING S, V14, P43
   Rogers E. M., 1995, DIFFUSION INNOVATION
   Russell M., 1994, ADM MANUAL 16PF
   Salgado JF, 1997, J APPL PSYCHOL, V82, P30, DOI 10.1037/0021-9010.82.1.30
   Saucier GG L.R., 1996, 5 FACTOR MODEL PERSO
   SHEPPARD BH, 1988, J CONSUM RES, V15, P325, DOI 10.1086/209170
   Stevens C. D., 2003, J PERSONAL SELLING S, V23, P25
   Szajna B, 1996, MANAGE SCI, V42, P85, DOI 10.1287/mnsc.42.1.85
   Taylor S, 1995, MIS QUART, V19, P561, DOI 10.2307/249633
   Tupes E. C., 1961, RECURRENT PERSONALIT, P61
   Vancouver JB, 2002, J APPL PSYCHOL, V87, P506, DOI 10.1037//0021-9010.87.3.506
   Venkatesh V, 2000, MANAGE SCI, V46, P186, DOI 10.1287/mnsc.46.2.186.11926
   Venkatesh V, 2000, MIS QUART, V24, P115, DOI 10.2307/3250981
   Venkatesh V, 2000, ORGAN BEHAV HUM DEC, V83, P33, DOI 10.1006/obhd.2000.2896
   WEITZ BA, 1981, J MARKETING, V45, P85, DOI 10.2307/1251723
   Werbel JD, 1999, RES PERS H, V17, P209
   Westphal JD, 1997, ADMIN SCI QUART, V42, P366, DOI 10.2307/2393924
   WOODRUFFE C, 1985, J PERS SOC PSYCHOL, V48, P1240
   ZMUD RW, 1992, J PROD INNOVAT MANAG, V9, P148
NR 73
TC 10
Z9 10
U1 2
U2 35
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1090-8471
EI 1520-6564
J9 HUM FACTOR ERGON MAN
JI Hum. Factors Ergonom. Manuf. Serv. Ind.
PD JUL-AUG
PY 2013
VL 23
IS 4
BP 294
EP 305
DI 10.1002/hfm.20311
PG 12
WC Engineering, Manufacturing; Ergonomics
SC Engineering
GA 162PH
UT WOS:000320277000004
DA 2018-12-27
ER

PT J
AU Derosa, G
   Ragonesi, PD
   Carbone, A
   Fogari, E
   D'Angelo, A
   Cicero, AFG
   Maffioli, P
AF Derosa, Giuseppe
   Ragonesi, Pietro D.
   Carbone, Anna
   Fogari, Elena
   D'Angelo, Angela
   Cicero, Arrigo F. G.
   Maffioli, Pamela
TI RETRACTED: Evaluation of the positive effects on insulin-resistance and
   beta-cell measurements of vildagliptin in addition to metformin in type
   2 diabetic patients (Retracted article. See vol. 121, pg. 255, 2017)
SO PHARMACOLOGICAL RESEARCH
LA English
DT Article; Retracted Publication
DE Insulin-resistance; Metformin; Omentin-1; Vaspin; Vildagliptin; Visfatin
ID DIABETES-MELLITUS; ADIPOSE-TISSUE; EUROPEAN-ASSOCIATION; GLUCOSE;
   ADIPOKINE; VISFATIN; OMENTIN; ADIPOCYTOKINE; OBESITY
AB We evaluated the positive effects of vildagliptin in addition to metformin on glycemic control and beta-cell function in type 2 diabetic patients.
   One hundred and seventy-one type 2 diabetic patients were instructed to add vildaglipin 50 mg twice a day or placebo to metformin for 12 months. Body mass index (BMI), glycemic control, fasting plasma insulin (FPI), HOMA-IR, HOMA-beta, fasting plasma proinsulin (FPPr), proinsulin/fasting plasma insulin ratio (Pr/FPI ratio), C-peptide, glucagon, vaspin, visfatin, and omentin-1 were evaluated. Before, and after 12 months since the addition of vildagliptin, patients underwent a combined euglycemic hyperinsulinemic and hyperglycemic clamp, with subsequent arginine stimulation.
   Vildagliptin + metformin were more effective than placebo + metformin in reducing body weight and BMI, glycemic control, HOMA-IR, glucagon and insulin resistance measurements. Vildagliptin + metformin gave also a better increase of HOMA-beta, and of all beta-cell parameters after the clamp. We also recorded a significant correlation between M value increase and the decrease of vaspin, visfatin, and omentin-1 obtained with vildagliptin + metformin.
   Vildagliptin, in addition to metformin, proved to be effective in improving beta-cell function and in reducing insulin resistance measurements. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Derosa, Giuseppe; Fogari, Elena; D'Angelo, Angela; Maffioli, Pamela] Univ Pavia, Dept Internal Med & Therapeut, I-27100 Pavia, Italy.
   [Derosa, Giuseppe] Univ Pavia, Ctr Study Endocrine Metab Pathophysiol & Clin Res, I-27100 Pavia, Italy.
   [Ragonesi, Pietro D.] San Carlo Hosp, Diabet Care Unit, Milan, Italy.
   [Carbone, Anna] Hosp Ctr Diabet, Lodi, Italy.
   [Cicero, Arrigo F. G.] Univ Bologna, G Descovich Atherosclerosis Study Ctr, Bologna, Italy.
RP Derosa, G (reprint author), Univ Pavia, Dept Internal Med & Therapeut, Fdn IRCCS Policlin S Matteo, PAVIA, Ple C Golgi 2, I-27100 Pavia, Italy.
EM giuseppe.derosa@unipv.it
OI Cicero, Arrigo/0000-0002-4367-3884
CR Batista CMDS, 2007, DIABETES, V56, P1655, DOI 10.2337/db06-1506
   Bogardus Clifton, 1996, P459
   Bunck MC, 2009, DIABETES CARE, V32, P762, DOI 10.2337/dc08-1797
   BUNN HF, 1978, SCIENCE, V200, P21, DOI 10.1126/science.635569
   DEFRONZO RA, 1979, AM J PHYSIOL, V237, pE214
   DEFRONZO RA, 1988, DIABETES, V37, P667, DOI 10.2337/diab.37.6.667
   Derosa G, 2010, HORM METAB RES, V42, P663, DOI 10.1055/s-0030-1255036
   Derosa G, 2012, DIABETES TECHNOL THE, V14, P350, DOI 10.1089/dia.2011.0204
   Derosa G, 2011, DIABETES METAB SYNDR, V4, P263, DOI 10.2147/DMSO.S16361
   Derosa G, 2010, METABOLISM, V59, P887, DOI [10.1016/j.metabo1.2009.10.007, 10.1016/j.metabol.2009.10.007]
   El Kenz Hanane, 2004, Clin Lab, V50, P171
   El-Mesallamy HO, 2011, METABOLISM, V60, P63, DOI 10.1016/j.metabol.2010.04.008
   *EUR DIAB POL GROU, 1999, DIABETIC MED, V16, P716
   FASCHING P, 1994, METABOLISM, V43, P385, DOI 10.1016/0026-0495(94)90109-0
   Fukuhara A, 2005, SCIENCE, V307, P426, DOI 10.1126/science.1097243
   HEDING LG, 1972, DIABETOLOGIA, V8, P260, DOI 10.1007/BF01225569
   Hida K, 2005, P NATL ACAD SCI USA, V102, P10610, DOI 10.1073/pnas.0504703102
   Hoist JJ, 1982, BIOCHEM J, V207, P381
   Houssa P, 1998, CLIN CHEM, V44, P1514
   Hug C, 2005, SCIENCE, V307, P366, DOI 10.1126/science.1106933
   Korner A, 2007, J CLIN ENDOCR METAB, V92, P4783, DOI 10.1210/jc.2007-1304
   Kralisch S, 2005, EXPERT OPIN PHARMACO, V6, P863, DOI 10.1517/14656566.6.863
   Lichtenstein AH, 2006, ARTERIOSCL THROM VAS, V26, P2186, DOI 10.1161/01.ATV.0000238352.25222.5e
   MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883
   Nathan DM, 2009, DIABETES CARE, V32, P193, DOI 10.2337/dc08-9025
   Ryden L, 2007, EUR HEART J, V28, P88, DOI [10.1093/eurheartj/ehl260, 10.1093/eurheartj/ehm124]
   Schaffler A, 2005, BBA-GENE STRUCT EXPR, V1732, P96, DOI 10.1016/j.bbaexp.2005.11.005
   Tan BK, 2008, DIABETES, V57, P801, DOI 10.2337/db07-0990
   Wallace TM, 2004, DIABETES CARE, V27, P1487, DOI 10.2337/diacare.27.6.1487
   Weir GC, 1994, JOSLINS DIABETES MEL, P240
   Weyer C, 1999, J CLIN INVEST, V104, P787, DOI 10.1172/JCI7231
   Winer B. J., 1971, STAT PRINCIPLES EXPT
   Yang RZ, 2006, AM J PHYSIOL-ENDOC M, V290, pE1253, DOI 10.1152/ajpendo.00572.2004
   You BS, 2008, DIABETES, V57, P372, DOI 10.2337/db07-1045
NR 34
TC 15
Z9 16
U1 2
U2 8
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1043-6618
J9 PHARMACOL RES
JI Pharmacol. Res.
PD JUL
PY 2013
VL 73
BP 20
EP 26
DI 10.1016/j.phrs.2013.04.005
PG 7
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 169AX
UT WOS:000320750400003
PM 23624419
DA 2018-12-27
ER

PT J
AU Mohanty, P
   Das, J
AF Mohanty, P.
   Das, J.
TI RETRACTED: Synthetic seed technology for short term conservation of
   medicinal orchid Dendrobium densiflorum Lindl. Ex Wall and assessment of
   genetic fidelity of regenerants (Retracted article. See vol. 72, pg.
   209, 2014)
SO PLANT GROWTH REGULATION
LA English
DT Article; Retracted Publication
DE Short term storage; Dendrobium densiflorum; Encapsulation; Genetic
   fidelity
ID PROTOCORM-LIKE BODIES; SHOOT TIPS; ALGINATE-ENCAPSULATION;
   PLANT-REGENERATION; ENDANGERED ORCHID; SOMATIC EMBRYOS; L.; STORAGE;
   CRYOPRESERVATION; GERMPLASM
AB Artificial seeds were obtained through encapsulation of protocorm-like bodies (PLBs) of Dendrobium densiflorum in calcium alginate beads. This paper demonstrates the alginate-encapsulation and conversion (complete plantlet regeneration) from PLBs, the effect of storage conditions (at different temperature; 4, 8, 16 A degrees C, RT and duration; 15, 30, 45, 60, 75, 90 days) on viability of encapsulated plant materials as well as the assessment of genetic fidelity of the regenerants. Individual PLBs were encapsulated in calcium alginate beads for mass propagation, short-term storage and germplasm sharing. The superior gel matrix for encapsulation was obtained using 3 % sodium alginate and 100 mM calcium chloride (CaCl2 center dot 2H(2)O). The highest percentage of conversion (100 %) of encapsulated PLBs (capsules) was obtained on MS2 medium (MS medium + 2 mg/l BAP). Capsules were successfully stored till 60 days at 8 A degrees C with conversion frequency of 95.5 %. Plantlets regenerated from encapsulated beads were acclimatized successfully with 95 % survival rate. A total of 40 primers were screened, out of which 10 primers successfully generated 39 scorable bands, ranging from 0.2 to 1.3 kb amplicons. The uniform RAPD banding profile among the plantlets derived from encapsulated PLBs following 60 days of storage confirmed genetic fidelity.
C1 [Mohanty, P.] Natl Res Ctr Orchids, Pakyong 737106, Sikkim, India.
   [Das, J.] Sikkim Ctr, IBSD, Plant Bioresources Div, Tadong 737102, Gangtok, India.
RP Das, J (reprint author), Sikkim Ctr, IBSD, Plant Bioresources Div, Tadong 737102, Gangtok, India.
EM biotechjay@yahoo.co.in
RI Iqbal, Mohamed/N-1515-2013
FU DBT, Government of India
FX Authors are thankful to DBT, Government of India for providing the
   financial assistance to carry out the research work.
CR Agnihotri RK, 2009, ACTA PHYSIOL PLANT, V31, P961, DOI 10.1007/s11738-009-0311-6
   Ara H, 2000, CURR SCI INDIA, V78, P1438
   Bao XS, 2001, MED PLANTS DENDROBIU
   Bekheet S. A., 2007, J APPL SCI RES, V3, P859
   Boerner Andreas, 2006, Biotechnology Journal, V1, P1393, DOI 10.1002/biot.200600131
   Cassells AC, 2001, PLANT CELL TISS ORG, V64, P145, DOI 10.1023/A:1010692104861
   CHETIA S, 1998, INDIAN J EXP BIOL, V136, P108
   Corrie Shashi, 1993, Indian Journal of Experimental Biology, V31, P61
   DAHMEN J, 1975, ACTA CHEM SCAND B, V29, P627, DOI 10.3891/acta.chem.scand.29b-0627
   Danso KE, 2003, PLANT CELL REP, V21, P718, DOI 10.1007/s00299-003-0594-9
   Das MC, 2011, J HORTIC SCI BIOTECH, V86, P611
   Datta KB, 1999, CURR SCI INDIA, V76, P1142
   Dixit S, 2003, CRYOLETTERS, V24, P77
   Fan CQ, 2000, CHINESE CHEM LETT, V11, P705
   Fan CQ, 2001, PHYTOCHEMISTRY, V57, P1255, DOI 10.1016/S0031-9422(01)00168-6
   Gantait S, 2012, PLANT GROWTH REGUL, V68, P303, DOI 10.1007/s10725-012-9699-x
   GHOSH B, 1994, PLANT CELL REP, V13, P381, DOI 10.1007/BF00234142
   Haggman HM, 1998, PLANT CELL TISS ORG, V54, P45, DOI 10.1023/A:1006104325426
   Hao YJ, 2003, PLANT CELL TISS ORG, V72, P253, DOI 10.1023/A:1022388728497
   Hirai D., 2000, Cryopreservation of tropical plant germplasm: current research progress and application. Proceedings of an international workshop, Tsukuba, Japan, October, 1998, P205
   Jokipii S, 2004, PLANT SCI, V166, P799, DOI 10.1016/j.plantsci.2003.11.017
   Liu YG, 2004, PLANT SCI, V166, P677, DOI 10.1016/j.plantsci.2003.11.003
   Luo JP, 2008, PLANT CELL TISS ORG, V93, P333, DOI 10.1007/s11240-008-9381-1
   Mandal AB, 2007, CURR SCI INDIA, V93, P369
   Martin KP, 2003, IN VITRO CELL DEV-PL, V39, P322, DOI 10.1079/IVP2002399
   Mohanraj R., 2009, Asian Journal of Biotechnology, V1, P124, DOI 10.3923/ajbkr.2009.124.128
   Mohanty P, 2012, BIO-TECHNOL, DOI [10.1007/s13205-012-0090-4, DOI 10.1007/S13205-012-0090-4]
   MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x
   Naik SK, 2006, SCI HORTIC-AMSTERDAM, V108, P247, DOI 10.1016/j.scienta.2006.01.030
   Nyende AB, 2003, IN VITRO CELL DEV-PL, V39, P540, DOI 10.1079/IVP2003442
   Puchooa D., 2004, International Journal of Agriculture and Biology, V6, P884
   Rai MK, 2008, SCI HORTIC-AMSTERDAM, V118, P33, DOI 10.1016/j.scienta.2008.05.017
   REDENBAUGH K, 1987, HORTSCIENCE, V22, P803
   Saiprasad GVS, 2003, IN VITRO CELL DEV-PL, V39, P42, DOI 10.1079/IVP2002360
   Scocchi A, 2004, EUPHYTICA, V135, P29, DOI 10.1023/B:EUPH.0000009538.01279.d3
   SINGH F, 1991, Lindleyana, V6, P61
   Srivastava V, 2009, PLANT CELL TISS ORG, V99, P193, DOI 10.1007/s11240-009-9593-z
   Standardi A, 1998, INT J PLANT SCI, V159, P968, DOI 10.1086/314087
   TALAPATRA SK, 1984, J INDIAN CHEM SOC, V61, P1010
   Tang J, 2004, CHINESE CHEM LETT, V15, P63
   Xu H, 2006, PLANTA MED, V72, P89, DOI 10.1055/s-2005-916228
   Yang L, 2006, J CHROMATOGR A, V1104, P230, DOI 10.1016/j.chroma.2005.12.012
   Zheng WP, 2000, J ASIAN NAT PROD RES, V2, P301, DOI 10.1080/10286020008041369
NR 43
TC 4
Z9 5
U1 1
U2 43
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0167-6903
EI 1573-5087
J9 PLANT GROWTH REGUL
JI Plant Growth Regul.
PD JUL
PY 2013
VL 70
IS 3
BP 297
EP 303
DI 10.1007/s10725-013-9801-z
PG 7
WC Plant Sciences
SC Plant Sciences
GA 164WO
UT WOS:000320442500010
DA 2018-12-27
ER

PT J
AU Lin, YW
   Ren, LL
   Xiong, H
   Du, W
   Yu, YN
   Sun, TT
   Weng, YR
   Wang, ZH
   Wang, JL
   Wang, YC
   Cui, Y
   Sun, DF
   Han, ZG
   Shen, N
   Zou, WP
   Xu, J
   Chen, HY
   Cao, WB
   Hong, J
   Fang, JY
AF Lin, Yan-Wei
   Ren, Lin-Lin
   Xiong, Hua
   Du, Wan
   Yu, Ya-Nan
   Sun, Tian-Tian
   Weng, Yu-Rong
   Wang, Zhen-hua
   Wang, Ji-Lin
   Wang, Ying-Chao
   Cui, Yun
   Sun, Dan-Feng
   Han, Ze-Guang
   Shen, Nan
   Zou, Weiping
   Xu, Jie
   Chen, Hao-yan
   Cao, Weibiao
   Hong, Jie
   Fang, Jing-Yuan
TI RETRACTED: Role of STAT3 and vitamin D receptor in EZH2-mediated
   invasion of human colorectal cancer (Retracted article. See vol. 238,
   pg. 599, 2016)
SO JOURNAL OF PATHOLOGY
LA English
DT Article; Retracted Publication
DE colorectal cancer; invasion; EZH2; vitamin D receptor; STAT3
ID EPITHELIAL-MESENCHYMAL TRANSITION; GROUP PROTEIN EZH2; E-CADHERIN;
   SIGNALING PATHWAY; COLON-CANCER; HISTONE METHYLTRANSFERASE;
   HEPATOCELLULAR-CARCINOMA; BIOLOGICAL BEHAVIOR; GROWTH-INHIBITION;
   PROSTATE-CANCER
AB The polycomb group protein enhancer of zeste homologue 2 (EZH2), which has histone methyltransferase (HMT) activity, is overexpressed in malignant tumours. However, the role of EZH2 in colorectal cancer (CRC) invasion is little known. Here we investigated the clinical significance, biological effects, and mechanisms of EZH2 signalling. Knockdown of EZH2 significantly reduced cell invasion and secretion of matrix metalloproteinases 2/9 (MMP2/9) in in vitro studies. Knockdown of EZH2 dramatically increased overall survival and decreased metastasis of lung in in vivo studies. Conversely, overexpression of EZH2 significantly increased lung metastasis and shortened overall survival when compared with control tumours. EZH2-induced CRC cell invasion may depend on down-regulation of vitamin D receptor (VDR), which is considered to be a marker of CRC invasion. EZH2 regulates the histone trimethylation of lysine 27 (H3K27me3) in the VDR promoter. Moreover, we found that STAT3 directly binds to the EZH2 promoter and regulates VDR down-regulation in CRC cells. Significant inverse correlations were observed between the expression of EZH2 and pSTAT3 and that of VDR in CRC tissues compared with normal tissue in patients. We show the role of EZH2 in CRC metastasis and identify VDR as a target gene of EZH2. EZH2 expression may be directly regulated by STAT3, and STAT3 may play an important role in EZH2-mediated VDR down-regulation in CRC. This pathway may provide potential targets in aggressive CRC. Copyright (c) 2013 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
C1 [Lin, Yan-Wei; Ren, Lin-Lin; Xiong, Hua; Du, Wan; Yu, Ya-Nan; Sun, Tian-Tian; Weng, Yu-Rong; Wang, Zhen-hua; Wang, Ji-Lin; Wang, Ying-Chao; Cui, Yun; Sun, Dan-Feng; Xu, Jie; Chen, Hao-yan; Hong, Jie; Fang, Jing-Yuan] Shanghai Jiao Tong Univ, Div Gastroenterol & Hepatol, Renji Hosp, Sch Med,Shanghai Inst Digest Dis, Shanghai 200001, Peoples R China.
   [Lin, Yan-Wei; Ren, Lin-Lin; Xiong, Hua; Du, Wan; Yu, Ya-Nan; Sun, Tian-Tian; Weng, Yu-Rong; Wang, Zhen-hua; Wang, Ji-Lin; Wang, Ying-Chao; Cui, Yun; Sun, Dan-Feng; Xu, Jie; Chen, Hao-yan; Hong, Jie; Fang, Jing-Yuan] Shanghai Jiao Tong Univ, Sch Med, Key Lab Gastroenterol & Hepatol, Minist Hlth, Shanghai 200001, Peoples R China.
   [Lin, Yan-Wei; Ren, Lin-Lin; Xiong, Hua; Du, Wan; Yu, Ya-Nan; Sun, Tian-Tian; Weng, Yu-Rong; Wang, Zhen-hua; Wang, Ji-Lin; Wang, Ying-Chao; Cui, Yun; Sun, Dan-Feng; Xu, Jie; Chen, Hao-yan; Hong, Jie; Fang, Jing-Yuan] Shanghai Jiao Tong Univ, Sch Med, State Key Lab Oncogene & Related Genes, Shanghai 200001, Peoples R China.
   [Han, Ze-Guang] Chinese Natl Human Genome Ctr, Shanghai Minist Key Lab Dis & Hlth Genom, Shanghai, Peoples R China.
   [Shen, Nan] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Div Rheumatol, Shanghai 200030, Peoples R China.
   [Zou, Weiping] Univ Michigan, Dept Surg, Ann Arbor, MI 48109 USA.
   [Cao, Weibiao] Brown Univ, Dept Pathol & Med, Warren Alpert Med Sch, Providence, RI 02912 USA.
   [Cao, Weibiao] Rhode Isl Hosp, Providence, RI USA.
RP Fang, JY (reprint author), Shanghai Jiao Tong Univ, Div Gastroenterol & Hepatol, Renji Hosp, Sch Med,Shanghai Inst Digest Dis, 145 Middle Shandong Rd, Shanghai 200001, Peoples R China.
EM wcao@hotmail.com; jiehong97@gmail.com; jingyuanfang@yahoo.com
OI Shen, Nan/0000-0002-5875-4417
FU National Natural Science Foundation of Key Program [30830055]; Ministry
   of Public Health, China [200802094]; Ministry of Education
   [20090073110077]; National Natural Science Foundation [81001070,
   91129724, 31271366]; Shanghai Rising-Star Program [12QA1402000]
FX This work was supported by grants from the National Natural Science
   Foundation of Key Program (No. 30830055), the Ministry of Public Health,
   China (No. 200802094), the Ministry of Education (No. 20090073110077) to
   FJY; the grant from the National Natural Science Foundation (No.
   81001070) to SDF; the grant from the National Natural Science Foundation
   (No. 91129724), National Natural Science Foundation (No. 31271366) and
   Shanghai Rising-Star Program (No: 12QA1402000) to HJ.
CR Bachmann IM, 2006, J CLIN ONCOL, V24, P268, DOI 10.1200/JCO.2005.01.5180
   Bates RC, 2005, CANCER BIOL THER, V4, P365
   Cao Q, 2008, ONCOGENE, V27, P7274, DOI 10.1038/onc.2008.333
   Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997
   Chang CJ, 2011, CANCER CELL, V19, P86, DOI 10.1016/j.ccr.2010.10.035
   Chen YC, 2007, HEPATOLOGY, V46, P200, DOI 10.1002/hep.21668
   de Krijger I, 2011, J PATHOL, V224, P438, DOI 10.1002/path.2922
   Deeb KK, 2007, NAT REV CANCER, V7, P684, DOI 10.1038/nrc2196
   EISMAN JA, 1987, CANCER RES, V47, P21
   Evans SRT, 1998, CLIN CANCER RES, V4, P1591
   Fang J, 2011, AM J MED SCI, V342, P198, DOI 10.1097/MAJ.0b013e31821335a9
   Fearon ER, 2011, ANNU REV PATHOL-MECH, V6, P479, DOI 10.1146/annurev-pathol-011110-130235
   Fujii S, 2011, ONCOGENE, V30, P4118, DOI 10.1038/onc.2011.118
   Fujii S, 2008, J BIOL CHEM, V283, P17324, DOI 10.1074/jbc.M800224200
   Gire W, 2004, EMBO J, V23, P2554, DOI 10.1038/sj.emboj.7600259
   Gupta RA, 2010, NATURE, V464, P1071, DOI 10.1038/nature08975
   HAUSSLER MR, 1969, P NATL ACAD SCI USA, V62, P155, DOI 10.1073/pnas.62.1.155
   Huang C, 2011, NEOPLASMA, V58, P396, DOI 10.4149/neo_2011_05_396
   Larriba MJ, 2009, CARCINOGENESIS, V30, P1459, DOI 10.1093/carcin/bgp140
   Kirmizis A, 2004, GENE DEV, V18, P1592, DOI 10.1101/gad.1200204
   Kirmizis A, 2003, MOL CANCER THER, V2, P113
   Langlois MJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015742
   Lassmann S, 2007, J CLIN PATHOL, V60, P173, DOI 10.1136/jcp.2005.035113
   Markowitz SD, 2002, CANCER CELL, V1, P233, DOI 10.1016/S1535-6108(02)00053-3
   Matusiak D, 2005, CANCER EPIDEM BIOMAR, V14, P2370, DOI 10.1158/1055-9965.EPI-05-0257
   Ng K, 2008, J CLIN ONCOL, V26, P2984, DOI 10.1200/JCO.2007.15.1027
   Palmer HG, 2001, J CELL BIOL, V154, P369, DOI 10.1083/jcb.200102028
   Raman JD, 2005, CLIN CANCER RES, V11, P8570, DOI 10.1158/1078-0432.CCR-05-1047
   Rao ZY, 2010, CARCINOGENESIS, V31, P1576, DOI 10.1093/carcin/bgq150
   Samuels Y, 2005, CANCER CELL, V7, P561, DOI 10.1016/j.ccr.2005.05.014
   Sasaki M, 2008, LAB INVEST, V88, P873, DOI 10.1038/labinvest.2008.52
   SHABAHANG M, 1994, CANCER RES, V54, P4057
   SHABAHANG M, 1993, CANCER RES, V53, P3712
   Shin YJ, 2012, PLOS ONE, V7
   Simon JA, 2008, MUTAT RES-FUND MOL M, V647, P21, DOI 10.1016/j.mrfmmm.2008.07.010
   Spano JP, 2006, EUR J CANCER, V42, P2668, DOI 10.1016/j.ejca.2006.07.006
   Spina CS, 2007, J STEROID BIOCHEM, V103, P757, DOI 10.1016/j.jsbmb.2006.12.040
   Tong ZT, 2012, ONCOGENE, V31, P583, DOI 10.1038/onc.2011.254
   van Engeland M, 2011, J CLIN ONCOL, V29, P1382, DOI 10.1200/JCO.2010.28.2319
   Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075
   Varambally S, 2008, SCIENCE, V322, P1695, DOI 10.1126/science.1165395
   Velichutina I, 2010, BLOOD, V116, P5247, DOI 10.1182/blood-2010-04-280149
   VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M
   Xiong H, 2008, NEOPLASIA, V10, P287, DOI 10.1593/neo.07971
   Xiong H, 2012, J BIOL CHEM, V287, P5819, DOI 10.1074/jbc.M111.295964
   Yadav A, 2011, MOL CANCER RES, V9, P1658, DOI 10.1158/1541-7786.MCR-11-0271
   Yeh HY, 2009, BMC MED GENOMICS, V2, DOI 10.1186/1755-8794-2-70
NR 47
TC 27
Z9 32
U1 2
U2 28
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3417
EI 1096-9896
J9 J PATHOL
JI J. Pathol.
PD JUL
PY 2013
VL 230
IS 3
BP 277
EP 290
DI 10.1002/path.4179
PG 14
WC Oncology; Pathology
SC Oncology; Pathology
GA 160LW
UT WOS:000320122100006
PM 23424038
DA 2018-12-27
ER

PT J
AU Mahesh, BV
   Raman, RKS
   Scattergood, RO
   Koch, CC
AF Mahesh, B. V.
   Raman, R. K. Singh
   Scattergood, R. O.
   Koch, C. C.
TI RETRACTED: Fe-Cr-Ni-Zr alloys with bi-modal grain size distribution:
   Synthesis, mechanical properties and oxidation resistance (Retracted
   article. See vol. 660, pg. 251, 2016)
SO MATERIALS SCIENCE AND ENGINEERING A-STRUCTURAL MATERIALS PROPERTIES
   MICROSTRUCTURE AND PROCESSING
LA English
DT Article; Retracted Publication
DE Bimodal grain-size distribution; Nanocrystalline Fe-Cr alloys; High
   temperature oxidation; SIMS depth profiling
ID NANOCRYSTALLINE MATERIALS; HOT EXTRUSION; HIGH-STRENGTH; GROWTH; IRON;
   BEHAVIOR; MICROSTRUCTURE; STABILIZATION; CONSOLIDATION; DEFORMATION
AB This is an investigation of the hypothesis that a bimodal grain size distribution (50% nanocrystalline and 50% microcrystalline) may confer considerable oxidation resistance to an Fe-Cr based alloys at much lower Cr contents as compared to a microcrystalline Fe-Cr alloy yet achieve considerably superior mechanical properties as compared to an entirely nanocrystalline alloy of same composition. Cylindrical pellets of Fe-Cr-Ni-Zr alloys, with varying Cr and Zr content, were produced using mechanical alloying-hot compaction route. New synthesis routes for bimodal, nanocrystalline and microcrystalline Fe-Cr-Ni-Zr alloys have been proposed in this study. Mechanical properties of these alloys have been compared using hardness and shear punch tests. Oxidation resistance of these alloys was compared by subjecting them to oxidation in air at 550 degrees C for up to 150 h. It is suggested that for bimodal alloys, the nanocrystalline component helped in significantly improving the high temperature oxidation resistance whereas the microcrystalline component imparted considerable ductility, thereby, providing a combination of the two attractive properties. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Mahesh, B. V.; Raman, R. K. Singh] Monash Univ, Dept Mech & Aerosp Engn, Clayton, Vic 3800, Australia.
   [Raman, R. K. Singh] Monash Univ, Dept Chem Engn, Clayton, Vic 3800, Australia.
   [Scattergood, R. O.; Koch, C. C.] NC State Univ, Dept Mat Sci & Engn, Raleigh, NC USA.
RP Mahesh, BV (reprint author), Monash Univ, Dept Mech & Aerosp Engn, Clayton, Vic 3800, Australia.
EM Mahesh.Venkataraman@monash.edu
FU Australian Research Council (ARC)
FX The authors would like to acknowledge the support of Australian Research
   Council (ARC) for a Discovery grant for the initial part of the project.
   The authors are also thankful to Dr. David Nelson, University of Western
   Sydney, for his support with SIMS characterization work.
CR BASU SN, 1991, OXID MET, V36, P281, DOI 10.1007/BF00662967
   Bonetti E, 1999, NANOSTRUCT MATER, V12, P685, DOI 10.1016/S0965-9773(99)00217-2
   Cheng S, 2005, ACTA MATER, V53, P1521, DOI 10.1016/j.actamat.2004.12.005
   Choi JH, 2001, J ALLOY COMPD, V315, P178, DOI 10.1016/S0925-8388(00)01213-5
   Dapeng Z., 2011, MATER LETT, V65, P1672
   Darling K.A., 2009, THESIS NC STATE U RA
   Darling KA, 2008, SCRIPTA MATER, V59, P530, DOI 10.1016/j.scriptamat.2008.04.045
   DEKEIJSER TH, 1982, J APPL CRYSTALLOGR, V15, P308, DOI 10.1107/S0021889882012035
   Ehlers J, 2006, CORROS SCI, V48, P3428, DOI 10.1016/j.corsci.2006.02.002
   GIGGINS CS, 1969, T METALL SOC AIME, V245, P2509
   GLEITER H, 1989, PROG MATER SCI, V33, P223, DOI 10.1016/0079-6425(89)90001-7
   Gleiter H, 2000, ACTA MATER, V48, P1, DOI 10.1016/S1359-6454(99)00285-2
   Guduru RK, 2007, ADV ENG MATER, V9, P855, DOI 10.1002/adem.200700181
   Guduru RK, 2005, MAT SCI ENG A-STRUCT, V395, P307, DOI 10.1016/j.msea.2004.12.048
   Gupta R, 2008, MAT SCI ENG A-STRUCT, V494, P253, DOI 10.1016/j.msea.2008.04.019
   HORIBE S, 1975, CORROS SCI, V15, P589, DOI 10.1016/0010-938X(75)90025-6
   Ji Y, 2000, SCRIPTA MATER, V42, P1017, DOI 10.1016/S1359-6462(00)00317-1
   Karimpoor AA, 2003, SCRIPTA MATER, V49, P651, DOI 10.1016/S1359-6462(03)00397-X
   Kirchheim R., 1992, Nanostructured Materials, V1, P167, DOI 10.1016/0965-9773(92)90071-5
   Koch CC, 2005, ADV ENG MATER, V7, P787, DOI 10.1002/adem.200500094
   KORTH GE, 1995, METALL MATER TRANS A, V26, P2571, DOI 10.1007/BF02669415
   KRILL CE, 1995, MATER SCI FORUM, V179-, P443, DOI 10.4028/www.scientific.net/MSF.179-181.443
   LEDJEFF K, 1981, OXID MET, V15, P485, DOI 10.1007/BF00603539
   Lee Z, 2005, MAT SCI ENG A-STRUCT, V410, P462, DOI 10.1016/j.msea.2005.08.104
   Legros M, 2000, PHILOS MAG A, V80, P1017, DOI 10.1080/01418610008212096
   Liu YD, 2007, J ALLOY COMPD, V440, P154, DOI 10.1016/j.jallcom.2006.09.060
   Lu K, 1996, MAT SCI ENG R, V16, P161, DOI 10.1016/0927-796X(95)00187-5
   LUCAS GE, 1983, J NUCL MATER, V117, P327, DOI 10.1016/0022-3115(83)90041-7
   Malow TR, 1997, ACTA MATER, V45, P2177, DOI 10.1016/S1359-6454(96)00300-X
   MERZ MD, 1979, METALL TRANS A, V10, P71, DOI 10.1007/BF02686409
   Michels A, 1999, ACTA MATER, V47, P2143, DOI 10.1016/S1359-6454(99)00079-8
   Millett PC, 2006, ACTA MATER, V54, P297, DOI 10.1016/j.actamat.2005.07.024
   Moelle CH, 1995, NANOSTRUCT MATER, V6, P421, DOI 10.1016/0965-9773(95)00086-0
   Moon KI, 1999, J ALLOY COMPD, V291, P312, DOI 10.1016/S0925-8388(99)00299-6
   Nakayama T., 1973, Journal of the Japan Institute of Metals, V37, P1313
   Raman RKS, 2010, PHILOS MAG, V90, P3233, DOI 10.1080/14786435.2010.484402
   Raman RKS, 2009, CORROS SCI, V51, P316, DOI 10.1016/j.corsci.2008.10.020
   RAMAN RKS, 1994, MAT SCI ENG A-STRUCT, V185, P97, DOI 10.1016/0921-5093(94)90932-6
   Rees EE, 2003, APPL SURF SCI, V203, P660, DOI 10.1016/S0169-4332(02)00786-9
   ROY RA, 1984, MATER RES BULL, V19, P169, DOI 10.1016/0025-5408(84)90087-4
   SASA K, 1977, CORROS SCI, V17, P783, DOI 10.1016/0010-938X(77)90074-9
   Sevillano JG, 2004, SCRIPTA MATER, V51, P795, DOI 10.1016/j.scriptamat.2004.05.015
   SEYBOLT AU, 1960, J ELECTROCHEM SOC, V107, P147, DOI 10.1149/1.2427643
   Suryanarayana C, 1997, METALL MATER TRANS A, V28, P293, DOI 10.1007/s11661-997-0132-4
   SURYANARAYANA C, 1995, INT MATER REV, V40, P41, DOI 10.1179/imr.1995.40.2.41
   Tellkamp VL, 2001, METALL MATER TRANS A, V32, P2335, DOI 10.1007/s11661-001-0207-6
   Toloczko MB, 2002, J NUCL MATER, V307, P1619, DOI 10.1016/S0022-3115(02)01258-8
   TRAPP S, 1995, PHYS REV LETT, V75, P3760, DOI 10.1103/PhysRevLett.75.3760
   Vajpai SK, 2008, METALL MATER TRANS A, V39A, P2725, DOI 10.1007/s11661-008-9617-z
   Vajpai SK, 2009, J ALLOY COMPD, V476, P311, DOI 10.1016/j.jallcom.2008.08.051
   Wang YM, 2004, ACTA MATER, V52, P1699, DOI 10.1016/j.actamat.2003.12.022
   Wang ZB, 2003, ACTA MATER, V51, P4319, DOI 10.1016/S1359-6454(03)00260-X
   WEISSMULLER J, 1994, J MATER RES, V9, P4, DOI 10.1557/JMR.1994.0004
   WEISSMULLER J, 1993, NANOSTRUCT MATER, V3, P261, DOI 10.1016/0965-9773(93)90088-S
   Witkin D, 2003, SCRIPTA MATER, V49, P297, DOI 10.1016/S1359-6462(03)00283-5
   WYNBLATT P, 1977, SURF SCI, V65, P511, DOI 10.1016/0039-6028(77)90462-9
   Wynblatt P, 2006, METALL MATER TRANS A, V37A, P2595, DOI 10.1007/BF02586096
   Youssef KM, 2004, APPL PHYS LETT, V85, P929, DOI 10.1063/1.1779342
NR 58
TC 6
Z9 6
U1 2
U2 22
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 0921-5093
EI 1873-4936
J9 MAT SCI ENG A-STRUCT
JI Mater. Sci. Eng. A-Struct. Mater. Prop. Microstruct. Process.
PD JUL 1
PY 2013
VL 574
BP 235
EP 242
DI 10.1016/j.msea.2013.02.049
PG 8
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary;
   Metallurgy & Metallurgical Engineering
SC Science & Technology - Other Topics; Materials Science; Metallurgy &
   Metallurgical Engineering
GA 146JT
UT WOS:000319088100030
DA 2018-12-27
ER

PT J
AU Dasgupta, N
   Biswas, P
   Kumar, R
   Kumar, N
   Bera, B
   Das, S
AF Dasgupta, Nirjhar
   Biswas, Prosenjit
   Kumar, Rakesh
   Kumar, Narendra
   Bera, Biswajit
   Das, Sauren
TI RETRACTED: Antioxidants and ROS scavenging ability in ten Darjeeling tea
   clones may serve as markers for selection of potentially adapted clones
   against abiotic stress (Retracted article. See vol. 22, pg. 287, 2016)
SO PHYSIOLOGY AND MOLECULAR BIOLOGY OF PLANTS
LA English
DT Article; Retracted Publication
ID CAMELLIA-SINENSIS; LYCOPERSICON-PENNELLII; ASCORBATE PEROXIDASE;
   PHENOLIC-COMPOUNDS; HYDROGEN-PEROXIDE; SALINITY STRESS; FLAVONOIDS; L.;
   RADICALS; EXTRACTS
AB Ten Darjeeling tea clones (BT15/263, RR17/144, B777, T253, B157, Sundaram, HV39, AV2, K1/1 and TTV1) were collected from the experimental garden of Darjeeling Tea Research and Development Centre, Kurseong. Total phenol, flavonoids and two antioxidating enzymes (peroxidase and superoxide dismutase) were estimated. The total phenol ranged between 241 and 28 GAE mg g(-1) of leaf dry weight. The highest amount obtained in four clones, B15/263 (241.47), RR17/144 (221.2), B777 (154.54) and B157 (140.23 mg g(-1)). Flavonoids were estimated as Catechin equivalent (CE) and ranged between 56.88 and 20.81 CE mg g(-1) leaf dry weight. Higher amounts occurred in BT15/263 (56.88 mg g(-1)), B777 (56.69) and RR17/144 (48.63). Antioxidant activities were measured following DPPH and ABTS free radicle scavenging procedures and the results were well according to total polyphenol content among the clones (in total phenols, ranges of correlation in DPPH assay were r (2) = 0.990-0.989, p a parts per thousand currency signaEuro parts per thousand 0.05; in flavonoids r (2) = 0.954, p a parts per thousand currency signaEuro parts per thousand 0.01-0.987, p a parts per thousand currency signaEuro parts per thousand 0.05). Similarly, ABTS percent scavenging results were quiet significant. The IC50 values were determined for both DPPH and ABTS assay. PAGE expressions of isoforms in two antioxidative enzymes and quantification of them also varied much among the investigated clones. The incidence of total phenols, flavonoids, PRX and SOD and ROS scavenging assay in in-situ condition, might be used as biochemical markers towards the superior adaptability against abiotic stress. In the present work, four clones (B15/263, B777, RR17/144 and B157) would be designated as comparatively better suited to the predicted abiotic stress.
RP Das, S (reprint author), Indian Stat Inst, Agr & Ecol Res Unit, 203 BT Rd, Kolkata 700108, India.
EM sauren@isical.ac.in
CR Abogadallah GM, 2010, PLANT SIGNAL BEHAV, V5, P369, DOI 10.4161/psb.5.4.10873
   Alscher RG, 1997, PHYSIOL PLANTARUM, V100, P224, DOI 10.1034/j.1399-3054.1997.1000203.x
   Anesini C, 2008, J AGR FOOD CHEM, V56, P9225, DOI 10.1021/jf8022782
   Arnao MB, 2000, TRENDS FOOD SCI TECH, V11, P419, DOI 10.1016/S0924-2244(01)00027-9
   ASADA K, 1992, PHYSIOL PLANTARUM, V85, P235, DOI 10.1111/j.1399-3054.1992.tb04728.x
   Asha KK, 2012, INDIAN J GEO-MAR SCI, V41, P259
   Bandyopadhaya T, 2008, ASSAM REV TEA NEWS, V97, P30
   Bandyopadhyay T., 2011, International Journal of Plant Breeding and Genetics, V5, P23, DOI 10.3923/ijpbg.2011.23.33
   Banerjee D, 2008, AFR J BIOTECHNOL, V7, P805
   Barua DN, 2008, SCI PRACTICE TEA CUL, P164
   BLOIS MS, 1958, NATURE, V181, P1199, DOI 10.1038/1811199a0
   CARR M K V, 1972, Experimental Agriculture, V8, P1, DOI 10.1017/S0014479700023449
   Chandini SK, 2008, FOOD CHEM, V107, P707, DOI 10.1016/j.foodchem.2007.08.081
   CHANG HT, 1981, ACTA SCI NATURALIUM, V1, P1
   Chang HT, 1984, FOOD CHEM TOXICOL
   Cheruiyot EK, 2007, BIOSCI BIOTECH BIOCH, V71, P2190, DOI 10.1271/bbb.70156
   Cotelle N, 1996, FREE RADICAL BIO MED, V20, P35, DOI 10.1016/0891-5849(95)02014-4
   Das S, 1997, ANN BOT-LONDON, V79, P565, DOI 10.1006/anbo.1996.0384
   Dasgupta N, 2011, ACTA PHYSIOL PLANT, V33, P803, DOI 10.1007/s11738-010-0605-8
   Devi SR, 1998, PLANT SCI, V138, P157
   Diaz J, 2001, PLANT SCI, V161, P179, DOI 10.1016/S0168-9452(01)00410-1
   Diplock AT, 1997, FREE RADICAL RES, V27, P511, DOI 10.3109/10715769709065791
   DIXON RA, 1995, PLANT CELL, V7, P1085, DOI 10.1105/tpc.7.7.1085
   Duan XJ, 2006, FOOD CHEM, V95, P37, DOI 10.1016/j.foodchem.2004.12.015
   Duh PD, 1999, FOOD SCI TECHNOL-LEB, V32, P269
   ELLIS R, 1995, EXP AGR, V31, P307, DOI 10.1017/S0014479700025485
   FOYER CH, 1994, PLANT CELL ENVIRON, V17, P507, DOI 10.1111/j.1365-3040.1994.tb00146.x
   Grace ESC, 2000, PHIL T R SOC LOND, V355, P1499
   Graham HN, 1999, WILEY ENCY FOOD SCI, V1-4, P2292
   Gramza A, 2005, POL J ENVIRON STUD, V14, P861
   Grudarzi M, 2009, J APPL SCI, V9, P348
   HALLIWELL B, 1994, ENVIRON HEALTH PERSP, V102, P5, DOI 10.2307/3432205
   Hasegawa PM, 2000, ANNU REV PLANT PHYS, V51, P463, DOI 10.1146/annurev.arplant.51.1.463
   HATANO T, 1989, CHEM PHARM BULL, V37, P2016
   Huda-Faujan N, 2009, AFR J BIOTECHNOL, V8, P484
   Humphries AW, 1964, NEW PHYTOL, V64, P115
   IMLAY JA, 1988, SCIENCE, V240, P640, DOI 10.1126/science.2834821
   Jeyaramraja P, 2003, J SCI FOOD AGR, V83, P1187, DOI 10.1002/jsfa.1440
   Jia Z, 1999, FOOD CHEM, V64, P555, DOI 10.1016/S0308-8146(98)00102-2
   Kavitha K, 2008, PLANT PHYSIOL BIOCH, V46, P794, DOI 10.1016/j.plaphy.2008.05.008
   Keith H, 1983, ANAL BIOCHEM, V135, P280
   KINGDONWARD F, 1950, NATURE, V165, P297, DOI 10.1038/165297a0
   KINSELLA JE, 1993, FOOD TECHNOL-CHICAGO, V47, P85
   Lakshman RB, 2012, INT J RES PHARM BIOM, V3, P1139
   Lovala A, 2000, PHYSIOL PLANTARUM, V109, P260
   Masood A, 2006, ENVIRON EXP BOT, V58, P216, DOI 10.1016/j.envexpbot.2005.08.002
   MEIR S, 1995, J AGR FOOD CHEM, V43, P1813, DOI 10.1021/jf00055a012
   Middleton Jr E., 1993, ADV RES 1986, P619
   Midori M, 2003, PHYTOTHER RES, V17, P566
   Ming TienLu, 1996, Acta Botanica Yunnanica, V18, P1
   Mittler R, 2002, TRENDS PLANT SCI, V7, P405, DOI 10.1016/S1360-1385(02)02312-9
   Mittova V, 2002, PHYSIOL PLANTARUM, V115, P393, DOI 10.1034/j.1399-3054.2002.1150309.x
   Mittova V, 2000, PHYSIOL PLANTARUM, V110, P42, DOI 10.1034/j.1399-3054.2000.110106.x
   Ng'etich W. K., 2000, Tea, V21, P60
   Ostrowska J., 2001, BROMATOL TOXICOL CHE, V2, P131
   Parida AK, 2004, TREES-STRUCT FUNCT, V18, P167, DOI 10.1007/s00468-003-0293-8
   PARRY AD, 1994, PLANT PHYSIOL, V106, P195, DOI 10.1104/pp.106.1.195
   Pietta PG, 2000, J NAT PROD, V63, P1035, DOI 10.1021/np9904509
   Prochazkova D, 2007, BIOL PLANTARUM, V51, P401, DOI 10.1007/s10535-007-0088-7
   Re R, 1999, FREE RADICAL BIO MED, V26, P1231, DOI 10.1016/S0891-5849(98)00315-3
   Ribeiro AB, 2002, ECLET QUIM, V27
   RICHARDS A. V., 1966, TEA QUART, V37, P154
   Sakihama Y, 2002, BIOL PLANTARUM, V45, P249, DOI 10.1023/A:1015152908241
   Schlesier K, 2002, FREE RADICAL RES, V36, P177, DOI 10.1080/10715760290006411
   Sekihama Y, 2002, TOXICOLOGY, V177, P67
   Sgherri C, 2003, PHYSIOL PLANTARUM, V118, P21, DOI 10.1034/j.1399-3054.2003.00068.x
   Shanmugarajah V., 1994, Sri Lanka Journal of Tea Science, V63, P94
   SHANNON LM, 1966, J BIOL CHEM, V241, P2166
   Singh ID, 1992, TEA CULTIVARS DARJEE
   SINGLETON V. L., 1965, AMER J ENOL VITICULT, V16, P144
   Stephen W, 1989, EXP AGR, V25, P45
   Takahama U, 2000, J PLANT RES, V113, P301, DOI 10.1007/PL00013933
   TANTON TW, 1982, EXP AGR, V18, P47, DOI 10.1017/S0014479700013417
   Waheed A., 2012, J MAT ENV SCI, V3, P395
   WIGHT W, 1962, CURR SCI INDIA, V31, P298
   Wijeratne MA, 1996, WATER AIR SOIL POLL, V92, P87
   Winkel-Shirley B, 2002, CURR OPIN PLANT BIOL, V5, P218, DOI 10.1016/S1369-5266(02)00256-X
   Wojtaszek P, 1997, BIOCHEM J, V322, P681, DOI 10.1042/bj3220681
   Yamasaki H, 1997, PLANT PHYSIOL, V115, P1405, DOI 10.1104/pp.115.4.1405
   Yildirim A, 2001, J AGR FOOD CHEM, V49, P4083, DOI 10.1021/jf0103572
   Ziying Yang, 2007, Asia Pacific Journal of Clinical Nutrition, V16, P148
   Zurina M., 2010, World Applied Sciences Journal, V10, P525
NR 82
TC 3
Z9 4
U1 2
U2 20
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0971-5894
EI 0974-0430
J9 PHYSIOL MOL BIOL PLA
JI Physiol. Mol. Biol. Plants
PD JUL
PY 2013
VL 19
IS 3
BP 421
EP 433
DI 10.1007/s12298-013-0187-1
PG 13
WC Plant Sciences
SC Plant Sciences
GA 186BB
UT WOS:000322015100011
PM 24431510
OA Green Published
DA 2018-12-27
ER

PT J
AU Vallejo-Medina, P
   Sierra, JC
AF Vallejo-Medina, Pablo
   Carlos Sierra, Juan
TI RETRACTED: Adaptation, Equivalence, and Validation of the Changes in
   Sexual Functioning Questionnaire-Drugs in a Sample of Drug-Dependent Men
   (Retracted article. See vol. 42, pg. 386, 2016)
SO JOURNAL OF SEX & MARITAL THERAPY
LA English
DT Article; Retracted Publication
ID ASSERTIVENESS SCALE SAS; SHORT-FORM CSFQ-14; SPANISH VERSION;
   PSYCHOMETRIC PROPERTIES; LOGISTIC-REGRESSION; FUNCTION INVENTORY;
   DYSFUNCTION; ABUSE; RELIABILITY; INVARIANCE
AB This study aimed to adapt and validate the Changes in Sexual Functioning Questionnaire-short form in a sample of drug-dependent men, achieving equivalence. Participants were 301 drug-dependent and 202 nondrug-dependent men took part in this study. The analysis of invariance revealed strong factor equivalence (RMSEA = .06; 2/df = 2.66 and CFI = .01) for the 4-factor model (desire, pleasure, arousal, and orgasm). This model has shown the best fit indices. No items showed differential item functioning (R 2 Nagelkerke < .035). Reliability ranged from = 0.83 for pleasure to = 0.61 for orgasm. A comparison between the scores of control and experimental participants showed significant differences (CI = 99%) in all the dimensions. Thus, a worse sexual functioning has been observed in the drug consumer group. The adaptation of the Changes in Sexual Functioning Questionnaire-short form to drug-dependent individuals showed good psychometric properties.
C1 [Vallejo-Medina, Pablo; Carlos Sierra, Juan] Univ Granada, Fac Psicol, Granada 18011, Spain.
RP Vallejo-Medina, P (reprint author), Univ Granada, Fac Psicol, Granada 18011, Spain.
EM pvallejo@ugr.es
RI Vallejo-Medina, Pablo/P-8862-2018
OI Vallejo-Medina, Pablo/0000-0002-8527-1584
CR Avila Escribano J. J., 2004, ADICCIONES, V16, P1
   Bang-Ping J, 2009, J SEX MED, V6, P1072, DOI 10.1111/j.1743-6109.2007.00707.x
   Bobes J, 2000, J SEX MARITAL THER, V26, P119, DOI 10.1080/009262300278524
   Calafat A, 2008, ADICCIONES, V20, P37, DOI 10.20882/adicciones.287
   Sierra JC, 2011, AN PSICOL-SPAIN, V27, P17
   Carretero-Dios H, 2005, INT J CLIN HLTH PSYC, V5, P521
   Carretero-Dios H, 2007, INT J CLIN HLTH PSYC, V7, P863
   Cheung GW, 2002, STRUCT EQU MODELING, V9, P233, DOI 10.1207/S15328007SEM0902_5
   Clayton AH, 1997, PSYCHOPHARMACOL BULL, V33, P731
   COCORES JA, 1988, AM J DRUG ALCOHOL AB, V14, P169, DOI 10.3109/00952999809001544
   De Arcos FA, 2008, ADICCIONES, V20, P117
   DEGENHARDT L, 2003, INT J DRUG POLICY, V14, P17, DOI DOI 10.1016/S0955-3959(02)00200-1
   Dimitrov DM, 2010, MEAS EVAL COUNS DEV, V43, P121, DOI 10.1177/0748175610373459
   Emanuele MA, 1998, ALCOHOL HEALTH RES W, V22, P195
   Hidalgo MD, 2005, PSICOTHEMA, V17, P509
   Jiann B. P., 2008, CHONNAM MED J, V44, P117, DOI [10.4068/cmj.2008.44.3.117, DOI 10.4068/CMJ.2008.44.3.117]
   Jodoin MG, 2001, APPL MEAS EDUC, V14, P329, DOI 10.1207/S15324818AME1404_2
   Johnson SD, 2004, ARCH SEX BEHAV, V33, P55, DOI 10.1023/B:ASEB.0000007462.97961.5a
   Keller A, 2006, J SEX MARITAL THER, V32, P43, DOI 10.1080/00926230500232909
   Kurtz SP, 2005, AIDS BEHAV, V9, P63, DOI 10.1007/s10461-005-1682-3
   La Pera G, 2008, J SEX MED, V5, P164, DOI 10.1111/j.1743-6109.2007.00571.x
   Levy JJ, 2006, DROGUES SANTE SOC, V5, P11, DOI DOI 10.7202/015693AR
   Mc Cay R., 2005, CAN J HUM SEX, V14, P47
   MILLER TR, 1993, J EDUC MEAS, V30, P107, DOI 10.1111/j.1745-3984.1993.tb01069.x
   Montero I, 2007, INT J CLIN HLTH PSYC, V7, P847
   Morokoff PJ, 1997, J PERS SOC PSYCHOL, V73, P790, DOI 10.1037/0022-3514.73.4.790
   Nunnally J.C., 1995, PSYCHOMETRIC THEORY
   OLEARY MP, 1995, UROLOGY, V46, P697, DOI 10.1016/S0090-4295(99)80304-5
   Palha AP, 2008, ADV PSYCHOSOM MED, V29, P131, DOI 10.1159/000126628
   Palha AP, 2002, J SEX MARITAL THER, V28, P427, DOI 10.1080/00926230290001547
   Garcia-Portilla MP, 2011, J SEX MED, V8, P1371, DOI 10.1111/j.1743-6109.2010.02043.x
   Peugh J, 2001, J PSYCHOACTIVE DRUGS, V33, P223, DOI 10.1080/02791072.2001.10400569
   Rawson RA, 2002, J SUBST ABUSE TREAT, V22, P103, DOI 10.1016/S0740-5472(01)00215-X
   Rojas-Garcia A., 2011, TRASTORNOS ADICTIVOS, V13, P64
   Rosen RC, 1991, ANN REV SEX RES, V2, P119
   Santos-Iglesias P, 2010, INT J CLIN HLTH PSYC, V10, P553
   Smith S., 2007, PSYCHIATRY, V6, P111, DOI [10.1016/j.mppsy.2006.12.004, DOI 10.1016/J.MPPSY.2006.12.004]
   Vallejo-Medina P., 2011, MADR SPAIN 38 JORN N
   Vallejo-Medina P., 2011, ADAPTATION VALIDATIO
   Vallejo-Medina P, 2010, SEX DISABIL, V28, P105, DOI 10.1007/s11195-010-9146-8
   Vallejo-Medina P, 2009, ADICCIONES, V21, P221, DOI 10.20882/adicciones.232
NR 41
TC 5
Z9 5
U1 1
U2 9
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 0092-623X
EI 1521-0715
J9 J SEX MARITAL THER
JI J. Sex Marital Ther.
PD JUL 1
PY 2013
VL 39
IS 4
BP 368
EP 384
DI 10.1080/0092623X.2011.642493
PG 17
WC Psychology, Clinical; Family Studies
SC Psychology; Family Studies
GA 113GL
UT WOS:000316654500008
PM 23421763
DA 2018-12-27
ER

PT J
AU Lee, SL
   Chou, CC
   Chuang, HC
   Hsu, EC
   Chiu, PC
   Kulp, SK
   Byrd, JC
   Chen, CS
AF Lee, Su-Lin
   Chou, Chih-Chien
   Chuang, Hsiao-Ching
   Hsu, En-Chi
   Chiu, Po-Chen
   Kulp, Samuel K.
   Byrd, John C.
   Chen, Ching-Shih
TI RETRACTED: Functional Role of mTORC2 versus Integrin-Linked Kinase in
   Mediating Ser473-Akt Phosphorylation in PTEN-Negative Prostate and
   Breast Cancer Cell Lines (Retracted article. See vol. 13, art. e0202299,
   2018)
SO PLOS ONE
LA English
DT Article; Retracted Publication
ID EPITHELIAL-MESENCHYMAL TRANSITION; PROTEIN-KINASE; EXPRESSION INCREASES;
   AKT PHOSPHORYLATION; THERAPEUTIC TARGET; TUMOR PROGRESSION; INHIBITOR
   QLT0267; B/AKT ACTIVATION; E-CADHERIN; ILK
AB Although the rictor-mTOR complex (mTORC2) has been shown to act as phosphoinositide-dependent kinase (PDK) 2 in many cell types, other kinases have also been implicated in mediating Ser473-Akt phosphorylation. Here, we demonstrated the cell line specificity of integrin-linked kinase (ILK) versus mTORC2 as PDK2 in LNCaP and PC-3 prostate and MDA-MB-468 breast cancer cells, of which the PTEN-negative status allowed the study of Ser473-Akt phosphorylation independent of external stimulation. PC-3 and MDA-MB-468 cells showed upregulated ILK expression relative to LNCaP cells, which expressed a high abundance of mTOR. Exposure to Ku-0063794, a second-generation mTOR inhibitor, decreased Ser473-Akt phosphorylation in LNCaP cells, but not in PC-3 or MDA-MB-468 cells. In contrast, treatment with T315, a novel ILK inhibitor, reduced the phosphorylation of Ser473-Akt in PC-3 and MDA-MB-468 cells without affecting that in LNCaP cells. This cell line specificity was verified by comparing Ser473-Akt phosphorylation status after genetic knockdown of rictor, ILK, and other putative Ser-473-Akt kinases. Genetic knockdown of rictor, but not ILK or the other kinases examined, inhibited Ser473-Akt phosphorylation in LNCaP cells. Conversely, PC-3 and MDA-MB-468 cells were susceptible to the effect of ILK silencing on Ser473-Akt phosphorylation, while knockdown of rictor or any of the other target kinases had no appreciable effect. Co-immunoprecipitation analysis demonstrated the physical interaction between ILK and Akt in PC-3 cells, and T315 blocked ILK-mediated Ser473 phosphorylation of bacterially expressed Akt. ILK also formed complexes with rictor in PC-3 and MDA-MB-468 cells that were disrupted by T315, but such complexes were not observed in LNCaP cells. In the PTEN-functional MDA-MB-231 cell line, both T315 and Ku-0063794 suppressed EGF-induced Ser473-Akt phosphorylation. Inhibition of ILK by T315 or siRNA-mediated knockdown suppressed epithelial-mesenchymal transition in MDA-MB-468 and PC-3 cells. Thus, we hypothesize that ILK might bestow growth advantage and metastatic potential in the course of tumor progression.
C1 [Lee, Su-Lin; Chou, Chih-Chien; Chuang, Hsiao-Ching; Hsu, En-Chi; Chiu, Po-Chen; Kulp, Samuel K.; Byrd, John C.; Chen, Ching-Shih] Ohio State Univ, Coll Pharm, Div Med Chem, Columbus, OH 43210 USA.
   [Byrd, John C.] Ohio State Univ, Dept Internal Med, Div Hematol, Columbus, OH 43210 USA.
   [Chen, Ching-Shih] Natl Cheng Kung Univ, Inst Basic Med Sci, Tainan 70101, Taiwan.
RP Chen, CS (reprint author), Ohio State Univ, Coll Pharm, Div Med Chem, 500 W 12Th Ave, Columbus, OH 43210 USA.
EM chen.844@osu.edu
FU Public Health Service Grants from the National Cancer Institute
   [R01CA112250]; Stefanie Spielman Fund for Breast Cancer Research;
   Specialized Center of Research grant from the Leukemia and Lymphoma
   Society
FX This work was supported by Public Health Service Grants R01CA112250 from
   the National Cancer Institute, the Stefanie Spielman Fund for Breast
   Cancer Research to C. S. C, and a Specialized Center of Research grant
   from the Leukemia and Lymphoma Society to C. S. C. and J.C.B. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Abboud ER, 2007, INT J ONCOL, V30, P113
   Ahmed N, 2003, J PATHOL, V201, P229, DOI 10.1002/path.1441
   Bozulic L, 2008, MOL CELL, V30, P203, DOI 10.1016/j.molcel.2008.02.024
   Bravou V, 2006, J PATHOL, V208, P91, DOI 10.1002/path.1860
   Chan J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016984
   Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X
   Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211
   Dong LQ, 2005, AM J PHYSIOL-ENDOC M, V289, pE187, DOI 10.1152/ajpendo.00011.2005
   Edwards LA, 2005, ONCOGENE, V24, P3596, DOI 10.1038/sj.onc.1208427
   Edwards LA, 2008, MOL CANCER THER, V7, P59, DOI 10.1158/1535-7163.MCT-07-0329
   Eke I, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006434
   Esfandiarei Mitra, 2010, BMC Cell Biol, V11, P16, DOI 10.1186/1471-2121-11-16
   Evdokimova V, 2009, CANCER CELL, V15, P402, DOI 10.1016/j.ccr.2009.03.017
   Fan QW, 2011, AUTOPHAGY, V7, P536, DOI 10.4161/auto.7.5.14779
   Feng JH, 2004, J BIOL CHEM, V279, P41189, DOI 10.1074/jbc.M406731200
   Fukuda K, 2011, J BIOL CHEM, V286, P21886, DOI 10.1074/jbc.M111.240093
   Garcia-Martinez JM, 2009, BIOCHEM J, V421, P29, DOI 10.1042/BJ20090489
   Graff JR, 2001, CLIN CANCER RES, V7, P1987
   Grashoff C, 2003, EMBO REP, V4, P432, DOI 10.1038/sj.embor.embor801
   Hannigan G, 2005, NAT REV CANCER, V5, P51, DOI 10.1038/nrc1524
   Hresko RC, 2005, J BIOL CHEM, V280, P40406, DOI 10.1074/jbc.M508361200
   Huang Y, 2000, J CELL BIOL, V150, P861, DOI 10.1083/jcb.150.4.861
   Ishii T, 2001, J BIOL CHEM, V276, P42994, DOI 10.1074/jbc.M105198200
   Ito R, 2003, VIRCHOWS ARCH, V442, P118, DOI 10.1007/s00428-002-0718-6
   Jacobs Keith M, 2012, Int J Cell Biol, V2012, P930710, DOI 10.1155/2012/930710
   Kalra J, 2010, ONCOGENE, V29, P6343, DOI 10.1038/onc.2010.366
   Kalra J, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2252
   Kawakami Y, 2004, J BIOL CHEM, V279, P47720, DOI 10.1074/jbc.M408797200
   Koblinski JE, 2005, CANCER RES, V65, P7370, DOI 10.1158/0008-5472.CAN-05-0807
   Koul D, 2005, MOL CANCER THER, V4, P1681, DOI 10.1158/1535-7163.MCT-05-0258
   Lange A, 2009, NATURE, V461, P1002, DOI 10.1038/nature08468
   Lasham A, 2012, J NATL CANCER I, V104, P133, DOI 10.1093/jnci/djr512
   Lee SL, 2011, J MED CHEM, V54, P6364, DOI 10.1021/jm2007744
   Legate KR, 2006, NAT REV MOL CELL BIO, V7, P20, DOI 10.1038/nrm1789
   Leung-Hagesteijn C, 2005, MOL CELL BIOL, V25, P3648, DOI 10.1128/MCB.25.9.3648-3657.2005
   Lorenz K, 2007, J CELL BIOL, V177, P501, DOI 10.1083/jcb.200608125
   Lynch DK, 1999, ONCOGENE, V18, P8024
   McDonald PC, 2008, J CELL SCI, V121, P3121, DOI 10.1242/jcs.017996
   McDonald PC, 2008, CANCER RES, V68, P1618, DOI 10.1158/0008-5472.CAN-07-5869
   Mora A, 2004, SEMIN CELL DEV BIOL, V15, P161, DOI 10.1016/j.semcdb.2003.12.022
   Muranyi AL, 2009, EXP HEMATOL, V37, P450, DOI 10.1016/j.exphem.2009.01.002
   Partovian C, 2004, CELL SIGNAL, V16, P951, DOI 10.1016/j.cellsig.2004.01.008
   Pereira JA, 2009, J CELL BIOL, V185, P147, DOI 10.1083/jcb.200809008
   Persad S, 2000, P NATL ACAD SCI USA, V97, P3207, DOI 10.1073/pnas.060579697
   Persad S, 2003, CANCER METAST REV, V22, P375, DOI 10.1023/A:1023777013659
   Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200
   Pontier SM, 2010, ONCOGENE, V29, P3374, DOI 10.1038/onc.2010.86
   Riaz A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032081
   Sakai T, 2003, GENE DEV, V17, P926, DOI 10.1101/gad.255603
   Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148
   Sawai H, 2006, ONCOGENE, V25, P3237, DOI 10.1038/sj.onc.1209356
   Schaeffer DF, 2010, VIRCHOWS ARCH, V456, P261, DOI 10.1007/s00428-009-0866-z
   Serrano I, 2013, ONCOGENE, V32, P50, DOI 10.1038/onc.2012.30
   Stratford AL, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1767
   Su JL, 2010, J BIOL CHEM, V285, P31325, DOI 10.1074/jbc.M109.087122
   Tabe Y, 2007, CANCER RES, V67, P684, DOI 10.1158/0008-5472.CAN-06-3166
   Troussard AA, 2003, J BIOL CHEM, V278, P22374, DOI 10.1074/jbc.M303083200
   Troussard AA, 2006, CANCER RES, V66, P393, DOI 10.1158/0008-5472.CAN-05-2304
   Viniegra JG, 2005, J BIOL CHEM, V280, P4029, DOI 10.1074/jbc.M410344200
   Wang HV, 2008, J CELL BIOL, V180, P1037, DOI 10.1083/jcb.200707175
   Wang L, 2004, J BIOL CHEM, V279, P32444, DOI 10.1074/jbc.M313963200
   White DE, 2001, ONCOGENE, V20, P7064, DOI 10.1038/sj.onc.1204910
   White DE, 2006, GENE DEV, V20, P2355, DOI 10.1101/gad.1458906
   Wickstrom SA, 2010, EMBO J, V29, P281, DOI 10.1038/emboj.2009.376
   Younes MN, 2007, ARCH OTOLARYNGOL, V133, P15, DOI 10.1001/archotol.133.1.15
   Younes MN, 2005, MOL CANCER THER, V4, P1146, DOI 10.1158/1535-7163.MCT-05-0078
   Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173
NR 67
TC 22
Z9 23
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 19
PY 2013
VL 8
IS 6
AR e67149
DI 10.1371/journal.pone.0067149
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 190ST
UT WOS:000322361200121
PM 23840605
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Nandakumar, KS
   Collin, M
   Happonen, KE
   Croxford, AM
   Lundstrom, SL
   Zubarev, RA
   Rowley, MJ
   Blom, AM
   Holmdahl, R
AF Nandakumar, Kutty Selva
   Collin, Mattias
   Happonen, Kaisa E.
   Croxford, Allyson M.
   Lundstrom, Susanna L.
   Zubarev, Roman A.
   Rowley, Merrill J.
   Blom, Anna M.
   Holmdahl, Rikard
TI RETRACTED: Dominant suppression of inflammation by glycan-hydrolyzed IgG
   (Retracted article. See vol. 111, pg. 15851, 2014)
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article; Retracted Publication
DE collagen; endoglycosidase; glycosylation; monoclonal antibody;
   rheumatoid arthritis
ID CIRCULATING IMMUNE-COMPLEXES; II COLLAGEN; RHEUMATOID-ARTHRITIS;
   MONOCLONAL-ANTIBODY; ANTIINFLAMMATORY ACTIVITY; CRYSTAL-STRUCTURE; FC;
   GLYCOSYLATION; IMMUNOGLOBULIN; RECEPTOR
AB A unique anti-inflammatory property of IgG, independent of antigen specificity, is described. IgG with modification of the heavy-chain glycan on asparagine 297 by the streptococcal enzyme endo-beta-N-acetylglucosaminidase (EndoS) induced a dominant suppression of immune complex (IC)-mediated inflammation, such as arthritis, through destabilization of local ICs by fragment crystallizable-fragment crystallizable (Fc-Fc) interactions. Small amounts (250 mu g) of EndoS-hydrolyzed IgG were sufficient to inhibit arthritis in mice and most effective during the formation of ICs in the target tissue. The presence of EndoS-hydrolyzed IgG disrupted larger IC lattice formation both in vitro and in vivo, as visualized with anti-C3b staining. Neither complement binding in vitro nor antigen-antibody binding per se was affected.
C1 [Nandakumar, Kutty Selva; Holmdahl, Rikard] Karolinska Inst, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden.
   [Lundstrom, Susanna L.; Zubarev, Roman A.] Karolinska Inst, Dept Med Biochem & Biophys, Chem Div 1, S-17177 Stockholm, Sweden.
   [Collin, Mattias] Lund Univ, Dept Clin Sci, Div Infect Med, S-22184 Lund, Sweden.
   [Happonen, Kaisa E.; Blom, Anna M.] Lund Univ, Dept Lab Med Malmo, S-20502 Malmo, Sweden.
   [Croxford, Allyson M.; Rowley, Merrill J.] Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3800, Australia.
RP Nandakumar, KS (reprint author), Karolinska Inst, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden.
EM Nandakumar.Kutty-Selva@ki.se
RI Collin, Mattias/C-6398-2009; Nandakumar, Kutty Selva/D-5438-2011; Blom,
   Anna/B-9607-2009
OI Collin, Mattias/0000-0002-6166-7410; Nandakumar, Kutty
   Selva/0000-0001-7790-8197; Blom, Anna/0000-0002-1348-1734; Lundstrom,
   Susanna/0000-0003-2363-4287; Happonen, Kaisa/0000-0002-8346-6302
FU King Gustaf V:s 80 Years Foundation; Swedish Rheumatism Association; Ake
   Wiberg; Swedish Society for Medicine; Royal Physiografic Society in
   Lund; Medical Faculty at Lund University; Swedish governmental; Swedish
   Research Council [2009-2338, 2010-57X-20240, K2012-66X-14928-09-5];
   European Union [HEALTH-F2-2008-223404]; National Health and Medical
   Research Council of Australia
FX We thank Dr. Rajesh Ponnusamy for his help in measuring the sizes of ICs
   by DLS, Emma Mondoc for performing histology, and Carlos Palestro for
   taking care of animals. This study was supported by grants from King
   Gustaf V:s 80 Years Foundation, Swedish Rheumatism Association, Ake
   Wiberg, Alfred Osterlund, Petrus and Augusta Hedlund, Clas Groschinsky,
   Torsten och Ragnar Soderberg, the Swedish Society for Medicine, the
   Royal Physiografic Society in Lund, the Medical Faculty at Lund
   University, Swedish governmental funding for clinical research (A.L.F.),
   Hansa Medical AB, Swedish Research Council Grants 2009-2338,
   2010-57X-20240, and K2012-66X-14928-09-5, European Union MasterSwitch
   project Grant HEALTH-F2-2008-223404, and the National Health and Medical
   Research Council of Australia, an Arthritis Australia Project grant.
CR Albert H, 2008, P NATL ACAD SCI USA, V105, P15005, DOI 10.1073/pnas.0808248105
   Amirahmadi SF, 2004, IMMUNOL CELL BIOL, V82, P427, DOI 10.1111/j.1440-1711.2004.01267.x
   Anthony RM, 2011, NATURE, V475, P110, DOI 10.1038/nature10134
   Anthony RM, 2008, P NATL ACAD SCI USA, V105, P19571, DOI 10.1073/pnas.0810163105
   Barb AW, 2011, NAT CHEM BIOL, V7, P147, DOI 10.1038/NCHEMBIO.511
   COCHRANE CG, 1968, J EXP MED, V127, P137, DOI 10.1084/jem.127.1.137
   Collin M, 2001, EMBO J, V20, P3046, DOI 10.1093/emboj/20.12.3046
   COSIO FG, 1987, J IMMUNOL, V138, P2587
   DEISENHOFER J, 1981, BIOCHEMISTRY-US, V20, P2361, DOI 10.1021/bi00512a001
   EASTERBROOKSMITH SB, 1988, MOL IMMUNOL, V25, P1331, DOI 10.1016/0161-5890(88)90048-X
   Ferrara C, 2011, P NATL ACAD SCI USA, V108, P12669, DOI 10.1073/pnas.1108455108
   HOLMDAHL R, 1991, AUTOIMMUNITY, V10, P27, DOI 10.3109/08916939108997144
   Kaneko Y, 2006, SCIENCE, V313, P670, DOI 10.1126/science.1129594
   Karsten CM, 2012, IMMUNOBIOLOGY, V217, P1067, DOI 10.1016/j.imbio.2012.07.015
   Kolenko P, 2009, IMMUNOLOGY, V126, P378, DOI 10.1111/j.1365-2567.2008.02904.x
   Long YY, 2011, J MOL RECOGNIT, V24, P619, DOI 10.1002/jmr.1097
   Lood C, 2012, ARTHRITIS RHEUM-US, V64, P2698, DOI 10.1002/art.34454
   MAGEED RA, 1991, ANN RHEUM DIS, V50, P231, DOI 10.1136/ard.50.4.231
   Mimura Y, 2000, MOL IMMUNOL, V37, P697, DOI 10.1016/S0161-5890(00)00105-X
   MOLLER NPH, 1979, IMMUNOLOGY, V38, P631
   Mullazehi M, 2006, ARTHRITIS RHEUM-US, V54, P1759, DOI 10.1002/art.21892
   Nandakumar KS, 2003, AM J PATHOL, V163, P1827, DOI 10.1016/S0002-9440(10)63542-0
   Nandakumar KS, 2007, EUR J IMMUNOL, V37, P2973, DOI 10.1002/eji.200737581
   PAREKH RB, 1985, NATURE, V316, P452, DOI 10.1038/316452a0
   Rantapaa-Dahlqvist S, 2003, ARTHRITIS RHEUM, V48, P2741, DOI 10.1002/art.11223
   Sadik CD, 2012, P NATL ACAD SCI USA, V109, pE3177, DOI 10.1073/pnas.1213797109
   Sjoberg AP, 2007, J BIOL CHEM, V282, P10894, DOI 10.1074/jbc.M610256200
   Uysal H, 2008, MOL IMMUNOL, V45, P2196, DOI 10.1016/j.molimm.2007.12.005
   WOOLEY PH, 1984, MAYO CLIN PROC, V59, P737, DOI 10.1016/S0025-6196(12)65583-9
NR 29
TC 14
Z9 14
U1 2
U2 20
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JUN 18
PY 2013
VL 110
IS 25
BP 10252
EP 10257
DI 10.1073/pnas.1301480110
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 179DU
UT WOS:000321500200054
PM 23671108
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Yang, NJ
   Gao, F
   Nebel, CE
AF Yang, Nianjun
   Gao, Fang
   Nebel, Christoph E.
TI RETRACTED: Diamond Decorated with Copper Nanoparticles for
   Electrochemical Reduction of Carbon Dioxide (Retracted article. See vol.
   85, pg. 11159, 2013)
SO ANALYTICAL CHEMISTRY
LA English
DT Article; Retracted Publication
ID BORON-DOPED DIAMOND; IONIC LIQUID BMIMBF4; CO2 REDUCTION;
   ELECTROCATALYTIC REDUCTION; PLATINUM NANOPARTICLES; HIGH-PRESSURE;
   ELECTRODES; HYDROCARBONS; VOLTAMMETRY; CHEMISTRY
AB Electrochemical CO2 reduction has been investigated on a planar diamond electrode in aqueous and nonaqueous solutions. On a diamond electrode decorated with copper nanoparticles, CO2 reduction starts from -0.1 V versus a normal hydrogen electrode (NHE) when a mixture of water and ionic liquid ([H2O] = 10 mu M) is used. The current density reaches 5.1 +/- 0.1 mA cm(-2) for CO2 reduction at a potential of -1.3 V versus NHE. The main products are formic acid and formaldehyde. Moreover, the electrode system is stable and has a long lifetime. It is thus promising to be applied in the future for mass production of industrial chemicals and liquid fuels using CO2 as the source of raw material.
C1 [Yang, Nianjun; Gao, Fang; Nebel, Christoph E.] Fraunhofer Inst Appl Solid State Phys IAF, D-79108 Freiburg, Germany.
RP Yang, NJ (reprint author), Fraunhofer Inst Appl Solid State Phys IAF, Tullastr 72, D-79108 Freiburg, Germany.
EM nianjun.yang@iaf.fraunhofer.de
OI Yang, Nianjun/0000-0002-5558-2314
FU European Union Council under the project "MACTON" [238201]
FX The authors thank Dr. Waldemar Smirnov for helping the preparation of
   diamond electrodes, Dr. Guohua Zhao for assisting with GC-HPLC
   measurements, and the financial support from the European Union Council
   under the project "MACTON" (238201).
CR Bara JE, 2010, ACCOUNTS CHEM RES, V43, P152, DOI 10.1021/ar9001747
   Barton EE, 2008, J AM CHEM SOC, V130, P6342, DOI 10.1021/ja0776327
   Brillas E., 2011, DIAMOND
   Brulle T, 2011, PHYS CHEM CHEM PHYS, V13, P12883, DOI 10.1039/c1cp20852g
   Centi G, 2010, CATAL TODAY, V150, P151, DOI 10.1016/j.cattod.2009.09.009
   Chen Y., 2012, J AM CHEM SOC, V134, P1986
   Feng QJ, 2012, APPL SURF SCI, V258, P5005, DOI 10.1016/j.apsusc.2012.01.030
   Fujishima A., 2005, DIAMOND ELECTROCHEMI
   Funer M, 1998, APPL PHYS LETT, V72, P1149, DOI 10.1063/1.120997
   Gao F, 2013, ELECTROCHIM ACTA, V90, P445, DOI 10.1016/j.electacta.2012.12.050
   Gattrell M, 2006, J ELECTROANAL CHEM, V594, P1, DOI 10.1016/j.jelechem.2006.05.013
   Hara K, 1997, J ELECTROANAL CHEM, V421, P1, DOI 10.1016/S0022-0728(96)01028-5
   Hirota K, 1998, J PHYS CHEM B, V102, P9834, DOI 10.1021/jp9822945
   HORI Y, 1989, J CHEM SOC FARAD T 1, V85, P2309, DOI 10.1039/f19898502309
   Hori Y, 2008, MOD ASP ELECTROCHEM, P89
   HORI Y, 1983, J ELECTROCHEM SOC, V130, P2387, DOI 10.1149/1.2119593
   Hori Y., 1986, CHEM LETT, V897
   Hori Y., 1985, CHEM LETT, V1695
   Kuhl KP, 2012, ENERG ENVIRON SCI, V5, P7050, DOI 10.1039/c2ee21234j
   Li CW, 2012, J AM CHEM SOC, V134, P7231, DOI 10.1021/ja3010978
   Li WZ, 2010, ACS SYM SER, V1056, P55
   Martin HB, 1999, J ELECTROCHEM SOC, V146, P2959, DOI 10.1149/1.1392035
   McCreery RL, 2008, CHEM REV, V108, P2646, DOI 10.1021/cr068076m
   Nebel C. E., 2004, SEMICONDUCTORS AND S, V77
   Rees NV, 2011, ENERG ENVIRON SCI, V4, P403, DOI 10.1039/c0ee00580k
   Rosen BA, 2011, SCIENCE, V334, P643, DOI 10.1126/science.1209786
   Snuffin LL, 2011, J ELECTROCHEM SOC, V158, pF155, DOI 10.1149/1.3606487
   Song Y, 2007, ANAL CHEM, V79, P2412, DOI 10.1021/ac061543f
   Spataru N, 2003, J APPL ELECTROCHEM, V33, P1205, DOI 10.1023/B:JACH.0000003866.85015.b6
   Sullivan B. P., 1993, CARBON
   Szunerits S, 2008, J SOLID STATE ELECTR, V12, P1205, DOI 10.1007/s10008-007-0473-3
   Tomita Y, 2000, J ELECTROCHEM SOC, V147, P4164, DOI 10.1149/1.1394035
   VASSILIEV YB, 1985, J ELECTROANAL CHEM, V189, P295, DOI 10.1016/0368-1874(85)80074-5
   Waldvogel SR, 2012, ELECTROCHIM ACTA, V82, P434, DOI 10.1016/j.electacta.2012.03.173
   Waldvogel SR, 2012, TOP CURR CHEM, V320, P1, DOI 10.1007/128_2011_125
   Wang H, 2007, ELECTROCHEM COMMUN, V9, P2235, DOI 10.1016/j.elecom.2007.06.031
   Wang J., 2003, ELECTROCHEM SOC, V150, pE24
   Whipple DT, 2010, J PHYS CHEM LETT, V1, P3451, DOI 10.1021/jz1012627
   Yang H. Z., 2002, CHEM COMMUN, V274
   Yao SA, 2012, J AM CHEM SOC, V134, P15632, DOI 10.1021/ja304783j
   Zhong YL, 2010, CHEM-ASIAN J, V5, P1532, DOI 10.1002/asia.201000027
NR 41
TC 15
Z9 16
U1 2
U2 185
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0003-2700
EI 1520-6882
J9 ANAL CHEM
JI Anal. Chem.
PD JUN 18
PY 2013
VL 85
IS 12
BP 5764
EP 5769
DI 10.1021/ac400377y
PG 6
WC Chemistry, Analytical
SC Chemistry
GA 169AL
UT WOS:000320749200024
PM 23713706
DA 2018-12-27
ER

PT J
AU Wang, LS
   Zang, WD
   Sang, YX
   Xie, DL
   Wei, L
   Ji, WD
   Pan, YS
   Li, ZQ
   Shen, JW
   Shi, YY
AF Wang, Lishan
   Zang, Weidong
   Sang, Yunxia
   Xie, Dongli
   Wei, Li
   Ji, Weidong
   Pan, Yaosheng
   Li, Zhiqiang
   Shen, Jiawei
   Shi, Yongyong
TI RETRACTED: Association of Polymorphism rs198977 in Human Kallikrein-2
   Gene (KLK2) with Susceptibility of Prostate Cancer: A Meta-Analysis
   (Retracted article. See vol. 11, e0160298, 2016)
SO PLOS ONE
LA English
DT Article; Retracted Publication
ID ANTIGEN; RISK; METAANALYSIS; MARKERS; BIOPSY; FAMILY; TISSUE; HK2
AB Objectives: To assess the association of polymorphism rs198977 in the human kallikrein-2 gene (KLK2) and risk of prostate cancer (PCa).
   Methods: Two investigators independently searched the PubMed, Elsevier, EMBASE, Web of Science, Wiley Online Library and Chinese National Knowledge Infrastructure (CNKI). Pooled odds ratios (ORs) and 95% confidence intervals (95% CIs) for rs198977 and PCa were calculated in a fixed-effects model (the Mantel-Haenszel method) and a random-effects model (the DerSimonian and Laird method) when appropriate.
   Results: Six studies met the inclusion criteria in this meta-analysis, which included 5859 PCa cases and 4867 controls. Overall, rs198977 was associated with the PCa risk (TT+CT vs. CC, pooled OR = 1.163, 95% CI = 1.076-1.258, P-value <0.0001). When stratified by ethnicity, significant association was observed in Caucasian samples under both allele comparison (T vs. C, pooled OR = 1.152, 95% CI = 1.079-1.229, P-value <0.0001) and dominant model (TT+CT vs. CC, pooled OR = 1.197, 95% CI = 1.104-1.297, P-value <0.0001). In the overall analysis, a comparably significant increase in the frequency of allele T for rs198977 was detected between cases and controls in Caucasian.
   Conclusion: This meta-analysis suggests that rs198977 of KLK2 was associated with susceptibility of PCa in Caucasian and the allele T might increase the risk of PCa in Caucasian.
C1 [Wang, Lishan; Ji, Weidong; Pan, Yaosheng; Li, Zhiqiang; Shen, Jiawei; Shi, Yongyong] Shanghai Jiao Tong Univ, Bio X Inst, Key Lab Genet Dev & Neuropsychiat Disorders, Minist Educ, Shanghai 200030, Peoples R China.
   [Wang, Lishan; Zang, Weidong; Xie, Dongli; Wei, Li] FengHe ShangHai Informat Technol Co Ltd, Shanghai, Peoples R China.
   [Sang, Yunxia] Shanghai Jiao Tong Univ, Coll Pharm, Shanghai 200030, Peoples R China.
   [Ji, Weidong; Pan, Yaosheng; Shi, Yongyong] Shanghai Changning Mental Hlth Ctr, Shanghai, Peoples R China.
   [Ji, Weidong; Pan, Yaosheng; Shi, Yongyong] Shanghai Jiao Tong Univ, Inst Neuropsychiat Sci & Syst Biol Med, Shanghai 200030, Peoples R China.
RP Shi, YY (reprint author), Shanghai Jiao Tong Univ, Bio X Inst, Key Lab Genet Dev & Neuropsychiat Disorders, Minist Educ, Shanghai 200030, Peoples R China.
EM shiyongysyysyy@hotmail.com
FU Fenghe (ShangHai) Information Technology Co.
FX The authors named Lishan Wang, Weidong Zang, Dongli Xie and Li Wei are
   employed by Fenghe (ShangHai) Information Technology Co., whose company
   provided funding towards this study. There are no patents, products in
   development or marketed products to declare. This does not alter the
   authors' adherence to all the PLOS ONE policies on sharing data and
   materials.
CR Ahn J, 2008, NAT GENET, V40, P1032, DOI 10.1038/ng0908-1032
   CATALONA WJ, 1993, JAMA-J AM MED ASSOC, V270, P948, DOI 10.1001/jama.270.8.948
   CATALONA WJ, 1994, J UROLOGY, V152, P2031, DOI 10.1016/S0022-5347(17)32299-1
   Chiang CH, 2005, J UROLOGY, V173, P429, DOI 10.1097/01.ju.0000148964.92943.39
   Diamandis EP, 2000, TRENDS ENDOCRIN MET, V11, P54, DOI 10.1016/S1043-2760(99)00225-8
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Jemal A, 2010, CA-CANCER J CLIN, V60, P277, DOI [10.1002/caac.20073, 10.3322/caac.20073]
   Klein RJ, 2010, CANCER PREV RES, V3, P611, DOI 10.1158/1940-6207.CAPR-09-0206
   Langeberg WJ, 2007, FRONT BIOSCI-LANDMRK, V12, P4101, DOI 10.2741/2374
   Lichtenstein P, 2000, NEW ENGL J MED, V343, P78, DOI 10.1056/NEJM200007133430201
   Light R. J., 1984, SUMMING SCI REV RES
   Lintula S, 2005, PROSTATE, V63, P324, DOI 10.1002/pros.20194
   Mikolajczyk SD, 1999, INT J CANCER, V81, P438, DOI 10.1002/(SICI)1097-0215(19990505)81:3<438::AID-IJC18>3.0.CO;2-U
   Mittal RD, 2007, STEROIDS, V72, P335, DOI 10.1016/j.steroids.2006.12.004
   Nam RK, 2005, CLIN CANCER RES, V11, P8391, DOI 10.1158/1078-0432.CCR-05-1226
   Nam RK, 2003, J CLIN ONCOL, V21, P2312, DOI 10.1200/JCO.2003.11.007
   Nam RK, 2006, CLIN CANCER RES, V12, P6452, DOI 10.1158/1078-0432.CCR-06-1485
   Nogueira L, 2010, BJU INT, V105, P166, DOI 10.1111/j.1464-410X.2009.09088.x
   Partin AW, 1999, UROLOGY, V54, P839, DOI 10.1016/S0090-4295(99)00270-8
   REIGMAN PHJ, 1989, BIOCHEM BIOPH RES CO, V159, P95, DOI 10.1016/0006-291X(89)92409-1
   Shariat SF, 2011, ACTA ONCOL, V50, P61, DOI 10.3109/0284186X.2010.542174
   Siegel R, 2011, CA-CANCER J CLIN, V61, P212, DOI 10.3322/caac.20121
   Tremblay RR, 1997, AM J PATHOL, V150, P455
   Williams SA, 2010, PROSTATE, V70, P788, DOI 10.1002/pros.21111
   Yousef GM, 1999, ANTICANCER RES, V19, P2843
   Yousef GM, 2001, ENDOCR REV, V22, P184, DOI 10.1210/er.22.2.184
NR 27
TC 1
Z9 1
U1 1
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 18
PY 2013
VL 8
IS 6
AR e65651
DI 10.1371/journal.pone.0065651
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 166SA
UT WOS:000320576400017
PM 23824286
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Khaki, F
   Javanbakht, J
   Sasani, F
   Gharagozlou, MJ
   Bahrami, A
   Moslemzadeh, H
   Sheikhzadeh, R
AF Khaki, Fariba
   Javanbakht, Javad
   Sasani, Farhang
   Gharagozlou, Mohammad Javad
   Bahrami, Alimohammad
   Moslemzadeh, Hemmat
   Sheikhzadeh, Reza
TI RETRACTED: Cervical type AB thymoma (Mixed) tumour diagnosis in a mynah
   as a model to study human: clinicohistological, immunohistochemical and
   cytohistopathological study(Retracted article. See vol. 11, 2016)
SO DIAGNOSTIC PATHOLOGY
LA English
DT Article; Retracted Publication
DE Thymoma; Lymphocytic type; Diagnosis; Mynah; Neck
ID THYMIC EPITHELIAL TUMORS; FINE-NEEDLE-ASPIRATION;
   DIFFERENTIAL-DIAGNOSIS; CLASSIFICATION; CARCINOMA; FEATURES; DOGS
AB Thymoma is a primary mediastinal neoplasm arising from or exhibiting differentiation towards thymic epithelial cells, typically with the presence of non-neoplastic lymphocytes. A 13-year-old male Mynah bird (acridotheres tristis) was presented for evaluation of a 2.3 x 1.5 x 1.0 cm mass in the left ventrolateral cervical region. The clinical signs, radiology, cytohistopathology and immunohistochimy findings related to the thymoma are presented. These findings indicated that the tumor was a type AB thymoma according to the World Health Organization (WHO) and veterinary classification. Thymomas are rarely reported in avian species and this is the first report in a Mynah bird.
C1 [Khaki, Fariba; Javanbakht, Javad; Sasani, Farhang; Gharagozlou, Mohammad Javad] Univ Tehran, Dept Pathol, Fac Vet Med, Tehran, Iran.
   [Bahrami, Alimohammad] Univ Ilam, Fac Para Vet Med, Ilam, Iran.
   [Moslemzadeh, Hemmat] Urmia Univ, Fac Vet Med, Orumiyeh, Iran.
   [Sheikhzadeh, Reza] Teharn Univ, Fac Vet Med, Tehran, Iran.
RP Javanbakht, J (reprint author), Univ Tehran, Dept Pathol, Fac Vet Med, Tehran, Iran.
EM javadjavanbakht@ut.ac.ir
CR Alexiev BA, 2007, DIAGN PATHOL, V2, DOI 10.1186/1746-1596-2-13
   Ali SZ, 1998, ACTA CYTOL, V42, P845, DOI 10.1159/000331958
   ARONSOHN MG, 1984, J AM VET MED ASSOC, V184, P1355
   CAMPBELL JG, 1966, J PATHOL BACTERIOL, V92, P77, DOI 10.1002/path.1700920110
   Catherine A, 1989, CAN VET J, V35, P342
   Chen G, 2002, CANCER, V95, P420, DOI 10.1002/cncr.10665
   Day MJ, 1997, J SMALL ANIM PRACT, V38, P393, DOI 10.1111/j.1748-5827.1997.tb03492.x
   DEMINATTI MM, 1994, ANN GENET-PARIS, V37, P72
   Diaz-Figueroa O, 2004, J AVIAN MED SURG, V18, P51
   Feldman WH, 1936, AM J CANC, V26, P576
   FRANCIS D, 1971, J PATHOL, V103, P188, DOI 10.1002/path.1711030308
   Hodges RD, 1974, HISTOLOGY FOWL, P213
   JACKSON C, 1936, ONDERSTEPOORT J VET, V6, P199
   Jacobs R. M., 2002, Tumors in domestic animals, P119, DOI 10.1002/9780470376928.ch3
   KIRCHNER T, 1992, AM J SURG PATHOL, V16, P1153, DOI 10.1097/00000478-199212000-00003
   Kirchner T, 1989, PROGR SURGICAL PATHO, V10, P167
   Ma YQ, 2012, DIAGN PATHOL, V7, DOI 10.1186/1746-1596-7-120
   MAEDA H, 1994, AVIAN PATHOL, V23, P353, DOI 10.1080/03079459408419003
   MARINO M, 1985, VIRCHOWS ARCH A, V407, P119, DOI 10.1007/BF00737071
   Marx A, 1999, PATHOL RES PRACT, V195, P515, DOI 10.1016/S0344-0338(99)80001-6
   MOMOTANI E, 1981, AM J VET RES, V42, P114
   Moulton JE, 1990, TUMORS DOMESTIC ANIM, P267
   NAYLOR DC, 1988, J COMP PATHOL, V99, P187, DOI 10.1016/0021-9975(88)90071-0
   Okumura M, 2002, CANCER-AM CANCER SOC, V94, P624, DOI 10.1002/cncr.10226
   Patnaik AK, 2003, J FELINE MED SURG, V5, P27, DOI 10.1000/jfms.2002.0187
   Pellegrini N., 1961, Ann. Fac. Med. vet. Pisa, V14, P73
   QUINTANILLAMARTINEZ L, 1993, HUM PATHOL, V24, P958, DOI 10.1016/0046-8177(93)90109-T
   RIAZMONTAZER N, 1992, ACTA CYTOL, V36, P387
   Rieker RJ, 2007, DIAG PATHO, V2, P3
   ROSAI J, 1999, HISTOLOGICAL TYPING, P9
   Rosai J, 1999, HISTOLOGICAL TYPING
   Saro J, 2011, ONCOL LETT, V2, P1025, DOI 10.3892/ol.2011.383
   Sasaki H, 2002, INT J CANCER, V101, P342, DOI 10.1002/ijc.10624
   Shin HJC, 1998, ACTA CYTOL, V42, P855, DOI 10.1159/000331959
   TAO LC, 1984, ACTA CYTOL, V28, P165
   Zettl A, 2000, AM J PATHOL, V157, P257, DOI 10.1016/S0002-9440(10)64536-1
   ZUBAIDY AJ, 1980, AVIAN PATHOL, V9, P575, DOI 10.1080/03079458008418445
NR 37
TC 9
Z9 9
U1 2
U2 6
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1746-1596
J9 DIAGN PATHOL
JI Diagn. Pathol.
PD JUN 18
PY 2013
VL 8
AR 98
DI 10.1186/1746-1596-8-98
PG 7
WC Pathology
SC Pathology
GA 177NZ
UT WOS:000321383300001
PM 23777537
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Wang, XY
   Hao, JW
   Zhou, RJ
   Zhang, XS
   Yan, TZ
   Ding, DG
   Shan, L
   Liu, ZH
AF Wang, Xiangyang
   Hao, Jianwei
   Zhou, Ruijin
   Zhang, Xiangsheng
   Yan, Tianzhong
   Ding, Degang
   Shan, Lei
   Liu, Zhonghua
TI RETRACTED: Collecting duct carcinoma of the kidney: a
   clinicopathological study of five cases (Retracted article. See vol. 10,
   15, 2015)
SO DIAGNOSTIC PATHOLOGY
LA English
DT Article; Retracted Publication
DE Renal tumor; Collecting duct carcinoma; Diagnosis; Pathology
ID RENAL-CELL CARCINOMA; MEDULLARY CARCINOMA; SUBTYPES; TUMOR; CT
AB Objective: To investigate the clinicopathological features of collecting duct carcinoma (CDC) and improve its diagnosis and treatment.
   Methods: A retrospective analysis was performed with clinical data including follow-up results of five patients with CDC.
   Results: A total of 5 cases, including 4 males and 1 female, were included in this analysis with the average age 54 years (range 42 to 65). Patients mainly suffered from lumbar pain, hematuria, abdominal mass and low grade fever. Four patients underwent radical nephrectomy while another received palliative nephrectomy. Lymph node metastasis occurred in 3 cases and renal hilum fat metastasis happened to 2 other cases. Tumors was located in the renal medulla and presented invasive growth. They had a tubulopapillary architecture with the hobnail-shaped cells protruding into the glandular lumen, and were accompanied by interstitial fibrosis and dysplasia of epithelial cells in collecting ducts adjacent to the tumors. One tumor was staged at AJCC II, two at AJCC III and two at AJCC IV. Postoperative interferon immunotherapy was applied in 2 cases. Patients were followed up for 5 to 18 months and the average survival time was 10 months.
   Conclusion: The CDC exhibits special clinicopathological features, high degree of malignancy and poor prognosis. The diagnosis depends on the histopathological examination. Early detection and early surgical treatment are still the main methods to improve the prognosis of patients with CDC.
   Virtual Slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/3702794279387989
C1 [Wang, Xiangyang; Hao, Jianwei; Zhou, Ruijin; Zhang, Xiangsheng; Yan, Tianzhong; Ding, Degang; Shan, Lei; Liu, Zhonghua] Henan Prov Peoples Hosp, Dept Urol, Zhengzhou 450003, Peoples R China.
RP Hao, JW (reprint author), Henan Prov Peoples Hosp, Dept Urol, Zhengzhou 450003, Peoples R China.
EM haojianwei45@hotmail.com
CR [Anonymous], 2011, World J Surg Oncol, V9, P136, DOI 10.1186/1477-7819-9-136
   Bansal P, 2012, SAUDI J KIDNEY DIS T, V23, P810, DOI 10.4103/1319-2442.98166
   Chao D, 2002, J UROLOGY, V167, P71, DOI 10.1016/S0022-5347(05)65385-2
   Coogan CL, 1998, UROLOGY, V51, P1049, DOI 10.1016/S0090-4295(98)00104-6
   DAVIS CJ, 1995, AM J SURG PATHOL, V19, P1, DOI 10.1097/00000478-199501000-00001
   Del Sordo R, 2012, HUM PATHOL, V43, P1153, DOI 10.1016/j.humpath.2012.03.004
   DIMOPOULOS MA, 1993, BRIT J UROL, V71, P388, DOI 10.1111/j.1464-410X.1993.tb15978.x
   el Tazi M, 2011, WORLD J SURG ONCOL, V9, P73
   Gabriela Q-G, 2012, DIAGN PATHOL, V7, P21
   Husillos A, 2011, ACTAS UROL ESP, V35, P368, DOI 10.1016/j.acuro.2011.01.012
   Kim JK, 2002, AM J ROENTGENOL, V178, DOI 10.2214/ajr.178.6.1781499
   Leos K, 2012, DIAGN PATHOL, V7, P58
   Li BK, 2012, CUAJ-CAN UROL ASSOC, V6, pE97, DOI 10.5489/cuaj.11087
   Li M, 2001, MODERN PATHOL, V14, P623, DOI 10.1038/modpathol.3880361
   Ling Z, 2012, DIAGN PATHOL, V7, P77
   Lopez- Beltran A, 2004, EUR UROL, V2006, P798
   Ludwig BC, 2012, DIAGN PATHOL, V7, DOI 10.1186/1746-1596-7-95
   Miyake H, 2011, INT J CLIN ONCOL, V16, P153, DOI 10.1007/s10147-010-0116-z
   Orsola A, 2005, UROLOGY, V65, P49, DOI 10.1016/j.urology.2004.08.012
   Peyromaure M, 2003, J UROLOGY, V170, P1138, DOI 10.1097/01.ju.00000866106.40603.ad
   Singh Iqbal, 2002, International Urology and Nephrology, V34, P91, DOI 10.1023/A:1021315130481
   Tokuda N, 2006, J UROLOGY, V176, P40, DOI 10.1016/S0022-5347(06)00502-7
   Tsan-Yu H, 2011, DIAGN PATHOL, V6, P96
   Verdorfer I, 1998, INT J ONCOL, V13, P461
   Yang GE, 2012, CLIN RADIOL, V67, P936, DOI 10.1016/j.crad.2012.02.012
   Yoon SK, 2006, EUR J RADIOL, V57, P453, DOI 10.1016/j.ejrad.2005.09.009
   Zhang QF, 2012, DIAGN PATHOL, V7, DOI 10.1186/1746-1596-7-126
NR 27
TC 3
Z9 5
U1 3
U2 9
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1746-1596
J9 DIAGN PATHOL
JI Diagn. Pathol.
PD JUN 17
PY 2013
VL 8
AR 96
DI 10.1186/1746-1596-8-96
PG 5
WC Pathology
SC Pathology
GA 192MI
UT WOS:000322488300001
PM 23773436
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Khan, F
   Pandey, J
   Vikram, S
   Pal, D
   Cameotra, SS
AF Khan, Fazlurrahman
   Pandey, Janmejay
   Vikram, Surendra
   Pal, Deepika
   Cameotra, Swaranjit Singh
TI RETRACTED: Aerobic degradation of 4-nitroaniline (4-NA) via novel
   degradation intermediates by Rhodococcus sp strain FK48 (Retracted
   article. See vol. 340, pg.486, 2017)
SO JOURNAL OF HAZARDOUS MATERIALS
LA English
DT Article; Retracted Publication
DE 4-Aminophenol (4-AP); Biodegradation; 4-Nitroaniline (4-NA); Rhodococcus
   sp strain FK48
ID BIODEGRADATION; TOXICITY; IDENTIFICATION; WATER; RATS
AB An aerobic strain, Rhodococcus sp. strain FK48, capable of growing on 4-nitroaniline (4-NA) as the sole source of carbon, nitrogen, and energy has been isolated from enrichment cultures originating from contaminated soil samples. During growth studies with non- induced cells of FK48 catalyzed sequential denitrification (release of NO2 substituent) and deamination (release of NH2 substituent) of 4-NA. However, none of the degradation intermediates could be identified with growth studies. During resting cell studies, 4-NA-induced cells of strain FK48 transformed 4-NA via a previously unknown pathway which involved oxidative hydroxylation leading to formation of 4-aminophenol (4-AP). Subsequent degradation involved oxidated deamination of 4-AP and formation of 1,2,4-benzenetriol (BT) as the major identified terminal aromatic intermediate. Identification of these intermediates was ascertained by HPLC, and GC-MS analyses of the culture supernatants. 4-NA-induced cells of strain FK48 showed positive activity for 1,2,4-benzenetriol dioxygenase in spectrophotometric assay. This is the first conclusive study on aerobic microbial degradation of 4-NA and elucidation of corresponding metabolic pathway. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Khan, Fazlurrahman; Pandey, Janmejay; Vikram, Surendra; Pal, Deepika; Cameotra, Swaranjit Singh] CSIR, Inst Microbial Technol, Chandigarh 160036, India.
RP Cameotra, SS (reprint author), CSIR, Inst Microbial Technol, Sect 39-A, Chandigarh 160036, India.
EM ssc@imtech.res.in
FU Council for Scientific and Industrial Research (CSIR), India; Department
   of Biotechnology (DBT), India; CSIR, India
FX This study was funded in part by Council for Scientific and Industrial
   Research (CSIR), India and Department of Biotechnology (DBT), India. FK,
   JP, SV and DP acknowledge their research fellowship awards from CSIR,
   India. This is the IMTECH communication number 066/2012.
CR Assmann N, 1997, MUTAT RES-GEN TOX EN, V395, P139, DOI 10.1016/S1383-5718(97)00158-7
   Blasco R, 1999, J BACTERIOL, V181, P149
   Boon N, 2001, APPL ENVIRON MICROB, V67, P1107, DOI 10.1128/AEM.67.3.1107-1115.2001
   Chun J, 2007, INT J SYST EVOL MICR, V57, P2259, DOI 10.1099/ijs.0.64915-0
   Claver A, 2006, CHEMOSPHERE, V64, P1437, DOI 10.1016/j.chemosphere.2006.02.034
   Ghosh A, 2006, INT J SYST EVOL MICR, V56, P1965, DOI 10.1099/ijs.0.63939-0
   Gotz R, 1998, CHEMOSPHERE, V36, P2085, DOI 10.1016/S0045-6535(97)10094-7
   Hongsawat P, 2011, J HAZARD MATER, V186, P1300, DOI 10.1016/j.jhazmat.2010.12.002
   Khalid A, 2009, WATER RES, V43, P1110, DOI 10.1016/j.watres.2008.11.045
   LYONS CD, 1984, APPL ENVIRON MICROB, V48, P491
   MYERS LA, 1988, TOXICOL APPL PHARM, V95, P139
   NAIR RS, 1990, FUND APPL TOXICOL, V15, P607, DOI 10.1016/0272-0590(90)90045-L
   Pandey J, 2011, APPL MICROBIOL BIOT, V92, P597, DOI 10.1007/s00253-011-3254-y
   Qureshi A, 2007, INT BIODETER BIODEGR, V60, P215, DOI 10.1016/j.ibiod.2007.03.004
   Saupe A, 1999, CHEMOSPHERE, V39, P2325, DOI 10.1016/S0045-6535(99)00141-1
   Sun HH, 2007, J HAZARD MATER, V148, P172, DOI 10.1016/j.jhazmat.2007.02.022
   SUROVTSEVA E G, 1981, Mikrobiologiya, V50, P740
   Tamura K, 2011, MOL BIOL EVOL, V28, P2731, DOI 10.1093/molbev/msr121
   Tong CL, 2010, CHEMOSPHERE, V81, P430, DOI 10.1016/j.chemosphere.2010.06.066
   Wang GX, 2010, DRUG CHEM TOXICOL, V33, P238, DOI 10.3109/01480540903414156
   White GF, 1996, APPL ENVIRON MICROB, V62, P637
   Yao XF, 2011, MICROBIOL-SGM, V157, P721, DOI 10.1099/mic.0.045393-0
   Zhang LL, 2010, J HAZARD MATER, V179, P875, DOI 10.1016/j.jhazmat.2010.03.086
   ZOK S, 1991, SCI TOTAL ENVIRON, V109, P411, DOI 10.1016/0048-9697(91)90196-L
NR 24
TC 10
Z9 10
U1 6
U2 31
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0304-3894
EI 1873-3336
J9 J HAZARD MATER
JI J. Hazard. Mater.
PD JUN 15
PY 2013
VL 254
BP 72
EP 78
DI 10.1016/j.jhazmat.2013.03.021
PG 7
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA 173KS
UT WOS:000321079000009
PM 23587930
DA 2018-12-27
ER

PT J
AU Liu, ZQ
   Liu, GQ
   Chen, YH
   Huang, K
   Hu, Y
   Zhang, XN
   Cai, ZJ
   Liu, XS
   Fu, GL
AF Liu, Zheng-qi
   Liu, Gui-qiang
   Chen, Yuan-hao
   Huang, Kuan
   Hu, Ying
   Zhang, Xiang-nan
   Cai, Zheng-jie
   Liu, Xiao-shan
   Fu, Guo-lan
TI RETRACTED: Modification of spontaneous emission from fluorescent spheres
   by partially disordered photonic crystals (Retracted article. See vol.
   158, pg. 445, 2015)
SO MATERIALS LETTERS
LA English
DT Article; Retracted Publication
DE Optical materials and property; Luminescence; Spectroscopy
ID QUANTUM DOTS; BAND-GAPS; PHOTOLUMINESCENCE; FABRICATION; ARRAYS
AB Partially disordered three-dimensional photonic crystals (PCs) were fabricated by self-assembly of small polystyrene spheres doped with large fluorescent spheres. Photoluminescence measurements show that the introduced disorder largely affects the spontaneous emission (SE) behaviors of the fluorescent spheres. Two pronounced emission peaks found at 565 nm and 620 nm gradually merge into one emission peak with the doping concentration increase from 0.02 wt% to 0.20 wt%, accompanied by the red-shift of the main emission peak. The dynamic modification of SE originates from the deterioration of stop band of PCs due to the disorder aggravated by increasing the doping concentration. The efficient modification on the emission intensity and frequency indicates potential applications in random lasing. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Liu, Zheng-qi; Liu, Gui-qiang; Chen, Yuan-hao; Huang, Kuan; Hu, Ying; Zhang, Xiang-nan; Cai, Zheng-jie; Liu, Xiao-shan; Fu, Guo-lan] Jiangxi Normal Univ, Coll Phys & Commun Elect, Key Lab Optoelect & Telecommun Jiangxi, Nanchang 330022, Peoples R China.
   [Liu, Zheng-qi] Nanjing Univ, Dept Phys, Nanjing 210093, Jiangsu, Peoples R China.
   [Liu, Zheng-qi] Nanjing Univ, Natl Lab Solid State Microstruct, Nanjing 210093, Jiangsu, Peoples R China.
RP Liu, GQ (reprint author), Jiangxi Normal Univ, Coll Phys & Commun Elect, Key Lab Optoelect & Telecommun Jiangxi, Nanchang 330022, Peoples R China.
EM liougq@yahoo.com.cn
RI Liu, G. Q./L-9021-2013
FU National Natural Science Foundation of China [11004088, 11264017];
   Science and Technology Support Project [20112BBE50033]; Natural Science
   Foundation of Jiangxi Province [20122BAB202006]
FX Work was funded by the National Natural Science Foundation of China
   (Nos. 11004088 and 11264017), Science and Technology Support Project
   (No. 20112BBE50033) and Natural Science Foundation (No. 20122BAB202006)
   of Jiangxi Province.
CR Bjorknas K, 2003, J MATER SCI-MATER EL, V14, P397, DOI 10.1023/A:1023913104169
   Carcia PD, 2007, ADV MATER, V19, P2597
   Dorado LA, 2009, PHYS REV B, V79, DOI 10.1103/PhysRevB.79.045124
   Koenderink AF, 2005, OPT LETT, V30, P3210, DOI 10.1364/OL.30.003210
   Liang QX, 2012, MATER LETT, V79, P48, DOI 10.1016/j.matlet.2012.03.082
   Liu GQ, 2013, MATER LETT, V93, P42, DOI 10.1016/j.matlet.2012.11.062
   Liu GQ, 2012, MATER LETT, V68, P466, DOI 10.1016/j.matlet.2011.11.031
   Liu GQ, 2011, J OPTICS-UK, V13, DOI 10.1088/2040-8978/13/1/015106
   Liu GQ, 2010, THIN SOLID FILMS, V518, P5083, DOI 10.1016/j.tsf.2010.02.062
   Liu ZQ, 2010, CHINESE PHYS B, V19, DOI 10.1088/1674-1056/19/11/114210
   Liu ZQ, 2009, CHINESE PHYS B, V18, P2383, DOI 10.1088/1674-1056/18/6/044
   Palacios-Lidon E, 2005, J APPL PHYS, V97, DOI 10.1063/1.1851014
   Schofield AB, 2001, PHYS REV E, V64, DOI 10.1103/PhysRevE.64.051403
   Schroden RC, 2001, CHEM MATER, V13, P2945, DOI 10.1021/cm010230s
   Sigalas MM, 1999, PHYS REV B, V59, P12767, DOI 10.1103/PhysRevB.59.12767
   Su Y, 2011, MATER LETT, V65, P2693, DOI 10.1016/j.matlet.2011.05.112
   Toninelli C, 2008, PHYS REV LETT, V101, DOI 10.1103/PhysRevLett.101.123901
   Vlasov YA, 1999, PHYS REV B, V60, P1555, DOI 10.1103/PhysRevB.60.1555
   YABLONOVITCH E, 1987, PHYS REV LETT, V58, P2059, DOI 10.1103/PhysRevLett.58.2059
   Yang ZW, 2011, MATER LETT, V65, P1245, DOI 10.1016/j.matlet.2011.01.071
   Yang ZW, 2010, MATER LETT, V64, P1329, DOI 10.1016/j.matlet.2010.03.038
NR 21
TC 3
Z9 3
U1 4
U2 101
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0167-577X
EI 1873-4979
J9 MATER LETT
JI Mater. Lett.
PD JUN 15
PY 2013
VL 101
BP 44
EP 46
DI 10.1016/j.matlet.2013.03.069
PG 3
WC Materials Science, Multidisciplinary; Physics, Applied
SC Materials Science; Physics
GA 159VZ
UT WOS:000320076700012
DA 2018-12-27
ER

PT J
AU Narjis, A
   El Kaaouachi, A
   Dlimi, S
   Biskupski, G
   Daoudi, E
   Errai, M
   Sybous, A
   Limouny, L
AF Narjis, A.
   El Kaaouachi, A.
   Dlimi, S.
   Biskupski, G.
   Daoudi, E.
   Errai, M.
   Sybous, A.
   Limouny, L.
TI RETRACTED: Granular and intergranular conduction in La1.32Sr1.681Mn2O7
   layered manganite system (Retracted article. See vol. 430, pg. 114,
   2013)
SO PHYSICA B-CONDENSED MATTER
LA English
DT Article; Retracted Publication
DE Coulomb blockade; Spin polarization tunneling; lntergranular conduction
ID GIANT MAGNETORESISTANCE; TRILAYER JUNCTIONS; COULOMB-BLOCKADE; DOPED
   MANGANITES; METAL-FILMS; THIN-FILMS; TEMPERATURE; EXCHANGE;
   LA2/3SR1/3MNO3; LA0.7CA0.3MNO3
AB We report a comprehensive study of the electrical and magneto-transport properties of La1.32Sr1.68Mn2O7 layered manganite system under different pressures and in the temperature range of 4.2 K to 300 K. An increase in the resistivity at low temperature has been observed and explained in terms of Coulomb Blockade effect. Magnetoresistance data are explained by assuming that the transport occurs through the mechanism of intergranular as well as granular paths with a pronounced manifestation of Spin Polarization Tunneling phenomenon. By qualitatively comparing the relative fractions of these channels, we explain the resistivity behavior in each temperature range. (C) 2013 Elsevier By. All rights reserved.
C1 [Narjis, A.; El Kaaouachi, A.; Dlimi, S.; Daoudi, E.; Errai, M.; Sybous, A.; Limouny, L.] Univ Ibn Zohr, Fac Sci, Dept Phys, Res Grp ESNPS, Hay Dakhla 80000, Agadir, Morocco.
   [Biskupski, G.] Univ Sci & Technol, LSH, F-59655 Villeneuve Dascq, France.
RP Narjis, A (reprint author), Univ Ibn Zohr, Fac Sci, Dept Phys, Res Grp ESNPS, BP 8106, Hay Dakhla 80000, Agadir, Morocco.
EM NARJIS78@gmail.com
CR ABELES B, 1975, ADV PHYS, V24, P407, DOI 10.1080/00018737500101431
   ADKINS CJ, 1989, J PHYS-CONDENS MAT, V1, P1253, DOI 10.1088/0953-8984/1/7/009
   ANDERSON PW, 1955, PHYS REV, V100, P675, DOI 10.1103/PhysRev.100.675
   Baazaoui M, 2010, PHYSICA B, V405, P1470, DOI 10.1016/j.physb.2009.12.017
   Balcells L, 1998, PHYS REV B, V58, P14697, DOI 10.1103/PhysRevB.58.R14697
   Chen LP, 2008, CHINESE PHYS LETT, V25, P3381, DOI 10.1088/0256-307X/25/9/077
   Garcia-Hernandez M, 2000, PHYS REV B, V61, P9549, DOI 10.1103/PhysRevB.61.9549
   Garcia-Hernandez M., 1999, SUPERFICIES VACIO, V9, P44
   Han L, 2010, J MATER SCI TECHNOL, V26, P234, DOI 10.1016/S1005-0302(10)60039-4
   HELMAN JS, 1976, PHYS REV LETT, V37, P1429, DOI 10.1103/PhysRevLett.37.1429
   Hofener C, 2000, EUROPHYS LETT, V50, P681, DOI 10.1209/epl/i2000-00324-1
   Kumaresavanji M, 2009, J APPL PHYS, V106, DOI 10.1063/1.3256182
   Liang SZ, 2012, PHYS REV LETT, V109, DOI 10.1103/PhysRevLett.109.256601
   Lu Y, 1996, PHYS REV B, V54, pR8357, DOI 10.1103/PhysRevB.54.R8357
   Mahesh R, 1996, APPL PHYS LETT, V68, P2291, DOI 10.1063/1.116167
   Meneghini C, 2002, PHYS REV B, V65, DOI 10.1103/PhysRevB.65.012111
   Mishra DK, 2011, B MATER SCI, V34, P1501, DOI 10.1007/s12034-011-0350-7
   Mitani S, 1998, PHYS REV LETT, V81, P2799, DOI 10.1103/PhysRevLett.81.2799
   Mitani S, 1999, J MAGN MAGN MATER, V198-99, P179, DOI 10.1016/S0304-8853(98)01041-5
   Mostafa AG, 2008, J MAGN MAGN MATER, V320, P3356, DOI 10.1016/j.jmmm.2008.07.025
   Muduli P.K., 2009, J APPL PHYS, V105
   Muroi M, 2003, REV ADV MATER SCI, V5, P76
   Narjis A, 2013, J MAGN MAGN MATER, V332, P6, DOI 10.1016/j.jmmm.2012.12.002
   Narjis A, 2011, PHYSICA B, V406, P4155, DOI 10.1016/j.physb.2011.08.021
   Narjis A., 2012, J MOD PHYS, V3, P517
   Narjis A., 2013, MAT SCI SEMICON PROC, DOI DOI 10.1016/J.MSSP
   Nasri M, 2013, J ALLOY COMPD, V546, P84, DOI 10.1016/j.jallcom.2012.08.018
   NEUMEIER JJ, 1995, PHYS REV B, V52, pR7006, DOI 10.1103/PhysRevB.52.R7006
   Peters EC, 2012, PHYS STATUS SOLIDI B, V249, P2522, DOI 10.1002/pssb.201200177
   Prasad R, 2009, PHYS STATUS SOLIDI B, V246, P1662, DOI 10.1002/pssb.200844438
   Sakthipandi K, 2013, MATER CHARACT, V77, P70, DOI 10.1016/j.matchar.2012.12.013
   Sarkar T., 1996, APPL PHYS LETT, V69, P3266
   Sarkar T, 2012, NEW J PHYS, V14, DOI 10.1088/1367-2630/14/3/033026
   Shankar KS, 2004, SOLID STATE COMMUN, V129, P479, DOI 10.1016/j.ssc.2003.10.029
   SHENG P, 1992, PHILOS MAG B, V65, P357, DOI 10.1080/13642819208207638
   SHENG P, 1973, PHYS REV LETT, V31, P44, DOI 10.1103/PhysRevLett.31.44
   Sun JZ, 1997, APPL PHYS LETT, V70, P1769, DOI 10.1063/1.118651
   Sun JZ, 1998, APPL PHYS LETT, V73, P1008, DOI 10.1063/1.122068
   Tang YK, 2006, J MAGN MAGN MATER, V299, P260, DOI 10.1016/j.jmmm.2005.04.009
   Watanabe M, 2000, APPL PHYS LETT, V76, P3971, DOI 10.1063/1.126838
   Weissmuller J, 1997, ACTA MATER, V45, P1899, DOI 10.1016/S1359-6454(96)00314-X
   Yang XS, 2012, PHYSCS PROC, V27, P96, DOI 10.1016/j.phpro.2012.03.419
   Zhang N, 1997, PHYS REV B, V56, P8138, DOI 10.1103/PhysRevB.56.8138
NR 43
TC 1
Z9 1
U1 3
U2 19
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0921-4526
EI 1873-2135
J9 PHYSICA B
JI Physica B
PD JUN 15
PY 2013
VL 419
BP 7
EP 10
DI 10.1016/j.physb.2013.03.009
PG 4
WC Physics, Condensed Matter
SC Physics
GA 139RW
UT WOS:000318602700002
DA 2018-12-27
ER

PT J
AU Wang, HY
   Wang, GL
   Wang, CX
   Wei, Y
   Wen, ZT
   Wang, CY
   Zhu, A
AF Wang, Haiyun
   Wang, Guolin
   Wang, Chenxu
   Wei, Ying
   Wen, Zhiting
   Wang, Chunyan
   Zhu, Ai
TI RETRACTED: The Early Stage Formation of PI3K-AMPAR GluR2 Subunit Complex
   Facilitates the Long Term Neuroprotection Induced by Propofol
   Post-Conditioning in Rats (Retracted article. See vol. 13, artn
   E0196886, 2018)
SO PLOS ONE
LA English
DT Article; Retracted Publication
ID FOCAL CEREBRAL ISCHEMIA/REPERFUSION; CENTRAL-NERVOUS-SYSTEM;
   PHOSPHOINOSITIDE 3-KINASE/AKT; CALCIUM PERMEABILITY; SIGNALING PATHWAYS;
   FOREBRAIN ISCHEMIA; BRAIN ISCHEMIA; GLUTAMATE; NEUROGENESIS; RECEPTORS
AB Previously, we have shown that the phosphoinositide-3-kinase (PI3K) mediated acute (24 h) post-conditioning neuroprotection induced by propofol. We also found that propofol post-conditioning produced long term neuroprotection and inhibited the internalization of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor GluR2 subunit up to 28 days post middle cerebral artery occlusion (MCAO). However, the relationship between PI3K with AMPA receptor GluR2 subunit trafficking in propofol post-conditioning has never been explored. Here we showed that propofol post-conditioning promoted the binding of PI3K to the C-terminal of AMPA receptor GluR2 subunit and formed a complex within 1 day after transient MCAO. Interestingly, the enhanced activity of PI3K was observed in the hippocampus of post-conditioning rats at day 1 post ischemia, whereas the decrease of AMPA receptor GluR2 subunit internalization was found up to 28 days in the same group. Administration of PI3K selective antagonist wortmannin inhibited the improvement of spatial learning memory and the increase of neurogenesis in the dentate gyrus up to 28 days post ischemia. It also reversed the inhibition of AMPA receptor GluR2 internalization induced by propofol post-conditioning. Together, our data indicated the critical role of PI3K in regulating the long term neuroprotection induced by propofol post-conditioning. Moreover, this role was established by first day activation of PI3K and formation of PI3K-AMPA receptor GluR2 complex, thus stabilized the structure of postsnaptic AMPA receptor and inhibited the internalization of GluR2 subunit during the early stage of propofol post-conditioning.
C1 [Wang, Haiyun; Wang, Guolin; Wang, Chenxu; Wei, Ying; Wen, Zhiting; Wang, Chunyan; Zhu, Ai] Tianjin Med Univ Gen Hosp, Tianjin Res Inst Anesthesiol, Dept Anesthesiol, Tianjin, Peoples R China.
RP Wang, HY (reprint author), Tianjin Med Univ Gen Hosp, Tianjin Res Inst Anesthesiol, Dept Anesthesiol, Tianjin, Peoples R China.
EM wanghy819@hotmail.com
FU Natural Science Foundation of China [81071059, 81100984, 30972847];
   Science and Technology Supported Key Project of Tianjin [12ZCZDSY03000];
   Tianjin Health Bureau [09KZ106]
FX This work was supported by Natural Science Foundation of China
   (81071059, 81100984, 30972847), Science and Technology Supported Key
   Project of Tianjin (12ZCZDSY03000), Scientific Grant from Tianjin Health
   Bureau (09KZ106). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Arendt KL, 2010, NAT NEUROSCI, V13, P36, DOI 10.1038/nn.2462
   Barry MF, 2002, CURR OPIN NEUROBIOL, V12, P279, DOI 10.1016/S0959-4388(02)00329-X
   Bhattacharyya S, 2012, DIABETOLOGIA, V55, P194, DOI 10.1007/s00125-011-2333-z
   Boudreau AC, 2005, J NEUROSCI, V25, P9144, DOI 10.1523/JNEUROSCI.2252-05.2005
   Bredesen DE, 1995, ANN NEUROL, V38, P839, DOI 10.1002/ana.410380604
   Burnashev N, 1996, CURR OPIN NEUROBIOL, V6, P311, DOI 10.1016/S0959-4388(96)80113-9
   Chan PH, 2004, NEUROCHEM RES, V29, P1943, DOI 10.1007/s11064-004-6869-x
   CHOI DW, 1990, J NEUROSCI, V10, P2493
   CHOI DW, 1995, TRENDS NEUROSCI, V18, P58
   Chuang CC, 2007, ENDOCRINOLOGY, V148, P4267, DOI 10.1210/en.2007-0179
   Dingledine R, 1999, PHARMACOL REV, V51, P7
   Engelhard K, 2007, ANESTH ANALG, V104, P898, DOI 10.1213/01.ane.0000255730.73018.31
   Filippa N, 1999, MOL CELL BIOL, V19, P4989
   Franke TF, 2003, ONCOGENE, V22, P8983, DOI 10.1038/sj.onc.1207115
   Gryder DS, 2005, J NEUROCHEM, V94, P1728, DOI 10.1111/j.1471-4159.2005.03334.x
   Gu ZL, 2005, J NEUROSCI, V25, P4974, DOI 10.1523/JNEUROSCI.1086-05.2005
   HOLLMANN M, 1991, SCIENCE, V252, P851, DOI 10.1126/science.1709304
   HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335
   HUME RI, 1991, SCIENCE, V253, P1028, DOI 10.1126/science.1653450
   Jackson C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011962
   Lie DC, 2004, ANNU REV PHARMACOL, V44, P399, DOI 10.1146/annurev.pharmtox.44.101802.121631
   Liu BS, 2006, J NEUROSCI, V26, P5309, DOI 10.1523/JNEUROSCI.0567-06.2006
   Liu JL, 1998, J NEUROSCI, V18, P7768
   Lu C, 2011, J IMMUNOL, V187, P1458, DOI 10.4049/jimmunol.1003428
   MAYAT E, 1995, J NEUROSCI, V15, P2533
   MELDRUM BS, 1995, ANN NY ACAD SCI, V757, P492, DOI 10.1111/j.1749-6632.1995.tb17509.x
   MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4
   MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0
   Ohta H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017137
   Parent JM, 2003, NEUROSCIENTIST, V9, P261, DOI 10.1177/1073858403252680
   Peng PL, 2006, NEURON, V49, P719, DOI 10.1016/j.neuron.2006.01.025
   PUTTFARCKEN PS, 1993, BRAIN RES, V624, P223, DOI 10.1016/0006-8993(93)90081-W
   Ripple MO, 2005, BREAST CANCER RES TR, V93, P177, DOI 10.1007/s10549-005-4794-6
   Robin E, 2011, BRAIN RES, V1375, P137, DOI 10.1016/j.brainres.2010.12.054
   ROTHMAN SM, 1986, ANN NEUROL, V19, P105, DOI 10.1002/ana.410190202
   Schnell E, 2002, P NATL ACAD SCI USA, V99, P13902, DOI 10.1073/pnas.192511199
   Takasawa K, 2002, J CEREBR BLOOD F MET, V22, P299, DOI 10.1097/00004647-200203000-00007
   Tanaka H, 2000, BRAIN RES, V886, P190, DOI 10.1016/S0006-8993(00)02951-6
   Tonchev AB, 2011, ARCH ITAL BIOL, V149, P225, DOI 10.4449/aib.v149i2.1368
   Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X
   Wang HY, 2009, BRAIN RES, V1297, P177, DOI 10.1016/j.brainres.2009.08.054
   Wang HY, 2011, J NEUROCHEM, V119, P210, DOI 10.1111/j.1471-4159.2011.07400.x
   Xing BZ, 2008, J NEUROCHEM, V105, P1737, DOI 10.1111/j.1471-4159.2008.05276.x
   Yuan HS, 2006, J MED CHEM, V49, P740, DOI 10.1021/jm050699p
   Yuan H, 2009, BIOORG MED CHEM LETT, V19, P4223, DOI 10.1016/j.bmcl.2009.05.105
   Yun YJ, 2007, BIOL PHARM BULL, V30, P337, DOI 10.1248/bpb.30.337
   Zhang WQ, 2011, J CLIN NEUROSCI, V18, P685, DOI 10.1016/j.jocn.2010.08.027
   Zhang WQ, 2010, INT J MOL SCI, V11, P4407, DOI 10.3390/ijms11114407
   Zhao H, 2005, J NEUROSCI, V25, P9794, DOI 10.1523/JNEUROSCI.3163-05.2005
NR 49
TC 11
Z9 19
U1 1
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 11
PY 2013
VL 8
IS 6
AR e65187
DI 10.1371/journal.pone.0065187
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 169CU
UT WOS:000320755400012
PM 23776449
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Martin-Ordas, G
   Call, J
AF Martin-Ordas, Gema
   Call, Josep
TI RETRACTED: Episodic memory: a comparative approach (Retracted article.
   See vol. 7, 184, 2013)
SO FRONTIERS IN BEHAVIORAL NEUROSCIENCE
LA English
DT Review; Retracted Publication
DE episodic memory; episodic-like memory; semantic memory; autobiographical
   memory; non-human animals
ID MENTAL TIME-TRAVEL; WESTERN SCRUB-JAYS; WHERE-WHEN MEMORY; RECEIVER
   OPERATING CHARACTERISTICS; RATS RATTUS-NORVEGICUS; AUTOBIOGRAPHICAL
   MEMORY; RECOGNITION MEMORY; APHELOCOMA-COERULESCENS; SEMANTIC MEMORY;
   ASSOCIATIVE INFORMATION
AB Historically, episodic memory has been described as autonoetic, personally relevant, complex, context-rich, and allowing mental time travel. In contrast, semantic memory, which is theorized to be free of context and personal relevance, is noetic and consists of general knowledge off acts about the world. The field of comparative psychology has adopted this distinction in order to study episodic memory in non-human animals. Our aim in this article is not only to reflect on the concept of episodic memory and the experimental approaches used in comparative psychology to study this phenomenon, but also to provide a critical analysis of these paradigms. We conclude the article by providing new avenues for future research.
C1 [Martin-Ordas, Gema] Aarhus Univ, Ctr Autobiog Memory Res, Aarhus, Denmark.
   [Call, Josep] Max Planck Inst Evolutionary Anthropol, Leipzig, Germany.
RP Martin-Ordas, G (reprint author), Ctr Autobiog Memory Res, Dept Psychol, Bartholins Alle 9, DK-8000 Aarhus C, Denmark.
EM ordas@psy.au.dk
FU Danish National Research Foundation [DNRF93]
FX This work was supported by the Danish National Research Foundation
   (DNRF93).
CR Anderson RJ, 2009, MEMORY, V17, P367, DOI 10.1080/09658210902751669
   Arndt J, 2002, J EXP PSYCHOL LEARN, V28, P830, DOI 10.1037//0278-7393.28.5.830
   Atance CM, 2001, TRENDS COGN SCI, V5, P533, DOI 10.1016/S1364-6613(00)01804-0
   Babb SJ, 2005, LEARN MOTIV, V36, P177, DOI 10.1016/j.lmot.2005.02.009
   Babb SJ, 2006, LEARN BEHAV, V34, P124, DOI 10.3758/BF03193188
   Barsalou L. W., 1988, REMEMBERING RECONSID, P193, DOI DOI 10.1017/CBO9780511664014.009
   Basile BM, 2011, CURR BIOL, V21, P774, DOI 10.1016/j.cub.2011.03.044
   BAUER PJ, 2007, REMEMBERINGTHE TIMES
   Berntsen D, 2009, INVOLUNTARY AUTOBIOGRAPHICAL MEMORIES: AN INTRODUCTION TO THE UNBIDDEN PAST, P1, DOI 10.1017/CBO9780511575921
   Berntsen D, 1996, APPL COGNITIVE PSYCH, V10, P435, DOI 10.1002/(SICI)1099-0720(199610)10:5<435::AID-ACP408>3.0.CO;2-L
   Bird LR, 2003, J COMP PSYCHOL, V117, P176, DOI 10.1037/0735-7036.117.2.176
   Boyer P, 2008, TRENDS COGN SCI, V12, P219, DOI 10.1016/j.tics.2008.03.003
   Cabeza R, 2007, TRENDS COGN SCI, V11, P219, DOI 10.1016/j.tics.2007.02.005
   Chalfonte BL, 1996, MEM COGNITION, V24, P403, DOI 10.3758/BF03200930
   Cheke LG, 2012, BIOL LETTERS, V8, P171, DOI 10.1098/rsbl.2011.0909
   Cheke LG, 2010, WIRES COGN SCI, V1, P915, DOI 10.1002/wcs.59
   Clayton NS, 1998, NATURE, V395, P272, DOI 10.1038/26216
   Clayton NS, 1999, J COMP PSYCHOL, V113, P403, DOI 10.1037//0735-7036.113.4.403
   Clayton NS, 2003, NAT REV NEUROSCI, V4, P685, DOI 10.1038/nrn1180
   Clayton NS, 2003, J EXP PSYCHOL ANIM B, V29, P14, DOI 10.1037//0097-7403.29.1.14
   Clayton NS, 1999, ANIM BEHAV, V57, P435, DOI 10.1006/anbe.1998.0989
   Clayton NS, 2001, J EXP PSYCHOL ANIM B, V27, P17, DOI 10.1037//0097-7403.27.1.17
   Clayton NS, 1999, J EXP PSYCHOL ANIM B, V25, P82, DOI 10.1037//0097-7403.25.1.82
   Conway MA, 2000, PSYCHOL REV, V107, P261, DOI 10.1037//0033-295X.107.2.261
   Conway MA, 2001, PHILOS T R SOC B, V356, P1375, DOI 10.1098/rstb.2001.0940
   CONWAY MA, 2000, HDB NEUROPSYCHOLOGY, V2, P281
   Conway MA, 2009, NEUROPSYCHOLOGIA, V47, P2305, DOI 10.1016/j.neuropsychologia.2009.02.003
   Corballis MC, 2013, TRENDS COGN SCI, V17, P5, DOI 10.1016/j.tics.2012.10.009
   Correia SPC, 2007, CURR BIOL, V17, P856, DOI 10.1016/j.cub.2007.03.063
   Crystal JD, 2013, CURR BIOL, V23, P387, DOI 10.1016/j.cub.2013.01.023
   Crystal JD, 2009, BEHAV PROCESS, V80, P269, DOI 10.1016/j.beproc.2008.09.009
   D'Argembeau A, 2011, J EXP PSYCHOL GEN, V140, P258, DOI 10.1037/a0022581
   D'Argembeau A, 2011, APPL COGNITIVE PSYCH, V25, P96, DOI 10.1002/acp.1647
   de Kort SR, 2005, LEARN MOTIV, V36, P159, DOI 10.1016/j.lmot.2005.02.008
   Dekleva M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016593
   Dere E, 2006, NEUROSCI BIOBEHAV R, V30, P1206, DOI 10.1016/j.neubiorev.2006.09.005
   Dere E, 2005, NEUROBIOL LEARN MEM, V84, P214, DOI 10.1016/j.nlm.2005.07.002
   Dessalles JL, 2007, BEHAV BRAIN SCI, V30, P321, DOI 10.1017/S0140525X07002063
   Dudai Y, 2005, NATURE, V434, P567, DOI 10.1038/434567a
   Dufour V, 2008, BEHAV PROCESS, V79, P19, DOI 10.1016/j.beproc.2008.04.003
   Eacott MJ, 2012, LEARN MOTIV, V43, P200, DOI 10.1016/j.lmot.2012.05.012
   Eacott MJ, 2010, NEUROPSYCHOLOGIA, V48, P2273, DOI 10.1016/j.neuropsychologia.2009.11.002
   Eacott MJ, 2005, Q J EXP PSYCHOL-B, V58, P202, DOI 10.1080/02724990444000203
   Eacott MJ, 2005, LEARN MEMORY, V12, P221, DOI 10.1101/lm.92505
   Eacott MJ, 2004, J NEUROSCI, V24, P1948, DOI 10.1523/JNEUROSCI.2975-03.2004
   Easton A, 2012, LEARN MEMORY, V19, P146, DOI 10.1101/lm.025676.112
   Easton A, 2009, HIPPOCAMPUS, V19, P837, DOI 10.1002/hipo.20567
   Ebbinghaus H, 1964, MEMORY CONTRIBUTION
   Eichenbaum H, 1997, SCIENCE, V277, P330, DOI 10.1126/science.277.5324.330
   Eichenbaum H, 2005, LEARN MOTIV, V36, P190, DOI 10.1016/j.lmot.2005.02.006
   Ergorul C, 2004, LEARN MEMORY, V11, P397, DOI 10.1101/lm.73304
   Ferkin MH, 2008, ANIM COGN, V11, P147, DOI 10.1007/s10071-007-0101-8
   Fortin NJ, 2004, NATURE, V431, P188, DOI 10.1038/nature02853
   Friedman WJ, 2007, BEHAV BRAIN SCI, V30, P323, DOI 10.1017/S0140525X07002087
   FRIEDMAN WJ, 1993, PSYCHOL BULL, V113, P44, DOI 10.1037/0033-2909.113.1.44
   Gadian DG, 2000, BRAIN, V123, P499, DOI 10.1093/brain/123.3.499
   GAFFAN D, 1994, J COGNITIVE NEUROSCI, V6, P305, DOI 10.1162/jocn.1994.6.4.305
   Gaffan D, 1991, Hippocampus, V1, P262, DOI 10.1002/hipo.450010311
   Graham KS, 2003, COGN AFFECT BEHAV NE, V3, P234, DOI 10.3758/CABN.3.3.234
   Greenberg DL, 2010, J INT NEUROPSYCH SOC, V16, P748, DOI 10.1017/S1355617710000676
   Hampton RR, 2005, LEARN MOTIV, V36, P245, DOI 10.1016/j.lmot.2005.02.004
   Hampton RR, 2004, CURR OPIN NEUROBIOL, V14, P192, DOI 10.1016/j.conb.2004.03.006
   Henderson J, 2006, CURR BIOL, V16, P512, DOI 10.1016/j.cub.2006.01.054
   Hirano M, 1998, PERCEPT MOTOR SKILL, V87, P99, DOI 10.2466/pms.1998.87.1.99
   HOCKLEY WE, 1992, J EXP PSYCHOL LEARN, V18, P1321, DOI 10.1037//0278-7393.18.6.1321
   Hodges JR, 2001, NEUROCASE, V7, P31, DOI 10.1093/neucas/7.1.31
   Holland SM, 2011, ANIM COGN, V14, P95, DOI 10.1007/s10071-010-0346-5
   HOROWITZ MJ, 1975, ARCH GEN PSYCHIAT, V32, P1457
   Kapur N, 1999, PSYCHOL BULL, V125, P800, DOI 10.1037/0033-2909.125.6.800
   Kart-Teke E, 2006, NEUROBIOL LEARN MEM, V85, P173, DOI 10.1016/j.nlm.2005.10.002
   Kelley R, 2001, J EXP PSYCHOL LEARN, V27, P701, DOI 10.1037/0278-7393.27.3.701
   Klein SB, 2012, MIND, V121, P677, DOI 10.1093/mind/fzs080
   Klein SB, 2013, FRONT BEHAV NEUROSCI, V7, DOI 10.3389/fnbeh.2013.00003
   Klein SB, 2012, SOC COGNITION, V30, P474, DOI 10.1521/soco.2012.30.4.474
   Langston RF, 2010, HIPPOCAMPUS, V20, P1139, DOI 10.1002/hipo.20714
   Levine B, 2002, PSYCHOL AGING, V17, P677, DOI 10.1037//0882-7974.17.4.677
   Lu HB, 2012, P NATL ACAD SCI USA, V109, P3979, DOI 10.1073/pnas.1200506109
   MANDLER G, 1994, ATTENTION PERFORM, V15, P3
   Martin-Ordas G, 2012, LEARN MOTIV, V43, P209, DOI 10.1016/j.lmot.2012.05.011
   Martin-Ordas G, 2010, ANIM COGN, V13, P331, DOI 10.1007/s10071-009-0282-4
   McKenzie TLB, 2005, LEARN MOTIV, V36, P260, DOI 10.1016/j.lmot.2005.02.011
   McKinnon MC, 2006, NEUROPSYCHOLOGIA, V44, P2421, DOI 10.1016/j.neuropsychologia.2006.04.010
   Menzel E, 2005, MISSING LINK COGNITI, P188
   Miyashita Y, 2004, SCIENCE, V306, P435, DOI 10.1126/science.1101864
   Morris RGM, 1997, PHILOS T ROY SOC B, V352, P1489, DOI 10.1098/rstb.1997.0136
   Mulcahy NJ, 2006, SCIENCE, V312, P1038, DOI 10.1126/science.1125456
   Naqshbandi M, 2006, J COMP PSYCHOL, V120, P345, DOI 10.1037/0735-7036.120.4.345
   Neary D, 1998, NEUROLOGY, V51, P1546, DOI 10.1212/WNL.51.6.1546
   NEISSER U, 1981, COGNITION, V9, P1, DOI 10.1016/0010-0277(81)90011-1
   NELSON K, 1992, HUM DEV, V35, P172, DOI 10.1159/000277149
   Newcombe NS, 2007, ADV CHILD DEV BEHAV, V35, P37
   Osvath M, 2008, ANIM COGN, V11, P661, DOI 10.1007/s10071-008-0157-0
   Pillemer D. B., 2001, REV GEN PSYCHOL, V5, P123, DOI [DOI 10.1037/1089-2680.5.2.123, 10.1037/1089-2680.5.2.123]
   Pillemer DB, 2003, MEMORY, V11, P193, DOI 10.1080/09658210244000360
   Piolino P, 2009, NEUROPSYCHOLOGIA, V47, P2314, DOI 10.1016/j.neuropsychologia.2009.01.020
   Premack D, 2007, P NATL ACAD SCI USA, V104, P13861, DOI 10.1073/pnas.0706147104
   Raby CR, 2007, NATURE, V445, P919, DOI 10.1038/nature05575
   Raby CR, 2009, BEHAV PROCESS, V80, P314, DOI 10.1016/j.beproc.2008.12.005
   Reynolds M, 1999, BEHAV RES THER, V37, P201, DOI 10.1016/S0005-7967(98)00132-6
   Roberts WA, 2008, SCIENCE, V320, P113, DOI 10.1126/science.1152709
   Rotello CM, 2000, J MEM LANG, V43, P67, DOI 10.1006/jmla.1999.2701
   Rubin DC, 2006, PERSPECT PSYCHOL SCI, V1, P277, DOI 10.1111/j.1745-6916.2006.00017.x
   Rubin DC, 2003, MEM COGNITION, V31, P887, DOI 10.3758/BF03196443
   Rubin DC, 1986, AUTOBIOGRAPHICAL MEM, P202, DOI DOI 10.1017/CB09780511558313.018
   SALWICZEK LH, 2008, COGNITIVE PSYCHOL ME, P441
   Sauvage MM, 2008, NAT NEUROSCI, V11, P16, DOI 10.1038/nn2016
   Schacter DL, 2007, NATURE, V445, P27, DOI 10.1038/445027a
   Schwartz Bennett L., 2005, P225
   Schwartz BL, 2005, LEARN MOTIV, V36, P226, DOI 10.1016/j.lmot.2005.02.012
   Schwartz BL, 2002, ANIM COGN, V5, P85, DOI 10.1007/s10071-002-0132-0
   Skov-Rackette SI, 2006, J EXP PSYCHOL ANIM B, V32, P345, DOI 10.1037/0097-7403.32.4.345
   Slotnick SD, 2000, J EXP PSYCHOL LEARN, V26, P1499, DOI 10.1037//0278-7393.26.6.1499
   SNOWDEN J, 1994, COGNITIVE NEUROPSYCH, V11, P265, DOI 10.1080/02643299408251976
   Squire LR, 2004, ANNU REV NEUROSCI, V27, P279, DOI 10.1146/annurev.neuro.27.070203.144130
   SQUIRE LR, 1992, J COGNITIVE NEUROSCI, V4, P232, DOI 10.1162/jocn.1992.4.3.232
   STEVENSON I, 1995, J NERV MENT DIS, V183, P452, DOI 10.1097/00005053-199507000-00005
   Suddendorf T, 2006, SCIENCE, V312, P1006, DOI 10.1126/science.1129217
   Suddendorf T, 2003, TRENDS COGN SCI, V7, P437, DOI 10.1016/j.tics.2003.08.010
   Suddendorf T, 1997, GENET SOC GEN PSYCH, V123, P133
   Suddendorf T, 2007, BEHAV BRAIN SCI, V30, P299, DOI 10.1017/S0140525X07001975
   Thompson C. P., 1996, AUTOBIOGRAPHICAL MEM
   Tulving E, 1998, HIPPOCAMPUS, V8, P198, DOI 10.1002/(SICI)1098-1063(1998)8:3<198::AID-HIPO2>3.3.CO;2-J
   Tulving E, 2002, ANNU REV PSYCHOL, V53, P1, DOI 10.1146/annurev.psych.53.100901.135114
   Tulving E., 1972, ORG MEMORY, P381
   Tulving E, 1983, ELEMENTS EPISODIC ME
   Tulving E., 2005, MISSING LINK COGNITI, P3, DOI DOI 10.1093/ACPROF:OSO/9780195161564.003.0001
   VarghaKhadem F, 1997, SCIENCE, V277, P376, DOI 10.1126/science.277.5324.376
   Wheeler MA, 1997, PSYCHOL BULL, V121, P331, DOI 10.1037/0033-2909.121.3.331
   Wheeler MA, 2001, COGN AFFECT BEHAV NE, V1, P22, DOI 10.3758/CABN.1.1.22
   Wixted JT, 2008, LEARN MEMORY, V15, P687, DOI 10.1101/lm.1077708
   Yonelinas AP, 2002, J MEM LANG, V46, P441, DOI 10.1006/jmla.2002.2864
   Yonelinas AP, 1997, MEM COGNITION, V25, P747, DOI 10.3758/BF03211318
   Yonelinas AP, 1999, J EXP PSYCHOL LEARN, V25, P514, DOI 10.1037/0278-7393.25.2.514
   Yonelinas AP, 2001, PHILOS T R SOC B, V356, P1363, DOI 10.1098/rstb.2001.0939
   Yonelinas AP, 1999, J EXP PSYCHOL LEARN, V25, P1415, DOI 10.1037/0278-7393.25.6.1415
   Zentall TR, 2001, PSYCHON B REV, V8, P685, DOI 10.3758/BF03196204
   Zhou WY, 2012, CURR BIOL, V22, P1149, DOI 10.1016/j.cub.2012.04.040
   Zhou WY, 2009, P NATL ACAD SCI USA, V106, P9525, DOI 10.1073/pnas.0904360106
   Zinkivskay A, 2009, ANIM COGN, V12, P119, DOI 10.1007/s10071-008-0176-x
NR 139
TC 3
Z9 3
U1 6
U2 64
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1662-5153
J9 FRONT BEHAV NEUROSCI
JI Front. Behav. Neurosci.
PD JUN 11
PY 2013
VL 7
AR UNSP 63
DI 10.3389/fnbeh.2013.00063
PG 13
WC Behavioral Sciences; Neurosciences
SC Behavioral Sciences; Neurosciences & Neurology
GA 162ZN
UT WOS:000320304900001
PM 23781179
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Chavan, CF
   Manuel, AL
   Mouthon, M
   Spierer, L
AF Chavan, Camille F.
   Manuel, Aurelie L.
   Mouthon, Michael
   Spierer, Lucas
TI RETRACTED: Spontaneous pre-stimulus fluctuations in the activity of
   right fronto-parietal areas influence inhibitory control performance
   (Retracted article. See vol. 7, pg. 923, 2013)
SO FRONTIERS IN HUMAN NEUROSCIENCE
LA English
DT Article; Retracted Publication
DE inhibitory control; Go/NoGo; pre-stimulus period; inferior frontal; EEG;
   topography; electrical source estimation
ID PRESUPPLEMENTARY MOTOR AREA; EVENT-RELATED FMRI; TRANSCRANIAL MAGNETIC
   STIMULATION; ANTERIOR CINGULATE CORTEX; INFERIOR FRONTAL GYRUS;
   RESPONSE-INHIBITION; BRAIN ACTIVITY; COGNITIVE CONTROL; GO/NOGO TASK;
   NEURAL BASIS
AB Inhibitory control refers to the ability to suppress planned or ongoing cognitive or motor processes. Electrophysiological indices of inhibitory control failure have been found to manifest even before the presentation of the stimuli triggering the inhibition, suggesting that pre-stimulus brain-states modulate inhibition performance. However, previous electrophysiological investigations on the state-dependency of inhibitory control were based on averaged event-related potentials (ERPs), a method eliminating the variability in the ongoing brain activity not time-locked to the event of interest. These studies thus left unresolved whether spontaneous variations in the brain-state immediately preceding unpredictable inhibition-triggering stimuli also influence inhibitory control performance. To address this question, we applied single-trial EEG topographic analyses on the time interval immediately preceding NoGo stimuli in conditions where the responses to NoGo trials were correctly inhibited [correct rejection (CR)] vs. committed [false alarms (FAs)] during an auditory spatial Go/NoGo task. We found a specific configuration of the EEG voltage field manifesting more frequently before correctly inhibited responses to NoGo stimuli than before FAs. There was no evidence for an EEG topography occurring more frequently before FAs than before CR. The visualization of distributed electrical source estimations of the EEG topography preceding successful response inhibition suggested that it resulted from the activity of a right fronto-parietal brain network. Our results suggest that the fluctuations in the ongoing brain activity immediately preceding stimulus presentation contribute to the behavioral outcomes during an inhibitory control task. Our results further suggest that the state-dependency of sensory-cognitive processing might not only concern perceptual processes, but also high-order, top-down inhibitory control mechanisms.
C1 [Chavan, Camille F.; Mouthon, Michael; Spierer, Lucas] Univ Fribourg, Dept Med, Fac Sci, Neurol Unit, CH-1700 Fribourg, Switzerland.
   [Manuel, Aurelie L.] Vaudois Univ, Ctr Hosp, Neuropsychol & Neurorehabil Serv, Lausanne, Switzerland.
   [Manuel, Aurelie L.] Univ Lausanne, Lausanne, Switzerland.
RP Chavan, CF (reprint author), Univ Fribourg, Dept Med, Fac Sci, Lab Cognit & Neurol Sci,Neurol Unit, PER 09,Chemin Musee 5, CH-1700 Fribourg, Switzerland.
EM camille.chavan@unifr.ch
RI Centre d'imagerie Biomedicale, CIBM/B-5740-2012
OI Manuel, Aurelie/0000-0002-8301-033X
FU Swiss National Science Foundation [320030_143348]; Center for Biomedical
   Imaging of Geneva; Center for Biomedical Imaging of Lausanne
FX This work was supported by a grant from the Swiss National Science
   Foundation to Lucas Spierer (#320030_143348). The Cartool software has
   been programmed by Denis Brunet (Functional Brain Mapping Laboratory,
   Geneva, Switzerland) and supported by the Center for Biomedical Imaging
   of Geneva and Lausanne. We thank David Magezi, David Souto and the
   reviewers for their valuable comments.
CR Allain S, 2004, NEUROSCI LETT, V372, P161, DOI 10.1016/j.neulet.2004.09.036
   Arieli A, 1996, SCIENCE, V273, P1868, DOI 10.1126/science.273.5283.1868
   Aron AR, 2007, J NEUROSCI, V27, P11860, DOI 10.1523/JNEUROSCI.3644-07.2007
   Aron AR, 2007, NEUROSCIENTIST, V13, P214, DOI 10.1177/1073858407299288
   Aron AR, 2011, BIOL PSYCHIAT, V69, pE55, DOI 10.1016/j.biopsych.2010.07.024
   Aron AR, 2006, J NEUROSCI, V26, P2424, DOI 10.1523/JNEUROSCI.4682-05.2006
   Aron AR, 2003, NAT NEUROSCI, V6, P115, DOI 10.1038/nn1003
   Bernasconi F, 2011, INT J PSYCHOPHYSIOL, V79, P244, DOI 10.1016/j.ijpsycho.2010.10.017
   BLAUERT J, 1997, SPATIAL HEARING
   Boulinguez P, 2008, J NEUROPHYSIOL, V99, P1572, DOI 10.1152/jn.01198.2007
   Braver TS, 2001, CEREB CORTEX, V11, P825, DOI 10.1093/cercor/11.9.825
   Britz J, 2011, HUM BRAIN MAPP, V32, P1432, DOI 10.1002/hbm.21117
   Britz J, 2010, NEUROIMAGE, V49, P2774, DOI 10.1016/j.neuroimage.2009.10.033
   Britz J, 2009, CEREB CORTEX, V19, P55, DOI 10.1093/cercor/bhn056
   Brodbeck V, 2012, NEUROIMAGE, V62, P2129, DOI 10.1016/j.neuroimage.2012.05.060
   Brunet D, 2011, COMPUT INTEL NEUROSC, DOI 10.1155/2011/813870
   Burle B, 2002, PSYCHOL RES-PSYCH FO, V66, P324, DOI 10.1007/s00426-002-0105-6
   Cai WD, 2012, J NEUROPHYSIOL, V108, P380, DOI 10.1152/jn.00132.2012
   Chambers CD, 2009, NEUROSCI BIOBEHAV R, V33, P631, DOI 10.1016/j.neubiorev.2008.08.016
   Claffey MP, 2010, NEUROPSYCHOLOGIA, V48, P541, DOI 10.1016/j.neuropsychologia.2009.10.015
   Criaud M, 2012, FRONT PSYCHOL, V3, DOI 10.3389/fpsyg.2012.00059
   DECARY A, 1995, NEUROPSYCHOLOGIA, V33, P1243, DOI 10.1016/0028-3932(95)00040-A
   Dillon DG, 2007, APPL PREV PSYCHOL, V12, P99, DOI 10.1016/j.appsy.2007.09.004
   Duque J, 2012, J NEUROSCI, V32, P806, DOI 10.1523/JNEUROSCI.4299-12.2012
   Egner T, 2005, NEUROIMAGE, V24, P539, DOI 10.1016/j.neuroimage.2004.09.007
   Eichele H, 2010, FRONT HUM NEUROSCI, V4, DOI 10.3389/fnhum.2010.00065
   FERBERT A, 1992, J PHYSIOL-LONDON, V453, P525, DOI 10.1113/jphysiol.1992.sp019243
   Floden D, 2006, J COGNITIVE NEUROSCI, V18, P1843, DOI 10.1162/jocn.2006.18.11.1843
   Fox MD, 2006, NAT NEUROSCI, V9, P23, DOI 10.1038/nn1616
   Fox MD, 2007, NAT REV NEUROSCI, V8, P700, DOI 10.1038/nrn2201
   Garavan H, 1999, P NATL ACAD SCI USA, V96, P8301, DOI 10.1073/pnas.96.14.8301
   Grave-de Peralta R, 2004, REV NEUROLOGIA, V39, P748
   Hajcak G, 2005, BIOL PSYCHOL, V70, P67, DOI 10.1016/j.biopsycho.2004.12.001
   Hampshire A, 2010, NEUROIMAGE, V50, P1313, DOI 10.1016/j.neuroimage.2009.12.109
   Ikeda A, 2000, BRAIN, V123, P1710, DOI 10.1093/brain/123.8.1710
   Inase M, 1999, BRAIN RES, V833, P191, DOI 10.1016/S0006-8993(99)01531-0
   Jahfari S, 2010, J COGNITIVE NEUROSCI, V22, P1479, DOI 10.1162/jocn.2009.21307
   Kaiser S, 2006, INT J PSYCHOPHYSIOL, V61, P279, DOI 10.1016/j.ijpsycho.2005.09.006
   Koenig T, 2002, NEUROIMAGE, V16, P41, DOI 10.1006/nimg.2002.1070
   Koenig T, 1999, EUR ARCH PSY CLIN N, V249, P205, DOI 10.1007/s004060050088
   Kondakor I, 1997, J NEURAL TRANSM, V104, P161, DOI 10.1007/BF01273178
   KONDAKOR I, 1995, J MED ENG TECHNOL, V19, P66, DOI 10.3109/03091909509030277
   KRZANOWSKI WJ, 1988, BIOMETRICS, V44, P23, DOI 10.2307/2531893
   LEHMANN D, 1980, ELECTROEN CLIN NEURO, V48, P609, DOI 10.1016/0013-4694(80)90419-8
   LEHMANN D, 1987, ELECTROEN CLIN NEURO, V67, P271, DOI 10.1016/0013-4694(87)90025-3
   Lehmann D, 1994, Int J Neurosci, V74, P239
   Li CSR, 2006, J NEUROSCI, V26, P186, DOI 10.1523/JNEUROSCI.3741-05.2006
   Liddle PF, 2001, HUM BRAIN MAPP, V12, P100, DOI 10.1002/1097-0193(200102)12:2<100::AID-HBM1007>3.0.CO;2-6
   LUDERS HO, 1995, ADV NEUROL, V67, P115
   Majid DSA, 2012, CEREB CORTEX, V22, P363, DOI 10.1093/cercor/bhr112
   Manuel AL, 2010, J NEUROSCI, V30, P13670, DOI 10.1523/JNEUROSCI.2064-10.2010
   Masaki H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038006
   Menendez RGD, 2001, BRAIN TOPOGR, V14, P131, DOI 10.1023/A:1012944913650
   Menon V, 2001, HUM BRAIN MAPP, V12, P131, DOI 10.1002/1097-0193(200103)12:3<131::AID-HBM1010>3.0.CO;2-C
   Michel C., 2009, ELECT NEUROIMAGING
   Michel CM, 2004, CLIN NEUROPHYSIOL, V115, P2195, DOI 10.1016/j.clinph.2004.06.001
   Mohr C, 2005, CEREB CORTEX, V15, P1451, DOI 10.1093/cercor/bhi025
   Muller TJ, 2005, J NEURAL TRANSM, V112, P565, DOI 10.1007/s00702-004-0194-z
   Murray MM, 2008, BRAIN TOPOGR, V20, P249, DOI 10.1007/s10548-008-0054-5
   O'Connell RG, 2009, J NEUROSCI, V29, P8604, DOI 10.1523/JNEUROSCI.5967-08.2009
   OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4
   Palva JM, 2012, NEUROIMAGE, V62, P2201, DOI 10.1016/j.neuroimage.2012.02.060
   PASCUALMARQUI RD, 1995, IEEE T BIO-MED ENG, V42, P658, DOI 10.1109/10.391164
   Pegna AJ, 1997, HUM BRAIN MAPP, V5, P410, DOI 10.1002/(SICI)1097-0193(1997)5:6<410::AID-HBM2>3.0.CO;2-6
   PERRIN F, 1987, ELECTROEN CLIN NEURO, V66, P75, DOI 10.1016/0013-4694(87)90141-6
   Picton TW, 2007, CEREB CORTEX, V17, P826, DOI 10.1093/cercor/bhk031
   Picton TW, 2000, PSYCHOPHYSIOLOGY, V37, P127, DOI 10.1017/S0048577200000305
   Ress D, 2000, NAT NEUROSCI, V3, P940
   Ridderinkhof KR, 2003, NEUROSCI LETT, V348, P1, DOI 10.1016/S0304-3940(03)00566-4
   Rieger M, 2003, NEUROPSYCHOLOGY, V17, P272, DOI 10.1037/0894-4105.17.2.272
   Rubia K, 2003, NEUROIMAGE, V20, P351, DOI 10.1016/S1053-8119(03)00275-1
   Smith JL, 2011, PSYCHIAT RES-NEUROIM, V193, P177, DOI 10.1016/j.pscychresns.2011.03.002
   Solanto MV, 2009, J NEUROIMAGING, V19, P205, DOI 10.1111/j.1552-6569.2008.00289.x
   Spierer L, 2007, J NEUROSCI, V27, P5474, DOI 10.1523/JNEUROSCI.0764-07.2007
   Spierer L, 2011, HEARING RES, V271, P88, DOI 10.1016/j.heares.2010.03.086
   Steinhauser M, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00097
   Tamm L, 2004, J AM ACAD CHILD PSY, V43, P1430, DOI 10.1097/01.chi.0000140452.51205.8d
   van Veen V, 2001, NEUROIMAGE, V14, P1302, DOI 10.1006/nimg.2001.0923
   Vocat R, 2008, NEUROPSYCHOLOGIA, V46, P2545, DOI 10.1016/j.neuropsychologia.2008.04.006
   Yazawa S, 2000, EXP BRAIN RES, V131, P165, DOI 10.1007/s002219900311
NR 80
TC 1
Z9 1
U1 1
U2 11
PU FRONTIERS RESEARCH FOUNDATION
PI LAUSANNE
PA PO BOX 110, LAUSANNE, 1015, SWITZERLAND
SN 1662-5161
J9 FRONT HUM NEUROSCI
JI Front. Hum. Neurosci.
PD JUN 6
PY 2013
VL 7
AR 238
DI 10.3389/fnhum.2013.00238
PG 9
WC Neurosciences; Psychology
SC Neurosciences & Neurology; Psychology
GA 157QK
UT WOS:000319913900001
PM 23761747
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Hires, SA
   Efros, AL
   Svoboda, K
AF Hires, S. Andrew
   Efros, Alexander L.
   Svoboda, Karel
TI RETRACTED: Whisker Dynamics Underlying Tactile Exploration (Retracted
   article. See vol. 33, pg. 14974, 2013)
SO JOURNAL OF NEUROSCIENCE
LA English
DT Article; Retracted Publication
ID RADIAL DISTANCE DETERMINATION; TRIGEMINAL GANGLION NEURONS; RAT
   VIBRISSAL SYSTEM; OBJECT LOCALIZATION; BARREL CORTEX; MYSTACIAL
   VIBRISSAE; RESPONSES; RESONANCE; FEATURES; DISCRIMINATION
AB Rodents explore the world by palpating objects with their whiskers. Whiskers interact with objects, causing stresses in whisker follicles and spikes in sensory neurons, which are interpreted by the brain to produce tactile perception. The mechanics of the whisker thus couple self-movement and the structure of the world to sensation. Whiskers are elastic thin rods; hence, they tend to vibrate. Whisker vibrations could be a key ingredient of rodent somatosensation. However, the specific conditions under which vibrations contribute appreciably to the stresses in the follicle remain unclear. We present an analytical solution for the deformation of individual whiskers in response to a time-varying force. We tracked the deformation of mouse whiskers during a pole localization task to extract the whisker Young's modulus and damping coefficient. We further extracted the time course and amplitude of steady-state forces during whisker-object contact. We use our model to calculate the relative contribution of steady-state and vibrational forces to stresses in the follicle in a variety of active sensation tasks and during the passive whisker stimuli typically used for sensory physiology. Vibrational stresses are relatively more prominent compared with steady-state forces for short contacts and for contacts close to the whisker tip. Vibrational stresses are large for texture discrimination, and under some conditions, object localization tasks. Vibrational stresses are negligible for typical ramp-and-hold stimuli. Our calculation provides a general framework, applicable to most experimental situations.
C1 [Hires, S. Andrew; Svoboda, Karel] Janelia Farm Res Campus, Howard Hughes Med Inst, Ashburn, VA 20147 USA.
   [Efros, Alexander L.] USN, Ctr Computat Mat Sci, Res Lab, Washington, DC 20375 USA.
RP Hires, SA (reprint author), Janelia Farm Res Campus, Howard Hughes Med Inst, 19700 Helix Dr, Ashburn, VA 20147 USA.
EM hiresa@janelia.hhmi.org; efros@nrl.navy.mil
FU Howard Hughes Medical Institute; Office of Naval Research (ONR) through
   the Naval Research Laboratory's Basic Research Program; APIG group of
   Janelia Farm
FX This work was supported by the Howard Hughes Medical Institute. A.L.E
   acknowledges support of the Office of Naval Research (ONR) through the
   Naval Research Laboratory's Basic Research Program and thanks the APIG
   group of Janelia Farm for hospitality and additional support. We thank
   David Golomb for helpful discussions.
CR Andermann ML, 2004, NEURON, V42, P451, DOI 10.1016/S0896-6273(04)00198-9
   Anjum F, 2006, P NATL ACAD SCI USA, V103, P16544, DOI 10.1073/pnas.0605573103
   Arabzadeh E, 2005, PLOS BIOL, V3, P155, DOI 10.1371/journal.pbio.0030017
   Arabzadeh E, 2006, J NEUROSCI, V26, P9216, DOI 10.1523/JNEUROSCI.1491-06.2006
   Birdwell JA, 2007, J NEUROPHYSIOL, V98, P2439, DOI 10.1152/jn.00707.2006
   Boubenec Y, 2012, FRONT BEHAV NEUROSCI, V6, DOI 10.3389/fnbeh.2012.00074
   Brecht M, 1997, BEHAV BRAIN RES, V84, P81, DOI 10.1016/S0166-4328(97)83328-1
   CARVELL GE, 1990, J NEUROSCI, V10, P2638
   Clack NG, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002591
   CONWAY HD, 1964, ASME J APPL MECH, P329
   Dehnhardt G, 2001, SCIENCE, V293, P102, DOI 10.1126/science.1060514
   DORFL J, 1982, J ANAT, V135, P147
   Euler L, 1744, OPERA OMNIA 1, P231
   GIBSON JM, 1983, SOMATOSENS RES, V1, P51, DOI 10.3109/07367228309144540
   GOTTSCHALDT KM, 1981, SCIENCE, V214, P183, DOI 10.1126/science.7280690
   Haidarliu S, 2011, ANAT REC, V294, P764, DOI 10.1002/ar.21371
   Han SM, 1999, J SOUND VIB, V225, P935, DOI 10.1006/jsvi.1999.2257
   Hartmann MJ, 2003, J NEUROSCI, V23, P6510
   Hill DN, 2008, J NEUROSCI, V28, P3438, DOI 10.1523/JNEUROSCI.5008-07.2008
   HUTSON KA, 1986, J NEUROPHYSIOL, V56, P1196
   Jadhav SP, 2009, NAT NEUROSCI, V12, P792, DOI 10.1038/nn.2328
   Kelly SG, 2011, MECH VIBRATIONS THEO
   Kleinfeld D, 2011, NEURON, V72, P455, DOI 10.1016/j.neuron.2011.10.009
   Knutsen PM, 2008, NEURON, V59, P35, DOI 10.1016/j.neuron.2008.05.013
   Knutsen PM, 2006, J NEUROSCI, V26, P8451, DOI 10.1523/JNEUROSCI.1516-06.2006
   Krupa DJ, 2001, J NEUROSCI, V21, P5752
   Mathews J, 1964, MATH METHODS PHYS
   Mehta SB, 2007, PLOS BIOL, V5, P309, DOI 10.1371/journal.pbio.0050015
   MELARAGNO HP, 1953, ANAT REC, V115, P129, DOI 10.1002/ar.1091150202
   Mitchinson B, 2007, P R SOC B, V274, P1035, DOI 10.1098/rspb.2006.0347
   Montemurro MA, 2007, J NEUROPHYSIOL, V98, P1871, DOI 10.1152/jn.00593.2007
   Neimark MA, 2003, J NEUROSCI, V23, P6499
   O'Connor DH, 2010, NEURON, V67, P1048, DOI 10.1016/j.neuron.2010.08.026
   O'Connor DH, 2010, J NEUROSCI, V30, P1947, DOI 10.1523/JNEUROSCI.3762-09.2010
   Pammer L, 2013, J NEUROSCI, V33, P6726, DOI 10.1523/JNEUROSCI.4316-12.2013
   Quist BW, 2012, J NEUROPHYSIOL, V107, P2298, DOI 10.1152/jn.00372.2011
   Quist BW, 2011, J BIOMECH, V44, P2775, DOI 10.1016/j.jbiomech.2011.08.027
   Ritt JT, 2008, NEURON, V57, P599, DOI 10.1016/j.neuron.2007.12.024
   SHIPLEY MT, 1974, J NEUROPHYSIOL, V37, P73
   SIMONS DJ, 1978, J NEUROPHYSIOL, V41, P798
   Simony E, 2010, J NEUROSCI, V30, P8935, DOI 10.1523/JNEUROSCI.0172-10.2010
   Solomon JH, 2006, NATURE, V443, P525, DOI 10.1038/443525a
   Solomon JH, 2011, PHILOS T R SOC B, V366, P3049, DOI 10.1098/rstb.2011.0166
   Stuttgen MC, 2008, J NEUROPHYSIOL, V100, P1879, DOI 10.1152/jn.90511.2008
   Stuttgen MC, 2006, J NEUROSCI, V26, P7933, DOI 10.1523/JNEUROSCI.1864-06.2006
   Szwed M, 2006, J NEUROPHYSIOL, V95, P791, DOI 10.1152/jn.00571.2005
   Szwed M, 2003, NEURON, V40, P621, DOI 10.1016/S0896-6273(03)00671-8
   Timoshenko S, 1937, VIBRATION PROBLEMS E
   Vincent Stella Burnham, 1912, Behavior Monographs Cambridge Mass, V1
   Von Heimendahl M, 2007, PLOS BIOL, V5, P2696, DOI 10.1371/journal.pbio.0050305
   Wilent WB, 2004, J NEUROSCI, V24, P3985, DOI 10.1523/JNEUROSCI.5782-03.2004
   Wolfe J, 2008, PLOS BIOL, V6, P1661, DOI 10.1371/journal.pbio.0060215
   ZUCKER E, 1969, BRAIN RES, V12, P138, DOI 10.1016/0006-8993(69)90061-4
NR 53
TC 2
Z9 2
U1 2
U2 26
PU SOC NEUROSCIENCE
PI WASHINGTON
PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA
SN 0270-6474
J9 J NEUROSCI
JI J. Neurosci.
PD JUN 5
PY 2013
VL 33
IS 23
BP 9576
EP 9591
DI 10.1523/JNEUROSCI.5846-12.2013
PG 16
WC Neurosciences
SC Neurosciences & Neurology
GA 158IS
UT WOS:000319963300002
PM 23739955
OA Bronze
DA 2018-12-27
ER

PT J
AU Lu, YY
   An, LJ
   Wang, SQ
   Wang, ZG
AF Lu, Yuyuan
   An, Lijia
   Wang, Shi-Qing
   Wang, Zhen-Gang
TI RETRACTED: Evolution of Chain Conformation and Entanglements during
   Startup Shear (Retracted article. See vol. 6, pg. 344, 2017)
SO ACS MACRO LETTERS
LA English
DT Article; Retracted Publication
ID MOLECULAR-DYNAMICS SIMULATION; POLYMER DYNAMICS; TUBE THEORY; REPTATION;
   MELTS; CROSSOVER; LIQUIDS
AB Using Brownian dynamics simulation, we determine chain dimensions in an entangled polymer melt undergoing startup shear at a rate lower than the reciprocal of the Rouse time yet higher than the reciprocal reptation time. Here the tube model expects negligible chain stretching. In contrast, our simulation shows the deformed coil to conform closely to affine deformation. We find that the total number of entanglements decreases with increasing shear. Remarkably, up to many Rouse time, the decline in the number of initial entanglements is slower than that under the quiescent condition. These results point to fundamental deficiencies in the molecular picture of the tube model for startup shear.
C1 [Lu, Yuyuan; An, Lijia] Chinese Acad Sci, Changchun Inst Appl Chem, State Key Lab Polymer Phys & Chem, Changchun 130022, Peoples R China.
   [Wang, Shi-Qing] Univ Akron, Dept Polymer Sci, Akron, OH 44325 USA.
   [Wang, Zhen-Gang] CALTECH, Div Chem & Chem Engn, Pasadena, CA 91125 USA.
RP An, LJ (reprint author), Chinese Acad Sci, Changchun Inst Appl Chem, State Key Lab Polymer Phys & Chem, Changchun 130022, Peoples R China.
EM ljan@ciac.jl.cn; swang@uakron.edu; zgw@caltech.edu
FU National Natural Science Foundation of China [21120102037]; Special
   Funds for National Basic Research Program of China [2012CB821500]; US
   National Science Foundation [DMR-0821697, DMR-1105135]
FX This work is supported, in part, by the National Natural Science
   Foundation of China (No. 21120102037) and further subsidized by the
   Special Funds for National Basic Research Program of China (No.
   2012CB821500). S.Q.W. acknowledges support from the US National Science
   Foundation (DMR-0821697 and DMR-1105135).
CR Adams JM, 2009, PHYS REV LETT, V102, DOI 10.1103/PhysRevLett.102.067801
   Archer LA, 1999, J RHEOL, V43, P1555, DOI 10.1122/1.551060
   Astarita G, 1974, PRINCIPLES NONNEWTON
   Bent J, 2003, SCIENCE, V301, P1691, DOI 10.1126/science.1086952
   Bird R.B., 1987, DYNAMICS POLYM LIQUI
   de Gennes P. G., 1979, SCALING CONCEPTS POL
   Doi M, 1986, THEORY POLYM DYNAMIC
   Ebert U, 1997, PHYS REV LETT, V78, P1592, DOI 10.1103/PhysRevLett.78.1592
   Everaers R, 1996, J MOL MODEL, V2, P293, DOI 10.1007/s0089460020293
   GREEN MS, 1946, J CHEM PHYS, V14, P80, DOI 10.1063/1.1724109
   Kaye A., 1962, NONNEWTONIAN FLOW IN
   KREMER K, 1988, PHYS REV LETT, V61, P566, DOI 10.1103/PhysRevLett.61.566
   KREMER K, 1990, J CHEM PHYS, V92, P5057, DOI 10.1063/1.458541
   Kroger M, 2000, PHYS REV LETT, V85, P1128, DOI 10.1103/PhysRevLett.85.1128
   Kumar S, 2001, J CHEM PHYS, V114, P6937, DOI 10.1063/1.1358860
   Larson RG, 2007, J POLYM SCI POL PHYS, V45, P3240, DOI 10.1002/polb.21332
   Likhtman AE, 2007, MACROMOLECULES, V40, P6748, DOI 10.1021/ma070843b
   Likhtman AE, 2009, J NON-NEWTON FLUID, V157, P158, DOI 10.1016/j.jnnfm.2008.11.008
   LODGE AS, 1964, ELASTIC LIQUIDS
   McLeish TCB, 2002, ADV PHYS, V51, P1379, DOI 10.1080/00018730210153216
   Morse DC, 2001, PHYS REV E, V63, DOI 10.1103/PhysRevE.63.031502
   Qin J, 2012, J RHEOL, V56, P707, DOI 10.1122/1.4708594
   Rubinstein M., 2003, POLYM PHYS
   Schleger P, 1998, PHYS REV LETT, V81, P124, DOI 10.1103/PhysRevLett.81.124
   SHAFFER JS, 1994, J CHEM PHYS, V101, P4205, DOI 10.1063/1.467470
   SMITH SW, 1995, PHYS REV LETT, V75, P1316, DOI 10.1103/PhysRevLett.75.1316
   Sukumaran SK, 2005, J POLYM SCI POL PHYS, V43, P917, DOI 10.1002/polb.20384
   Sussman DM, 2012, MACROMOLECULES, V45, P3270, DOI 10.1021/ma300006s
   Sussman DM, 2011, J CHEM PHYS, V135, DOI 10.1063/1.3651143
   Sussman DM, 2011, PHYS REV LETT, V107, DOI 10.1103/PhysRevLett.107.078102
   Wang SQ, 2007, J CHEM PHYS, V127, DOI 10.1063/1.2753156
   Wang SQ, 2006, PHYS REV LETT, V97, DOI 10.1103/PhysRevLett.97.187801
   Wang YY, 2009, J RHEOL, V53, P1389, DOI 10.1122/1.3208063
NR 33
TC 19
Z9 19
U1 6
U2 85
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 2161-1653
J9 ACS MACRO LETT
JI ACS Macro Lett.
PD JUN
PY 2013
VL 2
IS 6
BP 561
EP 565
DI 10.1021/mz400145m
PG 5
WC Polymer Science
SC Polymer Science
GA 204JZ
UT WOS:000323362900022
DA 2018-12-27
ER

PT J
AU Cao, LY
   Wang, LH
   Zheng, M
   Cao, H
   Ding, L
   Zhang, XL
   Fu, Y
AF Cao, Lingyan
   Wang, Linhai
   Zheng, Min
   Cao, Hong
   Ding, Lian
   Zhang, Xiaolan
   Fu, Ying
TI RETRACTED: Arabidopsis AUGMIN Subunit8 Is a Microtubule Plus-End Binding
   Protein That Promotes Microtubule Reorientation in Hypocotyls (Retracted
   article. See vol. 29, pg. 2305, 2017)
SO PLANT CELL
LA English
DT Article; Retracted Publication
ID DESTABILIZING CORTICAL MICROTUBULES; CELLULOSE SYNTHASE COMPLEXES;
   DIRECTIONAL CELL EXPANSION; HANDED HELICAL GROWTH; EPIDERMAL-CELLS;
   FUNCTIONAL ASSOCIATION; DYNAMIC INSTABILITY; ARRAY ORGANIZATION;
   HIGHER-PLANTS; LIVING CELLS
AB In plant cells, cortical microtubules provide tracks for cellulose-synthesizing enzymes and regulate cell division, growth, and morphogenesis. The role of microtubules in these essential cellular processes depends on the spatial arrangement of the microtubules. Cortical microtubules are reoriented in response to changes in cell growth status and cell shape. Therefore, an understanding of the mechanism that underlies the change in microtubule orientation will provide insight into plant cell growth and morphogenesis. This study demonstrated that AUGMIN subunit8 (AUG8) in Arabidopsis thaliana is a novel microtubule plus-end binding protein that participates in the reorientation of microtubules in hypocotyls when cell elongation slows down. AUG8 bound to the plus ends of microtubules and promoted tubulin polymerization in vitro. In vivo, AUG8 was recruited to the microtubule branch site immediately before nascent microtubules branched out. It specifically associated with the plus ends of growing cortical microtubules and regulated microtubule dynamics, which facilitated microtubule reorientation when microtubules changed their growth trajectory or encountered obstacle microtubules during microtubule reorientation. This study thus reveals a novel mechanism underlying microtubule reorientation that is critical for modulating cell elongation in Arabidopsis.
C1 [Cao, Lingyan; Wang, Linhai; Zheng, Min; Cao, Hong; Fu, Ying] China Agr Univ, Coll Biol Sci, State Key Lab Plant Physiol & Biochem, Beijing 100193, Peoples R China.
   [Ding, Lian; Zhang, Xiaolan] China Agr Univ, Beijing Key Lab Growth & Dev Regulat Protected Ve, Dept Vegetable Sci, Beijing 100193, Peoples R China.
RP Fu, Y (reprint author), China Agr Univ, Coll Biol Sci, State Key Lab Plant Physiol & Biochem, Beijing 100193, Peoples R China.
EM yingfu@cau.edu.cn
FU National Basic Research Program of China [2012CB114200]; Natural Science
   Foundation of China [31070160, 90817105];  [NCET-08-0526]
FX We thank Ming Yuan (China Agricultural University) and Zhenbiao Yang
   (University of California, Riverside, CA) for critical reading and
   comments on the article. We thank David W. Ehrhardt for helpful
   discussions and advice. We thank Anne Mie C. Emons at Wageningen
   University, The Netherlands, for providing Arabidopsis seeds that
   express mCherry-TUA5 and Shanjin Huang (Institute of Botany, Chinese
   Academy of Sciences) for providing Arabidopsis seeds that express
   mCherry-EB1 (plasmid provided by Bo Liu [University of California,
   Davis, CA] and Zhaosheng Kong [Institute of Microbiology, Chinese
   Academy of Sciences]). This research was supported by the National Basic
   Research Program of China (2012CB114200), the Natural Science Foundation
   of China (31070160 and 90817105), and NCET-08-0526.
CR Abe T, 2005, PLANT J, V43, P191, DOI 10.1111/j.1365-313X.2005.02442.x
   Albrecht V, 2010, PLANT CELL, V22, P3423, DOI 10.1105/tpc.110.074781
   Ambrose C, 2013, DEV CELL, V24, P649, DOI 10.1016/j.devcel.2013.02.007
   Ambrose C, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1444
   Ambrose JC, 2007, PLANT CELL, V19, P2763, DOI 10.1105/tpc.107.053777
   BALUSKA F, 1992, J CELL SCI, V103, P191
   Baskin TI, 2012, CELL ADHES MIGR, V6, P404, DOI 10.4161/cam.21121
   Bisgrove SR, 2008, PLANT CELL, V20, P396, DOI 10.1105/tpc.107.056846
   Bisgrove SR, 2004, PLANT PHYSIOL, V136, P3855, DOI 10.1104/pp.104.051037
   Bringmann M, 2012, PLANT CELL, V24, P163, DOI 10.1105/tpc.111.093575
   Buschmann H, 2004, CURR BIOL, V14, P1515, DOI 10.1016/j.cub.2004.08.033
   Castoldi M, 2003, PROTEIN EXPRES PURIF, V32, P83, DOI 10.1016/S1046-5928(03)00218-3
   Chan J, 2003, NAT CELL BIOL, V5, P967, DOI 10.1038/ncb1057
   Chan J, 2007, NAT CELL BIOL, V9, P171, DOI 10.1038/ncb1533
   Crowell EF, 2011, PLANT CELL, V23, P2592, DOI 10.1105/tpc.111.087338
   Crowell EF, 2010, CR BIOL, V333, P320, DOI 10.1016/j.crvi.2010.01.007
   Crowell EF, 2009, PLANT CELL, V21, P1141, DOI 10.1105/tpc.108.065334
   DeBolt S, 2007, P NATL ACAD SCI USA, V104, P5854, DOI 10.1073/pnas.0700789104
   Dixit R, 2006, MOL BIOL CELL, V17, P1298, DOI 10.1091/mbc.E05-09-0864
   Dixit R, 2004, PLANT CELL, V16, P3274, DOI 10.1105/tpc.104.026930
   Ehrhardt DW, 2008, CURR OPIN CELL BIOL, V20, P107, DOI 10.1016/j.ceb.2007.12.004
   Ehrhardt DW, 2006, ANNU REV PLANT BIOL, V57, P859, DOI 10.1146/annurev.arplant.57.032905.105329
   FABRI CO, 1994, PLANT J, V5, P149, DOI 10.1046/j.1365-313X.1994.5010149.x
   Fu Y, 2005, CELL, V120, P687, DOI 10.1016/j.cell.2004.12.026
   Fu Y, 2002, PLANT CELL, V14, P777, DOI 10.1105/tpc.001537
   Fu Y, 2009, CURR BIOL, V19, P1827, DOI 10.1016/j.cub.2009.08.052
   Gendreau E, 1997, PLANT PHYSIOL, V114, P295, DOI 10.1104/pp.114.1.295
   Goshima G, 2008, J CELL BIOL, V181, P421, DOI 10.1083/jcb.200711053
   Granger CL, 2001, PROTOPLASMA, V216, P201, DOI 10.1007/BF02673872
   Gutierrez R, 2009, NAT CELL BIOL, V11, P797, DOI 10.1038/ncb1886
   Hamada T, 2004, PLANT CELL PHYSIOL, V45, P1233, DOI 10.1093/pcp/pch145
   Hejatko J, 2006, NAT PROTOC, V1, P1939, DOI 10.1038/nprot.2006.333
   Ho CMK, 2011, PLANT CELL, V23, P2606, DOI 10.1105/tpc.111.086892
   Hotta T, 2012, PLANT CELL, V24, P1494, DOI 10.1105/tpc.112.096610
   Hwang JU, 2008, CURR BIOL, V18, P1907, DOI 10.1016/j.cub.2008.11.057
   HYMAN AA, 1991, J CELL SCI, P125
   Ishida T, 2007, J PLANT RES, V120, P61, DOI 10.1007/s10265-006-0039-y
   Kakar K, 2013, NATURE, V495, P529, DOI 10.1038/nature11980
   Kirik A, 2012, PLANT CELL, V24, P1158, DOI 10.1105/tpc.111.094367
   Kirik V, 2007, J CELL SCI, V120, P4416, DOI 10.1242/jcs.024950
   Li JJ, 2011, PLANT CELL, V23, P4411, DOI 10.1105/tpc.111.092684
   Li SD, 2012, P NATL ACAD SCI USA, V109, P185, DOI 10.1073/pnas.1118560109
   Lloyd C, 2011, INT REV CEL MOL BIO, V287, P287, DOI 10.1016/B978-0-12-386043-9.00007-4
   LODISH H, 2007, MOL CELL BIOL
   Lucas J, 2008, CURR OPIN PLANT BIOL, V11, P94, DOI 10.1016/j.pbi.2007.12.001
   Lucas JR, 2011, PLANT CELL, V23, P1889, DOI 10.1105/tpc.111.084970
   Manna T, 2008, BIOCHEMISTRY-US, V47, P779, DOI 10.1021/bi701912g
   Mao TL, 2005, PLANT PHYSIOL, V138, P654, DOI 10.1104/pp.104.052456
   Mathur J, 2003, CURR BIOL, V13, P1991, DOI 10.1016/j.cub.2003.10.033
   Murata T, 2005, NAT CELL BIOL, V7, P961, DOI 10.1038/ncb1306
   Nakajima K, 2004, PLANT CELL, V16, P1178, DOI 10.1105/tpc.017830
   Nakamura M, 2004, PLANT CELL PHYSIOL, V45, P1330, DOI 10.1093/pcp/pch300
   Nakamura M, 2010, NAT CELL BIOL, V12, P1064, DOI 10.1038/ncb2110
   Naoi K, 2004, PLANT CELL, V16, P1841, DOI 10.1105/tpc.021865
   Paradez A, 2006, CURR OPIN PLANT BIOL, V9, P571, DOI 10.1016/j.pbi.2006.09.005
   Paredez AR, 2006, SCIENCE, V312, P1491, DOI 10.1126/science.1126551
   Petry S, 2013, CELL, V152, P768, DOI 10.1016/j.cell.2012.12.044
   Pignocchi C, 2009, PLANT CELL, V21, P90, DOI 10.1105/tpc.108.061812
   Sambade A, 2012, PLANT CELL, V24, P192, DOI 10.1105/tpc.111.093849
   Sedbrook JC, 2004, PLANT CELL, V16, P1506, DOI 10.1105/tpc.020644
   Shaw SL, 2003, SCIENCE, V300, P1715, DOI 10.1126/science.1083529
   Smith LG, 2005, ANNU REV CELL DEV BI, V21, P271, DOI 10.1146/annurev.cellbio.21.122303.114901
   Sugimoto K, 2000, PLANT PHYSIOL, V124, P1493, DOI 10.1104/pp.124.4.1493
   Szymanski DB, 2009, CURR BIOL, V19, pR800, DOI 10.1016/j.cub.2009.07.056
   Thitamadee S, 2002, NATURE, V417, P193, DOI 10.1038/417193a
   TOSO RJ, 1993, BIOCHEMISTRY-US, V32, P1285, DOI 10.1021/bi00056a013
   Ueda K, 2000, PROTOPLASMA, V213, P28, DOI 10.1007/BF01280502
   Ueda K, 1999, PROTOPLASMA, V206, P201, DOI 10.1007/BF01279267
   Uehara R, 2009, P NATL ACAD SCI USA, V106, P6998, DOI 10.1073/pnas.0901587106
   Van Damme D, 2004, PLANT PHYSIOL, V136, P3956, DOI 10.1104/pp.104.051623
   Vaughan KT, 2005, J CELL BIOL, V171, P197, DOI 10.1083/jcb.200509150
   Wang X, 2007, PLANT CELL, V19, P877, DOI 10.1105/tpc.106.048579
   Wasteneys GO, 2009, TRENDS CELL BIOL, V19, P62, DOI 10.1016/j.tcb.2008.11.004
   Wasteneys GO, 2004, CURR OPIN PLANT BIOL, V7, P651, DOI 10.1016/j.ppi.2004.09.008
   Whittington AT, 2001, NATURE, V411, P610, DOI 10.1038/35079128
   Yao M, 2008, J CELL SCI, V121, P2372, DOI 10.1242/jcs.030221
   YUAN M, 1994, P NATL ACAD SCI USA, V91, P6050, DOI 10.1073/pnas.91.13.6050
NR 77
TC 20
Z9 22
U1 3
U2 23
PU AMER SOC PLANT BIOLOGISTS
PI ROCKVILLE
PA 15501 MONONA DRIVE, ROCKVILLE, MD 20855 USA
SN 1040-4651
EI 1532-298X
J9 PLANT CELL
JI Plant Cell
PD JUN
PY 2013
VL 25
IS 6
BP 2187
EP 2201
DI 10.1105/tpc.113.113472
PG 15
WC Biochemistry & Molecular Biology; Plant Sciences; Cell Biology
SC Biochemistry & Molecular Biology; Plant Sciences; Cell Biology
GA 190VV
UT WOS:000322371500023
PM 23735294
OA Bronze, Green Published
DA 2018-12-27
ER

PT J
AU Kim, YW
   Chun, HJ
   Kim, IW
   Liu, HB
   Ahn, WS
AF Kim, Yong-Wan
   Chun, Heung Jae
   Kim, In-Wook
   Liu, Hai-Bo
   Ahn, Woong Shick
TI RETRACTED: Antimicrobial and antifungal effects of green tea extracts
   against microorganisms causing vaginitis (Retracted article. See vol.
   23, pg. 1005, 2014)
SO FOOD SCIENCE AND BIOTECHNOLOGY
LA English
DT Article; Retracted Publication
DE green tea extract; antimicrobial; antifungal; vaginal-related pathogen
ID BACTERIAL VAGINOSIS; ANTIBACTERIAL ACTIVITY; ELUTION SYSTEM;
   POLYPHENOLS; CATECHINS; CARCINOGENESIS; INHIBITION; THERAPIES; CAFFEINE
AB Green tea extracts (GTE) including catechins and caffeine possess strong antimicrobial activity against a variety of microorganisms. In this study, we examined their possible antimicrobial and antifungal effects on bacteria (Proteus mirabilis and Streptococcus pyogenes) and yeast species (Candida albicans) that cause vaginitis. The GTE and ethyl acetate fractions exhibited strong growth inhibitory activity against P. mirabilis and S. pyogenes, whereas the aqueous fraction possessed poor antimicrobial activity. Among the catechins, epigallocatechin gallate showed strong antibacterial activity. C. albicans was potently inhibited by the methylene chloride fraction and caffeine, while antifungal activity of GTE was contributed by caffeine. Furthermore, we evaluated whether in vitro activity of GTE included purified solvent fractions that were stable to heat and pH. Antimicrobial activity was potent in alkaline environment for P. mirabilis and acid environment for S. pyogenes and C. albicans. Herein GTE can be a valuable therapeutic agent for the treatment of vaginal-related pathogens.
C1 [Ahn, Woong Shick] Catholic Univ Korea, Dept Obstet & Gynecol, Coll Med, Seoul 137701, South Korea.
   [Kim, Yong-Wan; Kim, In-Wook; Liu, Hai-Bo] Catholic Univ Korea, Catholic Res Inst Med Sci, Seoul 137701, South Korea.
   [Chun, Heung Jae] Catholic Univ Korea, Inst Cell & Tissue Engn, Seoul 137701, South Korea.
RP Ahn, WS (reprint author), Catholic Univ Korea, Dept Obstet & Gynecol, Coll Med, Seoul 137701, South Korea.
EM ahnlab@catholic.ac.kr
FU Technology Development Program for Agriculture and Forestry, Ministry of
   Agriculture and Forestry, Republic of Korea [202013-3]
FX This study was supported by Technology Development Program for
   Agriculture and Forestry (202013-3), Ministry of Agriculture and
   Forestry, Republic of Korea.
CR AHN Y-J, 1990, Microbial Ecology in Health and Disease, V3, P335
   Amarowicz R, 2000, NAHRUNG, V44, P60, DOI [10.1002/(SICI)1521-3803(20000101)44:1<60::AID-FOOD60>3.0.CO;2-L, 10.1002/(SICI)1521-3803(20000101)44:1<60::AID-FOOD60>3.3.CO;2-C]
   Astill C, 2001, J AGR FOOD CHEM, V49, P5340, DOI 10.1021/jf010759+
   Banerjee S, 2005, EUR J CANCER PREV, V14, P215, DOI 10.1097/00008469-200506000-00004
   Chou CC, 1999, INT J FOOD MICROBIOL, V48, P125, DOI 10.1016/S0168-1605(99)00034-3
   Cooper R, 2005, J ALTERN COMPLEM MED, V11, P639, DOI 10.1089/acm.2005.11.639
   Dalluge JJ, 1998, J CHROMATOGR A, V793, P265, DOI 10.1016/S0021-9673(97)00906-0
   FUKAI K, 1991, AGR BIOL CHEM TOKYO, V55, P1895, DOI 10.1080/00021369.1991.10870886
   Guo QN, 1996, BBA-LIPID LIPID MET, V1304, P210, DOI 10.1016/S0005-2760(96)00122-1
   HARA Y, 1989, J JPN SOC FOOD SCI, V36, P996
   Hashimoto T, 1999, BIOSCI BIOTECH BIOCH, V63, P2252, DOI 10.1271/bbb.63.2252
   HILL GB, 1993, AM J OBSTET GYNECOL, V169, P450, DOI 10.1016/0002-9378(93)90339-K
   Hirasawa M, 2004, J ANTIMICROB CHEMOTH, V53, P225, DOI 10.1093/jac/dkh046
   Hirasawa M, 2002, J PERIODONTAL RES, V37, P433, DOI 10.1034/j.1600-0765.2002.01640.x
   IKIGAI H, 1993, BIOCHIM BIOPHYS ACTA, V1147, P132, DOI 10.1016/0005-2736(93)90323-R
   Ju J, 2005, CANCER RES, V65, P10623, DOI 10.1158/0008-5472-05-1949
   Kagaku JN, 1978, LAB AGR CHEM, P221
   Lin YS, 2003, J AGR FOOD CHEM, V51, P1864, DOI 10.1021/jf021066b
   Mabe K, 1999, ANTIMICROB AGENTS CH, V43, P1788, DOI 10.1128/AAC.43.7.1788
   Matsuo N, 1997, ALLERGY, V52, P58, DOI 10.1111/j.1398-9995.1997.tb02546.x
   Melnick SJ, 2006, J PEDIAT HEMATOL ONC, V28, P221, DOI 10.1097/01.mph.0000212922.16427.04
   Okubo S, 1991, Nihon Saikingaku Zasshi, V46, P509
   SAKANAKA S, 1989, AGR BIOL CHEM TOKYO, V53, P2307, DOI 10.1080/00021369.1989.10869665
   Thorsen P, 1998, AM J OBSTET GYNECOL, V178, P580, DOI 10.1016/S0002-9378(98)70442-9
   TODA M, 1990, Japanese Journal of Bacteriology, V45, P561
   Van Kessel K, 2003, OBSTET GYNECOL SURV, V58, P351, DOI 10.1097/00006254-200305000-00024
   Wang HF, 2000, FOOD CHEM, V68, P115, DOI 10.1016/S0308-8146(99)00179-X
   Wang LF, 2000, J AGR FOOD CHEM, V48, P4227, DOI 10.1021/jf0003597
   Yang CS, 2002, ANNU REV PHARMACOL, V42, P25, DOI 10.1146/annurev.pharmtox.42.082101.154309
   Yoshino K, 1996, J FOOD HYG SOC JPN, V37, P104
NR 30
TC 6
Z9 6
U1 1
U2 36
PU KOREAN SOCIETY FOOD SCIENCE & TECHNOLOGY-KOSFOST
PI SEOUL
PA #605, KOREA SCI TECHNOL CENT, 635-4 YEOKSAM-DONG, KANGNAM-GU, SEOUL,
   135-703, SOUTH KOREA
SN 1226-7708
EI 2092-6456
J9 FOOD SCI BIOTECHNOL
JI Food Sci. Biotechnol.
PD JUN
PY 2013
VL 22
IS 3
BP 713
EP 719
DI 10.1007/s10068-013-0136-3
PG 7
WC Food Science & Technology
SC Food Science & Technology
GA 173HX
UT WOS:000321071000017
DA 2018-12-27
ER

PT J
AU Sansregret, R
   Dufour, V
   Langlois, M
   Daayf, F
   Dunoyer, P
   Voinnet, O
   Bouarab, K
AF Sansregret, Raphael
   Dufour, Vanessa
   Langlois, Mathieu
   Daayf, Fouad
   Dunoyer, Patrice
   Voinnet, Olivier
   Bouarab, Kamal
TI RETRACTED: Extreme Resistance as a Host Counter-counter Defense against
   Viral Suppression of RNA Silencing (Retracted article. See vol. 11,
   e1005207, 2015)
SO PLOS PATHOGENS
LA English
DT Article; Retracted Publication
ID SMALL INTERFERING RNA; TOBACCO-MOSAIC-VIRUS; TURNIP-CRINKLE-VIRUS;
   BUSHY-STUNT-VIRUS; TOMBUSVIRUS-ENCODED P19; NICOTIANA-BENTHAMIANA;
   ANTIVIRAL DEFENSE; ARABIDOPSIS-THALIANA; INNATE IMMUNITY; PLANT IMMUNITY
AB RNA silencing mediated by small RNAs (sRNAs) is a conserved regulatory process with key antiviral and antimicrobial roles in eukaryotes. A widespread counter-defensive strategy of viruses against RNA silencing is to deploy viral suppressors of RNA silencing (VSRs), epitomized by the P19 protein of tombusviruses, which sequesters sRNAs and compromises their downstream action. Here, we provide evidence that specific Nicotiana species are able to sense and, in turn, antagonize the effects of P19 by activating a highly potent immune response that protects tissues against Tomato bushy stunt virus infection. This immunity is salicylate- and ethylene-dependent, and occurs without microscopic cell death, providing an example of "extreme resistance" (ER). We show that the capacity of P19 to bind sRNA, which is mandatory for its VSR function, is also necessary to induce ER, and that effects downstream of P19-sRNA complex formation are the likely determinants of the induced resistance. Accordingly, VSRs unrelated to P19 that also bind sRNA compromise the onset of P19-elicited defense, but do not alter a resistance phenotype conferred by a viral protein without VSR activity. These results show that plants have evolved specific responses against the damages incurred by VSRs to the cellular silencing machinery, a likely necessary step in the never-ending molecular arms race opposing pathogens to their hosts.
C1 [Sansregret, Raphael; Dufour, Vanessa; Langlois, Mathieu; Bouarab, Kamal] Univ Sherbrooke, Fac Sci, Ctr SEVE, Dept Biol, Quebec City, PQ, Canada.
   [Daayf, Fouad] Univ Manitoba, Dept Plant Sci, Winnipeg, MB R3T 2N2, Canada.
   [Dunoyer, Patrice; Voinnet, Olivier] Univ Strasbourg, CNRS, Inst Biol Mol Plantes, Strasbourg, France.
   [Voinnet, Olivier] ETH, Swiss Fed Inst Technol, Dept Biol, Zurich, Switzerland.
RP Sansregret, R (reprint author), Univ Sherbrooke, Fac Sci, Ctr SEVE, Dept Biol, Quebec City, PQ, Canada.
EM voinneto@ethz.ch; Kamal.Bouarab@USherbrooke.ca
OI Daayf, Fouad/0000-0001-8912-0460
FU Natural Sciences and Engineering Research Council of Canada (NSERC);
   Bettencourt Foundation; French Academy of Science; Agence National pour
   la Recherche [ANR-08-JCJC-0063, ANR-10-LABX-36]
FX RS is a fellow of the FQRNT. KB and FD are supported by Discovery grants
   from the Natural Sciences and Engineering Research Council of Canada
   (NSERC). OV was supported by an award from the Bettencourt Foundation
   and the Louis D. Prize from the French Academy of Science. PD was
   supported by the Agence National pour la Recherche (ANR-08-JCJC-0063 and
   ANR-10-LABX-36). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Alamillo JM, 2006, PLANT J, V48, P217, DOI 10.1111/j.1365-313X.2006.02861.x
   Anandalakshmi R, 1998, P NATL ACAD SCI USA, V95, P13079, DOI 10.1073/pnas.95.22.13079
   Angel CA, 2013, MOL PLANT MICROBE IN, V26, P240, DOI 10.1094/MPMI-06-12-0157-R
   Angel CA, 2011, MOL PLANT MICROBE IN, V24, P91, DOI 10.1094/MPMI-04-10-0089
   Aoyama T, 1997, PLANT J, V11, P605, DOI 10.1046/j.1365-313X.1997.11030605.x
   Azevedo J, 2010, GENE DEV, V24, P904, DOI 10.1101/gad.1908710
   Baulcombe DC, 2004, TRENDS BIOCHEM SCI, V29, P279, DOI 10.1016/j.tibs.2004.04.007
   Baumberger N, 2007, CURR BIOL, V17, P1609, DOI 10.1016/j.cub.2007.08.039
   Bendahmane A, 1999, PLANT CELL, V11, P781
   Bent AF, 2007, ANNU REV PHYTOPATHOL, V45, P399, DOI 10.1146/annurev.phyto.45.062806.094427
   Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110
   Bortolamiol D, 2007, CURR BIOL, V17, P1615, DOI 10.1016/j.cub.2007.07.061
   Bouarab K, 2002, NATURE, V418, P889, DOI 10.1038/nature00950
   Brigneti G, 1998, EMBO J, V17, P6739, DOI 10.1093/emboj/17.22.6739
   Bucher E, 2006, J GEN VIROL, V87, P3697, DOI 10.1099/vir.0.82276-0
   Chen HY, 2008, EMBO REP, V9, P754, DOI 10.1038/embor.2008.118
   Choi CW, 2004, J GEN VIROL, V85, P3415, DOI 10.1099/vir.0.80326-0
   Chu M, 2000, VIROLOGY, V266, P79, DOI 10.1006/viro.1999.0071
   Cordelier S, 2003, PLANT MOL BIOL, V51, P109, DOI 10.1023/A:1020722102871
   Csorba T, 2007, J VIROL, V81, P11768, DOI 10.1128/JVI.01230-07
   Csorba T, 2010, PLANT J, V62, P463, DOI 10.1111/j.1365-313X.2010.04163.x
   Deleris A, 2006, SCIENCE, V313, P68, DOI 10.1126/science.1128214
   Ding SW, 2007, CELL, V130, P413, DOI 10.1016/j.cell.2007.07.039
   Dodds PN, 2010, NAT REV GENET, V11, P539, DOI 10.1038/nrg2812
   Dunoyer P, 2002, PLANT J, V29, P555, DOI 10.1046/j.0960-7412.2001.01242.x
   Dunoyer P, 2004, PLANT CELL, V16, P1235, DOI 10.1105/tpc.020719
   Dunoyer P, 2010, EMBO J, V29, P1699, DOI 10.1038/emboj.2010.65
   Eggenberger AL, 2008, MOL PLANT MICROBE IN, V21, P931, DOI 10.1094/MPMI-21-7-0931
   El Oirdi M, 2007, NEW PHYTOL, V175, P131, DOI 10.1111/j.1469-8137.2007.02086.x
   Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301
   Friedrich L, 1995, PLANT MOL BIOL, V29, P959, DOI 10.1007/BF00014969
   Fritig B, 1998, CURR OPIN IMMUNOL, V10, P16, DOI 10.1016/S0952-7915(98)80025-3
   Garcia D, 2012, MOL CELL, V48, P109, DOI 10.1016/j.molcel.2012.07.028
   Hamilton A, 2002, EMBO J, V21, P4671, DOI 10.1093/emboj/cdf464
   Hamilton AJ, 1999, SCIENCE, V286, P950, DOI 10.1126/science.286.5441.950
   Hammond SM, 2000, NATURE, V404, P293
   Harvey JJW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014639
   Hemmes H, 2007, RNA, V13, P1079, DOI 10.1261/rna.444007
   Himber C, 2003, EMBO J, V22, P4523, DOI 10.1093/emboj/cdg431
   HORSCH RB, 1985, SCIENCE, V227, P1229
   Jaubert M, 2011, PLANT PHYSIOL, V156, P1556, DOI 10.1104/pp.111.178012
   Jay F, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002035
   Ji LH, 2001, MOL PLANT MICROBE IN, V14, P715, DOI 10.1094/MPMI.2001.14.6.715
   Jones JDG, 2006, NATURE, V444, P323, DOI 10.1038/nature05286
   Kang BC, 2005, ANNU REV PHYTOPATHOL, V43, P581, DOI 10.1146/annurev.phyto.43.011205.141140
   Katiyar-Agarwal S, 2007, METHOD ENZYMOL, V427, P215, DOI 10.1016/S0076-6879(07)27012-0
   Katiyar-Agarwal S, 2006, P NATL ACAD SCI USA, V103, P18002, DOI 10.1073/pnas.0608258103
   Katiyar-Agarwal S, 2010, ANNU REV PHYTOPATHOL, V48, P225, DOI 10.1146/annurev-phyto-073009-114457
   Kim MG, 2009, PLANT J, V57, P645, DOI 10.1111/j.1365-313X.2008.03716.x
   Knoester M, 1998, P NATL ACAD SCI USA, V95, P1933, DOI 10.1073/pnas.95.4.1933
   Lakatos L, 2004, EMBO J, V23, P876, DOI 10.1038/sj.emboj.7600096
   Lakatos L, 2006, EMBO J, V25, P2768, DOI 10.1038/sj.emboj.7601164
   Li F, 2012, P NATL ACAD SCI USA, V109, P1790, DOI 10.1073/pnas.1118282109
   Li HW, 1999, EMBO J, V18, P2683, DOI 10.1093/emboj/18.10.2683
   Menard R, 2004, PLANT CELL, V16, P3020, DOI 10.1105/tpc.104.024968
   Merai Z, 2006, J VIROL, V80, P5747, DOI 10.1128/JVI.01963-05
   Navarro L, 2006, SCIENCE, V312, P436, DOI 10.1126/science.1126088
   Navarro L, 2008, SCIENCE, V321, P964, DOI 10.1126/science.1159505
   Oh HS, 2010, MOL PLANT MICROBE IN, V23, P727, DOI 10.1094/MPMI-23-6-0727
   Oh JW, 1995, MOL PLANT MICROBE IN, V8, P979, DOI 10.1094/MPMI-8-0979
   Omarov R, 2006, J VIROL, V80, P3000, DOI 10.1128/JVI.80.6.3000-3008.2006
   Papp I, 2003, PLANT PHYSIOL, V132, P1382, DOI 10.1104/pp.103.021980
   Peart JR, 2002, PLANT J, V29, P569, DOI 10.1046/j.1365-313X.2002.029005569.x
   Qiao YL, 2013, NAT GENET, V45, P330, DOI 10.1038/ng.2525
   Qu F, 2008, P NATL ACAD SCI USA, V105, P14732, DOI 10.1073/pnas.0805760105
   Ruiz-Ferrer V, 2009, ANNU REV PLANT BIOL, V60, P485, DOI 10.1146/annurev.arplant.043008.092111
   Scholthof HB, 2006, NAT REV MICROBIOL, V4, P405, DOI 10.1038/nrmicro1395
   SCHOLTHOF HB, 1995, PLANT CELL, V7, P1157
   Scholthof HB, 2011, PLANT PHYSIOL, V156, P1548, DOI 10.1104/pp.111.178764
   Schott G, 2012, EMBO J, V31, P2553, DOI 10.1038/emboj.2012.92
   Shivaprasad PV, 2012, PLANT CELL, V24, P859, DOI 10.1105/tpc.111.095380
   Silhavy D, 2002, EMBO J, V21, P3070, DOI 10.1093/emboj/cdf312
   van Loon LC, 2006, ANNU REV PHYTOPATHOL, V44, P135, DOI 10.1146/annurev.phyto.44.070505.143425
   Varallyay E, 2010, EMBO J, V29, P3507, DOI 10.1038/emboj.2010.215
   Vargason JM, 2003, CELL, V115, P799, DOI 10.1016/S0092-8674(03)00984-X
   Voinnet O, 1999, P NATL ACAD SCI USA, V96, P14147, DOI 10.1073/pnas.96.24.14147
   Voinnet O, 2000, CELL, V103, P157, DOI 10.1016/S0092-8674(00)00095-7
   Voinnet O, 2009, CELL, V136, P669, DOI 10.1016/j.cell.2009.01.046
   Wang LY, 2012, MOL PLANT MICROBE IN, V25, P648, DOI 10.1094/MPMI-06-11-0155
   Wang XB, 2011, PLANT CELL, V23, P1625, DOI 10.1105/tpc.110.082305
   Wen RH, 2013, MOL PLANT MICROBE IN, V26, P203, DOI 10.1094/MPMI-06-12-0156-R
   Ye KQ, 2003, NATURE, V426, P874, DOI 10.1038/nature02213
   Zhai JX, 2011, GENE DEV, V25, P2540, DOI 10.1101/gad.177527.111
   Zhang XM, 2011, MOL CELL, V42, P356, DOI 10.1016/j.molcel.2011.04.010
   Zhang Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028073
   Zhao YJ, 2000, MOL PLANT MICROBE IN, V13, P1015, DOI 10.1094/MPMI.2000.13.9.1015
   Zipfel C, 2009, CURR OPIN PLANT BIOL, V12, P414, DOI 10.1016/j.pbi.2009.06.003
NR 87
TC 29
Z9 29
U1 13
U2 87
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7366
EI 1553-7374
J9 PLOS PATHOG
JI PLoS Pathog.
PD JUN
PY 2013
VL 9
IS 6
AR e1003435
DI 10.1371/journal.ppat.1003435
PG 13
WC Microbiology; Parasitology; Virology
SC Microbiology; Parasitology; Virology
GA 175CG
UT WOS:000321206600040
PM 23785291
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Prasad, AS
   Dolia, SN
   Pareek, SP
   Samariya, A
   Sharma, PK
   Dhawan, MS
AF Prasad, Arun S.
   Dolia, S. N.
   Pareek, S. P.
   Samariya, Arvind
   Sharma, P. K.
   Dhawan, M. S.
TI RETRACTED: Sol-gel synthesized high anisotropy magnetic nanoparticles of
   NiCr (x) Fe2-x O-4 (Retracted article. See vol. 73, pg. 518, 2015)
SO JOURNAL OF SOL-GEL SCIENCE AND TECHNOLOGY
LA English
DT Article; Retracted Publication
DE Nanostructures; Sol-gel growth; Debye-Scherrer powder method; Mossbauer
   spectroscopy
ID CATION DISTRIBUTION; FERRITE
AB The nanoparticles of NiCr (x) Fe2-x O-4 were synthesized through sol-gel reactions involving nitrates of Ni, Cr and Fe in an aqueous medium containing citric acid. The cubic spinel structure in single phase with nanometric crystallite size of similar to 5 nm, the spherical morphology and magnetic relaxations were examined through XRD, TEM and Mossbauer techniques. The abnormal occurrence of finite remanance (M (r) ) and coercivity (H (c) ) resulted in the room temperature dc magnetization measurements for the small particles authenticate the ferrimagnetic regime, as proposed by the room temperature Mossbauer results of the samples, with a proximate superparamagnetic regime still at lower particle volumes. This could be attributed to the antiferromagnetic spin interactions of chromium ions at octahedral sites and subsequently the over-occupancy of the rest of the cations at tetrahedral sites. In justification to this, the magnetocrystalline anisotropy constant, K, is estimated to have value relatively high of the order of 10(7) erg/cm(3) at room temperature for all studied concentrations.
C1 [Dolia, S. N.; Pareek, S. P.; Samariya, Arvind; Sharma, P. K.; Dhawan, M. S.] Univ Rajasthan, Dept Phys, Jaipur 302004, Rajasthan, India.
EM asp.physics@gmail.com
CR Ashiq MN, 2009, J ALLOY COMPD, V486, P640, DOI 10.1016/j.jallcom.2009.07.007
   BEAN CP, 1959, J APPL PHYS, V30, P1976, DOI 10.1063/1.1735100
   BRAND RA, 1987, NUCL INSTRUM METH B, V28, P398, DOI 10.1016/0168-583X(87)90182-0
   CHAPPERT J, 1967, PHYS REV LETT, V19, P570, DOI 10.1103/PhysRevLett.19.570
   Grainger DW, 2003, ADV DRUG DELIVER REV, V55, P311, DOI 10.1016/S0169-409X(02)00222-3
   Hood JD, 2002, SCIENCE, V296, P2404, DOI 10.1126/science.1070200
   Iqbal MJ, 2007, SCRIPTA MATER, V57, P1093, DOI 10.1016/j.scriptamat.2007.08.017
   Klemmer TJ, 2002, APPL PHYS LETT, V81, P2220, DOI 10.1063/1.1507837
   Klung H. P., 1974, XRAY DIFFRACTION PRO
   Niemeyer CM, 2001, ANGEW CHEM INT EDIT, V40, P4128, DOI 10.1002/1521-3773(20011119)40:22<4128::AID-ANIE4128>3.0.CO;2-S
   Prasad AS, 2010, MOD PHYS LETT B, V24, P1987, DOI 10.1142/S0217984910024389
   Rais A, 2005, PHYS STATUS SOLIDI B, V242, P1497, DOI 10.1002/pssb.200440022
   Roy MK, 2006, J PHYS-CONDENS MAT, V18, P7273, DOI 10.1088/0953-8984/18/31/021
   Singhal S, 2007, J SOLID STATE CHEM, V180, P296, DOI 10.1016/j.jssc.2006.10.010
   Skumryev V, 2003, NATURE, V423, P850, DOI 10.1038/nature01687
NR 15
TC 3
Z9 3
U1 1
U2 14
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0928-0707
EI 1573-4846
J9 J SOL-GEL SCI TECHN
JI J. Sol-Gel Sci. Technol.
PD JUN
PY 2013
VL 66
IS 3
BP 372
EP 377
DI 10.1007/s10971-013-3019-4
PG 6
WC Materials Science, Ceramics
SC Materials Science
GA 162RX
UT WOS:000320284100003
DA 2018-12-27
ER

PT J
AU Kadam, RS
   Ramamoorthy, P
   LaFlamme, DJ
   McKinsey, TA
   Kompella, UB
AF Kadam, Rajendra S.
   Ramamoorthy, Preveen
   LaFlamme, Daniel J.
   McKinsey, Timothy A.
   Kompella, Uday B.
TI RETRACTED: Hypoxia Alters Ocular Drug Transporter Expression and
   Activity in Rat and Calf Models: Implications for Drug Delivery
   (Retracted article. See vol. 12, pg. 2559, 2015)
SO MOLECULAR PHARMACEUTICS
LA English
DT Article; Retracted Publication
DE hypoxia; drug transporters; ocular; blood-retinal barrier
ID MESSENGER-RNA EXPRESSION; BLOOD-RETINAL BARRIERS; TIME PCR EXPERIMENTS;
   ACUTE-RENAL-FAILURE; AMINO-ACID; MULTIDRUG-RESISTANCE; UP-REGULATION;
   GLUCOSE-TRANSPORT; ENDOTHELIAL-CELLS; GENE-EXPRESSION
AB Chronic hypoxia, a key stimulus for neovascularization, has been implicated in the pathology of proliferative diabetic retinopathy, retinopathy of prematurity, and wet age related macular degeneration. The aim of the present study was to determine the effect of chronic hypoxia on drug transporter mRNA expression and activity in ocular barriers. Sprague-Dawley rats were exposed to hypobaric hypoxia (P-B = 380 mmHg) for 6 weeks, and neonatal calves were maintained under hypobaric hypoxia (P-B = 445 mmHg) for 2 weeks. Age matched controls for rats, and calves were maintained at ambient altitude and normoxia. The effect of hypoxia on transporter expression was analyzed by qRT-PCR analysis of transporter mRNA expression in hypoxic and control rat choroid-retina. The effect of hypoxia on the activity of PEPT, OCT, ATB(0+), and MCT transporters was evaluated using in vitro transport studies of model transporter substrates across calf cornea and sclera-choroid-RPE (SCRPE). Quantitative gene expression analysis of 84 transporters in rat choroid-retina showed that 29 transporter genes were up regulated or down regulated by >= 1.5-fold in hypoxia. Nine ATP binding cassette (ABC) families of efflux transporters including MRP3, MRP4, MRP5, MRP6, MRP7, Abca17, Abc2, Abc3, and RGD1562128 were up-regulated. For solute carrier family transporters, 11 transporters including SLC10a1, SLC16a3, SLC22a7, SLC22a8, SLC29a1, SLC29a2, SLC2a1, SLC3a2, SLC5a4, SLC7a11, and SLC7a4 were up regulated, while 4 transporters including SLC22a2 SLC22a9, SLC28a1, and SLC7a9 were down-regulated in hypoxia. Of the three aquaporin (Aqp) water channels, Aqp-9 was down-regulated, and Aqp-1 was up regulated during hypoxia. Gene expression analysis showed down regulation of OCT-1, OCT-2, and ATB(0+) and up regulation of MCT-3 in hypoxic rat choroid-retina, without any effect on the expression of PEPT-1 and PEPT-2. Functional activity assays of PEPT, OCT, ATB(0+), and MCT transporters in calf ocular tissues showed that PEPT, OCT, and ATB(0+). functional activity was down-regulated, whereas MCT functional activity was up regulated in hypoxic cornea and SCRPE. Gene expression analysis of these transporters in rat tissues was consistent with the functional transport assays except for PEPT transporters. Chronic hypoxia results in significant alterations in the mRNA expression and functional activity of solute transporters in ocular tissues.
C1 [Kadam, Rajendra S.; Kompella, Uday B.] Univ Colorado, Aurora, CO 80045 USA.
   [McKinsey, Timothy A.] Univ Colorado, Div Cardiol & Med, Aurora, CO 80045 USA.
   [Ramamoorthy, Preveen; LaFlamme, Daniel J.] Natl Jewish Hlth, Dept Med, Denver, CO 80206 USA.
RP Kompella, UB (reprint author), Univ Colorado, Skaggs Sch Pharm & Pharmaceut Sci, Dept Pharmaceut Sci, Anschutz Med Campus 12850 E 19th Ave, Aurora, CO 80045 USA.
EM uday.kompella@ucdenver.edu
FU NIH [EY018940, EY017533]
FX This work was supported by NIH grants EY018940 and EY017533. The authors
   are thankful to Drs. Kurt Stenmark and Adil Anwar of University of
   Colorado Anschutz Medical Campus for providing hypoxic calf eyes.
CR Abreu-Rodriguez I, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028385
   Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236
   Arjamaa O, 2006, EXP EYE RES, V83, P473, DOI 10.1016/j.exer.2006.01.016
   Beattie JR, 2010, FASEB J, V24, P4816, DOI 10.1096/fj.10-166090
   Berk JL, 2000, J APPL PHYSIOL, V89, P1425
   Burke B, 2003, AM J PATHOL, V163, P1233, DOI 10.1016/S0002-9440(10)63483-9
   Bustin SA, 2010, BMC MOL BIOL, V11, DOI 10.1186/1471-2199-11-74
   Bustin SA, 2009, CLIN CHEM, V55, P611, DOI 10.1373/clinchem.2008.112797
   CARTEE GD, 1991, J APPL PHYSIOL, V70, P1593
   Casanello P, 2005, CIRC RES, V97, P16, DOI 10.1161/01.RES.0000172568.49367.f8
   Casanello P, 2009, PLACENTA, V30, P625, DOI 10.1016/j.placenta.2009.04.010
   Chang TT, 2011, MOL PHARMACEUT, V8, P117, DOI 10.1021/mp100137q
   Chaudary N, 2004, CARDIOVASC RES, V61, P780, DOI 10.1016/j.cardiores.2003.11.031
   Chidlow G, 2005, AM J PHYSIOL-CELL PH, V288, pC416, DOI 10.1152/ajpcell.00037.2004
   Comerford KM, 2002, CANCER RES, V62, P3387
   Cunha-Vaz JG, 2004, EXP EYE RES, V78, P715, DOI 10.1016/S0014-4835(03)00213-6
   Di Giusto G, 2009, J HISTOCHEM CYTOCHEM, V57, P17, DOI 10.1369/jhc.2008.951582
   Dibas A., 2008, REGULATION TRANSPORT, P157
   Duvvuri S, 2004, CURR DRUG METAB, V5, P507, DOI 10.2174/1389200043335342
   Foldager CB, 2009, BMC MOL BIOL, V10, DOI 10.1186/1471-2199-10-94
   Fradette C, 2007, DRUG METAB DISPOS, V35, P765, DOI 10.1124/dmd.106.013508
   Gariano RF, 2005, NATURE, V438, P960, DOI 10.1038/nature04482
   Greenbaum D, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-117
   Grimm C, 2012, HIGH ALT MED BIOL, V13, P169, DOI 10.1089/ham.2012.1031
   Hammermann R, 2000, MOL PHARMACOL, V58, P1294
   Ito A, 2003, INVEST OPHTH VIS SCI, V44, P4877, DOI 10.1167/iovs.02-1108
   Ito A, 2002, INVEST OPHTH VIS SCI, V43, P858
   Jones HN, 2007, PLACENTA, V28, P763, DOI 10.1016/j.placenta.2007.05.002
   Jong NN, 2011, J PHARMACOL EXP THER, V338, P537, DOI 10.1124/jpet.111.181297
   Jonker JW, 2004, J PHARMACOL EXP THER, V308, P2, DOI 10.1124/jpet.103.053298
   Kadam RS, 2013, DRUG METAB DISPOS, V41, P466, DOI 10.1124/dmd.112.045674
   Kadam RS, 2011, INVEST OPHTH VIS SCI, V52, P5387, DOI 10.1167/iovs.10-6233
   Kadam RS, 2010, J PHARMACOL EXP THER, V332, P1107, DOI 10.1124/jpet.109.161570
   Kaneko K, 2008, MICROVASC RES, V75, P297, DOI 10.1016/j.mvr.2007.12.003
   Kansara V, 2007, J OCUL PHARMACOL TH, V23, P321, DOI 10.1089/iop.2006.0150
   Krishnamurthy P, 2004, J BIOL CHEM, V279, P24218, DOI 10.1074/jbc.M313599200
   Leonard R, 2002, STAT VISION IMPAIRME, P1
   Lu JW, 2010, INVEST OPHTH VIS SCI, V51, P5034, DOI 10.1167/iovs.10-5501
   Lutsenko S, 2007, PHYSIOL REV, V87, P1011, DOI 10.1152/physrev.00004.2006
   MacCormick IJC, 2012, HIGH ALT MED BIOL, V13, P263, DOI 10.1089/ham.2011.1097
   Majumdar S, 2009, PHARM RES-DORDR, V26, P1261, DOI 10.1007/s11095-008-9730-0
   Morris ME, 2008, AAPS J, V10, P311, DOI 10.1208/s12248-008-9035-6
   Nelson DM, 2003, AM J PHYSIOL-CELL PH, V284, pC310, DOI 10.1152/ajpcell.00253.2002
   Nyengaard JR, 2004, DIABETES, V53, P2931, DOI 10.2337/diabetes.53.11.2931
   Okamoto M, 2009, NEUROCHEM INT, V55, P789, DOI 10.1016/j.neuint.2009.08.001
   Payet O, 2004, NEUROSCI LETT, V356, P148, DOI 10.1016/j.neulet.2003.11.036
   Rytting E, 2007, J PHARM PHARMACOL, V59, P1095, DOI 10.1211/jpp.59.8.0006
   SABiosciences, WEB BAS PCR ARR DAT
   Schneider R, 2007, AM J PHYSIOL-RENAL, V292, pF1599, DOI 10.1152/ajprenal.00473.2006
   Schwartz IF, 2002, KIDNEY INT, V62, P1700, DOI 10.1046/j.1523-1755.2002.t01-1-00622.x
   Semenza GL, 2001, CURR OPIN CELL BIOL, V13, P167, DOI 10.1016/S0955-0674(00)00194-0
   Shih AY, 2006, J NEUROSCI, V26, P10514, DOI 10.1523/JNEUROSCI.31787-06.2006
   Shortt AJ, 2004, J ANAT, V205, P349, DOI 10.1111/j.0021-8782.2004.00351.x
   Sonna LA, 2003, PHYSIOL GENOMICS, V12, P195, DOI 10.1152/physiolgenomics.00104.2002
   Stefansson E, 2011, PROG RETIN EYE RES, V30, P72, DOI 10.1016/j.preteyeres.2010.09.003
   Tachikawa Masanori, 2007, V46, P83
   Takagi H, 1998, DIABETES, V47, P1480, DOI 10.2337/diabetes.47.9.1480
   Tomi M, 2005, INVEST OPHTH VIS SCI, V46, P2522, DOI 10.1167/iovs-04-1175
   Tomi M, 2010, EXPERT OPIN DRUG MET, V6, P1111, DOI 10.1517/17425255.2010.486401
   Ullah MS, 2006, J BIOL CHEM, V281, P9030, DOI 10.1074/jbc.M511397200
   Wartenberg M, 2003, FASEB J, V17, P503, DOI 10.1096/fj.02-0358fje
   Wasa M, 2004, BBA-GEN SUBJECTS, V1670, P49, DOI 10.1016/j.bagen.2003.10.012
   White C, 2009, J CELL SCI, V122, P1315, DOI 10.1242/jcs.043216
   Wu CP, 2011, MOL PHARMACEUT, V8, P1996, DOI 10.1021/mp200261n
   Yamamoto N, 2001, MOL BRAIN RES, V90, P26, DOI 10.1016/S0169-328X(01)00064-X
   Yin J, 2006, CANCER RES, V66, P2937, DOI 10.1158/0008-5472.CAN-05-2615
   Zamudio S, 2006, PLACENTA, V27, P49, DOI 10.1016/j.placenta.2004.12.010
   Zhang T, 2008, DRUG METAB DISPOS, V36, P1300, DOI 10.1124/dmd.108.021121
NR 68
TC 4
Z9 7
U1 2
U2 16
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1543-8384
J9 MOL PHARMACEUT
JI Mol. Pharm.
PD JUN
PY 2013
VL 10
IS 6
BP 2350
EP 2361
DI 10.1021/mp3007133
PG 12
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA 159AE
UT WOS:000320015600026
PM 23607566
OA Green Accepted
DA 2018-12-27
ER

PT J
AU Kim, IC
   Lee, JH
   Bang, G
   Choi, SH
   Kim, YH
   Kim, KP
   Kim, HK
   Ro, J
AF Kim, Il Chan
   Lee, Jeong Hwa
   Bang, Geul
   Choi, Seung Ho
   Kim, Young Hwan
   Kim, Kwang Pyo
   Kim, Hark Kyun
   Ro, Jungsil
TI RETRACTED: Lipid Profiles for HER2-positive Breast Cancer (Retracted
   article. See vol. 35, pg. 6354, 2015)
SO ANTICANCER RESEARCH
LA English
DT Article; Retracted Publication
DE MALDI; breast cancer; HER2; lipid; profiles
ID MASS-SPECTROMETRY; RECEPTOR STATUS; CELLS; CLASSIFICATION; METABOLISM;
   INCREASE
AB Background: Accumulating data indicate that human epidermal growth factor receptor-2 (HER2)-positive breast cancer is a heterogeneous disease. We undertook a study to correlate lipid profiles with heterogeneous clinicopathological features of HER2-positive breast cancer. Materials and Methods: Histology-directed matrix-assisted laser desorption/ionization (MALDI) -mass spectrometry (MS) analyses were performed on 22 retrospective frozen tissue samples collected from patients with HER2-positive metastatic breast cancer, in order to correlate lipid profiles with clinicopathological characterisitics. Additionally, a pair of tumor and adjacent normal tissue was profiled to identify cancer-associated changes in lipid profiles. Results: Sphingomyelin 34:1, phosphatidylcholine (PC) 32:0, and PC 34:1, and PC 36:2 were overexpressed in HER2-positive breast cancer compared to adjacent normal tissue (HER2 signature). Lipid MALDI-MS profiles were different between Ki-67-high and Ki-67-low tumors. The proliferation signature (Ki-67-high vs. Ki-67-low) and the HER2 signature (cancer vs. normal) did not significantly overlap with each other. Conclusion: For the first time to our knowledge, this study describes lipid profiles correlated with various clinicopathological characteristics of HER2-positive breast cancer. Lipid profiling might be helpful for the molecular characterization of this disease.
C1 [Kim, Il Chan; Choi, Seung Ho; Kim, Hark Kyun; Ro, Jungsil] Natl Canc Ctr, Goyang 410769, Gyeonggi, South Korea.
   [Lee, Jeong Hwa; Kim, Kwang Pyo] Konkuk Univ, Dept Mol Biotechnol, Seoul, South Korea.
   [Bang, Geul; Kim, Young Hwan] Korea Basic Sci Inst, Div Mass Spectrometry Res, Ochang, South Korea.
   [Kim, Young Hwan] Chungnam Natl Univ, Grad Sch Analyt Sci & Technol, Taejon, South Korea.
RP Kim, HK (reprint author), Natl Canc Ctr, Res Inst, Biomol Funct Res Branch, 323 Ilsanro, Goyang 410769, Gyeonggi, South Korea.
EM hlcim@ncc.re.kr; jungsro@ncc.re.kr
FU Converging Research Center Program through the Ministry of Education,
   Science and Technology of Korea [2012K001506]; Proteogenomic Research
   Program through the National Research Foundation of Korea; Korean
   Ministry of Education, Science and Technology; Korea Basic Science
   Institute [G31123]
FX This work was supported by grants from the Converging Research Center
   Program (2012K001506) through the Ministry of Education, Science and
   Technology of Korea and by the Proteogenomic Research Program through
   the National Research Foundation of Korea funded by the Korean Ministry
   of Education, Science and Technology. Dr. Y. H. Kim was supported by a
   grant of Korea Basic Science Institute (G31123).
CR Aboagye EO, 1999, CANCER RES, V59, P80
   Balluff B, 2010, J PROTEOME RES, V9, P6317, DOI 10.1021/pr100573s
   Banez-Coronel M, 2008, CURR CANCER DRUG TAR, V8, P709, DOI 10.2174/156800908786733432
   BOUGNOUX P, 1992, BREAST CANCER RES TR, V20, P185
   Chughtai K, 2013, J LIPID RES, V54, P333, DOI 10.1194/jlr.M027961
   Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026
   Glunde K, 2005, CANCER RES, V65, P11034, DOI 10.1158/0008-5472.CAN-05-1807
   Hilvo M, 2011, CANCER RES, V71, P3236, DOI 10.1158/0008-5472.CAN-10-3894
   Jacobs TW, 1999, J CLIN ONCOL, V17, P1983, DOI 10.1200/JCO.1999.17.7.1983
   Kang HS, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-465
   Lee GK, 2012, LUNG CANCER, V76, P197, DOI 10.1016/j.lungcan.2011.10.016
   Doria ML, 2012, BREAST CANCER RES TR, V133, P635, DOI 10.1007/s10549-011-1823-5
   RATNAM S, 1995, ARCH BIOCHEM BIOPHYS, V323, P313, DOI 10.1006/abbi.1995.9959
   Rauser S, 2010, J PROTEOME RES, V9, P1854, DOI 10.1021/pr901008d
   Rodriguez-Gonzalez A, 2004, ONCOGENE, V23, P8247, DOI 10.1038/sj.onc.1208045
   Shanta SR, 2011, ANAL CHEM, V83, P1252, DOI 10.1021/ac1029659
   Simon R, 2007, CANCER INFORM, V3, P11
   SMITH TAD, 1991, BRIT J CANCER, V64, P821, DOI 10.1038/bjc.1991.407
   Vaz-Luis I, 2013, ANN ONCOL, V24, P283, DOI 10.1093/annonc/mds286
NR 19
TC 16
Z9 17
U1 3
U2 23
PU INT INST ANTICANCER RESEARCH
PI ATHENS
PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22,
   ATHENS 19014, GREECE
SN 0250-7005
EI 1791-7530
J9 ANTICANCER RES
JI Anticancer Res.
PD JUN
PY 2013
VL 33
IS 6
BP 2467
EP 2472
PG 6
WC Oncology
SC Oncology
GA 165LC
UT WOS:000320484400016
PM 23749897
DA 2018-12-27
ER

PT J
AU Li, SR
   Zhang, Y
   Deng, KJ
   Peng, JH
   Zeng, XL
   Zhang, HQ
   Ren, ZL
AF Li, Shuangrong
   Zhang, Yong
   Deng, Kejun
   Peng, Jinhua
   Zeng, Xuelian
   Zhang, Huaiqiong
   Ren, Zhenglong
TI RETRACTED: Analysis of DNA methylation polymorphism in a set of stable
   chromosome translocation lines (Retracted article. See vol. 32, pg. 987,
   2013)
SO MOLECULAR BREEDING
LA English
DT Article; Retracted Publication
DE Triticum aestivum; Chromosome translocation lines; Hybrid vigor;
   Epigenetics; DNA methylation; Methylation-sensitive amplification
   polymorphism
ID GENE-EXPRESSION; ARABIDOPSIS ALLOTETRAPLOIDS; CYTOSINE METHYLATION;
   EPIGENETIC INHERITANCE; TRANSPOSABLE ELEMENTS; ZIZANIA-LATIFOLIA;
   BRASSICA-NAPUS; HYBRID VIGOR; SMALL RNAS; WHEAT
AB Interspecific hybridization is associated with the origin of novel traits and confers increased vigor compared with the parent lines, although its molecular basis is poorly understood. We report here the identification of genetic and epigenetic changes in a set of wheat-rye translocation lines (R59, R57, and R25) which exhibited novel heritable morphological characteristics compared with the parent lines (MY11 and L155). Genome in situ hybridization and amplified fragment length polymorphism analyses revealed no obvious variations in the primary structure of the genome in different translocation lines, with the exception of the same 1RS chromosome translocation. Global assessment of the extent and pattern of cytosine methylation alterations by methylation-sensitive amplified polymorphism (MSAP) analyses revealed differences in the extent of genomic DNA methylation between the rye and wheat parent lines. Fully-methylated sites were significantly increased and hemi-methylated sites were markedly decreased in the genome of translocation lines compared with the wheat parental cultivar MY11. Comparisons of different MSAP patterns revealed both monomorphic and polymorphic sites between translocation lines and wheat parents. Sequencing of 44 isolated fragments that showed methylation alterations indicated that cellular genes and especially transposable elements were targets for methylation alterations in translocation lines. The present study provides further understanding of the rules governing the distribution and existence of DNA methylation variations induced in the wheat genome during alien germplasm introduction. Furthermore, our study provides insights into the relationship between DNA methylation and hybrid vigor as well as a theoretical basis for further fundamental research and breeding application.
C1 [Li, Shuangrong; Zhang, Yong; Deng, Kejun; Peng, Jinhua; Zeng, Xuelian] Univ Elect Sci & Technol China, Sch Life Sci & Technol, Chengdu 610054, Peoples R China.
   [Zhang, Huaiqiong; Ren, Zhenglong] Sichuan Agr Univ, State Key Lab Plant Breeding & Genet, Yaan 625014, Peoples R China.
RP Zhang, Y (reprint author), Univ Elect Sci & Technol China, Sch Life Sci & Technol, Chengdu 610054, Peoples R China.
EM zhangyong916@uestc.edu.cn; renzllab@sicau.edu.cn
FU National Natural Science Foundation of China [30900779, 31271420,
   30730065, 31271722]; China Postdoctoral Science Foundation [20070411158]
FX The authors would like to thank two anonymous reviewers for critical and
   constructive suggestions on this manuscript. This work was supported by
   grants from the National Natural Science Foundation of China (nos.
   30900779, 31271420, 30730065, and 31271722), and the China Postdoctoral
   Science Foundation (no. 20070411158).
CR Adams KL, 2004, GENETICS, V168, P2217, DOI 10.1534/genetics.104.033522
   Albertin W, 2006, GENETICS, V173, P1101, DOI 10.1534/genetics.106.057554
   Birchler JA, 2010, PLANT CELL, V22, P2105, DOI 10.1105/tpc.110.076133
   Bottley A, 2006, PLANT J, V47, P897, DOI 10.1111/j.1365-313X.2006.02841.x
   Bourc'his D, 2004, NATURE, V431, P96, DOI 10.1038/nature02886
   BUSHUK W, 1978, CAN J PLANT SCI, V58, P505, DOI 10.4141/cjps78-076
   Cantu D, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-408
   Cheng C, 2006, MOL GENET GENOMICS, V276, P378, DOI 10.1007/s00438-006-0141-9
   Comai L, 2000, PLANT CELL, V12, P1551, DOI 10.1105/tpc.12.9.1551
   Dong ZY, 2006, THEOR APPL GENET, V113, P196, DOI 10.1007/s00122-006-0286-2
   Gaeta RT, 2007, PLANT CELL, V19, P3403, DOI 10.1105/tpc.107.054346
   GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9
   Groszmann M, 2011, P NATL ACAD SCI USA, V108, P2617, DOI 10.1073/pnas.1019217108
   Guimil S, 2006, TRENDS PLANT SCI, V11, P601, DOI 10.1016/j.tplants.2006.10.001
   Hofmann NR, 2012, PLANT CELL, V24, P841, DOI 10.1105/tpc.112.240312
   Jin HJ, 2008, THEOR APPL GENET, V117, P1271, DOI 10.1007/s00122-008-0861-9
   Lister R, 2008, CELL, V133, P523, DOI 10.1016/j.cell.2008.03.029
   Liu ZL, 2004, PLANT MOL BIOL, V54, P571, DOI 10.1023/B:PLAN.0000038270.48326.7a
   Madlung A, 2002, PLANT PHYSIOL, V129, P733, DOI 10.1104/pp.003095
   MURRAY MG, 1980, NUCLEIC ACIDS RES, V8, P4321, DOI 10.1093/nar/8.19.4321
   Rangwala SH, 2004, CURR OPIN GENET DEV, V14, P686, DOI 10.1016/j.gde.2004.09.009
   Ren TianHeng, 2011, Journal of Triticeae Crops, V31, P430
   REN Z, 1991, Scientia Agricultura Sinica, V24, P18
   Ren Zhenglong, 1993, Acta Genetica Sinica, V20, P312
   Ren ZL, 1997, SCI CHINA SER C, V27, P258
   Rieseberg LH, 2003, SCIENCE, V301, P1211, DOI 10.1126/science.1086949
   Salmon A, 2005, MOL ECOL, V14, P1163, DOI 10.1111/j.1365-294X.2005.02488.x
   Saze H, 2003, NAT GENET, V34, P65, DOI 10.1038/ng1138
   Scascitelli M, 2010, GENETICS, V184, P975, DOI 10.1534/genetics.109.112557
   Shaked H, 2001, PLANT CELL, V13, P1749
   Shen HS, 2012, PLANT CELL, V24, P875, DOI 10.1105/tpc.111.094870
   Soltis PS, 2009, ANNU REV PLANT BIOL, V60, P561, DOI 10.1146/annurev.arplant.043008.092039
   Tang ZX, 2009, PLANT BREEDING, V128, P524, DOI 10.1111/j.1439-0523.2008.01598.x
   Uauy C, 2006, SCIENCE, V314, P1298, DOI 10.1126/science.1133649
   VOS P, 1995, NUCLEIC ACIDS RES, V23, P4407, DOI 10.1093/nar/23.21.4407
   Wang H, 2009, BMC PLANT BIOL, V9, DOI 10.1186/1471-2229-9-63
   Wang JL, 2004, GENETICS, V167, P1961, DOI 10.1534/genetics.104.027896
   Wang JL, 2006, GENETICS, V172, P507, DOI 10.1534/genetics.105.047894
   Zhang J, 1996, EUPHYTICA, V90, P315, DOI 10.1007/BF00027482
   Zhang X, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000032
   Zhang Y, 2005, SILVAE GENET, V54, P211, DOI 10.1515/sg-2005-0031
   Zhang Y, 2008, CHINESE SCI BULL, V53, P58, DOI 10.1007/s11434-008-0049-3
   Zhao XX, 2007, PLANT SCI, V172, P930, DOI 10.1016/j.plantsci.2007.01.002
NR 43
TC 1
Z9 3
U1 4
U2 36
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1380-3743
EI 1572-9788
J9 MOL BREEDING
JI Mol. Breed.
PD JUN
PY 2013
VL 32
IS 1
BP 165
EP 176
DI 10.1007/s11032-013-9860-x
PG 12
WC Agronomy; Plant Sciences; Genetics & Heredity; Horticulture
SC Agriculture; Plant Sciences; Genetics & Heredity
GA 165DK
UT WOS:000320463000013
DA 2018-12-27
ER

PT J
AU Chen, YS
   Lee, CH
   Hung, MY
   Pan, HA
   Chiou, JC
   Huang, GS
AF Chen, Yu-Shiun
   Lee, Chia-Hui
   Hung, Meng-Yen
   Pan, Hsu-An
   Chiou, Jin-Chern
   Huang, G. Steven
TI RETRACTED: DNA sequencing using electrical conductance measurements of a
   DNA polymerase (Retracted article. See vol. 10, pg. 563, 2015)
SO NATURE NANOTECHNOLOGY
LA English
DT Article; Retracted Publication
ID GOLD NANOPARTICLES; HUMAN GENOME; MOLECULE; ENZYME; TECHNOLOGIES;
   NANOPORE; MUTANT; MODE
AB The development of personalized medicine-in which medical treatment is customized to an individual on the basis of genetic information-requires techniques that can sequence DNA quickly and cheaply. Single-molecule sequencing technologies, such as nanopores, can potentially be used to sequence long strands of DNA without labels or amplification, but a viable technique has yet to be established. Here, we show that single DNA molecules can be sequenced by monitoring the electrical conductance of a phi29 DNA polymerase as it incorporates unlabelled nucleotides into a template strand of DNA. The conductance of the polymerase is measured by attaching it to a protein transistor that consists of an antibody molecule (immunoglobulin G) bound to two gold nanoparticles, which are in turn connected to source and drain electrodes. The electrical conductance of the DNA polymerase exhibits well-separated plateaux that are similar to 3 pA in height. Each plateau corresponds to an individual base and is formed at a rate of similar to 22 nucleotides per second. Additional spikes appear on top of the plateaux and can be used to discriminate between the four different nucleotides. We also show that the sequencing platform works with a variety of DNA polymerases and can sequence difficult templates such as homopolymers.
C1 [Chen, Yu-Shiun] Natl Chiao Tung Univ, Dept Biol Sci & Technol, Hsinchu, Taiwan.
   [Chen, Yu-Shiun; Pan, Hsu-An; Chiou, Jin-Chern; Huang, G. Steven] Natl Chiao Tung Univ, Biomed Elect Translat Res Ctr, Hsinchu, Taiwan.
   [Lee, Chia-Hui; Hung, Meng-Yen; Pan, Hsu-An; Huang, G. Steven] Natl Chiao Tung Univ, Dept Mat Sci & Engn, Hsinchu, Taiwan.
   [Chiou, Jin-Chern] Natl Chiao Tung Univ, Inst Elect & Control Engn, Hsinchu, Taiwan.
RP Huang, GS (reprint author), Natl Chiao Tung Univ, Biomed Elect Translat Res Ctr, 1001 Univ Rd, Hsinchu, Taiwan.
EM gstevehuang@mail.nctu.edu.tw
FU 'Aim for the Top University Plan' of the National Chiao Tung University;
   Ministry of Education, Taiwan, China; Nanotechnology National project of
   the National Science Counsel, Taiwan [101-2120-M-009-008]; National
   Health Research Institute grant [NHRI-EX102-10249EI]; Air Force Office
   of Scientific Research (AFOSR) [FA2386-11-1-4094, AOARD-13-4035]
FX This work was partially supported by the 'Aim for the Top University
   Plan' of the National Chiao Tung University and the Ministry of
   Education, Taiwan, China. This work was also partly supported by
   Nanotechnology National project 101-2120-M-009-008 of the National
   Science Counsel, Taiwan, and a National Health Research Institute grant
   (NHRI-EX102-10249EI). The authors acknowledge funding support from the
   Air Force Office of Scientific Research (AFOSR, FA2386-11-1-4094;
   special grant AOARD-13-4035).
CR Bashir A, 2012, NAT BIOTECHNOL, V30, P701, DOI 10.1038/nbt.2288
   Bedford E, 1997, P NATL ACAD SCI USA, V94, P479, DOI 10.1073/pnas.94.2.479
   Bentley DR, 2006, CURR OPIN GENET DEV, V16, P545, DOI 10.1016/j.gde.2006.10.009
   BLANCO L, 1989, J BIOL CHEM, V264, P8935
   Camps M, 2004, CELL CYCLE, V3, P116
   Chen YS, 2012, NAT NANOTECHNOL, V7, P197, DOI [10.1038/nnano.2012.7, 10.1038/NNANO.2012.7]
   Cherf GM, 2012, NAT BIOTECHNOL, V30, P344, DOI 10.1038/nbt.2147
   Choi YK, 2012, SCIENCE, V335, P319, DOI 10.1126/science.1214824
   Eisenstein M, 2012, NAT BIOTECHNOL, V30, P295, DOI 10.1038/nbt0412-295
   English BP, 2006, NAT CHEM BIOL, V2, P87, DOI 10.1038/nchembio759
   Gupta PK, 2008, TRENDS BIOTECHNOL, V26, P602, DOI 10.1016/j.tibtech.2008.07.003
   Harris TD, 2008, SCIENCE, V320, P106, DOI 10.1126/science.1150427
   Huang GS, 2006, NANO LETT, V6, P2467, DOI 10.1021/nl061598x
   HUNKAPILLER T, 1991, SCIENCE, V254, P59, DOI 10.1126/science.1925562
   Johne R, 2009, TRENDS MICROBIOL, V17, P205, DOI 10.1016/j.tim.2009.02.004
   Kircher M, 2010, BIOESSAYS, V32, P524, DOI 10.1002/bies.200900181
   Koren S, 2012, NAT BIOTECHNOL, V30, P692, DOI 10.1038/nbt.2280
   LEHMAN IR, 1958, J BIOL CHEM, V233, P163
   Levene MJ, 2003, SCIENCE, V299, P682, DOI 10.1126/science.1079700
   Li YR, 2009, NAT BIOTECHNOL, V27, P820, DOI 10.1038/nbt0909-820
   Manrao EA, 2012, NAT BIOTECHNOL, V30, P349, DOI 10.1038/nbt.2171
   MCCARTHY D, 1976, J MOL BIOL, V106, P963, DOI 10.1016/0022-2836(76)90346-6
   Pennisi E, 2012, SCIENCE, V336, P534, DOI 10.1126/science.336.6081.534
   Pushkarev D, 2009, NAT BIOTECHNOL, V27, P847, DOI 10.1038/nbt.1561
   Ronaghi M, 1996, ANAL BIOCHEM, V242, P84, DOI 10.1006/abio.1996.0432
   SANGER F, 1977, NATURE, V265, P687, DOI 10.1038/265687a0
   SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463
   Schadt EE, 2010, HUM MOL GENET, V19, pR227, DOI 10.1093/hmg/ddq416
   Schatz MC, 2010, GENOME RES, V20, P1165, DOI 10.1101/gr.101360.109
   Schneider GF, 2012, NAT BIOTECHNOL, V30, P326, DOI 10.1038/nbt.2181
   Shendure J, 2004, NAT REV GENET, V5, P335, DOI 10.1038/nrg1325
   Shendure J, 2005, SCIENCE, V309, P1728, DOI 10.1126/science.1117389
   Shendure J, 2008, NAT BIOTECHNOL, V26, P1135, DOI 10.1038/nbt1486
   Sherwood P, 2003, NATURE, V422, P806, DOI 10.1038/422806a
   Turcatti G, 2008, NUCLEIC ACIDS RES, V36, DOI 10.1093/nar/gkn021
   Warshel A, 2006, CHEM REV, V106, P3210, DOI 10.1021/cr0503106
NR 36
TC 23
Z9 27
U1 3
U2 101
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1748-3387
EI 1748-3395
J9 NAT NANOTECHNOL
JI Nat. Nanotechnol.
PD JUN
PY 2013
VL 8
IS 6
BP 452
EP 458
DI 10.1038/NNANO.2013.71
PG 7
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
SC Science & Technology - Other Topics; Materials Science
GA 158NS
UT WOS:000319979400018
PM 23644569
DA 2018-12-27
ER

PT J
AU Anderson, DE
   Vogel, EK
   Awh, E
AF Anderson, David E.
   Vogel, Edward K.
   Awh, Edward
TI RETRACTED: A Common Discrete Resource for Visual Working Memory and
   Visual Search (Retracted article. See vol. 26, pg. 1527, 2015)
SO PSYCHOLOGICAL SCIENCE
LA English
DT Article; Retracted Publication
DE visual attention; visual memory; evoked potentials; working memory;
   visual search; ERP; N2pc
ID INDIVIDUAL-DIFFERENCES; SELECTIVE ATTENTION; EXECUTIVE ATTENTION;
   FEATURE-INTEGRATION; NEURAL MEASURES; TOP-DOWN; CAPACITY;
   REPRESENTATIONS; CONJUNCTIONS; AUTOMATICITY
AB Visual search, a dominant paradigm within attention research, requires observers to rapidly identify targets hidden among distractors. Major models of search presume that working memory (WM) provides the on-line work space for evaluating potential targets. According to this hypothesis, individuals with higher WM capacity should search more efficiently, because they should be able to apprehend a larger number of search elements at a time. Nevertheless, no compelling evidence of such a correlation has emerged, and this null result challenges a growing consensus that there is strong overlap between the neural processes that limit internal storage and those that limit external selection. Here, we provide multiple demonstrations of robust correlations between WM capacity and search efficiency, and we document a key boundary condition for observing this link. Finally, examination of a neural measure of visual selection capacity (the N2pc) demonstrates that visual search and WM storage are constrained by a common discrete resource.
C1 [Anderson, David E.; Vogel, Edward K.; Awh, Edward] Univ Oregon, Eugene, OR 97403 USA.
RP Awh, E (reprint author), 1227 Univ Oregon, Eugene, OR 97403 USA.
EM awh@uoregon.edu
FU NIMH NIH HHS [R01 MH087214, R01MH077105, R01 MH077105]
CR Anderson D. E., J EXPT PSYC IN PRESS
   Anderson DE, 2011, J NEUROSCI, V31, P1128, DOI 10.1523/JNEUROSCI.4125-10.2011
   Awh E, 2006, NEUROSCIENCE, V139, P201, DOI 10.1016/j.neuroscience.2005.08.023
   Awh E, 2001, TRENDS COGN SCI, V5, P119, DOI 10.1016/S1364-6613(00)01593-X
   Baddeley A. D, 1986, WORKING MEMORY
   BOUMA H, 1970, NATURE, V226, P177, DOI 10.1038/226177a0
   Brainard DH, 1997, SPATIAL VISION, V10, P433, DOI 10.1163/156856897X00357
   BUNDESEN C, 1990, PSYCHOL REV, V97, P523, DOI 10.1037//0033-295X.97.4.523
   Chun MM, 2011, NEUROPSYCHOLOGIA, V49, P1407, DOI 10.1016/j.neuropsychologia.2011.01.029
   COHEN A, 1991, J EXP PSYCHOL HUMAN, V17, P891, DOI 10.1037/0096-1523.17.4.891
   Cowan N, 2001, BEHAV BRAIN SCI, V24, P87, DOI 10.1017/S0140525X01003922
   DESIMONE R, 1995, ANNU REV NEUROSCI, V18, P193, DOI 10.1146/annurev.neuro.18.1.193
   Downing PE, 2000, PSYCHOL SCI, V11, P467, DOI 10.1111/1467-9280.00290
   Drew T, 2008, J NEUROSCI, V28, P4183, DOI 10.1523/JNEUROSCI.0556-08.2008
   DUNCAN J, 1989, PSYCHOL REV, V96, P433, DOI 10.1037//0033-295X.96.3.433
   Emrich SM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008042
   Engle RW, 2002, CURR DIR PSYCHOL SCI, V11, P19, DOI 10.1111/1467-8721.00160
   Ester E. E., 2012, COGNITIVE NEUROSCIEN, P99
   Ester EF, 2012, J NEUROSCI, V32, P7169, DOI 10.1523/JNEUROSCI.1218-12.2012
   FISHER DL, 1982, PSYCHOL REV, V89, P662, DOI 10.1037/0033-295X.89.6.662
   Gazzaley A., 2011, TRENDS COGN SCI, V16, P129
   Halberda J, 2006, PSYCHOL SCI, V17, P572, DOI 10.1111/j.1467-9280.2006.01746.x
   Horowitz TS, 1998, NATURE, V394, P575, DOI 10.1038/29068
   Kane MJ, 2006, J EXP PSYCHOL LEARN, V32, P749, DOI 10.1037/0278-7393.32.4.749
   LOGAN GD, 1979, J EXP PSYCHOL HUMAN, V5, P189
   LOGAN GD, 1978, J EXP PSYCHOL GEN, V107, P32, DOI 10.1037//0096-3445.107.1.32
   Luck SJ, 1997, COGNITIVE PSYCHOL, V33, P64, DOI 10.1006/cogp.1997.0660
   LUCK SJ, 1994, PSYCHOPHYSIOLOGY, V31, P291, DOI 10.1111/j.1469-8986.1994.tb02218.x
   Luck SJ, 1997, NATURE, V390, P279, DOI 10.1038/36846
   McCarley JS, 2003, PSYCHOL SCI, V14, P422, DOI 10.1111/1467-9280.01457
   McCollough AW, 2007, CORTEX, V43, P77, DOI 10.1016/S0010-9452(08)70447-7
   Oh SH, 2004, PSYCHON B REV, V11, P275, DOI 10.3758/BF03196570
   Pagano S, 2012, NEUROPSYCHOLOGIA, V50, P754, DOI 10.1016/j.neuropsychologia.2012.01.009
   PASHLER H, 1987, PERCEPT PSYCHOPHYS, V41, P191, DOI 10.3758/BF03208218
   Pelli DG, 1997, SPATIAL VISION, V10, P437, DOI 10.1163/156856897X00366
   Peterson MS, 2001, PSYCHOL SCI, V12, P287, DOI 10.1111/1467-9280.00353
   Poole BJ, 2009, Q J EXP PSYCHOL, V62, P1430, DOI 10.1080/17470210802479329
   PYLYSHYN Z W, 1988, Spatial Vision, V3, P179, DOI 10.1163/156856888X00122
   Smith E E, 1999, Science, V283, P1657
   Sobel KV, 2007, PSYCHON B REV, V14, P840, DOI 10.3758/BF03194109
   Soto D, 2008, TRENDS COGN SCI, V12, P342, DOI 10.1016/j.tics.2008.05.007
   TREISMAN AM, 1980, COGNITIVE PSYCHOL, V12, P97, DOI 10.1016/0010-0285(80)90005-5
   Unsworth N, 2007, PSYCHOL REV, V114, P104, DOI 10.1037/0033-295X.114.1.104
   Vogel EK, 2008, CURR DIR PSYCHOL SCI, V17, P171, DOI 10.1111/j.1467-8721.2008.00569.x
   Vogel EK, 2004, NATURE, V428, P748, DOI 10.1038/nature02447
   Vogel EK, 1998, J EXP PSYCHOL HUMAN, V24, P1656, DOI 10.1037/0096-1523.24.6.1656
   Wolfe Jeremy M., 2005, P101, DOI 10.1016/B978-012375731-9/50021-5
   WOLFE JM, 1994, PSYCHON B REV, V1, P202, DOI 10.3758/BF03200774
   Wolfe JM, 1998, PSYCHOL SCI, V9, P33, DOI 10.1111/1467-9280.00006
   Woodman GF, 2007, J EXP PSYCHOL HUMAN, V33, P363, DOI 10.1037/0096-1523.33.2.363
   Woodman GF, 2001, PSYCHOL SCI, V12, P219, DOI 10.1111/1467-9280.00339
   Zhang WW, 2008, NATURE, V453, P233, DOI 10.1038/nature06860
NR 52
TC 39
Z9 41
U1 2
U2 36
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0956-7976
EI 1467-9280
J9 PSYCHOL SCI
JI Psychol. Sci.
PD JUN
PY 2013
VL 24
IS 6
BP 929
EP 938
DI 10.1177/0956797612464380
PG 10
WC Psychology, Multidisciplinary
SC Psychology
GA 159EA
UT WOS:000320026000013
PM 23572280
OA Green Accepted
DA 2018-12-27
ER

PT J
AU Qi, GQ
   Fan, HP
   Wu, G
   Song, SY
   Wei, D
   Bai, Q
AF Qi, Guoquan
   Fan, Haiping
   Wu, Gang
   Song, Shengyin
   Wei, Dong
   Bai, Qiang
TI RETRACTED: Study on the magnetic viscosity of Nd45Pr15Fe30-xCoxAl10
   (x=0, 10) bulk amorphous Alloys (Retracted article. See vol. 430, pg.
   115, 2013)
SO PHYSICA B-CONDENSED MATTER
LA English
DT Article; Retracted Publication
DE Magnetic viscosity; Bulk amorphous; Hard magnets
ID GLASS-FORMING ALLOY; METALLIC-GLASS; ND60FE30AL10; MICROSTRUCTURE; AL
AB The bulk amorphous Nd45Pr15Fe30-xCoxAl10 (x=0, 10) alloys, which were prepared by arc melting and investigated by XRD and VSM, present hard magnetic behavior at room temperature. The intrinsic coercivity of the bulk amorphous increased with increasing Co addition. A single sharp and narrow peak close to the coercivity appeared in the irreversible susceptibility (chi(irr)) curve for each alloy. The addition of Co has little influence on the magnetic viscosity of the alloys. With the substitution of Co for Fe, the fluctuation field H-f increased from 9.9 mT to 11.5 mT, and the activation volume V-a increased from 2.9 x 10(-18) cm(3) to 3.6 x 10(-18) cm(3), which leads to an increase of the activation diameter D-a from 17.7 nm to 19.0 nm. The value of D-a deduced from the magnetic viscosity measurements is similar to the size of clusters of Nd-based bulk amorphous alloys, which may be responsible for the hard magnetic property exhibited at room temperature. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Qi, Guoquan; Wu, Gang; Song, Shengyin; Wei, Dong; Bai, Qiang] CNPC, Tubular Goods Res Inst, Xian 710065, Peoples R China.
   [Fan, Haiping] State Nucl Power Engn Co, Shanghai 200233, Peoples R China.
RP Qi, GQ (reprint author), CNPC, Tubular Goods Res Inst, Xian 710065, Peoples R China.
EM qiguoquan@cnpc.com.cn
CR Billoni OV, 2002, PHYSICA B, V320, P288, DOI 10.1016/S0921-4526(02)00717-2
   Collocott SJ, 2008, J MAGN MAGN MATER, V320, P2089, DOI 10.1016/j.jmmm.2008.03.029
   Collocott SJ, 2002, PHYS REV B, V66, DOI 10.1103/PhysRevB.66.224420
   Inoue A, 1997, SCI REP RES TOHOKU A, V44, P261
   Inoue A, 1998, APPL PHYS LETT, V73, P744, DOI 10.1063/1.121987
   McCallum RW, 2006, J MAGN MAGN MATER, V299, P265, DOI 10.1016/j.jmmm.2005.04.013
   Mingxiang P., 2002, INTERMETALLICS, V10, P1215
   Schneider S, 2002, APPL PHYS LETT, V80, P1749, DOI 10.1063/1.1458070
   STREET R, 1994, J APPL PHYS, V76, P6386, DOI 10.1063/1.358275
   Sun ZG, 2003, J MAGN MAGN MATER, V261, P122, DOI 10.1016/S0304-8853(02)01460-9
   TOMKA GJ, 1994, J PHYS D APPL PHYS, V27, P1601, DOI 10.1088/0022-3727/27/8/003
   Urreta S.E., 2004, REV MAT, V9, P158
   Wei BC, 2002, ACTA MATER, V50, P4357, DOI 10.1016/S1359-6454(02)00272-0
   Wohlforth E.P., 1984, J PHYS F MET PHYS, V14, P2155
   Xia L, 2003, J PHYS D APPL PHYS, V36, P775, DOI 10.1088/0022-3727/36/7/301
   Zhang Y, 2001, J MATER RES, V16, P1675, DOI 10.1557/JMR.2001.0232
NR 16
TC 1
Z9 1
U1 2
U2 20
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0921-4526
EI 1873-2135
J9 PHYSICA B
JI Physica B
PD JUN 1
PY 2013
VL 418
BP 65
EP 68
DI 10.1016/j.physb.2013.03.003
PG 4
WC Physics, Condensed Matter
SC Physics
GA 139RK
UT WOS:000318601400011
DA 2018-12-27
ER

PT J
AU Wang, JH
   Xu, YM
   Fu, Q
   Yu, JJ
   Chen, Z
   Liu, ZS
   Li, C
   Guo, H
   Xie, MK
AF Wang, Jihong
   Xu, Yuemin
   Fu, Qiang
   Yu, Jianjun
   Chen, Zhong
   Liu, Zhangshun
   Li, Chao
   Guo, Hui
   Xie, Mingkai
TI RETRACTED: Association of GSTT1 gene polymorphisms with the risk of
   prostate cancer: an updating meta-analysis (Retracted article. See
   April, 2017)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE Prostate cancer; Susceptibility; Glutathione transferase; GSTT1; Genetic
   polymorphism
ID GLUTATHIONE-S-TRANSFERASES; JAPANESE POPULATION; AFRICAN DESCENT; HUMAN
   ERYTHROCYTES; P1 POLYMORPHISMS; DRUG-METABOLISM; ETHYLENE-OXIDE; THETA
   GSTT1; GSTM1; SUSCEPTIBILITY
AB It has been demonstrated that the glutathione S-transferase (GST) superfamily helps remove carcinogens from the body and thus might be associated with prostate cancer risk. In recent years, GSTT1 polymorphism has been extensively studied as a potential prostate cancer risk factor; however, the results are inconsistent. To investigate the association between GSTT1 and prostate cancer, we conducted a meta-analysis of 33 studies with 6,697 prostate patients and 7,643 controls. For GSTM1 null versus present genotype, the random effects odds ratio was 0.98 (95 % confidence interval (CI) 0.83-1.16) based on a wide population. Subgroup analyses in the different ethnic groups and different controls were performed. The OR was 1.01 (95 % CI 0.86-1.19) in Caucasians, 1.01 (95 % CI 0.70-1.47) in Asians, and 0.77 (95 % CI 0.42-1.42) in Africans. The OR was 0.98 (95 % CI 0.82-1.16) in non-benign prostate hyperplasia (BPH) controls and 1.09 (95 % CI 0.66-1.79) in BPH controls. In conclusion, our present meta-analysis demonstrates that there is no association between GSTT1 polymorphism and prostate cancer, even in the sub-analysis concerning different races and control sources. The direction of further research should focus not only on the simple relationship of GSTT1 and prostate cancer but also on gene-environment interaction and distinctions of different GSTs.
C1 [Wang, Jihong; Xu, Yuemin; Fu, Qiang; Yu, Jianjun; Chen, Zhong; Liu, Zhangshun; Li, Chao; Guo, Hui; Xie, Mingkai] Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 6, Dept Urol, Shanghai 200233, Peoples R China.
RP Xu, YM (reprint author), Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 6, Dept Urol, 600 Yishan Rd, Shanghai 200233, Peoples R China.
EM yueminxudr@163.com
CR Agalliu I, 2006, PROSTATE, V66, P146, DOI 10.1002/pros.20305
   Ashtiani ZO, 2011, PATHOL ONCOL RES, V17, P269, DOI 10.1007/s12253-010-9309-z
   Autrup JLC, 1999, EUR J CANCER PREV, V8, P525, DOI 10.1097/00008469-199912000-00008
   Beer TM, 2002, PROSTATE CANCER P D, V5, P22, DOI 10.1038/sj/pcan/4500549
   Caceres DD, 2005, EUR J EPIDEMIOL, V20, P79, DOI 10.1007/s10654-004-1632-9
   Catsburg C, 2012, CARCINOGENESIS, V33, P1352, DOI 10.1093/carcin/bgs175
   Choubey VK, 2013, PROSTATE, V73, P146, DOI 10.1002/pros.22549
   FOST U, 1991, HUM EXP TOXICOL, V10, P25, DOI 10.1177/096032719101000105
   Gronberg H, 2003, LANCET, V361, P859, DOI 10.1016/S0140-6736(03)12713-4
   Gsur A, 2001, INT J CANCER, V95, P152, DOI 10.1002/1097-0215(20010520)95:3<152::AID-IJC1026>3.0.CO;2-S
   GUENGERICH FP, 1995, PHARMACOGENETICS, V5, pS103, DOI 10.1097/00008571-199512001-00010
   Haas GP, 1997, CA-CANCER J CLIN, V47, P273, DOI 10.3322/canjclin.47.5.273
   HALLIER E, 1994, ARCH TOXICOL, V68, P423, DOI 10.1007/s002040050092
   HALLIER E, 1990, INT ARCH OCC ENV HEA, V62, P221, DOI 10.1007/BF00379437
   Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Joseph MA, 2004, NUTR CANCER, V50, P206, DOI 10.1207/s15327914nc5002_11
   KAWAJIRI K, 1993, CRIT REV ONCOL HEMAT, V14, P77, DOI 10.1016/1040-8428(93)90007-Q
   Kidd LR, 2003, EUR J CANCER PREV, V12, P317, DOI 10.1097/01.cej.0000082922.97406.3e
   Komiya Y, 2005, J CANCER RES CLIN, V131, P238, DOI 10.1007/s00432-004-0634-z
   Kote-Jarai Z, 2001, PHARMACOGENETICS, V11, P325, DOI 10.1097/00008571-200106000-00007
   Kumar V, 2011, DIS MARKERS, V30, P163, DOI 10.3233/DMA-2011-0774
   Kwon DD, 2011, KOREAN J UROL, V52, P247, DOI 10.4111/kju.2011.52.4.247
   Lavender NA, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-397
   Lima MM, 2008, FOLIA BIOL-PRAGUE, V54, P102
   Lof A, 2000, PHARMACOGENETICS, V10, P645, DOI 10.1097/00008571-200010000-00007
   Mallick S, 2007, UROLOGY, V69, P1165, DOI 10.1016/j.urology.2007.02.039
   MANNERVIK B, 1992, BIOCHEM J, V282, P305, DOI 10.1042/bj2820305
   Medeiros R, 2004, PROSTATE, V58, P414, DOI 10.1002/pros.10348
   Meyer UA, 1996, J PHARMACOKINET BIOP, V24, P449, DOI 10.1007/BF02353473
   Mittal R D, 2004, Indian J Cancer, V41, P115
   Mittal Rama Devi, 2006, Asian Pac J Cancer Prev, V7, P444
   Mo ZN, 2009, PROSTATE, V69, P662, DOI 10.1002/pros.20907
   Murata M, 2001, CANCER LETT, V165, P171, DOI 10.1016/S0304-3835(01)00398-6
   Nakazato H, 2003, ANTICANCER RES, V23, P2897
   Nam RK, 2003, CANCER EPIDEM BIOMAR, V12, P1429
   Nemesure B, 2013, J IMMIGR MINOR HEALT, V15, P1107, DOI 10.1007/s10903-012-9710-7
   Nock NL, 2007, CANCER EPIDEM BIOMAR, V16, P1236, DOI 10.1158/1055-9965.EPI-06-0736
   Ntais C, 2005, CANCER EPIDEM BIOMAR, V14, P176
   PEMBLE S, 1994, BIOCHEM J, V300, P271, DOI 10.1042/bj3000271
   Rebbeck TR, 1999, CANCER EPIDEM BIOMAR, V8, P283
   Rebbeck TR, 1997, CANCER EPIDEM BIOMAR, V6, P733
   Rodrigues IS, 2011, UROL ONCOL-SEMIN ORI, V29, P654, DOI 10.1016/j.urolonc.2010.01.009
   Ryberg D, 1997, CARCINOGENESIS, V18, P1285, DOI 10.1093/carcin/18.7.1285
   Safarinejad MR, 2011, PROSTATE CANCER P D, V14, P105, DOI 10.1038/pcan.2010.54
   SEIDEGARD J, 1986, CARCINOGENESIS, V7, P751, DOI 10.1093/carcin/7.5.751
   Silig Y, 2006, CANCER INVEST, V24, P41, DOI 10.1080/07357900500449579
   Sivonova M, 2009, J EXP CLIN CANC RES, V28, DOI 10.1186/1756-9966-28-32
   Souiden Y, 2010, CANCER EPIDEMIOL, V34, P598, DOI 10.1016/j.canep.2010.06.002
   Srivastava DSL, 2005, BJU INT, V95, P170, DOI 10.1111/j.1464-410X.2005.05271.x
   Steinhoff C, 2000, ARCH TOXICOL, V74, P521, DOI 10.1007/s002040000161
   Taioli E, 2011, CARCINOGENESIS, V32, P1361, DOI 10.1093/carcin/bgr119
   Taningher M, 1999, MUTAT RES-REV MUTAT, V436, P227, DOI 10.1016/S1383-5742(99)00005-8
   Thakur H, 2011, MOL BIOL REP, V38, P1733, DOI 10.1007/s11033-010-0287-8
   Thier R, 1999, ARCH TOXICOL, V73, P197, DOI 10.1007/s002040050606
   Wei BB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046982
   WIDERSTEN M, 1991, BIOCHEM J, V276, P519, DOI 10.1042/bj2760519
   WIENCKE JK, 1995, CANCER EPIDEM BIOMAR, V4, P253
   Yang J, 2006, FRONT BIOSCI, V11, P2052
   Zuccolo L, 2013, INT J CANCER, V132, P2176, DOI 10.1002/ijc.27877
NR 60
TC 6
Z9 6
U1 3
U2 9
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD JUN
PY 2013
VL 34
IS 3
BP 1431
EP 1440
DI 10.1007/s13277-012-0640-8
PG 10
WC Oncology
SC Oncology
GA 149YI
UT WOS:000319356900014
PM 23456766
DA 2018-12-27
ER

PT J
AU Wang, XY
   Liang, Y
   Wang, J
   Wang, M
AF Wang, Xinyan
   Liang, Yu
   Wang, Jun
   Wang, Min
TI RETRACTED: Effect of NS-398, a cyclooxygenase-2 selective inhibitor, on
   the cytotoxicity of cytotoxic T lymphocytes to ovarian carcinoma cells
   (Retracted article. See vol. 36, pg. 7297, 2015)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE COX-2; CTLs; Cytotoxicity; NS-398; Ovarian carcinoma
ID CANCER CELLS; PANCREATIC-CANCER; EXPRESSION; APOPTOSIS; COX-2; NS398;
   SYNTHASE-2; BALANCE; GROWTH; GENE
AB Cyclooxygenase-2 (COX-2) is a key limited enzyme of prostaglandin (PG) synthesis and has been demonstrated to be overexpressed in cancer. N-[2-(cyclohexyloxy)-4-nitropheny]-methane sulfonamide (NS-398) is a special inhibitor of COX-2 and may suppress PGE2 release and promote immune response mechanism of cytotoxic T lymphocytes (CTLs). We aimed to investigate the effect of NS-398 on the PGE2 release, proliferation of ovarian carcinoma cell line CAOV3, and immune cytotoxicity of CTLs. CAOV3 cells were incubated with 0, 50, and 100 mu mol/L NS-398 for 24, 48, and 72 h. Cell viability was determined by trypan blue staining. PGE(2) was measured using radioimmunoassay. CTLs were generated from peripheral blood mononuclear cells after stimulated by CAOV3 cells or CAOV3 cells treated with NS-398 when IL-2 existed. The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay was used to evaluate the cytotoxicity of CTLs. As expected, the amount, cell density, cellular volume, and growth speed of CAOV3 cells incubated with NS-398 were significantly decreased compared with control group. This difference became more obvious with an increase in the NS-398 concentration and incubation time. Similarly, PGE(2) released from CAOV3 cells treated with 50 and 100 mu mol/L NS-398 was significantly decreased compared with control group (P < 0.05). There was also significance in PGE(2) between the two groups treated with 50 and 100 mu mol/L NS-398 (P < 0.05). Compared with control group, the killing rates of CTLs to CAOV3 treated with 50 and 100 mu mol/L NS-398 were significantly increased (P < 0.05). However, there is no significant difference between them. Together, our results suggest that NS-398 could be useful in prevention and therapy of ovarian carcinoma.
C1 [Wang, Xinyan; Wang, Jun; Wang, Min] China Med Univ, Shengjing Hosp, Dept Gynecol & Obstet, Shenyang 110004, Peoples R China.
   [Liang, Yu] China Med Univ, Shenyang 110001, Peoples R China.
   [Liang, Yu] Weikang Hosp, Shenyang 110021, Peoples R China.
RP Wang, M (reprint author), China Med Univ, Shengjing Hosp, Dept Gynecol & Obstet, 36 Sanhao St, Shenyang 110004, Peoples R China.
EM wm21st@hotmail.com
FU Natural Science Foundation of China [30973189]
FX This work is supported by the Natural Science Foundation of China (Grant
   Number: 30973189).
CR APPLEBY SB, 1994, BIOCHEM J, V302, P723, DOI 10.1042/bj3020723
   Athanassiadou P, 2008, PATHOL RES PRACT, V204, P241, DOI 10.1016/j.prp.2007.11.004
   Bowen NJ, 2009, BMC MED GENOMICS, V2, DOI 10.1186/1755-8794-2-71
   Chang HC, 2001, ONCOL REP, V8, P1321
   Huang M, 1998, CANCER RES, V58, P1208
   INOUE H, 1995, J BIOL CHEM, V270, P24965, DOI 10.1074/jbc.270.42.24965
   Kase S, 2004, J EXP CLIN CANC RES, V23, P301
   Liu XH, 1998, CANCER RES, V58, P4245
   Matsubayashi H, 2007, CANCER BIOL THER, V6, P1569, DOI 10.4161/cbt.6.10.4711
   MORITA I, 1995, J BIOL CHEM, V270, P10902, DOI 10.1074/jbc.270.18.10902
   Nizamutdinova IT, 2009, ARCH PHARM RES, V32, P99, DOI 10.1007/s12272-009-1123-3
   Park Mi Kyung, 2005, Cancer Res Treat, V37, P313, DOI 10.4143/crt.2005.37.5.313
   SANO H, 1995, CANCER RES, V55, P3785
   Sharma S, 2003, CLIN CANCER RES, V9, P961
   Smyth GP, 2003, ANN SURG ONCOL, V10, P455, DOI 10.1245/ASO.2003.06.036
   Sombroek CC, 2002, J IMMUNOL, V168, P4333, DOI 10.4049/jimmunol.168.9.4333
   Spivak B, 1999, CLIN NEUROPHARMACOL, V22, P98, DOI 10.1097/00002826-199903000-00006
   Stolina M, 2000, J IMMUNOL, V164, P361, DOI 10.4049/jimmunol.164.1.361
   Valmori D, 2000, CANCER RES, V60, P4499
   Wang XH, 2009, J HUAZHONG U SCI-MED, V29, P761, DOI 10.1007/s11596-009-0618-y
   Youns M, 2011, EUR J PHARMACOL, V650, P170, DOI 10.1016/j.ejphar.2010.10.026
   Zhu J, 2012, FRONT BIOSCI ELITE E, V4, P2745
NR 22
TC 7
Z9 7
U1 3
U2 13
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD JUN
PY 2013
VL 34
IS 3
BP 1517
EP 1522
DI 10.1007/s13277-013-0677-3
PG 6
WC Oncology
SC Oncology
GA 149YI
UT WOS:000319356900025
PM 23456767
DA 2018-12-27
ER

PT J
AU Wang, LS
   Zang, WD
   Xie, DL
   Ji, WD
   Pan, YS
   Li, ZQ
   Shen, JW
   Shi, YY
AF Wang, Lishan
   Zang, Weidong
   Xie, Dongli
   Ji, Weidong
   Pan, Yaosheng
   Li, Zhiqiang
   Shen, Jiawei
   Shi, Yongyong
TI RETRACTED: Comparison of hepatocellular carcinoma (HCC),
   cholangiocarcinoma (CC), and combined HCC-CC (CHC) with each other based
   on microarray dataset (Retracted article. See vol. 36, pg. 7299, 2015)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE Hepatocellular carcinoma; Cholangiocarcinoma; Gene expression profiling;
   Biomarkers
ID PROTEIN-INTERACTION NETWORKS; ENRICHMENT ANALYSIS; FACTOR-VII; CANCER;
   IDENTIFICATION; RECURRENCE; PREDICTION; COMPLEXES; CIRRHOSIS; TIME
AB Liver carcinomas have been classified into three types: hepatocellular carcinoma (HCC), cholangiocarcinoma (CC), and combined HCC-CC (CHC). We aim to find the common and different characteristic of these three types of liver cancer. The gene expression profiling of HCC, CC, and CHC were compared with each other, and enrichment pathways and processes in these three liver cancers were also identified. Using GSE15765 datasets downloaded from NCBI GEO database, the gene expression profiling of HCC, CC, and CHC were compared with each other (HCC compared with CC, HCC compared with CHC, and CC compared with HCC). Then, the differentially expressed genes (DEGs) were identified in these three groups respectively, and three PPI networks were constructed for DEGs in each group. Subsequently, the clusters in these networks were identified and further analyzed by ClusterONE and MCODE. Finally, gene set enrichment analysis enrichment analysis was performed to illustrate altered pathways and processes for each type of liver cancer. A total of 112, 530, and 64 DEGs were identified in three groups, respectively, and three PPI networks were constructed respectively for the corresponding group. Through the cluster analysis, we found some new differential marker genes for distinguishing the difference between these three types of liver cancer. We also indicated that we can distinguish HCC with CC through altered pathways and processes. Our findings develop new biomarkers for categorizing the primary liver cancer and may improve patient prognosis of these cancers. However, further validation is required since our results were based on microarray data derived from a small sample size.
C1 [Wang, Lishan; Ji, Weidong; Pan, Yaosheng; Li, Zhiqiang; Shen, Jiawei; Shi, Yongyong] Shanghai Jiao Tong Univ, Minist Educ, Key Lab Genet Dev & Neuropsychiat Disorders, Bio X Inst, Shanghai 200030, Peoples R China.
   [Wang, Lishan; Zang, Weidong; Xie, Dongli] FengHe ShangHai Informat Technol Co Ltd, Shanghai, Peoples R China.
   [Ji, Weidong; Pan, Yaosheng; Shi, Yongyong] Shanghai Changning Mental Hlth Ctr, Shanghai 200042, Peoples R China.
   [Ji, Weidong; Pan, Yaosheng; Shi, Yongyong] Shanghai Jiao Tong Univ, Inst Neuropsychiatr Sci & Syst Biol Med, Shanghai 200042, Peoples R China.
RP Shi, YY (reprint author), Shanghai Jiao Tong Univ, Inst Neuropsychiatr Sci & Syst Biol Med, Shanghai 200042, Peoples R China.
EM shiyongyongsh@hotmail.com
FU Natural Science Foundation of China [81130022, 81272302, 31000553,
   81121001]; National 863 project [2012AA02A515]; 973 Program
   [2010CB529600]; Program for Changjiang Scholars and Innovative Research
   Team in University [IRT1025]; Foundation for the Author of National
   Excellent Doctoral Dissertation of China [201026]; Shanghai Municipal
   Education Commission; Shanghai Education Development Foundation
   [12SG17]; Shanghai Rising-Star Program [12QA1401900]
FX This work was supported by the Natural Science Foundation of China
   (81130022, 81272302, 31000553, 81121001), the National 863 project
   (2012AA02A515), the 973 Program (2010CB529600), Program for Changjiang
   Scholars and Innovative Research Team in University (IRT1025), the
   Foundation for the Author of National Excellent Doctoral Dissertation of
   China (201026), the "Shu Guang" project supported by Shanghai Municipal
   Education Commission and Shanghai Education Development
   Foundation(12SG17), Shanghai Rising-Star Program (12QA1401900).
CR Bader GD, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471-2105-4-2
   Bieker R, 2009, BLOOD, V113, P5019, DOI 10.1182/blood-2008-04-150318
   Chaerkady R, 2008, J PROTEOME RES, V7, P4289, DOI 10.1021/pr800197z
   Cheng P, 2012, ASIAN PAC J CANCER P, V13, P3741, DOI 10.7314/APJCP.2012.13.8.3741
   Comunale MA, 2006, J PROTEOME RES, V5, P308, DOI 10.1021/pr050328x
   DERRICK TR, 1994, MED SCI SPORT EXER, V26, P919
   FAN ST, 1994, NEW ENGL J MED, V331, P1547, DOI 10.1056/NEJM199412083312303
   Goodman ZD, 2006, CANCER, V55, P124
   Koizume S, 2006, CANCER RES, V66, P9453, DOI 10.1158/0008-5472.CAN-06-1803
   Kojiro M, 2011, CANCER GENET-SER, P37, DOI 10.1007/978-1-4419-6082-5_3
   Lau WY, 2010, ANZ J SURG, V80, P75, DOI 10.1111/j.1445-2197.2009.05205.x
   Lazaridis KN, 2012, TXB CLIN GASTROENTER, P580
   Lo RCL, 2011, CHINESE J CANCER RES, V23, P245, DOI 10.1007/s11670-011-0245-6
   Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180
   Nepusz T, 2012, NAT METHODS, V9, P471, DOI [10.1038/nmeth.1938, 10.1038/NMETH.1938]
   OCKNER RK, 1993, HEPATOLOGY, V18, P669, DOI 10.1002/hep.1840180327
   Ohishi W, 2011, HEPATOLOGY, V53, P1237, DOI 10.1002/hep.24207
   Papatheodoridis GV, 1999, J HEPATOL, V31, P747, DOI 10.1016/S0168-8278(99)80357-2
   Prasad TSK, 2009, NUCLEIC ACIDS RES, V37, pD767, DOI 10.1093/nar/gkn892
   Seimiya M, 2008, HEPATOLOGY, V48, P519, DOI 10.1002/hep.22364
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Smyth G. K., 2004, STAT APPL GENET MOL, V3, DOI DOI 10.2202/1544-6115.1027
   Stark C, 2011, NUCLEIC ACIDS RES, V39, pD698, DOI 10.1093/nar/gkq1116
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   VANSTEENBERGEN W, 1993, ACTA CLIN BELG, V48, P171, DOI 10.1080/17843286.1993.11718305
   Woo HG, 2008, CLIN CANCER RES, V14, P2056, DOI 10.1158/1078-0432.CCR-07-1473
   Yi X, 2008, MOL CELL PROTEOMICS, V7, P315, DOI 10.1074/mcp.M700116-MCP200
NR 27
TC 8
Z9 8
U1 2
U2 13
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD JUN
PY 2013
VL 34
IS 3
BP 1679
EP 1684
DI 10.1007/s13277-013-0702-6
PG 6
WC Oncology
SC Oncology
GA 149YI
UT WOS:000319356900044
PM 23532688
DA 2018-12-27
ER

PT J
AU Zhang, YS
   Xie, JZ
   Zhong, JL
   Li, YY
   Wang, RQ
   Qin, YZ
   Lou, HX
   Gao, ZH
   Qu, XJ
AF Zhang, Yu-Sheng
   Xie, Ji-Zhen
   Zhong, Julia-Li
   Li, Yuan-Yuan
   Wang, Rui-Qi
   Qin, Yi-Zhuo
   Lou, Hong-Xiang
   Gao, Zu-Hua
   Qu, Xian-Jun
TI RETRACTED: Acetyl-11-keto-beta-boswellic acid (AKBA) inhibits human
   gastric carcinoma growth through modulation of the Wnt/beta-catenin
   signaling pathway (Retracted article. See vol. 1850, pg. 254, 2015)
SO BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS
LA English
DT Article; Retracted Publication
DE Gastric carcinoma; Acetyl-11-keto-beta-boswellic acid (AKBA); Inhibitory
   effect; Apoptosis; Wnt/beta-catenin
ID NF-KAPPA-B; PROSTATE-CANCER CELLS; BOSWELLIC ACID; IN-VITRO;
   BETA-CATENIN; INVASION; EXPRESSION; STOMACH; CARCINOGENESIS;
   P21(WAF1/CIP1)
AB Background: Acetyl-11-keto-beta-boswellic acid (AKBA) is a derivative of boswellic acid, an active component of Boswellia serrata gum resin. We examined the effect of AKBA on human gastric carcinoma growth and explored the underlying molecular mechanisms.
   Methods: Inhibition of cancer cell growth was estimated by colorimetric and clonogenic assays. Cell cycle distribution was analyzed by flow cytometry and apoptosis determined using Annexin V-FITC/PI staining and DNA ladder quantification. After three weeks of oral AKBA administration in nude mice bearing cancer xenografts, animals were sacrificed and xenografts removed for TUNEL staining and western blot analysis.
   Results: AKBA exhibited anti-cancer activity in vitro and in vivo. With oral application in mice, AKBA significantly inhibited SGC-7901 and MKN-45 xenografts without toxicity. This effect might be associated with its roles in cell cycle arrest and apoptosis induction. The results also showed activation of p21(waf1/Cip1) and p53 in mitochondria and increased cleaved caspase-9, caspase-3, and PARP and Bax/Bcl-2 ratio after AKBA treatment Further analysis suggested that these effects might arise from AKBA's modulation of the aberrant Wnt/beta-catenin signaling pathway. Upon AKBA treatment, beta-catenin expression in nuclei was inhibited, and membrane beta-catenin was activated. In the same sample, active GSK3 beta was increased and its non-active form decreased. Levels of cyclin D1, PCNA, survivin, c-Myc, MMP-2, and MMP-7, downstream targets of Wnt/beta-catenin, were inhibited.
   Conclusions: AKBA effects on human gastric carcinoma growth were associated with its activity in modulating the Wnt/beta-catenin signaling pathway.
   General significance: AKBA could be useful in the treatment of gastric cancers. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Zhang, Yu-Sheng; Li, Yuan-Yuan; Wang, Rui-Qi; Qin, Yi-Zhuo; Lou, Hong-Xiang; Qu, Xian-Jun] Shandong Univ, Dept Pharmacol, Key Lab Chem Biol, Sch Pharmaceut Sci, Jinan 250100, Peoples R China.
   [Xie, Ji-Zhen] Shandong Ctr Drug Evaluat & Certificat, Jinan, Peoples R China.
   [Zhong, Julia-Li] Chongqing Univ, Base Project Biomech & Tissue Repair Engn 111, Key Lab Biorheol Sci & Technol, Bioengn Coll, Chongqing 630044, Peoples R China.
   [Gao, Zu-Hua] McGill Univ, Dept Pathol, Montreal, PQ, Canada.
RP Gao, ZH (reprint author), McGill Univ, Dept Pathol, Montreal, PQ, Canada.
EM zu-hua.gao@mcgill.ca; qxj@sdu.edu.cn
FU Natural Science Foundation of China [91229113, 81173090, 81072665]
FX This project was supported by the Natural Science Foundation of China
   (Grant nos. 91229113, 81173090, and 81072665).
CR Abdel-Tawab M, 2011, CLIN PHARMACOKINET, V50, P349, DOI 10.2165/11586800-000000000-00000
   Abraham SC, 2003, MODERN PATHOL, V16, P786, DOI 10.1097/01.MP.0000080349.37658.5E
   An YT, 2011, DRUG DISCOV THER, V5, P76, DOI 10.5582/ddt.2011.v5.2.76
   Baradaran-Heravi A, 2012, AM J MED GENET A, V158A, P2204, DOI 10.1002/ajmg.a.35532
   Bauer KS, 1998, BIOCHEM PHARMACOL, V55, P1827, DOI 10.1016/S0006-2952(98)00046-X
   Cai C, 2012, MOL MED REP, V5, P1191, DOI 10.3892/mmr.2012.802
   Chiba T, 2012, GASTROENTEROLOGY, V143, P550, DOI 10.1053/j.gastro.2012.07.009
   Devgan V, 2005, GENE DEV, V19, P1485, DOI 10.1101/gad.341405
   Fishman P, 2004, ONCOGENE, V23, P2465, DOI 10.1038/sj.onc.1207355
   Hawkes WC, 2011, BIOCHEM BIOPH RES CO, V413, P36, DOI 10.1016/j.bbrc.2011.08.032
   He WC, 2012, J AM SOC NEPHROL, V23, P294, DOI 10.1681/ASN.2011050490
   Jang BG, 2011, PATHOBIOLOGY, V78, P302, DOI 10.1159/000321703
   Kolligs FT, 2002, DIGESTION, V66, P131, DOI 10.1159/000066755
   Kuhl S.J., 2012, BIOCHIM BIOPHYS ACTA, V1830, P2297
   Lee KH, 2007, EUR SURG RES, V39, P208, DOI 10.1159/000101452
   Lee KH, 2012, CLIN EXP METASTAS, V29, P263, DOI 10.1007/s10585-011-9449-x
   Li Q, 2012, FRONT BIOSCI-LANDMRK, V17, P2383, DOI 10.2741/4059
   Li YS, 2011, J INT MED RES, V39, P2141, DOI 10.1177/147323001103900610
   Liu H.P., 2012, INT J CANCER, DOI DOI 10.1002/FIC.27929
   Nunez F., 2011, PLOS ONE, V6
   Park B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026943
   Qiao L, 2009, DRUG RESIST UPDATE, V12, P55, DOI 10.1016/j.drup.2009.02.002
   Sengupta K, 2011, MOL CELL BIOCHEM, V354, P189, DOI 10.1007/s11010-011-0818-1
   Shao L, 2010, BIOSCI TRENDS, V4, P249
   Sharma S, 2004, PHYTOMEDICINE, V11, P255, DOI 10.1078/0944-7113-00290
   Singh S, 2008, PHYTOMEDICINE, V15, P408, DOI 10.1016/j.phymed.2008.02.017
   Sinha VR, 2007, J PHARM PHARMACOL, V59, P359, DOI 10.1211/jpp.59.3.0004
   Stathopoulos GP, 2013, CANCER CHEMOTH PHARM, V71, P413, DOI 10.1007/s00280-012-2022-8
   Sugai T, 2010, BMC GASTROENTEROL, V10, DOI 10.1186/1471-230X-10-55
   Takada Y, 2006, J IMMUNOL, V176, P3127, DOI 10.4049/jimmunol.176.5.3127
   Takahashi-Yanaga F, 2009, J PHARMACOL SCI, V109, P179, DOI 10.1254/jphs.08R28FM
   Van Veldhuizen PJ, 2008, INT J CANCER, V122, P567, DOI 10.1002/ijc.23117
   Wee J, 2012, MED HYPOTHESES, V79, P833, DOI 10.1016/j.mehy.2012.09.003
   Wogan GN, 2004, SEMIN CANCER BIOL, V14, P473, DOI 10.1016/j.semcancer.2004.06.010
   Xue X, 2012, LUNG CANCER, V76, P300, DOI 10.1016/j.lungcan.2011.12.013
   Yadav VR, 2012, INT J CANCER, V130, P2176, DOI 10.1002/ijc.26251
   Yang WC, 2005, AM J PATHOL, V166, P1239, DOI 10.1016/S0002-9440(10)62342-5
   Yuan HQ, 2008, BIOCHEM PHARMACOL, V75, P2112, DOI 10.1016/j.bcp.2008.03.005
   Yue B, 2013, CANCER LETT, V328, P104, DOI 10.1016/j.canlet.2012.09.002
   Zhang N, 2012, INT J ONCOL, V40, P2038, DOI 10.3892/ijo.2012.1395
   Zhang Y, 2009, LIPIDS HEALTH DIS, V8, DOI 10.1186/1476-511X-8-51
   Zhao CR, 2012, TOXICOL APPL PHARM, V262, P293, DOI 10.1016/j.taap.2012.05.006
   Zhao L, 2010, CANCER BIOL THER, V9, P42, DOI 10.4161/cbt.9.1.10282
   Zheng HC, 2010, HUM PATHOL, V41, P1255, DOI 10.1016/j.humpath.2010.02.003
NR 44
TC 16
Z9 19
U1 70
U2 97
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0304-4165
EI 1872-8006
J9 BBA-GEN SUBJECTS
JI Biochim. Biophys. Acta-Gen. Subj.
PD JUN
PY 2013
VL 1830
IS 6
BP 3604
EP 3615
DI 10.1016/j.bbagen.2013.03.003
PG 12
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 148GL
UT WOS:000319232400030
PM 23500016
DA 2018-12-27
ER

PT J
AU Havas, M
   Marrongelle, J
AF Havas, Magda
   Marrongelle, Jeffrey
TI RETRACTED: Replication of heart rate variability provocation study with
   2.4-GHz cordless phone confirms original findings (Retracted article.
   See vol. 33, pg. 335, 2014)
SO ELECTROMAGNETIC BIOLOGY AND MEDICINE
LA English
DT Article; Retracted Publication
DE heart rate variability; mobile phone; tachycardia; arrhythmia; microwave
   radiation; radio frequency radiation; electrohypersensitivity; autonomic
   nervous system
ID ELECTROMAGNETIC HYPERSENSITIVITY; FIELDS
AB This is a replication of a study that we previously conducted in Colorado with 25 subjects designed to test the effect of electromagnetic radiation generated by the base station of a cordless phone on heart rate variability (HRV). In this study, we analyzed the response of 69 subjects between the ages of 26 and 80 in both Canada and the USA. Subjects were exposed to radiation for 3-min intervals generated by a 2.4-GHz cordless phone base station (3-8 mu W/cm(2)). A fewparticipants had a severe reaction to the radiation with an increase in heart rate and altered HRV indicative of an alarm response to stress. Based on the HRV analyses of the 69 subjects, 7% were classified as being " moderately to very" sensitive, 29% were " little to moderately" sensitive, 30% were " not to little" sensitive and 6% were " unknown". These results are not psychosomatic and are not due to electromagnetic interference. Twenty-five percent of the subjects' self-proclaimed sensitivity corresponded to that based on the HRV analysis, while32% overestimated their sensitivity and 42% did not know whether or not they were electrically sensitive. Of the 39 participants who claimed to experience some electrical hypersensitivity, 36% claimed they also reacted to a cordless phone and experienced heart symptoms and, of these, 64% were classified as having some degree of electrohypersensitivity (EHS) based on their HRV response. Novel findings include documentation of a delayed response to radiation. Orthostatic HRV testing combined with provocation testing may provide a diagnostic tool for some sufferers of EHS when they are exposed to electromagnetic emitting devices. The protocol used underestimates reaction to electromagnetic radiation for those who have a delayed autonomic nervous system reaction and it may under diagnose those who have adrenal exhaustion as their ability to mount a response to a stressor is diminished.
C1 [Havas, Magda] Trent Univ, Peterborough, ON K9J 7B8, Canada.
   [Marrongelle, Jeffrey] Bioenergimed Metab Inst, Schyylkill Haven, PA USA.
RP Havas, M (reprint author), Trent Univ, Peterborough, ON K9J 7B8, Canada.
EM mhavas@trentu.ca
CR Andrzejak R, 2008, IND HEALTH, V46, P409, DOI 10.2486/indhealth.46.409
   Austrian Medical Association, 2012, GUID AUSTR MED ASS D
   Bevington M, 2010, ELECTROMAGNETIC SENS
   Cleary SF, 1969, S P RICHM VIRG SEPT
   Eltiti S, 2007, BIOELECTROMAGNETICS, V28, P137, DOI 10.1002/bem.20279
   Havas M, 2012, P 7 INT WORKSH BIOL
   Havas M., 2010, EUR J ONCOL, V5, P273
   Johansson O, 2006, ELECTROMAGN BIOL MED, V25, P245, DOI 10.1080/15368370601044150
   McCarty DE, 2011, INT J NEUROSCI, V121, P670, DOI 10.3109/00207454.2011.608139
   Mohamed FA, 2011, LIFE SCI J, V8, P260
   Riftine A, 2002, THEOR REV CLIN USE
   Rubin GJ, 2011, BIOELECTROMAGNETICS, V32, P593, DOI 10.1002/bem.20690
   Rubin GJ, 2010, BIOELECTROMAGNETICS, V31, P1, DOI 10.1002/bem.20536
   Rubin GJ, 2005, PSYCHOSOM MED, V67, P224, DOI 10.1097/01.psy.0000155664.13300.64
NR 14
TC 5
Z9 7
U1 4
U2 27
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1536-8378
EI 1536-8386
J9 ELECTROMAGN BIOL MED
JI Electromagn. Biol. Med.
PD JUN
PY 2013
VL 32
IS 2
BP 253
EP 266
DI 10.3109/15368378.2013.776437
PG 14
WC Biology; Biophysics
SC Life Sciences & Biomedicine - Other Topics; Biophysics
GA 144LA
UT WOS:000318939500016
PM 23675629
DA 2018-12-27
ER

PT J
AU Travnik, L
   Djordjevic, S
   Rozman, S
   Hribernik, M
   Dahmane, R
AF Travnik, Ludvik
   Djordjevic, Srdjan
   Rozman, Sergej
   Hribernik, Marija
   Dahmane, Raja
TI RETRACTED: Muscles within muscles: a tensiomyographic and histochemical
   analysis of the normal human vastus medialis longus and vastus medialis
   obliquus muscles (Retracted article. See vol. 223, pg. 420, 2013)
SO JOURNAL OF ANATOMY
LA English
DT Article; Retracted Publication
DE histochemistry; tensiomyography; vastus medialis longus; vastus medialis
   obliquus
ID HUMAN SKELETAL-MUSCLE; ELECTROMECHANICAL DELAY; FIBER TYPES; NONINVASIVE
   ESTIMATION; TRAPEZIUS MUSCLE; BICEPS; CONTRACTIONS
AB The aim of this study was to show the connection between structure (anatomical and histochemical) and function (muscle contraction properties) of vastus medialis obliquus (VMO) and vastus medialis longus (VML). The non-invasive tensiomyography (TMG) method was used to determine the contractile properties (contraction time; Tc) of VML and VMO muscle, as a reflection of the ratio between the slow and fast fibers in two groups of nine young men. VML and VMO significantly (P<0.01) differ in the proportion of type 1 (59.6:44%) and type 2b (6.3:15%) fibers. The VML muscle is almost entirely composed of type 1 and type 2a fibers. In many samples of this muscle no type 2b fibers were found. The proportion of slow-twitch type 1 fibers is nearly twice as high as the proportion of fast-twitch type 2a fibers. These observations indicate that VML is a slower and more fatigue-resistant muscle than VMO muscle. These characteristics correspond to the different functions of the VML, which is an extensor of the knee, and to the VMO, which maintains the stable position of the patella in the femoral groove. Our results obtained by TMG provided additional evidence that muscle fibers within the segments of VM muscle were not homogenous with regard to their contractile properties, thereby confirming the histochemical results. Tc can be attributed to the higher percentage of slow-twitch fibers type 1. The statistically shorter Tc (P0.001) of VMO (22.8 +/- 4.0ms) compared with VML (26.7 +/- 4.0ms) in our study is consistent with previously found differences in histochemical, morphological and electrophysiological data. In conclusion, the results of this study provide evidence that the VML and VMO muscles are not only anatomically and histochemically different muscles, but also functionally different biological structures.
C1 [Travnik, Ludvik] Univ Med Ctr, Dept Orthoped Surg, Ljubljana, Slovenia.
   [Djordjevic, Srdjan] Univ Primorska, Fac Math Nat Sci & Informat Technol, Koper, Slovenia.
   [Djordjevic, Srdjan; Rozman, Sergej] TMG BMC, Ljubljana, Slovenia.
   [Hribernik, Marija; Dahmane, Raja] Univ Ljubljana, Inst Anat, Fac Med, Ljubljana 61000, Slovenia.
RP Dahmane, R (reprint author), Univ Ljubljana, Inst Anat, Fac Med, Korytkova 2, Ljubljana 61000, Slovenia.
EM raja.dahmane@guest.arnes.si
CR BOSE K, 1980, ORTHOPEDICS, V3, P880, DOI 10.3928/0147-7447-19800901-12
   BROOKE MH, 1970, ARCH NEUROL-CHICAGO, V23, P369, DOI 10.1001/archneur.1970.00480280083010
   Brown JMM, 1993, ELECTROMYOGR CLIN NE, V33, P1
   Carrasco L, 2011, EUR J APPL PHYSIOL, V111, P2271, DOI 10.1007/s00421-011-1848-9
   CAVANAGH PR, 1979, EUR J APPL PHYSIOL, V42, P159, DOI 10.1007/BF00431022
   Dahmane R, 2005, J BIOMECH, V38, P2451, DOI 10.1016/j.jbiomech.2004.10.020
   Dahmane R, 2001, MED BIOL ENG COMPUT, V39, P51, DOI 10.1007/BF02345266
   Dahmane R, 2006, MED BIOL ENG COMPUT, V44, P999, DOI 10.1007/s11517-006-0114-5
   GOLDSPINK G, 1992, AM J PHYSIOL, V262, pR356
   GUTH L, 1970, EXP NEUROL, V28, P365, DOI 10.1016/0014-4886(70)90244-X
   Hubbard JK, 1997, ANAT RECORD, V249, P135
   Hug F, 2011, MUSCLE NERVE, V43, P441, DOI 10.1002/mus.21948
   Hunter AM, 2012, J ELECTROMYOGR KINES, V22, P334, DOI 10.1016/j.jelekin.2012.01.009
   JOHNSON G, 1994, CLIN BIOMECH, V9, P44, DOI 10.1016/0268-0033(94)90057-4
   JOHNSON MA, 1973, J NEUROL SCI, V18, P111, DOI 10.1016/0022-510X(73)90023-3
   LINDMAN R, 1990, AM J ANAT, V189, P236, DOI 10.1002/aja.1001890306
   McAndrew D. J., 2006, J APPL RES, V6, P142
   NARICI MV, 1992, EUR J APPL PHYSIOL O, V65, P438, DOI 10.1007/BF00243511
   Nordez A, 2009, J APPL PHYSIOL, V106, P1970, DOI 10.1152/japplphysiol.00221.2009
   NYGAARD E, 1982, ANAT REC, V203, P451, DOI 10.1002/ar.1092030404
   PADYKULA HA, 1955, J HISTOCHEM CYTOCHEM, V3, P170, DOI 10.1177/3.3.170
   Peeler J, 2007, CLIN ANAT, V20, P307, DOI 10.1002/ca.20375
   PETTE D, 1985, MUSCLE NERVE, V8, P676, DOI 10.1002/mus.880080810
   PETTE D, 1980, PLASTICITY MUSCLE
   Rainoldi A, 2008, J ELECTROMYOGR KINES, V18, P1032, DOI 10.1016/j.jelekin.2007.05.008
   Rey E, 2012, J ELECTROMYOGR KINES, V22, P866, DOI 10.1016/j.jelekin.2012.06.003
   SANDSTEDT ER, 1981, ACTA NEUROL SCAND, V64, P427
   Sasaki K, 2011, MED SCI SPORT EXER, V43, P1200, DOI 10.1249/MSS.0b013e318209312c
   Simunic B, 2012, J ELECTROMYOGR KINES, V22, P527, DOI 10.1016/j.jelekin.2012.04.003
   Simunic B, 2011, MED SCI SPORT EXER, V43, P1619, DOI 10.1249/MSS.0b013e31821522d0
   Smith TO, 2009, CLIN ANAT, V22, P183, DOI 10.1002/ca.20737
   Speakman H G, 1977, Physiotherapy, V63, P249
   STARON RS, 1984, J HISTOCHEM CYTOCHEM, V32, P146, DOI 10.1177/32.2.6229571
   TESCH PA, 1984, J APPL PHYSIOL, V56, P35
   Tous-Fajardo J, 2010, J ELECTROMYOGR KINES, V20, P761, DOI 10.1016/j.jelekin.2010.02.008
   TRAVNIK L, 1995, J ANAT, V187, P403
   WEINSTABL R, 1989, SURG RADIOL ANAT, V11, P17, DOI 10.1007/BF02102239
   Wickham JB, 1998, EUR J APPL PHYSIOL, V78, P219, DOI 10.1007/s004210050410
   ZHOU S, 1995, EUR J APPL PHYSIOL, V70, P138, DOI 10.1007/BF00361541
NR 39
TC 7
Z9 8
U1 3
U2 26
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0021-8782
EI 1469-7580
J9 J ANAT
JI J. Anat.
PD JUN
PY 2013
VL 222
IS 6
BP 580
EP 587
DI 10.1111/joa.12045
PG 8
WC Anatomy & Morphology
SC Anatomy & Morphology
GA 147HV
UT WOS:000319158200003
PM 23586984
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Kim, JS
   Sklarz, T
   Banks, LB
   Gohil, M
   Waickman, AT
   Skuli, N
   Krock, BL
   Luo, CT
   Hu, WH
   Pollizzi, KN
   Li, MO
   Rathmell, JC
   Birnbaum, MJ
   Powell, JD
   Jordan, MS
   Koretzky, GA
AF Kim, Jiyeon S.
   Sklarz, Tammarah
   Banks, Lauren B.
   Gohil, Mercy
   Waickman, Adam T.
   Skuli, Nicolas
   Krock, Bryan L.
   Luo, Chong T.
   Hu, Weihong
   Pollizzi, Kristin N.
   Li, Ming O.
   Rathmell, Jeffrey C.
   Birnbaum, Morris J.
   Powell, Jonathan D.
   Jordan, Martha S.
   Koretzky, Gary A.
TI RETRACTED: Natural and inducible T(H)17 cells are regulated differently
   by Akt and mTOR pathways (Retracted article. See vol. 15, pg. 996, 2014)
SO NATURE IMMUNOLOGY
LA English
DT Article; Retracted Publication
ID ARYL-HYDROCARBON RECEPTOR; KINASE-B-ALPHA; T-CELLS; TRANSCRIPTION
   FACTORS; INSULIN-RESISTANCE; FOXP3 EXPRESSION; TARGET GENES; TH17 CELLS;
   ACTIVATION; ISOFORMS
AB Natural T helper 17 (nT(H)17) cells are a population of interleukin 17 (IL-17)-producing cells that acquire effector function in the thymus during development. Here we demonstrate that the serine/threonine kinase Akt has a critical role in regulating nT(H)17 cell development. Although Akt and the downstream mTORC1-ARNT-HIF alpha axis were required for generation of inducible T(H)17 (iT(H)17) cells, nT(H)17 cells developed independently of mTORC1. In contrast, mTORC2 and inhibition of Foxo proteins were critical for development of nT(H)17 cells. Moreover, distinct isoforms of Akt controlled the generation of T(H)17 cell subsets, as deletion of Akt2, but not of Akt1, led to defective generation of iT(H)17 cells. These findings define mechanisms regulating nT(H)17 cell development and reveal previously unknown roles of Akt and mTOR in shaping subsets of T cells.
C1 [Kim, Jiyeon S.; Sklarz, Tammarah; Banks, Lauren B.; Gohil, Mercy; Skuli, Nicolas; Krock, Bryan L.; Koretzky, Gary A.] Univ Penn, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA.
   [Kim, Jiyeon S.; Banks, Lauren B.] Univ Penn, Perelman Sch Med, Med Scientist Training Program, Philadelphia, PA 19104 USA.
   [Waickman, Adam T.; Pollizzi, Kristin N.; Powell, Jonathan D.] Johns Hopkins Univ, Sch Med, Dept Oncol, Sidney Kimmel Comprehens Canc Res Ctr, Baltimore, MD 21205 USA.
   [Luo, Chong T.; Li, Ming O.] Mem Sloan Kettering Canc Ctr, Program Immunol, New York, NY 10021 USA.
   [Hu, Weihong; Rathmell, Jeffrey C.] Duke Univ, Dept Immunol, Dept Pharmacol & Canc Biol, Sarah W Stedman Nutr & Metab Ctr, Durham, NC USA.
   [Birnbaum, Morris J.] Univ Penn, Perelman Sch Med, Inst Diabet Obes & Metab, Philadelphia, PA 19104 USA.
   [Jordan, Martha S.] Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA.
   [Koretzky, Gary A.] Univ Penn, Dept Med, Philadelphia, PA 19104 USA.
RP Jordan, MS (reprint author), Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA.
EM jordanm@mail.med.upenn.edu; koretzky@mail.med.upenn.edu
OI Birnbaum, Morris/0000-0001-9972-8680
FU US National Institutes of Health [R01 DK56886, 5K01AR52802, R37GM053256]
FX We thank B. Stiles (University of Southern California) for tissue from
   Akt1<SUP>-/-</SUP> mice; members of the Stem Cell and
   Xenotransplantation Core facility of the University of Pennsylvania for
   assistance with obtaining previously collected and de-identified human
   fetal thymic tissue; B. Monks for invaluable technical assistance and
   animal husbandry; L. Dipilato (University of Pennsylvania) for Akt
   inhibitors and helpful suggestions; S. Carty and T. Kambayashi for
   critically reading the manuscript; J. Stadanlick for editorial
   assistance; and members of the Koretzky and Jordan laboratories for
   helpful discussions. This work was supported by grants from US National
   Institutes of Health R01 DK56886 (M.J.B.), 5K01AR52802 (M.S.J.) and
   R37GM053256 (G.A.K.).
CR Bae SS, 2003, J BIOL CHEM, V278, P49530, DOI 10.1074/jbc.M306782200
   Beurel E, 2011, J IMMUNOL, V186, P1391, DOI 10.4049/jimmunol.1003511
   Bruick RK, 2003, GENE DEV, V17, P2614, DOI 10.1101/gad.1145503
   Brunet A, 2001, MOL CELL BIOL, V21, P952, DOI 10.1128/MCB.21.3.952-965.2001
   Chen J, 2010, BLOOD, V115, P4237, DOI 10.1182/blood-2009-11-255323
   Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728
   Cosmi L, 2008, J EXP MED, V205, P1903, DOI 10.1084/jem.20080397
   Dang EV, 2011, CELL, V146, P772, DOI 10.1016/j.cell.2011.07.033
   Delgoffe GM, 2011, NAT IMMUNOL, V12, P295, DOI 10.1038/ni.2005
   Delgoffe GM, 2009, IMMUNITY, V30, P832, DOI 10.1016/j.immuni.2009.04.014
   Duvel K, 2010, MOL CELL, V39, P171, DOI 10.1016/j.molcel.2010.06.022
   Dummler B, 2007, BIOCHEM SOC T, V35, P231, DOI 10.1042/BST0350231
   Elson DA, 2000, CANCER RES, V60, P6189
   Gonzalez E, 2009, CELL CYCLE, V8, P2502, DOI 10.4161/cc.8.16.9335
   Gonzalez E, 2009, P NATL ACAD SCI USA, V106, P7004, DOI 10.1073/pnas.0901933106
   Gruber M, 2007, P NATL ACAD SCI USA, V104, P2301, DOI 10.1073/pnas.0608382104
   Guertin DA, 2006, DEV CELL, V11, P859, DOI 10.1016/j.devcel.2006.10.007
   Gulen MF, 2012, IMMUNITY, V37, P800, DOI 10.1016/j.immuni.2012.08.019
   Harada Y, 2010, J EXP MED, V207, P1381, DOI 10.1084/jem.20100004
   Haxhinasto S, 2008, J EXP MED, V205, P565, DOI 10.1084/jem.20071477
   Jacinto E, 2006, CELL, V127, P125, DOI 10.1016/j.cell.2006.08.033
   Juntilla MM, 2007, P NATL ACAD SCI USA, V104, P12105, DOI 10.1073/pnas.0705285104
   Kane LP, 2003, IMMUNOL REV, V192, P7, DOI 10.1034/j.1600-065X.2003.00008.x
   Kim JS, 2011, J EXP MED, V208, P2201, DOI 10.1084/jem.20110680
   Korn T, 2009, ANNU REV IMMUNOL, V27, P485, DOI 10.1146/annurev.immunol.021908.132710
   Kurebayashi Y, 2012, CELL REPORTS, V1, P360, DOI 10.1016/j.celrep.2012.02.007
   Laplante M, 2009, J CELL SCI, V122, P3589, DOI 10.1242/jcs.051011
   Lazorchak AS, 2010, MOL CELL, V39, P433, DOI 10.1016/j.molcel.2010.07.031
   Leavens KF, 2009, CELL METAB, V10, P405, DOI 10.1016/j.cmet.2009.10.004
   Lee K, 2012, J EXP MED, V209, P713, DOI 10.1084/jem.20111470
   Lee K, 2010, IMMUNITY, V32, P743, DOI 10.1016/j.immuni.2010.06.002
   Mao CC, 2007, J IMMUNOL, V178, P5443, DOI 10.4049/jimmunol.178.9.5443
   Marks BR, 2009, NAT IMMUNOL, V10, P1125, DOI 10.1038/ni.1783
   McManus EJ, 2005, EMBO J, V24, P1571, DOI 10.1038/sj.emboj.7600633
   Ouyang W, 2010, NAT IMMUNOL, V11, P618, DOI 10.1038/ni.1884
   Powell JD, 2012, ANNU REV IMMUNOL, V30, P39, DOI 10.1146/annurev-immunol-020711-075024
   Powolny-Budnicka I, 2011, IMMUNITY, V34, P364, DOI 10.1016/j.immuni.2011.02.019
   Quintana FJ, 2008, NATURE, V453, P65, DOI 10.1038/nature06880
   Rathmell JC, 2003, EUR J IMMUNOL, V33, P2223, DOI 10.1002/eji.200324048
   Sauer S, 2008, P NATL ACAD SCI USA, V105, P7797, DOI 10.1073/pnas.0800928105
   Shi LZ, 2011, J EXP MED, V208, P1367, DOI 10.1084/jem.20110278
   Tomita S, 2000, MOL ENDOCRINOL, V14, P1674, DOI 10.1210/me.14.10.1674
   van der Vos KE, 2011, ANTIOXID REDOX SIGN, V14, P579, DOI 10.1089/ars.2010.3419
   Veldhoen M, 2008, NATURE, V453, P106, DOI 10.1038/nature06881
   Walker KS, 1998, BIOCHEM J, V331, P299, DOI 10.1042/bj3310299
   Wan Q, 2011, J EXP MED, V208, P1875, DOI 10.1084/jem.20102516
   Yang ZZ, 2005, MOL CELL BIOL, V25, P10407, DOI 10.1128/MCB.25.23.10407-10418.2005
   Zhou GL, 2006, J BIOL CHEM, V281, P36443, DOI 10.1074/jbc.M600788200
NR 48
TC 48
Z9 53
U1 4
U2 28
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1529-2908
EI 1529-2916
J9 NAT IMMUNOL
JI Nat. Immunol.
PD JUN
PY 2013
VL 14
IS 6
BP 611
EP +
DI 10.1038/ni.2607
PG 9
WC Immunology
SC Immunology
GA 146RG
UT WOS:000319107600014
PM 23644504
OA Green Accepted
DA 2018-12-27
ER

PT J
AU Barnett, RLE
AF Barnett, R. -L. Etienne
TI RETRACTED: Around the void: on the trivial (Retracted article. See vol.
   42, pg. 359, 2015)
SO NEOHELICON
LA French
DT Article; Retracted Publication
AB In the universe of text(s), even the most anodyne of elements is oft commissioned to subserve some prescribed function, to fulfill some ordained purpose, to evince some sanctioned principle of interpretability. Whence the enigma: in that literature is quite often unable to confront and tackle reality in any explicit manner (loathe to the possibility of vacuity), the text resorts to a sustaining allegorization, thus metamorphosing objects into signs and world-centered phenomena into discourse. Even Beckett's duo, eternally waiting, makes sense out of the futile if sustaining "act of anticipation." Much literature quests desperately to obviate such alibis, and, in consequence, confronts us with awkward configurations of banality, aridity, sterility. By inhibiting the elegance of rhetoric and the notion of heroic postures, contemporary writers plunge their characters into the very staleness and indifference that issue from an anomic world. While the modern day hero does not combat dragons or fight off monsters, protagonists do grapple with the aporia borne of inane minutia, all the hostile trivialities that birth and sustain an inhospitable resistance to reality. In the face of such opprobrium, the reader can but discern over-arching invocations of derision, of lives turned inward upon themselves, devoid of any co-extensive reason or being. Which begs the question: do such strategies successfully occlude the vision of terrifying emptiness? One can adduce instances in which this subduing or exhausting of otherness appears to forge a narrow path to some "minimal plenitude". Significance effaced, nothingness is perhaps yet superseded by the motivated extraction of some anodyne, surfacial pleasure from the simplest physical presence of "things," from the momentary delight of the senses, from the palpable drum-beat of existence. However ostensibly salutary this recourse to the senses, the reader is, at the same time, disarmed, debilitated, indeed betrayed, by the very textual maneuvers to which he is subjected. Conventional meaning is supplanted by its explicit displacement, nay, circumvention. Whence, a curious dynamic is birthed.
C1 [Barnett, R. -L. Etienne] Off Univ Provost, Atlanta, GA 30360 USA.
   [Barnett, R. -L. Etienne] Frederick A Treuhaft Fdn, Atlanta, GA 30360 USA.
   [Barnett, R. -L. Etienne] Univ Atlanta, Atlanta, GA 30360 USA.
   [Barnett, R. -L. Etienne] CNRS, F-75005 Paris, France.
RP Barnett, RLE (reprint author), Off Univ Provost, Atlanta, GA 30360 USA.
EM RL_Barnett@msn.com
CR Auerbach E., 1992, MIMESIS REPRESENTATI
   Auge M., 2001, ETHNOLOGUE METRO
   Autin-Grenier P., 1993, JE NE SUIS PAS HEROS
   Autin-Grenier P., 2005, RADIS BLEUS
   Barnett R.-L. E., 2012, EXEGESIS, V9, P88
   Barnett R.-L. E., 2012, MARGE LECT EXCENTRAT
   Barnett R.-L. E., 2013, ETUDES LETT, V94, P143
   Barnett R.-L. E., 2008, DEGRES REV SYNTHESE, V64, P127
   Barnett R.-L. E., 2010, STUDIES APPL CRITICA, V3, P108
   Barnett R.-L. E., 2007, LITTERATURES, V88, P164
   Barnett RLE, 2008, NEOHELICON, V35, P181, DOI 10.1007/s11059-008-4013-7
   Barthes R., 2002, NEUTRE NOTES COURS C
   Barthes R., 1993, EFFET REEL
   Barthes R., 1981, POINT ROBBE GRILLET
   BECKETT S, 1957, FIN PARTIE
   Begout B., 2003, LIEU COMMUN
   Begout Bruce, 2005, DECOUVERTE QUOTIDIEN
   Bernheim E., 1987, COUPLE
   Blanckeman Bruno, 2000, RECITS INDECIDABLES
   Butor M., 1965, 6 810 000 LITRES EAR
   CASTORIADIS C., 1996, CARREFOURS LABYRINTH, V4
   Char R., 1977, RECHERCHE BASE SOMME
   Chevillard E., 1992, CAOUTCHOUC DECIDEMEN
   Cioran E. M., 1987, INCONVENIENT ETRE NE
   Cousseau A., 2001, TEMPS LETT QUELLES P, P305
   DANTO A., 1989, TRANSFIGURATION BANA
   Decarie I., 2003, ACCESSOIRES LIT EPRE
   Delerm P., 1998, MOUSSE METAPHYSIQUE
   Deleuze Gilles, 1969, LOGIQUE SENS
   Deleuze Gilles, 1993, CRITIQUE CLIN
   Derrida Jacques, 1967, ECRITURE DIFFERENCE
   Deutsch M., 1988, SIT VENIA VERBO
   Droit R.-P., 2001, 101 EXPERIENCES PHIL
   Echenoz J., 2003, PIANO
   Eco U., 1994, 6 PROMENADES BOIS RO
   Gruillot E., 2005, PETITES CHRONIQUES V
   Huglo M.-P., 1997, METAMORPHOSES INSIGH
   Huglo M.-P., 2007, TEMPS ZERO, V2
   Janvier L., 1988, MONSTRE VA
   Jourde P., 2004, PRECIS LIT 21 SIECLE
   Jourde Pierre, 2005, LIT AUTHENTICITE REE
   Lacan J., 1940, PSYCHOSE PARANOIAQUE
   Laclavetine J.-M., 1991, DOUCEUR
   Laufer L., 2001, ETRE INDIFFERENT TEN
   Laurens C, 1999, QUELQUES UNS
   Laurent J., 1954, PETIT CANARD
   Le Roux Ph., 1990, INSIGNIFIANCE RECHER
   Leiris M., 1996, AFRIQUE FANTOME
   Lyon-Caen B., 2005, LIEUX REALISME
   Michea J.-C., 2007, EMPIRE MOINDRE MAL
   Oster Ch., 1989, VOLLEY BALL
   PEREC G, 1989, INFRA ORDINAIRE
   Perec G., 1967, HOMME QUI DORT
   Perec G., 1965, CHOSES
   Pons E., 2006, JE VIENS TUER MA FEM
   Pujade-Renaud C., 1999, PLATON ETAIT MALADE
   Quintane N., 2007, OREILLE CHIEN
   Ranciere J, 2000, PARTAGE SENSIBLE
   RANCIERE Jacques, 2001, INCONSCIENT ESTHETIQ
   Rasson L., 1997, POUVOIR INFIME VARIA
   Rosset C., 2001, REGIME PASSIONS
   Rosset C., 1979, OBJET SINGULIER
   Salvaire L., 1995, PUISSANCE MOUCHES
   Sartre Jean- Paul, 1981, OEUVRES ROMANESQUES, pxlvii
   Schor N., 1994, LECT DETAIL
   Schreiber B., 1987, TRAVERSE DIMANCHE
   Serieux P., 1979, FOLIES RAISONNATES D
   Sheringham M., 2006, EVERYDAY LIFE THEORI
   Toussaint J.-P., 2002, FAIRE AMOUR
   Toussaint J.-P., 1995, SALLE BAIN
   WITTGENSTEIN Ludwig, 1992, TRACTATUS LOGICOPHIL
NR 71
TC 1
Z9 1
U1 0
U2 3
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0324-4652
EI 1588-2810
J9 NEOHELICON
JI Neohelicon
PD JUN
PY 2013
VL 40
IS 1
BP 99
EP 114
DI 10.1007/s11059-013-0186-9
PG 16
WC Literature
SC Literature
GA 149ZO
UT WOS:000319360200009
DA 2018-12-27
ER

PT J
AU Wang, J
   Li, F
   Li, QF
   Sun, JL
   Chen, GX
AF Wang, Jing
   Li, Fang
   Li, Qifang
   Sun, Jianli
   Chen, Guang-Xin
TI RETRACTED: Polystyrene-b-poly(ethylene oxide) block copolymer thin films
   as templates for carbon nanotube dispersion (Retracted article. See vol.
   665, pg. 196, 2018)
SO THIN SOLID FILMS
LA English
DT Article; Retracted Publication
DE Carbon nanotubes; Block copolymer; Localization; Thin films
AB method for the selective self-assembly of polymer-functionalized carbon nanotubes (CNTs) in polystyrene-block- poly(ethylene oxide) (PS-b-PEO) copolymer was developed. Aqueous substrate was combined with solvent annealing. PEO-covered CNTs were prepared to form a PEO-covered CNT/water solution that was applied as a complex substrate for the PS-b-PEO template. The proposed method facilitated the selective assembly of the CNTs onto the PEO microphase. This selective assembly is a versatile approach that may open a route for the controlled assembly of anisotropic nanostructured materials with desirable patterns on soft substrate. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Wang, Jing; Li, Fang; Sun, Jianli; Chen, Guang-Xin] Beijing Univ Chem Technol, Key Lab Preparat & Proc Novel Polymer Mat Beijing, Beijing 100029, Peoples R China.
   [Li, Qifang; Chen, Guang-Xin] Beijing Univ Chem Technol, Coll Mat Sci & Engn, Beijing 100029, Peoples R China.
RP Li, QF (reprint author), Beijing Univ Chem Technol, Coll Mat Sci & Engn, Beijing 100029, Peoples R China.
EM qflee@mail.buct.edu.cn; gxchen@mail.buct.edu.cn
FU Natural Science Foundation of China (NSFC) [21074009, 51173009]
FX The authors gratefully acknowledge financial support of this work coming
   from the Natural Science Foundation of China (NSFC) ( No. 21074009 and
   No. 51173009).
CR Chen GX, 2005, J PHYS CHEM B, V109, P22237, DOI 10.1021/jp054768n
   Chen HY, 2010, POLYMER, V51, P5869, DOI 10.1016/j.polymer.2010.10.011
   Hu JT, 2001, SCIENCE, V292, P2060, DOI 10.1126/science.1060810
   Jana NR, 2004, ANGEW CHEM INT EDIT, V43, P1536, DOI 10.1002/anie.200352260
   Li CX, 2009, MACROMOLECULES, V42, P5793, DOI 10.1021/ma900861s
   Liu AJ, 1996, MACROMOLECULES, V29, P8000, DOI 10.1021/ma960796f
   Liu YT, 2009, CARBON, V47, P1883, DOI 10.1016/j.carbon.2009.03.038
   Long RQ, 2001, J AM CHEM SOC, V123, P2058, DOI 10.1021/ja003830l
   Park I, 2007, SENSOR ACTUAT B-CHEM, V126, P301, DOI 10.1016/j.snb.2006.12.045
   Peponi L, 2010, CARBON, V48, P2590, DOI 10.1016/j.carbon.2010.03.062
   Sun J.L., 2010, THESIS BEIJING U CHE
   TRENT JS, 1984, MACROMOLECULES, V17, P2930, DOI 10.1021/ma00142a087
   Wang J, 2011, J PHYS CHEM B, V115, P2824, DOI 10.1021/jp111115x
   Yuan WZ, 2011, MATER LETT, V65, P793, DOI 10.1016/j.matlet.2010.11.043
   Zhang QL, 2006, J AM CHEM SOC, V128, P3898, DOI 10.1021/ja058615p
NR 15
TC 1
Z9 1
U1 3
U2 49
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 0040-6090
J9 THIN SOLID FILMS
JI Thin Solid Films
PD JUN 1
PY 2013
VL 536
BP 191
EP 195
DI 10.1016/j.tsf.2013.04.002
PG 5
WC Materials Science, Multidisciplinary; Materials Science, Coatings &
   Films; Physics, Applied; Physics, Condensed Matter
SC Materials Science; Physics
GA 144XI
UT WOS:000318974800029
DA 2018-12-27
ER

PT J
AU Barwood, CHS
   Murdoch, BE
AF Barwood, Caroline H. S.
   Murdoch, Bruce E.
TI RETRACTED: Unravelling the influence of mild traumatic brain injury
   (MTBI) on cognitive-linguistic processing: A comparative group analysis
   (Retracted article. See vol. 31, pg. 1552, 2017)
SO BRAIN INJURY
LA English
DT Article; Retracted Publication
DE Cognition; high-level language; language; mild traumatic brain injury;
   TBI
ID CLOSED-HEAD-INJURY; DIFFUSE AXONAL INJURY; LANGUAGE; IMPAIRMENT;
   SUBSEQUENT; DISCOURSE; SEQUELAE
AB Background: Cognitive-linguistic deficits often accompany traumatic brain injury (TBI) and can negatively impact communicative competency. The linguistic sequelae underpinning mild TBI (MTBI) remain largely unexplored in contemporary literature.
   Objectives: The present research methods aim to provide group evidence pertaining to the influence of MTBI on linguistic and higher-level language processing. Extrapolating on the findings of recent case reports, it is hypothesized that performance of the MTBI patients will be significantly reduced compared to normal controls performance on the employed high-level linguistic tasks.
   Methods: Sixteen patients with MTBI and 16 age-and education-matched normal control participants were assessed using a comprehensive battery of cognitive-linguistic assessments.
   Results: The results demonstrated statistically significant differences between MTBI and normal control group performance across a number of higher-level linguistic, general cognitive and general language tasks. MTBI group performance was significantly lower than the normal control group on tasks requiring complex lexical semantic operations and memory demands, including: Recall, organization, making inferences, naming and perception/discrimination.
   Conclusions: These outcomes confer that post-MTBI, cognitive, high-level language and isolated general language performance (e. g. naming) is significantly reduced in MTBI patients, compared to normal controls. Furthermore, the detailed cognitive-linguistic profile offered provides a necessary direction for the identification of areas of linguistic decline in MTBI and targets for therapeutic intervention of impaired cognitive-linguistic processes to ultimately improve communicative outcomes in MTBI.
C1 [Barwood, Caroline H. S.; Murdoch, Bruce E.] Univ Queensland, Ctr Neurogen Commun Disorders Res, Sch Hlth & Rehabil Sci, Brisbane, Qld 4072, Australia.
RP Barwood, CHS (reprint author), Univ Queensland, Ctr Neurogen Commun Disorders Res, Sch Hlth & Rehabil Sci, Brisbane, Qld 4072, Australia.
EM c.barwood@uq.edu.au
FU Motor Accident Insurance Commission (MAIC) of Queensland
FX This research was funded by a grant from the Motor Accident Insurance
   Commission (MAIC) of Queensland. The authors report no conflicts of
   interest.
CR ADAMS JH, 1984, LANCET, V2, P1420
   ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610
   ALEXANDER MP, 1989, BRAIN LANG, V37, P656, DOI 10.1016/0093-934X(89)90118-1
   Bernstein DM, 1999, BRAIN INJURY, V13, P151, DOI 10.1080/026990599121683
   Borgaro SR, 2003, BRAIN INJURY, V17, P189, DOI 10.1080/0269905021000013183
   Brooks J, 1999, J TRAUMA, V46, P159, DOI 10.1097/00005373-199901000-00027
   Davis GA, 2004, BRAIN LANG, V89, P508, DOI 10.1016/j.bandl.2004.01.003
   Douglas JM, 2010, J SPEECH LANG HEAR R, V53, P365, DOI 10.1044/1092-4388(2009/08-0205)
   Duff MC, 2002, BRAIN INJURY, V16, P773, DOI 10.1080/02699050210128870
   Goldstein FC, 2001, J INT NEUROPSYCH SOC, V7, P373, DOI 10.1017/S1355617701733115
   Gronwal D., 1989, MILD HEAD INJURY, P153
   Henderson J., 1992, SCALES COGNITIVE ABI
   Hinchliffe FJ, 1998, BRAIN INJURY, V12, P109, DOI 10.1080/026990598122746
   Hinchliffe FJ, 2001, TRAUMATIC BRAIN INJU, P199
   Huisingh R, 1990, WORD TEST REVISED TE
   Kaplan E., 2001, BOSTON NAMING TEST
   Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI [DOI 10.1097/00001199-199309000-00010, 10.1016/1annemergmed.2006.08.032]
   King KA, 2006, BRAIN INJURY, V20, P725, DOI 10.1080/02699050600743824
   Levin HS, 1989, MILD HEAD INJURY
   MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574
   Parker RS, 1996, NEUROPSYCHOL REV, V6, P135, DOI 10.1007/BF01874895
   Ross S R, 1997, Appl Neuropsychol, V4, P165, DOI 10.1207/s15324826an0403_4
   SARNO MT, 1980, J NERV MENT DIS, V168, P685, DOI 10.1097/00005053-198011000-00008
   Spreen O, 1969, NEUROSENSORY CTR COM
   Tucker FM, 1998, BRAIN INJURY, V12, P783, DOI 10.1080/026990598122179
   Turkstra Lyn, 2005, Seminars in Speech and Language, V26, P213, DOI 10.1055/s-2005-922100
   Umile EM, 2002, ARCH PHYS MED REHAB, V83, P1506, DOI 10.1053/apmr.2002.35092
   Whelan BM, 2003, J NEUROL NEUROSUR PS, V74, P1543, DOI 10.1136/jnnp.74.11.1543
   Whelan BM, 2002, APHASIOLOGY, V16, P1213, DOI 10.1080/02687030244000446
   Whelan BM, 2007, J HEAD TRAUMA REHAB, V22, P192, DOI 10.1097/01.HTR.0000271120.04405.db
   Whelan BM, 2006, BRAIN LANG, V99, P183, DOI 10.1016/j.bandl.2006.06.100
   Wiig E., 1989, TEST LANGUAGE COMPET
   WIIG EH, 1974, PERCEPT MOTOR SKILL, V38, P171, DOI 10.2466/pms.1974.38.1.171
   Wong MN, 2010, APHASIOLOGY, V24, P1155, DOI 10.1080/02687030903168212
NR 34
TC 5
Z9 5
U1 5
U2 16
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0269-9052
EI 1362-301X
J9 BRAIN INJURY
JI Brain Inj.
PD JUN
PY 2013
VL 27
IS 6
BP 671
EP 676
DI 10.3109/02699052.2013.775500
PG 6
WC Neurosciences; Rehabilitation
SC Neurosciences & Neurology; Rehabilitation
GA 143QO
UT WOS:000318882500005
PM 23611468
DA 2018-12-27
ER

PT J
AU Lin, KL
   Yang, HY
   Gao, ZY
   Li, F
   Yu, SN
AF Lin, Kailei
   Yang, Huayan
   Gao, Zhengya
   Li, Feng
   Yu, Shaoning
TI RETRACTED: Overestimated accuracy of circular dichroism in determining
   protein secondary structure (Retracted article. See vol. 43, pg. 227,
   2014)
SO EUROPEAN BIOPHYSICS JOURNAL WITH BIOPHYSICS LETTERS
LA English
DT Article; Retracted Publication
DE Circular dichroism (CD); FTIR; Protein secondary structure; Protein CD
ID TRANSFORM INFRARED-SPECTROSCOPY; AMP RECEPTOR PROTEIN; REFERENCE
   DATABASES; SPECTRA; CONFORMATION; DYNAMICS; BINDING; POLYPEPTIDES;
   CALMODULIN; ENZYMES
AB Circular dichroism (CD) is a spectroscopic technique widely used for estimating protein secondary structures in aqueous solution, but its accuracy has been doubted in recent work. In the present paper, the contents of nine globular proteins with known secondary structures were determined by CD spectroscopy and Fourier transform infrared spectroscopy (FTIR) in aqueous solution. A large deviation was found between the CD spectra and X-ray data, even when the experimental conditions were optimized. The content determined by FTIR was in good agreement with the X-ray crystallography data. Therefore, CD spectra are not recommended for directly calculating the content of a protein's secondary structure.
C1 [Lin, Kailei; Yang, Huayan; Gao, Zhengya; Li, Feng; Yu, Shaoning] Fudan Univ, Dept Chem, Shanghai 200433, Peoples R China.
RP Yu, SN (reprint author), Fudan Univ, Dept Chem, Shanghai 200433, Peoples R China.
EM yushaoning@fudan.edu.cn
FU National Natural Science Foundation of China [21275032, 30970631];
   Shanghai Leading Academic Discipline Project [B109]
FX This project was supported in part by grants from the National Natural
   Science Foundation of China (No. 21275032 and 30970631) and Shanghai
   Leading Academic Discipline Project (No. B109).
CR Adler A J, 1973, Methods Enzymol, V27, P675
   ANDERSON DG, 1968, BIOCHEMISTRY-US, V7, P1637, DOI 10.1021/bi00845a004
   ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383
   Arrondo JLR, 1999, PROG BIOPHYS MOL BIO, V72, P367, DOI 10.1016/S0079-6107(99)00007-3
   Barth A, 2007, BBA-BIOENERGETICS, V1767, P1073, DOI 10.1016/j.bbabio.2007.06.004
   BYLER DM, 1986, BIOPOLYMERS, V25, P469, DOI 10.1002/bip.360250307
   CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343
   CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002
   Cowieson NP, 2008, PROTEINS, V70, P1142, DOI 10.1002/prot.21631
   DONG A, 1990, BIOCHEMISTRY-US, V29, P3303, DOI 10.1021/bi00465a022
   DONG AC, 1994, METHOD ENZYMOL, V232, P139
   Dong AC, 2002, BIOCHEMISTRY-US, V41, P6660, DOI 10.1021/bi020036z
   Ganesan A, 2009, CHEMPHYSCHEM, V10, P1492, DOI 10.1002/cphc.200800759
   Gao ZY, 2012, INT J BIOL MACROMOL, V50, P1, DOI 10.1016/j.ijbiomac.2011.08.016
   Garnier C, 2002, J BIOL CHEM, V277, P12208, DOI 10.1074/jbc.M111874200
   Goormaghtigh E, 2006, BIOPHYS J, V90, P2946, DOI 10.1529/biophysj.105.072017
   Goormaghtigh E, 1999, BBA-REV BIOMEMBRANES, V1422, P105, DOI 10.1016/S0304-4157(99)00004-0
   Gottarelli G, 2008, CHIRALITY, V20, P471, DOI 10.1002/chir.20459
   GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031
   Greenfield NJ, 1996, ANAL BIOCHEM, V235, P1, DOI 10.1006/abio.1996.0084
   HOLZWARTH G, 1965, J AM CHEM SOC, V87, P218, DOI 10.1021/ja01080a015
   Janes RW, 2005, BIOINFORMATICS, V21, P4230, DOI 10.1093/bioinformatics/bti690
   JOHNSON WC, 1990, PROTEINS, V7, P205, DOI 10.1002/prot.340070302
   JOHNSON WC, 1985, METHOD BIOCHEM ANAL, V31, P61, DOI 10.1002/9780470110522.ch2
   Jung C, 2000, J MOL RECOGNIT, V13, P325, DOI 10.1002/1099-1352(200011/12)13:6<325::AID-JMR507>3.0.CO;2-C
   KALNIN NN, 1990, BIOPOLYMERS, V30, P1273, DOI 10.1002/bip.360301311
   KAUPPINEN JK, 1981, APPL SPECTROSC, V35, P271, DOI 10.1366/0003702814732634
   Kelly SM, 2000, CURR PROTEIN PEPT SC, V1, P349, DOI 10.2174/1389203003381315
   Kelly SM, 2005, BBA-PROTEINS PROTEOM, V1751, P119, DOI 10.1016/j.bbapap.2005.06.005
   Kong J, 2007, ACTA BIOCH BIOPH SIN, V39, P549, DOI 10.1111/j.1745-7270.2007.00320.x
   LEE DC, 1990, BIOCHEMISTRY-US, V29, P9185, DOI 10.1021/bi00491a012
   LEVITT M, 1977, J MOL BIOL, V114, P181, DOI 10.1016/0022-2836(77)90207-8
   Li F, 2012, EUR BIOPHYS J BIOPHY, V41, P607, DOI 10.1007/s00249-012-0828-2
   Liu KZ, 2002, CLIN CHEM, V48, P499
   Matsuo K, 2005, J BIOCHEM, V138, P79, DOI 10.1093/jb/mvi101
   MAUNE JF, 1992, J BIOL CHEM, V267, P5286
   Navea S, 2006, PROTEINS, V63, P527, DOI 10.1002/prot.20890
   OBERFELDER RW, 1984, BIOCHEMISTRY-US, V23, P3813, DOI 10.1021/bi00312a004
   PRIBIC R, 1993, ANAL BIOCHEM, V214, P366, DOI 10.1006/abio.1993.1511
   PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006
   Qiu R, 2011, ACTA CRYSTALLOGR F, V67, P953, DOI 10.1107/S1744309111024900
   SARVER RW, 1991, ANAL BIOCHEM, V194, P89, DOI 10.1016/0003-2697(91)90155-M
   Sreerama N, 2000, ANAL BIOCHEM, V287, P252, DOI 10.1006/abio.2000.4880
   SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079
   SUSI H, 1986, METHOD ENZYMOL, V130, P290
   VANSTOKKUM IHM, 1990, ANAL BIOCHEM, V191, P110, DOI 10.1016/0003-2697(90)90396-Q
   VENYAMINOV SY, 1993, ANAL BIOCHEM, V214, P17, DOI 10.1006/abio.1993.1450
   Whitmore L, 2008, BIOPOLYMERS, V89, P392, DOI 10.1002/bip.20853
   Wu GR, 2012, INT J BIOL MACROMOL, V50, P1011, DOI 10.1016/j.ijbiomac.2012.02.017
NR 49
TC 6
Z9 6
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0175-7571
EI 1432-1017
J9 EUR BIOPHYS J BIOPHY
JI Eur. Biophys. J. Biophys. Lett.
PD JUN
PY 2013
VL 42
IS 6
BP 455
EP 461
DI 10.1007/s00249-013-0896-y
PG 7
WC Biophysics
SC Biophysics
GA 148CX
UT WOS:000319221500004
PM 23467783
DA 2018-12-27
ER

PT J
AU Gao, F
   Taha, AY
   Ma, KZ
   Chang, LS
   Kiesewetter, D
   Rapoport, SI
AF Gao, Fei
   Taha, Ameer Y.
   Ma, Kaizong
   Chang, Lisa
   Kiesewetter, Dale
   Rapoport, Stanley I.
TI RETRACTED: Aging decreases rate of docosahexaenoic acid
   synthesis-secretion from circulating unesterified alpha-linolenic acid
   by rat liver (Retracted article. See vol. 36, pg. 1565, 2014)
SO AGE
LA English
DT Article; Retracted Publication
DE Liver; Synthesis-secretion rate; Conversion; Aging; Age; Metabolism;
   Alpha-linolenic acid; n-3 Polyunsaturated fatty acids (n-3 PUFAs);
   Docosahexaenoic acid (DHA); Lipid
ID N-3 PUFA DEPRIVATION; AGE-RELATED-CHANGES; POLYUNSATURATED FATTY-ACIDS;
   HORMONE-SENSITIVE LIPASE; BRAIN PHOSPHOLIPIDS; LIPOPROTEIN-LIPASE;
   DELTA-6-DESATURASE ACTIVITY; FISCHER-344 RATS; NERVOUS-SYSTEM;
   FRONTAL-CORTEX
AB Docosahexaenoic acid (DHA, 22:6n-3), an n-3 polyunsaturated fatty acid (PUFA) found at high concentrations in brain and retina and critical to their function, can be obtained from fish products or be synthesized from circulating alpha-linolenic acid (alpha-LNA, 18:3n-3) mainly in the liver. With aging, liver synthetic enzymes are reported reduced or unchanged in the rat. To test whether liver synthesis-secretion of DHA from alpha-LNA changes with age, we measured whole-body DHA conversion coefficients and rates in unanesthetized adult male Fischer-344 rats aged 10, 20, or 30 months, fed an eicosapentaenoic acid (EPA, 20:5n-3)- and DHA-containing diet. Unesterified [U- (13) C]alpha-LNA bound to albumin was infused intravenously for 2 h, while [(13) C]-esterified n-3 PUFAs were measured in arterial plasma, as were unlabeled unesterified and esterified PUFA concentrations. Plasma unesterified n-3 PUFA concentrations declined with age, but esterified n-3 PUFA concentrations did not change significantly. Calculated conversion coefficients were not changed significantly with age, whereas synthesis-secretion rates (product of conversion coefficient and unesterified plasma alpha-LNA concentration) of esterified DHA and n-3 DPA were reduced. Turnovers of esterified n-3 PUFAs in plasma decreased with age, whereas half-lives increased. The results suggest that hepatic capacity to synthesize DHA and other n-3 PUFAs from circulating alpha-LNA is maintained with age in the rat, but that reduced plasma alpha-LNA availability reduces net synthesis-secretion. As unesterified plasma DHA is the form that is incorporated preferentially into brain phospholipid, its reduced synthesis may be deleterious to brain function in aged rats.
C1 [Gao, Fei; Taha, Ameer Y.; Ma, Kaizong; Chang, Lisa; Rapoport, Stanley I.] NIA, Brain Physiol & Metab Sect, NIH, Bethesda, MD 20892 USA.
   [Kiesewetter, Dale] Natl Inst Biomed Imaging & Bioengn, Lab Mol Imaging & Nanomed, NIH, Bethesda, MD 20892 USA.
   [Gao, Fei] Harvard Univ, Brigham & Womens Hosp, Sch Med, Ctr Expt Therapeut & Reperfus Injury, Boston, MA 02115 USA.
RP Gao, F (reprint author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Ctr Expt Therapeut & Reperfus Injury, 77 Ave Louis Pasteur, Boston, MA 02115 USA.
EM fgao1@partners.org
FU National Institute on Aging; National Institute of Biomedical Imaging
   and Bioengineering, National Institutes of Health
FX This work was supported by the Intramural Research Programs of the
   National Institute on Aging, and National Institute of Biomedical
   Imaging and Bioengineering, National Institutes of Health.
CR Ahmadian M, 2009, DIABETES, V58, P855, DOI 10.2337/db08-1644
   Aid S, 2007, BRAIN RES BULL, V73, P108, DOI 10.1016/j.brainresbull.2007.02.015
   Balkan J, 2002, INT J VITAM NUTR RES, V72, P315, DOI 10.1024/0300-9831.72.5.315
   Bey L, 2001, J APPL PHYSIOL, V91, P687
   BEZARD J, 1994, REPROD NUTR DEV, V34, P539, DOI 10.1051/rnd:19940603
   BONADONNA RC, 1994, AM J PHYSIOL, V266, pE501
   BORDONI A, 1988, BIOCHEM INT, V17, P1001
   Bourre J M, 2004, J Nutr Health Aging, V8, P163
   BOURRE JM, 1990, LIPIDS, V25, P354, DOI 10.1007/BF02544347
   BOURRE JM, 1992, NEUROSCI LETT, V141, P65, DOI 10.1016/0304-3940(92)90335-5
   BRENNER R R, 1981, Progress in Lipid Research, V20, P41, DOI 10.1016/0163-7827(81)90012-6
   Caimari A, 2008, INT J OBESITY, V32, P1193, DOI 10.1038/ijo.2008.69
   CARLILE SI, 1985, ARCH GERONTOL GERIAT, V4, P133, DOI 10.1016/0167-4943(85)90027-5
   Chen CT, 2008, J LIPID RES, V49, P147, DOI 10.1194/jlr.M700386-JLR200
   Chen CT, 2011, J NEUROCHEM, V116, P363, DOI 10.1111/j.1471-4159.2010.07116.x
   Chen CT, 2009, PROSTAG LEUKOTR ESS, V80, P157, DOI 10.1016/j.plefa.2009.01.005
   Chen S, 2007, BBA-MOL CELL BIOL L, V1771, P1319, DOI 10.1016/j.bbalip.2007.08.001
   Chowdhury KK, 2011, EXP GERONTOL, V46, P73, DOI 10.1016/j.exger.2010.10.006
   Conquer JA, 2000, LIPIDS, V35, P1305, DOI 10.1007/s11745-000-0646-3
   DeMar JC, 2006, BBA-MOL CELL BIOL L, V1761, P1050, DOI 10.1016/j.bbalip.2006.06.006
   DeMar JC, 2005, J NEUROCHEM, V94, P1063, DOI 10.1111/j.1471-4159.2005.03258.x
   DeMar JC, 2004, J NEUROCHEM, V91, P1125, DOI 10.1111/j.1471-4159.2004.02789.x
   DINH L, 1995, ANN NUTR METAB, V39, P117, DOI 10.1159/000177851
   Engler MM, 1998, BIOCHEM MOL BIOL INT, V46, P1117
   Favreliere S, 2000, NEUROBIOL AGING, V21, P653, DOI 10.1016/S0197-4580(00)00170-6
   Fortier M, 2010, PROSTAG LEUKOTR ESS, V82, P277, DOI 10.1016/j.plefa.2010.02.010
   Gao F, 2010, J LIPID RES
   Gao F, 2011, BBA-MOL CELL BIOL L, V1811, P484, DOI 10.1016/j.bbalip.2011.05.008
   Gao F, 2009, J LIPID RES, V50, P749, DOI 10.1194/jlr.D800056-JLR200
   GAVINO VC, 1992, LIPIDS, V27, P950, DOI 10.1007/BF02535570
   Giusto NM, 2002, NEUROCHEM RES, V27, P1513, DOI 10.1023/A:1021604623208
   Goldberg IJ, 1996, J LIPID RES, V37, P693
   Gomez-Perez Y, 2011, REJUV RES, V14, P153, DOI 10.1089/rej.2010.1107
   Hamilton MT, 2001, INT J SPORT NUTR EXE, V11, pS97, DOI 10.1123/ijsnem.11.s1.s97
   Han LD, 2011, ANAL CHIM ACTA, V689, P85, DOI 10.1016/j.aca.2011.01.034
   HORROBIN DF, 1981, MED HYPOTHESES, V7, P1211, DOI 10.1016/0306-9877(81)90064-5
   Igarashi M, 2008, J LIPID RES, V49, P1735, DOI 10.1194/jlr.M800093-JLR200
   Igarashi M, 2007, J LIPID RES, V48, P1150, DOI 10.1194/jlr.M600549-JLR200
   Igarashi M, 2010, J PSYCHIATR RES, V44, P177, DOI 10.1016/j.jpsychires.2009.08.001
   Jaworski K, 2009, NAT MED, V15, P159, DOI 10.1038/nm.1904
   Kim HW, 2011, MOL PSYCHIATR, V16, P419, DOI 10.1038/mp.2009.137
   Kim HY, 2007, J BIOL CHEM, V282, P18661, DOI 10.1074/jbc.R700015200
   Kim HW, 2011, PROSTAG LEUKOTR ESS, V85, P361, DOI 10.1016/j.plefa.2011.08.002
   Kuriki K, 2003, J NUTR, V133, P3643
   LONDON ED, 1981, J NEUROCHEM, V37, P217, DOI 10.1111/j.1471-4159.1981.tb05311.x
   LOPEZ GH, 1995, COMP BIOCHEM PHYS B, V112, P331, DOI 10.1016/0305-0491(95)00079-8
   Plourde M, 2011, NUTR METABOLISM LOND, V27, P8
   Purdon D, 1997, J LIPID RES, V38, P526
   Raclot T, 2001, J LIPID RES, V42, P2049
   Rahman T, 2010, PROSTAG LEUKOTR ESS, V82, P141, DOI 10.1016/j.plefa.2009.11.003
   Rao JS, 2007, MOL PSYCHIATR, V12, P151, DOI 10.1038/sj.mp.4001887
   Rapoport SI, 2011, PROSTAGLANDINS OTHER
   Rapoport SI, 2010, PROSTAG LEUKOTR ESS, V82, P273, DOI 10.1016/j.plefa.2010.02.015
   Salem N, 2001, LIPIDS, V36, P945, DOI 10.1007/s11745-001-0805-6
   SCOTT BL, 1989, P NATL ACAD SCI USA, V86, P2903, DOI 10.1073/pnas.86.8.2903
   Smith QR, 2001, J MOL NEUROSCI, V16, P167, DOI 10.1385/JMN:16:2-3:167
   SODERBERG M, 1990, J NEUROCHEM, V54, P415, DOI 10.1111/j.1471-4159.1990.tb01889.x
   Song BJ, 2010, LIPIDS, V45, P291, DOI 10.1007/s11745-010-3398-z
   Sprecher H, 2000, BBA-MOL CELL BIOL L, V1486, P219, DOI 10.1016/S1388-1981(00)00077-9
   Strokin M, 2003, BRIT J PHARMACOL, V139, P1014, DOI 10.1038/sj.bjp.0705326
   STUBBS CD, 1984, BIOCHIM BIOPHYS ACTA, V779, P89, DOI 10.1016/0304-4157(84)90005-4
   Tucker MZ, 2003, AM J PHYSIOL-ENDOC M, V285, pE827, DOI 10.1152/ajpendo.00222.2002
   Wang Y, 2006, J LIPID RES, V47, P2028, DOI 10.1194/jlr.M600177-JLR200
   Yi LZ, 2006, FEBS LETT, V580, P6837, DOI 10.1016/j.febslet.2006.11.043
NR 64
TC 8
Z9 8
U1 2
U2 25
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0161-9152
EI 1574-4647
J9 AGE
JI Age
PD JUN
PY 2013
VL 35
IS 3
BP 597
EP 608
DI 10.1007/s11357-012-9390-1
PG 12
WC Geriatrics & Gerontology
SC Geriatrics & Gerontology
GA 133XL
UT WOS:000318174100007
PM 22388930
OA Green Published
DA 2018-12-27
ER

PT J
AU Kumru, H
   Benito, J
   Murillo, N
   Valls-Sole, J
   Valles, M
   Lopez-Blazquez, R
   Costa, U
   Tormos, JM
   Pascual-Leone, A
   Vidal, J
AF Kumru, Hatice
   Benito, Jesus
   Murillo, Narda
   Valls-Sole, Josep
   Valles, Margarita
   Lopez-Blazquez, Raquel
   Costa, Ursula
   Tormos, Josep M.
   Pascual-Leone, Alvaro
   Vidal, Joan
TI RETRACTED: Effects of High-Frequency Repetitive Transcranial Magnetic
   Stimulation on Motor and Gait Improvement in Incomplete Spinal Cord
   Injury Patients (Retracted article. See vol. 28, pg. 504, 2014)
SO NEUROREHABILITATION AND NEURAL REPAIR
LA English
DT Article; Retracted Publication
DE incomplete SCI; functional improvement; transcranial magnetic
   stimulation; rehabilitation
ID CORTICOSPINAL TRACT; SPASTICITY; WALKING; CORTEX; EXCITABILITY; TRIAL;
   RELIABILITY; PERFORMANCE; ACTIVATION; PLASTICITY
AB Objective. Incomplete spinal cord injury (SCI) patients have the potential to regain some ambulatory function, and optimal reorganization of remaining circuits can contribute to this recovery. We hypothesized that repetitive transcranial magnetic stimulation (rTMS) may promote active recovery of motor function during gait rehabilitation. Methods. A total of 17 incomplete SCI patients were randomized to receive active rTMS or sham stimulation coupled with rehabilitation therapy; 3 patients who began in the sham group crossed over to the active rTMS group after a washout period of more than 3 weeks. Active rTMS consisted of 15 daily sessions over the leg motor area (at 20 Hz). We compared lower-extremity motor score (LEMS), 10-m walking test for walking speed, timed up and go, Walking Index for SCI Scale, Modified Ashworth Scale, and Spinal Cord Injury Spasticity Evaluation Tool at baseline, after the last session, and 2 weeks later in the active rTMS and sham stimulation groups. Results. A significant improvement was observed after the last rTMS session in the active group for LEMS, walking speed, and spasticity. Improvement in walking speed was maintained during the follow-up period. Sham stimulation did not induce any improvement in LEMS, gait assessment, and spasticity after the last session and neither during follow-up. Conclusion. In incomplete SCI, 15 daily sessions of high-frequency rTMS can improve motor score, walking speed, and spasticity in the lower limbs. The study provides evidence for the therapeutic potential of rTMS in the lower extremities in SCI rehabilitation.
C1 [Kumru, Hatice; Benito, Jesus; Murillo, Narda; Valles, Margarita; Lopez-Blazquez, Raquel; Costa, Ursula; Tormos, Josep M.; Vidal, Joan] UAB, Inst Univ Neurorehab Adscrit, Inst Guttmann, Barcelona, Spain.
   [Kumru, Hatice; Benito, Jesus; Murillo, Narda; Valles, Margarita; Lopez-Blazquez, Raquel; Costa, Ursula; Tormos, Josep M.; Vidal, Joan] Univ Autonoma Barcelona, E-08193 Barcelona, Spain.
   [Valls-Sole, Josep] Univ Barcelona, IDIBAPS, Barcelona, Spain.
   [Pascual-Leone, Alvaro] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
   [Pascual-Leone, Alvaro] Harvard Univ, Sch Med, Boston, MA USA.
RP Kumru, H (reprint author), Hosp Neurorehab Inst Guttmann, Cami Can Ruti S-N, Barcelona 08916, Spain.
EM hkumru@guttmann.com
FU FIS [PI10/00442, PI082004]; Foundation La Marato TV3 [071931, 110930,
   110931]; Catedra BBVA [CAT06/023]
FX The authors disclosed receipt of the following financial support for the
   research, authorship, and/or publication of this article: This work was
   supported in part by grants from the FIS (PI10/00442) and (PI082004);
   the Foundation La Marato TV3 (071931), (110930), (110931); and the
   Catedra BBVA (CAT06/023).
CR Adams MM, 2007, ARCH PHYS MED REHAB, V88, P1185, DOI 10.1016/j.apmr.2007.06.012
   Association ASI, 2002, INT STAND NEUR CLASS
   Barthelemy D, 2011, PROG BRAIN RES, V192, P181, DOI 10.1016/B978-0-444-53355-5.00012-9
   Baumer T, 2003, NEUROIMAGE, V20, P550, DOI 10.1016/S1053-8119(03)00310-0
   Belci M, 2004, SPINAL CORD, V42, P417, DOI 10.1038/sj.sc.3101613
   Benito-Penalva J, 2012, ARCH PHYS MED REHAB, V93, P404, DOI 10.1016/j.apmr.2011.08.028
   Bowden M, 2009, J SPINAL CORD MED, V32, P183, DOI 10.1080/10790268.2009.11760770
   Centonze D, 2007, NEUROLOGY, V68, P1045, DOI 10.1212/01.wnl.0000257818.16952.62
   Cooke SF, 2006, BRAIN, V129, P1659, DOI 10.1093/brain/awl082
   Craven BC, 2010, SPINAL CORD, V48, P207, DOI 10.1038/sc.2009.107
   Ditunno JE, 2007, NEUROREHAB NEURAL RE, V21, P539, DOI 10.1177/1545968307301880
   Dobkin B, 2007, NEUROREHAB NEURAL RE, V21, P25, DOI 10.1177/1545968306295556
   Dobkin BH, 2000, PROG BRAIN RES, V128, P99
   Finnerty GT, 1999, NATURE, V400, P367
   Grosbras MH, 2003, EUR J NEUROSCI, V18, P3121, DOI 10.1046/j.1460-9568.2003.03055.x
   Hicks AL, 2005, SPINAL CORD, V43, P291, DOI 10.1038/sj.sc.3101710
   Hiscock A, 2008, NEUROREHAB NEURAL RE, V22, P228, DOI 10.1177/1545968307307115
   Kirshblum SC, 1998, ARCH PHYS MED REHAB, V79, P1456, DOI 10.1016/S0003-9993(98)90244-1
   Kumru H, 2010, NEUROREHAB NEURAL RE, V24, P435, DOI 10.1177/1545968309356095
   Kuppuswamy A, 2011, CLIN NEUROPHYSIOL, V122, P2452, DOI 10.1016/j.clinph.2011.04.022
   Lance JW, 1980, SPASTICITY DISORDERE, P485
   Leuner B, 2004, MOL NEUROBIOL, V29, P117, DOI 10.1385/MN:29:2:117
   Maeda F, 2000, EXP BRAIN RES, V133, P425, DOI 10.1007/s002210000432
   Marino R. J, 2003, J SPINAL CORD MED S1, V26, pS50, DOI DOI 10.1179/107902611X13186000420242
   Matsuzaki M, 2004, NATURE, V429, P761, DOI 10.1038/nature02617
   Nielsen JB, 2003, NEUROSCIENTIST, V9, P195, DOI 10.1177/1073585403251978
   PASCUALLEONE A, 1994, BRAIN, V117, P847, DOI 10.1093/brain/117.4.847
   Peinemann A, 2004, CLIN NEUROPHYSIOL, V115, P1519, DOI 10.1016/j.clinph.2004.02.005
   Petersen JA, 2012, NEUROREHAB NEURAL RE, V26, P939, DOI 10.1177/1545968312438437
   Rossier P, 2001, ARCH PHYS MED REHAB, V82, P9, DOI 10.1053/apmr.2001.9396
   Siebner HR, 2000, NEUROLOGY, V54, P956, DOI 10.1212/WNL.54.4.956
   Skold C, 1999, ARCH PHYS MED REHAB, V80, P1548, DOI 10.1016/S0003-9993(99)90329-5
   Sparing R, 2001, J CLIN NEUROPHYSIOL, V18, P326, DOI 10.1097/00004691-200107000-00004
   Thomas SL, 2005, J NEUROPHYSIOL, V94, P2844, DOI 10.1152/jn.00532.2005
   van Hedelt HJA, 2008, NEUROL RES, V30, P61, DOI 10.1179/016164107X230775
   Wang RY, 2012, NEUROREHAB NEURAL RE, V26, P222, DOI 10.1177/1545968311423265
   WATERS RL, 1994, ARCH PHYS MED REHAB, V75, P756
   Winchester P, 2005, NEUROREHAB NEURAL RE, V19, P313, DOI 10.1177/1545968305281515
   Winchester P, 2005, JSCM, V28, P139
NR 39
TC 22
Z9 22
U1 4
U2 18
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1545-9683
EI 1552-6844
J9 NEUROREHAB NEURAL RE
JI Neurorehabil. Neural Repair
PD JUN
PY 2013
VL 27
IS 5
BP 421
EP 429
DI 10.1177/1545968312471901
PG 9
WC Clinical Neurology; Rehabilitation
SC Neurosciences & Neurology; Rehabilitation
GA 136KC
UT WOS:000318359800004
PM 23322551
DA 2018-12-27
ER

PT J
AU Chatterjee, P
   Rose, RL
   Sinha, J
AF Chatterjee, Promothesh
   Rose, Randall L.
   Sinha, Jayati
TI RETRACTED: Why money meanings matter in decisions to donate time and
   money (Retracted article. See vol. 27, pg. 409, 2016)
SO MARKETING LETTERS
LA English
DT Article; Retracted Publication
DE Money; Priming; Charity; Donation; Helping; Credit
ID CREDIT; HAPPINESS; PAYMENTS; BEHAVIOR; REQUEST; PAY
AB Most charitable organizations cannot accomplish their missions without asking for money. This is paradoxical because recent research suggests that mentioning money primes a self-sufficient mindset, thus undermining the very behaviors these organizations desire to elicit. We offer an important qualification to this problematic effect. We find that priming cash concepts reduces willingness to help others, while activating credit card concepts reverses these effects. To explain our findings, in three studies we show that priming cash concepts makes costs associated with donating time or money more salient in the decision context, thereby reducing willingness to give help and to receive it. However, priming credit card concepts makes the benefits of donation more salient.
C1 [Chatterjee, Promothesh] Univ Kansas, Sch Business, Lawrence, KS 66045 USA.
   [Rose, Randall L.] Univ S Carolina, Darla Moore Sch Business, Columbia, SC 29208 USA.
   [Sinha, Jayati] Univ Arizona, Eller Coll Management, Tucson, AZ 85721 USA.
RP Sinha, J (reprint author), Univ Arizona, Eller Coll Management, McClelland Hall 320 Y, Tucson, AZ 85721 USA.
EM chatterjee@ku.edu; roser@moore.sc.edu; jsinha@email.arizona.edu
CR AUNE RK, 1994, J APPL SOC PSYCHOL, V24, P546, DOI 10.1111/j.1559-1816.1994.tb00598.x
   Bargh J. A, 2000, HDB RES METHODS SOCI, P253
   BELK RW, 1990, J ECON PSYCHOL, V11, P35, DOI 10.1016/0167-4870(90)90046-C
   BLOOM PN, 1981, J MARKETING, V45, P79, DOI 10.2307/1251667
   Briers B, 2006, PSYCHOL SCI, V17, P939, DOI 10.1111/j.1467-9280.2006.01808.x
   Chatterjee P, 2012, J CONSUM RES, V38, P1129, DOI 10.1086/661730
   CIALDINI RB, 1976, J APPL PSYCHOL, V61, P295, DOI 10.1037/0021-9010.61.3.295
   Dunn EW, 2008, SCIENCE, V319, P1687, DOI 10.1126/science.1150952
   FEINBERG RA, 1986, J CONSUM RES, V13, P348, DOI 10.1086/209074
   Liu W, 2008, J CONSUM RES, V35, P543, DOI 10.1086/588699
   MCSWEENEY FK, 1984, J CONSUM RES, V11, P619, DOI 10.1086/208999
   Mendoza NA, 1997, ADV CONSUM RES, V24, P499
   Preacher KJ, 2008, BEHAV RES METHODS, V40, P879, DOI 10.3758/BRM.40.3.879
   Prelec D, 1998, MARKET SCI, V17, P4, DOI 10.1287/mksc.17.1.4
   Prelec D, 2001, MARKET LETT, V12, P5, DOI 10.1023/A:1008196717017
   REINGEN PH, 1978, J CONSUM RES, V5, P96, DOI 10.1086/208720
   Shimp TA, 2000, J BUS RES, V48, P17, DOI 10.1016/S0148-2963(98)00071-X
   Small DA, 2003, J RISK UNCERTAINTY, V26, P5, DOI 10.1023/A:1022299422219
   Soman D, 2001, J CONSUM RES, V27, P460, DOI 10.1086/319621
   Thomas M, 2011, J CONSUM RES, V38, P126, DOI 10.1086/657331
   Vohs KD, 2008, CURR DIR PSYCHOL SCI, V17, P208, DOI 10.1111/j.1467-8721.2008.00576.x
   Vohs KD, 2006, SCIENCE, V314, P1154, DOI 10.1126/science.1132491
   WEYANT JM, 1987, J APPL SOC PSYCHOL, V17, P392, DOI 10.1111/j.1559-1816.1987.tb00320.x
   Zelizer V., 1997, SOCIAL MEANING MONEY
   Zhao XS, 2010, J CONSUM RES, V37, P197, DOI 10.1086/651257
   Zhou XY, 2009, PSYCHOL SCI, V20, P700, DOI 10.1111/j.1467-9280.2009.02353.x
NR 26
TC 8
Z9 8
U1 1
U2 63
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0923-0645
EI 1573-059X
J9 MARKET LETT
JI Mark. Lett.
PD JUN
PY 2013
VL 24
IS 2
BP 109
EP 118
DI 10.1007/s11002-012-9215-0
PG 10
WC Business
SC Business & Economics
GA 131EL
UT WOS:000317975200001
DA 2018-12-27
ER

PT J
AU Pridgeon, JW
   Klesius, PH
AF Pridgeon, Julia W.
   Klesius, Phillip H.
TI RETRACTED: Development of live attenuated Streptococcus agalactiae as
   potential vaccines by selecting for resistance to sparfloxacin
   (Retracted article. See vol. 34, pg. 4642, 2016)
SO VACCINE
LA English
DT Article; Retracted Publication
DE Streptococcus agalactiae; Sparfloxacin; Resistance; Attenuation; Vaccine
ID TILAPIA OREOCHROMIS-NILOTICUS; EDWARDSIELLA-ICTALURI VACCINE; GROUP-B
   STREPTOCOCCUS; CHANNEL CATFISH; AEROMONAS-HYDROPHILA; PFGE GENOTYPE;
   NOVOBIOCIN; INFECTION; EFFICACY; FISH
AB To develop attenuated bacteria as potential live vaccines, sparfloxacin was used in this study to modify 40 isolates of Streptococcus agalactiae. Majority of S. agalactiae used in this study were able to develop at least 80-fold resistance to sparfloxacin. When the virulence of the sparfloxacin-resistant S. agalactiae isolates were tested in 10-12 g Nile tilapia by intraperitoneal injection at dose of 2 x 10(7) CPU/fish, 31 were found to be avirulent to fish. Of the 31 avirulent sparfloxacin-resistant S. agalactiae isolates, 30 provided 75-100% protection to 10-12 g Nile tilapia against challenges with a virulent S. agalactiae isolate Sag 50. When the virulence of the 30 sparfloxacin-resistant S. agalactiae isolates was tested in 3-5 g Nile tilapia by intraperitoneal injection at dose of 2 x 10(7) CPU/fish, six were found to be avirulent to 3-5 g Nile tilapia. Of the six avirulent sparfloxacin-resistant S. agalactiae isolates, four provided 3-5 g Nile tilapia 100% protection against challenges with homologous isolates, including Sag 97-spar isolate that was non-hemolytic. However, Sag 97-spar failed to provide broad cross-protection against challenges with heterologous isolates. When Nile tilapia was vaccinated with a polyvalent vaccine consisting of 30 sparfloxacin-resistant S. agalactiae isolates at dose of 2 x 10(6) CFU/fish, the polyvalent vaccine provided significant (P<0.001) protection to both 3-5 g and 15-20 g Nile tilapia against challenges with 30 parent isolates of S. agalactiae. Taken together, our results suggest that a polyvalent vaccine consisting of various strains of S. agalactiae might be essential to provide broader protection to Nile tilapia against infections caused by S. agalactiae. Published by Elsevier Ltd.
C1 [Pridgeon, Julia W.; Klesius, Phillip H.] USDA ARS, Aquat Anim Hlth Res Unit, Auburn, AL 36832 USA.
RP Pridgeon, JW (reprint author), USDA ARS, Aquat Anim Hlth Res Unit, 990 Wire Rd, Auburn, AL 36832 USA.
EM Julia.Pridgeon@ars.usda.gov
FU USDA/ARS CRIS project [6420-32000-024-00D]
FX We thank Drs. Dunhua Zhang (USDA-ARS) and Mediha Aksoy (Tuskegee
   University) for critical reviews of the manuscript. We thank Beth
   Peterman (USDA-ARS) for her excellent technical support. We also thank
   the management team of the Aquatic Animal Health Research Unit for daily
   care and management of the fish. This study was supported by the
   USDA/ARS CRIS project #6420-32000-024-00D. The use of trade, firm, or
   corporate names in this publication is for the information and
   convenience of the reader. Such use does not constitute an official
   endorsement or approval by the United States Department of Agriculture
   or the Agricultural Research Service of any product or service to the
   exclusion of others that may be suitable.
CR Abuseliana AF, 2011, J ANIM VET ADV, V10, P914
   Al-Marzouk Ahmed, 2004, Journal of Aquaculture in the Tropics, V19, P103
   Amend D. F., 1981, DEV BIOL STAND, V49, P447
   Bowater RO, 2012, J FISH DIS, V35, P173, DOI 10.1111/j.1365-2761.2011.01332.x
   Chen M, 2012, VET MICROBIOL, V159, P526, DOI 10.1016/j.vetmic.2012.04.035
   Chen M, 2012, VACCINE, V30, P6088, DOI 10.1016/j.vaccine.2012.07.044
   DEPAOLA A, 1995, APPL ENVIRON MICROB, V61, P2335
   ELSEA SH, 1992, J BIOL CHEM, V267, P13150
   Evans JJ, 2004, VACCINE, V22, P3769, DOI 10.1016/j.vaccine.2004.03.012
   Evans JJ, 2002, J FISH DIS, V25, P505, DOI 10.1046/j.1365-2761.2002.00392.x
   Glibert Patricia M., 2002, Harmful Algae, V1, P215, DOI 10.1016/S1568-9883(02)00013-6
   Heath PT, 2011, EXPERT REV VACCINES, V10, P685, DOI [10.1586/erv.11.61, 10.1586/ERV.11.61]
   Jenkins JA, 1998, J AQUAT ANIM HEALTH, V10, P69, DOI 10.1577/1548-8667(1998)010<0069:EOMFTP>2.0.CO;2
   Klesius PH, 1999, ADV VETER MED AP, V41, P523
   LEUNG KY, 1995, J FISH DIS, V18, P435, DOI 10.1111/j.1365-2761.1995.tb00335.x
   McCallum N, 2006, ANTIMICROB AGENTS CH, V50, P2352, DOI 10.1128/AAC.00073-06
   Pasnik DJ, 2005, J FISH DIS, V28, P205, DOI 10.1111/j.1365-2761.2005.00619.x
   Pridgeon JW, 2012, J APPL MICROBIOL, V113, P1319, DOI 10.1111/j.1365-2672.2012.05430.x
   Pridgeon JW, 2011, J APPL MICROBIOL, V111, P114, DOI 10.1111/j.1365-2672.2011.05030.x
   Pridgeon JW, 2011, VACCINE, V29, P5986, DOI 10.1016/j.vaccine.2011.06.036
   Pridgeon JW, 2011, VACCINE, V29, P5631, DOI 10.1016/j.vaccine.2011.06.016
   Sheehan B., 2009, AQUACULTURE ASIA PAC, V5, P26
   Shoemaker CA, 2007, VACCINE, V25, P1126, DOI 10.1016/j.vaccine.2006.09.055
   WATTS JL, 1984, VET MICROBIOL, V9, P571, DOI 10.1016/0378-1135(84)90019-1
   Ye X, 2011, FISHERIES SCI, V77, P623, DOI 10.1007/s12562-011-0365-4
   Zdragas A., 2005, J HELL VET MED SOC, V56, P114
NR 26
TC 16
Z9 19
U1 3
U2 18
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 31
PY 2013
VL 31
IS 24
BP 2705
EP 2712
DI 10.1016/j.vaccine.2013.03.066
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 167MB
UT WOS:000320635000009
PM 23583891
DA 2018-12-27
ER

PT J
AU Anderson, DE
   Ester, EF
   Serences, JT
   Awh, E
AF Anderson, David E.
   Ester, Edward F.
   Serences, John T.
   Awh, Edward
TI RETRACTED: Attending Multiple Items Decreases the Selectivity of
   Population Responses in Human Primary Visual Cortex (Retracted article.
   See vol. 36, pg. 4404, 2016)
SO JOURNAL OF NEUROSCIENCE
LA English
DT Article; Retracted Publication
ID WORKING-MEMORY; NEURONAL SYNCHRONIZATION; SPATIAL ATTENTION; MACAQUE V1;
   ORIENTATION; SEARCH; LIMITS; REPRESENTATIONS; MECHANISM; CODES
AB Multiple studies have documented an inverse relationship between the number of to-be-attended or remembered items in a display ("set size") and task performance. The neural source of this decline in cognitive performance is currently under debate. Here, we used a combination of fMRI and a forward encoding model of orientation selectivity to generate population tuning functions for each of two stimuli while human observers attended either one or both items. We observed (1) clear population tuning functions for the attended item(s) that peaked at the stimulus orientation and decreased monotonically as the angular distance from this orientation increased, (2) a set-size-dependent decline in the relative precision of orientation-specific population responses, such that attending two items yielded a decline in selectivity of the population tuning function for each item, and (3) that the magnitude of the loss of precision in population tuning functions predicted individual differences in the behavioral cost of attending an additional item. These findings demonstrate that attending multiple items degrades the precision of perceptual representations for the target items and provides a straightforward account for the associated impairments in visually guided behavior.
C1 [Anderson, David E.; Awh, Edward] Univ Oregon, Dept Psychol, Eugene, OR 97403 USA.
   [Ester, Edward F.; Serences, John T.] Univ Calif San Diego, Dept Psychol, La Jolla, CA 92093 USA.
   [Serences, John T.] Univ Calif San Diego, Neurosci Grad Program, La Jolla, CA 92093 USA.
RP Anderson, DE (reprint author), 1227 Univ Oregon, Dept Psychol, Eugene, OR 97403 USA.
EM dendersn@gmail.com; awh@uoregon.edu
FU National Institute of Mental Health Grant [R01-MH087214]
FX This work was supported by National Institute of Mental Health Grant
   R01-MH087214 (E.A.).
CR Anderson DE, 2013, PSYCHOL SCI, V24, P929, DOI 10.1177/0956797612464380
   Anderson DE, 2012, ATTEN PERCEPT PSYCHO, V74, P891, DOI 10.3758/s13414-012-0292-1
   Anderson DE, 2011, J NEUROSCI, V31, P1128, DOI 10.1523/JNEUROSCI.4125-10.2011
   Boynton GM, 1996, J NEUROSCI, V16, P4207
   Brainard DH, 1997, SPATIAL VISION, V10, P433, DOI 10.1163/156856897X00357
   Brouwer GJ, 2011, J NEUROPHYSIOL, V106, P2108, DOI 10.1152/jn.00540.2011
   Brouwer GJ, 2009, J NEUROSCI, V29, P13992, DOI 10.1523/JNEUROSCI.3577-09.2009
   BUNDESEN C, 1990, PSYCHOL REV, V97, P523, DOI 10.1037//0033-295X.97.4.523
   Canolty RT, 2010, TRENDS COGN SCI, V14, P506, DOI 10.1016/j.tics.2010.09.001
   ECKHORN R, 1988, BIOL CYBERN, V60, P121, DOI 10.1007/BF00202899
   Eckstein MP, 2000, PERCEPT PSYCHOPHYS, V62, P425, DOI 10.3758/BF03212096
   Emrich SM, 2013, J NEUROSCI, V33, P6516, DOI 10.1523/JNEUROSCI.5732-12.2013
   ENGEL AK, 1991, P NATL ACAD SCI USA, V88, P9136, DOI 10.1073/pnas.88.20.9136
   ENGEL SA, 1994, NATURE, V369, P525, DOI 10.1038/369525a0
   Ester EF, 2009, J NEUROSCI, V29, P15258, DOI 10.1523/JNEUROSCI.4388-09.2009
   FISHER DL, 1984, COGNITIVE PSYCHOL, V16, P449, DOI 10.1016/0010-0285(84)90017-3
   Freeman J, 2011, J NEUROSCI, V31, P4792, DOI 10.1523/JNEUROSCI.5160-10.2011
   Fries P, 2005, TRENDS COGN SCI, V9, P474, DOI 10.1016/j.tics.2005.08.011
   Fries P, 2001, SCIENCE, V291, P1560, DOI 10.1126/science.1055465
   Gandhi SP, 1999, P NATL ACAD SCI USA, V96, P3314, DOI 10.1073/pnas.96.6.3314
   GEISLER WS, 1995, PSYCHOL REV, V102, P356, DOI 10.1037//0033-295X.102.2.356
   Genovese CR, 2002, NEUROIMAGE, V15, P870, DOI 10.1006/nimg.2001.1037
   GRAY CM, 1989, NATURE, V338, P334, DOI 10.1038/338334a0
   Gur M, 2005, CEREB CORTEX, V15, P1207, DOI 10.1093/cercor/bhi003
   Harrison SA, 2009, NATURE, V458, P632, DOI 10.1038/nature07832
   Haynes JD, 2005, NAT NEUROSCI, V8, P686, DOI 10.1038/nn1445
   Jehee JFM, 2011, J NEUROSCI, V31, P8210, DOI 10.1523/JNEUROSCI.6153-09.2011
   Jensen O, 2007, TRENDS COGN SCI, V11, P267, DOI 10.1016/j.tics.2007.05.003
   Kamitani Y, 2005, NAT NEUROSCI, V8, P679, DOI 10.1038/nn1444
   Kastner S, 2000, ANNU REV NEUROSCI, V23, P315, DOI 10.1146/annurev.neuro.23.1.315
   Kastner S, 1998, SCIENCE, V282, P108, DOI 10.1126/science.282.5386.108
   LISMAN JE, 1995, SCIENCE, V267, P1512, DOI 10.1126/science.7878473
   Martinez-Trujillo JC, 2004, CURR BIOL, V14, P744, DOI 10.1016/j.cub.2004.04.028
   Palmer EM, 2011, ATTEN PERCEPT PSYCHO, V73, P2413, DOI 10.3758/s13414-011-0199-2
   PALMER J, 1993, J EXP PSYCHOL HUMAN, V19, P108, DOI 10.1037//0096-1523.19.1.108
   PALMER J, 1990, J EXP PSYCHOL HUMAN, V16, P332, DOI 10.1037/0096-1523.16.2.332
   PALMER J, 1995, CURR DIR PSYCHOL SCI, V4, P118, DOI 10.1111/1467-8721.ep10772534
   Palmer John, 1996, Investigative Ophthalmology and Visual Science, V37, pS15
   Pelli DG, 1997, SPATIAL VISION, V10, P437, DOI 10.1163/156856897X00366
   Pestilli F, 2011, NEURON, V72, P832, DOI 10.1016/j.neuron.2011.09.025
   POSNER MI, 1980, J EXP PSYCHOL GEN, V109, P160, DOI 10.1037/0096-3445.109.2.160
   Pouget A, 2003, ANNU REV NEUROSCI, V26, P381, DOI 10.1146/annurev.neuro.26.041002.131112
   Raffone A, 2001, J COGNITIVE NEUROSCI, V13, P766, DOI 10.1162/08989290152541430
   Ringach DL, 2002, J NEUROPHYSIOL, V87, P1018, DOI 10.1152/jn.00614.2001
   Ringach DL, 2002, J NEUROSCI, V22, P5639
   Roelfsema PR, 1996, J COGNITIVE NEUROSCI, V8, P603, DOI 10.1162/jocn.1996.8.6.603
   Saproo S, 2010, J NEUROPHYSIOL, V104, P885, DOI 10.1152/jn.00369.2010
   Sasaki Y, 2006, NEURON, V51, P661, DOI 10.1016/j.neuron.2006.07.021
   SCHILLER PH, 1976, J NEUROPHYSIOL, V39, P1320
   Scolari M, 2012, J NEUROSCI, V32, P7723, DOI 10.1523/JNEUROSCI.5558-11.2012
   Serences JT, 2007, NEURON, V55, P301, DOI 10.1016/j.neuron.2007.06.015
   Serences JT, 2012, NEUROPSYCHOLOGIA, V50, P435, DOI 10.1016/j.neuropsychologia.2011.07.013
   Serences JT, 2009, PSYCHOL SCI, V20, P207, DOI 10.1111/j.1467-9280.2009.02276.x
   Serences JT, 2009, NEUROIMAGE, V44, P223, DOI 10.1016/j.neuroimage.2008.07.043
   SERENO MI, 1995, SCIENCE, V268, P889, DOI 10.1126/science.7754376
   Siegel M, 2008, NEURON, V60, P709, DOI 10.1016/j.neuron.2008.09.010
   SINGER W, 1995, ANNU REV NEUROSCI, V18, P555, DOI 10.1146/annurev.ne.18.030195.003011
   Swindale NV, 1998, BIOL CYBERN, V78, P45, DOI 10.1007/s004220050411
   Swisher JD, 2010, J NEUROSCI, V30, P325, DOI 10.1523/JNEUROSCI.4811-09.2010
   Treue S, 1999, NATURE, V399, P575, DOI 10.1038/21176
   Verghese P, 2001, NEURON, V31, P523, DOI 10.1016/S0896-6273(01)00392-0
   Wilken P, 2004, J VISION, V4, P1120, DOI 10.1167/4.12.11
   Zhang WW, 2008, NATURE, V453, P233, DOI 10.1038/nature06860
NR 63
TC 12
Z9 12
U1 3
U2 22
PU SOC NEUROSCIENCE
PI WASHINGTON
PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA
SN 0270-6474
J9 J NEUROSCI
JI J. Neurosci.
PD MAY 29
PY 2013
VL 33
IS 22
BP 9273
EP 9282
DI 10.1523/JNEUROSCI.0239-13.2013
PG 10
WC Neurosciences
SC Neurosciences & Neurology
GA 152XV
UT WOS:000319566300005
PM 23719796
OA Green Accepted, Bronze
DA 2018-12-27
ER

PT J
AU Mokhtari, B
   Pourabdollah, K
AF Mokhtari, Bahram
   Pourabdollah, Kobra
TI RETRACTED: Synthesis and Evaluation of an Organometallic pH-Responsive
   Nanocomposite (Retracted article. See vol. 43, pg. 1577, 2013)
SO SYNTHESIS AND REACTIVITY IN INORGANIC METAL-ORGANIC AND NANO-METAL
   CHEMISTRY
LA English
DT Article; Retracted Publication
DE chemical graft polymerization; nanocomposite pH-sensitive; streaming
   potential
ID THERMOSENSITIVE MEMBRANES; RIBOFLAVIN PERMEATION; SENSITIVE MEMBRANES;
   CONTROLLED-RELEASE; POLYMER MEMBRANE; INSULIN DELIVERY; DRUG PERMEATION;
   TEMPERATURE; PERMEABILITY; PLASMA
AB A novel pH-sensitive membrane was synthesized by grafting poly acrylic acid onto a plane alumina ceramic nanocomposite in order to control the liquid permeation. The ceramic membrane was treated by -methacryloxypropyl trimethoxy silane (KH-570), and then it was facilitated graft polymerization of acrylic acid. The surface property of this nanocomposite was analyzed by SEM, FT-IR, contact angle, and streaming potential. Based on the results, the water filtration rate was higher at lower pHs and was lower at higher pHs. Moreover, the grafted membrane demonstrated a rapid and reversible response to environmental pHs in the range of pH 1.06.0.
C1 [Mokhtari, Bahram; Pourabdollah, Kobra] Islamic Azad Univ, RCRC, Shahreza Branch, Shahreza, Iran.
RP Pourabdollah, K (reprint author), Islamic Azad Univ, RCRC, Shahreza Branch, POB 8648146411, Shahreza, Iran.
EM pourabdollah@iaush.ac.ir
FU Islamic Azad University (Shahreza branch); Iran Nanotechnology
   Initiative Council
FX This work was supported by Islamic Azad University (Shahreza branch) and
   Iran Nanotechnology Initiative Council.
CR Cao XZ, 2008, J MEMBRANE SCI, V312, P15, DOI 10.1016/j.memsci.2007.12.006
   CARTIER S, 1995, J MEMBRANE SCI, V106, P17, DOI 10.1016/0376-7388(95)00073-L
   Choi YJ, 2000, IND ENG CHEM RES, V39, P2491, DOI 10.1021/ie9907627
   Chu LY, 2004, J CONTROL RELEASE, V97, P43, DOI 10.1016/j.jconrel.2004.02.026
   Chu LY, 2002, ADV MATER, V14, P386, DOI 10.1002/1521-4095(20020304)14:5<386::AID-ADMA386>3.0.CO;2-I
   Hesampour M, 2008, J MEMBRANE SCI, V310, P85, DOI 10.1016/j.memsci.2007.10.038
   Hu K, 2007, J MEMBRANE SCI, V301, P19, DOI 10.1016/j.memsci.2007.05.031
   Ito Y, 1997, J AM CHEM SOC, V119, P1619, DOI 10.1021/ja963418z
   Lai PS, 2006, J MEMBRANE SCI, V275, P89, DOI 10.1016/j.memsci.2005.09.007
   Lee YM, 1997, POLYMER, V38, P1227, DOI 10.1016/S0032-3861(96)00548-4
   LEE YM, 1995, POLYMER, V36, P81, DOI 10.1016/0032-3861(95)90678-U
   Liu NG, 2003, ANGEW CHEM INT EDIT, V42, P1731, DOI 10.1002/anie.200250189
   Lue SJ, 2008, J MEMBRANE SCI, V321, P146, DOI 10.1016/j.memsci.2008.04.053
   Lue SJ, 2007, J MEMBRANE SCI, V301, P142, DOI 10.1016/j.memsci.2007.06.020
   Mika AM, 1999, J MEMBRANE SCI, V153, P45, DOI 10.1016/S0376-7388(98)00246-4
   Ng LT, 2008, RADIAT PHYS CHEM, V77, P192, DOI 10.1016/j.radphyschem.2007.06.001
   Peng T, 2000, J APPL POLYM SCI, V76, P778, DOI 10.1002/(SICI)1097-4628(20000509)76:6<778::AID-APP3>3.0.CO;2-2
   Sun YM, 1996, J MEMBRANE SCI, V110, P211, DOI 10.1016/0376-7388(95)00251-0
   Vertommen MAME, 2008, J MEMBRANE SCI, V322, P243, DOI 10.1016/j.memsci.2008.05.044
   Xie R, 2007, J MEMBRANE SCI, V289, P76, DOI 10.1016/j.memsci.2006.11.040
   Yang B, 2005, J MEMBRANE SCI, V258, P133, DOI 10.1016/j.memsci.2005.03.013
   Ying L, 2004, J MEMBRANE SCI, V243, P253, DOI 10.1016/j.memsci.2004.06.028
   Yoshino J, 2008, TETRAHEDRON, V64, P7774, DOI 10.1016/j.tet.2008.05.128
   Zhang K, 2004, BIOMATERIALS, V25, P5281, DOI 10.1016/j.biomaterials.2003.12.032
   Zhang K, 2002, J CONTROL RELEASE, V80, P169, DOI 10.1016/S0168-3659(02)00024-X
NR 25
TC 1
Z9 1
U1 4
U2 36
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1553-3174
EI 1553-3182
J9 SYNTH REACT INORG M
JI Synth. React. Inorg. Met.-Org. Nano-Metal Chem.
PD MAY 28
PY 2013
VL 43
IS 5
BP 588
EP 593
DI 10.1080/15533174.2012.751422
PG 6
WC Chemistry, Inorganic & Nuclear; Nanoscience & Nanotechnology
SC Chemistry; Science & Technology - Other Topics
GA 105LC
UT WOS:000316070000011
DA 2018-12-27
ER

PT J
AU Alsbeih, G
   El-Sebaie, M
   Al-Harbi, N
   Al-Hadyan, K
   Shoukri, M
   Al-Rajhi, N
AF Alsbeih, Ghazi
   El-Sebaie, Medhat
   Al-Harbi, Najla
   Al-Hadyan, Khaled
   Shoukri, Mohamed
   Al-Rajhi, Nasser
TI RETRACTED: SNPs in genes implicated in radiation response are associated
   with radiotoxicity and evoke roles as predictive and prognostic
   biomarkers (Retracted article. See vol. 13, artn. 79, 2018)
SO RADIATION ONCOLOGY
LA English
DT Article; Retracted Publication
DE Single nucleotide polymorphism (SNP); Radiosensitivity; Late reactions
   to radiotherapy; Fibrosis; Follow up; Nasopharyngeal carcinoma
ID SINGLE-NUCLEOTIDE POLYMORPHISMS; INDUCED SUBCUTANEOUS FIBROSIS; NORMAL
   TISSUE COMPLICATIONS; RADIOTHERAPY; RISK; CANCER; XRCC1;
   RADIOSENSITIVITY; VARIANTS; TGFB1
AB Background: Biomarkers are needed to individualize cancer radiation treatment. Therefore, we have investigated the association between various risk factors, including single nucleotide polymorphisms (SNPs) in candidate genes and late complications to radiotherapy in our nasopharyngeal cancer patients.
   Methods: A cohort of 155 patients was included. Normal tissue fibrosis was scored using RTOG/EORTC grading system. A total of 45 SNPs in 11 candidate genes (ATM, XRCC1, XRCC3, XRCC4, XRCC5, PRKDC, LIG4, TP53, HDM2, CDKN1A, TGFB1) were genotyped by direct genomic DNA sequencing. Patients with severe fibrosis (cases, G3-4, n = 48) were compared to controls (G0-2, n = 107).
   Results: Univariate analysis showed significant association (P < 0.05) with radiation complications for 6 SNPs (ATM G/A rs1801516, HDM2 promoter T/G rs2279744 and T/A rs1196333, XRCC1 G/A rs25487, XRCC5 T/C rs1051677 and TGFB1 C/T rs1800469). In addition, Kaplan-Meier analyses have also highlighted significant association between genotypes and length of patients' follow-up after radiotherapy. Multivariate logistic regression has further sustained these results suggesting predictive and prognostic roles of SNPs.
   Conclusions: Univariate and multivariate analysis suggest that radiation toxicity in radiotherapy patients are associated with certain SNPs, in genes including HDM2 promoter studied for the 1st time. These results support the use of SNPs as genetic predictive markers for clinical radiosensitivity and evoke a prognostic role for length of patients' follow-up after radiotherapy.
C1 [Alsbeih, Ghazi; Al-Harbi, Najla; Al-Hadyan, Khaled] King Faisal Specialist Hosp & Res Ctr, Dept Biomed Phys, Radiat Biol Sect, Riyadh 11211, Saudi Arabia.
   [El-Sebaie, Medhat; Al-Rajhi, Nasser] King Faisal Specialist Hosp & Res Ctr, Ctr Oncol, Radiat Oncol Sect, Riyadh 11211, Saudi Arabia.
   [Shoukri, Mohamed] King Faisal Specialist Hosp & Res Ctr, Natl Biotechnol Ctr, Riyadh 11211, Saudi Arabia.
RP Alsbeih, G (reprint author), King Faisal Specialist Hosp & Res Ctr, Dept Biomed Phys, Radiat Biol Sect, POB 3354, Riyadh 11211, Saudi Arabia.
EM galsbeih@kfshrc.edu.sa
FU KFSHRC grant [2000 031, 2040 025]
FX We wish to thank Dr. B. Meyer, Mr. M. Rajab for helping in DNA
   sequencing, Ms. M. Al-Buhairi, L. A. Venturina S. Al-Qahtani and N.
   Venturina for technical help and Dr. B. Moftah for continuous support.
   Funded by KFSHRC grant 2000 031 and 2040 025.
CR Al-Amro A, 2005, INT J RADIAT ONCOL, V62, P508, DOI 10.1016/j.ijrobp.2004.09.050
   Al-Hadyan KS, 2012, GENET TEST MOL BIOMA, V16, P95, DOI 10.1089/gtmb.2011.0126
   Alsbeih G, 2010, RADIAT RES, V173, P505, DOI 10.1667/RR1769.1
   Alsbeih G, 2007, INT J RADIAT ONCOL, V68, P229, DOI 10.1016/j.ijrobp.2006.12.050
   Alsbeih GA, 2009, CLIN CANCER RES, V15, P7352, DOI 10.1158/1078-0432.CCR-09-0960
   Andreassen CN, 2006, INT J RADIAT BIOL, V82, P577, DOI 10.1080/09553000600876637
   Andreassen CN, 2006, INT J RADIAT ONCOL, V64, P776, DOI 10.1016/j.ijrobp.2005.09.014
   Andreassen CN, 2003, RADIOTHER ONCOL, V69, P127, DOI 10.1016/j.radonc.2003.09.010
   Andreassen CN, 2005, ACTA ONCOL, V44, P801, DOI 10.1080/02841860500374513
   Azria D, 2008, CLIN CANCER RES, V14, P6284, DOI 10.1158/1078-0432.CCR-08-0700
   Barnett GC, 2012, LANCET ONCOL, V13, P65, DOI 10.1016/S1470-2045(11)70302-3
   Bond GL, 2004, CELL, V119, P591, DOI 10.1016/j.cell.2004.11.022
   Cargill M, 1999, NAT GENET, V22, P231
   Chang-Claude J, 2005, CLIN CANCER RES, V11, P4802, DOI 10.1158/1078-0432.CCR-04-2657
   COX JD, 1995, INT J RADIAT ONCOL, V31, P1341, DOI 10.1016/0360-3016(95)00060-C
   Kerns SL, 2010, INT J RADIAT ONCOL, V78, P1292, DOI 10.1016/j.ijrobp.2010.07.036
   Parliament MB, 2012, LANCET ONCOL, V13, P7, DOI 10.1016/S1470-2045(11)70331-X
   Talbot CJ, 2012, BRIT J CANCER, V107, P748, DOI 10.1038/bjc.2012.290
   West CML, 2007, CLIN ONCOL-UK, V19, P470, DOI 10.1016/j.cton.2007.02.016
   West C, 2010, INT J RADIAT ONCOL, V76, P1295, DOI 10.1016/j.ijrobp.2009.12.017
   Zhu Y, 2004, CANCER RES, V64, P2251, DOI 10.1158/0008-5472.CAN-03-2800
NR 21
TC 17
Z9 17
U1 1
U2 8
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1748-717X
J9 RADIAT ONCOL
JI Radiat. Oncol.
PD MAY 22
PY 2013
VL 8
AR 125
DI 10.1186/1748-717X-8-125
PG 7
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA 160MB
UT WOS:000320122600001
PM 23697595
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Yang, YJ
   Li, SB
   Zhang, LN
   Xu, JH
   Yang, WY
   Jiang, YD
AF Yang, Yajie
   Li, Shibin
   Zhang, Luning
   Xu, Jianhua
   Yang, Wenyao
   Jiang, Yadong
TI RETRACTED: Vapor Phase Polymerization Deposition of Conducting
   Polymer/Graphene Nanocomposites as High Performance Electrode Materials
   (Retracted article. See vol. 8, pg. 19185, 2016)
SO ACS APPLIED MATERIALS & INTERFACES
LA English
DT Article; Retracted Publication
DE vapor phase polymerization; conducting polymers; graphene;
   nanocomposites; solid tantalum electrolyte capacitor
ID POLYMERS; GROWTH; FILMS
AB In this paper, we report chemical vapor phase polymerization (VPP) deposition of novel poly(3,4-ethylenedioxythiophene) (PEDOT)/graphene nanocomposites as solid tantalum electrolyte capacitor cathode films. The PEDOT/graphene films were successfully prepared on porous tantalum pentoxide surface as cathode films through the VPP procedure. The results indicated that the high conductivity nature of PEDOT/graphene leads to the decrease of cathode films resistance and contact resistance between PEDOT/graphene and carbon paste. This nanocomposite cathode film based capacitor showed ultralow equivalent series resistance (ESR) ca. 12 m Omega and exhibited better capacitance frequency performance than the PEDOT based capacitor. The leakage current investigation revealed that the device encapsulation process does not influence capacitor leakage current, indicating the excellent mechanical strength of PEDOT-graphene films. The graphene showed a distinct protection effect on the dielectric layer from possible mechanical damage. This high conductivity and mechanical strength graphene based conducting polymer nanocomposites indicated a promising application future for organic electrode materials.
C1 [Yang, Yajie; Li, Shibin; Zhang, Luning; Xu, Jianhua; Yang, Wenyao; Jiang, Yadong] Univ Elect Sci & Technol China, State Key Lab Elect Thin Films & Integrated Devic, Sch Optoelect Informat, Chengdu 610054, Peoples R China.
RP Li, SB (reprint author), Univ Elect Sci & Technol China, State Key Lab Elect Thin Films & Integrated Devic, Sch Optoelect Informat, Chengdu 610054, Peoples R China.
EM shibinli@uestc.edu.cn
FU National Science Foundation of China (NSFC) [61101029, 61204098];
   Fundamental Research Funds for the Central Universities [ZYGX2010J057];
   A Plan for Supporting the New Century Talents [NCET-12-0091]
FX The work was supported by the National Science Foundation of China
   (NSFC) (No. 61101029 and No. 61204098),the Fundamental Research Funds
   for the Central Universities (No. ZYGX2010J057), and A Plan for
   Supporting the New Century Talents (No. NCET-12-0091).
CR Acqua L. D., 2006, SYNTHETIC MET, V156, P379, DOI DOI 10.1016/J.SYNTHMET.2005.12.021
   Adam S. B., 2011, J POWER SOURCES, V196, P1, DOI DOI 10.1016/J.JP0WS0UR.2010.06.084
   Chronakis IS, 2006, POLYMER, V47, P1597, DOI 10.1016/j.polymer.2006.01.032
   Ci L, 2008, NANO LETT, V8, P2762, DOI 10.1021/nl8012715
   Fichet O, 2002, THIN SOLID FILMS, V411, P280, DOI 10.1016/S0040-6090(02)00271-7
   Friedrich J., 2004, ADV MATER, V4, P116
   Gunes S, 2007, CHEM REV, V107, P1324, DOI 10.1021/cr050149z
   Han YH, 2011, MACROMOL CHEM PHYS, V212, P521, DOI 10.1002/macp.201000634
   Heeger AJ, 2001, ANGEW CHEM INT EDIT, V40, P2591, DOI 10.1002/1521-3773(20010716)40:14<2591::AID-ANIE2591>3.0.CO;2-0
   Jung MH, 2008, LANGMUIR, V24, P9825, DOI 10.1021/la8014207
   Kelly TL, 2009, ACS APPL MATER INTER, V1, P2536, DOI 10.1021/am900575v
   Khomenko V, 2005, ELECTROCHIM ACTA, V50, P2499, DOI 10.1016/j.electacta.2004.10.078
   Kim JY, 2007, ADV MATER, V19, P3501, DOI 10.1002/adma.200602163
   Kudoh Y, 1999, SYNTHETIC MET, V102, P973, DOI 10.1016/S0379-6779(98)01012-1
   Madl CM, 2011, SYNTHETIC MET, V161, P1159, DOI 10.1016/j.synthmet.2011.03.024
   Sreenivasan R, 2009, CHEM VAPOR DEPOS, V15, P77, DOI 10.1002/cvde.200800040
   Tanriverdi EE, 2011, NANO-MICRO LETT, V3, P99, DOI 10.3786/nml.v3i2.p99-107
   Tenhaeff WE, 2008, ADV FUNCT MATER, V18, P979, DOI 10.1002/adfm.200701479
   Wallace G., 2004, MACROMOLECULES, V37, P5930, DOI DOI 10.1021/MA049365K
   Wang Y, 2009, J PHYS CHEM C, V113, P10346, DOI 10.1021/jp903583e
   West K., 2004, MACROMOLECULES, V37, P4538, DOI DOI 10.1021/MA049864L
NR 21
TC 32
Z9 32
U1 5
U2 124
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1944-8244
J9 ACS APPL MATER INTER
JI ACS Appl. Mater. Interfaces
PD MAY 22
PY 2013
VL 5
IS 10
BP 4350
EP 4355
DI 10.1021/am4003815
PG 6
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
SC Science & Technology - Other Topics; Materials Science
GA 152SK
UT WOS:000319551200050
PM 23621384
DA 2018-12-27
ER

PT J
AU Tavasoly, A
   Javanbakht, J
   Khaki, F
   Hosseini, E
   Bahrami, A
   Hassan, MA
   Mirabad, M
AF Tavasoly, Abbas
   Javanbakht, Javad
   Khaki, Fariba
   Hosseini, Ehsan
   Bahrami, Alimohammad
   Hassan, Mehdi Aghamohammad
   Mirabad, Mohammadmehdi
TI RETRACTED: Ulnar malignant peripheral nerve sheath tumour diagnosis in a
   mixed-breed dog as a model to study human: histologic,
   immunohistochemical, and clinicopathologic study(Retracted article. See
   vol. 11, 2016)
SO DIAGNOSTIC PATHOLOGY
LA English
DT Article; Retracted Publication
DE Dog; Pathology; Immunohistochemistry; Tumor; Markers
ID EPITHELIOID SCHWANNOMA; TRITON TUMORS; HOLSTEIN COW; DIFFERENTIATION;
   NEUROFIBROMA; DIVERGENT; CATTLE; SOLITARY
AB Canine Malignant Peripheral Nerve Sheath Tumors (MPNSTs) are uncommonly reported in the ulnar, since they are underestimated relative to the more common spindle cell tumours of soft tissue. In dogs, MPNST accounts for 27% of nervous system tumours. In man, MPNST represents 5-10% of all soft tissue sarcomas and is often associated with neurofibromatosis type 1 (NF-1). An 8-year-old, 9 kg, female mixed-breed dog with a subcutaneous mass on the upper right side of the ulnar region was presented to the small animal research and teaching hospital of Tehran University. The dog was anorexic with general weakness. The mass (7 x 4 cm) was removed surgically and processed routinely. Microscopically, the mass was composed of highly cellular areas with a homogeneous population of round or spindle cells, high cellular pleomorphism, high mitotic index and various morphologic patterns. Furthermore, spindle cells arranged in densely or loosely sweeping fascicles, interlacing whorls, or storiform patterns together with wavy cytoplasm, nuclear palisades, and round cells were arranged in sheets or cords with a meshwork of intratumoral nerve fibers. In addition, in this case the presence of neoplastic cells within the blood vessels was observed. Immunohistochemically, tumor was positive for vimentin and S-100 protein. The histopathologic features coupled with the S-100 and vimentin immunoreactivity led to a diagnosis of malignant neurofibroma.
   To the best of our knowledge, primary ulnar MPNST has not been reported in animals. This is the first documentation of an ulnar malignant peripheral nerve sheath tumour in a dog.
C1 [Tavasoly, Abbas; Javanbakht, Javad; Khaki, Fariba] Univ Tehran, Fac Vet Med, Dept Pathol, Tehran, Iran.
   [Hosseini, Ehsan; Bahrami, Alimohammad] Univ Ilam, Paravet Fac Ilam, Ilam, Iran.
   [Hassan, Mehdi Aghamohammad; Mirabad, Mohammadmehdi] Univ Tehran, Dept Clin Sci, Fac Vet Med, Tehran, Iran.
RP Javanbakht, J (reprint author), Univ Tehran, Fac Vet Med, Dept Pathol, Tehran, Iran.
EM javadjavanbakht@ut.ac.ir
CR Abe S, 1998, MODERN PATHOL, V11, P747
   Anderson GM, 1999, J AM ANIM HOSP ASSOC, V35, P319, DOI 10.5326/15473317-35-4-319
   Bergmann W, 2009, J COMP PATHOL, V141, P195, DOI 10.1016/j.jcpa.2009.03.009
   Beytut E, 2006, J COMP PATHOL, V134, P260, DOI 10.1016/j.jcpa.2005.10.006
   BROOKS JSJ, 1985, CANCER-AM CANCER SOC, V55, P2543, DOI 10.1002/1097-0142(19850601)55:11<2543::AID-CNCR2820551105>3.0.CO;2-4
   Chijiwa K, 2004, VET PATHOL, V41, P307, DOI 10.1354/vp.41-4-307
   DAIMARU Y, 1984, HUM PATHOL, V15, P768, DOI 10.1016/S0046-8177(84)80169-0
   DUCATMAN BS, 1984, CANCER, V54, P1049, DOI 10.1002/1097-0142(19840915)54:6<1049::AID-CNCR2820540620>3.0.CO;2-1
   Enzinger FM, 2001, SOFT TISSUE TUMORS, p[215, 1209, 1405]
   Goldschmidt M. H., 2002, Tumors in domestic animals, P45, DOI 10.1002/9780470376928.ch2
   Gulati N, 2011, ANN DIAGN PATHOL, V15, P441, DOI 10.1016/j.anndiagpath.2010.06.002
   Hendrick MJ, 1998, WHO INT HISTOLOGICAL, P26
   JOHNSON RC, 1988, VET REC, V123, P649
   Kameyama M, 2000, J VET MED SCI, V62, P125, DOI 10.1292/jvms.62.125
   Kandemir NO, 2010, DIAGN PATHOL, V5, DOI 10.1186/1746-1596-5-12
   Kim DY, 2003, J VET DIAGN INVEST, V15, P174, DOI 10.1177/104063870301500214
   KIRYU H, 1992, AM J DERMATOPATH, V14, P255, DOI 10.1097/00000372-199206000-00013
   Kitamura M, 2010, DIAGN PATHOL, V5, DOI 10.1186/1746-1596-5-2
   Koestner A., 2002, Tumors in domestic animals, P697, DOI 10.1002/9780470376928.ch14
   Koestner A, 1999, WHO INT HISTOLOGICAL, P37
   Koestner A, 2002, TUMORS DOMESTIC ANIM, P717
   LASKIN WB, 1991, AM J SURG PATHOL, V15, P1136, DOI 10.1097/00000478-199112000-00004
   Lee RM, 2011, J PEDIATR SURG, V46, P554, DOI 10.1016/j.jpedsurg.2010.11.029
   Mandrioli L, 2005, VET REC, V156, P552, DOI 10.1136/vr.156.17.552
   McMenamin ME, 2001, AM J SURG PATHOL, V25, P13, DOI 10.1097/00000478-200101000-00002
   Morphopoulos GD, 1996, HISTOPATHOLOGY, V28, P401
   Murcia PR, 2008, VET REC, V163, P331, DOI 10.1136/vr.163.11.331
   Nielsen AB, 2011, VET PATHOL, V48, P796, DOI 10.1177/0300985810388521
   Ohno J, 2010, DIAGN PATHOL, V5, DOI 10.1186/1746-1596-5-61
   OMI K, 1994, J COMP PATHOL, V111, P1, DOI 10.1016/S0021-9975(05)80106-9
   Patnaik AK, 2002, VET PATHOL, V39, P406, DOI 10.1354/vp.39-3-406
   PATNAIK AK, 1984, VET PATHOL, V21, P483, DOI 10.1177/030098588402100505
   Peek SF, 1997, VET REC, V140, P504, DOI 10.1136/vr.140.19.504
   Pumarola M, 1996, VET PATHOL, V33, P434, DOI 10.1177/030098589603300411
   Qiao JJ, 2012, DIAGN PATHOL, V7, DOI 10.1186/1746-1596-7-166
   ROBBINS P, 1994, PATHOL RES PRACT, V190, P412
   Santin EA, 1996, VET PATHOL, V33, P362
   Sasaki K, 2010, DIAGN PATHOL, V5, DOI 10.1186/1746-1596-5-51
   Saunders MO, 2003, EQUINE DERMATOLOGY, P733
   Scheithauer BW, 1999, ATLAS TUMOR PATHOL, P303
   Shaktawat SS, 2007, DIAGN PATHOL, V2, DOI 10.1186/1746-1596-2-47
   Summers BA, 1995, VET NEUROPATHOLOGY, P472
   Takeuchi A, 2001, HISTOPATHOLOGY, V39, P298, DOI 10.1046/j.1365-2559.2001.01212.x
   Weiss SW, 2008, ENZINGER WEISSS SOFT, P825
   WONG SY, 1991, CANCER-AM CANCER SOC, V67, P1076, DOI 10.1002/1097-0142(19910215)67:4<1076::AID-CNCR2820670435>3.0.CO;2-C
   WOODRUFF JM, 1993, CANCER, V72, P3618, DOI 10.1002/1097-0142(19931215)72:12<3618::AID-CNCR2820721212>3.0.CO;2-#
   WOODRUFF JM, 1994, AM J SURG PATHOL, V18, P882, DOI 10.1097/00000478-199409000-00003
   Yamada M, 1998, J COMP PATHOL, V119, P75, DOI 10.1016/S0021-9975(98)80073-X
   Ziadi A, 2010, AURIS NASUS LARYNX, V37, P539, DOI 10.1016/j.anl.2010.02.009
NR 49
TC 15
Z9 15
U1 2
U2 9
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1746-1596
J9 DIAGN PATHOL
JI Diagn. Pathol.
PD MAY 20
PY 2013
VL 8
AR 86
DI 10.1186/1746-1596-8-86
PG 6
WC Pathology
SC Pathology
GA 176DB
UT WOS:000321282500001
PM 23688209
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Cho, JA
   Lee, AH
   Platzer, B
   Cross, BCS
   Gardner, BM
   De Luca, H
   Luong, P
   Harding, HP
   Glimcher, LH
   Walter, P
   Fiebiger, E
   Ron, D
   Kagan, JC
   Lencer, WI
AF Cho, Jin A.
   Lee, Ann-Hwee
   Platzer, Barbara
   Cross, Benedict C. S.
   Gardner, Brooke M.
   De Luca, Heidi
   Luong, Phi
   Harding, Heather P.
   Glimcher, Laurie H.
   Walter, Peter
   Fiebiger, Edda
   Ron, David
   Kagan, Jonathan C.
   Lencer, Wayne I.
TI RETRACTED: The Unfolded Protein Response Element IRE1 alpha Senses
   Bacterial Proteins Invading the ER to Activate RIG-I and Innate Immune
   Signaling (Retracted article. See vol. 23, pg. 571, 2018)
SO CELL HOST & MICROBE
LA English
DT Article; Retracted Publication
ID TOLL-LIKE RECEPTOR; ENDOPLASMIC-RETICULUM; CHOLERA-TOXIN; RNASE-L;
   MAMMALIAN-CELLS; MESSENGER-RNAS; MECHANISM; STRESS; SENSITIVITY;
   TRANSPORT
AB The plasma membrane and all membrane-bound organelles except for the Golgi and endoplasmic reticulum (ER) are equipped with pattern-recognition molecules to sense microbes or their products and induce innate immunity for host defense. Here, we report that inositol-requiring-1 alpha (IRE1 alpha), an ER protein that signals in the unfolded protein response (UPR), is activated to induce inflammation by binding a portion of cholera toxin as it co-opts the ER to cause disease. Other known UPR transducers, including the IRE1 alpha-dependent transcription factor XBP1, are dispensable for this signaling. The inflammatory response depends instead on the RNase activity of IRE1 alpha to degrade endogenous mRNA, a process termed regulated IRE1 alpha-dependent decay (RIDD) of mRNA. The mRNA fragments produced engage retinoic-acid inducible gene 1 (RIG-I), a cytosolic sensor of RNA viruses, to activate NF-kappa B and interferon pathways. We propose IRE1 alpha provides for a generalized mechanism of innate immune surveillance originating within the ER lumen.
C1 [Cho, Jin A.; Platzer, Barbara; De Luca, Heidi; Luong, Phi; Fiebiger, Edda; Kagan, Jonathan C.; Lencer, Wayne I.] Boston Childrens Hosp, Dept Med, Div GI Cell Biol, Boston, MA 02115 USA.
   [Lee, Ann-Hwee; Glimcher, Laurie H.; Fiebiger, Edda; Kagan, Jonathan C.; Lencer, Wayne I.] Harvard Univ, Sch Med, Harvard Digest Dis Ctr, Boston, MA 02115 USA.
   [Lee, Ann-Hwee] Weill Cornell Med Coll, Dept Pathol & Lab Med, New York, NY 10065 USA.
   [Glimcher, Laurie H.] Weill Cornell Med Coll, Dept Med, New York, NY 10065 USA.
   [Cross, Benedict C. S.; Harding, Heather P.; Ron, David] Univ Cambridge, Metab Res Labs, Cambridge CB2 0QQ, England.
   [Cross, Benedict C. S.; Harding, Heather P.; Ron, David] NIHR, Cambridge Biomed Res Ctr, Cambridge CB2 0QQ, England.
   [Gardner, Brooke M.; Walter, Peter] Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94158 USA.
   [Walter, Peter] Howard Hughes Med Inst, Chevy Chase, MD USA.
RP Lencer, WI (reprint author), Boston Childrens Hosp, Dept Med, Div GI Cell Biol, Boston, MA 02115 USA.
EM wayne.lencer@childrens.harvard.edu
OI Lencer, Wayne/0000-0001-7346-2730
FU NIH [DK48106, DK084424, DK090603]; Harvard Digestive Diseases Center
   [P30 DK34854, DK083894]; CCFA; Pathogenesis of Infectious Disease Award
   from the Burroughs Wellcome Fund; Wellcome Trust Principal Research
   Fellowship [084812/Z/08/Z];  [AI093589];  [R01AI075037]; 
   [1K01DK093597-01A1];  [R01DK082448];  [R01DK089211]
FX This study was supported by NIH grants DK48106, DK084424, and DK090603
   and Harvard Digestive Diseases Center grant P30 DK34854 (W. I. L.);
   DK083894 and a CCFA Fellowship (J.A.C.); a Pathogenesis of Infectious
   Disease Award from the Burroughs Wellcome Fund and AI093589 (J.C.K.);
   R01AI075037 (E. F.); 1K01DK093597-01A1(B. P.); R01DK082448 (L. H. G.);
   R01DK089211 (A-H. L); and a Wellcome Trust Principal Research Fellowship
   (084812/Z/08/Z; D. R.). P. W. is an investigator of the Howard Hughes
   Medical Institute. We thank James DeCaprio for the gift of SV40 virus
   and Andrew McCluskey and John Collier for the gift of recombinant
   Diphtheria toxins.
CR Barton GM, 2009, NAT REV IMMUNOL, V9, P535, DOI 10.1038/nri2587
   Bertolotti A, 2001, J CLIN INVEST, V107, P585, DOI 10.1172/JCI11476
   BORK P, 1993, FEBS LETT, V334, P149, DOI 10.1016/0014-5793(93)81701-Z
   Credle JJ, 2005, P NATL ACAD SCI USA, V102, P18773, DOI 10.1073/pnas.0509487102
   Cross BCS, 2012, P NATL ACAD SCI USA, V109, pE869, DOI 10.1073/pnas.1115623109
   Dixit G, 2008, EXP BIOL MED, V233, P163, DOI 10.3181/0705-RM-132
   Dong BH, 2001, RNA, V7, P361, DOI 10.1017/S1355838201002230
   Fujinaga Y, 2003, MOL BIOL CELL, V14, P4783, DOI 10.1091/mbc.E03-06-0354
   Gardner BM, 2011, SCIENCE, V333, P1891, DOI 10.1126/science.1209126
   Gonzalez TN, 1999, EMBO J, V18, P3119, DOI 10.1093/emboj/18.11.3119
   Hollien J, 2006, SCIENCE, V313, P104, DOI 10.1126/science.1129631
   Hollien J, 2009, J CELL BIOL, V186, P323, DOI 10.1083/jcb.200903014
   Imagawa Y, 2008, FEBS LETT, V582, P656, DOI 10.1016/j.febslet.2008.01.038
   Iwawaki T, 2001, NAT CELL BIOL, V3, P158, DOI 10.1038/35055065
   Jobling MG, 2001, J BACTERIOL, V183, P4024, DOI 10.1128/JB.183.13.4024-4032.2001
   Kaser A, 2008, CELL, V134, P743, DOI 10.1016/j.cell.2008.07.021
   Kato H, 2008, J EXP MED, V205, P1601, DOI 10.1084/jem.20080091
   Kawai T, 2008, ANN NY ACAD SCI, V1143, P1, DOI 10.1196/annals.1443.020
   Lee AH, 2003, MOL CELL BIOL, V23, P7448, DOI 10.1128/MCB.23.21.7448-7459.2003
   LENCER WI, 1992, J CELL BIOL, V117, P1197, DOI 10.1083/jcb.117.6.1197
   Li T, 2012, P NATL ACAD SCI USA, V109, P10558, DOI 10.1073/pnas.1203447109
   Lindenbach BD, 2005, SCIENCE, V309, P623, DOI 10.1126/science.1114016
   Loo YM, 2011, IMMUNITY, V34, P680, DOI 10.1016/j.immuni.2011.05.003
   Malathi K, 2007, NATURE, V448, P816, DOI 10.1038/nature06042
   Malathi K, 2010, RNA, V16, P2108, DOI 10.1261/rna.2244210
   Martinon F, 2010, NAT IMMUNOL, V11, P411, DOI 10.1038/ni.1857
   Pahl HL, 1996, J CELL BIOL, V132, P511, DOI 10.1083/jcb.132.4.511
   Poeck H, 2010, NAT IMMUNOL, V11, P63, DOI 10.1038/ni.1824
   Rehwinkel J, 2010, SCIENCE, V327, P284, DOI 10.1126/science.1185068
   Richardson CE, 2010, NATURE, V463, P1092, DOI 10.1038/nature08762
   Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199
   SANDVIG K, 1992, NATURE, V358, P510, DOI 10.1038/358510a0
   Saslowsky DE, 2010, J CLIN INVEST, V120, P4399, DOI 10.1172/JCI42958
   Sun QM, 2006, IMMUNITY, V24, P633, DOI 10.1016/j.immuni.2006.04.004
   Tsai B, 2001, CELL, V104, P937, DOI 10.1016/S0092-8674(01)00289-6
   Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664
   Wernick NLB, 2010, J BIOL CHEM, V285, P6145, DOI 10.1074/jbc.M109.062067
NR 37
TC 70
Z9 72
U1 1
U2 11
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 1931-3128
EI 1934-6069
J9 CELL HOST MICROBE
JI Cell Host Microbe
PD MAY 15
PY 2013
VL 13
IS 5
BP 558
EP 569
DI 10.1016/j.chom.2013.03.011
PG 12
WC Microbiology; Parasitology; Virology
SC Microbiology; Parasitology; Virology
GA AA1IW
UT WOS:000330850800009
PM 23684307
OA Green Accepted, Bronze
DA 2018-12-27
ER

PT J
AU Bo, TL
   Zheng, XJ
   Duan, SZ
   Liang, YR
AF Bo, Tian-Li
   Zheng, Xiao-Jing
   Duan, Shao-Zhen
   Liang, Yi-Rui
TI RETRACTED: The influence of sand diameter and wind velocity on sand
   particle lift-off and incident angles in the windblown sand flux
   (Retracted article. See vol. 319, pg. 147, 2015)
SO SEDIMENTARY GEOLOGY
LA English
DT Article; Retracted Publication
DE Probability distribution; Windblown sand flux; Sand diameter; Friction
   wind velocity; Incident angle; Lift-off angle
ID AEOLIAN SALTATION; BOUNDARY-LAYER; BLOWN SAND; IMPACT PROCESS;
   COLLISIONS; BED; TRANSPORT; GRAINS; TUNNEL; CLOUD
AB The problem of impact entrainment is one of the central issues in understanding the process of saltation. In this paper, through improving the experimental scheme of Particle Image Velocimetry (PIV) and data processing methods using wind tunnel data, the measurement of sand particle lift-off and incident angles near the sand bed was achieved. Based on experimental data, we analyze the probability distribution of sand particle lift-off and incident angles and the influence of wind velocity and sand diameter on the probability distribution, as well as the relation between incident angle and lift-off angle. The results demonstrate that wind velocity and sand diameter have no obvious influence on the distribution shape of sand particle lift-off and incident angles. However, wind velocity will influence the decay constant and amplitude of the probability distribution. (c) 2013 Elsevier B.V. All rights reserved.
C1 [Bo, Tian-Li] Lanzhou Univ, Key Lab Mech Western Disaster & Environm, Lanzhou 730000, Peoples R China.
   Lanzhou Univ, Dept Mech, Lanzhou 730000, Peoples R China.
RP Bo, TL (reprint author), Lanzhou Univ, Key Lab Mech Western Disaster & Environm, Lanzhou 730000, Peoples R China.
EM btl@lzu.edu.cn
FU National Natural Science Foundation of China [11072097, 11232006,
   11202088, 10972164, 11121202]; National Key Technology RD Program
   [2013BAC07B01]; Science Foundation of Ministry of Education of China
   [308022]; Fundamental Research Funds for the Central Universities
   [Izujbky-2009-k01]; Project of the Ministry of Science and Technology of
   China [2009CB421304]
FX This research was supported by a grant from the National Natural Science
   Foundation of China (No. 11072097, No. 11232006, No. 11202088, No.
   10972164, No. 11121202), National Key Technology R&D Program
   (2013BAC07B01), the Science Foundation of Ministry of Education of China
   (No. 308022), Fundamental Research Funds for the Central Universities
   (Izujbky-2009-k01) and the Project of the Ministry of Science and
   Technology of China (No. 2009CB421304). The authors express their
   sincere appreciation to the supports.
CR ADRIAN RJ, 1991, ANNU REV FLUID MECH, V23, P261, DOI 10.1146/annurev.fl.23.010191.001401
   Anderson R. S., 1991, ACTA MECHANICA S, V1, P21, DOI DOI 10.1007/978-3-7091-6706-9_
   ANDERSON RS, 1988, SCIENCE, V241, P820, DOI 10.1126/science.241.4867.820
   ANDERSON RS, 1986, GEOL SOC AM BULL, V97, P523, DOI 10.1130/0016-7606(1986)97<523:STBWTA>2.0.CO;2
   Andreotti B, 2004, J FLUID MECH, V510, P47, DOI 10.1017/S0022112004009073
   Baek SJ, 1996, EXP FLUIDS, V22, P23, DOI 10.1007/BF01893303
   Bagnold R. A, 1941, PHYS BLOWN SAND DESE, DOI 10.1007/978-94-009-5682-7
   BISAL F., 1962, CANADIAN JOUR SOIL SCI, V42, P81
   Cheng H, 2006, J GEOPHYS RES-ATMOS, V111, DOI 10.1029/2006JD007069
   Cheng H, 2009, POWDER TECHNOL, V192, P99, DOI 10.1016/j.powtec.2008.12.001
   CHEPIL WS, 1945, SOIL SCI, V60, P397, DOI 10.1097/00010694-194511000-00005
   Creyssels M, 2009, J FLUID MECH, V625, P47, DOI 10.1017/S0022112008005491
   Dong ZB, 2004, EARTH SURF PROC LAND, V29, P343, DOI 10.1002/esp.1030
   Dong ZB, 2002, EARTH SURF PROC LAND, V27, P641, DOI 10.1002/esp.341
   Gonzalez R. C., 2003, DIGITAL IMAGE PROCES
   Greeley R, 1996, SEDIMENTOLOGY, V43, P41, DOI 10.1111/j.1365-3091.1996.tb01458.x
   Hubert M, 2004, GRANUL MATTER, V6, P159, DOI 10.1007/s10035-004-0166-x
   Iversen J. D, 1985, WIND GEOLOGICAL PROC
   JENSEN JI, 1986, SEDIMENTOLOGY, V33, P547, DOI 10.1111/j.1365-3091.1986.tb00760.x
   Kang LQ, 2008, GEOMORPHOLOGY, V97, P438, DOI 10.1016/j.geomorph.2007.08.018
   Lammel M, 2012, NEW J PHYS, V14, DOI 10.1088/1367-2630/14/9/093037
   LING YQ, 1980, ACTA GEOGRAPHICA SIN, V35, P174
   Livingstone I., 1996, AEOLIAN GEOMORPHOLOG
   MCEWAN IK, 1992, SEDIMENTOLOGY, V39, P971, DOI 10.1111/j.1365-3091.1992.tb01991.x
   McEwan IK, 1991, ACTA MECH S, V1, P53
   MITHA S, 1986, ACTA MECH, V63, P267, DOI 10.1007/BF01182553
   Mizushima J, 2009, PHYS FLUIDS, V21, DOI 10.1063/1.3054637
   NALPANIS P, 1993, J FLUID MECH, V251, P661, DOI 10.1017/S0022112093003568
   OWEN PR, 1964, J FLUID MECH, V20, P225, DOI 10.1017/S0022112064001173
   Pahtz T, 2012, NEW J PHYS, V14, DOI 10.1088/1367-2630/14/4/043035
   Pye K., 1990, AEOLIAN SAND SAND DU
   Rasmussen K.R., 2005, POWDERS GRAINS, V2, P967
   Rice MA, 1996, SEDIMENTOLOGY, V43, P21, DOI 10.1111/j.1365-3091.1996.tb01456.x
   RICE MA, 1995, SEDIMENTOLOGY, V42, P695, DOI 10.1111/j.1365-3091.1995.tb00401.x
   RUMPEL DA, 1985, SEDIMENTOLOGY, V32, P267, DOI 10.1111/j.1365-3091.1985.tb00509.x
   Sorensen M, 1996, SEDIMENTOLOGY, V43, P65, DOI 10.1111/j.1365-3091.1996.tb01460.x
   Sorensen M., 1991, ACTA MECH S, V1, P67
   STANISLAS M, 2000, PARTICLE IMAGE VELOC
   Stockman ES, 2009, COMBUST FLAME, V156, P1453, DOI 10.1016/j.combustflame.2009.02.006
   Tapia H. S., 2006, EL ROB AUT MECH C, P325, DOI 10. 1109/CERMA. 2006. 118
   Tong D, 2012, J GEOPHYS RES-ATMOS, V117, DOI 10.1029/2011JD017424
   Tsuchiya Y., 1970, P 12 C COAST ENG AM, V3, P1417
   UNGAR JE, 1987, SEDIMENTOLOGY, V34, P289, DOI 10.1111/j.1365-3091.1987.tb00778.x
   Volino RJ, 2009, J FLUID MECH, V635, P75, DOI 10.1017/S0022112009007617
   WERNER BT, 1988, SEDIMENTOLOGY, V35, P189, DOI 10.1111/j.1365-3091.1988.tb00944.x
   WERNER BT, 1990, J GEOL, V98, P1, DOI 10.1086/629371
   WHITE BR, 1982, INT J MULTIPHAS FLOW, V8, P459, DOI 10.1016/0301-9322(82)90018-0
   WHITE BR, 1977, J FLUID MECH, V81, P497, DOI 10.1017/S0022112077002183
   WILLETTS BB, 1986, ACTA MECH, V63, P255, DOI 10.1007/BF01182552
   WILLETTS BB, 1989, EARTH SURF PROCESSES, V14, P719, DOI 10.1002/esp.3290140806
   WILLETTS BB, 1988, EARTH SURF PROCESSES, V13, P717, DOI 10.1002/esp.3290130806
   Xie L, 2005, ACTA MECH SINICA, V21, P564, DOI 10.1007/s10409-005-0078-y
   Yang P, 2007, GEOMORPHOLOGY, V89, P320, DOI 10.1016/j.geomorph.2006.12.012
   Zhang W, 2007, J VISUAL-JAPAN, V10, P39, DOI 10.1007/BF03181802
   Zheng XJ, 2005, PHYS LETT A, V341, P107, DOI 10.1016/j.physleta.2005.04.084
   Zou X.Y., 1999, CHINESE SCI BULL, V44, P1084
   ZOU XY, 1994, CHINESE SCI BULL, V39, P1016
   Zou XY, 2001, GEOMORPHOLOGY, V36, P155, DOI 10.1016/S0169-555X(00)00038-6
NR 58
TC 3
Z9 3
U1 4
U2 30
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0037-0738
EI 1879-0968
J9 SEDIMENT GEOL
JI Sediment. Geol.
PD MAY 15
PY 2013
VL 290
BP 149
EP 156
DI 10.1016/j.sedgeo.2013.03.013
PG 8
WC Geology
SC Geology
GA 152NB
UT WOS:000319537300011
DA 2018-12-27
ER

PT J
AU Zhu, BY
   Li, XJ
   Zhang, YY
   Ye, CW
   Wang, Y
   Cai, SW
   Huang, HQ
   Cai, Y
   Yeh, SY
   Huang, ZH
   Chen, RH
   Tao, YR
   Wen, XQ
AF Zhu, Baoyi
   Li, Xiaojuan
   Zhang, Yuying
   Ye, Chunwei
   Wang, Yu
   Cai, Songwang
   Huang, Huaiqiu
   Cai, Yi
   Yeh, Shuyuan
   Huang, Zhenhua
   Chen, Ruihan
   Tao, Yiran
   Wen, Xingqiao
TI RETRACTED: Cross-talk of alpha tocopherol-associated protein and JNK
   controls the oxidative stress-induced apoptosis in prostate cancer cells
   (Retracted article. See vol. 137, pg. 2040, 2015)
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article; Retracted Publication
DE prostate cancer; alpha tocopherol associated protein; oxidative stress;
   signal transduction; c-Jun N-terminal kinase; apoptosis
ID ADENOASSOCIATED VIRUS; SIGNAL-TRANSDUCTION; ANTICANCER DRUGS;
   EPITHELIAL-CELLS; GENE-TRANSFER; KINASE; ROS; EXPRESSION; SUCCINATE;
   PATHWAY
AB Excess intracellular reactive oxygen species (ROS) beyond a threshold can induce apoptosis in cancer cells. However, the signal pathways that can augment the proapoptotic function of ROS remain largely unknown. We previously identified a tumor suppressor, alpha-tocopherol-associated protein (TAP), yet little is known regarding the role of TAP in the apoptotic signaling in prostate cancer. Interestingly, we recently found that exposure of prostate cancer cells to hydrogen peroxide (H2O2) resulted in induced apoptosis as well as increased expression of TAP. Small interfering RNA (siRNA) mediated silencing of endogenous TAP expression conferred effective protection from H2O2-induced apoptosis. Further mechanistic study showed exposure of prostate cancer cells to H2O2 resulted in increased phosphorylation of both JNK and c-Jun, and TAP siRNA effectively decreased H2O2-induced JNK and c-Jun phosphorylation. Immunoprecipitation experiments revealed that JNK physically associates with TAP. Furthermore, signaling downstream of JNK to the AP-1 complex and BH-3-only subfamily were found to be regulated on changing the TAP expression status. TAP could also promote the oxidative stress-induced apoptosis effect of docetaxel. In the mice xenograft model, H2O2 treatment induced TAP expression, JNK phosphorylation and apoptosis of prostate cancer. Recombinant adeno-associated virus 2 (rAAV2)-TAP injection significantly sensitizes this H2O2 proapoptotic effect. Together, we have identified a novel functional mechanism that the cross-talk of TAP-JNK is involved in oxidative stress-induced apoptosis in prostate cancer cells. Disrupting the redox balance of cancer cells by this signaling may enable therapeutic selectivity and provide benefit to overcome the drug resistance of prostate cancer.
C1 [Zhu, Baoyi; Ye, Chunwei; Wang, Yu; Cai, Yi; Tao, Yiran; Wen, Xingqiao] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Urol, Guangzhou 510630, Guangdong, Peoples R China.
   [Li, Xiaojuan] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Hlth Care, Guangzhou 510630, Guangdong, Peoples R China.
   [Zhang, Yuying; Huang, Zhenhua] Sun Yet Sen Univ, Zhongshan Med Sch, Dept Pharmacol, Guangzhou 510080, Guangdong, Peoples R China.
   [Cai, Songwang] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Cadiothoraci Surg, Guangzhou 510630, Guangdong, Peoples R China.
   [Huang, Huaiqiu] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Dermatol, Guangzhou 510630, Guangdong, Peoples R China.
   [Yeh, Shuyuan] Univ Rochester, Med Ctr, George Whipple Lab Canc Res, Dept Urol, Rochester, NY 14642 USA.
   [Chen, Ruihan] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Emergency, Guangzhou 510630, Guangdong, Peoples R China.
RP Wen, XQ (reprint author), Sun Yat Sen Univ, Affiliated Hosp 3, Dept Urol, 600 Tianhe Rd, Guangzhou 510630, Guangdong, Peoples R China.
EM xingqiaowen@yahoo.com
FU National Natural Science Foundation of China [81072115, 30872585,
   30600620, 30901768]; 985 Project (Sun Yat-sen University)
   [82000-3281901]; Planned Science and Technology Project of Guangdong
   Province [2008B030301299]; Fundamental Research Funds for the Central
   Universities [10ykpy06]; Program for New Century Excellent Talents in
   University [NCET-11-0541]; Ministry of Education, China [DOD
   W81XWH-08-1-0078]
FX Grant sponsor: National Natural Science Foundation of China, Grant
   numbers: 81072115, 30872585, 30600620 and 30901768; Grant sponsor: 985
   Project (Sun Yat-sen University), Grant number: 82000-3281901; Grant
   sponsor: Planned Science and Technology Project of Guangdong Province,
   Grant number: 2008B030301299; Grant sponsor: Fundamental Research Funds
   for the Central Universities, Grant number: 10ykpy06; Grant sponsor:
   Program for New Century Excellent Talents in University, Grant number:
   NCET-11-0541, Grant sponsor: Ministry of Education, China; Grant number:
   DOD W81XWH-08-1-0078 (S. Y.)
CR Acharya A, 2010, OXID MED CELL LONGEV, V3, P23, DOI 10.4161/oxim.3.1.10095
   Aitken ML, 2001, HUM GENE THER, V12, P1907, DOI 10.1089/104303401753153956
   Alexandre J, 2006, J NATL CANCER I, V98, P236, DOI 10.1093/jnci/djj049
   Arruda VR, 2001, MOL THER, V4, P586, DOI 10.1006/mthe.2001.0491
   Bartlett JS, 1998, HUM GENE THER, V9, P1181, DOI 10.1089/hum.1998.9.8-1181
   Benhar M, 2002, EMBO REP, V3, P420, DOI 10.1093/embo-reports/kvf094
   Circu ML, 2010, FREE RADICAL BIO MED, V48, P749, DOI 10.1016/j.freeradbiomed.2009.12.022
   Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1
   Fischer AC, 2003, MOL THER, V8, P918, DOI 10.1016/j.ymthe.2003.08.015
   Gogvadze V, 2010, INT J CANCER, V127, P1823, DOI 10.1002/ijc.25204
   Grieger JC, 2005, ADV BIOCHEM ENG BIOT, V99, P119, DOI 10.1007/10_005
   Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041
   Khandrika L, 2009, CANCER LETT, V282, P125, DOI 10.1016/j.canlet.2008.12.011
   Kumar B, 2008, CANCER RES, V68, P1777, DOI 10.1158/0008-5472.CAN-07-5259
   Lau ATY, 2008, J CELL BIOCHEM, V104, P657, DOI 10.1002/jcb.21655
   Li L, 2008, CANCER RES, V68, P434, DOI 10.1158/0008-5472.CAN-07-2931
   Lu J, 2007, P NATL ACAD SCI USA, V104, P12288, DOI 10.1073/pnas.0701549104
   Ma C, 2007, J BIOL CHEM, V282, P30901, DOI 10.1074/jbc.M608694200
   Maguire AM, 2008, NEW ENGL J MED, V358, P2240, DOI 10.1056/NEJMoa0802315
   Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119
   Mizumachi T, 2008, ONCOGENE, V27, P831, DOI 10.1038/sj.onc.1210681
   Neuzil J, 2006, BIOCHEM BIOPH RES CO, V343, P1113, DOI 10.1016/j.bbrc.2006.03.052
   Ni J, 2005, CANCER RES, V65, P9807, DOI 10.1158/0008-5472.CAN-05-1334
   Nicklin SA, 2001, MOL THER, V4, P174, DOI 10.1006/mthe.2001.0424
   Simizu S, 1998, J BIOL CHEM, V273, P26900, DOI 10.1074/jbc.273.41.26900
   Stapelberg M, 2005, J BIOL CHEM, V280, P25369, DOI 10.1074/jbc.M414498200
   Stocker A, 2002, STRUCTURE, V10, P1533, DOI 10.1016/S0969-2126(02)00884-5
   Tang XJ, 2011, EUR J PHARMACOL, V650, P72, DOI 10.1016/j.ejphar.2010.09.076
   Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803
   Wang J, 2008, CANCER BIOL THER, V7, P1875, DOI 10.4161/cbt.7.12.7067
   Wen XQ, 2007, ASIAN J ANDROL, V9, P206, DOI 10.1111/j.1745-7262.2007.00236.x
   Wen XQ, 2009, UROLOGY, V73, P1407, DOI 10.1016/j.urology.2008.09.041
   Weston CR, 2007, CURR OPIN CELL BIOL, V19, P142, DOI 10.1016/j.ceb.2007.02.001
   Yamamoto K, 1999, MOL CELL BIOL, V19, P8469
   Yamauchi J, 2001, BIOCHEM BIOPH RES CO, V285, P295, DOI 10.1006/bbrc.2001.5162
   Yanamadala V, 2007, J BIOL CHEM, V282, P24352, DOI 10.1074/jbc.M702804200
   Zimmer S, 2000, J BIOL CHEM, V275, P25672, DOI 10.1074/jbc.M000851200
NR 37
TC 16
Z9 16
U1 3
U2 55
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7136
EI 1097-0215
J9 INT J CANCER
JI Int. J. Cancer
PD MAY 15
PY 2013
VL 132
IS 10
BP 2270
EP 2282
DI 10.1002/ijc.27927
PG 13
WC Oncology
SC Oncology
GA 097ZO
UT WOS:000315512300005
PM 23129185
OA Bronze
DA 2018-12-27
ER

PT J
AU Swanepoel, AC
   Pretorius, E
AF Swanepoel, Albe C.
   Pretorius, Etheresia
TI RETRACTED: Red blood cell and platelet interactions in healthy females
   during early and late pregnancy, as well as postpartum (Retracted
   article. See vol. 123, pg. 1769, 2014)
SO BLOOD
LA English
DT Editorial Material; Retracted Publication
C1 [Swanepoel, Albe C.; Pretorius, Etheresia] Univ Pretoria, ZA-0002 Pretoria, South Africa.
RP Swanepoel, AC (reprint author), Univ Pretoria, ZA-0002 Pretoria, South Africa.
RI Pretorius, Etheresia/P-2978-2016
OI Pretorius, Etheresia/0000-0002-9108-2384; Swanepoel,
   Albe/0000-0001-5732-5007
NR 0
TC 1
Z9 1
U1 2
U2 10
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD MAY 9
PY 2013
VL 121
IS 19
BP 3788
EP 3788
DI 10.1182/blood-2013-01-480053
PG 1
WC Hematology
SC Hematology
GA 184EO
UT WOS:000321870900007
PM 23802272
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Yi, P
   Park, JS
   Melton, DA
AF Yi, Peng
   Park, Ji-Sun
   Melton, Douglas A.
TI RETRACTED: Betatrophin: A Hormone that Controls Pancreatic beta Cell
   Proliferation (Retracted article. See vol. 168, pg. 326, 2017)
SO CELL
LA English
DT Article; Retracted Publication
ID HYDRODYNAMICS-BASED TRANSFECTION; INSULIN-RESISTANT STATES; ADULT-MOUSE
   PANCREAS; GLUCOSE-INFUSION; COMPENSATORY GROWTH; PRIMARY MECHANISM;
   DIABETIC-RATS; PLASMID DNA; MICE; MASS
AB Replenishing insulin-producing pancreatic beta cell mass will benefit both type I and type II diabetics. In adults, pancreatic beta cells are generated primarily by self-duplication. We report on a mouse model of insulin resistance that induces dramatic pancreatic beta cell proliferation and beta cell mass expansion. Using this model, we identify a hormone, betatrophin, that is primarily expressed in liver and fat. Expression of betatrophin correlates with beta cell proliferation in other mouse models of insulin resistance and during gestation. Transient expression of betatrophin in mouse liver significantly and specifically promotes pancreatic beta cell proliferation, expands beta cell mass, and improves glucose tolerance. Thus, betatrophin treatment could augment or replace insulin injections by increasing the number of endogenous insulin-producing cells in diabetics.
C1 [Yi, Peng; Park, Ji-Sun; Melton, Douglas A.] Harvard Univ, Howard Hughes Med Inst, Harvard Stem Cell Inst, Dept Stem Cell & Regenerat Biol, Cambridge, MA 02138 USA.
RP Melton, DA (reprint author), Harvard Univ, Howard Hughes Med Inst, Harvard Stem Cell Inst, Dept Stem Cell & Regenerat Biol, 7 Divin Ave, Cambridge, MA 02138 USA.
EM dmelton@harvard.edu
FU NIH [RC4DK090781]; Harvard Stem Cell Institute
FX We thank Lauge Schaffer and Aaron Tward for sharing reagents. P.Y. was
   supported by a fellowship from the Helen Hay Whitney Foundation. D.A.M
   is an Investigator of the Howard Hughes Medical Institute. This work was
   supported by grants from the NIH (RC4DK090781) and the Harvard Stem Cell
   Institute. D.A.M. and P.Y. are listed as inventors on a U.S. Patent
   Application based on this work. Further studies on betatrophin are being
   pursued as a joint effort with Evotec and Janssen. We thank Dena Cohen,
   Sinisa Hrvatin, Ornella Barrandon, and Peter Carolan for comments on the
   manuscript.
CR Alonso LC, 2007, DIABETES, V56, P1792, DOI 10.2337/db06-1513
   Bernard C, 1998, DIABETES, V47, P1058, DOI 10.2337/diabetes.47.7.1058
   Bock T, 2003, DIABETES, V52, P1716, DOI 10.2337/diabetes.52.7.1716
   BONNERWEIR S, 1989, DIABETES, V38, P49, DOI 10.2337/diabetes.38.1.49
   Bruning JC, 1997, CELL, V88, P561, DOI 10.1016/S0092-8674(00)81896-6
   Cano DA, 2008, DIABETES, V57, P958, DOI 10.2337/db07-0913
   Crabtree JS, 2003, MOL CELL BIOL, V23, P6075, DOI 10.1128/MCB.23.17.6075-6085.2003
   Dong XY, 2004, INT J CANCER, V112, P239, DOI 10.1002/ijc.20363
   Dor Y, 2004, NATURE, V429, P41, DOI 10.1038/nature02520
   Drucker DJ, 2006, CELL METAB, V3, P153, DOI 10.1016/j.cmet.2006.01.004
   El Ouaamari A, 2013, CELL REP, V3, P401, DOI 10.1016/j.celrep.2013.01.007
   Fajas L, 2004, J CLIN INVEST, V113, P1288, DOI 10.1172/JCI200418555
   Flier SN, 2001, P NATL ACAD SCI USA, V98, P7475, DOI 10.1073/pnas.131192998
   GAPP DA, 1983, DIABETOLOGIA, V25, P439, DOI 10.1007/BF00282525
   Georgia S, 2004, J CLIN INVEST, V114, P963, DOI 10.1172/JC1200422098
   HARVEY M, 1995, CANCER RES, V55, P1146
   Heit JJ, 2006, NATURE, V443, P345, DOI 10.1038/nature05097
   Iglesias A, 2004, J CLIN INVEST, V113, P1398, DOI 10.1172/JCI200418879
   Imai J, 2008, SCIENCE, V322, P1250, DOI 10.1126/science.1163971
   Karnik SK, 2007, SCIENCE, V318, P806, DOI 10.1126/science.1146812
   Kubota N, 2000, DIABETES, V49, P1880, DOI 10.2337/diabetes.49.11.1880
   Kulkarni RN, 2004, J CLIN INVEST, V114, P828, DOI 10.1172/JCI200421845
   Kushner JA, 2005, MOL CELL BIOL, V25, P3752, DOI 10.1128/MCB.25.9.3752-3762.2005
   Latres E, 2000, EMBO J, V19, P3496, DOI 10.1093/emboj/19.13.3496
   Liu F, 1999, GENE THER, V6, P1258, DOI 10.1038/sj.gt.3300947
   Meier JJ, 2008, DIABETES, V57, P1584, DOI 10.2337/db07-1369
   Michael MD, 2000, MOL CELL, V6, P87, DOI 10.1016/S1097-2765(00)00010-1
   Nir T, 2007, J CLIN INVEST, V117, P2553, DOI 10.1172/JCI32959
   Okada T, 2007, P NATL ACAD SCI USA, V104, P8977, DOI 10.1073/pnas.0608703104
   Paris M, 2003, ENDOCRINOLOGY, V144, P2717, DOI 10.1210/en.2002-221112
   PARSONS JA, 1992, ENDOCRINOLOGY, V130, P1459, DOI 10.1210/en.130.3.1459
   Pei XH, 2004, MOL CELL BIOL, V24, P6653, DOI 10.1128/mcb.24.15.6653-6664.2004
   Pick A, 1998, DIABETES, V47, P358, DOI 10.2337/diabetes.47.3.358
   Porat S, 2011, CELL METAB, V13, P440, DOI 10.1016/j.cmet.2011.02.012
   Quagliarini F, 2012, P NATL ACAD SCI USA, V109, P19751, DOI 10.1073/pnas.1217552109
   Rane SG, 1999, NAT GENET, V22, P44
   Ren G, 2012, AM J PHYSIOL-ENDOC M, V303, pE334, DOI 10.1152/ajpendo.00084.2012
   Rieck S, 2009, MOL ENDOCRINOL, V23, P1702, DOI 10.1210/me.2009-0144
   Sachdeva MM, 2009, MOL ENDOCRINOL, V23, P747, DOI 10.1210/me.2008-0400
   Schaffer L, 2008, BIOCHEM BIOPH RES CO, V376, P380, DOI 10.1016/j.bbrc.2008.08.151
   Scheen AJ, 1996, DIABETES METAB, V22, P105
   Song YK, 2002, METHOD ENZYMOL, V346, P92
   Talchai C, 2012, CELL, V150, P1223, DOI 10.1016/j.cell.2012.07.029
   Terauchi Y, 2007, J CLIN INVEST, V117, P246, DOI 10.1172/JCI17645
   Teta M, 2005, DIABETES, V54, P2557, DOI 10.2337/diabetes.54.9.2557
   Teta M, 2007, DEV CELL, V12, P817, DOI 10.1016/j.devcel.2007.04.011
   TOMITA T, 1992, PANCREAS, V7, P367, DOI 10.1097/00006676-199205000-00015
   Uchida T, 2005, NAT MED, V11, P175, DOI 10.1038/nm1187
   Wang Q, 2002, DIABETOLOGIA, V45, P1263, DOI 10.1007/s00125-002-0828-3
   Wild S, 2004, DIABETES CARE, V27, P1047, DOI 10.2337/diacare.27.5.1047
   WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480
   Xu G, 1999, DIABETES, V48, P2270, DOI 10.2337/diabetes.48.12.2270
   Xu XB, 2008, CELL, V132, P197, DOI 10.1016/j.cell.2007.12.015
   Yant SR, 2000, NAT GENET, V25, P35, DOI 10.1038/75568
   Zhang GF, 1999, HUM GENE THER, V10, P1735, DOI 10.1089/10430349950017734
   Zhang R, 2012, BIOCHEM BIOPH RES CO, V424, P786, DOI 10.1016/j.bbrc.2012.07.038
NR 56
TC 289
Z9 318
U1 5
U2 116
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0092-8674
EI 1097-4172
J9 CELL
JI Cell
PD MAY 9
PY 2013
VL 153
IS 4
BP 747
EP 758
DI 10.1016/j.cell.2013.04.008
PG 12
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 143CN
UT WOS:000318844000006
PM 23623304
OA Bronze, Green Accepted
DA 2018-12-27
ER

PT J
AU Mahmood, K
   Park, SB
   Sung, HJ
AF Mahmood, Khalid
   Park, Seung Bin
   Sung, Hyung Jin
TI RETRACTED: Fabrication of Tantalum and Nitrogen Codoped ZnO (Ta, N-ZnO)
   Thin Films Using the Electrospay: Twin Applications as an Excellent
   Transparent Electrode and a Field Emitter (Retracted article. See vol.
   7, pg. 26005, 2015)
SO ACS APPLIED MATERIALS & INTERFACES
LA English
DT Article; Retracted Publication
DE Co-doped ZnO thin films; conductivity; optical properties; electrospray;
   field-emission
ID CHEMICAL-VAPOR-DEPOSITION; SOL-GEL METHOD; ZINC-OXIDE;
   OPTICAL-PROPERTIES; ELECTRICAL-PROPERTIES; ATMOSPHERIC-PRESSURE;
   THERMAL-TREATMENT; SPRAY-PYROLYSIS; EMISSION; BORON
AB The realization of stable p-type nitrogen-doped ZnO thin films with durable and controlled growth is important for the fabrication of nanoscale electronic and optoelectronic devices. ZnO thin films codoped with tantalum and nitrogen (Ta, N-ZnO) were fabricated by using the electrospraying method at an atmospheric pressure. X-ray diffraction (XRD) studies demonstrated that all the prepared films were polycrystalline in nature with hexagonal wurtzite structure. In addition, a shift in the XRD patterns was observed, and the crystal orientation was changed at a certain amount of nitrogen (>6 at.%) in the starting solution. Analysis of X-ray diffraction patterns and X-ray photoelectron spectra revealed that nitrogen which was combined with the zinc atom (N-Zn) was successfully doped into the ZnO crystal lattice. It was also observed that 2 at.% tantalum and 6 at.% nitrogen (2 at.% Ta and 6 at.% N) were the optimal dopant amounts to achieve the minimum resistivity of about 9.70 x 10(-5) Omega cm and the maximum transmittance of 98% in the visible region. Consequently, the field-emission characteristics of such a Ta, N-ZnO emitter can exhibit the higher current density of 1.33 mA cm(-2), larger field-enhancement factor (beta) of 4706, lower turn-on field of 2.6 V mu m(-1), and lower threshold field of 3.5 V mu m(-1) attributed to the enhanced conductivity and better crystallinity of films. Moreover, the obtained values of resistivity were closest to the lowest resistivity values among the doped ZnO films as well as to the indium tin oxide (ITO) resistivity values that were previously studied. We confirmed that the tantalum and nitrogen atoms substitution in the ZnO lattice induced positive effects in terms of enhancing the free carrier concentration which will further improve the electrical, optical, and field-emission properties. The proposed electrospraying method was well suitable for the fabrication of Ta, N-ZnO thin films at optimum conditions with superior electrical, optical, and field-emission characteristics, implying the potential applications as both a transparent electrode and field-emission (FE) devices.
C1 [Mahmood, Khalid; Park, Seung Bin] Korea Adv Inst Sci & Technol, Dept Chem & Biomol Engn, Taejon 305701, South Korea.
   [Mahmood, Khalid; Sung, Hyung Jin] Korea Adv Inst Sci & Technol, Dept Mech Engn, Taejon 305701, South Korea.
RP Park, SB (reprint author), Korea Adv Inst Sci & Technol, Dept Chem & Biomol Engn, 291 Daehak Ro, Taejon 305701, South Korea.
EM SeungBinPark@kaist.ac.kr
RI Sung, Hyung Jin/C-1884-2011; Park, Seung/B-8360-2011
OI Sung, Hyung Jin/0000-0002-4671-3626; 
FU Korea government
FX This work was supported by the 2010 Research Fund by the Korea
   government.
CR Abrarov SM, 2006, OPT COMMUN, V259, P378, DOI 10.1016/j.optcom.2005.08.048
   Ambrosini A, 2002, CHEM MATER, V14, P58, DOI 10.1021/cm010073x
   [Anonymous], 1967, POWD DIFFR FIL
   ATANASSOVA E, 1995, APPL SURF SCI, V84, P193, DOI 10.1016/0169-4332(94)00538-9
   Bian JM, 2004, APPL PHYS LETT, V84, P541, DOI 10.1063/1.1644331
   BURSTEIN E, 1954, PHYS REV, V93, P632, DOI 10.1103/PhysRev.93.632
   Chaabouni F, 2004, MAT SCI ENG B-SOLID, V109, P236, DOI 10.1016/j.mseb.2003.10.105
   Chen M, 1978, ELEMENTS XRAY DIFFRA, P102
   Deng H, 2004, THIN SOLID FILMS, V458, P43, DOI 10.1016/j.tsf.2003.11.288
   Du GT, 2005, APPL PHYS LETT, V87, DOI 10.1063/1.2132528
   El Manounia A., 2006, SUPERLATTICE MICROST, V39, P185
   Fancher CA, 1998, J CHEM PHYS, V109, P8426, DOI 10.1063/1.477505
   Fowler RH, 1928, P R SOC LOND A-CONTA, V119, P173, DOI 10.1098/rspa.1928.0091
   Gao L, 2011, APPL SURF SCI, V257, P2498, DOI 10.1016/j.apsusc.2010.10.009
   Hao XT, 2001, APPL SURF SCI, V183, P137, DOI 10.1016/S0169-4332(01)00582-7
   HU JH, 1992, J APPL PHYS, V72, P5381, DOI 10.1063/1.351977
   HU JH, 1991, SOL CELLS, V30, P437, DOI 10.1016/0379-6787(91)90076-2
   HU JH, 1992, MATER RES SOC SYMP P, V242, P743, DOI 10.1557/PROC-242-743
   Hwang KS, 2007, CERAM INT, V33, P505, DOI 10.1016/j.ceramint.2005.10.023
   Jin YZ, 2008, NANO LETT, V8, P1649, DOI 10.1021/nl0803702
   Jo SH, 2004, APPL PHYS LETT, V85, P1407, DOI 10.1063/1.1784543
   Joeph M, 2001, PHYSICA B, V302, P140
   Joseph B, 2006, CERAM INT, V32, P487, DOI 10.1016/j.ceramint.2005.03.029
   Kim GH, 2011, MATER CHEM PHYS, V131, P77, DOI 10.1016/j.matchemphys.2011.07.055
   Kim G, 2009, APPL PHYS A-MATER, V97, P821, DOI 10.1007/s00339-009-5317-9
   Kim H, 2000, J APPL PHYS, V88, P6021, DOI 10.1063/1.1318368
   Kim SM, 2009, J ELECTROCERAM, V23, P341, DOI 10.1007/s10832-008-9452-z
   Lee JH, 2003, J CRYST GROWTH, V247, P119, DOI 10.1016/S0022-0248(02)01907-3
   Lee JH, 2003, THIN SOLID FILMS, V426, P94, DOI 10.1016/S0040-6090(03)00014-2
   Lide D. R, 2000, CHEM RUBBER CO HDB C
   Lin SS, 2004, SURF COAT TECH, V185, P222, DOI 10.1016/j.surfcoat.2003.11.014
   Look DC, 2002, APPL PHYS LETT, V81, P1830, DOI 10.1063/1.1504875
   Lu YM, 2001, MATER CHEM PHYS, V72, P269, DOI 10.1016/S0254-0584(01)00450-3
   Mahmood K, 2013, J MATER CHEM A, V1, P4826, DOI 10.1039/c3ta10587c
   Mahmood K, 2012, SURF COAT TECH, V206, P4730, DOI 10.1016/j.surfcoat.2012.01.047
   Marotti RE, 2006, SOL ENERG MAT SOL C, V90, P2356, DOI 10.1016/j.solmat.2006.03.008
   Minami T, 2005, SEMICOND SCI TECH, V20, pS35, DOI 10.1088/0268-1242/20/4/004
   Muiva CM, 2011, CERAM INT, V37, P555, DOI 10.1016/j.ceramint.2010.09.042
   Nunes P, 2002, VACUUM, V64, P281, DOI 10.1016/S0042-207X(01)00322-0
   Palmer GB, 1997, CHEM MATER, V9, P3121, DOI 10.1021/cm9704037
   Paraguay DF, 2000, THIN SOLID FILMS, V373, P137, DOI 10.1016/S0040-6090(00)01120-2
   Robbins JJ, 2005, THIN SOLID FILMS, V473, P35, DOI 10.1016/j.tsf.2004.06.154
   Ryu YR, 2000, J CRYST GROWTH, V216, P330, DOI 10.1016/S0022-0248(00)00437-1
   Sanmyo M, 2003, CHEM MATER, V15, P819, DOI 10.1021/cm025747y
   Shan FK, 2004, J EUR CERAM SOC, V24, P1015, DOI 10.1016/S0955-2219(03)00397-2
   Soci C, 2007, NANO LETT, V7, P1003, DOI 10.1021/nl070111x
   Wang RP, 1996, CHEM MATER, V8, P433, DOI 10.1021/cm950372k
   Wang XB, 2006, J PHYS D APPL PHYS, V39, P4992, DOI 10.1088/0022-3727/39/23/014
   Xue XY, 2006, APPL PHYS LETT, V89, DOI 10.1063/1.2236288
   Yan XB, 2008, CARBON, V46, P753, DOI 10.1016/j.carbon.2008.01.027
   Yuan GD, 2005, APPL PHYS LETT, V86, DOI 10.1063/1.1928318
   Zhang SB, 2001, PHYS REV B, V63, DOI 10.1103/PhysRevB.63.075205
   Zhao Q, 2005, APPL PHYS LETT, V86
   Zhou HM, 2007, THIN SOLID FILMS, V515, P6909, DOI 10.1016/j.tsf.2007.01.041
   Zhu YW, 2003, APPL PHYS LETT, V83, P144, DOI 10.1063/1.1589166
NR 55
TC 10
Z9 10
U1 3
U2 66
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1944-8244
J9 ACS APPL MATER INTER
JI ACS Appl. Mater. Interfaces
PD MAY 8
PY 2013
VL 5
IS 9
BP 3722
EP 3730
DI 10.1021/am4003342
PG 9
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
SC Science & Technology - Other Topics; Materials Science
GA 143AQ
UT WOS:000318839100034
PM 23547983
DA 2018-12-27
ER

PT J
AU Li, W
   Yu, J
   Liu, Y
   Huang, XJ
   Abumaria, N
   Zhu, Y
   Huang, X
   Xiong, WX
   Ren, C
   Liu, XG
   Chui, DH
   Liu, GS
AF Li, Wei
   Yu, Jia
   Liu, Yong
   Huang, Xiaojie
   Abumaria, Nashat
   Zhu, Ying
   Huang, Xian
   Xiong, Wenxiang
   Ren, Chi
   Liu, Xian-Guo
   Chui, Dehua
   Liu, Guosong
TI RETRACTED: Elevation of Brain Magnesium Prevents and Reverses Cognitive
   Deficits and Synaptic Loss in Alzheimer's Disease Mouse Model (Retracted
   article. See vol. 34, pg. 5733, 2014)
SO JOURNAL OF NEUROSCIENCE
LA English
DT Article; Retracted Publication
ID NMDA RECEPTOR TRAFFICKING; APP TRANSGENIC MICE; MEMORY DEFICITS;
   AMYLOID-BETA; PLASTICITY; CALCIUM; DYSFUNCTION; BACE1; NEUROPATHOLOGY;
   TRANSMITTER
AB Profound synapse loss is one of the major pathological hallmarks associated with Alzheimer's disease (AD) and might underlie memory impairment. Our previous work demonstrated that the magnesium ion is a critical factor in controlling synapse density/plasticity. Here, we investigated whether elevation of brain magnesium by the use of a recently developed compound, magnesium-L-threonate (MgT), can ameliorate the AD-like pathologies and cognitive deficits in the APPswe/PS1dE9 mice, a transgenic (Tg) mouse model of AD. MgT treatment reduced A beta plaque and prevented synapse loss and memory decline in the Tg mice. Strikingly, MgT treatment was effective even when given to the mice at the end stage of their AD-like pathological progression. To explore how elevation of brain magnesium ameliorates the AD-like pathologies in the brains of Tg mice, we studied molecules critical for APP metabolism and signaling pathways implicated in synaptic plasticity/density. In the Tg mice, the NMDAR/CREB/BDNF signaling was downregulated, whereas calpain/calcineurin/Cdk5 neurodegenerative signaling and beta-secretase (BACE1) expression were upregulated. MgT treatment prevented the impairment of these signaling pathways, stabilized BACE1 expression, and reduced soluble APP beta and beta-C-terminal fragments in the Tg mice. At the molecular level, elevation of extracellular magnesium prevented the high-A beta-induced reductions in synaptic NMDARs by preventing calcineurin overactivation in hippocampal slices. Correlation studies suggested that the protection of NMDAR signaling might underlie the stabilization of BACE1 expression. Our results suggest that elevation of brain magnesium exerts substantial synap-toprotective effects in a mouse model of AD and may have therapeutic potential for treating AD in humans.
C1 [Li, Wei; Huang, Xiaojie; Abumaria, Nashat; Zhu, Ying; Huang, Xian; Xiong, Wenxiang; Ren, Chi; Liu, Guosong] Tsinghua Univ, Sch Med, Tsinghua Peking Ctr Life Sci, Beijing 100084, Peoples R China.
   [Yu, Jia; Chui, Dehua] Peking Univ, Hlth Sci Ctr, Neurosci Res Inst, Beijing 100191, Peoples R China.
   [Liu, Yong; Liu, Xian-Guo] Sun Yat Sen Univ, Zhongshan Sch Med, Dept Physiol, Guangzhou 510080, Guangdong, Peoples R China.
   [Liu, Guosong] Univ Texas Austin, Ctr Learning & Memory, Austin, TX 78712 USA.
RP Liu, GS (reprint author), Tsinghua Univ, Sch Med, Tsinghua Peking Ctr Life Sci, Beijing 100084, Peoples R China.
EM liu.guosong@gmail.com
RI Yu, Jia/J-2792-2014; Liu, Xian-Guo/G-7228-2011
OI Liu, Xian-Guo/0000-0002-4352-8687
FU National Basic Research Program of China [2009CB941303, 2011CB302201,
   2013CB835102]; National Natural Science Foundation of China [30970957]
FX This work was supported by the National Basic Research Program of China
   (Grant 2009CB941303 and Grant 2011CB302201 to G.L.), and Grant
   2013CB835102 to N.A., and the National Natural Science Foundation of
   China (Grant 30970957 to X-G. L.). We thank Jack L. Feldman for comments
   on the manuscript and Jiangyang Lu for technical support in electron
   microscopy.
CR Alberdi E, 2010, CELL CALCIUM, V47, P264, DOI 10.1016/j.ceca.2009.12.010
   Andrasi E, 2005, J ALZHEIMERS DIS, V7, P273
   Barbagallo M, 2011, MAGNESIUM RES, V24, pS115, DOI 10.1684/mrh.2011.0287
   Bernardo A, 2009, NEUROBIOL AGING, V30, P1777, DOI 10.1016/j.neurobiolaging.2007.12.022
   Bezprozvanny I, 2008, TRENDS NEUROSCI, V31, P454, DOI 10.1016/j.tins.2008.06.005
   Borchelt DR, 1997, NEURON, V19, P939, DOI 10.1016/S0896-6273(00)80974-5
   Cisse M, 2011, NATURE, V469, P47, DOI 10.1038/nature09635
   Costa-Mattioli M, 2009, NEURON, V61, P10, DOI 10.1016/j.neuron.2008.10.055
   Costantini C, 2005, BIOCHEM J, V391, P59, DOI 10.1042/BJ20050700
   De Rosa R, 2005, P NATL ACAD SCI USA, V102, P3811, DOI 10.1073/pnas.0500195102
   Devi L, 2012, NEUROPSYCHOPHARMACOL, V37, P434, DOI 10.1038/npp.2011.191
   Dineley KT, 2007, NEUROBIOL LEARN MEM, V88, P217, DOI 10.1016/j.nlm.2007.03.010
   Ding Y, 2008, J NEUROSCI, V28, P11622, DOI 10.1523/JNEUROSCI.3153-08.2008
   Duley L, 2002, LANCET, V359, P1877
   ENNACEUR A, 1988, BEHAV BRAIN RES, V31, P47, DOI 10.1016/0166-4328(88)90157-X
   Greer PL, 2008, NEURON, V59, P846, DOI 10.1016/j.neuron.2008.09.002
   Hawasli AH, 2007, NAT NEUROSCI, V10, P880, DOI 10.1038/nn1914
   Holtzman D. M., 2011, SCI TRANSL MED, V3, p77sr1
   HUBBARD JI, 1968, J PHYSIOL-LONDON, V196, P75, DOI 10.1113/jphysiol.1968.sp008495
   HUBBARD JI, 1968, J PHYSIOL-LONDON, V194, P355, DOI 10.1113/jphysiol.1968.sp008413
   Jack CR, 2010, LANCET NEUROL, V9, P119, DOI 10.1016/S1474-4422(09)70299-6
   JANG H, 2010, P NATL ACAD SCI US
   Kuchibhotla KV, 2008, NEURON, V59, P214, DOI 10.1016/j.neuron.2008.06.008
   Lau CG, 2007, NAT REV NEUROSCI, V8, P413, DOI 10.1038/nrn2153
   LEUNG LS, 1979, BRAIN RES, V176, P49
   Lu JF, 2000, CLIN PHARMACOKINET, V38, P305, DOI 10.2165/00003088-200038040-00002
   Martin SJ, 2000, ANNU REV NEUROSCI, V23, P649, DOI 10.1146/annurev.neuro.23.1.649
   Matsuoka Y, 2008, J PHARMACOL EXP THER, V325, P146, DOI 10.1124/jpet.107.130526
   McConlogue L, 2007, J BIOL CHEM, V282, P26326, DOI 10.1074/jbc.M611687200
   Minoshima S, 1997, ANN NEUROL, V42, P85, DOI 10.1002/ana.410420114
   MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0
   Nagahara AH, 2009, NAT MED, V15, P331, DOI 10.1038/nm.1912
   Nikolaev A, 2009, NATURE, V457, P981, DOI 10.1038/nature07767
   Palop JJ, 2007, NEURON, V55, P697, DOI 10.1016/j.neuron.2007.07.025
   Palop JJ, 2010, NAT NEUROSCI, V13, P812, DOI 10.1038/nn.2583
   Palop JJ, 2009, ARCH NEUROL-CHICAGO, V66, P435, DOI 10.1001/archneurol.2009.15
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Reger MA, 2008, NEUROLOGY, V70, P440, DOI 10.1212/01.WNL.0000265401.62434.36
   Reiserer RS, 2007, GENES BRAIN BEHAV, V6, P54, DOI 10.1111/j.1601-183X.2006.00221.x
   Ren WJ, 2011, NEUROPSYCHOPHARMACOL, V36, P979, DOI 10.1038/npp.2010.236
   Rockenstein E, 2003, J NEURAL TRANSM, V110, P1313, DOI 10.1007/s00702-003-0025-7
   Roe CM, 2008, ARCH NEUROL-CHICAGO, V65, P1467, DOI 10.1001/archneur.65.11.1467
   Salter MW, 2004, NAT REV NEUROSCI, V5, P317, DOI 10.1038/nrn1368
   Sanchez PE, 2012, P NATL ACAD SCI USA, V109, pE2895, DOI 10.1073/pnas.1121081109
   Savva GM, 2009, NEW ENGL J MED, V360, P2302, DOI 10.1056/NEJMoa0806142
   Selkoe DJ, 2002, SCIENCE, V298, P789, DOI 10.1126/science.1074069
   Selkoe DJ, 2011, COLD SPRING HARB PER, V3
   Shi J, 2000, NEURON, V28, P103, DOI 10.1016/S0896-6273(00)00089-1
   Simpkins KL, 2003, J NEUROSCI, V23, P11322
   Singer O, 2005, NAT NEUROSCI, V8, P1343, DOI 10.1038/nn1531
   Slutsky I, 2004, NEURON, V44, P835, DOI 10.1016/j.neuron.2004.11.013
   Slutsky I, 2010, NEURON, V65, P165, DOI 10.1016/j.neuron.2009.12.026
   Snyder EM, 2005, NAT NEUROSCI, V8, P1051, DOI 10.1038/nn1503
   Sperling RA, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002609
   Tamayev R, 2012, EMBO MOL MED, V4, P171, DOI 10.1002/emmm.201100195
   TERRY RD, 1991, ANN NEUROL, V30, P572, DOI 10.1002/ana.410300410
   Verpelli C, 2010, J NEUROSCI, V30, P5830, DOI 10.1523/JNEUROSCI.0119-10.2010
   Wei F, 2002, NEURON, V36, P713, DOI 10.1016/S0896-6273(02)01019-X
   Witkowski M, 2011, MAGNESIUM RES, V24, P163, DOI 10.1684/mrh.2011.0292
NR 59
TC 21
Z9 24
U1 6
U2 68
PU SOC NEUROSCIENCE
PI WASHINGTON
PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA
SN 0270-6474
J9 J NEUROSCI
JI J. Neurosci.
PD MAY 8
PY 2013
VL 33
IS 19
BP 8423
EP 8441
DI 10.1523/JNEUROSCI.4610-12.2013
PG 19
WC Neurosciences
SC Neurosciences & Neurology
GA 142CZ
UT WOS:000318775200030
PM 23658180
OA Bronze
DA 2018-12-27
ER

PT J
AU Gao, J
   Guo, Z
   Wang, L
   Jiang, W
AF Gao, J.
   Guo, Z.
   Wang, L.
   Jiang, W.
TI RETRACTED: Magnesia-Zircon Brick: Evolution of Microstructure,
   Properties and Performance with Increasing Sintering Temperature
   (Retracted article. See vol. 45, pg. 387, 2013)
SO SCIENCE OF SINTERING
LA English
DT Article; Retracted Publication
DE Magnesia-Zircon; Microstructure; Properties; Performance
AB Depending on phase components and densification, Magnesia-Zircon brick varies in appearance from white to veined and then brown with increasing sintering temperature. Properties including bulk density, apparent porosity and hot modulus of rupture as well as performance embodied with creep resistance and refractoriness continue to improve with sustaining enhancement of sintering temperature. Exceptionally, cold crushing strength first increases then decreases with rising sintering temperature and a peak exists at 1550 degrees C. Microstructural evolution suffers zircon decomposition companying by silica escape, forsterite formation, matrix solidification and zirconia coagulation, until a zirconia/forsterite composites belt tightly coating on magnesia aggregates. Excessive coagulation of zirconia caused by oversintering probably results in microcracks formation and defects enlargement thereby degrades cold crushing strength.
C1 [Gao, J.; Wang, L.; Jiang, W.] Donghua Univ, Coll Mat Sci & Engn, Shanghai 201600, Peoples R China.
   [Gao, J.; Guo, Z.] RHI Refractories Dalian Co Ltd, Dalian 116600, Liaoning, Peoples R China.
RP Wang, L (reprint author), Donghua Univ, Coll Mat Sci & Engn, 2999 North Renmin Rd, Shanghai 201600, Peoples R China.
EM wanglj@dhu.edu.cn
RI Wang, LianJun/H-6490-2011
OI Wang, LianJun/0000-0003-3709-9801
CR BUSBY T, 1991, GLASS IND        JUL, P23
   Heilemann G, 2007, CERAM ENG SCI PROC, V28, P183
   Meynckens JP, 2008, ADV MATER RES-SWITZ, V39-40, P619, DOI 10.4028/www.scientific.net/AMR.39-40.619
   Peng C, 2009, SCI SINTER, V41, P11, DOI 10.2298/SOS0901011P
   SCHMALENBACH B, 2001, P UN INT TECH C REFR, V2, P1135
   TRIESSNIG A, 1987, Patent No. 4651810
   WEICHERT T, 1995, CERAMIC ENG SCI P, V16, P68
   ZAWRAH MF, 2005, REFRACTORIES ENG, V14, P16
NR 8
TC 1
Z9 1
U1 2
U2 23
PU INT INST SCIENCE SINTERING (I I S S)
PI BELGRADE
PA C/O ITN SANU, KNEZ MIHAILOVA 35/IV, PO BOX 315, 11000 BELGRADE,
   YUGOSLAVIA
SN 0350-820X
J9 SCI SINTER
JI Sci. Sinter.
PD MAY-AUG
PY 2013
VL 45
IS 2
BP 181
EP 188
DI 10.2298/SOS1302181G
PG 8
WC Materials Science, Ceramics; Metallurgy & Metallurgical Engineering
SC Materials Science; Metallurgy & Metallurgical Engineering
GA 206VA
UT WOS:000323550700007
OA DOAJ Gold
DA 2018-12-27
ER

PT J
AU Saraf, SK
   Singh, RP
   Singh, V
   Varma, A
AF Saraf, Shyam K.
   Singh, Ravindra P.
   Singh, Vakil
   Varma, Ashish
TI RETRACTED: Pullout strength of misplaced pedicle screws in the thoracic
   and lumbar vertebrae - A cadaveric study (Retracted article. See vol.
   48, pg. 144, 2014)
SO INDIAN JOURNAL OF ORTHOPAEDICS
LA English
DT Article; Retracted Publication
DE Misplaced pedicle screw; pullout strength; vertebra
ID FIXATION STRENGTH; OUT STRENGTH; SPINE; AUGMENTATION; ARCHITECTURE;
   DIAMETER
AB Background: The objective of this cadaveric study was to analyze the effects of iatrogenic pedicle perforations from screw misplacement on the mean pullout strength of lower thoracic and lumbar pedicle screws. We also investigated the effect of bone mineral density (BMD), diameter of pedicle screws, and the region of spine on the pullout strength of pedicle screws.
   Materials and Methods: Sixty fresh human cadaveric vertebrae (D10-L2) were harvested. Dual-energy X-ray absorptiometry (DEXA) scan of vertebrae was done for BMD. Titanium pedicle screws of different diameters (5.2 and 6.2 mm) were inserted in the thoracic and lumbar segments after dividing the specimens into three groups: a) standard pedicle screw (no cortical perforation); b) screw with medial cortical perforation; and c) screw with lateral cortical perforation. Finally, pullout load of pedicle screws was recorded using INSTRON Universal Testing Machine.
   Results: Compared with standard placement, medially misplaced screws had 9.4% greater mean pullout strength and laterally misplaced screws had 47.3% lesser mean pullout strength. The pullout strength of the 6.2 mm pedicle screws was 33% greater than that of the 5.2 mm pedicle screws. The pullout load of pedicle screws in lumbar vertebra was 13.9% greater than that in the thoracic vertebra (P = 0.105), but it was not statistically significant. There was no significant difference between pullout loads of vertebra with different BMD (P = 0.901).
   Conclusion: The mean pullout strength was less with lateral misplaced pedicle screws while medial misplaced pedicle screw had more pullout strength. The pullout load of 6.2 mm screws was greater than that of 5.2 mm pedicle screws. No significant correlation was found between bone mineral densities and the pullout strength of vertebra. Similarly, the pullout load of screw placed in thoracic and lumbar vertebrae was not significantly different.
C1 [Saraf, Shyam K.; Singh, Ravindra P.; Singh, Vakil; Varma, Ashish] Banaras Hindu Univ, Inst Med Sci, Dept Orthopaed, Varanasi 221005, Uttar Pradesh, India.
RP Saraf, SK (reprint author), Banaras Hindu Univ, Inst Med Sci, Dept Orthopaed, Varanasi 221005, Uttar Pradesh, India.
EM sksaraf36@hotmail.com
RI Singh, Vakil/F-6689-2014
OI Singh, Vakil/0000-0003-4111-8016
CR Barber JW, 1998, J SPINAL DISORD, V11, P215
   Brasiliense LBC, 2010, J NEUROSURG-SPINE, V12, P503, DOI 10.3171/2009.11.SPINE09408
   Burval DJ, 2007, SPINE, V32, P1077, DOI 10.1097/01.brs.0000261566.38422.40
   DVORAK M, 1993, SPINE, V18, P1689, DOI 10.1097/00007632-199309000-00018
   Fakhouri SF, 2011, ADV MECH ENG, V2011, P6
   GEORGE DC, 1991, SPINE, V16, P181, DOI 10.1097/00007632-199102000-00015
   Hirano T, 1997, SPINE, V22, P2504, DOI 10.1097/00007632-199711010-00007
   Inceoglu S, 2005, SPINE, V30, P1485, DOI 10.1097/01.brs.0000168373.24644.9f
   Kote R, 1997, SPINE, V22, P1836
   Kothe R, 1996, SPINE, V21, P264, DOI 10.1097/00007632-199602010-00002
   Krag MH, 1990, LUMBAR SPINE, P916
   MISENHIMER GR, 1989, SPINE, V14, P367, DOI 10.1097/00007632-198904000-00004
   ROYCAMILLE R, 1986, CLIN ORTHOP RELAT R, P7
   Santoni BG, 2008, SPINE J, V9, P366
   WEINSTEIN JN, 1992, CLIN ORTHOP RELAT R, P34
   White KK, 2006, SPINE, V31, pE355, DOI 10.1097/01.brs.0000219394.48091.d6
   WITTENBERG RH, 1993, CLIN ORTHOP RELAT R, P278
   Yuksel KZ, 2007, SPINE J, V7, P286, DOI 10.1016/j.spinee.2005.12.007
   Zhang QH, 2004, J BIOMECH, V37, P479, DOI 10.1016/j.jbiomech.2003.09.005
NR 19
TC 6
Z9 6
U1 2
U2 9
PU MEDKNOW PUBLICATIONS & MEDIA PVT LTD
PI MUMBAI
PA B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075,
   INDIA
SN 0019-5413
EI 1998-3727
J9 INDIAN J ORTHOP
JI Indian J. Orthop.
PD MAY-JUN
PY 2013
VL 47
IS 3
BP 238
EP 243
DI 10.4103/0019-5413.111502
PG 6
WC Orthopedics
SC Orthopedics
GA 207QS
UT WOS:000323618600004
PM 23798753
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Mohanty, AK
   Senapati, MR
   Lenka, SK
AF Mohanty, Aswini Kumar
   Senapati, Manas Ranjan
   Lenka, Saroj Kumar
TI RETRACTED: An improved data mining technique for classification and
   detection of breast cancer from mammograms (Retracted article. See vol.
   27, pg. 249, 2016)
SO NEURAL COMPUTING & APPLICATIONS
LA English
DT Article; Retracted Publication
DE Data mining; Computer-aided diagnosis; Mammogram classification;
   Statistical features; Gray level co-occurrence matrix features;
   Association rule mining; Region of interest
ID DIGITAL MAMMOGRAMS; DIAGNOSIS; SYSTEM; CAD
AB The high incidence of breast cancer in women has increased significantly in the recent years. Mammogram breast X-ray imaging is considered the most effective, low-cost, and reliable method in early detection of breast cancer. Although general rules for the differentiation between benign and malignant breast lesion exist, only 15-30% of masses referred for surgical biopsy are actually malignant. Physician experience of detecting breast cancer can be assisted by using some computerized feature extraction and classification algorithms. Computer-aided classification system was used to help in diagnosing abnormalities faster than traditional screening program without the drawback attribute to human factors. In this work, an approach is proposed to develop a computer-aided classification system for cancer detection from digital mammograms. The proposed system consists of three major steps. The first step is region of interest (ROI) extraction of 256 x 256 pixels size. The second step is the feature extraction; we used a set of 26 features, and we found that these features are capable of differentiating between normal and cancerous breast tissues in order to minimize the classification error. The third step is the classification process; we used the technique of the association rule mining to classify between normal and cancerous tissues. The proposed system was shown to have the large potential for cancer detection from digital mammograms.
C1 [Mohanty, Aswini Kumar] SOA Univ, Bhubaneswar, Orissa, India.
   [Senapati, Manas Ranjan] Krupajal Engn Coll, Dept Comp Sci, Bhubaneswar 752002, Orissa, India.
   [Lenka, Saroj Kumar] Modi Univ, Dept Comp Sci, Lakshmangarh 332311, Rajasthan, India.
RP Mohanty, AK (reprint author), SOA Univ, Bhubaneswar, Orissa, India.
EM asw_moh@yahoo.com; manas_senapati@sify.com; lenka.sarojkumar@gmail.com
OI Lenka, Saroj/0000-0002-6282-2611
CR Bing Liu, 1998, Proceedings Fourth International Conference on Knowledge Discovery and Data Mining, P80
   Brake GMT, 1999, IEEE T MED IMAGING, V18, P628, DOI 10.1109/42.790462
   Cheng HD, 1998, IEEE T MED IMAGING, V17, P442, DOI 10.1109/42.712133
   Fogel DB, 1997, CANCER LETT, V119, P93, DOI 10.1016/S0304-3835(97)00259-0
   Furuya S., 2004, Systems and Computers in Japan, V35, P72, DOI 10.1002/scj.10587
   Gonzalez RC, 2002, DIGITAL IMAGE PROCES, P76
   Hagihara Y., 2005, Systems and Computers in Japan, V36, P65, DOI 10.1002/scj.20173
   HARALICK RM, 1973, IEEE T SYST MAN CYB, VSMC3, P610, DOI 10.1109/TSMC.1973.4309314
   Kobatake H, 1999, IEEE T MED IMAGING, V18, P369, DOI 10.1109/42.774164
   LE CT, 2003, INTRO BIOSTATISTICS
   Marx C, 2004, EUR J RADIOL, V51, P66, DOI 10.1016/S0720-048X(03)00144-X
   Ribeiro MX, 2008, IEEE T MULTIMEDIA, V10, P277, DOI 10.1109/TMM.2007.911837
   Sajda P, 2002, IEEE T MED IMAGING, V21, P239, DOI 10.1109/42.996342
   Sampat MP, 2005, HANDBOOK OF IMAGE AND VIDEO PROCESSING, 2ND EDITION, P1195, DOI 10.1016/B978-012119792-6/50130-3
   Senapati MR, 2013, NEURAL COMPUT APPL, V22, P125, DOI 10.1007/s00521-011-0670-y
   Thangavel K, 2009, International Journal of Recent Trends in Engineering, V2, P233
   Verma B, 2001, IEEE T INF TECHNOL B, V5, P46, DOI 10.1109/4233.908389
   Walker R. F., 1995, Conference Proceedings DICTA-95. Digital Image Computing: Techniques and Applications, P643
   WINSBERG F, 1967, RADIOLOGY, V89, P211, DOI 10.1148/89.2.211
   Youssry N, 2002, ACBME, P109
   Yu SY, 2000, IEEE T MED IMAGING, V19, P115, DOI 10.1109/42.836371
   Zaiane O. R., 2000, Proceedings of 16th International Conference on Data Engineering (Cat. No.00CB37073), P461, DOI 10.1109/ICDE.2000.839445
NR 22
TC 12
Z9 12
U1 3
U2 21
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0941-0643
EI 1433-3058
J9 NEURAL COMPUT APPL
JI Neural Comput. Appl.
PD MAY
PY 2013
VL 22
SU 1
BP S303
EP S310
DI 10.1007/s00521-012-0834-4
PG 8
WC Computer Science, Artificial Intelligence
SC Computer Science
GA 205AR
UT WOS:000323413300026
DA 2018-12-27
ER

PT J
AU Ge, YZ
   Xu, MY
   Mi, JC
AF Ge Yang-Zhen
   Xu Min-Yi
   Mi Jian-Chun
TI RETRACTED: Wavelet analysis of passive temperature in a turbulent
   cylinder wake (Retracted Article)
SO ACTA PHYSICA SINICA
LA Chinese
DT Article; Retracted Publication
DE turbulent wake; passive scalar; wavelets
ID EVOLUTION
AB A wavelet multi-resolution technique is applied to analysing the temperature field simultaneously obtained by a rake of 16 cold-wires in the turbulent near-wake of a slightly heated circular cylinder with a diameter of d = 12.7 mm in a range of x/d from 3 to 20, where x is the downstream distance from the cylinder axis. This technique enables us to decompose the fluctuating temperature field into a number of wavelet components based on different characteristic frequency bandwidths or scales, which are representative of the temperature fields of different scales. The turbulent mixing characteristics of various fluctuating scales are examined in terms of instantaneous temperature contours of each wavelet component. The flow structures and intermittent processing of various scales are visualized. The streamwise evolutions of temperature variance of various scales suggest that the intermediate-scale structures make larger contribution to the total temperature than the large- and small-scale structures. The wavelet auto-correlation function indicates that the large- and intermediate-scale structures display larger correlation and the wavelet component of higher frequency loses coherence quickly.
C1 [Ge Yang-Zhen; Xu Min-Yi; Mi Jian-Chun] Peking Univ, State Key Lab Turbulence & Complex Syst, Beijing 100871, Peoples R China.
RP Mi, JC (reprint author), Peking Univ, State Key Lab Turbulence & Complex Syst, Beijing 100871, Peoples R China.
EM jcmi@coe.pku.edu.cn
RI Mi, Jianchun/N-3796-2013
OI xu, minyi/0000-0002-3772-8340
FU National Natural Science Foundation of China [10921202, 11072005]
FX Project supported by the National Natural Science Foundation of China
   (Grant Nos. 10921202, 11072005).
CR ANTONIA RA, 1986, J FLUID MECH, V163, P393, DOI 10.1017/S0022112086002343
   Daubechies I, 1992, 61 SOC IND APPL MATH, P357
   FREYMUTH P, 1971, PHYS FLUIDS, V14, P2574, DOI 10.1063/1.1693376
   Hassan A, 2004, PHYS REV LETT, V93
   LARUE JC, 1974, PHYS FLUIDS, V17, P873, DOI 10.1063/1.1694823
   Lepore J, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.034501
   Li H, 1998, J FLUID ENG-T ASME, V120, P778, DOI 10.1115/1.2820738
   Mi J, 2011, EXP FLUIDS, V50, P429, DOI 10.1007/s00348-010-0944-7
   Mi J, 1999, INT COMMUN HEAT MASS, V26, P45, DOI 10.1016/S0735-1933(98)00120-1
   Rinoshika A, 2005, J FLUID MECH, V524, P229, DOI 10.1017/S0022112004002319
   Rinoshika A, 2007, INT J HEAT FLUID FL, V28, P948, DOI 10.1016/j.ijheatfluidflow.2006.12.001
   SREENIVASAN KR, 1981, PHYS FLUIDS, V24, P1232, DOI 10.1063/1.863525
   Zhou Y, 2005, PHYS REV E, V71-4
NR 13
TC 1
Z9 1
U1 6
U2 19
PU CHINESE PHYSICAL SOC
PI BEIJING
PA P O BOX 603, BEIJING 100080, PEOPLES R CHINA
SN 1000-3290
J9 ACTA PHYS SIN-CH ED
JI Acta Phys. Sin.
PD MAY
PY 2013
VL 62
IS 10
AR 104701
DI 10.7498/aps.62.104701
PG 12
WC Physics, Multidisciplinary
SC Physics
GA 157BC
UT WOS:000319869300045
DA 2018-12-27
ER

PT J
AU Fridell, G
AF Fridell, Gavin
TI RETRACTED: Politicising Debt and Development: activist voices on social
   justice in the new millennium (Retracted article. See vol. 34, pg. 1305,
   2013)
SO THIRD WORLD QUARTERLY
LA English
DT Article; Retracted Publication
AB In contrast to mainstream development economists' and policy makers' insistence that relatively straightforward technical and apolitical solutions exist to the problems of debt and development, debt is inscribed in powerful, unequal and contested structures and relations This is vividly depicted in this special section of activist vignettes written by representatives of key international ngos working on debt justiceJubilee Debt Campaign, the Center for Economic and Policy Research, the Halifax Initiative and Inter Pares. Written with the passion and determination that come from years of mobilising and supporting grassroots struggles, these vignettes reveal the often obscure or unspoken relations of power that underpin the highly unequal dynamics of debt on a global scale, while promoting and offering fresh insights from a diverse array of new initiatives and subversive tactics that confront the dominant debt and development paradigm. They offer sober reflection on what on-the-ground organisations need to do to get things done in continuing and future battles for debt justice.
C1 St Marys Univ, Dept Int Dev Studies, Halifax, NS B3H 3C3, Canada.
RP Fridell, G (reprint author), St Marys Univ, Dept Int Dev Studies, 923 Robie St, Halifax, NS B3H 3C3, Canada.
EM Gavin.Fridell@SMU.ca
CR Abrahamsen R, 2003, AFR AFFAIRS, V102, P203
   Abrahamsen Rita, 2000, DISCIPLINING DEMOCRA
   Attarah L, 2005, PLAYING CHICKEN GHAN
   Atwood M, 2000, BLIND ASSASSIN, P12
   Bond P, 2006, THIRD WORLD Q, V27, P339, DOI 10.1080/01436590500432622
   Escobar A, 1995, ENCOUNTERING DEV MAK, P52
   Henry J., 2012, PRICE OFFSHORE REVIS
   Henry J, 2007, GAME OLD EMPIRE, P232
   Howell J., 2002, CIVIL SOC DEV CRITIC
   IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2004, IARC Monogr Eval Carcinog Risks Hum, V83, P1
   Kapoor I, 2008, POSTCOLONIAL POLIT, V1, P76
   Manji F, 1998, DEV RIGHTS, P13
   Murphy B, 2000, DEV PRACTICE, V10
   Ndikumana L., 2011, AFRICAS ODIOUS DEBTS
   Pender J, 2001, THIRD WORLD Q, V22, P397
   Sachs JD, 2005, END POVERTY EC POSSI, P346
   Smillie I, 1995, ALMS BAZAAR ALTRUISM
   Smith BH, 1988, PRIVATE ACTION PUBLI
   Sogge D, 2002, GIVE TAKE WHATS WRON
   Tsikata D, 2005, CODESRIA B, V3-4, P56
   van Rooy A, 1998, CIVIL SOC AID IND
   Wallace T., 2004, SOCIALIST REGISTER, V40, P202
   World Bank, WORLD DEV IND
   *WORLD BANK, GLOB DEV FIN
NR 24
TC 4
Z9 4
U1 2
U2 9
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 0143-6597
EI 1360-2241
J9 THIRD WORLD Q
JI Third World Q.
PD MAY 1
PY 2013
VL 34
IS 4
BP 726
EP 745
DI 10.1080/01436597.2013.786294
PG 20
WC Planning & Development
SC Public Administration
GA 154DL
UT WOS:000319651600011
DA 2018-12-27
ER

PT J
AU Wang, LM
   Wang, YJ
   Cui, M
   Luo, WJ
   Wang, XJ
   Barber, PA
   Chen, ZY
AF Wang, Li-Mei
   Wang, Yong-Jiu
   Cui, Min
   Luo, Wen-Juan
   Wang, Xiao-Ji
   Barber, Philip A.
   Chen, Zhe-Yu
TI RETRACTED: A dietary polyphenol resveratrol acts to provide
   neuroprotection in recurrent stroke models by regulating AMPK and SIRT1
   signaling, thereby reducing energy requirements during ischemia
   (Retracted article. See vol. 43, pg. 990, 2016)
SO EUROPEAN JOURNAL OF NEUROSCIENCE
LA English
DT Article; Retracted Publication
DE intracellular ATP level; intracellular NAD; NADH ratio; recurrent stroke
   model; RSV neuroprotection; SIRT1 and AMPK signaling
ID FOCAL CEREBRAL-ISCHEMIA; SKELETAL-MUSCLE; RATS; BRAIN; METABOLISM;
   PREVENTION; MECHANISM; CARDIOPROTECTION; PHOSPHORYLATION; DEACETYLASE
AB Polyphenol resveratrol (RSV) has been associated with Silent Information Regulator T1 (SIRT1) and AMP-activated protein kinase (AMPK) metabolic stress sensors and probably responds to the intracellular energy status. Our aim here was to investigate the neuroprotective effects of RSV and its association with SIRT1 and AMPK signaling in recurrent ischemia models. In this study, elderly male Wistar rats received a combination of two mild transient middle cerebral artery occlusions (tMCAOs) as an in vivo recurrent ischemic model. Primary cultured cortical neuronal cells subjected to combined oxygenglucose deprivation (OGD) were used as an in vitro recurrent ischemic model. RSV administration significantly reduced infarct volumes, improved behavioral deficits and protected neuronal cells from cell death in recurrent ischemic stroke models in vivo and in vitro. RSV treatments significantly increased the intracellular NAD+/NADH ratio, AMPK and SIRT1 activities, decreased energy assumption and restored cell energy ATP level. SIRT1 and AMPK inhibitors and specific small interfering RNA (siRNA) for SIRT1 and AMPK significantly abrogated the neuroprotection induced by RSV. AMPK-siRNA and inhibitor decreased SIRT1 activities; however, SIRT1-siRNA and inhibitor had no impact on phospho-AMPK (p-AMPK) levels. These results indicated that the neuroprotective effects of RSV increased the intracellular NAD+/NADH ratio as well as AMPK and SIRT1 activities, thereby reducing energy ATP requirements during ischemia. SIRT1 is a downstream target of p-AMPK signaling induced by RSV in the recurrent ischemic stroke model.
C1 [Wang, Li-Mei; Cui, Min; Chen, Zhe-Yu] Shandong Univ, Sch Med, Shandong Prov Key Lab Mental Disorders, Dept Neurobiol, Jinan 250100, Shandong, Peoples R China.
   [Wang, Li-Mei; Barber, Philip A.] Univ Calgary, Dept Clin Neurosci, Calgary, AB, Canada.
   [Wang, Yong-Jiu] Tianjin Med Univ, Gen Hosp, Dept Neurol, Tianjin 300052, Peoples R China.
   [Luo, Wen-Juan] Qingdao Univ, Coll Med, Affiliated Hosp, Dept Ophthalmol, Qingdao 266003, Shandong, Peoples R China.
   [Wang, Xiao-Ji] Jiangxi Sci & Technol Normal Univ, Sch Pharm, Nanchang 330013, Jiangxi, Peoples R China.
RP Wang, LM (reprint author), Shandong Univ, Sch Med, Shandong Prov Key Lab Mental Disorders, Dept Neurobiol, Jinan 250100, Shandong, Peoples R China.
EM limeiwang@sdu.edu.cn; zheyuchen@sdu.edu.cn
RI Barber, Philip/C-7108-2016
FU National Natural Science Foundation of China [31130026]; State Program
   of National Natural Science Foundation of China for Innovative Research
   Group [81021001]; Independent Innovation Foundation of Shandong
   University (II-FSDU); Natural Science Foundation of JiangXi Province
   [GJJ12591]
FX We thank Dr Darren. L. Clark for technical assistance with the recurrent
   stroke model and cortical neuronal cell culture. We thank Dr Robert
   Edwards for proof-reading the manuscript. This work was supported by the
   National Natural Science Foundation of China (31130026), the State
   Program of National Natural Science Foundation of China for Innovative
   Research Group (No. 81021001), the Independent Innovation Foundation of
   Shandong University (II-FSDU) and the Natural Science Foundation of
   JiangXi Province (GJJ12591). The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Baur JA, 2006, NAT REV DRUG DISCOV, V5, P493, DOI 10.1038/nrd2060
   Benjelloun N, 1999, STROKE, V30, P1916, DOI 10.1161/01.STR.30.9.1916
   Borra MT, 2005, J BIOL CHEM, V280, P17187, DOI 10.1074/jbc.M501250200
   Bradamante S, 2003, EUR J PHARMACOL, V465, P115, DOI 10.1016/S0014-2999(03)01441-9
   Canto C, 2009, NATURE, V458, P1056, DOI 10.1038/nature07813
   Carling D, 2004, TRENDS BIOCHEM SCI, V29, P18, DOI 10.1016/j.tibs.2003.11.005
   Chandratheva A, 2009, NEUROLOGY, V72, P1941, DOI 10.1212/WNL.0b013e3181a826ad
   Correia M, 2006, STROKE, V37, P50, DOI 10.1161/01.STR.0000195209.26543.8f
   Dal-Pan A, 2011, AGE, V33, P15, DOI 10.1007/s11357-010-9156-6
   Das M, 2010, MOL ASPECTS MED, V31, P503, DOI 10.1016/j.mam.2010.09.001
   Dasgupta B, 2007, P NATL ACAD SCI USA, V104, P7217, DOI 10.1073/pnas.0610068104
   Della-Morte D, 2009, NEUROSCIENCE, V159, P993, DOI 10.1016/j.neuroscience.2009.01.017
   Domoki F., 2009, AM J PHYSIOL-CELL PH, V296, P97
   Dong WP, 2008, J VASC SURG, V48, P709, DOI 10.1016/j.jvs.2008.04.007
   Dudley J, 2012, J NUTR BIOCHEM, V23, P852, DOI 10.1016/j.jnutbio.2012.04.006
   Ferrara N, 2008, REJUV RES, V11, P139, DOI 10.1089/rej.2007.0576
   Finkel T, 2009, NATURE, V460, P587, DOI 10.1038/nature08197
   Guarani V, 2011, NATURE, V473, P234, DOI 10.1038/nature09917
   Hardie DG, 2007, NAT REV MOL CELL BIO, V8, P774, DOI 10.1038/nrm2249
   Huang SS, 2001, LIFE SCI, V69, P1057, DOI 10.1016/S0024-3205(01)01195-X
   Imai S, 2000, COLD SPRING HARB SYM, V65, P297, DOI 10.1101/sqb.2000.65.297
   Jager S, 2007, P NATL ACAD SCI USA, V104, P12017, DOI 10.1073/pnas.0705070104
   Johnston DCC, 2004, CAN MED ASSOC J, V170, P1134, DOI 10.1503/cmaj.1021148
   Kopp P, 1998, EUR J ENDOCRINOL, V138, P619, DOI 10.1530/eje.0.1380619
   La-Morte D., 2009, NEUROSCIENCE, V159, P993
   Li C, 2010, NEUROCHEM INT, V56, P495, DOI 10.1016/j.neuint.2009.12.009
   LIN TN, 1993, STROKE, V24, P117, DOI 10.1161/01.STR.24.1.117
   Liu C, 2010, J BIOL CHEM, V285, P15346, DOI 10.1074/jbc.M110.102491
   MacDougall Niall J J, 2009, Expert Rev Cardiovasc Ther, V7, P1103, DOI 10.1586/erc.09.77
   Murayama A, 2008, CELL, V133, P627, DOI 10.1016/j.cell.2008.03.030
   Nakano A, 2010, NAT CELL BIOL, V12, P583, DOI 10.1038/ncb2060
   Pallas M, 2008, NEUROSCIENCE, V154, P1388, DOI 10.1016/j.neuroscience.2008.04.065
   Pallas M, 2009, CURR NEUROVASC RES, V6, P70, DOI 10.2174/156720209787466019
   Paolucci S, 2003, CEREBROVASC DIS, V15, P98, DOI 10.1159/000067137
   Penumathsa SV, 2009, CAN J PHYSIOL PHARM, V87, P275, DOI 10.1139/Y09-013
   Qiao M, 2009, J NEUROSCI METH, V184, P244, DOI 10.1016/j.jneumeth.2009.08.010
   Qiao M, 2009, INT J DEV NEUROSCI, V27, P691, DOI 10.1016/j.ijdevneu.2009.07.004
   Raval AP, 2006, J CEREBR BLOOD F MET, V26, P1141, DOI 10.1038/sj.jcbfm.9600262
   Roquer J, 2010, J NEUROL, V257, P947, DOI 10.1007/s00415-009-5443-5
   Rothwell PM, 2005, NEUROLOGY, V64, P817, DOI 10.1212/01.WNL.0000152985.32732.EE
   Sakata Y, 2010, EXP NEUROL, V224, P325, DOI 10.1016/j.expneurol.2010.03.032
   Shichita T., 2011, INFLAMM REGEN, V31, P102
   Shin JA, 2010, J NEUROIMMUNOL, V227, P93, DOI 10.1016/j.jneuroim.2010.06.017
   Sinha K, 2002, LIFE SCI, V71, P655, DOI 10.1016/S0024-3205(02)01691-0
   Smith JM, 2007, BRAIN, V130, P915, DOI 10.1093/brain/awl393
   Spence JD, 2010, NAT REV NEUROL, V6, P477, DOI 10.1038/nrneurol.2010.114
   Suwa M, 2003, J APPL PHYSIOL, V94, P185, DOI 10.1152/japplphysiol.00295.2002
   Troyano A, 2001, J BIOL CHEM, V276, P47107, DOI 10.1074/jbc.M104516200
   Tsai SK, 2007, J VASC SURG, V46, P346, DOI 10.1016/j.jvs.2007.04.044
   Turnley AM, 1999, J NEUROCHEM, V72, P1707, DOI 10.1046/j.1471-4159.1999.721707.x
   Walle T, 2004, FREE RADICAL BIO MED, V36, P829, DOI 10.1016/j.freeradbiomed.2004.01.002
   Walle T, 2004, DRUG METAB DISPOS, V32, P1377, DOI 10.1124/dmd.104.000885
   Wood JG, 2004, NATURE, V430, P686, DOI 10.1038/nature02789
   Yang J, 2010, CHEM-EUR J, V16, P12808, DOI 10.1002/chem.201002020
   Yi C. O., 2011, ANAT CELL BIOL, V4, P194
   Yousuf S, 2009, BRAIN RES, V1250, P242, DOI 10.1016/j.brainres.2008.10.068
   Zhang F., 2011, EUR J PHARMACOL, V636, P1
NR 57
TC 40
Z9 42
U1 4
U2 36
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0953-816X
EI 1460-9568
J9 EUR J NEUROSCI
JI Eur. J. Neurosci.
PD MAY
PY 2013
VL 37
IS 10
BP 1669
EP 1681
DI 10.1111/ejn.12162
PG 13
WC Neurosciences
SC Neurosciences & Neurology
GA 148AK
UT WOS:000319213900012
PM 23461657
DA 2018-12-27
ER

PT J
AU White, BP
   Molloy, ME
   Zhao, HP
   Zhang, YY
   Tonetti, DA
AF White, Bethany Perez
   Molloy, Mary Ellen
   Zhao, Huiping
   Zhang, Yiyun
   Tonetti, Debra A.
TI RETRACTED: Extranuclear ER alpha is associated with regression of T47D
   PKC alpha-overexpressing, tamoxifen-resistant breast cancer (Retracted
   article. See vol. 16, 2017)
SO MOLECULAR CANCER
LA English
DT Article; Retracted Publication
DE Breast cancer; PKC alpha; Extranuclear ER alpha; Tamoxifen; Raloxifene
ID ESTROGEN-RECEPTOR-ALPHA; KINASE-C-ALPHA; BREAST-CANCER CELLS;
   PLASMA-MEMBRANE; ENDOCRINE THERAPY; ATHYMIC MICE; PATHWAY ACTIVATION;
   BINDING-SITES; SRC PROMOTES; MCF-7 CELLS
AB Background: Prior to the introduction of tamoxifen, high dose estradiol was used to treat breast cancer patients with similar efficacy as tamoxifen, albeit with some undesirable side effects. There is renewed interest to utilize estradiol to treat endocrine resistant breast cancers, especially since findings from several preclinical models and clinical trials indicate that estradiol may be a rational second-line therapy in patients exhibiting resistance to tamoxifen and/or aromatase inhibitors. We and others reported that breast cancer patients bearing protein kinase C alpha (PKC alpha)-expressing tumors exhibit endocrine resistance and tumor aggressiveness. Our T47D:A18/PKC alpha preclinical model is tamoxifen-resistant, hormone-independent, yet is inhibited by 17 beta-estradiol (E2) in vivo. We previously reported that E2-induced T47D:A18/PKC alpha tumor regression requires extranuclear ER alpha and interaction with the extracellular matrix.
   Methods: T47D:A18/PKC alpha cells were grown in vitro using two-dimensional (2D) cell culture, three-dimensional (3D) Matrigel and in vivo by establishing xenografts in athymic mice. Immunofluoresence confocal microscopy and co-localization were applied to determine estrogen receptor alpha (ER alpha) subcellular localization. Co-immunoprecipitation and western blot were used to examine interaction of ER alpha with caveolin-1.
   Results: We report that although T47D:A18/PKC alpha cells are cross-resistant to raloxifene in cell culture and in Matrigel, raloxifene induces regression of tamoxifen-resistant tumors. ER alpha rapidly translocates to extranuclear sites during T47D: A18/PKC alpha tumor regression in response to both raloxifene and E2, whereas ER alpha is primarily localized in the nucleus in proliferating tumors. E2 treatment induced complete tumor regression whereas cessation of raloxifene treatment resulted in tumor regrowth accompanied by re-localization of ER alpha to the nucleus. T47D:A18/neo tumors that do not overexpress PKC alpha maintain ER alpha in the nucleus during tamoxifen-mediated regression. An association between ER alpha and caveolin-1 increases in tumors regressing in response to E2.
   Conclusions: Extranuclear ER alpha plays a role in the regression of PKC alpha-overexpressing tamoxifen-resistant tumors. These studies underline the unique role of extranuclear ER alpha in E2- and raloxifene-induced tumor regression that may have implications for treatment of endocrine-resistant PKC alpha-expressing tumors encountered in the clinic.
C1 [White, Bethany Perez; Molloy, Mary Ellen; Zhao, Huiping; Tonetti, Debra A.] Univ Illinois, Coll Pharm, Dept Biopharmaceut Sci, 833 S Wood St, Chicago, IL 60611 USA.
RP Tonetti, DA (reprint author), Univ Illinois, Coll Pharm, Dept Biopharmaceut Sci, 833 S Wood St, Chicago, IL 60611 USA.
EM dtonetti@uic.edu
FU NIH/NCI [RO1 CA122914]; NIH/NIGMS [T32 BM070388]
FX These studies were supported in part by NIH/NCI RO1 CA122914 (to DAT)
   and NIH/NIGMS T32 BM070388 (to BPW and MEM). The authors thank Jae Woo
   Choi for performing mass spectrometry on serum samples in the laboratory
   of Dr. Gregory Thatcher. We also would like to acknowledge the
   Histopathology Core and the Confocal Microscopy Facility of the Research
   Resources Center at the University of Illinois at Chicago for providing
   services and expertise.
CR Acconcia F, 2005, MOL BIOL CELL, V16, P231
   Acconcia F, 2004, BIOCHEM BIOPH RES CO, V316, P878, DOI 10.1016/j.bbrc.2004.02.129
   Ainsworth PD, 2004, EUR J CANCER, V40, P2269, DOI 10.1016/j.ejca.2004.06.027
   Ali S, 2009, LIFE SCI, V84, P766, DOI 10.1016/j.lfs.2009.03.007
   Assender JW, 2007, J CLIN PATHOL, V60, P1216, DOI 10.1136/jcp.2006.041616
   Castoria G, 2001, EMBO J, V20, P6050, DOI 10.1093/emboj/20.21.6050
   Chakravarty D, 2010, CANCER RES, V70, P4092, DOI 10.1158/0008-5472.CAN-09-3834
   Chisamore MJ, 2001, CLIN CANCER RES, V7, P3156
   Ellis MJ, 2009, JAMA-J AM MED ASSOC, V302, P774, DOI 10.1001/jama.2009.1204
   Fan P, 2007, CANCER RES, V67, P1352, DOI 10.1158/0008-5472.CAN-06-1020
   Giretti MS, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002238
   Gutierrez S, 2012, MOL CELL ENDOCRINOL, V355, P169, DOI 10.1016/j.mce.2012.02.008
   Kelly MJ, 2001, TRENDS ENDOCRIN MET, V12, P152, DOI 10.1016/S1043-2760(01)00377-0
   Kerfoot C, 2004, J HISTOCHEM CYTOCHEM, V52, P419, DOI 10.1177/002215540405200314
   Kousteni S, 2001, CELL, V104, P719, DOI 10.1016/S0092-8674(02)08100-X
   Kumar R, 2002, NATURE, V418, P654, DOI 10.1038/nature00889
   Lahn M, 2004, ONCOLOGY-BASEL, V67, P1, DOI 10.1159/000080279
   Levin ER, 2008, BREAST CANCER RES TR, V108, P351, DOI 10.1007/s10549-007-9618-4
   Levin ER, 2012, CLIN CANCER RES, V18, P6, DOI 10.1158/1078-0432.CCR-11-2547
   Lin X, 2006, CARCINOGENESIS, V27, P1538, DOI 10.1093/carcin/bgl002
   Longo M, 2004, BONE, V34, P100, DOI 10.1016/j.bone.2003.09.007
   Lonne GK, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-76
   Lonning PE, 2001, BREAST CANCER RES TR, V67, P111, DOI 10.1023/A:1010619225209
   Marquez DC, 2001, ONCOGENE, V20, P5420, DOI 10.1038/sj.onc.1204729
   Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x
   Molloy CA, 2000, J BIOL CHEM, V275, P12565, DOI 10.1074/jbc.275.17.12565
   NARDULLI AM, 1986, ENDOCRINOLOGY, V119, P2038, DOI 10.1210/endo-119-5-2038
   Nemere I, 1998, BIOCHEM BIOPH RES CO, V248, P443, DOI 10.1006/bbrc.1998.8492
   NEWTON AC, 2009, AM J PHYSIOL-ENDOC M, V298, pE395, DOI DOI 10.1152/AJPEND0.00477.2009)
   Nicholson RI, 2005, BREAST CANCER RES TR, V93, pS3, DOI 10.1007/s10549-005-9036-4
   O'Regan RM, 2002, J NATL CANCER I, V94, P274, DOI 10.1093/jnci/94.4.274
   OBRIAN CA, 1989, CANCER RES, V49, P3215
   Osborne CK, 2011, ANNU REV MED, V62, P233, DOI 10.1146/annurev-med-070909-182917
   Pedram A, 2007, J BIOL CHEM, V282, P22278, DOI 10.1074/jbc.M611877200
   Razandi M, 2003, MOL CELL BIOL, V23, P1633, DOI 10.1128/MCB.23.5.1633-1646.2003
   Reid G, 2003, MOL CELL, V11, P695, DOI 10.1016/S1097-2765(03)00090-X
   Schiff R, 2005, CANCER CHEMOTH PHARM, V56, pS10, DOI 10.1007/s00280-005-0108-2
   Seo HS, 1998, INT J CANCER, V78, P760, DOI 10.1002/(SICI)1097-0215(19981209)78:6<760::AID-IJC14>3.0.CO;2-U
   Simoncini T, 2000, NATURE, V407, P538, DOI 10.1038/35035131
   Song RXD, 2010, J STEROID BIOCHEM, V118, P219, DOI 10.1016/j.jsbmb.2009.09.018
   Song RX, 2004, P NATL ACAD SCI USA, V101, P2076, DOI 10.1073/pnas.0308334100
   Song RXD, 2002, MOL ENDOCRINOL, V16, P116, DOI 10.1210/me.16.1.116
   Stoica GE, 2003, ONCOGENE, V22, P7998, DOI 10.1038/sj.onc.1206769
   Stoica GE, 2003, MOL ENDOCRINOL, V17, P818, DOI 10.1210/me.2002.0330
   Tan M, 2006, ONCOGENE, V25, P3286, DOI 10.1038/sj.onc.1209361
   Tonetti DA, 2003, BRIT J CANCER, V88, P1400, DOI 10.1038/sj.bjc.6600923
   Tonetti DA, 2000, BRIT J CANCER, V83, P782, DOI 10.1054/bjoc.2000.1326
   Tonetti DA, 2012, INT J BREAST CANC, V2012
   Watson CS, 1999, P SOC EXP BIOL MED, V220, P9, DOI 10.1046/j.1525-1373.1999.d01-2.x
   Welsh AW, 2012, CLIN CANCER RES, V18, P118, DOI 10.1158/1078-0432.CCR-11-1236
   Wijayaratne AL, 2001, J BIOL CHEM, V276, P35684, DOI 10.1074/jbc.M101097200
   Yang ZB, 2004, CLIN CANCER RES, V10, P3621, DOI 10.1158/1078-0432.CCR-0740-3
   Yao K, 2000, CLIN CANCER RES, V6, P2028
   Yudt MR, 1999, BIOCHEMISTRY-US, V38, P14146, DOI 10.1021/bi9911132
   Zhang YY, 2009, MOL CANCER RES, V7, P498, DOI 10.1158/1541-7786.MCR-08-0415
NR 55
TC 6
Z9 6
U1 3
U2 13
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1476-4598
J9 MOL CANCER
JI Mol. Cancer
PD MAY 1
PY 2013
VL 12
AR 34
DI 10.1186/1476-4598-12-34
PG 13
WC Biochemistry & Molecular Biology; Oncology
SC Biochemistry & Molecular Biology; Oncology
GA 149AX
UT WOS:000319291500001
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Maoui, A
   Kherouf, M
   Kachi, S
   Nouar, T
AF Maoui, A.
   Kherouf, M.
   Kachi, S.
   Nouar, T.
TI RETRACTED: Variographic analysis of chemical and piezometric data from
   the sandstone aquifer of Ain Oussera, Algeria (Retracted article. See
   vol. 10, 2017)
SO ARABIAN JOURNAL OF GEOSCIENCES
LA English
DT Article; Retracted Publication
DE Hydrochemistry; Ain Oussera; Geostatistics; Piezometric level; Algeria
AB The perturbation of piezometric level and the bad water quality in Ain Oussera plain represents a serious problem for local authorities and water resources managers. The spatial distribution of piezometric level and chemical data was analyzed by applying geostatistical methods, which provide an indication of the uncertainty of the estimation using the computer software VARIOWIN 2.2 (Pannatier 1996). In this paper, the evolution of the piezometric level and hydrochemical data by referring to other research campaigns was studied. Two campaigns were chosen; September 2001 and May 2008 for pizometric level and 1994 and 2004 for chemical data. In the beginning, elementary statistics has been carried out to understand the statistical distribution and performed an analysis of variance for comparison between two campaigns. Geostatistics for modeling and cartography were applied. The results showed that piezometric levels admit spherical model that the direction of groundwater flow is from southwest to northeast. High nugget effect characterizes piezometric data and chemical data, linked to the presence of microregions due to excessive pumping and local evaporitics formations. Anisotropy is observed in the northeast-southeast direction from which a spatial continuity in this direction can be deduced.
C1 [Maoui, A.; Kherouf, M.; Kachi, S.; Nouar, T.] Univ Guelma, Lab Civil Engn & Hydraul LCGH, Guelma 24000, Algeria.
RP Maoui, A (reprint author), Univ Guelma, Lab Civil Engn & Hydraul LCGH, BP 401, Guelma 24000, Algeria.
EM maoui_ammar@yahoo.fr
OI tahar, nouar/0000-0003-0626-1634
CR Ahmed S, 1985, S184 CFSG CGMM EC MI
   ANRH, 2008, AG NAT RESS HYDR PIE
   Ayad A, 1983, 84DHG018
   Baillargeon S, 2005, THESIS U LAVAL CANAD
   Caritini C, 1970, GEOLOGICAL STUDY REG, VII, p305p
   Caritini C, 1970, GEOLOGICAL STUDY REG, VI, p236p
   Chauvet P, 1992, TRAITEMENT DONNEES S, P43
   De Marsily G, 1986, QUANTITATIVE HYDROGE, P203
   DELHOMME JP, 1979, WATER RESOUR RES, V15, P269, DOI 10.1029/WR015i002p00269
   Edmunds WM, 2003, APPL GEOCHEM, V18, P805, DOI 10.1016/S0883-2927(02)00189-0
   Gratton Y, 2002, KRIGEAGE METHODE OPT
   Isaaks E.H., 1989, INTRO APPL GEOSTATIS
   Kitanidis P.K., 1997, INTRO GEOSTATISTICS, P249
   Maoui A, 2007, THESIS U ANNABA ALGE
   Maoui A, 2010, ENVIRON EARTH SCI, V60, P689, DOI 10.1007/s12665-009-0207-1
   Matheron G, 1971, CAH CTR MORPHOLOGIE, V5
   Mebrouk N, 1994, THESIS ORAN ES SENIA
   O.N.S, 2007, OFF NAT STAT QUELQ S
   Pannatier Y., 1996, VARIOWIN SOFTWARE SP
   Saibi H, 2009, ARAB J GEOSCI, V2, P83, DOI 10.1007/s12517-008-0021-1
NR 20
TC 1
Z9 1
U1 3
U2 9
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 1866-7511
EI 1866-7538
J9 ARAB J GEOSCI
JI Arab. J. Geosci.
PD MAY
PY 2013
VL 6
IS 5
BP 1307
EP 1324
DI 10.1007/s12517-011-0422-4
PG 18
WC Geosciences, Multidisciplinary
SC Geology
GA 137NQ
UT WOS:000318443000001
DA 2018-12-27
ER

PT J
AU Li, JF
   Lee, SMY
   Liu, WM
AF Li, Jianfeng
   Lee, Sandra M. Y.
   Liu, Wenmao
TI RETRACTED: Emergency response plans optimization for unexpected
   environmental pollution incidents using an open space emergency
   evacuation model (Retracted article. See vol. 95, pg. 273, 2015)
SO PROCESS SAFETY AND ENVIRONMENTAL PROTECTION
LA English
DT Article; Retracted Publication
DE Heavy gas diffusion; Numerical simulation; Crowd evacuation; Emergency
   rescue; Stochastic Markov model
ID NETWORKS
AB The objective of this research is to model the crowd evacuation process providing dynamic spatial-temporal distribution information, which can minimize the human exposure risk (death or casualties) on the population implied by a specific evacuation policy when he or she was exposed to adverse effects under accidents. An open space evacuation model based on the stochastic Markov process was introduced here to estimate the spatial-temporal distribution of the evacuees during evacuation covering the estimation of affected areas, space discretization, nodes and links creation, etc. Then, according to the solution of the Markov process providing the expected distribution of the evacuees in the nodes of the area as a function of time and the dose-response relationship, the people's health effects (e.g., death, several kinds of injuries, etc.) suffered in the evacuation process can be calculated, so that the accident's health consequence can be determined. Finally, different emergency response policies can be evaluated with corresponding health consequence, so that the emergency policy can be optimized. (C) 2012 The Institution of Chemical Engineers. Published by Elsevier B.V. All rights reserved.
C1 [Li, Jianfeng; Liu, Wenmao] Tsinghua Univ, Sch Environm, Beijing 100084, Peoples R China.
   [Lee, Sandra M. Y.] Tsinghua Univ, Sch Architecture, Beijing 100084, Peoples R China.
RP Lee, SMY (reprint author), Sch Architecture, Room 504,Tsinghua Pk, Beijing, Peoples R China.
EM 999forever@sina.com.cn
FU Critical National Natural Science Foundation of China [20937002/B07,
   20100480016]; National Natural Science Foundation for the Youth
   [41105099]
FX The study is financially supported by financially supported by the
   Critical National Natural Science Foundation of China (20937002/B07 and
   20100480016) and The National Natural Science Foundation for the Youth
   (No. 41105099).
CR Carey M, 2004, COMPUT OPER RES, V31, P1583, DOI 10.1016/S0305-0548(03)00109-6
   CHALMET LG, 1982, MANAGE SCI, V28, P86, DOI 10.1287/mnsc.28.1.86
   Feinberg W.E., 1997, J MATH SOCIOL, V20, P247
   Georgiadou PS, 2007, RELIAB ENG SYST SAFE, V92, P1388, DOI 10.1016/j.ress.2006.09.009
   HAN AF, 1990, J TRANSP ENG-ASCE, V116, P821, DOI 10.1061/(ASCE)0733-947X(1990)116:6(821)
   Hara F., 1978, Proceedings of the International Conference on Cybernetics and Society, P820
   Hobeika AG, 1998, IEEE T ENG MANAGE, V45, P192, DOI 10.1109/17.669768
   HOBEIKA AG, 1985, EMERGENCY PLANNING S, V15, P23
   Hu P., 2004, INTEGRATED SOLUTIONS
   Lan CJ, 1999, TRANSPORT RES C-EMER, V7, P305, DOI 10.1016/S0968-090X(99)00025-X
   PAPAZOGLOU IA, 1992, J LOSS PREVENT PROC, V5, P181, DOI 10.1016/0950-4230(92)80022-Z
   Rogers G.O., 1990, ORNL6615
   Seagle J. P., 1985, SIMULATION SERIES, V15, P66
   Sinkko K, 2004, RADIAT PROT DOSIM, V109, P127, DOI 10.1093/rpd/nch258
   SMITH JM, 1991, TRANSPORT RES B-METH, V25, P373
   Southworth F., 1991, ORNLTM11740
   THOMPSON PA, 1995, FIRE SAFETY J, V24, P149, DOI 10.1016/0379-7112(95)00020-T
   TNO Committee for the Prevention of Disasters, 1997, 14E CPR TNO COMM PRE
NR 18
TC 4
Z9 4
U1 3
U2 48
PU INST CHEMICAL ENGINEERS
PI RUGBY
PA 165-189 RAILWAY TERRACE, DAVIS BLDG, RUGBY CV21 3HQ, ENGLAND
SN 0957-5820
EI 1744-3598
J9 PROCESS SAF ENVIRON
JI Process Saf. Environ. Protect.
PD MAY
PY 2013
VL 91
IS 3
BP 213
EP 220
DI 10.1016/j.psep.2012.05.005
PG 8
WC Engineering, Environmental; Engineering, Chemical
SC Engineering
GA 137TA
UT WOS:000318459800006
DA 2018-12-27
ER

PT J
AU Bahadori, A
   Zendehboudi, S
   Zahedi, G
AF Bahadori, Alireza
   Zendehboudi, Sohrab
   Zahedi, Gholamreza
TI RETRACTED: A review of geothermal energy resources in Australia: Current
   status and prospects (Retracted article. See vol. 43, pg. 1469, 2015)
SO RENEWABLE & SUSTAINABLE ENERGY REVIEWS
LA English
DT Review; Retracted Publication
DE Geothermal energy; Australia; Renewable energy; Carbon emission
   reduction; Sustainable energy
ID TECHNOLOGY
AB Australia has considerable hot rock geothermal energy potential. This results from the widespread occurrence of basement rocks (granites in particular) in which heat is generated by natural radioactive decay. There are extensive areas where temperatures are estimated to reach at least 200 C at around 5 km depth. In Australia, there is also potential for lower temperature geothermal resources associated with naturally-circulating waters in aquifers deep in a number of sedimentary basins (Hot Sedimentary Aquifer Geothermal). These are potentially suitable for electricity generation and direct use.
   This paper will focus on the need to improve geothermal energy utilization in Australia, challenges facing it and the future benefits, This study shows, there is a significant potential for energy savings through greater use of geothermal energy in some regions of Australia. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Bahadori, Alireza] So Cross Univ, Sch Environm Sci & Engn, Lismore, NSW 2480, Australia.
   [Zendehboudi, Sohrab] Univ Waterloo, Dept Chem Engn, Waterloo, ON N2L 3G1, Canada.
   [Zahedi, Gholamreza] Univ Teknol Malaysia, Fac Chem Engn, Proc Syst Engn Ctr PROSPECT, Utm Johor, Malaysia.
RP Bahadori, A (reprint author), So Cross Univ, Sch Environm Sci & Engn, Lismore, NSW 2480, Australia.
EM Alireza.bahadori@scu.edu.au
RI Bahadori, Alireza/J-3868-2015
OI Bahadori, Alireza/0000-0001-7080-4299; ZAHEDI,
   GHOLAMREZA/0000-0001-8780-4287
CR ABARE (Australian Bureau of Agricultural and Resource Economics), 2009, EL GEN MAJ DEV PROJ
   ABARE (Australian Bureau of Agricultural and Resource Economics), 2010, AUSTR EN PROJ 2029 3
   Allen A, 2010, P 2010 WORLD GEOTH C, P9
   Anne-Maree Dowdn, 2011, ENERG POLICY, V39, P6301
   [Anonymous], 2008, AUSTR GOV CARB POLL
   Australian Government, 2008, CARB POLL RED SCHEM
   Australian Government Department of Resources Energy and Tourism (RET), 2008, AUSTR GEOTH IND DEV
   Australian Government Department of Resources Energy and Tourism (RET), 2008, AUSTR GEOTH IND TECH
   Badescu V, 2007, RENEW ENERG, V32, P895, DOI 10.1016/j.renene.2006.04.006
   Bahadori A, 2013, RENEW SUST ENERG REV, V18, P1, DOI 10.1016/j.rser.2012.10.003
   Barbier E, 2002, RENEW SUST ENERG REV, V6, P3, DOI 10.1016/S1364-0321(02)00002-3
   Bignall G, 2005, P 2005 WORLD GEOTH C, P7
   Cataldi R, 1999, STORIES HEATED EARTH, P580
   de Moel M, 2010, RENEW SUST ENERG REV, V14, P2683, DOI 10.1016/j.rser.2010.07.027
   Dowd AM, 2011, ENERG POLICY, V39, P6301, DOI 10.1016/j.enpol.2011.07.029
   Energy and Geoscience Institute, 2001, GEOTH EN CLEAN SUST
   Epstein CM, 1998, P 2 STOCKT INT GEOTH
   Geodynamics Ltd, 2009, PRES AUSTR GEOTH EN
   Geothermal Research Centre, 2012, EC
   Goldstein BA, 2008, GEOTHERMAL RESOURCES, V32, P79
   Habermehl R., 2002, GHC B AUSTR, V23, P20
   He MM, 2006, P EC C R STOCKT COLL
   Hepbasli A, 2003, ENERG SOURCE, V25, P667, DOI 10.1080/00908310390212381
   IEA, 2009, WORLD EN BAL
   Kagel A., 2006, HDB EXTERNALITIES EM
   Matthews C, 2009, EXPLOR GEOPHYS, V38, P260
   MIT, 2006, FUT GEOTH EN IMP ENH
   Najafi G, 2011, RENEW SUST ENERG REV, V15, P3946, DOI 10.1016/j.rser.2011.07.032
   OECD/IEA, 2009, WORLD EN OUTL 2009
   PIRSA (Primary Industries and Resources-South Australia), 2009, RAD NAT OCC RAD MAT
   Somerville M, 1994, 243 EN RES DEV CORP, P133
   WEC, 2007, SURV EN RES 2007
   Yusaf T, 2011, RENEW SUST ENERG REV, V15, P2214, DOI 10.1016/j.rser.2011.01.018
   Zahedi A, 2010, RENEW SUST ENERG REV, V14, P3252, DOI 10.1016/j.rser.2010.07.033
   Zahedi A, 2010, RENEW SUST ENERG REV, V14, P2208, DOI 10.1016/j.rser.2010.03.026
NR 35
TC 20
Z9 20
U1 2
U2 52
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1364-0321
J9 RENEW SUST ENERG REV
JI Renew. Sust. Energ. Rev.
PD MAY
PY 2013
VL 21
BP 29
EP 34
DI 10.1016/j.rser.2012.12.020
PG 6
WC GREEN & SUSTAINABLE SCIENCE & TECHNOLOGY; Energy & Fuels
SC Science & Technology - Other Topics; Energy & Fuels
GA 125JW
UT WOS:000317537100003
DA 2018-12-27
ER

PT J
AU Cao, P
   Liang, Y
   Gao, X
   Zhao, MG
   Liang, GB
AF Cao, Peng
   Liang, Yong
   Gao, Xu
   Zhao, Ming-Guang
   Liang, Guo-Biao
TI RETRACTED: Administration of MS-275 Improves Cognitive Performance and
   Reduces Cell Death Following Traumatic Brain Injury in Rats (Retracted
   article. See vol. 20, pg. 1011, 2014)
SO CNS NEUROSCIENCE & THERAPEUTICS
LA English
DT Article; Retracted Publication
DE Hippocampus; Histone deacetylase; Inflammation; Morris water maze;
   MS-275; Traumatic brain injury
ID LATERAL FLUID-PERCUSSION; HISTONE DEACETYLASE INHIBITORS; ACUTE NEURONAL
   DEGENERATION; HDAC INHIBITORS; BEHAVIORAL DEFICITS; HUNTINGTONS-DISEASE;
   FLUORO-JADE; MOUSE MODEL; HEAD-INJURY; IN-VIVO
AB Aims The MS-275 is a selective inhibitor of class I histone deacetylases (HDACs), which has been reported as a potential strategy in some central nervous system diseases associated with neurodegeneration and disturbed learning. However, its role in traumatic brain injury is not well defined. In this study, we examined the behavioralcognitive performance as well as histology outcome in adult rats to evaluate whether postinjury administration of MS-275 (15 and 45mg/kg) would provide neuroprotection benefits and ameliorate cognitive deficits following fluid percussion injury. Methods Traumatic brain injury (2.15 ATMs) was produced using a fluid percussion device with the lateral orientation. MS-275 was administered (15 and 45mg/kg) systemically once daily for 7days starting at 30min after lateral fluid percussion TBI. Acquisition of spatial learning and memory retention was assessed using the Morris water maze (MWM) on days 1014 after TBI. Brain tissues were collected and stained with Fluoro-Jade B histofluorescence (for degenerating neurons) at 24h after injury and cresyl violet (for long-term neuronal survival) on day 14 postinjury. Results Behavioral outcome after TBI revealed MS-275 treatment groups, at all doses examined, performed significantly better in the Morris Water Maze (P<0.001). Acute histology analysis demonstrated that 45mg/kg MS-275 significantly reduced the number of degenerating neurons in the ipsilateral CA23 hippocampus at 24h postinjury (P=0.007). There was a trend for MS-275 to increase the survival of neurons in the CA23 hippocampus on 14days after TBI (P=0.164). Conclusion Our present data highlight the fact that MS-275 may provide neuroprotective effect and improve cognitive performance after TBI. We concluded that MS-275 is a potential novel treatment and will have an ameliorative effect on some of the pathological features associated with TBI.
C1 [Cao, Peng; Liang, Yong; Gao, Xu; Zhao, Ming-Guang; Liang, Guo-Biao] Shenyang Northern Hosp, Dept Neurosurg, 83 Wenhua Rd, Shenyang 110018, Liaoning Provin, Peoples R China.
RP Liang, GB (reprint author), Shenyang Northern Hosp, Dept Neurosurg, 83 Wenhua Rd, Shenyang 110018, Liaoning Provin, Peoples R China.
EM liangguobiaosy@gmail.com
CR Adcock IM, 2007, BRIT J PHARMACOL, V150, P829, DOI 10.1038/sj.bjp.0707166
   Bin Z, 2008, BRAIN RES, V1226, P181
   Butler KV, 2008, CURR PHARM DESIGN, V14, P505
   Carbonnel WS, 1999, ACTA NEUROPATHOL, V98, P396, DOI 10.1007/s004010051100
   Charrueau C, 2009, J NEUROTRAUM, V26, P1911, DOI 10.1089/neu.2008.0737
   Cook AM, 2008, NUTR CLIN PRACT, V23, P608, DOI 10.1177/0884533608326060
   Dash PK, 2009, NEUROSCIENCE, V163, P1, DOI 10.1016/j.neuroscience.2009.06.028
   Dash PK, 2004, NEUROCHEM RES, V29, P1275, DOI 10.1023/B:NERE.0000023614.30084.eb
   De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321
   Deshpande LS, 2008, NEUROSCI LETT, V441, P115, DOI 10.1016/j.neulet.2008.05.113
   Dietrich WD, 2004, ACTA NEUROCHIR SUPPL, V89, P69
   DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110
   Faraco G, 2006, MOL PHARMACOL, V70, P1876, DOI 10.1124/mol.106.027912
   Faul M., 2010, TRAUMATIC BRAIN INJU
   Feng JF, 2011, BRAIN RES, V1395, P62, DOI 10.1016/j.brainres.2011.04.022
   Ferrante RJ, 2003, J NEUROSCI, V23, P9418
   Gao WM, 2006, BRAIN RES, V1070, P31, DOI 10.1016/j.brainres.2005.11.038
   Gardian G, 2005, J BIOL CHEM, V280, P556, DOI 10.1074/jbc.M410210200
   Glauben R, 2006, J IMMUNOL, V176, P5015, DOI 10.4049/jimmunol.176.8.5015
   Gurkoff GG, 2006, BRAIN RES, V1077, P24, DOI 10.1016/j.brainres.2006.01.011
   Hallam TM, 2004, J NEUROTRAUM, V21, P521, DOI 10.1089/089771504774129865
   Hamm RJ, 2001, J NEUROTRAUM, V18, P1207, DOI 10.1089/089771501317095241
   Holloway R, 2007, ACTA NEUROCHIR, V149, P919, DOI 10.1007/s00701-007-1241-y
   Kazantsev AG, 2008, NAT REV DRUG DISCOV, V7, P854, DOI 10.1038/nrd2681
   Kilgore M, 2010, NEUROPSYCHOPHARMACOL, V35, P870, DOI 10.1038/npp.2009.197
   Kim BT, 2001, J NEUROSURG, V95, P674, DOI 10.3171/jns.2001.95.4.0674
   Kim HJ, 2007, J PHARMACOL EXP THER, V321, P892, DOI 10.1124/jpet.107.120188
   Korzus E, 2004, NEURON, V42, P961, DOI 10.1016/j.neuron.2004.06.002
   KOTAPKA MJ, 1994, J NEUROTRAUM, V11, P317, DOI 10.1089/neu.1994.11.317
   Kozikowski AP, 2007, J MED CHEM, V50, P3054, DOI 10.1021/jm070178x
   Kwon SH, 2002, J BIOL CHEM, V277, P2073, DOI 10.1074/jbc.M106699200
   Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001
   Levenson JM, 2005, NAT REV NEUROSCI, V6, P108, DOI 10.1038/nrn1604
   Lin HS, 2007, BRIT J PHARMACOL, V150, P862, DOI 10.1038/sj.bjp.0707165
   Lyeth BG, 2001, EXP NEUROL, V169, P191, DOI 10.1006/exnr.2001.7643
   MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9
   Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005
   Morrison B, 2011, ANNU REV BIOMED ENG, V13, P91, DOI 10.1146/annurev-bioeng-071910-124706
   Riba-Bosch A, 2004, NEUROSCIENCE, V125, P803, DOI 10.1016/j.neuroscience.2004.02.017
   Saito A, 1999, P NATL ACAD SCI USA, V96, P4592, DOI 10.1073/pnas.96.8.4592
   Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X
   Schmued LC, 2000, TOXICOL PATHOL, V28, P91, DOI 10.1177/019262330002800111
   Simonini MV, 2006, P NATL ACAD SCI USA, V103, P1587, DOI 10.1073/pnas.0510341103
   Sinn DI, 2007, NEUROBIOL DIS, V26, P464, DOI 10.1016/j.nbd.2007.02.006
   Teasdale GM, 1998, NEUROSURGERY, V43, P723, DOI 10.1097/00006123-199810000-00001
   Thomas EA, 2009, MOL NEUROBIOL, V40, P33, DOI 10.1007/s12035-009-8067-y
   Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42
   Wang HC, 2007, EXP NEUROL, V206, P59, DOI 10.1016/j.expneurol.2007.03.031
   Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131
   Zhang ZY, 2010, NEUROSCIENCE, V169, P370, DOI 10.1016/j.neuroscience.2010.04.074
   Zhao XR, 2003, GLIA, V44, P140, DOI 10.1002/glia.10283
   Zhong CL, 2005, J NEUROTRAUM, V22, P266, DOI 10.1089/neu.2005.22.266
NR 52
TC 11
Z9 11
U1 3
U2 18
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-5930
EI 1755-5949
J9 CNS NEUROSCI THER
JI CNS Neurosci. Ther.
PD MAY
PY 2013
VL 19
IS 5
BP 337
EP 345
DI 10.1111/cns.12082
PG 9
WC Neurosciences; Pharmacology & Pharmacy
SC Neurosciences & Neurology; Pharmacology & Pharmacy
GA 133BQ
UT WOS:000318112800007
PM 23551690
DA 2018-12-27
ER

PT J
AU Negrato, CA
   Gomes, MB
AF Negrato, Carlos Antonio
   Gomes, Marilia Brito
TI RETRACTED: Historical facts of screening and diagnosing diabetes in
   pregnancy (Retracted article. See vol. 6, 59, 2014)
SO DIABETOLOGY & METABOLIC SYNDROME
LA English
DT Review; Retracted Publication
DE History of diabetes; Diabetes in pregnancy; Screening diabetes in
   pregnancy; Diagnosing diabetes in pregnancy
ID INTERNATIONAL WORKSHOP-CONFERENCE; CARBOHYDRATE-METABOLISM; PREDIABETIC
   STATE; GLUCOSE TOLERANCE; MELLITUS; RECOMMENDATIONS; HYPERGLYCEMIA;
   CRITERIA
AB Diabetes is the most common metabolic disorder affecting pregnancy. Its prevalence seems to be growing in parallel with the epidemics of overweight and obesity. Recognizing and treating diabetes or any degree of glucose intolerance in pregnancy results in lowering maternal and fetal complications. These patients present higher risk for excessive weight gain, preeclampsia, cesarean sections, a high risk of developing type 2 diabetes and cardiovascular disease in the future. Infants born to these mothers are at higher risk for macrosomia and birth trauma, and after delivery, these infants have a higher risk of developing hypoglycemia, hypocalcemia, hyperbilirubinemia, respiratory distress syndrome, polycythemia and subsequent obesity and type 2 diabetes. Despite several international workshops and a lot of research there is still no unique approach to diagnose and treat diabetes in pregnancy. Who, when and how to screen and diagnose diabetes in pregnancy has been debated in the literature for so many decades and this debate seems to be endless. We present the evolution that screening and diagnosing diabetes in pregnancy has had over time. Besides many evidence of the benefits these procedures bring, health care providers still often prefer to use alternate criteria for this purpose. The myriad of maternal and fetal complications that could be avoided with an appropriate and simple screening procedure are ignored. Robust clinical trials such as the Hyperglycemia and Adverse Pregnancy Outcomes (HAPO) study have shown how harmful can even slightly altered blood glucose levels be, but it has been found a resistance in the adoption of the new criteria proposed after this and other trials by many diabetes organizations. These organizations state that these new criteria would increase the incidence of diabetes in pregnancy, would imply in longer term follow-up of these patients and would pose an economic problem; they also state that alerting too many people in order to benefit a relatively few potential diabetics would arise psychologic ill-effects. We think that health care providers should look for an uniformity in the screening and diagnosing diabetes in pregnancy based on evidence based medicine and not on specialists consensus.
C1 [Negrato, Carlos Antonio] Baurus Diabet Assoc, Dept Internal Med, BR-17012433 Sao Paulo, Brazil.
   [Gomes, Marilia Brito] State Univ Hosp Rio de Janeiro, Dept Internal Med, Diabet Unit, Rio De Janeiro, Brazil.
RP Negrato, CA (reprint author), Baurus Diabet Assoc, Dept Internal Med, BR-17012433 Sao Paulo, Brazil.
EM carlosnegrato@uol.com.br
RI Negrato, Carlos/F-8363-2013
CR Alberti KGMM, 1998, DIABETIC MED, V15, P539, DOI 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S
   American Diabetes Association, 2009, DIABETES CARE, V32, P62
   American Diabetes Association (ADA), 2011, DIABETES CARE S1, V34, pS62, DOI DOI 10.2337/DC11-S062
   [Anonymous], 1985, Diabetes, V34 Suppl 2, P1
   [Anonymous], 1883, COMPT RENDUS SOC BIO, V5, P193
   Bennewitz HG, 1824, THESIS U BERLIN
   Brasil. Ministerio da Saude, 2010, GEST ALT RISC MAN TE, P302
   CARPENTER MW, 1982, AM J OBSTET GYNECOL, V144, P768, DOI 10.1016/0002-9378(82)90349-0
   CARRINGTON ER, 1957, OBSTET GYNECOL, V9, P664, DOI 10.1097/00006250-195706000-00008
   COLLIER E, 1991, DIABETES, V40, P197, DOI 10.2337/diabetes.40.2.197
   CONN JW, 1961, AM J MED, V31, P839, DOI 10.1016/0002-9343(61)90023-7
   Dubreuil G, 1920, COMPT RENDUS SOC BIO, V133, P1490
   Duncan JM, 1882, T OBSTET SOC LONDON, V24, P256
   FREINKEL N, 1980, DIABETES CARE, V3, P399, DOI 10.2337/diacare.3.3.399
   Graham G, 1924, Proc R Soc Med, V17, P102
   Hadden DR, 1975, CARBOHYD METABOL, P19
   HARRIS M, 1979, DIABETES, V28, P1039
   HOET JP, 1954, DIABETES, V3, P1
   Hofmeister Ztschr F, 1877, HOFMEISTER Z F, V1, P101
   JACKSON W. P. U., 1953, S AFRICAN MED JOUR, V27, P795
   JACKSON WPU, 1960, DIABETES, V9, P373, DOI 10.2337/diab.9.5.373
   Jovanovic L, 2001, JAMA-J AM MED ASSOC, V286, P2516, DOI 10.1001/jama.286.20.2516
   Knopp RH, 2002, DIABETES CARE, V25, P943, DOI 10.2337/diacare.25.5.943
   Lambie CG, 1926, J OBSTET GYN BR EMP, V33, P563
   Lecorche, 1885, ANN GYNECOL OBST, P257
   Lever JCW, 1847, GUYS HOSP REPORT, P3
   Mestman JH, 2002, ENDOCRINOLOGIST, V12, DOI 10.1097/00019616-200205000-00010
   Metzger BE, 1998, DIABETES CARE, V21, pB161
   Metzger BE, 2008, NEW ENGL J MED, V358, P1991, DOI 10.1056/NEJMoa0707943
   Metzger BE, 2007, DIABETES CARE, V30, pS251, DOI 10.2337/dc07-s225
   Metzger BE, 2010, DIABETES CARE, V33, P676, DOI 10.2337/dc09-1848
   MILLER HC, 1945, NEW ENGL J MED, V233, P376, DOI 10.1056/NEJM194509272331302
   MOSS JM, 1951, ANN INTERN MED, V34, P678, DOI 10.7326/0003-4819-34-3-678
   Negrato CA, 2010, DIABETOL METAB SYNDR, V2, DOI 10.1186/1758-5996-2-27
   OSULLIVAN JB, 1964, DIABETES, V13, P278
   PEDERSEN J, 1956, LANCET, V270, P607
   Professional Practice Committee/American Diabetes Association, 2004, DIABETES CARE S1, V27, pS5
   Reichelt Angela J., 2002, Arq Bras Endocrinol Metab, V46, P574, DOI 10.1590/S0004-27302002000500012
   Reveno WS, 1923, JAMA-J AM MED ASSOC, V81, P2001
   Skipper E, 1933, Q J MED, V2, P353
   UNGER RH, 1958, DIABETES, V7, P455, DOI 10.2337/diab.7.6.455
   Von Noorden C, 1917, ZUCKERKRANKHEIT, V4
   Walker A, 1927, P ROY SOC MED, Vxxi, P13
   WHITE P, 1949, AM J MED, V7, P609, DOI 10.1016/0002-9343(49)90382-4
   WILKERSON HLC, 1957, DIABETES, V6, P324, DOI 10.2337/diab.6.4.324
   Williams JW, 1909, AM J MED SCI, V137, P1
NR 46
TC 6
Z9 7
U1 2
U2 17
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1758-5996
J9 DIABETOL METAB SYNDR
JI Diabetol. Metab. Syndr.
PD MAY 1
PY 2013
VL 5
AR 22
DI 10.1186/1758-5996-5-22
PG 8
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 137EC
UT WOS:000318417100001
PM 23634949
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Chen, CW
   Lee, KL
   Tseng, CP
   Yang, HC
   Liu, CC
AF Chen, Cheng-Wu
   Lee, King-Ling
   Tseng, Chun-Pin
   Yang, Han-Chung
   Liu, Chia-Chi
TI RETRACTED: The Relationship between Personality Traits and Sales Force
   Automation Usage: A Preliminary Study (Retracted article. See vol. 26,
   pg. 292, 2016)
SO HUMAN FACTORS AND ERGONOMICS IN MANUFACTURING & SERVICE INDUSTRIES
LA English
DT Review; Retracted Publication
DE Pharmaceutical company; Personality traits; Human factor; Taiwanese
   enterprises; Sales force automation
ID CUSTOMER RELATIONSHIP MANAGEMENT; TECHNOLOGY ACCEPTANCE MODEL; BRIGGS
   TYPE INDICATOR; BIG 5; JOB-PERFORMANCE; 5-FACTOR MODEL;
   INFORMATION-TECHNOLOGY; DECISION-MAKING; USER ACCEPTANCE;
   PHARMACEUTICAL-INDUSTRY
AB Sales force automation (SFA) came to cognition and officially gained momentum in the 1990s (Taylor, 1993). SFA provides salespeople with speedy information access, diminishing the time needed to prepare for calls and cutting down on the number of follow-ups, particularly for urgent need of further information support (Taylor, 1993). This study attempts to look specifically at the utilizationindividual impact link. In particular, the close link of the personality type of the sales representative to the individual performance usage of the sales forces automation systems in the pharmaceutical industry in Taiwan. This study provides insight into how the personality traits of the individual medical representatives of pharmaceutical companies in Taiwan could influence the adoption of innovative technology, the sales force automation system. (c) 2012 Wiley Periodicals, Inc.
C1 [Chen, Cheng-Wu] Natl Kaohsiung Marine Univ, Inst Maritime Informat & Technol, Kaohsiung 80543, Taiwan.
   [Chen, Cheng-Wu] Natl Cheng Kung Univ, Global Earth Observat & Data Anal Ctr, Tinan, Taiwan.
   [Lee, King-Ling] Univ Maryland, Univ Coll, Adelphi, MD USA.
   [Tseng, Chun-Pin] Armaments Bur, Chung Shan Inst Sci & Technol, Tao Yuan, Taiwan.
   [Yang, Han-Chung] Shu Te Univ, Dept Leisure Recreat & Tourism Management, Kaohsiung, Taiwan.
   [Liu, Chia-Chi] Natl Kaohsiung First Univ Sci & Technol, Coll Management, Kaohsiung, Taiwan.
RP Chen, CW (reprint author), Natl Kaohsiung Marine Univ, Inst Maritime Informat & Technol, Kaohsiung 80543, Taiwan.
EM chengwu@mail.nkmu.edu.tw
FU National Science Council (NSC) of Taiwan, Republic of China [NSC
   100-2221-E-022-013-MY2, NSC 100-2628-E-022-002-MY2]
FX The author acknowledges the financial support from the National Science
   Council (NSC) of Taiwan, Republic of China, under project number NSC
   100-2221-E-022-013-MY2 and NSC 100-2628-E-022-002-MY2. The authors are
   also most grateful for the kind assistance of Professor Waldemar
   Karwowski, chief editor of Human Factors and Ergonomics in Manufacturing
   & Service Industries, and the constructive suggestions of the anonymous
   reviewers, all of which have led to making several corrections and
   suggestions that have greatly aided us in the presentation of this
   article.
CR Abbott Julie, 2001, J DATABASE MARKETING, V9, P24
   Ahearne M, 2005, IND MARKET MANAG, V34, P379, DOI 10.1016/j.indmarman.2004.09.020
   AJZEN I, 1991, ORGAN BEHAV HUM DEC, V50, P179, DOI 10.1016/0749-5978(91)90020-T
   Allik J, 1997, PERS INDIV DIFFER, V23, P809, DOI 10.1016/S0191-8869(97)00103-7
   Allport G. W., 1936, PSYCHOL MONOGR, V47, P211
   Allport G. W., 1961, PATTERN GROWTH PERSO
   Allport GW, 1937, PERSONALITY PSYCHOL
   Anton J., 2002, CUSTOMER RELATIONSHI
   Aranya N., 1986, CONTEMP ACCOUNT RES, V3, P184
   Austin EJ, 2005, PERS INDIV DIFFER, V38, P547, DOI 10.1016/j.paid.2004.05.009
   Barbaranelli C, 2003, PERS INDIV DIFFER, V34, P645, DOI 10.1016/S0191-8869(02)00051-X
   BARNETT JH, 1989, J BUS ETHICS, V8, P747, DOI 10.1007/BF00383775
   BARRICK MR, 1991, PERS PSYCHOL, V44, P1, DOI 10.1111/j.1744-6570.1991.tb00688.x
   Barrick MR, 2002, J APPL PSYCHOL, V87, P43, DOI 10.1037//0021-9010.87.1.43
   Bartlett B., 1999, PEST CONTROL, V67, P50
   BEM SL, 1981, PSYCHOL REV, V88, P369, DOI 10.1037/0033-295X.88.4.369
   Bentum R.V., 2005, DATABASE MARKETING C, V13, P28
   Berardi L. P., 2003, PHARM IND MARKET DYN
   Bhalla G., 2004, INT J MED MARKETING, V4, P370
   Blackman MC, 1998, J EXP SOC PSYCHOL, V34, P164, DOI 10.1006/jesp.1997.1347
   Blais W., 2000, STRATEGIC FINANCE, V81, P88
   Block J, 2001, J RES PERS, V35, P98, DOI 10.1006/jrpe.2000.2293
   BORKENAU P, 1992, J PERS SOC PSYCHOL, V62, P645, DOI 10.1037//0022-3514.62.4.645
   Buehrer RE, 2005, IND MARKET MANAG, V34, P389, DOI 10.1016/j.indmarman.2004.09.017
   BURGER GK, 1982, J PERS ASSESS, V46, P175, DOI 10.1207/s15327752jpa4602_13
   Burke MJ, 2009, INT J INTERCULT REL, V33, P475, DOI 10.1016/j.ijintrel.2009.05.005
   Butler F., 2001, INT J MED MARKETING, V1, P2003
   Buttle F, 2006, INT J MANAG REV, V8, P213, DOI 10.1111/j.1468-23370.2006.00128.x
   Byrne Z. E., 2004, J VOCAT BEHAV, V66, P326
   Cattell HEP, 1996, EUR REV APPL PSYCHOL, V46, P5
   Cattell R.B., 1973, PERSONALITY MOOD QUE
   Cattell R. B., 1946, DESCRIPTION MEASUREM
   Cheng M. S., 2004, J AM ACAD BUSINESS, P439
   Churchill G., 1990, SALES FORCE MANAGEME
   CHURCHILL GA, 1985, J MARKETING RES, V22, P103, DOI 10.2307/3151357
   Conte JM, 2005, HUM PERFORM, V18, P427, DOI 10.1207/s15327043hup1804_8
   Cooper A, 2000, J SOC WORK PRACT, V14, P5
   Costa Jr P. T., 1992, REVISED NEO PERSONAL
   Costa P. T., 1999, PERSONALITY PSYCHOL, V7, P29
   Costa PT, 1997, J PERS ASSESS, V68, P86, DOI 10.1207/s15327752jpa6801_7
   COSTA PT, 1976, J GERONTOL, V31, P564, DOI 10.1093/geronj/31.5.564
   COSTA PT, 1998, REVISED NEO PERSONAL
   Costello K, 1993, Nurs Manage, V24, P46
   CRON WL, 1986, J MARKETING RES, V23, P119, DOI 10.2307/3151659
   CROW SM, 1991, SEX ROLES, V25, P255, DOI 10.1007/BF00289858
   DANKO WD, 1983, J ADVERTISING RES, V23, P39
   DAVIS FD, 1989, MANAGE SCI, V35, P982, DOI 10.1287/mnsc.35.8.982
   DAVIS FD, 1989, MIS QUART, V13, P319, DOI 10.2307/249008
   Deeter-Schmelz DR, 2007, J MARKET THEORY PRAC, V15, P145, DOI 10.2753/MTP1069-6679150204
   DeFruyt F, 1997, PERS INDIV DIFFER, V23, P87, DOI 10.1016/S0191-8869(97)00004-4
   DeLone WH, 1992, INFORM SYST RES, V3, P60, DOI 10.1287/isre.3.1.60
   DICKERSON MD, 1983, J CONSUM RES, V10, P225, DOI 10.1086/208961
   DIGMAN JM, 1981, MULTIVAR BEHAV RES, V16, P149, DOI 10.1207/s15327906mbr1602_2
   DIGMAN JM, 1990, ANNU REV PSYCHOL, V41, P417, DOI 10.1146/annurev.ps.41.020190.002221
   Dole D., 2001, MANAGERIAL AUDITING, V16, P234
   DOLLINGER SJ, 1991, J RES PERS, V25, P276, DOI 10.1016/0092-6566(91)90020-Q
   ECCLES JS, 1987, PSYCHOL WOMEN QUART, V11, P135, DOI 10.1111/j.1471-6402.1987.tb00781.x
   Engle RL, 2000, J BUS IND MARK, V15, P216, DOI 10.1108/08858620010335083
   Erffmeyer R. C., 2001, J PERSONAL SELLING S, V21, P167
   Eysenck H. J., 1967, BIOL BASIS PERSONALI
   EYSENCK HJ, 1992, PERS INDIV DIFFER, V13, P667, DOI 10.1016/0191-8869(92)90237-J
   EYSENCK HJ, 1991, PERS INDIV DIFFER, V12, P773, DOI 10.1016/0191-8869(91)90144-Z
   Faraj S, 2000, MANAGE SCI, V46, P1554, DOI 10.1287/mnsc.46.12.1554.12072
   Feig N., 2005, COMMUNITY BANKER, V14, P34
   Field A., 2003, HARVARD MANAGEMENT C, P3
   FILSINGER EE, 1979, J PSYCHOL, V102, P275, DOI 10.1080/00223980.1979.9923499
   FISKE DW, 1949, J ABNORM SOC PSYCH, V44, P329, DOI 10.1037/h0057198
   Fleeson W, 1998, J RES PERS, V32, P411, DOI 10.1006/jrpe.1998.2229
   Fornaciari C. J., 2000, ACAD MANAGEMENT P ME, pB1
   Frank RE, 1964, P AM MARK ASS, P312
   FUNDER DC, 1987, J PERS SOC PSYCHOL, V52, P409, DOI 10.1037//0022-3514.52.2.409
   Funder DC, 1997, HDB PERSONALITY PSYC, P617, DOI DOI 10.1016/B978-012134645-4/50025-1
   Fung K. B., 2000, THESIS NATL TAIWAN U
   Furnham A, 2004, PERS INDIV DIFFER, V36, P705, DOI 10.1016/S0191-8869(03)00128-4
   Galton F., 1884, FORTNIGHTLY REV, V36, P179
   Goldberg L. R., 1999, PERSONALITY PSYCHOL, V7, P7, DOI DOI 10.1016/J.JRP.2014.05.003
   Goldberg LR, 2006, J RES PERS, V40, P84, DOI 10.1016/j.jrp.2005.08.007
   GOLDBERG LR, 1990, J PERS SOC PSYCHOL, V59, P1216, DOI 10.1037/0022-3514.59.6.1216
   GOLDBERG LR, 1993, AM PSYCHOL, V48, P26, DOI 10.1037/0003-066X.48.1.26
   GOODHUE DL, 1995, MIS QUART, V19, P213, DOI 10.2307/249689
   GUILFORD JB, 1959, PERSONALITY
   HARRIS EE, 1967, SOCIOL QUART, V8, P543
   Harris JA, 2003, PERS INDIV DIFFER, V35, P1903, DOI 10.1016/S0191-8869(03)00039-4
   Harrison DA, 1997, INFORM SYST RES, V8, P171, DOI 10.1287/isre.8.2.171
   HARTWICK J, 1994, MANAGE SCI, V40, P440, DOI 10.1287/mnsc.40.4.440
   HARVEY RJ, 1994, J PERS ASSESS, V62, P116, DOI 10.1207/s15327752jpa6201_11
   HARVEY RJ, 1994, J PERS ASSESS, V63, P181, DOI 10.1207/s15327752jpa6301_15
   Hashem G, 2007, TOTAL QUAL MANAG BUS, V18, P631, DOI 10.1080/14783360701349435
   Hirsh JB, 2008, J RES PERS, V42, P1323, DOI 10.1016/j.jrp.2008.04.006
   Hodson G, 1999, J RES PERS, V33, P253, DOI 10.1006/jrpe.1999.2244
   Hogan R, 1996, AM PSYCHOL, V51, P469, DOI 10.1037//0003-066X.51.5.469
   Hung YC, 2005, IND MANAGE DATA SYST, V105, P164, DOI 10.1109/02635570510583307
   Ilie V, 2005, INF RESOUR MANAG J, V18, P13, DOI 10.4018/irmj.2005070102
   Ingram TN, 2002, IND MARKET MANAG, V31, P559, DOI 10.1016/S0019-8501(02)00175-X
   Jackson T. W., 2005, DATABASE MARKETING C, V13, P76
   Jain VK, 1996, PSYCHOL REP, V78, P938, DOI 10.2466/pr0.1996.78.3.938
   JOHNSON JL, 1995, PERS INDIV DIFFER, V18, P127, DOI 10.1016/0191-8869(94)00109-6
   Jones E., 2002, J PERSONAL SELLING S, V22, P145, DOI DOI 10.1080/08853134.2002.10754303
   Judge TA, 1999, PERS PSYCHOL, V52, P621, DOI 10.1111/j.1744-6570.1999.tb00174.x
   Karahanna E, 1999, MIS QUART, V23, P183, DOI 10.2307/249751
   KATZ E, 1963, AM SOCIOL REV, V28, P237, DOI 10.2307/2090611
   Keillor B. D., 1997, J BUS IND MARK, V12, P209
   King SF, 2008, IND MARKET MANAG, V37, P421, DOI 10.1016/j.indmarman.2007.02.005
   Kornor H, 2004, SCAND J PSYCHOL, V45, P49, DOI 10.1111/j.1467-9450.2004.00377.x
   KRUG SE, 1986, PSYCHOL REP, V59, P683, DOI 10.2466/pr0.1986.59.2.683
   LAMONT LM, 1977, J MARKETING RES, V14, P517, DOI 10.2307/3151192
   Landry TD, 2005, J PERS SELL SALES M, V25, P231, DOI 10.1080/08853134.2005.10749061
   Lee DG, 2006, PERS INDIV DIFFER, V40, P27, DOI 10.1016/j.paid.2005.05.010
   Lifelong Learning, 2005, MARKET REPORT, V10, P1
   Mabon H, 1998, HUM PERFORM, V11, P289, DOI 10.1207/s15327043hup1102&3_9
   Markus ML, 2001, J MANAGE INFORM SYST, V18, P57
   Maslow A., 1954, MOTIVATION PERSONALI
   Mathieson K, 1991, INFORM SYST RES, V2, P173, DOI 10.1287/isre.2.3.173
   Matthews G, 1998, PERSONALITY TRAITS
   McCrae R. R, 2003, PERSONALITY ADULTHOO
   McCrae R. R., 1996, 5 FACTOR MODEL PERSO, P51
   McCrae RR, 2004, J RES PERS, V38, P179, DOI 10.1016/S0092-6566(03)00056-4
   McCrae RR, 2004, PERS INDIV DIFFER, V36, P587, DOI 10.1016/S0191-8869(03)00118-1
   MCCRAE RR, 1992, J PERS, V60, P175, DOI 10.1111/j.1467-6494.1992.tb00970.x
   McCrae RR, 2002, J RES PERS, V36, P307, DOI 10.1016/S0092-6566(02)00011-9
   MCCRAE RR, 1993, J PERS, V61, P1, DOI 10.1111/j.1467-6494.1993.tb00276.x
   MCCRAE RR, 1991, J COUNS DEV, V69, P367, DOI 10.1002/j.1556-6676.1991.tb01524.x
   McCrae RR, 2002, 5 FACTOR MODEL PERSO
   MCDANIEL MA, 1988, J APPL PSYCHOL, V73, P327, DOI 10.1037/0021-9010.73.2.327
   McDonald M., 2007, TRAVEL WEEKLY, V66, P17
   MCENRUE MP, 1988, ACAD MANAGE J, V31, P175, DOI 10.2307/256504
   McGovern T., 2004, BENEFITS Q, V20, P26
   McGrew G., 1995, NATIONS RESTAURANT N, V29, P32
   McKim B., 2000, J DATABASE MARKETING, V8, P224
   McLarney-Vesotski AR, 2006, J RES PERS, V40, P652, DOI 10.1016/j.jrp.2005.07.001
   McPherson B., 1999, BUSINESS COMMUNICATI, V62, P46
   Meyer M, 2005, J STRATEG MARK, V13, P175, DOI 10.1080/09652540500171357
   Midgley D. F., 1983, J CONSUM RES, V4, P229
   MILLER A, 1991, PERSONALITY TYPES MO
   Miller P., 1999, CATALOG AGE, V16, P49
   Minton H. L., 1980, DIFFERENTIAL PSYCHOL
   Mirels HL, 1998, PERS INDIV DIFFER, V25, P663, DOI 10.1016/S0191-8869(98)00084-1
   MONCRIEF WC, 1986, J MARKETING RES, V23, P261
   Morahan-Martin J., 1998, CYBERPSYCHOLOGY BEHA, V1, P3, DOI DOI 10.1089/CPB.1998.1.3
   Morgan AJ, 2001, IND MARKET MANAG, V30, P463, DOI 10.1016/S0019-8501(99)00115-7
   Morris MG, 2000, PERS PSYCHOL, V53, P375, DOI 10.1111/j.1744-6570.2000.tb00206.x
   Mount MK, 1998, HUM PERFORM, V11, P145, DOI 10.1207/s15327043hup1102&3_3
   Mustonen-Ollila E, 2003, INFORM SYST J, V13, P275, DOI 10.1046/j.1365-2575.2003.00141.x
   Neuman GA, 1998, J BUS PSYCHOL, V13, P263, DOI 10.1023/A:1022963108025
   Nieszczezewski J, 1996, Nurs Manage, V27, P58
   Nordvik H, 1998, SCAND J PSYCHOL, V39, P61, DOI 10.1111/1467-9450.00057
   NORMAN WT, 1963, J ABNORM PSYCHOL, V66, P574, DOI 10.1037/h0040291
   Nourayi M. M., 1993, J ED BUSINESS, V69, P111, DOI DOI 10.1080/08832323.1993.10117667
   O'Hara Bradley S., 1991, J PERSONAL SELLING S, V11, P61
   Olver JM, 2003, PERS INDIV DIFFER, V35, P109, DOI 10.1016/S0191-8869(02)00145-9
   Parks L, 2009, PERS INDIV DIFFER, V47, P675, DOI 10.1016/j.paid.2009.06.002
   PARTHASARATHY M, 1997, J BUS IND MARK, V12, P196, DOI DOI 10.1108/08858629710188036
   PAUNONEN SV, 1989, J PERS SOC PSYCHOL, V56, P823, DOI 10.1037//0022-3514.56.5.823
   Paunonen SV, 2001, J RES PERS, V35, P78, DOI 10.1006/jrpe.2000.2309
   PEABODY D, 1989, J PERS SOC PSYCHOL, V57, P552, DOI 10.1037/0022-3514.57.3.552
   PETERS MP, 1973, J MARKETING RES, V10, P312, DOI 10.2307/3149701
   Petersen G. S., 1997, HIGH IMPACT SALES FO
   Pierce D., 2005, PROF SAF, V50, P42
   Plank Richard E, 1994, J PERSONAL SELLING S, V14, P43
   Pulkkinen L, 1996, J PERS SOC PSYCHOL, V70, P1288, DOI 10.1037/0022-3514.70.6.1288
   Pullig C, 2002, J BUS RES, V55, P401, DOI 10.1016/S0148-2963(00)00159-4
   Rasmusson E, 1999, SALES MARK MANAG, V151, P34
   Raymark PH, 1997, PERS PSYCHOL, V50, P723, DOI 10.1111/j.1744-6570.1997.tb00712.x
   Raymond M, 1994, MAINTAINING CUSTOMER, V14, P67
   RICE GH, 1989, J OCCUP PSYCHOL, V62, P177, DOI 10.1111/j.2044-8325.1989.tb00488.x
   Ricks J., 1998, J MARKETING MANAGEME, V8, P7
   Robertson T. S., 1971, INNOVATIVE BEHAV COM
   ROBERTSON TS, 1967, J MARKETING, V31, P14, DOI 10.2307/1249295
   ROBERTSON TS, 1984, CONSUMER BEHAV
   Robins RW, 1996, J PERS SOC PSYCHOL, V70, P157, DOI 10.1037/0022-3514.70.1.157
   Robinson, 2000, CUSTOMER RELATIONSHI, V34, P67
   Robinson DF, 2003, HEALTH CARE MANAGE R, V28, P68, DOI 10.1097/00004010-200301000-00008
   Rogers E. M., 1983, DIFFUSION INNOVATION
   Romano NC, 2001, INT J ELECTRON COMM, V6, P61, DOI 10.1080/10864415.2001.11044232
   Rombel A., 2001, GLOBAL FINANCE, V15, P37
   ROTHSTEIN MG, 1994, J EDUC PSYCHOL, V86, P516, DOI 10.1037/0022-0663.86.4.516
   Rowley J., 2005, MARKETING REV, V5, P175
   Ryals L, 2005, J MARKETING, V69, P252, DOI 10.1509/jmkg.2005.69.4.252
   SAGER JK, 1986, IND MARKET MANAG, V15, P319, DOI 10.1016/0019-8501(86)90024-6
   Salgado JF, 1997, J APPL PSYCHOL, V82, P30, DOI 10.1037/0021-9010.82.1.30
   SAUCIER G, 1994, J PERS ASSESS, V63, P506, DOI 10.1207/s15327752jpa6303_8
   SAXE R, 1982, J MARKETING RES, V19, P343, DOI 10.2307/3151568
   SCHMIDT FL, 1986, J APPL PSYCHOL, V71, P432, DOI 10.1037/0021-9010.71.3.432
   Schnabl H., 1991, J EVOLUTIONARY EC, V1, P65
   Schultz RJ, 2000, J BUS IND MARK, V15, P200, DOI 10.1108/08858620010335056
   SCHUTTENBERG EM, 1990, CAREER DEV Q, V39, P60, DOI 10.1002/j.2161-0045.1990.tb00236.x
   Seis T. F., 1970, J COUNS PSYCHOL, V17, P27
   SHEPPARD BH, 1988, J CONSUM RES, V15, P325, DOI 10.1086/209170
   Shih CF, 2004, J MARKETING, V68, P59, DOI 10.1509/jmkg.68.1.59.24029
   Singh J, 2000, J MARKETING, V64, P15, DOI 10.1509/jmkg.64.2.15.17998
   Smith PC, 1955, J APPL PSYCHOL, V39, P322, DOI 10.1037/h0043258
   Soldz S, 1999, J RES PERS, V33, P208, DOI 10.1006/jrpe.1999.2243
   Speier C, 2002, J MARKETING, V66, P98, DOI 10.1509/jmkg.66.3.98.18510
   Stevens C, 2003, J PERSONAL SELLING S, V23, P23
   Strack S, 1999, J PERS ASSESS, V72, P426, DOI 10.1207/S15327752JP720307
   Tamosiuniere R., 2007, J BUS ECON MANAG, V8, P67
   Tanner JF, 2005, J PERS SELL SALES M, V25, P169, DOI 10.1080/08853134.2005.10749057
   TASHAKKORI A, 1991, GENET SOC GEN PSYCH, V117, P133
   TAYLOR JW, 1977, J MARKETING RES, V14, P104, DOI 10.2307/3151066
   Taylor S, 1995, MIS QUART, V19, P561, DOI 10.2307/249633
   Taylor T. C., 1994, SALES PROCESS EN DEC, P19
   TETT RP, 1991, PERS PSYCHOL, V44, P703
   Thomas A., 2000, J PSYCHOL TYPE, V55, P35
   Tomal D., 1992, SUPERVISION, V53, P12
   Tupes E. C., 1961, 6197 USAF ASD, P61
   Turnball P. W., 1980, EUR J MARKETING, V14, P31
   Urbanskiene R, 2008, INZ EKON, P51
   Vargo SL, 2004, J MARKETING, V68, P1, DOI 10.1509/jmkg.68.1.1.24036
   Venkatesh V, 2003, MIS QUART, V27, P425
   Venkatesh V, 2000, INFORM SYST RES, V11, P342, DOI 10.1287/isre.11.4.342.11872
   Venkatesh V, 2000, ORGAN BEHAV HUM DEC, V83, P33, DOI 10.1006/obhd.2000.2896
   Wainwright DW, 2007, J INF TECHNOL, V22, P44, DOI 10.1057/palgrave.jit.2000093
   WATSON D, 1989, J PERS SOC PSYCHOL, V57, P120, DOI 10.1037/0022-3514.57.1.120
   WATSON D, 1984, PSYCHOL BULL, V96, P465, DOI 10.1037//0033-2909.96.3.465
   WEED SE, 1976, J APPL PSYCHOL, V61, P58, DOI 10.1037/0021-9010.61.1.58
   WEITZ BA, 1981, J MARKETING, V45, P85, DOI 10.2307/1251723
   Westphal JD, 1997, ADMIN SCI QUART, V42, P366, DOI 10.2307/2393924
   WILLIAMS RL, 1995, J PERS ASSESS, V64, P494, DOI 10.1207/s15327752jpa6403_8
   Wu K, 2008, PERS INDIV DIFFER, V44, P656, DOI 10.1016/j.paid.2007.09.025
   Zack MH, 1999, CALIF MANAGE REV, V41, P125, DOI 10.2307/41166000
   Zinkhan G. M., 1993, J MARKETING, V57, P130
   Zoltners A. A., 2001, COMPLETE GUIDE ACCEL
NR 222
TC 11
Z9 11
U1 3
U2 29
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1090-8471
EI 1520-6564
J9 HUM FACTOR ERGON MAN
JI Hum. Factors Ergonom. Manuf. Serv. Ind.
PD MAY-JUN
PY 2013
VL 23
IS 3
BP 243
EP 253
DI 10.1002/hfm.20313
PG 11
WC Engineering, Manufacturing; Ergonomics
SC Engineering
GA 129QM
UT WOS:000317856800008
DA 2018-12-27
ER

PT J
AU Hosien, MA
   Selim, SM
AF Hosien, M. A.
   Selim, S. M.
TI RETRACTED: Experimental study of cavitation criterion in centrifugal
   pumps (Retracted article. See vol. 17, pg. 87, 2014)
SO JOURNAL OF VISUALIZATION
LA English
DT Article; Retracted Publication
DE Cavitation inception; Net positive suction head; Visualization
AB Pumps are designed and manufactured to operate far from the cavitation condition. Pump designers define the cavitation inception point as the point where the head drops by 3 %. This definition is incorrect, because the first appearance of vapour bubbles is observed earlier than 3 % drop in the head. Therefore, using 3 % drop in head, as indication parameter for cavitation inception has always resulted in damage in pumps during operation. This paper describes visual studies conducted to determine the variation of net positive suction head with flow rate, rotational speed and water temperature. The experiments showed that the visual incipient of cavitation in the pump was existed long before drop in pump head occurs. A special correlation between the visual inception cavitation net positive suction head and net positive suction head corresponding to 3 % drop in head was developed at various operating conditions.
C1 [Hosien, M. A.; Selim, S. M.] Minoufiya Univ, Fac Engn, Dept Power Mech Engn, Shibin Al Kawm, Egypt.
RP Hosien, MA (reprint author), Minoufiya Univ, Fac Engn, Dept Power Mech Engn, Shibin Al Kawm, Egypt.
EM mohamed_abdelaziz14@yahoo.com
CR Alfayez L, 2004, P 26 EUR C AC EM TES, P15
   El-kadi MA, 2001, ENG RES J HELWAN U, V77, P200
   Hirschi R, 1998, J FLUID ENG-T ASME, V120, P705, DOI 10.1115/1.2820727
   Hofmann M., 2001, P 4 INT S CAV CAV 01
   McNulty PJ, 1982, J FLUIDS ENG
   SLOTEMAN DP, 2007, P 23 INT PUMP US S T, P29
   Wulff DL, 2006, ED NOTES, P1
   Yamaguchi H, 1983, 2ND IME C CAV EDIN, P167
NR 8
TC 3
Z9 3
U1 2
U2 52
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1343-8875
EI 1875-8975
J9 J VISUAL-JAPAN
JI J. Vis.
PD MAY
PY 2013
VL 16
IS 2
BP 99
EP 110
DI 10.1007/s12650-012-0149-7
PG 12
WC Computer Science, Interdisciplinary Applications; Imaging Science &
   Photographic Technology
SC Computer Science; Imaging Science & Photographic Technology
GA 127GZ
UT WOS:000317687300002
DA 2018-12-27
ER

PT J
AU Gao, Y
   Huang, CQ
   Zhao, KX
   Ma, LY
   Qiu, X
   Zhang, L
   Xiu, Y
   Chen, L
   Lu, W
   Huang, CX
   Tang, Y
   Xiao, Q
AF Gao, Yuan
   Huang, Changquan
   Zhao, Kexiang
   Ma, Louyan
   Qiu, Xuan
   Zhang, Lei
   Xiu, Yun
   Chen, Lin
   Lu, Wei
   Huang, Chunxia
   Tang, Yong
   Xiao, Qian
TI RETRACTED: Depression as a risk factor for dementia and mild cognitive
   impairment: a meta-analysis of longitudinal studies (Retracted article.
   See vol. 30, pg. 435, 2015)
SO INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY
LA English
DT Review; Retracted Publication
DE depression; dementia; mild cognitive impairment; meta-analysis
ID ALZHEIMERS-DISEASE; SYMPTOMS; COMMUNITY; COHORT; EPIDEMIOLOGY; HEALTH
AB Background This study examined whether depression was a risk factor for onset of dementia including Alzheimer's disease (AD), vascular dementia (VD) and any dementia, and mild cognitive impairment (MCI) by using a quantitative meta-analysis of longitudinal studies. Methods EMBASE and MEDLINE were searched for articles published up to February 2011. All studies that examined the relationship between depression and the onset of dementia or MCI were included. Pooled relative risk was calculated using fixed-effects models. Results Twelve studies met our inclusion criteria for this meta-analysis. All subjects were without dementia or MCI at baseline. Four, two, five, and four studies compared the incidence of AD, VD, any dementia, and MCI between subjects with or without depression, respectively. After pooling all the studies, subjects with depression had higher incidence of AD (relative risk (RR):1.66, 95% confidence interval (CI): 1.292.14), VD (RR: 1.89, 95% CI: 1.193.01), any dementia (RR: 1.55, 95% CI: 1.312.83), and MCI (RR: 1.97, 95% CI: 1.532.54) than those without depression. Conclusions The quantitative meta-analysis showed that depression was a major risk factor for incidence of dementia (including AD, VD, and any dementia) and MCI. Copyright (c) 2012 John Wiley & Sons, Ltd.
C1 [Gao, Yuan; Huang, Changquan; Zhao, Kexiang; Ma, Louyan; Xiao, Qian] Chongqing Med Univ, Dept Geriatr, Affiliated Hosp 1, Chongqing, Peoples R China.
   [Huang, Changquan] Third Hosp Mianyang, Dept Geriatr, Mianyang, Sichuan, Peoples R China.
   [Ma, Louyan] Ninth Hosp XiAn, Dept Geriatr, Xian, Shanxi, Peoples R China.
   [Qiu, Xuan; Zhang, Lei; Chen, Lin; Lu, Wei; Tang, Yong] Chongqing Med Univ, Lab Stem Cells & Tissue Engn, Chongqing, Peoples R China.
   [Qiu, Xuan; Zhang, Lei; Chen, Lin; Lu, Wei; Tang, Yong] Chongqing Med Univ, Dept Histol & Embryol, Chongqing, Peoples R China.
   [Xiu, Yun] Chongqing Med Univ, Inst Life Sci, Chongqing, Peoples R China.
   [Huang, Chunxia] Chongqing Med Univ, Dept Physiol, Chongqing, Peoples R China.
RP Xiao, Q (reprint author), Chongqing Med Univ, Dept Geriatr, Affiliated Hosp 1, Chongqing, Peoples R China.
EM xiaoqian1956@126.com
FU Key Projects of Medical Science; Chongqing Municipal Health Bureau in
   China [2010-1-8]; Natural Science Foundation of Chongqing in China
   (CSTC) [2010BB5396]; National Foundation of Natural Science of China
   [81170752]
FX This work was funded by the Key Projects of Medical Science sponsored by
   Chongqing Municipal Health Bureau in China (2010-1-8) and by the Natural
   Science Foundation of Chongqing in China (CSTC, 2010BB5396). The study
   is also supported by the National Foundation of Natural Science of China
   (No. 81170752).
CR Becker JT, 2009, AM J GERIAT PSYCHIAT, V17, P653, DOI 10.1097/JGP.0b013e3181aad1fe
   Biessels GJ, 2006, LANCET NEUROL, V5, P64, DOI 10.1016/S1474-4422(05)70284-2
   Bruscoli M, 2004, INT PSYCHOGERIATR, V16, P129, DOI 10.1017/S1041610204000092
   Cervilla JA, 2000, J NEUROL NEUROSUR PS, V68, P622, DOI 10.1136/jnnp.68.5.622
   Cole MG, 1999, AM J PSYCHIAT, V156, P1182
   Dal Forno G, 2005, ANN NEUROL, V57, P381, DOI 10.1002/ana.20405
   Diaz-Ruiz C, 2009, ARDIOVASC PSYCHIAT N
   Ferri CP, 2005, LANCET, V366, P2112, DOI 10.1016/S0140-6736(05)67889-0
   Gaugler JE, 2005, PSYCHOL AGING, V20, P100, DOI 10.1037/0882-7974.20.1.100
   Hebert R, 2000, STROKE, V31, P1487, DOI 10.1161/01.STR.31.7.1487
   Huang CQ, 2011, INT PSYCHOGERIATR, V23, P516, DOI 10.1017/S1041610210000049
   Khedr EM, 2009, NEUROPSYCH DIS TREAT, V5, P103
   Leung Justin W. C., 2003, Current Drug Targets - CNS and Neurological Disorders, V2, P363, DOI 10.2174/1568007033482715
   Lindeboom J, 2004, EUR J PHARMACOL, V490, P83, DOI 10.1016/j.ejphar.2004.02.046
   Lindsay J, 2002, AM J EPIDEMIOL, V156, P445, DOI 10.1093/aje/kwf074
   Livingston G, 2008, J NEUROL NEUROSUR PS, V79, P641, DOI 10.1136/jnnp.2007.126706
   Mezuk B, 2008, DIABETES CARE, V31, P2383, DOI 10.2337/dc08-0985
   Muller M, 2007, DEMENT GERIATR COGN, V24, P185, DOI 10.1159/000105927
   Ng TP, 2009, J AM GERIATR SOC, V57, P1058, DOI 10.1111/j.1532-5415.2009.02262.x
   Paillard-Borg S, 2009, DEMENT GERIATR COGN, V28, P136, DOI 10.1159/000235576
   Panza F, 2008, INT J GERIATR PSYCH, V23, P726, DOI 10.1002/gps.1967
   Reitz C, 2011, NAT REV NEUROL, V7, P137, DOI 10.1038/nrneurol.2011.2
   Saczynski JS, 2010, NEUROLOGY, V75, P35, DOI 10.1212/WNL.0b013e3181e62138
   STEWART AL, 1993, J CONSULT CLIN PSYCH, V61, P849, DOI 10.1037/0022-006X.61.5.849
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Tyas SL, 2001, INT J EPIDEMIOL, V30, P590, DOI 10.1093/ije/30.3.590
   Wilkosz PA, 2006, AM J GERIAT PSYCHIAT, V14, P352, DOI 10.1097/01.JGP.0000192500.25940.1b
NR 27
TC 69
Z9 72
U1 3
U2 74
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0885-6230
EI 1099-1166
J9 INT J GERIATR PSYCH
JI Int. J. Geriatr. Psychiatr.
PD MAY
PY 2013
VL 28
IS 5
BP 441
EP 449
DI 10.1002/gps.3845
PG 9
WC Geriatrics & Gerontology; Gerontology; Psychiatry
SC Geriatrics & Gerontology; Psychiatry
GA 123BO
UT WOS:000317363400001
PM 22815126
DA 2018-12-27
ER

PT J
AU Lee, BS
   Dekker, JD
   Lee, BK
   Iyer, VR
   Sleckman, BP
   Arthur, LS
   Ippolito, GC
   Tucker, PW
AF Lee, Baeck-seung
   Dekker, Joseph D.
   Lee, Bum-kyu
   Iyer, Vishwanath R.
   Sleckman, Barry P.
   Shaffer, Arthur L., III
   Ippolito, Gregory C.
   Tucker, Philip W.
TI RETRACTED: The BCL11A Transcription Factor Directly Activates RAG Gene
   Expression and V(D)J Recombination (Retracted article. See vol. 37, art
   no e00358-17, 2017)
SO MOLECULAR AND CELLULAR BIOLOGY
LA English
DT Article; Retracted Publication
ID B-CELL DEVELOPMENT; ZINC-FINGER PROTEIN; CHRONIC LYMPHOCYTIC-LEUKEMIA;
   PRE-B; LYMPHOID DEVELOPMENT; T-LYMPHOCYTES; DIFFERENTIATION; PROMOTER;
   MICE; CANCER
AB Recombination-activating gene 1 protein (RAG1) and RAG2 are critical enzymes for initiating variable-diversity-joining (VDJ) segment recombination, an essential process for antigen receptor expression and lymphocyte development. The transcription factor BCL11A is required for B cell development, but its molecular function(s) in B cell fate specification and commitment is unknown. We show here that the major B cell isoform, BCL11A-XL, binds the RAG1 promoter and Erag enhancer to activate RAG1 and RAG2 transcription in pre-B cells. We employed BCL11A overexpression with recombination substrates in a cultured pre-B cell line as well as Cre recombinase-mediated Bcl11a(lox/lox) deletion in explanted murine pre-B cells to demonstrate direct consequences of BCL11A/RAG modulation on V(D)J recombination. We conclude that BCL11A is a critical component of a transcriptional network that regulates B cell fate by controlling V(D)J recombination.
C1 [Lee, Baeck-seung; Dekker, Joseph D.; Lee, Bum-kyu; Iyer, Vishwanath R.; Ippolito, Gregory C.; Tucker, Philip W.] Univ Texas Austin, Inst Cellular & Mol Biol, Austin, TX 78712 USA.
   [Sleckman, Barry P.] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO USA.
   [Shaffer, Arthur L., III] NCI, Metab Branch, Ctr Canc Res, Bethesda, MD 20892 USA.
RP Tucker, PW (reprint author), Univ Texas Austin, Inst Cellular & Mol Biol, Austin, TX 78712 USA.
EM philtucker@mail.utexas.edu
RI Dekker, Joseph/G-4924-2013
OI Dekker, Joseph/0000-0002-2068-3529; Ippolito,
   Gregory/0000-0002-7565-7002
FU NIH [F32-CA110624, RO1-CA31534]; Cancer Prevention Research Institute
   [CPRIT RP100612]; Marie Betzner Morrow Endowment
FX G.C.I. acknowledges support from NIH grant F32-CA110624, and P.W.T.
   acknowledges support from NIH grant RO1-CA31534, the Cancer Prevention
   Research Institute (grant CPRIT RP100612), and the Marie Betzner Morrow
   Endowment.
CR Amin RH, 2008, NAT IMMUNOL, V9, P613, DOI 10.1038/ni.1612
   Angelin-Duclos C, 1998, MOL CELL BIOL, V18, P6253, DOI 10.1128/MCB.18.11.6253
   Avram D, 2000, J BIOL CHEM, V275, P10315, DOI 10.1074/jbc.275.14.10315
   Bond HM, 2004, BLOOD, V103, P2062, DOI 10.1182/blood-2003-07-2388
   Borghesi L, 2005, J EXP MED, V202, P1669, DOI 10.1084/jem.20051190
   Bredemeyer AL, 2006, NATURE, V442, P466, DOI 10.1038/nature04866
   Brown ST, 1997, J IMMUNOL, V158, P5071
   Chen ZS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020475
   Cismasiu VB, 2005, ONCOGENE, V24, P6753, DOI 10.1038/sj.onc.1208904
   Corcoran AE, 1996, EMBO J, V15, P1924, DOI 10.1002/j.1460-2075.1996.tb00543.x
   Corcoran AE, 1998, NATURE, V391, P904, DOI 10.1038/36122
   Dengler HS, 2008, NAT IMMUNOL, V9, P1388, DOI 10.1038/ni.1667
   FELL HP, 1986, SCIENCE, V232, P491, DOI 10.1126/science.3961491
   Fitzsimmons SP, 2007, J IMMUNOL, V179, P5264, DOI 10.4049/jimmunol.179.8.5264
   Fu WJJ, 2006, COMPUT BIOL CHEM, V30, P21, DOI 10.1016/j.compbiolchem.2005.10.005
   Fuller K, 1997, MOL IMMUNOL, V34, P939, DOI 10.1016/S0161-5890(97)00000-X
   Goldmit M, 2005, NAT IMMUNOL, V6, P198, DOI 10.1038/ni1154
   Hsu LY, 2003, IMMUNITY, V19, P105, DOI 10.1016/S1074-7613(03)00181-X
   Hu H, 2006, NAT IMMUNOL, V7, P819, DOI 10.1038/ni1358
   Inoue J, 2006, J IMMUNOL, V176, P5871, DOI 10.4049/jimmunol.176.10.5871
   Kishi H, 2002, BLOOD, V99, P576, DOI 10.1182/blood.V99.2.576
   Laszkiewicz A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044807
   Lauring J, 1999, MOL CELL BIOL, V19, P2601
   LIN WC, 1994, P NATL ACAD SCI USA, V91, P2733, DOI 10.1073/pnas.91.7.2733
   Liu H, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-18
   Liu PT, 2003, NAT IMMUNOL, V4, P525, DOI 10.1038/ni925
   Lu RQ, 2003, GENE DEV, V17, P1703, DOI 10.1101/gad.1104803
   Ma SB, 2008, BLOOD, V111, P1396, DOI 10.1182/blood-2007-08-110106
   Matthews JM, 2000, EUR J BIOCHEM, V267, P1030, DOI 10.1046/j.1432-1327.2000.01095.x
   MCBLANE JF, 1995, CELL, V83, P387, DOI 10.1016/0092-8674(95)90116-7
   Mitelman F, 2004, NAT GENET, V36, P331, DOI 10.1038/ng1335
   MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G
   Muljo SA, 2003, NAT IMMUNOL, V4, P31, DOI 10.1038/ni870
   Nakamura T, 2000, MOL CELL BIOL, V20, P3178, DOI 10.1128/MCB.20.9.3178-3186.2000
   Ngo VN, 2006, NATURE, V441, P106, DOI 10.1038/nature04687
   Ochiai K, 2012, NAT IMMUNOL, V13, P300, DOI 10.1038/ni.2210
   OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047
   Perkins EJ, 2004, NUCLEIC ACIDS RES, V32, P1942, DOI 10.1093/nar/gkh523
   Pulford K, 2006, LEUKEMIA, V20, P1439, DOI 10.1038/sj.leu.2404260
   Qiu XY, 2003, CANCER RES, V63, P6488
   RAMSDEN DA, 1994, J IMMUNOL, V153, P1150
   Raney BJ, 2011, NUCLEIC ACIDS RES, V39, pD871, DOI 10.1093/nar/gkq1017
   Reyes JC, 1997, J CELL BIOL, V137, P263, DOI 10.1083/jcb.137.2.263
   Reynaud D, 2008, NAT IMMUNOL, V9, P927, DOI 10.1038/ni.1626
   RICHARDSON AL, 1992, ONCOGENE, V7, P961
   Sandelin A, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-99
   Sankaran VG, 2009, NATURE, V460, P1093, DOI 10.1038/nature08243
   Satterwhite E, 2001, BLOOD, V98, P3413, DOI 10.1182/blood.V98.12.3413
   Schatz DG, 2004, IMMUNOL REV, V200, P5, DOI 10.1111/j.0105-2896.2004.00173.x
   Seita J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040321
   Shaffer AL, 2000, IMMUNITY, V13, P199, DOI 10.1016/S1074-7613(00)00020-0
   SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C
   Su AI, 2004, P NATL ACAD SCI USA, V101, P6062, DOI 10.1073/pnas.0400782101
   Suzuki T, 2002, NAT GENET, V32, P166, DOI 10.1038/ng949
   Tsang AP, 1997, CELL, V90, P109, DOI 10.1016/S0092-8674(00)80318-9
   VANGENT DC, 1995, CELL, V81, P925, DOI 10.1016/0092-8674(95)90012-8
   Verkoczy L, 2005, IMMUNITY, V22, P519, DOI 10.1016/j.immuni.2005.03.006
   Wakabayashi Y, 2003, NAT IMMUNOL, V4, P533, DOI 10.1038/ni927
   Wei XC, 2005, EUR J IMMUNOL, V35, P612, DOI 10.1002/eji.200425185
   Wei XC, 2002, J IMMUNOL, V169, P873, DOI 10.4049/jimmunol.169.2.873
   Xu J, 2011, SCIENCE, V334, P993, DOI 10.1126/science.1211053
   Xu J, 2010, GENE DEV, V24, P783, DOI 10.1101/gad.1897310
   Yu Y, 2012, J EXP MED, V209, P2467, DOI 10.1084/jem.20121846
   Yuan JS, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-85
   Zheng H, 2007, CELL BIOL INT, V31, P82, DOI 10.1016/j.cellbi.2006.09.009
NR 65
TC 9
Z9 10
U1 2
U2 20
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0270-7306
EI 1098-5549
J9 MOL CELL BIOL
JI Mol. Cell. Biol.
PD MAY
PY 2013
VL 33
IS 9
BP 1768
EP 1781
DI 10.1128/MCB.00987-12
PG 14
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 121VS
UT WOS:000317273300008
PM 23438597
OA Bronze, Green Published
DA 2018-12-27
ER

PT J
AU Zhang, P
   Yue, SZ
   Jiang, YJ
   Zhang, XJ
   Liu, Y
AF Zhang Peng
   Yue Shuangzhu
   Jiang Yongjie
   Zhang Xinjun
   Liu Ying
TI RETRACTED: TNF receptor-associated factor 6 regulates proliferation,
   apoptosis, and invasion of glioma cells (Retracted article. See vol.
   415, pg. 207, 2016)
SO MOLECULAR AND CELLULAR BIOCHEMISTRY
LA English
DT Article; Retracted Publication
DE Glioma; TRAF6; Proliferation; Apoptosis; Invasion
ID NF-KAPPA-B; MOLECULAR-MECHANISMS; UP-REGULATION; ALPHA-KINASE;
   ACTIVATION; CANCER; MIGRATION; GROWTH; OSTEOCLASTOGENESIS;
   IDENTIFICATION
AB Tumor necrosis factor receptor-associated factor 6 (TRAF6), which plays an important role in inflammation and immune response, is an essential adaptor protein for the NF-kappa B (nuclear factor kappa B) signaling pathway. Recent studies have shown that TRAF6 played an important role in tumorigenesis and invasion by suppressing NF-kappa B activation. However, up to now, the biologic role of TRAF6 in glioma has still remained unknown. To address the expression of TRAF6 in glioma cells, four glioma cell lines (U251, U-87MG, LN-18, and U373) and a non-cancerous human glial cell line SVG p12 were used to explore the protein expression of TRAF6 by Western blot. Our results indicated that TRAF6 expression was upregulated in human glioma cell lines, especially in metastatic cell lines. To investigate the role of TRAF6 in cell proliferation, apoptosis, invasion, and migration of glioma, we generated human glioma U-87MG cell lines in which TRAF6 was either overexpressed or depleted. Subsequently, the effects of TRAF6 on cell viability, cell cycle distribution, apoptosis, invasion, and migration in U-87MG cells were determined with 3-(4,5-dimethylthiazol-2-yl) 2,5-diphenyl tetrazolium bromide (MTT) assay, flow cytometry analysis, transwell invasion assay, and wound-healing assay. The results showed that knockdown of TRAF6 could decrease cell viability, suppress cell proliferation, invasion and migration, and promote cell apoptosis, whereas overexpression of TRAF6 displayed the opposite effects. In addition, the effects of TRAF6 on the expression of phosphor-NF-kappa B (p-p65), cyclin D1, caspase 3, and MMP-9 were also probed. Knockdown of TRAF6 could lower the expression of p-p65, cyclin D1, and MMP-9, and raise the expression of caspase 3. All these results suggested that TRAF6 might be involved in the potentiation of growth, proliferation, invasion, and migration of U-87MG cell, as well as inhibition of apoptosis of U-87MG cell by abrogating activation of NF-kappa B.
C1 [Zhang Peng; Yue Shuangzhu] Xinxiang Med Univ, Dept Neurosurg, Affiliated Hosp 1, Xinxiang 453100, Henan, Peoples R China.
   [Jiang Yongjie; Liu Ying] Xinxiang Med Univ, Dept Obstet & Gynaecol, Affiliated Hosp 1, Xinxiang 453100, Peoples R China.
   [Zhang Xinjun] Xinxiang Med Univ, Dept Urol, Affiliated Hosp 1, Xinxiang 453100, Peoples R China.
RP Zhang, P (reprint author), Xinxiang Med Univ, Dept Neurosurg, Affiliated Hosp 1, 88 Jian Kang Rd, Xinxiang 453100, Henan, Peoples R China.
EM zhangpeng_hn@163.com
CR Baldwin AS, 2012, IMMUNOL REV, V246, P327, DOI 10.1111/j.1600-065X.2012.01095.x
   Chaudhry SI, 2013, ONCOGENE, V32, P747, DOI 10.1038/onc.2012.91
   Cock-Rada AM, 2012, CANCER RES, V72, P810, DOI 10.1158/0008-5472.CAN-11-1052
   Farias-Eisner G, 2012, BRIT J NEUROSURG, V26, P189, DOI 10.3109/02688697.2011.629698
   Ferguson SD, 2011, DM-DIS MON, V57, P558, DOI 10.1016/j.disamonth.2011.08.020
   Ge Y, 2012, GENE, V508, P157, DOI 10.1016/j.gene.2012.07.045
   Gupta SC, 2010, BBA-GENE REGUL MECH, V1799, P775, DOI 10.1016/j.bbagrm.2010.05.004
   Hamidi A, 2012, J BIOL CHEM, V287, P123, DOI 10.1074/jbc.M111.285122
   Hartupee J, 2008, J BIOL CHEM, V283, P15689, DOI 10.1074/jbc.M801346200
   Ichikawa H, 2005, J IMMUNOL, V174, P7383, DOI 10.4049/jimmunol.174.11.7383
   Inubushi T, 2012, J BIOL CHEM, V287, P23527, DOI 10.1074/jbc.M111.324673
   Jacobs W, 1997, J NEURO-ONCOL, V32, P93, DOI 10.1023/A:1005777711567
   Jee BK, 2006, BIOCHEM BIOPH RES CO, V342, P655, DOI 10.1016/j.bbrc.2006.01.153
   Jia L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032584
   Jin HR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040355
   Kang Kyeongah, 2012, Immune Netw, V12, P104, DOI 10.4110/in.2012.12.3.104
   Li YF, 2012, HUM REPROD, V27, P2096, DOI 10.1093/humrep/des110
   Lim KH, 2012, IMMUNOL REV, V246, P359, DOI 10.1111/j.1600-065X.2012.01105.x
   Ling J, 2012, CANCER LETT, V322, P119, DOI 10.1016/j.canlet.2012.02.033
   Liu H, 2012, J CANCER RES CLIN, V138, P1853, DOI 10.1007/s00432-012-1255-6
   Liu YQ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038000
   Maruyama K, 2012, J BIOL CHEM, V287, P29114, DOI 10.1074/jbc.M112.347799
   Meng QH, 2005, ACTA PHARMACOL SIN, V26, P492, DOI 10.1111/j.1745-7254.2005.00087.x
   Meng QB, 2012, MOL CELL BIOCHEM, V371, P177, DOI 10.1007/s11010-012-1434-4
   Prasad S, 2012, CLIN CANCER RES, V18, P4942, DOI 10.1158/1078-0432.CCR-11-2805
   Rainov Nikolai G, 2011, Sultan Qaboos Univ Med J, V11, P5
   Sarkar D, 2008, CANCER RES, V68, P1478, DOI 10.1158/0008-5472.CAN-07-6164
   Schneider M, 2012, NAT IMMUNOL, V13, P823, DOI 10.1038/ni.2378
   Sung BY, 2008, MOL CANCER THER, V7, P191, DOI 10.1158/1535-7163.MCT-07-0406
   Tao T, 2012, MOL BIOL CELL, V23, P2635, DOI 10.1091/mbc.E11-09-0805
   Tran NL, 2006, CANCER RES, V66, P9535, DOI 10.1158/0008-5472.CAN-06-0418
   Tsuchiya Y, 2010, MOL CELL, V39, P570, DOI 10.1016/j.molcel.2010.07.030
   Walecki J, 2003, ACAD RADIOL, V10, P145, DOI 10.1016/S1076-6332(03)80038-7
   Walsh MC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0004064
   Wang HJ, 2010, EUR J CANCER, V46, P2295, DOI 10.1016/j.ejca.2010.05.012
   Yamanaka R, 2012, ADV EXP MED BIOL, V746, P187, DOI 10.1007/978-1-4614-3146-6_15
   Yang LF, 2009, ONCOL REP, V22, P121, DOI 10.3892/or_00000414
   Zhong L, 2013, TUMOR BIOL, V34, P231, DOI 10.1007/s13277-012-0543-8
   Zhou FF, 2012, J BIOL CHEM, V287, P11002, DOI 10.1074/jbc.M111.328187
NR 39
TC 2
Z9 2
U1 2
U2 11
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0300-8177
EI 1573-4919
J9 MOL CELL BIOCHEM
JI Mol. Cell. Biochem.
PD MAY
PY 2013
VL 377
IS 1-2
BP 87
EP 96
DI 10.1007/s11010-013-1573-2
PG 10
WC Cell Biology
SC Cell Biology
GA 114QU
UT WOS:000316758000009
DA 2018-12-27
ER

PT J
AU Algi, F
AF Algi, Fatih
TI RETRACTED: Novel donor-acceptor type thiophene pyridine conjugates:
   synthesis and ion recognition features (Retracted article. See vol. 69,
   pg. 8831, 2013)
SO TETRAHEDRON
LA English
DT Article; Retracted Publication
DE Donor-acceptor; 2,2 '-Bipyridine; Thiophene; 1,10-Phenanthroline; Ion
   recognition; Copper (II); Fluorescence; Colorimetric
ID LIGHT-EMITTING-DIODES; TURN-ON FLUORESCENT; COPPER HOMEOSTASIS;
   ELECTRON-TRANSFER; CHARGE-TRANSFER; RED-SHIFT; POLYMERS; SENSOR; CU2+;
   EMISSION
AB In order to reveal the effect of the donor units on the structure-property relationship, three novel directly linked donor-acceptor type systems, 1-3, which are based on thiophene and pyridine conjugates, are designed, synthesized and characterized by spectroscopic methods. It is noteworthy that these D-A systems exhibit distinct electrochemical and optical features depending on the strength of the D-unit or the conjugation length. Furthermore, it is found that two of these novel systems, 2 and 3, can be used in both chromogenic and fluorogenic detection of Cu2+ among other ions. (C) 2013 Elsevier Ltd. All rights reserved.
C1 Canakkale Onsekiz Mart Univ, LOM, TR-17100 Canakkale, Turkey.
RP Algi, F (reprint author), Canakkale Onsekiz Mart Univ, LOM, TR-17100 Canakkale, Turkey.
EM falgi@comu.edu.tr
FU Scientific and Technological Research Council of Turkey (TUBITAK)
   [109R009]
FX F.A. is indebted to Scientific and Technological Research Council of
   Turkey (TUBITAK, Contract No. 109R009) for financial support, which came
   in the early critical stage of his career. European Cooperation in
   Science and Technology (COST) and Canakkale Onsekiz Mart University
   (COMU BAP 2010/32 and 2010/180) are also gratefully acknowledged. The
   author thanks Dr. S. Tirkes and Dr. A. Cihaner for CV measurements.
CR Algi MP, 2012, CHEM COMMUN, V48, P10219, DOI 10.1039/c2cc34842j
   [Anonymous], 1996, GUID DRINK WAT QUAL
   Balan A, 2011, POLYM CHEM-UK, V2, P1029, DOI 10.1039/c1py00007a
   Balan A, 2010, J MATER CHEM, V20, P9861, DOI 10.1039/c0jm01815e
   Beaujuge PM, 2010, CHEM REV, V110, P268, DOI 10.1021/cr900129a
   Boudreault PLT, 2011, CHEM MATER, V23, P456, DOI 10.1021/cm1021855
   Callan JF, 2005, TETRAHEDRON, V61, P8551, DOI 10.1016/j.tet.2005.05.043
   Chandrasekhar V, 2011, CHEM-ASIAN J, V6, P2246, DOI 10.1002/asia.201100032
   Chandrasekhar V, 2011, TETRAHEDRON LETT, V52, P1938, DOI 10.1016/j.tetlet.2011.02.051
   Chen CT, 2005, CHEM COMMUN, P3980, DOI 10.1039/b506409k
   Chevallier F, 2009, CHEM COMMUN, P692, DOI 10.1039/b815656e
   Cihaner A, 2008, ADV FUNCT MATER, V18, P3583, DOI 10.1002/adfm.200801094
   Czarnik A. W., 1993, FLUORESCENT CHEMOSEN
   Dance ZEX, 2008, J AM CHEM SOC, V130, P830, DOI 10.1021/ja077386z
   de Silva AP, 2000, COORDIN CHEM REV, V205, P41, DOI 10.1016/S0010-8545(00)00238-1
   de Silva AP, 1997, CHEM REV, V97, P1515, DOI 10.1021/cr960386p
   Dodani SC, 2011, J AM CHEM SOC, V133, P8606, DOI 10.1021/ja2004158
   Forgues S. F., 1988, J PHYS CHEM, V92, P6233
   Gaggelli E, 2006, CHEM REV, V106, P1995, DOI 10.1021/cr040410w
   Garcia-Beltran O, 2012, TETRAHEDRON LETT, V53, P5280, DOI 10.1016/j.tetlet.2012.07.082
   Goel A, 2008, ORG LETT, V10, P2553, DOI 10.1021/ol8008182
   Goswami S, 2010, ORG LETT, V12, P856, DOI 10.1021/ol9029066
   GREENHAM NC, 1993, NATURE, V365, P628, DOI 10.1038/365628a0
   Gunbas G, 2012, CHEM COMMUN, V48, P1083, DOI 10.1039/c1cc14992j
   HAVINGA EE, 1993, SYNTHETIC MET, V55, P299, DOI 10.1016/0379-6779(93)90949-W
   Heeney M, 2007, CHEM COMMUN, P5061, DOI 10.1039/b712398a
   Helal A, 2011, TETRAHEDRON, V67, P2794, DOI 10.1016/j.tet.2011.01.093
   Hou J, 2011, TETRAHEDRON LETT, V52, P2710, DOI 10.1016/j.tetlet.2011.03.082
   Icli M, 2010, CHEM MATER, V22, P4034, DOI 10.1021/cm100805g
   Icli M, 2010, ORG ELECTRON, V11, P1255, DOI 10.1016/j.orgel.2010.05.001
   Irvin DJ, 1999, CHEM COMMUN, P2121, DOI 10.1039/a904584h
   Jenkins IH, 1996, CHEM MATER, V8, P2444, DOI 10.1021/cm960207k
   Jisha VS, 2009, J ORG CHEM, V74, P6667, DOI 10.1021/jo901164w
   Kim JS, 2007, CHEM REV, V107, P3780, DOI 10.1021/cr068046j
   King SM, 2009, ADV FUNCT MATER, V19, P586, DOI 10.1002/adfm.200801237
   Koval IA, 2006, CHEM SOC REV, V35, P814, DOI 10.1039/b516250p
   Lin WC, 2010, TALANTA, V81, P1209, DOI 10.1016/j.talanta.2010.02.012
   Linder MC, 1996, AM J CLIN NUTR, V63, P797
   Liu YL, 2011, ORG BIOMOL CHEM, V9, P432, DOI 10.1039/c0ob00411a
   Liu ZP, 2012, ORG LETT, V14, P4378, DOI 10.1021/ol301849z
   Mashraqui SH, 2008, TETRAHEDRON LETT, V49, P3739, DOI 10.1016/j.tetlet.2008.04.041
   Millhauser GL, 2004, ACCOUNTS CHEM RES, V37, P79, DOI 10.1021/ar0301678
   Ozkut MI, 2012, MACROMOLECULES, V45, P729, DOI 10.1021/ma202331t
   Pamuk M, 2012, TETRAHEDRON LETT, V53, P7117, DOI 10.1016/j.tetlet.2012.10.082
   Pamuk M, 2010, POLYMER, V51, P62, DOI 10.1016/j.polymer.2009.11.009
   Paul BK, 2011, J PHOTOCH PHOTOBIO A, V220, P153, DOI 10.1016/j.jphotochem.2011.04.006
   PINHEY JT, 1988, J CHEM SOC PERK T 1, P2415, DOI 10.1039/p19880002415
   Saitoh Y, 1997, CAN J CHEM, V75, P1336, DOI 10.1139/v97-160
   Shen QP, 2012, CHEM COMMUN, V48, P281, DOI 10.1039/c1cc16049d
   Shortreed M, 1996, ANAL CHEM, V68, P1414, DOI 10.1021/ac950944k
   Thompson BC, 2008, ANGEW CHEM INT EDIT, V47, P58, DOI 10.1002/anie.200702506
   UAUY R, 1998, AM J CLIN NUTR S, V67, P952
   Wang HY, 2010, SENSOR ACTUAT B-CHEM, V150, P798, DOI 10.1016/j.snb.2010.07.025
   Weerasinghe AJ, 2011, TETRAHEDRON LETT, V52, P5648, DOI 10.1016/j.tetlet.2011.08.092
   Xi PX, 2010, SENSOR ACTUAT B-CHEM, V148, P337, DOI 10.1016/j.snb.2010.05.004
   Xu XJ, 2007, ADV MATER, V19, P1281, DOI 10.1002/adma.200601919
   Xu ZC, 2005, ORG LETT, V7, P3029, DOI 10.1021/ol051131d
   Zhu SS, 1997, J AM CHEM SOC, V119, P12568, DOI 10.1021/ja972794w
   Zhu Y, 2005, CHEM MATER, V17, P5225, DOI 10.1021/cm050743p
NR 59
TC 4
Z9 4
U1 5
U2 65
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0040-4020
J9 TETRAHEDRON
JI Tetrahedron
PD APR 29
PY 2013
VL 69
IS 17
BP 3523
EP 3529
DI 10.1016/j.tet.2013.03.008
PG 7
WC Chemistry, Organic
SC Chemistry
GA 116ZU
UT WOS:000316922700001
DA 2018-12-27
ER

PT J
AU Nassirpour, R
   Mehta, PP
   Baxi, SM
   Yin, MJ
AF Nassirpour, Rounak
   Mehta, Pramod P.
   Baxi, Sangita M.
   Yin, Min-Jean
TI RETRACTED: miR-221 Promotes Tumorigenesis in Human Triple Negative
   Breast Cancer Cells (Retracted article. See vol. 12, art no e0175869,
   2017)
SO PLOS ONE
LA English
DT Article; Retracted Publication
ID ESTROGEN-RECEPTOR-ALPHA; HEPATOCELLULAR-CARCINOMA; TAMOXIFEN RESISTANCE;
   MICRORNAS; EXPRESSION; SLUG; PROLIFERATION; DEGRADATION; P27(KIP1);
   PATTERNS
AB Patients with triple-negative breast cancers (TNBCs) typically have a poor prognosis. TNBCs are characterized by their resistance to apoptosis, aggressive cellular proliferation, migration and invasion, and currently lack molecular markers and effective targeted therapy. Recently, miR-221/miR-222 have been shown to regulate ER alpha expression and ER alpha-mediated signaling in luminal breast cancer cells, and also to promote EMT in TNBCs. In this study, we characterized the role of miR-221 in a panel of TNBCs as compared to other breast cancer types. miR-221 knockdown not only blocked cell cycle progression, induced cell apoptosis, and inhibited cell proliferation in-vitro but it also inhibited in-vivo tumor growth by targeting p27(kip1). Furthermore, miR-221 knockdown inhibited cell migration and invasion by altering E-cadherin expression, and its regulatory transcription factors Snail and Slug in human TNBC cell lines. Therefore, miR-221 functions as an oncogene and is essential in regulating tumorigenesis in TNBCs both in vitro as well as in vivo.
C1 [Nassirpour, Rounak; Mehta, Pramod P.; Baxi, Sangita M.; Yin, Min-Jean] Pfizer Worldwide Res & Dev, Oncol Res, San Diego, CA USA.
RP Yin, MJ (reprint author), Pfizer Worldwide Res & Dev, Oncol Res, San Diego, CA USA.
EM min-jean.yin@pfizer.com
RI Baxi, Sangita/K-6865-2016
CR Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Bidard FC, 2007, ANN ONCOL, V18, P1285, DOI 10.1093/annonc/mdm360
   Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101
   Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997
   Carey LA, 2006, JAMA-J AM MED ASSOC, V295, P2492, DOI 10.1001/jama.295.21.2492
   Cochrane Dawn R., 2010, Hormones & Cancer, V1, P306, DOI 10.1007/s12672-010-0043-5
   Dent R, 2007, CLIN CANCER RES, V13, P4429, DOI 10.1158/1078-0432.CCR-06-3045
   Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840
   Fornari F, 2008, ONCOGENE, V27, P5651, DOI 10.1038/onc.2008.178
   Galardi S, 2007, J BIOL CHEM, V282, P23716, DOI 10.1074/jbc.M701805200
   Garofalo M, 2009, CANCER CELL, V16, P498, DOI 10.1016/j.ccr.2009.10.014
   Gramantieri L, 2009, CLIN CANCER RES, V15, P5073, DOI 10.1158/1078-0432.CCR-09-0092
   Guttilla IK, 2012, BREAST CANCER RES TR, V132, P75, DOI 10.1007/s10549-011-1534-y
   Hajra KM, 2002, CANCER RES, V62, P1613
   Howe EN, 2012, J MAMMARY GLAND BIOL, V17, P65, DOI 10.1007/s10911-012-9244-6
   Kang SP, 2008, CURR OPIN OBSTET GYN, V20, P40, DOI 10.1097/GCO.0b013e3282f40de9
   Kim D, 2010, J BIOL CHEM, V285, P26900, DOI 10.1074/jbc.M110.115105
   Lambertini E, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-445
   le Sage C, 2007, EMBO J, V26, P3699, DOI 10.1038/sj.emboj.7601790
   Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3
   Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315
   Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702
   Lu YZ, 2011, J BIOL CHEM, V286, P42292, DOI 10.1074/jbc.M111.270926
   Lu ZM, 2010, CELL CYCLE, V9, P2342, DOI 10.4161/cc.9.12.11988
   Miller TE, 2008, J BIOL CHEM, V283, P29897, DOI 10.1074/jbc.M804612200
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Radojicic J, 2011, CELL CYCLE, V10, P507, DOI 10.4161/cc.10.3.14754
   Rakha EA, 2009, PATHOLOGY, V41, P40, DOI 10.1080/00313020802563510
   Rao X, 2011, ONCOGENE, V30, P1082, DOI 10.1038/onc.2010.487
   Riedl SJ, 2004, NAT REV MOL CELL BIO, V5, P897, DOI 10.1038/nrm1496
   Sanchez-Tillo E, 2012, CELL MOL LIFE SCI, V69, P3429, DOI 10.1007/s00018-012-1122-2
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   Stinson S, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001538
   Sun T, 2009, CANCER RES, V69, P3356, DOI 10.1158/0008-5472.CAN-08-4112
   Tait SWG, 2010, NAT REV MOL CELL BIO, V11, P621, DOI 10.1038/nrm2952
   Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007
   Zhang CZ, 2010, INT J ONCOL, V37, P1621, DOI 10.3892/ijo_00000816
   Zhao JJ, 2008, J BIOL CHEM, V283, P31079, DOI 10.1074/jbc.M806041200
NR 39
TC 56
Z9 59
U1 1
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 24
PY 2013
VL 8
IS 4
AR e62170
DI 10.1371/journal.pone.0062170
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 136DE
UT WOS:000318340400078
PM 23637992
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Mahmood, K
   Kang, HW
   Park, SB
   Sung, HJ
AF Mahmood, Khalid
   Kang, Hyun Wook
   Park, Seung Bin
   Sung, Hyung Jin
TI RETRACTED: Hydrothermally Grown Upright-Standing Nanoporous Nanosheets
   of Iodine-Doped ZnO (ZnO:I) Nanocrystallites for a High-Efficiency
   Dye-Sensitized Solar Cell (Retracted article. See vol. 7, pg. 26006,
   2015)
SO ACS APPLIED MATERIALS & INTERFACES
LA English
DT Article; Retracted Publication
DE ZnO nanosheets; nanocrystalline; dye-sensitized solar cell;
   hydrothermal; light scattering
ID HIGH CONVERSION EFFICIENCY; ZINC-OXIDE NANOSHEET; ENERGY-CONVERSION;
   PHOTOELECTROCHEMICAL PERFORMANCE; NANOWIRE ARRAYS; FILMS; TIO2;
   ELECTRODES; LIGHT; AGGREGATION
AB Upright-standing nanoporous nanosheets of iodine-doped ZnO (ZnO:I nanocrsytallites were grown hydrothermally at low temperature and studied as dyesensitized solar-cell electrodes. The highest overall energy-conversion efficiency of,similar to 6.6% was achieved with the film consisted of nanosheets of ZnO:I nanocrystallites. This efficiency was significantly improved than the 3.2% achieved for ZnO:I films only including nanosized crystallites, and higher than the 2.4% for undoped ZnO nanosheet film. The nanosheets of ZnO:I nanocrsytallites were proven to be positive in causing light scattering in a broad wavelength region and, therefore, enhancing the light harvesting capability of the photoelectrode film and thus, promotes the solar cell performance. The fabricated cells exhibited highly durable cell performances, even after a month under atmospheric conditions. Electrochemical impedance spectroscopy (EIS) data confirmed that iodine doping was helpful to lower the recombination resistance and prolonged electron lifetime of the ZnO:I cells, hence diminishing the recombination process. The efficiency achieved for the best DSSC in this work was much better than ever reported for a ZnO-based DSSC.
C1 [Mahmood, Khalid; Park, Seung Bin] Korea Adv Inst Sci & Technol, Dept Chem & Biomol Engn, Taejon 305701, South Korea.
   [Mahmood, Khalid; Kang, Hyun Wook; Sung, Hyung Jin] Korea Adv Inst Sci & Technol, Dept Mech Engn, Taejon 305701, South Korea.
RP Park, SB (reprint author), Korea Adv Inst Sci & Technol, Dept Chem & Biomol Engn, 291 Daehak Ro, Taejon 305701, South Korea.
EM SeungBinPark@kaist.ac.kr
RI Park, Seung/B-8360-2011; Sung, Hyung Jin/C-1884-2011; Kang, Hyun
   Wook/A-3152-2014
OI Sung, Hyung Jin/0000-0002-4671-3626; 
FU National Research Foundation of Korea (NRF); Korea government (MEST)
   [2010-0027634]
FX This work was supported by the National Research Foundation of Korea
   (NRF) grant funded by the Korea government (MEST) (2010-0027634).
CR Akhtar MS, 2008, ELECTROCHIM ACTA, V53, P7869, DOI 10.1016/j.electacta.2008.05.055
   Anta JA, 2012, J PHYS CHEM C, V116, P11413, DOI 10.1021/jp3010025
   Baxter JB, 2005, APPL PHYS LETT, V86, DOI 10.1063/1.1861510
   Chen LC, 2008, J PHOTOCH PHOTOBIO A, V199, P170, DOI 10.1016/j.jphotochem.2008.05.022
   Chiba Y, 2006, JPN J APPL PHYS 2, V45, pL638, DOI 10.1143/JJAP.45.L638
   Chou TP, 2007, ADV MATER, V19, P2588, DOI 10.1002/adma.200602927
   Du Pasquier A, 2006, APPL PHYS LETT, V89, DOI 10.1063/1.2420779
   Gao YF, 2007, CRYST GROWTH DES, V7, P2467, DOI 10.1021/cg060934k
   Gratzel M, 2005, INORG CHEM, V44, P6841, DOI 10.1021/ic0508371
   Gratzel M, 2001, NATURE, V414, P338, DOI 10.1038/35104607
   Guillen E, 2011, ENERG ENVIRON SCI, V4, P3400, DOI 10.1039/c0ee00500b
   Guo M, 2005, J SOLID STATE CHEM, V178, P3210, DOI 10.1016/j.jssc.2005.07.013
   Guo M, 2004, CHINESE CHEM LETT, V15, P1113
   Hosono E, 2005, ADV MATER, V17, P2091, DOI 10.1002/adma.200500275
   Hosono E, 2008, DALTON T, P5439, DOI 10.1039/b800907d
   Kakiuchi K, 2006, J PHOTOCH PHOTOBIO A, V179, P81, DOI 10.1016/j.jphotochem.2005.07.018
   Lagemaat J., 2000, J PHYS CHEM B, V104, P2044
   Lai YH, 2010, J MATER CHEM, V20, P9379, DOI 10.1039/c0jm01787f
   Law M, 2005, NAT MATER, V4, P455, DOI 10.1038/nmat1387
   Lee WJ, 2004, JPN J APPL PHYS 1, V43, P152, DOI 10.1146/JJAP.43.152
   Li J, 2009, J ALLOY COMPD, V481, P735, DOI 10.1016/j.jallcom.2009.03.094
   Mahmood K, 2012, J CRYST GROWTH, V347, P104, DOI 10.1016/j.jcrysgro.2012.03.033
   Memarian N, 2011, ANGEW CHEM INT EDIT, V50, P12321, DOI 10.1002/anie.201104605
   Moon SJ, 2010, J PHYS CHEM LETT, V1, P1524, DOI 10.1021/jz100308q
   Moon SJ, 2009, J PHYS CHEM C, V113, P16816, DOI 10.1021/jp9033722
   NAZEERUDDIN MK, 1993, J AM CHEM SOC, V115, P6382, DOI 10.1021/ja00067a063
   Otsuka A, 2006, CHEM LETT, V35, P666, DOI 10.1246/cl.2006.666
   Papageorgiou N, 1997, J ELECTROCHEM SOC, V144, P876, DOI 10.1149/1.1837502
   Paulose M, 2006, J PHYS D APPL PHYS, V39, P2498, DOI 10.1088/0022-3727/39/12/005
   Qian JF, 2009, ADV MATER, V21, P3663, DOI 10.1002/adma.200900525
   Rensmo H, 1997, J PHYS CHEM B, V101, P2598, DOI 10.1021/jp962918b
   Suliman AE, 2007, SOL ENERG MAT SOL C, V91, P1658, DOI 10.1016/j.solmat.2007.05.014
   Vayssieres L, 2003, ADV MATER, V15, P464, DOI 10.1002/adma.200390108
   Wang H, 2006, APPL PHYS LETT, V89, DOI 10.1063/1.2221502
   Wang HL, 2001, J PHYS CHEM B, V105, P2529, DOI 10.1021/jp0036083
   Wang K, 2008, ADV MATER, V20, P3248, DOI 10.1002/adma.200800145
   Xu F, 2010, J PHYS CHEM C, V114, P2776, DOI 10.1021/jp910363w
   Xu H, 2010, ELECTROCHIM ACTA, V55, P2280, DOI 10.1016/j.electacta.2009.11.067
   Yang XD, 2013, ENERG ENVIRON SCI, V6, P54, DOI 10.1039/c2ee22998f
   Yang XY, 2009, NANO LETT, V9, P2331, DOI 10.1021/nl900772q
   Yang ZZ, 2009, J PHYS CHEM C, V113, P20521, DOI 10.1021/jp908678x
   Yella A, 2011, SCIENCE, V334, P629, DOI 10.1126/science.1209688
   Zeng LY, 2006, PLASMA SCI TECHNOL, V8, P172, DOI 10.1088/1009-0630/8/2/10
   Zhang QF, 2008, ANGEW CHEM INT EDIT, V47, P2402, DOI 10.1002/anie.200704919
   Zhang QF, 2009, ADV MATER, V21, P4087, DOI 10.1002/adma.200803827
   Zhao D, 2008, J PHYS CHEM C, V112, P5993, DOI 10.1021/jp712049c
NR 46
TC 27
Z9 27
U1 6
U2 101
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1944-8244
J9 ACS APPL MATER INTER
JI ACS Appl. Mater. Interfaces
PD APR 24
PY 2013
VL 5
IS 8
BP 3075
EP 3084
DI 10.1021/am3032729g
PG 10
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
SC Science & Technology - Other Topics; Materials Science
GA 134JA
UT WOS:000318205000035
PM 23510487
DA 2018-12-27
ER

PT J
AU Nagalingam, RS
   Sundaresan, NR
   Gupta, MP
   Geenen, DL
   Solaro, RJ
   Gupta, M
AF Nagalingam, Raghu S.
   Sundaresan, Nagalingam R.
   Gupta, Mahesh P.
   Geenen, David L.
   Solaro, R. John
   Gupta, Madhu
TI RETRACTED: A Cardiac-enriched MicroRNA, miR-378, Blocks Cardiac
   Hypertrophy by Targeting Ras Signaling(Retracted article. See vol. 292,
   pg. 5123, 2017)
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article; Retracted Publication
ID FOCAL ADHESION KINASE; DIACYLGLYCEROL-BINDING MOTIFS;
   NUCLEOTIDE-RELEASING PROTEIN; MUTATIONS CAUSE NOONAN; SIGNALING
   PATHWAYS; GENE-EXPRESSION; THERAPEUTIC TARGET; PRESSURE-OVERLOAD;
   HEART-FAILURE; CARDIOMYOCYTE
AB Understanding the regulation of cardiomyocyte growth is crucial for the management of adverse ventricular remodeling and heart failure. MicroRNA-378 (miR-378) is a newly described member of the cardiac-enriched miRNAs, which is expressed only in cardiac myocytes and not in cardiac fibroblasts. We have previously shown that miR-378 regulates cardiac growth during the postnatal period by direct targeting of IGF1R (Knezevic, I., Patel, A., Sundaresan, N. R., Gupta, M. P., Solaro, R. J., Nagalingam, R. S., and Gupta, M. (2012) J. Biol. Chem. 287, 12913-12926). Here, we report that miR-378 is an endogenous negative regulator of cardiac hypertrophy, and its levels are down-regulated during hypertrophic growth of the heart and during heart failure. In primary cultures of cardiomyocytes, overexpression of miR-378 blocked phenylephrine (PE)-stimulated Ras activity and also prevented activation of two major growth-promoting signaling pathways, PI3K-AKT and Raf1-MEK1-ERK1/2, acting downstream of Ras signaling. Overexpression of miR-378 suppressed PE-induced phosphorylation of S6 ribosomal kinase, pERK1/2, pAKT, pGSK-3 beta, and nuclear accumulation of NFAT. There was also suppression of the fetal gene program that was induced by PE. Experiments carried out to delineate the mechanism behind the suppression of Ras, led us to identify Grb2, an upstream component of Ras signaling, as a bona fide direct target of miR-378-mediated regulation. Deficiency of miR-378 alone was sufficient to induce fetal gene expression, which was prevented by knocking down Grb2 expression and blocking Ras activation, thus suggesting that miR-378 interferes with Ras activation by targeting Grb2. Our study demonstrates that miR-378 is an endogenous negative regulator of Ras signaling and cardiac hypertrophy and its deficiency contributes to the development of cardiac hypertrophy.
C1 [Nagalingam, Raghu S.; Geenen, David L.; Solaro, R. John; Gupta, Madhu] Univ Illinois, Dept Physiol & Biophys, Chicago, IL 60612 USA.
   [Nagalingam, Raghu S.; Geenen, David L.; Solaro, R. John; Gupta, Madhu] Univ Illinois, Ctr Cardiovasc Res, Chicago, IL 60612 USA.
   [Sundaresan, Nagalingam R.; Gupta, Mahesh P.] Univ Chicago, Dept Surg, Comm Cellular & Mol Physiol, Chicago, IL 60637 USA.
RP Gupta, M (reprint author), Univ Illinois, Dept Physiol & Biophys MC 901, 835 S Wolcott Ave, Chicago, IL 60612 USA.
EM guptam@uic.edu
FU National Institutes of Health [RO1 HL 22231, RO1 HL 83423, PO1 HL
   062426]
FX This work was supported, in whole or in part, by National Institutes of
   Health Grants Multi P. I. RO1 HL 22231 (to M. G. and R. J. S.), RO1 HL
   83423 (to M. P. G.), and PO1 HL 062426 (to R. J. S.).
CR Barron AJ, 2003, BIOCHEM J, V371, P71, DOI 10.1042/BJ20021395
   Betel D, 2008, NUCLEIC ACIDS RES, V36, pD149, DOI 10.1093/nar/gkm995
   Callis TE, 2009, J CLIN INVEST, V119, P2772, DOI 10.1172/JCI36154
   Care A, 2007, NAT MED, V13, P613, DOI 10.1038/nm1582
   Carrer M, 2012, P NATL ACAD SCI USA, V109, P15330, DOI 10.1073/pnas.1207605109
   Casci T, 1999, CELL, V96, P655, DOI 10.1016/S0092-8674(00)80576-0
   Ciuffini L, 2008, ONCOGENE, V27, P528, DOI 10.1038/sj.onc.1210665
   Denayer E, 2007, EUR J PEDIATR, V166, P1091, DOI 10.1007/s00431-007-0535-7
   DiMichele LA, 2006, CIRC RES, V99, P636, DOI 10.1161/01.RES.0000240498.44752.d6
   Dimmeler S, 2010, EUR HEART J, V31, P2705, DOI 10.1093/eurheartj/ehq221
   Dong DL, 2010, HYPERTENSION, V55, P946, DOI 10.1161/HYPERTENSIONAHA.109.139519
   Dorn GW, 2005, J CLIN INVEST, V115, P527, DOI 10.1172/JCI200524178
   Duisters RF, 2009, CIRC RES, V104, P170, DOI 10.1161/CIRCRESAHA.108.182535
   Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082
   Elia L, 2009, CIRCULATION, V120, P2377, DOI 10.1161/CIRCULATIONAHA.109.879429
   Freire G, 2007, J MOL CELL CARDIOL, V43, P465, DOI 10.1016/j.yjmcc.2007.07.046
   Frey N, 2004, CIRCULATION, V109, P1580, DOI 10.1161/01.CIR.0000120390.68287.BB
   Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201
   Gupta M, 1998, MOL CELL BIOL, V18, P7243, DOI 10.1128/MCB.18.12.7243
   Gupta MP, 2008, J BIOL CHEM, V283, P10135, DOI 10.1074/jbc.M710277200
   Haghikia A, 2011, EUR HEART J, V32, P1287, DOI 10.1093/eurheartj/ehq369
   Harris IS, 2004, CIRCULATION, V110, P718, DOI 10.1161/01.CIR.0000138190.50127.6A
   Heineke J, 2006, NAT REV MOL CELL BIO, V7, P589, DOI 10.1038/nrm1983
   Hennersdorf MG, 2001, J HYPERTENS, V19, P167, DOI 10.1097/00004872-200102000-00002
   Ho PD, 1998, J BIOL CHEM, V273, P21730, DOI 10.1074/jbc.273.34.21730
   Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703
   Hua YN, 2012, J CELL MOL MED, V16, P83, DOI 10.1111/j.1582-4934.2011.01307.x
   HUNTER JJ, 1995, J BIOL CHEM, V270, P23173, DOI 10.1074/jbc.270.39.23173
   Ikeda S, 2009, MOL CELL BIOL, V29, P2193, DOI 10.1128/MCB.01222-08
   John B, 2004, PLOS BIOL, V2, P1862, DOI 10.1371/journal.pbio.0020363
   Knezevic I, 2012, J BIOL CHEM, V287, P12913, DOI 10.1074/jbc.M111.331751
   Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536
   Krenz M, 2008, P NATL ACAD SCI USA, V105, P18930, DOI 10.1073/pnas.0806556105
   Lee CHJ, 1996, J NEUROSCI, V16, P6784
   Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035
   Li Q, 2010, AM J PHYSIOL-HEART C, V298, pH1340, DOI 10.1152/ajpheart.00592.2009
   Li Q, 2010, J CELL SCI, V123, P2444, DOI 10.1242/jcs.067165
   Lin ZQ, 2009, P NATL ACAD SCI USA, V106, P12103, DOI 10.1073/pnas.0811371106
   Liu N, 2008, GENE DEV, V22, P3242, DOI 10.1101/gad.1738708
   LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B
   Malumbres M, 2003, NAT REV CANCER, V3, P459, DOI 10.1038/nrc1097
   Maragkakis M, 2009, NUCLEIC ACIDS RES, V37, pW273, DOI 10.1093/nar/gkp292
   Marin TM, 2011, J CLIN INVEST, V121, P1026, DOI 10.1172/JCI44972
   Martins PAD, 2010, NAT CELL BIOL, V12, P1220, DOI 10.1038/ncb2126
   Matkovich SJ, 2010, CIRC RES, V106, P166, DOI 10.1161/CIRCRESAHA.109.202176
   Matsui T, 2002, J BIOL CHEM, V277, P22896, DOI 10.1074/jbc.M200347200
   Matsui T, 2003, CELL CYCLE, V2, P220, DOI 10.4161/cc.2.3.381
   Mitchell S, 2006, PHYSIOL GENOMICS, V25, P50, DOI 10.1152/physiolgenomics.00224.2005
   Nakamura T, 2007, J CLIN INVEST, V117, P2123, DOI 10.1172/JC130756
   Nakamura T, 2009, P NATL ACAD SCI USA, V106, P15436, DOI 10.1073/pnas.0903302106
   Nguyen A, 2002, MOL CELL BIOL, V22, P3035, DOI 10.1128/MCB.22.9.3035-3045.2002
   Obata K, 2005, BIOCHEM BIOPH RES CO, V338, P1299, DOI 10.1016/j.bbrc.2005.10.083
   Ocampo C, 2003, MOL CELL BIOCHEM, V251, P139, DOI 10.1023/A:1025450403668
   Pandit B, 2007, NAT GENET, V39, P1007, DOI 10.1038/ng2073
   Pillai VB, 2010, J BIOL CHEM, V285, P3133, DOI 10.1074/jbc.M109.077271
   Proud CG, 2004, CARDIOVASC RES, V63, P403, DOI 10.1016/j.cardiores.2004.02.003
   Pyronnet S, 2000, BIOCHEM PHARMACOL, V60, P1237, DOI 10.1016/S0006-2952(00)00429-9
   Rane S, 2010, CELL SIGNAL, V22, P1054, DOI 10.1016/j.cellsig.2010.02.008
   Roberts AE, 2007, NAT GENET, V39, P70, DOI 10.1038/ng1926
   Sanna B, 2005, MOL CELL BIOL, V25, P865, DOI 10.1128/MCB.25.3.865-878.2005
   Sayed D, 2008, MOL BIOL CELL, V19, P3272, DOI 10.1091/mbc.E08-02-0159
   Sayed D, 2007, CIRC RES, V100, P416, DOI 10.1161/01.RES.0000257913.42552.23
   SCHLAEPFER DD, 1994, NATURE, V372, P786
   Schubbert S, 2006, NAT GENET, V38, P331, DOI 10.1038/ng1748
   Small EM, 2010, CIRCULATION, V121, P1022, DOI 10.1161/CIRCULATIONAHA.109.889048
   Stone James C, 2011, Genes Cancer, V2, P320, DOI 10.1177/1947601911408082
   Sucharov C, 2008, J MOL CELL CARDIOL, V45, P185, DOI 10.1016/j.yjmcc.2009.04.014
   Sugden PH, 2008, BRIT J PHARMACOL, V153, pS137, DOI 10.1038/sj.bjp.0707659
   Sugden PH, 2003, CIRC RES, V93, P1179, DOI 10.1161/01.RES.0000106132.04301.F5
   Sugden PH, 2000, TRENDS CARDIOVAS MED, V10, P1, DOI 10.1016/S1050-1738(00)00038-4
   Sundaresan NR, 2012, NAT MED, V18, P1643, DOI 10.1038/nm.2961
   Sundaresan NR, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001465
   Sundaresan NR, 2009, J CLIN INVEST, V119, P2758, DOI 10.1172/JCI39162
   Tartaglia M, 2006, AM J HUM GENET, V78, P279, DOI 10.1086/499925
   Thum T, 2008, NATURE, V456, P980, DOI 10.1038/nature07511
   Tidyman WE, 2009, CURR OPIN GENET DEV, V19, P230, DOI 10.1016/j.gde.2009.04.001
   Torsoni AS, 2003, CIRC RES, V93, P140, DOI 10.1161/01.RES.0000081595.25297.1B
   Ucar A, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2090
   Vakili BA, 2001, AM HEART J, V141, P334, DOI 10.1067/mhj.2001.113218
   van Rooij E, 2008, P NATL ACAD SCI USA, V105, P13027, DOI 10.1073/pnas.0805038105
   van Rooij E, 2006, P NATL ACAD SCI USA, V103, P18255, DOI 10.1073/pnas.0608791103
   Wang K, 2010, J BIOL CHEM, V285, P11903, DOI 10.1074/jbc.M109.098004
   Wu X, 2011, J CLIN INVEST, V121, P1009, DOI 10.1172/JCI44929
   Yang Y, 2002, J BIOL CHEM, V277, P25756, DOI 10.1074/jbc.M202575200
   Yang YF, 2011, CIRC RES, V108, P305, DOI 10.1161/CIRCRESAHA.110.228437
   Zarich N, 2006, MOL BIOL CELL, V17, P3591, DOI 10.1091/mbc.E05-12-1104
   Zhang SS, 2003, J CLIN INVEST, V111, P833, DOI 10.1172/JCI200316290
NR 87
TC 54
Z9 59
U1 2
U2 18
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD APR 19
PY 2013
VL 288
IS 16
BP 11216
EP 11232
DI 10.1074/jbc.M112.442384
PG 17
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 130KW
UT WOS:000317915500025
PM 23447532
OA Bronze, Green Published
DA 2018-12-27
ER

PT J
AU Liu, WL
   Wang, ZK
   Guo, M
AF Liu, Wanli
   Wang, Zhankui
   Guo, Meng
TI RETRACTED: Novel Control Algorithm for the Foot Placement of a Walking
   Bipedal Robot (Retracted article. See vol. 11, 11, 2014)
SO INTERNATIONAL JOURNAL OF ADVANCED ROBOTIC SYSTEMS
LA English
DT Article; Retracted Publication
DE Foot Placement; Control Algorithm; Walking Bipedal Robot
ID GENERATION; DESIGN
AB A novel control algorithm for the foot placement of walking bipedal robots is proposed which can output the optimal step time and step location to obtain a desired walking gait from every feasible robot state. The step time and step location are determined by approximating the robot dynamics with the 3D linear inverted pendulum model and analytically solving the constraint equations. Intensive simulation studies are conducted to check the validity of the theoretical results. The results of this study show that the proposed control algorithm can get the system to a desired gait cycle from every feasible state within a finite number of steps.
C1 [Liu, Wanli; Guo, Meng] China Univ Min & Technol, Sch Mech & Elect Engn, Xuzhou, Peoples R China.
   [Wang, Zhankui] Henan Inst Sci & Technol, Xinxiang, Henan, Peoples R China.
RP Liu, WL (reprint author), China Univ Min & Technol, Sch Mech & Elect Engn, Xuzhou, Peoples R China.
EM liuwanli218@126.com
FU Fundamental Research Funds for the Central Universities [2012QNA24]
FX The Fundamental Research Funds for the Central Universities (2012QNA24)
   sponsored this project. The authors would like to express their sincere
   thanks to them.
CR Alghooneh M, 2012, INT J SMART SENS INT, V5, P329
   Cardenas-Maciel SL, 2011, APPL SOFT COMPUT, V11, P5306, DOI 10.1016/j.asoc.2011.05.030
   Chen CY, 2012, J VIB CONTROL, V18, P577, DOI 10.1177/1077546310371349
   Dehghani R, 2010, INT J HUM ROBOT, V7, P535, DOI 10.1142/S0219843610002258
   Englsberger J, 2011, IEEE INT C INT ROBOT, P4420, DOI 10.1109/IROS.2011.6048045
   Hanafiah Yussof, 2011, INT J ADV ROBOT SYST, V8, P1
   Kanniah J, 2008, INT J HUM ROBOT, V5, P609, DOI 10.1142/S0219843608001583
   Kim JY, 2011, INT J HUM ROBOT, V8, P275, DOI 10.1142/S0219843611002502
   Kim JY, 2010, ADV ROBOTICS, V24, P2137, DOI 10.1163/016918610X534295
   Liu GL, 2008, ARTIF LIFE ROBOT, V12, P264, DOI 10.1007/s10015-007-0479-z
   Liu WL, 2010, MEAS SCI TECHNOL, V21, DOI 10.1088/0957-0233/21/6/065103
   Phipps CC, 2008, IEEE T ROBOT, V24, P1302, DOI 10.1109/TRO.2008.2007936
   Wang TT, 2012, J BIONIC ENG, V9, P29, DOI 10.1016/S1672-6529(11)60094-2
   Yamashita A., 2011, INT J AUTOM TECHNOL, V5, P639
NR 14
TC 1
Z9 1
U1 3
U2 27
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1729-8814
J9 INT J ADV ROBOT SYST
JI Int. J. Adv. Robot. Syst.
PD APR 19
PY 2013
VL 10
AR 202
DI 10.5772/55909
PG 7
WC Robotics
SC Robotics
GA 131AQ
UT WOS:000317963100001
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Khan, F
   Pal, D
   Vikram, S
   Cameotra, SS
AF Khan, Fazlurrahman
   Pal, Deepika
   Vikram, Surendra
   Cameotra, Swaranjit Singh
TI RETRACTED: Metabolism of 2-Chloro-4-Nitroaniline via Novel Aerobic
   Degradation Pathway by Rhodococcus sp Strain MB-P1 (Retracted article.
   See vol. 9, e102862, 2014)
SO PLOS ONE
LA English
DT Article; Retracted Publication
ID CATECHOL 1,2-DIOXYGENASE; ERYTHROPOLIS AN-13; P-NITROPHENOL;
   GENE-CLUSTER; MICROBIAL-METABOLISM; AROMATIC-AMINES; BIODEGRADATION;
   ANILINE; PURIFICATION; 4-NITROANILINE
AB 2-chloro-4-nitroaniline (2-C-4-NA) is used as an intermediate in the manufacture of dyes, pharmaceuticals, corrosion inhibitor and also used in the synthesis of niclosamide, a molluscicide. It is marked as a black-listed substance due to its poor biodegradability. We report biodegradation of 2-C-4-NA and its pathway characterization by Rhodococcus sp. strain MB-P1 under aerobic conditions. The strain MB-P1 utilizes 2-C-4-NA as the sole carbon, nitrogen, and energy source. In the growth medium, the degradation of 2-C-4-NA occurs with the release of nitrite ions, chloride ions, and ammonia. During the resting cell studies, the 2-C-4-NA-induced cells of strain MB-P1 transformed 2-C-4-NA stoichiometrically to 4-amino-3-chlorophenol (4-A-3-CP), which subsequently gets transformed to 6-chlorohydroxyquinol (6-CHQ) metabolite. Enzyme assays by cell-free lysates prepared from 2-C-4-NA-induced MB-P1 cells, demonstrated that the first enzyme in the 2-C-4-NA degradation pathway is a flavin-dependent monooxygenase that catalyzes the stoichiometric removal of nitro group and production of 4-A-3-CP. Oxygen uptake studies on 4-A-3-CP and related anilines by 2-C-4-NA-induced MB-P1 cells demonstrated the involvement of aniline dioxygenase in the second step of 2-C-4-NA degradation. This is the first report showing 2-C-4-NA degradation and elucidation of corresponding metabolic pathway by an aerobic bacterium.
C1 [Khan, Fazlurrahman; Pal, Deepika; Vikram, Surendra; Cameotra, Swaranjit Singh] CSIR, Inst Microbial Technol, Chandigarh, India.
RP Cameotra, SS (reprint author), CSIR, Inst Microbial Technol, Chandigarh, India.
EM ssc@imtech.res.in
FU CSIR, India
FX FK, DP and SV acknowledge their research fellowship awards from CSIR,
   India. This is the IMTECH communication number 094/2012.
CR Altschuh J, 1999, CHEMOSPHERE, V39, P1871, DOI 10.1016/S0045-6535(99)00082-X
   AOKI K, 1983, AGR BIOL CHEM TOKYO, V47, P1611, DOI 10.1080/00021369.1983.10865822
   AOKI K, 1984, AGR BIOL CHEM TOKYO, V48, P2087, DOI 10.1080/00021369.1984.10866453
   APAJALAHTI JHA, 1987, J BACTERIOL, V169, P5125, DOI 10.1128/jb.169.11.5125-5130.1987
   Arora P. K., 2010, Journal of Bioremediation and Biodegradation, V1, P1000112, DOI 10.4172/2155-6199.1000112
   Arora PK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038676
   BEUNINK J, 1990, APPL MICROBIOL BIOT, V34, P108
   Boon N, 2001, APPL ENVIRON MICROB, V67, P1107, DOI 10.1128/AEM.67.3.1107-1115.2001
   Borcherding J, 2001, ARCH ENVIRON CON TOX, V40, P497, DOI 10.1007/s002440010202
   CANTON JH, 1985, REGUL TOXICOL PHARM, V5, P123, DOI 10.1016/0273-2300(85)90026-1
   Cottalasso D, 1991, Med Lav, V82, P253
   ESPINOSAAGUIRRE JJ, 1991, MUTAT RES, V264, P139, DOI 10.1016/0165-7992(91)90131-M
   Fazlurrahman, 2009, LETT APPL MICROBIOL, V49, P721, DOI 10.1111/j.1472-765X.2009.02724.x
   Ghosh A, 2010, ENVIRON SCI TECHNOL, V44, P1069, DOI 10.1021/es9034123
   Golovleva L A, 1991, Biodegradation, V2, P201, DOI 10.1007/BF00124494
   Graebing PW, 2004, J AGR FOOD CHEM, V52, P870, DOI 10.1021/jf030520o
   Hampercht R, 2000, ULLMANS ENCY IND CHE
   Hongsawat P, 2011, J HAZARD MATER, V186, P1300, DOI 10.1016/j.jhazmat.2010.12.002
   Kadiyala V, 1998, APPL ENVIRON MICROB, V64, P2479
   Kahng HY, 2000, FEMS MICROBIOL LETT, V190, P215, DOI 10.1016/S0378-1097(00)00338-4
   Katsivela E, 1999, APPL ENVIRON MICROB, V65, P1405
   Khalid A, 2009, WATER RES, V43, P1110, DOI 10.1016/j.watres.2008.11.045
   Kitagawa W, 2004, J BACTERIOL, V186, P4894, DOI 10.1128/JB.186.15.4894-4902.2004
   Kutty R, 2000, CAN J MICROBIOL, V46, P211, DOI 10.1139/cjm-46-3-211
   Larkin MJ, 2005, CURR OPIN BIOTECH, V16, P282, DOI 10.1016/j.copbio.2005.04.007
   LEWIS RJ, 2002, HAWLEYS CONDENSED CH
   LI DY, 1991, APPL ENVIRON MICROB, V57, P1920
   Liang O, 2005, MICROBIOL-SGM, V151, P3435, DOI 10.1099/mic.0.28137-0
   Liu Z, 2002, APPL MICROBIOL BIOT, V58, P679, DOI 10.1007/s00253-002-0933-8
   Lovley DR, 2003, NAT REV MICROBIOL, V1, P35, DOI 10.1038/nrmicro731
   Lyman WJ, 1990, HDB CHEM PROPERTY ES, p[7, 7, 8]
   Manickam N, 2006, APPL MICROBIOL BIOT, V69, P580, DOI 10.1007/s00253-005-0162-z
   Matsumura E, 2006, BIOCHEM J, V393, P219, DOI 10.1042/BJ20050740
   MURAKAMI S, 1991, SOIL BIOL BIOCHEM, V23, P815
   Murakami S, 1997, GENE, V185, P49, DOI 10.1016/S0378-1119(96)00629-4
   Nishino SF, 2004, PSEUDOMONAS, VOL 3: BIOSYNTHESIS OF MACROMOLECULES AND MOLECULAR METABOLISM, P575
   Nordin K, 2005, APPL ENVIRON MICROB, V71, P6538, DOI 10.1128/AEM.71.11.6538-6544.2005
   Padilla L, 2000, J BASIC MICROB, V40, P243, DOI 10.1002/1521-4028(200008)40:4<243::AID-JOBM243>3.0.CO;2-D
   Paul D, 2005, TRENDS BIOTECHNOL, V23, P135, DOI 10.1016/j.tibtech.2005.01.001
   Perry LL, 2007, J BACTERIOL, V189, P7563, DOI 10.1128/JB.01849-06
   Qu Y, 2010, APPL ENVIRON MICROB, V76, P1417, DOI 10.1128/AEM.02816-09
   Qureshi A, 2007, INT BIODETER BIODEGR, V60, P215, DOI 10.1016/j.ibiod.2007.03.004
   Sanchez MA, 2007, APPL ENVIRON MICROB, V73, P201
   Saupe A, 1999, CHEMOSPHERE, V39, P2325, DOI 10.1016/S0045-6535(99)00141-1
   Schnorbach HJ, 2008, ULLMANNS ENCY IND CH
   SCHUKAT B, 1983, CURR MICROBIOL, V9, P81, DOI 10.1007/BF01568913
   Shettigar M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051162
   Shin KA, 2009, APPL ENVIRON MICROB, V75, P2694, DOI 10.1128/AEM.02198-08
   Strachan PD, 1998, BIOCHEM J, V333, P741, DOI 10.1042/bj3330741
   STRUIJS J, 1986, SCI TOTAL ENVIRON, V57, P161, DOI 10.1016/0048-9697(86)90020-3
   Sun HH, 2007, J HAZARD MATER, V148, P172, DOI 10.1016/j.jhazmat.2007.02.022
   Takeo M, 2008, J BACTERIOL, V190, P7367, DOI 10.1128/JB.00742-08
   Tong CL, 2010, CHEMOSPHERE, V81, P430, DOI 10.1016/j.chemosphere.2010.06.066
   Travkin VM, 2003, J ENVIRON SCI HEAL B, V38, P121, DOI 10.1081/PFC-120018443
   Vangnai AS, 2007, FEMS MICROBIOL LETT, V268, P209, DOI 10.1111/j.1574-6968.2006.00579.x
   Wei M, 2010, BIODEGRADATION, V21, P915, DOI 10.1007/s10532-010-9351-2
   White GF, 1996, APPL ENVIRON MICROB, V62, P637
   Wu JF, 2006, APPL ENVIRON MICROB, V72, P1759, DOI 10.1128/AEM.72.3.1765.2006
   Yao XF, 2011, MICROBIOL-SGM, V157, P721, DOI 10.1099/mic.0.045393-0
   ZABORINA O, 1995, J BACTERIOL, V177, P229, DOI 10.1128/jb.177.1.229-234.1995
   ZEYER J, 1985, APPL ENVIRON MICROB, V50, P447
   Zhang LL, 2010, J HAZARD MATER, V179, P875, DOI 10.1016/j.jhazmat.2010.03.086
NR 62
TC 8
Z9 10
U1 4
U2 41
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 17
PY 2013
VL 8
IS 4
AR e62178
DI 10.1371/journal.pone.0062178
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 130IK
UT WOS:000317907200124
PM 23614030
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Wang, LS
   Zang, WD
   Liu, J
   Xie, DL
   Ji, WD
   Pan, YS
   Li, ZQ
   Shen, JW
   Shi, YY
AF Wang, Lishan
   Zang, Weidong
   Liu, Jiang
   Xie, Dongli
   Ji, Weidong
   Pan, Yaosheng
   Li, Zhiqiang
   Shen, Jiawei
   Shi, Yongyong
TI RETRACTED: Association of CYP2A6*4 with Susceptibility of Lung Cancer: A
   Meta-Analysis (Retracted article. See vol. 11, e160299, 2016)
SO PLOS ONE
LA English
DT Article; Retracted Publication
ID GENETIC POLYMORPHISMS; NICOTINE METABOLISM; SMOKING-BEHAVIOR;
   C-OXIDATION; HUMAN LIVER; RISK; DELETION; IDENTIFICATION; METAANALYSIS;
   POPULATION
AB Objectives: To assess the association between the variant of Cytochrome P450 2A6 whole gene deletion (CYP2A6*4) polymorphism and risk of lung cancer.
   Methods: Two investigators independently searched the PubMed, Elsevier, EMBASE, Web of Science, Wiley Online Library and Chinese National Knowledge Infrastructure (CNKI). Pooled odds ratios (ORs) and 95% confidence intervals (95% CIs) for CYP2A6*4 and lung cancer were calculated in a fixed-effects model (the Mantel-Haenszel method) and a random-effects model (the DerSimonian and Laird method) when appropriate.
   Results: This meta-analysis included seven eligible studies, which included 2524 lung cancer cases and 2258 controls (cancer-free). Overall, CYP2A6*4 was associated with the risk of lung cancer (allele*4 vs. allele non-*4, pooled OR = 0.826, 95% CI = 0.725-0.941, P-value = 0.004). When stratifying for population, significant association was observed in Asian (additive model, pooled OR = 0.794, 95% CI = 0.694-0.909, P-value = 0.001; dominant model, pooled OR = 0.827, 95% CI = 0.709-0.965, P-value = 0.016; recessive model (pooled OR = 0.444, 95% CI = 0.293-0.675, P-value <0.0001). In the overall analysis, a comparably significant decrease in the frequency of *4/*4 genotype was detected between cases and controls in Asian while no *4/*4 genotype was detected in Caucasian in collected data.
   Conclusion: This meta-analysis suggests that the CYP2A6*4 polymorphism is associated with susceptibility of lung cancer in Asian. The whole gene deletion of CYP2A6 may decrease the risk of lung cancer in Asian samples.
C1 [Wang, Lishan; Ji, Weidong; Pan, Yaosheng; Li, Zhiqiang; Shen, Jiawei; Shi, Yongyong] Shanghai Jiao Tong Univ, Minist Educ, Bio X Inst, Shanghai 200030, Peoples R China.
   [Wang, Lishan; Ji, Weidong; Pan, Yaosheng; Li, Zhiqiang; Shen, Jiawei; Shi, Yongyong] Shanghai Jiao Tong Univ, Minist Educ, Affiliated Changning Mental Hlth Ctr, Key Lab Genet Dev & Neuropsychiat Disorders, Shanghai 200030, Peoples R China.
   [Wang, Lishan; Zang, Weidong; Xie, Dongli] FengHe ShangHai Informat Technol Co Ltd, Shanghai, Peoples R China.
   [Liu, Jiang] E China Normal Univ, Sch Life Sci, Inst Biomed Sci, Shanghai Key Lab Regulatory Biol, Shanghai 200062, Peoples R China.
   [Liu, Jiang] Hangzhou Normal Univ, Sch Med, Inst Aging Res, Hangzhou, Zhejiang, Peoples R China.
   [Ji, Weidong; Pan, Yaosheng; Shi, Yongyong] Shanghai Changning Mental Hlth Ctr, Shanghai, Peoples R China.
   [Ji, Weidong; Pan, Yaosheng; Shi, Yongyong] Shanghai Jiao Tong Univ, Inst Neuropsychiat Sci & Syst Biol Med, Shanghai 200030, Peoples R China.
RP Shi, YY (reprint author), Shanghai Jiao Tong Univ, Minist Educ, Bio X Inst, Shanghai 200030, Peoples R China.
EM shiyongyongsh@hotmail.com
CR Ariyoshi N, 2004, PHARMACOGENETICS, V14, P701, DOI 10.1097/00008571-200410000-00008
   BOYLE P, 1995, LUNG CANCER-J IASLC, V12, P167, DOI 10.1016/0169-5002(95)00443-5
   Ding XX, 2003, ANNU REV PHARMACOL, V43, P149, DOI 10.1146/annurev.pharmtox.43.100901.140251
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Fujieda M, 2004, CARCINOGENESIS, V25, P2451, DOI 10.1093/carcin/bgh258
   Gambier N, 2005, PHARMACOGENOMICS J, V5, P271, DOI 10.1038/sj.tpj.6500314
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Hoffman SMG, 2001, PHARMACOGENETICS, V11, P687, DOI 10.1097/00008571-200111000-00007
   Koskela S, 1999, BIOCHEM PHARMACOL, V57, P1407, DOI 10.1016/S0006-2952(99)00015-5
   Light R. J., 1984, SUMMING SCI REV RES
   Loriot MA, 2001, PHARMACOGENETICS, V11, P39, DOI 10.1097/00008571-200102000-00005
   Miyamoto M, 1999, BIOCHEM BIOPH RES CO, V261, P658, DOI 10.1006/bbrc.1999.1089
   Nakada T, 2012, J TOXICOL SCI, V37, P555
   Nakajima M, 1996, DRUG METAB DISPOS, V24, P1212
   Nakajima M, 2001, CLIN PHARMACOL THER, V69, P72, DOI 10.1067/mcp.2001.112688
   Oscarson M, 1999, FEBS LETT, V460, P321, DOI 10.1016/S0014-5793(99)01364-2
   Parkin DM, 2001, EUR J CANCER, V37, pS4
   Peamkrasatam S, 2006, DRUG METAB PHARMACOK, V21, P475, DOI 10.2133/dmpk.21.475
   Tamaki Y, 2011, DRUG METAB PHARMACOK, V26, P516, DOI 10.2133/dmpk.DMPK-11-RG-046
   Tan W, 2001, INT J CANCER, V95, P96, DOI 10.1002/1097-0215(20010320)95:2<96::AID-IJC1017>3.0.CO;2-2
   Tyndale RF, 2002, THER DRUG MONIT, V24, P163, DOI 10.1097/00007691-200202000-00026
   Vasconcelos GM, 2005, PHARMACOGENOMICS J, V5, P42, DOI 10.1038/sj.tpj.6500290
   Wassenaar CA, 2011, J NATL CANCER I, V103, P1342, DOI 10.1093/jnci/djr237
   Xu C, 2002, BIOCHEM BIOPH RES CO, V290, P318, DOI 10.1006/bbrc.2001.6209
   Yamazaki H, 1999, ARCH TOXICOL, V73, P65, DOI 10.1007/s002040050588
   Yoshida R, 2002, BRIT J CLIN PHARMACO, V54, P511, DOI 10.1046/j.1365-2125.2002.01667.x
NR 26
TC 11
Z9 11
U1 2
U2 18
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 9
PY 2013
VL 8
IS 4
AR e59556
DI 10.1371/journal.pone.0059556
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 130JB
UT WOS:000317909600008
PM 23585826
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Demir, M
   Oba, E
   Dirim, B
   Ozdal, E
   Can, E
AF Demir, Mehmet
   Oba, Ersin
   Dirim, Burcu
   Ozdal, Erhan
   Can, Efe
TI RETRACTED: Cental macular thickness in patients with type 2 diabetes
   mellitus without clinical retinopathy (Retracted article. See vol. 15,
   pg. 167, 2015)
SO BMC OPHTHALMOLOGY
LA English
DT Article; Retracted Publication
DE Diabetes mellitus; Central macular thickness; Glycosylated hemoglobin;
   Fasting plasma glucose level
ID OPTICAL COHERENCE TOMOGRAPHY; RETINAL VEIN OCCLUSION; GLYCOSYLATED
   HEMOGLOBIN; LASER PHOTOCOAGULATION; EDEMA SECONDARY; DIAGNOSIS; EYES;
   OCT
AB Background: An increase in macular thickness due to fluid accumulation in the macula in patients with diabetes mellitus. Optical coherence tomography (OCT) has been shown to be highly reproducible in measuring macular thickness in normal individuals and diabetic patients. OCT can detect subtle changes of macular thickness. The aim of this study is to compare central macular thickness (CMT) of diabetic patients with type 2 diabetes without clinical retinopathy and normal controls, in order to assess possible increased macular thickness associated with diabetes mellitus.
   Methods: Optical coherence tomography (OCT) measurements were performed in 124 eyes of 62 subjects with diabetes mellitus without clinically retinopathy (study group: 39 female, 23 male, mean age: 55.06 +/- 9.77 years) and in 120 eyes of 60 healthy subjects (control group: 35 female, 25 male, mean age: 55.78 +/- 10.34 years). Blood biochemistry parameters were analyzed in all cases. The data for central macular thickness (at 1 mm) and the levels of the fasting plasma glucose and glycosylated hemoglobin (HbA1c) were compared in both groups.
   Results: The mean central macular thickness was 232.12 +/- 24.41 mu m in the study group and 227.19 +/- 29.94 mu m in the control group.
   The mean HbA1c level was 8.92 +/- 2.58% in the study group and 5.07 +/- 0.70% in the control group (p=0.001). No statistically significant relationship was found between CMT, HbA1c, and fasting plasma glucose level in either group (p=0.05).
   Conclusions: Central macular thickness was not significantly thicker in patients with type 2 diabetes without clinical retinopathy than in healthy subjects.
C1 [Demir, Mehmet; Oba, Ersin; Dirim, Burcu; Ozdal, Erhan; Can, Efe] Sisli Etfal Training & Res Hosp, Eye Clin, TR-34400 Istanbul, Turkey.
RP Demir, M (reprint author), Sisli Etfal Training & Res Hosp, Eye Clin, Karayollari Mah Abdi Ipekci Bulvari 32 Avrupa Tem, TR-34400 Istanbul, Turkey.
EM ersinoba@yahoo.com
CR Ben Yahia S, 2011, OCUL IMMUNOL INFLAMM, V19, P293, DOI 10.3109/09273948.2011.582219
   Browning DJ, 2008, AM J OPHTHALMOL, V145, P889, DOI 10.1016/j.ajo.2008.01.007
   Browning DJ, 2004, OPHTHALMOLOGY, V111, P712, DOI 10.1016/j.ophtha.2003.06.028
   Chou TH, 2009, EYE, V23, P1360, DOI 10.1038/eye.2008.279
   Gardner TW, 2009, ACTA OPHTHALMOL, V87, P709, DOI 10.1111/j.1755-3768.2009.01545.x
   Girach A, 2007, INT J CLIN PRACT, V61, P88, DOI 10.1111/j.1742-1241.2006.01211.x
   HEE MR, 1995, ARCH OPHTHALMOL-CHIC, V113, P1019, DOI 10.1001/archopht.1995.01100080071031
   Ibrahim MA, 2012, EYE, V26, P454, DOI 10.1038/eye.2011.293
   Kwon Soon Il, 2011, Korean J Ophthalmol, V25, P238, DOI 10.3341/kjo.2011.25.4.238
   Medina FJL, 2012, AM J OPHTHALMOL, V153, P536, DOI 10.1016/j.ajo.2011.08.008
   Moon SW, 2011, GRAEF ARCH CLIN EXP, V249, P839, DOI 10.1007/s00417-010-1562-z
   Moreira Rodrigo O., 2001, International Ophthalmology, V24, P331, DOI 10.1023/B:INTE.0000006784.52885.e9
   Ogino K, 2011, INVEST OPHTH VIS SCI, V52, P3514, DOI 10.1167/iovs.10-7142
   ROSENSTOCK J, 1986, AM J MED, V81, P1012, DOI 10.1016/0002-9343(86)90398-0
   Sakata K, 2007, OPHTHALMOLOGY, V114, P2061, DOI 10.1016/j.ophtha.2007.01.003
   Schneeberg AE, 2003, OPHTHALMOLOGE, V100, P960, DOI 10.1007/s00347-003-0822-2
   Song Ju Hwan, 2011, Korean J Ophthalmol, V25, P156, DOI 10.3341/kjo.2011.25.3.156
   Suzuma K, 2011, JPN J OPHTHALMOL, V55, P620, DOI 10.1007/s10384-011-0085-4
   Takatsuna Y, 2011, JPN J OPHTHALMOL, V55, P365, DOI 10.1007/s10384-011-0033-3
   Udaondo P, 2011, ARCH OPHTHALMOL-CHIC, V129, P283, DOI 10.1001/archophthalmol.2011.8
   Vemala R, 2011, EYE, V25, P900, DOI 10.1038/eye.2011.84
   Virgili G, 2011, COCHRANE DB SYST REV, V7, DOI DOI 10.1002/14651858.CD008081.PUB2
   Yeung L, 2010, ACTA OPHTHALMOL, V88, P753, DOI 10.1111/j.1755-3768.2009.01711.x
NR 23
TC 6
Z9 6
U1 3
U2 11
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD APR 9
PY 2013
VL 13
AR 11
DI 10.1186/1471-2415-13-11
PG 4
WC Ophthalmology
SC Ophthalmology
GA 124TM
UT WOS:000317489900001
PM 23570310
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Estruch, R
   Ros, E
   Salas-Salvado, J
   Covas, MI
   Corella, D
   Aros, F
   Gomez-Gracia, E
   Ruiz-Gutierrez, V
   Fiol, M
   Lapetra, J
   Lamuela-Raventos, RM
   Serra-Majem, L
   Pinto, X
   Basora, J
   Munoz, MA
   Sorli, JV
   Martinez, JA
   Martinez-Gonzalez, MA
AF Estruch, Ramon
   Ros, Emilio
   Salas-Salvado, Jordi
   Covas, Maria-Isabel
   Corella, Dolores
   Aros, Fernando
   Gomez-Gracia, Enrique
   Ruiz-Gutierrez, Valentina
   Fiol, Miquel
   Lapetra, Jose
   Maria Lamuela-Raventos, Rosa
   Serra-Majem, Lluis
   Pinto, Xavier
   Basora, Josep
   Angel Munoz, Miguel
   Sorli, Jose V.
   Alfredo Martinez, Jose
   Angel Martinez-Gonzalez, Miguel
CA PREDIMED Study Investigators
TI RETRACTED: Primary Prevention of Cardiovascular Disease with a
   Mediterranean Diet (Retracted article. See vol. 378, pg. 2441, 2018)
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article; Retracted Publication
ID CORONARY-HEART-DISEASE; OLIVE OIL INTAKE; RANDOMIZED-TRIAL; METABOLIC
   SYNDROME; RISK-FACTORS; PROSPECTIVE COHORT; STYLE DIET; ADHERENCE;
   INTERVENTION; NUTRITION
AB BACKGROUND
   Observational cohort studies and a secondary prevention trial have shown an inverse association between adherence to the Mediterranean diet and cardiovascular risk. We conducted a randomized trial of this diet pattern for the primary prevention of cardiovascular events.
   METHODS
   In a multicenter trial in Spain, we randomly assigned participants who were at high cardiovascular risk, but with no cardiovascular disease at enrollment, to one of three diets: a Mediterranean diet supplemented with extra-virgin olive oil, a Mediterranean diet supplemented with mixed nuts, or a control diet (advice to reduce dietary fat). Participants received quarterly individual and group educational sessions and, depending on group assignment, free provision of extra-virgin olive oil, mixed nuts, or small nonfood gifts. The primary end point was the rate of major cardiovascular events (myocardial infarction, stroke, or death from cardiovascular causes). On the basis of the results of an interim analysis, the trial was stopped after a median follow-up of 4.8 years.
   RESULTS
   A total of 7447 persons were enrolled (age range, 55 to 80 years); 57% were women. The two Mediterranean-diet groups had good adherence to the intervention, according to self-reported intake and biomarker analyses. A primary end-point event occurred in 288 participants. The multivariable-adjusted hazard ratios were 0.70 (95% confidence interval [CI], 0.54 to 0.92) and 0.72 (95% CI, 0.54 to 0.96) for the group assigned to a Mediterranean diet with extra-virgin olive oil (96 events) and the group assigned to a Mediterranean diet with nuts (83 events), respectively, versus the control group (109 events). No diet-related adverse effects were reported.
   CONCLUSIONS
   Among persons at high cardiovascular risk, a Mediterranean diet supplemented with extra-virgin olive oil or nuts reduced the incidence of major cardiovascular events. (Funded by the Spanish government's Instituto de Salud Carlos III and others; Controlled-Trials.com number, ISRCTN35739639.)
C1 [Estruch, Ramon; Ros, Emilio; Salas-Salvado, Jordi; Covas, Maria-Isabel; Corella, Dolores; Fiol, Miquel; Lapetra, Jose; Maria Lamuela-Raventos, Rosa; Basora, Josep; Sorli, Jose V.; Alfredo Martinez, Jose] Inst Salud Carlos III, Ctr Invest Biomed Red Fisiopatol Obesidad & Nutr, Madrid, Spain.
   [Estruch, Ramon; Salas-Salvado, Jordi; Aros, Fernando; Gomez-Gracia, Enrique; Ruiz-Gutierrez, Valentina; Maria Lamuela-Raventos, Rosa; Serra-Majem, Lluis; Pinto, Xavier; Basora, Josep; Sorli, Jose V.; Alfredo Martinez, Jose; Angel Martinez-Gonzalez, Miguel] Inst Salud Carlos III, PREDIMED Prevenc Dieta Mediterranea Network RD 06, Madrid, Spain.
   [Estruch, Ramon] Univ Barcelona, Inst Invest Biomed August Pi & Sunyer, Hosp Clin, Dept Internal Med, Barcelona, Spain.
   [Ros, Emilio] Univ Barcelona, Hosp Clin, Inst Invest Biomed August Pi & Sunyer, Lipid Clin,Dept Endocrinol & Nutr, Barcelona, Spain.
   [Salas-Salvado, Jordi] Univ Rovira & Virgili, Inst Invest Sanitaria Pere Virgili, Hosp Univ St Joan, Dept Human Nutr, E-43201 Reus, Spain.
   [Covas, Maria-Isabel] Inst Recerca Hosp del Mar, Cardiovasc & Nutr Res Grp, Barcelona, Spain.
   [Corella, Dolores] Univ Valencia, Dept Prevent Med, Valencia, Spain.
   [Aros, Fernando] Univ Hosp Alava, Dept Cardiol, Vitoria, Spain.
   [Gomez-Gracia, Enrique] Univ Malaga, Dept Prevent Med, E-29071 Malaga, Spain.
   [Ruiz-Gutierrez, Valentina] CSIC, Inst Grasa, E-41080 Seville, Spain.
   [Fiol, Miquel] Univ Balearic Isl, Inst Hlth Sci IUNICS, Palma De Mallorca, Spain.
   [Fiol, Miquel] Hosp Son Espases, Palma De Mallorca, Spain.
   [Lapetra, Jose] San Pablo Hlth Ctr, Primary Care Div Seville, Dept Family Med, Seville, Spain.
   [Maria Lamuela-Raventos, Rosa] Univ Barcelona, Inst Invest Nutr & Seguridad Alimentaria, Sch Pharm, Dept Nutr & Food Sci,Xarxa Referencia Tecnol Alim, Barcelona, Spain.
   [Serra-Majem, Lluis] Univ Palmas de Gran Canaria, Dept Clin Sci, Las Palmas Gran Canaria, Spain.
   [Pinto, Xavier] Hosp Univ Bellvitge, Lipids & Vasc Risk Unit, Barcelona, Spain.
   [Basora, Josep] Inst Invest Atencio Primaria Jordi Gol, Catalan Inst Hlth, Primary Care Div, Tarragona, Spain.
   [Angel Munoz, Miguel] Inst Invest Atencio Primaria Jordi Gol, Catalan Inst Hlth, Primary Care Div, Barcelona, Spain.
   [Sorli, Jose V.] Valencia Inst Hlth, Primary Care Div, Valencia, Spain.
   [Alfredo Martinez, Jose] Univ Navarra, Dept Nutr & Food Sci, E-31080 Pamplona, Spain.
   [Alfredo Martinez, Jose] Univ Navarra, Dept Physiol, E-31080 Pamplona, Spain.
   [Alfredo Martinez, Jose] Univ Navarra, Dept Toxicol, E-31080 Pamplona, Spain.
   [Angel Martinez-Gonzalez, Miguel] Univ Navarra, Dept Prevent Med, E-31080 Pamplona, Spain.
   [Angel Martinez-Gonzalez, Miguel] Univ Navarra, Dept Publ Hlth, E-31080 Pamplona, Spain.
RP Estruch, R (reprint author), Hosp Clin Barcelona, Dept Internal Med, Villarroel 170, Barcelona 08036, Spain.
EM restruch@clinic.ub.es; mamartinez@unav.es
RI Salas-Salvado, Jordi/C-7229-2017; Gonzalez, Carlos A/O-4651-2014; Fiol,
   Miguel/F-6793-2016; Algorta, Jaime/K-9002-2012; Marti,
   Amelia/H-1192-2017; Lapetra, Jose/F-2552-2015; Lamuela Raventos,
   Rosa/F-3986-2016; Santos-Lozano, JM/J-9312-2018; Ortega-Calvo,
   Manuel/D-6960-2015; Mitjavila, Maria Teresa/D-7474-2014; Bes-Rastrollo,
   Maira/A-1329-2009; Fito, Montserrat/C-1822-2012; Bullo,
   Monica/F-2925-2016; Razquin, Cristina/H-2366-2017; Martinez-Lapiscina,
   Elena H/L-1161-2014; IBIS, ATENCION PRIMARIA/I-3524-2016
OI Salas-Salvado, Jordi/0000-0003-2700-7459; Gonzalez, Carlos
   A/0000-0003-2822-9715; Fiol, Miguel/0000-0002-5370-1391; Algorta,
   Jaime/0000-0002-7042-5675; Marti, Amelia/0000-0001-9832-7981; Lamuela
   Raventos, Rosa/0000-0002-1287-4560; Santos-Lozano,
   JM/0000-0001-7097-5653; Ortega-Calvo, Manuel/0000-0003-2391-0106;
   Mitjavila, Maria Teresa/0000-0002-1550-6253; Bes-Rastrollo,
   Maira/0000-0002-9139-4206; Fito, Montserrat/0000-0002-1817-483X; Bullo,
   Monica/0000-0002-0218-7046; Razquin, Cristina/0000-0003-3480-2645;
   Martinez-Lapiscina, Elena H/0000-0003-4272-0826; Medina-Remon,
   Alexander/0000-0003-1985-7592; Toledo, Estefania/0000-0002-6263-4434;
   Serra-Majem, Lluis/0000-0002-9658-9061; Costa,
   Bernardo/0000-0003-1985-8376; Martinez-Gonzalez, Miguel
   A./0000-0002-3917-9808; Munoz, Miguel-Angel/0000-0002-4083-3248; Pinto
   Sala, Xavier/0000-0002-2216-2444; Corbella, Emili/0000-0001-8818-1907;
   BABIO SANCHEZ, NANCY/0000-0003-3527-5277; ELOSUA,
   ROBERTO/0000-0001-8235-0095; Martinez Hernandez, J
   Alfredo/0000-0001-5218-6941; Ros, Emilio/0000-0002-2573-1294; Basora,
   Josep/0000-0003-0278-1149; Marrugat, Jaume/0000-0003-3320-554X; Cabre
   Vila, Juan Jose/0000-0003-1082-6861; Fernandez-Crehuet Navajas,
   Joaquin/0000-0002-1173-9906; Prieto, Rafel M./0000-0001-8814-900X;
   ZAZPE, ITZIAR/0000-0002-8787-2981
FU Spanish government, Instituto de Salud Carlos III (ISCIII) [RTIC
   G03/140, RTIC RD 06/0045]; Centro Nacional de Investigaciones
   Cardiovasculares [CNIC 06/2007]; Fondo de Investigacion Sanitaria-Fondo
   Europeo de Desarrollo Regional [PI04-2239, PI 05/2584, CP06/00100,
   PI07/0240, PI07/1138, PI07/0954, PI 07/0473, PI10/01407, PI10/02658,
   PI11/01647, P11/02505]; Ministerio de Ciencia e Innovacion
   [AGL-2009-13906-C02, AGL2010-22319-C03]; Fundacion Mapfre, Consejeria de
   Salud de la Junta de Andalucia [PI0105/2007]; Public Health Division of
   the Department of Health of the Autonomous Government of Catalonia,
   Generalitat Valenciana [ACOMP06109, GVACOMP2010-181, GVACOMP2011-151,
   CS2010-AP-111, CS2011-AP-042]; Regional Government of Navarra [P27/2011]
FX Supported by the official funding agency for biomedical research of the
   Spanish government, Instituto de Salud Carlos III (ISCIII), through
   grants provided to research networks specifically developed for the
   trial (RTIC G03/140, to Dr. Estruch; RTIC RD 06/0045, to Dr.
   Martinez-Gonzalez and through Centro de Investigacion Biomedica en Red
   de Fisiopatologia de la Obesidad y Nutricion [CIBERobn]), and by grants
   from Centro Nacional de Investigaciones Cardiovasculares (CNIC 06/2007),
   Fondo de Investigacion Sanitaria-Fondo Europeo de Desarrollo Regional
   (PI04-2239, PI 05/2584, CP06/00100, PI07/0240, PI07/1138, PI07/0954, PI
   07/0473, PI10/01407, PI10/02658, PI11/01647, and P11/02505), Ministerio
   de Ciencia e Innovacion (AGL-2009-13906-C02 and AGL2010-22319-C03),
   Fundacion Mapfre 2010, Consejeria de Salud de la Junta de Andalucia
   (PI0105/2007), Public Health Division of the Department of Health of the
   Autonomous Government of Catalonia, Generalitat Valenciana (ACOMP06109,
   GVACOMP2010-181, GVACOMP2011-151, CS2010-AP-111, and CS2011-AP-042), and
   Regional Government of Navarra (P27/2011).
CR Martinez-Gonzalez MA, 2012, INT J EPIDEMIOL, V41, P377, DOI 10.1093/ije/dyq250
   Bendinelli B, 2011, AM J CLIN NUTR, V93, P275, DOI 10.3945/ajcn.110.000521
   Buckland G, 2012, BRIT J NUTR, V108, P2075, DOI 10.1017/S000711451200298X
   Buckland G, 2012, AM J CLIN NUTR, V96, P142, DOI 10.3945/ajcn.111.024216
   de Lorgeril M, 1999, CIRCULATION, V99, P779, DOI 10.1161/01.CIR.99.6.779
   DELORGERIL, 1995, LANCET, V345, P738
   DELORGERIL M, 1994, LANCET, V343, P1454, DOI 10.1016/S0140-6736(94)92580-1
   Esposito K, 2004, JAMA-J AM MED ASSOC, V292, P1440, DOI 10.1001/jama.292.12.1440
   Esposito K, 2010, DIABETES RES CLIN PR, V89, P97, DOI 10.1016/j.diabres.2010.04.019
   Estruch R, 2006, ANN INTERN MED, V145, P1, DOI 10.7326/0003-4819-145-1-200607040-00004
   Fernandez-Ballarth JD, 2010, BRIT J NUTR, V103, P1808, DOI 10.1017/S0007114509993837
   Fito M, 2007, ARCH INTERN MED, V167, P1195, DOI 10.1001/archinte.167.11.1195
   Fuentes F, 2001, ANN INTERN MED, V134, P1115, DOI 10.7326/0003-4819-134-12-200106190-00011
   Furberg CD, 2002, JAMA-J AM MED ASSOC, V288, P2998
   Howard BV, 2006, JAMA-J AM MED ASSOC, V295, P655, DOI 10.1001/jama.295.6.655
   Jacobs DR, 2009, AM J CLIN NUTR, V89, pS1543, DOI 10.3945/ajcn.2009.26736B
   Kastorini CM, 2011, AM HEART J, V162, P717, DOI 10.1016/j.ahj.2011.07.012
   Kastorini CM, 2011, J AM COLL CARDIOL, V57, P1299, DOI 10.1016/j.jacc.2010.09.073
   Kris-Etherton P, 2001, CIRCULATION, V103, P1823, DOI 10.1161/01.CIR.103.13.1823
   Kris-Etherton PN, 2008, J NUTR, V138, p1746S
   Martinez-Gonzalez MA, 2008, BRIT MED J, V336, P1348, DOI 10.1136/bmj.39561.501007.BE
   Mena MP, 2009, AM J CLIN NUTR, V89, P248, DOI 10.3945/ajcn.2008.26094
   Mente A, 2009, ARCH INTERN MED, V169, P659, DOI 10.1001/archinternmed.2009.38
   Mueller-Nordhorn J, 2008, EUR HEART J, V29, P1316, DOI 10.1093/eurheartj/ehm604
   OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245
   Ros E, 2010, CURR ATHEROSCLER REP, V12, P397, DOI 10.1007/s11883-010-0132-5
   Salas-Salvado J, 2008, ARCH INTERN MED, V168, P2449, DOI 10.1001/archinte.168.22.2449
   Salas-Salvado J, 2011, DIABETES CARE, V34, P14, DOI 10.2337/dc10-1288
   Samieri C, 2011, NEUROLOGY, V77, P418, DOI 10.1212/WNL.0b013e318220abeb
   Schroder H, 2011, J NUTR, V141, P1140, DOI 10.3945/jn.110.135566
   Serra-Majem L, 2006, NUTR REV, V64, pS27, DOI 10.1301/nr.2006.feb.S27-S47
   Shai I, 2009, NEW ENGL J MED, V361, P2681
   Sofi F, 2010, AM J CLIN NUTR, V92, P1189, DOI 10.3945/ajcn.2010.29673
   Trichopoulou A, 2009, BRIT MED J, V338, DOI 10.1136/bmj.b2337
   Vincent-Baudry S, 2005, AM J CLIN NUTR, V82, P964
   WILLETT WC, 1995, AM J CLIN NUTR, V61, p1402S, DOI 10.1093/ajcn/61.6.1402S
   Zazpe I, 2008, J AM DIET ASSOC, V108, P1134, DOI 10.1016/j.jada.2008.04.011
NR 37
TC 1995
Z9 2034
U1 105
U2 865
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD APR 4
PY 2013
VL 368
IS 14
BP 1279
EP 1290
DI 10.1056/NEJMoa1200303
PG 12
WC Medicine, General & Internal
SC General & Internal Medicine
GA 117YT
UT WOS:000316989900005
PM 23432189
OA Green Published
DA 2018-12-27
ER

PT J
AU Dionysopoulos, D
   Koliniotou-Koumpia, E
   Helvatzoglou-Antoniades, M
   Kotsanos, N
AF Dionysopoulos, Dimitrios
   Koliniotou-Koumpia, Eugenia
   Helvatzoglou-Antoniades, Maria
   Kotsanos, Nikolaos
TI RETRACTED: Fluoride release and recharge abilities of contemporary
   fluoride-containing restorative materials and dental adhesives
   (Retracted article. See vol. 34, pg. 410, 2015)
SO DENTAL MATERIALS JOURNAL
LA English
DT Article; Retracted Publication
DE Fluoride release; Fluoride recharge; Restorative materials; Dental
   adhesives
ID GLASS-IONOMER CEMENTS; RESIN COMPOSITE; COMPOMER; INHIBITION; FILLERS;
   SILICA; ACID; TERM
AB The aim of this study was to evaluate the fluoride release of five fluoride-releasing restorative materials and three dental adhesives, before and after NaF solution treatment. Five restorative materials (Fuji IX GP, GC Corp.; Ketac N100, 3M ESPE; Dyract Extra, Dentsply; Beautifil II, Shofu Inc.; Wave, SDI) and three dental adhesives (Stae, SDI; Fluorobond - II Shofu Inc.; Prime & Bond NT, Dentsply) were investigated before and after NaF solution treatment. A fluoride ion-selective electrode was to measure fluoride concentrations. During the 86-day period before NaF solution treatment, Fuji IX GP released the highest amount of fluoride among the restorative materials while Prime & Bond NT was the highest among the dental adhesives. After NaF solution treatment, Fuji IX GP again ranked the highest in fluoride release among the restorative materials while Fluorobond II ranked the highest among dental adhesives. It was concluded that the compositions and setting mechanisms of fluoride-containing dental materials influenced their fluoride release and recharge abilities.
C1 [Dionysopoulos, Dimitrios; Koliniotou-Koumpia, Eugenia; Helvatzoglou-Antoniades, Maria] Aristotle Univ Thessaloniki, Fac Dent, Dept Operat Dent, Thessaloniki, Greece.
   [Kotsanos, Nikolaos] Aristotle Univ Thessaloniki, Fac Dent, Dept Pediat Dent, Thessaloniki, Greece.
RP Dionysopoulos, D (reprint author), Aristotle Univ Thessaloniki, Fac Dent, Dept Operat Dent, Thessaloniki, Greece.
EM ddiondent@gmail.com
CR Attar N, 2002, J ORAL REHABIL, V29, P791, DOI 10.1046/j.1365-2842.2002.00902.x
   Attin T, 1999, J ORAL REHABIL, V26, P388, DOI 10.1046/j.1365-2842.1999.00413.x
   Cildir SK, 2005, DENT MATER J, V24, P92
   DeSchepper E J, 1991, Quintessence Int, V22, P215
   Dhondt CL, 2001, J DENT RES, V80, P1402, DOI 10.1177/00220345010800050301
   DIJKMAN GEHM, 1992, CARIES RES, V26, P351, DOI 10.1159/000261467
   Dionysopoulos P, 2003, J ORAL REHABIL, V30, P866, DOI 10.1046/j.1365-2842.2003.00993.x
   Eliades G, 1998, DENT MATER, V14, P57, DOI 10.1016/S0109-5641(98)00010-4
   Featherstone J D, 1990, J Dent Res, V69 Spec No, P620
   Ferracane JL, 1998, AM J DENT, V11, P23
   Glasspoole EA, 2001, AM J DENT, V14, P8
   Grobler SR, 1998, J DENT, V26, P259, DOI 10.1016/S0300-5712(97)00011-0
   Han LL, 2002, DENT MATER J, V21, P285, DOI 10.4012/dmj.21.285
   Han LL, 2002, DENT MATER J, V21, P9, DOI 10.4012/dmj.21.9
   Hara AT, 2005, EUR J ORAL SCI, V113, P245, DOI 10.1111/j.1600-0722.2005.00214.x
   Ikemura K, 2003, DENT MATER, V19, P137, DOI 10.1016/S0109-5641(02)00022-2
   Ikemura K, 2008, DENT MATER J, V27, P315, DOI 10.4012/dmj.27.315
   Itota T, 2004, DENT MATER, V20, P789, DOI 10.1016/j.dental.2003.11.009
   Itota T, 1999, Dent Mater J, V18, P347
   Jacobson APM, 1991, CARIES RES, V25, P230
   Karantakis P, 2000, OPER DENT, V25, P20
   Markovic Dejan Lj, 2008, BMC Oral Health, V8, P21, DOI 10.1186/1472-6831-8-21
   Mukai Y, 2005, DENT MATER J, V24, P172, DOI 10.4012/dmj.24.172
   Preston AJ, 2003, DENT MATER, V19, P32, DOI 10.1016/S0109-5641(02)00011-8
   Preston AJ, 1999, J ORAL REHABIL, V26, P123, DOI 10.1046/j.1365-2842.1999.00357.x
   Shaw AJ, 1998, J DENT, V26, P355, DOI 10.1016/S0300-5712(97)00016-X
   Suljak J P, 1996, Quintessence Int, V27, P635
   Tam LE, 1997, OPER DENT, V22, P4
   Ten Cate J M, 1990, J Dent Res, V69 Spec No, P614
   Tjandrawinata R, 2004, DENT MATER J, V23, P305, DOI 10.4012/dmj.23.305
   Wiegand A, 2007, DENT MATER, V23, P343, DOI 10.1016/j.dental.2006.01.022
   Williams JA, 2001, J ORAL REHABIL, V28, P41, DOI 10.1046/j.1365-2842.2001.00628.x
   Williams JA, 1999, BIOMATERIALS, V20, P1327, DOI 10.1016/S0142-9612(99)00035-6
   Yaman Sis Darendeliler, 2004, J Oral Sci, V46, P45, DOI 10.2334/josnusd.46.45
   Yap AUJ, 2002, OPER DENT, V27, P259
   Yip HK, 2000, QUINTESSENCE INT, V31, P261
   Yli-Urpo H, 2004, J BIOMATER APPL, V19, P5, DOI 10.1177/0085328204044538
NR 37
TC 27
Z9 30
U1 3
U2 17
PU JAPANESE SOC DENTAL MATERIALS DEVICES
PI TOKYO
PA C/O KOKU HOKEN KYOKAI, 1-43-9 KOMAGOME TS BDG, KOMAGOME, TOSHIMA-KU,
   TOKYO, 170-0003, JAPAN
SN 0287-4547
J9 DENT MATER J
JI Dent. Mater. J.
PD APR
PY 2013
VL 32
IS 2
BP 296
EP 304
DI 10.4012/dmj.2012-144
PG 9
WC Dentistry, Oral Surgery & Medicine; Materials Science, Biomaterials
SC Dentistry, Oral Surgery & Medicine; Materials Science
GA 205TJ
UT WOS:000323467400013
PM 23538766
OA Bronze
DA 2018-12-27
ER

PT J
AU Schwentner, C
   Todenhofer, T
   Seibold, J
   Alloussi, S
   Aufderklamm, S
   Mischinger, J
   Stenzl, A
   Gakis, G
AF Schwentner, C.
   Todenhoefer, T.
   Seibold, J.
   Alloussi, S.
   Aufderklamm, S.
   Mischinger, J.
   Stenzl, A.
   Gakis, G.
TI RETRACTED: Cost Effective Laparoendoscopic Single-Site Surgery with a
   Reusable Platform (Retracted article. See vol. 19, 2015)
SO JSLS-JOURNAL OF THE SOCIETY OF LAPAROENDOSCOPIC SURGEONS
LA English
DT Article; Retracted Publication
DE LESS; Single-port; Reusable platform; Cost; Nephrectomy
ID CONVENTIONAL LAPAROSCOPIC NEPHRECTOMY; RADICAL PROSTATECTOMY; CLINICAL
   REPORT; PORT; CHOLECYSTECTOMY; FEASIBILITY; INSTRUMENTS; LESS
AB Background and Objectives: Many disposable platforms have been applied in laparoendoscopic single-site surgery (LESS). Besides technical issues, cost is one of the limiting factors for its widespread acceptance. The current study describes the first completely reusable LESS-platform.
   Methods: We performed LESS-procedures in 52 patients including nephrectomy (18), adrenalectomy (2), partial nephrectomy (3), pyeloplasty (4), renal cyst ablation (4), pelvic lymphadenectomy (15), and lymphocele ablation (6). All procedures were conducted using a novel reusable single-port device (X-Cone, Karl-Storz) with a simplified set of instruments. We obtained perioperative and demographic data, including a visual analogue pain scale (VAS), and a complication reporting system based on Clavien grading.
   Results: Mean age was 50.04 y. Conversion to standard laparoscopy was necessary in 3 cases and addition of a needlescopic instrument in 6 cases. There was no open conversion. Intra-and postoperative complications occurred in 3 (Clavien II in 2 and III in 1) cases. Mean operative time was 110, 90, and 89 min, and hospital stay was 4.9, 3.1, and 3.6 d for nephrectomy, pelvic lymphadenectomy, and pyeloplasty, respectively. Mean VAS was 2.13, 1.07, and 1.5 while blood loss was 81.3 mL, 25.67 mL, and 17.5 mL, respectively. Mean lymph node yield was 15 (range, 8 to 21).
   Conclusions: A completely reusable LESS-platform is applicable to various uses in urology, yielding favorable functional and cosmetic results. Reusable materials are useful to reduce the cost of LESS, further increasing its acceptance. LESS with a completely reusable platform is more cost effective than standard laparoscopy.
C1 [Schwentner, C.; Todenhoefer, T.; Seibold, J.; Alloussi, S.; Aufderklamm, S.; Mischinger, J.; Stenzl, A.; Gakis, G.] Univ Tubingen, Dept Urol, D-72076 Tubingen, Germany.
RP Schwentner, C (reprint author), Univ Tubingen, Dept Urol, Hoppe Seyler Str 3, D-72076 Tubingen, Germany.
EM christian.schwentner@med.uni-tuebingen.de
CR Adler S, 2005, SURG ENDOSC, V19, P268, DOI 10.1007/s00464-003-9232-4
   Autorino R, 2011, J ENDOUROL, V25, P419, DOI 10.1089/end.2010.0415
   Autorino R, 2011, EUR UROL, V59, P26, DOI 10.1016/j.eururo.2010.08.030
   Canes D, 2010, EUR UROL, V57, P95, DOI 10.1016/j.eururo.2009.07.023
   Dapri Giovanni, 2010, Surg Technol Int, V20, P21
   Davis JW, 2011, BJU INT, V108, P993, DOI 10.1111/j.1464-410X.2011.10454.x
   Desai MM, 2008, UROLOGY, V72, P960, DOI 10.1016/j.urology.2008.06.007
   Desai MM, 2008, BJU INT, V101, P83, DOI 10.1111/j.1464-410X.2007.07359.x
   Desai MM, 2009, UROLOGY, V74, P805, DOI 10.1016/j.urology.2009.02.083
   Dindo D, 2004, ANN SURG, V240, P205, DOI 10.1097/01.sla.0000133083.54934.ae
   Fan XX, 2012, EUR UROL, V62, P601, DOI 10.1016/j.eururo.2012.05.055
   Gaboardi F, 2011, BJU INT, V107, P460, DOI 10.1111/j.1464-410X.2010.09475.x
   Gettman MT, 2011, EUR UROL, V59, P231, DOI 10.1016/j.eururo.2010.11.016
   Gill IS, 2010, SURG ENDOSC, V24, P762, DOI 10.1007/s00464-009-0688-8
   Greco F, 2012, EUR UROL, V62, P168, DOI 10.1016/j.eururo.2011.10.002
   Haber GP, 2010, UROLOGY, V76, P1279, DOI 10.1016/j.urology.2010.06.070
   Jeon HG, 2010, J UROLOGY, V183, P1866, DOI 10.1016/j.juro.2010.01.023
   Kaouk JH, 2009, BJU INT, V103, P366, DOI 10.1111/j.1464-410X.2008.07949.x
   Krajinovic K, 2011, SURG INNOV, V18, P39, DOI 10.1177/1553350610389195
   Muller EM, 2010, INT J SURG, V8, P64, DOI 10.1016/j.ijsu.2009.11.003
   Nagele U, 2011, WORLD J UROL
   Nicolay LI, 2011, J ENDOUROL, V25, P1187, DOI 10.1089/end.2010.0623
   Ramalingam Manickam, 2010, Diagn Ther Endosc, V2010, P598165, DOI 10.1155/2010/598165
   Raman JD, 2007, UROLOGY, V70, P1039, DOI 10.1016/j.urology.2007.10.001
   Raman JD, 2009, EUR UROL, V55, P1198, DOI 10.1016/j.eururo.2008.08.019
   Rane A, 2008, UROLOGY, V72, P260, DOI 10.1016/j.urology.2008.01.078
   Schwentner I, 2007, J EVAL CLIN PRACT, V13, P942, DOI 10.1111/j.1365-2753.2006.00823.x
   Seo IY, 2011, J ENDOUROL, V25, P465, DOI 10.1089/end.2010.0465
   Stolzenburg JU, 2009, EUR UROL, V56, P644, DOI 10.1016/j.eururo.2009.06.022
   Stolzenburg JU, 2011, WORLD J UROL
   Stroup SP, 2010, BJU INT, V106, P934, DOI 10.1111/j.1464-410X.2010.09673.x
   Tugcu V, 2010, J ENDOUROL, V24, P1315, DOI 10.1089/end.2010.0048
   White WM, 2009, UROLOGY, V74, P801, DOI 10.1016/j.urology.2009.04.030
   Yu HY, 2012, J UROLOGY, V187, P1392, DOI 10.1016/j.juro.2011.11.089
NR 34
TC 5
Z9 5
U1 2
U2 9
PU SOC LAPAROENDOSCOPIC SURGEONS
PI MIAMI
PA 7330 SW 62 PL, STE 410, MIAMI, FL 33143-4825 USA
SN 1086-8089
J9 JSLS-J SOC LAPAROEND
JI JSLS-J. Soc. Laparoendosc. Surg.
PD APR-JUN
PY 2013
VL 17
IS 2
BP 285
EP 291
DI 10.4293/108680813X13654754534477
PG 7
WC Surgery
SC Surgery
GA 200CV
UT WOS:000323045800017
PM 23925023
OA Other Gold, Green Published
DA 2018-12-27
ER

PT J
AU Xiang, Q
   Wang, CL
   Song, S
   Jing, R
AF Xiang, Qiong
   Wang, Chang-Lin
   Song, Shuo
   Jing, Rui
TI RETRACTED: Interaction of Somatostatin receptor-2 and Neuropeptide Y
   receptor-1 in mice dorsal root ganglion neurons on the Pinch-nerve
   injury model (Retracted article. See vol. 110, pg. 273, 2013)
SO PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR
LA English
DT Article; Retracted Publication
DE Somatostatin receptor-2 SST2; Neuropeptide Y receptors-1 Y1;
   Interaction; Dorsal root ganglion DRG; Pinch-nerve injury
ID PERIPHERAL NEUROPATHY; PAIN; EXPRESSION; RAT; IMMUNOFLUORESCENCE;
   PHARMACOLOGY; TYROSINE
AB The aim of this paper was to evaluate the interactions of Somatostatin receptor-2 (SST2) and Neuropeptide Y receptors-1 (Y1) by molecular, pharmacological and behavioral studies. Double-immunolabeling of SST2 and Y1 has shown the colocalization of these two receptors in the dorsal root ganglion (DRG) neurons. On the basis of the Pinch nerve injury model, the mechanical hyperalgesia and severely painful behavior (autotomy) were detected after the application of SST2 antibody (anti-SST2; 200 mu g/kg) on the pinch-injured nerve. The differential distribution of Y1 and up-regulation of PKC expression in DRGs were observed after anti-SST2 treatment. Our results indicated for the first time the interactions of SST2 and Y1 in DRGs, which have functional role in pain modulation and might give rise to explore possible novel therapeutic strategies against pain. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Xiang, Qiong; Wang, Chang-Lin; Song, Shuo] Harbin Inst Technol, Sch Life Sci & Technol, Harbin 150001, Peoples R China.
   [Jing, Rui] Harbin Inst Technol, Sch Management, Harbin 150001, Peoples R China.
   [Song, Shuo] Univ Freiburg, Inst Expt & Clin Pharmacol & Toxicol, D-79106 Freiburg, Germany.
RP Xiang, Q (reprint author), Harbin Inst Technol, Sch Life Sci & Technol, Harbin 150001, Peoples R China.
EM xq_119@163.com
FU Harbin Institute of Technology
FX We are grateful to Professor Tomas Hokfelt and Dr. T.-J. S. Shi
   (Department of Neuroscience, Karolinska Institutet, Sweden) for their
   great supervision contribution. We thank Professor Stefan Schulz
   (Department of Pharmacology and Toxicology, Otto-Von-Guericke
   University, Magdeburg) for his generous donations of SST2 antiserum. The
   work was supported by Harbin Institute of Technology Research Award Fund
   for Dr. T.-J. S. Shi.
CR Barnes NM, 1999, NEUROPHARMACOLOGY, V38, P1083, DOI 10.1016/S0028-3908(99)00010-6
   Brain SD, 2006, BRIT J PHARMACOL, V147, pS202, DOI 10.1038/sj.bjp.0706461
   Branchek T, 1998, ANN NY ACAD SCI, V863, P94, DOI 10.1111/j.1749-6632.1998.tb10687.x
   Brumovsky P, 2007, TRENDS PHARMACOL SCI, V28, P93, DOI 10.1016/j.tips.2006.12.003
   Chabre M, 2009, TRENDS PHARMACOL SCI, V30, P182, DOI 10.1016/j.tips.2009.01.003
   Elliott DE, 1999, EUR J IMMUNOL, V29, P2454, DOI 10.1002/(SICI)1521-4141(199908)29:08<2454::AID-IMMU2454>3.0.CO;2-H
   Forbes S, 2012, BR J PHARM
   Guo W, 2008, EMBO J, V27, P2293, DOI 10.1038/emboj.2008.153
   Hofland LJ, 1999, J CLIN ENDOCR METAB, V84, P775, DOI 10.1210/jc.84.2.775
   Hokfelt T, 2007, PEPTIDES, V28, P365, DOI 10.1016/j.peptides.2006.07.024
   JOHNSON GD, 1981, J IMMUNOL METHODS, V43, P349, DOI 10.1016/0022-1759(81)90183-6
   KAJANDER KC, 1992, NEUROSCI LETT, V138, P225, DOI 10.1016/0304-3940(92)90920-3
   Lemons LL, 2012, NEUROSCIENCE
   Marchand JE, 1999, PAIN, V79, P187, DOI 10.1016/S0304-3959(98)00165-1
   Milligan G, 2009, BRIT J PHARMACOL, V158, P5, DOI 10.1111/j.1476-5381.2009.00169.x
   Pitcher GM, 2000, EUR J NEUROSCI, V12, P2006, DOI 10.1046/j.1460-9568.2000.00087.x
   PLATT JL, 1983, J HISTOCHEM CYTOCHEM, V31, P840, DOI 10.1177/31.6.6341464
   Rowlands DK, 2012, CELL BIOL INT, V36, P63, DOI 10.1042/CBI20110015
   Shi TJS, 2006, NEUROSCIENCE, V140, P293, DOI 10.1016/j.neuroscience.2006.02.009
   Stengel A, 2010, PHYSIOL BEHAV, V101, P614, DOI 10.1016/j.physbeh.2010.09.009
   Xin W, 2012, INT J NEUROSCI, V122, P154, DOI 10.3109/00207454.2011.635828
   Zhang X, 1996, NEUROSCI RES, V25, P359
NR 22
TC 1
Z9 2
U1 3
U2 15
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0091-3057
J9 PHARMACOL BIOCHEM BE
JI Pharmacol. Biochem. Behav.
PD APR
PY 2013
VL 105
BP 71
EP 75
DI 10.1016/j.pbb.2013.02.001
PG 5
WC Behavioral Sciences; Neurosciences; Pharmacology & Pharmacy
SC Behavioral Sciences; Neurosciences & Neurology; Pharmacology & Pharmacy
GA 136TX
UT WOS:000318387400010
PM 23402941
DA 2018-12-27
ER

PT J
AU Senyigit, E
AF Senyigit, E.
TI RETRACTED: The analysis of heuristics for supplier selection and
   purchase problem under stochastic demand (Retracted Article)
SO INTERNATIONAL JOURNAL OF PRODUCTION RESEARCH
LA English
DT Correction; Retracted Publication
OI Senyigit, Ercan/0000-0002-9388-2633
CR Senyigit E, 2013, NEURAL COMPUT APPL, V22, P403, DOI 10.1007/s00521-011-0704-5
NR 1
TC 0
Z9 0
U1 2
U2 23
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0020-7543
EI 1366-588X
J9 INT J PROD RES
JI Int. J. Prod. Res.
PD APR 1
PY 2013
VL 51
IS 8
BP 2568
EP 2568
DI 10.1080/00207543.2012.750084
PG 1
WC Engineering, Industrial; Engineering, Manufacturing; Operations Research
   & Management Science
SC Engineering; Operations Research & Management Science
GA 097FU
UT WOS:000315460200024
OA Bronze
DA 2018-12-27
ER

PT J
AU Ramello, S
AF Ramello, Stefano
TI RETRACTED: Same sex acts involving older men. An ethnographic study
   (Retracted article. See vol. 31, pg. 182, 2014)
SO JOURNAL OF AGING STUDIES
LA English
DT Article; Retracted Publication
DE Older men; Sexuality; Homosexual; Gay; Bathhouses; Aging; Ethnography
ID HIGHWAY REST AREA; PARTICIPANT OBSERVATION; QUALITATIVE RESEARCH; GAY
   BATHS; DISSATISFACTION; COMMUNICATION; ENCOUNTERS; SETTINGS; IDENTITY;
   CULTURE
AB For many men in modern Western societies it is not uncommon to have anonymous same-sex acts in cruising places with a varying frequency depending on many factors, e.g. their biographical history, marital status, religion, and age. This paper looks at generational differences in the Italian gay community and specifically contrasts both setting and patterns of social interaction of two cohorts of men (older men and younger adults) patronizing bathhouses. The meaning of adult development and aging of sexual minorities is little understood in Italy. For the first time in history, a generation of self-identified gay men is approaching retirement, and yet we do not understand what well-being and successful development in later life mean in this community. Moreover, the aging processes among gay men who are already in their retirement years, many of whom are still "closeted," remain invisible. The ethnographic report, based on two years of participant observation, reveals the culture of the gay bath and the social and sexual spaces of older and younger gay men and their self-definitions and relationship to the "gay community". (C) 2012 Elsevier Inc. All rights reserved.
EM stefano.ramello@gmail.com
CR Adler P. A., 1994, HDB QUALITATIVE RES, P377
   American Sociological Association, 2008, COD ETH
   Barbagli M., 2001, OMOSESSUALI MODERNI
   Barilli G. Rossi, 1999, MOVIMENTO GAY ITALIA
   Becker G. S, 1975, HUMAN CAPITAL
   Beren SE, 1996, INT J EAT DISORDER, V20, P135, DOI 10.1002/(SICI)1098-108X(199609)20:2<135::AID-EAT3>3.0.CO;2-H
   Bernard H, 1994, RES METHODS ANTHR
   Bertone C., 2008, SITUATION HOMOPHOBIA
   Bertone C., 2003, DIVERSI CHI
   BOLTON R, 1994, GLQ-J LESBIAN GAY ST, V1, P255
   Bolton R., 1995, TABOO SEX IDENTITY E, P140
   Bourdieu P, 1994, PRACTICAL REASON
   Bourdieu Pierre, 1980, LOGIC PRACTICE
   Brown MT, 2009, SEX RES SOC POLICY, V6, P65, DOI 10.1525/srsp.2009.6.4.65
   Capron A.M, 1989, MED ETHICS, P125
   Cartabia M., 2008, LEGAL STUDY HOMOPHOB
   Chauncey George, 1994, GAY NEW YORK GENDER
   Cicourel Aaron V, 1964, METHOD MEASUREMENT S
   Clarke L., 1996, NT RES, V1, P431
   COLEMAN JS, 1988, AM J SOCIOL, V94, pS95, DOI 10.1086/228943
   CORZINE J, 1977, URBAN LIFE, V6, P171, DOI 10.1177/089124167700600203
   Cotts Watkins S., 2009, HDB SOCIOLOGY HLTH I
   D'Emilio John, 1983, SEXUAL POLITICS SEXU
   DELPH EW, 1978, SILENT COMMUNITY PUB
   DENZIN NK, 1970, RES ACT
   DENZIN NK, 1989, INTERPRETIVE INTERAC
   Dillon P., 1999, CULTURE HLTH SEXUALI, V1, P317, DOI DOI 10.1080/136910599300914
   Dowd JJ, 2012, J AGING STUD, V26, P285, DOI 10.1016/j.jaging.2012.01.004
   DRUMMOND M, 2010, GAY LESBIAN ISSUES P, V6, P31
   Drummond Murray, 2005, MEN MASC, V7, P270, DOI [10.1177/1097184X04271357, DOI 10.1177/1097184X04271357]
   Drummond Murray, 2006, GAY LESBIAN ISSUES P, V2, P60
   Eliasoph N, 2003, AM J SOCIOL, V108, P735, DOI 10.1086/367920
   Ellingson S., 2004, SEXUAL ORG CITY, P349
   Elliott R, 1999, BRIT J CLIN PSYCHOL, V38, P215, DOI 10.1348/014466599162782
   Fenkl EA, 2012, J LGBT ISS COUNS, V6, P162, DOI 10.1080/15538605.2012.711514
   Fox RC, 2007, J HOMOSEXUAL, V52, P33, DOI 10.1300/J082v52n03_03
   Fredriksen-Goldsen K., 2006, RES AGING, V32, P372
   Friend RA, 1980, ALTERNATIVE LIFESTYL, V3, P231, DOI [10.1007/BF01083517, DOI 10.1007/BF01083517]
   Goffman E, 1959, PRESENTATION SELF EV
   Goffman Erving, 1967, INTERACTION RITUAL E
   Goltz DB, 2007, WESTERN J COMM, V71, P93, DOI 10.1080/10570310701348783
   Green AI, 2008, SOCIOL THEOR, V26, P25, DOI 10.1111/j.1467-9558.2008.00317.x
   GRUBE J, 1990, J HOMOSEXUAL, V20, P119
   Hajek C, 2002, J COMMUN, V52, P698, DOI 10.1111/j.1460-2466.2002.tb02569.x
   HARRY J, 1978, ARCH SEX BEHAV, V7, P199, DOI 10.1007/BF01542379
   HERZOG DB, 1991, J NERV MENT DIS, V179, P356, DOI 10.1097/00005053-199106000-00009
   Horn G. C., 1998, HLTH DIFF 2 C MELB A
   Humphreys L, 1975, TEAROOM TRADE IMPERS
   JOHNSON M, 1992, INT J NURS STUD, V29, P213, DOI 10.1016/0020-7489(92)90010-E
   KELLY J, 1977, GERONTOLOGIST, V17, P328, DOI 10.1093/geront/17.4.328
   Kennedy S., 2008, ADVOCATE, V1012, P32
   Keogh P, 1999, SOC AS AIDS, P121
   LEE JA, 1987, J HOMOSEXUAL, V13, P43, DOI 10.1300/J082v13n04_03
   Li J, 2008, QUAL REP, V13, P100
   Lindlof T. R., 2002, QUALITATIVE COMMUNIC
   MAYS N, 1995, BRIT MED J, V311, P182, DOI 10.1136/bmj.311.6998.182
   Mills C. W., 1959, SOCIOLOGICAL IMAGINA
   Mulhall A, 2003, J ADV NURS, V41, P306, DOI 10.1046/j.1365-2648.2003.02514.x
   Olsen W. K., 2004, DEV SOCIOLOGY
   Pietila I, 2011, J AGING STUD, V25, P380, DOI 10.1016/j.jaging.2011.01.005
   Pugh S., 2002, HDB LESBIAN GAY STUD, P161
   Putnam R. D., 1993, MAKING DEMOCRACY WOR
   Rogers E., 1978, ALIVE, V1, P20
   Rosenfeld D, 1999, J AGING STUD, V13, P121, DOI 10.1016/S0890-4065(99)80047-4
   Rosenfeld D., 2003, CHANGING GUARD LESBI
   Schaffer R., 1973, WILL YOU STILL NEED
   Schlesinger B., 1995, SENIORS SEXUALITY EX, P5
   Schuster E, 1996, J AGING STUD, V10, P57, DOI 10.1016/S0890-4065(96)90017-1
   Seal DW, 2000, HEALTH EDUC BEHAV, V27, P10, DOI 10.1177/109019810002700102
   Simon W., 1988, THEORIES HUMAN SEXUA, P363
   Somlai AM, 2001, AIDS CARE, V13, P503, DOI 10.1080/09540120120058030
   Spradley J. P., 1980, PARTICIPANT OBSERVAT
   STYLES J, 1979, URBAN LIFE, V8, P135, DOI 10.1177/089124167900800202
   Swidler Ann, 2001, TALK LOVE CULTURE MA
   Tattelman Ira, 1999, PUBLIC SEX GAY SPACE, P71
   TEDLOCK B, 1991, J ANTHROPOL RES, V47, P69, DOI 10.1086/jar.47.1.3630581
   Tewksbury R, 2002, DEVIANT BEHAV, V23, P75, DOI 10.1080/016396202317192035
   Tewksbury R, 1996, DEVIANT BEHAV, V17, P1, DOI 10.1080/01639625.1996.9968012
   Troiden R. R., 1974, SEXUAL DEVIANCE SEXU, P211
   VANLIESHOUT M, 1995, J HOMOSEXUAL, V29, P19, DOI 10.1300/J082v29n01_02
   Weber Max, 1949, METHODOLOGY SOCIAL S
   WEINBERG MS, 1970, SOC PROBL, V17, P528
   Williams A, 1998, J APPL COMMUN RES, V26, P139, DOI 10.1080/00909889809365496
   Williams A, 1996, HUM COMMUN RES, V23, P220, DOI 10.1111/j.1468-2958.1996.tb00393.x
   2003, MERRIAM WEBSTER ONLI
NR 85
TC 3
Z9 3
U1 1
U2 15
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0890-4065
EI 1879-193X
J9 J AGING STUD
JI J. Aging Stud.
PD APR
PY 2013
VL 27
IS 2
BP 121
EP 134
DI 10.1016/j.jaging.2012.12.005
PG 14
WC Gerontology
SC Geriatrics & Gerontology
GA 137VU
UT WOS:000318467100004
PM 23561277
DA 2018-12-27
ER

PT J
AU Xu, MX
   Tan, BC
   Zhou, W
   Wei, T
   Lai, WH
   Tan, JW
   Dong, JH
AF Xu, Min-Xuan
   Tan, Bing-Chang
   Zhou, Wei
   Wei, Ting
   Lai, Wei-Hong
   Tan, Jing-Wang
   Dong, Jia-Hong
TI RETRACTED: Resolvin D1, an Endogenous Lipid Mediator for Inactivation of
   Inflammation-Related Signaling Pathways in Microglial Cells, Prevents
   Lipopolysaccharide-Induced Inflammatory Responses (Retracted article.
   See vol. 19, pg. 541, 2013)
SO CNS NEUROSCIENCE & THERAPEUTICS
LA English
DT Article; Retracted Publication
DE Lipopolysaccharide; Microglial cells; Nerve inflammation;
   Phosphorylation; Resolvin D1
ID LIPOXIN A(4) RECEPTOR; NEURODEGENERATION; IDENTIFICATION; ANGIOGENESIS
AB Backgrounds and aim Microglial cells as an important part of central nervous system (CNS) have generally believed to play significant role in the process leading to a number of neurodegenerative disorders including Parkinson's disease, Alzheimer's disease, prion diseases, multiple sclerosis, HIV-dementia, and stroke. Although different diseases have quite different pathogenesis, the activation of microglia was shared with all of them. Recently, the resolvin D1 (RvD1) as an endogenous antiinflammatory lipid mediator has been confirmed to be involved in the treatment of inflammation-related neuronal injury in neurodegenerative diseases. Therefore, the inhibition of microglia-activated inflammation has been considered as a major treatment strategy in neurodegenerative disease therapy. However, the molecular mechanisms of RvD1 in microglial cells remain unknown and still do not be reported. Methods We taken murine microglia as the experimental sample, and Western blotting, ELISA, reverse-transcriptase PCR, real-time PCR, and electrophoretic mobility shift assay were used to study whether the RvD1 inhibit inflammation of microglial cells. The tumor necrosis factor (TNF-), IL-1, inducible nitric oxide synthase (iNOS) expression, nuclear factor-B (NF-B) activation, and mitogen-activated protein kinase (MAPK) pathways were investigated in lipopolysaccharide (LPS)-activated primary microglia. Results Our data suggested that RvD1 inhibited the production of LPS-induced microglia inflammatory mediators and TNF-, IL-1, and iNOS expression. In addition, according to the study of related signaling pathways, RvD1 attenuated LPS-induced microglia NF-B activation,MAPK phosphorylation, and activator protein-1 transcriptional activity. Conclusion This is the first study to demonstrate that RvD1 effects on the reduction of pro-inflammatory responses in LPS-induced microglial cells. The mechanisms underlying these effects may include its potent intracellular NF-B down-regulation and subsequent pro-inflammatory cytokines release in LPS-activated microglia.
C1 [Xu, Min-Xuan; Tan, Bing-Chang; Tan, Jing-Wang; Dong, Jia-Hong] Chinese Peoples Liberat Army Gen Hosp, PLA Med Sch, Chinese PLA Med Sch, Beijing 100038, Peoples R China.
   [Tan, Bing-Chang] Guizhou Univ, Coll Anim Sci, Guiyang, Peoples R China.
   [Zhou, Wei] Soochow Univ, Sch Med, Dept Cell Biol, Suzhou, Peoples R China.
   [Wei, Ting] Southeast Univ, Res Ctr Learning Sci, Nanjing, Jiangsu, Peoples R China.
   [Lai, Wei-Hong] Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA.
   [Dong, Jia-Hong] Peoples Liberat Army Gen Hosp, Inst Hepatobiliary Surg, Beijing 100853, Peoples R China.
   [Dong, Jia-Hong] PLA Med Sch, Beijing 100853, Peoples R China.
RP Tan, JW (reprint author), Chinese Peoples Liberat Army Gen Hosp, PLA Med Sch, Chinese PLA Med Sch, Beijing 100038, Peoples R China.
EM tanjingwang02@yahoo.com.cn; dongjh301@163.com
FU Research Center of Biomedical engineering, Chinese PLA General Hospital,
   Chinese PLA Medical School, Beijing, China; National High-tech R&D
   Program of China [2012BAI06Bo1]; National Ministry of Health, China
   [200802012]; National S&T Major Project for infectious disease of China
   [2012Zx10002-017]
FX We thank Yi-Cheng Zhu, Yao Xu, Jin-Ke Liu, Heng-Zhi Tan, and Xi-Ming Ba
   for their valuable comments, and the support of Research Center of
   Biomedical engineering, Chinese PLA General Hospital, Chinese PLA
   Medical School, Beijing, 100038, China.; This work was supported by the
   National High-tech R&D Program of China (No. 2012BAI06Bo1); National
   Ministry of Health, China (No: 200802012) and National S&T Major Project
   for infectious disease of China (No. 2012Zx10002-017).
CR Amor S, 2010, IMMUNOLOGY, V129, P154, DOI 10.1111/j.1365-2567.2009.03225.x
   Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038
   Block ML, 2005, PROG NEUROBIOL, V76, P77, DOI 10.1016/j.pneurobio.2005.06.004
   Chiang N, 2003, BRIT J PHARMACOL, V139, P89, DOI 10.1038/sj.bjp.0705220
   Connor KM, 2007, NAT MED, V13, P868, DOI 10.1038/nm1591
   Costigan M, 2009, ANNU REV NEUROSCI, V32, P1, DOI 10.1146/annurev.neuro.051508.135531
   FIORE S, 1994, J EXP MED, V180, P253, DOI 10.1084/jem.180.1.253
   Gulian D, 1986, J NEUROSCI, P2163
   Jin YP, 2009, INVEST OPHTH VIS SCI, V50, P4743, DOI 10.1167/iovs.08-2462
   Krishnamoorthy S, 2010, P NATL ACAD SCI USA, V107, P1660, DOI 10.1073/pnas.0907342107
   Lull ME, 2010, NEUROTHERAPEUTICS, V7, P354, DOI 10.1016/j.nurt.2010.05.014
   MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890
   Polazzi E, 2002, REV NEUROSCIENCE, V13, P221
   Serhan CN, 2008, NAT REV IMMUNOL, V8, P349, DOI 10.1038/nri2294
   Serhan CN, 2002, J EXP MED, V196, P1025, DOI 10.1084/jem.20020760
   Streit WJ, 2005, NEUROL RES, V27, P685, DOI 10.1179/016164105X49463
   Sun YP, 2007, J BIOL CHEM, V282, P9323, DOI 10.1074/jbc.M609212200
   Takano T, 1997, J EXP MED, V185, P1693, DOI 10.1084/jem.185.9.1693
   Vaughn MW, 2002, J IMMUNOL, V169, P3363, DOI 10.4049/jimmunol.169.6.3363
   Xu ZZ, 2013, J NEUROIMMUNE PHARM, V8, P37, DOI 10.1007/s11481-012-9394-8
NR 20
TC 28
Z9 31
U1 4
U2 23
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-5930
J9 CNS NEUROSCI THER
JI CNS Neurosci. Ther.
PD APR
PY 2013
VL 19
IS 4
BP 235
EP 243
DI 10.1111/cns.12069
PG 9
WC Neurosciences; Pharmacology & Pharmacy
SC Neurosciences & Neurology; Pharmacology & Pharmacy
GA 114PI
UT WOS:000316754000005
PM 23521911
DA 2018-12-27
ER

PT J
AU Watthanasurorot, A
   Jiravanichpaisal, P
   Soderhall, K
   Soderhall, I
AF Watthanasurorot, Apiruck
   Jiravanichpaisal, Pikul
   Soderhall, Kenneth
   Soderhall, Irene
TI RETRACTED: A calreticulin/gC1qR complex prevents cells from dying: a
   conserved mechanism from arthropods to humans (Retracted article. See
   vol. 7, pg. 588, 2015)
SO JOURNAL OF MOLECULAR CELL BIOLOGY
LA English
DT Article; Retracted Publication
DE apoptosis; calreticulin; gC1qR; virus; cancer
ID ENDOPLASMIC-RETICULUM; INDUCED APOPTOSIS; PROTEIN P32/GC1QR;
   CELLULAR-PROTEINS; BINDING-PROTEIN; DEATH; CANCER; SURFACE; GC1QR; C1Q
AB The crossroad between cell death and proliferation is a general target for viral infections because viruses need to obstruct apoptosis to use cells for their own replication. Inducing immunogenic cell death in proliferating cells is also an important aim of anticancer chemotherapy. The C1q-binding proteins calreticulin (CRT) and gC1qR are highly conserved ubiquitous proteins, which are putative targets for viral manipulation and are associated with cancer. Here we show that these proteins form a complex in the cytoplasm as a response to viral infection resulting in apoptosis prevention. The formation of a cytosolic CRT/gC1qR complex prevents cell death by reducing gC1qR translocation into the mitochondria, and we provide evidence that this mechanism is conserved from arthropods to human cancer cells. Furthermore, we show that it is possible to prevent this complex from being formed in cancer cells. When the peptides of the complex proteins are overexpressed in these cells, the cells undergo apoptosis. This finding shows a causal link between virus and cancer and may be used to develop new tools in anticancer or antiviral therapy.
C1 [Watthanasurorot, Apiruck; Jiravanichpaisal, Pikul; Soderhall, Kenneth; Soderhall, Irene] Uppsala Univ, Evolutionary Biol Ctr, Dept Comparat Physiol, SE-75236 Uppsala, Sweden.
   [Jiravanichpaisal, Pikul] Natl Sci & Technol Dev Agcy NSTDA, Aquat Mol Genet & Biotechnol Lab, Natl Ctr Genet Engn & Biotechnol BIOTEC, Klongluang 12120, Pathumthani, Thailand.
   [Soderhall, Kenneth] Uppsala Univ, Sci Life Lab, SE-75236 Uppsala, Sweden.
RP Soderhall, I (reprint author), Uppsala Univ, Evolutionary Biol Ctr, Dept Comparat Physiol, Norbyvagen 18A, SE-75236 Uppsala, Sweden.
EM irene.soderhall@ebc.uu.se
FU Swedish Research Council [VR 319-2010-650, 621-2009-5715, 621-2011-4797]
FX This work was supported by the Swedish Research Council (VR
   319-2010-650, 621-2009-5715 to K. S., and 621-2011-4797 to I.S.).
CR Afshar N, 2005, MOL CELL BIOL, V25, P8844, DOI 10.1128/MCB.25.20.8844-8853.2005
   Barber GN, 2001, CELL DEATH DIFFER, V8, P113, DOI 10.1038/sj.cdd.4400823
   Bedard K, 2005, INT REV CYTOL, V245, P91, DOI 10.1016/S0074-7696(05)45004-4
   Boevink P, 2005, PLANT PHYSIOL, V138, P1815, DOI 10.1104/pp.105.066761
   CHEN A, 1994, J IMMUNOL, V153, P1430
   Chen MH, 2005, PLANT PHYSIOL, V138, P1866, DOI 10.1104/pp.105.064386
   Chen YB, 2009, J SURG ONCOL, V100, P382, DOI 10.1002/jso.21329
   Chowdhury AR, 2008, EXP CELL RES, V314, P651, DOI 10.1016/j.yexcr.2007.10.033
   EGGLETON P, 1995, J CLIN INVEST, V95, P1569, DOI 10.1172/JCI117830
   Fogal V, 2008, CANCER RES, V68, P7210, DOI 10.1158/0008-5472.CAN-07-6752
   Galluzzi L, 2010, J Intern Med, V267, P526, DOI 10.1111/j.1365-2796.2010.02223.x
   Gao LJ, 2011, INT J ONCOL, V39, P1265, DOI 10.3892/ijo.2011.1108
   GHEBREHIWET B, 1995, J IMMUNOL, V155, P2614
   Ghebrehiwet B, 1997, J IMMUNOL, V159, P1429
   Ghebrehiwet B, 2004, MOL IMMUNOL, V41, P173, DOI 10.1016/j.molimm.2004.03.014
   Ghebrehiwet B, 2001, IMMUNOL REV, V180, P65, DOI 10.1034/j.1600-065X.2001.1800106.x
   GHEBREHIWET B, 1994, J EXP MED, V179, P1809, DOI 10.1084/jem.179.6.1809
   Green DR, 2009, NAT REV IMMUNOL, V9, P353, DOI 10.1038/nri2545
   Gu PQ, 2012, REPROD SCI, V19, P181, DOI 10.1177/1933719111415866
   Gupta S, 2010, INT J CELL BIOL, V2010, DOI DOI 10.1155/2010/17021520169117
   Hay S, 2002, J GEN VIROL, V83, P1547, DOI 10.1099/vir.O.18189-O
   Holaska JM, 2001, J CELL BIOL, V152, P127, DOI 10.1083/jcb.152.1.127
   Hong SH, 2004, CANCER RES, V64, P5504, DOI 10.1158/0008-5472.CAN-04-0077
   Hu QL, 2005, J BIOCHEM MOL BIOL, V38, P709
   Itahana K, 2008, CANCER CELL, V13, P542, DOI 10.1016/j.ccr.2008.04.002
   Jiang JZ, 1999, P NATL ACAD SCI USA, V96, P3572, DOI 10.1073/pnas.96.7.3572
   Kageyama S, 2004, CLIN CHEM, V50, P857, DOI 10.1373/clinchem.2003.027425
   Kamal A, 2006, APOPTOSIS, V11, P861, DOI 10.1007/s10495-006-5396-4
   Kepp O, 2009, APOPTOSIS, V14, P364, DOI 10.1007/s10495-008-0303-9
   Kepp O, 2009, CURR OPIN ONCOL, V21, P71, DOI 10.1097/CCO.0b013e32831bc375
   Kim KB, 2011, J BIOL CHEM, V286, P23093, DOI 10.1074/jbc.M111.233304
   Kim KB, 2009, PROTEOMICS, V9, P2373, DOI 10.1002/pmic.200800811
   Kroemer G, 2007, PHYSIOL REV, V87, P99, DOI 10.1152/physrev.00013.2006
   Limjindaporn T, 2009, BIOCHEM BIOPH RES CO, V379, P196, DOI 10.1016/j.bbrc.2008.12.070
   Lin XH, 2010, J BIOL CHEM, V285, P28577, DOI 10.1074/jbc.M110.138560
   Luhrmann A, 2010, P NATL ACAD SCI USA, V107, P18997, DOI 10.1073/pnas.1004380107
   Michalak M, 1999, BIOCHEM J, V344, P281, DOI 10.1042/0264-6021:3440281
   Michalak M, 2009, BIOCHEM J, V417, P651, DOI 10.1042/BJ20081847
   Nakamura K, 2000, J CELL BIOL, V150, P731, DOI 10.1083/jcb.150.4.731
   Obeid M, 2007, NAT MED, V13, P54, DOI 10.1038/nm1523
   Panaretakis T, 2008, CELL DEATH DIFFER, V15, P1499, DOI 10.1038/cdd.2008.67
   Panaretakis T, 2009, EMBO J, V28, P578, DOI 10.1038/emboj.2009.1
   Ravichandran KS, 2011, IMMUNITY, V35, P445, DOI 10.1016/j.immuni.2011.09.004
   Shivapurkar N, 2003, J CELL BIOCHEM, V88, P885, DOI 10.1002/jcb.10440
   SINGH NK, 1994, P NATL ACAD SCI USA, V91, P12770, DOI 10.1073/pnas.91.26.12770
   Soderhall I, 2005, J IMMUNOL, V174, P6153, DOI 10.4049/jimmunol.174.10.6153
   van Leeuwen HC, 2001, J CELL SCI, V114, P2115
   Waterhouse NJ, 2007, APOPTOSIS, V12, P631, DOI 10.1007/s10495-007-0057-9
   Watthanasurorot A, 2010, J VIROL, V84, P10844, DOI 10.1128/JVI.01045-10
   Xie XX, 2005, VIRUS RES, V108, P63, DOI 10.1016/j.virusres.2004.08.002
   Xu LJ, 2009, P NATL ACAD SCI USA, V106, P1530, DOI 10.1073/pnas.0811029106
   Zitvogel L, 2010, CLIN CANCER RES, V16, P3100, DOI 10.1158/1078-0432.CCR-09-2891
NR 52
TC 21
Z9 21
U1 2
U2 23
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1674-2788
EI 1759-4685
J9 J MOL CELL BIOL
JI J. Mol. Cell Biol.
PD APR
PY 2013
VL 5
IS 2
BP 120
EP 131
DI 10.1093/jmcb/mjt005
PG 12
WC Cell Biology
SC Cell Biology
GA 113WX
UT WOS:000316701200006
PM 23378602
OA Bronze
DA 2018-12-27
ER

PT J
AU McKeon, J
   Kappelgaard, AM
   Wisniewski, T
   Seitz, L
   Pollock, R
   Qian, YJ
AF McKeon, Jessica
   Kappelgaard, Anne-Marie
   Wisniewski, Tami
   Seitz, Lisa
   Pollock, Richard
   Qian, Yujun
TI RETRACTED: Evaluation of Product Wastage From Modern Human Growth
   Hormone Administration Devices (Retracted article. See vol. 28, pg. 517,
   2013)
SO JOURNAL OF PEDIATRIC NURSING-NURSING CARE OF CHILDREN & FAMILIES
LA English
DT Meeting Abstract; Retracted Publication
C1 [McKeon, Jessica; Wisniewski, Tami] Novo Nordisk Inc, Princeton, NJ USA.
   [Kappelgaard, Anne-Marie; Qian, Yujun] Novo Nordisk AS, DK-2880 Bagsvaerd, Denmark.
   [Seitz, Lisa] Novo Nordisk Pharma GmbH, Mainz, Germany.
   [Pollock, Richard] Ossian Hlth Econ & Commun GmbH, Basel, Switzerland.
NR 0
TC 1
Z9 1
U1 3
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0882-5963
J9 J PEDIATR NURS
JI J. Pediatr. Nurs.
PD APR
PY 2013
VL 28
IS 2
BP 208
EP 208
DI 10.1016/j.pedn.2013.02.017
PG 1
WC Nursing; Pediatrics
SC Nursing; Pediatrics
GA 115WN
UT WOS:000316842700032
DA 2018-12-27
ER

PT J
AU Huang, HW
   Chang, HW
   Wang, HC
   Lu, CJ
   Chen, SW
   Yi, SC
   Wang, HY
   Cho, CL
   Wu, CH
   Yang, JG
   Tseng, CN
AF Huang, Hurng-Wern
   Chang, Hsueh-Wei
   Wang, Hui-Chun
   Lu, Chiu-Jin
   Chen, Shaio-Wen
   Yi, Szu-Cheng
   Wang, Hay-Yan
   Cho, Chung-Lung
   Wu, Cheng-Hsuan
   Yang, Jyuer-Ger
   Tseng, Chao-Neng
TI RETRACTED: Inosine-specific cleavage of RNA for microarray analysis of
   RNA A-to-I editing targets (Retracted article. See vol. 29, pg. 521,
   2013)
SO KAOHSIUNG JOURNAL OF MEDICAL SCIENCES
LA English
DT Article; Retracted Publication
DE ADAR; Adenosine deamination; I-specific cleavage; Microarray; RNA
   editing
ID DYSCHROMATOSIS SYMMETRICA HEREDITARIA; AMPA RECEPTOR CHANNELS;
   ADENOSINE-DEAMINASE; MESSENGER-RNA; FOREBRAIN ISCHEMIA; UNWINDING
   ACTIVITY; ENZYME ADAR1; GENE; MUTATION; IDENTIFICATION
AB Dysregulations of RNA A-to-I editing are associated with developmental defects in mouse and human diseases. Although several methods of identifying RNA A-to-I editing sites are currently available, most of the critical editing targets responsible for the important biological functions of adenosine deaminases that act on RNA (ADARs) remain unknown. Here we report a modified I-specific cleavage method that improves the quality of the RNA product. Preliminary microarray comparison of RNAs subjected to I-specific cleavage or mock digestion reported 165 genes that showed more than 0.2-fold reductions due to the cleavage. Six of the 165 genes were randomly selected for further verification, and three were verified to be targets of I-specific cleavage. This method may provide an alternative method of identifying novel RNA A-to-I editing sites using a microarray and facilitate the inquiry into the roles of RNA A-to-I editing in various biological processes. Copyright (C) 2012, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. All rights reserved.
C1 [Huang, Hurng-Wern; Lu, Chiu-Jin] Natl Sun Yat Sen Univ, Inst Biomed Sci, Kaohsiung 80424, Taiwan.
   [Chang, Hsueh-Wei; Wang, Hui-Chun; Tseng, Chao-Neng] Kaohsiung Med Univ, Grad Inst Nat Prod, Kaohsiung 807, Taiwan.
   [Chang, Hsueh-Wei; Chen, Shaio-Wen; Yi, Szu-Cheng; Tseng, Chao-Neng] Kaohsiung Med Univ, Dept Biomed Sci & Environm Biol, Kaohsiung 807, Taiwan.
   [Chang, Hsueh-Wei] Kaohsiung Med Univ, Ctr Excellence Environm Med, Kaohsiung 807, Taiwan.
   [Wang, Hay-Yan; Cho, Chung-Lung; Yang, Jyuer-Ger] Natl Sun Yat Sen Univ, Dept Biol Sci, Kaohsiung 80424, Taiwan.
   [Wu, Cheng-Hsuan; Yang, Jyuer-Ger] Changhua Christian Hosp, Reprod Med Ctr, Changhua, Taiwan.
   [Wu, Cheng-Hsuan] Chung Shan Med Univ, Inst Med, Taichung, Taiwan.
   [Yang, Jyuer-Ger] Changhua Christian Hosp, Dept Obstet & Gynecol, Changhua, Taiwan.
   [Tseng, Chao-Neng] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Ctr Canc, Kaohsiung 807, Taiwan.
RP Tseng, CN (reprint author), Kaohsiung Med Univ, Grad Inst Nat Prod, 100 Shih Chuan 1st Rd, Kaohsiung 807, Taiwan.
EM cntseng@kmu.edu.tw
FU Kaohsiung Medical University Research Foundation [KMU-M100001,
   KMU-M110010]; NSYSU-KMU Joint Research Project [NSYSUKMU 101-02,
   KMU-EM-99-1.4]; Department of Health, Executive Yuan, R.O.C. (Taiwan)
   [DOH100-TD-C-111-002]
FX This work was supported in part by the Kaohsiung Medical University
   Research Foundation under the grants KMU-M100001, KMU-M110010 (to
   C.N.T.), NSYSU-KMU Joint Research Project #NSYSUKMU 101-02 (to C.N.T.
   and C. L. C.), and KMU-EM-99-1.4 (to H. W. C.); and by the Department of
   Health, Executive Yuan, R.O.C. (Taiwan) under the grant
   DOH100-TD-C-111-002 (to C.N.T.).
CR BASILIO C, 1962, P NATL ACAD SCI USA, V48, P613, DOI 10.1073/pnas.48.4.613
   Bass BL, 2006, COLD SPRING HARB SYM, V71, P285, DOI 10.1101/sqb.2006.71.037
   BASS BL, 1988, CELL, V55, P1089, DOI 10.1016/0092-8674(88)90253-X
   BURNASHEV N, 1992, NEURON, V8, P189, DOI 10.1016/0896-6273(92)90120-3
   Burns CM, 1997, NATURE, V387, P303, DOI 10.1038/387303a0
   Cenci C, 2008, J BIOL CHEM, V283, P7251, DOI 10.1074/jbc.M708316200
   Chen CX, 2000, RNA, V6, P755, DOI 10.1017/S1355838200000170
   Gan ZJ, 2006, J BIOL CHEM, V281, P33386, DOI 10.1074/jbc.M604484200
   Hartner JC, 2004, J BIOL CHEM, V279, P4894, DOI 10.1074/jbc.M311347200
   Higuchi M, 2000, NATURE, V406, P78
   HUME RI, 1991, SCIENCE, V253, P1028, DOI 10.1126/science.1653450
   Hundley HA, 2010, TRENDS BIOCHEM SCI, V35, P377, DOI 10.1016/j.tibs.2010.02.008
   Iizasa H, 2009, NAT IMMUNOL, V10, P16, DOI 10.1038/ni0109-16
   Kawahara Y, 2004, NATURE, V427, P801, DOI 10.1038/427801a
   KIM U, 1994, J BIOL CHEM, V269, P13480
   KIM U, 1994, P NATL ACAD SCI USA, V91, P11457, DOI 10.1073/pnas.91.24.11457
   Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098
   Liu SH, 2004, NEURON, V43, P43, DOI 10.1016/j.neuron.2004.06.017
   Maas S, 2001, P NATL ACAD SCI USA, V98, P14687, DOI 10.1073/pnas.251531398
   Miyamura Y, 2003, AM J HUM GENET, V73, P693, DOI 10.1086/378209
   Morse DP, 1997, BIOCHEMISTRY-US, V36, P8429, DOI 10.1021/bi9709607
   Morse DP, 1999, P NATL ACAD SCI USA, V96, P6048, DOI 10.1073/pnas.96.11.6048
   Nishikura K, 2006, NAT REV MOL CELL BIO, V7, P919, DOI 10.1038/nrn2061
   Niswender CM, 2001, NEUROPSYCHOPHARMACOL, V24, P478, DOI 10.1016/S0893-133X(00)00223-2
   Ohlson J, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/bar/gnil169
   Paul MS, 1998, EMBO J, V17, P1120, DOI 10.1093/emboj/17.4.1120
   Paz N, 2007, GENOME RES, V17, P1586, DOI 10.1101/gr.6493107
   Peng PL, 2006, NEURON, V49, P719, DOI 10.1016/j.neuron.2006.01.025
   Price RD, 2001, J BIOL CHEM, V276, P44663, DOI 10.1074/jbc.M106745200
   Rabinovici R, 2001, CIRC RES, V88, P1066, DOI 10.1161/hh1001.090877
   Singh M, 2007, J BIOL CHEM, V282, P22448, DOI 10.1074/jbc.M700265200
   SOMMER B, 1991, CELL, V67, P11, DOI 10.1016/0092-8674(91)90568-J
   Struhalla M, 2004, CHEMBIOCHEM, V5, P200, DOI 10.1002/cbic.200300715
   WAGNER RW, 1989, P NATL ACAD SCI USA, V86, P2647, DOI 10.1073/pnas.86.8.2647
   Wang Q, 2000, SCIENCE, V290, P1765, DOI 10.1126/science.290.5497.1765
   Wang QD, 2004, J BIOL CHEM, V279, P4952, DOI 10.1074/jbc.M310162200
   Xing QH, 2006, ARCH DERMATOL RES, V297, P139, DOI 10.1007/s00403-005-0589-1
   XuFeng R, 2009, P NATL ACAD SCI USA, V106, P17763, DOI 10.1073/pnas.0903324106
   Yang JH, 2003, IMMUNOLOGY, V109, P15, DOI 10.1046/j.1365-2567.2003.01598.x
   Zhang FM, 2007, SHOCK, V27, P214, DOI 10.1097/01.shk.0000238072.51653.f2
NR 40
TC 1
Z9 1
U1 1
U2 11
PU ELSEVIER TAIWAN
PI TAIPEI
PA RM N-412, 4F, CHIA HSIN BUILDING 11, NO 96, ZHONG SHAN N ROAD SEC 2,
   TAIPEI, 10449, TAIWAN
SN 1607-551X
J9 KAOHSIUNG J MED SCI
JI Kaohsiung J. Med. Sci.
PD APR
PY 2013
VL 29
IS 4
BP 179
EP 186
DI 10.1016/j.kjms.2012.08.031
PG 8
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 117DC
UT WOS:000316931300001
PM 23541262
OA DOAJ Gold
DA 2018-12-27
ER

PT J
AU Chen, HW
   Hong, HF
   Zhu, ZQ
   Liu, JF
AF Chen, Huiwen
   Hong, Haifa
   Zhu, Zhongqun
   Liu, Jinfen
TI RETRACTED: Continuous Cerebral and Myocardial Perfusion During One-Stage
   Repair for Aortic Coarctation With Ventricular Septal Defect (Retracted
   article. See vol. 34, pg. 1522, 2013)
SO PEDIATRIC CARDIOLOGY
LA English
DT Article; Retracted Publication
DE Aortic coarctation; Continuous cerebral and myocardial perfusion; Deep
   hypothermic circulatory arrest; Mild hypothermia
ID HYPOTHERMIC CARDIOPULMONARY BYPASS; CIRCULATORY ARREST; ARCH REPAIR;
   CARDIAC-SURGERY; SINGLE-STAGE; OPERATION
AB Controversy still exists concerning the use of deep hypothermic circulatory arrest (DHCA) and selective antegrade cerebral perfusion (SACP) for repair of aortic coarctation (CoA) with ventricular septal defect (VSD). This report therefore describes outcomes of patients undergoing continuous cerebral and myocardial perfusion (CCMP) under mild hypothermia compared with DHCA and SACP. Retrospective analysis was performed for 110 consecutive patients undergoing anatomic reconstruction of CoA with VSD closure between 1999 and 2011. Patients repaired under CCMP with mild hypothermia (32 A degrees C) (group A, n = 60) were compared with those repaired under DHCA (18 A degrees C) and SACP (group B, n = 50). In group A, the single arterial cannula perfusion technique was used for 15 patients (25 %), and the dual arterial cannula perfusion technique was used for 45 patients (75 %). The preoperative data were similar in the two groups. Group A had no hospital mortalities, compared with two mortalities (4 %) in group B. Group A had shorter myocardial ischemic and cardiopulmonary times, fewer delayed sternal closures, a shorter time to extubation, lower postoperative lactate levels, and fewer patients with low cardiac output requiring extracorporeal membrane oxygenation or with multiorgan failure than group B. During the postoperative course, no clinical or electrical neurologic events occurred in either group. The mean follow-up period was 5.2 +/- A 3.2 years for group A and 7.5 +/- A 3.1 years for group B (P = 0.048). One late death occurred in group B and no late deaths in group A. The actuarial survival for the two groups was similar (100 % for group A vs 96 % for group B; P = 0.264). The freedom from all types of cardiac reintervention was 96.7 % in group A and 89.6 % in group B (P = 0.688). All the patients were free of neurologic symptoms. The authors' perfusion strategy using CCMP with mild hypothermia for repair of CoA with VSD is feasible, safe, and associated with improved postoperative recovery and should be the method of choice.
C1 [Chen, Huiwen; Hong, Haifa; Zhu, Zhongqun; Liu, Jinfen] Shanghai Jiao Tong Univ, Ctr Heart, Shanghai Childrens Med Ctr, Sch Med, Shanghai 200030, Peoples R China.
RP Chen, HW (reprint author), Shanghai Jiao Tong Univ, Ctr Heart, Shanghai Childrens Med Ctr, Sch Med, Dongfang Rd 1678, Shanghai 200030, Peoples R China.
EM hwhwc@hotmail.com
FU Shanghai Nature Science foundation [09ZR1419500]; Shanghai Hygiene
   Science Research Project [2008017]
FX This report belongs to the following research project: Shanghai Nature
   Science foundation No. 09ZR1419500, Shanghai Hygiene Science Research
   Project No. 2008017.
CR Algra SO, 2012, J THORAC CARDIOV SUR, V143, P375, DOI 10.1016/j.jtcvs.2011.08.006
   Aydemir NA, 2012, EUR J CARDIO-THORAC, V41, P581, DOI 10.1093/ejcts/ezr002
   Brouwer RMHJ, 1996, J THORAC CARDIOV SUR, V111, P168, DOI 10.1016/S0022-5223(96)70413-0
   CAMPBELL M, 1970, BRIT HEART J, V32, P633
   Cobanoglu A, 1998, EUR J CARDIO-THORAC, V14, P19, DOI 10.1016/S1010-7940(98)00142-0
   Corno AF, 2001, EUR J CARDIO-THORAC, V20, P1202, DOI 10.1016/S1010-7940(01)00996-4
   Fruh S, 2011, EUR J CARDIO-THORAC, V39, P898, DOI 10.1016/j.ejcts.2010.09.048
   Gaynor JW, 1995, SURG CHEST, P1281
   Harrington DK, 2004, ANN THORAC SURG, V78, P596, DOI 10.1016/j.athoracsur.2004.01.012
   Hirotani T, 2000, EUR J CARDIO-THORAC, V18, P545, DOI 10.1016/S1010-7940(00)00533-9
   Hoffman JIE, 2002, J AM COLL CARDIOL, V39, P1890, DOI 10.1016/S0735-1097(02)01886-7
   Howell NJ, 2011, CIRCULATION, V123, P170, DOI 10.1161/CIRCULATIONAHA.110.945170
   Ishino K, 2000, EUR J CARDIO-THORAC, V17, P538, DOI 10.1016/S1010-7940(00)00409-7
   Jacobs JP, 2006, ANN THORAC SURG, V81, P1937, DOI 10.1016/j.athoracsur.2005.11.063
   Lewis ME, 2002, J AM COLL CARDIOL, V39, P102, DOI 10.1016/S0735-1097(01)01694-1
   Lim HG, 2010, ANN THORAC SURG, V90, P50, DOI 10.1016/j.athoracsur.2010.03.067
   Ly M, 2011, ANN THORAC SURG, V92, P942, DOI 10.1016/j.athoracsur.2011.03.006
   MacDonald Malcolm J, 2002, Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu, V5, P95, DOI 10.1053/pcsu.2002.31503
   Mangano CTM, 2001, CIRCULATION, V104, pI276
   Oppido G, 2006, ANN THORAC SURG, V82, P2233, DOI 10.1016/j.athoracsur.2006.06.042
   Pigula FA, 2000, J THORAC CARDIOV SUR, V119, P331, DOI 10.1016/S0022-5223(00)70189-9
   SANO S, 1990, ANN THORAC SURG, V49, P970, DOI 10.1016/0003-4975(90)90878-A
   Walters HL, 2008, J THORAC CARDIOV SUR, V135, P754, DOI 10.1016/j.jtcvs.2007.12.008
NR 23
TC 1
Z9 3
U1 4
U2 11
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0172-0643
EI 1432-1971
J9 PEDIATR CARDIOL
JI Pediatr. Cardiol.
PD APR
PY 2013
VL 34
IS 4
BP 872
EP 879
DI 10.1007/s00246-012-0561-8
PG 8
WC Cardiac & Cardiovascular Systems; Pediatrics
SC Cardiovascular System & Cardiology; Pediatrics
GA 117MP
UT WOS:000316957900013
PM 23132178
DA 2018-12-27
ER

PT J
AU Li, CY
   Yuan, P
   Lin, SS
   Song, CF
   Guan, WY
   Yuan, L
   Lai, RB
   Gao, Y
   Wang, Y
AF Li, Chun-Yu
   Yuan, Peng
   Lin, Shu-Sen
   Song, Cheng-Fei
   Guan, Wei-Yu
   Yuan, Lu
   Lai, Rong-Bin
   Gao, Ying
   Wang, Yan
TI RETRACTED: Matrix metalloproteinase 9 expression and prognosis in
   colorectal cancer: a meta-analysis (Retracted article. See April, 2017)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE Matrix metalloproteinase-9; Colorectal cancer; Survival; Meta-analysis
ID GELATINASE-B EXPRESSION; MATRIX METALLOPROTEINASES; MMP-9; SURVIVAL;
   DISEASE
AB Matrix metalloproteinase-9 (MMP-9) is an important member of the matrix metalloproteinase family and is considered to be involved in the invasion and metastasis of cancer cells. Many studies were published to assess the prognostic role of MMP-9 overexpression in patients with colorectal cancer, but the findings from those studies were inconsistent. We searched eligible studies in Pubmed, Embase, and Web of Science databases. Thirteen studies with a total of 2, 390 CRC patients were finally included into the meta-analysis. The pooled hazard ratios (HRs) with the corresponding 95 % confidence interval (95 % CIs) for overall and progression-free survival were calculated by using meta-analysis. There were nine studies with a total of 1,674 colorectal cancer patients relating the progression-free survival, and eight studies with a total of 1,379 colorectal cancer patients relating the overall survival. Overall, MMP-9 overexpression was associated with poorer progression-free survival in patients with colorectal cancer (fixed-effects HR 1.81, 95 % CI 1.48-2.20, P < 0.001; random-effects HR 1.92, 95 % CI 1.46-2.53, P < 0.001). In addition, MMP-9 overexpression was also associated with poorer overall survival in patients with colorectal cancer (fixed-effects HR 1.74, 95 % CI 1.39-2.19, P < 0.001; random-effects HR 1.78, 95 % CI 1.31-2.41, P < 0.001). MMP-9 expression is associated with the prognosis of patients with colorectal cancer, and patients with higher MMP-9 expression have poorer survival.
C1 [Li, Chun-Yu; Yuan, Peng; Lin, Shu-Sen; Song, Cheng-Fei; Guan, Wei-Yu; Yuan, Lu; Lai, Rong-Bin; Wang, Yan] China Med Univ, Affiliated Hosp 4, Anorectal Dept, Shenyang 110032, Peoples R China.
   [Gao, Ying] China Med Univ, Affiliated Hosp 4, Dept Pathol, Shenyang 110032, Peoples R China.
RP Li, CY (reprint author), China Med Univ, Affiliated Hosp 4, Anorectal Dept, Chongshan East Rd 4, Shenyang 110032, Peoples R China.
EM lcysj19@163.com; gaoyingsj@126.com
CR Bendardaf R, 2010, CANCER INVEST, V28, P38, DOI 10.3109/07357900802672761
   Buhmeida Abdelbaset, 2009, J Gastrointest Cancer, V40, P91, DOI 10.1007/s12029-009-9091-x
   Cho YB, 2007, HUM PATHOL, V38, P1603, DOI 10.1016/j.humpath.2007.03.018
   Cho Young Rak, 2005, Cancer Res Treat, V37, P354, DOI 10.4143/crt.2005.37.6.354
   Chu DK, 2012, ANN SURG ONCOL, V19, P318, DOI 10.1245/s10434-011-1686-3
   Cunningham D, 2010, LANCET, V375, P1030, DOI 10.1016/S0140-6736(10)60353-4
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Des Guetz G, 2006, BRIT J CANCER, V94, P1823, DOI 10.1038/sj.bjc.6603176
   Fang YJ, 2010, TUMOR BIOL, V31, P651, DOI 10.1007/s13277-010-0082-0
   Fearon ER, 2011, ANNU REV PATHOL-MECH, V6, P479, DOI 10.1146/annurev-pathol-011110-130235
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Jensen SA, 2010, EUR J CANCER, V46, P3233, DOI 10.1016/j.ejca.2010.07.046
   Kessenbrock K, 2010, CELL, V141, P52, DOI 10.1016/j.cell.2010.03.015
   Koskensalo S, 2011, TUMOR BIOL, V32, P259, DOI 10.1007/s13277-010-0080-2
   Lampropoulos P, 2012, TUMOR BIOL, V33, P1005, DOI 10.1007/s13277-012-0333-3
   Langers AMJ, 2008, BRIT J CANCER, V98, P1820, DOI 10.1038/sj.bjc.6604380
   Langers AMJ, 2012, BRIT J CANCER, V106, P1495, DOI 10.1038/bjc.2012.80
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Morrison CJ, 2009, CURR OPIN CELL BIOL, V21, P645, DOI 10.1016/j.ceb.2009.06.006
   Mott JD, 2004, CURR OPIN CELL BIOL, V16, P558, DOI 10.1016/j.ceb.2004.07.010
   Ogata Y, 2006, CANCER CHEMOTH PHARM, V57, P577, DOI 10.1007/s00280-005-0081-9
   Page-McCaw A, 2007, NAT REV MOL CELL BIO, V8, P221, DOI 10.1038/nrm2125
   Parks WC, 2004, NAT REV IMMUNOL, V4, P617, DOI 10.1038/nri1418
   Parmar MKB, 1998, STAT MED, V17, P2815, DOI 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8
   Popat S, 2004, J CLIN ONCOL, V22, P529, DOI 10.1200/JCO.2004.05.064
   Takeuchi T, 2004, CLIN CANCER RES, V10, P5572, DOI 10.1158/1078-0432.CCR-03-0656
   Tierney JF, 2007, TRIALS, V8, DOI 10.1186/1745-6215-8-16
   Unsal D, 2008, AM J CLIN ONCOL-CANC, V31, P55, DOI 10.1097/COC.0b013e318068b4e2
   Walther A, 2009, NAT REV CANCER, V9, P489, DOI 10.1038/nrc2645
   Zeng ZS, 1996, J CLIN ONCOL, V14, P3133, DOI 10.1200/JCO.1996.14.12.3133
   Zhang Y, 2012, J CANC RES CLIN ONCO
   Zhou YN, 2010, TUMOR BIOL, V31, P549, DOI 10.1007/s13277-010-0068-y
NR 32
TC 27
Z9 31
U1 4
U2 18
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD APR
PY 2013
VL 34
IS 2
BP 735
EP 741
DI 10.1007/s13277-012-0601-2
PG 7
WC Oncology
SC Oncology
GA 109JX
UT WOS:000316364500015
PM 23269605
DA 2018-12-27
ER

PT J
AU Zhang, RC
   Mou, SH
AF Zhang, Ri-Chu
   Mou, Si-Hua
TI RETRACTED: Polymorphisms of excision repair gene XPD Lys751Gln and hOGG1
   Ser326Cys might not be associated with hepatocellular carcinoma risk: a
   meta-analysis (Retracted article. See April, 2017)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE XPD; hOGG1; Polymorphism; Hepatocellular carcinoma; Meta-analysis
ID LUNG-CANCER SUSCEPTIBILITY; HEPATITIS-B; ASP312ASN; XRCC1; BIAS
AB The xeroderma pigmentosum group D (XPD) and human 8-oxoguanine glycosylase 1 (hOGG1) genes have been suggested to play an important role in the pathogenesis of hepatocellular carcinoma (HCC). However, the results have been inconsistent. In this study, we performed a meta-analysis to clarify the associations of polymorphisms of XPD and hOGG1 genes with HCC risk. Published literature from PubMed, EMBASE, and Chinese National Knowledge Infrastructure were retrieved. Pooled odds ratio (OR) with 95 % confidence interval (CI) was calculated using a fixed- or random-effects model. Seven studies (1,955 HCC cases and 2,023 controls) for XPD Lys751Gln polymorphism and six studies (1,470 HCC cases and 1,541 controls) for hOGG1 Ser326Cys polymorphism were included in the final meta-analysis. For XPD Lys751Gln polymorphism, no significant association was found under all genetic models (Gln/Gln vs Lys/Lys OR = 1.09, 95 % CI = 0.28-4.18; Gln/Lys vs Lys/Lys OR = 1.41, 95 % CI = 0.81-2.44; dominant model OR = 1.40, 95 % CI = 0.77-2.57; recessive model OR = 1.02, 95 % CI = 0.33-3.23). For hOGG1 Ser326Cys polymorphism, there was a significant association of this polymorphism with HCC risk under heterogeneous codominant model (OR = 1.38, 95 % CI = 1.01-1.88) and dominant model (OR = 1.57, 95 % CI = 1.14-2.16). The sensitivity analysis indicated that the significant association between hOGG1 Ser326Cys polymorphism and HCC risk was not robust. The present meta-analysis has limited evidence to support the association of XPD Lys751Gln and hOGG1 Ser326Cys polymorphisms with HCC risk. Further, large-scale studies with the consideration for gene-gene/gene-environment interactions should be conducted to investigate the association.
C1 [Zhang, Ri-Chu] Taizhou Municipal Hosp, Dept Gen Surg, Taizhou 318000, Peoples R China.
   [Mou, Si-Hua] Taizhou Municipal Hosp, Dept Clin Lab, Taizhou 318000, Peoples R China.
RP Mou, SH (reprint author), Taizhou Municipal Hosp, Dept Clin Lab, Taizhou 318000, Peoples R China.
EM sihuamou@163.com
FU Zhejiang Medicine, Health, and Science [2010KYB127]; Zhejiang Province
   Chinese Medicine Research Program [2012ZA130]; Zhejiang Gong Yi Xing
   Technology Application Project [2012C33025]
FX The work was funded by the Zhejiang Medicine, Health, and Science (no.
   2010KYB127), Zhejiang Province Chinese Medicine Research Program
   (2012ZA130), and Zhejiang Gong Yi Xing Technology Application Project
   (2012C33025).
CR BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Benhamou S, 2002, MUTAGENESIS, V17, P463, DOI 10.1093/mutage/17.6.463
   Boiteux S, 2000, ARCH BIOCHEM BIOPHYS, V377, P1, DOI 10.1006/abbi.2000.1773
   Chen CC, 2005, INT J EPIDEMIOL, V34, P1310, DOI 10.1093/ije/dyi191
   Cui X, 2010, MED J CHIN PEOPLE HL, V22, P912
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Duan XL, 2012, ASIAN PAC J CANCER P, V13, P3299, DOI 10.7314/APJCP.2012.13.7.3299
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Feng Z, 2012, MOL BIOL REP, V39, P57, DOI 10.1007/s11033-011-0710-9
   Gao J, 2012, ASIAN PAC J CANCER P, V13, P743, DOI 10.7314/APJCP.2012.13.3.743
   Gulnaz A, 2013, EUR J GASTROEN HEPAT, V25, P166, DOI 10.1097/MEG.0b013e328359a775
   Hu H, 2012, YIYAO QIANYAN, V2, P143
   JI L, 2011, J HYGIENE RES, V7, P705
   Li BR, 2012, ASIAN PAC J CANCER P, V13, P1145, DOI 10.7314/APJCP.2012.13.4.1145
   Liu J, 2011, ASIAN PAC J CANCER P, V12, P2491
   Long XD, 2009, BMC CANCER, V17, P400
   Long XD, 2010, HEPATOLOGY, V52, P1301, DOI 10.1002/hep.23807
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Mi YY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044756
   Pabalan N, 2010, BREAST CANCER RES TR, V124, P531, DOI 10.1007/s10549-010-0863-6
   Raza SA, 2007, BRIT J CANCER, V96, P1127, DOI 10.1038/sj.bjc.6603649
   Sakamoto T, 2006, J EPIDEMIOL, V16, P233, DOI 10.2188/jea.16.233
   Shen M, 2003, CANCER EPIDEM BIOMAR, V12, P1234
   Tang G, 2011, SHANDONG MED J, V51, P19
   Wang A, 2008, CHIN J GASTROENTEROL, V17, P854
   Weiss JM, 2005, MOL CARCINOGEN, V42, P127, DOI 10.1002/mc.20067
   Xie W., 2007, THESIS GUANGXI MED U, P1
   [许丽 Xu Li], 2004, [肿瘤, Tumor], V24, P526
   Xue HP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043431
   Yuan H, 2011, GENET MOL RES, V10, P3356, DOI 10.4238/2011.November.22.6
   Yuan T, 2012, DIGEST DIS SCI, V57, P2451, DOI 10.1007/s10620-012-2192-6
   Yuan T, 2012, EXP THER MED, V4, P285, DOI 10.3892/etm.2012.581
   Yuan WG, 2010, BREAST CANCER RES TR, V122, P835, DOI 10.1007/s10549-009-0722-5
   [张昊 Zhang Hao], 2005, [中国肿瘤临床, Chinese Journal of Clinical Oncology], V32, P841
   Zhong DN, 2012, SCI REP-UK, V2, DOI 10.1038/srep00548
   Zhu SM, 2012, UROL INT, V89, P233, DOI 10.1159/000339603
NR 36
TC 11
Z9 11
U1 4
U2 13
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD APR
PY 2013
VL 34
IS 2
BP 901
EP 907
DI 10.1007/s13277-012-0625-7
PG 7
WC Oncology
SC Oncology
GA 109JX
UT WOS:000316364500035
PM 23271362
DA 2018-12-27
ER

PT J
AU Dong, YH
   Zhuang, L
   Ma, WY
AF Dong, Yuhao
   Zhuang, Le
   Ma, Weiyuan
TI RETRACTED: Comprehensive assessment of the association of ERCC2
   Lys751Gln polymorphism with susceptibility to cutaneous melanoma
   (Retracted article. See April, 2017)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE ERCC2; Polymorphism; Cutaneous melanoma; Meta-analysis
ID REPAIR GENES; CANCER-RISK; SKIN-CANCER; MALIGNANT-MELANOMA; XPD;
   METAANALYSIS; PATHWAY; ERA
AB Previous studies evaluating the association between excision repair cross-complimentary group 2 (ERCC2) Lys751Gln polymorphism and susceptibility to cutaneous melanoma reported conflicting findings. We searched PubMed and Wangfang Medical databases up to October 16, 2012 to identify eligible studies. A total of 8 case-control studies including 3,492 cases and 5,381 controls were included in the meta-analysis. Statistical analysis was performed with Review Manage version 5.1. Odds ratios (ORs) with 95 % confidence intervals (95 %CIs) were used to assess the strength of the association. There was no obvious between-study heterogeneity among those eight studies under all four comparison models. Overall, there was a significant association between ERCC2 Lys751Gln polymorphism and susceptibility to cutaneous melanoma under three genetic models (for Gln versus Lys: OR = 1.08, 95 % CI = 1.01-1.15, P = 0.02; for GlnGln versus LysLys: OR = 1.16, 95 % CI = 1.01-1.33, P = 0.03; for GlnGln/LysGln versus LysLys: OR = 1.10, 95 % CI = 1.01-1.21, P = 0.04). Sensitivity analysis by omitting one study a time showed the significance of the pooled ORs was stable under all those three genetic models above. Therefore, the meta-analysis suggests that there is a significant association between ERCC2 Lys751Gln polymorphism and susceptibility to cutaneous melanoma.
C1 [Dong, Yuhao] Shandong Univ, Sch Med, Jinan 250012, Peoples R China.
   [Zhuang, Le; Ma, Weiyuan] Shandong Univ, Qilu Hosp, Dept Dermatol, Jinan 250012, Peoples R China.
RP Ma, WY (reprint author), Shandong Univ, Qilu Hosp, Dept Dermatol, Jinan 250012, Peoples R China.
EM mweiyuan@yahoo.cn
CR Baccarelli A, 2004, BRIT J CANCER, V90, P497, DOI 10.1038/sj.bjc.6601385
   Benhamou S, 2002, MUTAGENESIS, V17, P463, DOI 10.1093/mutage/17.6.463
   Chin L, 2006, GENE DEV, V20, P2149, DOI 10.1101/gad.1437206
   COCHRAN WG, 1954, BIOMETRICS, V10, P101, DOI 10.2307/3001666
   Cotignola J, 2012, J INVEST DERMATOL, V132, P1471, DOI 10.1038/jid.2012.15
   Deans AJ, 2011, NAT REV CANCER, V11, P467, DOI 10.1038/nrc3088
   Debniak T, 2006, BREAST CANCER RES TR, V98, P209, DOI 10.1007/s10549-005-9151-2
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Diaz-Lagares A, 2011, TUMOR BIOL, V32, P1155, DOI 10.1007/s13277-011-0218-x
   Fecher LA, 2007, J CLIN ONCOL, V25, P1606, DOI 10.1200/JCO.2006.06.0442
   Feng Z, 2012, MOL BIOL REP, V39, P57, DOI 10.1007/s11033-011-0710-9
   Gray-Schopfer V, 2007, NATURE, V445, P851, DOI 10.1038/nature05661
   Han JL, 2005, CANCER EPIDEM BIOMAR, V14, P1539, DOI 10.1158/1055-9965.EPI-04-0846
   Jiang Jun, 2009, V471, P305, DOI 10.1007/978-1-59745-416-2_16
   Kertat K, 2008, ONCOL REP, V20, P179
   Kirkwood JM, 2008, J CLIN ONCOL, V26, P3445, DOI 10.1200/JCO.2007.14.6423
   Kumar A, 2012, TUMOR BIOL, V33, P111, DOI 10.1007/s13277-011-0253-7
   Li CY, 2006, CANCER EPIDEM BIOMAR, V15, P2526, DOI 10.1158/1055-9965.EPI-06-0672
   Lieber MR, 2010, ANNU REV BIOCHEM, V79, P181, DOI 10.1146/annurev.biochem.052308.093131
   Lindgren T, 2012, TUMOR BIOL, V33, P689, DOI 10.1007/s13277-012-0329-z
   Liu YH, 2010, CURR OPIN GENET DEV, V20, P239, DOI 10.1016/j.gde.2010.02.001
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Millikan RC, 2006, CARCINOGENESIS, V27, P610, DOI 10.1093/carcin/bgi252
   Mitra D, 2012, NATURE, V491, P449, DOI 10.1038/nature11624
   Nar R, 2012, TUMOR BIOL, V33, P2107, DOI 10.1007/s13277-012-0470-8
   Povey JE, 2007, CARCINOGENESIS, V28, P1087, DOI 10.1093/carcin/bgl257
   Ransom M, 2010, CELL, V140, P183, DOI 10.1016/j.cell.2010.01.004
   Rigel DS, 2010, CA-CANCER J CLIN, V60, P301, DOI 10.3322/caac.20074
   Romano E, 2011, LANCET ONCOL, V12, P913, DOI 10.1016/S1470-2045(10)70274-6
   Thompson JF, 2009, LANCET, V374, P362, DOI 10.1016/S0140-6736(09)61397-0
   Vizkeleti L, 2012, TUMOR BIOL, V33, P2189, DOI 10.1007/s13277-012-0480-6
   Wheless L, 2012, J INVEST DERMATOL, V132, P1354, DOI 10.1038/jid.2012.4
   Winsey SL, 2000, CANCER RES, V60, P5612
   Xue HP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043431
   Zhong SL, 2011, CANCER EPIDEM BIOMAR, V20, P2429, DOI 10.1158/1055-9965.EPI-11-0520
NR 35
TC 8
Z9 8
U1 6
U2 20
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD APR
PY 2013
VL 34
IS 2
BP 1155
EP 1160
DI 10.1007/s13277-013-0657-7
PG 6
WC Oncology
SC Oncology
GA 109JX
UT WOS:000316364500063
PM 23494240
DA 2018-12-27
ER

PT J
AU Pan, TY
   Wang, ZY
AF Pan, Tongyan
   Wang, Zhaoyang
TI RETRACTED: Investigation of coating delamination on steels by surface
   topography and Volta potential difference (Retracted article. See vol.
   19, pg. 941, 2015)
SO JOURNAL OF SOLID STATE ELECTROCHEMISTRY
LA English
DT Article; Retracted Publication
DE Carbon steel; Epoxy coating; Coating delamination; Scanning Kelvin probe
   force microscopy
ID PROBE FORCE MICROSCOPY; FILIFORM CORROSION; AA2024-T3; SKPFM; INHIBITION
AB Corrosion-induced delamination of an epoxy coating on the AISI/SAE 1045 carbon steel was studied under a humid atmospheric condition (temperature of 25 A degrees C, one standard atmospheric pressure, and relative humidity of 90 %) by the technique of scanning Kelvin probe force microscopy (SKPFM). Surface-polished 1045 samples were first cold coated with the epoxy and then subject to the atmospheric corrosion under the humid atmospheric condition. At specified time intervals, surface Volta potential of the samples was measured using the SKPFM over the dry surface of epoxy coating. The map of Volta potentials demonstrated high contrasts among three characteristic zones: intact steel-epoxy interface, delaminated interface, and interface with active corrosion, which based on a rigorous calibration procedure were then linked to the actual corrosion potential of the steel (measured using a potentiostat w.r.t. a saturated calomel electrode). The SKPFM was found to be able to provide a mean of direct and nondestructive detection of early active corrosion and coating delamination of steels at a submicroscopic resolution, which outperformed the conventional electrochemical techniques for such purposes.
C1 [Pan, Tongyan; Wang, Zhaoyang] Catholic Univ Amer, Washington, DC 20064 USA.
RP Pan, TY (reprint author), Catholic Univ Amer, 620 Michigan Ave NE, Washington, DC 20064 USA.
EM pan@cua.edu; wangz@cua.edu
RI Pan, Tongyan/F-6824-2012
CR Dickie R. A., 1986, POLYM MAT CORROSION
   Feser R, 1990, THESIS U CLAUSTHAL Z
   Guillaumin V, 2001, J ELECTROCHEM SOC, V148, pB163, DOI 10.1149/1.1359199
   Leblanc P, 2002, J ELECTROCHEM SOC, V149, pB239, DOI 10.1149/1.1471546
   Leblanc PP, 2004, J ELECTROCHEM SOC, V151, pB105, DOI 10.1149/1.1641038
   LEIDHEISER H, 1983, PROG ORG COAT, V11, P19, DOI 10.1016/0033-0655(83)80002-8
   Leidheiser JH, 1981, CORROSION CONTROL OR
   Mansfeld F., 1987, CORROSION MECH
   NONNENMACHER M, 1991, APPL PHYS LETT, V58, P2921, DOI 10.1063/1.105227
   NONNENMACHER M, 1991, J VAC SCI TECHNOL B, V9, P1358, DOI 10.1116/1.585196
   Pan TY, 2013, SPECTROSC LETT, V46, P268, DOI 10.1080/00387010.2012.725235
   Pan TY, 2012, INT J ELECTROCHEM SC, V7, P9325
   Pan TY, 2012, ANAL LETT, V45, P2580, DOI 10.1080/00032719.2012.694944
   Pan TY, 2012, J APPL ELECTROCHEM, V42, P1049, DOI 10.1007/s10800-012-0479-0
   Rohwerder M, 2001, GALVATECH, P585
   Rohwerder M, 2007, ELECTROCHIM ACTA, V53, P290, DOI 10.1016/j.electacta.2007.03.016
   Schmidt W, 1998, CORROS SCI, V40, P1441, DOI 10.1016/S0010-938X(98)00044-4
   Schmutz P, 1998, J ELECTROCHEM SOC, V145, P2295, DOI 10.1149/1.1838634
   Senoz C, 2011, ELECTROCHIM ACTA, V56, P9588, DOI 10.1016/j.electacta.2011.02.052
   STRATMANN M, 1994, ELECTROCHIM ACTA, V39, P1207, DOI 10.1016/0013-4686(94)E0038-2
   TRASATTI S, 1991, ELECTROCHIM ACTA, V36, P1657, DOI 10.1016/0013-4686(91)85023-Z
   TRASATTI S, 1990, ELECTROCHIM ACTA, V35, P269, DOI 10.1016/0013-4686(90)85069-Y
   Williams G, 2002, J ELECTROCHEM SOC, V149, pB154, DOI 10.1149/1.1457983
   Williams G, 2001, J ELECTROCHEM SOC, V148, pB377, DOI 10.1149/1.1396336
   Williams G., 2001, PHYSCHEMCOMM, V4, P26
NR 25
TC 2
Z9 2
U1 2
U2 21
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1432-8488
EI 1433-0768
J9 J SOLID STATE ELECTR
JI J. Solid State Electrochem.
PD APR
PY 2013
VL 17
IS 4
BP 1109
EP 1115
DI 10.1007/s10008-012-1972-4
PG 7
WC Electrochemistry
SC Electrochemistry
GA 105QY
UT WOS:000316088000021
DA 2018-12-27
ER

PT J
AU Basu, S
   Dahl, KN
   Rohde, GK
AF Basu, S.
   Dahl, K. N.
   Rohde, G. K.
TI RETRACTED: Localizing and extracting filament distributions from
   microscopy images (Retracted article. See vol. 254, pg. 166, 2014)
SO JOURNAL OF MICROSCOPY
LA English
DT Article; Retracted Publication
DE Biological filament networks; centreline curvature; curvilinear
   structures; local network topology
ID CYTOSKELETAL ORGANIZATION; FLUORESCENCE MICROSCOPY;
   QUANTITATIVE-ANALYSIS; ACTIN; ORIENTATION; NETWORKS; CELLS
AB Detailed quantitative measurements of biological filament networks represent a crucial step in understanding architecture and structure of cells and tissues, which in turn explain important biological events such as wound healing and cancer metastases. Confocal microscope images of biological specimens marked for different structural proteins constitute an important source for observing and measuring meaningful parameters of biological networks. Unfortunately, current efforts at quantitative estimation of architecture and orientation of biological filament networks from microscopy images are predominantly limited to visual estimation and indirect experimental inference. Here we describe a new method for localizing and extracting filament distributions from 2D confocal microscopy images. The method combines a filter-based detection of pixels likely to contain a filament with a constrained reverse diffusion-based approach for localizing the filaments centrelines. We show with qualitative and quantitative experiments, using both simulated and real data, that the new method can provide more accurate centreline estimates of filament in comparison to other approaches currently available. In addition, we show the algorithm is more robust with respect to variations in the initial filter-based filament detection step often used. We demonstrate the application of the method in extracting quantitative parameters from an experiment that seeks to quantify the effects of carbon nanotubes on actin cytoskeleton in live HeLa cells. We show that their presence can disrupt the overall actin cytoskeletal organization in such cells.
C1 [Basu, S.; Rohde, G. K.] Carnegie Mellon Univ, Ctr Bioimage Informat, Pittsburgh, PA 15213 USA.
   [Dahl, K. N.; Rohde, G. K.] Carnegie Mellon Univ, Dept Biomed Engn, Pittsburgh, PA 15213 USA.
   [Dahl, K. N.] Carnegie Mellon Univ, Dept Chem Engn, Pittsburgh, PA 15213 USA.
   [Rohde, G. K.] Carnegie Mellon Univ, Dept Elect & Comp Engn, Pittsburgh, PA 15213 USA.
RP Rohde, GK (reprint author), Carnegie Mellon Univ, Ctr Bioimage Informat, Pittsburgh, PA 15213 USA.
EM gustavor@cmu.edu
OI Rohde, Gustavo/0000-0003-1703-9035
FU  [NIH GM090033]
FX The authors would like to thank Mohammad F. Islam and the multiphoton
   laser scanning confocal facility in Material Science at Carnegie Mellon
   University (NSF MRI DMR-0619424, also to KND). S. B. and G. K. R.
   acknowledge support from grant NIH GM090033.
CR Bitplane, 2012, BITPL SCI SOFTW
   Box M. J., 1969, NONLINEAR OPTIMISATI
   Chang S, 2001, ST HEAL T, V84, P901
   David D. L., 2001, MULTISCALE MULTIRESO, V20, P149
   Disanza A, 2005, CELL MOL LIFE SCI, V62, P955, DOI 10.1007/s00018-004-4472-6
   Fleischer F, 2007, NEW J PHYS, V9, DOI 10.1088/1367-2630/9/11/420
   Frangi AF, 1998, LECT NOTES COMPUT SC, V1496, P130
   Gonzales R.C., 1992, DIGITAL IMAGE PROCES
   Goodman J. W., 1996, INTRO FOURIER OPTICS
   GRAHAM RL, 1985, ANN HIST COMPUT, V7, P43
   Haralick R. M., 1992, COMPUTER ROBOT VISIO, VII
   Holt BD, 2010, ACS NANO, V4, P4872, DOI 10.1021/nn101151x
   Huang B, 2010, CELL, V143, P1047, DOI 10.1016/j.cell.2010.12.002
   Karlon WJ, 1999, ANN BIOMED ENG, V27, P712, DOI 10.1114/1.226
   Lichtenstein N, 2003, CYTOM PART A, V54A, P8, DOI 10.1002/cyto.a.10053
   Longair M., 2010, SIMPLE NEURITE TRACE
   Loss LA, 2011, IEEE T MED IMAGING, V30, P1503, DOI 10.1109/TMI.2011.2129526
   OTT A, 1993, PHYS REV E, V48, pR1642, DOI 10.1103/PhysRevE.48.R1642
   PETROLL WM, 1993, J CELL SCI, V104, P353
   Selvin P. R., 2010, ILLINOIS TOOL FIONA
   Shariff A, 2010, CYTOM PART A, V77A, P457, DOI 10.1002/cyto.a.20854
   Thomason DB, 1996, J APPL PHYSIOL, V81, P1522
   Wang YL, 2007, J MICROSC-OXFORD, V228, P123, DOI 10.1111/j.1365-2818.2007.01834.x
   Wearne SL, 2005, NEUROSCIENCE, V136, P661, DOI 10.1016/j.neuroscience.2005.05.053
   Weichsel J, 2010, CYTOM PART A, V77A, P52, DOI 10.1002/cyto.a.20818
   Xu T, 2011, I S BIOMED IMAGING, P1334, DOI 10.1109/ISBI.2011.5872647
NR 26
TC 6
Z9 6
U1 1
U2 22
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-2720
EI 1365-2818
J9 J MICROSC-OXFORD
JI J. Microsc..
PD APR
PY 2013
VL 250
IS 1
BP 57
EP 67
DI 10.1111/jmi.12018
PG 11
WC Microscopy
SC Microscopy
GA 100VK
UT WOS:000315732200007
PM 23458491
OA Green Accepted
DA 2018-12-27
ER

PT J
AU Kakar, K
   Zhang, HT
   Scheres, B
   Dhonukshe, P
AF Kakar, Klementina
   Zhang, Hongtao
   Scheres, Ben
   Dhonukshe, Pankaj
TI RETRACTED: CLASP-mediated cortical microtubule organization guides PIN
   polarization axis (Retracted article. See vol. 508, 2014)
SO NATURE
LA English
DT Article; Retracted Publication
ID AUXIN-EFFLUX; PLANT DEVELOPMENT; ARABIDOPSIS ROOT; PLASMA-MEMBRANE;
   CELL-DIVISION; ENDOCYTOSIS; PROTEINS; LOCALIZATION; CYTOKINESIS;
   TRANSPORT
AB Recent evidence indicates a correlation between orientation of the plant cortical microtubule cytoskeleton and localization of polar cargoes(1). However, the molecules and mechanisms that create this correlation have remained unknown. Here we show that, in Arabidopsis thaliana, the microtubule orientation regulators CLASP(2,3) and MAP65 (refs 3, 4) control the abundance of polarity regulator PINOID kinase(5,6) at the plasma membrane. By localized upregulation of clathrin-dependent endocytosis(7) at cortical microtubule- and clathrin-rich domains orthogonal to the axis of polarity, PINOID accelerates the removal of auxin transporter PIN proteins(8-10) from those sites. This mechanism links directional microtubule organization to the polar localization of auxin transporter PIN proteins, and clarifies how microtubule-enriched cell sides are kept distinct from polar delivery domains. Our results identify the molecular machinery that connects microtubule organization to the regulation of the axis of PIN polarization.
C1 [Kakar, Klementina; Zhang, Hongtao; Scheres, Ben; Dhonukshe, Pankaj] Univ Utrecht, Dept Biol, NL-3584 CH Utrecht, Netherlands.
   [Zhang, Hongtao] Univ Utrecht, Bijvoet Ctr Biomol Res, NL-3584 CH Utrecht, Netherlands.
   [Zhang, Hongtao] Univ Utrecht, Utrecht Inst Pharmaceut Sci, NL-3584 CH Utrecht, Netherlands.
   [Zhang, Hongtao; Scheres, Ben] Netherlands Prote Ctr, NL-3584 CH Utrecht, Netherlands.
   [Scheres, Ben] Wageningen Univ Res, NL-6708 PB Wageningen, Netherlands.
   [Dhonukshe, Pankaj] VIB, Dept Plant Syst Biol, B-9052 Ghent, Belgium.
   [Dhonukshe, Pankaj] Univ Ghent, Dept Plant Biotechnol & Bioinformat, B-9052 Ghent, Belgium.
RP Dhonukshe, P (reprint author), Univ Utrecht, Dept Biol, NL-3584 CH Utrecht, Netherlands.
EM pankaj.dhonukshe@psb.ugent.be
OI Scheres, Ben/0000-0001-5400-9578
FU Utrecht University; Netherlands Organisation for Scientific Research
   VIDI; European Research Council; European Research Council Advanced
   Investigator grant; Netherlands Organisation for Scientific Research
   Spinoza; Netherlands Proteomics Centre
FX We thank M. Estelle, G. Wasteneys, K. Hayashi, C. Luschnig, I. Hwang, M.
   Sasabe and M. Heisler for sharing published material. We thank F. Kindt
   and R. Leito for photography and image processing, and the Akhmanova
   laboratory for the western blotting facility. This work was supported by
   the Utrecht University's Starting Independent Investigator, the
   Netherlands Organisation for Scientific Research VIDI and European
   Research Council Starting Investigator grants to P. D., and the European
   Research Council Advanced Investigator grant, the Netherlands
   Organisation for Scientific Research Spinoza and Netherlands Proteomics
   Centre grants to B. S. K. K. was recruited from grants of P. D., and
   H.Z. was supported by grants of B.S.
CR Abas L, 2006, NAT CELL BIOL, V8, P249, DOI 10.1038/ncb1369
   Ambrose C, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1444
   Ambrose JC, 2007, PLANT CELL, V19, P2763, DOI 10.1105/tpc.107.053777
   Benkova E, 2003, CELL, V115, P591, DOI 10.1016/S0092-8674(03)00924-3
   Blilou I, 2005, NATURE, V433, P39, DOI 10.1038/nature03184
   Dharmasiri N, 2005, DEV CELL, V9, P109, DOI 10.1016/j.devcel.2005.05.014
   Dhonukshe P, 2006, DEV CELL, V10, P137, DOI 10.1016/j.devcel.2005.11.015
   Dhonukshe P, 2005, BMC BIOL, V3, DOI 10.1186/1741-7007-3-11
   Dhonukshe P, 2008, NATURE, V456, P962, DOI 10.1038/nature07409
   Dhonukshe P, 2007, CURR BIOL, V17, P520, DOI 10.1016/j.cub.2007.01.052
   Dhonukshe P, 2012, CELL, V149, P383, DOI 10.1016/j.cell.2012.02.051
   Dhonukshe P, 2010, DEVELOPMENT, V137, P3245, DOI 10.1242/dev.052456
   DiLaurenzio L, 1996, CELL, V86, P423, DOI 10.1016/S0092-8674(00)80115-4
   Friml J, 2004, SCIENCE, V306, P862, DOI 10.1126/science.1100618
   Fu Y, 2005, CELL, V120, P687, DOI 10.1016/j.cell.2004.12.026
   Galinha C, 2007, NATURE, V449, P1053, DOI 10.1038/nature06206
   Geldner N, 2001, NATURE, V413, P425, DOI 10.1038/35096571
   Hayashi K, 2008, P NATL ACAD SCI USA, V105, P5632, DOI 10.1073/pnas.0711146105
   Heisler MG, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000516
   Heisler MG, 2005, CURR BIOL, V15, P1899, DOI 10.1016/j.cub.2005.09.052
   Karahara I, 2009, PLANT J, V57, P819, DOI 10.1111/j.1365-313X.2008.03725.x
   Kim YW, 2001, PLANT PHYSIOL, V127, P1243, DOI 10.1104/pp.010450
   Konopka CA, 2008, PLANT CELL, V20, P1363, DOI 10.1105/tpc.108.059428
   Kotogany E, 2010, PLANT METHODS, V6, DOI 10.1186/1746-4811-6-5
   Li R, 2008, NAT REV MOL CELL BIO, V9, P860, DOI 10.1038/nrm2522
   Michniewicz M, 2007, CELL, V130, P1044, DOI 10.1016/j.cell.2007.07.033
   Nagawa S, 2012, PLOS BIOL, V10, DOI 10.1371/journal.pbio.1001299
   Sasabe M, 2011, PLANT SIGNAL BEHAV, V6, P743, DOI 10.4161/psb.6.5.15146
   Sauer M, 2006, NAT PROTOC, V1, P98, DOI 10.1038/nprot.2006.15
   Smertenko A, 2000, NAT CELL BIOL, V2, P750, DOI 10.1038/35036390
   Stepanova AN, 2008, CELL, V133, P177, DOI 10.1016/j.cell.2008.01.047
   Wisniewska J, 2006, SCIENCE, V312, P883, DOI 10.1126/science.1121356
   Xu J, 2005, PLANT CELL, V17, P525, DOI 10.1105/tpc.104.028449
   Xu TD, 2010, CELL, V143, P99, DOI 10.1016/j.cell.2010.09.003
NR 34
TC 19
Z9 22
U1 2
U2 86
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD MAR 28
PY 2013
VL 495
IS 7442
BP 529
EP +
DI 10.1038/nature11980
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 113QN
UT WOS:000316682800050
PM 23515161
DA 2018-12-27
ER

PT J
AU Valencia, A
   Sapp, E
   Kimm, JS
   McClory, H
   Reeves, PB
   Alexander, J
   Ansong, KA
   Masso, N
   Frosch, MP
   Kegel, KB
   Li, XY
   DiFiglia, M
AF Valencia, Antonio
   Sapp, Ellen
   Kimm, Jeffrey S.
   McClory, Hollis
   Reeves, Patrick B.
   Alexander, Jonathan
   Ansong, Kwadwo A.
   Masso, Nicholas
   Frosch, Matthew P.
   Kegel, Kimberly B.
   Li, Xueyi
   DiFiglia, Marian
TI RETRACTED: Elevated NADPH oxidase activity contributes to oxidative
   stress and cell death in Huntington's disease (Retracted article. See
   vol. 26, pg. 4314, 2017)
SO HUMAN MOLECULAR GENETICS
LA English
DT Article; Retracted Publication
ID TRANSGENIC MOUSE MODEL; LIPID RAFTS; INTRANUCLEAR INCLUSIONS; NEURITE
   OUTGROWTH; MUTANT HUNTINGTIN; CYTOCHROME-C; EARLY MOTOR; ACTIVATION;
   NEURONS; BRAIN
AB A mutation in the huntingtin (Htt) gene produces mutant Htt and Huntington's disease (HD), a neurodegenerative disorder. HD patients have oxidative damage in the brain, but the causes are unclear. Compared with controls, we found brain levels of NADPH oxidase (NOX) activity, which produces reactive oxygen species (ROS), elevated in human HD postmortem cortex and striatum and highest in striatum of presymptomatic individuals. Synaptosome fractions from cortex and striatum of HD140Q/140Q mice had elevated NOX activity at 3 months of age and a further rise at 6 and 12 months compared with synaptosomes of age-matched wild-type (WT) mice. High NOX activity in primary cortical and striatal neurons of HD140Q/140Q mice correlated with more ROS and neurite swellings. These features and neuronal cell death were markedly reduced by treatment with NOX inhibitors such as diphenyleneiodonium (DPI), apocynin (APO) and VAS2870. The rise in ROS levels in mitochondria of HD140Q/140Q neurons followed the rise in NOX activity and inhibiting only mitochondrial ROS was not neuroprotective. Mutant Htt colocalized at plasma membrane lipid rafts with gp91-phox, a catalytic subunit for the NOX2 isoform. Assembly of NOX2 components at lipid rafts requires activation of Rac1 which was also elevated in HD140Q/140Q neurons. HD140Q/140Q mice bred to gp91-phox knock-out mice had lower NOX activity in the brain and in primary neurons, and neurons had normal ROS levels and significantly improved survival. These findings suggest that increased NOX2 activity at lipid rafts is an early and major source of oxidative stress and cell death in HD140Q/140Q neurons.
C1 [Valencia, Antonio; Sapp, Ellen; Kimm, Jeffrey S.; McClory, Hollis; Reeves, Patrick B.; Alexander, Jonathan; Ansong, Kwadwo A.; Masso, Nicholas; Kegel, Kimberly B.; Li, Xueyi; DiFiglia, Marian] Massachusetts Gen Hosp East, Dept Neurol, Charlestown, MA 02129 USA.
   [Valencia, Antonio; Sapp, Ellen; Kimm, Jeffrey S.; McClory, Hollis; Reeves, Patrick B.; Alexander, Jonathan; Ansong, Kwadwo A.; Masso, Nicholas; Kegel, Kimberly B.; Li, Xueyi; DiFiglia, Marian] Harvard Univ, Sch Med, Charlestown, MA 02129 USA.
   [Frosch, Matthew P.] Massachusetts Gen Hosp, CS Kubik Lab Neuropathol, Pathol Serv, Boston, MA 02114 USA.
   [Frosch, Matthew P.] Harvard Univ, Sch Med, Boston, MA 02114 USA.
RP DiFiglia, M (reprint author), Massachusetts Gen Hosp East, Dept Neurol, 114,16th St,Room 2002, Charlestown, MA 02129 USA.
EM difiglia@helix.mgh.harvard.edu
FU Hereditary Disease Foundation; Fundacion Mexico en Harvard A.C.; CHDI
   Foundation; HDSA Foundation; NIH-NINDS [NS74381]
FX This study was supported by fellowships from the Hereditary Disease
   Foundation to A.V. and X.L., Fundacion Mexico en Harvard A.C. to A.V.,
   and CHDI and HDSA Foundations and NIH-NINDS NS74381 to M.D.
CR Altenhofer S, 2012, CELL MOL LIFE SCI, V69, P2327, DOI 10.1007/s00018-012-1010-9
   Anantharam V, 2007, NEUROTOXICOLOGY, V28, P988, DOI 10.1016/j.neuro.2007.08.008
   Archer SL, 1999, P NATL ACAD SCI USA, V96, P7944, DOI 10.1073/pnas.96.14.7944
   Bedard K, 2007, PHYSIOL REV, V87, P245, DOI 10.1152/physrev.00044.2005
   Bertoni A, 2011, J BIOL CHEM, V286, P4727, DOI 10.1074/jbc.M110.156521
   Bogdanov MB, 2001, J NEUROCHEM, V79, P1246, DOI 10.1046/j.1471-4159.2001.00689.x
   Brennan AM, 2009, NAT NEUROSCI, V12, P857, DOI 10.1038/nn.2334
   Chen CM, 2007, BIOCHEM BIOPH RES CO, V359, P335, DOI 10.1016/j.bbrc.2007.05.093
   Chen H, 2011, ANTIOXID REDOX SIGN, V14, P1505, DOI 10.1089/ars.2010.3576
   Choi DH, 2012, ANTIOXID REDOX SIGN, V16, P1033, DOI 10.1089/ars.2011.3960
   Cummings DM, 2009, J NEUROSCI, V29, P10371, DOI 10.1523/JNEUROSCI.1592-09.2009
   De Luca G, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000266
   DeCoursey TE, 2008, CELL MOL LIFE SCI, V65, P2554, DOI 10.1007/s00018-008-8056-8
   del Hoyo P, 2006, NEUROCHEM RES, V31, P1103, DOI 10.1007/s11064-006-9110-2
   Demaurex N, 2009, NAT NEUROSCI, V12, P819, DOI 10.1038/nn0709-819
   DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990
   DIFIGLIA M, 1995, NEURON, V14, P1075, DOI 10.1016/0896-6273(95)90346-1
   Dohi K, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-41
   Dugan LL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005518
   DUSI S, 1993, BIOCHEM J, V296, P367, DOI 10.1042/bj2960367
   Dyer RB, 2001, NAT GENET, V29, P270, DOI 10.1038/ng745
   Faurschou M, 2003, MICROBES INFECT, V5, P1317, DOI 10.1016/j.micinf.2003.09.008
   Gerstner B, 2008, J NEUROSCI, V28, P1236, DOI 10.1523/JNEUROSCI.3213-07.2008
   Groemping Y, 2005, BIOCHEM J, V386, P401, DOI 10.1042/BJ20041835
   Guidetti P, 2001, EXP NEUROL, V169, P340, DOI 10.1006/exnr.2000.7626
   Ha JS, 2010, EXP CELL RES, V316, P1651, DOI 10.1016/j.yexcr.2010.03.021
   HAJOS F, 1975, BRAIN RES, V93, P485, DOI 10.1016/0006-8993(75)90186-9
   Hersch SM, 2006, NEUROLOGY, V66, P250, DOI 10.1212/01.wnl.0000194318.74946.b6
   Hickey MA, 2008, NEUROSCIENCE, V157, P280, DOI 10.1016/j.neuroscience.2008.08.041
   Ibi M, 2006, FREE RADICAL BIO MED, V40, P1785, DOI 10.1016/j.freeradbiomed.2006.01.009
   Kaltenbach LS, 2007, PLOS GENET, V3, P689, DOI 10.1371/journal.pgen.0030082
   Kannan KB, 2007, J IMMUNOL, V178, P5253, DOI 10.4049/jimmunol.178.8.5253
   Kawakami-Mori F, 2012, AM J PHYSIOL-ENDOC M, V302, pE425, DOI 10.1152/ajpendo.00227.2011
   Kegel KB, 2009, J NEUROCHEM, V110, P1585, DOI 10.1111/j.1471-4159.2009.06255.x
   Kim D, 2010, P NATL ACAD SCI USA, V107, P14851, DOI 10.1073/pnas.1009926107
   Kirkland RA, 2007, J NEUROSCI, V27, P11315, DOI 10.1523/JNEUROSCI.3590-07.2007
   Kleinschnitz C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000479
   Klepac N, 2007, J NEUROL, V254, P1676, DOI 10.1007/s00415-007-0611-y
   KOSHKIN V, 1993, FEBS LETT, V327, P57, DOI 10.1016/0014-5793(93)81039-3
   Laforet GA, 2001, J NEUROSCI, V21, P9112, DOI 10.1523/JNEUROSCI.21-23-09112.2001
   Lam GY, 2010, SEMIN IMMUNOPATHOL, V32, P415, DOI 10.1007/s00281-010-0221-0
   Larsen KE, 2002, J NEUROSCI, V22, P8951
   Lee MS, 2000, NATURE, V405, P360, DOI 10.1038/35012636
   Li XY, 2010, J NEUROSCI, V30, P4552, DOI 10.1523/JNEUROSCI.5865-09.2010
   Ma L, 2004, BRAIN RES, V1018, P10, DOI 10.1016/j.brainres.2004.05.052
   Maksimovic I D, 2001, Vojnosanit Pregl, V58, P237
   Maldonado PD, 2010, J NEUROSCI RES, V88, P620, DOI 10.1002/jnr.22240
   Malla RR, 2010, INT J ONCOL, V37, P1483, DOI 10.3892/ijo_00000801
   Martinez A, 2010, BRAIN PATHOL, V20, P281, DOI 10.1111/j.1750-3639.2009.00326.x
   Menalled LB, 2003, J COMP NEUROL, V465, P11, DOI 10.1002/cne.10776
   Miyano K, 2012, METHODS MOL BIOL, V827, P195, DOI 10.1007/978-1-61779-442-1_14
   Munnamalai V, 2009, J NEUROCHEM, V108, P644, DOI 10.1111/j.1471-4159.2008.05787.x
   Murotomi K, 2011, MOL CELL NEUROSCI, V46, P681, DOI 10.1016/j.mcn.2011.01.009
   ODONNELL VB, 1993, BIOCHEM J, V290, P41, DOI 10.1042/bj2900041
   Perez-Severiano F, 2004, NEUROCHEM RES, V29, P729, DOI 10.1023/B:NERE.0000018843.83770.4b
   Perez-Severiano F, 2000, BRAIN RES, V862, P234, DOI 10.1016/S0006-8993(00)02082-5
   Pestana RRF, 2010, NEUROSCI LETT, V484, P187, DOI 10.1016/j.neulet.2010.08.049
   POLLOCK JD, 1995, NAT GENET, V9, P202, DOI 10.1038/ng0295-202
   Ricart KC, 2001, NEUROCHEM RES, V26, P801, DOI 10.1023/A:1011660001941
   Richards P, 2011, CELL DEATH DIFFER, V18, P191, DOI 10.1038/cdd.2010.127
   Roediger B, 2003, NEUROBIOL DIS, V13, P222, DOI 10.1016/S0969-9961(03)00038-X
   Samhan-Arias AK, 2009, MOL CELL NEUROSCI, V40, P14, DOI 10.1016/j.mcn.2008.08.013
   Sapp E, 1999, J NEUROPATH EXP NEUR, V58, P165, DOI 10.1097/00005072-199902000-00006
   Sapp E, 2001, J NEUROPATH EXP NEUR, V60, P161, DOI 10.1093/jnen/60.2.161
   Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1
   Schilling G, 2001, NEUROSCI LETT, V315, P149, DOI 10.1016/S0304-3940(01)02326-6
   Serrano F, 2003, BRAIN RES, V988, P193, DOI 10.1016/S0006-8993(03)03364-X
   Shao DM, 2003, FEBS LETT, V550, P101, DOI 10.1016/S0014-5793(03)00845-7
   SHPUNGIN S, 1989, J BIOL CHEM, V264, P9195
   Sorce S, 2010, J NEUROSCI, V30, P11317, DOI 10.1523/JNEUROSCI.1491-10.2010
   Stack EC, 2006, BBA-MOL BASIS DIS, V1762, P373, DOI 10.1016/j.bbadis.2005.11.002
   Stack EC, 2008, ANN NY ACAD SCI, V1147, P79, DOI 10.1196/annals.1427.008
   STOLK J, 1994, AM J RESP CELL MOL, V11, P95, DOI 10.1165/ajrcmb.11.1.8018341
   Stoy N, 2005, J NEUROCHEM, V93, P611, DOI 10.1111/j.1471-4159.2005.03070.x
   Suzukawa K, 2000, J BIOL CHEM, V275, P13175, DOI 10.1074/jbc.275.18.13175
   Tejada-Simon MV, 2005, MOL CELL NEUROSCI, V29, P97, DOI 10.1016/j.mcn.2005.01.007
   Ushio-Fukai M, 2007, ANTIOXID REDOX SIGN, V9, P731, DOI 10.1089/ars.2007.1556
   Valencia A, 2004, FREE RADICAL BIO MED, V36, P1112, DOI 10.1016/j.freeradbiomed.2004.02.013
   Valencia A, 2001, J NEUROSCI RES, V64, P284, DOI 10.1002/jnr.1077
   Valencia A, 2012, NEUROREPORT, V23, P10, DOI 10.1097/WNR.0b013e32834d92e6
   Valencia A, 2010, J NEUROSCI RES, V88, P179, DOI 10.1002/jnr.22184
   Vaughn AE, 2008, NAT CELL BIOL, V10, P1477, DOI 10.1038/ncb1807
   Vilhardt F, 2004, EMBO J, V23, P739, DOI 10.1038/sj.emboj.7600066
   Yoshioka H, 2011, J CEREBR BLOOD F MET, V31, P868, DOI 10.1038/jcbfm.2010.166
   Zaidi A, 2009, FREE RADICAL BIO MED, V47, P1507, DOI 10.1016/j.freeradbiomed.2009.08.018
   Zhang AY, 2006, HYPERTENSION, V47, P74, DOI 10.1161/01.HYP.0000196727.53300.62
NR 86
TC 63
Z9 66
U1 2
U2 22
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD MAR 15
PY 2013
VL 22
IS 6
BP 1112
EP 1131
DI 10.1093/hmg/dds516
PG 20
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 108MD
UT WOS:000316296600005
PM 23223017
OA Green Published
DA 2018-12-27
ER

PT J
AU Wang, F
   Sen, S
   Zhang, Y
   Ahmad, I
   Zhu, XY
   Wilson, IA
   Smider, VV
   Magliery, TJ
   Schultz, PG
AF Wang, Feng
   Sen, Shiladitya
   Zhang, Yong
   Ahmad, Insha
   Zhu, Xueyong
   Wilson, Ian A.
   Smider, Vaughn V.
   Magliery, Thomas J.
   Schultz, Peter G.
TI RETRACTED: Somatic hypermutation maintains antibody thermodynamic
   stability during affinity maturation (Retracted article. See vol. 114,
   pg.E7855, 2017)
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article; Retracted Publication
ID ALDOLASE ANTIBODIES; CRYSTAL-STRUCTURE; PHAGE DISPLAY; IN-VITRO;
   EVOLUTION; CATALYSIS; BINDING; SELECTION; OKT3; EXPRESSION
AB Somatic hypermutation and clonal selection lead to B cells expressing high-affinity antibodies. Here we show that somatic mutations not only play a critical role in antigen binding, they also affect the thermodynamic stability of the antibody molecule. Somatic mutations directly involved in antigen recognition by antibody 93F3, which binds a relatively small hapten, reduce the melting temperature compared with its germ-line precursor by up to 9 degrees C. The destabilizing effects of these mutations are compensated by additional somatic mutations located on surface loops distal to the antigen binding site. Similarly, somatic mutations enhance both the affinity and thermodynamic stability of antibody OKT3, which binds the large protein antigen CD3. Analysis of the crystal structures of 93F3 and OKT3 indicates that these somatic mutations modulate antibody stability primarily through the interface of the heavy and light chain variable domains. The historical view of antibody maturation has been that somatic hypermutation and subsequent clonal selection increase antigen antibody specificity and binding energy. Our results suggest that this process also optimizes protein stability, and that many peripheral mutations that were considered to be neutral are required to offset deleterious effects of mutations that increase affinity. Thus, the immunological evolution of antibodies recapitulates on a much shorter timescale the natural evolution of enzymes in which function and thermodynamic stability are simultaneously enhanced through mutation and selection.
C1 [Wang, Feng; Zhang, Yong; Ahmad, Insha; Schultz, Peter G.] Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA.
   [Zhu, Xueyong; Wilson, Ian A.; Smider, Vaughn V.] Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA.
   [Wang, Feng; Zhang, Yong; Ahmad, Insha; Schultz, Peter G.] Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA.
   [Sen, Shiladitya; Magliery, Thomas J.] Ohio State Univ, Dept Chem & Biochem, Columbus, OH 43210 USA.
RP Magliery, TJ (reprint author), Ohio State Univ, Dept Chem & Biochem, Columbus, OH 43210 USA.
EM magliery.1@osu.edu; schultz@scripps.edu
RI Magliery, Thomas/B-6050-2009
OI Magliery, Thomas/0000-0003-0779-1477
FU National Institutes of Health (NIH) [R01 GM062159, R01 GM083114]; Skaggs
   Institute for Chemical Biology
FX This work was supported by National Institutes of Health (NIH) Grant R01
   GM062159 (to P.G.S.), The Skaggs Institute for Chemical Biology
   (P.G.S.), and NIH Grant R01 GM083114 (to T.J.M.).
CR Bradbury ARM, 2011, NAT BIOTECHNOL, V29, P245, DOI 10.1038/nbt.1791
   Burnet F. M, 1959, CLONAL SELECTION THE
   Ewert S, 2003, J MOL BIOL, V325, P531, DOI 10.1016/S0022-2836(02)01237-8
   Forrer P, 1999, CURR OPIN STRUC BIOL, V9, P514, DOI 10.1016/S0959-440X(99)80073-6
   Halabi N, 2009, CELL, V138, P774, DOI 10.1016/j.cell.2009.07.038
   He F, 2010, J PHARM SCI-US, V99, P1707, DOI 10.1002/jps.21955
   JERNE NK, 1955, P NATL ACAD SCI USA, V41, P849, DOI 10.1073/pnas.41.11.849
   Jung S, 1999, J MOL BIOL, V294, P163, DOI 10.1006/jmbi.1999.3196
   KIM S, 1981, CELL, V27, P573, DOI 10.1016/0092-8674(81)90399-8
   King AC, 2011, PROTEIN SCI, V20, P1546, DOI 10.1002/pro.680
   Kjer-Nielsen L, 2004, P NATL ACAD SCI USA, V101, P7675, DOI 10.1073/pnas.0402295101
   Kwon WS, 1996, PROTEIN ENG, V9, P1197, DOI 10.1093/protein/9.12.1197
   Lavinder JJ, 2009, J AM CHEM SOC, V131, P3794, DOI 10.1021/ja8049063
   Levin KB, 2009, NAT STRUCT MOL BIOL, V16, P1049, DOI 10.1038/nsmb.1670
   MATSUMURA M, 1985, J BIOL CHEM, V260, P5298
   Monsellier E, 2006, J MOL BIOL, V362, P580, DOI 10.1016/j.jmb.2006.07.044
   Patten PA, 1996, SCIENCE, V271, P1086, DOI 10.1126/science.271.5252.1086
   Romesberg FE, 1998, BIOCHEMISTRY-US, V37, P14404, DOI 10.1021/bi981578c
   Romesberg FE, 1998, SCIENCE, V279, P1929, DOI 10.1126/science.279.5358.1929
   Soskine M, 2010, NAT REV GENET, V11, P572, DOI 10.1038/nrg2808
   STEIPE B, 1994, J MOL BIOL, V240, P188, DOI 10.1006/jmbi.1994.1434
   Tanaka F, 2004, J MOL BIOL, V335, P1007, DOI 10.1016/j/jmb.2003.11.014
   Teng G, 2007, ANNU REV GENET, V41, P107, DOI 10.1146/annurev.genet.41.110306.130340
   Tokuriki N, 2009, CURR OPIN STRUC BIOL, V19, P596, DOI 10.1016/j.sbi.2009.08.003
   TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0
   Ulrich HD, 1997, NATURE, V389, P271
   VANWAUWE JP, 1980, J IMMUNOL, V124, P2708
   Vasserot AP, 2003, DRUG DISCOV TODAY, V8, P118, DOI 10.1016/S1359-6446(02)02590-4
   WAGNER J, 1995, SCIENCE, V270, P1797, DOI 10.1126/science.270.5243.1797
   Wang XJ, 2002, J MOL BIOL, V320, P85, DOI 10.1016/S0022-2836(02)00400-X
   WOODLE ES, 1992, J IMMUNOL, V148, P2756
   Worn A, 1998, BIOCHEMISTRY-US, V37, P13120, DOI 10.1021/bi980712q
   WU TT, 1970, J EXP MED, V132, P211, DOI 10.1084/jem.132.2.211
   Yin J, 2003, P NATL ACAD SCI USA, V100, P856, DOI 10.1073/pnas.0235873100
   Zhu XY, 2009, J AM CHEM SOC, V131, P18206, DOI 10.1021/ja907271a
   Zhu XY, 2004, J MOL BIOL, V343, P1269, DOI 10.1016/j.jmb.2004.08.102
NR 36
TC 47
Z9 47
U1 2
U2 37
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAR 12
PY 2013
VL 110
IS 11
BP 4261
EP 4266
DI 10.1073/pnas.1301810110
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 107RK
UT WOS:000316238300030
PM 23440204
OA Bronze, Green Published
DA 2018-12-27
ER

PT J
AU Barry, SP
   Ounzain, S
   McCormick, J
   Scarabelli, TM
   Chen-Scarabelli, C
   Saravolatz, LII
   Faggian, G
   Mazzucco, A
   Suzuki, H
   Thiemermann, C
   Knight, RA
   Latchman, DS
   Stephanou, A
AF Barry, Sean P.
   Ounzain, Samir
   McCormick, James
   Scarabelli, Tiziano M.
   Chen-Scarabelli, Carol
   Saravolatz, Louis I. I.
   Faggian, Giuseppe
   Mazzucco, Alessandro
   Suzuki, Hisanori
   Thiemermann, Christoph
   Knight, Richard A.
   Latchman, David S.
   Stephanou, Anastasis
TI RETRACTED: Enhanced IL-17 signalling following myocardial
   ischaemia/reperfusion injury (Retracted article. See vol. 274, pg. 404,
   2019)
SO INTERNATIONAL JOURNAL OF CARDIOLOGY
LA English
DT Article; Retracted Publication
DE IL-17; Myocardial; Ischaemia/reperfusion; IL-17 receptor; Cxcl1; MAPK
ID GENE-EXPRESSION; INTERLEUKIN-17; CELLS; INTERFACE; RECEPTOR; PROTEIN;
   ALPHA; PCR
AB Background: IL-17A and IL-17F are pro-inflammatory cytokines which induce the expression of several cytokines, chemokines and matrix metalloproteinases (MMPs) in target cells. IL-17 cytokines have recently attracted huge interest due to their pathogenic role in diseases such as arthritis and inflammatory bowel disease although a role for IL-17 cytokines in myocardial infarction (MI) has not previously been described.
   Methods: In vivo MI was performed by coronary artery occlusion in the absence or presence of a neutralizing IL-17 antibody for blocking IL-17 actions in vivo. IL-17 signaling was also assessed in isolated primary cardiomyocytes by Western blot, mRNA expression and immunostaining.
   Results: Expression of IL-17A, IL-17F and the IL-17 receptor (IL-17RA) were all increased following MI. Expression of several IL-17 target genes, including Cxcl1, Cxcl2, IL-1 beta, iNOS and IL-6 was also upregulated following MI. In addition, IL-17A promoted the expression of Cxcl1 and IL-6 in isolated cardiomyocytes in a MAPK and PI(3) K-dependent manner. IL-17A and ischaemia/reperfusion (I/R) injury were found to have an additive effect on Cxcl1 expression, suggesting that IL-17 may enhance myocardial neutrophil recruitment during MI. Moreover, protein levels of both IL-17R and IL-17A were enhanced following in vivo MI. Finally, blocking IL-17 signaling in vivo reduced the levels of apoptotic cell death markers following in vivo MI.
   Conclusions: These data imply that the expression of IL-17 cytokines and their receptor are elevated during myocardial I/R injury and may play a fundamental role in post infarct inflammatory and apoptotic responses. (C) 2011 Elsevier Ireland Ltd. All rights reserved.
C1 [Barry, Sean P.] Trinity Coll Dublin, St Jamess Hosp, Inst Mol Med, Dublin 8, Ireland.
   [Ounzain, Samir; McCormick, James; Knight, Richard A.; Latchman, David S.; Stephanou, Anastasis] UCL, Med Mol Biol Unit, Inst Child Hlth, London WC1N 1EH, England.
   [Scarabelli, Tiziano M.; Chen-Scarabelli, Carol; Saravolatz, Louis I. I.] Wayne State Univ, Sch Med, St John Hosp, Ctr Heart & Vessel Preclin Studies, Detroit, MI USA.
   [Scarabelli, Tiziano M.; Chen-Scarabelli, Carol; Saravolatz, Louis I. I.] Wayne State Univ, Sch Med, Med Ctr, Detroit, MI USA.
   [Faggian, Giuseppe; Mazzucco, Alessandro] Univ Verona, Div Cardiac Surg, I-37100 Verona, Italy.
   [Suzuki, Hisanori] Univ Verona, Sez Chim Biol, Dipartimento Sci Morfol Biomed, I-37134 Verona, Italy.
   [Thiemermann, Christoph] Queen Mary Univ London, Ctr Translat Med & Therapeut, William Harvey Res Inst, St Bartholomews & Royal London Sch Med & Dent, London, England.
RP Stephanou, A (reprint author), UCL, Med Mol Biol Unit, Inst Child Hlth, 30 Guilford St, London WC1N 1EH, England.
EM a.stephanou@ich.ucl.ac.uk
RI Faggian, Giuseppe/J-4590-2018
OI Faggian, Giuseppe/0000-0001-5371-5761
FU British Heart Foundation [FS/03/111]; Irish Research Council for
   Science, Engineering and Technology (IRCSET)
FX This study was generously funded by the British Heart Foundation
   (FS/03/111). SB was also funded by the Irish Research Council for
   Science, Engineering and Technology (IRCSET).
CR Afzali B, 2010, CLIN EXP IMMUNOL, V159, P120, DOI 10.1111/j.1365-2249.2009.04038.x
   Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535
   Baldeviano GC, 2010, CIRC RES, V106, P1646, DOI 10.1161/CIRCRESAHA.109.213157
   Barry SP, 2007, TRENDS MOL MED, V13, P82, DOI 10.1016/j.molmed.2006.12.002
   Barry SP, 2010, J MOL ENDOCRINOL, V45, P69, DOI 10.1677/JME-09-0148
   Barry SP, 2009, BIOCHEM BIOPH RES CO, V385, P324, DOI 10.1016/j.bbrc.2009.05.051
   Chang SH, 2006, J BIOL CHEM, V281, P35603, DOI 10.1074/jbc.C60050056200
   Chang SH, 2009, CYTOKINE, V46, P7, DOI 10.1016/j.cyto.2008.12.024
   Das Sarma J, 2009, J NEUROINFLLAMMATION, V6, P1
   Dong C, 2008, NAT REV IMMUNOL, V8, P337, DOI 10.1038/nri2295
   Frangogiannis NG, 2006, CURR MED CHEM, V13, P1877, DOI 10.2174/092986706777585086
   Hartupee J, 2007, J IMMUNOL, V179, P4135, DOI 10.4049/jimmunol.179.6.4135
   Honorati MC, 2001, RHEUMATOLOGY, V40, P522, DOI 10.1093/rheumatology/40.5.522
   Iyoda M, 2010, AM J PHYSIOL-RENAL, V298, pF779, DOI 10.1152/ajprenal.00198.2009
   Knight RA, 2008, FEBS LETT, V582, P984, DOI 10.1016/j.febslet.2008.02.035
   Li L, 2010, J CLIN INVEST, V120, P331, DOI 10.1172/JCI38702
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Mann DL, 2004, CIRCULATION, V109, P1594, DOI 10.1161/01.CIR.0000124490.27666.B2
   McGeachy MJ, 2008, IMMUNITY, V28, P445, DOI 10.1016/j.immuni.2008.03.001
   Numasaki M, 2004, IMMUNOL LETT, V93, P39, DOI 10.1016/j.imlet.2004.01.014
   Onishi RM, 2010, IMMUNOLOGY, V129, P311, DOI 10.1111/j.1365-2567.2009.03240.x
   Pappu R, 2010, J CLIN IMMUNOL, V30, P185, DOI 10.1007/s10875-010-9369-6
   Reiner A, 2003, BIOINFORMATICS, V19, P368, DOI 10.1093/bioinformatics/btf877
   Sanges R, 2007, BIOINFORMATICS, V23, P3406, DOI 10.1093/bioinformatics/btm469
   Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73
   Shahrara S, 2010, J IMMUNOL, V184, P4479, DOI 10.4049/jimmunol.0901942
   Sivarajah A, 2005, J PHARMACOL EXP THER, V313, P896, DOI 10.1124/jpet.104.080598
   Venkatachalam K, 2008, AM J PHYSIOL-HEART C, V294, pH2078, DOI 10.1152/ajpheart.01363.2007
   Wettenhall JM, 2006, BIOINFORMATICS, V22, P897, DOI 10.1093/bioinformatics/btl025
   Xu S, 2010, CELL MOL IMMUNOL, V7, P164, DOI 10.1038/cmi.2010.21
NR 30
TC 27
Z9 29
U1 0
U2 26
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0167-5273
EI 1874-1754
J9 INT J CARDIOL
JI Int. J. Cardiol.
PD MAR 10
PY 2013
VL 163
IS 3
BP 326
EP 334
DI 10.1016/j.ijcard.2011.08.849
PG 9
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 092XJ
UT WOS:000315156000024
PM 22030025
OA Green Published, Other Gold
DA 2018-12-27
ER

PT J
AU Rustam, S
   Rashid, K
   Zaman, K
AF Rustam, Sehrish
   Rashid, Kashif
   Zaman, Khalid
TI RETRACTED: The relationship between audit committees, compensation
   incentives and corporate audit fees in Pakistan (Retracted article. See
   vol. 45, pg. 287, 2015)
SO ECONOMIC MODELLING
LA English
DT Article; Retracted Publication
DE Audit committees; Compensation incentives; Corporate audit fees; Panel
   regression; Pakistan
ID EARNINGS MANAGEMENT; NONAUDIT SERVICES; EMPIRICAL-EVIDENCE; OWNERSHIP
   STRUCTURE; EQUITY INCENTIVES; FIRM PERFORMANCE; LITIGATION RISK; AGENCY
   PROBLEMS; CEO INCENTIVES; BONUS SCHEMES
AB The objective of the study is to examine the association between audit committees, compensation incentives and corporate audit fees in Pakistan by using the data of fifty firms that are listed on the Karachi Stock Exchange (KSE), Pakistan during the years of 2007-2011. Panel data technique is used in this study, as the data set contains cross-sectional units over several time periods. Panel data control for cross sectional heterogeneity by observing individual firm and reduces the risk of biasness and collinearity among variables. The result of panel regression indicates that audit committee activity and committee member's independence are significantly associated to audit fee levels, consistent with the argument that audit committees complement the work of external auditors in monitoring management. In contrast, chief executive officers (CEO) pay incentives both short term and long term neither complement nor substitute for audit effort in disciplining Pakistan's firm management. Further results on the full sample of firms reveal significant differences in determinants of audit fees between the years examined. Finally, the results of control variables suggest a significant association between non-audit fee, board meetings, ROA (return on assets), sales and firm foreign operations with the audit fees in the selected market. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Rustam, Sehrish; Rashid, Kashif; Zaman, Khalid] COMSATS Inst Informat Technol, Dept Management Sci, Abbottabad, Pakistan.
RP Zaman, K (reprint author), COMSATS Inst Informat Technol, Dept Management Sci, Abbottabad, Pakistan.
EM sehrish_rustam@hotmail.com; mkrashid@ciit.net.pk;
   khalidzaman@ciit.net.pk
RI alrefaei, hessa/F-1443-2015
CR Abbott LJ, 2004, AUDITING-J PRACT TH, V23, P69, DOI 10.2308/aud.2004.23.1.69
   Abbott LJ, 2003, AUDITING-J PRACT TH, V22, P17, DOI 10.2308/aud.2003.22.2.17
   Abbott LJ, 2000, AUDITING-J PRACT TH, V19, P47, DOI 10.2308/aud.2000.19.2.47
   Adelopo I, 2012, SOC RESPONSIB J, V8, P471, DOI 10.1108/17471111211272066
   Agrawal A, 2005, J LAW ECON, V48, P371, DOI 10.1086/430808
   Alali F, 2011, MANAG AUDIT J, V26, P90, DOI 10.1108/02686901111094994
   Ananthanarayanan U., 2011, THESIS MASSEY U NZ
   Anderson RC, 2004, J ACCOUNT ECON, V37, P315, DOI 10.1016/j.jacceco.2004.01.004
   Anjam Z., 2011, THESIS BLEKINGE I TE
   Armstrong C.S., 2009, ROLE INFORM FINANCIA
   Arshad A.M., 2011, GLOBAL J MANAGEMENT, V11
   Ashbaugh H, 2003, ACCOUNT REV, V78, P611, DOI 10.2308/accr.2003.78.3.611
   Baysinger B. D., 1985, J LAW ECON ORGAN, V1, P101
   Beasley M., 2000, ACCOUNT HORIZ, V14, P441, DOI DOI 10.2308/ACCH.2000.14.4.441
   Beasley MS, 1996, ACCOUNT REV, V71, P443
   BEBCHUK LUCIAN A., 2004, PAY PERFORMANCE UNFU
   Bedard JC, 2004, ACCOUNT REV, V79, P277, DOI 10.2308/accr.2004.79.2.277
   Bedard J, 2004, AUDITING-J PRACT TH, V23, P13, DOI 10.2308/aud.2004.23.2.13
   Bell T., 2001, J ACCOUNT RES, V42, P625
   Bell TB, 2001, J ACCOUNTING RES, V39, P35, DOI 10.1111/1475-679X.00002
   Bertrand M, 2001, Q J ECON, V116, P901, DOI 10.1162/00335530152466269
   Bliss MA, 2007, MANAG AUDIT J, V22, P716, DOI 10.1108/02686900710772609
   Blue Ribbon Committee, 1999, REP REC BLUE RIBB CO
   Bolton B., 2012, ACCOUNTING IN PRESS, DOI DOI 10.1111/J.1467-629X.2012.00504
   Braiotta L., 2000, AUDIT COMMITTEE HDB
   Brown D.L., 2004, CORPORATE GOVERNANCE
   Burns N, 2006, J FINANC ECON, V79, P35, DOI 10.1016/j.jfineco.2004.12.003
   Bushman RM, 2006, J ACCOUNT ECON, V42, P107, DOI 10.1016/j.jacceco.2005.10.005
   Cadbury Adrian, 1992, CADBURY REPORT
   Carcello JV, 2000, ACCOUNT REV, V75, P453, DOI 10.2308/accr.2000.75.4.453
   Carcello JV, 2003, ACCOUNT REV, V78, P95, DOI 10.2308/accr.2003.78.1.95
   Carcello JV, 2002, CONTEMP ACCOUNT RES, V19, P365, DOI 10.1506/CHWK-GMQ0-MLKE-K03V
   Cheema A., 2003, CORPORATE GOVERNANCE
   Cheng Q, 2005, ACCOUNT REV, V80, P441, DOI 10.2308/accr.2005.80.2.441
   CHOW CW, 1982, ACCOUNT REV, V57, P272
   Claessens S, 2000, J FINANC ECON, V58, P81, DOI 10.1016/S0304-405X(00)00067-2
   Coffee JC, 2005, OXFORD REV ECON POL, V21, P198, DOI 10.1093/oxrep/gri012
   Cohen J, 2002, CONTEMP ACCOUNT RES, V19, P573, DOI 10.1506/983M-EPXG-4Y0R-J9YK
   Cohen JR, 2000, AUDITING-J PRACT TH, V19, P133, DOI 10.2308/aud.2000.19.2.133
   Collier P., 1996, EUROPEAN ACCOUNTING, V5, P177, DOI DOI 10.1080/09638189600000012
   Conger JA, 1998, HARVARD BUS REV, V76, P136
   Core JE, 1999, J FINANC ECON, V51, P371, DOI 10.1016/S0304-405X(98)00058-0
   Dalton DR, 1999, ACAD MANAGE J, V42, P674, DOI 10.2307/256988
   Davidson RA, 1996, J ACCOUNTING RES, V34, P111, DOI 10.2307/2491334
   DAVIS LR, 1993, ACCOUNT REV, V68, P135
   DeAngelo L., 1981, J ACCOUNT ECON, V3, P183, DOI DOI 10.1016/0165-4101(81)90002-1
   Dechow P., 1996, CONTEMP ACCOUNT RES, V13, P1, DOI DOI 10.1111/J.1911-3846.1996.TB00489.X
   Defond M., 1998, CONTEMP ACCOUNT RES, V15, P1, DOI DOI 10.1111/J.1911-3846.1998.TB00547.X
   DEFOND ML, 1991, ACCOUNT REV, V66, P643
   DEFOND ML, 1992, AUDITING-J PRACT TH, V11, P16
   DeZoort F.T., 2001, AUDITING J PRACTICE, V20
   Dezoort FT, 2001, CONTEMP ACCOUNT RES, V18, P257, DOI 10.1506/7ERQ-LD54-BTQV-TUVE
   Dezoort FT, 1998, ACCOUNT ORG SOC, V23, P1, DOI 10.1016/S0361-3682(97)00029-9
   Dhaliwal D. S, 2006, AUDIT COMMITTEE FINA
   Edmans A, 2009, REV FINANC STUD, V22, P4881, DOI 10.1093/rfs/hhn117
   Erickson M, 2006, J ACCOUNTING RES, V44, P113, DOI 10.1111/j.1475-679X.2006.00194.x
   FAMA EF, 1983, J LAW ECON, V26, P327, DOI 10.1086/467038
   Felo A. J., 2003, AUDIT COMMITTEE CHAR
   Feng M, 2011, J ACCOUNT ECON, V51, P21, DOI 10.1016/j.jacceco.2010.09.005
   Ferguson A, 2003, ACCOUNT REV, V78, P429, DOI 10.2308/accr.2003.78.2.429
   Francis J.R., 2002, DO LARGE ACCOUNTING
   FRANCIS JR, 1987, ACCOUNT REV, V62, P145
   Frankel RM, 2002, ACCOUNT REV, V77, P71, DOI 10.2308/accr.2002.77.s-1.71
   Franks J, 2001, J FINANC INTERMED, V10, P209, DOI 10.1006/jfin.2001.0317
   Gabaix X, 2008, Q J ECON, V123, P49, DOI 10.1162/qjec.2008.123.1.49
   GAVER JJ, 1995, J ACCOUNT ECON, V19, P3, DOI 10.1016/0165-4101(94)00358-C
   Giannetti M, 2011, J FINANC INTERMED, V20, P633, DOI 10.1016/j.jfi.2011.04.003
   Goodwin-Stewart J, 2006, ACCOUNT FINANC, V46, P387, DOI 10.1111/j.1467-629X.2006.00174.x
   Gordon JN, 2002, U CHICAGO LAW REV, V69, P1233, DOI 10.2307/1600646
   Gregg P, 2012, INT REV FINANC, V12, P89, DOI 10.1111/j.1468-2443.2011.01136.x
   Griffin P.A., 2008, J CONTEMP ACCOUNT EC, V4, P18, DOI DOI 10.1016/S1815-5669(10)70028-X
   Gul FA, 2001, AUDITING-J PRACT TH, V20, P71, DOI 10.2308/aud.2001.20.2.71
   Gul FA, 2006, J ACCOUNTING RES, V44, P931, DOI 10.1111/j.1475-679X.2006.00220.x
   Hamid M.A., 2012, J BUS POLICY RES, V7, P140
   Hanlon M, 2003, J ACCOUNT ECON, V36, P3, DOI 10.1016/j.jacceco.2003.10.008
   Hashim U.J.B., 2011, INT B BUSINESS ADM, P50
   Hay D, 2008, INT J AUDIT, V12, P9, DOI 10.1111/j.1099-1123.2008.00367.x
   Hay DC, 2006, CONTEMP ACCOUNT RES, V23, P141, DOI 10.1506/4XR4-KT5V-E8CN-91GX
   HEALY PM, 1985, J ACCOUNT ECON, V7, P85, DOI 10.1016/0165-4101(85)90029-1
   Ho S. S., 2001, J INT ACCOUNTING AUD, V10, P139, DOI [10.1016/S1061-9518(01)00041-6, DOI 10.1016/S1061-9518(01)00041-6]
   HOLTHAUSEN RW, 1995, J ACCOUNT ECON, V19, P29, DOI 10.1016/0165-4101(94)00376-G
   Hosseini S. J. F., 2010, AFRICAN J AGR RES, V6, P451
   Ibrahim, 2006, WASHINGTON U GLOBAL, V5, P323
   Ismail H., 2008, MALAYSIAN ACCOUNTING, V7, P21
   Jayaraman S., 2012, EFFECT AUDITOR EXPER
   JENSEN MC, 1976, J FINANC ECON, V3, P305, DOI 10.1016/0304-405X(76)90026-X
   Jiang J, 2010, J FINANC ECON, V96, P513, DOI 10.1016/j.jfineco.2010.02.007
   Johl S, 2012, INT J ACCOUNT, V47, P302, DOI 10.1016/j.intacc.2012.07.002
   Johnstone KM, 2001, ACCOUNT REV, V76, P199, DOI 10.2308/accr.2001.76.2.199
   KALBERS LP, 1993, AUDITING-J PRACT TH, V12, P24
   Kannan Y.H., 2009, THESIS FLORIDA ATLAN
   KAPLAN SE, 1985, AUDITING-J PRACT TH, V5, P12
   Kim Y., 2011, CEO EQUITY INCENTIVE
   Kinney WR, 2004, J ACCOUNTING RES, V42, P561, DOI 10.1111/j.1475-679X.2004.t01-1-00141.x
   Klein A, 2002, J ACCOUNT ECON, V33, P375, DOI 10.1016/S0165-4101(02)00059-9
   KNAPP MC, 1985, ACCOUNT REV, V60, P202
   Knechel W.R., 2008, AUDITOR PROVIDED NON
   KREUTZFELDT RW, 1986, AUDITING-J PRACT TH, V6, P20
   Krishnan G.V., 2006, J ACCOUNTING AUDITIN, V24, P115
   Kuhnen C.M., 2008, EXECUTIVE RAY HIDDEN
   La Porta R, 1999, J FINANC, V54, P471, DOI 10.1111/0022-1082.00115
   Larcker DF, 2004, J ACCOUNTING RES, V42, P625, DOI 10.1111/j.1475-679X.2004.t01-1-00143.x
   LARCKER DF, 1983, J ACCOUNT ECON, V5, P3, DOI 10.1016/0165-4101(83)90003-4
   Maher M.W., 1985, PRICING AUDIT UNPUB
   McMullen DA, 1996, AUDITING-J PRACT TH, V15, P87
   MENON K, 1994, J ACCOUNT PUBLIC POL, V13, P121, DOI 10.1016/0278-4254(94)90016-7
   Mitra S, 2007, REV QUANT FINANC ACC, V28, P257, DOI 10.1007/s11156-006-0014-7
   Mohamad S., 2001, J MALAYSIAN I ACCOUN, V14, P8
   Mohiuddin M., 2010, J BUSINESS EC, V9, P97
   Moradi J., 2012, ASIAN EC FINANCIAL R, V2, P358
   Murphy K. J., 1998, EXECUTIVE COMPENSATI
   Murphy KJ, 2007, MANAGERIAL CAPITAL M
   Murphy KJ, 1999, HDB LABOR EC B, P2485, DOI DOI 10.1016/S1573-4463(99)30024-9
   Naser K., 2007, SCI J ADM DEV, V5, P84
   National Association of Corporate Directors (NACD), 2000, REP NACD BLUE RIBB C
   Niemi L., 2002, INT J AUDITING, V6, P37
   Nishat S.R.M., 2004, CORPORATE GOVERNANCE
   Norman CS, 2011, ACCOUNT ORG SOC, V36, P102, DOI 10.1016/j.aos.2011.02.004
   Nosheen S., 2011, 3 SAICON INT C MAN B
   OKEEFE TB, 1994, J ACCOUNTING RES, V32, P241, DOI 10.2307/2491284
   PALMROSE ZV, 1986, J ACCOUNTING RES, V24, P405, DOI 10.2307/2491144
   POUND J, 1995, HARVARD BUS REV, V73, P89
   PRATT J, 1994, ACCOUNT REV, V69, P639
   Public Oversight Board (POB) ofthe SEC Practice Section, 1993, SPEC REP ISS CONFR A
   Raghunandan K, 2006, AUDITING-J PRACT TH, V25, P99, DOI 10.2308/aud.2006.25.1.99
   Raghunandan K., 2007, ACCOUNT HORIZ, V21, P265, DOI DOI 10.2308/ACCH.2007.21.3.265
   Rainsbury E. A., 2009, J CONTEMP ACCOUNT EC, V5, P20, DOI DOI 10.1016/J.JCAE.2009.03.002
   Rais R.B., 2005, 0639 CMER LAH U MAN
   Rani M., 2011, THESIS AUCKLAND U TE
   Razman S.R., 2004, MICG PUBLICATION, P154
   Richardson V., 2002, REV QUANTITATIVE FIN, V18
   Robina I., 2007, RELATIONSHIP CORPORA
   Ross Booth J., 2012, ACCOUNTING FINANCE R, V1, P76
   Shah A. S. Z., 2009, LAHORE J EC, V14, P139
   Shah SZA, 2011, AFR J BUS MANAGE, V5, P515
   Shah Z.A., 2009, INT RES J FINANCE EC, P148
   SIMON DT, 1985, AUDITING-J PRACT TH, V5, P71
   Simunic D.A., 1980, J ACCOUNT RES, P679
   Simunic DA, 1996, AUDITING-J PRACT TH, V15, P119
   Soltani B., 2007, AUDITING INT APPROAC
   Stewart J, 2007, INT J AUDIT, V11, P51, DOI 10.1111/j.1099-1123.2007.00356.x
   TEHRANIAN H, 1987, J FINANC, V42, P933, DOI 10.2307/2328299
   Tervio M, 2008, AM ECON REV, V98, P642, DOI 10.1257/aer.98.3.642
   Tsui J., 2001, J ACCOUNTING AUDITIN, V16, P189, DOI DOI 10.1177/0148558X0101600303
   Vafeas N, 1999, J FINANC ECON, V53, P113, DOI 10.1016/S0304-405X(99)00018-5
   Vafeas N, 2007, REV QUANT FINANC ACC, V28, P241, DOI 10.1007/s11156-006-0012-
   WALLACE WA, 1984, HARVARD BUS REV, V62, P16
   WATTS RL, 1983, J LAW ECON, V26, P613, DOI 10.1086/467051
   Wysocki P, 2010, J ACCOUNT ECON, V49, P155, DOI 10.1016/j.jacceco.2009.11.002
   Xie B, 2003, J CORP FINANC, V9, P295, DOI 10.1016/S0929-1199(02)00006-8
   Yatim P, 2006, MANAG AUDIT J, V21, P757, DOI 10.1108/02686900610680530
   Zaheer Z., 2006, WORKSH COMM SECR GLO
NR 152
TC 8
Z9 8
U1 2
U2 58
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0264-9993
EI 1873-6122
J9 ECON MODEL
JI Econ. Model.
PD MAR
PY 2013
VL 31
BP 697
EP 716
DI 10.1016/j.econmod.2013.01.008
PG 20
WC Economics
SC Business & Economics
GA 113CK
UT WOS:000316643600081
DA 2018-12-27
ER

PT J
AU Bhattacharya, A
   Manudhane, KS
   Maddula, SR
   Sreekanth, BR
   Thota, S
   Bandichhor, R
AF Bhattacharya, Apurba
   Manudhane, Kushal S.
   Maddula, Srinivasula Reddy
   Sreekanth, B. R.
   Thota, Sridhar
   Bandichhor, Rakeshwar
TI RETRACTED: Crystallization Engineering in Aza-Steroid: Application in
   the Development of Finasteride (Retracted article. See vol. 20, pg.
   1689, 2016)
SO ORGANIC PROCESS RESEARCH & DEVELOPMENT
LA English
DT Article; Retracted Publication
ID 5-ALPHA-REDUCTASE INHIBITOR; RESOLUTION; CRYSTALS
AB Novel and robust crystallization approach based on solid solution formation was developed for the purification of finasteride. This is an unprecedented approach that describes the use of pure finasteride 1 to purify different lots of finasteride 1 (impure) contaminated with dihydrofinasteride 2.
C1 Dr Reddys Labs Ltd, Ctr Excellence Res & Dev, Qutubullapur 500072, Andhra Pradesh, India.
   [Manudhane, Kushal S.; Maddula, Srinivasula Reddy; Thota, Sridhar; Bandichhor, Rakeshwar] Dr Reddys Labs Ltd, Integrated Prod Dev, Qutubullapur 500072, Andhra Pradesh, India.
   [Bhattacharya, Apurba] Texas A&I Univ, Dept Chem, Kingsville, TX 78363 USA.
   Dr Reddys Labs Ltd, Dept Analyt Res, Hyderabad 500049, Andhra Pradesh, India.
   [Thota, Sridhar] Dr Reddys Labs Ltd, Discovery Res, Hyderabad 500049, Andhra Pradesh, India.
RP Bandichhor, R (reprint author), Dr Reddys Labs Ltd, Integrated Prod Dev, Qutubullapur 500072, Andhra Pradesh, India.
EM rakeshwarb@drreddys.com
CR BHATTACHARYA A, 1988, J AM CHEM SOC, V110, P3318, DOI 10.1021/ja00218a062
   Breuer M, 2004, ANGEW CHEM INT EDIT, V43, P788, DOI 10.1002/anie.200300599
   DALLOB AL, 1994, J CLIN ENDOCR METAB, V79, P703, DOI 10.1210/jc.79.3.703
   Karrothu SB, 2007, ORG PROCESS RES DEV, V11, P889, DOI 10.1021/op700104f
   Kenny B, 1997, J MED CHEM, V40, P1293, DOI 10.1021/jm960697s
   Klussmann M, 2007, J AM CHEM SOC, V129, P7657, DOI 10.1021/ja0708870
   McCague R, 2007, TETRAHEDRON LETT, V48, P869, DOI 10.1016/j.tetlet.2006.11.131
   Meanwell NA, 2008, ANNU REP MED CHEM, V43, P373, DOI 10.1016/S0065-7743(08)00022-5
   Othman A, 2007, J PHARM SCI-US, V96, P1380, DOI 10.1002/jps.20940
   RITTMASTER RS, 1994, NEW ENGL J MED, V330, P120
   Schultheiss N, 2009, CRYST GROWTH DES, V9, P2950, DOI 10.1021/cg900129f
   SUDDUTH SL, 1993, PHARMACOTHERAPY, V13, P309
   Tamura R, 2002, J AM CHEM SOC, V124, P13139, DOI 10.1021/ja020454r
   Vishweshwar P, 2006, J PHARM SCI-US, V95, P499, DOI 10.1002/jps.20578
   WALSH DS, 1995, ARCH DERMATOL, V131, P1373, DOI 10.1001/archderm.131.12.1373
NR 15
TC 1
Z9 1
U1 4
U2 7
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1083-6160
EI 1520-586X
J9 ORG PROCESS RES DEV
JI Org. Process Res. Dev.
PD MAR
PY 2013
VL 17
IS 3
BP 599
EP 602
DI 10.1021/op300142a
PG 4
WC Chemistry, Applied; Chemistry, Organic
SC Chemistry
GA 109NP
UT WOS:000316375600036
DA 2018-12-27
ER

PT J
AU Watthanasurorot, A
   Saelee, N
   Phongdara, A
   Roytrakul, S
   Jiravanichpaisal, P
   Soderhall, K
   Soderhall, I
AF Watthanasurorot, Apiruck
   Saelee, Netnapa
   Phongdara, Amornrat
   Roytrakul, Sittiruk
   Jiravanichpaisal, Pikul
   Soderhall, Kenneth
   Soderhall, Irene
TI RETRACTED: Astakine 2-the Dark Knight Linking Melatonin to Circadian
   Regulation in Crustaceans (Retracted article. See vol. 11, e1005222,
   2015)
SO PLOS GENETICS
LA English
DT Article; Retracted Publication
ID SUPRACHIASMATIC NUCLEUS; CLOCK GENE; TEMPORAL ORGANIZATION;
   N-ACETYLTRANSFERASE; MESSENGER-RNA; CRAYFISH; RHYTHMS; EXPRESSION;
   SLEEP; IDENTIFICATION
AB Daily, circadian rhythms influence essentially all living organisms and affect many physiological processes from sleep and nutrition to immunity. This ability to respond to environmental daily rhythms has been conserved along evolution, and it is found among species from bacteria to mammals. The hematopoietic process of the crayfish Pacifastacus leniusculus is under circadian control and is tightly regulated by astakines, a new family of cytokines sharing a prokineticin (PROK) domain. The expression of AST1 and AST2 are light-dependent, and this suggests an evolutionarily conserved function for PROK domain proteins in mediating circadian rhythms. Vertebrate PROKs are transmitters of circadian rhythms of the suprachiasmatic nucleus (SCN) in the brain of mammals, but the mechanism by which they function is unknown. Here we demonstrate that high AST2 expression is induced by melatonin in the brain. We identify RACK1 as a binding protein of AST2 and further provide evidence that a complex between AST2 and RACK1 functions as a negative-feedback regulator of the circadian clock. By DNA mobility shift assay, we showed that the AST2-RACK1 complex will interfere with the binding between BMAL1 and CLK and inhibit the E-box binding activity of the complex BMAL1-CLK. Finally, we demonstrate by gene knockdown that AST2 is necessary for melatonin-induced inhibition of the complex formation between BMAL1 and CLK during the dark period. In summary, we provide evidence that melatonin regulates AST2 expression and thereby affects the core clock of the crustacean brain. This process may be very important in all animals that have AST2 molecules, i.e. spiders, ticks, crustaceans, scorpions, several insect groups such as Hymenoptera, Hemiptera, and Blattodea, but not Diptera and Coleoptera. Our findings further reveal an ancient evolutionary role for the prokineticin superfamily protein that links melatonin to direct regulation of the core clock gene feedback loops.
C1 [Watthanasurorot, Apiruck; Saelee, Netnapa; Jiravanichpaisal, Pikul; Soderhall, Kenneth; Soderhall, Irene] Uppsala Univ, Dept Comparat Physiol, Uppsala, Sweden.
   [Phongdara, Amornrat] Prince Songkla Univ, Fac Sci, Ctr Genom & Bioinformat Res, Hat Yai, Thailand.
   [Roytrakul, Sittiruk] NSTDA, Natl Ctr Genet Engn & Biotechnol BIOTEC, Prote Res Lab, Genome Inst, Pathum Thani, Thailand.
   [Jiravanichpaisal, Pikul] NSTDA, Natl Ctr Genet Engn & Biotechnol BIOTEC, Aquat Mol Genet & Biotechnol Lab, Pathum Thani, Thailand.
RP Watthanasurorot, A (reprint author), Uppsala Univ, Dept Comparat Physiol, Uppsala, Sweden.
EM Irene.Soderhall@ebc.uu.se
FU Swedish Research Council VR [319-2010-650, 621-2009-5715,
   621-2011-4797]; Swedish Science Research Council FORMAS [223-2011-606]
FX This work was supported by the Swedish Research Council VR
   (http://www.vr.se) (319-2010-650, 621-2009-5715 to KS and 621-2011-4797
   to IS) and by the Swedish Science Research Council FORMAS to KS
   (223-2011-606). The funders had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR Allada R, 2001, ANNU REV NEUROSCI, V24, P1091, DOI 10.1146/annurev.neuro.24.1.1091
   Bae K, 1998, MOL CELL BIOL, V18, P6142, DOI 10.1128/MCB.18.10.6142
   Carrillo DR, 2012, ACTA CRYSTALLOGR F, V68, P867, DOI 10.1107/S1744309112027480
   CASSONE VM, 1986, PHYSIOL BEHAV, V36, P1111, DOI 10.1016/0031-9384(86)90488-9
   Chen JC, 2005, MOL PHARMACOL, V67, P2070, DOI 10.1124/mol.105.011619
   Cheng MY, 2002, NATURE, V417, P405, DOI 10.1038/417405a
   Dijk DJ, 1997, J BIOL RHYTHM, V12, P627, DOI 10.1177/074873049701200618
   Escamilla-Chimal EG, 2010, J EXP BIOL, V213, P3723, DOI 10.1242/jeb.047548
   Giebultowicz JM, 2000, CURR BIOL, V10, P107, DOI 10.1016/S0960-9822(00)00299-2
   Glossop NRJ, 1999, SCIENCE, V286, P766, DOI 10.1126/science.286.5440.766
   Hardeland R, 2003, J PINEAL RES, V34, P233, DOI 10.1034/j.1600-079X.2003.00040.x
   Hardeland R, 2011, PROG NEUROBIOL, V93, P350, DOI 10.1016/j.pneurobio.2010.12.004
   Helfrich-Forster C, 1998, CHRONOBIOL INT, V15, P567, DOI 10.3109/07420529808993195
   Ishikawa T, 2002, GENES CELLS, V7, P1073, DOI 10.1046/j.1365-2443.2002.00579.x
   JOHNSON RF, 1988, BRAIN RES, V460, P297, DOI 10.1016/0006-8993(88)90374-5
   King DP, 1997, CELL, V89, P641, DOI 10.1016/S0092-8674(00)80245-7
   Krauchi K, 2001, NEUROPSYCHOPHARMACOL, V25, pS92, DOI 10.1016/S0893-133X(01)00315-3
   Lee C, 1999, MOL CELL BIOL, V19, P5316
   Lee CG, 1998, NEURON, V21, P857, DOI 10.1016/S0896-6273(00)80601-7
   Lin XH, 2011, BLOOD, V117, P6417, DOI 10.1182/blood-2010-11-320614
   Lin XH, 2010, J BIOL CHEM, V285, P28577, DOI 10.1074/jbc.M110.138560
   Lissoni P, 1998, NAT IMMUN, V16, P1, DOI 10.1159/000069464
   Lowrey PL, 2004, ANNU REV GENOM HUM G, V5, P407, DOI 10.1146/annurev.genom.5.061903.175925
   MAESTRONI GJM, 1986, J NEUROIMMUNOL, V13, P19, DOI 10.1016/0165-5728(86)90047-0
   Mendez-Ferrer S, 2009, CURR OPIN HEMATOL, V16, P235, DOI 10.1097/MOH.0b013e32832bd0f5
   Mendoza-Vargas L, 2009, COMP BIOCHEM PHYS A, V154, P486, DOI 10.1016/j.cbpa.2009.07.025
   Monnier J, 2008, FEBS J, V275, P4014, DOI 10.1111/j.1742-4658.2008.06559.x
   Negri L, 2005, BRIT J PHARMACOL, V146, P625, DOI 10.1038/sj.bjp.0706376
   Negri L, 2009, INT REV NEUROBIOL, V85, P145, DOI 10.1016/S0074-7742(09)85011-3
   Oishi K, 1998, BIOCHEM BIOPH RES CO, V253, P199, DOI 10.1006/bbrc.1998.9779
   Petrovsky N, 2001, IMMUNOL CELL BIOL, V79, P350, DOI 10.1046/j.1440-1711.2001.01029.x
   PITTENDRIGH CS, 1993, ANNU REV PHYSIOL, V55, P16
   Poirel VJ, 2003, NEUROSCIENCE, V120, P745, DOI 10.1016/S0306-4522(03)00344-0
   Prosser HM, 2007, P NATL ACAD SCI USA, V104, P648, DOI 10.1073/pnas.0606884104
   Robles MS, 2010, SCIENCE, V327, P463, DOI 10.1126/science.1180067
   Rosbash M, 1996, COLD SPRING HARB SYM, V61, P265
   SANDEMAN D, 1992, BIOL BULL, V183, P304, DOI 10.2307/1542217
   Saper CB, 2005, NATURE, V437, P1257, DOI 10.1038/nature04284
   Sharma VK, 1999, CHRONOBIOL INT, V16, P163, DOI 10.3109/07420529909019083
   Shearman LP, 2000, SCIENCE, V288, P1013, DOI 10.1126/science.288.5468.1013
   SHIBATA S, 1989, NEUROSCI LETT, V97, P140, DOI 10.1016/0304-3940(89)90153-5
   Stone EF, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002445
   Sullivan JM, 2009, CHRONOBIOL INT, V26, P1136, DOI 10.1080/07420520903217960
   Tilden AR, 2003, BRAIN RES, V992, P252, DOI 10.1016/j.brainres.2003.08.053
   Tilden AR, 2001, GEN COMP ENDOCR, V122, P233, DOI 10.1006/gcen.2001.7641
   Urayama K, 2007, FASEB J, V21, P2980, DOI 10.1096/fj.07-8116com
   Verde MA, 2007, COMP BIOCHEM PHYS A, V147, P983, DOI 10.1016/j.cbpa.2007.03.004
   Wang GK, 2001, J NEUROBIOL, V47, P161, DOI 10.1002/neu.1024
   Watthanasurorot A, 2011, CELL MOL LIFE SCI, V68, P315, DOI 10.1007/s00018-010-0458-8
   Weaver DR, 1998, J BIOL RHYTHM, V13, P100, DOI 10.1177/074873098128999952
   Wilsbacher LD, 2002, P NATL ACAD SCI USA, V99, P489, DOI 10.1073/pnas.012248599
   Withyachumnarnkul B, 1999, J PINEAL RES, V26, P174, DOI 10.1111/j.1600-079X.1999.tb00580.x
   Yamazaki S, 2000, SCIENCE, V288, P682, DOI 10.1126/science.288.5466.682
NR 53
TC 10
Z9 11
U1 3
U2 23
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7390
EI 1553-7404
J9 PLOS GENET
JI PLoS Genet.
PD MAR
PY 2013
VL 9
IS 3
AR e1003361
DI 10.1371/journal.pgen.1003361
PG 19
WC Genetics & Heredity
SC Genetics & Heredity
GA 116EY
UT WOS:000316866700038
PM 23555281
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Sallustio, F
   Costantino, V
   Cox, SN
   Loverre, A
   Divella, C
   Rizzi, M
   Schena, FP
AF Sallustio, Fabio
   Costantino, Vincenzo
   Cox, Sharon N.
   Loverre, Antonia
   Divella, Chiara
   Rizzi, Marco
   Schena, Francesco P.
TI RETRACTED: Human renal stem/progenitor cells repair tubular epithelial
   cell injury through TLR2-driven inhibin-A and microvesicle-shuttled
   decorin (Retracted article. See vol. 87, pg. 482, 2015)
SO KIDNEY INTERNATIONAL
LA English
DT Article; Retracted Publication
DE renal injury; renal proximal tubule cell; renal stem cell
ID ACUTE KIDNEY INJURY; STEM-CELLS; ENHANCED APOPTOSIS; ENDOTHELIAL-CELLS;
   PROGENITOR CELLS; ACTIVIN-A; SYSTEM; KINASE; PATHOPHYSIOLOGY;
   REGENERATION
AB Acute kidney injury (AKI) is emerging as a worldwide public health problem. Recent studies have focused on the possibility of using human adult renal stem/progenitor cells (ARPCs) to improve the repair of AKI. Here we studied the influence of ARPCs on the healing of cisplatin-injured renal proximal tubular epithelial cells. Tubular, but not glomerular, ARPCs provided a protective effect promoting proliferation of surviving tubular cells and inhibiting cisplatin-induced apoptosis. The recovery effect was specific to tubular ARPCs, occurred only after damage sensing, and was completely cancelled by TLR2 blockade on tubular ARPCs. Moreover, tubular, but not glomerular, ARPCs were resistant to the apoptotic effect of cisplatin. Tubular ARPCs operate mainly through the engagement of TLR2, the secretion of inhibin-A protein, and microvesicle-shuttled decorin, inhibin-A, and cyclin D1 mRNAs. These factors worked synergistically and were essential to the repair process. The involvement of tubular ARPC-secreted inhibin-A and decorin mRNA in the pathophysiology of AKI was also confirmed in transplant patients affected by delayed graft function. Hence, identification of this TLR2-driven recovery mechanism may shed light on new therapeutic strategies to promote the recovery capacity of the kidney in acute tubular damage. Use of these components, derived from ARPCs, avoids injecting stem cells. Kidney International (2013) 83, 392-403; doi:10.1038/ki.2012.413; published online 16 January 2013
C1 [Sallustio, Fabio; Costantino, Vincenzo; Cox, Sharon N.; Loverre, Antonia; Divella, Chiara; Schena, Francesco P.] Univ Bari, Dept Emergency & Organ Transplantat, I-70010 Valenzano, BA, Italy.
   [Sallustio, Fabio; Schena, Francesco P.] CARSO Consortium, Valenzano, BA, Italy.
   [Rizzi, Marco] Univ Bari, Dept Human Anat & Histol, I-70010 Valenzano, BA, Italy.
   [Schena, Francesco P.] Schena Fdn, Res Ctr Renal Dis, Bari, Italy.
RP Schena, FP (reprint author), Univ Bari, Dept Emergency & Organ Transplantat, CARSO Consortium, I-70010 Valenzano, BA, Italy.
EM fp.schena@nephro.uniba.it
RI Divella, Chiara/K-2783-2016; Sallustio, Fabio/H-1587-2016; Cox,
   Sharon/H-1306-2015; Schena, Francesco/K-6982-2016; Sallustio,
   Fabio/D-2326-2011
OI Divella, Chiara/0000-0003-2717-3158; Cox, Sharon/0000-0002-8488-440X;
   Schena, Francesco/0000-0001-7927-5207; Sallustio,
   Fabio/0000-0002-5132-6532
FU 'Regione Puglia'; MiUR [2008 M9WSJX, 134/2011, RBAP11B2SX]
FX This study was supported by grants from 'Regione Puglia' (Progetto
   strategico 2009 BISIMANE 44/09) and the MiUR (PRIN 2008 M9WSJX; PON-REC
   ONEV 134/2011; FIRB RBAP11B2SX). We thank Professor Battaglia M and
   Professor Di Tonno P for harvesting the renal tissue and Dr Curci C for
   her support in the experiments. A European patent PCT11566D53 was issued
   to the University of Bad.
CR Anders HJ, 2011, KIDNEY INT, V80, P915, DOI 10.1038/ki.2011.217
   Anders HJ, 2011, J AM SOC NEPHROL, V22, P1007, DOI 10.1681/ASN.2010080798
   Angelotti ML, 2012, STEM CELLS, V30, P1714, DOI 10.1002/stem.1130
   Antenos M, 2008, J BIOL CHEM, V283, P33059, DOI 10.1074/jbc.M804190200
   Bonventre JV, 2011, J CLIN INVEST, V121, P4210, DOI 10.1172/JCI45161
   Bonventre VJ, 2003, J AM SOC NEPHROL, V14, P55
   Bruno S, 2009, J AM SOC NEPHROL, V20, P1053, DOI 10.1681/ASN.2008070798
   Bussolati B, 2005, AM J PATHOL, V166, P545, DOI 10.1016/S0002-9440(10)62276-6
   Bussolati B, 2009, CURR STEM CELL RES T, V4, P2, DOI 10.2174/157488809787169129
   Camussi G, 2010, CURR OPIN NEPHROL HY, V19, P7, DOI 10.1097/MNH.0b013e328332fb6f
   Cho HJ, 2010, J BIOL CHEM, V285, P25500, DOI 10.1074/jbc.M109.091413
   Deregibus MC, 2007, BLOOD, V110, P2440, DOI 10.1182/blood-2007-03-078709
   Eltzschig HK, 2011, NAT MED, V17, P1391, DOI 10.1038/nm.2507
   Gatti S, 2011, NEPHROL DIAL TRANSPL, V26, P1474, DOI 10.1093/ndt/gfr015
   Hammerman MR, 2000, AM J KIDNEY DIS, V36, P520
   Huang HM, 2004, BIOCHEM BIOPH RES CO, V320, P1247, DOI 10.1016/j.bbrc.2004.06.083
   Humphreys BD, 2008, CELL STEM CELL, V2, P284, DOI 10.1016/j.stem.2008.01.014
   Humphreys BD, 2011, P NATL ACAD SCI USA, V108, P9226, DOI 10.1073/pnas.1100629108
   Kol A, 1999, J CLIN INVEST, V103, P571, DOI 10.1172/JCI5310
   Lichtnekert J, 2009, AM J PHYSIOL-RENAL, V296, pF867, DOI 10.1152/ajprenal.90213.2008
   Lindgren D, 2011, AM J PATHOL, V178, P828, DOI 10.1016/j.ajpath.2010.10.026
   Maeshima A, 2002, J AM SOC NEPHROL, V13, P2850, DOI 10.1097/01.ASN.0000035086.93977.E9
   MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066
   Merline R, 2009, J PHYSIOL PHARMACOL, V60, P5
   Nash K, 2002, AM J KIDNEY DIS, V39, P930, DOI 10.1053/ajkd.2002.32766
   Nony PA, 2003, J PHARMACOL EXP THER, V304, P905, DOI 10.1124/jpet.102.035022
   Papa S, 2007, J BIOL CHEM, V282, P19029, DOI 10.1074/jbc.M703112200
   Procino G, 2011, CELL PHYSIOL BIOCHEM, V28, P683, DOI 10.1159/000335762
   Rovere-Querini P, 2004, EMBO REP, V5, P825, DOI 10.1038/sj.embor.7400205
   Sagrinati C, 2006, J AM SOC NEPHROL, V17, P2443, DOI 10.1681/ASN.2006010089
   Sallustio F, 2010, FASEB J, V24, P514, DOI 10.1096/fj.09-136481
   Schaefer L, 2002, AM J PATHOL, V160, P1181, DOI 10.1016/S0002-9440(10)64937-1
   Schonherr E, 2005, J BIOL CHEM, V280, P15767, DOI 10.1074/jbc.M500451200
   Schonherr E, 2001, J CELL PHYSIOL, V187, P37, DOI 10.1002/1097-4652(2001)9999:9999<::AID-JCP1048>3.0.CO;2-W
   Sharfuddin AA, 2011, NAT REV NEPHROL, V7, P189, DOI 10.1038/nrneph.2011.16
   Villanueva S, 2008, AM J PHYSIOL-REG I, V294, P819
   Wagener O E, 1995, New Horiz, V3, P634
   Wallin RPA, 2002, TRENDS IMMUNOL, V23, P130, DOI 10.1016/S1471-4906(01)02168-8
   Welt C, 2002, EXP BIOL MED, V227, P724
   Xaus J, 2001, BLOOD, V98, P2124, DOI 10.1182/blood.V98.7.2124
   Zanin-Zhorov A, 2006, J CLIN INVEST, V116, P2022, DOI 10.1172/JCI28423
   Zumbrun SD, 2009, J CELL BIOCHEM, V108, P1220, DOI 10.1002/jcb.22354
NR 42
TC 49
Z9 51
U1 6
U2 36
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0085-2538
EI 1523-1755
J9 KIDNEY INT
JI Kidney Int.
PD MAR
PY 2013
VL 83
IS 3
BP 392
EP 403
DI 10.1038/ki.2012.413
PG 12
WC Urology & Nephrology
SC Urology & Nephrology
GA 106PD
UT WOS:000316156100011
PM 23325086
OA Bronze
DA 2018-12-27
ER

PT J
AU Oh, CS
   Han, CS
AF Oh, Chang-Sup
   Han, Chang-Suk
TI RETRACTED: Microstructures and morphologies of B2-Ordered NiAl(Co) and
   FeAl(Co)(Retracted article. See vol. 21, pg. 615, 2015)
SO METALS AND MATERIALS INTERNATIONAL
LA English
DT Article; Retracted Publication
DE intermetallics; aging; mechanical properties; transmission electron
   microscopy (TEM); fine precipitation
ID MARTENSITIC-TRANSFORMATION; ELECTRON-DIFFRACTION; ALLOYS; NI2AL; PHASE;
   FE
AB Fine dispersion of disordered phases is obtained in a Ni-Al-Co and Fe-Al-Co ternary system. A transmission electron microscopy investigation has been performed in the present work on the precipitation of supersaturated B2-ordered (Ni,Co)Al and alpha-Fe in B2-ordered FeAl(Co) with different stoichiometries. Precipitation behavior and hardening were investigated by measuring the hardness variation. The hardness of (Ni,Co)Al and B2-FeAl(Co) increased appreciably by the fine precipitation of (Ni,Co)(2)Al, alpha-Fe, and overage softening occurred after prolonged aging. In case of B2-ordered (Ni,Co)Al, the (Ni,Co)(2)Al phase had a hexagonal structure and took a rod-like shape with the long axis of the rod parallel to the aOE (c) 111 > directions of the B2 matrix. By aging at temperatures below 873 K, a long period superlattice structure appeared in the hexagonal (Ni,Co)(2)Al phase. The orientation relationship between the (Ni,Co)(2)Al precipitates and the B2-(Ni,Co)Al matrix was (0001)(p)//(111)(B2) and , where the suffix p and B2 denote the (Ni,Co)(2)Al precipitate and the B2-(Ni,Co)Al matrix, respectively. (Ni,Co)Al hardened appreciably by the fine precipitation of the (Ni,Co)(2)Al phase. On the other hand, in case of B2-FeAl(Co), the disordered alpha-Fe phase was present as a precipitate in a B2-FeAl(Co) matrix and had a cubic-cubic orientation with the matrix. At the early aging periods, prismatic dislocation loops formed in the B2-FeAl(Co) matrix. B2-FeAl(Co) matrix was typically hardened by the precipitation of alpha-Fe.
C1 [Oh, Chang-Sup] Korea Inst Sci & Technol Informat, Reseat Program, Taejon 305806, South Korea.
   [Han, Chang-Suk] Hoseo Univ, Dept Def Sci & Technol, Asan 336795, Chungnam, South Korea.
RP Han, CS (reprint author), Hoseo Univ, Dept Def Sci & Technol, 165 Sechul Ri, Asan 336795, Chungnam, South Korea.
EM hancs@hoseo.edu
FU Reseat program of KISTI through NRF; MEST
FX This research was supported by Reseat program of KISTI through NRF
   funded by MEST.
CR Ackermann H., 1987, CALPHAD M 14 IRS, P15
   Bei H., 2006, MAT RES SOC, V1124
   Campillo B., 2001, ADV MAT PROCESSING, P863
   CHANG YA, 1982, PROG SOLID STATE CH, V14, P221, DOI 10.1016/0079-6786(82)90004-8
   Choi C. S., 1999, J KOREAN INST MET MA, V37, P170
   Darolia R., 2004, MET MATER INT, V10, P679
   Han SO, 2010, KOREAN J MET MATER, V48, P1070, DOI 10.3365/KJMM.2010.48.12.1070
   Hangen UD, 1999, INTERMETALLICS, V7, P501, DOI 10.1016/S0966-9795(98)00101-0
   Hubert-Protopescu M., 1991, TERNARY ALLOYS, V4, P234
   ISHIDA K, 1991, METALL TRANS A, V22, P441, DOI 10.1007/BF02656811
   Ishida K., 1995, MECH PROPERTIES PHAS, V1995, P77
   Jeong SH, 1998, MET MATER-KOREA, V4, P1077, DOI 10.1007/BF03025979
   Kataeva NV, 2006, MAT SCI ENG A-STRUCT, V438, P312, DOI 10.1016/j.msea.2006.02.081
   Khan T., 1990, HIGH TEMPERATURE ALU, P219
   Kim IS, 2011, KOREAN J MET MATER, V49, P535, DOI 10.3365/KJMM.2011.49.7.535
   Kim K. B., 1999, J KOREAN INST MET MA, V37, P794
   Kozakai T., 1991, P INT S INT COMP, P257
   Lee HY, 2009, J KOREAN INST MET MA, V47, P267
   Matsuura K, 2001, MATER T JIM, V42, P263, DOI 10.2320/matertrans.42.263
   Mendiratta M. G., 1987, High-Temperature Ordered Intermetallic Alloys II Symposium, P393
   Mendiratta M. G., 1982, INT P 3 C RAP SOL PR, P112
   Mendiratta M. G., 1987, METALL T, V18, P989
   MIYAZAKI T, 1987, ACTA METALL MATER, V35, P317, DOI 10.1016/0001-6160(87)90240-9
   Morgan E. R., 1955, METAL PROGR, V68, P126
   MUTO S, 1993, ACTA METALL MATER, V41, P2377, DOI 10.1016/0956-7151(93)90317-L
   NAKA S, 1992, NATO ADV SCI I E-APP, V213, P645
   REYNAUD F, 1976, J APPL CRYSTALLOGR, V9, P263, DOI 10.1107/S0021889876011333
   ROBERTSON IM, 1983, PHILOS MAG A, V48, P421, DOI 10.1080/01418618308234902
   Song S. H., 2003, J KOREAN INST MET MA, V41, P813
   Song SH, 2004, MET MATER-INT, V10, P307, DOI 10.1007/BF03185978
   Sykes C., 1934, J IRON STEEL I, V130, P389
NR 31
TC 1
Z9 1
U1 2
U2 26
PU KOREAN INST METALS MATERIALS
PI SEOUL
PA KIM BLDG 6TH FLOOR, SEOCHO-DAERO 56 GIL 38, SEOCHO-GU, SEOUL 137-881,
   SOUTH KOREA
SN 1598-9623
EI 2005-4149
J9 MET MATER INT
JI Met. Mater.-Int.
PD MAR
PY 2013
VL 19
IS 2
BP 189
EP 195
DI 10.1007/s12540-013-2008-z
PG 7
WC Materials Science, Multidisciplinary; Metallurgy & Metallurgical
   Engineering
SC Materials Science; Metallurgy & Metallurgical Engineering
GA 108IM
UT WOS:000316286200008
DA 2018-12-27
ER

PT J
AU Jacinto-Aleman, LF
   Garcia-Carranca, A
   Leyba-Huerta, ER
   Zenteno-Galindo, E
   Jimenez-Farfan, MD
   Hernandez-Guerrero, JC
AF Jacinto-Aleman, Luis-Fernando
   Garcia-Carranca, Alejandro
   Leyba-Huerta, Elba-Rosa
   Zenteno-Galindo, Edgar
   Jimenez-Farfan, Maria-Dolores
   Hernandez-Guerrero, Juan-Carlos
TI RETRACTED: erbB expression changes in ethanol and 7, 12-dimethylbenz (a)
   anthracene-induced oral carcinogenesis (Retracted article. See vol. 19,
   pg. E98, 2014)
SO MEDICINA ORAL PATOLOGIA ORAL Y CIRUGIA BUCAL
LA English
DT Article; Retracted Publication
DE erbB; 7,12-dimethylbenz(a)anthracene; oral squamous cell carcinoma
ID SQUAMOUS-CELL CARCINOMA; HAMSTER-CHEEK POUCH; EPITHELIAL DYSPLASIA;
   SIGNALING NETWORK; CANCER; ALCOHOL; RECEPTORS; EGFR;
   7,12-DIMETHYLBENZ(A)ANTHRACENE; COMBINATION
AB Objetive: The aim of this study was to determine erbB expression in normal mucosa, oral dysplasia, and invasive carcinomas developed in the hamster's buccal pouch chemical carcinogenesis model.
   Study design: Fifty Syrian golden hamsters were equally divided in five groups (A-E); two controls and three experimental group exposed to alcohol, DMBA, or both for 14 weeks. Number of tumors per cheek, volume, histological condition, erbB expression were determined and results were analyzed by the Mann-Whitney U and Dunn's test.
   Results: Control groups and those exposed to alcohol (A, B and C respectively) only presented clinical and histological normal mucosa; while those exposed to DMBA or DMBA plus alcohol (D and E groups) developed dysplasia and invasive carcinomas. erbB2, erbB3, and erbB4 increased their expression in alcohol-exposed mucosa, dysplasia, and invasive carcinomas. We observed a similar expression level for erbB2 in dysplasia and carcinomas; while, erbB3 and erbB4 were similar only in carcinomas.
   Conclusion: The DMBA and alcohol can be considered as carcinogen and promoter for oral carcinogenesis. The erbB expression is different according to their histological condition, suggesting differential participation of the erbB family in oral carcinogenesis induced by alcohol and DMBA.
C1 [Jacinto-Aleman, Luis-Fernando; Jimenez-Farfan, Maria-Dolores; Hernandez-Guerrero, Juan-Carlos] Univ Nacl Autonoma Mexico, Sch Dent, Postgrad & Res Div, Immunol Lab, Mexico City 04510, DF, Mexico.
   [Garcia-Carranca, Alejandro] Univ Nacl Autonoma Mexico, Biomed Reseach Inst, Mexico City 04510, DF, Mexico.
   [Garcia-Carranca, Alejandro] Hlth Minist, Natl Canc Inst, Mexico City, DF, Mexico.
   [Leyba-Huerta, Elba-Rosa] Univ Nacl Autonoma Mexico, Sch Dent, Postgrad & Res Div, Oral Pathol Lab, Mexico City 04510, DF, Mexico.
   [Zenteno-Galindo, Edgar] Univ Nacl Autonoma Mexico, Sch Med, Biochemestry Dept, Mexico City 04510, DF, Mexico.
RP Jacinto-Aleman, LF (reprint author), Univ Nacl Autonoma Mexico, Fac Odontol, DEPeI, Lab Inmunol, Circuito Inst S-N Ciudad Univ, Mexico City 04510, DF, Mexico.
EM inmuno1@live.com.mx
OI Zenteno, Edgar/0000-0001-5603-4072
FU PAPIIT [IN217912]; Universidad Nacional Autonoma de Mexico; 
   [CONACYT-167474]
FX This work was supported by grants from PAPIIT IN217912, Universidad
   Nacional Autonoma de Mexico and CONACYT-167474.
CR Baan R, 2007, LANCET ONCOL, V8, P292, DOI 10.1016/S1470-2045(07)70099-2
   Boeing H, 2002, IARC Sci Publ, V156, P151
   Chung YL, 2009, CARCINOGENESIS, V30, P1387, DOI 10.1093/carcin/bgp079
   Corrao G, 2004, PREV MED, V38, P613, DOI 10.1016/j.ypmed.2003.11.027
   Del Sordo R, 2010, J ORAL PATHOL MED, V39, P79, DOI 10.1111/j.1600-0714.2009.00815.x
   DIPPLE A, 1983, CANCER RES, V43, P4132
   Ekberg T, 2005, INT J ONCOL, V26, P1177
   ELZAY RP, 1966, J DENT RES, V45, P1788, DOI 10.1177/00220345660450063401
   Fong Y, 2008, J CHIN MED ASSOC, V71, P123, DOI 10.1016/S1726-4901(08)70003-0
   Herbst RS, 2004, INT J RADIAT ONCOL, V59, P21, DOI 10.1016/j.ijrobp.2003.11.041
   Holbro T, 2004, ANNU REV PHARMACOL, V44, P195, DOI 10.1146/annurev.pharmtox.44.101802.121440
   Howie NM, 2001, ORAL DIS, V7, P349, DOI 10.1034/j.1601-0825.2001.00731.x
   Jacinto-Aleman LF, 2010, J ORAL PATHOL MED, V39, P709, DOI 10.1111/j.1600-0714.2010.00918.x
   Lee LL, 2002, BONE, V30, P917, DOI 10.1016/S8756-3282(02)00726-3
   Letchoumy Paramasivame Vidjaya, 2007, J Carcinog, V6, P19, DOI 10.1186/1477-3163-6-19
   Lin SY, 2001, NAT CELL BIOL, V3, P802, DOI 10.1038/ncb0901-802
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   MORRIS AL, 1961, J DENT RES, V40, P3, DOI 10.1177/00220345610400012001
   Morse DE, 2007, CANCER CAUSE CONTROL, V18, P919, DOI 10.1007/s10552-007-9026-4
   Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159
   Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74
   Rautava J, 2008, ORAL ONCOL, V44, P227, DOI 10.1016/j.oraloncology.2007.02.012
   Speight PM, 2007, HEAD NECK PATHOL, V1, P61, DOI 10.1007/s12105-007-0014-5
   Suresh K, 2010, PHARMACOL REP, V62, P1178, DOI 10.1016/S1734-1140(10)70380-7
   Valraktaris E, 2008, ORAL ONCOL, V44, P315, DOI 10.1016/j.oraloncology.2007.08.015
   Xia WY, 1999, CLIN CANCER RES, V5, P4164
   Xu M, 2010, ALCOHOL CLIN EXP RES, V34, P751, DOI 10.1111/j.1530-0277.2010.01147.x
   Yoshida T, 2005, CANCER RES, V65, P9611, DOI 10.1158/0008-5472.CAN-05-0817
   Yu HS, 2010, CHEM-BIOL INTERACT, V188, P367, DOI 10.1016/j.cbi.2010.08.005
   Zaczek A, 2005, HISTOL HISTOPATHOL, V20, P1005, DOI 10.14670/HH-20.1005
NR 30
TC 2
Z9 2
U1 3
U2 11
PU MEDICINA ORAL S L
PI VALENCIA
PA CALLE DANIEL BALACIART N 4 PTA 17, VALENCIA, 46020, SPAIN
SN 1698-6946
J9 MED ORAL PATOL ORAL
JI Med. Oral Patol. Oral Cir. Bucal
PD MAR
PY 2013
VL 18
IS 2
BP E325
EP E331
AR 18068
DI 10.4317/medoral.18068
PG 7
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA 101HS
UT WOS:000315766400024
PM 23229248
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Fastame, MC
   Penna, MP
AF Fastame, Maria C.
   Penna, Maria P.
TI RETRACTED: Does Social Desirability Confound the Assessment of
   Self-Reported Measures of Well-Being and Metacognitive Efficiency in
   Young and Older Adults? (Retracted article. See vol. 36, pg. 394, 2013)
SO CLINICAL GERONTOLOGIST
LA English
DT Article; Retracted Publication
DE aging; metacognition; social desirability; well-being
ID SCALES; MODELS; BIAS; AGE; PERSONALITY; SARDINIA; VALIDITY; FAMILY; MOOD
AB Social desirability is a multicomponent personality trait referring to the tendency of individuals to regulate their answers to establish a positive impression, avoid criticism, or satisfy a need for social approval. This study investigated the role played by the socially desirable response style assessed with the Marlowe-Crowne Social Desirability Scale on self-rated measures of affect (Center of Epidemiological Studies of Depression Scale), metacognitive efficiency (Sensitivity to Memory Questionnaire and Cognitive Failures Questionnaire), and self-perceived psychological wellness (Psychological Wellness and Aging Questionnaire) in a sample composed of young (M = 24.6 years), old (M = 69.4 years), and very old (M = 81.9 years) adults counterbalanced by gender and education ( 8 years versus > 8 years). Results revealed that social desirability alone predicted measures of affect and emotional competencies, and contributed to predicting personal satisfaction, general perceived wellness, and self-rated cognitive efficiency. Overall, the present outcomes suggest clinical psychologists should pay attention to the crucial interference of social desirability in assessing wellness even in late adulthood, that is, in a developmental phase thought to be mainly characterized by reduced control of physical and psychological functions.
C1 [Fastame, Maria C.; Penna, Maria P.] Univ Cagliari, I-09123 Cagliari, Italy.
RP Fastame, MC (reprint author), Univ Cagliari, Dipartimento Pedag, Via Is Mirrionis 1, I-09123 Cagliari, Italy.
EM chiara.fastame@unica.it
OI Penna, Maria Pietronilla/0000-0002-0982-3893
FU Regione Autonoma Sardegna [CRP2_7]
FX This research was supported by grant number CRP2_7 from Regione Autonoma
   Sardegna, given to the first author according to regional law 7/2007,
   "Promotion of Scientific Research and Technological Innovation in
   Sardinia," within the European Programme PO Sardegna European Social
   Fund (FSE) 2007-2013. The authors thank Professor Aristide Saggino for
   providing the Italian version of Crowne and Marlowe's Social
   Desirability Scale and the heads of the social service departments of
   the cities of Arzana, Lanusei, Elini, and Villagrande Strisaili
   (province of Ogliastra) for their kind support in contacting the
   participants in the research.
CR ARNOLD HJ, 1981, ACAD MANAGE J, V24, P377, DOI 10.2307/255848
   Backstrom M, 2009, J RES PERS, V43, P335, DOI 10.1016/j.jrp.2008.12.013
   Baltes PB, 1997, AM PSYCHOL, V52, P366, DOI 10.1037/0003-066X.52.4.366
   Bandura A., 1997, SELF EFFICACY EXERCI
   BAUMEISTER RF, 1989, J SOC CLIN PSYCHOL, V8, P176, DOI 10.1521/jscp.1989.8.2.176
   BECK AT, 1972, POSTGRAD MED, V52, P81, DOI 10.1080/00325481.1972.11713319
   Borella E, 2007, AGING CLIN EXP RES, V19, P200, DOI 10.1007/BF03324690
   BROADBENT DE, 1982, BRIT J CLIN PSYCHOL, V21, P1, DOI 10.1111/j.2044-8260.1982.tb01421.x
   Campbell TS, 2004, J PAIN, V5, P183, DOI 10.1016/j.jpain..2004.02.305
   CAPPELIEZ P, 1989, Clinical Gerontologist, V9, P45
   CARSTENSEN LL, 1983, J GERONTOL, V38, P713, DOI 10.1093/geronj/38.6.713
   Cornoldi C., 2003, PSICOLOGIA CONT, V1, P4
   CROWNE DP, 1960, J CONSULT PSYCHOL, V24, P349, DOI 10.1037/h0047358
   Dawes SE, 2011, AGEING SOC, V31, P438, DOI 10.1017/S0144686X10001029
   De Beni R., 2007, BAC BENESERE ABILITA
   Derogatis L, 1982, BRIEF SYMPTOM INVENT
   Dijkstra W, 2001, QUAL QUANT, V35, P107, DOI 10.1023/A:1004816210439
   Eller C., 2011, MYTH MATRIARCHAL PRE
   FAVA GA, 1983, J CLIN PSYCHOL, V39, P249, DOI 10.1002/1097-4679(198303)39:2<249::AID-JCLP2270390218>3.0.CO;2-Y
   FLAVELL J. H., 1985, COGNITIVE DEV
   FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6
   GANSTER DC, 1983, ACAD MANAGE J, V26, P321, DOI 10.2307/255979
   HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56
   Holtgraves T, 2004, PERS SOC PSYCHOL B, V30, P161, DOI 10.1177/0146167203259930
   Huang CY, 1998, J CLIN PSYCHOL, V54, P517, DOI 10.1002/(SICI)1097-4679(199806)54:4<517::AID-JCLP13>3.0.CO;2-I
   Johnson T., 2002, VALIDATION CROWNE MA
   King MF, 2000, PSYCHOL MARKET, V17, P79, DOI 10.1002/(SICI)1520-6793(200002)17:2<79::AID-MAR2>3.0.CO;2-0
   KLASSEN D, 1975, J CONSULT CLIN PSYCH, V43, P448, DOI 10.1037/h0076863
   Konstabel K, 2006, EUR J PERSONALITY, V20, P549, DOI 10.1002/per.593
   KOZMA A, 1987, J GERONTOL, V42, P56, DOI 10.1093/geronj/42.1.56
   Laicardi C, 1997, WAIS R CONTRIBUTO TA
   Martin KA, 2000, BASIC APPL SOC PSYCH, V22, P169, DOI 10.1207/S15324834BASP2203_5
   MCCRAE RR, 1983, J CONSULT CLIN PSYCH, V51, P882, DOI 10.1037/0022-006X.51.6.882
   NEDERHOF AJ, 1985, EUR J SOC PSYCHOL, V15, P263, DOI 10.1002/ejsp.2420150303
   OPPO A, 1990, J FAM HIST, V15, P483, DOI 10.1177/036319909001500127
   PAULHUS DL, 1984, J PERS SOC PSYCHOL, V46, P598, DOI 10.1037//0022-3514.46.3.598
   Phillips LH, 2006, AGING MENT HEALTH, V10, P250, DOI 10.1080/13607860500310385
   Poulain M, 2004, EXP GERONTOL, V39, P1423, DOI 10.1016/j.exger.2004.06.016
   RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306
   RAY JJ, 1988, PERS INDIV DIFFER, V9, P417, DOI 10.1016/0191-8869(88)90106-7
   Soubelet A, 2011, J PERS, V79, P741, DOI 10.1111/j.1467-6494.2011.00700.x
   STUKENBERG KW, 1990, PSYCHOL ASSESSMENT, V2, P134, DOI DOI 10.1037/1040-3590.2.2.134
   WECHSLER D, 1974, WECHSLER ADULT INTEL
NR 43
TC 8
Z9 8
U1 4
U2 31
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 0731-7115
EI 1545-2301
J9 CLIN GERONTOLOGIST
JI Clin. Gerontol.
PD MAR 1
PY 2013
VL 36
IS 2
BP 95
EP 112
DI 10.1080/07317115.2012.749319
PG 18
WC Geriatrics & Gerontology; Gerontology; Psychiatry
SC Geriatrics & Gerontology; Psychiatry
GA 097GQ
UT WOS:000315462400001
DA 2018-12-27
ER

PT J
AU Hu, L
   Zhao, JJ
   Liu, JR
   Gong, NY
   Chen, LL
AF Hu, Li
   Zhao, Jiajia
   Liu, Jiarong
   Gong, Niya
   Chen, Lili
TI RETRACTED: Effects of adipose stem cell-conditioned medium on the
   migration of vascular endothelial cells, fibroblasts and keratinocytes
   (Retracted article. See vol. 12, pg. 3137, 2016)
SO EXPERIMENTAL AND THERAPEUTIC MEDICINE
LA English
DT Article; Retracted Publication
DE adipose stem cell-conditioned medium; vascular endothelial cells;
   fibroblasts; keratinocytes; migration
ID IN-VITRO; TISSUE; ANGIOGENESIS; PROLIFERATION; INVOLVEMENT; GROWTH
AB Adipose stem cell-conditioned medium (ASC-CM) has been successfully used to treat multiple types of tissue and organ defects, including skin wounds both in vitro and in vivo. However, the mechanisms through which ASC-CM promotes wound healing remain unclear. We hypothesized that the wound healing effect of ASC-CM is mediated in part by the promotion of the migration of vascular endothelial cells, fibroblasts and keratinocytes, the three cell types essential for wound healing. We reported that ASC-CM stimulated the migration of these cells sequentially, and endothelial cells were the first cell type to respond to ASC-CM stimulation (4 h), followed by fibroblasts (12 h) and then keratinocytes (24 h). We also determined the optimal concentration of ASC-CM in stimulating these cells (50% dilution) in addition to the optimal time to intervene in order to maximize the wound healing activity of ASC-CM. Our data suggest an important role for ASC-CM in wound healing, possibly through the synthetic action of multiple adipose stem cell-derived cytokines that in turn promote cell migration. Thus, ASC-CM appears to have significant potential in wound healing applications.
C1 [Hu, Li; Zhao, Jiajia; Liu, Jiarong; Gong, Niya; Chen, Lili] Huazhong Univ Sci & Technol, Wuhan Union Hosp, Tongji Med Coll, Dept Stomatol, Wuhan 430030, Hubei, Peoples R China.
RP Chen, LL (reprint author), Huazhong Univ Sci & Technol, Wuhan Union Hosp, Tongji Med Coll, Dept Stomatol, 1277 Jiefang Ave, Wuhan 430030, Hubei, Peoples R China.
EM chenlili@whuh.com
FU National Natural Science Foundation of China [31110103905]
FX This study was supported supported by a major grant from the National
   Natural Science Foundation of China (no. 31110103905).
CR Bae JS, 2002, BIOCHEM BIOPH RES CO, V294, P940, DOI 10.1016/S0006-291X(02)00576-4
   Baraniak PR, 2010, REGEN MED, V5, P121, DOI 10.2217/RME.09.74
   Bunnell BA, 2008, METHODS, V45, P115, DOI 10.1016/j.ymeth.2008.03.006
   Cao GY, 2002, AM J PHYSIOL-CELL PH, V282, pC1181, DOI 10.1152/ajpcell.00524.2001
   Casteilla Louis, 2011, World J Stem Cells, V3, P25, DOI 10.4252/wjsc.v3.i4.25
   Fernyhough ME, 2008, BIOCHEM BIOPH RES CO, V368, P455, DOI 10.1016/j.bbrc.2008.01.113
   Fu XB, 2007, WOUND REPAIR REGEN, V15, P540, DOI 10.1111/j.1524-475X.2007.00262.x
   Hakkinen Lari, 2001, Methods in Cell Science, V23, P189, DOI 10.1023/A:1016385109922
   Hong SJ, 2010, CURR OPIN ORGAN TRAN, V15, P86, DOI 10.1097/MOT.0b013e328334f074
   Kanazawa S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012228
   Kim WS, 2007, J DERMATOL SCI, V48, P15, DOI 10.1016/j.jdermsci.2007.05.018
   Kondo T, 2010, FORENSIC SCI INT, V203, P93, DOI 10.1016/j.forsciint.2010.07.004
   Li S, 2005, J CELL BIOCHEM, V96, P1110, DOI 10.1002/jcb.20614
   Liebl J, 2010, J BIOL CHEM, V285, P35932, DOI 10.1074/jbc.M110.126177
   Liu JR, 2011, TISSUE ENG PART B-RE, V17, P25, DOI [10.1089/ten.teb.2010.0489, 10.1089/ten.TEB.2010.0489]
   Maheshwari G, 1999, BIOPHYS J, V76, P2814, DOI 10.1016/S0006-3495(99)77435-7
   Sterodimas A, 2010, J PLAST RECONSTR AES, V63, P1886, DOI 10.1016/j.bjps.2009.10.028
   Trochon V, 1996, INT J CANCER, V66, P664, DOI 10.1002/(SICI)1097-0215(19960529)66:5<664::AID-IJC14>3.0.CO;2-4
   Walter MNM, 2010, EXP CELL RES, V316, P1271, DOI 10.1016/j.yexcr.2010.02.026
   Yuan ZL, 2011, TISSUE ENG PART B-RE, V17, P373, DOI [10.1089/ten.TEB.2011.0041, 10.1089/ten.teb.2011.0041]
   Zuk PA, 2001, TISSUE ENG, V7, P211, DOI 10.1089/107632701300062859
NR 21
TC 26
Z9 27
U1 2
U2 9
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792-0981
EI 1792-1015
J9 EXP THER MED
JI Exp. Ther. Med.
PD MAR
PY 2013
VL 5
IS 3
BP 701
EP 706
DI 10.3892/etm.2013.887
PG 6
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 096SB
UT WOS:000315423500008
PM 23403954
OA Bronze, Green Published
DA 2018-12-27
ER

PT J
AU Wang, N
   Li, M
   Zang, WQ
   Ma, YY
   Wang, YY
   Zhao, GQ
AF Wang, Na
   Li, Min
   Zang, Wen-Qiao
   Ma, Yun-Yun
   Wang, Yuan-Yuan
   Zhao, Guo-Qiang
TI RETRACTED: Effects of cyclin E gene silencing on the proliferation of
   esophageal cancer cell lines, EC9706, Eca109 and KYSE30 (Retracted
   article. See vol. 17, pg. 6202, 2018)
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article; Retracted Publication
DE cyclin E; esophageal cancer cell lines; RNAi; proliferation
ID RNA INTERFERENCE; OVEREXPRESSION; EXPRESSION; CARCINOMA; THERAPY;
   PROGNOSIS; SIRNA; CDKS; P53
AB In order to observe the effects of cyclin E gene silencing by small interfering RNA (siRNA) on the growth, proliferation, invasion and apoptosis of esophageal cancer cell lines, including EC9706, Eca109 and KYSE30, siRNA vectors targeting cyclin E gene were constructed and then transfected into the EC9706, Eca109 and KYSE30 human esophageal cancer cell lines. Cyclin E mRNA and protein expression were determined by RT-PCR and western blotting. Cell proliferation and clonality were detected using a CCK-8 test and soft agar colony formation assay. Cell cycle distribution, apoptosis and invasion of EC9706, Eca109 and KYSE30 cells were evaluated with flow cytometry and a transwell culture system. After siRNA vectors targeting the cyclin E gene were transfected into EC9706, Eca109 and KYSE30 cell lines, compared with blank and negative control groups, the expression of cyclin E mRNA and protein (P<0.01), colony-forming units and the number of cells penetrating the transwell membrane (P<0.05) were significantly decreased, the cells in the S and G2/M phase were reduced, the cells in the G0/G1 phase were increased and the apoptosis rate was increased (P<0.01) in the experimental groups. Cyclin E gene silencing effectively inhibits growth, proliferation and invasion of esophageal cancer cells.
C1 [Wang, Na; Li, Min; Zang, Wen-Qiao; Wang, Yuan-Yuan; Zhao, Guo-Qiang] Zhengzhou Univ, Dept Microbiol & Immunol, Coll Basic Med Sci, Zhengzhou 450001, Peoples R China.
   [Ma, Yun-Yun] Henan Med Coll Staff & Workers, Dept Immunol & Microbiol, Zhengzhou 451191, Peoples R China.
RP Zhao, GQ (reprint author), Zhengzhou Univ, Dept Microbiol & Immunol, Coll Basic Med Sci, 100 Kexue Rd, Zhengzhou 450001, Peoples R China.
EM zhaogq@zzu.edu.cn
CR Berretta Massimiliano, 2012, Front Biosci (Elite Ed), V4, P351
   Chen YK, 2009, NUTRITION, V25, P753, DOI 10.1016/j.nut.2009.02.002
   Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107
   Erdman SE, 2010, INT J CANCER, V127, P768, DOI 10.1002/ijc.25430
   Fujii S, 1998, J EXP CLIN CANC RES, V17, P491
   Gondi CS, 2009, J CELL PHYSIOL, V220, P285, DOI 10.1002/jcp.21790
   Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a
   He J, 2006, J BIOL CHEM, V281, P35598, DOI 10.1074/jbc.C600200200
   Islami F, 2009, INT J CANCER, V125, P491, DOI 10.1002/ijc.24445
   Jankovic R, 2009, J BUON, V14, pS43
   Kim DH, 2007, NAT REV GENET, V8, P173, DOI 10.1038/nrg2006
   KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y
   Liang YL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012860
   Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065
   Mazumder S, 2007, CELL CYCLE, V6, P1437
   McCaffrey AP, 2002, NATURE, V418, P38, DOI 10.1038/418038a
   Meng XL, 2012, CANCER METAST REV, V31, P247, DOI 10.1007/s10555-011-9342-8
   Meng XL, 2006, MED HYPOTHESES, V66, P486, DOI 10.1016/j.mehy.2005.09.041
   Sanchez I, 2005, SEMIN CELL DEV BIOL, V16, P311, DOI 10.1016/j.semcdb.2005.02.007
   Satyanarayana A, 2009, ONCOGENE, V28, P2925, DOI 10.1038/onc.2009.170
   Sauer K, 1995, Prog Cell Cycle Res, V1, P125
   Schildkraut JM, 2008, CANCER EPIDEM BIOMAR, V17, P585, DOI 10.1158/1055-9965.EPI-07-0596
   Sharp PA, 2001, GENE DEV, V15, P485, DOI 10.1101/gad.880001
   Shimada H, 2002, J GASTROENTEROL, V37, P87, DOI 10.1007/BF03326422
   Shimada H, 2008, ANN THORAC CARDIOVAS, V14, P3
   Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138
   Stamatakos M, 2010, WORLD J SURG ONCOL, V8, DOI 10.1186/1477-7819-8-111
   Taghavi N, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-138
   Tanaka T, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-83
   Xie FJ, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-86
   Zhou YJ, 2011, EJSO-EUR J SURG ONC, V37, P1078, DOI 10.1016/j.ejso.2011.08.139
NR 31
TC 2
Z9 2
U1 3
U2 9
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791-2997
EI 1791-3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD MAR
PY 2013
VL 7
IS 3
BP 799
EP 804
DI 10.3892/mmr.2013.1280
PG 6
WC Oncology; Medicine, Research & Experimental
SC Oncology; Research & Experimental Medicine
GA 096SC
UT WOS:000315423600013
PM 23338900
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Wei, YC
   Fu, LM
   Lin, CH
AF Wei, Yi-Chi
   Fu, Lung-Ming
   Lin, Che-Hsin
TI RETRACTED: Electrophoresis separation and electrochemical detection on a
   novel thread-based microfluidic device (Retracted article. See vol. 15,
   pg. 137, 2013)
SO MICROFLUIDICS AND NANOFLUIDICS
LA English
DT Article; Retracted Publication
ID PAPER-BASED MICROFLUIDICS; LOW-COST; CHIPS; MICROCHANNELS; DIAGNOSTICS;
   FABRICATION; VERSATILE; PLATFORM; WAX
AB This article describes a thread-based microfluidic system for rapid and low-cost electrophoresis separation and electrochemical (EC) detection of ion samples. Instead of using liquid channel for sample separation, thin polyester threads of various diameters are used as the routes for separating the samples with electrophoresis. Hot-pressed PMMA chip with protruding sleeper structures are adopted to set up the polyester threads and for electrochemical detecting the ion samples on the thread. Plasma treatment greatly improves the wetability of thin threads and surface quality of the threads. The measured electrical currents on plasma-treated threads are ten times greater than the threads without treatment. Results indicate that nice redox signals can be obtained by measuring ferric cyanide salt on the polyester thread. The estimated detection limit for EC sensing of potassium ferricyanide (K3Fe(CN)(6)) is around 6.25 mu M using the developed thread-based microfluidic device. Mixed-ion samples (Cl-, Br-, and I-) and bio-sample are successfully separated and detected using the developed thread-based microfluidic device.
C1 [Wei, Yi-Chi; Lin, Che-Hsin] Natl Sun Yat Sen Univ, Dept Mech & Electromech Engn, Kaohsiung 804, Taiwan.
   [Fu, Lung-Ming] Natl Pingtung Univ Sci & Technol, Grad Inst Mat Engn, Pingtung 912, Taiwan.
RP Lin, CH (reprint author), Natl Sun Yat Sen Univ, Dept Mech & Electromech Engn, Kaohsiung 804, Taiwan.
EM chehsin@mail.nsysu.edu.tw
RI Lin, chehsin/C-7300-2008
OI Lin, chehsin/0000-0002-0722-4854
CR Becker H, 2000, ELECTROPHORESIS, V21, P12, DOI 10.1002/(SICI)1522-2683(20000101)21:1<12::AID-ELPS12>3.0.CO;2-7
   Bhandari P, 2011, LAB CHIP, V11, P2493, DOI 10.1039/c1lc20373h
   Bruzewicz DA, 2008, ANAL CHEM, V80, P3387, DOI 10.1021/ac702605a
   Cai DK, 2010, MICROFLUID NANOFLUID, V9, P855, DOI 10.1007/s10404-010-0596-1
   Carrilho E, 2009, ANAL CHEM, V81, P7091, DOI 10.1021/ac901071p
   Chitnis G, 2011, LAB CHIP, V11, P1161, DOI [10.1039/c0lc00512f, 10.1039/c01c00512f]
   Dungchai W, 2011, ANALYST, V136, P77, DOI 10.1039/c0an00406e
   Dungchai W, 2009, ANAL CHEM, V81, P5821, DOI 10.1021/ac9007573
   Fiorini GS, 2005, BIOTECHNIQUES, V38, P429, DOI 10.2144/05383RV02
   Hong TF, 2010, MICROFLUID NANOFLUID, V9, P1125, DOI 10.1007/s10404-010-0633-0
   Hug TS, 2006, MICROFLUID NANOFLUID, V2, P117, DOI 10.1007/s10404-005-0051-x
   Jokerst JC, 2012, ANAL CHEM, V84, P2900, DOI 10.1021/ac203466y
   Lankelma J, 2012, ANAL CHEM, V84, P4147, DOI 10.1021/ac3003648
   Lee GB, 2005, ELECTROPHORESIS, V26, P4616, DOI 10.1002/elps.200500382
   Lee GB, 2003, SENSOR ACTUAT A-PHYS, V103, P165, DOI 10.1016/S0924-4247(02)00305-9
   Li X, 2010, CELLULOSE, V17, P649, DOI 10.1007/s10570-010-9401-2
   Li X, 2010, ACS APPL MATER INTER, V2, P1, DOI 10.1021/am9006148
   Li X, 2008, ANAL CHEM, V80, P9131, DOI 10.1021/ac801729t
   Lin CH, 2008, MICROFLUID NANOFLUID, V5, P403, DOI 10.1007/s10404-008-0259-7
   Lu Y, 2009, ELECTROPHORESIS, V30, P1497, DOI 10.1002/elps.200800563
   Martinez AW, 2007, ANGEW CHEM INT EDIT, V46, P1318, DOI 10.1002/anie.200603817
   Prakash AR, 2008, MICROFLUID NANOFLUID, V4, P451, DOI 10.1007/s10404-007-0195-y
   Reches M, 2010, ACS APPL MATER INTER, V2, P1722, DOI 10.1021/am1002266
   Tsao CW, 2009, MICROFLUID NANOFLUID, V6, P1, DOI 10.1007/s10404-008-0361-x
   Zhu Y, 2010, MICROFLUID NANOFLUID, V8, P275, DOI 10.1007/s10404-009-0516-4
NR 25
TC 1
Z9 1
U1 3
U2 44
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 1613-4982
EI 1613-4990
J9 MICROFLUID NANOFLUID
JI Microfluid. Nanofluid.
PD MAR
PY 2013
VL 14
IS 3-4
BP 723
EP 730
DI 10.1007/s10404-012-1091-7
PG 8
WC Nanoscience & Nanotechnology; Instruments & Instrumentation; Physics,
   Fluids & Plasmas
SC Science & Technology - Other Topics; Instruments & Instrumentation;
   Physics
GA 094XQ
UT WOS:000315299100030
DA 2018-12-27
ER

PT J
AU Naing, AH
   Kim, CK
   Yun, BJ
   Jin, JY
   Lim, KB
AF Naing, Aung Htay
   Kim, Chang Kil
   Yun, Baek Ji
   Jin, Jo Yu
   Lim, Ki Byung
TI RETRACTED: Primary and secondary somatic embryogenesis in Chrysanthemum
   cv. Euro (Retracted article. See vol. 89, pg. 360, 2014)
SO PLANT CELL TISSUE AND ORGAN CULTURE
LA English
DT Article; Retracted Publication
DE Chrysanthemum; Plant growth regulators (PGRs); Somatic embryogenesis;
   Secondary somatic embryogenesis; Sucrose; Timentin
ID AGROBACTERIUM-MEDIATED TRANSFORMATION; PLANT-REGENERATION; SHOOT
   REGENERATION; LEAF EXPLANTS; ANTIBIOTICS; TUMEFACIENS; CULTURES; GROWTH;
   ELIMINATION; MATURATION
AB Somatic embryogenesis was induced from in vivo grown leaf explants of Chrysanthemum cv. Euro incubated on Murashige and Skoog (MS) medium supplemented with 2.0 mg/L 2,4-dichlorophenoxyacetic acid and 2.0 mg/L Kinetin, yielding the highest mean number of embryos (42 +/- A 5.97) per explant after 5 weeks of culture. We evaluated the effects of basal medium, various concentrations of sucrose, and timentin on the proliferation of secondary somatic embryos. MS medium was observed to be the more effective in promoting the proliferation of somatic embryos than half-strength Murashige and Skoog (1/2MS). In addition, timentin was also more efficient in induction of secondary embryogenesis than sucrose. Whole plantlets were obtained by culturing of secondary embryos on hormone-free MS medium and successfully acclimated in the green house.
C1 [Naing, Aung Htay; Kim, Chang Kil; Yun, Baek Ji; Jin, Jo Yu; Lim, Ki Byung] Kyungpook Natl Univ, Dept Hort Sci, Taegu 702701, South Korea.
RP Lim, KB (reprint author), Kyungpook Natl Univ, Dept Hort Sci, Taegu 702701, South Korea.
EM kblim@knu.ac.kr
FU KGSP (Korean Government Scholarship Program); Kyungpook National
   University Research Fund, Republic of Korea
FX This work was supported by KGSP (Korean Government Scholarship Program),
   and Kyungpook National University Research Fund, 2012, Republic of
   Korea.
CR Agarwal S, 2004, SCI HORTIC-AMSTERDAM, V102, P359, DOI 10.1016/j.scienta.2004.04.002
   Akula A, 2000, PLANT CELL REP, V19, P1140, DOI 10.1007/s002990000239
   BAKER CM, 1995, PLANT CELL TISS ORG, V40, P249, DOI 10.1007/BF00048131
   Bao Y, 2012, PLANT CELL TISS ORG, V109, P411, DOI 10.1007/s11240-011-0105-6
   Baskaran P, 2012, PLANT CELL TISS ORG, V109, P517, DOI 10.1007/s11240-012-0118-9
   Cheng ZM, 1998, PLANT CELL REP, V17, P646, DOI 10.1007/s002990050458
   Hammerschlag FA, 1997, J AM SOC HORTIC SCI, V122, P758
   Ikeda-Iwai M, 2003, PLANT J, V34, P107, DOI 10.1046/j.1365-313X.2003.016011.x
   KAMADA H, 1993, PLANT TISSUE CULTURE, V10, P38, DOI DOI 10.5511/PLANTBI0TECHN0L0GY1984.10.38
   Karami O, 2008, PLANT CELL TISS ORG, V92, P273, DOI 10.1007/s11240-007-9332-2
   Ling HQ, 1998, PLANT CELL REP, V17, P843, DOI 10.1007/s002990050495
   Little EL, 2000, PLANT CELL REP, V19, P351, DOI 10.1007/s002990050739
   Mandal AKA, 2005, BIOL PLANTARUM, V49, P29, DOI 10.1007/s10535-005-0033-6
   MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x
   Naing AungHtay, 2011, American Journal of Plant Sciences, V2, P262, DOI 10.4236/ajps.2011.22028
   NAKANO M, 1993, J PLANT PHYSIOL, V141, P721, DOI 10.1016/S0176-1617(11)81581-6
   Neves L. O. Das, 1999, Plant Cell Reports, V18, P398
   Parimalan R, 2011, PLANT CELL TISS ORG, V105, P317, DOI 10.1007/s11240-010-9870-x
   PAVINGEROVA D, 1994, PLANT SCI, V97, P95, DOI 10.1016/0168-9452(94)90111-2
   ROBERTS DR, 1991, PHYSIOL PLANTARUM, V83, P247, DOI 10.1111/j.1399-3054.1991.tb02149.x
   Rout GR, 1997, SCI HORTIC-AMSTERDAM, V69, P239, DOI 10.1016/S0304-4238(97)00008-3
   ROUT GR, 1991, PLANT CELL TISS ORG, V27, P65, DOI 10.1007/BF00048208
   SARMA KS, 1995, J EXP BOT, V46, P1779, DOI 10.1093/jxb/46.11.1779
   Shackelford NJ, 1996, PLANT MOL BIOL REP, V14, P50, DOI 10.1007/BF02671902
   Shinoyama H., 2004, PLANT BIOTECHNOL, V21, P25
   Tanaka K, 2000, PLANT CELL REP, V19, P946, DOI 10.1007/s002990000225
   Tang H, 2000, PLANT CELL REP, V19, P881, DOI 10.1007/s002990000201
   Vasic D, 2002, PLANT CELL REP, V2, P121
   Yang XY, 2012, PLANT CELL TISS ORG, V109, P213, DOI 10.1007/s11240-011-0087-4
   YEPES LM, 1994, PLANT CELL TISS ORG, V37, P257
NR 30
TC 12
Z9 13
U1 1
U2 40
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0167-6857
EI 1573-5044
J9 PLANT CELL TISS ORG
JI Plant Cell Tissue Organ Cult.
PD MAR
PY 2013
VL 112
IS 3
BP 361
EP 368
DI 10.1007/s11240-012-0243-5
PG 8
WC Biotechnology & Applied Microbiology; Plant Sciences
SC Biotechnology & Applied Microbiology; Plant Sciences
GA 094PW
UT WOS:000315277300010
OA Other Gold
DA 2018-12-27
ER

PT J
AU Zaman, K
   Khan, MM
   Ahmad, M
AF Zaman, Khalid
   Khan, Muhammad Mushtaq
   Ahmad, Mehboob
TI RETRACTED: Factors affecting commercial energy consumption in Pakistan:
   Progress in energy (Retracted article. See vol. 45, pg. 903, 2015)
SO RENEWABLE & SUSTAINABLE ENERGY REVIEWS
LA English
DT Review; Retracted Publication
DE Commercial energy consumption; Oil consumption.; Gas consumption;
   Electricity consumption; Coal consumption; Fuel factors; Pakistan
ID ENVIRONMENTAL KUZNETS CURVE; GRANGER CAUSALITY TESTS; ECONOMIC-GROWTH;
   ELECTRICITY CONSUMPTION; CO2 EMISSIONS; BIVARIATE COINTEGRATION;
   SUSTAINABLE DEVELOPMENT; INDUSTRIAL-PRODUCTION; EMPIRICAL-EVIDENCE;
   RENEWABLE ENERGY
AB The purpose of this study is to identify major macroeconomic factors that enhance energy consumption for Pakistan through the cointegration, error correction model and Granger causality tests over a 32-year time period, i.e., between 1980 and 2011. The study employed the bivariate cointegration technique to estimate the long-run relationship between the variables; an error correction model was used to determine the short-run dynamics of the system, while Granger causality test was used to find the directions between these variables. The study investigates the relation between four energy consumption variables (i.e., oil/petroleum consumption, gas consumption, electricity consumption and coal consumption) and four macroeconomic factors which have further sub-classifications, i.e., balance of payment (BOP) factors (i.e., exports, imports, trade deficit, worker's remittances and current account balance), fuel factors (i.e., carbon dioxide emissions, natural resource depletion and net forest depletion), agricultural crops yield per hectare (i.e., wheat, rice, sugarcane, maize and cotton) and industrial production items (i.e., beverages, cigarettes, motor tyres, motor tubes, cycle tyres and cycle. tubes) in order to manage robust data analysis. The result confirms the long-run relationship between total commercial energy consumption and macroeconomic factors in Pakistan, as oil/petroleum consumption increases exports, fuel factors, agricultural crops yield per hectare and industrial items; however, the intensity of these factors are different in nature. Carbon dioxide emissions, net forest depletion, beverages, motor tyres and motor tubes are more elastic with oil/petroleum consumption. However, oil/petroleum consumption decreases trade deficit and workers' remittances in Pakistan. Gas, electricity and coal consumption increases agricultural crops yield per hectare and industrial production which shows that as agriculture and industry modernizes, energy demand increases. Energizing the food production chain is an essential feature of agricultural development which is a prime factor in helping to achieve food security in Pakistan. The empirical results only moderately support the conventional view that energy consumption has significant long-run casual effect on macroeconomic variables in Pakistan. The present study finds. evident of unidirectional causality between the commercial energy consumption factors and macroeconomic factors in Pakistan. However, there is some bidirectional causality exist which is running between electricity consumption (EC) and exports, EC to imports, EC to carbon emissions, EC to natural resource depletion (NRD) and EC to wheat. The results conclude that macroeconomic variables tend to positively respond to total primary energy consumption. This indicates that increasing total commercial energy consumption may cause growth variables which show that Pakistan is an input-driven economy. (C) 2012 Elsevier Ltd.. All rights reserved.
C1 [Zaman, Khalid] COMSATS Inst Informat Technol, Dept Management Sci, Abbottabad, Pakistan.
   [Khan, Muhammad Mushtaq] COMSATS Inst Informat Technol, Abbottabad, Pakistan.
   [Ahmad, Mehboob] Bahria Univ, Islamabad, Pakistan.
RP Zaman, K (reprint author), COMSATS Inst Informat Technol, Dept Management Sci, Abbottabad, Pakistan.
EM khalidzaman@ciit.net.pk; khanmni@ciit.net.pk; mmehboobahmad@gmail.com
CR Ahmed J., 2011, J EC INT FINANCE, V3, P176
   Ahmed K, 2012, PROC ECON FINANC, V1, P4, DOI 10.1016/S2212-5671(12)00003-2
   Akdemir S, 2012, J FOOD AGRIC ENVIRON, V10, P473
   Ali G, 2012, RENEW SUST ENERG REV, V16, P775, DOI 10.1016/j.rser.2011.09.003
   Andreoni V, 2012, ENERGY, V44, P682, DOI 10.1016/j.energy.2012.05.024
   Ang JB, 2008, J POLICY MODEL, V30, P271, DOI 10.1016/j.jpolmod.2007.04.010
   Ang JB, 2007, ENERG POLICY, V35, P4772, DOI 10.1016/j.enpol.2007.03.032
   Apergis N, 2012, ENERG SOURCE PART B, V7, P314, DOI 10.1080/15567249.2011.601530
   Apergis N, 2010, APPL ENERG, V87, P1972, DOI 10.1016/j.apenergy.2009.11.035
   Apergis N, 2010, ENERG POLICY, V38, P1353, DOI 10.1016/j.enpol.2009.11.016
   Atif R. M., 2010, J INT ACAD RES, V10, P30
   Atif RM, 2012, WORLD APPL SCI J, V17, P91
   Badiani R, 2011, SEM PART UC BERK
   Bekhet H. A., 2009, INT BUS RES, V2, P152
   Bhutto AW, 2012, RENEW SUST ENERG REV, V16, P2762, DOI 10.1016/j.rser.2012.02.043
   Bowden N, 2009, J POLICY MODEL, V31, P180, DOI 10.1016/j.jpolmod.2008.09.001
   Brandt AR, 2011, SUSTAINABILITY-BASEL, V3, P1833, DOI 10.3390/su3101833
   Chen ST, 2007, ENERG POLICY, V35, P2611, DOI 10.1016/j.enpol.2006.10.001
   Ciarreta A, 2006, ELECT CONSUMPTION EC
   Davidson O., 2002, CLIMATE CHANGE SUSTA
   Davis SJ, 2010, P NATL ACAD SCI USA, V107, P5687, DOI 10.1073/pnas.0906974107
   Denison E.F., 1985, TRENDS AM EC GROWTH
   Dodzin S, 2004, J DEV ECON, V75, P319, DOI 10.1016/j.jdeveco.2003.08.006
   Dunkerley J, 1981, ENERGY DEV COUNTRIES
   ENGLE RF, 1987, ECONOMETRICA, V55, P251, DOI 10.2307/1913236
   FAO, 2000, 4 FAO
   FAO, 1995, EN AGR
   FRAITURE CH., 2008, WATER POLICY, P67
   Freitas L. C., 2011, ENERG POLICY, V39, P1495
   Ghosh S, 2002, ENERG POLICY, V30, P125, DOI 10.1016/S0301-4215(01)00078-7
   Ghosh S, 2010, ENERG POLICY, V38, P3008, DOI 10.1016/j.enpol.2010.01.040
   GOP, 2011, EC SURV PAK 2010 11
   GOP, 2012, EC SURV PAK 2011 12
   GOP, 2010, EC SURV PAK 2009 201
   GRANGER CWJ, 1981, J ECONOMETRICS, V16, P121, DOI 10.1016/0304-4076(81)90079-8
   Greene DL, 2009, REDUCING OIL USE CO2
   Halicioglu F, 2010, 9 MEEA ANN INT C JUN
   Halicioglu F, 2009, ENERG POLICY, V37, P1156, DOI 10.1016/j.enpol.2008.11.012
   Haq N, 2007, ENERGY CRISES PAKIST
   Hassan R, 2009, ENERG POLICY, V37, P1195, DOI 10.1016/j.enpol.2008.10.049
   HES, 2011, FACT IN AFF REN EN T
   Hossain S, 2012, GLOBAL J MANAGEMENT, V12, P40
   Hussain M, 2012, INT J ENERGY SECTOR, V6
   International Energy Agency, 2008, WORLDW TRENDS EN US
   International Energy Outlook, 2011, DOEEIA0484 INT EN OU
   Pachauri RK, 2007, CLIM CHANG 2007 SYNT
   Jacobsen H. K., 2000, ECON SYST RES, V12, P319
   Jaffe AB, 1999, 19 KSG
   Jan I, 2012, RENEW SUST ENERG REV, V16, P3200, DOI 10.1016/j.rser.2012.02.038
   Javaid M.A., 2011, INT J BASIC APPL SCI, V11, P38
   JOHANSEN S, 1991, ECONOMETRICA, V59, P1551, DOI 10.2307/2938278
   Jumbe CBL, 2004, ENERG ECON, V26, P61, DOI 10.1016/S0140-9883(03)00058-6
   Kahrl F, 2008, CHINA ECON REV, V19, P649, DOI 10.1016/j.chieco.2008.05.004
   Kebede E, 2010, ENERG ECON, V32, P532, DOI 10.1016/j.eneco.2010.02.003
   Khan MA, 2009, 24 PSDE C PAK I DEV
   Khan MA, 2010, RENEW SUST ENERG REV, V14, P2179, DOI 10.1016/j.rser.2010.03.016
   Komleh SHP, 2011, ENERGY, V36, P3335, DOI 10.1016/j.energy.2011.03.029
   Kouakou AK, 2011, ENERG POLICY, V39, P3638, DOI 10.1016/j.enpol.2011.03.069
   KRAFT J, 1978, J ENERGY DEV, V3, P401
   KRAVIS IB, 1970, ECON J, V80, P850, DOI 10.2307/2229902
   Kumar S, 2012, ENERG EXPLOR EXPLOIT, V30, P499, DOI 10.1260/0144-5987.30.3.499
   Lewis C. A., 1997, R112 ETSU
   Lin SJ, 1996, ENERGY J, V17, P1
   Lin X, 1995, ECON SYST RES, V7, P67
   Mansur ET, 2008, J ENVIRON ECON MANAG, V55, P175, DOI 10.1016/j.jeem.2007.10.001
   Martinez DM, 2008, ENERG POLICY, V36, P1430, DOI 10.1016/j.enpol.2007.12.016
   Narayan PK, 2005, ENERG POLICY, V33, P1109, DOI 10.1016/j.enpol.2003.11.010
   Nash HA, 2009, J CLEAN PROD, V17, P496, DOI 10.1016/j.jclepro.2008.08.020
   Nssir M, 2011, ENERG POLICY, V39, P1857
   OECD, 1997, 16 OECD
   Omer AM, 2008, RENEW SUST ENERG REV, V12, P2265, DOI 10.1016/j.rser.2007.05.001
   PECK M, 2007, DISCOVER, V28, P12
   PHILLIPS PCB, 1990, ECONOMETRICA, V58, P165, DOI 10.2307/2938339
   Renewable Energy Foundation (REF), 2011, EN POL CONS HARDSH
   Rongqin Z, 2011, J GEOGRAPHICAL SCI, V21, P285
   Sadorsky P, 2012, ENERG ECON, V34, P476, DOI 10.1016/j.eneco.2011.12.008
   Sahir MH, 2007, ENERG POLICY, V35, P2031, DOI 10.1016/j.enpol.2006.08.010
   Saidur R, 2009, ENERG POLICY, V37, P4104, DOI 10.1016/j.enpol.2009.04.052
   Sari R, 2008, ENERG ECON, V30, P2302, DOI 10.1016/j.eneco.2007.10.002
   Shahbaz M, 2012, ECON MODEL, V29, P2310, DOI 10.1016/j.econmod.2012.06.027
   Shyam M., 2002, ENERGY SUSTAIN DEV, V6, P37
   Siddiqui R, 2011, PIDE WORKING PAPERS, V2011, P75
   SOLOW RM, 1978, AM ECON, V22, P5, DOI 10.1177/056943457802200201
   STOUT BA, 1990, HDB ENERGY WORLD AGR
   Sultan R, 2011, ICITI C P
   Suri V, 1998, ECOL ECON, V25, P195, DOI 10.1016/S0921-8009(97)00180-8
   Tosun J., 2011, EUROPEAN INTEGRATION, V15, P1
   Tsai WT, 2010, RENEW SUST ENERG REV, V14, P2131, DOI 10.1016/j.rser.2010.03.027
   Tsai WT, 2005, RENEW SUST ENERG REV, V9, P119, DOI 10.1016/j.rser.2004.01.014
   UNEP, 2010, ASS ENV IMP CONS PRO
   UNIDO, 2011, REN EN IND APPL ASS
   Vera I, 2007, ENERGY, V32, P875, DOI 10.1016/j.energy.2006.08.006
   Weubles DJ, 2001, FUEL PROCESSING TECH, V71, P99
   World Bank, 2011, WORLD DEV IND WDI
   World Bank, 2010, SUBS EN SECT OV
   World Energy Council, 2008, EN EFF POL WORLD REV
   Zaman K, 2012, INT J ECOLOGICAL EC, V25, P85
   Zaman K., 2011, INT J RURAL MANAGEME, V7, P27
   Zaman K, 2012, ENERG POLICY, V50, P623, DOI 10.1016/j.enpol.2012.08.003
   Zaman K, 2012, ECON MODEL, V29, P1632, DOI 10.1016/j.econmod.2012.05.024
   Zaman K, 2012, ENERG POLICY, V44, P268, DOI 10.1016/j.enpol.2012.01.050
   Zaman K, 2011, INT J GREEN ENERGY, V8, P820, DOI 10.1080/15435075.2011.602157
   Zaman K, 2010, J ENVIRON PLANN MAN, V53, P977, DOI 10.1080/09640568.2010.495537
   Ziramba E, 2009, ENERG POLICY, V37, P2214, DOI 10.1016/j.enpol.2009.01.048
NR 104
TC 17
Z9 17
U1 4
U2 68
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1364-0321
J9 RENEW SUST ENERG REV
JI Renew. Sust. Energ. Rev.
PD MAR
PY 2013
VL 19
BP 107
EP 135
DI 10.1016/j.rser.2012.11.013
PG 29
WC GREEN & SUSTAINABLE SCIENCE & TECHNOLOGY; Energy & Fuels
SC Science & Technology - Other Topics; Energy & Fuels
GA 089IU
UT WOS:000314905000009
DA 2018-12-27
ER

PT J
AU Dwivedi, AK
   Dubey, VK
AF Dwivedi, A. K.
   Dubey, V. K.
TI RETRACTED: Advancements in morphometric differentiation: a review on
   stock identification among fish populations (Retracted article. See vol.
   23, pg. 557, 2013)
SO REVIEWS IN FISH BIOLOGY AND FISHERIES
LA English
DT Review; Retracted Publication
DE Stock identification; Morphometry; Fish population
ID SYMPATRIC STICKLEBACKS GASTEROSTEUS; CHARR SALVELINUS-ALPINUS;
   LACUSTRINE BROOK CHARR; MORPHOLOGICAL VARIATION; PHENOTYPIC PLASTICITY;
   TROPHIC POLYMORPHISM; TRACHURUS TRACHURUS; MERISTIC VARIATION; FORAGING
   BEHAVIOR; BRITISH-COLUMBIA
AB Identifying intraspecific units or stocks of a species with unique morphological characteristics has now become more powerful and enables a better management of these subunits of species and ensures better management and conservation of the fishery resources. These morphometric characteristics typically show ontogenic changes in body shape particularly rapid at key life history stages. For about the past 50 years, traditional multivariate morphometrics, accounting for variation in size and shape, have successfully discriminated many fish stocks throughout the world, however, they have always been criticized because of several biases and weaknesses. To contribute to the advancement of fish stock identification, a new technology based on "Truss Network System" has emerged as a new tool with more effective strategies for descriptions of shape, better data collection and diversified analytical tools. In the present communication, recent developments made in the discipline of morphometric differentiation in body shape among fish populations are briefly reviewed and it appears that the truss based techniques has now been proved to be more effective than manual distance measurement for the management of fishery resources throughout the world. However in India, these techniques have not been commonly applied in fisheries research to discriminate fish stocks. The study expands the potential through various advancements in morphometric differentiation analysis which could serve as a tool for stock identification among fish populations.
C1 [Dwivedi, A. K.; Dubey, V. K.] Natl Bur Fish Genet Resources, Lucknow 226002, Uttar Pradesh, India.
RP Dwivedi, AK (reprint author), Natl Bur Fish Genet Resources, Canal Ring Rd, Lucknow 226002, Uttar Pradesh, India.
EM arvindbio@rediffmail.com
CR ALI MY, 1974, CAN J ZOOL, V52, P959, DOI 10.1139/z74-128
   Bagherian A., 2009, Animal Biodiversity and Conservation, V32, P1
   BEACHAM TD, 1990, CAN J ZOOL, V68, P225, DOI 10.1139/z90-033
   Begg GA, 1999, FISH RES, V43, P1, DOI 10.1016/S0165-7836(99)00062-4
   Bektas Y, 2009, J ANIM VET ADV, V8, P511
   Bertrand M, 2008, J FISH BIOL, V72, P555, DOI 10.1111/j.1095-8649.2007.01720.x
   Blackith RE, 1971, MULTIVARIATE MORPHOM
   BLACKSTONE NW, 1987, SYST ZOOL, V36, P76, DOI 10.2307/2413310
   BOOKE HE, 1981, CAN J FISH AQUAT SCI, V38, P1479, DOI 10.1139/f81-200
   BOOKSTEIN FL, 1982, ANNU REV ECOL SYST, V13, P451, DOI 10.1146/annurev.es.13.110182.002315
   Bookstein FL, 1985, ACAD NAT SCI PHILADE, V15, P277
   Bookstein FL, 1990, U MICHIGAN MUSEUM ZO, P215
   BRONMARK C, 1992, SCIENCE, V258, P1348, DOI 10.1126/science.258.5086.1348
   BURNABY TP, 1966, BIOMETRICS, V22, P96, DOI 10.2307/2528217
   Cadrin Steven X., 2005, P153, DOI 10.1016/B978-012154351-8/50008-3
   Cadrin SX, 1999, FISH RES, V43, P129, DOI 10.1016/S0165-7836(99)00070-3
   Cadrin SX, 2005, ICES J MAR SCI, V62, P683, DOI 10.1016/j.icesjms.2005.02.006
   Cadrin SX, 2000, REV FISH BIOL FISHER, V10, P91, DOI 10.1023/A:1008939104413
   Cakmak E, 2010, TURK J FISH AQUAT SC, V10, P87, DOI 10.4194/trjfas.2010.0113
   CAMPBELL NA, 1976, AUST J ZOOL, V24, P105, DOI 10.1071/ZO9760105
   CARVALHO GR, 1993, J FISH BIOL, V43, P53, DOI 10.1111/j.1095-8649.1993.tb01179.x
   Cavalcanti MJ, 1999, ZOOL STUD, V38, P287
   Chamarthi S, 2008, MAR GEOD, V31, P160, DOI 10.1080/01490410802265476
   CHEN W-Y, 1989, Journal of the Fisheries Society of Taiwan, V16, P153
   Conover DO, 1998, B MAR SCI, V62, P477
   CORRUCCINI RS, 1983, AM J PHYS ANTHROPOL, V60, P451, DOI 10.1002/ajpa.1330600406
   CORTI M, 1988, CAN J FISH AQUAT SCI, V45, P1548, DOI 10.1139/f88-183
   CREECH S, 1992, J FISH BIOL, V41, P341, DOI 10.1111/j.1095-8649.1992.tb02663.x
   Currens KP, 1989, EVOLUTION, V48, P1723
   Day T, 1996, OECOLOGIA, V108, P380, DOI 10.1007/BF00334665
   DAY T, 1994, EVOLUTION, V48, P1723, DOI 10.1111/j.1558-5646.1994.tb02208.x
   Falconer D. S., 1981, INTRO QUANTITATIVE G
   Ferguson A, 1995, J FISH BIOL, V47, P103, DOI 10.1111/j.1095-8649.1995.tb06048.x
   Fernandez Irene, 1993, Matsya, V15-16, P1
   Gopikrishna G., 2006, Journal of the Marine Biological Association of India, V48, P220
   GOULD SJ, 1966, BIOL REV, V41, P587, DOI 10.1111/j.1469-185X.1966.tb01624.x
   Grimes C. B., 1987, P STOCK ID WORKSH, P186
   GRUDZIEN TA, 1984, EVOLUTION, V38, P402, DOI 10.1111/j.1558-5646.1984.tb00298.x
   Haas TC, 2010, BIOL LETTERS, V6, P803, DOI 10.1098/rsbl.2010.0401
   HADDON M, 1995, MAR BIOL, V123, P19, DOI 10.1007/BF00350319
   Hammer H. D. A. T., 2001, PALAEONTOL ELECTRON, V4, P9, DOI DOI 10.1016/J.BCP.2008.05.025
   Hard JJ, 1995, AM FISH S S, V17, P304
   Hatcher L, 2003, STEP STEP APPROACH U, P57
   Hatfield T, 1997, AM NAT, V149, P1009, DOI 10.1086/286036
   HEDGECOCK D, 1989, FISH B-NOAA, V87, P653
   Hossain MAR, 2010, ZOOL STUD, V49, P556
   Hubbs CL, 1947, CRANBROOK I SCI B, V26, P186
   HUMPHRIES JM, 1981, SYST ZOOL, V30, P291, DOI 10.2307/2413251
   Huxley J. S., 1932, PROBLEMS RELATIVE GR
   Ibanez-Aguirre AL, 2006, SCI MAR, V70, P139, DOI 10.3989/scimar.2006.70n1139
   IHSSEN PE, 1981, CAN J FISH AQUAT SCI, V38, P1838, DOI 10.1139/f81-230
   Imre I, 2002, J FISH BIOL, V61, P1171, DOI 10.1006/jfbi.2002.2131
   Jayasankar P., 2004, Asian Fisheries Science, V17, P201
   Jerry DR, 1998, J FISH BIOL, V52, P829, DOI 10.1006/jfbi.1997.0629
   JOLICOEUR P, 1963, BIOMETRICS, V19, P497, DOI 10.2307/2527939
   Junquera S, 1993, GILCHRIST FISH BIOL, V27, P23
   KINSEY ST, 1994, MAR BIOL, V118, P309, DOI 10.1007/BF00349798
   Klingenberg CP, 1996, NATO ADV SCI INST SE, V284, P23
   Knudsen R, 2007, EVOL ECOL RES, V9, P1005
   KOLLA V, 1976, MAR GEOL, V21, P255, DOI 10.1016/0025-3227(76)90010-4
   Lakra WS, 2010, FISH CHIMES, V30, P102
   Lanyon L.E., 1985, P1
   LANYON LE, 1984, CALCIFIED TISSUE INT, V36, pS56, DOI 10.1007/BF02406134
   LAVIN PA, 1987, CAN J FISH AQUAT SCI, V44, P1820, DOI 10.1139/f87-226
   LEE P J, 1971, Fisheries Research Board of Canada Technical Report, V244, P1
   LINDSEY CC, 1962, CAN J ZOOLOG, V40, P271, DOI 10.1139/z62-028
   Lowe SA, 1998, FISH B-NOAA, V96, P502
   Mamuris Z, 1998, J FISH BIOL, V52, P107, DOI 10.1111/j.1095-8649.1998.tb01556.x
   Marcus LF, 1990, SPECIAL PUBLICATION, V2, P77
   Martin WR, 1949, PUBLICATIONS ONTARIO, V78
   Martin WR, 1949, U TORONTO STUDIES BI, V58
   MCPHAIL JD, 1984, CAN J ZOOL, V62, P1402, DOI 10.1139/z84-201
   MCPHAIL JD, 1992, CAN J ZOOL, V70, P361, DOI 10.1139/z92-054
   MELVIN GD, 1992, CAN J FISH AQUAT SCI, V49, P266, DOI 10.1139/f92-031
   MEYER A, 1987, EVOLUTION, V41, P1357, DOI 10.1111/j.1558-5646.1987.tb02473.x
   MEYER A, 1990, BIOL J LINN SOC, V39, P279, DOI 10.1111/j.1095-8312.1990.tb00517.x
   Misra RK, 1999, FISH RES, V42, P191, DOI 10.1016/S0165-7836(99)00046-6
   Murta AG, 2000, ICES J MAR SCI, V57, P1240, DOI 10.1006/jmsc.2000.0810
   Nishida T., 1992, Fisheries Oceanography, V1, P143, DOI 10.1111/j.1365-2419.1992.tb00033.x
   Omoniyi T, 2007, W AFR J APPL ECOL, V12, P101
   Pakkasmaa S, 2001, BIOL J LINN SOC, V72, P231, DOI 10.1006/bijl.2000.0488
   Peres-Neto PR, 2004, OECOLOGIA, V140, P36, DOI 10.1007/s00442-004-1562-y
   Pimentel R.A., 1979, MORPHOMETRICS MULTIV
   Poulet N, 2005, AQUAT SCI, V67, P122, DOI 10.1007/s00027-004-0772-z
   Proulx R, 2004, EVOL ECOL RES, V6, P503
   Quilang JP, 2007, J APPL ICHTHYOL, V23, P561, DOI 10.1111/j.1439-0426.2007.00862.x
   REIST JD, 1985, CAN J ZOOL, V63, P1429, DOI 10.1139/z85-213
   Reyment R, 1990, U MICHIGAN MUSEUM ZO, V2, P123
   Reyment R. A., 1984, MULTIVARIATE MORPHOM
   Ricker W. E., 1975, FISHERIES RES BOARD, V191, P382
   RIDDELL BE, 1981, CAN J FISH AQUAT SCI, V38, P321, DOI 10.1139/f81-043
   Rincon PA, 2000, MAR BIOL, V136, P715, DOI 10.1007/s002270050731
   ROBINSON BW, 1995, COPEIA, P294
   Robinson BW, 2002, CAN J FISH AQUAT SCI, V59, P1819, DOI 10.1139/F02-144
   ROBINSON BW, 1994, AM NAT, V144, P596, DOI 10.1086/285696
   ROHLF FJ, 1993, TRENDS ECOL EVOL, V8, P129, DOI 10.1016/0169-5347(93)90024-J
   ROHLF FJ, 1987, SYST ZOOL, V36, P356, DOI 10.2307/2413400
   Rohlf FJ, 2006, TPSDIG2 VERSION 2 1
   Royce W, 1957, US FISH WILDLIFE SER, V208, P7
   RYMAN N, 1984, HEREDITY, V53, P687, DOI 10.1038/hdy.1984.127
   Sacotte S, 2006, EVOL ECOL RES, V8, P843
   Saila SB, 1987, P STOCK ID WORKSH, V199, P149
   Saini A, 2008, INTEGR ZOOL, V3, P219, DOI 10.1111/j.1749-4877.2008.00099.x
   Sajina AM, 2011, FISH RES, V108, P100, DOI 10.1016/j.fishres.2010.12.006
   Sarkar UK, 2009, ELECT J ICHTHYOLOGY, V2, P59
   Sarkar UK, 2010, INDIAN J ANIM SCI S1, V80, P85
   SAS Institute Inc, 1990, SAS STAT US GUID VER
   Serajuddin M, 2004, APPL FISH AQUAC, V4, P25
   Sheehan TE, 2005, T AM FISH SOC, V134, P775, DOI 10.1577/T04-067.1
   Shepherd G, 1999, N AM J FISH MANAGE, V11, P139
   SKULASON S, 1993, ANIM BEHAV, V45, P1179, DOI 10.1006/anbe.1993.1140
   Skulason S, 1996, CAN J FISH AQUAT SCI, V53, P1807, DOI 10.1139/cjfas-53-8-1807
   SKULASON S, 1989, BIOL J LINN SOC, V38, P281, DOI 10.1111/j.1095-8312.1989.tb01579.x
   SNORRASON SS, 1994, BIOL J LINN SOC, V52, P1
   SOLOW AR, 1990, ECOLOGY, V71, P2379, DOI 10.2307/1938650
   SPSS, 2011, 10 0 STAT PACK
   STRAUSS RE, 1982, SYST ZOOL, V31, P113, DOI 10.2307/2413032
   STRAUSS RE, 1985, SYST ZOOL, V34, P381, DOI 10.2307/2413203
   SUMANTADINATA K, 1990, NIPPON SUISAN GAKK, V56, P879
   Suneetha Gunawickrama KB, 2007, RUHUNA J SCI, V2, P70
   SURRE C, 1986, CAN J ZOOL, V64, P2430, DOI 10.1139/z86-363
   Swain Douglas P., 2005, P45, DOI 10.1016/B978-012154351-8/50005-8
   Swain DP, 1999, FISH RES, V43, P113, DOI 10.1016/S0165-7836(99)00069-7
   SYSTAT, 2002, SYSTAT WIND VERS 10
   Teissier G, 1960, PHYSL CRUSTACEA, P537
   THORPE RS, 1983, J ZOOL, V199, P421
   TODD TN, 1981, CAN J FISH AQUAT SCI, V38, P59, DOI 10.1139/f81-008
   Trapani J, 2003, J FISH BIOL, V62, P276, DOI 10.1049/j.0022-1112.2003.00006.x
   Turan C, 2005, FOLIA ZOOL, V54, P165
   Turan C, 2004, TURK J VET ANIM SCI, V28, P865
   Turan Cemal, 1999, Turkish Journal of Zoology, V23, P259
   Tzeng TD, 2004, FISH RES, V68, P45, DOI 10.1016/j.fishres.2004.02.011
   WAINWRIGHT PC, 1991, FUNCT ECOL, V5, P40, DOI 10.2307/2389554
   Walsh MG, 2001, ESTUARIES, V24, P41, DOI 10.2307/1352811
   WIMBERGER PH, 1991, EVOLUTION, V45, P1545, DOI 10.1111/j.1558-5646.1991.tb02662.x
   WIMBERGER PH, 1992, BIOL J LINN SOC, V45, P197, DOI 10.1111/j.1095-8312.1992.tb00640.x
   WINANS GA, 1984, CAN J FISH AQUAT SCI, V41, P1150, DOI 10.1139/f84-136
   Winans GA, 1987, P STOCK ID WORKSH, V199, P135
   WITTE F, 1990, NETH J ZOOL, V40, P278
   ZELDITCH ML, 1992, EVOLUTION, V46, P1164, DOI 10.1111/j.1558-5646.1992.tb00626.x
NR 140
TC 6
Z9 8
U1 6
U2 66
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0960-3166
EI 1573-5184
J9 REV FISH BIOL FISHER
JI Rev. Fish. Biol. Fish.
PD MAR
PY 2013
VL 23
IS 1
BP 23
EP 39
DI 10.1007/s11160-012-9279-1
PG 17
WC Fisheries; Marine & Freshwater Biology
SC Fisheries; Marine & Freshwater Biology
GA 092AF
UT WOS:000315090500002
DA 2018-12-27
ER

PT J
AU Chen, CW
   Chang, ML
   Tseng, CP
   Chen, BC
   Chang, YYC
AF Chen, Cheng-Wu
   Chang, Min-Li
   Tseng, Chun-Pin
   Chen, Bo-Chen
   Chang, Yevvon Yi-Chi
TI RETRACTED: Critical Human Factor Evaluation of Knowledge Sharing
   Intention in Taiwanese Enterprises (Retracted article. See vol. 26, pg.
   290, 2016)
SO HUMAN FACTORS AND ERGONOMICS IN MANUFACTURING & SERVICE INDUSTRIES
LA English
DT Article; Retracted Publication
DE Knowledge management (KM); Knowledge sharing; Human factor; Taiwanese
   enterprises; Small and medium enterprises (SMEs)
ID MANAGEMENT-SYSTEMS; COMMUNITIES; PERFORMANCE; STICKINESS; TRUST; FIRM
AB Knowledge management (KM) is important in the Taiwan business world. Only 0.1% of SMEs, however, have been guided by the Small and Medium Enterprise Administration (SMEA) to introduce knowledge management from 1993 through 2008. The population of KM-implementing SMEs is low. The climate of knowledge sharing has been recognized as the critical factor to successful KM. According to the research results obtained in this study, relation-based motivation is positively related to one's intention to share knowledge. Individual workers can have increased relation-based motivation to become leaders of SMEs building the culture of interpersonal trust and offering group-based reward mechanisms in an organization. This research can help business managers to identify the motivational elements that can encourage investment and propose pragmatic suggestions for introducing initiatives to reinvigorate the number of SMEs implementing KM in Taiwan. (c) 2012 Wiley Periodicals, Inc.
C1 [Chen, Cheng-Wu] Natl Kaohsiung Marine Univ, Inst Maritime Informat & Technol, Kaohsiung, Taiwan.
   [Chang, Min-Li] Univ Maryland, Univ Coll, College Pk, MD 20742 USA.
   [Tseng, Chun-Pin] Armaments Bur, Chung Shan Inst Sci & Technol, Tao Yuan, Taiwan.
   [Chen, Bo-Chen; Chang, Yevvon Yi-Chi] Tunghai Univ, Dept Hospitality Management, Taichung 40704, Taiwan.
RP Chen, CW (reprint author), Natl Kaohsiung Marine Univ, Inst Maritime Informat & Technol, Kaohsiung 80543, Taiwan.
EM chengwu@mail.nkmu.edu.tw
FU National Science Council of Taiwan, R.O.C. [NSC 100-2221-E-022-013-MY2,
   NSC 100-2628-E-022-002-MY2]
FX This work was supported by the National Science Council of Taiwan,
   R.O.C., under project number NSC 100-2221-E-022-013-MY2 and NSC
   100-2628-E-022-002-MY2. We thank Waldemar Karwowski, Editor-in-Chief of
   Human Factors and Ergonomics in Manufacturing & Service Industries, and
   we are grateful for the constructive suggestions of the anonymous
   reviewers, all of which led to the making of corrections that have
   greatly aided us in the publication of this article.
CR Alavi M, 2001, MIS QUART, V25, P107, DOI 10.2307/3250961
   Anantatmula V. S., 2008, J INFORM KNOWLEDGE M, V38, P445
   Anitesh B., 1997, J INF SCI, V23, P239
   [Anonymous], 2009, WHITE PAPER SMALL ME
   BOLAND RJ, 1995, ORGAN SCI, V6, P350, DOI 10.1287/orsc.6.4.350
   Borgatti SP, 2003, MANAGE SCI, V49, P432, DOI 10.1287/mnsc.49.4.432.14428
   Bowman BJ, 2002, INFORM SYST MANAGE, V19, P32, DOI 10.1201/1078/43201.19.3.20020601/37168.5
   Burgess D., 2005, Journal of Business Communication, V42, P324, DOI 10.1177/0021943605279485
   Burt RS, 1997, ADMIN SCI QUART, V42, P339, DOI 10.2307/2393923
   Butler JK, 1999, GROUP ORGAN MANAGE, V24, P217, DOI 10.1177/1059601199242005
   Cabrera A, 2002, ORGAN STUD, V23, P687, DOI 10.1177/0170840602235001
   Chan I., 2006, KNOWLEDGE MANAGEMENT, V9, P8
   Chen C.W., 2011, HUMAN FACTORS ERGONO, V22
   Chen C.W., 2011, HUMAN FACTORS UNPUB
   Choi B, 2003, INFORM MANAGE-AMSTER, V40, P403, DOI 10.1016/S0378-7206(02)00060-5
   Choi SY, 2008, J INF SCI, V34, P742, DOI 10.1177/0165551507087710
   Clark BH, 2005, J STRATEG MARK, V13, P241, DOI 10.1080/09652540500338014
   Desouza K. C., 2006, Journal of Knowledge Management, V10, P32, DOI 10.1108/13673270610650085
   DeVellis R.F, 1998, SCALE DEV THEORY APP
   Grant RM, 1996, STRATEGIC MANAGE J, V17, P109, DOI 10.1002/smj.4250171110
   Gupta AK, 2000, SLOAN MANAGE REV, V42, P71
   Gupta KS, 2008, KNOWL PROCESS MANAG, V15, P186, DOI 10.1002/kpm.309
   Huysman M, 2006, J INF TECHNOL, V21, P40, DOI 10.1057/palgrave.jit.2000053
   Lee J.H., 2006, INFORM RESOURCES MAN, V19, P48, DOI DOI 10.4018/IRMJ
   Lesser EL, 2001, IBM SYST J, V40, P831, DOI 10.1147/sj.404.0831
   Nahapiet J, 1998, ACAD MANAGE REV, V23, P242, DOI 10.2307/259373
   O'Dell C, 1998, CALIF MANAGE REV, V40, P154, DOI 10.2307/41165948
   Politis J. D., 2003, Journal of Knowledge Management, V7, P55, DOI 10.1108/13673270310505386
   Reid F., 2003, EMPLOYMENT RELATIONS, V30, P43, DOI DOI 10.1002/ERT.10097
   Roth A. V., 1994, STRATEGY LEADERSHIP, V22, P26
   Rothschild ML, 1999, J MARKETING, V63, P24, DOI 10.2307/1251972
   Saunders M., 2007, RES METHODS BUSINESS
   Siemsen E, 2008, J OPER MANAG, V26, P426, DOI 10.1016/j.jom.2007.09.001
   Siemsen E, 2007, MANAGE SCI, V53, P1533, DOI 10.1287/mnsc.1070.0714
   Srivastava A., 2002, J LEADERSH ORG STUD, V9, P64, DOI [10.1177/107179190200900105, DOI 10.1177/107179190200900105]
   Staples DS, 2008, INFORM SYST J, V18, P617, DOI 10.1111/j.1365-2575.2007.00244.x
   Su C.-J., 2007, J GLOBAL BUSINESS TE, V3, P1
   Szulanski G, 1996, STRATEGIC MANAGE J, V17, P27, DOI 10.1002/smj.4250171105
   Szulanski G, 2000, ORGAN BEHAV HUM DEC, V82, P9, DOI 10.1006/obhd.2000.2884
   Szulanski G, 2004, ORGAN SCI, V15, P600, DOI 10.1287/orsc.1040.0096
   Walker G, 1997, ORGAN SCI, V8, P109, DOI 10.1287/orsc.8.2.109
   Wasko MM, 2000, J STRATEGIC INF SYST, V9, P155
   Widen-Wulff G, 2007, INF RESOUR MANAG J, V20, P46, DOI 10.4018/irmj.2007010104
   Yu S. H, 2007, J KNOWLEDGE MANAGEME, V11, P39
NR 44
TC 36
Z9 37
U1 3
U2 78
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1090-8471
EI 1520-6564
J9 HUM FACTOR ERGON MAN
JI Hum. Factors Ergonom. Manuf. Serv. Ind.
PD MAR-APR
PY 2013
VL 23
IS 2
BP 95
EP 106
DI 10.1002/hfm.20300
PG 12
WC Engineering, Manufacturing; Ergonomics
SC Engineering
GA 089PA
UT WOS:000314921300003
DA 2018-12-27
ER

PT J
AU Goldust, M
   Talebi, M
   Majidi, J
   Saatlou, MAR
   Rezaee, E
AF Goldust, Mohamad
   Talebi, Mahnaz
   Majidi, Jafar
   Saatlou, Mohammad Amin Rezazadeh
   Rezaee, Elham
TI RETRACTED: Evaluation of Antiphospholipid Antibodies in Youths Suffering
   from Cerebral Ischemia (Retracted article. See vol. 123, pg. 597, 2013)
SO INTERNATIONAL JOURNAL OF NEUROSCIENCE
LA English
DT Article; Retracted Publication
DE anticardiolipin; antiphospholipid antibodies (APA); cerebral stroke
ID ANTICARDIOLIPIN ANTIBODIES; YOUNG-PATIENTS; LUPUS ANTICOAGULANT; STROKE;
   PATIENT; CIRCULATION; DISORDERS; EVENTS
AB Objective: Cerebral stroke in young adults is not uncommon. Venous thromboses resulting from antiphospholipid antibodies (APAs) are one of causes of stroke in youths. This study aimed at evaluating the role of APAs in young patients with ischemic strokes. Methods: In this case-control study, 25 patients with diagnosis of ischemic stroke or transient ischemia attack in case group and 40 patients in control group were studied during one year. Medical history was obtained from all the patients. Levels of anticardiolipin and antiphospholipid antibodies including both IgG and IgM, were evaluated in all patients before consuming warfarin and using ELISA method. Results: Antiphospholipid antibodies or anticardiolipin antibody was high in six (24%) patients. In the control group, only two subjects had abnormally increased amounts of at least one antibody. The difference was significant between the case and control groups (P < .05). The study demonstrated that history of at least one cerebral ischemic event was observed in two out of 6 patients (33.3%) with high APAs and two out of 19 patients (10.5%) without higher APAs. Conclusion: APAs increase risk of ischemic strokes independently or in association with other vascular risk factors.
C1 [Goldust, Mohamad] Tabriz Univ Med Sci, Student Res Comm, Tabriz, Iran.
   [Talebi, Mahnaz] Tabriz Univ Med Sci, Dept Neurol, Tabriz, Iran.
   [Majidi, Jafar] Tabriz Univ Med Sci, Dept Immunol, Tabriz, Iran.
   [Saatlou, Mohammad Amin Rezazadeh] Tabriz Univ Med Sci, Tabriz, Iran.
   [Rezaee, Elham] Shahid Beheshti Univ Med Sci, Dept Med Chem, Tehran, Iran.
RP Goldust, M (reprint author), Tabriz Univ Med Sci, Student Res Comm, Tabriz, Iran.
EM Drmgoldust@yahoo.com
CR Carhuapoma J R, 1999, J Stroke Cerebrovasc Dis, V8, P51, DOI 10.1016/S1052-3057(99)80054-8
   Cimaz R, 2008, LUPUS, V17, P777, DOI 10.1177/0961203308094362
   Ciubotaru CR, 2002, JCR-J CLIN RHEUMATOL, V8, P332, DOI 10.1097/00124743-200212000-00010
   Gupta PK, 2007, J THROMB THROMBOLYS, V23, P241, DOI 10.1007/s11239-006-9041-4
   Heil JW, 2008, J CHILD NEUROL, V23, P1049, DOI 10.1177/0883073808319076
   HESS DC, 1993, J RHEUMATOL, V20, P610
   Hughes G R, 1984, Contrib Nephrol, V43, P9
   Kalashnikova LA, 1997, ZH NEVROPATOL PSIKH, V97, P59
   Kalashnikova LA, 1998, TERAPEVT ARKH, V70, P48
   KUSHNER M, 1989, STROKE, V20, P225, DOI 10.1161/01.STR.20.2.225
   Legierse CM, 2008, EUR J DERMATOL, V18, P322, DOI 10.1684/ejd.2008.0397
   Levine SR, 1996, LUPUS, V5, P347, DOI 10.1177/096120339600500503
   Lonnebakken Mai Tone, 2008, Eur J Echocardiogr, V9, P192, DOI 10.1093/ejechocard/jem067
   Muscal E, 2010, LUPUS, V19, P406, DOI 10.1177/0961203309360808
   NENCINI P, 1992, STROKE, V23, P189, DOI 10.1161/01.STR.23.2.189
   Ortiz GA, 2011, ARCH NEUROL-CHICAGO, V68, P1587, DOI 10.1001/archneurol.2011.838
   Patrignani A, 2009, G ITAL CARDIOL, V10, P259, DOI 10.1714/585.6913
   Rahemtullah A, 2007, ARCH PATHOL LAB MED, V131, P890
   Svenungsson E, 2010, ANN RHEUM DIS, V5, P840
   Tietjen GE, 1998, NEUROLOGY, V50, P1433, DOI 10.1212/WNL.50.5.1433
   TRIMBLE M, 1990, AM J MED, V88, P593, DOI 10.1016/0002-9343(90)90523-G
   Urbanus RT, 2009, LANCET NEUROL, V8, P998, DOI 10.1016/S1474-4422(09)70239-X
   van Goor MPJ, 2004, ACTA NEUROL SCAND, V109, P410, DOI 10.1111/j.1600-0404.2004.00241.x
   Verro P, 1998, STROKE, V29, P2245, DOI 10.1161/01.STR.29.11.2245
   Wani AM, 2010, BMJ CASE REP, V2010
NR 25
TC 1
Z9 4
U1 3
U2 11
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0020-7454
EI 1563-5279
J9 INT J NEUROSCI
JI Int. J. Neurosci.
PD MAR
PY 2013
VL 123
IS 3
BP 209
EP 212
DI 10.3109/00207454.2012.749256
PG 4
WC Neurosciences
SC Neurosciences & Neurology
GA 089GE
UT WOS:000314898000010
PM 23231732
DA 2018-12-27
ER

PT J
AU Zhang, YT
   Dong, X
   Li, GX
   Li, WC
   Zhang, BL
   Du, GT
AF Zhang, Yuantao
   Dong, Xin
   Li, Guoxing
   Li, Wancheng
   Zhang, Baolin
   Du, Guotong
TI RETRACTED: High quality N-polar GaN two-dimensional growth on c-plane
   sapphire by metalorganic vapor phase epitaxy (Retracted article. See
   vol. 503, pg. 65, 2018)
SO JOURNAL OF CRYSTAL GROWTH
LA English
DT Article; Retracted Publication
DE Morphology; X-ray diffraction; Metalorganic vapor phase epitaxy;
   Semiconducting gallium nitride
ID NUCLEATION LAYER; FACE; HETEROSTRUCTURES; DEPOSITION
AB We report the growth of atomically smooth N-polar GaN on c-plane sapphire by metalorganic vapor phase epitaxy. A two-step growth technique was adopted; low-temperature growth of GaN buffer before high-temperature GaN growth. The complete two-dimensional N-polar GaN growth process was recorded by in situ reflectance. The phase composition of the low-temperature GaN was examined by X-ray diffraction pole figure measurements. The thickness of the low-temperature GaN buffer dramatically affected the crystalline and electronic properties of the N-polar GaN. A very small full width at half maximum for the (0 0 0 2) X-ray rocking curve, 51 arcs, was obtained for 700-nm-thick N-polarity GaN by optimizing the buffer thickness. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Zhang, Yuantao; Dong, Xin; Li, Guoxing; Li, Wancheng; Zhang, Baolin; Du, Guotong] Jilin Univ, Coll Elect Sci & Engn, State Key Lab Integrated Optoelect, Changchun 130012, Peoples R China.
RP Zhang, YT (reprint author), Jilin Univ, Coll Elect Sci & Engn, State Key Lab Integrated Optoelect, Changchun 130012, Peoples R China.
EM zhangyt@j1u.edu.cn
FU National Natural Science Foundation of China [61106003]
FX This research is supported by National Natural Science Foundation of
   China (No. 61106003).
CR Aleksov A, 2006, APPL PHYS LETT, V89, DOI 10.1063/1.2244046
   Ambacher O, 1999, J APPL PHYS, V85, P3222, DOI 10.1063/1.369664
   Chowdhury A, 2003, APPL PHYS LETT, V83, P1077, DOI 10.1063/1.1599044
   Keller S, 2008, J APPL PHYS, V103, DOI 10.1063/1.2838214
   Keller S, 2007, APPL PHYS LETT, V90, DOI 10.1063/1.2738381
   Keller S, 2006, JPN J APPL PHYS 2, V45, pL322, DOI 10.1143/JJAP.45.L322
   Narayan J, 2006, J APPL PHYS, V99, DOI 10.1063/1.2178660
   Ng HM, 2003, JPN J APPL PHYS 2, V42, pL1405, DOI 10.1143/JJAP.42.L1405
   Ng HM, 2003, J APPL PHYS, V94, P650, DOI 10.1063/1.1582233
   Sumiya M, 2000, J APPL PHYS, V88, P1158, DOI 10.1063/1.373791
   Sun Q, 2008, APPL PHYS LETT, V93, DOI 10.1063/1.2993333
   Sun Q, 2009, J CRYST GROWTH, V311, P2948, DOI 10.1016/j.jcrysgro.2009.01.059
   Wu XH, 1996, APPL PHYS LETT, V68, P1371, DOI 10.1063/1.116083
   Xu K, 2003, APPL PHYS LETT, V83, P251, DOI 10.1063/1.1592309
NR 14
TC 2
Z9 2
U1 6
U2 87
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0022-0248
EI 1873-5002
J9 J CRYST GROWTH
JI J. Cryst. Growth
PD MAR 1
PY 2013
VL 366
BP 35
EP 38
DI 10.1016/j.jcrysgro.2012.12.030
PG 4
WC Crystallography; Materials Science, Multidisciplinary; Physics, Applied
SC Crystallography; Materials Science; Physics
GA 088HN
UT WOS:000314824800007
DA 2018-12-27
ER

PT J
AU Bardaweel, HK
   Zamuruyev, K
   Delplanque, JP
   Davis, CE
AF Bardaweel, Hamzeh K.
   Zamuruyev, Konstantin
   Delplanque, Jean-Pierre
   Davis, Cristina E.
TI RETRACTED: Wettability-gradient-driven micropump for transporting
   discrete liquid drops (Retracted article. See vol. 23, pg. 069701, 2013)
SO JOURNAL OF MICROMECHANICS AND MICROENGINEERING
LA English
DT Article; Retracted Publication
ID SUPER-HYDROPHOBIC SURFACES; SUPERHYDROPHOBIC SURFACE; DRUG-DELIVERY;
   SOLID-SURFACE; WATER; CONDENSATION; MOTION; SYSTEMS
AB In this paper, we report our efforts toward building a microelectromechanical system-based micropump. The micropump is driven by a wettability gradient and used to transport discrete drops. The gradient in wettability is distributed axisymmetrically, with hydrophobicity of the micropump surface decreasing radially toward the center. Both physical and chemical properties of the surface are altered to obtain the wettability gradient needed for driving the drops. The surface of the micropump is, first, patterned with pre-designed micro-features that define the roughness of the surface and, then, coated with a low-energy interface film. Results show that drops deposited on the surface of the micropump move, in a directional way, along the wettability gradient. The average velocity of the deposited drops is 5 mm s(-1). Measured contact angles decrease gradually from 157.0 degrees to 124.2 degrees toward the center of the micropump surface. Maximum driving force exerted by the solid surface on the drops is 12.82 mu N. The average size of the drops transported on the surface of the micropump is 2 mu L.
C1 [Bardaweel, Hamzeh K.] Univ Jordan, Fac Engn, Dept Mech Engn, Amman 11942, Jordan.
   [Zamuruyev, Konstantin; Delplanque, Jean-Pierre; Davis, Cristina E.] Univ Calif Davis, Dept Mech & Aerosp Engn, Davis, CA 95616 USA.
RP Davis, CE (reprint author), Univ Calif Davis, Dept Mech & Aerosp Engn, 1 Shields Ave, Davis, CA 95616 USA.
EM cedavis@ucdavis.edu
RI Davis, Cristina/C-4437-2008
OI Delplanque, Jean-Pierre/0000-0003-1774-1641
CR Callies M, 2005, SOFT MATTER, V1, P55, DOI 10.1039/b501657f
   CASSIE ABD, 1948, DISCUSS FARADAY SOC, V3, P11, DOI 10.1039/df9480300011
   CHAUDHURY MK, 1992, SCIENCE, V256, P1539, DOI 10.1126/science.256.5063.1539
   Cheng YT, 2005, APPL PHYS LETT, V87, DOI 10.1063/1.2130392
   Dorrer C, 2009, SOFT MATTER, V5, P51, DOI 10.1039/b811945g
   Fang GP, 2008, LANGMUIR, V24, P11651, DOI 10.1021/la802033q
   Hong X, 2007, J AM CHEM SOC, V129, P1478, DOI 10.1021/ja065537c
   Khoo H. S., 2006, INT C MICR MED BIOL, P273
   Kricka LJ, 2001, CLIN CHIM ACTA, V307, P219, DOI 10.1016/S0009-8981(01)00451-X
   Lau KKS, 2003, NANO LETT, V3, P1701, DOI 10.1021/nl034704t
   Leung YF, 2001, BIOTECHNIQUES, V30, P334, DOI 10.2144/01302tt02
   MANZ A, 1990, SENSOR ACTUAT B-CHEM, V1, P244, DOI 10.1016/0925-4005(90)80209-I
   Moumen N, 2006, LANGMUIR, V22, P2682, DOI 10.1021/la053060x
   Narhe RD, 2006, EUROPHYS LETT, V75, P98, DOI 10.1209/epl/i2006-10069-9
   Nisar A, 2008, SENSOR ACTUAT B-CHEM, V130, P917, DOI 10.1016/j.snb.2007.10.064
   Subramanian RS, 2005, LANGMUIR, V21, P11844, DOI 10.1021/la051943i
   Tsai NC, 2007, SENSOR ACTUAT A-PHYS, V134, P555, DOI 10.1016/j.sna.2006.06.014
   Varanasi KK, 2009, APPL PHYS LETT, V95, DOI 10.1063/1.3200951
   WENZEL RN, 1949, J PHYS COLLOID CHEM, V53, P1466, DOI 10.1021/j150474a015
   Wier KA, 2006, LANGMUIR, V22, P2433, DOI 10.1021/la0525877
   Woias P, 2005, SENSOR ACTUAT B-CHEM, V105, P28, DOI 10.1016/j.snb.2004.02.033
   Woodward I, 2003, LANGMUIR, V19, P3432, DOI 10.1021/la020427e
   Woodward IS, 2006, PLASMA CHEM PLASMA P, V26, P507, DOI 10.1007/s11090-006-9032-4
   Yang JT, 2006, J MICROELECTROMECH S, V15, P697, DOI 10.1109/JMEMS.2006.876791
   Zhu L, 2006, SENSOR ACTUAT A-PHYS, V130, P595, DOI 10.1016/j.sna.2005.12.005
NR 25
TC 6
Z9 7
U1 4
U2 70
PU IOP PUBLISHING LTD
PI BRISTOL
PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND
SN 0960-1317
J9 J MICROMECH MICROENG
JI J. Micromech. Microeng.
PD MAR
PY 2013
VL 23
IS 3
AR 035036
DI 10.1088/0960-1317/23/3/035036
PG 7
WC Engineering, Electrical & Electronic; Nanoscience & Nanotechnology;
   Instruments & Instrumentation; Physics, Applied
SC Engineering; Science & Technology - Other Topics; Instruments &
   Instrumentation; Physics
GA 088EO
UT WOS:000314816800037
DA 2018-12-27
ER

PT J
AU Zhang, W
   Du, Y
   Bai, M
   Xi, Y
   Li, ZY
   Miao, JT
AF Zhang, Wei
   Du, Ying
   Bai, Miao
   Xi, Ye
   Li, Zhuyi
   Miao, Jianting
TI RETRACTED: S14G-humanin inhibits A beta 1-42 fibril formation,
   disaggregates preformed fibrils, and protects against A beta-induced
   cytotoxicity in vitro (Retracted article. See vol. 22, pg. 434, 2016)
SO JOURNAL OF PEPTIDE SCIENCE
LA English
DT Article; Retracted Publication
DE Alzheimer's disease; amyloid-beta protein; S14G-humanin; Thioflavin T;
   electron microscopy; cytotoxicity
ID AMYLOID-BETA-PROTEIN; NEURONAL CELL-DEATH; SMALL-MOLECULE INHIBITORS;
   ALZHEIMERS-DISEASE; A-BETA; RESCUE FACTOR; NEUROPROTECTIVE FACTOR;
   THERAPEUTIC TARGET; IN-VIVO; HUMANIN
AB The aggregation of soluble amyloid-beta (A) peptide into oligomers/fibrils is one of the key pathological features in Alzheimer's disease (AD). The A aggregates are considered to play a pivotal role in the pathogenesis of AD. Therefore, inhibiting A aggregation and destabilizing preformed A fibrils would be an attractive therapeutic target for prevention and treatment of AD. S14G-humanin (HNG), a synthetic derivative of Humanin (HN), has been shown to be a strong neuroprotective agent against various AD-related insults. Recent studies have shown that HNG can significantly improve cognitive deficits and reduce insoluble A levels as well as amyloid plaque burden without affecting amyloid precursor protein processing and A production in transgenic AD models. However, the potential mechanisms by which HNG reduces A-related pathology in vivo remain obscure. In the present study, we found that HNG could significantly inhibit monomeric A142 aggregation into fibrils and destabilize preformed A142 fibrils in a concentration-dependent manner by Thioflavin T fluorescence assay. In transmission electron microscope study, we observed that HNG was effective in inhibiting A142 fibril formation and disrupting preformed A142 fibrils, exhibiting various types of amorphous aggregates without identifiable A fibrils. Furthermore, HNG-treated monomeric or fibrillar A142 was found to significantly reduce A142-mediated cytotoxic effects on PC12 cells in a dose-dependent manner by MTT assay. Collectively, our results demonstrate for the first time that HNG not only inhibits A142 fibril formation but also disaggregates preformed A142 fibrils, which provides the novel evidence that HNG may have anti-A aggregation and fibrillogenesis, and fibril-destabilizing properties. Together with previous studies, we concluded that HNG may have promising therapeutic potential as a multitarget agent for the prevention and/or treatment of AD. Copyright (c) 2013 European Peptide Society and John Wiley & Sons, Ltd.
C1 [Zhang, Wei; Du, Ying; Bai, Miao; Xi, Ye; Li, Zhuyi; Miao, Jianting] Fourth Mil Med Univ, Dept Neurol, Tangdu Hosp, Xian 710038, Shaanxi Provinc, Peoples R China.
   [Du, Ying; Bai, Miao; Xi, Ye; Li, Zhuyi] Fourth Mil Med Univ, Inst Funct Brain Disorders, Tangdu Hosp, Xian 710038, Shaanxi Provinc, Peoples R China.
RP Miao, JT (reprint author), Fourth Mil Med Univ, Dept Neurol, Tangdu Hosp, Xian 710038, Shaanxi Provinc, Peoples R China.
EM lizhuyi@fmmu.edu.cn; jtmiao@fmmu.edu.cn
FU National Natural Science Foundation of China [81271193, 30870842,
   30801215]
FX This work was financially supported by the research grants from the
   National Natural Science Foundation of China (81271193, 30870842, and
   30801215). We are very grateful to Dr Gonghao He (Department of
   Pharmacology, Fourth Military Medical University, China) for his
   excellent technical assistance and Dr Changsheng Chen (Department of
   Medical Statistics, Fourth Military Medical University, China) for his
   expert technical assistance in statistical analyses.
CR Abramowski D, 2012, J NEUROSCI, V32, P1273, DOI 10.1523/JNEUROSCI.4586-11.2012
   Arakawa T, 2008, CURR MED CHEM, V15, P2086, DOI 10.2174/092986708785747616
   Benaki D, 2006, BIOCHEM BIOPH RES CO, V349, P634, DOI 10.1016/j.bbrc.2006.08.087
   DaSilva KA, 2010, EXP NEUROL, V223, P311, DOI 10.1016/j.expneurol.2009.08.032
   Datki Z, 2003, BRAIN RES BULL, V62, P223, DOI 10.1016/j.brainresbull.2003.09.011
   Durairajan SSK, 2008, NEUROCHEM INT, V52, P741, DOI 10.1016/j.neuint.2007.09.006
   Estrada LD, 2007, CURR TOP MED CHEM, V7, P115, DOI 10.2174/156802607779318262
   Frisardi V, 2010, CURR ALZHEIMER RES, V7, P40, DOI 10.2174/156720510790274400
   Galimberti D, 2011, CNS NEUROL DISORD-DR, V10, P163, DOI 10.2174/187152711794480438
   Giovanna C, 2010, AMINO ACIDS, V38, P1101, DOI 10.1007/s00726-009-0319-7
   Guo F, 2010, SYNAPSE, V64, P83, DOI 10.1002/syn.20707
   Hao JA, 2010, NEUROPEPTIDES, V44, P305, DOI 10.1016/j.npep.2010.03.001
   Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994
   Hashimoto Y, 2001, P NATL ACAD SCI USA, V98, P6336, DOI 10.1073/pnas.101133498
   Hirohata M, 2012, BBA-MOL BASIS DIS, V1822, P1316, DOI 10.1016/j.bbadis.2012.05.006
   Jana A, 2010, J NEUROSCI, V30, P12676, DOI 10.1523/JNEUROSCI.1243-10.2010
   KIRSCHNER DA, 1986, P NATL ACAD SCI USA, V83, P503, DOI 10.1073/pnas.83.2.503
   Kunesova G, 2008, PEPTIDES, V29, P1982, DOI 10.1016/j.peptides.2008.06.019
   Levine H, 2007, AMYLOID, V14, P185, DOI 10.1080/13506120701461020
   Lleo A, 2006, ANNU REV MED, V57, P513, DOI 10.1146/annurev.med.57.121304.131442
   Maftei M, 2012, J PEPT SCI, V18, P373, DOI 10.1002/psc.2404
   McShane R, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003154.pub5
   Miao JT, 2008, NEUROPEPTIDES, V42, P557, DOI 10.1016/j.npep.2008.08.004
   Naito A, 2007, BBA-BIOMEMBRANES, V1768, P1900, DOI 10.1016/j.bbamem.2007.03.025
   Nath S, 2012, J NEUROSCI, V32, P8767, DOI 10.1523/JNEUROSCI.0615-12.2012
   Nie Q, 2011, ACTA PHARMACOL SIN, V32, P545, DOI 10.1038/aps.2011.14
   Niikura T, 2006, CURR NEUROPHARMACOL, V4, P139, DOI 10.2174/157015906776359577
   Niikura T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016259
   Nishimoto I, 2004, TRENDS MOL MED, V10, P102, DOI 10.1016/j.molmed.2004.01.001
   Ohyagi Y, 2008, CURR ALZHEIMER RES, V5, P555, DOI 10.2174/156720508786898514
   Picone P, 2009, BIOPHYS J, V96, P4200, DOI 10.1016/j.bpj.2008.11.056
   Querfurth HW, 2010, NEW ENGL J MED, V362, P329, DOI 10.1056/NEJMra0909142
   Re F, 2010, CURR MED CHEM, V17, P2990, DOI 10.2174/092986710791959729
   Sadowski MJ, 2006, P NATL ACAD SCI USA, V103, P18787, DOI 10.1073/pnas.0604011103
   Seltzer B, 2006, J INT MED RES, V34, P339, DOI 10.1177/147323000603400401
   Smith M, 2006, ALZ DIS ASSOC DIS, V20, P133, DOI 10.1097/00002093-200607000-00002
   St George-Hyslop PH, 2005, CR BIOL, V328, P119, DOI 10.1016/j.crvi.2004.10.013
   Stromer T, 2005, MICROSC RES TECHNIQ, V67, P210, DOI 10.1002/jemt.20190
   Tajima H, 2005, J NEUROSCI RES, V79, P714, DOI 10.1002/jnr.20391
   Tanzi RE, 2005, CELL, V120, P545, DOI 10.1016/j.cell.2005.02.008
   Tomic JL, 2009, NEUROBIOL DIS, V35, P352, DOI 10.1016/j.nbd.2009.05.024
   van Marum RJ, 2008, FUND CLIN PHARMACOL, V22, P265, DOI 10.1111/j.1472-8206.2008.00578.x
   Walsh DM, 2007, J NEUROCHEM, V101, P1172, DOI 10.1111/j.1471-4159.2006.04426.x
   Wang MS, 2010, BIOTECHNOL PROGR, V26, P1172, DOI 10.1002/btpr.396
   Yamin G, 2008, CURR PHARM DESIGN, V14, P3231, DOI 10.2174/138161208786404137
   Yoshiike Y, 2001, J BIOL CHEM, V276, P32293, DOI 10.1074/jbc.M010706200
   Zapala B, 2010, PHARMACOL REP, V62, P767, DOI 10.1016/S1734-1140(10)70337-6
   Zhang W, 2011, PHARM BIOCH BEHAV, V100, P361
   Zhang W, 2009, PEPTIDES, V30, P1197, DOI 10.1016/j.peptides.2009.02.017
   Zou P, 2003, PEPTIDES, V24, P679, DOI 10.1016/S0196-9781(03)00131-1
NR 50
TC 12
Z9 12
U1 4
U2 26
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1075-2617
EI 1099-1387
J9 J PEPT SCI
JI J. Pept. Sci.
PD MAR
PY 2013
VL 19
IS 3
BP 159
EP 165
DI 10.1002/psc.2484
PG 7
WC Biochemistry & Molecular Biology; Chemistry, Analytical
SC Biochemistry & Molecular Biology; Chemistry
GA 092ED
UT WOS:000315101100004
PM 23349038
DA 2018-12-27
ER

PT J
AU Abraham, CZ
   Lioupis, C
AF Abraham, Cherrie Z.
   Lioupis, Christos
TI RETRACTED: Treatment of aortic arch aneurysms with a modular
   transfemoral multibranched stent-graft: Initial experience (Retracted
   article. See vol. 146, pg. 737, 2013)
SO JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY
LA English
DT Article; Proceedings Paper; Retracted Publication
CT Aortic Surgery Symposium of the
   American-Association-for-Thoracic-Surgery (AATS)
CY APR 26-27, 2012
CL New York, NY
SP Amer Assoc Thorac Surg
ID A DISSECTION; REPAIR; FENESTRATION; RECONSTRUCTION; PLACEMENT; ARTERY
AB Objective: To present an initial experience with a new modular transfemoral multibranched stent-graft for treating aortic arch aneurysms.
   Methods: Six patients, considered high risk for open surgery, were treated with a custom-made branched stent-graft. Two patients had aortic arch aneurysms, three had descending thoracic aortic aneurysms involving the distal arch, and one had a saccular aneurysm of the arch adjacent to the origin of the innominate artery. All patients had undergone a staged left carotid subclavian bypass before the endovascular procedure. Each branched graft had a 12-mm side branch for the innominate artery and an 8-mm side branch for the left common carotid artery. The branches were extended into their respective target arteries with covered self-expanding stents.
   Results: Aneurysm exclusion without endoleak was successful in 5 of the 6 patients, and 11 of the 12 target vessels were successfully cannulated and preserved. Patient 1 developed a type I endoleak that was managed successfully with coiling and gluing of the aneurysm sac. Patients 2, 3, 5, and 6 had uneventful placement of the prostheses, with successful exclusion of the aneurysm sac. In patient 4, cannulation of the innominate branch was unsuccessful, and an extra-anatomic bypass was necessary to perfuse the right carotid and vertebral arteries.
   Conclusions: We have demonstrated the technical feasibility of a modular transfemoral branched stent-graft for treatment of aortic arch aneurysms. Our initial experience has shown that the method is relatively safe. Longterm follow-up is necessary to evaluate the efficacy and safety of this new device. (J Thorac Cardiovasc Surg 2013;145:S110-7)
C1 [Abraham, Cherrie Z.; Lioupis, Christos] McGill Univ, Jewish Gen Hosp, Dept Surg, Div Vasc Surg, Montreal, PQ H3T 1E2, Canada.
RP Abraham, CZ (reprint author), McGill Univ, Jewish Gen Hosp, Dept Surg, Div Vasc Surg, Pavilion E110,3755 Cote Ste Catherine, Montreal, PQ H3T 1E2, Canada.
EM cherriezack@gmail.com
CR Anderson JL, 2005, J VASC SURG, V42, P600, DOI 10.1016/j.jvs.2005.05.063
   Anderson JL, 2001, J ENDOVASC THER, V8, P3, DOI 10.1583/1545-1550(2001)008<0003:EAGWRA>2.0.CO;2
   Antoniou GA, 2010, EUR J VASC ENDOVASC, V39, P683, DOI 10.1016/j.ejvs.2010.02.002
   Appoo JJ, 2006, J CARDIOTHOR VASC AN, V20, P3, DOI 10.1053/j.jvca.2005.08.005
   Byrne J, 2007, EUR J VASC ENDOVASC, V34, P444, DOI 10.1016/j.ejvs.2007.05.016
   Chiesa R, 2010, J ENDOVASC THER, V17, P1, DOI 10.1583/09-2884.1
   Chuter TAM, 2003, J VASC SURG, V38, P859, DOI 10.1016/S0741-5214(03)01023-1
   Chuter Timothy A M, 2007, Perspect Vasc Surg Endovasc Ther, V19, P188, DOI 10.1177/1531003507304165
   Greenberg RK, 2005, CIRCULATION, V112, P2619, DOI 10.1161/CIRCULATIONAHA.105.552398
   Greenberg RK, 2010, RUTHERFORDS VASCULAR, P2075
   Ihnken K, 2004, J THORAC CARDIOV SUR, V127, P1808, DOI 10.1016/j.jteves.2003.12.019
   Inoue K, 1999, CIRCULATION, V100, P316
   Kawaguchi S, 2008, J VASC SURG, V48, p24S, DOI 10.1016/j.jvs.2008.08.037
   Kolbel T, 2010, J ENDOVASC THER, V17, P744, DOI 10.1583/10-3189.1
   Lioupis Christos, 2011, Perspect Vasc Surg Endovasc Ther, V23, P202, DOI 10.1177/1531003511413608
   Manning BJ, 2010, J VASC SURG, V52, P491, DOI 10.1016/j.jvs.2009.07.088
   McWilliams RG, 2004, J ENDOVASC THER, V11, P170, DOI 10.1583/03-1180.1
   Moon MC, 2011, J VASC SURG, V53, P942, DOI 10.1016/j.jvs.2010.10.067
   Sobocinski J, 2011, EUR J VASC ENDOVASC, V78, P455
   Sonesson B, 2009, J VASC SURG, V49, P1589, DOI 10.1016/j.jvs.2009.02.007
   Sugiura K, 2009, J CARDIOVASC SURG, V50, P475
   Svensson LG, 2004, ANN THORAC SURG, V78, P109, DOI 10.1016/j.athorascur.2004.02.098
   Zhang HK, 2004, EUR J CARDIO-THORAC, V26, P857, DOI 10.1016/j.ejcts.2004.07.008
   Zimpfer D, 2006, ANN THORAC SURG, V82, P747, DOI 10.1016/j.athoracsur.2005.11.066
NR 24
TC 5
Z9 7
U1 2
U2 11
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0022-5223
EI 1097-685X
J9 J THORAC CARDIOV SUR
JI J. Thorac. Cardiovasc. Surg.
PD MAR
PY 2013
VL 145
IS 3
SU S
BP S110
EP S117
DI 10.1016/j.jtcvs.2012.11.064
PG 8
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery
SC Cardiovascular System & Cardiology; Respiratory System; Surgery
GA 089BQ
UT WOS:000314884000021
PM 23410767
OA Bronze
DA 2018-12-27
ER

PT J
AU Chaturvedi, SK
   Shanmugam, P
   Yang, CS
   Guven, U
AF Chaturvedi, Sudhir Kumar
   Shanmugam, Palanisamy
   Yang, Chan-Su
   Guven, Ugur
TI RETRACTED: Detection of Ocean Wave Parameters Using Synthetic Aperture
   Radar (SAR) Data (Retracted article. See vol. 67, pg. 927, 2014)
SO JOURNAL OF NAVIGATION
LA English
DT Article; Retracted Publication
DE Ocean Waves; Wave parameters; Fast Fourier Transform (FFT); SAR-ocean
   imaging; Dispersion relation
ID IMAGE SPECTRA; RESOLUTION
AB This study describes the estimation of spherical wave parameters that appears in Synthetic Aperture Radar (SAR) images acquired over the coast of Chukk, Micronesia. The main causes for the interaction of SAR signals with ocean waves can be retrieved through the Bragg scattering mechanism. Dominant wavelengths were retrieved by means of Fast Fourier Transform (FFT) analysis in terms of peak frequency responses. Sea surface slopes were then obtained from the dispersion relation with consideration of different water wave conditions for each subset area, and wave heights were estimated with the use of dominant wavelengths and sea surface slopes. The work presented in this paper may be useful to retrieve the various wave parameters over different regions. The method used is a novel technique to correlate the relationship between SAR image parameters and dispersion relation.
C1 [Chaturvedi, Sudhir Kumar; Guven, Ugur] UPES, Dehra Dun, India.
   [Shanmugam, Palanisamy] Indian Inst Technol Madras, Chennai, Tamil Nadu, India.
   [Yang, Chan-Su] Korea Ocean Res & Dev Inst, Ansan, South Korea.
RP Chaturvedi, SK (reprint author), UPES, Dehra Dun, India.
EM sudhir.avionics@gmail.com
RI Guven, Ugur/F-5648-2011
OI Guven, Ugur/0000-0003-1901-3066; Shanmugam,
   Palanisamy/0000-0002-5659-4464
CR ALPERS W, 1983, J GEOPHYS RES-OCEANS, V88, P1745, DOI 10.1029/JC088iC03p01745
   Frank M. M., 1986, IEEE T GEOSCI REMOTE, V24, P543
   HASSELMANN K, 1991, J GEOPHYS RES-OCEANS, V96, P10713, DOI 10.1029/91JC00302
   Hasselmann S, 1996, J GEOPHYS RES-OCEANS, V101, P16615, DOI 10.1029/96JC00798
   Kim DJ, 2009, KOREAN J REMOTE SENS, V25, P243
   KROGSTAD HE, 1992, J GEOPHYS RES-OCEANS, V97, P2421, DOI 10.1029/91JC03010
   Kuo YY, 1999, OCEAN ENG, V26, P1125, DOI 10.1016/S0029-8018(98)00058-4
   Leo H., 2007, WAVES OCEANIC COASTA
   OUCHI K, 1994, IEEE T GEOSCI REMOTE, V32, P1004, DOI 10.1109/36.312889
   Ouchi K., 2010, P 4 JOINT PI S ALOS
   Shiroto N., 2010, P 32 S REM SENS, P19
   VACHON PW, 1994, ATMOS OCEAN, V32, P83, DOI 10.1080/07055900.1994.9649491
   VACHON PW, 1991, IEEE T GEOSCI REMOTE, V29, P105, DOI 10.1109/36.103299
   Valenzuela G. R., 1978, Boundary-Layer Meteorology, V13, P61, DOI 10.1007/BF00913863
NR 14
TC 4
Z9 5
U1 1
U2 18
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 0373-4633
EI 1469-7785
J9 J NAVIGATION
JI J. Navig.
PD MAR
PY 2013
VL 66
IS 2
BP 283
EP 293
DI 10.1017/S0373463312000562
PG 11
WC Engineering, Marine; Oceanography
SC Engineering; Oceanography
GA 083LS
UT WOS:000314466200008
OA Bronze
DA 2018-12-27
ER

PT J
AU Tewari, A
   Ludwig, W
   Takenaka, A
   Srivastava, A
   Chopra, S
   Pham, A
   Sooriakumaran, P
   Durand, M
   Chughtai, B
   Gruschow, S
   Peyser, A
   Harneja, N
   Leung, R
   Lee, R
   Herman, M
   Robinson, B
   Shevchuk, M
AF Tewari, Ashutosh
   Ludwig, Wesley
   Takenaka, Atsushi
   Srivastava, Abhishek
   Chopra, Sameer
   Pham, Anthony
   Sooriakumaran, Prasanna
   Durand, Matthieu
   Chughtai, Bilal
   Gruschow, Siobhan
   Peyser, Alexandra
   Harneja, Niyati
   Leung, Robert
   Lee, Richard
   Herman, Michael
   Robinson, Brian
   Shevchuk, Maria
TI RETRACTED: Reply from Authors re: Declan G. Murphy, Anthony J. Costello.
   How Can the Autonomic Nervous System Contribute to Urinary Continence
   Following Radical Prostatectomy? A "Boson-like" Conundrum. Eur Urol
   2013;63:445-7 Sparing of the Neurovascular Bundle Leads to Improved
   Rates of Continence (Retracted article. See vol. 66, pg. 1194, 2014)
SO EUROPEAN UROLOGY
LA English
DT Editorial Material; Retracted Publication
ID URETHRAL SPHINCTER; RETURN
C1 Cornell Univ, LeFrak Inst Robot Surg, Weill Med Coll, New York Presbyterian Hosp, New York, NY 10065 USA.
   Cornell Univ, New York Presbyterian Hosp, Prostate Canc Inst, James Buchanan Brady Fdn Dept Urol,Weill Med Coll, New York, NY 10065 USA.
RP Tewari, A (reprint author), Cornell Univ, LeFrak Inst Robot Surg, Weill Med Coll, 525 E 68th St,Starr 900, New York, NY 10065 USA.
EM ashtewarimd@gmail.com
CR Akita K, 2003, SURG RADIOL ANAT, V25, P387, DOI 10.1007/s00276-003-0151-9
   GOSLING JA, 1975, BRIT J UROL, V47, P549, DOI 10.1111/j.1464-410X.1975.tb06260.x
   Ko YH, 2012, J UROLOGY, V187, P190, DOI 10.1016/j.juro.2011.09.037
   Murphy DG, 2013, EUR UROL, V63, P445, DOI 10.1016/j.eururo.2012.08.031
   NARAYAN P, 1995, J UROLOGY, V153, P337, DOI 10.1097/00005392-199502000-00012
   Srivastava A, 2013, EUR UROL, V63, P438, DOI 10.1016/j.eururo.2012.07.009
   Steiner M S, 2000, Semin Urol Oncol, V18, P9
   Strasser H, 2000, WORLD J UROL, V18, P324, DOI 10.1007/s003450000145
   Takenaka A, 2005, UROLOGY, V65, P136, DOI 10.1016/j.urology.2004.08.028
   Takenaka A, 2007, J UROLOGY, V177, P225, DOI 10.1016/j.juro.2006.08.104
NR 10
TC 1
Z9 1
U1 3
U2 14
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0302-2838
EI 1873-7560
J9 EUR UROL
JI Eur. Urol.
PD MAR
PY 2013
VL 63
IS 3
BP 447
EP 449
DI 10.1016/j.eururo.2012.09.021
PG 4
WC Urology & Nephrology
SC Urology & Nephrology
GA 078NZ
UT WOS:000314107100012
PM 23079055
DA 2018-12-27
ER

PT J
AU Wang, ZW
   Ali, S
   Banerjee, S
   Bao, B
   Li, YW
   Azmi, AS
   Korc, M
   Sarkar, FH
AF Wang, Zhiwei
   Ali, Shadan
   Banerjee, Sanjeev
   Bao, Bin
   Li, Yiwei
   Azmi, Asfar S.
   Korc, Murray
   Sarkar, Fazlul H.
TI RETRACTED: Activated K-Ras and INK4a/Arf deficiency promote
   aggressiveness of pancreatic cancer by induction of EMT consistent with
   cancer stem cell phenotype (Retracted article. See vol. 231, pg. 2304,
   2016)
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article; Retracted Publication
ID EPITHELIAL-MESENCHYMAL TRANSITION; GROWTH-FACTOR-D; FACTOR-KAPPA-B;
   PROSTATE-CANCER; INHIBITS INVASION; DOWN-REGULATION; ADENOCARCINOMA;
   NOTCH-1; ANGIOGENESIS; INACTIVATION
AB Pancreatic ductal adenocarcinoma (PDAC) is one of the most frequently diagnosed cancers and the fourth leading cause of cancer-related death in the United States, suggesting that there is an urgent need to design novel strategies for achieving better treatment outcome of patients diagnosed with PDAC. Our previous study has shown that activation of Notch and NF-?B play a critical role in the development of PDAC in the compound K-RasG12D and Ink4a/Arf deficient transgenic mice. However, the exact molecular mechanism by which mutated K-Ras and Ink4a/Arf deficiency contribute to progression of PDAC remains largely elusive. In the present study, we used multiple methods, such as real-time RT-PCR, Western blotting assay, and immunohistochemistry to gain further mechanistic insight. We found that the deletion of Ink4a/Arf in K-RasG12D expressing mice led to high expression of PDGF-D signaling pathway in the tumor and tumor-derived cell line (RInk-1 cells). Furthermore, PDGF-D knock-down in RInk-1 cells resulted in the inhibition of pancreatosphere formation and down-regulation of EZH2, CD44, EpCAM, and vimentin. Moreover, we demonstrated that epithelialmesenchymal transition (EMT) was induced in the compound mice, which is linked with aggressiveness of PDAC. In addition, we demonstrated that tumors from compound transgenic mice have higher expression of cancer stem cell (CSC) markers. These results suggest that the acquisition of EMT phenotype and induction of CSC characteristics could be linked with the aggressiveness of PDAC mediated in part through the activation of PDGF-D, signaling. J. Cell. Physiol. 228: 556562, 2013. (C) 2012 Wiley Periodicals, Inc.
C1 [Wang, Zhiwei; Banerjee, Sanjeev; Bao, Bin; Li, Yiwei; Azmi, Asfar S.; Sarkar, Fazlul H.] Wayne State Univ, Dept Pathol, Karmanos Canc Inst, Sch Med, Detroit, MI 48201 USA.
   [Ali, Shadan; Sarkar, Fazlul H.] Wayne State Univ, Dept Oncol, Karmanos Canc Inst, Sch Med, Detroit, MI 48201 USA.
   [Korc, Murray] Indiana Univ, Dept Med, Indianapolis, IN USA.
RP Sarkar, FH (reprint author), Wayne State Univ, Dept Pathol, Karmanos Canc Inst, Sch Med, 740 HWCRC,4100 JohnR St, Detroit, MI 48201 USA.
EM fsarkar@med.wayne.edu
OI AZMI, ASFAR/0000-0003-1178-9505
FU National Cancer Institute [R01CA131151, R01CA132794, 1R01CA154321, NIH
   R01CA131151]; NIH; NSFC [81172087]
FX Contract grant sponsor: National Cancer Institute;; Contract grant
   numbers: R01CA131151, R01CA132794, 1R01CA154321.; Contract grant
   sponsor: NIH.; Contract grant sponsor: NSFC;; Contract grant number:
   81172087.; The authors' work was funded by grants from the National
   Cancer Institute, NIH R01CA131151, R01CA132794, and R01CA154321 to
   F.H.S. This work was also supported by grants from the NSFC (No.
   81172087). We also sincerely thank both Puschelberg and Guido foundation
   for their generous contributions to our research.
CR Aguirre AJ, 2003, GENE DEV, V17, P3112, DOI 10.1101/gad.1158703
   Ahmad A, 2011, BREAST CANCER RES TR, V126, P15, DOI 10.1007/s10549-010-0883-2
   Ali S, 2012, J CELL PHYSIOL, V227, P3373, DOI 10.1002/jcp.24036
   Bao B, 2011, J CELL BIOCHEM, V112, P2296, DOI 10.1002/jcb.23150
   Bao B, 2011, CANCER LETT, V307, P26, DOI 10.1016/j.canlet.2011.03.012
   Bao B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017850
   Brembeck FH, 2003, CANCER RES, V63, P2005
   Cano C, 2010, THESCIENTIFICWORLDJO, V10, P1947, DOI 10.1100/tsw.2010.183
   Deramaudt T, 2005, BBA-REV CANCER, V1756, P97, DOI 10.1016/j.bbcan.2005.08.003
   Devarajan E, 2012, INT J CANCER, V131, P1023, DOI 10.1002/ijc.26493
   Friedlander SYG, 2009, CANCER CELL, V16, P379, DOI 10.1016/j.ccr.2009.09.027
   Grippo PJ, 2010, CANCER PREV RES, V3, P1382, DOI 10.1158/1940-6207.CAPR-10-0258
   Hanlon L, 2010, CANCER RES, V70, P4280, DOI 10.1158/0008-5472.CAN-09-4645
   Hotz B, 2007, CLIN CANCER RES, V13, P4769, DOI 10.1158/1078-0432.CCR-06-2926
   Iyer RV, 2007, ANN SURG ONCOL, V14, P3202, DOI 10.1245/s10434-007-9539-9
   Ji BA, 2009, GASTROENTEROLOGY, V137, P1072, DOI 10.1053/j.gastro.2009.05.052
   Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129
   Kong DJ, 2008, STEM CELLS, V26, P1425, DOI 10.1634/stemcells.2007-1076
   Kong D, 2008, CANCER RES, V68, P1927, DOI 10.1158/0008-5472.CAN-07-3241
   Kong Dejuan, 2011, Cancers (Basel), V3, P716, DOI 10.3390/cancers30100716
   Kong DJ, 2009, STEM CELLS, V27, P1712, DOI 10.1002/stem.101
   Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027
   Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620
   Rasheed ZA, 2010, JNCI-J NATL CANCER I, V102, P340, DOI 10.1093/jnci/djp535
   Scheel C, 2011, CELL, V145, P926, DOI 10.1016/j.cell.2011.04.029
   Seeley ES, 2009, CANCER RES, V69, P422, DOI 10.1158/0008-5472.CAN-08-1290
   Sethi S, 2011, TRANSL ONCOL, V4, P212, DOI 10.1593/tlo.10244
   Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138
   Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007
   Ustach CV, 2010, CANCER RES, V70, P9631, DOI 10.1158/0008-5472.CAN-10-0511
   Ustach CV, 2005, MOL CELL BIOL, V25, P6279, DOI 10.1128/MCB.25.14.6279-6288.2005
   Wang ZW, 2007, CANCER RES, V67, P11377, DOI 10.1158/0008-5472.CAN-07-2803
   Wang ZW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020537
   Wang ZW, 2011, NAT REV GASTRO HEPAT, V8, P27, DOI 10.1038/nrgastro.2010.188
   Wang Z, 2010, BBA-REV CANCER, V1806, P122, DOI 10.1016/j.bbcan.2010.04.003
   Wang ZW, 2009, CURR DRUG TARGETS, V10, P38, DOI 10.2174/138945009787122914
   Wang ZW, 2006, CANCER RES, V66, P2778, DOI 10.1158/0008-5472.CAN-05-4281
NR 37
TC 36
Z9 36
U1 2
U2 64
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0021-9541
EI 1097-4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD MAR
PY 2013
VL 228
IS 3
BP 556
EP 562
DI 10.1002/jcp.24162
PG 7
WC Cell Biology; Physiology
SC Cell Biology; Physiology
GA 048LL
UT WOS:000311912900008
PM 22806240
OA Green Accepted
DA 2018-12-27
ER

PT J
AU Vazin, F
AF Vazin, Farshid
TI RETRACTED: Water stress effects on Cumin (Cuminum cyminum L.) yield and
   oil essential components (Retracted article. See vol. 151, pg. 135,
   2013)
SO SCIENTIA HORTICULTURAE
LA English
DT Article; Retracted Publication
DE Water deficit; Cumin cyminum; Fatty acids; Essential oils; p-Menta-1;
   3-Diene-7-al; Cuminaldehyde
ID SESAMUM-INDICUM L.; USE EFFICIENCY; IRRIGATION FREQUENCY;
   CHEMICAL-COMPOSITION; ION ACCUMULATION; THYMUS-VULGARIS; SALT STRESS;
   PLANT; SUNFLOWER; GROWTH
AB The effects of water deficit on yield, fatty acids and essential oil yield and composition of Cumin (Cuminum cyminum L.) were investigated. Plants were treated with different levels of water deficit (I-100, I-50 and 10). Plant growth (height and dry matter weight) was significantly reduced by I-0. This last caused also important reductions of the seed yield and yield components. Drought decreased significantly the fatty acid content and the double bond index (DBI) degree. This later was provoked mainly by a strong reduction of oleic, linolenic and petroselinic acid proportions and the disappearance of palmitoleic and arachidinic acid. Besides, moderate water deficit increased the essential oil yield (expressed as g/100 g on the basis of dry matter weight). The main essential oil constituents were p-Menta-1,3-diene-7-al, cuminaldehyde, gamma-Terpinene, p-Cymene and beta-Pinene which showed a decreasing of their contents under I-0. (C) 2012 Elsevier B.V. All rights reserved:
C1 Islamic Azad Univ, Gonabad Branch, Gonabad, Iran.
RP Vazin, F (reprint author), Islamic Azad Univ, Gonabad Branch, Gonabad, Iran.
EM farshidvazin@gmail.com
CR Adams R. P, 2001, IDENTIFICATION ESSEN
   Ahmadian A, 2011, AFR J AGR RES, V6, P2309
   Albouchi Ali, 2003, Secheresse (Montrouge), V14, P137
   Alishah H. M., 2006, Journal of Biological Sciences, V6, P763
   Allen R. G., 1998, FAO Irrigation and Drainage Paper
   Ashraf M, 2006, J ARID ENVIRON, V64, P209, DOI 10.1016/j.jaridenv.2005.04.015
   Ashraf M, 2004, BIOL PLANTARUM, V48, P461, DOI 10.1023/B:BIOP.0000041105.89674.d1
   Aziz EA, 2008, AM EURAS J AGR ENV S, V4, P443
   Baher ZF, 2002, FLAVOUR FRAG J, V17, P275, DOI 10.1002/ffj.1097
   Baldini M., 2002, Italian Journal of Agronomy, V6, P119
   Baldini M., 2000, P 15 INT SUNFL C TOU, VI, pA79
   Behera S, 2004, FOOD CHEM, V87, P25, DOI 10.1016/j.foodchem.2003.10.012
   BENSON AA, 1960, BIOCHIM BIOPHYS ACTA, V41, P328, DOI 10.1016/0006-3002(60)90016-0
   Bettaieb I, 2009, SCI HORTIC-AMSTERDAM, V120, P271, DOI 10.1016/j.scienta.2008.10.016
   Bligh E. G., 1959, BIOCHIM BIOPHYS ACTA, V41, P328
   BOYER JS, 1982, SCIENCE, V218, P443, DOI 10.1126/science.218.4571.443
   CECCHI G, 1985, REV FR CORPS GRAS, V32, P163
   Chaves MM, 2003, FUNCT PLANT BIOL, V30, P239, DOI 10.1071/FP02076
   CONNOR DJ, 1992, FIELD CROP RES, V30, P333, DOI 10.1016/0378-4290(92)90006-U
   DAVIES NW, 1990, J CHROMATOGR, V503, P1, DOI 10.1016/S0021-9673(01)81487-4
   Delfine S, 2005, AGR ECOSYST ENVIRON, V106, P243, DOI 10.1016/j.agee.2004.10.012
   DEVOS CHR, 1993, PLANT PHYSIOL BIOCH, V31, P151
   Dunford N. T., 2005, J APPL HORTICULTURE, V7, P20
   Eiasu BK, 2009, AGR WATER MANAGE, V96, P991, DOI 10.1016/j.agwat.2009.01.012
   Flagella Z., 2000, P 15 INT SUNFL C TOU, V1, pC139
   Gigon A, 2004, ANN BOT-LONDON, V94, P345, DOI 10.1093/aob/mch150
   Harvell C. D., 1999, WHY INDUCIBLE DEFENS, P3
   Hendawy S.F., 2005, J APPL SCI RES, V1, P147
   Iacobellis NS, 2005, J AGR FOOD CHEM, V53, P57, DOI 10.1021/jf0487351
   Jirovets L., 2005, J FOOD SCI TECHNOL, V40
   Jordan MJ, 2006, IND CROP PROD, V24, P253, DOI 10.1016/j.indcrop.2006.06.011
   Karam F, 2007, AGR WATER MANAGE, V90, P213, DOI 10.1016/j.agwat.2007.03.009
   Khalid A., 2006, INT AGROPHYS, V20, P1
   Khazaie HR, 2008, IND CROP PROD, V27, P315, DOI 10.1016/j.indcrop.2007.11.007
   Kim KS, 2007, J PLANT PHYSIOL, V164, P1134, DOI 10.1016/j.jplph.2006.07.004
   Laribi B., 2011, Advances in Environmental Biology, V5, P257
   Li R, 2004, FLAVOUR FRAG J, V19, P311, DOI 10.1002/ffj.1302
   Li Y. J., 2007, J LIB INF SCI AGR, V19, P159
   [陆占国 LU Zhanguo], 2008, [化学研究与应用, Chemical Research and Application], V20, P647
   Marrink SJ, 1996, FARADAY DISCUSS, V103, P191, DOI 10.1039/fd9960300191
   MARZOUK B, 1981, OLEAGINEUX, V36, P77
   Penuelas J, 2002, NEW PHYTOL, V155, P227, DOI 10.1046/j.1469-8137.2002.00457.x
   Qiu Y, 2001, J HYDROL, V240, P243, DOI 10.1016/S0022-1694(00)00362-0
   Radhouane L, 2008, CR BIOL, V331, P206, DOI 10.1016/j.crvi.2007.12.004
   Rebey IB, 2012, IND CROP PROD, V36, P238, DOI 10.1016/j.indcrop.2011.09.013
   ROSENTHAL GA, 1991, PHYTOCHEMISTRY, V30, P1055, DOI 10.1016/S0031-9422(00)95170-7
   Rotundo JL, 2009, FIELD CROP RES, V110, P147, DOI 10.1016/j.fcr.2008.07.012
   RUSSELL NJ, 1984, TRENDS BIOCHEM SCI, V9, P108, DOI 10.1016/0968-0004(84)90106-3
   Sangwan NS, 2001, PLANT GROWTH REGUL, V34, P3, DOI 10.1023/A:1013386921596
   Sawadogo Mahamadou, 2006, Biotechnologie Agronomie Societe et Environnement, V10, P43
   Schafer Holger, 2009, Biotechnology Journal, V4, P1684, DOI 10.1002/biot.200900229
   Siemens DH, 2002, ECOLOGY, V83, P505, DOI 10.2307/2680031
   SIONIT N, 1973, J AGR SCI-CAMBRIDGE, V81, P113, DOI 10.1017/S002185960005838X
   *STATS INC, 1998, STATISTICA WIND COMP
   TALHA M, 1975, J AGR SCI, V84, P49, DOI 10.1017/S0021859600071860
   Ucan K, 2007, FIELD CROP RES, V101, P249, DOI 10.1016/j.fcr.2006.11.011
   UNGER PW, 1982, SOIL SCI SOC AM J, V46, P1072, DOI 10.2136/sssaj1982.03615995004600050037x
   Viera H.J., 1991, PESQUI AGROPECU BRAS, V9, P1035
   WINK M, 1999, ANN PLANT REV, V3
   Yin CY, 2005, ENVIRON EXP BOT, V53, P315, DOI 10.1016/j.envexpbot.2004.04.004
NR 60
TC 3
Z9 3
U1 2
U2 34
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0304-4238
EI 1879-1018
J9 SCI HORTIC-AMSTERDAM
JI Sci. Hortic.
PD FEB 28
PY 2013
VL 151
BP 135
EP 141
DI 10.1016/j.scienta.2012.12.018
PG 7
WC Horticulture
SC Agriculture
GA 100MZ
UT WOS:000315706600019
DA 2018-12-27
ER

PT J
AU Shi, L
   Zheng, HJ
   Zheng, H
   Borkowski, BA
   Shi, D
   Gonen, T
   Jiang, QX
AF Shi, Liang
   Zheng, Hongjin
   Zheng, Hui
   Borkowski, Brian A.
   Shi, Dan
   Gonen, Tamir
   Jiang, Qiu-Xing
TI RETRACTED: Voltage sensor ring in a native structure of a
   membrane-embedded potassium channel (Retracted article. See vol. 110,
   pg. 7097, 2013)
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article; Retracted Publication
DE cryo-EM; electron crystallography; membrane protein
ID DEPENDENT K+ CHANNEL; GATED SODIUM-CHANNEL; ION CHANNELS;
   CRYSTAL-STRUCTURE; FUNCTIONAL-ANALYSIS; LIPID-MEMBRANE; DOMAIN;
   MOVEMENT; MODEL; S4
AB Voltage-gated ion channels support electrochemical activity in cells and are largely responsible for information flow throughout the nervous systems. The voltage sensor domains in these channels sense changes in transmembrane potential and control ion flux across membranes. The X-ray structures of a few voltage-gated ion channels in detergents have been determined and have revealed clear structural variations among their respective voltage sensor domains. More recent studies demonstrated that lipids around a voltage-gated channel could directly alter its conformational state in membrane. Because of these disparities, the structural basis for voltage sensing in native membranes remains elusive. Here, through electron-crystallographic analysis of membrane-embedded proteins, we present the detailed view of a voltage-gated potassium channel in its inactivated state. Contrary to all known structures of voltage-gated ion channels in detergents, our data revealed 6 unique conformation in which the four voltage sensor domains of a voltage-gated potassium channel from Aeropyrum pernix (KvAP) form a ring structure that completely surrounds the pore domain of the channel. Such a structure is named the voltage sensor ring. Our biochemical and electrophysiological studies support that the voltage sensor ring represents a physiological conformation. These data together suggest that lipids exert strong effects on the channel structure and that these effects may be changed upon membrane disruption. Our results have wide implications for lipid protein interactions in general and for the mechanism of voltage sensing in particular.
C1 [Shi, Liang; Zheng, Hui; Borkowski, Brian A.; Jiang, Qiu-Xing] Univ Texas SW Med Ctr Dallas, Dept Cell Biol, Dallas, TX 75390 USA.
   [Zheng, Hongjin; Shi, Dan; Gonen, Tamir] Howard Hughes Med Inst, Ashburn, VA 20147 USA.
RP Gonen, T (reprint author), Howard Hughes Med Inst, Janelia Farm Res Campus, Ashburn, VA 20147 USA.
EM gonent@janelia.hhmi.org; qiu-xing.jiang@utsouthwestern.edu
FU National Institutes of Health [R01GM088745, R01GM093271]; American Heart
   Association [12IRG9400019]; Welch Foundation [I-1684]; Howard Hughes
   Medical Institute
FX We thank Dr. Roderick MacKinnon (The Rockefeller University) for his
   generous support in the early stage of the 2D crystallization of the
   KvAP in membranes, and Drs. Da-Neng Wang (New York University), David
   Stokes (New York University and New York Structural Biology Center),
   Thomas Walz (Harvard Medical School), Yoshinori Fujiyoshi (Kyoto
   University), and Wah Chiu (Baylor College of Medicine) for offering
   support and advice in the project development and technical
   modifications, and/or providing access to their microscopes. We thank
   Dr. Puey Ounjai (currently at Berkeley National Laboratory) for
   performing some useful tests in improving the crystal quality and in
   cryoprotecting 2D crystals, and Dr. Anchi Cheng (The Scripps Research
   Institute) for her valuable advice in symmetry test during our
   crystallographic analysis. Dr. Richard Aldrich at University of
   Texas-Austin, Dr. Kenton Swartz at National Institutes of
   Health/National Institute of Neurological Disorders and Stroke, and Drs.
   Lily Huang, Lora Hooper, Youxing Jiang, Sandra Schmid, and Michael Rosen
   at University of Texas Southwestern offered valuable comments on the
   manuscript. We are indebted to Drs. Karel Svoboda, Gabe Murphy, Michael
   Tadross, Edwin McCleskey, Brett Mensh, and Gabrielle Edgerton (Janelia
   Farm Research Campus, Howard Hughes Medical Institute) for critical
   reading of the manuscript. This research project has been supported by
   National Institutes of Health Grants R01GM088745 and R01GM093271 (to
   O.-X.J.), American Heart Association Grant 12IRG9400019 (to Or-X.J), and
   Welch Foundation Grant I-1684 (to Q.-X.J.). The T.G. laboratory is
   supported by the Howard Hughes Medical Institute.
CR AMOS LA, 1983, PROG BIOPHYS MOL BIO, V39, P183
   Aziz QH, 2002, J BIOL CHEM, V277, P42719, DOI 10.1074/jbc.M207258200
   Bezanilla F, 2000, PHYSIOL REV, V80, P555
   Bocksteins E, 2011, EUR BIOPHYS J BIOPHY, V40, P783, DOI 10.1007/s00249-011-0694-3
   Chakrapani S, 2008, STRUCTURE, V16, P398, DOI 10.1016/j.str.2007.12.015
   Clayton GM, 2008, P NATL ACAD SCI USA, V105, P1511, DOI 10.1073/pnas.0711533105
   Cuello LG, 2004, SCIENCE, V306, P491, DOI 10.1126/science.1101373
   Elliott DJS, 2004, EMBO J, V23, P4717, DOI 10.1038/sj.emboj.7600484
   Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493
   Gonen T, 2005, NATURE, V438, P633, DOI 10.1038/nature04321
   Grabe M, 2007, NATURE, V445, P550, DOI 10.1038/nature05494
   Haitin Y, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001935
   HEGINBOTHAM L, 1994, BIOPHYS J, V66, P1061, DOI 10.1016/S0006-3495(94)80887-2
   HENDERSON R, 1990, J MOL BIOL, V213, P899, DOI 10.1016/S0022-2836(05)80271-2
   HENDERSON R, 1975, NATURE, V257, P28, DOI 10.1038/257028a0
   HODGKIN AL, 1952, J PHYSIOL-LONDON, V116, P424, DOI 10.1113/jphysiol.1952.sp004716
   HODGKIN AL, 1952, J PHYSIOL-LONDON, V117, P500, DOI 10.1113/jphysiol.1952.sp004764
   JAN LY, 1990, NATURE, V345, P672, DOI 10.1038/345672a0
   Jiang QX, 2012, CURR OPIN STRUC BIOL, V22, P529, DOI 10.1016/j.sbi.2012.03.009
   Jiang QX, 2004, NATURE, V430, P806, DOI 10.1038/nature02735
   Jiang YX, 2003, NATURE, V423, P42, DOI 10.1038/nature01581
   Jiang YX, 2003, NATURE, V423, P33, DOI 10.1038/nature01580
   Lee SY, 2005, P NATL ACAD SCI USA, V102, P15441, DOI 10.1073/pnas.0507651102
   Li HL, 1998, J MOL BIOL, V282, P211, DOI 10.1006/jmbi.1998.2016
   Long SB, 2007, NATURE, V450, P376, DOI 10.1038/nature06265
   MILLER C, 1991, SCIENCE, V252, P1092, DOI 10.1126/science.252.5009.1092
   Murata Y, 2005, NATURE, V435, P1239, DOI 10.1038/nature03650
   Nagura H, 2010, BIOCHEM BIOPH RES CO, V399, P341, DOI 10.1016/j.bbrc.2010.07.070
   PAPAZIAN DM, 1995, NEURON, V14, P1293, DOI 10.1016/0896-6273(95)90276-7
   Payandeh J, 2012, NATURE, V486, P135, DOI 10.1038/nature11077
   Payandeh J, 2011, NATURE, V475, P353, DOI 10.1038/nature10238
   Posson DJ, 2008, NEURON, V59, P98, DOI 10.1016/j.neuron.2008.05.006
   Posson DJ, 2005, NATURE, V436, P848, DOI 10.1038/nature03819
   Ramsey IS, 2006, NATURE, V440, P1213, DOI 10.1038/nature04700
   Ruta V, 2005, CELL, V123, P463, DOI 10.1016/j.cell.2005.08.041
   Ruta V, 2003, NATURE, V422, P180, DOI 10.1038/nature01473
   Sasaki M, 2006, SCIENCE, V312, P589, DOI 10.1126/science.1122352
   Schmidt D, 2006, NATURE, V444, P775, DOI 10.1038/nature05416
   Schoppa NE, 1998, J GEN PHYSIOL, V111, P313, DOI 10.1085/jgp.111.2.313
   SIGWORTH FJ, 1994, Q REV BIOPHYS, V27, P1, DOI 10.1017/S0033583500002894
   Swartz KJ, 2008, NATURE, V456, P891, DOI 10.1038/nature07620
   Tanford C., 1980, HYDROPHOBIC EFFECT F, P233
   Tao X, 2008, J MOL BIOL, V382, P24, DOI 10.1016/j.jmb.2008.06.085
   Tao X, 2010, SCIENCE, V328, P67, DOI 10.1126/science.1185954
   Vamvouka M, 2008, PROTEIN SCI, V17, P506, DOI 10.1110/ps.073310008
   Xu YP, 2008, NATURE, V451, P826, DOI 10.1038/nature06618
   ZAGOTTA WN, 1994, J GEN PHYSIOL, V103, P321, DOI 10.1085/jgp.103.2.321
   Zhang X, 2012, NATURE, V486, P130, DOI 10.1038/nature11054
   Zheng H, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1254
NR 49
TC 2
Z9 2
U1 2
U2 2
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD FEB 26
PY 2013
VL 110
IS 9
BP 3369
EP 3374
DI 10.1073/pnas.1218203110
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 102JW
UT WOS:000315841900040
PM 23401554
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Bhadra, D
   Masud, MG
   De, SK
   Chaudhuri, BK
AF Bhadra, Debabrata
   Masud, Md. G.
   De, S. K.
   Chaudhuri, B. K.
TI RETRACTED: Observation of large magnetodielectric and direct
   magnetoelectric behavior in LCMO/PVDF 0-3 nanocomposites (Retracted
   article. See vol. 105, 239901, 2014)
SO APPLIED PHYSICS LETTERS
LA English
DT Article; Retracted Publication
ID COMPOSITES; MAGNETOSTRICTION
AB A two-phase multifunctional La2CoMnO6 (LCMO)/Poly-vinylidene fluoride 0-3 flexible nanocomposite (NCOMP) thick films have been prepared. Interestingly, this NCOMP shows linear increase of magnetoelectric voltage coefficient (MVC) with applied dc magnetic-bias fields up to 5 kOe, exhibiting no sign of hysteresis. For the typical LCMO concentration, f(LCMO) = 0.15, the maximum MVC measured is 1.45mVcm(-1) Oe(-1) (using 50kHz resonant signal). This low dielectric loss (similar to 0.12) NCOMP also showed intriguing high magnetodielectric effect (similar to 10%) around the ferromagnetic transition temperature (T-c similar to 230K) with minimal leakage current. Such results make the present nanocomposite significantly important for the development of magnetic field tuned electronic devices. (C) 2013 American Institute of Physics. [http://dx.doi.org/10.1063/1.4793307]
C1 [Bhadra, Debabrata] Bhairab Ganguly Coll, Dept Phys, Kolkata 700032, India.
   [Bhadra, Debabrata; Masud, Md. G.; Chaudhuri, B. K.] Indian Assoc Cultivat Sci, Dept Solid State Phys, Kolkata 700032, India.
   [De, S. K.] Indian Assoc Cultivat Sci, Dept Mat Sci, Kolkata 700032, India.
   [Chaudhuri, B. K.] NIT Rourkela, Dept Phys, Rourkela 769008, Orissa, India.
RP Chaudhuri, BK (reprint author), Indian Assoc Cultivat Sci, Dept Solid State Phys, Kolkata 700032, India.
EM sspbkc23@gmail.com
RI Masud, Md Golam/J-8500-2014
OI Masud, Md Golam/0000-0002-3760-9691; Bhadra,
   Debabrata/0000-0001-5746-3506
FU CSIR, Government of India; IACS
FX G.M. and B. K. C. are thankful to CSIR, Government of India for
   financial assistance. D. B. also would like to acknowledge IACS for
   research funding for successful completion of the research work.
CR Almond DP, 2006, J PHYS D APPL PHYS, V39, P1295, DOI 10.1088/0022-3727/39/7/S03
   ASTROV DN, 1961, SOV PHYS JETP-USSR, V13, P729
   Atou T, 1999, J SOLID STATE CHEM, V145, P639, DOI 10.1006/jssc.1999.8267
   Bednarek S, 2006, J MAGN MAGN MATER, V301, P200, DOI 10.1016/j.jmmm.2005.05.041
   Bhadra D, 2012, J PHYS D APPL PHYS, V45, DOI 10.1088/0022-3727/45/48/485002
   Bhadra D, 2010, J APPL PHYS, V107, DOI 10.1063/1.3437633
   BROWN WF, 1968, PHYS REV, V168, P574, DOI 10.1103/PhysRev.168.574
   Chu BJ, 2007, APPL PHYS LETT, V91, DOI 10.1063/1.2786839
   Dass RI, 2003, PHYS REV B, V67, DOI 10.1103/PhysRevB.67.014401
   Eerenstein W, 2006, NATURE, V442, P759, DOI 10.1038/nature05023
   FAWCETT E, 1968, J APPL PHYS, V39, P576, DOI 10.1063/1.2163528
   Fiebig M, 2005, J PHYS D APPL PHYS, V38, pR123, DOI 10.1088/0022-3727/38/8/R01
   Hill NA, 2000, J PHYS CHEM B, V104, P6694, DOI [10.1021/jp000114x, 10.1021/jpc00114x]
   Hur N, 2004, NATURE, V429, P392, DOI 10.1038/nature02572
   Laletin VM, 2002, FERROELECTRICS, V280, P343, DOI 10.1080/00150190190028202
   LANDAU LD, 1960, ELECTRODYNAMICS CONT, P119
   Li JJ, 2009, ADV MATER, V21, P217, DOI 10.1002/adma.200801106
   Lin YQ, 2011, J AM CERAM SOC, V94, P782, DOI 10.1111/j.1551-2916.2010.04139.x
   Nan CW, 2008, J APPL PHYS, V103, DOI 10.1063/1.2836410
   Padhan P, 2009, J PHYS-CONDENS MAT, V21, DOI 10.1088/0953-8984/21/30/306004
   Ramachandran B, 2012, APPL PHYS LETT, V100, DOI 10.1063/1.4729415
   Ramesh R, 2007, NAT MATER, V6, P21, DOI 10.1038/nmat1805
   Rao SS, 2010, J PHYS-CONDENS MAT, V22, DOI 10.1088/0953-8984/22/11/116004
   Srinivasan G, 2004, APPL PHYS LETT, V85, P2550, DOI 10.1063/1.1795365
   VANDENBOOMGAARD J, 1974, J MATER SCI, V9, P1705, DOI 10.1007/BF00540770
   VANDENBOOMGAARD J, 1976, FERROELECTRICS, V14, P727, DOI 10.1080/00150197608236711
   Wong CK, 2007, J APPL PHYS, V102, DOI 10.1063/1.2781513
   Yao YP, 2011, J APPL PHYS, V110, DOI 10.1063/1.3603042
   Zhang JX, 2009, J APPL PHYS, V105, DOI 10.1063/1.3078111
   Zhang QM, 1998, SCIENCE, V280, P2101, DOI 10.1126/science.280.5372.2101
NR 30
TC 11
Z9 11
U1 7
U2 81
PU AMER INST PHYSICS
PI MELVILLE
PA 1305 WALT WHITMAN RD, STE 300, MELVILLE, NY 11747-4501 USA
SN 0003-6951
EI 1077-3118
J9 APPL PHYS LETT
JI Appl. Phys. Lett.
PD FEB 18
PY 2013
VL 102
IS 7
AR 072902
DI 10.1063/1.4793307
PG 5
WC Physics, Applied
SC Physics
GA 099CK
UT WOS:000315596700050
DA 2018-12-27
ER

PT J
AU Gui, SX
   Sang, XZ
   Zheng, L
   Ze, YG
   Zhao, XY
   Sheng, L
   Sun, QQ
   Cheng, Z
   Cheng, J
   Hu, RP
   Wang, L
   Hong, FS
   Tang, M
AF Gui, Suxin
   Sang, Xuezi
   Zheng, Lei
   Ze, Yuguan
   Zhao, Xiaoyang
   Sheng, Lei
   Sun, Qingqing
   Cheng, Zhe
   Cheng, Jie
   Hu, Renping
   Wang, Ling
   Hong, Fashui
   Tang, Meng
TI RETRACTED: Intragastric exposure to titanium dioxide nanoparticles
   induced nephrotoxicity in mice, assessed by physiological and gene
   expression modifications (Retracted article. See vol. 12, pg. 22, 2015)
SO PARTICLE AND FIBRE TOXICOLOGY
LA English
DT Article; Retracted Publication
DE Titanium dioxide nanoparticles; Nephrotoxicity; Oxidative stress;
   Gene-expressed profile; Mice
ID LONG-TERM EXPOSURE; OXIDATIVE DAMAGE; MOLECULAR-MECHANISM; QUANTITATIVE
   PCR; PARTICLE-SIZE; ANATASE TIO2; CELLS; APOPTOSIS; BIODISTRIBUTION;
   KIDNEY
AB Background: Numerous studies have demonstrated that titanium dioxide nanoparticles (TiO2 NPs) induced nephrotoxicity in animals. However, the nephrotoxic multiple molecular mechanisms are not clearly understood.
   Methods: Mice were exposed to 2.5, 5 and 10 mg/kg TiO2 NPs by intragastric administration for 90 consecutive days, and their growth, element distribution, and oxidative stress in kidney as well as kidney gene expression profile were investigated using whole-genome microarray analysis technique.
   Results: Our findings suggest that TiO2 NPs resulted in significant reduction of renal glomerulus number, apoptosis, infiltration of inflammatory cells, tissue necrosis or disorganization of renal tubules, coupled with decreased body weight, increased kidney indices, unbalance of element distribution, production of reactive oxygen species and peroxidation of lipid, protein and DNA in mouse kidney tissue. Furthermore, microarray analysis showed significant alterations in the expression of 1, 246 genes in the 10 mg/kg TiO2 NPs-exposed kidney. Of the genes altered, 1006 genes were associated with immune/inflammatory responses, apoptosis, biological processes, oxidative stress, ion transport, metabolic processes, the cell cycle, signal transduction, cell component, transcription, translation and cell differentiation, respectively. Specifically, the vital up-regulation of Bcl6, Cfi and Cfd caused immune/inflammatory responses, the significant alterations of Axud1, Cyp4a12a, Cyp4a12b, Cyp4a14, and Cyp2d9 expression resulted in severe oxidative stress, and great suppression of Birc5, Crap2, and Tfrc expression led to renal cell apoptosis.
   Conclusions: Axud1, Bcl6, Cf1, Cfd, Cyp4a12a, Cyp4a12b, Cyp2d9, Birc5, Crap2, and Tfrc may be potential biomarkers of kidney toxicity caused by TiO2 NPs exposure.
C1 [Gui, Suxin; Sang, Xuezi; Zheng, Lei; Ze, Yuguan; Zhao, Xiaoyang; Sheng, Lei; Sun, Qingqing; Cheng, Zhe; Cheng, Jie; Hu, Renping; Wang, Ling; Hong, Fashui] Soochow Univ, Coll Med, Suzhou 215123, Peoples R China.
   [Tang, Meng] Southeast Univ, Sch Publ Hlth, Key Lab Environm Med & Engn, Minist Educ, Nanjing 210009, Jiangsu, Peoples R China.
   [Tang, Meng] Southeast Univ, Jiangsu key Lab Biomat & Devices, Nanjing 210009, Jiangsu, Peoples R China.
RP Tang, M (reprint author), Southeast Univ, Sch Publ Hlth, Key Lab Environm Med & Engn, Minist Educ, Nanjing 210009, Jiangsu, Peoples R China.
EM tm@seu.edu.cn
FU National Natural Science Foundation of China [81273036, 30901218,
   81172697]; Priority Academic Program Development of Jiangsu Higher
   Education Institutions; Major State Basic Research Development Program
   of China (973 Program) [2006CB705602]; National Important Project on
   Scientific Research of China [2011CB933404]; National Ideas Foundation
   of Student of Soochow University [111028534]
FX This work was supported by the National Natural Science Foundation of
   China (grant No. 81273036, 30901218, 81172697), A Project Funded by the
   Priority Academic Program Development of Jiangsu Higher Education
   Institutions, the Major State Basic Research Development Program of
   China (973 Program) (grant No. 2006CB705602), National Important Project
   on Scientific Research of China (grant No. 2011CB933404) and the
   National Ideas Foundation of Student of Soochow University (grant No.
   111028534).
CR Abrera-Abeleda MA, 2007, KIDNEY INT, V71, P1142, DOI 10.1038/sj.ki.5002235
   BAYNE K, 1996, AM PHYS SOC PHYSL, V39, P208
   Bihui H.Y., 1997, NAT GENET, V16, P161
   Buege J A, 1978, Methods Enzymol, V52, P302
   Burns AA, 2009, NANO LETT, V9, P442, DOI 10.1021/nl803405h
   COON MJ, 1992, FASEB J, V6, P669
   Cui YL, 2012, TOXICOL SCI, V128, P171, DOI 10.1093/toxsci/kfs153
   Cui YL, 2010, J HAZARD MATER, V183, P874, DOI 10.1016/j.jhazmat.2010.07.109
   De Jong WH, 2008, BIOMATERIALS, V29, P1912, DOI 10.1016/j.biomaterials.2007.12.037
   Fagan JM, 1999, INT J BIOCHEM CELL B, V31, P751, DOI 10.1016/S1357-2725(99)00034-5
   Gao GD, 2012, J HAZARD MATER, V243, P19, DOI 10.1016/j.jhazmat.2012.08.049
   Gelis C, 2003, PHOTODERMATOL PHOTO, V19, P242, DOI 10.1034/j.1600-0781.2003.00045.x
   Gerhold DL, 2002, NAT GENET, V32, P547, DOI 10.1038/ng1042
   Gingras S, PLOS ONE, V200, pe808
   Gingras S, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000808
   Glavic A, 2009, MECH DEVELOP, V126, P184, DOI 10.1016/j.mod.2008.11.005
   Grober Oli MV, 2011, BMC GENOMICS, V12, P36
   Gui SX, 2011, J HAZARD MATER, V195, P365, DOI 10.1016/j.jhazmat.2011.08.055
   Gurr JR, 2005, TOXICOLOGY, V213, P66, DOI 10.1016/j.tox.2005.05.007
   Hu RP, 2011, J HAZARD MATER, V191, P32, DOI 10.1016/j.jhazmat.2011.04.027
   Huang S, 2009, TOXICOL APPL PHARM, V241, P182, DOI 10.1016/j.taap.2009.08.013
   Huda S, 2010, ACS APPL MATER INTER, V2, P1206, DOI 10.1021/am100045v
   Hyndman D, 2003, CHEM-BIOL INTERACT, V143, P621, DOI 10.1016/S0009-2797(02)00193-X
   Jain TK, 2008, MOL PHARM, V5, P316, DOI 10.1021/mp7001285
   Jeon YM, 2010, MOL CELL TOXICOL, V6, P419, DOI 10.1007/s13273-010-0055-9
   Jin Y, 2007, ANNU REV PHARMACOL, V47, P263, DOI 10.1146/annurev.pharmtox.47.120505.105337
   Kacharmina JE, 1999, METHOD ENZYMOL, V303, P13
   Kakinoki K, 2005, CHEM PHARM BULL, V53, P811, DOI 10.1248/cpb.53.811
   Ke LD, 2000, MOL CELL PROBE, V14, P127, DOI 10.1006/mcpr.2000.0288
   Kowalik TF, 1998, CELL GROWTH DIFFER, V9, P113
   L'Azou B, 2008, PART FIBRE TOXICOL, V5, DOI 10.1186/1743-8977-5-22
   Li JF, 2010, NATURE, V464, P392, DOI 10.1038/nature08907
   Li N, 2010, TOXICOL LETT, V195, P161, DOI 10.1016/j.toxlet.2010.03.1116
   Liao MY, 2012, ENVIRON TOXICOL PHAR, V34, P67, DOI 10.1016/j.etap.2011.05.014
   Lin J, 2010, J BIOL CHEM, V285, P30634
   Liu Huiting, 2010, Toxicological and Environmental Chemistry, V92, P175, DOI 10.1080/02772240902732530
   Liu HT, 2009, BIOL TRACE ELEM RES, V129, P170, DOI 10.1007/s12011-008-8285-6
   Liu WH, 2002, BIOCHEM BIOPH RES CO, V294, P347, DOI 10.1016/S0006-291X(02)00478-3
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Ma LL, 2010, BIOMATERIALS, V31, P99, DOI 10.1016/j.biomaterials.2009.09.028
   Martin FM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016894
   Meena R, 2012, TOXICOL ENVIRON CHEM, V94, P146, DOI 10.1080/02772248.2011.638441
   Mostad EJ, 2011, EXP BIOL MED, V236, P298, DOI 10.1258/ebm.2010.010256
   Muller DN, 2007, BIOCHEM J, V403, P109, DOI 10.1042/BJ20061328
   Nemmar A, 2002, CIRCULATION, V105, P411, DOI 10.1161/hc0402.104118
   NOUROOZZADEH J, 1994, ANAL BIOCHEM, V220, P403, DOI 10.1006/abio.1994.1357
   Oberdorster G, 2005, ENVIRON HEALTH PERSP, V113, P823, DOI 10.1289/ehp.7339
   Oliveira CPMS, 2001, TRANSPL P, V33, P3010, DOI 10.1016/S0041-1345(01)02288-6
   Pablos JL, 2003, J IMMUNOL, V170, P2147, DOI 10.4049/jimmunol.170.4.2147
   Park EJ, 2009, TOXICOLOGY, V260, P37, DOI 10.1016/j.tox.2009.03.005
   Penning TM, 1997, ENDOCR REV, V18, P281, DOI 10.1210/er.18.3.281
   Prohaska JR, 2004, J NUTR, V134, P1003
   Pujalte I, 2011, PART FIBRE TOXICOL, V8, DOI 10.1186/1743-8977-8-10
   Qia J, 2006, BIOCHEM BIOPH RES CO, V349, P303
   Rose KL, 2008, J CLIN INVEST, V118, P608, DOI 10.1172/JCI32525
   Sanchez-Sanchez N, 2004, BLOOD, V104, P619, DOI 10.1182/blood-2003-11-3943
   Schipper ML, 2009, SMALL, V5, P126, DOI 10.1002/smll.200800003
   Schwab K, 2003, KIDNEY INT, V64, P1588, DOI 10.1046/j.1523-1755.2003.00276.x
   Skikne BS, 2008, AM J HEMATOL, V83, P872, DOI 10.1002/ajh.21279
   Sobocanec S, 2010, FREE RADICAL RES, V44, P181, DOI 10.3109/10715760903390820
   Sun QQ, 2012, J BIOMED MATER RES A, V100A, P2554, DOI 10.1002/jbm.a.34190
   Tapryal N, 2009, J BIOL CHEM, V284, P1873, DOI 10.1074/jbc.M804079200
   Wang JX, 2007, TOXICOL LETT, V168, P176, DOI 10.1016/j.toxlet.2006.12.001
   Yang J, 2007, FREE RADICAL RES, V41, P1099, DOI 10.1080/10715760701499356
   Yang P, 2002, MATER LETT, V57, P794, DOI 10.1016/S0167-577X(02)00875-3
   You YH, 2010, WORLD J GASTROENTERO, V16, P1385, DOI 10.3748/wjg.v16.i11.1385
   Zhang WF, 2000, J PHYS D APPL PHYS, V33, P912, DOI 10.1088/0022-3727/33/8/305
   Zhao JF, 2010, J EXP NANOSCI, V5, P447, DOI 10.1080/17458081003628931
   Zhong F, 2013, INFLAMMATION, V36, P80, DOI 10.1007/s10753-012-9522-x
NR 69
TC 43
Z9 43
U1 4
U2 51
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1743-8977
J9 PART FIBRE TOXICOL
JI Part. Fibre Toxicol.
PD FEB 13
PY 2013
VL 10
AR 4
DI 10.1186/1743-8977-10-4
PG 16
WC Toxicology
SC Toxicology
GA 206MR
UT WOS:000323526200001
PM 23406204
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Tobon-Velasco, JC
   Limon-Pacheco, JH
   Orozco-Ibarra, M
   Macias-Silva, M
   Vazquez-Victorio, G
   Cuevas, E
   Ali, SF
   Cuadrado, A
   Pedraza-Chaverri, J
   Santamaria, A
AF Tobon-Velasco, Julio C.
   Limon-Pacheco, Jorge H.
   Orozco-Ibarra, Marisol
   Macias-Silva, Marina
   Vazquez-Victorio, Genaro
   Cuevas, Elvis
   Ali, Syed F.
   Cuadrado, Antonio
   Pedraza-Chaverri, Jose
   Santamaria, Abel
TI RETRACTED: 6-OHDA-induced apoptosis and mitochondrial dysfunction are
   mediated by early modulation of intracellular signals and interaction of
   Nrf2 and NF-kappa B factors (Retracted article. See vol. 390, pg. 167,
   2017)
SO TOXICOLOGY
LA English
DT Article; Retracted Publication
DE 6-Hydroxydopamine; Nrf2/NF-kappa B pathways; Mitochondrial dysfunction;
   Apoptosis; Kinases signaling
ID RESPIRATORY COMPLEX-I; CYTOCHROME-C RELEASE; NEURONAL CELL-DEATH;
   PARKINSONS-DISEASE; OXIDATIVE STRESS; PC12 CELLS; DOPAMINERGIC-NEURONS;
   NEUROBLASTOMA-CELLS; DISTINCT MECHANISMS; HYDROGEN-PEROXIDE
AB 6-Hydroxydopainine (6-OHDA) is a neurotoxin that generates an experimental model of Parkinson's disease in rodents and is commonly employed to induce a lesion in dopaminergic pathways. The characterization of those molecular mechanisms linked to 6-OHDA-induced early toxicity is needed to better understand the cellular events further leading to neurodegeneration. The present work explored how 6-OHDA triggers early downstream signaling pathways that activate neurotoxicity in the rat striatum. Mitochondrial function, caspases-dependent apoptosis, kinases signaling (Akt, ERK 1/2, SAP/JNK and p38) and crosstalk between nuclear factor kappa B (NF-kappa B) and nuclear factor-erythroid-2-related factor 2 (Nrf2) were evaluated at early times post-lesion. We found that 6-OHDA initiates cell damage via mitochondrial complex I inhibition, cytochrome c and apoptosis-inducing factor (AIF) release, as well as activation of caspases 9 and 3 to induce apoptosis, kinase signaling modulation and NF-kappa B-mediated inflammatory responses, accompanied by inhibition of antioxidant systems regulated by the Nrf2 pathway. Our results suggest that kinases SAP/JNK and p38 up-regulation may play a role in the early stages of 6-OHDA toxicity to trigger intrinsic pathways for apoptosis and enhanced NF-kappa B activation. In turn, these cellular events inhibit the activation of cytoprotective mechanisms, thereby leading to a condition of general damage. (C) 2012 Elsevier Ireland Ltd. All rights reserved.
C1 [Tobon-Velasco, Julio C.; Santamaria, Abel] SSA, Inst Nacl Neurol & Neurocirugia, Lab Aminoacidos Excitadores, Mexico City 14269, DF, Mexico.
   [Tobon-Velasco, Julio C.; Limon-Pacheco, Jorge H.; Pedraza-Chaverri, Jose] Univ Nacl Autonoma Mexico, Fac Quim, Dept Biol, Mexico City 04510, DF, Mexico.
   [Limon-Pacheco, Jorge H.; Orozco-Ibarra, Marisol] SSA, Inst Nacl Neurol & Neurocirugia, Lab Neurobiol Mol & Celular INNN UNAM, Mexico City 14269, DF, Mexico.
   [Macias-Silva, Marina; Vazquez-Victorio, Genaro] Univ Nacl Autonoma Mexico, Inst Fisiol Celular, Dept Biol Celular & Desarrollo, Mexico City 04510, DF, Mexico.
   [Cuevas, Elvis; Ali, Syed F.; Santamaria, Abel] US FDA, Natl Ctr Toxicol Res, Div Neurotoxicol, Jefferson, AR 72079 USA.
   [Cuadrado, Antonio] Ctr Invest Red Sobre Enfermedades Neurodegenerat, Inst Invest Biomed Alberto Sols UAM CSIC, Madrid, Spain.
RP Santamaria, A (reprint author), SSA, Inst Nacl Neurol & Neurocirugia, Lab Aminoacidos Excitadores, Mexico City 14269, DF, Mexico.
EM pedraza@unam.mx; absada@yahoo.com
OI Cuadrado, Antonio/0000-0002-3444-9012
FU PAPIIT/UNAM [IN201910]; CONACyT [129838, 168356]; CONACyT-Mexico
   [239757, 46497]; Santander Bank
FX This work was supported in part by PAPIIT/UNAM (IN201910) and CONACyT
   (129838 J.P.-C.) and (168356 MO-I). J.C. Tobon-Velasco is scholarship
   holder from CONACyT-Mexico (239757, 46497), and gratefully acknowledges
   Santander Bank for the fellowship and scholarship student exchange. J.H.
   Limon-Pacheco is grant-fellowship from CONACYT 129838- J.P.-C. Authors
   would like to thank Dr. Isabel Lastres-Becker (IIB-UAM and CIBERNED) and
   Dr. Monica Torres-Ramos (INNN-MVS/SSA) for critical reading of the
   manuscript and stimulating discussions. We also thank Drs. Ismael Torres
   and Enrique Pinzon for their support in supplying experimental animals,
   and M.Sc. Omar N. Medina-Campos (FQ-UNAM) for technical support.
CR Andreadi CK, 2006, MOL PHARMACOL, V69, P1033, DOI 10.1124/mol.105.018374
   ANDREW R, 1993, NEUROCHEM RES, V18, P1175, DOI 10.1007/BF00978370
   Blum D, 2001, PROG NEUROBIOL, V65, P135, DOI 10.1016/S0301-0082(01)00003-X
   Bove J, 2012, NEUROSCIENCE, V211, P51, DOI 10.1016/j.neuroscience.2011.10.057
   Brown GC, 2004, BBA-BIOENERGETICS, V1658, P44, DOI 10.1016/j.bbabio.2004.06.016
   Cano-Ramirez D, 2012, J BIOCHEM MOL TOXIC, V26, P206, DOI 10.1002/jbt.21404
   Tobon-Velasco JC, 2012, FREE RADICAL BIO MED, V53, P1024, DOI 10.1016/j.freeradbiomed.2012.06.040
   Cesar Tobon-Velasco Julio, 2010, Central Nervous System Agents in Medicinal Chemistry, V10, P278
   Choi WS, 1999, J NEUROSCI RES, V57, P86, DOI 10.1002/(SICI)1097-4547(19990701)57:1<86::AID-JNR9>3.0.CO;2-E
   COHEN G, 1974, J BIOL CHEM, V249, P2447
   Cohen G, 2000, ANN NY ACAD SCI, V899, P112
   Deshmukh M, 2000, J CELL BIOL, V150, P131, DOI 10.1083/jcb.150.1.131
   Dodel RC, 1999, MOL BRAIN RES, V64, P141, DOI 10.1016/S0169-328X(98)00318-0
   Elkon H, 2004, J MOL NEUROSCI, V24, P387, DOI 10.1385/JMN:24:3:387
   Fiskum G, 2003, ANN NY ACAD SCI, V991, P111
   Glinka Y, 1997, J NEURAL TRANSM-SUPP, P55
   Glinka Y, 1996, J NEUROCHEM, V66, P2004
   Glinka Y, 1998, EUR J PHARMACOL, V351, P121, DOI 10.1016/S0014-2999(98)00279-9
   GLINKA YY, 1995, EUR J PHARM-ENVIRON, V292, P329, DOI 10.1016/0926-6917(95)90040-3
   Hanrott K, 2008, EUR J NEUROSCI, V27, P1086, DOI 10.1111/j.1460-9568.2008.06097.x
   Henchcliffe C, 2008, NAT CLIN PRACT NEURO, V4, P600, DOI 10.1038/ncpneuro0924
   Holtz WA, 2005, ANTIOXID REDOX SIGN, V7, P639, DOI 10.1089/ars.2005.7.639
   Iglesias-Gonzalez J, 2012, NEUROCHEM RES, V37, P2150, DOI 10.1007/s11064-012-0838-6
   Jordan J, 2004, J NEUROCHEM, V89, P124, DOI 10.1046/j.1471-4159.2003.02299.x
   Kanthasamy A, 2010, NEUROTOXICOLOGY, V31, P555, DOI 10.1016/j.neuro.2009.12.003
   Khodagholi F, 2011, MOL CELL BIOCHEM, V354, P97, DOI 10.1007/s11010-011-0809-2
   Kim-Han JS, 2007, ANTIOXID REDOX SIGN, V9, P2255, DOI 10.1089/ars.2007.1791
   Krohn AJ, 1999, J NEUROSCI, V19, P7394, DOI 10.1523/JNEUROSCI.19-17-07394.1999
   Lee E, 2012, FREE RADICAL BIO MED, V52, P1067, DOI 10.1016/j.freeradbiomed.2011.12.016
   Linert W, 1996, BBA-MOL BASIS DIS, V1316, P160, DOI 10.1016/0925-4439(96)00020-8
   Long JG, 2009, LIFE SCI, V85, P276, DOI 10.1016/j.lfs.2009.05.019
   Lotharius J, 1999, J NEUROSCI, V19, P1284
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   Miller RL, 2009, NEUROCHEM RES, V34, P55, DOI 10.1007/s11064-008-9656-2
   Mirandola SR, 2010, J NEUROSCI RES, V88, P630, DOI 10.1002/jnr.22239
   Naoi M, 2009, J NEURAL TRANSM, V116, P1371, DOI 10.1007/s00702-009-0309-7
   Saito Y, 2007, FREE RADICAL BIO MED, V42, P675, DOI 10.1016/j.freeradbiomed.2006.12.004
   Smigrodzki R, 2004, NEUROBIOL AGING, V25, P1273, DOI 10.1016/j.neurobiolaging.2004.02.020
   Stefanis L, 1999, J NEUROSCI, V19, P6235
   Storch A, 2000, J NEURAL TRANSM, V107, P281, DOI 10.1007/s007020050023
   SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111
   Tarabin V, 2004, N-S ARCH PHARMACOL, V369, P563, DOI 10.1007/s00210-004-0938-1
   Tsang AHK, 2009, BBA-MOL BASIS DIS, V1792, P643, DOI 10.1016/j.bbadis.2008.12.006
   Tusi SK, 2010, APOPTOSIS, V15, P738, DOI 10.1007/s10495-010-0496-6
   Wigdal SS, 2002, J NEUROCHEM, V82, P1029, DOI 10.1046/j.1471-4159.2002.01049.x
   Yuyama K, 2003, J NEUROSCI RES, V73, P351, DOI 10.1002/jnr.10669
   Zhou F, 2007, NEUROPSYCHOPHARMACOL, V32, P2570, DOI 10.1038/sj.npp.1301381
   Zhou J, 2002, FEBS LETT, V526, P21, DOI 10.1016/S0014-5793(02)03107-1
NR 48
TC 33
Z9 36
U1 1
U2 24
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0300-483X
J9 TOXICOLOGY
JI Toxicology
PD FEB 8
PY 2013
VL 304
BP 109
EP 119
DI 10.1016/j.tox.2012.12.011
PG 11
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA 111LH
UT WOS:000316522300013
PM 23274087
DA 2018-12-27
ER

PT J
AU Lia, G
   Rigato, A
   Long, E
   Chagneau, C
   Le Masson, M
   Allemand, JF
   Michel, B
AF Lia, Giuseppe
   Rigato, Annafrancesca
   Long, Emilie
   Chagneau, Carine
   Le Masson, Marie
   Allemand, Jean-Francois
   Michel, Benedicte
TI RETRACTED: RecA-Promoted, RecFOR-Independent Progressive Disassembly of
   Replisomes Stalled by Helicase Inactivation (Retracted article. See vol.
   54, pg. 537, 2014)
SO MOLECULAR CELL
LA English
DT Article; Retracted Publication
ID ARRESTED REPLICATION FORKS; LIVING BACTERIAL-CELLS; STRAND BREAK REPAIR;
   ESCHERICHIA-COLI; DNA-REPLICATION; RECOMBINATION PROTEINS; INSTABILITY;
   DYNAMICS; POLYMERASE; EXCHANGE
AB In all organisms, replication impairment is a recognized source of genomic instability, raising an increasing interest in the fate of inactivated replication forks. We used Escherichia coli strains with a temperature-inactivated replicative helicase (DnaB) and in vivo single-molecule microscopy to quantify the detailed molecular processing of stalled replication forks. After helicase inactivation, RecA binds to blocked replication forks and is essential for the rapid release of hPol III. The entire holoenzyme is disrupted little by little, with some components lost in few minutes, while others are stable in 70% of cells for at least 1 hr. Although replisome dissociation is delayed in a recA mutant, it is not affected by RecF or RecO inactivation. RecFOR are required for full RecA filaments formation, and we propose that polymerase clearance can be catalyzed by short, RecFOR-independent RecA filaments. Our results identify a function for the universally conserved, central recombination protein RecA.
C1 [Lia, Giuseppe; Rigato, Annafrancesca; Long, Emilie; Chagneau, Carine; Le Masson, Marie; Michel, Benedicte] CNRS, Ctr Genet Mol, UPR3404, F-91198 Gif Sur Yvette, France.
   [Lia, Giuseppe; Rigato, Annafrancesca; Long, Emilie; Chagneau, Carine; Le Masson, Marie; Michel, Benedicte] Univ Paris 11, F-91405 Orsay, France.
   [Lia, Giuseppe; Rigato, Annafrancesca; Long, Emilie; Allemand, Jean-Francois] Univ Paris 06, Lab Phys Stat, Ecole Normale Super, CNRS,UMR 8550, F-75231 Paris 05, France.
   [Lia, Giuseppe; Rigato, Annafrancesca; Long, Emilie; Allemand, Jean-Francois] Univ Paris Diderot, Dept Phys, F-75231 Paris 05, France.
   [Allemand, Jean-Francois] Ecole Normale Super, CNRS, IBENS, Dept Biol,UMR 8542, F-75231 Paris 05, France.
RP Lia, G (reprint author), CNRS, Ctr Genet Mol, UPR3404, F-91198 Gif Sur Yvette, France.
EM lia@cgm.cnrs-gif.fr; benedicte.michel@cgm.cnrs-gif.fr
FU "Prix coup d'elan" from the foundation Bettencourt-Schueller; ARC
   postdoctoral grant [A2009]; ANR; IUF;  [ANR-BLAN08-3_309268]
FX We thank Dr. D. Bensimon (ENS Paris) and Dr. S. Lovett (Brandeis
   University) for their very helpful reading of the manuscript. Work in
   B.M.'s laboratory was supported by ANR-BLAN08-3_309268 and by a "Prix
   coup d'elan" from the foundation Bettencourt-Schueller. G.L. was
   supported by an ARC postdoctoral grant (No. A2009). Work in J-F.A.'s
   laboratory was supported by ANR and IUF.
CR Aguilera A, 2008, NAT REV GENET, V9, P204, DOI 10.1038/nrg2268
   Atkinson J, 2011, NUCLEIC ACIDS RES, V39, P949, DOI 10.1093/nar/gkq889
   Branzei D, 2010, NAT REV MOL CELL BIO, V11, P208, DOI 10.1038/nrm2852
   Colnaghi R, 2011, SEMIN CELL DEV BIOL, V22, P875, DOI 10.1016/j.semcdb.2011.07.010
   Costanzo V, 2011, DNA REPAIR, V10, P1060, DOI 10.1016/j.dnarep.2011.07.009
   Dalrymple BP, 2001, P NATL ACAD SCI USA, V98, P11627, DOI 10.1073/pnas.191384398
   Elf J, 2007, SCIENCE, V316, P1191, DOI 10.1126/science.1141967
   English BP, 2011, P NATL ACAD SCI USA, V108, pE365, DOI 10.1073/pnas.1102255108
   Galletto R, 2006, NATURE, V443, P875, DOI 10.1038/nature05197
   HILL TM, 1990, P NATL ACAD SCI USA, V87, P2481, DOI 10.1073/pnas.87.7.2481
   Joo C, 2006, CELL, V126, P515, DOI 10.1016/j.cell.2006.06.042
   Kim SS, 1996, CELL, V84, P643, DOI 10.1016/S0092-8674(00)81039-9
   Kliszczak AE, 2011, SCI REP-UK, V1, DOI 10.1038/srep00095
   Kuzminov A, 1999, MICROBIOL MOL BIOL R, V63, P751
   Lambert S, 2007, DNA REPAIR, V6, P1042, DOI 10.1016/j.dnarep.2007.02.024
   Lia G, 2012, SCIENCE, V335, P328, DOI 10.1126/science.1210400
   Long DT, 2011, SCIENCE, V333, P84, DOI 10.1126/science.1204258
   MCHENRY C, 1977, J BIOL CHEM, V252, P6478
   McHenry CS, 2011, ANNU REV BIOCHEM, V80, P403, DOI 10.1146/annurev-biochem-061208-091655
   McInerney P, 2007, J BIOL CHEM, V282, P25903, DOI 10.1074/jbc.M703777200
   Michel B, 2007, DNA REPAIR, V6, P967, DOI 10.1016/j.dnarep.2007.02.016
   Morimatsu K, 2003, MOL CELL, V11, P1337, DOI 10.1016/S1097-2765(03)00188-6
   Petermann E, 2010, NAT REV MOL CELL BIO, V11, P683, DOI 10.1038/nrm2974
   Petermann E, 2010, MOL CELL, V37, P492, DOI 10.1016/j.molcel.2010.01.021
   REGISTER JC, 1985, J BIOL CHEM, V260, P2308
   Renzette N, 2005, MOL MICROBIOL, V57, P1074, DOI 10.1111/j.1365-2958.2005.04755.x
   Reyes-Lamothe R, 2008, CELL, V133, P90, DOI 10.1016/j.cell.2008.01.044
   Reyes-Lamothe R, 2010, SCIENCE, V328, P498, DOI 10.1126/science.1185757
   Roy R, 2009, NATURE, V461, P1092, DOI 10.1038/nature08442
   Sakai A, 2009, J BIOL CHEM, V284, P3264, DOI 10.1074/jbc.M807220200
   SALUJA D, 1995, J BACTERIOL, V177, P1104, DOI 10.1128/jb.177.4.1104-1111.1995
   Schlacher K, 2011, CELL, V145, P529, DOI 10.1016/j.cell.2011.03.041
   Seigneur M, 2000, MOL MICROBIOL, V38, P565, DOI 10.1046/j.1365-2958.2000.02152.x
   Seigneur M, 1998, CELL, V95, P419, DOI 10.1016/S0092-8674(00)81772-9
   Shereda RD, 2008, CRIT REV BIOCHEM MOL, V43, P289, DOI [10.1080/10409230802341296, 10.1080/10409230802341296 ]
   Shima N, 2007, NAT GENET, V39, P93, DOI 10.1038/ng1936
   Sirbu BM, 2011, GENE DEV, V25, P1320, DOI 10.1101/gad.2053211
   van Loenhout MTJ, 2009, NUCLEIC ACIDS RES, V37, P4089, DOI 10.1093/nar/gkp326
   Wang YX, 2005, NAT GENET, V37, P750, DOI 10.1038/ng1587
   Xie XS, 2008, ANNU REV BIOPHYS, V37, P417, DOI 10.1146/annurev.biophys.37.092607.174640
   Zhou RB, 2011, CELL, V146, P222, DOI 10.1016/j.cell.2011.06.036
NR 41
TC 11
Z9 11
U1 1
U2 27
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1097-2765
EI 1097-4164
J9 MOL CELL
JI Mol. Cell
PD FEB 7
PY 2013
VL 49
IS 3
BP 547
EP 557
DI 10.1016/j.molcel.2012.11.018
PG 11
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 087VO
UT WOS:000314792500017
PM 23260658
OA Bronze
DA 2018-12-27
ER

PT J
AU Kumar, A
   Adhikari, S
   Banerjee, S
   Roy, S
AF Kumar, Atul
   Adhikari, Satyabrata
   Banerjee, Subhashish
   Roy, Sovik
TI RETRACTED: Optimal quantum communication using multiparticle partially
   entangled states (Retracted article. See vol. 87, 059904, 2013)
SO PHYSICAL REVIEW A
LA English
DT Article; Retracted Publication
ID TELEPORTATION
AB We propose a three-qubit partially entangled set of states as a shared resource for optimal and faithful quantum information processing. We show that our states always violate the Svetlichny inequality, which is a Bell-type inequality whose violation is a sufficient condition for the confirmation of genuine three-qubit nonlocality. Although our states can be physically realized from the generalized Greenberger-Horne-Zeilinger (GGHZ) states using a simple quantum circuit, the nonlocal properties of the set are quite different from the GGHZ states. Instead, they are similar to the maximal slice (MS) states, even though our states are not locally equivalent to the MS states. Unlike other two- and three-qubit partially entangled states, quantum teleportation using our states results in faithful transmission of information with unit probability and unit fidelity by performing only standard measurements for the sender, controller, and receiver. We further demonstrate that dense coding also leads to the deterministic transfer of a maximum number of bits from the sender to the receiver. We also introduce witness operators able to experimentally detect the family of states introduced. This work highlights the importance of both the local as well as nonlocal aspects of quantum correlations in multiqubit systems. DOI: 10.1103/PhysRevA.87.022307
C1 [Kumar, Atul; Adhikari, Satyabrata; Banerjee, Subhashish] Indian Inst Technol Rajasthan, Jodhpur, Rajasthan, India.
   [Roy, Sovik] Techno India, Kolkata 700091, India.
RP Kumar, A (reprint author), Indian Inst Technol Rajasthan, Jodhpur, Rajasthan, India.
EM atulk@iitj.ac.in; satya@iitj.ac.in; subhashish@iitj.ac.in;
   sovikr@rediffmail.com
CR Acin A, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.040401
   Agrawal P, 2002, PHYS LETT A, V305, P12, DOI 10.1016/S0375-9601(02)01383-X
   Agrawal P, 2006, PHYS REV A, V74, DOI 10.1103/PhysRevA.74.062320
   Bandyopadhyay S, 2000, PHYS REV A, V62, DOI 10.1103/PhysRevA.62.012308
   BENNETT CH, 1992, PHYS REV LETT, V69, P2881, DOI 10.1103/PhysRevLett.69.2881
   BENNETT CH, 1993, PHYS REV LETT, V70, P1895, DOI 10.1103/PhysRevLett.70.1895
   Bennett CH, 1996, PHYS REV A, V53, P2046, DOI 10.1103/PhysRevA.53.2046
   Bostrom K, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.187902
   Bruss D, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.210501
   Buscemi F, 2012, PHYS REV LETT, V108, DOI 10.1103/PhysRevLett.108.200401
   Carteret HA, 2000, J PHYS A-MATH GEN, V33, P4981, DOI 10.1088/0305-4470/33/28/303
   Coffman V, 2000, PHYS REV A, V61, DOI 10.1103/PhysRevA.61.052306
   Dur W, 2000, PHYS REV A, V62, DOI 10.1103/PhysRevA.62.062314
   Ganguly N, 2011, PHYS REV LETT, V107, DOI 10.1103/PhysRevLett.107.270501
   Ganguly N, 2009, PHYS REV A, V80, DOI 10.1103/PhysRevA.80.032331
   Gao T, 2004, Z NATURFORSCH A, V59, P597
   Ghose S, 2009, PHYS REV LETT, V102, DOI 10.1103/PhysRevLett.102.250404
   GREENBERGER DM, 1990, AM J PHYS, V58, P1131, DOI 10.1119/1.16243
   Hao JC, 2001, PHYS REV A, V63, part. no., DOI 10.1103/PhysRevA.63.054301
   Karlsson A, 1998, PHYS REV A, V58, P4394, DOI 10.1103/PhysRevA.58.4394
   Man ZX, 2007, PHYS REV A, V75, DOI 10.1103/PhysRevA.75.052306
   MOR T, ARXIVQUANTPH9906039
   Sawicki A., ARXIV10090293V1
   Shi BS, 2002, PHYS LETT A, V296, P161, DOI 10.1016/S0375-9601(02)00257-8
   SVETLICHNY G, 1987, PHYS REV D, V35, P3066, DOI 10.1103/PhysRevD.35.3066
   ZUKOWSKI M, 1993, PHYS REV LETT, V71, P4287, DOI 10.1103/PhysRevLett.71.4287
NR 26
TC 6
Z9 7
U1 2
U2 20
PU AMER PHYSICAL SOC
PI COLLEGE PK
PA ONE PHYSICS ELLIPSE, COLLEGE PK, MD 20740-3844 USA
SN 2469-9926
EI 2469-9934
J9 PHYS REV A
JI Phys. Rev. A
PD FEB 7
PY 2013
VL 87
IS 2
AR 022307
DI 10.1103/PhysRevA.87.022307
PG 6
WC Optics; Physics, Atomic, Molecular & Chemical
SC Optics; Physics
GA 087JT
UT WOS:000314758300004
DA 2018-12-27
ER

PT J
AU Chen, WD
   Yu, DN
   Forman, BM
   Huang, WD
   Wang, YD
AF Chen, Wei-Dong
   Yu, Donna
   Forman, Barry M.
   Huang, Wendong
   Wang, Yan-Dong
TI RETRACTED: Deficiency of G-Protein-Coupled Bile Acid Receptor Gpbar1
   (TGR5) Enhances Chemically Induced Liver Carcinogenesis (Retracted
   article. See vol. 58, pg. 1194, 2013)
SO HEPATOLOGY
LA English
DT Article; Retracted Publication
ID NF-KAPPA-B; HEPATOCELLULAR-CARCINOMA; MEDIATED APOPTOSIS; MOLECULAR
   TARGETS; POTENTIAL TARGET; CANCER; STAT3; INFLAMMATION; CELLS;
   ACTIVATION
AB Gpbar1 (TGR5), a membrane-bound bile acid receptor, is well known for its roles in regulation of energy homeostasis and glucose metabolism. TGR5 activation also inhibits nuclear factor kappa B (NF-kappa B)-mediated inflammation. Here we show that TGR5 deficiency enhances chemically induced liver carcinogenesis, and that TGR5 is a negative regulator of signal transducer and activator of transcription 3 (STAT3) signaling. Mice lacking TGR5 were much more susceptible to diethylnitrosamine (DEN)-induced acute liver injury and liver carcinogenesis than wildtype (WT) mice. Consistent with the increasing incidence of liver cancer in TGR5(-/-) mice, hepatocyte death, compensatory proliferation, and gene expression of certain inflammatory cytokines and matrix metalloproteinases were more sensitive to DEN induction in the absence of TGR5 signaling. In vitro, TGR5 activation greatly inhibited proliferation and migration of human liver cancer cells. We then found that TGR5 activation strongly suppressed STAT3 signaling in vitro and in vivo. Furthermore, we observed that TGR5 antagonizes the STAT3 pathway through suppressing STAT3 phosphorylation, its transcription activity, and DNA binding activity, which suggests that TGR5 antagonizes liver tumorigenesis at least in part by inhibiting STAT3 signaling. Conclusion: These findings identify TGR5 as a novel liver tumor suppressor that may serve as an attractive therapeutic tool for human liver cancer. (HEPATOLOGY 2013;57:656-666)
C1 [Chen, Wei-Dong; Wang, Yan-Dong] Northeast Ohio Med Univ, Dept Integrat Med Sci, Rootstown, OH 44272 USA.
   [Chen, Wei-Dong] Henan Univ, Sch Med, Key Lab Receptors Mediated Gene Regulat & Drug Di, Kaifeng, Peoples R China.
   [Yu, Donna; Forman, Barry M.; Huang, Wendong; Wang, Yan-Dong] City Hope Natl Med Ctr, BeckmanRes Inst, Dept Gene Regulat & Drug Discovery, Duarte, CA 91010 USA.
RP Wang, YD (reprint author), Northeast Ohio Med Univ, Dept Integrat Med Sci, Rootstown, OH 44272 USA.
EM whuang@coh.org; yandong_wang@yahoo.com.cn
FU National Natural Science Foundation of China [81270522]; NCI
   [R01-139158]; City of Hope GI Cancer Program GI Cancer Research Pilot
   Fund
FX Supported by the National Natural Science Foundation of China (Grant No.
   81270522) to W.-D. C., NCI R01-139158 to W. H.; the City of Hope GI
   Cancer Program GI Cancer Research Pilot Fund to Y.-D.W.
CR Alas S, 2003, CLIN CANCER RES, V9, P316
   Bharti AC, 2002, BIOCHEM PHARMACOL, V64, P883, DOI 10.1016/S0006-2952(02)01154-1
   Buettner R, 2002, CLIN CANCER RES, V8, P945
   Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4
   Chen LP, 2009, DIGEST DIS SCI, V54, P547, DOI 10.1007/s10620-008-0401-0
   Chen WD, 2010, HEPATOLOGY, V51, P953, DOI 10.1002/hep.23390
   Crissey MAS, 1999, HEPATOLOGY, V30, P1187, DOI 10.1002/hep.510300520
   Dorsam RT, 2007, NAT REV CANCER, V7, P79, DOI 10.1038/nrc2069
   He GB, 2011, CELL RES, V21, P159, DOI 10.1038/cr.2010.183
   He GB, 2010, CANCER CELL, V17, P286, DOI 10.1016/j.ccr.2009.12.048
   Hedvat M, 2009, CANCER CELL, V16, P487, DOI 10.1016/j.ccr.2009.10.015
   Hotamisligil GS, 2008, INT J OBESITY, V32, pS52, DOI 10.1038/ijo.2008.238
   Huynh H, 2010, BIOCHEM PHARMACOL, V80, P550, DOI 10.1016/j.bcp.2010.03.034
   Kawamata Y, 2003, J BIOL CHEM, V278, P9435, DOI 10.1074/jbc.M209706200
   Kortylewski M, 2007, J IMMUNOTHER, V30, P131, DOI 10.1097/01.cji.0000211327.76266.65
   Lee H, 2011, CURR TOP MICROBIOL, V344, P41, DOI 10.1007/82_2010_51
   Lee H, 2009, CANCER CELL, V15, P283, DOI 10.1016/j.ccr.2009.02.015
   Li WC, 2006, CLIN CANCER RES, V12, P7140, DOI 10.1158/1078-0432.CCR-06-0484
   Maruyama T, 2006, J ENDOCRINOL, V191, P197, DOI 10.1677/joe.1.06546
   Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0
   Naugler WE, 2007, SCIENCE, V317, P121, DOI 10.1126/science.1140485
   Ng KTP, 2011, EUR J CANCER, V47, P2299, DOI 10.1016/j.ejca.2011.05.032
   Ohta A, 2001, NATURE, V414, P916, DOI 10.1038/414916a
   Pellicciari R, 2007, J MED CHEM, V50, P4265, DOI 10.1021/jm070633p
   Pikarsky E, 2004, NATURE, V431, P461, DOI 10.1038/nature02924
   Qiu W, 2011, HEPATOLOGY, V54, P1249, DOI 10.1002/hep.24516
   Rolli M, 2003, P NATL ACAD SCI USA, V100, P9482, DOI 10.1073/pnas.1633689100
   Sarkar FH, 2008, FRONT BIOSCI-LANDMRK, V13, P2950, DOI 10.2741/2900
   Schneider C, 2012, GUT
   Senft C, 2011, J NEURO-ONCOL, V101, P393, DOI 10.1007/s11060-010-0273-y
   Shih YW, 2009, HEPATOL RES, V39, P998, DOI 10.1111/j.1872-034X.2009.00540.x
   Sun BC, 2012, J HEPATOL, V56, P704, DOI 10.1016/j.jhep.2011.09.020
   Tang Y, 2011, INT J CANCER, V128, P847, DOI 10.1002/ijc.25638
   Thomas C, 2009, CELL METAB, V10, P167, DOI 10.1016/j.cmet.2009.08.001
   Vassileva G, 2006, BIOCHEM J, V398, P423, DOI 10.1042/BJ20060537
   Wang YD, 2008, HEPATOLOGY, V48, P1632, DOI 10.1002/hep.22519
   Wang YD, 2011, HEPATOLOGY, V54, P1421, DOI 10.1002/hep.24525
   Watanabe M, 2006, NATURE, V439, P484, DOI 10.1038/nature04330
   Weber A, 2011, SWISS MED WKLY, V141, DOI 10.4414/smw.2011.13197
   Wellen KE, 2005, J CLIN INVEST, V115, P1111, DOI 10.1172/JCI200525102
   Wuertz K, 2012, EUR CELLS MATER, V23, P119
   Wuertz K, 2012, EUR CELLS MATER, V23, P103
   Yoshizaki T, 2010, AM J PHYSIOL-ENDOC M, V298, pE419, DOI 10.1152/ajpendo.00417.2009
   Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275
   Yu H, 2007, NAT REV IMMUNOL, V7, P41, DOI 10.1038/nri1995
   Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734
NR 46
TC 17
Z9 19
U1 3
U2 20
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD FEB
PY 2013
VL 57
IS 2
BP 656
EP 666
DI 10.1002/hep.26019
PG 11
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 099TA
UT WOS:000315643400025
PM 22911633
OA Green Accepted
DA 2018-12-27
ER

PT J
AU El-ghonemy, AMK
AF El-ghonemy, A. M. K.
TI RETRACTED: Waste energy recovery in seawater reverse osmosis
   desalination plants. Part 1: Review (Retracted article. See vol. 22, pg.
   734, 2013)
SO RENEWABLE & SUSTAINABLE ENERGY REVIEWS
LA English
DT Review; Retracted Publication
DE Desalination; Seawater reverse osmosis (SWRO); Energy recovery devices
   (ERD)
ID WORK EXCHANGER; SYSTEMS; DEVICES
AB The reduction of energy consumption constitutes one of the major thrust areas of research in seawater reverse osmosis (SWRO) desalination plants. The cost of energy in the SWRO process is usually about 30-50% of the total production cost of water and can be as much as 75% of the operating cost, depending on the cost of electricity. Thus, energy forms the major contributing factor in determining the water production cost. Hence reducing the energy consumption, which is mainly due to wastage of energy in high-pressure brine, is a major goal of desalination industries.
   Energy recovery devices are employed in seawater reverse osmosis (SWRO) desalination plants to recover the high pressure energy from the membrane exhaust stream (60:80 bar) and return it back to the process. Because of this high exhaust (concentrate) pressures at high flow rates, the membrane exhaust stream contains a considerable amount of energy to be recovered. Recently, isobaric energy recovery devices and turbochargers have been used for SWRO performance improvement. These devices are intended to provide greater energy-savings and greater capacity than was previously achievable.
   This paper gives a comprehensive overview of the available energy recovery devices (ERDs) that can be used in seawater reverse osmosis (SWRO) systems, with emphasis on technologies and economics. A comparative study between different ERDs technologies as well as performance and economics has been done. These include turbines, turbochargers and isobaric devices at different design configurations. Special attention is given to the use of ERDs in seawater RU desalination. Finally, some general guidelines are given for selection of ERDs and parameters that need to be considered (specific power consumption kW h/m(3), energy saving%, and the corresponding cost saving). (C) 2012 Elsevier Ltd. All rights reserved.
C1 Al Jouf Univ, Coll Engn, Skaka City El Jouf, Skaka, Saudi Arabia.
RP El-ghonemy, AMK (reprint author), Al Jouf Univ, Coll Engn, Skaka City El Jouf, Skaka, Saudi Arabia.
EM amghonemy@yahoo.com
RI El-Ghonemy, Amin/D-3938-2014
OI El-Ghonemy, Amin/0000-0003-4147-4010
CR Al-Hawaj OM, 2003, DESALINATION, V157, P23, DOI 10.1016/S0011-9164(03)00378-3
   Andrews WT, 2001, DESALINATION, V138, P201, DOI 10.1016/S0011-9164(01)00265-X
   Baig MB, 1998, DESALINATION, V118, P5, DOI 10.1016/S0011-9164(98)00068-X
   E-Ghonemy AMK, 2012, RENEW SUST ENERG REV, V16, P4597, DOI 10.1016/j.rser.2012.05.009
   EI-Ghonemy AMK, 2012, RENEW SUST ENERG REV, V16, P1537, DOI 10.1016/j.rser.2011.11.002
   El-Dessouki H. T., 2002, FUNDAMENTALS SALT WA
   El-Ghonemy AMK, 2012, RENEW SUST ENERG REV, V16, P4016, DOI 10.1016/j.rser.2012.03.057
   Eltawil MA, 2009, RENEW SUST ENERG REV, V13, P2245, DOI 10.1016/j.rser.2009.06.011
   Energy Recovery Inc, 2005, EN REC DEV PERF AN
   Erik D, 2011, IDA WORLD C PERTH CO
   Farooque AM, 2008, DESALINATION, V219, P137, DOI 10.1016/j.desal.2007.06.004
   Farooque AM, 2008, COMP STUDY VARIOUS E
   Harris C, 1999, DESALINATION, V125, P173, DOI 10.1016/S0011-9164(99)00136-8
   Kalogirou SA, 2005, PROG ENERG COMBUST, V31, P242, DOI 10.1016/j.pecs.2005.03.001
   Leandro S., 2008, PERFORMANCE CURVES P
   Liu C, 2011, DESALINATION, V276, P352, DOI 10.1016/j.desal.2011.03.074
   MacHarg JP, 2003, DESALINATION, V153, P253, DOI 10.1016/S0011-9164(02)01144-X
   MICKOLS WE, 2005, P INT DES ASS WORLD
   Migliorini G, 2004, DESALINATION, V165, P289, DOI 10.1016/j.desal.2004.06.034
   Oklejas Jr E., 2007, P AM MEMBR TECHN ASS
   Penate B, 2011, ENERGY, V36, P613, DOI 10.1016/j.energy.2010.09.056
   Pique GG., 2005, DESALINATION WATER R, V15/3
   Poovanaesvaran P, 2011, DESALIN WATER TREAT, V27, P210, DOI 10.5004/dwt.2011.1824
   Rahman MM, 2011, THESIS U S FLORIDA
   Richard L., 2009, RETROFITS IMPROVE DE
   Seacord T, 2006, AM MEMBR TECHN ASS B
   Stover EL, 2007, P INT DES ASS WORLD
   Stover R., 2005, SUSTAINABLE DESALINA
   Stover RL, 2007, DESALINATION, V203, P168, DOI 10.1016/j.desal.2006.03.528
   Stover RL., 2006, DESALINATION, P40
   Thomson A., 2003, THESIS LOUGHBOROUGH
   Trieb F, 2009, COMBINED SOLAR POWER
   Verdier F., 2011, MENA REGIONAL WATE 2
   Water Middle East Bahrain, 2007, PLANT DES PERF PX PR
   William T, 2001, DESALINATION, V138, P201
NR 35
TC 9
Z9 10
U1 3
U2 84
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1364-0321
J9 RENEW SUST ENERG REV
JI Renew. Sust. Energ. Rev.
PD FEB
PY 2013
VL 18
BP 6
EP 22
DI 10.1016/j.rser.2012.09.022
PG 17
WC GREEN & SUSTAINABLE SCIENCE & TECHNOLOGY; Energy & Fuels
SC Science & Technology - Other Topics; Energy & Fuels
GA 094DX
UT WOS:000315244300002
DA 2018-12-27
ER

PT J
AU Kadam, RS
   Vooturi, SK
   Kompella, UB
AF Kadam, Rajendra S.
   Vooturi, Sunil K.
   Kompella, Uday B.
TI RETRACTED: Immunohistochemical and Functional Characterization of
   Peptide, Organic Cation, Neutral and Basic Amino Acid, and
   Monocarboxylate Drug Transporters in Human Ocular Tissues (Retracted
   article. See vol. 43, pg. 234, 2015)
SO DRUG METABOLISM AND DISPOSITION
LA English
DT Article; Retracted Publication
ID MONOESTER GANCICLOVIR PRODRUGS; CONJUNCTIVAL EPITHELIAL-CELLS; PIGMENTED
   RABBIT CONJUNCTIVA; CARRIER-MEDIATED TRANSPORT; 8 BETA-BLOCKERS;
   OLIGOPEPTIDE TRANSPORTER; H+/PEPTIDE SYMPORTER; CHOROID-RPE; EXPRESSION;
   DELIVERY
AB Since there is paucity of information on solute transporters in human ocular tissues, the aim of this study was immunohistochemical and functional characterization of peptide transporters (PEPT), organic cation transporters (OCTs), neutral and basic amino acid transporters (ATB(0,+)), and monocarboxylate transporters (MCTs) in human ocular barriers. Immunohistochemical localization of transporters was achieved using 5-mu m-thick paraffin-embedded sections of whole human eyes. In vitro transport studies were carried out across human cornea and sclera-choroid-retinal pigment epithelium (SCRPE) using a cassette of specific substrates in the presence and absence of inhibitors to determine the role of transporters in transtissue solute delivery. Immunohistochemistry showed the expression of PEPT-1, PEPT-2, ATB(0,+), OCT-1, OCT-2, MCT-1, and MCT-3 in human ocular tissues. PEPT-1, PEPT-2, OCT-1, MCT-1, and ATB(0,+) expression was evident in the cornea, conjunctiva, ciliary epithelium, and neural retina. Expression of PEPT-1, PEPT-2, and OCT-1 was evident in choroid tissue as well. OCT-2 expression could be seen in the corneal and conjunctival epithelia, whereas MCT-3 expression was confined to the RPE layer. OCT-2 expression was evident in conjunctival blood vessel walls, whereas PEPT-1, PEPT-2, and OCT-1 were expressed in the choroid. Preliminary transport studies indicated inward transport of Gly-Sar (PEPT substrate), 1-methyl-4-phenylpyridinium (MPP+) (OCT substrate), and L-tryptophan (ATB(0,+) substrate) across cornea as well as SCRPE. For phenylacetic acid (MCT substrate), transporter-mediated inward transport across the cornea and outward transport across SCRPE were evident. Thus, PEPT, OCT, and ATB(0,+) are influx transporters present in human ocular barriers, and they can potentially be used for transporter-guided retinal drug delivery after topical, transscleral, and systemic administrations.
C1 [Kadam, Rajendra S.; Vooturi, Sunil K.; Kompella, Uday B.] Univ Colorado, Dept Pharmaceut Sci, Aurora, CO 80045 USA.
   [Kompella, Uday B.] Univ Colorado, Dept Ophthalmol, Aurora, CO 80045 USA.
   [Kompella, Uday B.] Univ Colorado, Dept Bioengn, Aurora, CO 80045 USA.
RP Kompella, UB (reprint author), Univ Colorado, Skaggs Sch Pharm & Pharmaceut Sci, Dept Pharmaceut Sci, Anschutz Med Campus,12850 E Montview Blvd, Aurora, CO 80045 USA.
EM uday.kompella@ucdenver.edu
FU National Institutes of Health National Eye Institute [R01EY018940,
   R01EY017533]
FX This work was supported by National Institutes of Health National Eye
   Institute [Grants R01EY018940 and R01EY017533].
CR Anand BS, 2002, PHARM RES-DORDR, V19, P1194, DOI 10.1023/A:1019806411610
   Basu SK, 1998, INVEST OPHTH VIS SCI, V39, P2365
   Biegel A, 2006, AMINO ACIDS, V31, P137, DOI 10.1007/s00726-006-0331-0
   Brandsch M, 1999, EUR J BIOCHEM, V266, P502, DOI 10.1046/j.1432-1327.1999.00885.x
   Chidlow G, 2005, AM J PHYSIOL-CELL PH, V288, pC416, DOI 10.1152/ajpcell.00037.2004
   Cortes-Campos C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016411
   Ganapathy M. E., 2005, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V5, P357, DOI 10.2174/156800805774912953
   Garrett Q, 2008, INVEST OPHTH VIS SCI, V49, P4844, DOI 10.1167/iovs.07-1528
   Giacomini KM, 2010, NAT REV DRUG DISCOV, V9, P215, DOI 10.1038/nrd3028
   Guo AL, 1999, J PHARMACOL EXP THER, V289, P448
   Gygi SP, 1999, MOL CELL BIOL, V19, P1720
   Gynther M, 2008, J MED CHEM, V51, P932, DOI 10.1021/jm701175d
   Hatanaka T, 2004, J PHARMACOL EXP THER, V308, P1138, DOI 10.1124/jpet.103.057109
   Horibe Y, 1998, INVEST OPHTH VIS SCI, V39, P1436
   Hosoya K, 2001, PHARM RES-DORDR, V18, P1669, DOI 10.1023/A:1013310210710
   Jain-Vakkalagadda B, 2004, MOL PHARMACEUT, V1, P338, DOI 10.1021/mp0499499
   Jong NN, 2011, J PHARMACOL EXP THER, V338, P537, DOI 10.1124/jpet.111.181297
   Jonker JW, 2004, J PHARMACOL EXP THER, V308, P2, DOI 10.1124/jpet.103.053298
   Kadam RS, 2011, INVEST OPHTH VIS SCI, V52, P5387, DOI 10.1167/iovs.10-6233
   Kadam RS, 2009, J CHROMATOGR B, V877, P253, DOI 10.1016/j.jchromb.2008.12.027
   Kansara V, 2007, J OCUL PHARMACOL TH, V23, P321, DOI 10.1089/iop.2006.0150
   Karunakaran S, 2008, BIOCHEM J, V414, P343, DOI 10.1042/BJ20080622
   Kimura N, 2005, PHARM RES-DORDR, V22, P255, DOI 10.1007/s11095-004-1193-3
   Kompella U. B., 2003, OPHTHALMIC DRUG DELI, P13
   Kompella UB, 2010, THER DELIV, V1, P435, DOI 10.4155/TDE.10.40
   Majumdar S, 2005, J OCUL PHARMACOL TH, V21, P463, DOI 10.1089/jop.2005.21.463
   Majumdar S, 2009, PHARM RES-DORDR, V26, P1261, DOI 10.1007/s11095-008-9730-0
   Ocheltree SM, 2003, PHARMACEUT RES, V20, P1364, DOI 10.1023/A:1025741723724
   Okamoto M, 2009, NEUROCHEM INT, V55, P789, DOI 10.1016/j.neuint.2009.08.001
   Pedersen JM, 2008, J MED CHEM, V51, P3275, DOI 10.1021/jm7015683
   Peura L, 2011, MOL PHARMACEUT, V8, P1857, DOI 10.1021/mp2001878
   Philp NJ, 2003, INVEST OPHTH VIS SCI, V44, P1716, DOI 10.1167/iovs.02-0287
   Smith DE, 2004, ADV DRUG DELIVER REV, V56, P1765, DOI 10.1016/j.addr.2004.07.008
   Sugano K, 2010, NAT REV DRUG DISCOV, V9, P597, DOI 10.1038/nrd3187
   Sun L, 1996, DIPEPTIDE TRANSPORT
   TSUJI A, 1994, PHARMACEUT RES, V11, P30, DOI 10.1023/A:1018933324914
   Ueda H, 2000, INVEST OPHTH VIS SCI, V41, P870
   Umapathy NS, 2004, PHARM RES, V21, P1303, DOI 10.1023/B:PHAM.0000033019.49737.28
   Umehara KI, 2007, XENOBIOTICA, V37, P618, DOI 10.1080/00498250701397705
   WELLER S, 1993, CLIN PHARMACOL THER, V54, P595, DOI 10.1038/clpt.1993.196
   Xu SJ, 2010, MOL VIS, V16, P1823
   Zhang T, 2008, DRUG METAB DISPOS, V36, P1300, DOI 10.1124/dmd.108.021121
NR 42
TC 10
Z9 10
U1 2
U2 11
PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA
SN 0090-9556
EI 1521-009X
J9 DRUG METAB DISPOS
JI Drug Metab. Dispos.
PD FEB
PY 2013
VL 41
IS 2
BP 466
EP 474
DI 10.1124/dmd.112.045674
PG 9
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 095RO
UT WOS:000315352400026
PM 23169611
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Meng, J
   Xing, JM
   Ma, XW
   Cao, WP
   Lu, J
   Wang, YZ
   Gao, XY
   Sun, BY
   Liang, XJ
   Zhao, YL
AF Meng, Jie
   Xing, Jianmin
   Ma, Xiaowei
   Cao, Weipeng
   Lu, Juan
   Wang, Yingze
   Gao, Xueyun
   Sun, Baoyun
   Liang, Xingjie
   Zhao, Yuliang
TI RETRACTED: Metallofullerol nanoparticles with low toxicity inhibit tumor
   growth by induction of G0/G1 arrest (Retracted article. See vol. 8, pg.
   1356, 2013)
SO NANOMEDICINE
LA English
DT Article; Retracted Publication
DE cell cycle; G0/G1 arrest; metallofullerene; nanomedicine; nanoparticle
ID CELL-CYCLE PROGRESSION; PROLIFERATION; CHECKPOINT; CISPLATIN; APOPTOSIS;
   CANCER; FORM; CDK4; P21; D1
AB Aims: [Gd@C-82(OH)(22)](n) is a new type of nanoparticle with potent antineoplastic activity and low toxicity compared with traditional drugs. In this study, we explored, for the first time, the effect of [Gd@C-82(OH)(22)](n) on the cell cycle using human breast cancer MCF-7 and human umbilical vein endothelial ECV304 cell lines by flow cytometry. Methods: Cell viability was assessed through CCK-8 assay, and MCF-7 tumor-bearing mice were examined after 2 weeks of treatment with [Gd@C-82(OH)(22)](n). Cell cycle-related gene expression was detected by microarray and confirmed by real-time PCR and RNAi. Results: Cell viability studies confirmed that [Gd@C-82(OH)(22)](n) inhibits breast cancer effectively with very low toxicity. Flow cytometric data and microarray results reveal that [Gd@C-82(OH)(22)](n) mediates G0/G1 arrest in both cell lines by regulating the expression of several genes, such as cyclin D2, cyclin E and CDK4, among others, in the related cell cycle. Conclusion: Results further demonstrated that [Gd@C-82(OH)(22)](n) could inhibit tumor growth by inducing tumor cell and vein endothelial cell G0/G1 arrest, which may explain the low toxicity of [Gd@C-82(OH)(22)](n).
C1 [Meng, Jie; Ma, Xiaowei; Cao, Weipeng; Lu, Juan; Wang, Yingze; Liang, Xingjie; Zhao, Yuliang] Natl Ctr Nanosci & Technol China, CAS Kay Lab Biomed Effects Nanomat & Nanosafety, Beijing 100190, Peoples R China.
   [Xing, Jianmin] Beijing Univ Chinese Med, Ctr Evidence Based Chinese Med, Beijing 100029, Peoples R China.
   [Gao, Xueyun; Sun, Baoyun; Zhao, Yuliang] Chinese Acad Sci, CAS Kay Lab Biomed Effects Nanomat & Nanosafety, Beijing 100049, Peoples R China.
   [Gao, Xueyun; Sun, Baoyun; Zhao, Yuliang] Chinese Acad Sci, Inst High Energy Phys, Key Lab Nucl Tech, Beijing 100049, Peoples R China.
RP Meng, J (reprint author), Natl Ctr Nanosci & Technol China, CAS Kay Lab Biomed Effects Nanomat & Nanosafety, Beijing 100190, Peoples R China.
EM mengj@nanoctr.cn; liangxj@nanoctr.cn
FU National Key Basic Research Program of China (MOST 973 Projects)
   [2009CB930200, 2011CB933403]; National Natural Science Foundation of
   China [31000451, 30970784]
FX This work was financially supported by the National Key Basic Research
   Program of China (MOST 973 Projects 2009CB930200 and 2011CB933403), and
   the National Natural Science Foundation of China (Program number:
   31000451 and 30970784). The authors have no other relevant affiliations
   or financial involvement with any organization or entity with a
   financial interest in or financial conflict with the subject matter or
   materials discussed in the manuscript apart from those disclosed.
CR An HX, 1999, AM J PATHOL, V154, P113, DOI 10.1016/S0002-9440(10)65257-1
   BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812
   Cao X, 2012, MED ONCOL, V29, P1190, DOI 10.1007/s12032-011-9937-5
   Chen CY, 2005, NANO LETT, V5, P2050, DOI 10.1021/nl051624b
   Fillmore HL, 2011, NANOMEDICINE-UK, V6, P449, DOI [10.2217/NNM.10.134, 10.2217/nnm.10.134]
   Kisielewska J, 2009, DEV BIOL, V334, P383, DOI 10.1016/j.ydbio.2009.07.043
   Kozar K, 2005, CELL CYCLE, V4, P388, DOI 10.4161/cc.4.3.1551
   KRATSCHMER W, 1990, NATURE, V347, P354, DOI 10.1038/347354a0
   Kumar KS, 2007, ANTICANCER RES, V27, P465
   Liang LH, 2011, ACTA PHARMACOL SIN, V32, P1311, DOI 10.1038/aps.2011.103
   Liang XJ, 2010, P NATL ACAD SCI USA, V107, P7449, DOI 10.1073/pnas.0909707107
   Liu G, 2005, CANCER CELL, V7, P113, DOI 10.1016/j.ccr.2005.01.019
   Liu Q, 2009, PHYTOMEDICINE, V16, P916, DOI 10.1016/j.phymed.2009.04.008
   Meng H, 2010, ACS NANO, V4, P2773, DOI 10.1021/nn100448z
   Meng J, 2011, NANOSCALE, V3, P4713, DOI 10.1039/c1nr10898k
   Meng J, 2010, J NANOSCI NANOTECHNO, V10, P8610, DOI 10.1166/jnn.2010.2691
   Moon DO, 2011, CELL MOL LIFE SCI, V68, P3249, DOI 10.1007/s00018-011-0626-5
   Oka H, 2006, MUTAT RES-GEN TOX EN, V606, P52, DOI 10.1016/j.mrgentox.2006.02.001
   Ortega S, 2002, BBA-REV CANCER, V1602, P73, DOI 10.1016/S0304-419X(02)00037-9
   Song MC, 2012, MOL CELL BIOCHEM, V360, P103, DOI 10.1007/s11010-011-1048-2
   Sun BY, 2002, CARBON, V40, P1591, DOI 10.1016/S0008-6223(02)00021-0
   Tamamori-Adachi M, 2008, CELL CYCLE, V7, P3768, DOI 10.4161/cc.7.23.7239
   Tsutsui T, 1999, MOL CELL BIOL, V19, P7011
   van Vugt MATM, 2005, CANCER RES, V65, P7037, DOI 10.1158/0008-5472.CAN-05-1054
   Wang YZ, 2010, CURR DRUG METAB, V11, P507, DOI 10.2174/138920010791636149
   Yang SH, 2007, TOXICON, V49, P966, DOI 10.1016/j.toxicon.2007.01.005
NR 26
TC 5
Z9 5
U1 3
U2 46
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1743-5889
EI 1748-6963
J9 NANOMEDICINE-UK
JI Nanomedicine
PD FEB
PY 2013
VL 8
IS 2
BP 203
EP 213
DI 10.2217/NNM.12.95
PG 11
WC Biotechnology & Applied Microbiology; Nanoscience & Nanotechnology
SC Biotechnology & Applied Microbiology; Science & Technology - Other
   Topics
GA 087VD
UT WOS:000314791200015
PM 22934979
DA 2018-12-27
ER

PT J
AU Damjanoski, I
   Muller, J
   Schnoller, TJ
   Kufer, R
   Rinnab, L
AF Damjanoski, I.
   Mueller, J.
   Schnoeller, T. J.
   Kuefer, R.
   Rinnab, L.
TI RETRACTED: Histopathology reports of findings of prostate needle
   biopsies. Individual treatment (Retracted article. See vol. 57, pg. 593,
   2018)
SO UROLOGE
LA German
DT Article; Retracted Publication
DE Prostate cancer; Prostate needle biopsy; Gleason score; Proliferation,
   atypical small acinar; Neoplasia, prostatic intraepithelial
ID SMALL ACINAR PROLIFERATION; PERINEURAL INVASION; INTRAEPITHELIAL
   NEOPLASIA; RADICAL PROSTATECTOMY; CANCER DETECTION;
   CLINICAL-SIGNIFICANCE; CONSECUTIVE PATIENTS; BIOCHEMICAL FAILURE;
   SATURATION BIOPSY; PROGNOSTIC ROLE
AB This survey-based study examined which information urologists extract from prostate needle biopsy reports and what is needed for clinical management of prostate cancer patients.
   A questionnaire was developed to investigate several topics related to prostate cancer biopsies and four different clinical situations were explored separately, depending on whether the urologist intended a curative or palliative treatment.
   A total of 95 out of 282 (33 %) urologists responded to the questionnaire and returned anonymous responses. On average the participants had a professional career of 13 years (range 6 months to 38 years), 22 (23 %) urologists performed radical prostatectomy, 73 (77 %) were not surgically active, 55 (58 %) took 10-12 scores within the framework of the proposed first biopsy setting, 32 (34 %) took 6-8 scores and 6 (6 %) > 12 scores. Urologists with a professional career < 15 years took significantly more biopsies. The primary and secondary Gleason patterns were required for only 36 (38 %) respondents to make treatment decisions. In prostate needle biopsies containing only a single focus of prostate cancer only 44 (48 %) of the respondents would request a Gleason score if not provided in the initial report. In addition to the Gleason score other information used by urologists to make treatment decisions included perineural invasion (60 %), periprostatic infiltration (57 %), extraprostatic spread (57 %) and the percentage of core involvement by cancer (13 %). Interestingly, in biopsies with multiple positive cores from separate locations 84 out of 95 urologists (88 %) used the highest Gleason grade to determine the treatment plan. The term atypical small acinar proliferation (ASAP) was uniformly considered sufficient to retake biopsies by 44 % (42/92) of urologists and only 53 % (49/92) of urologists performed rebiopsies in the case of high grade prostatic intraepithelial neoplasia (PIN).
   In this sample of 95 urologists there was high variability in the way clinicians used prostate needle biopsy pathology reports. The results of this survey underline that improved communication between urologists and pathologists is necessary.
C1 [Damjanoski, I.; Mueller, J.; Schnoeller, T. J.] Urol Univ Klin Ulm, D-89075 Ulm, Germany.
   [Kuefer, R.] Urol Zentrum Goppingen, Goppingen, Germany.
RP Damjanoski, I (reprint author), Urol Univ Klin Ulm, Prittwitzstr 43, D-89075 Ulm, Germany.
EM Ilija.damjanoski@gmail.com
RI Schnoeller, Thomas/H-4465-2014
OI Schnoeller, Thomas/0000-0003-3617-1111
CR Abuzallouf S, 2004, J UROLOGY, V171, P2122, DOI 10.1097/01.ju.0000123981.03084.06
   Anderson PR, 1998, INT J RADIAT ONCOL, V41, P1087, DOI 10.1016/S0360-3016(98)00167-9
   Andriole G, 2004, J UROLOGY, V172, P1314, DOI 10.1097/01.ju.0000139320.78673.2.a
   Andriole GL, 2010, NEW ENGL J MED, V362, P1192, DOI 10.1056/NEJMoa0908127
   Beard CJ, 2004, INT J RADIAT ONCOL, V58, P19, DOI 10.1016/S0360-3016(03)01433-0
   Borboroglu PG, 2001, J UROLOGY, V166, P866, DOI 10.1016/S0022-5347(05)65853-3
   Bostwick DG, 2004, MODERN PATHOL, V17, P360, DOI 10.1038/modpathol.3800053
   BOSTWICK DG, 1993, HUM PATHOL, V24, P298, DOI 10.1016/0046-8177(93)90041-E
   CARTER BS, 1991, CANCER SURV, V11, P5
   CARTER BS, 1992, P NATL ACAD SCI USA, V89, P3367, DOI 10.1073/pnas.89.8.3367
   CARTER HB, 1992, JAMA-J AM MED ASSOC, V267, P2215, DOI 10.1001/jama.267.16.2215
   Castellucci P, 2011, NUCL MED COMMUN, V32, P475, DOI 10.1097/MNM.0b013e3283455765
   Choi WW, 2011, J UROLOGY, V185, P1645, DOI 10.1016/j.juro.2010.12.033
   D'Amico AV, 2001, J UROLOGY, V165, P126, DOI 10.1097/00005392-200101000-00031
   DAVIDSON D, 1995, J UROLOGY, V154, P1295, DOI 10.1016/S0022-5347(01)66840-X
   Descazeaud A, 2005, EUR UROL, V48, P911, DOI 10.1016/j.eururo.2005.07.011
   Deutsche Gesellschaft fur Urologie e. V, 2009, S3 LEITL FRUH DIAGN
   Djavan Bob, 2005, Can J Urol, V12 Suppl 1, P44
   Eichler K, 2006, J UROLOGY, V175, P1605, DOI 10.1016/S0022-5347(05)00957-2
   Endrizzi J, 2000, BJU INT, V85, P696, DOI 10.1046/j.1464-410x.2000.00518.x
   Epstein JI, 2005, AM J SURG PATHOL, V29, P1228, DOI 10.1097/01.pas.0000173646.99337.b1
   Epstein JI, 1996, AM J SURG PATHOL, V20, P286, DOI 10.1097/00000478-199603000-00004
   Epstein JI, 2010, J UROLOGY, V183, P433, DOI 10.1016/j.juro.2009.10.046
   Gutierrez C, 2011, ACTAS UROL ESP, V35, P347, DOI 10.1016/j.acuro.2011.01.009
   Handel LN, 2006, UROLOGY, V68, P1220, DOI 10.1016/j.urology.2006.08.1070
   Heidenreich A, 2011, 26 ANN EAU C VIENN
   Iczkowski KA, 1997, AM J SURG PATHOL, V21, P1489, DOI 10.1097/00000478-199712000-00012
   Jeon HG, 2009, INT J UROL, V16, P682, DOI 10.1111/j.1442-2042.2009.02331.x
   Kaplan SA, 2002, UROLOGY, V60, P464, DOI 10.1016/S0090-4295(02)01760-0
   Katz B, 2011, UROL ONCOL, V94, P3835
   Kramer BS, 2009, J UROLOGY, V181, P1642, DOI 10.1016/j.juro.2009.01.071
   Kronz JD, 1999, CANCER, V86, P2426, DOI 10.1002/(SICI)1097-0142(19991201)86:11<2426::AID-CNCR34>3.3.CO;2-V
   Lee JT, 2010, KOREAN J UROL, V51, P745, DOI 10.4111/kju.2010.51.11.745
   Makarov DV, 2007, UROLOGY, V69, P1095, DOI 10.1016/j.urology.2007.03.042
   Masieri L, 2010, UROL INT, V85, P396, DOI 10.1159/000315491
   Montironi R, 2005, BJU INT, V95, P1146, DOI 10.1111/j.1464-410X.2005.05540.x
   Morakkabati-Spitz N, 2006, UROLOGE, V45, P702, DOI 10.1007/s00120-006-1063-1
   Muller J, 2012, UROLOGE, V51, P331, DOI 10.1007/s00120-012-2834-5
   Pelzer AE, 2005, EUR UROL, V48, P916, DOI 10.1016/j.eururo.2005.07.012
   Rabets JC, 2004, J UROLOGY, V172, P94, DOI 10.1097/01.ju.0000132134.10470.75
   Reske SN, 2006, J NUCL MED, V47, P1249
   Roehl KA, 2004, J UROLOGY, V172, P910, DOI 10.1097/01.ju.0000134888.22332.bb
   Rubin MA, 2004, AM J SURG PATHOL, V28, P946, DOI 10.1097/00000478-200407000-00016
   Sun L, 2007, BJU INT, V99, P753, DOI 10.1111/j.1464-410X.2006.06682.x
   Walz J, 2006, EUR UROL, V50, P498, DOI 10.1016/j.eururo.2006.03.026
   Werner MK, 2011, BRIT J RADIOL, V84, P65
   Wilt TJ, 2008, COCHRANE DB SYST REV, V16
   Yates DR, 2011, UROL ONCOL
   Zigeuner RE, 2003, UROLOGY, V62, P451, DOI 10.1016/S0090-4295(03)00459-X
NR 49
TC 6
Z9 6
U1 3
U2 7
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0340-2592
EI 1433-0563
J9 UROLOGE
JI Urologe
PD FEB
PY 2013
VL 52
IS 2
BP 226
EP 239
DI 10.1007/s00120-012-3008-1
PG 14
WC Urology & Nephrology
SC Urology & Nephrology
GA 091FV
UT WOS:000315035700009
PM 23064867
DA 2018-12-27
ER

PT J
AU Anderson, TD
   Miller, JI
   Fierobe, HP
   Clubb, RT
AF Anderson, Timothy D.
   Miller, J. Izaak
   Fierobe, Henri-Pierre
   Clubb, Robert T.
TI RETRACTED: Recombinant Bacillus subtilis That Grows on Untreated Plant
   Biomass (Retracted article. See vol. 81, pg. 7957, 2015)
SO APPLIED AND ENVIRONMENTAL MICROBIOLOGY
LA English
DT Article; Retracted Publication
ID LIGNOCELLULOSIC BIOMASS; ENZYMATIC-HYDROLYSIS; ETHANOL-PRODUCTION;
   CELL-WALL; SACCHAROMYCES-CEREVISIAE; SUGAR YIELDS;
   CLOSTRIDIUM-CELLULOLYTICUM; CELLULOSE HYDROLYSIS; ACID PRETREATMENT;
   ENZYMES
AB Lignocellulosic biomass is a promising feedstock to produce biofuels and other valuable biocommodities. A major obstacle to its commercialization is the high cost of degrading biomass into fermentable sugars, which is typically achieved using cellulolytic enzymes from Trichoderma reesei. Here, we explore the use of microbes to break down biomass. Bacillus subtilis was engineered to display a multicellulase-containing minicellulosome. The complex contains a miniscaffoldin protein that is covalently attached to the cell wall and three noncovalently associated cellulase enzymes derived from Clostridium cellulolyticum (Cel48F, Cel9E, and Cel5A). The minicellulosome spontaneously assembles, thus increasing the practicality of the cells. The recombinant bacteria are highly cellulolytic and grew in minimal medium containing industrially relevant forms of biomass as the primary nutrient source (corn stover, hatched straw, and switch grass). Notably, growth did not require dilute acid pretreatment of the biomass and the cells achieved densities approaching those of cells cultured with glucose. An analysis of the sugars released from acid-pretreated corn stover indicates that the cells have stable cellulolytic activity that enables them to break down 62.3% +/- 2.6% of the biomass. When supplemented with beta-glucosidase, the cells liberated 21% and 33% of the total available glucose and xylose in the biomass, respectively. As the cells display only three types of enzymes, increasing the number of displayed enzymes should lead to even more potent cellulolytic microbes. This work has important implications for the efficient conversion of lignocellulose to value-added biocommodities.
C1 [Anderson, Timothy D.; Miller, J. Izaak; Clubb, Robert T.] Univ Calif Los Angeles, UCLA DOE Inst Genom & Prote, Los Angeles, CA 90024 USA.
   [Anderson, Timothy D.; Miller, J. Izaak; Clubb, Robert T.] Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90024 USA.
   [Anderson, Timothy D.; Miller, J. Izaak; Clubb, Robert T.] Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90024 USA.
   [Fierobe, Henri-Pierre] IFR88 CNRS, Chim Bacterienne Lab, Marseille, France.
RP Clubb, RT (reprint author), Univ Calif Los Angeles, UCLA DOE Inst Genom & Prote, Los Angeles, CA 90024 USA.
EM rclubb@mbi.ucla.edu
FU Department of Energy [DE-FC-03-87ER60615]
FX This work was supported by Department of Energy grant
   DE-FC-03-87ER60615.
CR Akin DE, 2008, APPL BIOCHEM BIOTECH, V144, P59, DOI 10.1007/s12010-007-0053-0
   Anderson TD, 2011, APPL ENVIRON MICROB, V77, P4849, DOI 10.1128/AEM.02599-10
   Banerjee G, 2010, BIORESOURCE TECHNOL, V101, P9097, DOI 10.1016/j.biortech.2010.07.028
   Banerjee G, 2010, BIOTECHNOL BIOENG, V106, P707, DOI 10.1002/bit.22741
   Bayer EA, 2004, ANNU REV MICROBIOL, V58, P521, DOI 10.1146/annurev.micro.57.030502.091022
   Bayer EA, 1998, CURR OPIN STRUC BIOL, V8, P548, DOI 10.1016/S0959-440X(98)80143-7
   Blouzard JC, 2010, PROTEOMICS, V10, P541, DOI 10.1002/pmic.200900311
   Boerjan W, 2003, ANNU REV PLANT BIOL, V54, P519, DOI 10.1146/annurev.arplant.54.031902.134938
   Carroll A, 2009, ANNU REV PLANT BIOL, V60, P165, DOI 10.1146/annurev.arplant.043008.092125
   Demain AL, 2005, MICROBIOL MOL BIOL R, V69, P124, DOI 10.1128/MMBR.69.1.124-154.2005
   Ding SY, 2008, CURR OPIN BIOTECH, V19, P218, DOI 10.1016/j.copbio.2008.04.008
   Doi RH, 2004, NAT REV MICROBIOL, V2, P541, DOI 10.1038/nrmicro925
   Doi RH, 2008, ANN NY ACAD SCI, V1125, P267, DOI 10.1196/annals.1419.002
   EBERTS TJ, 1979, CLIN CHEM, V25, P1440
   Fan LH, 2012, P NATL ACAD SCI USA, V109, P13260, DOI 10.1073/pnas.1209856109
   Fierobe HP, 2005, J BIOL CHEM, V280, P16325, DOI 10.1074/jbc.M414449200
   FIEROBE HP, 1991, J BACTERIOL, V173, P7956, DOI 10.1128/jb.173.24.7956-7962.1991
   Garlock RJ, 2009, BIOTECHNOL BIOFUELS, V2, DOI 10.1186/1754-6834-2-29
   Ghose T.K., 1977, ADV BIOCHEM ENG, V6, P39
   Harris D, 2010, PLANT BIOTECHNOL J, V8, P244, DOI 10.1111/j.1467-7652.2009.00481.x
   Hendriks ATWM, 2009, BIORESOURCE TECHNOL, V100, P10, DOI 10.1016/j.biortech.2008.05.027
   Himmel ME, 2007, SCIENCE, V315, P804, DOI 10.1126/science.1137016
   Jensen JR, 2010, BIORESOURCE TECHNOL, V101, P2317, DOI 10.1016/j.biortech.2009.11.038
   Kerr RA, 2008, SCIENCE, V322, P1178, DOI 10.1126/science.322.5905.1178
   Kim Y, 2011, BIORESOURCE TECHNOL, V102, P11089, DOI 10.1016/j.biortech.2011.06.054
   la Grange DC, 2010, APPL MICROBIOL BIOT, V87, P1195, DOI 10.1007/s00253-010-2660-x
   Lanigan-Gerdes S, 2007, MOL MICROBIOL, V65, P1321, DOI 10.1111/j.1365-2958.2007.05869.x
   Li SS, 2011, APPL MICROBIOL BIOT, V91, P577, DOI 10.1007/s00253-011-3280-9
   Liao HH, 2011, BIOTECHNOL J, V6, P1409, DOI 10.1002/biot.201100157
   Lilly M, 2009, FEMS YEAST RES, V9, P1236, DOI 10.1111/j.1567-1364.2009.00564.x
   Lloyd TA, 2005, BIORESOURCE TECHNOL, V96, P1967, DOI 10.1016/j.biortech.2005.01.011
   Lynd LR, 2008, NAT BIOTECHNOL, V26, P169, DOI 10.1038/nbt0208-169
   Lynd LR, 2005, CURR OPIN BIOTECH, V16, P577, DOI 10.1016/j.copbio.2005.08.009
   Lynd LR, 2002, BIOTECHNOL BIOENG, V77, P467, DOI 10.1002/bit.10142
   LYND LR, 1989, APPL ENVIRON MICROB, V55, P3131
   McCann MC, 2008, CURR OPIN PLANT BIOL, V11, P314, DOI 10.1016/j.pbi.2008.04.001
   Mielenz JR, 2001, CURR OPIN MICROBIOL, V4, P324, DOI 10.1016/S1369-5274(00)00211-3
   Miller PS, 2010, ENVIRON TECHNOL, V31, P1005, DOI 10.1080/09593330903536113
   Olson DG, 2012, CURR OPIN BIOTECH, V23, P396, DOI 10.1016/j.copbio.2011.11.026
   Pauly M, 2010, CURR OPIN PLANT BIOL, V13, P305, DOI 10.1016/j.pbi.2009.12.009
   Ransom-Jones E, 2012, MICROB ECOL, V63, P267, DOI 10.1007/s00248-011-9998-1
   Reddy N, 2005, TRENDS BIOTECHNOL, V23, P22, DOI 10.1016/j.tibtech.2004.11.002
   Romero S, 2007, APPL ENVIRON MICROB, V73, P5190, DOI 10.1128/AEM.00625-07
   Schallmey M, 2004, CAN J MICROBIOL, V50, P1, DOI [10.1139/w03-076, 10.1139/W03-076]
   Steen EJ, 2010, NATURE, V463, P559, DOI 10.1038/nature08721
   Stulke J, 2000, ANNU REV MICROBIOL, V54, P849, DOI 10.1146/annurev.micro.54.1.849
   Tobisch S, 1997, J BACTERIOL, V179, P496, DOI 10.1128/jb.179.2.496-506.1997
   Tsai SL, 2009, APPL ENVIRON MICROB, V75, P6087, DOI 10.1128/AEM.01538-09
   WARDROP AB, 1969, AUST J BOT, V17, P229, DOI 10.1071/BT9690229
   Werpy T., 2004, TOP VALUE ADDED CHEM, V1
   Wilson DB, 2011, CURR OPIN MICROBIOL, V14, P259, DOI 10.1016/j.mib.2011.04.004
   Wilson DB, 2009, CURR OPIN BIOTECH, V20, P295, DOI 10.1016/j.copbio.2009.05.007
   Xue JF, 2011, APPL ENVIRON MICROB, V77, P2399, DOI 10.1128/AEM.02341-10
   Yeoman CJ, 2010, ADV APPL MICROBIOL, V70, P1, DOI 10.1016/S0065-2164(10)70001-0
   You C, 2012, APPL ENVIRON MICROB, V78, P1437, DOI 10.1128/AEM.07138-11
   Zhang XZ, 2011, METAB ENG, V13, P364, DOI 10.1016/j.ymben.2011.04.003
   Zhang XZ, 2010, ENG LIFE SCI, V10, P398, DOI 10.1002/elsc.201000011
   Zhang YH, 2003, ANAL CHEM, V75, P219, DOI 10.1021/ac020271n
   Zhao XB, 2009, APPL MICROBIOL BIOT, V82, P815, DOI 10.1007/s00253-009-1883-1
NR 59
TC 17
Z9 17
U1 3
U2 65
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0099-2240
EI 1098-5336
J9 APPL ENVIRON MICROB
JI Appl. Environ. Microbiol.
PD FEB
PY 2013
VL 79
IS 3
BP 867
EP 876
DI 10.1128/AEM.02433-12
PG 10
WC Biotechnology & Applied Microbiology; Microbiology
SC Biotechnology & Applied Microbiology; Microbiology
GA 076WL
UT WOS:000313989700014
PM 23183968
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Corcoles, JI
   Ortega, JF
   Hernandez, D
   Moreno, MA
AF Corcoles, J. I.
   Ortega, J. F.
   Hernandez, D.
   Moreno, M. A.
TI RETRACTED: Use of digital photography from unmanned aerial vehicles for
   estimation of leaf area index in onion (Allium cepa L.) (Retracted
   article. See vol. 51, pg. 140, 2013)
SO EUROPEAN JOURNAL OF AGRONOMY
LA English
DT Article; Retracted Publication
DE Leaf area index; Canopy cover; Aerial digital photography; Onion
ID SIMULATE YIELD RESPONSE; FAO CROP MODEL; VEGETATION COVER;
   IMAGE-ANALYSIS; WATER; GROWTH; NDVI; LAI; EVAPOTRANSPIRATION;
   INTERCEPTION
AB Canopy cover and structure, which have considerable effects on the interaction between vegetation and the environment, especially in the case of crops, can be represented by a few parameters, which are based on the calculation of different vegetation indexes. One of the most common indexes in agronomy is the leaf area index, which is a parameter associated with agronomic, biologic, environmental, and physiologic processes. The aim of this study is to evaluate a non-destructive method to measure canopy cover in an onion crop by means of aerial digital photography from unmanned aerial vehicles, and to determine the relationship with leaf area index obtained by using an automated infrared imaging system. The field experiment was conducted in a 4.75 ha commercial onion plot irrigated with a centre pivot system during the 2010 irrigation season. To determine the leaf area in the laboratory during crop development, data were sampled on three. At each sampling event, eight experimental plots of 1 m(2) were used. In each one of them, aerials photographies were taken by using a vertical take-off and landing quadracopter aircraft. Software for leaf area index calculation was developed to obtain canopy cover. Three models have been used to analyze the relationship between leaf area index and canopy cover. According to this, the model which best fits the relationship between leaf area index and canopy cover is the linear model. The relationship between both parameters was closer in the first stages than in more advanced stages. (c) 2012 Elsevier B.V. All rights reserved.
C1 [Corcoles, J. I.; Ortega, J. F.; Moreno, M. A.] UCLM, Reg Ctr Water Res CREA, Albacete 02071, Spain.
   [Hernandez, D.] UCLM, Inst Reg Dev, Albacete 02071, Spain.
RP Corcoles, JI (reprint author), UCLM, Reg Ctr Water Res CREA, Ctra Penas,Km 3 2, Albacete 02071, Spain.
EM JuanIgnacio.Corcoles@uclm.es; Jose.Ortega@uclm.es;
   David.Hernandez@uclm.es; MiguelAngel.Moreno@uclm.es
FU CICYT [AGL2007-66716-CO3-03]; Education Regional Government of C-LM
   [PCI08-0117]
FX We would like to thank to the CICYT for funding the national project
   (AGL2007-66716-CO3-03), and the Education Regional Government of C-LM
   for funding the project (PCI08-0117). We also wish to thank Aisco
   Equipment Europe, Ltd. and the Agro-environmental Training Centre
   ("Centro de Formacion Agroambiental") located in Albacete, for their
   support of this work by providing the products and facilities needed to
   carry out this experiment.
CR ACKLEY WILLIAM B., 1958, PROC AMER SOC HORT SCI, V72, P326
   ADAMS JB, 1995, REMOTE SENS ENVIRON, V52, P137, DOI 10.1016/0034-4257(94)00098-8
   Al-Jamal MS, 1999, APPL ENG AGRIC, V15, P659
   Astegiano E. D., 2001, Investigacion Agraria Produccion y Proteccion Vegetales, V16, P249
   Azzi G., 1959, ECOLOGIA AGRARIA
   BACHMANN P., 1965, SCHWEIZ Z FORSTWESEN, V116, P623
   Baker B, 1996, J PLANT PHYSIOL, V148, P530, DOI 10.1016/S0176-1617(96)80072-1
   BARET F, 1991, REMOTE SENS ENVIRON, V35, P161, DOI 10.1016/0034-4257(91)90009-U
   BAUSCH WC, 1987, T ASAE, V30, P703
   Bishop, 1995, NEURAL NETWORKS PATT
   Bossie M., 2009, IRRIG DRAIN, V23, P1
   Calera A, 2001, INT J REMOTE SENS, V22, P3357, DOI 10.1080/01431160010020100
   Calera A., 2010, 3 INT S REC ADV QUAN
   Campbell G.S., 1990, PLANT CANOPIES THEIR, P1
   Carlson TN, 1997, REMOTE SENS ENVIRON, V62, P241, DOI 10.1016/S0034-4257(97)00104-1
   Chen XX, 2004, REMOTE SENS ENVIRON, V91, P14, DOI 10.1016/j.rse.2003.11.003
   Chopade S. O., 1998, PKV Research Journal, V22, P44
   Condes S., 2005, CUADERNOS SOC ESPANO, V19, P63
   Darrow GM, 1932, PLANT PHYSIOL, V7, P745, DOI 10.1104/pp.7.4.745
   Daughtry C. S. T., 1990, REMOTE SENSING REV, V5, P45, DOI DOI 10.1080/02757259009532121
   de Juan J. A., 2003, SISTEMAS CULTIVO EVA
   Drost D., 1996, P INT C EV IRR SCHED, P54
   Enciso J, 2009, SCI HORTIC-AMSTERDAM, V120, P301, DOI 10.1016/j.scienta.2008.11.004
   FAO, 2011, FAO STAT DAT
   Feller C., 1995, Nachrichtenblatt des Deutschen Pflanzenschutzdienstes, V47, P193
   Frear D.H., 1935, PLANT PHYSIOL, V10, P69
   GALLAGHER JN, 1978, J AGR SCI, V91, P47, DOI 10.1017/S0021859600056616
   GAMIELY S, 1991, HORTSCIENCE, V26, P206
   GERDEL R. W., 1928, JOUR AMER SOC AGRON, V20, P635
   Gonzalez-Dugo MP, 2009, AGR FOREST METEOROL, V149, P1843, DOI 10.1016/j.agrformet.2009.06.012
   GOODALL DW, 1947, ANN BOT-LONDON, V11, P449, DOI 10.1093/oxfordjournals.aob.a083169
   Gupta RK, 2000, ADV SPACE RES, V26, P1047, DOI 10.1016/S0273-1177(99)01115-1
   Hammer GL, 1995, AGRON J, V87, P1085, DOI 10.2134/agronj1995.00021962008700060009x
   Hay R.K, 2006, PHYSL CROP YIELD
   HIBBARD RUFUS P., 1937, PAPERS MICHIGAN ACAD SCI ARTS ORIEL LETT, V23, P141
   Hooker RH, 1907, J R STAT SOC, V70, P1, DOI 10.2307/2339501
   Hunt E. Raymond Jr, 2005, Precision Agriculture, V6, P359, DOI 10.1007/s11119-005-2324-5
   Hunter R. S., 1948, J OPT SOC AM, V38, P661, DOI DOI 10.1364/JOSA.48.000985
   Jimenez M, 2010, J AGR SCI-CAMBRIDGE, V148, P139, DOI 10.1017/S002185960999061X
   Jimenez M., 2008, THESIS U CASTILLA LA
   Jones H.A., 1963, ONION THEIR ALLIES
   Keller J., 1990, SPRINKLE TRICKLE IRR
   KERSHAW JA, 1992, TREE PHYSIOL, V11, P411, DOI 10.1093/treephys/11.4.411
   Kiniry JR, 1996, AGRON J, V88, P602, DOI 10.2134/agronj1996.00021962008800040018x
   Kucharik CJ, 1998, AGR FOREST METEOROL, V91, P69, DOI 10.1016/S0168-1923(98)00064-1
   Kumar S, 2007, AGR WATER MANAGE, V89, P161, DOI 10.1016/j.agwat.2007.01.003
   Kvet J., 1971, METODY STUDIA FOTOSY, P315
   Lai S.H., 1994, ACTA HORTIC, V358, P221
   LAL KN, 1951, NATURE, V167, P72, DOI 10.1038/167072a0
   Llovet J., 2000, STATGRAPHICS PLUS 4
   Lopez-Serrano FR, 2000, AGR FOREST METEOROL, V101, P95, DOI 10.1016/S0168-1923(99)00171-9
   LYON CJ, 1948, PLANT PHYSIOL, V23, P634, DOI 10.1104/pp.23.4.634
   MARM, 2010, AN EST 2010
   MARSHALL J. K., 1968, PHOTOSYNTHETICA, V2, P41
   Merriam J. L., 1978, FARM IRRIGATION SYST
   Merriam J. L, 1980, ASAE MONOGRAPH, P721
   Miller E. C., 1938, PLANT PHYSL, V1
   MONDAL MF, 1986, ANN BOT-LONDON, V58, P187, DOI 10.1093/oxfordjournals.aob.a087197
   Montoro A., 2009, AGR WATER MANAGE, V96, P1031
   Nabney I., 2002, NETLAB ALGORITHMS PA
   Nyakwende E, 1997, J HORTIC SCI, V72, P255, DOI 10.1080/14620316.1997.11515512
   Papadakis J., 1966, CLIMATES WORLD THEIR
   Pereira L.S., 1999, CIGR HDB AGR ENG, VI, P213
   Raes D, 2009, AGRON J, V101, P438, DOI 10.2134/agronj2008.0140s
   RAY RC, 1989, SCI HORTIC-AMSTERDAM, V39, P181, DOI 10.1016/0304-4238(89)90131-3
   Ross J, 1981, RAD REGIME ARCHITECT
   RUCKENSTEIN E, 1976, CHEM ENG SCI, V31, P327
   Santa Olalla F. M. de, 2004, Agricultural Water Management, V68, P77
   Sarkar S, 2008, AGR WATER MANAGE, V95, P625, DOI 10.1016/j.agwat.2008.01.002
   Schalkoff R J., 1997, ARTIFICIAL NEURAL NE
   SELLERS PJ, 1985, INT J REMOTE SENS, V6, P1335, DOI 10.1080/01431168508948283
   Steduto P, 2009, AGRON J, V101, P426, DOI 10.2134/agronj2008.0139s
   Stockle CO, 2003, EUR J AGRON, V18, P289, DOI 10.1016/S1161-0301(02)00109-0
   TARBELL KA, 1991, T ASAE, V34, P2245
   Tei F, 1996, ANN BOT-LONDON, V78, P633, DOI 10.1006/anbo.1996.0171
   Teske ME, 2004, FOREST ECOL MANAG, V198, P341, DOI 10.1016/j.foreco.2004.05.031
   Thoday D, 1909, P R SOC LOND B-CONTA, V82, P1, DOI 10.1098/rspb.1909.0054
   Topcon, 2011, IM MAST US MAN
   USDA-NCRS, 2006, KEYS SOIL TAX
   WATSON DJ, 1947, ANN BOT-LONDON, V11, P41, DOI 10.1093/oxfordjournals.aob.a083148
   Winter E.J., 1956, GROWTH LEAVES, P151
   Yonekawa S, 1996, T ASAE, V39, P1525
NR 82
TC 11
Z9 12
U1 2
U2 55
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1161-0301
EI 1873-7331
J9 EUR J AGRON
JI Eur. J. Agron.
PD FEB
PY 2013
VL 45
BP 96
EP 104
DI 10.1016/j.eja.2012.11.001
PG 9
WC Agronomy
SC Agriculture
GA 082FK
UT WOS:000314377500011
DA 2018-12-27
ER

PT J
AU Mousa, OF
AF Mousa, Omar F.
TI RETRACTED: Multiscale Multiphysics Modeling and Fabrication of
   Three-Dimensional Multijunction Multiband Photovoltaic Solar Cell
   Based-Carbon Nanotube (Retracted article. See vol. 137, 017001, 2015)
SO JOURNAL OF SOLAR ENERGY ENGINEERING-TRANSACTIONS OF THE ASME
LA English
DT Article; Retracted Publication
DE solar cell; photovoltaic; carbon nanotube (CNT) BMWCNT; SWCNT; DC-DC; 1D
   junction; efficiency; power loss; nanotechnology; single-junction;
   multijunction; 3D multijunction; vertical junction; lateral junction
ID GENERATION; ENERGY
AB Multijunction multiband solar cells consisting of series-stacked p-n junction layers offer a significant improvement in efficiency over single-junction by generating power over a larger spectrum of sunlight. However, this paper presents a novel 3D multijunction multiband photovoltaic solar cell design that utilizes doped semiconductor bundled-multiwalled carbon nanotube (BMWCNT) and other nanomaterial. The 3D multijunction multiband photovoltaic based doped bundled-multiwalled carbon nanotube cultivates photons in three dimensions (vertical and lateral directions). It allows the creation of electron-hole pair not only from the top layer to bottom layer (z-axis direction) as the traditional 1D multijunction multiband but also in the x-axis (abscissa) and y-axis (ordinate) directions. The 3D multijunction multiband photovoltaic solar cell based doped semiconductor bundled-multiwalled carbon nanotube can optimize the efficiency beyond the limits of the current existing technology. This optimized efficiency is achieved by harvesting visible light and all spectrums of the light including the utilization of thermoelectric and the thermo-ionic features exist in nanotubes. [DOI: 10.1115/1.4007299]
C1 Univ Alabama, Dept Elect & Comp Engn, Tuscaloosa, AL 35401 USA.
RP Mousa, OF (reprint author), Univ Alabama, Dept Elect & Comp Engn, 1005 14th St 7C, Tuscaloosa, AL 35401 USA.
EM omar.f.mousa@ieee.org
CR Balzani V, 2008, CHEMSUSCHEM, V1, P26, DOI 10.1002/cssc.200700087
   Camacho RE, 2007, JOM-US, V59, P39, DOI 10.1007/s11837-007-0037-0
   Gabor NM, 2009, SCIENCE, V325, P1367, DOI 10.1126/science.1176112
   Goswami DY, 2004, SOL ENERGY, V76, P33, DOI 10.1016/S0038-092X(03)00103-8
   Hadipour A, 2008, ADV FUNCT MATER, V18, P169, DOI 10.1002/adfm.200700517
   HICKS LD, 1993, PHYS REV B, V47, P12727, DOI 10.1103/PhysRevB.47.12727
   Hubbard S. M., 2007, MATER RES SOC S P, V1017, P589
   Jin J.-M., 2002, FINITE ELEMENT METHO
   Kasap S. O., 2001, OPTOELECTRONICS PHOT
   Li H, 2009, IEEE T ELECTRON DEV, V56, P2202, DOI 10.1109/TED.2009.2028395
   Liu Z, 2007, APPL PHYS LETT, V90, DOI 10.1063/1.2746959
   Mousa O. F., 2010, 32 INT TEL EN C INTE, V1, P1
   Mousa OF, 2011, IEEE T ELECTRON DEV, V58, P2670, DOI 10.1109/TED.2011.2157932
   Naeemi A, 2006, IEEE ELECTR DEVICE L, V27, P338, DOI 10.1109/LED.2006.873765
   Park JY, 2004, NANO LETT, V4, P517, DOI 10.1021/nl035258c
   Sablon KA, 2011, NANO LETT, V11, P2311, DOI 10.1021/nl200543v
   Sui W., 2001, TIME DOMAIN COMPUTER
   SUI WQ, 1992, IEEE T MICROW THEORY, V40, P724, DOI 10.1109/22.127522
   Thess A, 1996, SCIENCE, V273, P483, DOI 10.1126/science.273.5274.483
   Tong L, 2001, IEEE MTT-S, P1023, DOI 10.1109/MWSYM.2001.967066
   Wang SJ, 2010, NANO LETT, V10, P2381, DOI 10.1021/nl100343j
   Zhu L., 2007, 12 INT S ADV PACK MA, P309
NR 22
TC 1
Z9 1
U1 3
U2 39
PU ASME
PI NEW YORK
PA TWO PARK AVE, NEW YORK, NY 10016-5990 USA
SN 0199-6231
EI 1528-8986
J9 J SOL ENERG-T ASME
JI J. Sol. Energy Eng. Trans.-ASME
PD FEB
PY 2013
VL 135
IS 1
AR 011019
DI 10.1115/1.4007299
PG 10
WC Energy & Fuels; Engineering, Mechanical
SC Energy & Fuels; Engineering
GA 077OQ
UT WOS:000314037400019
DA 2018-12-27
ER

PT J
AU Zhang, X
   Walumbwa, FO
   Aryee, S
   Chen, ZX
AF Zhang, Xiujuan
   Walumbwa, Fred O.
   Aryee, Samuel
   Chen, Zhen Xiong (George)
TI RETRACTED: Ethical leadership, employee citizenship and work withdrawal
   behaviors: Examining mediating and moderating processes (Retracted
   article. See vol. 25, pg. 1181, 2014)
SO LEADERSHIP QUARTERLY
LA English
DT Article; Retracted Publication
DE Ethical leadership; Politics perceptions; Emotional exhaustion;
   Uncertainty; Employee behaviors
ID CROSS-CULTURAL EXAMINATION; CORE JOB CHARACTERISTICS; ORGANIZATIONAL
   POLITICS; TRANSFORMATIONAL LEADERSHIP; EMOTIONAL EXHAUSTION;
   SELF-EFFICACY; DYSFUNCTIONAL CONSEQUENCES; METAANALYTIC EXAMINATION;
   OUTCOMES RELATIONSHIPS; PROCEDURAL JUSTICE
AB The present study examined the mediating and moderating processes in the relationship between ethical leadership and employee citizenship behavior as well as work withdrawal behavior using a sample of 277 employees and their supervisors from the People's Republic of China. Results revealed that ethical leadership negatively relates to politics perceptions and that politics perceptions partially mediate the negative influence of ethical leadership on uncertainty. We also found that uncertainty partially mediates the politics perceptions-emotional exhaustion relationship. Further, politics perceptions interact with political skill to influence emotional exhaustion through uncertainty. Finally, emotional exhaustion fully mediates the uncertainty-citizenship behavior as well as the uncertainty-work withdrawal behavior relationships. We discuss implications of these findings for research and practice. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Walumbwa, Fred O.] Arizona State Univ, WP Carey Sch Business, Tempe, AZ 85287 USA.
   [Zhang, Xiujuan] Sun Yat Sen Univ, Sch Business, Guangzhou 510275, Guangdong, Peoples R China.
   [Aryee, Samuel] Kings Coll London, Dept Management, London SE1 9NH, England.
   [Chen, Zhen Xiong (George)] Australian Natl Univ, Coll Business & Econ, Canberra, ACT 0200, Australia.
RP Walumbwa, FO (reprint author), Arizona State Univ, WP Carey Sch Business, Tempe, AZ 85287 USA.
EM mnszxj@mail.sysu.edu.cn; fred.walumbwa@asu.edu; samuel.aryee@kcl.ac.uk;
   George.chen@anu.edu.au
RI Chen, Zhen Xiong/R-4029-2018
OI Chen, Zhen Xiong/0000-0002-1537-2291
CR Ammeter AP, 2002, LEADERSHIP QUART, V13, P751, DOI 10.1016/S1048-9843(02)00157-1
   Aryee S, 2004, ORGAN BEHAV HUM DEC, V94, P1, DOI 10.1016/j.obhdp.2004.03.002
   Avey JB, 2011, J BUS ETHICS, V98, P573, DOI 10.1007/s10551-010-0610-2
   Avolio BJ, 2009, ANNU REV PSYCHOL, V60, P421, DOI 10.1146/annurev.psych.60.110707.163621
   BANDURA A, 1977, PSYCHOL REV, V84, P191, DOI 10.1037//0033-295X.84.2.191
   Bandura A, 1986, SOCIAL FDN THOUGHT A
   Barling J, 2010, HDB IND ORG PSYCHOL, P183
   BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173
   Berson Y, 2001, LEADERSHIP QUART, V12, P53, DOI 10.1016/S1048-9843(01)00064-9
   Blickle G, 2011, J APPL SOC PSYCHOL, V41, P488, DOI 10.1111/j.1559-1816.2010.00723.x
   Bliese P. D, 2000, MULTILEVEL THEORY RE, P349
   Bliese P. D., 2002, ADV MEASUREMENT DATA, P401
   Bliese PD, 1998, ORGAN RES METHODS, V1, P355, DOI 10.1177/109442819814001
   Bliese PD, 2002, LEADERSHIP QUART, V13, P3, DOI 10.1016/S1048-9843(01)00101-1
   Bolman L. G., 2008, REFRAMING ORG ARTIST
   Brislin R., 1980, HDB CROSS CULTURAL P, P389
   Brouer RL, 2011, J ORGAN BEHAV, V32, P869, DOI 10.1002/job.718
   Brown ME, 2005, ORGAN BEHAV HUM DEC, V97, P117, DOI 10.1016/j.obhdp.2005.03.002
   Brown ME, 2006, LEADERSHIP QUART, V17, P595, DOI 10.1016/j.leaqua.2006.10.004
   Brown ME, 2010, BUS ETHICS Q, V20, P583, DOI 10.5840/beq201020439
   Cantor N., 1987, PERSONALITY SOCIAL I
   Cascio W. F., 1991, COSTING HUMAN RESOUR
   Chang CH, 2009, ACAD MANAGE J, V52, P779, DOI 10.5465/AMJ.2009.43670894
   Colquitt JA, 2012, J APPL PSYCHOL, V97, P1, DOI 10.1037/a0025208
   Cropanzano R, 1997, J ORGAN BEHAV, V18, P159, DOI 10.1002/(SICI)1099-1379(199703)18:2<159::AID-JOB795>3.0.CO;2-D
   Cropanzano R, 2003, J APPL PSYCHOL, V88, P160, DOI 10.1037/0021-9010.88.1.160
   Dasborough M. T., 2003, BUILDING LEADERSHIP, V3, P58
   Davis WD, 2004, LEADERSHIP QUART, V15, P439, DOI 10.1016/j.leaqua.2004.05.002
   De Hoogh AHB, 2008, LEADERSHIP QUART, V19, P297, DOI 10.1016/j.leaqua.2008.03.002
   Detert JR, 2007, ACAD MANAGE J, V50, P869
   Detert JR, 2007, J APPL PSYCHOL, V92, P993, DOI 10.1037/0021-9010.92.4.993
   Dorfman P., 2004, HDB INT MANAGEMENT R, P265
   Elsesser KM, 2011, HUM RELAT, V64, P1555, DOI 10.1177/0018726711424323
   Ferris G. R., 2002, RES MULTILEVEL ISSUE, P179, DOI DOI 10.1016/S1475-9144(02)01034-2
   Ferris G. R., 1989, IMPRESSION MANAGEMEN, P143
   Ferris GR, 2007, J MANAGE, V33, P290, DOI 10.1177/0149206307300813
   FERRIS GR, 1994, J APPL SOC PSYCHOL, V24, P1204, DOI 10.1111/j.1559-1816.1994.tb01551.x
   Ferris GR, 2005, J MANAGE, V31, P126, DOI 10.1177/0149206304271386
   Ferris GR, 2000, RES SOC ORG, V17, P89
   FERRIS GR, 1999, 59 ANN AC MAN M CHIC
   FERRIS GR, 2005, POLITICAL SKILL WORK
   GANDZ J, 1980, ACAD MANAGE J, V23, P237, DOI 10.2307/255429
   GLICK WH, 1985, ACAD MANAGE REV, V10, P601, DOI 10.2307/258140
   Grandey AA, 1999, J VOCAT BEHAV, V54, P350, DOI 10.1006/jvbe.1998.1666
   Hall A. T., 2004, DARK SIDE ORG BEHAV, P237
   HANISCH KA, 1990, J VOCAT BEHAV, V37, P60, DOI 10.1016/0001-8791(90)90007-O
   Harrell-Cook G, 1999, J ORGAN BEHAV, V20, P1093, DOI 10.1002/(SICI)1099-1379(199912)20:7<1093::AID-JOB945>3.0.CO;2-#
   HOBFOLL SE, 1989, AM PSYCHOL, V44, P513, DOI 10.1037//0003-066X.44.3.513
   Hochwarter WA, 2003, J VOCAT BEHAV, V63, P438, DOI 10.1016/S0001-8791(02)00048-9
   Hochwarter WA, 2007, J APPL PSYCHOL, V92, P567, DOI 10.1037/0021-9010.92.2.567
   Hoffman BJ, 2007, J APPL PSYCHOL, V92, P555, DOI 10.1037/0021-9010.92.2.555
   Hofstede G. H., 2005, CULTURES ORG SOFTWAR
   House R. J, 1995, CHANGING NATURE WORK, P411
   House RJ, 1997, J MANAGE, V23, P409, DOI 10.1016/S0149-2063(97)90037-4
   JAMES LR, 1984, J APPL PSYCHOL, V69, P85, DOI 10.1037/0021-9010.69.1.85
   Joreskog K.G, 2001, LISREL 8 USERS REFER
   Kacmar KM, 2011, J APPL PSYCHOL, V96, P633, DOI 10.1037/a0021872
   Kacmar KM, 1999, RES PERS H, V17, P1
   Kacmar KM, 1997, J MANAGE, V23, P627, DOI 10.1177/014920639702300502
   Kacmar KM, 1999, HUM RELAT, V52, P383, DOI 10.1177/001872679905200305
   Kalshoven K, 2011, LEADERSHIP QUART, V22, P51, DOI 10.1016/j.leaqua.2010.12.007
   Kenny D. A., 1998, HDB SOCIAL PSYCHOL, P233, DOI DOI 10.1177/0146167208331253
   Kiffin-Petersen S. A., 2010, PERSONALITY INDIVIDU, V50, P43
   Kirkman BL, 2009, ACAD MANAGE J, V52, P744, DOI 10.5465/AMJ.2009.43669971
   Klein KJ, 2000, MULTILEVEL THEORY RE, P512
   Kramer R. M., 2001, SOCIAL IDENTITY PROC, P167
   Law KS, 1998, ACAD MANAGE REV, V23, P741
   Lee K, 2002, J APPL PSYCHOL, V87, P131, DOI 10.1037/0021-9010.87.1.131
   Lee RT, 1996, J APPL PSYCHOL, V81, P123, DOI 10.1037/0021-9010.81.2.123
   Lind EA, 2002, RES ORGAN BEHAV, V24, P181, DOI 10.1016/S0191-3085(02)24006-X
   MASLACH C, 1978, J SOC ISSUES, V34, P111, DOI 10.1111/j.1540-4560.1978.tb00778.x
   MASLACH C, 1981, J OCCUP BEHAV, V2, P99, DOI 10.1002/job.4030020205
   Maslach C, 1986, MASLACH BURNOUT INVE
   Mathieu JE, 2006, J ORGAN BEHAV, V27, P1031, DOI 10.1002/job.406
   Mayer DM, 2012, ACAD MANAGE J, V55, P151, DOI 10.5465/amj.2008.0276
   Mayer DM, 2009, ORGAN BEHAV HUM DEC, V108, P1, DOI 10.1016/j.obhdp.2008.04.002
   Miller BK, 2008, J BUS PSYCHOL, V22, P209, DOI 10.1007/s10869-008-9061-5
   Organ DW, 1997, HUM PERFORM, V10, P85, DOI 10.1207/s15327043hup1002_2
   PARKER CP, 1995, J MANAGE, V21, P891, DOI 10.1177/014920639502100505
   Perrewe PL, 2004, ACAD MANAGE J, V47, P141, DOI 10.2307/20159566
   Piccolo RF, 2006, ACAD MANAGE J, V49, P327
   Piccolo RF, 2010, J ORGAN BEHAV, V31, P259, DOI 10.1002/job.627
   Podsakoff NP, 2009, J APPL PSYCHOL, V94, P122, DOI 10.1037/a0013079
   Resick CJ, 2006, J BUS ETHICS, V63, P345, DOI 10.1007/s10551-005-3242-1
   Riordan CM, 2003, J APPL SOC PSYCHOL, V33, P37, DOI 10.1111/j.1559-1816.2003.tb02072.x
   Rosen CC, 2006, J APPL PSYCHOL, V91, P211, DOI 10.1037/0021-9010.91.1.211
   Rosen CC, 2009, ORGAN BEHAV HUM DEC, V108, P202, DOI 10.1016/j.obhdp.2008.07.003
   Rosen CC, 2009, HUM RELAT, V62, P27, DOI 10.1177/0018726708099836
   Schaubroeck J, 2007, J APPL PSYCHOL, V92, P1020, DOI 10.1037/0021-9010.92.4.1020
   Schaubroeck JM, 2012, ACAD MANAGE J, V55, P1053, DOI 10.5465/amj.2011.0064
   Selig J. P., 2008, MONTE CARLO METHOD A
   Shrout PE, 2002, PSYCHOL METHODS, V7, P422, DOI 10.1037//1082-989X.7.4.422
   Snijders TAB, 1999, MULTILEVEL ANAL INTR
   Trevino LK, 2000, CALIF MANAGE REV, V42, P128, DOI 10.2307/41166057
   Trevino LK, 2003, HUM RELAT, V56, P5, DOI 10.1177/0018726703056001448
   Valle M, 2000, HUM RELAT, V53, P359, DOI 10.1177/0018726700533004
   van Jaarsveld DD, 2010, J MANAGE, V36, P1486, DOI 10.1177/0149206310368998
   Vigoda-Gadot E, 2007, PERS REV, V36, P661, DOI 10.1108/00483480710773981
   Walumbwa FO, 2003, INT J HUM RESOUR MAN, V14, P1083, DOI 10.1080/0958519032000114219
   Walumbwa FO, 2008, J MANAGE, V34, P89, DOI 10.1177/0149206307308913
   Walumbwa FO, 2007, APPL PSYCHOL-INT REV, V56, P212, DOI 10.1111/j.1464-0597.2006.00241.x
   Walumbwa FO, 2012, LEADERSHIP QUART, V23, P953, DOI 10.1016/j.leaqua.2012.06.004
   Walumbwa FO, 2011, J OCCUP ORGAN PSYCH, V84, P153, DOI 10.1348/096317910X485818
   Walumbwa FO, 2011, ORGAN BEHAV HUM DEC, V115, P204, DOI 10.1016/j.obhdp.2010.11.002
   Walumbwa FO, 2010, LEADERSHIP QUART, V21, P901, DOI 10.1016/j.leaqua.2010.07.015
   Walumbwa FO, 2010, J APPL PSYCHOL, V95, P517, DOI 10.1037/a0018867
   Walumbwa FO, 2009, J APPL PSYCHOL, V94, P1275, DOI 10.1037/a0015848
   Wang P, 2007, PERS PSYCHOL, V60, P397, DOI 10.1111/j.1744-6570.2007.00078.x
   Weiss HM, 1996, RES ORGAN BEHAV, V18, P1
   Wright TA, 1998, J APPL PSYCHOL, V83, P486, DOI 10.1037/0021-9010.83.3.486
   Xie JL, 2008, J APPL PSYCHOL, V93, P831, DOI 10.1037/0021-9010.93.4.831
   Zellars KL, 2008, J ORGAN BEHAV, V29, P549, DOI 10.1002/job.484
   Zellars KL, 2000, J APPL SOC PSYCHOL, V30, P1570, DOI 10.1111/j.1559-1816.2000.tb02456.x
NR 113
TC 22
Z9 25
U1 5
U2 131
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1048-9843
EI 1873-3409
J9 LEADERSHIP QUART
JI Leadersh. Q.
PD FEB
PY 2013
VL 24
IS 1
BP 284
EP 297
DI 10.1016/j.leaqua.2012.11.008
PG 14
WC Psychology, Applied; Management
SC Psychology; Business & Economics
GA 080RQ
UT WOS:000314261400020
DA 2018-12-27
ER

PT J
AU Zhang, YN
   Liu, CB
AF Zhang, Yanan
   Liu, Chibo
TI RETRACTED: The interaction between smoking and GSTM1 variant on lung
   cancer in the Chinese population (Retracted article. See April, 2017)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE GSTM1; Polymorphism; Smoking; Interaction; Lung cancer; Meta-analysis
ID GLUTATHIONE-S-TRANSFERASE; METAANALYSIS; POLYMORPHISMS; RISK;
   SUSCEPTIBILITY; ASSOCIATION; GENES; GSTT1; CARCINOMA; CYP1A1
AB Smoking and the deletion of GSTM1 variant are two risk factors of lung cancer. This meta-analysis was performed to examine the GSTM1-smoking interaction on lung cancer in the Chinese population. PubMed, Web of Science, and other Chinese databases were searched to include all the related studies. The number of subjects with two GSTM1 genotypes across different smoking status was extracted. The pooled odds ratios (ORs) with 95 % confidence intervals (CIs) were calculated using fixed- or random-effect model. A total of 4,345 cases and 5,031 controls from 30 studies were included in the meta-analysis. Compared with nonsmokers having power GSTM1, the pooled ORs with 95 % CIs for lung cancer in smokers with power GSTM1, in nonsmokers with null GSTM1, and in smokers with null GSTM1 were 2.24 (1.82-2.76), 1.48 (1.23-1.79), and 4.18 (3.38-5.16), respectively. This meta-analysis showed that there was an interaction between the GSTM1 and smoking on the risk of lung cancer in the Chinese. Further studies are needed to examine the interactions between other environmental factors and GSTM1 on the risk of lung cancer.
C1 [Zhang, Yanan] Fudan Univ, Sch Publ Hlth, Dept Occupat Hlth & Toxicol, Shanghai 200032, Peoples R China.
   [Liu, Chibo] Taizhou Univ, Taizhou Municipal Hosp, Dept Clin Lab, Taizhou 318000, Peoples R China.
RP Liu, CB (reprint author), Taizhou Univ, Taizhou Municipal Hosp, Dept Clin Lab, Taizhou 318000, Peoples R China.
EM chibo_liu@163.com
FU Zhejiang Medicine, Health, and Science [2010KYB127]; Zhejiang Province
   Chinese medicine research program [2012ZA130]; Zhejiang Gong Yi Xing
   Technology Application Project [2011C33045]; Department of Laboratory
   Medicine, Taizhou Municipal Hospital
FX The work was funded by Zhejiang Medicine, Health, and Science (no.
   2010KYB127), Zhejiang Province Chinese medicine research program
   (2012ZA130) and Zhejiang Gong Yi Xing Technology Application Project
   (No. 2011C33045). The authors also thank the Department of Laboratory
   Medicine, Taizhou Municipal Hospital for the support.
CR ANTTILA S, 1991, INT J CANCER, V47, P681, DOI 10.1002/ijc.2910470509
   Bordow RA, 2004, RESP DIS MANUAL, P713
   Carlsten C, 2008, AM J EPIDEMIOL, V167, P759, DOI 10.1093/aje/kwm383
   Chang FH, 2009, ACAD J XIAN JIAOTONG, V21, P225
   Chen LH, 2003, INT J ADV MANUF TECH, V22, P1, DOI 10.1007/s00170-003-1621-2
   Chen Senqing, 2001, Mutation Research, V458, P41, DOI 10.1016/S1383-5726(01)00011-5
   Du GB, 2011, N SICHUAN MED COLL, P1
   Fan J, 2010, J ONCOLOGY, V16, P922
   Gao JR, 1998, CARCINOGENESIS TERAT, V10, P149
   Gao Y, 2000, MUTAT RES-GEN TOX EN, V464, P311, DOI 10.1016/S1383-5718(99)00208-9
   Gu YF, 2008, TUBER THOR TUMOR, V1, P16
   Han RL, 2012, CENTRAL S PHARM, V10, P1
   Harbord RM, 2006, STAT MED, V25, P3443, DOI 10.1002/sim.2380
   Hengstler JG, 1998, RECENT RES CANCER, V154, P47
   Jin YT, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-422
   Kiyohara Chikako, 2002, Environ Health Prev Med, V7, P47, DOI 10.1007/BF02897330
   Li DR, 2005, SICHUAN U, P67
   Li Y, 2004, ZHENGZHOU U, P1
   Liu Q, 2008, SHANDONG PROVINCIAL, P1
   Liu Y, 2012, ASIAN PAC J TROP MED, V5, P480, DOI 10.1016/S1995-7645(12)60083-2
   Lu WF, 2002, INT J CANCER, V102, P275, DOI 10.1002/jhc.10712
   Mo ZN, 2009, PROSTATE, V69, P662, DOI 10.1002/pros.20907
   NAKAJIMA T, 1995, CARCINOGENESIS, V16, P707, DOI 10.1093/carcin/16.4.707
   Peters JL, 2006, JAMA-J AM MED ASSOC, V295, P676, DOI 10.1001/jama.295.6.676
   PETRUZZELLI S, 1988, CANCER RES, V48, P4695
   [钱碧云 Qian BiYun], 2006, [中国肿瘤临床, Chinese Journal of Clinical Oncology], V33, P500
   [乔贵宾 Qiao Guibin], 2005, [第四军医大学学报, Journal of the Fourth Military Medical University], V26, P1008
   Qiu LX, 2010, BREAST CANCER RES TR, V121, P703, DOI 10.1007/s10549-009-0636-2
   Ragin CC, 2010, GENET MED, V12, P12, DOI 10.1097/GIM.0b013e3181c8e160
   Shi XQ, 2008, LUNG CANCER, V59, P155, DOI 10.1016/j.lungcan.2007.08.004
   Sun GF, 1997, CANCER LETT, V113, P169, DOI 10.1016/S0304-3835(97)04612-0
   Sun GF, 1995, CHIN J TUBERC RESP D, V18, P167
   Tripathy CB, 2006, HEAD NECK-J SCI SPEC, V28, P217, DOI 10.1002/hed.20295
   Vijayakrishnan J, 2010, HAEMATOL-HEMATOL J, V95, P1405, DOI 10.3324/haematol.2010.022095
   Wang DQ, 2007, CHINA J PREV MED, V8, P466
   Wang J, 2003, THEOR COMPUT SCI, V296, P1, DOI 10.1016/S0304-3975(02)00427-9
   [王启明 WANG Qiming], 2006, [肿瘤防治研究, Cancer Research on Prevention and Treatment], V33, P8
   Wang S, 2003, XIAN 4 MIL MED U, P35
   Wells G, NEWCASTLE OTTAWA SCA
   [夏英 XIA Ying], 2008, [中华放射医学与防护杂志, Chinese Journal of Radiological Medicine and Protection], V28, P327
   Yao ZG, 2012, CHINESE J MED GUIDE, V14, P185
   Yu L, 2011, EXP BIOL MED, V17, P3248
   [张吉凯 Zhang Jiakai], 2002, [中国病理生理杂志, Chinese Journal of Pathophysiology], V18, P352
   [张建军 ZHANG Jianjun], 2011, [建筑结构学报, Journal of Building Structures], V32, P56
   [章龙珍 Zhang Longzhen], 2002, [中国肿瘤临床, Chinese Journal of Clinical Oncology], V29, P536
   Zhang ZJ, 2011, AM J EPIDEMIOL, V173, P847, DOI 10.1093/aje/kwq480
   Zhao B, 2001, CANCER EPIDEM BIOMAR, V10, P1063
   Zheng DJ, 2010, TIANJIN MED U, P1
   Zhou XL, 2011, ZHENGZHOU U, P1
   Zhu Y, 2012, MOL BIOL REP, V39, P685, DOI 10.1007/s11033-011-0786-2
   Zhuo XL, 2009, J EXP CLIN CANC RES, V28, DOI 10.1186/1756-9966-28-46
NR 51
TC 8
Z9 8
U1 5
U2 20
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD FEB
PY 2013
VL 34
IS 1
BP 395
EP 401
DI 10.1007/s13277-012-0562-5
PG 7
WC Oncology
SC Oncology
GA 075HM
UT WOS:000313875400046
PM 23090633
DA 2018-12-27
ER

PT J
AU He, XJ
   Ruan, J
   Du, WD
   Cao, YX
   Chen, G
   Zuo, XB
   Peng, YW
   Wu, H
   Song, B
   Zhang, XJ
AF He, Xiao-Jin
   Ruan, Jian
   Du, Wei-Dong
   Cao, Yun-Xia
   Chen, Gang
   Zuo, Xian-Bo
   Peng, Yu-Wan
   Wu, Huan
   Song, Bing
   Zhang, Xue-Jun
TI RETRACTED: PRDM9 gene polymorphism may not be associated with defective
   spermatogenesis in the Chinese Han population (Retracted article. See
   vol. 61, pg. 251, 2015)
SO SYSTEMS BIOLOGY IN REPRODUCTIVE MEDICINE
LA English
DT Article; Retracted Publication
DE non-obstructive azoospermia; PRDM9; severe oligozoospermia; single
   nucleotide polymorphisms (SNPs)
ID SINGLE-NUCLEOTIDE POLYMORPHISMS; GENOME-WIDE ASSOCIATION; MEIOTIC
   RECOMBINATION; SUSCEPTIBILITY LOCI; MALE-INFERTILITY; MEISETZ GENE;
   METHYLTRANSFERASE; AZOOSPERMIA; HOTSPOTS
AB PRDM9 is essential for the progression through early meiotic prophase, including double strand break repair, homologous chromosome pairing, and sex body formation during spermatogenesis. In order to evaluate the association of the PRDM9 gene variants with defective spermatogenesis in the Chinese Han population, we assessed two single nucleotide polymorphisms (SNPs) in the PRDM9 gene (rs1874165 and rs2973631) using Sequenom iplex technology in 309 cases of severely defective spermatogenesis (199 cases with non-obstructive azoospermia and 110 cases with severe oligozoospermia) and 377 controls. The allele frequencies of the SNPs were not statistically different between the study groups and the controls (P = 0.95 in rs1874165 and P = 0.80 in rs2973631, respectively). The genetic model analysis of the two SNPs indicated that these SNPs variants may not be associated with defective spermatogenesis in the Chinese Han population.
C1 [He, Xiao-Jin; Cao, Yun-Xia; Peng, Yu-Wan; Wu, Huan; Song, Bing] Anhui Med Univ, Dept Obstet & Gynecol, Reprod Med Ctr, Affiliated Hosp 1, Hefei 230032, Peoples R China.
   [He, Xiao-Jin; Cao, Yun-Xia] Anhui Med Univ, Sch Publ Hlth, Anhui Prov Key Lab Populat Hlth & Aristogen, Hefei 230032, Peoples R China.
   [Ruan, Jian; Du, Wei-Dong] Anhui Med Univ, Key Lab Genome Res Anhui Prov, Hefei 230032, Peoples R China.
   [Ruan, Jian; Du, Wei-Dong] Anhui Med Univ, Dept Biol, Hefei 230032, Peoples R China.
   [Du, Wei-Dong; Chen, Gang; Zuo, Xian-Bo; Zhang, Xue-Jun] Anhui Med Univ, Minist Natl Sci & Technol, State Key Lab Incubat Base Dermatol, Hefei 230032, Peoples R China.
   [Du, Wei-Dong] Univ Ulm Klinikum, Sekt Expt Anaesthesiol, D-89075 Ulm, Germany.
RP Cao, YX (reprint author), Anhui Med Univ, Dept Obstet & Gynecol, Reprod Med Ctr, Affiliated Hosp 1, Hefei 230032, Peoples R China.
EM weidongdu@hotmail.com; caoyunxia6@126.com
RI Chen, Gang/G-2722-2010
CR Baudat F, 2010, SCIENCE, V327, P836, DOI 10.1126/science.1183439
   BELLEFROID EJ, 1991, P NATL ACAD SCI USA, V88, P3608, DOI 10.1073/pnas.88.9.3608
   Buard J, 2009, EMBO J, V28, P2616, DOI 10.1038/emboj.2009.207
   De Kretser DM, 1999, J CLIN ENDOCR METAB, V84, P3443, DOI 10.1210/jc.84.10.3443
   Han JW, 2009, NAT GENET, V41, P1234, DOI 10.1038/ng.472
   Hayashi K, 2006, CELL CYCLE, V5, P615, DOI 10.4161/cc.5.6.2572
   Hayashi K, 2005, NATURE, V438, P374, DOI 10.1038/nature04112
   Huynh T, 2002, HUM REPROD UPDATE, V8, P183, DOI 10.1093/humupd/8.2.183
   Irie S, 2009, J ANDROL, V30, P426, DOI 10.2164/jandrol.108.006262
   Miyamoto T, 2008, J ASSIST REPROD GEN, V25, P553, DOI 10.1007/s10815-008-9270-x
   Parvanov ED, 2010, SCIENCE, V327, P835, DOI 10.1126/science.1181495
   Quan C, 2010, NAT GENET, V42, P614, DOI 10.1038/ng.603
   Sadeghi-Nejad H, 2008, CURR OPIN UROL, V18, P628, DOI 10.1097/MOU.0b013e32831367dc
   Tempest HG, 2011, SYST BIOL REPROD MED, V57, P93, DOI 10.3109/19396368.2010.504879
   Vayena P., 2002, CURR PRACT CONTR ASS
NR 15
TC 1
Z9 1
U1 2
U2 18
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 1939-6368
EI 1939-6376
J9 SYST BIOL REPROD MED
JI Syst. Biol. Reprod. Med.
PD FEB
PY 2013
VL 59
IS 1
BP 38
EP 41
DI 10.3109/19396368.2012.723793
PG 4
WC Andrology; Reproductive Biology
SC Endocrinology & Metabolism; Reproductive Biology
GA 072MK
UT WOS:000313675400007
PM 23190393
DA 2018-12-27
ER

PT J
AU Melanko, S
   Larkin, KT
AF Melanko, Shane
   Larkin, Kevin T.
TI RETRACTED: Preference for immediate reinforcement over delayed
   reinforcement: relation between delay discounting and health behavior
   (Retracted article. See vol. 38, pg. 835, 2015)
SO JOURNAL OF BEHAVIORAL MEDICINE
LA English
DT Article; Retracted Publication
DE Delay discounting; Health behavior; Experiential Discounting Task;
   Impulsivity; Health decision making
ID BARRATT IMPULSIVENESS SCALE; PROBABILISTIC REWARDS; CIGARETTE-SMOKING;
   OBESE WOMEN; SELF-REPORT; SMOKERS; NONSMOKERS; INTELLIGENCE;
   PERSONALITY; CHOICES
AB Reinforcement from engaging in health behaviors is often delayed by several months or years, a circumstance partly responsible for some people's increased preference for engaging in unhealthy behaviors associated with immediate reinforcement. To examine whether individuals who discount the future engage in fewer health behaviors, 72 young adults completed questionnaires assessing health behaviors and impulsiveness and laboratory-behavioral measures of impulsive decision making. Regression analyses of impulsivity measures predicting health behavior were only significant for one measure, the Experiential Discounting Task, a task in which monetary consequences of choice were actually experienced by study participants. Participants who discounted most by delay (i.e., exhibited impulsive choice) engaged in fewer health behaviors than those who showed less impulsive responding. This task, in contrast to a hypothetical choice task or self-reported impulsiveness, measures the actual behavior of discounting by delay, and was the facet of impulsive decision making most closely associated with adopting a range of health behaviors.
C1 [Melanko, Shane; Larkin, Kevin T.] W Virginia Univ, Dept Psychol, Morgantown, WV 26505 USA.
RP Melanko, S (reprint author), W Virginia Univ, Dept Psychol, 53 Campus Dr,1212 Life Sci Bldg, Morgantown, WV 26505 USA.
EM Shane.melanko@mail.wvu.edu
CR Baker F, 2003, J ABNORM PSYCHOL, V112, P382, DOI 10.1037/0021-843X.112.3.382
   Baker TB, 2004, ANNU REV PSYCHOL, V55, P463, DOI 10.1146/annurev.psych.55.090902.142054
   Bickel W. K, 2003, TIME DECISION EC PSY, P419
   Bickel WK, 1999, PSYCHOPHARMACOLOGY, V146, P447, DOI 10.1007/PL00005490
   Centers for Disease Control and Prevention, BEH RISK FACT SURV S
   CHAPMAN GB, 1995, MED DECIS MAKING, V15, P373, DOI 10.1177/0272989X9501500408
   Corbin CB, 2006, CONCEPTS FITNESS WEL
   Cyders MA, 2011, CLIN PSYCHOL REV, V31, P965, DOI 10.1016/j.cpr.2011.06.001
   de Wit H, 2007, PERS INDIV DIFFER, V42, P111, DOI 10.1016/j.paid.2006.06.026
   Green L, 2004, PSYCHOL BULL, V130, P769, DOI 10.1037/0033-2909.130.5.769
   Green L, 1996, PSYCHOL AGING, V11, P79, DOI 10.1037/0882-7974.11.1.79
   Heron M., 2006, NATL VITAL STAT REPO, V57, P1
   Hollingshead AB, 1975, 4 FACTOR INDEX UNPUB
   Jabs J, 2006, APPETITE, V47, P196, DOI 10.1016/j.appet.2006.02.014
   Kirby KN, 1996, PSYCHON B REV, V3, P100, DOI 10.3758/BF03210748
   Krishnan-Sarin S, 2007, DRUG ALCOHOL DEPEN, V88, P79, DOI 10.1016/j.drugalcdep.2006.09.006
   Logue AW, 2001, PSYCHOL SCI, V12, P276, DOI 10.1111/1467-9280.00351
   Madden GJ, 2003, EXP CLIN PSYCHOPHARM, V11, P139, DOI 10.1037/1064-1297.11.2.139
   Madden GJ, 1997, EXP CLIN PSYCHOPHARM, V5, P256, DOI 10.1037//1064-1297.5.3.256
   Melanko S, 2009, EXP CLIN PSYCHOPHARM, V17, P258, DOI 10.1037/a0016461
   Myerson J, 2001, J EXP ANAL BEHAV, V76, P235, DOI 10.1901/jeab.2001.76-235
   Nederkoorn C, 2006, APPETITE, V47, P253, DOI 10.1016/j.appet.2006.05.008
   Olson EA, 2007, PERS INDIV DIFFER, V43, P1886, DOI 10.1016/j.paid.2007.06.016
   Patton JH, 1995, J CLIN PSYCHOL, V51, P768, DOI 10.1002/1097-4679(199511)51:6<768::AID-JCLP2270510607>3.0.CO;2-1
   Petry NM, 2002, PSYCHOPHARMACOLOGY, V162, P425, DOI 10.1007/s00213-002-1115-1
   Petry NM, 2001, J ABNORM PSYCHOL, V110, P482, DOI 10.1037/0021-843X.110.3.482
   Psychological Corporation, 1999, MAN WECHSL ABBR SCAL
   RACHLIN H, 2000, SCI SELF CONTROL
   RAINERI A, 1993, J BEHAV DECIS MAKING, V6, P77, DOI 10.1002/bdm.3960060202
   Reynolds B, 2006, PERS INDIV DIFFER, V40, P305, DOI 10.1016/j.paid.2005.03.024
   Reynolds B, 2004, BEHAV PROCESS, V67, P343, DOI 10.1016/j.beproc.2004.06.003
   Reynolds B, 2007, EXP CLIN PSYCHOPHARM, V15, P264, DOI 10.1037/1064-1297.15.3.264
   Reynolds B, 2006, BEHAV PHARMACOL, V17, P651, DOI 10.1097/FBP.0b013e3280115f99
   Reynolds B, 2009, DRUG ALCOHOL DEPEN, V99, P350, DOI 10.1016/j.drugalcdep.2008.07.015
   Richards JB, 1999, J EXP ANAL BEHAV, V71, P121, DOI 10.1901/jeab.1999.71-121
   Schroeder SA, 2007, NEW ENGL J MED, V357, P1221, DOI 10.1056/NEJMsa073350
   Shamosh NA, 2008, INTELLIGENCE, V36, P289, DOI 10.1016/j.intell.2007.09.004
   Smith PK, 2005, ECON HUM BIOL, V3, P259, DOI 10.1016/j.ehb.2005.05.001
   Stanford MS, 2009, PERS INDIV DIFFER, V47, P385, DOI 10.1016/j.paid.2009.04.008
   Vuchinich RE, 1998, EXP CLIN PSYCHOPHARM, V6, P292, DOI 10.1037//1064-1297.6.3.292
   Weller RE, 2008, APPETITE, V51, P563, DOI 10.1016/j.appet.2008.04.010
   Wilcox S, 2006, ARTHRIT RHEUM-ARTHR, V55, P616, DOI 10.1002/art.22098
   Yi R., 2009, IMPULSIVITY BEHAV NE, P191, DOI DOI 10.1037/12069-007
NR 43
TC 16
Z9 16
U1 2
U2 35
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0160-7715
EI 1573-3521
J9 J BEHAV MED
JI J. Behav. Med.
PD FEB
PY 2013
VL 36
IS 1
BP 34
EP 43
DI 10.1007/s10865-012-9399-z
PG 10
WC Psychology, Clinical
SC Psychology
GA 068KT
UT WOS:000313366300004
PM 22311103
DA 2018-12-27
ER

PT J
AU Lee, DJ
   Kang, SW
AF Lee, Doo Jae
   Kang, Sang Won
TI RETRACTED: Reactive oxygen species and tumor metastasis (Retracted
   article. See vol. 35, pg. 356, 2013)
SO MOLECULES AND CELLS
LA English
DT Review; Retracted Publication
DE cancer; EMT; invasion; migration; ROS
ID EPITHELIAL-MESENCHYMAL TRANSITION; EPIDERMAL-GROWTH-FACTOR; MEDIATED
   CELL-ADHESION; NF-KAPPA-B; PLASMINOGEN-ACTIVATOR; MATRIX
   METALLOPROTEINASES; TYROSINE PHOSPHORYLATION; HYDROGEN-PEROXIDE;
   IN-VIVO; DEPENDENT INHIBITION
AB The migration and invasion of cancer cells are the first steps in metastasis. Through a series of cellular responses, including cytoskeletal reorganization and degradation of the extracellular matrix, cancer cells are able to separate from the primary tumor and metastasize to distant locations in the body. In cancer cells, reactive oxygen species (ROS) play important roles in the migration and invasion of cells. Stimulation of cell surface receptors with growth factors and integrin assembly generates ROS, which relay signals from the cell surface to important signaling proteins. ROS then act within cells to promote migration and invasion. In this review, we collect recent evidence pointing towards the involvement of ROS in tumor metastasis and discuss the roles of ROS at different stages during the process of cancer cell migration, invasion and epithelial-mesenchymal transition.
C1 [Lee, Doo Jae; Kang, Sang Won] Ewha Womans Univ, Div Life & Pharmaceut Sci, Seoul 120750, South Korea.
   [Lee, Doo Jae; Kang, Sang Won] Ewha Womans Univ, Res Ctr Cellular Homeostasis, Seoul 120750, South Korea.
   [Kang, Sang Won] Ewha Womans Univ, Dept Life Sci, Seoul 120750, South Korea.
RP Kang, SW (reprint author), Ewha Womans Univ, Div Life & Pharmaceut Sci, Seoul 120750, South Korea.
EM kangsw@ewha.ac.kr
FU Drug Target Validation Program [2011-0030195]; Research Center for
   Cellular Homeostasis of the National Research Foundation
   [2012R1A5A1048236]; Korean government (Ministry of Education and Science
   Technology); Ewha Womans University
FX This study was supported by the Drug Target Validation Program
   (2011-0030195) and the Research Center for Cellular Homeostasis
   (2012R1A5A1048236) of the National Research Foundation funded by the
   Korean government (Ministry of Education and Science Technology). This
   work was partly supported by the intramural GT5 grants from Ewha Womans
   University. D. J. Lee was supported by a RP-Grant 2011 of Ewha Womans
   University.
CR Anastasiadis PZ, 2000, J CELL SCI, V113, P1319
   Arthur JR, 2000, CELL MOL LIFE SCI, V57, P1825
   Bae YS, 2011, MOL CELLS, V32, P491, DOI 10.1007/s10059-011-0276-3
   Barnett P, 2011, BIOCHEM BIOPH RES CO, V404, P34, DOI 10.1016/j.bbrc.2010.11.044
   Baum B, 2008, SEMIN CELL DEV BIOL, V19, P294, DOI 10.1016/j.semcdb.2008.02.001
   Binker MG, 2009, BIOCHEM BIOPH RES CO, V379, P445, DOI 10.1016/j.bbrc.2008.12.080
   Brazzolotto X, 1999, J BIOL CHEM, V274, P21625, DOI 10.1074/jbc.274.31.21625
   Brenneisen P, 2002, ANN NY ACAD SCI, V973, P31, DOI 10.1111/j.1749-6632.2002.tb04602.x
   Brooks SA, 2010, ACTA HISTOCHEM, V112, P3, DOI 10.1016/j.acthis.2008.11.022
   Broom OJ, 2006, J CELL PHYSIOL, V209, P950, DOI 10.1002/jcp.20796
   Cairo G, 1996, FASEB J, V10, P1326
   Cannito S, 2010, ANTIOXID REDOX SIGN, V12, P1383, DOI 10.1089/ars.2009.2737
   Cannito S, 2008, CARCINOGENESIS, V29, P2267, DOI 10.1093/carcin/bgn216
   Chiarugi P, 2003, J CELL BIOL, V161, P933, DOI 10.1083/jcb.200211118
   Chiarugi P, 2007, CELL SIGNAL, V19, P672, DOI 10.1016/j.cellsig.2006.11.009
   Chiu WT, 2010, NEUROBIOL DIS, V37, P118, DOI 10.1016/j.nbd.2009.09.015
   Comito G, 2011, FREE RADICAL BIO MED, V51, P893, DOI 10.1016/j.freeradbiomed.2011.05.042
   Curran S, 2004, CLIN CANCER RES, V10, P8229, DOI 10.1158/1078-0432.CCR-04-0424
   Dong R, 2007, BRAZ J MED BIOL RES, V40, P1071, DOI 10.1590/S0100-879X2007000800007
   Giannoni E, 2012, ANTIOXID REDOX SIGN, V16, P1248, DOI 10.1089/ars.2011.4280
   Gloire G, 2006, BIOCHEM PHARMACOL, V72, P1493, DOI 10.1016/j.bcp.2006.04.011
   Gregg D, 2004, ANTIOXID REDOX SIGN, V6, P757, DOI 10.1089/1523086041361604
   Ho BY, 2011, INT J BIOL SCI, V7, P869, DOI 10.7150/ijbs.7.869
   Honore S, 2003, EXP CELL RES, V285, P59, DOI 10.1016/S0014-4827(02)00038-1
   Hurd TR, 2012, TRENDS CELL BIOL, V22, P107, DOI 10.1016/j.tcb.2011.11.002
   Inumaru J, 2009, GENES CELLS, V14, P703, DOI 10.1111/j.1365-2443.2009.01303.x
   Kheradmand F, 1998, SCIENCE, V280, P898, DOI 10.1126/science.280.5365.898
   Kim MH, 2007, INT J MOL MED, V19, P689
   Lambeth JD, 2007, FREE RADICAL BIO MED, V43, P332, DOI 10.1016/j.freeradbiomed.2007.03.027
   LANDER HM, 1995, J BIOL CHEM, V270, P21195, DOI 10.1074/jbc.270.36.21195
   Lee KH, 2009, J EXP CLIN CANC RES, V28, DOI 10.1186/1756-9966-28-73
   Lee SB, 2006, J BIOL CHEM, V281, P36228, DOI 10.1074/jbc.M606702200
   Lin MT, 2003, MOL PHARMACOL, V64, P1029, DOI 10.1124/mol.64.5.1029
   Lowther WT, 2011, ANTIOXID REDOX SIGN, V15, P99, DOI 10.1089/ars.2010.3564
   Lukaszewicz-Zajac M, 2011, CLIN CHIM ACTA, V412, P1725, DOI 10.1016/j.cca.2011.06.003
   Meyer T, 1998, EUR J CANCER, V34, P214, DOI 10.1016/S0959-8049(97)10129-0
   Monaghan-Benson E, 2009, J BIOL CHEM, V284, P25602, DOI 10.1074/jbc.M109.009894
   Moskovitz J, 1997, P NATL ACAD SCI USA, V94, P9585, DOI 10.1073/pnas.94.18.9585
   Nelson KK, 2004, FREE RADICAL BIO MED, V37, P768, DOI 10.1016/j.freeradbiomed.2004.06.008
   Nigam S, 1998, J AM SOC NEPHROL, V9, P1787
   Nishikawa M, 2008, CANCER LETT, V266, P53, DOI 10.1016/j.canlet.2008.02.031
   Nwariaku FE, 2004, BLOOD, V104, P3214, DOI 10.1182/blood-2004-05-1868
   Pani G, 2000, J BIOL CHEM, V275, P38891, DOI 10.1074/jbc.M007319200
   Pelicano H, 2009, CANCER RES, V69, P2375, DOI 10.1158/0008-5472.CAN-08-3359
   PEPPELENBOSCH MP, 1995, CELL, V81, P849, DOI 10.1016/0092-8674(95)90005-5
   Pervaiz S, 2007, INT J BIOCHEM CELL B, V39, P1297, DOI 10.1016/j.biocel.2007.04.007
   Rabbani SA, 1998, INT J ONCOL, V12, P911
   Reddy SPM, 2002, AM J PHYSIOL-LUNG C, V283, pL1161, DOI 10.1152/ajplung.00140.2002
   Reuning U, 2003, CURR PHARM DESIGN, V9, P1529, DOI 10.2174/1381612033454612
   Rhee SG, 2005, CURR OPIN CELL BIOL, V17, P183, DOI 10.1016/j.ceb.2005.02.004
   Rhyu DY, 2005, J AM SOC NEPHROL, V16, P667, DOI 10.1681/ASN.2004050425
   Sangrar W, 2007, MOL CELL BIOL, V27, P6140, DOI 10.1128/MCB.01744-06
   Shinohara M, 2010, J BIOL CHEM, V285, P4481, DOI 10.1074/jbc.M109.071779
   Sorby M, 1996, J BIOL CHEM, V271, P10963
   Taddei ML, 2007, ANTIOXID REDOX SIGN, V9, P469, DOI 10.1089/ars.2006.1392
   Thews O, 2009, ADV EXP MED BIOL, V645, P95, DOI 10.1007/978-0-387-85998-9_15
   Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835
   Tobar N, 2010, MOL CELL BIOCHEM, V340, P195, DOI 10.1007/s11010-010-0418-5
   Tran H, 2003, MOL CELL BIOL, V23, P7177, DOI 10.1128/MCB.23.20.7177-7188.2003
   Ushio-Fukai M, 2009, ANTIOXID REDOX SIGN, V11, P1289, DOI [10.1089/ars.2008.2333, 10.1089/ARS.2008.2333]
   van Buul JD, 2005, J BIOL CHEM, V280, P21129, DOI 10.1074/jbc.M500898200
   van Wetering S, 2002, J CELL SCI, V115, P1837
   Werner E, 2002, J CELL BIOL, V158, P357, DOI 10.1083/jcb.200111028
   Woo CH, 2000, J BIOL CHEM, V275, P32357, DOI 10.1074/jbc.M005638200
   Wu R, 2007, MOL MED, V13, P143, DOI 10.2119/2007-00005.Wu
   Yamaoka-Tojo M, 2004, CIRC RES, V95, P276, DOI 10.1161/01.RES.0000136522.58649.60
   Yamaoka-Tojo M, 2006, ARTERIOSCL THROM VAS, V26, P1991, DOI 10.1161/01.ATV.0000231524.14873.e7
   Yang JQ, 2001, FREE RADICAL BIO MED, V31, P520, DOI 10.1016/S0891-5849(01)00613-X
   Yang SH, 2003, GENE, V320, P3, DOI 10.1016/S0378-1119(03)00816-3
   Zhang KH, 2009, CANCER RES, V69, P5340, DOI 10.1158/0008-5472.CAN-09-0112
NR 70
TC 24
Z9 25
U1 2
U2 4
PU KOREAN SOC MOLECULAR & CELLULAR  BIOLOGY
PI SEOUL
PA 635-4, YUCKSAM-DONG, GANGNAM-GU, SEOUL 135-703, SOUTH KOREA
SN 1016-8478
EI 0219-1032
J9 MOL CELLS
JI Mol. Cells
PD FEB
PY 2013
VL 35
IS 2
BP 93
EP 98
DI 10.1007/s10059-013-0034-9
PG 6
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 098XL
UT WOS:000315582300002
PM 23456330
OA Green Published
DA 2018-12-27
ER

PT J
AU Liu, WH
   Liu, JJ
   Wu, J
   Zhang, LL
   Liu, F
   Yin, L
   Zhang, MM
   Yu, B
AF Liu, Wen-hua
   Liu, Jing-jin
   Wu, Jian
   Zhang, Lu-lu
   Liu, Fang
   Yin, Li
   Zhang, Mao-mao
   Yu, Bo
TI RETRACTED: Novel Mechanism of Inhibition of Dendritic Cells Maturation
   by Mesenchymal Stem Cells via Interleukin-10 and the JAK1/STAT3
   Signaling Pathway (Retracted article. See vol. 13, art no E0194455,
   2018)
SO PLOS ONE
LA English
DT Article; Retracted Publication
ID ANTIGEN-PRESENTING CELLS; VERSUS-HOST-DISEASE; BONE-MARROW; T-CELLS;
   BLOOD MONOCYTES; STROMAL CELLS; IFN-GAMMA; IL-10; DIFFERENTIATION;
   ACTIVATION
AB Mesenchymal stem cells (MSCs) can suppress dendritic cells (DCs) maturation and function, mediated by soluble factors, such as indoleamine 2,3-dioxygenase (IDO), prostaglandin E-2 (PGE(2)), and nitric oxide (NO). Interleukin-10 (IL-10) is a common immunosuppressive cytokine, and the downstream signaling of the JAK-STAT pathway has been shown to be involved with DCs differentiation and maturation in the context of cancer. Whether IL-10 and/or the JAK-STAT pathway play a role in the inhibitory effect of MSCs on DCs maturation remains controversial. In our study, we cultured MSCs and DCs derived from rat bone marrow under different culturing conditions. Using Transwell plates, we detected by ELISA that the level of IL-10 significantly increased in the supernatants of MSC-DC co-cultures at 48 hours. The cell immunofluorescence assay suggested that the MSCs secreted more IL-10 than the DCs in the co-cultures. Adding exogenous IL-10 to the DCs monoculture or MSC-DC co-cultures stimulated IL-10 and led to a decrease in IL-12, and lower expression of the DCs surface markers CD80, CD86, OX62, MHC-II and CD11b/c. Supplementing the culture with an IL-10 neutralizing antibody (IL-10NA) showed precisely the opposite effect of adding IL-10. Moreover, we demonstrated that the JAK-STAT signaling pathway is involved in inhibiting DCs maturation. Both JAK1 and STAT3 expression and IL-10 secretion decreased markedly after adding a JAK inhibitor (AG490) to the co-culture plate. We propose that there is an IL-10 positive feedback loop, which may explain our observations of elevated IL-10 and enhanced JAK1 and STAT3 expression. Overall, we demonstrated that MSCs inhibit the maturation of DCs through the stimulation of IL-10 secretion, and by activating the JAK1 and STAT3 signaling pathway.
C1 [Liu, Wen-hua] Harbin Med Univ, Affiliated Hosp 2, Intens Care Unit ICU Dept, Harbin, Province Heilon, Peoples R China.
   [Liu, Jing-jin; Wu, Jian; Zhang, Lu-lu; Liu, Fang; Yin, Li; Zhang, Mao-mao; Yu, Bo] Harbin Med Univ, Affiliated Hosp 2, Dept Cardiol, Harbin, Province Heilon, Peoples R China.
RP Yu, B (reprint author), Harbin Med Univ, Affiliated Hosp 2, Dept Cardiol, Harbin, Province Heilon, Peoples R China.
EM yubodr@163.com
FU Heilongjiang Provincial Health Department [2011-087]; Heilongjiang
   Provincial Education Department (12521265), China
FX This project was supported by research grants from Heilongjiang
   Provincial Health Department issued in 2011 (2011-087), Heilongjiang
   Provincial Education Department issued in 2012 (12521265), China. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Aldinucci A, 2010, J IMMUNOL, V185, P5102, DOI 10.4049/jimmunol.1001332
   Bishopric NH, 2008, CIRC RES, V103, P125, DOI 10.1161/CIRCRESAHA.108.180596
   Chen L, 2007, STEM CELLS DEV, V16, P719, DOI 10.1089/scd.2007.0065
   Conzelmann M, 2010, BIOCHEM PHARMACOL, V80, P2074, DOI 10.1016/j.bcp.2010.07.040
   Corinti S, 2001, J IMMUNOL, V166, P4312, DOI 10.4049/jimmunol.166.7.4312
   Djouad F, 2007, STEM CELLS, V25, P2025, DOI 10.1634/stemcells.2006-0548
   Groux H, 2003, J AUTOIMMUN, V20, P281, DOI 10.1016/S0896-8411(03)00044-1
   Hirata N, 2009, CELL IMMUNOL, V258, P9, DOI 10.1016/j.cellimm.2009.03.006
   Kamdje AHN, 2011, BLOOD, V118, P380, DOI 10.1182/blood-2010-12-326694
   Kim YH, 2011, MOL MED, V17, P697, DOI 10.2119/molmed.2010.00098
   Krampera M, 2003, BLOOD, V101, P3722, DOI 10.1182/blood-2002-07-2104
   Kronsteiner B, 2011, CELL IMMUNOL, V267, P30, DOI 10.1016/j.cellimm.2010.11.001
   Le Blanc K, 2004, LANCET, V363, P1439, DOI 10.1016/S0140-6736(04)16104-7
   Lee Eun Byul, 2010, Immune Netw, V10, P219, DOI 10.4110/in.2010.10.6.219
   Li H, 2008, STEM CELLS, V26, P2531, DOI 10.1634/stemcells.2008-0146
   Li YP, 2008, J IMMUNOL, V180, P1598, DOI 10.4049/jimmunol.180.3.1598
   MACATONIA SE, 1995, J IMMUNOL, V154, P5071
   Majumdar MK, 2003, J BIOMED SCI, V10, P228, DOI 10.1159/000068710
   Manuzak J, 2012, CLIN VACCINE IMMUNOL, V19, P1207, DOI 10.1128/CVI.00282-12
   Meisel R, 2004, BLOOD, V103, P4619, DOI 10.1182/blood-2003-11-3909
   Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683
   Murray PJ, 2007, J IMMUNOL, V178, P2623, DOI 10.4049/jimmunol.178.5.2623
   Nefedova Y, 2007, CURR CANCER DRUG TAR, V7, P71, DOI 10.2174/156800907780006887
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Posselt G, 2011, J IMMUNOL, V187, P2875, DOI 10.4049/jimmunol.1003348
   Ren GW, 2008, J IMMUNOL, V181, P3277, DOI 10.4049/jimmunol.181.5.3277
   Spaggiari GM, 2008, BLOOD, V111, P1327, DOI 10.1182/blood-2007-02-074997
   Spaggiari GM, 2009, BLOOD, V113, P6576, DOI 10.1182/blood-2009-02-203943
   Steinman RM, 2003, ANNU REV IMMUNOL, V21, P685, DOI 10.1146/annurev.immunol.21.120601.141040
   Szade K, 2011, MOL CELLS, V31, P497, DOI 10.1007/s10059-011-2176-y
   Wang XL, 2006, STEM CELLS, V24, P482, DOI 10.1634/stemcells.2005-0219
   Zhang B, 2009, BLOOD, V113, P46, DOI 10.1182/blood-2008-04-154138
   Zhang MM, 2011, J IMMUNOL, V187, P1674, DOI 10.4049/jimmunol.1001937
   Zhao ZG, 2012, IMMUNOL INVEST, V41, P183, DOI 10.3109/08820139.2011.607877
   Zhou LJ, 1996, P NATL ACAD SCI USA, V93, P2588, DOI 10.1073/pnas.93.6.2588
NR 35
TC 51
Z9 52
U1 1
U2 21
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 30
PY 2013
VL 8
IS 1
AR e55487
DI 10.1371/journal.pone.0055487
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 098QM
UT WOS:000315563800159
PM 23383203
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Al-Gayyar, MMH
   Mysona, BA
   Matragoon, S
   Abdelsaid, MA
   El-Azab, MF
   Shanab, AY
   Ha, YJ
   Smith, SB
   Bollinger, KE
   El-Remessy, AB
AF Al-Gayyar, Mohammed M. H.
   Mysona, Barbara A.
   Matragoon, Suraporn
   Abdelsaid, Mohammed A.
   El-Azab, Mona F.
   Shanab, Ahmed Y.
   Ha, Yonju
   Smith, Sylvia B.
   Bollinger, Kathryn E.
   El-Remessy, Azza B.
TI RETRACTED: Diabetes and Overexpression of proNGF Cause Retinal
   Neurodegeneration via Activation of RhoA Pathway(Retracted article. See
   vol 12,art no e0186748, 2017)
SO PLOS ONE
LA English
DT Article; Retracted Publication
ID NERVE GROWTH-FACTOR; SPINAL-CORD-INJURY; GANGLION-CELLS; PROTEIN-KINASE;
   FAMILY GTPASES; RAT RETINA; DEATH; INHIBITION; APOPTOSIS; P75
AB Our previous studies showed positive correlation between accumulation of proNGF, activation of RhoA and neuronal death in diabetic models. Here, we examined the neuroprotective effects of selective inhibition of RhoA kinase in the diabetic rat retina and in a model that stably overexpressed the cleavage-resistance proNGF plasmid in the retina. Male Sprague-Dawley rats were rendered diabetic using streptozotosin or stably express cleavage-resistant proNGF plasmid. The neuroprotective effects of the intravitreal injection of RhoA kinase inhibitor Y27632 were examined in vivo. Effects of proNGF were examined in freshly isolated primary retinal ganglion cell (RGC) cultures and RGC-5 cell line. Retinal neurodegeneration was assessed by counting TUNEL-positive and Brn-3a positive retinal ganglion cells. Expression of proNGF, p75(NTR), cleaved-PARP, caspase-3 and p38MAPK/JNK were examined by Western-blot. Activation of RhoA was assessed by pull-down assay and G-LISA. Diabetes and overexpression of proNGF resulted in retinal neurodegeneration as indicated by 9- and 6-fold increase in TUNEL-positive cells, respectively. In vitro, proNGF induced 5-fold cell death in RGC-5 cell line, and it induced >10-fold cell death in primary RGC cultures. These effects were associated with significant upregulation of p75(NTR) and activation of RhoA. While proNGF induced TNF-alpha expression in vivo, it selectively activated RhoA in primary RGC cultures and RGC-5 cell line. Inhibiting RhoA kinase with Y27632 significantly reduced diabetes- and proNGF-induced activation of proapoptotic p38MAPK/JNK, expression of cleaved-PARP and caspase-3 and prevented retinal neurodegeneration in vivo and in vitro. Taken together, these results provide compelling evidence for a causal role of proNGF in diabetes-induced retinal neurodegeneration through enhancing p75(NTR) expression and direct activation of RhoA and p38MAPK/JNK apoptotic pathways.
C1 [Al-Gayyar, Mohammed M. H.; Mysona, Barbara A.; Matragoon, Suraporn; Abdelsaid, Mohammed A.; El-Azab, Mona F.; Shanab, Ahmed Y.; El-Remessy, Azza B.] Univ Georgia, Coll Pharm, Program Clin & Expt Therapeut, Athens, GA 30602 USA.
   [El-Remessy, Azza B.] Georgia Hlth Sci Univ, Dept Pharmacol & Toxicol, Augusta, GA USA.
   [Ha, Yonju; Smith, Sylvia B.] Georgia Hlth Sci Univ, Dept Cell Biol & Anat, Augusta, GA USA.
   [Smith, Sylvia B.; El-Remessy, Azza B.] Georgia Hlth Sci Univ, Dept Ophthalmol, Augusta, GA USA.
   [Al-Gayyar, Mohammed M. H.; Mysona, Barbara A.; Matragoon, Suraporn; Abdelsaid, Mohammed A.; El-Azab, Mona F.; Shanab, Ahmed Y.; Ha, Yonju; Smith, Sylvia B.; Bollinger, Kathryn E.; El-Remessy, Azza B.] Georgia Hlth Sci Univ, Vis Discovery Inst, Augusta, GA USA.
   [Al-Gayyar, Mohammed M. H.; Mysona, Barbara A.; Matragoon, Suraporn; Abdelsaid, Mohammed A.; El-Azab, Mona F.; Shanab, Ahmed Y.; El-Remessy, Azza B.] Charlie Norwood Vet Affairs Med Ctr, Augusta, GA USA.
RP El-Remessy, AB (reprint author), Univ Georgia, Coll Pharm, Program Clin & Expt Therapeut, Athens, GA 30602 USA.
EM aelremessy@georgiahealth.edu
RI Al-Gayyar, Mohammed/E-8250-2014; El-Azab, Mona/M-9420-2014
OI Al-Gayyar, Mohammed/0000-0003-4777-3919; El-Azab,
   Mona/0000-0003-4982-445X; El-Remessy, Azza/0000-0003-4386-1989
FU Juvenile Diabetes Research Foundation [2-2008-149]; NIH [RO1 EY022408,
   R01 EY014560]; Vision Discovery Institute, Georgia Health Science
   University; AHA; Islamic Development Bank
FX This work was supported by a career development award from Juvenile
   Diabetes Research Foundation grant (2-2008-149) to ABE and NIH RO1
   EY022408 to ABE and a Grant from Vision Discovery Institute, Georgia
   Health Science University to ABE and KEB, NIH R01 EY014560 to SBS and
   post-doctoral fellowship from AHA to BAM and a post-doctoral fellowship
   from Islamic Development Bank to MFE. Funding entities had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Al-Gayyar MMH, 2011, DIABETOLOGIA
   Al-Gayyar MMH, 2010, AM J PATHOL, V177, P1187, DOI 10.2353/ajpath.2010.091289
   Ali TK, 2008, DIABETES, V57, P889, DOI 10.2337/db07-1669
   Ali TK, 2011, DIABETOLOGIA
   Arthur WT, 2002, BIOL RES, V35, P239, DOI 10.4067/S0716-97602002000200016
   Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0
   CARMIGNOTO G, 1991, EXP NEUROL, V111, P302, DOI 10.1016/0014-4886(91)90097-V
   CasacciaBonnefil P, 1996, NATURE, V383, P716, DOI 10.1038/383716a0
   Coassin M, 2008, GRAEF ARCH CLIN EXP, V246, P1743, DOI 10.1007/s00417-008-0913-5
   Dong M, 2010, DRUG DISCOV TODAY, V15, P622, DOI 10.1016/j.drudis.2010.06.011
   Dubreuil CI, 2003, J CELL BIOL, V162, P233, DOI 10.1083/jcb.200301080
   Dun Y, 2007, INVEST OPHTH VIS SCI, V48, P4785, DOI 10.1167/iovs.07-0343
   El-Remessy AB, 2010, EXP DIABETES RES, DOI 10.1155/2010/247861
   Fahnestock M, 2004, J NEUROCHEM, V89, P581, DOI 10.1111/j.1471-4159.2004.02340.x
   Fujimura M, 2011, TOXICOL APPL PHARM, V250, P1, DOI 10.1016/j.taap.2010.09.011
   HAMMES HP, 1995, MOL MED, V1, P527, DOI 10.1007/BF03401589
   He Y, 2008, ARTHRITIS RHEUM, V58, P3366, DOI 10.1002/art.23986
   Hirata A, 2008, GRAEF ARCH CLIN EXP, V246, P51, DOI 10.1007/s00417-007-0666-6
   Hu B, 1999, NEUROREPORT, V10, P1293, DOI 10.1097/00001756-199904260-00026
   Huang EJ, 2003, ANNU REV BIOCHEM, V72, P609, DOI 10.1146/annurev.biochem.72.121801.161629
   Irving EA, 2000, MOL BRAIN RES, V77, P65, DOI 10.1016/S0169-328X(00)00043-7
   Ito T, 2007, SPINE, V32, P2070, DOI 10.1097/BRS.0b013e318145a502
   Kawasaki H, 1997, J BIOL CHEM, V272, P18518, DOI 10.1074/jbc.272.30.18518
   Krishnamoorthy RR, 2001, MOL BRAIN RES, V86, P1, DOI 10.1016/S0169-328X(00)00224-2
   Kummer JL, 1997, J BIOL CHEM, V272, P20490, DOI 10.1074/jbc.272.33.20490
   Lebrun-Julien F, 2010, P NATL ACAD SCI USA, V107, P3817, DOI 10.1073/pnas.0909276107
   Lebrun-Julien F, 2009, MOL CELL NEUROSCI, V40, P410, DOI 10.1016/j.mcn.2008.12.005
   Linseman DA, 2008, FRONT BIOSCI-LANDMRK, V13, P657, DOI 10.2741/2710
   Masoudi R, 2009, J BIOL CHEM, V284, P18424, DOI 10.1074/jbc.M109.007104
   Matragoon S, 2012, MOL VIS, V18, P2993
   Mielke K, 2000, MOL BRAIN RES, V75, P128, DOI 10.1016/S0169-328X(99)00308-3
   Miloso M, 2008, CURR MED CHEM, V15, P538, DOI 10.2174/092986708783769731
   Mysona BA, 2012, INVEST OPHTH VIS SCI, V53, P2003
   Nwariaku FE, 2003, J APPL PHYSIOL, V95, P1889, DOI 10.1152/japplphysiol.00225.2003
   Nwariaku FE, 2002, SHOCK, V18, P82, DOI 10.1097/00024382-200207000-00015
   Purves T, 2001, FASEB J, V15, P2508, DOI 10.1096/fj.01-0253hyp
   Rao VP, 2007, BIODRUGS, V21, P167, DOI 10.2165/00063030-200721030-00004
   Segain JP, 2003, GASTROENTEROLOGY, V124, P1180, DOI 10.1016/S0016-5085(03)00283-X
   Semenova MM, 2007, NAT NEUROSCI, V10, P436, DOI 10.1038/nn1869
   Shanab AY, 2012, NEUROBIOL DIS, V48, P556, DOI 10.1016/j.nbd.2012.07.025
   Suzuki A, 1998, J NEUROSCI RES, V54, P27, DOI 10.1002/(SICI)1097-4547(19981001)54:1<27::AID-JNR4>3.0.CO;2-J
   von Bartheld CS, 1998, HISTOL HISTOPATHOL, V13, P437, DOI 10.14670/HH-13.437
   XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326
   Xu FF, 2009, NEUROSCI LETT, V454, P81, DOI 10.1016/j.neulet.2009.02.036
   Yune TY, 2007, J NEUROSCI, V27, P7751, DOI 10.1523/JNEUROSCI.1661-07.2007
NR 45
TC 20
Z9 21
U1 1
U2 13
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 24
PY 2013
VL 8
IS 1
AR e54692
DI 10.1371/journal.pone.0054692
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 077JK
UT WOS:000314023600094
PM 23365678
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Spence, S
   Fitzsimons, A
   Boyd, CR
   Kessler, J
   Fitzgerald, D
   Elliott, J
   Gabhann, JN
   Smith, S
   Sica, A
   Hams, E
   Saunders, SP
   Jefferies, CA
   Fallon, PG
   McAuley, DF
   Kissenpfennig, A
   Johnston, JA
AF Spence, Shaun
   Fitzsimons, Amy
   Boyd, Caroline R.
   Kessler, Julia
   Fitzgerald, Denise
   Elliott, Joanne
   Gabhann, Joan Ni
   Smith, Siobhan
   Sica, Antonio
   Hams, Emily
   Saunders, Sean P.
   Jefferies, Caroline A.
   Fallon, Padraic G.
   McAuley, Danny F.
   Kissenpfennig, Adrien
   Johnston, James A.
TI RETRACTED: Suppressors of Cytokine Signaling 2 and 3 Diametrically
   Control Macrophage Polarization (Retracted article. See vol. 40, pg.
   1002, 2014)
SO IMMUNITY
LA English
DT Article; Retracted Publication
ID DENDRITIC CELLS; T-CELLS; ALTERNATIVE ACTIVATION; ALLERGIC RESPONSES;
   FAMILY PROTEINS; SOCS PROTEINS; IN-VIVO; DIFFERENTIATION; INFLAMMATION;
   EXPRESSION
AB Suppressors of cytokine signaling (SOCS) are important regulators of lipopolysaccharide (LPS) and cytokine responses but their role in macrophage polarization is unknown. We have shown here that myeloid-restricted Socs3 deletion (Socs3(Lyz2cre)) resulted in resistance to LPS-induced endotoxic shock, whereas Socs2(-/-) mice were highly susceptible. We observed striking bias toward M2-like macrophages in Socs3(Lyz2cre) mice, whereas the M1-like population was enriched in Socs2-/- mice. Adoptive transfer experiments showed that responses to endotoxic shock and polymicrobial sepsis were transferable and macrophage dependent. Critically, this dichotomous response was associated with enhanced regulatory T (Treg) cell recruitment by Socs3(Lyz2cre) ells whereas Treg cell recruitment was absent in the presence of Socs2(-/-) macrophages. In addition, altered polarization coincided with enhanced interferon-gamma (IFN-gamma)-induced signal transducer and activator of transcription-1 (STAT1) activation in Socs2-/- macrophages and enhanced interleukin-4 (IL-4) plus IL-13-induced STAT6 phosphorylation in Socs3(Lyz2cre) macro-phages. SOCS, therefore, are essential controllers of macrophage polarization, regulating inflammatory responses.
C1 [Spence, Shaun; Fitzsimons, Amy; Boyd, Caroline R.; Kessler, Julia; Fitzgerald, Denise; Elliott, Joanne; McAuley, Danny F.; Kissenpfennig, Adrien; Johnston, James A.] Queens Univ Belfast, Sch Med Dent & Biomed Sci, Ctr Infect & Immun, Belfast BT9 7BL, Antrim, North Ireland.
   [Gabhann, Joan Ni; Smith, Siobhan; Jefferies, Caroline A.] Royal Coll Surgeons Ireland, RSCI Res Inst, Dublin 2, Ireland.
   [Sica, Antonio] Humanitas Clin & Res Ctr, I-20089 Rozzano, Italy.
   [Sica, Antonio] Univ Piemonte Orientale, Dept Pharmaceut Sci, I-28100 Novara, Italy.
   [Hams, Emily; Saunders, Sean P.; Fallon, Padraic G.] Univ Dublin Trinity Coll, St Jamess Hosp, Inst Mol Med, Dublin 8, Ireland.
   [Fallon, Padraic G.] Univ Dublin Trinity Coll, Trinity Biomed Sci Inst, Dublin 2, Ireland.
   [Fallon, Padraic G.] Our Ladys Childrens Hosp Crumlin, Natl Childrens Res Ctr, Dublin 12, Ireland.
RP Johnston, JA (reprint author), Amgen Inc, Inflammat Res, 1 Amgen Ctr Dr, Thousand Oaks, CA 91320 USA.
EM jamesj03@amgen.com
OI Ni Gabhann, Joan/0000-0002-4247-3952; Fallon,
   Padraic/0000-0002-8401-7293
FU Science Foundation Ireland; Wellcome Trust
FX The authors would like to thank C. McFarlane, H. Carroll, and J. Burrows
   for helpful discussions and L. Hanna and other members of the Queens
   University of Belfast biological research unit for technical aid and
   expertise. P.G.F. was supported by Science Foundation Ireland and
   Wellcome Trust.
CR Alexander WS, 1999, CELL, V98, P597, DOI 10.1016/S0092-8674(00)80047-1
   Auffray C, 2009, ANNU REV IMMUNOL, V27, P669, DOI 10.1146/annurev.immunol.021908.132557
   Biswas SK, 2010, NAT IMMUNOL, V11, P889, DOI 10.1038/ni.1937
   Ghosn EEB, 2010, P NATL ACAD SCI USA, V107, P2568, DOI 10.1073/pnas.0915000107
   Chen Z, 2006, P NATL ACAD SCI USA, V103, P8137, DOI 10.1073/pnas.0600666103
   Clausen BE, 1999, TRANSGENIC RES, V8, P265, DOI 10.1023/A:1008942828960
   Croker BA, 2003, NAT IMMUNOL, V4, P540, DOI 10.1038/ni931
   Dalpke A, 2008, IMMUNOBIOLOGY, V213, P225, DOI 10.1016/j.imbio.2007.10.008
   Dickensheets H, 2007, GENES IMMUN, V8, P21, DOI 10.1038/sj.gene.6364352
   Dimitriou ID, 2008, IMMUNOL REV, V224, P265, DOI 10.1111/j.1600-065X.2008.00659.x
   Egwuagu CE, 2002, J IMMUNOL, V168, P3181, DOI 10.4049/jimmunol.168.7.3181
   Geissmann F, 2010, SCIENCE, V327, P656, DOI 10.1126/science.1178331
   Gordon S, 2010, IMMUNITY, V32, P593, DOI 10.1016/j.immuni.2010.05.007
   Hams E, 2011, SHOCK, V36, P295, DOI 10.1097/SHK.0b013e318225ad7e
   Hashimoto M, 2009, CANCER SCI, V100, P730, DOI 10.1111/j.1349-7006.2009.01098.x
   Jensen KDC, 2011, CELL HOST MICROBE, V9, P472, DOI 10.1016/j.chom.2011.04.015
   Knosp CA, 2011, J EXP MED, V208, P1523, DOI 10.1084/jem.20101167
   Krausgruber T, 2011, NAT IMMUNOL, V12, P231, DOI 10.1038/ni.1990
   KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P
   Liu Y, 2008, J IMMUNOL, V180, P6270, DOI 10.4049/jimmunol.180.9.6270
   Lolmede K, 2009, J LEUKOCYTE BIOL, V85, P779, DOI 10.1189/jlb.0908579
   Machado FS, 2006, NAT MED, V12, P330, DOI 10.1038/nm1355
   Mansell A, 2006, NAT IMMUNOL, V7, P148, DOI 10.1038/ni1299
   Mantovani A., 2011, YIN YANG CANC RELATE
   Mantovani A, 2011, NAT MED, V17, P285, DOI 10.1038/nm0311-285
   Mantovani A, 2010, CURR OPIN IMMUNOL, V22, P231, DOI 10.1016/j.coi.2010.01.009
   Matsumura Y, 2007, J IMMUNOL, V179, P2170, DOI 10.4049/jimmunol.179.4.2170
   Metcalf D, 2000, NATURE, V405, P1069, DOI 10.1038/35016611
   Nakagawa R, 2002, IMMUNITY, V17, P677, DOI 10.1016/S1074-7613(02)00449-1
   Pelegrin P, 2009, EMBO J, V28, P2114, DOI 10.1038/emboj.2009.163
   Piessevaux J, 2006, J BIOL CHEM, V281, P32953, DOI 10.1074/jbc.M600776200
   Quiding-Jarbrink M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015018
   Rivollier A, 2012, J EXP MED, V209, P139, DOI 10.1084/jem.20101387
   Ryo A, 2003, MOL CELL, V12, P1413, DOI 10.1016/S1097-2765(03)00490-8
   Schutyser E, 2002, J BIOL CHEM, V277, P24584, DOI 10.1074/jbc.M112275200
   Seki Y, 2003, NAT MED, V9, P1047, DOI 10.1038/nm896
   Soltys J, 2002, J IMMUNOL, V168, P1903, DOI 10.4049/jimmunol.168.4.1903
   Stevenson NJ, 2009, J LEUKOCYTE BIOL, V85, P289, DOI 10.1189/jlb.0708394
   Takahashi Y, 2003, EMBO J, V22, P372, DOI 10.1093/emboj/cdg057
   Tanaka K, 2008, J IMMUNOL, V180, P3746, DOI 10.4049/jimmunol.180.6.3746
   Tannahill GM, 2005, MOL CELL BIOL, V25, P9115, DOI 10.1128/MCB.25.20.9115-9126.2005
   Wang YC, 2010, CANCER RES, V70, P4840, DOI 10.1158/0008-5472.CAN-10-0269
   Whitmarsh RJ, 2011, CELL HOST MICROBE, V10, P224, DOI 10.1016/j.chom.2011.07.009
   Yasukawa H, 2003, NAT IMMUNOL, V4, P551, DOI 10.1038/ni938
   Yoshimura A, 2004, J LEUKOCYTE BIOL, V75, P422, DOI 10.1189/jlb.0403194
   Yoshimura Akihiko, 2009, Keio Journal of Medicine, V58, P73
   Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734
   Zhao J, 2010, CLIN EXP IMMUNOL, V160, P479, DOI 10.1111/j.1365-2249.2010.04089.x
   Zheng ZM, 1996, IMMUNOLOGY, V87, P544, DOI 10.1046/j.1365-2567.1996.513591.x
   Zhu JF, 2010, IMMUNOL REV, V238, P247, DOI 10.1111/j.1600-065X.2010.00951.x
NR 50
TC 55
Z9 67
U1 3
U2 47
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1074-7613
EI 1097-4180
J9 IMMUNITY
JI Immunity
PD JAN 24
PY 2013
VL 38
IS 1
BP 66
EP 78
DI 10.1016/j.immuni.2012.09.013
PG 13
WC Immunology
SC Immunology
GA 079TQ
UT WOS:000314195500010
PM 23177319
OA Bronze
DA 2018-12-27
ER

PT J
AU Jiang, P
   Zang, WD
   Wang, LS
   Xu, Y
   Liu, Y
   Deng, SX
AF Jiang Pu
   Zang Weidong
   Wang Lishan
   Xu Ying
   Liu Yang
   Deng Shi-xiong
TI RETRACTED: Protein-protein interaction and SNP analysis in intraductal
   papillary mucinous neoplasm (Retracted article. See vol. 578 pg. 139,
   2016)
SO GENE
LA English
DT Article; Retracted Publication
DE Pancreatic cancer; Protein-protein interaction; SNP
ID DUCTAL ADENOCARCINOMA; PANCREATIC-CANCER; CELL-GROWTH; DATABASE; MYC;
   PROGRESSION; APOPTOSIS; BRCA1
AB Intraductal papillary mutinous neoplasm (IPMN) is a type of tumor that grows within the pancreatic ducts. It is a progress from hyperplasia to intraductal adenoma (IPMA), to noninvasive carcinoma, and ultimately to invasive carcinoma (IPMC). The objective of this study was to explore the molecular mechanism of the progression from IPMA to IPMC. By using the GSE19650 affymetrix microarray data accessible from Gene Expression Omnibus (CEO) database, we first identified the differentially expressed genes (DEGs) between IPMA and IPMC, followed by the protein-protein interaction and single-nucleotide polymorphism (SNP) analysis of the DEGs. Our study identified thousands of DEGs which involved regulation of cell cycle and apoptosis in this progression from IPMA to IPMC. Protein-protein interaction network construction found that MYC, IL6ST, NR3C1, CREBBP, GATA1 and LRP1 might play an important role in the progression. Furthermore, the SNP analysis confirmed the association between BRAC1 and pancreas cancer. In conclusion, our data provide a comprehensive bioinformatics analysis of genes and pathways which may be involved in the progression of IPMN from IPMA to IPMC. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Jiang Pu; Deng Shi-xiong] Chongqing Med Univ, Coll Basic Med, Dept Forens Med, Chongqing 400016, Peoples R China.
   [Zang Weidong; Wang Lishan] Shanghai Jiao Tong Univ, Dept Biol, Shanghai 200240, Peoples R China.
   [Xu Ying; Liu Yang] Childrens Hosp, Dept Anesthesiol, Key Lab Dev Dis Childhood Chongqing, Chongqing 400014, Peoples R China.
   [Xu Ying; Liu Yang] Childrens Hosp, Minist Educ, Chongqing 400014, Peoples R China.
RP Deng, SX (reprint author), Chongqing Med Univ, Coll Basic Med, Dept Forens Med, Chongqing 400016, Peoples R China.
EM dengshixiongshx@hotmail.com
CR Adhikary S, 2005, NAT REV MOL CELL BIO, V6, P635, DOI 10.1038/nrm1703
   Altshuler D, 2000, NATURE, V407, P513, DOI 10.1038/35035083
   Andrejevic-Blant S, 2007, VIRCHOWS ARCH, V451, P863, DOI 10.1007/s00428-007-0512-6
   Bassi C, 2008, J GASTROINTEST SURG, V12, P645, DOI 10.1007/s11605-007-0447-x
   Bussom S, 2010, J PANCREAS, V11, P131
   Chatr-Aryamontri A, 2007, NUCLEIC ACIDS RES, V35, pD572, DOI 10.1093/nar/gkl950
   Corcoran RB, 2011, CANCER RES, V71, P5020, DOI 10.1158/0008-5472.CAN-11-0908
   Diboun I, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-252
   EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9
   Fritz S, 2010, PANCREAS, V39, P308, DOI 10.1097/MPA.0b013e3181bd5c10
   Furukawa T, 2005, MODERN PATHOL, V18, P1034, DOI 10.1038/modpathol.3800383
   Greer JB, 2007, GUT, V56, P601, DOI 10.1136/gut.2006.101220
   Hirakawa M, 2002, NUCLEIC ACIDS RES, V30, P158, DOI 10.1093/nar/30.1.158
   Hiraoka N, 2011, GASTROENTEROLOGY, V140, P310, DOI 10.1053/j.gastro.2010.10.009
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Hulsegge Ina, 2009, BMC Proc, V3 Suppl 4, pS10, DOI 10.1186/1753-6561-3-S4-S10
   Kitago M, 2004, INT J CANCER, V110, P177, DOI 10.1002/ijc.20084
   Lynch HT, 2005, CANCER GENET CYTOGEN, V158, P119, DOI 10.1016/j.cancergencyto.2004.01.032
   Massague J, 2004, NATURE, V432, P298, DOI 10.1038/nature03094
   Miyasaka Y, 2007, CLIN CANCER RES, V13, P4371, DOI 10.1158/1078-0432.CCR-07-0032
   Ogata H, 1999, NUCLEIC ACIDS RES, V27, P29, DOI 10.1093/nar/27.1.29
   Pelengaris S, 2002, CELL, V109, P321, DOI 10.1016/S0092-8674(02)00738-9
   Prasad TSK, 2009, NUCLEIC ACIDS RES, V37, pD767, DOI 10.1093/nar/gkn892
   Semba S, 2003, PANCREAS, V26, P250, DOI 10.1097/00006676-200304000-00008
   Smigielski EM, 2000, NUCLEIC ACIDS RES, V28, P352, DOI 10.1093/nar/28.1.352
   Stark C, 2011, NUCLEIC ACIDS RES, V39, pD698, DOI 10.1093/nar/gkq1116
   Takuma K, 2011, WORLD J SURG ONCOL, V9, DOI 10.1186/1477-7819-9-153
   Williams S, 1996, NEW ZEAL MED J, V109, P38
NR 28
TC 4
Z9 4
U1 4
U2 18
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-1119
EI 1879-0038
J9 GENE
JI Gene
PD JAN 15
PY 2013
VL 513
IS 1
BP 219
EP 224
DI 10.1016/j.gene.2012.10.047
PG 6
WC Genetics & Heredity
SC Genetics & Heredity
GA 082IO
UT WOS:000314385700027
PM 23107772
DA 2018-12-27
ER

PT J
AU Hsieh, TY
   Chang, TC
   Chen, TC
   Tsai, MY
   Chen, YT
AF Hsieh, Tien-Yu
   Chang, Ting-Chang
   Chen, Te-Chih
   Tsai, Ming-Yen
   Chen, Yu-Te
TI RETRACTED: Investigating degradation behavior of InGaZnO thin-film
   transistors induced by charge-trapping effect under DC and AC gate bias
   stress (Retracted article. See vol. 665, pg. 195, 2018)
SO THIN SOLID FILMS
LA English
DT Article; Retracted Publication
DE Indium Gallium Zinc Oxide (IGZO); Thin film transistors (TFTs);
   Charge-Trapping; Bias Stress
ID ROOM-TEMPERATURE
AB This paper investigates the degradation mechanism of amorphous InGaZnO thin-film transistors under DC and AC gate bias stress. Comparing the degradation behavior at equal accumulated effective stress time, more pronounced threshold voltage shift under AC positive gate bias stress in comparison with DC stress indicates extra electron-trapping phenomenon that occurs in the duration of rising/falling time in pulse. Contrarily, illuminated AC negative gate bias stress exhibits much less threshold voltage shift than DC stress, suggesting that the photo-generated hole does not have sufficient time to drift to the interface of IGZO/gate insulator and causes hole-trapping under AC operation. Since the evolution of threshold voltage fits the stretched-exponential equation well, the different degradation tendencies under DC/AC stress can be attributed to the different electron- and hole-trapping efficiencies, and this is further verified by varying pulse waveform. (c) 2012 Elsevier B.V. All rights reserved.
C1 [Hsieh, Tien-Yu; Chang, Ting-Chang; Chen, Te-Chih] Natl Sun Yat Sen Univ, Dept Phys, Kaohsiung 80424, Taiwan.
   [Chang, Ting-Chang] Natl Cheng Kung Univ, Adv Optoelect Technol Ctr, Tainan 70101, Taiwan.
   [Tsai, Ming-Yen; Chen, Yu-Te] Natl Sun Yat Sen Univ, Dept Photon, Kaohsiung 80424, Taiwan.
RP Chang, TC (reprint author), Natl Sun Yat Sen Univ, Dept Phys, 70 Lien Hai Rd, Kaohsiung 80424, Taiwan.
EM tcchang@mail.phys.nsysu.edu.tw
FU National Science Council of the Republic of China [NSC
   100-2120-M-110-003]
FX This work was performed at National Science Council Core Facilities
   Laboratory for Nano-Science and Nano-Technology in Kaohsiung-Pingtung
   area, and assisted with AU Optronics. The authors would like to
   acknowledge the financial support of the National Science Council of the
   Republic of China under Contract No. NSC 100-2120-M-110-003.
CR Chen TC, 2011, APPL PHYS LETT, V99, DOI 10.1063/1.3609873
   Chen TC, 2010, APPL PHYS LETT, V97, DOI 10.1063/1.3481676
   Chen YC, 2010, APPL PHYS LETT, V96, DOI 10.1063/1.3457996
   Chung WF, 2011, APPL PHYS LETT, V98, DOI 10.1063/1.3580614
   Fortunato EMC, 2005, ADV MATER, V17, P590, DOI 10.1002/adma.200400368
   Fung TC, 2009, J APPL PHYS, V106, DOI 10.1063/1.3234400
   Gorrn P, 2007, APPL PHYS LETT, V91, DOI 10.1063/1.2806934
   Hayashi R, 2007, J SOC INF DISPLAY, V15, P915, DOI 10.1889/1.2812992
   Kimura M, 2010, APPL PHYS LETT, V97, DOI 10.1063/1.3502563
   LEE HN, 2007, SID CAL US, P1826
   Lee JM, 2008, APPL PHYS LETT, V93, DOI 10.1063/1.2977865
   Liu PT, 2009, APPL PHYS LETT, V95, DOI 10.1063/1.3272016
   Lopes ME, 2009, APPL PHYS LETT, V95, DOI 10.1063/1.3187532
   Nomura K, 2004, NATURE, V432, P488, DOI 10.1038/nature03090
   Nomura K, 2011, APPL PHYS LETT, V99, DOI 10.1063/1.3622121
   Shin J. H., 2009, ETRI, V31, P1
NR 16
TC 6
Z9 6
U1 2
U2 60
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 0040-6090
J9 THIN SOLID FILMS
JI Thin Solid Films
PD JAN 15
PY 2013
VL 528
BP 53
EP 56
DI 10.1016/j.tsf.2012.09.093
PG 4
WC Materials Science, Multidisciplinary; Materials Science, Coatings &
   Films; Physics, Applied; Physics, Condensed Matter
SC Materials Science; Physics
GA 078RB
UT WOS:000314115800010
DA 2018-12-27
ER

PT J
AU Kaur, P
   Soni, AK
   Gosain, A
AF Kaur, Prabhjot
   Soni, A. K.
   Gosain, Anjana
TI RETRACTED: A robust kernelized intuitionistic fuzzy c-means clustering
   algorithm in segmentation of noisy medical images (Retracted article.
   See vol. 34, pg. 709, 2013)
SO PATTERN RECOGNITION LETTERS
LA English
DT Article; Retracted Publication
DE Fuzzy clustering; Intuitionistic fuzzy c-means; Robust image
   segmentation; RBF kernel based intuitionistic fuzzy c-means; Fuzzy
   c-means
AB This paper presents an automatic effective intuitionistic fuzzy c-means which is an extension of standard intuitionisitc fuzzy c-means (IFCM). We present a model called RBF Kernel based intuitionistic fuzzy c-means (KIFCM) where IFCM is extended by adopting a kernel induced metric in the data space to replace the original Euclidean norm metric. By using kernel function it becomes possible to cluster data, which is linearly non-separable in the original space, into homogeneous groups by transforming the data into high dimensional space. Proposed clustering method is applied on synthetic data-sets referred from various papers, real data-sets from Public Library UCI, Simulated and Real MR brain images. Experimental results are given to show the effectiveness of proposed method in contrast to conventional fuzzy c-means, possibilistic c-means, possibilistic fuzzy c-means, noise clustering, kernelized fuzzy c-means, type-2 fuzzy c-means, kernelized type-2 fuzzy c-means, and intuitionistic fuzzy c-means. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Kaur, Prabhjot] Maharaja Surajmal Inst Technol, Dept Informat Technol, New Delhi 110058, India.
   [Soni, A. K.] Sharda Univ, Dept Comp Sci, Greater Noida, Uttar Pradesh, India.
   [Gosain, Anjana] Guru Gobind Singh Indraprastha Univ, USIT, Dept Informat Technol, New Delhi, India.
RP Kaur, P (reprint author), Maharaja Surajmal Inst Technol, Dept Informat Technol, C-4 Janakpuri, New Delhi 110058, India.
EM thisisprabhjot@gmail.com; ak.soni@sharda.ac.in;
   anjana_gosain@hotmail.com
CR Atanassov K. T., 2003, INTUITIONISTIC FUZZY
   Atanassov's K.T., 1983, INTUITIONISTIC FUZZY, P983
   Bensaid AM, 1996, IEEE T FUZZY SYST, V4, P112, DOI 10.1109/91.493905
   Bezdek J.C., 1981, PATTERN RECOGNITION
   Chaira T, 2011, APPL SOFT COMPUT, V11, P1711, DOI 10.1016/j.asoc.2010.05.005
   Dave R. N., 1997, IEEE T FUZZY SYSTEMS, V5
   Dunn J.C., 1973, J CYBERNETICS, V3, P32, DOI DOI 10.1080/01969727308546046
   Kang JY, 2009, DIGIT SIGNAL PROCESS, V19, P309, DOI 10.1016/j.dsp.2007.11.005
   Krishnapuram R., 1993, IEEE Transactions on Fuzzy Systems, V1, P98, DOI 10.1109/91.227387
   Masulli F, 1999, ARTIF INTELL MED, V16, P129, DOI 10.1016/S0933-3657(98)00069-4
   Pal NR, 2005, IEEE T FUZZY SYST, V13, P517, DOI 10.1109/TFUZZ.2004.840099
   Rhee F.C.H., 2001, P JOINT 9 IFSA WORLD, V4, p[25, 1926]
   Yang Z, 2009, APPL SOFT COMPUT, V9, P80, DOI 10.1016/j.asoc.2008.03.009
   ZADEH LA, 1965, FUZZY SETS INFORM CO, V8, P338, DOI DOI 10.1016/S0019-9958(65)90241-X
   Zhang Hong-mei, 2007, Control and Decision, V22, P882
NR 15
TC 19
Z9 20
U1 5
U2 47
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0167-8655
EI 1872-7344
J9 PATTERN RECOGN LETT
JI Pattern Recognit. Lett.
PD JAN 15
PY 2013
VL 34
IS 2
BP 163
EP 175
DI 10.1016/j.patrec.2012.09.015
PG 13
WC Computer Science, Artificial Intelligence
SC Computer Science
GA 071QE
UT WOS:000313608500008
DA 2018-12-27
ER

PT J
AU Pan, ZC
   Tian, XL
   Wu, SK
   Yu, X
   Li, ZL
   Deng, JF
   Xiao, CM
   Hu, GH
   Wei, ZG
AF Pan, Zhanchang
   Tian, Xinlong
   Wu, Shoukun
   Yu, Xia
   Li, Zhuliang
   Deng, Jianfeng
   Xiao, Chumin
   Hu, Guanghui
   Wei, Zhigang
TI RETRACTED: Investigation of structural, optical and electronic
   properties in Al-Sn co-doped ZnO thin films (Retracted article. See vol.
   351, pg. 1224, 2015)
SO APPLIED SURFACE SCIENCE
LA English
DT Article; Retracted Publication
DE Al-Sn co-doped ZnO; XPS; Optical bandgap; Sol-gel method
ID SOL-GEL METHOD; ELECTRICAL-PROPERTIES; TEMPERATURE; GROWTH; TRANSPARENT;
   DEPOSITION; CELLS; PHOTOLUMINESCENCE; NANOSTRUCTURES; CONDUCTIVITY
AB Al-Sn co-doped ZnO (ATZO) nanocrystals were successfully synthesized onto glass substrates by the sol-gel processing. The structure and morphology of the films are characterized by X-ray diffraction (XRD), scanning electron microscopy (SEM), transmission electron microscopy (TEM) and high resolution transmission electron microscopy (HRTEM). The results indicated that co-doped ZnO films showed a preferred orientation toward the c-axis and the full width at half maximum (FWHM) of the (0 0 2) plane increased first and then decreased, reaching a minimum of about 0.213 with Sn concentration of 2%. The effects of various Sn concentrations on electrical and optical properties were also investigated by 4-point probe device and ultraviolet-visible (UV-vis) spectroscopy, respectively. The X-ray photoelectron spectroscopy (XPS) study showed Sn-O and Al-O bonding in the synthesized co-doped ZnO thin films, which confirmed the substitution of Zn2+ by Sn and Al ions. Room temperature photoluminescence (PL) was observed for pure and co-doped ZnO thin films and the origin of these emissions was discussed. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Pan, Zhanchang; Tian, Xinlong; Yu, Xia; Xiao, Chumin; Hu, Guanghui; Wei, Zhigang] Guangdong Univ Technol, Sch Chem Engn & Light Ind, Guangzhou 510006, Guangdong, Peoples R China.
   [Wu, Shoukun; Li, Zhuliang; Deng, Jianfeng] Huizhou King Brother Elect Technol Co Ltd, Huizhou 516083, Peoples R China.
RP Tian, XL (reprint author), Guangdong Univ Technol, Sch Chem Engn & Light Ind, Guangzhou 510006, Guangdong, Peoples R China.
EM panzhanchang@163.com; tianxinlong2010@163.com; lizl@kbsems.com
FU National Natural Science Foundation of China [20803014]; Scientific and
   Technological Projects in Guangdong Province [2011B031000013]; Huizhou
   Daya Bay Technological Projects [20110111]; 211 Funding Program of
   Guangdong Province
FX This research was financially supported by the National Natural Science
   Foundation of China (20803014), Scientific and Technological Projects in
   Guangdong Province (No. 2011B031000013), Huizhou Daya Bay Technological
   Projects (20110111) and the 211 Funding Program of Guangdong Province.
CR Aksoy S, 2012, J ALLOY COMPD, V512, P171, DOI 10.1016/j.jallcom.2011.09.058
   Ameen S, 2012, CHEM ENG J, V187, P351, DOI 10.1016/j.cej.2012.01.097
   Barick KC, 2010, J COLLOID INTERF SCI, V349, P19, DOI 10.1016/j.jcis.2010.05.036
   Benelmadjat H, 2009, OPT LASER TECHNOL, V41, P630, DOI 10.1016/j.optlastec.2008.09.011
   Caglar Y, 2009, SUPERLATTICE MICROST, V46, P469, DOI 10.1016/j.spmi.2009.05.005
   Carreras P, 2011, THIN SOLID FILMS, V520, P1223, DOI 10.1016/j.tsf.2011.06.078
   Casanova JR, 2011, APPL SURF SCI, V257, P10045, DOI 10.1016/j.apsusc.2011.06.136
   Chen YW, 2005, J CHEM PHYS, V123, DOI 10.1063/1.2009731
   Cheng BC, 2004, ADV FUNCT MATER, V14, P913, DOI 10.1002/adfm.200305097
   Choi BG, 2005, J EUR CERAM SOC, V25, P2161, DOI 10.1016/j.jeurceramsoc.2005.03.023
   Fiddes AJC, 1996, J CRYST GROWTH, V159, P210, DOI 10.1016/0022-0248(95)00707-5
   Houng B, 2012, CERAM INT, V38, P801, DOI 10.1016/j.ceramint.2011.08.007
   Ilican S, 2010, APPL SURF SCI, V256, P7204, DOI 10.1016/j.apsusc.2010.05.052
   Jeong SH, 2004, THIN SOLID FILMS, V447, P105, DOI 10.1016/j.tsf.2003.09.031
   Jeong SH, 2003, J PHYS D APPL PHYS, V36, P2017, DOI 10.1088/0022-3727/36/16/316
   Jung M, 2011, OPT MATER, V33, P280, DOI 10.1016/j.optmat.2010.08.029
   Kim CE, 2010, THIN SOLID FILMS, V518, P6304, DOI 10.1016/j.tsf.2010.03.042
   Kim YH, 2009, APPL SURF SCI, V255, P7251, DOI 10.1016/j.apsusc.2009.03.075
   Kim YS, 2007, APPL SURF SCI, V253, P4911, DOI 10.1016/j.apsusc.2006.10.068
   Kirby SD, 2009, THIN SOLID FILMS, V517, P1958, DOI 10.1016/j.tsf.2008.10.066
   KUROYANAGI A, 1989, JPN J APPL PHYS 1, V28, P219, DOI 10.1143/JJAP.28.219
   Lee W., 2011, CURRENT APPL PHYS
   Lin JC, 2009, THIN SOLID FILMS, V517, P4715, DOI 10.1016/j.tsf.2009.03.022
   Lupan O, 2010, APPL SURF SCI, V256, P1895, DOI 10.1016/j.apsusc.2009.10.032
   Ma LG, 2011, APPL SURF SCI, V257, P10036, DOI 10.1016/j.apsusc.2011.06.134
   Mahmoud WE, 2011, J CRYST GROWTH, V327, P52, DOI 10.1016/j.jcrysgro.2011.05.003
   Muller J, 2004, SOL ENERGY, V77, P917, DOI 10.1016/j.solener.2004.03.015
   Musat V, 2004, SURF COAT TECH, V180, P659, DOI 10.1016/j.surfcoat.2003.10.112
   NATSUME Y, 1992, J APPL PHYS, V72, P4203, DOI 10.1063/1.352231
   Ong CK, 2001, APPL SURF SCI, V185, P47, DOI 10.1016/S0169-4332(01)00589-X
   Ri KH, 2011, APPL SURF SCI, V258, P1283, DOI 10.1016/j.apsusc.2011.07.022
   Schuler T, 2006, THIN SOLID FILMS, V502, P67, DOI 10.1016/j.tsf.2005.07.246
   Shao JZ, 2010, THIN SOLID FILMS, V518, P5288, DOI 10.1016/j.tsf.2010.04.068
   Shin BK, 2011, MAT SCI SEMICON PROC, V14, P23, DOI 10.1016/j.mssp.2010.12.013
   Suzuki S, 2003, THIN SOLID FILMS, V434, P14, DOI 10.1016/S0040-6090(03)00463-2
   Tolcin A.C., 2010, MINERAL COMMODITY SU, P74
   Tsay CY, 2008, THIN SOLID FILMS, V517, P1032, DOI 10.1016/j.tsf.2008.06.030
   Vimalkumar TV, 2011, APPL SURF SCI, V257, P8334, DOI 10.1016/j.apsusc.2011.03.118
   Wei XQ, 2007, MATER CHEM PHYS, V101, P285, DOI 10.1016/j.matchemphys.2006.05.005
   Xu PS, 2003, NUCL INSTRUM METH B, V199, P286, DOI 10.1016/S0168-583X(02)01425-8
   Yang JH, 2008, APPL SURF SCI, V255, P2646, DOI 10.1016/j.apsusc.2008.08.001
   Yen WT, 2010, APPL SURF SCI, V257, P960, DOI 10.1016/j.apsusc.2010.08.001
   Zhang CY, 2010, J PHYS CHEM SOLIDS, V71, P364, DOI 10.1016/j.jpcs.2010.01.001
   Zhang ZY, 2011, SUPERLATTICE MICROST, V49, P644, DOI 10.1016/j.spmi.2011.04.002
   ZIQIANG X, 2006, MAT SCI SEMICON PROC, V9, P132
NR 45
TC 40
Z9 42
U1 5
U2 101
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0169-4332
EI 1873-5584
J9 APPL SURF SCI
JI Appl. Surf. Sci.
PD JAN 15
PY 2013
VL 265
BP 870
EP 877
DI 10.1016/j.apsusc.2012.11.139
PG 8
WC Chemistry, Physical; Materials Science, Coatings & Films; Physics,
   Applied; Physics, Condensed Matter
SC Chemistry; Materials Science; Physics
GA 062XT
UT WOS:000312958500133
DA 2018-12-27
ER

PT J
AU Wang, YH
   Wei, L
   Yuan, J
   Wang, RW
   Lu, JD
   Ji, LL
AF Wang, Y. H.
   Wei, L.
   Yuan, J.
   Wang, R. W.
   Lu, J. D.
   Ji, L. L.
TI RETRACTED: Optical limiting performance of Ag nanoclusters synthesized
   by ion implantation (Retracted article. See vol. 309, pg. 359, 2013)
SO OPTICS COMMUNICATIONS
LA English
DT Article; Retracted Publication
DE Ion implantation; Ag nanoparticles; Optical limiting; MATLAB
ID CU NANOCLUSTERS; ABSORPTION-SPECTRUM; NANOPARTICLES; NONLINEARITIES;
   CLUSTERS; MATRIX
AB Metal nanoparticles synthesized by 200 keV Ag ions into silica with dose of 2 x 10(17) ions/cm(2) has been studied. Third-order nonlinear optical properties of the nanoparticles were measured at 1064 nm excitations using the Z-scan technique. Results of the investigation of nonlinear refraction by the single beam Z-scan configuration are presented and the mechanisms responsible for the nonlinear response were discussed. Curve fitting analysis, based on MATLAB features for Ag nanoparticle optical limiting experiment, is used. The results show that Ag nanoparticles display a refractive optical limiting effect at 1064 nm. Published by Elsevier B.V.
C1 [Wang, Y. H.; Yuan, J.; Wang, R. W.; Lu, J. D.; Ji, L. L.] Wuhan Univ Sci & Technol, Hubei Prov Key Lab Syst Sci Met Proc, Wuhan 430081, Peoples R China.
   [Wei, L.] Henan Univ, Sch Phys & Elect, Kaifeng 475001, Peoples R China.
RP Wang, YH (reprint author), Wuhan Univ Sci & Technol, Hubei Prov Key Lab Syst Sci Met Proc, Wuhan 430081, Peoples R China.
EM wyh61@163.com
FU National Natural Science Foundation of China [10805035]
FX This work was supported by the National Natural Science Foundation of
   China. (No.10805035).
CR Battaglin G, 2001, APPL PHYS LETT, V78, P3953, DOI 10.1063/1.1380243
   CLARO F, 1982, PHYS REV B, V25, P7875, DOI 10.1103/PhysRevB.25.7875
   Francois L, 2000, J PHYS CHEM B, V104, P6133, DOI 10.1021/jp9944482
   Ganeev RA, 2004, PHYS STATUS SOLIDI B, V241, P935, DOI 10.1002/pssb.200301947
   Ganeev RA, 2001, J PHYS D APPL PHYS, V34, P1602, DOI 10.1088/0022-3727/34/11/308
   GERARDY JM, 1983, PHYS REV B, V27, P6446, DOI 10.1103/PhysRevB.27.6446
   Liu ZX, 1998, APPL PHYS LETT, V72, P1823, DOI 10.1063/1.121196
   Mie G, 1908, ANN PHYS-BERLIN, V25, P377
   Ryasnyanskiy AI, 2007, OPT COMMUN, V273, P538, DOI 10.1016/j.optcom.2007.01.013
   SHEIKBAHAE M, 1990, IEEE J QUANTUM ELECT, V26, P760, DOI 10.1109/3.53394
   SHEIKBAHAE M, 1990, PHYS REV LETT, V65, P96, DOI 10.1103/PhysRevLett.65.96
   Stepanov AL, 2011, REV ADV MATER SCI, V27, P115
   Stepanov AL, 2010, REV ADV MATER SCI, V26, P1
   Wang YH, 2006, PHYS LETT A, V357, P364, DOI 10.1016/j.physleta.2006.04.073
   Wang YH, 2010, VACUUM, V85, P207, DOI 10.1016/j.vacuum.2010.05.015
   Wang YH, 2010, PHYSICA B, V405, P2848, DOI 10.1016/j.physb.2010.04.010
   Wang YH, 2010, PHYSICA B, V405, P2664, DOI 10.1016/j.physb.2010.03.046
   Wang YH, 2010, OPT COMMUN, V283, P486, DOI 10.1016/j.optcom.2009.10.035
   Wang YH, 2009, PHYSICA B, V404, P4295, DOI 10.1016/j.physb.2009.08.016
   Wang YH, 2006, PHYSICA E, V33, P244, DOI 10.1016/j.physe.2006.02.006
   Yu MX, 2009, VACUUM, V83, P980, DOI 10.1016/j.vacuum.2008.11.009
NR 21
TC 3
Z9 4
U1 2
U2 52
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0030-4018
EI 1873-0310
J9 OPT COMMUN
JI Opt. Commun.
PD JAN 15
PY 2013
VL 287
BP 237
EP 240
DI 10.1016/j.optcom.2012.09.046
PG 4
WC Optics
SC Optics
GA 059EX
UT WOS:000312688300040
DA 2018-12-27
ER

PT J
AU Wang, XF
   Chen, GM
   Zhang, J
AF Wang, Xiufang
   Chen, Guangmei
   Zhang, Jun
TI RETRACTED: Synthesis and characterization of novel Cu2O/PANI composite
   photocatalysts with enhanced photocatalytic activity and stability
   (Retracted article. See vol. 41, pg. 153, 2013)
SO CATALYSIS COMMUNICATIONS
LA English
DT Article; Retracted Publication
DE Cu2O; Polyaniline; Nanocomposites; Photocatalytic activity
ID MONOLAYER POLYANILINE; CU2O NANOCRYSTALS; THIN-FILMS; PHOTOACTIVITY;
   CUO; HYBRIDIZATION; OXIDE
AB The Cu2O/polyaniline (PANI) nanocomposites have been successfully synthesized by a simple, one-step hydrothermal method. The Cu2O nanoparticles with the diameter of 40 nm disperse in the PANI. The nanocomposites, for the first time, are used as photocatalyst for the degradation of organic pollutants. The combination of Cu2O nanoparticles with PANI leads to high photocatalytic activity for the degradation of the dyes under visible light irradiation, which is much higher than that of TiO2 and pure Cu2O. A possible photocatalytic mechanism is proposed to explain the improvement of the photocatalytic activity. Crown Copyright (C) 2012 Published by Elsevier B.V. All rights reserved.
C1 [Wang, Xiufang; Chen, Guangmei; Zhang, Jun] Anhui Univ Architecture, Sch Mat & Chem Engn, Hefei 230601, Peoples R China.
RP Wang, XF (reprint author), Anhui Univ Architecture, Sch Mat & Chem Engn, Ziyun Rd 292, Hefei 230601, Peoples R China.
EM wxfrye159@sina.com
FU Doctoral Scientific Research Fund of Anhui University of Architecture
   [K02633]; Natural Science Foundation of Anhui Province Education Office
   [KJ2012B043]
FX This work is supported by the Doctoral Scientific Research Fund of Anhui
   University of Architecture (K02633), and the Natural Science Foundation
   of Anhui Province Education Office (KJ2012B043).
CR Ai ZH, 2009, J PHYS CHEM C, V113, P20896, DOI 10.1021/jp9083647
   Akhavan O, 2011, J MATER CHEM, V21, P12935, DOI 10.1039/c1jm11813g
   Akhavan O, 2011, J MATER CHEM, V21, P9634, DOI 10.1039/c0jm04364h
   Akhavan O, 2010, SURF COAT TECH, V205, P219, DOI 10.1016/j.surfcoat.2010.06.036
   Akhavan O, 2009, THIN SOLID FILMS, V517, P6700, DOI 10.1016/j.tsf.2009.05.016
   Balamurugan B, 2001, THIN SOLID FILMS, V396, P90, DOI 10.1016/S0040-6090(01)01216-0
   Cai WD, 2010, APPL CATAL B-ENVIRON, V101, P160, DOI 10.1016/j.apcatb.2010.09.031
   Esteban-Tejeda L, 2009, NANOTECHNOLOGY, V20, DOI 10.1088/0957-4484/20/50/505701
   Gao F, 2009, CHEM COMMUN, P3571, DOI 10.1039/b904801d
   Ge L, 2012, J MATER CHEM, V22, P11843, DOI 10.1039/c2jm16241e
   Heinlaan M, 2008, CHEMOSPHERE, V71, P1308, DOI 10.1016/j.chemosphere.2007.11.047
   Kabra K, 2004, IND ENG CHEM RES, V43, P7683, DOI 10.1021/ie0498551
   Kuo CH, 2010, NANO TODAY, V5, P106, DOI 10.1016/j.nantod.2010.02.001
   Meng XY, 2012, RSC ADV, V2, P2875, DOI 10.1039/c2ra01197b
   Pang H, 2010, CRYSTENGCOMM, V12, P406, DOI 10.1039/b904705k
   Perelshtein I, 2009, SURF COAT TECH, V204, P54, DOI 10.1016/j.surfcoat.2009.06.028
   Shi H, 2012, CRYSTENGCOMM, V14, P278, DOI 10.1039/c1ce05868a
   Sun SD, 2011, CRYSTENGCOMM, V13, P2217, DOI 10.1039/c0ce00679c
   Vijayan BK, 2010, J PHYS CHEM C, V114, P21262, DOI 10.1021/jp108659a
   Wang XF, 2011, J MATER CHEM, V21, P9641, DOI 10.1039/c0jm04558f
   White B, 2006, NANO LETT, V6, P2095, DOI 10.1021/nl061457v
   Xiong P, 2012, J MATER CHEM, V22, P17485, DOI 10.1039/c2jm31522j
   Yao KX, 2010, J AM CHEM SOC, V132, P6131, DOI 10.1021/ja100151f
   Zhang H, 2010, J PHYS CHEM C, V114, P5822, DOI 10.1021/jp910930t
   Zhang H, 2009, J PHYS CHEM C, V113, P4605, DOI 10.1021/jp810748u
   Zhong JH, 2011, INORG CHEM, V50, P757, DOI 10.1021/ic1017664
NR 26
TC 16
Z9 18
U1 7
U2 165
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1566-7367
EI 1873-3905
J9 CATAL COMMUN
JI Catal. Commun.
PD JAN 10
PY 2013
VL 31
BP 57
EP 61
DI 10.1016/j.catcom.2012.11.012
PG 5
WC Chemistry, Physical
SC Chemistry
GA 087CX
UT WOS:000314740000012
DA 2018-12-27
ER

PT J
AU Tako, E
   Hoekenga, OA
   Kochian, LV
   Glahn, RP
AF Tako, Elad
   Hoekenga, Owen A.
   Kochian, Leon V.
   Glahn, Raymond P.
TI RETRACTED: High bioavailablilty iron maize (Zea mays L.) developed
   through molecular breeding provides more absorbable iron in vitro
   (Caco-2 model) and in vivo (Gallus gallus)(Retracted article. See vol.
   14, pg. 126, 2015)
SO NUTRITION JOURNAL
LA English
DT Article; Retracted Publication
DE Maize; Biofortification; Iron bioavailability; In vitro digestion/Caco-2
   cell model; Broiler chicken; Intestine
ID BEANS PHASEOLUS-VULGARIS; POULTRY GALLUS-GALLUS; MICRONUTRIENT
   MALNUTRITION; DIGESTION/CACO-2 MODEL; PHENOLIC ANTIOXIDANTS;
   NUTRITIONAL-VALUE; COMMON BEANS; DIET PROVIDE; PURPLE CORN; RED
AB Background: Iron (Fe) deficiency is the most common micronutrient deficiency worldwide. Iron biofortification is a preventative strategy that alleviates Fe deficiency by improving the amount of absorbable Fe in crops. In the present study, we used an in vitro digestion/Caco 2 cell culture model as the guiding tool for breeding and development of two maize (Zea mays L.) lines with contrasting Fe bioavailability (ie. Low and High). Our objective was to confirm and validate the in vitro results and approach. Also, to compare the capacities of our two maize hybrid varieties to deliver Fe for hemoglobin (Hb) synthesis and to improve the Fe status of Fe deficient broiler chickens.
   Methods: We compared the Fe-bioavailability between these two maize varieties with the presence or absence of added Fe in the maize based-diets. Diets were made with 75% (w/w) maize of either low or high Fe-bioavailability maize, with or without Fe (ferric citrate). Chicks (Gallus gallus) were fed the diets for 6 wk. Hb, liver ferritin and Fe related transporter/enzyme gene-expression were measured. Hemoglobin maintenance efficiency (HME) and total body Hb Fe values were used to estimate Fe bioavailability from the diets.
   Results: DMT-1, DcytB and ferroportin expressions were higher (P < 0.05) in the "Low Fe" group than in the "High Fe" group (no added Fe), indicating lower Fe status and adaptation to less Fe-bioavailability. At times, Hb concentrations (d 21,28,35), HME (d 21), Hb-Fe (as from d 14) and liver ferritin were higher in the "High Fe" than in the "Low Fe" groups (P < 0.05), indicating greater Fe absorption from the diet and improved Fe status.
   Conclusions: We conclude that the High Fe-bioavailability maize contains more bioavailable Fe than the Low Fe-bioavailability maize, presumably due to a more favorable matrix for absorption. Maize shows promise for Fe biofortification; therefore, human trials should be conducted to determine the efficacy of consuming the high bioavailable Fe maize to reduce Fe deficiency.
C1 [Tako, Elad; Hoekenga, Owen A.; Kochian, Leon V.; Glahn, Raymond P.] Cornell Univ, USDA ARS Robert W Holley Ctr Agr & Hlth, Ithaca, NY 14853 USA.
RP Tako, E (reprint author), Cornell Univ, USDA ARS Robert W Holley Ctr Agr & Hlth, 538 Tower Rd, Ithaca, NY 14853 USA.
EM et79@cornell.edu
OI Kochian, Leon/0000-0003-3416-089X
CR Adom KK, 2002, J AGR FOOD CHEM, V50, P6182, DOI 10.1021/jf0205099
   Aluru MR, 2011, J AGR FOOD CHEM, V59, P12954, DOI 10.1021/jf203485a
   Au AP, 2000, J NUTR, V130, P1329
   Baltussen R, 2004, J NUTR, V134, P2678
   Baxter I, 2010, BRIEF FUNCT GENOMICS, V9, P149, DOI 10.1093/bfgp/elp055
   Beiseigel JM, 2007, AM J CLIN NUTR, V86, P388
   Bouis HE, 2011, FOOD NUTR BULL, V32, pS31, DOI 10.1177/15648265110321S105
   Cannon E. K., 2011, INT J PLANT GENOMICS, V92, P30
   Cevallos-Casals BA, 2003, J AGR FOOD CHEM, V51, P3313, DOI 10.1021/jf034109c
   De Rosa MC, 2007, GENE, V398, P162, DOI 10.1016/j.gene.2007.02.048
   Dewanto V, 2002, J AGR FOOD CHEM, V50, P3010, DOI 10.1021/jf0115589
   Etcheverry P, 2004, J NUTR, V134, P93
   Fairweather-Tait S, 2007, INT J VITAM NUTR RES, V77, P158, DOI 10.1024/0300-9831.77.3.158
   FAO, 2012, FAOSTAT FOOD SUPPL D
   Glahn RP, 1998, J NUTR, V128, P1555
   Graham RD, 2001, ADV AGRON, V70, P77, DOI 10.1016/S0065-2113(01)70004-1
   Haas JD, 2005, J NUTR, V135, P2823
   Heffner EL, 2010, CROP SCI, V50, P1681, DOI 10.2135/cropsci2009.11.0662
   Hoekenga OA, 2011, PLANT GENET RESOUR-C, V9, P327, DOI 10.1017/S1479262111000116
   Hurrell R, 2010, AM J CLIN NUTR, V91, p1461S, DOI 10.3945/ajcn.2010.28674F
   Lee H, 2002, GENETICS, V161, P905
   Lonnerdal B, 2007, INT J VITAM NUTR RES, V77, P152, DOI 10.1024/0300-9831.77.3.152
   Lonnerdal B, 2011, J AGR FOOD CHEM, V59, P4755, DOI 10.1021/jf1043663
   Lung'aho MG, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020429
   Lynch SR, 2005, BEST PRACT RES CL HA, V18, P333, DOI 10.1016/j.beha.2004.09.003
   Mahler GJ, 2012, NAT NANOTECHNOL, V7, P264, DOI [10.1038/NNANO.2012.3, 10.1038/nnano.2012.3]
   Mete A, 2005, AVIAN PATHOL, V34, P430, DOI 10.1080/03079450500267908
   Neumann CG, 2004, PEDIATR ANN, V33, P658, DOI 10.3928/0090-4481-20041001-09
   Niwa T, 2003, J AGR FOOD CHEM, V51, P90, DOI 10.1021/jf020758x
   Paran I, 2003, TRENDS GENET, V19, P303, DOI 10.1016/S0168-9525(03)00117-3
   PASSANITI A, 1989, BIOCHEM J, V258, P413, DOI 10.1042/bj2580413
   Peirson SN, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng073
   Petry N, 2010, J NUTR, V140, P1977, DOI 10.3945/jn.110.125369
   Pixley KV, 2011, FIELD CROP RES, V123, P153, DOI 10.1016/j.fcr.2011.05.011
   Scheers NM, 2008, EUR J NUTR, V47, P401, DOI 10.1007/s00394-008-0741-8
   Schnable PS, 2009, SCIENCE, V326, P1112, DOI 10.1126/science.1178534
   SHANE JM, 1995, J AM DIET ASSOC, V95, P40, DOI 10.1016/S0002-8223(95)00011-9
   Stoltzfus RJ, 2001, J NUTR, V131, p565S, DOI 10.1093/jn/131.2.565S
   Sturkie P., 2000, AVIAN PHYSL
   Tako E, 2010, POULTRY SCI, V89, P514, DOI 10.3382/ps.2009-00326
   Tako E, 2011, NUTR J, V10, DOI 10.1186/1475-2891-10-113
   Tako E, 2010, INT J VITAM NUTR RES, V80, P416, DOI 10.1024/0300-9831/a000028
   Tako E, 2009, J NUTR, V139, P305, DOI 10.3945/jn.108.098657
   Tako E, 2009, J AGR FOOD CHEM, V57, P3134, DOI 10.1021/jf803647m
   Tan SY, 2008, J AGR FOOD CHEM, V56, P5008, DOI 10.1021/jf8000026
   Tanumihardjo SA, 2010, INT J VITAM NUTR RES, V80, P336, DOI 10.1024/0300-9831/a000042
   Tontisirin K, 2002, P NUTR SOC, V61, P243, DOI 10.1079/PNS2002155
   Tsuda T, 2003, J NUTR, V133, P2125
   Welch Ross M., 2000, Food and Nutrition Bulletin, V21, P428
   Wettasinghe M, 2002, J AGR FOOD CHEM, V50, P1267, DOI 10.1021/jf010526i
   *WHO, 2001, IR DEF AN ASS PREV C, P15
   Yadgary L, 2011, POULTRY SCI, V90, P410, DOI 10.3382/ps.2010-01075
NR 52
TC 24
Z9 25
U1 4
U2 4
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1475-2891
J9 NUTR J
JI Nutr. J.
PD JAN 4
PY 2013
VL 12
AR 3
DI 10.1186/1475-2891-12-3
PG 11
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 084FY
UT WOS:000314524800001
PM 23286295
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Pretorius, E
   Lipinski, B
AF Pretorius, E.
   Lipinski, B.
TI RETRACTED: Iron alters red blood cell morphology (Retracted article. See
   vol. 123, pg. 1769, 2014)
SO BLOOD
LA English
DT Editorial Material; Retracted Publication
RI Pretorius, Etheresia/P-2978-2016
OI Pretorius, Etheresia/0000-0002-9108-2384
NR 0
TC 19
Z9 19
U1 2
U2 10
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD JAN 3
PY 2013
VL 121
IS 1
BP 9
EP 9
DI 10.1182/blood-2012-09-454793
PG 1
WC Hematology
SC Hematology
GA 065EH
UT WOS:000313130400005
PM 23409279
OA Bronze
DA 2018-12-27
ER

PT J
AU Hazani, AA
   Ibrahim, MM
   Shehata, AI
   El-Gaaly, GA
   Daoud, M
   Fouad, D
   Rizwana, H
   Moubayed, NMS
AF Hazani, Amal A.
   Ibrahim, Mohamed M.
   Shehata, Afaf I.
   El-Gaaly, Gehan A.
   Daoud, Mohamed
   Fouad, Dalia
   Rizwana, Humaira
   Moubayed, Nadine M. S.
TI RETRACTED: ECOTOXICITY OF AG-NANOPARTICLES ON TWO MICROALGAE, CHLORELLA
   VULGARIS AND DUNALIELLA TERTIOLECTA (Retracted article. See vol. 68, pg.
   243, 2016)
SO ARCHIVES OF BIOLOGICAL SCIENCES
LA English
DT Article; Retracted Publication
DE Antioxidant; Chlorella; Dunaliella; nanoparticles; oxidative stress
ID TOXICITY; SILVER; BIOAVAILABILITY; NANOMATERIALS; ASSAY; FATE
AB The increasing application of nanotechnology highlights the need to clarify and understand it. In this work, the subacute toxicity of Ag-NPs to the fresh water microalga Chlorella vulgaris and marine microalga Dunaliella tertiolecta were assessed. The effect of Ag-NPs was induced by exposing both algae to increasing concentrations of Ag-NPs (0, 10, 50, 100 and 200 mg/L). Cellular viability and reactive oxygen species (ROS) formation were determined to evaluate the toxic effect of Ag-NPs on algal growth. Superoxide dismutase (SOD), catalase (CAT) and peroxidase (POD) activities and lipid peroxidation (MDA) levels in the algal cells varied with the concentration of Ag-NPs suspensions and exposure times (up to 8 d). As a result, 100 and 200 mg/L Ag-NPs caused a statistically significant decrease in cell viability, as well as SOD, CAT and POD activities, and a significant increase in ROS formation and MDA levels in tissues (P<0.05), suggesting that the algal cells exposed to these two concentrations of Ag-NPs suffered from oxidative stress. The extent of depletion of antioxidant enzyme activities and the elevation of MDA in Dunaliella tertiolecta was the greatest, indicating that Dunaliella tertiolecta might be the most susceptible to Ag-NP exposure. These results indicated a potential risk from Ag-NPs released into the aqueous environment.
C1 [Hazani, Amal A.; Ibrahim, Mohamed M.; Shehata, Afaf I.; El-Gaaly, Gehan A.] King Saud Univ, Coll Sci, Dept Bot & Microbiol, Riyadh 11451, Saudi Arabia.
   [Ibrahim, Mohamed M.] Univ Alexandria, Fac Sci, Dept Bot & Microbiol, Alexandria, Egypt.
   [Daoud, Mohamed; Fouad, Dalia] King Saud Univ, Coll Sci, Dept Biochem, Riyadh 11451, Saudi Arabia.
RP Hazani, AA (reprint author), King Saud Univ, Coll Sci, Dept Bot & Microbiol, Riyadh 11451, Saudi Arabia.
CR Adams NWH, 1998, ENVIRON TOXICOL CHEM, V17, P625, DOI 10.1897/1551-5028(1998)017<0625:ROAIWT>2.3.CO;2
   Barnett BP, 2007, NAT MED, V13, P986, DOI 10.1038/nm1581
   BEAUCHAM.C, 1971, ANAL BIOCHEM, V44, P276, DOI 10.1016/0003-2697(71)90370-8
   BEAUMONT F, 1990, PLANT SCI, V72, P19, DOI 10.1016/0168-9452(90)90182-N
   Boyle T. P., 1984, ALGAE ECOLOGICAL IND, P237
   Buege J A, 1978, Methods Enzymol, V52, P302
   CHANCE B, 1955, METHOD ENZYMOL, V2, P764, DOI 10.1016/S0076-6879(55)02300-8
   Choi JE, 2010, AQUAT TOXICOL, V100, P151, DOI 10.1016/j.aquatox.2009.12.012
   Dimkpa CO, 2013, ENVIRON SCI TECHNOL, V47, P1082, DOI 10.1021/es302973y
   Dong Y, 2007, BIOMATERIALS, V28, P4154, DOI 10.1016/j.biomaterials.2007.05.026
   Erickson RJ, 1998, ENVIRON TOXICOL CHEM, V17, P572, DOI 10.1897/1551-5028(1998)017<0572:EOLTCO>2.3.CO;2
   Fang YZ, 2002, THEORY APPL FREE RAD, P122
   Gerber Isak B, 2003, Methods Cell Sci, V25, P115
   Handy RD, 2008, ECOTOXICOLOGY, V17, P315, DOI 10.1007/s10646-008-0206-0
   He D, 2012, ENVIRON SCI TECHNOL, V46, P8731, DOI 10.1021/es300588a
   Ibrahim MM, 2011, FRESEN ENVIRON BULL, V20, P1871
   Kachynski AV, 2008, J PHYS CHEM C, V112, P10721, DOI 10.1021/jp801684j
   Klaine SJ, 2008, ENVIRON TOXICOL CHEM, V27, P1825, DOI 10.1897/08-090.1
   Krishnaraj C., 2012, PROCESS BIOCHEM, V10, P234
   Lens Marko, 2009, Recent Pat Biotechnol, V3, P118, DOI 10.2174/187220809788700166
   Luoma SN, 2008, METAL CONTAMINATION IN AQUATIC ENVIRONMENTS: SCIENCE AND LATERAL MANAGEMENT, P1
   LUOMA SN, 1995, MAR POLLUT BULL, V31, P44, DOI 10.1016/0025-326X(95)00081-W
   MCLACHLAN J, 1960, CAN J MICROBIOL, V6, P367, DOI 10.1139/m60-041
   Navarro E, 2008, ENVIRON SCI TECHNOL, V42, P8959, DOI 10.1021/es801785m
   Nel A, 2006, SCIENCE, V311, P622, DOI 10.1126/science.1114397
   OLIVEIRA L, 1980, NEW PHYTOL, V85, P385, DOI 10.1111/j.1469-8137.1980.tb03177.x
   Oukarroum A, 2012, ECOTOX ENVIRON SAFE, V78, P80, DOI 10.1016/j.ecoenv.2011.11.012
   Pandey S, 2003, SCI TOTAL ENVIRON, V309, P105, DOI 10.1016/S0048-9697(03)00006-8
   Park JBK, 2010, WATER SCI TECHNOL, V61, P633, DOI 10.2166/wst.2010.951
   Patra J. K., 2009, J MICROBIOL, V5, P128
   Perreault F, 2011, ECOTOX ENVIRON SAFE, V74, P1021, DOI 10.1016/j.ecoenv.2011.01.016
   Ratte HT, 1999, ENVIRON TOXICOL CHEM, V18, P89, DOI 10.1897/1551-5028(1999)018<0089:BATOSC>2.3.CO;2
   Regel RH, 2002, AQUAT TOXICOL, V59, P209, DOI 10.1016/S0166-445X(01)00254-5
   Renault S, 2008, GOLD BULL, V41, P116, DOI 10.1007/BF03216589
   RIPPKA R, 1979, J GEN MICROBIOL, V111, P1, DOI 10.1099/00221287-111-1-1
   Sadiq I.M., 2011, ECOTOX ENVIRON SAFE, V74, P1180
   Shrivastava S., 2007, NANOTECHNOLOGY, V18, DOI DOI 10.1088/0957-4484/18/22/225103
   Tungittiplakorn W, 2004, ENVIRON SCI TECHNOL, V38, P1605, DOI 10.1021/es0348997
   van der Oost R, 2003, ENVIRON TOXICOL PHAR, V13, P57, DOI 10.1016/S1382-6689(02)00126-6
   Van Hoecke K., 2008, ENVIRON TOXICOL CHEM, V27, P127
   Wei CX, 2010, J ENVIRON SCI-CHINA, V22, P155, DOI 10.1016/S1001-0742(09)60087-5
   Wei D., 2008, NANOTECHNOLOGY, V19, P222
   Zhang XZ, 2007, CHEMOSPHERE, V67, P160, DOI 10.1016/j.chemosphere.2006.09.003
NR 43
TC 9
Z9 11
U1 6
U2 59
PU INST BIOLOSKA ISTRAZIVANJA SINISA STANKOVIC
PI BEOGRAD
PA 29 NOVEMBRA 142, BEOGRAD, 11060, SERBIA
SN 0354-4664
EI 1821-4339
J9 ARCH BIOL SCI
JI Arch. Biol. Sci.
PY 2013
VL 65
IS 4
BP 1447
EP +
DI 10.2298/ABS1304447H
PG 11
WC Biology
SC Life Sciences & Biomedicine - Other Topics
GA 298LY
UT WOS:000330326600021
OA DOAJ Gold
DA 2018-12-27
ER

PT J
AU Xiang, F
   Yong, H
   Dandan, S
   Jiexian, Z
AF Xiang, F.
   Yong, H.
   Dandan, S.
   Jiexian, Z.
TI RETRACTED: An Image Retrieval Method based on Hu Invariant Moment and
   Improved Annular Histogram (Retracted Article)
SO ELEKTRONIKA IR ELEKTROTECHNIKA
LA English
DT Article; Retracted Publication
DE Image retrieval; Hu invariant moment; annular histogram; shape
   information
AB Image retrieval methods based on annular histogram of feature points are calculation efficient, invariant to image rotation and translation transform. However, these methods have two main disadvantages. One is that the annular histogram can't describe the spatial distribution of feature points accurately, thus different images may have similar annular histogram. Another one is the methods based on feature points cannot describe the shape information of object. These disadvantages affect the retrieval accuracy to a certain extent. In this paper, an image retrieval method based on Hu invariant moments and improved annular histogram is proposed. Firstly, edge of image is detected and feature points are calculated based on the edge curvature. Then, image features are described based on both the edge and points. Annular histogram combined with standard deviation ellipse method is used to describe the spatial distribution of feature points. Hu invariant moment of the edge is used to represent the object's shape information. Finally, the similarity is measured based on both the point feature and the shape feature. Experiment results show that the proposed method can improve the image retrieval precision effectively.
C1 [Xiang, F.; Yong, H.; Dandan, S.; Jiexian, Z.] Nanchang Hangkong Univ, Sch Software, Nanchang 330063, Jiangxi, Peoples R China.
RP Xiang, F (reprint author), Nanchang Hangkong Univ, Sch Software, Nanchang 330063, Jiangxi, Peoples R China.
EM fxfb163@163.com
FU Science and Technology Project of Jiangxi Province [20122BBF60072];
   Youth Science Foundation of Jiangxi province [20132BAB211021]
FX This research was funded by grant (No. 20122BBF60072) from the Science
   and Technology Project of Jiangxi Province and grant (No.
   20132BAB211021) from the Youth Science Foundation of Jiangxi province.
   This research was performed in cooperation with the Institutions.
CR CANNY J, 1986, IEEE T PATTERN ANAL, V8, P679, DOI 10.1109/TPAMI.1986.4767851
   Ding GG, 2010, IEICE ELECTRON EXPR, V7, P7, DOI 10.1587/elex.7.7
   Fu Xiang, 2010, Chinese Journal of Lasers, V37, P774, DOI 10.3788/CJL20103703.0774
   [高月芳 GAO Yue-fang], 2009, [中国图象图形学报, Journal of Image and Graphics], V14, P1494
   [黄元元 HUANG Yuanyuan], 2010, [中国图象图形学报, Journal of Image and Graphics], V15, P637
   Li S, 2009, IEEE T SYST MAN CY A, V39, P227, DOI 10.1109/TSMCA.2008.2007988
   Li Wei, 2007, COMPUTE ENG DESIGN, V28, P2595
   Liu Tao, 2011, Geomatics and Information Science of Wuhan University, V36, P1149
   [孟繁杰 Meng Fanjie], 2010, [光电子·激光, Journal of Optoelectronics·Laser], V21, P936
   Qi H, 2010, PATTERN RECOGN, V43, P2017, DOI 10.1016/j.patcog.2010.01.007
   [束鑫 SHU Xin], 2009, [光电子·激光, Journal of Optoelectronics·Laser], V20, P1385
   Su Xiao-Hong, 2009, Chinese Journal of Computers, V32, P2221, DOI 10.3724/SP.J.1016.2009.02221
NR 12
TC 3
Z9 5
U1 7
U2 26
PU KAUNAS UNIV TECHNOLOGY
PI KAUNAS
PA KAUNAS UNIV TECHNOL, DEPT ELECTRONICS ENGINEERING, STUDENTU STR 50,
   KAUNAS, LT-51368, LITHUANIA
SN 1392-1215
J9 ELEKTRON ELEKTROTECH
JI Elektron. Elektrotech.
PY 2013
VL 19
IS 10
BP 114
EP 118
DI 10.5755/j01.eee.19.10.3925
PG 5
WC Engineering, Electrical & Electronic
SC Engineering
GA 303QJ
UT WOS:000330689000026
DA 2018-12-27
ER

PT J
AU Napoleao, P
   Selas, M
   Freixo, C
   Carmo, MM
   Viegas-Crespo, AM
   Ferreira, RC
   Pinheiro, T
AF Napoleao, Patricia
   Selas, Mafalda
   Freixo, Claudia
   Carmo, Miguel Mota
   Viegas-Crespo, Ana Maria
   Ferreira, Rui Cruz
   Pinheiro, Teresa
TI RETRACTED: T lymphocytes alterations are associated with oxidized LDL,
   troponin T, white blood cells and C-reactive protein during acute
   myocardial infarction (Retracted article. See vol. 57, pg. 213, 2014)
SO CLINICAL HEMORHEOLOGY AND MICROCIRCULATION
LA English
DT Article; Retracted Publication
DE T lymphocytes; oxidized LDL; cardiac troponin T; C-reactive protein;
   acute coronary syndromes; longitudinal study
ID LOW-DENSITY-LIPOPROTEIN; ACUTE CORONARY SYNDROMES; HUMAN ATHEROSCLEROTIC
   PLAQUES; ARTERY-DISEASE; COSTIMULATION; INFLAMMATION; INDUCTION;
   SEVERITY; PLASMA
AB BACKGROUND: Auto-immune responses are associated with oxidized LDL (ox-LDL) release, a key factor in plaque destabilization. Data on the relationship between ox-LDL and T lymphocytes in human populations remains scarce. T cells also react with other molecules from the lesion and/or damage the myocardium.
   OBJECTIVE: The objective of the present study was to examine the relationship between circulating T lymphocytes, ox-LDL, markers of myocardial necrosis (cTnT), myocardial dysfunction (N-terminal pro-brain natriuretic peptide - NT-proBNP) and inflammation (C-reactive protein - CRP) in the setting of acute myocardial infarction.
   METHODS: A longitudinal study of 55 patients with ST-elevation myocardial infarction (STEMI) were evaluated at three time points: admission, 2 and 40 days following admission, together with 30 patients with stable angina (SA) and 56 subjects without coronary artery disease serving as controls (CTR).
   RESULTS: STEMI patients had maximal ox-LDL values and minimal levels of CD3+ T lymphocytes at admission, which was normalized during the recovery period. The increasing trend of CD3+ T cells was positively associated with an ox-LDL decline over time. CRP and cTnT longitudinal variations were negatively associated with the CD3+ T-cell increasing trend. These associations were not found in SA patients or controls.
   CONCLUSIONS: The associations found between CD3+ T lymphocytes, ox-LDL and cTnT suggest a specificity of the immune response in AMI towards arterial and myocardial inflammation and remodelling.
C1 [Napoleao, Patricia] Univ Lisbon, Unidade Biol Microvasc & Inflamacao, Inst Mol Med, Fac Med, P-1200 Lisbon, Portugal.
   [Napoleao, Patricia; Pinheiro, Teresa] Univ Tecn Lisboa, Inst Super Tecn, Inst Tecnol & Nucl, Grp Estudos Biomed,Unidade Fis & Aceleradores, P-1100 Lisbon, Portugal.
   [Selas, Mafalda; Freixo, Claudia; Carmo, Miguel Mota; Ferreira, Rui Cruz] Ctr Hosp Lisboa Cent, Hosp Santa Marta, Serv Cardiol, Lisbon, Portugal.
   [Carmo, Miguel Mota] Univ Nova Lisboa, Fac Ciencias Med, Ctr Estudos Doencas Cron, P-1200 Lisbon, Portugal.
   [Viegas-Crespo, Ana Maria] Univ Aveiro, Ctr Estudos Ambiente & Mar, P-3800 Aveiro, Portugal.
   [Viegas-Crespo, Ana Maria] Univ Lisbon, Fac Ciencias, Dept Biol Anim, P-1200 Lisbon, Portugal.
   [Pinheiro, Teresa] Univ Lisbon, Ctr Fis Nucl, P-1200 Lisbon, Portugal.
RP Napoleao, P (reprint author), Inst Mol Med, Unidade Biol Microvasc & Inflamacao, Av Prof Egas Moniz, P-1649028 Lisbon, Portugal.
EM pnapoleao@fm.ul.pt
RI CESAM, UA/M-3762-2015
OI Napoleao, Patricia/0000-0002-5896-1440; Pinheiro,
   Teresa/0000-0002-1836-2603; Carmo, Miguel/0000-0001-6865-4332
FU Fundacao para a Ciencia e Tecnologia [SFRM/BPD/6308/2009,
   PIC/IC/82734/2007]; Liga dos Amigos do Hospital de Santa Marta
FX This work was supported by the Fundacao para a Ciencia e Tecnologia
   (SFRM/BPD/6308/2009 and PIC/IC/82734/2007); and by Liga dos Amigos do
   Hospital de Santa Marta.
CR [Anonymous], 2010, CLIN HEMORHEOL MICRO, V44, P1
   Benagiano M, 2003, P NATL ACAD SCI USA, V100, P6658, DOI 10.1073/pnas.1135726100
   Blum A, 2003, EUR J INTERN MED, V14, P407, DOI [10.1016/j.ejim.2003.09.002, DOI 10.1016/J.EJIM.2003.09.002]
   Bodi V, 2008, AM HEART J, V156, P1065, DOI 10.1016/j.ahj.2008.07.008
   Bustamante M, 2007, CELL MOL BIOL, V53, pOL954, DOI 10.1170/109
   CasparBauguil S, 1997, TRANSPLANT P, V29, P2328, DOI 10.1016/S0041-1345(97)00387-4
   Cheng X, 2005, J CLIN IMMUNOL, V25, P246, DOI 10.1007/s10875-005-4088-0
   Collinson PO, 2007, MED PRIN PRACT, V16, P247, DOI 10.1159/000102146
   Dragu R, 2008, ATHEROSCLEROSIS, V196, P405, DOI 10.1016/j.atherosclerosis.2006.11.022
   Ehara S, 2002, J DIABETES COMPLICAT, V16, P60, DOI 10.1016/S1056-8727(01)00210-0
   Ehara S, 2001, CIRCULATION, V103, P1955
   Frostegard J, 1999, ATHEROSCLEROSIS, V145, P33, DOI 10.1016/S0021-9150(99)00011-8
   FROSTEGARD J, 1992, ARTERIOSCLER THROMB, V12, P461, DOI 10.1161/01.ATV.12.4.461
   Fu PF, 2006, CLIN HEMORHEOL MICRO, V34, P169
   Gotsman I, 2008, CIRC RES, V103, P1220, DOI 10.1161/CIRCRESAHA.108.182428
   Greco TP, 2010, AM J CLIN PATHOL, V133, P737, DOI 10.1309/AJCP88WVRDRDFBAS
   Harlan LM, 2007, ATHEROSCLEROSIS, V193, P309, DOI 10.1016/j.atherosclerosis.2006.09.008
   Hartford M, 2006, INT J CARDIOL, V108, P55, DOI 10.1016/j.ijcard.2005.04.004
   Holvoet P, 1998, CIRCULATION, V98, P1487, DOI 10.1161/01.CIR.98.15.1487
   Holvoet P, 2001, ARTERIOSCL THROM VAS, V21, P844, DOI 10.1161/01.ATV.21.5.844
   Inoue T., 2002, CARDIOLOGY, V98, P3
   Larbi A, 2005, RADIAT PHYS CHEM, V72, P387, DOI 10.1016/j.radphyschem.2004.02.010
   MCMURRAY HF, 1993, J CLIN INVEST, V92, P1004, DOI 10.1172/JCI116605
   Napoleao Patricia, 2009, Rev Port Cardiol, V28, P303
   Naruko T, 2006, ARTERIOSCL THROM VAS, V26, P877, DOI 10.1161/01.ATV.0000209886.31510.7f
   Palinski W, 1996, J CLIN INVEST, V98, P800, DOI 10.1172/JCI118853
   Panteghini M, 2004, EUR HEART J, V25, P1187, DOI 10.1016/j.ehj.2004.04.026
   STEMME S, 1995, P NATL ACAD SCI USA, V92, P3893, DOI 10.1073/pnas.92.9.3893
   Steppich BA, 2007, ATHEROSCLEROSIS, V190, P443, DOI 10.1016/j.atherosclerosis.2006.02.034
   Stocker R, 2004, PHYSIOL REV, V84, P1381, DOI 10.1152/physrev.00047.2003
   Twisk JWR, 2004, APPL LONGITUDINAL DA
   Wu R, 1996, SCAND J IMMUNOL, V43, P381, DOI 10.1046/j.1365-3083.1996.d01-51.x
   Zurgil N, 2004, CELL BIOCHEM BIOPHYS, V40, P97, DOI 10.1385/CBB:40:2:097
NR 33
TC 1
Z9 1
U1 2
U2 10
PU IOS PRESS
PI AMSTERDAM
PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS
SN 1386-0291
EI 1875-8622
J9 CLIN HEMORHEOL MICRO
JI Clin. Hemorheol. Microcirc.
PY 2013
VL 55
IS 3
BP 349
EP 358
DI 10.3233/CH-121644
PG 10
WC Hematology; Peripheral Vascular Disease
SC Hematology; Cardiovascular System & Cardiology
GA 279KN
UT WOS:000328959000007
PM 24361942
DA 2018-12-27
ER

PT J
AU Olama, MM
   Djouadi, SM
   Li, YY
   Fathy, A
AF Olama, Mohammed M.
   Djouadi, Seddik M.
   Li, Yanyan
   Fathy, Aly
TI RETRACTED: Modeling, Real-Time Estimation, and Identification of UWB
   Indoor Wireless Channels (Retracted article. artn 1325490, 2017)
SO INTERNATIONAL JOURNAL OF ANTENNAS AND PROPAGATION
LA English
DT Article; Retracted Publication
ID ULTRAWIDEBAND PROPAGATION CHANNELS; STOCHASTIC DIFFERENTIAL-EQUATIONS;
   STATISTICAL-MODEL; SIMULATION; NUMBER; RADAR; NOISE
AB Stochastic differential equations (SDEs) are used to model ultrawideband (UWB) indoor wireless channels. We show that the impulse responses for time-varying indoor wireless channels can be approximated in a mean-square sense as close as desired by impulse responses that can be realized by SDEs. The state variables represent the inphase and quadrature components of the UWB channel. The expected maximization and extended Kalman filter are employed to recursively identify and estimate the channel parameters and states, respectively, fromonline received signal strength measured data. Both resolvable and nonresolvable multipath received signals are considered and represented as small-scaled Nakagami fading. The proposed models together with the estimation algorithm are tested using UWB indoor measurement data demonstrating the method's viability and the results are presented.
C1 [Olama, Mohammed M.] Oak Ridge Natl Lab, Computat Sci & Engn Div, Oak Ridge, TN 37831 USA.
   [Djouadi, Seddik M.; Li, Yanyan; Fathy, Aly] Univ Tennessee, Elect Engn & Comp Sci Dept, Knoxville, TN 37996 USA.
RP Olama, MM (reprint author), Oak Ridge Natl Lab, Computat Sci & Engn Div, POB 2008,MS 6085, Oak Ridge, TN 37831 USA.
EM olamahussemm@ornl.gov
FU US Department of Energy [DE-AC05-00OR22725]; NSF [CMMI-1334094]
FX This paper has been authored by employees of UT-Battelle, LLC, under
   Contract no. DE-AC05-00OR22725 with the US Department of Energy. Also,
   this work was supported in part by NSF Grant no. CMMI-1334094.
CR Astrom KJ, 1970, INTRO STOCHASTIC CON
   Baddour KE, 2005, IEEE T WIREL COMMUN, V4, P1650, DOI 10.1109/TWC.2005.850327
   Beaulieu NC, 2005, IEEE T VEH TECHNOL, V54, P413, DOI 10.1109/TVT.2004.841555
   Cassioli D, 2002, IEEE J SEL AREA COMM, V20, P1247, DOI [10.1109/JSAC.2002.801228, 10.1109/JSAC.2002.801228.]
   Charalambous CD, 2005, IEEE T INFORM THEORY, V51, P4396, DOI 10.1109/TIT.2005.858984
   Chung P.-J., 2004, P 3 IEEE SENS ARR MU, P221
   Djouadi SM, 2008, IEEE SIGNAL PROC LET, V15, P896, DOI 10.1109/LSP.2008.2005449
   Federal Communications Commission, 2002, 0248 FED COMM COMM
   Feng T, 2007, IEEE T COMMUN, V55, P1478, DOI 10.1109/TCOMM.2007.902531
   Field TR, 2003, J MATH PHYS, V44, P5212, DOI [10.1063/1.1611264, 10.1063/1.1611264#]
   Fishler E, 2005, IEEE T SIGNAL PROCES, V53, P3543, DOI 10.1109/TSP.2005.853099
   Karedal J., 2004, P 60 IEEE VEH TECHN, V1, P81
   KUNISCH J, 2002, P IEEE C ULTR WID SY, P19
   Molisch A, 2005, WIRELESS COMMUNICATI
   Molisch AF, 2005, IEEE T VEH TECHNOL, V54, P1528, DOI 10.1109/TVT.2005.856194
   Molisch AF, 2006, IEEE T ANTENN PROPAG, V54, P3151, DOI 10.1109/TAP.2006.883983
   Olama M. M., 2007, RES LETT SIGNAL PROC, V2007
   Olama M. M., 2006, EURASIP J APPL SIGNA, V2006
   Olama M. M., 2007, P AM CONTR C JUL, P3100
   Olama MM, 2009, IEEE T WIREL COMMUN, V8, P1754, DOI 10.1109/TWC.2009.071068
   Qiu RC, 2006, IEEE T WIREL COMMUN, V5, P2685, DOI 10.1109/TWC.2006.04068
   Quinlan A., 2007, EURASIP J ADV SIGNAL, V2007
   Radoi E, 2004, EURASIP J APPL SIG P, V2004, P1177, DOI 10.1155/S1110865704401097
   SALEH AAM, 1987, IEEE J SEL AREA COMM, V5, P128, DOI 10.1109/JSAC.1987.1146527
   Schatten R., 1960, NORM IDEALS COMPLETE
   Schmidt E, 1907, MATH ANN, V64, P161, DOI 10.1007/BF01449890
   Sklar B., 2001, DIGITAL COMMUNICATIO
   Venkatesh S., 2004, P IEEE ANT PROP S, P946
   Wilson W., 1996, LINEAR SYSTEM THEORY
   Win MZ, 1998, IEEE COMMUN LETT, V2, P36, DOI 10.1109/4234.660796
   Y Li, 2008, P COMP INT BIOINF CO, P195
   Yacoub MD, 1999, IEEE T VEH TECHNOL, V48, P790, DOI 10.1109/25.764995
   Zhang CM, 2006, IEEE MTT S INT MICR, P106, DOI 10.1109/MWSYM.2006.249940
NR 33
TC 2
Z9 2
U1 2
U2 9
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1687-5869
EI 1687-5877
J9 INT J ANTENN PROPAG
JI Int. J. Antennas Propag.
PY 2013
AR 467670
DI 10.1155/2013/467670
PG 8
WC Engineering, Electrical & Electronic; Telecommunications
SC Engineering; Telecommunications
GA 271MB
UT WOS:000328394900001
OA DOAJ Gold
DA 2018-12-27
ER

PT J
AU Wang, L
   Jiang, SY
AF Wang, Lei
   Jiang, Shuyun
TI RETRACTED: Performance Analysis of High-Speed Deep/Shallow Recessed
   Hybrid Bearing (Retracted article. See 798350, 2014)
SO MATHEMATICAL PROBLEMS IN ENGINEERING
LA English
DT Article; Retracted Publication
ID JOURNAL BEARING; STABILITY; POCKETS; SYSTEM
AB The present paper proposes a theoretical analysis of the performance of deep/shallow recessed hybrid bearing. It is intended that, on the basis of the numerical results drawn from this study, appropriate shallow recess depth and width can be determined for use in the bearing design process. By adopting bulk flow theory, the turbulent Reynolds equation and energy equation are modified and solved numerically including concentrated inertia effects at the recess edge with different depth and width of shallow recess. The results indicate that the load capacity, drag torque increases as the depth of shallow recess is shallower and the width ratio (half angle of deep recess versus half angle of shallow recess) is smaller. In contrast, the flow rate decreases as the depth of shallow recess is shallower and the width ratio is smaller. Nevertheless, the appropriate design of the depth and width of shallow recess might well induce the performance of high-speed deep/shallow recessed hybrid bearing.
C1 [Wang, Lei; Jiang, Shuyun] Southeast Univ, Sch Mech Engn, Nanjing 211189, Jiangsu, Peoples R China.
RP Jiang, SY (reprint author), Southeast Univ, Sch Mech Engn, Nanjing 211189, Jiangsu, Peoples R China.
EM jiangshyseu@gmail.com
FU National Science Foundation [50775036, 11172065]; Jiangsu
   University-Industry Collaboration Project [BY2012199]
FX The authors gratefully acknowledge the support of the National Science
   Foundation through Grant nos. 50775036, 11172065 and Jiangsu
   University-Industry Collaboration Project through Grant no. BY2012199.
CR Abele E, 2010, CIRP ANN-MANUF TECHN, V59, P781, DOI 10.1016/j.cirp.2010.05.002
   Chen CH, 2005, IND LUBR TRIBOL, V57, P41, DOI 10.1108/00368790510575978
   Chen CH, 2002, TRIBOL INT, V35, P849, DOI 10.1016/S0301-679X(02)00070-1
   Chen CH, 2006, J SOUND VIB, V297, P635, DOI 10.1016/j.jsv.2006.04.008
   Chen W., 2010, P STLE ASME INT JOIN, P91
   Chun SM, 2001, TRIBOL INT, V34, P397
   CONSTANTINESCU VN, 1976, J LUBRIC TECH-T ASME, V98, P167, DOI 10.1115/1.3452757
   Frene J., TRIBOLOGY INT, V39, P734
   Guo H, 2009, J TRIBOLOGY, V131, P701
   Guo H, 2011, ADV MATER RES-SWITZ, V291-294, P1516, DOI 10.4028/www.scientific.net/AMR.291-294.1516
   Guo H, 2009, TRIBOL T, V52, P204, DOI 10.1080/10402000802354061
   Hamrock B., 2004, FUNDAMENTALS FLUID F
   Heinrichson N, 2007, J TRIBOL-T ASME, V129, P895, DOI 10.1115/1.2768609
   Helene M, 2003, J TRIBOL-T ASME, V125, P283, DOI 10.1115/1.1537233
   HIRS GG, 1973, J LUBRIC TECH-T ASME, V95, P137, DOI 10.1115/1.3451752
   Pan D, 2009, LUBR ENG, V34, P11
   Rowe W. B., 1974, P 6 S GAS BEAR
   SZERI AZ, 1998, FLUID FILM LUBRICATI
   [熊万里 XIONG Wanli], 2009, [机械工程学报, Chinese Journal of Mechanical Engineering], V45, P1
NR 19
TC 1
Z9 1
U1 4
U2 21
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1024-123X
EI 1563-5147
J9 MATH PROBL ENG
JI Math. Probl. Eng.
PY 2013
AR 918767
DI 10.1155/2013/918767
PG 9
WC Engineering, Multidisciplinary; Mathematics, Interdisciplinary
   Applications
SC Engineering; Mathematics
GA 266IV
UT WOS:000328018200001
OA DOAJ Gold
DA 2018-12-27
ER

PT J
AU Shi, WC
   Hu, SP
   Wang, WH
   Zhou, XH
   Qiu, W
AF Shi, Wanchun
   Hu, Siping
   Wang, Wenhua
   Zhou, Xiaohui
   Qiu, Wei
TI RETRACTED: Skeletal Muscle-Specific CPT1 Deficiency Elevates Lipotoxic
   Intermediates but Preserves Insulin Sensitivity (Retracted article. See
   784502, 2014)
SO JOURNAL OF DIABETES RESEARCH
LA English
DT Article; Retracted Publication
ID CARNITINE PALMITOYLTRANSFERASE 1B; FAT; RESISTANCE; OXIDATION; GLUCOSE;
   MICE; QUANTIFICATION; HOMEOSTASIS; INHIBITION; METABOLISM
AB Objective. By specific knockout of carnitine palmitoyl transferase 1b (CPT1b) in skeletal muscles, we explored the effect of CPT1b deficiency on lipids and insulin sensitivity. Methods. Mice with specific knockout of CPT1b in skeletal muscles (CPT1b M-/-) were used for the experiment group, with littermate C57BL/6 as controls (CPT1b). General and metabolic profiles were measured and compared between groups. mRNA expression and CPT1 activity were measured in skeletal muscle tissues and compared between groups. Mitochondrial fatty acid oxidation (FAO), triglycerides (TAGs), diglycerides (DAGs), and ceramides were examined in skeletal muscles in two groups. Phosphorylated AKT (pAkt) and glucose transporter 4 (Glut4) were determined with real-time polymerase chain reaction (RT-PCR). Insulin tolerance test, glucose tolerance test, and pyruvate oxidation were performed in both groups. Results. CPT1b M-/- model was successfully established, with impaired muscle CPT1 activity. Compared with CPT1b mice, CPT1b M-/- mice had similar food intake but lower body weight or fat mass and higher lipids but similar glucose or insulin levels. Their mitochondrial FAO of skeletal muscles was impaired. There were lipids accumulations (TAGs, DAGs, and ceramides) in skeletal muscle. However, pAkt and Glut4, insulin sensitivity, glucose tolerance, and pyruvate oxidation were preserved. Conclusion. Skeletal muscle-specific CPT1 deficiency elevates lipotoxic intermediates but preserves insulin sensitivity.
C1 [Shi, Wanchun; Wang, Wenhua; Zhou, Xiaohui; Qiu, Wei] Huzhou Cent Hosp, Dept Endocrinol, Hangzhou 313000, Zhejiang, Peoples R China.
   [Hu, Siping] Huzhou Cent Hosp, Dept Anesthesiol, Hangzhou 313000, Zhejiang, Peoples R China.
RP Qiu, W (reprint author), Huzhou Cent Hosp, Dept Endocrinol, Hangzhou 313000, Zhejiang, Peoples R China.
EM dr.wei.qiu@outlook.com
CR Auinger A, 2013, BRIT J NUTR, V109, P810, DOI 10.1017/S0007114512002656
   BONORA E, 1987, DIABETES METAB, V13, P116
   Bruce CR, 2009, DIABETES, V58, P550, DOI 10.2337/db08-1078
   Dobbins RL, 2001, DIABETES, V50, P123, DOI 10.2337/diabetes.50.1.123
   Dragano NRV, 2013, BRIT J NUTR, V110, P447, DOI 10.1017/S0007114512005090
   Gostissa M, 2013, P NATL ACAD SCI USA, V110, P2934, DOI 10.1073/pnas.1222570110
   He L, 2012, CIRCULATION, V126, P1705, DOI 10.1161/CIRCULATIONAHA.111.075978
   Hojlund K, 2008, ENDOCRIN METAB CLIN, V37, P713, DOI 10.1016/j.ecl.2008.06.006
   Ji S, 2008, MOL GENET METAB, V93, P314, DOI 10.1016/j.ymgme.2007.10.006
   Ka S, 2013, PHYSIOL GENOMICS, V45, P367, DOI 10.1152/physiolgenomics.00078.2012
   Kerner J, 2004, J BIOL CHEM, V279, P41104, DOI 10.1074/jbc.M406570200
   Keung W, 2013, DIABETES, V62, P711, DOI 10.2337/db12-0259
   Krssak M, 1999, DIABETOLOGIA, V42, P113, DOI 10.1007/s001250051123
   Kumashiro N, 2013, DIABETES, V62, P2183, DOI 10.2337/db12-1311
   Lanza IR, 2013, AM J PHYSIOL-ENDOC M, V304, pE1391, DOI 10.1152/ajpendo.00584.2012
   Lawrence JC, 2011, OBESITY, V19, P43, DOI 10.1038/oby.2010.148
   Leskinen H, 2007, RAPID COMMUN MASS SP, V21, P2361, DOI 10.1002/rcm.3090
   Madsen KL, 2013, J CLIN ENDOCR METAB, V98, P1667, DOI 10.1210/jc.2012-3791
   Marcelino H, 2013, DIABETES, V62, P362, DOI 10.2337/db12-0255
   Martins AR, 2012, LIPIDS HEALTH DIS, V11, DOI 10.1186/1476-511X-11-30
   Miljkovic I, 2009, OBESITY, V17, P1396, DOI 10.1038/oby.2008.677
   Muoio DM, 2012, DIABETOLOGIA, V55, P2551, DOI 10.1007/s00125-012-2597-y
   Nowotny B, 2013, DIABETES, V62, P2240, DOI 10.2337/db12-1179
   Sahle FF, 2012, J PHARMACEUT BIOMED, V60, P7, DOI 10.1016/j.jpba.2011.10.032
   Shailendra A., 2013, J GASTROEN HEPATOL, V28, P1403
   Srikanthan P, 2012, MAGN RESON INSIGHTS, V5, P29, DOI 10.4137/MRI.S10489
   Szendroedi J, 2012, NAT REV ENDOCRINOL, V8, P92, DOI 10.1038/nrendo.2011.138
   Turner N, 2013, DIABETOLOGIA, V56, P1638, DOI 10.1007/s00125-013-2913-1
   Ukropcova B, 2005, J CLIN INVEST, V115, P1934, DOI 10.1172/JCI24332
   van de Weijer T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0051648
   Wang S, 2009, INT J OBESITY, V33, P481, DOI 10.1038/ijo.2008.277
   Wang SY, 2011, METABOLISM, V60, P1090, DOI 10.1016/j.metabol.2010.12.001
   Yang WY, 2010, NEW ENGL J MED, V362, P1090, DOI 10.1056/NEJMoa0908292
   Yoon SA, 2013, BIOCHEM BIOPH RES CO, V432, P553, DOI 10.1016/j.bbrc.2013.02.067
   Zhang LY, 2010, BBA-MOL CELL BIOL L, V1801, P1, DOI 10.1016/j.bbalip.2009.09.014
   Zhao ZW, 2011, ALCOHOL CLIN EXP RES, V35, P229, DOI 10.1111/j.1530-0277.2010.01338.x
   Zheng RM, 2013, P NATL ACAD SCI USA, V110, pE1631, DOI 10.1073/pnas.1219542110
   Zielke HR, 2007, J NEUROSCI RES, V85, P3145, DOI 10.1002/jnr.21424
NR 38
TC 5
Z9 5
U1 3
U2 16
PU HINDAWI PUBLISHING CORPORATION
PI NEW YORK
PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA
SN 2314-6745
EI 2314-6753
J9 J DIABETES RES
JI J. Diabetes Res.
PY 2013
AR 163062
DI 10.1155/2013/163062
PG 7
WC Endocrinology & Metabolism; Medicine, Research & Experimental
SC Endocrinology & Metabolism; Research & Experimental Medicine
GA 256SY
UT WOS:000327335400001
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Zhang, XH
   Xu, MM
   Liu, XG
   Zhang, F
   Wei, Y
   Meng, S
   Dai, XH
   Duan, AZ
   Deng, XL
AF Zhang, Xuehui
   Xu, Mingming
   Liu, Xinggang
   Zhang, Feng
   Wei, Yan
   Meng, Song
   Dai, Xiaohan
   Duan, Aizhu
   Deng, Xuliang
TI RETRACTED: Restoration of Critical-Sized Defects in the Rabbit Mandible
   Using Autologous Bone Marrow Stromal Cells Hybridized with
   Nano-beta-tricalcium Phosphate/Collagen Scaffolds (Retracted article.
   See pg. 37312, 2015)
SO JOURNAL OF NANOMATERIALS
LA English
DT Article; Retracted Publication
ID CALCIUM-PHOSPHATE; COMPOSITE SCAFFOLDS; CANCELLOUS BONE; IN-VIVO;
   TISSUE; HYDROXYAPATITE; REGENERATION; REPAIR; BIOCOMPATIBILITY;
   OSTEOGENESIS
AB Nano-beta-tricalcium phosphate/collagen (n-beta-TCP/Col) is considered with good osteoconductivity. However, the therapeutic effectiveness of n-beta-TCP/Col scaffolds in combination with autologous bone marrow stromal cells (BMSCs) remains to be elucidated for the repair of critical-sized bone defects. In this study, we found that n-beta-TCP/Col scaffolds exhibited high biocompatibility in vitro. The introduction of BMSCs expanded in vitro to the scaffolds dramatically enhanced their efficiency to restore critical-sized bone defects, especially during the initial stage after implantation. Collectively, these results suggest that autologous BMSCs in n-beta-TCP/Col scaffolds have the potential to be applied in bone tissue engineering.
C1 [Zhang, Xuehui; Xu, Mingming; Liu, Xinggang; Wei, Yan; Meng, Song; Dai, Xiaohan; Duan, Aizhu; Deng, Xuliang] Peking Univ Sch & Hosp Stomatol, Dept Geriatr Dent, Beijing 100081, Peoples R China.
   [Zhang, Xuehui] Tsinghua Univ, Dept Mat Sci & Engn, State Key Lab New Ceram & Fine Proc, Beijing 100084, Peoples R China.
   [Zhang, Feng] 2nd Hosp Beijing Armed Police Force, Oral Clin, Beijing 100037, Peoples R China.
   [Deng, Xuliang] Natl Engn Lab Digital & Mat Technol Stomatol, Beijing 100081, Peoples R China.
RP Deng, XL (reprint author), Peking Univ Sch & Hosp Stomatol, Dept Geriatr Dent, Beijing 100081, Peoples R China.
EM kqdengxuliang@bjmu.edu.cn
RI Wei, Yen/H-5329-2012
FU National Basic Research Program of China [2012CB933900]; Beijing
   Municipal Science and Technology Commission [Z121100005212007]; National
   Natural Science Foundation of China [81171000]; National High Technology
   Research and Development Program of China [2012AA022501]; Peking
   University-Tsinghua University Joint Center for Life Sciences
FX This work was supported by the National Basic Research Program of China
   (2012CB933900), Beijing Municipal Science and Technology Commission
   (Z121100005212007), the National Natural Science Foundation of China
   (81171000), and the National High Technology Research and Development
   Program of China (2012AA022501). Additionally, the authors also would
   like to acknowledge the support of the Peking University-Tsinghua
   University Joint Center for Life Sciences.
CR Beckman M. J., 2004, ENCY BIOMATERIALS BI, P324
   Brkovic BMB, 2012, CLIN ORAL INVEST, V16, P581, DOI 10.1007/s00784-011-0531-1
   Bruder SP, 1999, CLIN ORTHOP RELAT R, pS68
   Chen KY, 2013, J TISSUE ENG REGEN M, V7, P708, DOI 10.1002/term.1461
   Dong JA, 2002, BIOMATERIALS, V23, P4493, DOI 10.1016/S0142-9612(02)00193-X
   Guo H, 2009, ACTA BIOMATER, V5, P268, DOI 10.1016/j.actbio.2008.07.018
   Hollinger J O, 1990, J Craniofac Surg, V1, P60, DOI 10.1097/00001665-199001000-00011
   Hollister SJ, 2005, NAT MATER, V4, P518, DOI 10.1038/nmat1421
   Hutmacher DW, 2000, BIOMATERIALS, V21, P2529, DOI 10.1016/S0142-9612(00)00121-6
   Kikuchi M, 2004, BIOMATERIALS, V25, P5979, DOI 10.1016/j.biomaterials.2004.02.001
   Kim HW, 2005, BIOMATERIALS, V26, P5221, DOI 10.1016/j.biomaterials.2005.01.047
   Kruyt MC, 2006, TISSUE ENG, V12, P309, DOI 10.1089/ten.2006.12.309
   Kurashina K, 1997, BIOMATERIALS, V18, P147, DOI 10.1016/S0142-9612(96)00173-1
   Kurashina K, 2002, BIOMATERIALS, V23, P407, DOI 10.1016/S0142-9612(01)00119-3
   Li YB, 2003, J MATER SCI LETT, V22, P1015, DOI 10.1023/A:1024741426069
   Liu GP, 2008, J MATER SCI-MATER M, V19, P2367, DOI 10.1007/s10856-007-3348-3
   Liu T, 2013, BONE, V56, P110, DOI 10.1016/j.bone.2013.05.017
   Liu XH, 2004, ANN BIOMED ENG, V32, P477, DOI 10.1023/B:ABME.0000017544.36001.8e
   Liu YL, 2010, J R SOC INTERFACE, V7, pS631, DOI 10.1098/rsif.2010.0115.focus
   Mankani MH, 2006, STEM CELLS, V24, P2140, DOI 10.1634/stemcells.2005-0567
   Marom R, 2005, J CELL PHYSIOL, V202, P41, DOI 10.1002/jcp.20109
   Mate-Sanchez de Val J. E., J BIOMEDI A IN PRESS
   Matsuno T, 2006, DENT MATER J, V25, P138, DOI 10.4012/dmj.25.138
   Minamide A, 2005, SPINE, V30, P1134, DOI 10.1097/01.brs.0000162394.75425.04
   Nishikawa M, 2004, CELL TRANSPLANT, V13, P367, DOI 10.3727/000000004783983819
   Salgado AJ, 2004, MACROMOL BIOSCI, V4, P743, DOI 10.1002/mabi.200400026
   Sawada Y, 2011, J BIOMED MATER RES B, V98B, P217, DOI 10.1002/jbm.b.31783
   Stucki U, 2001, CLIN ORAL IMPLAN RES, V12, P121, DOI 10.1034/j.1600-0501.2001.012002121.x
   Wang HN, 2007, BIOMATERIALS, V28, P3338, DOI 10.1016/j.biomaterials.2007.04.014
   Wei GB, 2004, BIOMATERIALS, V25, P4749, DOI 10.1016/j.biomaterials.2003.12.005
   Xu HHK, 2005, BIOMATERIALS, V26, P1337, DOI 10.1016/j.biomaterials.2004.04.043
   Yuan J, 2007, BIOMATERIALS, V28, P1005, DOI 10.1016/j.biomaterials.2006.10.015
   Zhang X, 2012, INT J ORAL MAX SURG, V41, P1330, DOI 10.1016/j.ijom.2012.05.014
   Zou C, 2005, BIOMATERIALS, V26, P5276, DOI 10.1016/j.biomaterials.2005.01.064
NR 34
TC 2
Z9 2
U1 2
U2 19
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1687-4110
EI 1687-4129
J9 J NANOMATER
JI J. Nanomater.
PY 2013
AR 913438
DI 10.1155/2013/913438
PG 8
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
SC Science & Technology - Other Topics; Materials Science
GA 254XJ
UT WOS:000327202500001
OA DOAJ Gold
DA 2018-12-27
ER

PT J
AU Bai, RX
   Zhang, HK
   Mei, FM
   Wang, S
   Li, T
   Gu, YL
   Li, GX
AF Bai, Rongxian
   Zhang, Hongkun
   Mei, Fuming
   Wang, Shu
   Li, Tao
   Gu, Yanlong
   Li, Guangxing
TI RETRACTED: One-pot synthesis of glycidol from glycerol and dimethyl
   carbonate over a highly efficient and easily available solid catalyst
   NaAlO2 (Retracted article. See vol. 18, pg. 6144, 2016)
SO GREEN CHEMISTRY
LA English
DT Article; Retracted Publication
ID BASE CATALYST; SODIUM ALUMINATE; SOYBEAN OIL; TRANSESTERIFICATION;
   BIODIESEL; CHEMICALS; BIOMASS; OXIDE; UREA
AB The one-pot synthesis of glycidol from glycerol and dimethyl carbonate (DMC) was developed by using a solid base catalyst. A series of solid base catalysts have been investigated in this reaction. It was found that NaAlO2, a cheap and easily available raw material, was a highly efficient heterogeneous catalyst for the one-pot synthesis of glycidol, and it can be easily recovered and reused. Under the reaction conditions of a DMC glycerol molar ratio of 2, catalyst glycerol weight ratio of 3%, reaction time of 90 min, and temperature of 80-92 degrees C, the conversion of glycerol and the selectivity to glycidol reached 94.7% and 80.7%, respectively. Activity tests of the catalyst after exposure to the air showed that, to a certain extent, the NaAlO2 catalyst is tolerant to water and carbon dioxide, which makes the present system a practically interesting process for glycidol synthesis.
C1 [Bai, Rongxian; Zhang, Hongkun; Mei, Fuming; Wang, Shu; Li, Tao; Gu, Yanlong; Li, Guangxing] Huazhong Univ Sci & Technol, Hubei Key Lab Mat Chem & Serv Failure, Key Lab Large Format Battery Mat & Syst, Minist Educ,Sch Chem & Chem Engn, Wuhan 430074, Peoples R China.
   [Gu, Yanlong] Chinese Acad Sci, Lanzhou Inst Chem Phys, State Key Lab Oxo Synth & Select Oxidat, Lanzhou 730000, Peoples R China.
RP Gu, YL (reprint author), Huazhong Univ Sci & Technol, Hubei Key Lab Mat Chem & Serv Failure, Key Lab Large Format Battery Mat & Syst, Minist Educ,Sch Chem & Chem Engn, 1037 Luoyu Rd, Wuhan 430074, Peoples R China.
EM klgyl@hust.edu.cn; ligxabc@163.com
FU National Natural Science Foundation of China [21173089]
FX The authors thank the Analytical and Testing Centre, Huazhong University
   of Science and Technology, China for the characterization analysis. The
   authors thank for National Natural Science Foundation of China for the
   financial support (21173089). Chutian Scholar Program of the Hubei
   provincial government and the Cooperative Innovation Center of Catalysts
   Materials of Hubei Province are also acknowledged.
CR Bai RX, 2013, FUEL PROCESS TECHNOL, V106, P209, DOI 10.1016/j.fuproc.2012.07.027
   Bancquart S, 2001, APPL CATAL A-GEN, V218, P1, DOI 10.1016/S0926-860X(01)00579-8
   Behr A, 2008, GREEN CHEM, V10, P13, DOI 10.1039/b710561d
   Bolivar-Diaz CL, 2013, APPL CATAL B-ENVIRON, V129, P575, DOI 10.1016/j.apcatb.2012.10.004
   CARDILLO P, 1991, J LOSS PREVENT PROC, V4, P242, DOI 10.1016/0950-4230(91)85007-G
   Claude S., 2000, U.S. Patent, Patent No. [6,025,504, 6025504]
   Climent MJ, 2010, J CATAL, V269, P140, DOI 10.1016/j.jcat.2009.11.001
   Contreras C, 2006, ADV TECHNOL MAT MAT, V8, P122, DOI DOI 10.2240/AZ0J0M00220
   Corma A, 2007, CHEM REV, V107, P2411, DOI 10.1021/cr050989d
   Gade SM, 2012, CATAL COMMUN, V27, P184, DOI 10.1016/j.catcom.2012.07.003
   HANSON RM, 1991, CHEM REV, V91, P437, DOI 10.1021/cr00004a001
   Juben N. C., 2007, ANGEW CHEM INT EDIT, V46, P7164
   Kouzu M, 2008, APPL CATAL A-GEN, V334, P357, DOI 10.1016/j.apcata.2007.10.023
   [刘学民 LIU Xuemin], 2009, [化工进展, Chemical Industry and Engineering Progress], V28, P1445
   Granados ML, 2009, APPL CATAL B-ENVIRON, V89, P265, DOI 10.1016/j.apcatb.2009.02.014
   Malkemus J., 1953, U5, Patent No. 2856413
   Mutreja V, 2012, J OLEO SCI, V61, P665, DOI 10.5650/jos.61.665
   Ochoa-Gomez JR, 2012, GREEN CHEM, V14, P3368, DOI 10.1039/c2gc35992h
   Ochoa-Gomez JR, 2012, ORG PROCESS RES DEV, V16, P389, DOI 10.1021/op200369v
   Ochoa-Gomez JR, 2009, APPL CATAL A-GEN, V366, P315, DOI 10.1016/j.apcata.2009.07.020
   Oliveira LCA, 2012, APPL CATAL B-ENVIRON, V117, P29, DOI 10.1016/j.apcatb.2011.12.043
   Pagliaro M, 2007, ANGEW CHEM INT EDIT, V46, P4434, DOI 10.1002/anie.200604694
   Pagliaro M, 2008, RSC GREEN CHEM SER, P1
   Palomo JM, 2005, TETRAHEDRON-ASYMMETR, V16, P869, DOI 10.1016/j.tetasy.2004.12.027
   Rokicki G, 2005, GREEN CHEM, V7, P529, DOI 10.1039/b501597a
   Madronero CVR, 2010, ING INVEST, V30, P16
   Uno M., 2011, U.S. Patent, Patent No. [7,888,517 B2, 7888517]
   Valange S, 2007, J CATAL, V251, P113, DOI 10.1016/j.jcat.2007.07.004
   Viola E, 2012, CATAL TODAY, V179, P185, DOI 10.1016/j.cattod.2011.08.050
   Wan T, 2009, ENERG FUEL, V23, P1089, DOI 10.1021/ef800904b
   Wang LG, 2011, CATAL COMMUN, V12, P1458, DOI 10.1016/j.catcom.2011.05.027
   Wu P, 2003, J CATAL, V214, P317, DOI 10.1016/S0021-9517(02)00170-7
NR 32
TC 27
Z9 27
U1 5
U2 89
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1463-9262
EI 1463-9270
J9 GREEN CHEM
JI Green Chem.
PY 2013
VL 15
IS 10
BP 2929
EP 2934
DI 10.1039/c3gc40855h
PG 6
WC Chemistry, Multidisciplinary; GREEN & SUSTAINABLE SCIENCE & TECHNOLOGY
SC Chemistry; Science & Technology - Other Topics
GA 233TY
UT WOS:000325593600038
DA 2018-12-27
ER

PT J
AU Guo, J
   Dai, BX
AF Guo, Jia
   Dai, Bin-Xiang
TI RETRACTED: Three Homoclinic Solutions for Second-Order p-Laplacian
   Differential System (Retracted article. See 798572, 2014)
SO ABSTRACT AND APPLIED ANALYSIS
LA English
DT Article; Retracted Publication
ID BOUNDARY-VALUE-PROBLEMS; CRITICAL-POINTS THEOREM; HAMILTONIAN-SYSTEMS;
   VARIATIONAL-METHODS; POSITIVE SOLUTIONS; ORBITS; POTENTIALS; EXISTENCE
AB We consider second-order p-Laplacian differential system. By using three critical points theorem, we establish the new criterion to guarantee that this p-Laplacian differential system has at least three homoclinic solutions. An example is presented to illustrate the main result.
C1 [Guo, Jia; Dai, Bin-Xiang] Cent S Univ, Sch Math & Stat, Changsha 410075, Hunan, Peoples R China.
RP Dai, BX (reprint author), Cent S Univ, Sch Math & Stat, Changsha 410075, Hunan, Peoples R China.
EM bxdai@csu.edu.cn
FU National Natural Science Foundation of China [11271371, 10971229]
FX This work is supported by the National Natural Science Foundation of
   China (nos. 11271371 and 10971229).
CR Afrouzi GA, 2008, NONLINEAR ANAL-THEOR, V69, P3330, DOI 10.1016/j.na.2007.09.022
   Bai L, 2011, APPL MATH COMPUT, V217, P9895, DOI 10.1016/j.amc.2011.03.097
   Bonanno G, 2003, NONLINEAR ANAL-THEOR, V54, P1, DOI 10.1016/S0362-546X(03)00027-0
   Bonanno G, 2009, APPL MATH COMPUT, V210, P294, DOI 10.1016/j.amc.2008.12.081
   Daouas A., 2010, NONLINEAR DYNAMICS S, V10, P339
   Daouas A, 2011, NONLINEAR ANAL-THEOR, V74, P3407, DOI 10.1016/j.na.2011.03.001
   Du ZJ, 2008, APPL MATH COMPUT, V205, P231, DOI 10.1016/j.amc.2008.07.011
   He TS, 2010, J COMPUT APPL MATH, V233, P2506, DOI 10.1016/j.cam.2009.10.032
   Izydorek M, 2005, J DIFFER EQUATIONS, V219, P375, DOI 10.1016/j.jde.2005.06.029
   Lv X, 2010, NONLINEAR ANAL-THEOR, V72, P390, DOI 10.1016/j.na.2009.06.073
   Mawhin J, 1989, APPL MATH SCI
   Ou ZQ, 2004, J MATH ANAL APPL, V291, P203, DOI 10.1016/j.jmaa.2003.10.026
   Ricceri B, 2000, MATH COMPUT MODEL, V32, P1485, DOI 10.1016/S0895-7177(00)00220-X
   Ricceri B, 2000, ARCH MATH, V75, P220, DOI 10.1007/s000130050496
   Simon J., 1978, LECT NOTES MATH, P205
   Tang XH, 2011, NONLINEAR ANAL-THEOR, V74, P6314, DOI 10.1016/j.na.2011.06.010
   Tang XH, 2009, NONLINEAR ANAL-THEOR, V71, P1140, DOI 10.1016/j.na.2008.11.038
   Tian Y, 2008, P EDINBURGH MATH SOC, V51, P509, DOI 10.1017/S0013091506001532
   Tian Y, 2008, ROCKY MT J MATH, V38, P309, DOI 10.1216/RMJ-2008-38-1-309
   Tian Y, 2009, ROCKY MT J MATH, V39, P325, DOI 10.1216/RMJ-2009-39-1-325
   Wan LL, 2010, ACTA MATH SCI, V30, P312
   Wei JC, 2010, J MATH ANAL APPL, V366, P694, DOI 10.1016/j.jmaa.2009.12.024
   Wu DL, 2010, J MATH ANAL APPL, V367, P154, DOI 10.1016/j.jmaa.2009.12.046
   Yang J, 2009, NONLINEAR ANAL-REAL, V10, P1417, DOI 10.1016/j.nonrwa.2008.01.013
   Yang JB, 2009, APPL MATH COMPUT, V214, P424, DOI 10.1016/j.amc.2009.04.008
   Yang L, 2011, NONLINEAR ANAL-THEOR, V74, P6459, DOI 10.1016/j.na.2011.06.029
   Yang MH, 2011, NONLINEAR ANAL-THEOR, V74, P2635, DOI 10.1016/j.na.2010.12.019
   Zhang QY, 2010, NONLINEAR ANAL-THEOR, V72, P894, DOI 10.1016/j.na.2009.07.021
   Zhang ZH, 2010, NONLINEAR ANAL-THEOR, V72, P1809, DOI 10.1016/j.na.2009.09.022
NR 29
TC 1
Z9 1
U1 3
U2 18
PU HINDAWI PUBLISHING CORPORATION
PI NEW YORK
PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA
SN 1085-3375
EI 1687-0409
J9 ABSTR APPL ANAL
JI Abstract Appl. Anal.
PY 2013
AR 183585
DI 10.1155/2013/183585
PG 10
WC Mathematics, Applied; Mathematics
SC Mathematics
GA 225DF
UT WOS:000324941900001
OA DOAJ Gold
DA 2018-12-27
ER

PT J
AU Zhou, ZH
   Wang, CX
   Liu, HB
   Huang, QH
   Wang, M
   Lei, YX
AF Zhou, Zhiheng
   Wang, Caixia
   Liu, Haibai
   Huang, Qinhai
   Wang, Min
   Lei, Yixiong
TI RETRACTED: Cadmium Induced Cell Apoptosis, DNA Damage, Decreased DNA
   Repair Capacity, and Genomic Instability during Malignant Transformation
   of Human Bronchial Epithelial Cells (Retracted article. See vol. 11, pg.
   246, 2014)
SO INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
LA English
DT Article; Retracted Publication
DE Cadmium chloride; DNA damage; DNA repair genes; genomic instability
ID TESTICULAR LEYDIG-CELLS; ENVIRONMENTAL CADMIUM; RAT; EXPOSURE; CHLORIDE;
   CARCINOGENESIS; PROSTATE; HEPATOTOXICITY; PROLIFERATION; CANCER
AB Cadmium and its compounds are well-known human carcinogens, but the mechanisms underlying the carcinogenesis are not entirely understood. Our study was designed to elucidate the mechanisms of DNA damage in cadmium-induced malignant transformation of human bronchial epithelial cells. We analyzed cell cycle, apoptosis, DNA damage, gene expression, genomic instability, and the sequence of exons in DNA repair genes in several kinds of cells. These cells consisted of untreated control cells, cells in the fifth, 15th, and 35th passage of cadmium-treated cells, and tumorigenic cells from nude mice using flow cytometry, Hoechst 33258 staining, comet assay, quantitative real-time polymerase chain reaction (PCR), Western blot analysis, random amplified polymorphic DNA (RAPD)-PCR, and sequence analysis. We observed a progressive increase in cell population of the G0/G1 phase of the cell cycle and the rate of apoptosis, DNA damage, and cadmium-induced apoptotic morphological changes in cerebral cortical neurons during malignant transformation. Gene expression analysis revealed increased expression of cell proliferation (PCNA), cell cycle (CyclinD1), pro-apoptotic activity (Bax), and DNA damage of the checkpoint genes ATM, ATR, Chk1, Chk2, Cdc25A. Decreased expression of the anti-apoptotic gene Bcl-2 and the DNA repair genes hMSH2, hMLH1, ERCC1, ERCC2, and hOGG1 was observed. RAPD-PCR revealed genomic instability in cadmium-exposed cells, and sequence analysis showed mutation of exons in hMSH2, ERCC1, XRCC1, and hOGG1 in tumorigenic cells. This study suggests that Cadmium can increase cell apoptosis and DNA damage, decrease DNA repair capacity, and cause mutations, and genomic instability leading to malignant transformation. This process could be a viable mechanism for cadmium-induced cancers.
C1 [Zhou, Zhiheng; Liu, Haibai; Huang, Qinhai; Wang, Min; Lei, Yixiong] Guangzhou Med Univ, Sch Publ Hlth, Guangzhou 510182, Guangdong, Peoples R China.
   [Wang, Caixia] Guangzhou Med Univ, Guangzhou Peoples Hosp 1, Dept Internal Med, Guangzhou 510180, Guangdong, Peoples R China.
RP Lei, YX (reprint author), Guangzhou Med Univ, Sch Publ Hlth, 195 Dongfengxi Rd, Guangzhou 510182, Guangdong, Peoples R China.
EM gz-leizeng@163.com
FU National Natural Science Foundation of China [81202236, 81072322];
   Science and Technology Planning Project of Guangdong Municipality, China
   [2013J410037]
FX This work was supported by the National Natural Science Foundation of
   China (81202236 Zhou, Z.H; 81072322 to Lei, Y.X) and the Science and
   Technology Planning Project of Guangdong Municipality, China
   (2013J410037).
CR Achanzar WE, 2001, CANCER RES, V61, P455
   Andrighetti-Frohner CR, 2006, MUTAT RES-GEN TOX EN, V603, P97, DOI 10.1016/j.mrgentox.2005.11.001
   Arriazu R, 2005, PROSTATE, V63, P347, DOI 10.1002/pros.20192
   *ATSDR, 1997, TOX PROF CA IN PRESS
   Bialkowski K, 1999, CARCINOGENESIS, V20, P1621, DOI 10.1093/carcin/20.8.1621
   Bjerregaard HF, 2007, ATLA-ALTERN LAB ANIM, V35, P343
   Blottner S, 1999, REPROD TOXICOL, V13, P261, DOI 10.1016/S0890-6238(99)00014-3
   Brama M, 2007, MOL CELL ENDOCRINOL, V264, P102, DOI 10.1016/j.mce.2006.10.013
   Cao F, 2007, TOXICOL APPL PHARM, V218, P174, DOI 10.1016/j.taap.2006.10.031
   Fang MZ, 2002, TOXICOLOGY, V177, P253, DOI 10.1016/S0300-483X(02)00229-9
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/j.cell.2011.02.013
   Harstad EB, 2002, TOXICOL APPL PHARM, V179, P155, DOI 10.1006/taap.2001.9362
   Hossain S, 2009, NEUROTOXICOLOGY, V30, P544, DOI 10.1016/j.neuro.2009.06.001
   IARC, 1993, BER CADM MERC EXP GL, P119
   Jin YH, 2003, NAT GENET, V34, P326, DOI 10.1038/ng1172
   Koyu A., 2006, MOL CELL BIOCHEM, V20, P1
   Krumschnabel G, 2010, AQUAT TOXICOL, V99, P73, DOI 10.1016/j.aquatox.2010.04.005
   Lei YX, 2008, BIOMED ENVIRON SCI, V21, P332, DOI 10.1016/S0895-3988(08)60051-3
   Lin YF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046807
   MANCA D, 1991, TOXICOLOGY, V67, P303, DOI 10.1016/0300-483X(91)90030-5
   Migliarini B, 2005, GEN COMP ENDOCR, V142, P241, DOI 10.1016/j.ygcen.2004.12.012
   Mikhailova MV, 1997, CANCER LETT, V115, P141, DOI 10.1016/S0304-3835(97)04720-4
   Misra UK, 2002, CELL SIGNAL, V14, P327, DOI 10.1016/S0898-6568(01)00268-6
   Nordberg G, 2002, AMBIO, V31, P478, DOI 10.1639/0044-7447(2002)031[0478:LBDARD]2.0.CO;2
   Nordberg M, 1992, IARC Sci Publ, P293
   Saidi SA, 2013, EXP TOXICOL PATHOL, V65, P1025, DOI 10.1016/j.etp.2013.03.001
   Satarug S, 2003, TOXICOL LETT, V137, P65, DOI 10.1016/S0378-4274(02)00381-8
   Schopfer J, 2010, BIOL TRACE ELEM RES, V134, P180, DOI 10.1007/s12011-010-8636-y
   Sens DA, 2004, TOXICOL SCI, V79, P56, DOI 10.1093/toxsci/kfh086
   Sheng Jian Qiu, 2006, Chin J Dig Dis, V7, P197, DOI 10.1111/j.1443-9573.2006.00269.x
   Sieber OM, 2003, NAT REV CANCER, V3, P701, DOI 10.1038/nrc1170
   Singh KP, 2008, GENE, V408, P18, DOI 10.1016/j.gene.2007.10.022
   Singh KP, 2007, INT J ONCOL, V30, P253
   Singh KP, 2009, CANCER LETT, V279, P84, DOI 10.1016/j.canlet.2009.01.023
   Slebos RJC, 2006, MUTAT RES-FUND MOL M, V602, P92, DOI 10.1016/j.mrfmmm.2006.08.003
   Swaddiwudhipong Witaya, 2010, Journal of the Medical Association of Thailand, V93, P1217
   TERRACIO L, 1988, ARCH TOXICOL, V61, P450, DOI 10.1007/BF00293691
   Thevenod F, 2000, J BIOL CHEM, V275, P1887, DOI 10.1074/jbc.275.3.1887
   Tzirogiannis KN, 2003, ARCH TOXICOL, V77, P694, DOI 10.1007/s00204-003-0499-y
   Waalkes MP, 2003, MUTAT RES-FUND MOL M, V533, P107, DOI 10.1016/j.mrfmmm.2003.07.011
   Wei WQ, 2011, BMB REP, V44, P317, DOI 10.5483/BMBRep.2011.44.5.317
   Xie JX, 2006, TOXICOL SCI, V91, P299, DOI 10.1093/toxsci/kfj131
   Xu CY, 1996, TOXICOLOGY, V107, P1, DOI 10.1016/0300-483X(95)03195-L
   Yuan Y, 2012, BIOMED ENVIRON SCI, V25, P172, DOI 10.3967/0895-3988.2012.02.008
NR 44
TC 22
Z9 27
U1 70
U2 95
PU IVYSPRING INT PUBL
PI LAKE HAVEN
PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
SN 1449-1907
J9 INT J MED SCI
JI Int. J. Med. Sci.
PY 2013
VL 10
IS 11
BP 1485
EP 1496
DI 10.7150/ijms.6308
PG 12
WC Medicine, General & Internal
SC General & Internal Medicine
GA 218DX
UT WOS:000324414100009
PM 24046522
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Ozdemir, O
   Erol, AYG
AF Ozdemir, Oner
   Erol, Azize Yasemin Goksu
TI RETRACTED: Preventative and Therapeutic Probiotic Use in Allergic Skin
   Conditions: Experimental and Clinical Findings (Retracted article. See
   965213, 2014)
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Review; Retracted Publication
ID PLACEBO-CONTROLLED TRIAL; LACTOBACILLUS-JOHNSONII NCC533; RANDOMIZED
   CONTROLLED-TRIAL; LACTIC-ACID BACTERIA; ATOPIC ECZEMA/DERMATITIS
   SYNDROME; ACIDOPHILUS STRAIN L-55; DENDRITIC CELL-FUNCTION; REGULATORY
   T-CELLS; 1ST 6 MONTHS; DOUBLE-BLIND
AB Probiotics are ingested live microbes that can modify intestinal microbial populations in a way that benefits the host. The interest in probiotic preventative/therapeutic potential in allergic diseases stemmed from the fact that probiotics have been shown to improve intestinal dysbiosis and permeability and to reduce inflammatory cytokines in human and murine experimental models. Enhanced presence of probiotic bacteria in the intestinal microbiota is found to correlate with protection against allergy. Therefore, many studies have been recently designed to examine the efficacy of probiotics, but the literature on the allergic skin disorders is still very scarce. Here, our objective is to summarize and evaluate the available knowledge from randomized or nonrandomized controlled trials of probiotic use in allergic skin conditions. Clinical improvement especially in IgE-sensitized eczema and experimental models such as atopic dermatitis-like lesions (trinitrochlorobenzene and picryl chloride sensitizations) and allergic contact dermatitis (dinitrofluorobenzene sensitization) has been reported. Although there is a very promising evidence to recommend the addition of probiotics into foods, probiotics do not have a proven role in the prevention or the therapy of allergic skin disorders. Thus, being aware of possible measures, such as probiotics use, to prevent/heal atopic diseases is essential for the practicing allergy specialist.
C1 [Ozdemir, Oner] Sakarya Univ, Fac Med, Res & Training Hosp, Dept Pediat,Div Allergy & Immunol, TR-54100 Adapazari, Sakarya, Turkey.
   [Erol, Azize Yasemin Goksu] Afyon Kocatepe Univ, Fac Med, Dept Histol & Embryol, TR-03200 Afyon, Turkey.
RP Ozdemir, O (reprint author), Sakarya Univ, Fac Med, Res & Training Hosp, Dept Pediat,Div Allergy & Immunol, Adnan Menderes Caddesi,Saglik Sokak 195, TR-54100 Adapazari, Sakarya, Turkey.
EM ozdemir_oner@hotmail.com
CR Abrahamsson TR, 2007, J ALLERGY CLIN IMMUN, V119, P1174, DOI 10.1016/j.jaci.2007.01.007
   Bermudez-Brito M, 2012, ANN NUTR METAB, V61, P160, DOI 10.1159/000342079
   Betsi GL, 2008, AM J CLIN DERMATOL, V9, P93, DOI 10.2165/00128071-200809020-00002
   Boguniewicz M, 2001, SEMIN CUTAN MED SURG, V20, P217, DOI 10.1053/sder.2001.29379
   Bottcher MF, 2008, PEDIAT ALLERG IMM-UK, V19, P497, DOI 10.1111/j.1399-3038.2007.00687.x
   Boyle RJ, 2011, ALLERGY, V66, P509, DOI 10.1111/j.1398-9995.2010.02507.x
   Boyle RJ, 2009, CLIN EXP ALLERGY, V39, P1117, DOI 10.1111/j.1365-2222.2009.03305.x
   Braat H, 2004, AM J CLIN NUTR, V80, P1618
   Brouwer ML, 2006, CLIN EXP ALLERGY, V36, P899, DOI 10.1111/j.1365-2222.2006.02513.x
   Cebra JJ, 1999, AM J CLIN NUTR, V69, p1046S, DOI 10.1093/ajcn/69.5.1046s
   Chapat L, 2004, EUR J IMMUNOL, V34, P2520, DOI 10.1002/eji.200425139
   Christensen HR, 2002, J IMMUNOL, V168, P171, DOI 10.4049/jimmunol.168.1.171
   Cukrowska B, 2001, IMMUNOBIOLOGY, V204, P425, DOI 10.1078/0171-2985-00052
   Darsow U, 2010, J EUR ACAD DERMATOL, V24, P317, DOI 10.1111/j.1468-3083.2009.03415.x
   Dotterud CK, 2010, BRIT J DERMATOL, V163, P616, DOI 10.1111/j.1365-2133.2010.09889.x
   Fiocchi A, 2012, WORLD ALLERGY ORGAN, V5, P148, DOI 10.1097/WOX.0b013e3182784ee0
   Folster-Holst R, 2006, BRIT J DERMATOL, V155, P1256, DOI 10.1111/j.1365-2133.2006.07558.x
   Food and Agriculture Organization and World Health Organization, 1012001 FAOWHO
   Fujimura T, 2008, BRIT J DERMATOL, V158, P1256, DOI 10.1111/j.1365-2133.2008.08504.x
   Gerasimov SV, 2010, AM J CLIN DERMATOL, V11, P351, DOI 10.2165/11531420-000000000-00000
   Goto K, 2011, J VET MED SCI, V73, P649, DOI 10.1292/jvms.10-0457
   Granato D, 2004, INFECT IMMUN, V72, P2160, DOI 10.1128/IAI.72.4.2160-2169.2004
   Gruber C, 2007, ALLERGY, V62, P1270, DOI 10.1111/j.1398-9995.2007.01543.x
   Gueniche A, 2006, EUR J DERMATOL, V16, P511, DOI 10.1684/ejd.2006.0023
   Hacini-Rachinel F, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004903
   Hart AL, 2004, GUT, V53, P1602, DOI 10.1136/gut.2003.037325
   Hattori Kazuhiro, 2003, Arerugi, V52, P20
   Hayashi A, 2009, J DAIRY RES, V76, P158, DOI 10.1017/S0022029908003725
   Hoang Ba X., 2010, Inflammation & Allergy Drug Targets, V9, P192
   Hoarau C, 2006, J ALLERGY CLIN IMMUN, V117, P696, DOI 10.1016/j.jaci.2005.10.043
   Huurre A, 2008, CLIN EXP ALLERGY, V38, P1342, DOI 10.1111/j.1365-2222.2008.03008.x
   Inoue R, 2007, BRIT J DERMATOL, V156, P499, DOI 10.1111/j.1365-2133.2006.07695.x
   Inoue R, 2007, FEMS IMMUNOL MED MIC, V50, P67, DOI 10.1111/j.1574-695X.2007.00233.x
   Isolauri E, 2001, AM J CLIN NUTR, V73, p444S, DOI 10.1093/ajcn/73.2.444s
   Isolauri E., 1996, NUTR TODAY S, V31, P285
   Isolauri E, 2002, CURR OPIN ALLERGY CL, V2, P263, DOI 10.1097/00130832-200206000-00018
   Jin HL, 2009, J INVEST DERMATOL, V129, P31, DOI 10.1038/jid.2008.106
   KAILA M, 1992, PEDIATR RES, V32, P141, DOI 10.1203/00006450-199208000-00002
   Kalliomaki M, 2007, J ALLERGY CLIN IMMUN, V119, P1019, DOI 10.1016/j.jaci.2006.12.608
   Kalliomaki M, 2010, J NUTR, V140, p713S, DOI [10.3946/jn.109.113761, 10.3945/jn.109.113761]
   Kim JY, 2013, J APPL MICROBIOL, V115, P517, DOI 10.1111/jam.12229
   Kim JY, 2010, PEDIAT ALLERG IMM-UK, V21, pE386, DOI 10.1111/j.1399-3038.2009.00958.x
   Kirjavainen PV, 2002, GUT, V51, P51, DOI 10.1136/gut.51.1.51
   Kirjavainen PV, 2003, J PEDIATR GASTR NUTR, V36, P223, DOI 10.1097/00005176-200302000-00012
   Kopp MV, 2008, PEDIATRICS, V121, pE850, DOI 10.1542/peds.2007-1492
   Kuitunen M, 2009, J ALLERGY CLIN IMMUN, V123, P335, DOI 10.1016/j.jaci.2008.11.019
   Kukkonen K, 2007, J ALLERGY CLIN IMMUN, V119, P192, DOI 10.1016/j.jaci.2006.09.009
   Kukkonen K, 2010, PEDIATR ALLERGY IMMU, V21, P67, DOI 10.1111/j.1399-3038.2009.00907.x
   Kwon HK, 2010, P NATL ACAD SCI USA, V107, P2159, DOI 10.1073/pnas.0904055107
   Lavasani S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009009
   Lodinova-Zadnikova R, 2003, INT ARCH ALLERGY IMM, V131, P209, DOI 10.1159/000071488
   Maassen CBM, 2000, VACCINE, V18, P2613, DOI 10.1016/S0264-410X(99)00378-3
   Majamaa H, 1997, J ALLERGY CLIN IMMUN, V99, P179, DOI 10.1016/S0091-6749(97)70093-9
   Marschan E, 2008, CLIN EXP ALLERGY, V38, P611, DOI 10.1111/j.1365-2222.2008.02942.x
   Marsella R, 2012, VET IMMUNOL IMMUNOP, V146, P185, DOI 10.1016/j.vetimm.2012.02.013
   Marsella R, 2009, AM J VET RES, V70, P735, DOI 10.2460/ajvr.70.6.735
   Matsumoto M, 2007, CLIN EXP ALLERGY, V37, P358, DOI 10.1111/j.1365-2222.2007.02642.x
   Metchnikoff E, 1907, PROLONGATION LIFE OP
   Moroi M, 2011, J DERMATOL, V38, P131, DOI 10.1111/j.1346-8138.2010.00939.x
   Niers L, 2009, ALLERGY, V64, P1349, DOI 10.1111/j.1398-9995.2009.02021.x
   Niers LEM, 2007, CLIN EXP IMMUNOL, V149, P344, DOI 10.1111/j.1365-2249.2007.03421.x
   Niers LEM, 2005, CLIN EXP ALLERGY, V35, P1481, DOI 10.1111/j.1365-2222.2005.02375.x
   Novak Natalija, 2003, Journal of Allergy and Clinical Immunology, V112, pS128, DOI 10.1016/j.jaci.2003.09.032
   Ogawa T, 2006, FEMS IMMUNOL MED MIC, V46, P400, DOI 10.1111/j.1574-695X.2006.00046.x
   Ozdemir O, 2010, CLIN EXP IMMUNOL, V160, P295, DOI 10.1111/j.1365-2249.2010.04109.x
   Ozdemir O, 2010, ALLERGY ASTHMA PROC, V31, P103, DOI 10.2500/aap.2010.31.3313
   Park CW, 2008, J MED FOOD, V11, P405, DOI 10.1089/jmf.2007.0144
   Pelucchi C, 2012, EPIDEMIOLOGY, V23, P402, DOI 10.1097/EDE.0b013e31824d5da2
   Pessi T, 2001, INT IMMUNOPHARMACOL, V1, P211, DOI 10.1016/S1567-5769(00)00018-7
   Pohjavuori E, 2004, J ALLERGY CLIN IMMUN, V114, P131, DOI 10.1016/j.jaci.2004.03.036
   Prescott SL, 2005, CLIN EXP ALLERGY, V35, P1557, DOI 10.1111/j.1365-2222.2005.02376.x
   Prescott SL, 2007, J ALLERGY CLIN IMMUN, V120, P255, DOI 10.1016/j.jaci.2007.04.027
   Rosenfeldt V, 2003, J ALLERGY CLIN IMMUN, V111, P389, DOI 10.1067/mai.2003.389
   Ruemmele FM, 2009, J PEDIATR GASTR NUTR, V48, P126, DOI 10.1097/MPG.0b013e31817d80ca
   Salfeld P, 2009, J ALLERGY CLIN IMMUN, V124, P170, DOI 10.1016/j.jaci.2009.02.038
   Salminen SJ, 2005, J NUTR, V135, P1294
   Sawada J, 2007, CLIN EXP ALLERGY, V37, P296, DOI 10.1111/j.1365-2222.2006.02645.x
   Segawa S, 2008, BIOL PHARM BULL, V31, P884, DOI 10.1248/bpb.31.884
   Shiohara T, 2004, J DERMATOL SCI, V36, P1, DOI 10.1016/j.jdermsci.2004.02.013
   Sistek D, 2006, CLIN EXP ALLERGY, V36, P629, DOI 10.1111/j.1365-2222.2006.02485.x
   Smits HH, 2005, J ALLERGY CLIN IMMUN, V115, P1260, DOI 10.1016/j.jaci.2005.03.036
   Soh SE, 2009, CLIN EXP ALLERGY, V39, P571, DOI 10.1111/j.1365-2222.2008.03133.x
   Sudo N, 1997, J IMMUNOL, V159, P1739
   Sunada Y, 2007, BIOL PHARM BULL, V30, P2163, DOI 10.1248/bpb.30.2163
   Sunada Y, 2008, INT IMMUNOPHARMACOL, V8, P1761, DOI 10.1016/j.intimp.2008.08.011
   Tanaka A, 2008, EUR J DERMATOL, V18, P136, DOI 10.1684/ejd.2008.0350
   Tanaka A, 2009, EXP DERMATOL, V18, P1022, DOI 10.1111/j.1600-0625.2009.00895.x
   Taylor AL, 2007, J ALLERGY CLIN IMMUN, V119, P184, DOI 10.1016/j.jaci.2006.08.036
   Thomas DJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016577
   Viljanen M, 2005, ALLERGY, V60, P494, DOI 10.1111/j.1398-9995.2004.00514.x
   Viljanen M, 2005, PEDIATR ALLERGY IMMU, V16, P65, DOI 10.1111/j.1399-3038.2005.00224.x
   Wakabayashi H, 2008, INT ARCH ALLERGY IMM, V145, P141, DOI 10.1159/000108139
   Walker WA, 2008, CLIN INFECT DIS, V46, pS87, DOI 10.1086/523335
   Watanabe T, 2009, J NUTR SCI VITAMINOL, V55, P271, DOI 10.3177/jnsv.55.271
   Weise C, 2011, EXP DERMATOL, V20, P805, DOI 10.1111/j.1600-0625.2011.01326.x
   West CE, 2009, PEDIATR ALLERGY IMMU, V20, P430, DOI 10.1111/j.1399-3038.2009.00745.x
   Weston S, 2005, ARCH DIS CHILD, V90, P892, DOI 10.1136/adc.2004.060673
   Wickens K, 2008, J ALLERGY CLIN IMMUN, V122, P788, DOI 10.1016/j.jaci.2008.07.011
   Won TJ, 2011, J APPL MICROBIOL, V110, P1195, DOI 10.1111/j.1365-2672.2011.04981.x
   Won TJ, 2012, CELL IMMUNOL, V277, P49, DOI 10.1016/j.cellimm.2012.05.013
   Woo SI, 2010, ANN ALLERG ASTHMA IM, V104, P343, DOI 10.1016/j.anai.2010.01.020
NR 101
TC 2
Z9 3
U1 2
U2 23
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314-6133
EI 2314-6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PY 2013
AR 932391
DI 10.1155/2013/932391
PG 17
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA 218FN
UT WOS:000324418300001
PM 24078929
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Talukdar, D
   Talukdar, T
AF Talukdar, Dibyendu
   Talukdar, Tulika
TI RETRACTED: Superoxide-Dismutase Deficient Mutants in Common Beans
   (Phaseolus vulgaris L.): Genetic Control, Differential Expressions of
   Isozymes, and Sensitivity to Arsenic (Retracted article. See 5705968,
   2016)
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Article; Retracted Publication
ID OXIDATIVE STRESS; REACTIVE OXYGEN; ROOT-GROWTH; ANTIOXIDANT METABOLISM;
   NULL MUTANTS; PLANTS; CADMIUM; ACCUMULATION; MUTATIONS; TOLERANCE
AB Two common bean (Phaseolus vulgaris L.) mutants, sodPv 1 and sodPv 2, exhibiting foliar superoxide dismutase (SOD) activity of only 25% and 40% of their mother control (MC) cv. VL 63 were isolated in EMS-mutagenized (0.15%, 8 h) M2 progeny. Native-PAGE analysis revealed occurrence of Mn SOD, Fe SOD, Cu/Zn SOD I and Cu/Zn SOD II isozymes in MC, while Fe SOD, and Mn SOD were not formed in sodPv 1 and sodPv 2 leaves, respectively. In-gel activity of individual isozymes differed significantly among the parents. SOD deficiency is inherited as recessive mutations, controlled by two different nonallelic loci. Gene expressions using qRT PCR confirmed higher expressions of Cu/Zn SOD transcripts in both mutants and the absence of Fe SOD in sodPv 1 and Mn SOD in sodPv 2. In 50 mu M arsenic, Cu/Zn SODs genes were further upregulated but other isoforms downregulated in the two mutants, maintaining SOD activity in its control level. In an F 2 double mutants of sodPv 1 x sodPv 2, no Fe SOD, and Mn SOD expressions were detectable, while both Cu/Zn SODs are down-regulated and arsenic-induced leaf necrosis appeared. In contrast to both mutants, ROS-imaging study revealed overaccumulation of both superoxides and H2O2 in leaves of double mutant.
C1 [Talukdar, Dibyendu] Univ Calcutta, Dept Bot, RPM Coll, Hooghly 712258, W Bengal, India.
   [Talukdar, Tulika] Univ Kalyani, Dept Bot, Krishnagar Govt Coll, Krishnanagar 741101, W Bengal, India.
RP Talukdar, D (reprint author), Univ Calcutta, Dept Bot, RPM Coll, Hooghly 712258, W Bengal, India.
EM dibyendutalukdar9@gmail.com
CR Alscher RG, 2002, J EXP BOT, V53, P1331, DOI 10.1093/jexbot/53.372.1331
   Apel K, 2004, ANNU REV PLANT BIOL, V55, P373, DOI 10.1146/annurev.arplant.55.031903.141701
   Bandeoglu E, 2004, PLANT GROWTH REGUL, V42, P69, DOI 10.1023/B:GROW.0000014891.35427.7b
   BEYER WF, 1987, ANAL BIOCHEM, V161, P559, DOI 10.1016/0003-2697(87)90489-1
   BOWLER C, 1994, CRIT REV PLANT SCI, V13, P199
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   CHARY P, 1994, GENETICS, V137, P723
   Dibyendu Talukdar, 2013, International Journal of Agricultural Science and Research (IJASR), V3, P217
   Dibyendu Talukdar, 2012, Journal of Crop Science and Biotechnology, V15, P325, DOI 10.1007/s12892-012-0065-3
   Dibyendu Talukdar, 2012, Bioremediation, Biodiversity and Bioavailability, V6, P75
   Dibyendu Talukdar, 2011, Current Research Journal of Biological Sciences, V3, P116
   Fambrini M, 1997, J EXP BOT, V48, P1143, DOI 10.1093/jxb/48.5.1143
   Foyer CH, 2003, PHYSIOL PLANTARUM, V119, P355, DOI 10.1034/j.1399-3054.2003.00223.x
   FRIDOVICH I, 1995, ANNU REV BIOCHEM, V64, P97, DOI 10.1146/annurev.bi.64.070195.000525
   Gomes-Junior RA, 2006, CHEMOSPHERE, V65, P1330, DOI 10.1016/j.chemosphere.2006.04.056
   GRALLA EB, 1991, J BACTERIOL, V173, P5918, DOI 10.1128/jb.173.18.5918-5920.1991
   GRIFFIN JD, 1989, CROP SCI, V29, P968, DOI 10.2135/cropsci1989.0011183X002900040029x
   Halliwell B, 2006, PLANT PHYSIOL, V141, P312, DOI 10.1104/pp.106.077073
   Kayihan C, 2012, BIOL PLANTARUM, V56, P693, DOI 10.1007/s10535-012-0143-x
   Kopyra M, 2003, PLANT PHYSIOL BIOCH, V41, P1011, DOI 10.1016/j.plaphy.2003.09.003
   Kumar A., 2012, SCI REPORTS, V2
   Laspina NV, 2005, PLANT SCI, V169, P323, DOI 10.1016/j.plantsci.2005.02.007
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lopez-Millan AF, 2005, PLANT SCI, V168, P1015, DOI 10.1016/j.plantsci.2004.11.018
   Mascher R, 2002, PLANT SCI, V163, P961, DOI 10.1016/S0168-9452(02)00245-5
   McKersie BD, 2000, PLANT PHYSIOL, V122, P1427, DOI 10.1104/pp.122.4.1427
   Morgan MJ, 2008, PLANT PHYSIOL, V147, P101, DOI 10.1104/pp.107.113613
   Myouga F, 2008, PLANT CELL, V20, P3148, DOI 10.1105/tpc.108.061341
   Ortega-Villasante C, 2005, J EXP BOT, V56, P2239, DOI 10.1093/jxb/eri223
   PERLTREVES R, 1991, PLANT MOL BIOL, V17, P745, DOI 10.1007/BF00037058
   Rahman MA, 2008, ECOTOX ENVIRON SAFE, V69, P317, DOI 10.1016/j.ecoenv.2007.01.005
   Rodriguez-Serrano M, 2006, PLANT CELL ENVIRON, V29, P1532, DOI 10.1111/j.1365-3040.2006.01531.x
   Singh HP, 2007, PLANT GROWTH REGUL, V53, P65, DOI 10.1007/s10725-007-9205-z
   Stoeva N, 2005, BIOL PLANTARUM, V49, P293, DOI 10.1007/s10535-005-3296-z
   Talukdar D, 2012, BIOL PLANTARUM, V56, P675, DOI 10.1007/s10535-012-0245-5
   Talukdar D, 2011, INDIAN J FUNDAMENTAL, V1, P263
   Talukdar D, 2013, INT J PHARM BIO SCI, V4, P694
   Talukdar D., 2013, INT J BOT RES, V3, P1
   Talukdar D, 2013, RUSS J PLANT PHYSL+, V60, P652, DOI 10.1134/S1021443713050130
   Talukdar D, 2013, PHYSIOL MOL BIOL PLA, V19, P69, DOI 10.1007/s12298-012-0140-8
   Talukdar D, 2012, SCI WORLD J, P1, DOI 10.1100/2012/345983
   Talukdar D, 2011, J MED PLANTS RES, V5, P3619
   Talukdar D, 2011, J CROP IMPROV, V25, P161, DOI 10.1080/15427528.2011.547323
   Talukdar D, 2009, J GENET, V88, P165, DOI 10.1007/s12041-009-0024-z
   Tsyganov VE, 2007, ANN BOT-LONDON, V99, P227, DOI 10.1093/aob/mcl261
   Weeden N. F., 1988, PISUM NEWSLETT, V20, P44
NR 46
TC 10
Z9 10
U1 2
U2 13
PU HINDAWI PUBLISHING CORP
PI NEW YORK
PA 315 MADISON AVE 3RD FLR, STE 3070, NEW YORK, NY 10017 USA
SN 2314-6133
EI 2314-6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PY 2013
AR 782450
DI 10.1155/2013/782450
PG 11
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA 215DN
UT WOS:000324189700001
PM 24078924
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Allahviranloo, T
   Avazpour, L
   Ebadi, MJ
   Baleanu, D
   Salahshour, S
AF Allahviranloo, Tofigh
   Avazpour, Lutfi
   Ebadi, Mohammad J.
   Baleanu, Dumitru
   Salahshour, Soheil
TI RETRACTED: Retracted: Fuzzy fractional Ostrowski inequality with Caputo
   differentiability (Retracted article. See 2013)
SO JOURNAL OF INEQUALITIES AND APPLICATIONS
LA English
DT Article; Retracted Publication
DE fuzzy fractional Ostrowski inequality; fuzzy Caputo differentiability;
   Hukuhara difference; fuzzy-valued function
ID GRUSS TYPE; IMPROVEMENT
AB The use of fractional inequalities in mathematical models is increasingly widespread in recent years. In this manuscript, we firstly propose the right Caputo derivative of fuzzy-valued functions about fractional order v (0 < v < 1). To this end, we consider two types of differentiability (similar to the non-fractional case). Then we derive the equivalent integral forms of original fuzzy fractional differential equations. Finally, we prove the fuzzy Ostrowski inequality involving three functions under Caputo's differentiability. In this regard, we state some new results.
C1 [Allahviranloo, Tofigh] Islamic Azad Univ, Sci & Res Branch, Dept Math, Tehran, Iran.
   [Avazpour, Lutfi] Islamic Azad Univ, Yasooj Branch, Dept Math, Yasuj, Iran.
   [Ebadi, Mohammad J.] Chabahar Maritime Univ, Fac Marine Sci, Chabahar, Iran.
   [Baleanu, Dumitru] Cankaya Univ, Dept Math & Comp Sci, TR-06530 Ankara, Turkey.
   [Baleanu, Dumitru] King Abdulaziz Univ, Fac Engn, Dept Chem & Mat Engn, Jeddah 21413, Saudi Arabia.
   [Baleanu, Dumitru] Inst Space Sci, Bucharest, Romania.
   [Salahshour, Soheil] Islamic Azad Univ, Mobarakeh Branch, Young Researchers & Elite Club, Mobarakeh, Iran.
RP Avazpour, L (reprint author), Islamic Azad Univ, Yasooj Branch, Dept Math, Yasuj, Iran.
EM avazpour.l@gmail.com
OI Allahviranloo, Tofigh/0000-0002-6673-3560
CR Allahviranloo T, 2012, J MATH ANAL APPL, V395, P191, DOI 10.1016/j.jmaa.2012.05.016
   Allahviranloo T, 2012, SOFT COMPUT, V16, P297, DOI 10.1007/s00500-011-0743-y
   Allahviranloo T, 2010, SOFT COMPUT FUS FDN, V7, P1247
   Allahviranloo T, 2010, INF PROC MANAG UNCER
   Alomari M, 2010, APPL MATH LETT, V23, P1071, DOI 10.1016/j.aml.2010.04.038
   Alomari M, 2010, PREPRINT
   Anastassiou GA, 2010, STUD FUZZ SOFT COMP, V251, P65
   Anastassiou GA, 2009, CHAOS SOLITON FRACT, V42, P365, DOI 10.1016/j.chaos.2008.12.013
   Bohner EA, 2011, NONLINEAR DYN SYST T, V8, P651
   BOHNER M., 2008, JIPAM J INEQUAL PURE, V9
   Cheng XL, 2001, COMPUT MATH APPL, V42, P109, DOI 10.1016/S0898-1221(01)00135-3
   Dragomir S. S., 1997, TAMKANG J MATH, V28, P239
   Dragomir SS, 1997, COMPUT MATH APPL, V33, P15, DOI 10.1016/S0898-1221(97)00084-9
   Lu ZX, 2008, COMPUT MATH APPL, V56, P2043, DOI 10.1016/j.camwa.2008.03.032
   Matic M, 2000, COMPUT MATH APPL, V39, P161, DOI 10.1016/S0898-1221(99)00342-9
   Milovanovif GV, 1976, U BEOGRAD PUBL EL MF, V44, P155
   Ostrowski A, 1938, COMMENT MATH HELV, V10, P226, DOI DOI 10.1007/BF01214290
   Pachpatte B. G., 2001, TAMKANG J MATH, V32, P45
   Pachpatte B. G., 2005, AN STIINT U AI CUZA, V51, P377
   Pachpatte BG, 2000, J MATH ANAL APPL, V249, P583, DOI 10.1006/jmaa.2000.6913
   Rafiq A, 2007, APPL MATH MECH-ENGL, V28, P901, DOI 10.1007/s10483-007-0707-z
   Salahshour S, 2012, ADV DIFFER EQU, V112, P1
   Sarikaya MZ, 2010, ACTA MATH U COMEN, V1, P129
   Tseng KL, 2008, TAIWAN J MATH, V12, P2427, DOI 10.11650/twjm/1500405188
   Ujevic N, 2004, COMPUT MATH APPL, V48, P145, DOI 10.1016/j.camwa.2003.09.026
NR 25
TC 1
Z9 1
U1 3
U2 16
PU SPRINGER INTERNATIONAL PUBLISHING AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND
SN 1029-242X
J9 J INEQUAL APPL
JI J. Inequal. Appl.
PY 2013
AR 50
DI 10.1186/1029-242X-2013-50
PG 9
WC Mathematics, Applied; Mathematics
SC Mathematics
GA 217QW
UT WOS:000324375900001
OA DOAJ Gold
DA 2018-12-27
ER

PT J
AU Panda, J
   Sahoo, BM
   Mishra, NK
   Padhi, SK
   Mishra, J
AF Panda, Jnyanaranjan
   Sahoo, Biswa Mohan
   Mishra, Nikunja Kishor
   Padhi, Sai Krushna
   Mishra, Jitendriya
TI RETRACTED: Microwave Mediated Organic Reaction: A Convenient Approach
   for Rapid and Efficient Synthesis of Biologically Active Substituted
   1,3-Dihydro-2H-indol-2-one Derivatives (Retracted article. See pg. 2957,
   2015)
SO JOURNAL OF NANOMATERIALS
LA English
DT Article; Retracted Publication
ID VITRO CYTOTOXICITY EVALUATION; MANNICH-BASES; ISATIN DERIVATIVES;
   ANTIVIRAL ACTIVITY; ANTIBACTERIAL; SCHIFF
AB A simple and efficient method has been developed for the synthesis of 1,3-dihydro-2H-indol-2-one derivatives using microwave irradiation technique. By taking advantage of the efficient source of energy of microwave, compound libraries for lead generation and optimization can be assembled in a fraction of time. In the present work, first the Schiff's bases are synthesized by reaction of isatin with substituted anilines in the presence of acetic acid under microwave heating. Then the condensation of Schiff bases with different secondary amines in the presence of formaldehyde produces Mannich bases. The newly synthesized Mannich bases were characterized by means of spectral data and then evaluated for anthelmintic activity against Pheretima posthuma ( Indian earthworm) and compared with standard albendazole. The compounds were evaluated at the concentrations of 10, 20, and 50 mg/mL. The effect of the standard drug albendazole at 10 mg/mL was also evaluated. The results of the present study indicate that some of the test compounds significantly demonstrated paralysis and also caused death of worms in a dose-dependent manner.
C1 [Panda, Jnyanaranjan; Sahoo, Biswa Mohan; Mishra, Nikunja Kishor; Padhi, Sai Krushna] Roland Inst Pharmaceut Sci, Dept Pharmaceut Chem, Berhampur 760010, Odisha, India.
   [Mishra, Jitendriya] Panjab Univ, UGC Ctr Adv Study CAS, Univ Inst Pharmaceut Sci, Chandigarh 160014, India.
RP Panda, J (reprint author), Roland Inst Pharmaceut Sci, Dept Pharmaceut Chem, Berhampur 760010, Odisha, India.
EM jnyana@rediffmail.com
CR Aboul-Fadl T, 2010, INT J RES PHARM SCI, V1, P113
   Bal TR, 2005, BIOORG MED CHEM LETT, V15, P4451, DOI 10.1016/j.bmcl.2005.07.046
   Blakemore R., 1999, T ROYAL ZOOLOGICAL S
   da Silva JFM, 2001, J BRAZIL CHEM SOC, V12, P273, DOI 10.1590/S0103-50532001000300002
   Dewan SK, 2006, INDIAN J CHEM B, V45, P2337
   Dhamija H. K., 2011, PHARMACOLOGYONLINE, V3, P740
   Glover V, 1998, STRESS MEDICINE, V14, P225, DOI 10.1002/(SICI)1099-1700(1998100)14:4<225::AID-SMI801>3.0.CO;2-P
   Hussein M.A., 2005, B PHARM SCI, V28, P131
   Jarrahpour A, 2007, MOLECULES, V12, P1720, DOI 10.3390/12081720
   Kappe CO, 2004, ANGEW CHEM INT EDIT, V43, P6250, DOI 10.1002/anie.200400655
   Khan S, 2006, J PHARM RES, V5, P61
   Laporterie A., 2002, MICROWAVES ORGANIC S
   Medvedev A, 2005, STRESS, V8, P175, DOI 10.1080/10253890500342321
   Medvedev AE, 2004, NEUROTOXICOLOGY, V25, P185, DOI 10.1016/S0161-813X(03)00098-6
   Medvedev AE, 1996, BIOCHEM PHARMACOL, V52, P385, DOI 10.1016/0006-2952(96)00206-7
   Panda J., 2013, J NANOPARTICLES, V2013
   Pandeya SN, 1999, FARMACO, V54, P624, DOI 10.1016/S0014-827X(99)00075-0
   Pandeya SN, 2002, ARCH PHARM, V335, P129, DOI 10.1002/1521-4184(200204)335:4<129::AID-ARDP129>3.0.CO;2-W
   Patel A., 2006, IRAN J PHARM REC, V4, P249
   Patro VJ, 2012, J INDIAN CHEM SOC, V89, P913
   Selvam P, 2008, INDIAN J PHARM SCI, V70, P91, DOI 10.4103/0250-474X.40339
   SINGH SP, 1983, CURR SCI INDIA, V52, P766
   Singh T. J., 1971, INDIAN J PHARM, V3, P187
   Somani R., 2010, INT J CHEMTECH RES, V2, P172
   Sridhar SK, 2001, EUR J MED CHEM, V36, P615, DOI 10.1016/S0223-5234(01)01255-7
   Sriram D, 2005, MED CHEM RES, V14, P211, DOI 10.1007/s00044-005-0135-x
   Sriram D, 2005, J PHARM PHARM SCI, V8, P565
   Strauss CR, 2006, TOP CURR CHEM, V266, P199, DOI 10.1007/128_060
   Trapti Rastogi, 2009, Asian Journal of Research in Chemistry (AJRC), V2, P181
   Verma Manjusha, 2004, Acta Pharmaceutica (Zagreb), V54, P49
   Vine KL, 2007, BIOORGAN MED CHEM, V15, P931, DOI 10.1016/j.bmc.2006.10.035
   Yogeeswari P, 2005, BIOMED PHARMACOTHER, V59, P501, DOI 10.1016/j.biopha.2005.06.006
NR 32
TC 0
Z9 0
U1 1
U2 7
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1687-4110
EI 1687-4129
J9 J NANOMATER
JI J. Nanomater.
PY 2013
AR 272598
DI 10.1155/2013/272598
PG 8
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
SC Science & Technology - Other Topics; Materials Science
GA 215EW
UT WOS:000324193300001
OA DOAJ Gold
DA 2018-12-27
ER

PT J
AU Salama, SM
   Abdulla, MA
   AlRashdi, AS
   Hadi, AHA
AF Salama, Suzy M.
   Abdulla, Mahmood A.
   AlRashdi, Ahmed S.
   Hadi, A. Hamid A.
TI RETRACTED: Mechanism of Hepatoprotective Effect of Boesenbergia rotunda
   in Thioacetamide-Induced Liver Damage in Rats (Retracted article. See
   art no 1072403, 2018)
SO EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article; Retracted Publication
ID CANCER-CELLS; FIBROSIS; APOPTOSIS; ACTIVATION; INHIBITORS; CIRRHOSIS;
   EXTRACT; INJURY; METALLOPROTEINASES; CYTOCHROME-P450
AB Background. Researchers focused on developing traditional therapies as pharmacological medicines to treat liver cirrhosis. Objectives. Evaluating the hepatoprotective activity of Boesenbergia rotunda (BR) rhizome ethanolic extract on thioacetamide-induced liver cirrhosis in rats. Methods. Male Sprague-Dawley rats were intraperitoneally injected with 200 mg/kg TAA3 times/week and daily oral administration of 250mg/kg, 500mg/kg of BR extract, and 50mg/kg of the reference drug Silymarin for 8 weeks. At the end of the experiment, Masson's trichrome staining was used to measure the degree of liver fibrosis. Hepatic antioxidant enzymes (CAT and GPx), nitrotyrosine, cytochrome (P450 2E1), matrix metalloproteinase (MMP-2 and MMP-9), tissue inhibitor of metalloproteinase (TIMP-1), and urinary 8-hydroxyguanosine were measured. Serum levels of transforming growth factor TGF-beta 1, nuclear transcription factor NF-kappa B, proinflammatory cytokine IL-6, and caspase-3 were evaluated. Serum protein expression and immunohistochemistry of proapoptotic Bax and antiapoptotic Bcl-2 proteins were measured and confirmed by immunohistochemistry of Bax, Bcl-2, and proliferating cell nuclear antigen (PCNA). Results. BR treatment improved liver histopathology, immunohistochemistry, and biochemistry, triggered apoptosis, and inhibited cytokines, extracellular matrix proteins, and hepatocytes proliferation. Conclusion. Liver cirrhosis progression can be inhibited by the antioxidant and anti-inflammatory activities of BR ethanolic extract while preserving the normal liver status.
C1 [Salama, Suzy M.; Abdulla, Mahmood A.; AlRashdi, Ahmed S.] Univ Malaya, Dept Biomed Sci, Fac Med, Kuala Lumpur 50603, Malaysia.
   [Hadi, A. Hamid A.] Univ Malaya, Dept Chem, Fac Sci, Kuala Lumpur 50603, Malaysia.
RP Abdulla, MA (reprint author), Univ Malaya, Dept Biomed Sci, Fac Med, Kuala Lumpur 50603, Malaysia.
EM mahmood955@yahoo.com
FU University of Malaya through University Malaya Research Grant
   [PV042-2011A]; HIR Grant [F000009-21001]
FX This study was financially supported by the University of Malaya through
   University Malaya Research Grant PV042-2011A and HIR Grant
   (F000009-21001). The authors are thankful to the staffs of Department of
   Molecular Medicine and Clinical Diagnostic Laboratory of University
   Malaya.
CR Abdelwahab SI, 2011, J ETHNOPHARMACOL, V137, P963, DOI 10.1016/j.jep.2011.07.010
   Abraham David, 2005, Current Vascular Pharmacology, V3, P369
   Alshawsh MA, 2011, EVID-BASED COMPL ALT, P1, DOI 10.1155/2011/103039
   Amali AA, 2006, J BIOMED SCI, V13, P225, DOI 10.1007/s11373-005-9055-5
   Amin ZA, 2012, EVID-BASED COMPL ALT, DOI 10.1155/2012/241583
   An Jeung Hee, 2006, Korean J Hepatol, V12, P93
   Arthur MJP, 2000, AM J PHYSIOL-GASTR L, V279, pG245
   Aydin AF, 2010, PEPTIDES, V31, P67, DOI 10.1016/j.peptides.2009.11.028
   Bassiouny AR, 2011, INT J CLIN EXP PATHO, V4, P692
   Bruck R, 2007, LIVER INT, V27, P373, DOI 10.1111/j.1478-3231.2007.01453.x
   Chen LH, 2006, WORLD J GASTROENTERO, V12, P5175
   Chilakapati J, 2007, TOXICOLOGY, V230, P105, DOI 10.1016/j.tox.2006.11.050
   Choudhury JD, 2012, IJBPR, V3, P848
   Daly AK, 2009, NAT GENET, V41, P816, DOI 10.1038/ng.379
   Djordjevic VB, 2004, INT REV CYTOL, V237, P57, DOI 10.1016/S0074-7696(04)37002-6
   Edgtton KL, 2004, KIDNEY INT, V66, P68, DOI 10.1111/j.1523-1755.2004.00707.x
   Elsharkawy AM, 2005, APOPTOSIS, V10, P927, DOI 10.1007/s10495-005-1055-4
   Emi M, 2005, BREAST CANCER RES, V7, pR940, DOI 10.1186/bcr1323
   Gressner O. A., 2007, COMP HEPATOLOGY, V6
   Kang MH, 2009, CLIN CANCER RES, V15, P1126, DOI 10.1158/1078-0432.CCR-08-0144
   Karamanakos PN, 2009, ARCH TOXICOL, V83, P571, DOI 10.1007/s00204-008-0350-6
   Khanna D, 2007, CURR OPIN PHARMACOL, V7, P344, DOI 10.1016/j.coph.2007.03.002
   Kim HK, 2009, WORLD J GASTROENTERO, V15, P5200, DOI 10.3748/wjg.15.5200
   Kim KH, 2000, TOXICOL LETT, V114, P225, DOI 10.1016/S0378-4274(00)00168-5
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   Mahmood AA, 2010, J MED PLANTS RES, V4, P1570
   Mandrekar P, 2009, J HEPATOL, V50, P1258, DOI 10.1016/j.jhep.2009.03.007
   Mehendale HM, 2005, TOXICOL PATHOL, V33, P41, DOI 10.1080/01926230590881808
   Mori A, 2004, ACTA MED OKAYAMA, V58, P111
   Moungjaroen J, 2006, J PHARMACOL EXP THER, V319, P1062, DOI 10.1124/jpet.106.110965
   Muriel P, 2009, HEPATOL INT, V3, P526, DOI 10.1007/s12072-009-9158-6
   Nadzri N. Muhammad, 2013, EVID-BASED COMPL ALT, V2013
   Ng KB, 2013, BMC COMPLEM ALTERN M, V13, DOI 10.1186/1472-6882-13-41
   Okazaki I., 2003, EXTRACELLULAR MATRIX
   Okuyama H, 2004, COMP HEPATOL, V3, pS6
   Park SY, 2010, J KOREAN MED SCI, V25, P570, DOI 10.3346/jkms.2010.25.4.570
   Pham-Huy Lien Ai, 2008, Int J Biomed Sci, V4, P89
   Pradhan SC, 2006, INDIAN J MED RES, V124, P491
   Raison CL, 2005, CNS DRUGS, V19, P105, DOI 10.2165/00023210-200519020-00002
   Rho HS, 2011, MOLECULES, V16, P3338, DOI 10.3390/molecules16043338
   Sadasivan S, 2006, J ETHNOPHARMACOL, V106, P245, DOI 10.1016/j.jep.2006.01.002
   Sakr S. A., 2012, LIFE SCI, V9
   Salama S. M., 2013, BMC COMPLEMENTARY AL, V13
   Salama SM, 2012, EVID-BASED COMPL ALT, DOI 10.1155/2012/137083
   Sarkar Mrinal K, 2007, Pathophysiology, V14, P113, DOI 10.1016/j.pathophys.2007.08.001
   Shindo K, 2006, BIOSCI BIOTECH BIOCH, V70, P2281, DOI 10.1271/bbb.60086
   Sindhu RK, 2006, FREE RADICAL RES, V40, P921, DOI 10.1080/10715760600801272
   Voravuthikunchai S, 2005, PHARM BIOL, V43, P701, DOI 10.1080/13880200500385194
   Wang ME, 2012, J NUTR BIOCHEM, V23, P1352, DOI 10.1016/j.jnutbio.2011.08.004
   Wang N, 2008, J ETHNOPHARMACOL, V116, P1, DOI 10.1016/j.jep.2007.08.031
   Wang Y, 2005, WORLD J GASTROENTERO, V11, P3549, DOI 10.3748/wjg.v11.i23.3549
   Wu LL, 2004, CLIN CHIM ACTA, V339, P1, DOI 10.1016/j.cccn.2003.09.010
   Yang HY, 2005, J NAT PROD, V68, P101, DOI 10.1021/np0497907
   Yap ALC, 2007, MALAYSIAN J ANAL SCI, V11, P154
   Zeisberg M, 2007, J BIOL CHEM, V282, P23337, DOI 10.1074/jbc.M700194200
NR 55
TC 10
Z9 10
U1 65
U2 73
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1741-427X
EI 1741-4288
J9 EVID-BASED COMPL ALT
JI Evid.-based Complement Altern. Med.
PY 2013
AR 157456
DI 10.1155/2013/157456
PG 13
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA 202ZF
UT WOS:000323259100001
PM 23997791
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Attri, P
   Arora, B
   Choi, EH
AF Attri, Pankaj
   Arora, Bharti
   Choi, Eun Ha
TI RETRACTED: Utility of plasma: a new road from physics to
   chemistry(Retracted article. See vol.7,pg.15735,2017)
SO RSC ADVANCES
LA English
DT Review; Retracted Publication
ID ATMOSPHERIC-PRESSURE PLASMA; DIELECTRIC BARRIER DISCHARGE;
   CHEMICAL-VAPOR-DEPOSITION; VOLATILE ORGANIC-COMPOUNDS;
   INDUCTIVELY-COUPLED PLASMAS; NONTHERMAL PLASMA; GLOW-DISCHARGE;
   NITRIC-OXIDE; HYDROGEN-PEROXIDE; FIELD-EMISSION
AB In recent years, plasma has proved to have great promise in the fields of chemistry, biology, physics, biotechnological and medical sciences. In this review, we discuss plasma versatility and applicability in various areas, such as interactions with biomolecules, biomedical treatments, chemical synthesis, removal of volatile organic compounds, electrochemical reactions, nanoscience, surface modifications, food engineering and water purification applications. Specially, we discuss how we can increase the utility of plasma in various phases of chemistry and biochemistry. We also shed light on the aspect that plasma can be a new source of green chemistry.
C1 [Attri, Pankaj; Choi, Eun Ha] Kwangwoon Univ, Dept Elect & Biol Phys, Plasma Biosci Res Ctr, Seoul, South Korea.
   [Arora, Bharti] Univ Delhi, Dept Chem, Delhi 110007, India.
RP Attri, P (reprint author), Kwangwoon Univ, Dept Elect & Biol Phys, Plasma Biosci Res Ctr, Seoul, South Korea.
EM chem.pankaj@gmail.com; ehchoi@kw.ac.kr
OI Attri, Pankaj/0000-0002-5036-7877
FU SRC program of National Research Foundation of Korea (NRF); Korean
   Government (MEST) [20100029418]; Kwangwoon University
FX We gratefully acknowledge the SRC program of National Research
   Foundation of Korea (NRF) Grant funded by the Korean Government (MEST)
   (No. 20100029418) and in part by the research grant of Kwangwoon
   University in 2013.
CR Abramzon N, 2006, IEEE T PLASMA SCI, V34, P1304, DOI 10.1109/TPS.2006.877515
   Anders A, 2007, J PHYS D APPL PHYS, V40, P2272, DOI 10.1088/0022-3727/40/8/S06
   [Anonymous], 1999, ALT DIS OX EPA GUID
   Attri P, 2012, RSC ADV, V2, P7146, DOI 10.1039/c2ra20085f
   Attri P, 2012, J KOREAN PHYS SOC, V60, P959, DOI 10.3938/jkps.60.959
   Babayan SE, 2001, PLASMA SOURCES SCI T, V10, P573, DOI 10.1088/0963-0252/10/4/305
   Badr Y, 2008, J HAZARD MATER, V154, P245, DOI 10.1016/j.jhazmat.2007.10.020
   Bai JW, 2009, NANO LETT, V9, P2083, DOI 10.1021/nl900531n
   Banhart F, 2009, NANOSCALE, V1, P201, DOI 10.1039/b9nr00127a
   Basaran P, 2008, FOOD MICROBIOL, V25, P626, DOI 10.1016/j.fm.2007.12.005
   Bogaerts A, 2002, SPECTROCHIM ACTA B, V57, P609, DOI 10.1016/S0584-8547(01)00406-2
   Brandenburg R, 2007, CONTRIB PLASM PHYS, V47, P72, DOI 10.1002/ctpp.200710011
   Brown GC, 2002, FREE RADICAL BIO MED, V33, P1440, DOI 10.1016/S0891-5849(02)01112-7
   Bruno G., 1995, PLASMA DEPOSITION AM
   Byeon JH, 2009, NANOSCALE, V1, P339, DOI 10.1039/b9nr00058e
   Canal C, 2009, PLASMA PROCESS POLYM, V6, P686, DOI 10.1002/ppap.200950011
   Cannillo V, 2010, J EUR CERAM SOC, V30, P2031, DOI 10.1016/j.jeurceramsoc.2010.04.021
   Cao W, 2009, INT J FOOD MICROBIOL, V130, P88, DOI 10.1016/j.ijfoodmicro.2008.12.021
   Carey J. H., 1992, Water Pollution Research Journal of Canada, V27, P1
   Cernetti P, 2007, CHEM VAPOR DEPOS, V13, P345, DOI 10.1002/cvde.200606559
   Chae HJ, 2001, IMMUNOPHARM IMMUNOT, V23, P187, DOI 10.1081/IPH-100103859
   Chae JO, 2004, IEEE T PLASMA SCI, V32, P493, DOI 10.1109/TPS.2004.826030
   Chang MB, 2004, CATAL TODAY, V89, P109, DOI 10.1016/j.cattod.2003.11.016
   Chen JR, 2007, LWT-FOOD SCI TECHNOL, V40, P249, DOI 10.1016/j.lwt.2005.10.011
   Cheng QJ, 2010, J MATER CHEM, V20, P5853, DOI 10.1039/c0jm01060j
   Cheruthazhekatt S, 2010, J APPL BIOMED, V8, P55, DOI 10.2478/v10136-009-0013-9
   Chiang WH, 2009, ACS NANO, V3, P4023, DOI 10.1021/nn901222t
   Chiang WH, 2009, NAT MATER, V8, P882, DOI [10.1038/NMAT2531, 10.1038/nmat2531]
   Choi J. H., 2010, ADV NAT SCI-NANOSCI, V1
   Choi J, 2010, PLASMA PROCESS POLYM, V7, P258, DOI 10.1002/ppap.200900079
   CLEMENTS JS, 1987, IEEE T IND APPL, V23, P224, DOI 10.1109/TIA.1987.4504897
   COBURN JW, 1979, J APPL PHYS, V50, P3189, DOI 10.1063/1.326355
   COLBERT DT, 1994, SCIENCE, V266, P1218, DOI 10.1126/science.266.5188.1218
   Cook JA, 2004, SEMIN RADIAT ONCOL, V14, P259, DOI 10.1016/j.semradonc.2004.04.001
   COOPER P, 1993, J SOC DYERS COLOUR, V109, P97
   Davies RH, 2003, J VET MED B, V50, P38, DOI 10.1046/j.1439-0450.2003.00622.x
   Dawe RS, 2003, BRIT J DERMATOL, V149, P669, DOI 10.1046/j.1365-2133.2003.05498.x
   Delagrange S, 2006, APPL CATAL B-ENVIRON, V68, P92, DOI 10.1016/j.apcatb.2006.07.002
   Demidiouk V, 2003, J KOREAN PHYS SOC, V42, pS966
   Deminsky M, 2002, PURE APPL CHEM, V74, P413, DOI 10.1351/pac200274030413
   Deng XT, 2007, APPL PHYS LETT, V90, DOI 10.1063/1.2410219
   Deng XT, 2007, J APPL PHYS, V101, DOI 10.1063/1.2717576
   Denysenko I, 2007, APPL PHYS LETT, V90, DOI 10.1063/1.2750392
   Ding HX, 2006, J PHYS D APPL PHYS, V39, P3603, DOI 10.1088/0022-3727/39/16/012
   Ding Z, 2004, BIOMATERIALS, V25, P1059, DOI 10.1016/S0142-9612(03)00615-X
   Dowling J, 2009, EYE, V23, P1999, DOI 10.1038/eye.2008.385
   Dumpala S, 2009, DIAM RELAT MATER, V18, P1262, DOI 10.1016/j.diamond.2009.04.004
   Einaga H., 2001, IEEE T IND APPL, V37, P858
   Elias DC, 2009, SCIENCE, V323, P610, DOI 10.1126/science.1167130
   ELIASSON B, 1987, J PHYS D APPL PHYS, V20, P1421, DOI 10.1088/0022-3727/20/11/010
   ELIASSON B, 1991, IEEE T PLASMA SCI, V19, P309, DOI 10.1109/27.106829
   EVANS D, 1993, J APPL PHYS, V74, P5378, DOI 10.1063/1.354241
   Fernandez-Gutierrez SA, 2010, IEEE T PLASMA SCI, V38, P957, DOI 10.1109/TPS.2010.2042078
   Frank J. F., 2003, Food Protection Trends, V23, P654
   Fridman A, 2005, J PHYS D APPL PHYS, V38, pR1, DOI 10.1088/0022-3727/38/2/R01
   FRIDMAN G, 2006, 37 AIAA PLASM DYN LA
   Fridman G, 2008, PLASMA PROCESS POLYM, V5, P503, DOI 10.1002/ppap.200700154
   Fridman G, 2006, PLASMA CHEM PLASMA P, V26, P425, DOI 10.1007/s11090-006-9024-4
   Fuhrmann H, 2010, J SCI FOOD AGR, V90, P593, DOI 10.1002/jsfa.3853
   Furusho H, 2009, CHEM MATER, V21, P3526, DOI 10.1021/cm803290b
   Gancarz I, 2003, EUR POLYM J, V39, P2217, DOI 10.1016/S0014-3057(03)00160-5
   Gao CH, 2001, J FOOD SCI, V66, P89
   Gibalov VI, 2000, J PHYS D APPL PHYS, V33, P2618, DOI 10.1088/0022-3727/33/20/315
   Goossens O, 2001, SURF COAT TECH, V142, P474, DOI 10.1016/S0257-8972(01)01140-9
   Goree J, 2006, IEEE T PLASMA SCI, V34, P1317, DOI 10.1109/TPS.2006.878431
   GOSTEV V, 2006, 3 INT WORKSH MICR IW
   Goto M., 2008, 11 EUR M SUP FLUIDS, P12
   Gould J., 1995, RAINWATER CATCHEMENT
   Grill A., 1994, COLD PLASMA MAT FABR
   Guo YF, 2006, J MOL CATAL A-CHEM, V245, P93, DOI 10.1016/j.molcata.2005.09.013
   Han SB, 2007, PLASMA SOURCES SCI T, V16, P413, DOI 10.1088/0963-0252/16/2/026
   Hawa T, 2008, J PHYS CHEM C, V112, P14796, DOI 10.1021/jp800780s
   Herrera F, 2001, WATER RES, V35, P750, DOI 10.1016/S0043-1354(00)00295-5
   Herrmann HW, 1999, PHYS PLASMAS, V6, P2284, DOI 10.1063/1.873480
   HICKLING A, 1964, T FARADAY SOC, V60, P783, DOI 10.1039/tf9646000783
   Hierro E, 2009, INT J FOOD MICROBIOL, V135, P125, DOI 10.1016/j.ijfoodmicro.2009.07.034
   Hiramatsu M, 2004, APPL PHYS LETT, V84, P4708, DOI 10.1063/1.1762702
   Hofmann S, 2003, J APPL PHYS, V94, P6005, DOI 10.1063/1.1614432
   Huang SY, 2010, APPL PHYS LETT, V97, DOI 10.1063/1.3517507
   Hwang H, 2011, LAB CHIP, V11, P33, DOI [10.1039/c0lc00117a, 10.1039/c01c0011a]
   Iacopi F, 2007, NANOTECHNOLOGY, V18, DOI 10.1088/0957-4484/18/50/505307
   Ichiki T, 2003, THIN SOLID FILMS, V435, P62, DOI 10.1016/S0040-6090(03)00370-5
   IIJIMA S, 1991, NATURE, V354, P56, DOI 10.1038/354056a0
   Intriago L, 2006, MICROPOR MESOPOR MAT, V91, P161, DOI 10.1016/j.micromeso.2005.11.043
   Janca J, 1999, SURF COAT TECH, V116, P547, DOI 10.1016/S0257-8972(99)00256-X
   Jasinski M., 2008, ISNTPT 6, V6, P134
   Jeong JY, 1998, PLASMA SOURCES SCI T, V7, P282, DOI 10.1088/0963-0252/7/3/005
   Jessen B, 2003, INT BIODETER BIODEGR, V51, P265, DOI 10.1016/S0964-8305(03)00046-5
   Jiang CQ, 2009, PLASMA PROCESS POLYM, V6, P479, DOI 10.1002/ppap.200800133
   Jiao LY, 2010, NANO RES, V3, P387, DOI 10.1007/s12274-010-1043-z
   Jiao S, 2001, J APPL PHYS, V90, P118, DOI 10.1063/1.1377301
   Julak J, 2011, PLASMA PROCESS POLYM, V8, P316, DOI 10.1002/ppap.201000100
   Kalghatgi S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016270
   Kalghatgi SU, 2007, IEEE T PLASMA SCI, V35, P1559, DOI 10.1109/TPS.2007.905953
   Kalghatgi SU, 2008, IEEE ENG MED BIO, P3578, DOI 10.1109/IEMBS.2008.4649979
   Kieft IE, 2005, IEEE T PLASMA SCI, V33, P771, DOI 10.1109/TPS.2005.844528
   Kieft IE, 2006, IEEE T PLASMA SCI, V34, P1331, DOI 10.1109/TPS.2006.876511
   Kim HH, 2005, J PHYS D APPL PHYS, V38, P1292, DOI 10.1088/0022-3727/38/8/029
   Kim HH, 2008, APPL CATAL B-ENVIRON, V79, P356, DOI 10.1016/j.apcatb.2007.10.038
   Kim HH, 2006, IEEE T PLASMA SCI, V34, P984, DOI 10.1109/TPS.2006.875728
   Kim K, 2004, BIOMATERIALS, V25, P33, DOI 10.1016/S0142-9612(03)00469-1
   Kirson ED, 2007, P NATL ACAD SCI USA, V104, P10152, DOI 10.1073/pnas.0702916104
   Kobayashi K, 2000, J PHYS CHEM B, V104, P6318, DOI 10.1021/jp993218k
   Kogelschatz U, 2002, IEEE T PLASMA SCI, V30, P1400, DOI 10.1109/TPS.2002.804201
   Kong M. G., 2009, NEW J PHYS, V11
   Koo IG, 2005, J MATER CHEM, V15, P4125, DOI 10.1039/b508420b
   Kortshagen U., 2009, J PHYS D, V42
   Kroncke KD, 1997, NITRIC OXIDE-BIOL CH, V1, P107, DOI 10.1006/niox.1997.0118
   Krotz F, 2004, ARTERIOSCL THROM VAS, V24, P1988, DOI 10.1161/01.ATV.0000145574.90840.7d
   Kuo S., 2009, NEW J PHYS, V11
   Kuo SP, 2010, IEEE T PLASMA SCI, V38, P1908, DOI 10.1109/TPS.2010.2047028
   Kusic H, 2005, J ADV OXID TECHNOL, V8, P172
   KUZMICHEV AI, 2001, P INT S HIGH PRESS L, P402
   Laroussi M, 1999, IEEE T PLASMA SCI, V27, P34, DOI 10.1109/27.763016
   Laroussi M, 2005, APPL PHYS LETT, V87, DOI 10.1063/1.2045549
   Laroussi M., 2001, P EL PORTSM VA, P33
   Laroussi M, 2006, PLASMA PROCESS POLYM, V3, P470, DOI 10.1002/ppap.200600005
   Lee HW, 2010, PLASMA PROCESS POLYM, V7, P274, DOI 10.1002/ppap.200900083
   Lee HW, 2009, J ENDODONT, V35, P587, DOI 10.1016/j.joen.2009.01.008
   Lehnert BE, 2002, HUM EXP TOXICOL, V21, P65, DOI 10.1191/0960327102ht212oa
   Levchenko I, 2007, APPL PHYS LETT, V91, DOI 10.1063/1.2784932
   Levchenko I, 2008, APPL PHYS LETT, V93, DOI 10.1063/1.3012572
   Levchenko I, 2009, CARBON, V47, P344, DOI 10.1016/j.carbon.2008.10.005
   Li G, 2008, APPL PHYS LETT, V92, DOI 10.1063/1.2938692
   Li HP, 2011, PLASMA PROCESS POLYM, V8, P224, DOI 10.1002/ppap.201000035
   Lingareddy E., 2011, INT J CHEM ENV ENG, V2, P87
   Liu CJ, 2006, PURE APPL CHEM, V78, P1227, DOI 10.1351/pac200678061227
   Liu CJ, 2002, CATAL TODAY, V72, P173, DOI 10.1016/S0920-5861(01)00491-6
   Loeb L. B., 1965, ELECT CORONAS THEIR
   Losic D, 2008, NANOTECHNOLOGY, V19, DOI 10.1088/0957-4484/19/24/245704
   Lu B, 2006, J HAZARD MATER, V137, P633, DOI 10.1016/j.jhazmat.2006.02.012
   Lu X., 2008, J APPL PHYS, V104
   Lu XP, 2009, IEEE T PLASMA SCI, V37, P668, DOI 10.1109/TPS.2009.2015454
   Magureanu M, 2007, PLASMA CHEM PLASMA P, V27, P679, DOI 10.1007/s11090-007-9103-1
   Magureanu M, 2007, APPL CATAL B-ENVIRON, V74, P270, DOI 10.1016/j.apcatb.2007.02.019
   Magureanu M, 2011, WATER RES, V45, P3407, DOI 10.1016/j.watres.2011.03.057
   Magureanu M, 2007, APPL CATAL B-ENVIRON, V76, P275, DOI 10.1016/j.apeatb.2007.05.030
   Malik MA, 2005, IEEE T PLASMA SCI, V33, P50, DOI 10.1109/TPS.2004.842323
   Malik MA, 2003, PLASMA SOURCES SCI T, V12, pS26, DOI 10.1088/0963-0252/12/4/317
   Mander PK, 2006, J IMMUNOL, V176, P1046, DOI 10.4049/jimmunol.176.2.1046
   Manolache S, 1997, MOLECULES, V2, P158, DOI 10.3390/21100158
   Manos D. L., 1989, PLASMA ETCHING INTRO
   Mariotti D., 2009, J PHYS D, V42
   Matsumoto O, 1998, J PHYS IV, V8, P411, DOI 10.1051/jp4:1998736
   Matzing H, 1996, PURE APPL CHEM, V68, P1089, DOI 10.1351/pac199668051089
   Mendis DA, 2000, IEEE T PLASMA SCI, V28, P1304, DOI 10.1109/27.893321
   Ming-gong C., 2011, INT C MAT REN EN ENV, V2, P1506
   Misra NN, 2011, FOOD ENG REV, V3, P159, DOI 10.1007/s12393-011-9041-9
   Moisan M, 2001, INT J PHARMACEUT, V226, P1, DOI 10.1016/S0378-5173(01)00752-9
   Montie TC, 2000, IEEE T PLASMA SCI, V28, P41, DOI 10.1109/27.842860
   Moreau M, 2008, BIOTECHNOL ADV, V26, P610, DOI 10.1016/j.biotechadv.2008.08.001
   Morent R, 2006, J ADV OXID TECHNOL, V9, P53
   Morrow R, 1997, J PHYS D APPL PHYS, V30, P3099, DOI 10.1088/0022-3727/30/22/008
   Muranyi P, 2007, J APPL MICROBIOL, V103, P1535, DOI 10.1111/j.1365-2672.2007.03385.x
   Nan KH, 2005, J BIOMED MATER RES B, V75B, P328, DOI 10.1002/jbm.b.30310
   Nandamuri G, 2010, APPL PHYS LETT, V96, DOI 10.1063/1.3387812
   Nehra V, 2008, INT J ENG, V2, P53
   Niemira BA, 2008, J FOOD PROTECT, V71, P1357, DOI 10.4315/0362-028X-71.7.1357
   Nourbakhsh A, 2010, NANOTECHNOLOGY, V21, DOI 10.1088/0957-4484/21/43/435203
   Nozaki T., 2001, 15 INT S PLASM CHEM
   Nuccitelli R, 2006, BIOCHEM BIOPH RES CO, V343, P351, DOI 10.1016/j.bbrc.2006.02.181
   O'Connell D, 2011, APPL PHYS LETT, V98, DOI 10.1063/1.3521502
   OGUMI Z, 1992, SOLID STATE IONICS, V58, P345, DOI 10.1016/0167-2738(92)90139-G
   OGUMI Z, 1992, J APPL PHYS, V72, P1577, DOI 10.1063/1.351727
   Ohkawa H, 2006, SURF COAT TECH, V200, P5829, DOI 10.1016/j.surfcoat.2005.08.124
   Ohsawa A, 2000, J PHYS D APPL PHYS, V33, P1487, DOI 10.1088/0022-3727/33/12/310
   Oishi Y., 2009, ELECTROSTATIC PRECIP, P690
   Olofsson BA, 2007, MOL CANCER RES, V5, P1319, DOI 10.1158/1541-7786.MCR-07-0374
   Ostrikov K, 2011, J PHYS D APPL PHYS, V44, DOI 10.1088/0022-3727/44/17/174001
   Pan J, 2010, IEEE T PLASMA SCI, V38, P3143, DOI 10.1109/TPS.2010.2066291
   Park GY, 2012, PLASMA SOURCES SCI T, V21, DOI 10.1088/0963-0252/21/4/043001
   Park JK, 2011, INT ENDOD J, V44, P170, DOI 10.1111/j.1365-2591.2010.01828.x
   PEARLMAN NW, 1991, ARCH SURG-CHICAGO, V126, P1018
   Pekarek S, 2006, PLASMA PROCESS POLYM, V3, P308, DOI 10.1002/ppap.200500155
   Philip N, 2002, IEEE T PLASMA SCI, V30, P1429, DOI 10.1109/TPS.2002.804203
   Piroi M. M., 2009, INT S PLASM CHEM ISP
   Polytarchou C, 2005, J BIOL CHEM, V280, P40428, DOI 10.1074/jbc.M505120200
   Ptasinska Sylwia, 2009, Journal of Physics: Conference Series, V194, DOI 10.1088/1742-6596/194/15/152029
   Ptasinska S, 2010, PHYS CHEM CHEM PHYS, V12, P7779, DOI [10.1039/e001188f, 10.1039/c001188f]
   Qu LT, 2010, NANOTECHNOLOGY, V21, DOI 10.1088/0957-4484/21/30/305602
   Ragni L, 2010, J FOOD ENG, V100, P125, DOI 10.1016/j.jfoodeng.2010.03.036
   Ramen F., 2006, ALBUCASIS ABU ALQASI
   Rauen U, 2007, AM J PHYSIOL-CELL PH, V292, pC1440, DOI 10.1152/ajpcell.00366.2006
   Reddy EL, 2013, INT J ENERG RES, V37, P1280, DOI 10.1002/er.2924
   Reddy PMK, 2012, IND ENG CHEM RES, V51, P11097, DOI 10.1021/ie301122p
   Richardson J. P., 2000, P IEEE INT C PLASM S, P109
   Richmonds C, 2011, J AM CHEM SOC, V133, P17582, DOI 10.1021/ja207547b
   Robertson J., 2008, APPL PHYS LETT, V93
   Robinson J. A., 1997, IEEE IAS ANN M NEW O, V3, P1797
   Rodriguez-Romo LA, 2005, J FOOD PROTECT, V68, P711, DOI 10.4315/0362-028X-68.4.711
   Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905
   Roland U, 2002, CATAL TODAY, V73, P315, DOI 10.1016/S0920-5861(02)00015-9
   Rosocha L. A., 2000, ELECT DISCHARGES ENV, P244
   Rostaing J., 2007, US Patent App., Patent No. [090/304,950, 090304950]
   Rudolph R, 2003, PLASMAS POLYM, V8, P153, DOI 10.1023/A:1023954629461
   Rutala WA, 1998, AM J INFECT CONTROL, V26, P393, DOI 10.1016/S0196-6553(98)70034-3
   Rutberg Ph. G., 2011, IOP C SER MAT SCI EN, V19
   Samukawa S, 1996, PLASMA SOURCES SCI T, V5, P132, DOI 10.1088/0963-0252/5/2/004
   Schneider J, 2005, SURF COAT TECH, V200, P962, DOI 10.1016/j.surfcoat.2005.01.114
   Schutze A, 1998, IEEE T PLASMA SCI, V26, P1685, DOI 10.1109/27.747887
   Selcuk M, 2008, BIORESOURCE TECHNOL, V99, P5104, DOI 10.1016/j.biortech.2007.09.076
   Selvan ST, 2010, LANGMUIR, V26, P11631, DOI 10.1021/la903512m
   Shang NG, 2009, ACS NANO, V3, P1032, DOI 10.1021/nn900167p
   Sharma A, 2006, IEEE T PLASMA SCI, V34, P1290, DOI 10.1109/TPS.2006.878377
   Sharma R, 2005, IEEE T IND APPL, V41, P1373, DOI 10.1109/TIA.2005.853394
   Shashurin A, 2008, APPL PHYS LETT, V93, DOI 10.1063/1.3020223
   Shekhter AB, 1998, B EXP BIOL MED+, V126, P829, DOI 10.1007/BF02446923
   Shekhter AB, 2005, NITRIC OXIDE-BIOL CH, V12, P210, DOI 10.1016/j.niox.2005.03.004
   Shin HS, 2009, J BIOACT COMPAT POL, V24, P316, DOI 10.1177/0883911509104273
   Shiratani M, 2007, SURF COAT TECH, V201, P5468, DOI 10.1016/j.surfcoat.2006.07.012
   Simoes M, 2010, LWT-FOOD SCI TECHNOL, V43, P573, DOI 10.1016/j.lwt.2009.12.008
   Sladek REJ, 2004, IEEE T PLASMA SCI, V32, P1540, DOI 10.1109/TPS.2004.832636
   Stalder K. R., 2003, P GAS EL C SAN FRANC, P16
   Stan GE, 2010, DIG J NANOMATER BIOS, V5, P705
   Stoffels E, 2003, J PHYS D APPL PHYS, V36, P2908, DOI 10.1088/0022-3727/36/23/007
   Stoffels E., 2007, P INT C PLASM MED CO, P14
   Stoffels E, 2008, PLASMA PROCESS POLYM, V5, P599, DOI 10.1002/ppap.200800028
   Stoffels E, 2008, IEEE T PLASMA SCI, V36, P1441, DOI 10.1109/TPS.2008.2001084
   Stolz W., 2007, P 1 INT C PLASM MED, P15
   Stypczynska A, 2010, CHEM PHYS LETT, V500, P313, DOI 10.1016/j.cplett.2010.10.016
   Subrahmanyam C, 2006, APPL CATAL B-ENVIRON, V65, P150, DOI 10.1016/j.apcatb.2006.01.006
   Subrahmanyarn C, 2007, PLASMA CHEM PLASMA P, V27, P13, DOI 10.1007/s11090-006-9039-x
   SUGIYAMA K, 1986, PLASMA CHEM PLASMA P, V6, P179, DOI 10.1007/BF00571275
   Sun P, 2010, IEEE T PLASMA SCI, V38, P1892, DOI 10.1109/TPS.2009.2039585
   Sun Q, 2005, CHINESE CHEM LETT, V16, P839
   Takai E, 2012, PLASMA PROCESS POLYM, V9, P77, DOI 10.1002/ppap.201100063
   Tam E, 2009, NANOTECHNOLOGY, V20, DOI 10.1088/0957-4484/20/37/375603
   Tang X., 2011, ISPC 20 PHIL US, P52
   Tang XL, 2012, J PHYS CHEM C, V116, P10017, DOI 10.1021/jp300664f
   Tendero C, 2006, SPECTROCHIM ACTA B, V61, P2, DOI 10.1016/j.sab.2005.10.003
   Teng LH, 2004, SOLID STATE ELECTRON, V48, P309, DOI 10.1016/S0038-1101(03)00303-4
   Teo KBK, 2002, APPL PHYS LETT, V80, P2011, DOI 10.1063/1.1461868
   TEZUKA M, 1993, DENKI KAGAKU, V61, P794
   Thannickal VJ, 2000, AM J PHYSIOL-LUNG C, V279, pL1005
   Tipa RS, 2011, IEEE T PLASMA SCI, V39, P2978, DOI 10.1109/TPS.2011.2159868
   Tsai SH, 1999, ELECTROCHEM SOLID ST, V2, P247, DOI 10.1149/1.1390800
   Tsakadze E, 2002, INT J MOD PHYS B, V16, P1143, DOI 10.1142/S0217979202011019
   Tsakadze ZL, 2007, CARBON, V45, P2022, DOI 10.1016/j.carbon.2007.05.030
   Tsakadze ZL, 2005, SURF COAT TECH, V191, P49, DOI 10.1016/j.surfcoat.2004.02.020
   Tsaneva VN, 2002, VACUUM, V69, P261, DOI 10.1016/S0042-207X(02)00342-1
   Turtoi M, 2007, J FOOD ENG, V83, P47, DOI 10.1016/j.jfoodeng.2006.11.017
   Uhm HS, 2012, J APPL PHYS, V111, DOI 10.1063/1.3689848
   Uhm HS, 2011, APPL PHYS LETT, V99, DOI 10.1063/1.3672052
   Uskokovic V, 2011, J BIOMED MATER RES B, V96B, P152, DOI 10.1002/jbm.b.31746
   Van Durme J, 2007, APPL CATAL B-ENVIRON, V74, P161, DOI 10.1016/j.apcatb.2007.02.006
   Van Durme J, 2008, APPL CATAL B-ENVIRON, V78, P324, DOI 10.1016/j.apcatb.2007.09.035
   Vandamme M, 2011, PLASMA MED, V31, P27, DOI DOI 10.1615/PLASMAMED.V1.I1.30
   Vandenbroucke A, 2010, INT J PLASMA ENV SCI, V4, P135
   Vandenbulcke L, 2009, APPL PHYS LETT, V94, DOI 10.1063/1.3075604
   Vasilev K, 2010, BIOMATERIALS, V31, P532, DOI 10.1016/j.biomaterials.2009.09.074
   Vasilev K, 2009, EXPERT REV MED DEVIC, V6, P553, DOI 10.1586/ERD.09.36
   Veprek S., 1980, TOPICS CURRENT CHEM
   Vinu A, 2006, SCI TECHNOL ADV MAT, V7, P753, DOI 10.1016/j.stam.2006.10.007
   Vleugels M, 2005, IEEE T PLASMA SCI, V33, P824, DOI 10.1109/TPS.2005.844524
   Walsh J. L., 2007, APPL PHYS LETT, V91, P1
   Wang HY, 2010, BIOMATERIALS, V31, P8181, DOI 10.1016/j.biomaterials.2010.07.054
   Wang XH, 2005, J AM CHEM SOC, V127, P10982, DOI 10.1021/ja051240n
   Wang YJ, 2010, ADV MATER, V22, P4293, DOI 10.1002/adma.201001497
   Wang Y, 2010, ACS NANO, V4, P6146, DOI 10.1021/nn1017389
   Weltmann K.-D., 2008, J PHYS D, V41
   Wilhelm R, 1999, NATO ASI 3 HIGH TECH, V67, P123
   Xu SY, 2005, PLASMA PROCESS POLYM, V2, P373, DOI 10.1002/ppap.200400094
   Yajadda MMA, 2010, APPL PHYS LETT, V97, DOI 10.1063/1.3504260
   Yan W, 2012, ACS APPL MATER INTER, V4, P2637, DOI 10.1021/am300300f
   Yang J, 1997, APPL PHYS LETT, V70, P2975, DOI 10.1063/1.118761
   Yang QQ, 2005, PLASMA SCI TECHNOL, V7, P2660
   Yasuda H., 1985, PLASMA POLYM
   Yasuda H, 2008, PLASMA PROCESS POLYM, V5, P615, DOI 10.1002/ppap.200800036
   YASUDA HK, 1990, PLASMA POLYM PLASMA
   Yonson S, 2006, J PHYS D APPL PHYS, V39, P3508, DOI 10.1088/0022-3727/39/16/S08
   YOST RA, 1983, MASS SPECTROM REV, V2, P1, DOI 10.1002/mas.1280020102
   Yun H, 2010, FOOD CONTROL, V21, P1182, DOI 10.1016/j.foodcont.2010.02.002
   Zhang X., 2009, J APPL PHYS, V105
   Zheng J, 2008, ACS NANO, V2, P134, DOI 10.1021/nn700363t
   Zheng J, 2010, ADV MATER, V22, P1451, DOI 10.1002/adma.200903147
   Zhong-ai H., 2001, PLASMA SCI TECHNOL, V3, P927
   Zhu T, 2009, INT J ENVIRON SCI TE, V6, P141, DOI 10.1007/BF03326068
NR 277
TC 58
Z9 59
U1 5
U2 85
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2046-2069
J9 RSC ADV
JI RSC Adv.
PY 2013
VL 3
IS 31
BP 12540
EP 12567
DI 10.1039/c3ra41277f
PG 28
WC Chemistry, Multidisciplinary
SC Chemistry
GA 183CM
UT WOS:000321791200005
DA 2018-12-27
ER

PT J
AU Hashimov, AM
   Nayir, A
   Kazimov, SA
   Bondyakov, AS
   Hasanova, SI
AF Hashimov, A. M.
   Nayir, A.
   Kazimov, S. A.
   Bondyakov, A. S.
   Hasanova, S. I.
TI RETRACTED: Methods of Improving Superconductive Fault Current Limiting
   Devices in Power Engineering (Retracted Article)
SO ELEKTRONIKA IR ELEKTROTECHNIKA
LA English
DT Article; Retracted Publication
DE Superconductive; fault currents; cryostat; transformers
AB Superconducting fault current limiter is a fundamentally new type of device that has no direct analogue among the traditional electrical equipments. The basis of most of its variety, subject to intensive research in the world, is based on the principle of transition-temperature superconductors in the resistive (normal) condition when the current extended, flowing through the superconducting fault current limiter, above defined value. The problem of scaling on superconducting power of current-limiting transformer-type device has been investigated. Opportunities of increasing nominal power of such device based on experiments and calculations have been proposed.
C1 [Hashimov, A. M.; Kazimov, S. A.; Bondyakov, A. S.; Hasanova, S. I.] Azerbaijan Natl Acad Sci, Inst Phys, AZ-1143 Baku, Azerbaijan.
   [Nayir, A.] Fatih Univ, TR-34500 Istanbul, Turkey.
RP Hashimov, AM (reprint author), Azerbaijan Natl Acad Sci, Inst Phys, H Javid Av 33, AZ-1143 Baku, Azerbaijan.
EM anayir@fatih.edu.tr
CR Dmitriyev Y. V., 2010, P TPE 6 INT C, P196
   Fleishman L. S., 2005, POW STATIONS
   Glebov I. A., 1985, PROBLEM INPUT CURREN, P208
   Kazimov Sh, 2006, P 3 INT C ANK TURK, P118
   Kryuchkov I. P., 2006, CALCULATION SHORT CI, P416
   Rettelbach T, 2003, SUPERCOND SCI TECH, V16, P645, DOI 10.1088/0953-2048/16/5/318
   Shazimov K., 2009, POWER ENG PROBLEMS, P98
   Vasiliev A. A., 1990, ELECT PART STATIONS, P576
   Volkov E. P., 2009, ENERGY
NR 9
TC 0
Z9 0
U1 4
U2 14
PU KAUNAS UNIV TECHNOLOGY
PI KAUNAS
PA KAUNAS UNIV TECHNOL, DEPT ELECTRONICS ENGINEERING, STUDENTU STR 50,
   KAUNAS, LT-51368, LITHUANIA
SN 1392-1215
J9 ELEKTRON ELEKTROTECH
JI Elektron. Elektrotech.
PY 2013
VL 19
IS 3
BP 33
EP 36
DI 10.5755/j01.eee.19.3.1441
PG 4
WC Engineering, Electrical & Electronic
SC Engineering
GA 165PT
UT WOS:000320496500007
DA 2018-12-27
ER

PT J
AU Shah, BA
AF Shah, Babar Ali
TI RETRACTED: Status of groundwater arsenic pollution in Holocene aquifers
   from parts of the Ghaghara Basin, India: Its relation to geomorphology
   and hydrogeological setting(Retracted article. See vol.96, pg.84, 2016)
SO PHYSICS AND CHEMISTRY OF THE EARTH
LA English
DT Article; Retracted Publication
DE Groundwater As; Ghaghara Basin; Older Alluvium; Holocene aquifer;
   Geomorphology
ID MIDDLE GANGA PLAIN; QUATERNARY STRATIGRAPHY; DRINKING-WATER; BANGLADESH;
   CONTAMINATION; BENGAL; DISTRICT; BIHAR
AB A groundwater arsenic (As) survey was carried out for the first time in Faizabad, Gonda, and Basti districts of UP and 38%, 61%, and 42% of tubewells in these districts, respectively have As > 10 mu g/l (WHO guideline). Moreover, 15%, 45%, and 26% of tubewells in Faizabad, Gonda, and Basti districts, respectively have As above 50 mu g/l, the Indian standards for As in drinking water. About 86%, 69%, and 35% of tubewells in Faizabad, Gonda, and Basti districts, respectively are from shallow depth (21-45 m), and it is worth noticing that 47% As-contaminated (As > 10 mu g/l) tubewells in these three districts are located within the depth of 10-35 m in the Holocene Newer Alluvium aquifers. The high content of As (7.11 mg/kg) is recorded in suspended river sediments of the Ghaghara River as well. Most of the As-contaminated tubewells in Faizabad, Gonda, and Basti districts are located close to abandoned or present meander channels and floodplains of the Ghaghara River. In contrast, tubewells in Faizabad, Ayodhya, and Nawabganj towns are As-safe because of their positions on the Pleistocene Older Alluvium upland surfaces. Deeper tubewells (>50 m) in the Pleistocene Older Alluvium aquifers are suggested as option for As-safe groundwater. (C) 2013 Elsevier Ltd. All rights reserved.
C1 Jadavpur Univ, Dept Geol, Kolkata 700032, India.
RP Shah, BA (reprint author), Jadavpur Univ, Dept Geol, Kolkata 700032, India.
EM bashahju@yahoo.com
FU Department of Science and Technology; Council of Scientific and
   Industrial Research
FX I thank IICB-Kolkata for As analysis. The author would like to thank
   local field assistants from UP for helping to collect tubewells water
   and borehole sediments. The suggestions and comments of the three
   anonymous reviewers and editors are greatly appreciated. The financial
   support of this study came from Department of Science and Technology
   Fast Track Young Scientist Scheme and Council of Scientific and
   Industrial Research Scientists' Pool Scheme, which is gratefully
   acknowledged.
CR Acharyya SK, 2010, CURR SCI INDIA, V99, P1787
   Acharyya SK, 2000, ENVIRON GEOL, V39, P1127, DOI 10.1007/s002540000107
   Acharyya SK, 2007, J ENVIRON SCI HEAL A, V42, P1795, DOI 10.1080/10934520701566744
   Akai J, 2004, APPL GEOCHEM, V19, P215, DOI 10.1016/j.apgeochem.2003.09.008
   Anawar HM, 2003, J GEOCHEM EXPLOR, V77, P109, DOI 10.1016/S0375-6742(02)00273-X
   Berg M, 2001, ENVIRON SCI TECHNOL, V35, P2621, DOI 10.1021/es010027y
   Bhattacharjee S, 2005, CHEMOSPHERE, V58, P1203, DOI 10.1016/j.chemosphere.2004.09.055
   BHATTACHARYA P, 1997, WATER RESOUR DEV, V13, P79, DOI DOI 10.1080/07900629749944
   Biswas D, 2008, TOXICOL APPL PHARM, V230, P57, DOI 10.1016/j.taap.2008.02.003
   Bureau of Indian Standards, 2003, IND STAND DRINK WAT, V2
   Chakraborti D, 2003, ENVIRON HEALTH PERSP, V111, P1194, DOI 10.1289/ehp.5966
   Dhar RK, 1997, CURR SCI INDIA, V73, P48
   Dwivedi GN, 1997, J GEOL SOC INDIA, V49, P193
   Getrost H., 1975, ORGANIC REAGENTS TRA
   Guillot S, 2007, J ENVIRON SCI HEAL A, V42, P1785, DOI 10.1080/10934520701566702
   Gurung J, 2005, ENVIRON GEOL, V49, P98, DOI 10.1007/s00254-005-0063-6
   Kinniburgh D. G., 2001, WC0019 BRIT GEOL SUR
   Kumar G, 1996, GEOL SURV INDIA SPL, V21, P173
   Nickson R, 1998, NATURE, V395, P338, DOI 10.1038/26387
   Nickson RT, 2005, APPL GEOCHEM, V20, P55, DOI 10.1016/j.apgeochem.2004.06.004
   Pascoe EH, 1964, GEOL SURV IND, VIII, P1980
   Pathak BD, 1978, B GEOL SURV IND SR B, V44, P1
   Polya DA, 2005, MINERAL MAG, V69, P807, DOI 10.1180/0026461056950290
   Ravenscroft P., 2008, POLLUTION GLOBAL SYN
   Shah BA, 2008, ENVIRON GEOL, V53, P1553, DOI 10.1007/s00254-007-0766-y
   Shamsudduha M, 2008, J CONTAM HYDROL, V99, P112, DOI 10.1016/j.jconhyd.2008.03.010
   Singh IB, 2004, J GEOL SOC INDIA, V64, P431
   Singh M, 2010, ENVIRON EARTH SCI, V59, P1703, DOI 10.1007/s12665-009-0152-z
   Srivastava NK, 2009, GROUND WATER BROCHUR, P2008
   SUN GF, 2001, ENV SCI, V8, P425
   Tewari AP, 1977, HIMAL GEOL, V7, P235
   Tseng CH, 2000, ENVIRON HEALTH PERSP, V108, P847, DOI 10.1289/ehp.00108847
   von Bromssen M, 2007, SCI TOTAL ENVIRON, V379, P121, DOI 10.1016/j.scitotenv.2006.06.028
   WHO, 1993, GUID DRINK WAT QUAL, VI
NR 34
TC 3
Z9 3
U1 3
U2 26
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1474-7065
EI 1873-5193
J9 PHYS CHEM EARTH
JI Phys. Chem. Earth
PY 2013
VL 58-60
BP 68
EP 76
DI 10.1016/j.pce.2013.04.015
PG 9
WC Geosciences, Multidisciplinary; Meteorology & Atmospheric Sciences;
   Water Resources
SC Geology; Meteorology & Atmospheric Sciences; Water Resources
GA 171DA
UT WOS:000320904100010
DA 2018-12-27
ER

PT J
AU Huang, HS
   Hwang, YH
AF Huang, Ho-Shuenn
   Hwang, Yao-Hsin
TI RETRACTED: Fluid Flow Simulations Based on an Equation-Solving Solution
   Gradient Strategy (Retracted article. See 874351, 2014)
SO MATHEMATICAL PROBLEMS IN ENGINEERING
LA English
DT Article; Retracted Publication
ID NAVIER-STOKES EQUATIONS; BACKWARD-FACING STEP; ACCURATE DISCRETIZATION;
   INCOMPRESSIBLE-FLOW; DIFFUSION EQUATION; POLYGONAL GRIDS; PART I;
   COMPACT; SCHEME; FORMULATION
AB A compact and accurate discretization for fluid flow simulations is introduced in this paper. Contrary to the common wisdom in a convectional scheme, the solution gradient required for a high-resolution scheme is provided by solving its corresponding difference equation rather than by interpolation from solution values at neighboring computational nodes. To achieve this goal, a supplementary equation and its associated control volume are proposed to retain a compact and accurate discretization. Scheme essentials are exposed by numerical analyses on simple one-dimensional modeled problems to reveal its formal accuracy. Several test problems are solved to illustrate the feasibility of present formulation. From the obtained numerical results, it is evident that the proposed scheme will be a useful tool to simulate fluid flow problems in arbitrary domains.
C1 [Huang, Ho-Shuenn] Natl Kaohsiung Marine Univ, Dept Naval Architecture & Ocean Engn, Kaohsiung 811, Taiwan.
   [Hwang, Yao-Hsin] Natl Kaohsiung Marine Univ, Dept Marine Engn, Kaohsiung 811, Taiwan.
RP Huang, HS (reprint author), Natl Kaohsiung Marine Univ, Dept Naval Architecture & Ocean Engn, Kaohsiung 811, Taiwan.
EM hoshuenn@webmail.nkmu.edu.tw
CR ARMALY BF, 1983, J FLUID MECH, V127, P473, DOI 10.1017/S0022112083002839
   Barth TJ, 1990, 900013 AIAA
   Erturk E, 2008, COMPUT FLUIDS, V37, P633, DOI 10.1016/j.compfluid.2007.09.003
   GHIA U, 1982, J COMPUT PHYS, V48, P387, DOI 10.1016/0021-9991(82)90058-4
   Hwang YH, 2011, NUMER HEAT TR B-FUND, V59, P381, DOI 10.1080/10407790.2011.572725
   Hwang YH, 2010, NUMER HEAT TR B-FUND, V58, P440, DOI 10.1080/10407790.2010.522873
   Hwang YH, 2010, NUMER HEAT TR B-FUND, V58, P193, DOI [10.1080/10407790.2010.508656, 10.1080/10407790.2010.508657]
   Hwang YH, 2010, NUMER HEAT TR B-FUND, V58, P170, DOI [10.1080/10407790.2010.508656, 10.1080/10407790.2010.508657]
   Hwang YH, 2010, NUMER HEAT TR B-FUND, V58, P145, DOI 10.1080/10407790.2010.508655
   HWANG YH, 1995, NUMER HEAT TR B-FUND, V27, P323, DOI 10.1080/10407799508914960
   Hwang YH, 1997, NUMER HEAT TR B-FUND, V32, P321, DOI 10.1080/10407799708915012
   HWANG YH, 1994, J COMPUT PHYS, V110, P134, DOI 10.1006/jcph.1994.1010
   HWANG YH, 1995, NUMER HEAT TR B-FUND, V27, P337, DOI 10.1080/10407799508914961
   HWANG YH, 1993, NUMER HEAT TR B-FUND, V23, P237, DOI 10.1080/10407799308914899
   Kulikovsky AA, 2001, J COMPUT PHYS, V173, P716, DOI 10.1006/jcph.2001.6909
   LO SH, 1985, INT J NUMER METH ENG, V21, P1403, DOI 10.1002/nme.1620210805
   Moukalled F, 1997, NUMER HEAT TR B-FUND, V31, P91, DOI 10.1080/10407799708915101
   Ollivier-Gooch C, 2002, J COMPUT PHYS, V181, P729, DOI 10.1006/jcph.2002.7159
   Patankar SV, 1980, NUMERICAL HEAT TRANS
   SHYY W, 1985, J COMPUT PHYS, V57, P415, DOI 10.1016/0021-9991(85)90188-3
NR 20
TC 1
Z9 1
U1 2
U2 10
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1024-123X
EI 1563-5147
J9 MATH PROBL ENG
JI Math. Probl. Eng.
PY 2013
AR 409846
DI 10.1155/2013/409846
PG 19
WC Engineering, Multidisciplinary; Mathematics, Interdisciplinary
   Applications
SC Engineering; Mathematics
GA 165VZ
UT WOS:000320515000001
OA DOAJ Gold
DA 2018-12-27
ER

PT J
AU Kajani, MT
   Kilicman, A
   Maleki, M
AF Kajani, Majid Tavassoli
   Kilicman, Adem
   Maleki, Mohammad
TI RETRACTED: The Rational Third-Kind Chebyshev Pseudospectral Method for
   the Solution of the Thomas-Fermi Equation over Infinite Interval
   (Retracted article. See 585162, 2015)
SO MATHEMATICAL PROBLEMS IN ENGINEERING
LA English
DT Article; Retracted Publication
ID ORDINARY DIFFERENTIAL-EQUATIONS; SEMIINFINITE INTERVAL; PERTURBATIVE
   APPROACH; NONLINEAR PROBLEMS; ANALYTIC SOLUTION; SPECTRAL METHODS;
   SERIES SOLUTION; TAU-METHOD
AB We propose a pseudospectral method for solving the Thomas-Fermi equation which is a nonlinear ordinary differential equation on semi-infinite interval. This approach is based on the rational third-kind Chebyshev pseudospectral method that is indeed a combination of Tau and collocation methods. This method reduces the solution of this problem to the solution of a system of algebraic equations. Comparison with some numerical solutions shows that the present solution is highly accurate.
C1 [Kajani, Majid Tavassoli] Islamic Azad Univ, Dept Math, Khorasgan Branch, Esfahan 81595158, Iran.
   [Kilicman, Adem] Univ Putra Malaysia, Dept Math, Serdang 43400, Selangor, Malaysia.
   [Maleki, Mohammad] Islamic Azad Univ, Dept Math, Mobarakeh Branch, Esfahan 81595158, Iran.
RP Kilicman, A (reprint author), Univ Putra Malaysia, Dept Math, Serdang 43400, Selangor, Malaysia.
EM akilicman@putra.upm.edu.my
FU Universiti Putra Malaysia under the ERGS Grant Scheme [5527068]
FX The authors express their sincere thanks to the referees for their
   comments on the earlier version of this paper and their helpful
   suggestions. The second author also gratefully acknowledges that this
   paper was partially supported by the Universiti Putra Malaysia under the
   ERGS Grant Scheme having Project no. 5527068.
CR Abramowitz M., 1972, HDB MATH FUNCTIONS
   Adomian G, 1998, APPL MATH LETT, V11, P131, DOI 10.1016/S0893-9659(98)00046-9
   Ben-Yu Guo, 2000, Journal of Scientific Computing, V15, P117, DOI 10.1023/A:1007698525506
   BENDER CM, 1989, J MATH PHYS, V30, P1447, DOI 10.1063/1.528326
   Boyd JP, 2013, J COMPUT APPL MATH, V244, P90, DOI 10.1016/j.cam.2012.11.015
   Boyd JP, 2003, J COMPUT PHYS, V188, P56, DOI 10.1016/S0021-9991(03)00127-X
   BOYD JP, 1987, J COMPUT PHYS, V70, P63, DOI 10.1016/0021-9991(87)90002-7
   BOYD JP, 1982, J COMPUT PHYS, V45, P43, DOI 10.1016/0021-9991(82)90102-4
   Boyd JP, 2001, CHEBYSHEV FOURIER SP
   CEDILLO A, 1993, J MATH PHYS, V34, P2713, DOI 10.1063/1.530090
   Chandrasekhar S., 1957, INTRO STUDY STELLAR
   Dadkhah Tirani M., 2011, P INT C COMP APPL MA, P835
   Davis H. T, 1962, INTRO NONLINEAR DIFF
   Guo BY, 2000, NUMER MATH, V86, P635, DOI 10.1007/s002110000168
   Guo BY, 2000, J COMPUT MATH, V18, P95
   Khan H, 2007, PHYS LETT A, V365, P111, DOI 10.1016/j.physleta.2006.12.064
   KOBAYASHI S, 1955, J PHYS SOC JPN, V10, P759, DOI 10.1143/JPSJ.10.759
   LAURENZI BJ, 1990, J MATH PHYS, V31, P2535, DOI 10.1063/1.528998
   Liao S., 2004, PERTURBATION INTRO H, V2
   Liao SJ, 2003, APPL MATH COMPUT, V144, P495, DOI 10.1016/S0096-3003(02)00423-X
   Maday Y., 1985, RECH AEROSPATIALE, V6, P1
   Mandelzweig VB, 2001, COMPUT PHYS COMMUN, V141, P268, DOI 10.1016/S0010-4655(01)00415-5
   Notaris SE, 1997, J COMPUT APPL MATH, V81, P83, DOI 10.1016/S0377-0427(97)00018-6
   Parand K, 2004, PHYS SCRIPTA, V69, P353, DOI 10.1238/Physica.Regular.069a00353
   Parand K, 2004, APPL MATH COMPUT, V149, P893, DOI 10.1016/j.amc.2003.09.006
   Parand K, 2004, INT J COMPUT MATH, V81, P73, DOI 10.1080/00207160310001614981
   Ramos JI, 2004, COMPUT PHYS COMMUN, V158, P12, DOI 10.1016/j.comphy.2003.11.003
   Shen J, 2000, SIAM J NUMER ANAL, V38, P1113, DOI 10.1137/S0036142999362936
   Siyyam HI, 2001, J COMPUT ANAL APPL, V3, P173, DOI 10.1023/A:1010141309991
   Tavassoli Kajani M., 2011, P INT C COMP APPL MA, P840
   Wazwaz AM, 1999, APPL MATH COMPUT, V105, P11, DOI 10.1016/S0096-3003(98)10090-5
   Yao BH, 2008, APPL MATH COMPUT, V203, P396, DOI 10.1016/j.amc.2008.04.050
NR 32
TC 1
Z9 1
U1 3
U2 12
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1024-123X
EI 1563-5147
J9 MATH PROBL ENG
JI Math. Probl. Eng.
PY 2013
AR 537810
DI 10.1155/2013/537810
PG 6
WC Engineering, Multidisciplinary; Mathematics, Interdisciplinary
   Applications
SC Engineering; Mathematics
GA 177AX
UT WOS:000321349000001
OA DOAJ Gold
DA 2018-12-27
ER

PT J
AU Manivasagan, P
   Venkatesan, J
   Sivakumar, K
   Kim, SK
AF Manivasagan, Panchanathan
   Venkatesan, Jayachandran
   Sivakumar, Kannan
   Kim, Se-Kwon
TI RETRACTED: Marine actinobacterial metabolites: Current status and future
   perspectives (Retracted article. See vol. 211, pg. 69, 2018)
SO MICROBIOLOGICAL RESEARCH
LA English
DT Review; Retracted Publication
DE Marine actinobacteria; Metabolites; Antibiotics; Melanin; Enzymes
ID 16S RIBOSOMAL-RNA; ACTINOMYCETE SALINISPORA-TROPICA; STREPTOMYCES-SP;
   ALPHA-AMYLASE; CELLULASE PRODUCTION; GENUS STREPTOMYCES; ANTIFUNGAL
   ACTIVITY; OCEAN SEDIMENTS; DRUG DISCOVERY; SP-NOV.
AB Marine actinobacteriology is one of the major emerging areas of research in tropics. Marine actinobacteria are the most economically as well as biotechnologically valuable prokaryotes. Many representatives of the order Actinomycetales are prolific producers of thousands of biologically active secondary metabolites. Among the actinobacteria, streptomycetes group are considered economically important because out of the approximately more than 10,000 known antibiotics, 50-55% are produced by this genus. The ecological role of actinobacteria in the marine ecosystem is largely neglected and various assumptions meant there was little incentive to isolate marine strains for search and discovery of new drugs. The search for and discovery of novel actinobacteria are of significant interest to drug discovery due to a growing need for the development of new and potent therapeutic agents. In this review an evaluation is made on the present state of research on marine actinobacterial metabolites and its perspectives. The highlights include the production and biotechnological applications of metabolites such as antibiotics, anticancer compounds, melanins, enzymes and enzyme inhibitors, single cell protein and as probiotics in aquaculture. With increasing advancement in science and technology, there would be greater demands in future for new bioactive compounds synthesized by actinobacteria from various marine sources. (C) 2013 Elsevier GmbH. All rights reserved.
C1 [Manivasagan, Panchanathan; Kim, Se-Kwon] Pukyong Natl Univ, Dept Chem, Marine Biotechnol Lab, Pusan 608737, South Korea.
   [Manivasagan, Panchanathan; Venkatesan, Jayachandran; Kim, Se-Kwon] Pukyong Natl Univ, Marine Bioproc Res Ctr, Pusan 608737, South Korea.
   [Venkatesan, Jayachandran; Kim, Se-Kwon] Pukyong Natl Univ, Dept Chem, Pusan 608737, South Korea.
   [Sivakumar, Kannan] Annamalai Univ, Fac Marine Sci, Ctr Adv Study Marine Biol, Parangipettai 608502, Tamil Nadu, India.
RP Kim, SK (reprint author), Pukyong Natl Univ, Dept Chem, Marine Biotechnol Lab, Pusan 608737, South Korea.
EM sknkim@pknu.ac.kr
RI Manivasagan, Panchanathan/O-2669-2013
OI Manivasagan, Panchanathan/0000-0002-9548-0451; Kim,
   Se-Kwon/0000-0001-6507-9539
FU Ministry of Land, Transport and Maritime Affairs, Republic of Korea
FX The authors acknowledge the Marine Bioprocess Research Center of the
   Marine Biotechnology Project, funded by the Ministry of Land, Transport
   and Maritime Affairs, Republic of Korea, for his support and
   encouragement.
CR Abdelmohsen UR, 2010, MAR DRUGS, V8, P399, DOI 10.3390/md8030399
   Al-Sane NA, 2002, KUWAIT J SCI ENG, V29, P125
   Al-Zarban SS, 2002, KUWAIT J SCI ENG, V29, P99
   ALLDREDGE AL, 1988, PROG OCEANOGR, V20, P41, DOI 10.1016/0079-6611(88)90053-5
   Amal AM, 2011, RES J CHEM SCI, V1, P22
   Andersson MA, 1998, APPL ENVIRON MICROB, V64, P4767
   Anitha A, 2009, ACAD J PLANT SCI, V2, P119
   AOKI H, 1976, J ANTIBIOT, V29, P492, DOI 10.7164/antibiotics.29.492
   AOYAGI T, 1992, J ANTIBIOT, V45, P1795, DOI 10.7164/antibiotics.45.1795
   ARAI T, 1972, APPL MICROBIOL, V23, P402
   Arasu MV, 2008, J MYCOL MED, V18, P147, DOI 10.1016/j.mycmed.2008.07.004
   Arumugam M, 2010, APPL MICROBIOL BIOT, V86, P109, DOI 10.1007/s00253-009-2311-2
   Arunachalam R., 2010, Current Research in Bacteriology, V3, P15
   Asolkar RN, 2006, J NAT PROD, V69, P1756, DOI 10.1021/np0603828
   Balachandran C., 2012, Asian Pacific Journal of Tropical Biomedicine, V2, pS392
   Berdy J, 2005, J ANTIBIOT, V58, P1, DOI 10.1038/ja.2005.1
   BERDY J, 1980, PROCESS BIOCHEM, V15, P28
   BERGER LR, 1958, BIOCHIM BIOPHYS ACTA, V29, P522
   Bertsch A, 2005, BIORESOURCE TECHNOL, V96, P1703, DOI 10.1016/j.biortech.2004.12.026
   Betina V., 1983, CHEM BIOL ANTIBIOTIC
   BEWICK MWM, 1976, MICROBIOS, V16, P191
   BEYER M, 1985, APPL MICROBIOL BIOT, V23, P140
   Bhat MK, 2000, BIOTECHNOL ADV, V18, P355, DOI 10.1016/S0734-9750(00)00041-0
   Bibb MJ, 2005, CURR OPIN MICROBIOL, V8, P208, DOI 10.1016/j.mib.2005.02.016
   Blunt JW, 2007, CHEMINFORM, V38
   BOCKLE B, 1995, APPL ENVIRON MICROB, V61, P3705
   Bode HB, 2002, CHEMBIOCHEM, V3, P619, DOI 10.1002/1439-7633(20020703)3:7<619::AID-CBIC619>3.0.CO;2-9
   BODE W, 1992, EUR J BIOCHEM, V204, P433, DOI 10.1111/j.1432-1033.1992.tb16654.x
   Bruns A, 2003, INT J SYST EVOL MICR, V53, P1917, DOI 10.1099/ijs.0.02735-0
   Bruntner C, 2005, J ANTIBIOT, V58, P346, DOI 10.1038/ja.2005.43
   Buchert J, 1997, NICH WORLD TEXT WORL, P284
   Bull AT, 2007, TRENDS MICROBIOL, V15, P491, DOI 10.1016/j.tim.2007.10.004
   Bull AT, 2000, MICROBIOL MOL BIOL R, V64, P573, DOI 10.1128/MMBR.64.3.573-606.2000
   Bull AT, 2005, ANTON LEEUW INT J G, V87, P65, DOI 10.1007/s10482-004-6562-8
   BURG RW, 1979, ANTIMICROB AGENTS CH, V15, P361, DOI 10.1128/AAC.15.3.361
   Butler MJ, 1998, CAN J MICROBIOL, V44, P1115, DOI 10.1139/cjm-44-12-1115
   Chakraborty S, 2012, INDIAN J BIOTECHNOL, V11, P427
   Chakraborty S, 2011, J MOL CATAL B-ENZYM, V68, P52, DOI 10.1016/j.molcatb.2010.09.009
   Chakraborty S, 2009, J MOL CATAL B-ENZYM, V58, P17, DOI 10.1016/j.molcatb.2008.10.011
   CHANDRAMOHAN D, 1972, CURR SCI INDIA, V41, P245
   Chao YP, 2007, J ENVIRON SCI-CHINA, V19, P1125, DOI 10.1016/S1001-0742(07)60183-1
   Charoensopharat K, 2010, AFR J BIOTECHNOL, V7, P1362
   Chauhan D, 2005, CANCER CELL, V8, P407, DOI 10.1016/j.ccr.2005.10.013
   Chen CC, 1997, ENZYME MICROB TECH, V20, P39, DOI 10.1016/S0141-0229(97)82192-8
   Chitte RR, 1999, LETT APPL MICROBIOL, V28, P131, DOI 10.1046/j.1365-2672.1999.00484.x
   Cho JY, 2006, J NAT PROD, V69, P425, DOI 10.1021/np050402q
   Clancy CMR, 2001, BIOCHEMISTRY-US, V40, P13353, DOI 10.1021/bi010786t
   CLAUS H, 1985, LANDWIRT FORSCH, V38, P48
   CONN HO, 1977, GASTROENTEROLOGY, V72, P573
   Coombs JT, 2004, BIOL CONTROL, V29, P359, DOI 10.1016/j.biocontrol.2003.08.001
   Dahiya Neetu, 2005, Electron. J. Biotechnol., V8, P14
   Das M, 2007, APPL ENVIRON MICROB, V73, P756, DOI 10.1128/AEM.01170-06
   Das S, 2008, APPL MICROBIOL BIOT, V81, P419, DOI 10.1007/s00253-008-1731-8
   Das S, 2008, CHIN J OCEANOL LIMN, V26, P166, DOI 10.1007/s00343-008-0166-5
   Das S, 2006, CURR SCI INDIA, V90, P1325
   Das S, 2010, AQUACULTURE, V305, P32, DOI 10.1016/j.aquaculture.2010.04.001
   Dastager SG, 2008, CURR MICROBIOL, V57, P638, DOI 10.1007/s00284-008-9257-y
   Dastager SG, 2006, AFR J BIOTECHNOL, V5, P1131
   Davidson RN, 2009, T ROY SOC TROP MED H, V103, P653, DOI 10.1016/j.trstmh.2008.09.008
   De Azeredo LAI, 2004, ENZYME MICROB TECH, V34, P354, DOI 10.1016/j.enzmictec.2003.11.015
   de Lima ALG, 2005, ENZYME MICROB TECH, V37, P272, DOI 10.1016/j.enzmictec.2005.03.016
   Demain A L, 1998, Int Microbiol, V1, P259
   Devendra Kumar, 2012, Research Journal of Agricultural Science, V44, P184
   Dixit VS, 2000, BBA-GEN SUBJECTS, V1523, P261, DOI 10.1016/S0304-4165(00)00132-X
   Donia M, 2003, LANCET INFECT DIS, V3, P338, DOI 10.1016/S1473-3099(03)00655-8
   DOULL JL, 1994, J IND MICROBIOL, V13, P120, DOI 10.1007/BF01584109
   DOZIE INS, 1994, WORLD J MICROB BIOT, V10, P563, DOI 10.1007/BF00367668
   Egan S, 1998, APPL ENVIRON MICROB, V64, P5061
   El-Bondkly AM, 2010, CAN J MICROBIOL, V56, P748, DOI [10.1139/W10-058, 10.1139/w10-058]
   Ellaiah P, 2004, ASIAN J MICROBIOL BI, V6, P53
   Esawy MA, 2007, RES J AGR BIOL SCI, V3, P808
   Falagas ME, 2008, EXPERT REV ANTI-INFE, V6, P593, DOI 10.1586/14787210.6.5.593
   Faust U, 1987, FUNDAMENTALS BIOTECH
   Feling RH, 2003, ANGEW CHEM INT EDIT, V42, P355, DOI 10.1002/anie.200390115
   Fenical W, 2006, NAT CHEM BIOL, V2, P666, DOI 10.1038/nchembio841
   Fiedler HP, 2008, J ANTIBIOT, V61, P158, DOI 10.1038/ja.2008.125
   Fiedler HP, 2005, ANTON LEEUW INT J G, V87, P37, DOI 10.1007/s10482-004-6538-8
   Fourati-Ben Fguira L, 2005, RES MICROBIOL, V156, P341, DOI 10.1016/j.resmic.2004.10.006
   Fox JL, 2006, NAT BIOTECHNOL, V24, P1521, DOI 10.1038/nbt1206-1521
   Frandberg E, 2000, CAN J MICROBIOL, V46, P753, DOI 10.1139/cjm-46-8-753
   Friedrich AB, 1996, APPL ENVIRON MICROB, V62, P2875
   Fujii I, 1998, CHEM INF, V29
   FUJIWARA A, 1986, CRIT REV BIOTECHNOL, V3, P133
   Gandhimathi R, 2008, J MYCOL MED, V18, P16, DOI 10.1016/j.mycmed.2007.11.001
   Ganesan S, 2011, AFR J MICROBIOL RES, V5, P3437
   Gao XC, 2012, MICROBIOL RES, V167, P616, DOI 10.1016/j.micres.2012.02.008
   Gao XiaoNing, 2010, Journal of Zhejiang University (Agriculture and Life Sciences), V36, P615
   Georis J, 2000, PROTEIN SCI, V9, P466
   Germano S, 2003, ENZYME MICROB TECH, V32, P246, DOI 10.1016/S0141-0229(02)00283-1
   Gesheva V, 2005, MICROBIOL RES, V160, P243, DOI 10.1016/j.micres.2004.06.005
   GOODAY GW, 1990, ADV MICROB ECOL, V11, P387
   GOODFELLOW M, 1983, ANNU REV MICROBIOL, V37, P189, DOI 10.1146/annurev.mi.37.100183.001201
   Goodfellow M., 1984, BIOL BIOCH BIOMEDICA, P453
   Goodfellow M, 1994, HDB NEW BACTERIAL SY, P3
   Gorajana A, 2005, J ANTIBIOT, V58, P526, DOI 10.1038/ja.2005.72
   GRIFFITH RS, 1981, REV INFECT DIS, V3, pS200
   Grossart HP, 2004, FEMS MICROBIOL ECOL, V47, P387, DOI 10.1016/S0168-6496(03)00305-2
   Haefner B, 2003, DRUG DISCOV TODAY, V8, P536, DOI 10.1016/S1359-6446(03)02713-2
   Haggag WM, 2012, J MICROBIOL RES, V2, P145
   Han SK, 2003, INT J SYST EVOL MICR, V53, P2061, DOI 10.1099/ijs.0.02627-0
   Handelsman J, 2004, MICROBIOL MOL BIOL R, V68, P669, DOI 10.1128/MMBR.68.4.669-685.2004
   Hansen LH, 2001, APPL ENVIRON MICROB, V67, P239, DOI 10.1128/AEM.67.1.239-244.2001
   HATSU M, 1992, J ANTIBIOT, V45, P320, DOI 10.7164/antibiotics.45.320
   Hayakawa Y, 2007, J ANTIBIOT, V60, P196, DOI 10.1038/ja.2007.22
   Heald SC, 2001, ANTON LEEUW INT J G, V80, P169, DOI 10.1023/A:1012227302373
   Helaly SE, 2011, ORG LETT, V13, P1052, DOI 10.1021/ol1031014
   HELMKE E, 1984, INT J SYST BACTERIOL, V34, P127, DOI 10.1099/00207713-34-2-127
   Hernandez ILC, 2004, J BRAZIL CHEM SOC, V15, P441, DOI 10.1590/S0103-50532004000300017
   HERR RR, 1967, J AM CHEM SOC, V89, P4808, DOI 10.1021/ja00994a053
   Hoefs R, 2000, EUR J ORG CHEM, V2000, P1883
   Hohmann C, 2009, J ANTIBIOT, V62, P99, DOI 10.1038/ja.2008.24
   HOLLSTEIN U, 1974, CHEM REV, V74, P625, DOI 10.1021/cr60292a002
   HOLZ R, 1970, J GEN PHYSIOL, V56, P125, DOI 10.1085/jgp.56.1.125
   Huang YF, 2006, NAT PROD RES, V20, P1207, DOI 10.1080/14786410600899142
   Hussein AM, 2007, J CHEM TECH BIOTECH, V53, P147
   Imada C, 2005, ANTON LEEUW INT J G, V87, P59, DOI 10.1007/s10482-004-6544-x
   Imada C, 2004, MAR BIOTECHNOL, V6, P193, DOI 10.1007/s10126-003-0027-3
   IMAI H, 1987, J ANTIBIOT, V40, P1475, DOI 10.7164/antibiotics.40.1475
   IWAI Y, 1982, J ANTIBIOT, V35, P123, DOI 10.7164/antibiotics.35.123
   Jensen PR, 2007, APPL ENVIRON MICROB, V73, P1146, DOI 10.1128/AEM.01891-06
   Jensen PR, 2005, ENVIRON MICROBIOL, V7, P1039, DOI 10.1111/j.1462-2920.2005.00785.x
   Jensen PR, 2005, ANTON LEEUW INT J G, V87, P43, DOI 10.1007/s10482-004-6540-1
   JENSEN PR, 1991, APPL ENVIRON MICROB, V57, P1102
   Jeong SY, 2006, J ANTIBIOT, V59, P234, DOI 10.1038/ja.2006.33
   JUKES TH, 1985, REV INFECT DIS, V7, P702
   KALA RR, 1993, INDIAN J MAR SCI, V22, P297
   Kanoh K, 2005, J ANTIBIOT, V58, P289, DOI 10.1038/ja.2005.36
   Karthik L, 2010, PHARMACOLOGYONLINE, V1, P221
   Kavitha A, 2011, ANN MICROBIOL, V61, P597, DOI 10.1007/s13213-010-0178-1
   Kehrenberg C, 2007, ANTIMICROB AGENTS CH, V51, P2244, DOI 10.1128/AAC.00229-07
   Kennedy J, 2010, MAR DRUGS, V8, P608, DOI 10.3390/md8030608
   Kim JM, 2001, PROCESS BIOCHEM, V37, P287, DOI 10.1016/S0032-9592(01)00206-0
   Kim KJ, 2003, J BIOCHEM MOL BIOL, V36, P185
   Kim TK, 2005, ENVIRON MICROBIOL, V7, P509, DOI 10.1111/j.1462-2920.2004.00716.x
   Kimura KI, 1997, J ANTIBIOT, V50, P373, DOI 10.7164/antibiotics.50.373
   Kock I, 2005, J ANTIBIOT, V58, P530, DOI 10.1038/ja.2005.73
   Kohilu U, 2001, ENZYME MICROB TECHNO, V28, P606
   Korkmaz H, 2003, ANN MICROBIOL, V53, P85
   Krishna P, 2008, WORLD J MICROB BIOT, V24, P3079, DOI 10.1007/s11274-008-9801-8
   Kumar CG, 1999, BIOTECHNOL ADV, V17, P561, DOI 10.1016/S0734-9750(99)00027-0
   Kumar SS, 2006, CURR SCI INDIA, V91, P807
   KUNZ C, 1992, FEMS MICROBIOL LETT, V90, P105, DOI 10.1111/j.1574-6968.1992.tb05135.x
   Kurtboke DI, 2012, APPL MICROBIOL BIOT, V93, P1843, DOI 10.1007/s00253-012-3898-2
   KUTZNER H, 1968, Landwirtschaftliche Forschung, V21, P48
   Kwon HC, 2006, J AM CHEM SOC, V128, P1622, DOI 10.1021/ja0558948
   Lam KS, 2006, CURR OPIN MICROBIOL, V9, P245, DOI 10.1016/j.mib.2006.03.004
   Lechevalier H., 1982, DEV APPL MICROBIOLOG, P3
   Lee H, 2002, APPL BIOCHEM BIOTECH, V97, P123, DOI 10.1385/ABAB:97:2:123
   Lee HS, 2005, J NAT PROD, V68, P623, DOI 10.1021/np040220g
   Lemriss S, 2003, CAN J MICROBIOL, V49, P669, DOI 10.1139/W03-088
   Li AY, 2002, CHEM BIOL, V9, P1017, DOI 10.1016/S1074-5521(02)00223-5
   Li DH, 2006, ARCH PHARM RES, V29, P624, DOI 10.1007/BF02968245
   Li FC, 2005, J NAT PROD, V68, P349, DOI 10.1021/np030518r
   Li J, 2008, BEILSTEIN J ORG CHEM, V4, DOI 10.3762/bjoc.4.46
   Lin Wen-Po, 2005, Journal of Microbiology Immunology and Infection, V38, P320
   Lu JS, 2012, MICROBIOL RES, V167, P590, DOI 10.1016/j.micres.2012.06.001
   Mabrouk MEM, 2008, WORLD J MICROB BIOT, V24, P2331, DOI 10.1007/s11274-008-9748-9
   Macherla VR, 2005, J NAT PROD, V68, P780, DOI 10.1021/np049597c
   Maeda A, 1995, CHEM INFORM, V26, P976
   Magarvey NA, 2004, APPL ENVIRON MICROB, V70, P7520, DOI 10.1128/AEM.70.12.7520-7529.2004
   Majumdar P, 2005, CHEM RES TOXICOL, V18, P1830, DOI 10.1021/tx050232h
   Maldonado LA, 2005, INT J SYST EVOL MICR, V55, P1759, DOI 10.1099/ijs.0.63625-0
   Manam RR, 2005, J NAT PROD, V68, P240, DOI 10.1021/np049725x
   Manju K. G., 1997, Indian Journal of Experimental Biology, V35, P53
   Mao YQ, 1999, CHEM BIOL, V6, P251, DOI 10.1016/S1074-5521(99)80040-4
   Da Vinha FNM, 2011, APPL BIOCHEM BIOTECH, V164, P256, DOI 10.1007/s12010-010-9132-8
   MARTIN JF, 1980, MICROBIOL REV, V44, P230
   MASCARETTI OA, 2003, BACTERIA VERSUS ANTI
   Maskey RP, 2003, Z NATURFORSCH B, V58, P692
   Mathivanan N, 1998, CAN J MICROBIOL, V44, P646, DOI 10.1139/cjm-44-7-646
   Matsui I, 2000, FEBS LETT, V467, P195, DOI 10.1016/S0014-5793(00)01156-X
   Mehta VJ, 2006, BIORESOURCE TECHNOL, V97, P1650, DOI 10.1016/j.biortech.2005.07.023
   MENCHER JR, 1962, J GEN MICROBIOL, V28, P665, DOI 10.1099/00221287-28-4-665
   Miller ED, 2007, J ORG CHEM, V72, P323, DOI 10.1021/jo061064g
   Mincer TJ, 2005, APPL ENVIRON MICROB, V71, P7019, DOI 10.1128/AEM.71.11.7019-7028.2005
   Mincer TJ, 2002, APPL ENVIRON MICROB, V68, P5005, DOI 10.1128/AEM.68.10.5005-5011.2002
   Mitra P, 2005, J SCI IND RES INDIA, V64, P978
   MIYASHITA K, 1991, J GEN MICROBIOL, V137, P2065, DOI 10.1099/00221287-137-9-2065
   Mohamedin AH, 1999, INT BIODETER BIODEGR, V43, P13, DOI 10.1016/S0964-8305(98)00061-4
   Monciardini P, 2002, FEMS MICROBIOL ECOL, V42, P419, DOI [10.1111/j.1574-6941.2002.tb01031.x, 10.1016/S0168-6496(02)00353-7]
   MOORMANN M, 1993, APPL ENVIRON MICROB, V59, P1573
   MORAN MA, 1995, APPL ENVIRON MICROB, V61, P3695
   Mukherjee G., 2004, Indian Journal of Experimental Biology, V42, P541
   Mukhopadhyay R. P., 1993, Indian Journal of Experimental Biology, V31, P557
   MUKHOPADHYAY RP, 1990, INDIAN J EXP BIOL, V28, P575
   Murugan M, 2007, J SCI IND RES INDIA, V66, P388
   NAKAMURA H, 1977, J ANTIBIOT, V30, P714, DOI 10.7164/antibiotics.30.714
   Nakamura H, 2001, 68 PULP PAP RES C P, P18
   Nascimento RP, 2009, LETT APPL MICROBIOL, V48, P529, DOI 10.1111/j.1472-765X.2009.02575.x
   NICKEL JC, 1985, ANTIMICROB AGENTS CH, V27, P619, DOI 10.1128/AAC.27.4.619
   Niehaus F, 1999, APPL MICROBIOL BIOT, V51, P711, DOI 10.1007/s002530051456
   Niladevi KN, 2005, ACTINOMYCETOLOGICA, V19, P40
   Nimnoi P, 2010, BIOCHEM SYST ECOL, V38, P595, DOI 10.1016/j.bse.2010.07.005
   Ninawe S, 2006, CURR MICROBIOL, V53, P178, DOI 10.1007/s00284-005-0285-6
   Oh DC, 2008, J NAT PROD, V71, P570, DOI 10.1021/np0705155
   Olano C, 2009, NAT PROD REP, V26, P628, DOI 10.1039/b822528a
   OMURA S, 1987, J ANTIBIOT, V40, P1619, DOI 10.7164/antibiotics.40.1619
   Pandey A, 2005, AFR J BIOTECHNOL, V4, P909
   Penn K, 2009, ISME J, V3, P1193, DOI 10.1038/ismej.2009.58
   PESCHKE U, 1995, MOL MICROBIOL, V16, P1137, DOI 10.1111/j.1365-2958.1995.tb02338.x
   Pestka S, 1974, Methods Enzymol, V30, P261
   PISANO MA, 1992, APPL MICROBIOL BIOT, V36, P553
   Poornima R., 2008, Trends in Applied Sciences Research, V3, P45
   Prapagdee B, 2008, INT J BIOL SCI, V4, P330
   PRICE JS, 1975, J BACTERIOL, V124, P1574
   Projan SJ, 2003, CURR OPIN MICROBIOL, V6, P427, DOI 10.1016/j.mib.2003.08.003
   Prudhomme J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002335
   Quadri SR, 2012, WORLD J SCI TECHNOL, V2, P8
   Radzom M, 2006, J ANTIBIOT, V59, P315, DOI 10.1038/ja.2006.45
   Rahman H, 2010, MAR DRUGS, V8, P498, DOI 10.3390/md8030498
   Raja S, 2010, INDIAN J MICROBIOL, V50, P233, DOI 10.1007/s12088-010-0046-5
   Ramesh S, 2009, WORLD J MICROB BIOT, V25, P2103, DOI 10.1007/s11274-009-0113-4
   Ramesh S, 2009, BIOPROC BIOSYST ENG, V32, P791, DOI 10.1007/s00449-009-0305-1
   Rath CM, 2011, ACS CHEM BIOL, V6, P1244, DOI 10.1021/cb200244t
   Ravikumar S, 2012, ASIAN PAC J TROP MED, V5, P887, DOI 10.1016/S1995-7645(12)60165-5
   Riedlinger J, 2004, J ANTIBIOT, V57, P271, DOI 10.7164/antibiotics.57.271
   Riesenfeld CS, 2004, ANNU REV GENET, V38, P525, DOI 10.1146/annurev.genet.38.072902.091216
   Riley PA, 1997, INT J BIOCHEM CELL B, V29, P1235, DOI 10.1016/S1357-2725(97)00013-7
   SALEH EA, 1985, ZBL MIKROBIOL, V140, P325
   Salomon CE, 2004, NAT PROD REP, V21, P105, DOI 10.1039/b301384g
   Sanchez S, 2002, ENZYME MICROB TECH, V31, P895, DOI 10.1016/S0141-0229(02)00172-2
   Schiewe HJ, 1999, J ANTIBIOT, V52, P635, DOI 10.7164/antibiotics.52.635
   Schultz M, 1997, NACHR CHEM TECH LAB, V45, P159
   Schumacher RW, 2003, J NAT PROD, V66, P1291, DOI 10.1021/np020549e
   Shata Hoda Mohamed Abdel Halim, 2012, Journal of Applied Biological Chemistry, V55, P149, DOI 10.3839/jabc.2012.023
   SINGH B, 1954, BRIT MED J, V1, P130, DOI 10.1136/bmj.1.4854.130
   Singh G, 2005, ASIAN J MICROBIOL BI, V7, P383
   Singh LS, 2009, J MYCOL MED, V19, P225, DOI 10.1016/j.mycmed.2009.07.006
   Singh MP, 2000, ANTIMICROB AGENTS CH, V44, P2154, DOI 10.1128/AAC.44.8.2154-2159.2000
   Sivakumar K., 2007, Indian Journal of Microbiology, V47, P186, DOI 10.1007/s12088-007-0039-1
   Socha AM, 2006, BIOORGAN MED CHEM, V14, P8446, DOI 10.1016/j.bmc.2006.08.038
   Soria-Mercado IE, 2005, J NAT PROD, V68, P904, DOI 10.1021/np058011z
   Spano L, 1975, ENZYMATIC HYDROLYSIS
   Sriyapai T, 2011, J BIOSCI BIOENG, V111, P528, DOI 10.1016/j.jbiosc.2010.12.024
   Stach JEM, 2003, ENVIRON MICROBIOL, V5, P828, DOI 10.1046/j.1462-2920.2003.00483.x
   Stamford TLM, 2001, BIORESOURCE TECHNOL, V76, P137, DOI 10.1016/S0960-8524(00)00089-4
   Staunton J, 2001, NAT PROD REP, V18, P380, DOI 10.1039/a909079g
   Subramani R, 2012, MICROBIOL RES, V167, P571, DOI 10.1016/j.micres.2012.06.005
   Suguna S., 2012, International Journal of Pharmaceutical and Biological Archives, V3, P601
   Sujatha P, 2005, MICROBIOL RES, V160, P119, DOI 10.1016/j.micres.2004.10.006
   Sun CH, 2007, J ANTIBIOT, V60, P211, DOI 10.1038/ja.2007.25
   Sun W, 2010, ANTON LEEUW INT J G, V98, P65, DOI 10.1007/s10482-010-9430-8
   Sundaram Ravikumar, 2011, Journal of Pharmacy Research, V4, P294
   Syed DG, 2009, J IND MICROBIOL BIOT, V36, P189, DOI 10.1007/s10295-008-0484-9
   Syed DG, 2009, BIORESOURCE TECHNOL, V100, P1868, DOI 10.1016/j.biortech.2008.09.047
   Taechowisan T, 2003, WORLD J MICROB BIOT, V19, P381, DOI 10.1023/A:1023901107182
   Taibi Z, 2012, APPL BIOCHEM BIOTECH, V166, P663, DOI 10.1007/s12010-011-9457-y
   TAKAHASHI I, 1988, J ANTIBIOT, V41, P1151, DOI 10.7164/antibiotics.41.1151
   Takano H, 2003, GENE, V320, P127, DOI 10.1016/S0378-1119(03)00818-7
   Takano H, 2007, GENE, V393, P43, DOI 10.1016/j.gene.2007.01.026
   TAKIZAWA M, 1993, APPL ENVIRON MICROB, V59, P997
   TANAKA Y, 1990, ACTINOMYCETOLOGICA, V4, P13, DOI DOI 10.3209/SAJ.4_13
   Tanaka Y, 1998, CHEMINFORM, V29, P1036
   Tatineni R, 2008, BIORESOURCE TECHNOL, V99, P1596, DOI 10.1016/j.biortech.2007.04.019
   Techapun C, 2003, PROCESS BIOCHEM, V38, P1327, DOI 10.1016/S0032-9592(02)00331-X
   Thakur D, 2007, J MYCOL MED, V17, P242, DOI 10.1016/j.mycmed.2007.08.001
   TIUNOVA NA, 1976, MICROBIOLOGY+, V45, P246
   Tsujibo H, 2003, APPL ENVIRON MICROB, V69, P894, DOI 10.1128/AEM.69.2.894-900.2003
   Tsujibo H, 2000, BIOSCI BIOTECH BIOCH, V64, P2445, DOI 10.1271/bbb.64.2445
   Udwary DW, 2007, P NATL ACAD SCI USA, V104, P10376, DOI 10.1073/pnas.0700962104
   Usuki H, 2006, J PESTIC SCI, V31, P41, DOI 10.1584/jpestics.31.41
   Uyeda M, 2001, BIOSCI BIOTECH BIOCH, V65, P1252, DOI 10.1271/bbb.65.1252
   Valli S., 2012, Asian Pacific Journal of Tropical Biomedicine, V2, P469, DOI 10.1016/S2221-1691(12)60078-1
   Van Wyk J, 2001, J SOLID WASTE TECHNO, V27, P82
   Vasanthabharathi V, 2011, AFR J BIOTECHNOL, V10, P11224
   Venter JC, 2004, SCIENCE, V304, P66, DOI 10.1126/science.1093857
   VEZINA C, 1975, J ANTIBIOT, V28, P721, DOI 10.7164/antibiotics.28.721
   VIGAL T, 1991, MOL GEN GENET, V225, P278, DOI 10.1007/BF00269860
   Wang YH, 2005, PROCESS BIOCHEM, V40, P1161, DOI 10.1016/j.procbio.2004.04.010
   Ward AC, 2006, CURR OPIN MICROBIOL, V9, P279, DOI 10.1016/j.mib.2006.04.004
   Wawrik B, 2005, APPL ENVIRON MICROB, V71, P2232, DOI 10.1128/AEM.71.5.2232-2238.2005
   Weber T, 2003, J BIOTECHNOL, V106, P221, DOI 10.1016/j.jbiotec.2003.08.004
   WERNER G, 1984, J ANTIBIOT, V37, P110, DOI 10.7164/antibiotics.37.110
   WEYLAND H, 1969, NATURE, V223, P858, DOI 10.1038/223858a0
   WILLIAMS CM, 1991, POULTRY SCI, V70, P85, DOI 10.3382/ps.0700085
   Williams PG, 2005, J ORG CHEM, V70, P6196, DOI 10.1021/jo050511
   WINDISH WALTER W., 1965, ADVANCE APPL MICROBIOL, V7, P273, DOI 10.1016/S0065-2164(08)70389-7
   Wright GD, 2007, TRENDS MOL MED, V13, P260, DOI 10.1016/j.molmed.2007.04.004
   Wu SJ, 2006, J ANTIBIOT, V59, P331, DOI 10.1038/ja.2006.46
   Yadav A, 2011, RES J MICROBIOL, V6, P693
   Yadav AK, 2009, J MYCOL MED, V19, P234, DOI 10.1016/j.mycmed.2009.07.005
   You JL, 2007, APPL MICROBIOL BIOT, V76, P1137, DOI 10.1007/s00253-007-1074-x
   You JL, 2005, WORLD J MICROB BIOT, V21, P679, DOI 10.1007/sl1274-004-3851-3
   ZENOVA G. M., 1965, MIKROBIOLO GIYA, V34, P278
   Zhang L., 2005, NATURAL PRODUCTS DRU
   Zotchev SB, 2012, J BIOTECHNOL, V158, P168, DOI 10.1016/j.jbiotec.2011.06.002
NR 286
TC 86
Z9 94
U1 2
U2 85
PU ELSEVIER GMBH, URBAN & FISCHER VERLAG
PI JENA
PA OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY
SN 0944-5013
J9 MICROBIOL RES
JI Microbiol. Res.
PY 2013
VL 168
IS 6
BP 311
EP 332
DI 10.1016/j.micres.2013.02.002
PG 22
WC Microbiology
SC Microbiology
GA 174TH
UT WOS:000321177800001
PM 23480961
OA Bronze
DA 2018-12-27
ER

PT J
AU Wang, DQ
   Zhu, HT
   Zhu, Y
   Liu, YF
   Shen, HL
   Yin, RG
   Zhang, ZJ
   Su, ZL
AF Wang, Dongqing
   Zhu, Haitao
   Zhu, Ying
   Liu, Yanfang
   Shen, Huiling
   Yin, Ruigen
   Zhang, Zhijian
   Su, Zhaoliang
TI RETRACTED: CD133(+)/CD44(+)/Oct4(+)/Nestin(+) stem-like cells isolated
   from Panc-1 cell line may contribute to multi-resistance and metastasis
   of pancreatic cancer (Retracted article. See vol. 120, pg. 302, 2018)
SO ACTA HISTOCHEMICA
LA English
DT Article; Retracted Publication
DE Pancreatic cancer stem cell; Panc-1; MDR1; Drug-resistance
ID CLINICAL BENEFIT; GEMCITABINE; IDENTIFICATION; GLIOBLASTOMA; THERAPY;
   POPULATION; CARCINOMA; EXPANSION
AB Pancreatic cancer is an aggressive malignant disease. Owing to the lack of early symptoms, accompanied by extensive metastasis and high resistance to chemotherapy, pancreatic adenocarcinoma becomes the fourth leading cause of cancer-related deaths. In this study, we identified a subpopulation of cells isolated from the Panc-1 cell line and named pancreatic cancer stem-like cells. These Panc-1 stem-like cells expressed high levels of CD133/CD44/Oct4/Nestin. Compared to Panc-1 cells, Panc-1 stem-like cells were resistant to gemcitabine and expressed high levels of MDR1; furthermore, Panc-1 stem-like cells have high anti-apoptotic, but weak proliferative potential. These results indicated that Panc-1 stem-like cells, as a novel group, may be a potential major cause of pancreatic cancer multidrug resistance and extensive metastasis. (C) 2012 Elsevier GmbH. All rights reserved.
C1 [Wang, Dongqing; Zhu, Haitao; Zhu, Ying; Yin, Ruigen] Jiangsu Univ, Affiliated Hosp, Zhenjiang 212001, Peoples R China.
   [Liu, Yanfang; Shen, Huiling] Jiangsu Univ, Affiliated Peoples Hosp, Zhenjiang 212008, Peoples R China.
   [Zhang, Zhijian; Su, Zhaoliang] Jiangsu Univ, Dept & Lab Immunol, Zhenjiang 212008, Peoples R China.
RP Shen, HL (reprint author), Jiangsu Univ, Affiliated Peoples Hosp, Zhenjiang 212008, Peoples R China.
EM shenhuiling0826@163.com; szl30@yeah.net
FU National Natural Science Foundation of China [81001319, 81101677];
   Natural Science Foundation of Jiangsu Province [BK2011487]; Social
   Development Foundation of Zhenjiang City [SZC201130128]; High-Tech of
   Jiangsu University [11JDG128]
FX This study was supported by the National Natural Science Foundation of
   China (Grant no. 81001319, 81101677), the Natural Science Foundation of
   Jiangsu Province (Grant no. BK2011487), the Social Development
   Foundation of Zhenjiang City (Grant no. SZC201130128), and the High-Tech
   of Jiangsu University (Grant no. 11JDG128).
CR Albini A, 2011, CURR PHARM BIOTECHNO, V12, P171, DOI 10.2174/138920111794295756
   Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236
   Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730
   Braat H, 2012, CANCER LETT, V318, P1, DOI 10.1016/j.canlet.2011.11.034
   Burris H, 1997, EUR J CANCER, V33, pS18, DOI 10.1016/S0959-8049(96)00324-3
   Burris HA, 1997, J CLIN ONCOL, V15, P2403, DOI 10.1200/JCO.1997.15.6.2403
   Carlesso N, 2010, CURR OPIN HEMATOL, V17, P281, DOI 10.1097/MOH.0b013e32833a25d8
   Di Fiore R, 2009, J CELL PHYSIOL, V219, P301, DOI 10.1002/jcp.21667
   Eramo A, 2008, CELL DEATH DIFFER, V15, P504, DOI 10.1038/sj.cdd.4402283
   Galli R, 2004, CANCER RES, V64, P7011, DOI 10.1158/0008-5472.CAN-04-1364
   Ghods AJ, 2007, STEM CELLS, V25, P1645, DOI 10.1634/stemcells.2006-0624
   Hermann PC, 2008, CELL CYCLE, V7, P188, DOI 10.4161/cc.7.2.5326
   Hermann PC, 2009, EXPERT OPIN BIOL TH, V9, P1271, DOI 10.1517/14712590903246362
   Hong SP, 2009, INT J CANCER, V125, P2323, DOI [10.1002/ijc.2403, 10.1002/ijc.24573]
   Huang Y, 2007, CANCER METAST REV, V26, P183, DOI 10.1007/s10555-007-9050-6
   Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006
   Kawasaki BT, 2008, MOL INTERV, V8, P174, DOI 10.1124/mi.8.4.9
   Konopleva M, 2009, DRUG RESIST UPDATE, V12, P103, DOI 10.1016/j.drup.2009.06.001
   Li CW, 2007, CANCER RES, V67, P1030, DOI 10.1158/0008-5472.CAN-06-2030
   Lowery MA, 2010, ONCOLOGY-NY, V24, P1339
   Marsden CG, 2009, METHODS MOL BIOL, V590, P363, DOI 10.1007/978-1-60327-378-7_23
   Na YR, 2009, TUMOR BIOL, V30, P300, DOI 10.1159/000261073
   Nieto J, 2008, ONCOLOGIST, V13, P562, DOI 10.1634/theoncologist.2007-0181
   Ponti D, 2005, CANCER RES, V65, P5506, DOI 10.1158/0008-5472.CAN-05-0626
   Reed JC, 2006, NAT CLIN PRACT ONCOL, V3, P388, DOI 10.1038/ncponc0538
   Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384
   Rosenberg L, 1997, INT J PANCREATOL, V22, P81
   Rothenberg ML, 1996, CANCER, V78, P627
   Salmaggi A, 2006, GLIA, V54, P850, DOI 10.1002/glia.20414
   Sneddon JB, 2007, CELL STEM CELL, V1, P607, DOI 10.1016/j.stem.2007.11.009
   Stavrovskaya AA, 2008, BIOCHEMISTRY-MOSCOW+, V73, P592, DOI 10.1134/S0006297908050118
   Takaishi S, 2009, STEM CELLS, V27, P1006, DOI 10.1002/stem.30
   Yin T, 2011, INT J MOL SCI, V12, P1595, DOI 10.3390/ijms12031595
   Yuan XP, 2004, ONCOGENE, V23, P9392, DOI 10.1038/sj.onc.1208311
   Zhong Y, 2010, CANCER LETT, V299, P150, DOI 10.1016/j.canlet.2010.08.013
NR 35
TC 25
Z9 26
U1 4
U2 22
PU ELSEVIER GMBH, URBAN & FISCHER VERLAG
PI JENA
PA OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY
SN 0065-1281
EI 1618-0372
J9 ACTA HISTOCHEM
JI Acta Histochem.
PY 2013
VL 115
IS 4
BP 349
EP 356
DI 10.1016/j.acthis.2012.09.007
PG 8
WC Cell Biology
SC Cell Biology
GA 160WH
UT WOS:000320150700008
PM 23036582
DA 2018-12-27
ER

PT J
AU He, WW
   Zhang, LF
   Han, B
   Cheng, L
   Zhou, NC
   Liu, Z
   Cheng, ZP
AF He, Weiwei
   Zhang, Lifen
   Han, Bing
   Cheng, Liang
   Zhou, Nianchen
   Liu, Zhuang
   Cheng, Zhenping
TI RETRACTED: Hydrophilic hybrid materials with magnetism & NIR
   fluorescence via surface-initiated RAFT polymerization(Retracted
   article. See vol. 1, pg. 6673, 2013)
SO JOURNAL OF MATERIALS CHEMISTRY B
LA English
DT Article; Retracted Publication
ID IRON-OXIDE NANOPARTICLES; BIOMEDICAL APPLICATIONS; CHARGE-TRANSFER;
   RESONANCE; PROBES; SHELL; NANOCOMPOSITES; NANOCRYSTALS; LUMINESCENT;
   TECHNOLOGY
AB In the current work, one monomer (denoted as M-HB) capable of emitting near infrared (NIR) fluorescence under UV light excitation is prepared and employed to perform (co)polymerization with a commercial hydrophilic and biocompatible monomer, poly(ethylene glycol) monomethyl ether methacrylate (PEGMA), on the surface of silica coated iron oxide nanoparticles (NPs). PEGMA is used to either copolymerize or chain-extend MHB after polymerization to improve the hydrophilicity of the NPs which is essential for practical application in bio-related areas. The as-prepared NPs in different surface modification steps were investigated by Fourier transfer infrared (FT-IR), thermogravimetric analysis (TGA), transmission electron microscope (TEM) and UV-vis spectroscopic techniques. The crystal form of the NPs was checked by powder X-ray diffraction (XRD) and it showed that the magnetic core is made up of ferroferric oxide. The magnetic properties of the NPs were measured by vibrating-sample magnetometer (VSM) and all NPs exhibited superparamagnetism. The final NPs possessing magnetic and NIR fluorescent properties have potential applications in biological areas as dual-model imaging agents, and their application as contrast agents for magnetic resonance imaging (MRI) is investigated.
C1 [He, Weiwei; Zhang, Lifen; Han, Bing; Zhou, Nianchen; Cheng, Zhenping] Soochow Univ, Coll Chem Chem Engn & Mat Sci, Dept Polymer Sci & Engn, Jiangsu Key Lab Adv Funct Polymer Design & Applic, Suzhou 215123, Peoples R China.
   [Cheng, Liang; Liu, Zhuang] Soochow Univ, Jiangsu Key Lab Carbon Based Funct Mat & Devices, Funct Nano & So Mat Lab FUNSOM, Suzhou 215123, Peoples R China.
RP He, WW (reprint author), Soochow Univ, Coll Chem Chem Engn & Mat Sci, Dept Polymer Sci & Engn, Jiangsu Key Lab Adv Funct Polymer Design & Applic, Suzhou 215123, Peoples R China.
EM lcheng2@suda.edu.cn; chengzhenping@suda.edu.cn
RI Liang, Cheng/K-9840-2015
FU National Natural Science Foundation of China [21174096, 21274100,
   21234005]; Specialized Research Fund for the Doctoral Program of Higher
   Education [20103201110005]; Project of International Cooperation of the
   Ministry of Science and Technology of China [2011DFA50530]; Project
   Funded by the Priority Academic Program Development of Jiangsu Higher
   Education Institutions (PAPD)
FX The financial support from the National Natural Science Foundation of
   China (no. 21174096, 21274100 and 21234005), the Specialized Research
   Fund for the Doctoral Program of Higher Education (no. 20103201110005),
   the Project of International Cooperation of the Ministry of Science and
   Technology of China (no. 2011DFA50530), and the Project Funded by the
   Priority Academic Program Development of Jiangsu Higher Education
   Institutions (PAPD) is gratefully acknowledged.
CR Ahmed N, 2012, SOFT MATTER, V8, P2554, DOI 10.1039/c2sm06872a
   Badilita V, 2012, SOFT MATTER, V8, P10583, DOI 10.1039/c2sm26065d
   Cheng L, 2011, ANGEW CHEM INT EDIT, V50, P7385, DOI 10.1002/anie.201101447
   Corot C, 2006, ADV DRUG DELIVER REV, V58, P1471, DOI 10.1016/j.addr.2006.09.013
   Corr SA, 2008, J AM CHEM SOC, V130, P4214, DOI 10.1021/ja710172z
   Corr SA, 2008, NANOSCALE RES LETT, V3, P87, DOI 10.1007/s11671-008-9122-8
   Dubus S, 2006, ANAL CHEM, V78, P4457, DOI 10.1021/ac060486n
   Frangioni JV, 2003, CURR OPIN CHEM BIOL, V7, P626, DOI 10.1016/j.cbpa.2003.08.007
   Gaponik N, 2004, LANGMUIR, V20, P1449, DOI 10.1021/la035914o
   Gupta AK, 2005, BIOMATERIALS, V26, P3995, DOI 10.1016/j.biomaterials.2004.10.012
   Hirata N, 2009, BIOORGAN MED CHEM, V17, P3775, DOI 10.1016/j.bmc.2009.04.048
   Huh YM, 2005, J AM CHEM SOC, V127, P12387, DOI 10.1021/ja052337c
   Huijser S, 2012, MACROMOLECULES, V45, P4500, DOI 10.1021/ma300400d
   Jarzyna PA, 2009, BIOMATERIALS, V30, P6947, DOI 10.1016/j.biomaterials.2009.09.004
   Josephson L, 2002, BIOCONJUGATE CHEM, V13, P554, DOI 10.1021/bc015555d
   Karton-Lifshin N, 2011, J AM CHEM SOC, V133, P10960, DOI 10.1021/ja203145v
   Lee CM, 2011, BIOCONJUGATE CHEM, V22, P186, DOI 10.1021/bc100241a
   Lee ESM, 2010, BIOMATERIALS, V31, P3296, DOI 10.1016/j.biomaterials.2010.01.037
   Li CZ, 2005, MACROMOLECULES, V38, P5929, DOI 10.1021/ma050216r
   Li Q, 2011, SOFT MATTER, V7, P6958, DOI 10.1039/c1sm05211j
   Lim Yong Taik, 2003, Mol Imaging, V2, P50, DOI 10.1162/153535003765276282
   Lin YS, 2006, CHEM MATER, V18, P5170, DOI 10.1021/cm061976z
   Liu JL, 2011, LANGMUIR, V27, P12684, DOI 10.1021/la202749v
   Medintz IL, 2005, NAT MATER, V4, P435, DOI 10.1038/nmat1390
   Neoh KG, 2012, SOFT MATTER, V8, P2057, DOI 10.1039/c1sm06846f
   Pauli J, 2010, J FLUORESC, V20, P681, DOI 10.1007/s10895-010-0603-7
   Peng XJ, 2005, J AM CHEM SOC, V127, P4170, DOI 10.1021/ja043413z
   Qian G, 2008, CHEM MATER, V20, P6208, DOI 10.1021/cm801911n
   Safarik I, 2012, SOFT MATTER, V8, P5407, DOI 10.1039/c2sm06861c
   Samanta A, 2010, CHEM COMMUN, V46, P7406, DOI 10.1039/c0cc02366c
   Sharma P, 2006, ADV COLLOID INTERFAC, V123, P471, DOI 10.1016/j.cis.2006.05.026
   Shi XY, 2008, ADV MATER, V20, P1671, DOI 10.1002/adma.200702770
   Skaat H, 2009, BIOCHEM BIOPH RES CO, V386, P645, DOI 10.1016/j.bbrc.2009.06.110
   Tartaj P, 2011, ADV MATER, V23, P5243, DOI 10.1002/adma.201101368
   Thivierge C, 2011, MACROMOLECULES, V44, P4012, DOI 10.1021/ma200174w
   Tung CH, 2004, BIOPOLYMERS, V76, P391, DOI 10.1002/bip.20139
   Wang DS, 2004, NANO LETT, V4, P409, DOI 10.1021/nl035010n
   Won J, 2005, SCIENCE, V309, P121, DOI 10.1126/science.1112869
   Wuang SC, 2008, BIOMATERIALS, V29, P2270, DOI 10.1016/j.biomaterials.2008.01.028
   Xu H, 2011, BIOMATERIALS, V32, P9364, DOI 10.1016/j.biomaterials.2011.08.053
   Yang F, 2009, BIOMATERIALS, V30, P3882, DOI 10.1016/j.biomaterials.2009.03.051
   Yuan L, 2013, CHEM SOC REV, V42, P622, DOI 10.1039/c2cs35313j
   Yuan L, 2012, J AM CHEM SOC, V134, P1200, DOI 10.1021/ja209292b
   Yue W, 2009, J MATER CHEM, V19, P2199, DOI 10.1039/b818885h
   Zaheer A, 2001, NAT BIOTECHNOL, V19, P1148, DOI 10.1038/nbt1201-1148
   Zhao LL, 2011, SOFT MATTER, V7, P6144, DOI 10.1039/c1sm05305a
   Zhou J, 2010, BIOMATERIALS, V31, P3287, DOI 10.1016/j.biomaterials.2010.01.040
   Zhou LL, 2009, MATER LETT, V63, P1567, DOI 10.1016/j.matlet.2009.03.030
NR 48
TC 3
Z9 3
U1 3
U2 49
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2050-750X
EI 2050-7518
J9 J MATER CHEM B
JI J. Mat. Chem. B
PY 2013
VL 1
IS 26
BP 3257
EP 3266
DI 10.1039/c3tb20262c
PG 10
WC Materials Science, Biomaterials
SC Materials Science
GA 162NN
UT WOS:000320272000003
DA 2018-12-27
ER

PT J
AU Mrcelic, GJ
   Sliskovic, M
AF Mrcelic, Gorana Jelic
   Sliskovic, Merica
TI RETRACTED: THE EVALUATION OF FISH FARMING IMPACT BY NUTRIENT CONTENT AND
   CHLOROPHYLL A IN MALA LAMLJANA BAY (Retracted article. See vol. 67, pg.
   1437, 2015)
SO ARCHIVES OF BIOLOGICAL SCIENCES
LA English
DT Article; Retracted Publication
DE Fish farm; cages; nutrients content; chlorophyll a; phytoplankton
   species
AB This paper offers a brief review of the impacts of fish farming on the nutrient content and chlorophyll a in Mala Lamljana Bay, Croatia. Local loading of nitrogen and phosphorous compounds in fish farms can be very significant and can represent the largest source of N and P in a given area. Low N and P concentrations, low chlorophyll a concentration and a great variety of phytoplankton species were found in the bay, despite the high nutrient loading during the long history of farming in the bay. The phytoplankton community consisted mostly of diatoms and partly of dinoflagellates. Skeletonema costatum and Chaetoceros compressus were the dominant species (90%) in summer chlorophyll, which is typical for Middle Adriatic oligotrophic coastal waters. Nevertheless, further studies are required to determine changes in water column factors and planktonic communities in this area.
C1 [Mrcelic, Gorana Jelic; Sliskovic, Merica] Fac Maritime Studies Split, Split 21000, Croatia.
RP Mrcelic, GJ (reprint author), Fac Maritime Studies Split, Zrinjskofrankopanska 38, Split 21000, Croatia.
RI Jelic Mrcelic, Gorana/G-6577-2017
OI Jelic Mrcelic, Gorana/0000-0002-6424-2215; Sliskovic,
   Merica/0000-0003-3951-9822
CR Bergheim A, 1996, AQUACULTURE AND WATER RESOURCE MANAGEMENT, P50
   Einen O., 1995, Aquaculture Research, V26, P701, DOI 10.1111/j.1365-2109.1995.tb00960.x
   Enell M., 1989, VATTEN, V39, P369
   Gowen R. J., 1992, ASSESSMENT PREDICTIO
   Grasshoff K., 1976, METHODS SEAWATER ANA, P307
   Hargrave B. T., 2001, IMPACTS FRESHWATER M
   HOLM-HANSEN OSMUND, 1965, J CONS CONS PERMS INTE EXPLOR MER, V30, P3
   Lee G. F., 1979, ESTUARIES NUTRIENTS, P549
   Marasovic I., 1991, Acta Adriatica, V32, P719
   Schindler D. W., 1979, ESTUARIES NUTRIENTS, P71
   Seitzinger SP, 1999, LIMNOL OCEANOGR, V44, P721, DOI 10.4319/lo.1999.44.3.0721
   Telfer T. C., 2010, MONITORING ENV EFFEC
   Wu RSS, 1999, MAR POLLUT BULL, V39, P11, DOI 10.1016/S0025-326X(99)00014-4
NR 13
TC 0
Z9 0
U1 3
U2 16
PU INST BIOLOSKA ISTRAZIVANJA SINISA STANKOVIC
PI BEOGRAD
PA 29 NOVEMBRA 142, BEOGRAD, 11060, SERBIA
SN 0354-4664
EI 1821-4339
J9 ARCH BIOL SCI
JI Arch. Biol. Sci.
PY 2013
VL 65
IS 2
BP 567
EP 570
DI 10.2298/ABS1302567J
PG 4
WC Biology
SC Life Sciences & Biomedicine - Other Topics
GA 142VP
UT WOS:000318826000019
OA DOAJ Gold
DA 2018-12-27
ER

PT J
AU Papp, B
   Szurdoki, E
   Pantovic, J
   Sabovljevic, MS
AF Papp, Beata
   Szurdoki, Erzsebet
   Pantovic, Jovana
   Sabovljevic, M. S.
TI RETRACTED: PHYSCOMITRIUM EURYSTOMUM AND POHLIA PROLIGERA, NEW MOSSES IN
   THE BRYOPHYTE FLORA OF SERBIA (Retracted article. See vol. 68, pg. 241,
   2016)
SO ARCHIVES OF BIOLOGICAL SCIENCES
LA English
DT Article; Retracted Publication
DE Mosses; the Balkans; Serbia; new national records
ID EUROPE; CHECKLIST
AB Physcomitrium eurystomum Sendtn. and Pohlia proligera (Kindb.) Lindb. ex Broth, were recently discovered as new moss species for the bryophyte flora of Serbia. Both species were recorded in the Vlasina Lake area, a large highland wetland plateau in southeastern Serbia.
C1 [Papp, Beata; Szurdoki, Erzsebet] Hungarian Nat Hist Museum, Dept Bot, H-1476 Budapest, Hungary.
   [Pantovic, Jovana; Sabovljevic, M. S.] Univ Belgrade, Inst Bot & Bot Garden, Fac Biol, Belgrade 11000, Serbia.
RP Papp, B (reprint author), Hungarian Nat Hist Museum, Dept Bot, H-1476 Budapest, Hungary.
OI Sabovljevic, Marko/0000-0001-5809-0406
CR Blazencic J., 1997, VLASINSKO JEZERO HID
   Dierssen K., 2001, BRYOPHYTORUM BIBLIOT, V56, P1
   Dull R., 1985, BRYOL BEITR, V5, P110
   Dull R., 1984, BRYOLOGISCHE BEITRAG, V4, P1
   Ellis LT, 2012, J BRYOL, V34, P45, DOI 10.1179/1743282011Y.0000000042
   Ellis LT, 2011, J BRYOL, V33, P66, DOI 10.1179/1743282010Y.0000000014
   Hill MO, 2006, J BRYOL, V28, P198, DOI 10.1179/174328206X119998
   McDaniel SF, 2010, EVOLUTION, V64, P217, DOI 10.1111/j.1558-5646.2009.00797.x
   Papp B., 2009, PLANT FUNGAL HABITAT, P541
   Papp B, 2012, NOVA HEDWIGIA, V95, P221, DOI 10.1127/0029-5035/2012/0039
   Pavletic Z., 1955, PRODROMUS FLORE BRIO
   Randelovic V, 2010, FLORA VEGETACIJA VLA, P448
   Ros R. M., CRYPTOGAMIE IN PRESS
   Sabovljevi M., 2004, BRAUN BLANQUETIA, V34, P21
   Sabovljevic M, 2001, BIOL CONSERV, V101, P73, DOI 10.1016/S0006-3207(01)00043-X
   SABOVLJEVIC M, 2008, PHYTOLOGIA BALCANICA, V14, P159
   Sabovljevic Marko, 2006, Phytologia Balcanica, V12, P169
   Sabovljevic M, 2011, REV ECOL-TERRE VIE, V66, P399
NR 18
TC 4
Z9 6
U1 3
U2 10
PU INST BIOLOSKA ISTRAZIVANJA SINISA STANKOVIC
PI BEOGRAD
PA 29 NOVEMBRA 142, BEOGRAD, 11060, SERBIA
SN 0354-4664
EI 1821-4339
J9 ARCH BIOL SCI
JI Arch. Biol. Sci.
PY 2013
VL 65
IS 2
BP 703
EP 706
DI 10.2298/ABS1302703P
PG 4
WC Biology
SC Life Sciences & Biomedicine - Other Topics
GA 142VP
UT WOS:000318826000036
OA DOAJ Gold
DA 2018-12-27
ER

PT J
AU Ihara, Y
   Hyodo, H
   Sukegawa, S
   Murakami, H
   Morimatsu, F
AF Ihara, Yasuhiro
   Hyodo, Hideki
   Sukegawa, Shin
   Murakami, Hiroshi
   Morimatsu, Fumiki
TI RETRACTED: Isolation, characterization, and effect of administration in
   vivo, a novel probiotic strain from pig feces (Retracted article. See
   vol. 87, pg. 308, 2016)
SO ANIMAL SCIENCE JOURNAL
LA English
DT Article; Retracted Publication
DE E. faecium NHRD IHARA; IgA; lactic acid bacteria (LAB); pig Peyer's
   patch; probiotic
ID LACTIC-ACID BACTERIA; ENTEROCOCCUS-FAECIUM; ESCHERICHIA-COLI; VACCINE
   DEVELOPMENT; MUCOSAL IMMUNITY; DIARRHEA; PIGLETS; SYSTEM; SAFETY; SF68
AB From porcine rectal swabs or feces, we isolated lactic acid bacteria and used porcine Peyer's patch cells to select them for inducibility of IgA production as an indicator of probiotic effects. The strain selected as a new probiotic was named Enterococcus faeciumNHRD IHARA. To verify the probiotic effects of this strain in vivo, 536 piglets at age 25 days were assigned to either the trial group, which administrated the strain, or the control group. An increase in IgA in the feces was observed at age 45 days (P<0.05 compared with the control group); a significant increase in serum IgA was also observed at the end of the study (P<0.01) in the trial group. In addition, significant differences between the groups in terms of body weight (P<0.05) and average daily gain (P<0.01) were observed. The rate of detection of swine-pathogenic Escherichia coli gene in the feces tended to be lower in the trial group than in the controls. The novel probiotic strain; E.faeciumNHRD IHARA may have beneficial effects on swine growth by inducing IgA production and reducing rates of colonization by pathogens in the body.
C1 [Ihara, Yasuhiro; Hyodo, Hideki; Sukegawa, Shin; Murakami, Hiroshi; Morimatsu, Fumiki] Nippon Meat Packers Inc, Ctr Res & Dev, Tsukuba, Ibaraki 3002646, Japan.
RP Ihara, Y (reprint author), Nippon Meat Packers Inc, Ctr Res & Dev, Tsukuba, Ibaraki 3002646, Japan.
EM ya.ihara@nipponham.co.jp
CR Abe F, 1995, J DAIRY SCI, V78, P2838, DOI 10.3168/jds.S0022-0302(95)76914-4
   BARROW PA, 1980, J APPL BACTERIOL, V48, P147, DOI 10.1111/j.1365-2672.1980.tb05216.x
   Benyacoub J, 2005, J NUTR, V135, P1171
   Benyacoub J, 2003, J NUTR, V133, P1158
   Blanco M, 1997, J CLIN MICROBIOL, V35, P2958
   FACKLAM R, 1995, CLIN MICROBIOL REV, V8, P479, DOI 10.1128/CMR.8.4.479
   FRANGAKIS MV, 1982, J IMMUNOL METHODS, V48, P33, DOI 10.1016/0022-1759(82)90207-1
   Franz CMAP, 2011, INT J FOOD MICROBIOL, V151, P125, DOI 10.1016/j.ijfoodmicro.2011.08.014
   Fukushima Y, 1999, INT J FOOD MICROBIOL, V46, P193, DOI 10.1016/S0168-1605(98)00183-4
   FULLER R, 1973, J APPL BACTERIOL, V36, P131, DOI 10.1111/j.1365-2672.1973.tb04080.x
   HOLMGREN J, 1992, IMMUNOBIOLOGY, V184, P157, DOI 10.1016/S0171-2985(11)80473-0
   Homan WL, 2002, J CLIN MICROBIOL, V40, P1963, DOI 10.1128/JCM.40.6.1963-1971.2002
   JAYARAO BM, 1991, VET MICROBIOL, V26, P301, DOI 10.1016/0378-1135(91)90023-9
   Kyriakis S. C., 2003, Asian-Australasian Journal of Animal Sciences, V16, P1326
   Lamm ME, 1998, AM J PHYSIOL-GASTR L, V274, pG614, DOI 10.1152/ajpgi.1998.274.4.G614
   Maia OB, 2001, VET MICROBIOL, V79, P183, DOI 10.1016/S0378-1135(00)00383-7
   Maruta Kiyoshi, 1996, Animal Science and Technology, V67, P403
   MAYRAMAKINEN A, 1983, J APPL BACTERIOL, V55, P241, DOI 10.1111/j.1365-2672.1983.tb01321.x
   MCGHEE JR, 1992, VACCINE, V10, P75, DOI 10.1016/0264-410X(92)90021-B
   Mevius DJ, 1999, INT J ANTIMICROB AG, V11, P101, DOI 10.1016/S0924-8579(98)00093-4
   Mitsuoka T., 1991, BIFIDUS, V5, P1
   Nagafuchi S, 1999, BIOSCI BIOTECH BIOCH, V63, P474, DOI 10.1271/bbb.63.474
   Noamani BN, 2003, VET MICROBIOL, V97, P87, DOI 10.1016/j.vetmic.2003.08.006
   Parma AE, 2000, VET MICROBIOL, V72, P269, DOI 10.1016/S0378-1135(99)00167-4
   PERDIGON G, 1991, J DAIRY RES, V58, P485, DOI 10.1017/S0022029900030090
   Saarela M, 2000, J BIOTECHNOL, V84, P197, DOI 10.1016/S0168-1656(00)00375-8
   Salminen S, 1998, INT J FOOD MICROBIOL, V44, P93, DOI 10.1016/S0168-1605(98)00128-7
   Scharek L, 2005, VET IMMUNOL IMMUNOP, V105, P151, DOI 10.1016/j.vetimm.2004.12.022
   Scharek L, 2007, ARCH ANIM NUTR, V61, P223, DOI 10.1080/17450390701431540
   Shimoda Y, 2000, SHIMADZU REV, V57, P121
   Shu Q, 2001, J PEDIATR GASTR NUTR, V33, P171, DOI 10.1097/00005176-200108000-00014
   Simon O., 2005, ADV PORK PROD, V16, P161
   Swanson KS, 2002, J NUTR, V132, P980
   van Heugten E, 2003, J ANIM SCI, V81, P1004
   YASUI H, 1995, J INFECT DIS, V172, P403, DOI 10.1093/infdis/172.2.403
NR 35
TC 8
Z9 9
U1 3
U2 19
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1344-3941
EI 1740-0929
J9 ANIM SCI J
JI Anim. Sci. J.
PY 2013
VL 84
IS 5
BP 434
EP 441
DI 10.1111/asj.12020
PG 8
WC Agriculture, Dairy & Animal Science
SC Agriculture
GA 144PG
UT WOS:000318951300009
PM 23607635
DA 2018-12-27
ER

PT J
AU Fang, SY
   Wu, YH
   Wu, N
   Zhang, J
   An, J
AF Fang, Shuyu
   Wu, Yanhua
   Wu, Na
   Zhang, Jing
   An, Jing
TI RETRACTED: Recent Advances in DENV Receptors(Retracted article. See
   684690, 2013)
SO SCIENTIFIC WORLD JOURNAL
LA English
DT Review; Retracted Publication
ID DENGUE-VIRUS-INFECTION; HEPARAN-SULFATE PROTEOGLYCANS; HUMAN
   ENDOTHELIAL-CELLS; HUMAN DENDRITIC CELLS; ENVELOPE PROTEIN; DC-SIGN;
   INSECT CELLS; DOMAIN-III; LAMININ RECEPTOR; C6/36 CELLS
AB Dengue is an old disease caused by the mosquito-borne dengue viruses (DENVs), which have four antigenically distinct serotypes (DENV1-4). Infection by any of them can cause dengue fever (DF) and/or a more serious disease, that is, dengue hemorrhagic fever (DHF) or dengue shock syndrome (DSS). In recent decades, incidence of dengue disease has increased 30-fold, putting a third to half of the world's population living in dengue-endemic areas at high infection risk. However, the pathogenesis of the disease is still poorly understood. The virus binding with its host cell is not only a first and critical step in their replication cycle but also a key factor for the pathogenicity. In recent years, there have been significant advances in understanding interactions of DENVs with their target cells such as dendritic cells (DC), macrophages, endothelial cells, and hepatocytes. Although DENVs reportedly attach to a variety of receptors on these cells, consensus DENV receptors have not been defined. In this review, we summarize receptors for DENVs on different cells identified in recent years.
C1 [Fang, Shuyu; Wu, Yanhua; Wu, Na; Zhang, Jing; An, Jing] Capital Med Univ, Sch Basic Med Sci, Dept Microbiol, Beijing 100069, Peoples R China.
RP An, J (reprint author), Capital Med Univ, Sch Basic Med Sci, Dept Microbiol, Beijing 100069, Peoples R China.
EM anjing@ccmu.edu.cn
FU National Key Programs on Basic Research of China [2011CB504703];
   National Natural Science Foundation of China [81271839]; Beijing
   Municipal Commission of Education [SQKM201210025005]
FX This work was supported by Grants from the National Key Programs on
   Basic Research of China (2011CB504703,
   http://www.973.gov.cn/English/Index.aspx), the National Natural Science
   Foundation of China (81271839, http://www.nsfc.gov.cn/), and the Funding
   Project of Beijing Municipal Commission of Education (SQKM201210025005,
   http://www.bjedu.gov.cn/publish/portal0/tab40/).
CR Alen MMF, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021658
   Alen MMF, 2009, VIROLOGY, V387, P67, DOI 10.1016/j.virol.2009.01.043
   Bashirova AA, 2001, J EXP MED, V193, P671, DOI 10.1084/jem.193.6.671
   Bielefeldt-Ohmann H, 2001, VIRUS RES, V73, P81, DOI 10.1016/S0168-1702(00)00233-1
   Bosch I, 2002, J VIROL, V76, P5588, DOI 10.1128/JVI.76.11.5588-5597.2002
   Bressanelli S, 2004, EMBO J, V23, P728, DOI 10.1038/sj.emboj.7600064
   Cabrera-Hernandez A., 2005, Dengue Bulletin, V29, P119
   Cabrera-Hernandez A, 2007, J MED VIROL, V79, P386, DOI 10.1002/jmv.20786
   Chen ST, 2008, NATURE, V453, P672, DOI 10.1038/nature07013
   Chen YC, 1999, J VIROL, V73, P2650
   Chen YP, 1997, NAT MED, V3, P866, DOI 10.1038/nm0897-866
   Chin JFL, 2007, MICROBES INFECT, V9, P1, DOI 10.1016/j.micinf.2006.09.009
   Couvelard A, 1999, HUM PATHOL, V30, P1106, DOI 10.1016/S0046-8177(99)90230-7
   Dalrymple N, 2011, J VIROL, V85, P9478, DOI 10.1128/JVI.05008-11
   Engering A, 2004, AM J PATHOL, V164, P1587, DOI 10.1016/S0002-9440(10)63717-0
   Germi R, 2002, VIROLOGY, V292, P162, DOI 10.1006/viro.2001.1232
   Gotte M, 2003, FASEB J, V17, P575, DOI 10.1096/fj.02-0739rev
   Hacker K, 2009, J GEN VIROL, V90, P2097, DOI 10.1099/vir.0.012120-0
   HALSTEAD SB, 1977, J EXP MED, V146, P201, DOI 10.1084/jem.146.1.201
   Halstead SB, 2007, LANCET, V370, P1644, DOI 10.1016/S0140-6736(07)61687-0
   Hilgard P, 2000, HEPATOLOGY, V32, P1069, DOI 10.1053/jhep.2000.18713
   Huerre MR, 2001, VIRCHOWS ARCH, V438, P107
   Hundt C, 2001, EMBO J, V20, P5876, DOI 10.1093/emboj/20.21.5876
   Hung JJ, 2004, J VIROL, V78, P378, DOI 10.1128/JVI.78.1.378-388.2004
   Jindadamrongwech S, 2004, ARCH VIROL, V149, P915, DOI 10.1007/s00705-003-0263-x
   Kielian M, 2006, NAT REV MICROBIOL, V4, P67, DOI 10.1038/nrmicro1326
   Kiessling F, 1999, CELL TISSUE RES, V297, P131, DOI 10.1007/s004410051340
   Kuadkitkan A, 2010, VIROLOGY, V406, P149, DOI 10.1016/j.virol.2010.07.015
   Liew KJL, 2004, J MED VIROL, V72, P597, DOI 10.1002/jmv.20034
   Lin YL, 2002, ANTIVIR RES, V56, P93, DOI 10.1016/S0166-3542(02)00095-5
   Lozach PY, 2005, J BIOL CHEM, V280, P23698, DOI 10.1074/jbc.M504337200
   Marks RM, 2001, J MED CHEM, V44, P2178, DOI 10.1021/jm000412i
   Martinez-Barragan JD, 2001, J VIROL, V75, P7818, DOI 10.1128/JVI.75.17.7818-7827.2001
   McMinn PC, 1997, J GEN VIROL, V78, P2711, DOI 10.1099/0022-1317-78-11-2711
   Mendoza MY, 2002, AM J TROP MED HYG, V67, P76, DOI 10.4269/ajtmh.2002.67.76
   Mercado-Curiel R. F., 2006, BMC MICROBIOLOGY, V6
   MERTENS G, 1992, J BIOL CHEM, V267, P20435
   Miller JL, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.0040017
   Miller S, 2008, NAT REV MICROBIOL, V6, P363, DOI 10.1038/nrmicro1890
   Miller S, 2007, J BIOL CHEM, V282, P8873, DOI 10.1074/jbc.M609919200
   Mukhopadhyay S, 2005, NAT REV MICROBIOL, V3, P13, DOI 10.1038/nrmicro1067
   Munoz MD, 1998, FEMS MICROBIOL LETT, V168, P251
   Navarro-Sanchez E, 2003, EMBO REP, V4, P723, DOI 10.1038/sj.embor.embor866
   Paingankar MS, 2010, ARCH VIROL, V155, P1453, DOI 10.1007/s00705-010-0728-7
   Pattnaik P, 2007, J CHROMATOGR B, V846, P184, DOI 10.1016/j.jchromb.2006.08.051
   Perera R, 2008, CURR OPIN MICROBIOL, V11, P369, DOI 10.1016/j.mib.2008.06.004
   Pokidysheva E, 2006, CELL, V124, P485, DOI 10.1016/j.cell.2005.11.042
   Rosen L, 1999, AM J TROP MED HYG, V61, P720, DOI 10.4269/ajtmh.1999.61.720
   Sakoonwatanyoo P, 2006, INTERVIROLOGY, V49, P161, DOI 10.1159/000089377
   SalasBenito JS, 1997, J VIROL, V71, P7246
   Smith DR, 2012, INSECT MOL BIOL, V21, P1, DOI 10.1111/j.1365-2583.2011.01098.x
   Soilleux EJ, 2000, J IMMUNOL, V165, P2937, DOI 10.4049/jimmunol.165.6.2937
   Stiasny K, 2003, J VIROL, V77, P7856, DOI 10.1128/JVI.77.14.7856-7862.2003
   Stiasny K, 2007, PLOS PATHOG, V3, P191, DOI 10.1371/journal.ppat.0030020
   Tassaneetrithep B, 2003, J EXP MED, V197, P823, DOI 10.1084/jem.20021840
   Thaisomboonsuk BK, 2005, AM J TROP MED HYG, V72, P375, DOI 10.4269/ajtmh.2005.72.375
   Thepparit C, 2004, J VIROL, V78, P12647, DOI 10.1128/JVI.78.22.12647-12656.2004
   Thepparit C, 2004, INTERVIROLOGY, V47, P78, DOI 10.1159/000077830
   Triantafilou K, 2001, NAT IMMUNOL, V2, P338, DOI 10.1038/86342
   Valle JRD, 2005, J VIROL, V79, P4557, DOI 10.1128/JVI.79.8.4557-4567.2005
   Wei HY, 2003, J GEN VIROL, V84, P3095, DOI 10.1099/vir.0.19308-0
   Welsch S, 2009, CELL HOST MICROBE, V5, P365, DOI 10.1016/j.chom.2009.03.007
   Wu SJL, 2000, NAT MED, V6, P816
   Zhang JL, 2007, BIOCHEM BIOPH RES CO, V356, P763, DOI 10.1016/j.bbrc.2007.03.051
NR 64
TC 5
Z9 5
U1 3
U2 19
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1537-744X
J9 SCI WORLD J
JI Sci. World J.
PY 2013
AR 684690
DI 10.1155/2013/684690
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 141OM
UT WOS:000318734500001
PM 23737723
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Mahmood, K
   Park, SB
   Sung, HJ
AF Mahmood, Khalid
   Park, Seung Bin
   Sung, Hyung Jin
TI RETRACTED: Enhanced photoluminescence, Raman spectra and field-emission
   behavior of indium-doped ZnO nanostructures(Retracted article. See vol.
   5, pg. 4336, 2017)
SO JOURNAL OF MATERIALS CHEMISTRY C
LA English
DT Article; Retracted Publication
ID LOW-TEMPERATURE GROWTH; ZINC-OXIDE NANOWIRES; OPTICAL-PROPERTIES;
   NANOROD ARRAYS; CARBON; FILMS; AL; SCATTERING; TETRAPOD; CRYSTALS
AB Indium-doped (In-doped) ZnO nanostructures with four different morphologies, namely nanochips, nanotripods, nanorods, and nanodisks, have been successfully synthesized by a simple hydrothermal method. The effects of indium dopant and various morphologies on the structural, optical and field-emission properties of these ZnO nanostructures were investigated. The XRD patterns demonstrated that the In-doped ZnO nanostructures exhibited the hexagonal wurtzite structure with preferential orientation along the (0 0 2) crystal plane, and a slight difference in lattice parameters was detected among the samples with various morphologies. The doped nanostructures were found to be single crystals grown along the c-axis. The composition of the doped ZnO nanostructures was confirmed by X-ray diffraction (XRD), X-ray photospectroscopy (XPS), and energy-dispersive spectroscopy (EDS). The photoluminescence (PL) spectra of doped ZnO nanostructures having a blue-shift in the UV region show a prominent tuning in the optical band gap, without any significant peak relating to intrinsic defects. From Raman spectra, the 437 cm(-1) mode corresponds to the E-2 mode for wurtzite ZnO crystals with very sharp features which revealed the better crystallinity of samples. The lowest turn-on field of the field-emission was found to be similar to 2.5 V mu m(-1) and the highest emission current density of 1.13 mA cm(-2) was also obtained for In-doped ZnO nanochips under a field of 6.3 V mu m(-1). The field enhancement factor beta was estimated to be 10 640 +/- 3 in the case of doped nanochips, which was much higher than that of any previous report. Moreover, the doped ZnO nanostructures exhibit good long period emission current stability with a variation of less than 5% during 25 h under a field of 6.3 V mu m(-1). The superior field-emission properties were attributed to the better morphologies, In-doping and better crystallinity of In-doped ZnO nanostructures.
C1 [Mahmood, Khalid; Park, Seung Bin] Korea Adv Inst Sci & Technol, Dept Chem & Biomol Engn, Taejon 305701, South Korea.
   [Mahmood, Khalid; Sung, Hyung Jin] Korea Adv Inst Sci & Technol, Dept Mech Engn, Taejon 305701, South Korea.
RP Mahmood, K (reprint author), Korea Adv Inst Sci & Technol, Dept Chem & Biomol Engn, 291 Daehak Ro, Taejon 305701, South Korea.
EM SeungBinPark@kaist.ac.kr
RI Park, Seung/B-8360-2011; Sung, Hyung Jin/C-1884-2011
OI Sung, Hyung Jin/0000-0002-4671-3626
FU National Research Foundation of Korea (NRF); Korea government (MEST)
   [2010-0027634]
FX This work was supported by the National Research Foundation of Korea
   (NRF) grant funded by the Korea government (MEST) (no. 2010-0027634).
CR Ahmad M, 2011, ACS APPL MATER INTER, V3, P1299, DOI 10.1021/am200099c
   Ahmad M, 2011, J MATER CHEM, V21, P599, DOI 10.1039/c0jm01645d
   Ahmad M, 2010, MATER SCI ENG B-ADV, V174, P55, DOI 10.1016/j.mseb.2010.03.039
   Ahmad M, 2009, J PHYS D APPL PHYS, V42, DOI 10.1088/0022-3727/42/16/165406
   ARGUELLO CA, 1969, PHYS REV, V181, P1351, DOI 10.1103/PhysRev.181.1351
   Bae SY, 2005, APPL PHYS LETT, V86, DOI 10.1063/1.1851591
   Bae SY, 2005, J PHYS CHEM B, V109, P2526, DOI 10.1021/jp0458708
   Bagnall DM, 1998, APPL PHYS LETT, V73, P1038, DOI 10.1063/1.122077
   Bundesmann C, 2003, APPL PHYS LETT, V83, P1974, DOI 10.1063/1.1609251
   Chen CH, 2010, CHEM PHYS LETT, V490, P176, DOI 10.1016/j.cplett.2010.03.033
   Chen MY, 2007, NANOTECHNOLOGY, V18, DOI 10.1088/0957-4484/18/45/455706
   Chen YW, 2005, J CHEM PHYS, V123, DOI 10.1063/1.2009731
   COLON XC, 2009, NANOTECHNOLOGY, V20
   DAMEN TC, 1966, PHYS REV, V142, P570, DOI 10.1103/PhysRev.142.570
   DEHEER WA, 1995, SCIENCE, V270, P1179, DOI 10.1126/science.270.5239.1179
   Fancher CA, 1998, J CHEM PHYS, V109, P8426, DOI 10.1063/1.477505
   Fang TH, 2010, CURR APPL PHYS, V10, P1076, DOI 10.1016/j.cap.2010.01.001
   Fang YG, 2012, NANOSCALE RES LETT, V7, DOI 10.1186/1556-276X-7-197
   Frolov VD, 2001, DIAM RELAT MATER, V10, P1719, DOI 10.1016/S0925-9635(01)00402-2
   Gautam UK, 2009, ADV FUNCT MATER, V19, P131, DOI 10.1002/adfm.200801259
   Greene LE, 2005, NANO LETT, V5, P1231, DOI 10.1021/nl050788p
   Hong J. F., 2006, NANOTECHNOLOGY, V17, pS231
   Hu JQ, 2003, APPL PHYS LETT, V82, P1401, DOI 10.1063/1.1558899
   Huang MH, 2001, ADV MATER, V13, P113, DOI 10.1002/1521-4095(200101)13:2<113::AID-ADMA113>3.0.CO;2-H
   Huang YH, 2006, J NANOSCI NANOTECHNO, V6, P787, DOI 10.1166/jnn.2006.086
   Jie JS, 2004, CHEM PHYS LETT, V387, P466, DOI 10.1016/j.cplett.2004.02.045
   Jie JS, 2004, J PHYS CHEM B, V108, P17027, DOI 10.1021/jp0484783
   Jo SH, 2004, APPL PHYS LETT, V85, P1407, DOI 10.1063/1.1784543
   Kong YC, 2001, APPL PHYS LETT, V78, P407, DOI 10.1063/1.1342050
   Lamb DA, 2004, J CRYST GROWTH, V273, P111, DOI 10.1016/j.jcrysgro.2004.08.027
   Lee JH, 2009, APPL PHYS A-MATER, V97, P403, DOI 10.1007/s00339-009-5226-y
   Li Y, 2000, APPL PHYS LETT, V76, P2011, DOI 10.1063/1.126238
   Liao L, 2005, NANOTECHNOLOGY, V16, P985, DOI 10.1088/0957-4484/16/6/061
   Lide D. R, 2000, CHEM RUBBER CO HDB C
   Mahmood K, 2013, J MATER CHEM A, V1, P4826, DOI 10.1039/c3ta10587c
   Mahmood K, 2012, J CRYST GROWTH, V347, P104, DOI 10.1016/j.jcrysgro.2012.03.033
   Pan N, 2010, NANOTECHNOLOGY, V21, DOI 10.1088/0957-4484/21/22/225707
   Park KC, 1997, THIN SOLID FILMS, V305, P201, DOI 10.1016/S0040-6090(97)00215-0
   Park YK, 2009, J NANOSCI NANOTECHNO, V9, P5745, DOI 10.1166/jnn.2009.1247
   Peng ZW, 2010, APPL SURF SCI, V256, P6814, DOI 10.1016/j.apsusc.2010.04.094
   Qi J, 2006, APPL PHYS LETT, V89, DOI 10.1063/1.2422899
   SANON G, 1991, PHYS REV B, V44, P5672, DOI 10.1103/PhysRevB.44.5672
   SERNELIUS BE, 1988, PHYS REV B, V37, P10244, DOI 10.1103/PhysRevB.37.10244
   Tzeng YF, 2010, ACS APPL MATER INTER, V2, P331, DOI 10.1021/am900490m
   Vanheusden K, 1996, J APPL PHYS, V79, P7983, DOI 10.1063/1.362349
   Vayssieres L, 2003, ADV MATER, V15, P464, DOI 10.1002/adma.200390108
   Wan Q, 2003, APPL PHYS LETT, V83, P2253, DOI 10.1063/1.1612899
   Wander A, 2001, PHYS REV LETT, V86, P3811, DOI 10.1103/PhysRevLett.86.3811
   Wang B, 2007, J CRYST GROWTH, V304, P73, DOI 10.1016/j.jcrysgro.2007.01.047
   Wu HC, 2010, J PHYS CHEM C, V114, P130, DOI 10.1021/jp908566q
   Xu CX, 2003, APPL PHYS LETT, V83, P3806, DOI 10.1063/1.1625774
   Yan HL, 2011, J MATER SCI-MATER EL, V22, P724, DOI 10.1007/s10854-010-0200-1
   Yan XB, 2008, CARBON, V46, P753, DOI 10.1016/j.carbon.2008.01.027
   Yang PD, 2002, ADV FUNCT MATER, V12, P323, DOI 10.1002/1616-3028(20020517)12:5<323::AID-ADFM323>3.0.CO;2-G
   Yi SH, 2007, J COLLOID INTERF SCI, V313, P705, DOI 10.1016/j.jcis.2007.05.006
   Zeng HB, 2009, ADV FUNCT MATER, V19, P3165, DOI 10.1002/adfm.200900714
   Zeng HB, 2006, APPL PHYS LETT, V88, DOI 10.1063/1.2196051
   Zhang H, 2007, J PHYS CHEM C, V111, P12939, DOI 10.1021/jp074086v
   Zhang Y, 2003, APPL PHYS LETT, V83, P4631, DOI 10.1063/1.1630849
   Zhao J, 2010, MATER LETT, V64, P569, DOI 10.1016/j.matlet.2009.11.074
   Zhao Q, 2006, NANOTECHNOLOGY, V17, pS351, DOI 10.1088/0957-4484/17/11/S20
   Zhao Q, 2005, APPL PHYS LETT, V86, DOI 10.1063/1.1931831
   Zhao Q, 2010, APPL PHYS A-MATER, V100, P165, DOI 10.1007/s00339-010-5636-x
   Zhao Q, 2010, NANOTECHNOLOGY, V21, DOI 10.1088/0957-4484/21/9/095701
   Zhou HJ, 2008, APPL PHYS LETT, V92, DOI 10.1063/1.2907197
NR 65
TC 84
Z9 85
U1 4
U2 126
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2050-7526
EI 2050-7534
J9 J MATER CHEM C
JI J. Mater. Chem. C
PY 2013
VL 1
IS 18
BP 3138
EP 3149
DI 10.1039/c3tc00082f
PG 12
WC Materials Science, Multidisciplinary; Physics, Applied
SC Materials Science; Physics
GA 127JH
UT WOS:000317694100012
DA 2018-12-27
ER

PT J
AU Hussain, H
   Al-Harrasi, A
   Al-Rawahi, A
   Hussain, J
AF Hussain, Hidayat
   Al-Harrasi, Ahmed
   Al-Rawahi, Ahmed
   Hussain, Javid
TI RETRACTED: Chemistry and Biology of Essential Oils of Genus
   Boswellia(Retracted article. See 605304, 2014)
SO EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Review; Retracted Publication
ID BREAST-CANCER CELLS; ACTIVATED PROTEIN-KINASE; RESIN ESSENTIAL OILS;
   OLEO-GUM-RESIN; BOSWELLIA-CARTERI; ANTIMICROBIAL ACTIVITY; IN-VITRO;
   ANTIOXIDANT ACTIVITIES; TRITERPENE ACIDS; FRANKINCENSE OIL
AB The properties of Boswellia plants have been exploited for millennia in the traditional medicines of Africa, China, and especially in the Indian Ayurveda. In Western countries, the advent of synthetic drugs has obscured the pharmaceutical use of Boswellia, until it was reported that an ethanolic extract exerts anti-inflammatory and antiarthritic effects. Frankincense was commonly used for medicinal purposes. This paper aims to provide an overview of current knowledge of the volatile constituents of frankincense, with explicit consideration concerning the diverse Boswellia species. Altogether, more than 340 volatiles in Boswellia have been reported in the literature. In particular, a broad diversity has been found in the qualitative and quantitative composition of the volatiles with respect to different varieties of Boswellia. A detailed discussion of the various biological activities of Boswellia frankincense is also presented.
C1 [Hussain, Hidayat; Al-Harrasi, Ahmed; Al-Rawahi, Ahmed; Hussain, Javid] Univ Nizwa, Coll Arts & Sci, Dept Biol Sci & Chem, Birkat Al Mouz 616, Nizwa, Oman.
   [Hussain, Hidayat] Univ Paderborn, Dept Chem, D-33098 Paderborn, Germany.
RP Hussain, H (reprint author), Univ Nizwa, Coll Arts & Sci, Dept Biol Sci & Chem, Birkat Al Mouz 616, Nizwa, Oman.
EM hidayat110@gmail.com
CR Abdoul-latif FM, 2012, INT J MMENT MOD SCI, V1, P1
   Aggarwal KK, 2002, FLAVOUR FRAG J, V17, P59, DOI 10.1002/ffj.1040
   Akihisa T, 2006, BIOL PHARM BULL, V29, P1976, DOI 10.1248/bpb.29.1976
   Al-Harrasi A, 2008, MOLECULES, V13, P2181, DOI 10.3390/molecules13092181
   Al-Saidi S, 2012, CHEM BIODIVERS, V9, P615, DOI 10.1002/cbdv.201100189
   Ali N. A. Awadh, 2009, REC NAT PROD, V2, P6
   Ammon HPT, 2006, PLANTA MED, V72, P1100, DOI 10.1055/s-2006-947227
   Banno N, 2006, J ETHNOPHARMACOL, V107, P249, DOI 10.1016/j.jep.2006.03.006
   Baratta M. T., 1998, Journal of Essential Oil Research, V10, P618
   Basar S, 2001, FLAVOUR FRAG J, V16, P315, DOI 10.1002/ffj.992
   Basar S., 2005, THESIS U HAMBURG HAM
   Baser KHC, 2003, FLAVOUR FRAG J, V18, P153, DOI 10.1002/ffj.1166
   Beeram M, 2007, ANN ONCOL, V18, P1323, DOI 10.1093/annonc/mdm170
   Buchele B, 2006, PLANTA MED, V72, P1285, DOI 10.1055/s-2006-951680
   Camarda L, 2007, ANN CHIM-ROME, V97, P837, DOI 10.1002/adic.200790068
   CARSON CF, 1995, J APPL BACTERIOL, V78, P264, DOI 10.1111/j.1365-2672.1995.tb05025.x
   Cicenas J, 2005, BREAST CANCER RES, V7, pR394, DOI 10.1186/bcr1015
   Cui YK, 2006, CANCER RES, V66, P5950, DOI 10.1158/0008-5472.CAN-05-3243
   DeGraffenried LA, 2004, CLIN CANCER RES, V10, P8059, DOI 10.1158/1078-0432.CCR-04-0035
   Dekebo A, 1999, B CHEM SOC ETHIOPIA, V13, P93
   Dekebo A, 2002, B CHEM SOC ETHIOPIA, V16, P87
   Dekebo A., 2001, THESIS ADDIS ABABA U
   Fan AY, 2005, J ETHNOPHARMACOL, V101, P104, DOI 10.1016/j.jep.2005.03.033
   Feng XL, 2011, MOL CELL BIOL, V31, P3457, DOI 10.1128/MCB.05523-11
   Frank MB, 2009, BMC COMPLEM ALTERN M, V9, DOI 10.1186/1472-6882-9-6
   Frogne T, 2005, ENDOCR-RELAT CANCER, V12, P599, DOI 10.1677/erc.1.00946
   Gee JMW, 2001, INT J CANCER, V95, P247, DOI 10.1002/1097-0215(20010720)95:4<247::AID-IJC1042>3.0.CO;2-S
   Gozgit JM, 2006, MOL CANCER RES, V4, P905, DOI 10.1158/1541-7786.MCR-06-0147
   Hamm S, 2005, PHYTOCHEMISTRY, V66, P1499, DOI 10.1016/j.phytochem.2005.04.025
   Kindeya G. H., 2003, THESIS CULVILLIER GO
   Lev DC, 2004, BRIT J CANCER, V91, P795, DOI 10.1038/sj.bjc.6602051
   Liang ZX, 2004, CANCER RES, V64, P4302, DOI 10.1158/0008-5472.CAN-03-3958
   Lin HJ, 2005, BRIT J CANCER, V93, P1372, DOI 10.1038/sj.bjc.6602862
   Liu JJ, 2009, ANTICANCER RES, V29, P2987
   Marongiu B, 2006, FLAVOUR FRAG J, V21, P718, DOI 10.1002/ffj.1718
   Mertens M, 2009, FLAVOUR FRAG J, V24, P279, DOI 10.1002/ffj.1942
   Mikhaeil BR, 2003, Z NATURFORSCH C, V58, P230
   Mimica-Dukic N, 2003, PLANTA MED, V69, P413, DOI 10.1055/s-2003-39704
   Mimica-Dukic N, 2004, J AGR FOOD CHEM, V52, P2485, DOI 10.1021/jf030698a
   Miyazawa M, 2005, J AGR FOOD CHEM, V53, P1765, DOI 10.1021/jf040019b
   Mothana RAA, 2011, FOOD CHEM, V126, P1149, DOI 10.1016/j.foodchem.2010.11.150
   Moussaieff A, 2009, J PHARM PHARMACOL, V61, P1281, DOI 10.1211/jpp/61.10.0003
   Obermann H., 1977, DRAGOCO REP, V24, P260
   PAILER M, 1981, MONATSH CHEM, V112, P341, DOI 10.1007/BF00900765
   Pattnaik S, 1997, MICROBIOS, V89, P39
   Perez-Tenorio G, 2002, BRIT J CANCER, V86, P540, DOI 10.1038/sj/bjc/6600126
   Poeckel D, 2006, CURR MED CHEM, V13, P3359, DOI 10.2174/092986706779010333
   Ruberto G, 2000, FOOD CHEM, V69, P167, DOI 10.1016/S0308-8146(99)00247-2
   Safayhi H, 2000, PLANTA MED, V66, P110, DOI 10.1055/s-2000-11136
   Safayhi H., 1997, PHARM ZTG, V142, P3277
   Sasaki CY, 1998, BIOTECHNIQUES, V24, P1038, DOI 10.2144/98246cr04
   Schillaci D, 2008, LETT APPL MICROBIOL, V47, P433, DOI 10.1111/j.1472-765X.2008.02469.x
   Shah BA, 2009, NAT PROD REP, V26, P72, DOI 10.1039/b809437n
   Shanghai Scientific and Technologic Press, 1985, DICT CHINESE TRADITI
   Shao Y, 1998, PLANTA MED, V64, P328, DOI 10.1055/s-2006-957444
   Singh B, 2007, FLAVOUR FRAG J, V22, P145, DOI 10.1002/ffj.1772
   STRAPPAGHETTI G, 1982, PHYTOCHEMISTRY, V21, P2114, DOI 10.1016/0031-9422(82)83057-4
   Suhail MM, 2011, BMC COMPLEM ALTERN M, V11, DOI 10.1186/1472-6882-11-129
   SUTHERLAND RM, 1979, INT J RADIAT ONCOL, V5, P1225, DOI 10.1016/0360-3016(79)90643-6
   Svensson S, 2005, ONCOGENE, V24, P4370, DOI 10.1038/sj.onc.1208626
   TUCKER AO, 1986, ECON BOT, V40, P425, DOI 10.1007/BF02859654
   Van Vuuren SF, 2010, S AFR J BOT, V76, P686, DOI 10.1016/j.sajb.2010.06.001
   Verghese J., 1987, Flavour and Fragrance Journal, V2, P99, DOI 10.1002/ffj.2730020304
   Vollesen K., 1989, FLORA ETHIOPIA, V3, P442
   WAHAB SMA, 1987, PLANTA MED, P382, DOI 10.1055/s-2006-962745
   Wesenberg-Ward K. E., 2005, Biofilms, V2, P63, DOI 10.1017/S1479050505001687
   WEST GW, 1980, CANCER RES, V40, P3665
   Woolley CL, 2012, J CHROMATOGR A, V1261, P158, DOI 10.1016/j.chroma.2012.06.073
NR 68
TC 4
Z9 4
U1 2
U2 42
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1741-427X
EI 1741-4288
J9 EVID-BASED COMPL ALT
JI Evid.-based Complement Altern. Med.
PY 2013
AR 140509
DI 10.1155/2013/140509
PG 12
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA 106UC
UT WOS:000316169200001
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Salar, L
   Zaman, K
   Khilji, BA
   Khan, MM
   Lodhi, MS
AF Salar, Laleena
   Zaman, Khalid
   Khilji, Bashir Ahmad
   Khan, Muhammad Mushtaq
   Lodhi, Mohammad Saeed
TI RETRACTED: The consequences of revenue gap in Pakistan: Unveiling the
   reality (Retracted article. See vol. 45, pg. 284, 2015)
SO ECONOMIC MODELLING
LA English
DT Article; Retracted Publication
DE Revenue gap; External debt; Price level; Economic growth; Cointegration;
   Pakistan
ID DEVELOPING-COUNTRIES; TAX-REVENUE; ECONOMY; COINTEGRATION; TAXATION;
   IMPACT; LEVEL
AB The purpose of this study is to investigate the major macroeconomic factors that enhance revenue gap for Pakistan through the co-integration and error correction model over a 36-year time period, i.e. between 1975 and 2010. The study employed the bounds testing approach of cointegration to estimate the long-run relationship between the variables, while an error correction model was used to determine the short-run dynamics of the system. The study was limited to a few variables, including economic growth, imports, unemployment rate, external debt and consumer price index, in order to manage robust data analysis. These variables are selected because of their vital importance to an emerging economy like Pakistan. Both short and long-run results confirm that except consumer price index, all other explanatory variables are positively associated with the revenue gap in Pakistan. The results suggest that changes in price level decrease the revenue gap in the short-run which indicates the "Patinkin effect" but these results disappear in the short-run. The results further point out that the speed of adjustment is rather slow for equations to return to their equilibrium level, once it has been shocked. The result of Granger causality test shows that there is a bidirectional causality relationship between revenue gap and imports on one hand, and between revenue gap and underground economy on the other hand. Moreover, unidirectional causality runs from debt, unemployment and inflation towards imports. There is a bidirectional causality runs between debt and imports, between unemployment and imports and between inflation and imports in Pakistan. (c) 2012 Elsevier B.V. All rights reserved.
C1 [Salar, Laleena; Zaman, Khalid; Khan, Muhammad Mushtaq; Lodhi, Mohammad Saeed] COMSATS Inst Informat Technol, Dept Management Sci, Abbottabad, Pakistan.
   [Khilji, Bashir Ahmad] Preston Univ, Islamabad, Pakistan.
RP Zaman, K (reprint author), COMSATS Inst Informat Technol, Dept Management Sci, Abbottabad, Pakistan.
EM laleena_salar@hotmail.com; khalidzaman@ciit.net.pk; kdrbashir@yahoo.com;
   khanmm@ciit.net.pk; saeedlodhi@ciit.net.pk
CR Ahmed QM, 2010, EUROPEAN J SOCIAL SC, V13, P408
   Ahmed R.A., 2008, WORKING PAPER SERIES
   Akram N., 2010, 25 PSDE C HELD 16 18
   Alexandru Adriana Anamaria, 2010, WSEAS Transactions on Business and Economics, V7, P359
   Alm J., 2007, 0732 INT STUD PROGR
   [Anonymous], 2012, BUSINESS RECORDER
   Ayyagari M., 2010, 5389 WORLD BANK
   Azhar B.A., 1996, PAKISTAN DEV REV, V35, P657
   BAGACHWA MSD, 1995, WORLD DEV, V23, P1387, DOI 10.1016/0305-750X(95)00055-H
   Bajada C, 1999, ECON REC, V75, P369, DOI 10.1111/j.1475-4932.1999.tb02573.x
   Baunsgaard T, 2010, J PUBLIC ECON, V94, P563, DOI 10.1016/j.jpubeco.2009.11.007
   Bukhari H., 2011, WEEKLY TAX J, P83
   Cardoso E, 1998, INT MONET FUND S PAP, V45, P619
   CHAU G, 2009, J ACCOUNTING TAXATIO, V1, P34
   Chaudhary M.A., 2001, PAKISTAN EC SOCIAL R, VXXXIX, P25
   Chaudhry I. S., 2010, PAKISTAN J SOCIAL SC, V30, P439
   CHELLIAH RJ, 1971, INT MONET FUND S PAP, V18, P254
   Cobham A., 2005, QEH WORKING PAPER SE, V129
   Desai M., 2005, WORKING PAPER SERIES
   Eichhorn C., 2004, IMPLICATIONS T UNPUB
   Enders W., 2004, APPL ECONOMETRIC TIM
   Erard B., 1997, 976 CARL U
   FREY BS, 1984, EUR ECON REV, V26, P33, DOI 10.1016/0014-2921(84)90020-5
   Ghura D., 1998, 98135 IMF
   Giles D.E.A., 1999, EC96461
   Gupta A. S., 2007, 184 IMF
   Gupta S., 2003, 176 IMF
   HINRICHS HH, 1965, ECON J, V75, P546, DOI 10.2307/2228952
   Hudson J, 2012, SOUTH EAST EUR J E B, V7, P99, DOI 10.2478/v10033-012-0010-x
   IFS, 2011, INT FIN STAT 2011
   Ilyas M., 2010, INT J HUMAN SOCIAL S, V5, P753
   Inam M., 2008, J MANAGERIAL SCI, V2, P97
   IRS, 2007, RED FED TAX GA REP I
   Jamal N., 2011, DAWN NEWSPAPER  0214
   Jayasinghe M., 2007, PAKISTAN PRELIMINARY
   Kemal M., 2007, PAKISTAN I DEV EC WO
   Kirchler E, 2003, J ECON PSYCHOL, V24, P535, DOI 10.1016/S0167-4870(02)00164-2
   Kolm A.S., 2003, WORKING PAPER SERIES
   Kusi N.K., 1998, 74 AFR EC RES CONS
   Lacko M., 1999, 9905 U LINZ DEP EC
   Liew V. K., 2004, EC B, V3, P1
   LOTZ JR, 1967, INT MONET FUND S PAP, V14, P478
   Lutkepohl Helmuth, 1991, INTRO MULTIPLE TIME
   Mackinnon JG, 1996, J APPL ECONOMET, V11, P601, DOI 10.1002/(SICI)1099-1255(199611)11:6<601::AID-JAE417>3.0.CO;2-T
   Mazhar U., 2011, PUBLIC CHOICE SOC PA
   Nagy-Eltony M., 2002, API WORKING PAPER SE
   Narayan PK, 2005, ECON MODEL, V22, P423, DOI 10.1016/j.econmod.2004.06.004
   O'Higgins M., 1985, EC SHADOW EC C P BEI, P127
   Palil Mohd Rizal, 2011, AUSTR J BASIC APPL S, V5, P557
   Pasha A.G., 2010, LAHORE J EC, V15, P171
   PATINKIN D, 1993, J ECON PERSPECT, V7, P103, DOI 10.1257/jep.7.2.103
   PERMAN R, 1991, J ECON STUD, V18, P3
   Pesaran MH, 2001, J APPL ECONOM, V16, P289, DOI 10.1002/jae.616
   Pyle D.J., 1989, TAX EVASION BLACK EC, P212
   Rifkin D., 2008, GEORGETOWN LAW FACUL
   Rimmer D., 2010, CLOSING TAX GAP
   Sancak C., 2010, 71 IMF
   SBP, 2012, HDB STAT PAK EC
   Schneider F., 2006, IZA DISCUSSION PAPER
   Siddiqi M. W., 2011, INT J HUMAN SOCIAL S, V6, P89
   Slemrod J, 2007, J ECON PERSPECT, V21, P25, DOI 10.1257/jep.21.1.25
   Sookram S., 2005, TAX EVASION HIDDEN E
   Tabandeh R., 2012, PERSIDANGAN KEBANGSA
   TANZI V, 1978, INT MONET FUND S PAP, V25, P417
   TANZI V, 1989, INT MONET FUND S PAP, V36, P633
   TANZI V, 1992, OPEN EC STRUCTURAL A
   Tanzi V., 1987, THEORY TAXATION DEV
   WBS, 2012, WORLD BANK STAT TAX
   WDI, 2012, WORLD DEV IND
   Webber C., 1986, HIST TAXATION EXPEND, P734
   Yasmine B., 2004, LAHORE J EC, V9, P93
NR 71
TC 2
Z9 2
U1 1
U2 17
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0264-9993
EI 1873-6122
J9 ECON MODEL
JI Econ. Model.
PD JAN
PY 2013
VL 30
BP 281
EP 294
DI 10.1016/j.econmod.2012.09.015
PG 14
WC Economics
SC Business & Economics
GA 090TJ
UT WOS:000315002600032
DA 2018-12-27
ER

PT J
AU Zaman, K
   Khilji, BA
AF Zaman, Khalid
   Khilji, Bashir Ahmad
TI RETRACTED: The relationship between growth-inequality-poverty triangle
   and pro-poor growth policies in Pakistan: The twin disappointments
   (Retracted article. See vol. 45, pg. 285, 2015)
SO ECONOMIC MODELLING
LA English
DT Article; Retracted Publication
DE Poverty; Growth; Inequality; Pro-growth; Pro-poor growth; Pakistan
ID INCOME INEQUALITY; 1980S
AB The objective of the study is to examine the relationship between growth, inequality and poverty in the context of rural, urban and national levels. Further, this study evaluates pro-poor growth policies in Pakistan during the period of 1964-2011. The regression model encompassing the impact of economic growth and inequality on poverty reflects that a 1% increase in income while keeping the distribution constant reduces poverty around 0.162% in rural, 0.256% in urban, 0.471% in national pooled and 0.276% in national weighted regression. An increase in Gini coefficient while holding the income constant tends to increase poverty in the national weighted by 2.641%, and in the national pooled around 1.721% respectively. Subsequently, at urban and rural regions, it creates proportionally more poor households in the urban areas (elasticity 1.231) than in the rural areas (elasticity 0.928). The study measures pro-poor growth index that captures gains and losses of growth rates due to changes in the distribution of consumption. The gains imply pro-poor growth, while the losses imply anti-poor growth. Total growth spells in this study are 180 including 20 surveys for rural, 20 surveys for urban and 20 surveys for overall Pakistan. However, the study used three different poverty measures i.e., household count (HHC), poverty gap (PG) and squared poverty gap (SPG), evaluating 60 surveys for each poverty measure. The results conclude that out of the 180 growth spells, 63 growth spells had negative growth rates and 117 spells had positive growth rates. Of the 117 spells when growth rates were positive, growth was pro-poor in 64 cases and anti-poor in 53 cases. In 25 out of 63 spells of negative growth rates, the poor suffered proportionally a greater decline in their consumption compared to the non-poor. Thus, growth processes have not generally been favorable to the poor. (c) 2012 Elsevier B.V. All rights reserved.
C1 [Zaman, Khalid] Preston Univ, Dept Econ, Islamabad, Pakistan.
   [Zaman, Khalid] COMSATS Inst Informat Technol, Dept Management Sci, Abbottabad, Pakistan.
   [Khilji, Bashir Ahmad] Preston Univ, Islamabad, Pakistan.
RP Zaman, K (reprint author), COMSATS Inst Informat Technol, Dept Management Sci, Abbottabad, Pakistan.
EM khalidzaman@ciit.net.pk; kdrbashir@yahoo.com
CR ADB, 2011, GLOB FOOD PRIC INFL
   Agrawal P., 2008, ASIAN DEV REV, V24, P90
   Aigbokhan B.E., 2008, 3 ACGSMPAMS UNECA
   Ali S. S., 1999, PAKISTAN DEV REV 2, V38, P837
   Amjad Rashid, 1982, PRIVATE IND INVESTME
   ANAND S, 1993, J DEV ECON, V41, P19, DOI 10.1016/0304-3878(93)90035-L
   Anwar Talat, 2006, CHANGES INEQUALITY C
   Asad M.A., 2011, PAKISTAN EC SOCIAL R, V49, P69
   Asghar N., 2012, AFRICAN J BUSINESS M, V6, P845
   ATKINSON AB, 1970, J ECON THEORY, V2, P244, DOI 10.1016/0022-0531(70)90039-6
   BHAGWATI JN, 1988, WORLD DEV, V16, P539, DOI 10.1016/0305-750X(88)90184-2
   Bhatti N., 2012, Journal of Management and Sustainability, V2, P227
   Bourguignon F., 2004, IND COUNC RES INT EC
   Bourguignon F., 2004, WORKING PAPERS INDIA
   Burki S.J., 1999, PAKISTAN 50 YEARS NA, P1
   Chani M.I., 2011, WORLD APPL SCI J, V14, P1058
   Chaudhry I.S., 2012, INT RES J FINANCE EC, V10, P78
   Cheema A.R., 2012, J RES INT BUSINESS M, V2, P1
   Cheema A.R., 2010, ECON SOC REV, V48, P279
   Chudhry I. M., 2006, PAKISTAN EC SOC REV, V44, P259
   DATT G, 1992, J DEV ECON, V38, P275, DOI 10.1016/0304-3878(92)90001-P
   Deininger K, 1996, WORLD BANK ECON REV, V10, P565, DOI 10.1093/wber/10.3.565
   FOSTER J, 1984, ECONOMETRICA, V52, P761, DOI 10.2307/1913475
   Gelaw F., 2009, INT ASS AGR EC C BEI
   GoP, 2009, EC SURV PAK
   GoP, 2000, EC SURV PAK
   GoP, 2011, EC SURV PAK
   GoP, 2010, EC SURV PAK
   Grunewald N., 2011, DISCUSSION PAPERS U
   Hadnes M., 2008, SOCIAL ECOLOGICAL MA, P106
   Hamid N., 1974, PAKISTAN EC SOCIAL R, V12, P255
   Haq R., 2009, PIDE WORKING PAPERS, P52
   Heshmati A., 2004, 1338 IZA
   HIES, 2011, HOUS INT EC SURV
   Hussain A., 2006, ENCY PAKISTAN
   Idress M., 2006, THESIS QUAID I AZAM
   KAKWANI N, 1993, REV INCOME WEALTH, P121
   Kakwani N., 1980, INCOME INEQUALITY PO
   Kakwani N., 2004, PAKISTAN DEV REV, V42, P417
   Kakwani N, 2008, REV INCOME WEALTH, V54, P643, DOI 10.1111/j.1475-4991.2008.00293.x
   Kakwani Nanak, 2000, ASIAN DEV REV, V18, P1
   Khan M.H., 2002, WP0285 IMF
   Khan M. M., 2012, SOCIAL CHANGE, V42, P249
   Klasen S., 2004, P ABCDE EUR
   Klasen S., 2009, DETERMINANTS PROPOOR
   Kraay A., 2004, 3225 WORLD BANK
   Kuznets S, 1955, AM ECON REV, V45, P1
   Lohano H.R., 2009, 157 CHRON POV RES CT
   Lombardo V., 2011, RIV ITALIANA EC, VXVI, P241
   Lopez J.H., 2008, WORKING PAPER SERIES, V3814
   Lopez J. H., 2004, PROPOOR GROWTH UNPUB
   Luo X., 2008, 4700 WORLD BANK
   Malinen T., 2007, 193 HELS CTR EC RES
   Maltsoglou I., 2005, 21 PPLPI
   Naseem S.M., 1977, RURAL POVERTY LANDLE
   OECD, 2006, PROM PROP GROWTH POL
   OECD, 2007, OECD OBSERVER
   Okidi J., 2004, OPERATIONALISING PRO
   Omer M., 2008, S ASIA EC J, V9, P51
   Pasha H.A., 2004, PROPOOR GROWTH POLIC
   PIHS, 2005, PAK INT HOUS SURV
   RAVALLION M, 1995, ECON LETT, V48, P411, DOI 10.1016/0165-1765(94)00620-H
   Ravallion M, 2003, ECON LETT, V78, P93, DOI 10.1016/S0165-1765(02)00205-7
   Ravallion M., 2005, 3579 WORLD BANK
   RAVALLION M, 2004, 3242 WORLD BANK
   Rodriguez ER, 1998, ECON DEV CULT CHANGE, V46, P329, DOI 10.1086/452341
   Saboor A., 2004, THESIS U AGR FAISALA
   Sen A, 1973, EC INEQUALITY
   Shorrocks A., 2005, GROWTH INEQUALITY PO, P1
   Son H.H., 2004, 2 IPC UNDP
   Son HH, 2004, ECON LETT, V82, P307, DOI 10.1016/j.econlet.2003.08.003
   Son HH, 2008, WORLD DEV, V36, P1048, DOI 10.1016/j.worlddev.2007.10.002
   Tahir M., 2014, J EC SUSTAINABLE DEV, V10, P137
   Theil H., 1967, EC INFORM THEORY
   Ugoh SC, 2009, AFR J BUS MANAGE, V3, P847
   UNU-WIDER, 2008, POV GROWTH IN TRIANG
   Watts H., 1968, UNDERSTANDING POVERT
   World Bank, 2011, FOOD PRIC WATCH
   World Bank, 2011, CHOOS EST POV IND
   Zaman K., 2011, AFROASIAN J RURAL DE, V44, P7
   Zaman K., 2011, J EC SOCIAL DEV, V13, P110
   Zaman K., 2009, INT J RURAL MANAGEME, V5, P217
   Zaman K., 2010, INT J TRADE EC FINAN, V1, P73
   Zaman K., 2011, J YASAR U, V21, P3523
   Zaman K., 2011, J INF TECHNOL, V11, P59
   Zaman K., 2008, 2 INT C ASS QUAL HIG
   Zaman K., 2010, INT RES J FINANCE EC, V3, P32
   Zaman K., 2010, INDIAN J EC 3, VXIC, P561
   Zaman K., 2010, J HUMANITIES SOCIAL, VXVIII, P109
   Zaman K., 2009, PAKISTAN J SOCIAL SC, V29, P211
   Zaman K., 2008, INT J RURAL MANAGEME, V4, P201
   Zaman K., 2011, ROMANIAN J FISCAL PO, V2, P24
   Zaman K., 2012, INT J EC BUSINESS RE, V4, P485
   Zaman K, 2012, ECON MODEL, V29, P1220, DOI 10.1016/j.econmod.2012.04.020
   Zaman K, 2010, J ENVIRON PLANN MAN, V53, P977, DOI 10.1080/09640568.2010.495537
   Zaman K, 2012, RECENT PAT ANTI-CANC, V7, P1
NR 96
TC 6
Z9 6
U1 3
U2 27
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0264-9993
EI 1873-6122
J9 ECON MODEL
JI Econ. Model.
PD JAN
PY 2013
VL 30
BP 375
EP 393
DI 10.1016/j.econmod.2012.09.023
PG 19
WC Economics
SC Business & Economics
GA 090TJ
UT WOS:000315002600042
DA 2018-12-27
ER

PT J
AU Zaman, K
   Khilji, BA
AF Zaman, Khalid
   Khilji, Bashir Ahmad
TI RETRACTED: The relationship between growth and poverty in forecasting
   framework: Pakistan's future in the year 2035 (Retracted article. See
   vol. 45, pg. 286, 2015)
SO ECONOMIC MODELLING
LA English
DT Article; Retracted Publication
DE Poverty; Growth; Income inequality; Variance decomposition; Impulse
   response function; Pakistan
ID ECONOMIC-GROWTH; INCOME-DISTRIBUTION; INEQUALITY; MACROECONOMICS;
   LOOKING
AB Forecasting poverty in the future is mostly a matter of forecasting economic growth. The objective of the study is to examine the inter-temporal link between growth and poverty in Pakistan, over the next 25 years period i.e., from the years 2011 to 2035. The generalized version of variance decomposition and impulse response analysis is operated in this study to test the temporal causality among poverty measures (i.e., head count ratio, poverty gap and squared poverty gap), growth measures (i.e., average household income, industry value added and agriculture value added) and income inequality to see if the growth of income and poverty measures contains considerable information to predict each other, on the sectoral level of Pakistan i.e., rural, urban and national level. The results of variance decomposition analysis show that shock to household counts initially accounts for a considerable portion of the forecast error variance of average household income in all rural, urban and at national level respectively. Household counts have the highest impact on average income in Pakistan (approximately 93.2%), followed by urban region (approximately 90.5% in average) and the lowest in rural areas (approximately 82.3%) both in short- and long-run. Impulse response analysis demonstrates that growth, poverty measures and income inequality are so strongly knitted to one another that any positive shock to any one of them would be beneficial on the one hand and may be harmful on the other hand. The vicious cycle of poverty can only be scratched by giving consistent positive shocks to growth and negative shocks to income inequality. (c) 2012 Elsevier B.V. All rights reserved.
C1 [Zaman, Khalid] Preston Univ, Dept Econ, Islamabad, Pakistan.
   [Zaman, Khalid] COMSATS Inst Informat Technol, Dept Management Sci, Abbottabad, Pakistan.
   [Khilji, Bashir Ahmad] Preston Univ, Islamabad, Pakistan.
RP Zaman, K (reprint author), COMSATS Inst Informat Technol, Dept Management Sci, Abbottabad, Pakistan.
EM khalidzaman@ciit.net.pk; kdrbashir@yahoo.com
CR Aguirregabiria V., 2003, ENCY WORLD POVERTY
   Ajilore T., 2012, INT J SUSTAINABLE EC, V4, P35
   ALESINA A, 1994, Q J ECON, V109, P465, DOI 10.2307/2118470
   Ali AAG, 2000, J AFR ECON, V9, P9, DOI 10.1093/jafeco/9.Supplement_1.9
   Amjad R., 1997, Pakistan Development Review, V36, P39
   Anwar T., 2002, PAKISTAN DEV REV 2, V41, P859
   Anwar T., 2008, GROWTH POVERTY INEQU
   Anwar Talat, 2006, CHANGES INEQUALITY C
   Atkinson AB, 1997, ECON J, V107, P297, DOI 10.1111/j.0013-0133.1997.159.x
   Barro R.J., 1995, EC GROWTH
   Bourguignon F, 2002, AM ECON REV, V92, P727, DOI 10.1257/00028280260344443
   Bourguignon F, 2004, POVERTY GROWTH INEQU
   Deininger K, 1998, J DEV ECON, V57, P259, DOI 10.1016/S0304-3878(98)00099-6
   Forbes KJ, 2000, AM ECON REV, V90, P869, DOI 10.1257/aer.90.4.869
   GALOR O, 1993, REV ECON STUD, V60, P35, DOI 10.2307/2297811
   GOP, 2011, EC SURV PAK 2010 201
   GOP, 2012, EC SURV PAK 2011 12
   Grossman G. M., 1991, INNOVATION GROWTH GL
   Hanmer L., 2000, DEV POLICY REV, V18, P11
   Hanmer L., 2009, WILL GROWTH HALVE GL
   Heltberg R., 2001, POVERTY ELASTICITY G
   Hillebrand E., 2009, FAO EXP M FEED WORLD
   Hughes B.B., 2006, ANN M INT STUD ASS S
   Jamal H., 2006, PAK DEV REV, V45, P439
   Khan M. M., 2012, SOCIAL CHANGE, V42, P249
   Koop G, 1996, J ECONOMETRICS, V74, P119, DOI 10.1016/0304-4076(95)01753-4
   Kraay A, 2004, IS GROWTH PROPOOR EV
   Kurita K, 2011, ASIAN ECON J, V25, P3, DOI 10.1111/j.1467-8381.2011.02046.x
   Kuznets S, 1955, AM ECON REV, V45, P1
   Li H., 1998, REV DEV ECON, V2, P318, DOI DOI 10.1111/1467-9361.00045
   Lutkepohl Helmuth, 1991, INTRO MULTIPLE TIME
   Malik M. H., 1988, Pakistan Development Review, V27, P509
   Mallick S.K., 2012, S S W ASIA DEV PAPER
   McKay A., 1997, J INT DEV, V9, P665
   Mogull R.G., 2004, J APPL BUSINESS RES, V20, P51
   Naschold F., 2002, 2 OV DEV I MOK OXF P
   Pesaran HH, 1998, ECON LETT, V58, P17, DOI 10.1016/S0165-1765(97)00214-0
   Pesaran M.H., 1997, WORKING MICROFIT 4 0
   PPAF, 2012, PAK POV ALL FUND
   PSLM, 2011, PAK SOC LIV STAND ME
   Ravallion M, 2001, WORLD DEV, V29, P1803, DOI 10.1016/S0305-750X(01)00072-9
   Ravallion M., 1994, POVERTY COMP FUNDAME, V56
   Renwick N, 2011, THIRD WORLD Q, V32, P65, DOI 10.1080/01436597.2011.543814
   ROMER PM, 1987, AM ECON REV, V77, P56
   ROMER PM, 1990, J POLIT ECON, V98, pS71, DOI 10.1086/261725
   Saboor A., 2004, THESIS U AGR FAISALA
   Shorrocks A., 2004, GROWTH INEQUALITY PO
   SIMS CA, 1980, ECONOMETRICA, V48, P1, DOI 10.2307/1912017
   SOLOW RM, 1956, Q J ECON, V70, P65, DOI 10.2307/1884513
   Tahir M., 2014, J EC SUSTAINABLE DEV, V10, P137
   UNDP, 2011, HUM DEV REP ENV TREN
   World Bank, 2005, WORLD BANK COUNTRY, P1, DOI 10.1596/978-0-8213-6226-6
   World Bank, 2006, SUMM KEY FIND REC PA
   World Bank, 2009, POVCAL NET DAT
   Zaman K., 2011, AFROASIAN J RURAL DE, V44, P7
   Zaman K., 2011, J EC SOCIAL DEV, V13, P110
   Zaman K., 2009, INT J RURAL MANAGEME, V5, P217
   Zaman K., 2011, J YASAR U, V21, P3523
   Zaman K., 2011, J INF TECHNOL, V11, P59
   Zaman K., 2010, INT RES J FINANCE EC, V3, P32
   Zaman K., 2010, INDIAN J EC 3, VXIC, P561
   Zaman K., 2010, INT J TRADE EC FINAN, V1, P303
   Zaman K., 2010, J HUMANITIES SOCIAL, VXVIII, P109
   Zaman K., 2009, PAKISTAN J SOCIAL SC, V29, P211
   Zaman K., 2008, INT J RURAL MANAGEME, V4, P201
   Zaman K., 2011, ROMANIAN J FISCAL PO, V2, P24
   Zaman K., 2012, INT J EC BUSINESS RE, V4, P485
   Zaman K, 2012, ECON MODEL, V29, P1220, DOI 10.1016/j.econmod.2012.04.020
   Zaman K, 2010, J ENVIRON PLANN MAN, V53, P977, DOI 10.1080/09640568.2010.495537
   Zaman K, 2012, RECENT PAT ANTI-CANC, V7, P1
NR 70
TC 5
Z9 5
U1 2
U2 25
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0264-9993
EI 1873-6122
J9 ECON MODEL
JI Econ. Model.
PD JAN
PY 2013
VL 30
BP 468
EP 491
DI 10.1016/j.econmod.2012.07.021
PG 24
WC Economics
SC Business & Economics
GA 090TJ
UT WOS:000315002600051
DA 2018-12-27
ER

PT J
AU Wang, ZF
   Wang, NP
   Harmouche, S
   Philip, T
   Pang, XF
   Bai, F
   Zhao, ZQ
AF Wang, Zhang-Feng
   Wang, Ning-Ping
   Harmouche, Suzanna
   Philip, Tiji
   Pang, Xue-Fen
   Bai, Feng
   Zhao, Zhi-Qing
TI RETRACTED: Postconditioning promotes the cardiac repair through
   balancing collagen degradation and synthesis after myocardial infarction
   in rats (Retracted article. See vol. 110, 12, 2015)
SO BASIC RESEARCH IN CARDIOLOGY
LA English
DT Article; Retracted Publication
DE Cardiac repair; Collagen; Extracellular matrix; Postconditioning; TGF
   beta 1/Smad pathway
ID K-ATP CHANNELS; PERCUTANEOUS CORONARY INTERVENTION; ISCHEMIA-REPERFUSION
   INJURY; HEART-FAILURE; TNF-ALPHA; MATRIX METALLOPROTEINASES;
   MAGNETIC-RESONANCE; GROWTH-FACTOR; CARDIOPROTECTION; INHIBITION
AB Postconditioning (Postcon) reduces infarct size. However, its role in modulation of cardiac repair after infarction is uncertain. This study tested the hypothesis that Postcon inhibits adverse cardiac repair by reducing degradation of extracellular matrix (ECM) and synthesis of collagens via modulating matrix metalloproteinase (MMP) activity and transforming growth factor (TGF) beta 1/Smad signaling pathway. Sprague-Dawley rats were subjected to 45 min ischemia followed by 3 h, 7 or 42 days of reperfusion, respectively. In acute studies, four cycles of 10/10 s Postcon significantly reduced infarct size, which was blocked by administration of a mitochondrial K-ATP channel blocker, 5-hydroxydecanoate (5-HD) at reperfusion. In chronic studies, Postcon inhibited MMP activity and preserved ECM from degradation as evidenced by reduced extent of collagen-rich scar and increased mass of viable myocardium. Along with a reduction in collagen synthesis and fibrosis, Postcon significantly down-regulated expression of TGF beta 1 and phospho-Smad2/3, and up-regulated Smad7 as compared to the control, consistent with a reduction in the population of alpha-smooth muscle actin expressing myofibroblasts within the infarcted myocardium. At 42 days of reperfusion, echocardiography showed significant improvements in left ventricular end-diastolic volume and ejection fraction. The wall thickness of the infarcted middle anterior septum in the Postcon was also significantly greater than that in the control. The beneficial effects of Postcon on cardiac repair were comparable to preconditioning and still evident after a blockade with 5-HD. These data suggest that Postcon is effective to promote cardiac repair and preserve cardiac function; protection is potentially mediated by inhibiting ECM degradation and collagen synthesis.
C1 [Wang, Zhang-Feng; Wang, Ning-Ping; Harmouche, Suzanna; Philip, Tiji; Zhao, Zhi-Qing] Mercer Univ, Sch Med, Cardiovasc Res Lab, Savannah, GA 31404 USA.
   [Wang, Zhang-Feng] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Otolaryngol, Guangzhou 510275, Guangdong, Peoples R China.
   [Pang, Xue-Fen; Bai, Feng; Zhao, Zhi-Qing] Shanxi Med Univ, Dept Physiol, Taiyuan, Shanxi, Peoples R China.
   [Zhao, Zhi-Qing] Mercer Univ, Sch Med, Dept Basic Biomed Sci, Savannah, GA 31404 USA.
RP Zhao, ZQ (reprint author), Mercer Univ, Sch Med, Dept Basic Biomed Sci, 4700 Water Ave, Savannah, GA 31404 USA.
EM zhao_z@mercer.edu
FU Mercer University School of Medicine; National Natural Science
   Foundation of China [81170145/H0203]
FX This study was supported in part by a seed Grant from the Mercer
   University School of Medicine and National Natural Science Foundation of
   China (81170145/H0203).
CR Bell RM, 2012, J MOL CELL CARDIOL, V53, P24, DOI 10.1016/j.yjmcc.2012.04.001
   Belvisi MG, 2003, INFLAMM RES, V52, P95, DOI 10.1007/s000110300020
   Berthonneche C, 2004, AM J PHYSIOL-HEART C, V287, pH340, DOI 10.1152/ajpheart.01210.2003
   Boengler K, 2010, BASIC RES CARDIOL, V105, P771, DOI 10.1007/s00395-010-0124-1
   Brown RD, 2005, ANNU REV PHARMACOL, V45, P657, DOI 10.1146/annurev.pharmtox.45.120403.095802
   Bujak M, 2007, CARDIOVASC RES, V74, P184, DOI 10.1016/j.cardiores.2006.10.002
   Cheung PY, 2000, CIRCULATION, V101, P1833, DOI 10.1161/01.CIR.101.15.1833
   Cohen MV, 2007, CIRCULATION, V115, P1895, DOI 10.1161/CIRCULATIONAHA.106.675710
   Dobaczewski M, 2010, CIRC RES, V107, P418, DOI 10.1161/CIRCRESAHA.109.216101
   Douhidel O, 2008, AM J PHYSIOL-HEART C, V295, pH1508, DOI [10.1152/ajpheart.00379.2008, DOI 10.1152/AJPHEART.00379.2008]
   Euler-Taimor G, 2006, CARDIOVASC RES, V69, P15, DOI 10.1016/j.cardiores.2005.07.007
   Falk V, 2002, EUR J CARDIO-THORAC, V22, P53, DOI 10.1016/S1010-7940(02)00207-5
   Freixa X, 2012, EUR HEART J, V33, P103, DOI 10.1093/eurheartj/ehr297
   Garcia S, 2011, J CARDIOVASC TRANSL, V4, P92, DOI 10.1007/s12265-010-9252-0
   Granfeldt A, 2012, ACTA ANAESTH SCAND, V56, P48, DOI 10.1111/j.1399-6576.2011.02577.x
   Hausenloy DJ, 2011, ANTIOXID REDOX SIGN, V14, P893, DOI 10.1089/ars.2010.3360
   Heinzel FR, 2005, CIRC RES, V97, P583, DOI 10.1161/01.RES.0000181171.65293.65
   Heusch G, 2006, BASIC RES CARDIOL, V101, P354, DOI 10.1007/s00395-006-0589-0
   Heusch G, 2013, LANCET, V381, P166, DOI 10.1016/S0140-6736(12)60916-7
   Heusch G, 2012, EUR HEART J, V33, P13, DOI 10.1093/eurheartj/ehr341
   Heusch G, 2011, CIRC RES, V109, P1302, DOI 10.1161/CIRCRESAHA.111.255604
   Hinz B, 2007, J INVEST DERMATOL, V127, P526, DOI 10.1038/sj.jid.5700613
   Kin H, 2008, SHOCK, V29, P761, DOI 10.1097/SHK.0b013e31815cfd5a
   Kleinbongard P, 2010, PHARMACOL THERAPEUT, V127, P295, DOI 10.1016/j.pharmthera.2010.05.002
   Leconte C, 2009, STROKE, V40, P3349, DOI 10.1161/STROKEAHA.109.557314
   Lindsey ML, 2003, ANN MED, V35, P316, DOI 10.1080/07853890310001285
   Lonborg J, 2010, AM HEART J, V160, P1085, DOI 10.1016/j.ahj.2010.09.026
   Lonborg J, 2010, CIRC-CARDIOVASC INTE, V3, P34, DOI 10.1161/CIRCINTERVENTIONS.109.905521
   Luo WJ, 2007, J THORAC CARDIOV SUR, V133, P1373, DOI 10.1016/j.jtcvs.2007.01.028
   Minatoguchi S, 2004, CIRCULATION, V109, P2572, DOI 10.1161/01.CIR.0000129770.93985.3E
   Mykytenko J, 2008, BASIC RES CARDIOL, V103, P472, DOI 10.1007/s00395-008-0731-2
   Okada H, 2005, CIRCULATION, V111, P2430, DOI 10.1161/01.CIR.0000165066.71481.8E
   Pain T, 2000, CIRC RES, V87, P460
   Payne TR, 2007, J AM COLL CARDIOL, V50, P1677, DOI 10.1016/j.jacc.2007.04.100
   Penna C, 2006, BASIC RES CARDIOL, V101, P180, DOI 10.1007/s00395-006-0584-5
   Penna C, 2012, BASIC RES CARDIOL, V107, DOI 10.1007/s00395-012-0272-6
   Prasad A, 2009, CIRCULATION, V120, P2105, DOI 10.1161/CIRCULATIONAHA.108.814640
   Przyklenk K, 2011, ANTIOXID REDOX SIGN, V14, P781, DOI 10.1089/ars.2010.3343
   Ren CC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003851
   Rohde LE, 1999, J AM COLL CARDIOL, V33, P835, DOI 10.1016/S0735-1097(98)00602-0
   Roubille F, 2011, CIRCULATION, V124, P1330, DOI 10.1161/CIRCULATIONAHA.111.031864
   Sadat Umar, 2008, Expert Rev Cardiovasc Ther, V6, P999, DOI 10.1586/14779072.6.7.999
   Sandu N, 2010, EXPERT REV CARDIOVAS, V8, P479, DOI [10.1586/erc.09.180, 10.1586/ERC.09.180]
   Schwartz Longacre L, 2011, CIRCULATION, V124, P1172, DOI 10.1161/CIRCULATIONAHA.111.032698
   Sorensson P, 2010, HEART, V96, P1710, DOI 10.1136/hrt.2010.199430
   Spinale FG, 2002, J CARD FAIL, V8, pS332, DOI 10.1054/jcaf.2002.129259
   Staat P, 2005, CIRCULATION, V112, P2143, DOI 10.1161/CIRCULATIONAHA.105.558122
   Sun HY, 2005, AM J PHYSIOL-HEART C, V288, pH1900, DOI 10.1152/ajpheart.01244.2003
   Sun Y, 2009, CARDIOVASC RES, V81, P482, DOI 10.1093/cvr/cvn333
   Tao ZY, 2004, LIFE SCI, V74, P1561, DOI 10.1016/j.lfs.2003.09.042
   Tessone A, 2005, CARDIOVASC DRUG THER, V19, P383, DOI 10.1007/s10557-005-5201-6
   Thibault H, 2008, CIRCULATION, V117, P1037, DOI 10.1161/CIRCULATIONAHA.107.729780
   Tsang A, 2004, CIRC RES, V95, P230, DOI 10.1161/01.RES.0000138303.76488.fe
   Vinten-Johansen J, 2005, BASIC RES CARDIOL, V100, P295, DOI 10.1007/s00395-005-0523-x
   Wang BQ, 2007, AM J PHYSIOL-HEART C, V293, pH1282, DOI 10.1152/ajpheart.00910.2006
   Wei M, 2011, CIRC RES, V108, P1220, DOI 10.1161/CIRCRESAHA.110.236190
   Yang Xin-Chun, 2007, J Invasive Cardiol, V19, P424
   Yuan SM, 2010, INTERACT CARDIOV TH, V11, P455, DOI 10.1510/icvts.2010.234773
   Zhao ZQ, 2010, J AM COLL CARDIOL, V55, P1250, DOI 10.1016/j.jacc.2009.10.049
   Zhao ZQ, 2003, AM J PHYSIOL-HEART C, V285, pH579, DOI 10.1152/ajpheart.01069.2002
   Zhao ZQ, 2000, J SURG RES, V94, P133, DOI 10.1006/jsre.2000.6029
   Zhou CH, 2012, INT J CARDIOL, V162, P59, DOI 10.1016/j.ijcard.2012.09.174
NR 62
TC 24
Z9 25
U1 4
U2 20
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0300-8428
EI 1435-1803
J9 BASIC RES CARDIOL
JI Basic Res. Cardiol.
PD JAN
PY 2013
VL 108
IS 1
AR 318
DI 10.1007/s00395-012-0318-9
PG 15
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 085VF
UT WOS:000314641700010
PM 23203208
DA 2018-12-27
ER

PT J
AU Derosa, G
   Cicero, AFG
   Carbone, A
   Querci, F
   Fogari, E
   D'Angelo, A
   Maffioli, P
AF Derosa, Giuseppe
   Cicero, Arrigo F. G.
   Carbone, Anna
   Querci, Fabrizio
   Fogari, Elena
   D'Angelo, Angela
   Maffioli, Pamela
TI RETRACTED: Variation of some inflammatory markers in hypertensive
   patients after 1 year of olmesartan/amlodipine single-pill combination
   compared with olmesartan or amlodipine monotherapies (Retracted article.
   See vol. 9, pg. 821, 2015)
SO JOURNAL OF THE AMERICAN SOCIETY OF HYPERTENSION
LA English
DT Article; Retracted Publication
DE Amlodipine; hypertension; olmesartan; tumor necrosis factor-alpha
ID TYPE-2 DIABETIC-PATIENTS; NECROSIS-FACTOR-ALPHA; INSULIN-RESISTANCE;
   TNF-ALPHA; TELMISARTAN; SENSITIVITY; OBESITY; MICROALBUMINURIA;
   ROSIGLITAZONE; MANAGEMENT
AB The purpose of this study was to evaluate a fixed olmesartan/amlodipine combination on blood pressure control, lipid profile, insulin sensitivity, and some inflammatory markers compared with single-drug monotherapy. A total of 276 hypertensive patients were randomly assigned to olmesartan 20 mg, amlodipine 10 mg, or a single pill containing olmesartan/amlodipine combination 20/5 mg for 12 months. We evaluated the following at baseline and after 6 and 12 months: body weight, body mass index, systolic (SBP) and diastolic blood pressures (DBP), fasting plasma glucose (FPG), fasting plasma insulin (FPI), lipid profile, tumor necrosis factor-alpha (TNF-alpha), retinol binding protein-4 (RBP-4), and interleukins 6 and 7 (IL-6 and IL-7). At baseline, and after 6 and 12 months, patients underwent an euglycemic, hyperinsulinemic clamp. The olmesartan/amlodipine combination provided a greater decrease of SBP and DPB compared with amlodipine and olmesartan monotherapies. The olmesartan/amlodipine combination decreased FPG after 12 months compared with amlodipine monotherapy. The combination decreased FPI and homeostasis model assessment index and increased M value both compared with baseline and with olmesartan and amlodipine monotherapies. Olmesartan/amlodipine decreased IL-7, but not IL-6, compared with single drug components. The olmesartan/amlodipine combination is effective and safe in reducing blood pressure and has some additive effects not shown by single drugs, such as an improvement of IL-7. J Am Soc Hypertens 2013;7(1):32-39. (C) 2013 American Society of Hypertension. All rights reserved.
C1 [Derosa, Giuseppe; Fogari, Elena; D'Angelo, Angela; Maffioli, Pamela] Univ Pavia, Dept Internal Med & Therapeut, I-27100 Pavia, Italy.
   [Cicero, Arrigo F. G.] Univ Bologna, G Descovich Atherosclerosis Study Ctr, Bologna, Italy.
   [Carbone, Anna] Hosp Ctr Diabet, Lodi, Italy.
   [Querci, Fabrizio] Osped Pesenti Fenaroli, Bergamo, Italy.
RP Derosa, G (reprint author), Univ Pavia, Dept Internal Med & Therapeut, Fdn IRCCS Policlin S Matteo, Ple C Golgi 2, I-27100 Pavia, Italy.
EM giuseppe.derosa@unipv.it
RI Derosa, Giuseppe/F-2615-2012
OI Derosa, Giuseppe/0000-0003-3573-4760; Cicero,
   Arrigo/0000-0002-4367-3884; D'Angelo, Angela/0000-0003-3008-9264;
   Fogari, Elena/0000-0002-9446-7546
CR Aguilar M, 1999, DIABETIC MED, V16, P716
   Cho YM, 2006, DIABETES CARE, V29, P2457, DOI 10.2337/dc06-0360
   DEFRONZO RA, 1979, AM J PHYSIOL, V237, pE214
   Derosa G, 2007, J CLIN PHARM THER, V32, P261, DOI 10.1111/j.1365-2710.2007.00820.x
   Derosa G, 2006, HYPERTENS RES, V29, P849, DOI 10.1291/hypres.29.849
   Derosa G, 2010, HYPERTENS RES, V33, P790, DOI 10.1038/hr.2010.85
   FERRANNINI E, 1987, NEW ENGL J MED, V317, P350, DOI 10.1056/NEJM198708063170605
   Fogari R, 2002, AM J HYPERTENS, V15, P1042, DOI 10.1016/S0895-7061(02)03017-0
   Fogari R, 2009, HORM METAB RES, V41, P893, DOI 10.1055/s-0029-1237359
   Fogari R, 2008, INTERNAL MED, V47, P361, DOI 10.2169/internalmedicine.47.0449
   Fogari R, 2007, AM J HYPERTENS, V20, P417, DOI 10.1016/j.amjhyper.2006.10.002
   Fogari R, 2012, CLIN CARDIOL, V35, P359, DOI 10.1002/clc.21994
   FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499
   Fry TJ, 2002, BLOOD, V99, P3892, DOI 10.1182/blood.V99.11.3892
   HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182
   HEDING LG, 1972, DIABETOLOGIA, V8, P260, DOI 10.1007/BF01225569
   Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20020407
   Hotamisligil GS, 1999, J INTERN MED, V245, P621, DOI 10.1046/j.1365-2796.1999.00490.x
   HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183
   Khan SS, 2004, CYTOM PART B-CLIN CY, V61B, P35, DOI 10.1002/cyto.b.20021
   KLOSE S, 1978, J CLIN CHEM CLIN BIO, V15, P121
   Lichtenstein AH, 2006, ARTERIOSCL THROM VAS, V26, P2186, DOI 10.1161/01.ATV.0000238352.25222.5e
   Lloyd-Jones D, 2009, CIRCULATION, V119, P480, DOI [10.1161/CIRCULATIONAHA.108.191261, 10.1161/CIRCULATIONAHA.108.191259]
   Mancia G, 2009, J HYPERTENS, V27, P2121, DOI 10.1097/HJH.0b013e328333146d
   Martinez-Martin FJ, 2011, J HUM HYPERTENS, V25, P346, DOI 10.1038/jhh.2010.104
   MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883
   Ong KL, 2007, HYPERTENSION, V49, P69, DOI 10.1161/01.HYP.0000252676.46043.18
   Pimenta E, 2008, VASC HEALTH RISK MAN, V4, P653
   Punzi Henry, 2012, Ther Adv Cardiovasc Dis, V6, P149
   Shimoda S, 2012, INTERNAL MED, V51, P2091, DOI 10.2169/internalmedicine.51.7408
   Sjoholm A, 2006, DIABETES-METAB RES, V22, P4, DOI 10.1002/dmrr.568
   Song MC, 2005, CRIT CARE MED, V33, pS463, DOI 10.1097/01.CCM.0000186784.62662.AI
   Takebayashi K, 2007, J CLIN ENDOCR METAB, V92, P2712, DOI 10.1210/jc.2006-1249
   Uysal KT, 1997, NATURE, V389, P610, DOI 10.1038/39335
   WAHLEFELD AW, 1974, METHOD ENZYMAT AN, P18
   Winer B. J., 1971, STAT PRINCIPLES EXPT
   Zhang M, 1988, CYTOKINE HDB
NR 37
TC 9
Z9 12
U1 2
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1933-1711
EI 1878-7436
J9 J AM SOC HYPERTENS
JI J. Am. Soc. Hypertens.
PD JAN-FEB
PY 2013
VL 7
IS 1
BP 32
EP 39
DI 10.1016/j.jash.2012.11.006
PG 8
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 085LT
UT WOS:000314617000005
PM 23321403
DA 2018-12-27
ER

PT J
AU Verma, A
   Giridhar, R
   Kanhed, A
   Sinha, A
   Modh, P
   Yadav, MR
AF Verma, Amit
   Giridhar, Rajani
   Kanhed, Ashish
   Sinha, Anshuman
   Modh, Pratik
   Yadav, Mange R.
TI RETRACTED: Novel 2-Aminobenzamides as Potential Orally Active
   Antithrombotic Agents (Retracted article. See vol. 6, pg. 226, 2015)
SO ACS MEDICINAL CHEMISTRY LETTERS
LA English
DT Article; Retracted Publication
DE 2-aminobenzamide; antithrombotic agents; ionic liquid; thromboembolic
   disorders; antiplatelet
ID FACTOR XA INHIBITORS; ATRIAL-FIBRILLATION; FACTOR-V; PROTHROMBIN;
   ACTIVATION; ASSAY
AB In an effort to develop potent antithrombotic agents, a series of novel 2-aminobenzamide derivatives were synthesized and screened for their in vivo antithrombotic activity. Among the 23 compounds tested, compound (8g) showed the most promising antithrombotic activity, which was comparable with clinically used aspirin or warfarin, but at variance with these standard drugs, 8g did not exhibit the increased bleeding time, suggesting its potential as a novel antithrombotic agent.
C1 [Verma, Amit; Giridhar, Rajani; Kanhed, Ashish; Sinha, Anshuman; Modh, Pratik; Yadav, Mange R.] Maharaja Sayajirao Univ Baroda, Fac Engn & Technol, Dept Pharm, Vadodara 390001, Gujarat, India.
RP Yadav, MR (reprint author), Maharaja Sayajirao Univ Baroda, Fac Engn & Technol, Dept Pharm, Vadodara 390001, Gujarat, India.
EM mryadav11@yahoo.co.in
FU AICTE, New Delhi
FX A.V. thanks AICTE, New Delhi, for NDF-fellowship.
CR [Anonymous], 2009, GLID VERS 5 5
   Beight D. W., 2002, U.S. Patent, Patent No. [6417200B1, 6417200]
   Chaireti R, 2009, THROMB RES, V124, P178, DOI 10.1016/j.thromres.2008.12.033
   DEJANA E, 1979, THROMB RES, V15, P191, DOI 10.1016/0049-3848(79)90064-1
   Diao XQ, 2011, ORG LETT, V13, P6422, DOI 10.1021/ol202721h
   DIMINNO G, 1983, J PHARMACOL EXP THER, V225, P57
   Essler M, 2000, ANN NY ACAD SCI, V905, P282
   Hirayama F, 2011, J MED CHEM, V54, P8051, DOI 10.1021/jm200868m
   Hsieh PW, 2007, BIOORG MED CHEM LETT, V17, P1812, DOI 10.1016/j.bmcl.2006.12.038
   Kochanny MJ, 2007, BIOORGAN MED CHEM, V15, P2127, DOI 10.1016/j.bmc.2006.12.019
   Koshio H, 2005, BIOORGAN MED CHEM, V13, P1305, DOI 10.1016/j.bmc.2004.11.005
   Mann KG, 2003, ARTERIOSCL THROM VAS, V23, P17, DOI 10.1161/01.ATV.0000046238.23903.FC
   Nazare M, 2012, ANGEW CHEM INT EDIT, V51, P905, DOI 10.1002/anie.201107091
   Piccini JP, 2010, CURR OPIN CARDIOL, V25, P312, DOI 10.1097/HCO.0b013e32833a524f
   ROSENBERG JS, 1975, J BIOL CHEM, V250, P1607
   Sobieraj-Teague M, 2009, SEMIN THROMB HEMOST, V35, P515, DOI 10.1055/s-0029-1234147
   Verma A, 2012, TETRAHEDRON LETT, V53, P2954, DOI 10.1016/j.tetlet.2012.03.060
   Zhang PL, 2009, BIOORG MED CHEM LETT, V19, P2186, DOI 10.1016/j.bmcl.2009.02.114
NR 18
TC 3
Z9 3
U1 4
U2 15
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1948-5875
J9 ACS MED CHEM LETT
JI ACS Med. Chem. Lett.
PD JAN
PY 2013
VL 4
IS 1
BP 32
EP 36
DI 10.1021/ml300217f
PG 5
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 068ZH
UT WOS:000313404200014
PM 24900559
OA Green Published
DA 2018-12-27
ER

PT J
AU Saleh, AI
AF Saleh, Ahmed I.
TI RETRACTED: New probabilistic models for managing user's locations in PCS
   networks (Retracted article. See vol. 97, pg. 981, 2015)
SO COMPUTING
LA English
DT Article; Retracted Publication
DE PCS networks; Mobility management; Paging
ID PERSONAL COMMUNICATION-SYSTEMS; MOBILITY MANAGEMENT; UPDATE; SCHEME
AB Personal communication service (PCS) networks enable mobile terminals (MTs) to communicate regardless of their locations. However, in order to guarantee an efficient service delivery, MTs' real time locations should be perfectly managed. Location management (LM) includes two fundamental processes; registration and paging. The former is concerned with the reporting of the current locations of the MTs, while the latter is used to locate a MT. Both processes incur signaling cost across the wireless channel. The more the location updates, the less the paging signaling cost, thus there is a tradeoff in terms of signaling cost. Due to the scarcity of PCS wireless bandwidth, it is important to reduce that signaling cost. As The blanket paging in current mobile networks wastes a lot of wireless bandwidth, we focus on the subject of paging and try to reduce the paging signaling cost under a predefined delay bound. Our contribution can be summarized as: (i) establishing a family of probability based paging strategies; (ii) introducing a novel topology for PCS registration area, which is called the hot spot topology (HST); (iii) based on HST, a novel LM strategy, which is called "Flower Based Strategy" had been introduced. Experimental results had shown that that the proposed paging strategies substantially lower the signaling cost of paging compared to the blanket one with a negligible increase in paging delay.
C1 Mansoura Univ, Dept Comp Engn & Syst, Fac Engn, Mansoura, Egypt.
RP Saleh, AI (reprint author), Mansoura Univ, Dept Comp Engn & Syst, Fac Engn, Mansoura, Egypt.
EM aisaleh@yahoo.com
CR Abutaleb A, 1997, WIREL NETW, V3, P205, DOI 10.1023/A:1019157217684
   Akyildiz IF, 1999, P IEEE, V87, P1347, DOI 10.1109/5.775420
   Akyildiz IF, 1996, IEEE ACM T NETWORK, V4, P629, DOI 10.1109/90.532871
   Aljadhai A, 2001, IEEE J SEL AREA COMM, V19, P1915, DOI 10.1109/49.957307
   Bar-Noy A, 2007, P IEEE INF
   Bar-Noy A, 1995, WIREL NETW, V1, P175, DOI 10.1007/BF01202540
   BARNOY A, 1993, IEEE INFOCOM SER, P1232, DOI 10.1109/INFCOM.1993.253385
   Beheshti B. D., 2007, IEEE SYST APPL TECHN, P1
   Bejerano Y, 2006, IEEE ACM T NETWORK, V14, P438, DOI 10.1109/TNET.2006.872555
   Bhadauria VS, 2009, 2009 IEEE INTERNATIONAL ADVANCE COMPUTING CONFERENCE, VOLS 1-3, P878, DOI 10.1109/IADCC.2009.4809131
   Biswash S, 2009, P NAT SEM REC ADV IN, P30
   Biswash SK, 2009, P ICM2CS JNU NEW DEL, P276
   Bo-Kyung Lee, 1999, Gateway to 21st Century Communications Village. VTC 1999-Fall. IEEE VTS 50th Vehicular Technology Conference (Cat. No.99CH36324), P2158, DOI 10.1109/VETECF.1999.797320
   Brown TX, 1997, IEEE T VEH TECHNOL, V46, P269, DOI 10.1109/25.580765
   Casares-Giner V, 2009, PROCEEDINGS OF THE 2009 SIXTH INTERNATIONAL CONFERENCE ON INFORMATION TECHNOLOGY: NEW GENERATIONS, VOLS 1-3, P1171, DOI 10.1109/ITNG.2009.273
   Hwang HW, 2000, IEEE COMMUN LETT, V4, P149, DOI 10.1109/4234.846494
   Kim K, 2009, INT J WIRELESS PERSO, V53, P179
   Kim S. S., 2010, ICIC EXPRESS LETT B, V1, P39, DOI DOI 10.1145/1900354.1900397
   Kondepu K, 2008, IEEE VTS VEH TECHNOL, P2182, DOI 10.1109/VETECS.2008.487
   Kondepu K, 2009, 2009 FIRST INTERNATIONAL CONFERENCE ON COMMUNICATION SYSTEMS AND NETWORKS (COMSNETS 2009), P570
   Kumar C, 2008, P NAT SEM FRONT EL C, P109
   Markande S, 2009, INT J ELECT ENG RES, V1, P63
   Prajapati N, 2010, INT J APPL GRAPH THE, V2, P1
   Pratim B, 2009, ADV WIRELESS MOBILE, V2, P39
   Rajagopal S, 2002, 10TH IEEE INTERNATIONAL CONFERENCE ON NETWORKS (ICON 2002), PROCEEDINGS, P229, DOI 10.1109/ICON.2002.1033316
   Rose C, 1995, WIREL NETW, V1, P211, DOI 10.1007/BF01202543
   Saleh Ahmed I., 2010, International Journal of Mobile Network Design and Innovation, V3, P169, DOI 10.1504/IJMNDI.2010.038098
   Selvan C, 2010, INT J COMPUTER SCI I, V7, P37
   Singh JAP, 2010, 2010 INTERNATIONAL CONFERENCE ON SIGNAL ACQUISITION AND PROCESSING: ICSAP 2010, PROCEEDINGS, P238, DOI 10.1109/ICSAP.2010.57
   Singh J Amar Pratap, 2010, Proceedings of the Second International Conference on Communication Software and Networks (ICCSN 2010), P343, DOI 10.1109/ICCSN.2010.60
   Xiao Y, 2003, IEEE COMMUN LETT, V7, P358, DOI 10.1109/LCOMM.2003.813812
   XIE H, 1993, 1993 43RD IEEE VEHICULAR TECHNOLOGY CONFERENCE, P536, DOI 10.1109/VETEC.1993.507529
   Yan Z, 2009, J NETW COMPUT APPL, V32, P483, DOI 10.1016/j.jnca.2008.02.012
   Zhao C, 2010, COMPEL, V29, P468, DOI 10.1108/03321641011014922
NR 34
TC 4
Z9 4
U1 3
U2 7
PU SPRINGER WIEN
PI WIEN
PA SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA
SN 0010-485X
EI 1436-5057
J9 COMPUTING
JI Computing
PD JAN
PY 2013
VL 95
IS 1
BP 25
EP 66
DI 10.1007/s00607-012-0210-3
PG 42
WC Computer Science, Theory & Methods
SC Computer Science
GA 064KH
UT WOS:000313073300002
DA 2018-12-27
ER

PT J
AU Ray, S
   Talukdar, A
   Kundu, S
   Khanra, D
   Sonthalia, N
AF Ray, Sayantan
   Talukdar, Arunansu
   Kundu, Supratip
   Khanra, Dibbendhu
   Sonthalia, Nikhil
TI RETRACTED: Diagnosis and management of miliary tuberculosis: current
   state and future perspectives (Retracted article. See vol. 11, 1457,
   2015)
SO THERAPEUTICS AND CLINICAL RISK MANAGEMENT
LA English
DT Review; Retracted Publication
DE Mycobacterium tuberculosis; human immunodeficiency virus; diagnostic
   tests; biomarkers; antituberculosis drugs; vaccine
ID IMMUNODEFICIENCY-VIRUS-INFECTION; HIGH-RESOLUTION CT; ACTIVE
   ANTIRETROVIRAL THERAPY; RESPIRATORY-DISTRESS-SYNDROME;
   DRUG-SUSCEPTIBILITY ASSAY; MYCOBACTERIUM-TUBERCULOSIS; PLEURAL FLUID;
   EXTRAPULMONARY TUBERCULOSIS; CLINICAL-MANIFESTATIONS; PULMONARY
   TUBERCULOSIS
AB Tuberculosis (TB) remains one of the most important causes of death from an infectious disease, and it poses formidable challenges to global health at the public health, scientific, and political level. Miliary TB is a potentially fatal form of TB that results from massive lymphohematogenous dissemination of Mycobacterium tuberculosis bacilli. The epidemiology of miliary TB has been altered by the emergence of the human immunodeficiency virus (HIV) infection and widespread use of immunosuppressive drugs. Diagnosis of miliary TB is a challenge that can perplex even the most experienced clinicians. There are nonspecific clinical symptoms, and the chest radiographs do not always reveal classical miliary changes. Atypical presentations like cryptic miliary TB and acute respiratory distress syndrome often lead to delayed diagnosis. High-resolution computed tomography (HRCT) is relatively more sensitive and shows randomly distributed miliary nodules. In extrapulmonary locations, ultrasonography, CT, and magnetic resonance imaging are useful in discerning the extent of organ involvement by lesions of miliary TB. Recently, positron-emission tomographic CT has been investigated as a promising tool for evaluation of suspected TB. Fundus examination for choroid tubercles, histopathological examination of tissue biopsy specimens, and rapid culture methods for isolation of M. tuberculosis in sputum, body fluids, and other body tissues aid in confirming the diagnosis. Several novel diagnostic tests have recently become available for detecting active TB disease, screening for latent M. tuberculosis infection, and identifying drug-resistant strains of M. tuberculosis. However, progress toward a robust point-of-care test has been limited, and novel biomarker discovery remains challenging. A high index of clinical suspicion and early diagnosis and timely institution of antituberculosis treatment can be lifesaving. Response to first-line antituberculosis drugs is good, but drug-induced hepatotoxicity and drug-drug interactions in HIV/TB coinfected patients create significant problems during treatment. Data available from randomized controlled trials are insufficient to define the optimum regimen and duration of treatment in patients with drug-sensitive as well as drug-resistant miliary TB, including those with HIV/AIDS, and the role of adjunctive corticosteroid treatment has not been properly studied. Research is going on worldwide in an attempt to provide a more effective vaccine than bacille Calmette-Guerin. This review highlights the epidemiology and clinical manifestation of miliary TB, challenges, recent advances, needs, and opportunities related to TB diagnostics and treatment.
C1 [Ray, Sayantan; Talukdar, Arunansu; Kundu, Supratip; Khanra, Dibbendhu; Sonthalia, Nikhil] Med Coll & Hosp, Dept Med, Kolkata 700073, W Bengal, India.
RP Ray, S (reprint author), Med Coll & Hosp, Dept Med, 88 Coll St, Kolkata 700073, W Bengal, India.
EM sayantan.ray30@gmail.com
CR ADERELE WI, 1978, E AFR MED J, V55, P166
   AINSLIE GM, 1992, THORAX, V47, P513, DOI 10.1136/thx.47.7.513
   Al-Jahdali H, 2000, INT J TUBERC LUNG D, V4, P252
   [Anonymous], 2008, GLOB TUB CONTR SURV
   [Anonymous], 1975, LANCET, V1, P985
   ASADA Y, 1991, HUM PATHOL, V22, P92, DOI 10.1016/0046-8177(91)90068-Z
   Baker SK, 2004, TUBERCULOSIS, P427
   BIEHL JP, 1958, AM REV TUBERC PULM, V77, P605
   Blumberg Henry M, 2003, Am J Respir Crit Care Med, V167, P603
   Boehme CC, 2010, NEW ENGL J MED, V363, P1005, DOI 10.1056/NEJMoa0907847
   BRAIDY J, 1981, CAN MED ASSOC J, V124, P748
   BRAUN MM, 1993, JAMA-J AM MED ASSOC, V269, P2865, DOI 10.1001/jama.269.22.2865
   CAMPBELL IG, 1973, CAN MED ASSOC J, V108, P1517
   Cattamanchi A, 2011, JAIDS-J ACQ IMM DEF, V56, P230, DOI 10.1097/QAI.0b013e31820b07ab
   Centers for Disease Control and Prevention, 2011, REP TUB US 2010
   Collins HL, 2001, IMMUNOLOGY, V103, P1, DOI 10.1046/j.1365-2567.2001.01236.x
   COPE AP, 1990, J INFECTION, V21, P293, DOI 10.1016/0163-4453(90)94029-Y
   Crump JA, 1998, CLIN INFECT DIS, V26, P1008, DOI 10.1086/517636
   Cunha BA, 2009, HEART LUNG, V38, P77, DOI 10.1016/j.hrtlng.2008.03.002
   Daikos GL, 1998, CLIN INFECT DIS, V27, P205, DOI 10.1086/514608
   Das Manoja, 2004, Indian Journal of Pediatrics, V71, P553, DOI 10.1007/BF02724303
   del Giudice P, 2000, CLIN INFECT DIS, V30, P201, DOI 10.1086/313587
   Directorate General of Health Services, 2004, RNTCP PERF REP IND 4
   DIVINAGRACIA R, 1999, TUBERCULOSIS NONTUBE, P271
   Dooley DP, 1997, CLIN INFECT DIS, V25, P872, DOI 10.1086/515543
   FELSON B, 1977, JAMA-J AM MED ASSOC, V237, P1104, DOI 10.1001/jama.237.11.1104
   Garg RK, 2010, CLIN NEUROL NEUROSUR, V112, P188, DOI 10.1016/j.clineuro.2009.11.013
   GELB AF, 1973, AM REV RESPIR DIS, V108, P1327
   Ghanashyam Bharathi, 2011, Expert Rev Anti Infect Ther, V9, P381, DOI 10.1586/eri.11.18
   Goldsack NR, 2003, SEX TRANSM INFECT, V79, P337, DOI 10.1136/sti.79.4.337
   Goo JM, 2000, RADIOLOGY, V216, P117, DOI 10.1148/radiology.216.1.r00jl19117
   GRIECO MH, 1974, AM REV RESPIR DIS, V109, P554
   Gurkan F, 1998, SCAND J INFECT DIS, V30, P359
   Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD
   HAAS DW, 1994, AM J MED, V96, P439, DOI 10.1016/0002-9343(94)90171-6
   HARRIES AD, 2004, TB HIV CLIN MANUAL
   Helb D, 2010, J CLIN MICROBIOL, V48, P229, DOI 10.1128/JCM.01463-09
   Hnizdo E, 2000, THORAX, V55, P32, DOI 10.1136/thorax.55.1.32
   Hopewell PC, 2006, LANCET INFECT DIS, V6, P710, DOI 10.1016/S1473-3099(06)70628-4
   Hussain SF, 2004, INT J TUBERC LUNG D, V8, P493
   HUSSEY G, 1991, PEDIATR INFECT DIS J, V10, P832, DOI 10.1097/00006454-199111000-00008
   Ichiya Y, 1996, Ann Nucl Med, V10, P185
   JACQUES J, 1970, THORAX, V25, P237, DOI 10.1136/thx.25.2.237
   JAMIESON DH, 1993, PEDIATR RADIOL, V23, P380, DOI 10.1007/BF02011965
   Jehle AW, 2004, CLIN INFECT DIS, V38, pE32, DOI 10.1086/381441
   JONES BE, 1993, AM REV RESPIR DIS, V148, P1292, DOI 10.1164/ajrccm/148.5.1292
   Kanduma E, 2003, J APPL MICROBIOL, V94, P781, DOI 10.1046/j.1365-2672.2003.01918.x
   Kaufmann SHE, 2010, LANCET, V375, P2110, DOI 10.1016/S0140-6736(10)60393-5
   Kim DK, 2008, EUR RESPIR J, V32, P1031, DOI 10.1183/09031936.00174907
   Kim JY, 2010, BRIT J RADIOL, V83, P206, DOI 10.1259/bjr/95169618
   KIM JH, 1990, REV INFECT DIS, V12, P583
   KIM P K, 1969, Yonsei Medical Journal, V10, P146
   Kuijl C, 2007, NATURE, V450, P725, DOI 10.1038/nature06345
   Kuo PH, 2001, CHEST, V119, P1961, DOI 10.1378/chest.119.6.1961
   Kwong JS, 1996, CHEST, V110, P339, DOI 10.1378/chest.110.2.339
   Lado FLL, 1999, SCAND J INFECT DIS, V31, P387
   Lange C, 2010, RESPIROLOGY, V15, P220, DOI 10.1111/j.1440-1843.2009.01692.x
   Lawn SD, 2012, LANCET INFECT DIS, V12, P201, DOI 10.1016/S1473-3099(11)70251-1
   Lee M P, 2000, Respirology, V5, P423, DOI 10.1046/j.1440-1843.2000.00287.x
   Leyten EMS, 2006, MICROBES INFECT, V8, P2052, DOI 10.1016/j.micinf.2006.03.018
   Loebinger MR, 2007, CHEST, V132, P279, DOI 10.1378/chest.06-2751
   Long R, 1997, INT J TUBERC LUNG D, V1, P52
   MAARTENS G, 1990, AM J MED, V89, P291, DOI 10.1016/0002-9343(90)90340-J
   MALLINSON WJW, 1981, Q J MED, V50, P137
   MASSARO D, 1964, ANN INTERN MED, V60, P231, DOI 10.7326/0003-4819-60-2-231
   Matsushima T, 2005, INTERNAL MED, V44, P687, DOI 10.2169/internalmedicine.44.687
   MCGUINNESS G, 1992, J COMPUT ASSIST TOMO, V16, P384, DOI 10.1097/00004728-199205000-00009
   MEREDITH SK, 1992, THORAX, V47, P770
   Mert A, 2001, Respirology, V6, P217, DOI 10.1046/j.1440-1843.2001.00328.x
   Minion J, 2011, EUR RESPIR J, V38, P1398, DOI 10.1183/09031936.00025711
   Miyoshi I, 2005, INTERNAL MED, V44, P622, DOI 10.2169/internalmedicine.44.622
   Mohan A, 1996, Indian J Chest Dis Allied Sci, V38, P157
   Moore DAJ, 2004, J CLIN MICROBIOL, V42, P4432, DOI 10.1128/JCM.42.10.4432-4437.2004
   Moore DAJ, 2006, NEW ENGL J MED, V355, P1539, DOI 10.1056/NEJMoa055524
   Mori T, 2009, J INFECT CHEMOTHER, V15, P143, DOI 10.1007/s10156-009-0686-8
   MUNT PW, 1972, MEDICINE, V51, P139, DOI 10.1097/00005792-197203000-00004
   Murray CJL, 1997, LANCET, V349, P1436, DOI 10.1016/S0140-6736(96)07495-8
   Murray RA, 2006, J IMMUNOL, V177, P5647, DOI 10.4049/jimmunol.177.8.5647
   Mwaba P, 2011, TROP MED INT HEALTH, V16, P819, DOI 10.1111/j.1365-3156.2011.02777.x
   *NAT AIDS CONTR OR, 2008, HIV SENT SURV HIV ES
   [National Institute for Health and Clinical Excellence National Collaborating Centre for Chronic Conditions], 2006, TUB CLIN DIAGN MAN T, P63
   NIEUWLAND Y, 1992, POSTGRAD MED J, V68, P677, DOI 10.1136/pgmj.68.802.677
   Ohi M, 1990, Kekkaku, V65, P847
   ONADEKO BO, 1975, E AFR MED J, V52, P390
   ORMEROD LP, 1997, CLIN TUBERCULOSIS, P76
   Parida SK, 2010, CURR OPIN IMMUNOL, V22, P374, DOI 10.1016/j.coi.2010.04.006
   Pasipanodya JG, 2007, CHEST, V131, P1817, DOI 10.1378/chest.06-2949
   PENNER C, 1995, AM J RESP CRIT CARE, V151, P867
   PETER G, 1992, PEDIATRICS, V89, P161
   Pipavath SNJ, 2007, INDIAN J MED RES, V126, P193
   Pozniak AL, 2011, HIV MED, V12, P517, DOI 10.1111/j.1468-1293.2011.00954.x
   PRABHAKARAN D, 1990, American Review of Respiratory Disease, V141, pA51
   Price M, 1968, Tubercle, V49, P377, DOI 10.1016/S0041-3879(68)80018-2
   PROUDFOOT AT, 1969, BMJ-BRIT MED J, V2, P273, DOI 10.1136/bmj.2.5652.273
   PROUT S, 1980, S AFR MED J, V58, P835
   Rahajoe N N, 1990, Paediatr Indones, V30, P233
   Rana SV, 2010, CLIN NEUROL NEUROSUR, V112, P424, DOI 10.1016/j.clineuro.2010.02.012
   Rodrigues C, 2009, INDIAN J MED MICROBI, V27, P217, DOI 10.4103/0255-0857.53203
   RODRIGUES LC, 1993, INT J EPIDEMIOL, V22, P1154, DOI 10.1093/ije/22.6.1154
   Rook GAW, 2004, TRENDS IMMUNOL, V25, P483, DOI 10.1016/j.it.2004.06.005
   ROSE AG, 1987, ARCH PATHOL LAB MED, V111, P422
   ROSENBERG MJ, 1978, CHEST, V73, P536, DOI 10.1378/chest.73.4.536
   Runo JR, 2003, RESPIRATION, V70, P529, DOI 10.1159/000074213
   SAHN SA, 1974, AM J MED, V56, P495, DOI 10.1016/0002-9343(74)90482-3
   SHAFER RW, 1991, MEDICINE, V70, P384, DOI 10.1097/00005792-199111000-00004
   Shao CZ, 2003, CHINESE MED J-PEKING, V116, P1717
   Sharma Niraj, 2002, Indian J Chest Dis Allied Sci, V44, P125
   Sharma PK, 2009, AM J RESP CRIT CARE, V179, P1061, DOI 10.1164/rccm.200804-529OC
   Sharma SK, 2007, INDIAN J MED RES, V125, P182
   Sharma SK, 2006, INDIAN J MED RES, V124, P411
   Sharma S K, 2001, Indian J Chest Dis Allied Sci, V43, P149
   Sharma SK, 2005, INDIAN J MED RES, V121, P550
   Sharma SK, 2005, J CLIN LAB ANAL, V19, P40, DOI 10.1002/jcla.20054
   SHARMA SK, 1988, TUBERCLE, V69, P175, DOI 10.1016/0041-3879(88)90018-9
   Sharma SK, 2004, INDIAN J MED RES, V120, P316
   Sharma SK, 2004, J INTERF CYTOK RES, V24, P213, DOI 10.1089/107999004323034088
   SHARMA SK, 1992, AM REV RESPIR DIS, V145, P1167, DOI 10.1164/ajrccm/145.5.1167
   Sharma SK, 2002, J CLIN IMMUNOL, V22, P345, DOI 10.1023/A:1020604331886
   SHARMA SK, 1995, QJM-MON J ASSOC PHYS, V88, P29
   SHARMA SK, 2004, INDIAN J TUBERC, V51, P5
   Sharma SK, 2009, TUBERCULOSIS, P493
   Sharma SK, 2011, TUBERCULOSIS AND NONTUBERCULOUS MYCOBACTERIAL INFECTIONS, 6TH EDITION, P415
   Shikama ML, 2009, INT J TUBERC LUNG D, V13, P377
   SHRIBMAN JH, 1983, BRIT MED J, V287, P1593, DOI 10.1136/bmj.287.6405.1593-a
   Singh K J, 2001, J Assoc Physicians India, V49, P790
   SLAVIN RE, 1980, MEDICINE, V59, P352, DOI 10.1097/00005792-198009000-00003
   Steiner PE, 1937, AM REV TUBERC, V36, P692
   SUN TN, 1981, CHINESE MED J-PEKING, V94, P309
   SYDOW M, 1992, RESP MED, V86, P517, DOI 10.1016/S0954-6111(96)80014-X
   Teklu B, 1977, Ethiop Med J, V15, P39
   THEUER CP, 1990, J INFECT DIS, V162, P8, DOI 10.1093/infdis/162.1.8
   Thwaites GE, 2004, NEW ENGL J MED, V351, P1741, DOI 10.1056/NEJMoa040573
   Van Dyck P, 2003, EUR RADIOL, V13, P1771, DOI 10.1007/s00330-002-1612-y
   WAINWRIGHT J, 1979, S AFR MED J, V56, P731
   WALLIS PJW, 1984, THORAX, V39, P155, DOI 10.1136/thx.39.2.155
   Wares F, 2005, TUBERCULOSIS CONTROL, P95
   Weyer K, 2011, J INFECT DIS, V204, pS1196, DOI 10.1093/infdis/jir452
   WHO, 2009, TREATM TUB GUID
   WHO, 2009, RAP ADV ANT THER HIV
   WILLCOX PA, 1986, THORAX, V41, P681, DOI 10.1136/thx.41.9.681
   WILLCOX PA, 1989, RESP MED, V83, P195, DOI 10.1016/S0954-6111(89)80031-9
   WILLIAMS MH, 1973, AM REV RESPIR DIS, V107, P858
   World Health Organization, 2010, US INT GAMM REL ASS
   World Health Organization, 2011, WHO REP GLOB TUB CON
   World Health Organization, 2003, TREATM TUB GUID NAT
   Yu RS, 2004, WORLD J GASTROENTERO, V10, P1639, DOI 10.3748/wjg.v10.i11.1639
   YU YL, 1986, Q J MED, V59, P421
NR 147
TC 19
Z9 21
U1 2
U2 49
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-203X
J9 THER CLIN RISK MANAG
JI Therap. Clin. Risk Manag.
PY 2013
VL 9
BP 9
EP 26
DI 10.2147/TCRM.S29179
PG 18
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA 066QS
UT WOS:000313235900001
PM 23326198
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Caduco, M
   Comin, A
   Toffoletto, M
   Munegato, D
   Sartori, E
   Celestino, M
   Salata, C
   Parolin, C
   Palu, G
   Calistri, A
AF Caduco, Martina
   Comin, Alessandra
   Toffoletto, Marta
   Munegato, Denis
   Sartori, Elena
   Celestino, Michele
   Salata, Cristiano
   Parolin, Cristina
   Palu, Giorgio
   Calistri, Arianna
TI RETRACTED: Tsg101 Interacts with Herpes Simplex Virus 1 VP1/2 and Is a
   Substrate of VP1/2 Ubiquitin-Specific Protease Domain Activity
   (Retracted article. See vol. 87, pg. 6537, 2013)
SO JOURNAL OF VIROLOGY
LA English
DT Article; Retracted Publication
ID TEGUMENT PROTEIN; MULTIVESICULAR BODIES; UL36 GENE; TYPE-1; EXPRESSION;
   CYSTEINE; EGRESS; LIGASE; VP1-2
AB Ubiquitination/deubiquitination of key factors represent crucial steps in the biogenesis of multivesicular body (MVB) and sorting of transmembrane proteins. We and others previously demonstrated that MVB is involved in herpes simplex virus 1 (HSV-1) envelopment and budding. Here, we report that the HSV-1 large tegument protein, VP1/2, interacts with and regulates the ubiquitination of Tsg101, a cellular protein essential in MVB formation, thus identifying the first cellular substrate of a herpes-viral deubiquitinating enzyme.
C1 [Caduco, Martina; Comin, Alessandra; Toffoletto, Marta; Munegato, Denis; Sartori, Elena; Celestino, Michele; Salata, Cristiano; Palu, Giorgio; Calistri, Arianna] Univ Padua, Dept Mol Med, Padua, Italy.
   [Parolin, Cristina] Univ Padua, Dept Biol, Padua, Italy.
RP Palu, G (reprint author), Univ Padua, Dept Mol Med, Padua, Italy.
EM giorgio.palu@unipd.it; arianna.calistri@unipd.it
FU MIUR-PRIN [20072J9RWM_004, 2007M52HTT_004]; University of Padova;
   Regione Veneto
FX This work was supported by the MIUR-PRIN-2007 (grant no. 20072J9RWM_004
   and 2007M52HTT_004) to C.P. and G.P., respectively, grants from the
   University of Padova (Ex-60%) to C.P., G.P., and A.C., and a grant from
   Regione Veneto to G.P.
CR Abaitua F, 2009, J GEN VIROL, V90, P2353, DOI 10.1099/vir.0.012492-0
   Amit I, 2004, GENE DEV, V18, P1737, DOI 10.1101/gad.294904
   Boettcher S, 2008, J VIROL, V82, P6009, DOI 10.1128/JVI.00280-08
   Bolstad M, 2011, J VIROL, V85, P8738, DOI 10.1128/JVI.00798-11
   Calistri A, 2009, REV MED VIROL, V19, P31, DOI 10.1002/rmv.588
   Calistri A, 2007, J VIROL, V81, P11468, DOI 10.1128/JVI.01364-07
   Crump CA, 2007, J VIROL, V81, P7380, DOI 10.1128/JVI.00222-07
   Desai PJ, 2000, J VIROL, V74, P11608, DOI 10.1128/JVI.74.24.11608-11618.2000
   Fuchs W, 2004, J VIROL, V78, P11879, DOI 10.1128/JVI.78.21.11879-11889.2004
   Jarosinski K, 2007, P NATL ACAD SCI USA, V104, P20025, DOI 10.1073/pnas.0706295104
   Kattenhorn LM, 2005, MOL CELL, V19, P547, DOI 10.1016/j.molcel.2005.07.003
   KNIPE DM, 1981, J VIROL, V38, P539
   Lee JI, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000387
   Lee JIH, 2006, J VIROL, V80, P12086, DOI 10.1128/JVI.01184-06
   Luxton GWG, 2006, J VIROL, V80, P201, DOI 10.1128/JVI.80.1.201-209.2006
   McDonald B, 2008, MOL BIOL CELL, V19, P754, DOI 10.1091/mbc.E07-09-0957
   MCGEOCH DJ, 1988, J GEN VIROL, V69, P1531, DOI 10.1099/0022-1317-69-7-1531
   Pawliczek T, 2009, J VIROL, V83, P11254, DOI 10.1128/JVI.00574-09
   Polo S, 2002, NATURE, V416, P451, DOI 10.1038/416451a
   Shields SB, 2011, TRAFFIC, V12, P1306, DOI 10.1111/j.1600-0854.2011.01242.x
   Strack B, 2003, CELL, V114, P689, DOI 10.1016/S0092-8674(03)00653-6
   Wang JL, 2006, J VIROL, V80, P6003, DOI 10.1128/JVI.00401-06
NR 22
TC 4
Z9 4
U1 2
U2 12
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD JAN
PY 2013
VL 87
IS 1
BP 692
EP 696
DI 10.1128/JVI.01969-12
PG 5
WC Virology
SC Virology
GA 055ZB
UT WOS:000312455500063
PM 23077308
OA Bronze, Green Published
DA 2018-12-27
ER

PT J
AU Senthilkumara, K
   Kalaivani, T
   Kanagesan, S
   Balasubramanian, V
AF Senthilkumara, K.
   Kalaivani, T.
   Kanagesan, S.
   Balasubramanian, V.
TI RETRACTED: Low temperature method for synthesis of ZnS quantum dots and
   its luminescence characterization studies (Retracted article. See vol.
   443, pg. 657, 2018)
SO APPLIED SURFACE SCIENCE
LA English
DT Article; Retracted Publication
DE ZnS quantum dots; Blue shift; Semiconductors; HRTEM
ID THIN-FILMS; OPTICAL-PROPERTIES; NANOPARTICLES; SIZE; NANOCRYSTALS;
   ABSORPTION; GROWTH; SURFACE; STATES
AB Zinc Sulfide (ZnS) quantum dots of sizes 2.68-4.8 nm, embedded on polyvinyl alcohol (PVA) matrix, have been synthesized at 70 degrees C by wet chemical method. X-ray diffraction (XRD), high resolution transmission electron microscopy (HRTEM), scanning electron microscopy (SEM), UV-vis spectroscopy and photoluminescence (PL) Spectroscopy has been adopted for sample characterization. Optical absorption spectra showed strong blue shift, which is an indication of strong quantum confinement. Photoluminescence spectra of the sample have been recorded at room temperature and observed two peaks centred around 415 nm and 440 nm. We have assigned the first peak due to band gap transitions while the later due to sulfur vacancy in the sample. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Senthilkumara, K.] AMET Univ, Dept Phys, Madras 603112, Tamil Nadu, India.
   [Senthilkumara, K.; Kalaivani, T.] SRM Univ, Dept Phys, Madras 603203, Tamil Nadu, India.
   [Balasubramanian, V.] AMET Univ, Dept Chem, Madras 603112, Tamil Nadu, India.
   [Kanagesan, S.] Univ Putra Malaysia, Inst Adv Technol, Mat Synth & Characterizat Lab MSCL, Serdang 43400, Selangor, Malaysia.
RP Senthilkumara, K (reprint author), AMET Univ, Dept Phys, Madras 603112, Tamil Nadu, India.
EM senovi2007@gmail.com
OI Samikannu, Dr. Kanagesan/0000-0001-5003-7088; Senthilkumar,
   Kittusamy/0000-0002-3420-8163
FU AMET University, Chennai; SRM University, Chennai
FX This work was supported by AMET University, Chennai and SRM University,
   Chennai. The authors thank Mr J. Balakrishnan and Mr M. Sivakumar,
   Department of Chemistry, AMET University, Chennai for their help in this
   work.
CR Barman J, 2009, INT J MOD PHYS B, V23, P545, DOI 10.1142/S0217979209049917
   BHARGAVA RN, 1994, PHYS REV LETT, V72, P416, DOI 10.1103/PhysRevLett.72.416
   BRUS L, 1991, APPL PHYS A-MATER, V53, P465, DOI 10.1007/BF00331535
   Chen W, 1997, J APPL PHYS, V82, P3111, DOI 10.1063/1.366152
   Denzler D, 1998, J APPL PHYS, V84, P2841, DOI 10.1063/1.368425
   Ghosh PK, 2007, MATER RES BULL, V42, P505, DOI 10.1016/j.materresbull.2006.06.019
   Joshi GP, 2003, INDIAN J PURE AP PHY, V41, P462
   Kalita PK, 2003, B MATER SCI, V26, P613, DOI 10.1007/BF02704325
   Kanemoto M, 1996, J CHEM SOC FARADAY T, V92, P2401, DOI 10.1039/ft9969202401
   Kar S, 2006, J PHYS CHEM B, V110, P4542, DOI 10.1021/jp056058n
   Klug H.P., 1954, XRAY DIFFRACTION PRO, V9, P512
   Kumbhojkar N, 2000, J APPL PHYS, V88, P6260, DOI 10.1063/1.1321027
   Lakshmi PVB, 2009, CRYST RES TECHNOL, V44, P153, DOI 10.1002/crat.200800271
   Liu S, 2009, NANOTECHNOLOGY, V20, DOI 10.1088/0957-4484/20/23/235603
   Mews A, 1996, PHYS REV B, V53, P13242, DOI 10.1103/PhysRevB.53.R13242
   Murase N, 1999, J PHYS CHEM B, V103, P754, DOI 10.1021/jp9828179
   Nanda J, 2001, J APPL PHYS, V90, P2504, DOI 10.1063/1.1389521
   Nanda KK, 1998, NANOSTRUCT MATER, V10, P1401, DOI 10.1016/S0965-9773(99)00014-8
   Nath S., 2008, INT J NANOTECHNOL, V2, P47
   Rasyogi C.K., 2009, ASIAN J CHEM, V21, pS039
   Ruda H.E., 1992, WIDE GAP 2 4 COMPOUN
   Sahraei R, 2008, MATER LETT, V62, P4345, DOI 10.1016/j.matlet.2008.07.022
   Vasa P, 2005, APPL PHYS LETT, V87, DOI 10.1063/1.2007871
   Wageh S, 2003, J CRYST GROWTH, V255, P332, DOI 10.1016/S0022-0248(03)01258-2
   YOFFE AD, 1993, ADV PHYS, V42, P173, DOI 10.1080/00018739300101484
   YUANG YS, 1994, J APPL PHYS, V76, P3041, DOI 10.1063/1.357483
   Zdyb A, 2008, MATER SCI-POLAND, V26, P389
   Zhu BL, 2004, CHINESE CHEM LETT, V15, P97
NR 28
TC 9
Z9 9
U1 2
U2 61
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0169-4332
EI 1873-5584
J9 APPL SURF SCI
JI Appl. Surf. Sci.
PD JAN 1
PY 2013
VL 264
BP 17
EP 20
DI 10.1016/j.apsusc.2012.09.026
PG 4
WC Chemistry, Physical; Materials Science, Coatings & Films; Physics,
   Applied; Physics, Condensed Matter
SC Chemistry; Materials Science; Physics
GA 049SX
UT WOS:000312004800004
DA 2018-12-27
ER

PT J
AU Senosy, MM
   Youssef, MM
   Zaher, MA
AF Senosy, M. M.
   Youssef, M. M.
   Zaher, M. Abdel
TI RETRACTED: Thickness variation of the sedimentary cover in the south
   Western Desert of Egypt as deduced from Bouguer gravity and drill-hole
   data (Retracted article. See vol. 80, pg. 80, 2013)
SO JOURNAL OF AFRICAN EARTH SCIENCES
LA English
DT Article; Retracted Publication
DE Bouguer gravity; Subsurface structures; Groundwater occurrences
ID INVERSION; DEPTH
AB Bouguer gravity anomaly mapped at a scale of 1:500,000 and the lithological logs of about 120 deep wells were used to determine the thickness of the sedimentary sequence containing the main sandstone water formation in important area of Egypt. The area is located in the southern part of the Western Desert bounded by the latitudes 22 degrees 00'-26 degrees 30' N, and longitudes 28 degrees 30'-33 degrees 00' E. The predominant structures affecting the basement rocks and the sedimentary cover were also studied. The gravity stripping approach was applied to eliminate the gravity effects caused by sedimentary sequence and to separate density anomalies within the sedimentary fill from the influence of rocks at deeper levels in the crystalline crust.
   The present study indicated that the surface of the basement rocks is highly rugged and mostly controlled by structures which have a direct effect on thickness variation of the sedimentary cover all over the area. Regionally the area is characterized by two major intracratonic basins (the Dahkla Basin and the Nile valley Basin) separated by a NE-SW trending swell of the Kharga uplift and bounded at the south by the Oweinat-Bir Safsaf-Aswan uplift. These major tectonic units are controlled by fault structures trending in N-S, E-W, NE-SW, NW-SE, which cut the basement rocks and extend upward in the sedimentary cover. The maximum thickness of sandstone formations is recorded at west Oweinat, west Kurkur, southwest of Aswan, Gramashin. Dakhla oasis and some localities west of Sohag and Qena towns. At these localities the thickness ranges between 600 and 900 m. As this formation is the main water aquifer in the study area, therefore these localities are characterized by the presence of big amount of groundwater. Accordingly, these areas must take the priority in the sustainable development programs of southern Egypt. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Senosy, M. M.; Youssef, M. M.] Assiut Univ, Fac Sci, Dept Geol, Assiut 71515, Egypt.
   [Zaher, M. Abdel] Natl Res Inst Astron & Geophys, Helwan, Egypt.
RP Senosy, MM (reprint author), Assiut Univ, Fac Sci, Dept Geol, Assiut 71515, Egypt.
EM mmsenosy@yahoo.com
CR Abdel Zaher M., 2008, P INT S EARTH SCI TE, P267
   Abu El-Ata A.S., 1985, GEOLOGICAL SURVEY EG, P124
   Abu El-Ata A.S., 1991, GEOLOGICAL SURVEY EG, P103
   Barakat M. G., 1966, EGYPT J GEOL, V10, P145
   BERNAU R, 1987, J AFR EARTH SCI, V6, P79, DOI 10.1016/0899-5362(87)90109-6
   Borsting Pedersen L., 1977, Geophysical Prospecting, V25, P199
   CHAI YF, 1988, GEOPHYSICS, V53, P837, DOI 10.1190/1.1442518
   Dobrin M. B., 1983, INTRO GEOPHYSICAL PR
   El Etr HA, 1982, RES CENT AIN SHAMS U, V2, P123
   El-Younsy A.R., 1991, B FAC SCI ASSIUT U, V20, P193
   GUSPI F, 1990, GEOEXPLORATION, V26, P253, DOI 10.1016/0016-7142(90)90007-F
   Hendriks F., 1984, BERL OWISSENSCHAFTLI, V50, P117
   Hermina M., 1990, GEOLOGY EGYPT
   Hinze W J., 1990, GEOTECHNICAL ENV GEO, VI, P75
   Kiltzsch E, 1984, BERL GEOWISS ABH A, V50, P23
   Kiltzsch E., 1987, BERLINER GEOWISS A A, V75, P97
   Li YG, 1998, GEOPHYSICS, V63, P109, DOI 10.1190/1.1444302
   Nettleton L.L., 1976, GRAVITY MAGNETICS OI
   Nettleton L. L., 1976, GRAVITY MAGNETIC OIL
   Oldenburg D. W, 1974, GEOPHYSICS, V39, P394
   Parasniss D.S., 1997, PRINCIPLES APPL GEOP, P429
   PATERSON NR, 1985, GEOPHYSICS, V50, P2558, DOI 10.1190/1.1441884
   REAMER SK, 1989, GEOPHYSICS, V54, P486, DOI 10.1190/1.1442675
   RIAD S, 1977, GEOPHYSICS, V42, P1207, DOI 10.1190/1.1440785
   Robaszynski F., 1984, Revue de Micropaleontologie, V26, P145
   Schandelmeier H, 1987, BERL GEOWISS ABH A, V75, P5
   Senosy M., 2003, EGYPT J GEOL, V47, P387
   Telford WM, 1990, APPL GEOPHYS
   Ward S.H., 1990, GEOTECHNICAL ENV GEO
   Wycisk P., 1993, CATENA S, V26, P67
NR 30
TC 0
Z9 0
U1 3
U2 11
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1464-343X
EI 1879-1956
J9 J AFR EARTH SCI
JI J. Afr. Earth Sci.
PD JAN
PY 2013
VL 77
BP 11
EP 21
DI 10.1016/j.jafrearsci.2012.09.007
PG 11
WC Geosciences, Multidisciplinary
SC Geology
GA 052BX
UT WOS:000312173800002
DA 2018-12-27
ER

PT J
AU Verma, M
   Shulga, N
   Pastorino, JG
AF Verma, Manish
   Shulga, Nataly
   Pastorino, John G.
TI RETRACTED: Sirtuin-4 modulates sensitivity to induction of the
   mitochondrial permeability transition pore (Retracted article. See vol.
   1857, pg. 1641, 2016)
SO BIOCHIMICA ET BIOPHYSICA ACTA-BIOENERGETICS
LA English
DT Article; Retracted Publication
DE Sirtuin-4; Mitochondria; Permeability transition pore; Oxidative stress
ID RAT-LIVER MITOCHONDRIA; NECROSIS-FACTOR-ALPHA; GLUTAMATE-DEHYDROGENASE;
   ADP-RIBOSYLATION; CYCLOPHILIN-D; CELL-DEATH; BRAIN MITOCHONDRIA; ENERGY
   HOMEOSTASIS; DIVALENT-CATIONS; MEMBRANE
AB The sustained opening of the mitochondrial permeability transition pore (PTP) is a decisive event in the onset of irreversible cell injury. The PIP is modulated by numerous exogenous and endogenous effectors, including mitochondrial membrane potential, ions and metabolites. Mitochondrial sirtuins have recently emerged as pivotal mediators of mitochondrial metabolism. In the present study, we demonstrate that sirt-4 modulates sensitivity to PTP onset induced by calcium and the oxidative cross linking reagent phenylarsine oxide, and PTP dependent cytotoxicity brought about by TNF or doxorubicin. Moreover, the ability of sirt-4 to modulate onset of the PTP is dependent on the expression of glutamate dehydrogenase-1. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Pastorino, John G.] Univ Med & Dent New Jersey, Sch Osteopath Med, Dept Mol Biol, Ctr Sci, Stratford, NJ 08084 USA.
RP Pastorino, JG (reprint author), Univ Med & Dent New Jersey, Sch Osteopath Med, Dept Mol Biol, Ctr Sci, Room 316, Stratford, NJ 08084 USA.
EM pastorjg@umdnj.edu
FU National Cancer Institute; National Institute of Alcohol Abuse and
   Alcoholism
FX This work was supported in part from grants from the National Cancer
   Institute and the National Institute of Alcohol Abuse and Alcoholism.
CR Ahn BH, 2008, P NATL ACAD SCI USA, V105, P14447, DOI 10.1073/pnas.0803790105
   Ahuja N, 2007, J BIOL CHEM, V282, DOI 10.1074/jbc.M705488200
   Baines CP, 2005, NATURE, V434, P658, DOI 10.1038/nature03434
   BERNARDI P, 1992, J BIOL CHEM, V267, P2934
   BERNARDI P, 1992, J BIOL CHEM, V267, P8834
   Bradham CA, 1998, MOL CELL BIOL, V18, P6353, DOI 10.1128/MCB.18.11.6353
   Cardoso S, 2008, FREE RADICAL BIO MED, V45, P1395, DOI 10.1016/j.freeradbiomed.2008.08.008
   Chevrollier A, 2005, J BIOENERG BIOMEMBR, V37, P307, DOI 10.1007/s10863-005-8642-5
   CHEVROLLIER A, 2010, BIOCHIM BIOPHYS ACTA, V1807, P562
   Choi MM, 2005, FEBS LETT, V579, P4125, DOI 10.1016/j.febslet.2005.06.041
   Di Lisa F, 2001, J BIOL CHEM, V276, P2571, DOI 10.1074/jbc.M006825200
   FREI B, 1988, BIOCHEMISTRY-US, V27, P529, DOI 10.1021/bi00402a004
   Fujimoto K, 2010, J CLIN INVEST, V120, P4031, DOI 10.1172/JCI44011
   Fujimoto K, 2010, P NATL ACAD SCI USA, V107, P10214, DOI 10.1073/pnas.0914209107
   Garcia-Ruiz C, 2002, J BIOL CHEM, V277, P36443, DOI 10.1074/jbc.M206021200
   Haigis MC, 2006, CELL, V126, P941, DOI 10.1016/j.cell.2006.06.057
   Halestrap AP, 1997, MOL CELL BIOCHEM, V174, P167, DOI 10.1023/A:1006879618176
   Herrero-Yraola A, 2001, EMBO J, V20, P2404, DOI 10.1093/emboj/20.10.2404
   Kapoor RR, 2009, EUR J ENDOCRINOL, V161, P731, DOI 10.1530/EJE-09-0615
   Karaca M, 2011, NEUROCHEM INT, V59, P510, DOI 10.1016/j.neuint.2011.03.024
   Korge P, 2001, AM J PHYSIOL-HEART C, V280, pH2203
   LENARTOWICZ E, 1991, J BIOENERG BIOMEMBR, V23, P679, DOI 10.1007/BF00785817
   Li M, 2012, ARCH BIOCHEM BIOPHYS, V519, P69, DOI 10.1016/j.abb.2011.10.015
   MASMOUDI A, 1988, J NEUROCHEM, V51, P188, DOI 10.1111/j.1471-4159.1988.tb04854.x
   Montaigne D, 2011, MITOCHONDRION, V11, P22, DOI 10.1016/j.mito.2010.06.001
   Nakagawa T, 2005, NATURE, V434, P652, DOI 10.1038/nature03317
   Nakagawa T, 2009, CELL, V137, P560, DOI 10.1016/j.cell.2009.02.026
   Pastorino JG, 1996, J BIOL CHEM, V271, P29792, DOI 10.1074/jbc.271.47.29792
   RICHTER C, 1988, FREE RADICAL BIO MED, V4, P365, DOI 10.1016/0891-5849(88)90088-3
   RICHTER C, 1983, P NATL ACAD SCI-BIOL, V80, P3188, DOI 10.1073/pnas.80.11.3188
   Sharov VG, 2007, J MOL CELL CARDIOL, V42, P150, DOI 10.1016/j.yjmcc.2006.09.013
   Shulga N, 2010, J CELL SCI, V123, P894, DOI 10.1242/jcs.061846
   SZABO I, 1992, J BIOL CHEM, V267, P2940
   Tomita T, 2011, J BIOL CHEM, V286, P37406, DOI 10.1074/jbc.M111.260265
   Zhou SY, 2001, CANCER RES, V61, P771
NR 35
TC 19
Z9 20
U1 1
U2 20
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0005-2728
EI 0006-3002
J9 BBA-BIOENERGETICS
JI Biochim. Biophys. Acta-Bioenerg.
PD JAN
PY 2013
VL 1827
IS 1
BP 38
EP 49
DI 10.1016/j.bbabio.2012.09.016
PG 12
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 052CD
UT WOS:000312174400005
PM 23044393
OA Bronze, Green Accepted
DA 2018-12-27
ER

PT J
AU Dominguez-Gonzalez, M
   Nogales-Perez, A
   Navarrete, SV
AF Dominguez-Gonzalez, Manuel
   Nogales-Perez, Adolfo
   Vazquez Navarrete, Sofia
TI RETRACTED: Granular Cell Tumor of the Vulva (Retracted article. See vol.
   17, pg. 366, 2013)
SO JOURNAL OF LOWER GENITAL TRACT DISEASE
LA English
DT Article; Retracted Publication
DE granular cell tumor; Abrikossoff's tumor; vulva
AB Background. Granular cell tumors are uncommon neoplasms that can involve the skin and subcutaneous tissue. Currently, they are thought to be of neurogenic origin and most likely originate from Schwann cells.
   Case Presentation. This is a case of a 33-year-old woman with a growing vulvar tumor during the past year. Physical examination reveals a 2 x 1-cm mass in the lower third of the right labium majus and adjacent perineal skin. The lesion is excised, and the pathological report informs of the presence of a granular cell tumor.
   Conclusions. Granular cell tumors are uncommon neoplasms but should always be included as a possibility in the differential diagnosis of vulvar lesions. The treatment of choice is local wide excision, which is curative in most of the cases.
C1 [Dominguez-Gonzalez, Manuel; Nogales-Perez, Adolfo; Vazquez Navarrete, Sofia] La Linea Concepc Hosp, Cadiz, Spain.
RP Dominguez-Gonzalez, M (reprint author), La Linea Concepc Hosp, Cadiz, Spain.
EM manueldominguezg@hotmail.com
CR An JS, 2007, YONSEI MED J, V48, P727, DOI 10.3349/ymj.2007.48.4.727
   Chambers D C, 1979, J Natl Med Assoc, V71, P1071
   Cheewakriangkrai C, 2005, GYNECOL ONCOL, V97, P656, DOI 10.1016/j.ygyno.2004.12.058
   Giuliani M, 2004, Minerva Stomatol, V53, P465
   Laxmisha C, 2007, J EUR ACAD DERMATOL, V21, P392, DOI 10.1111/j.1468-3083.2006.01862.x
   Mehta V, 2010, INDIAN J DERMATOL VE, V76, P263, DOI 10.4103/0378-6323.62966
   Vered M, 2009, J ORAL PATHOL MED, V38, P150, DOI 10.1111/j.1600-0714.2008.00725.x
NR 7
TC 2
Z9 2
U1 2
U2 9
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1089-2591
EI 1526-0976
J9 J LOW GENIT TRACT DI
JI J. Low. Genit. Tract. Dis.
PD JAN
PY 2013
VL 17
IS 1
BP 82
EP 84
DI 10.1097/LGT.0b013e3182554a48
PG 3
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 051FJ
UT WOS:000312111300017
PM 22885645
DA 2018-12-27
ER

PT J
AU Ebrahimnezhad, Z
   Zarghami, N
   Keyhani, M
   Amirsaadat, S
   Akbarzadeh, A
   Rahmati, M
   Taheri, ZM
   Nejati-Koshki, K
AF Ebrahimnezhad, Zohreh
   Zarghami, Nosratollah
   Keyhani, Manoutchehr
   Amirsaadat, Soumaye
   Akbarzadeh, Abolfazl
   Rahmati, Mohammad
   Taheri, Zohreh Mohammad
   Nejati-Koshki, Kazem
TI RETRACTED: Inhibition of hTERT Gene Expression by Silibinin-Loaded
   PLGA-PEG-Fe3O4 in T47D Breast Cancer Cell Line (Retracted article. See
   vol. 8, pg. 321, 2018)
SO BIOIMPACTS
LA English
DT Article; Retracted Publication
DE Telomerase; Breast Cancer; Silibinin; PLGA-PEG-Fe3O4; Real-Time PCR; MTT
   Assay
ID TELOMERASE ACTIVITY; NANOPARTICLES; LIPOSOMES
AB Introduction: Nowadays, using drug delivery is an essential method to improve cancer therapy through decreasing drug toxicity and increasing efficiency of treatment. Silibinin (C25H22O10), a polyphenolic flavonoid which is isolated from the milk thistle plant, has various applications in cancer therapy but it has hydrophobic structure with low water solubility and bioavailability. To increase the effect of silibinin, silibinin-loaded PLGA-PEG-Fe3O4 was prepared to determine the inhibitory effect of this nanodrug on Telomerase gene expression. Methods: The rate of silibinin loaded into PLGA-PEGFe3O4 was measured. Then, the cytotoxic effect of silibinin-loaded PLGA-PEG-Fe3O4 was determined by Methyl Thiazol Tetrazolium (MTT) assay. After that, inhibition of Telomerase gene expression was indicated through Real-time PCR. Results: Data analysis from MTT assay showed that silibinin-loaded PLGA-PEG-Fe3O4 had dose dependent cytotoxic effect on T47D cell line. MTT assay showed no cytotoxic effect of free PLGA-PEG-Fe3O4 on T47D breast cancer cell line. Real Time PCR analysis showed that the level of telomerase gene expression more efficiently decreased with silibinin-loaded PLGA-PEG-Fe3O4 than with free silibinin alone. Conclusion: The present study indicates that this nanodrug causes down-regulation of Telomerase gene expression in cancer cells. Therefore, PLGA-PEG-Fe3O4 could be an appropriate carrier for hydrophobic agents such as silibinin to improve their action in cancer therapy.
C1 [Ebrahimnezhad, Zohreh; Zarghami, Nosratollah; Amirsaadat, Soumaye] Tabriz Univ Med Sci, TB & Lung Res Ctr, Tabriz, Iran.
   [Ebrahimnezhad, Zohreh; Zarghami, Nosratollah; Rahmati, Mohammad] Tabriz Univ Med Sci, Fac Med, Dept Clin Biochem & Lab, Tabriz, Iran.
   [Keyhani, Manoutchehr] Univ Tehran Med Sci, Fac Med, Tehran, Iran.
   [Akbarzadeh, Abolfazl] Tabriz Univ Med Sci, Fac Adv Med Sci, Dept Med Nanotechnol, Tabriz, Iran.
   [Taheri, Zohreh Mohammad] Natl Res Inst TB & Lung Dis, Tehran, Iran.
   [Nejati-Koshki, Kazem] Tabriz Univ Med Sci, Fac Adv Med Sci, Dept Med Biotechnol, Tabriz, Iran.
RP Zarghami, N (reprint author), Tabriz Univ Med Sci, TB & Lung Res Ctr, Tabriz, Iran.
EM zarghami@tbzmed.ac.ir
OI Akbarzadeh, Abolfazl/0000-0001-9941-0357; Nejati-Koshki,
   Kazem/0000-0002-1777-5924; Zarghami, Nosratollah/0000-0002-4236-4537
FU Tuberculosis and Lung Research Center of Tabriz University of Medical
   Sciences
FX This work was supported by Tuberculosis and Lung Research Center of
   Tabriz University of Medical Sciences and we thank this centre for
   funding the study.
CR Akbarzadeh A, 2012, INT J NANOMED, V7, P511, DOI 10.2147/IJN.S24326
   Ali I, 2011, CURR CANCER DRUG TAR, V11, P135, DOI 10.2174/156800911794328493
   Avgoustakis K, 2002, J CONTROL RELEASE, V79, P123, DOI 10.1016/S0168-3659(01)00530-2
   Bhatia N, 1999, CANCER LETT, V147, P77, DOI 10.1016/S0304-3835(99)00276-1
   Chen PN, 2006, J DENT RES, V85, P220, DOI 10.1177/154405910608500303
   Dilnawaz F, 2010, BIOMATERIALS, V31, P3694, DOI 10.1016/j.biomaterials.2010.01.057
   Kazemi F, 2011, AFR J BIOTECHNOL, V10, P19481, DOI 10.5897/AJB11.1228
   Kedar E, 1997, J IMMUNOTHER, V20, P180, DOI 10.1097/00002371-199705000-00003
   Kennedy S, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2770
   Kim NW, 1997, EUR J CANCER, V33, P781, DOI 10.1016/S0959-8049(97)00057-9
   Kim S, 2009, J ETHNOPHARMACOL, V126, P252, DOI 10.1016/j.jep.2009.08.032
   LINGNER J, 1995, SCIENCE, V269, P1533, DOI 10.1126/science.7545310
   Noh EM, 2011, J BREAST CANCER, V14, P8, DOI 10.4048/jbc.2011.14.1.8
   Raina K, 2007, ACTA PHARMACOL SIN, V28, P1466, DOI 10.1111/j.1745-7254.2007.00691.x
   STOLNIK S, 1994, PHARMACEUT RES, V11, P1800, DOI 10.1023/A:1018931820564
   Strahl C, 1996, MOL CELL BIOL, V16, P53
   Thelen P, 2004, J UROLOGY, V171, P1934, DOI 10.1097/01.ju.0000121329.37206.1b
   Tian N, 2010, HEALTH PLACE, V16, P209, DOI 10.1016/j.healthplace.2009.09.012
   Yassaee VR, 2002, BREAST CANCER RES, V4, DOI 10.1186/bcr443
   Yasui K, 2000, BIOL PHARM BULL, V23, P318
   Yoo HS, 2001, J CONTROL RELEASE, V70, P63, DOI 10.1016/S0168-3659(00)00340-0
   Zambaux MF, 1999, J CONTROL RELEASE, V60, P179, DOI 10.1016/S0168-3659(99)00073-5
NR 22
TC 41
Z9 42
U1 2
U2 10
PU TABRIZ UNIV MEDICAL SCIENCES & HEALTH SERVICES
PI TABRIZ
PA DANESHGHAH ST, TABRIZ, REPUBLIC ISLAMIC 51664-14766, IRAN
SN 2228-5652
EI 2228-5660
J9 BIOIMPACTS
JI BioImpacts
PY 2013
VL 3
IS 2
BP 67
EP 74
DI 10.5681/bi.2013.005
PG 8
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA V4F1N
UT WOS:000218875400003
PM 23878789
OA DOAJ Gold
DA 2018-12-27
ER

PT J
AU Bhandari, V
   Lohia, M
AF Bhandari, Vipul
   Lohia, Meenal
TI RETRACTED: An Unusual Case of Bilateral Vitreous Haemorrhage following
   Snake Bite (Retracted article. See art no 6235787, 2018)
SO CASE REPORTS IN MEDICINE
LA English
DT Article; Retracted Publication
AB A-45-year-oldman presented to uswith diminution of vision in both eye following snake bite. On examination vision in the right eye (RE) was 6/36 and vision in left eye (LE) was hand movement positive and fundus examination revealed a subhyloid haemorrhage, left eye showed vitreous haemorrhage. Patient was advised bed rest, vitamin C tablets and oral steroids.
C1 [Bhandari, Vipul; Lohia, Meenal] Sunkuru Iye Cure Inst, Aalborg, Denmark.
RP Lohia, M (reprint author), Sunkuru Iye Cure Inst, Aalborg, Denmark.
EM lohiameenal@gmail.com
CR Bhalla A., 2004, J. Venom. Anim. Toxins incl. Trop. Dis, V10, P311, DOI 10.1590/S1678-91992004000300009
   Rao B M, 1977, Indian J Ophthalmol, V25, P1
   Tungpakorn N, 2010, J VENOM ANIM TOXINS, V16, P519, DOI 10.1590/S1678-91992010000300020
NR 3
TC 1
Z9 1
U1 0
U2 0
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1687-9627
EI 1687-9635
J9 CASE REP MED
JI Case Rep. Med.
PY 2013
AR UNSP 640582
DI 10.1155/2013/640582
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA V25ZF
UT WOS:000215261800167
PM 24454404
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Cheng, MR
   Xu, HZ
   Wang, Y
   Chen, HX
   He, B
   Gao, XY
   Li, YC
   Han, J
   Zhang, ZP
AF Cheng, Mingrong
   Xu, Hongzhi
   Wang, Yong
   Chen, Houxiang
   He, Bing
   Gao, Xiaoyan
   Li, Yingchun
   Han, Jiang
   Zhang, Zhiping
TI RETRACTED: Glycyrrhetinic acid-modified chitosan nanoparticles enhanced
   the effect of 5-fluorouracil in murine liver cancer model via regulatory
   T-cells (Retracted article. See vol. 8, pg. 921, 2014)
SO DRUG DESIGN DEVELOPMENT AND THERAPY
LA English
DT Article; Retracted Publication
DE hepatic carcinoma; regulatory T cells; glycyrrhetinic acid; targeted
   therapy; 5-fluorouracil
ID IN-VIVO; TARGETED DELIVERY; OVARIAN-CANCER; COLON-CANCER; TREG CELLS;
   SYSTEM; DRUGS; CYTOTOXICITY; DERIVATIVES; EXPRESSION
AB Modified chitosan nanoparticles are a promising platform for drug, such as 5-fluorouracil (5-FU), gene, and vaccine delivery. Here, we used chitosan and hepatoma cell-specific binding molecule glycyrrhetinic acid (GA) to synthesize glycyrrhetinic acid-modified chitosan (GA-CTS). The synthetic product was confirmed by infrared spectroscopy and hydrogen nuclear magnetic resonance. By combining GA-CTS and 5-FU, we obtained a GA-CTS/5-FU nanoparticle, with a particle size of 193.7 nm, drug loading of 1.56%, and a polydispersity index of 0.003. The GA-CTS/5-FU nanoparticle provided a sustained-release system comprising three distinct phases of quick, steady, and slow release. In vitro data indicated that it had a dose-and time-dependent anticancer effect. The effective drug exposure time against hepatic cancer cells was increased in comparison with that observed with 5-FU. In vivo studies on an orthotropic liver cancer mouse model demonstrated that GA-CTS/5-FU significantly inhibited cancer cell proliferation, resulting in increased survival time. The antitumor mechanisms for GA-CTS/5-FU nanoparticle were possibly associated with an increased expression of regulatory T-cells, decreased expression of cytotoxic T-cell and natural killer cells, and reduced levels of interleukin-2 and interferon gamma.
C1 [Cheng, Mingrong; Han, Jiang; Zhang, Zhiping] Pudong New Area Dist Zhoupu Hosp, Dept Gen Surg, Shanghai, Peoples R China.
   [Cheng, Mingrong; Li, Yingchun] Pudong New Area Dist Zhoupu Hosp, Dept Endoscopy, Shanghai, Peoples R China.
   [Xu, Hongzhi; He, Bing] Fudan Univ, Shanghai Peoples Hosp 5, Dept Gen Surg, Shanghai 200433, Peoples R China.
   [Wang, Yong] Wuhan Univ Technol, Sch Mat Sci & Engn, Wuhan 430070, Peoples R China.
   [Chen, Houxiang] Zhejiang Huafon Spandex Co Ltd, Zhejiang Huafon Fiber Res Inst, Wenzhou, Peoples R China.
   [Gao, Xiaoyan] Pudong New Area Dist Zhoupu Hosp, Dept Plast Surg, Shanghai, Peoples R China.
RP Wang, Y (reprint author), Wuhan Univ Technol, Sch Mat Sci & Engn, Youyi Ave, Wuhan 430070, Peoples R China.
EM wangyong@whut.edu.cn; 2011cmr@sina.com
FU Natural Science Foundation of Shanghai [12nm0502202, 114119a4700];
   Pudong New Area Science and Technology Development Fund [PKJ2012-Y24];
   Minhang District Natural Science Foundation of Shanghai [2010MHZ023]
FX This work was supported by the Natural Science Foundation of Shanghai
   (12nm0502202 and 114119a4700); Pudong New Area Science and Technology
   Development Fund (PKJ2012-Y24); Minhang District Natural Science
   Foundation of Shanghai (2010MHZ023).
CR Arulmozhi V, 2013, COLLOID SURFACE B, V110, P313, DOI 10.1016/j.colsurfb.2013.03.039
   Bamias A, 2008, GYNECOL ONCOL, V108, P421, DOI 10.1016/j.ygyno.2007.10.018
   Bergmann C, 2011, EUR J IMMUNOL, V41, P3564, DOI 10.1002/eji.201141532
   Chen Y, 2012, ONKOLOGIE, V35, P480, DOI 10.1159/000341825
   Cheng MR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047115
   Fang JY, 2008, CURR DRUG METAB, V9, P592, DOI 10.2174/138920008785821693
   Hamman JH, 2010, MAR DRUGS, V8, P1305, DOI 10.3390/md8041305
   He ZY, 2010, INT J PHARMACEUT, V397, P147, DOI 10.1016/j.ijpharm.2010.06.029
   Hibasami H, 2006, INT J MOL MED, V17, P215
   Huang W, 2011, J MATER SCI-MATER M, V22, P853, DOI 10.1007/s10856-011-4262-2
   Huang W, 2010, ACTA BIOMATER, V6, P3927, DOI 10.1016/j.actbio.2010.04.021
   Huang X, 2013, J OCUL PHARMACOL TH, V29, P208, DOI 10.1089/jop.2012.0184
   Javid A, 2013, CHEM BIOL DRUG DES, V82, P296, DOI 10.1111/cbdd.12145
   Jeong HG, 2002, PHARMACOL RES, V46, P221, DOI 10.1016/S1043-6618(02)00121-4
   Johnson KR, 1997, CLIN CANCER RES, V3, P1739
   Lallemand B, 2011, MINI-REV MED CHEM, V11, P881, DOI 10.2174/138955711796575443
   Li JF, 2010, MOL MED REP, V3, P959, DOI 10.3892/mmr.2010.374
   Ligabue A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047318
   Mao CM, 2008, ONKOLOGIE, V31, P243, DOI 10.1159/000121360
   Nabeya Y, 2011, CANCER SCI, V102, P1509, DOI 10.1111/j.1349-7006.2011.01978.x
   NEGISHI M, 1991, BIOCHIM BIOPHYS ACTA, V1066, P77, DOI 10.1016/0005-2736(91)90253-5
   Oh IH, 2013, BIOMATERIALS, V34, P6454, DOI 10.1016/j.biomaterials.2013.05.017
   Park JH, 2010, ADV DRUG DELIVER REV, V62, P28, DOI 10.1016/j.addr.2009.10.003
   Patravale VB, 2004, J PHARM PHARMACOL, V56, P827, DOI 10.1211/0022357023691
   Ramstead AG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050546
   Ramstead AG, 2012, J INTERF CYTOK RES, V32, P563, DOI 10.1089/jir.2012.0073
   Sellitto A, 2011, J CLIN IMMUNOL, V31, P1095, DOI 10.1007/s10875-011-9585-8
   Shi Yan-Xia, 2004, Ai Zheng, V23, P597
   Takahashi Y, 2004, SURG TODAY, V34, P855, DOI 10.1007/s00595-004-2835-0
   Tian Q, 2012, NANOMED-NANOTECHNOL, V8, P870, DOI 10.1016/j.nano.2011.11.002
   Tian Q, 2010, BIOMATERIALS, V31, P4748, DOI 10.1016/j.biomaterials.2010.02.042
   Toriumi F, 2004, ANTICANCER RES, V24, P2455
   Whiteside TL, 2012, SEMIN CANCER BIOL, V22, P327, DOI 10.1016/j.semcancer.2012.03.004
   Wu TT, 2012, TRANSPL IMMUNOL, V27, P30, DOI 10.1016/j.trim.2012.05.001
   Xu J, 2012, INT J BIOL MACROMOL, V50, P438, DOI 10.1016/j.ijbiomac.2011.12.034
   Yan SF, 2011, EUR J PHARM BIOPHARM, V78, P336, DOI 10.1016/j.ejpb.2010.12.031
   Yu JM, 2009, J PHARM PHARMACOL, V61, P713, DOI [10.1211/jpp/61.06.0003, 10.1211/jpp.61.06.0003]
   Zanon RG, 2010, NEUROPATH APPL NEURO, V36, P515, DOI 10.1111/j.1365-2990.2010.01095.x
   Zhao MF, 2013, BIOMED RES INT, DOI 10.1155/2013/430861
   Zhu LZ, 2009, COLLOID SURFACE B, V68, P1, DOI 10.1016/j.colsurfb.2008.07.020
NR 40
TC 12
Z9 12
U1 0
U2 0
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1177-8881
J9 DRUG DES DEV THER
JI Drug Des. Dev. Ther.
PY 2013
VL 7
BP 1287
EP 1299
DI 10.2147/DDDT.S52809
PG 13
WC Chemistry, Medicinal; Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 239IR
UT WOS:000326016500001
PM 24187487
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Chia, NKH
   Kee, NKN
AF Chia, Noel
   Kee, Norman
TI RETRACTED: Gender differences in the reading process of six-year-olds in
   Singapore (Retracted article. See vol. 187, pg. 2015, 2017)
SO EARLY CHILD DEVELOPMENT AND CARE
LA English
DT Article; Retracted Publication
DE comprehension; fluency; gender differences; phonemic awareness; phonics;
   reading; vocabulary
AB Reading is a complex developmental process that involves decoding print, monitoring comprehension, and establishing meaningful connections with prior knowledge and experience. It concerns the mastery of five reading-related components: phonemic awareness, phonics, fluency, vocabulary, and comprehension. The focus of this study examined these five components for 65 six-year-old children from three Montessori schoolhouses and correlations between and among the factors in order to see whether there were gender differences in reading and to discuss possible causes of differences.
C1 [Chia, Noel; Kee, Norman] Nanyang Technol Univ, Natl Inst Educ, Early Childhood & Special Educ Acad Grp, Singapore, Singapore.
RP Chia, NKH (reprint author), Nanyang Technol Univ, Natl Inst Educ, Early Childhood & Special Educ Acad Grp, Singapore, Singapore.
EM kokhwee.chia@nie.edu.sg
CR Anderson R.C., 1984, HDB READING RES, P225
   BANDURA A, 1989, AM PSYCHOL, V44, P1175, DOI 10.1037//0003-066X.44.9.1175
   Bandura A., 1988, AUSTR J MANAGEMENT, V13, P275, DOI DOI 10.1177/031289628801300210
   Berglund E, 2005, SCAND J PSYCHOL, V46, P485, DOI 10.1111/j.1467-9450.2005.00480.x
   Braunger J., 2001, BUILDING KNOWLEDGE B
   Bromley K. D., 1988, LANGUAGE ARTS EXPLOR
   Bruner J., 1985, CULTURE COMMUNICATIO, P21
   Buehl D., 2001, CLASSROOM STRATEGIES
   Cakir O., 2008, EDUCATION, V129, P315
   Carnine D. W, 2004, DIRECT INSTRUCTION R
   Carver R. P., 1977, READING RES Q, V13, P8
   Carver RP, 1998, J LEARN DISABIL, V31, P453, DOI 10.1177/002221949803100504
   Chall J. S., 1990, READING CRISIS WHY P
   Chatterji M, 2006, J EDUC PSYCHOL, V98, P489, DOI 10.1037/0022-0663.98.3.489
   CHI FM, 1995, J READING, V38, P638
   Chia N. K. H., 1999, SOC READING LITERACY, V11, P9
   Chia N. K. H., 1996, ED TODAY, V46, P66
   Chia N. K. H., 2007, ASCD REV, V13, P5
   Chia N. K. H., 2010, READING DISABILITIES
   Chia N. K. H., 1994, ED TODAY, V44, P45
   Chia N. K. H., 1992, ED TODAY, V42, P32
   Chia N. K. H., 2003, TEACHING TIPS TEACHE, P21
   Chia N. K. H., 2004, SOC READING LITERACY, V17, P3
   Chiu MM, 2006, SCI STUD READ, V10, P331, DOI 10.1207/s1532799xssr1004_1
   Clay M., 1975, WHAT DID I WRITE
   Clay M. M., 1993, READING RECOVERY GUI
   Cox KE, 2001, CONTEMP EDUC PSYCHOL, V26, P116, DOI 10.1006/ceps.1999.1044
   CRONBACH LJ, 1951, PSYCHOMETRIKA, V16, P297, DOI DOI 10.1007/BF02310555
   Cullingford C., 2001, CHILDREN LEARN READ
   Cunningham A., 1998, AM EDUC, V22, P8
   de Beaugrande R., 1982, LANGUAGE COMPREHENSI, P179
   Derry SJ, 1999, RUTG INV SYMP EDUC S, P197
   Durkin D., 1993, TEACHING THEM READ
   Edmunds KM, 2006, READ TEACH, V59, P414, DOI 10.1598/RT.59.51
   Ehri LC, 1998, WORD RECOGNITION IN BEGINNING LITERACY, P3
   Evans R., 2008, METACOGNITIVE APPROA
   FEINGOLD A, 1994, SEX ROLES, V30, P81, DOI 10.1007/BF01420741
   Galsworthy MJ, 2000, DEVELOPMENTAL SCI, V3, P206, DOI 10.1111/1467-7687.00114
   GRAESSER AC, 1994, PSYCHOL REV, V101, P371, DOI 10.1037/0033-295X.101.3.371
   Hackman DA, 2009, TRENDS COGN SCI, V13, P65, DOI 10.1016/j.tics.2008.11.003
   Hammill D., 2002, COMPREHENSIVE RECEPT
   Hart B, 1995, MEANINGFUL DIFFERENC
   HEATH SB, 1982, LANG SOC, V11, P49, DOI 10.1017/S0047404500009039
   Huey E.B., 1908, PSYCHOL PEDAGOGY REA
   HYDE JS, 1988, PSYCHOL BULL, V104, P53, DOI 10.1037/0033-2909.104.1.53
   Johnston R. S., 2009, CONT PERSPECTIVES RE, P221
   KOHN A, 1993, PHI DELTA KAPPAN, V74, P783
   Kurby CA, 2005, READ PSYCHOL, V26, P335, DOI 10.1080/02702710500285870
   LAMME LL, 1976, THE READING TEACHER, V30, P21
   Lanse H. W., 2008, READ WELL THINK WELL
   Latham R., 1979, MODERN VIEW READING
   Latham R., 1987, TEACHING READING IS
   Law S, 2012, THESIS
   Learning Point Associates, 2004, CLOS LOOK 5 ESS COMP
   Lee A., 1980, LEARNING LOSE, P121
   Locke A, 2002, INT J LANG COMM DIS, V37, P3, DOI 10.1080/13682820110089911
   Logan S, 2010, EDUC REV, V62, P175, DOI 10.1080/00131911003637006
   Logan S, 2009, J RES READ, V32, P199, DOI 10.1111/j.1467-9817.2008.01389.x
   McCarthey S. J., 1992, READING WRITING CONN, P2
   MCKENNA MC, 1995, READ RES QUART, V30, P934, DOI 10.2307/748205
   McMahon M., 1997, ASCILITE C PERTH
   Meyer MS, 1999, ANN DYSLEXIA, V49, P283, DOI 10.1007/s11881-999-0027-8
   Morgan PL, 2007, EXCEPT CHILDREN, V73, P165, DOI 10.1177/001440290707300203
   Morrow L., 1990, EARLY CHILDHOOD RES, V5, P537, DOI DOI 10.1016/0885-2006(90)90018-V
   Moseley D., 2003, WORD RECOGNITION PHO
   Mullis I.V.S., 2007, PIRLS 2006 INT REPOR
   Nagy W. E., 2000, HDB READING RES, V3, P269
   National Reading Panel, 2000, TEACH CHILDR READ EV
   Neale M.D., 1999, NEALE ANAL READING A
   Nunnually J., 1994, PSYCHOMETRIC THEORY
   Pardo LS, 2004, READ TEACH, V58, P272, DOI 10.1598/RT.58.3.5
   Paris SG, 1990, DIMENSIONS THINKING, P15
   Parish-Morris J., 2008, BIENN INT C INF STUD
   Perfetti C., 2007, SCI READING HDB, P227
   Pikulski JJ, 2005, READ TEACH, V58, P510, DOI 10.1598/RT.58.6.2
   Pressley M, 2000, HDB READING RES, VIII, P545
   REINKING D, 1985, READ RES QUART, V20, P536, DOI 10.2307/747941
   Ruddell R. B., 1994, THEORETICAL MODELS P, P44
   Ruddell R. B., 2004, THEORETICAL MODELS P, P94
   Scarborough HS, 1998, ANN DYSLEXIA, V48, P115, DOI 10.1007/s11881-998-0006-5
   Schank S. C., 1977, SCRIPTS PLANS GOALS
   Scribner S, 1981, PSYCHOL LITERACY
   Sheridan E. M., 1982, SEX STEREOTYPES READ
   Singer M, 2004, MEM COGNITION, V32, P1223, DOI 10.3758/BF03206314
   STANOVICH KE, 1980, READ RES QUART, V16, P32, DOI 10.2307/747348
   Sulzby E, 1986, EMERGENT LIT WRITING, P50
   Taboada A, 2009, READ WRIT, V22, P85, DOI 10.1007/s11145-008-9133-y
   Teale W. H., 1986, EMERGENT LIT WRITING, P173
   van den Broek P., 1994, HDB PSYCHOLINGUISTIC, P539
   Vygotsky L, 1978, MIND SOC DEV HIGHER
   Wallace T., 2007, 12 I COMM INT
   Wang JHY, 2004, READ RES QUART, V39, P162, DOI 10.1598/RRQ.39.2.2
   Weaver C., 2009, READING PROCESS BRIE
   Wendling B. J., 2009, ESSENTIALS EVIDENCEB
   Westerlund M, 2008, CHILD CARE HLTH DEV, V34, P257, DOI 10.1111/j.1365-2214.2007.00801.x
   WHITE TG, 1990, J EDUC PSYCHOL, V82, P281, DOI 10.1037//0022-0663.82.2.281
   Wiley J, 2003, DISCOURSE PROCESS, V36, P109, DOI 10.1207/S15326950DP3602_2
   WOLF M, 2003, PREVENTING REMEDIATI, P355
NR 98
TC 1
Z9 1
U1 0
U2 0
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 0300-4430
EI 1476-8275
J9 EARLY CHILD DEV CARE
JI Early Child Dev. Care
PY 2013
VL 183
IS 10
SI SI
BP 1432
EP 1448
DI 10.1080/03004430.2013.788812
PG 17
WC Education & Educational Research; Psychology, Developmental
SC Education & Educational Research; Psychology
GA V77AY
UT WOS:000211953900007
DA 2018-12-27
ER

PT S
AU Buttaro, L
AF Buttaro, L.
BE Chova, LG
   Martinez, AL
   Torres, IC
TI RETRACTED: THE EDUCATION OF CHILDREN OF IMMIGRANTS: A CROSS CULTURAL
   STUDY BETWEEN NEW YORK AND ROME (Retracted Article)
SO EDULEARN13: 5TH INTERNATIONAL CONFERENCE ON EDUCATION AND NEW LEARNING
   TECHNOLOGIES
SE EDULEARN Proceedings
LA English
DT Proceedings Paper; Retracted Publication
CT 5th International Conference on Education and New Learning Technologies
   (EDULEARN)
CY JUL 01-03, 2013
CL Barcelona, SPAIN
DE Achievement gap; English language learners; professional development;
   second language acquisition; Italy
C1 [Buttaro, L.] Adelphi Univ, Garden City, NY 21402 USA.
EM buttaro@adelphi.edu
NR 0
TC 0
Z9 0
U1 1
U2 1
PU IATED-INT ASSOC TECHNOLOGY EDUCATION & DEVELOPMENT
PI VALENICA
PA LAURI VOLPI 6, VALENICA, BURJASSOT 46100, SPAIN
SN 2340-1117
BN 978-84-616-3822-2
J9 EDULEARN PROC
PY 2013
BP 5919
EP +
PG 2
WC Education & Educational Research
SC Education & Educational Research
GA BB8LM
UT WOS:000346798305131
DA 2018-12-27
ER

PT J
AU Lymperopoulos, A
AF Lymperopoulos, Anastasios
TI RETRACTED: Physiology and pharmacology of the cardiovascular adrenergic
   system (Retracted article. See vol. 6, 379, 2015)
SO FRONTIERS IN PHYSIOLOGY
LA English
DT Review; Retracted Publication
DE adrenergic nervous system; heart failure; cardiac myocyte; adrenal
   gland; catecholamine; adrenergic receptor
ID COUPLED RECEPTOR KINASES; SYMPATHETIC-NERVOUS-SYSTEM;
   CONGESTIVE-HEART-FAILURE; BETA(2)-ADRENERGIC RECEPTOR;
   ALPHA(2)-ADRENOCEPTOR SUBTYPES; CATECHOLAMINE RELEASE; DOWN-REGULATION;
   MYOCARDIAL-INFARCTION; BETA-ADRENOCEPTORS; CARDIAC MYOCYTES
AB Heart failure (HF), the leading cause of death in the western world, ensues in response to cardiac injury or insult and represents the inability of the heart to adequately pump blood and maintain tissue perfusion. It is characterized by complex interactions of several neurohormonal mechanisms that get activated in the syndrome in order to try and sustain cardiac output in the face of decompensating function. The most prominent among these neurohormonal mechanisms is the adrenergic (or sympathetic) nervous system (ANS), whose activity and outflow are greatly elevated in HE Acutely, provided that the heart still works properly, this activation of the ANS will promptly restore cardiac function according to the fundamental Frank-Starling law of cardiac function. However, if the cardiac insult persists over time, this law no longer applies and ANS will not be able to sustain cardiac function. This is called decompensated HF, and the hyperactive ANS will continue to "push" the heart to work at a level much higher than the cardiac muscle can handle. From that point on, ANS hyperactivity becomes a major problem in HF, conferring significant toxicity to the failing heart and markedly increasing its morbidity and mortality. The present review discusses the role of the ANS in cardiac physiology and in HF pathophysiology, the mechanisms of regulation of ANS activity and how they go awry in chronic HF, and, finally, the molecular alterations in heart physiology that occur in HF along with their pharmacological and therapeutic implications for the failing heart.
C1 Nova SE Univ, Coll Pharm, Dept Pharmaceut Sci, Lab Study Neurohormonal Control Circulat, Ft Lauderdale, FL 33328 USA.
RP Lymperopoulos, A (reprint author), Nova SE Univ, Coll Pharm, Dept Pharmaceut Sci, Lab Study Neurohormonal Control Circulat, 3200 S Univ Dr,HPD Terry Bldg Room 1338, Ft Lauderdale, FL 33328 USA.
EM al806@nova.edu
CR Aggarwal A, 2002, CIRCULATION, V105, P1031, DOI 10.1161/hc0902.105724
   Aggarwal A, 2001, J AM COLL CARDIOL, V37, P1246, DOI 10.1016/S0735-1097(01)01121-4
   Armour JA, 2004, AM J PHYSIOL-REG I, V287, pR262, DOI 10.1152/ajpregu.00183.2004
   ARRIZA JL, 1992, J NEUROSCI, V12, P4045
   Backs J, 2001, J MOL CELL CARDIOL, V33, P461, DOI 10.1006/jmcc.2000.1319
   Brede M, 2003, MOL ENDOCRINOL, V17, P1640, DOI 10.1210/me.2003-0035
   Brede M, 2002, CIRCULATION, V106, P2491, DOI 10.1161/01.0000036600.39600.66
   BRISTOW MR, 1986, CIRC RES, V59, P297, DOI 10.1161/01.RES.59.3.297
   BRISTOW MR, 1982, NEW ENGL J MED, V307, P205, DOI 10.1056/NEJM198207223070401
   BRODDE OE, 1993, PHARMACOL THERAPEUT, V60, P405, DOI 10.1016/0163-7258(93)90030-H
   Brum PC, 2002, AM J PHYSIOL-HEART C, V283, pH1838, DOI 10.1152/ajpheart.01063.2001
   BYLUND DB, 1994, PHARMACOL REV, V46, P121
   Chesley A, 2000, CIRC RES, V87, P1172, DOI 10.1161/01.RES.87.12.1172
   COLUCCI WS, 1986, NEW ENGL J MED, V314, P290, DOI 10.1056/NEJM198601303140506
   Communal C, 1999, CIRCULATION, V100, P2210, DOI 10.1161/01.CIR.100.22.2210
   Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362
   Docherty JR, 2002, AUTON NEUROSCI-BASIC, V96, P8, DOI 10.1016/S1566-0702(01)00375-7
   Dorn GW, 1999, P NATL ACAD SCI USA, V96, P6400, DOI 10.1073/pnas.96.11.6400
   Du XJ, 2006, CARDIOVASC RES, V71, P735, DOI 10.1016/j.cardiores.2006.06.015
   DZAU VJ, 1981, CIRCULATION, V63, P645, DOI 10.1161/01.CIR.63.3.645
   Eaton MJ, 2004, MOL CELL ENDOCRINOL, V228, P39, DOI 10.1016/j.mce.2003.02.001
   Ferguson SSG, 2001, PHARMACOL REV, V53, P1
   Gauthier C, 1998, J CLIN INVEST, V102, P1377, DOI 10.1172/JCI2191
   Hein L, 1999, NATURE, V402, P181
   Hogg K, 2005, PROG CARDIOVASC DIS, V47, P357, DOI 10.1016/j.pcad.2005.02.001
   Kaye D, 2005, CARDIOVASC RES, V66, P256, DOI 10.1016/j.cardiores.2005.02.012
   KNOWLTON KU, 1993, J BIOL CHEM, V268, P15374
   Lang CC, 1997, HYPERTENSION, V30, P392, DOI 10.1161/01.HYP.30.3.392
   Leineweber K, 2002, J AM COLL CARDIOL, V40, P1459, DOI 10.1016/S0735-1097(02)02168-X
   Liggett SB, 2000, CIRCULATION, V101, P1707
   Lindley TE, 2004, CIRC RES, V94, P402, DOI 10.1161/01.RES.0000112964.40701.93
   Lohse MJ, 2003, CIRC RES, V93, P896, DOI 10.1161/01.RES.0000102042.83024.CA
   Lymperopoulos A, 2008, MOL THER, V16, P302, DOI 10.1038/sj.mt.6300371
   Lymperopoulos A, 2007, TRENDS MOL MED, V13, P503, DOI 10.1016/j.molmed.2007.10.005
   Lymperopoulos A, 2007, NAT MED, V13, P315, DOI 10.1038/nm1553
   Lymperopoulos A, 2012, HYPERTENSION, V60, P12, DOI 10.1161/HYPERTENSIONAHA.112.197020
   Lymperopoulos A, 2012, CURR PHARM DESIGN, V18, P186, DOI 10.2174/138161212799040510
   Lymperopoulos A, 2012, PHARMACOGENOMICS, V13, P323, DOI [10.2217/PGS.11.178, 10.2217/pgs.11.178]
   Lymperopoulos A, 2010, J BIOL CHEM, V285, P16378, DOI 10.1074/jbc.M109.077859
   MALLIANI A, 1983, J AUTONOM NERV SYST, V7, P295, DOI 10.1016/0165-1838(83)90082-6
   Mann DL, 2005, CIRCULATION, V111, P2837, DOI 10.1161/CIRCULATIONAHA.104.500546
   Morris MJ, 1997, HYPERTENSION, V29, P137, DOI 10.1161/01.HYP.29.1.137
   Moura E, 2006, BRIT J PHARMACOL, V149, P1049, DOI 10.1038/sj.bjp.0706950
   Mudd JO, 2008, NATURE, V451, P919, DOI 10.1038/nature06798
   Nikolaev VO, 2010, SCIENCE, V327, P1653, DOI 10.1126/science.1185988
   Penn RB, 2000, TRENDS CARDIOVAS MED, V10, P81, DOI 10.1016/S1050-1738(00)00053-0
   Pepper GS, 1999, ARCH INTERN MED, V159, P225, DOI 10.1001/archinte.159.3.225
   Philipp M, 2004, PHARMACOL THERAPEUT, V101, P65, DOI 10.1016/j.pharmthera.2003.10.004
   Philipp M, 2002, AM J PHYSIOL-REG I, V283, pR287, DOI 10.1152/ajpregu.00123.2002
   PIERPONT GL, 1985, J LAB CLIN MED, V106, P205
   REGITZ V, 1991, EUR HEART J, V12, P171, DOI 10.1093/eurheartj/12.suppl_D.171
   Reiter E, 2006, TRENDS ENDOCRIN MET, V17, P159, DOI 10.1016/j.tem.2006.03.008
   Rengo G, 2012, BRIT J PHARMACOL, V166, P2430, DOI 10.1111/j.1476-5381.2012.01972.x
   Rengo G, 2012, CIRC-HEART FAIL, V5, P385, DOI 10.1161/CIRCHEARTFAILURE.112.966895
   Rengo G, 2011, J MOL CELL CARDIOL, V50, P785, DOI 10.1016/j.yjmcc.2010.08.014
   Rengo G, 2010, AM J PHYSIOL-HEART C, V298, pH2032, DOI 10.1152/ajpheart.00702.2009
   Rockman HA, 2002, NATURE, V415, P206, DOI 10.1038/415206a
   Rozec B, 2009, J AM COLL CARDIOL, V53, P1532, DOI 10.1016/j.jacc.2008.11.057
   Shannon R, 2006, AM HEART J, V152, P842, DOI 10.1016/j.ahj.2006.050.017
   Skeberdis VA, 2008, J CLIN INVEST, V118, P3219, DOI 10.1172/JCI32519
   Triposkiadis F, 2009, J AM COLL CARDIOL, V54, P1747, DOI 10.1016/j.jacc.2009.05.015
   Wang H, 2004, CIRC RES, V94, P843, DOI 10.1161/01.RES.0000120864.21172.5A
   Woodcock EA, 2008, CARDIOVASC RES, V77, P452, DOI 10.1093/cvr/cvm078
   Wright H, 2007, NAT AREA J, V27, P115
   Zhu WZ, 2001, P NATL ACAD SCI USA, V98, P1607, DOI 10.1073/pnas.98.4.1607
   Zipes Douglas P, 2008, Cleve Clin J Med, V75 Suppl 2, pS94
NR 66
TC 14
Z9 15
U1 2
U2 11
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015,
   SWITZERLAND
SN 1664-042X
J9 FRONT PHYSIOL
JI Front. Physiol.
PY 2013
VL 4
AR 240
DI 10.3389/fphys.2013.00240
PG 7
WC Physiology
SC Physiology
GA AX2LA
UT WOS:000346774000237
PM 24027534
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Collins, CS
AF Collins, Christopher S.
TI RETRACTED: A higher education learning profile in the Asia-Pacific
   (retracted article)
SO JOURNAL OF ASIAN PUBLIC POLICY
LA English
DT Article; Retracted Publication
DE learning outcomes; higher education; assessment; Asia-Pacific economies
AB The purpose of this article is to expand knowledge beyond quality and assessment practices in the Asia-Pacific region to develop a profile about the nature of learning domains and degree qualifications. Using a policy research and analysis framework, data were collected from 16 of the 21 APEC economies about higher education systems and learning outcomes. This article evaluates the learning outcomes used throughout the region for a focus on workforce development and capacity building and addresses the regional landscape across Asia-Pacific economies for higher education learning domains or outcomes, student mobility, and regional cooperation.
C1 [Collins, Christopher S.] Azusa Pacific Univ, Dept Higher Educ, Azusa, CA 91702 USA.
RP Collins, CS (reprint author), Azusa Pacific Univ, Dept Higher Educ, Azusa, CA 91702 USA.
EM christopher.s.collins@gmail.com
FU Asia-Pacific Economic Cooperation (APEC)
FX A version of this article was developed with the support of and for the
   Asia-Pacific Economic Cooperation (APEC).
CR Anderson D. S., 1991, KNOWLEDGE POLICY IMP
   [Anonymous], 2008, ED MAL JOURN EXC
   [Anonymous], 2009, MAPP QUAL FRAM APEC
   APEC, 2011, QUAL HIGH ED ID DEV
   Australian Qualifications Framework Council, 2011, AUSTR QUAL FRAM
   Baunto A.L., 2011, ED SE ASIA, P53
   Benavot A, 2007, GROWTH NATL LEARNING
   Bresciani M. J., 2006, OUTCOMES BASED ACAD
   Collins C.S., 2011, EXCELLENCE HIGHER ED, V2, P29
   Collins CS, 2008, INT PERSP EDUC SOC, V9, P177, DOI 10.1016/S1479-3679(08)00007-8
   ENQA, 2009, STAND GUID QUAL ASS
   Ewell P., 1997, HDB UNDERGRADUATE CU
   Ewell P. T., 2002, BUILDING SCHOLARSHIP, P3
   Goodchild L.F., 1989, HIST HIGHER ED ASHE
   Hawkins J.N., 2011, QUALITY HIGHER ED ID
   International Network of Quality Assurance Agencies in Higher Education (INQAAHE), 2007, GUID GOOD PRACT QUAL
   JPKE, 2007, BRUN DAR LONG TERM D
   Kamens DH, 2010, COMP EDUC REV, V54, P5
   Koretz D.M., 2008, MEASURING WHAT ED TE
   Lee M., 2011, QUALITY HIGHER ED ID
   Lumina Foundation, 2011, DEGR QUAL PROF
   Majchrzak A, 1984, METHODS POLICY RES
   Maki P., 2004, ASSESSING STUDENT LE
   McNeely C, 1994, ED POLICY ANAL ARCH, V2
   Neubauer D., 2011, QUALITY HIGHER ED ID
   OECD, 2006, ED GLANC 2006
   Sanyal B.C., 1981, HIGHER ED LABOUR MAR
   Schuller T, 2009, INT STUD HIGH EDUC, P64
   Tan J., 2011, ED SE ASIA, P157
   Thailand Ministry of Education, 2008, LEARN SOC THAIL
   Trow M, 1996, HIGH EDUC POLICY, V9, P309, DOI DOI 10.1016/S0952-8733(96)00029-3
   Uvalic-Trumbic S., 2009, INT ORG HIGHER ED PO
   World Bank, 2011, LEARN ALL INV PEOPL
NR 33
TC 1
Z9 1
U1 1
U2 1
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 1751-6234
EI 1751-6242
J9 J ASIAN PUBLIC POLIC
JI J. Asian Public Policy
PY 2013
VL 6
IS 3
BP 247
EP 262
DI 10.1080/17516234.2013.850220
PG 16
WC Area Studies
SC Area Studies
GA V12KK
UT WOS:000214344500004
DA 2018-12-27
ER

PT J
AU Bamidele, O
AF Bamidele, Oluwaseun
TI RETRACTED: Climate Change, War, and Global Struggle (Retracted article.
   See vol. 28, pg. 268, 2016)
SO PEACE REVIEW-A JOURNAL OF SOCIAL JUSTICE
LA English
DT Article; Retracted Publication
C1 [Bamidele, Oluwaseun] Faith Acad Canaanland, Dept Liberal Arts & Social Sci, Civic Educ Unit, Ota, Nigeria.
RP Bamidele, O (reprint author), Faith Acad Canaanland, Dept Liberal Arts & Social Sci, Civic Educ Unit, Ota, Nigeria.
EM oluwaseun.bamidele@gmail.com
CR Barnet J., 2001, 7 TYND CTR CLIM CHAN
   Intergovernmental Panel on Climate Change, 2001, CLIMATE CHANGE 2001
   Lee J., 2009, CLIMATE CHANGE ARMED
NR 3
TC 2
Z9 2
U1 0
U2 0
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 1040-2659
EI 1469-9982
J9 PEACE REV
JI Peace Rev.
PY 2013
VL 25
IS 4
BP 510
EP 517
DI 10.1080/10402659.2013.846163
PG 8
WC International Relations
SC International Relations
GA V68LT
UT WOS:000211373600006
DA 2018-12-27
ER

PT J
AU Anagnostopoulos, C
   Shilbury, D
AF Anagnostopoulos, Christos
   Shilbury, David
TI RETRACTED: Implementing corporate social responsibility in English
   football Towards multi-theoretical integration (Retracted article. See
   vol. 21, 2018)
SO SPORT BUSINESS AND MANAGEMENT-AN INTERNATIONAL JOURNAL
LA English
DT Article; Retracted Publication
DE CSR; Football; Implementation; Multi-theoretical; Paradox; Sport
AB Purpose - The purpose of this paper is to bridge the micro-macro divide by trying to integrate the micro-domain's focus on individuals (i.e. managers) with the meso-domain's and macro-domain's focus (i.e. leagues/football clubs and the socio-political environment, respectively). The examination takes place within the context of English football and in relation to the implementation of corporate social responsibility (CSR).
   Design/methodology/approach - The paper draws on data collected by 21 charitable foundation managers of the top two divisions of English football. The interviews were recorded and transcribed verbatim from digital voice recorders and were analysed using grounded theory coding techniques.
   Findings - The study found a paradoxical context in which foundation managers make strategic decisions in an endeavour to harmonise multiple environmental and institutional "recipes". Managers are confident that they have the capability to do so, yet realise that this capability is the result of a heavy reliance on external and internal resources. These considerations come together to create the micro-context, here identified as a dysfunctional setting, in which managers are required to make the decisions that confirm their role as managers. Therefore, multiple, and often contradictory, theoretical perspectives are in play and explain the foundation managers' role in the implementation process.
   Originality/value - The paper moves away from mono-theoretical approaches that have been mainly used for the examination of CSR in the sporting context, and by placing its focus on the individual level of analysis illustrates the complexity of the CSR implementation process.
C1 [Anagnostopoulos, Christos] Coventry Business Sch, Sport & Event Management Dept, Coventry, W Midlands, England.
   [Anagnostopoulos, Christos] Ctr Int Business Sport CIBS, Amsterdam, Netherlands.
   [Shilbury, David] Deakin Univ, Sch Management & Mkt, Sport Management, Melbourne, Australia.
   [Shilbury, David] Deakin Univ, Sch Management & Mkt, Melbourne, Australia.
RP Anagnostopoulos, C (reprint author), Coventry Business Sch, Sport & Event Management Dept, Coventry, W Midlands, England.
EM aa9711@coventry.ac.uk
CR Aguinis H, 2012, J MANAGE, V38, P932, DOI 10.1177/0149206311436079
   Anagnostopoulos C., 2013, HDB SPORT CORPORATE, P91
   Anagnostopoulos C., 2012, CONTEXTUALISING RES, P65
   Arino A, 2005, EUR MANAG REV, V2, P15, DOI 10.1057/palgrave.emr.1500026
   Babiak K, 2011, CORP SOC RESP ENV MA, V18, P11, DOI 10.1002/csr.229
   Babiak K, 2010, J MANAGE ORGAN, V16, P528, DOI 10.5172/jmo.2010.16.4.528
   Babiak K, 2009, J SPORT MANAGE, V23, P717, DOI 10.1123/jsm.23.6.717
   Bingham T, 2013, VOLUNTAS, V24, P606, DOI 10.1007/s11266-012-9275-z
   Breitbarth T., 2012, CONTEXTUALISING RES, P45
   Breitbarth T, 2011, THUNDERBIRD INT BUS, V53, P721, DOI 10.1002/tie.20448
   Breitbarth T, 2008, EUR SPORT MANAG Q, V8, P179, DOI 10.1080/16184740802024484
   Brown A., 2010, SOCIAL COMMUNITY VAL
   BROWN A., 2006, FOOTBALL ITS COMMUNI
   Conn D., 2005, GUARDIAN, P9
   Conn D., 2011, GUARDIAN, P9
   Cornforth C., 2003, GOVERNANCE PUBLIC NO, P1
   Crane A., 2009, OXFORD HDB CORPORATE, P568
   Davis JH, 1997, ACAD MANAGE REV, V22, P20, DOI 10.5465/AMR.1997.9707180258
   Deloitte, 2012, ANN REV FOOTB FIN
   DIMAGGIO PJ, 1983, AM SOCIOL REV, V48, P147, DOI 10.2307/2095101
   Doherty A, 2013, J SPORT MANAGE, V27, P1
   EXTEJT M, 2004, INT J SPORT MANAGEME, V5, P215
   Ferkins L, 2012, J SPORT MANAGE, V26, P67, DOI 10.1123/jsm.26.1.67
   Ferkins L, 2009, J SPORT MANAGE, V23, P245, DOI 10.1123/jsm.23.3.245
   Freeman E., 1984, STRATEGIC MANAGEMENT
   Garcia B., 2008, THESIS
   Garriga E, 2004, J BUS ETHICS, V53, P51, DOI 10.1023/B:BUSI.0000039399.90587.34
   Giulianotti R., 2002, Journal of Sport & Social Issues, V26, P25, DOI 10.1177/0193723502261003
   Hamil S., 2010, Soccer and Society, V11, P354
   Hamil S., 2010, MANAGING FOOTBALL IN
   Hamil S, 2011, EUR SPORT MANAG Q, V11, P143, DOI 10.1080/16184742.2011.559136
   Herman D., 1981, CORPORATE CONTROL CO
   Hovemann G., 2011, J SPONSORSHIP, V4, P338
   Inoue Y, 2011, J SPORT MANAGE, V25, P531, DOI 10.1123/jsm.25.6.531
   Jenkins H., 2012, ITS NOT JUST GAME CO
   JENSEN MC, 1976, J FINANC ECON, V3, P305, DOI 10.1016/0304-405X(76)90026-X
   Johns G, 2006, ACAD MANAGE REV, V31, P386, DOI 10.5465/AMR.2006.20208687
   Johns G, 2001, J ORGAN BEHAV, V22, P31, DOI 10.1002/job.80
   Johnson JL, 1996, J MANAGE, V22, P409, DOI 10.1016/S0149-2063(96)90031-8
   Kelso P., 2005, GUARDIAN SPORT  1207, P2
   King A., 2003, EUROPEAN RITUAL FOOT
   Kolyperas D., 2011, International Journal of Sport Management and Marketing, V10, P83, DOI 10.1504/IJSMM.2011.043612
   Mace M. L., 1971, DIRECTORMYTH REALI
   McGuire B., 2008, Soccer and Society, V9, P439, DOI 10.1080/14660970802257481
   Mellor G., 2008, Soccer and Society, V9, P313, DOI 10.1080/14660970802008942
   Mitchell RK, 1997, ACAD MANAGE REV, V22, P853, DOI 10.2307/259247
   Morgan S., 2010, J SPONSORSHIP, V4, P15
   MUTH M, 1998, CORPORATE GOVERNANCE, V6, P5, DOI DOI 10.1111/1467-8683.00076
   Neuman LW, 2000, SOCIAL RES METHODS Q
   Parnell D., 2013, Soccer and Society, V14, P35, DOI 10.1080/14660970.2012.692678
   Pratt MG, 2009, ACAD MANAGE J, V52, P856, DOI 10.5465/AMJ.2009.44632557
   Slack R, 2008, J APPL ACCOUNT RES, V9, P17, DOI 10.1108/09675420810886105
   Stiles P, 2001, J MANAGE STUD, V38, P627, DOI 10.1111/1467-6486.00252
   Tacon R., 2007, Managing Leisure, V12, P1, DOI 10.1080/13606710601056422
   Taylor N., 2004, BRIT FOOTBALL SOCIAL, P47
   Trendafilova S., 2013, INT J SPORT MANAGEME, V13, P1, DOI [10.1504/IJSMM.2013.055199, DOI 10.1504/IJSMM.2013.055199]
   Trendafilova S, 2013, SPORT MANAG REV, V16, P298, DOI 10.1016/j.smr.2012.12.006
   Walters G., 2011, BIRKBECK SPORT BUSIN, V4, P1
   Walters G., 2013, ROUTLEDGE HDB SPORT
   Walters G, 2009, J CORPORATE CITIZENS, V35, P81, DOI DOI 10.9774/GLEAF.4700.2009.AU.00008
   Walters G, 2010, J MANAGE ORGAN, V16, P566, DOI 10.5172/jmo.2010.16.4.566
   Walters G, 2009, MANAGE DECIS, V47, P51, DOI 10.1108/00251740910929696
   Yang D., 2005, BUSINESS STRATEGY RE, V16, P38
NR 63
TC 21
Z9 21
U1 0
U2 0
PU EMERALD GROUP PUBLISHING LTD
PI BINGLEY
PA HOWARD HOUSE, WAGON LANE, BINGLEY BD16 1WA, W YORKSHIRE, ENGLAND
SN 2042-678X
EI 2042-6798
J9 SPORT BUS MANAG
JI Sport Bus. Manag.
PY 2013
VL 3
IS 4
SI SI
BP 268
EP 284
DI 10.1108/SBM-05-2013-0009
PG 17
WC Hospitality, Leisure, Sport & Tourism
SC Social Sciences - Other Topics
GA V18EW
UT WOS:000214735700002
DA 2018-12-27
ER

PT J
AU Lega, F
   Mengoni, A
AF Lega, Federico
   Mengoni, Alessandro
TI RETRACTED: Profiling the different needs and expectations of patients
   for population-based medicine: a case study using segmentation analysis
   (Retracted article. See vol. 13, 180, 2013)
SO BMC HEALTH SERVICES RESEARCH
LA English
DT Article; Retracted Publication
ID HEALTH-CARE; CLUSTER-ANALYSIS; SATISFACTION; QUALITY; RELIABILITY;
   CONCORDANCE; HOSPITALS; EMERGENCY; PHYSICIAN; SERVICES
AB Background: This study illustrates an evidence-based method for the segmentation analysis of patients that could greatly improve the approach to population-based medicine, by filling a gap in the empirical analysis of this topic. Segmentation facilitates individual patient care in the context of the culture, health status, and the health needs of the entire population to which that patient belongs. Because many health systems are engaged in developing better chronic care management initiatives, patient profiles are critical to understanding whether some patients can move toward effective self-management and can play a central role in determining their own care, which fosters a sense of responsibility for their own health. A review of the literature on patient segmentation provided the background for this research.
   Method: First, we conducted a literature review on patient satisfaction and segmentation to build a survey. Then, we performed 3,461 surveys of outpatient services users. The key structures on which the subjects' perception of outpatient services was based were extrapolated using principal component factor analysis with varimax rotation. After the factor analysis, segmentation was performed through cluster analysis to better analyze the influence of individual attitudes on the results.
   Results: Four segments were identified through factor and cluster analysis: the "unpretentious," the "informed and supported," the "experts" and the "advanced" patients. Their policies and managerial implications are outlined.
   Conclusions: With this research, we provide the following:
   -a method for profiling patients based on common patient satisfaction surveys that is easily replicable in all health systems and contexts;
   -a proposal for segments based on the results of a broad-based analysis conducted in the Italian National Health System (INHS).
   Segments represent profiles of patients requiring different strategies for delivering health services. Their knowledge and analysis might support an effort to build an effective population-based medicine approach.
C1 [Lega, Federico] Bocconi Univ, Dept Policy Anal & Publ Management, Cergas, I-20136 Milan, Italy.
   [Lega, Federico] Bocconi Univ, Area PMP SDA Bocconi, I-20136 Milan, Italy.
   [Mengoni, Alessandro] ASUR Marche, I-60100 Ancona, Italy.
RP Lega, F (reprint author), Bocconi Univ, Dept Policy Anal & Publ Management, Cergas, Via Rontgen 1, I-20136 Milan, Italy.
EM federico.lega@unibocconi.it
CR Akukwe C, 1999, J R SOC PROMO HEALTH, V119, P42, DOI 10.1177/146642409911900109
   American Medical Association Council on Long Range Planning and Development, 2008, RAD PHYS PERF MEAS S, P1
   Anderson GF, 2000, HEALTH AFFAIR, V19, P191, DOI 10.1377/hlthaff.19.3.191
   [Anonymous], 2008, REG TOSC 2008 2010 2
   BRADFIELD GE, 1975, CAN J BOT, V53, P495, DOI 10.1139/b75-060
   Brusco MJ, 2012, J OPER MANAG, V30, P454, DOI 10.1016/j.jom.2012.06.001
   Calkins E, 1999, NEW WAYS CARE OLDER
   CAMPBELL DT, 1959, PSYCHOL BULL, V56, P81, DOI 10.1037/h0046016
   CAREY RG, 1993, MED CARE, V31, P834, DOI 10.1097/00005650-199309000-00008
   Crow R, 2002, HEALTH TECHNOL ASSES, V6, P32
   Dalzell M D, 1998, Manag Care, V7, P30
   Dargie C, 2000, J FUTURES STUD STRAT, V2, P401
   DEMPSTER AP, 1977, J ROY STAT SOC B MET, V39, P1
   FORGY EW, 1965, BIOMETRICS, V21, P768
   Gabbott M, 1994, J Health Care Mark, V14, P28
   Garratt AM, 2005, QUAL SAF HEALTH CARE, V14, P433, DOI 10.1136/qshc.2004.014423
   Greenlick M R, 1995, HMO Pract, V9, P120
   GREENLICK MR, 1992, JAMA-J AM MED ASSOC, V267, P1645, DOI 10.1001/jama.267.12.1645
   HALL JA, 1990, SOC SCI MED, V30, P811, DOI 10.1016/0277-9536(90)90205-7
   Hartigan J. A., 1979, Applied Statistics, V28, P100, DOI 10.2307/2346830
   Hekkert KD, 2009, SOC SCI MED, V69, P68, DOI 10.1016/j.socscimed.2009.04.016
   Henley E, 1999, Fam Med, V31, P501
   Hutchison B, 2003, CAN MED ASSOC J, V168, P977
   Iacobucci D, 2003, J CONSUM PSYCHOL, V13, P478, DOI 10.1207/S15327663JCP1304_14
   Institute for the Future, 2004, AM LIF SURV
   Institute for the Future, 2003, HLTH NUTR ONL SURV
   Institute for the Future, 2005, PERS HLTH EC MAPP CO
   ISTAT - National Institute for Statistics, 2010, ANN REPORT
   Johns MME, 2008, ACAD MED, V83, P706, DOI 10.1097/ACM.0b013e31817eb579
   Johnson RA, 2007, APPL MULTIVARIATE ST
   Judge Institute of Management, 2002, HOP FEARS FUT HLTH S
   Kaldenberg DO, 1999, HEALTH CARE MANAGE R, V24, P73
   Kirsner RS, 1998, AM J MANAG CARE, V4, P1571
   Leese M, 2001, CLUSTER ANAL
   Lega F, 2005, ORG DESIGN DEV HLTH
   Lega F, 2008, HEALTH POLICY, V88, P326, DOI 10.1016/j.healthpol.2008.04.005
   Lega F, 2012, J HEALTHC MANAG, V57, P17
   Marinker M, 1997, BRIT MED J, V314, P747, DOI 10.1136/bmj.314.7082.747
   MILLIGAN GW, 1980, PSYCHOMETRIKA, V45, P325, DOI 10.1007/BF02293907
   Milligan GW, 1996, CLUSTERING CLASSIFIC
   Mooi E, 2011, CONCISE GUIDE TO MARKET RESEARCH: THE PROCESS, DATA, AND METHODS USING IBM SPSS STATISTICS, P1, DOI 10.1007/978-3-642-12541-6
   Morrison M, 2003, HLTH MARK Q, V20, P4
   Mullen PD, 1997, BRIT MED J, V314, P691, DOI 10.1136/bmj.314.7082.691
   NUTTING PA, 1987, J FAM PRACTICE, V24, P83
   PUNJ G, 1983, J MARKETING RES, V20, P134, DOI 10.2307/3151680
   Rivo M L, 1998, Fam Pract Manag, V5, P37
   Romesburg C., 2004, CLUSTER ANAL RES
   Roos NP, 1996, MILBANK Q, V74, P3, DOI 10.2307/3350429
   Royal Pharmaceutical Society of Great Britain, 1997, COMPL CONC SHAR GOAL
   Rust G, 1997, HOSP PRACT, V32, P64, DOI 10.1080/21548331.1997.11443508
   Saila T, 2008, J EVAL CLIN PRACT, V14, P148, DOI 10.1111/j.1365-2753.2007.00824.x
   Schulz E, 2004, HEALTH POLICY, V67, P57, DOI 10.1016/S0168-8510(03)00083-6
   Sheth J, 1985, GROUP PRACT J, V34
   Sheth J N, 1985, Group Pract J, V34, P51
   Sitzia J, 1997, SOC SCI MED, V45, P1829, DOI 10.1016/S0277-9536(97)00128-7
   Smith W, 1997, AUST NZ J PUBL HEAL, V21, P127, DOI 10.1111/j.1467-842X.1997.tb01671.x
   Snyderman R, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-2-104
   Snyderman R, 2003, ACAD MED, V78, P1079, DOI 10.1097/00001888-200311000-00002
   Snyderman R, 2008, ACAD MED, V83, P707, DOI 10.1097/ACM.0b013e31817ec800
   Street RL, 2008, ANN FAM MED, V6, P198, DOI 10.1370/afm.821
   Valery PC, 2000, ANN EPIDEMIOL, V10, P504, DOI 10.1016/S1047-2797(00)00070-3
   VELDMAN DJ, 1967, FORTRAN PROGRAMMING, P308
   Von Korff M, 1997, ANN INTERN MED, V127, P1097, DOI 10.7326/0003-4819-127-12-199712150-00008
   Wagner E H, 1996, Manag Care Q, V4, P12
   Wagner EH, 1996, MILBANK Q, V74, P511, DOI 10.2307/3350391
   Wanless D., 2002, SECURING OUR FUTURE
   WARD JH, 1963, J AM STAT ASSOC, V58, P236, DOI 10.2307/2282967
   WHO, 2006, WORLD HLTH REP
   *WHO REG OFF EUR, 1999, HLTH 21 HLTH ALL 21
NR 69
TC 3
Z9 3
U1 1
U2 27
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1472-6963
J9 BMC HEALTH SERV RES
JI BMC Health Serv. Res.
PD DEC 21
PY 2012
VL 12
AR 473
DI 10.1186/1472-6963-12-473
PG 12
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA 091GG
UT WOS:000315036800001
PM 23256543
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Maitra, M
   Cano, CA
   Garcia, CK
AF Maitra, Meenakshi
   Cano, Christopher A.
   Garcia, Christine Kim
TI RETRACTED: Mutant surfactant A2 proteins associated with familial
   pulmonary fibrosis and lung cancer induce TGF-beta 1 secretion
   (Retracted article. See vol. 112, pg. E5222, 2015)
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article; Retracted Publication
DE genetics; idiopathic pulmonary fibrosis; IPF
ID ENDOPLASMIC-RETICULUM STRESS; EPITHELIAL-MESENCHYMAL TRANSITION;
   TGF-BETA; TRANSFORMING GROWTH-FACTOR-BETA-1; CASPASE-3 ACTIVATION;
   EXTRACELLULAR-MATRIX; CELLS; MUTATIONS; MICE; TELOMERASE
AB Mutations in the genes encoding the lung surfactant proteins are found in patients with interstitial lung disease and lung cancer, but their pathologic mechanism is poorly understood. Here we show that bronchoalveolar lavage fluid from humans heterozygous for a missense mutation in the gene encoding surfactant protein (SP)-A2 (SFTPA2) contains more TGF-beta 1 than control samples. Expression of mutant SP-A2 in lung epithelial cells leads to secretion of latent TGF-beta 1, which is capable of autocrine and paracrine signaling. TGF-beta 1 secretion is not observed in lung epithelial cells expressing the common SP-A2 variants or other misfolded proteins capable of increasing cellular endoplasmic reticulum stress. Activation of the unfolded protein response is necessary for maximal TGF-beta 1 secretion because gene silencing of the unfolded protein response transducers leads to an similar to 50% decrease in mutant SP-A2-mediated TGF-beta 1 secretion. Expression of the mutant SP-A2 proteins leads to the coordinated increase in gene expression of TGF-beta 1 and two TGF-beta 1-binding proteins, LTBP-1 and LTBP-4; expression of the latter is necessary for secretion of this cytokine. Inhibition of the TGF-beta autocrine positive feedback loop by a pan-TGF-beta-neutralizing antibody, a TGF-beta receptor antagonist, or LTBP gene silencing results in the reversal of TGF-beta-mediated epithelial-to-mesenchymal transition and cell death. Because secretion of latent TGF-beta 1 is induced specifically by mutant SP-A2 proteins, therapeutics targeted to block this pathway may be especially beneficial for this molecularly defined subgroup of patients.
C1 [Maitra, Meenakshi; Cano, Christopher A.; Garcia, Christine Kim] Univ Texas SW Med Ctr Dallas, Eugene McDermott Ctr Human Growth & Dev, Dallas, TX 75229 USA.
   [Garcia, Christine Kim] Univ Texas SW Med Ctr Dallas, Dept Internal Med, Div Pulm & Crit Care Med, Dallas, TX 75229 USA.
RP Garcia, CK (reprint author), Univ Texas SW Med Ctr Dallas, Eugene McDermott Ctr Human Growth & Dev, Dallas, TX 75229 USA.
EM christine.garcia@utsouthwestern.edu
FU National Institutes of Health [R01 HL093096]; Doris Duke Charitable
   Foundation; University of Texas Southwestern Medical Scientist Training
   Program; National Heart, Lung and Blood Institute
FX We thank J. Goldstein and J. Minna for cell lines, P. Thomas for the
   cystic fibrosis transmembrane regulator constructs and antibody, H.
   Hobbs for the PCSK9 constructs, J. Horton for the PCSK9 antibody, J.
   Garcia for the pLenti6 DsRed-shRNA expression vector, C.-H. Heldin for
   the anti-LTBP antibody, J. Kozlitina for statistical assistance, J.
   Minna, P. Thomas, and R. Brekken for helpful discussions, and W. Wei and
   Z. Hu for excellent technical support. This work was supported by
   National Institutes of Health Grant R01 HL093096 and the Doris Duke
   Charitable Foundation. C.C. is supported by the University of Texas
   Southwestern Medical Scientist Training Program and a National Heart,
   Lung and Blood Institute research supplement to promote diversity in
   health-related research.
CR Armanios MY, 2007, NEW ENGL J MED, V356, P1317, DOI 10.1056/NEJMoa066157
   Bartoszewski R, 2008, AM J RESP CELL MOL, V39, P448, DOI 10.1165/rcmb.2008-0065OC
   Bonniaud P, 2004, J IMMUNOL, V173, P2099, DOI 10.4049/jimmunol.173.3.2099
   Bridges JP, 2003, J BIOL CHEM, V278, P52739, DOI 10.1074/jbc.M309599200
   BROEKELMANN TJ, 1991, P NATL ACAD SCI USA, V88, P6642, DOI 10.1073/pnas.88.15.6642
   de Leon AD, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010680
   Hiwatari N, 1997, TOHOKU J EXP MED, V181, P285, DOI 10.1620/tjem.181.285
   Kim KK, 2006, P NATL ACAD SCI USA, V103, P13180, DOI 10.1073/pnas.0605669103
   Kim KK, 2009, J CLIN INVEST, V119, P213, DOI 10.1172/JCI36940
   KIM SJ, 1989, J BIOL CHEM, V264, P7041
   Lawson WE, 2011, P NATL ACAD SCI USA, V108, P10562, DOI 10.1073/pnas.1107559108
   Lepparanta O, 2012, CELL TISSUE RES, V348, P491, DOI 10.1007/s00441-012-1385-9
   Li M, 2011, J CLIN INVEST, V121, P277, DOI 10.1172/JCI42090
   Maitra M, 2010, J BIOL CHEM, V285, P22103, DOI 10.1074/jbc.M110.121467
   Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001
   MIYAZONO K, 1991, EMBO J, V10, P1091, DOI 10.1002/j.1460-2075.1991.tb08049.x
   Mulugeta S, 2005, AM J RESP CELL MOL, V32, P521, DOI 10.1165/rcmb.2005-0009OC
   Mulugeta S, 2007, AM J PHYSIOL-LUNG C, V293, pL720, DOI 10.1152/ajplung.00025.2007
   Munger JS, 1999, CELL, V96, P319, DOI 10.1016/S0092-8674(00)80545-0
   Neptune ER, 2003, NAT GENET, V33, P407, DOI 10.1038/ng1116
   Raghu G, 2011, AM J RESP CRIT CARE, V183, P788, DOI 10.1164/rccm.2009-040GL
   Ramirez RD, 2004, CANCER RES, V64, P9027, DOI 10.1158/0008-5472.CAN-04-3703
   Roberson EC, 2012, AM J RESP CELL MOL, V46, P573, DOI 10.1165/rcmb.2010-0460OC
   Sime PJ, 1997, J CLIN INVEST, V100, P768, DOI 10.1172/JCI119590
   Solovyan VT, 2006, J CELL PHYSIOL, V207, P445, DOI 10.1002/jcp.20607
   ten Dijke P, 2007, NAT REV MOL CELL BIO, V8, P857, DOI 10.1038/nrm2262
   Tsakiri KD, 2007, P NATL ACAD SCI USA, V104, P7552, DOI 10.1073/pnas.0701009104
   Wang WJ, 2003, J CELL SCI, V116, P683, DOI 10.1242/jcs.00267
   Wang Y, 2009, AM J HUM GENET, V84, P52, DOI 10.1016/j.ajhg.2008.11.010
   Willis BC, 2005, AM J PATHOL, V166, P1321, DOI 10.1016/S0002-9440(10)62351-6
   Zhao ZZ, 2006, AM J HUM GENET, V79, P514, DOI 10.1086/507488
   Zhong Q, 2011, AM J RESP CELL MOL, V45, P498, DOI 10.1165/rcmb.2010-0347OC
NR 32
TC 24
Z9 24
U1 1
U2 9
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD DEC 18
PY 2012
VL 109
IS 51
BP 21064
EP 21069
DI 10.1073/pnas.1217069110
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 065BZ
UT WOS:000313123700065
PM 23223528
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Ye, YP
   Fehr, KT
   Faulstich, M
   Wolf, G
AF Ye, Yaping
   Fehr, Karl Thomas
   Faulstich, Martin
   Wolf, Gerhard
TI RETRACTED: Chemical Densification of Plasma Sprayed Yttria Stabilized
   Zirconia (YSZ) Coatings for High Temperature Wear and Corrosion
   Resistance (Retracted article. See vol. 267, pg. 229, 2013)
SO APPLIED SURFACE SCIENCE
LA English
DT Correction; Retracted Publication
C1 [Ye, Yaping; Fehr, Karl Thomas; Faulstich, Martin; Wolf, Gerhard] Univ Munich, Sekt Mineral Petr & Geochem, Dept Geo & Umweltwissensch, D-80539 Munich, Germany.
   [Ye, Yaping; Fehr, Karl Thomas; Faulstich, Martin; Wolf, Gerhard] AZT Entwicklungszentrum, Sulzbach Rosenberg, Germany.
RP Ye, YP (reprint author), Univ Munich, Sekt Mineral Petr & Geochem, Dept Geo & Umweltwissensch, D-80539 Munich, Germany.
EM yeyaping1010@hotmail.com
CR Ye YP, 2012, APPL SURF SCI, V263, P827, DOI 10.1016/j.apsusc.2012.08.114
NR 1
TC 2
Z9 2
U1 3
U2 29
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0169-4332
EI 1873-5584
J9 APPL SURF SCI
JI Appl. Surf. Sci.
PD DEC 15
PY 2012
VL 263
BP 827
EP 827
DI 10.1016/j.apsusc.2012.08.114
PG 1
WC Chemistry, Physical; Materials Science, Coatings & Films; Physics,
   Applied; Physics, Condensed Matter
SC Chemistry; Materials Science; Physics
GA 039BJ
UT WOS:000311217500129
DA 2018-12-27
ER

PT J
AU Jia, J
   Zhang, W
   Liu, JY
   Chen, G
   Liu, H
   Zhong, HY
   Liu, B
   Cai, Y
   Zhang, JL
   Zhao, YF
AF Jia, Jun
   Zhang, Wei
   Liu, Jian-Ying
   Chen, Gang
   Liu, Hui
   Zhong, Hao-Yan
   Liu, Bing
   Cai, Yu
   Zhang, Jia-Li
   Zhao, Yi-Fang
TI RETRACTED: Epithelial Mesenchymal Transition Is Required for Acquisition
   of Anoikis Resistance and Metastatic Potential in Adenoid Cystic
   Carcinoma (Retracted article. See vol. 9, e108117, 2014)
SO PLOS ONE
LA English
DT Article; Retracted Publication
ID CIRCULATING TUMOR-CELLS; BREAST-CANCER PATIENTS; TRANSCRIPTION FACTOR
   SLUG; HEPATOCYTE GROWTH-FACTOR; STEM-CELL; PERIPHERAL-BLOOD;
   SALIVARY-GLAND; E-CADHERIN; EGFR; PATHWAYS
AB Human adenoid cystic carcinoma (ACC) is characterized by diffused invasion of the tumor into adjacent organs and early distant metastasis. Anoikis resistance and epithelial mesenchymal transition (EMT) are considered prerequisites for cancer cells to metastasize. Exploring the relationship between these processes and their underlying mechanism of action is a promising way to better understand ACC tumors. We initially established anoikis-resistant sublines of ACC cells; the variant cells revealed a mesenchymal phenotype through Slug-mediated EMT-like transformation and displayed enhanced metastatic potential both in vitro and in vivo. Suppression of EMT by knockdown of Slug significantly impaired anoikis resistance, migration, and invasion of the variant cells. With overexpression of Slug and Twist, we determined that induction of EMT in normal ACC cells could prevent anoikis, albeit partially. These findings strongly suggest that EMT is indispensable in anoikis resistance, at least in ACC cells. Furthermore, we found that the EGFR/PI3K/Akt pathway acts as the common regulator for EMT-like transformation and anoikis resistance, as confirmed by their specific inhibitors. Gefitinib and LY294003 restored the sensibilities of anoikis-resistant cells to anoikis and simultaneously impaired their metastatic potential. In addition, the results from our in vivo model of metastasis suggest that pretreatment with gefitinib promotes mouse survival by alleviating pulmonary metastasis. Most importantly, immunohistochemistry of human ACC specimens showed a correlation between the overexpression of Slug and EGFR staining. This study has demonstrated that Slug-mediated EMT-like transformation is required by human ACC cells to achieve anoikis resistance and their metastatic potential. Targeting the EGFR/PI3K/Akt pathway holds potential as a preventive strategy against distant metastasis of ACC.
C1 [Jia, Jun; Zhang, Wei; Liu, Jian-Ying; Chen, Gang; Liu, Hui; Zhong, Hao-Yan; Cai, Yu; Zhang, Jia-Li; Zhao, Yi-Fang] Wuhan Univ, Sch & Hosp Stomatol, Minist Educ, State Key Lab Breeding Base Basic Sci Stomatol, Wuhan 430072, Peoples R China.
   [Jia, Jun; Zhang, Wei; Liu, Jian-Ying; Chen, Gang; Liu, Hui; Zhong, Hao-Yan; Cai, Yu; Zhang, Jia-Li; Zhao, Yi-Fang] Wuhan Univ, Sch & Hosp Stomatol, Minist Educ, Key Lab Oral Biomed, Wuhan 430072, Peoples R China.
   [Jia, Jun; Zhang, Wei; Chen, Gang; Zhong, Hao-Yan; Liu, Bing; Cai, Yu; Zhao, Yi-Fang] Wuhan Univ, Sch & Hosp Stomatol, Dept Oral & Maxillofacial Surg, Wuhan 430072, Peoples R China.
   [Zhang, Jia-Li] Wuhan Univ, Sch & Hosp Stomatol, Dept Pathol, Wuhan 430072, Peoples R China.
RP Zhao, YF (reprint author), Wuhan Univ, Sch & Hosp Stomatol, Minist Educ, State Key Lab Breeding Base Basic Sci Stomatol, Wuhan 430072, Peoples R China.
EM yifang@whuss.com
FU National Natural Science Foundation of China [81102054, 30973330,
   81170977]
FX This work was supported by the grants from The National Natural Science
   Foundation of China (81102054, 30973330, 81170977). The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Baker MK, 2003, CLIN CANCER RES, V9, P4865
   Bonnomet A, 2011, ONCOGENE
   Catalano A, 2004, J BIOL CHEM, V279, P46706, DOI 10.1074/jbc.M406696200
   Chiarugi P, 2008, BIOCHEM PHARMACOL, V76, P1352, DOI 10.1016/j.bcp.2008.07.023
   Claperon A, 2011, ONCOGENE
   Danila DC, 2011, CANCER J, V17, P438, DOI 10.1097/PPO.0b013e31823e69ac
   Dhasarathy A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026514
   Dong L, 2011, J DENT RES, V90, P804, DOI 10.1177/0022034511401407
   Ellington CL, 2012, CANCER
   Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098
   Gaafar RM, 2011, EUR J CANCER, V47, P2331, DOI 10.1016/j.ejca.2011.06.045
   Gan Y, 2010, ONCOGENE, V29, P4947, DOI 10.1038/onc.2010.240
   Grande M, 2002, J CELL SCI, V115, P4227, DOI 10.1242/jcs.00091
   Guadamillas MC, 2011, J CELL SCI, V124, P3189, DOI 10.1242/jcs.072165
   Guan XF, 1997, INT J ORAL MAX SURG, V26, P116, DOI 10.1016/S0901-5027(05)80830-6
   Guo WJ, 2012, CELL, V148, P1015, DOI 10.1016/j.cell.2012.02.008
   Hung CM, 2011, J AGR FOOD CHEM, V59, P9683, DOI 10.1021/jf2021489
   Ito FA, 2009, ANAL QUANT CYTOL, V31, P280
   Jiang JA, 2010, ORAL SURG ORAL MED O, V110, P764, DOI 10.1016/j.tripleo.2010.06.015
   Kallergi G, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2896
   Kang M, 2012, BIOCH J
   Kasimir-Bauer S, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3099
   Khan AJ, 2001, INT J CANCER, V96, P149, DOI 10.1002/ijc.1013
   Komatsubara Hideki, 2005, Kobe Journal of Medical Sciences, V51, P67
   Kumar S, 2011, MOL CELL BIOL, V31, P4036, DOI 10.1128/MCB.01342-10
   Kurrey NK, 2009, STEM CELLS, V27, P2059, DOI 10.1002/stem.154
   Liotta LA, 2004, NATURE, V430, P973, DOI 10.1038/430973a
   Pallier K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029954
   Park S, 2011, BIOCHEM BIOPH RES CO, V407, P680, DOI 10.1016/j.bbrc.2011.03.075
   Paterlini-Brechot P, 2007, CANCER LETT, V253, P180, DOI 10.1016/j.canlet.2006.12.014
   Paz-Ares L, 2010, J CELL MOL MED, V14, P51, DOI 10.1111/j.1582-4934.2009.00991.x
   Perez-Losada J, 2003, ONCOGENE, V22, P4205, DOI 10.1038/sj.onc.1206467
   Persson M, 2009, P NATL ACAD SCI USA, V106, P18740, DOI 10.1073/pnas.0909114106
   Pozharskaya V, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007559
   Rhim AD, 2012, CELL, V148, P349, DOI 10.1016/j.cell.2011.11.025
   Riethdorf S, 2008, PATHOBIOLOGY, V75, P140, DOI 10.1159/000123852
   Smit MA, 2011, ONCOGENE, V30, P3735, DOI 10.1038/onc.2011.96
   Smit MA, 2009, MOL CELL BIOL, V29, P3722, DOI 10.1128/MCB.01164-08
   Sun Q, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031093
   Sun ZJ, 2011, MOL PHARMACOL, V79, P106, DOI 10.1124/mol.110.066910
   Sun ZJ, 2010, APOPTOSIS, V15, P850, DOI 10.1007/s10495-010-0497-5
   Tang YL, 2010, J ORAL PATHOL MED, V39, P775, DOI 10.1111/j.1600-0714.2010.00913.x
   Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007
   Toiyama Y, 2012, INT J CANCER, V130, P2912, DOI 10.1002/ijc.26330
   Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024
   Zhou CC, 2012, J ORAL PATHOL MED, V41, P424, DOI 10.1111/j.1600-0714.2011.01114.x
   Zuo JH, 2011, J CELL BIOCHEM, V112, P2508, DOI 10.1002/jcb.23175
NR 47
TC 25
Z9 25
U1 1
U2 23
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 14
PY 2012
VL 7
IS 12
AR e51549
DI 10.1371/journal.pone.0051549
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 055AJ
UT WOS:000312386800051
PM 23272116
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Narayan, N
   Lee, IH
   Borenstein, R
   Sun, JH
   Wong, R
   Tong, G
   Fergusson, MM
   Liu, J
   Rovira, II
   Cheng, HL
   Wang, GH
   Gucek, M
   Lombard, D
   Alt, FW
   Sack, MN
   Murphy, E
   Cao, L
   Finkel, T
AF Narayan, Nisha
   Lee, In Hye
   Borenstein, Ronen
   Sun, Junhui
   Wong, Renee
   Tong, Guang
   Fergusson, Maria M.
   Liu, Jie
   Rovira, Ilsa I.
   Cheng, Hwei-Ling
   Wang, Guanghui
   Gucek, Marjan
   Lombard, David
   Alt, Fredrick W.
   Sack, Michael N.
   Murphy, Elizabeth
   Cao, Liu
   Finkel, Toren
TI RETRACTED: The NAD-dependent deacetylase SIRT2 is required for
   programmed necrosis (Retracted article. See vol. 506, pg. 516, 2014)
SO NATURE
LA English
DT Article; Retracted Publication
ID INDUCED CELL-DEATH; RIP1; APOPTOSIS; AUTOPHAGY; PHOSPHORYLATION;
   IDENTIFICATION; NECROPTOSIS; ACTIVATION; MECHANISMS; REGULATOR
AB Although initially viewed as unregulated, increasing evidence suggests that cellular necrosis often proceeds through a specific molecular program. In particular, death ligands such as tumour necrosis factor (TNF)-alpha activate necrosis by stimulating the formation of a complex containing receptor-interacting protein 1 (RIP1) and receptor-interacting protein 3 (RIP3). Relatively little is known regarding how this complex formation is regulated. Here, we show that the NAD-dependent deacetylase SIRT2 binds constitutively to RIP3 and that deletion or knockdown of SIRT2 prevents formation of the RIP1-RIP3 complex in mice. Furthermore, genetic or pharmacological inhibition of SIRT2 blocks cellular necrosis induced by TNF-alpha. We further demonstrate that RIP1 is a critical target of SIRT2-dependent deacetylation. Using gain- and loss-of-function mutants, we demonstrate that acetylation of RIP1 lysine 530 modulates RIP1-RIP3 complex formation and TNF-alpha-stimulated necrosis. In the setting of ischaemia-reperfusion injury, RIP1 is deacetylated in a SIRT2-dependent fashion. Furthermore, the hearts of Sirt2(-/-) mice, or wild-type mice treated with a specific pharmacological inhibitor of SIRT2, show marked protection from ischaemic injury. Taken together, these results implicate SIRT2 as an important regulator of programmed necrosis and indicate that inhibitors of this deacetylase may constitute a novel approach to protect against necrotic injuries, including ischaemic stroke and myocardial infarction.
C1 [Narayan, Nisha; Lee, In Hye; Borenstein, Ronen; Fergusson, Maria M.; Liu, Jie; Rovira, Ilsa I.; Sack, Michael N.; Finkel, Toren] NHLBI, Ctr Mol Med, NIH, Bethesda, MD 20892 USA.
   [Sun, Junhui; Wong, Renee; Tong, Guang; Murphy, Elizabeth] NHLBI, Syst Biol Ctr, NIH, Bethesda, MD 20892 USA.
   [Tong, Guang] Fourth Mil Med Univ, Xijing Hosp, Dept Cardiovasc Surg, Xian 710032, Peoples R China.
   [Cheng, Hwei-Ling; Alt, Fredrick W.] Childrens Hosp, Howard Hughes Med Inst, Program Cellular & Mol Med, Boston, MA 02115 USA.
   [Cheng, Hwei-Ling; Alt, Fredrick W.] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA.
   [Cheng, Hwei-Ling; Alt, Fredrick W.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA.
   [Wang, Guanghui; Gucek, Marjan] NHLBI, Prote Core, NIH, Bethesda, MD 20892 USA.
   [Lombard, David] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA.
   [Lombard, David] Univ Michigan, Inst Gerontol, Ann Arbor, MI 48109 USA.
   [Cao, Liu] China Med Univ, Key Lab Med Cell Biol, Shenyang 110001, Peoples R China.
RP Finkel, T (reprint author), NHLBI, Ctr Mol Med, NIH, Bldg 10, Bethesda, MD 20892 USA.
EM finkelt@nih.gov
OI Lombard, David/0000-0002-4292-0185
FU NIH
FX We are grateful to M. Lenardo for providing the RIP1-deficient Jurkat
   cell line, X. Wang for the Flag-tagged RIP3 plasmid and Y. Zhao for
   helpful discussions. This work was supported by NIH Intramural funds.
   F.W.A. is an Investigator of the Howard Hughes Medical Institute.
CR Beirowski B, 2011, P NATL ACAD SCI USA, V108, pE952, DOI 10.1073/pnas.1104969108
   Cho Y, 2009, CELL, V137, P1112, DOI 10.1016/j.cell.2009.05.037
   Christofferson DE, 2010, CURR OPIN CELL BIOL, V22, P263, DOI 10.1016/j.ceb.2009.12.003
   Csonka C, 2010, J PHARMACOL TOX MET, V61, P163, DOI 10.1016/j.vascn.2010.02.014
   Degterev A, 2005, NAT CHEM BIOL, V1, P112, DOI 10.1038/nchembio711
   Degterev A, 2008, NAT CHEM BIOL, V4, P313, DOI 10.1038/nchembio.83
   Fearns C, 2006, J BIOL CHEM, V281, P34592, DOI 10.1074/jbc.M604019200
   Finkel T, 2009, NATURE, V460, P587, DOI 10.1038/nature08197
   Gao E, 2010, CIRC RES, V107, P1445, DOI 10.1161/CIRCRESAHA.110.223925
   He SD, 2009, CELL, V137, P1100, DOI 10.1016/j.cell.2009.05.021
   Houtkooper RH, 2010, ENDOCR REV, V31, P194, DOI 10.1210/er.2009-0026
   Kim HS, 2011, CANCER CELL, V20, P487, DOI 10.1016/j.ccr.2011.09.004
   Lee IH, 2008, P NATL ACAD SCI USA, V105, P3374, DOI 10.1073/pnas.0712145105
   Lee IH, 2009, J BIOL CHEM, V284, P6322, DOI 10.1074/jbc.M807135200
   Li A, 2006, BIOCHEM BIOPH RES CO, V350, P818, DOI 10.1016/j.bbrc.2006.08.199
   Lim SY, 2007, CARDIOVASC DRUG THER, V21, P467, DOI 10.1007/s10557-007-6067-6
   Mahul-Mellier AL, 2012, BBA-MOL CELL RES, V1823, P1353, DOI 10.1016/j.bbamcr.2012.05.022
   McComb S, 2012, CELL DEATH DIFFER, V19, P1791, DOI 10.1038/cdd.2012.59
   Nemoto S, 2005, J BIOL CHEM, V280, P16456, DOI 10.1074/jbc.M501485200
   North BJ, 2003, MOL CELL, V11, P437, DOI 10.1016/S1097-2765(03)00038-8
   North BJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000784
   Outeiro TF, 2007, SCIENCE, V317, P516, DOI 10.1126/science.1143780
   Sun JH, 2007, CIRC RES, V101, P1155, DOI 10.1161/CIRCRESAHA.107.155879
   Sun XQ, 2002, J BIOL CHEM, V277, P9505, DOI 10.1074/jvc.M109488200
   Thomas M, 1996, ONCOGENE, V13, P471
   Ting AT, 1996, EMBO J, V15, P6189, DOI 10.1002/j.1460-2075.1996.tb01007.x
   Vandenabeele P, 2010, NAT REV MOL CELL BIO, V11, P700, DOI 10.1038/nrm2970
   Vucic D, 2011, NAT REV MOL CELL BIO, V12, P439, DOI 10.1038/nrm3143
   Yuan JY, 2010, GENE DEV, V24, P2592, DOI 10.1101/gad.1984410
   Zhang DW, 2009, SCIENCE, V325, P332, DOI 10.1126/science.1172308
   Zhao Y, 2010, NAT CELL BIOL, V12, P665, DOI 10.1038/ncb2069
   Zheng LX, 2006, MOL CELL BIOL, V26, P3505, DOI 10.1128/MCB.26.9.3505-3513.2006
NR 32
TC 95
Z9 99
U1 5
U2 100
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD DEC 13
PY 2012
VL 492
IS 7428
BP 199
EP +
DI 10.1038/nature11700
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 053GM
UT WOS:000312259300031
PM 23201684
DA 2018-12-27
ER

PT J
AU El Fatemi, H
   Chahbouni, S
   Jayi, S
   Moumna, K
   Melhouf, MA
   Bannani, A
   Mesbahi, O
   Amarti, A
AF El Fatemi, Hinde
   Chahbouni, Sanae
   Jayi, Sofia
   Moumna, Kaoutar
   Melhouf, My Abdelilah
   Bannani, Abdelaziz
   Mesbahi, Omar
   Amarti, Afaf
TI RETRACTED: Luminal B tumors are the most frequent molecular subtype in
   breast cancer of North African women: an immunohistochemical profile
   study from Morocco (Retracted article. See vol. 8, pg. 127, 2013)
SO DIAGNOSTIC PATHOLOGY
LA English
DT Article; Retracted Publication
DE Breast cancer; Molecular classification; Luminal B subtype; Staging;
   Antibodies; Immunohistochemistry
ID GROWTH-FACTOR RECEPTOR; CLINICAL IMPLICATIONS; LOBULAR NEOPLASIA; TIGHT
   JUNCTIONS; PHASE-II; CARCINOMA; GEFITINIB; EXPRESSION; PORTRAITS;
   APOPTOSIS
AB Background: Breast cancer may be classified into luminal A, luminal B, HER2+/ER-, basal-like and normal-like subtypes based on gene expression profiling or immunohistochemical (IHC) characteristics. The aim of our study is to show the molecular profile characteristic of breast cancer in the North African population of Morocco. This work showed preliminary results and correlations with clinicopathological and histological parameters. Three hundred and ninety primary breast carcinomas tumor tissues were immunostained for ER, PR, HER2, CK5/6, CK8/18 and Ki67 using paraffin tissue.
   Methods: We reviewed 390 cases of breast cancer diagnosed on January 2008 to December 2011 at the Department of pathology, Hassan II teaching hospital, Fez, Morocco. Age, size tumor, metastatic profile, node involvement profile, histological type and immunohistochemical profile were studied.
   Results: The average age was 46 years; our patients were diagnosed late with a high average tumor size. Luminal B subtype was more prevalent (41.8%), followed by luminal A (30.5%), basal-like (13, 6%), Her2-overexpressing (9, 2%), and unclassified subtype (4.9%).
   Conclusion: This study showed that molecular classification and biological profile may be different according to geographical distribution, to encourage further studies to know the genomic profile of tumors and the environment.
   Virtual slide: http://www.diagnosticpathology.diagnomx.eu/vs/1675272504826544
C1 [El Fatemi, Hinde; Chahbouni, Sanae; Moumna, Kaoutar; Melhouf, My Abdelilah; Amarti, Afaf] Hassan II Teaching Hosp, Dept Pathol, Fes, Morocco.
   [Jayi, Sofia; Bannani, Abdelaziz] Hassan II Teaching Hosp, Dept Gynecol, Fes, Morocco.
   [Mesbahi, Omar] Hassan II Teaching Hosp, Dept Oncol, Fes, Morocco.
RP El Fatemi, H (reprint author), Hassan II Teaching Hosp, Dept Pathol, Fes, Morocco.
EM hinde0012@hotmail.com
CR Abdel-Fatah TMA, 2007, AM J SURG PATHOL, V31, P417, DOI 10.1097/01.pas.0000213368.41251.b9
   American Joint Committee on Cancer, 2010, AJCC CANC STAGING HD
   Arvydas L, 2012, DIAGN PATHOL, V7, P27
   Baselga J, 2005, J CLIN ONCOL, V23, P5323, DOI 10.1200/JCO.2005.08.326
   Bhargava R, 2009, INT J CLIN EXP PATHO, V2, P444
   Bockbrader KM, 2005, ONCOGENE, V24, P7381, DOI 10.1038/sj.onc.1208888
   Bratthauer GL, 2002, VIRCHOWS ARCH, V440, P134, DOI 10.1007/s00428-001-0541-5
   Ciardiello F, 2006, BRIT J CANCER, V94, P1604, DOI 10.1038/sj.bjc.6603141
   dos Santos PB, 2012, DIAGN PATHOL, V7, DOI 10.1186/1746-1596-7-104
   ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x
   Gomes DS, 2011, DIAGN PATHOL, V6, DOI 10.1186/1746-1596-6-74
   Kobayashi S, 2005, NEW ENGL J MED, V352, P786, DOI 10.1056/NEJMoa044238
   Kristensen VN, 2011, EMBO MOL MED, V3, P183, DOI 10.1002/emmm.201100128
   Kurebayashi J, 2007, BREAST, V16, pS72, DOI 10.1016/j.breast.2007.07.017
   MariadelasMercedes N, 2012, DIAGN PATHOL, V7, P73
   Matter K, 2003, NAT REV MOL CELL BIO, V4, P225, DOI 10.1038/nrm1055
   Peng XH, 2007, MOL PHARMACOL, V71, P101, DOI 10.1124/mol.106.027367
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Prat A, 2012, NAT REV CLIN ONCOL, V9, P48, DOI 10.1038/nrclinonc.2011.178
   Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635
   Ross JS, 2004, MOL CELL PROTEOMICS, V3, P379, DOI 10.1074/mcp.R400001-MCP200
   Sorlie T, 2004, EUR J CANCER, V40, P2667, DOI 10.1016/j.ejca.2004.08.021
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   Tang P, 2008, HUM PATHOL, V39, P506, DOI 10.1016/j.humpath.2007.09.005
   Tavassoli FA, 2003, PATHOLOGY GENETICS T
   Tsuda H, 2005, CANCER SCI, V96, P48, DOI 10.1111/j.1349-7006.2005.00009.x
   Tsukita S, 2001, NAT REV MOL CELL BIO, V2, P285, DOI 10.1038/35067088
   Tsukita S, 1999, TRENDS CELL BIOL, V9, P268, DOI 10.1016/S0962-8924(99)01578-0
   Tsutsui S, 2002, CLIN CANCER RES, V8, P3454
   Walker RA, 1999, BREAST CANCER RES TR, V53, P167, DOI 10.1023/A:1006194700667
   Wolff AC, 2007, J CLIN ONCOL, V25, P118, DOI 10.1200/JCO.2006.09.2775
   Yutao Z, 2011, DIAGN PATHOL, V6, P49
NR 32
TC 12
Z9 14
U1 2
U2 11
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1746-1596
J9 DIAGN PATHOL
JI Diagn. Pathol.
PD DEC 7
PY 2012
VL 7
AR 170
DI 10.1186/1746-1596-7-170
PG 7
WC Pathology
SC Pathology
GA 066ZP
UT WOS:000313261400001
PM 23216981
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Wang, XD
   Ward, PA
AF Wang, Xiangdong
   Ward, Peter A.
TI RETRACTED: Opportunities and challenges of disease biomarkers: a new
   section in the journal of translational medicine (Retracted article. See
   vol. 11, 144, 2012)
SO JOURNAL OF TRANSLATIONAL MEDICINE
LA English
DT Review; Retracted Publication
ID DRUG
AB Disease biomarkers are defined to diagnose various phases of diseases, monitor severities of diseases and responses to therapies, or predict prognosis of patients. Disease-specific biomarkers should benefit drug discovery and development, integrate multidisciplinary sciences, be validated by molecular imaging. The opportunities and challenges in biomarker development are emphasized and considered. The Journal of Translational Medicine opens a new Section of Disease Biomarkers to bridge identification and validation of gene or protein-based biomarkers, network biomarkers, dynamic network biomarkers in human diseases, patient phenotypes, and clinical applications. Disease biomarkers are also important for determining drug effects, target specificities and binding, dynamic metabolism and pharmacological kinetics, or toxicity profiles.
C1 [Wang, Xiangdong] Fudan Univ, Zhongshan Hosp, Qing Pu Branch, Dept Resp Med,Biomed Res Ctr, Shanghai 200433, Peoples R China.
   [Wang, Xiangdong] Univ Lund Hosp, S-22185 Lund, Sweden.
   [Ward, Peter A.] Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI USA.
RP Wang, XD (reprint author), Fudan Univ, Zhongshan Hosp, Qing Pu Branch, Dept Resp Med,Biomed Res Ctr, Shanghai 200433, Peoples R China.
EM xiangdong.wang@clintransmed.org
RI Wang, Xiangdong/F-2913-2014
FU NIGMS NIH HHS [R01 GM029507]
CR Chen H, 2012, J CELL MOL MED, V16, P1286, DOI 10.1111/j.1582-4934.2011.01416.x
   Chen H, 2012, J PROTEOMICS, V75, P2835, DOI 10.1016/j.jprot.2012.01.027
   Galban CJ, 2012, NAT MED, V18, P1711, DOI 10.1038/nm.2971
   Hampel H, 2010, NAT REV DRUG DISCOV, V9, P560, DOI 10.1038/nrd3115
   Kelloff GJ, 2012, NAT REV DRUG DISCOV, V11, P201, DOI 10.1038/nrd3651
   Marko-Varga G, 2012, CLIN TRANSL MED, V1, DOI 10.1186/2001-1326-1-8
   Soler Artigas M, 2011, NAT GENET, V43, P1082, DOI 10.1038/ng.941
   Wang Xiangdong, 2011, J Clin Bioinforma, V1, P28, DOI 10.1186/2043-9113-1-28
   Wang Xiangdong, 2011, J Clin Bioinforma, V1, P1, DOI 10.1186/2043-9113-1-1
   Wu DJ, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-71
   Yan DH, 2012, ANN APPL STAT, V6, P1280, DOI 10.1214/12-AOAS543
   Zethelius B, 2008, NEW ENGL J MED, V358, P2107, DOI 10.1056/NEJMoa0707064
NR 12
TC 7
Z9 7
U1 3
U2 18
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1479-5876
J9 J TRANSL MED
JI J. Transl. Med.
PD DEC 5
PY 2012
VL 10
AR 240
DI 10.1186/1479-5876-10-240
PG 4
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 072AK
UT WOS:000313640000001
PM 23217078
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Co, CC
   Ho, CC
   Kumar, G
AF Co, Carlos C.
   Ho, Chia-Chi
   Kumar, Girish
TI RETRACTED: Motility-Based Cell Sorting by Planar Cell Chromatography
   (Retracted article. See vol. 90, pg. 5972, 2018)
SO ANALYTICAL CHEMISTRY
LA English
DT Article; Retracted Publication
ID MIGRATION; SIGNALS; SEPARATION; ANISOTROPY; POLARITY; DENSITY
AB We report here a new methodology for sorting mammalian cells based on their intrinsic motility on planar substrates, independent of chemoattractants and external fields. This biological analogue of thin layer chromatography consists of arrays of asymmetric adhesive islands on tissue culture dishes that rectify the random movement of cells and direct their migration in a specific direction. We demonstrated the use of planar cell chromatography in the separation of mixtures of 3T3 fibroblasts that express constitutively active Rac1 or RhoA and mixtures of 3T3 fibroblasts and SH-SY5Y neuroblastoma cells.
C1 [Co, Carlos C.; Ho, Chia-Chi; Kumar, Girish] Univ Cincinnati, Chem Engn Program, Cincinnati, OH 45221 USA.
   [Kumar, Girish] US FDA, Div Biol, Ctr Devices & Radiol Hlth, Silver Spring, MD 20993 USA.
RP Ho, CC (reprint author), Univ Cincinnati, Chem Engn Program, Cincinnati, OH 45221 USA.
EM chiachi.ho@uc.edu
FU National Institutes of Health [R01EB010043, R21EB005348]; National
   Science Foundation [CBET0928219]
FX This work was supported by the National Institutes of Health
   (R01EB010043 and R21EB005348) and the National Science Foundation
   (CBET0928219). We thank Dr. Yi Zheng's laboratory for providing the
   constitutively active Rac1 and RhoA fibroblasts.
CR Bernard A, 2001, NAT BIOTECHNOL, V19, P866, DOI 10.1038/nbt0901-866
   Chen CS, 1997, SCIENCE, V276, P1425, DOI 10.1126/science.276.5317.1425
   DeForest CA, 2009, NAT MATER, V8, P659, DOI [10.1038/NMAT2473, 10.1038/nmat2473]
   FULWYLER MJ, 1965, SCIENCE, V150, P910, DOI 10.1126/science.150.3698.910
   Guo FK, 2006, J BIOL CHEM, V281, P18652, DOI 10.1074/jbc.M603508200
   Jiang XY, 2005, P NATL ACAD SCI USA, V102, P975, DOI 10.1073/pnas.0408954102
   JULIUS MH, 1972, P NATL ACAD SCI USA, V69, P1934, DOI 10.1073/pnas.69.7.1934
   Khetani SR, 2006, CURR OPIN BIOTECH, V17, P524, DOI 10.1016/j.copbio.2006.08.009
   Kim DH, 2009, BIOMATERIALS, V30, P5433, DOI 10.1016/j.biomaterials.2009.06.042
   Kim DH, 2009, ADV FUNCT MATER, V19, P1579, DOI 10.1002/adfm.200801174
   Kloxin AM, 2009, SCIENCE, V324, P59, DOI 10.1126/science.1169494
   Kumar G, 2003, LANGMUIR, V19, P10550, DOI 10.1021/la035309l
   Kumar G, 2007, ADV MATER, V19, P1084, DOI 10.1002/adma.200601629
   Kushiro K, 2010, ADV MATER, V22, P4516, DOI 10.1002/adma.201001619
   Mahmud G, 2009, NAT PHYS, V5, P606, DOI 10.1038/NPHYS1306
   MILLER HC, 1971, SCIENCE, V171, P913, DOI 10.1126/science.171.3974.913
   Mun KS, 2013, ADV HEALTHC MATER, V2, P334, DOI 10.1002/adhm.201200141
   Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053
   Thery M, 2006, P NATL ACAD SCI USA, V103, P19771, DOI 10.1073/pnas.0609267103
   Voldman J, 1999, ANNU REV BIOMED ENG, V1, P401, DOI 10.1146/annurev.bioeng.1.1.401
   Voldman J, 2009, NAT PHYS, V5, P536, DOI 10.1038/nphys1349
   Xu JS, 2003, CELL, V114, P201, DOI 10.1016/S0092-8674(03)00555-5
NR 22
TC 6
Z9 6
U1 1
U2 16
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0003-2700
EI 1520-6882
J9 ANAL CHEM
JI Anal. Chem.
PD DEC 4
PY 2012
VL 84
IS 23
BP 10160
EP 10164
DI 10.1021/ac302855m
PG 5
WC Chemistry, Analytical
SC Chemistry
GA 047CM
UT WOS:000311815300003
PM 23140541
OA Green Accepted
DA 2018-12-27
ER

PT J
AU Mousa, OF
AF Mousa, Omar F.
TI RETRACTED: Multiscale Multiphysics Modeling, Analysis, Simulation, and
   Fabrication of Carbon Nanotube-Based Integrated Power Inductor for
   System On-Chip With Magnetic Cores (Retracted article. See vol. 137,
   017001, 2015)
SO JOURNAL OF ENERGY RESOURCES TECHNOLOGY-TRANSACTIONS OF THE ASME
LA English
DT Article; Retracted Publication
DE inductor; power inductor; carbon nanotube; CNT; MWCNT; BMWCNT; SWCNT;
   quality factor; dc-dc; integrated; efficiency; power loss; power
   inductor with magnetic cores; thin magnetic cores; nanotechnology
AB The magnetics of power electronics has particular potential for improvement, as these components are typically the largest and volumetrically inefficient in a power circuit. Nowadays, the trend is to develop multiscale multiphysics structures to yield performance characteristics favorable in power electronic devices and power converters' applications. As the dimensions of materials are reduced to the nanometer realm, they often exhibit novel and interesting behavior, which constitute the basis for a new generation of electronic devices. Nanoparticles physical and chemical properties behavior is unique and peculiar compared to conventional or classical materials, for instance, silicon is a semiconductor while silicon nanowire is a good conductor. Hence, the exploitation and exploration of nanotechnology is critical to achieving reliable nanometer-based power devices with small footprint and reduced power consumption, among others. Nanotechnology-based power inductor that utilizes bundled-multiwalled carbon nanotubes and thin magnetic plates as cores can provide high-power-density, low-power-loss, and high performance in a small size for system on-chip (SoC). The bundled-multiwalled carbon nanotubes based power inductor with single-layer and three turns occupies an area of 0.1225 mm2 exhibits an inductance of 263 nH, a quality factor of 771 at 20 MHz, and a dc rated current of 200 mA. The fabrication, design, analysis, multiscale multiphysics modeling, and simulation results of the bundled-multiwalled carbon nanotubes based power inductor are presented. [DOI:10.1115/1.4007663]
C1 [Mousa, Omar F.] Univ Alabama, Dept Elect & Comp Engn, Tuscaloosa, AL 35404 USA.
RP Mousa, OF (reprint author), 1005 14th St 7C, Tuscaloosa, AL 35401 USA.
EM Omar.f.mousa@ieee.org
CR Abu Qahouq J. A., 2011, U.S. Patent Application Serial, Patent No. [61/482,514, 61482514]
   BEACH DB, 2007, ASME J ENERGY RESOUR, V129, P29, DOI DOI 10.1115/1.242496
   CARCASCI C, 1996, ASME J ENERGY RESOUR, V118, P36
   Himelic J. B., 2011, ASME J ENERGY RESOUR, V133
   Jin J.-M., 2002, FINITE ELEMENT METHO
   Li H, 2009, IEEE T ELECTRON DEV, V56, P2202, DOI 10.1109/TED.2009.2028395
   Mousa OF, 2011, IEEE T ELECTRON DEV, V58, P2670, DOI 10.1109/TED.2011.2157932
   Nieuwoudt A, 2008, IEEE T ELECTRON DEV, V55, P298, DOI 10.1109/TED.2007.911091
   RAMAPRABHU V, 2004, ASME J ENERGY RESOUR, V126, P231, DOI DOI 10.1115/1.1789523
   Sui W., 2001, DOMAIN COMPUTER ANAL
   SUI WQ, 1992, IEEE T MICROW THEORY, V40, P724, DOI 10.1109/22.127522
   Thess A, 1996, SCIENCE, V273, P483, DOI 10.1126/science.273.5274.483
   Tong L, 2001, IEEE MTT-S, P1023, DOI 10.1109/MWSYM.2001.967066
   Whittaker T. J. T., 1985, ASME J ENERGY RESOUR, V107, P74
   Zhu L., 2007, 12 INT S ADV PACK MA, P309
NR 15
TC 1
Z9 1
U1 3
U2 31
PU ASME
PI NEW YORK
PA TWO PARK AVE, NEW YORK, NY 10016-5990 USA
SN 0195-0738
J9 J ENERG RESOUR-ASME
JI J. Energy Resour. Technol.-Trans. ASME
PD DEC
PY 2012
VL 134
IS 4
AR 042002
DI 10.1115/1.4007663
PG 9
WC Energy & Fuels
SC Energy & Fuels
GA 077NM
UT WOS:000314034400010
DA 2018-12-27
ER

PT J
AU Zheng, RJ
   Zhou, LC
   Pan, F
AF Zheng Rongjian
   Zhou Lincheng
   Pan Feng
TI RETRACTED: Modeling and Fault Monitoring of Bioprocess Using Generalized
   Additive Models (GAMs) and Bootstrap (Retracted article. See vol. 21,
   pg. 270, 2013)
SO CHINESE JOURNAL OF CHEMICAL ENGINEERING
LA English
DT Article; Proceedings Paper; Retracted Publication
CT 23rd Chinese Process Control Conference (CPCC)
CY AUG 11-12, 2012
CL Xiamen, PEOPLES R CHINA
SP Chem Ind & Engn Soc China (CIESC), Chem Ind Press
DE bioprocess fault monitoring; generalized additive model; glutamic acid
   fermentation; bootstrap; modeling
ID MOVING WINDOW; DIAGNOSIS; TREND; MPCA
AB Fault monitoring of bioprocess is important to ensure safety of a reactor and maintain high quality of products. It is difficult to build an accurate mechanistic model for a bioprocess, so fault monitoring based on rich historical or online database is an effective way. A group of data based on bootstrap method could be resampling stochastically, improving generalization capability of model. In this paper, online fault monitoring of generalized additive models (GAMs) combining with bootstrap is proposed for glutamate fermentation process. GAMs and bootstrap are first used to decide confidence interval based on the online and off-line normal sampled data from glutamate fermentation experiments. Then GAMs are used to online fault monitoring for time, dissolved oxygen, oxygen uptake rate, and carbon dioxide evolution rate. The method can provide accurate fault alarm online and is helpful to provide useful information for removing fault and abnormal phenomena in the fermentation.
C1 [Zheng Rongjian; Zhou Lincheng; Pan Feng] Jiangnan Univ, Minist Educ, Key Lab Adv Proc Control Light Ind, Wuxi 214122, Peoples R China.
   [Zheng Rongjian] Huaiyin Inst Technol, Fac Elect Engn, Huaian 223003, Peoples R China.
RP Zheng, RJ (reprint author), Jiangnan Univ, Minist Educ, Key Lab Adv Proc Control Light Ind, Wuxi 214122, Peoples R China.
EM zhengrjian@yahoo.com.cn
CR Cox ME, 2005, MAR POLLUT BULL, V51, P89, DOI 10.1016/j.marpolbul.2004.10.039
   Efron B, 2003, STAT SCI, V18, P135, DOI 10.1214/ss/1063994968
   EFRON B, 1979, SIAM REV, V21, P460, DOI 10.1137/1021092
   Gao D, 2010, CHINESE J CHEM ENG, V18, P265, DOI 10.1016/S1004-9541(08)60352-3
   GU C, 1992, J COMPUT GRAPH STAT, V1, P169, DOI DOI 10.2307/1390840
   HAYNOR DR, 1989, IEEE T MED IMAGING, V8, P337, DOI 10.1109/42.41486
   Li LL, 2005, CHINESE J CHEM ENG, V13, P783
   Mao Y, 2007, CHINESE J CHEM ENG, V15, P233, DOI 10.1016/S1004-9541(07)60064-0
   Morton R, 2008, WATER RESOUR RES, V44, DOI 10.1029/2007WR006191
   Stine RA, 2001, SOCIOL METHOD RES, V30, P124, DOI 10.1177/0049124101030001011
   Wang ZF, 2007, CHINESE J CHEM ENG, V15, P92
   Wood SN, 2008, J ROY STAT SOC B, V70, P495, DOI 10.1111/j.1467-9868.2007.00646.x
   Wood SN, 2006, AUST NZ J STAT, V48, P445, DOI 10.1111/j.1467-842X.2006.00450.x
   Woods DC, 2006, TECHNOMETRICS, V48, P284, DOI 10.1198/004017005000000571
   Zhang Q, 2006, CHINESE J CHEM ENG, V14, P207, DOI 10.1016/S1004-9541(06)60060-8
   Zhao LJ, 2005, CHINESE J CHEM ENG, V13, P649
   Zhao X, 2006, CHINESE J CHEM ENG, V14, P759, DOI 10.1016/S1004-9541(07)60008-1
   Zhou SY, 2005, CHINESE J CHEM ENG, V13, P388
   ZOUBIR AM, 1995, IEEE T SIGNAL PROCES, V43, P1386, DOI 10.1109/78.388852
   Zoubir AM, 1998, IEEE SIGNAL PROC MAG, V15, P56, DOI 10.1109/79.647043
NR 20
TC 0
Z9 0
U1 2
U2 16
PU CHEMICAL INDUSTRY PRESS
PI BEIJING
PA NO. 3 HUIXINLI CHAOYANGQU, BEIJING 100029, PEOPLES R CHINA
SN 1004-9541
EI 2210-321X
J9 CHINESE J CHEM ENG
JI Chin. J. Chem. Eng.
PD DEC
PY 2012
VL 20
IS 6
BP 1180
EP 1183
PG 4
WC Engineering, Chemical
SC Engineering
GA 073XL
UT WOS:000313776300023
DA 2018-12-27
ER

PT J
AU Yang, Y
   Cho, YI
   Fridman, A
AF Yang, Yong
   Cho, Young I.
   Fridman, Alexander
TI RETRACTED: Temporally resolved imaging on quenching and re-ignition of
   nanosecond underwater discharge (Retracted article. See vol. 3, 079901,
   2013)
SO AIP ADVANCES
LA English
DT Article; Retracted Publication
ID LIQUIDS; ELECTRONS; TRANSPORT
AB This paper presents the temporally resolved images of plasma discharge in de-ionized water. The discharge was produced by high voltage pulses with 0.3 ns rise time and 10 ns duration. The temporal resolution of the imaging system was one nanosecond. A unique three-stage process, including a fast ignition at the leading edge of the pulse, quenching at the plateau of the pulse, and self re-ignition at the trailing edge of the pulse, was observed in a single pulse cycle. The maximum measured propagation velocity of the plasma discharge was about 1000 km/s. The possibility of direct ionization in water under high reduced electric field conditions was discussed. Copyright 2012 Author(s). This article is distributed under a Creative Commons Attribution 3.0 Unported License. [http://dx.doi.org/10.1063/1.4769080]
C1 [Yang, Yong] Huazhong Univ Sci & Technol, State Key Lab Adv Electromagnet Engn & Technol, Wuhan 430074, Hubei, Peoples R China.
   [Cho, Young I.; Fridman, Alexander] Drexel Univ, Dept Mech Engn, Philadelphia, PA 19104 USA.
RP Yang, Y (reprint author), Huazhong Univ Sci & Technol, State Key Lab Adv Electromagnet Engn & Technol, Wuhan 430074, Hubei, Peoples R China.
EM yangyong@hust.edu.cn
FU National Natural Science Foundation of China [11205065]
FX This work was supported by a grant from the National Natural Science
   Foundation of China (Grant No. 11205065).
CR Akiyama H, 2000, IEEE T DIELECT EL IN, V7, P646, DOI 10.1109/94.879360
   An W, 2007, J APPL PHYS, V101, DOI 10.1063/1.2437675
   ATRAZHEV VM, 1991, IEEE T ELECTR INSUL, V26, P586, DOI 10.1109/14.83675
   Atrazhev VM, 1998, IEEE T DIELECT EL IN, V5, P450, DOI 10.1109/94.689434
   Bruggeman P, 2009, J PHYS D APPL PHYS, V42, DOI 10.1088/0022-3727/42/5/053001
   Ceccato PH, 2010, J PHYS D APPL PHYS, V43, DOI 10.1088/0022-3727/43/17/175202
   GIANTURCO FA, 1980, J PHYS B-AT MOL OPT, V13, P613, DOI 10.1088/0022-3700/13/3/022
   Graham WG, 2011, J PHYS D APPL PHYS, V44, DOI 10.1088/0022-3727/44/17/174037
   Hagelaar GJM, 2005, PLASMA SOURCES SCI T, V14, P722, DOI 10.1088/0963-0252/14/4/011
   Hayashi M., 1987, SWARM STUDIES INELAS, P167
   Kolb JF, 2008, J PHYS D APPL PHYS, V41, DOI 10.1088/0022-3727/41/23/234007
   Locke BR, 2006, IND ENG CHEM RES, V45, P882, DOI 10.1021/ie050981u
NR 12
TC 1
Z9 1
U1 3
U2 27
PU AMER INST PHYSICS
PI MELVILLE
PA CIRCULATION & FULFILLMENT DIV, 2 HUNTINGTON QUADRANGLE, STE 1 N O 1,
   MELVILLE, NY 11747-4501 USA
SN 2158-3226
J9 AIP ADV
JI AIP Adv.
PD DEC
PY 2012
VL 2
IS 4
AR 042153
DI 10.1063/1.4769080
PG 6
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary;
   Physics, Applied
SC Science & Technology - Other Topics; Materials Science; Physics
GA 061DX
UT WOS:000312828700066
OA DOAJ Gold
DA 2018-12-27
ER

PT J
AU Feng, FF
   Li, ZW
   Potts-Kant, EN
   Wu, YM
   Foster, WM
   Williams, KL
   Hollingsworth, JW
AF Feng, Feifei
   Li, Zhuowei
   Potts-Kant, Erin N.
   Wu, Yiming
   Foster, W. Michael
   Williams, Kristi L.
   Hollingsworth, John W.
TI RETRACTED: Hyaluronan Activation of the Nlrp3 Inflammasome Contributes
   to the Development of Airway Hyperresponsiveness (Retracted article. See
   vol. 123, pg. A172, 2015)
SO ENVIRONMENTAL HEALTH PERSPECTIVES
LA English
DT Article; Retracted Publication
DE asthma; environment; extracellular matrix; innate immunity; ozone;
   toll-like receptor
ID TOLL-LIKE RECEPTOR-4; EPITHELIAL PERMEABILITY; INTERLEUKIN-1 RECEPTOR;
   BRONCHIAL REACTIVITY; OZONE EXPOSURE; SMOOTH-MUSCLE; UNITED-STATES;
   MORTALITY; IMMUNITY; INJURY
AB BACKGROUND: The role of the Nlrp3 inflammasome in nonallergic airway hyperresponsiveness (AHR) has not previously been reported. Recent evidence supports both interleultin (IL) 1 beta and short fragments of hyaluronan (HA) as contributors to the biological response to inhaled ozone.
   OBJECTIVE: Because extracellular secretion of IL-1 beta requires activation of the inflammasome, we investigated the role of the inflammasome proteins ASC, caspase1, and Nlrp3 in the biological response to ozone and HA.
   METHODS: C57BL/6J wild-type mice and mice deficient in ASC, caspasel, or Nlrp3 were exposed to ozone (1 ppm for 3 hr) or HA followed by analysis of airway resistance, cellular inflammation, and total protein and cytokines in bronchoalveolar lavage fluid (BALF). Transcription levels of IL-1 beta and IL-18 were determined in two populations of lung macrophages. In addition, we examined levels of cleaved caspasel and cleaved IL-1 beta as markers of inflammasome activation in isolated alveolar macrophages harvested from BALF from HA-treated mice.
   RESULTS: We observed that genes of the Nlrp3 inflammasome were required for development of AHR following exposure to either ozone or HA fragments. These genes are partially required for the cellular inflammatory response to ozone. The expression of IL-1 beta mRNA in alveolar macrophages was up-regulated after either ozone or HA challenge and was not dependent on the Nlrp3 inflammasome. However, soluble levels of IL-1 beta protein were dependent on the inflammasome after challenge with either ozone or HA. HA challenge resulted in cleavage of macrophage-derived caspasel and IL-1 beta, suggesting a role for alveolar macrophages in Nlrp3-dependent AHR.
   CONCLUSIONS: The Nlrp3 inflammasome is required for the development of ozone-induced reactive airways disease.
C1 [Feng, Feifei; Li, Zhuowei; Potts-Kant, Erin N.; Foster, W. Michael; Williams, Kristi L.; Hollingsworth, John W.] Duke Univ, Dept Med, Div Pulm Allergy & Crit Care Med, Sch Med,Med Ctr, Durham, NC 27710 USA.
   [Feng, Feifei; Wu, Yiming] Zhengzhou Univ, Coll Publ Hlth, Dept Occupat & Environm Hlth, Zhengzhou, Henan, Peoples R China.
   [Williams, Kristi L.] Duke Univ, Sch Nursing, Med Ctr, Durham, NC 27710 USA.
   [Hollingsworth, John W.] Duke Univ, Dept Immunol, Sch Med, Med Ctr, Durham, NC 27710 USA.
RP Hollingsworth, JW (reprint author), Duke Univ, Dept Med, Div Pulm Allergy & Crit Care Med, Sch Med,Med Ctr, DUMC 103004,106 Res Dr, Durham, NC 27710 USA.
EM hollingsworth@duke.edu
FU National Institutes of Health [ES016126, AI081672, ES020350, ES020426,
   AI089756]; China Scholarship Council
FX This work was supported by National Institutes of Health grants
   ES016126, AI081672, ES020350, and ES020426 (to J.W.H.); AI089756 (to
   K.L.W.); and an unrestricted educational grant from the China
   Scholarship Council (to F.F.).
CR Al-Hegelan M, 2011, IMMUNOL RES, V49, P173, DOI 10.1007/s12026-010-8180-z
   Backus GS, 2010, ENVIRON HEALTH PERSP, V118, P1721, DOI 10.1289/ehp.1002182
   Barker BR, 2011, CURR OPIN IMMUNOL, V23, P591, DOI 10.1016/j.coi.2011.07.005
   Bauernfeind F, 2011, J IMMUNOL, V187, P613, DOI 10.4049/jimmunol.1100613
   Bell ML, 2006, ENVIRON HEALTH PERSP, V114, P532, DOI 10.1289/ehp.8816
   Bell ML, 2004, JAMA-J AM MED ASSOC, V292, P2372, DOI 10.1001/jama.292.19.2372
   Berman JD, 2012, ENVIRON HEALTH PERSP, V120, P1404, DOI 10.1289/ehp.1104851
   Caceres AI, 2009, P NATL ACAD SCI USA, V106, P9099, DOI 10.1073/pnas.0900591106
   Chang HH, 2010, INT J ENV RES PUB HE, V7, P2866, DOI 10.3390/ijerph7072866
   Dentener MA, 2005, THORAX, V60, P114, DOI 10.1136/thx.2003.020842
   Foster WM, 2000, J APPL PHYSIOL, V89, P1804
   Garantziotis S, 2010, AM J RESP CRIT CARE, V181, P666, DOI 10.1164/rccm.200903-0381OC
   Garantziotis S, 2009, J BIOL CHEM, V284, P11309, DOI 10.1074/jbc.M802400200
   Guarda G, 2011, J IMMUNOL, V186, P2529, DOI 10.4049/jimmunol.1002720
   HATCH GE, 1994, AM J RESP CRIT CARE, V150, P676, DOI 10.1164/ajrccm.150.3.8087337
   Hoffman HM, 2011, J BIOL CHEM, V286, P10889, DOI 10.1074/jbc.R110.135491
   Hollingsworth JW, 2004, AM J RESP CRIT CARE, V170, P126, DOI 10.1164/rccm.200311-1499OC
   Ito K, 2005, EPIDEMIOLOGY, V16, P446, DOI 10.1097/01.ede.0000165821.90114.7f
   Jin CC, 2010, J CLIN IMMUNOL, V30, P628, DOI 10.1007/s10875-010-9440-3
   Johnston RA, 2007, AM J RESP CELL MOL, V37, P477, DOI 10.1165/rcmb.2006-0315OC
   KEHRL HR, 1987, AM REV RESPIR DIS, V135, P1124
   Kim CS, 2011, AM J RESP CRIT CARE, V183, P1215, DOI 10.1164/rccm.201011-1813OC
   Kleeberger SR, 2001, AM J PHYSIOL-LUNG C, V280, pL326
   KOREN HS, 1989, AM REV RESPIR DIS, V139, P407, DOI 10.1164/ajrccm/139.2.407
   LANG JWB, 2011, J ALLERGY CLIN IMMUN, V3, P403
   Li ZW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027137
   Li ZW, 2010, J IMMUNOL, V185, P6891, DOI 10.4049/jimmunol.1000283
   Moore PE, 2001, J APPL PHYSIOL, V91, P1467
   National Research Council, 1996, GUID CAR US LAB AN
   Park JW, 2004, AM J RESP CELL MOL, V30, P830, DOI 10.1165/rcmb.2003.0373OC
   Peden DB, 2011, IMMUNOL REV, V242, P91, DOI 10.1111/j.1600-065X.2011.01035.x
   Que LG, 2011, J APPL PHYSIOL, V111, P679, DOI 10.1152/japplphysiol.00337.2011
   SAHU S, 1978, BIOCHEM J, V173, P565, DOI 10.1042/bj1730565
   Samet JM, 2011, NEW ENGL J MED, V365, P198, DOI 10.1056/NEJMp1103332
   Sutterwala FS, 2006, IMMUNITY, V24, P317, DOI 10.1016/j.immuni.2006.02.004
   Taylor KR, 2007, J BIOL CHEM, V282, P18265, DOI 10.1074/jbc.M606352200
   Ting JPY, 2008, NAT REV IMMUNOL, V8, P372, DOI 10.1038/nri2296
   Verhein KC, 2008, AM J RESP CELL MOL, V39, P730, DOI 10.1165/rcmb.2008-0045OC
   WIESTER MJ, 1988, TOXICOL APPL PHARM, V96, P140, DOI 10.1016/0041-008X(88)90256-6
   Williams AS, 2008, EUR RESPIR J, V32, P571, DOI 10.1183/09031936.00121607
   Williams AS, 2007, J APPL PHYSIOL, V103, P1189, DOI 10.1152/japplphysiol.00172.2007
   Wu ZX, 2008, RESP PHYSIOL NEUROBI, V164, P300, DOI 10.1016/j.resp.2008.07.019
   Yamasaki K, 2009, J BIOL CHEM, V284, P12762, DOI 10.1074/jbc.M806084200
NR 43
TC 13
Z9 16
U1 2
U2 15
PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE
PI RES TRIANGLE PK
PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233,
   RES TRIANGLE PK, NC 27709-2233 USA
SN 0091-6765
EI 1552-9924
J9 ENVIRON HEALTH PERSP
JI Environ. Health Perspect.
PD DEC
PY 2012
VL 120
IS 12
BP 1692
EP 1698
DI 10.1289/ehp.1205188
PG 7
WC Environmental Sciences; Public, Environmental & Occupational Health;
   Toxicology
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health; Toxicology
GA 056QB
UT WOS:000312504900029
PM 23010656
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Leal, E
   Villanova, FE
   Lin, WC
   Hu, F
   Liu, QF
   Liu, YB
   Cui, SJ
AF Leal, Elcio
   Villanova, Fabiola E.
   Lin, Wencheng
   Hu, Feng
   Liu, Qinfang
   Liu, Yebing
   Cui, Shangjin
TI RETRACTED: Interclade recombination in porcine parvovirus strains
   (Retracted article. See vol. 94, pg. 464, 2013)
SO JOURNAL OF GENERAL VIROLOGY
LA English
DT Article; Retracted Publication
ID CANINE PARVOVIRUS; DETECTING RECOMBINATION; SEQUENCE ALIGNMENTS; MOSAIC
   STRUCTURE; DNA-REPLICATION; RAPID EVOLUTION; MOLECULAR CLOCK;
   HEPATITIS-C; VIRUS; RESISTANCE
AB A detailed analysis of the Ns1/Vp1Vp2 genome region of the porcine parvovirus (PPV) strains isolated from vaccinated animals was performed. We found many inconsistencies in the phylogenetic trees of these viral isolates, such as low statistical support and strains with long branches in the phylogenetic trees. Thus, we used distance-based and phylogenetic methods to distinguish de facto recombinants from spurious recombination signals. We found a mosaic virus in which the Ne1 gene was acquired from one PPV clade and the Vp1 Vp2 gene was acquired from a distinct phylogenetic clade. We also described the interclade mosaic structure of the Vp1 Vp2 gene of a reference strain. If recombination is an adaptive mechanism over the course of PPV evolution, we would likely observe increasing numbers of chimeric strains over time. However, when the PPV sequences isolated from 1964 to 2011 were analysed, only two chimeric strains were detected. Thus, PPV recombination is an independent event, resulting from close contact between animals housed in high-density conditions.
C1 [Leal, Elcio; Villanova, Fabiola E.] Fed Univ Para, BR-66059 Belem, Para, Brazil.
   [Liu, Yebing] China Inst Vet Drug Control, Beijing 100081, Peoples R China.
RP Leal, E (reprint author), Fed Univ Para, BR-66059 Belem, Para, Brazil.
EM elcioleal@gmail.com; cuishangjin@yahoo.cn
OI Leal, Elcio/0000-0003-3463-0492
FU National Natural Science Foundation of China [31001069, 31172349,
   31172341]; Fundacao de Amparo e Desenvolvimento da Pesquisa (FADESP);
   Pro-Reitoria de Pesquisa e Pos-Graduacao (PROPESP) [11/2012]
FX We would like to thank Dr Professor Joaquim Segales, Jens Nielsen, Lars
   Erik Larsen, Anette Botner, Mette Sif Hansen and Louise Lohse, who
   provided DNA, virus samples or technology support. This work was
   supported by the National Natural Science Foundation of China (nos
   31001069, 31172349 and 31172341). E. L. was supported by the Fundacao de
   Amparo e Desenvolvimento da Pesquisa (FADESP) and Pro-Reitoria de
   Pesquisa e Pos-Graduacao (PROPESP) (grant no. 11/2012)
CR Abe Kenji, 2007, Int J Med Sci, V4, P105
   Ane C, 2011, GENOME BIOL EVOL, V3, P246, DOI 10.1093/gbe/evr013
   Awadalla P, 2003, NAT REV GENET, V4, P50, DOI 10.1038/nrg964
   Bartosch B, 2004, J VIROL, V78, P13880, DOI 10.1128/JVI.78.24.13880-13890.2004
   Bay RA, 2011, J MOL EVOL, V73, P273, DOI 10.1007/s00239-011-9473-0
   Boni MF, 2007, GENETICS, V176, P1035, DOI 10.1534/genetics.106.068874
   Cadar D, 2012, INFECT GENET EVOL, V12, P420, DOI 10.1016/j.meegid.2012.01.014
   Cheng WX, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-50
   Christensen J, 2002, J VIROL, V76, P6518, DOI 10.1128/JVI.76.13.6518-6531.2002
   Cotmore SF, 1998, J VIROL, V72, P8477
   Crotty S, 2000, NAT MED, V6, P1375
   Csagola A, 2012, ARCH VIROL, V157, P1003, DOI 10.1007/s00705-012-1257-3
   Etherington GJ, 2005, BIOINFORMATICS, V21, P278, DOI 10.1093/bioinformatics/bth500
   Grigoras I, 2010, J VIROL, V84, P9105, DOI 10.1128/JVI.00607-10
   Guindon S, 2003, SYST BIOL, V52, P696, DOI 10.1080/10635150390235520
   HASEGAWA M, 1985, J MOL EVOL, V22, P160, DOI 10.1007/BF02101694
   HOGAN A, 1986, MOL CELL BIOL, V6, P3005, DOI 10.1128/MCB.6.8.3005
   Hughes ML, 2007, J BACTERIOL, V189, P7531, DOI 10.1128/JB.00767-07
   Husmeier D, 2008, STAT APPL GENET MOL, V7
   Huson DH, 2006, MOL BIOL EVOL, V23, P254, DOI 10.1093/molbev/msj030
   Jayaraman A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017616
   Kaneko H, 2011, J GEN VIROL, V92, P1251, DOI 10.1099/vir.0.030361-0
   Kapoor A, 2010, J INFECT DIS, V201, P1633, DOI 10.1086/652416
   KELLAM P, 1995, J VIROL, V69, P669
   KRESSE JI, 1985, VET MICROBIOL, V10, P525, DOI 10.1016/0378-1135(85)90061-6
   Larkin MA, 2007, BIOINFORMATICS, V23, P2947, DOI 10.1093/bioinformatics/btm404
   Lauring AS, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001005
   Leal E, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011833
   Leitner T, 1999, P NATL ACAD SCI USA, V96, P10752, DOI 10.1073/pnas.96.19.10752
   Lopez-Bueno A, 2006, CURR TOP MICROBIOL, V299, P349
   Lukashov VV, 2001, J VIROL, V75, P2729, DOI 10.1128/JVI.75.6.2729-2740.2001
   Margeridon-Thermet S, 2010, VIRUSES-BASEL, V2, P2696, DOI 10.3390/v2122696
   Martin DP, 2011, VIRUSES-BASEL, V3, P1699, DOI 10.3390/v3091699
   Martin DP, 2005, BIOINFORMATICS, V21, P260, DOI 10.1093/bioinformatics/bth490
   Martins LD, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002651
   Maydt J, 2006, BIOINFORMATICS, V22, P1064, DOI 10.1093/bioinformatics/btl057
   MCCLURKIN AW, 1966, CAN J COMP MED VET S, V30, P190
   Mengeling W. L., 2006, DIS SWINE
   Mild M, 2007, J VIROL, V81, P3369, DOI 10.1128/JVI.01295-06
   Milne I, 2004, BIOINFORMATICS, V20, P1806, DOI 10.1093/bioinformatics/bth155
   Mochizuki M, 2008, J VET MED SCI, V70, P1305, DOI 10.1292/jvms.70.1305
   Moutouh L, 1996, P NATL ACAD SCI USA, V93, P6106, DOI 10.1073/pnas.93.12.6106
   Noppornpanth S, 2006, J VIROL, V80, P7569, DOI 10.1128/JVI.00312-06
   Nora T, 2007, J VIROL, V81, P7620, DOI 10.1128/JVI.00083-07
   Norberg P, 2007, J VIROL, V81, P13158, DOI 10.1128/JVI.01310-07
   Norja P, 2008, J VIROL, V82, P6427, DOI 10.1128/JVI.00471-08
   Ohshima T, 2009, J VET MED SCI, V71, P403, DOI 10.1292/jvms.71.403
   ORAVEERAKUL K, 1992, J VIROL, V66, P715
   Papke RT, 2007, P NATL ACAD SCI USA, V104, P14092, DOI 10.1073/pnas.0706358104
   Pereira CAD, 2007, INFECT GENET EVOL, V7, P399, DOI 10.1016/j.meegid.2006.03.007
   Pond SLK, 2006, BIOINFORMATICS, V22, P3096, DOI 10.1093/bioinformatics/btl474
   Posada D, 2002, MOL BIOL EVOL, V19, P708, DOI 10.1093/oxfordjournals.molbev.a004129
   Posada D, 2001, P NATL ACAD SCI USA, V98, P13757, DOI 10.1073/pnas.241370698
   Rambaut A, 2004, NAT REV GENET, V5, P52, DOI 10.1038/nrg1246
   Sanjuan R, 2010, J VIROL, V84, P9733, DOI 10.1128/JVI.00694-10
   SAWYER S, 1989, MOL BIOL EVOL, V6, P526
   Schierup MH, 2005, BMC EVOL BIOL, V5, DOI 10.1186/1471-2148-5-52
   Schultz AK, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-265
   Shackelton LA, 2006, J VIROL, V80, P3666, DOI 10.1128/JVI.80.7.3666-3669.2006
   Shangjin C, 2009, VIRUS RES, V140, P209, DOI 10.1016/j.virusres.2008.11.003
   SMITH JM, 1992, J MOL EVOL, V34, P126
   Stainton D, 2012, J GEN VIROL, V93, P1103, DOI 10.1099/vir.0.040337-0
   Streck AF, 2011, J GEN VIROL, V92, P2628, DOI 10.1099/vir.0.033662-0
   Tamura K, 2007, MOL BIOL EVOL, V24, P1596, DOI 10.1093/molbev/msm092
   Westesson O, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000318
   Wiuf C, 2001, MOL BIOL EVOL, V18, P1929, DOI 10.1093/oxfordjournals.molbev.a003733
   Worobey M, 2001, MOL BIOL EVOL, V18, P254, DOI 10.1093/oxfordjournals.molbev.a003799
   Zeeuw EJL, 2007, J GEN VIROL, V88, P420, DOI 10.1099/vir.0.82302-0
   Zell R, 2012, J VIROL, V86, P1608, DOI 10.1128/JVI.06233-11
NR 69
TC 6
Z9 6
U1 3
U2 35
PU MICROBIOLOGY SOC
PI LONDON
PA CHARLES DARWIN HOUSE, 12 ROGER ST, LONDON WC1N 2JU, ERKS, ENGLAND
SN 0022-1317
EI 1465-2099
J9 J GEN VIROL
JI J. Gen. Virol.
PD DEC
PY 2012
VL 93
BP 2692
EP 2704
DI 10.1099/vir.0.045765-0
PN 12
PG 13
WC Biotechnology & Applied Microbiology; Virology
SC Biotechnology & Applied Microbiology; Virology
GA 063UM
UT WOS:000313027500019
PM 22993191
OA Bronze
DA 2018-12-27
ER

PT J
AU Grace-Lynn, C
   Chen, Y
   Latha, LY
   Kanwar, JR
   Jothy, SL
   Vijayarathna, S
   Sasidharan, S
AF Grace-Lynn, Chong
   Chen, Yeng
   Latha, Lachimanan Yoga
   Kanwar, Jagat R.
   Jothy, Subramanion L.
   Vijayarathna, Soundararajan
   Sasidharan, Sreenivasan
TI RETRACTED: Evaluation of the Hepatoprotective Effects of Lantadene A, a
   Pentacyclic Triterpenoid of Lantana Plants against Acetaminophen-induced
   Liver Damage (Retracted article. See vol. 18, pg. 3839, 2013)
SO MOLECULES
LA English
DT Article; Retracted Publication
DE acetaminophen; hepatoprotective; antioxidant activity; lantadene A;
   triterpenes
ID VITRO ANTIOXIDANT ACTIVITY; INDUCED HEPATOTOXICITY; CAMARA
AB The aim of the present study was to evaluate the hepatoprotective activity of lantadene A against acetaminophen-induced liver toxicity in mice was studied. Activity was measured by monitoring the levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP) and bilirubin, along with histopathological analysis. Silymarin was used as positive control. A bimodal pattern of behavioural toxicity was exhibited by the lantadene A-treated group at the beginning of the treatment. However, treatment with lantadene A and silymarin resulted in an increase in the liver weight compared with the acetaminophen treated group. The results of the acetaminophen-induced liver toxicity experiments showed that mice treated with lantadene A (500 mg/kg) showed a significant decrease in the activity of ALT, AST and ALP and the level of bilirubin, which were all elevated in the acetaminophen treated group (p < 0.05). Histological studies supported the biochemical findings and a maximum improvement in the histoarchitecture was seen. The lantadene A-treated group showed remarkable protective effects against histopathological alterations, with comparable results to the silymarin treated group. The current study confirmed the hepatoprotective effects of lantadene A against the model hepatotoxicant acetaminophen, which is likely related to its potent antioxidative activity.
C1 [Grace-Lynn, Chong; Latha, Lachimanan Yoga; Jothy, Subramanion L.; Vijayarathna, Soundararajan; Sasidharan, Sreenivasan] Univ Sains Malaysia, Inst Res Mol Med INFORMM, George Town 11800, Malaysia.
   [Chen, Yeng] Univ Malaya, Fac Dent, Dent Res & Training Unit, Kuala Lumpur 50603, Malaysia.
   [Chen, Yeng] Univ Malaya, Fac Dent, Oral Canc Res & Coordinating Ctr OCRCC, Kuala Lumpur 50603, Malaysia.
   [Kanwar, Jagat R.] Deakin Univ, IFM, Sch Med SoM, Nanomed Lab Immunol & Mol Biomed Res LIMBR,Fac Hl, Waurn Ponds, Vic 3217, Australia.
RP Sasidharan, S (reprint author), Univ Sains Malaysia, Inst Res Mol Med INFORMM, George Town 11800, Malaysia.
EM gracelynn87@gmail.com; chenyeng@um.edu.my; latha_usm@yahoo.com;
   jagat.kanwar@deakin.edu.au; jothylachumy@yahoo.com;
   vijaya_r_1984@yahoo.com; srisasidharan@yahoo.com
RI Chen, Yeng/A-6873-2011; Management Center, Dental Research/C-2478-2013;
   VIJAYARATHNA, SOUNDARARAJAN/Q-3238-2016; Jothy Lachumy,
   Subramanion/I-5868-2012; Sasidharan, Sreenivasan/A-6913-2011
OI Chen, Yeng/0000-0002-0064-7678; Sasidharan,
   Sreenivasan/0000-0002-7705-1418
FU Universiti Sains Malaysia [304/CIPPM/6312034]; Ministry of Higher
   Education of Malaysian Government
FX This project was funded by USM Short Term Grant (304/CIPPM/6312034) from
   Universiti Sains Malaysia. Chong Grace-Lynn is supported by the MyMaster
   fellowship from Ministry of Higher Education of Malaysian Government.
CR Bhoopat L, 2011, J ETHNOPHARMACOL, V136, P55, DOI 10.1016/j.jep.2011.03.061
   Burke MD, 2002, CLIN LAB MED, V22, P377, DOI 10.1016/S0272-2712(01)00002-6
   Chichewicz R., 2004, MED RES REV, V24, P90
   Cullen JM, 2005, TOXICOL PATHOL, V33, P6, DOI 10.1080/01926230590522428
   da Rocha RP, 2008, J BACTERIOL, V190, P1209, DOI 10.1128/JB.01419-07
   Grace-Lynn C, 2012, MOLECULES, V17, P11185, DOI 10.3390/molecules170911185
   HART NK, 1976, AUST J CHEM, V29, P655, DOI 10.1071/CH9760655
   Jaeschke H, 2006, TOXICOL SCI, V89, P31, DOI 10.1093/toxsci/kfi336
   Kew MC, 2000, LANCET, V355, P591, DOI 10.1016/S0140-6736(99)00219-6
   KIND PRN, 1954, J CLIN PATHOL, V7, P322, DOI 10.1136/jcp.7.4.322
   Krasutsky PA, 2006, NAT PROD REP, V23, P919, DOI 10.1039/b606816b
   Malloy HT, 1937, J BIOL CHEM, V119, P481
   Nwaehujor C. O., 2012, Asian Journal of Biochemistry, V7, P182, DOI 10.3923/ajb.2012.182.193
   Pari L, 2004, PHARMACOL RES, V49, P481, DOI 10.1016/j.phrs.2003.11.005
   PASS MA, 1986, AUST VET J, V63, P169, DOI 10.1111/j.1751-0813.1986.tb02965.x
   Patocka J., 2003, J APPL BIOMED, V1, P7
   Pour BM, 2011, MOLECULES, V16, P3663, DOI 10.3390/molecules16053663
   Rajic A, 2000, PLANTA MED, V66, P206, DOI 10.1055/s-2000-8657
   RAO PG, 1993, INDIAN DRUGS, V30, P41
   REITMAN S, 1957, AM J CLIN PATHOL, V28, P56
   Sasidharan S, 2010, MOLECULES, V15, P4478, DOI 10.3390/molecules15064478
   SHARMA OP, 1988, TOXICON, V26, P975, DOI 10.1016/0041-0101(88)90196-1
   SHARMA OP, 1989, J SCI IND RES INDIA, V48, P471
   Sheng HM, 2011, NAT PROD REP, V28, P543, DOI 10.1039/c0np00059k
   Thurnher D, 2003, HEAD NECK-J SCI SPEC, V25, P732, DOI 10.1002/hed.10231
   ZIMMERMANN M, 1983, PAIN, V16, P109, DOI 10.1016/0304-3959(83)90201-4
NR 26
TC 5
Z9 5
U1 3
U2 23
PU MDPI AG
PI BASEL
PA POSTFACH, CH-4005 BASEL, SWITZERLAND
SN 1420-3049
J9 MOLECULES
JI Molecules
PD DEC
PY 2012
VL 17
IS 12
BP 13937
EP 13947
DI 10.3390/molecules171213937
PG 11
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
SC Biochemistry & Molecular Biology; Chemistry
GA 058BD
UT WOS:000312608200019
PM 23178309
OA DOAJ Gold
DA 2018-12-27
ER

PT J
AU Marichal, RL
   Gonzalez, EJ
   Marichal, GN
AF Marichal, R. L.
   Gonzalez, E. J.
   Marichal, G. N.
TI RETRACTED: Hopf bifurcation stability in Hopfield neural networks
   (Retracted article. See vol. 45, pg. 151, 2013)
SO NEURAL NETWORKS
LA English
DT Article; Retracted Publication
DE Neural networks; Hopf bifurcation; Arnold tongue; Quasi-periodic orbit
ID MULTI-DELAYS; 2 NEURONS; TIME; SYSTEM; MODEL; OSCILLATORS; DYNAMICS;
   LOCKING
AB In this paper we consider a simple discrete Hopfield neural network model and analyze local stability using the associated characteristic model. In order to study the dynamic behavior of the quasi-periodic orbit, the Hopf bifurcation must be determined. For the case of two neurons, we find one necessary condition that yields the Hopf bifurcation. In addition, we determine the stability and direction of the Hopf bifurcation by applying normal form theory and the center manifold theorem. An example is given and a numerical simulation is performed to illustrate the results. We analyze the influence of bias weights on the stability of the quasi-periodic orbit and study the phase-locking phenomena for certain experimental results with Arnold Tongues in a particular weight configuration. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Marichal, R. L.; Gonzalez, E. J.; Marichal, G. N.] Univ La Laguna, Dept Syst Engn & Control & Comp Architecture, Tenenfe 38208, Canary Islands, Spain.
RP Marichal, RL (reprint author), Univ La Laguna, Dept Syst Engn & Control & Comp Architecture, Avda Francisco Sanchez S-N,Edf Informat, Tenenfe 38208, Canary Islands, Spain.
EM rlmarpla@ull.es
FU Spanish government's Ministry of Science and Innovation
   [DPI2010-20751-C02-02]
FX This work was financed by project DPI2010-20751-C02-02 of the Spanish
   government's Ministry of Science and Innovation. The authors also thank
   the anonymous referees very much for their constructive comments.
CR Cao JD, 1999, PHYS LETT A, V261, P303, DOI 10.1016/S0375-9601(99)00552-6
   Coombes S, 1999, PHYS REV E, V60, P2086, DOI 10.1103/PhysRevE.60.2086
   Dhooge A., 2011, CL MATCONT CONTINUAT
   Guo SJ, 2008, NONLINEAR ANAL-REAL, V9, P1323, DOI 10.1016/j.nonrwa.2007.03.002
   Guo SJ, 2008, NEUROCOMPUTING, V71, P1422, DOI 10.1016/j.neucom.2007.05.011
   Guo SJ, 2003, PHYSICA D, V183, P19, DOI 10.1016/S0167-2789(03)00159-3
   Hale J., 1991, TEXTS APPL MATH DYNA
   He WL, 2007, APPL MATH MODEL, V31, P2111, DOI 10.1016/j.apm.2006.08.006
   Hush DR, 1993, IEEE SIGNAL PROC MAG, V10, P8, DOI 10.1109/79.180705
   Kaslik E, 2009, CHAOS SOLITON FRACT, V39, P83, DOI 10.1016/j.chaos.2007.01.126
   Kaslik E, 2007, CHAOS SOLITON FRACT, V34, P1245, DOI 10.1016/j.chaos.2006.03.107
   Kuznetsov Y., 2010, APPL MATH SCI ELEMEN
   Li X., 2011, APPL MATH SCI, V5, P2077
   Liao XF, 2001, PHYSICA D, V149, P123, DOI 10.1016/S0167-2789(00)00197-4
   MARCUS CM, 1989, PHYS REV A, V40, P501, DOI 10.1103/PhysRevA.40.501
   Marichal R. L., 2006, WSEAS Transactions on Systems, V5, P119
   Martignoli S, 2008, DISCRETE CONT DYN-B, V9, P145
   Pasemann F, 2003, LECT NOTES COMPUT SC, V2686, P144
   Pasemann F, 2002, NETWORK-COMP NEURAL, V13, P195, DOI 10.1088/0954-898X/13/2/303
   Robinson R., 1999, STUDIES ADV MATH DYN
   TANK DW, 1987, P NATL ACAD SCI USA, V84, P1896, DOI 10.1073/pnas.84.7.1896
   Tino P, 2001, NEURAL COMPUT, V13, P1379, DOI 10.1162/08997660152002898
   Wang X., 1992, IJCNN International Joint Conference on Neural Networks (Cat. No.92CH3114-6), P517, DOI 10.1109/IJCNN.1992.227122
   Wei JJ, 2006, DYNAM CONT DIS SER A, V13, P177
   Wei JJ, 2008, NONLINEAR ANAL-REAL, V9, P2234, DOI 10.1016/j.nonrwa.2007.08.008
   Williams RJ, 1989, NEURAL COMPUT, V1, P270, DOI 10.1162/neco.1989.1.2.270
   Yuan ZH, 2005, J COMPUT APPL MATH, V177, P89, DOI 10.1016/j.cam.2004.09.010
   Yuan ZH, 2004, APPL MATH LETT, V17, P1239, DOI 10.1016/j.aml.2004.03.004
   Zhang CR, 2007, CHAOS SOLITON FRACT, V31, P1232, DOI 10.1016/j.chaos.2005.10.074
   Zhang CR, 2005, CHAOS SOLITON FRACT, V25, P129, DOI [10.1016/j.chaos.2004.09.099, 10.1016/j.choas.2004.09.099]
NR 30
TC 8
Z9 8
U1 3
U2 34
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0893-6080
EI 1879-2782
J9 NEURAL NETWORKS
JI Neural Netw.
PD DEC
PY 2012
VL 36
BP 51
EP 58
DI 10.1016/j.neunet.2012.09.007
PG 8
WC Computer Science, Artificial Intelligence; Neurosciences
SC Computer Science; Neurosciences & Neurology
GA 062LM
UT WOS:000312921300007
PM 23037776
DA 2018-12-27
ER

PT J
AU Pan, TY
   Xia, KM
AF Pan, Tongyan
   Xia, Kaiming
TI RETRACTED: Micromechanical Evaluation of the Damping Behavior of
   Modified Silica Fume Admixed Concrete (Retracted article. See vol. 140,
   08514001, 2014)
SO JOURNAL OF ENGINEERING MECHANICS
LA English
DT Article; Retracted Publication
DE Damping capability; Modified silica fume; Loss modulus; Loss tangent;
   Storage modulus; Micromechanical modeling
ID HOT MIX ASPHALT; COMPOSITES; MODEL
AB Vibration reduction or damping capability is highly desired for structural stability when hazardous impact loads are applied to a concrete structure. Damping capability of concrete structures depends primarily on the viscoelastic response of concrete material to the magnitudes and frequencies of impact loads, which in turn requires a minimum level of stiffness and damping capacity of concrete. A common industrial byproduct material-silica fume that showed certain antishock potential when mixed with concretes-was modified with silane in this study toward improved capabilities in both stiffness and damping. To evaluate the effectiveness of the modified silica fume (MSF), a series of dynamic flexural tests and numerical analyses were conducted, of which the results are presented. A three-dimensional micromechanical model was developed based on the discrete element method (DEM), which was then employed to study the stiffness and damping behavior of the admixed concrete. A 10% usage of MSF (by weight of cement) was found to significantly enhance the storage and loss moduli and the loss tangent of concrete. The DEM model developed can be used for evaluating and designing energy-absorbing concretes for general military and civil uses. DOI: 10.1061/(ASCE)EM.1943-7889.0000446. (C) 2012 American Society of Civil Engineers.
C1 [Pan, Tongyan] Catholic Univ Amer, Dept Civil Engn, Washington, DC 20064 USA.
   [Xia, Kaiming] Colorado Sch Mines, Div Engn, Golden, CO 80401 USA.
RP Pan, TY (reprint author), Catholic Univ Amer, Dept Civil Engn, 620 Michigan Ave NE, Washington, DC 20064 USA.
EM pan@cua.edu; kaiming.xia@gmail.com
RI Pan, Tongyan/F-6824-2012
CR ALKHAJA WA, 1994, CONSTR BUILD MATER, V8, P169, DOI DOI 10.1016/S0950-0618(09)90030-7
   ASTM, 2007, C192C192M ASTM
   Banthia N., 1994, ACI, P91
   Carpenter S. H., 2006, J ASS ASPHALT PAVING, V7, P1169
   Chang KNG, 1997, J ENG MECH-ASCE, V123, P495, DOI 10.1061/(ASCE)0733-9399(1997)123:5(495)
   Chen J., 2010, P TRANSP RES BOARD A, P122
   CUNDALL PA, 1979, GEOTECHNIQUE, V29, P47, DOI 10.1680/geot.1979.29.1.47
   DU J, 1989, J ENG MECH-ASCE, V115, P2136, DOI 10.1061/(ASCE)0733-9399(1989)115:10(2136)
   Ferry J. D., 1980, VISCOELASTIC PROPERT
   FERRY JD, 1991, MACROMOLECULES, V24, P5237, DOI 10.1021/ma00019a001
   Formica G, 2010, J SOUND VIB, V329, P1875, DOI 10.1016/j.jsv.2009.11.020
   Itasca, 2011, PFC3D 5 0 MAN
   Kim YR, 2008, KSCE J CIV ENG, V12, P109, DOI 10.1007/s12205-008-0109-x
   Malhotra V., 1993, CONCRETE INT, V15, P23
   Menard K. P., 1999, DYNAMIC MECH ANAL PR
   OHAMA Y, 1989, CARBON, V27, P729, DOI 10.1016/0008-6223(89)90206-6
   PAN T, 2005, TRANSPORT RES REC, V1929, P1, DOI DOI 10.3141/1929-01
   Pan TY, 2007, J TEST EVAL, V35, P177
   Pan TY, 2011, J ENG MECH-ASCE, V137, P334, DOI 10.1061/(ASCE)EM.1943-7889.0000232
   Pan TY, 2006, J TRANSP ENG-ASCE, V132, P580, DOI 10.1061/(ASCE)0733-947X(2006)132.7(580)
   Zhong XX, 1999, J ENG MECH-ASCE, V125, P1280, DOI 10.1061/(ASCE)0733-9399(1999)125:11(1280)
NR 21
TC 4
Z9 4
U1 4
U2 41
PU ASCE-AMER SOC CIVIL ENGINEERS
PI RESTON
PA 1801 ALEXANDER BELL DR, RESTON, VA 20191-4400 USA
SN 0733-9399
EI 1943-7889
J9 J ENG MECH
JI J. Eng. Mech.
PD DEC
PY 2012
VL 138
IS 12
BP 1411
EP 1419
DI 10.1061/(ASCE)EM.1943-7889.0000446
PG 9
WC Engineering, Mechanical
SC Engineering
GA 059IG
UT WOS:000312697100002
DA 2018-12-27
ER

PT J
AU Young, DA
   Blake, DF
   Brown, LH
AF Young, Derelle A.
   Blake, Denise F.
   Brown, Lawrence H.
TI RETRACTED: Transcutaneous oximetry measurement: normal values for the
   upper limb (Retracted article. See vol. 46, pg. 54, 2016)
SO DIVING AND HYPERBARIC MEDICINE
LA English
DT Article; Retracted Publication
DE Transcutaneous oximetry; hyperbaric oxygen therapy; wounds; patient
   monitoring; standards
ID CUTANEOUS OXYGEN-TENSION; TCPO2 MEASUREMENTS; NORMAL VOLUNTEERS;
   PRESSURE; RELIABILITY; DISEASE
AB (Young DA, Blake DF and Brown LH. Transcutaneous oximetry measurement: normal values for the upper limb. Diving and Hyperbaric Medicine. 2012;42(4): 208-213.) Introduction: Several studies define normal transcutaneous oximetry measurements (TCOM) for the chest and lower limb, but not the upper limb. Standardised healthy-subject reference values for upper limb TCOM would make interpretation of these measurements in disease or injury more meaningful.
   Aim: To determine 'normal' TCOM values for the upper limb in healthy non-smoking adults.
   Method: Thirty-two healthy volunteers (16 male, 16 female) had TCOM performed on the chest and at five upper limb positions: lateral aspect of the upper arm midway between the shoulder and elbow; lateral aspect of the forearm, dorsum of the hand, thenar and hypothenar eminences. Measurements were taken using the TCM400 Monitoring System (Radiometer) with subjects breathing room air and whilst breathing 100% oxygen.
   Results: Room-air TCOM values (mean (SD), 95% confidence interval (CI)) were: chest: 50 (11.4) mmHg, 95% CI 46.0 to 54.2; upper arm: 53 (9.3) mmHg, 95% CI 49.7 to 56.4; forearm: 45 (11.3) mmHg, 95% CI 40.4 to 48.6; dorsum of hand: 39(8.5) mmHg, 95% CI 35.5 to 41.7; thenar eminence: 54(7.7) mmHg, 95% CI 51.7 to 57.2; and hypothenar eminence: 57 (7.5) mmHg, 95% CI 54.1 to 59.6. All readings showed a substantial increase when subjects breathed 100% oxygen. Using the currently accepted threshold for tissue hypoxia of < 40 mmHg, six forearm and 14 dorsum of the hand TCOM readings would have been classified as hypoxic.
   Conclusion: Normal upper limb TCOM readings are less than those established for the lower limb. Using lower-limb reference standards could result in false-positive determinations of tissue hypoxia. We recommend TCOM <= 30 mmHg as indicative of tissue hypoxia in the upper arm, thenar and hypothenar eminences, and <= 20 mmHg in the forearm and dorsum of the hand.
C1 [Young, Derelle A.] Townsville Hosp, Hyperbar Med Unit, Townsville, Qld, Australia.
   [Blake, Denise F.] Townsville Hosp, Dept Emergency Med, Townsville, Qld, Australia.
   [Blake, Denise F.] James Cook Univ, Sch Marine & Trop Biol, Townsville, Qld 4811, Australia.
   [Brown, Lawrence H.] James Cook Univ, Anton Breinl Ctr Publ Hlth & Trop Med, Townsville, Qld 4811, Australia.
RP Young, DA (reprint author), Townsville Hosp, Hyperbar Med Unit, 100 Angus Smith Dr, Douglas, Qld 4814, Australia.
EM Derelle_Young@health.qld.gov.au
FU Clinical Nurse Action Research Fund at The Townsville Hospital
FX The authors gratefully acknowledge the financial assistance received
   from the Clinical Nurse Action Research Fund at The Townsville Hospital,
   and thank our subjects for their participation.
CR Babilas P, 2008, SKIN RES TECHNOL, V14, P304, DOI 10.1111/j.1600-0846.2008.00295.x
   Bartels C, 1996, VASCULAR SURG, V30, P215, DOI 10.1177/153857449603000308
   CLARKE D, 1997, TRANSCUTANEOUS MONIT
   COLEMAN LS, 1986, CLIN PHYS PHYSIOL M, V7, P259, DOI 10.1088/0143-0815/7/3/006
   Daviet JC, 2004, ARCH PHYS MED REHAB, V85, P1102, DOI 10.1016/j.apmr.2003.09.034
   de Meijer VE, 2008, J VASC SURG, V48, P382, DOI 10.1016/j.jvs.2008.03.010
   Dooley J, 1997, UNDERSEA HYPERBAR M, V24, P235
   DOWD GSE, 1983, CLIN PHYS PHYSIOL M, V4, P65, DOI 10.1088/0143-0815/4/1/006
   DOWD GSE, 1983, J BONE JOINT SURG BR, V65, P79
   Fife CE, 2009, UNDERSEA HYPERBAR M, V36, P43
   Harissis H, 2008, DIALYSIS TRANSPLANT, V37, P67, DOI 10.1002/dat.20169
   HAUSER CJ, 1983, ANN SURG, V197, P337, DOI 10.1097/00000658-198303000-00014
   HUCH R, 1981, CRIT CARE MED, V9, P694, DOI 10.1097/00003246-198110000-00004
   Kurabayashi H, 1996, AM J PHYS MED REHAB, V75, P353, DOI 10.1097/00002060-199609000-00010
   Manabe S, 2004, ANN THORAC SURG, V77, P2066, DOI 10.1016/j.athoracsur.2003.10.052
   Mayrovitz HN, 2005, LYMPHOLOGY, V38, P81
   MORITZ AR, 1947, AM J PATHOL, V23, P695
   OLERUD JE, 1987, SCAND J CLIN LAB INV, V47, P535
   Radiometer Medical ApS, 2005, TCM400 TRANSC PO2 MO
   Rich K, 2001, J Vasc Nurs, V19, P55, DOI 10.1067/mvn.2001.115782
   Sheffield PJ, 1998, UNDERSEA HYPERBAR M, V25, P179
   Sheffield PJ., 1998, BLOOD GAS NEWS, V7, P10
   SILVERSTEIN JL, 1988, ARCH DERMATOL, V124, P1379, DOI 10.1001/archderm.124.9.1379
   Smart DR, 2006, DIVING HYPERB MED, V36, P72
   WORKMAN WT, 1983, CONTINUOUS TRANSCUTA, P637
NR 25
TC 4
Z9 4
U1 2
U2 7
PU SOUTH PACIFIC UNDERWATER MED SOC
PI MELBOURNE
PA C/O AUSTRALIAN & NEW ZEALAND COLL ANAESTHETISTS, 630 ST KILDA RD,
   MELBOURNE, VIC 3004, AUSTRALIA
SN 1833-3516
J9 DIVING HYPERB MED
JI Diving Hyperb. Med.
PD DEC
PY 2012
VL 42
IS 4
BP 208
EP 213
PG 6
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 053NO
UT WOS:000312279900005
PM 23258457
DA 2018-12-27
ER

PT J
AU Lee, CK
   Park, JW
AF Lee, Chul-Ku
   Park, Jae-Won
TI RETRACTED: Comparison of Mechanical Properties and Sensitization of Clad
   Steel Weld Zone with FCAW (Retracted article. See vol. 15, pg. 589,
   2014)
SO INTERNATIONAL JOURNAL OF PRECISION ENGINEERING AND MANUFACTURING
LA English
DT Article; Retracted Publication
DE Clad steel; Sensitization; Inter-granular stress corrosion crack; Degree
   of sensitization; Oxalic etching
ID STAINLESS-STEEL
AB This study aims at developing on-site techniques to evaluate the sensitization of stainless steels. Sensitization and mechanical properties of clad metals in hot-rolled clad steel plates, STS 316 steel plate and carbon steel (A516), are investigated at the specific conditions of post heat treatment and welds which are multiple-layers-thick or are repeated for repair Sectioned weldments and external surfaces are investigated to reveal the degree of sensitization by evaluating Micro Vickers hardness test, tensile test and etching. The results are compared with those of EPR tests. As test conditions, clad steel plates are butt-welded by FCAW + SMAW. and heat treatments are conducted at a temperature of 625 degrees C for 80, 160, 320, 640 and 1280 minutes, using the time of heat treatment as a variable. The change of corrosion resistance is also evaluated for these specimens. As the heat treatment time increases in case of carbon steel (A516), the annealing effect causes the tensile strength to decrease. The micro-hardness gradually increased, and decreased after 640 min. Elongation and contraction of the area also increased gradually After oxalic acid etch tests and EPR tests on STS316, clad metal shows STEP structure with no sensitization. It can be concluded that there is no effect on the corrosion resistance of clad metals by use of the test results on multi-layered and repair welds.
C1 [Park, Jae-Won] Seoul Natl Univ Sci & Technol, Grad Sch NID Fus Technol, Seoul 139743, South Korea.
   [Lee, Chul-Ku] Seoul Natl Univ Sci & Technol, Dept Mech & Automot Engn, Seoul 139743, South Korea.
RP Park, JW (reprint author), Seoul Natl Univ Sci & Technol, Grad Sch NID Fus Technol, Seoul 139743, South Korea.
EM weldingtig@naver.com
CR Aydogdu GH, 2006, CORROS SCI, V48, P3565, DOI 10.1016/j.corsci.2006.01.003
   BELL FC, 1976, METALLOGRAPHY, V9, P91, DOI 10.1016/0026-0800(76)90008-2
   Clarke W. L, 1981, NUREGCR1095 NAT TECH
   CLARKE WL, 1980, MATER PERFORMANCE, V19, P16
   Interante C. G, 1982, BASIC ASPECTS PROBLE, V3
   Jeong HS, 2010, INT J PRECIS ENG MAN, V11, P83, DOI [10.1007/S12541-010-0010-7, 10.1007/s12541-010-0010-7]
   Kim W. G, 2006, P KSPE SPRING C, P105
   Kim WK, 2010, INT J PRECIS ENG MAN, V11, P931, DOI 10.1007/s12541-010-0113-1
   Liljas M, 1994, P 4 INT C DUPL STAIN, V2, P13
   Majidi A. P., 1984, J CORROS SCI KOREA, V11, P584
   Na Gee-Dae, 2007, [Journal of Manufacturing Engineening & Technology, 한국생산제조시스템학회지], V16, P24
   Yoo Young-Tae, 2004, [Journal of Manufacturing Engineening & Technology, 한국생산제조시스템학회지], V13, P67
NR 12
TC 2
Z9 2
U1 4
U2 23
PU KOREAN SOC PRECISION ENG
PI SEOUL
PA RM 306, KWANGMYUNG BLDG, 5-4 NONHYUN-DONG, KANGNAM-GU, SEOUL, 135-010,
   SOUTH KOREA
SN 2234-7593
EI 2005-4602
J9 INT J PRECIS ENG MAN
JI Int. J. Precis. Eng. Manuf.
PD DEC
PY 2012
VL 13
IS 12
BP 2209
EP 2214
DI 10.1007/s12541-012-0293-y
PG 6
WC Engineering, Manufacturing; Engineering, Mechanical
SC Engineering
GA 047BL
UT WOS:000311812600017
DA 2018-12-27
ER

PT J
AU Savine, AC
   Braver, TS
AF Savine, Adam C.
   Braver, Todd S.
TI RETRACTED: Local and global effects of motivation on cognitive control
   (Retracted article. See vol. 13, pg. 586, 2013)
SO COGNITIVE AFFECTIVE & BEHAVIORAL NEUROSCIENCE
LA English
DT Article; Retracted Publication
DE Cognitive control; Motivation; Reward; Context; Individual differences;
   Task switching
ID DORSOLATERAL PREFRONTAL CORTEX; SPEED-ACCURACY TRADEOFF; WORKING-MEMORY;
   DIFFUSION-MODEL; INTEGRATIVE THEORY; ATTENTIONAL EFFORT; GOAL SYSTEMS;
   REWARD; DOPAMINE; TASK
AB Motivation has been found to enhance cognitive control, but the mechanisms by which this occurs are still poorly understood. Cued motivational incentives (e.g., monetary rewards) can modulate cognitive processing locally-that is, on a trial-by-trial basis (incentive cue effect). Recently, motivational incentives have also been found to produce more global and tonic changes in performance, as evidenced by performance benefits on nonincentive trials occurring within incentive blocks (incentive context effect). In two experiments involving incentivized cued task switching, we provide systematic evidence that the two effects are dissociable. Through behavioral, diffusion-modeling, and individual-differences analyses, we found dissociations between local and global motivational effects that were linked to specific properties of the incentive signals (i.e., timing), while also ruling out alternative interpretations (e.g., practice and speed-accuracy trade-off effects). These results provide important clues regarding the neural mechanisms by which motivation exerts both global and local influences on cognitive control.
C1 [Savine, Adam C.; Braver, Todd S.] Washington Univ, Dept Psychol, St Louis, MO 63130 USA.
RP Savine, AC (reprint author), Washington Univ, Dept Psychol, Campus Box 1125, St Louis, MO 63130 USA.
EM acsavine@go.wustl.edu; tbraver@wustl.edu
OI Braver, Todd/0000-0002-2631-3393
FU NIH [2R56MH066078]; NRSA [1F31DA032152-01A1]
FX This work was supported by NIH Grant No. 2R56MH066078 awarded to T. S.
   B. and predoctoral NRSA fellowship 1F31DA032152-01A1 awarded to A. C. S.
   We thank Samuel Moore for his help with portions of this project.
CR Aarts E, 2010, NEUROPSYCHOPHARMACOL, V35, P1943, DOI 10.1038/npp.2010.68
   Aarts H, 2008, SOC COGNITION, V26, P555, DOI 10.1521/soco.2008.26.5.555
   Aston-Jones G, 2005, ANNU REV NEUROSCI, V28, P403, DOI 10.1146/annurev.neuro.28.061604.135709
   Balci F, 2011, ATTEN PERCEPT PSYCHO, V73, P640, DOI 10.3758/s13414-010-0049-7
   Ballard IC, 2011, J NEUROSCI, V31, P10340, DOI 10.1523/JNEUROSCI.0895-11.2011
   Beck SM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009251
   Berridge KC, 2004, PHYSIOL BEHAV, V81, P179, DOI 10.1016/j.physbeh.2004.02.004
   Berridge KC, 2007, PSYCHOPHARMACOLOGY, V191, P391, DOI 10.1007/s00213-006-0578-x
   Bijleveld E, 2011, J EXP SOC PSYCHOL, V47, P865, DOI 10.1016/j.jesp.2011.03.002
   Bijleveld E, 2009, PSYCHOL SCI, V20, P1313, DOI 10.1111/j.1467-9280.2009.02443.x
   Bogacz R, 2010, TRENDS NEUROSCI, V33, P10, DOI 10.1016/j.tins.2009.09.002
   Braver T. S., 2012, 2 ROADS SUCCES UNPUB
   Braver T. S., 2007, VARIATION WORKING ME, P76, DOI [DOI 10.1093/ACPROF:OSO/9780195168648.003.0004, 10.1093/acprof:oso/9780195168648.003.0004]
   Braver TS, 2000, CONTROL OF COGNITIVE PROCESSES: ATTENTION AND PERFORMANCE XVIII, P713
   CARVER CS, 1994, J PERS SOC PSYCHOL, V67, P319, DOI 10.1037//0022-3514.67.2.319
   Chiew KS, 2011, FRONT PSYCHOL, V2, DOI 10.3389/fpsyg.2011.00325
   Cohen J, 2002, CURR OPIN NEUROBIOL, V12, P223, DOI 10.1016/S0959-4388(02)00314-8
   Cools R, 2008, NEUROSCIENTIST, V14, P381, DOI 10.1177/1073858408317009
   Dreisbach G, 2006, BRAIN COGNITION, V60, P11, DOI 10.1016/j.bandc.2005.08.003
   Durstewitz D, 1999, J NEUROSCI, V19, P2807
   Dutilh G, 2011, COGNITIVE SCI, V35, P211, DOI 10.1111/j.1551-6709.2010.01147.x
   Eccles JS, 2002, ANNU REV PSYCHOL, V53, P109, DOI 10.1146/annurev.psych.53.100901.135153
   Engelmann JB, 2007, EMOTION, V7, P668, DOI 10.1037/1528-3542.7.3.668
   Engelmann JB, 2009, FRONT HUM NEUROSCI, V3, DOI 10.3389/neuro.09.004.2009
   Fishbach A, 2004, J EXP SOC PSYCHOL, V40, P723, DOI 10.1016/j.jesp.2004.04.001
   Forstmann BU, 2008, P NATL ACAD SCI USA, V105, P17538, DOI 10.1073/pnas.0805903105
   Furey ML, 1997, P NATL ACAD SCI USA, V94, P6512, DOI 10.1073/pnas.94.12.6512
   Grace AA, 2007, TRENDS NEUROSCI, V30, P220, DOI 10.1016/j.tins.2007.03.003
   Hubner R, 2010, PSYCHON B REV, V17, P821, DOI 10.3758/PBR.17.6821
   Jimura K, 2010, P NATL ACAD SCI USA, V107, P8871, DOI 10.1073/pnas.1002007107
   Karayanidis F, 2010, FRONT PSYCHOL, V1, DOI 10.3389/fpsyg.2010.00025
   Karayanidis F, 2009, COGN AFFECT BEHAV NE, V9, P202, DOI 10.3758/CABN.9.2.202
   Koo M, 2008, J PERS SOC PSYCHOL, V94, P183, DOI 10.1037/0022-3514.94.2.183
   Krawczyk DC, 2007, BRAIN RES, V1141, P168, DOI 10.1016/j.brainres.2007.01.052
   Kruglanski AW, 2002, ADV EXP SOC PSYCHOL, V34, P331, DOI 10.1016/S0065-2601(02)80008-9
   Leon MI, 1999, NEURON, V24, P415, DOI 10.1016/S0896-6273(00)80854-5
   Locke HS, 2008, COGN AFFECT BEHAV NE, V8, P99, DOI 10.3758/CABN.8.1.99
   Madden DJ, 2010, NEUROIMAGE, V52, P643, DOI 10.1016/j.neuroimage.2010.04.249
   Mansfield EL, 2011, J NEUROSCI, V31, P14688, DOI 10.1523/JNEUROSCI.2390-11.2011
   Markman AB, 2005, J EXP THEOR ARTIF IN, V17, P371, DOI 10.1080/09528130500283915
   Meiran N, 2000, CONTROL OF COGNITIVE PROCESSES: ATTENTION AND PERFORMANCE XVIII, P377
   MEYER DE, 1990, ATTENTION PERFORM, P173
   Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167
   Mueller J, 2007, EUR J NEUROSCI, V26, P3661, DOI 10.1111/j.1460-9568.2007.05949.x
   Murphy BL, 1996, P NATL ACAD SCI USA, V93, P1325, DOI 10.1073/pnas.93.3.1325
   Niv Y, 2007, PSYCHOPHARMACOLOGY, V191, P507, DOI 10.1007/s00213-006-0502-4
   Padmala S, 2011, J COGNITIVE NEUROSCI, V23, P3419, DOI 10.1162/jocn_a_00011
   Padmala S, 2010, NEUROPSYCHOLOGIA, V48, P558, DOI 10.1016/j.neuropsychologia.2009.10.017
   Pessiglione M, 2006, NATURE, V442, P1042, DOI 10.1038/nature05051
   Pessoa L, 2010, FRONT NEUROSCI-SWITZ, V4, DOI [10.3389/fnins.2010.00017, 10.3389/fnhum.2010.00064]
   Pessoa L, 2009, TRENDS COGN SCI, V13, P160, DOI 10.1016/j.tics.2009.01.006
   Pochon JB, 2002, P NATL ACAD SCI USA, V99, P5669, DOI 10.1073/pnas.082111099
   POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.neuro.13.1.25
   Ratcliff R, 1998, PSYCHOL SCI, V9, P347, DOI 10.1111/1467-9280.00067
   Ratcliff R, 2002, PSYCHON B REV, V9, P438, DOI 10.3758/BF03196302
   RATCLIFF R, 1978, PSYCHOL REV, V85, P59, DOI 10.1037//0033-295X.85.2.59
   Ratcliff R, 2008, NEURAL COMPUT, V20, P873, DOI 10.1162/neco.2008.12-06-420
   Salamone JD, 2007, PSYCHOPHARMACOLOGY, V191, P389, DOI 10.1007/s00213-006-0623-9
   Sarter M, 2006, BRAIN RES REV, V51, P145, DOI 10.1016/j.brainresrev.2005.11.002
   Savine AC, 2010, J NEUROSCI, V30, P10294, DOI 10.1523/JNEUROSCI.2052-10.2010
   Savine AC, 2010, COGNITION EMOTION, V24, P338, DOI 10.1080/02699930903381564
   Schneider W, 2002, E PRIME USERS GUIDE
   Schott BH, 2007, BRAIN, V130, P2412, DOI 10.1093/brain/awm147
   Schott BH, 2008, J NEUROSCI, V28, P14311, DOI 10.1523/JNEUROSCI.2058-08.2008
   Schultz W, 2002, NEURON, V36, P241, DOI 10.1016/S0896-6273(02)00967-4
   Schultz W, 2000, NAT REV NEUROSCI, V1, P199, DOI 10.1038/35044563
   Small DM, 2005, CEREB CORTEX, V15, P1855, DOI 10.1093/cercor/bhi063
   St Peters M, 2011, J NEUROSCI, V31, P9760, DOI 10.1523/JNEUROSCI.1902-11.2011
   STRAYER DL, 1994, PSYCHOL AGING, V9, P589, DOI 10.1037//0882-7974.9.4.589
   Tassin J., 1997, ADV PHARMACOL, V<IT>42</IT>, P712
   Taylor SF, 2004, NEUROIMAGE, V21, P1045, DOI 10.1016/j.neuroimage.2003.10.032
   van Veen V, 2008, J COGNITIVE NEUROSCI, V20, P1952, DOI 10.1162/jocn.2008.20146
   Veling H, 2010, MOTIV EMOTION, V34, P184, DOI 10.1007/s11031-010-9160-2
   Vijayraghavan S, 2007, NAT NEUROSCI, V10, P376, DOI 10.1038/nn1846
   Wagenmakers EJ, 2008, J MEM LANG, V58, P140, DOI 10.1016/j.jml.2007.04.006
   Wagenmakers EJ, 2007, PSYCHON B REV, V14, P3, DOI 10.3758/BF03194023
   Watanabe M, 2002, J NEUROSCI, V22, P2391, DOI 10.1523/JNEUROSCI.22-06-02391.2002
   WICKELGREN WA, 1977, ACTA PSYCHOL, V41, P67, DOI 10.1016/0001-6918(77)90012-9
NR 78
TC 3
Z9 3
U1 2
U2 38
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1530-7026
EI 1531-135X
J9 COGN AFFECT BEHAV NE
JI Cogn. Affect. Behav. Neurosci.
PD DEC
PY 2012
VL 12
IS 4
BP 692
EP 718
DI 10.3758/s13415-012-0113-y
PG 27
WC Behavioral Sciences; Neurosciences
SC Behavioral Sciences; Neurosciences & Neurology
GA 042VF
UT WOS:000311498900007
PM 22875410
OA Bronze
DA 2018-12-27
ER

PT J
AU Chen, XG
   Liang, LY
   Hu, X
   Chen, Y
AF Chen, Xiaogang
   Liang, Liying
   Hu, Xiao
   Chen, Yu
TI RETRACTED: Glutathione S-transferase P1 gene Ile105Val polymorphism
   might be associated with lung cancer risk in the Chinese Han population
   (Retracted article. See April, 2017)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE GSTP1; Genetic polymorphism; Meta-analysis; Lung cancer
ID METABOLIZING-ENZYMES; METAANALYSIS; GSTP1; SUSCEPTIBILITY; GSTM1;
   VARIANTS; GSTT1; EPIDEMIOLOGY; NQO1; BIAS
AB Genetic variations in glutathione S-transferase P1 (GSTP1) gene have been suggested to be involved in the development of cancer. However, the results from the studies regarding the association between GSTP1 Ile105Val polymorphism and lung cancer risk in the Chinese population have been inconsistent. Thus, we conducted a meta-analysis to investigate the association. Published literature from PubMed, Chinese Biomedical Literature Database, Chinese Wanfang Data, and Chinese National Knowledge Infrastructure databases were searched for eligible publications. Pooled odds ratios (ORs) with 95 % confidence intervals (CIs) were calculated using random or fixed effect model. Ten studies (1,506 cases/1,714 controls) were included in the meta-analysis. The results suggested that GSTP1 Ile105Val polymorphism was marginally associated with lung cancer risk in the Chinese Han population under a multiplicative model (G vs. A, odds ratio (OR) = 1.22, 95 % confidence interval = 1.02-1.46), under a homogeneous codominant model (GG vs. AA, OR = 1.67, 95 % CI = 1.14-2.45), under a heterogeneous codominant model (GA vs. AA, OR = 1.15, 95 % CI = 0.98-1.35), under a dominant model (GG + GA vs. AA, OR = 1.21, 95 % CI = 1.04-1.39), and under a recessive model (GG vs. GA + AA, OR = 1.59, 95 % CI = 1.09-2.31), respectively. Moreover, after adjusted for age, gender, and smoking status, the significant association under dominant model remained (OR = 1.27, 95 % CI = 1.07-1.51). This meta-analysis suggested that there might be an association between GSTP1 Ile105Val polymorphism and lung cancer in the Chinese Han population.
C1 [Chen, Xiaogang; Hu, Xiao; Chen, Yu] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Lab Med, Hangzhou 310003, Zhejiang, Peoples R China.
   [Liang, Liying] Zhejiang Univ, Sch Hosp Huajiachi, Hangzhou 310003, Zhejiang, Peoples R China.
RP Chen, Y (reprint author), Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Lab Med, 79 Qingchun Rd, Hangzhou 310003, Zhejiang, Peoples R China.
EM yuchen1965@126.com
CR Alberg AJ, 2005, J CLIN ONCOL, V23, P3175, DOI 10.1200/JCO.2005.10.462
   AliOsman F, 1997, J BIOL CHEM, V272, P10004
   ANTTILA S, 1993, CANCER RES, V53, P5643
   Bai T, 2005, ZHONG GUO YAO LI TON, V2, P30
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Butkiewicz D, 2000, ENVIRON MOL MUTAGEN, V35, P99, DOI 10.1002/(SICI)1098-2280(2000)35:2<99::AID-EM4>3.0.CO;2-2
   Cao YF, 2005, J CHANGZHI MED COLL, V19, P86
   Chan EC, 2005, CANCER GENET CYTOGEN, V162, P10, DOI 10.1016/j.cancergencyto.2005.03.008
   Chan-Yeung M, 2004, LUNG CANCER-J IASLC, V45, P155, DOI 10.1016/j.lungcan.2004.01.016
   Chen HC, 2006, DIS MARKERS, V22, P141, DOI 10.1155/2006/436497
   Coles BF, 2003, BIOFACTORS, V17, P115, DOI 10.1002/biof.5520170112
   Cote ML, 2009, AM J EPIDEMIOL, V169, P802, DOI 10.1093/aje/kwn417
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Economopoulos KP, 2010, INT J GYNECOL CANCER, V20, P732, DOI 10.1111/IGC.0b013e3181dedeb5
   Economopoulos KP, 2010, EUR J CANCER, V46, P1617, DOI 10.1016/j.ejca.2010.02.009
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516
   Guo P, 2012, ANN ONCOL, V23, P2755, DOI 10.1093/annonc/mds069
   Guo ZL, 2005, THESIS SICHUAN U, P1
   Han ZM, 2003, THESIS HUAZHONG SCI, P1
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hirvonen A, 1999, ENVIRON HEALTH PERSP, V107, P37, DOI 10.2307/3434470
   Hua F, 2010, THESIS TIANJIN MED U, P1
   Kellen E, 2007, AM J EPIDEMIOL, V165, P1221, DOI 10.1093/aje/kwm003
   Lam WK, 2004, INT J TUBERC LUNG D, V8, P1045
   Langevin SM, 2010, PHARMACOGENET GENOM, V20, P586, DOI 10.1097/FPC.0b013e32833c3892
   Liang Ge-Yu, 2004, Yichuan, V26, P584
   Liang GY, 2005, CANCER LETT, V223, P265, DOI 10.1016/j.canlet.2004.12.042
   Lin PP, 2003, LUNG CANCER-J IASLC, V40, P123, DOI 10.1016/S0169-5002(03)00027-8
   Lu S, 2011, BREAST CANCER RES TR, V125, P253, DOI 10.1007/s10549-010-0969-x
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Mo ZN, 2009, PROSTATE, V69, P662, DOI 10.1002/pros.20907
   Nie LH, 2002, CHINA PUBLIC HLTH, V18, P791
   Sheweita SA, 2003, CURR DRUG METAB, V4, P45, DOI 10.2174/1389200033336919
   Singh Madhu S., 2009, V472, P243, DOI 10.1007/978-1-60327-492-0_10
   Strange R C, 1999, IARC Sci Publ, P231
   Strange RC, 2001, MUTAT RES-FUND MOL M, V482, P21, DOI 10.1016/S0027-5107(01)00206-8
   Sundberg K, 1998, CARCINOGENESIS, V19, P433, DOI 10.1093/carcin/19.3.433
   Tamaki Y, 2011, DRUG METAB PHARMACOK, V26, P516, DOI 10.2133/dmpk.DMPK-11-RG-046
   Wang JW, 2003, CANCER LETT, V201, P185, DOI 10.1016/S0304-3835(03)00480-4
   Watson MA, 1998, CARCINOGENESIS, V19, P275, DOI 10.1093/carcin/19.2.275
   White DL, 2008, AM J EPIDEMIOL, V167, P377, DOI 10.1093/aje/kwm315
   World Health Organization, 2011, CANCER
   Ye Z, 2006, PLOS MED, V3, P524, DOI 10.1371/journal.pmed.0030091
   Yin Q, 2009, THESIS NEIMENGGU MED, P1
   Yue Z, 2010, CHIN J CANC PREV TRE, V16, P1441
   Zendehdel K, 2009, CANCER CAUSE CONTROL, V20, P2031, DOI 10.1007/s10552-009-9399-7
   [张体艳 ZHANG Tiyan], 2006, [郑州大学学报. 医学版, Journal of Zhengzhou University.Medical Sciences], V41, P448
   Zhou Y, 2009, EUR J CANCER, V45, P1438, DOI 10.1016/j.ejca.2008.12.020
NR 49
TC 11
Z9 11
U1 4
U2 8
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD DEC
PY 2012
VL 33
IS 6
BP 1973
EP 1981
DI 10.1007/s13277-012-0457-5
PG 9
WC Oncology
SC Oncology
GA 038VF
UT WOS:000311201500017
PM 22797821
DA 2018-12-27
ER

PT J
AU Pan, TY
   Sun, L
   Yu, QF
AF Pan, Tongyan
   Sun, Lu
   Yu, Qifeng
TI RETRACTED: An atomistic-based chemophysical environment for evaluating
   asphalt oxidation and antioxidants (Retracted article. See vol. 20,
   2432, 2014)
SO JOURNAL OF MOLECULAR MODELING
LA English
DT Article; Retracted Publication
DE Asphalt; Atomistic modeling; Lignin; Oxidative aging; Quantum chemistry;
   XPS
ID ELECTRONEGATIVITY EQUALIZATION METHOD; REACTIVE FORCE-FIELD; MOLECULAR
   SIMULATION; IRON OXIDATION; STEEL SURFACE; SPECTROSCOPY; PETROLEUM;
   PASSIVATION; MECHANISM; DYNAMICS
AB Asphalt binders in service conditions are subject to oxidative aging that involves the reactions between oxygen molecules and the component species of bulk asphalt. As a result, significant alterations can occur to the desired physical and/or mechanical properties of asphalt. A common practice to alleviate asphalt aging has been to employ different chemical additives or modifiers as antioxidants. The current state of knowledge in asphalt oxidation and antioxidant evaluation is centered on determining the degradation of asphalt physical properties, mainly the viscosity and ductility. Such practices, although meeting direct engineering needs, do not contribute to the fundamental understanding of the aging and anti-oxidation mechanisms, and thereby developing anti-aging strategies. From this standpoint, this study was initiated to study the chemical and physical bases of asphalt oxidation, as well as the anti-oxidation mechanisms of bio-based antioxidants using the coniferyl-alcohol lignin as an example. A quantum chemistry (QC) based chemophysical environment is developed, in which the various chemical reactions between asphalt component species and oxygen, as well as the incurred physical changes are studied. X-ray photoelectron spectroscopy (XPS) was used to validate the modified and unmodified asphalt models.
C1 [Pan, Tongyan; Sun, Lu; Yu, Qifeng] Catholic Univ Amer, Washington, DC 20064 USA.
RP Pan, TY (reprint author), Catholic Univ Amer, 620 Michigan Ave NE, Washington, DC 20064 USA.
EM pan@cua.edu; sunl@cua.edu; yuq@cua.edu
RI Pan, Tongyan/F-6824-2012
CR Artok L, 1999, ENERG FUEL, V13, P287, DOI 10.1021/ef980216a
   BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118
   Bishara SW, 2005, 42 PET ASPH RES C CH
   Boeriu CG, 2004, IND CROP PROD, V20, P205, DOI 10.1016/j.indcrop.2004.04.022
   Boerjan W, 2003, ANNU REV PLANT BIOL, V54, P519, DOI 10.1146/annurev.arplant.54.031902.134938
   Branthaver J. F., 1993, SHRPA368 NAT RES COU, V2
   BRINK DL, 1966, ADV CHEM SER, P177
   Bryan C. C., 1954, US Patent, Patent No. [2 ,692,291, 2692291]
   Chenoweth K, 2008, J PHYS CHEM A, V112, P1040, DOI 10.1021/jp709896w
   CORBETT LW, 1969, ANAL CHEM, V41, P576, DOI 10.1021/ac60273a004
   Davis T. C., 1967, P ASS ASPHALT PAVING, V36, P1
   Dizhbite T, 2004, BIORESOURCE TECHNOL, V95, P309, DOI 10.1016/j.biortech.2004.02.024
   Gelius U., 1970, Physica Scripta, V2, DOI 10.1088/0031-8949/2/1-2/014
   Griffin RL, 1959, J CHEM ENG DATA, V4, P349
   Groenzin H, 2000, ENERG FUEL, V14, P677, DOI 10.1021/ef990225z
   Hveem FN, 1959, AM SOC TEST MAT, V277, P1
   JANSSENS GOA, 1995, J PHYS CHEM-US, V99, P3251, DOI 10.1021/j100010a041
   KELEMEN SR, 1990, FUEL, V69, P939, DOI 10.1016/0016-2361(90)90001-7
   Kowalewski I, 1996, ENERG FUEL, V10, P97, DOI 10.1021/ef950106t
   Kuzina S. I., 1993, J POLYM SCI A, VA35, P798
   Lindberg BJ, 1970, PHYS SCRIPTA, V1, P288
   LUCENA MCC, 2004, MAT RES, V7, P529, DOI DOI 10.1590/S1516-14392004000400004
   McNichol D., 2005, PAVING WAY ASPHALT A
   MORTIER WJ, 1986, J AM CHEM SOC, V108, P4315, DOI 10.1021/ja00275a013
   Njo SL, 1998, J MOL CATAL A-CHEM, V134, P79, DOI 10.1016/S1381-1169(98)00024-7
   Pan T, 2011, INT J ELECTROCHEM SC, V8
   Pan T, 2011, ELECTROCATALYSIS-US, V2, P307, DOI 10.1007/s12678-011-0068-8
   Pan TY, 2011, ACTA METALL SIN-ENGL, V24, P415, DOI 10.11890/1006-7191-116-415
   Pan TY, 2011, MATER LETT, V65, P3223, DOI 10.1016/j.matlet.2011.07.024
   Pan TY, 2011, CHEM PHYS LETT, V511, P315, DOI 10.1016/j.cplett.2011.06.041
   Pan TY, 2008, J ASSOC ASPHALT PAV, V77, P773
   Parr R. G., 1989, DENSITY FUNCTIONAL T
   Petersen J.C., 1993, TRANSPORT RES REC, V1391, P1
   Petersen J. C., 1984, T RES REC, V999, P13
   Petersen J.C., 1983, P ASS ASPHALT PAVING, V52, P32
   Petersen JC, 1998, PET SCI TECHNOL, V16, P1023, DOI 10.1080/10916469808949823
   Petersen JC, 1998, TRANSPORT RES REC, P47, DOI 10.3141/1638-06
   Plancher H., 1976, P ASS ASPHALT PAVING, V45, P1
   Ruan YH, 2003, ENERG FUEL, V17, P991, DOI 10.1021/ef020221l
   RUIZ JM, 1982, ANAL CHEM, V54, P688, DOI 10.1021/ac00241a020
   Shi X, 2009, OPEN CIVIL ENG J, V3, P16
   STORM DA, 1994, ENERG FUEL, V8, P561, DOI 10.1021/ef00045a007
   Usmani A. M., 1997, ASPHALT SCI TECHNOLO
   van Duin ACT, 2001, J PHYS CHEM A, V105, P9396, DOI 10.1021/jp004368u
   VERLET L, 1967, PHYS REV, V159, P98, DOI 10.1103/PhysRev.159.98
   Wess J, 2004, 59 WHO
   White RM, 1970, P ASS ASPHALT PAVING, V39, P498
   Zhang LQ, 2007, J CHEM PHYS, V127, DOI 10.1063/1.2799189
NR 48
TC 4
Z9 4
U1 4
U2 34
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1610-2940
EI 0948-5023
J9 J MOL MODEL
JI J. Mol. Model.
PD DEC
PY 2012
VL 18
IS 12
BP 5113
EP 5126
DI 10.1007/s00894-012-1512-2
PG 14
WC Biochemistry & Molecular Biology; Biophysics; Chemistry,
   Multidisciplinary; Computer Science, Interdisciplinary Applications
SC Biochemistry & Molecular Biology; Biophysics; Chemistry; Computer
   Science
GA 041KG
UT WOS:000311400100016
PM 22772829
DA 2018-12-27
ER

PT J
AU Rampersaud, N
   Harkavyi, A
   Giordano, G
   Lever, R
   Whitton, J
   Whitton, PS
AF Rampersaud, N.
   Harkavyi, A.
   Giordano, G.
   Lever, R.
   Whitton, J.
   Whitton, P. S.
TI RETRACTED: Exendin-4 reverts behavioural and neurochemical dysfunction
   in a pre-motor rodent model of Parkinson's disease with noradrenergic
   deficit (Retracted article. See vol. 169, pg. 717, 2013)
SO BRITISH JOURNAL OF PHARMACOLOGY
LA English
DT Article; Retracted Publication
DE 6-OHDA; DSP-4; exendin-4; force swim test; novel object recognition;
   Parkinson's disease; pre-motor; sucrose preference
ID GLUCAGON-LIKE PEPTIDE-1; TYROSINE-HYDROXYLASE GENE; LOCUS-CERULEUS
   LESIONS; SUBSTANTIA-NIGRA; DOPAMINERGIC-NEURONS; RECEPTOR STIMULATION;
   STRIATAL DOPAMINE; ARRIVE GUIDELINES; NONMOTOR SYMPTOMS; ANIMAL-MODEL
AB BACKGROUND AND PURPOSE
   Parkinson's disease (PD) is characterized by progressive dopaminergic cell loss; however, the noradrenergic system exhibits degeneration as well. Noradrenergic deficit in PD may be responsible for certain non-motor symptoms of the pathology, including psychiatric disorders and cognitive decline. The aim of this study was to generate a pre-motor rodent model of PD with noradrenergic denervation, and to assess whether treatment with exendin-4 (EX-4), a glucagon-like peptide 1 receptor agonist, could reverse impairment exhibited by our model.
   EXPERIMENTAL APPROACH
   We generated a model of PD utilizing N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine and 6-hydroxydopamine to create partial lesions of both the noradrenergic and dopaminergic systems respectively. We then assessed the validity of our model using an array of behavioural paradigms and biochemical techniques. Finally, we administered EX-4 over a 1 week period to determine therapeutic efficacy.
   KEY RESULTS
   Our model exhibits anhedonia and decreased object recognition as indicated by a decrease in sucrose preference, increased immobility in the forced swim test and reduced novel object exploration. Tissue and extracellular dopamine and noradrenaline were reduced in the frontal cortex and striatum. TH+ cell counts decreased in the locus coeruleus and substantia nigra. Treatment with EX-4 reversed behavioural impairment and restored extracellular/tissue levels of both dopamine and noradrenaline and TH+ cell counts.
   CONCLUSION AND IMPLICATIONS
   We conclude that early treatment with EX-4 may reverse certain neuropsychiatric dysfunction and restore dopamine and noradrenaline content.
C1 [Rampersaud, N.; Harkavyi, A.; Giordano, G.; Lever, R.; Whitton, J.; Whitton, P. S.] UCL, Sch Pharm, Fac Life Sci, Dept Pharmacol, London WC1N 1AX, England.
RP Rampersaud, N (reprint author), UCL, Sch Pharm, Fac Life Sci, Dept Pharmacol, 29-39 Brunswick Sq, London WC1N 1AX, England.
EM n.rampersaud@ucl.ac.uk
FU Michael J. Fox Foundation; Parkinson's UK
FX This study was supported by the Michael J. Fox Foundation. AH was funded
   by Parkinson's UK. We would also like to thank Dr Mohammed Hankir of
   Oxford University, Department of Physiology, Anatomy, and Genetics, and
   Ms. Saleema Rampersaud of Hudson County Schools of Technology, for
   reviewing and revising this manuscript.
CR Arango V, 1996, ALCOHOL CLIN EXP RES, V20, P1141, DOI 10.1111/j.1530-0277.1996.tb01102.x
   Archer T, 2006, J NEURAL TRANSM, V113, P1119, DOI 10.1007/s00702-005-0402-5
   Bambico FR, 2009, EUR NEUROPSYCHOPHARM, V19, P215, DOI 10.1016/j.euroneuro.2008.11.005
   Benarroch EE, 2009, NEUROLOGY, V73, P1699, DOI 10.1212/WNL.0b013e3181c2937c
   Bertilsson G, 2008, J NEUROSCI RES, V86, P326, DOI 10.1002/jnr.21483
   BIGGS CS, 1992, J NEUROCHEM, V59, P1702, DOI 10.1111/j.1471-4159.1992.tb11001.x
   Bowenkamp KE, 1996, EXP BRAIN RES, V111, P1
   Braak H, 2003, NEUROBIOL AGING, V24, P197, DOI 10.1016/S0197-4580(02)00065-9
   Branchi I, 2008, J NEUROSCI RES, V86, P2050, DOI 10.1002/jnr.21642
   CHANPALAY V, 1989, J COMP NEUROL, V287, P373, DOI 10.1002/cne.902870308
   Chaudhuri KR, 2006, LANCET NEUROL, V5, P235, DOI 10.1016/S1474-4422(06)70373-8
   Chen XQ, 2008, MOL PHARMACOL, V73, P1816, DOI 10.1124/mol.107.043968
   Cohen AD, 2011, BRAIN RES, V1370, P80, DOI 10.1016/j.brainres.2010.11.006
   Cummings JL, 1999, INT J GERIATR PSYCH, V14, P711, DOI 10.1002/(SICI)1099-1166(199909)14:9<711::AID-GPS4>3.3.CO;2-T
   Dauer W, 2003, NEURON, V39, P889, DOI 10.1016/S0896-6273(03)00568-3
   de Lau LML, 2006, LANCET NEUROL, V5, P525, DOI 10.1016/S1474-4422(06)70471-9
   DeCastro M, 2005, MOL BRAIN RES, V142, P28, DOI 10.1016/j.molbrainres.2005.09.002
   Delaville C, 2011, FRONT SYST NEUROSCI, V5, DOI 10.3389/fnsys.2011.00031
   Du YS, 2001, P NATL ACAD SCI USA, V98, P14669, DOI 10.1073/pnas.251341998
   ENNACEUR A, 1988, BEHAV BRAIN RES, V31, P47, DOI 10.1016/0166-4328(88)90157-X
   Fan R, 2010, DIABETES OBES METAB, V12, P815, DOI 10.1111/j.1463-1326.2010.01238.x
   FORNAI F, 1995, EUR J PHARMACOL, V283, P99, DOI 10.1016/0014-2999(95)00313-A
   Frisina PG, 2009, PARKINSONISM RELAT D, V15, P144, DOI 10.1016/j.parkreldis.2008.04.038
   Gallwitz B, 2011, DRUGS, V71, P1675, DOI 10.2165/11592810-000000000-00000
   Harkavyi A, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-19
   Harkavyi A, 2010, BRIT J PHARMACOL, V159, P495, DOI 10.1111/j.1476-5381.2009.00486.x
   HORNYKIEWICZ O., 1963, WIENER KLIN WOCHENSCHR, V75, P309
   Iravani MM, 2005, EUR J NEUROSCI, V22, P317, DOI 10.1111/j.1460-9568.2005.04220.x
   Isacson R, 2011, EUR J PHARMACOL, V650, P249, DOI 10.1016/j.ejphar.2010.10.008
   Jardanhazi-Kurutz D, 2010, NEUROCHEM INT, V57, P375, DOI 10.1016/j.neuint.2010.02.001
   Kilkenny C, 2010, BRIT J PHARMACOL, V160, P1577, DOI 10.1111/j.1476-5381.2010.00872.x
   Kim SY, 2010, BRAIN RES, V1348, P105, DOI 10.1016/j.brainres.2010.05.097
   Kim S, 2009, J ENDOCRINOL, V202, P431, DOI 10.1677/JOE-09-0132
   Klimek V, 1997, J NEUROSCI, V17, P8451
   LATEGAN AJ, 1990, BRAIN RES, V523, P134, DOI 10.1016/0006-8993(90)91646-X
   LeDoux JE, 2000, ANNU REV NEUROSCI, V23, P155, DOI 10.1146/annurev.neuro.23.1.155
   Lees AJ, 2009, LANCET, V373, P2055, DOI 10.1016/S0140-6736(09)60492-X
   Li YZ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032008
   Li YZ, 2009, P NATL ACAD SCI USA, V106, P1285, DOI 10.1073/pnas.0806720106
   MARIE RM, 1995, J NEURAL TRANSM-PARK, V9, P55, DOI 10.1007/BF02252963
   Martin B, 2009, DIABETES, V58, P318, DOI 10.2337/db08-0799
   MAVRIDIS M, 1991, NEUROSCIENCE, V41, P507, DOI 10.1016/0306-4522(91)90345-O
   Mayberg H S, 1995, Adv Neurol, V65, P49
   McGrath JC, 2010, BRIT J PHARMACOL, V160, P1573, DOI 10.1111/j.1476-5381.2010.00873.x
   Merchenthaler I, 1999, J COMP NEUROL, V403, P261, DOI 10.1002/(SICI)1096-9861(19990111)403:2<261::AID-CNE8>3.0.CO;2-5
   Owen AM, 2004, NEUROSCIENTIST, V10, P525, DOI 10.1177/1073858404266776
   Paxinos G., 1982, RAT BRAIN STEREOTAXI
   Perry T, 2002, J PHARMACOL EXP THER, V302, P881, DOI 10.1124/jpet.102.037481
   Piech-Dumas KM, 2001, J NEUROCHEM, V76, P1376, DOI 10.1046/j.1471-4159.2001.00127.x
   PORSOLT RD, 1978, EUR J PHARMACOL, V47, P379, DOI 10.1016/0014-2999(78)90118-8
   Remy P, 2005, BRAIN, V128, P1314, DOI 10.1093/brain/awh445
   Ressler KJ, 1999, BIOL PSYCHIAT, V46, P1219, DOI 10.1016/S0006-3223(99)00127-4
   Rommelfanger KS, 2007, BIOCHEM PHARMACOL, V74, P177, DOI 10.1016/j.bcp.2007.01.036
   Roozendaal B, 2008, NEUROBIOL LEARN MEM, V90, P576, DOI 10.1016/j.nlm.2008.06.010
   ROSS RA, 1974, BRAIN RES, V73, P161, DOI 10.1016/0006-8993(74)91016-6
   SACHS C, 1975, BIOCHEM PHARMACOL, V24, P1, DOI 10.1016/0006-2952(75)90304-4
   Schrag A, 2004, J NEUROL, V251, P795, DOI 10.1007/s00415-004-0483-3
   Shiba M, 2000, MOVEMENT DISORD, V15, P669, DOI 10.1002/1531-8257(200007)15:4<669::AID-MDS1011>3.0.CO;2-5
   Srinivasan J, 2003, EUR J NEUROSCI, V17, P2586, DOI 10.1046/j.1460-9568.2003.02684.x
   Tadaiesky MT, 2008, NEUROSCIENCE, V156, P830, DOI 10.1016/j.neuroscience.2008.08.035
   Tolosa E, 2007, PARKINSONISM RELAT D, V13, pS2, DOI 10.1016/j.parkreldis.2007.06.007
   Wang SH, 2009, J PSYCHOPHARMACOL, V23, P295, DOI 10.1177/0269881108089814
   Wang Y, 2010, BRAIN RES, V1310, P189, DOI 10.1016/j.brainres.2009.10.070
   Winter C, 2007, BEHAV BRAIN RES, V184, P133, DOI 10.1016/j.bbr.2007.07.002
   Zarow C, 2003, ARCH NEUROL-CHICAGO, V60, P337, DOI 10.1001/archneur.60.3.337
   Ziemssen T, 2007, PARKINSONISM RELAT D, V13, P323, DOI 10.1016/j.parkreldis.2006.12.014
NR 66
TC 12
Z9 14
U1 2
U2 26
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0007-1188
EI 1476-5381
J9 BRIT J PHARMACOL
JI Br. J. Pharmacol.
PD DEC
PY 2012
VL 167
IS 7
BP 1467
EP 1479
DI 10.1111/j.1476-5381.2012.02100.x
PG 13
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 032QK
UT WOS:000310733800007
PM 22774922
OA Green Published
DA 2018-12-27
ER

PT J
AU Abdulraheem, A
   Mustafa, S
   Al-Saffar, N
   Shahjahan, M
AF Abdulraheem, Abdulkareem
   Mustafa, Seham
   Al-Saffar, Nabeel
   Shahjahan, Muhammed
TI RETRACTED: Detection of bacterial endotoxin in drinking tap and bottled
   water in Kuwait (Retracted article. See vol. 185, pg. 6219, 2013)
SO ENVIRONMENTAL MONITORING AND ASSESSMENT
LA English
DT Article; Retracted Publication
DE Endotoxin; Tap water; Bottled water; LAL test
ID LIMULUS LYSATE TEST; RAPID DETECTION; IN-VITRO; ASSAY; COAGULATION;
   MENINGITIS
AB This study was carried out to measure and compare the concentration of bacterial endotoxin in a variety of samples from drinking tap and bottled water available in Kuwait by using the Limulus Amoebocyte lysate test. A total of 29 samples were tested. Samples were collected from a variety of locations throughout the six governorates of Kuwait and 23 brands of local and imported bottled water samples were collected from the local market. The concentration of bacterial endotoxin was measured by using the standard Limulus Amoebocyte lysate test, gel clot method. This study showed that measured endotoxin concentrations in tap drinking water varied from 2.4 to 33.8 EU/ml with the average endotoxin concentration of 14.2 EU/ml. While the results of endotoxin concentrations in the bottled water were < 0.03 to 20.1 EU/ml with an average of 1.96 EU/ml. The average concentration of endotoxin in bottled water is 13.5 % of the average concentration of endotoxin in tap drinking water. This experimental investigation has proved that drinking bottled water has less endotoxin as compared to tap water in Kuwait. It is also demonstrated that the endotoxin concentration did not exceed the acceptable level in drinking tap water.
C1 [Abdulraheem, Abdulkareem; Mustafa, Seham; Al-Saffar, Nabeel] Coll Hlth Sci, Dept Pharmaceut Sci, Publ Author Appl Educ & Training, Safat 13092, Kuwait.
   [Shahjahan, Muhammed] Minist Hlth, Qual Control Ctr, Safat, Kuwait.
RP Mustafa, S (reprint author), Coll Hlth Sci, Dept Pharmaceut Sci, Publ Author Appl Educ & Training, POB 23167, Safat 13092, Kuwait.
EM mustafaseham@yahoo.com
CR Ahmad M, 2009, ENVIRON MONIT ASSESS, V159, P1, DOI 10.1007/s10661-008-0608-8
   Anderson WB, 2003, WATER RES, V37, P4553, DOI 10.1016/j.waters.2003.08.016
   Anderson WB, 2002, CAN J MICROBIOL, V48, P567, DOI 10.1139/W02-061
   Braude A. I., 1982, MICROBIOLOGY, P796
   COOPER JF, 1971, J LAB CLIN MED, V78, P138
   CUEVAS P, 1972, ARCH SURG-CHICAGO, V104, P319
   CUEVAS P, 1972, SURG GYNECOL OBSTETR, V134, P953
   DILUZIO NR, 1973, NATURE, V244, P49, DOI 10.1038/244049a0
   HINDMAN SH, 1975, LANCET, V2, P732
   JORGENSEN JH, 1973, APPL MICROBIOL, V26, P521
   JORGENSEN JH, 1975, AM J CLIN PATHOL, V63, P142
   JORGENSEN JH, 1973, APPL MICROBIOL, V26, P38
   LEVIN J, 1972, ANN INTERN MED, V76, P1, DOI 10.7326/0003-4819-76-1-1
   LEVIN J, 1968, THROMB DIATH HAEMOST, V19, P186
   Madigan M. T., 2000, BROCK BIOL MICROORGA, P793
   NACHUM R, 1973, NEW ENGL J MED, V289, P931, DOI 10.1056/NEJM197311012891801
   Prescott L. M., 2005, MICROBIOLOGY, P633
   Prescott L. M, 2002, MICROBIOLOGY, P799
   RAETZ CRH, 1993, J BACTERIOL, V175, P5745
   Rapala J, 2002, WATER RES, V36, P2627, DOI 10.1016/S0043-1354(01)00478-X
   Reyes MI, 2008, P R HEALTH SCI J, V27, P21
   ROJASCORONA RR, 1969, P SOC EXP BIOL MED, V132, P599
   ROSS S, 1975, JAMA-J AM MED ASSOC, V233, P1366, DOI 10.1001/jama.233.13.1366
   ROWE MI, 1975, ANN SURG, V182, P280, DOI 10.1097/00000658-197509000-00010
NR 24
TC 3
Z9 7
U1 3
U2 30
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0167-6369
EI 1573-2959
J9 ENVIRON MONIT ASSESS
JI Environ. Monit. Assess.
PD DEC
PY 2012
VL 184
IS 12
BP 7323
EP 7328
DI 10.1007/s10661-011-2501-0
PG 6
WC Environmental Sciences
SC Environmental Sciences & Ecology
GA 032TO
UT WOS:000310742200020
PM 22270589
DA 2018-12-27
ER

PT J
AU Yazdan, P
AF Yazdan, Pedram
TI RETRACTED: Update on the Genetics of Androgenetic Alopecia, Female
   Pattern Hair Loss, and Alopecia Areata: Implications for Molecular
   Diagnostic Testing (Retracted article. See vol. 34, pg. 48, 2015)
SO SEMINARS IN CUTANEOUS MEDICINE AND SURGERY
LA English
DT Article; Retracted Publication
DE androgenetic alopecia; female pattern hair loss; alopecia areata;
   genetics; molecular diagnostic testing; therapy
ID GENOME-WIDE ASSOCIATION; HUMAN SCALP EXPLANTS; C3H/HEJ MOUSE MODEL;
   RECEPTOR GENE; SUSCEPTIBILITY VARIANTS; POSTMENOPAUSAL WOMEN;
   MULTIPLE-SCLEROSIS; AUTOIMMUNE-DISEASE; PSORIASIS-VULGARIS; IMMUNE
   PRIVILEGE
AB Androgenetic alopecia, female pattern hair loss, and alopecia areata are among the most common forms of nonscarring hair loss encountered in clinical practice. Although the exact pathogenesis of these forms of alopecia remains to be clarified, genetic factors appear to have a significant contribution to their pathogenesis. Current treatment strategies are limited and their effectiveness remains modest at best. This review summarizes the current purported pathogenesis and recent genetic discoveries relating to these forms of alopecia. The role of molecular diagnostic testing is also discussed in relation to its future clinical utility for the prediction of developing hair loss, the diagnosis of the type of alopecia, prediction of disease severity, development of novel therapeutic and preventative targeted treatments, as well as determination of response to therapy. Semin Cutan Med Surg 31:258-266 (C) 2012 Frontline Medical Communications
C1 Northwestern Univ, Dept Dermatol, Feinberg Sch Med, Chicago, IL 60611 USA.
RP Yazdan, P (reprint author), Northwestern Univ, Dept Dermatol, Feinberg Sch Med, 676 N St Clair St,Suite 1600, Chicago, IL 60611 USA.
EM p-pouryazdanparast@fsm.northwestem.edu
CR Alfonso M, 2005, CURR MED RES OPIN, V21, P1829, DOI 10.1185/030079905X61820
   Ali I, 2011, BRIT J DERMATOL, V164, P508, DOI 10.1111/j.1365-2133.2010.10156.x
   Alkhalifah A, 2010, J AM ACAD DERMATOL, V62, P177, DOI 10.1016/j.jaad.2009.10.032
   Barahmani N, 2009, J AM ACAD DERMATOL, V61, P581, DOI 10.1016/j.jaad.2009.04.031
   Beghe B, 2010, ALLERGY, V65, P474, DOI 10.1111/j.1398-9995.2009.02167.x
   Birch MP, 2001, BRIT J DERMATOL, V144, P297, DOI 10.1046/j.1365-2133.2001.04018.x
   Bottema RWB, 2010, INT ARCH ALLERGY IMM, V153, P259, DOI 10.1159/000314366
   Bowes J, 2011, ANN RHEUM DIS, V70, P1016, DOI 10.1136/ard.2010.143123
   Brockschmidt FF, 2011, BRIT J DERMATOL, V165, P1293, DOI 10.1111/j.1365-2133.2011.10708.x
   Bubulya A, 1996, J BIOL CHEM, V271, P24583, DOI 10.1074/jbc.271.40.24583
   Carroll JM, 2002, J INVEST DERMATOL, V119, P392, DOI 10.1046/j.1523-1747.2002.01811.x
   Chu SY, 2011, J AM ACAD DERMATOL, V65, P949, DOI 10.1016/j.jaad.2010.08.032
   Cobb JE, 2010, EXP DERMATOL, V19, P1026, DOI 10.1111/j.1600-0625.2010.01132.x
   Cobb JE, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005081
   Coda AB, 2010, GENES IMMUN, V11, P531, DOI 10.1038/gene.2010.32
   Coda AB, 2011, GENOMICS, V98, P431, DOI 10.1016/j.ygeno.2011.08.009
   COLOMBE BW, 1995, J AM ACAD DERMATOL, V33, P757
   Delamere FM, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004413.pub2
   Dy LC, 2011, DERMATOL THER, V24, P369, DOI 10.1111/j.1529-8019.2011.01414.x
   El-Samahy MH, 2009, INT J DERMATOL, V48, P584, DOI 10.1111/j.1365-4632.2009.03991.x
   Ellis JA, 1998, J INVEST DERMATOL, V110, P849, DOI 10.1046/j.1523-1747.1998.00224.x
   Ellis JA, 2001, CLIN DERMATOL, V19, P149, DOI 10.1016/S0738-081X(00)00125-5
   Ellis JA, 2001, J INVEST DERMATOL, V116, P452, DOI 10.1046/j.1523-1747.2001.01261.x
   Ellis JA, 2007, HUM GENET, V121, P451, DOI 10.1007/s00439-006-0317-8
   Ellis JA, 2010, AGING HAIR, P221, DOI 10.1007/978-3-642-02636-2_21
   Eudy G, 2006, SEMIN CUTAN MED SURG, V25, P35, DOI 10.1016/j.sder.2006.01.005
   Finner AM, 2011, DERMATOL THER, V24, P348, DOI 10.1111/j.1529-8019.2011.01413.x
   Forstbauer LM, 2012, EUR J HUM GENET, V20, P326, DOI 10.1038/ejhg.2011.185
   Gan DCC, 2005, J INVEST DERM SYMP P, V10, P184, DOI 10.1111/j.1087-0024.2005.10102.x
   Gilhar A, 1998, J CLIN INVEST, V101, P62, DOI 10.1172/JCI551
   Gilhar A, 2002, ARCH DERMATOL, V138, P916, DOI 10.1001/archderm.138.7.916
   Gilhar A, 2007, J CLIN INVEST, V117, P2019, DOI 10.1172/JCI31942
   Gilhar A, 2012, NEW ENGL J MED, V366, P1515, DOI 10.1056/NEJMra1103442
   Goh C, 2006, J EUR ACAD DERMATOL, V20, P1055, DOI 10.1111/j.1468-3083.2006.01676.x
   Gregersen PK, 2009, ANNU REV IMMUNOL, V27, P363, DOI 10.1146/annurev.immunol.021908.132653
   Haiman CA, 2007, CANCER RES, V67, P1893, DOI 10.1158/0008-5472.CAN-06-4123
   HAMILTON JB, 1951, ANN NY ACAD SCI, V53, P708, DOI 10.1111/j.1749-6632.1951.tb31971.x
   HAMILTON JB, 1960, J CLIN ENDOCR METAB, V20, P1309, DOI 10.1210/jcem-20-10-1309
   Han A, 2006, SEMIN CUTAN MED SURG, V25, P11, DOI 10.1016/j.sder.2006.01.003
   Hillmer AM, 2005, AM J HUM GENET, V77, P140, DOI 10.1086/431425
   Hillmer AM, 2008, NAT GENET, V40, P1279, DOI 10.1038/ng.228
   Hillmer AM, 2008, AM J HUM GENET, V82, P737, DOI 10.1016/j.ajhg.2007.11.014
   Hoss DM, 1999, SEMIN CUTAN MED SURG, V18, P84, DOI 10.1016/S1085-5629(99)80013-3
   Ito T, 2004, AM J PATHOL, V164, P623, DOI 10.1016/S0002-9440(10)63151-3
   Ito T, 2008, J INVEST DERMATOL, V128, P1196, DOI 10.1038/sj.jid.5701183
   Jackow C, 1998, J AM ACAD DERMATOL, V38, P418, DOI 10.1016/S0190-9622(98)70499-2
   Jagielska D, 2012, J INVEST DERMATOL, V132, P2192, DOI 10.1038/jid.2012.129
   JENKINS EP, 1992, J CLIN INVEST, V89, P293, DOI 10.1172/JCI115574
   John KKG, 2011, J INVEST DERMATOL, V131, P1169, DOI 10.1038/jid.2010.427
   Kaufman KD, 2002, MOL CELL ENDOCRINOL, V198, P89, DOI 10.1016/S0303-7207(02)00372-6
   Kaufman KD, 2008, EUR J DERMATOL, V18, P400, DOI [10.1684/ejd.200800636, 10.1684/ejd.2008.0436]
   Keene S, 2011, DERMATOL THER, V24, P296, DOI 10.1111/j.1529-8019.2011.01407.x
   Lueking A, 2005, MOL CELL PROTEOMICS, V4, P1382, DOI 10.1074/mcp.T500004-MCP200
   LYNFIELD YL, 1960, J INVEST DERMATOL, V35, P323, DOI 10.1038/jid.1960.127
   Martinez A, 2010, ANN RHEUM DIS, V69, P309, DOI 10.1136/ard.2008.098376
   Martinez-Mir A, 2007, AM J HUM GENET, V80, P316, DOI 10.1086/511442
   McDonagh AJG, 2002, CLIN EXP DERMATOL, V27, P409, DOI 10.1046/j.1365-2230.2002.01077.x
   McElwee KJ, 1996, BRIT J DERMATOL, V135, P211, DOI 10.1111/j.1365-2133.1996.tb01149.x
   McElwee KJ, 2005, J INVEST DERMATOL, V124, P947, DOI 10.1111/j.0022-202X.2005.23692.x
   McMichael AJ, 2007, J AM ACAD DERMATOL, V57, pS49, DOI 10.1016/j.jaad.2006.02.045
   Miteva M, 2012, EXPERT OPIN PHARMACO, V13, P1271, DOI 10.1517/14656566.2012.685160
   Muto M, 2011, J DERMATOL SCI, V62, P70, DOI 10.1016/j.jdermsci.2010.10.012
   Natarajan K, 2002, ANNU REV IMMUNOL, V20, P853, DOI 10.1146/annurev.immunol.20.100301.064812
   Nischwitz S, 2011, ACTA NEUROL SCAND, V123, P400, DOI 10.1111/j.1600-0404.2010.01421.x
   NORWOOD OT, 1975, SOUTHERN MED J, V68, P1359, DOI 10.1097/00007611-197511000-00009
   Nyholt DR, 2003, J INVEST DERMATOL, V121, P1561, DOI 10.1111/j.1523-1747.2003.12615.x
   Oh HS, 1996, P NATL ACAD SCI USA, V93, P12525, DOI 10.1073/pnas.93.22.12525
   Ohnemus U, 2006, ENDOCR REV, V27, P677, DOI 10.1210/er.2006-0020
   Olsen EA, 2001, J AM ACAD DERMATOL, V45, pS70, DOI 10.1067/mjd.2001.117426
   Orme S, 1999, BRIT J DERMATOL, V141, P521
   PAUS R, 1993, YALE J BIOL MED, V66, P541
   Paus R, 2005, TRENDS IMMUNOL, V26, P32, DOI 10.1016/j.it.2004.09.014
   Petukhova L, 2011, DERMATOL THER, V24, P326, DOI 10.1111/j.1529-8019.2011.01411.x
   Petukhova L, 2010, NATURE, V466, P113, DOI 10.1038/nature09114
   Prodi DA, 2008, J INVEST DERMATOL, V128, P2268, DOI 10.1038/jid.2008.60
   Rhodes T, 1998, DERMATOL SURG, V24, P1330, DOI 10.1111/j.1524-4725.1998.tb00009.x
   Richards JB, 2008, NAT GENET, V40, P1282, DOI 10.1038/ng.255
   SAFAVI K, 1992, ARCH DERMATOL, V128, P702, DOI 10.1001/archderm.1992.01680150136027
   Sato A. A., 2008, SKIN SURG, V17, P80
   Sawaya M E, 1998, J Cutan Med Surg, V3, P9
   Siebenhaar F, 2007, J INVEST DERMATOL, V127, P1489, DOI 10.1038/sj.jid.5700704
   Simpson D, 2004, DRUGS, V64, P1213, DOI 10.2165/00003495-200464110-00005
   Singh TP, 2010, J IMMUNOL, V184, P7257, DOI 10.4049/jimmunol.0903719
   Stefanato CM, 2010, HISTOPATHOLOGY, V56, P24, DOI 10.1111/j.1365-2559.2009.03439.x
   Subramanya RD, 2010, GENOMICS, V96, P146, DOI 10.1016/j.ygeno.2010.05.002
   Sundberg JP, 2004, J INVEST DERMATOL, V123, P294, DOI 10.1111/j.0022-202X.2004.23222.x
   Tang LR, 2003, J AM ACAD DERMATOL, V49, P229, DOI 10.1067/S0190-9622(03)000777-1
   Tosti A, 2006, J AM ACAD DERMATOL, V55, P438, DOI 10.1016/j.jaad.2006.05.008
   Trueb RM, 2010, AGING HAIR, P1
   Wakisaka N, 2005, J INVEST DERM SYMP P, V10, P293, DOI 10.1111/j.1087-0024.2005.10123.x
   Yamazaki M, 2011, J DERMATOL, V38, P680, DOI 10.1111/j.1346-8138.2010.01060.x
   Yip L, 2012, BRIT J DERMATOL, V166, P1131, DOI 10.1111/j.1365-2133.2011.10702.x
   Yip L, 2009, BRIT J DERMATOL, V161, P289, DOI 10.1111/j.1365-2133.2009.09186.x
   Zhernakova A, 2009, NAT REV GENET, V10, P43, DOI 10.1038/nrg2489
   Zoledziewska M, 2009, GENES IMMUN, V10, P15, DOI 10.1038/gene.2008.84
NR 95
TC 6
Z9 8
U1 2
U2 3
PU FRONTLINE MEDICAL COMMUNICATIONS
PI THE WOODLANDS
PA WRIGHTS MEDIA, 2407 TIMBERLOCH PLACE, SUITE B, THE WOODLANDS, TX 77386
   USA
SN 1085-5629
EI 1558-0768
J9 SEMIN CUTAN MED SURG
JI Semin. Cutan. Med. Surg.
PD DEC
PY 2012
VL 31
IS 4
BP 258
EP 266
DI 10.1016/j.sder.2012.08.003
PG 9
WC Dermatology; Surgery
SC Dermatology; Surgery
GA 050GU
UT WOS:000312042000008
PM 23174496
DA 2018-12-27
ER

PT J
AU Mansour, A
   Ali, M
   Helmy, H
   Kassim, S
AF Mansour, Amal
   Ali, Marwa
   Helmy, Hussein
   Kassim, Samar
TI RETRACTED: Human papillomavirus-16 (HPV-16) infection association with
   CIAP-2 expression in head and neck cancer (Retracted article. See vol.
   31, 766, 2014)
SO MEDICAL ONCOLOGY
LA English
DT Article; Retracted Publication
DE Human papillomavirus; IAPs; CIAP; Apoptosis; RT-PCR; PCR
ID SQUAMOUS-CELL CARCINOMA; OROPHARYNGEAL CANCER; APOPTOSIS; INHIBITOR;
   EPIDEMIOLOGY; SURVIVAL; TYPE-16; RISK
AB Human papillomavirus (HPV-16) E6 proteins inhibit apoptosis in both p53-dependent and p53-independent manners. So it was relevant to assess the impact of such infection on head and neck cancers and its relation to the inhibitors of apoptosis (IAPs). CIAP2 is one of these IAPs that is postulated to upregulated by E6 proteins of HPV-16 by amplification of the locus bearing it in many tissues. In this study, we aimed to search for the amplification of the locus bearing CIAP-2 and its relation to HPV-16 in head and neck cancer that may have prognostic and therapeutic impacts on these patients. Total 30 patients diagnosed as head and neck cancer (2 tissue samples were taken from each patient: from the tumor and from the safety margin). All samples were subjected to qualitative polymerase chain reaction analysis for HPV-16 and qualitative and semiquantitative reverse transcription polymerase chain reaction of CIAP-2. There was a significant association between HPV-16 and CIAP2 positivity and head and neck tumors (P = 0.01). CIAP-2 expression in malignant tissues was highly associated with HPV-16 infection with 73.9% sensitivity and absolute specificity.
C1 [Mansour, Amal; Ali, Marwa; Kassim, Samar] Ain Shams Univ, Dept Med Biochem, Fac Med, Cairo 11381, Egypt.
   [Helmy, Hussein] Ain Shams Univ, Dept Otolaryngol, Fac Med, Cairo 11381, Egypt.
RP Mansour, A (reprint author), Ain Shams Univ, Dept Med Biochem, Fac Med, Cairo 11381, Egypt.
EM amal.bary@gmail.com
RI Kassim, Samar/G-4701-2015
OI Kassim, Samar/0000-0002-4359-6620
FU Faculty of medicine, Ain Shams University
FX This work was done by the financial support of Faculty of medicine, Ain
   Shams University.
CR Acha-Sagredo A, 2010, MED ORAL PATOL ORAL, V15, pE1, DOI 10.4317/medoral.15.e1
   [Anonymous], 2010, WORLD HLTH STAT ANN, P23
   Bandala E, 2001, BIOCHEM PHARMACOL, V62, P13, DOI 10.1016/S0006-2952(01)00632-3
   Cao DF, 2010, HUM PATHOL, V41, P535, DOI 10.1016/j.humpath.2009.09.006
   D'Souza G, 2007, NEW ENGL J MED, V356, P1944, DOI 10.1056/NEJMoa065497
   Fakhry C, 2008, J NATL CANCER I, V100, P261, DOI 10.1093/jnci/djn011
   Fleskens S, 2009, HEAD NECK ONCOL, V1, DOI 10.1186/1758-3284-1-11
   Gillison Maura L, 2003, J Natl Cancer Inst Monogr, P57
   Gunnell AS, 2006, CANCER EPIDEM BIOMAR, V15, P2141, DOI 10.1158/1055-9965.EPI-06-0399
   Hasegawa T, 2003, BLOOD, V101, P1164, DOI 10.1182/blood-2002-05-1505
   Heck JE, 2010, INT J EPIDEMIOL, V39, P166, DOI 10.1093/ije/dyp350
   Herrero R, 2003, J NATL CANCER I, V95, P1772, DOI 10.1093/jnci/djg/107
   Hunter AM, 2007, APOPTOSIS, V12, P1543, DOI 10.1007/s10495-007-0087-3
   KENNEDY IM, 1991, J VIROL, V65, P2093
   Kreimer AR, 2006, INT J CANCER, V118, P2293, DOI 10.1002/ijc.21577
   Kreimer AR, 2005, CANCER EPIDEM BIOMAR, V14, P467, DOI 10.1158/1055-9965.EPI-04-0551
   Lindel K, 2001, CANCER-AM CANCER SOC, V92, P805, DOI 10.1002/1097-0142(20010815)92:4<805::AID-CNCR1386>3.0.CO;2-9
   Louvanto K, 2011, ACTA OBSTET GYN SCAN, V90, P167, DOI 10.1111/j.1600-0412.2010.01029.x
   Lowe SW, 2000, CARCINOGENESIS, V21, P485, DOI 10.1093/carcin/21.3.485
   McKay SP, 2005, LARYNGOSCOPE, V115, P1428, DOI 10.1097/01.mlg.0000168091.50584.b4
   Meadus W. J., 2003, Biological Procedures Online, V5, P20, DOI 10.1251/bpo43
   Mehanna H, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c1439
   METZ CE, 1978, SEMIN NUCL MED, V8, P283, DOI 10.1016/S0001-2998(78)80014-2
   Misawa K, 2009, INT J OTORHINOLARYNG, V2, P1528
   Molinolo AA, 2008, ORAL ONCOL, V10, P1016
   Rosenquist K, 2005, ACTA OTO-LARYNGOL, V125, P1327, DOI 10.1080/00016480510012273
   Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830
   Smith SD, 2001, JAMA-J AM MED ASSOC, V285, P324, DOI 10.1001/jama.285.3.324
   Steinberg B, 2010, APMIS, V118, P421, DOI 10.1111/j.1600-0463.2010.02622.x
   Van Themsche C, 2009, J BIOL CHEM, V284, P20462, DOI 10.1074/jbc.C109.009522
   Warnakulasuriya S, 2009, ORAL ONCOL, V45, P309, DOI 10.1016/j.oraloncology.2008.06.002
   Worden FP, 2008, J CLIN ONCOL, V26, P3138, DOI 10.1200/JCO.2007.12.7597
NR 32
TC 4
Z9 5
U1 3
U2 15
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 1357-0560
EI 1559-131X
J9 MED ONCOL
JI Med. Oncol.
PD DEC
PY 2012
VL 29
IS 4
BP 2459
EP 2465
DI 10.1007/s12032-011-0143-2
PG 7
WC Oncology
SC Oncology
GA 019BJ
UT WOS:000309711600024
PM 22215414
DA 2018-12-27
ER

PT J
AU Xu, JC
   Shen, ZZ
   Valentini, B
AF Xu Juncai
   Shen Zhenzhong
   Valentini, Bernhard
TI RETRACTED: Study of the New Leon model for concrete failure (Retracted
   article. See vol. 249, pg. 163, 2013)
SO JOURNAL OF COMPUTATIONAL AND APPLIED MATHEMATICS
LA English
DT Article; Retracted Publication
DE Leon model; Gradient enhance damage model; Finite element; Concrete
   failure
ID FRACTURE
AB The New Leon model (NLM) is based on a combination of the flow theory of plasticity and damage mechanics. First, the damage evolution law of the model, which yields finite element mesh size-dependent results, was regularized. The slope of the softening curve predicted by the model was slightly too flat compared with uniaxial tensile test results: thus, the evolution law of the damage variable was enhanced to correct defects. The yield function of the New Leon model had two vertices at the intersection with the hydrostatic axis. To avoid this problem, the stress state was assumed to be projected onto the hydrostatic axis in the first vertex and along the hydrostatic axis in the second. The New Leon model was then compared with the Extended Leon model in a first experiment by Hurlbut and a second experiment by Imran. Finally, the New Leon, extended finite element, and gradient enhanced damage models were applied to plain concrete tests to simulate the cracking of concrete, and crack mouth opening displacement results were obtained. Compared with other models, the New Leon model yielded values that were generally in better agreement with the experimental results. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Xu Juncai; Shen Zhenzhong] Hohai Univ, Coll Water Conservancy & Hydroelect Engn, Nanjing, Jiangsu, Peoples R China.
   [Xu Juncai; Valentini, Bernhard] Univ Innsbruck, Fac Civil Engn, A-6020 Innsbruck, Austria.
RP Shen, ZZ (reprint author), Hohai Univ, Coll Water Conservancy & Hydroelect Engn, Nanjing, Jiangsu, Peoples R China.
EM juncaixu@gmail.com; zhzhshen@hhu.edu.cn
CR CEB-90, 1991, B INFORM COMMITTEE E
   Etse, 1992, THESIS U FRIDERICIAN
   ETSE G, 1994, J ENG MECH-ASCE, V120, P1983, DOI 10.1061/(ASCE)0733-9399(1994)120:9(1983)
   Feist, 2004, THESIS U INNSBRUCK
   Feist C, 2007, COMPUT CONCRETE, V4, P49, DOI 10.12989/cac.2007.4.1.049
   GOPALARATNAM VS, 1985, J AM CONCRETE I, V82, P310
   Grassl P, 2006, INT J NUMER ANAL MET, V30, P71, DOI 10.1002/nag.479
   Grassl P, 2002, INT J SOLIDS STRUCT, V39, P5205, DOI 10.1016/S0020-7683(02)00408-0
   Grassl P, 2006, INT J SOLIDS STRUCT, V43, P7166, DOI 10.1016/j.ijsolstr.2006.06.032
   Imran I, 1996, ACI MATER J, V93, P589
   Jirasek, 2002, INELASTIC ANAL STRUC
   Kang HD, 1999, J ENG MECH-ASCE, V125, P941, DOI 10.1061/(ASCE)0733-9399(1999)125:8(941)
   Leon A, 1935, BETON EISEN, V34, P130
   MENETREY P, 1995, ACI STRUCT J, V92, P311
   Pivonka P, 2004, INT J NUMER METH ENG, V60, P549, DOI 10.1002/nme.975
   Poh LH, 2009, INT J SOLIDS STRUCT, V46, P4369, DOI 10.1016/j.ijsolstr.2009.08.025
   PRAMONO E, 1989, J ENG MECH, V115, P1183, DOI 10.1061/(ASCE)0733-9399(1989)115:6(1183)
   Sancho JM, 2007, INT J NUMER ANAL MET, V31, P173, DOI 10.1002/nag.540
   Willam, JAP US S FIN EL FIN, P360
   Willam, 1975, SEM CONCR STRUCT SUB, V19, P369
   Willam, 1985, FINITE ELEMENT ANAL, V10, P226
NR 21
TC 3
Z9 3
U1 6
U2 37
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0377-0427
EI 1879-1778
J9 J COMPUT APPL MATH
JI J. Comput. Appl. Math.
PD DEC
PY 2012
VL 236
IS 18
SI SI
BP 4873
EP 4881
DI 10.1016/j.cam.2012.02.002
PG 9
WC Mathematics, Applied
SC Mathematics
GA 987OC
UT WOS:000307425900026
OA Bronze
DA 2018-12-27
ER

PT J
AU Halford, B
AF Halford, Bethany
TI RETRACTED: HEXACYCLINOL REPORT RETRACTED (Retracted article. See vol.
   90, pg. 4, 2012)
SO CHEMICAL & ENGINEERING NEWS
LA English
DT News Item; Retracted Publication
CR LaClair J. J, 2012, ANGEW CHEM INT EDIT, V51, P11661, DOI DOI 10.1002/ANIE.201206869
NR 1
TC 0
Z9 0
U1 1
U2 11
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0009-2347
EI 1520-605X
J9 CHEM ENG NEWS
JI Chem. Eng. News
PD NOV 19
PY 2012
VL 90
IS 47
BP 10
EP 10
PG 1
WC Chemistry, Multidisciplinary; Engineering, Chemical
SC Chemistry; Engineering
GA 042LD
UT WOS:000311471800011
DA 2018-12-27
ER

PT J
AU Iacono, F
   Prezioso, D
   Illiano, E
   Ruffo, A
   Romeo, G
   Amato, B
AF Iacono, Fabrizio
   Prezioso, Domenico
   Illiano, Ester
   Ruffo, Antonio
   Romeo, Giuseppe
   Amato, Bruno
TI RETRACTED: Observational study: daily treatment with a new compound
   "tradamixina" plus serenoa repens for two months improved the lower
   urinary tract symptoms (Retracted article. See vol. 16, pg. 23, 2016)
SO BMC SURGERY
LA English
DT Article; Proceedings Paper; Retracted Publication
CT 25th National Congress of the Italian-Society-of-Geriatric-Surgery
CY MAY 10-11, 2012
CL Padova, ITALY
SP Italian Soc Geriatr Surg
ID BENIGN PROSTATIC HYPERPLASIA; INTERNATIONAL CONTINENCE SOCIETY;
   NITRIC-OXIDE SYNTHASE; MARINE BROWN ALGA; TRIBULUS-TERRESTRIS;
   OVERACTIVE BLADDER; ARACHIDONIC-ACID; RECEPTORS; INNERVATION;
   ANTAGONISTS
AB Background: Lower urinary tract symptoms (LUTS) are associated with great emotional costs to individuals and substantial economic costs to society. This study seeks to evaluate the effect of a new natural compound "Tradamixina plus Serenoa Repens" in order to improve lower urinary tract symptoms.
   Methods: 100 patients (>= 45years) who had had LUTS/BPH for >6 mo at screening and with IPSS - The international Prostate symptom scores- >= 13 and maximum urinary flow rate (Qmax) >= 4 to <= 15 ml/s. were recruited. The compound "Tradamixina plus Serenoa Repens" (80 mg of Alga Ecklonia Bicyclis, 100 mg of Tribulus Terrestris and 100 mg of D-Glucosamine and N-Acetyl-D-Glucosamine plus 320 mg of Serenoa Repens) was administered daily for 2 months. At visit and after 60 days of treatment patients were evaluated by means of detailed medical urological history, clinical examination, laboratory investigations (total PSA), and instrumental examination like urolfowmetry. Efficacy measures included IPSS-International Prostate Sympto, BPH Impact Index (BII), Quality-of-Life (QoL) Index. Measures were assessed at baseline and end point (12 wk or end of therapy) and also at screening, 1 and 4 wk for IPSS, and 4 wk for BII. Statistical significance was interpreted only if the results of the preceding analysis were significant at the 0.05 level.
   Results: After 2 months of treatment the change from baseline to week 12 relative to "Tradamixina plus Seronea Repens" in total IPSS and Qol was statistically significant. Differences from baseline in BII were statistically significant for "Tradamixina plus Seronea Repens" above all differences in BII were also significant at 4 wk (LSmean +/- SE: -0.8 +/- 0.2). In the distribution of subjects over the PGI-I and CGI-I response categories were significant for"Tradamixina plus Seronea Repens" (PGI-I: p = 0.001; CGI-I). We also observed a decrease of total PSA.
   Conclusion: The daily treatment with a new compound "Tradamixina plus Serenoa Repens" for 2 months improved the male sexual function, it improved the bother symptoms which affect the patient's quality of life, improved uroflowmetric parameters, and we also observed a decrease of serum PSA level.
C1 [Iacono, Fabrizio; Prezioso, Domenico; Illiano, Ester; Ruffo, Antonio; Romeo, Giuseppe] Univ Naples Federico II, Dept Urol, I-80131 Naples, Italy.
   [Amato, Bruno] Univ Naples Federico II, Dept Gen Geriatr Oncol Surg & Adv Technol, I-80131 Naples, Italy.
RP Illiano, E (reprint author), Univ Naples Federico II, Dept Urol, Via S Pansini 5, I-80131 Naples, Italy.
EM ester.illiano@inwind.it
OI Iacono, Fabrizio/0000-0003-1064-649X; Amato, Bruno/0000-0002-4262-8467;
   Illiano, Ester/0000-0001-5660-1815
CR Abrams P, 2003, UROLOGY, V61, P37, DOI 10.1016/S0090-4295(02)02243-4
   Adaikan P. G., 2000, Annals Academy of Medicine Singapore, V29, P22
   Andersson KE, 2007, NEUROUROL URODYNAM, V26, P934, DOI 10.1002/nau.20500
   Anglin IE, 2002, PROSTATE CANCER P D, V5, P88, DOI 10.1038/sj.pcan.4500561
   Bent S, 2006, NEW ENGL J MED, V354, P557, DOI 10.1056/NEJMoa053085
   BOSTWICK DG, 1992, CANCER, V70, P291, DOI 10.1002/1097-0142(19920701)70:1+<291::AID-CNCR2820701317>3.0.CO;2-4
   BRUSCHINI H, 1978, INVEST UROL, V15, P288
   BURNETT AL, 1995, UROLOGY, V45, P435, DOI 10.1016/S0090-4295(99)80012-0
   CAINE M, 1975, BRIT J UROL, V47, P193, DOI 10.1111/j.1464-410X.1975.tb03947.x
   CHAPPLE CR, 1991, J UROLOGY, V146, P1637, DOI 10.1016/S0022-5347(17)38203-4
   Chung H, EFFECT KP 2647TM PAT
   Colasanti M, 2000, TRENDS PHARMACOL SCI, V21, P249, DOI 10.1016/S0165-6147(00)01499-1
   Colasanti M, 1999, J BIOL CHEM, V274, P9915, DOI 10.1074/jbc.274.15.9915
   Colasanti M, 1997, J BIOL CHEM, V272, P7582, DOI 10.1074/jbc.272.12.7582
   Debruyne F, 2002, EUR UROL, V41, P497, DOI 10.1016/S0302-2838(02)00066-0
   Di Silverio F, 1992, EUR UROL, V2, p[309, 14]
   Dinh DT, 2001, ENDOCRINOLOGY, V142, P1349, DOI 10.1210/en.142.3.1349
   Dreikorn K, 1989, NEW DEV BIOSCIENCES, p[109, 31]
   Engstrom G, 2005, BJU INT, V95, P810, DOI 10.1111/j.1464-410X.2005.05406.x
   Gauthaman K, 2002, LIFE SCI, V71, P1385, DOI 10.1016/S0024-3205(02)01858-1
   Gradini R, 1999, J PATHOL, V189, P224
   HIGGINS JRA, 1989, PROSTATE, P5
   Hu TW, 2003, UROLOGY, V61, P1123, DOI 10.1016/S0090-4295(03)00009-8
   Irwin DE, 2006, EUR UROL, V50, P1306, DOI 10.1016/j.eururo.2006.09.019
   ISAACS JT, 1993, EUR UROL, V25, P6
   Jung WK, 2009, J AGR FOOD CHEM, V57, P4439, DOI 10.1021/jf9003913
   Jung WK, 2009, FOOD CHEM TOXICOL, V47, P410, DOI 10.1016/j.fct.2008.11.041
   JUNGBLUT T, 1989, UROL INT, V44, P352, DOI 10.1159/000281539
   LANGE W, 1990, UROL RES, V18, P337, DOI 10.1007/BF00300783
   LEPOR H, 1984, J UROLOGY, V132, P1226, DOI 10.1016/S0022-5347(17)50110-X
   Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709
   Li Y, 2009, BIOORGAN MED CHEM, V17, P1963, DOI 10.1016/j.bmc.2009.01.031
   Lin VK, 2001, UROLOGY, V57, P170, DOI 10.1016/S0090-4295(00)00842-6
   Mariotto S, 2007, CURR MED CHEM, V14, P1940
   Marwick C, 1995, JAMA, V273, p[607, 9]
   McGuire E, 1987, DETRUSOR RESPONSE OB, P221
   Neychev VK, 2005, J ETHNOPHARMACOL, V101, P319, DOI 10.1016/j.jep.2005.05.017
   Palomba L, 2004, FREE RADICAL BIO MED, V36, P319, DOI 10.1016/j.freeradbiomed.2003.10.026
   Partin JV, 2003, BRIT J CANCER, V88, P1615, DOI 10.1038/sj.bjc.6600961
   Peters TJ, 1997, J UROLOGY, V157, P885, DOI 10.1016/S0022-5347(01)65075-4
   Rosen R, 2003, EUR UROL, V44, P637, DOI 10.1016/j.eururo.2003.08.015
   SMITH ER, 1970, INVEST UROL, V7, P313
   TAKEDA M, 1995, UROLOGY, V45, P440, DOI 10.1016/S0090-4295(99)80013-2
   TSUJII T, 1992, BRIT J PHARMACOL, V107, P803, DOI 10.1111/j.1476-5381.1992.tb14527.x
   Willetts KE, 2003, BJU INT, V92, P267, DOI 10.1046/j.1464-410X.2003.04316.x
NR 45
TC 2
Z9 3
U1 2
U2 8
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2482
J9 BMC SURG
JI BMC Surg.
PD NOV 15
PY 2012
VL 12
SU 1
AR S22
DI 10.1186/1471-2482-12-S1-S22
PG 8
WC Surgery
SC Surgery
GA 059OF
UT WOS:000312714100002
PM 23173650
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Amato, B
   Compagna, R
   Della Corte, GA
   Martino, G
   Bianco, T
   Coretti, G
   Rossi, R
   Braucci, A
   Aprea, G
   Zeppa, P
   Puzziello, A
   Terranova, C
AF Amato, Bruno
   Compagna, Rita
   Della Corte, Gianni Antonio
   Martino, Giovanni
   Bianco, Tommaso
   Coretti, Guido
   Rossi, Roberto
   Braucci, Antonio
   Aprea, Giovanni
   Zeppa, Pio
   Puzziello, Alessandro
   Terranova, Claudio
TI RETRACTED: Peripheral blood mono-nuclear cells implantation in patients
   with peripheral arterial disease: a pilot study for clinical and
   biochemical outcome of neoangiogenesis (Retracted article. See vol. 16,
   pg. 24, 2016)
SO BMC SURGERY
LA English
DT Article; Retracted Publication
ID ENDOTHELIAL PROGENITOR CELLS; ISCHEMIC HINDLIMB MODEL; BONE-MARROW
   CELLS; THERAPEUTIC ANGIOGENESIS; LIMB ISCHEMIA; GROWTH;
   NEOVASCULARIZATION; TRANSPLANTATION; MECHANISMS
AB Background: Substantial progresses in the management of peripheral arterial disease (PAD) have been made in the past two decades. Progress in the understanding of the endothelial-platelet interaction during health and disease state has resulted in better antiplatelet drugs that can prevent platelet aggregation, activation and thrombosis during angioplasty and stenting. A role in physiological and pathological angiogenesis in adults has been recently shown in bone marrow-derived circulating endothelial progenitors (BM-DCEPs) identified in the peripheral blood. These findings have paved the way for the development of therapeutic neovascularization techniques using endothelial progenitors.
   Methods: This pilot study includes five patients, aged 60 to 75, with a history of claudication and recruited from September 2010 to February 2011 at the A.O.U. Federico II of Naples. PBMNCs have been implanted three times in the limb with the worst ABI value in all the patients included in the study. The clinical follow up was performed during the subsequent 12 months from the beginning of the treatment.
   Results: In four patients there was a regression of ulcerative lesions. One patient's condition improved after the first implantation but later did not respond to the further treatments. All patients achieved a pain relief as judged by the numeric pain scale. Pain relief remained satisfactory in three patients for one year. Pain gradually returned to the pre-treatment level in two patients. All patients referred an ameliorating in their quality of life expressed even by an improvement in claudication free walking distance. These improvements are reflected also by intra-arterial digital subtraction angiography (IADSA) that shows an improvement of arterial vascularization.
   Conclusions: The data from this study suggest an efficacy of BM-DCEPs implantation in terms of improvement of the vascularization and quality of life in patients affected by Peripheral Arterial Disease. Nevertheless a double-blind placebo-controlled study is needed to confirm our findings.
C1 [Amato, Bruno; Compagna, Rita; Della Corte, Gianni Antonio; Martino, Giovanni; Bianco, Tommaso; Coretti, Guido; Rossi, Roberto; Braucci, Antonio; Aprea, Giovanni] Univ Naples Federico II, Dept Gen Geriatr Oncol Surg & Adv Technol, I-801311 Naples, Italy.
   [Zeppa, Pio] Univ Salerno, Dept Med & Surg, Salerno, Italy.
   [Puzziello, Alessandro] Magna Graecia Univ Catanzaro, Dept Med & Surg Sci, Catanzaro, Italy.
   [Terranova, Claudio] Padova Univ Hosp, Dept Mol Med, I-35126 Padua, Italy.
RP Amato, B (reprint author), Univ Naples Federico II, Dept Gen Geriatr Oncol Surg & Adv Technol, Via S Pansini 5, I-801311 Naples, Italy.
EM bruno.amato@unina.it
OI Amato, Bruno/0000-0002-4262-8467
CR Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964
   Asahara T, 1999, CIRC RES, V85, P221, DOI 10.1161/01.RES.85.3.221
   Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651
   Dormandy J A, 2000, J Vasc Surg, V31, pS1
   Ferrara N, 1999, NAT MED, V5, P1359, DOI 10.1038/70928
   HARADA K, 1994, J CLIN INVEST, V94, P623, DOI 10.1172/JCI117378
   Ikenaga S, 2001, J SURG RES, V96, P277, DOI 10.1006/jsre.2000.6080
   Junji Moriya, 2009, CIRC-CARDIOVASC INTE, V2, P245
   Kinnaird T, 2004, CIRC RES, V95, P354, DOI 10.1161/01.RES.0000137878.26174.66
   Li TS, 2002, AM J PHYSIOL-HEART C, V283, pH468, DOI 10.1152/ajpheart.00261.2002
   Norstanstig J, 2011, EUR J VASC ENDOVASC, V42, P220
   Prochazka V, 2010, CELL TRANSPLANT, V19, P1413, DOI 10.3727/096368910X514170
   Rafii S, 2003, NAT MED, V9, P702, DOI 10.1038/nm0603-702
   Shi Q, 1998, BLOOD, V92, P362
   Shintani S, 2001, CIRCULATION, V103, P897, DOI 10.1161/01.CIR.103.6.897
   TAKESHITA S, 1994, J CLIN INVEST, V93, P662, DOI 10.1172/JCI117018
   Tateishi-Yuyama E, 2002, LANCET, V360, P427, DOI 10.1016/S0140-6736(02)09670-8
   Tateno K, 2006, CIRC RES, V98, P1194, DOI 10.1161/01.RES.0000219901.13974.15
   Urbich C, 2004, CIRC RES, V95, P343, DOI 10.1161/01.RES.0000137877.89448.78
   Yla-Herttuala S, 2003, NAT MED, V9, P694, DOI 10.1038/nm0603-694
NR 20
TC 11
Z9 13
U1 2
U2 9
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2482
J9 BMC SURG
JI BMC Surg.
PD NOV 15
PY 2012
VL 12
SU 1
AR S1
DI 10.1186/1471-2482-12-S1-S1
PG 5
WC Surgery
SC Surgery
GA 037WO
UT WOS:000311137400001
PM 23173612
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Michor, EL
   Berg, JC
AF Michor, Edward L.
   Berg, John C.
TI RETRACTED: Extension to the Charge Fluctuation Model for the Prediction
   of the Conductivity of Apolar, Reverse Micellar Systems (Retracted
   article. See vol. 32, pg. 2525, 2016)
SO LANGMUIR
LA English
DT Article; Retracted Publication
ID MICROEMULSIONS; MEDIA; COLLOIDS; WATER
AB This paper presents an extension to current theory regarding charging behavior in apolar, micellar systems. Electrical conductivity in such systems accompanying the formation of neutral reverse micelles is commonly explained by the possibility of intermicellar collisions resulting in a pair of oppositely charged micelles. The sequestration of the resulting charges within the micelles prevents their immediate recombination. The current theory underlying the charging process has thus far been applied in only approximate form, and is only used to validate experimental trends and to abstract values for the fraction of charged micelles. The-extended theory proposed here uses knowledge of the solvent and surfactant characteristics, together with water content, to predict solution conductivity in absolute terms. It is verified in experiments with the solvent Isopar-L and surfactants Aerosol OT, OLOA 11000, and Span 80, in which significant differences from the approximate theory are observed.
C1 [Michor, Edward L.; Berg, John C.] Univ Washington, Dept Chem Engn, Seattle, WA 98195 USA.
RP Berg, JC (reprint author), Univ Washington, Dept Chem Engn, Box 351750, Seattle, WA 98195 USA.
EM berg@cheme.washington.edu
FU Xerox Corporation; University of Washington Center for Surfaces,
   Polymers and Colloids
FX This work was supported by a gift from the Xerox Corporation and by the
   University of Washington Center for Surfaces, Polymers and Colloids.
CR ALMELA A, 1993, J SOLUTION CHEM, V22, P231, DOI 10.1007/BF00649246
   EICKE HF, 1989, J PHYS CHEM-US, V93, P314, DOI 10.1021/j100338a062
   Gacek M, 2012, LANGMUIR, V28, P11633, DOI 10.1021/la302806y
   Gacek M, 2012, LANGMUIR, V28, P3032, DOI 10.1021/la204000t
   Guo Q, 2010, LANGMUIR, V26, P3203, DOI 10.1021/la903182e
   HALL DG, 1990, J PHYS CHEM-US, V94, P429, DOI 10.1021/j100364a072
   KALLAY N, 1990, J PHYS CHEM-US, V94, P4755, DOI 10.1021/j100374a070
   KOTLARCHYK M, 1985, J PHYS CHEM-US, V89, P4382, DOI 10.1021/j100266a046
   MORRISON ID, 1993, COLLOID SURFACE A, V71, P1, DOI 10.1016/0927-7757(93)80026-B
   Parent ME, 2011, LANGMUIR, V27, P11845, DOI 10.1021/la202660d
   PARSEGIAN A, 1969, NATURE, V221, P844, DOI 10.1038/221844a0
   Poovarodom S, 2010, J COLLOID INTERF SCI, V346, P370, DOI 10.1016/j.jcis.2010.03.012
   Roberts GS, 2008, LANGMUIR, V24, P6530, DOI 10.1021/la703908n
   Shen Y, 2008, LANGMUIR, V24, P10665, DOI 10.1021/la801416a
NR 14
TC 7
Z9 7
U1 5
U2 29
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0743-7463
J9 LANGMUIR
JI Langmuir
PD NOV 13
PY 2012
VL 28
IS 45
BP 15751
EP 15755
DI 10.1021/la303455n
PG 5
WC Chemistry, Multidisciplinary; Chemistry, Physical; Materials Science,
   Multidisciplinary
SC Chemistry; Materials Science
GA 038RH
UT WOS:000311191300001
PM 23098157
DA 2018-12-27
ER

PT J
AU Lokireddy, S
   Wijesoma, IW
   Teng, S
   Bonala, S
   Gluckman, PD
   McFarlane, C
   Sharma, M
   Kambadur, R
AF Lokireddy, Sudarsanareddy
   Wijesoma, Isuru W.
   Teng, Serena
   Bonala, Sabeera
   Gluckman, Peter D.
   McFarlane, Craig
   Sharma, Mridula
   Kambadur, Ravi
TI RETRACTED: The Ubiquitin Ligase Mul1 Induces Mitophagy in Skeletal
   Muscle in Response to Muscle-Wasting Stimuli (Retracted article. See
   vol. 22, pg. 1090, 2015)
SO CELL METABOLISM
LA English
DT Article; Retracted Publication
ID MITOCHONDRIAL FUSION; SARCOMERIC PROTEINS; CANCER CACHEXIA; MYOSTATIN;
   DEGRADATION; AUTOPHAGY; ATROPHY; MECHANISM; PATHWAY; E3
AB Recent research reveals that dysfunction and subsequent loss of mitochondria (mitophagy) is a potent inducer of skeletal muscle wasting. However, the molecular mechanisms that govern the deregulation of mitochondrial function during muscle wasting are unclear. In this report, we show that different muscle-wasting stimuli upregulated mitochondrial E3 ubiquitin protein ligase 1 (Mul1), through a mechanism involving FoxO1/3 transcription factors. Overexpression of Mul1 in skeletal muscles and myoblast cultures was sufficient for the induction of mitophagy. Consistently, Mul1 suppression not only protected against mitophagy but also partially rescued the muscle wasting observed in response to muscle-wasting stimuli. In addition, upregulation of Mul1, while increasing mitochondrial fission, resulted in ubiquitination and degradation of the mitochondrial fusion protein Mfn2. Collectively, these data explain the molecular basis for the loss of mitochondrial number during muscle wasting.
C1 [Sharma, Mridula] Natl Univ Singapore, YLL Sch Med, Dept Biochem, Singapore 117597, Singapore.
   [Lokireddy, Sudarsanareddy; Wijesoma, Isuru W.; Teng, Serena; Bonala, Sabeera; Kambadur, Ravi] Nanyang Technol Univ, Sch Biol Sci, Singapore 637551, Singapore.
   [Gluckman, Peter D.; McFarlane, Craig; Kambadur, Ravi] Singapore Inst Clin Sci A STAR, Brenner Ctr Mol Med, Singapore 117609, Singapore.
RP Sharma, M (reprint author), Natl Univ Singapore, YLL Sch Med, Dept Biochem, Singapore 117597, Singapore.
EM bchmridu@nus.edu.sg; kravi@ntu.edu.sg
FU Ministry of Education, National Research Foundation; Agency for Science,
   Technology, and Research (A*STAR)
FX We thank Addgene (Cambridge, USA), for providing RFP-LC3 (Dr. Tamotsu
   Yoshimori, 21075), EGFP-LC3 (Dr. Karla Kirkegaard, 11546), HA-Foxo1
   (pCMV5), HA-Foxo1ADA (pCMV5), GFP-FoxO1, (Dr. Domenico Accili, 12142,
   12143, 17551), FLAG-FoxO3a WT, HA-FoxO3 TM (Dr. Michael Greenberg, 8360,
   1788), and pcDNA GFP FoxO1 AAA (Dr. William Sellers, 9023) constructs.
   We would like to thank the Ministry of Education, National Research
   Foundation and the Agency for Science, Technology, and Research (A*STAR)
   for funding this project.
CR Bach D, 2003, J BIOL CHEM, V278, P17190, DOI 10.1074/jbc.M212754200
   Bechet D, 2005, INT J BIOCHEM CELL B, V37, P2098, DOI 10.1016/j.biocel.2005.02.029
   Bodine SC, 2001, NAT CELL BIOL, V3, P1014, DOI 10.1038/ncb1101-1014
   Chen HC, 2007, CELL, V130, P548, DOI 10.1016/j.cell.2007.06.026
   Chen HC, 2010, CELL, V141, P280, DOI 10.1016/j.cell.2010.02.026
   Clarke BA, 2007, CELL METAB, V6, P376, DOI 10.1016/j.cmet.2007.09.009
   Cohen S, 2009, J CELL BIOL, V185, P1083, DOI 10.1083/jcb.200901052
   Dodson S, 2011, ANNU REV MED, V62, P265, DOI 10.1146/annurev-med-061509-131248
   Evans WJ, 2010, AM J CLIN NUTR, V91, p1123S, DOI 10.3945/ajcn.2010.28608A
   Gegg ME, 2010, HUM MOL GENET, V19, P4861, DOI 10.1093/hmg/ddq419
   Geisler S, 2010, NAT CELL BIOL, V12, P119, DOI 10.1038/ncb2012
   Gomes LC, 2011, NAT CELL BIOL, V13, P589, DOI 10.1038/ncb2220
   Irwin WA, 2003, NAT GENET, V35, P367, DOI 10.1038/ng1270
   Kambadur R, 1997, GENOME RES, V7, P910, DOI 10.1101/gr.7.9.910
   Katayama H, 2011, CHEM BIOL, V18, P1042, DOI 10.1016/j.chembiol.2011.05.013
   Kogure T, 2006, NAT BIOTECHNOL, V24, P577, DOI 10.1038/nbt1207
   Lecker SH, 2003, CURR OPIN CLIN NUTR, V6, P271, DOI 10.1097/01.mco.0000068963.34812.e5
   Lee SJ, 2001, P NATL ACAD SCI USA, V98, P9306, DOI 10.1073/pnas.151270098
   Li W, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001487
   Lin JD, 2005, CELL METAB, V1, P361, DOI 10.1016/j.cmet.2005.05.004
   Lokireddy S, 2011, AM J PHYSIOL-CELL PH, V301, pC1316, DOI 10.1152/ajpcell.00114.2011
   Lokireddy S, 2011, MOL ENDOCRINOL, V25, P1936, DOI 10.1210/me.2011-1124
   Mammucari C, 2007, CELL METAB, V6, P458, DOI 10.1016/j.cmet.2007.11.001
   Masiero E, 2009, CELL METAB, V10, P507, DOI 10.1016/j.cmet.2009.10.008
   McFarlane C, 2006, J CELL PHYSIOL, V209, P501, DOI 10.1002/jcp.20757
   Nakamura N, 2006, EMBO REP, V7, P1019, DOI 10.1038/sj.embor.7400790
   O'Leary MFN, 2009, AUTOPHAGY, V5, P230, DOI 10.4161/auto.5.2.7391
   Park YE, 2009, AUTOPHAGY, V5, P795, DOI 10.4161/auto.8901
   Romanello V, 2010, EMBO J, V29, P1774, DOI 10.1038/emboj.2010.60
   Sandri M, 2004, CELL, V117, P399, DOI 10.1016/S0092-8674(04)00400-3
   Soriano FX, 2006, DIABETES, V55, P1783, DOI 10.2337/db05-0509
   Temiz P, 2009, J NEUROL SCI, V278, P25, DOI 10.1016/j.jns.2008.11.010
   Zhang BC, 2008, CELL RES, V18, P900, DOI 10.1038/cr.2008.75
   Zhao J, 2007, CELL METAB, V6, P472, DOI 10.1016/j.cmet.2007.11.004
   Zhou XL, 2010, CELL, V142, P531, DOI 10.1016/j.cell.2010.07.011
   Zimmers TA, 2002, SCIENCE, V296, P1486, DOI 10.1126/science.1069525
NR 36
TC 111
Z9 113
U1 4
U2 26
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1550-4131
EI 1932-7420
J9 CELL METAB
JI Cell Metab.
PD NOV 7
PY 2012
VL 16
IS 5
BP 613
EP 624
DI 10.1016/j.cmet.2012.10.005
PG 12
WC Cell Biology; Endocrinology & Metabolism
SC Cell Biology; Endocrinology & Metabolism
GA 046LE
UT WOS:000311765700010
PM 23140641
OA Bronze
DA 2018-12-27
ER

PT J
AU Bencherif, M
   Chermitti, A
AF Bencherif, M.
   Chermitti, A.
TI RETRACTED: New method to assess the loss parameters of the photovoltaic
   modules (Retracted article. See vol. 6, 049901, 2014)
SO JOURNAL OF RENEWABLE AND SUSTAINABLE ENERGY
LA English
DT Article; Retracted Publication
ID SOLAR-CELL PARAMETERS; CURRENT-VOLTAGE; SERIES RESISTANCE; T
   MEASUREMENTS; PV-MODULE; EXTRACTION; SIMULATION; SYSTEM; ARRAY; MODEL
AB The determination of an effective method able to estimate the parameters of a photovoltaic panel is essential for the development and the performance of analysis of such equipment. In this paper, we present a new simple and effective method in order to extract the parameters of the photovoltaic (PV) modules by using the standard diode model. This model requires the five parameters be known, the photocurrent Iph, the reverse saturation current Is, the resistance Rs, the shunt resistance Rsh, and the curve fitting parameter A (the ideality factor) or the thermal voltage a. In order to find the five parameters, we formulated an equation binding only the two loss parameters Rs and Rsh. In order to solve this equation and to determine the shunt resistance and the thermal voltage, we expose the computation models of the series resistance Rs, which give excellent approximations. While the other parameters Iph and Is depend exclusively on the parameters Rs, Rsh, a, and the short circuit current Isc, and the open circuit voltage Voc. This method is validated experimentally by three different flat plat PV modules of various technologies (monocrystalline, polycrystalline, and thin film panels) and manufacturers. (C) 2012 American Institute of Physics. [http://dx.doi.org/10.1063/1.4767812]
C1 [Bencherif, M.; Chermitti, A.] Univ Abou Bekr Belkaid Tlemcen, Dept Phys, Lab Renewable Energies & Mat, Tilimsen 13200, Algeria.
RP Bencherif, M (reprint author), Univ Abou Bekr Belkaid Tlemcen, Dept Phys, Lab Renewable Energies & Mat, Tilimsen 13200, Algeria.
CR BASHAHU M, 1995, RENEW ENERG, V6, P129, DOI 10.1016/0960-1481(94)E0021-V
   Borowy BS, 1996, IEEE T ENERGY CONVER, V11, P367, DOI 10.1109/60.507648
   Carrero C, 2010, RENEW ENERG, V35, P1103, DOI 10.1016/j.renene.2009.10.025
   Dib S., 1999, ACT PASSIVE ELECT CO, V22, P157
   Duffie J. A., 1991, SOLAR ENG THERMAL PR, P770
   Gow JA, 1999, IEE P-ELECT POW APPL, V146, P193, DOI 10.1049/ip-epa:19990116
   Haouari-Merbah M, 2005, SOL ENERG MAT SOL C, V87, P225, DOI 10.1016/j.solmat.2004.07.019
   Hussein R, 2001, SOL ENERG MAT SOL C, V69, P123, DOI 10.1016/S0927-0248(00)00385-8
   Ikegami T, 2001, SOL ENERG MAT SOL C, V67, P389, DOI 10.1016/S0927-0248(00)00307-X
   Kalogirou S., 2009, SOLAR ENERGY ENG PRO, P477
   Macabebe EQB, 2008, S AFR J SCI, V104, P401
   Nieuwenhout F, 2007, PROG PHOTOVOLTAICS, V15, P387, DOI 10.1002/pip.748
   Ortiz-Conde A, 2006, SOL ENERG MAT SOL C, V90, P352, DOI 10.1016/j.solmat.2005.04.023
   Ouennoughi Z, 1999, SOLID STATE ELECTRON, V43, P1985, DOI 10.1016/S0038-1101(99)00174-4
   PRIYANKA ML, 2007, SOL ENERG MAT SOL C, V91, P137
   Radziemska E, 2005, ENERG CONVERS MANAGE, V46, P1485, DOI 10.1016/j.enconman.2004.08.004
   Salinger J, 2006, ACTA POLYTECH, V46, P25
   Thongpron J, 2006, SOL ENERG MAT SOL C, V90, P3078, DOI 10.1016/j.solmat.2006.06.029
   Tivanov M, 2005, SOL ENERG MAT SOL C, V87, P457, DOI 10.1016/j.solmat.2004.07.033
   Villalva MG, 2009, IEEE T POWER ELECTR, V24, P1198, DOI 10.1109/TPEL.2009.2013862
   Villalva MG, 2009, BRAZILIAN J POWER EL, V14, P35
   VISHNOI A, 1993, IEE PROC-G, V140, P155, DOI 10.1049/ip-g-2.1993.0025
NR 22
TC 5
Z9 5
U1 3
U2 27
PU AMER INST PHYSICS
PI MELVILLE
PA CIRCULATION & FULFILLMENT DIV, 2 HUNTINGTON QUADRANGLE, STE 1 N O 1,
   MELVILLE, NY 11747-4501 USA
SN 1941-7012
J9 J RENEW SUSTAIN ENER
JI J. Renew. Sustain. Energy
PD NOV 1
PY 2012
VL 4
IS 6
AR 063115
DI 10.1063/1.4767812
PG 19
WC GREEN & SUSTAINABLE SCIENCE & TECHNOLOGY; Energy & Fuels
SC Science & Technology - Other Topics; Energy & Fuels
GA 079EQ
UT WOS:000314153600021
DA 2018-12-27
ER

PT J
AU Wang, YS
   He, MR
   Zhang, CY
   Fan, SH
   Ma, J
   Li, HF
AF Wang Yan-Song
   He Ming-Rui
   Zhang Chun-Ye
   Fan Shi-Hua
   Ma Ji
   Li Hua-Feng
TI RETRACTED: Determination of Multiresidual Fungicides in Environmental
   Water Samples by High Performance Liquid Chromatography Tandem Mass
   Spectrometry (Retracted Article)
SO CHINESE JOURNAL OF ANALYTICAL CHEMISTRY
LA Chinese
DT Article; Retracted Publication
DE Liquid chromatography-tandem mass spectrometry; Multiresidual
   fungicides; Solid phase extratione; Modifier; Environmental water
ID FLUMORPH RESIDUES; EXTRACTION; MICROEXTRACTION; DERIVATIZATION;
   PYRIMETHANIL; VEGETABLES; BENALAXYL; FRUITS; WINE
AB A sensitive multiresidual analytical method for simultaneous analysis of multiresidual fungicides in environmental water samples was developed. The method was based on solid phase extraction (SPE) followed by high performance liquid chromatography tandem mass spectrometry (LC-MS/MS). Qualitative and quantitative detection for the analytes was carried out under the multiple reaction monitoring (MRM) in positive ionization mode after chromatography separation. In this method we have studied the conversion rule, identified the chromatogram retention time of Z-isomer and E-isomer of flumorph and dimethomorph, confirmed their chromatographic behavior by monitoring concentrations of two isomers of them at room temperature under sunlight and optimized parameters that may affect the SPE procedure efficiency: the column type, the wash solvent and the elution solvent. The recoveries of the SPE gave levels ranged from 70.18% to 108.87%, all recoveries were acceptable, with relative standard deviation (RSD) <= 16.7. The limit of quantification (LOQ, S/N = 10) varied between 0.003 and 0.03 mu g/L (except for fenhexamid 0.3 mu g/L). The developed method was applied for the determination of multiresidual fungicides in 100 tap water samples and 6 environmental samples collected from Liaoning province in China. Total fungicides were not found in tap water samples. Azoxystrobin (0.051 mu g/L), metalaxyl (0.217 mu g/L) and dimethomorph (Z, E) 0.015 mu g/L) were found in Pu river sample, dimethomorph (Z, E) (0.004 mu g/L) was found in Hun river sample, the highest concentration level of metalaxyl was 0.217 mu g/L in Pu river, the rest of fungicides remained undetected in river samples.
C1 [Wang Yan-Song; Fan Shi-Hua] Northeastern Univ, Coll Sci, Shenyang 110004, Peoples R China.
   [Wang Yan-Song; He Ming-Rui; Zhang Chun-Ye; Ma Ji; Li Hua-Feng] Shenyang Supervis & Inspect Inst Prod Qual, Shenyang 110022, Peoples R China.
RP Wang, YS (reprint author), Northeastern Univ, Coll Sci, Shenyang 110004, Peoples R China.
EM wys5715@126.com
CR Baggiani C, 2007, J CHROMATOGR A, V1141, P158, DOI 10.1016/j.chroma.2006.12.016
   Ballesteros-Gomez A, 2010, J CHROMATOGR A, V1217, P5913, DOI 10.1016/j.chroma.2010.07.032
   Baneriee K, 2007, J CHROMATOGR A, V1173, P98, DOI 10.1016/j.chroma.2007.10.013
   Baugros JB, 2008, ANAL CHIM ACTA, V607, P191, DOI 10.1016/j.aca.2007.11.036
   Cheng J, 2011, ANAL CHIM ACTA, V701, P86, DOI 10.1016/j.aca.2011.04.058
   Deak E, 2010, FOOD RES INT, V43, P2452, DOI 10.1016/j.foodres.2010.09.014
   Dujakovic N, 2010, ANAL CHIM ACTA, V678, P63, DOI 10.1016/j.aca.2010.08.016
   Ferrer C, 2011, TALANTA, V83, P1552, DOI 10.1016/j.talanta.2010.11.061
   Giraudi G, 1999, ANAL CHIM ACTA, V392, P85, DOI 10.1016/S0003-2670(98)00858-7
   Hayama T, 2007, J CHROMATOGR A, V1141, P251, DOI 10.1016/j.chroma.2006.12.038
   Liu C, 2009, CHEMOSPHERE, V76, P609, DOI 10.1016/j.chemosphere.2009.04.052
   Liu DH, 2006, ANAL CHIM ACTA, V555, P210, DOI 10.1016/j.aca.2005.09.022
   Marin JM, 2009, J CHROMATOGR A, V1216, P1410, DOI 10.1016/j.chroma.2008.12.094
   Moral A, 2009, J CHROMATOGR A, V1216, P3740, DOI 10.1016/j.chroma.2009.03.018
   Pan HJ, 2004, ANAL CHIM ACTA, V527, P61, DOI 10.1016/j.aca.2004.08.016
   Tang T, 2010, ANAL CHIM ACTA, V680, P26, DOI 10.1016/j.aca.2010.09.034
   Wang C, 2011, J HAZARD MATER, V185, P71, DOI 10.1016/j.jhazmat.2010.08.124
   Wang YS, 2012, CHINESE J ANAL CHEM, V40, P286, DOI 10.3724/SP.J.1096.2012.10463
   Wang YS, 2011, TALANTA, V86, P221, DOI 10.1016/j.talanta.2011.09.004
   WU Jie-Shan, 2011, J AGR SCI TECHNOL, V50, P754
   Wu QH, 2009, ANAL CHIM ACTA, V638, P139, DOI 10.1016/j.aca.2009.02.017
   Zhou QX, 2007, ANAL CHIM ACTA, V602, P223, DOI 10.1016/j.aca.2007.09.038
NR 22
TC 3
Z9 3
U1 10
U2 43
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0253-3820
EI 1872-2040
J9 CHINESE J ANAL CHEM
JI Chin. J. Anal. Chem.
PD NOV
PY 2012
VL 40
IS 11
BP 1764
EP 1771
DI 10.3724/SP.J.1096.2012.20100
PG 8
WC Chemistry, Analytical
SC Chemistry
GA 074SE
UT WOS:000313832800018
DA 2018-12-27
ER

PT J
AU Zhang, HT
   Sun, ZY
   Zhu, XY
   Chen, KW
   Qian, ZL
   Yang, HL
AF Zhang, H. T.
   Sun, Z. Y.
   Zhu, X. Y.
   Chen, K. W.
   Qian, Z. L.
   Yang, H. L.
TI RETRACTED: Kyphoplasty for the Treatment of Very Severe Osteoporotic
   Vertebral Compression Fracture (Retracted article. See vol. 55, pg. 759,
   2013)
SO JOURNAL OF INTERNATIONAL MEDICAL RESEARCH
LA English
DT Article; Retracted Publication
DE KYPHOPLASTY; KYPHOTIC ANGLE; OSTEOPOROSIS; VERTEBRAL BODY HEIGHT
   VARIATION; VERY SEVERE OSTEOPOROTIC VERTEBRAL COMPRESSION FRACTURE
ID OF-THE-LITERATURE; CONSERVATIVE TREATMENT; NEUROLOGICAL DEFICITS;
   BALLOON KYPHOPLASTY; MANAGEMENT; VERTEBROPLASTY
AB OBJECTIVE: A retrospective evaluation of the clinical outcome and technical feasibility of kyphoplasty for the treatment of very severe osteoporotic vertebral compression fracture (vsOVCF). METHODS: Patients with vsOVCF were treated with kyphoplasty and followed-up for 1 year. Vertebral body height variation, kyphotic angle, back pain (visual analogue scale [VAS]) and Oswestry disability index (ODI) were evaluated preoperatively, postoperatively, 1 month, 3 months and 1 year after treatment. RESULTS: In total, 35 patients (49 vertebrae) were treated with kyphoplasty. There were no cases of spinal or extraspinal injury, infection, bleeding, pulmonary embolism, epidural cement leakage, stroke or cardiac arrest as a result of treatment. There were significant postoperative improvements in all outcome measures (vertebral body height variation, kyphotic angle, VAS and ODI); these improvements were maintained during the follow-up period. CONCLUSION: Kyphoplasty is an effective and minimally invasive procedure for the treatment of vsOVCF.
C1 [Zhang, H. T.; Sun, Z. Y.; Zhu, X. Y.; Chen, K. W.; Qian, Z. L.; Yang, H. L.] Soochow Univ, Affiliated Hosp 1, Dept Orthopaed Surg, Suzhou 215006, Jiangsu, Peoples R China.
RP Qian, ZL (reprint author), Soochow Univ, Affiliated Hosp 1, Dept Orthopaed Surg, 188 Shizi St, Suzhou 215006, Jiangsu, Peoples R China.
EM soochowspine@139.com
CR Bornemann R, 2012, Z ORTHOP UNFALLCHIR, V150, P392, DOI 10.1055/s-0031-1298547
   COOPER C, 1992, J BONE MINER RES, V7, P221
   Czerwinski Edward, 2003, Ortop Traumatol Rehabil, V5, P40
   Duque G, 2008, J AM GERIATR SOC, V56, P935, DOI 10.1111/j.1532-5415.2008.01764.x
   Fabeck L, 2008, Rev Med Brux, V29, P317
   Felder-Puig R, 2009, ORTHOPADE, V38, P606, DOI 10.1007/s00132-009-1446-2
   Fuentes S, 2007, J NEUROSURG-SPINE, V6, P284, DOI 10.3171/spi.2007.6.3.284
   Fuentes S, 2009, NEUROSURGERY, V64, P350, DOI 10.1227/01.NEU.0000337066.59130.61
   Kaneda K, 1997, J BONE JOINT SURG AM, V79A, P69, DOI 10.2106/00004623-199701000-00008
   Karlsson Magnus K, 2005, Lakartidningen, V102, P1644
   Karlsson MK, 2005, LAKARTIDNINGEN, V102, P1648
   Lemke Denise M, 2005, J Am Acad Nurse Pract, V17, P268, DOI 10.1111/j.1745-7599.2005.0045.x
   Lim BG, 2011, PAIN PHYSICIAN, V14, P539
   Liu Jie, 2008, Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi, V22, P399
   Longo UG, 2012, J BONE JOINT SURG BR, V94B, P152, DOI 10.1302/0301-620X.94B2.26894
   Melton LJ, 1997, SPINE, V22, p2S, DOI 10.1097/00007632-199712151-00002
   Movrin I, 2010, ARCH ORTHOP TRAUM SU, V130, P1157, DOI 10.1007/s00402-010-1106-3
   Muller CW, 2010, ORTHOPADE, V39, P417, DOI 10.1007/s00132-009-1576-6
   Nanri Yasuhiro, 2007, Nihon Rinsho, V65 Suppl 9, P471
   Pateder DB, 2007, ORTHOP CLIN N AM, V38, P409, DOI 10.1016/j.ocl.2007.03.010
   Pratt RK, 2002, SPINE, V27, P84, DOI 10.1097/00007632-200201010-00020
   Qian ZL, 2011, J CLIN NEUROSCI, V18, P763, DOI 10.1016/j.jocn.2010.09.021
   Sambrook P, 2006, LANCET, V367, P2010, DOI 10.1016/S0140-6736(06)68891-0
   Sietsma M S, 2008, Ned Tijdschr Geneeskd, V152, P944
   Sun ZY, 2012, PAIN PHYSICIAN, V15, P95
   Syed Mubin I, 2007, Pain Physician, V10, P367
   Taylor RS, 2007, EUR SPINE J, V16, P1085, DOI 10.1007/s00586-007-0308-z
   Taylor RS, 2006, SPINE, V31, P2747, DOI 10.1097/01.brs.0000244639.71656.7d
   Truumees E, 2001, SPINE, V26, P930, DOI 10.1097/00007632-200104150-00016
   Wang Jian, 2009, Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi, V23, P68
   Watts NB, 2001, OSTEOPOROSIS INT, V12, P429, DOI 10.1007/s001980170086
   Yang HL, 2008, J INT MED RES, V36, P1056, DOI 10.1177/147323000803600524
   Yang HL, 2007, J SPINAL DISORD TECH, V20, P221, DOI 10.1097/01.bsd.0000211273.74238.0e
NR 33
TC 5
Z9 9
U1 6
U2 20
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0300-0605
EI 1473-2300
J9 J INT MED RES
JI J. Int. Med. Res.
PD NOV-DEC
PY 2012
VL 40
IS 6
BP 2394
EP 2400
DI 10.1177/030006051204000638
PG 7
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA 070UO
UT WOS:000313538300038
PM 23321197
OA DOAJ Gold
DA 2018-12-27
ER

PT J
AU Xu, BJ
   Liu, L
   Liu, L
   Li, XP
   Li, XF
   Wang, X
AF Xu, Benjin
   Liu, Ling
   Liu, Li
   Li, Xinping
   Li, Xiaofang
   Wang, Xin
TI RETRACTED: A Multiplex PCR Assay for the Rapid and Sensitive Detection
   of Methicillin-Resistant Staphylococcus aureus and Simultaneous
   Discrimination of Staphylococcus aureus from Coagulase-Negative
   Staphylococci (Retracted article. See vol. 79, pg. IV, 2014)
SO JOURNAL OF FOOD SCIENCE
LA English
DT Article; Retracted Publication
DE analytical specificity; detection; MRSA; multiplex PCR
ID UNITED-STATES; STRAIN ST398; GENES; INFECTIONS; PREVALENCE; MECA; MEAT;
   FOOD; MRSA; PATHOGENS
AB Methicillin-resistant Staphylococcus aureus (MRSA) is a global health concern, which had been detected in food and food production animals. Conventional testing for detection of MRSA takes 3 to 5 d to yield complete information of the organism and its antibiotic sensitivity pattern. So, a rapid method is needed to diagnose and treat the MRSA infections. The present study focused on the development of a multiplex PCR assay for the rapid and sensitive detection of MRSA. The assay simultaneously detected 4 genes, namely, 16S rRNA of the Staphylococcus genus, femA of S. aureus, mecA that encodes methicillin resistance, and one internal control. It was rapid and yielded results within 4 h. The analytical sensitivity and specificity of the multiplex PCR assay was evaluated by comparing it with the conventional method. The analytical sensitivity of the multiplex PCR assay at the DNA level was 10 ng DNA. The analytical specificity was evaluated with 10 reference staphylococci strains and was 100%. The diagnostic evaluation of MRSA was carried out using 360 foodborne staphylococci isolates, and showed 99.1% of specificity, 96.4% of sensitivity, 97.5% of positive predictive value, and 97.3% of negative predictive value compared to the conventional method. The inclusion of an internal control in the multiplex PCR assay is important to exclude false-negative cases. This test can be used as an effective diagnostic and surveillance tool to investigate the spread and emergence of MRSA.
C1 [Xu, Benjin; Li, Xinping] NW A&F Univ, Coll Vet Med, Yangling 712100, Shaanxi, Peoples R China.
   [Xu, Benjin; Liu, Li; Wang, Xin] NW A&F Univ, Coll Food Sci & Engn, Yangling 712100, Shaanxi, Peoples R China.
   [Liu, Ling; Li, Xiaofang] Tianshui Normal Univ, Coll Life Sci & Chem, Tianshui 741001, Gansu, Peoples R China.
RP Xu, BJ (reprint author), NW A&F Univ, Coll Vet Med, Yangling 712100, Shaanxi, Peoples R China.
EM xbj262020105@163.com
FU Changjiang Scholar Program of China; Special Funds for Talents from
   Northwest A F Univ. [Z111021002]
FX This research was supported in part by Changjiang Scholar Program of
   China and Special Funds for Talents from Northwest A & F Univ. (Nr.
   Z111021002).
CR Akineden O, 2001, CLIN DIAGN LAB IMMUN, V8, P959, DOI 10.1128/CDLI.8.5.959-964.2001
   de Boer E, 2009, INT J FOOD MICROBIOL, V134, P52, DOI 10.1016/j.ijfoodmicro.2008.12.007
   Francois P, 2003, J CLIN MICROBIOL, V41, P254, DOI 10.1128/JCM.41.1.254-260.2003
   Frazee BW, 2005, ANN EMERG MED, V45, P311, DOI 10.1016/j.annemergmed.2004.10.011
   Hashimoto Hajime, 1994, Japanese Journal of Antibiotics, V47, P575
   Hasman H, 2010, VET MICROBIOL, V141, P326, DOI 10.1016/j.vetmic.2009.09.025
   Huebner J, 1999, ANNU REV MED, V50, P223
   HURLIMANNDALEL RL, 1992, ANTIMICROB AGENTS CH, V36, P2617, DOI 10.1128/AAC.36.12.2617
   Khanna T, 2008, VET MICROBIOL, V128, P298, DOI 10.1016/j.vetmic.2007.10.006
   Klevens RM, 2007, JAMA-J AM MED ASSOC, V298, P1763, DOI 10.1001/jama.298.15.1763
   KLOOS WE, 1994, CLIN MICROBIOL REV, V7, P117
   KLUYTMANS J, 1995, J CLIN MICROBIOL, V33, P1121
   Lim D, 2002, NAT STRUCT BIOL, V9, P870, DOI 10.1038/nsb858
   Lim SK, 2010, J MICROBIOL BIOTECHN, V20, P775, DOI 10.4014/jmb.0912.12022
   Lu S., 2010, J APPL PREV MED, V16, P271
   Mead PS, 1999, EMERG INFECT DIS, V5, P607, DOI 10.3201/eid0505.990502
   Mehrotra M, 2000, J CLIN MICROBIOL, V38, P1032
   Mohanasoundaram KM, 2008, INDIAN J MED RES, V127, P78
   Mulvey MR, 2005, EMERG INFECT DIS, V11, P844, DOI 10.3201/eid1106.041146
   Murray P. R, 2003, MANUAL CLIN MICROBIO
   Nemati M, 2008, ANTIMICROB AGENTS CH, V52, P3817, DOI 10.1128/AAC.00613-08
   Nolte F, 2006, MOL DIAGNOSTIC METHO
   Perreten V, 1998, SYST APPL MICROBIOL, V21, P113, DOI 10.1016/S0723-2020(98)80014-3
   Pu SH, 2009, APPL ENVIRON MICROB, V75, P265, DOI 10.1128/AEM.01110-08
   Rajan L, 2007, J INFECTION, V55, P353, DOI 10.1016/j.jinf.2007.06.005
   Rasheed MU, 2010, ASIAN PAC J TROP MED, V3, P741, DOI 10.1016/S1995-7645(10)60178-2
   Smith TC, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004258
   Su C, 2000, VET MICROBIOL, V71, P53, DOI 10.1016/S0378-1135(99)00139-X
   UNAL S, 1992, J CLIN MICROBIOL, V30, P1685
   Van Loo IHM, 2007, EMERG INFECT DIS, V13, P1753, DOI 10.3201/eid1311.070358
   VANNUFFEL P, 1995, J CLIN MICROBIOL, V33, P2864
   von Eiff C, 2002, LANCET INFECT DIS, V2, P677, DOI 10.1016/S1473-3099(02)00438-3
   von Eiff C, 2001, POSTGRAD MED, V110, P63, DOI 10.3810/pgm.2001.10.1046
   Wikler MA, 2006, PERFORMANCE STANDARD
   Wu SW, 1996, MICROB DRUG RESIST, V2, P435, DOI 10.1089/mdr.1996.2.435
   Zhang KY, 2005, J CLIN MICROBIOL, V43, P5026, DOI 10.1128/JCM.43.10.5026-5033.2005
NR 36
TC 5
Z9 5
U1 3
U2 20
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-1147
EI 1750-3841
J9 J FOOD SCI
JI J. Food Sci.
PD NOV
PY 2012
VL 77
IS 11
BP M638
EP M642
DI 10.1111/j.1750-3841.2012.02959.x
PG 5
WC Food Science & Technology
SC Food Science & Technology
GA 057GX
UT WOS:000312552200023
PM 23106158
DA 2018-12-27
ER

PT J
AU Hassan, SA
   Zaman, K
AF Hassan, Syeda Anam
   Zaman, Khalid
TI RETRACTED: Effect of oil prices on trade balance: New insights into the
   cointegration relationship from Pakistan (Retracted article. See vol.
   45, pg. 281, 2015)
SO ECONOMIC MODELLING
LA English
DT Article; Retracted Publication
DE Trade balance; Exchange rate; Output gap; Oil prices; Bounds testing
   approach; Pakistan
ID IMPORTING DEVELOPING-COUNTRIES; REAL EXCHANGE-RATE; ECONOMY; IMPACT;
   WELFARE; TESTS
AB Global oil price shock waves and continuous trade imbalance have raised serious alarms among the policy makers around the world, because of its aggressive impacts for the net oil-importing economies. The objective of this study is to investigate the impact of rising oil prices on the trade balance of Pakistan by using ARDL approach. Further, this study explores the causality direction between trade balance and oil price shocks in the context of Pakistan over a period of 1975-2010. The result shows that there is a significant negative relationship among oil prices, exchange rate and trade balance in Pakistan, i.e., if there is 1% increase in oil prices and exchange rate, the trade balance decreases by 0.382% and 0.342% respectively. This infers that oil prices and exchange rate induces trade imbalance in Pakistan. In addition, there is a positive relationship between output gap and trade balance which infers inefficient resource allocation and utilization in production. In the short run, there is a positive relationship among exchange rate, output gap and trade balance in Pakistan which shows that an increase in oil prices increases the net income flow in terms of huge cost payments for imports and increases the trade deficit in an economy. The result of Granger causality indicates that there is a bidirectional causality between oil prices and exchange rate in Pakistan which infers that Pakistan has to invest in alternative energy projects to reduce its dependence on oil imports, while there is a unidirectional causality running from oil prices to trade imbalance. This implies that the high oil prices are more appropriate than output gap because it covered all range cause of trade imbalance. The usage of oil in both forms as a fuel and energy can be substituted by solar energy, hydropower, coal energy, and wind energy and high oil demand can be reduced by the establishment of transport infrastructure. The intense need is to redefine and adopt practical step in energy conservation. Regulations, standards, and targets are important in order to provide direction of efficient level of utilization of oil as a fuel. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Hassan, Syeda Anam; Zaman, Khalid] COMSATS Inst Informat Technol, Dept Management Sci, Abbottabad, Pakistan.
RP Zaman, K (reprint author), COMSATS Inst Informat Technol, Dept Management Sci, Abbottabad, Pakistan.
EM anum_hassan1992@yahoo.com; khalidzaman@ciit.net.pk
CR ADB, 2005, CHALL HIGH OIL PRIC
   ADO, 2010, AS DEV OUTL 2010, P1
   AFDB, 2007, 93 AFDB
   Ahmed I., 2011, FINANCE MARKETS BUSI
   Ahmed V., 2010, LAHORE J EC, V15, P45
   Akpan E., 2007, OIL PRICES SHOCKS NI
   Akpan E. O., 2009, EUR REP DEV ERD C AC
   [Anonymous], 2012, EC B NAT BANK PAK
   Appleyard D., 2001, INT EC
   Aurangzeb, 2012, EC FINANCE REV, V1, P25
   Ayyoub M., 2011, PAKISTAN J SOCIAL SC, V31, P51
   Backus D., 1998, J INT ECON, V50, P185
   Bacon R., 2006, 32306 ESMAP WORLD BA
   Bacon R., 2010, PHASING OUT SUBSIDIE
   Baffes J., 2007, 4333 WORLD BANK
   Baloch Q.B., 2009, DIALOGUE, V3, P148
   Barrell R., 2004, AUSTR CENTR BANK SEM
   Belkar R., 2007, CURRENT ACCOUNT DEFI
   Bernanke BS, 1997, BROOKINGS PAP ECO AC, P91
   Blanchard O., 2007, 13368 NBER
   Bodenstein M., 2007, OIL SHOCKS EXTERNAL
   Central Bank of Egypt, 2011, ECON REV, V51, P1
   Chishti A., 2008, TRADE08C3C18 CERIS
   Dash A.K., 2005, BILATERAL J CURVE IN
   Dawson J., 2004, PARK PLACE EC, V14, P23
   Deserres A., 1995, 2 BANK CAN
   Deutch J., 2010, OIL GAS ENERGY SECUR
   Effiong E., 2010, 51 ANN C NIG EC SOC
   EIA, 2011, INT EN OUTL PAK EN P
   Elmi Z., 2011, AUSTR J BASIC APPL S, V5, P627
   Enders W., 2004, APPL ECONOMETRIC TIM
   Energy Revolution Report, 2010, BLUEPR REV BROK EN E
   Gallo A, 2010, ENERGY, V35, P4126, DOI 10.1016/j.energy.2010.06.033
   GEWEKE J, 1982, J AM STAT ASSOC, V77, P304, DOI 10.2307/2287238
   GISSER M, 1986, J MONEY CREDIT BANK, V18, P95, DOI 10.2307/1992323
   Government of Pakistan, 2006, EC SURV 2005 06
   Government of Pakistan, 2011, EC SURV 2010 2011
   GRABOWSKI R, 1994, J DEV AREAS, V28, P535
   Hakura D. S., 2008, WP08216 IMF
   HANSON K, 1993, J AGR RESOUR ECON, V18, P96
   Harri A., 2008, J AGR APPL EC, V41, P501
   HOFFMANN L, 1983, WELTWIRTSCH ARCH, V119, P297, DOI 10.1007/BF02706428
   *IEA, 2004, AN IMP HIGH OIL PRIC
   IEA, 2009, IMP FIN EC CRIS GLOB
   IFS, 2011, INT FIN STAT 2011
   Islam R., 1981, BANGLADESH DEV STUDI, V9, P1
   Jamali M., 2011, MODERN APPL SCI, V5, P1
   Khan A.A., 2007, PAKISTAN DEV REV, V35, P747
   Khan F., 2012, ALTERNATIVE ENERGY S
   Kiani A., 2009, INT J BUSINESS SOCIA, V2, P1
   Kilian L, 2009, J INT ECON, V77, P181, DOI 10.1016/j.jinteco.2009.01.001
   Kooros S.K., 2006, INT RES J FINANCE EC, V6, P136
   Lane P., 2011, I INT INTEGRATION ST
   Lane PR, 2002, EUR ECON REV, V46, P1049, DOI 10.1016/S0014-2921(02)00160-5
   Lardic S, 2006, ENERG POLICY, V34, P3910, DOI 10.1016/j.enpol.2005.09.019
   Laugerud T., 2009, ENHANCING FOOD SECUR
   Le T., 2011, INT FINANCE DISCUSSI
   Liew V. K., 2004, EC B, V3, P1
   Lund, 2008, EN SEC EUR WORK PAP
   Lutkepohl Helmuth, 1991, INTRO MULTIPLE TIME
   Mackinnon JG, 1996, J APPL ECONOMET, V11, P601, DOI 10.1002/(SICI)1099-1255(199611)11:6<601::AID-JAE417>3.0.CO;2-T
   Mahboob R., 2012, THAR COAL CAN ENERGI
   Malik A., 2008, PAKISTAN DEV REV, V47, P425
   Malik A., 2010, S ASIA EC J, V11, P23
   Malik A., 2008, PAKISTAN IS COPING C
   Mirza J., 2012, ENERGY SUPPLIES LEAN
   Mohammad S., 2010, EUROPEAN J SCI RES, V41, P543
   Mussa M., 2000, IMPACT HIGHER OIL PR
   Nakov A., 2007, INFLATION OUTPUT GAP
   Nakov A., 2007, FEDERAL RESERVE BANK
   Narayan PK, 2005, ECON MODEL, V22, P423, DOI 10.1016/j.econmod.2004.06.004
   Nikbakht L., 2010, BUS INTELL J, V3, P83
   Otto G., 2003, AUSTR EC REV, V36, P350
   Ozlale U, 2010, ENERG POLICY, V38, P4489, DOI 10.1016/j.enpol.2010.03.082
   Pakistan Economy Profile, 2012, PAKISTAN EC PROFILE
   Pesaran MH, 2001, J APPL ECONOM, V16, P289, DOI 10.1002/jae.616
   Rasmussen Tobias N., 2011, WP11194 IMF
   Rasool A.K., 2012, 5 STEPS SOLVING PAKI
   Rautava J, 2004, J COMP ECON, V32, P315, DOI 10.1016/j.jce.2004.02.006
   Regnier E, 2007, ENERG ECON, V29, P405, DOI 10.1016/j.eneco.2005.11.003
   Rock M. T., 2002, Journal of International Development, V14, P485, DOI 10.1002/jid.889
   Sanchez MV, 2011, DEV ECON, V49, P321, DOI 10.1111/j.1746-1049.2011.00137.x
   SBP, 2006, IMPL LIB TRAD INV IN
   Schubert S.F., 2009, DYNAMIC EFFECTS OIL
   Schubert SF, 2011, OPEN ECON REV, V22, P365, DOI 10.1007/s11079-011-9202-8
   Sengonul A, 2011, AFR J BUS MANAGE, V5, P8707
   Shao Z., 2008, EXCHANGE RATE CHANGE
   Sherbaz S., 2006, 24 M PSDE PAK DEV RE, P1
   Singh T., 2009, J EC SURVEYS, V21, P26
   State Bank of Pakistan Annual Report, 2001, STAT BANK PAK ANN RE
   Trung L.V., 2011, IMPACT OIL PRICES RE
   Waliullah K.M.K., 2010, LAHORE J EC, V15, P1
   Waseem M.T., 2002, FINANCE MARKETS MAGA
   Williams J.L., 2011, WORLD MOTION IMPORTA
   Wilson P, 2001, OPEN ECON REV, V12, P389, DOI 10.1023/A:1017982901034
   World Bank, 2008, GROWTH REP STRAT SUS
   World Economic outlook, 2011, SLOW GROWTH RIS RISK
   Zaouali S, 2007, OPEC ENERGY REV, V31, P191, DOI 10.1111/j.1468-0076.2007.00183.x
NR 98
TC 12
Z9 12
U1 3
U2 28
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0264-9993
EI 1873-6122
J9 ECON MODEL
JI Econ. Model.
PD NOV
PY 2012
VL 29
IS 6
BP 2125
EP 2143
DI 10.1016/j.econmod.2012.07.006
PG 19
WC Economics
SC Business & Economics
GA 038OT
UT WOS:000311184700006
DA 2018-12-27
ER

PT J
AU Naz, F
   Mohsin, A
   Zaman, K
AF Naz, Farah
   Mohsin, Asma
   Zaman, Khalid
TI RETRACTED: Exchange rate pass-through in to inflation: New insights in
   to the cointegration relationship from Pakistan (Retracted article. See
   vol. 45, pg. 282, 2015)
SO ECONOMIC MODELLING
LA English
DT Article; Retracted Publication
DE Exchange rate; Domestic prices; Cointegration; Structural VAR; Pakistan
ID IMPORT PRICES; INDUSTRY; MODEL
AB Understanding the impact of exchange rate movements on prices is critical from a policy perspective in order to gauge the appropriate monetary policy response to currency movements. This study assesses the extent to which the movements in exchange rate affect domestic consumer prices in Pakistan by analyzing quarterly data from 1982 Q1 to 2010 Q4. The structural VAR (WAR) model is used to estimate the exchange rate pass-through to inflation in Pakistan. Further, impulse response function and variance decomposition are used to measure the exchange rate pass-through to domestic prices. The major findings of this study are as follows: (i) the exchange rate movements have only a moderate effect on domestic prices, (ii) for consumer prices, ERPT elasticity is around 0.042 in the short run and 0.137 in the long run, (iii) up to 90% of the price level changes are explained by its own shocks in the long run. The study concludes that the effect of an exchange rate shock on domestic prices is quite gradual, taking about 14 quarters to arrive at the full impact. The immediate effect of a structural one standard deviation shock to the exchange rate (which is 0.045 increase, or 4.5% appreciation) is about 0.001 (or 0.1%) decrease in the price level. This entails an impact elasticity of 0.042. The full effect of this shock, realized after about 14 quarters, is about 0.0062 (or 0.62%) decrease in the price level. This implies a dynamic pass-through elasticity of 0.137. The result highlights the importance of other factors that play significant roles in the Pakistan's inflationary process, e.g. supply shocks. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Naz, Farah; Mohsin, Asma; Zaman, Khalid] COMSATS Inst Informat Technol, Dept Management Sci, Abbottabad, Pakistan.
RP Zaman, K (reprint author), COMSATS Inst Informat Technol, Dept Management Sci, Abbottabad, Pakistan.
EM farah@ciit.net.pk; asmamohsin@ciit.net.pk; khalidzaman@ciit.net.pk
CR Ahmadi R., 2012, MIDDLE E J SCI RES, V11, P610
   Ahmed M, 1998, PAKISTAN DEV REV 2, V37, P1123
   Akbari Ather H., 2006, SBP RES B, V2, P169
   Akhtar S., 2008, EFFECTIVENESS MONETA
   Ali M. S. B., 2011, INT J EC FINANCE, V3, P119
   Anderton B., 2003, EUROPEAN CENTRAL BAN
   Auer R, 2009, J MONEY CREDIT BANK, V41, P151, DOI 10.1111/j.1538-4616.2008.00202.x
   Bailliu J, 2004, 200421 BANK CAN
   Basher S., 2010, OPEC ENERGY REV, V36, P170
   Bernanke B., 1986, CARNEGIE ROCHESTER S, V25, P49
   BLS, 2010, PRIC IND
   Bordo Michael D., 2000, 7724 NBER
   Brun-Aguerre R, 2012, J INT MONEY FINANC, V31, P818, DOI 10.1016/j.jimonfin.2012.01.009
   Campa JM, 2005, REV ECON STAT, V87, P679, DOI 10.1162/003465305775098189
   CHOUDHRI EU, 2001, 01194 IMF
   Cunningham A., 1999, MONETARY POLICY RULE
   Devereux M.B., 2003, PRICE SETTING EXCHAN
   DORNBUSCH R, 1987, AM ECON REV, V77, P93
   Enders W., 2004, APPL ECONOMETRIC TIM
   Engel C., 1996, W5646 NBER
   FEINBERG RM, 1989, REV ECON STAT, V71, P505, DOI 10.2307/1926908
   Ferrantino M.J., 2012, 201201A US INT TRAD
   Fjaertoft D.B., 2011, MONETARY POLICY RUSS
   Flamini A, 2007, J INT MONEY FINANC, V26, P1113, DOI 10.1016/j.jimonfin.2007.06.003
   Gagnon J.E., 2001, 704 FED RES SYST INT
   Ghosh A., 2007, 200701 COL COLL
   Goldberg PK, 1997, J ECON LIT, V35, P1243
   GOLDBERG PK, 1995, ECONOMETRICA, V63, P891, DOI 10.2307/2171803
   GOP, 2011, EC SURV PAK 2010 11
   GOP, 2012, EC SURV PAK 2011 12
   GOP, 2010, EC SURV PAK 2009 10
   GoP, 1999, EC SURV PAK 1998 99
   Gregorio J., 2007, CENTRAL BANK CHILE W
   Gregorio J.D., 2005, 21 M LAT AM NETW CEN
   Hassan R., 2011, LAHORE J EC, V16, P111
   Hooper Peter, 1989, BROOKINGS PAPERS EC, V1, P297
   Hossain M., 2009, EXCHANGE RATE MANAGE
   Hussain K., 2009, 41 CID
   IMF, 1999, INT FIN STAT YB
   IMF, 1998, INT FIN STAT YB
   IMF, 2000, INT FIN STAT YB
   IMF, 2012, CURR COMP OFF FOR EX
   IMF, 1993, INT FIN STAT YB
   Jabara C.L., 2009, DO EXCHANGE RATES AF
   Jaffri A.A., 2010, PAKISTAN DEV REV, V49, P19
   Janjua M.A., 2007, LAHORE J EC, P125
   JOHANSEN S, 1990, OXFORD B ECON STAT, V52, P169, DOI 10.1111/j.1468-0084.1990.mp52002003.x
   Kashif S., 2011, RELATIONSHIP EXCHANG
   Khan M., 2010, EUROPEAN J SOCIAL SC, V14, P34
   Khan M., 2008, J ECON, V13, P29
   Khan M.A., 2011, 25 PSDE C PAK I DEV
   Khan M.Z., 1999, LIBERALIZATION EC CR, V9
   Khan SU, 2011, J ASIAN ECON, V22, P540, DOI 10.1016/j.asieco.2011.08.006
   Kilic R., 2010, TUSIAD KOC U EC RES
   Kim KH, 1998, APPL ECON, V30, P613, DOI 10.1080/000368498325606
   Landerretche O., 1999, 55 CENTR BANK CHIL
   Liang F., 2007, EXPLAINING EXCHANGE
   Lown C., 2005, FINANCIAL SECTOR WEA
   Makin J., 2001, BALANCE PAYMENTS EXC
   Mallick S, 2008, IMF STAFF PAPERS, V55, P83, DOI 10.1057/palgrave.imfsp.9450027
   McCarthy J., 1999, 79 BIS
   McCarthy J., 2006, PASS THROUGH E UNPUB
   McCarthy J., 2000, STAFF REPORTS
   Mwase N., 2006, INT MONETARY FUND WO
   Nyder Z., 2004, WPSBP200405
   Osbat C., 2006, SECTORAL EXCHA UNPUB
   OYINLOLA M. ABIMBOLA, 2009, Journal of Economic Development, V34, P97
   Pesaran MH, 2001, J APPL ECONOM, V16, P289, DOI 10.1002/jae.616
   Rajmund M., 2009, 19282 MPRA
   Reinert K.A., 2009, PRINCETON ENCY WORLD, V1
   Restrepo J., 2001, WORKING PAPERS CENTR
   Rogoff K., 1998, JUN 22 23 1998 BANK
   Rowland P., 2004, EXCHANGE RATE PASS T
   Sahminan S., 2002, EXCHANGE RATE PASS T
   Sanusi A. R., 2010, W AFRICAN J MONETARY, V10, P25
   Sasaki Y., 2005, EFFECT PASS THROUGH
   SBP, 2009, STAT BANK PAK ANN RE, VI
   Sekine T., 2006, BANK INT SETTLEMENTS
   SHAPIRO MD, 1988, NBER MACROECON ANN, V3, P111, DOI 10.2307/3584944
   Shintani M., 2009, VANDERBILT U WORKING
   Shu CE, 2008, CELL MOL BIOENG, V1, P1, DOI 10.1007/s12195-008-0003-0
   Siddiqui M.A., 2009, EUROPEAN J EC FINANC, V8, P81
   Siddiqui R., 1999, PAKISTAN DEV REV, V38, P1059
   Sims C. A., 1986, Q REV FEDERAL RE WIN, V10, P2
   SIMS CA, 1980, ECONOMETRICA, V48, P1, DOI 10.2307/1912017
   Stulz J., 2007, EC STUDIES
   Takhtamanova Y., 2008, 13 FED RES BANK SAN
   Taylor JB, 2000, EUR ECON REV, V44, P1389, DOI 10.1016/S0014-2921(00)00037-4
   Velasco A., 1999, EXCHANGE RATE POLICI
   Vigfusson R., 2007, BOARD GOVERNORS FEDE
   Volkan A., 2007, 062007 TURK EC ASS
   WCY, 1984, WORLD CURR YB 1983 8
   WCY, 1987, WORLD CURR YB 1986 8
   WCY, 1993, WORLD CURR YB 1992 9
   Yuko H., 2007, RIETI DISCUSSION PAP, V07-E-039
   Zorzi M.C., 2007, EUROPEAN CENTRAL BAN
NR 96
TC 2
Z9 3
U1 2
U2 18
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0264-9993
EI 1873-6122
J9 ECON MODEL
JI Econ. Model.
PD NOV
PY 2012
VL 29
IS 6
BP 2205
EP 2221
DI 10.1016/j.econmod.2012.07.012
PG 17
WC Economics
SC Business & Economics
GA 038OT
UT WOS:000311184700014
DA 2018-12-27
ER

PT J
AU Zhang, YL
   Jiang, CY
AF Zhang Yan-Li
   Jiang Cheng-Yu
TI RETRACTED: Science China: life science in reform in retrospect on
   progresses in 2010-2011 (Retracted article. See vol. 40, pg. 686, 2013)
SO PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS
LA Chinese
DT Editorial Material; Retracted Publication
ID PINUS DENSIFLORA STANDS; BIOMASS CARBON STOCKS; SOIL ORGANIC-CARBON;
   STEM-CELLS; TRANSLATIONAL MEDICINE; INFLAMMATORY RESPONSES;
   GENE-EXPRESSION; IN-VITRO; PROTEOMICS; DISEASE
EM Jiang@pumc.edu.cn
CR Bouma G, 2011, BLOOD
   Cao J, 2011, SCI CHINA LIFE SCI, V54, P34, DOI 10.1007/s11427-010-4122-1
   Carafoli E, 2011, SCI CHINA LIFE SCI, V54, P686, DOI 10.1007/s11427-011-4200-z
   Cartwright EJ, 2011, SCI CHINA LIFE SCI, V54, P691, DOI 10.1007/s11427-011-4199-1
   Chakroborty S, 2011, SCI CHINA LIFE SCI, V54, P752, DOI 10.1007/s11427-011-4205-7
   Chen DX, 2010, SCI CHINA LIFE SCI, V53, P798, DOI 10.1007/s11427-010-4024-2
   Chen M, 2010, SCI CHINA LIFE SCI, V53, P257, DOI 10.1007/s11427-010-0025-4
   Chen Z, 2011, SCI CHINA LIFE SCI, V54, P1074, DOI 10.1007/s11427-011-4231-5
   Cheng GH, 2010, SCI CHINA LIFE SCI, V53, P157, DOI 10.1007/s11427-010-0041-4
   Choi S, 2010, SCI CHINA LIFE SCI, V53, P784, DOI 10.1007/s11427-010-4025-1
   Dai XX, 2011, SCI CHINA LIFE SCI, V54, P68, DOI 10.1007/s11427-010-4116-z
   Duan SM, 2010, SCI CHINA LIFE SCI, V53, P330, DOI 10.1007/s11427-010-0067-7
   Fang JY, 2010, SCI CHINA LIFE SCI, V53, P757, DOI 10.1007/s11427-010-4029-x
   Fang JY, 2010, SCI CHINA LIFE SCI, V53, P753, DOI 10.1007/s11427-010-4032-2
   Feng W, 2011, SCI CHINA LIFE SCI, V54, P1103, DOI 10.1007/s11427-011-4249-8
   Feng YL, 2011, SCI CHINA LIFE SCI, V54, P1113, DOI 10.1007/s11427-011-4257-8
   Galione A, 2011, SCI CHINA LIFE SCI, V54, P725, DOI 10.1007/s11427-011-4207-5
   Gao X, 2010, SCI CHINA LIFE SCI, V53, P22, DOI 10.1007/s11427-010-0027-2
   Gu JL, 2011, SCI CHINA LIFE SCI, V54, P793, DOI 10.1007/s11427-011-4215-5
   Gui JF, 2010, SCI CHINA LIFE SCI, V53, P409, DOI 10.1007/s11427-010-0092-6
   Gui JF, 2010, SCI CHINA LIFE SCI, V53, P399, DOI 10.1007/s11427-010-0091-7
   Guo AK, 2010, SCI CHINA LIFE SCI, V53, P374, DOI 10.1007/s11427-010-0073-9
   He FC, 2011, SCI CHINA LIFE SCI, V54, P1, DOI 10.1007/s11427-010-4131-0
   He HQ, 2010, SCI CHINA LIFE SCI, V53, P241, DOI 10.1007/s11427-010-0006-7
   Hou XM, 2010, SCI CHINA LIFE SCI, V53, P248, DOI 10.1007/s11427-010-0034-3
   Hu W, 2010, SCI CHINA LIFE SCI, V53, P401, DOI 10.1007/s11427-010-0088-2
   Huang Y, 2010, SCI CHINA LIFE SCI, V53, P766, DOI 10.1007/s11427-010-4022-4
   Jia Q, 2010, SCI CHINA LIFE SCI, V53, P94, DOI 10.1007/s11427-010-0003-x
   Jiang CY, 2011, SCI CHINA LIFE SCI, V54, P1071, DOI 10.1007/s11427-011-4260-0
   Jiao JW, 2010, SCI CHINA LIFE SCI, V53, P338, DOI 10.1007/s11427-010-0070-z
   Ju YF, 2011, SCI CHINA LIFE SCI, V54, P16, DOI 10.1007/s11427-010-4115-0
   Kim SR, 2010, SCI CHINA LIFE SCI, V53, P885, DOI 10.1007/s11427-010-4017-1
   Kimlicka L, 2011, SCI CHINA LIFE SCI, V54, P712, DOI 10.1007/s11427-011-4198-2
   Kwak DA, 2010, SCI CHINA LIFE SCI, V53, P898, DOI 10.1007/s11427-010-4019-z
   Lee HC, 2011, SCI CHINA LIFE SCI, V54, P699, DOI 10.1007/s11427-011-4197-3
   Li C, 2010, SCI CHINA LIFE SCI, V53, P447, DOI 10.1007/s11427-010-0052-1
   Li GQ, 2011, SCI CHINA LIFE SCI, V54, P403, DOI 10.1007/s11427-011-4163-0
   Li JY, 2010, SCI CHINA LIFE SCI, V53, P2, DOI 10.1007/s11427-010-0028-1
   Li NS, 2011, SCI CHINA LIFE SCI, V54, P1089, DOI 10.1007/s11427-010-4100-7
   Li SL, 2011, SCI CHINA LIFE SCI, V54, P393, DOI 10.1007/s11427-011-4165-y
   Li WS, 2010, SCI CHINA LIFE SCI, V53, P462, DOI 10.1007/s11427-010-0084-6
   Liu DS, 2010, SCI CHINA LIFE SCI, V53, P207, DOI 10.1007/s11427-010-0016-5
   Liu Q, 2011, SCI CHINA LIFE SCI, V54, P1081, DOI 10.1007/s11427-011-4253-z
   Liu SJ, 2010, SCI CHINA LIFE SCI, V53, P416, DOI 10.1007/s11427-010-0057-9
   Liu SQ, 2010, SCI CHINA LIFE SCI, V53, P229, DOI 10.1007/s11427-010-0038-z
   Liu Y, 2010, SCI CHINA LIFE SCI, V53, P169, DOI 10.1007/s11427-010-0044-1
   Luo ZG, 2010, SCI CHINA LIFE SCI, V53, P315, DOI 10.1007/s11427-010-0069-5
   Ma H, 2011, SCI CHINA LIFE SCI, V54, P39, DOI 10.1007/s11427-010-4111-4
   Ma WH, 2010, SCI CHINA LIFE SCI, V53, P841, DOI 10.1007/s11427-010-4020-6
   Maki M, 2011, SCI CHINA LIFE SCI, V54, P770, DOI 10.1007/s11427-011-4204-8
   Meng R, 2010, SCI CHINA LIFE SCI, V53, P87, DOI 10.1007/s11427-010-0004-9
   Mi W, 2011, SCI CHINA LIFE SCI, V54, P25, DOI 10.1007/s11427-010-4120-3
   Miao YW, 2010, SCI CHINA LIFE SCI, V53, P267, DOI 10.1007/s11427-010-0026-3
   Niu XB, 2010, SCI CHINA LIFE SCI, V53, P455, DOI 10.1007/s11427-010-0078-4
   Noh NJ, 2010, SCI CHINA LIFE SCI, V53, P822, DOI 10.1007/s11427-010-4018-0
   Pan S, 2011, SCI CHINA LIFE SCI, V54, P763, DOI 10.1007/s11427-011-4203-9
   Poo MM, 2010, SCI CHINA LIFE SCI, V53, P301, DOI 10.1007/s11427-010-0066-8
   Qi GR, 2010, SCI CHINA LIFE SCI, V53, P19, DOI 10.1007/s11427-010-0015-6
   Qin Z, 2010, SCI CHINA LIFE SCI, V53, P868, DOI 10.1007/s11427-010-4023-3
   Ren ZH, 2011, SCI CHINA LIFE SCI, V54, P981, DOI 10.1007/s11427-011-4239-x
   Rivas M, 2011, SCI CHINA LIFE SCI, V54, P786, DOI 10.1007/s11427-011-4196-4
   Santella L, 2011, SCI CHINA LIFE SCI, V54, P733, DOI 10.1007/s11427-011-4202-x
   Shao C, 2011, SCI CHINA LIFE SCI, V54, P409, DOI 10.1007/s11427-011-4162-1
   Sun P, 2010, SCI CHINA LIFE SCI, V53, P223, DOI 10.1007/s11427-010-0047-y
   Supnet C, 2011, SCI CHINA LIFE SCI, V54, P744, DOI 10.1007/s11427-011-4201-y
   Tang F, 2010, SCI CHINA LIFE SCI, V53, P172, DOI 10.1007/s11427-010-0045-0
   Tang H, 2010, SCI CHINA LIFE SCI, V53, P190, DOI 10.1007/s11427-010-0040-5
   Wang CJ, 2010, SCI CHINA LIFE SCI, V53, P858, DOI 10.1007/s11427-010-4028-y
   Wang DC, 2010, SCI CHINA LIFE SCI, V53, P13, DOI [10.1007/s11427-010-0019-2, 10.1007/s11427-010-0033-4]
   Wang LA, 2010, SCI CHINA LIFE SCI, V53, P851, DOI 10.1007/s11427-010-4027-z
   Wang LS, 2011, SCI CHINA LIFE SCI, V54, P209, DOI 10.1007/s11427-010-4123-0
   Wang RW, 2010, SCI CHINA LIFE SCI, V53, P139, DOI 10.1007/s11427-010-0007-6
   Wang SD, 2010, SCI CHINA LIFE SCI, V53, P183, DOI 10.1007/s11427-010-0043-2
   Wang SQ, 2011, SCI CHINA LIFE SCI, V54, P683, DOI 10.1007/s11427-011-4208-4
   Wang YY, 2010, SCI CHINA LIFE SCI, V53, P159, DOI 10.1007/s11427-010-0050-3
   Wang YZ, 2010, SCI CHINA LIFE SCI, V53, P342, DOI 10.1007/s11427-010-0060-1
   Wang YA, 2011, SCI CHINA LIFE SCI, V54, P3, DOI 10.1007/s11427-010-4107-0
   Wu JY, 2011, SCI CHINA LIFE SCI, V54, P290, DOI 10.1007/s11427-011-4148-z
   Wu SB, 2011, SCI CHINA LIFE SCI, V54, P54, DOI 10.1007/s11427-010-4108-z
   Wu S, 2010, SCI CHINA LIFE SCI, V53, P385, DOI 10.1007/s11427-010-0063-y
   Xu B, 2010, SCI CHINA LIFE SCI, V53, P776, DOI 10.1007/s11427-010-4030-4
   Xu HY, 2010, SCI CHINA LIFE SCI, V53, P435, DOI 10.1007/s11427-010-0058-8
   Yang TH, 2010, SCI CHINA LIFE SCI, V53, P811, DOI 10.1007/s11427-010-4021-5
   Yao HS, 2010, SCI CHINA LIFE SCI, V53, P363, DOI 10.1007/s11427-010-0071-y
   Yi MS, 2010, SCI CHINA LIFE SCI, V53, P426, DOI 10.1007/s11427-010-0079-3
   Yuan XB, 2010, SCI CHINA LIFE SCI, V53, P304, DOI 10.1007/s11427-010-0068-6
   Yue ZC, 2010, SCI CHINA LIFE SCI, V53, P78, DOI 10.1007/s11427-010-0010-y
   Zeng GQ, 2011, SCI CHINA LIFE SCI, V54, P1077, DOI 10.1007/s11427-011-4262-y
   Zhang LG, 2010, SCI CHINA LIFE SCI, V53, P195, DOI 10.1007/s11427-010-0059-7
   Zhang LL, 2010, SCI CHINA LIFE SCI, V53, P286, DOI 10.1007/s11427-010-0046-z
   Zhang M, 2010, SCI CHINA LIFE SCI, V53, P112, DOI 10.1007/s11427-010-0013-8
   Zhang QZ, 2010, SCI CHINA LIFE SCI, V53, P831, DOI 10.1007/s11427-010-4026-0
   Zhang W, 2011, SCI CHINA LIFE SCI, V54, P780, DOI 10.1007/s11427-011-4206-6
   Zhang XH, 2010, SCI CHINA LIFE SCI, V53, P322, DOI 10.1007/s11427-010-0062-z
   Zhang X, 2010, SCI CHINA LIFE SCI, V53, P356, DOI 10.1007/s11427-010-0065-9
   Zhang Y, 2011, SCI CHINA LIFE SCI, V54, P1097, DOI 10.1007/s11427-011-4241-3
   Zhang YS, 2010, SCI CHINA LIFE SCI, V53, P16, DOI 10.1007/s11427-010-0008-5
   Zhang YY, 2011, SCI CHINA LIFE SCI, V54, P1096, DOI 10.1007/s11427-011-4259-6
   Zhang ZQ, 2011, SCI CHINA LIFE SCI, V54, P1085, DOI 10.1007/s11427-011-4252-0
   Zheng Y, 2010, SCI CHINA LIFE SCI, V53, P107, DOI 10.1007/s11427-010-0001-z
   Zhou JW, 2010, SCI CHINA LIFE SCI, V53, P348, DOI 10.1007/s11427-010-0061-0
   Zhou N, 2011, SCI CHINA LIFE SCI, V54, P48, DOI 10.1007/s11427-010-4119-9
   Zhou ST, 2011, SCI CHINA LIFE SCI, V54, P502, DOI 10.1007/s11427-011-4177-7
   Zhou XG, 2010, SCI CHINA LIFE SCI, V53, P44, DOI 10.1007/s11427-010-0023-6
   Zhu B, 2010, SCI CHINA LIFE SCI, V53, P292, DOI 10.1007/s11427-010-0048-x
NR 105
TC 1
Z9 1
U1 6
U2 22
PU CHINESE ACAD SCIENCES, INST BIOPHYSICS
PI BEIJING
PA 15 DATUN RD, CHAOYAND DISTRICT, BEIJING, 100101, PEOPLES R CHINA
SN 1000-3282
J9 PROG BIOCHEM BIOPHYS
JI Prog. Biochem. Biophys.
PD NOV
PY 2012
VL 39
IS 11
BP 1066
EP 1072
DI 10.3724/SP.J.1206.2012.00470
PG 7
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 043EF
UT WOS:000311525000006
DA 2018-12-27
ER

PT J
AU Justa, N
   Weber, K
   Klein, D
   Mueller, RS
   Sauter-Louis, C
   Hartmann, K
AF Justa, N.
   Weber, K.
   Klein, D.
   Mueller, R. S.
   Sauter-Louis, C.
   Hartmann, K.
TI RETRACTED: Efficacy and Adverse Effects of
   (R)-9-(2-phosphonylmethoxypropyl)-2,6-diaminopurine in Feline
   Immunodeficiency Virus-Infected Cats (Retracted article. See vol. 27,
   pg. 997, 2013)
SO JOURNAL OF VETERINARY INTERNAL MEDICINE
LA English
DT Article; Retracted Publication
DE Acyclic nucleoside phosphonates; Antiretroviral therapy; FIV; PMPDAP
ID ACYCLIC NUCLEOTIDE ANALOGS; POLYMERASE-CHAIN-REACTION; NUCLEOSIDE
   PHOSPHONATES; PHYLOGENETIC ANALYSIS; ANTIVIRAL ACTIVITY; LOAD
   DETERMINATION; LEUKEMIA-VIRUS; CENTRAL-EUROPE; IN-VIVO; POTENT
AB Background (R)-9-(2-phosphonylmethoxypropyl)-2,6-diaminopurine (PMPDAP) is active against feline immunodeficiency virus (FIV) in vitro, and is less toxic than other acyclic nucleoside phosphonates. Its efficacy in naturally infected cats has not been evaluated in large controlled studies.
   Hypothesis/Objectives: PMPDAP is effective in naturally FIV-infected cats with minimal adverse effects.
   Animals: Forty-five privately owned cats naturally infected with FIV.
   Methods: Prospective, randomized, placebo-controlled, double-blinded clinical study. Cats were randomly assigned to be treated with PMPDAP (25 mg/kg) daily, PMPDAP 3 times a week, or placebo for a period of 6 weeks.
   Results: Administration of PMPDAP to FIV-infected cats did not lead to detectable improvements in clinical, virological, or immunological variables. Proviral load (FIV copies/106 cells) did not change significantly during treatment (placebo group: from 9505 +/- 10119 to 8564 +/- 8615; PMPDAP 3 times a week: from 4818 +/- 4426 to 5041 +/- 6197; PMPDAP daily: from 3525 +/- 5038 to 3167 +/- 5824). There was a significant decrease of red blood cell counts (x1012/L) (from 8.91 +/- 1.82 to 7.34 +/- 1.79 in cats treated 3 times per week (P < .001), and from 8.96 +/- 1.13 to 6.01 +/- 1.36 in cats treated daily (P < .001)), as well as of packed cell volume, and hemoglobin in both groups receiving PMPDAP.
   Conclusions and Clinical Importance: Administration of PMPDAP was not associated with significant improvements in clinical, immunological, or virological parameters, but treatment was associated with adverse effects, mainly anemia. Thus, PMPDAP, as administered in this study, cannot be recommended for treatment of FIV-infected cats.
C1 [Justa, N.; Weber, K.; Mueller, R. S.; Hartmann, K.] LMU Univ Munich, Clin Small Anim Med, D-80539 Munich, Germany.
   [Klein, D.] Univ Vet Med, Vetcore Facil Res, Vienna, Austria.
   [Sauter-Louis, C.] LMU Univ Munich, Clin Ruminants, D-80539 Munich, Germany.
RP Hartmann, K (reprint author), LMU Univ Munich, Clin Small Anim Med, Vet Str 13, D-80539 Munich, Germany.
EM hartmann@lmu.de
FU Okapi Sciences NV, Heverlee, Belgium
FX Okapi Sciences NV, Heverlee, Belgium, provided the drug and placebo,
   financial support of the study, and assistance to recruit cats.
CR BALZARINI J, 1993, ANTIMICROB AGENTS CH, V37, P332, DOI 10.1128/AAC.37.2.332
   BALZARINI J, 1988, BIOCHEM PHARMACOL, V37, P2847, DOI 10.1016/0006-2952(88)90049-4
   Balzarini J, 1996, BIOCHEM BIOPH RES CO, V219, P337, DOI 10.1006/bbrc.1996.0234
   BENDINELLI M, 1995, CLIN MICROBIOL REV, V8, P87, DOI 10.1128/CMR.8.1.87
   DECLERCQ E, 1987, ANTIVIR RES, V8, P261
   DONOVAN RM, 1991, J ACQ IMMUN DEF SYND, V4, P766
   EGBERINK H, 1990, P NATL ACAD SCI USA, V87, P3087, DOI 10.1073/pnas.87.8.3087
   EGBERINK HF, 1991, J AM VET MED ASSOC, V199, P1485
   HART S, 1995, J VET MED A, V42, P397, DOI 10.1111/j.1439-0442.1995.tb00392.x
   Hartmann AD, 2012, J FELINE MED SURG, V14, P107, DOI 10.1177/1098612X11431040
   Hartmann K, 1995, FELINE PRACT, V23, P13
   HARTMANN K, 1992, VET IMMUNOL IMMUNOP, V35, P167, DOI 10.1016/0165-2427(92)90129-E
   Hartmann K, 1998, Eur J Med Res, V3, P95
   HASCHEK WM, 1990, FUND APPL TOXICOL, V14, P764, DOI 10.1016/0272-0590(90)90301-Y
   Hoffmann-Fezer G, 1991, Tierarztl Prax, V19, P682
   HOLY A, 1987, COLLECT CZECH CHEM C, V52, P2801, DOI 10.1135/cccc19872801
   HOLY A, 1990, ANTIVIR RES, V13, P295, DOI 10.1016/0166-3542(90)90014-X
   HOLY A, 1987, COLLECT CZECH CHEM C, V52, P2775, DOI 10.1135/cccc19872775
   HOOVER EA, 1991, ANTIVIR RES, V16, P77, DOI 10.1016/0166-3542(91)90060-5
   ISHIDA T, 1992, VET IMMUNOL IMMUNOP, V35, P15, DOI 10.1016/0165-2427(92)90117-9
   Klein D, 2000, WIEN TIERARZTL MONAT, V87, P269
   Klein D, 2001, J ACQ IMMUN DEF SYND, V26, P8
   Klein D, 2000, GENE THER, V7, P458, DOI 10.1038/sj.gt.3301112
   Klein D, 1999, ELECTROPHORESIS, V20, P291, DOI 10.1002/(SICI)1522-2683(19990201)20:2<291::AID-ELPS291>3.0.CO;2-R
   NORTH TW, 1989, ANTIMICROB AGENTS CH, V33, P915, DOI 10.1128/AAC.33.6.915
   Nunez M, 2006, J HEPATOL, V44, pS132, DOI 10.1016/j.jhep.2005.11.027
   Otova B, 1997, FOLIA BIOL-PRAGUE, V43, P225
   Pisarev VM, 1997, MOL PHARMACOL, V52, P63
   Steinrigl A, 2003, J GEN VIROL, V84, P1301, DOI 10.1099/vir.0.18736-0
   Steinrigl A, 2010, VET IMMUNOL IMMUNOP, V134, P82, DOI 10.1016/j.vetimm.2009.10.013
   TANABETOCHIKURA A, 1992, ANTIVIR RES, V19, P161, DOI 10.1016/0166-3542(92)90075-G
   VAHLENKAMP TW, 1995, ANTIMICROB AGENTS CH, V39, P746, DOI 10.1128/AAC.39.3.746
NR 32
TC 2
Z9 2
U1 6
U2 18
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1939-1676
J9 J VET INTERN MED
JI J. Vet. Intern. Med.
PD NOV-DEC
PY 2012
VL 26
IS 6
BP 1267
EP 1273
DI 10.1111/j.1939-1676.2012.01007.x
PG 7
WC Veterinary Sciences
SC Veterinary Sciences
GA 041FQ
UT WOS:000311384300005
PM 23039914
DA 2018-12-27
ER

PT J
AU Erdur, B
   Ozturk, Y
   Gurbuz, ED
   Yilmaz, O
AF Erdur, Baris
   Ozturk, Yesim
   Gurbuz, Ebru D.
   Yilmaz, Ozlem
TI RETRACTED: Comparison of Sequential and Standard Therapy for
   Helicobacter pylori Eradication in Children and Investigation of
   Clarithromycin Resistance (Retracted article. See vol. 56, pg. 239,
   2013)
SO JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION
LA English
DT Article; Retracted Publication
DE children; clarithromycin resistance; Helicobacter pylori; sequential
   therapy
ID IN-SITU HYBRIDIZATION; NONINVASIVE TESTS; TRIPLE THERAPY; INFECTION;
   DIAGNOSIS; MANAGEMENT; STRAINS; TURKEY
AB Aims: The aim of the present study was to compare the efficacy of sequential and standard triple-drug regimen for Helicobacter pylori (H pylori) eradication in children and to determine the primary resistance rate to clarithromycin.
   Methods: Children with H pylori infection randomized to receive either standard regimen (n = 28) consisting of lansoprazole for 30 days, amoxicillin and clarithromycin for 14 days or sequential regimen (n = 16) consisting of lansoprazole for 30 days, amoxicillin for 7 days, followed by clarithromycin and metronidazole for the next 7 days. Clarithromycin susceptibility of H pylori was assessed with fluorescence in-situ hybridization technique. Eradication was controlled by C-13 urea breath test or monoclonal stool antigen test 4 weeks after the end of the therapy.
   Results: H pylori eradication rate was higher in the sequential therapy group (93.7%), compared with the standard therapy group (46.4%) (P = 0.002). There was no difference in adverse drug reactions and in compliance to the treatment between the groups. Primary clarithromycin resistance rate for H pylori was found as 25.7% (n = 9). All of the patients having clarithromycin resistance were coincidentally in the standard therapy group. After the exclusion of these 9 patients, sequential therapy was again found to be more effective than the standard therapy (P = 0.02).
   Conclusions: Sequential therapy seems highly effective for eradicating H pylori in children; however, the difference between 2 groups in resistant strains was the limitation of the study. Our country needs to reassess the effectiveness of standard triple therapy regimen for H pylori eradication.
C1 [Erdur, Baris; Ozturk, Yesim] Dokuz Eylul Univ, Sch Med, Dept Pediat Gastroenterol Hepatol & Nutr, TR-35340 Izmir, Turkey.
   [Gurbuz, Ebru D.; Yilmaz, Ozlem] Dokuz Eylul Univ, Sch Med, Dept Med Microbiol, TR-35340 Izmir, Turkey.
RP Erdur, B (reprint author), Dokuz Eylul Univ, Sch Med, Dept Pediat Gastroenterol Hepatol & Nutr, TR-35340 Izmir, Turkey.
EM bariserdur@yahoo.com
CR Caristo E, 2008, HELICOBACTER, V13, P557, DOI 10.1111/j.1523-5378.2008.00642.x
   Cetinkaya ZA, 2010, HELICOBACTER, V15, P143, DOI 10.1111/j.1523-5378.2010.00747.x
   Feydt-Schmidt A, 2002, ALIMENT PHARM THERAP, V16, P2073, DOI 10.1046/j.0269-2813.2002.01382.x
   Francavilla R, 2005, GASTROENTEROLOGY, V129, P1414, DOI 10.1053/j.gastro.2005.09.007
   Francavilla R, 2010, J PEDIATR-US, V157, P228, DOI 10.1016/j.jpeds.2010.02.007
   Gatta L, 2003, CLIN MICROBIOL INFEC, V9, P489, DOI 10.1046/j.1469-0691.2003.00707.x
   Gatta L, 2009, AM J GASTROENTEROL, V104, P3069, DOI 10.1038/ajg.2009.555
   Gerrits MM, 2006, LANCET INFECT DIS, V6, P699, DOI 10.1016/S1473-3099(06)70627-2
   Gisbert JP, 2010, J CLIN GASTROENTEROL, V44, P313, DOI 10.1097/MCG.0b013e3181c8a1a3
   Gisbert JP, 2010, EXPERT OPIN PHARMACO, V11, P905, DOI 10.1517/14656561003657152
   Gisbert JP, 2004, HELICOBACTER, V9, P347, DOI 10.1111/j.1083-4389.2004.00235.x
   Kadaylfci A, 2006, CLIN THER, V28, P1960, DOI 10.1016/j.clinthera.2006.11.011
   Kalach N, 2001, ANTIMICROB AGENTS CH, V45, P2134, DOI 10.1128/AAC.45.7.2134-2135.2001
   Krogfelt KA, 2005, HELICOBACTER, V10, P5, DOI 10.1111/j.1523-5378.2005.00341.x
   Lopez T, 2004, HELICOBACTER, V9, P674, DOI 10.1111/j.1083-4389.2004.00282.x
   Malfertheiner P, 2007, GUT, V56, P772, DOI 10.1136/gut.2006.101634
   Megraud F, 2005, J PEDIATR-US, V146, P198, DOI 10.1016/j.jpeds.2004.10.044
   Oderda G, 2007, HELICOBACTER, V12, P150, DOI 10.1111/j.1523-5378.2007.00485.x
   Onder G, 2007, J CLIN GASTROENTEROL, V41, P747, DOI 10.1097/MCG.0b013e31802e7ee7
   Ozcay F, 2004, HELICOBACTER, V9, P242, DOI 10.1111/j.1083-4389.2004.00230.x
   Roberts MC, 2004, MOL BIOTECHNOL, V28, P47, DOI 10.1385/MB:28:1:47
   Simsek H, 2005, HELICOBACTER, V10, P360, DOI 10.1111/j.1523-5378.2005.00325.x
   Vilaichone RK, 2006, GASTROENTEROL CLIN N, V35, P229, DOI 10.1016/j.gtc.2006.03.004
   Yilmaz O, 2007, HELICOBACTER, V12, P136, DOI 10.1111/j.1523-5378.2007.00483.x
NR 24
TC 11
Z9 15
U1 2
U2 16
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0277-2116
EI 1536-4801
J9 J PEDIATR GASTR NUTR
JI J. Pediatr. Gastroenterol. Nutr.
PD NOV
PY 2012
VL 55
IS 5
BP 530
EP 533
DI 10.1097/MPG.0b013e3182575f9c
PG 4
WC Gastroenterology & Hepatology; Nutrition & Dietetics; Pediatrics
SC Gastroenterology & Hepatology; Nutrition & Dietetics; Pediatrics
GA 030LH
UT WOS:000310571700016
PM 22465935
OA Bronze
DA 2018-12-27
ER

PT J
AU Winkler, DD
   Zhou, H
   Dar, MA
   Zhang, ZG
   Luger, K
AF Winkler, Duane D.
   Zhou, Hui
   Dar, Mohd A.
   Zhang, Zhiguo
   Luger, Karolin
TI RETRACTED: Yeast CAF-1 assembles histone (H3-H4)(2) tetramers prior to
   DNA deposition (Retracted article. See vol. 45, pg. 9811, 2017)
SO NUCLEIC ACIDS RESEARCH
LA English
DT Article; Retracted Publication
ID NUCLEOSOME CORE PARTICLE; RECOMBINANT HISTONES;
   SACCHAROMYCES-CEREVISIAE; REPLICATION INVITRO; CHAPERONE RTT106;
   STRUCTURAL BASIS; IN-VITRO; CHROMATIN; REPAIR; LYSINE-56
AB Following acetylation, newly synthesized H3-H4 is directly transferred from the histone chaperone anti-silencing factor 1 (Asf1) to chromatin assembly factor 1 (CAF-1), another histone chaperone that is critical for the deposition of H3-H4 onto replicating DNA. However, it is unknown how CAF-1 binds and delivers H3-H4 to the DNA. Here, we show that CAF-1 binds recombinant H3-H4 with 10- to 20-fold higher affinity than H2A-H2B in vitro, and H3K56Ac increases the binding affinity of CAF-1 toward H3-H4 2-fold. These results provide a quantitative thermodynamic explanation for the specific H3-H4 histone chaperone activity of CAF-1. Surprisingly, H3-H4 exists as a dimer rather than as a canonical tetramer at mid-to-low nanomolar concentrations. A single CAF-1 molecule binds a cross-linked (H3-H4)(2) tetramer, or two H3-H4 dimers that contain mutations at the (H3-H4)(2) tetramerization interface. These results suggest that CAF-1 binds to two H3-H4 dimers in a manner that promotes formation of a (H3-H4)(2) tetramer. Consistent with this idea, we confirm that CAF-1 synchronously binds two H3-H4 dimers derived from two different histone genes in vivo. Together, the data illustrate a clear mechanism for CAF-1-associated H3-H4 chaperone activity in the context of de novo nucleosome (re)assembly following DNA replication.
C1 [Winkler, Duane D.; Luger, Karolin] Colorado State Univ, Howard Hughes Med Inst, Ft Collins, CO 80523 USA.
   [Winkler, Duane D.; Luger, Karolin] Colorado State Univ, Dept Biochem & Mol Biol, Ft Collins, CO 80523 USA.
   [Zhou, Hui; Dar, Mohd A.; Zhang, Zhiguo] Mayo Clin, Dept Biochem & Mol Biol, Rochester, MN 55905 USA.
RP Luger, K (reprint author), Colorado State Univ, Howard Hughes Med Inst, Ft Collins, CO 80523 USA.
EM Zhang.Zhiguo@mayo.edu; Karolin.luger@colostate.edu
FU National Institutes of Health [GM- 067777, F32GM096531, GM72719]; Howard
   Hughes Medical Institute
FX Funding for open access charge: The National Institutes of Health [GM-
   067777 to K. L., F32GM096531 to D. D. W. and GM72719 to Z.Z.]; Howard
   Hughes Medical Institute (to K.L.).
CR Andrews AJ, 2008, J BIOL CHEM, V283, P32412, DOI 10.1074/jbc.M805918200
   Andrews AJ, 2010, MOL CELL, V37, P834, DOI 10.1016/j.molcel.2010.01.037
   Bowman A, 2012, METHODS MOL BIOL, V833, P373, DOI 10.1007/978-1-61779-477-3_22
   Bowman A, 2011, MOL CELL, V41, P398, DOI 10.1016/j.molcel.2011.01.025
   Burgess RJ, 2010, MOL CELL, V37, P469, DOI 10.1016/j.molcel.2010.01.020
   Campos EI, 2010, NAT STRUCT MOL BIOL, V17, P1343, DOI 10.1038/nsmb.1911
   Campos EI, 2009, ANNU REV GENET, V43, P559, DOI 10.1146/annurev.genet.032608.103928
   Collins SR, 2007, MOL CELL PROTEOMICS, V6, P439, DOI 10.1074/mcp.M600381-MCP200
   Donham DC, 2011, NUCLEIC ACIDS RES, V39, P5449, DOI 10.1093/nar/gkr097
   Driscoll R, 2007, SCIENCE, V315, P649, DOI 10.1126/science.1135862
   Dyer PN, 2004, METHOD ENZYMOL, V375, P23
   Elsasser SJ, 2012, BBA-GENE REGUL MECH, V1819, P211, DOI 10.1016/j.bbagrm.2011.07.007
   English CM, 2006, CELL, V127, P495, DOI 10.1016/j.cell.2006.08.047
   Fazly A, 2012, J BIOL CHEM, V287, P10753, DOI 10.1074/jbc.M112.347450
   Gerard A, 2006, EMBO REP, V7, P817, DOI 10.1038/sj.embor.7400750
   Goldberg AD, 2007, CELL, V128, P635, DOI 10.1016/j.cell.2007.02.006
   Goldberg AD, 2010, CELL, V140, P678, DOI 10.1016/j.cell.2010.01.003
   Groth A, 2007, CELL, V128, P721, DOI 10.1016/j.cell.2007.01.030
   Han JH, 2007, J BIOL CHEM, V282, P28587, DOI 10.1074/jbc.M702496200
   Han JH, 2007, SCIENCE, V315, P653, DOI 10.1126/science.1133234
   Hieb AR, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gkr1045
   Kaufman PD, 1997, GENE DEV, V11, P345, DOI 10.1101/gad.11.3.345
   KAUFMAN PD, 1995, CELL, V81, P1105, DOI 10.1016/S0092-8674(05)80015-7
   Li Q, 2008, CELL, V134, P244, DOI 10.1016/j.cell.2008.06.018
   Linger J, 2005, GENETICS, V171, P1513, DOI 10.1534/genetics.105.043000
   Luger K, 1999, METHOD ENZYMOL, V304, P3
   Luger K, 1997, NATURE, V389, P251
   Luger K, 1999, METH MOL B, V119, P1
   Moggs JG, 2000, MOL CELL BIOL, V20, P1206, DOI 10.1128/MCB.20.4.1206-1218.2000
   Nakano S, 2011, CELL, V147, P1525, DOI 10.1016/j.cell.2011.11.053
   Natsume R, 2007, NATURE, V446, P338, DOI 10.1038/nature05613
   Park YJ, 2004, J BIOL CHEM, V279, P24274, DOI 10.1074/jbc.M313152200
   Quivy JP, 2001, EMBO J, V20, P2015, DOI 10.1093/emboj/20.8.2015
   Ransom M, 2010, CELL, V140, P183, DOI 10.1016/j.cell.2010.01.004
   Ridgway P, 2000, J CELL SCI, V113, P2647
   Sharp JA, 2001, CURR BIOL, V11, P463, DOI 10.1016/S0960-9822(01)00140-3
   Shibahara K, 2000, P NATL ACAD SCI USA, V97, P7766, DOI 10.1073/pnas.97.14.7766
   Sirbu BM, 2011, GENE DEV, V25, P1320, DOI 10.1101/gad.2053211
   SMITH S, 1989, CELL, V58, P15, DOI 10.1016/0092-8674(89)90398-X
   STILLMAN B, 1986, CELL, V45, P555, DOI 10.1016/0092-8674(86)90287-4
   Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412
   Su D, 2012, NATURE, V483, P104, DOI 10.1038/nature10861
   Tagami H, 2004, CELL, V116, P51, DOI 10.1016/S0092-8674(03)01064-X
   Tsubota T, 2007, MOL CELL, V25, P703, DOI 10.1016/j.molcel.2007.02.006
   Tyler JK, 1999, NATURE, V402, P555, DOI 10.1038/990147
   Verreault A, 1996, CELL, V87, P95, DOI 10.1016/S0092-8674(00)81326-4
   Winkler DD, 2012, METHOD ENZYMOL, V512, P243, DOI 10.1016/B978-0-12-391940-3.00011-1
   Winkler DD, 2011, J BIOL CHEM, V286, P41883, DOI 10.1074/jbc.M111.301465
   Xu M, 2010, SCIENCE, V328, P94, DOI 10.1126/science.1178994
   Zhang H, 2012, J BIOL CHEM, V287, P6573, DOI 10.1074/jbc.M111.312637
   Zhou H, 2006, BIOCHEMISTRY-US, V45, P2852, DOI 10.1021/bi0521083
NR 51
TC 48
Z9 48
U1 4
U2 12
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-1048
EI 1362-4962
J9 NUCLEIC ACIDS RES
JI Nucleic Acids Res.
PD NOV
PY 2012
VL 40
IS 20
BP 10139
EP 10149
DI 10.1093/nar/gks812
PG 11
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 035TC
UT WOS:000310970700024
PM 22941638
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Luo, CH
   O'Niell, W
   Nzengung, V
AF Luo, Chunhui
   O'Niell, Walter
   Nzengung, Valentine
TI RETRACTED: Pilot-Scale Demonstration of In Situ Chemical Reduction
   Technology at a Formerly Used Defense Site (Retracted article. See vol.
   226, pg. 2176, 2015)
SO WATER AIR AND SOIL POLLUTION
LA English
DT Article; Retracted Publication
DE Munition; Explosives; Soil; Reduction; In situ; Remediation;
   Nitroaromatics
ID ALKALINE-HYDROLYSIS; REDOX MANIPULATION; EXPLOSIVES RDX; GROUNDWATER;
   DITHIONITE; FATE
AB This paper describes results of the first field demonstration conducted to evaluate an innovative in situ chemical reduction technology to rapidly degrade 81 m(2) of high concentrations of explosives contaminated soils at Ravenna Army Ammunition Plant, Ravenna, Ohio, USA. The primary explosives of concern and associated baseline levels of contamination were 2,4,6-trinitrotoluene (TNT) (383 mg/kg), hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX) (180 mg/kg), and octahydro-1,3,5,7-tetranitro-1,3,5,7-tetrazocine (HMX) (15 mg/kg). The in situ chemical treatment process involved selected reductant of sodium hydrosulfite (Na2S2O4) at optimal pH (9-10) with appropriate buffers (e. g., sodium bicarbonate and potassium carbonate) that, when mixed with water, generate free radicals that react very rapidly to degrade nitroaromatics to carbon dioxide (CO2), formate (HCOO-), and gaseous nitrogen compounds (NOx). Significant reductions in TNT, RDX, and HMX (>95 %) were observed within 24 h and achieved response complete in under 2 weeks after in situ application of the buffered sodium hydrosulfite.
C1 [Luo, Chunhui; O'Niell, Walter; Nzengung, Valentine] PLANTECO Environm Consultants LLC, Athens, GA 30605 USA.
   [O'Niell, Walter; Nzengung, Valentine] Univ Georgia, Dept Geol, Athens, GA 30602 USA.
RP Luo, CH (reprint author), PLANTECO Environm Consultants LLC, 337 S Milledge Ave, Athens, GA 30605 USA.
EM chunhui.luo@gmail.com
FU US Army Corps of Engineers
FX The authors thank the US Army Corps of Engineers for funding and
   assistance. Special thanks to Mr. J.C. King, Mr. Stacey K. Hirata, Ms.
   Lara Beasley, and Mr. Julian Chu for early direction for funding the
   demonstration/validation of MuniRem (TM). The authors are thankful for
   the technical support and administration assistance by Mr. Brian Jordan,
   Ms. Madline Livermore, and Ms. Pauline Sanchez from HTRW Section of the
   USACE Albuquerque District. The authors are thankful for the site
   selection support by Mr. Mike J. Saffran, Mr. Chris Karem, and Ms. Kari
   Meiers from the USACE Louisville District. The authors also want to
   acknowledge the Ravenna site staff: Mr. David Gomez, Mr. Derek Kinder,
   Ms. Christy Esler, Mr. Jim D. McGhee, and Mr. Mark Patterson. The
   authors also appreciate the cooperation of Ms. Eileen Mohr of the Ohio
   EPA. Mr. Geoff Carton deserves many thanks for reviewing documents and
   providing very useful comments and recommendations. Each individual
   noted in this acknowledgement receives our many thanks for his or her
   specific contribution that culminated in a very successful
   demonstration/validation of our patented product, MuniRem (TM). The
   mention of U. S. Federal and State agencies does not in any way or form
   represent an endorsement of the technologies and products included in
   this paper.
CR Amonette J. E., 1994, IN SITU REMEDIATION, P851
   Ayoub K, 2010, J HAZARD MATER, V178, P10, DOI 10.1016/j.jhazmat.2010.02.042
   Balakrishnan VK, 2003, ENVIRON SCI TECHNOL, V37, P1838, DOI 10.1021/es020959h
   Best EPH, 1999, CHEMOSPHERE, V38, P3383, DOI 10.1016/S0045-6535(98)00550-5
   Boparai HK, 2008, CHEMOSPHERE, V71, P933, DOI 10.1016/j.chemosphere.2007.11.001
   Clausen J, 2004, ENVIRON POLLUT, V129, P13, DOI 10.1016/j.envpol.2003.10.002
   Fruchter JS, 2000, GROUND WATER MONIT R, V20, P66, DOI 10.1111/j.1745-6592.2000.tb00267.x
   Heilmann HM, 1996, ENVIRON SCI TECHNOL, V30, P1485, DOI 10.1021/es9504101
   Istok JD, 1999, GROUND WATER, V37, P884, DOI 10.1111/j.1745-6584.1999.tb01187.x
   Lewis TA, 2004, J ENVIRON MANAGE, V70, P291, DOI 10.1016/j.jenvman.2003.12.005
   Lubbert R. F., 2000, FEDERAL FACILITIES E, V11, P5
   MacDonald J. A., 2001, ENVIRON SCI TECHNOL, V35, p372A
   MacDonald JA, 2009, ENVIRON SCI TECHNOL, V43, P259, DOI 10.1021/es8014106
   Nzengung VA, 2001, ENVIRON SCI TECHNOL, V35, P2244, DOI 10.1021/es001578b
   Pantea D, 2006, CHEMOSPHERE, V65, P821, DOI 10.1016/j.chemosphere.2006.03.027
   Sheremata TW, 2001, ENVIRON SCI TECHNOL, V35, P1037, DOI 10.1021/es001389t
   Singh B, 2012, CRIT REV MICROBIOL, V38, P152, DOI 10.3109/1040841X.2011.640979
   Su CM, 2005, ENVIRON SCI TECHNOL, V39, P6208, DOI 10.1021/es050185f
NR 18
TC 3
Z9 3
U1 4
U2 33
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0049-6979
EI 1573-2932
J9 WATER AIR SOIL POLL
JI Water Air Soil Pollut.
PD NOV
PY 2012
VL 223
IS 9
BP 5807
EP 5815
DI 10.1007/s11270-012-1318-y
PG 9
WC Environmental Sciences; Meteorology & Atmospheric Sciences; Water
   Resources
SC Environmental Sciences & Ecology; Meteorology & Atmospheric Sciences;
   Water Resources
GA 035AG
UT WOS:000310913400023
DA 2018-12-27
ER

PT J
AU Mhadhbi, L
   Beiras, R
AF Mhadhbi, Lazhar
   Beiras, Ricardo
TI RETRACTED: Acute Toxicity of Seven Selected Pesticides (Alachlor,
   Atrazine, Dieldrin, Diuron, Pirimiphos-Methyl, Chlorpyrifos, Diazinon)
   to the Marine Fish (Turbot, Psetta maxima) (Retracted article. See vol.
   227, pg. 275, 2016)
SO WATER AIR AND SOIL POLLUTION
LA English
DT Article; Retracted Publication
DE Turbot; Early life stage; Acute toxicity; Sublethal effects; Pesticides
ID EARLY-LIFE STAGES; ACETYLCHOLINESTERASE INHIBITION;
   OREOCHROMIS-NILOTICUS; PSETTA-MAXIMA; NILE TILAPIA; EXPOSURE; ZEBRAFISH;
   EMBRYOS; LARVAL; EMBRYOTOXICITY
AB The present study evaluated the short-term toxicity of seven selected pesticides: four insecticides (chlorpyrifos, dieldrin, diazinon and pirimiphosmethyl) and three herbicides (diuron, alachlor and atrazine). With this aim, a standard toxicity test with the highly sensitive early life stages (ELS) of a marine fish was used. The turbot, Psetta maxima, is abundant in shallow estuarine and costal habitats and is currently the most commonly cultivated fish species in Galicia, NW Spain. According to the turbot ELS test results, chlorpyrifos was the most toxic pesticide tested for both embryos and larvae and was followed in order of decreasing toxicity by dieldrin, pirimiphos-methyl, diazinon, alachlor, atrazine and diuron. Larvae were more sensitive than embryos to the seven pesticides. The median lethal concentrations of the selected pesticides during a 48- and a 96-h exposure for turbot embryos and larvae were, respectively (in micrograms per litre): chlorpyrifos, 116.6 and 94.65; dieldrin, 146 and 97; pirimiphos-methyl, 560 and 452; diazinon, 1,837 and 1,230; alachlor, 2,177 and 2,233; diuron, 10,076 and 7,826; and atrazine, 11,873 and 9,957. According to their acute toxicity, the insecticides were more toxic than the herbicides. Furthermore, all insecticides and herbicides appear to be teratogenic to turbot ELS.
C1 [Mhadhbi, Lazhar] Univ Carthage, Fac Sci Bizerte, Unite Hydrobiol, Lab Biosurveillance Environm, Zarzouna 7021, Tunisia.
   [Mhadhbi, Lazhar; Beiras, Ricardo] Estn Ciencias Marinas Toralla ECIMAT, Vigo 36331, Galicia, Spain.
RP Mhadhbi, L (reprint author), Univ Carthage, Fac Sci Bizerte, Unite Hydrobiol, Lab Biosurveillance Environm, Zarzouna 7021, Tunisia.
EM lazhar@uvigo.es
OI Mhadhbi, Lazhar/0000-0001-5498-4349; Beiras, Ricardo/0000-0002-1010-2647
FU MAE-PCI (Ministry of Foreign Affairs, Spain); Ministry of Higher
   Education, Scientific Research and Technology in Tunisia; Spanish
   Ministry of Science and Innovation (MCINN) through the research project
   Environmental Quality Criteria for Marine Ecosystems (ENVICRISYS)
FX The authors gratefully acknowledge the cooperation of all the workers
   and personnel at the ECIMAT and Laboratory of Marine Ecology, especially
   those workers who willingly participated in the hatchery, Damian Costas
   and Arantxa Martinez. The authors would like to thank David Chavarrias
   (Insuina S. L., Mougas, Galicia, Spain). This study was financially
   supported by MAE-PCI (Ministry of Foreign Affairs, Spain), Ministry of
   Higher Education, Scientific Research and Technology in Tunisia and the
   Spanish Ministry of Science and Innovation (MCINN) through the research
   project Environmental Quality Criteria for Marine Ecosystems
   (ENVICRISYS).
CR ADEMA DMM, 1981, CHEMOSPHERE, V10, P533, DOI 10.1016/0045-6535(81)90255-1
   AGUIAR LH, 2004, ENVIRON RES, V95, P224
   Aydin R, 2005, PESTIC BIOCHEM PHYS, V82, P220, DOI 10.1016/j.pestbp.2005.03.001
   Banaee M, 2011, PESTIC BIOCHEM PHYS, V99, P1, DOI 10.1016/j.pestbp.2010.09.001
   Barbieri E, 2009, ECOTOXICOLOGY, V18, P55, DOI 10.1007/s10646-008-0256-3
   BARRY MJ, 1995, AQUAT TOXICOL, V32, P115, DOI 10.1016/0166-445X(94)00084-4
   Belden JB, 2006, ENVIRON TOXICOL CHEM, V25, P623, DOI 10.1897/05-370R.1
   BIRGE WJ, 1983, FUND APPL TOXICOL, V3, P237, DOI 10.1016/S0272-0590(83)80134-1
   BRODERIUS SJ, 1995, ENVIRON TOXICOL CHEM, V14, P1591, DOI 10.1897/1552-8618(1995)14[1591:UOJTRT]2.0.CO;2
   Brown MD, 1998, J AM MOSQUITO CONTR, V14, P463
   Chaturvedi L. D., 1991, Uttar Pradesh Journal of Zoology, V11, P93
   De Silva PMCS, 2002, ECOTOX ENVIRON SAFE, V53, P248, DOI 10.1006/eesa.2002.2209
   Eder KJ, 2009, ECOTOX ENVIRON SAFE, V72, P182, DOI 10.1016/j.ecoenv.2008.04.020
   Foekema EM, 2008, AQUAT TOXICOL, V90, P197, DOI 10.1016/j.aquatox.2008.08.015
   Gagnon M. M., 2009, MAR POLLUT B, V58, P1078
   Giari L, 2008, ECOTOX ENVIRON SAFE, V70, P400, DOI 10.1016/j.ecoenv.2007.08.013
   Giron-Perez MI, 2007, FISH SHELLFISH IMMUN, V23, P760, DOI 10.1016/j.fsi.2007.02.004
   GORGE G, 1990, ECOTOX ENVIRON SAFE, V20, P246, DOI 10.1016/0147-6513(90)90004-O
   Hallare A, 2006, ECOTOX ENVIRON SAFE, V63, P378, DOI 10.1016/j.ecoenv.2005.07.006
   Hamm JT, 2000, AQUAT TOXICOL, V48, P403, DOI 10.1016/S0166-445X(99)00065-X
   Hughes J. S., 1973, ACUTE TOXICITY 30 CH
   Humphrey C, 2003, ENVIRON TOXICOL, V18, P418, DOI 10.1002/tox.10144
   Hutchinson TH, 1998, CHEMOSPHERE, V36, P129, DOI 10.1016/S0045-6535(97)10025-X
   JARVINEN AW, 1983, ECOTOX ENVIRON SAFE, V7, P423, DOI 10.1016/0147-6513(83)90008-8
   Kammann U, 2009, ENVIRON SCI POLLUT R, V16, P227, DOI 10.1007/s11356-008-0097-x
   Karen DJ, 1998, PESTIC BIOCHEM PHYS, V60, P167, DOI 10.1006/pest.1998.2345
   Kienle C, 2009, ECOTOX ENVIRON SAFE, V72, P1740, DOI 10.1016/j.ecoenv.2009.04.014
   Kikuchi M, 1996, NIPPON SUISAN GAKK, V62, P414
   KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302
   Kumar A, 2011, PESTIC BIOCHEM PHYS, V99, P170, DOI 10.1016/j.pestbp.2010.11.014
   Lakra WS, 2009, INDIAN J ANIM SCI, V79, P93
   Lawal M O, 2010, Pak J Biol Sci, V13, P405, DOI 10.3923/pjbs.2010.405.408
   Macek K.J., 2003, CHRONIC TOXICITY ATR
   Mensink B. J. W. G., 2008, ENV RISK LIMITS PIRI
   Mhadhbi L, 2012, ENVIRON SCI POLLUT R, V19, P708, DOI 10.1007/s11356-011-0602-5
   Mhadhbi L, 2010, AQUAT LIVING RESOUR, V23, P209, DOI 10.1051/alr/2010014
   Modra H, 2011, B ENVIRON CONTAM TOX, V86, P601, DOI 10.1007/s00128-011-0273-4
   Nebeker AV, 1998, ARCH ENVIRON CON TOX, V35, P441, DOI 10.1007/s002449900400
   NESKOVIC NK, 1993, ECOTOX ENVIRON SAFE, V25, P173, DOI 10.1006/eesa.1993.1016
   Nwani CD, 2010, INT J ENV RES PUB HE, V7, P3298, DOI 10.3390/ijerph7083298
   OECD, 1998, GUID TEST CHEM
   Peakall David B., 1996, P73
   PED, 2000, PEST EC DAT FORM ENV
   Peebua P, 2008, J ENVIRON BIOL, V29, P325
   Pesando D, 2004, AQUAT TOXICOL, V66, P225, DOI 10.1016/j.aquatox.2003.09.007
   Phillips TA, 2003, ARCH ENVIRON CON TOX, V45, P258, DOI 10.1007/s00244-002-0066-1
   Phillips TA, 2002, ENVIRON TOXICOL CHEM, V21, P1469, DOI [10.1897/1551-5028(2002)021<1469:ATACII>2.0.CO;2, 10.1002/etc.5620210719]
   Phyu YL, 2006, SCI TOTAL ENVIRON, V356, P86, DOI 10.1016/j.scitotenv.2005.04.003
   Rao J Venkateswara, 2005, Int J Environ Res Public Health, V2, P478, DOI 10.3390/ijerph2005030013
   SHARMA RM, 1990, B ENVIRON CONTAM TOX, V44, P443, DOI 10.1007/BF01701227
   Sparling DW, 2007, ENVIRON POLLUT, V147, P535, DOI 10.1016/j.envpol.2006.10.036
   USEPA, 1986, 440586005 USEPA, P64
   Zucker E., 1985, US EPA PUBLICATION
NR 53
TC 28
Z9 29
U1 2
U2 88
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0049-6979
EI 1573-2932
J9 WATER AIR SOIL POLL
JI Water Air Soil Pollut.
PD NOV
PY 2012
VL 223
IS 9
BP 5917
EP 5930
DI 10.1007/s11270-012-1328-9
PG 14
WC Environmental Sciences; Meteorology & Atmospheric Sciences; Water
   Resources
SC Environmental Sciences & Ecology; Meteorology & Atmospheric Sciences;
   Water Resources
GA 035AG
UT WOS:000310913400032
DA 2018-12-27
ER

PT J
AU Sophocleous, M
AF Sophocleous, Marios
TI RETRACTED: Conserving and Extending the Useful Life of the Largest
   Aquifer in North America: The Future of the High Plains/Ogallala Aquifer
   (Retracted article. See vol. 52, pg. 323, 2014)
SO GROUND WATER
LA English
DT Article; Retracted Publication
ID HIGH-PLAINS AQUIFER; WATER CONSERVATION; GROUNDWATER; MANAGEMENT;
   KANSAS; SUSTAINABILITY; TECHNOLOGY; REGION; USA
AB The water-level decline of the High Plains/Ogallala aquifer is one of the largest water management concerns in the United States. The economy and livelihood of people living in that vast region depend almost exclusively on water extracted from that aquifer. A debate about its future is ongoing, and questions remain as to how best to conserve the groundwater resource. Maintaining the aquifer will require reductions in pumping and irrigated hectarage and adopting additional conservation measures. Eventually, the agricultural system will have to be based dominantly on the renewable water resources of the region. In effect, this means a limited-irrigation and/or dry-farming regime. What Kansas is currently doing to further extend the life of the aquifer is presented here together with additional measures that could be taken. A key management approach to help sustain the aquifer in western Kansas is to divide the aquifer into subunits on which to base localized management decisions. Another recently adopted measure is the establishment of local enhanced management areas, which would allow locally agreed upon specific corrective controls in those areas. History has shown that incentive and voluntary plans alone have not been successful in halting water-level declines. Thus, limits and timelines need to be set and checks must be in place to enforce strict administration of conservation measures. It is advocated that water laws be reformed and modernized so that water rights are constrained by the current availability of water and the preservation of the resource base for future generations.
C1 Univ Kansas, Kansas Geol Survey, Lawrence, KS 66047 USA.
RP Sophocleous, M (reprint author), Univ Kansas, Kansas Geol Survey, 1930 Constant Ave, Lawrence, KS 66047 USA.
EM marios@kgs.ku.edu
FU National Science Foundation [1039247]
FX This work was supported, in part, by the National Science Foundation
   under award 1039247. The author is thankful to the three anonymous
   journal reviewers and the Editor-in-Chief for their constructive review
   comments. Dustin Fross of the Kansas Geological Survey (KGS) compiled
   the data on irrigation systems in Figure 2. Cathy Evans (KGS) reviewed
   the original and all subsequent manuscript additions offering highly
   constructive comments that improved the article. Susan Stover of the
   Kansas Water Office and Jim Butler and Dan Merriam of KGS also provided
   useful reviews of earlier drafts of this article. Mark Schoneweis of KGS
   embellished all figures.
CR Amosson S, 2009, EC IMPACTS SELECTED
   [Anonymous], 2011, ENH MAN
   BEUMONT P, 1985, ENVIRON CONSERV, V12, P119
   Charalambous AN, 2011, Q J ENG GEOL HYDROGE, V44, P147, DOI 10.1144/1470-9236/09-052
   CIER (Center for Integrative Environmental Research), 2008, EC IMP CLIM CHANG KA, P18
   DWR (Division of Water Resources Kansas Department of Agriculture), 2012, DWR CURRENTS EL 0126
   Fort D. D., 2011, IDAHO LAW REV, V47, P325
   Golden B., 2006, 0603 KANS STAT U DEP
   Gurdak J. J., 2009, 1337 US GEOL SURV
   Gutentag E. D., 1984, US GEOLOGICAL SURVEY, P63
   Hardberger A., 2004, TEX TECH LAW REV, V35, P1211
   Harshberger G., 2012, COMMUNICATION
   Huffaker R, 2003, INT J WATER RESOUR D, V19, P37, DOI 10.1080/0790062032000040764
   Huffaker R., 1995, CHOICES, V4, P24
   Johnson N, 2001, SCIENCE, V292, P1071, DOI 10.1126/science.1058821
   Kansas Water Office (KWO), 2009, KANS WAT PLAN
   Kwasniak Arlene J, 2010, U DENVER WATER LAW R, V13, P321
   Luckey R. R., 1999, WRIR994104 USGS, P68
   Mann RA, 2009, TEX LAW REV, V88, P391
   Miller R. D., 1999, 12 KANS GEOL SURV, P4
   Ojima D.S, 2002, PREPARING CHANGING C
   Peterson J.M., 2003, CHOICES MAGAZINE, V1, P15
   Pfeiffer L., U CALIFORNIA AGR RES, V12, P1
   Poff NL, 1997, BIOSCIENCE, V47, P769, DOI 10.2307/1313099
   Sophocleous M, 2005, HYDROGEOL J, V13, P351, DOI 10.1007/s10040-004-0385-6
   Sophocleous M, 2000, J HYDROL, V235, P27, DOI 10.1016/S0022-1694(00)00263-8
   Sophocleous M. A., 2011, GROUNDWATER MANAGEME, P325
   Sophocleous M, 2007, GROUND WATER, V45, P393, DOI 10.1111/j.1745-6584.2007.00322.x
   Sophocleous M, 2012, J HYDROL, V414, P550, DOI 10.1016/j.jhydrol.2011.11.002
   Sophocleous M, 2010, HYDROGEOL J, V18, P559, DOI 10.1007/s10040-009-0540-1
   Toll M., 2011, U COLO L REV, V82, P595
   Upendram S, 2007, J CONTEMP WAT RES ED, V137, P40, DOI 10.1111/j.1936-704X.2007.mp137001005.x
   Waskom R., 2006, GREAT PLAINS SOIL FE, P122
   White SE, 1996, SOC SCI J, V33, P437, DOI 10.1016/S0362-3319(96)90016-6
   Whittlesey N, 2003, DEV WATER SCI, V50, P53
   Wilson B. B., 2008, 200820 KANS GEOL SUR, P99
   Zellmer S., 2008, CREIGHTON LAW REV, V41, P385
NR 37
TC 15
Z9 15
U1 1
U2 115
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0017-467X
EI 1745-6584
J9 GROUND WATER
JI Ground Water
PD NOV-DEC
PY 2012
VL 50
IS 6
BP 831
EP 839
DI 10.1111/j.1745-6584.2012.00965.x
PG 9
WC Geosciences, Multidisciplinary; Water Resources
SC Geology; Water Resources
GA 032OR
UT WOS:000310729100006
PM 22823563
DA 2018-12-27
ER

PT J
AU Xu, HB
   Jiang, RH
   Xiao, HP
AF Xu, H. -B.
   Jiang, R. -H.
   Xiao, H-P.
TI RETRACTED: Clofazimine in the treatment of multidrug-resistant
   tuberculosis (Retracted article. See vol. 69, pg. e1, 2014)
SO CLINICAL MICROBIOLOGY AND INFECTION
LA English
DT Article; Retracted Publication
DE Clofazimine; extensively drug-resistant; multidrug resistance; treatment
   outcomes; tuberculosis
ID MYCOBACTERIUM-TUBERCULOSIS
AB Clin Microbiol Infect 2012; 18: 11041110 Abstract Clofazimine has shown activity against Mycobacterium tuberculosis, including multidrug-resistant strains in vitro and in animal studies. However, clinical experience with clofazimine in multidrug-resistant tuberculosis (MDR-TB) is scarce. We reported our clinical experience with 39 MDR-TB patients treated with combination regimens that included clofazimine. From January 2008 to March 2011, 39 patients received clofazimine for the treatment of MDR-TB in Shanghai Pulmonary Hospital. Patients had isolates resistant to a median of six drugs (range, 211 drugs). Of the 39 cases, 36 had cavitary changes noted on initial chest radiograph or chest computed tomography, and positive sputum-smear microscopy results at the time of MDR-TB diagnosis. At data censure, 15 of the 39 patients had successful therapy, with at least five consistently negative cultures documented for the final 12 months of treatment. Eleven continued to receive treatment. There were no deaths. Thirteen patients had a poor outcome, including four defaults and nine treatment failures. Culture conversion occurred in 22 cases at a median of 12 weeks. Side-effects occurred in 34 patients, mainly including skin discolouration, ichthyosis and gastrointestinal adverse events. No patients reported significant toxicity likely to be attributable to clofazimine therapy. Adverse events were managed by combinations of dose adjustment and symptom management. In our experience, clofazimine was well tolerated and may have efficacy in the treatment of MDR-TB.
C1 [Xu, H. -B.] Tongji Univ, Sch Med, Shanghai Peoples Hosp 10, Dept Clin Pharm, Shanghai 200072, Peoples R China.
   [Jiang, R. -H.; Xiao, H-P.] Tongji Univ, Sch Med, Shanghai Pulm Hosp, Dept TB, Shanghai 200072, Peoples R China.
RP Xu, HB (reprint author), Tongji Univ, Sch Med, Shanghai Peoples Hosp 10, Dept Clin Pharm, Shanghai 200072, Peoples R China.
EM xuhongbin119@yahoo.cn
FU Scientific Research Foundation of Shanghai Pharmaceutical Society
   [2009-YY-01-013]
FX This work was partly supported by Scientific Research Foundation of
   Shanghai Pharmaceutical Society (Grant No. 2009-YY-01-013). The authors
   have no conflict of interests.
CR American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America, 2003, AM J RESP CRIT CARE, V167, P603
   Anger HA, 2010, J ANTIMICROB CHEMOTH, V65, P775, DOI 10.1093/jac/dkq017
   [Anonymous], 2008, Tuberculosis (Edinb), V88, P96, DOI 10.1016/S1472-9792(08)70006-4
   BARRY VC, 1957, NATURE, V179, P1013, DOI 10.1038/1791013a0
   Centers for Disease Control and Prevention, 2006, MMWR-MORBID MORTAL W, V55, P1176
   Condos Rany, 2008, Chest, V134, P187, DOI 10.1378/chest.07-1988
   Cynamon MH, 1999, ANTIMICROB AGENTS CH, V43, P1189, DOI 10.1128/AAC.43.5.1189
   Fortun J, 2005, J ANTIMICROB CHEMOTH, V56, P180, DOI 10.1093/jac/dki148
   ISEMAN MD, 1993, NEW ENGL J MED, V329, P784
   Laserson KF, 2005, INT J TUBERC LUNG D, V9, P640
   Lu Yu, 2008, Zhonghua Jiehe He Huxi Zazhi, V31, P752
   Mitnick CD, 2008, NEW ENGL J MED, V359, P563, DOI 10.1056/NEJMoa0800106
   Nachega J. B., 2003, CLIN INFECT DIS, V36, P24
   Reddy VM, 1999, J ANTIMICROB CHEMOTH, V43, P615, DOI 10.1093/jac/43.5.615
   Rodriguez JC, 2004, J ANTIMICROB CHEMOTH, V53, P441, DOI 10.1093/jac/dkh119
   Schecter GF, 2010, CLIN INFECT DIS, V50, P49, DOI 10.1086/648675
   von der Lippe B, 2006, J INFECTION, V52, P92, DOI 10.1016/j.jinf.2005.04.007
   World Health Organization, 2009, WHOHTMTB2009411
NR 18
TC 32
Z9 34
U1 4
U2 11
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1198-743X
EI 1469-0691
J9 CLIN MICROBIOL INFEC
JI Clin. Microbiol. Infect.
PD NOV
PY 2012
VL 18
IS 11
BP 1104
EP 1110
DI 10.1111/j.1469-0691.2011.03716.x
PG 7
WC Infectious Diseases; Microbiology
SC Infectious Diseases; Microbiology
GA 023WZ
UT WOS:000310069400016
PM 22192631
OA Bronze
DA 2018-12-27
ER

PT J
AU Lichtenthaler, U
   Muethel, M
AF Lichtenthaler, Ulrich
   Muethel, Miriam
TI RETRACTED: The Impact of Family Involvement on Dynamic Innovation
   Capabilities: Evidence From German Manufacturing Firms (Retracted
   article. See vol. 38, pg. 977, 2014)
SO ENTREPRENEURSHIP THEORY AND PRACTICE
LA English
DT Article; Retracted Publication
ID ABSORPTIVE-CAPACITY; STRATEGIC MANAGEMENT; MODERATING ROLE; PERFORMANCE;
   OWNERSHIP; GOVERNANCE; PERSPECTIVE; BUSINESS; ENTREPRENEURSHIP;
   STEWARDSHIP
AB Drawing on the capability-based view, we provide new theoretical arguments related to innovation capabilities rather than realized innovation output in firms with family involvement. We focus on technology-based product innovation capabilities and use data from a sample of 119 German manufacturing firms to show that family involvement is positively related to dynamic innovation capabilities. Specifically, the degree of family involvement, which describes the owner family's ability to influence firm behavior, is positively related to sensing innovation opportunities and to transforming a firm's innovation processes, while it is insignificantly related to seizing innovation opportunities. The findings suggest that dynamic innovation capabilities are an important characteristic that differs between firms with varying levels of family involvement.
C1 [Lichtenthaler, Ulrich] Univ Mannheim, D-68131 Mannheim, Germany.
   [Muethel, Miriam] WHU Otto Beisheim Sch Management, D-56179 Vallendar, Germany.
RP Lichtenthaler, U (reprint author), Univ Mannheim, D-68131 Mannheim, Germany.
EM lichtenthaler@uni-mannheim.de; miriam.muethel@whu.edu
CR Agarwal R, 2009, ORGAN SCI, V20, P281, DOI 10.1287/orsc.1090.0423
   Anderson RC, 2003, J LAW ECON, V46, P653, DOI 10.1086/377115
   Arregle JL, 2007, J MANAGE STUD, V44, P73, DOI 10.1111/j.1467-6486.2007.00665.x
   ASTRACHAN J.H., 2002, FAMILY BUSINESS REV, V15, P45, DOI DOI 10.1111/J.1741-6248.2002.00045.X
   Atuahene-Gima K, 2005, J PROD INNOVAT MANAG, V22, P464, DOI 10.1111/j.1540-5885.2005.00144.x
   BROWN SL, 1995, ACAD MANAGE REV, V20, P343, DOI 10.2307/258850
   Carney M, 2005, ENTREP THEORY PRACT, V29, P249, DOI 10.1111/j.1540-6520.2005.00081.x
   Chang EPC, 2009, FAM BUS REV, V22, P279, DOI 10.1177/0894486509332327
   Chen HL, 2009, FAM BUS REV, V22, P347, DOI 10.1177/0894486509341062
   Chrisman J. J., 2012, ACAD MANAGE IN PRESS
   Chrisman J. J., 2012, ENTREPRENEU IN PRESS
   Chrisman J. J., 1999, ENTREP THEORY PRACT, V23, P19
   Chrisman JJ, 2010, FAM BUS REV, V23, P9, DOI 10.1177/0894486509357920
   Chrisman JJ, 2009, ENTREP THEORY PRACT, V33, P739, DOI 10.1111/j.1540-6520.2009.00324.x
   Chrisman JJ, 2005, ENTREP THEORY PRACT, V29, P555, DOI 10.1111/j.1540-6520.2005.00098.x
   Cooper RG, 1999, J PROD INNOVAT MANAG, V16, P333, DOI 10.1016/S0737-6782(99)00005-3
   Craig JBL, 2006, FAM BUS REV, V19, P1, DOI 10.1111/j.1741-6248.2006.00056.x
   Czarnitzki D, 2009, J ECON BEHAV ORGAN, V71, P372, DOI 10.1016/j.jebo.2009.03.017
   Debicki BJ, 2009, FAM BUS REV, V22, P151, DOI 10.1177/0894486509333598
   Demsetz H, 2001, J CORP FINANC, V7, P209, DOI 10.1016/S0929-1199(01)00020-7
   Dyer G., 2006, ENTREP THEORY PRACT, V30, P785
   Eddleston KA, 2008, J MANAGE STUD, V45, P26, DOI 10.1111/j.1467-6486.2007.00717.x
   Eddleston KA, 2007, J BUS VENTURING, V22, P545, DOI 10.1016/j.jbusvent.2006.06.004
   Eddleston KA, 2010, ENTREP THEORY PRACT, V34, P1043, DOI 10.1111/j.1540-6520.2010.00412.x
   Eisenhardt KM, 2000, STRATEGIC MANAGE J, V21, P1105, DOI 10.1002/1097-0266(200010/11)21:10/11<1105::AID-SMJ133>3.0.CO;2-E
   Fiegener MK, 2010, J MANAGE STUD, V47, P296, DOI 10.1111/j.1467-6486.2009.00892.x
   Garg VK, 2003, STRATEGIC MANAGE J, V24, P725, DOI 10.1002/smj.335
   Gedajlovic E, 2010, ENTREP THEORY PRACT, V34, P1145, DOI 10.1111/j.1540-6520.2010.00418.x
   Gomez-Mejia LR, 2001, ACAD MANAGE J, V44, P81, DOI 10.2307/3069338
   Gomez-Mejia LR, 2007, ADMIN SCI QUART, V52, P106, DOI 10.2189/asqu.52.1.106
   Gomez-Mejia LR, 2010, J MANAGE STUD, V47, P223, DOI 10.1111/j.1467-6486.2009.00889.x
   Greenwood R, 2010, ACAD MANAGE PERSPECT, V24, P78, DOI 10.5465/AMP.2010.55206386
   Hair J., 2006, MULTIVARIATE DATA AN
   Heeley MB, 2007, ACAD MANAGE J, V50, P209
   Helfat C. E., 2007, DYNAMIC CAPABILITIES
   Hultink EJ, 2002, J PROD INNOVAT MANAG, V19, P199, DOI 10.1111/1540-5885.1930199
   Jaskiewicz P, 2005, FAM BUS REV, V18, P179, DOI 10.1111/j.1741-6248.2005.00041.x
   JAWORSKI BJ, 1993, J MARKETING, V57, P57, DOI 10.2307/1252057
   Kellermanns FW, 2008, ENTREP THEORY PRACT, V32, P999, DOI 10.1111/j.1540-6520.2008.00268.x
   Kellermanns FW, 2008, FAM BUS REV, V21, P1, DOI 10.1111/j.1741-6248.2007.00107.x
   Kellermanns FW, 2006, ENTREP THEORY PRACT, V30, P809, DOI 10.1111/j.1540-6520.2006.00153.x
   Klein SB, 2005, ENTREP THEORY PRACT, V29, P321, DOI 10.1111/j.1540-6520.2005.00086.x
   Le Breton-Miller I, 2006, ENTREP THEORY PRACT, V30, P731, DOI 10.1111/j.1540-6520.2006.00147.x
   Lichtenthaler U., 2012, J PRODUCT I IN PRESS
   Lichtenthaler U, 2010, CALIF MANAGE REV, V53, P154, DOI 10.1525/cmr.2010.53.1.154
   Lichtenthaler U, 2009, J MANAGE STUD, V46, P1315, DOI 10.1111/j.1467-6486.2009.00854.x
   Lichtenthaler U, 2009, ACAD MANAGE J, V52, P822, DOI 10.5465/AMJ.2009.43670902
   Ling Y, 2010, J MANAGE STUD, V47, P322, DOI 10.1111/j.1467-6486.2009.00893.x
   MACDONALD S, 1993, J PROD INNOVAT MANAG, V10, P417
   Marsh SJ, 2006, J PROD INNOVAT MANAG, V23, P422, DOI 10.1111/j.1540-5885.2006.00214.x
   Miller D, 2006, FAM BUS REV, V19, P73, DOI 10.1111/j.1741-6248.2006.00063.x
   Miller D., 2005, MANAGING LONG RUN LE
   Miller D, 2008, J MANAGE STUD, V45, P51, DOI 10.1111/j.1467-6486.2007.00718.x
   Miller D, 2010, STRATEGIC MANAGE J, V31, P201, DOI 10.1002/smj.802
   MISHRA CS, 1999, ENTREP THEORY PRACT, V23, P53
   Muethel M, 2011, J INT BUS STUD, V42, P183, DOI 10.1057/jibs.2010.47
   Muethel M, 2010, J INT MANAG, V16, P234, DOI 10.1016/j.intman.2010.06.003
   Munari F, 2010, RES POLICY, V39, P1093, DOI 10.1016/j.respol.2010.05.004
   NELSON RR, 1991, STRATEGIC MANAGE J, V12, P61, DOI 10.1002/smj.4250121006
   O'Reilly CA, 2008, RES ORGAN BEHAV, V28, P185, DOI 10.1016/j.riob.2008.06.002
   Peng MW, 2010, J MANAGE STUD, V47, P253, DOI 10.1111/j.1467-6486.2009.00890.x
   Rothaermel FT, 2007, ORGAN SCI, V18, P898, DOI 10.1287/orsc.1070.0291
   Schulze WS, 2010, J MANAGE STUD, V47, P191, DOI 10.1111/j.1467-6486.2009.00887.x
   Schulze WS, 2003, ACAD MANAGE J, V46, P179, DOI 10.2307/30040613
   Sciascia S, 2008, FAM BUS REV, V21, P331, DOI 10.1111/j.1741-6248.2008.00133.x
   Sethi R, 2008, J MARKETING, V72, P118, DOI 10.1509/jmkg.72.1.118
   Shanker M, 1996, FAMILY BUSINESS REV, V9, P107, DOI DOI 10.1111/J.1741-6248.1996.00107.X
   Sharma P., 2004, FAMILY BUSINESS REV, V27, P1
   Sirmon D. G., 2003, ENTREP THEORY PRACT, V27, P339, DOI DOI 10.1111/1540-8520.T01-1-00013
   Sirmon DG, 2008, ENTREP THEORY PRACT, V32, P979, DOI 10.1111/j.1540-6520.2008.00267.x
   Steijvers T, 2009, FAM BUS REV, V22, P333, DOI 10.1177/0894486509338291
   Teece DJ, 2007, STRATEG MANAGE J, V28, P1319, DOI 10.1002/smj.640
   Teece DJ, 1997, STRATEGIC MANAGE J, V18, P509, DOI 10.1002/(SICI)1097-0266(199708)18:7<509::AID-SMJ882>3.0.CO;2-Z
   Tripsas M., 1997, IND CORP CHANGE, V6, P341
   Verbeke A, 2010, ENTREP THEORY PRACT, V34, P1173, DOI 10.1111/j.1540-6520.2010.00419.x
   Zahra A., 2004, FAMILY BUSINESS REV, V15, P331, DOI [10.1111/j.1741-6248.2004.00022.x, DOI 10.1111/J.1741-6248.2004.00022.X]
   Zahra SA, 2005, FAM BUS REV, V18, P23, DOI 10.1111/j.1741-6248.2005.00028.x
   Zahra SA, 2000, ACAD MANAGE J, V43, P925, DOI 10.2307/1556420
   Zahra SA, 2004, ENTREP THEORY PRACT, V28, P363, DOI 10.1111/j.1540-6520.2004.00051.x
   Zahra SA, 2007, J BUS RES, V60, P1070, DOI 10.1016/j.jbusres.2006.12.014
   Zahra SA, 2006, J MANAGE STUD, V43, P917, DOI 10.1111/j.1467-6486.2006.00616.x
   Zahra SA, 2010, J MANAGE STUD, V47, P345, DOI 10.1111/j.1467-6486.2009.00894.x
   Zellweger T. M., 2012, ORG SCI IN PRESS
NR 83
TC 15
Z9 17
U1 3
U2 95
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1042-2587
EI 1540-6520
J9 ENTREP THEORY PRACT
JI Entrep. Theory Pract.
PD NOV
PY 2012
VL 36
IS 6
SI SI
BP 1235
EP 1253
DI 10.1111/j.1540-6520.2012.00548.x
PG 19
WC Business
SC Business & Economics
GA 030VY
UT WOS:000310599400009
DA 2018-12-27
ER

PT J
AU Wei, WZ
   Liu, W
   Cassol, CA
   Zheng, WY
   Asa, SL
   Ezzat, S
AF Wei, Wangzhi
   Liu, Wei
   Cassol, Clarissa A.
   Zheng, Weiyue
   Asa, Sylvia L.
   Ezzat, Shereen
TI RETRACTED: The Breast Cancer Susceptibility Gene Product Fibroblast
   Growth Factor Receptor 2 Serves as a Scaffold for Regulation of NF-kappa
   B Signaling (Retracted article. See vol. 38, 2018)
SO MOLECULAR AND CELLULAR BIOLOGY
LA English
DT Article; Retracted Publication
ID EPITHELIAL-MESENCHYMAL TRANSITION; GENOME-WIDE ASSOCIATION; PROGRESSION;
   EXPRESSION; COMPLEX; SPECIFICITY; CARCINOMA; PATHWAYS; REVEALS; VARIANT
AB Fibroblast growth factor (FGF) receptor 2 (FGFR2) has been identified in genome-wide association studies to be associated with increased breast cancer risk; however, its mechanism of action remains unclear. Here we show that the two major FGFR2 alternatively spliced isoforms, FGFR2-IIIb and FGFR2-IIIc, interact with I kappa B kinase beta and its downstream target, NF-kappa B. FGFR2 inhibits nuclear RelA/p65 NF-kappa B translocation and activity and reduces expression of dependent transcripts, including interleukin-6. These interactions result in diminished STAT3 phosphorylation and reduced breast cancer cell growth, motility, and invasiveness. FGFR2 also arrests the epithelial cell-to-mesenchymal cell transition (EMT), resulting in attenuated neoplastic growth in orthotopic xenografts of breast cancer cells. Our studies provide strong evidence for the protective effects of FGFR2 on tumor progression. We propose that FGFR2 serves as a scaffold for multiple components of the NF-kappa B signaling complex. Through these interactions, FGFR2 isoforms can respond to tissue-specific FGF signals to modulate epithelial cell-stromal cell communications in cancer progression.
C1 [Wei, Wangzhi; Liu, Wei; Cassol, Clarissa A.; Zheng, Weiyue; Asa, Sylvia L.; Ezzat, Shereen] Univ Toronto, Ontario Canc Inst, Univ Hlth Network, Toronto, ON, Canada.
   [Wei, Wangzhi; Ezzat, Shereen] Univ Toronto, Dept Med, Univ Hlth Network, Toronto, ON, Canada.
   [Liu, Wei; Cassol, Clarissa A.; Asa, Sylvia L.] Univ Toronto, Dept Pathol, Univ Hlth Network, Toronto, ON, Canada.
RP Ezzat, S (reprint author), Univ Toronto, Ontario Canc Inst, Univ Hlth Network, Toronto, ON, Canada.
EM shereen.ezzat@utoronto.ca
OI Asa, Sylvia/0000-0001-8418-5054
FU Canadian Institutes of Health Research [MOP-86493]; Ontario Ministry of
   Health and Long-Term Care
FX This work was supported by the Canadian Institutes of Health Research
   (MOP-86493) and the Ontario Ministry of Health and Long-Term Care.
CR Baraniak AP, 2003, MOL CELL BIOL, V23, P9327, DOI 10.1128/MCB.23.24.9327-9337.2003
   Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238
   Berishaj M, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1680
   Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5
   Chan KS, 2004, J CLIN INVEST, V114, P720, DOI 10.1172/JCI200421032
   DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455
   Drafahl KA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014412
   Easton DF, 2007, NATURE, V447, P1087, DOI 10.1038/nature05887
   Foubert E, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2585
   Gilmore TD, 2006, ONCOGENE, V25, P6680, DOI 10.1038/sj.onc.1209954
   GIVOL D, 1992, FASEB J, V6, P3362
   Hacker Hans, 2006, Sci STKE, V2006, pre13, DOI 10.1126/stke.3572006re13
   Hunter DJ, 2007, NAT GENET, V39, P870, DOI 10.1038/ng2075
   Iliopoulos D, 2009, CELL, V139, P693, DOI 10.1016/j.cell.2009.10.014
   Jacobs MD, 1998, CELL, V95, P749, DOI 10.1016/S0092-8674(00)81698-0
   Johnston CL, 1995, J BIOL CHEM, V270, P30643, DOI 10.1074/jbc.270.51.30643
   Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219
   Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870
   Kim Y, 2011, CELL PHYSIOL BIOCHEM, V28, P175, DOI 10.1159/000331729
   Kozlowski L, 2003, Rocz Akad Med Bialymst, V48, P82
   Lee JM, 2006, J CELL BIOL, V172, P973, DOI 10.1083/jcb.200601018
   Logullo AF, 2010, ONCOL REP, V23, P313, DOI 10.3892/or_00000638
   Luo YD, 2006, J CELL BIOCHEM, V97, P1241, DOI 10.1002/jcb.20724
   Meyer KB, 2008, PLOS BIOL, V6, P1098, DOI 10.1371/journal.pbio.0060108
   Salgado R, 2003, INT J CANCER, V103, P642, DOI 10.1002/ijc.10833
   Sullivan NJ, 2009, ONCOGENE, V28, P2940, DOI 10.1038/onc.2009.180
   THISSE B, 1995, DEV DYNAM, V203, P377, DOI 10.1002/aja.1002030309
   Thisse B, 2005, DEV BIOL, V287, P390, DOI 10.1016/j.ydbio.2005.09.011
   Tobin NP, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-417
   YAN GC, 1992, BIOCHEM BIOPH RES CO, V183, P423, DOI 10.1016/0006-291X(92)90498-A
   Yeh PY, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-53
   Zhan LX, 2008, CELL, V135, P865, DOI 10.1016/j.cell.2008.09.045
   Zhang XL, 2012, P NATL ACAD SCI USA, V109, P2790, DOI 10.1073/pnas.1100764108
   Zhu XG, 2010, AM J PATHOL, V177, P2860, DOI 10.2353/ajpath.2010.100509
   Zhu XG, 2009, MOL ENDOCRINOL, V23, P1397, DOI 10.1210/me.2009-0071
NR 35
TC 17
Z9 17
U1 0
U2 4
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0270-7306
EI 1098-5549
J9 MOL CELL BIOL
JI Mol. Cell. Biol.
PD NOV
PY 2012
VL 32
IS 22
BP 4662
EP 4673
DI 10.1128/MCB.00935-12
PG 12
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 029ZA
UT WOS:000310536000014
PM 22988296
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Takano, H
   Hasegawa, H
   Narumi, H
   Shindo, S
   Mizuma, H
   Kuwabara, Y
   Kobayashi, Y
   Komuro, I
AF Takano, H.
   Hasegawa, H.
   Narumi, H.
   Shindo, S.
   Mizuma, H.
   Kuwabara, Y.
   Kobayashi, Y.
   Komuro, I.
CA VART Investigators
TI RETRACTED: Effects of valsartan and amlodipine on home blood pressure
   and cardiovascular events in Japanese hypertensive patients: a
   subanalysis of the VART (Retracted article. See vol. 29, pg. 337, 2015)
SO JOURNAL OF HUMAN HYPERTENSION
LA English
DT Article; Retracted Publication
DE angiotensin II receptor blocker; calcium channel blocker; home blood
   pressure; left ventricular hypertrophy
ID LEFT-VENTRICULAR MASS; END-POINT REDUCTION; CHRONIC HEART-FAILURE;
   TARGET-ORGAN DAMAGE; LOSARTAN INTERVENTION; RANDOMIZED-TRIAL;
   DIABETIC-NEPHROPATHY; CARDIAC-HYPERTROPHY; ANGIOTENSIN-II; FOLLOW-UP
AB The Valsartan Amlodipine Randomized Trial (VART) was performed to compare the beneficial effects of valsartan and amlodipine on cardiovascular events in Japanese hypertensive patients. In this subanalysis of the VART, we assessed the relationship between home blood pressure (HBP) levels and cardiovascular events in the enrolled patients. We enrolled 1021 patients with mild-to-moderate hypertension in the VART. The participants were allocated randomly to either the valsartan group or the amlodipine group. The primary end point was a composite of all-cause death, sudden death, cerebrovascular events, cardiac events, vascular events and renal events. A total of 621 patients (valsartan group: 305 and amlodipine group: 316) completed the measurements of HBP (morning and evening) throughout the trial. Both the agents evenly and significantly lowered morning HBP and evening HBP throughout the trial. There was no significant difference in the primary end point between the two groups. However, we observed significant decreases in the left ventricular mass index and urinary albumin to creatinine ratio in the valsartan group but not in the amlodipine group. There were no significant differences in HBP levels and the main outcome of the cardiovascular events between the valsartan and amlodipine groups. However, in the valsartan group, significant improvements in left ventricular hypertrophy and microalbuminuria were observed. Journal of Human Hypertension (2012) 26, 656-663; doi: 10.1038/jhh.2011.91; published online 13 October 2011
C1 [Takano, H.] Chiba Univ, Dept Cardiovasc Sci & Med, Grad Sch Med, Chuo Ku, Chiba 2608670, Japan.
   [Komuro, I.] Osaka Univ, Grad Sch Med, Dept Cardiovasc Med, Osaka, Japan.
RP Takano, H (reprint author), Chiba Univ, Dept Cardiovasc Sci & Med, Grad Sch Med, Chuo Ku, 1-8-1 Inohana, Chiba 2608670, Japan.
EM htakano-cib@umin.ac.jp
CR Agarwal R, 2011, HYPERTENSION, V57, P29, DOI 10.1161/HYPERTENSIONAHA.110.160911
   Andersen S, 2000, KIDNEY INT, V58, P2129
   BIKKINA M, 1994, JAMA-J AM MED ASSOC, V272, P33, DOI 10.1001/jama.272.1.33
   Chugh Atul, 2007, J Clin Hypertens (Greenwich), V9, P196, DOI 10.1111/j.1524-6175.2007.06445.x
   Cohn JN, 2001, NEW ENGL J MED, V345, P1667, DOI 10.1056/NEJMoa010713
   Dahlof B, 2002, LANCET, V359, P995, DOI 10.1016/S0140-6736(02)08089-3
   Eguchi K, 2010, AM J HYPERTENS, V23, P522, DOI 10.1038/ajh.2010.17
   Gaede P, 2003, NEW ENGL J MED, V348, P383, DOI 10.1056/NEJMoa021778
   Gerstein HC, 2000, DIABETES CARE, V23, pB35
   Gerstein HC, 2001, JAMA-J AM MED ASSOC, V286, P421, DOI 10.1001/jama.286.4.421
   Hillege HL, 2002, CIRCULATION, V106, P1777, DOI 10.1161/01.CIR.0000031732.78052.81
   Ibsen H, 2005, HYPERTENSION, V45, P198, DOI 10.1161/01.HYP.0000154082.72286.2a
   Imanishi M, 1999, DIABETOLOGIA, V42, P999, DOI 10.1007/s001250051259
   Jager A, 1999, ARTERIOSCL THROM VAS, V19, P617, DOI 10.1161/01.ATV.19.3.617
   Kaneda R, 2005, AM J HYPERTENS, V18, P1528, DOI 10.1016/j.amjhyper.2005.06.015
   Kario K, 2003, CIRCULATION, V107, P1401, DOI 10.1161/01.CIR.0000056521.67546.AA
   Kario K, 2008, J HYPERTENS, V26, P1257, DOI 10.1097/HJH.0b013e3282fd173c
   Kim K, 2004, J CLIN PHARMACOL, V44, P1083, DOI 10.1177/0091270004268128
   Langham RG, 2002, DIABETOLOGIA, V45, P1572, DOI 10.1007/s00125-002-0946-y
   LEVY D, 1990, NEW ENGL J MED, V322, P1561, DOI 10.1056/NEJM199005313222203
   Lindholm LH, 2002, LANCET, V359, P1004, DOI 10.1016/S0140-6736(02)08090-X
   Metoki H, 2006, HYPERTENSION, V47, P149, DOI 10.1161/01.HYP.0000198541.12640.0f
   Mochizuki S, 2007, LANCET, V369, P1431, DOI 10.1016/S0140-6736(07)60669-2
   NAGANO M, 1991, J HYPERTENS, V9, P595, DOI 10.1097/00004872-199107000-00003
   Narumi H, 2011, HYPERTENS RES, V34, P62, DOI 10.1038/hr.2010.186
   Ogihara T, 2008, HYPERTENSION, V51, P393, DOI 10.1161/HYPERTENSIONAHA.107.098475
   Ogihara T, 2009, HYPERTENS RES, V32, P3, DOI 10.1038/hr.2008.15
   Ohkubo T, 2004, J HYPERTENS, V22, P1099, DOI 10.1097/01.hjh.0000125406.50839.15
   Okin PM, 2006, CIRCULATION, V113, P1588, DOI 10.1161/CIRCULATIONAHA.105.574822
   Parving HH, 2001, NEW ENGL J MED, V345, P870, DOI 10.1056/NEJMoa011489
   Pfeffer MA, 2003, LANCET, V362, P759, DOI 10.1016/S0140-6736(03)14282-1
   Roest M, 2001, CIRCULATION, V103, P3057, DOI 10.1161/hc2501.091353
   Sawada T, 2009, EUR HEART J, V30, P2461, DOI 10.1093/eurheartj/ehp363
   Stergiou GS, 2007, AM J HYPERTENS, V20, P616, DOI 10.1016/j.amjhyper.2006.12.013
   Tomita K, 2007, DIABETES CARE, V30, P1581, DOI 10.2337/dc06-2493
   TREVISAN R, 1995, AM J HYPERTENS, V8, P876, DOI 10.1016/0895-7061(95)00162-I
   Tsunoda S, 2002, HYPERTENS RES, V25, P167, DOI 10.1291/hypres.25.167
   Uzu T, 2008, HYPERTENS RES, V31, P1171, DOI 10.1291/hypres.31.1171
   Wright JT, 2002, JAMA-J AM MED ASSOC, V288, P2421, DOI 10.1001/jama.288.19.2421
   YAMAZAKI T, 1995, CIRC RES, V77, P258, DOI 10.1161/01.RES.77.2.258
   Yasunari K, 2004, J AM COLL CARDIOL, V43, P2116, DOI 10.1016/j.jacc.2003.12.051
NR 41
TC 5
Z9 6
U1 2
U2 11
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9240
EI 1476-5527
J9 J HUM HYPERTENS
JI J. Hum. Hypertens.
PD NOV
PY 2012
VL 26
IS 11
BP 656
EP 663
DI 10.1038/jhh.2011.91
PG 8
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 022MK
UT WOS:000309963300004
PM 21993491
OA Bronze
DA 2018-12-27
ER

PT J
AU Chen, SZ
   Charness, ME
AF Chen, Suzhen
   Charness, Michael E.
TI RETRACTED: Ethanol disrupts axon outgrowth stimulated by netrin-1, GDNF,
   and L1 by blocking their convergent activation of Src family kinase
   signaling (Retracted article. See vol. 132, pg. 756, 2015)
SO JOURNAL OF NEUROCHEMISTRY
LA English
DT Article; Retracted Publication
DE alcohol; axon outgrowth; CGN; GDNF; netrin-1; Src family kinase
ID CEREBELLAR GRANULE CELLS; DEPENDENT NEUROPROTECTIVE PROTEIN; NEURITE
   OUTGROWTH; TYROSINE PHOSPHORYLATION; ADHESION MOLECULE; NERVOUS-SYSTEM;
   LIPID RAFTS; C-RET; NEURONS; GUIDANCE
AB Pre-natal alcohol exposure causes fetal alcohol spectrum disorders (FASD), the most common, preventable cause of developmental disability. The developing cerebellum is particularly vulnerable to the effects of ethanol. We reported that ethanol inhibits the stimulation of axon outgrowth in cerebellar granule neurons (CGN) by NAP, an active motif of activity-dependent neuroprotective protein (ADNP), by blocking NAP activation of Fyn kinase and its downstream signaling molecule, the scaffolding protein Cas. Here, we asked whether ethanol inhibits the stimulation of axon outgrowth by diverse axon guidance molecules through a common action on the Src family kinases (SFK). We first demonstrated that netrin-1, glial cell line-derived neurotrophic factor (GDNF), and neural cell adhesion molecule L1 stimulate axon outgrowth in CGNs by activating SFK, Cas, and extracellular signal-regulated kinase 1 and 2 (ERK1/2). The specific SFK inhibitor, PP2, blocked the stimulation of axon outgrowth and the activation of the SFK-Cas-ERK1/2 signaling pathway by each of these axon-guidance molecules. In contrast, brain-derived neurotrophic factor (BDNF) stimulated axon outgrowth and activated ERK1/2 without first activating SFK or Cas. Clinically relevant concentrations of ethanol inhibited axon outgrowth and the activation of the SFK-Cas-ERK1/2 pathway by netrin-1, GDNF, and L1, but did not disrupt BDNF-induced axon outgrowth or ERK1/2 activation. These results indicate that SFK, but not ERK1/2, is a primary target for ethanol inhibition of axon outgrowth. The ability of ethanol to block the convergent activation of the SFK-Cas-ERK1/2 pathway by netrin-1, GDNF, L1, and ADNP could contribute significantly to the pathogenesis of FASD.
C1 [Chen, Suzhen] VA Boston Healthcare Syst, W Roxbury, MA 02132 USA.
   Harvard Univ, Dept Neurol, Sch Med, W Roxbury, MA USA.
RP Chen, SZ (reprint author), VA Boston Healthcare Syst, 1400 VFW Pkwy, W Roxbury, MA 02132 USA.
EM suzhen_chen@hms.harvard.edu
FU ABMRF; National Institute on Alcohol Abuse and Alcoholism
   [2R01AA012974]; NIAAA, as a component of the Collaborative Initiative on
   Fetal Alcohol Spectrum Disorders [U24-AA014811]; Medical Research
   Service, Department of Veterans Affairs
FX We thank Carrie Menkari, Devon M. Fitzgerald, and Lazaros Yiannos for
   their excellent technical assistance. This study was supported in part
   by the ABMRF Award (S. C.), the National Institute on Alcohol Abuse and
   Alcoholism Grant 2R01AA012974 (M. E. C.), NIAAA U24-AA014811, as a
   component of the Collaborative Initiative on Fetal Alcohol Spectrum
   Disorders (M. E. C) and the Medical Research Service, Department of
   Veterans Affairs (M. E. C). Dr. Charness is a member of the scientific
   advisory board for Allon Therapeutics, which is developing clinical
   applications for NAPVSIPQ (NAP). Dr. Charness holds stock options in
   Allon Therapeutics, and has two patents related to the study to declare.
   This does not alter the authors' adherence to all the Journal of
   Neurochemistry policies on sharing data and materials. Conceived and
   designed the experiments: SC, MC; Performed the experiments: SC;
   Analyzed the data: SC, MC; Wrote the paper: SC, MC.
CR Airaksinen MS, 2002, NAT REV NEUROSCI, V3, P383, DOI 10.1038/nrn812
   Bearer CF, 1999, J BIOL CHEM, V274, P13264, DOI 10.1074/jbc.274.19.13264
   Burazin TCD, 1999, MOL BRAIN RES, V73, P151, DOI 10.1016/S0169-328X(99)00217-X
   Chen S, 1999, J NEUROBIOL, V38, P428, DOI 10.1002/(SICI)1097-4695(19990215)38:3<428::AID-NEU10>3.0.CO;2-6
   Chen SZ, 2008, P NATL ACAD SCI USA, V105, P19962, DOI 10.1073/pnas.0807758105
   Chen SY, 2005, DEV NEUROSCI-BASEL, V27, P13, DOI 10.1159/000084528
   Chen SZ, 2003, MOL CELL NEUROSCI, V22, P227, DOI 10.1016/S1044-7431(02)00014-3
   Dahme M, 1997, NAT GENET, V17, P346, DOI 10.1038/ng1197-346
   Defilippi P, 2006, TRENDS CELL BIOL, V16, P257, DOI 10.1016/j.tcb.2006.03.003
   FISHER HR, 1987, CAN J PUBLIC HEALTH, V78, P300
   Forcet C, 2002, NATURE, V417, P443, DOI 10.1038/nature748
   FRANSEN E, 1995, EUR J HUM GENET, V3, P273
   Gerlai R, 2001, EUR J NEUROSCI, V14, P1153, DOI 10.1046/j.0953-816x.2001.01724.x
   Guimond MO, 2010, MOL CELL NEUROSCI, V45, P201, DOI 10.1016/j.mcn.2010.06.011
   Haspel J, 2001, BIOTECHNIQUES, V30, P60, DOI 10.2144/01301st01
   Hoffman EJ, 2008, NEUROSCIENCE, V157, P556, DOI 10.1016/j.neuroscience.2008.08.071
   Hoyme HE, 2005, PEDIATRICS, V115, P39, DOI 10.1542/peds.2004-0259
   Huang J, 2006, MOL BIOL CELL, V17, P3187, DOI 10.1091/mbc.E05-12-1122
   Huang ZY, 2007, DEVELOPMENT, V134, P2337, DOI 10.1242/dev.004242
   IGNELZI MA, 1994, NEURON, V12, P873, DOI 10.1016/0896-6273(94)90339-5
   Jaatinen P, 2008, CEREBELLUM, V7, P332, DOI 10.1007/s12311-008-0034-z
   KEILHAUER G, 1985, NATURE, V316, P728, DOI 10.1038/316728a0
   Lindsley TA, 2003, DEV BRAIN RES, V147, P191, DOI 10.1016/j.debbrainres.2003.10.015
   Liu GF, 2004, NAT NEUROSCI, V7, P1222, DOI 10.1038/nn1331
   Liu GF, 2007, J NEUROSCI, V27, P957, DOI 10.1523/JNEUROSCI.4616-06.2007
   Livesey FJ, 1999, CELL MOL LIFE SCI, V56, P62, DOI 10.1007/s000180050006
   Loers G, 2005, J NEUROCHEM, V92, P1463, DOI 10.1111/j.1471-4159.2004.02983.x
   Maness PF, 2007, NAT NEUROSCI, V10, P19, DOI 10.1038/nn1827
   Nishio H, 2001, J NEUROCHEM, V76, P1073, DOI 10.1046/j.1471-4159.2001.00143.x
   Numakawa T, 2010, HISTOL HISTOPATHOL, V25, P237, DOI 10.14670/HH-25.237
   Ohrtman JD, 2006, ALCOHOL, V39, P29, DOI 10.1016/j.alcohol.2006.06.011
   Pantera B, 2009, J NEUROCHEM, V110, P194, DOI 10.1111/j.1471-4159.2009.06123.x
   Paratcha G, 2008, TRENDS NEUROSCI, V31, P384, DOI 10.1016/j.tins.2008.05.003
   Pinhasov A, 2003, DEV BRAIN RES, V144, P83, DOI 10.1016/S0165-3806(03)00162-7
   PLEIMAN CM, 1993, MOL CELL BIOL, V13, P5877, DOI 10.1128/MCB.13.9.5877
   Ramanathan R, 1996, J CELL BIOL, V133, P381, DOI 10.1083/jcb.133.2.381
   Ramseger R, 2009, J BIOL CHEM, V284, P7697, DOI 10.1074/jbc.M806719200
   RATHJEN FG, 1984, EMBO J, V3, P461, DOI 10.1002/j.1460-2075.1984.tb01828.x
   Riley EP, 2004, AM J MED GENET C, V127C, P35, DOI 10.1002/ajmg.c.30014
   Sariola H, 2003, J CELL SCI, V116, P3855, DOI 10.1242/jcs.00786
   Schmid RS, 2000, J NEUROSCI, V20, P4177
   SEGAL RA, 1995, J NEUROSCI, V15, P4970
   Sepulveda B, 2011, NEUROSCIENCE, V180, P30, DOI 10.1016/j.neuroscience.2011.02.018
   Serafini T, 1996, CELL, V87, P1001, DOI 10.1016/S0092-8674(00)81795-X
   Sun KLW, 2011, DEVELOPMENT, V138, P2153, DOI 10.1242/dev.044529
   Suvarna N, 2005, J BIOL CHEM, V280, P31450, DOI 10.1074/jbc.M504120200
   Tang NF, 2011, J NEUROCHEM, V119, P859, DOI 10.1111/j.1471-4159.2011.07467.x
   Trupp M, 1997, J NEUROSCI, V17, P3554
   Tucker BA, 2008, CELL SIGNAL, V20, P241, DOI 10.1016/j.cellsig.2007.10.014
   UMEMORI H, 1992, MOL BRAIN RES, V16, P303, DOI 10.1016/0169-328X(92)90239-8
   Wang VY, 2001, NAT REV NEUROSCI, V2, P484, DOI 10.1038/35081558
   Yeaney NK, 2009, J NEUROCHEM, V110, P779, DOI 10.1111/j.1471-4159.2009.06143.x
NR 52
TC 13
Z9 15
U1 2
U2 17
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3042
EI 1471-4159
J9 J NEUROCHEM
JI J. Neurochem.
PD NOV
PY 2012
VL 123
IS 4
BP 602
EP 612
DI 10.1111/j.1471-4159.2012.07954.x
PG 11
WC Biochemistry & Molecular Biology; Neurosciences
SC Biochemistry & Molecular Biology; Neurosciences & Neurology
GA 021WU
UT WOS:000309916900014
PM 22924694
OA Green Accepted
DA 2018-12-27
ER

PT J
AU Wang, LM
   Shearer, GC
   Budamagunta, MS
   Voss, JC
   Molfino, A
   Kaysen, GA
AF Wang, Limin
   Shearer, Gregory C.
   Budamagunta, Madhu S.
   Voss, John C.
   Molfino, Alessio
   Kaysen, George A.
TI RETRACTED: Proteinuria decreases tissue lipoprotein receptor levels
   resulting in altered lipoprotein structure and increasing lipid levels
   (Retracted article. See vol. 83, pg. 1207, 2013)
SO KIDNEY INTERNATIONAL
LA English
DT Article; Retracted Publication
DE apolipoprotein E; lipids; metabolism; proteinuria; VLDL
ID LOW-DENSITY-LIPOPROTEIN; VERY-LOW-DENSITY; APOLIPOPROTEIN-E STRUCTURE;
   CHRONIC KIDNEY-DISEASE; DOWN-REGULATION; NEPHROTIC SYNDROME; VLDL
   RECEPTOR; HEYMANN NEPHRITIS; GENE-EXPRESSION; FOCAL GLOMERULOSCLEROSIS
AB Rats with nephrotic syndrome (NS) have a fivefold increase in lipids and a similar decrease in triglyceride-rich lipoprotein (TRL) clearance. Lipoprotein lipase (LPL) is reduced both in NS and in the Nagase analbuminemic rat. These rats have nearly normal triglyceride levels and TRL clearance, suggesting that reduction in LPL alone is insufficient to cause increased TRL levels. Apolipoprotein E (apoE) was decreased in lipoprotein fractions in NS, but not in analbuminemia. Here we tested whether decreased apoE binding to lipoproteins in NS contributes to hyperlipidemia by decreasing their affinity for lipoprotein receptors. Plasma apoE was increased 60% in both NS and analbuminemia compared with control (CTRL) as a result of a 60% decreased apoE clearance. Very-low-density lipoprotein and high-density lipoprotein in NS had significantly less apoE per mole of phospholipid compared with analbuminemia or CTRL and significantly greater lipid content; however, apoE binding did not differ by lipoprotein class or group. There was a significant reduction of receptors for lipoproteins in nearly all tissues in NS compared with CTRL and analbuminemia. Thus, apoE within lipoprotein fractions was reduced by dilution resulting from expansion of the lipid fraction due to decreased lipolysis and not to differing affinity for apoE. Decreased lipoprotein receptors result from proteinuria and contribute to hyperlipidemia in NS. Kidney International (2012) 82, 990-999; doi:10.1038/ki.2012.244; published online 11 July 2012
C1 [Wang, Limin; Molfino, Alessio; Kaysen, George A.] Univ Calif Davis, Div Nephrol, Dept Internal Med, Davis, CA 95616 USA.
   [Wang, Limin; Shearer, Gregory C.; Kaysen, George A.] No Calif Hlth Care Syst, Dept Vet Affairs, Mather, CA USA.
   [Budamagunta, Madhu S.; Voss, John C.; Kaysen, George A.] Univ Calif Davis, Dept Biochem & Mol Med, Sch Med, Davis, CA 95616 USA.
RP Wang, LM (reprint author), Univ Calif Davis, Div Nephrol, Dept Internal Med, GBSF 6300,451 E Hlth Sci Dr, Davis, CA 95616 USA.
EM lwang@ucdavis.edu; gakaysen@ucdavis.edu
RI Shearer, Gregory/B-7309-2014
FU research service of the Department of Veteran's Affairs (USA)
FX We thank Kathie Howes for technical assistance. The study was supported
   by the research service of the Department of Veteran's Affairs (USA). We
   are also grateful to Dr William Couser for the supplied FX1A antibodies.
CR AlHaideri M, 1997, BIOCHEMISTRY-US, V36, P12766, DOI 10.1021/bi9631024
   Appel LJ, 2008, ARCH INTERN MED, V168, P832, DOI 10.1001/archinte.168.8.832
   Beigneux AP, 2007, CELL METAB, V5, P279, DOI 10.1016/j.cmet.2007.02.002
   Beigneux AP, 2009, J LIPID RES, V50, pS57, DOI 10.1194/jlr.R800030-JLR200
   BERLINER LJ, 1982, ANAL BIOCHEM, V119, P450, DOI 10.1016/0003-2697(82)90612-1
   BROWN MS, 1984, SCI AM, V251, P58, DOI 10.1038/scientificamerican1184-58
   CHAPMAN MJ, 1981, J LIPID RES, V22, P339
   Chen SE, 1999, POULTRY SCI, V78, P1241, DOI 10.1093/ps/78.9.1241
   Chomiki N, 2001, EUR J BIOCHEM, V268, P903, DOI 10.1046/j.1432-1327.2001.01946.x
   DAVIES RW, 1990, J CLIN INVEST, V86, P600, DOI 10.1172/JCI114750
   Gin P, 2007, BBA-MOL CELL BIOL L, V1771, P1464, DOI 10.1016/j.bbalip.2007.10.005
   Gotch FA, 2003, SEMIN DIALYSIS, V16, P474, DOI 10.1046/j.1525-139X.2003.16102.x
   Hatters DM, 2006, TRENDS BIOCHEM SCI, V31, P445, DOI 10.1016/j.tibs.2006.06.008
   Hatters DM, 2005, J BIOL CHEM, V280, P34288, DOI 10.1074/jbc.M506044200
   HICKMAN MA, 1994, HUM GENE THER, V5, P1477, DOI 10.1089/hum.1994.5.12-1477
   Ishibashi S, 1996, J BIOL CHEM, V271, P22422, DOI 10.1074/jbc.271.37.22422
   JI ZS, 1995, J LIPID RES, V36, P583
   KAYSEN GA, 1995, AM J KIDNEY DIS, V26, P178, DOI 10.1016/0272-6386(95)90172-8
   KAYSEN GA, 1993, AM J KIDNEY DIS, V22, P128, DOI 10.1016/S0272-6386(12)70178-6
   KAYSEN GA, 1992, AM J PHYSIOL, V263, pF335
   KAYSEN GA, 1995, AM J PHYSIOL-RENAL, V268, pF532
   KITA T, 1982, P NATL ACAD SCI-BIOL, V79, P5693, DOI 10.1073/pnas.79.18.5693
   KITA T, 1982, P NATL ACAD SCI-BIOL, V79, P3623, DOI 10.1073/pnas.79.11.3623
   Liang KH, 1997, KIDNEY INT, V51, P1761, DOI 10.1038/ki.1997.242
   Liang KH, 1997, KIDNEY INT, V51, P1933, DOI 10.1038/ki.1997.263
   Liang KH, 1999, KIDNEY INT, V56, P621, DOI 10.1046/j.1523-1755.1999.00585.x
   Meir KS, 2004, ARTERIOSCL THROM VAS, V24, P1006, DOI 10.1161/01.ATV.0000128849.12617.f4
   NICHOLS AV, 1986, METHOD ENZYMOL, V128, P417
   Oda MN, 2003, NAT STRUCT BIOL, V10, P455, DOI 10.1038/nsb931
   Out R, 2005, J LIPID RES, V46, P1172, DOI 10.1194/jlr.M400361-JLR200
   Out R, 2004, J BIOL CHEM, V279, P18401, DOI 10.1074/jbc.M401170200
   Petrlova J, 2011, PROTEINS, V79, P402, DOI 10.1002/prot.22891
   RUBINSZTEIN DC, 1990, J CLIN INVEST, V86, P1306, DOI 10.1172/JCI114839
   Saito H, 2004, PROG LIPID RES, V43, P350, DOI 10.1016/j.plipres.2004.05.002
   Santo SMSE, 2005, J LIPID RES, V46, P1097, DOI 10.1194/jlr.C500007-JLR200
   Sato T, 2003, KIDNEY INT, V64, P1780, DOI 10.1046/j.1523-1755.2003.00281.x
   Sato T, 2002, KIDNEY INT, V61, P157, DOI 10.1046/j.1523-1755.2002.00104.x
   Shearer GC, 2006, KIDNEY INT, V70, P647, DOI 10.1038/sj.ki.5000318
   Shearer GC, 2000, KIDNEY INT, V57, P2268, DOI 10.1046/j.1523-1755.2000.00087.x
   Shearer GC, 2004, KIDNEY INT, V65, P228, DOI 10.1111/j.1523-1755.2004.00373.x
   Shearer GC, 2001, AM J KIDNEY DIS, V38, P1385, DOI 10.1053/ajkd.2001.29263
   Shearer GC, 2001, AM J KIDNEY DIS, V37, pS119, DOI 10.1053/ajkd.2001.20766
   Shore VG, 1991, ANAL FATS OILS LIPOP, P573
   SUN X, 1992, AM J PHYSIOL, V262, pF755
   SUN XH, 1993, AM J PHYSIOL, V264, pF441
   TAKAHASHI S, 1992, P NATL ACAD SCI USA, V89, P9252, DOI 10.1073/pnas.89.19.9252
   Tetali SD, 2006, J LIPID RES, V47, P1358, DOI 10.1194/jlr.M500559-JLR200
   Van Eck M, 2008, J LIPID RES, V49, P136, DOI 10.1194/jlr.M700355-JLR200
   Vaziri ND, 1997, KIDNEY INT, V51, P913, DOI 10.1038/ki.1997.129
   Vaziri ND, 1996, KIDNEY INT, V50, P887, DOI 10.1038/ki.1996.388
   Vaziri ND, 2003, KIDNEY INT, V63, P1964, DOI 10.1046/j.1523-1755.2003.00941.x
   Vaziri ND, 2001, AM J PHYSIOL-RENAL, V280, pF823
   Vaziri ND, 2012, CLIN EXP NEPHROL, V16, P238, DOI 10.1007/s10157-011-0549-3
   Veniant MM, 2000, J CLIN INVEST, V106, P1501, DOI 10.1172/JCI10695
   von Eckardstein A, 2001, ARTERIOSCL THROM VAS, V21, P13, DOI 10.1161/01.ATV.21.1.13
   Wang LM, 2008, AM J PHYSIOL-HEART C, V295, pH237, DOI 10.1152/ajpheart.01366.2007
   Wang LM, 2008, COMPARATIVE MED, V58, P151
   WEBB JC, 1994, HUM MOL GENET, V3, P531, DOI 10.1093/hmg/3.4.531
   Young SG, 2007, CURR OPIN LIPIDOL, V18, P389, DOI 10.1097/MOL.0b013e3281527914
   Young SG, 2011, J LIPID RES, V52, P1869, DOI 10.1194/jlr.R018689
NR 60
TC 9
Z9 9
U1 2
U2 11
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0085-2538
EI 1523-1755
J9 KIDNEY INT
JI Kidney Int.
PD NOV
PY 2012
VL 82
IS 9
BP 990
EP 999
DI 10.1038/ki.2012.244
PG 10
WC Urology & Nephrology
SC Urology & Nephrology
GA 022SD
UT WOS:000309981700008
PM 22785171
OA Bronze
DA 2018-12-27
ER

PT J
AU Kuo, HM
   Chen, CW
   Hsu, CH
AF Kuo, Hui-Ming
   Chen, Cheng-Wu
   Hsu, Chih-Hung
TI RETRACTED: A study of a B2C supporting interface design system for the
   elderly (Retracted article. See vol. 26, pg. 288, 2016)
SO HUMAN FACTORS AND ERGONOMICS IN MANUFACTURING & SERVICE INDUSTRIES
LA English
DT Article; Retracted Publication
DE Elderly; Internet shopping; Supporting interface design system (SIDS);
   Mental workload
ID INFORMATION
AB People are now living longer because of advances in medical science, resulting in the percentage of the elderly in the population increasing year by year. These older individuals cannot move about like youngsters do. Internet shopping could become one of the most important shopping channels for them. According to related domestic and foreign survey results, this is confirmed by the increased percentage of elderly Internet shoppers. A lot of consumers, however, are still not satisfied with their Internet shopping experiences. Many have had the experience of giving up before completing the purchasing procedure. The key factors included in such procedures are rather complex, and user interfaces are not necessarily well-designed. Nowadays, most websites are still designed for the convenience of the seller instead of the consumers. Often consumers find that their interfaces are complex and hard to use and that they require a high mental workload. Based on the behavioral model of older Internet consumers and difficulties they have encountered, and after exploring the information provided by shopping websites and evaluating the status of their current interface design, this study proposes an example of a supporting interface design system (SIDS) for the elderly. The effects of the SIDS are verified experimentally. A total of 12 subjects participated in the experiment. The results showed that the SIDS could successfully reduce the time spent by the elderly subjects on inputting data during the shopping process and the number of repetitions and the time spent on searching for, examining, and comparing products. Furthermore, it was also helpful to reduce the mental workload caused by Internet shopping. (c) 2012 Wiley Periodicals, Inc.
C1 [Chen, Cheng-Wu] Natl Kaohsiung Marine Univ, Inst Maritime Informat & Technol, Kaohsiung 80543, Taiwan.
   [Kuo, Hui-Ming] Shu Te Univ, Dept Logist Management, Yen Chau 82445, Kaohsiung Count, Taiwan.
   [Chen, Cheng-Wu] Natl Cheng Kung Univ, Global Earth Observat & Data Anal Ctr, Tainan 701, Taiwan.
   [Hsu, Chih-Hung] Hsiuping Inst Technol, Inst Lean Prod Management, Dali 412, Taichung County, Taiwan.
RP Chen, CW (reprint author), Natl Kaohsiung Marine Univ, Inst Maritime Informat & Technol, Kaohsiung 80543, Taiwan.
EM chengwu@mail.nkmu.edu.tw
FU National Science Council of Taiwan, R.O.C. [NSC 98-2221-E-366-003, NSC
   98-2221-E-366-006-MY2]
FX We acknowledge the financial support from the National Science Council
   of Taiwan, R.O.C., under project numbers NSC 98-2221-E-366-003 and NSC
   98-2221-E-366-006-MY2. The authors are also grateful for the assistance
   of Professor Waldemar Karwowski, Chief Editor of Human Factors and
   Ergonomics in Manufacturing & Service Industries, and the constructive
   suggestions of the anonymous reviewers, all of which have led to the
   making of several corrections and suggestions that have greatly aided us
   in the presentation of this article.
CR Chen H. I., 2005, ANAL TAIWAN INTERNET
   Chen H. I., 2005, DEV TRENDS US INTERN
   CHEN HI, 2005, DEV TRENDS W EUROPE
   Czaja S. J., 1997, HDB HUMAN COMPUTER I
   Huang MH, 2000, INT J INFORM MANAGE, V20, P337, DOI 10.1016/S0268-4012(00)00027-X
   Kelly C. L., 1999, BEHAV INFORM TECHNOL, V14, P107
   Kuo HM, 2009, IN C IND ENG ENG MAN, P852, DOI 10.1109/IEEM.2009.5372897
   Kuo H. M., 2007, J ERGONOMIC STUDY, V9, P45
   Kuo H. M., 2009, J INFORM OPTIMIZATIO, V30, P447
   Kuo H. M., 2010, INT J RES SURVEYS IC, V4, P615
   KUO HM, 2005, J ERGONOMICS STUDIES, V7, P9
   Kuo HM, 2010, INT J INNOV COMPUT I, V6, P3507
   Lee Y. P., 2003, FAMILY NETWORK APPL
   Lu P. H., 2003, THESIS I SHOU U KAOH
   Park D. C., 2000, COGNITIVE AGING PRIM, P3, DOI [DOI 10.1186/S12883-015-0454-6, 10.1186/S12883-015-0454-6]
   Wang E. M., 2005, MODERN IND ENG INNOV, P694
   Wang M. Y., 2005, J CHINESE I IND ENG, V22, P379
NR 17
TC 28
Z9 29
U1 3
U2 39
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1090-8471
EI 1520-6564
J9 HUM FACTOR ERGON MAN
JI Hum. Factors Ergonom. Manuf. Serv. Ind.
PD NOV-DEC
PY 2012
VL 22
IS 6
BP 528
EP 540
DI 10.1002/hfm.20297
PG 13
WC Engineering, Manufacturing; Ergonomics
SC Engineering
GA 019QI
UT WOS:000309754000005
DA 2018-12-27
ER

PT J
AU Huang, PH
   Chen, CY
   Chang, CJ
   Lo, DC
   Huang, CC
AF Huang, Po-Hsuan
   Chen, Chen-Yuan
   Chang, Chin-Jui
   Lo, D. C.
   Huang, Cheng-Chieh
TI RETRACTED: Computer-aided ergonomics and visualization for improving 3D
   display techniques (Retracted article. See vol. 26, pg. 289, 2016)
SO HUMAN FACTORS AND ERGONOMICS IN MANUFACTURING & SERVICE INDUSTRIES
LA English
DT Article; Retracted Publication
DE Three-dimensional (3D) display; Flash; Filter glasses; Ergonomics;
   Visualization
ID NONLINEAR STRUCTURAL SYSTEMS; FUZZY LYAPUNOV METHOD; STABILITY ANALYSIS;
   IEEE 802.15.4; TIME-DELAY; MODEL; PERFORMANCE; ROBOT
AB Although there have been numerous studies regarding three-dimensional (3D) display techniques and Flash technology, there has been little discussion of how to apply the 3D display technique to Flash applications. In this study, we develop a method that uses passive 3D display glasses, which are cheaper than other 3D display techniques, to reduce the cost and popularize this technique for web applications. The 3D red-blue filter glasses are inexpensive and can be manufactured easily. We also look at how to construct a Flash game and test its 3D effects using the red-blue filter glasses. (c) 2012 Wiley Periodicals, Inc.
C1 [Chen, Chen-Yuan; Huang, Cheng-Chieh] Natl Pingtung Univ Educ, Dept & Grad Sch Comp Sci, Pingtung 90003, Taiwan.
   [Huang, Po-Hsuan] Natl Cent Univ, Dept Comp Sci & Informat Engn, Jhongli 32001, Taoyuan County, Taiwan.
   [Chen, Chen-Yuan] Natl Cheng Kung Univ, Global Earth Observat & Data Anal Ctr GEODAC, Tainan 701, Taiwan.
   [Chen, Chen-Yuan] Natl Kaohsiung First Univ Sci & Technol, Dept Informat Management, Kaohsiung 811, Taiwan.
   [Chang, Chin-Jui] Transworld Univ, Dept Informat Management, Touliu 64063, Yunlin, Taiwan.
   [Lo, D. C.] Natl Kaohsiung Marine Univ, Inst Maritime Informat & Technol, Kaohsiung 80543, Taiwan.
RP Chen, CY (reprint author), Natl Pingtung Univ Educ, Dept & Grad Sch Comp Sci, 4-18 Ming Shen Rd, Pingtung 90003, Taiwan.
EM cyc@mail.npue.edu.tw
FU National Science Council, Republic of China [NSC 99-2628-E-153-001, NSC
   100-2628-E-153-001]
FX We appreciate the financial support in the form of research grants to
   Chen-Yuan Chen from the National Science Council, Republic of China
   (Grant Nos. NSC 99-2628-E-153-001, and NSC 100-2628-E-153-001). We are
   also grateful for the assistance of the Editor of Human Factors and
   Ergonomics in Manufacturing & Service Industries and for the
   constructive suggestions from the anonymous reviewers, all of which have
   led to the making of several corrections and have greatly aided us in
   improving this article.
CR [Anonymous], 2009, BIOANALYSIS, V1, P514
   Chang BW, 2010, INT J RADIAT ONCOL, V78, pS314, DOI 10.1016/j.ijrobp.2010.07.745
   Chen CW, 2011, J VIB CONTROL, V17, P1241, DOI [10.1177/1077546309352827, 10.1177/10775463093S2827]
   Chen CY, 2012, J VIB CONTROL, V18, P417, DOI 10.1177/1077546310395971
   Chen CY, 2012, J VIB CONTROL, V18, P973, DOI 10.1177/1077546310395974
   Chen CY, 2012, J VIB CONTROL, V18, P983, DOI 10.1177/1077546310397561
   Chen CY, 2011, INT J INNOV COMPUT I, V7, P5245
   Chen CY, 2011, J MAR SCI TECH-JAPAN, V16, P100, DOI 10.1007/s00773-010-0112-z
   Chen CW, 2007, INT J ARTIF INTELL T, V16, P545, DOI 10.1142/S0218213007003400
   Chen CW, 2007, J VIB CONTROL, V13, P1519, DOI 10.1177/1077546307073690
   Chen CW, 2007, ENG COMPUTATION, V24, P116, DOI 10.1108/02644400710729536
   Chen CW, 2011, J VIB CONTROL, V17, P1693, DOI 10.1177/1077546310379625
   Chen CW, 2010, MATH PROBL ENG, DOI 10.1155/2010/120403
   Chen CW, 2011, NEURAL COMPUT APPL, V20, P527, DOI 10.1007/s00521-011-0576-8
   Chen CW, 2011, APPL SOFT COMPUT, V11, P2735, DOI 10.1016/j.asoc.2010.11.004
   Chen CW, 2010, J MAR SCI TECH-TAIW, V18, P644
   Chen CW, 2010, J VIB CONTROL, V16, P1651, DOI 10.1177/1077546309104185
   Chen CW, 2010, ENG COMPUTATION, V27, P186, DOI 10.1108/02644401011022364
   Chen CW, 2010, INT J INNOV COMPUT I, V6, P1793
   Chen CW, 2009, MATH COMPUT SIMULAT, V80, P402, DOI 10.1016/j.matcom.2009.08.001
   Chen CW, 2009, INT J UNCERTAIN FUZZ, V17, P705, DOI 10.1142/S0218488509006224
   Chen CW, 2009, INT J UNCERTAIN FUZZ, V17, P667, DOI 10.1142/S0218488509006200
   Chen CW, 2009, EXPERT SYST APPL, V36, P4765, DOI 10.1016/j.eswa.2008.06.062
   Chen CW, 2011, INT J PHYS SCI, V6, P4492
   Chen CW, 2011, INT J PHYS SCI, V6, P3585
   Chen L, 2010, NEUROUROL URODYNAM, V29, P822
   Gerantabee F., 2008, FLASH CS4 PROFESSION
   Gillespie T, 2000, LIBR J, V125, P125
   Hurwicz M, 2002, COMPUT GRAPH WORLD, V25, P62
   Louis N, 2010, EUR J VASC ENDOVASC, V40, P340, DOI 10.1016/j.ejvs.2010.05.019
   Shih BY, 2012, J VIB CONTROL, V18, P859, DOI 10.1177/1077546311407649
   Shih BY, 2011, J VIB CONTROL, V17, P1567, DOI 10.1177/1077546310372004
   Shih BY, 2013, COMPUT APPL ENG EDUC, V21, P343, DOI 10.1002/cae.20478
   Shih BY, 2010, INT J INNOV COMPUT I, V6, P5511
   Shih BY, 2010, INT J PHYS SCI, V5, P884
   Shih BY, 2011, SCI RES ESSAYS, V6, P5342
   Shih BY, 2011, INT J PHYS SCI, V6, P5054
   Shih CH, 2011, INT J INNOV COMPUT I, V7, P2225
   Shih CH, 2010, MATH PROBL ENG, DOI 10.1155/2010/481438
   Wan-I Lee, 2012, Human Factors and Ergonomics in Manufacturing, V22, P188, DOI 10.1002/hfm.20272
   Yang J, 2005, WORLD WIDE WEB, V8, P495, DOI 10.1007/s11280-005-0905-x
NR 41
TC 13
Z9 13
U1 2
U2 21
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1090-8471
EI 1520-6564
J9 HUM FACTOR ERGON MAN
JI Hum. Factors Ergonom. Manuf. Serv. Ind.
PD NOV-DEC
PY 2012
VL 22
IS 6
BP 556
EP 561
DI 10.1002/hfm.20298
PG 6
WC Engineering, Manufacturing; Ergonomics
SC Engineering
GA 019QI
UT WOS:000309754000007
DA 2018-12-27
ER

PT J
AU Yue, C
   Yan, ZJ
   Wu, KR
   Su, XJ
   Hu, JS
   Ma, JW
   Guo, CM
   Fang, HW
   Su, R
   Zhang, Y
   Zhang, QH
AF Yue, Cheng
   Yan Ze-jun
   Wu, Ke-rong
   Su, Xin-jun
   Hu, Jia-sheng
   Ma, Jian-wei
   Guo, Chuan-min
   Fang, Hai-wei
   Su, Rui
   Zhang, Yao
   Zhang, Qing-hua
TI RETRACTED: A Randomized Clinical Study of Circumcision with a Ring
   Device Versus Conventional Circumcision (Retracted article. See vol.
   188, pg. 2443, 2012)
SO JOURNAL OF UROLOGY
LA English
DT Article; Retracted Publication
DE penis; circumcision, male; equipment and supplies; complications;
   patient safety
ID HIV PREVENTION; KENYAN MEN; TRIAL; AFRICA
AB Purpose: We investigated the safety and efficacy of Shang Ring T male circumcision and conventional sleeve resection circumcision in a randomized study.
   Materials and Methods: During the same period, 479 cases of Shang Ring circumcision and 354 of sleeve resection circumcision were performed. Complete followup data were evaluated on the 2 groups. Operative time, pain score, blood loss, postoperative complications, wound healing time and treatment costs were compared.
   Results: There was no statistically significant difference in average age and foreskin status between the 2 groups preoperatively (p > 0.05). Compared to the conventional group, there were shorter operative time, less blood loss and a lower intraoperative pain score in the ring group (p < 0.05). In addition, ring male circumcision showed a lower complication rate than conventional circumcision (6.89% vs 13.28%, p = 0.002). However, wound healing time in the ring group was longer than in the conventional group (mean +/- SD 19.86 +/- 5.24 vs 13.42 +/- 2.35 days, p < 0.001).
   Conclusions: Shang Ring male circumcision is a safe, efficient procedure with a relatively low complication rate and high patient satisfaction. It may be worthwhile to popularize this method, especially in countries where the general population has low to limited resources.
C1 [Yue, Cheng; Yan Ze-jun; Wu, Ke-rong; Su, Xin-jun; Hu, Jia-sheng; Ma, Jian-wei; Guo, Chuan-min; Fang, Hai-wei; Su, Rui] Ningbo Univ, Coll Med, Hosp 1, Dept Urol, Ningbo 315211, Zhejiang, Peoples R China.
   [Zhang, Yao] Cixi Tradit Chinese Med Hosp, Cixi, Peoples R China.
   [Zhang, Qing-hua] Taizhou First Peoples Hosp, Taizhou, Peoples R China.
RP Yue, C (reprint author), Ningbo Univ, Coll Med, Hosp 1, Dept Urol, Ningbo 315211, Zhejiang, Peoples R China.
EM dongbaba2@hotmail.com
FU Ningbo Rural Innovation and Development Fund [2011C91028]
FX Supported by the Ningbo Rural Innovation and Development Fund
   (2011C91028).
CR Auvert B, 2005, PLOS MED, V2, P1112, DOI 10.1371/journal.pmed.0020298
   Bailey RC, 2007, LANCET, V369, P643, DOI 10.1016/S0140-6736(07)60312-2
   Barone MA, 2011, JAIDS-J ACQ IMM DEF, V57, pE7, DOI 10.1097/QAI.0b013e3182158967
   Bhan Anant, 2009, Indian J Med Ethics, V6, P169
   Cheng Yue, 2009, Zhonghua Nan Ke Xue, V15, P584
   Dunsmuir WD, 1999, BJU INT, V83, P1, DOI 10.1046/j.1464-410x.1999.0830s1001.x
   Gray RH, 2007, LANCET, V369, P657, DOI 10.1016/S0140-6736(07)60313-4
   Hargreave T, 2010, ASIAN J ANDROL, V12, P628, DOI 10.1038/aja.2010.59
   Hirbod T, 2010, AM J PATHOL, V176, P2798, DOI 10.2353/ajpath.2010.090926
   Hughes KH, 2007, ISSUES SCI TECHNOL, V23, P13
   Lagarde E, 2009, SAMJ S AFR MED J, V99, P163
   Masson P, 2010, NAT REV UROL, V7, P638, DOI 10.1038/nrurol.2010.167
   Musau P, 2011, J UROLOGY, V186, P1923, DOI 10.1016/j.juro.2011.07.027
   Peng YF, 2008, ASIAN J ANDROL, V10, P447, DOI 10.1111/j.1745-7262.2008.00411.x
   Williams BG, 2006, PLOS MED, V3, P1032, DOI 10.1371/journal.pmed.0030262
   Yue CPL, 2010, SURG TRAINING MANUAL
NR 16
TC 9
Z9 10
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0022-5347
EI 1527-3792
J9 J UROLOGY
JI J. Urol.
PD NOV
PY 2012
VL 188
IS 5
BP 1849
EP 1854
DI 10.1016/j.juro.2012.07.048
PG 6
WC Urology & Nephrology
SC Urology & Nephrology
GA 028QY
UT WOS:000310438600063
PM 22999700
DA 2018-12-27
ER

PT J
AU Chirica, I
   Beznea, EF
AF Chirica, Ionel
   Beznea, Elena-Felicia
TI RETRACTED: Buckling behavior of the multiple delaminated composite
   plates under shear and axial compression (Retracted article. See vol.
   109, pg. 400, 2015)
SO COMPUTATIONAL MATERIALS SCIENCE
LA English
DT Article; Proceedings Paper; Retracted Publication
CT 21st International Workshop on Computational Mechanics of Materials
   (IWCMM)
CY AUG 22-24, 2011
CL Univ Limerick, Limerick, IRELAND
HO Univ Limerick
DE Composite laminated plates; Double delamination; Shear and axial
   buckling
ID INPLANE SHEAR; PANELS; WIDTH; LOAD
AB In the paper, a methodology to evaluate the influence of the double delaminations on the buckling and postbuckling behavior of the composite plates under shear and compression loading, used in ship hull structure, is presented. The parametric calculus was done for various positions of delaminations and seven values of loading ratios. The numerical and experimental tests on the delaminated plates are presented. Composite plates containing a multiple number of delaminations are analyzed with respect to combined boundary shear and axial compression buckling. Finally, the graphical results for one position of the delamination through the thickness and two cases of position of delaminations in the case of double delaminated plate and seven values of loading ratio are presented. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Chirica, Ionel; Beznea, Elena-Felicia] Dunarea de Jos Univ Galati, Galati 800008, Romania.
RP Chirica, I (reprint author), Dunarea de Jos Univ Galati, 47 Domneasca Str, Galati 800008, Romania.
EM ionel.chirica@ugal.ro
CR Adams D.F., 2003, EXPT CHARCTERIZATION
   Altenbach H., 2001, MECH COMPOSITE STRUC
   Ambarcumyan S. A., 1991, THEORY ANISOTROPIC P
   Beznea EF, 2011, ADVANCES IN COMPOSITE MATERIALS - ECODESIGN AND ANALYSIS, P383
   Cappello F, 2006, COMPOS SCI TECHNOL, V66, P264, DOI [10.1016/j.compscitech.2005.04.036, 10.1016/i.compscitech.2005.04.036]
   Clouston P., 1998, J MATER CIVIL ENG, P112
   GRENESTEDT JL, 1991, STRUCT OPTIMIZATION, V3, P115, DOI 10.1007/BF01743281
   Han SC, 2006, INT J SOLIDS STRUCT, V43, P5713, DOI 10.1016/j.ijsolstr.2005.08.004
   Huang HY, 1998, INT J SOLIDS STRUCT, V35, P1355, DOI 10.1016/S0020-7683(97)00110-8
   Hwang SF, 2001, COMPOS STRUCT, V53, P235, DOI 10.1016/S0263-8223(01)00007-1
   Kassapoglou C., 2010, DESIGN ANAL COMPOSIT
   Kharazi M, 2008, THIN WALL STRUCT, V46, P939, DOI 10.1016/j.tws.2008.01.005
   Kharazi M., 2008, JAST, V5, P13
   Loughlan J, 1999, THIN WALL STRUCT, V34, P97, DOI 10.1016/S0263-8231(99)00009-9
   Mallela UK, 2006, THIN WALL STRUCT, V44, P354, DOI 10.1016/j.tws.2006.03.008
   Manshadi BD, 2011, J COMPOS CONSTR, V15, P431, DOI 10.1061/(ASCE)CC.1943-5614.0000167
   Ovesy HR, 2011, J ENG MECH-ASCE, V137, P87, DOI 10.1061/(ASCE)EM.1943-7889.0000205
   Papadopoulos L, 2007, COMPOS PART A-APPL S, V38, P1425, DOI 10.1016/j.compositesa.2006.05.008
   Park D.Y., 2006, KSCE J CIV ENG, V10, P17
   ROTHWELL A, 1980, J STRAIN ANAL ENG, V15, P209, DOI 10.1243/03093247V154209
   Sadowski T, 2012, COMP MATER SCI, V52, P231, DOI 10.1016/j.commatsci.2010.12.016
   Sadowski T, 2009, COMP MATER SCI, V46, P687, DOI 10.1016/j.commatsci.2009.06.006
   Stan F, 2011, MATER PLAST, V48, P1
   Thurley G.J., 1995, BUCKLING POSTBUCKLIN
   Tsai SW, 1980, INTRO COMPOSITE MAT
   Zor M, 2009, J REINF PLAST COMP, V28, P305, DOI 10.1177/0731684407084244
NR 26
TC 16
Z9 16
U1 2
U2 20
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0927-0256
EI 1879-0801
J9 COMP MATER SCI
JI Comput. Mater. Sci.
PD NOV
PY 2012
VL 64
BP 173
EP 178
DI 10.1016/j.commatsci.2012.03.032
PG 6
WC Materials Science, Multidisciplinary
SC Materials Science
GA 000OO
UT WOS:000308396200036
DA 2018-12-27
ER

PT J
AU Grabowska, E
   Reszczynska, J
   Zaleska, A
AF Grabowska, Ewelina
   Reszczynska, Joanna
   Zaleska, Adriana
TI RETRACTED: Mechanism of phenol photodegradation in the presence of pure
   and modified-TiO2: A review (Retracted article. See vol. 135, pg. 331,
   2018)
SO WATER RESEARCH
LA English
DT Review; Retracted Publication
DE Phenol; Heterogeneous photocatalysis; TiO2; Doped-TiO2; Intermediate
   products; OH radicals
ID PHOTOCATALYTIC WATER-TREATMENT; QUANTUM YIELD; FORMALDEHYDE FORMATION;
   SOLAR PHOTOCATALYSIS; PHOTONIC EFFICIENCY; TIO2 PHOTOCATALYSTS;
   AQUEOUS-SOLUTIONS; DEGRADATION; OXIDATION; KINETICS
AB In recent years, the application of heterogeneous photocatalytic water purification processes has gained wide attention due to its effectiveness in degrading and mineralizing the recalcitrant organic compounds as well as the possibility of utilizing the solar UV and visible-light spectrum. By far, titania has played a much larger role in this scenario compared to other semiconductor photocatalysts due to its costly effectiveness, inert nature and photostability. A substantial amount of research has focused on the enhancement of TiO2 photocatalysis by modification with metal, non-metal and ion doping.
   This paper aims to review and summarize the recent works on the titanium dioxide (TiO2) photocatalytic oxidation of phenol and discusses various mechanisms of phenol photodegradation (indicating the intermediates products) and formation of OH radicals. Phenol degradation pathway in both systems, TiO2/UV and doped-TiO2/Vis, are described. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Grabowska, Ewelina; Reszczynska, Joanna; Zaleska, Adriana] Gdansk Univ Technol, Dept Chem Technol, PL-80233 Gdansk, Poland.
RP Grabowska, E (reprint author), Gdansk Univ Technol, Dept Chem Technol, G Narutowicza 11-12, PL-80233 Gdansk, Poland.
EM egrab@chem.pg.gda.pl
CR Ahmaruzzaman M, 2008, ADV COLLOID INTERFAC, V143, P48, DOI 10.1016/j.cis.2008.07.002
   Arques A, 2007, J HAZARD MATER, V146, P447, DOI 10.1016/j.jhazmat.2007.04.046
   Asahi R, 2001, SCIENCE, V293, P269, DOI 10.1126/science.1061051
   Bahnemann D, 2004, SOL ENERGY, V77, P445, DOI 10.1016/j.solener.2004.03.031
   Bekkouche S, 2004, DESALINATION, V166, P355, DOI 10.1016/j.desal.2004.06.090
   Calace N, 2002, ENVIRON POLLUT, V118, P315, DOI 10.1016/S0269-7491(01)00303-7
   Chen DW, 1999, APPL CATAL B-ENVIRON, V23, P143, DOI 10.1016/S0926-3373(99)00068-5
   Chong MN, 2010, WATER RES, V44, P2997, DOI 10.1016/j.watres.2010.02.039
   Devi LG, 2011, J MOL CATAL A-CHEM, V334, P65, DOI 10.1016/j.molcata.2010.10.025
   Esswein AJ, 2007, CHEM REV, V107, P4022, DOI 10.1021/cr050193e
   Friedmann D, 2010, APPL CATAL B-ENVIRON, V99, P398, DOI 10.1016/j.apcatb.2010.05.014
   Fujishima A., 2000, J PHOTOCH PHOTOBIO C, V1, P1, DOI DOI 10.1016/S1389-5567(00)00002-2
   Gaya UI, 2008, J PHOTOCH PHOTOBIO C, V9, P1, DOI 10.1016/j.jphotochemrev.2007.12.003
   Gorska P, 2009, SEP PURIF TECHNOL, V68, P90, DOI 10.1016/j.seppur.2009.04.012
   Grabowska E., 2012, APPL CATAL B-ENVIRON, P117
   Grabowska E, 2012, APPL CATAL B-ENVIRON, V117, P351, DOI 10.1016/j.apcatb.2012.02.003
   Guo ZF, 2006, CHEM ENG J, V119, P55, DOI 10.1016/j.cej.2006.01.017
   He Feng, 2004, J Zhejiang Univ Sci, V5, P198, DOI 10.1631/jzus.2004.0198
   Herrmann JM, 2005, TOP CATAL, V34, P49, DOI 10.1007/s11244-005-3788-2
   HOFFMANN MR, 1995, CHEM REV, V95, P69, DOI 10.1021/cr00033a004
   Ihara T, 2003, APPL CATAL B-ENVIRON, V42, P403, DOI 10.1016/S0926-3373(02)00269-2
   Irie H, 2003, J PHYS CHEM B, V107, P5483, DOI 10.1021/jp030133h
   Kudo A, 2009, CHEM SOC REV, V38, P253, DOI 10.1039/b800489g
   Leary R, 2011, CARBON, V49, P741, DOI 10.1016/j.carbon.2010.10.010
   Louit G, 2005, RADIAT PHYS CHEM, V72, P119, DOI 10.1016/j.radphyschem.2004.09.007
   Malato S, 2009, CATAL TODAY, V147, P1, DOI 10.1016/j.cattod.2009.06.018
   Neamtu M, 2003, J PHOTOCH PHOTOBIO A, V161, P87, DOI 10.1016/S1010-6030(03)00270-3
   OKAMOTO K, 1985, B CHEM SOC JPN, V58, P2023, DOI 10.1246/bcsj.58.2023
   Parkin IP, 2005, J MATER CHEM, V15, P1689, DOI 10.1039/b412803f
   Peiro AM, 2001, APPL CATAL B-ENVIRON, V30, P359, DOI 10.1016/S0926-3373(00)00248-4
   Pera-Titus M, 2004, APPL CATAL B-ENVIRON, V47, P219, DOI 10.1016/j.apcatb.2003.09.010
   Pirkanniemi K, 2002, CHEMOSPHERE, V48, P1047, DOI 10.1016/S0045-6535(02)00168-6
   Rodriguez I, 2000, J CHROMATOGR A, V885, P291, DOI 10.1016/S0021-9673(00)00116-3
   Roy SC, 2010, ACS NANO, V4, P1259, DOI 10.1021/nn9015423
   Santos A, 2002, APPL CATAL B-ENVIRON, V39, P97, DOI 10.1016/S0926-3373(02)00087-5
   Sobczynski A, 2004, J MOL CATAL A-CHEM, V213, P225, DOI 10.1016/j.molcata.2003.12.006
   Sopyan I, 2011, INDIAN J CHEM TECHN, V18, P263
   Stroyuk AL, 2009, THEOR EXP CHEM+, V45, P209, DOI 10.1007/s11237-009-9095-4
   Sun LZ, 1996, J PHYS CHEM-US, V100, P4127, DOI 10.1021/jp9505800
   Thiruvenkatachari R, 2008, KOREAN J CHEM ENG, V25, P64, DOI 10.1007/s11814-008-0011-8
   Tryba B, 2006, J PHOTOCH PHOTOBIO A, V179, P224, DOI 10.1016/j.jphotochem.2005.08.019
   Tryba B, 2006, APPL CATAL B-ENVIRON, V63, P215, DOI 10.1016/j.apcatb.2005.09.011
   Tryba B, 2007, APPL CATAL B-ENVIRON, V71, P163, DOI 10.1016/j.apcatb.2005.12.036
   Wang C, 2001, WATER SCI TECHNOL, V44, P279
   Wang CY, 2002, J PHOTOCH PHOTOBIO A, V148, P169, DOI 10.1016/S1010-6030(02)00087-4
   Zhao J, 2003, BUILD ENVIRON, V38, P645, DOI 10.1016/S0360-1323(02)00212-3
   Zhao XJ, 2008, J NON-CRYST SOLIDS, V354, P1424, DOI 10.1016/j.jnoncrysol.2006.10.093
NR 47
TC 209
Z9 217
U1 17
U2 445
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0043-1354
J9 WATER RES
JI Water Res.
PD NOV 1
PY 2012
VL 46
IS 17
BP 5453
EP 5471
DI 10.1016/j.watres.2012.07.048
PG 19
WC Engineering, Environmental; Environmental Sciences; Water Resources
SC Engineering; Environmental Sciences & Ecology; Water Resources
GA 013HS
UT WOS:000309297100001
PM 22921392
DA 2018-12-27
ER

PT J
AU Chen, J
   Liu, XY
   Zhang, J
   Zhao, YR
AF Chen, Jie
   Liu, Xiaoyan
   Zhang, Jie
   Zhao, Yueran
TI RETRACTED: Targeting HMGB1 inhibits ovarian cancer growth and metastasis
   by lentivirus-mediated RNA interference (Retracted article. See vol.
   230, pg. 2579, 2015)
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article; Retracted Publication
ID MOBILITY GROUP BOX-1; GLYCATION END-PRODUCTS; TUMOR PROGRESSION;
   GASTRIC-CANCER; EXPRESSION; RAGE; CELLS; CARCINOMA; RECEPTOR;
   INFLAMMATION
AB High-mobility group box 1 (HMGB1), a nuclear and extracellular protein, is implicated in the development and progression of some types of cancers. However, no information is available to date regarding the function of HMGB1 in ovarian cancer. In this study, we performed cDNA microarray analysis and identified HMGB1 as a gene dramatically elevated in the highly invasive subclone S1 compared with the low invasive subclone S21 derived from the same cell line SKOV3. Then lentivirus vector with HMGB1 shRNA was constructed and infected the highly invasive cell line S1, A1, and HO8910PM. Real-time RT-PCR, Western blot, and IHC results confirmed the down-regulation of HMGB1 expression by its shRNA was about 80-90% at both the mRNA and protein levels. Knockdown of HMGB1 significantly suppressed ovarian cancer cell proliferation and induced cell cycle arrest at the G1/G0 phase, which was accompanied by decreased expressions of cyclin D1 and PCNA. Furthermore, knockdown of HMGB1 induced ovarian cancer cell apoptosis, which was mediated by increased expression of Bax and decreased expression of Bcl-2. Finally, knockdown of HMGB1 significantly inhibited ovarian cancer cell invasion and metastasis, which was regulated by decreased expressions of MMP2 and MMP9. Serum HMGB1 levels in patients with epithelial ovarian cancer were significantly higher than that in patients with benign ovarian tumor and healthy controls. These results indicate that HMGB1 is a newly identified gene associated with ovarian cancer growth and metastasis. HMGB1 may serve as a new therapeutic target for the treatment of ovarian cancer in the future. J. Cell. Physiol. 227: 36293638, 2012. (C) 2012 Wiley Periodicals, Inc.
C1 [Zhang, Jie; Zhao, Yueran] Shandong Univ, Cent Lab, Shandong Prov Hosp, Jinan 250021, Peoples R China.
   [Chen, Jie] Shandong Univ, Dept Maternal & Child Hlth Care, Sch Publ Hlth, Jinan 250021, Peoples R China.
   [Liu, Xiaoyan] Shandong Univ, Dept Obstet & Gynecol, Qilu Hosp, Jinan 250021, Peoples R China.
RP Zhang, J (reprint author), Shandong Univ, Cent Lab, Shandong Prov Hosp, Jinan 250021, Peoples R China.
EM zhangjie19630711@163.com; yrzhao@sdu.edu.cn
FU Department of Science and Technology of Shandong Province [2007BS03025]
FX Contract grant sponsor: Department of Science and Technology of Shandong
   Province;; Contract grant number: 2007BS03025.
CR Akaike H, 2007, ANTICANCER RES, V27, P449
   ALBINI A, 1987, CANCER RES, V47, P3239
   Bao GQ, 2010, WORLD J SURG ONCOL, V8, DOI 10.1186/1477-7819-8-52
   Bast RC, 2009, NAT REV CANCER, V9, P415, DOI 10.1038/nrc2644
   Bauvois B, 2012, BBA-REV CANCER, V1825, P29, DOI 10.1016/j.bbcan.2011.10.001
   BERNUES J, 1986, BIOCHIM BIOPHYS ACTA, V866, P242, DOI 10.1016/0167-4781(86)90049-7
   Bourboulia D, 2010, SEMIN CANCER BIOL, V20, P161, DOI 10.1016/j.semcancer.2010.05.002
   Brezniceanu ML, 2003, FASEB J, V17, P1295, DOI 10.1096/fj.02-0621fje
   Brun JL, 2000, GYNECOL ONCOL, V78, P21, DOI 10.1006/gyno.2000.5805
   Campana L, 2008, CURR OPIN IMMUNOL, V20, P518, DOI 10.1016/j.coi.2008.04.012
   Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543
   Chen J, 2009, J CANCER RES CLIN, V135, P909, DOI 10.1007/s00432-008-0526-8
   Cho KR, 2009, ANNU REV PATHOL-MECH, V4, P287, DOI 10.1146/annurev.pathol.4.110807.092246
   Chung HW, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-38
   Dumitriu IE, 2005, J IMMUNOL, V174, P7506, DOI 10.4049/jimmunol.174.12.7506
   Ellerman JE, 2007, CLIN CANCER RES, V13, P2836, DOI 10.1158/1078-0432.CCR-06-1953
   GE H, 1994, J BIOL CHEM, V269, P17136
   Gnanasekar M, 2009, INT J ONCOL, V34, P425, DOI 10.3892/ijo_00000166
   Huang WC, 2010, CYTOKINE, V51, P119, DOI 10.1016/j.cyto.2010.02.021
   Ishiguro H, 2005, PROSTATE, V64, P92, DOI 10.1002/pros.20219
   Ito N, 2007, J LEUKOCYTE BIOL, V81, P75, DOI 10.1189/jlb.0306169
   Jemal A, 2010, CA-CANCER J CLIN, V60, P277, DOI [10.1002/caac.20073, 10.3322/caac.20073]
   Kelly PN, 2011, CELL DEATH DIFFER, V18, P1414, DOI 10.1038/cdd.2011.17
   Leclerc E, 2009, REV NEUROSCIENCE, V20, P95
   Liu PL, 2010, AM J RESP CELL MOL, V43, P530, DOI 10.1165/rcmb.2009-0269OC
   Naryzhny SN, 2008, CELL MOL LIFE SCI, V65, P3789, DOI 10.1007/s00018-008-8305-x
   Park S, 2011, FRONT BIOSCI-LANDMRK, V16, P486, DOI 10.2741/3700
   Shang GH, 2009, RESP MED, V103, P1949, DOI 10.1016/j.rmed.2009.05.019
   Sheng XG, 2009, CROAT MED J, V50, P455, DOI 10.3325/cmj.2009.50.455
   Shenhua X, 1999, J EXP CLIN CANC RES, V18, P233
   Sims GP, 2010, ANNU REV IMMUNOL, V28, P367, DOI 10.1146/annurev.immunol.021908.132603
   Song B., 2011, CELL BIOCH FUNCT
   Tafani M, 2011, CARCINOGENESIS, V32, P1167, DOI 10.1093/carcin/bgr101
   Taguchi A, 2000, NATURE, V405, P354
   Tang DL, 2010, BBA-GENE REGUL MECH, V1799, P131, DOI 10.1016/j.bbagrm.2009.11.014
   WEN L, 1989, NUCLEIC ACIDS RES, V17, P1197, DOI 10.1093/nar/17.3.1197
   Wu D, 2008, J PATHOL, V216, P167, DOI 10.1002/path.2391
   Yang H, 2010, BBA-GENE REGUL MECH, V1799, P149, DOI [10.1016/j.bbagrm.2009.11.049, 10.1016/j.bbagrm.2009.11.019]
   Yang L, 2011, LEUKEMIA LYMPHOMA, V53, P315
   Yao XJ, 2010, J CANCER RES CLIN, V136, P677, DOI 10.1007/s00432-009-0706-1
   Yu Yan, 2008, Ai Zheng, V27, P929
   Zhang LQ, 2011, CLIN LUNG CANC
NR 42
TC 27
Z9 33
U1 67
U2 88
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0021-9541
EI 1097-4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD NOV
PY 2012
VL 227
IS 11
BP 3629
EP 3638
DI 10.1002/jcp.24069
PG 10
WC Cell Biology; Physiology
SC Cell Biology; Physiology
GA 976UD
UT WOS:000306610200012
PM 22331597
DA 2018-12-27
ER

PT J
AU Baxi, SM
   Tan, W
   Murphy, ST
   Smeal, T
   Yin, MJ
AF Baxi, Sangita M.
   Tan, Wei
   Murphy, Sean T.
   Smeal, Tod
   Yin, Min-Jean
TI RETRACTED: Targeting 3-Phosphoinoside-Dependent Kinase-1 to Inhibit
   Insulin-Like Growth Factor-I Induced AKT and p70 S6 Kinase Activation in
   Breast Cancer Cells (Retracted article. See vol. 12, art no e0175772,
   2017)
SO PLOS ONE
LA English
DT Article; Retracted Publication
ID RECEPTOR; PDK1; METASTASIS; PHOSPHORYLATION; DOWNSTREAM; RESISTANCE;
   DISCOVERY; HERCEPTIN; SURVIVAL; INVASION
AB Binding of IGF to IGF-IR activates PI3K to generate PIP3 which in turn recruits and activates proteins that contain a pleckstrin homology (PH) domain, including AKT and PDK1. PDK1 is highly expressed in breast tumor samples and breast cancer cell lines. Here we demonstrate that targeting PDK1 with the potent and selective PDK1 inhibitor PF-5177624 in the IGF-PI3K pathway blocks breast cancer cell proliferation and transformation. Breast cancer cell lines MCF7 and T47D, representing the luminal ER positive subtype and harboring PIK3CA mutations, were most responsive to IGF-I induction resulting in upregulated AKT and p70S6K phosphorylation via PDK1 activation. PF-5177624 downregulated AKT and p70S6K phosphorylation, blocked cell cycle progression, and decreased cell proliferation and transformation to block IGFR-I induced activation in breast cancer cells. These results may provide insight into clinical strategies for developing an IGFR-I inhibitor and/or a PDK1 inhibitor in luminal breast cancer patients.
C1 [Baxi, Sangita M.; Tan, Wei; Smeal, Tod; Yin, Min-Jean] Pfizer Worldwide Res & Dev, Oncol Res, San Diego, CA USA.
   [Murphy, Sean T.] Pfizer Worldwide Res & Dev, Med Chem, San Diego, CA USA.
RP Yin, MJ (reprint author), Pfizer Worldwide Res & Dev, Oncol Res, San Diego, CA USA.
EM min-jean.yin@pfizer.com
RI Baxi, Sangita/K-6865-2016
CR Alberobello AT, 2010, J BIOL CHEM, V285, P6563, DOI 10.1074/jbc.M109.097410
   Bayascas JR, 2005, CURR BIOL, V15, P1839, DOI 10.1016/j.cub.2005.08.066
   Becker MA, 2011, MOL ENDOCRINOL, V25, P516, DOI 10.1210/me.2010-0373
   Bobkova EV, 2010, J BIOL CHEM, V285, P18838, DOI 10.1074/jbc.M109.089946
   Camirand A, 2005, BREAST CANCER RES, V7, pR570, DOI 10.1186/bcr1028
   Dunn SE, 1998, CANCER RES, V58, P3353
   Ellwood-Yen K, 2011, CANCER RES, V71, P3052, DOI 10.1158/0008-5472.CAN-10-2282
   Feldman RI, 2005, J BIOL CHEM, V280, P19867, DOI 10.1074/jbc.M501367200
   Flynn P, 2000, CURR BIOL, V10, P1439, DOI 10.1016/S0960-9822(00)00801-0
   Hankinson SE, 1998, LANCET, V351, P1393, DOI 10.1016/S0140-6736(97)10384-1
   Huang XP, 2010, CANCER RES, V70, P1204, DOI 10.1158/0008-5472.CAN-09-3321
   Jackson JG, 2001, ONCOGENE, V20, P7318, DOI 10.1038/sj.onc.1204920
   Jin Q, 2008, J MAMMARY GLAND BIOL, V13, P485, DOI 10.1007/s10911-008-9107-3
   Lann D, 2008, J MAMMARY GLAND BIOL, V13, P371, DOI 10.1007/s10911-008-9100-x
   Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042
   Lin HJ, 2005, BRIT J CANCER, V93, P1372, DOI 10.1038/sj.bjc.6602862
   Liu Y, 2009, MOL CANCER RES, V7, P944, DOI 10.1158/1541-7786.MCR-08-0368
   Lu YH, 2001, JNCI-J NATL CANCER I, V93, P1852, DOI 10.1093/jnci/93.24.1852
   Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009
   Maurer M, 2009, CANC RES
   Mora A, 2004, SEMIN CELL DEV BIOL, V15, P161, DOI 10.1016/j.semcdb.2003.12.022
   Murphy ST, 2011, J MED CHEM, V54, P8490, DOI 10.1021/jm201019k
   Nagashima K, 2011, J BIOL CHEM, V286, P6433, DOI 10.1074/jbc.M110.156463
   Nahta R, 2005, CANCER RES, V65, P11118, DOI 10.1158/0008-5472.CAN-04-3841
   Pollak M, 2008, NAT REV CANCER, V8, P915, DOI 10.1038/nrc2536
   Sachdev D, 2004, J BIOL CHEM, V279, P5017, DOI 10.1074/jbc.M305403200
   Sachdev D, 2010, ONCOGENE, V29, P251, DOI 10.1038/onc.2009.316
   Sachdev D, 2008, J MAMMARY GLAND BIOL, V13, P431, DOI 10.1007/s10911-008-9105-5
   Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148
   Vasudevan KM, 2009, CANCER CELL, V16, P21, DOI 10.1016/j.ccr.2009.04.012
   Werner Haim, 2009, Archives of Physiology and Biochemistry, V115, P58, DOI 10.1080/13813450902783106
   Wu JH, 2011, CANCER RES, V71, P2622, DOI 10.1158/0008-5472.CAN-10-3837
   Yee D, 2006, BRIT J CANCER, V94, P465, DOI 10.1038/sj.bjc.6602963
   Zeng X, 2002, CANCER RES, V62, P3538
NR 34
TC 12
Z9 13
U1 1
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 31
PY 2012
VL 7
IS 10
AR e48402
DI 10.1371/journal.pone.0048402
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 030WJ
UT WOS:000310600500124
PM 23119004
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Jeong, HJ
   Kim, DW
   Kim, MJ
   Woo, SJ
   Kim, HR
   Kim, SM
   Jo, HS
   Hwang, HS
   Kim, DS
   Cho, SW
   Won, MH
   Han, KH
   Park, J
   Eum, WS
   Choi, SY
AF Jeong, Hoon Jae
   Kim, Dae Won
   Kim, Mi Jin
   Woo, Su Jung
   Kim, Hye Ri
   Kim, So Mi
   Jo, Hyo Sang
   Hwang, Hyun Sook
   Kim, Duk-Soo
   Cho, Sung-Woo
   Won, Moo Ho
   Han, Kyu Hyung
   Park, Jinseu
   Eum, Won Sik
   Choi, Soo Young
TI RETRACTED: Protective effects of transduced Tat-DJ-1 protein against
   oxidative stress and ischemic brain injury (Retracted article. See vol.
   45, e24, 2013)
SO EXPERIMENTAL AND MOLECULAR MEDICINE
LA English
DT Article; Retracted Publication
DE brain ischemia; CA1 region; hippocampal; cell survival; neurons; PARK7
   protein; human; reactive oxygen species; toxicity
ID FOCAL CEREBRAL-ISCHEMIA; DISEASE GENE DJ-1; EFFICIENTLY PROTECTS;
   PARKINSONS-DISEASE; NEURONAL APOPTOSIS; FREE-RADICALS; DAMAGE;
   NEURODEGENERATION; REPERFUSION; TECHNOLOGY
AB Reactive oxygen species (ROS) contribute to the development of a number of neuronal diseases including ischemia. DJ-1, also known to PARK7, plays an important role in transcriptional regulation, acting as molecular chaperone and antioxidant. In the present study, we investigated whether DJ-1 protein shows a protective effect against oxidative stress-induced neuronal cell death in vitro and in ischemic animal models in vivo. To explore DJ-1 protein's potential role in protecting against ischemic cell death, we constructed cell permeable Tat-DJ-1 fusion proteins. Tat-DJ-1 protein efficiently transduced into neuronal cells in a dose-and time-dependent manner. Transduced Tat-DJ-1 protein increased cell survival against hydrogen peroxide (H2O2) toxicity and also reduced intracellular ROS. In addition, Tat-DJ-1 protein inhibited DNA fragmentation induced by H2O2. Furthermore, in animal models, immunohistochemical analysis revealed that Tat-DJ-1 protein prevented neuronal cell death induced by transient forebrain ischemia in the CA1 region of the hippocampus. These results demonstrate that transduced Tat-DJ-1 protein protects against cell death in vitro and in vivo, suggesting that the transduction of Tat-DJ-1 may be useful as a therapeutic agent for ischemic injuries related to oxidative stress.
C1 [Jeong, Hoon Jae; Kim, Dae Won; Kim, Mi Jin; Woo, Su Jung; Kim, Hye Ri; Kim, So Mi; Jo, Hyo Sang; Hwang, Hyun Sook; Han, Kyu Hyung; Park, Jinseu; Eum, Won Sik; Choi, Soo Young] Hallym Univ, Res Inst Biosci & Biotechnol, Dept Biomed Sci, Chunchon 200702, South Korea.
   [Kim, Duk-Soo] Soonchunhyang Univ, Coll Med, Dept Anat, Cheonan 330090, South Korea.
   [Cho, Sung-Woo] Univ Ulsan, Coll Med, Dept Biochem & Mol Biol, Seoul 138736, South Korea.
   [Won, Moo Ho] Kangwon Natl Univ, Sch Med, Dept Neurobiol, Chunchon 200701, South Korea.
RP Eum, WS (reprint author), Hallym Univ, Res Inst Biosci & Biotechnol, Dept Biomed Sci, Chunchon 200702, South Korea.
EM wseum@hallym.ac.kr; sychoi@hallym.ac.kr
FU Brain Research Center [2010K000808]; National Research Foundation
   [2012-0006695]; Ministry of Education, Science and Technology, Korea
FX This work was supported by a research grant from the Brain Research
   Center of the 21st Century Frontier Research Program (2010K000808) and
   in part by a Priority Research Centers Program grant (2012-0006695)
   through the National Research Foundation funded by the Ministry of
   Education, Science and Technology, Korea.
CR Alexandrova M, 2004, J CLIN NEUROSCI, V11, P501, DOI 10.1016/j.jocn.2003.10.015
   Aleyasin H, 2007, P NATL ACAD SCI USA, V104, P18748, DOI 10.1073/pnas.0709379104
   An JJ, 2008, FEBS J, V275, P1296, DOI 10.1111/j.1742-4658.2008.06291.x
   Andersen JK, 2004, NAT MED, V10, pS18, DOI 10.1038/nm1434
   Bonifati V, 2003, SCIENCE, V299, P256, DOI 10.1126/science.1077209
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Chan PH, 2001, J CEREBR BLOOD F MET, V21, P2, DOI 10.1097/00004647-200101000-00002
   Choi HS, 2006, FREE RADICAL BIO MED, V41, P1058, DOI 10.1016/j.freeadbiomed.2006.06.006
   Dietz GPH, 2010, CURR PHARM BIOTECHNO, V11, P167, DOI 10.2174/138920110790909731
   Eum WS, 2004, FREE RADICAL BIO MED, V37, P1656, DOI 10.1016/j.freeradbiomed.2004.07.028
   FLOYD RA, 1990, FASEB J, V4, P2587
   Gupta A, 2008, ANN NEUROL, V64, pS3, DOI 10.1002/ana.21573
   Halliwell B, 1996, ANNU REV NUTR, V16, P33, DOI 10.1146/annurev.nutr.16.1.33
   Hata R, 2000, J CEREBR BLOOD F MET, V20, P937, DOI 10.1097/00004647-200006000-00006
   Kwon HY, 2000, FEBS LETT, V485, P163, DOI 10.1016/S0014-5793(00)02215-8
   Lee SJ, 2003, J BIOL CHEM, V278, P44552, DOI 10.1074/jbc.M304517200
   Lucas JI, 2007, MOL BIOL EVOL, V24, P551, DOI 10.1093/molbev/msl186
   Nagakubo D, 1997, BIOCHEM BIOPH RES CO, V231, P509, DOI 10.1006/bbrc.1997.6132
   Schaller B, 2004, J CEREBR BLOOD F MET, V24, P351, DOI 10.1097/00004647-200404000-00001
   Wadia JS, 2003, CURR PROTEIN PEPT SC, V4, P97, DOI 10.2174/1389203033487289
   Wadia JS, 2002, CURR OPIN BIOTECH, V13, P52, DOI 10.1016/S0958-1669(02)00284-7
   Wang Q, 2005, J NEUROSCI RES, V82, P138, DOI 10.1002/jnr.20610
   Wilson MA, 2004, P NATL ACAD SCI USA, V101, P1531, DOI 10.1073/pnas.0308089100
   Xu J, 2005, HUM MOL GENET, V14, P1231, DOI 10.1093/hmg/ddi134
   Yanagida T, 2009, OXID MED CELL LONGEV, V2, P36, DOI 10.4161/oxim.2.1.7985
   Yanagisawa D, 2008, J CEREBR BLOOD F MET, V28, P563, DOI 10.1038/sj.jcbfm.9600553
   Zhou WB, 2006, J MOL BIOL, V356, P1036, DOI 10.1016/j.imb.2005.12.030
NR 27
TC 13
Z9 13
U1 1
U2 14
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1226-3613
EI 2092-6413
J9 EXP MOL MED
JI Exp. Mol. Med.
PD OCT 31
PY 2012
VL 44
IS 10
BP 586
EP 593
DI 10.3858/emm.2012.44.10.067
PG 8
WC Biochemistry & Molecular Biology; Medicine, Research & Experimental
SC Biochemistry & Molecular Biology; Research & Experimental Medicine
GA 033CP
UT WOS:000310770700003
PM 22847454
OA Green Published, Other Gold
DA 2018-12-27
ER

PT J
AU Lisa, S
   Domingo, B
   Martinez, J
   Gilch, S
   Llopis, JF
   Schatzl, HM
   Gasset, M
AF Lisa, Silvia
   Domingo, Beatriz
   Martinez, Javier
   Gilch, Sabine
   Llopis, Juan F.
   Schaetzl, Hermann M.
   Gasset, Maria
TI RETRACTED: Failure of Prion Protein Oxidative Folding Guides the
   Formation of Toxic Transmembrane Forms (Retracted article. See vol. 292,
   pg. 20045, 2017)
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article; Retracted Publication
ID ENDOPLASMIC-RETICULUM; PATHOGENIC MUTATIONS; DISULFIDE BOND; CELL-LINE;
   WILD-TYPE; METHIONINE SULFOXIDES; MEMBRANE INSERTION; HYDROPHOBIC CORE;
   QUALITY-CONTROL; IN-VITRO
AB The mechanism by which pathogenic mutations in the globular domain of the cellular prion protein (PrPC) increase the likelihood of misfolding and predispose to diseases is not yet known. Differences in the evidences provided by structural and metabolic studies of these mutants suggest that in vivo folding could be playing an essential role in their pathogenesis. To address this role, here we use the single or combined M206S and M213S artificial mutants causing labile folds and express them in cells. We find that these mutants are highly toxic, fold as transmembrane PrP, and lack the intramolecular disulfide bond. When the mutations are placed in a chain with impeded transmembrane PrP formation, toxicity is rescued. These results suggest that oxidative folding impairment, as on aging, can be fundamental for the genesis of intracellular neurotoxic intermediates key in prion neurodegenerations.
C1 [Lisa, Silvia; Martinez, Javier; Gasset, Maria] CSIC, Inst Quim Fis Rocasolano, E-28006 Madrid, Spain.
   [Domingo, Beatriz; Llopis, Juan F.] Univ Castilla La Mancha, Ctr Reg Invest Biomed, Albacete 02006, Spain.
   [Domingo, Beatriz; Llopis, Juan F.] Univ Castilla La Mancha, Fac Med, Albacete 02006, Spain.
   [Gilch, Sabine; Schaetzl, Hermann M.] Univ Wyoming, Dept Vet Sci, Laramie, WY 82071 USA.
   [Gilch, Sabine; Schaetzl, Hermann M.] Univ Wyoming, Dept Mol Biol, Laramie, WY 82071 USA.
RP Gasset, M (reprint author), CSIC, Inst Quim Fis Rocasolano, Serrano 119, E-28006 Madrid, Spain.
EM mgasset@iqfr.csic.es
RI Gasset, Maria/K-4339-2012; Llopis, Juan/I-2622-2012
OI Gasset, Maria/0000-0001-6436-4055; Llopis, Juan/0000-0002-9460-0642;
   Domingo, Beatriz/0000-0001-9430-4803
FU Spanish Ministerio de Economia y Competitividad Grant [BFU2009-07971];
   Fundacion Cien-Fundacion Reina Sofia grant; Alberta Prions Research
   Institute grant; Formacion del Personal Investigador Ph.D. grants
FX This work was supported by the Spanish Ministerio de Economia y
   Competitividad Grant BFU2009-07971 (to M. G.), a Fundacion
   Cien-Fundacion Reina Sofia grant (to M. G.), and an Alberta Prions
   Research Institute grant (to H. M. S.).; Supported by Formacion del
   Personal Investigador Ph.D. grants.
CR Adrover M, 2010, J BIOL CHEM, V285, P21004, DOI 10.1074/jbc.M110.111815
   Aguzzi A, 2009, PHYSIOL REV, V89, P1105, DOI 10.1152/physrev.00006.2009
   Anelli T, 2003, EMBO J, V22, P5015, DOI 10.1093/emboj/cdg491
   Anelli T, 2008, EMBO J, V27, P315, DOI 10.1038/sj.emboj.7601974
   Anelli T, 2007, EMBO J, V26, P4177, DOI 10.1038/sj.emboj.7601844
   Apetri AC, 2004, J BIOL CHEM, V279, P18008, DOI 10.1074/jbc.M313581200
   Ashok A, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000479
   Birkett CR, 2001, EMBO J, V20, P3351, DOI 10.1093/emboj/20.13.3351
   Bosques CJ, 2003, P NATL ACAD SCI USA, V100, P7593, DOI 10.1073/pnas.1232504100
   Calzolai L, 2000, P NATL ACAD SCI USA, V97, P8340, DOI 10.1073/pnas.97.15.8340
   Campana V, 2006, J CELL SCI, V119, P433, DOI 10.1242/jcs.02768
   Canello T, 2008, BIOCHEMISTRY-US, V47, P8866, DOI 10.1021/bi800801f
   Canello T, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000977
   Capellari S, 1999, J BIOL CHEM, V274, P34846, DOI 10.1074/jbc.274.49.34846
   Chakrabarti O, 2009, TRENDS BIOCHEM SCI, V34, P287, DOI 10.1016/j.tibs.2009.03.001
   Colombo G, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004296
   Drisaldi B, 2003, J BIOL CHEM, V278, P21732, DOI 10.1074/jbc.M213247200
   Emerman AB, 2010, MOL BIOL CELL, V21, P4325, DOI 10.1091/mbc.E10-09-0742
   FRA AM, 1993, EMBO J, V12, P4755, DOI 10.1002/j.1460-2075.1993.tb06164.x
   GASSET M, 1992, P NATL ACAD SCI USA, V89, P10940, DOI 10.1073/pnas.89.22.10940
   Gregersen N, 2010, METHODS MOL BIOL, V648, P3, DOI 10.1007/978-1-60761-756-3_1
   GUENZI S, 1994, EUR J IMMUNOL, V24, P2477, DOI 10.1002/eji.1830241033
   Harris DA, 2003, BRIT MED BULL, V66, P71, DOI 10.1093/bmb/66.1.71
   Hartl FU, 2009, NAT STRUCT MOL BIOL, V16, P574, DOI 10.1038/nsmb.1591
   Hegde RS, 1999, NATURE, V402, P822, DOI 10.1038/45574
   Hegde RS, 1998, SCIENCE, V279, P827, DOI 10.1126/science.279.5352.827
   Hetz C, 2005, J NEUROSCI, V25, P2793, DOI 10.1523/JNEUROSCI.4090-04.2005
   Ivanova L, 2001, J BIOL CHEM, V276, P42409, DOI 10.1074/jbc.M106928200
   Juanes ME, 2009, J BIOL CHEM, V284, P2787, DOI 10.1074/jbc.M804051200
   Kiachopoulos S, 2005, J BIOL CHEM, V280, P9320, DOI 10.1074/jbc.M412525200
   Kim PS, 1998, ENDOCR REV, V19, P173, DOI 10.1210/er.19.2.173
   Kim SJ, 2002, MOL BIOL CELL, V13, P3775, DOI 10.1091/mbc.E02-05-0293
   Kuwahara C, 1999, NATURE, V400, P225, DOI 10.1038/22241
   Lee S, 2003, NAT STRUCT BIOL, V10, P725, DOI 10.1038/nsb961
   Liemann S, 1999, BIOCHEMISTRY-US, V38, P3258, DOI 10.1021/bi982714g
   Lisa S, 2010, CELL MOL LIFE SCI, V67, P2825, DOI 10.1007/s00018-010-0363-1
   Lorenz H, 2002, J BIOL CHEM, V277, P8508, DOI 10.1074/jbc.M110197200
   Lucassen R, 2003, BIOCHEMISTRY-US, V42, P4127, DOI 10.1021/bi027218d
   Maiti NR, 2001, J BIOL CHEM, V276, P2427, DOI 10.1074/jbc.M007862200
   Makarava N, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002419
   Meli M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019093
   Muramoto T, 1997, NAT MED, V3, P750, DOI 10.1038/nm0797-750
   Nishimura T, 2008, BIOCHEM BIOPH RES CO, V377, P1047, DOI 10.1016/j.bbrc.2008.10.087
   Nuss JE, 2008, BIOCHEM BIOPH RES CO, V365, P355, DOI 10.1016/j.bbrc.2007.10.194
   Orsi A, 2007, PRION, V1, P236, DOI 10.4161/pri.1.4.5727
   PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962
   Prusiner SB, 2001, NEW ENGL J MED, V344, P1516, DOI 10.1056/NEJM200105173442006
   Rane NS, 2004, EMBO J, V23, P4550, DOI 10.1038/sj.emboj.7600462
   Reddy MM, 1996, AM J PHYSIOL-CELL PH, V271, pC486
   Resenberger UK, 2011, TOP CURR CHEM, V305, P101, DOI 10.1007/128_2011_160
   Riek R, 1996, NATURE, V382, P180, DOI 10.1038/382180a0
   Riemer J, 2009, SCIENCE, V324, P1284, DOI 10.1126/science.1170653
   Rosenmann H, 2001, J NEUROCHEM, V76, P1654, DOI 10.1046/j.1471-4159.2001.00195.x
   Schiff E, 2008, TRAFFIC, V9, P1101, DOI 10.1111/j.1600-0854.2008.00746.x
   Shin JY, 2009, MOL CELLS, V27, P673, DOI 10.1007/s10059-009-0089-9
   Shin JI, 2008, BIOCHEM BIOPH RES CO, V377, P995, DOI 10.1016/j.bbrc.2008.10.095
   SITIA R, 1990, CELL, V60, P781, DOI 10.1016/0092-8674(90)90092-S
   Stewart RS, 2005, J BIOL CHEM, V280, P15855, DOI 10.1074/jbc.M412298200
   Stewart RS, 2001, MOL BIOL CELL, V12, P881, DOI 10.1091/mbc.12.4.881
   Tabrett CA, 2010, BIOCHEM J, V428, P169, DOI 10.1042/BJ20091635
   TURK E, 1988, EUR J BIOCHEM, V176, P21, DOI 10.1111/j.1432-1033.1988.tb14246.x
   van der Kamp MW, 2010, J MOL BIOL, V404, P732, DOI 10.1016/j.jmb.2010.09.060
   Vetrugno V, 1999, NEUROSCI LETT, V270, P41, DOI 10.1016/S0304-3940(99)00460-7
   Wang F, 2010, SCIENCE, V327, P1132, DOI 10.1126/science.1183748
   Wang X, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014602
   Wang Y, 2008, BIOCHEM J, V409, P623, DOI 10.1042/BJ20071492
   Watts JC, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000608
   Yanai A, 1999, FEBS LETT, V460, P11, DOI 10.1016/S0014-5793(99)01316-2
   Yin SM, 2007, P NATL ACAD SCI USA, V104, P7546, DOI 10.1073/pnas.0610827104
   Zahn R, 2000, P NATL ACAD SCI USA, V97, P145, DOI 10.1073/pnas.97.1.145
NR 70
TC 10
Z9 11
U1 5
U2 17
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD OCT 26
PY 2012
VL 287
IS 44
BP 36693
EP 36701
DI 10.1074/jbc.M112.398776
PG 9
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 030RT
UT WOS:000310588500007
PM 22955286
OA Bronze, Green Published
DA 2018-12-27
ER

PT J
AU Wansink, B
   Just, DR
   Payne, CR
AF Wansink, Brian
   Just, David R.
   Payne, Collin R.
TI RETRACTED: Can Branding Improve School Lunches? (Retracted article. See
   vol. 171, pg. 1230, 2017)
SO ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE
LA English
DT Letter; Retracted Publication
ID EXTRINSIC REWARDS; CHILDREN
C1 [Wansink, Brian; Just, David R.] Cornell Univ, Dept Appl Econ & Management, Ithaca, NY 14853 USA.
   [Payne, Collin R.] New Mexico State Univ, Dept Mkt, Las Cruces, NM 88003 USA.
RP Wansink, B (reprint author), Cornell Univ, Dept Appl Econ & Management, 15 Warren Hall, Ithaca, NY 14853 USA.
EM wansink@cornell.edu
RI Just, David/K-7302-2012
OI Just, David/0000-0002-7471-5178
CR Boyland EJ, 2011, PEDIATRICS, V128, pE93, DOI 10.1542/peds.2010-1859
   Deci EL, 1999, PSYCHOL BULL, V125, P692, DOI 10.1037//0033-2909.125.6.692
   Deci EL, 1999, PSYCHOL BULL, V125, P627, DOI 10.1037/0033-2909.125.6.627
   Institute of Medicine Committee on Food Marketing and the Diets of Children and Youth, 2008, FOOD MARK CHILDR THR
   MIZERSKI R, 1995, J MARKETING, V59, P58, DOI 10.2307/1252328
   Roberto CA, 2010, PEDIATRICS, V126, P88, DOI 10.1542/peds.2009-3433
   Wansink B, PREV MED IN PRESS
NR 7
TC 27
Z9 27
U1 3
U2 21
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 1072-4710
EI 1538-3628
J9 ARCH PEDIAT ADOL MED
JI Arch. Pediatr. Adolesc. Med.
PD OCT 23
PY 2012
VL 166
IS 10
BP 967
EP 968
DI 10.1001/archpediatrics.2012.999
PG 2
WC Pediatrics
SC Pediatrics
GA 014ZL
UT WOS:000309414400018
PM 22911396
OA Bronze
DA 2018-12-27
ER

PT J
AU Aghajani, M
   Mahdavi, MRV
   Najafabadi, MK
   Ghazanfari, T
AF Aghajani, Marjan
   Mahdavi, Mohammad Reza Vaez
   Najafabadi, Mohsen Khalili
   Ghazanfari, Tooba
TI RETRACTED: The Effect of Social Stress on Chronic Pain Perception in
   Female and Male Mice (Retracted article. See vol. 11, e0156567, 2016)
SO PLOS ONE
LA English
DT Article; Retracted Publication
ID INDUCED ANALGESIA; SOCIOECONOMIC-STATUS; GENDER-DIFFERENCES;
   FOOD-DEPRIVATION; FORMALIN TEST; RATS; ANTINOCICEPTION; INFLAMMATION;
   HYPERALGESIA; SENSITIVITY
AB The current investigations on social stress primarily point to the negative health consequences of being in a stressful social hierarchy. The repetitive nature of such stressors seems to affect behavioral response to pain both in rodents and humans. Moreover, a large discrepancy in the possibility of social stresses affecting pain perception in the two genders exists. The present study examined the effect of chronic social stress on nociceptive responses of both sexes by implementing of food deprivation, food intake inequality and unstable social status (cage-mate change every 3 days) for a period of 14 days in 96 Balb/c mice. In this regard we injected 20 mu l formalin 2% into the plantar surface of hind paw at the end of stress period and scored pain behaviors of all subjects, then serum concentrations of proinflammatory cytokines were measured. Our results showed that there was significant difference in chronic phase of formalin test following implementation of food deprivation and inequality (P<0.05) as compared to control group, so that pain perception was decreased considerably and this decline in inequality exposed subjects was well above isolated ones (P<0.05); whereas unstable social situation did not affect pain perception. Moreover, IL-1 and IL-6 concentrations in serum of stressed mice of both genders were well above control group (P<0.05). Finally, despite chronic pain perception in control and unstable male subjects was larger than females; the decrease of chronic pain perception in male stressed animals (poverty and inequality experienced subjects) was much more than stressed females. These results revealed that although food deprivation and social inequality can induce hypoalgesia, some socioeconomic situations like social instability don't affect pain sensation, whereas there were similar increases of proinflammatory cytokines level in all socially stressed subjects. In addition, males display larger hypoalgesic responses to inequality as compared with females.
C1 [Aghajani, Marjan; Mahdavi, Mohammad Reza Vaez; Najafabadi, Mohsen Khalili] Shahed Univ, Fac Med Sci, Dept Physiol, Tehran, Iran.
   [Aghajani, Marjan; Mahdavi, Mohammad Reza Vaez; Ghazanfari, Tooba] Shahed Univ, Equ & Hlth Res Dept, Tehran, Iran.
   [Aghajani, Marjan; Ghazanfari, Tooba] Shahed Univ, Fac Med Sci, Dept Immunol, Tehran, Iran.
RP Mahdavi, MRV (reprint author), Shahed Univ, Fac Med Sci, Dept Physiol, Tehran, Iran.
EM vaezmahdavi@shaded.ac.ir
OI , marjan/0000-0002-7617-271X; vaez-mahdavi,
   Mohammad-Reza/0000-0002-1490-4364
FU Shahed Medical University [87/14/A/P]
FX This research was provided by financial support and supervision of
   Shahed Medical University (grant number: 87/14/A/P) but this funding
   source had no involvement in study design; in the collection, analysis,
   and interpretation of data; in the writing of the report; or in the
   decision to submit the paper for publication.
CR ALMAY BGL, 1980, PSYCHOPHARMACOLOGY, V67, P139, DOI 10.1007/BF00431968
   Baigi A, 2001, EUR J PUBLIC HEALTH, V11, P420, DOI 10.1093/eurpub/11.4.420
   Barrett AC, 2002, EUR J PHARMACOL, V452, P163, DOI 10.1016/S0014-2999(02)02274-4
   Berkley KJ, 2006, AM J PHYSIOL-REG I, V291, pR241, DOI 10.1152/ajpregu.00287.2006
   Bi S, 2003, AM J PHYSIOL-REG I, V285, pR1030, DOI 10.1152/ajpregu.00734.2002
   Bileviciute-Ljungar I, 2006, J PHARMACOL EXP THER, V317, P220, DOI 10.1124/jpet.105.096032
   Bodnar RJ, 2010, HORM BEHAV, V58, P72, DOI 10.1016/j.yhbeh.2009.09.012
   Borsook TK, 2010, PAIN, V151, P372, DOI 10.1016/j.pain.2010.07.022
   Brekke M, 2002, SOC SCI MED, V54, P221, DOI 10.1016/S0277-9536(01)00018-1
   Butler RK, 2009, PROG NEUROBIOL, V88, P184, DOI 10.1016/j.pneurobio.2009.04.003
   Cicero TJ, 2002, J PHARMACOL EXP THER, V300, P695, DOI 10.1124/jpet.300.2.695
   Craig KD, 2006, WALL MELZACKS TXB PA, P231
   Dao TTT, 2000, J OROFAC PAIN, V14, P169
   Davies KA, 2009, EUR J PAIN, V13, P635, DOI 10.1016/j.ejpain.2008.07.003
   Farrell C., 2008, TACKLING HLTH INEQUA
   Fillingim R B, 2000, Curr Rev Pain, V4, P24
   Fillingim RB, 2000, NEUROSCI BIOBEHAV R, V24, P485, DOI 10.1016/S0149-7634(00)00017-8
   Fillingim RB, 2009, J PAIN, V10, P447, DOI 10.1016/j.jpain.2008.12.001
   Ford GK, 2008, PAIN, V140, P3, DOI 10.1016/j.pain.2008.09.023
   Gaumond I, 2005, BRAIN RES, V1052, P105, DOI 10.1016/j.brainres.2005.06.011
   Gioiosa L, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004143
   Glynn P, 1999, THORAX, V54, P51, DOI 10.1136/thx.54.1.51
   Greenspan JD, 2007, PAIN, V132, pS26, DOI 10.1016/j.pain.2007.10.014
   Hargraves WA, 2005, PAIN, V114, P455, DOI 10.1016/j.pain.2005.01.010
   Heidary F, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003705
   Hoff J, 2000, LAB ANIMAL, V29, P47
   Imbe H, 2006, FRONT BIOSCI-LANDMRK, V11, P2179, DOI 10.2741/1960
   Institute for Laboratory Animal Research, 2009, REC ASS PAIN, P47
   Jablonska B, 2006, EUR J PAIN, V10, P435, DOI 10.1016/j.ejpain.2005.06.003
   Jordan KP, 2008, PAIN, V137, P652, DOI 10.1016/j.pain.2008.02.030
   Kasdallah AG, 2005, CR BIOL, V328, P463, DOI 10.1016/j.crvi.2005.02.003
   Klatzkin RR, 2010, EUR J PAIN, V14, P77, DOI 10.1016/j.ejpain.2009.01.002
   Latza U, 2000, SPINE, V25, P1390, DOI 10.1097/00007632-200006010-00011
   Machelska H, 2003, J NEUROIMMUNOL, V141, P30, DOI 10.1016/S0165-5728(03)00213-3
   Marcinkiewcz CA, 2009, BRAIN RES, V1251, P112, DOI 10.1016/j.brainres.2008.11.042
   McEwen BS, 2010, METABOLISM, V59, pS9, DOI 10.1016/j.metabol.2010.07.012
   Mogil JS, 2000, NEUROSCI BIOBEHAV R, V24, P375, DOI 10.1016/S0149-7634(00)00015-4
   Mojarab S., 2010, World Applied Sciences Journal, V8, P680
   Myers CD, 2003, CLIN J PAIN, V19, P225, DOI 10.1097/00002508-200307000-00005
   Nikolov V, 2010, PROCD SOC BEHV, V5, P289, DOI 10.1016/j.sbspro.2010.07.090
   Oyebode P, 2004, ADV PSYCHIAT TREAT, V10, P216, DOI [DOI 10.1192/APT.10.3.216, 10.1192/apt.10.3.216]
   POTTER M, 1985, CURR TOP MICROBIOL, V122, P1
   Racine M, 2012, PAIN, V153, P619, DOI 10.1016/j.pain.2011.11.026
   Riecke BF, 2010, OSTEOARTHR CARTILAGE, V18, P746, DOI 10.1016/j.joca.2010.02.012
   Rivat C, 2007, NEUROPSYCHOPHARMACOL, V32, P2217, DOI 10.1038/sj.npp.1301340
   Saastamoinen P, 2005, PAIN, V114, P364, DOI 10.1016/j.pain.2004.12.033
   SAPOLSKY RM, 1992, PSYCHONEUROENDOCRINO, V17, P701, DOI 10.1016/0306-4530(92)90029-7
   Sherman JJ, 2006, AM J PHYSIOL-REG I, V291, pR245, DOI 10.1152/ajpregu.00920.2005
   Silasi G, 2008, BEHAV BRAIN RES, V188, P219, DOI 10.1016/j.bbr.2007.10.030
   Spooner MF, 2007, NEUROSCIENCE, V150, P675, DOI 10.1016/j.neuroscience.2007.09.037
   Stein C, 2003, NAT MED, V9, P1003, DOI 10.1038/nm908
   Sternberg WF, 1999, PHYSIOL BEHAV, V68, P63, DOI 10.1016/S0031-9384(99)00164-X
   Sufka KJ, 1998, EUR J PAIN-LONDON, V2, P351, DOI 10.1016/S1090-3801(98)90033-7
   Tatli MM, 2000, PEDIATR INT, V42, P289, DOI 10.1046/j.1442-200x.2000.01217.x
   vanHaasteren GAC, 1996, J ENDOCRINOL, V150, P169, DOI 10.1677/joe.0.1500169
   Vendruscolo LF, 2004, BRAIN RES, V1030, P277, DOI 10.1016/j.brainres.2004.10.016
   Villemure C, 2002, PAIN, V95, P195, DOI 10.1016/S0304-3959(02)00007-6
   Vincler M, 2001, PHARMACOL BIOCHEM BE, V69, P315, DOI 10.1016/S0091-3057(01)00506-8
   VONKNORRING L, 1979, NEUROPSYCHOBIOLOGY, V5, P322, DOI 10.1159/000117698
   YAMADA K, 1995, BEHAV BRAIN RES, V67, P133, DOI 10.1016/0166-4328(94)00150-E
   ZIMMERMANN M, 1983, PAIN, V16, P109, DOI 10.1016/0304-3959(83)90201-4
NR 61
TC 8
Z9 8
U1 1
U2 16
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 17
PY 2012
VL 7
IS 10
AR e47218
DI 10.1371/journal.pone.0047218
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 038AF
UT WOS:000311146900046
PM 23082150
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Adegbite, SA
AF Adegbite, S. A.
TI RETRACTED: Measuring the adhesion of alumina coatings onto Fecralloy
   supports using a mechanical testing system (Retracted article. See vol.
   314, pg. 1093, 2014)
SO APPLIED SURFACE SCIENCE
LA English
DT Article; Retracted Publication
DE Fecralloy; Adhesion; Coating; Alumina; Support; Mechanical; Catalyst
ID GAMMA-AL2O3 LAYERS; METALLIC MONOLITHS; DEPOSITION; EMISSIONS;
   VISCOSITY; OXIDATION; CATALYSTS; STRENGTH; REACTORS
AB Tightening legislation for vehicles across the world has caused the use of monolith catalysts in automotive emission control to become ubiquitous. Control of the surface adhesion of the platinum group metal (PGM) coating onto the monolith block, to maximise catalytic performance for a minimum PGM loading, is therefore paramount. In this paper, an automatic film application is used for coating gamma-alumina slurries onto Fecralloy (R), an integral component of metallic monolith catalysts, to achieve the desired coating properties. A newly devised dual compression-tension technique using a mechanical testing system (MTS) is used for measuring the coating adhesion. This method involves compression of the coating with a probe at a fixed load, and then removing the probe together with the coating at right angles to the substrate surface at a speed of 10 mm/min. The MTS results are compared with those from conventional ultrasonic vibration tests. It is found that at 40 wt% solids concentration, the coatings of the finest particles (d(0.9) of 12.14 mu m) showed the best adhesion with an ultimate strength of 0.59 MPa and 85-90 mass% coating removal. (C) 2012 Elsevier B. V. All rights reserved.
C1 Univ Birmingham, Birmingham B15 2TT, W Midlands, England.
RP Adegbite, SA (reprint author), Univ Birmingham, Birmingham B15 2TT, W Midlands, England.
EM s.adegbite@surrey.ac.uk
FU Engineering and Physical Sciences Research Council (EPSRC); Johnson
   Matthey Plc
FX The author would like to thank the Engineering and Physical Sciences
   Research Council (EPSRC) and Johnson Matthey Plc for funding this
   research project.
CR Almeida LC, 2010, STUD SURF SCI CATAL, V175, P25, DOI 10.1016/S0167-2991(10)75004-7
   [Anonymous], 2006, AUT FILM APPL MAN
   Ashby M. F., 1996, ENG MAT, V1, P77
   Avila P, 2005, CHEM ENG J, V109, P11, DOI 10.1016/j.cej.2005.02.025
   Barnes HA, 2000, J NON-NEWTON FLUID, V94, P213, DOI 10.1016/S0377-0257(00)00162-2
   Burgos N, 2003, J MATER CHEM, V13, P1458, DOI 10.1039/b212242a
   CYBULSKI A, 1994, CHEM ENG SCI, V49, P19, DOI 10.1016/0009-2509(94)85030-5
   Cybulski A., 2006, STRUCTURED CATALYSIS
   Fei W, 2003, SURF ENG, V19, P189, DOI 10.1179/026708403225006249
   Haagen-Smith A., 1954, JAPCA-INT J AIR POLL, V4, P136
   HAAGENSMIT AJ, 1953, IND ENG CHEM, V45, P2086, DOI 10.1021/ie50525a044
   HOFFMAN RL, 1992, J RHEOL, V36, P947, DOI 10.1122/1.550324
   Jia LW, 2007, SURF COAT TECH, V201, P7159, DOI 10.1016/j.surfcoat.2007.01.023
   Kestenbaum H, 2002, IND ENG CHEM RES, V41, P710, DOI 10.1021/ie010306u
   Meille V, 2006, APPL CATAL A-GEN, V315, P1, DOI 10.1016/j.apcata.2006.08.031
   Nievergeld A., 1998, AUTOMATIVE EXHAUST G
   Pavlina EJ, 2008, J MATER ENG PERFORM, V17, P888, DOI 10.1007/s11665-008-9225-5
   Sun H, 2007, APPL SURF SCI, V253, P3303, DOI 10.1016/j.apsusc.2006.07.044
   Truyen D, 2006, THIN SOLID FILMS, V495, P257, DOI 10.1016/j.tsf.2005.08.200
   Twigg MV, 2007, APPL CATAL B-ENVIRON, V70, P2, DOI 10.1016/j.apcatb.2006.02.029
   Twigg MV, 2006, CATAL TODAY, V117, P407, DOI 10.1016/j.cattod.2006.06.044
   Valentini M, 2001, CATAL TODAY, V69, P307, DOI 10.1016/S0920-5861(01)00383-2
   Wei Y, 1998, INT J FRACTURE, V93, P315, DOI 10.1023/A:1007545200315
   Williams JL, 2001, CATAL TODAY, V69, P3, DOI 10.1016/S0920-5861(01)00348-0
   Xu C, 2007, PROCEEDINGS OF THE ASME INTERNATIONAL CONFERENCE ON MANUFACTURING SCIENCE AND ENGINEERING - 2007, P887, DOI 10.1115/MSEC2007-31038
   Zhao S, 2003, SURF COAT TECH, V167, P97, DOI 10.1016/S0257-8972(02)00859-9
NR 26
TC 5
Z9 5
U1 3
U2 39
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0169-4332
EI 1873-5584
J9 APPL SURF SCI
JI Appl. Surf. Sci.
PD OCT 15
PY 2012
VL 259
BP 338
EP 342
DI 10.1016/j.apsusc.2012.07.046
PG 5
WC Chemistry, Physical; Materials Science, Coatings & Films; Physics,
   Applied; Physics, Condensed Matter
SC Chemistry; Materials Science; Physics
GA 028QJ
UT WOS:000310436900054
OA Other Gold
DA 2018-12-27
ER

PT J
AU Lou, S
   Di, DL
AF Lou, Song
   Di, Duolong
TI RETRACTED: Adsorption Features of Flavonoids on Macroporous Adsorption
   Resins Functionalized with Ionic Liquids (Retracted article. See vol.
   16, pg. 1329, 2015)
SO CHEMPHYSCHEM
LA English
DT Article; Retracted Publication
DE adsorption; flavonoids; ionic liquids; surface science; resins
ID SELF-ASSEMBLED MONOLAYERS; POLYCHLORINATED-BIPHENYLS; ALKANETHIOLATE
   MONOLAYERS; PREPARATIVE PURIFICATION; POLYMERIC ADSORBENT;
   GAS-CHROMATOGRAPHY; STATIONARY PHASES; GOLD SURFACES; SEPARATION;
   KINETICS
AB A series of macroporous adsorption resins (MARs) with novel structures is synthesized via FriedelCrafts catalyzed reaction. The adsorption kinetics of the synthetic resins with respect to the purification effect is systematically investigated by means of the response surface methodology (RSM). The kinetic data cannot be fitted to the classical model because it does not take multicompartments and desorption rates into consideration. A new multicompartment louver-tide theory is thus developed considering that adsorption is an indefinite dynamic equilibrium process, which can be divided into innumerable ingredients with different desorption rates. This theory produces much better fits to the experimental data and provides a quantitative explanation with multicompartments and adsorption/desorption rates.
C1 [Lou, Song; Di, Duolong] Chinese Acad Sci, Lanzhou Inst Chem Phys, Key Lab Chem NW Plant Resources, Lanzhou 730000, Peoples R China.
   [Lou, Song; Di, Duolong] Chinese Acad Sci, Lanzhou Inst Chem Phys, Key Lab Nat Med Gansu Prov, Lanzhou 730000, Peoples R China.
   [Lou, Song] Chinese Acad Sci, Grad Univ, Beijing 100049, Peoples R China.
   [Di, Duolong] Lanzhou Inst Chem Phys, Ctr Resource Chem & New Mat, Qingdao 266100, Peoples R China.
RP Di, DL (reprint author), Chinese Acad Sci, Lanzhou Inst Chem Phys, Key Lab Chem NW Plant Resources, Tianshui Middle Rd 18, Lanzhou 730000, Peoples R China.
EM didl@licp.cas.cn
RI Lou, Song/I-4023-2014
FU Chinese Academy of Sciences (CAS); National Natural Sciences Foundation
   of China (NSFC) [20974116]
FX This research project was financially supported by the "Hundred Talents
   Program" of the Chinese Academy of Sciences (CAS) and the National
   Natural Sciences Foundation of China (NSFC No. 20974116).
CR ABRAHAM MH, 1993, CHEM SOC REV, V22, P73, DOI 10.1039/cs9932200073
   Adams CJ, 2000, GREEN CHEM, V2, P21, DOI 10.1039/a908167d
   ALVES CA, 1992, J AM CHEM SOC, V114, P1222, DOI 10.1021/ja00030a015
   Anderson JL, 2003, ANAL CHEM, V75, P4851, DOI 10.1021/ac0345749
   Anderson JL, 2002, J AM CHEM SOC, V124, P14247, DOI 10.1021/ja028156h
   Armstrong DW, 1999, ANAL CHEM, V71, P3873, DOI 10.1021/ac990443p
   BERENS AR, 1981, J DISPER SCI TECHNOL, V2, P359, DOI 10.1080/01932698108943918
   BRYANT MA, 1991, J AM CHEM SOC, V113, P3629, DOI 10.1021/ja00010a001
   Carmichael AJ, 1999, ORG LETT, V1, P997, DOI 10.1021/ol9907771
   CARROLL KM, 1994, ENVIRON SCI TECHNOL, V28, P253, DOI 10.1021/es00051a011
   Chen ZB, 2010, J PHYS CHEM B, V114, P4841, DOI 10.1021/jp910115q
   Crittenden JC, 1999, ENVIRON SCI TECHNOL, V33, P2926, DOI 10.1021/es981082i
   Decher G, 1997, SCIENCE, V277, P1232, DOI 10.1126/science.277.5330.1232
   Du XL, 2008, CHEM ENG TECHNOL, V31, P87, DOI 10.1002/ceat.200700347
   FINKLEA HO, 1987, LANGMUIR, V3, P409, DOI 10.1021/la00075a024
   Fischer M, 2009, CHEMPHYSCHEM, V10, P2647, DOI 10.1002/cphc.200900459
   FULLER J, 1994, J CHEM SOC CHEM COMM, P299, DOI 10.1039/c39940000299
   Geng XT, 2009, J CHROMATOGR A, V1216, P8331, DOI 10.1016/j.chroma.2009.09.015
   Georgiadis R, 2000, J AM CHEM SOC, V122, P3166, DOI 10.1021/ja9930824
   Gokmen V, 2002, J FOOD ENG, V53, P221, DOI 10.1016/S0260-8774(01)00160-1
   Gordon CM, 1998, J MATER CHEM, V8, P2627, DOI 10.1039/a806169f
   Huddleston JG, 1998, CHEM COMMUN, P1765, DOI 10.1039/a803999b
   Karachevtsev VA, 2008, CHEMPHYSCHEM, V9, P2010, DOI 10.1002/cphc.200800182
   Kim HS, 2009, CHEMPHYSCHEM, V10, P1270, DOI 10.1002/cphc.200900001
   LAIBINIS PE, 1991, J AM CHEM SOC, V113, P7152, DOI 10.1021/ja00019a011
   Li C, 2011, J SCI FOOD AGR, V91, P2826, DOI 10.1002/jsfa.4528
   Liao S, 2000, J AM CHEM SOC, V122, P3688, DOI 10.1021/ja9905804
   Liu YF, 2010, FOOD CHEM, V123, P1027, DOI 10.1016/j.foodchem.2010.05.055
   Lou S, 2012, IND ENG CHEM RES, V51, P2682, DOI 10.1021/ie201494k
   Lou S, 2011, LANGMUIR, V27, P9314, DOI 10.1021/la200858c
   Lui YF, 2011, J AGR FOOD CHEM, V59, P9629, DOI 10.1021/jf2020232
   Ma CY, 2009, J SEP SCI, V32, P185, DOI 10.1002/jssc.200800438
   NUZZO RG, 1987, J AM CHEM SOC, V109, P733, DOI 10.1021/ja00237a017
   Panek JJ, 2011, CHEMPHYSCHEM, V12, P2484, DOI 10.1002/cphc.201100067
   Qiu HD, 2006, J CHROMATOGR A, V1103, P265, DOI 10.1016/j.chroma.2005.11.035
   QUANG CY, 1993, ANAL CHEM, V65, P3354, DOI 10.1021/ac00071a003
   Ren P, 2008, REACT FUNCT POLYM, V68, P899, DOI 10.1016/j.reactfunctpolym.2008.01.002
   Renner C, 2006, J AM CHEM SOC, V128, P620, DOI 10.1021/ja0560229
   SANDERS JR, 1986, J ELECTROCHEM SOC, V133, P325, DOI 10.1149/1.2108570
   SHETTY PH, 1987, J CHROMATOGR, V411, P61, DOI 10.1016/S0021-9673(00)93960-8
   SING KSW, 1985, PURE APPL CHEM, V57, P603, DOI 10.1351/pac198557040603
   Ten Hulscher TEM, 1999, ENVIRON SCI TECHNOL, V33, P126, DOI 10.1021/es980091o
   Ueta H, 2008, CHEMPHYSCHEM, V9, P2372, DOI 10.1002/cphc.200800294
   WALCZAK MM, 1991, J AM CHEM SOC, V113, P2370, DOI 10.1021/ja00007a004
   Welton T, 1999, CHEM REV, V99, P2071, DOI 10.1021/cr980032t
   Yanes EG, 2001, ANAL CHEM, V73, P3838, DOI 10.1021/ac010263r
   Yetilmezsoy K, 2009, J HAZARD MATER, V171, P551, DOI 10.1016/j.jhazmat.2009.06.035
   Zeng XW, 2009, J HAZARD MATER, V169, P1022, DOI 10.1016/j.jhazmat.2009.04.044
   Zhang WZ, 2003, ANAL LETT, V36, P827, DOI 10.1081/AL-120018802
NR 49
TC 4
Z9 5
U1 0
U2 0
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1439-4235
EI 1439-7641
J9 CHEMPHYSCHEM
JI ChemPhysChem
PD OCT 8
PY 2012
VL 13
IS 14
BP 3330
EP 3339
DI 10.1002/cphc.201200238
PG 10
WC Chemistry, Physical; Physics, Atomic, Molecular & Chemical
SC Chemistry; Physics
GA 015SH
UT WOS:000309465900013
PM 22811393
DA 2018-12-27
ER

PT J
AU Cintra, DE
   Ropelle, ER
   Vitto, MF
   Luciano, TF
   Souza, DR
   Engelmann, J
   Marques, SO
   Lira, FS
   de Pinho, RA
   Pauli, JR
   De Souza, CT
AF Cintra, Dennys E.
   Ropelle, Eduardo R.
   Vitto, Marcelo F.
   Luciano, Thais F.
   Souza, Daniela R.
   Engelmann, Julia
   Marques, Scherolin O.
   Lira, Fabio S.
   de Pinho, Ricardo A.
   Pauli, Jose R.
   De Souza, Claudio T.
TI RETRACTED: Reversion of hepatic steatosis by exercise training in obese
   mice: The role of sterol regulatory element-binding protein-1c
   (Retracted article. See vol. 193, pg. 309, 2018)
SO LIFE SCIENCES
LA English
DT Article; Retracted Publication
DE Sterol regulatory element-binding protein-1c; Exercise training; Hepatic
   steatosis
ID FATTY LIVER-DISEASE; STEAROYL-COA DESATURASE-1; SHORT-TERM INHIBITION;
   INSULIN-RESISTANCE; SKELETAL-MUSCLE; WEIGHT-LOSS; EXPRESSION; RATS;
   DEFICIENCY; METABOLISM
AB Aim: The dysregulation of regulatory element-binding protein-1c (SREBP-1c) is associated with hepatic steatosis. However, effects of exercise on SREBP-1c protein level in liver have not been investigated. Thus, in this study we investigated if reversion of the hepatic steatosis-induced by exercise training is related with levels of SREBP-1c.
   Main methods: Mice were divided into two groups: control lean mice (CT), fed on standard rodent chow, and obese mice (HF), fed on a high-fat diet for 2 months. After this period obese mice were divided in two groups: obese mice and obese mice submitted to exercise (HF + EXE). The HF + EXE group performed a running program of 50 min per day, 5 days per week, for 8 weeks. Forty-eight hours after the last exercise session, biochemical, immunoblotting, histology and immunohistochemistry analyses were performed.
   Key findings: Livers of HF mice showed increased SREBP-1c, FAS (Fatty Acid Synthase), SCD1 (Stearoyl-CoA Desaturase1) and CPT1 (Carnitine Palmitoyl Transferase1) protein levels (3.4, 5.0, 2.6 and 2.9 times, respectively), though ACC (Acetyl-CoA Carboxilase) phosphorylation dropped 4.2 times. In livers of HF + EXE, levels of SREBP-1c, FAS, SCDI and CPTI decreased 2.1, 1.9, 1.8, and 2.7 times, respectively), while ACC phosphorylation increased 3.0 times. Lower SREBP-1c protein levels after exercise were confirmed also by immunohistochemistry. Total liver lipids content was higher in HF (2.2 times) when compared to CT, and exercise training reduced it significantly (1.7 times).
   Significance: Our study allows concluding that the reduction in SREBP-1c protein levels is associated with steatosis reversion induced by exercise training. Crown Copyright (c) 2012 Published by Elsevier Inc. All rights reserved.
C1 [Vitto, Marcelo F.; Luciano, Thais F.; Souza, Daniela R.; Engelmann, Julia; Marques, Scherolin O.; Lira, Fabio S.; de Pinho, Ricardo A.; De Souza, Claudio T.] Univ Extremo Sul Catarinense, Lab Fisiol & Bioquim Exercicio, Programa Posgrad Ciencias Saude, Unidade Acad Ciencias Saude, BR-88806000 Criciuma, SC, Brazil.
   [Cintra, Dennys E.; Ropelle, Eduardo R.; Pauli, Jose R.] Univ Estadual Campinas, Fac Sci Appl, UNICAMP, Limeira, SP, Brazil.
RP De Souza, CT (reprint author), Univ Extremo Sul Catarinense, Lab Fisiol & Bioquim Exercicio, Programa Posgrad Ciencias Saude, Unidade Acad Ciencias Saude, BR-88806000 Criciuma, SC, Brazil.
EM ctsouza@unesc.net
RI Ropelle, Eduardo/C-3977-2012; Pinho, Ricardo/G-2643-2012; Lira,
   Fabio/M-9922-2014
OI Ropelle, Eduardo/0000-0003-1655-9557; Pinho,
   Ricardo/0000-0003-3116-4553; 
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq);
   University Southern of Santa Catarina (UNESC)
FX This work was supported by the Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq) and University Southern of Santa
   Catarina (UNESC).
CR ABUELHEIGA L, 1995, P NATL ACAD SCI USA, V92, P4011, DOI 10.1073/pnas.92.9.4011
   Ahmed MH, 2007, DRUG DISCOV TODAY, V12, P740, DOI 10.1016/j.drudis.2007.07.009
   Araujo EP, 2004, J ENDOCRINOL, V181, P25, DOI 10.1677/joe.0.1810025
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5
   Camacho RC, 2006, AM J PHYSIOL-ENDOC M, V290, pE405, DOI 10.1152/ajpendo.00385.2005
   Cohen P, 2002, SCIENCE, V297, P240, DOI 10.1126/science.1071527
   De Souza CT, 2005, DIABETOLOGIA, V48, P1860, DOI 10.1007/s00125-005-1866-4
   FERNANDO P, 1993, CAN J PHYSIOL PHARM, V71, P854, DOI 10.1139/y93-128
   Frederico MJS, 2011, SCAND J GASTROENTERO, V46, P1381, DOI 10.3109/00365521.2011.613945
   Goodpaster BH, 2001, J CLIN ENDOCR METAB, V86, P5755, DOI 10.1210/jc.86.12.5755
   Gutierrez-Juarez R, 2006, J CLIN INVEST, V116, P1686, DOI 10.1172/JCI26991
   Ikeda S, 2002, BIOCHEM BIOPH RES CO, V296, P395, DOI 10.1016/S0006-291X(02)00883-5
   Johnson NA, 2009, HEPATOLOGY, V50, P1105, DOI 10.1002/hep.23129
   Jump DB, 2011, CURR OPIN CLIN NUTR, V14, P115, DOI 10.1097/MCO.0b013e328342991c
   Knebel B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031812
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Liang GS, 2002, J BIOL CHEM, V277, P9520, DOI 10.1074/jbc.M111421200
   Marques CMM, 2010, BRAZ J MED BIOL RES, V43, P467, DOI 10.1590/S0100-879X2010007500030
   Miyazaki M, 2000, J BIOL CHEM, V275, P30132, DOI 10.1074/jbc.M005488200
   Miyazaki M, 2007, CELL METAB, V6, P484, DOI 10.1016/j.cmet.2007.10.014
   Nadeau KJ, 2006, AM J PHYSIOL-ENDOC M, V291, pE90, DOI 10.1152/ajpendo.00543.2005
   Nohturfft A, 2000, CELL, V102, P315, DOI 10.1016/S0092-8674(00)00037-4
   Nohturfft A, 1999, P NATL ACAD SCI USA, V96, P11235, DOI 10.1073/pnas.96.20.11235
   Rector RS, 2008, J PHYSIOL-LONDON, V586, P4241, DOI 10.1113/jphysiol.2008.156745
   Rector RS, 2008, AM J PHYSIOL-GASTR L, V294, pG619, DOI 10.1152/ajpgi.00428.2007
   Rector RS, 2011, J APPL PHYSIOL, V111, P1828, DOI 10.1152/japplphysiol.00384.2011
   Ruderman NB, 1999, AM J PHYSIOL-ENDOC M, V276, pE1
   Savage DB, 2006, J CLIN INVEST, V116, P817, DOI 10.1172/JCI27300
   Schultz A, 2012, EXP TOXICOL PATHOL, V64, P273, DOI 10.1016/j.etp.2010.08.019
   Shimano H, 1997, J CLIN INVEST, V99, P846, DOI 10.1172/JCI119248
   Takekoshi K, 2006, METABOLISM, V55, P1122, DOI 10.1016/j.metabol.2006.04.007
   Wang R, 2010, BIOCHEM J, V430, P245, DOI 10.1042/BJ20100701
   WANG XD, 1993, J BIOL CHEM, V268, P14497
   Yahagi N, 2002, J BIOL CHEM, V277, P19353, DOI 10.1074/jbc.M201584200
   Yang ZX, 2010, HEPATOL INT, V4, P741, DOI 10.1007/s12072-010-9202-6
   Yasari S, 2010, MOL CELL BIOCHEM, V335, P291, DOI 10.1007/s11010-009-0279-y
   You M, 2004, ALCOHOL, V34, P39, DOI 10.1016/j.alcohol.2004.07.004
NR 38
TC 21
Z9 24
U1 2
U2 9
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0024-3205
EI 1879-0631
J9 LIFE SCI
JI Life Sci.
PD OCT 5
PY 2012
VL 91
IS 11-12
BP 395
EP 401
DI 10.1016/j.lfs.2012.08.002
PG 7
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA 018FI
UT WOS:000309645100006
PM 22906631
OA Bronze
DA 2018-12-27
ER

PT J
AU Liu, ML
   Wang, GD
   Gomez-Fernandez, CR
   Guo, SC
AF Liu, Mingli
   Wang, Guangdi
   Gomez-Fernandez, Carmen R.
   Guo, Shanchun
TI RETRACTED: GREB1 Functions as a Growth Promoter and Is Modulated by
   IL6/STAT3 in Breast Cancer (Retracted article. See vol. 9, e102287,
   2014)
SO PLOS ONE
LA English
DT Article; Retracted Publication
ID ESTROGEN-RECEPTOR-ALPHA; NF-KAPPA-B; TAMOXIFEN RESISTANCE; ENDOCRINE
   THERAPY; EXPRESSION SIGNATURE; RANDOMIZED-TRIAL; MICROARRAY DATA;
   CROSS-TALK; FOLLOW-UP; PROGNOSIS
AB Background: Growth Regulation by Estrogen in Breast cancer (GREB1) was an estrogen receptor (ER) target gene, and GREB1 expression inversely correlated with HER2 status, possibly as a surrogate marker for ER status and a predictor for tamoxifen resistance in breast cancer patients. In the present study, we examine the function and regulation of GREB1 in breast cancer, with the goal to develop GREB1 as a biomarker in breast cancer with de novo and acquired tamoxifen resistance.
   Methods: We overexpressed GREB1 using adenovirus containing the full length GREB1 cDNA (Ad-GREB1) in breast cancer cell lines. The soft agar assay was used as a measure of anchorage independent growth. The effects of GREB1 on cell proliferation in MCF-7 cells transduced with Ad-GREB1 were also measured by the me olic activity using AlamarBlue assay. We tested whether there was interaction between STAT3 and ER, which could repress GREB1 expression by immunoprecipitation assay. The effects of IL-6/JAK/STAT3 cascade activation on estrogen-induced GREB1 promoter activity were determined by luciferase assay and those on gene expression were measured by real time reverse transcription polymerase chain reaction (qRT-PCR).
   Results: We found that the ability of breast cancer cells to grow in soft agar is enhanced following GREB1 transfection. In MCF-7 cells transduced with Ad-GREB1 or transfected with siRNA GREB1, the metabolic activity was increased or completely abolished, suggesting that GREB1 may function as a growth promoter in breast cancer. E2 treatment increased GREB1 promoter luciferase activity. IL-6 inhibited E2-induced GREB1 transcription activity and GREB1 mRNA expression. Constitutively expressing active STAT3 construct (STAT3-C) dramatically decreased GREB1 transcription.
   Conclusions: These data indicate that overexpression of GREB1 promotes cell proliferation and increases the clonogenic ability in breast cancer cells. Moreover, Il6/STAT3 modulates estrogen-induced GREB1 transcriptional activity in breast cancer cells.
C1 [Liu, Mingli; Guo, Shanchun] Morehouse Sch Med, Dept Microbiol Biochem & Immunol, Atlanta, GA 30310 USA.
   [Wang, Guangdi] Xavier Univ Louisiana, Dept Chem, New Orleans, LA USA.
   [Liu, Mingli; Gomez-Fernandez, Carmen R.] Univ Miami Sch Med, Dept Med, Dept Pathol, Miami, FL USA.
RP Liu, ML (reprint author), Morehouse Sch Med, Dept Microbiol Biochem & Immunol, Atlanta, GA 30310 USA.
EM mliu@msm.edu; gwang@xula.edu; sguo@msm.edu
FU Woman's Cancer Association of the University of Miami; RCMI grant
   [5G12RR026260]; Imaging Core at the University of Miami
FX This work was partly supported by a grant from the Woman's Cancer
   Association of the University of Miami awarded to ML and RCMI grant
   5G12RR026260 to GW. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.; The authors thank the Imaging Core at the University of
   Miami for providing access to Zeiss LSM 510 confocal microscope and
   study support.
CR BENZ CC, 1992, BREAST CANCER RES TR, V24, P85, DOI 10.1007/BF01961241
   Berishaj M, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1680
   Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296
   Boersma BJ, 2008, INT J CANCER, V122, P1324, DOI 10.1002/ijc.23237
   Chin K, 2006, CANCER CELL, V10, P529, DOI 10.1016/j.ccr.2006.10.009
   CLARK GM, 1983, BREAST CANCER RES TR, V3, P157, DOI 10.1007/BF01803558
   Clarke R, 2001, PHARMACOL REV, V53, P25
   DANFORTH DN, 1993, CANCER RES, V53, P1538
   Deschenes J, 2007, J BIOL CHEM, V282, P17335, DOI 10.1074/jbc.C700030200
   Desmedt C, 2007, CLIN CANCER RES, V13, P3207, DOI 10.1158/1078-0432.CCR-06-2765
   Dolled-Filhart M, 2003, CLIN CANCER RES, V9, P594
   Dowsett M, 2008, CLIN CANCER RES, V14, P8019, DOI 10.1158/1078-0432.CCR-08-0974
   Fennessy M, 2004, BRIT J SURG, V91, P699, DOI 10.1002/bjs.4603
   Fernandes A, 1999, INT J CANCER, V83, P564, DOI 10.1002/(SICI)1097-0215(19991112)83:4<564::AID-IJC20>3.0.CO;2-Q
   Gee JM, 2005, ENDOCR-RELAT CANCER, V12, pS99, DOI 10.1677/erc.1.01005
   Ghosh MG, 2000, CANCER RES, V60, P6367
   Ginestier C, 2006, CLIN CANCER RES, V12, P4533, DOI 10.1158/1078-0432.CCR-05-2339
   Goetz MP, 2008, CLIN CANCER RES, V14, P5864, DOI 10.1158/1078-0432.CCR-08-0619
   Goetz MP, 2006, CLIN CANCER RES, V12, P2080, DOI 10.1158/1078-0432.CCR-05-1263
   Gupta N, 2012, CELL SIGNAL, V24, P151, DOI 10.1016/j.cellsig.2011.08.016
   Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9
   Hamburger AW, 2008, J MAMMARY GLAND BIOL, V13, P225, DOI 10.1007/s10911-008-9077-5
   Henriksen KL, 2008, ACTA ONCOL, V47, P795, DOI 10.1080/02841860802026993
   Hess KR, 2006, J CLIN ONCOL, V24, P4236, DOI 10.1200/JCO.2006.05.6861
   HOROBIN JM, 1991, BRIT J SURG, V78, P213, DOI 10.1002/bjs.1800780228
   Huang E, 2003, LANCET, V361, P1590, DOI 10.1016/S0140-6736(03)13308-9
   Hurtado A, 2008, NATURE, V456, P663, DOI 10.1038/nature07483
   Ingle JN, 2006, BREAST CANCER RES TR, V98, P217, DOI 10.1007/s10549-005-9152-1
   Ivshina AV, 2006, CANCER RES, V66, P10292, DOI 10.1158/0008-5472.CAN-05-4414
   Johnson MD, 2004, BREAST CANCER RES TR, V85, P151, DOI 10.1023/B:BREA.0000025406.31193.e8
   Jorda M, 2010, BREAST CANC RES TREA, V122, P371
   JORDAN VC, 1988, CRC CR REV CL LAB SC, V26, P97, DOI 10.3109/10408368809106860
   Lippman Marc E, 2008, Trans Am Clin Climatol Assoc, V119, P77
   Liu M, 2010, BREAST CANC RES TREA, V122, P371
   Loi S, 2007, CRIT REV ONCOL HEMAT, V61, P187, DOI 10.1016/j.critrevonc.2006.09.005
   Loi S, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-239
   Miller LD, 2005, P NATL ACAD SCI USA, V102, P13550, DOI 10.1073/pnas.0506230102
   Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799
   Nedergaard L, 1996, PATHOL RES PRACT, V192, P983, DOI 10.1016/S0344-0338(96)80039-2
   Osborne CK, 2003, J NATL CANCER I, V95, P353, DOI 10.1093/jnci/95.5.353
   Osborne CK, 2005, CLIN CANCER RES, V11, p865S
   Osborne CK, 2005, BREAST, V14, P458, DOI 10.1016/j.breast.2005.08.024
   Rae JM, 2006, PROSTATE, V66, P886, DOI 10.1002/pros.20403
   Rae JM, 2005, BREAST CANCER RES TR, V92, P141, DOI 10.1007/s10549-005-1483-4
   Rhodes DR, 2004, P NATL ACAD SCI USA, V101, P9309, DOI 10.1073/pnas.0401994101
   Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2
   Richardson AL, 2006, CANCER CELL, V9, P121, DOI 10.1016/j.ccr.2006.01.013
   Riggins RB, 2008, CANCER RES, V68, P8908, DOI 10.1158/0008-5472.CAN-08-2669
   Ring A, 2004, ENDOCR-RELAT CANCER, V11, P643, DOI 10.1677/erc.1.00776
   Singer CF, 2008, BBA-REV CANCER, V1786, P105, DOI 10.1016/j.bbcan.2008.02.003
   Sun J, 2007, MOL ENDOCRINOL, V21, P2651, DOI 10.1210/me.2007-0082
   Taylor KM, 2007, MOL MED, V13, P396, DOI 10.2119/2007-00040.Taylor
   van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967
   Vendrell JA, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2158
   Wang Y, 2004, FEBS LETT, V572, P238, DOI 10.1016/j.febslet.2004.06.098
   Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1
   Wilson BJ, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-49
   Yamamoto T, 2000, FEBS LETT, V486, P143, DOI 10.1016/S0014-5793(00)02296-1
   Yamashita H, 2008, INT J CLIN ONCOL, V13, P380, DOI 10.1007/s10147-008-0818-7
   ZABEL U, 1993, EMBO J, V12, P201, DOI 10.1002/j.1460-2075.1993.tb05646.x
   Zhao HJ, 2004, MOL BIOL CELL, V15, P2523, DOI 10.1091/mbc.E03-11-0786
   Zhou Y, 2005, ENDOCR-RELAT CANCER, V12, pS37, DOI 10.1677/erc.1.00977
   Zhou YM, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-59
NR 63
TC 25
Z9 26
U1 1
U2 13
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 3
PY 2012
VL 7
IS 10
AR e46410
DI 10.1371/journal.pone.0046410
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 015NU
UT WOS:000309454000039
PM 23056300
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU El-Ghonemy, AMK
AF El-Ghonemy, A. M. K.
TI RETRACTED: Fresh water production from/by atmospheric air for arid
   regions, using solar energy: Review (Retracted article. See vol. 22, pg.
   735, 2013)
SO RENEWABLE & SUSTAINABLE ENERGY REVIEWS
LA English
DT Review; Retracted Publication
DE Fresh water; Atmospheric air; Humidification-dehumidification; Review
ID DESALINATION STATION; DEHUMIDIFICATION; EXTRACTION; SYSTEM;
   HUMIDIFICATION; CYCLE; ABSORPTION; SORBENTS
AB Shortage of drinking water is chronic, severe, and wide-spread in the regions of Northern Africa, Middle East, and Central and Southern Asia. Conventional processes like MSF and RO require large amounts of energy in the form of thermal energy (for MSF) or electric power (for RO). Most desalination plants using these technologies are fossil-fuel driven. This results in a large carbon footprint for the desalination plant, and sensitivity to the price and availability of oil.
   Decentralized water production is important for regions which have neither the infrastructure nor the economic resources to run MSF or RO plants and which are sufficiently distant from large scale production facilities that pipeline distribution is prohibitive. Many such regions are found in the developing world in regions of high incidence of solar radiation. Accordingly, the problem of providing arid areas with fresh water can be solved by extracting water from Atmospheric air.
   The Atmospheric air is considered a huge and renewable source of fresh water. The atmosphere contains about 12,900 km(3) of fresh water, whereas liquid water resources of inhabited lands is about 12,500 km(3).
   In this paper, atmospheric water vapor processing (AWVP) technology is reviewed. These processors are machines which extract water molecules from the atmosphere, ultimately causing a phase change from vapor to liquid. Three classes of machines have been proposed. These classes are either cool a surface below the dew point of the ambient air, concentrate water vapor through use of solid or liquid desiccants, or induce and control convection in a tower structure. The review is extended to cover different humidification and dehumidification (H-DH) techniques in which air is used as a medium to carry water in the form of vapor. The study concentrates on the extracting potable water from air especially with respect to the remote/rural arid places. Finally, different technological processes to extract water from the ambient air using solar energy as a power source are focused with discussing their strengths and limitations. (C) 2012 Elsevier Ltd. All rights reserved.
C1 Al Jouf Univ, Coll Engn, Ksa, Saudi Arabia.
RP El-Ghonemy, AMK (reprint author), Al Jouf Univ, Coll Engn, Ksa, Saudi Arabia.
EM amghonemy@yahoo.com
RI El-Ghonemy, Amin/D-3938-2014
OI El-Ghonemy, Amin/0000-0003-4147-4010
CR Abualhamayel HI, 1997, DESALINATION, V113, P51, DOI 10.1016/S0011-9164(97)00114-8
   Al-Hallaj S, 1998, DESALINATION, V120, P273, DOI 10.1016/S0011-9164(98)00224-0
   Al-hassan GA, 2009, WATER RESOUR MANAG, V23, P2805, DOI 10.1007/s11269-009-9410-9
   [Anonymous], ASHRAE HDB FUND
   Aristov YI, 1999, SOL ENERGY, V66, P165, DOI 10.1016/S0038-092X(98)00110-8
   Bar E, 2004, DESALINATION, V165, P335, DOI 10.1016/j.desal.2004.06.038
   Bardi U, 2008, DESALINATION, V220, P588, DOI 10.1016/j.desal.2007.04.059
   Beckman JR, 1999, 98FC810049
   Beckmann JR, 2005, US Patent, Patent No. [6,911,121, 6911121]
   Ben Bacha H, 2003, RENEW ENERG, V28, P2335, DOI 10.1016/S0960-1481(03)00167-8
   Ben Bacha H, 1999, RENEW ENERG, V18, P349
   Beysens D, 2000, SECHERESSE, V11, P4
   Bourouni K, 2001, DESALINATION, V137, P167, DOI 10.1016/S0011-9164(01)00215-6
   Chafik E, 2003, DESALINATION, V156, P333, DOI 10.1016/S0011-9164(03)00364-3
   EI-Ghonemy AMK, 2012, RENEW SUST ENERG REV, V16, P1537, DOI 10.1016/j.rser.2011.11.002
   El-Dessouki H. T., 2002, FUNDAMENTALS SALT WA
   EL-Sharkawy I, 2000, THESIS MANSOURA U
   Elsarrag E, 2011, CIBSE TECHN C DEM U
   Farid MM, 2003, DESALINATION, V151, P153, DOI 10.1016/S0011-9164(02)00994-3
   Gad HE, 2001, RENEW ENERG, V22, P541, DOI 10.1016/S0960-1481(00)00112-9
   Gordeeva LG, 1998, REACT KINET CATAL L, V65, P153, DOI 10.1007/BF02475329
   Habeebullah BA, 2009, DESALINATION, V237, P330, DOI 10.1016/j.desal.2008.01.025
   Hamed A., 2011, NATURAL RESOURCES, V2, P8, DOI DOI 10.4236/NR.201121002
   Hamed AM, 2000, RENEW ENERG, V19, P625, DOI 10.1016/S0960-1481(99)00068-3
   Hamed AM, 2003, RENEW ENERG, V28, P1587, DOI 10.1016/S0960-1481(03)00005-3
   Hamed AM, 2010, J HEAT MASS TRANSF, V4, P213
   Hamed AM, 2000, INT J RENEWABLE ENER, V2, P244
   Jacobs AFG, 2008, ATMOS RES, V87, P377, DOI 10.1016/j.atmosres.2007.06.007
   Kabeel AE, 2007, RENEW ENERG, V32, P157, DOI 10.1016/j.renene.2006.01.015
   Kabeel AE, 2006, INT J ENERG RES, V30, P381, DOI 10.1002/er.1155
   KHALIL A, 1993, DESALINATION, V93, P587, DOI 10.1016/0011-9164(93)80133-8
   KOBAYASHI M, 1963, SOL ENERGY, V7, P93, DOI 10.1016/0038-092X(63)90034-3
   Muller-Holst H, 1998, RENEW ENERG, V14, P311, DOI 10.1016/S0960-1481(98)00083-4
   Parekh S, 2004, DESALINATION, V160, P167, DOI 10.1016/S0011-9164(04)90007-0
   Prakash G, 2010, POTENTIAL SOLAR DRIV
   Roland V, 2001, WATER RES, V35, P1
   Shanmugam G, 2004, INT C WAT RES AR ENV
   Sofrata H, 1981, P SOL DES WORKSH, P71
   Sultan A, 2004, RENEW ENERG, V29, P1515, DOI 10.1016/S0960-1481(03)00020-X
   Tygarinov V., 1947, Patent, Patent No. 69751
   Wahlgren RV, 2001, WATER RES, V35, P1, DOI 10.1016/S0043-1354(00)00247-5
   Wang GQ, 2007, J HYDRO-ENVIRON RES, V1, P1, DOI 10.1016/j.jher.2007.03.001
   Zheng QR, 2011, INT C COMP DISTR CON
NR 43
TC 11
Z9 12
U1 2
U2 70
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1364-0321
J9 RENEW SUST ENERG REV
JI Renew. Sust. Energ. Rev.
PD OCT
PY 2012
VL 16
IS 8
BP 6384
EP 6422
DI 10.1016/j.rser.2012.06.029
PG 39
WC GREEN & SUSTAINABLE SCIENCE & TECHNOLOGY; Energy & Fuels
SC Science & Technology - Other Topics; Energy & Fuels
GA 038OU
UT WOS:000311184800073
DA 2018-12-27
ER

PT J
AU Lopes, RJG
   Quinta-Ferreira, RM
AF Lopes, Rodrigo J. G.
   Quinta-Ferreira, Rosa M.
TI RETRACTED: A hybrid CFD framework for fluidized bed ozonation reactors
   coupling interface tracking and discrete particle methods(Retracted
   article. See vol. 233, pg. 378, 2013)
SO CHEMICAL ENGINEERING JOURNAL
LA English
DT Article; Proceedings Paper; Retracted Publication
CT 22nd International Symposium on Chemical Reaction Engineering (ISCRE)
CY SEP 02-05, 2012
CL Maastricht, NETHERLANDS
DE Interface tracking; Discrete particle method; Fluidized bed reactor;
   Catalytic ozonation; Hydrodynamics; Reactive flow
ID BUBBLE-COLUMN; NUMERICAL-SIMULATION; SURFACE-TENSION; MASS-TRANSFER;
   FLOW; DYNAMICS; BEHAVIOR; SYSTEMS; VOLUME; MODEL
AB In this work, a fluidized bed reactor was investigated theoretically and experimentally for the catalytic ozonation of phenol-like pollutants. First, an interface tracking sub-model dealing with the individual motion of ozone bubbles in the continuous phase, and a discrete particle sub-model accounting for the trajectories of the solid particles were embedded accordingly into a hybrid CFD framework. Second, the effect of physicochemical properties including the surface tension and fluid viscosity was thoroughly evaluated at different hydrodynamic flow regimes. Afterwards, the influence of ozone velocity was quantified both on the gas and liquid superficial velocities and on the detoxification efficiency of liquid pollutants. Here, the interface tracking-discrete particle hybrid model was found to slightly overestimate radial bubble velocities being almost negligible in the center region of the fluidized bed reactor. As the surface tension increased, the mineralization efficiency was considerably lower and became higher when low-viscosity conditions were used for the ozonation of organic pollutants. Finally, the morphological features of interstitial flow maps at different hydrodynamic and reactive catalytic ozonation conditions highlighted the occurrence of bubble plume-like structures which affected the overall decontamination efficiency of phenol-like pollutants within the gas-liquid-solid ozonation reactor. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Lopes, Rodrigo J. G.; Quinta-Ferreira, Rosa M.] Univ Coimbra, Dept Chem Engn, GERSE, CIEPQPF, P-3030790 Coimbra, Portugal.
RP Lopes, RJG (reprint author), Univ Coimbra, Dept Chem Engn, GERSE, CIEPQPF, Rua Silvio Lima,Polo 2 Pinhal de Marrocos, P-3030790 Coimbra, Portugal.
EM rodrigo@eq.uc.pt
CR Behjat Y, 2011, INT COMMUN HEAT MASS, V38, P100, DOI 10.1016/j.icheatmasstransfer.2010.09.014
   BRACKBILL JU, 1992, J COMPUT PHYS, V100, P335, DOI 10.1016/0021-9991(92)90240-Y
   COVER AE, 1973, CHEM ENG PROG, V69, P31
   Delnoij E, 1999, CHEM ENG SCI, V54, P2217, DOI 10.1016/S0009-2509(98)00362-5
   Delnoij E, 1997, CHEM ENG SCI, V52, P1429, DOI 10.1016/S0009-2509(96)00515-5
   Delnoij E, 1997, CHEM ENG SCI, V52, P3623, DOI 10.1016/S0009-2509(97)00268-6
   Di Renzo A, 2007, CHEM ENG SCI, V62, P116, DOI 10.1016/j.ces.2006.08.009
   Dudukovic MP, 1999, CHEM ENG SCI, V54, P1975, DOI 10.1016/S0009-2509(98)00367-4
   Fan L.-S., 1989, BUTTERWORTH SERIES C
   Fox RO, 1998, CHEM ENG PROCESS, V37, P521, DOI 10.1016/S0255-2701(98)00059-2
   Gerlach D, 2006, INT J HEAT MASS TRAN, V49, P740, DOI 10.1016/j.ijheatmasstransfer.2005.07.045
   Gerlinger W, 2000, CHEM ENG SCI, V55, P4255, DOI 10.1016/S0009-2509(00)00064-6
   HIRT CW, 1981, J COMPUT PHYS, V39, P201, DOI 10.1016/0021-9991(81)90145-5
   Hoomans BPB, 1996, CHEM ENG SCI, V51, P99, DOI 10.1016/0009-2509(95)00271-5
   Huang XY, 2011, PARTICUOLOGY, V9, P441, DOI 10.1016/j.partic.2011.03.005
   Krishna R, 2001, CHEM ENG RES DES, V79, P283, DOI 10.1205/026387601750281815
   Kulkarni AA, 2005, IND ENG CHEM RES, V44, P5873, DOI 10.1021/ie049131p
   Lain S, 1999, CHEM ENG SCI, V54, P4913, DOI 10.1016/S0009-2509(99)00212-2
   Li Y, 1999, CHEM ENG SCI, V54, P5101, DOI 10.1016/S0009-2509(99)00263-8
   Lopes RJG, 2011, CHEM ENG J, V172, P476, DOI 10.1016/j.cej.2011.06.043
   Mazzei L, 2008, CHEM ENG SCI, V63, P5831, DOI 10.1016/j.ces.2008.08.029
   Montastruc L, 2009, CHEM ENG J, V148, P139, DOI 10.1016/j.cej.2008.08.035
   OSHER S, 1988, J COMPUT PHYS, V79, P12, DOI 10.1016/0021-9991(88)90002-2
   Pan Y, 2000, AICHE J, V46, P434, DOI 10.1002/aic.690460303
   Panneerselvam R, 2009, CHEM ENG SCI, V64, P1119, DOI 10.1016/j.ces.2008.10.052
   Pfleger D, 2001, CHEM ENG SCI, V56, P1737, DOI 10.1016/S0009-2509(00)00403-6
   Prosperetti A., 2001, DROP SURFACE INTERAC, V21
   Roghair I, 2011, CHEM ENG SCI, V66, P3204, DOI 10.1016/j.ces.2011.02.030
   SATTERFIELD CN, 1980, CHEM ENG SCI, V35, P195, DOI 10.1016/0009-2509(80)80087-X
   Sivaguru K, 2009, CHEM ENG J, V155, P207, DOI 10.1016/j.cej.2009.07.037
   UNVERDI SO, 1992, J COMPUT PHYS, V100, P25, DOI 10.1016/0021-9991(92)90307-K
   Yang GQ, 2007, CHEM ENG SCI, V62, P2, DOI 10.1016/j.ces.2006.08.021
   Yang N., 2005, CHINA PART, V3, P78
NR 33
TC 4
Z9 4
U1 5
U2 35
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 1385-8947
EI 1873-3212
J9 CHEM ENG J
JI Chem. Eng. J.
PD OCT 1
PY 2012
VL 207
SI SI
BP 403
EP 413
DI 10.1016/j.cej.2012.06.143
PG 11
WC Engineering, Environmental; Engineering, Chemical
SC Engineering
GA 038OR
UT WOS:000311184500043
DA 2018-12-27
ER

PT J
AU Cucchiara, S
   Stronati, L
   Aloi, M
AF Cucchiara, Salvatore
   Stronati, Laura
   Aloi, Marina
TI RETRACTED: Interactions Between Intestinal Microbiota and Innate Immune
   System in Pediatric Inflammatory Bowel Disease (Retracted article. See
   vol. 48, pg. 565, 2014)
SO JOURNAL OF CLINICAL GASTROENTEROLOGY
LA English
DT Article; Retracted Publication
DE intestinal microbiota; immune system; pediatric inflammatory bowel
   disease
ID CROHNS-DISEASE; GUT MICROBIOTA; ADHERENT; COLI; HOMEOSTASIS;
   PATHOGENESIS; GENETICS; PROTEIN; AUTOPHAGY; CELLS
AB Inflammatory bowel disease (IBD) is the result of an altered immune homeostasis within the intestinal mucosa against the gut microbiota, leading to chronic inflammation in genetically predisposed individuals. Under normal conditions, the immune system defends against pathogens and prevents the passage of excessive intestinal bacteria; regulatory pathways must maintain a low-grade, controlled inflammation in a healthy gut, but also induce a protective response against pathogens. The innate immune system is the first-line defense from microbes; dendritic cells, macrophages, and epithelial cells produce an initial, immediate response. The immune system constantly controls commensal bacteria and utilizes constitutive antimicrobial mechanisms to sustain immune homeostasis. The discovery that several genes linked to IBD modulate microbial recognition and innate immune pathways, such as nucleotide oligomerization domain 2 (Nod2), and genes that mediate autophagy (ie, ATG16L1, IRGM), has highlighted the critical role of host-microbe interactions in controlling intestinal immune homeostasis. Commensal microorganisms actively interact with the intestinal mucosa and influence the activity of the immune system as well as the amplitude of the immune response. In contrast, host factors can influence microbes, which in turn modulate disease susceptibility. In this paper, we focus on the mechanisms that mediate host-microbe interactions and how the disruption of this balance leads to chronic intestinal inflammation in IBD.
C1 [Cucchiara, Salvatore; Aloi, Marina] Univ Roma La Sapienza, Dept Pediat, Pediat Gastroenterol & Liver Unit, I-00161 Rome, Italy.
RP Cucchiara, S (reprint author), Univ Roma La Sapienza, Dept Pediat, Pediat Gastroenterol & Liver Unit, Viale Regina Elena 324, I-00161 Rome, Italy.
EM salvatore.cucchiara@uniroma1.it
OI Cucchiara, Salvatore/0000-0002-2939-9698
CR Abraham C, 2011, GASTROENTEROLOGY, V140, P1729, DOI 10.1053/j.gastro.2011.02.012
   Andersson U, 2000, J EXP MED, V192, P565, DOI 10.1084/jem.192.4.565
   Benchimol EI, 2011, INFLAMM BOWEL DIS, V17, P423, DOI 10.1002/ibd.21349
   Bevins CL, 2011, NAT REV MICROBIOL, V9, P356, DOI 10.1038/nrmicro2546
   Blumberg R, 2011, GASTROENTEROLOGY, V140, P1701, DOI 10.1053/j.gastro.2011.03.013
   Bringer MA, 2006, CELL MICROBIOL, V8, P471, DOI 10.1111/j.1462-5822.2005.00639.x
   Bringer MA, 2005, INFECT IMMUN, V73, P712, DOI 10.1128/IAI.73.2.712-721.2005
   Chassaing B, 2011, GASTROENTEROLOGY, V140, P1720, DOI 10.1053/j.gastro.2011.01.054
   Cho JH, 2011, GASTROENTEROLOGY, V140, P1704, DOI 10.1053/j.gastro.2011.02.046
   Fava F, 2011, WORLD J GASTROENTERO, V17, P557, DOI 10.3748/wjg.v17.i5.557
   Frank DN, 2007, P NATL ACAD SCI USA, V104, P13780, DOI 10.1073/pnas.0706625104
   Hammer HF, 2011, DIGEST DIS, V29, P550, DOI 10.1159/000332981
   Harris HE, 2004, EUR J IMMUNOL, V34, P1503, DOI 10.1002/eji.200424916
   Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107
   Hugot P, 2011, NATURE, V411, P599
   Iebba V, 2011, DIGEST DIS, V29, P531, DOI 10.1159/000332969
   Kaser A, 2011, CELL MOL LIFE SCI, V68, P3643, DOI 10.1007/s00018-011-0827-y
   Khor B, 2011, NATURE, V474, P307, DOI 10.1038/nature10209
   Lapaquette P, 2010, CELL MICROBIOL, V12, P99, DOI 10.1111/j.1462-5822.2009.01381.x
   Lees CW, 2011, GUT, V60, P1739, DOI 10.1136/gut.2009.199679
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   MacDonald TT, 2011, GASTROENTEROLOGY, V140, P1768, DOI 10.1053/j.gastro.2011.02.047
   Maloy KJ, 2011, NATURE, V474, P298, DOI 10.1038/nature10208
   Meconi S, 2007, CELL MICROBIOL, V9, P1252, DOI 10.1111/j.1462-5822.2006.00868.x
   Negroni A, 2012, INFLAMM BOWEL DIS, V18, P913, DOI 10.1002/ibd.21899
   Packey CD, 2009, CURR OPIN INFECT DIS, V22, P292, DOI 10.1097/QCO.0b013e32832a8a5d
   Rescigno M, 2011, TRENDS IMMUNOL, V32, P256, DOI 10.1016/j.it.2011.04.003
   Schirbel A, 2011, EXPERT REV GASTROENT, V5, P33, DOI 10.1586/EGH.10.76
   Scott CL, 2011, TRENDS IMMUNOL, V32, P412, DOI 10.1016/j.it.2011.06.003
   Sepehri S, 2011, INFLAMM BOWEL DIS, V17, P1451, DOI 10.1002/ibd.21509
   Shaw MH, 2011, TRENDS IMMUNOL, V32, P73, DOI 10.1016/j.it.2010.12.007
   Strober W, 2011, MUCOSAL IMMUNOL, V4, P484, DOI 10.1038/mi.2011.29
   Strober W, 2010, NAT MED, V16, P1195, DOI 10.1038/nm1110-1195
   Sun LL, 2011, CURR OPIN GASTROEN, V27, P321, DOI 10.1097/MOG.0b013e32834661b4
   Thomazini CM, 2011, INT J MED MICROBIOL, V301, P475, DOI 10.1016/j.ijmm.2011.04.015
NR 35
TC 19
Z9 19
U1 2
U2 18
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0192-0790
EI 1539-2031
J9 J CLIN GASTROENTEROL
JI J. Clin. Gastroenterol.
PD OCT
PY 2012
VL 46
IS 9
SU 1
BP S64
EP S66
DI 10.1097/MCG.0b013e31826a857f
PG 3
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 029DP
UT WOS:000310475300013
PM 22955361
DA 2018-12-27
ER

PT J
AU Kichigina, G
AF Kichigina, Galina
TI RETRACTED: Disease, Health Care and Government in Late Imperial Russia
   (Retracted article. See vol. 59, pg. 649, 2015)
SO MEDICAL HISTORY
LA English
DT Book Review; Retracted Publication
C1 [Kichigina, Galina] Univ Toronto, Toronto, ON M5S 1A1, Canada.
RP Kichigina, G (reprint author), Univ Toronto, Toronto, ON M5S 1A1, Canada.
CR Henze Charlotte E., 2011, DIS HLTH CARE GOVT L
NR 1
TC 1
Z9 1
U1 3
U2 6
PU CAMBRIDGE UNIV PRESS
PI CAMBRIDGE
PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND
SN 0025-7273
EI 2048-8343
J9 MED HIST
JI Med. Hist.
PD OCT
PY 2012
VL 56
IS 4
BP 600
EP 601
DI 10.1017/mdh.2012.62
PG 2
WC Health Care Sciences & Services; History & Philosophy Of Science
SC Health Care Sciences & Services; History & Philosophy of Science
GA 037TX
UT WOS:000311130500018
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Abou-Jaoude, MM
   Abou-Jaoude, WJ
   Almawi, WY
AF Abou-Jaoude, Maroun M.
   Abou-Jaoude, Walid J.
   Almawi, Wassim Y.
TI RETRACTED: Sex Matching Plays a Role in Outcome of Kidney Transplant
   (Retracted article. See vol. 11, pg. 85, 2013)
SO EXPERIMENTAL AND CLINICAL TRANSPLANTATION
LA English
DT Article; Retracted Publication
DE Gender matching; Graft function; Immunosuppression; Kidney transplant
ID RENAL-TRANSPLANTATION; GRAFT-SURVIVAL; DONOR GENDER; RISK-FACTORS; TERM;
   AGE; IMPACT; SIZE
AB Objectives: The effect of sex matching between donors and recipients was studied in 135 kidney transplant operations performed in our center between December 1998 and December 2007.
   Materials and Methods: Patients were divided into 4 groups: group 1 (63 patients, male donor-male recipient), group 2 (25 patients, male donor-female recipient), group 3 (37 patients, female donor-male recipient), and group 4 (10 patients, female donor-female recipient). Except for donor age, recipient body mass index and donor-recipient HLA AB-DR matching, recipient, and donor demographics, and the immunosuppression were comparable in all groups.
   Results: Acute rejection and the need for anti-thymocyte globulin Fresenius rescue therapy were comparable between the 4 donor-recipient combinations. Excellent 1-year actuarial patient and graft survival, comparable hospital stay, and incidence of delayed graft and slow graft function were comparable between the 4 groups. One death occurred, each, in groups 1 and 2; posttransplant complications being comparable. While 1-year graft survival (death censored and uncensored) were comparable, 1-year graft function (serum creatinine) showed that the worst graft function was seen in group 3 (female-to-male). Significant differences between the 4 patient groups also were seen in pretransplant and posttransplant hemoglobin levels as well as in posttransplant arterial hypertension and high-density lipoprotein cholesterol blood levels. Other metabolic indices were generally comparable between the 4 patient groups.
   Conclusions: These results revealed that sex mismatching (group 2, male donor to female recipient) had the best 1-year graft function but the same 1-year patient and graft survival.
C1 [Almawi, Wassim Y.] Arabian Gulf Univ, Coll Med & Med Sci, Dept Med Biochem, Manama, Bahrain.
   [Abou-Jaoude, Maroun M.; Abou-Jaoude, Walid J.] Middle E Inst Hlth, Transplantat Unit, Bsalim, Lebanon.
RP Almawi, WY (reprint author), Arabian Gulf Univ, Coll Med & Med Sci, Dept Med Biochem, POB 22979, Manama, Bahrain.
EM wassim@agu.edu.bh
CR Al-Khaldi A, 2006, J HEART LUNG TRANSPL, V25, P461, DOI 10.1016/j.healun.2005.11.456
   Ben Hamida F, 1999, TRANSPLANT P, V31, P3338, DOI 10.1016/S0041-1345(99)00817-9
   BRENNER BM, 1992, J AM SOC NEPHROL, V3, P1038
   BRENNER BM, 1992, J AM SOC NEPHROL, V3, P162
   Busson M, 1997, CLIN TRANSPLANT, V11, P15
   Dunn TB, 2011, AM J TRANSPLANT, V11, P2132, DOI 10.1111/j.1600-6143.2011.03640.x
   Hariharan S, 2002, KIDNEY INT, V62, P311, DOI 10.1046/j.1523-1755.2002.00424.x
   Kaneku Hugo K, 2006, Clin Transpl, P1
   Kasiske BL, 2011, AM J KIDNEY DIS, V57, P466, DOI 10.1053/j.ajkd.2010.10.054
   Kwon OJ, 2004, TRANSPLANT P, V36, P2040, DOI 10.1016/j.transproceed.2004.07.046
   Lankarani MM, 2009, ANN TRANSPL, V14, P20
   Li C, 2011, HEPATOB PANCREAT DIS, V10, P248, DOI 10.1016/S1499-3872(11)60041-6
   MACKENZIE HS, 1995, KIDNEY INT S, V52, pS38
   Nicholson ML, 2000, BRIT J SURG, V87, P314, DOI 10.1046/j.1365-2168.2000.01390.x
   Oien CM, 2007, TRANSPLANTATION, V83, P600, DOI 10.1097/01.tp.0000255583.34329.dd
   Pessione F, 2003, TRANSPLANTATION, V75, P361, DOI 10.1097/01.TP.0000044171.97375.61
   Poggio ED, 2006, AM J TRANSPLANT, V6, P616, DOI 10.1111/j.1600-6143.2005.01225.x
   RICHIE RE, 1983, ANN SURG, V197, P672, DOI 10.1097/00000658-198306000-00005
   Silbiger SR, 2003, ADV RENAL REPLACE TH, V10, P3, DOI 10.1053/jarr.2003.50001
   Tamura MK, 2012, KIDNEY INT, V82, P261, DOI 10.1038/ki.2011.384
   Zeier M, 2002, J AM SOC NEPHROL, V13, P2570, DOI 10.1097/01.ASN.0000030078.74889.69
NR 21
TC 5
Z9 6
U1 1
U2 7
PU BASKENT UNIV
PI ANKARA
PA TASKENT CADDESI NO 77, KAT 4, BAHCELIEVLER, ANKARA, 06490, TURKEY
SN 1304-0855
J9 EXP CLIN TRANSPLANT
JI Exp. Clin. Transplant.
PD OCT
PY 2012
VL 10
IS 5
BP 466
EP 470
DI 10.6002/ect.2011.0205
PG 5
WC Transplantation
SC Transplantation
GA 028GZ
UT WOS:000310412100008
PM 23031085
OA Bronze
DA 2018-12-27
ER

PT J
AU Mahawar, M
   Singh, A
   Jalgaonkar, K
AF Mahawar, Manoj
   Singh, Anupama
   Jalgaonkar, Kirti
TI RETRACTED: Utility of apple pomace as a substrate for various products:
   A review (Retracted article. See vol. 91, pg. 700, 2013)
SO FOOD AND BIOPRODUCTS PROCESSING
LA English
DT Review; Retracted Publication
DE Apple pomace; Waste utilization; Biotransformation; Industrial products
ID SOLID-STATE FERMENTATION; ETHANOL FERMENTATION; PROCESSING WASTES; FEED;
   IMPROVEMENT; QUALITY; FRUIT
AB In large scale apple juice industry, about 75% of apple is utilized for juice and the remaining 25% is the by-product, i.e. apple pomace. In India, more than 500 apple processing industries produces 1.3 million tonnes of apple pomace per annum which involves an annual disposal expenditure of $10 million. Generally, apple pomace is thrown away which causes environmental pollution and only approximately 10,000 tonnes of apple pomace is being utilized. As pomace is a part of the fruit, it has potential for being transformed into various edible and industrial products. It is a rich source (amount per 100 g) of carbohydrate (11.8 g), pectin (16.95 g), crude fibre (2.3 g) and minerals (0.3 g) and as such is a good source of nutrients. This paper reviews the work done to utilize this precious resource which can prove useful for setting up of small scale industries. (C) 2012 The Institution of Chemical Engineers. Published by Elsevier B.V. All rights reserved.
C1 [Mahawar, Manoj] Indian Agr Res Inst, Dept Agr Engn, New Delhi 110012, India.
   [Singh, Anupama] Govind Ballabh Pant Univ Agr & Technol, Dept PHPFE, Pantnagar 263145, Uttarakhand, India.
   [Jalgaonkar, Kirti] Indian Agr Res Inst, Dept Post Harvest Technol, New Delhi 110012, India.
RP Mahawar, M (reprint author), Indian Agr Res Inst, Dept Agr Engn, New Delhi 110012, India.
EM manojmahawar362@gmail.com
CR Agrahari P. R., 2003, INDIAN FOOD PACKER, V57, P56
   Alwood W.B., 1903, USDA BUR CHEM B, V71
   Bae D. H., 1994, Korean Journal of Dairy Science, V16, P295
   Barwal V.S., 1996, J FOOD SCI TECHNOL, V28, P257
   Bates A. W., 2001, IFT ANN M NEW ORL LO
   Bhushan S, 2008, CRIT REV BIOTECHNOL, V28, P285, DOI [10.1080/07388550802368895, 10.1080/07388550802368895 ]
   Bielig H., 1984, Process for manufacture of bakery products and patisserie products. German Democratic Republic Patent DD, Patent No. 213587
   CAPREZ A, 1987, LEBENSM WISS TECHNOL, V20, P245
   CARSON KJ, 1994, J FOOD SCI, V59, P1213, DOI 10.1111/j.1365-2621.1994.tb14679.x
   Chantanta D.K., 2008, INTERNET J MICROBIOL, V5
   Eingor M.R, 1984, KHLEBOPEKARNAYA KOND, V2, P24
   Ezhov V.N., 1993, Wasteless. Processing of apple pressings. USSR Patent SU, Patent No. [1 785 639, 1785639]
   Fischer R., 1984, Fluessiges Obst, V51, P534
   FRANCIELO V, 2008, CRITICAL REV BIOTECH, V28, P1
   Gentschev L. N., 1988, Industrielle Obst- und Gemueseverwertung, V73, P17
   GUPTA LK, 1990, J SCI FOOD AGR, V50, P55, DOI 10.1002/jsfa.2740500107
   Hang Y. D., 1994, Lebensmittel-Wissenschaft and Technologie, V27, P587, DOI 10.1006/fstl.1994.1115
   HANG Y D, 1986, MIRCEN Journal of Applied Microbiology and Biotechnology, V2, P283, DOI 10.1007/BF00933494
   Hang Y. D., 1989, PROCESSED APPLE PROD, P365
   Hang Y.D., 1987, J FOOD SCI TECHNOL, V41, P115
   HANG YD, 1981, APPL ENVIRON MICROB, V42, P1128
   HANG YD, 1982, J FOOD SCI, V47, P1851, DOI 10.1111/j.1365-2621.1982.tb12897.x
   HANG YD, 1988, NUTR REP INT, V38, P207
   HANG YD, 1984, BIOTECHNOL LETT, V6, P763, DOI 10.1007/BF00133071
   Hendriks ATWM, 2009, BIORESOURCE TECHNOL, V100, P10, DOI 10.1016/j.biortech.2008.05.027
   Hinsch D., 1992, Process for utilization of wastes from apple peeling plants and the products. German Federal Republic Patent DE, Patent No. [4115 162 C1, 4115162]
   HOURS RA, 1988, BIOL WASTE, V23, P221, DOI 10.1016/0269-7483(88)90036-5
   IHL M, 1992, REV ESP CIEN TEC ALI, V32, P185
   Ivy R., 2006, THESIS GBPUA T PANTN
   Jain A., 2006, THESIS GBPUA T PANTN
   JEWELL WJ, 1984, J FOOD SCI, V49, P407, DOI 10.1111/j.1365-2621.1984.tb12433.x
   Johar D.S., 1960, J FOOD SCI, P82
   Joshi V.K., 1999, BIOTECHNOLOGY FOOD F, V1, P124
   Joshi V.K., 1997, DIRECTORATE EXTENSIO, P1
   Joshi V.K., 1991, FOOD BEVERAGE WORLD, V17, P9
   Joshi V.K., 1994, SOLID STATE FERMENTA, P3
   Joshi V.K., 1991, J HORTIC, V48, P321
   Joshi V.K., 1996, BEVERAGE FOOD WORLD, V22, P60
   Joshi VK, 1996, BIORESOURCE TECHNOL, V56, P251, DOI 10.1016/0960-8524(96)00040-5
   Joshi VK, 1996, J FOOD SCI TECH MYS, V33, P414
   JOSHI VK, 1995, CURR SCI INDIA, V69, P263
   Joshi VK, 2000, ACTA ALIMENT HUNG, V29, P323, DOI 10.1556/AAlim.29.2000.4.2
   Kaur M., 1989, THESIS PUNJAB U CHAN
   Kaushal N.K., 1995, INDIAN FOOD PACKER, V49, P17
   Kaushal NK, 2002, J FOOD SCI TECH MYS, V39, P388
   Kennedy M. J., 1994, Australasian Biotechnology, V4, P43
   Khosravy D.K., 1999, FANNI VA MUHANDISI I, V10, P55
   Kumar G., 2008, THESIS GBPUA T PANTN
   LANE AG, 1979, FOOD TECHNOL AUST, V31, P201
   Laufenberg G, 2003, BIORESOURCE TECHNOL, V87, P167, DOI 10.1016/S0960-8524(02)00167-0
   Manimehalai N., 2007, BEV FOOD WORLD, V34, P53
   Maria C.O., 2009, IND CROP PROD, V30, P24
   MILLER JE, 1982, BIOTECHNOL BIOENG, P183
   NARANG MP, 1985, AGR WASTES, V13, P15, DOI 10.1016/0141-4607(85)90008-3
   National horticultural board, 2010, SEL STAT WIS AR PROD
   NGADI MO, 1992, J FOOD ENG, V17, P97, DOI 10.1016/0260-8774(92)90055-B
   Patt V.A., 1984, KHLEBOPEKARNAYA KOND, V1, P18
   POTTER NN, 1978, FOOD SCI
   RAHMAT H, 1995, WORLD J MICROB BIOT, V11, P168, DOI 10.1007/BF00704641
   Ramm A., 1994, Industrielle Obst- und Gemueseverwertung, V79, P2
   Rashad M.M., 2009, INDIAN FOOD PACKER, V48, P47
   Rotova G.P., 1983, PISHCHEVAYA PROMYSCH, V1, P49
   Royer G, 2006, LWT-FOOD SCI TECHNOL, V39, P1022, DOI 10.1016/j.lwt.2006.02.015
   SAKAI T, 1980, APPL ENVIRON MICROB, V39, P908
   Shah G. H., 1994, Indian Food Packer, V48, P47
   Sharma R.C., 2001, APPLE IMPROVEMENT PR, P428
   Sharma T. R., 1985, Indian Food Packer, V39, P53
   Singh P.N., 2009, BIOTECHNOLOGY AGROIN, P14
   Sun J, 2007, FOOD SCI TECHNOL INT, V13, P91, DOI 10.1177/1082013207078525
   USDA, 2010, OFF USDA EST
   Vasil'ev Y.I., 1976, KONSERV OVOSHCE, V3, P32
   VOGET CE, 1985, BIOTECHNOL LETT, V7, P43, DOI 10.1007/BF01032418
   WALTER RH, 1985, J FOOD SCI, V50, P747, DOI 10.1111/j.1365-2621.1985.tb13787.x
   WALTER RH, 1976, J AGR FOOD CHEM, V24, P1244, DOI 10.1021/jf60208a044
   WANG HJ, 1989, J FOOD SCI, V54, P618, DOI 10.1111/j.1365-2621.1989.tb04665.x
   Waugh A. J. B., 1981, South African Food Review, V8, P27
   Woodams EE, 1995, LEBENSM WISS TECHNOL, V28, P348
   Xiaoqiong F., 2009, INT J HYDROGEN ENERG
   Xuan J., 2008, RENEW SUST ENERG REV, V13, P1301
   Yasuhito M., 2006, J BREWING SOC JAPAN, V101, P711
   Zhong-Sun T., 2009, ELECT J BIOTECHNOL, V12
NR 81
TC 11
Z9 11
U1 3
U2 72
PU INST CHEMICAL ENGINEERS
PI RUGBY
PA 165-189 RAILWAY TERRACE, DAVIS BLDG, RUGBY CV21 3HQ, ENGLAND
SN 0960-3085
EI 1744-3571
J9 FOOD BIOPROD PROCESS
JI Food Bioprod. Process.
PD OCT
PY 2012
VL 90
IS C4
BP 597
EP 605
DI 10.1016/j.fbp.2012.04.007
PG 9
WC Biotechnology & Applied Microbiology; Engineering, Chemical; Food
   Science & Technology
SC Biotechnology & Applied Microbiology; Engineering; Food Science &
   Technology
GA 033TH
UT WOS:000310823500001
DA 2018-12-27
ER

PT J
AU Amedei, A
   Prisco, D
   D'Elios, MM
AF Amedei, Amedeo
   Prisco, Domenico
   D'Elios, Mario Milco
TI RETRACTED: Multiple Sclerosis: The Role of Cytokines in Pathogenesis and
   in Therapies (Retracted article. See vol. 17, pg. 1021, 2016)
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Review; Retracted Publication
DE multiple sclerosis; cytokines; T helper cells (Th); Interleukin-17
   (IL-17); Interferons (IFNs)
ID EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; CENTRAL-NERVOUS-SYSTEM;
   MYELIN BASIC-PROTEIN; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS;
   REGULATORY T-CELLS; INTERFERON-BETA TREATMENT; MESSENGER-RNA EXPRESSION;
   BLOOD-BRAIN-BARRIER; IFN-GAMMA GENE; TH17 CELLS
AB Multiple sclerosis, the clinical features and pathological correlate for which were first described by Charcot, is a chronic neuroinflammatory disease with unknown etiology and variable clinical evolution. Although neuroinflammation is a descriptive denominator in multiple sclerosis based on histopathological observations, namely the penetration of leukocytes into the central nervous system, the clinical symptoms of relapses, remissions and progressive paralysis are the result of losses of myelin and neurons. In the absence of etiological factors as targets for prevention and therapy, the definition of molecular mechanisms that form the basis of inflammation, demyelination and toxicity for neurons have led to a number of treatments that slow down disease progression in specific patient cohorts, but that do not cure the disease. Current therapies are directed to block the immune processes, both innate and adaptive, that are associated with multiple sclerosis. In this review, we analyze the role of cytokines in the multiple sclerosis pathogenesis and current/future use of them in treatments of multiple sclerosis.
C1 [Amedei, Amedeo; D'Elios, Mario Milco] Univ Florence, Dept Internal Med, I-50134 Florence, Italy.
   [Amedei, Amedeo; Prisco, Domenico; D'Elios, Mario Milco] Azienda Osped Univ Careggi, Dept Biomed, Patol Med Unit, I-20134 Florence, Italy.
   [Amedei, Amedeo; D'Elios, Mario Milco] Univ Florence, Ctr Oncol Minimally Invas Surg, I-50134 Florence, Italy.
   [Prisco, Domenico] Univ Florence, Dept Med & Surg Crit Care, I-50134 Florence, Italy.
RP Amedei, A (reprint author), Univ Florence, Dept Internal Med, Largo Brambilla 3, I-50134 Florence, Italy.
EM aamedei@unifi.it; priscod@aou-careggi.toscana.it; delios@unifi.it
OI D'Elios, Mario Milco/0000-0001-9160-0930; Prisco,
   Domenico/0000-0002-7787-9610
FU Italian Ministry of University and Research; Ente Cassa di Risparmio di
   Firenze
FX We thank Italian Ministry of University and Research and Ente Cassa di
   Risparmio di Firenze for supporting our studies.
CR Adorini L, 1996, AUTOIMMUNITY, V23, P53, DOI 10.3109/08916939608995329
   Aggarwal S, 2003, J BIOL CHEM, V278, P1910, DOI 10.1074/jbc.M207577200
   Allende ML, 2002, BBA-MOL CELL BIOL L, V1582, P222, DOI 10.1016/S1388-1981(02)00175-0
   Anderson AC, 2000, J EXP MED, V191, P761, DOI 10.1084/jem.191.5.761
   ANDO DG, 1989, CELL IMMUNOL, V124, P132, DOI 10.1016/0008-8749(89)90117-2
   Annunziato F, 2007, J EXP MED, V204, P1849, DOI 10.1084/jem.20070663
   Antel J, 2006, J NEUROIMMUNOL, V180, P3, DOI 10.1016/j.jneuroim.2006.06.032
   Axtell RC, 2011, TRENDS IMMUNOL, V32, P272, DOI 10.1016/j.it.2011.03.008
   Barten LJ, 2010, DRUG DES DEV THER, V4, P343, DOI 10.2147/DDDT.S9331
   Bates D, 2009, Int MS J, V16, P75
   BENNUN A, 1981, EUR J IMMUNOL, V11, P195, DOI 10.1002/eji.1830110307
   Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753
   BEUTLER E, 1992, LANCET, V340, P952, DOI 10.1016/0140-6736(92)92826-2
   Bielekova B, 2010, NEUROLOGY, V74, pS31, DOI 10.1212/WNL.0b013e3181c97ed3
   Bielekova B, 2009, ARCH NEUROL-CHICAGO, V66, P483, DOI 10.1001/archneurol.2009.50
   BILLIAU A, 1977, ANTIMICROB AGENTS CH, V12, P11, DOI 10.1128/AAC.12.1.11
   Brinkmann V, 2002, J BIOL CHEM, V277, P21453, DOI 10.1074/jbc.C220176200
   Brinkmann V, 2009, BRIT J PHARMACOL, V158, P1173, DOI 10.1111/j.1476-5381.2009.00451.x
   Broberg EK, 2004, NEUROSCI LETT, V364, P173, DOI 10.1016/j.neulet.2004.04.059
   CARSON DA, 1983, BLOOD, V62, P737
   Chen Z, 2008, IMMUNOL RES, V41, P87, DOI 10.1007/s12026-007-8014-9
   Compston A., 2005, MCALPINES MULTIPLE S
   Conti L, 2012, J IMMUNOL, V188, P1011, DOI 10.4049/jimmunol.1004013
   Cua DJ, 2003, NATURE, V421, P744, DOI 10.1038/nature01355
   Dandekar AA, 2001, J VIROL, V75, P6115, DOI 10.1128/JVI.75.13.6115-6120.2001
   Das Sarma Jayasri, 2009, J Neuroinflammation, V6, P14, DOI 10.1186/1742-2094-6-14
   De Jonga B.A., 2006, J NEUROIMMUNOL, V126, P172
   Deshpande P, 2007, J IMMUNOL, V178, P6695, DOI 10.4049/jimmunol.178.11.6695
   Dhib-Jalbut S, 2002, NEUROLOGY, V58, pS3, DOI 10.1212/WNL.58.8_suppl_4.S3
   DIJKSTRA CD, 1992, J NEUROIMMUNOL, V40, P183, DOI 10.1016/0165-5728(92)90132-5
   Donati C, 2004, FASEB J, V18, P449, DOI 10.1096/fj.04-1780fje
   EBERS GC, 1986, NEW ENGL J MED, V315, P1638, DOI 10.1056/NEJM198612253152603
   EBERS GC, 1993, NEUROEPIDEMIOLOGY, V12, P1, DOI 10.1159/000110293
   Edwards LJ, 2010, CYTOKINE, V50, P19, DOI 10.1016/j.cyto.2009.12.003
   Ehling Rainer, 2010, Central Nervous System Agents in Medicinal Chemistry, V10, P3
   Ferber IA, 1996, J IMMUNOL, V156, P5
   Fillatreau S, 2008, NAT REV IMMUNOL, V8, P391, DOI 10.1038/nri2315
   Fitzgerald DC, 2007, J IMMUNOL, V179, P3268, DOI 10.4049/jimmunol.179.5.3268
   Fletcher JM, 2010, CLIN EXP IMMUNOL, V162, P1, DOI 10.1111/j.1365-2249.2010.04143.x
   Fort MM, 2001, IMMUNITY, V15, P985, DOI 10.1016/S1074-7613(01)00243-6
   GENAIN CP, 1994, J CLIN INVEST, V94, P1339, DOI 10.1172/JCI117454
   GIJBELS K, 1992, J NEUROIMMUNOL, V41, P29, DOI 10.1016/0165-5728(92)90192-N
   Giovannoni G, 2011, LANCET NEUROL, V10, P329, DOI 10.1016/S1474-4422(11)70023-0
   Giovannoni G, 2010, NEW ENGL J MED, V362, P416, DOI 10.1056/NEJMoa0902533
   Giraudon P, 2009, REV NEUROL-FRANCE, V165, P789, DOI 10.1016/j.neurol.2009.07.004
   Goris A, 1999, J INTERF CYTOK RES, V19, P1037, DOI 10.1089/107999099313262
   Gran B, 2002, J IMMUNOL, V169, P7104, DOI 10.4049/jimmunol.169.12.7104
   Gutcher I, 2006, NAT IMMUNOL, V7, P946, DOI 10.1038/ni1377
   Haak S, 2009, J CLIN INVEST, V119, P61, DOI 10.1172/JCI35997
   Haas J, 2005, EUR J IMMUNOL, V35, P3343, DOI 10.1002/eji.200526065
   Halin C, 2005, BLOOD, V106, P1314, DOI 10.1182/blood-2004-09-3687
   Harada J, 2004, J NEUROCHEM, V88, P1026, DOI 10.1046/j.1471-4159.2003.02219.x
   Harrington LE, 2005, NAT IMMUNOL, V6, P1123, DOI 10.1038/ni1254
   Hartung HP, 2002, LANCET, V360, P2018, DOI 10.1016/S0140-6736(02)12023-X
   Hawker K, 2009, ANN NEUROL, V66, P460, DOI 10.1002/ana.21867
   Hedegaard CJ, 2008, IMMUNOLOGY, V125, P161, DOI 10.1111/j.1365-2567.2008.02837.x
   Hemmer B, 2006, NAT CLIN PRACT NEURO, V2, P201, DOI 10.1038/ncpneuro0154
   Hohlfeld R, 2011, NAT REV NEUROL, V7, P425, DOI 10.1038/nrneurol.2011.105
   Hong J, 2005, P NATL ACAD SCI USA, V102, P6449, DOI 10.1073/pnas.0502187102
   Ifergan I, 2008, BRAIN, V131, P785, DOI 10.1093/brain/awm295
   Imam SA, 2007, J NEUROIMMUNOL, V190, P139, DOI 10.1016/j.jneuroim.2007.07.016
   Jager A, 2009, J IMMUNOL, V183, P7169, DOI 10.4049/jimmunol.0901906
   Jolly PS, 2004, J EXP MED, V199, P959, DOI 10.1084/jem.20030680
   Jung S, 2004, J NEUROIMMUNOL, V148, P63, DOI 10.1016/j.jneuroim.2003.11.014
   Kang ZZ, 2010, IMMUNITY, V32, P414, DOI 10.1016/j.immuni.2010.03.004
   Kataoka H, 2005, CELL MOL IMMUNOL, V2, P439
   Komiyama Y, 2006, J IMMUNOL, V177, P566, DOI 10.4049/jimmunol.177.1.566
   Korn T, 2007, NATURE, V448, P484, DOI 10.1038/nature05970
   Korn T, 2009, ANNU REV IMMUNOL, V27, P485, DOI 10.1146/annurev.immunol.021908.132710
   Korn T, 2008, J NEUROL, V255, P2, DOI 10.1007/s00415-008-6001-2
   Krakauer M, 2008, MULT SCLER J, V14, P622, DOI 10.1177/1352458507087136
   Krakowski M, 1996, EUR J IMMUNOL, V26, P1641, DOI 10.1002/eji.1830260735
   Krump-Konvalinkova V, 2005, ARTERIOSCL THROM VAS, V25, P546, DOI 10.1161/01.ATV.0000154360.36106.d9
   Kuchroo VK, 2002, ANNU REV IMMUNOL, V20, P101, DOI 10.1146/annurev.immunol.20.081701.141316
   Langrish CL, 2005, J EXP MED, V201, P233, DOI 10.1084/jem.20041257
   Larochelle C, 2011, FEBS LETT, V585, P3770, DOI 10.1016/j.febslet.2011.04.066
   Lees JR, 2008, J IMMUNOL, V180, P8066, DOI 10.4049/jimmunol.180.12.8066
   Li YH, 2007, BRAIN, V130, P490, DOI 10.1093/brain/awl273
   Lim SY, 2010, INT J CLIN PRACT, V64, P637, DOI 10.1111/j.1742-1241.2009.02261.x
   Linker RA, 2008, J NEUROIMMUNOL, V205, P64, DOI 10.1016/j.jneuroim.2008.09.007
   Liu XB, 2008, J IMMUNOL, V180, P6070, DOI 10.4049/jimmunol.180.9.6070
   Lock C, 2002, NAT MED, V8, P500, DOI 10.1038/nm0502-500
   Lopez-Diego RS, 2008, NAT REV DRUG DISCOV, V7, P909, DOI 10.1038/nrd2358
   Lovett-Racke AE, 2011, BBA-MOL BASIS DIS, V1812, P246, DOI 10.1016/j.bbadis.2010.05.012
   Ma XY, 2010, J IMMUNOL, V184, P4898, DOI 10.4049/jimmunol.1000142
   Mangan PR, 2006, NATURE, V441, P231, DOI 10.1038/nature04754
   Marino K, 2010, NAT CHEM BIOL, V6, P713, DOI [10.1038/NCHEMBIO.437, 10.1038/nchembio.437]
   Matloubian M, 2004, NATURE, V427, P355, DOI 10.1038/nature02284
   Matusevicius D, 1999, MULT SCLER J, V5, P101, DOI 10.1191/135245899678847275
   Mehling M, 2010, NEUROLOGY, V75, P403, DOI 10.1212/WNL.0b013e3181ebdd64
   Merkler D, 2006, BRAIN PATHOL, V16, P117, DOI 10.1111/j.1750-3639.2006.00004.x
   Miljkovic D, 2007, J NEUROSCI RES, V85, P3598, DOI 10.1002/jnr.21453
   Minagar A, 2010, EXPERT OPIN BIOL TH, V10, P421, DOI 10.1517/14712591003586806
   MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.iy.07.040189.001045
   Mueller AM, 2009, J NEUROIMMUNOL, V209, P57, DOI 10.1016/j.jneuroim.2009.01.024
   Murphy AC, 2010, BRAIN BEHAV IMMUN, V24, P641, DOI 10.1016/j.bbi.2010.01.014
   Murray TJ, 2005, MULTIPLE SCLEROSIS H
   Naismith RT, 2010, NEUROLOGY, V74, P1860, DOI 10.1212/WNL.0b013e3181e24373
   Neukirch F, 1997, J ALLERGY CLIN IMMUN, V99, P270
   NEUMANN H, 1995, SCIENCE, V269, P549, DOI 10.1126/science.7624779
   Noseworthy JH, 1999, NATURE, V399, pA40, DOI 10.1038/399a040
   Nowak EC, 2009, J EXP MED, V206, P1653, DOI 10.1084/jem.20090246
   Oksenberg JR, 2010, NAT REV NEUROL, V6, P429, DOI 10.1038/nrneurol.2010.91
   OPDENAKKER G, 1994, IMMUNOL TODAY, V15, P103, DOI 10.1016/0167-5699(94)90151-1
   Paemen L, 1994, Eur J Neurol, V1, P55, DOI 10.1111/j.1468-1331.1994.tb00051.x
   PANITCH HS, 1987, NEUROLOGY, V37, P1097, DOI 10.1212/WNL.37.7.1097
   Parham C, 2002, J IMMUNOL, V168, P5699, DOI 10.4049/jimmunol.168.11.5699
   Park H, 2005, NAT IMMUNOL, V6, P1133, DOI 10.1038/ni1261
   PETTE M, 1990, NEUROLOGY, V40, P1770, DOI 10.1212/WNL.40.11.1770
   Pot C, 2009, J IMMUNOL, V183, P797, DOI 10.4049/jimmunol.0901233
   Probert L, 2000, BRAIN, V123, P2005, DOI 10.1093/brain/123.10.2005
   Ramgolam VS, 2011, J IMMUNOL, V186, P4518, DOI 10.4049/jimmunol.1000271
   Ramgolam VS, 2009, J IMMUNOL, V183, P5418, DOI 10.4049/jimmunol.0803227
   Ransohoff RM, 2003, NAT REV IMMUNOL, V3, P569, DOI 10.1038/nri1130
   Rouach N, 2006, EUR J NEUROSCI, V23, P1453, DOI 10.1111/j.1460-9568.2006.04671.x
   SCHLUESENER HJ, 1985, J IMMUNOL, V135, P3128
   Singh SP, 2008, J IMMUNOL, V180, P214, DOI 10.4049/jimmunol.180.1.214
   Steinman L, 2003, NAT REV IMMUNOL, V3, P483, DOI 10.1038/nri1108
   Steinman L, 2010, NAT IMMUNOL, V11, P41, DOI 10.1038/ni.1803
   Strader CR, 2011, J NAT PROD, V74, P900, DOI 10.1021/np2000528
   Stromnes IM, 2008, NAT MED, V14, P337, DOI 10.1038/nm1715
   Sutton C, 2006, J EXP MED, V203, P1685, DOI 10.1084/jem.20060285
   Sweeney CM, 2011, BRAIN BEHAV IMMUN, V25, P1170, DOI 10.1016/j.bbi.2011.03.007
   Tao R, 2009, J CARDIOVASC PHARM, V53, P486, DOI 10.1097/FJC.0b013e3181a7b58a
   Tran EH, 2000, J IMMUNOL, V164, P2759, DOI 10.4049/jimmunol.164.5.2759
   Tzartos JS, 2008, AM J PATHOL, V172, P146, DOI 10.2353/ajpath.2008.070690
   Valenzuela RM, 2007, MULT SCLER J, V13, P754, DOI 10.1177/1352458506074510
   Van Doorn R, 2010, GLIA, V58, P1465, DOI 10.1002/glia.21021
   Vieira PL, 2003, J IMMUNOL, V170, P4483, DOI 10.4049/jimmunol.170.9.4483
   Vogelgesang A, 2010, ACTA NEUROL SCAND, V122, P237, DOI 10.1111/j.1600-0404.2009.01295.x
   Vollmer TL, 2005, J IMMUNOL, V174, P2696, DOI 10.4049/jimmunol.174.5.2696
   Webb M, 2004, J NEUROIMMUNOL, V153, P108, DOI 10.1016/j.jneuroim.2004.04.015
   Weinstock-Guttman B, 2008, EXPERT OPIN BIOL TH, V8, P1435, DOI [10.1517/14712590802333063, 10.1517/14712598.8.9.1435 ]
   Wiendl H, 2008, J NEUROL, V255, P1449, DOI 10.1007/s00415-008-0061-1
   Xiao BG, 1998, J NEUROIMMUNOL, V89, P113, DOI 10.1016/S0165-5728(98)00123-4
   Yang L, 2008, NATURE, V454, P350, DOI 10.1038/nature07021
   Yates D, 2010, NAT REV NEUROL, V6, P57, DOI [10.1038/nrneurol.2010.20, 10.1038/nrneurol.2010.154, 10.1038/nrneurol.2009.230, 10.1038/nrneurol.2010.58, 10.1038/nrneurol.2010.169]
   Yura M, 2001, J AUTOIMMUN, V17, P17, DOI 10.1006/jaut.2001.0520
   Zabad RK, 2007, MULT SCLER, V13, P517, DOI 10.1177/1352458506070319
   ZAMVIL SS, 1990, ANNU REV IMMUNOL, V8, P579, DOI 10.1146/annurev.iy.08.040190.003051
   Zhang GX, 2003, J IMMUNOL, V170, P2153, DOI 10.4049/jimmunol.170.4.2153
   Zhang ZL, 2010, SEMIN IMMUNOPATHOL, V32, P55, DOI 10.1007/s00281-009-0190-3
   Zhou LA, 2007, NAT IMMUNOL, V8, P967, DOI 10.1038/ni1488
   Zuvich RL, 2009, SEMIN IMMUNOL, V21, P328, DOI 10.1016/j.smim.2009.08.003
NR 144
TC 35
Z9 35
U1 2
U2 30
PU MDPI AG
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD OCT
PY 2012
VL 13
IS 10
BP 13438
EP 13460
DI 10.3390/ijms131013438
PG 23
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
SC Biochemistry & Molecular Biology; Chemistry
GA 031YE
UT WOS:000310677800073
PM 23202961
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Aicardi, G
AF Aicardi, Giorgio
TI RETRACTED: Age-Related Impairment of Visual Recognition Memory
   Correlates with Impaired Synaptic Distribution of GluA2 and Protein
   Kinase M zeta in the Dentate Gyrus (Retracted article. See vol. 16, pg.
   339, 2013)
SO REJUVENATION RESEARCH
LA English
DT Editorial Material; Retracted Publication
ID AMPA-RECEPTOR TRAFFICKING; LONG-TERM POTENTIATION; PKM-ZETA;
   NEUROTROPHIC FACTOR; MAMMALIAN TARGET; WORKING-MEMORY; PLASTICITY;
   RAPAMYCIN; DECLINE; DISEASE
AB Age-related functional alterations in the perforant path projection from the entorhinal cortex to the dentate gyrus (DG) of the hippocampus play a major role in age-related memory impairments, but little is known about the molecular mechanisms responsible for these changes. In a recent study, young and aged monkeys were tested on the visual recognition memory test "delayed nonmatching-to-sample"; then, electron microscopic immunocytochemistry was performed in the hippocampal DG to determine the subcellular localization of the GluA2 subunit of the glutamate alpha-amino-3-hydroxy-5-methyl-4- isoxazole-propionic acid receptor (AMPAR) and protein kinase M zeta (PKM zeta), which promotes memory storage by regulating GluA2-containing AMPAR trafficking. The results obtained suggest that age-related deficits in visual recognition memory are coupled with impairment in PKM zeta-dependent maintenance of GluA2 at the synapse. Together with previous evidences of the critical role of PKM zeta in memory consolidation, these data render this enzyme an attractive potential therapeutic target for treating age-related memory decline, and support the view that the pharmacological manipulation of AMPAR trafficking in the synapses may provide new insights in the search of memory enhancers for aged individuals, including those affected by Alzheimer disease.
C1 [Aicardi, Giorgio] Univ Bologna, Dept Human & Gen Physiol, I-40127 Bologna, Italy.
   [Aicardi, Giorgio] Univ Bologna, Interdept Ctr Luigi Galvani Study Biophys Bioinfo, I-40127 Bologna, Italy.
RP Aicardi, G (reprint author), Univ Bologna, Dept Human & Gen Physiol, Via San Donato 19-2, I-40127 Bologna, Italy.
EM giorgio.aicardi@unibo.it
CR Aicardi G, 2004, P NATL ACAD SCI USA, V101, P15788, DOI 10.1073/pnas.040696101
   Anggono V, 2012, CURR OPIN NEUROBIOL, V22, P461, DOI 10.1016/j.conb.2011.12.006
   Balietti M, 2012, REJUV RES, V15, P235, DOI 10.1089/rej.2012.1318
   Casoli T, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2010.11.012
   Di Stefano G, 2010, REJUV RES, V13, P224, DOI 10.1089/rej.2009.0965
   Fortin DA, 2012, J NEUROSCI, V32, P8127, DOI 10.1523/JNEUROSCI.6034-11.2012
   Halloran J, 2012, NEUROSCIENCE, V223, P102, DOI 10.1016/j.neuroscience.2012.06.054
   Hara Y, 2012, J NEUROSCI, V32, P7336, DOI 10.1523/JNEUROSCI.0605-12.2012
   Hara Y, 2011, J NEUROSCI, V31, P7737, DOI 10.1523/JNEUROSCI.0822-11.2011
   Henley JM, 2011, TRENDS NEUROSCI, V34, P258, DOI 10.1016/j.tins.2011.02.004
   Heyman E, 2012, PSYCHONEUROENDOCRINO, V37, P844, DOI 10.1016/j.psyneuen.2011.09.017
   Hoeffer CA, 2010, TRENDS NEUROSCI, V33, P67, DOI 10.1016/j.tins.2009.11.003
   Hu HL, 2007, CELL, V131, P160, DOI 10.1016/j.cell.2007.09.017
   Lamprecht R, 2004, NAT REV NEUROSCI, V5, P45, DOI 10.1038/nrn1301
   Mendelsohn AR, 2012, REJUV RES, V15, P334, DOI 10.1089/rej.2012.1347
   Mendelsohn AR, 2012, REJUV RES, V15, P98, DOI 10.1089/rej.2012.1312
   Mendelsohn AR, 2011, REJUV RES, V14, P557, DOI 10.1089/rej.2011.1247
   Mendelsohn AR, 2011, REJUV RES, V14, P437, DOI 10.1089/rej.2011.1238
   Migues PV, 2010, NAT NEUROSCI, V13, P630, DOI 10.1038/nn.2531
   Platano D, 2008, REJUV RES, V11, P341, DOI 10.1089/rej.2008.0725
   Sacktor TC, 2011, NAT REV NEUROSCI, V12, P9, DOI 10.1038/nrn2949
   Santi S, 2006, EMBO J, V25, P4372, DOI 10.1038/sj.emboj.7601303
   Shema R, 2011, SCIENCE, V331, P1207, DOI 10.1126/science.1200215
   Shema R, 2009, LEARN MEMORY, V16, P122, DOI 10.1101/lm.1183309
   Slipczuk L, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006007
   Tang BL, 2009, CELL ADHES MIGR, V3, P118, DOI 10.4161/cam.3.1.7254
   Tully K, 2010, MOL BRAIN, V3, DOI 10.1186/1756-6606-3-15
   Walker ML, 2008, BIOL REPROD, V79, P398, DOI 10.1095/biolreprod.108.068536
   Wang M, 2011, NATURE, V476, P210, DOI 10.1038/nature10243
   Winter B, 2007, NEUROBIOL LEARN MEM, V87, P597, DOI 10.1016/j.nlm.2006.11.003
   Yao YD, 2008, J NEUROSCI, V28, P7820, DOI 10.1523/JNEUROSCI.0223-08.2008
   Yassa MA, 2010, P NATL ACAD SCI USA, V107, P12687, DOI 10.1073/pnas.1002113107
   Zheng ZQ, 2010, J BIOL CHEM, V285, P34708, DOI 10.1074/jbc.M110.150821
NR 33
TC 2
Z9 2
U1 3
U2 8
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1549-1684
EI 1557-8577
J9 REJUV RES
JI Rejuv. Res.
PD OCT
PY 2012
VL 15
IS 5
BP 530
EP 533
DI 10.1089/rej.2012.1375
PG 4
WC Geriatrics & Gerontology
SC Geriatrics & Gerontology
GA 029YK
UT WOS:000310533600011
PM 22985047
DA 2018-12-27
ER

PT J
AU Wansink, B
   Just, DR
   Payne, CR
   Klinger, MZ
AF Wansink, Brian
   Just, David R.
   Payne, Collin R.
   Klinger, Matthew Z.
TI RETRACTED: Attractive names sustain increased vegetable intake in
   schools (Retracted article. See vol. 110, pg. 116, 2018)
SO PREVENTIVE MEDICINE
LA English
DT Article; Retracted Publication
DE Food intake; Obesity; School lunches; Nutrition; Healthy
ID TASTE; SOY
AB Objective: This study will determine if the selective use of attractive names can be a sustainable, scalable means to increase the selection of vegetables in school lunchrooms.
   Methods: Study 1 paired an attractive name with carrots in five elementary schools (n =147) and measured selection and consumption over a week compared to controls. Study 2 tracked food sales of vegetables in two elementary schools (n = 1017) that were systematically attractively named or not named over a two-month period. Both studies were conducted in New York in 2011.
   Results: Study 1 found that elementary students ate twice the percentage of their carrots if attractively named as "X-ray Vision Carrots," than if un-named or generically named as the "Food of the Day." Study 2 found that elementary school students were 16% more likely to persistently choose more hot vegetable dishes (p<0.001) when they were given fun or attractive names.
   Discussion: Attractive names effectively and persistently increased healthy food consumption in elementary schools. The scalability of this is underscored by the success of Study 2. which was implemented and executed for negligible cost by a high school student volunteer. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Wansink, Brian; Just, David R.] Cornell Univ, Dept Appl Econ & Management, Ithaca, NY 14853 USA.
   [Payne, Collin R.] New Mexico State Univ, Coll Business, Las Cruces, NM 88003 USA.
   [Klinger, Matthew Z.] Half Hollow Hills High Sch E, Dix Hills, NY 11746 USA.
RP Wansink, B (reprint author), Cornell Univ, Dept Appl Econ & Management, 15 Warren Hall, Ithaca, NY 14853 USA.
EM wansink@cornell.edu; drj3@cornell.edu; crp@nmsu.edu;
   mklimkli123@gmail.com
RI Just, David/K-7302-2012
OI Just, David/0000-0002-7471-5178
FU Robert Wood Johnson Foundation through its Healthy Eating Research
   program; United States Department of Agriculture's Food Nutrition
   Service and Economic Research Center
FX The authors thank Julia Hastings-Black for editorial assistance. Study 1
   was funded by the Robert Wood Johnson Foundation through its Healthy
   Eating Research program. Study 2 was funded by the United States
   Department of Agriculture's Food Nutrition Service and Economic Research
   Center.
CR Campbell K, 2001, Obes Rev, V2, P149, DOI 10.1046/j.1467-789x.2001.00035.x
   Cardello A.V., 1996, FOOD CHOICE ACCEPTAN
   Keren R, 2004, PHARMACOECONOMICS, V22, P71, DOI 10.2165/00019053-200422020-00001
   Tuorila H.M., 1998, FOOD QUAL PREFER, V13, P561
   Wansink B, 2002, J SENS STUD, V17, P483, DOI 10.1111/j.1745-459X.2002.tb00360.x
   Wansink B, 2005, FOOD QUAL PREFER, V16, P393, DOI 10.1016/j.foodqual.2004.06.005
   Wansink B, 2003, J FOOD SCI, V68, P2604, DOI 10.1111/j.1365-2621.2003.tb07068.x
   Wansink B., 2001, Cornell Hotel and Restaurant Administration Quarterly, V42, P68, DOI 10.1016/S0010-8804(01)81011-9
NR 8
TC 79
Z9 79
U1 2
U2 36
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0091-7435
EI 1096-0260
J9 PREV MED
JI Prev. Med.
PD OCT
PY 2012
VL 55
IS 4
BP 330
EP 332
DI 10.1016/j.ypmed.2012.07.012
PG 3
WC Public, Environmental & Occupational Health; Medicine, General &
   Internal
SC Public, Environmental & Occupational Health; General & Internal Medicine
GA 028CM
UT WOS:000310400400012
PM 22846502
DA 2018-12-27
ER

PT J
AU Lee, CY
   Ho, KL
   Lee, DJ
   Su, A
   Chang, JS
AF Lee, Chin-Yu
   Ho, Kuo-Ling
   Lee, Duu-Jong
   Su, Ay
   Chang, Jo-Shu
TI RETRACTED: Electricity harvest from wastewaters using microbial fuel
   cell with sulfide as sole electron donor (Retracted article. See vol.
   38, pg. 3809, 2013)
SO INTERNATIONAL JOURNAL OF HYDROGEN ENERGY
LA English
DT Article; Proceedings Paper; Retracted Publication
CT Asian Bio-Hydrogen and Biorefinery Symposium (ABBS)
CY OCT 13-15, 2011
CL Bogor, INDONESIA
DE Electricity; Toxicity; Sulfide; Microbial fuel cell
ID WASTE-WATER TREATMENT; OXIDATION; REMOVAL; GENERATION; SYSTEM; POWER;
   FLOOR; H2S
AB Toxicity prevents the bioenergy content of certain industrial effluents from being recovered. In operation of microbial fuel cell (MFC), microorganisms can be inhibited with high levels of sulfides. This study applied a pure culture, an autotrophic denitrifier, Pseudomonas sp. C27, to start up a two-chambered MFC using sulfide as the sole electron donor. The experimental results revealed that the MFC can successfully convert sulfide to elementary sulfur with electricity generation at a maximum power density of 29.3 mW m(-2). With no use of external organic carbon sources, the present device introduces a route for treating sulfide laden wastewaters with electricity harvest. Copyright (C) 2012, Hydrogen Energy Publications, LLC. Published by Elsevier Ltd. All rights reserved.
C1 [Lee, Chin-Yu; Ho, Kuo-Ling; Lee, Duu-Jong] Natl Taiwan Univ, Dept Chem Engn, Taipei 10764, Taiwan.
   [Lee, Duu-Jong] Natl Taiwan Univ Sci & Technol, Dept Chem Engn, Taipei, Taiwan.
   [Chang, Jo-Shu] Natl Cheng Kung Univ, Dept Chem Engn, Tainan, Taiwan.
   [Su, Ay] Yuan Ze Univ, Dept Mech Engn, Fuel Cell Ctr, Tao Yuan 320, Taiwan.
   [Chang, Jo-Shu] Natl Cheng Kung Univ, Ctr Biosci & Biotechnol, Tainan 70101, Taiwan.
   [Chang, Jo-Shu] Natl Cheng Kung Univ, Res Ctr Energy Technol & Strategy, Tainan 70101, Taiwan.
RP Lee, DJ (reprint author), Natl Taiwan Univ, Dept Chem Engn, 1,Sec 4,Roosevelt Rd, Taipei 10764, Taiwan.
EM djlee@ntu.edu.tw
FU National Taiwan University; NSFC [51176037]
FX This work was financially supported by the National Taiwan University
   (Toward Top University Project) and project NSFC No. 51176037.
CR Adav SS, 2010, BIOTECHNOL ADV, V28, P255, DOI 10.1016/j.biotechadv.2009.08.006
   Chen CA, 2010, J HAZARD MATER, V179, P1147, DOI 10.1016/j.jhazmat.2010.02.065
   Chen C, 2009, BIORESOURCE TECHNOL, V100, P2316, DOI 10.1016/j.biortech.2008.10.023
   Chung YC, 2004, J AIR WASTE MANAGE, V54, P450, DOI 10.1080/10473289.2004.10470915
   Chung YC, 2006, ENVIRON ENG SCI, V23, P942, DOI 10.1089/ees.2006.23.942
   Cooney MJ, 1996, ENZYME MICROB TECH, V18, P358, DOI 10.1016/0141-0229(95)00132-8
   HABERMANN W, 1991, APPL MICROBIOL BIOT, V35, P128
   Ho KL, 2010, INT J HYDROGEN ENERG, V35, P10239, DOI 10.1016/j.ijhydene.2010.07.155
   Kim JR, 2005, APPL MICROBIOL BIOT, V68, P23, DOI 10.1007/s00253-004-1845-6
   Lee DJ, 2011, INT J HYDROGEN ENERG, V36, P13907, DOI 10.1016/j.ijhydene.2011.03.053
   Liu FC, 2010, THESIS NATL TAIWAN U
   Liu H, 2004, ENVIRON SCI TECHNOL, V38, P2281, DOI 10.1021/es034923g
   Logan BE, 2009, NAT REV MICROBIOL, V7, P375, DOI 10.1038/nrmicro2113
   Nielsen ME, 2009, ENVIRON SCI TECHNOL, V43, P8671, DOI 10.1021/es9013773
   Pikaar I, 2011, WATER RES, V45, P2281, DOI 10.1016/j.watres.2010.12.025
   Rabaey K, 2006, ENVIRON SCI TECHNOL, V40, P5218, DOI 10.1021/es060382u
   Rai C, 1996, ENVIRON PROG, V15, P6, DOI 10.1002/ep.670150113
   Ryckelynck N, 2005, BIOGEOCHEMISTRY, V76, P113, DOI 10.1007/s10533-005-2671-3
   Sun M, 2010, BIOSENS BIOELECTRON, V26, P470, DOI 10.1016/j.bios.2010.07.074
   Sun M, 2009, ENVIRON SCI TECHNOL, V43, P3372, DOI 10.1021/es802809m
   Tai J, 2010, INT J HYDROGEN ENERG, V35, P13345, DOI 10.1016/j.ijhydene.2009.11.111
   Tender LM, 2002, NAT BIOTECHNOL, V20, P821, DOI 10.1038/nbt716
   Wang YR, 2001, J ELECTROANAL CHEM, V497, P163
   Zhang BG, 2009, J CHEM TECHNOL BIOT, V84, P1780, DOI 10.1002/jctb.2244
   Zhang BG, 2009, BIORESOURCE TECHNOL, V100, P5687, DOI 10.1016/j.biortech.2009.06.045
   Zuo Y, 2006, APPL ENVIRON MICROB, V74, P3130
NR 26
TC 5
Z9 5
U1 3
U2 65
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0360-3199
EI 1879-3487
J9 INT J HYDROGEN ENERG
JI Int. J. Hydrog. Energy
PD OCT
PY 2012
VL 37
IS 20
BP 15787
EP 15791
DI 10.1016/j.ijhydene.2012.03.114
PG 5
WC Chemistry, Physical; Electrochemistry; Energy & Fuels
SC Chemistry; Electrochemistry; Energy & Fuels
GA 020EC
UT WOS:000309790700090
DA 2018-12-27
ER

PT J
AU Setare, MR
   Momeni, D
   Myrzakulov, R
   Raza, M
AF Setare, M. R.
   Momeni, D.
   Myrzakulov, R.
   Raza, Muhammad
TI RETRACTED: Holographic superconductors in the AdS black hole with a
   magnetic charge (Retracted article. See vol. 86, 069701, 2012)
SO PHYSICA SCRIPTA
LA English
DT Article; Retracted Publication
ID STRING THEORY; WEYL CORRECTIONS; FIELD
AB In this work, we study the analytical properties of a 2 + 1-dimensional magnetically charged holographic superconductor in AdS(4). We obtain the critical chemical potential mu(c) analytically, using the Sturm-Liouville variational approach. Further, by applying the perturbation scheme, we obtain the electrical conductivity of the model. We observe that the real part of the sigma increases and the imaginary part of the conductivity decreases monotonously versus the frequency omega. Each module of sigma has a minimum value, which is similar to the case of the uncharged Schwarachild-AdS background. Further, we also conclude that the value of omega(g)/T-c increases. For the condensate operator O-2 we find that, as the frequency omega increases for fixed H, the real part has a common behavior. However, the imaginary part possesses a minimum value in this case and the location of this minimum value changes along right when H increases. We find that at omega = 0, the real part of conductivity behaves as a delta function and the imaginary part exists as a pole in the background. This pole may be related to the existence of a magnetic monopole. Also, the obtained analytic result can be used to back up numerical computations in the holographic superconductor in the probe limit.
C1 [Setare, M. R.] Payame Noor Univ, Dept Sci, Bijar, Iran.
   [Momeni, D.; Myrzakulov, R.] Eurasian Natl Univ, Eurasian Int Ctr Theoret Phys, Astana 010008, Kazakhstan.
RP Setare, MR (reprint author), Payame Noor Univ, Dept Sci, Bijar, Iran.
EM rezakord@ipm.ir; d.momeni@yahoo.com; rmyrzakulov@csufresno.edu;
   mreza06@gmail.com
RI Myrzakulov, Ratbay/O-7973-2014
OI Myrzakulov, Ratbay/0000-0002-5274-0815
CR Aharony O, 2000, PHYS REP, V323, P183, DOI 10.1016/S0370-1573(99)00083-6
   Ammon M, 2010, PHYS LETT B, V686, P192, DOI 10.1016/j.physletb.2010.02.021
   Ammon M, 2009, J HIGH ENERGY PHYS, DOI 10.1088/1126-6708/2009/10/067
   Ammon M, 2009, PHYS LETT B, V680, P516, DOI 10.1016/j.physletb.2009.09.029
   Aprile F, 2010, PHYS REV D, V81, DOI 10.1103/PhysRevD.81.026009
   BARDEEN J, 1957, PHYS REV, V108, P1175, DOI 10.1103/PhysRev.108.1175
   Basu P, 2010, PHYS LETT B, V689, P45, DOI 10.1016/j.physletb.2010.04.042
   Basu P, 2009, PHYS REV D, V79, DOI 10.1103/PhysRevD.79.045010
   BREITENLOHNER P, 1982, ANN PHYS-NEW YORK, V144, P249, DOI 10.1016/0003-4916(82)90116-6
   Brynjolfsson EJ, 2010, J PHYS A-MATH THEOR, V43, DOI 10.1088/1751-8113/43/6/065401
   Cai R, 2009, ARXIV09114867
   Cai RG, 2010, PHYS REV D, V81, DOI 10.1103/PhysRevD.81.066003
   Cremonesi S, 2010, J HIGH ENERGY PHYS, DOI 10.1007/JHEP04(2010)048
   Denef F, 2009, ARXIV09011160
   Gauntlett JP, 2010, J HIGH ENERGY PHYS, DOI 10.1007/JHEP02(2010)060
   Gauntlett JP, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.151601
   Gregory R, 2009, J HIGH ENERGY PHYS, DOI 10.1088/1126-6708/2009/10/010
   Gubser SS, 2005, CLASSICAL QUANT GRAV, V22, P5121, DOI 10.1088/0264-9381/22/23/013
   Gubser SS, 1998, PHYS LETT B, V428, P105, DOI 10.1016/S0370-2693(98)00377-3
   Gubser SS, 2008, PHYS REV D, V78, DOI 10.1103/PhysRevD.78.065034
   Gubser SS, 2010, PHYS LETT B, V683, P201, DOI 10.1016/j.physletb.2009.12.017
   Gubser SS, 2009, PHYS REV D, V80, DOI 10.1103/PhysRevD.80.105007
   Gubser SS, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.141601
   Gubser SS, 2008, PHYS REV LETT, V101, DOI 10.1103/PhysRevLett.101.191601
   Gubser SS, 2008, J HIGH ENERGY PHYS
   Hartnoll SA, 2008, PHYS REV LETT, V101, DOI 10.1103/PhysRevLett.101.031601
   Hartnoll SA, 2009, CLASSICAL QUANT GRAV, V26, DOI 10.1088/0264-9381/26/22/224002
   Hartnoll SA, 2008, J HIGH ENERGY PHYS, DOI 10.1088/1126-6708/2008/12/015
   Herzog CP, 2009, J PHYS A-MATH THEOR, V42, DOI 10.1088/1751-8113/42/34/343001
   Herzog CP, 2009, PHYS REV D, V79, DOI 10.1103/PhysRevD.79.066002
   Herzog CP, 2009, J HIGH ENERGY PHYS, DOI 10.1088/1126-6708/2009/04/126
   Horowitz GT, 2009, J HIGH ENERGY PHYS, DOI 10.1088/1126-6708/2009/11/015
   Horowitz GT, 2008, PHYS REV D, V78, DOI 10.1103/PhysRevD.78.126008
   Konoplya RA, 2010, PHYS LETT B, V686, P199, DOI 10.1016/j.physletb.2010.02.048
   Maa D-Z, 2011, PHYS LETT B, V704, P604
   Maeda K, 2010, PHYS REV D, V81, DOI 10.1103/PhysRevD.81.026002
   Maeda K, 2009, PHYS REV D, V79, DOI 10.1103/PhysRevD.79.126004
   Maldacena J M, 1998, ADV THEOR MATH PHYS, V2, P231, DOI DOI 10.1023/A:1026654312961
   Momeni D, 2012, INT J MOD PHYS A, V27, DOI 10.1142/S0217751X1250128X
   Momeni D, 2012, EPL-EUROPHYS LETT, V97, DOI 10.1209/0295-5075/97/61001
   Momeni D, 2011, MOD PHYS LETT A, V26, P2889, DOI 10.1142/S0217732311037169
   Momeni D, 2011, J HIGH ENERGY PHYS, DOI 10.1007/JHEP05(2011)118
   Nakano E, 2008, PHYS REV D, V78, DOI 10.1103/PhysRevD.78.046004
   Pan QY, 2012, J HIGH ENERGY PHYS, DOI 10.1007/JHEP06(2012)087
   Pan QY, 2010, PHYS REV D, V81, DOI 10.1103/PhysRevD.81.106007
   Roberts MM, 2008, J HIGH ENERGY PHYS, DOI 10.1088/1126-6708/2008/08/035
   ROMANS LJ, 1992, NUCL PHYS B, V383, P395, DOI 10.1016/0550-3213(92)90684-4
   Setare MR, 2011, EPL-EUROPHYS LETT, V96, DOI 10.1209/0295-5075/96/60006
   Sin S, 2009, ARXIV09094857
   Sonner J, 2009, PHYS REV D, V80, DOI 10.1103/PhysRevD.80.084031
   Vakkuri E K, 2008, J HIGH ENERGY PHYS, V09, P130
   Witten E., 1998, ADV THEOR MATH PHYS, V2, P253, DOI [DOI 10.1016/S0370-1573(99)00083-6, 10.4310/ATMP.1998.v2.n2.a2]
   Wu JP, 2011, PHYS LETT B, V697, P153, DOI 10.1016/j.physletb.2011.01.045
   Zeng HB, 2011, J HIGH ENERGY PHYS, DOI 10.1007/JHEP05(2011)002
   Zeng HB, 2009, PHYS REV D, V80, DOI 10.1103/PhysRevD.80.066001
NR 55
TC 2
Z9 2
U1 2
U2 13
PU IOP PUBLISHING LTD
PI BRISTOL
PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND
SN 0031-8949
J9 PHYS SCRIPTA
JI Phys. Scr.
PD OCT
PY 2012
VL 86
IS 4
AR 045005
DI 10.1088/0031-8949/86/04/045005
PG 6
WC Physics, Multidisciplinary
SC Physics
GA 018KL
UT WOS:000309659100005
DA 2018-12-27
ER

PT J
AU Haghayeghi, R
   Nastac, L
AF Haghayeghi, R.
   Nastac, L.
TI RETRACTED: Microstructural evolution of AA7449 aerospace alloy refined
   by intensive shearing (Retracted article. See vol. 19, pg. 901, 2013)
SO METALS AND MATERIALS INTERNATIONAL
LA English
DT Article; Retracted Publication
DE melting; casting; solidification; nucleation; grain refinement
ID GRAIN-REFINEMENT; HETEROGENEOUS NUCLEATION; ALUMINUM-ALLOYS;
   SOLIDIFICATION BEHAVIOR; MELT SHEARING; AZ91D ALLOY; AL
AB Many aerospace alloys are sensitive to their composition thus cannot be chemically grain refined. In addition, only 1% grain refiners can act as nuclei for refining the structure. In this paper, physical refinement by intensive shearing above liquidus as an alternative technique will be investigated for AA7449 aerospace alloy. The results can open a new gateway for aerospace industry for refining their microstructure.
C1 [Haghayeghi, R.] Brunel Univ, Design & Eng Dept, Uxbridge UB8 3PH, Middx, England.
   [Haghayeghi, R.] Azad Univ, Sci & Res Branch, Dept Mat Engn, Tehran 1477893855, Iran.
   [Nastac, L.] Univ Alabama, Dept Met & Mat Engn, Tuscaloosa, AL 35487 USA.
RP Haghayeghi, R (reprint author), Brunel Univ, Design & Eng Dept, Uxbridge UB8 3PH, Middx, England.
EM Reza.Haghayeghi@Brunel.ac.uk
FU Department of Trade and Industry (DTI), the UK
FX The authors would like to express their appreciation to Brunel
   University team for helping us in running the experiments. Our gratitude
   to the Department of Trade and Industry (DTI), the UK for their
   financial support of the project.
CR Aluminium Association, 1987, STAND TEST PROC AL A
   [Anonymous], 2002, STAND TEST DET AV GR, P256
   Barker J. A., 1963, LATTICE THEORIES LIQ, P50
   Blaak R, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.068303
   Brennen C. E., 1995, CAVITATION BUBBLES D, P124
   Brodova I. G., 2002, LIQUID METAL PROCESS, P68
   Chakraborty M, 2005, T INDIAN I METALS, V58, P661
   COTTERILL RMJ, 1980, J CRYST GROWTH, V48, P582, DOI 10.1016/0022-0248(80)90269-9
   Eskin DG, 1996, Z METALLKD, V87, P295
   ESKIN GI, 1995, ULTRASON SONOCHEM, V2, pS137, DOI 10.1016/1350-4177(95)00020-7
   Eustathopoulos N, 1998, MAT SCI ENG A-STRUCT, V249, P176, DOI 10.1016/S0921-5093(98)00521-8
   Fan Z, 2005, MAT SCI ENG A-STRUCT, V412, P298, DOI 10.1016/j.msea.2005.09.001
   Fan Z, 2005, ACTA MATER, V53, P4345, DOI 10.1016/j.actamat.2005.05.033
   Fan Z, 2009, ACTA MATER, V57, P4891, DOI 10.1016/j.actamat.2009.06.052
   Fox S, 2000, SCRIPTA MATER, V43, P881, DOI 10.1016/S1359-6462(00)00506-6
   Greer A. L., 2003, SOLIDIFICATION CASTI, P199
   Greer AL, 2003, PHILOS T R SOC A, V361, P479, DOI 10.1098/rsta.2002.1147
   Haghayeghi R, 2009, J ALLOY COMPD, V485, P807, DOI 10.1016/j.jallcom.2009.06.085
   Haghayeghi R, 2009, J ALLOY COMPD, V481, P358, DOI 10.1016/j.jallcom.2009.02.135
   Haghayeghi R, 2008, SOL ST PHEN, V141-143, P403, DOI 10.4028/www.scientific.net/SSP.141-143.403
   Hitchcock M, 2007, ACTA MATER, V55, P1589, DOI 10.1016/j.actamat.2006.10.018
   Li HT, 2011, J CRYST GROWTH, V314, P285, DOI 10.1016/j.jcrysgro.2010.10.168
   Lowe A., 2010, THIXOFORMING
   Murty BS, 2002, INT MATER REV, V47, P3, DOI 10.1179/095066001225001049
   Nastac L, 1999, ACTA MATER, V47, P4253, DOI 10.1016/S1359-6454(99)00325-0
   Nastac L., 2004, MODELING SIMULATION, P262
   Nastac L., 2012, IOP C SER MAT SCI EN, P17
   Nastac L, 2011, METALL MATER TRANS B, V42, P1297, DOI 10.1007/s11663-011-9539-9
   PALBERG T, 1995, J CHEM PHYS, V102, P5082, DOI 10.1063/1.469558
   Quested TE, 2005, ACTA MATER, V53, P2683, DOI 10.1016/actamat.2005.02.028
   Warner T.J., 1997, 3 ASM C SYNTH PROC M, P77
   Zuo Y, 2011, SCRIPTA MATER, V64, P209, DOI 10.1016/j.scriptamat.2010.09.046
NR 32
TC 3
Z9 3
U1 3
U2 16
PU KOREAN INST METALS MATERIALS
PI SEOUL
PA KIM BLDG 6TH FLOOR, SEOCHO-DAERO 56 GIL 38, SEOCHO-GU, SEOUL 137-881,
   SOUTH KOREA
SN 1598-9623
EI 2005-4149
J9 MET MATER INT
JI Met. Mater.-Int.
PD OCT
PY 2012
VL 18
IS 5
BP 777
EP 782
DI 10.1007/s12540-012-5005-8
PG 6
WC Materials Science, Multidisciplinary; Metallurgy & Metallurgical
   Engineering
SC Materials Science; Metallurgy & Metallurgical Engineering
GA 018RX
UT WOS:000309681400006
DA 2018-12-27
ER

PT J
AU Patrick, BA
   Jaiswal, AK
AF Patrick, B. A.
   Jaiswal, A. K.
TI RETRACTED: Stress-induced NQO1 controls stability of C/EBP alpha against
   20S proteasomal degradation to regulate p63 expression with implications
   in protection against chemical-induced skin cancer (Retracted article.
   See vol. 36, pg. 2920, 2017)
SO ONCOGENE
LA English
DT Article; Retracted Publication
DE NQO1; C/EBP alpha; 20S proteasome; skin differentiation; p63
ID QUINONE OXIDOREDUCTASE-1; NAD(P)H-QUINONE OXIDOREDUCTASE-1; SKIN
   CARCINOGENESIS; MICE LEADS; MOUSE SKIN; P53; GENE; APOPTOSIS; NAD(P)H;
   SUSCEPTIBILITY
AB Previously, we have shown a role of cytosolic NAD(P)H: quinone oxidoreductase 1 (NQO1) in the stabilization of p63 against 20S proteasomal degradation resulting in thinning of the epithelium and chemical-induced skin cancer (Oncogene (2011) 30, 1098-1107). Current studies have demonstrated that NQO1 control of CCAAT-enhancer binding protein (C/EBP alpha) against 20S proteasomal degradation also contributes to the upregulation of p63 expression and protection. Western and immunohistochemistry analysis revealed that disruption of the NQO1 gene in mice and mouse keratinocytes led to degradation of C/EBP alpha and loss of p63 gene expression. p63 promoter mutagenesis, transfection and chromatin immunoprecipitation assays identified a C/EBP alpha-binding site between nucleotide position -185 and -174 that bound to C/EBP alpha and upregulated p63 gene expression. Co-immunoprecipitation and immunoblot analysis demonstrated that 20S proteasomes directly interacted and degraded C/EBP alpha. NQO1 direct interaction with C/EBP alpha led to stabilization of C/EBP alpha against 20S proteasomal degradation. NQO1 protection of C/EBP alpha required binding of NADH with NQO1. Exposure of skin and keratinocytes to the chemical stress agent benzo(a)pyrene led to induction of NQO1 and stabilization of C/EBP alpha protein, resulting in an increase in p63 RNA and protein in wildtype but not in NQO1-/- mice. Collectively, the current data combined with previous data suggest that stress induction of NQO1 through both stabilization of C/EBP alpha and increase in p63 and direct stabilization of p63 controls keratinocyte differentiation, leading to protection against chemical-induced skin carcinogenesis. The studies are significant as 2-4% human individuals are homozygous and 23% are heterozygous for the NQO1P187S mutation and might be susceptible to stress-induced skin diseases. Oncogene (2012) 31, 4362-4371; doi:10.1038/onc.2011.600; published online 16 January 2012
C1 [Patrick, B. A.; Jaiswal, A. K.] Univ Maryland, Sch Med, Dept Pharmacol & Expt Therapeut, 655 W Baltimore St,Howard Hall 404, Baltimore, MD 21201 USA.
RP Jaiswal, AK (reprint author), Univ Maryland, Sch Med, Dept Pharmacol & Expt Therapeut, 655 W Baltimore St,Howard Hall 404, Baltimore, MD 21201 USA.
EM ajaiswal@som.umaryland.edu
FU NIH [RO1 ES007943]; NIEHS [RO1 ES007943]; NIEHS training grant
   [ES007263]
FX We thank our colleagues for helpful discussions and suggestions. This
   study was supported by NIH Grant RO1 ES007943. BAP was partly supported
   by grant ES007263. AKJ was supported by NIEHS grant RO1 ES007943. BAP
   was supported by grant RO1 ES007943 and also in part is supported by
   NIEHS training grant ES007263.
CR Adler J, 2010, MOL CELL BIOL, V30, P3767, DOI 10.1128/MCB.00899-09
   Ahn KS, 2006, J BIOL CHEM, V281, P19798, DOI 10.1074/jbc.M601162200
   Asher G, 2005, GENE DEV, V19, P316, DOI 10.1101/gad.319905
   Asher G, 2001, P NATL ACAD SCI USA, V98, P1188, DOI 10.1073/pnas.021558898
   Asher G, 2002, P NATL ACAD SCI USA, V99, P13125, DOI 10.1073/pnas.202480499
   Garate M, 2008, EMBO REP, V9, P576, DOI 10.1038/embor.2008.48
   Gong X, 2007, CANCER RES, V67, P5380, DOI 10.1158/0008-5472.CAN-07-0323
   Higashikawa K, 2007, CANCER RES, V67, P9207, DOI 10.1158/0008-5472.CAN-07-0932
   Iskander K, 2005, CANCER RES, V65, P2054, DOI 10.1158/0008-5472.CAN-04-3157
   Jaiswal AK, 1999, PHARMACOGENETICS, V9, P413, DOI 10.1097/00008571-199906000-00020
   Kaspar JW, 2009, FREE RADICAL BIO MED, V47, P1304, DOI 10.1016/j.freeradbiomed.2009.07.035
   King KE, 2007, MOL CARCINOGEN, V46, P716, DOI 10.1002/mc.20337
   Long DJ, 2000, CANCER RES, V60, P5913
   Long DJ, 2001, JNCI-J NATL CANCER I, V93, P1166, DOI 10.1093/jnci/93.15.1166
   Long DJ, 2000, CHEM-BIOL INTERACT, V129, P99, DOI 10.1016/S0009-2797(00)00200-3
   Mills AA, 1999, NATURE, V398, P708
   Moll UM, 2004, MOL CANCER RES, V2, P371
   Patrick BA, 2011, ONCOGENE, V30, P1098, DOI 10.1038/onc.2010.491
   Pietsch EC, 2008, ONCOGENE, V27, P6507, DOI 10.1038/onc.2008.315
   Radjendirane V, 1998, J BIOL CHEM, V273, P7382, DOI 10.1074/jbc.273.13.7382
   Ross D, 2004, DRUG METAB REV, V36, P639, DOI 10.1081/DMR-200033465
   Siegel D, 2001, MOL PHARMACOL, V59, P263
   Sigrist CJA, 2010, NUCLEIC ACIDS RES, V38, pD161, DOI 10.1093/nar/gkp885
   TRAVER RD, 1992, CANCER RES, V52, P797
   Vasiliou Vasilis, 2006, Human Genomics, V2, P329
   ZHANG YS, 1994, P NATL ACAD SCI USA, V91, P3147, DOI 10.1073/pnas.91.8.3147
NR 26
TC 12
Z9 13
U1 3
U2 7
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
EI 1476-5594
J9 ONCOGENE
JI Oncogene
PD OCT
PY 2012
VL 31
IS 40
BP 4362
EP 4371
DI 10.1038/onc.2011.600
PG 10
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA 017LL
UT WOS:000309591300003
PM 22249251
OA Green Accepted, Bronze
DA 2018-12-27
ER

PT J
AU Fonseca, SG
   Urano, F
   Weir, GC
   Gromada, J
   Burcin, M
AF Fonseca, Sonya G.
   Urano, Fumihiko
   Weir, Gordon C.
   Gromada, Jesper
   Burcin, Mark
TI RETRACTED: Wolfram syndrome 1 and adenylyl cyclase 8 interact at the
   plasma membrane to regulate insulin production and secretion (Retracted
   article. See vol. 17, pg. 105, 2015)
SO NATURE CELL BIOLOGY
LA English
DT Article; Retracted Publication
ID PANCREATIC BETA-CELLS; ENDOPLASMIC-RETICULUM STRESS; GLUCOSE; CAMP;
   WFS1; GENE; APOPTOSIS; GLP-1; MICE; EXOCYTOSIS
AB Endoplasmic reticulum (ER) stress causes pancreatic beta-cell dysfunction and contributes to beta-cell loss and the progression of type 2 diabetes(1,2). Wolfram syndrome 1 (WFS1) has been shown to be an important regulator of the ER stress signalling pathway(3); however, its role in beta-cell function remains unclear. Here we provide evidence that WFS1 is essential for glucose-and glucagon-like peptide 1 (GLP-1)-stimulated cyclic AMP production and regulation of insulin biosynthesis and secretion. Stimulation with glucose causes WFS1 translocation from the ER to the plasma membrane, where it forms a complex with adenylyl cyclase 8 (AC8), an essential cAMP-generating enzyme in the beta-cell that integrates glucose and GLP-1 signalling(4). ER stress and mutant WFS1 inhibit complex formation and activation of AC8, reducing cAMP synthesis and insulin secretion. These findings reveal that an ER-stress-related protein has a distinct role outside the ER regulating both insulin biosynthesis and secretion. The reduction of WFS1 protein on the plasma membrane during ER stress is a contributing factor for beta-cell dysfunction and progression of type 2 diabetes.
C1 [Fonseca, Sonya G.; Gromada, Jesper; Burcin, Mark] Novartis Inst BioMed Res, Cardiovasc & Metab Dis Area, Cambridge, MA 02139 USA.
   [Urano, Fumihiko] Washington Univ, Sch Med, Dept Med, Div Endocrinol Metab & Lipid Res, St Louis, MO 63110 USA.
   [Weir, Gordon C.] Joslin Diabet Ctr, Boston, MA 02215 USA.
RP Fonseca, SG (reprint author), Novartis Inst BioMed Res, Cardiovasc & Metab Dis Area, Cambridge, MA 02139 USA.
EM sonya.fonseca@novartis.com
FU NIH [DK067493, DK016746, P60 DK020579, RR024992, UL1 TR000448]; JDRF
   [11-2011-40]
FX We thank M. Hara, Y. Adachi, Y. Murakami, L. Leahy, K. Sargent, B.
   O'Sullivan-Murphy, J. Hollister-Lock, J. Brown, K. Lipson, D.
   Ahern-Ridlon and X. Wang, for expert technical support; and C. Fonseca,
   S. Bonner-Weir and G. Waters for data discussions and comments on the
   manuscript. This work was supported by grants from the NIH (DK067493,
   DK016746, P60 DK020579, RR024992 and UL1 TR000448) and JDRF (11-2011-40)
   to F.U.
CR Alarcon C, 2002, DIABETES, V51, P2496, DOI 10.2337/diabetes.51.8.2496
   Dachicourt N, 1996, AM J PHYSIOL-ENDOC M, V271, pE725
   Delmeire D, 2003, DIABETOLOGIA, V46, P1383, DOI 10.1007/s00125-003-1203-8
   Dolz M, 2011, AM J PHYSIOL-ENDOC M, V301, pE797, DOI 10.1152/ajpendo.00652.2010
   Fonseca SG, 2005, J BIOL CHEM, V280, P39609, DOI 10.1074/jbc.M507426200
   Fonseca SG, 2010, J CLIN INVEST, V120, P744, DOI 10.1172/JCI39678
   Hardy C, 1999, AM J HUM GENET, V65, P1279, DOI 10.1086/302609
   Hatanaka M, 2011, HUM MOL GENET, V20, P1274, DOI 10.1093/hmg/ddq568
   Henquin JC, 2000, DIABETES, V49, P1751, DOI 10.2337/diabetes.49.11.1751
   Holz GG, 2008, AM J PHYSIOL-CELL PH, V294, pC4, DOI 10.1152/ajpcell.00522.2007
   HOLZ GG, 1993, NATURE, V361, P362, DOI 10.1038/361362a0
   Huang CJ, 2007, AM J PHYSIOL-ENDOC M, V293, pE1656, DOI 10.1152/ajpendo.00318.2007
   Idevall-Hagren O, 2010, J BIOL CHEM, V285, P23005, DOI 10.1074/jbc.M109.095992
   Ishihara H, 2004, HUM MOL GENET, V13, P1159, DOI 10.1093/hmg/ddh125
   Kakiuchi C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004134
   KARASIK A, 1989, DIABETES CARE, V12, P135, DOI 10.2337/diacare.12.2.135
   Laybutt DR, 2007, DIABETOLOGIA, V50, P752, DOI 10.1007/s00125-006-0590-z
   Marchetti P, 2007, DIABETOLOGIA, V50, P2486, DOI 10.1007/s00125-007-0816-8
   MONTANA E, 1993, J CLIN INVEST, V91, P780, DOI 10.1172/JCI116297
   Pinto C, 2008, J PHARMACOL EXP THER, V325, P27, DOI 10.1124/jpet.107.131904
   Riggs AC, 2005, DIABETOLOGIA, V48, P2313, DOI 10.1007/s00125-005-1947-4
   Roger B, 2011, DIABETOLOGIA, V54, P390, DOI 10.1007/s00125-010-1955-x
   Seino S, 2005, PHYSIOL REV, V85, P1303, DOI 10.1152/physrev.00001.2005
   Shen JS, 2004, J BIOL CHEM, V279, P43046, DOI 10.1074/jbc.M408466200
   Takeda K, 2001, HUM MOL GENET, V10, P477, DOI 10.1093/hmg/10.5.477
   Walz HA, 2007, CELL SIGNAL, V19, P1505, DOI 10.1016/j.cellsig.2007.01.030
   Yajima H, 1999, DIABETES, V48, P1006, DOI 10.2337/diabetes.48.5.1006
   Zinchuk V., 2008, CURR PROTOC CELL BIO
NR 28
TC 40
Z9 40
U1 3
U2 11
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1465-7392
EI 1476-4679
J9 NAT CELL BIOL
JI Nat. Cell Biol.
PD OCT
PY 2012
VL 14
IS 10
BP 1105
EP +
DI 10.1038/ncb2578
PG 15
WC Cell Biology
SC Cell Biology
GA 016UA
UT WOS:000309543800019
PM 22983116
OA Green Accepted
DA 2018-12-27
ER

PT J
AU Gonfiotti, A
   Jaus, MO
   Barale, D
   Baiguera, S
   Polizzi, L
   Jungebluth, P
   Paoletti, M
   Pistolesi, M
   Macchiarini, P
AF Gonfiotti, Alessandro
   Jaus, Massimo Osvaldo
   Barale, Daniel
   Baiguera, Silvia
   Polizzi, Leonardo
   Jungebluth, Philipp
   Paoletti, Matteo
   Pistolesi, Massimo
   Macchiarini, Paolo
TI RETRACTED: Development and Validation of a New Outcome Score in
   Subglottic Stenosis (Retracted article. See vol. 94, pg. 2184, 2012)
SO ANNALS OF THORACIC SURGERY
LA English
DT Correction; Retracted Publication
ID LARYNGOTRACHEAL STENOSIS; TRACHEAL ANASTOMOSIS; RESECTION; AIRWAY;
   RECONSTRUCTION; MANAGEMENT; LARYNGEAL; CLASSIFICATION; ADULTS
AB Background. We prospectively evaluated a clinical and endoscopic score, the tracheal endoscopic clinical score (TECS), developed as a disease-specified outcome measure in adult patients undergoing operation for subglottic stenosis. We also performed a retrospective chart review to identify preoperative and intraoperative risk factors for worse TECS.
   Methods. The TECS includes endoscopic (vocal cord and glottic function, anastomotic healing, and patency) and interview (respiration, voice, swallow) variables, and was administered at 6-month follow-up. Endoscopic and subjective domains were weighted to obtain a continuous TECS index ranging from 0 (best) to 1 (worse). The TECS and preoperative variables relationships were evaluated by univariate and multivariate analysis.
   Results. We collected data (January 2009 to December 2010) from 30 patients (mean age, 48.3 +/- 19 years) undergoing subglottic resection and primary reconstruction. Stenosis etiology was postintubation (n = 8), idiopathic (n = 2), tracheostomy (n = 18), and malignant (n = 2). Surgery included Pearson operation with (n = 7) or without (n = 23) a Liberman-Mathisen cricoplasty. Mean length of resected trachea was 30.5 +/- 13.5 mm, and mean hospital stay was 7.4 days. Mortality rate was 1 patient (3.3%). The univariate analysis showed positive correlation between 6-month TECS and degree of stenosis (McCaffrey and Cotton scale 0 to 4) stage 4, tracheostomy or T-tube at surgery, bottleneck-type transition stenosis, and resection length. At multivariate analysis, the presence of tracheostomy, bottleneck-type transition stenosis and resection length were indicators of worse postoperative functional result.
   Conclusions. The TECS seems to be a valid and simple instrument to identify preoperative variables predicting worse results and to assess postoperative outcome. Validation on larger series is necessary. (Ann Thorac Surg 2012;94:1065-72) (C) 2012 by The Society of Thoracic Surgeons
C1 [Macchiarini, Paolo] Univ Hosp Careggi, European Ctr Thorac Res, I-50134 Florence, Italy.
   Univ Hosp Careggi, Dept Internal Med, I-50134 Florence, Italy.
RP Macchiarini, P (reprint author), Univ Hosp Careggi, European Ctr Thorac Res, Largo Brambilla 3, I-50134 Florence, Italy.
EM paolo.macchiarini@ki.se
RI Macchiarini, Paolo/E-6878-2013
OI GONFIOTTI, Alessandro/0000-0003-2724-9474
CR D'Andrilli A, 2008, EUR J CARDIO-THORAC, V33, P440, DOI 10.1016/j.ejcts.2007.12.014
   FLETCHER CM, 1959, BMJ-BRIT MED J, V2, P257, DOI 10.1136/bmj.2.5147.257
   Freitag L, 2007, EUR RESPIR J, V30, P7, DOI 10.1183/09031936.00132804
   GAISSERT HA, 1994, J THORAC CARDIOV SUR, V107, P600
   George M, 2005, EUR ARCH OTO-RHINO-L, V262, P609, DOI 10.1007/s00405-004-0887-9
   George M, 2010, INT J PEDIATR OTORHI, V74, P154, DOI 10.1016/j.ijporl.2009.10.026
   George M, 2010, J THORAC CARDIOV SUR, V139, P411, DOI 10.1016/j.jtcvs.2009.05.010
   GRILLO HC, 1982, ANN THORAC SURG, V33, P3, DOI 10.1016/S0003-4975(10)63191-8
   GRILLO HC, 1993, ANN THORAC SURG, V56, P80, DOI 10.1016/0003-4975(93)90406-8
   Grillo HC, 1999, GEN THORACIC SURG, P873
   Liberman M, 2009, J THORAC CARDIOV SUR, V137, P573, DOI 10.1016/j.jtcvs.2008.11.020
   Macchiarini P, 2001, J THORAC CARDIOV SUR, V121, P68, DOI 10.1067/mtc.2001.111420
   MACCHIARINI P, 1993, EUR J CARDIO-THORAC, V7, P300, DOI 10.1016/1010-7940(93)90171-7
   Macchiarini P, 2010, ANN THORAC SURG, V89, P387, DOI 10.1016/j.athoracsur.2009.10.044
   MADDAUS MA, 1992, J THORAC CARDIOV SUR, V104, P1443
   Mathisen D J, 1996, Chest Surg Clin N Am, V6, P853
   Mathisen D J, 1998, Curr Probl Surg, V35, P453, DOI 10.1016/S0011-3840(98)80014-2
   MCCAFFREY TV, 1992, LARYNGOSCOPE, V102, P1335, DOI 10.1288/00005537-199212000-00004
   Monnier P., 1999, INT J PEDIATR OTORHI, V49, P283
   MONTGOMERY WW, 1974, ARCH OTOLARYNGOL, V99, P255
   Myer C M 3rd, 1995, Ear Nose Throat J, V74, P560
   PEARSON FG, 1975, J THORAC CARDIOV SUR, V70, P806
   Smith LP, 2010, ARCH OTOLARYNGOL, V136, P60, DOI 10.1001/archoto.2009.201
   Vondrys D, 2011, ANN THORAC SURG, V92, P1870, DOI 10.1016/j.athoracsur.2011.07.042
   Wood DE, 2003, ANN THORAC SURG, V76, P167, DOI 10.1016/S0003-4975(03)00033-X
   Wright CD, 2004, J THORAC CARDIOV SUR, V128, P731, DOI 10.1016/j.jtcvs.2004.07.005
   Yamamoto K, 2011, ANN THORAC SURG, V91, P1747, DOI 10.1016/j.athoracsur.2011.02.071
NR 27
TC 3
Z9 3
U1 3
U2 20
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0003-4975
J9 ANN THORAC SURG
JI Ann. Thorac. Surg.
PD OCT
PY 2012
VL 94
IS 4
BP 1065
EP 1072
DI 10.1016/j.athoracsur.2012.05.107
PG 8
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery
SC Cardiovascular System & Cardiology; Respiratory System; Surgery
GA 016OJ
UT WOS:000309528300015
PM 22858276
DA 2018-12-27
ER

PT J
AU Persson, EC
   Shiels, MS
   Dawsey, SM
   Bhatia, K
   Anderson, LA
   Engels, EA
AF Persson, E. Christina
   Shiels, Meredith S.
   Dawsey, Sanford M.
   Bhatia, Kishor
   Anderson, Lesley A.
   Engels, Eric A.
TI RETRACTED: Increased Risk of Stomach and Esophageal Malignancies in
   People With AIDS (Retracted article. See vol. 150, pg. 1048, 2016)
SO GASTROENTEROLOGY
LA English
DT Article; Retracted Publication
DE MALT Lymphoma; Epidemiology; Virus-Associated Cancers; Immunosuppression
ID HELICOBACTER-PYLORI INFECTION; ACTIVE ANTIRETROVIRAL THERAPY;
   EPSTEIN-BARR-VIRUS; HIV-POSITIVE PATIENTS; UNITED-STATES;
   GASTRIC-CANCER; TRANSPLANT RECIPIENTS; ENDOSCOPIC FINDINGS;
   LOW-PREVALENCE; LUNG-CANCER
AB BACKGROUND & AIMS: People infected with human immunodeficiency virus (HIV) have an increased risk of some malignancies, but little is known about the effects of infection on risk of cancers of the upper gastrointestinal tract. We evaluated the risks of different histologic and anatomic subtypes of carcinomas and non-Hodgkin lymphomas (NHLs) of the stomach and esophagus in people with acquired immunodeficiency syndrome (AIDS). METHODS: We analyzed data from the HIV/AIDS Cancer Match Study, which links data collected from 1980 to 2007 for 16 US population-based HIV and AIDS and cancer registries. We compared risks of stomach and esophageal malignancies in people with AIDS (N = 596,955) with those of the general population using standardized incidence ratios (SIRs). We assessed calendar trends using Poisson regression. RESULTS: People with AIDS had increased risks of carcinomas of the esophagus (SIR, 1.69; 95% confidence interval [CI], 1.37-2.07; n = 95) and stomach (SIR, 1.44; 95% CI, 1.17-1.76; n = 96). Risk was increased for esophageal adenocarcinoma (SIR, 1.91; 95% CI, 1.31-2.70) and squamous cell carcinoma (SIR, 1.47; 95% CI, 1.10-1.92). People with AIDS had greater risks of carcinomas of the gastric cardia (SIR, 1.36; 95% CI, 0.83-2.11) and noncardia (SIR, 1.53; 95% CI, 1.12-2.05) than the general population. Although most stomach and esophageal NHLs that developed in people with AIDS were diffuse large B-cell lymphomas, these individuals also had an increased risk of stomach mucosa-associated lymphoid tissue lymphoma (SIR, 5.99; 95% CI, 3.19-10.2; n = 13). The incidence of carcinomas remained fairly constant over time, but rates of NHL decreased from 1980 to 2007 (P-trend < .0001). CONCLUSIONS: People with AIDS are at increased risk for developing esophageal and stomach carcinomas and NHLs. Although the incidence of NHL decreased from 1980 to 2007 as treatments for HIV infection improved, HIV-infected individuals face continued risks of esophageal and stomach carcinomas.
C1 [Persson, E. Christina] NCI, Div Canc Epidemiol & Genet, NIH, Dept Hlth & Human Serv, Rockville, MD 20852 USA.
   [Anderson, Lesley A.] Queens Univ Belfast, Ctr Publ Hlth, Inst Clin & Populat Sci, Canc Epidemiol & Hlth Serv Res Grp, Belfast, Antrim, North Ireland.
RP Persson, EC (reprint author), NCI, Div Canc Epidemiol & Genet, NIH, Dept Hlth & Human Serv, 6120 Execut Blvd, Rockville, MD 20852 USA.
EM christina.persson@nih.gov
OI Anderson, Lesley/0000-0002-1000-3649
FU Intramural Research Program of the National Cancer Institute; National
   Institutes of Health; Department of Health and Human Services [Z01
   CP010150-12]
FX Supported by the Intramural Research Program of the National Cancer
   Institute, National Institutes of Health, and Department of Health and
   Human Services grant Z01 CP010150-12.
CR Anderson WF, 2010, JAMA-J AM MED ASSOC, V303, P1723, DOI 10.1001/jama.2010.496
   [Anonymous], 1994, IARC Monogr Eval Carcinog Risks Hum, V61, P1
   [Anonymous], 1992, MMWR Recomm Rep, V41, P1
   Awerkiew S, 2003, MED MICROBIOL IMMUN, V192, P137, DOI 10.1007/s00430-002-0128-z
   BATTAN R, 1990, AM J GASTROENTEROL, V85, P1576
   Boyle B A, 2001, AIDS Read, V11, P387
   Boyle BA, 2001, AIDS READ, V11, P397
   Carbone A, 2003, LANCET ONCOL, V4, P22, DOI 10.1016/S1470-2045(03)00957-4
   Chow WH, 1998, CANCER RES, V58, P588
   Cook MB, 2010, JNCI-J NATL CANCER I, V102, P1344, DOI 10.1093/jnci/djq289
   CORREA P, 1995, AM J SURG PATHOL, V19, pS37
   Cote TR, 1997, INT J CANCER, V73, P645, DOI 10.1002/(SICI)1097-0215(19971127)73:5<645::AID-IJC6>3.3.CO;2-H
   de Villiers EM, 1999, INT J CANCER, V81, P225
   Engels EA, 2006, J CLIN ONCOL, V24, P1383, DOI 10.1200/JCO.2005.03.4413
   Engels EA, 2006, AIDS, V20, P1645, DOI 10.1097/01.aids.0000238411.75324.59
   Engels EA, 2011, JAMA-J AM MED ASSOC, V306, P1891, DOI 10.1001/jama.2011.1592
   Epeldegui M, 2006, CURR OPIN ONCOL, V18, P444, DOI 10.1097/01.cco.0000239882.23839.e5
   Fabris P, 1997, DIGEST DIS SCI, V42, P289, DOI 10.1023/A:1018801532136
   Fialho ABC, 2011, BMC GASTROENTEROL, V11, DOI 10.1186/1471-230X-11-13
   FRANCIS ND, 1990, J CLIN PATHOL, V43, P60, DOI 10.1136/jcp.43.1.60
   Freedman ND, 2007, AM J EPIDEMIOL, V165, P1424, DOI 10.1093/aje/kwm051
   Freedman ND, 2011, GUT, V60, P1029, DOI 10.1136/gut.2010.233866
   Frisch M, 2001, JAMA-J AM MED ASSOC, V285, P1736, DOI 10.1001/jama.285.13.1736
   Fritz A, 2000, INT CLASSIFICATION D
   Gallagher B, 2001, AM J EPIDEMIOL, V154, P544, DOI 10.1093/aje/154.6.544
   Gritz ER, 2004, NICOTINE TOB RES, V6, P71, DOI 10.1080/14622200310001656885
   Grulich AE, 2007, LANCET, V370, P59, DOI 10.1016/S0140-6736(07)61050-2
   Hessol NA, 2007, AM J EPIDEMIOL, V165, P1143, DOI 10.1093/aje/kwm017
   Hestvik E, 2011, J INT AIDS SOC, V14, DOI 10.1186/1758-2652-14-34
   Jackman RP, 2006, EPIDEMIOL INFECT, V134, P460, DOI 10.1017/S0950268805005169
   Kamangar F, 2006, JNCI-J NATL CANCER I, V98, P1445, DOI 10.1093/jnci/djj393
   Kamangar F, 2006, INT J CANCER, V119, P579, DOI 10.1002/ijc.21871
   Kim J, 2009, PATHOLOGY, V41, P593, DOI 10.1080/00313020903071454
   Lv FJ, 2007, WORLD J GASTROENTERO, V13, P5492, DOI 10.3748/wjg.v13.i41.5492
   Marshall MM, 2011, ADDICT BEHAV, V36, P61, DOI 10.1016/j.addbeh.2010.08.022
   Mbulaiteye SM, 2009, FRONT BIOSCI-LANDMRK, V14, P1490, DOI 10.2741/3320
   Murphy G, 2009, GASTROENTEROLOGY, V137, P824, DOI 10.1053/j.gastro.2009.05.001
   Newnham A, 2005, BRIT J CANCER, V92, P194, DOI 10.1038/sj.bjc.6602273
   Nkuize M, 2010, HIV MED, V11, P412, DOI 10.1111/j.1468-1293.2009.00807.x
   Patel P, 2008, ANN INTERN MED, V148, P728, DOI 10.7326/0003-4819-148-10-200805200-00005
   Petry NM, 1999, INT J STD AIDS, V10, P561, DOI 10.1258/0956462991914654
   Rastegar DA, 2010, ARCH INTERN MED, V170, P916, DOI 10.1001/archinternmed.2010.113
   Rock V. J., 2007, Morbidity and Mortality Weekly Report, V56, P1157
   Romanelli F, 2007, AIDS PATIENT CARE ST, V21, P908, DOI 10.1089/apc.2006.0215
   Sayi A, 2009, J IMMUNOL, V182, P7085, DOI 10.4049/jimmunol.0803293
   Schlansky B, 2011, AM J GASTROENTEROL, V106, P1978, DOI 10.1038/ajg.2011.213
   Shiels MS, 2011, J NATL CANCER I, V103, P753, DOI 10.1093/jnci/djr076
   Silverberg MJ, 2009, AIDS, V23, P2337, DOI 10.1097/QAD.0b013e3283319184
   Stebbing J, 2010, ARCH INTERN MED, V170, P203, DOI 10.1001/archinternmed.2009.490
   Steenland K, 2004, AM J EPIDEMIOL, V160, P384, DOI 10.1093/aje/kwh211
   STOLTE M, 1992, LANCET, V339, P745, DOI 10.1016/0140-6736(92)90645-J
   Thompson SC, 1996, AIDS CARE, V8, P5, DOI 10.1080/09540129650125957
   Trivers KF, 2008, INT J CANCER, V123, P1422, DOI 10.1002/ijc.23691
   Wang J, 1999, CANCER EPIDEM BIOMAR, V8, P1111
   Webb PM, 2001, GUT, V49, P347
   Welage LS, 1995, CLIN INFECT DIS, V21, P1431, DOI 10.1093/clinids/21.6.1431
NR 56
TC 19
Z9 20
U1 1
U2 8
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0016-5085
EI 1528-0012
J9 GASTROENTEROLOGY
JI Gastroenterology
PD OCT
PY 2012
VL 143
IS 4
BP 943
EP +
DI 10.1053/j.gastro.2012.07.013
PG 10
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 014FY
UT WOS:000309361800026
PM 22796240
OA Green Accepted
DA 2018-12-27
ER

PT J
AU Dey, AB
   Mohanan, S
   Damodaran, D
   Soneja, M
   Jain, N
   Mohan, A
   Vikram, NK
   Sood, R
AF Dey, A. B.
   Mohanan, Sandeep
   Damodaran, Deepak
   Soneja, Manish
   Jain, Neetu
   Mohan, Anant
   Vikram, Naval Kishore
   Sood, Rita
TI RETRACTED: Radiation accident at Mayapuri scrap market, Delhi, 2010
   (Retracted article. See vol. 152, pg. 481, 2012)
SO RADIATION PROTECTION DOSIMETRY
LA English
DT Article; Proceedings Paper; Retracted Publication
CT 13th Radiation Emergency Medical Preparedness and Assistance Network
   (REMPAN)
CY FEB 16-18, 2011
CL Nagasaki, JAPAN
ID INFECTIOUS-DISEASES SOCIETY; CLINICAL-PRACTICE GUIDELINE; ANTIMICROBIAL
   AGENTS; NEUTROPENIC PATIENTS; MANAGEMENT; CONSENSUS; EXPOSURE; AMERICA;
   UPDATE
AB This article reports the accidental public radiation exposure in a scrap market in Delhi, India, on March 2010. The source, a gamma unit containing Cobalt-60 pencils, was improperly disposed of by a research institution in violation of national regulations for radiation protection and safety of radioactive sources. The unit was sold off to unsuspecting scrap dealers who dismantled the equipment. This event subsequently caused the most severe radiation accident reported in India to date, resulting in seven radiation injuries and one death. The clinical course of five of the patients treated at the All India Institute of Medical Sciences hospital, New Delhi, is summarised in this report. All five patients suffered from the haematological form of the acute radiation syndrome and local cutaneous radiation injury as well. While four patients exposed to doses between 0.6 and 2.8 Gy survived with intensive or supportive treatment, the patient with the highest exposure of 3.1 Gy died due to acute respiratory distress syndrome and multi-organ failure on Day 16 after hospitalisation. The incident highlights the current gaps in the knowledge, infrastructure and legislation in handling radioactive materials. Medical institutions need to formulate individualised triage and management guidelines to immediately respond to future public radiological accidents.
C1 [Dey, A. B.; Mohanan, Sandeep; Damodaran, Deepak; Soneja, Manish; Jain, Neetu; Mohan, Anant; Vikram, Naval Kishore; Sood, Rita] All India Inst Med Sci, Dept Med, New Delhi 110029, India.
RP Dey, AB (reprint author), All India Inst Med Sci, Dept Med, New Delhi 110029, India.
EM abdey@hotmail.com
OI Soneja, Manish/0000-0002-8619-7929
CR Anspaugh L., 2000, SOURCES EFFECTS IONI, VI
   BARANOV A, 1989, NEW ENGL J MED, V321, P205, DOI 10.1056/NEJM198907273210401
   BENDER MA, 1995, STEM CELLS, V13, P172
   Bergmann H., 1997, RADIOACTIVE ISOTOPES
   Bhushan V., 1973, 3 IRPA C P
   Bodey GP, 2005, CLIN INFECT DIS, V40, pS239, DOI 10.1086/427328
   Dainiak N, 2011, DISASTER MED PUBLIC, V5, P202, DOI 10.1001/dmp.2011.68
   Dorr H, 2011, BMC MED, V9, DOI 10.1186/1741-7015-9-126
   Freifeld AG, 2011, CLIN INFECT DIS, V52, P427, DOI 10.1093/cid/ciq147
   Freifeld AG, 2011, CLIN INFECT DIS, V52, pE56, DOI 10.1093/cid/cir073
   Gangadharan P., 1988, 7 IRPA C P
   Goans R. E., 2010, MED MANAGEMENT RADIO
   Gourmelon P, 2010, HEALTH PHYS, V98, P825, DOI 10.1097/HP.0b013e3181ce64d4
   Herodin F, 2005, FOLIA HISTOCHEM CYTO, V43, P223
   International Atomic Energy Agency, 1993, RAD ACC SOR
   Johnston W. R., DATABASE RADIOLOGICA
   Peter R. U., 2001, Radioprotection, V36, P451, DOI 10.1051/radiopro:2001103
   Radiation Injury Treatment Network, 2010, AC RAD SYNDR TREATM
   Rao S., 1977, 4 IRPA C P
   Turai I., 1998, SAF SER INT AT EN AG
   Turai I., 2002, FOLLOW DELAYED HLTH
   Wen HW, 2006, RADIAT PHYS CHEM, V75, P596, DOI 10.1016/j.radphyschem.2005.12.031
NR 22
TC 4
Z9 5
U1 2
U2 15
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0144-8420
EI 1742-3406
J9 RADIAT PROT DOSIM
JI Radiat. Prot. Dosim.
PD OCT
PY 2012
VL 151
IS 4
BP 645
EP 651
DI 10.1093/rpd/ncs162
PG 7
WC Environmental Sciences; Public, Environmental & Occupational Health;
   Nuclear Science & Technology; Radiology, Nuclear Medicine & Medical
   Imaging
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health; Nuclear Science & Technology; Radiology, Nuclear Medicine &
   Medical Imaging
GA 015UB
UT WOS:000309470700009
PM 22914329
OA Bronze
DA 2018-12-27
ER

PT J
AU Takai, N
   Kira, N
   Ishii, T
   Yoshida, T
   Nishida, M
   Nishida, Y
   Nasu, K
   Takano, M
   Midori, H
   Koga, S
   Narahara, H
AF Takai, Noriyuki
   Kira, Naoko
   Ishii, Terukazu
   Yoshida, Toshie
   Nishida, Masakazu
   Nishida, Yoshihiro
   Nasu, Kaei
   Takano, Masayuki
   Midori, Haruna
   Koga, Satoko
   Narahara, Hisashi
TI RETRACTED: A translocator protein ligand PK11195 shows antigrowth
   activity in human choriocarcinoma cells (Retracted article. See vol. 36,
   pg. 7293, 2015)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE Translocator protein ligand; PK11195; Cell cycle; Apoptosis;
   Choriocarcinoma
ID MITOCHONDRIAL PERMEABILITY TRANSITION; RECEPTOR INDUCE APOPTOSIS;
   OVARIAN-CANCER CELLS; BENZODIAZEPINE-RECEPTOR; CYCLE ARREST;
   TROPHOBLASTIC DISEASE; HUMAN ENDOMETRIAL; MANAGEMENT; RESISTANCE;
   PK-11195
AB The potential anticancer agent 1-(2-chlorophenyl-N-methylpropyl)-3-isoquinolinecarboxamide (PK11195), a translocator protein ligand (initially described as a ligand for the peripheral benzodiazepine receptor), induces apoptosis in some lines of human tumor cells. We investigated the effect of PK11195 in the choriocarcinoma cell line, BeWo. BeWo cells were treated with various concentrations of PK11195, and changes in cell growth, the cell cycle, apoptosis, and related parameters were examined. A WST-1 assay showed that BeWo cells were sensitive to the growth inhibitory effect of PK11195. In contrast, the nonsite selective ligand diazepam has a little effect on these cells. Cell cycle analysis indicated that exposure to PK11195 decreased the proportion of cells in the S phase and increased the proportion in the G0/G1 phases of the cell cycle. Induction of apoptosis was confirmed by Annexin V staining of externalized phosphatidylserine, by the loss of mitochondrial transmembrane potential, and by antibodies directed against histones from fragmented DNA. This induction occurred in conjunction with the altered expression of genes related to cell growth, malignant phenotype, and apoptosis. These results suggest that PK11195 may serve as a therapeutic agent for the treatment of choriocarcinoma.
C1 [Takai, Noriyuki; Kira, Naoko; Ishii, Terukazu; Yoshida, Toshie; Nishida, Masakazu; Nishida, Yoshihiro; Nasu, Kaei; Takano, Masayuki; Midori, Haruna; Koga, Satoko; Narahara, Hisashi] Oita Univ, Fac Med, Dept Obstet & Gynecol, Yufu, Oita 8795593, Japan.
RP Takai, N (reprint author), Oita Univ, Fac Med, Dept Obstet & Gynecol, 1-1 Idaigaoka,Hasama Machi, Yufu, Oita 8795593, Japan.
EM takai@oita-u.ac.jp
FU Ministry of Education, Culture, Sports, Science, and Technology, Japan
   [21592139]; Oita University
FX This study was supported by a Grant-in-Aid (No. 21592139 to NT) for
   Scientific Research from the Ministry of Education, Culture, Sports,
   Science, and Technology, Japan and by a Research Fund at the Discretion
   of the President, Oita University (HN).
CR ANSSEAU M, 1991, PHARMACOPSYCHIATRY, V24, P8, DOI 10.1055/s-2007-1014425
   BERKOWITZ RS, 1984, GYNECOL ONCOL, V19, P173, DOI 10.1016/0090-8258(84)90177-X
   Chen Y, 2001, CANCER RES, V61, P6437
   Decaudin D, 2002, CANCER RES, V62, P1388
   DEJONG D, 1994, CANCER RES, V54, P256
   FERRY A, 1989, FUNDAM CLIN PHARM, V3, P383, DOI 10.1111/j.1472-8206.1989.tb00679.x
   Gonzalez-Polo RA, 2005, ONCOGENE, V24, P7503, DOI 10.1038/sj.onc.1208907
   Hirsch T, 1997, BIOSCIENCE REP, V17, P67, DOI 10.1023/A:1027339418683
   Johnson DG, 1999, ANNU REV PHARMACOL, V39, P295, DOI 10.1146/annurev.pharmtox.39.1.295
   Jones WB, 1997, INT J GYNECOL CANCER, V7, P27, DOI 10.1046/j.1525-1438.1997.00409.x
   Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614
   Kyushima N, 2002, J CANCER RES CLIN, V128, P307, DOI 10.1007/s00432-002-0328-3
   LEFUR G, 1983, LIFE SCI, V32, P1839, DOI 10.1016/0024-3205(83)90062-0
   Ly JD, 2003, APOPTOSIS, V8, P115, DOI 10.1023/A:1022945107762
   Maaser K, 2001, BRIT J CANCER, V85, P1771, DOI 10.1054/bjoc.2001.2181
   Muscarella DE, 2003, TOXICOL SCI, V74, P66, DOI 10.1093/toxsci/kfg052
   Papadopoulos V, 2006, TRENDS PHARMACOL SCI, V27, P402, DOI 10.1016/j.tips.2006.06.005
   Rimon G, 1997, J NEUROSCI RES, V48, P563, DOI 10.1002/(SICI)1097-4547(19970615)48:6<563::AID-JNR9>3.0.CO;2-8
   SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1
   SURWIT EA, 1980, OBSTET GYNECOL, V55, P565
   Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25
   Sutter AP, 2002, INT J CANCER, V102, P318, DOI 10.1002/ijc.10724
   Takai N, 2004, CLIN CANCER RES, V10, P1141, DOI 10.1158/1078-0432.CCR-03-0100
   Takai N, 2008, GYNECOL ONCOL, V111, P336, DOI 10.1016/j.ygyno.2008.08.004
   Takai N, 2008, INT J MOL MED, V21, P637
   ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A
NR 26
TC 5
Z9 5
U1 1
U2 7
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD OCT
PY 2012
VL 33
IS 5
BP 1505
EP 1510
DI 10.1007/s13277-012-0401-8
PG 6
WC Oncology
SC Oncology
GA 014DF
UT WOS:000309354600028
PM 22528948
DA 2018-12-27
ER

PT J
AU Jiang, T
   Liu, SY
   Xiao, XS
   Tao, XF
   Liu, GH
   Wang, JL
AF Jiang, Tao
   Liu, Shiyuan
   Xiao, XiangSheng
   Tao, XiaoFeng
   Liu, GuangHua
   Wang, JinLin
TI RETRACTED: Diagnosis of rejection after liver transplantation: use of
   phosphorus-31 magnetic resonance spectroscopy (P-31-MRS)(Retracted
   article. See vol. 41, pg. 1876, 2016)
SO ABDOMINAL IMAGING
LA English
DT Article; Retracted Publication
DE Magnetic resonance spectroscopy; Liver transplantation; Rejection;
   Energy metabolites; Phospholipids; In vivo
ID IN-VIVO; DUCTOPENIC REJECTION; ELECTRON-MICROSCOPY; RAT-LIVER;
   CIRRHOSIS; INVIVO; P-31-NMR; FEATURES; DISEASE
AB In vivo hepatic phosphorus-31 magnetic resonance spectroscopy (P-31-MRS) provides non-invasive information about phospholipid metabolism. Aims: To delineate P-31-MRS abnormalities in patients with chronic rejection and to charactererize spectral changes by pathology.
   Sixty-six liver transplant recipients (18 with chronic rejection and 48 with normal graft function) and 38 controls (23 healthy volunteers and fifteen patients with biliary duct stricture) were studied with in vivo P-31-MRS. All the data and peak values were calibrated and calculated by the software of spectroscopy analysis GE, and the pH values were calculated by the Malloy's formula, then the peak area ratios and altitudes of metabolites relative to adenosine triphosphate (beta-ATP)and phosphate (Pi) were measured.
   (a) The peak area ratios and altitudes of PME and PDE in biliary duct stricture group and chronic rejection group were higher than those of healthy volunteer group and normal graft function group. Patients with chronic rejection had significant differences in the peak area ratios of PME: beta-ATP (P < 0.05) and PDE: beta-ATP (P < 0.05) and in the altitudes of PME: beta-ATP (P < 0.05) as compared with the other groups. (b) The ratios of beta-ATP/Pi decreased in biliary duct stricture group, while they increased in chronic rejection group. There was no difference between the four groups. There were similar changes in the ratios of PME/Pi, but there was significant difference between the chronic rejection group and the other three groups. (c) pH values increased in biliary duct stricture group and chronic rejection group, though the difference was not significant with the healthy control group. (d) Histological specimens showed focal loss of hepatocytes, degeneration, and hepatocytic atrophy.
   P-31-MRS imaging is valuable in detecting the metabolism of the liver after transplantation, and suggests that further investigation of alterations in the phospholipid metabolism may be a useful future direction of research.
C1 [Jiang, Tao; Liu, Shiyuan; Xiao, XiangSheng; Tao, XiaoFeng; Liu, GuangHua; Wang, JinLin] Second Mil Med Univ, Dept Radiol, Changzheng Hosp, Shanghai, Peoples R China.
RP Liu, SY (reprint author), Second Mil Med Univ, Dept Radiol, Changzheng Hosp, Feng Yang Rd 415, Shanghai, Peoples R China.
EM laijiangtaotao@yahoo.com.cn
CR European FK506 multicenter liver study group, 1994, J GERONTOL B-PSYCHOL, V344, P423
   MALLOY CR, 1986, BIOCHIM BIOPHYS ACTA, V885, P1, DOI 10.1016/0167-4889(86)90032-7
   Mann DV, 2002, GUT, V50, P118, DOI 10.1136/gut.50.1.118
   MENON DK, 1995, HEPATOLOGY, V21, P417, DOI 10.1016/0270-9139(95)90102-7
   MUNAKATA T, 1993, NMR BIOMED, V6, P168, DOI 10.1002/nbm.1940060211
   MURPHY EJ, 1992, BIOCHIM BIOPHYS ACTA, V1135, P27, DOI 10.1016/0167-4889(92)90162-5
   MURPHY EJ, 1989, MAGNET RESON MED, V12, P282, DOI 10.1002/mrm.1910120218
   NG TC, 1989, RADIOLOGY, V170, P875, DOI 10.1148/radiology.170.3.2916046
   NOACK KB, 1991, TRANSPLANT P, V23, P1448
   OBERHAENSLI R, 1990, GUT, V31, P463, DOI 10.1136/gut.31.4.463
   Oberhaensli RD, 1998, J GERONTOL B-PSYCHOL, V5, P8
   RUBIN R, 1993, HUM PATHOL, V24, P643, DOI 10.1016/0046-8177(93)90245-C
   RUIZCABELLO J, 1992, NMR BIOMED, V5, P226, DOI 10.1002/nbm.1940050506
   SHINKWIN MA, 1991, CANCER-AM CANCER SOC, V67, P1849, DOI 10.1002/1097-0142(19910401)67:7<1849::AID-CNCR2820670706>3.0.CO;2-E
   Tang ZQ, 1993, MODERN ONCOLOGY, P47
   Taylor-Robinson SD, 1998, GUT, V42, P735, DOI 10.1136/gut.42.5.735
   TaylorRobinson SD, 1997, LIVER, V17, P198
   TAYLORROBINSON SD, 1995, BBA-MOL BASIS DIS, V1272, P113, DOI 10.1016/0925-4439(95)00074-E
   Uberbaenshi RD, 1986, BRIT J RADIOL, V59, P695
   WIESNER RH, 1993, MAYO CLIN PROC, V68, P69, DOI 10.1016/S0025-6196(12)60022-6
NR 20
TC 5
Z9 6
U1 3
U2 8
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0942-8925
EI 1432-0509
J9 ABDOM IMAGING
JI Abdom. Imaging
PD OCT
PY 2012
VL 37
IS 5
BP 788
EP 794
DI 10.1007/s00261-008-9451-1
PG 7
WC Gastroenterology & Hepatology; Radiology, Nuclear Medicine & Medical
   Imaging
SC Gastroenterology & Hepatology; Radiology, Nuclear Medicine & Medical
   Imaging
GA 011MZ
UT WOS:000309170400016
PM 23166917
DA 2018-12-27
ER

PT J
AU Niv, Y
   Boltin, D
   Halpern, M
   Cohen, M
   Levi, Z
   Vilkin, A
   Morgenstern, S
   Manugian, V
   St Lawrence, E
   Gagneux, P
   Batra, SK
   Ho, SB
AF Niv, Yaron
   Boltin, Doron
   Halpern, Marisa
   Cohen, Miriam
   Levi, Zohar
   Vilkin, Alex
   Morgenstern, Sara
   Manugian, Vahig
   St Lawrence, Erica
   Gagneux, Pascal
   Batra, Surinder K.
   Ho, Samuel B.
TI RETRACTED: Membrane-Bound Mucins and Mucin Terminal Glycans Expression
   in Idiopathic or Helicobacter pylori, NSAID Associated Peptic Ulcers
   (Retracted article. See vol. 58, pg. 1812, 2013)
SO DIGESTIVE DISEASES AND SCIENCES
LA English
DT Article; Retracted Publication
DE Idiopathic ulcer; Mucin; MUC1; MUC4; MUC17; SNA; ECA; Helicobacter
   pylori
ID GASTRIC MUCIN; DUODENAL-ULCERS; SYDNEY SYSTEM; INFECTION; PATHOGENESIS;
   PREVALENCE; DISEASE; MUC5AC
AB The ratio of Helicobacter pylori/NSAID-negative gastric ulcers is increasing. Idiopathic gastric ulcers have unique clinical and endoscopic features, and are associated with more bleeding complications and a higher mortality. Alterations in gastric mucin expression and sialylation pattern may be important in ulcer pathogenesis.
   The purpose of this study was to determine the expression pattern of membrane-bound mucins and side chain sugars in H. pylori associated-, NSAID-, and idiopathic-gastric ulcers.
   We randomly selected 92 patients with H. pylori (group 1, n = 30), NSAID (group 2, n = 18), combined H. pylori and NSAID associated gastric ulcers (group 3, n = 24), and patients with idiopathic gastric ulcers (group 4, n = 20). Immunohistochemistry for T-cell CD4/CD8, MUC1, MUC4, MUC17, and ECA and SNA lectins staining was performed on sections from the ulcer margins. Inflammation score was assessed according to the Sydney system.
   Bleeding and mortality rates were significantly higher in group 4. CD4 positive T cell count was higher in H. pylori positive patients (P = 0.009). Staining intensity of MUC17 was higher in group 1 than in group 4, foveola and glands alike, with 11.50 +/- A 3.47 versus 6.80 +/- A 4.02, and 9.61 +/- A 4.26 versus 7.59 +/- A 3.26, respectively (P < 0.0001). This was a mirror image with MUC1. SNA lectin staining was increased in group 4, in parallel to MUC1 expression, indicating more abundant alpha 2-6 sialylation in that group.
   Cytoplasmic MUC17 staining was significantly decreased in the cases with idiopathic ulcer. The opposite was demonstrated for MUC1. This observation might be important, since different mucins with altered sialylation patterns likely differ in their protection efficiency against acid and pepsin.
C1 [Niv, Yaron; Boltin, Doron; Levi, Zohar; Vilkin, Alex] Tel Aviv Univ, Dept Gastroenterol, Rabin Med Ctr, IL-49100 Petah Tiqwa, Israel.
   [Halpern, Marisa] Hasharon Hosp, Rabin Med Ctr, Dept Pathol, Petah Tiqwa, Israel.
   [Cohen, Miriam; Gagneux, Pascal] Univ Calif San Diego, Dept Cellular & Mol Med, Glycobiol Res & Training Ctr, San Diego, CA 92103 USA.
   [Morgenstern, Sara] Beilinson Med Ctr, Rabin Med Ctr, Dept Pathol, Petah Tiqwa, Israel.
   [Manugian, Vahig; St Lawrence, Erica; Ho, Samuel B.] Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA.
   [Manugian, Vahig; St Lawrence, Erica; Ho, Samuel B.] VA San Diego Healthcare Syst, San Diego, CA USA.
   [Batra, Surinder K.] Univ Nebraska, Dept Biochem & Mol Biol, Omaha, NE 68182 USA.
RP Niv, Y (reprint author), Tel Aviv Univ, Dept Gastroenterol, Rabin Med Ctr, 39 Jabotinski St, IL-49100 Petah Tiqwa, Israel.
EM nivyaron80@gmail.com
OI Levi, Zohar/0000-0003-2456-8891
FU National Institute of Neurological Disorders and Stroke [P30 NS047101];
   G. Harold and Leila Y. Mathers Charitable Foundation [*** CSD018]
FX The work was supported by National Institute of Neurological Disorders
   and Stroke (grant P30 NS047101; Neurosciences Microscopy Shared
   Facility, UCSD) and grant *** CSD018 from the G. Harold and Leila Y.
   Mathers Charitable Foundation (P. Gagneux). Sukhwinder Kaur, Srustidhar
   Das, and Poonam Sharma performed the MUC4 staining.
CR Celli JP, 2009, P NATL ACAD SCI USA, V106, P14321, DOI 10.1073/pnas.0903438106
   Chan HLY, 2001, GASTROINTEST ENDOSC, V53, P438, DOI 10.1067/mge.2001.112840
   DEBOECK H, 1984, ARCH BIOCHEM BIOPHYS, V234, P297, DOI 10.1016/0003-9861(84)90352-7
   Dixon MF, 1996, AM J SURG PATHOL, V20, P1161, DOI 10.1097/00000478-199610000-00001
   Elitsur Y, 2001, HELICOBACTER, V6, P239, DOI 10.1046/j.1523-5378.2001.00034.x
   Gisbert JP, 2009, ALIMENT PHARM THER, V30, P791, DOI 10.1111/j.1365-2036.2009.04105.x
   Gisbert JP, 1999, DIGEST DIS SCI, V44, P2295, DOI 10.1023/A:1026669123593
   Ho SB, 2004, DIGEST DIS SCI, V49, P1598, DOI 10.1023/B:DDAS.0000043371.12671.98
   Hyvarinen H, 1996, DIGESTION, V57, P305, DOI 10.1159/000201350
   Jyotheeswaran S, 1998, AM J GASTROENTEROL, V93, P574
   Kawakubo M, 2004, SCIENCE, V305, P1003, DOI 10.1126/science.1099250
   Kobayashi M, 2009, GLYCOBIOLOGY, V19, P453, DOI 10.1093/glycob/cwp004
   Linden S, 2010, HELICOBACTER, V15, P251, DOI 10.1111/j.1523-5378.2010.00765.x
   Luu Y, 2010, INT J BIOCHEM CELL B, V42, P996, DOI 10.1016/j.biocel.2010.03.001
   MCCOLL KEL, 1993, GUT, V34, P762, DOI 10.1136/gut.34.6.762
   McColl KEL, 2009, AM J GASTROENTEROL, V104, P190, DOI 10.1038/ajg.2008.11
   Niv Y, 2008, WORLD J GASTROENTERO, V14, P2139, DOI 10.3748/wjg.14.2139
   Niv Y, 2011, GASTROENTEROLOGY, V140, pS732
   Niv Y, 2010, MED HYPOTHESES, V75, P433, DOI 10.1016/j.mehy.2010.04.015
   PRICE AB, 1991, J GASTROEN HEPATOL, V6, P209, DOI 10.1111/j.1440-1746.1991.tb01468.x
   SHIBUYA N, 1987, J BIOL CHEM, V262, P1596
   Stromberg E, 2003, FEMS IMMUNOL MED MIC, V36, P159, DOI 10.1016/S0928-8244(03)00026-9
   Tanaka S, 2003, HEPATO-GASTROENTEROL, V50, P1739
   Tsuji H, 1999, J GASTROENTEROL, V34, P455, DOI 10.1007/s005350050296
   Tsukashita S, 2001, INT J CANCER, V94, P166, DOI 10.1002/ijc.1460
   Wong GLH, 2009, GASTROENTEROLOGY, V137, P525, DOI 10.1053/j.gastro.2009.05.006
   Xia HHX, 2001, ALIMENT PHARM THERAP, V15, P1875, DOI 10.1046/j.1365-2036.2001.01115.x
NR 27
TC 3
Z9 3
U1 2
U2 15
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0163-2116
EI 1573-2568
J9 DIGEST DIS SCI
JI Dig. Dis. Sci.
PD OCT
PY 2012
VL 57
IS 10
BP 2535
EP 2544
DI 10.1007/s10620-012-2205-5
PG 10
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 012HQ
UT WOS:000309227300011
PM 22576713
DA 2018-12-27
ER

PT J
AU Rampersaud, N
   Harkavyi, A
   Giordano, G
   Lever, R
   Whitton, J
   Whitton, PS
AF Rampersaud, N.
   Harkavyi, A.
   Giordano, G.
   Lever, R.
   Whitton, J.
   Whitton, P. S.
TI RETRACTED: Exendin-4 reverses biochemical and behavioral deficits in a
   pre-motor rodent model of Parkinson's disease with combined
   noradrenergic and serotonergic lesions (Retracted article. See vol. 47,
   pg. 221, 2013)
SO NEUROPEPTIDES
LA English
DT Article; Retracted Publication
DE 6-OHDA; DSP-4; Exendin-4; Force swim test; Novel object recognition;
   Parkinson's disease; Pre-motor; pCA; Parachloroamphetamine; Sucrose
   preference
ID GLUCAGON-LIKE PEPTIDE-1; FORCED SWIM TEST; OBJECT-RECOGNITION MEMORY;
   LOCUS-CERULEUS LESIONS; RAT-BRAIN; DOPAMINERGIC-NEURONS; NONMOTOR
   SYMPTOMS; SUBSTANTIA-NIGRA; ANIMAL-MODEL; NEUROCHEMICAL ALTERATIONS
AB Research on Parkinson's disease (PD) has mainly focused on the degeneration of the dopaminergic neurons of nigro-striatal pathway; however, post-mortem studies have demonstrated that other brain regions such as the locus coeruleus (LC) and raphe nuclei (RN) are significantly affected as well. Degeneration of these crucial neuronal cell bodies may be responsible for depressive behavior and cognitive decline present in the pre-motor stage of PD. We have thus set out to create a pre-motor rodent model of PD which mimics the early stages of the condition. N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4), a selective noradrenergic neurotoxin, and parachloroampetamine (pCA), a selective serotonergic neurotoxin, were utilized concomitantly with bilateral 6-hydroxydopamine (6-OHDA) injections into the striatum to produce a pre-motor rodent model of PD with partial deficits in the dopaminergic, noradrenergic, and serotonergic systems. Our model exhibited a depressive/anhedonic condition as assessed using sucrose preference testing and the forced swim test. Our model also demonstrated deficits in object memory. These behavioral impairments were accompanied by a decline in both tissue and extracellular levels of all three neurotransmitters in both the frontal cortex and striatum. Immunohistochemistry also revealed a decrease in TH+ cells in the LC and substantia nigra. Exendin-4 (EX-4), a glucagon-like peptide-1 receptor (GLP-1R) agonist, promoted recovery of both the biochemical and behavioral dysfunction exhibited by our model. EX-4 was able to preserve the functional integrity of the dopaminergic, noradrenergic, and serotonergic systems. In conclusion, we have generated a novel animal model of PD that recapitulates certain pre-motor symptomology. These symptoms and causative physiology are ameliorated upon treatment with EX-4 and thus it could be used as a possible therapy for the non-motor symptoms prominent in the early stages of PD. (c) 2012 Elsevier Ltd. All rights reserved.
C1 [Rampersaud, N.; Harkavyi, A.; Giordano, G.; Lever, R.; Whitton, J.; Whitton, P. S.] UCL Sch Pharm, London WC1N 1AX, England.
RP Rampersaud, N (reprint author), UCL Sch Pharm, 29-39 Brunswick Sq, London WC1N 1AX, England.
EM n.rampersaud@ucl.ac.uk
FU Michael J. Fox. Foundation grant code EEXQ; Michael J. Fox Foundation
FX The work presented in this paper has been funded by the Michael J. Fox.
   Foundation grant code EEXQ.; This study was supported by the Michael J.
   Fox Foundation. We would also like to thank Dr. Mohammed Hankir of
   Oxford University, Department of Physiology, Anatomy, and Genetics and
   Ms. Saleema Rampersaud of Hudson County Schools of Technology, for
   reviewing and revising this manuscript.
CR Albin RL, 2008, J CEREBR BLOOD F MET, V28, P441, DOI 10.1038/sj.jcbfm.9600599
   Arango V, 1996, ALCOHOL CLIN EXP RES, V20, P1141, DOI 10.1111/j.1530-0277.1996.tb01102.x
   Archer T, 2006, J NEURAL TRANSM, V113, P1119, DOI 10.1007/s00702-005-0402-5
   Bertilsson G, 2008, J NEUROSCI RES, V86, P326, DOI 10.1002/jnr.21483
   BIGGS CS, 1992, J NEUROCHEM, V59, P1702, DOI 10.1111/j.1471-4159.1992.tb11001.x
   BORSINI F, 1986, PHYSIOL BEHAV, V38, P385, DOI 10.1016/0031-9384(86)90110-1
   Botton PH, 2010, BEHAV BRAIN RES, V214, P254, DOI 10.1016/j.bbr.2010.05.034
   Bowenkamp KE, 1996, EXP BRAIN RES, V111, P1
   Braak H, 2003, NEUROBIOL AGING, V24, P197, DOI 10.1016/S0197-4580(02)00065-9
   Branchi I, 2008, J NEUROSCI RES, V86, P2050, DOI 10.1002/jnr.21642
   Burn DJ, 2002, MOVEMENT DISORD, V17, P445, DOI 10.1002/mds.10114
   Buteau J, 2004, DIABETOLOGIA, V47, P806, DOI 10.1007/s00125-004-1379-6
   CASTREN E, 1995, NEUROSCIENCE, V64, P71, DOI 10.1016/0306-4522(94)00386-J
   CHANPALAY V, 1989, J COMP NEUROL, V287, P373, DOI 10.1002/cne.902870308
   Chaudhuri KR, 2006, LANCET NEUROL, V5, P235, DOI 10.1016/S1474-4422(06)70373-8
   Chen XQ, 2008, MOL PHARMACOL, V73, P1816, DOI 10.1124/mol.107.043968
   Cohen AD, 2011, BRAIN RES, V1370, P80, DOI 10.1016/j.brainres.2010.11.006
   Da Cunha C, 2001, BEHAV BRAIN RES, V124, P9, DOI 10.1016/S0166-4328(01)00211-X
   Da Cunha C, 2007, NEUROBIOL LEARN MEM, V87, P451, DOI 10.1016/j.nlm.2006.12.004
   Dauer W, 2003, NEURON, V39, P889, DOI 10.1016/S0896-6273(03)00568-3
   Delaville C, 2011, FRONT SYST NEUROSCI, V5, DOI 10.3389/fnsys.2011.00031
   Du YS, 2001, P NATL ACAD SCI USA, V98, P14669, DOI 10.1073/pnas.251341998
   Dunkley PR, 2004, J NEUROCHEM, V91, P1025, DOI 10.1111/j.1471-4159.2004.2797.x
   Ferro MM, 2005, J NEUROSCI METH, V148, P78, DOI 10.1016/j.jneumeth.2005.04.005
   Filbin MT, 2003, NAT REV NEUROSCI, V4, P703, DOI 10.1038/nrn1195
   FINK JS, 1980, NEUROSCI LETT, V17, P61, DOI 10.1016/0304-3940(80)90062-2
   FOGUET M, 1993, EMBO J, V12, P903, DOI 10.1002/j.1460-2075.1993.tb05731.x
   Fornai F, 2005, P NATL ACAD SCI USA, V102, P3413, DOI 10.1073/pnas.0409713102
   FORNAI F, 1995, EUR J PHARMACOL, V283, P99, DOI 10.1016/0014-2999(95)00313-A
   Frisina PG, 2009, PARKINSONISM RELAT D, V15, P144, DOI 10.1016/j.parkreldis.2008.04.038
   Gueorguiev VD, 2006, J BIOL CHEM, V281, P10188, DOI 10.1074/jbc.M513806200
   Guttman M, 2007, EUR J NEUROL, V14, P523, DOI 10.1111/j.1468-1331.2007.01727.x
   Harkavyi A, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-19
   Harkavyi A, 2010, BRIT J PHARMACOL, V159, P495, DOI 10.1111/j.1476-5381.2009.00486.x
   HIRSCH E, 1988, NATURE, V334, P345, DOI 10.1038/334345a0
   Iravani MM, 2005, EUR J NEUROSCI, V22, P317, DOI 10.1111/j.1460-9568.2005.04220.x
   Isacson R, 2011, EUR J PHARMACOL, V650, P249, DOI 10.1016/j.ejphar.2010.10.008
   Ishihara L, 2006, ACTA NEUROL SCAND, V113, P211, DOI 10.1111/j.1600-0404.2006.00579.x
   Jardanhazi-Kurutz D, 2010, NEUROCHEM INT, V57, P375, DOI 10.1016/j.neuint.2010.02.001
   Jellinger KA, 1999, J NEURAL TRANSM-SUPP, P1
   Jenkins TA, 2010, BEHAV BRAIN RES, V208, P479, DOI 10.1016/j.bbr.2009.12.030
   Kerenyi L, 2003, ARCH NEUROL-CHICAGO, V60, P1223, DOI 10.1001/archneur.60.9.1223
   Kim SY, 2010, BRAIN RES, V1348, P105, DOI 10.1016/j.brainres.2010.05.097
   Kim S, 2009, J ENDOCRINOL, V202, P431, DOI 10.1677/JOE-09-0132
   Kish SJ, 2003, ADV NEUROL, V91, P39
   Klimek V, 1997, J NEUROSCI, V17, P8451
   Kornum BR, 2006, NEUROSCI LETT, V392, P129, DOI 10.1016/j.neulet.2005.09.013
   LATEGAN AJ, 1990, BRAIN RES, V523, P134, DOI 10.1016/0006-8993(90)91646-X
   LeDoux JE, 2000, ANNU REV NEUROSCI, V23, P155, DOI 10.1146/annurev.neuro.23.1.155
   Lee S, 2010, MOL BRAIN, V3, DOI 10.1186/1756-6606-3-8
   Leentjens AFG, 2003, INT J GERIATR PSYCH, V18, P552, DOI 10.1002/gps.865
   LEES AJ, 1983, BRAIN, V106, P257, DOI 10.1093/brain/106.2.257
   LEONARD BE, 1976, PSYCHOPHARMACOLOGIA, V46, P11, DOI 10.1007/BF00421543
   Li YZ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032008
   Li YZ, 2010, J NEUROCHEM, V113, P1621, DOI 10.1111/j.1471-4159.2010.06731.x
   Li YZ, 2003, J BIOL CHEM, V278, P471, DOI 10.1074/jbc.M209423200
   Lieben CKJ, 2004, BEHAV BRAIN RES, V151, P53, DOI 10.1016/j.bbr.2003.08.002
   Lieberman A, 2006, ACTA NEUROL SCAND, V113, P1, DOI 10.1111/j.1600-0404.2006.00536.x
   MARIE RM, 1995, J NEURAL TRANSM-PARK, V9, P55, DOI 10.1007/BF02252963
   Martin B, 2009, DIABETES, V58, P318, DOI 10.2337/db08-0799
   MAVRIDIS M, 1991, NEUROSCIENCE, V41, P507, DOI 10.1016/0306-4522(91)90345-O
   Mayberg H S, 1995, Adv Neurol, V65, P49
   MAYBERG HS, 1994, J NEUROPSYCH CLIN N, V6, P428
   MAYEUX R, 1990, J CLIN PSYCHIAT, V51, P20
   MAYEUX R, 1990, J CLIN PSYCHIAT S, V51, P24
   Merchenthaler I, 1999, J COMP NEUROL, V403, P261, DOI 10.1002/(SICI)1096-9861(19990111)403:2<261::AID-CNE8>3.0.CO;2-5
   Na SJ, 2010, NEUROCHEM RES, V35, P761, DOI 10.1007/s11064-010-0133-3
   Nilsson FM, 2001, ACTA PSYCHIAT SCAND, V104, P380, DOI 10.1034/j.1600-0447.2001.00372.x
   NISHIMURA H, 1988, PHYSIOL BEHAV, V42, P93, DOI 10.1016/0031-9384(88)90266-1
   O'Meara G, 2000, P NATL ACAD SCI USA, V97, P11569, DOI 10.1073/pnas.210254597
   Olanow CW, 1999, ANNU REV NEUROSCI, V22, P123, DOI 10.1146/annurev.neuro.22.1.123
   Owen AM, 2004, NEUROSCIENTIST, V10, P525, DOI 10.1177/1073858404266776
   Packard MG, 2002, ANNU REV NEUROSCI, V25, P563, DOI 10.1146/annurev.neuro.25.112701.142937
   Park A, 2009, J NEUROL, V256, pS293, DOI 10.1007/s00415-009-5240-1
   Perry T, 2002, J PHARMACOL EXP THER, V300, P958, DOI 10.1124/jpet.300.3.958
   Perry T, 2002, J PHARMACOL EXP THER, V302, P881, DOI 10.1124/jpet.102.037481
   Perry TA, 2004, CURR DRUG TARGETS, V5, P565, DOI 10.2174/1389450043345245
   Politis M, 2011, THESCIENTIFICWORLDJO, V11, P1726, DOI 10.1100/2011/172893
   Politis M, 2010, NEUROBIOL DIS, V40, P216, DOI 10.1016/j.nbd.2010.05.028
   PORSOLT RD, 1978, EUR J PHARMACOL, V47, P379, DOI 10.1016/0014-2999(78)90118-8
   Reksidler AB, 2007, EUR J PHARMACOL, V560, P163, DOI 10.1016/j.ejphar.2006.12.032
   Remy P, 2005, BRAIN, V128, P1314, DOI 10.1093/brain/awh445
   Ressler KJ, 1999, BIOL PSYCHIAT, V46, P1219, DOI 10.1016/S0006-3223(99)00127-4
   Rommelfanger KS, 2007, BIOCHEM PHARMACOL, V74, P177, DOI 10.1016/j.bcp.2007.01.036
   Roozendaal B, 2008, NEUROBIOL LEARN MEM, V90, P576, DOI 10.1016/j.nlm.2008.06.010
   ROSS SB, 1976, BRIT J PHARMACOL, V58, P521, DOI 10.1111/j.1476-5381.1976.tb08619.x
   SAINTCYR JA, 1988, BRAIN, V111, P941, DOI 10.1093/brain/111.4.941
   Santiago RM, 2010, PROG NEURO-PSYCHOPH, V34, P1104, DOI 10.1016/j.pnpbp.2010.06.004
   SAUER H, 1994, NEUROSCIENCE, V59, P401, DOI 10.1016/0306-4522(94)90605-X
   Schmidt HD, 2010, NEUROPSYCHOPHARMACOL, V35, P2378, DOI 10.1038/npp.2010.114
   Schuurman AG, 2002, NEUROLOGY, V58, P1501, DOI 10.1212/WNL.58.10.1501
   Shimohama S, 2003, TRENDS MOL MED, V9, P360, DOI 10.1016/S1471-4914(03)00117-5
   Spiegel J, 2006, J NEUROL, V253, P2, DOI 10.1007/s00415-006-4002-6
   Srinivasan J, 2003, EUR J NEUROSCI, V17, P2586, DOI 10.1046/j.1460-9568.2003.02684.x
   Sy HN, 2010, PHARMACOL BIOCHEM BE, V95, P158, DOI 10.1016/j.pbb.2009.12.020
   Tadaiesky MT, 2008, NEUROSCIENCE, V156, P830, DOI 10.1016/j.neuroscience.2008.08.035
   Taylor TN, 2009, J NEUROSCI, V29, P8103, DOI 10.1523/JNEUROSCI.1495-09.2009
   Tolosa E, 2007, PARKINSONISM RELAT D, V13, pS2, DOI 10.1016/j.parkreldis.2007.06.007
   Torriero S, 2007, NEUROPSYCHOLOGIA, V45, P1208, DOI 10.1016/j.neuropsychologia.2006.10.007
   Wang Y, 2010, BRAIN RES, V1310, P189, DOI 10.1016/j.brainres.2009.10.070
   Weintraub D, 2008, AM J MANAG CARE, V14, pS59
   Winter C, 2007, BEHAV BRAIN RES, V184, P133, DOI 10.1016/j.bbr.2007.07.002
   Wong FK, 2010, BEHAV PHARMACOL, V21, P278, DOI 10.1097/FBP.0b013e32833aec02
   Yamamoto H, 2003, J NEUROSCI, V23, P2939
   Ziemssen T, 2007, PARKINSONISM RELAT D, V13, P323, DOI 10.1016/j.parkreldis.2006.12.014
NR 105
TC 17
Z9 17
U1 2
U2 23
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0143-4179
J9 NEUROPEPTIDES
JI Neuropeptides
PD OCT
PY 2012
VL 46
IS 5
BP 183
EP 193
DI 10.1016/j.npep.2012.07.004
PG 11
WC Endocrinology & Metabolism; Neurosciences
SC Endocrinology & Metabolism; Neurosciences & Neurology
GA 012PL
UT WOS:000309248900001
PM 22921965
DA 2018-12-27
ER

PT J
AU Marik, PE
AF Marik, P. E.
TI RETRACTED: The malignant obesity hypoventilation syndrome (MOHS)
   (Retracted article. See vol. 15, pg. 358, 2014)
SO OBESITY REVIEWS
LA English
DT Review; Retracted Publication
DE Diastolic heart failure; metabolic syndrome; obesity; obesity
   hypoventilation syndrome
ID OBSTRUCTIVE SLEEP-APNEA; BODY-MASS INDEX; VENTRICULAR DIASTOLIC
   FUNCTION; PRESERVED EJECTION FRACTION; SERUM 25-HYDROXYVITAMIN D;
   VITAMIN-D DEFICIENCY; BARIATRIC SURGERY; WEIGHT-LOSS; MORBID-OBESITY;
   HEART-FAILURE
AB We have coined the term malignant obesity hypoventilation syndrome (MOHS) to describe a severe multisystem disease due to the systemic effects of obesity. Patients with this syndrome have severe obesity-related hypoventilation together with systemic hypertension, diabetes and the metabolic syndrome, left ventricular hypertrophy with diastolic dysfunction, pulmonary hypertension and hepatic dysfunction. This syndrome is largely unrecognized as physicians do not make the association between the patients' multiple medical problems and obesity. Because of the delayed diagnosis and progressive morbidities of this condition, all patients with a body mass index of more than 40 kg m-2 should be screened for MOHS. The management of patients with MOHS includes short-term measures to improve the patients' medical condition and long-term measures to achieve enduring weight loss. Bariatric surgery reverses or improves the multiple metabolic and organ dysfunctions associated with MOHS and should be strongly considered in these patients.
C1 Eastern Virginia Med Sch, Dept Med, Div Pulm & Crit Care Med, Norfolk, VA 23507 USA.
RP Marik, PE (reprint author), Eastern Virginia Med Sch, Dept Med, Div Pulm & Crit Care Med, 825 Fairfax Ave,Suite 410, Norfolk, VA 23507 USA.
EM marikpe@evms.edu
CR ALEXANDER JK, 1985, PROG CARDIOVASC DIS, V27, P325, DOI 10.1016/S0033-0620(85)80002-5
   Algahim MF, 2010, AM J MED, V123, P549, DOI 10.1016/j.amjmed.2009.11.020
   Andersen A, 2008, EUR J HEART FAIL, V10, P1158, DOI 10.1016/j.ejheart.2008.09.016
   [Anonymous], 1992, AM J CLIN NUTR, V55, P615
   Baz-Hecht M, 2010, CURR OPIN ENDOCRINOL, V17, P113, DOI 10.1097/MED.0b013e3283372859
   Berg G, 2001, CHEST, V120, P377, DOI 10.1378/chest.120.2.377
   BLOCK AJ, 1980, AM J MED, V69, P75, DOI 10.1016/0002-9343(80)90502-1
   BURWELL CS, 1959, AM J MED, V21, P811
   Chahal H, 2012, CHEST, V141, P388, DOI 10.1378/chest.11-0172
   Chami HA, 2008, CIRCULATION, V117, P2599, DOI 10.1161/CIRCULATIONAHA.107.717892
   Cheng S, 2010, DIABETES, V59, P242, DOI 10.2337/db09-1011
   de Llano LAP, 2005, CHEST, V128, P587, DOI 10.1378/chest.128.2.587
   Dixon JB, 2001, GASTROENTEROLOGY, V121, P91, DOI 10.1053/gast.2001.25540
   Ebinc H, 2008, ENDOCR J, V55, P523, DOI 10.1507/endocrj.K07E-098
   Finucane MM, 2011, LANCET, V377, P557, DOI 10.1016/S0140-6736(10)62037-5
   Fish E, 2010, J SURG RES, V164, P198, DOI 10.1016/j.jss.2010.06.029
   Flegal KM, 2012, JAMA-J AM MED ASSOC, V307, P491, DOI 10.1001/jama.2012.39
   Freedman DS, 2002, JAMA-J AM MED ASSOC, V288, P1758, DOI 10.1001/jama.288.14.1758
   Garza CA, 2010, AM J CARDIOL, V105, P550, DOI 10.1016/j.amjcard.2009.09.057
   Gilbert-Diamond D, 2010, AM J CLIN NUTR, V92, P1446, DOI 10.3945/ajcn.2010.29746
   Greenburg DL, 2009, AM J MED, V122, P535, DOI 10.1016/j.amjmed.2008.10.037
   Guazzi M, 2011, CIRCULATION, V124, P164, DOI 10.1161/CIRCULATIONAHA.110.983866
   Guazzi M, 2011, CIRC-HEART FAIL, V4, P8, DOI 10.1161/CIRCHEARTFAILURE.110.944694
   Hirani A, 2008, CRIT CARE SHOCK, V110, P132
   Hunley Tracy E, 2010, Curr Opin Nephrol Hypertens, V19, P227, DOI 10.1097/MNH.0b013e3283374c09
   Jhaveri RR, 2009, SURG OBES RELAT DIS, V5, P648, DOI 10.1016/j.soard.2009.01.011
   Jorde R, 2010, EUR J NUTR, V49, P401, DOI 10.1007/s00394-010-0098-7
   Kapsimalis F, 2002, SLEEP, V25, P412
   KASPER EK, 1992, AM J CARDIOL, V70, P921, DOI 10.1016/0002-9149(92)90739-L
   Kaw R, 2009, CHEST, V136, P787, DOI 10.1378/chest.09-0615
   Kessler R, 2001, CHEST, V120, P369, DOI 10.1378/chest.120.2.369
   Lacalzada CC, 2008, EUR RESPIR J, V32, P817, DOI 10.1183/09031936.00059508
   Lagunova Z, 2010, MOL NUTR FOOD RES, V54, P1127, DOI 10.1002/mnfr.200900512
   Leung CC, 2010, AM J CARDIOL, V106, P284, DOI 10.1016/j.amjcard.2010.02.039
   Libhaber CD, 2009, AM J CARDIOL, V104, P1527, DOI 10.1016/j.amjcard.2009.07.020
   Lumachi F, 2010, IN VIVO, V24, P329
   Malavazos AE, 2008, HYPERTENSION, V51, pE8, DOI 10.1161/HYPERTENSIONAHA.107.105346
   Marik PE, 2012, J INTENSIVE CARE MED, DOI [10.1177/0885066612444257, DOI 10.1177/0885066612444257]
   Masa JF, 2001, CHEST, V119, P1102, DOI 10.1378/chest.119.4.1102
   Masaidi M, 2009, BLOOD PRESSURE, V18, P23, DOI 10.1080/08037050902850226
   McGavock JM, 2006, ANN INTERN MED, V144, P517, DOI 10.7326/0003-4819-144-7-200604040-00011
   McTigue K, 2006, JAMA-J AM MED ASSOC, V296, P79, DOI 10.1001/jama.296.1.79
   Mokhlesi B, 2007, SLEEP BREATH, V11, P117, DOI 10.1007/s11325-006-0092-8
   Nagendran J, 2007, CIRCULATION, V116, P238, DOI 10.1161/CIRCULATIONAHA.106.655266
   Navaneethan SD, 2009, SURG OBES RELAT DIS, V5, P662, DOI 10.1016/j.soard.2009.01.006
   Nguyen NT, 2008, J AM COLL SURGEONS, V207, P928, DOI 10.1016/j.jamcollsurg.2008.08.022
   Nikooyeh B, 2011, AM J CLIN NUTR, V93, P764, DOI 10.3945/ajcn.110.007336
   Nowbar S, 2004, AM J MED, V116, P1, DOI 10.1016/j.amjmed.2003.08.022
   Osei K, 2010, J CLIN ENDOCR METAB, V95, P4220, DOI 10.1210/jc.2010-1550
   Othman M, 2009, NEPHRON CLIN PRACT, V113, pC16, DOI 10.1159/000228071
   Owan Theophilus, 2007, Curr Heart Fail Rep, V4, P221, DOI 10.1007/s11897-007-0016-3
   Piper AJ, 2011, AM J RESP CRIT CARE, V183, P292, DOI 10.1164/rccm.201008-1280CI
   Priou P, 2010, CHEST, V138, P84, DOI 10.1378/chest.09-2472
   Resta Onofrio, 2002, Sleep Breath, V6, P11, DOI 10.1055/s-2002-23151
   Rodrigues SL, 2010, HYPERTENS RES, V33, P83, DOI 10.1038/hr.2009.188
   Rubino F, 2010, ANN SURG, V251, P399, DOI 10.1097/SLA.0b013e3181be34e7
   Russo C, 2011, J AM COLL CARDIOL, V57, P1368, DOI 10.1016/j.jacc.2010.10.042
   Schauer PR, 2012, NEW ENGL J MED, V366, P1567, DOI 10.1056/NEJMoa1200225
   Serra A, 2008, KIDNEY INT, V73, P947, DOI 10.1038/sj.ki.5002796
   SHARP JT, 1964, J CLIN INVEST, V43, P728, DOI 10.1172/JCI104957
   Sjostrom L, 2007, NEW ENGL J MED, V357, P741, DOI 10.1056/NEJMoa066254
   Standing Committee on the Scientific Evaluation of Dietary Reference Intakes Food and Nutrition Board Insitute of Medicine, 2010, DIET REF INT CAL VIT
   SUGERMAN HJ, 1992, AM J CLIN NUTR, V55, P597
   SUGERMAN HJ, 1988, ANN SURG, V207, P604, DOI 10.1097/00000658-198805000-00015
   Talmor D, 2008, NEW ENGL J MED, V359, P2095, DOI 10.1056/NEJMoa0708638
   Trakada GP, 2010, SLEEP BREATH, V14, P381, DOI 10.1007/s11325-010-0360-5
   Tzotzas T, 2010, J CLIN ENDOCR METAB, V95, P4251, DOI 10.1210/jc.2010-0757
   Vgontzas Alexandros N., 2008, Archives of Physiology and Biochemistry, V114, P211, DOI 10.1080/13813450802364627 
   Wang YC, 2011, LANCET, V378, P815, DOI 10.1016/S0140-6736(11)60814-3
   WEISINGE.JR, 1974, ANN INTERN MED, V81, P440, DOI 10.7326/0003-4819-81-4-440
NR 70
TC 13
Z9 13
U1 3
U2 11
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1467-7881
EI 1467-789X
J9 OBES REV
JI Obes. Rev.
PD OCT
PY 2012
VL 13
IS 10
BP 902
EP 909
DI 10.1111/j.1467-789X.2012.01014.x
PG 8
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 011TH
UT WOS:000309187500006
PM 22708580
DA 2018-12-27
ER

PT J
AU Lagha, A
   Chraiet, N
   Ayadi, M
   Krimi, S
   Allani, B
   Rifi, H
   Raies, H
   Mezlini, A
AF Lagha, Aymen
   Chraiet, Nesrine
   Ayadi, Mouna
   Krimi, Sarra
   Allani, Bassem
   Rifi, Hela
   Raies, Henda
   Mezlini, Amel
TI RETRACTED: Systemic therapy in the management of metastatic or advanced
   salivary gland cancers (Retracted article. See vol. 78, pg. 229, 2018)
SO ORAL ONCOLOGY
LA English
DT Review; Retracted Publication
DE Review; Salivary glands; Adenocystic; Adenocarcinoma; Mucoepidermoid;
   Treatment; Chemotherapy; Targeted therapy; Hormone therapy
ID ADENOID-CYSTIC-CARCINOMA; LOW-GRADE ADENOCARCINOMA; GROWTH-FACTOR
   RECEPTOR; PHASE-II TRIAL; CISPLATIN COMBINATION CHEMOTHERAPY; C-KIT
   EXPRESSION; IMATINIB MESYLATE; MUCOEPIDERMOID CARCINOMA;
   PROGESTERONE-RECEPTORS; C-ERBB-2 ONCOPROTEIN
AB Salivary gland cancers are very rare tumors. They are characterized by a histologic heterogeneity and a poor outcome. According to this rarity, few prospective data are available to date. No standard recommendations could be held for the use of systemic therapy in these tumors. Several case reports and small studies have investigated the contribution of different agents of chemotherapy. With the extension of molecular biology approach in oncology several signaling pathways have been discovered in different cancers including salivary gland cancers; thus a number of targeted therapies have been investigated. This paper reviewed exhaustively the studies investigating the role of systemic therapies (chemotherapy, targeted therapy, hormone therapy) in salivary gland cancers. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Lagha, Aymen; Chraiet, Nesrine; Ayadi, Mouna; Krimi, Sarra; Allani, Bassem; Rifi, Hela; Raies, Henda; Mezlini, Amel] Salah Azaiez Inst, Dept Med Oncol, Tunis, Tunisia.
RP Lagha, A (reprint author), Salah Azaiez Inst, Dept Med Oncol, Blvd 9 Avril, Tunis, Tunisia.
EM aymen.lagha@hotmail.com
CR Agulnik M, 2007, J CLIN ONCOL, V25, P3978, DOI 10.1200/JCO.2007.11.8612
   AIROLDI M, 1989, TUMORI, V75, P252
   Airoldi M, 2000, ANTICANCER RES, V20, P3781
   Airoldi M, 2001, CANCER, V91, P541, DOI 10.1002/1097-0142(20010201)91:3<541::AID-CNCR1032>3.0.CO;2-Y
   ALBERTS DS, 1981, CANCER, V47, P645, DOI 10.1002/1097-0142(19810215)47:4<645::AID-CNCR2820470404>3.0.CO;2-A
   Alcedo JC, 2004, HEAD NECK-J SCI SPEC, V26, P829, DOI 10.1002/hed.20094
   Argiris A, 2011, CANCER-AM CANCER SOC, V117, P3374, DOI 10.1002/cncr.25852
   BELANI CP, 1988, MED PEDIATR ONCOL, V16, P197, DOI 10.1002/mpo.2950160309
   Belli F, 1999, Clin Ter, V150, P77
   Cho KJ, 1999, HEAD NECK-J SCI SPEC, V21, P414
   CREAGAN ET, 1988, CANCER, V62, P2313, DOI 10.1002/1097-0142(19881201)62:11<2313::AID-CNCR2820621110>3.0.CO;2-4
   DEHAAN LD, 1992, HEAD NECK-J SCI SPEC, V14, P273
   DIMERY IW, 1990, J CLIN ONCOL, V8, P1056, DOI 10.1200/JCO.1990.8.6.1056
   DIMERY IW, 1987, ARCH OTOLARYNGOL, V113, P1082
   Dodd RL, 2006, ORAL ONCOL, V42, P759, DOI 10.1016/j.oraloncology.2006.01.001
   Dori S, 2000, ORAL ONCOL, V36, P450, DOI 10.1016/S1368-8375(00)00029-4
   DOri S, 2002, J ORAL PATHOL MED, V31, P463, DOI 10.1034/j.1600-0714.2002.00017.x
   DREYFUSS AI, 1987, CANCER, V60, P2869, DOI 10.1002/1097-0142(19871215)60:12<2869::AID-CNCR2820601203>3.0.CO;2-Y
   Edwards PC, 2003, ORAL SURG ORAL MED O, V95, P586, DOI 10.1067/moe.2003.31
   EISENBERGER MA, 1985, CANCER TREAT REP, V69, P319
   Elkin AD, 2008, J CANCER RES CLIN, V134, P1151, DOI 10.1007/s00432-008-0377-3
   Eveson JW, 2005, WHO CLASSIFICATION T, P209
   Faivre S, 2005, J CLIN ONCOL, V23, P6271, DOI 10.1200/JCO.2005.01.6055
   Fan CY, 2001, ARCH OTOLARYNGOL, V127, P1075, DOI 10.1001/archotol.127.9.1075
   GAFFNEY EV, 1995, ENDOCR RES, V21, P635, DOI 10.3109/07435809509030479
   Gedlicka C, 2002, ANTI-CANCER DRUG, V13, P491, DOI 10.1097/00001813-200206000-00007
   GIANNONI C, 1995, OTOLARYNG HEAD NECK, V112, P391, DOI 10.1016/S0194-5998(95)70272-5
   Gibbons MD, 2001, LARYNGOSCOPE, V111, P1373, DOI 10.1097/00005537-200108000-00011
   Gilbert J, 2006, HEAD NECK-J SCI SPEC, V28, P197, DOI 10.1002/hed.20327
   Glisson B, 2004, CLIN CANCER RES, V10, P944, DOI 10.1158/1078-0432.CCR-03-0253
   Glisson B, 2005, P AM SOC CLIN ONCOL, V23
   Guigay JM, 2007, P AM SOC CLIN ONCOL, V25
   Guzzo M, 2010, CRIT REV ONCOL HEMAT, V74, P134, DOI 10.1016/j.critrevonc.2009.10.004
   Haddad R, 2003, ORAL ONCOL, V39, P724, DOI 10.1016/S1368-8375(03)00097-6
   Hill ME, 1997, ORAL ONCOL, V33, P275, DOI 10.1016/S0964-1955(97)00026-2
   Holst VA, 1999, MODERN PATHOL, V12, P956
   Hotte SJ, 2005, J CLIN ONCOL, V23, P585, DOI 10.1200/JCO.2005.06.125
   Jaehne M, 2005, CANCER, V103, P2526, DOI 10.1002/cncr.21116
   Jeannon JP, 1999, CLIN OTOLARYNGOL, V24, P52, DOI 10.1046/j.1365-2273.1999.00211.x
   Jeng YM, 2000, CANCER LETT, V154, P107, DOI 10.1016/S0304-3835(00)00387-6
   JONES AS, 1993, BRIT J CANCER, V67, P112, DOI 10.1038/bjc.1993.19
   Kaidar-Person O, 2011, MED ONCOL
   KAPLAN MJ, 1986, OTOLARYNG HEAD NECK, V95, P165, DOI 10.1177/019459988609500206
   KARJA V, 1994, ORL J OTO-RHINO-LARY, V56, P206
   KERNOHAN NM, 1991, J PATHOL, V163, P77, DOI 10.1002/path.1711630113
   Khan AJ, 2001, INT J CANCER, V96, P149, DOI 10.1002/ijc.1013
   Kusafuka K, 1991, Kokubyo Gakkai Zasshi, V58, P696
   Laurie SA, 2006, J CLIN ONCOL, V24, P2673, DOI 10.1200/JCO.2005.05.3026
   Laurie SA, 2011, LANCET ONCOL, V12, P815, DOI 10.1016/S1470-2045(10)70245-X
   Laurie SA, 2010, CANCER, V116, P362, DOI 10.1002/cncr.24745
   LICITRA L, 1991, CANCER, V68, P1874, DOI 10.1002/1097-0142(19911101)68:9<1874::AID-CNCR2820680904>3.0.CO;2-S
   Licitra L, 1996, ANN ONCOL, V7, P640
   Lin CH, 2005, HEAD NECK-J SCI SPEC, V27, P1022, DOI 10.1002/hed.20274
   Locati LD, 2009, ORAL ONCOL, V45, P574, DOI 10.1016/j.oraloncology.2008.07.010
   Locati LD, 2003, ANN ONCOL, V14, P1327, DOI 10.1093/annonc/mdg331
   MATTOX DE, 1990, INVEST NEW DRUG, V8, P105, DOI 10.1007/BF00216934
   MILLER AS, 1994, ORAL SURG ORAL MED O, V77, P36, DOI 10.1016/S0030-4220(06)80104-0
   Mino M, 2003, MODERN PATHOL, V16, P1224, DOI 10.1097/01.MP.0000096046.42833.C7
   Nabili V, 2007, HEAD NECK-J SCI SPEC, V29, P907, DOI 10.1002/hed.20614
   Nashed M, 2009, J LARYNGOL OTOL, V123, P250, DOI 10.1017/S0022215108002314
   Ochel HJ, 2005, ANTICANCER RES, V25, P3659
   Oliveira AM, 2003, MODERN PATHOL, V16, p221A
   OZONO S, 1992, CELL STRUCT FUNCT, V17, P169, DOI 10.1247/csf.17.169
   Pedani F, 2003, EJC SUPPL, V1, pS44
   Penner CR, 2002, MODERN PATHOL, V15, P687, DOI 10.1097/01.MP.0000018973.17736.F8
   Pfeffer MR, 2007, ORAL ONCOL, V43, P33, DOI 10.1016/j.oraloncology.2005.12.026
   Pires FR, 2004, PATHOL ONCOL RES, V10, P166, DOI 10.1007/BF03033746
   POSNER MR, 1982, CANCER, V50, P2261, DOI 10.1002/1097-0142(19821201)50:11<2261::AID-CNCR2820501105>3.0.CO;2-E
   Prat A, 2008, HEAD NECK-J SCI SPEC, V30, P680, DOI 10.1002/hed.20714
   PRESS MF, 1994, CANCER RES, V54, P5675
   Raguse J, 2004, ORAL ONCOL, V40, P5
   Ross PJ, 2009, CLIN ONCOL-UK, V21, P311, DOI 10.1016/j.clon.2008.12.009
   Ruzich JC, 2002, HEAD NECK-J SCI SPEC, V24, P406, DOI 10.1002/hed.10034
   SCHRAMM VL, 1981, ARCH OTOLARYNGOL, V107, P739
   Shadaba A, 1997, J LARYNGOL OTOL, V111, P1186
   SHICK PC, 1995, ORAL SURG ORAL MED O, V80, P440, DOI 10.1016/S1079-2104(05)80338-5
   Shintani S, 1995, ANTICANCER RES, V15, P2623
   SHRESTHA P, 1992, J ORAL PATHOL MED, V21, P477, DOI 10.1111/j.1600-0714.1992.tb00978.x
   Slevin NJ, 2005, EJC SUPPL, V3, P292
   Spiers, 1996, Cancer Control, V3, P336
   SUEN JY, 1982, LARYNGOSCOPE, V92, P235
   SUGANO S, 1992, LARYNGOSCOPE, V102, P923, DOI 10.1288/00005537-199208000-00013
   Sung MW, 2003, ARCH OTOLARYNGOL, V129, P1193, DOI 10.1001/archotol.129.11.1193
   TANNOCK IF, 1980, CANCER, V46, P452, DOI 10.1002/1097-0142(19800801)46:3<452::AID-CNCR2820460305>3.0.CO;2-Z
   Terhaard CHJ, 2004, HEAD NECK-J SCI SPEC, V26, P681, DOI 10.1002/hed.10400
   TRIOZZI PL, 1987, CANCER, V59, P887, DOI 10.1002/1097-0142(19870301)59:5<887::AID-CNCR2820590505>3.0.CO;2-8
   TSUKUDA M, 1993, J CANCER RES CLIN, V119, P756, DOI 10.1007/BF01195348
   van Herpen CML, 2008, EUR J CANCER, V44, P2542, DOI 10.1016/j.ejca.2008.08.014
   VANDERHULST RWM, 1994, LANCET, V344, P817, DOI 10.1016/S0140-6736(94)92372-8
   VENOOK AP, 1987, J CLIN ONCOL, V5, P951, DOI 10.1200/JCO.1987.5.6.951
   Vered M, 2002, HEAD NECK-J SCI SPEC, V24, P632, DOI 10.1002/hed.10104
   VERMORKEN JB, 1993, ANN ONCOL, V4, P785, DOI 10.1093/oxfordjournals.annonc.a058665
   Verweij J, 1996, ANN ONCOL, V7, P867
   Weed DT, 2004, HEAD NECK-J SCI SPEC, V26, P353, DOI 10.1002/hed.10387
   Zhang JL, 2009, CELL PROLIFERAT, V42, P150, DOI 10.1111/j.1365-2184.2009.00588.x
   Zhang JL, 2005, CLIN CANCER RES, V11, P7334, DOI 10.1158/1078-0432.CCR-05-0241
NR 96
TC 21
Z9 21
U1 0
U2 6
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1368-8375
EI 1879-0593
J9 ORAL ONCOL
JI Oral Oncol.
PD OCT
PY 2012
VL 48
IS 10
BP 948
EP 957
DI 10.1016/j.oraloncology.2012.05.004
PG 10
WC Oncology; Dentistry, Oral Surgery & Medicine
SC Oncology; Dentistry, Oral Surgery & Medicine
GA 010SO
UT WOS:000309114600010
PM 22698431
DA 2018-12-27
ER

PT J
AU Wu, CY
AF Wu, Chong-Yih
TI RETRACTED: On right congruences of semigroups having no proper essential
   right congruences (Retracted article. See vol. 87, pg. 495, 2013)
SO SEMIGROUP FORUM
LA English
DT Article; Retracted Publication
DE Essential right congruence; C-Subset; Annihilator
AB A right congruence rho in a semigroup S is essential if for any right congruence sigma we have rho a sigma=iota (the identity relation) implies sigma=iota. Clearly, the universal relation, nu, is an essential right congruence. We say rho is proper if rho not equal nu. In this paper we get a necessary and sufficient condition for a semigroup with an identity element 1 and having no proper essential right congruences to have a distributive lattice of right congruences.
C1 Natl Pingtung Inst Commerce, Ctr Gen Educ, Pingtung, Taiwan.
RP Wu, CY (reprint author), Natl Pingtung Inst Commerce, Ctr Gen Educ, Pingtung, Taiwan.
EM cwu@npic.edu.tw
CR Clifford A. H, 1961, ALGEBRAIC THEORY SEM, VI
   DEAN RA, 1964, PAC J MATH, V14, P1187, DOI 10.2140/pjm.1964.14.1187
   OEHMKE RH, 1991, ACTA MATH HUNG, V57, P73, DOI 10.1007/BF01903806
   Ore O., 1938, DUKE MATH J, V4, P247
   Szasz G, 1963, INTRO LATTICE THEORY
   Wu CY, 1998, SEMIGROUP FORUM, V57, P127, DOI 10.1007/PL00005961
NR 6
TC 1
Z9 1
U1 3
U2 9
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0037-1912
EI 1432-2137
J9 SEMIGROUP FORUM
JI Semigr. Forum
PD OCT
PY 2012
VL 85
IS 2
BP 369
EP 380
DI 10.1007/s00233-012-9423-1
PG 12
WC Mathematics
SC Mathematics
GA 004ST
UT WOS:000308702100012
DA 2018-12-27
ER

PT J
AU Li, B
   Liao, XL
   Zheng, L
   Zhu, XD
   Wang, Z
   Fan, HS
   Zhang, XD
AF Li, Bo
   Liao, Xiaoling
   Zheng, Li
   Zhu, Xiangdong
   Wang, Zhe
   Fan, Hongsong
   Zhang, Xingdong
TI RETRACTED: Effect of nanostructure on osteoinduction of porous biphasic
   calcium phosphate ceramics (Retracted article. See vol. 9, pg. 7070,
   2013)
SO ACTA BIOMATERIALIA
LA English
DT Article; Retracted Publication
DE Nanotopography; Bone tissue engineering; Calcium phosphate; Protein
   adsorption; Gene expression
ID HYDROXYAPATITE NANOCRYSTALS; CELLULAR BIOCOMPATIBILITY; CARBONATED
   HYDROXYAPATITE; PROTEIN ADSORPTION; BONE SUBSTITUTE; 2.45 GHZ; 2 KINDS;
   ALUMINA; MICROENVIRONMENT; BIOMATERIALS
AB In order to evaluate the effect of the nanostructure of calcium phosphate ceramics on osteoinductive potential, porous biphasic calcium phosphate (BCP) ceramics with a nano- or submicron structure were prepared via microwave sintering and compared to conventional BCP ceramics. The selective protein adsorption of bovine serum albumin and lysozyme (LSZ) and the osteogenic differentiation of human mesenchymal stem cells in vitro was investigated. Porous BCP nanoceramics showed higher ability to adsorb proteins, especially low molecular weight protein of LSZ, than conventional BCP ceramics, and the BCP nanoceramics promoted bone sialoprotein expression more than conventional BCP did. Further in vivo study to investigate ectopic bone formation and bone repair efficiency proved the highly osteoinductive potential of nanostructured BCP ceramics. The results suggest that nanostructured BCP ceramics have the potential to become a new generation of bioceramics for bone tissue engineering grafts. (C) 2012 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.
C1 [Li, Bo; Liao, Xiaoling] Chongqing Univ Sci & Technol, Inst Biomat & Living Cell Imaging Technol, Sch Met & Mat Engn, Chongqing 401331, Peoples R China.
   [Li, Bo; Zheng, Li; Zhu, Xiangdong; Wang, Zhe; Fan, Hongsong; Zhang, Xingdong] Sichuan Univ, Natl Engn Res Ctr Biomat, Chengdu 610064, Peoples R China.
RP Li, B (reprint author), Chongqing Univ Sci & Technol, Inst Biomat & Living Cell Imaging Technol, Sch Met & Mat Engn, Chongqing 401331, Peoples R China.
EM Leewave@126.com; zhangxd@scu.edu.cn
FU National Basic Research Program of China [G2011CB606201]; National
   Natural Science Foundation of China [81101154]; Natural Science
   Foundation Project of CQ CSTC [2010BB5294]; Natural Science Key
   Foundation Project of CQ in China [CSTC2012JJB0097]; Research Foundation
   of Chongqing University of Science Technology [CK2010B27]
FX This work was financially supported by National Basic Research Program
   of China (Contract No. G2011CB606201), National Natural Science
   Foundation of China (Contract Grant No. 81101154). Natural Science
   Foundation Project of CQ CSTC (Contract No. 2010BB5294), Natural Science
   Key Foundation Project of CQ in China (CSTC2012JJB0097), and Research
   Foundation of Chongqing University of Science & Technology (Contract No.
   CK2010B27). We thank Mrs. Hui Wang for assistance with the SEM analysis.
CR Barradas AMC, 2011, EUR CELLS MATER, V21, P407, DOI 10.22203/eCM.v021a31
   Bhat BM, 2008, J CELL BIOCHEM, V103, P1912, DOI 10.1002/jcb.21581
   Brosnan KH, 2003, J AM CERAM SOC, V86, P1307, DOI 10.1111/j.1151-2916.2003.tb03467.x
   Capuccini C, 2009, J BIOMED MATER RES A, V89A, P594, DOI 10.1002/jbm.a.31975
   Christenson EM, 2007, J ORTHOP RES, V25, P11, DOI 10.1002/jor.20305
   Cui FZ, 2007, MAT SCI ENG R, V57, P1, DOI 10.1016/j.mser.2007.04.001
   DEGROOT K, 1980, BIOMATERIALS, V1, P47, DOI 10.1016/0142-9612(80)90059-9
   DUCHEYNE P, 1981, J BIOMED MATER RES, V15, P441, DOI 10.1002/jbm.820150315
   Fratzl P, 2007, PROG MATER SCI, V52, P1263, DOI 10.1016/j.pmatsci.2007.06.001
   Fujii E, 2006, ACTA BIOMATER, V2, P69, DOI 10.1016/j.actbio.2005.09.002
   Guo XY, 2007, J BIOMED MATER RES A, V82A, P1022, DOI 10.1002/jbm.a.31200
   Habibovic P, 2005, BIOMATERIALS, V26, P3565, DOI 10.1016/j.biomaterials.2004.09.056
   Habibovic P, 2008, BIOMATERIALS, V29, P944, DOI 10.1016/j.biomaterials.2007.10.023
   Hench LL, 1998, J AM CERAM SOC, V81, P1705
   JARCHO M, 1981, CLIN ORTHOP RELAT R, P259
   Kang YQ, 2011, BIOMATERIALS, V32, P6119, DOI 10.1016/j.biomaterials.2011.05.015
   Kruyt MC, 2004, J ORTHOPAED RES, V22, P544, DOI 10.1016/j.orthres.2003.10.010
   Kruyt MC, 2006, BIOMATERIALS, V27, P5099, DOI 10.1016/j.biomaterials.2006.05.048
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Lafon JP, 2008, J EUR CERAM SOC, V28, P139, DOI 10.1016/j.jeurceramsoc.2007.06.009
   Landi E, 2003, J EUR CERAM SOC, V23, P2931, DOI 10.1016/S0955-2219(03)00304-2
   Li B, 2009, ACTA BIOMATER, V5, P134, DOI 10.1016/j.actbio.2008.07.035
   Liang G, 2005, BIOMATERIALS, V26, P4265, DOI 10.1016/j.biomaterials.2004.10.035
   Liu H, 2007, BIOMATERIALS, V28, P354, DOI 10.1016/j.biomaterials.2006.08.049
   Meijer GJ, 2008, BIOMATERIALS, V29, P3053, DOI 10.1016/j.biomaterials.2008.03.012
   Mendonca G, 2008, BIOMATERIALS, V29, P3822, DOI 10.1016/j.biomaterials.2008.05.012
   Mizuno M, 2004, J EUR CERAM SOC, V24, P387, DOI 10.1016/S0955-2219(03)00217-6
   Okada S, 2011, J CERAM SOC JPN, V119, P635, DOI 10.2109/jcersj2.119.635
   Okada S, 2010, ACTA BIOMATER, V6, P591, DOI 10.1016/j.actbio.2009.07.037
   Pezzatini S, 2006, J BIOMED MATER RES A, V76A, P656, DOI 10.1002/jbm.a.30524
   RIPAMONTI U, 1991, J BONE JOINT SURG AM, V73A, P692, DOI 10.2106/00004623-199173050-00007
   Scopelliti PE, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011862
   Webster TJ, 2001, TISSUE ENG, V7, P291, DOI 10.1089/10763270152044152
   Yuan HP, 1998, J MATER SCI-MATER M, V9, P717, DOI 10.1023/A:1008998817977
   Yuan HP, 1999, BIOMATERIALS, V20, P1799, DOI 10.1016/S0142-9612(99)00075-7
   Yuan HP, 2010, P NATL ACAD SCI USA, V107, P13614, DOI 10.1073/pnas.1003600107
   Zhang XD, 1991, BIOCERAMICS HUMAN BO, P408
   Zhao Y, 2007, J BIOMED MATER RES B, V83B, P121, DOI 10.1002/jbm.b.30774
   Zhu XD, 2007, J MATER SCI-MATER M, V18, P2243, DOI 10.1007/s10856-006-0057-2
   Zhu XD, 2010, ACTA BIOMATER, V6, P1536, DOI 10.1016/j.actbio.2009.10.032
NR 40
TC 29
Z9 30
U1 4
U2 13
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1742-7061
EI 1878-7568
J9 ACTA BIOMATER
JI Acta Biomater.
PD OCT
PY 2012
VL 8
IS 10
BP 3794
EP 3804
DI 10.1016/j.actbio.2012.06.021
PG 11
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA 013JJ
UT WOS:000309301400026
PM 22729020
DA 2018-12-27
ER

PT J
AU Chidume, CE
   Shehu, Y
AF Chidume, C. E.
   Shehu, Y.
TI RETRACTED: Approximation of solutions of generalized equations of
   Hammerstein type (Retracted article. See vol. 82, pg. 158, 2013)
SO NONLINEAR ANALYSIS-THEORY METHODS & APPLICATIONS
LA English
DT Article; Retracted Publication
DE Accretive operators; Equations of Hammerstein type; Strong convergence;
   2-uniformly smooth real Banach space
ID NONLINEAR INTEGRAL-EQUATIONS; BANACH-SPACES; ITERATIVE APPROXIMATION;
   MONOTONE OPERATORS; SYSTEMS; INEQUALITIES; SEMIGROUPS; EXISTENCE;
   MAPPINGS
AB Let E be a 2-uniformly smooth real Banach space. For each i = 1, 2, . . . , m, let F-i, K-i : E -> E be bounded and accretive mappings. Assume that the generalized Hammerstein equation u + Sigma(m)(i = 1) K(i)F(i)u = 0 has a solution in E. We construct a new explicit iterative sequence and prove strong convergence of the sequence to a solution of the generalized Hammerstein equation. Our result improves, generalizes and extends the results of Chidume and Ofoedu [C.E. Chidume, E.U. Ofoedu, Solution of nonlinear integral equations of Hammerstein type, Nonlinear Anal. 74 (2011) 4293-4299] and Chidume and Shehu [C.E. Chidume, Y. Shehu, Approximation of solutions of generalized equations of Hammerstein type, Comput. Math. Appl. 63 (2012) 966-974]. (c) 2012 Elsevier Ltd. All rights reserved.
C1 [Chidume, C. E.; Shehu, Y.] African Univ Sci & Technol, Math Inst, Abuja, Nigeria.
RP Chidume, CE (reprint author), African Univ Sci & Technol, Math Inst, Abuja, Nigeria.
EM cchidume@aust.edu.ng
OI shehu, yekini/0000-0001-9224-7139
CR Banach S., 1932, MONOGRAFIE MAT PWN
   Berinde V., 2002, ITERATIVE APPROXIMAT
   Berinde V, 2007, LECT NOTES MATH, V1912, P1
   BREZIS H, 1975, B AM MATH SOC, V81, P73, DOI 10.1090/S0002-9904-1975-13641-X
   BREZIS H, 1974, B AM MATH SOC, V80, P567, DOI 10.1090/S0002-9904-1974-13500-7
   BREZIS H, 1975, ADV MATH, V18, P115, DOI 10.1016/0001-8708(75)90155-3
   Browder F. E., 1971, CONTRIBUTIONS NONLIN, P425
   BROWDER FE, 1967, B AM MATH SOC, V73, P875, DOI 10.1090/S0002-9904-1967-11823-8
   BROWDER FE, 1970, B AM MATH SOC, V76, P700, DOI 10.1090/S0002-9904-1970-12511-3
   BROWDER FE, 1969, B AM MATH SOC, V75, P1347, DOI 10.1090/S0002-9904-1969-12420-1
   CHANG S, 2002, ITERATIVE METHODS NO
   Chepanovich R.Sh., 1984, PUBL I MATH-BEOGRAD, V35, P119
   Chidume C., 2009, LECT NOTES MATH, V1965, P326
   Chidume CE, 2012, COMPUT MATH APPL, V63, P966, DOI 10.1016/j.camwa.2011.12.001
   Chidume CE, 2012, ABSTR APPL ANAL, DOI 10.1155/2012/681348
   Chidume CE, 2011, NONLINEAR ANAL-THEOR, V74, P4293, DOI 10.1016/j.na.2011.02.017
   Chidume CE, 2009, NONLINEAR ANAL-THEOR, V70, P4086, DOI 10.1016/j.na.2008.08.017
   Chidume CE, 2009, NONLINEAR ANAL-THEOR, V70, P4071, DOI 10.1016/j.na.2008.08.016
   Cioranescu I, 1990, GEOMETRY BANACH SPAC
   De D.G. Figueiredo, 1973, B AM MATH SOC, V40, P470
   Dolezale V., 1979, STUDIES AUTOMATION C
   Goebel K, 1984, UNIFORM CONVEXITY HY
   Gupta C.P., 1975, COMMENT MATH U CAROL, V16, P377
   GUPTA CP, 1977, J MATH ANAL APPL, V58, P344, DOI 10.1016/0022-247X(77)90212-8
   Hammerstein A, 1930, ACTA MATH-DJURSHOLM, V54, P117, DOI 10.1007/BF02547519
   Infante G, 2009, NONLINEAR ANAL-THEOR, V71, P1301, DOI 10.1016/j.na.2008.11.095
   Joshi M., 1974, COMMENT MATH U CAROL, V15, P283
   KATO T, 1967, J MATH SOC JPN, V19, P508, DOI 10.2969/jmsj/01940508
   Mann W. R., 1953, B AM MATH SOC, V4, P506
   Pascali D., 1978, NONLINEAR MAPPINGS M
   REICH S, 1981, J MATH ANAL APPL, V79, P113, DOI 10.1016/0022-247X(81)90013-5
   Reich S., 1994, J MATH ANAL APPL, V183, P118
   REICH S, 1992, B AM MATH SOC, V26, P367, DOI DOI 10.1090/S0273-0979-1992-00287-2
   Shioji N, 1997, P AM MATH SOC, V125, P3641, DOI 10.1090/S0002-9939-97-04033-1
   Xu H-K, 2002, J LOND MATH SOC, V66, P1
   XU HK, 1991, NONLINEAR ANAL-THEOR, V16, P1127, DOI 10.1016/0362-546X(91)90200-K
   XU ZB, 1991, J MATH ANAL APPL, V157, P189, DOI 10.1016/0022-247X(91)90144-O
   Yang ZL, 2005, J MATH ANAL APPL, V311, P600, DOI 10.1016/j.jmaa.2005.03.084
NR 38
TC 1
Z9 1
U1 2
U2 10
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0362-546X
J9 NONLINEAR ANAL-THEOR
JI Nonlinear Anal.-Theory Methods Appl.
PD OCT
PY 2012
VL 75
IS 15
BP 5894
EP 5904
DI 10.1016/j.na.2012.06.003
PG 11
WC Mathematics, Applied; Mathematics
SC Mathematics
GA 976RU
UT WOS:000306602800014
DA 2018-12-27
ER

PT J
AU Ali, S
   Banerjee, S
   Logna, F
   Bao, B
   Philip, PA
   Korc, M
   Sarkar, FH
AF Ali, Shadan
   Banerjee, Sanjeev
   Logna, Farah
   Bao, Bin
   Philip, Philip A.
   Korc, Murray
   Sarkar, Fazlul H.
TI RETRACTED: Inactivation of Ink4a/Arf leads to deregulated expression of
   miRNAs in K-Ras transgenic mouse model of pancreatic cancer (Retracted
   article. See vol. 231, pg. 2303, 2016)
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article; Retracted Publication
ID MATRIX-METALLOPROTEINASE EXPRESSION; CELL LUNG-CANCER; DUCTAL
   ADENOCARCINOMA; PRECURSOR LESIONS; BREAST-CANCER; KAPPA-B; GROWTH; MICE;
   KRAS; METASTASIS
AB Human pancreatic cancer (PC) is an aggressive disease, which has been recapitulated in transgenic animal model that provides unique opportunity for mechanistic understanding of disease progression and also for testing the efficacy of novel therapeutics. Emerging evidence suggests deregulated expression of microRNAs (miRNAs) in human PC, and thus we investigated the expression of miRNAs in pancreas tissues obtained from transgenic mouse models of K-Ras (K), Pdx1-Cre (C), K-Ras;Pdx1-Cre (KC), and K-Ras;Pdx1-Cre;INK4a/Arf (KCI), initially from pooled RNA samples using miRNA profiling, and further confirmed in individual specimens by quantitative RT-PCR. We found over-expression of miR-21, miR-221, miR-27a, miR-27b, and miR-155, and down-regulation of miR-216a, miR-216b, miR-217, and miR-146a expression in tumors derived from KC and KCI mouse model, which was consistent with data from KCI-derived RInk-1 cells. Mechanistic investigations revealed a significant induction of EGFR, K-Ras, and MT1-MMP protein expression in tissues from both KC and KCI mouse compared to tissues from K or C, and these results were consistent with similar findings in RInk-1 cells compared to human MIAPaCa-2 cells. Furthermore, miR-155 knock-down in RInk-1 cells resulted in the inhibition of cell growth and colony formation consistent with down-regulation of EGFR, MT1-MMP, and K-Ras expression. In addition, miR-216b which target Ras, and forced re-expression of miR-216b in RInk-1 cells showed inhibition of cell proliferation and colony formation, which was correlated with reduced expression of Ras, EGFR, and MT1-MMP. These findings suggest that these models would be useful for preclinical evaluation of novel miRNA-targeted agents for designing personalized therapy for PC. J. Cell. Physiol. 227: 33733380, 2012. (C) 2011 Wiley Periodicals, Inc.
C1 [Sarkar, Fazlul H.] Wayne State Univ, Sch Med, Dept Pathol, Karmanos Canc Inst,Hudson Webber Canc Res Ctr 740, Detroit, MI 48201 USA.
   [Ali, Shadan; Philip, Philip A.; Sarkar, Fazlul H.] Wayne State Univ, Karmanos Canc Inst, Dept Oncol, Detroit, MI 48201 USA.
   [Korc, Murray] Indiana Univ, Dept Med, Indianapolis, IN USA.
RP Sarkar, FH (reprint author), Wayne State Univ, Sch Med, Dept Pathol, Karmanos Canc Inst,Hudson Webber Canc Res Ctr 740, 4100 John R St, Detroit, MI 48201 USA.
EM fsarkar@med.wayne.edu
FU National Cancer Institute [5R01CA131151, 3R01CA131151-02S109,
   1R01CA132794]; National Cancer Institute, NIH [5R01CA131151,
   3R01CA131151-02S109, 1R01CA132794]
FX Contract grant sponsor: National Cancer Institute;; Contract grant
   numbers: 5R01CA131151, 3R01CA131151-02S109, 1R01CA132794.; This work was
   funded by grants from the National Cancer Institute, NIH 5R01CA131151,
   3R01CA131151-02S109, and 1R01CA132794 awarded to FHS. We also thank
   Puschelberg and Guido foundations for their generous contribution.
CR Aguirre AJ, 2003, GENE DEV, V17, P3112, DOI 10.1101/gad.1158703
   Ali S, 2011, AM J TRANSL RES, V3, P28
   Ali S, 2010, CANCER RES, V70, P3606, DOI 10.1158/0008-5472.CAN-09-4598
   Bao B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017850
   Carriere C, 2009, BIOCHEM BIOPH RES CO, V382, P561, DOI 10.1016/j.bbrc.2009.03.068
   Cheung W, 2008, PANCREATOLOGY, V8, P608, DOI 10.1159/000161012
   Cook N, 2008, METHOD ENZYMOL, V439, P73, DOI 10.1016/S0076-6879(07)00406-5
   D'Alessio S, 2008, J BIOL CHEM, V283, P87, DOI 10.1074/jbc.M705492200
   Dangi-Garimella S, 2011, CANCER RES, V71, P1019, DOI 10.1158/0008-5472.CAN-10-1855
   du Rieu MC, 2010, CLIN CHEM, V56, P603, DOI 10.1373/clinchem.2009.137364
   Edmonds MD, 2009, INT J CANCER, V125, P1778, DOI 10.1002/ijc.24616
   Frese KK, 2007, NAT REV CANCER, V7, P645, DOI 10.1038/nrc2192
   Gadgeel SM, 2007, CANCER-AM CANCER SOC, V110, P2775, DOI 10.1002/cncr.23100
   Gadgeel SM, 2009, CANCER-AM CANCER SOC, V115, P2165, DOI 10.1002/cncr.24250
   Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X
   Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023
   Hruban RH, 2006, CANCER RES, V66, P95, DOI 10.1158/0008-5472.CAN-05-2168
   Kim ST, 2011, MOL CANCER THER, V10, P1993, DOI 10.1158/1535-7163.MCT-11-0269
   Kogo R, 2011, CLIN CANCER RES, V17, P4277, DOI 10.1158/1078-0432.CCR-10-2866
   Kranenburg O, 2004, BBA-REV CANCER, V1654, P23, DOI 10.1016/j.bbcan.2003.09.004
   Krantz SB, 2011, MOL CANCER RES, V9, P1294, DOI 10.1158/1541-7786.MCR-11-0023
   LaConti JJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020687
   Li YW, 2010, CANCER RES, V70, P1486, DOI 10.1158/0008-5472.CAN-09-2792
   Macdonald JS, 2005, INVEST NEW DRUG, V23, P485, DOI 10.1007/s10637-005-2908-y
   Machova Polakova Katerina, 2011, Mol Cancer, V10, P41, DOI 10.1186/1476-4598-10-41
   Maniati E, 2011, J CLIN INVEST, V121, P4685, DOI 10.1172/JCI45797
   McGowan PM, 2008, ANN ONCOL, V19, P1566, DOI 10.1093/annonc/mdn180
   Mohammed A, 2010, CANCER PREV RES, V3, P1417, DOI 10.1158/1940-6207.CAPR-10-0038
   Mohri D, 2011, J GASTROENTEROL
   Nakata K, 2011, SURGERY, V150, P916, DOI 10.1016/j.surg.2011.06.017
   O'Connell RM, 2007, P NATL ACAD SCI USA, V104, P1604, DOI 10.1073/pnas.0610731104
   Ohashi K, 2009, CANCER RES, V69, P7088, DOI 10.1158/0008-5472.CAN-08-4205
   Olive KP, 2009, SCIENCE, V324, P1457, DOI 10.1126/science.1171362
   Ottaviano AJ, 2006, CANCER RES, V66, P7032, DOI 10.1158/0008-5472.CAN-05-4421
   Perentes JY, 2011, CANCER RES, V71, P4527, DOI 10.1158/0008-5472.CAN-10-4376
   Pryczynicz A, 2008, ANTICANCER RES, V28, P1399
   Pylayeva-Gupta Y, 2011, NAT REV CANCER, V11, P761, DOI 10.1038/nrc3106
   Ray KC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016786
   Rodriguez A, 2007, SCIENCE, V316, P608, DOI 10.1126/science.1139253
   Sarkar FH, 2009, MINERVA CHIR, V64, P489
   Seeley ES, 2009, CANCER RES, V69, P422, DOI 10.1158/0008-5472.CAN-08-1290
   Shields MA, 2011, J BIOL CHEM, V286, P10495, DOI 10.1074/jbc.M110.195628
   Siegel R, 2011, CA-CANCER J CLIN, V61, P212, DOI 10.3322/caac.20121
   SMIT VTHBM, 1988, NUCLEIC ACIDS RES, V16, P7773, DOI 10.1093/nar/16.16.7773
   Talotta F, 2009, ONCOGENE, V28, P73, DOI 10.1038/onc.2008.370
   Tuveson DA, 2005, COLD SH Q B, V70, P65, DOI 10.1101/sqb.2005.70.040
   Wang ZW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020537
   Wang ZW, 2010, DRUG RESIST UPDATE, V13, P109, DOI 10.1016/j.drup.2010.07.001
   Xiong HQ, 2006, DRUGS, V66, P1059, DOI 10.2165/00003495-200666080-00003
   Zhao WG, 2010, CARCINOGENESIS, V31, P1726, DOI 10.1093/carcin/bgq160
   Zhao Y, 2011, ENV SCI TECHNOL
NR 51
TC 41
Z9 44
U1 3
U2 18
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0021-9541
EI 1097-4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD OCT
PY 2012
VL 227
IS 10
BP 3373
EP 3380
DI 10.1002/jcp.24036
PG 8
WC Cell Biology; Physiology
SC Cell Biology; Physiology
GA 961ZY
UT WOS:000305509900003
PM 22213426
OA Green Accepted
DA 2018-12-27
ER

PT J
AU Li, CY
   Yang, GH
   Ruan, J
AF Li, Changyong
   Yang, Guohua
   Ruan, Jie
TI RETRACTED: Sphingosine kinase-1/sphingosine-1-phosphate receptor type 1
   signalling axis is induced by transforming growth factor-beta 1 and
   stimulates cell migration in RAW264.7 macrophages (Retracted article.
   See vol. 440, pg. 804, 2013)
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article; Retracted Publication
DE Sphingosine kinase-1; Sphingosine-1-phosphate; TGF-beta 1; Cell
   migration; Macrophages
ID GROWTH-FACTOR-BETA; LYMPHOCYTE EGRESS; SPHINGOSINE-1-PHOSPHATE;
   ACTIVATION; DISEASE; SPHINGOLIPIDS; INHIBITION; PROMOTION; MOTILITY;
   KINASES
AB Macrophage recruitment to sites of inflammation is an essential step in host defense. However, the signals regulating the mobilization of these cells are still not fully understood. Sphingosine-1-phosphate (S1P), a pleiotropic bioactive lipid mediator, is known to regulate an array of biological activities in various cell types. Here, we investigated the roles of SIP and SIP receptors (S1PRs) in macrophage migration in vitro. Furthermore, we explored the cross-talk between transforming growth factor-beta 1 (TGF-beta 1) and S1P signalling pathways in this process. We found that SW exerted a powerful migratory action on RAW264.7 macrophages, as determined in Boyden chambers. IV oreover, by employing RNA interference technology and pharmacological tools, we have demonstrated.:hat S1PR1, but not S1PR2 and S1PR3, is required for S1P-induced macrophage migration. Importantly, we observed a pronounced increase in sphingosine kinase-1 (SphK1) mRNA expression and subsequently increase in SI P production, following transforming growth factor-beta 1 (TGF-beta 1) stimulation in RAW264.7 macrophages. The expression of S1PR1, but not S1PR2 and S1PR3, was also significantly up-regulated after TGF-beta 1 stimulation. Interestingly, exogenously added S1P-induced up-regulation of SphK1 and the synthesis of additional Si P, suggesting a self-amplifying loop of S1P to enhance macrophage migration. In conclusion, our results reveal that SphK1/S1PR1 signalling axis is induced by TGF-beta 1 and stimulates cell migration in RAW 264.7 macrophages. This study provides new clues for the molecular mechanisms of macrophage recruitment during inflammation. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Li, Changyong] Wuhan Univ, Sch Basic Med Sci, Dept Physiol, Wuhan 430072, Peoples R China.
   [Yang, Guohua] Wuhan Univ, Sch Basic Med Sci, Dept Med Genet, Wuhan 430072, Peoples R China.
   [Ruan, Jie] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Cardiol, Wuhan 430074, Peoples R China.
   [Ruan, Jie] Wuhan Asia Heart Hosp, Dept Cardiol, Wuhan, Peoples R China.
RP Li, CY (reprint author), 185 Donghu Rd, Wuhan 430071, Hubei Province, Peoples R China.
EM li_changyong@yahoo.com.cn
FU Specialized Research Fund for the Doctoral Program of Higher Education
   [20101107120014]; Fundamental Research Funds for the Central
   Universities (Wuhan University)
FX This work was supported by grant from the Specialized Research Fund for
   the Doctoral Program of Higher Education (20101107120014), and the
   Fundamental Research Funds for the Central Universities (Wuhan
   University).
CR Billich A, 2003, J BIOL CHEM, V278, P47408, DOI 10.1074/jbc.M307687200
   Blom T, 2010, BMC CELL BIOL, V11, DOI 10.1186/1471-2121-11-45
   Cencetti F, 2010, MOL BIOL CELL, V21, P1111, DOI 10.1091/mbc.E09-09-0812
   Gellings Lowe N, 2009, CARDIOVASC RES, V82, P303, DOI 10.1093/cvr/cvp056
   Hannun YA, 2008, NAT REV MOL CELL BIO, V9, P139, DOI 10.1038/nrm2329
   Hisamatsu T, 2008, CURR OPIN GASTROEN, V24, P448, DOI 10.1097/MOG.0b013e3282ff8b0c
   Hobson JP, 2001, SCIENCE, V291, P1800, DOI 10.1126/science.1057559
   Keul P, 2011, CIRC RES, V108, P314, DOI 10.1161/CIRCRESAHA.110.235028
   Lebman DA, 2008, J LIPID RES, V49, P1388, DOI 10.1194/jlr.R800008-JLR200
   Li CY, 2011, J HEPATOL, V54, P1205, DOI 10.1016/j.jhep.2010.08.028
   Li CY, 2009, AM J PATHOL, V175, P1464, DOI 10.2353/ajpath.2009.090037
   Li CY, 2009, J HEPATOL, V50, P1174, DOI 10.1016/j.jhep.2009.01.028
   Liu XH, 2011, J CELL PHYSIOL, V226, P2370, DOI 10.1002/jcp.22572
   Maceyka M, 2012, TRENDS CELL BIOL, V22, P50, DOI 10.1016/j.tcb.2011.09.003
   Malchnkhuu E, 2008, BIOCHEM BIOPH RES CO, V366, P963, DOI 10.1016/j.bbrc.2007.12.054
   Matloubian M, 2004, NATURE, V427, P355, DOI 10.1038/nature02284
   Michaud J, 2010, J IMMUNOL, V184, P1475, DOI 10.4049/jimmunol.0901586
   Miller AV, 2008, MOL CELL BIOL, V28, P4142, DOI 10.1128/MCB.01465-07
   Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448
   Pappu R, 2007, SCIENCE, V316, P295, DOI 10.1126/science.1139221
   Ryu Y, 2002, CIRC RES, V90, P325, DOI 10.1161/hh0302.104455
   Sanchez T, 2004, J CELL BIOCHEM, V92, P913, DOI 10.1002/jcb.20127
   Schwab SR, 2005, SCIENCE, V309, P1735, DOI 10.1126/science.1113640
   Spiegel S, 2002, TRENDS CELL BIOL, V12, P236, DOI 10.1016/S0962-8924(02)02277-8
   Takuwa Y., 2012, BIOCH BIOPHYS ACTA
   Wang F, 1999, J BIOL CHEM, V274, P35343, DOI 10.1074/jbc.274.50.35343
   Yamanaka M, 2004, J BIOL CHEM, V279, P53994, DOI 10.1074/jbc.M410144200
   Yang L, 2012, AM J PATHOL, V181, P85, DOI 10.1016/j.ajpath.2012.03.014
   Zhou L, 2009, CELL MOL LIFE SCI, V66, P192, DOI 10.1007/s00018-008-8308-7
NR 29
TC 12
Z9 13
U1 3
U2 12
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD SEP 28
PY 2012
VL 426
IS 3
BP 415
EP 420
DI 10.1016/j.bbrc.2012.08.108
PG 6
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 024RC
UT WOS:000310125300023
PM 22960176
DA 2018-12-27
ER

PT J
AU Cao, FJ
   Yin, AL
   Wen, G
   Sheikh, AM
   Tauqeer, Z
   Malik, M
   Nagori, A
   Schirripa, M
   Schirripa, F
   Merz, G
   Brown, WT
   Li, XH
AF Cao, Fujiang
   Yin, Ailan
   Wen, Guang
   Sheikh, Ashfaq M.
   Tauqeer, Zujaja
   Malik, Mazhar
   Nagori, Amenah
   Schirripa, Michael
   Schirripa, Frank
   Merz, George
   Brown, W. Ted
   Li, Xiaohong
TI RETRACTED: Alteration of astrocytes and Wnt/beta-catenin signaling in
   the frontal cortex of autistic subjects (Retracted article. See vol. 13,
   106, 2016)
SO JOURNAL OF NEUROINFLAMMATION
LA English
DT Article; Retracted Publication
DE Autism; Astrocytes; Morphology; Wnt/beta-catenin pathway; Neural
   plasticity
ID FIBRILLARY ACIDIC PROTEIN; CENTRAL-NERVOUS-SYSTEM; NEURONAL
   DIFFERENTIATION; INFLAMMATORY RESPONSE; CEREBROSPINAL-FLUID; INBRED
   STRAINS; MICE; BRAIN; CHILDREN; CNS
AB Background: Autism is a neurodevelopmental disorder characterized by impairments in social interaction, verbal communication and repetitive behaviors. To date the etiology of this disorder is poorly understood. Studies suggest that astrocytes play critical roles in neural plasticity by detecting neuronal activity and modulating neuronal networks. Recently, a number of studies suggested that an abnormal function of glia/astrocytes may be involved in the development of autism. However, there is yet no direct evidence showing how astrocytes develop in the brain of autistic individuals.
   Methods: Study subjects include brain tissue from autistic subjects, BTBR T + tfJ (BTBR) and Neuroligin (NL)-3 knock-down mice. Western blot analysis, Immunohistochemistry and confocal microscopy studies have be used to examine the density and morphology of astrocytes, as well as Wnt and beta-catenin protein expression.
   Results: In this study, we demonstrate that the astrocytes in autisitcsubjects exhibit significantly reduced branching processes, total branching length and cell body sizes. We also detected an astrocytosis in the frontal cortex of autistic subjects. In addition, we found that the astrocytes in the brain of an NL3 knockdown mouse exhibited similar alterations to what we found in the autistic brain. Furthermore, we detected that both Wnt and beta-catenin proteins are decreased in the frontal cortex of autistic subjects. Wnt/beta-catenin pathway has been suggested to be involved in the regulation of astrocyte development.
   Conclusions: Our findings imply that defects in astrocytes could impair neuronal plasticity and partially contribute to the development of autistic-like behaviors in both humans and mice. The alteration of Wnt/beta-catenin pathway in the brain of autistic subjects may contribute to the changes of astrocytes.
C1 [Cao, Fujiang; Yin, Ailan; Sheikh, Ashfaq M.; Tauqeer, Zujaja; Malik, Mazhar; Nagori, Amenah; Schirripa, Michael; Schirripa, Frank; Li, Xiaohong] New York State Inst Basic Res Dev Disabil, Dept Neurochem, Staten Isl, NY 10314 USA.
   [Wen, Guang] New York State Inst Basic Res Dev Disabil, Dept Dev Neurobiol, New York, NY USA.
   [Merz, George; Brown, W. Ted] New York State Inst Basic Res Dev Disabil, New York, NY 10314 USA.
   [Cao, Fujiang] Tianjin Med Univ, Gen Hosp, Dept Orthopaed, Tianjin, Peoples R China.
RP Li, XH (reprint author), New York State Inst Basic Res Dev Disabil, Dept Neurochem, 1050 Forest Hill Rd, Staten Isl, NY 10314 USA.
EM xiaohongli99@gmail.com
OI Wen, Guang Gary/0000-0001-6844-7528
FU NYS Office for People with Developmental Disabilities; Rural India
   Charitable Trust; Richmond County Savings Foundation; Northfield Bank
   Foundation
FX This work was supported by the NYS Office for People with Developmental
   Disabilities, the Rural India Charitable Trust, Richmond County Savings
   Foundation and Northfield Bank Foundation.
CR AHLSEN G, 1993, BIOL PSYCHIAT, V33, P734, DOI 10.1016/0006-3223(93)90124-V
   Anderova M, 2001, GLIA, V35, P189, DOI 10.1002/glia.1084
   Ashwood P, 2006, J NEUROIMMUNOL, V173, P126, DOI 10.1016/j.jneuroim.2005.12.007
   Ballas U, 2009, NAT NEUROSCI, V12, P311
   BAORTO DM, 1992, J CELL BIOL, V117, P357, DOI 10.1083/jcb.117.2.357
   Bechmann I, 2007, TRENDS IMMUNOL, V28, P5, DOI 10.1016/j.it.2006.11.007
   Bolivar VJ, 2007, BEHAV BRAIN RES, V176, P21, DOI 10.1016/j.bbr.2006.09.007
   Chahrour M, 2007, NEURON, V56, P422, DOI 10.1016/j.neuron.2007.10.001
   Chez MG, 2007, PEDIATR NEUROL, V36, P361, DOI 10.1016/j.pediatrneurol.2007.01.012
   Croonenberghs J, 2002, NEUROPSYCHOBIOLOGY, V45, P1, DOI 10.1159/000048665
   Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8
   Farias GG, 2010, DEV DYNAM, V239, P94, DOI 10.1002/dvdy.22065
   Farina C, 2007, TRENDS IMMUNOL, V28, P138, DOI 10.1016/j.it.2007.01.005
   Fatemi SH, 2008, SYNAPSE, V62, P501, DOI 10.1002/syn.20519
   Freeman MR, 2010, SCIENCE, V330, P774, DOI 10.1126/science.1190928
   Gilbert M, 2001, GLIA, V34, P151, DOI 10.1002/glia.1050
   Graf ER, NEUREXINS INDUCE DIF
   Herx LM, 2000, J IMMUNOL, V165, P2232, DOI 10.4049/jimmunol.165.4.2232
   Herx LM, 2001, J NEUROPATH EXP NEUR, V60, P961, DOI 10.1093/jnen/60.10.961
   Hirabayashi Y, 2004, DEVELOPMENT, V131, P2791, DOI 10.1242/dev.01165
   Hughes EG, 2004, MOL BRAIN RES, V124, P114, DOI 10.1016/j.molbrainres.2004.02.021
   Hughes EG, 2010, MOL CELL NEUROSCI, V43, P136, DOI 10.1016/j.mcn.2009.10.004
   Ingh VK, 1996, J NEUROIMMUNOL, V66, P143
   Israsena N, 2004, DEV BIOL, V268, P220, DOI 10.1016/j.ydbio.2003.12.024
   Jamain S, 2003, NAT GENET, V34, P27, DOI 10.1038/ng1136
   Jyonouchi H, 2001, J NEUROIMMUNOL, V120, P170, DOI 10.1016/S0165-5728(01)00421-0
   Kettenmann H, 2011, FORTSCHR NEUROL PSYC, V79, P588, DOI 10.1055/s-0031-1281704
   L'Episcopo F, 2011, MOL NEURODEGENER, V6, DOI 10.1186/1750-1326-6-49
   Laurence JA, 2005, CEREBELLUM, V4, P206, DOI 10.1080/14734220500208846
   Levinson JN, 2010, NEUROSCIENCE, V165, P782, DOI 10.1016/j.neuroscience.2009.11.016
   Li XH, 2009, J NEUROIMMUNOL, V207, P111, DOI 10.1016/j.jneuroim.2008.12.002
   Lioy DT, 2011, NATURE, V475, P497, DOI 10.1038/nature10214
   Machon O, 2007, DEV BIOL, V311, P223, DOI 10.1016/j.ydbio.2007.08.038
   Marui T, 2010, INT J NEUROPSYCHOPH, V13, P443, DOI 10.1017/S1461145709990903
   Mason JL, 2001, J NEUROSCI, V21, P7046, DOI 10.1523/JNEUROSCI.21-18-07046.2001
   McFarlane HG, 2008, GENES BRAIN BEHAV, V7, P152, DOI 10.1111/j.1601-183X.2007.00330.x
   Miller FD, 2007, NEURON, V54, P357, DOI 10.1016/j.neuron.2007.04.019
   Moy SS, 2007, BEHAV BRAIN RES, V176, P4, DOI 10.1016/j.bbr.2006.07.030
   Pekny M, 2004, J PATHOL, V204, P428, DOI 10.1002/path.1645
   Penkowa M, 1999, GLIA, V25, P343
   Shelley J, 2010, BMC NEUROSCI, V11, P132
   Silverman JL, 2009, NEUROPSYCHOPHARMACOL, V35, P976, DOI DOI 10.1038/NPP.2009.201
   Stephenson DT, 2011, MOL AUTISM, V2, DOI 10.1186/2040-2392-2-7
   STOSCHECK CM, 1990, METHOD ENZYMOL, V182, P50
   Sullivan R, 2004, GLIA, V45, P155, DOI 10.1002/glia.10317
   Swartz KR, 2001, BRAIN RES, V896, P86, DOI 10.1016/S0006-8993(01)02013-3
   Tabuchi K, 2007, SCIENCE, V318, P71, DOI 10.1126/science.1146221
   Thomas NS, 1999, HUM GENET, V104, P43, DOI 10.1007/s004390050908
   Torres-Platas SG, 2011, NEUROPSYCHOPHARMACOL, V36, P2650, DOI 10.1038/npp.2011.154
   Vargas DL, 2005, ANN NEUROL, V57, P67, DOI 10.1002/ana.20315
   Varoqueaux F, 2006, NEURON, V51, P741, DOI 10.1016/j.neuron.2006.09.003
   Wassink TH, 2001, AM J MED GENET, V105, P406, DOI 10.1002/ajmg.1401
   White BD, 2010, STEM CELLS, V28, P297, DOI 10.1002/stem.268
   Zhang C, 2009, J NEUROSCI, V29, P10843, DOI 10.1523/JNEUROSCI.1248-09.2009
   Zhou CJ, 2006, NEUROSCIENCE, V142, P1119, DOI 10.1016/j.neuroscience.2006.07.007
   Zhou CJ, 2004, J NEUROSCI, V24, P121, DOI 10.1523/JNEUROSCI.4071-03.2004
NR 56
TC 23
Z9 24
U1 3
U2 24
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1742-2094
J9 J NEUROINFLAMM
JI J. Neuroinflamm.
PD SEP 21
PY 2012
VL 9
AR 223
DI 10.1186/1742-2094-9-223
PG 11
WC Immunology; Neurosciences
SC Immunology; Neurosciences & Neurology
GA 087GV
UT WOS:000314750400001
PM 22999633
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Hale, LP
   Kant, EP
   Greer, PK
   Foster, WM
AF Hale, Laura P.
   Kant, Erin Potts
   Greer, Paula K.
   Foster, W. Michael
TI RETRACTED: Iron Supplementation Decreases Severity of Allergic
   Inflammation in Murine Lung (Retracted article. See vol. 11, e0155387,
   2016)
SO PLOS ONE
LA English
DT Article; Retracted Publication
ID PERITONEAL MAST-CELLS; HISTAMINE-RELEASE; ASTHMA PHENOTYPE; MEDICAL
   PROGRESS; AIRWAY; DISEASE; MODEL; DESFERRIOXAMINE; EXPRESSION;
   TRANSFERRIN
AB The incidence and severity of allergic asthma have increased over the last century, particularly in the United States and other developed countries. This time frame was characterized by marked environmental changes, including enhanced hygiene, decreased pathogen exposure, increased exposure to inhaled pollutants, and changes in diet. Although iron is well-known to participate in critical biologic processes such as oxygen transport, energy generation, and host defense, iron deficiency remains common in the United States and world-wide. The purpose of these studies was to determine how dietary iron supplementation affected the severity of allergic inflammation in the lungs, using a classic model of IgE-mediated allergy in mice. Results showed that mice fed an iron-supplemented diet had markedly decreased allergen-induced airway hyperreactivity, eosinophil infiltration, and production of pro-inflammatory cytokines, compared with control mice on an unsupplemented diet that generated mild iron deficiency but not anemia. In vitro, iron supplementation decreased mast cell granule content, IgE-triggered degranulation, and production of pro-inflammatory cytokines post-degranulation. Taken together, these studies show that iron supplementation can decrease the severity of allergic inflammation in the lung, potentially via multiple mechanisms that affect mast cell activity. Further studies are indicated to determine the potential of iron supplementation to modulate the clinical severity of allergic diseases in humans.
C1 [Hale, Laura P.; Greer, Paula K.] Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA.
   [Kant, Erin Potts; Foster, W. Michael] Duke Univ, Med Ctr, Dept Med, Div Allergy Pulm & Crit Care Med, Durham, NC 27710 USA.
   [Hale, Laura P.] Duke Univ, Med Ctr, Human Vaccine Inst, Durham, NC USA.
RP Hale, LP (reprint author), Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA.
EM laura.hale@duke.edu
FU NIH [ES 016347, AI 081672]
FX This work was funded by NIH grants ES 016347 and AI 081672 to WMF and by
   additional funds paid out of LPH's "discretionary account" rather than
   from existing grants. The funds in the discretionary account are derived
   from payments to LPH for services that she renders and are personal
   funds, diverted for use in the laboratory, rather than being taken as
   income. The National Institutes of Health had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Barnes PJ, 2008, J CLIN INVEST, V118, P3546, DOI 10.1172/JCI36130
   Beasley R, 2002, J ALLERGY CLIN IMMUN, V109, pS482, DOI 10.1067/mai.2002.122716
   Berrozpe G, 1999, BLOOD, V94, P2658
   Boyce JA, 2012, J ALLERGY CLIN IMMUN, V129, P335, DOI 10.1016/j.jaci.2011.12.968
   Centers for Disease Control and Prevention (CDC), 2002, MMWR Morb Mortal Wkly Rep, V51, P897
   Chichlowski M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012220
   Cho KJ, 2010, J IMMUNOL, V185, P6329, DOI 10.4049/jimmunol.1001213
   Clark SF, 2008, NUTR CLIN PRACT, V23, P128, DOI 10.1177/0884533608314536
   Echtenacher B, 1996, NATURE, V381, P75, DOI 10.1038/381075a0
   Fahy JV, 2010, NEW ENGL J MED, V363, P2233, DOI 10.1056/NEJMra0910061
   Gaga M, 2005, CLIN EXP ALLERGY, V35, P954, DOI 10.1111/j.1365-2222.2005.02281.x
   Gandon Y, 2004, LANCET, V363, P357, DOI 10.1016/S0140-6736(04)15436-6
   GROSSWEEGE W, 1986, AGENTS ACTIONS, V19, P10
   Hale LP, 2006, INT IMMUNOPHARMACOL, V6, P2038, DOI 10.1016/j.intimp.2006.08.007
   Institute for Laboratory Animal Research (ILAR), 1995, NUTR REQ LAB AN, P80
   Jeong HJ, 2003, BIOCHEM BIOPH RES CO, V306, P805, DOI 10.1016/S0006-291X(03)01073-8
   Jin C, 2011, J CLIN INVEST, V121, P941, DOI 10.1172/JCI43584
   Karman J, 2010, INT IMMUNOL, V22, P593, DOI 10.1093/intimm/dxq044
   Kim HY, 2010, NAT IMMUNOL, V11, P577, DOI 10.1038/ni.1892
   Lee P, 2005, P NATL ACAD SCI USA, V102, P1906, DOI 10.1073/pnas.0409808102
   Lombardo T, 1996, AM J HEMATOL, V51, P90, DOI 10.1002/(SICI)1096-8652(199601)51:1<90::AID-AJH15>3.0.CO;2-F
   Maazi H, 2011, CLIN EXP IMMUNOL, V166, P80, DOI 10.1111/j.1365-2249.2011.04448.x
   MAGRO AM, 1983, IMMUNOLOGY, V49, P1
   Malaviya R, 1996, NATURE, V381, P77, DOI 10.1038/381077a0
   McLachlan JB, 2003, NAT IMMUNOL, V4, P1199, DOI 10.1038/ni1005
   Moorman Jeanne E., 2007, Morbidity and Mortality Weekly Report, V56, P1
   Paradkar PN, 2008, BLOOD, V112, P866, DOI 10.1182/blood-2007-12-126854
   Rao NL, 2010, AM J RESP CRIT CARE, V181, P899, DOI 10.1164/rccm.200807-1158OC
   Reuter S, 2010, INT ARCH ALLERGY IMM, V151, P214, DOI 10.1159/000242359
   Schmidt PJ, 2008, CELL METAB, V7, P205, DOI 10.1016/j.cmet.2007.11.016
   SHALIT M, 1991, J ALLERGY CLIN IMMUN, V88, P854, DOI 10.1016/0091-6749(91)90241-F
   Shin JS, 2006, J IMMUNOL, V177, P5791, DOI 10.4049/jimmunol.177.9.5791
   Shore SA, 2003, J CLIN INVEST, V112, P495, DOI 10.1172/JCI200319642
   Song KS, 2009, AM J RESP CELL MOL, V41, P40, DOI 10.1165/rcmb.2008-0280OC
   Torrace JD, 1980, TISSUE IRON STORES
   Vanderford DA, 2010, EXP DERMATOL, V19, P518, DOI 10.1111/j.1600-0625.2009.01032.x
   Weiss G, 2005, NEW ENGL J MED, V352, P1011, DOI 10.1056/NEJMra041809
   Williams CMM, 2000, J EXP MED, V192, P455, DOI 10.1084/jem.192.3.455
   Wolters PJ, 2005, CLIN EXP ALLERGY, V35, P82, DOI 10.1111/j.1365-2222.2005.02136.x
NR 39
TC 9
Z9 9
U1 1
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 20
PY 2012
VL 7
IS 9
AR e45667
DI 10.1371/journal.pone.0045667
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 014PT
UT WOS:000309388900089
PM 23029172
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Mohajel, N
   Najafabadi, AR
   Azadmanesh, K
   Vatanara, A
   Amini, M
   Moazenil, E
   Rahimi, A
   Gilani, K
AF Mohajel, Nasir
   Najafabadi, Abdolhossein R.
   Azadmanesh, Kayhan
   Vatanara, Alireza
   Amini, Mohsen
   Moazenil, Esmail
   Rahimi, Amirabbas
   Gilani, Kambiz
TI RETRACTED: Drying of a plasmid containing formulation: chitosan as a
   protecting agent (Retracted article. See vol. 24, 11, 2016)
SO DARU-JOURNAL OF PHARMACEUTICAL SCIENCES
LA English
DT Article; Retracted Publication
DE Nanocomplex; Polymeric gene delivery; Gene therapy; Spray-drying;
   Freeze-drying
ID SPRAY-DRIED POWDERS; NONVIRAL GENE DELIVERY; EXPRESSION; STABILITY;
   COMPLEXES; THERAPY; DISPERSIBILITY; NANOPARTICLES; ENHANCE; HUMANS
AB Background: The purpose of the study. Along with research on development of more efficient gene delivery systems, it is necessary to search on stabilization processes to extend their active life span. Chitosan is a nontoxic, biocompatible and available gene delivery carrier. The aim of this study was to assess the ability of this polymer to preserve transfection efficiency during spray-drying and a modified freeze-drying process in the presence of commonly used excipients.
   Method: Molecular weight of chitosan was reduced by a chemical reaction and achieved low molecular weight chitosan (LMWC) was complexed with pDNA. Obtained nanocomplex suspensions were diluted by solutions of lactose and leucine, and these formulations were spray dried or freeze dried using a modified technique. Size, polydispersity index, zeta potential, intensity of supercoiled DNA band on gel electrophoresis, and transfection efficiency of reconstituted nanocomplexes were compared with freshly prepared ones.
   Results and major conclusion: Size distribution profiles of both freeze dried, and 13 out of 16 spray-dried nanocomplexes remained identical to freshly prepared ones. LMWC protected up to 100% of supercoiled structure of pDNA in both processes, although DNA degradation was higher in spray-drying of the nanocomplexes prepared with low N/P ratios. Both techniques preserved transfection efficiency similarly even in lower N/P ratios, where supercoiled DNA content of spray dried formulations was lower than freeze-dried ones. Leucine did not show a significant effect on properties of the processed nanocomplexes. It can be concluded that LMWC can protect DNA structure and transfection efficiency in both processes even in the presence of leucine.
C1 [Mohajel, Nasir; Najafabadi, Abdolhossein R.; Vatanara, Alireza; Moazenil, Esmail; Gilani, Kambiz] Univ Tehran Med Sci, Sch Pharm, Dept Pharmaceut, Aerosol Res Lab, Tehran, Iran.
   [Mohajel, Nasir] Shahid Sadoughi Univ Med Sci, Fac Pharm, Dept Pharmaceut, Yazd, Iran.
   [Azadmanesh, Kayhan] Pasteur Inst Iran, Dept Virol, Tehran, Iran.
   [Amini, Mohsen] Univ Tehran Med Sci, Sch Pharm, Dept Med Chem, Tehran, Iran.
   [Rahimi, Amirabbas] Pasteur Inst Iran, Dept Nanobiotechnol, Tehran, Iran.
RP Gilani, K (reprint author), Univ Tehran Med Sci, Sch Pharm, Dept Pharmaceut, Aerosol Res Lab, Tehran, Iran.
EM gilani@sina.tums.ac.ir
RI Rouholamini najafabadi, Abdolhossein/A-3838-2017; Azadmanesh,
   kayhan/W-2445-2017
OI Azadmanesh, kayhan/0000-0002-7165-9043; Rahimi,
   Amirabbas/0000-0002-1982-8081
FU Pasteur Institute of Iran [427]
FX Financial support for this work was provided by research grant NO. 427
   from Pasteur Institute of Iran.
CR Abdelwahed W, 2006, ADV DRUG DELIVER REV, V58, P1688, DOI 10.1016/j.addr.2006.09.017
   Anchordoquy TJ, 2000, J PHARM SCI, V89, P289, DOI 10.1002/(SICI)1520-6017(200003)89:3<289::AID-JPS1>3.3.CO;2-E
   Anchordoquy TJ, 1998, J PHARM SCI, V87, P1046, DOI 10.1021/js9801891
   Anderson DG, 2003, ANGEW CHEM INT EDIT, V42, P3153, DOI 10.1002/anie.200351244
   Davies LA, 2008, MOL THER, V16, P1283, DOI 10.1038/mt.2008.96
   Glover DJ, 2005, NAT REV GENET, V6, P299, DOI 10.1038/nrg1577
   Grenha A, 2005, EUR J PHARM SCI, V25, P427, DOI 10.1016/j.ejps.2005.04.009
   Koping-Hoggard M, 2004, GENE THER, V11, P1441, DOI 10.1038/sj.gt.3302312
   Koping-Hoggard M, 2001, GENE THER, V8, P1108, DOI 10.1038/sj.gt.3301492
   Kuo JHS, 2004, J PHARM PHARMACOL, V56, P27, DOI 10.1211/0022357022494
   Li HY, 2005, J GENE MED, V7, P1035, DOI 10.1002/jgm.749
   Li HY, 2005, J GENE MED, V7, P343, DOI 10.1002/jgm.654
   Li HY, 2003, J DRUG TARGET, V11, P425, DOI 10.1080/10611860410001659786
   LYSTSOV V N, 1969, Biofizika, V14, P219
   LYSTSOV V. N., 1966, BIOFIZIKA, V11, P726
   Mao SR, 2010, ADV DRUG DELIVER REV, V62, P12, DOI 10.1016/j.addr.2009.08.004
   Mao SR, 2004, INT J PHARM, V281, P45, DOI 10.1016/j.ijpharm.2004.05.019
   Mohri K, 2010, J CONTROL RELEASE, V144, P221, DOI 10.1016/j.jconrel.2010.02.018
   Molina MDC, 2007, BBA-BIOMEMBRANES, V1768, P669, DOI 10.1016/j.bbamem.2006.12.004
   NABEL GJ, 1993, P NATL ACAD SCI USA, V90, P11307, DOI 10.1073/pnas.90.23.11307
   Okamoto H, 2003, J PHARM SCI, V92, P371, DOI 10.1002/jps.10285
   Seville PC, 2002, J GENE MED, V4, P428, DOI 10.1002/jgm.282
   Strand SP, 2010, BIOMATERIALS, V31, P975, DOI 10.1016/j.biomaterials.2009.09.102
   Talsma H, 1997, INT J PHARM, V157, P233, DOI 10.1016/S0378-5173(97)00244-5
   Wong YL, 2007, P NATL ACAD SCI USA, V104, P2591, DOI 10.1073/pnas.0611430104
   Zheng-Rong L, 2004, STABILITY PROTEINS N
NR 26
TC 1
Z9 1
U1 2
U2 16
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 2008-2231
J9 DARU
JI DARU
PD SEP 10
PY 2012
VL 20
AR 29
DI 10.1186/2008-2231-20-29
PG 9
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 057ZN
UT WOS:000312603500001
PM 23351334
OA Green Published, Other Gold
DA 2018-12-27
ER

PT J
AU Bai, L
   Wang, XH
   Jin, FM
   Yang, Y
   Qian, GH
   Duan, CZ
AF Bai, Lu
   Wang, Xiaohui
   Jin, Fangmin
   Yang, Yan
   Qian, Guanhua
   Duan, Changzhu
TI RETRACTED: UHRF2, another E3 ubiquitin ligase for p53 (Retracted
   article. See vol. 440, pg. 803, 2013)
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article; Retracted Publication
DE UHRF2; p53; Ubiquitin ligase; Cell cycle; Epigenetics
ID CELL-CYCLE NETWORK; NIRF; DNA; PROTEIN; ARREST; PHASE
AB UHRF2, ubiquitin-like with PHD and ring finger domains 2, is a nuclear E3 ubiquitin ligase, which is involved in cell cycle and epigenetic regulation. UHRF2 interacts with multiple cell cycle proteins, including cyclins (A2, B1, D1, and El), CDK2, and pRb: moreover. UHRF2 could ubiquitinate cyclin D1 and cyclin El. Also, UHRF2 has been shown to be implicated in epigenetic regulation by associating with DNMTs, G9a, HDAC1, H3K9me2/3 and hemi-methylated DNA. We found that UHRF2 associates with tumor suppressor protein p53, and p53 is ubiquitinated by UHRF2 in vivo and in vitro. Given that both UHRF2 and p53 are involved in cell cycle regulation, this study may suggest a novel signaling pathway on cell proliferation. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Bai, Lu; Wang, Xiaohui; Jin, Fangmin; Yang, Yan; Qian, Guanhua; Duan, Changzhu] Chongqing Med Univ, Dept Cell Biol & Med Genet, Chongqing 400016, Peoples R China.
   [Duan, Changzhu] Chongqing Med Univ, Fac Lab Med, Minist Educ, Key Lab Clin Lab Diagnost, Chongqing 400016, Peoples R China.
RP Duan, CZ (reprint author), Chongqing Med Univ, Dept Cell Biol & Med Genet, 1 Yixueyuan Rd, Chongqing 400016, Peoples R China.
EM duanchzhu@cqmu.edu.cn
FU National Natural Science Foundation of China [30872248]
FX This work was supported by the National Natural Science Foundation of
   China (No. 30872248).
CR Allende-Vega N, 2010, SEMIN CANCER BIOL, V20, P29, DOI 10.1016/j.semcancer.2009.10.004
   Aylon Y, 2011, CURR OPIN GENET DEV, V21, P86, DOI 10.1016/j.gde.2010.10.002
   Bartkova J, 2003, ARCH ORAL BIOL, V48, P125, DOI 10.1016/S0003-9969(02)00202-9
   Brady CA, 2010, J CELL SCI, V123, P2527, DOI 10.1242/jcs.064501
   Bronner C, 2007, PHARMACOL THERAPEUT, V115, P419, DOI 10.1016/j.pharmthera.2007.06.003
   Brooks CL, 2011, FEBS LETT, V585, P2803, DOI 10.1016/j.febslet.2011.05.022
   Brooks CL, 2010, CELL RES, V20, P614, DOI 10.1038/cr.2010.53
   Das SK, 2005, BBA-GEN SUBJECTS, V1726, P328, DOI 10.1016/j.bbagen.2005.09.007
   Funk JO, 1997, GENE DEV, V11, P2090, DOI 10.1101/gad.11.16.2090
   Hock A, 2010, INT J BIOCHEM CELL B, V42, P1618, DOI 10.1016/j.biocel.2010.06.011
   Iwata A, 2009, J BIOL CHEM, V284, P9796, DOI 10.1074/jbc.M809739200
   Korenjak M, 2005, CURR OPIN GENET DEV, V15, P520, DOI 10.1016/j.gde.2005.07.001
   Lee JT, 2010, CELL DEATH DIFFER, V17, P86, DOI 10.1038/cdd.2009.77
   Li YY, 2004, BIOCHEM BIOPH RES CO, V319, P464, DOI 10.1016/j.bbrc.2004.04.190
   Marine JC, 2010, CELL DEATH DIFFER, V17, P93, DOI 10.1038/cdd.2009.68
   Mori T, 2004, FEBS LETT, V557, P209, DOI 10.1016/S0014-5793(03)01495-9
   Mori T, 2002, BIOCHEM BIOPH RES CO, V296, P530, DOI 10.1016/S0006-291X(02)00890-2
   Mori T, 2012, FEBS LETT, V586, P1570, DOI 10.1016/j.febslet.2012.04.038
   Mori T, 2011, CELL CYCLE, V10, P3284, DOI 10.4161/cc.10.19.17176
   Munger K, 2002, VIRUS RES, V89, P213, DOI 10.1016/S0168-1702(02)00190-9
   Pichler G, 2011, J CELL BIOCHEM, V112, P2585, DOI 10.1002/jcb.23185
   Tsvetkov P, 2010, CELL DEATH DIFFER, V17, P103, DOI 10.1038/cdd.2009.67
   Unoki M, 2004, ONCOGENE, V23, P7601, DOI 10.1038/sj.onc.1208053
   Zhang JQ, 2011, CELL RES, V21, P1723, DOI 10.1038/cr.2011.176
NR 24
TC 4
Z9 7
U1 3
U2 17
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD SEP 7
PY 2012
VL 425
IS 4
BP 908
EP 911
DI 10.1016/j.bbrc.2012.08.009
PG 4
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 009HU
UT WOS:000309017700036
PM 22902639
DA 2018-12-27
ER

PT J
AU Piao, F
   Mishra, MK
   Jang, DO
AF Piao, Fengnu
   Mishra, Mithilesh Kumar
   Jang, Doo Ok
TI RETRACTED: Asymmetric synthesis of highly enantioenriched 2-substituted
   piperidines and 6-substituted piperidine-2-ones by a combination
   enantioselective hydrazone allylation with ring closing metathesis
   (Retracted article. See vol. 71, pg. 889, 2015)
SO TETRAHEDRON
LA English
DT Article; Retracted Publication
DE Alkaloid; Piperidine; Piperidinone; Homoallylamine; Allylation;
   Hydrazone; Ring closing metathesis
ID INDIUM-MEDIATED ALLYLATION; BARBIER-TYPE ALLYLATION; RADICAL-ADDITION;
   HOMOALLYLIC AMINES; AMMONIUM-SALTS; ALKALOIDS; 2-ARYL-4-PIPERIDONES;
   ACYLHYDRAZONES; PYRROLIDINES; ALDIMINES
AB An efficient method for the asymmetric synthesis of highly optically pure 2-substituted piperidines and 6-substituted piperidine-2-ones from aldehydes was developed by a sequence of enantioselective hydrazone allylation and ring closing metathesis. This method was found to be effective for a variety of substrates, showing substrate generality. The method's synthetic utility was illustrated in concise synthesis of the alkaloid (R)-(-)-coniine. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Piao, Fengnu; Mishra, Mithilesh Kumar; Jang, Doo Ok] Yonsei Univ, Dept Chem, Wonju 220710, South Korea.
RP Jang, DO (reprint author), Yonsei Univ, Dept Chem, Wonju 220710, South Korea.
EM dojang@yonsei.ac.kr
FU Korea Research Foundation [KRF-2009-0074839, KRF-2011-0021279]; Korean
   Government
FX This work was supported by a Korea Research Foundation Grant
   (KRF-2009-0074839 and KRF-2011-0021279), which was funded by the Korean
   Government.
CR Agami C, 2000, TETRAHEDRON-ASYMMETR, V11, P4639, DOI 10.1016/S0957-4166(00)00462-6
   Sirvent JA, 2012, CHEM COMMUN, V48, P2543, DOI 10.1039/c2cc17493f
   Andres JM, 2000, EUR J ORG CHEM, P1719
   Buckingham J., 2010, DICT ALKALOIDS
   BURK MJ, 1992, J AM CHEM SOC, V114, P6266, DOI 10.1021/ja00041a067
   Cho DH, 2006, CHEM COMMUN, P5045, DOI 10.1039/b613045c
   Coldham I, 2010, CHEM-EUR J, V16, P4082, DOI 10.1002/chem.200903059
   Colpaert F, 2011, J ORG CHEM, V76, P234, DOI 10.1021/jo1020807
   COMINS DL, 1992, J ORG CHEM, V57, P5807, DOI 10.1021/jo00048a003
   Cook GR, 2005, ORG LETT, V7, P2767, DOI 10.1021/ol051160o
   Cook GR, 2004, ORG LETT, V6, P1741, DOI 10.1021/ol0496172
   Cooper IR, 2003, TETRAHEDRON LETT, V44, P403, DOI 10.1016/S0040-4039(02)02428-0
   Cooper IR, 2002, CHEM COMMUN, P1372, DOI 10.1039/b202940e
   Davies SG, 2002, SYNLETT, P1146
   DIEZ A, 1993, HETEROCYCLES, V36, P2451
   ENDERS D, 1993, LIEBIGS ANN CHEM, P173
   Etayo P, 2008, EUR J ORG CHEM, P3474, DOI 10.1002/ejoc.200800069
   Felpin FX, 2003, EUR J ORG CHEM, P3693, DOI 10.1002/ejoc.200300193
   Fiorelli C, 2007, J ORG CHEM, V72, P6022, DOI 10.1021/jo0703000
   Foubelo F, 2004, TETRAHEDRON-ASYMMETR, V15, P3823, DOI 10.1016/j.tetasy.2004.10.031
   FU GC, 1993, J AM CHEM SOC, V115, P9856, DOI 10.1021/ja00074a085
   Gonzalez-Gomez JC, 2010, J ORG CHEM, V75, P6308, DOI 10.1021/jo101379u
   Hietanen A, 2010, EUR J ORG CHEM, P909, DOI 10.1002/ejoc.200901216
   Hunt J.C.A., 2002, J CHEM SOC P2, P2378
   Jacobsen MF, 2004, J ORG CHEM, V69, P4792, DOI 10.1021/jo0358170
   Jang DO, 2008, J AM CHEM SOC, V130, P16152, DOI 10.1021/ja807685r
   Kanda Y, 2003, CHIRALITY, V15, P89, DOI 10.1002/chir.10151
   Kargbo R, 2007, J AM CHEM SOC, V129, P3846, DOI 10.1021/ja070742t
   Kargbo RB, 2007, CURR ORG CHEM, V11, P1287, DOI 10.2174/138527207782023139
   Kim SY, 2010, CHEM-EUR J, V16, P13046, DOI 10.1002/chem.201002071
   Kim SJ, 2010, J AM CHEM SOC, V132, P12168, DOI 10.1021/ja1035336
   KUDZMA LV, 1989, J MED CHEM, V32, P2534, DOI 10.1021/jm00132a007
   Lebrun S, 2007, ORG LETT, V9, P2473, DOI 10.1021/ol070757w
   Lesma G, 2004, TETRAHEDRON, V60, P6437, DOI 10.1016/j.tet.2004.06.051
   Liu JD, 2011, ADV SYNTH CATAL, V353, P2721, DOI 10.1002/adsc.201100282
   Makino K, 2009, TETRAHEDRON, V65, P9468, DOI 10.1016/j.tet.2009.08.064
   MEHMANDOUST M, 1989, J CHEM SOC CHEM COMM, P1185, DOI 10.1039/c39890001185
   Monaco MR, 2011, ORG LETT, V13, P4546, DOI 10.1021/ol2017406
   Passarella D, 2005, TETRAHEDRON-ASYMMETR, V16, P2225, DOI 10.1016/j.tetasy.2005.05.032
   Reddy LR, 2010, J ORG CHEM, V75, P2236, DOI 10.1021/jo902710s
   RUBIRALTA M, 1991, J ORG CHEM, V56, P6292, DOI 10.1021/jo00022a015
   Rubiralta M., 1991, PIPERIDINE STRUCTURE
   Samanta D, 2009, J ORG CHEM, V74, P7183, DOI 10.1021/jo901195g
   Sano S, 2002, TETRAHEDRON LETT, V43, P281, DOI 10.1016/S0040-4039(01)02135-9
   SCHNEIDER MJ, 1996, ALKAL CHEM, V10, P155
   Tan KL, 2007, ANGEW CHEM INT EDIT, V46, P1315, DOI 10.1002/anie.200603354
   Tang T, 2005, SYNLETT, P231, DOI 10.1055/s-2004-837194
   Vilaivan T, 2005, J ORG CHEM, V70, P3464, DOI 10.1021/jo0477244
   Yus M, 2011, CHEM REV, V111, P7774, DOI 10.1021/cr1004474
NR 49
TC 5
Z9 5
U1 4
U2 19
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0040-4020
J9 TETRAHEDRON
JI Tetrahedron
PD SEP 2
PY 2012
VL 68
IS 35
BP 7050
EP 7055
DI 10.1016/j.tet.2012.06.061
PG 6
WC Chemistry, Organic
SC Chemistry
GA 983NT
UT WOS:000307126700006
DA 2018-12-27
ER

PT J
AU Ren, DP
   Bi, Q
   Li, L
   Gao, YQ
   Liang, Y
   Li, YJ
   Liu, J
   Peng, L
   Xiao, JH
AF Ren, Dongping
   Bi, Qi
   Li, Li
   Gao, Yongqiang
   Liang, Yu
   Li, Yingju
   Liu, Jun
   Peng, Li
   Xiao, Jianhua
TI RETRACTED: Myeloid-derived suppressor cells accumulate in the liver site
   after sepsis to induce immunosuppression (Retracted article. See vol.
   283, pg. 91, 2013)
SO CELLULAR IMMUNOLOGY
LA English
DT Article; Retracted Publication
DE CLP; Myeloid-derived suppressor cells; Sepsis; Immune suppression
ID PROGENITOR CELLS; CECAL LIGATION; T-CELLS; MECHANISM; DIFFERENTIATION;
   DYSFUNCTION; MONOCYTES; RESPONSES; PUNCTURE; EVASION
AB Myeloid-derived suppressor cells (MDSCs) play a major role in modulating immune response, but only a few reports focused on MDSCs in the liver of sepsis states. Here, we investigated the changes in MDSCs in liver of the cecal ligation and puncture (CLP) mice. The results of flow cytometry showed that MDSCs accumulate in the liver site of mice after CLP for 7 days (CLP7d model mice) and settled to the livers of both normal and LPS stimulated mice. In vitro experiment showed a strong suppressive effect of MDSCs on the proliferation of CD4+ T lymphocytes of spleen. Furthermore, adoptive transfer of the liver MDSCs from CLP7d miceincreased the survival rate of acute hepatic failure (AHF) model mice in vivo. In conclusion, our data suggest that sepsis-induced liver MDSCs may have exert a key role in maintaining the immune homoeostasis in liver during the sepsis state. (c) 2012 Elsevier Inc. All rights reserved.
C1 [Bi, Qi] Beijing Anzhen Hosp, Beijing 100092, Peoples R China.
EM jhxiao223@163.com
FU National Natural Science Foundation of China [30972576, 81101247];
   Scientific Research Fund of the scientific and technological department
   Hunan province [2010SK3038]
FX We thank professor Hui Zeng and PhD Xuming Guo for providing helpful
   discussion and critical reviews of this manuscript, as well as MD
   Zhongtao Du and PhD Beibei Wang for technical directions. This work was
   supported by the National Natural Science Foundation of China
   (No.30972576, No.81101247), Scientific Research Fund of the scientific
   and technological department Hunan province (No.2010SK3038).
CR Arora M, 2011, INT IMMUNOPHARMACOL, V11, P827, DOI 10.1016/j.intimp.2011.01.034
   Corzo CA, 2009, J IMMUNOL, V182, P5693, DOI 10.4049/jimmunol.0900092
   De Wilde V, 2009, AM J TRANSPLANT, V9, P2034, DOI 10.1111/j.1600-6143.2009.02757.x
   Delano MJ, 2007, J EXP MED, V204, P1463, DOI 10.1016/jem.20062602
   GABRILOVICH DI, 2007, CANCER RES, V67, P426
   Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506
   Gallina G, 2006, J CLIN INVEST, V116, P2777, DOI 10.1172/JCI28828
   Greifenberg V, 2009, EUR J IMMUNOL, V39, P2865, DOI 10.1002/eji.200939486
   Highfill SL, 2010, BLOOD, V116, P5738, DOI 10.1182/blood-2010-06-287839
   Huang B, 2006, CANCER RES, V66, P1123, DOI 10.1158/0008-5472CAN-05-1299
   Kusmartsev S, 2006, CANCER IMMUNOL IMMUN, V55, P237, DOI 10.1007/s00262-005-0048-z
   Lagasse E, 1996, J IMMUNOL METHODS, V197, P139, DOI 10.1016/0022-1759(96)00138-X
   Li HQ, 2009, J IMMUNOL, V182, P240, DOI 10.4049/jimmunol.182.1.240
   Maier S, 2004, SHOCK, V21, P505, DOI 10.1097/01.shk.0000126906.52367.dd
   Makarenkova VP, 2006, J IMMUNOL, V176, P2085, DOI 10.4049/jimmunol.176.4.2085
   Massberg S, 2007, CELL, V131, P994, DOI 10.1016/j.cell.2007.09.047
   Mazzoni A, 2002, J IMMUNOL, V168, P689, DOI 10.4049/jimmunol.168.2.689
   Morales JK, 2010, BREAST CANCER RES TR, V123, P39, DOI 10.1007/s10549-009-0622-8
   Quah BJC, 2007, NAT PROTOC, V2, P2049, DOI 10.1038/nprot.2007.296
   Rittirsch D, 2009, NAT PROTOC, V4, P31, DOI 10.1038/nprot.2008.214
   Sawanobori Y, 2008, BLOOD, V111, P5457, DOI 10.1182/blood-2008-01-136895
   Serafini P, 2008, CANCER RES, V68, P5439, DOI 10.1158/0008-5472.CAN-07-6621
   Sica A, 2007, J CLIN INVEST, V117, P1155, DOI 10.1172/JCI31422
   Sierra MD, 2010, BLOOD, V115, P3970, DOI 10.1182/blood-2009-10-246967
   Slaney CY, 2011, IMMUNOL CELL BIOL, V89, P7, DOI 10.1038/icb.2010.110
   Veltman JD, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-464
   Yang RC, 2006, CANCER RES, V66, P6807, DOI 10.1158/0008-5472.CAN-05-3755
   Zea AH, 2005, CANCER RES, V65, P3044, DOI 10.1158/0008-5472.CAN-04-4505
NR 28
TC 4
Z9 4
U1 4
U2 18
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0008-8749
J9 CELL IMMUNOL
JI Cell. Immunol.
PD SEP
PY 2012
VL 279
IS 1
BP 12
EP 20
DI 10.1016/j.cellimm.2012.08.005
PG 9
WC Cell Biology; Immunology
SC Cell Biology; Immunology
GA 080QU
UT WOS:000314259200002
PM 23026740
DA 2018-12-27
ER

PT J
AU Santander, S
   Alcaine, C
   Lyahyai, J
   Perez, MA
   Rodellar, C
   Doblare, M
   Ochoa, I
AF Santander, Sonia
   Alcaine, Clara
   Lyahyai, Jaber
   Angeles Perez, Maria
   Rodellar, Clementina
   Doblare, Manuel
   Ochoa, Ignacio
TI RETRACTED: In vitro osteoinduction of human mesenchymal stem cells in
   biomimetic surface modified titanium alloy implants (Retracted article.
   See vol. 33, pg. 148, 2014)
SO DENTAL MATERIALS JOURNAL
LA English
DT Article; Retracted Publication
DE Osteoinduction; Biomimetic surface; Titanium implant; Human mesenchymal
   stem cells; Combined surface treatment
ID OSTEOBLAST-LIKE CELLS; BONE SIALOPROTEIN; CBFA1 CONTRIBUTES;
   OSTEOPONTIN; ROUGHNESS; OSSEOINTEGRATION; DIFFERENTIATION; TOPOGRAPHY;
   EXPRESSION; RESPONSES
AB Interaction between cells and implant surface is crucial for clinical success. This interaction and the associated surface treatment are essential for achieving a fast osseointegration process. Several studies of different topographical or chemical surface modifications have been proposed previously in literature. The Biomimetic Advanced Surface (BAS) topography is a combination of a shot blasting and anodizing procedure. Macroroughness, microporosity of titanium oxide and Calcium/Phosphate ion deposition is obtained. Human mesenchymal stem cells (hMCSs) response in vitro to this treatment has been evaluated. The results obtained show an improved adhesion capacity and a higher proliferation rate when hMSCs are cultured on treated surfaces. This biomimetic modification of the titanium surface induces the expression of osteblastic differentiation markers (RUNX2 and Osteopontin) in the absence of any externally provided differentiation factor. As a main conclusion, our biomimetic surface modification could lead to a substantial improvement in osteoinduction in titanium alloy implants.
C1 [Santander, Sonia; Alcaine, Clara; Angeles Perez, Maria; Doblare, Manuel; Ochoa, Ignacio] Univ Zaragoza, Aragon Inst Engn Res, Grp Struct Mech & Mat Modelling GEMM, E-50009 Zaragoza, Spain.
   [Lyahyai, Jaber; Rodellar, Clementina] Univ Zaragoza, Aragon Inst Engn Res, Lagenbio Ingen, E-50009 Zaragoza, Spain.
EM iochgar@unizar.es
RI Lyahyai, Jaber/C-4341-2011; Ochoa, Ignacio/G-8776-2015; Perez, Maria
   Angeles/F-7584-2010
OI Ochoa, Ignacio/0000-0003-2410-5678; Perez, Maria
   Angeles/0000-0002-2901-4188; /0000-0001-8741-6452
FU Instituto de Salud Carlos III (ISCIII) through the CIBER initiative
FX This work was supported by the Instituto de Salud Carlos III (ISCIII)
   through the CIBER initiative. Titanium discs were unconditionally
   donated for this study by Avinent (Barcelona, Spain). The authors thank
   Lot-Oriel for their kind support in topographical characterization and
   also to Guillermo Antorrena and Carolina Prozzi for their technical
   support.
CR ALBREKTSSON T, 1981, ACTA ORTHOP SCAND, V52, P155, DOI 10.3109/17453678108991776
   Albrektsson T, 2004, INT J PROSTHODONT, V17, P544
   Albrektsson T, 2004, INT J PROSTHODONT, V17, P536
   Albrektsson T, 2001, EUR SPINE J, V10, pS96, DOI 10.1007/s005860100282
   Anselme K, 2006, J MATER SCI-MATER M, V17, P471, DOI 10.1007/s10856-006-8475-8
   Anselme K, 2002, J BIOMED MATER RES, V60, P529, DOI 10.1002/jbm.10101
   Banerjee C, 1996, P NATL ACAD SCI USA, V93, P4968, DOI 10.1073/pnas.93.10.4968
   Boyan BD, 1998, J BIOMED MATER RES, V39, P77, DOI 10.1002/(SICI)1097-4636(199801)39:1<77::AID-JBM10>3.0.CO;2-L
   Boyd AR, 2010, J MATER SCI-MATER M, V21, P2317, DOI 10.1007/s10856-009-3965-0
   Brunette D M, 1988, Int J Oral Maxillofac Implants, V3, P231
   Cheng ZK, 2008, CARDIOVASC DRUG THER, V22, P363, DOI 10.1007/s10557-008-6110-2
   Coelho PG, 2009, J BIOMED MATER RES B, V88B, P387, DOI 10.1002/jbm.b.31090
   Conserva E, 2010, INT J ORAL MAX IMPL, V25, P1099
   Damsky CH, 1999, BONE, V25, P95, DOI 10.1016/S8756-3282(99)00106-4
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3
   Ellingsen JE, 2004, INT J ORAL MAX IMPL, V19, P659
   Endres S, 2008, J MATER SCI-MATER M, V19, P1117, DOI 10.1007/s10856-007-3086-6
   Eriksson C, 2001, BIOMATERIALS, V22, P1987, DOI 10.1016/S0142-9612(00)00382-3
   Heo YY, 2010, ORAL DIS, V17, P320
   Hood JD, 2002, NAT REV CANCER, V2, P91, DOI 10.1038/nrc727
   Javed A, 2001, MOL CELL BIOL, V21, P2891, DOI 10.1128/MCB.21.8.2891-2905.2001
   Jayaraman M, 2004, BIOMATERIALS, V25, P625, DOI 10.1016/S0142-9612(03)00571-4
   Karsenty G, 1999, GENE DEV, V13, P3037, DOI 10.1101/gad.13.23.3037
   Kern B, 2001, J BIOL CHEM, V276, P7101, DOI 10.1074/jbc.M006215200
   Kieswetter K, 1996, J BIOMED MATER RES, V32, P55, DOI 10.1002/(SICI)1097-4636(199609)32:1<55::AID-JBM7>3.0.CO;2-O
   Komori T, 2008, FRONT BIOSCI-LANDMRK, V13, P898, DOI 10.2741/2730
   Komori T, 2010, CELL TISSUE RES, V339, P189, DOI 10.1007/s00441-009-0832-8
   Kurella A, 2005, J BIOMATER APPL, V20, P5, DOI 10.1177/0885328205052974
   Lamolle SF, 2009, BIOMATERIALS, V30, P736, DOI 10.1016/j.biomaterials.2008.10.052
   Lavenus S, 2010, INT J BIOMATER, V2010
   Le Guehennec L, 2007, DENT MATER, V23, P844, DOI 10.1016/j.dental.2006.06.025
   Llopis-Hernandez V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019610
   Malyankar UM, 1997, KIDNEY INT, V51, P1766, DOI 10.1038/ki.1997.243
   Mangano C, 2010, BIOMATERIALS, V31, P3543, DOI 10.1016/j.biomaterials.2010.01.056
   MARTIN JY, 1995, J BIOMED MATER RES, V29, P389, DOI 10.1002/jbm.820290314
   McKee MD, 1996, MICROSC RES TECHNIQ, V33, P141, DOI 10.1002/(SICI)1097-0029(19960201)33:2<141::AID-JEMT5>3.0.CO;2-W
   McKee MD, 1996, J BONE MINER RES, V11, P873
   Meirelles L, 2008, J BIOMED MATER RES A, V87A, P624, DOI 10.1002/jbm.a.31736
   Meirelles L, 2008, J BIOMED MATER RES A, V87A, P299, DOI 10.1002/jbm.a.31744
   Monjo M, 2008, BIOMATERIALS, V29, P3771, DOI 10.1016/j.biomaterials.2008.06.001
   Nayab SN, 2007, J BIOMED MATER RES A, V83A, P296, DOI 10.1002/jbm.a.31218
   Omar O, 2010, J MATER SCI-MATER M, V21, P969
   Park JW, 2009, ACTA BIOMATER, V5, P3272, DOI 10.1016/j.actbio.2009.04.038
   PORTER JA, 2005, GEN DENT, V53, P433
   PORTER JA, 2005, GEN DENT, V53, P446
   Porter Judith A, 2005, Gen Dent, V53, P423
   PULEO DA, 1991, J BIOMED MATER RES, V25, P711, DOI 10.1002/jbm.820250603
   Puleo DA, 1999, BIOMATERIALS, V20, P2311, DOI 10.1016/S0142-9612(99)00160-X
   Qu J, 1996, Oral Dis, V2, P102
   Raines AL, 2010, BIOMATERIALS, V31, P4909, DOI 10.1016/j.biomaterials.2010.02.071
   ROSS FP, 1993, J BIOL CHEM, V268, P9901
   Roynesdal AK, 1998, INT J ORAL MAX IMPL, V13, P500
   Schwartz Z, 1999, Adv Dent Res, V13, P38
   Sul YT, 2005, BIOMATERIALS, V26, P6720, DOI 10.1016/j.biomaterials.2005.04.058
   Thirunavukkarasu K, 2000, J BIOL CHEM, V275, P25163, DOI 10.1074/jbc.M000322200
   Wall I, 2009, BONE, V45, P17, DOI 10.1016/j.bone.2009.03.662
   Yang YZ, 2005, BIOMATERIALS, V26, P327, DOI 10.1016/j.biomaterials.2004.02.029
   Zhang F, 2010, J ORAL MAXIL SURG, V68, P1131, DOI 10.1016/j.joms.2009.12.027
   Zhu XL, 2004, BIOMATERIALS, V25, P4087, DOI 10.1016/j.biomaterials.2003.11.011
NR 59
TC 6
Z9 8
U1 2
U2 34
PU JAPANESE SOC DENTAL MATERIALS DEVICES
PI TOKYO
PA C/O KOKU HOKEN KYOKAI, 1-43-9 KOMAGOME TS BDG, KOMAGOME, TOSHIMA-KU,
   TOKYO, 170-0003, JAPAN
SN 0287-4547
J9 DENT MATER J
JI Dent. Mater. J.
PD SEP
PY 2012
VL 31
IS 5
BP 843
EP 850
DI 10.4012/dmj.2012-015
PG 8
WC Dentistry, Oral Surgery & Medicine; Materials Science, Biomaterials
SC Dentistry, Oral Surgery & Medicine; Materials Science
GA 055PQ
UT WOS:000312429300019
PM 23037849
OA Bronze
DA 2018-12-27
ER

PT J
AU Boonanantanasarn, K
   Janebodin, K
   Suppakpatana, P
   Arayapisit, T
   Rodsutthi, JA
   Chunhabundit, P
   Boonanuntanasarn, S
   Sripairojthikoon, W
AF Boonanantanasarn, Kanitsak
   Janebodin, Kajohnkiart
   Suppakpatana, Prapan
   Arayapisit, Tawepong
   Rodsutthi, Jit-aree
   Chunhabundit, Panjit
   Boonanuntanasarn, Surintorn
   Sripairojthikoon, Wanida
TI RETRACTED: Morinda citrifolia leaves enhance osteogenic differentiation
   and mineralization of human periodontal ligament cells (Retracted
   article. See vol. 33, pg. 149, 2014)
SO DENTAL MATERIALS JOURNAL
LA English
DT Article; Retracted Publication
DE Morinda citrifolia; Osteogenic differentiation; Mineralization;
   Periodontal ligament cells
ID EXTRACELLULAR-MATRIX PROTEINS; IN-VITRO; ALKALINE-PHOSPHATASE; NONI
   FRUIT; REGENERATION; NODULES; BONE; RAT; FIBROBLASTS; EXPRESSION
AB This present study investigated the potential of Morinda citrifolia leaf aqueous extract to induce osteogenic differentiation and matrix mineralization of human periodontal ligament (hPDL) cells. Human periodontal ligament cells were cultured in complete medium, ascorbic acid with beta-glycerophosphate, or Morinda citrifolia leaf aqueous extract. Morinda citrifolia leaf aqueous extract significantly increased alkaline phosphatase activity compared to culturing in complete medium or ascorbic acid with p-glycerophosphate. Matrix-containing mineralized nodules were formed only when the cells were cultured in the presence of Morinda citrifolia leaf aqueous extract. These nodules showed positive alizarin red S staining and were rich in calcium and phosphorus according to energy dispersive X-ray analysis. In conclusion, Morinda citrifolia leaf extract promoted osteogenic differentiation and matrix mineralization in human periodontal ligament cells, a clear indication of the therapeutic potential of Moraida citrifolia leaves in bone and periodontal tissue regeneration.
C1 [Boonanantanasarn, Kanitsak; Janebodin, Kajohnkiart; Suppakpatana, Prapan; Arayapisit, Tawepong; Rodsutthi, Jit-aree; Chunhabundit, Panjit; Sripairojthikoon, Wanida] Mahidol Univ, Dept Anat, Fac Dent, Bangkok 10400, Thailand.
   [Boonanantanasarn, Kanitsak] SUNY Buffalo, Sch Dent Med, Dept Oral Biol, Buffalo, NY 14214 USA.
   [Boonanuntanasarn, Surintorn] Suranaree Univ Technol, Inst Agr Technol, Nakhon Ratchasima 30000, Thailand.
RP Boonanantanasarn, K (reprint author), Mahidol Univ, Dept Anat, Fac Dent, Bangkok 10400, Thailand.
EM dtkba@mahidol.ac.th
FU Faculty of Dentistry. Mahidol University, Bangkok, Thailand
FX The authors would like to thank Associate Professor R. Surarit (Mahidol
   University) for the donation of MC3T3-E1 cells used in this study. The
   authors also thank Drs. S.R. Gill, R. Dziak (The State University of New
   York at Buffalo), and B. Foster (University of Washington) for kindly
   reviewing this manuscript. This study was supported by funding from the
   Faculty of Dentistry. Mahidol University, Bangkok, Thailand.
CR Akihisa T, 2007, CHEM BIODIVERS, V4, P224, DOI 10.1002/cbdv.200790027
   Al-Jallad HF, 2006, MATRIX BIOL, V25, P135, DOI 10.1016/j.matbio.2005.11.001
   ARONOW MA, 1990, J CELL PHYSIOL, V143, P213, DOI 10.1002/jcp.1041430203
   BELLOWS CG, 1991, BONE MINER, V14, P27, DOI 10.1016/0169-6009(91)90100-E
   Chen FM, 2010, TISSUE ENG PART B-RE, V16, P219, DOI [10.1089/ten.teb.2009.0562, 10.1089/ten.TEB.2009.0562]
   Chien HH, 1999, J PERIODONTAL RES, V34, P301, DOI 10.1111/j.1600-0765.1999.tb02258.x
   CHO MI, 1992, CALCIFIED TISSUE INT, V50, P459, DOI 10.1007/BF00296778
   CHUNG CH, 1992, CALCIFIED TISSUE INT, V51, P305, DOI 10.1007/BF00334492
   Deng SX, 2007, J NAT PROD, V70, P859, DOI 10.1021/np0605539
   Dong G, 2001, Hua Xi Kou Qiang Yi Xue Za Zhi, V19, P146
   GERLIER D, 1986, J IMMUNOL METHODS, V94, P57, DOI 10.1016/0022-1759(86)90215-2
   Han X, 2003, J DENT RES, V82, P454, DOI 10.1177/154405910308200610
   Hirazumi A, 1996, P W PHARMACOL SOC, V39, P7
   Isaka J, 2001, J PERIODONTOL, V72, P314, DOI 10.1902/jop.2001.72.3.314
   Kawase T, 2005, IN VITRO CELL DEV-AN, V41, P171, DOI 10.1290/0502013.1
   Lekic P, 2001, J PERIODONTAL RES, V36, P71, DOI 10.1034/j.1600-0765.2001.360202.x
   LOWRY OH, 1954, J BIOL CHEM, V207, P19
   MAILHOT JM, 1995, J CLIN PERIODONTOL, V22, P679, DOI 10.1111/j.1600-051X.1995.tb00826.x
   McClatchey Will, 2002, Integr Cancer Ther, V1, P110, DOI 10.1177/1534735402001002002
   Morishita M, 1999, J CLIN PERIODONTOL, V26, P748, DOI 10.1034/j.1600-051X.1999.t01-7-261101.x
   Murakami Y, 2003, J PERIODONTOL, V74, P780, DOI 10.1902/jop.2003.74.6.780
   Nayak BS, 2009, EVID-BASED COMPL ALT, V6, P351, DOI 10.1093/ecam/nem127
   Nohutcu RM, 1997, J PERIODONTOL, V68, P320, DOI 10.1902/jop.1997.68.4.320
   Ohno S, 2002, J DENT RES, V81, P822, DOI 10.1177/154405910208101205
   Orciani M, 2009, ACTA HISTOCHEM, V111, P15, DOI 10.1016/j.acthis.2008.02.005
   Ouyang HJ, 2000, ARCH ORAL BIOL, V45, P293, DOI 10.1016/S0003-9969(99)00142-9
   Parikh S N, 2002, J Postgrad Med, V48, P142
   Pihlstrom BL, 2005, LANCET, V366, P1809, DOI 10.1016/S0140-6736(05)67728-8
   Potterat O, 2007, PLANTA MED, V73, P191, DOI 10.1055/s-2007-967115
   QUARLES LD, 1992, J BONE MINER RES, V7, P683
   Raja S, 2009, INT J DENT HYG, V7, P82, DOI 10.1111/j.1601-5037.2009.00380.x
   RAMAKRISHNAN PR, 1995, CALCIFIED TISSUE INT, V57, P52, DOI 10.1007/BF00298997
   Rodrigues TLS, 2007, J CLIN PERIODONTOL, V34, P514, DOI 10.1111/j.1600-051X.2007.01090.x
   Sant'Ana ACP, 2007, J PERIODONTOL, V78, P2007, DOI 10.1902/jop.2007.070119
   Shimono M, 2003, MICROSC RES TECHNIQ, V60, P491, DOI 10.1002/jemt.10290
   Suh N, 2003, CANCER RES, V63, P1371
   Sukumar Sujith, 2008, Acta Medica (Hradec Kralove), V51, P203
   Taba M Jr, 2005, Orthod Craniofac Res, V8, P292
   Wang MY, 2002, ACTA PHARMACOL SIN, V23, P1127
   West BJ, 2009, J NAT MED, V63, P351, DOI 10.1007/s11418-009-0327-7
   Zhang JF, 2010, MOL CELL ENDOCRINOL, V314, P70, DOI 10.1016/j.mce.2009.08.012
   Zhao M, 2003, J DENT RES, V82, P23, DOI 10.1177/154405910308200106
NR 42
TC 3
Z9 3
U1 3
U2 18
PU JAPANESE SOC DENTAL MATERIALS DEVICES
PI TOKYO
PA C/O KOKU HOKEN KYOKAI, 1-43-9 KOMAGOME TS BDG, KOMAGOME, TOSHIMA-KU,
   TOKYO, 170-0003, JAPAN
SN 0287-4547
J9 DENT MATER J
JI Dent. Mater. J.
PD SEP
PY 2012
VL 31
IS 5
BP 863
EP 871
DI 10.4012/dmj.2012-053
PG 9
WC Dentistry, Oral Surgery & Medicine; Materials Science, Biomaterials
SC Dentistry, Oral Surgery & Medicine; Materials Science
GA 055PQ
UT WOS:000312429300022
PM 23037852
OA Bronze
DA 2018-12-27
ER

PT J
AU Gao, XG
   Han, JB
   Lu, ZC
   Li, YF
   He, CB
AF Gao, Xianggang
   Han, Jiabo
   Lu, Zhichuang
   Li, Yunfeng
   He, Chongbo
TI RETRACTED: Characterization of the spotted seal Phoca largha
   transcriptome using Illumina paired-end sequencing and development of
   SSR markers (Retracted article. See vol. 8, pg. 163, 2013)
SO COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY D-GENOMICS & PROTEOMICS
LA English
DT Article; Retracted Publication
DE Spotted seal (Phoca largha); Illumina paired-end sequencing; Expressed
   sequence tag (EST); Simple sequence repeat (SSR); Pinniped
ID GENE-EXPRESSION; RNA-SEQ; SKIN TRANSCRIPTOME; POPULATION; GENOME;
   TECHNOLOGIES; POLYMORPHISM; DISCOVERY; HOKKAIDO; VITULINA
AB Next-generation sequencing provides a powerful new approach for developing functional genomic tools for non-model species. This study aims to investigate the spotted seal (Phoca largha) transcriptome by the approach of Illumina paired-end sequencing technology. We obtained a total of 52,146,394 reads for the mixed tissues of liver and spleen from spotted seal. The de novo assemblies yielded 354,014 contigs and 178,466 unigenes. In addition, bioinformatics analysis revealed a total of 4425 simple sequence repeats (SSRs). Fifty SSRs were randomly selected to validate amplification and determine the degree of polymorphism in the genomic DNA pools. Thirty-five primer pairs successfully amplified expected DNA fragments and detected significant polymorphism among 28 spotted seal individuals. These results contribute to the understanding of the genetic makeup of spotted seal transcriptome and provide useful information for functional genomic research in this species. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Gao, Xianggang; Han, Jiabo; Lu, Zhichuang; Li, Yunfeng; He, Chongbo] Liaoning Ocean & Fisheries Sci Res Inst, Dalian 116023, Liaoning, Peoples R China.
   [Gao, Xianggang; Han, Jiabo; Li, Yunfeng; He, Chongbo] Key Lab Marine Fishery Mol Biol, Dalian 116023, Liaoning, Peoples R China.
RP Han, JB (reprint author), Liaoning Ocean & Fisheries Sci Res Inst, Dalian 116023, Liaoning, Peoples R China.
EM jbhan@sina.com; hechongbo@hotmail.com
FU Liaoning Scientific Research Program of Ocean and Fisheries Department
   [200920]; Public Science and Technology Research Funds Projects of Ocean
   [201105011]; National Natural Science Foundation of China [30972246]
FX This work was supported by grants from the Liaoning Scientific Research
   Program of Ocean and Fisheries Department (No. 200920), the Public
   Science and Technology Research Funds Projects of Ocean (No. 201105011)
   and the National Natural Science Foundation of China (No. 30972246).
CR Bahn SY, 2009, MITOCHONDR DNA, V20, P105, DOI 10.3109/19401730903137070
   Collins LJ, 2008, GENOME INFORM SER, V21, P3
   Conesa A, 2005, BIOINFORMATICS, V21, P3674, DOI 10.1093/bioinformatics/bti610
   Englbrecht CC, 2000, MOL ECOL, V9, P709, DOI 10.1046/j.1365-294x.2000.00912.x
   Gavery MR, 2012, COMP BIOCHEM PHYS D, V7, P94, DOI 10.1016/j.cbd.2011.12.003
   Grabherr MG, 2011, NAT BIOTECHNOL, V29, P644, DOI 10.1038/nbt.1883
   Han Jia-bo, 2007, Fisheries Science (Liaoning), V26, P74
   Han JB, 2010, ANN ZOOL FENN, V47, P15, DOI 10.5735/086.047.0102
   [韩家波 Han Jiabo], 2005, [海洋环境科学, Marine Environmental Science], V24, P51
   Hegedus Z, 2009, MOL IMMUNOL, V46, P2918, DOI 10.1016/j.molimm.2009.07.002
   Hoffman JI, 2011, MOL ECOL RESOUR, V11, P703, DOI 10.1111/j.1755-0998.2011.02999.x
   Huang WC, 2008, GENOME RES, V18, P1538, DOI 10.1101/gr.076067.108
   Ierardi JL, 2009, COMP BIOCHEM PHYS D, V4, P154, DOI 10.1016/j.cbd.2009.01.004
   Iseli C, 1999, Proc Int Conf Intell Syst Mol Biol, P138
   Li HJ, 2010, AQUAT BIOL, V11, P193, DOI 10.3354/ab00308
   Li HJ, 2011, MOL BIOL REP, V38, P769, DOI 10.1007/s11033-010-0165-4
   Li HJ, 2011, J GENET, V90, pE30
   Li L., 2006, GENOME RES, V16, P1
   Li RQ, 2010, GENOME RES, V20, P265, DOI 10.1101/gr.097261.109
   Li RQ, 2010, NATURE, V463, P311, DOI 10.1038/nature08696
   Li X., 2010, TRENDS EVOL BIOL, V1, P33
   Liu WD, 2011, J WORLD AQUACULT SOC, V42, P456, DOI 10.1111/j.1749-7345.2011.00486.x
   Liu ZJ, 2004, AQUACULTURE, V238, P1, DOI 10.1016/j.aquaculture.2004.05.027
   Mancia A, 2007, DEV COMP IMMUNOL, V31, P520, DOI 10.1016/j.dci.2006.07.011
   Mizuno AW, 2003, ZOOL SCI, V20, P783, DOI 10.2108/zsj.20.783
   Mortazavi A, 2008, NAT METHODS, V5, P621, DOI 10.1038/nmeth.1226
   Nakagawa E, 2010, ZOOL SCI, V27, P263, DOI 10.2108/zsj.27.263
   Rosenkranz R, 2008, GENOMICS, V92, P187, DOI 10.1016/j.ygeno.2008.05.011
   Santure AW, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-283
   SHAUGHNESSY PD, 1977, J ZOOL, V182, P385
   Shen YJ, 2012, COMP BIOCHEM PHYS C, V155, P102, DOI 10.1016/j.cbpc.2011.03.012
   SLADE RW, 1992, P ROY SOC B-BIOL SCI, V249, P163, DOI 10.1098/rspb.1992.0099
   Sun L, 2011, COMP BIOCHEM PHYS D, V6, P195, DOI 10.1016/j.cbd.2011.03.002
   Uccelli A, 1997, J IMMUNOL, V158, P1201
   Vera JC, 2008, MOL ECOL, V17, P1636, DOI 10.1111/j.1365-294X.2008.03666.x
   Wang B, 2010, NUCLEIC ACIDS RES, V38, P5075, DOI 10.1093/nar/gkq256
   Wang S, 1998, CHINA RED DATA BOOK
   Wang XW, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-400
   Wei WL, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-451
   Whitehead A, 2003, MOL ECOL, V12, P2817, DOI 10.1046/j.1365-294X.2003.01933.x
   Won C, 2004, ORYX, V38, P109, DOI 10.1017/S0030605304000171
   Ye J, 2006, NUCLEIC ACIDS RES, V34, pW293, DOI 10.1093/nar/gkl1031
   Yeh F.C., 2000, POPGENE 32 MICROSOFT
   Zhang Ting, 2011, Acta Theriologica Sinica, V31, P219
NR 44
TC 8
Z9 11
U1 4
U2 36
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1744-117X
EI 1878-0407
J9 COMP BIOCHEM PHYS D
JI Comp. Biochem. Physiol. D-Genomics Proteomics
PD SEP
PY 2012
VL 7
IS 3
BP 277
EP 284
DI 10.1016/j.cbd.2012.05.001
PG 8
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 996SU
UT WOS:000308115900007
PM 22677091
DA 2018-12-27
ER

PT J
AU El-Hashash, AHK
   Turcatel, G
   Varma, S
   Berika, M
   Al Alam, D
   Warburton, D
AF El-Hashash, Ahmed H. K.
   Turcatel, Gianluca
   Varma, Saaket
   Berika, Mohamed
   Al Alam, Denise
   Warburton, David
TI RETRACTED: Eya1 protein phosphatase regulates tight junction formation
   in lung distal epithelium (Retracted article. See vol. 130, pg. 3601,
   2017)
SO JOURNAL OF CELL SCIENCE
LA English
DT Article; Retracted Publication
DE Eya1; Tight junction; Lung; aPKC zeta; Notch1
ID KINASE-C ACTIVATION; EMBRYONIC LUNG; BRANCHING MORPHOGENESIS; SPINDLE
   ORIENTATION; E-CADHERIN; CELL-FATE; MAP KINASE; COMPLEX;
   PHOSPHORYLATION; POLARITY
AB Little is known about the regulatory mechanisms underlying lung epithelial tight junction (TJ) assembly, which is inextricably linked to the preservation of epithelial polarity, and is highly coordinated by proteins that regulate epithelial cell polarity, such as aPKC zeta. We recently reported that Eya1 phosphatase functions through aPKC zeta-Notch1 signaling to control cell polarity in the lung epithelium. Here, we have extended these observations to TJ formation to demonstrate that Eya1 is crucial for the maintenance of TJ protein assembly in the lung epithelium, probably by controlling aPKC zeta phosphorylation levels, aPKC zeta-mediated TJ protein phosphorylation and Notch1-Cdc42 activity. Thus, TJs are disassembled after interfering with Eya1 function in vivo or during calcium-induced TJ assembly in vitro. These effects are reversed by reintroduction of wild-type Eya1 or partially inhibiting aPKC zeta in Eya1siRNA cells. Moreover, genetic activation of Notch1 rescues Eya1(-/-) lung epithelial TJ defects. These findings uncover novel functions for the Eya1-aPKC zeta-Notch1-Cdc42 pathway as a crucial regulatory mechanism of TJ assembly and polarity of the lung epithelium, providing a conceptual framework for future mechanistic and translational studies in this area.
C1 [El-Hashash, Ahmed H. K.; Turcatel, Gianluca; Varma, Saaket; Al Alam, Denise; Warburton, David] Childrens Hosp Los Angeles, Saban Res Inst, Dev Biol & Regenerat Med Program, Los Angeles, CA 90027 USA.
   [El-Hashash, Ahmed H. K.; Al Alam, Denise; Warburton, David] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA.
   [Berika, Mohamed] Mansoura Univ, Fac Med, Dept Anat, Mansoura, Egypt.
   [Berika, Mohamed] King Saud Univ, Coll Appl Med Sci, Rehabil Res Chair, Riyadh 11451, Saudi Arabia.
RP El-Hashash, AHK (reprint author), Childrens Hosp Los Angeles, Saban Res Inst, Dev Biol & Regenerat Med Program, 4661 Sunset Blvd, Los Angeles, CA 90027 USA.
EM aelhashash@chla.usc.edu; dwarburton@chla.usc.edu
RI Turcatel, Gianluca/P-5369-2014
FU National Institutes of Health National Heart, Lung and Blood Institute
   [P01 HL 60231, RO1 HL 44060, RO1 HL44977, RO1 HL104258]; National
   Institute of General Medicine [GM096195]; California Institute for
   Regenerative Medicine [TG2-01168]; Pasadena Guild Endowment; Webb
   Foundation; Garland Foundation; American Heart Association National
   Scientist Development [12SDG12120007]
FX This work was supported by National Institutes of Health National Heart,
   Lung and Blood Institute [grant numbers P01 HL 60231 to D. W., RO1s HL
   44060 to D. W., HL44977 to D. W., HL104258 to D. W.]; National Institute
   of General Medicine [grant number GM096195 to D. W.]; the California
   Institute for Regenerative Medicine [grant number TG2-01168 to A. H.
   E.]; the Pasadena Guild Endowment; the Webb Foundation; the Garland
   Foundation; and the American Heart Association National Scientist
   Development [grant number 12SDG12120007 to A. H. E.]. Deposited in PMC
   for release after 12 months.
CR Bruewer M, 2004, AM J PHYSIOL-CELL PH, V287, pC327, DOI 10.1152/ajpcell.00087.2004
   Buckley S, 2005, AM J PHYSIOL-LUNG C, V288, pL569, DOI 10.1152/ajplung.00278.2004
   Buteau J, 2001, DIABETES, V50, P2237, DOI 10.2337/diabetes.50.10.2237
   Carraro G, 2009, DEV BIOL, V333, P238, DOI 10.1016/j.ydbio.2009.06.020
   Cereijido M, 2000, AM J PHYSIOL-GASTR L, V279, pG477
   Chabu C, 2009, DEV BIOL, V330, P399, DOI 10.1016/j.ydbio.2009.04.014
   Chapman G, 2006, J CELL BIOL, V175, P535, DOI 10.1083/jcb.200602009
   Chen JH, 2006, MOL ENDOCRINOL, V20, P3293, DOI 10.1210/me.2006-0293
   Clarke H, 2000, EXP CELL RES, V261, P239, DOI 10.1006/excr.2000.5035
   Clarke H, 2000, J CELL SCI, V113, P3187
   Cook PJ, 2009, NATURE, V458, P591, DOI 10.1038/nature07849
   Dahan S, 2011, GASTROENTEROLOGY, V140, P550, DOI 10.1053/j.gastro.2010.10.057
   Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095
   del Moral PM, 2006, DEV BIOL, V293, P77, DOI 10.1016/j.ydbio.2006.01.020
   Del Moral PM, 2006, DEV BIOL, V290, P177, DOI 10.1016/j.ydbio.2005.11.022
   Dho SE, 2006, MOL BIOL CELL, V17, P4142, DOI 10.1091/mbc.E06-02-0097
   Dontu G, 2004, BREAST CANCER RES, V6, pR605, DOI 10.1186/bcr920
   DUTIL EM, 1994, J BIOL CHEM, V269, P29359
   Dutil EM, 1998, CURR BIOL, V8, P1366, DOI 10.1016/S0960-9822(98)00017-7
   El-Hashash AHK, 2006, DEV BIOL, V290, P13, DOI 10.1016/j.ydbio.2005.10.010
   El-Hashash AHK, 2005, DIFFERENTIATION, V73, P154, DOI 10.1111/j.1432-0436.2005.00013.x
   El-Hashash AHK, 2011, DEVELOPMENT, V138, P1395, DOI 10.1242/dev.058479
   El-Hashash AHK, 2011, DEV BIOL, V350, P112, DOI 10.1016/j.ydbio.2010.11.022
   Endo M, 2009, J BIOL CHEM, V284, P5107, DOI 10.1074/jbc.M807745200
   Farshori P, 1999, J MEMBRANE BIOL, V170, P147, DOI 10.1007/s002329900544
   Feigin ME, 2009, CURR OPIN CELL BIOL, V21, P694, DOI 10.1016/j.ceb.2009.07.003
   Fougerousse F, 2002, J MUSCLE RES CELL M, V23, P255, DOI 10.1023/A:1020990825644
   GONZALEZMARISCAL L, 1990, AM J PHYSIOL, V259, pC978
   Gopalakrishnan S, 1998, AM J PHYSIOL-CELL PH, V275, pC798, DOI 10.1152/ajpcell.1998.275.3.C798
   Hirai T, 2003, J BIOCHEM, V133, P1, DOI 10.1093/jb/mvg017
   Hirose T, 2002, J CELL SCI, V115, P2485
   Hsu SC, 1999, TRENDS CELL BIOL, V9, P150, DOI 10.1016/S0962-8924(99)01516-0
   Jaffe AB, 2008, J CELL BIOL, V183, P625, DOI 10.1083/jcb.200807121
   Jenic J, 2007, ANNU REV BIOCHEM, V76, P513, DOI 10.1146/annurev.biochem.76.052705.164916
   Kim SH, 2000, J BIOL CHEM, V275, P36999, DOI 10.1074/jbc.M003430200
   KOZMA R, 1995, MOL CELL BIOL, V15, P1942
   LIMATOLA C, 1994, BIOCHEM J, V304, P1001, DOI 10.1042/bj3041001
   Lipschutz JH, 2002, CURR BIOL, V12, pR212, DOI 10.1016/S0960-9822(02)00753-4
   Lum H, 2001, AM J PHYSIOL-LUNG C, V281, pL546
   Mazzon E, 2007, RESP RES, V8, DOI 10.1186/1465-9921-8-75
   Niessen CM, 2007, J INVEST DERMATOL, V127, P2525, DOI 10.1038/sj.jid.5700865
   Nunbhakdi-Craig V, 2002, J CELL BIOL, V158, P967, DOI 10.1083/jcb.200206114
   Ohno S, 2001, CURR OPIN CELL BIOL, V13, P641, DOI 10.1016/S0955-0674(00)00264-7
   Pandey RN, 2010, ONCOGENE, V29, P3715, DOI 10.1038/onc.2010.122
   Perl AKT, 2002, P NATL ACAD SCI USA, V99, P10482, DOI 10.1073/pnas.152238499
   Sakakibara A, 1997, J CELL BIOL, V137, P1393, DOI 10.1083/jcb.137.6.1393
   Schwamborn JC, 2004, NAT NEUROSCI, V7, P923, DOI 10.1038/nn1295
   Seth A, 2007, J BIOL CHEM, V282, P11487, DOI 10.1074/jbc.M610597200
   Shin K, 2006, ANNU REV CELL DEV BI, V22, P207, DOI 10.1146/annurev.cellbio.22.010305.104219
   Siller KH, 2009, NAT CELL BIOL, V11, P365, DOI 10.1038/ncb0409-365
   Smith CA, 2007, EMBO J, V26, P468, DOI 10.1038/sj.embro.7601495
   Soini Y, 2011, RESP RES, V12, DOI 10.1186/1465-9921-12-70
   Song JC, 2001, AM J PHYSIOL-CELL PH, V281, pC649
   Sontag JM, 2006, CELL MOL LIFE SCI, V63, P2979, DOI 10.1007/s00018-006-6300-7
   STUART RO, 1995, P NATL ACAD SCI USA, V92, P6072, DOI 10.1073/pnas.92.13.6072
   Suzuki A, 2002, J CELL SCI, V115, P3565, DOI 10.1242/jcs.00032
   Suzuki A, 2001, J CELL BIOL, V152, P1183, DOI 10.1083/jcb.152.6.1183
   Tefft D, 2005, DEV BIOL, V282, P422, DOI 10.1016/j.ydbio.2005.03.022
   Tefft D, 2002, AM J PHYSIOL-LUNG C, V283, pL700, DOI 10.1152/ajplung.00372.2001
   Tsukita S, 2001, NAT REV MOL CELL BIO, V2, P285, DOI 10.1038/35067088
   Tsukita S, 2008, ONCOGENE, V27, P6930, DOI 10.1038/onc.2008.344
   Xiong WJ, 2009, DEV CELL, V16, P271, DOI 10.1016/j.devcel.2008.12.005
   Xu PX, 1999, NAT GENET, V23, P113
   Xu PX, 2002, DEVELOPMENT, V129, P3033
   Yamanaka T, 2001, GENES CELLS, V6, P721, DOI 10.1046/j.1365-2443.2001.00453.x
   Yang XD, 2004, DEV BIOL, V269, P81, DOI 10.1016/j.ydbio.2004.01.014
   Zou D, 2004, DEVELOPMENT, V131, P5561, DOI 10.1242/dev.01437
NR 67
TC 9
Z9 9
U1 3
U2 5
PU COMPANY OF BIOLOGISTS LTD
PI CAMBRIDGE
PA BIDDER BUILDING CAMBRIDGE COMMERCIAL PARK COWLEY RD, CAMBRIDGE CB4 4DL,
   CAMBS, ENGLAND
SN 0021-9533
EI 1477-9137
J9 J CELL SCI
JI J. Cell Sci.
PD SEP 1
PY 2012
VL 125
IS 17
BP 4036
EP 4048
DI 10.1242/jcs.102848
PG 13
WC Cell Biology
SC Cell Biology
GA 030PJ
UT WOS:000310582300013
PM 22685326
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Yang, SZ
   Xie, N
   Cui, HC
   Banerjee, S
   Abraham, E
   Thannickal, VJ
   Liu, G
AF Yang, Shanzhong
   Xie, Na
   Cui, Huachun
   Banerjee, Sami
   Abraham, Edward
   Thannickal, Victor J.
   Liu, Gang
TI RETRACTED: miR-31 is a negative regulator of fibrogenesis and pulmonary
   fibrosis (Retracted article. See vol. 27, pg. 843, 2013)
SO FASEB JOURNAL
LA English
DT Article; Retracted Publication
DE fibroblasts; RhoA; integrin; alpha(5); contraction; migration
ID HUMAN LUNG FIBROBLASTS; MESENCHYMAL TRANSITION; GROWTH-FACTOR;
   TRANSFORMING GROWTH-FACTOR-BETA-1; MYOFIBROBLAST DIFFERENTIATION;
   MICRORNAS; ACTIVATION; BETA; EXPRESSION; TGF-BETA-1
AB Aberrant expression of miRNAs is closely associated with initiation and progression of pathological processes, including diabetes, cancer, and cardiovascular disease. However, the role of miRNAs in lung fibrosis is not well characterized. We sought to determine the role of miR-31 in regulating the fibrogenic, contractile, and migratory activities of lung fibroblasts and modulating of pulmonary fibrosis in vivo. In vivo lung fibrosis models and ex vivo cell culture systems were employed. Real-time PCR and Western blot analysis were used to determine gene expression levels. miR-31 mimics or inhibitors were transfected into pulmonary fibroblasts. Fibrogenic, contractile, and migratory activities of lung fibroblasts were determined. We found that miR-31 expression is reduced in the lungs of mice with experimental pulmonary fibrosis and in IPF fibroblasts. miR-31 inhibits the profibrotic activity of TGF-beta 1 in normal lung fibroblasts and diminishes the fibrogenic, contractile, and migratory activities of IPF fibroblasts. In these experiments, miR-31 was shown to directly target integrin alpha(5) and RhoA, two proteins that have been shown to regulate activation of fibroblasts. We found that levels of integrin alpha(5) and RhoA are up-regulated in fibrotic mouse lungs. Knockdown of integrin alpha(5) and RhoA attenuated fibrogenic, contractile, and migratory activities of IPF fibroblasts, in a manner similar to that observed with miR-31. We also found that introduction of miR-31 ameliorated experimental lung fibrosis in mice. Our data suggest that miR-31 is an important regulator of the pathological activities of lung fibroblasts and may be a potential target in the development of novel therapies to treat pathological fibrotic disorders, including pulmonary fibrosis.-Yang, S., Xie, N., Cui, H., Banerjee, S., Abraham, E., Thannickal, V. J., Liu, G. miR-31 is a negative regulator of fibrogenesis and pulmonary fibrosis. FASEB J. 26, 3790-3799 (2012). www.fasebj.org
C1 [Yang, Shanzhong; Xie, Na; Cui, Huachun; Banerjee, Sami; Thannickal, Victor J.; Liu, Gang] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA.
   [Abraham, Edward] Wake Forest Sch Med, Winston Salem, NC USA.
RP Liu, G (reprint author), Univ Alabama Birmingham, Dept Med, 901 19th St So,BMR 2 233, Birmingham, AL 35294 USA.
EM gliu@uab.edu
OI , Gang/0000-0002-6999-7633; Liu, Gang/0000-0003-2615-131X
FU U.S. National Institutes of Health [HL105473, HL097218, HL076206,
   HL067967, HL10781]; American Heart Association [10SDG4210009]
FX This work was supported by U.S. National Institutes of Health grants
   HL105473, HL097218, and HL076206 (to G. L.); HL067967 and HL10781 (to
   V.J.T.); and by American Heart Association award 10SDG4210009 (to G.
   L.). Author contributions: conception and design: G. L.; analysis and
   interpretation: S.Y., S. B., E. A., and G. L.; drafting the manuscript
   for important intellectual content: S.Y., N.X., H. C., V.J.T., E. A.,
   and G.L.
CR Ambros V, 2001, CELL, V107, P823, DOI 10.1016/S0092-8674(01)00616-X
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Bushati N, 2007, ANNU REV CELL DEV BI, V23, P175, DOI 10.1146/annurev.cellbio.23.090506.123406
   Cai GQ, 2010, EXP CELL RES, V316, P1600, DOI 10.1016/j.yexcr.2010.01.021
   Croce CM, 2009, NAT REV GENET, V10, P704, DOI 10.1038/nrg2634
   Croce CM, 2005, CELL, V122, P6, DOI 10.1016/j.cell.2005.06.036
   Cutroneo KR, 2007, J CELL PHYSIOL, V211, P585, DOI 10.1002/jcp.20972
   Degryse AL, 2011, AM J PHYSIOL-LUNG C, V300, pL887, DOI 10.1152/ajplung.00397.2010
   Engels BM, 2006, ONCOGENE, V25, P6163, DOI 10.1038/sj.onc.1209909
   Finlay GA, 2000, J BIOL CHEM, V275, P27650
   Gharaee-Kermani M, 2009, CURR MED CHEM, V16, P1400, DOI 10.2174/092986709787846497
   Kang HR, 2007, J BIOL CHEM, V282, P7723, DOI 10.1074/jbc.M610764200
   Kasai H, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-56
   Kim KK, 2006, P NATL ACAD SCI USA, V103, P13180, DOI 10.1073/pnas.0605669103
   Konigshoff M, 2009, J CLIN INVEST, V119, P772, DOI 10.1172/JCI33950
   Kondrikov D, 2011, FREE RADICAL BIO MED, V50, P1689, DOI 10.1016/j.freeradbiomed.2011.03.020
   Latronico MVG, 2009, NAT REV CARDIOL, V6, P418, DOI 10.1038/nrcardio.2009.56
   Lee Chun Geun, 2006, Proc Am Thorac Soc, V3, P476
   Liu G, 2008, FASEB J, V22, P2285, DOI 10.1096/fj.07-101816
   Liu G, 2010, J EXP MED, V207, P1589, DOI 10.1084/jem.20100035
   Mishra PK, 2009, J CELL MOL MED, V13, P778, DOI 10.1111/j.1582-4934.2009.00744.x
   Moore BB, 2008, AM J PHYSIOL-LUNG C, V294, pL152, DOI 10.1152/ajplung.00313.2007
   Munger JS, 1999, CELL, V96, P319, DOI 10.1016/S0092-8674(00)80545-0
   Pandey AK, 2009, CELL PHYSIOL BIOCHEM, V23, P221, DOI 10.1159/000218169
   Pandit KV, 2010, AM J RESP CRIT CARE, V182, P220, DOI 10.1164/rccm.200911-1698OC
   Patel S, 2005, J AM SOC NEPHROL, V16, P1977, DOI 10.1681/ASN.2004110943
   Ramos C, 2001, AM J RESP CELL MOL, V24, P591, DOI 10.1165/ajrcmb.24.5.4333
   Sheppard Dean, 2006, Proc Am Thorac Soc, V3, P413, DOI 10.1513/pats.200601-008AW
   Thannickal VJ, 2004, ANNU REV MED, V55, P395, DOI 10.1146/annurev.55.091902.103810
   Thannickal VJ, 2003, J BIOL CHEM, V278, P12384, DOI 10.1074/jbc.M208544200
   Thum T, 2008, CARDIOVASC RES, V79, P562, DOI 10.1093/cvr/cvn137
   Thum T, 2008, NATURE, V456, P980, DOI 10.1038/nature07511
   Tomasek JJ, 2002, NAT REV MOL CELL BIO, V3, P349, DOI 10.1038/nrm809
   Tsapara A, 2010, MOL BIOL CELL, V21, P860, DOI 10.1091/mbc.E09-07-0567
   Vuga LJ, 2009, AM J RESP CELL MOL, V41, P583, DOI 10.1165/rcmb.2008-0201OC
   Watts KL, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-88
   White LR, 2007, AM J PHYSIOL-RENAL, V292, pF567, DOI 10.1152/ajprenal.00212.2006
   Willis BC, 2005, AM J PATHOL, V166, P1321, DOI 10.1016/S0002-9440(10)62351-6
   Willis BC, 2007, AM J PHYSIOL-LUNG C, V293, pL525, DOI 10.1152/ajplung.00163.2007
   Wu Z, 2007, RESP RES, V8, DOI 10.1186/1465-9921-8-1
   Xia H, 2008, J EXP MED, V205, P1659, DOI 10.1084/jem.20080001
   Xu J, 2009, CELL RES, V19, P156, DOI 10.1038/cr.2009.5
   Yao HW, 2004, LIFE SCI, V76, P29, DOI 10.1016/j.lfs.2004.06.019
   Zeng Y, 2006, ONCOGENE, V25, P6156, DOI 10.1038/sj.onc.1209908
   Zhou Y, 2010, J BIOL CHEM, V285, P22382, DOI 10.1074/jbc.M110.126227
NR 45
TC 29
Z9 33
U1 4
U2 18
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
EI 1530-6860
J9 FASEB J
JI Faseb J.
PD SEP
PY 2012
VL 26
IS 9
BP 3790
EP 3799
DI 10.1096/fj.11-202366
PG 10
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA 000MY
UT WOS:000308391600019
PM 22661007
OA Green Published
DA 2018-12-27
ER

PT J
AU Flores, MBS
   Rocha, GZ
   Damas-Souza, DM
   Osorio-Costa, F
   Dias, MM
   Ropelle, ER
   Camargo, JA
   de Carvalho, RB
   Carvalho, HF
   Saad, MJA
   Carvalheira, JBC
AF Flores, Marcelo B. S.
   Rocha, Guilherme Z.
   Damas-Souza, Danilo M.
   Osorio-Costa, Felipe
   Dias, Marilia M.
   Ropelle, Eduardo R.
   Camargo, Juliana A.
   de Carvalho, Rita B.
   Carvalho, Hernandes F.
   Saad, Mario J. A.
   Carvalheira, Jose B. C.
TI RETRACTED: Obesity-Induced Increase in Tumor Necrosis Factor-alpha Leads
   to Development of Colon Cancer in Mice (Retracted article. See vol. 153,
   pg. 871, 2017)
SO GASTROENTEROLOGY
LA English
DT Article; Retracted Publication
DE JNK; Inflammation; Insulin Resistance; Mouse Model
ID COLITIS-ASSOCIATED CARCINOGENESIS; INSULIN-RECEPTOR SUBSTRATE-1; DEXTRAN
   SULFATE SODIUM; NF-KAPPA-B; COLORECTAL-CANCER; TNF-ALPHA; SERINE
   PHOSPHORYLATION; RHEUMATOID-ARTHRITIS; SIGNAL-TRANSDUCTION;
   ULCERATIVE-COLITIS
AB BACKGROUND & AIMS: Epidemiology studies have shown that obesity increases risk for colorectal cancer (CRC). We investigated the contribution of obesity-induced increases in levels of tumor necrosis factor (TNF)-alpha and hyperinsulinemia to the development of CRC in mice. METHODS: Lean and obese mice (C57BL6/J and ob/ob) were given a combination of azoxymethane and dextran sulfate sodium, which led to the development of CRC; lean and obese severe combined immunodeficient mice were injected with HT-29 cells. We analyzed the roles of TNF-alpha and insulin in the development of obesity-mediated CRC using immunoblot, immunohistochemical, and apoptosis assays. RESULTS: Genetic-and diet-induced obesity increased the incidence and size of tumors that developed after administration of azoxymethane and dextran sulfate sodium, compared with lean mice. HT-29 xenograft tumors grew more rapidly in obese than lean mice. Neutralization of TNF-alpha reduced activation of c-Jun N-terminal kinase, I kappa B kinase, and the phosphatidylinositol 3-kinase-Akt-mammalian target of rapamycin signaling pathway; it also reduced the growth and development of tumors in obese mice. Reducing levels of insulin levels had no effect on tumor growth in obese mice. CONCLUSIONS: TNF-alpha contributes to colon tumor growth in obese mice. Reagents that inhibit TNF-alpha might prevent the development or progression of CRC in obese individuals.
C1 [Flores, Marcelo B. S.; Rocha, Guilherme Z.; Osorio-Costa, Felipe; Dias, Marilia M.; Ropelle, Eduardo R.; Camargo, Juliana A.; de Carvalho, Rita B.; Saad, Mario J. A.; Carvalheira, Jose B. C.] Univ Estadual Campinas, Dept Internal Med, Fac Med Sci, BR-13083887 Campinas, SP, Brazil.
   [Damas-Souza, Danilo M.] Univ Estadual Campinas, Dept Anat Cell Biol Physiol & Biophys, BR-13083887 Campinas, SP, Brazil.
RP Carvalheira, JBC (reprint author), Univ Estadual Campinas, Dept Internal Med, Fac Med Sci, BR-13083887 Campinas, SP, Brazil.
EM carvalheirajbc@uol.com.br
RI Dias, Marilia/C-3014-2012; 5, INCT/H-4505-2013; Infabic,
   Inct/I-2128-2013; Carvalho, Hernandes/C-2046-2012; Damas-Souza,
   Danilo/N-9317-2014; Diabetes, Inct/I-2186-2013; Ropelle,
   Eduardo/C-3977-2012; 6, INCT/H-4795-2013; Rocha, Guilherme/J-9146-2014
OI Ropelle, Eduardo/0000-0003-1655-9557; Rocha,
   Guilherme/0000-0002-7403-3230
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo; Conselho Nacional
   de Desenvolvimento Cientifico e Tecnologico
FX This study was supported by grants from the Fundacao de Amparo a
   Pesquisa do Estado de Sao Paulo and the Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico.
CR Aguirre V, 2002, J BIOL CHEM, V277, P1531, DOI 10.1074/jbc.M101521200
   Araujo EP, 2007, ENDOCRINOLOGY, V148, P5991, DOI 10.1210/en.2007-0132
   Baggio LL, 2007, GASTROENTEROLOGY, V132, P2131, DOI 10.1053/j.gastro.2007.03.054
   Balkwill F, 2009, NAT REV CANCER, V9, P361, DOI 10.1038/nrc2628
   Barbuio R, 2007, J ENDOCRINOL, V194, P539, DOI 10.1677/JOE-07-0234
   Bernstein LE, 2006, ARCH INTERN MED, V166, P902, DOI 10.1001/archinte.166.8.902
   Calle EE, 2003, NEW ENGL J MED, V348, P1625, DOI 10.1056/NEJMoa021423
   Center MM, 2009, CA-CANCER J CLIN, V59, P366, DOI 10.3322/caac.20038
   Chen QQ, 2006, J RHEUMATOL, V33, P1061
   Endo H, 2009, GUT, V58, P1637, DOI 10.1136/gut.2009.183624
   Gao ZG, 2002, J BIOL CHEM, V277, P48115, DOI 10.1074/jbc.M209459200
   Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1
   Giovannucci E, 2002, GASTROENTEROL CLIN N, V31, P925, DOI 10.1016/S0889-8553(02)00057-2
   Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/j.cell.2011.02.013
   Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665
   Huang XL, 2011, INFLAMM RES, V60, P727, DOI 10.1007/s00011-011-0325-6
   Kim YJ, 2010, CANCER PREV RES, V3, P1314, DOI 10.1158/1940-6207.CAPR-09-0272
   Kiortsis DN, 2005, ANN RHEUM DIS, V64, P765, DOI 10.1136/ard.2004.026534
   Kojouharoff G, 1997, CLIN EXP IMMUNOL, V107, P353, DOI 10.1111/j.1365-2249.1997.291-ce1184.x
   Lee YH, 2003, J BIOL CHEM, V278, P2896, DOI 10.1074/jbc.M208359200
   Li B, 2009, CANCER RES, V69, P338, DOI 10.1158/0008-5472.CAN-08-1565
   Lugering A, 2001, GASTROENTEROLOGY, V121, P1145, DOI 10.1053/gast.2001.28702
   Ma J, 2004, JNCI-J NATL CANCER I, V96, P546, DOI 10.1093/jnci/djh082
   Naito Y, 2003, J GASTROEN HEPATOL, V18, P560, DOI 10.1046/j.1440-1746.2003.03034.x
   Neurath MF, 1997, EUR J IMMUNOL, V27, P1743, DOI 10.1002/eji.1830270722
   Onizawa M, 2009, AM J PHYSIOL-GASTR L, V296, pG850, DOI 10.1152/ajpgi.00071.2008
   Osorio-Costa F, 2009, ARQ BRAS ENDOCRINOL, V53, P213, DOI 10.1590/S0004-27302009000200013
   Paquot N, 2000, J CLIN ENDOCR METAB, V85, P1316, DOI 10.1210/jc.85.3.1316
   Park EJ, 2010, CELL, V140, P197, DOI 10.1016/j.cell.2009.12.052
   Popivanova BK, 2008, J CLIN INVEST, V118, P560, DOI [10.1172/JC132453, 10.1172/JCI32453]
   POWRIE F, 1994, IMMUNITY, V1, P553, DOI 10.1016/1074-7613(94)90045-0
   Ranganath LR, 1999, HORM METAB RES, V31, P262, DOI 10.1055/s-2007-978729
   Reddy SAG, 2000, J IMMUNOL, V164, P1355, DOI 10.4049/jimmunol.164.3.1355
   Renehan AG, 2004, LANCET, V363, P1346, DOI 10.1016/S0140-6736(04)16044-3
   Rocha GZ, 2011, CLIN CANCER RES, V17, P3993, DOI 10.1158/1078-0432.CCR-10-2243
   Ropelle ER, 2006, J PHYSIOL-LONDON, V577, P997, DOI 10.1113/jphysiol.2006.120006
   Rutgeerts P, 2005, NEW ENGL J MED, V353, P2462, DOI 10.1056/NEJMoa050516
   Sandhu MS, 2002, J NATL CANCER I, V94, P972
   Sinicrope FA, 2010, CLIN CANCER RES, V16, P1884, DOI 10.1158/1078-0432.CCR-09-2636
   Stathopoulos GT, 2007, CANCER RES, V67, P9825, DOI 10.1158/0008-5472.CAN-07-1064
   Walther A, 2009, NAT REV CANCER, V9, P489, DOI 10.1038/nrc2645
   Xu H, 2007, RHEUMATOLOGY, V46, P920, DOI 10.1093/rheumatology/kem014
   Zoncu R, 2011, NAT REV MOL CELL BIO, V12, P21, DOI 10.1038/nrm3025
NR 44
TC 43
Z9 44
U1 1
U2 20
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0016-5085
EI 1528-0012
J9 GASTROENTEROLOGY
JI Gastroenterology
PD SEP
PY 2012
VL 143
IS 3
BP 741
EP +
DI 10.1053/j.gastro.2012.05.045
PG 17
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 000PO
UT WOS:000308399300038
PM 22677195
DA 2018-12-27
ER

PT J
AU Subba-Reddy, CV
   Yunus, MA
   Goodfellow, IG
   Kao, CC
AF Subba-Reddy, Chennareddy V.
   Yunus, Muhammad Amir
   Goodfellow, Ian G.
   Kao, C. Cheng
TI RETRACTED: Norovirus RNA Synthesis Is Modulated by an Interaction
   between the Viral RNA-Dependent RNA Polymerase and the Major Capsid
   Protein, VP1 (Retracted article. See vol. 91, 2017)
SO JOURNAL OF VIROLOGY
LA English
DT Article; Retracted Publication
ID TRANSLATION TERMINATION-REINITIATION; MURINE NOROVIRUS; NORWALK VIRUS;
   COAT PROTEIN; REPLICATION COMPLEX; CORE PROTEIN; CALICIVIRUS;
   EXPRESSION; PATHOGENESIS; INFECTION
AB Using a cell-based assay for RNA synthesis by the RNA-dependent RNA polymerase (RdRp) of noroviruses, we previously observed that VP1, the major structural protein of the human GII.4 norovirus, enhanced the GII.4 RdRp activity but not that of the related murine norovirus (MNV) or other unrelated RNA viruses (C. V. Subba-Reddy, I. Goodfellow, and C. C. Kao, J. Virol. 85: 13027-13037, 2011). Here, we examine the mechanism of VP1 enhancement of RdRp activity and the mechanism of mouse norovirus replication. We determined that the GII.4 and MNV VP1 proteins can enhance cognate RdRp activities in a concentration-dependent manner. The VP1 proteins coimmunoprecipitated with their cognate RdRps. Coexpression of individual domains of VP1 with the viral RdRps showed that the VP1 shell domain (SD) was sufficient to enhance polymerase activity. Using SD chimeras from GII.4 and MNV, three loops connecting the central beta-barrel structure were found to be responsible for the species-specific enhancement of RdRp activity. A differential scanning fluorimetry assay showed that recombinant SDs can bind to the purified RdRps in vitro. An MNV replicon with a frameshift mutation in open reading frame 2 (ORF2) that disrupts VP1 expression was defective for RNA replication, as quantified by luciferase reporter assay and real-time quantitative reverse transcription-PCR (qRT-PCR). Trans-complementation of VP1 or its SD significantly recovered the VP1 knockout MNV replicon replication, and the presence or absence of VP1 affected the kinetics of viral RNA synthesis. The results document a regulatory role for VP1 in the norovirus replication cycle, further highlighting the paradigm of viral structural proteins playing additional functional roles in the virus life cycle.
C1 [Subba-Reddy, Chennareddy V.; Kao, C. Cheng] Indiana Univ, Dept Mol & Cellular Biochem, Bloomington, IN 47405 USA.
   [Yunus, Muhammad Amir; Goodfellow, Ian G.] Univ London Imperial Coll Sci Technol & Med, Dept Med, Virol Sect, London, England.
RP Kao, CC (reprint author), Indiana Univ, Dept Mol & Cellular Biochem, Bloomington, IN 47405 USA.
EM vchennar@indiana.edu; ckao@indiana.edu
RI Yunus, Amir/I-5812-2015
OI Yunus, Amir/0000-0002-7411-0769; Goodfellow, Ian/0000-0002-9483-510X
FU Indiana Economic Development Council; Wellcome Trust; Malaysian
   Government
FX Research by C.C.K. was supported by the Indiana Economic Development
   Council. Research by I.G.G. was supported by the Wellcome Trust, and
   M.A.Y. was supported by the Malaysian Government.
CR Atmar RL, 2006, GASTROENTEROL CLIN N, V35, P275, DOI 10.1016/j.gtc.2006.03.001
   Belliot G, 2005, J VIROL, V79, P2393, DOI 10.1128/JVI.79.4.2393-2403.2005
   Bertolotti-Ciarlet A, 2002, J VIROL, V76, P4044, DOI 10.1128/JVI.76.8.4044-4055.2002
   Bok K, 2011, P NATL ACAD SCI USA, V108, P325, DOI 10.1073/pnas.1014577107
   Bok K, 2009, J VIROL, V83, P11890, DOI 10.1128/JVI.00864-09
   Bol JF, 2005, ANNU REV PHYTOPATHOL, V43, P39, DOI 10.1146/annurev.phyto.43.101804.120505
   Bull RA, 2011, VIRUS GENES, V42, P16, DOI 10.1007/s11262-010-0535-y
   Bull RA, 2011, TRENDS MICROBIOL, V19, P233, DOI 10.1016/j.tim.2011.01.002
   Chaudhry Y, 2007, J GEN VIROL, V88, P2091, DOI 10.1099/vir.0.82940-0
   Chaudhry Y, 2006, J BIOL CHEM, V281, P25315, DOI 10.1074/jbc.M602230200
   Chen JB, 2000, J VIROL, V74, P4310, DOI 10.1128/JVI.74.9.4310-4318.2000
   Chen MH, 2004, J VIROL, V78, P4314, DOI 10.1128/JVI.78.8.4314-4322.2004
   Chinnaswamy S, 2008, J BIOL CHEM, V283, P20535, DOI 10.1074/jbc.M801490200
   CHO MW, 1994, VIROLOGY, V202, P129, DOI 10.1006/viro.1994.1329
   Clarke IN, 2000, J INFECT DIS, V181, pS309, DOI 10.1086/315575
   Donaldson EF, 2010, NAT REV MICROBIOL, V8, P231, DOI 10.1038/nrmicro2296
   Duizer E, 2004, J GEN VIROL, V85, P79, DOI 10.1099/vir.0.19478-0
   El-Hage N, 2003, J GEN VIROL, V84, P2761, DOI 10.1099/vir.0.19305-0
   Fullerton SWB, 2007, J VIROL, V81, P1858, DOI 10.1128/JVI.01462-06
   Glass PJ, 2000, J VIROL, V74, P6581, DOI 10.1128/JVI.74.14.6581-6591.2000
   Gohara DW, 1999, PROTEIN EXPRES PURIF, V17, P128, DOI 10.1006/prep.1999.1100
   Green KY, 2007, FIELDS VIROLOGY, P949
   Guogas LM, 2005, J VIROL, V79, P5752, DOI 10.1128/JVI.79.9.5752-5761.2005
   Hall AJ, 2012, CLIN INFECT DIS, V55, P216, DOI 10.1093/cid/cis386
   Hardy ME, 2005, FEMS MICROBIOL LETT, V253, P1, DOI 10.1016/j.femsle.2005.08.031
   Ilkow CS, 2008, J VIROL, V82, P4284, DOI 10.1128/JVI.02732-07
   JIANG X, 1993, VIROLOGY, V195, P51, DOI 10.1006/viro.1993.1345
   Kahan SM, 2011, VIROLOGY, V421, P202, DOI 10.1016/j.virol.2011.09.030
   Kaiser WJ, 2006, J GEN VIROL, V87, P363, DOI 10.1099/vir.0.81456-0
   Karst SM, 2010, VIRUSES-BASEL, V2, P748, DOI 10.3390/v2030748
   McCormick CJ, 2008, J VIROL, V82, P8917, DOI 10.1128/JVI.02362-07
   McDonald SM, 2011, J VIROL, V85, P3095, DOI 10.1128/JVI.02360-10
   McFadden N, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002413
   Meyers G, 2003, J BIOL CHEM, V278, P34051, DOI 10.1074/jbc.M304874200
   Napthine S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008390
   Neeleman L, 2001, P NATL ACAD SCI USA, V98, P14286, DOI 10.1073/pnas.251542798
   Niesen FH, 2007, NAT PROTOC, V2, P2212, DOI 10.1038/nprot.2007.321
   Patton JT, 1997, J VIROL, V71, P9618
   Prasad BVV, 1999, SCIENCE, V286, P287, DOI 10.1126/science.286.5438.287
   Ranjith-Kumar CT, 2009, J BIOL CHEM, V284, P1155, DOI 10.1074/jbc.M806219200
   Rohayem J, 2006, J VIROL, V80, P7060, DOI 10.1128/JVI.02195-05
   Shimoike T, 1999, J VIROL, V73, P9718
   Strong DW, 2012, J VIROL, V86, P2950, DOI 10.1128/JVI.07038-11
   Subba-Reddy CV, 2011, J VIROL, V85, P13027, DOI 10.1128/JVI.06191-11
   Vashist S, 2012, J VIROL METHODS, V184, P69, DOI 10.1016/j.jviromet.2012.05.012
   WITHERELL GW, 1991, PROG NUCLEIC ACID RE, V40, P185
   Wobus CE, 2004, PLOS BIOL, V2, P2076, DOI 10.1371/journal.pbio.0020432
   Wobus CE, 2006, J VIROL, V80, P5104, DOI 10.1128/JVI.02346-05
   Wolf M, 2008, NUCLEIC ACIDS RES, V36, P3054, DOI 10.1093/nar/gkn111
   Yi G, 2009, RNA, V15, P615, DOI 10.1261/rna.1375509
   Zhu J, 2007, P NATL ACAD SCI USA, V104, P3129, DOI 10.1073/pnas.0611617104
NR 51
TC 37
Z9 37
U1 3
U2 19
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD SEP
PY 2012
VL 86
IS 18
BP 10138
EP 10149
DI 10.1128/JVI.01208-12
PG 12
WC Virology
SC Virology
GA 999TI
UT WOS:000308337500054
PM 22787222
OA Bronze, Green Published
DA 2018-12-27
ER

PT J
AU Bittner, V
   Wenger, NK
   Waters, DD
   DeMicco, DA
   Messig, M
   LaRosa, JC
AF Bittner, Vera
   Wenger, Nanette K.
   Waters, David D.
   DeMicco, David A.
   Messig, Michael
   LaRosa, John C.
TI RETRACTED: Vitamin D levels do not predict cardiovascular events in
   statin-treated patients with stable coronary disease (Retracted article.
   See vol. 166, 2013)
SO AMERICAN HEART JOURNAL
LA English
DT Article; Retracted Publication
ID NUTRITION EXAMINATION SURVEY; CHRONIC KIDNEY-DISEASE; 3RD
   NATIONAL-HEALTH; HYPOVITAMINOSIS-D; HEART-DISEASE; UNITED-STATES; RISK;
   25-HYDROXYVITAMIN-D; PREVALENCE; ATORVASTATIN
AB Background This post hoc nested case-control analysis of the TNT study was designed to investigate whether baseline vitamin D level is a significant predictor of cardiovascular risk among statin-treated patients and whether changes in vitamin D after treatment with atorvastatin are associated with improved cardiovascular outcomes.
   Methods A total of 10,001 patients with stable coronary heart disease were randomized to atorvastatin 80 or 10 mg for a median of 4.9 years. This analysis included 1,509 patients (497 with a subsequent cardiovascular event and 1,012 without an event) with vitamin D levels determined at baseline and 1 year. Event rates were analyzed by Cox proportional hazard model by baseline vitamin D levels, with vitamin D as a continuous variable, and with change in vitamin D level as the predictor.
   Results Vitamin D deficiency (<15 ng/mL) or insufficiency (15-<30 ng/mL) was present in 108 (7.2%) of 1,509 and 625 (41.4%) of 1,509 of patients, whereas 46 (3.0%) of 1,509 had elevated vitamin D. There was no relationship between baseline vitamin D levels or change in vitamin D levels and cardiovascular events or mortality. Modeling of events with vitamin D as a continuous variable similarly showed no relationship of vitamin D to events. These findings held true after adjustment for seasonal variations in vitamin D and other confounders.
   Conclusion In statin-treated patients with stable coronary heart disease, vitamin D levels did not predict cardiovascular risk. Changes in plasma concentrations of vitamin D after 1 year of treatment made no contribution to the efficacy of atorvastatin therapy. (Am Heart J 2012;164:387-93.)
C1 [Bittner, Vera] Univ Alabama Birmingham, Birmingham, AL 35294 USA.
   [Wenger, Nanette K.] Emory Univ, Atlanta, GA 30322 USA.
   [Waters, David D.] San Francisco Gen Hosp, San Francisco, CA 94110 USA.
   [DeMicco, David A.; Messig, Michael] Pfizer Inc, New York, NY USA.
   [LaRosa, John C.] SUNY Hlth Sci Ctr, Brooklyn, NY 11203 USA.
RP Bittner, V (reprint author), Univ Alabama Birmingham, 701 19th St S,LHRB 310, Birmingham, AL 35294 USA.
EM vbittner@uab.edu
OI Bittner, Vera/0000-0001-9456-850X
FU Pfizer, Inc.; Pfizer; GlaxoSmithKline; Hoffman La Roche; Gilead;
   NIH/Abbott; Spirocor Ltd; NIH/Yale; Kowa; Amarin; CV Therapeutics;
   Sanofi-Aventis; Schering-Plough; AstraZeneca; Abbott; Merck; Boston
   Scientific; Medtronic; Gilead Sciences; Genzyme; Eli Lilly; National
   Heart, Lung, and Blood Institute; Anthera; Aegerion; Biosante;
   Bristol-Myers Squibb; Cerenis; Genentech; Merck/Schering-Plough; Roche
   CSL; Amgen; Pfizer Inc
FX This study was funded by Pfizer, Inc.; Dr Bittner has received research
   grants from Pfizer, GlaxoSmithKline, Hoffman La Roche, Gilead,
   NIH/Abbott, Spirocor Ltd, and NIH/Yale and consultant fees from Pfizer,
   Kowa, Amarin, and Hoffman La Roche. Dr Bittner has associations with
   Columbia University-NIH (trial DSMB), American Heart Association,
   American College of Cardiology, National Lipid Association, and the Food
   and Drug Administration (Endocrinologic and Metabolic Drugs Advisory
   Committee) and has been principal investigator or coinvestigator on
   several NIH trials.; Dr Wenger has received consulting fees from CV
   Therapeutics, Sanofi-Aventis, Schering-Plough, AstraZeneca, Abbott,
   Merck, Boston Scientific, Medtronic, Gilead Sciences, Genzyme, and
   Pfizer and grant support from CV Therapeutics, Sanofi-Aventis, Abbott,
   Eli Lilly, Pfizer, Merck, and the National Heart, Lung, and Blood
   Institute.; Dr Waters has received honoraria for speaking engagements
   and consulting fees from Anthera, Aegerion, Biosante, Bristol-Myers
   Squibb, Cerenis, Genentech, Merck/Schering-Plough, Pfizer Inc, and Roche
   CSL.; Dr LaRosa has received consultant fees from Pfizer and Amgen.
CR Aloia JF, 2007, AM J CARDIOL, V100, P1329, DOI 10.1016/j.amjcard.2007.05.024
   Anderson JL, 2010, AM J CARDIOL, V106, P963, DOI 10.1016/j.amjcard.2010.05.027
   Arsenault Benoit J, 2011, J Am Coll Cardiol, V57, P63, DOI 10.1016/j.jacc.2010.06.052
   Bailey RL, 2010, J NUTR, V140, P817, DOI 10.3945/jn.109.118539
   Chung Mei, 2009, Evid Rep Technol Assess (Full Rep), P1
   Committee to Review Dietary Reference Intakes for Vitamin D and Calcium Institute of Medicine National Research Council, 2011, DIET REF INT CALC VI
   Ertugrul DT, 2011, CARDIOVASC THER, V29, P146, DOI 10.1111/j.1755-5922.2010.00141.x
   Essebag V, 2003, AM HEART J, V146, P581, DOI 10.1016/S0002-8703(03)00512-X
   Fiscella K, 2010, ANN FAM MED, V8, P11, DOI 10.1370/afm.1035
   Giovannucci E, 2008, ARCH INTERN MED, V168, P1174, DOI 10.1001/archinte.168.11.1174
   Grandi NC, 2010, AM HEART J, V159, P1044, DOI 10.1016/j.ahj.2010.03.031
   Holick MF, 2006, MAYO CLIN PROC, V81, P353, DOI 10.4065/81.3.353
   Holick MF, 2009, ANN EPIDEMIOL, V19, P73, DOI 10.1016/j.annepidem.2007.12.001
   Kestenbaum B, 2011, J AM COLL CARDIOL, V58, P1433, DOI 10.1016/j.jacc.2011.03.069
   Kim DH, 2008, AM J CARDIOL, V102, P1540, DOI 10.1016/j.amjcard.2008.06.067
   LaRosa JC, 2005, NEW ENGL J MED, V352, P1425, DOI 10.1056/NEJMoa050461
   Li YC, 2002, J CLIN INVEST, V110, P229, DOI 10.1172/JCI200215219
   Mancuso P, 2008, J CARDIOVASC PHARM, V51, P559, DOI 10.1097/FJC.0b013e3181761906
   Martins D, 2007, ARCH INTERN MED, V167, P1159, DOI 10.1001/archinte.167.11.1159
   Mehrotra R, 2008, CLIN J AM SOC NEPHRO, V3, P1144, DOI 10.2215/CJN.05781207
   Mehrotra R, 2009, KIDNEY INT, V76, P977, DOI 10.1038/ki.2009.288
   Perez-Castrillon JL, 2007, AM J CARDIOL, V99, P903, DOI 10.1016/j.amjcard.2006.11.036
   Pittas AG, 2007, DIABETES CARE, V30, P980, DOI 10.2337/dc06-1994
   Pittas AG, 2010, ANN INTERN MED, V152, P307, DOI 10.7326/0003-4819-152-5-201003020-00009
   Rejnmark L, 2010, INT J ENDOCRINOL, DOI 10.1155/2010/957174
   Scragg R, 2007, AM J HYPERTENS, V20, P713, DOI 10.1016/j.amjhyper.2007.01.017
   Wallis DE, 2008, CIRCULATION, V118, P1476, DOI 10.1161/CIRCULATIONAHA.107.713339
   Wang TJ, 2008, CIRCULATION, V117, P503, DOI 10.1161/CIRCULATIONAHA.107.706127
   Waters DD, 2004, AM J CARDIOL, V93, P154, DOI 10.1016/j.amjcard.2003.09.031
   Yavuz B, 2009, CARDIOVASC DRUG THER, V23, P295, DOI 10.1007/s10557-009-6181-8
NR 30
TC 13
Z9 13
U1 1
U2 8
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-8703
EI 1097-5330
J9 AM HEART J
JI Am. Heart J.
PD SEP
PY 2012
VL 164
IS 3
BP 387
EP 393
DI 10.1016/j.ahj.2012.06.016
PG 7
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 004OD
UT WOS:000308690100016
PM 22980306
DA 2018-12-27
ER

PT J
AU Vartanian, AA
AF Vartanian, A. A.
TI RETRACTED: Signaling pathways in tumor vasculogenic mimicry (Retracted
   article. See vol. 78, pg. 678, 2013)
SO BIOCHEMISTRY-MOSCOW
LA English
DT Review; Retracted Publication
DE highly aggressive tumor; vasculogenic mimicry; signaling pathway;
   prognosis
ID HUMAN-MELANOMA CELLS; PROTEIN-KINASE-C; POTENTIAL THERAPEUTIC TARGET;
   INFLAMMATORY BREAST-CANCER; VASCULAR CHANNEL FORMATION; VEIN
   ENDOTHELIAL-CELLS; HUMAN UVEAL MELANOMA; IN-VITRO; AGGRESSIVE MELANOMA;
   MALIGNANT-MELANOMA
AB Solid tumor growth is dependent on the development of an adequate blood supply. For years, sprouting angiogenesis has been considered as the exclusive mechanism of tumor vascularization. However, in recent years, another mechanism of tumor vascularization has been identified that does not involve endothelial cells, a process called vasculogenic mimicry (VM). VM describes the unique ability of highly aggressive tumor cells to form vessel-like networks by virtue of their high plasticity. VM has been observed in several tumor types, and its occurrence is strongly associated with poor prognosis. This review focuses on signaling molecules and cascades involved in VM. In addition, the clinical significance of VM regardless of anti-angiogenesis treatment modalities is described.
C1 Russian Acad Med Sci, Inst Expt Diag & Biotherapy Tumors, Blokhin Russian Canc Res Ctr, Moscow 115478, Russia.
RP Vartanian, AA (reprint author), Russian Acad Med Sci, Inst Expt Diag & Biotherapy Tumors, Blokhin Russian Canc Res Ctr, Kashirskoe Shosse 24, Moscow 115478, Russia.
EM zhivotov57@mail.ru
CR Abbott DE, 2008, CANCER MICROENVIRON, V1, P13, DOI 10.1007/s12307-008-0004-5
   Azam F, 2010, EUR J CANCER, V46, P1323, DOI 10.1016/j.ejca.2010.02.020
   Basu GD, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1626
   Basu GD, 2005, BREAST CANCER RES, V7, pR422, DOI 10.1186/bcr1019
   Beese M, 2010, BMC CELL BIOL, V11, DOI 10.1186/1471-2121-11-68
   Bittner M, 2000, NATURE, V406, P536, DOI 10.1038/35020115
   Bos JL, 2006, TRENDS BIOCHEM SCI, V31, P680, DOI 10.1016/j.tibs.2006.10.002
   Brantley DM, 2002, ONCOGENE, V21, P7011, DOI 10.1038/sj.onc.1205679
   Brennan J, 2002, GENE DEV, V16, P2339, DOI 10.1101/gad.1016202
   Chen YW, 2012, J CELL PHYSIOL, V227, P2818, DOI 10.1002/jcp.23038
   Clarijs R, 2002, INVEST OPHTH VIS SCI, V43, P912
   de Botton S, 2002, BLOOD, V100, P1310, DOI 10.1182/blood-2002-03-0686
   De S, 2005, P NATL ACAD SCI USA, V102, P7589, DOI 10.1073/pnas.0502935102
   Disatnik MH, 1999, J BIOL CHEM, V274, P32486, DOI 10.1074/jbc.274.45.32486
   Duxbury MS, 2004, ONCOGENE, V23, P1448, DOI 10.1038/sj.onc.1207247
   Elzarrad K, 2009, CLIN EXP METASTAS, V26, P589, DOI 10.1007/s10585-009-9257-8
   Fan YZ, 2010, WORLD J GASTRO SURG, V2, P117, DOI 10.4240/wjgs.v2.i4.117
   Fernando P, 2002, P NATL ACAD SCI USA, V99, P11025, DOI 10.1073/pnas.162172899
   Folberg R, 2000, AM J PATHOL, V156, P361, DOI 10.1016/S0002-9440(10)64739-6
   Folberg R, 2004, APMIS, V112, P508, DOI 10.1111/j.1600-0463.2004.apm11207-0810.x
   Folkman J, 1996, EUR J CANCER, V32A, P2534, DOI 10.1016/S0959-8049(96)00423-6
   Ghafar MA, 2003, PROSTATE, V54, P58, DOI 10.1002/pros.10162
   HAUSER S, 1993, GROWTH FACTORS, V9, P259, DOI 10.3109/08977199308991586
   Helczynska K, 2003, CANCER RES, V63, P1441
   Hendrix MJC, 2007, NAT REV CANCER, V7, P246, DOI 10.1038/nrc2108
   Hendrix MJC, 2003, NAT REV CANCER, V3, P411, DOI 10.1038/nrc1092
   Hendrix MJC, 2003, ONCOGENE, V22, P3070, DOI 10.1038/sj.onc.1206447
   Hendrix MJC, 2002, CANCER RES, V62, P665
   Hendrix MJC, 2001, P NATL ACAD SCI USA, V98, P8018, DOI 10.1073/pnas.131209798
   Hess AR, 2006, CANCER BIOL THER, V5, P228, DOI 10.4161/cbt.5.2.2510
   Hess AR, 2005, CANCER RES, V65, P9851, DOI 10.1158/0008-5472.CAN-05-2172
   Hess AR, 2003, CANCER RES, V63, P4757
   Hess AR, 2001, CANCER RES, V61, P3250
   Hillen F, 2007, CANCER METAST REV, V26, P489, DOI 10.1007/s10555-007-9094-7
   Hiratsuka S, 1998, P NATL ACAD SCI USA, V95, P9349, DOI 10.1073/pnas.95.16.9349
   Hoijo Y., 2001, CLIN CANCER RES, V7, P661
   Ivy SP, 2009, NAT REV CLIN ONCOL, V6, P569, DOI 10.1038/nrclinonc.2009.130
   Jabobsson L., 2009, BIOCHEM SOC T, V37, P216
   James D, 2005, DEVELOPMENT, V132, P1273, DOI 10.1242/dev.01706
   Jogi A, 2004, EXP CELL RES, V295, P469, DOI 10.1016/j.yexcr.2004.01.013
   Jubb A. M., 2008, NAT REV CANCER, V6, P626
   Kamenetsky M, 2006, J MOL BIOL, V362, P623, DOI 10.1016/j.jmb.2006.07.045
   Kim K, 2009, ANN NY ACAD SCI, V1171, P111, DOI 10.1111/j.1749-6632.2009.04724.x
   Koch U, 2010, CURR TOP DEV BIOL, V92, P411, DOI 10.1016/S0070-2153(10)92013-9
   Kryston T. B., 2011, MUTAT RES, V711, P13
   Kuphal S, 2005, CANCER METAST REV, V24, P195, DOI 10.1007/s10555-005-1572-1
   Lau KS, 2008, GLYCOBIOLOGY, V18, P750, DOI 10.1093/glycob/cwn071
   Lewis JM, 1996, J CELL BIOL, V134, P1323, DOI 10.1083/jcb.134.5.1323
   Lissitzky JC, 2009, CANCER RES, V69, P802, DOI 10.1158/0008-5472.CAN-08-2391
   Liu FT, 2005, NAT REV CANCER, V5, P29, DOI 10.1038/nrc1527
   Lloyd RV, 2003, MICROSC RES TECHNIQ, V60, P244, DOI 10.1002/jemt.10263
   Luca M, 1997, AM J PATHOL, V151, P1105
   Maniotis AJ, 1999, AM J PATHOL, V155, P739, DOI 10.1016/S0002-9440(10)65173-5
   Maniotis AJ, 2002, LAB INVEST, V82, P1031, DOI 10.1097/01.LAB.0000024362.12721.67
   Margaryan N. V., 2008, CANCER BIOL THER, V8, P279
   Mei J., 2008, Experimental Oncology, V30, P29
   Montero AJ, 2011, DRUGS, V71, P1385, DOI 10.2165/11592590-000000000-00000
   Monzani E, 2008, STEM CELL REV, V4, P51, DOI 10.1007/s12015-008-9009-1
   Morrison SJ, 2006, NATURE, V441, P1068, DOI 10.1038/nature04956
   Mourad-Zeidan AA, 2008, AM J PATHOL, V173, P1839, DOI 10.2353/ajpath.2008.080380
   Munaron L, 2009, CURR MED CHEM, V16, P4691, DOI 10.2174/092986709789878210
   Nangia-Makker P, 2000, AM J PATHOL, V156, P899, DOI 10.1016/S0002-9440(10)64959-0
   Pellinen T, 2006, J CELL SCI, V119, P3723, DOI 10.1242/jcs.03216
   Podar K, 2002, J BIOL CHEM, V277, P7875, DOI 10.1074/jbc.M109068200
   Postovit LM, 2008, PIGM CELL MELANOMA R, V21, P348, DOI 10.1111/j.1755-148X.2008.00463.x
   Postovit LM, 2007, J CELL BIOCHEM, V101, P908, DOI 10.1002/jcb.21227
   Pothhammer T., 2005, CANCER RES, V65, P443
   Ribatti D, 2007, CANCER LETT, V248, P18, DOI 10.1016/j.canlet.2006.06.007
   Roscioni SS, 2008, N-S ARCH PHARMACOL, V377, P345, DOI 10.1007/s00210-007-0246-7
   Rothhammer T, 2007, ONCOGENE, V26, P4158, DOI 10.1038/sj.onc.1210182
   Rucci N, 2005, J CELL SCI, V118, P3263, DOI 10.1242/jcs.02436
   Ruf W, 2003, CANCER RES, V63, P5381
   Schwanbeck R, 2011, EUR J CELL BIOL, V90, P572, DOI 10.1016/j.ejcb.2010.10.004
   Seftor EA, 2002, CLIN EXP METASTAS, V19, P233, DOI 10.1023/A:1015591624171
   Seftor REB, 2001, CANCER RES, V61, P6322
   Segura I, 2002, FASEB J, V16, DOI 10.1096/fj.01-0819com
   Semenza GL, 2000, BIOCHEM PHARMACOL, V59, P47, DOI 10.1016/S0006-2952(99)00292-0
   Serini G, 2006, EXP CELL RES, V312, P651, DOI 10.1016/j.yexcr.2005.10.020
   Sharma N, 2002, PROSTATE, V50, P189, DOI 10.1002/pros.10048
   Sharma PS, 2011, CURR CANCER DRUG TAR, V11, P624
   Shirakawa K, 2003, BREAST CANCER RES, V5, P136, DOI 10.1186/bcr585
   Shirakawa K, 2001, CANCER RES, V61, P445
   Simon-Assmann P, 2011, INT J DEV BIOL, V55, P455, DOI 10.1387/ijdb.103223ps
   Sood AK, 2002, CANCER BIOL THER, V1, P661, DOI 10.4161/cbt.316
   Sordet O, 2002, BLOOD, V100, P4446, DOI 10.1182/blood-2002-06-1778
   Sounni NE, 2011, FRONT PHARMACOL, V2, DOI 10.3389/fphar.2011.00111
   Su W., 2008, INT J GYNECOL CANCER, V18, P475
   Sun BC, 2007, CANCER LETT, V249, P188, DOI 10.1016/j.canlet.2006.08.016
   Takanada K., 2011, FRONT BIOSCI-LANDMRK, V16, P31
   Tallquist MD, 1999, ONCOGENE, V18, P7917
   Topczewska JM, 2006, NAT MED, V12, P925, DOI 10.1038/nm1448
   Vailhe B, 2001, LAB INVEST, V81, P439, DOI 10.1038/labinvest.3780252
   Vallier L., 2005, APMIS, V113, P773
   van der Schaft DWJ, 2005, CANCER RES, V65, P11520, DOI 10.1158/008-5472.CAN-05-2468
   van der Schaft DWJ, 2004, J NATL CANCER I, V96, P1473, DOI 10.1093/jnci/djh267
   Vartanian A, 2011, MICROCIRCULATION, V18, P390, DOI 10.1111/j.1549-8719.2011.00102.x
   Vartanian A, 2011, MELANOMA RES, V21, P91, DOI 10.1097/CMR.0b013e328343a237
   Vartanian AA, 2007, MELANOMA RES, V17, P370, DOI 10.1097/CMR.0b013e3282f1d2ec
   Vartanian AA, 2007, MELANOMA RES, V17, P1, DOI 10.1097/CMR.0b013e3280112b76
   Vartanian AA, 2009, CAN J UROL, V16, P4726
   Wallez Y, 2006, TRENDS CARDIOVAS MED, V16, P55, DOI 10.1016/j.tcm.2005.11.008
   Westweber D., 2009, TRENDS CELL BIOL, V19, P8
   Yoon SO, 2003, J BIOCHEM MOL BIOL, V36, P128
   Yurugi-Kobayashi T, 2006, ARTERIOSCL THROM VAS, V26, P1977, DOI 10.1161/01.ATV.0000234978.10658.41
   Zermati Y, 2001, J EXP MED, V193, P247, DOI 10.1084/jem.193.2.247
NR 105
TC 16
Z9 22
U1 1
U2 26
PU MAIK NAUKA/INTERPERIODICA/SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013-1578 USA
SN 0006-2979
EI 1608-3040
J9 BIOCHEMISTRY-MOSCOW+
JI Biochem.-Moscow
PD SEP
PY 2012
VL 77
IS 9
BP 1044
EP 1055
DI 10.1134/S000629791209012X
PG 12
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 006JP
UT WOS:000308815700012
PM 23157265
DA 2018-12-27
ER

PT J
AU Zaman, K
   Izhar, Z
   Khan, MM
   Ahmad, M
AF Zaman, Khalid
   Izhar, Zeeshan
   Khan, Muhammad Mushtaq
   Ahmad, Mehboob
TI RETRACTED: The relationship between financial indicators and human
   development in Pakistan (Retracted article. See vol. 45, pg. 279, 2015)
SO ECONOMIC MODELLING
LA English
DT Article; Retracted Publication
DE Financial indicators; Economic growth; Human capital; Cointegration;
   Causality; Pakistan
ID AUTOREGRESSIVE TIME-SERIES; ECONOMIC-GROWTH; UNIT-ROOT; COINTEGRATION;
   INEQUALITY; COUNTRIES; INFERENCE
AB Every economy requires a sophisticated and efficient financial system to prosper its development. A healthy financial system may be integral to the sound fundamentals of an economy. The objective of the study is to investigate the impact of financial indicators on human development in Pakistan by using annual data from 1975 to 2010. Data is analyzed by cointegration theory, Granger causality test and variance decomposition, etc. The results reveal that financial development indicators act as an important driver for increase in human capital in Pakistan. Results indicate that causality runs from financial indicators to human capital except credit to private sector (CPS) but not vice versa. Financial indicators are closely associated with economic growth and human development in Pakistan. Variance decomposition analysis shows that among all the financial indicators, broad money supply (M-2) has exerted the largest contribution to changes in human capital. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Zaman, Khalid; Izhar, Zeeshan; Khan, Muhammad Mushtaq] COMSATS Inst Informat Technol, Dept Management Sci, Abbottabad, Pakistan.
   [Ahmad, Mehboob] Bahria Univ, Dept Econ, Islamabad, Pakistan.
RP Zaman, K (reprint author), COMSATS Inst Informat Technol, Dept Management Sci, Abbottabad, Pakistan.
EM khalidzaman@ciit.net.pk
CR Acharya D., 2009, INT RES J FINANCE EC, V24, P117
   Aghion P, 1999, J ECON LIT, V37, P1615, DOI 10.1257/jel.37.4.1615
   Al-Malkawi H.A., 2011, INT RES J FINANCE EC, V63, P129
   Ang J.B., 2009, ECON MODEL, V25, P38
   Ansari M. I., 2002, J ASIAN EC, V13, P72, DOI DOI 10.1016/S1049-0078(01)00113-0
   Apergis N, 2007, REV WORLD ECON, V143, P179, DOI 10.1007/s10290-007-0102-3
   Atif R. M., 2010, J INT ACAD RES, V10, P30
   Aziz J, 2002, 02194 IMF
   Bader S.A., 2006, FINANCIAL DEV EC GRO
   Beck T, 2007, J FINANC ECON, V85, P234, DOI 10.1016/j.jfineco.2006.07.002
   Clarke GRG, 2006, SOUTH ECON J, V72, P578, DOI 10.2307/20111834
   Demetriades PO, 1996, J DEV ECON, V51, P387, DOI 10.1016/S0304-3878(96)00421-X
   DICKEY DA, 1981, ECONOMETRICA, V49, P1057, DOI 10.2307/1912517
   DICKEY DA, 1979, J AM STAT ASSOC, V74, P427, DOI 10.2307/2286348
   Eng Y., 2011, BANK BANK SYSTEMS, V6, P62
   ENGLE RF, 1987, ECONOMETRICA, V55, P251, DOI 10.2307/1913236
   GoP, 2011, GOV PAK EC SURV PAK
   GRANGER CWJ, 1988, J ECON DYN CONTROL, V12, P551, DOI 10.1016/0165-1889(88)90055-3
   Halicioglu F, 2007, FINANCIAL DEV EC GRO
   IMF, 2005, IND FIN STRUCT DEV S
   Jalil A., 2008, J EC COOPERATION, V29, P29, DOI DOI 10.1016/J.BIOMATERIALS.2008.07.012
   JOHANSEN S, 1990, OXFORD B ECON STAT, V52, P169, DOI 10.1111/j.1468-0084.1990.mp52002003.x
   JOHANSEN S, 1988, J ECON DYN CONTROL, V12, P231, DOI 10.1016/0165-1889(88)90041-3
   Kakar Z.K., 2011, J INT ACAD RES, V11, P27
   Kelly A., 1980, INTERACTIONS EC DEMO
   Khan MA, 2008, S ASIA EC J, V9, P375, DOI DOI 10.1177/139156140800900206
   Khan MA, 2005, PAKISTAN DEV REV, V12, P819, DOI 10.30541/v44i4IIpp.819-837
   Khan MN, 2007, SURFACTANT SCI SER, V133, P1
   KING RG, 1993, Q J ECON, V108, P717, DOI 10.2307/2118406
   Levine R, 1997, J ECON LIT, V35, P688
   Luintel KB, 1999, J DEV ECON, V60, P381, DOI 10.1016/S0304-3878(99)00045-0
   Mackinnon JG, 1996, J APPL ECONOMET, V11, P601, DOI 10.1002/(SICI)1099-1255(199611)11:6<601::AID-JAE417>3.0.CO;2-T
   MANKIW NG, 1992, Q J ECON, V107, P407, DOI 10.2307/2118477
   Mavrotas G., 2009, UNU WIDER ANGLE NEWS
   McKinnon R. I., 1973, MONEY CAPITAL EC DEV
   OECD, 2009, SURV EX APPR MEAS SO
   Pesaran MH, 2001, J APPL ECONOM, V16, P289, DOI 10.1002/jae.616
   Pradhan J.P., 2002, S ASIA EC J, V3, P77
   Rahman H., 2007, 0707 PAU WP
   Ramirez A., 1998, QEH WORKING PAPER SE
   Ranis G, 2000, WORLD DEV, V28, P197, DOI 10.1016/S0305-750X(99)00131-X
   RANIS G., 2004, HUMAN DEV EC GROWTH
   Schumpter J.A., 1911, THEORY EC DEV
   Shahbaz M., 2008, INT RES J FINANCE EC, V14, P182
   Shaw E., 1973, FINANCIAL DEEPINGS E
   Singer T, 2007, E SCHERING RES FDN W, V59, P1
   TODA HY, 1995, J ECONOMETRICS, V66, P225, DOI 10.1016/0304-4076(94)01616-8
   UNCTAD, 1999, UNCTADOSGDP142
   Whiteley PF, 2000, POLIT STUD-LONDON, V48, P443, DOI 10.1111/1467-9248.00269
   WHO, 2006, REP CONS SOC DET HLT
   World Bank, 2010, WORLD DEV IND 2010
NR 51
TC 16
Z9 16
U1 0
U2 18
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0264-9993
EI 1873-6122
J9 ECON MODEL
JI Econ. Model.
PD SEP
PY 2012
VL 29
IS 5
BP 1515
EP 1523
DI 10.1016/j.econmod.2012.05.013
PG 9
WC Economics
SC Business & Economics
GA 996AJ
UT WOS:000308056100001
DA 2018-12-27
ER

PT J
AU Zaman, K
   Khan, MM
   Ahmad, M
   Khilji, BA
AF Zaman, Khalid
   Khan, Muhammad Mushtaq
   Ahmad, Mehboob
   Khilji, Bashir Ahmad
TI RETRACTED: The relationship between agricultural technologies and carbon
   emissions in Pakistan: Peril and promise (Retracted article. See vol.
   45, pg. 283, 2015)
SO ECONOMIC MODELLING
LA English
DT Article; Retracted Publication
DE Agricultural technologies; Carbon emissions; Economic growth; Tractors;
   Pakistan
ID AUTOREGRESSIVE TIME-SERIES; UNIT-ROOT; COINTEGRATION; INFERENCE
AB The objective of the study is to investigate the influence of agricultural technologies on carbon emissions in Pakistan by using annual data from 1975 to 2010. Data is analyzed by some econometrics techniques including cointegration theory, Granger causality test, variance decomposition, etc. The results reveal that agricultural technologies act as an important driver for increase in carbon emissions in Pakistan. Results indicate that unidirectional causality runs from agriculture machinery to carbon emissions but not vice versa. Agricultural technologies are closely associated with economic growth and carbon emissions in Pakistan. Variance decomposition analysis shows that among all the agricultural technologies, granting subsidies to the agriculture sector have exerts the largest contribution to changes in carbon emissions. Conversely, agricultural irrigated land seems relatively the least contributors on changes in carbon emissions due to infertility of total irrigated land available in Pakistan. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Zaman, Khalid] COMSATS Inst Informat Technol, Dept Management Sci, Tobe Camp, Pakistan.
   [Khan, Muhammad Mushtaq] COMSATS Inst Informat Technol, Dept Management Sci, Abbottabad, Pakistan.
   [Ahmad, Mehboob] Bahria Univ, Dept Management Sci, Islamabad, Pakistan.
   [Khilji, Bashir Ahmad] Preston Univ, Dept Econ, Islamabad, Pakistan.
RP Zaman, K (reprint author), COMSATS Inst Informat Technol, Dept Management Sci, Room 319,Block A,Univ Rd,Abbottabad Campus, Tobe Camp, Pakistan.
EM khalidzaman@ciit.net.pk
CR Acemoglu D, 2009, 15451 NBER
   [Anonymous], 2011, GREEN GROWTH STRAT F
   APCAEM, 2010, FEAS STUD APPL GREEN
   Cole MA, 2005, REV DEV ECON, V9, P530, DOI 10.1111/j.1467-9361.2005.00292.x
   DICKEY DA, 1981, ECONOMETRICA, V49, P1057, DOI 10.2307/1912517
   DICKEY DA, 1979, J AM STAT ASSOC, V74, P427, DOI 10.2307/2286348
   ENGLE RF, 1987, ECONOMETRICA, V55, P251, DOI 10.2307/1913236
   FAO, 2006, DEF CAUS GLOB WARM K
   Ghazinoory S, 2010, TECHNOL ECON DEV ECO, V16, P25, DOI 10.3846/tede.2010.02
   GoP, 2011, GOV PAK EC SURV PAK
   GoP, 2010, GOV PAK EC SURV PAK
   GRANGER CWJ, 1988, J ECON DYN CONTROL, V12, P551, DOI 10.1016/0165-1889(88)90055-3
   Grimes P., 2003, J WORLD SYSTEMS RES, V9, P261
   Grossman G. M., 1991, INNOVATION GROWTH GL
   Grossman G. M., 1993, US MEXICO FREE TRADE, P165
   GROSSMAN GM, 1995, Q J ECON, V110, P353, DOI 10.2307/2118443
   Hall B.H., 2010, ROL PAT PROT CLEAN G
   Pachauri RK, 2007, CLIM CHANG 2007 SYNT
   JOHANSEN S, 1990, OXFORD B ECON STAT, V52, P169, DOI 10.1111/j.1468-0084.1990.mp52002003.x
   JOHANSEN S, 1988, J ECON DYN CONTROL, V12, P231, DOI 10.1016/0165-1889(88)90041-3
   Jorgenson A. K., 2007, INT J COMP SOCIOL, V48, P29, DOI DOI 10.1177/0020715207072158
   Kecheng Q., 2010, CONSTRUCTION LOW CAR
   Kick E., 1997, J WORLD SYSTEMS RES, V3, P432
   Kurlavicius A., 2010, TECHNOLOGICAL EC DEV, V15, P294
   Linda J., 2001, CLIMATE CHANGE AGR S, P35
   Liu PD, 2011, TECHNOL ECON DEV ECO, V17, P74, DOI 10.3846/13928619.2011.554007
   Lucas R.E.B, 1992, INT TRADE ENV
   Michailidis A., 2011, TEECHNOLOGICAL EC DE, V16, P703
   Roberts T, 2003, J WORLD SYSTEMS RES, VIX, P277
   Sobotka A., 2010, TECHNOLOGICAL EC DEV, V15, P593
   Streimikiene D., 2010, TECHNOLOGICAL EC DEV, V14, P162
   Tamazian A, 2009, ENERG POLICY, V37, P246, DOI 10.1016/j.enpol.2008.08.025
   TODA HY, 1995, J ECONOMETRICS, V66, P225, DOI 10.1016/0304-4076(94)01616-8
   Tol RSJ, 2008, CLIMATIC CHANGE, V88, P21, DOI 10.1007/s10584-007-9253-4
   WHO World Health Organization, 2009, PROT HLTH CLIM CHANG
   World Bank, 2010, WORLD DEV IND 2010
   Zaman K, 2012, ENERG POLICY, V44, P268, DOI 10.1016/j.enpol.2012.01.050
   Zaman K, 2011, INT J GREEN ENERGY, V8, P820, DOI 10.1080/15435075.2011.602157
NR 38
TC 12
Z9 13
U1 3
U2 25
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0264-9993
EI 1873-6122
J9 ECON MODEL
JI Econ. Model.
PD SEP
PY 2012
VL 29
IS 5
BP 1632
EP 1639
DI 10.1016/j.econmod.2012.05.024
PG 8
WC Economics
SC Business & Economics
GA 996AJ
UT WOS:000308056100016
DA 2018-12-27
ER

PT J
AU Mohsin, A
   Zaman, K
AF Mohsin, Asma
   Zaman, Khalid
TI RETRACTED: Distributional effects of rising food prices in Pakistan:
   Evidence from HIES 2001-02 and 2005-06 survey (Retracted article. See
   vol. 45, pg. 280, 2015)
SO ECONOMIC MODELLING
LA English
DT Article; Retracted Publication
DE Food inflation; Distributional characteristics; Consumption basket;
   Agriculture; Pakistan
ID RESPONSES; POVERTY; INFLATION; WELFARE; IMPACT; POLICY
AB The distributional characteristic measures how evenly or unevenly commodity group is distributed over the household total expenditure. The present study investigates the distributional effects of rising food prices in Pakistan. For this purpose, this study focuses on two different household integrated economic surveys (HIES) i.e., 2001-02 and 2005-06 and analyze the distributional effects for rural and urban segments of Pakistan. As there are considerable differences in the composition of the consumption basket between rural and urban, so the survey data of both years is disaggregated into four sub-samples which may divide according to the expenditure levels of rural-urban segments based on head count index. The result reveals that the distributional characteristic of meat, fruits, soft drinks and all ready-made food products are low which implies that expenditures on these commodities are unevenly distributed over the total expenditures which favor rich families. It is evident that cereals, pulses and dairy products are the major source of welfare in rural-urban poors in Pakistan. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Mohsin, Asma; Zaman, Khalid] COMSATS Inst Informat Technol, Dept Management Sci, Abbottabad, Pakistan.
RP Zaman, K (reprint author), COMSATS Inst Informat Technol, Dept Management Sci, Abbottabad, Pakistan.
EM asmamohsin@ciit.net.pk; khalidzaman@ciit.net.pk
CR Abdullah M., 2012, World Applied Sciences Journal, V16, P933
   Ackah C., 2007, 0703 CREDIT U NOTT
   Adam C, 2011, J AFR ECON, V20, pI3, DOI 10.1093/jae/ejr012
   ADB, 2008, AS DEV BANK REP 2008
   Ahsan H., 2011, PIDE WORKING PAPERS, V76
   Aksoy M.A., 2007, 4642 WORLD BANK
   Ali M., 2008, Pakistan Development Review, V47, P531
   Arndt C, 2008, AGR ECON-BLACKWELL, V39, P497, DOI 10.1111/j.1574-0862.2008.00355.x
   Barrett CB, 1996, AM J AGR ECON, V78, P656, DOI 10.2307/1243283
   Binswanger H., 1984, 20 ARU WORLD BANK
   Boyce J., 1988, WAGE DETERMINATION R
   Cardwell R., 2008, 20091 CATPRN
   Creedy J., 1998, AUST ECON PAP, V37, P137
   Creedy J., 1997, AUSTR EC REV, V30, P125
   de Hoyos RE, 2011, REV DEV ECON, V15, P387, DOI 10.1111/j.1467-9361.2011.00615.x
   Dessus H., 2008, AGR EC, V39, P417
   Deve M.S., 2009, RISING FOOD PRICES F
   Drezgic S, 2008, ZB RAD EKON FAK RIJE, V26, P239
   Europa, 2011, 12011 EUR EUR COMM D
   FELDSTEIN MS, 1972, AM ECON REV, V62, P32
   Friedman J., 2011, 66305 HNP
   GMR, 2012, FOOD PRIC NUTR MILL
   GOP, 2011, EC SURV PAK 2010 11
   HATHAWAY DE, 1974, BROOKINGS PAP ECO AC, P63
   HIES, 2005, HOUS INT EC SURV
   HIES, 2001, HOUS INT EC SURV
   Hubbard C, 2007, FOOD POLICY, V32, P128, DOI 10.1016/j.foodpol.2006.03.012
   Hussain A., 2012, INT J DEV ISSUES, V11, P60
   Idrees M., 2008, PAKISTAN DEV REV, V47, P153
   Ivanic M, 2008, 4594 WORLD BANK
   Kalyoncu K., 2008, THESIS
   Khalid U., 2011, PIDE WORKING PAPERS, V80
   Liberati P, 2001, INT TAX PUBLIC FINAN, V8, P27, DOI 10.1023/A:1008789432330
   Madden D., 2009, UCD CTR EC WORKING P
   McKenzie DJ, 2006, ECON DEV CULT CHANGE, V55, P139, DOI 10.1086/505721
   MELLOR JW, 1978, ECON DEV CULT CHANGE, V27, P1, DOI 10.1086/451071
   NEWBERY DM, 1995, ECON J, V105, P847, DOI 10.2307/2235154
   Ozer H., 2003, Pakistan Development Review, V42, P29
   Polaski S., 2008, FAO EXP M POL EFF MA
   RAVALLION M, 1990, OXFORD ECON PAP, V42, P574, DOI 10.1093/oxfordjournals.oep.a041964
   Refaqat S., 2005, PAKISTAN DEV REV, V44, P841
   Valero-Gil JN, 2008, AGR ECON-BLACKWELL, V39, P485, DOI 10.1111/j.1574-0862.2008.00354.x
   Wodon Q, 2010, WORLD BANK RES OBSER, V25, P157, DOI 10.1093/wbro/lkp018
   Wood N., 2009, INT AGR TRAD RES CON
   Zezza A., 2008, 0807 ESA
NR 45
TC 2
Z9 2
U1 2
U2 14
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0264-9993
EI 1873-6122
J9 ECON MODEL
JI Econ. Model.
PD SEP
PY 2012
VL 29
IS 5
BP 1986
EP 1995
DI 10.1016/j.econmod.2012.06.002
PG 10
WC Economics
SC Business & Economics
GA 996AJ
UT WOS:000308056100052
DA 2018-12-27
ER

PT J
AU Tang, GW
   Hu, YM
   Yin, SA
   Wang, Y
   Dallal, GE
   Grusak, MA
   Russell, RM
AF Tang, Guangwen
   Hu, Yuming
   Yin, Shi-an
   Wang, Yin
   Dallal, Gerard E.
   Grusak, Michael A.
   Russell, Robert M.
TI RETRACTED: beta-Carotene in Golden Rice is as good as beta-carotene in
   oil at providing vitamin A to children (Retracted article. See vol. 102,
   pg. 715, 2015)
SO AMERICAN JOURNAL OF CLINICAL NUTRITION
LA English
DT Article; Retracted Publication
ID ISOTOPE REFERENCE METHOD; INTESTINAL ABSORPTION; CHINESE ADULTS;
   BIOEFFICACY; VEGETABLES; EQUIVALENCE; DEFICIENCY; PROVITAMIN;
   CONVERSION; INDONESIA
AB Background: Golden Rice (GR) has been genetically engineered to be rich in beta-carotene for use as a source of vitamin A.
   Objective: The objective was to compare the vitamin A value of beta-carotene in GR and in spinach with that of pure beta-carotene in oil when consumed by children.
   Design: Children (n = 68; age 6-8 y) were randomly assigned to consume GR or spinach (both grown in a nutrient solution containing 23 atom% (H2O)-H-2) or [H-2(8)]beta-carotene in an oil capsule. The GR and spinach beta-carotene were enriched with deuterium (H-2) with the highest abundance molecular mass (M) at M beta+C+H-2(10). [C-13(10)]Retinyl acetate in an oil capsule was administered as a reference dose. Serum samples collected from subjects were analyzed by using gas chromatography electron-capture negative chemical ionization mass spectrometry for the enrichments of labeled retinol: M-retinol+4 (from [H-2(8)]beta-carotene in oil), M-retinol+5 (from GR or spinach [H-2(10)]beta-carotene), and M-retinol+10 (from [C-13(10)]retinyl acetate).
   Results: Using the response to the dose of [C-13(10)]retinyl acetate (0.5 mg) as a reference, our results (with the use of AUC of molar enrichment at days 1, 3, 7, 14, and 21 after the labeled doses) showed that the conversions of pure beta-carotene (0.5 mg), GR beta-carotene (0.6 mg), and spinach beta-carotene (1.4 mg) to retinol were 2.0, 2.3, and 7.5 to 1 by weight, respectively.
   Conclusions: The beta-carotene in GR is as effective as pure beta-carotene in oil and better than that in spinach at providing vitamin A to children. A bowl of similar to 100 to 150 g cooked GR (50 g dry weight) can provide similar to 60% of the Chinese Recommended Nutrient Intake of vitamin A for 6-8-y-old children. This trial was registered at www.clinicaltrials.gov as NCT00680212. Am J Clin Nutr 2012;96:658-64.
C1 [Tang, Guangwen; Dallal, Gerard E.; Russell, Robert M.] Tufts Univ, USDA, Human Nutr Res Ctr Aging, Carotenoids & Hlth Lab, Boston, MA 02111 USA.
   [Hu, Yuming] Hunan Prov Ctr Dis Control & Prevent, Changsha, Hunan, Peoples R China.
   [Yin, Shi-an] Natl Inst Nutr & Food Safety, Beijing, Peoples R China.
   [Wang, Yin] Zhejiang Acad Med Sci, Hangzhou, Zhejiang, Peoples R China.
   [Grusak, Michael A.] Baylor Coll Med, Dept Pediat, ARS, USDA,Childrens Nutr Res Ctr, Houston, TX 77030 USA.
   [Russell, Robert M.] NIH, Off Dietary Supplements, Bethesda, MD 20892 USA.
RP Tang, GW (reprint author), Tufts Univ, Jean Mayer USDA, Human Nutr Res Ctr Aging, 711 Washington St, Boston, MA 02111 USA.
EM guangwen.tang@tufts.edu
FU US Department of Agriculture [581950-9-001, 58-6250-6-001,
   581950-7-707]; National Institute of Diabetes and Digestive and Kidney
   Diseases, NIH [NIDDK DK620021]; National Technology Research and
   Development Program in the 11th Five Year Plan of China [2008BAI58B03]
FX This material is based on work supported by the US Department of
   Agriculture under Cooperative Agreements 581950-9-001, 58-6250-6-001,
   and 581950-7-707; by a grant from the National Institute of Diabetes and
   Digestive and Kidney Diseases, NIH (NIDDK DK620021); and by a grant on
   spinach and pure labeled beta-carotene from the National Technology
   Research and Development Program in the 11th Five Year Plan of China
   (2008BAI58B03).
CR [Anonymous], 2001, DIETARY REFERENCE IN
   BLOMSTRA.R, 1967, SCAND J CLIN LAB INV, V19, P339, DOI 10.3109/00365516709090648
   Bouis HE, 2011, FOOD NUTR BULL, V32, pS31, DOI 10.1177/15648265110321S105
   *CHIN NUTR SOC, 2000, CHIN DRIS
   de Pee S, 1998, AM J CLIN NUTR, V68, P1058
   Furr HC, 2005, PUBLIC HEALTH NUTR, V8, P596, DOI 10.1079/PHN2004715
   GOODMAN DWS, 1966, J CLIN INVEST, V45, P1615, DOI 10.1172/JCI105468
   Grune T, 2010, J NUTR, V140, p2268S, DOI 10.3945/jn.109.119024
   Guideline WHO, 2011, VIT SUPPL INF CHILDR
   Haskell MJ, 2004, AM J CLIN NUTR, V80, P705
   Haskell MJ, 2003, AM J CLIN NUTR, V77, P681
   IDRC, 1997, MICR IN FOOD FORT EN
   Kendall MG, 1969, ADV THEORY STAT, V1, P232
   Keyou G, 1999, 1992 NATL NUTR SURVE, V2
   Mayo-Wilson E, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5094
   Mora JO, 2000, VITAMIN SUGAR FORTIF
   Muzhingi T, 2011, AM J CLIN NUTR, V94, P510, DOI 10.3945/ajcn.110.006486
   *NAT RES COUNC FOO, 1989, REC DIET ALL
   Nutrition WHO, MICR DEF
   Paine JA, 2005, NAT BIOTECHNOL, V23, P482, DOI 10.1038/nbt1082
   Palmer AC, 2010, FOOD REV INT, V26, P270, DOI 10.1080/87559129.2010.484116
   Ross AC, 2011, VITAM HORM, V86, P103, DOI 10.1016/B978-0-12-386960-9.00005-8
   Sauberlich H E, 1974, Vitam Horm, V32, P251
   Tang G, 1999, AM J CLIN NUTR, V70, P1069
   Tang Guangwen, 2000, Food and Nutrition Bulletin, V21, P161
   Tang GW, 2009, AM J CLIN NUTR, V89, P1776, DOI 10.3945/ajcn.2008.27119
   Tang GW, 2005, AM J CLIN NUTR, V82, P821
   Tang GW, 2003, AM J CLIN NUTR, V78, P259
   Underwood BA, 1996, FASEB J, V10, P1040
   van Lieshout M, 2001, AM J CLIN NUTR, V73, P949
   Wang J, 2008, AM J CLIN NUTR, V87, P1730
   Wang ZX, 2004, BRIT J NUTR, V91, P121, DOI 10.1079/BJN20031030
   West CE, 2002, J NUTR, V132, p2920S, DOI 10.1093/jn/132.9.2920S
   West K. P. J., 2010, WORLD NUTR, V1, P211
   World Health Organization, 2009, GLOB PREV VIT DEF PO
   Ye XD, 2000, SCIENCE, V287, P303, DOI 10.1126/science.287.5451.303
   You D, 2010, LEVELS TRENDS CHILD
NR 37
TC 65
Z9 74
U1 5
U2 185
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0002-9165
EI 1938-3207
J9 AM J CLIN NUTR
JI Am. J. Clin. Nutr.
PD SEP
PY 2012
VL 96
IS 3
BP 658
EP 664
DI 10.3945/ajcn.111.030775
PG 7
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 993MM
UT WOS:000307863800026
PM 22854406
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Iwamoto, J
   Sato, Y
   Takeda, T
   Matsumoto, H
AF Iwamoto, J.
   Sato, Y.
   Takeda, T.
   Matsumoto, H.
TI RETRACTED: Whole body vibration exercise improves body balance and
   walking velocity in postmenopausal osteoporotic women treated with
   alendronate: Galileo and Alendronate Intervention Trail (GAIT)
   (Retracted article. See vol. 18, pg. 280, 2018)
SO JOURNAL OF MUSCULOSKELETAL & NEURONAL INTERACTIONS
LA English
DT Article; Retracted Publication
DE Whole Body Vibration Exercise; Flexibility; Body Balance; Walking
   Velocity; Osteoporosis
ID RANDOMIZED CONTROLLED-TRIAL; BONE-MINERAL DENSITY; JAPANESE PATIENTS;
   OVARIECTOMIZED RATS; DIAGNOSTIC-CRITERIA; VERTEBRAL FRACTURES; MUSCLE
   STRENGTH; DOUBLE-BLIND; VITAMIN-D; FALLS
AB A randomized controlled trial was conducted to determine the effect of 6 months of whole body vibration (WBV) exercise on physical function in postmenopausal osteoporotic women treated with alendronate. Fifty-two ambulatory postmenopausal women with osteoporosis (mean age: 74.2 years, range: 51-91 years) were randomly divided into two groups: an exercise group and a control group. A four-minute WBV exercise was performed two days per week only in the exercise group. No exercise was performed in the control group. All the women were treated with alendronate. After 6 months of the WBV exercise, the indices for flexibility, body balance, and walking velocity were significantly improved in the exercise group compared with the control group. The exercise was safe and well tolerated. The reductions in serum alkaline phosphatase and urinary cross-linked N-terminal telopeptides of type I collagen during the 6-month period were comparable between the two groups. The present study showed the benefit and safety of WBV exercise for improving physical function in postmenopausal osteoporotic women treated with alendronate.
C1 [Iwamoto, J.; Takeda, T.; Matsumoto, H.] Keio Univ, Inst Integrated Sports Med, Sch Med, Shinjuku Ku, Tokyo 1608582, Japan.
   [Iwamoto, J.] Keiyu Orthopaed Hosp, Dept Orthopaed Surg, Gunma, Japan.
   [Sato, Y.] Mitate Hosp, Dept Neurol, Fukuoka, Japan.
RP Iwamoto, J (reprint author), Keio Univ, Inst Integrated Sports Med, Sch Med, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.
EM jiwamoto@a8.keio.jp
RI Matsumoto, Hideo/A-2304-2014
CR Bischoff-Ferrari HA, 2009, BRIT MED J, V339, DOI 10.1136/bmj.b3692
   Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140-6736(96)07088-2
   Cederholm TE, 2011, CLIN GERIATR MED, V27, P341, DOI 10.1016/j.cger.2011.04.001
   Chilibeck PD, 2002, CAN J PHYSIOL PHARM, V80, P941, DOI 10.1139/y02-126
   Conway GE, 2007, ERGONOMICS, V50, P228, DOI 10.1080/00140130600980888
   Cummings SR, 1998, JAMA-J AM MED ASSOC, V280, P2077, DOI 10.1001/jama.280.24.2077
   Fielding RA, 2011, J AM MED DIR ASSOC, V12, P249, DOI 10.1016/j.jamda.2011.01.003
   Fjeldstad C, 2009, MATURITAS, V63, P79, DOI 10.1016/j.maturitas.2009.03.013
   Frost HM, 1997, BONE, V20, P385, DOI 10.1016/S8756-3282(97)00019-7
   Fuchs RK, 2007, BONE, V41, P290, DOI 10.1016/j.bone.2007.04.179
   Ganz DA, 2007, JAMA-J AM MED ASSOC, V297, P77, DOI 10.1001/jama.297.1.77
   Gardner MM, 2000, BRIT J SPORT MED, V34, P7, DOI 10.1136/bjsm.34.1.7
   Iwamoto J, 2005, AGING CLIN EXP RES, V17, P157
   Iwamoto J, 2009, OSTEOPOROSIS INT, V20, P1233, DOI 10.1007/s00198-008-0794-9
   Iwamoto Jun, 2004, Keio Journal of Medicine, V53, P85, DOI 10.2302/kjm.53.85
   Iwamoto Jun, 2009, Ther Clin Risk Manag, V5, P773
   Iwamoto Jun, 2009, Ther Clin Risk Manag, V5, P499
   Kawanabe K, 2008, JPN J ORTHOP SPORTS, V28, P242
   Kawanabe Kazuhiro, 2007, Keio Journal of Medicine, V56, P28, DOI 10.2302/kjm.56.28
   Kushida K, 2002, CURR THER RES CLIN E, V63, P606, DOI 10.1016/S0011-393X(02)80065-0
   Kushida K, 2004, J BONE MINER METAB, V22, P462, DOI 10.1007/s00774-004-0508-0
   Lau RWK, 2011, CLIN REHABIL, V25, P975, DOI 10.1177/0269215511405078
   Lespessailles E, 2009, CALCIFIED TISSUE INT, V85, P146, DOI 10.1007/s00223-009-9269-z
   Nishizawa Y, 2005, J BONE MINER METAB, V23, P97, DOI 10.1007/s00774-004-0547-6
   Orimo H, 1998, J BONE MINER METAB, V16, P139, DOI 10.1007/s007740050038
   Orimo H, 2001, J BONE MINER METAB, V19, P331, DOI 10.1007/s007740170001
   Orimo H, 2011, LIFE SCI
   Rogan S, 2011, BMC GERIATR
   Runge M., 2006, Journal of Musculoskeletal & Neuronal Interactions, V6, P167
   Runge M., 2000, Journal of Musculoskeletal & Neuronal Interactions, V1, P61
   Sakamoto K, 2006, J ORTHOP SCI, V11, P467, DOI 10.1007/s00776-006-1057-2
   Sato Y, 2005, CEREBROVASC DIS, V20, P187, DOI 10.1159/000087203
   Schiessl H, 1998, BONE, V22, P1, DOI 10.1016/S8756-3282(97)00223-8
   Shiraki M, 1999, OSTEOPOROSIS INT, V10, P183, DOI 10.1007/s001980050214
   Slatkovska L, 2010, OSTEOPOROSIS INT, V21, P1969, DOI 10.1007/s00198-010-1228-z
   Suzuki T, 2008, J BONE MINER RES, V23, P1309, DOI 10.1359/JBMR.080328
   Uchida S, 2005, J BONE MINER METAB, V23, P382, DOI 10.1007/s00774-005-0616-5
   von Stengel S, 2012, SCAND J MED SCI SPOR, V22, P119, DOI 10.1111/j.1600-0838.2010.01126.x
   Wang CY, 2012, GERIATR GERONTOL INT, V12, P388, DOI 10.1111/j.1447-0594.2012.00851.x
   Wells GA, 2008, COCHRANE DB SYST REV, V23, DOI DOI 10.1002/14651858.CD001155.PUB2
NR 40
TC 25
Z9 26
U1 0
U2 10
PU JMNI
PI NAFPLION
PA 7 SPILIADOU SQ, NAFPLION, 21 100, GREECE
SN 1108-7161
J9 J MUSCULOSKEL NEURON
JI J. Musculoskelet. Neuronal Interact.
PD SEP
PY 2012
VL 12
IS 3
BP 136
EP 143
PG 8
WC Neurosciences; Physiology
SC Neurosciences & Neurology; Physiology
GA 002UV
UT WOS:000308562800003
PM 22947545
DA 2018-12-27
ER

PT J
AU Lugogo, NL
   Hollingsworth, JW
   Howell, DL
   Que, LG
   Francisco, D
   Church, TD
   Potts-Kant, EN
   Ingram, JL
   Wang, Y
   Jung, SH
   Kraft, M
AF Lugogo, Njira L.
   Hollingsworth, John W.
   Howell, Druhan L.
   Que, Loretta G.
   Francisco, Dave
   Church, Tony D.
   Potts-Kant, Erin N.
   Ingram, Jennifer L.
   Wang, Ying
   Jung, Sin-Ho
   Kraft, Monica
TI RETRACTED: Alveolar Macrophages from Overweight/Obese Subjects with
   Asthma Demonstrate a Proinflammatory Phenotype (Retracted article. See
   vol. 192, pg. 264, 2015)
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Article; Retracted Publication
DE tumor necrosis factor-alpha; leptin; innate immunity;
   lipopolysaccharide; environmental lung disease
ID BODY-MASS INDEX; ADIPOSE-TISSUE; LEPTIN RESISTANCE; INSULIN-RESISTANCE;
   ADULT ASTHMA; OBESITY; INFLAMMATION; MICE; ASSOCIATION; MECHANISMS
AB Rationale Obesity is associated with increased prevalence and severity of asthma. Adipose tissue macrophages can contribute to the systemic proinflammatory state associated with obesity. However, it remains unknown whether alveolar macrophages have a unique phenotype in overweight/obese patients with asthma.
   Objectives: We hypothesized that leptin levels would be increased in the bronchoalveolar lavage fluid from overweight/obese subjects and, furthermore, that leptin would alter the response of alveolar macrophages to bacterial LPS.
   Methods: Forty-two subjects with asthma and 46 healthy control subjects underwent research bronchoscopy. Bronchoalveolar lavage fluid from 66 was analyzed for the level of cellular inflammation, cytokines, and soluble leptin. Cultured primary macrophages from 22 subjects were exposed to LPS, leptin, or leptin plus LPS. Cytokines were measured in the supernatants.
   Measurements and Main Results: Leptin levels were increased in overweight/obese subjects, regardless of asthma status (P = 0.013), but were significantly higher in overweight/obese subjects with asthma. Observed levels of tumor necrosis factor-alpha were highest in overweight/obese subjects with asthma. Ex vivo studies of primary alveolar macrophages indicated that the response to LPS was most robust in alveolar macrophages from overweight/obese subjects with asthma and that preexposure to high-dose leptin enhanced the proinflammatory response. Leptin alone was sufficient to induce production of proinflammatory cytokines from macrophages derived from overweight/obese subjects with asthma.
   Conclusions: Ex vivo studies indicate that alveolar macrophages derived from overweight/obese subjects with asthma are uniquely sensitive to leptin. This macrophage phenotype, in the context of higher levels of soluble leptin, may contribute to the pathogenesis of airway disease associated with obesity.
C1 [Lugogo, Njira L.; Hollingsworth, John W.; Que, Loretta G.; Francisco, Dave; Church, Tony D.; Potts-Kant, Erin N.; Ingram, Jennifer L.; Wang, Ying; Kraft, Monica] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA.
   [Hollingsworth, John W.] Duke Univ, Med Ctr, Dept Immunol, Durham, NC 27710 USA.
   [Howell, Druhan L.] Univ S Alabama, Coll Med, Dept Med, Mobile, AL USA.
   [Howell, Druhan L.] Univ S Alabama, Coll Med, Dept Pediat, Mobile, AL USA.
   [Jung, Sin-Ho] Duke Univ, Med Ctr, Dept Biostat & Bioinformat, Durham, NC 27710 USA.
RP Lugogo, NL (reprint author), Duke Univ, Med Ctr, Dept Med, POB 2629, Durham, NC 27710 USA.
EM njira.lugogo@duke.edu
FU American Thoracic Society [07-012];  [P50-HL-084917];  [HL-05-009]; 
   [HL086887];  [ES016126];  [AI081672]
FX Supported by American Thoracic Society grant 07-012 and by grants
   P50-HL-084917, HL-05-009, HL086887, ES016126, and AI081672.
CR Barros LL, 2011, J ASTHMA, V48, P171, DOI 10.3109/02770903.2011.554940
   Beuther DA, 2007, AM J RESP CRIT CARE, V175, P661, DOI 10.1164/rccm.200611-1717OC
   Bibi H, 2004, J ASTHMA, V41, P403, DOI 10.1081/JAS-120026297
   Bu DX, 2011, CURR OPIN LIPIDOL, V22, P165, DOI 10.1097/MOL.0b013e3283453e41
   Chen Y, 2006, CHEST, V130, P890, DOI 10.1378/chest.130.3.890
   Correia MLG, 2002, DIABETES, V51, P439, DOI 10.2337/diabetes.51.2.439
   Dixon AE, 2011, J ALLERGY CLIN IMMUN, V128, P508, DOI 10.1016/j.jaci.2011.06.009
   Fantuzzi G, 2005, J ALLERGY CLIN IMMUN, V115, P911, DOI 10.1016/j.jaci.2005.02.023
   Hanefeld M, 2007, J AM COLL CARDIOL, V49, P290, DOI 10.1016/j.jacc.2006.08.054
   Hauner H, 2005, P NUTR SOC, V64, P163, DOI 10.1079/PNS2005428
   Holguin F, 2011, J ASTHMA, V48, P217, DOI 10.3109/02770903.2011.555033
   Kattan M, 2010, J ALLERGY CLIN IMMUN, V125, P584, DOI 10.1016/j.jaci.2010.01.053
   Komakula S, 2007, RESP RES, V8, DOI 10.1186/1465-9921-8-32
   Kraft M, 2002, CHEST, V121, P1782, DOI 10.1378/chest.121.6.1782
   Lessard A, 2011, BIOMARKERS, V16, P271, DOI 10.3109/1354750X.2010.550013
   Loerbroks A, 2008, ANN EPIDEMIOL, V18, P283, DOI 10.1016/j.annepidem.2007.11.001
   Loffreda S, 1998, FASEB J, V12, P57
   Lugogo N, 2011, AM J RESP CRIT CARE, V183
   Maneechotesuwan K, 2010, J ALLERGY CLIN IMMUN, V126, P754, DOI 10.1016/j.jaci.2010.08.005
   Mosen DM, 2008, J ALLERGY CLIN IMMUN, V122, P507, DOI 10.1016/j.jaci.2008.06.024
   Myers MG, 2008, ANNU REV PHYSIOL, V70, P537, DOI 10.1146/annurev.physiol.70.113006.100707
   Myers MG, 2010, TRENDS ENDOCRIN MET, V21, P643, DOI 10.1016/j.tem.2010.08.002
   Nystad W, 2004, AM J EPIDEMIOL, V160, P969, DOI 10.1093/aje/kwh303
   Shore SA, 2005, J ALLERGY CLIN IMMUN, V115, P103, DOI 10.1016/j.jaci.2004.10.007
   Sin DD, 2008, THORAX, V63, P1018, DOI 10.1136/thx.2007.086819
   Skurk T, 2005, MMW Fortschr Med, V147, P41
   Sood A, 2006, THORAX, V61, P300, DOI 10.1136/thx.2004.031468
   Straczkowski M, 2002, J CLIN ENDOCR METAB, V87, P4602, DOI 10.1210/jc.2002-020135
   Suganami T, 2007, ARTERIOSCL THROM VAS, V27, P84, DOI 10.1161/01.ATV.0000251608.09329.9a
   Sutherland ER, 2008, AM J RESP CRIT CARE, V178, P682, DOI 10.1164/rccm.200801-076OC
   Tilg H, 2006, NAT REV IMMUNOL, V6, P772, DOI 10.1038/nri1937
   Uysal KT, 1997, NATURE, V389, P610, DOI 10.1038/39335
   von Kries R, 2001, ALLERGY, V56, P318, DOI 10.1034/j.1398-9995.2001.00727.x
   Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246
   Wellen KE, 2003, J CLIN INVEST, V112, P1785, DOI 10.1172/JCI200320514
   Xu HY, 2003, J CLIN INVEST, V112, P1821, DOI 10.1172/JCI200319451
NR 36
TC 47
Z9 48
U1 2
U2 8
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1073-449X
EI 1535-4970
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PD SEP 1
PY 2012
VL 186
IS 5
BP 404
EP 411
DI 10.1164/rccm.201109-1671OC
PG 8
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA 998YY
UT WOS:000308277500007
PM 22773729
OA Green Published
DA 2018-12-27
ER

PT J
AU Moneim, WMA
   Yassa, HA
   George, SM
AF Moneim, Wafaa M. Abdel
   Yassa, Heba A.
   George, Safaa M.
TI RETRACTED: Suicide Trends in Upper Egypt (Retracted article. See vol.
   61, pg. 879, 2016)
SO JOURNAL OF FORENSIC SCIENCES
LA English
DT Article; Retracted Publication
DE forensic science; suicide; Assiut; Egypt; victims; violent; problem
ID GENDER-DIFFERENCES; DEPRESSION; RATES
AB Suicide is an important problem, ranking among the top 10 causes of death for individuals in all ages in developed countries. This article is a retrospective study evaluating suicide cases in Assiut, one of the largest provinces in Egypt, from 2005 to 2009. There were 117 cases, of which involved 68 male victims (58.12%) and 49 women (41.88%). Suicide rates ranged from 0.6 to 0.8 per 100,000. Age predominance was from 20 to =30 years. The method of suicide was different between male and female victims, as male victims tried to use more violent methods than females. The most common cause of death in men was usage of toxins and by hanging 29% and 28%, respectively, while in women was usage of toxins (70%). This study showed that suicide rates have increased since 1987, indicating a grave problem that needs to be solved.
C1 [Moneim, Wafaa M. Abdel; Yassa, Heba A.; George, Safaa M.] Assiut Univ, Fac Med, Forens Med & Clin Toxicol Dept, Asyut, Egypt.
RP Yassa, HA (reprint author), Assiut Univ, Fac Med, Forens Med & Clin Toxicol Dept, Asyut, Egypt.
EM heba_yassa@hotmail.com
CR Ajdacic-Gross V, 2008, B WORLD HEALTH ORGAN, V86, P726, DOI 10.2471/BLT.07.043489
   BARRACLOUGH BM, 1973, BRIT J PSYCHIAT, V122, P95, DOI 10.1192/bjp.122.1.95
   Bertolote J. M., 2015, SUICIDOLOGI, V7, DOI [DOI 10.1186/1477-7525-9-13, 10.5617/suicidologi.2330]
   Bjerkeset O, 2008, BRIT J PSYCHIAT, V192, P474, DOI 10.1192/bjp.bp.107.045203
   Byard Roger W, 2004, J Clin Forensic Med, V11, P123, DOI 10.1016/j.jcfm.2003.12.002
   Central Agency for Public Mobilization and Statistics Egypt, 2006, CIT POP
   Chang SS, 2010, SOC PSYCH PSYCH EPID, V45, P143, DOI 10.1007/s00127-009-0049-x
   Elhak SAG, 2009, J FORENSIC LEG MED, V16, P266, DOI 10.1016/j.jflm.2008.12.006
   Hawton K, 2000, BRIT J PSYCHIAT, V177, P484, DOI 10.1192/bjp.177.6.484
   Inoue Ken, 2007, Legal Medicine, V9, P139, DOI 10.1016/j.legalmed.2006.11.004
   Jaga Kushik, 2007, Reviews on Environmental Health, V22, P57
   Langhinrichsen-Rohling J, 2009, AGGRESS VIOLENT BEH, V14, P402, DOI 10.1016/j.avb.2009.06.010
   London L, 2005, AM J IND MED, V47, P308, DOI 10.1002/ajim.20147
   Marks M, 2001, THESIS STANFORD U ST
   Okasha A, 1983, SUICIDE ASIA NEAR E, P333
   Oner S, 2007, EUR PSYCHIAT, V22, P223, DOI 10.1016/j.eurpsy.2007.01.002
   Pritchard C, 2007, PSYCHOL MED, V37, P421, DOI [10.1017/S0033291706009159, 10.1017/S003391706009159]
   Radwan S, 2002, ECESWP70
   Rezaeian M, 2010, CRISIS, V31, P36, DOI 10.1027/0227-5910/a000005
   Rezaelan M., 2007, Eastern Mediterranean Health Journal, V13, P953
   SAINSBURY P, 1982, J EPIDEMIOL COMMUN H, V36, P43, DOI 10.1136/jech.36.1.43
   Stengel E, 1969, SUICIDE ATTEMPTED SU
   Varnik A, 2008, J EPIDEMIOL COMMUN H, V62, P545, DOI 10.1136/jech.2007.065391
   World Health Organization, 2011, WHO REP SUIC STAT
   World Health Organization [WHO], 2009, SUIC PREV SUPRE
   Yassa HA, 2009, ENVIRON TOXICOL PHAR, V28, P397, DOI 10.1016/j.etap.2009.07.003
NR 26
TC 2
Z9 2
U1 3
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-1198
EI 1556-4029
J9 J FORENSIC SCI
JI J. Forensic Sci.
PD SEP
PY 2012
VL 57
IS 5
BP 1247
EP 1251
DI 10.1111/j.1556-4029.2012.02247.x
PG 5
WC Medicine, Legal
SC Legal Medicine
GA 000MX
UT WOS:000308391500013
DA 2018-12-27
ER

PT J
AU Masoudi-Nejad, A
   Meshkin, A
   Haji-Eghrari, B
   Bidkhori, G
AF Masoudi-Nejad, Ali
   Meshkin, Alireza
   Haji-Eghrari, Behzad
   Bidkhori, Gholamreza
TI RETRACTED: Candidate gene prioritization (Retracted article. See vol.
   290, pg. 2357, 2015)
SO MOLECULAR GENETICS AND GENOMICS
LA English
DT Review; Retracted Publication
DE Candidate gene; Gene prioritization; Genetic disorder; Computational
   tools
ID COMPLEX HUMAN TRAITS; DISEASE GENES; DATA FUSION; IDENTIFICATION;
   ASSOCIATION; EXPRESSION; PHENOTYPE; CYTOSCAPE; NETWORKS; GENOME
AB Candidate gene identification is typically labour intensive, involving laboratory experiments required to corroborate or disprove any hypothesis for a nominated candidate gene being considered the causative gene. The traditional approach to reduce the number of candidate genes entails fine-mapping studies using markers and pedigrees. Gene prioritization establishes the ranking of candidate genes based on their relevance to the biological process of interest, from which the most promising genes can be selected for further analysis. To date, many computational methods have focused on the prediction of candidate genes by analysis of their inherent sequence characteristics and similarity with respect to known disease genes, as well as their functional annotation. In the last decade, several computational tools for prioritizing candidate genes have been proposed. A large number of them are web-based tools, while others are standalone applications that install and run locally. This review attempts to take a close look at gene prioritization criteria, as well as candidate gene prioritization algorithms, and thus provide a comprehensive synopsis of the subject matter.
C1 [Masoudi-Nejad, Ali; Meshkin, Alireza; Haji-Eghrari, Behzad; Bidkhori, Gholamreza] Univ Tehran, Inst Biochem & Biophys, Lab Syst Biol & Bioinformat LBB, Tehran, Iran.
RP Masoudi-Nejad, A (reprint author), Univ Tehran, Inst Biochem & Biophys, Lab Syst Biol & Bioinformat LBB, Tehran, Iran.
EM amasoudin@ibb.ut.ac.ir
CR Adie EA, 2006, BIOINFORMATICS, V22, P773, DOI 10.1093/bioinformatics/btk031
   Aerts S, 2006, NAT BIOTECHNOL, V24, P537, DOI 10.1038/nbt1203
   Auffray C, 2009, GENOME MED, V1, DOI 10.1186/gm2
   Braun TA, 2006, HUM MUTAT, V27, P195, DOI 10.1002/humu.20247
   Braun TA, 2003, J SUPERCOMPUT, V26, P7, DOI 10.1023/A:1024417200364
   Chen J., 2009, BMC BIOINFORMATICS, V10, P1
   Chen J, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-392
   Chen J, 2009, NUCLEIC ACIDS RES, V37, pW305, DOI 10.1093/nar/gkp427
   Chen YX, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021137
   Cheng D, 2008, NUCLEIC ACIDS RES, V36, pW399, DOI 10.1093/nar/gkn296
   De Bie T, 2007, BIOINFORMATICS, V23, pI125, DOI 10.1093/bioinformatics/btm187
   Franke L, 2006, AM J HUM GENET, V78, P1011, DOI 10.1086/504300
   Gaulton KJ, 2007, BIOINFORMATICS, V23, P1132, DOI 10.1093/bioinformatics/btm001
   George RA, 2006, NUCLEIC ACIDS RES, V34, P130
   Gibson G, 2009, NAT REV GENET, V10, P134, DOI 10.1038/nrg2502
   Hristovski D, 2005, INT J MED INFORM, V74, P289, DOI 10.1016/j.ijmedinf.2004.04.024
   Hutz JE, 2008, GENET EPIDEMIOL, V32, P779, DOI 10.1002/gepi.20346
   Kohler S, 2008, AM J HUM GENET, V82, P949, DOI 10.1016/j.ajhg.2008.02.013
   Kohl P, 2010, CLIN PHARMACOL THER, V88, P25, DOI 10.1038/clpt.2010.92
   Ma XT, 2007, BIOINFORMATICS, V23, P215, DOI 10.1093/bioinformatics/btl569
   Morrison JL, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-233
   Nabieva E, 2005, BIOINFORMATICS, V21, pI302, DOI 10.1093/bioinformatics/bti1044
   Nitsch D, 2011, NUCLEIC ACIDS RES, V39, pW334, DOI 10.1093/nar/gkr289
   Nitsch D, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-460
   O'Connor TP, 2006, NAT REV GENET, V7, P261, DOI 10.1038/nrg1829
   Oti M, 2006, J MED GENET, V43, DOI 10.1136/jmg.2006.041376
   Perez-Iratxeta C, 2005, BMC GENET, V6, DOI 10.1186/1471-2156-6-45
   Perez-Iratxeta C, 2002, NAT GENET, V31, P316, DOI 10.1038/ng895
   Pers TH, 2011, GENET EPIDEMIOL, V35, P318, DOI 10.1002/gepi.20580
   Radivojac P, 2008, PROTEINS, V72, P1030, DOI 10.1002/prot.21989
   Rossi S, 2006, NUCLEIC ACIDS RES, V34, pW285, DOI 10.1093/nar/gkl340
   Schlicker A, 2010, BIOINFORMATICS, V26, pi561, DOI 10.1093/bioinformatics/btq384
   Seelow D, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003874
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Smoot M, 2011, BIOINFORMATICS, V27, P1030, DOI 10.1093/bioinformatics/btr045
   TRANCHEVENT LC, 2010, BRIEF BIOINFORM, V11, P1
   Tranchevent LC, 2008, NUCLEIC ACIDS RES, V36, pW377, DOI 10.1093/nar/gkn325
   Turner FS, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-11-r75
   van Driel MA, 2006, EUR J HUM GENET, V14, P535, DOI 10.1038/sj.ejhg.5201585
   Van Vooren S, 2007, NUCLEIC ACIDS RES, V35, P2533, DOI 10.1093/nar/gkm054
   Vanunu O, 2008, P GERM C BIOINF BERL
   Xiong Q, 2008, BIOINFORMATICS, V24, P1011, DOI 10.1093/bioinformatics/btn002
   Yoshida Y, 2009, NUCLEIC ACIDS RES, V37, pW147, DOI 10.1093/nar/gkp384
   Yu W, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-528
   Yue P, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-166
   Zhu MJ, 2007, INT J BIOL SCI, V3, P420
NR 46
TC 13
Z9 14
U1 2
U2 23
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 1617-4615
EI 1617-4623
J9 MOL GENET GENOMICS
JI Mol. Genet. Genomics
PD SEP
PY 2012
VL 287
IS 9
BP 679
EP 698
DI 10.1007/s00438-012-0710-z
PG 20
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 995GD
UT WOS:000307995100001
PM 22893106
DA 2018-12-27
ER

PT J
AU Perron, GG
   Kryazhimskiy, S
   Rice, DP
   Buckling, A
AF Perron, Gabriel G.
   Kryazhimskiy, Sergey
   Rice, Daniel P.
   Buckling, Angus
TI RETRACTED: Multidrug Therapy and Evolution of Antibiotic Resistance:
   When Order Matters (Retracted article. See vol. 78, pg. 6137, 2012)
SO APPLIED AND ENVIRONMENTAL MICROBIOLOGY
LA English
DT Article; Retracted Publication
ID INTENSIVE-CARE-UNIT; ANTIMICROBIAL RESISTANCE; PSEUDOMONAS-AERUGINOSA;
   DRUG-RESISTANCE; MYCOBACTERIUM-TUBERCULOSIS; HELICOBACTER-PYLORI; COST;
   ADAPTATION; INFECTIONS; BACTERIA
AB The evolution of drug resistance among pathogenic bacteria has led public health workers to rely increasingly on multidrug therapy to treat infections. Here, we compare the efficacy of combination therapy (i.e., using two antibiotics simultaneously) and sequential therapy (i.e., switching two antibiotics) in minimizing the evolution of multidrug resistance. Using in vitro experiments, we show that the sequential use of two antibiotics against Pseudomonas aeruginosa can slow down the evolution of multiple-drug resistance when the two antibiotics are used in a specific order. A simple population dynamics model reveals that using an antibiotic associated with high costs of resistance first minimizes the chance of multidrug resistance evolution during sequential therapy under limited mutation supply rate. As well as presenting a novel approach to multidrug therapy, this work shows that costs of resistance not only influences the persistence of antibiotic-resistant bacteria but also plays an important role in the emergence of resistance.
C1 [Perron, Gabriel G.; Kryazhimskiy, Sergey; Rice, Daniel P.] Harvard Univ, FAS Ctr Syst Biol, Cambridge, MA 02138 USA.
   [Perron, Gabriel G.; Kryazhimskiy, Sergey; Rice, Daniel P.] Harvard Univ, Dept Organism & Evolutionary Biol, Cambridge, MA 02138 USA.
   [Perron, Gabriel G.; Buckling, Angus] Univ Oxford, Dept Zool, Oxford OX1 3PS, England.
   [Buckling, Angus] Univ Exeter, Tremough, Cornwall, England.
RP Perron, GG (reprint author), Harvard Univ, FAS Ctr Syst Biol, Cambridge, MA 02138 USA.
EM gperron@fas.harvard.edu
FU European Research Council (ERC); Leverhulme Trust; Clarendon Funds of
   the University of Oxford; National Science Engineering and Research
   Council of Canada (NSERC); Fond Quebecois pour la Recherche sur la
   Nature et les Technologies (FQRNT)
FX This work was funded by the European Research Council (ERC) and the
   Leverhulme Trust. G.G.P. was funded during this work by the Clarendon
   Funds of the University of Oxford and the National Science Engineering
   and Research Council of Canada (NSERC) and is now funded by the Fond
   Quebecois pour la Recherche sur la Nature et les Technologies (FQRNT).
CR Albert TJ, 2005, NAT METHODS, V2, P951, DOI 10.1038/NMETH805
   Andersson DI, 2010, NAT REV MICROBIOL, V8, P260, DOI 10.1038/nrmicro2319
   Andes D, 2004, CLIN LAB MED, V24, P477, DOI 10.1016/j.cll.2004.03.009
   Bal AM, 2010, ANN NY ACAD SCI, V1213, P81, DOI 10.1111/j.1749-6632.2010.05867.x
   Beardmore R. E., 2010, MATH BIOSCI ENG, V7, P26
   Beardmore RE, 2010, MATH BIOSCI ENG, V7, P923, DOI 10.3934/mbe.2010.7.923
   Bell G, 2008, SELECTION: THE MECHANISM OF EVOLUTION, 2ND EDITION, P1
   Bennett KM, 2007, J TRAUMA, V63, P307, DOI 10.1097/TA.0b013e318120595e
   Bergstrom CT, 2004, P NATL ACAD SCI USA, V101, P13285, DOI 10.1073/pnas.0402298101
   Bhusal Y, 2005, INT J ANTIMICROB AG, V26, P292, DOI 10.1016/j.ijantimicag.2005.05.005
   Bonhoeffer S, 2010, MATH BIOSCI ENG, V7, P919, DOI 10.3934/mbe.2010.7.919
   Campbell EA, 2001, CELL, V104, P901, DOI 10.1016/S0092-8674(01)00286-0
   CHIBA N, 1992, AM J GASTROENTEROL, V87, P1716
   DANIELS M, 1952, BRIT MED J, V1, P1162, DOI 10.1136/bmj.1.4769.1162
   Eber MR, 2010, ARCH INTERN MED, V170, P347, DOI 10.1001/archinternmed.2009.509
   Gagneux S, 2006, SCIENCE, V312, P1944, DOI 10.1126/science.1124410
   Gould I M, 2007, ANTIBIOTIC POLICIES
   HAUSER AR, 2007, ANTIBIOTICS BASICS C
   Kerr KG, 2009, J HOSP INFECT, V73, P338, DOI 10.1016/j.jhin.2009.04.020
   Kouyos RD, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1001094
   Levy SB, 2004, NAT MED, V10, pS122, DOI 10.1038/nm1145
   MacLean RC, 2010, NAT REV GENET, V11, P405, DOI 10.1038/nrg2778
   Ochman H, 2000, NATURE, V405, P299, DOI 10.1038/35012500
   Palumbi SR, 2001, SCIENCE, V293, P1786, DOI 10.1126/science.293.5536.1786
   Pearson A, 2009, J HOSP INFECT, V73, P296, DOI 10.1016/j.jhin.2009.08.016
   Perron GG, 2008, J EVOLUTION BIOL, V21, P1724, DOI 10.1111/j.1420-9101.2008.01596.x
   Perron GG, 2008, FEMS MICROBIOL LETT, V281, P17, DOI 10.1111/j.1574-6968.2007.01045.x
   Perron GG, 2007, P R SOC B, V274, P2351, DOI 10.1098/rspb.2007.0640
   Perron GG, 2012, P ROY SOC B-BIOL SCI, V279, P1477, DOI 10.1098/rspb.2011.1933
   Perron GG, 2010, AM NAT, V176, P303, DOI 10.1086/655217
   Pinheiro J. C., 2000, MIXED EFFECTS MODELS
   Radman M, 1975, Basic Life Sci, V5A, P355
   Reinhardt A, 2007, ANTIMICROB AGENTS CH, V51, P1341, DOI 10.1128/AAC.01278-06
   Sandiumenge A, 2006, J ANTIMICROB CHEMOTH, V57, P1197, DOI 10.1093/jac/dkl097
   Schrag SJ, 1997, P ROY SOC B-BIOL SCI, V264, P1287, DOI 10.1098/rspb.1997.0178
   Sharma D, 2007, J MOL BIOL, V374, P1065, DOI 10.1016/j.jmb.2007.10.003
   Stover CK, 2000, NATURE, V406, P959
   Trindade S, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000578
   Ward H, 2009, J EVOLUTION BIOL, V22, P997, DOI 10.1111/j.1420-9101.2009.01712.x
   Warren DK, 2004, CRIT CARE MED, V32, P2450, DOI 10.1097/01.CCM.0000147685.79487.28
   Yeh P, 2006, NAT GENET, V38, P489, DOI 10.1038/ng1755
   zur Wiesch PA, 2011, LANCET INFECT DIS, V11, P236, DOI 10.1016/S1473-3099(10)70264-4
NR 42
TC 15
Z9 15
U1 2
U2 28
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0099-2240
EI 1098-5336
J9 APPL ENVIRON MICROB
JI Appl. Environ. Microbiol.
PD SEP
PY 2012
VL 78
IS 17
BP 6137
EP 6142
DI 10.1128/AEM.01078-12
PG 6
WC Biotechnology & Applied Microbiology; Microbiology
SC Biotechnology & Applied Microbiology; Microbiology
GA 990DS
UT WOS:000307611800019
PM 22729549
OA Other Gold, Green Published
DA 2018-12-27
ER

PT J
AU Jung, M
   Kim, SH
   Hong, S
   Kang, YA
   Kim, SK
   Chang, J
   Rha, SY
   Kim, JH
   Kim, DJ
   Cho, BC
AF Jung, Minkyu
   Kim, Se Hyun
   Hong, Soojung
   Kang, Young Ae
   Kim, Se Kyu
   Chang, Joon
   Rha, Sun Young
   Kim, Jo Hang
   Kim, Dae Joon
   Cho, Byoung Chul
TI RETRACTED: Prognostic and Predictive Value of Carcinoembryonic Antigen
   and Cytokeratin-19 Fragments Levels in Advanced Non-Small Cell Lung
   Cancer Patients Treated with Gefitinib or Erlotinib (Retracted article.
   See vol. 54, pg. 269, 2013)
SO YONSEI MEDICAL JOURNAL
LA English
DT Article; Retracted Publication
DE Carcinoma; non-small-cell lung; biological markers; carcinoembryonic
   antigen; CYFRA 21-1; tyrosine kinase inhibitor
ID HUMAN-TUMOR-MARKER; CYFRA 21-1; SURVIVAL; MUTATIONS; CEA; CHEMOTHERAPY;
   CARCINOMA; DIAGNOSIS; DISEASE; NSE
AB Purpose: The prognostic and predictive value of pretreatment serum levels of carcinoembryonic antigen (CEA) and cytokeratin-19 fragments (CYFRA 21-1) were assessed in advanced non-small cell lung cancer (NSCLC) patients treated with gefitinib or erlotinib. Materials and Methods: Pretreatment CEA and CYFRA 21-1 were measured in 123 advanced NSCLC patients receiving gefitinib or erlotinib. High CEA levels (h-CEA) were significantly associated with females, patients with adenocarcinoma, and non-smokers. Results: Low CYFRA 21-1 levels (l-CYFRA) were significantly associated with a good performance status (ECOG PS 0-1). The overall response rate (RR) was 27.6%, and higher RR was associated with adenocarcinoma, h-CEA, and epidermal growth factor receptor (EGFR) mutation. Patients with h-CEA had significantly longer progression-free survival (PFS) (p=0.021). Patients with l-CYFRA had significantly longer PFS and overall survival (p=0.006 and p<0.001, respectively). Of note, h-CEA and I-CYFRA had good prognosis in patients with unknown EGFR mutation status or patients with squamous cell carcinoma (p=0.021 and p=0.015, respectively). A good ECOG PS (HR=0.45, p=0.017), h-CEA (HR=0.41, p=0.007), l-CYFRA 21-1 (HR=0.52, p=0.025), and an EGFR mutation (HR=0.22,p<0.001) were independently predictive of a longer PFS. Conclusion: h-CEA and I-CYFRA 21-1 may be prognostic and predictive serum markers for higher response and longer survival in patients with advanced NSCLC receiving gefitinib or erlotinib, especially in patients with unknown EGFR mutation status or patients with squamous cell carcinoma.
C1 [Cho, Byoung Chul] Yonsei Univ, Coll Med, Dept Internal Med, Div Med Oncol, Seoul 120752, South Korea.
   [Jung, Minkyu; Kim, Se Hyun; Hong, Soojung; Rha, Sun Young; Kim, Jo Hang; Cho, Byoung Chul] Yonsei Univ, Coll Med, Yonsei Canc Ctr, Seoul 120752, South Korea.
   [Kang, Young Ae; Kim, Se Kyu; Chang, Joon] Yonsei Univ, Coll Med, Dept Internal Med, Div Pulmonol, Seoul 120752, South Korea.
   [Kim, Dae Joon] Yonsei Univ, Coll Med, Dept Thorac & Cardiovasc Surg, Seoul 120752, South Korea.
RP Cho, BC (reprint author), Yonsei Univ, Coll Med, Dept Internal Med, Div Med Oncol, 50 Yonsei Ro, Seoul 120752, South Korea.
EM kdjcool@yuhs.ac; cbc1971@yuhs.ac
FU faculty research grant of Yonsei University College of Medicine
   [6-2007-0194]
FX This study was supported by a faculty research grant of Yonsei
   University College of Medicine for 6-2007-0194.
CR Ardizzoni A, 2006, CANCER-AM CANCER SOC, V107, P2842, DOI 10.1002/cncr.22330
   Barlesi F, 2005, BRIT J CANCER, V92, P13, DOI 10.1038/sj.bjc.6602296
   Barlesi F, 2004, RESP MED, V98, P357, DOI 10.1016/j.rmed.2003.11.003
   BENCHIMOL S, 1989, CELL, V57, P327, DOI 10.1016/0092-8674(89)90970-7
   Chiu CH, 2007, LUNG CANCER, V57, P213, DOI 10.1016/j.lungcan.2007.02.016
   FUJISHIMA T, 1995, RESPIRATION, V62, P317
   Gaughan Elizabeth M, 2011, Ther Adv Med Oncol, V3, P113, DOI 10.1177/1758834010397569
   GOLD P, 1965, J EXP MED, V121, P439, DOI 10.1084/jem.121.3.439
   Hammarstrom S, 1999, SEMIN CANCER BIOL, V9, P67, DOI 10.1006/scbi.1998.0119
   Han SW, 2005, J CLIN ONCOL, V23, P2493, DOI 10.1200/JCO.2005.01.388
   Herbst RS, 2010, J CLIN ONCOL, V28, DOI 10.1200/jco.2010.28.15_suppl.7609
   Holdenrieder S, 2009, LUNG CANCER, V63, P128, DOI 10.1016/j.lungcan.2008.05.001
   Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010
   Kao CH, 1999, ANTICANCER RES, V19, P4545
   Kim ES, 2008, LANCET, V372, P1809, DOI 10.1016/S0140-6736(08)61758-4
   Maheswaran S, 2008, NEW ENGL J MED, V359, P366, DOI 10.1056/NEJMoa0800668
   Matsuoka K, 2007, EUR J CARDIO-THORAC, V32, P435, DOI 10.1016/j.ejcts.2007.05.014
   Mok TS, 2009, NEW ENGL J MED, V361, P947, DOI 10.1056/NEJMoa0810699
   Molina R, 2003, TUMOR BIOL, V24, P209, DOI 10.1159/000074432
   Molina R, 2008, TUMOR BIOL, V29, P29
   Nisman B, 1998, CANCER-AM CANCER SOC, V82, P1850, DOI 10.1002/(SICI)1097-0142(19980515)82:10<1850::AID-CNCR6>3.0.CO;2-R
   Okada M, 2004, ANN THORAC SURG, V78, P1004, DOI 10.1016/j.athorascur.2004.03.019
   Okada M, 2004, ANN THORAC SURG, V78, P216, DOI 10.1016/j.athoracsur.2004.02.009
   Okamoto T, 2005, EUR J CANCER, V41, P1286, DOI 10.1016/j.ejca.2005.03.011
   Ordonez C, 2000, CANCER RES, V60, P3419
   Pujol JL, 2001, LUNG CANCER-J IASLC, V31, P221, DOI 10.1016/S0169-5002(00)00186-0
   Pujol L, 2004, BRIT J CANCER, V90, P2097, DOI 10.1038/sj.bjc.6601851
   RULE AH, 1972, NEW ENGL J MED, V287, P24, DOI 10.1056/NEJM197207062870106
   Screaton RA, 1997, J CELL BIOL, V137, P939, DOI 10.1083/jcb.137.4.939
   Shaw AT, 2011, LANCET ONCOL, V12, P1004, DOI 10.1016/S1470-2045(11)70232-7
   Shepherd FA, 2005, NEW ENGL J MED, V353, P123, DOI 10.1056/NEJMoa050753
   Shigematsu H, 2005, J NATL CANCER I, V97, P339, DOI 10.1093/jnci/dji055
   Shoji F, 2007, CANCER, V110, P2793, DOI 10.1002/cncr.23101
   STIEBER P, 1993, CLIN BIOCHEM, V26, P301, DOI 10.1016/0009-9120(93)90129-T
   Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205
   Travis WD, 1999, HISTOLOGICAL TYPING
NR 36
TC 12
Z9 14
U1 2
U2 17
PU YONSEI UNIV COLL MEDICINE
PI SEOUL
PA 50-1 YONSEI-RO, SEODAEMUN-GU, SEOUL 120-752, SOUTH KOREA
SN 0513-5796
EI 1976-2437
J9 YONSEI MED J
JI Yonsei Med. J.
PD SEP 1
PY 2012
VL 53
IS 5
BP 931
EP 939
DI 10.3349/ymj.2012.53.5.931
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA 995DA
UT WOS:000307986900008
PM 22869475
OA Green Published, Other Gold
DA 2018-12-27
ER

PT J
AU Samuel, JB
   Stanley, JA
   Vengatesh, G
   Princess, RA
   Muthusami, S
   Roopha, DP
   Suthagar, E
   Kumar, KM
   Sebastian, MS
   Aruldhas, MM
AF Samuel, Jawahar B.
   Stanley, Jone A.
   Vengatesh, Ganapathy
   Princess, Rajendran A.
   Muthusami, Sridhar
   Roopha, Dailiah P.
   Suthagar, Esakky
   Kumar, Kathiresh M.
   Sebastian, Maria S.
   Aruldhas, Michael M.
TI RETRACTED: Ameliorative effect of vitamin C on hexavalent
   chromium-induced delay in sexual maturation and oxidative stress in
   developing Wistar rat ovary and uterus (Retracted article. See vol. 32,
   pg. 192, 2016)
SO TOXICOLOGY AND INDUSTRIAL HEALTH
LA English
DT Article; Retracted Publication
DE Chromium; ovary; uterus; oxidative stress; sexual maturation; vitamin C
ID LIPID-PEROXIDATION; HYDROGEN-PEROXIDE; ASCORBIC-ACID; TOXICITY;
   EXPOSURE; MICE; GLUTATHIONE; CARCINOGENICITY; ABSORPTION; MECHANISMS
AB Hexavalent chromium (CrVI) is a highly toxic metal and major environmental pollutant and is extensively used in more than 50 industries. The major route of CrVI exposure for the general population is oral intake. Chromium is considered an important nutrient responsible for carbohydrate metabolism. However, excess CrVI exposure is associated with various pathological conditions including reproductive dysfunction. CrVI can traverse the placental barrier and cause wide range of abnormalities in fetal development. Cr is transported to offspring through mother's milk in lactating women exposed to CrVI. Therefore, the present study was carried out to determine the toxic effects of lactational CrVI exposure on ovary and uterus and the beneficial role of vitamin C in preventing/ameliorating the toxic effects of CrVI in developing female Wistar rats. Generation of oxidative stress is considered one of the plausible mechanisms behind Cr-induced cellular deteriorations. The present study evidenced a decrease in the specific activities of antioxidants, serum testosterone and progesterone and an increase in the levels of H2O2, lipid peroxidation (LPO) and follicle stimulating hormone in rats exposed to CrVI when compared to control. CrVI exposure also delayed the sexual maturation and extended the estrous cycle. Simultaneous administration of vitamin C significantly prevented the increase in LPO and enhanced the antioxidant status. These results suggest the protective effect of vitamin C against the CrVI exposure-induced toxicity and attest the significance of antioxidants in diet.
C1 [Samuel, Jawahar B.; Princess, Rajendran A.; Roopha, Dailiah P.] St Johns Coll, Dept Zool, Thirunelveli 627002, Tamil Nadu, India.
   [Stanley, Jone A.; Vengatesh, Ganapathy; Muthusami, Sridhar; Suthagar, Esakky; Kumar, Kathiresh M.; Aruldhas, Michael M.] Univ Madras, Dept Endocrinol, Dr ALM Post Grad Inst Basic Med Sci, Madras, Tamil Nadu, India.
   [Stanley, Jone A.] Texas A&M Univ, Coll Vet Med & Biomed Sci, Dept Vet Integrat Biosci, College Stn, TX USA.
   [Sebastian, Maria S.] St Xaviers Coll, Dept Zool, Thirunelveli, Tamil Nadu, India.
RP Samuel, JB (reprint author), St Johns Coll, Dept Zool, Thirunelveli 627002, Tamil Nadu, India.
EM drbjsamuel@yahoo.co.in
OI Stanley, Jone/0000-0003-0332-8370; Muthusami,
   Sridhar/0000-0002-3595-9081
CR Al-Hamood MH, 1998, REPROD FERT DEVELOP, V10, P179, DOI 10.1071/R97001
   Anderson RA, 2000, DIABETES METAB, V26, P22
   [Anonymous], 2007, WORLDS WORST POLL PL
   Aruldhas MM, 2005, HUM REPROD, V20, P2801, DOI 10.1093/humrep/dei148
   BAGCHI D, 1995, COMP BIOCHEM PHYS C, V110, P177, DOI 10.1016/0742-8413(94)00093-P
   Bagchi D, 2002, TOXICOLOGY, V175, P73, DOI 10.1016/S0300-483X(02)00062-8
   Bagchi D, 2001, MOL CELL BIOCHEM, V222, P149, DOI 10.1023/A:1017958028256
   Bailey MM, 2006, BIRTH DEFECTS RES B, V77, P244, DOI 10.1002/bdrb.20081
   BALL LM, 1981, J TOXICOL ENV HEALTH, V8, P629, DOI 10.1080/15287398109530097
   Banu SK, 2008, TOXICOL APPL PHARM, V232, P180, DOI 10.1016/j.taap.2008.06.002
   Barceloux DG, 1999, J TOXICOL-CLIN TOXIC, V37, P173, DOI 10.1081/CLT-100102418
   BURROWS D, 1978, BRIT J DERMATOL, V99, P587, DOI 10.1111/j.1365-2133.1978.tb02032.x
   Chandra P, 1997, ACS SYM SER, V664, P274, DOI 10.1145/264107.264209
   COHEN MD, 1993, CRIT REV TOXICOL, V23, P255, DOI 10.3109/10408449309105012
   DAVIDSON IW, 1972, ANAL CHEM, V44, P1808, DOI 10.1021/ac60319a021
   Dayan AD, 2001, HUM EXP TOXICOL, V20, P439, DOI 10.1191/096032701682693062
   DeFlora S, 1997, CARCINOGENESIS, V18, P531, DOI 10.1093/carcin/18.3.531
   DEVASAGAYAM TPA, 1987, BIOCHEM BIOPH RES CO, V145, P134, DOI 10.1016/0006-291X(87)91297-6
   Dey SK, 2003, J ENVIRON SCI-CHINA, V15, P356
   Greene LE, 2010, INT J OCCUP ENV HEAL, V16, P60
   HABIG WH, 1974, J BIOL CHEM, V249, P7130
   Halasova E, 2009, NEUROENDOCRINOL LETT, V30, P182
   HOLLAND MK, 1981, BIOCHEM J, V198, P273, DOI 10.1042/bj1980273
   Hoyer PB, 1996, ANNU REV PHARMACOL, V36, P307, DOI 10.1146/annurev.pa.36.040196.001515
   Huang YL, 1999, J TOXICOL ENV HEAL A, V56, P235, DOI 10.1080/009841099158088
   Jendryczko A, 1984, Ginekol Pol, V55, P691
   JUN Z, 1992, AM J IND MED, V21, P397, DOI 10.1002/ajim.4700210312
   Junaid M, 1996, B ENVIRON CONTAM TOX, V57, P327, DOI 10.1007/s001289900194
   Kaderabkova O, 1997, Vnitr Lek, V43, P388
   Kalahasthi RB, 2006, CHEM-BIOL INTERACT, V164, P192, DOI 10.1016/j.cbi.2006.09.012
   Kamath SM, 1997, J NUTR, V127, P478
   KAWANISHI S, 1986, J BIOL CHEM, V261, P5952
   Liu Yong, 2005, J Zhejiang Univ Sci B, V6, P540, DOI 10.1631/jzus.2005.B0540
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   MARKLUND S, 1974, EUR J BIOCHEM, V47, P469
   MERTZ W, 1993, J NUTR, V123, P626
   Metze D., 2005, HDB ELEMENTAL SPECIA, P120
   Mishra AK, 2010, ENV TOXICOLOGY
   Muthusami S, 2005, CLIN CHIM ACTA, V360, P81, DOI 10.1016/j.cccn.2005.04.014
   Qureshi IZ, 2010, TOXICOL IND HEALTH, V26, P349, DOI 10.1177/0748233710371109
   Rao MV, 2009, FOOD CHEM TOXICOL, V47, P1368, DOI 10.1016/j.fct.2009.03.018
   Rodriguez R, 2008, BIOL REPROD, V77, P215
   ROTRUCK JT, 1973, SCIENCE, V179, P588, DOI 10.1126/science.179.4073.588
   Rzeuski R, 1998, FLUORIDE, V31, P43
   Salnikow K, 2008, CHEM RES TOXICOL, V21, P28, DOI 10.1021/tx700198a
   Samanta L, 1999, ANDROLOGIA, V31, P83, DOI 10.1046/j.1439-0272.1999.00232.x
   Samuel JB, 2011, J MED TOXICOL, V7, P195, DOI 10.1007/s13181-011-0143-9
   Samuel JB, 2011, HUM EXP TOXICOL, V30, P91, DOI 10.1177/0960327110364638
   Samuel JB, 2001, THESIS MS U TIRUNELV
   Sawicka E, 2010, ACTA POL PHARM, V67, P706
   SHMITOVA L A, 1980, Gigiena Truda i Professional'nye Zabolevaniya, P33
   SINHA AK, 1972, ANAL BIOCHEM, V47, P389, DOI 10.1016/0003-2697(72)90132-7
   STAAL GEJ, 1969, BIOCHIM BIOPHYS ACTA, V185, P39, DOI 10.1016/0005-2744(69)90280-0
   Subramanian S, 2006, TOXICOL APPL PHARM, V215, P237, DOI 10.1016/j.taap.2006.03.004
   SUGIYAMA M, 1992, FREE RADICAL BIO MED, V12, P397, DOI 10.1016/0891-5849(92)90089-Y
   Susa N, 1996, ARCH TOXICOL, V71, P20, DOI 10.1007/s002040050353
   SUZUKI Y, 1990, IND HEALTH, V28, P9, DOI 10.2486/indhealth.28.9
   TRIVEDI B, 1989, REPROD TOXICOL, V3, P275, DOI 10.1016/0890-6238(89)90022-1
   Valko M, 2005, CURR MED CHEM, V12, P1161, DOI 10.2174/0929867053764635
   Zhang Z, 2001, MOL CELL BIOCHEM, V222, P77, DOI 10.1023/A:1017963307358
   Zhitkovich A, 2005, CHEM RES TOXICOL, V18, P3, DOI 10.1021/tx049774+
NR 61
TC 11
Z9 12
U1 2
U2 11
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0748-2337
EI 1477-0393
J9 TOXICOL IND HEALTH
JI Toxicol. Ind. Health
PD SEP
PY 2012
VL 28
IS 8
BP 720
EP 733
DI 10.1177/0748233711422728
PG 14
WC Public, Environmental & Occupational Health; Toxicology
SC Public, Environmental & Occupational Health; Toxicology
GA 984YX
UT WOS:000307231000005
PM 22033423
DA 2018-12-27
ER

PT J
AU Zhu, Q
   Liu, TT
AF Zhu, Qing
   Liu, Tongtao
TI RETRACTED: Fibroblast growth factor receptor 4 polymorphisms and
   coronary artery disease: a case control study (Retracted article. See
   vol. 43, pg. 751, 2016)
SO MOLECULAR BIOLOGY REPORTS
LA English
DT Article; Retracted Publication
DE Fibroblast growth factor receptor 4; Polymorphisms; Coronary artery
   disease
ID SMOOTH-MUSCLE-CELLS; FGF RECEPTOR; CANCER; PROMOTES; SUSCEPTIBILITY;
   OSTEOSARCOMA; ANGIOGENESIS; EXPRESSION; HEPARIN; BREAST
AB Fibroblast growth factors (FGFs) and their receptors (FGFRs) play important roles in vascular system. FGFR4 rs351855 (Gly388Arg) polymorphism has shown to be a risk factor for many diseases. The aim of this study was to investigate the association between FGFR4 polymorphisms and the susceptibility to coronary artery disease (CAD) in the Chinese population. We identified three polymorphisms in the FGFR4 gene, rs351855G/A (Gly388Arg), rs145302848C/G and rs147603016G/A, by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) in 658 CAD cases and 692 healthy controls. Results showed that frequencies of GA genotype, AA genotype and A allele in rs351855 (Gly388Arg) polymorphism were significantly lower in CAD patients than in controls [odds ratio (OR) = 0.79, 95 % confidence intervals (CI) 0.62-0.99, P = 0.042; OR = 0.58, 95 % CI 0.41-0.81, P = 0.002; and OR = 0.77, 95 % CI 0.66-0.90, P = 0.001, respectively]. The rs147603016GA genotype and A allele also showed lower numbers in CAD cases (OR = 0.58, 95 % CI 0.36-0.93, P = 0.025; and OR = 0.59, 95 % CI 0.40-0.95, P = 0.028). The rs145302848C/G polymorphism did not show any correlation with CAD. Haplotype analysis revealed that the prevalence of ACG haplotype (rs351855, rs145302848 and rs147603016) was significantly decreased in CAD patients (P = 0.002). Our data suggested that the FGFR4 rs351855G/A (Gly388Arg) and rs147603016G/A polymorphisms could act as protective factors against CAD in the Chinese population and indicated that a single gene polymorphism could have diverse functions in different diseases.
C1 [Zhu, Qing; Liu, Tongtao] Shandong Univ, Qilu Hosp, Dept Cardiol, Jinan 250012, Shandong, Peoples R China.
RP Liu, TT (reprint author), Shandong Univ, Qilu Hosp, Dept Cardiol, 107 Wenhua W Rd, Jinan 250012, Shandong, Peoples R China.
EM tongtaoliuql@126.com
CR BAIRD A, 1985, BIOCHEM BIOPH RES CO, V126, P358, DOI 10.1016/0006-291X(85)90614-X
   BJORNSSON TD, 1991, P NATL ACAD SCI USA, V88, P8651, DOI 10.1073/pnas.88.19.8651
   CASSCELLS W, 1992, P NATL ACAD SCI USA, V89, P7159, DOI 10.1073/pnas.89.15.7159
   CHAMPIONARNAUD P, 1991, ONCOGENE, V6, P979
   CUEVAS P, 1991, CIRC RES, V69, P360, DOI 10.1161/01.RES.69.2.360
   EISEMANN A, 1991, ONCOGENE, V6, P1195
   Eswarakumar VP, 2005, CYTOKINE GROWTH F R, V16, P139, DOI 10.1016/j.cytogfr.2005.01.001
   FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664
   Frullanti E, 2011, EUR J CANCER PREV, V20, P340, DOI 10.1097/CEJ.0b013e3283457274
   Gaziano TA, 2010, CURR PROB CARDIOLOGY, V35, P72, DOI [10.1016/j.cpcardio1.2009.10.002, 10.1016/j.cpcardiol.2009.10.002]
   HUGHES SE, 1993, CARDIOVASC RES, V27, P1214, DOI 10.1093/cvr/27.7.1214
   JAAKKOLA S, 1993, INT J CANCER, V54, P378, DOI 10.1002/ijc.2910540305
   JACKSON CL, 1993, AM J PATHOL, V143, P1024
   LEHTOLA L, 1992, INT J CANCER, V50, P598, DOI 10.1002/ijc.2910500419
   LEUNG HY, 1994, INT J CANCER, V59, P667, DOI 10.1002/ijc.2910590515
   LINDNER V, 1991, CIRC RES, V68, P106, DOI 10.1161/01.RES.68.1.106
   Liu Y, 2011, DNA CELL BIOL, V30, P1051, DOI 10.1089/dna.2011.1269
   Ma L, 2011, DNA CELL BIOL, V30, P1033, DOI 10.1089/dna.2011.1261
   MatsumotoYoshitomi S, 1997, INT J CANCER, V71, P442
   MIKAWA T, 1995, ANN NY ACAD SCI, V752, P506, DOI 10.1111/j.1749-6632.1995.tb17459.x
   NABEL EG, 1993, NATURE, V362, P844, DOI 10.1038/362844a0
   REIDY MA, 1991, ANN NY ACAD SCI, V638, P290, DOI 10.1111/j.1749-6632.1991.tb49039.x
   SCHWEIGERER L, 1987, NATURE, V325, P257, DOI 10.1038/325257a0
   Takahashi A, 1999, BIOCHEM BIOPH RES CO, V257, P855, DOI 10.1006/bbrc.1999.0465
   TAN EML, 1989, BIOCHEM BIOPH RES CO, V163, P84, DOI 10.1016/0006-291X(89)92102-5
   TEMPLETON TJ, 1992, DEV BIOL, V154, P169, DOI 10.1016/0012-1606(92)90057-N
   Wang JH, 2008, NEOPLASIA, V10, P847, DOI 10.1593/neo.08450
   Wang W, 2011, DNA CELL BIOL, V30, P925, DOI 10.1089/dna.2011.1211
   WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82
   WINKLES JA, 1987, P NATL ACAD SCI USA, V84, P7124, DOI 10.1073/pnas.84.20.7124
   Wu MT, 2002, J IMMUNOL, V168, P5096, DOI 10.4049/jimmunol.168.10.5096
   Xu W, 2010, EUR J CANCER, V46, P3332, DOI 10.1016/j.ejca.2010.06.017
   Yang Y, 2012, MOL CARCINOGEN, V51, P515, DOI 10.1002/mc.20805
NR 33
TC 8
Z9 8
U1 2
U2 7
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0301-4851
EI 1573-4978
J9 MOL BIOL REP
JI Mol. Biol. Rep.
PD SEP
PY 2012
VL 39
IS 9
BP 8679
EP 8685
DI 10.1007/s11033-012-1723-8
PG 7
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 979EX
UT WOS:000306799700013
PM 22696188
DA 2018-12-27
ER

PT J
AU Min, JW
   Mitsuhashi, H
AF Min, Jungwon
   Mitsuhashi, Hitoshi
TI RETRACTED: Dynamics of Unclosed Triangles in Alliance Networks:
   Disappearance of Brokerage Positions and Performance Consequences
   (Retracted article. See vol. 51, pg. 1023, 2014)
SO JOURNAL OF MANAGEMENT STUDIES
LA English
DT Article; Retracted Publication
DE codeshare alliances; dynamics of brokerage positions; network
   embeddedness; performance consequences
ID STRUCTURAL HOLES; SOCIAL-STRUCTURE; INTERORGANIZATIONAL IMITATION;
   COMPETITIVE DYNAMICS; PARTNER SELECTION; INTERFIRM RIVALRY;
   EMBEDDEDNESS; INNOVATION; GOVERNANCE; IMPACT
AB We depart from previous research on brokerage advantages in interorganizational networks by shifting focus to the dynamics of brokerage positions. We investigate causes of the disappearance of these positions and its influence on organizational performance. Using a subnetwork consisting of a broker and its two partners as the unit of analysis, we postulate that the brokerage position disappears either when the two partners develop ties or when the ties between the broker and the partners dissolve. We predict that the patterns of interactions in which this subnetwork is embedded exert multilevel influences on the disappearance, and that embedded structures promoting persistence constrain brokerage advantages. Our analysis of codeshare alliance data in the global airline industry supports the theory and demonstrates that the persistence of brokerage positions decreases broker performance. The findings explain why brokerage positions rarely persist and why the persistence of brokerage positions does not benefit brokers.
C1 [Min, Jungwon] Keio Univ, Grad Sch Business & Commerce, Minato Ku, Tokyo 1088345, Japan.
RP Min, JW (reprint author), Keio Univ, Grad Sch Business & Commerce, Minato Ku, Mita 2-15-45, Tokyo 1088345, Japan.
EM jwmin@z6.keio.jp
CR Ahuja G, 2000, ADMIN SCI QUART, V45, P425, DOI 10.2307/2667105
   Ahuja G, 2009, STRATEG MANAGE J, V30, P941, DOI 10.1002/smj.774
   [Anonymous], 2005, STAT STAT SOFTW REL
   Baum JAC, 1996, ACAD MANAGE J, V39, P255, DOI 10.2307/256781
   Baum JAC, 2012, ORGAN SCI, V23, P529, DOI 10.1287/orsc.1100.0566
   Belsley D. A., 1980, REGRESSION DIAGNOSTI
   Blossfeld H., 2007, EVENT HIST ANAL STAT
   Burt R, 1992, STRUCTURAL HOLES SOC
   Burt RS, 2007, ACAD MANAGE J, V50, P119, DOI 10.5465/AMJ.2007.24162082
   Burt RS, 2002, SOC NETWORKS, V24, P333, DOI 10.1016/S0378-8733(02)00017-5
   BURT RS, 2007, MISSING LINKS FORMAT, P100
   Chen GL, 2008, ACAD MANAGE J, V51, P954
   Chung S, 2000, STRATEGIC MANAGE J, V21, P1
   Coleman J. S., 1990, FDN SOCIAL THEORY
   COOK KS, 1978, AM SOCIOL REV, V43, P721, DOI 10.2307/2094546
   Davis GF, 1997, AM J SOCIOL, V103, P1, DOI 10.1086/231170
   Eisenhardt KM, 1996, ORGAN SCI, V7, P136, DOI 10.1287/orsc.7.2.136
   EMERSON RM, 1962, AM SOCIOL REV, V27, P31, DOI 10.2307/2089716
   Finlay W, 2000, WORK OCCUPATION, V27, P377, DOI 10.1177/0730888400027003006
   Garcia-Pont C, 2002, STRATEGIC MANAGE J, V23, P307, DOI 10.1002/smj.225
   Gargiulo M, 2000, ORGAN SCI, V11, P183, DOI 10.1287/orsc.11.2.183.12514
   Gimeno J, 2004, ACAD MANAGE J, V47, P820, DOI 10.2307/20159625
   Gleave S. D., 2007, COMPETITION IMPACT A
   Gnyawali DR, 2001, ACAD MANAGE REV, V26, P431, DOI 10.2307/259186
   Goerzen A, 2007, STRATEGIC MANAGE J, V28, P487, DOI 10.1002/smj.588
   GRANOVETTER M, 1985, AM J SOCIOL, V91, P481, DOI 10.1086/228311
   GRANOVETTER MS, 1973, AM J SOCIOL, V78, P1360, DOI 10.1086/225469
   Greve HR, 2010, ACAD MANAGE J, V53, P302, DOI 10.5465/AMJ.2010.49388955
   GULATI R, 1995, ACAD MANAGE J, V38, P85, DOI 10.2307/256729
   Gulati R, 1998, STRATEGIC MANAGE J, V19, P293, DOI 10.1002/(SICI)1097-0266(199804)19:4<293::AID-SMJ982>3.0.CO;2-M
   Gulati R, 1999, AM J SOCIOL, V104, P1439, DOI 10.1086/210179
   Gulati R., 2002, COMPANION ORG, P281
   Hagedoorn J, 2006, ACAD MANAGE REV, V31, P670, DOI 10.5465/AMR.2006.21318924
   Hagg I., 1983, FIRMS NETWORKS
   Hanlon P, 2007, GLOBAL AIRLINES COMP
   Hargadon A, 1997, ADMIN SCI QUART, V42, P716, DOI 10.2307/2393655
   Haunschild PR, 1997, ADMIN SCI QUART, V42, P472, DOI 10.2307/2393735
   HAUNSCHILD PR, 1993, ADMIN SCI QUART, V38, P564, DOI 10.2307/2393337
   Hoang H, 2005, ACAD MANAGE J, V48, P332, DOI 10.5465/AMJ.2005.16928417
   Koput K.W., 2000, SCI STRATEGY ORG EVO
   LARSON A, 1992, ADMIN SCI QUART, V37, P76, DOI 10.2307/2393534
   Lazzarini SG, 2007, STRATEGIC MANAGE J, V28, P345, DOI 10.1002/smj.587
   Li SX, 2002, ACAD MANAGE J, V45, P1104, DOI 10.2307/3069427
   McEvily B, 2005, STRATEGIC MANAGE J, V26, P1033, DOI 10.1002/smj.484
   Meuleman M, 2010, J MANAGE STUD, V47, P995, DOI 10.1111/j.1467-6486.2009.00897.x
   Mitsuhashi H, 2009, ACAD MANAGE J, V52, P975, DOI 10.5465/AMJ.2009.44634482
   Nunez-Nickel M, 2004, J MANAGE STUD, V41, P1131, DOI 10.1111/j.1467-6486.2004.00469.x
   Park SH, 2001, ORGAN SCI, V12, P37, DOI 10.1287/orsc.12.1.37.10118
   Pfeffer J., 1978, EXTERNAL CONTROL OR
   PODOLNY JM, 1994, ADMIN SCI QUART, V39, P458, DOI 10.2307/2393299
   Polidoro F, 2011, ACAD MANAGE J, V54, P203, DOI 10.5465/AMJ.2011.59215088
   Powell WW, 1996, ADMIN SCI QUART, V41, P116, DOI 10.2307/2393988
   Rider CI, 2009, ADMIN SCI QUART, V54, P575, DOI 10.2189/asqu.2009.54.4.575
   RING PS, 1994, ACAD MANAGE REV, V19, P90, DOI 10.2307/258836
   Rowley T. J., 2004, SCAND J MANAG, V20, P103, DOI DOI 10.1016/J.SCAMAN.2004.07.001
   Salman N, 2005, R&D MANAGE, V35, P203, DOI 10.1111/j.1467-9310.2005.00383.x
   Scott J, 2000, SOCIAL NETWORK ANAL
   Shipilov AV, 2006, ADV STRATEG MANAGE, V23, P481, DOI 10.1016/S0742-3322(06)23015-8
   Slangen AHL, 2008, J INT BUS STUD, V39, P472, DOI 10.1057/palgrave.jibs.8400356
   Uzzi B, 1997, ADMIN SCI QUART, V42, P35, DOI 10.2307/2393808
   Uzzi B, 1996, AM SOCIOL REV, V61, P674, DOI 10.2307/2096399
   Wellman B., 1988, SOCIAL STRUCTURES NE
   White S, 2005, J MANAGE STUD, V42, P1383, DOI 10.1111/j.1467-6486.2005.00548.x
   Zaheer A, 2005, STRATEGIC MANAGE J, V26, P809, DOI 10.1002/smj.482
   Zaheer A, 2009, ADMIN SCI QUART, V54, P1, DOI 10.2189/asqu.2009.54.1.1
NR 65
TC 11
Z9 11
U1 1
U2 69
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-2380
EI 1467-6486
J9 J MANAGE STUD
JI J. Manage. Stud.
PD SEP
PY 2012
VL 49
IS 6
BP 1078
EP 1108
DI 10.1111/j.1467-6486.2011.01035.x
PG 31
WC Business; Management
SC Business & Economics
GA 970MX
UT WOS:000306135900004
DA 2018-12-27
ER

PT J
AU Nahn, S
   Tsybychev, D
AF Nahn, Steve
   Tsybychev, Dmitri
TI RETRACTED: RECENT RESULTS FROM ATLAS AND CMS ON HIGGS, SUPERSYMMETRY AND
   PHYSICS BEYOND THE STANDARD MODEL SEARCHES (Retracted article. See vol.
   28, 1393001, 2013)
SO INTERNATIONAL JOURNAL OF MODERN PHYSICS A
LA English
DT Review; Retracted Publication
DE LHC; ATLAS; CMS; Higgs; supersymmetry; beyond Standard Model physics
ID ROOT-S=7 TEV; PP COLLISIONS; SUPERGAUGE TRANSFORMATIONS; HADRON
   COLLIDERS; BOSON; BREAKING; NEUTRINO; DETECTOR; PARTICLE; LEPTON
AB The large hadron collider (LHC) physics program is finally on the way to help uncover the mechanism responsible for electroweak symmetry breaking, with each of experiments collecting up to 5 fb(-1) of data at center-of-mass energy of 7 TeV. In this review, we summarize searches for physics beyond the Standard Model at ATLAS and CMS experiments at LHC.
C1 [Nahn, Steve] MIT, Dept Phys, Cambridge, MA 02139 USA.
   [Tsybychev, Dmitri] SUNY Stony Brook, Dept Phys & Astron, Stony Brook, NY 11794 USA.
RP Nahn, S (reprint author), MIT, Dept Phys, Cambridge, MA 02139 USA.
EM nahn@mit.edu; Dmitri.Tsybychev@stonybrook.edu
RI Tsybychev, Dmitri/J-3733-2017
FU NSF [PHY-1068677]; DoE [DE-FG02-05ER41360]
FX We thank CERN for the very successful operation of the LHC, as well as
   our colleagues from ATLAS and CMS for the tremendous amount of work and
   dedication to make the dawn of physics at LHC a great success. D.
   Tsybychev is supported by the NSF grant PHY-1068677 while S. Nahn is
   supported by DoE grant DE-FG02-05ER41360.
CR Aad G, 2011, PHYS REV LETT, V107, DOI 10.1103/PhysRevLett.107.221802
   Aad G, 2012, PHYS REV LETT, V109, DOI 10.1103/PhysRevLett.109.032001
   Aad G, 2012, PHYS REV LETT, V108, DOI 10.1103/PhysRevLett.108.261802
   Aad G, 2012, PHYS REV D, V85, DOI 10.1103/PhysRevD.85.112006
   Aad G, 2012, PHYS REV LETT, V108, DOI 10.1103/PhysRevLett.108.181802
   Aad G, 2012, PHYS LETT B, V710, P383, DOI 10.1016/j.physletb.2012.03.005
   Aad G, 2012, PHYS REV LETT, V108, DOI 10.1103/PhysRevLett.108.111803
   Aad G, 2012, PHYS LETT B, V710, P49, DOI 10.1016/j.physletb.2012.02.044
   Aad G, 2012, PHYS LETT B, V710, P67, DOI 10.1016/j.physletb.2012.02.051
   Aad G, 2011, PHYS REV LETT, V107, DOI 10.1103/PhysRevLett.107.231801
   Aad G, 2011, PHYS LETT B, V705, P28, DOI 10.1016/j.physletb.2011.09.093
   Aad G, 2008, J INSTRUM, V3, DOI 10.1088/1748-0221/3/08/S08003
   Aad G., ATLASCONF2012007
   Aad G., 2011, PHYS REV LETT, V108
   Aad G., J HIGH ENERGY UNPUB
   Aad G., PHYS REV D UNPUB
   Aad G., ATLASCONF2012038
   Aad G., PHYS REV LE IN PRESS
   Aad G., 2012, J HIGH ENERGY PHYS, V1204, P069
   Aad G., ATLASCONF2012041
   Aad G., PHYS REV LETT UNPUB
   ALVAREZGAUME L, 1982, NUCL PHYS B, V207, P96, DOI 10.1016/0550-3213(82)90138-9
   Alwall J, 2009, PHYS REV D, V79, DOI 10.1103/PhysRevD.79.075020
   ATLAS Collab. CMS Collab. and LHC Higgs Combination Group, 2011, D91 SECURESCM
   BAGGER J, 1988, PHYS REV D, V37, P1188, DOI 10.1103/PhysRevD.37.1188
   Baur U., 1987, International Journal of Modern Physics A, V2, P1285, DOI 10.1142/S0217751X87000661
   BAUR U, 1990, PHYS REV D, V42, P815, DOI 10.1103/PhysRevD.42.815
   Benedikt M., 2004, 3 LHC CERN
   Bruning O. S., 2004, 1 LHC CERN
   Bruning O. S., 2004, 2 LHC CERN
   Cacciari M, 2008, J HIGH ENERGY PHYS
   CHAMSEDDINE AH, 1982, PHYS REV LETT, V49, P970, DOI 10.1103/PhysRevLett.49.970
   Chatrchyan S, 2012, J HIGH ENERGY PHYS, DOI 10.1007/JHEP04(2012)036
   Chatrchyan S, 2012, PHYS LETT B, V713, P68, DOI 10.1016/j.physletb.2012.05.028
   Chatrchyan S, 2012, PHYS LETT B, V710, P91, DOI 10.1016/j.physletb.2012.02.076
   Chatrchyan S, 2012, PHYS LETT B, V710, P284, DOI 10.1016/j.physletb.2012.02.085
   Chatrchyan S, 2012, PHYS LETT B, V710, P403, DOI 10.1016/j.physletb.2012.03.003
   Chatrchyan S, 2012, J HIGH ENERGY PHYS, DOI 10.1007/JHEP03(2012)081
   Chatrchyan S, 2012, PHYS LETT B, V710, P26, DOI 10.1016/j.physletb.2012.02.064
   Chatrchyan S, 2012, J HIGH ENERGY PHYS, DOI 10.1007/JHEP03(2012)040
   Chatrchyan S, 2012, PHYS REV LETT, V108, DOI 10.1103/PhysRevLett.108.111804
   Chatrchyan S, 2011, PHYS REV LETT, V107, DOI 10.1103/PhysRevLett.107.271802
   Chatrchyan S, 2011, PHYS REV LETT, V107, DOI 10.1103/PhysRevLett.107.221804
   Chatrchyan S, 2011, PHYS LETT B, V704, P123, DOI 10.1016/j.physletb.2011.09.015
   Chatrchyan S, 2008, J INSTRUM, V3, DOI 10.1088/1748-0221/3/08/S08004
   Chatrchyan S., CMSPASSUS11013
   Chatrchyan S., CMSPASSUS09001
   Chatrchyan S., CMSPASSUS11004
   Chatrchyan S., CMSPASSUS11010
   Chatrchyan S., CMSPASSUS11005
   Chatrchyan S., J HIGH ENERGY UNPUB
   Chatrchyan S., CMSPASSUS11015
   Chatrchyan S., PHYS LETT B UNPUB
   Chatrchyan S., CMSPASSUS11008
   Chatrchyan S., CMSPASEXO11054
   Chatrchyan S., CMSPASEXO11099
   Chen M., LIMITS SIGNIFCANCE
   Cheng H.-C., 2008, J HIGH ENERGY PHYS, V0812, DOI DOI 10.1088/1126-6708/2008/12/063
   DINE M, 1982, PHYS LETT B, V110, P227, DOI 10.1016/0370-2693(82)91241-2
   DINE M, 1995, PHYS REV D, V51, P1362, DOI 10.1103/PhysRevD.51.1362
   Dine M, 1996, PHYS REV D, V53, P2658, DOI 10.1103/PhysRevD.53.2658
   DINE M, 1993, PHYS REV D, V48, P1277, DOI 10.1103/PhysRevD.48.1277
   Dittmaier S., 2011, CERN2011002
   EICHTEN E, 1984, REV MOD PHYS, V56, P579, DOI 10.1103/RevModPhys.56.579
   EICHTEN EJ, 1983, PHYS REV LETT, V50, P811, DOI 10.1103/PhysRevLett.50.811
   ENGLERT F, 1964, PHYS REV LETT, V13, P321, DOI 10.1103/PhysRevLett.13.321
   Erler J, 2010, PHYS REV LETT, V105, DOI 10.1103/PhysRevLett.105.031801
   FARRAR GR, 1978, PHYS LETT B, V76, P575, DOI 10.1016/0370-2693(78)90858-4
   FAYET P, 1977, PHYS LETT B, V69, P489, DOI 10.1016/0370-2693(77)90852-8
   FRAMPTON PH, 1987, PHYS LETT B, V190, P157, DOI 10.1016/0370-2693(87)90859-8
   GERVAIS JL, 1971, NUCL PHYS B, VB 34, P632, DOI 10.1016/0550-3213(71)90351-8
   GOLFAND YA, 1971, JETP LETT-USSR, V13, P323
   Gross E, 2010, EUR PHYS J C, V70, P525, DOI 10.1140/epjc/s10052-010-1470-8
   GURALNIK GS, 1964, PHYS REV LETT, V13, P585, DOI 10.1103/PhysRevLett.13.585
   Han T, 2010, J HIGH ENERGY PHYS, DOI 10.1007/JHEP12(2010)085
   HIGGS PW, 1964, PHYS REV LETT, V13, P508, DOI 10.1103/PhysRevLett.13.508
   HILL CT, 1990, PHYS LETT B, V241, P96, DOI 10.1016/0370-2693(90)91493-U
   Holdom Bob, 2009, PMC Physics A, V3, DOI 10.1186/1754-0410-3-4
   Junk T, 1999, NUCL INSTRUM METH A, V434, P435, DOI 10.1016/S0168-9002(99)00498-2
   KING SF, 1992, PHYS LETT B, V281, P295, DOI 10.1016/0370-2693(92)91143-W
   Langacker P, 2009, REV MOD PHYS, V81, P1199, DOI 10.1103/RevModPhys.81.1199
   Lester CG, 1999, PHYS LETT B, V463, P99, DOI 10.1016/S0370-2693(99)00945-4
   MIYAZAWA H, 1966, PROG THEOR PHYS, V36, P1266, DOI 10.1143/PTP.36.1266
   NAPPI CR, 1982, PHYS LETT B, V113, P175, DOI 10.1016/0370-2693(82)90418-X
   NEVEU A, 1971, NUCL PHYS B, VB 31, P86, DOI 10.1016/0550-3213(71)90448-2
   NEVEU A, 1971, PHYS REV D, V4, P1109, DOI 10.1103/PhysRevD.4.1109
   RAMOND P, 1971, PHYS REV D, V3, P2415, DOI 10.1103/PhysRevD.3.2415
   Rogan C., CALT682790
   Simmons EH, 1997, PHYS REV D, V55, P1678, DOI 10.1103/PhysRevD.55.1678
   VOLKOV DV, 1973, PHYS LETT B, VB 46, P109, DOI 10.1016/0370-2693(73)90490-5
   WESS J, 1974, PHYS LETT B, VB 49, P52, DOI 10.1016/0370-2693(74)90578-4
   WESS J, 1974, NUCL PHYS B, VB 70, P39, DOI 10.1016/0550-3213(74)90355-1
NR 92
TC 1
Z9 1
U1 2
U2 12
PU WORLD SCIENTIFIC PUBL CO PTE LTD
PI SINGAPORE
PA 5 TOH TUCK LINK, SINGAPORE 596224, SINGAPORE
SN 0217-751X
EI 1793-656X
J9 INT J MOD PHYS A
JI Int. J. Mod. Phys. A
PD AUG 20
PY 2012
VL 27
IS 21
AR 1230020
DI 10.1142/S0217751X12300207
PG 35
WC Physics, Nuclear; Physics, Particles & Fields
SC Physics
GA 993GX
UT WOS:000307846600001
DA 2018-12-27
ER

PT J
AU Lokireddy, S
   Wijesoma, IW
   Bonala, S
   Wei, M
   Sze, SK
   McFarlane, C
   Kambadur, R
   Sharma, M
AF Lokireddy, Sudarsanareddy
   Wijesoma, Isuru Wijerupage
   Bonala, Sabeera
   Wei, Meng
   Sze, Siu Kwan
   McFarlane, Craig
   Kambadur, Ravi
   Sharma, Mridula
TI RETRACTED: Myostatin is a novel tumoral factor that induces cancer
   cachexia (Retracted article. See vol. 473, pg. 1111, 2016)
SO BIOCHEMICAL JOURNAL
LA English
DT Article; Retracted Publication
DE activin receptor type II B; autophagy-lysosome system; myostatin;
   nuclear factor kappa B (NF-kappa B); reactive oxygen species (ROS);
   skeletal muscle wasting; tumoral factor; ubiquitin-proteasome system
ID NF-KAPPA-B; SKELETAL-MUSCLE HYPERTROPHY; SIGNALING PATHWAYS; MYOBLAST
   DIFFERENTIATION; SARCOMERIC PROTEINS; CELL-PROLIFERATION; MITOCHONDRIAL
   E3; ATROPHY; PROTEASOME; MYOGENESIS
AB Humoral and tumoral factors collectively promote cancer-induced skeletal muscle wasting by increasing protein degradation. Although several humoral proteins, namely TNF alpha (tumour necrosis factor alpha) and IL (interleukin)-6, have been shown to induce skeletal muscle wasting, there is a lack of information regarding the tumoral factors that contribute to the atrophy of muscle during cancer cachexia. Therefore, in the present study, we have characterized the secretome of C26 colon cancer cells to identify the tumoral factors involved in cancer-induced skeletal muscle wasting. In the present study, we show that myostatin, a procachectic TGF beta (transforming growth factor beta) superfamily member, is abundantly secreted by C26 cells. Consistent with myostatin signalling during cachexia, treating differentiated C2C12 myotubes with C26 CM (conditioned medium) resulted in myotubular atrophy due to the up-regulation of muscle-specific E3 ligases, atrogin-1 and MuRF1 (muscle RING-finger protein 1), and enhanced activity of the ubiquitin proteasome pathway. Furthermore, the C26 CM also activated ActRIIB (activin receptor type II B)/Smad and NF-kappa B (nuclear factor kappa B) signalling, and reduced the activity of the IGF-I (insulin-like growth factor 1)/P13K (phosphoinositide 3-kinase)/Akt pathway, three salient molecular features of myostatin action in skeletal muscles. Antagonists to myostatin prevented C26 CM-induced wasting in muscle cell cultures, further confirming that tumoral myostatin may be a key contributor in the pathogenesis of cancer cachexia. Finally, we show that treatment with C26 CM induced the autophagy-lysosome pathway and reduced the number of mitochondria in myotubes. These two previously unreported observations were recapitulated in skeletal muscles collected from C26 tumour-bearing mice.
C1 [Sharma, Mridula] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Biochem, Singapore 117595, Singapore.
   [Lokireddy, Sudarsanareddy; Wijesoma, Isuru Wijerupage; Bonala, Sabeera; Wei, Meng; Sze, Siu Kwan; Kambadur, Ravi] Nanyang Technol Univ, Sch Biol Sci, Singapore, Singapore.
   [McFarlane, Craig; Kambadur, Ravi] ASTAR, Singapore Inst Clin Sci, Singapore, Singapore.
RP Sharma, M (reprint author), Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Biochem, Singapore 117595, Singapore.
EM bchmridu@nus.edu.sg
FU NICHD (National Institute of Child Health and Human Development); MOE
   (Ministry of Education), Singapore [T208B3211]; BMRC (Biomedical
   Research Council), Singapore [07/1/21/19/521]
FX We thank Esther Latres (Regeneron Pharmaceuticals, Tarrytown, NJ,
   U.S.A.) for providing the anti-atrogin-1 and anti-MuRF1 antibodies used
   in the present study. The MF20 and T14 monoclonal antibodies developed
   by Donald A. Fischman and Frank E. Stockdale respectively were obtained
   from the Developmental Studies Hybridoma Bank developed under the
   auspices of the NICHD (National Institute of Child Health and Human
   Development) and maintained by Department of Biology, The University of
   Iowa, Iowa City, IA, U.S.A. Finally, we thank Addgene (Cambridge, MA,
   U.S.A.) for providing the reporter vectors [FoxO3 (Dr Michael Greenberg,
   #1789), PGC-1 alpha (Dr Bruce Spiegelman, #8887) and 4X SBE (Dr Bert
   Vogelstein, #16495)].; This work was supported by the MOE (Ministry of
   Education), Singapore [grant number T208B3211] and BMRC (Biomedical
   Research Council), Singapore [grant number 07/1/21/19/521].
CR Acharyya S, 2004, J CLIN INVEST, V114, P370, DOI 10.1172/jci200420174
   Acharyya S, 2007, CLIN CANCER RES, V13, P1356, DOI 10.1158/1078-0432.CCR-06-2307
   Arthur PG, 2008, CURR OPIN CLIN NUTR, V11, P408, DOI 10.1097/MCO.0b013e328302f3fe
   Bakkar N, 2010, PHYSIOL REV, V90, P495, DOI 10.1152/physrev.00040.2009
   Bodine SC, 2001, NAT CELL BIOL, V3, P1014, DOI 10.1038/ncb1101-1014
   Cai DS, 2004, CELL, V119, P285, DOI 10.1016/j.cell.2004.09.027
   Chan CY, 2011, MOL CELL PROTEOMICS, V10, DOI DOI 10.1074/mcp.m110.004804
   Chen HC, 2010, CELL, V141, P280, DOI 10.1016/j.cell.2010.02.026
   Chen Y, 2009, CELL DEATH DIFFER, V16, P1040, DOI 10.1038/cdd.2009.49
   Clarke BA, 2007, CELL METAB, V6, P376, DOI 10.1016/j.cmet.2007.09.009
   Cohen S, 2009, J CELL BIOL, V185, P1083, DOI 10.1083/jcb.200901052
   Cosper PF, 2011, CANCER RES, V71, P1710, DOI 10.1158/0008-5472.CAN-10-3145
   DRISCOLL J, 1990, J BIOL CHEM, V265, P4789
   Fearon KCH, 2008, EUR J CANCER, V44, P1124, DOI 10.1016/j.ejca.2008.02.033
   Ge XJ, 2011, CELL RES, V21, P1591, DOI 10.1038/cr.2011.72
   Glass DJ, 2005, INT J BIOCHEM CELL B, V37, P1974, DOI 10.1016/j.biocel.2005.04.018
   Guttridge DC, 2004, CURR OPIN CLIN NUTR, V7, P443, DOI 10.1097/01.mco.0000134364.61406.26
   Henningsen J, 2010, MOL CELL PROTEOMICS, V9, P2482, DOI 10.1074/mcp.M110.002113
   HERSHKO A, 1988, J BIOL CHEM, V263, P15237
   Karbowski M, 2007, J CELL BIOL, V178, P71, DOI 10.1083/jcb.200611064
   Klimek MEB, 2010, BIOCHEM BIOPH RES CO, V391, P1548, DOI 10.1016/j.bbrc.2009.12.123
   Kowaltowski AJ, 2009, FREE RADICAL BIO MED, V47, P333, DOI 10.1016/j.freeradbiomed.2009.05.004
   Langley B, 2004, ONCOGENE, V23, P524, DOI 10.1038/sj.onc.1207144
   Langley B, 2002, J BIOL CHEM, V277, P49831, DOI 10.1074/jbc.M204291200
   Li W, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001487
   Lokireddy S, 2011, AM J PHYSIOL-CELL PH, V301, pC1316, DOI 10.1152/ajpcell.00114.2011
   Lokireddy S, 2011, MOL ENDOCRINOL, V25, P1936, DOI 10.1210/me.2011-1124
   McCroskery S, 2003, J CELL BIOL, V162, P1135, DOI 10.1083/jcb.200207056
   McFarlane C, 2005, DEV BIOL, V283, P58, DOI 10.1016/j.ydbio.2005.03.039
   McFarlane C, 2008, CURR OPIN CLIN NUTR, V11, P422, DOI 10.1097/MCO.0b013e32830007e2
   McFarlane C, 2006, J CELL PHYSIOL, V209, P501, DOI 10.1002/jcp.20757
   Meng W, 2008, ANAL CHEM, V80, P9797, DOI 10.1021/ac801344z
   Palomero J, 2008, ANTIOXID REDOX SIGN, V10, P1463, DOI 10.1089/ars.2007.2009
   Romanello V, 2010, EMBO J, V29, P1774, DOI 10.1038/emboj.2010.60
   Sandri M, 2004, CELL, V117, P399, DOI 10.1016/S0092-8674(04)00400-3
   Sengupta A, 2009, J BIOL CHEM, V284, P28319, DOI 10.1074/jbc.M109.024406
   Seoane J, 2004, CELL, V117, P211, DOI 10.1016/S0092-8674(04)00298-3
   Sriram S, 2011, AGING CELL, V10, P931, DOI 10.1111/j.1474-9726.2011.00734.x
   Tisdale M. J., 2009, CURR OPIN GASTROEN, V26, P146
   Tisdale Michael J, 2005, J Support Oncol, V3, P209
   Tisdale MJ, 2009, PHYSIOL REV, V89, P381, DOI 10.1152/physrev.00016.2008
   Tisdale MJ, 2005, PHYSIOLOGY, V20, P340, DOI 10.1152/physiol.00019.2005
   Waddell D. S., 2008, AM J PHYSIOL-ENDOC M, V295, P785
   Wang K, 2011, AUTOPHAGY, V7, P297, DOI 10.4161/auto.7.3.14502
   Youle RJ, 2011, NAT REV MOL CELL BIO, V12, P9, DOI 10.1038/nrm3028
   Zhou XL, 2010, CELL, V142, P531, DOI 10.1016/j.cell.2010.07.011
NR 46
TC 57
Z9 63
U1 3
U2 26
PU PORTLAND PRESS LTD
PI LONDON
PA CHARLES DARWIN HOUSE, 12 ROGER STREET, LONDON WC1N 2JU, ENGLAND
SN 0264-6021
EI 1470-8728
J9 BIOCHEM J
JI Biochem. J.
PD AUG 15
PY 2012
VL 446
BP 23
EP 36
DI 10.1042/BJ20112024
PN 1
PG 14
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 990JH
UT WOS:000307626300003
PM 22621320
OA Green Published, Other Gold
DA 2018-12-27
ER

PT J
AU Azakir, BA
   Di Fulvio, S
   Salomon, S
   Brockhoff, M
   Therrien, C
   Sinnreich, M
AF Azakir, Bilal A.
   Di Fulvio, Sabrina
   Salomon, Steven
   Brockhoff, Marielle
   Therrien, Christian
   Sinnreich, Michael
TI RETRACTED: Modular Dispensability of Dysferlin C2 Domains Reveals
   Rational Design for Mini-dysferlin Molecules (Retracted article. See
   vol. 292, pg. 12543, 2017)
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article; Retracted Publication
ID GIRDLE MUSCULAR-DYSTROPHY; SKELETAL-MUSCLE; MEMBRANE REPAIR; GENE;
   MUTATION; CELLS; CAVEOLIN-3; MYOPATHY; IMPACT
AB Dysferlin is a large transmembrane protein composed of a C-terminal transmembrane domain, two DysF domains, and seven C2 domains that mediate lipid-and protein-binding interactions. Recessive loss-of-function mutations in dysferlin lead to muscular dystrophies, for which no treatment is currently available. The large size of dysferlin precludes its encapsulation into an adeno-associated virus (AAV), the vector of choice for gene delivery to muscle. To design mini-dysferlin molecules suitable for AAV-mediated gene transfer, we tested internally truncated dysferlin constructs, each lacking one of the seven C2 domains, for their ability to localize to the plasma membrane and to repair laser-induced plasmalemmal wounds in dysferlin-deficient human myoblasts. We demonstrate that the dysferlin C2B, C2C, C2D, and C2E domains are dispensable for correct plasmalemmal localization. Furthermore, we show that the C2B, C2C, and C2E domains and, to a lesser extent, the C2D domain are dispensable for dysferlin membrane repair function. On the basis of these results, we designed small dysferlin molecules that can localize to the plasma membrane and reseal laser-induced plasmalemmal injuries and that are small enough to be incorporated into AAV. These results lay the groundwork for AAV-mediated gene therapy experiments in dysferlin-deficient mouse models.
C1 [Azakir, Bilal A.; Di Fulvio, Sabrina; Brockhoff, Marielle; Sinnreich, Michael] Univ Basel Hosp, Dept Neurol, Neuromuscular Res Grp, CH-4031 Basel, Switzerland.
   [Azakir, Bilal A.; Di Fulvio, Sabrina; Brockhoff, Marielle; Sinnreich, Michael] Univ Basel Hosp, Dept Biomed, Neuromuscular Res Grp, CH-4031 Basel, Switzerland.
   [Azakir, Bilal A.; Di Fulvio, Sabrina; Brockhoff, Marielle; Sinnreich, Michael] Univ Basel, CH-4031 Basel, Switzerland.
   [Salomon, Steven; Therrien, Christian] McGill Univ, Montreal Neurol Inst, Montreal, PQ H3A 2B4, Canada.
RP Sinnreich, M (reprint author), Univ Basel Hosp, Dept Neurol, Neuromuscular Res Grp, Petersgraben 4, CH-4031 Basel, Switzerland.
EM msinnreich@uhbs.ch
OI Therrien, Christian/0000-0001-5138-1323
FU Myosuisse; Association Francaise contre les Myopathies (AFM);
   MDAC-ALS-CIHR Partnership; Swiss National Science Foundation (SNF);
   Gebert Ruf Foundation; Uniscientia Foundation; German Ministry of
   Education and Research (BMBF, Bonn, Germany)
FX This work was supported by Myosuisse, the Association Francaise contre
   les Myopathies (AFM), the MDAC-ALS-CIHR Partnership, the Swiss National
   Science Foundation (SNF), the Gebert Ruf Foundation, and the Uniscientia
   Foundation.; We thank the Muscle Tissue Culture Collection for providing
   the myoblast samples used in this study. The Muscle Tissue Culture
   Collection is part of the German Muscular Dystrophy Network (MD-NET,
   service structure S1, 01GM0601), funded by the German Ministry of
   Education and Research (BMBF, Bonn, Germany). The Muscle Tissue Culture
   Collection is a partner of EuroBioBank and TREAT-NMD. We thank Dr. K.
   Bushby for the GFP cDNA, Beat Erne for excellent technical assistance,
   and Andrea Mansinho for help with the experiments.
CR Aartsma-Rus A, 2010, EUR J HUM GENET, V18, P889, DOI 10.1038/ejhg.2010.4
   Allocca M, 2008, J CLIN INVEST, V118, P1955, DOI 10.1172/JCI34316
   Azakir BA, 2012, J BIOL CHEM, V287, P10344, DOI 10.1074/jbc.M111.329078
   Azakir BA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010122
   Bansal D, 2003, NATURE, V423, P168, DOI 10.1038/nature01573
   Bashir R, 1998, NAT GENET, V20, P37
   Cai CX, 2009, J BIOL CHEM, V284, P15894, DOI 10.1074/jbc.M109.009589
   Davis DB, 2002, J BIOL CHEM, V277, P22883, DOI 10.1074/jbc.M201858200
   De Luna N, 2007, NEUROMUSCULAR DISORD, V17, P69, DOI 10.1016/j.nmd.2006.09.006
   Di Fulvio S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028563
   Grieger JC, 2005, J VIROL, V79, P9933, DOI 10.1128/JVI.79.15.9933-9944.2005
   Han WQ, 2012, J CELL SCI, V125, P1225, DOI 10.1242/jcs.094565
   Huang YC, 2007, FASEB J, V21, P732, DOI 10.1096/fj.06-6628com
   Illa I, 2001, ANN NEUROL, V49, P130, DOI 10.1002/1531-8249(200101)49:1<130::AID-ANA22>3.3.CO;2-S
   Klinge L, 2010, MUSCLE NERVE, V41, P166, DOI 10.1002/mus.21166
   Krahn M, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000951
   Lek A, 2010, BMC EVOL BIOL, V10, DOI 10.1186/1471-2148-10-231
   Lennon NJ, 2003, J BIOL CHEM, V278, P50466, DOI 10.1074/jbc.M307247200
   Liu J, 1998, NAT GENET, V20, P31
   Lostal W, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038036
   Lostal W, 2010, HUM MOL GENET, V19, P1897, DOI 10.1093/hmg/ddq065
   Matsuda C, 2001, HUM MOL GENET, V10, P1761, DOI 10.1093/hmg/10.17.1761
   Sinnreich M, 2006, NEUROLOGY, V66, P1114, DOI 10.1212/01.wnl.0000204358.89303.81
   Tang Y, 2010, EXPERT OPIN BIOL TH, V10, P395, DOI 10.1517/14712591003604690
   Therrien C, 2006, J NEUROL SCI, V250, P71, DOI 10.1016/j.jns.2006.07.004
   Therrien C, 2009, BIOCHEMISTRY-US, V48, P2377, DOI 10.1021/bi802242r
   Vandre DD, 2007, BIOL REPROD, V77, P533, DOI 10.1095/biolreprod.107.062190
   Wein N, 2010, HUM MUTAT, V31, P136, DOI 10.1002/humu.21160
   Wu ZJ, 2010, MOL THER, V18, P80, DOI 10.1038/mt.2009.255
NR 29
TC 15
Z9 15
U1 1
U2 10
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD AUG 10
PY 2012
VL 287
IS 33
BP 27629
EP 27636
DI 10.1074/jbc.M112.391722
PG 8
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 993FF
UT WOS:000307840700037
PM 22736764
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Prasad, AS
   Dolia, SN
   Dhawan, MS
   Kumar, S
   Reddy, VR
AF Prasad, Arun S.
   Dolia, S. N.
   Dhawan, M. S.
   Kumar, S.
   Reddy, V. R.
TI RETRACTED: Synthesis, Structural and Magnetic Properties of Polypyrrole
   Coated Ni0.2Ca0.8Fe2O4 Nanocomposite2 (Retracted article. See vol. 28,
   pg. 1425, 2015)
SO JOURNAL OF SUPERCONDUCTIVITY AND NOVEL MAGNETISM
LA English
DT Article; Retracted Publication
DE Nano composite; Superparamagnetism; X-ray diffraction (XRD); Mossbauer
   spectroscopy
ID COBALT FERRITES; SPINEL FERRITE; NANOPARTICLES; BEHAVIOR; ALLOYS
AB The nanoparticles of spinel ferrites having composition Ni0.2Ca0.8Fe2O4 were synthesized by an advanced sol-gel method and subsequently coated with intrinsically conducting polypyrrole (PPy) by chemical oxidative polymerization of the corresponding monomer (pyrrole) using ammonium peroxodisulphate as oxidant. The X-ray diffraction and TEM measurements were obtained to understand the crystalline structure, size and morphology of evolution of the samples. The dc electrical investigation revealed that at room temperature the surface conductivity increased from 2.8 x 10(-5) Scm(-1) to 1.5 x 10(-3) Scm(-1) on polymerization. Mossbauer investigations revealed that the polymerization causes migration of Fe3+ ions from A to B site, resulting to the enhancement of the observed hyperfine field. In agreement with this, the dc magnetization measurements performed on VSM revealed an enhancement in saturation magnetization in the M-H curves on polymerization. The value of blocking temperature (TB) is found to have credibly increased from 110 K to 130 K, which confirms the increase in crystallite size after polymerization.
C1 [Prasad, Arun S.] Arulmigu Meenakshi Amman Coll Engn, Dept Phys, Vadamavandal 604410, Tamil Nadu, India.
   [Dolia, S. N.; Dhawan, M. S.] Univ Rajasthan, Dept Phys, Jaipur 302004, Rajasthan, India.
   [Kumar, S.] ML Sukhadia Univ, Dept Phys, Udaipur 313002, Rajasthan, India.
   [Reddy, V. R.] UGC DAE CSR, Indore 452017, Madhya Pradesh, India.
RP Prasad, AS (reprint author), Arulmigu Meenakshi Amman Coll Engn, Dept Phys, Vadamavandal 604410, Tamil Nadu, India.
EM asp.physics@gmail.com
CR Ansari R, 2006, E-J CHEM, V3, P186, DOI DOI 10.1155/2006/860413
   Brabers V. A. M, 1999, HDB MAGNETIC MAT, P189
   BRAND RA, 1987, NUCL INSTRUM METH B, V28, P398, DOI 10.1016/0168-583X(87)90182-0
   Brusentsova TN, 2005, J MAGN MAGN MATER, V293, P298, DOI 10.1016/j.jmmm.2005.02.023
   Cedeno-Mattei Y, 2008, J APPL PHYS, V103, DOI 10.1063/1.2838215
   Chikazumi S., 1978, PHYS MAGNETISM
   Cullity B. D., 1978, ELEMENTS XRAY DIFFRA
   Dey A, 2005, J PHYS-CONDENS MAT, V17, P5895, DOI 10.1088/0953-8984/17/37/025
   Dolia SN, 2008, CURR APPL PHYS, V8, P620, DOI 10.1016/j.cap.2007.11.004
   Dolia SN, 2008, HYPERFINE INTERACT, V184, P75, DOI 10.1007/s10751-008-9769-7
   GOLDFARB RB, 1981, PHYS REV B, V24, P1360, DOI 10.1103/PhysRevB.24.1360
   Gul IH, 2008, J ALLOY COMPD, V465, P227, DOI 10.1016/j.jallcom.2007.11.006
   Hemeda O. M, 2004, J PHYS, V28, P121
   Liu C, 2000, PURE APPL CHEM, V72, P37, DOI 10.1351/pac200072010037
   Martinez B, 1996, J APPL PHYS, V79, P2580, DOI 10.1063/1.361125
   Nathani H, 2004, MAT SCI ENG B-SOLID, V113, P228, DOI 10.1016/j.mseb.2004.08.010
   POPE NM, 1994, J BIOMED MATER RES, V28, P449, DOI 10.1002/jbm.820280407
   Prasad AS, 2010, MOD PHYS LETT B, V24, P1987, DOI 10.1142/S0217984910024389
   Wang J, 2006, J ALLOY COMPD, V419, P155, DOI 10.1016/j.jallcom.2005.05.055
   Zeng H, 2004, APPL PHYS LETT, V85, P792, DOI 10.1063/1.1776632
NR 20
TC 6
Z9 6
U1 2
U2 18
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1557-1939
EI 1557-1947
J9 J SUPERCOND NOV MAGN
JI J. Supercond. Nov. Magn
PD AUG
PY 2012
VL 25
IS 6
BP 1921
EP 1927
DI 10.1007/s10948-012-1513-5
PG 7
WC Physics, Applied; Physics, Condensed Matter
SC Physics
GA 011IA
UT WOS:000309157100045
DA 2018-12-27
ER

PT J
AU Esposito, F
   Tornincasa, M
   Federico, A
   Chiappetta, G
   Pierantoni, GM
   Fusco, A
AF Esposito, F.
   Tornincasa, M.
   Federico, A.
   Chiappetta, G.
   Pierantoni, G. M.
   Fusco, A.
TI RETRACTED: High-mobility group A1 protein inhibits p53-mediated
   intrinsic apoptosis by interacting with Bcl-2 at mitochondria (Retracted
   article. See vol. 5, e1206, 2014)
SO CELL DEATH & DISEASE
LA English
DT Article; Retracted Publication
DE HMGA proteins; p53; Bcl-2; apoptosis; mitochondria
ID TRANSCRIPTION FACTOR HMGA2; RAT-THYROID CELLS; NEOPLASTIC
   TRANSFORMATION; P53-DEPENDENT APOPTOSIS; HMGI(Y) PROTEINS; EXPRESSION;
   GENE; P53; CARCINOMAS; CANCER
AB The high-mobility group A (HMGA) proteins are a family of non-histone chromatin factors, encoded by the HMGA1 and HMGA2 genes. Several studies demonstrate that HMGA proteins have a critical role in neoplastic transformation, and their overexpression is mainly associated with a highly malignant phenotype, also representing a poor prognostic index. Even though a cytoplasmic localization of these proteins has been previously reported in some highly malignant neoplasias, a clear role for this localization has not been defined. Here, we first confirm the localization of the HMGA1 proteins in the cytoplasm of cancer cells, and then we report a novel mechanism through which HMGA1 inhibits p53-mitochondrial apoptosis by counteracting the binding of p53 to the anti-apoptotic factor Bcl-2. Indeed, we demonstrate a physical and functional interaction between HMGA1 and Bcl-2 proteins. This interaction occurs at mitochondria interfering with the ability of p53 protein to bind Bcl-2, thus counteracting p53-mediated mitochondrial apoptosis. This effect is associated with the inhibition of cytochrome c release and activation of caspases. Consistent with this mechanism, a strong correlation between HMGA1 cytoplasmic localization and a more aggressive histotype of thyroid, breast and colon carcinomas has been observed. Therefore, cytoplasmic localization of HMGA1 proteins in malignant tissues is a novel mechanism of inactivation of p53 apoptotic function. Cell Death and Disease (2012) 3, e383; doi: 10.1038/cddis.2012.126; published online 30 August 2012
C1 [Esposito, F.; Tornincasa, M.; Federico, A.; Pierantoni, G. M.; Fusco, A.] Univ Naples Federico II, Fac Med & Chirurg Napoli, Dipartimento Biol & Patol Cellulare & Mol, Ist Endocrinol & Oncol Sperimentale CNR, I-80131 Naples, Italy.
   [Chiappetta, G.] Fdn Pascale, Ist Nazl Tumori, Naples, Italy.
   [Fusco, A.] NOGEC Naples Oncogenom Ctr CEINGE Biotecnol Avanz, Naples, Italy.
   [Fusco, A.] SEMM European Sch Mol Med, Naples, Italy.
RP Fusco, A (reprint author), Univ Naples Federico II, Fac Med & Chirurg Napoli, Dipartimento Biol & Patol Cellulare & Mol, Ist Endocrinol & Oncol Sperimentale CNR, Via Sergio Pansini 5, I-80131 Naples, Italy.
EM alfusco@unina.it
FU Associazione Italiana Ricerca sul Cancro (AIRC) [IG11477, MFAG11702];
   Ministero dell'Universita e della Ricerca Scientifica e Tecnologica
   (MIUR); NOGEC-Naples Oncogenomic Center; Associazione Partenopea per le
   Ricerche Oncologiche (APRO); FIRC fellowship
FX This work was supported by grants (IG11477 and MFAG11702) from the
   Associazione Italiana Ricerca sul Cancro (AIRC), and the Ministero
   dell'Universita e della Ricerca Scientifica e Tecnologica (MIUR). This
   work was supported from NOGEC-Naples Oncogenomic Center. We thank the
   Associazione Partenopea per le Ricerche Oncologiche (APRO) for its
   support. Francesco Esposito is recipient of a FIRC fellowship.
CR Abe N, 2002, PANCREAS, V25, P198, DOI 10.1097/01.MPA.0000018635.15184.82
   AKAO Y, 1994, CANCER RES, V54, P2468
   Arima Y, 2005, J BIOL CHEM, V280, P19166, DOI 10.1074/jbc.M410691200
   Bandiera A, 1998, CANCER RES, V58, P426
   BERLINGIERI MT, 1995, MOL CELL BIOL, V15, P1545
   Cattaruzzi G, 2007, NUCLEIC ACIDS RES, V35, P1751, DOI 10.1093/nar/gkl1106
   Chiappetta G, 1998, CANCER RES, V58, P4193
   Chiappetta G, 1996, ONCOGENE, V13, P2439
   Chiappetta G, 2004, CLIN CANCER RES, V10, P7637, DOI 10.1158/1078-0432.CCR-04-0291
   Chipuk JE, 2006, CELL DEATH DIFFER, V13, P994, DOI 10.1038/sj.cdd.4401908
   Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734
   De Martino I, 2009, ONCOGENE, V28, P1432, DOI 10.1038/onc.2008.495
   Deng XM, 2006, MOL CELL BIOL, V26, P4421, DOI 10.1128/MCB.01647-05
   Esposito F, 2010, CANCER RES, V70, P5379, DOI 10.1158/0008-5472.CAN-09-4199
   Fedele M, 2006, CANCER CELL, V9, P459, DOI 10.1016/j.ccr.2006.04.024
   Fedele M, 1996, CANCER RES, V56, P1896
   Federico A, 2009, CANCER RES, V69, P7079, DOI 10.1158/0008-5472.CAN-09-1542
   Fusco A, 2007, NAT REV CANCER, V7, P899, DOI 10.1038/nrc2271
   GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1
   JOHNSON KR, 1989, MOL CELL BIOL, V9, P2114, DOI 10.1128/MCB.9.5.2114
   Kim HP, 2001, IMMUNITY, V15, P159, DOI 10.1016/S1074-7613(01)00167-4
   MANFIOLETTI G, 1991, NUCLEIC ACIDS RES, V19, P6793, DOI 10.1093/nar/19.24.6793
   Masciullo V, 2003, CARCINOGENESIS, V24, P1191, DOI 10.1093/carcin/bgg075
   Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9
   Nagpal S, 1999, J BIOL CHEM, V274, P22563, DOI 10.1074/jbc.274.32.22563
   Pallante P, 2008, CANCER RES, V68, P6770, DOI 10.1158/0008-5472.CAN-08-0695
   Pentimalli F, 2003, CANCER RES, V63, P7423
   Pierantoni GM, 2006, CELL DEATH DIFFER, V13, P1554, DOI 10.1038/sj.cdd.4401839
   Pierantoni GM, 2007, J CLIN INVEST, V117, P693, DOI 10.1172/JC129852
   Pierantoni GM, 2001, ONCOGENE, V20, P6132, DOI 10.1038/sj.onc.1204635
   Reef S, 2006, MOL CELL, V22, P463, DOI 10.1016/j.molcel.2006.04.014
   Reeves R, 2005, DNA REPAIR, V4, P926, DOI 10.1016/j.dnarep.2005.04.010
   Scala S, 2000, P NATL ACAD SCI USA, V97, P4256, DOI 10.1073/pnas.070029997
   TAMIMI Y, 1993, CANCER RES, V53, P5512
   Tessari MA, 2003, MOL CELL BIOL, V23, P9104, DOI 10.1128/MCB.23.24.9104-9116.2003
   THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P
   Thuault S, 2006, J CELL BIOL, V174, P175, DOI 10.1083/jcb.200512110
   Vallone D, 1997, EMBO J, V16, P5310, DOI 10.1093/emboj/16.17.5310
   ZHOU XJ, 1995, NATURE, V376, P771, DOI 10.1038/376771a0
NR 39
TC 20
Z9 22
U1 1
U2 19
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD AUG
PY 2012
VL 3
AR e383
DI 10.1038/cddis.2012.126
PG 10
WC Cell Biology
SC Cell Biology
GA 002SC
UT WOS:000308553800024
PM 22932725
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Lopez-Serna, R
   Gomez-Amador, JL
   Barges-Coll, J
   Arriada-Mendicoa, N
   Romero-Vargas, S
   Ramos-Peek, M
   Celis-Lopez, MA
   Revuelta-Gutierrez, R
   Portocarrero-Ortiz, L
AF Lopez-Serna, Raul
   Luis Gomez-Amador, Juan
   Barges-Coll, Juan
   Arriada-Mendicoa, Nicasio
   Romero-Vargas, Samuel
   Ramos-Peek, Miguel
   Angel Celis-Lopez, Miguel
   Revuelta-Gutierrez, Rogelio
   Portocarrero-Ortiz, Lesly
TI RETRACTED: Knowledge of skull base anatomy and surgical implications of
   human sacrifice among pre-Columbian Mesoamerican cultures (Retracted
   article. See vol.45, artn no.E18, 2018)
SO NEUROSURGICAL FOCUS
LA English
DT Article; Retracted Publication
DE skull base; forensic anthropology; funeral rites; shamanism
AB Human sacrifice became a common cultural trait during the advanced phases of Mesoamerican civilizations. This phenomenon, influenced by complex religious beliefs, included several practices such as decapitation, cranial deformation, and the use of human cranial bones for skull mask manufacturing. Archaeological evidence suggests that all of these practices required specialized knowledge of skull base and upper cervical anatomy. The authors conducted a systematic search for information on skull base anatomical and surgical knowledge among Mesoamerican civilizations. A detailed exposition of these results is presented, along with some interesting information extracted from historical documents and pictorial codices to provide a better understanding of skull base surgical practices among these cultures. Paleoforensic evidence from the Great Temple of Tenochtitlan indicates that Aztec priests used a specialized decapitation technique, based on a deep anatomical knowledge. Trophy skulls were submitted through a stepwise technique for skull mask fabrication, based on skull base anatomical landmarks. Understanding pre-Columbian Mesoamerican religions can only be realized by considering them in their own time and according to their own perspective. Several contributions to medical practice might have arisen from anatomical knowledge emerging from human sacrifice and decapitation techniques. (http://thejns.org/doi/abs/10.3171/2012.6.FOCUS12120)
C1 [Lopez-Serna, Raul; Luis Gomez-Amador, Juan; Barges-Coll, Juan; Arriada-Mendicoa, Nicasio; Ramos-Peek, Miguel; Angel Celis-Lopez, Miguel; Revuelta-Gutierrez, Rogelio] Inst Nacl Neurol & Neurocirugia Manuel Velasco Su, Dept Neurosurg, Mexico City 14269, DF, Mexico.
   [Romero-Vargas, Samuel] Inst Nacl Rehabil, Dept Spine Surg, Mexico City, DF, Mexico.
   [Portocarrero-Ortiz, Lesly] Inst Nacl Neurol & Neurocirugia Manuel Velasco Su, Dept Neuroendocrinol, Mexico City, DF, Mexico.
RP Lopez-Serna, R (reprint author), Inst Nacl Neurol & Neurocirug, Dept Neurosurg, Av Insurgentes Sur 3877, Mexico City 14269, DF, Mexico.
EM raullopezserna@hotmail.com
OI Barges-Coll, Juan/0000-0003-2515-5810
CR Bartelink EJ, 2011, INT J OSTEOARCHAEOL, V21, P351, DOI 10.1002/oa.1135
   Benz Bruce F., 2006, HIST MAIZE MULTIDISC, P73
   Carrasco D., 2000, CITY SACRIFICE AZTEC
   Chavez-Balderas X, 1997, HUMAN SACRIFICE MORT, P1
   Demarest A. A., 1984, RITUAL HUMAN SACRIFI, P227
   Duran FD, 1994, CIVILIZATION AM INDI, P1
   Gonzalez Y, 1985, SACRIFICIO HUMANO EN, P1
   Goodrich JT, 2010, WORLD NEUROSURG, V74, P81, DOI 10.1016/j.wneu.2010.08.018
   Graulich M, 1999, RITOS AZTECAS FIESTA, P2
   Haglund W, 1997, FORENSIC TAPHONOMY P, P201
   Hassig R, 1995, AZTEC WARFARE IMPERI, P5
   Hubert H, 1971, MELANGES HIST RELIG, P1
   Johannessen S, 1994, CORN CULTURE PREHIST, P5
   Kirchhoff P, 2009, MESOAMERICA LIMITES, P2
   Markman PT, 1990, MASKS SPIRIT IMAGE M, P95
   Marlowe FW, 2005, EVOL ANTHROPOL, V14, P54, DOI 10.1002/evan.20046
   Morales F, 1993, FRANCISCANOS MUNDO R, P4
   Prescott WH, 1998, HIST CONQUEST MEXICO, P7
   Romero J, 1970, HDB MIDDLE AM INDIAN, P50
   Romero-Vargas S, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10200
NR 20
TC 3
Z9 3
U1 0
U2 21
PU AMER ASSOC NEUROLOGICAL SURGEONS
PI ROLLING MEADOWS
PA 5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA
SN 1092-0684
J9 NEUROSURG FOCUS
JI Neurosurg. Focus
PD AUG
PY 2012
VL 33
IS 2
AR E1
DI 10.3171/2012.6.FOCUS12120
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA 983MM
UT WOS:000307123400002
PM 22853827
OA Bronze
DA 2018-12-27
ER

PT J
AU Schumann, S
   van der Linden, N
   Klein, O
AF Schumann, Sandy
   van der Linden, Nicolas
   Klein, Olivier
TI RETRACTED: Bridging the Gap on Facebook: Assessing Intergroup Contact
   and Its Effects for Intergroup Relations (Retracted article. See vol.
   16, pg. 80, 2013)
SO CYBERPSYCHOLOGY BEHAVIOR AND SOCIAL NETWORKING
LA English
DT Article; Retracted Publication
ID CONFLICT; INTERNET
AB In line with Allport's contact hypothesis, previous research showed that direct intergroup contact can reduce prejudices. However, establishing face-to-face contact is not always feasible. We postulate that Facebook-groups are a setting where direct and observed intergroup contact can develop, reducing prejudices and increasing mutual acceptance. Analyzing the comments of nine Facebook-groups with the destructive and constructive conflict scale, our results indicated that the expression of prejudices decreased and that of mutual acceptance increased over time, both for in- and outgroup members of the Facebook-groups. Only the expression of less prejudices, but not that of more mutual acceptance was predicted by intergroup contact. The influence of group-based motivations on the engagement in intergroup contact is discussed, and the overall findings are integrated in Steele and Brown's process model of media practices.
C1 [Schumann, Sandy; van der Linden, Nicolas; Klein, Olivier] Univ Libre Brussels, Social Psychol Unit, Brussels, Belgium.
RP Schumann, S (reprint author), Univ Libre Brussels, Unite Psychol Sociale, Ave Franklin Roosevelt 50,CP 122, B-1050 Brussels, Belgium.
EM sandy.schumann@ulb.ac.be
OI Klein, Olivier/0000-0003-2737-8049
CR Aimichai-Hamburger Y, 2006, J COMPUT-MEDIAT COMM, V3
   Allport G. W., 1954, NATURE PREJUDICE
   Bar-On D., 2000, BRIDGING GAP
   boyd DM, 2007, J COMPUT-MEDIAT COMM, V1
   Buckingham D, 2008, YOUTH IDENTITY DIGIT
   Butler J., 1990, GENDER TROUBLE FEMIN
   Dovidio JF, 2011, GROUP PROCESS INTERG, V14, P147, DOI 10.1177/1368430210390555
   Durham MG, 1999, JOURNALISM MASS COMM, V76, P192
   Ellison NB, 2007, J COMPUT-MEDIAT COMM, V12, P1143, DOI DOI 10.1111/J.1083-6101.2007.00367.X
   Hoter E, 2000, INT REV RES OPEN DIS, V2, P1
   Kampf R, 2011, IACM JUL 3 6 IST TUR
   Kampf R, 2011, ISR AFF, V17, P384, DOI 10.1080/13537121.2011.584666
   Kraut RE, 2011, EVIDENCE BASED SOCIA
   Kushin M., 2009, 1 MONDAY, P14
   Maoz I, 2011, J PEACE RES, V48, P115, DOI 10.1177/0022343310389506
   Mazziotta A, 2011, GROUP PROCESS INTERG, V14, P255, DOI 10.1177/1368430210390533
   Negroponte N., 1996, BEING DIGITAL
   Pettigrew TF, 2006, J PERS SOC PSYCHOL, V90, P751, DOI 10.1037/0022-3514.90.5.751
   Samson K, 2010, P 23 ANN INT ASS CON
   Smith Eliot R., 2007, SOCIAL PSYCHOL
   STEELE JR, 1995, J YOUTH ADOLESCENCE, V24, P551, DOI 10.1007/BF01537056
   Stephan W. G., 2000, REDUCING PREJUDICE D, P23
   Stock O, 2009, AI SOC, V1, P51
   Turner J. C., 1986, PSYCHOL INTERGROUP R, P7, DOI DOI 10.1089/CPB.2008.0150
   Turner J. C., 1987, REDISCOVERING SOCIAL
   Tynes BM, 2008, CYBERPSYCHOL BEHAV, V11, P459, DOI 10.1089/cpb.2007.0085
   Viswanath B., 2009, WOSN 09, P37
   Wilhelm A., 2000, DEMOCRACY DIGITAL AG
   Yablon Yaacov B, 2007, New Dir Youth Dev, P99, DOI 10.1002/yd.237
   Yablon YB, 2001, ED MEDIA INT, V2-3, P175
NR 30
TC 9
Z9 9
U1 2
U2 25
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 2152-2715
J9 CYBERPSYCH BEH SOC N
JI Cyberpsychology Behav. Soc. Netw.
PD AUG
PY 2012
VL 15
IS 8
BP 411
EP 416
DI 10.1089/cyber.2011.0569
PG 6
WC Psychology, Social
SC Psychology
GA 993NA
UT WOS:000307865200006
PM 22823550
DA 2018-12-27
ER

PT J
AU Chen, H
   Tong, JB
   Zou, T
   Shi, HF
   Liu, JP
   Du, X
   Yang, JF
   Ma, CS
AF Chen, Hao
   Tong, Jiabin
   Zou, Tong
   Shi, Haifeng
   Liu, Junpeng
   Du, Xin
   Yang, Jiefu
   Ma, Changshen
TI RETRACTED: Fibroblast Growth Factor Receptor 4 Polymorphisms Are
   Associated with Coronary Artery Disease (Retracted article. See vol. 20,
   pg. 162, 2016)
SO GENETIC TESTING AND MOLECULAR BIOMARKERS
LA English
DT Article; Retracted Publication
ID SMOOTH-MUSCLE-CELLS; FGF RECEPTOR; PROMOTES; SUSCEPTIBILITY;
   OSTEOSARCOMA; ANGIOGENESIS; EXPRESSION; HEPARIN; BREAST; CANCER
AB Fibroblast growth factor receptor 4 (FGFR4) plays crucial roles in vascular smooth muscle cell proliferation and atherosclerosis and, therefore, may potentially affect the development of coronary artery disease (CAD). The aim of this study was to investigate the association between FGFR4 polymorphisms and the susceptibility to CAD in the Chinese population. Two polymorphisms, rs192201146G/A (Asp756Asn) and rs188755817C/G (Ser778Arg), were detected by polymerase chain reaction-restriction fragment length polymorphism and direct sequencing in 722 CAD cases and 802 age-matched controls. Data were analyzed using the chi-square test. Results showed that frequencies of rs192201146GA genotype and rs188755817CG genotype were significantly higher in CAD patients than in controls (odds ratio [OR] = 1.92, 95% confidence interval [CI] 1.11-3.28, p = 0.016, and OR = 1.87, 95% CI 1.06-3.30, p = 0.027). Similarly, numbers of the rs192201146A allele and the rs188755817G allele were significantly increased in CAD cases (OR = 1.89, 95% CI 1.11-3.22, p = 0.017, and OR = 1.85, 95% CI 1.06-3.24, p = 0.029). Haplotype analysis revealed that GG and AC (rs192201146 rs188755817) haplotypes had higher frequencies in CAD patients (OR = 2.75, p = 0.002 and OR = 2.69, p = 0.001). Our data suggested that the FGFR4 rs192201146 (Asp756Asn) and rs188755817 (Ser778Arg) polymorphisms could act as risk factors for CAD in the Chinese population.
C1 [Chen, Hao; Du, Xin; Ma, Changshen] Capital Med Univ, Anzhen Hosp, Div Cardiol, Beijing 100029, Peoples R China.
   [Chen, Hao; Tong, Jiabin; Zou, Tong; Shi, Haifeng; Liu, Junpeng; Yang, Jiefu] Beijing Hosp, Minist Hlth, Div Cardiol, Cardiac Pacing & Electrophysiol Lab, Beijing, Peoples R China.
RP Ma, CS (reprint author), Capital Med Univ, Anzhen Hosp, Div Cardiol, 2 Anzhen Rd, Beijing 100029, Peoples R China.
EM macchangsheng@126.com
CR BAIRD A, 1985, BIOCHEM BIOPH RES CO, V126, P358, DOI 10.1016/0006-291X(85)90614-X
   BJORNSSON TD, 1991, P NATL ACAD SCI USA, V88, P8651, DOI 10.1073/pnas.88.19.8651
   CASSCELLS W, 1992, P NATL ACAD SCI USA, V89, P7159, DOI 10.1073/pnas.89.15.7159
   CHAMPIONARNAUD P, 1991, ONCOGENE, V6, P979
   CUEVAS P, 1991, CIRC RES, V69, P360, DOI 10.1161/01.RES.69.2.360
   EISEMANN A, 1991, ONCOGENE, V6, P1195
   Eswarakumar VP, 2005, CYTOKINE GROWTH F R, V16, P139, DOI 10.1016/j.cytogfr.2005.01.001
   FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664
   Gaziano TA, 2010, CURR PROB CARDIOLOGY, V35, P72, DOI [10.1016/j.cpcardio1.2009.10.002, 10.1016/j.cpcardiol.2009.10.002]
   HUGHES SE, 1993, CARDIOVASC RES, V27, P1214, DOI 10.1093/cvr/27.7.1214
   JAAKKOLA S, 1993, INT J CANCER, V54, P378, DOI 10.1002/ijc.2910540305
   JACKSON CL, 1993, AM J PATHOL, V143, P1024
   LEHTOLA L, 1992, INT J CANCER, V50, P598, DOI 10.1002/ijc.2910500419
   LEUNG HY, 1994, INT J CANCER, V59, P667, DOI 10.1002/ijc.2910590515
   LINDNER V, 1991, CIRC RES, V68, P106, DOI 10.1161/01.RES.68.1.106
   Liu Y, 2011, DNA CELL BIOL, V30, P1051, DOI 10.1089/dna.2011.1269
   Ma L, 2011, DNA CELL BIOL, V30, P1033, DOI 10.1089/dna.2011.1261
   MatsumotoYoshitomi S, 1997, INT J CANCER, V71, P442
   MIKAWA T, 1995, ANN NY ACAD SCI, V752, P506, DOI 10.1111/j.1749-6632.1995.tb17459.x
   NABEL EG, 1993, NATURE, V362, P844, DOI 10.1038/362844a0
   REIDY MA, 1991, ANN NY ACAD SCI, V638, P290, DOI 10.1111/j.1749-6632.1991.tb49039.x
   SCHWEIGERER L, 1987, NATURE, V325, P257, DOI 10.1038/325257a0
   Shi YY, 2005, CELL RES, V15, P97, DOI 10.1038/sj.cr.7290272
   Takahashi A, 1999, BIOCHEM BIOPH RES CO, V257, P855, DOI 10.1006/bbrc.1999.0465
   TAN EML, 1989, BIOCHEM BIOPH RES CO, V163, P84, DOI 10.1016/0006-291X(89)92102-5
   TEMPLETON TJ, 1992, DEV BIOL, V154, P169, DOI 10.1016/0012-1606(92)90057-N
   Wang W, 2011, DNA CELL BIOL, V30, P925, DOI 10.1089/dna.2011.1211
   WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82
   WINKLES JA, 1987, P NATL ACAD SCI USA, V84, P7124, DOI 10.1073/pnas.84.20.7124
NR 29
TC 2
Z9 2
U1 5
U2 8
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1945-0265
EI 1945-0257
J9 GENET TEST MOL BIOMA
JI Genet. Test. Mol. Biomark.
PD AUG
PY 2012
VL 16
IS 8
BP 952
EP 956
DI 10.1089/gtmb.2012.0033
PG 5
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 999IN
UT WOS:000308303200023
PM 22587598
DA 2018-12-27
ER

PT J
AU Chung, G
   Kim, TH
   Shin, H
   Chae, E
   Yi, H
   Moon, H
   Kim, HJ
   Kim, JS
   Jung, SJ
   Oh, SB
AF Chung, Gehoon
   Kim, Tae-hyung
   Shin, Hyewon
   Chae, Eunhee
   Yi, Hanju
   Moon, Hongsik
   Kim, Hyun Jin
   Kim, Joong Soo
   Jung, Sung Jun
   Oh, Seog Bae
TI RETRACTED: A Novel Carbamoyloxy Arylalkanoyl Arylpiperazine Compound
   (SKL-NP) Inhibits Hyperpolarization-Activated Cyclic Nucleotide-Gated
   (HCN) Channel Currents in Rat Dorsal Root Ganglion Neurons (Retracted
   article. See vol. 16, pg. 367, 2012)
SO KOREAN JOURNAL OF PHYSIOLOGY & PHARMACOLOGY
LA English
DT Article; Retracted Publication
DE cAMP; G(i)-protein; Hyperpolarization-activated cyclic nucleotide-gated
   channel; I-h; Neuropathic pain
ID NEUROPATHIC PAIN; PACEMAKER CHANNELS; I-H
AB In this study, we determined mode of action of a novel carbamoyloxy arylalkanoyl arylpiperazine compound (SKL-NP) on hyperpolarization-activated cyclic nucleotide-gated (HCN) channel currents (I-n) that plays important roles in neuropathic pain. In small or medium-sized dorsal root ganglion (DRG) neurons (<40 mu m in diameter) exhibiting tonic firing and prominent I-h, SKL-NP inhibited I-h and spike firings in a concentration dependent manner (IC50 = 7.85 mu M) SKL-NP-induced inhibition of I-h was blocked by pretreatment of pertussis toxin (PTX) and N-ethylmaleimide (NEM) as well as 8-Br-cAMP, a membrane permeable cAMP analogue. These results suggest that SKL-NP modulates I-h in indirect manner by the activation of a Gi-protein coupled receptor that decreases intracellular CAMP concentration. Taken together, SKL-NP has the inhibitory effect on HCN channel currents (I-h) in DRG neurons of rats.
C1 [Chung, Gehoon; Kim, Tae-hyung; Kim, Joong Soo; Oh, Seog Bae] Seoul Natl Univ, Dept Neurobiol & Physiol, Sch Dent, Seoul 110749, South Korea.
   [Chung, Gehoon; Kim, Tae-hyung; Kim, Joong Soo; Oh, Seog Bae] Seoul Natl Univ, Dent Res Inst, Sch Dent, Natl Res Lab Pain, Seoul 110749, South Korea.
   [Shin, Hyewon; Chae, Eunhee; Yi, Hanju; Moon, Hongsik] SK Biopharmaceut Inc, Taejon 305712, South Korea.
   [Jung, Sung Jun] Hanyang Univ, Dept Physiol, Coll Med, Seoul 133791, South Korea.
   [Kim, Hyun Jin] Sungkyunkwan Univ, Dept Physiol, Sch Med, Suwon 440746, South Korea.
RP Oh, SB (reprint author), Seoul Natl Univ, Dept Neurobiol & Physiol, Sch Dent, 103 Daehakro, Seoul 110749, South Korea.
EM eurijj@naver.com; odolbae@snu.ac.kr
FU Hanyang University [HY-201000000000283]
FX This work was supported by the research fund of Hanyang University
   (HY-201000000000283).
CR Binshtok AM, 2007, NATURE, V449, P607, DOI 10.1038/nature06191
   Campbell JN, 2006, NEURON, V52, P77, DOI 10.1016/j.neuron.2006.09.021
   Chaplan SR, 2003, J NEUROSCI, V23, P1169
   Dunlop J, 2009, CURR PHARM DESIGN, V15, P1767, DOI 10.2174/138161209788186281
   Emery EC, 2011, SCIENCE, V333, P1462, DOI 10.1126/science.1206243
   INGRAM SL, 1994, NEURON, V13, P179, DOI 10.1016/0896-6273(94)90468-5
   Jiang YQ, 2008, NEUROCHEM RES, V33, P1979, DOI 10.1007/s11064-008-9717-6
   Kouranova EV, 2008, NEUROSCIENCE, V153, P1008, DOI 10.1016/j.neuroscience.2008.03.032
   Momin A, 2008, J PHYSIOL-LONDON, V586, P5911, DOI 10.1113/jphysiol.2008.163154
   SHAPIRO MS, 1994, J NEUROSCI, V14, P7109
   Wahl-Schott C, 2009, CELL MOL LIFE SCI, V66, P470, DOI 10.1007/s00018-008-8525-0
   Wickenden AD, 2009, CURR PHARM DESIGN, V15, P2149, DOI 10.2174/138161209788489122
   Yeon KY, 2011, PAIN, V152, P2108, DOI 10.1016/j.pain.2011.05.018
NR 13
TC 1
Z9 1
U1 2
U2 13
PU KOREAN JOURNAL OF PHYSIOLOGY & PHARMACOLOGY
PI SEOUL
PA C/O EDITORIAL OFFICE, 448-13 SEOKYO-DONG, SEOUL, SOUTH KOREA
SN 1226-4512
EI 2093-3827
J9 KOREAN J PHYSIOL PHA
JI KOREAN J. PHYSIOL. PHARMACOL.
PD AUG
PY 2012
VL 16
IS 4
BP 237
EP 241
DI 10.4196/kjpp.2012.16.4.237
PG 5
WC Pharmacology & Pharmacy; Physiology
SC Pharmacology & Pharmacy; Physiology
GA 995EH
UT WOS:000307990200003
PM 22915988
OA Green Published, Other Gold
DA 2018-12-27
ER

PT J
AU Dinopoulos, H
   Dimitriou, R
   Giannoudis, PV
AF Dinopoulos, Haralambos
   Dimitriou, Rozalia
   Giannoudis, Peter V.
TI RETRACTED: Bone graft substitutes: What are the options? (Retracted
   article. See vol. 11, pg. 115, 2013)
SO SURGEON-JOURNAL OF THE ROYAL COLLEGES OF SURGEONS OF EDINBURGH AND
   IRELAND
LA English
DT Review; Retracted Publication
DE Bone substitutes; Bone-void fillers; Osteobiologics; Bone grafts
ID PLATELET-RICH PLASMA; MESENCHYMAL STEM-CELLS; MARROW STROMAL CELLS;
   SPINE FUSION MODEL; DEMINERALIZED BONE; MORPHOGENETIC PROTEINS; IN-VIVO;
   FUTURE-DIRECTIONS; PROGENITOR CELLS; CALCIUM-SULFATE
AB Currently, a number of bone grafting materials are available in the clinical setting to enhance bone regeneration, varying from autologous bone to several bone graft substitutes. Although autologous bone remains the "gold standard" for stimulating bone repair and regeneration, the morbidity from its harvesting and its restricted availability generated the need for the development of other materials or strategies either to substitute autologous bone graft or expand its limited supply. Bone graft substitutes can possess one or more components: an osteoconductive matrix, acting as a scaffold; osteoinductive proteins and other growth factors to induce differentiation and proliferation of bone-forming cells; and osteogenic cells for bone formation. Based on their distinct properties, all these bone grafting alternatives have specific indications, and can be used either alone or in combination. In this review, we summarise the available bone grafting materials, focussing mainly on the various bone substitutes and their characteristics, in an effort to specify the for their use. (C) 2012 Royal College of Surgeons of Edinburgh (Scottish charity number SC005317) and Royal College of Surgeons in Ireland. Published by Elsevier Ltd. All rights reserved.
C1 [Dinopoulos, Haralambos; Dimitriou, Rozalia; Giannoudis, Peter V.] Leeds Gen Infirm, Acad Dept Trauma & Orthopaed Surg, Leeds LS1 3EX, W Yorkshire, England.
RP Giannoudis, PV (reprint author), Leeds Gen Infirm, Acad Dept Trauma & Orthopaed Surg, Clarendon Wing,Floor A,Great George St, Leeds LS1 3EX, W Yorkshire, England.
EM pgiannoudi@aol.com
CR Ahlmann E, 2002, J BONE JOINT SURG AM, V84A, P716, DOI 10.2106/00004623-200205000-00003
   Aloy-Prosper A, 2011, MED ORAL PATOL ORAL, V16, pE210, DOI 10.4317/medoral.16.e210
   Alsousou J, 2009, J BONE JOINT SURG BR, V91B, P987, DOI 10.1302/0301-620X.91B8.22546
   Argintar E, 2011, INJURY, V42, P730, DOI 10.1016/j.injury.2010.11.016
   Arinzeh TL, 2003, J BONE JOINT SURG AM, V85A, P1927, DOI 10.2106/00004623-200310000-00010
   Balcik C, 2007, ACTA BIOMATER, V3, P985, DOI 10.1016/j.actbio.2007.04.004
   Bauer TW, 2000, CLIN ORTHOP RELAT R, P10
   Bi L, 2010, BIOMATERIALS, V31, P3201, DOI 10.1016/j.biomaterials.2010.01.038
   Bielby R, 2007, INJURY, V38, pS26, DOI 10.1016/j.injury.2007.02.007
   Blokhuis TJ, 2009, INJURY, V40, P8, DOI 10.1016/S0020-1383(09)70004-X
   Bohner M, 2000, INJURY, V31, pS37
   Brydone AS, 2010, P I MECH ENG H, V224, P1329, DOI 10.1243/09544119JEIM770
   BUCK BE, 1989, CLIN ORTHOP RELAT R, P129
   Calori GM, 2009, INJURY, V40, P67
   Cao WP, 1996, CERAM INT, V22, P493, DOI 10.1016/0272-8842(95)00126-3
   Cenni E, 2010, J ORTHOP RES, V28, P792, DOI 10.1002/jor.21073
   Centers for Disease Control and Prevention (CDC), 2003, MMWR Morb Mortal Wkly Rep, V52, P273
   Chen Y, 2001, J Orthop Sci, V6, P199, DOI 10.1007/s007760100072
   CHIROFF RT, 1975, J BIOMED MATER RES, V9, P29, DOI 10.1002/jbm.820090407
   CONNOLLY JF, 1995, CLIN ORTHOP RELAT R, P8
   Cornell CN, 1999, ORTHOP CLIN N AM, V30, P591, DOI 10.1016/S0030-5898(05)70112-7
   Coughlin MJ, 2006, FOOT ANKLE INT, V27, P19, DOI 10.1177/107110070602700104
   Cox G, 2011, INT ORTHOP
   Curylo LJ, 1999, SPINE, V24, P434, DOI 10.1097/00007632-199903010-00004
   D'Ippolito G, 1999, J BONE MINER RES, V14, P1115, DOI 10.1359/jbmr.1999.14.7.1115
   Daculsi G, 1998, BIOMATERIALS, V19, P1473, DOI 10.1016/S0142-9612(98)00061-1
   Dallari D, 2007, J BONE JOINT SURG AM, V89A, P2413, DOI 10.2106/JBJS.F.01026
   De Long WG, 2007, J BONE JOINT SURG AM, V89A, P649, DOI 10.2106/JBJS.F.00465
   DELL PC, 1985, J BONE JOINT SURG AM, V67A, P105, DOI 10.2106/00004623-198567010-00013
   Desai Bharat M, 2007, Am J Orthop (Belle Mead NJ), V36, P8
   Dimitriou R, 2005, INJURY, V36, P1392, DOI 10.1016/j.injury.2005.07.019
   Dimitriou R, 2011, BMC MED, V9, DOI 10.1186/1741-7015-9-66
   Dinopoulos HTH, 2006, EXPERT OPIN DRUG SAF, V5, P847, DOI 10.1517/14740338.5.6.847
   Docquier PL, 2005, J BONE JOINT SURG AM, V87A, P2253, DOI 10.2106/JBJS.D.02540
   EINHORN TA, 1995, J BONE JOINT SURG AM, V77A, P940, DOI 10.2106/00004623-199506000-00016
   Farrington M, 1998, J HOSP INFECT, V38, P261, DOI 10.1016/S0195-6701(98)90075-5
   Finkemeier CG, 2002, J BONE JOINT SURG AM, V84A, P454, DOI 10.2106/00004623-200203000-00020
   Fleming JE, 2000, ORTHOP CLIN N AM, V31, P357, DOI 10.1016/S0030-5898(05)70156-5
   Forriol F, 2009, INJURY, V40, P44
   Geiger F, 2007, BONE, V41, P516, DOI 10.1016/j.bone.2007.06.018
   Ghosh SK, 2008, J BIOMED MATER RES B, V86B, P217, DOI 10.1002/jbm.b.31009
   Giannoudis PV, 2007, INJURY, V38, pS3, DOI 10.1016/S0020-1383(08)70003-2
   Giannoudis PV, 2009, INJURY, V40, P1
   Giannoudis PV, 2005, INJURY, V36, P20, DOI 10.1016/j.injury.2005.07.029
   Greenwald AS, 2001, J BONE JOINT SURG AM, V83A, P98, DOI 10.2106/00004623-200100022-00007
   GROSS U, 1981, J BIOMED MATER RES, V15, P291, DOI 10.1002/jbm.820150302
   Hak DJ, 2007, J AM ACAD ORTHOP SUR, V15, P525, DOI 10.5435/00124635-200709000-00003
   Hartmann EK, 2010, ARCH ORTHOP TRAUM SU, V130, P909, DOI 10.1007/s00402-009-1015-5
   Hernigou P, 2005, J BONE JOINT SURG AM, V87A, P1430, DOI 10.2106/JBJS.D.02215
   Horne LT, 2010, J HAND SURG-AM, V35A, P262, DOI 10.1016/j.jhsa.2009.10.034
   Huibregtse BA, 2000, J ORTHOPAED RES, V18, P18, DOI 10.1002/jor.1100180104
   Jager M, 2011, J ORTHOP RES, V29, P173, DOI 10.1002/jor.21230
   Jahangir AA, 2008, AAOS NOW
   Jenis Louis G, 2006, Spine J, V6, P14, DOI 10.1016/j.spinee.2005.08.014
   Kappe T, 2010, CELL TISSUE BANK, V11, P253, DOI 10.1007/s10561-009-9140-5
   Katz JM, 2009, J BIOMED MATER RES B, V89B, P127, DOI 10.1002/jbm.b.31195
   Keramaris NC, 2008, INJURY, V39, pS45, DOI 10.1016/S0020-1383(08)70015-9
   Khan SN, 2005, J AM ACAD ORTHOP SUR, V13, P77, DOI 10.5435/00124635-200501000-00010
   Kinnunen I, 2000, J CRANIO MAXILL SURG, V28, P229, DOI 10.1054/jcms.2000.0140
   Kopylov P, 1999, ACTA ORTHOP SCAND, V70, P1, DOI 10.3109/17453679909000946
   KRAUSE JO, 1995, J ORTHOP TRAUMA, V9, P145, DOI 10.1097/00005131-199504000-00010
   Laurencin C, 2006, EXPERT REV MED DEVIC, V3, P49, DOI 10.1586/17434440.3.1.49
   Lind M, 2005, INT ORTHOP, V29, P205, DOI 10.1007/s00264-005-0650-x
   Lowery GL, 1999, BONE, V25, p47S, DOI 10.1016/S8756-3282(99)00132-5
   Maeda ST, 2007, J APPL ORAL SCI, V15, P416, DOI 10.1590/S1678-77572007000500008
   Mankin HJ, 2005, CLIN ORTHOP RELAT R, P210, DOI 10.1097/01.blo.0000150371.77314.52
   Mazock JB, 2004, INT J ORAL MAX IMPL, V19, P586
   McGonagle D, 2007, CURR ORTHOPAED, V21, P262, DOI 10.1016/j.cuor.2007.07.004
   Mirzayan R, 2001, J BONE JOINT SURG AM, V83A, P355, DOI 10.2106/00004623-200103000-00006
   Moroni A, 2005, EXPERT REV MED DEVIC, V2, P465, DOI 10.1586/17434440.2.4.465
   Nandi SK, 2010, INDIAN J MED RES, V132, P15
   Nauth A, 2010, J ORTHOP TRAUMA, V24, P543, DOI 10.1097/BOT.0b013e3181ec4833
   Nguyen HQ, 2004, BIOMATERIALS, V25, P865, DOI 10.1016/S0142-9612(03)00607-0
   Noshi T, 2000, J BIOMED MATER RES, V52, P621
   Papathanasopoulos A, 2008, INJURY, V39, pS21, DOI 10.1016/S0020-1383(08)70012-3
   Patterson TE, 2008, J BONE JOINT SURG AM, V90A, P111, DOI 10.2106/JBJS.G.01572
   Peltola M, 2000, ACTA OTO-LARYNGOL, P167
   Peters CL, 2006, J BIOMED MATER RES A, V76A, P456, DOI 10.1002/jbm.a.30569
   Peterson B, 2004, J BONE JOINT SURG AM, V86A, P2243, DOI 10.2106/00004623-200410000-00016
   Pountos I, 2010, INT ORTHOP, V34, P3, DOI 10.1007/s00264-009-0892-0
   Raikin SM, 2005, FOOT ANKLE INT, V26, P449, DOI 10.1177/107110070502600604
   Robey PG, 2000, J CLIN INVEST, V105, P1489, DOI 10.1172/JCI10256
   Sanchez-Sotelo J, 2000, J BONE JOINT SURG BR, V82B, P856, DOI 10.1302/0301-620X.82B6.10317
   Sempuku T, 1996, J ORTHOPAED RES, V14, P907, DOI 10.1002/jor.1100140610
   Sen MK, 2007, INJURY, V38, pS75, DOI 10.1016/j.injury.2007.02.012
   Simpson AHRW, 2006, J BONE JOINT SURG BR, V88B, P701, DOI 10.1302/0301-620X.88B6
   St John Thomas A, 2003, Am J Orthop (Belle Mead NJ), V32, P18
   Tang CH, 2004, MOL PHARMACOL, V66, P440
   Tiedeman JJ, 1995, ORTHOPEDICS, V18, P1153
   Tynan JR, 2005, J VASC INTERV RADIOL, V16, P293, DOI 10.1097/01.RVI.0000142598.67437.37
   URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893
   Wang JC, 2007, EUR SPINE J, V16, P1233, DOI 10.1007/s00586-006-0282-x
   Watt FM, 2000, SCIENCE, V287, P1427, DOI 10.1126/science.287.5457.1427
NR 93
TC 48
Z9 50
U1 4
U2 58
PU ROYAL COLLEGE SURGEONS EDINBURGH
PI EDINBURGH
PA NICOLSON ST, EDINBURGH EH8 9DW, SCOTLAND
SN 1479-666X
J9 SURG-J R COLL SURG E
JI Surg. J. R. Coll. Surg. Edinb. Irel.
PD AUG
PY 2012
VL 10
IS 4
BP 230
EP 239
DI 10.1016/j.surge.2012.04.001
PG 10
WC Surgery
SC Surgery
GA 990HL
UT WOS:000307621500008
PM 22682580
DA 2018-12-27
ER

PT J
AU Nasehi, S
   Pourghassem, H
AF Nasehi, Saadat
   Pourghassem, Hossein
TI RETRACTED: A novel real-time patient-specific seizure diagnosis
   algorithm based on analysis of EEG and ECG signals using spectral and
   spatial features and improved particle swarm optimization classifier
   (Retracted article. See vol. 43, pg. 229, 2013)
SO COMPUTERS IN BIOLOGY AND MEDICINE
LA English
DT Article; Retracted Publication
DE Gabor functions; Seizure detection; Epilepsy; EEG; ECG; Improved
   particle swarm optimization (IPSO); Principal component analysis (PCA)
ID INFANTS
AB This paper proposes a novel real-time patient-specific seizure diagnosis algorithm based on analysis of electroencephalogram (EEG) and electrocardiogram (ECG) signals to detect seizure onset. In this algorithm, spectral and spatial features are selected from seizure and non-seizure EEG signals by Gabor functions and principal component analysis (PCA). Furthermore, four features based on heart rate acceleration are extracted from ECG signals to form feature vector. Then a neural network classifier based on improved particle swarm optimization (IPSO) learning algorithm is developed to determine an optimal nonlinear decision boundary. This classifier allows to adjust the parameters of the neural network classifier, efficiently. This algorithm can automatically detect the presence of seizures with minimum delay which is an important factor from a clinical viewpoint. The performance of the proposed algorithm is evaluated on a dataset consisting of 154 h records and 633 seizures from 12 patients. The results indicate that the algorithm can recognize the seizures with the smallest latency and higher good detection rate (GDR) than other presented algorithms in the literature. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Nasehi, Saadat; Pourghassem, Hossein] Islamic Azad Univ, Dept Elect Engn, Najafabad Branch, Esfahan, Iran.
RP Pourghassem, H (reprint author), Islamic Azad Univ, Dept Elect Engn, Najafabad Branch, Esfahan, Iran.
EM h_pourghasem@iaun.ac.ir
CR Barry-Greene R., 2006, CLIN NEUROPHYSIOL, V117, P200
   Benitez D, 2001, COMPUT BIOL MED, V31, P399, DOI 10.1016/S0010-4825(01)00009-9
   Boeringer DW, 2004, IEEE T ANTENN PROPAG, V52, P771, DOI 10.1109/TAP.2004.825102
   Casson AJ, 2010, IEEE ENG MED BIOL, V29, P44, DOI 10.1109/MEMB.2010.936545
   Celka P, 2002, IEEE T BIO-MED ENG, V49, P455, DOI 10.1109/10.995684
   Colditz P.B., P 10 INT C INF SCI S, P819
   DeGiorgio CM, 2006, EPILEPSIA, V47, P1213, DOI 10.1111/j.1528-1167.2006.00594.x
   GOTMAN J, 1990, ELECTROEN CLIN NEURO, V76, P317, DOI 10.1016/0013-4694(90)90032-F
   Greene BR, 2007, CLIN NEUROPHYSIOL, V118, P1348, DOI 10.1016/j.clinph.2007.02.015
   Guerrero-Mosquera C, 2010, IEEE ENG MED BIO, P4946, DOI 10.1109/IEMBS.2010.5627239
   Hoerth M, 2007, CLIN NEUROL NEUROSUR, V109, P788, DOI 10.1016/j.clineuro.2007.06.004
   Kharbouch A, 2011, EPILEPSY BEHAV, V22, pS29, DOI 10.1016/j.yebeh.2011.08.031
   Kramer U, 2011, J CLIN NEUROPHYSIOL, V28, P36, DOI 10.1097/WNP.0b013e3182051320
   Lin CJ, 2009, EXPERT SYST APPL, V36, P5402, DOI 10.1016/j.eswa.2008.06.110
   Lin CJ, 2009, NEUROCOMPUTING, V72, P1121, DOI 10.1016/j.neucom.2008.02.017
   Naschi S., 2011, IEEE 3 INT C SIGN PR, V1, P217
   Nasehi S., 2011, 2011 IEEE 3rd International Conference on Communication Software and Networks (ICCSN 2011), P114, DOI 10.1109/ICCSN.2011.6014686
   Nasehi S, 2011, IEEE INT C INT COMP, P193
   Nasehi S., 2011, IEEE 3 INT C SIGN PR, V1, P185
   Nasehi S., IEEE INT C INT COMP, P200
   Orosco L, 2010, IEEE ENG MED BIO, P951, DOI 10.1109/IEMBS.2010.5627564
   Sastry CS, 2007, PATTERN RECOGN LETT, V28, P293, DOI 10.1016/j.patrec.2006.07.015
   Sharma A, 2007, PATTERN RECOGN LETT, V28, P1151, DOI 10.1016/j.patrec.2007.01.012
   Shoeb A. H., 2009, THESIS MIT US
   Teune LK, 2007, SEIZURE-EUR J EPILEP, V16, P459, DOI 10.1016/j.seizure.2007.02.008
   Zhang YZ, 2010, COMPUT BIOL MED, V40, P889, DOI 10.1016/j.compbiomed.2010.09.010
NR 26
TC 4
Z9 4
U1 3
U2 28
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0010-4825
EI 1879-0534
J9 COMPUT BIOL MED
JI Comput. Biol. Med.
PD AUG
PY 2012
VL 42
IS 8
BP 848
EP 856
DI 10.1016/j.compbiomed.2012.06.008
PG 9
WC Biology; Computer Science, Interdisciplinary Applications; Engineering,
   Biomedical; Mathematical & Computational Biology
SC Life Sciences & Biomedicine - Other Topics; Computer Science;
   Engineering; Mathematical & Computational Biology
GA 987OX
UT WOS:000307428100007
PM 22795227
DA 2018-12-27
ER

PT J
AU Hanagiri, T
   Shigematsu, Y
   Kuroda, K
   Baba, T
   Shiota, H
   Ichiki, Y
   Nagata, Y
   Yasuda, M
   So, T
   Takenoyama, M
   Tanaka, F
AF Hanagiri, Takeshi
   Shigematsu, Yoshiki
   Kuroda, Koji
   Baba, Tetsuro
   Shiota, Hironobu
   Ichiki, Yoshinobu
   Nagata, Yoshika
   Yasuda, Manabu
   So, Tomoko
   Takenoyama, Mitsuhiro
   Tanaka, Fumihiro
TI RETRACTED: Antitumor activity of human gamma delta T cells transducted
   with CD8 and with T-cell receptors of tumor-specific cytotoxic T
   lymphocytes (Retracted article. See vol. 105, pg. 141, 2014)
SO CANCER SCIENCE
LA English
DT Article; Retracted Publication
ID ALPHA-BETA-GENES; LUNG-CANCER; EFFECTOR FUNCTIONS; IMMUNOTHERAPY;
   EXPRESSION; MELANOMA; ANTIGENS; VACCINES; THERAPY; PATIENT
AB The difficulty in the induction and preparation of a large number of autologous tumor-specific cytotoxic T lymphocytes (CTL) from individual patients is one of major problems in their application to adoptive immunotherapy. The present study tried to establish the useful antitumor effectors by using gamma delta T cells through tumor-specific TCRa beta genes transduction, and evaluated the efficacy of their adoptive transfer in a non-obese diabetic/severe combined immunodeficiency (NOD/SCID) mice model. The TCRa beta gene was cloned from the HLA-B15-restricted CTL clone specific of the Kita-Kyushu Lung Cancer antigen-1 (KK-LC-1). The cloned TCRa beta as well as the CD8 gene were transduced into gamma delta d T cells induced from peripheral blood lymphocytes (PBL). Cytotoxic T lymphocyte activity was examined using a standard 4 h 51Cr release assay. Mice with a xenotransplanted tumor were treated with an injection of effector cells. Successful transduction of TCRa beta was confirmed by the staining of KK-LC-1-specific tetramers. The gamma delta T cells transduced with TCR alpha beta and CD8 showed CTL activity against the KK-LC-1-positive lung cancer cell line in a HLA B15-restricted manner. Adoptive transfer of the effector cells in a mice model resulted in marked growth suppression of KK-LC-1- and HLA-B15-positive xenotransplanted tumors. Co-transducing TCRa beta and CD8 into gamma delta T cells yielded the same antigen-specific activity as an original CTL in vitro and in vivo. The TCRa beta gene transduction into gamma delta T cells is a promising strategy for developing new adoptive immunotherapy. (Cancer Sci 2012; 103: 14141419)
C1 [Hanagiri, Takeshi; Shigematsu, Yoshiki; Kuroda, Koji; Baba, Tetsuro; Shiota, Hironobu; Ichiki, Yoshinobu; Nagata, Yoshika; Yasuda, Manabu; So, Tomoko; Takenoyama, Mitsuhiro; Tanaka, Fumihiro] Univ Occupat & Environm Hlth, Sch Med, Dept Surg 2, Kitakyushu, Fukuoka 807, Japan.
RP Hanagiri, T (reprint author), Univ Occupat & Environm Hlth, Sch Med, Dept Surg 2, Kitakyushu, Fukuoka 807, Japan.
EM hanagiri@med.uoeh-u.ac.jp
FU UOEH Research Grant for the Promotion of Occupational Health; Ministry
   of Education, Culture, Sports, Science and Technology, Japan
FX This study was supported in part by a UOEH Research Grant for the
   Promotion of Occupational Health and a Grant-in-Aid for scientific
   research from the Ministry of Education, Culture, Sports, Science and
   Technology, Japan. We are grateful to Professor Kosei Yasumoto for
   critical advice and helpful suggestions. We also thank Yukiko Koyanagi,
   Misako Fukumoto and Yukari Furutani for their expert technical help.
CR Asamura H, 2008, J THORAC ONCOL, V3, P46, DOI 10.1097/JTO.0b013e31815e8577
   Bonneville M, 2010, NAT REV IMMUNOL, V10, P467, DOI 10.1038/nri2781
   Cohen CJ, 2007, CANCER RES, V67, P3898, DOI 10.1158/0008-5472.CAN-06-3986
   Dudley ME, 2005, J CLIN ONCOL, V23, P2346, DOI 10.1200/JCO.2005.00.240
   Fukuyama T, 2006, CANCER RES, V66, P4922, DOI 10.1158/0008-5472.CAN-05-3840
   Hiasa A, 2008, GENE THER, V15, P695, DOI 10.1038/sj.gt.3303099
   Hiasa A, 2009, GENE THER, V16, P620, DOI 10.1038/gt.2009.6
   Hughes MS, 2005, HUM GENE THER, V16, P457, DOI 10.1089/hum.2005.16.457
   Jemal A, 2010, CA-CANCER J CLIN, V60, P277, DOI [10.1002/caac.20073, 10.3322/caac.20073]
   JITSUKAWA S, 1987, J EXP MED, V166, P1192, DOI 10.1084/jem.166.4.1192
   Jungbluth AA, 2000, INT J CANCER, V85, P460, DOI 10.1002/(SICI)1097-0215(20000215)85:4<460::AID-IJC3>3.3.CO;2-E
   Kato Y, 2003, J IMMUNOL, V170, P3608, DOI 10.4049/jimmunol.170.7.3608
   Kimura H, 2008, ANTICANCER RES, V28, P1229
   Kitamura T, 2003, EXP HEMATOL, V31, P1007, DOI 10.1016/j.exphem.2003.07.005
   Kondo M, 2011, J VIS EXP
   Kunzmann V, 2000, BLOOD, V96, P384
   Melief CJM, 2000, ADV IMMUNOL, V75, P235, DOI 10.1016/S0065-2776(00)75006-1
   Mellstedt H, 2011, LUNG CANCER, V73, P11, DOI 10.1016/j.lungcan.2011.02.023
   Morgan RA, 2003, J IMMUNOL, V171, P3287, DOI 10.4049/jimmunol.171.6.3287
   Okamoto S, 2009, CANCER RES, V69, P9003, DOI 10.1158/0008-5472.CAN-09-1450
   Rosenberg SA, 2004, NAT MED, V10, P909, DOI 10.1038/nm1100
   Sangha R, 2007, CLIN CANCER RES, V13, p4652S, DOI 10.1158/1078-0432.CCR-07-0213
   Schaft N, 2003, J IMMUNOL, V170, P2186, DOI 10.4049/jimmunol.170.4.2186
   Shigematsu Y, 2010, LUNG CANCER, V68, P105, DOI 10.1016/j.lungcan.2009.05.010
   Sugaya M, 2002, CHEST, V122, P282, DOI 10.1378/chest.122.1.282
   Sugaya M, 2007, INT J CANCER, V120, P1055, DOI 10.1002/ijc.22396
   Szymczak AL, 2004, NAT BIOTECHNOL, V22, P589, DOI 10.1038/nbt957
   Thomas S, 2007, EXPERT OPIN BIOL TH, V7, P1207, DOI 10.1517/14712598.7.8.1207
   Todaro M, 2009, J IMMUNOL, V182, P7287, DOI 10.4049/jimmunol.0804288
   Wright SE, 2010, IMMUNOL INVEST, V39, P570, DOI 10.3109/08820131003713798
   Yoshida Y, 2011, SURG TODAY, V41, P606, DOI 10.1007/s00595-010-4478-7
NR 31
TC 9
Z9 11
U1 1
U2 12
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1349-7006
J9 CANCER SCI
JI Cancer Sci.
PD AUG
PY 2012
VL 103
IS 8
BP 1414
EP 1419
DI 10.1111/j.1349-7006.2012.02337.x
PG 6
WC Oncology
SC Oncology
GA 980OE
UT WOS:000306901900007
PM 22621620
OA Bronze
DA 2018-12-27
ER

PT J
AU Perez-Legaz, J
   Arroyo, A
   Moya, P
   Ruiz-Tovar, J
   Frangi, A
   Candela, F
   Oliver, MI
   Calpena, R
AF Perez-Legaz, Juan
   Arroyo, Antonio
   Moya, Pedro
   Ruiz-Tovar, Jaime
   Frangi, Andres
   Candela, Fernando
   Oliver, Miguel I.
   Calpena, Rafael
TI RETRACTED: Perianal Versus Endoanal Application of Glyceryl Trinitrate
   0.4% Ointment in the Treatment of Chronic Anal Fissure: Results of a
   Randomized Controlled Trial. Is This the Solution to the Headaches?
   (Retracted article. See vol. 56, pg. 802, 2013)
SO DISEASES OF THE COLON & RECTUM
LA English
DT Article; Proceedings Paper; Retracted Publication
CT Meeting of the Spanish-Society-of-Coloproctology
CY MAY 04-06, 2011
CL Zaragoza, SPAIN
SP Spanish Soc Coloproctol
DE Anal fissure; Nitroglycerin; Drug administration; Topical; Intra-anal;
   Sphincterotomy; Chemical sphincterotomy
ID NITROGLYCERIN OINTMENT; MANAGEMENT; THERAPY
AB BACKGROUND: Application of nitroglycerin (glyceryl trinitrate) ointment with perianal administration is a widely used treatment for chronic anal fissure. However, headache occurs after application in 20% to 70% patients and leads to withdrawal in 10% of patients.
   OBJECTIVE: The aim of the study was to investigate whether endoanal application of the ointment may lower the frequency of headaches without sacrificing effectiveness. compare the effects of perianal versus endoanal administration of nitroglycerin ointment on frequency of headache and rate of healing in the treatment of chronic anal fissure.
   DESIGN: This was a prospective randomized clinical trial (ClinicalTrial.gov, NCT01132391).
   SETTINGS AND PATIENTS: Study participants were consecutive patients with a diagnosis of chronic anal fissure treated at a university teaching hospital in Elche, Alicante, Spain.
   INTERVENTION: Patients were randomly assigned to receive perianal (n = 26) or endoanal (n = 26) administration of 0.4% nitroglycerin ointment (375 mg of ointment containing 1.5 mg of glyceryl trinitrate), applied every 12 hours over an 8-week period.
   MAIN OUTCOME MEASURES: The primary endpoint of the study was the number of patients with headache within 3 hours after application of the ointment, analyzed with the intention-to-treat principle. Intensity of headache pain was rated on a 10-point visual analog scale. Secondary endpoints included frequencies of fissure healing, anorectal pain, rectal bleeding, pruritus, and incontinence.
   RESULTS: Headaches were reported in 14 (54%) patients with perianal treatment and in 6 patients (23%) with anorectal treatment (p = 0.003). The median headache pain score was 6 (range, 0-10) in the perianal group and 4.5 (range, 0-10) in the endoanal group (p = 0.03). Disabling headaches led to crossover from perianal to endoanal treatment in 4 patients (15%), and from endoanal to perianal treatment in 1 patient (4%) (p = 0.004). Of the 4 patients who switched from perianal to endoanal treatment, 2 reported improvement in headaches and 2 stopped treatment. The patient who switched from endoanal to perianal treatment also showed no improvement and stopped treatment. The healing rate at 24-week follow-up was 62% (16 patients) with perianal treatment and 77% (20 patients) with endoanal treatment (p < 0.05).
   LIMITATIONS: Effects on sphincter pressure were not evaluated because manometric measurements were not available.
   CONCLUSIONS: Endoanal application significantly reduces the frequency of headaches due to treatment with 0.4% nitroglycerin ointment and results in a higher healing rate compared with perianal administration. However, roughly 1 in 4 patients still experiences headaches. Our data suggest that endoanal application may be a better option for treatment of anal fissure with nitroglycerin ointment.
C1 [Perez-Legaz, Juan; Arroyo, Antonio; Moya, Pedro; Ruiz-Tovar, Jaime; Frangi, Andres; Candela, Fernando; Oliver, Miguel I.; Calpena, Rafael] Univ Hosp Elche, Dept Surg, Coloproctol Unit, Elche 03202, Alicante, Spain.
   [Arroyo, Antonio; Ruiz-Tovar, Jaime; Candela, Fernando; Oliver, Miguel I.; Calpena, Rafael] Miguel Hernandez Univ, Sch Med, Dept Pathol & Surg, Alicante, Spain.
RP Arroyo, A (reprint author), Univ Hosp Elche, Dept Surg, Coloproctol Unit, C Huertos & Molinos S-N, Elche 03202, Alicante, Spain.
EM arroyocir@hotmail.com
RI Frangi, Alejandro/C-6500-2008
OI Frangi, Alejandro/0000-0002-2675-528X; Arroyo,
   Antonio/0000-0003-0157-5175
CR Altomare DF, 2011, TECH COLOPROCTOL, V15, P135, DOI 10.1007/s10151-011-0683-7
   Altomare DF, 2000, DIS COLON RECTUM, V43, P174, DOI 10.1007/BF02236977
   Ayantunde AA, 2006, WORLD J SURG, V30, P2246, DOI 10.1007/s00268-005-0664-y
   Azarnoff DL, 2007, DIS COLON RECTUM, V50, P509, DOI 10.1007/s10350-006-0818-5
   Cross KLR, 2008, COLORECTAL DIS, V10, P1, DOI 10.1111/j.1463-1318.2008.01681.x
   Ezri T, 2003, DIS COLON RECTUM, V46, P805, DOI 10.1097/01.DCR.0000070044.62336.1D
   Gagliardi G, 2010, TECH COLOPROCTOL, V14, P241, DOI 10.1007/s10151-010-0604-1
   Godlewski G, 2000, SURG CLIN N AM, V80, P319, DOI 10.1016/S0039-6109(05)70408-4
   Herzig DO, 2010, SURG CLIN N AM, V90, P33, DOI 10.1016/j.suc.2009.09.002
   Jonas M, 2001, GASTROENTEROL CLIN N, V30, P167, DOI 10.1016/S0889-8553(05)70172-2
   Jones OM, 2007, ANN ROY COLL SURG, V89, P576, DOI 10.1308/003588407X205576
   Kennedy ML, 1999, DIS COLON RECTUM, V42, P1000, DOI 10.1007/BF02236691
   Kielhorn J., 2006, DERMAL ABSORPTION
   Lubowski D, 2008, DIS COLON RECTUM, V51, P1157, DOI 10.1007/s10350-008-9198-3
   Lund J N, 2006, Tech Coloproctol, V10, P177, DOI 10.1007/s10151-006-0276-z
   Madoff RD, 2003, GASTROENTEROLOGY, V124, P235, DOI 10.1053/gast.2003.50005
   MARCIO J, 1993, DIS COLON RECTUM, V36, P77
   Nash G, 2008, COLORECTAL DIS, V10, P96, DOI 10.1111/j.1463-1318.2007.01322.x
   Nash GF, 2006, INT J CLIN PRACT, V60, P1411, DOI 10.1111/j.1742-1241.2006.00895.x
   Nelson R, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003431.pub2
   Nelson RL, 2012, COCHRANE DB SYST REV, V2, DOI DOI 10.1002/14651858.CD003431.PUB3
   OH C, 1995, DIS COLON RECTUM, V38, P378, DOI 10.1007/BF02054225
   Perez-Legaz J, 2011, TECH COLOPROCTOL, V15, P475, DOI 10.1007/s10151-011-0725-1
   Sands LR, 2006, DRUGS, V66, P350, DOI 10.2165/00003495-200666030-00007
   Scholefield JH, 2003, GUT, V52, P264, DOI 10.1136/gut.52.2.264
   SCHOUTEN WR, 1994, DIS COLON RECTUM, V37, P664, DOI 10.1007/BF02054409
   Steele SR, 2006, ALIMENT PHARM THERAP, V24, P247, DOI 10.1111/j.1365-2036.2006.02990.x
   Torrabadella L, 2006, DIS COLON RECTUM, V49, P865, DOI 10.1007/s10350-005-0270-y
NR 28
TC 6
Z9 6
U1 4
U2 12
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0012-3706
EI 1530-0358
J9 DIS COLON RECTUM
JI Dis. Colon Rectum
PD AUG
PY 2012
VL 55
IS 8
BP 893
EP 899
DI 10.1097/DCR.0b013e31825a9f1f
PG 7
WC Gastroenterology & Hepatology; Surgery
SC Gastroenterology & Hepatology; Surgery
GA 976TZ
UT WOS:000306609800011
PM 22810476
DA 2018-12-27
ER

PT J
AU Siddiqui, AA
   Jia, XL
   Schloegel, J
   Carias, L
   Ntumngia, F
   Shoham, M
   Casey, JL
   Foley, M
   Adams, JH
   King, CL
AF Siddiqui, Asim A.
   Jia Xainli
   Schloegel, Jesse
   Carias, Lenore
   Ntumngia, Francis
   Shoham, Menachem
   Casey, Joanne L.
   Foley, Michael
   Adams, John H.
   King, Christopher L.
TI RETRACTED: Fine Specificity of Plasmodium vivax Duffy Binding Protein
   Binding Engagement of the Duffy Antigen on Human Erythrocytes (Retracted
   article. See vol. 83, pg. 2593, 2015)
SO INFECTION AND IMMUNITY
LA English
DT Article; Retracted Publication
ID CHONDROITIN-SULFATE-A; BLOOD-GROUP; RECEPTOR-BINDING; INHIBITORY
   ANTIBODIES; LIGAND DOMAIN; INVASION; MALARIA; FALCIPARUM;
   IDENTIFICATION; RECOGNITION
AB Plasmodium vivax invasion of human erythrocytes requires interaction of the P. vivax Duffy binding protein (PvDBP) with its host receptor, the Duffy antigen (Fy) on the erythrocyte surface. Consequently, PvDBP is a leading vaccine candidate. The binding domain of PvDBP lies in a cysteine-rich portion of the molecule called region II (PvDBPII). PvDBPII contains three distinct subdomains based upon intramolecular disulfide bonding patterns. Subdomain 2 (SD2) is highly polymorphic and is thought to contain many key residues for binding to Fy, while SDI and SD3 are comparatively conserved and their role in Fy binding is not well understood. To examine the relative contributions of the different subdomains to binding to Fy and their abilities to elicit strain-transcending binding-inhibitory antibodies, we evaluated recombinant proteins from SDI +2, SD2, SD3, and SD3+, which includes 24 residues of SD2. All of the recombinant subdomains, except for SD2, bound variably to human erythrocytes, with constructs containing SD3 showing the best binding. Antisera raised in laboratory animals against SD3, SD3+, and SD2+3 inhibited the binding of full-length PvDBPII, which is strain transcending, whereas antisera generated to SD1+2 and SD2 failed to generate blocking antibodies. All of the murine monoclonal antibodies generated to full-length PvDBPII that had significant binding-inhibitory activity recognized only SD3. Thus, SD3 binds Fy and elicits blocking antibodies, indicating that it contains residues critical to Fy binding that could be the basis of a strain-transcending candidate vaccine against P. vivax.
C1 [Siddiqui, Asim A.; Jia Xainli; Carias, Lenore; King, Christopher L.] Case Western Reserve Univ, Ctr Global Hlth & Dis, Cleveland, OH 44106 USA.
   [Schloegel, Jesse; Ntumngia, Francis; Adams, John H.] Univ S Florida, Dept Global Hlth, Tampa, FL USA.
   [Shoham, Menachem] Case Western Reserve Univ, Dept Biochem, Cleveland, OH 44106 USA.
   [Casey, Joanne L.; Foley, Michael] La Trobe Univ, Dept Biochem, Bundoora, Vic 3086, Australia.
   [King, Christopher L.] Louis B Stokes VA Med Ctr, Vet Affairs Res Serv, Cleveland, OH USA.
RP King, CL (reprint author), Case Western Reserve Univ, Ctr Global Hlth & Dis, Cleveland, OH 44106 USA.
EM cxk21@case.edu
RI Adams, John/G-1800-2015
OI Adams, John/0000-0003-3707-7979
FU Veterans Affairs Research Service; NIH [R01 A1064478, AI33656]
FX This work was supported, in part, by the Veterans Affairs Research
   Service and NIH grants R01 A1064478 and AI33656.
CR Adams JH, 2001, TRENDS PARASITOL, V17, P297, DOI 10.1016/S1471-4922(01)01948-1
   ADAMS JH, 1992, P NATL ACAD SCI USA, V89, P7085, DOI 10.1073/pnas.89.15.7085
   Ampudia E, 1996, MOL BIOCHEM PARASIT, V78, P269, DOI 10.1016/S0166-6851(96)02611-4
   BARNWELL JW, 1989, J EXP MED, V169, P1795, DOI 10.1084/jem.169.5.1795
   Batchelor JD, 2011, NAT STRUCT MOL BIOL, V18, P908, DOI 10.1038/nsmb.2088
   Chitnis CE, 1996, J EXP MED, V184, P1531, DOI 10.1084/jem.184.4.1531
   CHITNIS CE, 1994, J EXP MED, V180, P497, DOI 10.1084/jem.180.2.497
   Choe H, 2005, MOL MICROBIOL, V55, P1413, DOI 10.1111/j.1365-2958.2004.04478.x
   Chootong P, 2010, INFECT IMMUN, V78, P1089, DOI 10.1128/IAI.01036-09
   Cole-Tobian J, 2003, MOL BIOCHEM PARASIT, V127, P121, DOI 10.1016/S0166-6851(02)00327-4
   Cole-Tobian JL, 2007, AM J TROP MED HYG, V77, P955, DOI 10.4269/ajtmh.2007.77.955
   Cole-Tobian JL, 2007, AM J TROP MED HYG, V76, P12, DOI 10.4269/ajtmh.2007.76.12
   Cole-Tobian JL, 2002, J INFECT DIS, V186, P531, DOI 10.1086/341776
   Coley AM, 2006, INFECT IMMUN, V74, P2628, DOI 10.1128/IAI.74.5.2628-2636.2006
   Genton B, 2002, J INFECT DIS, V185, P820, DOI 10.1086/339342
   Grimberg BT, 2007, PLOS MED, V4, P1940, DOI 10.1371/journal.pmed.0040337
   Hans D, 2005, MOL MICROBIOL, V55, P1423, DOI 10.1111/j.1365-2958.2005.04484.x
   HAYNES JD, 1988, J EXP MED, V167, P1873, DOI 10.1084/jem.167.6.1873
   Howell DPG, 2008, MOL MICROBIOL, V67, P78, DOI 10.1111/j.1365-2958.2007.06019.x
   Jia XL, 2002, J IMMUNOL, V169, P3200, DOI 10.4049/jimmunol.169.6.3200
   Jia XL, 2000, MOL BIOCHEM PARASIT, V111, P253, DOI 10.1016/S0166-6851(00)00315-7
   JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224
   King CL, 2008, P NATL ACAD SCI USA, V105, P8363, DOI 10.1073/pnas.0800371105
   King CL, 2011, P NATL ACAD SCI USA, V108, P20113, DOI 10.1073/pnas.1109621108
   MILLER LH, 1975, SCIENCE, V189, P561, DOI 10.1126/science.1145213
   MILLER LH, 1976, NEW ENGL J MED, V295, P302, DOI 10.1056/NEJM197608052950602
   Ntumngia FB, 2012, INFECT IMMUN, V80, P1203, DOI 10.1128/IAI.05924-11
   Ntumngia FB, 2012, CLIN VACCINE IMMUNOL, V19, P30, DOI 10.1128/CVI.05466-11
   Ouattara A, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-175
   Ranjan A, 1999, P NATL ACAD SCI USA, V96, P14067, DOI 10.1073/pnas.96.24.14067
   Russell B, 2011, BLOOD, V118, pE74, DOI 10.1182/blood-2011-04-348748
   Singh AP, 2002, MOL BIOCHEM PARASIT, V121, P21, DOI 10.1016/S0166-6851(02)00017-8
   Singh K, 2008, NAT STRUCT MOL BIOL, V15, P932, DOI 10.1038/nsmb.1479
   Singh K, 2010, J BIOL CHEM, V285, P24855, DOI 10.1074/jbc.M110.118612
   Singh S, 2001, J BIOL CHEM, V276, P17111, DOI 10.1074/jbc.M101531200
   Singh SK, 2006, NATURE, V439, P741, DOI 10.1038/nature04443
   Tran TM, 2005, CYTOM PART A, V63A, P59, DOI 10.1002/cyto.a.20098
   TSUBOI T, 1994, INFECT IMMUN, V62, P5581
   VanBuskirk KM, 2004, P NATL ACAD SCI USA, V101, P15754, DOI 10.1073/pnas.0405421101
   Walsh CT, 2006, POSTTRANSLATIONAL MO
   WERTHEIMER SP, 1989, EXP PARASITOL, V69, P340, DOI 10.1016/0014-4894(89)90083-0
NR 41
TC 12
Z9 12
U1 1
U2 10
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0019-9567
EI 1098-5522
J9 INFECT IMMUN
JI Infect. Immun.
PD AUG
PY 2012
VL 80
IS 8
BP 2920
EP 2928
DI 10.1128/IAI.00206-12
PG 9
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 977PQ
UT WOS:000306677300033
PM 22615246
OA Green Published, Other Gold
DA 2018-12-27
ER

PT J
AU Alijan-pour, J
   Abrari, K
   Bluki, TL
   Ghorbanian, MT
   Goudarzi, I
   Salmani, ME
   Mirshekar, M
AF Alijan-pour, J.
   Abrari, K.
   Bluki, T. Lashkar
   Ghorbanian, M. T.
   Goudarzi, I.
   Salmani, M. Elahdadi
   Mirshekar, M.
TI RETRACTED: Acute ethanol administration affects memory reactivation: A
   look at the neuronal density and apoptosis in the rat hippocampus
   (Retracted article. See vol. 125, pg. 85, 2014)
SO PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR
LA English
DT Article; Retracted Publication
DE Hippocampus; Reconsolidation; Contextual fear conditioning; Ethanol
ID TUNEL POSITIVE CELLS; PROTEIN-SYNTHESIS; CONDITIONED FEAR; PYRAMIDAL
   CELL; DENTATE GYRUS; C57BL/6 MICE; RECONSOLIDATION; ALCOHOL;
   NEUROTOXICITY; EXTINCTION
AB This study is an attempt to examine whether administration of ethanol after memory reactivation will modulate expression of memory in rats or not. We further examined whether this administration alters the number of tunnel positive cells in hippocampus.
   Adult male Wistar rats were trained in a fear conditioning system using two 1 s, 0.6 mA shock with an interval of 180 s. 24 h later the rats were returned to the chamber for reactivation, and then they were injected with ethanol (0.5, 1, 1.5 mg/kg) or saline, ip. Again, one, seven and fourteen days after reactivation, the rats were returned to the context for 5 min. The freezing time (absence of all movements except respiration) was scored in seconds.
   In the second experiment, after test 1, the animals were anesthetized and a transcardial perfuse with phosphate buffer and paraformaldehyde 4% was conducted. After post-fixation of brains 5-mu m sections were stained with cresyl violet.
   Finally, paraffin-embedded sections of 10 mu m were cut out throughout the tissue and each sample was processed with TUNEL The number of apoptotic cells in a 130 mu m-long segment of the hippocampal CA1 and CA3 fields and dentate gyrus was counted.
   The data demonstrate that ethanol exposure impairs post retrieval processes. Rats receiving ethanol (1.5 mg/kg) showed lower freezing levels during the first test. Moreover, ethanol decreases the density of CA1, CA3 and DG cells and increases the density of apoptotic cells in all regions of hippocampus. Therefore, ethanol exposure impairs reconsolidation of contextual fear conditioning probably via decreasing the density of CA1, CA3 and DG cells. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Alijan-pour, J.; Abrari, K.; Bluki, T. Lashkar; Ghorbanian, M. T.; Goudarzi, I.; Salmani, M. Elahdadi; Mirshekar, M.] Damghan Univ, Sch Biol, Damghan, Iran.
RP Abrari, K (reprint author), Damghan Univ, Sch Biol, POB 36715-364, Damghan, Iran.
EM abrari@du.ac.ir
OI Elahdadi Salmani, Mahmoud/0000-0001-5237-3958
FU Damghan University
FX This study was supported by Damghan University. We sincerely thank the
   Damghan University's research director for providing a grant for this
   work. There is no conflict of interest in this article.
CR Abrari K, 2008, NEUROBIOL LEARN MEM, V89, P178, DOI 10.1016/j.nlm.2007.07.005
   Alberini CM, 2005, TRENDS NEUROSCI, V28, P51, DOI 10.1016/j.tins.2004.11.001
   Bancroft J, 2002, THEORY PRACTICE HIST, P374
   Chen SY, 1996, ALCOHOL CLIN EXP RES, V20, P1071, DOI 10.1111/j.1530-0277.1996.tb01948.x
   CHIN JH, 1977, MOL PHARMACOL, V13, P435
   Crews FT, 2004, ALCOHOL CLIN EXP RES, V28, P350, DOI 10.1097/01.ALC.0000113416.65546.01
   DAVIS HP, 1978, PHARMACOL BIOCHEM BE, V8, P701, DOI 10.1016/0091-3057(78)90269-1
   Debiec J, 2002, NEURON, V36, P527, DOI 10.1016/S0896-6273(02)01001-2
   Dudai Y, 2004, ANNU REV PSYCHOL, V55, P51, DOI 10.1146/annurev.psych.55.090902.142050
   Duka T, 2001, PSYCHOPHARMACOLOGY, V153, P295, DOI 10.1007/s002130000564
   Duvarci S, 2004, J NEUROSCI, V24, P9269, DOI 10.1523/JNEUROSCI.2971-04.2004
   Gould TJ, 2003, J PSYCHOPHARMACOL, V17, P77, DOI 10.1177/0269881103017001702
   Gulick D, 2007, ALCOHOL CLIN EXP RES, V31, P1528, DOI 10.1111/j.1530-0277.2007.00458.x
   HERNANDEZ LL, 1990, DRUG DEVELOP RES, V20, P155, DOI 10.1002/ddr.430200204
   HERNANDEZ LL, 1986, BEHAV NEUROSCI, V100, P494, DOI 10.1037/0735-7044.100.4.494
   Hunt PS, 2009, NEUROBIOL LEARN MEM, V91, P73, DOI 10.1016/j.nlm.2008.10.001
   Ikegami Y, 2003, NEUROSCI LETT, V349, P201, DOI 10.1016/S0304-3940(03)00826-7
   Land C, 2004, INT J DEV NEUROSCI, V22, P355, DOI 10.1016/j.ijdevneu.2004.04.008
   Land C, 2004, NEUROBIOL LEARN MEM, V81, P75, DOI 10.1016/j.nlm.2003.08.005
   Matthews DB, 2004, NEUROBIOL LEARN MEM, V82, P299, DOI 10.1016/j.nlm.2004.06.007
   McGoey TN, 2003, CAN J PHYSIOL PHARM, V81, P476, DOI 10.1139/Y03-048
   Melia KR, 1996, NEUROSCIENCE, V74, P313, DOI 10.1016/0306-4522(96)00138-8
   Miki Takanori, 2008, Congenital Anomalies, V48, P110, DOI 10.1111/j.1741-4520.2008.00190.x
   MOYER JR, 1990, BEHAV NEUROSCI, V104, P243, DOI 10.1037/0735-7044.104.2.243
   Nader K, 2003, TRENDS NEUROSCI, V26, P65, DOI 10.1016/S0166-2236(02)00042-5
   Nixon K, 2002, J NEUROCHEM, V83, P1087, DOI 10.1046/j.1471-4159.2002.01214.x
   Nomura H, 2008, NEUROPSYCHOPHARMACOL, V33, P2912, DOI 10.1038/npp.2008.13
   PAULABARBOSA MM, 1991, ALCOHOL ALCOHOLISM, V26, P177, DOI 10.1093/oxfordjournals.alcalc.a045099
   Pawlak R, 2002, NEUROSCI LETT, V327, P83, DOI 10.1016/S0304-3940(02)00369-5
   Ryabinin AE, 1998, PSYCHOPHARMACOLOGY, V139, P34, DOI 10.1007/s002130050687
   Shirpoor A, 2009, FOOD CHEM, V113, P115, DOI 10.1016/j.foodchem.2008.07.034
   Suzuki A, 2004, J NEUROSCI, V24, P4787, DOI 10.1523/JNEUROSCI.5491-03.2004
   Tokunaga S, 2003, BRAIN RES, V967, P273, DOI 10.1016/S006-8993(02)04266-X
   Tran TD, 2003, NEUROTOXICOL TERATOL, V25, P519, DOI 10.1016/S0892-0362(03)00074-6
   Tufan AC, 2008, INT J NEUROSCI, V118, P647, DOI 10.1080/00207450601046871
   VanDoren MJ, 2000, J NEUROSCI, V20, P1982
   Vianna MRM, 2001, P NATL ACAD SCI USA, V98, P12251, DOI 10.1073/pnas.211433298
NR 37
TC 10
Z9 14
U1 3
U2 12
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0091-3057
J9 PHARMACOL BIOCHEM BE
JI Pharmacol. Biochem. Behav.
PD AUG
PY 2012
VL 102
IS 2
BP 321
EP 328
DI 10.1016/j.pbb.2012.04.008
PG 8
WC Behavioral Sciences; Neurosciences; Pharmacology & Pharmacy
SC Behavioral Sciences; Neurosciences & Neurology; Pharmacology & Pharmacy
GA 978WH
UT WOS:000306776000019
PM 22564862
DA 2018-12-27
ER

PT J
AU Takai, N
   Ueda, T
   Kira, N
   Ishii, T
   Yoshida, T
   Koga, S
   Nishida, M
   Nasu, K
   Narahara, H
AF Takai, Noriyuki
   Ueda, Tami
   Kira, Naoko
   Ishii, Terukazu
   Yoshida, Toshie
   Koga, Satoko
   Nishida, Masakazu
   Nasu, Kaei
   Narahara, Hisashi
TI RETRACTED: Calcium/calmodulin-dependent kinase inhibitor induces growth
   inhibition, cell cycle arrest, and apoptosis in human choriocarcinoma
   cells (Retracted article. See vol. 36, pg. 6585, 2015)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE Calcium/calmodulin-dependent kinase; KN-93; Cell cycle; Apoptosis;
   Choriocarcinoma
ID OVARIAN-CANCER CELLS; TROPHOBLASTIC DISEASE; HUMAN ENDOMETRIAL;
   PROGRESSION; CALMODULIN; ACTIVATION; EXPRESSION; MANAGEMENT; KN-93; IV
AB KN-93, a membrane-permeant calcium/calmodulin-dependent kinase-selective inhibitor, induces apoptosis in some lines of human tumor cells. We investigated the effect of KN-93 in the choriocarcinoma cell line, BeWo. BeWo cells were treated with various concentrations of KN-93, and changes in cell growth, the cell cycle, apoptosis, and related parameters were examined. A WST-1 assay showed that BeWo cells were sensitive to the growth inhibitory effect of KN-93. Cell cycle analysis indicated that exposure to KN-93 decreased the proportion of cells in the S phase and increased the proportion in the G0/G1 phases of the cell cycle. Induction of apoptosis was confirmed by Annexin V staining of externalized phosphatidylserine, by the loss of mitochondrial transmembrane potential, and by antibodies directed against histones from fragmented DNA. This induction occurred in conjunction with the altered expression of genes related to cell growth, malignant phenotype, and apoptosis. These results suggest that KN-93 may serve as a therapeutic agent for the treatment of choriocarcinoma.
C1 [Takai, Noriyuki; Ueda, Tami; Kira, Naoko; Ishii, Terukazu; Yoshida, Toshie; Koga, Satoko; Nishida, Masakazu; Nasu, Kaei; Narahara, Hisashi] Oita Univ, Dept Obstet & Gynecol, Fac Med, Yufu, Oita 8795593, Japan.
RP Takai, N (reprint author), Oita Univ, Dept Obstet & Gynecol, Fac Med, 1-1 Idaigaoka,Hasama Machi, Yufu, Oita 8795593, Japan.
EM takai@oita-u.ac.jp
FU Ministry of Education, Culture, Sports, Science, and Technology, Japan
   [21592139]; Oita University
FX This study was supported by a grant-in-aid (no. 21592139 to NT) for
   scientific research from the Ministry of Education, Culture, Sports,
   Science, and Technology, Japan, and a research fund at the discretion of
   the President, Oita University (HN).
CR BERKOWITZ RS, 1984, GYNECOL ONCOL, V19, P173, DOI 10.1016/0090-8258(84)90177-X
   Chen Y, 2001, CANCER RES, V61, P6437
   Johnson DG, 1999, ANNU REV PHARMACOL, V39, P295, DOI 10.1146/annurev.pharmtox.39.1.295
   Jones WB, 1997, INT J GYNECOL CANCER, V7, P27, DOI 10.1046/j.1525-1438.1997.00409.x
   Kahl CR, 2004, J BIOL CHEM, V279, P15411, DOI 10.1074/jbc.M312543200
   Kawamura KI, 1996, BIOCHEM PHARMACOL, V52, P1903, DOI 10.1016/S0006-2952(96)00692-2
   Kyushima N, 2002, J CANCER RES CLIN, V128, P307, DOI 10.1007/s00432-002-0328-3
   Matsushita M, 1998, J BIOL CHEM, V273, P21473, DOI 10.1074/jbc.273.34.21473
   Racioppi L, 2008, TRENDS IMMUNOL, V29, P600, DOI 10.1016/j.it.2008.08.005
   Rimon G, 1997, J NEUROSCI RES, V48, P563, DOI 10.1002/(SICI)1097-4547(19970615)48:6<563::AID-JNR9>3.0.CO;2-8
   Rodriguez-Mora OG, 2005, CANCER RES, V65, P5408, DOI 10.1158/0008-5472.CAN-05-0271
   Satsu H, 2004, FEBS LETT, V569, P123, DOI 10.1016/j.febslet.2004.05.062
   Shang SJ, 2003, INT J MOL MED, V11, P181
   SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1
   SUMI M, 1991, BIOCHEM BIOPH RES CO, V181, P968, DOI 10.1016/0006-291X(91)92031-E
   SURWIT EA, 1980, OBSTET GYNECOL, V55, P565
   Takai N, 2004, CLIN CANCER RES, V10, P1141, DOI 10.1158/1078-0432.CCR-03-0100
   Takai N, 2008, GYNECOL ONCOL, V111, P336, DOI 10.1016/j.ygyno.2008.08.004
   Takai N, 2008, INT J MOL MED, V21, P637
   Takai N, 2009, CANCER LETT, V277, P235, DOI 10.1016/j.canlet.2008.12.018
   TOKUMITSU H, 1994, J BIOL CHEM, V269, P28640
   TOMBES RM, 1995, CELL GROWTH DIFFER, V6, P1063
NR 22
TC 3
Z9 3
U1 1
U2 6
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD AUG
PY 2012
VL 33
IS 4
BP 1053
EP 1058
DI 10.1007/s13277-012-0339-x
PG 6
WC Oncology
SC Oncology
GA 978HN
UT WOS:000306731500018
PM 22290426
DA 2018-12-27
ER

PT J
AU Zhang, J
   Xu, F
   Ouyang, CH
AF Zhang, Jie
   Xu, Feng
   Ouyang, Chunhui
TI RETRACTED: Joint effect of polymorphism in the N-acetyltransferase 2
   gene and smoking on hepatocellular carcinoma (Retracted article. See
   April, 2017)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE N-acetyltransferase 2 gene; Polymorphism; Hepatocellular carcinoma;
   Meta-analysis
ID SURGICAL MEDICINE; CIGARETTE-SMOKING; NAT2; N-ACETYLTRANSFERASE-2;
   METAANALYSIS; CANCER; RISK; SUSCEPTIBILITY; DISEASE; IMPACT
AB The N-acetyltransferase 2 gene (NAT2) has been implicated in the development of hepatocellular carcinoma (HCC). However, the results have been inconsistent. In this study, the authors performed a meta-analysis to clarify the association between NAT2 polymorphism and HCC risk. Published literatures from PubMed, EMBASE, CNKI, and Wan Fang Data were retrieved. Pooled odds ratio (OR) with 95% confidence interval (CI) was calculated using fixed- or random-effects model. Eight studies including 1,084 HCC cases and 1,682 controls were identified for the data analysis. The overall result showed that there was no statistically significant association between NAT2 genotypes and HCC risk (slow acetylation vs. rapid/intermediate acetylation: OR = 1.03, 95% CI 0.86-1.24). In the stratified analyses, NAT2 genotypes were also not significantly associated with HCC risk among both Europeans (OR = 1.11, 95% CI 0.86-1.43) and East Asians (OR = 1.01, 95% CI 0.65-1.56). Further subgroup analyses based on the smoking status showed that the effect size was statistically significant among the smokers (OR = 2.09, 95% CI 1.07-4.09), but not among those who never smoked (OR = 1.26, 95% CI 0.88-1.82). The present meta-analysis indicated that NAT2 genotypes were not associated with increased risk of HCC among the overall population but increased the risk of HCC among the smokers.
C1 [Zhang, Jie; Ouyang, Chunhui] Cent S Univ, Dept Gastroenterol, Xiangya Hosp 2, Changsha 410011, Hunan, Peoples R China.
   [Xu, Feng] Cent S Univ, Dept Gen Surg, Xiangya Hosp 2, Changsha 410011, Hunan, Peoples R China.
RP Ouyang, CH (reprint author), Cent S Univ, Dept Gastroenterol, Xiangya Hosp 2, Changsha 410011, Hunan, Peoples R China.
EM ouyangch0@126.com
CR Agundez JAG, 1996, PHARMACOGENETICS, V6, P501
   Agundez JAG, 2002, SCAND J GASTROENTERO, V37, P99, DOI 10.1080/003655202753387437
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Blum H E, 2001, IARC Sci Publ, V154, P241
   Chen CJ, 1997, J GASTROEN HEPATOL, V12, pS294, DOI 10.1111/j.1440-1746.1997.tb00513.x
   Cui D, 2011, LUNG CANCER, V73, P153, DOI 10.1016/j.lungcan.2010.12.012
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Farker K, 2003, EXP TOXICOL PATHOL, V54, P387, DOI 10.1078/0940-2993-00275
   Farker K, 2002, INT J CLIN PHARM TH, V40, P120
   Gao Jian-ping, 2003, Zhonghua Gan Zang Bing Za Zhi, V11, P20
   Gelatti U, 2005, INT J CANCER, V115, P301, DOI 10.1002/ijc.20895
   Gong CM, 2011, MED ONCOL, V28, P365, DOI 10.1007/s12032-010-9423-5
   Hietanen E, 1997, ENVIRON HEALTH PERSP, V105, P749, DOI 10.2307/3433278
   Huang YS, 2003, AM J GASTROENTEROL, V98, P1417, DOI 10.1111/j.1572-0241.2003.07452.x
   Imaizumi T, 2009, CARCINOGENESIS, V30, P1729, DOI 10.1093/carcin/bgp191
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Parkin DM, 2001, INT J CANCER, V94, P153, DOI 10.1002/ijc.1440
   Pfau W, 1998, CANCER EPIDEM BIOMAR, V7, P1019
   Raimondi S, 2009, MUTAT RES-FUND MOL M, V670, P6, DOI 10.1016/j.mrfmmm.2009.06.013
   Sanderson S, 2007, AM J EPIDEMIOL, V166, P741, DOI 10.1093/aje/kwm167
   SMITH CAD, 1994, EUR J CANCER, V30A, P1921, DOI 10.1016/0959-8049(94)00382-F
   Ying XJ, 2011, J CANCER RES CLIN, V137, P1661, DOI 10.1007/s00432-011-1045-6
   Yu MW, 2000, GUT, V47, P703, DOI 10.1136/gut.47.5.703
   Zhang JA, 2010, BREAST CANCER RES TR, V123, P877, DOI 10.1007/s10549-010-0807-1
   Zhang XY, 2003, THESIS XIDIAN U, P1
   Zhong X, 2010, ARCH MED RES, V41, P275, DOI 10.1016/j.arcmed.2010.06.001
NR 27
TC 9
Z9 9
U1 8
U2 18
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD AUG
PY 2012
VL 33
IS 4
BP 1059
EP 1063
DI 10.1007/s13277-012-0340-4
PG 5
WC Oncology
SC Oncology
GA 978HN
UT WOS:000306731500019
PM 22293947
DA 2018-12-27
ER

PT J
AU Demirel, S
   Attigah, N
   Bruijnen, H
   Hakimi, M
   Macek, L
   Bockler, D
AF Demirel, Serdar
   Attigah, Nicolas
   Bruijnen, Hans
   Hakimi, Maani
   Macek, Laura
   Boeckler, Dittmar
TI RETRACTED: Eversion Carotid Endarterectomy is Associated With Impaired
   Postoperative Hemodynamic Stability Compared With the Conventional
   Technique (Retracted article. See vol. 27, pg. 129, 2012)
SO ANNALS OF VASCULAR SURGERY
LA English
DT Article; Retracted Publication
ID BLOOD-PRESSURE; PULSE PRESSURE; HYPERTENSION; COMPLICATIONS; SURGERY;
   RISK; BAROREFLEX
AB Background: Carotid endarterectomy is associated with a profound effect on blood pressure. The aim of this study was to evaluate 24-hour ambulatory blood pressure measurements (ABPMs) after eversion carotid endarterectomy (E-CEA) and conventional carotid endarterectomy (C-CEA).
   Methods: Seventy-one patients were included in this prospective study (E-CEA [37]/C-CEA [34]). Daytime (8 AM-10 PM) and nighttime (10 PM-8 AM) ABPMs were analyzed preoperatively and on postoperative days 1 and 3.
   Results: Patients' demographics and preoperative antihypertensive regimens were similar in the two groups. Compared with baseline, ABPM decreased on postoperative day 1 in the C-CEA group (P < 0.01) but normalized by day 3. By contrast, ABPM values were unchanged on day 1 in the E-CEA group but increased above baseline on day 3 (P < 0.01). E-CEA was associated with higher ABPM on day 1 (daytime: P < 0.001; nighttime: P < 0.01) and again on day 3 (daytime: P < 0.001; nighttime: P < 0.01). The use of vasodilators was more frequent in the E-CEA group, both in the recovery room (P = 0.007) and on the ward (P = 0.004).
   Conclusion: E-CEA may be associated with higher postoperative blood pressure and the need for more additional antihypertensive therapy in the postoperative period compared with C-CEA.
C1 [Demirel, Serdar; Attigah, Nicolas; Hakimi, Maani; Macek, Laura; Boeckler, Dittmar] Univ Hosp Ruprecht Karls, Dept Vasc & Endovasc Surg, Heidelberg, Germany.
   [Bruijnen, Hans] Univ Munich, Augsburg City Hosp, Dept Vasc Surg, Munich, Germany.
RP Demirel, S (reprint author), Heidelberg Univ, Dept Vasc & Endovasc Surg, Neuenheimer Feld 110, D-69120 Heidelberg, Germany.
EM serdar.demirel@med.uni-heidelberg.de
CR AbuRahma AF, 2010, J VASC SURG, V51, P1133, DOI 10.1016/j.jvs.2009.12.046
   AHN SS, 1989, J VASC SURG, V9, P351, DOI 10.1067/mva.1989.vs0090351
   ANGELLJAMES JE, 1974, BRIT J SURG, V61, P805, DOI 10.1002/bjs.1800611014
   ASIDDAO CB, 1982, ANESTH ANALG, V61, P631
   Berne RN, 1992, CARDIOVASCULAR PHYSL, P113
   BOVE EL, 1979, SURGERY, V85, P633
   CAFFERATA HT, 1982, ANN SURG, V196, P465, DOI 10.1097/00000658-198210000-00010
   Demirel S, 2011, J VASC SURG, V54, P80, DOI 10.1016/j.jvs.2010.11.106
   Dollery S.C., 1991, THERAPEUTIC DRUGS
   Englund R, 1986, Ann Vasc Surg, V1, P304, DOI 10.1016/S0890-5096(06)60124-6
   Franklin SS, 1999, PATHOL BIOL, V47, P594
   Franklin SS, 1999, CIRCULATION, V100, P354, DOI 10.1161/01.CIR.100.4.354
   Franklin SS, 1997, J HYPERTENS, V15, P1143, DOI 10.1097/00004872-199715100-00012
   HANS SS, 1995, AM SURGEON, V61, P356
   LEHV M S, 1970, Stroke, V1, P307
   Mehta M, 2001, J VASC SURG, V34, P839, DOI 10.1067/mva.2001.118817
   Nouraei SAR, 2005, J VASC SURG, V41, P631, DOI 10.1016/j.jvs.2005.01.009
   Palatini P., 1998, BLOOD PRESS MONIT, V3, P255
   PIEPGRAS DG, 1988, J NEUROSURG, V68, P532, DOI 10.3171/jns.1988.68.4.0532
   Robinson TG, 2003, STROKE, V34, P705, DOI 10.1161/01.STR.0000058493.94875.9F
   Rothwell PM, 2010, LANCET, V375, P895, DOI 10.1016/S0140-6736(10)60308-X
   Rothwell PM, 2005, LANCET, V366, P1773, DOI 10.1016/S0140-6736(05)67702-1
   Schaafsma A, 2002, EUR J VASC ENDOVASC, V23, P17, DOI 10.1053/ejvs.2001.1545
   Schneemilch CE, 2006, ANESTH ANALG, V103, P297, DOI 10.1213/01.ane.0000223673.68072.42
   Sigaudo-Roussel D, 2002, J VASC SURG, V36, P793, DOI 10.1067/mva.2002.126564
   Staessen JA, 2002, AM J HYPERTENS, V15, P835, DOI 10.1016/S0895-7061(02)02987-4
   SUNDT TM, 1981, MAYO CLIN PROC, V56, P533
   TOWNE JB, 1980, SURGERY, V88, P575
   WADE JG, 1970, NEW ENGL J MED, V282, P823, DOI 10.1056/NEJM197004092821501
   Wong JH, 1997, NEUROSURGERY, V41, P35, DOI 10.1097/00006123-199707000-00009
   Zanchetti A, 1997, AM J HYPERTENS, V10, P1069, DOI 10.1016/S0895-7061(97)00270-7
   Zarins CK, 2005, ATLAS VASCULAR SURG
NR 32
TC 5
Z9 5
U1 2
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0890-5096
EI 1615-5947
J9 ANN VASC SURG
JI Ann. Vasc. Surg.
PD AUG
PY 2012
VL 26
IS 6
BP 755
EP 765
DI 10.1016/j.avsg.2011.12.015
PG 11
WC Surgery; Peripheral Vascular Disease
SC Surgery; Cardiovascular System & Cardiology
GA 974LL
UT WOS:000306436700001
PM 22728106
DA 2018-12-27
ER

PT J
AU Lin, CM
   Feng, W
AF Lin, Chih-Ming
   Feng, Wayne
TI RETRACTED: Microarray and Synchronization of Neuronal Differentiation
   with Pathway Changes in the Kyoto Encyclopedia of Genes and Genomes
   (KEGG) Databank in Nerve Growth Factor-Treated PC12 Cells (Retracted
   article. See vol. 10, pg. 90, 2013)
SO CURRENT NEUROVASCULAR RESEARCH
LA English
DT Article; Retracted Publication
DE Kyoto encyclopedia of genes and genomes; mapk signaling pathway; nerve
   growth factor; neuronal cell differentiation; pc12 cells; trk signaling
   pathway
ID SYSTEMS BIOLOGY; EXPRESSION; INHIBITION; ACTIVATION; INDUCTION; FOS
AB The Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway database creates networks from interrelations between molecular biology and underlying chemical elements. This allows for analysis of biologic networks, genomic information, and higher-order functional information at a systems level. We performed microarray experiments and used the KEGG database, systems biology analysis, and annotation of pathway function to study nerve growth factor (NGF)-induced differentiation of PC12 cells. Cells were cultured to 70%-80% confluence, treated with NGF for 1 or 3 hours (h), and RNA was extracted. Stage 1 data analysis involved analysis of variance (ANOVA), and stage 2 involved cluster analysis and heat map generation. We identified 2020 NGF-induced PC12 genes (1038 at 1 h and 1554 at 3 h). Results showed changes in gene expression over time. We compared these genes with 6035 genes from the KEGG database. Cross-matching resulted in 830 genes. Among these, we identified 395 altered genes (155 at 1 h and 301 at 3 h; 2-fold increase from 1 h to 3 h). We identified 191 biologic pathways in the KEGG database; the top 15 showed correlations with neuronal differentiation (mitogen-activated protein kinase [MAPK] pathway: 35 genes at 1 h, 54 genes at 3 h; genes associated with axonal guidance: 12 at 1 h, 26 at 3 h; Wnt pathway: 16 at 1 h, 25 at 3 h; neurotrophin pathway: 4 at 1 h, 14 at 3 h). Thus, we identified changes in neuronal differentiation pathways with the KEGG database, which were synchronized with NGF-induced differentiation.
C1 [Lin, Chih-Ming] Beth Israel Deaconess Med Ctr, Dept Neurol, Stroke Div, Boston, MA 02215 USA.
   [Feng, Wayne] Med Univ S Carolina, MUSC Stroke Ctr, Charleston, SC 29425 USA.
   [Feng, Wayne] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA.
RP Lin, CM (reprint author), Beth Israel Deaconess Med Ctr, Dept Neurol, Stroke Div, Palmer 127,Brookline Ave,West Campus, Boston, MA 02215 USA.
EM josephsimion@gmail.com
CR Asakura K, 2009, BRAIN RES, V1301, P110, DOI 10.1016/j.brainres.2009.09.011
   Baginsky S, 2010, PLANT PHYSIOL, V152, P402, DOI 10.1104/pp.109.150433
   BARTEL DP, 1989, GENE DEV, V3, P304, DOI 10.1101/gad.3.3.304
   Crisanti P, 2005, J NEUROCHEM, V93, P1587, DOI 10.1111/j.1471-4159.2005.03157.x
   Csete ME, 2002, SCIENCE, V295, P1664, DOI 10.1126/science.1069981
   GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0
   Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27
   Kanehisa M, 2010, NUCLEIC ACIDS RES, V38, pD355, DOI 10.1093/nar/gkp896
   Kanehisa M, 2006, NUCLEIC ACIDS RES, V34, pD354, DOI 10.1093/nar/gkj102
   Khatri P, 2005, BIOINFORMATICS, V21, P3587, DOI 10.1093/bioinformatics/bti565
   Kitano H, 2002, SCIENCE, V295, P1662, DOI 10.1126/science.1069492
   Klukas C, 2007, BIOINFORMATICS, V23, P344, DOI 10.1093/bioinformatics/btl611
   Lee E, 2006, NEUROTOXICOLOGY, V27, P558, DOI 10.1016/j.neuro.2006.02.006
   Li Huai, 2009, V541, P249, DOI 10.1007/978-1-59745-243-4_12
   Mazzio E, 2001, NEUROTOXICOLOGY, V22, P283, DOI 10.1016/S0161-813X(01)00017-1
   Nankova BB, 2003, PEDIATR RES, V53, P113, DOI 10.1203/01.PDR.0000039764.38034.75
   Ogata H, 1999, NUCLEIC ACIDS RES, V27, P29, DOI 10.1093/nar/27.1.29
   Rezaee F, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009690
   Santos SDM, 2007, NAT CELL BIOL, V9, P324, DOI 10.1038/ncb1543
   Snoep JL, 2005, TOP CURR GENET, V13, P13, DOI 10.1007/b106456
   Song Y, 2006, BRAIN RES, V1085, P57, DOI 10.1016/j.brainres.2006.02.042
   Sun P, 2006, GENES CELLS, V11, P1097, DOI 10.1111/j.1365-2443.2006.01002.x
   TISCHLER AS, 1975, NATURE, V258, P341, DOI 10.1038/258341a0
   Vaudry D, 2002, SCIENCE, V296, P1648, DOI 10.1126/science.1071552
NR 24
TC 5
Z9 6
U1 5
U2 22
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1567-2026
EI 1875-5739
J9 CURR NEUROVASC RES
JI Curr. Neurovasc. Res.
PD AUG
PY 2012
VL 9
IS 3
BP 222
EP 229
PG 8
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 975OH
UT WOS:000306520100011
PM 22697417
DA 2018-12-27
ER

PT J
AU Safahieh, A
   Hedayati, A
   Savari, A
   Movahedinia, A
AF Safahieh, Alireza
   Hedayati, Aliakbar
   Savari, Ahmad
   Movahedinia, Abdolali
TI RETRACTED: Effect of sublethal dose of mercury toxicity on liver cells
   and tissue of yellowfin seabream(Retracted article. See vol. 33, pg.
   NP3-NP3, 2017)
SO TOXICOLOGY AND INDUSTRIAL HEALTH
LA English
DT Article; Retracted Publication
DE Cell; fish; histopathology; mercury; toxicology
ID HOPLIAS-MALABARICUS; NEOTROPICAL FISH; EXPOSURE; TRIBUTYLTIN; WATER;
   BIOAVAILABILITY; HISTOPATHOLOGY; MOSQUITOFISH; CADMIUM; STRESS
AB The aim of the present study was to provide baseline data on the prevalence of histopathological liver lesions in Acanthopagrus latus under experimental mercury exposure. Experimental study was at seawater recirculatory tanks. Mercury concentrations were determined using a standard cold vapour atomic absorption. Histopathological analyses were done in tissue processor and the slides were stained with haematoxylin and counterstained with eosin. There were many liver lesions including enlarged and lateral nuclei, nuclear degeneration and vacuolation; oncotic, apoptic, focal, massive, centrilobular and periportal necrosis; atrophy, lipidosis, hydropic and cloudy swelling, oval cell proliferation; bile stagnation, dilation of sinusoid, intracellular oedema and dark granules in both field and laboratory conditions. In conclusion the present investigation indicated that mercury is a toxic substance in yellowfin seabream and the sublethal concentrations of mercury may cause several changes in the histological indices of the studied fish, and we can use these changes as biomarkers of mercury detection.
C1 [Hedayati, Aliakbar] Islamic Azad Univ, Young Researchers Club, Gorgan Branch, Gorgan, Iran.
   [Safahieh, Alireza; Savari, Ahmad; Movahedinia, Abdolali] Univ Marine Sci & Technol, Dept Marine Biol, Khorramshahr, Iran.
RP Hedayati, A (reprint author), Islamic Azad Univ, Young Researchers Club, Gorgan Branch, Gorgan, Iran.
EM marinebiology1@gmail.com
RI Hedayati, Aliakbar/R-1734-2016
OI Hedayati, Aliakbar/0000-0001-7658-5314; Safahieh,
   Alireza/0000-0003-3721-0258
FU Iranian National Science Foundation (INSF) [88000678]
FX The authors are thankful to the Iranian National Science Foundation
   (INSF, grant number 88000678) for providing financial support and
   necessary facilities to conduct this study.
CR Adams S. M., 2002, AM FISH SOC, V3, P104
   Cengiz EI, 2001, J ENVIRON SCI HEAL B, V36, P75, DOI 10.1081/PFC-100000918
   Di Giulio RT, 2008, TOXICOLOGY FISHES, P632
   EPA, 1992, QUAL CRIT WAT
   Fanta E, 2003, ECOTOX ENVIRON SAFE, V54, P119, DOI 10.1016/S0147-6513(02)00044-1
   Figueiredo-Fernandes A, 2007, PESQUI VET BRASIL, V27, P103, DOI 10.1590/S0100-736X2007000300004
   Gabriel UU, 2007, J ANIM VET ADV, V6, P379
   Gernhofer M., 2001, Journal of Aquatic Ecosystem Stress and Recovery, V8, P241, DOI 10.1023/A:1012958804442
   Giari L, 2007, CHEMOSPHERE, V67, P1171, DOI 10.1016/j.chemosphere.2006.10.061
   GILL TS, 1993, ECOTOX ENVIRON SAFE, V25, P227, DOI 10.1006/eesa.1993.1021
   Gochfeld M, 2003, ECOTOX ENVIRON SAFE, V56, P174, DOI 10.1016/S0147-6513(03)00060-5
   Haschek WM, 2010, FUNDAMENTALS OF TOXICOLOGIC PATHOLOGY, 2ND EDITION, P1
   Hedayati A., 2010, WORLD J FISH MARINE, V2, P86
   HINTON DE, 2001, TARGET ORGAN TOXICIT, V1, P224
   Hodgson E, 2004, TXB MODERN TOXICOLOG, P168
   Jagoe CH, 1996, AQUAT TOXICOL, V34, P163, DOI 10.1016/0166-445X(95)00033-Z
   Mommsen TP, 2005, ENV TOXICOLOGY BIOCH, P287
   Pacheco M, 2002, ECOTOX ENVIRON SAFE, V53, P331, DOI 10.1016/S0147-6513(02)00017-9
   Rabitto IS, 2005, ECOTOX ENVIRON SAFE, V60, P147, DOI 10.1016/j.econenv.2004.03.002
   Ribeiro CAD, 2002, ENVIRON RES, V90, P217, DOI 10.1016/S0013-9351(02)00025-7
   Ribeiro CAO, 2006, ENVIRON RES, V101, P74, DOI 10.1016/j.envres.2005.11.005
   Ribeiro CAO, 2002, ECOTOX ENVIRON SAFE, V51, P161, DOI 10.1006/eesa.2001.2121
   RICE CD, 2001, TARGET ORGAN TOXICIT, V2, P96
   Safahieh Alireza, 2010, American-Eurasian Journal of Toxicological Sciences, V2, P162
   Shi JB, 2005, ENVIRON INT, V31, P357, DOI 10.1016/j.envint.2004.08.008
   Stehr CM, 2004, MAR ENVIRON RES, V57, P55, DOI 10.1016/S0141-1136(03)00060-6
   Teh SJ, 1997, AQUAT TOXICOL, V37, P51, DOI 10.1016/S0166-445X(96)00808-9
   Thophon S, 2003, ENVIRON POLLUT, V121, P307, DOI 10.1016/S0269-7491(02)00270-1
   Timbrell JA, 2009, PRINCIPLES BIOCH TOX, P176
NR 29
TC 4
Z9 6
U1 3
U2 16
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0748-2337
EI 1477-0393
J9 TOXICOL IND HEALTH
JI Toxicol. Ind. Health
PD AUG
PY 2012
VL 28
IS 7
BP 583
EP 592
DI 10.1177/0748233711416951
PG 10
WC Public, Environmental & Occupational Health; Toxicology
SC Public, Environmental & Occupational Health; Toxicology
GA 975RS
UT WOS:000306529300002
PM 21949090
DA 2018-12-27
ER

PT J
AU Cha, JY
   Kim, YS
   Moon, HI
   Cho, YS
AF Cha, Jae-Young
   Kim, Yong-Soon
   Moon, Hyung-In
   Cho, Young-Su
TI RETRACTED: Hepatoprotective effects on alcoholic liver disease of
   fermented silkworms with Bacillus subtilis and Aspergillus kawachii
   (Retracted article. See vol. 63, pg. 766, 2012)
SO INTERNATIONAL JOURNAL OF FOOD SCIENCES AND NUTRITION
LA English
DT Article; Retracted Publication
DE silkworms; fermented; alcoholic hepatotoxicity; oxidative stress
ID OXIDATIVE STRESS; ETHANOL-METABOLISM; ANIMAL-TISSUES; RATS; GLUTATHIONE;
   PROTEIN; DAMAGE; ACID; MICE; HEPATOTOXICITY
AB The purpose of this study was to investigate the protective effect of Bacillus subtilis fermented silkworm powder (BFSP) and Aspergillus kawachii fermented silkworms powder (AFSP) on alcohol-induced hepatotoxicity in Sprague-Dawley rats. Alcohol-feeding rats were fed with diets containing silkworm powder (SP) or both BFSP and AFSP at the 5% (w/w) levels for 4 weeks. Alcohol administration resulted in a significant increase in the activities of liver marker enzymes, aspartate aminotransferase (AST), gamma-glutamyl transpeptidase (gamma-GTP) and lactate dehydrogenase (LDH). Administration of BFSP markedly prevented alcohol-induced elevation of serum AST, gamma-GTP and LDH activities, and the levels of blood alcohol and acetaldehyde. Interestingly, in comparison with both SP and AFSP, BFSP administration drastically increased both hepatic alcohol dehydrogenase (ADH) and acetaldehyde dehydrogenase (ALDH) activities, suggesting that BFSP was more effective in the reduction of blood alcohol and acetaldehyde. BFSP administration showed the highest induction of hepatic ADH expression in alcohol-feeding rats. Also, alcohol treatment resulted in increasing lipid peroxidative index (thiobarbituric acid-reactive substances) and decreasing antioxidant status (reduced glutathione) in the liver. Thus, these results suggest that BFSP treatment improved the antioxidant status of alcoholic rats by decreasing the levels of lipid peroxidative index and by increasing the levels of antioxidant status in the liver and serum. Specially, the concentrations of serum total cholesterol, free fatty acid and hepatic triglyceride were increased, but these parameters were significantly influenced by the BFSP in the alcohol treatment. Unlike the action of alcohol treatment on fatty liver, BFSP administration attenuated lipid droplet accumulation in hepatocytes. A high level of ADH was also observed in AFSP administered rats; on the other hand, a significant change in ALDH was not observed. Therefore, the SP can be a promising candidate in the prevention alcohol-induced hepatotoxicity and oxidative stress.
C1 [Cho, Young-Su] Dong A Univ, Dept Biotechnol, Pusan 604714, South Korea.
   [Cha, Jae-Young] Daesun Distilling Co Ltd, Tech Res Inst, Pusan 619934, South Korea.
   [Kim, Yong-Soon] Natl Acad Agr Sci, RDA, Dept Agr Biol, Suwon 441707, South Korea.
   [Moon, Hyung-In] Dong A Univ, Dept Med Biotechnol, Pusan 604714, South Korea.
RP Cho, YS (reprint author), Dong A Univ, Dept Biotechnol, Hadan 2 Dong Sahagu, Pusan 604714, South Korea.
EM himun68@dau.ac.kr
FU Rural Development Administration [PJ0067382011]
FX This work was supported by Rural Development Administration Grant
   PJ0067382011. The authors report no conflicts of interest. The authors
   alone are responsible for the content and writing of the paper.
CR BALDI E, 1993, ITAL J GASTROENTEROL, V25, P429
   Balkan J, 2002, BIOL PHARM BULL, V25, P1231, DOI 10.1248/bpb.25.1231
   Baronian C., 2008, SIM NEWS, V98, P1173
   BEUTLER E, 1963, J LAB CLIN MED, V61, P882
   Cha JY, 2009, FOOD SCI BIOTECHNOL, V18, P1411
   Cha JY, 1998, BIOSCI BIOTECH BIOCH, V62, P508, DOI 10.1271/bbb.62.508
   FOLCH J, 1957, J BIOL CHEM, V226, P497
   Wardhani DH, 2009, J AGR FOOD CHEM, V57, P540, DOI 10.1021/jf802492s
   Hsu CC, 2004, J NUTR, V134, P149
   Ishizaki-Koizumi S, 2002, BIOCHEM BIOPH RES CO, V291, P738, DOI 10.1006/bbrc.2002.6508
   Kano M, 2002, J NUTR, V132, P238
   Kato N, 1998, BIOSCI BIOTECH BIOCH, V62, P145, DOI 10.1271/bbb.62.145
   Kishimoto R, 1997, J NUTR SCI VITAMINOL, V43, P613
   KOIVULA T, 1975, BIOCHEM PHARMACOL, V24, P1807, DOI 10.1016/0006-2952(75)90461-X
   Lee JH, 1999, KOREAN J FOOD SCI TE, V31, P802
   Li YG, 2008, ALCOHOL ALCOHOLISM, V43, P246, DOI 10.1093/alcalc/agm164
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   MAGONET E, 1992, BIOCHEM J, V287, P361, DOI 10.1042/bj2870361
   MCGOWAN MW, 1983, CLIN CHEM, V29, P538
   OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3
   Oliva L, 1998, ALCOHOL CLIN EXP RES, V22, P1538
   Petushok N. E., 2003, Toxicology Letters (Shannon), V144, ps116, DOI 10.1016/S0378-4274(03)90428-0
   Saravanan R, 2006, LIFE SCI, V78, P713, DOI 10.1016/j.lfs.2005.05.060
   Seo HJ, 2003, LIFE SCI, V73, P933, DOI 10.1016/S0024-3205(03)00358-8
   Shon MY, 2007, FOOD SCI BIOTECHNOL, V16, P967
   STIPANUK MH, 1992, J NUTR, V122, P420
   Sugiyama Y, 1998, J JPN SOC NUTR FOOD, V51, P189
   Tanaka R, 2007, BIOSCI BIOTECH BIOCH, V71, P3055, DOI 10.1271/bbb.70457
   Vasiliou V, 2000, BIOCHEM BIOPH RES CO, V273, P546, DOI 10.1006/bbrc.2000.2993
   Wang W, 2008, CURR PHARM BIOTECHNO, V9, P307, DOI 10.2174/138920108785161578
   Yoon JW, 2005, KOR J FOOD NUT, V18, P140
   차재영, 2009, [Journal of Life Science, 생명과학회지], V19, P1468
   Zima T, 2001, J BIOMED SCI, V8, P59, DOI 10.1159/000054014
   김용순, 2008, [Journal of Life Science, 생명과학회지], V18, P1342
   차재영, 2008, [Journal of Life Science, 생명과학회지], V18, P947
NR 35
TC 5
Z9 5
U1 1
U2 22
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0963-7486
EI 1465-3478
J9 INT J FOOD SCI NUTR
JI Int. J. Food Sci. Nutr.
PD AUG
PY 2012
VL 63
IS 5
BP 537
EP 547
DI 10.3109/09637486.2011.607801
PG 11
WC Food Science & Technology; Nutrition & Dietetics
SC Food Science & Technology; Nutrition & Dietetics
GA 974IL
UT WOS:000306427000004
PM 21838591
DA 2018-12-27
ER

PT J
AU Klamann, MKJ
   Maier, AKB
   Gonnermann, J
   Klein, JP
   Pleyer, U
AF Klamann, Matthias K. J.
   Maier, Anna-Karina B.
   Gonnermann, Johannes
   Klein, Julian P.
   Pleyer, Uwe
TI RETRACTED: Measurement of Dynamic Ocular Surface Temperature in Healthy
   Subjects Using a New Thermography Device (Retracted article. See vol.
   40, pg. 1296, 2015)
SO CURRENT EYE RESEARCH
LA English
DT Article; Retracted Publication
DE Ocular surface temperature; Reproducibility; Thermography; Tomey TG 1000
ID DRY EYE; CORNEAL TEMPERATURE; TEAR FILM; THERMAL PATTERNS
AB Purpose: To investigate the routine use and applicability of a new ocular thermography device (TG 1000; Tomey Corp, Nagoya, Japan) in healthy individuals.
   Methods: Sixty eyes of 30 healthy subjects were included in this prospective study. Intraobserver reproducibility was tested with an ocular surface-oriented infrared radiation thermographic device in a non-contact manner. Using a standard examination protocol, the ocular surface temperature was assessed by dynamic thermal imaging over a time period of 10 s. The procedure was repeated three times during a single session by one examiner. Intraclass correlation coefficients (ICC) were calculated.
   Results: Ocular surface temperature measurements were highly reproducible. The mean ocular surface temperature was 34.02 degrees C +/- 0.22. The ICC was 0.947%, 0.949%, and 0.955% for minimum, maximum, and mean temperatures, respectively.
   Conclusion: Ocular surface temperature measurements made using the Tomey TG 1000 in healthy subjects showed excellent intraobserver reproducibility. This novel non-invasive technique offers new options for increased understanding of the physiology of the ocular surface.
C1 [Klamann, Matthias K. J.; Maier, Anna-Karina B.; Gonnermann, Johannes; Klein, Julian P.; Pleyer, Uwe] Charite Univ Med Berlin, Dept Ophthalmol, D-13353 Berlin, Germany.
RP Klamann, MKJ (reprint author), Charite Univ Med Berlin, Dept Ophthalmol, Augustenburger Pl 1, D-13353 Berlin, Germany.
EM matthias.klamann@charite.de
RI Gonnermann, Johannes/J-8943-2015
CR EFRON N, 1989, CURR EYE RES, V8, P901
   Fujishima H, 1996, BRIT J OPHTHALMOL, V80, P29, DOI 10.1136/bjo.80.1.29
   Hamano H, 1976, J JPN CONTACT LENS S, V18, P1
   HAMANO T, 1991, Folia Ophthalmologica Japonica, V42, P719
   HOLMBERG A, 1952, Acta Ophthalmol (Copenh), V30, P348
   Kamao T, 2011, AM J OPHTHALMOL, V151, P782, DOI 10.1016/j.ajo.2010.10.033
   Kawasaki S, 2009, BRIT J OPHTHALMOL, V93, P1331, DOI 10.1136/bjo.2008.152066
   KURIHASHI K, 1977, J PEDIATR OPHTHALMOL, V14, P390
   Mapstone R, 1969, Trans Ophthalmol Soc U K, V88, P693
   MAPSTONE R, 1970, BRIT J OPHTHALMOL, V54, P751, DOI 10.1136/bjo.54.11.751
   MAPSTONE R, 1968, BRIT J OPHTHALMOL, V52, P729, DOI 10.1136/bjo.52.10.729
   MAPSTONE R, 1968, EXP EYE RES, V7, P237, DOI 10.1016/S0014-4835(68)80073-9
   MAPSTONE R, 1968, BRIT J OPHTHALMOL, V52, P917, DOI 10.1136/bjo.52.12.917
   MAPSTONE R, 1968, BRIT J OPHTHALMOL, V52, P818, DOI 10.1136/bjo.52.11.818
   MARTIN DK, 1986, ACTA OPHTHALMOL, V64, P512
   Morgan P B, 1999, Cont Lens Anterior Eye, V22, P11, DOI 10.1016/S1367-0484(99)80025-3
   Morgan P.B., 1996, J BRIT CONTACT LENS, V19, P7
   MORGAN PB, 1995, EYE, V9, P615, DOI 10.1038/eye.1995.149
   MORGAN PB, 1993, OPTOMETRY VISION SCI, V70, P568, DOI 10.1097/00006324-199307000-00008
   Mori A, 1997, AM J OPHTHALMOL, V124, P729, DOI 10.1016/S0002-9394(14)71689-7
   Purslow Christine, 2005, Cont Lens Anterior Eye, V28, P29, DOI 10.1016/j.clae.2004.10.001
   Tan LL, 2009, CONTACT LENS ANTERIO, V32, P78, DOI 10.1016/j.clae.2008.09.003
   TODA I, 1993, ACTA OPHTHALMOL, V71, P347, DOI 10.1111/j.1755-3768.1993.tb07146.x
   Tomlinson A, 2005, OCUL SURF, V3, P81, DOI 10.1016/S1542-0124(12)70157-X
   XU KP, 1995, ARCH OPHTHALMOL-CHIC, V113, P84, DOI 10.1001/archopht.1995.01100010086025
NR 25
TC 21
Z9 21
U1 3
U2 14
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0271-3683
EI 1460-2202
J9 CURR EYE RES
JI Curr. Eye Res.
PD AUG
PY 2012
VL 37
IS 8
BP 678
EP 683
DI 10.3109/02713683.2012.674610
PG 6
WC Ophthalmology
SC Ophthalmology
GA 971DH
UT WOS:000306183400003
PM 22559822
DA 2018-12-27
ER

PT J
AU Viani, GA
   da Silva, LGB
   Stefano, EJ
AF Viani, Gustavo Arruda
   Bernardes da Silva, Lucas Godoi
   Stefano, Eduardo Jose
TI RETRACTED: High-Dose Conformal Radiotherapy Reduces Prostate
   Cancer-Specific Mortality: Results of a Meta-analysis (Retracted
   article. See vol. 85, pg. 899, 2013)
SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
LA English
DT Article; Retracted Publication
DE High dose; Conformal radiotherapy; Prostrate cancer; Prostate
   cancer-specific mortality
ID RANDOMIZED CONTROLLED-TRIAL; EXTERNAL-BEAM RADIATION; ANDROGEN
   SUPPRESSION; DEFINITIVE RADIOTHERAPY; THERAPY; ADENOCARCINOMA;
   CARCINOMA; ADJUVANT; GY
AB Purpose: To determine in a meta-analysis whether prostate cancer-specific mortality (PCSM), biochemical or clinical failure (BCF), and overall mortality (OM) in men with localized prostate cancer treated with conformal high-dose radiotherapy (HDRT) are better than those in men treated with conventional-dose radiotherapy (CDRT).
   Methods and Materials: The MEDLINE, Embase, CANCERLIT, and Cochrane Library databases, as well as the proceedings of annual meetings, were systematically searched to identify randomized, controlled studies comparing conformal HDRT with CDRT for localized prostate cancer.
   Results: Five randomized, controlled trials (2508 patients) that met the study criteria were identified. Pooled results from these randomized, controlled trials showed a significant reduction in the incidence of PCSM and BCF rates at 5 years in patients treated with HDRT (p = 0.04 and p < 0.0001, respectively), with an absolute risk reduction (ARR) of PCSM and BCF at 5 years of 1.7% and 12.6%, respectively. Two trials evaluated PCSM with 10 years of follow up. The pooled results from these trials showed a statistical benefit for HDRT in terms of PCSM(p=0.03). In the subgroup analysis, trials that used androgen deprivation therapy (ADT) showed an ARR for BCF of 12.9% (number needed to treat=7.7, p < 0.00001), whereas trials without ADT had an ARR of 13.6% (number needed to treat=7, p < 0.00001). There was no difference in the OM rate at 5 and 10 years (p = 0.99 and p = 0.11, respectively) between the groups receiving HDRT and CDRT.
   Conclusions: This meta-analysis is the first study to show that HDRT is superior to CDRT in preventing disease progression and prostate cancerespecific death in trials that used conformational technique to increase the total dose. Despite the limitations of our study in evaluating the role of ADT and HDRT, our data show no benefit for HDRT arms in terms of BCF in trials with or without ADT. (C) 2012 Elsevier Inc.
C1 [Viani, Gustavo Arruda; Bernardes da Silva, Lucas Godoi; Stefano, Eduardo Jose] Marilia Med Sch, Dept Radiat Oncol, Sao Paulo, Brazil.
RP Viani, GA (reprint author), Marilia Med Sch, Dept Radiat Oncol, Maria Cecilia Alves 192, Sao Paulo, Brazil.
EM gusviani@gmail.com
CR Beckendorf V, 2004, INT J RADIAT ONCOL, V60, P1056, DOI 10.1016/j.ijrobp.2004.05.033
   D'Amico AV, 2008, JAMA-J AM MED ASSOC, V299, P289, DOI 10.1001/jama.299.3.289
   D'Amico AV, 2006, J CLIN ONCOL, V24, P4190, DOI 10.1200/JCO.2006.06.8239
   D'Amico AV, 2004, JAMA-J AM MED ASSOC, V292, P821, DOI 10.1001/jama.292.7.821
   Dearnaley DP, 2007, LANCET ONCOL, V8, P475, DOI 10.1016/S1470204S(07)70143-2
   Eade TN, 2007, INT J RADIAT ONCOL, V68, P682, DOI 10.1016/j.ijrobp.2007.01.008
   Kuban DA, 2008, INT J RADIAT ONCOL, V70, P67, DOI 10.1016/j.ijrobp.2007.06.054
   Laverdiere J, 2004, J UROLOGY, V171, P1137, DOI 10.1097/01.ju.0000112979.97941.7f
   Noel G, 2001, Cancer Radiother, V5, P205
   Peeters STH, 2006, J CLIN ONCOL, V24, P1990, DOI 10.1200/JCO.2005.05.2530
   Pilepich MV, 2001, INT J RADIAT ONCOL, V50, P1243, DOI 10.1016/S0360-3016(01)01579-6
   Pilepich MV, 2005, INT J RADIAT ONCOL, V61, P1285, DOI 10.1016/j.ijrobp.2004.08.047
   Roach M, 2000, INT J RADIAT ONCOL, V47, P617, DOI 10.1016/S0360-3016(00)00577-0
   Sathya JR, 2005, J CLIN ONCOL, V23, P1192, DOI 10.1200/JCO.2005.06.154
   SHIPLEY WU, 1995, INT J RADIAT ONCOL, V32, P3, DOI 10.1016/0360-3016(95)00063-5
   Viani GA, 2009, INT J RADIAT ONCOL, V74, P1405, DOI 10.1016/j.ijrobp.2008.10.091
   Zietman AL, 2005, JAMA-J AM MED ASSOC, V294, P1233, DOI 10.1001/jama.294.10.1233
   Zietman AL, 2010, J CLIN ONCOL, V28, P1106, DOI 10.1200/JCO.2009.25.8475
NR 18
TC 18
Z9 18
U1 2
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0360-3016
EI 1879-355X
J9 INT J RADIAT ONCOL
JI Int. J. Radiat. Oncol. Biol. Phys.
PD AUG 1
PY 2012
VL 83
IS 5
BP E619
EP E625
DI 10.1016/j.ijrobp.2012.01.051
PG 7
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA 970KT
UT WOS:000306128100009
PM 22768991
DA 2018-12-27
ER

PT J
AU Pusch, R
   Weston, R
AF Pusch, Roland
   Weston, Richard
TI RETRACTED: Superior techniques for disposal of highly radioactive waste
   (HLW) (Retracted article. See vol. 108, pg. 517, 2018)
SO PROGRESS IN NUCLEAR ENERGY
LA English
DT Article; Retracted Publication
DE Clay; Canisters; Disposal; Radioactive waste
AB The Swedish Nuclear Fuel and Waste Company (SKB) has recently worked out a concept, KBS-3V, for disposal of highly radioactive waste in the form of spent reactor fuel, and asked for the Government's approval and licensing. It implies blasting of tunnels at about 400 m depth and boring of large-diameter canister deposition holes extending vertically from the tunnel floor. The rock stresses will be critically high in the construction phase and lead to failure by spalling when the heat pulse from the canisters evolves. The canisters will be surrounded by dense expansive "buffer" clay for minimizing groundwater flow around and along them but the long-term performance of either of them is not adequately proven and the placement is impractical and risky. Four major changes of the concept would make it satisfactory. One involves reorientation of the deposition holes from vertical to 45 degrees inclination in two directions for reducing the risk of rock failure. A second is to prepare ready-made stiff units of "supercontainers" with highly compacted blocks of clay tightly surrounding the canisters for simpler and safer installation of clay blocks and canisters. A third is to surround the supercontainers by clay mud that provides the dense buffer with water from start and supports the surrounding rock when the thermal pulse begins to raise the rock stresses. A fourth is to replace the proposed smectite-rich buffer by clay with higher chemical stability and lower but sufficient expandability. A possible fifth change can be to manufacture homogeneous copper canisters of HIPOW type, which would radically reduce the risk of contamination of groundwater by released radionuclides. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Pusch, Roland] Lulea Univ Technol, Drawrite AB, S-22223 Lund, Sweden.
   [Weston, Richard] Lund Univ, Div Prod & Mech Engn, S-22100 Lund, Sweden.
RP Pusch, R (reprint author), Lulea Univ Technol, Drawrite AB, St Sodergatan 57A, S-22223 Lund, Sweden.
EM drawrite.se@gmail.com
CR Brady BHG, 1985, ROCK MECH UNDERGROUN
   Burstrom M, 2011, COMMUNICATION
   Herbert HJ, 2008, PHYS CHEM EARTH, V33, pS327, DOI 10.1016/j.pce.2008.10.005
   Kolarikova I, 2010, APPL CLAY SCI, V47, P10, DOI 10.1016/j.clay.2009.11.011
   Lonnerberg B, 1983, 8320 SKBKBS
   Pusch R., 1994, DEV GEOTECHNICAL ENG, V76
   Pusch R, 2006, MICROSTRUCTURE SMECT
   Pusch R., 1985, TR8512 SKB STRIP PRO, VII
   Pusch R., GEOLOGICAL IN PRESS
   Pusch R., 2008, GEOLOGICAL STORAGE R
   Pusch R, 2010, ENG GEOL, V116, P21, DOI 10.1016/j.enggeo.2010.07.002
   Sandstrom R, 2007, TR0702 SKB
   Svemar Ch, 2005, CLUSTER REPOSITORY P
   Xiaodong L, APPL CLAY S IN PRESS
   Yong RN, 2010, SPON RES, P1
NR 15
TC 9
Z9 9
U1 0
U2 11
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0149-1970
J9 PROG NUCL ENERG
JI Prog. Nucl. Energy
PD AUG
PY 2012
VL 59
BP 75
EP 85
DI 10.1016/j.pnucene.2012.01.005
PG 11
WC Nuclear Science & Technology
SC Nuclear Science & Technology
GA 967AG
UT WOS:000305877900011
DA 2018-12-27
ER

PT J
AU Zhang, JE
   Pritchard, E
   Hu, X
   Valentin, T
   Panilaitis, B
   Omenetto, FG
   Kaplan, DL
AF Zhang, Jeney
   Pritchard, Eleanor
   Hu, Xiao
   Valentin, Thomas
   Panilaitis, Bruce
   Omenetto, Fiorenzo G.
   Kaplan, David L.
TI RETRACTED: Stabilization of vaccines and antibiotics in silk and
   eliminating the cold chain (Retracted article. See vol. 109, pg. 11981,
   2012)
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article; Retracted Publication
DE measles; mumps; rubella; penicillin
ID RELEASE DRUG-DELIVERY; STABILITY; VIRUS; BIOMATERIALS; RESPONSES;
   MEASLES; FIBROIN; MUMPS; CHALLENGES; STORAGE
AB Sensitive biological compounds, such as vaccines and antibiotics, traditionally require a time-dependent "cold chain" to maximize therapeutic activity. This flawed process results in billions of dollars worth of viable drug loss during shipping and storage, and severely limits distribution to developing nations with limited infrastructure. To address these major limitations, we demonstrate self-standing silk protein biomaterial matrices capable of stabilizing labile vaccines and antibiotics, even at temperatures up to 60 degrees C over more than 6 months. Initial insight into the mechanistic basis for these findings is provided. Importantly, these findings suggest a transformative approach to the cold chain to revolutionize the way many labile therapeutic drugs are stored and utilized throughout the world.
C1 [Zhang, Jeney; Pritchard, Eleanor; Hu, Xiao; Valentin, Thomas; Panilaitis, Bruce; Omenetto, Fiorenzo G.; Kaplan, David L.] Tufts Univ, Dept Biomed Engn, Medford, MA 02155 USA.
   [Zhang, Jeney] Tufts Univ, Dept Chem & Biol Engn, Medford, MA 02155 USA.
RP Kaplan, DL (reprint author), Tufts Univ, Dept Biomed Engn, Medford, MA 02155 USA.
EM david.kaplan@tufts.edu
RI Hu, Xiao/F-2403-2012
OI Hu, Xiao/0000-0002-2579-2820
FU NIH (P41 Tissue Engineering Resource Center) [EB002520]; AFOSR
   [9550-10-1-0172zsAJMn];  [EY020856];  [DE017207-01];  [EB003210]
FX The technical assistance or advice of Nicholas Guziewicz, Michael
   Lovett, Nikola Kojic and Reid McCabe is gratefully acknowledged. We
   thank the NIH (P41 Tissue Engineering Resource Center EB002520) and
   EY020856, DE017207-01, EB003210 and AFOSR 9550-10-1-0172zsAJMn for
   support of this work.
CR Adu FD, 1996, PUBLIC HEALTH, V110, P325
   Altman GH, 2003, BIOMATERIALS, V24, P401, DOI 10.1016/S0142-9612(02)00353-8
   Arya SC, 2001, VACCINE, V19, P595
   Ausar SF, 2006, J BIOL CHEM, V281, P19478, DOI 10.1074/jbc.M603313200
   BENEDICT RG, 1945, J BACTERIOL, V49, P85
   BISHAI DM, 1992, PEDIATRICS, V89, P193
   BOYLE VJ, 1973, ANTIMICROB AGENTS CH, V3, P418, DOI 10.1128/AAC.3.3.418
   Brandau DT, 2003, J PHARM SCI-US, V92, P218, DOI 10.1002/jps.10296
   Chen DX, 2009, EXPERT REV VACCINES, V8, P547, DOI [10.1586/erv.09.20, 10.1586/ERV.09.20]
   Chen X, 2011, J CONTROL RELEASE, V152, P349, DOI 10.1016/j.jconrel.2011.02.026
   CHERIYAN E, 1993, ARCH DIS CHILD, V69, P600, DOI 10.1136/adc.69.5.600
   CHEYNE J, 1989, REV INFECT DIS, V11, pS617
   COLINET G, 1982, J BIOL STAND, V10, P341, DOI 10.1016/S0092-1157(82)80011-5
   Das P, 2004, LANCET INFECT DIS, V4, P719, DOI 10.1016/S1473-3099(04)01222-8
   Fleming A, 1929, BRIT J EXP PATHOL, V10, P226
   Galazka A, 1998, GLOBAL PROGRAMME VAC
   Gianfreda L, 1984, ENZYME MICROB TECHNO, V7, P78
   Guziewicz N, 2011, BIOMATERIALS, V32, P2642, DOI 10.1016/j.biomaterials.2010.12.023
   HALL WW, 1973, J GEN VIROL, V19, P175, DOI 10.1099/0022-1317-19-2-175
   Hu X, 2007, THERMOCHIM ACTA, V461, P137, DOI 10.1016/j.tca.2006.12.011
   Hu ZQ, 2001, J ANTIMICROB CHEMOTH, V48, P361, DOI 10.1093/jac/48.3.361
   Jin HJ, 2003, NATURE, V424, P1057, DOI 10.1038/nature01809
   Lawrence BD, 2008, BIOMACROMOLECULES, V9, P1214, DOI 10.1021/bm701235f
   Leal-Egana A, 2010, BIOTECHNOL APPL BIOC, V55, P155, DOI 10.1042/BA20090229
   Li S, 1994, BIOTECHNOL BIOENG, V48, P490
   Lu Q, 2010, MACROMOL BIOSCI, V10, P359, DOI 10.1002/mabi.200900388
   MCALEER WJ, 1980, J BIOL STAND, V8, P281, DOI 10.1016/S0092-1157(80)80005-9
   Meinel L, 2005, BIOMATERIALS, V26, P147, DOI 10.1016/j.biomaterials.2004.02.047
   MERZ DC, 1983, VIROLOGY, V131, P328, DOI 10.1016/0042-6822(83)90501-9
   Omenetto F, 2010, SCI AM, V303, P76, DOI 10.1038/scientificamerican1110-76
   PACKER L, 2002, METHODS ENZYMOLOGY, V349
   Panilaitis B, 2003, BIOMATERIALS, V24, P3079, DOI 10.1016/S0142-9612(03)00158-3
   Pritchard EM, 2012, BIOPOLYMERS, V97, P479, DOI 10.1002/bip.22026
   Pritchard EM, 2011, EXPERT OPIN DRUG DEL, V8, P797, DOI 10.1517/17425247.2011.568936
   Pritchard EM, 2010, J CONTROL RELEASE, V144, P159, DOI 10.1016/j.jconrel.2010.01.035
   Seo YK, 2009, J ORTHOP RES, V27, P495, DOI 10.1002/jor.20752
   Sun YC, 2004, ADV DRUG DELIVER REV, V56, P1481, DOI 10.1016/j.addr.2004.02.009
   Tsioris K, 2012, ADV FUNCT MATER, V22, P330, DOI 10.1002/adfm.201102012
   Vepari C, 2007, PROG POLYM SCI, V32, P991, DOI 10.1016/j.progpolymsci.2007.05.013
   Wang X, 2008, BIOMATERIALS, V29, P894, DOI 10.1016/j.biomaterials.2007.10.055
   Wang YZ, 2006, BIOMATERIALS, V27, P6064, DOI 10.1016/j.biomaterials.2006.07.008
   Waterman KC, 2005, INT J PHARM, V293, P101, DOI 10.1016/j.ijpharm.2004.12.013
   WHODavey S, 2000, KEY PROSPERITY SUCCE
   Wolfson LJ, 2008, B WORLD HEALTH ORGAN, V86, P27, DOI 10.2471/BLT.07.045096
   Worrall EE, 2000, VACCINE, V19, P834, DOI 10.1016/S0264-410X(00)00229-2
   Xuan RC, 2010, J ENVIRON SCI HEAL B, V45, P73, DOI 10.1080/03601230903404556
   Yager P, 2006, NATURE, V442, P412, DOI 10.1038/nature05064
NR 47
TC 95
Z9 98
U1 8
U2 90
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JUL 24
PY 2012
VL 109
IS 30
BP 11981
EP 11986
DI 10.1073/pnas.1206210109
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 981TD
UT WOS:000306992700029
PM 22778443
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Kheir, AEM
AF Kheir, Abdelmoneim E. M.
TI RETRACTED: Infantile colic, facts and fiction (Retracted article. See
   vol. 40, 9, 2014)
SO ITALIAN JOURNAL OF PEDIATRICS
LA English
DT Review; Retracted Publication
DE Colic; Crying; Infant; Baby
ID BREAST-FED INFANTS; PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND;
   GASTROESOPHAGEAL-REFLUX; SPINAL MANIPULATION; MATERNAL DIET; AROUSAL
   LEVEL; STIMULATION; ANAPHYLAXIS; SIMETHICONE
AB Infantile colic is one of the major challenges of parenthood. It is one of the common reasons parents seek medical advice during their child's first 3 months of life. It is defined as paroxysms of crying lasting more than 3 hours a day, occurring more than 3 days in any week for 3 weeks in a healthy baby aged 2 weeks to 4 months. Colic is a poorly understood phenomenon affecting up to 30% of babies, underlying organic causes of excessive crying account for less than 5%. Laboratory tests and radiological examinations are unnecessary if the infant is gaining weight normally and has a normal physical examination. Treatment is limited and drug treatment has no role in management. Probiotics are now emerging as promising agents in the treatment of infantile colic. Alternative medicine (Herbal tea, fennel, glucose and massage therapy) have not proved to be consistently helpful and some might even be dangerous. In conclusion infantile colic is a common cause of maternal distress and family disturbance, the cornerstone of management remains reassurance of parents regarding the benign and self-limiting nature of the illness. There is a critical need for more evidence based treatment protocols.
C1 Univ Khartoum, Fac Med, Dept Paediat, Khartoum, Sudan.
RP Kheir, AEM (reprint author), Univ Khartoum, Fac Med, Dept Paediat, Khartoum, Sudan.
EM moneimkheir62@hotmail.com
CR Akcam M, 2006, PEDIATR INT, V48, P125, DOI 10.1111/j.1442-200X.2006.02182.x
   [Anonymous], COLIC MERCK MANUALS
   Baker SS, 2000, PEDIATRICS, V106, P346
   Barr R G, 1998, Pediatrics, V102, P1282
   Barr RG, 2002, ARCH PEDIAT ADOL MED, V156, P1172, DOI 10.1001/archpedi.156.12.1172
   BRACKBILL Y, 1966, J EXP CHILD PSYCHOL, V4, P178, DOI 10.1016/0022-0965(66)90018-X
   BRACKBILL Y, 1971, CHILD DEV, V42, P17, DOI 10.1111/j.1467-8624.1971.tb03613.x
   Caffarelli C, 1996, ARCH DIS CHILD, V75, P141, DOI 10.1136/adc.75.2.141
   Caffarelli C, 1997, ALLERGY ASTHMA PROC, V18, P245, DOI 10.2500/108854197778594007
   Clifford TJ, 2002, ARCH PEDIAT ADOL MED, V156, P1123, DOI 10.1001/archpedi.156.11.1123
   Critch JN, 2011, PAED CHILD HEALT-CAN, V16, P47, DOI 10.1093/pch/16.1.47
   EVANS RW, 1981, LANCET, V1, P1340
   FORSYTH BWC, 1985, J PEDIATR-US, V106, P1012, DOI 10.1016/S0022-3476(85)80260-2
   Gerard CM, 2002, J PEDIATR-US, V141, P398, DOI 10.1067/mpd.2002.127508
   Greenes DS, 1998, ANN EMERG MED, V32, P680, DOI 10.1016/S0196-0644(98)70067-8
   Gupta SK, 2002, CURR OPIN PEDIATR, V14, P588, DOI 10.1097/01.MOP.0000028542.37171.34
   HARLEY LM, 1969, CLIN PEDIATR, V8, P138, DOI 10.1177/000992286900800305
   Hill DJ, 2005, PEDIATRICS, V116, pE709, DOI 10.1542/peds.2005-0147
   Hill DJ, 1995, J ALLERGY CLIN IMMUN, V96, P886, DOI 10.1016/S0091-6749(95)70224-5
   Hillemeier AC, 1996, PEDIATR CLIN N AM, V43, P197, DOI 10.1016/S0031-3955(05)70402-8
   ILLINGWORTH RS, 1954, ARCH DIS CHILD, V29, P165, DOI 10.1136/adc.29.145.165
   JAKOBSSON I, 1983, PEDIATRICS, V71, P268
   KRUGMAN RD, 1993, AM J DIS CHILD, V147, P517, DOI 10.1001/archpedi.1993.02160290023009
   Levitzky S, 2000, CLIN PEDIATR, V39, P395, DOI 10.1177/000992280003900703
   Lucassen PLBJ, 2000, PEDIATRICS, V106, P1349, DOI 10.1542/peds.106.6.1349
   Lucassen PLBJ, 1998, BMJ-BRIT MED J, V316, P1563, DOI 10.1136/bmj.316.7144.1563
   METCALF TJ, 1994, PEDIATRICS, V94, P29
   Olafsdottir E, 2001, ARCH DIS CHILD, V84, P138, DOI 10.1136/adc.84.2.138
   Orenstein SR, 1996, CLIN PEDIATR, V35, P607, DOI 10.1177/000992289603501201
   Pauli-Pott U, 2000, J PSYCHOSOM RES, V48, P125, DOI 10.1016/S0022-3999(99)00084-7
   POOLE SR, 1991, PEDIATRICS, V88, P450
   Roberts DM, 2004, AM FAM PHYSICIAN, V70, P735
   Savino F, 2002, J PEDIATR GASTR NUTR, V34, P417, DOI 10.1097/00005176-200204000-00020
   Savino F, 2007, ACTA PAEDIATR, V96, P1259, DOI 10.1111/j.1651-2227.2007.00428.x
   Savino F, 2007, PEDIATRICS, V119, pE124, DOI 10.1542/peds.2006-1222
   Savino F, 2010, PEDIATRICS, V126, pE526, DOI 10.1542/peds.2010-0433
   Shenassa ED, 2004, PEDIATRICS, V114, pE497, DOI 10.1542/peds.2004-1036
   van Sleuwen BE, 2007, PEDIATRICS, V120, pe1097, DOI 10.1542/peds.2006-2083
   VANDENDAELE LD, 1970, J PSYCHOL, V74, P161, DOI 10.1080/00223980.1970.9923725
   Weissbluth M, 1999, GELIS KAGANS CURRENT, P674
   WEIZMAN Z, 1993, J PEDIATR-US, V123, P670, DOI 10.1016/S0022-3476(05)80982-5
   WEIZMAN Z, 1993, J PEDIATR-US, V122, P650, DOI 10.1016/S0022-3476(05)83557-7
   WESSEL MA, 1954, PEDIATRICS, V14, P421
   White BP, 2000, CHILD DEV, V71, P862, DOI 10.1111/1467-8624.00196
   Wiberg JMM, 1999, J MANIP PHYSIOL THER, V22, P517, DOI 10.1016/S0161-4754(99)70003-5
NR 45
TC 19
Z9 20
U1 3
U2 59
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1720-8424
EI 1824-7288
J9 ITAL J PEDIATR
JI Ital. J. Pediatr.
PD JUL 23
PY 2012
VL 38
AR 34
DI 10.1186/1824-7288-38-34
PG 4
WC Pediatrics
SC Pediatrics
GA 983JH
UT WOS:000307115100001
PM 22823993
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Mahvi, AH
   Roodbari, AA
   Nodehi, RN
   Nasseri, S
   Dehghani, MH
   Alimohammadi, M
AF Mahvi, Amir Hossein
   Roodbari, Ali Akbar
   Nodehi, Ramin Nabizadeh
   Nasseri, Simin
   Dehghani, Mohammad Hadil
   Alimohammadi, Mahmood
TI RETRACTED: Improvement of Landfill Leachate Biodegradability with
   Ultrasonic Process (Retracted article. See vol. 9, e96133, 2014)
SO PLOS ONE
LA English
DT Article; Retracted Publication
ID AEROBIC BIOLOGICAL TREATMENT; ADVANCED OXIDATION PROCESSES;
   HEAVY-METALS; WASTE; ADSORPTION; FENTON; REDUCTION; TOXICITY; REMOVAL;
   REACTOR
AB Landfills leachates are known to contain recalcitrant and/or non-biodegradable organic substances and biological processes are not efficient in these cases. A promising alternative to complete oxidation of biorecalcitrant leachate is the use of ultrasonic process as pre-treatment to convert initially biorecalcitrant compounds to more readily biodegradable intermediates. The objectives of this study are to investigate the effect of ultrasonic process on biodegradability improvement. After the optimization by factorial design, the ultrasonic were applied in the treatment of raw leachates using a batch wise mode. For this, different scenarios were tested with regard to power intensities of 70 and 110 W, frequencies of 30, 45 and 60 KHz, reaction times of 30, 60, 90 and 120 minutes and pH of 3, 7 and 10. For determining the effects of catalysts on sonication efficiencies, 5 mg/l of TiO2 and ZnO have been also used. Results showed that when applied as relatively brief pre-treatment systems, the sonocatalysis processes induce several modifications of the matrix, which results in significant enhancement of its biodegradability. For this reason, the integrated chemical-biological systems proposed here represent a suitable solution for the treatment of landfill leachate samples.
C1 [Mahvi, Amir Hossein; Roodbari, Ali Akbar; Nodehi, Ramin Nabizadeh; Nasseri, Simin; Dehghani, Mohammad Hadil; Alimohammadi, Mahmood] Univ Tehran Med Sci, Sch Publ Hlth, Tehran, Iran.
   [Mahvi, Amir Hossein] Univ Tehran Med Sci, Natl Inst Hlth Res, Tehran, Iran.
   [Mahvi, Amir Hossein] Univ Tehran Med Sci, Inst Environm Res, Ctr Solid Waste Res, Tehran, Iran.
RP Mahvi, AH (reprint author), Univ Tehran Med Sci, Sch Publ Hlth, Tehran, Iran.
EM ahmahvi@yahoo.com
RI Alimohammadi, Mahmood/M-1286-2017
OI Alimohammadi, Mahmood/0000-0003-0850-154X; Roudbari,
   AliAkbar/0000-0002-9672-3646; nasseri, simin/0000-0003-4498-5617;
   dehghani, mohammad hadi/0000-0001-7516-8885
CR Anglada A, 2011, WATER RES, V45, P828, DOI 10.1016/j.watres.2010.09.017
   Atmaca E, 2009, J HAZARD MATER, V163, P109, DOI 10.1016/j.jhazmat.2008.06.067
   Aziz HA, 2011, DESALINATION, V276, P278, DOI 10.1016/j.desal.2011.03.063
   Bae BU, 1999, WATER RES, V33, P2669, DOI 10.1016/S0043-1354(98)00488-6
   Bashir MJK, 2010, J HAZARD MATER, V182, P115, DOI 10.1016/j.jhazmat.2010.06.005
   Ben Yahmed A, 2009, DESALINATION, V246, P378, DOI 10.1016/j.desal.2008.04.054
   Bidhendi ME, 2010, INT J ENVIRON SCI TE, V7, P545, DOI 10.1007/BF03326163
   Bila DM, 2005, J HAZARD MATER, V117, P235, DOI 10.1016/j.jhazmat.2004.09.022
   Chen CC, 2010, INT J ENVIRON SCI TE, V7, P447, DOI 10.1007/BF03326154
   Chianese A, 1999, WATER RES, V33, P647, DOI 10.1016/S0043-1354(98)00240-1
   CHIANG LC, 1995, WATER RES, V29, P671, DOI 10.1016/0043-1354(94)00146-X
   Cortez S, 2011, J ENVIRON MANAGE, V92, P749, DOI 10.1016/j.jenvman.2010.10.035
   de Morais JL, 2005, J HAZARD MATER, V123, P181, DOI 10.1016/j.jhazmat.2005.03.041
   Dehghani Mohammad Hadi, 2007, Journal of Zhejiang University-Science B, V8, P493, DOI 10.1631/jzus.2007.B0493
   Guo JS, 2010, J HAZARD MATER, V178, P699, DOI 10.1016/j.jhazmat.2010.01.144
   Kargi F, 2004, ENZYME MICROB TECH, V34, P422, DOI 10.1016/j.enzmictec.2003.11.016
   Kargi F, 2003, PROCESS BIOCHEM, V38, P1413, DOI 10.1016/S0032-9592(03)00030-X
   Kurniawan TA, 2009, WATER RES, V43, P4079, DOI 10.1016/j.watres.2009.06.060
   Leao S., 2004, Computers, Environment and Urban Systems, V28, P353, DOI 10.1016/S0198-9715(03)00043-7
   Li HJ, 2010, J ENVIRON SCI-CHINA, V22, P1116, DOI 10.1016/S1001-0742(09)60226-6
   Lim PE, 2010, CHEM ENG J, V159, P123, DOI 10.1016/j.cej.2010.02.064
   Lim YN, 2009, CHEM ENG J, V146, P86, DOI 10.1016/j.cej.2008.05.020
   Mahini A. Salman, 2006, International Journal of Environmental Science and Technology, V3, P435, DOI 10.1007/BF03325953
   Mahvi AH, 2009, IRAN J ENVIRON HEALT, V6, P233
   Mahvi AH, 2009, IRAN J PUBLIC HEALTH, V38, P1
   Ogundiran OO, 2008, INT J ENVIRON SCI TE, V5, P243, DOI 10.1007/BF03326018
   Pattnaik S, 2010, RESOUR CONSERV RECY, V54, P512, DOI 10.1016/j.resconrec.2009.10.008
   Pi KW, 2009, PROCESS SAF ENVIRON, V87, P191, DOI 10.1016/j.psep.2009.01.002
   Pilli S, 2011, ULTRASON SONOCHEM, V18, P1, DOI 10.1016/j.ultsonch.2010.02.014
   ROBINSON HD, 1983, WATER RES, V17, P1537, DOI 10.1016/0043-1354(83)90010-6
   Schoeman JJ, 2008, DESALINATION, V224, P178, DOI 10.1016/j.desal.2007.02.090
   SCHUK WW, 1986, WASTE MANAGE RES, V4, P265, DOI 10.1177/0734242X8600400133
   Scullion J, 2007, WATER RES, V41, P4129, DOI 10.1016/j.watres.2007.05.043
   Sun YJ, 2010, ULTRASON SONOCHEM, V17, P654, DOI 10.1016/j.ultsonch.2009.12.005
   Suthar S, 2008, INT J ENVIRON SCI TE, V5, P99, DOI 10.1007/BF03326002
   Vilar VJP, 2011, WATER RES, V45, P2647, DOI 10.1016/j.watres.2011.02.019
NR 36
TC 5
Z9 5
U1 3
U2 29
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 19
PY 2012
VL 7
IS 7
AR e27571
DI 10.1371/journal.pone.0027571
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 981GZ
UT WOS:000306956300001
PM 22829863
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Brass, DM
   Spencer, JC
   Li, ZW
   Potts-Kant, E
   Reilly, SM
   Dunkel, MK
   Latoche, JD
   Auten, RL
   Hollingsworth, JW
   Fattman, CL
AF Brass, David M.
   Spencer, Jennifer C.
   Li, Zhuowei
   Potts-Kant, Erin
   Reilly, Sarah M.
   Dunkel, Mary K.
   Latoche, Joseph D.
   Auten, Richard L.
   Hollingsworth, John W.
   Fattman, Cheryl L.
TI RETRACTED: Innate Immune Activation by Inhaled Lipopolysaccharide,
   Independent of Oxidative Stress, Exacerbates Silica-Induced Pulmonary
   Fibrosis in Mice (Retracted article. See vol. 11, e0155388, 2016)
SO PLOS ONE
LA English
DT Article; Retracted Publication
ID NALP3 INFLAMMASOME; LUNG INFLAMMATION; GENE-EXPRESSION; MACROPHAGES;
   MODEL; INTERLEUKIN-1-BETA; PROGRESSION; INHALATION; PARTICLES; APOPTOSIS
AB Acute exacerbations of pulmonary fibrosis are characterized by rapid decrements in lung function. Environmental factors that may contribute to acute exacerbations remain poorly understood. We have previously demonstrated that exposure to inhaled lipopolysaccharide (LPS) induces expression of genes associated with fibrosis. To address whether exposure to LPS could exacerbate fibrosis, we exposed male C57BL/6 mice to crystalline silica, or vehicle, followed 28 days later by LPS or saline inhalation. We observed that mice receiving both silica and LPS had significantly more total inflammatory cells, more whole lung lavage MCP-1, MIP-2, KC and IL-1 beta, more evidence of oxidative stress and more total lung hydroxyproline than mice receiving either LPS alone, or silica alone. Blocking oxidative stress with N-acetylcysteine attenuated whole lung inflammation but had no effect on total lung hydroxyproline. These observations suggest that exposure to innate immune stimuli, such as LPS in the environment, may exacerbate stable pulmonary fibrosis via mechanisms that are independent of inflammation and oxidative stress.
C1 [Brass, David M.; Spencer, Jennifer C.; Auten, Richard L.] Duke Univ, Med Ctr, Dept Pediat, Neonatol Div,Neonatal Perinatal Res Inst, Durham, NC 27710 USA.
   [Li, Zhuowei; Potts-Kant, Erin; Hollingsworth, John W.] Duke Univ, Med Ctr, Dept Med, Pulm Allergy & Crit Care Div, Durham, NC 27710 USA.
   [Reilly, Sarah M.; Dunkel, Mary K.; Latoche, Joseph D.; Fattman, Cheryl L.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Environm & Occupat Hlth, Pittsburgh, PA 15261 USA.
   [Hollingsworth, John W.] Duke Univ, Med Ctr, Dept Immunol, Durham, NC USA.
RP Brass, DM (reprint author), Duke Univ, Med Ctr, Dept Pediat, Neonatol Div,Neonatal Perinatal Res Inst, Durham, NC 27710 USA.
EM david.brass@duke.edu
FU March of Dimes [ES016126, ES016000, AI 081672]
FX Funding was provided by the March of Dimes, ES016126, ES016000, AI
   081672. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Beamer CA, 2005, AM J PHYSIOL-LUNG C, V289, pL186, DOI 10.1152/ajplung.00474.2004
   Beamer CA, 2012, TOXICOL SCI, V126, P554, DOI 10.1093/toxsci/kfs024
   Beamer CA, 2010, J LEUKOCYTE BIOL, V88, P547, DOI 10.1189/jlb.0210108
   Boon K, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005134
   Brass DM, 2010, AM J PHYSIOL-LUNG C, V299, pL664, DOI 10.1152/ajplung.00389.2009
   Brass DM, 2003, AM J PHYSIOL-LUNG C, V6, P6
   Brass DM, 2008, IMMUNOGENETICS, V13, P13
   Cassel SL, 2008, P NATL ACAD SCI USA, V105, P9035, DOI 10.1073/pnas.0803933105
   Cho HY, 2009, AM J RESP CRIT CARE, V179, P138, DOI 10.1164/rccm.200804-535OC
   Corbel M, 2001, INFLAMM RES, V50, P129, DOI 10.1007/s000110050736
   Dostert C, 2008, SCIENCE, V320, P674, DOI 10.1126/science.1156995
   GHIO AJ, 1994, AM J PHYSIOL-LUNG C, V267, pL686
   Gilberti RM, 2008, AM J RESP CELL MOL, V39, P619, DOI 10.1164/rcmb.2008-0046OC
   Hamilton RF, 2008, FREE RADICAL BIO MED, V44, P1246, DOI 10.1016/j.freeradbiomed.2007.12.027
   HEPPLESTON AG, 1975, AM J PATHOL, V78, P171
   Hornung V, 2008, NAT IMMUNOL, V9, P847, DOI 10.1038/ni.1631
   Kim Dong Soon, 2006, Proc Am Thorac Soc, V3, P285, DOI 10.1513/pats.200601-005TK
   Kim DS, 2006, EUR RESPIR J, V27, P143, DOI 10.1183/00936.06.00114004
   KONDOH Y, 1993, CHEST, V103, P1808, DOI 10.1378/chest.103.6.1808
   Kornum Jette B, 2008, BMC Pulm Med, V8, P24, DOI 10.1186/1471-2466-8-24
   Langley RJ, 2011, J TOXICOL ENV HEAL A, V74, P1261, DOI 10.1080/15287394.2011.595669
   Li H, 2009, INNATE IMMUN-LONDON, V15, P143, DOI 10.1177/1753425908101509
   LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5
   Lo Re S, 2011, AM J RESP CRIT CARE, V184, P1270, DOI 10.1164/rccm.201103-0516OC
   Lowry MH, 2008, AM J RESP CELL MOL, V38, P509, DOI 10.1165/rcmb.2007-0128OC
   Martinez FO, 2009, ANNU REV IMMUNOL, V27, P451, DOI 10.1146/annurev.immunol.021908.132532
   McMillan TR, 2008, AM J RESP CRIT CARE, V177, P771, DOI 10.1164/rccm.200708-1184OC
   Papanikolaou IC, 2010, CURR OPIN PULM MED, V2010, P13
   Park IN, 2007, CHEST, V132, P214, DOI 10.1378/chest.07-0323
   Peters JM, 1986, SILICOSIS, P219
   Porter DW, 2004, TOXICOL SCI, V79, P370, DOI 10.1093/toxsci/kfh110
   Potts-Kant EN, 2011, FREE RADIC BIOL MED
   Rabolli V, 2011, TOXICOL LETT, V203, P127, DOI 10.1016/j.toxlet.2011.03.009
   ROSEN SH, 1958, NEW ENGL J MED, V258, P1123, DOI 10.1056/NEJM195806052582301
   SARIH M, 1993, J LEUKOCYTE BIOL, V54, P407
   Selman M, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000482
   Shimbori C, 2012, INT ARCH ALLERGY IMM, V158, P241, DOI 10.1159/000331439
   Song JW, 2011, EUR RESPIR J, V37, P356, DOI 10.1183/09031936.00159709
   Srivastava KD, 2002, AM J RESP CRIT CARE, V165, P527, DOI 10.1164/rccm.2106009
   Tang YW, 2003, J CLIN MICROBIOL, V41, P2633, DOI 10.1128/JCM.41.6.2633-2640.2003
   Vannella KM, 2010, AM J RESP CRIT CARE, V181, P465, DOI 10.1164/rccm.200905-0798OC
   WOESSNER JF, 1961, ARCH BIOCHEM BIOPHYS, V93, P440, DOI 10.1016/0003-9861(61)90291-0
   Wohlford-Lenane CL, 1999, AM J PHYSIOL-LUNG C, V276, pL736, DOI 10.1152/ajplung.1999.276.5.L736
   Yu HB, 2008, CELL HOST MICROBE, V4, P198, DOI 10.1016/j.chom.2008.08.007
   Yucesoy B, 2001, AM J IND MED, V39, P286, DOI 10.1002/1097-0274(200103)39:3<286::AID-AJIM1016>3.0.CO;2-7
NR 45
TC 11
Z9 11
U1 1
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 16
PY 2012
VL 7
IS 7
AR e40789
DI 10.1371/journal.pone.0040789
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 974VS
UT WOS:000306466100068
PM 22815821
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Aviles, A
   Neri, N
   Fernandez, R
   Huerta-Guzman, J
   Nambo, MJ
AF Aviles, Agustin
   Neri, Natividad
   Fernandez, Raul
   Huerta-Guzman, Judith
   Nambo, Maria J.
TI RETRACTED: Randomized Clinical Trial to Assess the Efficacy of
   Radiotherapy in Primary Mediastinal Large B-Lymphoma (Retracted article.
   See vol. 85, pg. 286, 2013)
SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
LA English
DT Article; Retracted Publication
DE Chemotherapy; Doxorubicin; Primary mediastinal lymphoma; Radiotherapy;
   Rituximab
ID INVOLVED-FIELD RADIOTHERAPY; CELL LYMPHOMA; RADIATION-THERAPY; MACOP-B;
   CHEMOTHERAPY; RITUXIMAB; CHOP
AB Purpose: We developed a controlled clinical trial to assess the efficacy and toxicity of adjuvant-involved field radiotherapy (IFRT) in patients with primary mediastinal B-cell lymphoma that achieved complete response after the patients were treated with cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab (R-CHOP-14).
   Methods and Materials: Between January 2001 and June 2004, 124 consecutive patients who were in complete remission after dose dense chemotherapy and rituximab administration (R-CHOP14) were randomly assigned to received IFRT (30 Gy). Sixty-three patients received IFR, and 61 patients did not (control group).
   Results: The study aimed to include 182 patients in each arm but was closed prematurely because in a security analysis (June 2004), progression and early relapse were more frequent in patients that did not received IFRT. Patients were followed until March 2009, at which point actuarial curves at 10 years showed that progression free-survival was 72% in patients who received IFR and 20% in the control group (p < 0.001), overall survival was 72% and 31%, respectively (p < 0.001). Acute toxicity was mild and well tolerated.
   Discussion: Adjuvant radiotherapy to sites of bulky disease was the only difference to have an improvement in outcome in our patients; the use of rituximab during induction did not improve complete response rates and did affect overall survival; patients who received rituximab but not IFRT had a worse prognosis.
   Conclusions: The use of IFRT in patients with primary mediastinal B-cell lymphoma who achieved complete response remain as the best treatment available, even in patients that received rituximab during induction. (C) 2012 Elsevier Inc.
C1 [Aviles, Agustin] IMSS, Natl Med Ctr, Oncol Hosp, Oncol Res Unit, Mexico City, DF, Mexico.
   [Neri, Natividad; Huerta-Guzman, Judith; Nambo, Maria J.] IMSS, Natl Med Ctr, Oncol Hosp, Dept Hematol, Mexico City, DF, Mexico.
   [Fernandez, Raul] IMSS, Natl Med Ctr, Oncol Hosp, Dept Radiat Therapy, Mexico City, DF, Mexico.
RP Aviles, A (reprint author), Plaza Luis Cabrera 5, Mexico City, DF, Mexico.
EM agustin.aviles@imss.gob.mx
FU Mexican Institute of Social Security
FX This work was supported by resources of the Mexican Institute of Social
   Security. Conception, design analysis, and interpretation of data
CR Ahn HK, 2010, INT J HEMATOL, V91, P456, DOI 10.1007/s12185-010-0536-6
   Aviles A, 2002, ANN HEMATOL, V81, P368, DOI 10.1007/s00277-002-0473-4
   Cheson BD, 1999, J CLIN ONCOL, V17, P1244, DOI 10.1200/JCO.1999.17.4.1244
   De Sanctis V, 2008, INT J RADIAT ONCOL, V72, P1154, DOI 10.1016/j.ijrobp.2008.02.036
   Dunleavy K, 2006, BLOOD S1, V108
   Fietz T, 2009, ANN HEMATOL, V88, P433, DOI 10.1007/s00277-008-0625-2
   Jacobson JV, 1998, CANCER, V62, P1898
   KIRN D, 1993, J CLIN ONCOL, V11, P1336, DOI 10.1200/JCO.1993.11.7.1336
   Kolconie SV, 2006, INT J HEMATOL, V83, P331
   Martelli M, 2006, BLOOD S1, V108
   Martelli M, 2008, CRIT REV ONCOL HEMAT, V68, P256, DOI 10.1016/j.critrevonc.2008.07.020
   Massoud M, 2008, LEUKEMIA LYMPHOMA, V49, P1510, DOI 10.1080/10428190802203788
   Mazzarotto R, 2007, INT J RADIAT ONCOL, V68, P823, DOI 10.1016/j.ijrobp.2006.12.048
   Pugh TJ, 2010, INT J RADIAT ONCOL, V76, P845, DOI 10.1016/j.ijrobp.2009.02.045
   Rieger M, 2011, ANN ONCOL, V22, P664, DOI 10.1093/annonc/mdq418
   Rodriguez J, 2008, LEUKEMIA LYMPHOMA, V49, P1050, DOI 10.1080/10428190801958994
   Sacage KJ, 2006, ANN ONCOL, V17, P123
   Siracusano L, 2005, AM J HEMATOL, V78, P312, DOI 10.1002/ajh.20301
   van Besien K, 2001, J CLIN ONCOL, V19, P1855, DOI 10.1200/JCO.2001.19.6.1855
   Vassolakopulos TP, 2005, BLOOD S1, V106
   Wirth A, 2007, LEUKEMIA LYMPHOMA, V48, P2121, DOI 10.1080/10428190701636468
   Zinzani PL, 2009, CLIN LYMPHOMA MYELOM, V9, P381, DOI 10.3816/CLM.2009.n.074
   Zinzani PL, 2002, HAEMATOLOGICA, V87, P1258
NR 23
TC 6
Z9 9
U1 5
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0360-3016
EI 1879-355X
J9 INT J RADIAT ONCOL
JI Int. J. Radiat. Oncol. Biol. Phys.
PD JUL 15
PY 2012
VL 83
IS 4
BP 1227
EP 1231
DI 10.1016/j.ijrobp.2011.09.012
PG 5
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA 960WK
UT WOS:000305423400043
PM 22172907
DA 2018-12-27
ER

PT J
AU Rajendran, A
   Karthikeyan, C
   Rajathi, K
   Ragupathy, D
AF Rajendran, A.
   Karthikeyan, C.
   Rajathi, K.
   Ragupathy, D.
TI RETRACTED: An environmentally benign one pot synthesis of substituted
   quinolines catalysed by fluoroboric acid based ionic liquid (Retracted
   article. See vol. 125, pg. 695, 2013)
SO JOURNAL OF CHEMICAL SCIENCES
LA English
DT Article; Retracted Publication
DE One-pot synthesis; benign synthesis; ionic liquids; fluoroboric acid;
   quinolines
ID FRIEDLANDER SYNTHESIS; EFFICIENT; DERIVATIVES; CYCLIZATION
AB Organic synthesis generally required large amount of solvent, avoiding the use of organic solvents in synthesis is a paradigm shift directed at developing more benign chemistry, and with ionic liquids surprisingly can lead to access to new compounds. An elegant one-pot synthesis of quinoline derivatives has been achieved by reaction of substituted anilines with beta-ketoester at 60A degrees C in ethanol using an ionic liquid [Et3NH] (+) [BF4]as catalyst. All the reactions gave products with high degree of purity and excellent yield (78-93%) within the shorter span of time (20-65 min) than those reactions with conventional methods. The screening of solvents as well as the reuse of ionic liquid has been evaluated. The structure of the products has been elucidated by spectral and analytical data. The present scope and potential economic impact of the reaction are demonstrated by the synthesis of substituted quinolines. Remaining challenges and future perspectives of the new transformation are discussed.
C1 [Rajendran, A.] Sir Theagaraya Coll, Dept Chem, Madras 600021, Tamil Nadu, India.
   [Karthikeyan, C.; Rajathi, K.] Bharathiar Univ, Ctr Res & Dev, Coimbatore 641046, Tamil Nadu, India.
   [Ragupathy, D.] Kyungpook Natl Univ, Dept Appl Chem, Taegu 701702, South Korea.
RP Rajendran, A (reprint author), Sir Theagaraya Coll, Dept Chem, Madras 600021, Tamil Nadu, India.
EM annamalai_rajendran2000@yahoo.com
FU University Grants Commission, New Delhi [35-147/2009(SR)]
FX AR acknowledges the funding support given by the University Grants
   Commission, New Delhi for his major research project [F.No
   35-147/2009(SR)]. He thanks the principal and the management of Sir
   Theagaraya College, Chennai for the constant encouragement. His thanks
   are also due to Mr. P Sakthivel, Sastra University, Tanjore for the
   spectral recording.
CR AGRAWAL AK, 1991, MACROMOLECULES, V24, P6806, DOI 10.1021/ma00025a044
   Arcade A, 2003, SYN LETT, V203
   Arumugam P, 2005, CHEM LETT, V34, P314, DOI 10.1246/cl.2005.314
   Beckman EJ, 2004, J SUPERCRIT FLUID, V28, P121, DOI 10.1016/S0896-8446(03)00029-9
   Cheng, 1982, ORG REACTIONS, V28, P348
   Cho CS, 2000, CHEM COMMUN, P1885, DOI 10.1039/b005966h
   Du W, 2003, ORG LETT, V5, P1765, DOI 10.1021/ol0344319
   FRIEDLANDER P, 1882, CHEM BER, V15, P2572, DOI DOI 10.1002/CBER.188201502219
   Ghosh R, 2001, INDIAN J CHEM B, V40, P550
   Hoemann MZ, 2000, BIOORG MED CHEM LETT, V10, P2675, DOI 10.1016/S0960-894X(00)00542-4
   Hu YZ, 2003, ORG LETT, V5, P2251, DOI 10.1021/ol034559q
   Jenekhe SA, 2001, MACROMOLECULES, V34, P7315, DOI 10.1021/ma0100448
   Jiang B, 2002, J ORG CHEM, V67, P9449, DOI 10.1021/jo0204606
   Katrizky A R, 1984, COMPREHENSIVE HETERO, V2, P385
   Kidwai M, 2005, BIOORG MED CHEM LETT, V15, P915, DOI 10.1016/j.bmcl.2004.12.049
   Kidwai M, 2007, TETRAHEDRON LETT, V48, P8883, DOI 10.1016/j.tetlet.2007.10.050
   Kidwai M, 2007, GREEN CHEM, V9, P742, DOI 10.1039/b702287e
   Kidwai M, 2006, TETRAHEDRON LETT, V47, P8049, DOI 10.1016/j.tetlet.2006.09.066
   Kidwai M, 2009, INDIAN J CHEM B, V48, P746
   MANSKE RHF, 1953, ORG REACTIONS, V7, P59
   Ranu BC, 2000, EUR J ORG CHEM, P2347
   SKRAUP ZH, 1880, CHEM BER, V13, P2086
   Strekowski L, 2000, J FLUORINE CHEM, V104, P281, DOI 10.1016/S0022-1139(00)00252-9
   WALSER A, 1975, J HETEROCYCLIC CHEM, V12, P737, DOI 10.1002/jhet.5570120424
   Wu J, 2006, ORG BIOMOL CHEM, V4, P126, DOI 10.1039/b514635f
   Wu J, 2005, SYN LETT, V5, P2653
   Zhang X, 2001, MACROMOLECULES, V34, P7315
NR 27
TC 4
Z9 4
U1 4
U2 29
PU INDIAN ACAD SCIENCES
PI BANGALORE
PA C V RAMAN AVENUE, SADASHIVANAGAR, P B #8005, BANGALORE 560 080, INDIA
SN 0974-3626
EI 0973-7103
J9 J CHEM SCI
JI J. Chem. Sci.
PD JUL
PY 2012
VL 124
IS 4
BP 877
EP 881
DI 10.1007/s12039-012-0272-y
PG 5
WC Chemistry, Multidisciplinary
SC Chemistry
GA 999WK
UT WOS:000308345800016
DA 2018-12-27
ER

PT J
AU Meghashri, S
   Chauhan, JB
   Zameer, F
AF Meghashri, S.
   Chauhan, J. B.
   Zameer, F.
TI RETRACTED: Contribution of herbal principles towards cytoprotective,
   antioxidant and anti-Rhizopus activities (Retracted article. See vol.
   93, pg. 252, 2014)
SO SOUTH AFRICAN JOURNAL OF BOTANY
LA English
DT Article; Retracted Publication
DE Antioxidant; Anti-Rhizopus; Cytoprotective; DPPH; Herbal extracts;
   Oxidation
ID OXIDATIVE DAMAGE; EXTRACTS; CELLS
AB Herbal extracts (twenty extracts) obtained from 20 medicinal and aromatic plants were evaluated for their cytoprotectivity and antioxidant properties. Total phenol content and anti-Rhizopus activity were also determined. Results indicated that, out of 20 extracts evaluated, radical scavenging capacity and anti-Rhizopus activity were observed in aqueous extract of Ocimum tenuiflorum, Leucas aspera, Terminalia arjuna, Glycyrrhiza glabra and Nyctanthes arbortristis in a dose dependent manner. The total phenolic content was observed to be 1289, 3837, 372, 2831 and 1892 mu g GAE/g for O. tenuiflorum, L. aspera, T. arjuna, G. glabra and N. arbortristis respectively. The antioxidant activity correlates with the phenolic content of the extracts. At 1 mg/ml the above extracts showed 98% protection on erythrocyte and buccal cell oxidation. In DNA oxidation studies, higher protection was observed in O. tenuiflorum, L. aspera and N. arbortristis extracts. These results demonstrate that the cytoprotectivity and antioxidant potency of these extracts could be the basis for their alleged health promoting potential. They could serve as new sources of natural antioxidants or nutraceuticals with potential applications in reducing oxidative stress conditions. (c) 2012 SAAB. Published by Elsevier B.V. All rights reserved.
C1 [Meghashri, S.; Chauhan, J. B.; Zameer, F.] Univ Mysore, Dept Studies Biotechnol & Microbiol, Mahajana Life Sci Res Ctr, Pooja Bhagavat Mem Mahajana Post Grad Ctr, Mysore 570016, Karnataka, India.
RP Zameer, F (reprint author), Univ Mysore, Dept Studies Biotechnol & Microbiol, Mahajana Life Sci Res Ctr, Pooja Bhagavat Mem Mahajana Post Grad Ctr, Mysore 570016, Karnataka, India.
EM farhanzameeruom@gmail.com
FU Metagalli; Mysore; Mahajana Education Society
FX The authors thank the Director, Pooja Bhagavat Memorial Mahajana Post
   Graduate Centre, Metagalli, Mysore and Mahajana Education Society for
   their support and encouragement.
CR Battistelli M, 2005, EUR J HISTOCHEM, V49, P243
   BLOIS MS, 1958, NATURE, V181, P1199, DOI 10.1038/1811199a0
   Lima CF, 2007, CHEM-BIOL INTERACT, V167, P107, DOI 10.1016/j.cbi.2007.01.020
   Maltas E., 2012, Pharmacologia, V3, P113
   Meghashri S, 2010, FOOD CHEM, V122, P105, DOI 10.1016/j.foodchem.2010.02.023
   Northover J, 2002, CAN J PLANT PATHOL, V24, P144, DOI 10.1080/07060660309506989
   Roselli M., 2011, PHYTOTHERAPY RES
   Sethi Jyoti, 2004, Indian J Clin Biochem, V19, P152, DOI 10.1007/BF02894276
   Shivai S., 1983, CARCINOGENESIS, V4, P395
   Suwalsky M, 2007, FOOD CHEM TOXICOL, V45, P130, DOI 10.1016/j.fct.2006.08.010
   Wagner H, 1996, PLANT DRUG ANAL THIN
   Wong PYY, 2006, FOOD CHEM, V97, P505, DOI 10.1016/j.foodchem.2005.05.031
   Zhang ZZ, 2006, J AGR FOOD CHEM, V54, P3936, DOI 10.1021/jf060017m
NR 13
TC 1
Z9 1
U1 1
U2 14
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0254-6299
EI 1727-9321
J9 S AFR J BOT
JI S. Afr. J. Bot.
PD JUL
PY 2012
VL 81
BP 29
EP 33
DI 10.1016/j.sajb.2012.04.003
PG 5
WC Plant Sciences
SC Plant Sciences
GA 005DM
UT WOS:000308730700006
OA Other Gold
DA 2018-12-27
ER

PT J
AU Zhao, YL
   Zhang, LH
   Wu, F
AF Zhao, Yu-long
   Zhang, Lie-hui
   Wu, Feng
TI RETRACTED: Pressure transient analysis for multi-fractured horizontal
   well in shale gas reservoirs (Retracted article. See vol. 117, pg. 54,
   2014)
SO JOURNAL OF PETROLEUM SCIENCE AND ENGINEERING
LA English
DT Article; Retracted Publication
DE Shale gas reservoir; Multi-fractured horizontal well; Mathematical
   model; Desorption; Diffusion; Transient pressure analysis
AB This paper presents the Pressure Transient Analysis (PTA) of the multi-fractured horizontal well with the consideration of adsorption and desorption characteristics of shale gas reservoirs, which were rarely incorporated into previous PTA models. Point-source solutions are derived in Laplace transform domain by using the source function idea and solution of the mathematical model is obtained by the discrete and Gauss elimination methods. Pseudo-pressure and Pseudo-pressure derivative type curves are plotted in order to identify different flow regimes by using the Stehfest algorithm. And the effects of influence factors and flux distribution on discrete elements are also analyzed. The results obtained in this paper have important significance to understand the pressure characteristics and provide the theoretical basis and technical support for exploiting this reservoir efficiently. (c) 2012 Elsevier B.V. All rights reserved.
C1 [Zhao, Yu-long; Zhang, Lie-hui; Wu, Feng] SW Petr Univ, State Key Lab Oil & Gas Reservoir Geol & Exploita, Chengdu 610500, Sichuan, Peoples R China.
RP Zhang, LH (reprint author), SW Petr Univ, State Key Lab Oil & Gas Reservoir Geol & Exploita, Chengdu 610500, Sichuan, Peoples R China.
EM zhangliehui@vip.163.com
FU National Science Fund for Distinguished Young Scholars of China
   [51125019]; National Program on Key Basic Research Project (973 Program)
   [2011CB201005]
FX This work was supported by National Science Fund for Distinguished Young
   Scholars of China (Grant no. 51125019) and the National Program on Key
   Basic Research Project (973 Program, Grant no. 2011CB201005).
CR Belyadi A., 2010, SPE E REG M MORG W V
   Brown M.L., 2009, SPE ANN TECHN C EXH
   Cheng Y. M., 2011, SPE E REG M COL OH U
   Crosby DG, 2002, J PETROL SCI ENG, V35, P191, DOI 10.1016/S0920-4105(02)00243-7
   Everdingen V., 1949, T AIME, V186, P305
   Freeman C.M., 2010, THESIS TEXAS A M U
   Haider J.A., 2011, CAN UNC RES C CALG A
   Hill B., 2000, GAS TIPS, V6, P4
   Imad B., 2011, SPE W N AM REG M ANC
   Langmuir I, 1916, J AM CHEM SOC, V38, P2221, DOI 10.1021/ja02268a002
   Mattar L, 2008, SPE SHAL GAS PROD C
   Mayerhofer M.J, 2006, ANN TECHN C EXH SAN
   Medeiros F., 2007, INT PETR TECHN C DUB
   Ozkan E, 1992, INT J ROCK MECH MIN, V29, pA159
   Raghavan R., 1993, WELL TEST ANAL, P23
   Rasheed O. B., 2010, SPE N AFR TECHN C EX
   Restrepo D.P., 2008, THESIS U OKLAHOMA
   STEHFEST H, 1970, COMMUN ACM, V13, P47, DOI 10.1145/361953.361969
   Wan J, 2002, SPE J, V7, P437, DOI 10.2118/81190-PA
   Wang J.W., 2011, N AM UNC GAS C EXH W
   Wei Y, 2005, SPE ANN TECHN C EXH
NR 21
TC 13
Z9 15
U1 4
U2 50
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0920-4105
EI 1873-4715
J9 J PETROL SCI ENG
JI J. Pet. Sci. Eng.
PD JUL
PY 2012
VL 90-91
BP 31
EP 38
DI 10.1016/j.petrol.2012.04.006
PG 8
WC Energy & Fuels; Engineering, Petroleum
SC Energy & Fuels; Engineering
GA 990FA
UT WOS:000307615200005
DA 2018-12-27
ER

PT J
AU Huh, SU
   Lee, IJ
   Ham, BK
   Paek, KH
AF Huh, Sung Un
   Lee, In-Ju
   Ham, Byung-Kook
   Paek, Kyung-Hee
TI RETRACTED: Nicotiana tabacum Tsip1-Interacting Ferredoxin 1 Affects
   Biotic and Abiotic Stress Resistance (Retracted article. See vol. 35,
   pg. 176, 2013)
SO MOLECULES AND CELLS
LA English
DT Article; Retracted Publication
DE Cucumber mosaic virus; Nicotiana tabacum; NtTfd1; Tsip1; VIGS
ID PROTEIN; TOBACCO; LOCALIZATION; REDUCTASE; SURFACE
AB Tsip1, a Zn finger protein that was isolated as a direct interactor with tobacco stress-induced 1 (Tsi1), plays an important role in both biotic and abiotic stress signaling. To further understand Tsip1 function, we searched for more Tsip1-interacting proteins by yeast two-hybrid screening using a tobacco cDNA library. Screening identified a new Tsip1-interacting protein, Nicotiana tabacum Tsip1-interacting ferredoxin 1 (NtTfd1), and binding specificity was confirmed both in vitro and in vivo. The four repeats of a cysteine-rich motif (CXXCXGXG) of Tsip1 proved important for binding to NtTfd1. Virus-induced gene silencing of NtTfd1, Tsip1, and NtTfd1/Tsip1 rendered plants more susceptible to salinity stress compared with TRV2 control plants. NtTfd1- and Tsip1-silenced tobacco plants were more susceptible to infection by Cucumber mosaic virus compared with control plants. These results suggest that NtTfd1 might be involved in the regulation of biotic and abiotic stresses in chloroplasts by interaction with Tsip1.
C1 [Huh, Sung Un; Lee, In-Ju; Paek, Kyung-Hee] Korea Univ, Sch Life Sci & Biotechnol, Seoul 136701, South Korea.
   [Ham, Byung-Kook] Univ Calif Davis, Plant Biol Sect, Coll Biol Sci, Davis, CA 95616 USA.
RP Paek, KH (reprint author), Korea Univ, Sch Life Sci & Biotechnol, Seoul 136701, South Korea.
EM khpaek95@korea.ac.kr
FU Science Research Center-Engineering Research Center Program (Plant
   Signaling Network Research Center) of the Ministry of Education, Science
   and Technology [R11-2003-008-02001-0]; Mid-career Researcher-Program
   through a National Research Foundation; Ministry of Education Science
   and Technology (MEST) [2009-0085565]; Wujangchoon Project from the Rural
   Development Administration, Republic of Korea [PJ007850]
FX This work was supported by the Science Research Center-Engineering
   Research Center Program (Plant Signaling Network Research Center) of the
   Ministry of Education, Science and Technology (R11-2003-008-02001-0),
   the Mid-career Researcher-Program through a National Research Foundation
   grant funded by the Ministry of Education Science and Technology (MEST)
   (2009-0085565), and the Wujangchoon Project (PJ007850) from the Rural
   Development Administration, Republic of Korea.
CR Akashi T, 1999, J BIOL CHEM, V274, P29399, DOI 10.1074/jbc.274.41.29399
   AONO M, 1993, PLANT CELL PHYSIOL, V34, P129
   Caplan JL, 2008, CELL, V132, P449, DOI 10.1016/j.cell.2007.12.031
   Fukuyama K, 2004, PHOTOSYNTH RES, V81, P289, DOI 10.1023/B:PRES.0000036882.19322.0a
   Ham BK, 2006, PLANT CELL, V18, P2005, DOI 10.1105/tpc.106.043158
   Hanke GT, 2004, PLANT PHYSIOL, V134, P255, DOI 10.1104/pp.103.032755
   Hwang I, 2001, NATURE, V413, P383, DOI 10.1038/35096500
   Igarashi D, 2001, PLANT CELL, V13, P2483, DOI 10.1105/tpc.13.11.2483
   Jeon Y, 2010, MOL CELLS, V29, P175, DOI 10.1007/s10059-010-0011-5
   JOFUKU KD, 1994, PLANT CELL, V6, P1211, DOI 10.2307/3869820
   Park JM, 2001, PLANT CELL, V13, P1035, DOI 10.1105/tpc.13.5.1035
   Ratcliff F, 2001, PLANT J, V25, P237, DOI 10.1046/j.0960-7412.2000.00942.x
   Walter M, 2004, PLANT J, V40, P428, DOI 10.1111/j.1365-313X.2004.02219.x
   Weigel D., 2002, ARABIDOPSIS LAB MANU
   Yeung T, 2008, SCIENCE, V319, P210, DOI 10.1126/science.1152066
NR 15
TC 4
Z9 4
U1 2
U2 22
PU KOREAN SOC MOLECULAR & CELLULAR  BIOLOGY
PI SEOUL
PA 635-4, YUCKSAM-DONG, GANGNAM-GU, SEOUL 135-703, SOUTH KOREA
SN 1016-8478
EI 0219-1032
J9 MOL CELLS
JI Mol. Cells
PD JUL
PY 2012
VL 34
IS 1
BP 43
EP 52
DI 10.1007/s10059-012-0066-6
PG 10
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 985NO
UT WOS:000307273600006
PM 22699755
OA Green Published
DA 2018-12-27
ER

PT J
AU Kundu, P
   Mohanty, C
   Sahoo, SK
AF Kundu, Paromita
   Mohanty, Chandana
   Sahoo, Sanjeeb K.
TI RETRACTED: Antiglioma activity of curcumin-loaded lipid nanoparticles
   and its enhanced bioavailability in brain tissue for effective
   glioblastoma therapy (Retracted article. See vol. 9, pg. 7074, 2013)
SO ACTA BIOMATERIALIA
LA English
DT Article; Retracted Publication
DE Glioblastoma; Blood-brain barrier; Multi-drug resistance proteins;
   Curcumin; Telomerase
ID MULTIDRUG-RESISTANCE; HUMAN GLIOMA; MALIGNANT GLIOMA; CANCER-THERAPY;
   IN-VITRO; VIVO PHARMACOKINETICS; TELOMERASE ACTIVITY; BLOCK-COPOLYMERS;
   DRUG-DELIVERY; CELLS
AB Glioblastoma, the most aggressive form of brain and central nervous system tumours, is characterized by high rates proliferation, migration and invasion. The major road block in the delivery of drugs to the brain is the blood-brain barrier, along with the expression of various multi-drug resistance (MDR) proteins that cause the efflux of a wide range of chemotherapeutic drugs. Curcumin, a herbal drug, is known to inhibit cellular proliferation, migration and invasion and induce apoptosis of glioma cells. It also has the potential to modulate MDR in glioma cells. However, the greatest challenge in the administration of curcumin stems from its low bioavailability and high rate of metabolism. To circumvent the above pitfalls of curcumin we have developed curcumin-loaded glyceryl monooleate (GMO) nanoparticles (NP) coated with the surfactant Pluronic F-68 and vitamin E p-a-tocopheryl polyethylene glycol 1000 succinate (TPGS) for brain delivery. We demonstrated that our curcumin-loaded NPs inhibit cellular proliferation, migration and invasion along with a higher percentage of cell cycle arrest and telomerase inhibition, thus leading to a greater percentage apoptotic cell death in glioma cells compared with native curcumin. An in vivo study demonstrated enhanced bioavailability of curcumin in blood serum and brain tissue when delivered by curcumin-loaded GMO NPs compared with native curcumin in a rat model. Thus, curcumin-loaded GMO NPs can be used as an effective delivery system to overcome the challenges of drug delivery to the brain, providing a new approach to glioblastoma therapy. (C) 2012 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.
C1 [Kundu, Paromita; Mohanty, Chandana; Sahoo, Sanjeeb K.] Inst Life Sci, Bhubaneswar 751023, Orissa, India.
RP Sahoo, SK (reprint author), Inst Life Sci, Nalco Sq, Bhubaneswar 751023, Orissa, India.
EM sanjeebsahoo2005@gmail.com
FU University Grants Commission, Government of India
FX P.K. would like to thank the University Grants Commission, Government of
   India, for providing a junior research fellowship. We thank Mr. Bhavani
   Shankar Sahoo, Institute of Life Sciences, for his assistance with the
   confocal experiments.
CR Acharya S, 2011, BIOMATERIALS, V32, P5643, DOI 10.1016/j.biomaterials.2011.04.043
   Acharya S, 2009, BIOMATERIALS, V30, P5737, DOI 10.1016/j.biomaterials.2009.07.008
   Agarwal S, 2011, EXPERT REV MOL MED, V13, DOI 10.1017/S1462399411001888
   Aggarwal BB, 2006, EXPERT OPIN THER TAR, V10, P87, DOI 10.1517/14728222.10.1.87
   Aggarwal BB, 2007, ADV EXP MED BIOL, V595, P1
   Ampasavate C, 2010, PHYTOMEDICINE, V17, P506, DOI 10.1016/j.phymed.2009.09.004
   Anand P, 2007, MOL PHARMACEUT, V4, P807, DOI 10.1021/mp700113r
   Ballabh P, 2004, NEUROBIOL DIS, V16, P1, DOI 10.1016/j.nbd.2003.12.016
   Benyahia B, 2004, J NEURO-ONCOL, V66, P65, DOI 10.1023/B:NEON.0000013484.73208.a4
   Bisht Savita, 2007, Journal of Nanobiotechnology, V5, P3, DOI 10.1186/1477-3155-5-3
   Bogman K, 2003, J PHARM SCI, V92, P1250, DOI 10.1002/jps.10395
   Bollrath J, 2009, CANCER CELL, V15, P91, DOI 10.1016/j.ccr.2009.01.002
   Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5
   Calatozzolo C, 2005, J NEURO-ONCOL, V74, P113, DOI 10.1007/s11060-004-6152-7
   Chakraborty S, 2006, MUTAT RES-FUND MOL M, V596, P81, DOI 10.1016/j.mrfmmm.2005.12.007
   Chearwae W, 2006, CANCER CHEMOTH PHARM, V57, P376, DOI 10.1007/s00280-005-0052-1
   Das M, 2011, ACTA BIOMATER, V7, P355, DOI 10.1016/j.actbio.2010.08.010
   de Mendoza AEH, 2011, J CONTROL RELEASE, V156, P421, DOI 10.1016/j.jconrel.2011.07.030
   Dilnawaz F, 2010, BIOMATERIALS, V31, P3694, DOI 10.1016/j.biomaterials.2010.01.057
   Dintaman JM, 1999, PHARMACEUT RES, V16, P1550, DOI 10.1023/A:1015000503629
   Fernandes C, 2010, PHARMACOL RES, V62, P166, DOI 10.1016/j.phrs.2010.02.004
   Fulda S, 2006, ONCOGENE, V25, P4798, DOI 10.1038/sj.onc.1209608
   Furnari FB, 2007, GENE DEV, V21, P2683, DOI 10.1101/gad.1596707
   Ghersi-Egea JF, 2009, REV NEUROL-FRANCE, V165, P1029, DOI 10.1016/j.neurol.2009.09.011
   Guo JW, 2011, BIOMATERIALS, V32, P8010, DOI 10.1016/j.biomaterials.2011.07.004
   Gupta Y K, 2010, Indian J Physiol Pharmacol, V54, P99
   Harley CB, 2008, NAT REV CANCER, V8, P167, DOI 10.1038/nrc2275
   Jagetia GC, 2007, J CLIN IMMUNOL, V27, P19, DOI 10.1007/s10875-006-9066-7
   Kabanov AV, 2002, ADV DRUG DELIVER REV, V54, P223, DOI 10.1016/S0169-409X(02)00018-2
   Kanzawa T, 2003, BRIT J CANCER, V89, P922, DOI 10.1038/sj.bjc.6601193
   Karmakar S, 2007, NEUROCHEM RES, V32, P2103, DOI 10.1007/s11064-007-9376-z
   Karmakar S, 2006, NEUROSCI LETT, V407, P53, DOI 10.1016/j.neulet.2006.08.013
   Kreuter J, 2001, ADV DRUG DELIVER REV, V47, P65, DOI 10.1016/S0169-409X(00)00122-8
   Kulkarni SA, 2011, NANOMEDICINE-UK, V6, P377, DOI 10.2217/NNM.10.131
   Kunnumakkara AB, 2008, CANCER LETT, V269, P199, DOI 10.1016/j.canlet.2008.03.009
   Lai J, 2009, AAPS PHARMSCITECH, V10, P960, DOI 10.1208/s12249-009-9292-4
   Laquintana V, 2009, EXPERT OPIN DRUG DEL, V6, P1017, DOI 10.1517/17425240903167942
   Lim KJ, 2011, CANCER BIOL THER, V11, P464, DOI 10.4161/cbt.11.5.14410
   Luthra PM, 2009, BIOCHEM BIOPH RES CO, V384, P420, DOI 10.1016/j.bbrc.2009.04.149
   Miller DW, 1999, PHARM RES-DORDR, V16, P396, DOI 10.1023/A:1018873702411
   Misra R, 2011, MOL PHARMACEUT, V8, P852, DOI 10.1021/mp100455h
   Misra R, 2010, DRUG DISCOV TODAY, V15, P842, DOI 10.1016/j.drudis.2010.08.006
   Mohanty C, 2010, BIOMATERIALS, V31, P6597, DOI 10.1016/j.biomaterials.2010.04.062
   Mohanty C, 2010, NANOMEDICINE-UK, V5, P433, DOI [10.2217/nnm.10.9, 10.2217/NNM.10.9]
   Mukherjee S, 2007, MOL CELL BIOCHEM, V297, P31, DOI 10.1007/s11010-006-9319-z
   Nowacek A, 2009, NANOMEDICINE-UK, V4, P557, DOI [10.2217/nnm.09.38, 10.2217/NMM.09.38]
   Nowacek A, 2009, NANOMEDICINE-UK, V4, P541, DOI 10.2217/NNM.09.37
   Parhi P, 2011, ACTA BIOMATER, V7, P3656, DOI 10.1016/j.actbio.2011.06.015
   Parveen S, 2012, NANOMED-NANOTECHNOL, V8, P147, DOI 10.1016/j.nano.2011.05.016
   Petri B, 2007, J CONTROL RELEASE, V117, P51, DOI 10.1016/j,jconrel.2006.10.015
   Quezada C, 2011, REV MED CHILE, V139, P415, DOI [10.4067/S0034-98872011000400001, /S0034-98872011000400001]
   Sahoo SK, 2004, INT J CANCER, V112, P335, DOI 10.1002/ijc.20405
   Sahoo SK, 2003, DRUG DISCOV TODAY, V8, P1112, DOI 10.1016/S1359-6446(03)02903-9
   Sallam AS, 2002, EUR J PHARM BIOPHARM, V53, P343, DOI 10.1016/S0939-6411(02)00016-4
   Senft C, 2011, J NEURO-ONCOL, V101, P393, DOI 10.1007/s11060-010-0273-y
   Senft C, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-491
   Shao JF, 2011, ACTA BIOCH BIOPH SIN, V43, P267, DOI 10.1093/abbs/gmr011
   Tews DS, 2000, J NEURO-ONCOL, V50, P227, DOI 10.1023/A:1006491405010
   Tsai YM, 2011, INT J PHARMACEUT, V416, P331, DOI 10.1016/j.ijpharm.2011.06.030
   Van Meir EG, 2010, CA-CANCER J CLIN, V60, P166, DOI 10.3322/caac.20069
   Vandana M, 2010, BIOMATERIALS, V31, P9340, DOI 10.1016/j.biomaterials.2010.08.010
   Wagenknecht B, 1999, CELL PHYSIOL BIOCHEM, V9, P117, DOI 10.1159/000016308
   Weissenberger J, 2010, CLIN CANCER RES, V16, P5781, DOI 10.1158/1078-0432.CCR-10-0446
   Win KY, 2006, BIOMATERIALS, V27, P2285, DOI 10.1016/j.biomaterials.2005.11.008
   Zanotto-Filho A, 2011, J NUTR BIOCH
NR 65
TC 31
Z9 34
U1 5
U2 51
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1742-7061
EI 1878-7568
J9 ACTA BIOMATER
JI Acta Biomater.
PD JUL
PY 2012
VL 8
IS 7
BP 2670
EP 2687
DI 10.1016/j.actbio.2012.03.048
PG 18
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA 974NK
UT WOS:000306442400026
PM 22484149
DA 2018-12-27
ER

PT J
AU Zaman, K
   Khan, MM
   Ahmad, M
AF Zaman, Khalid
   Khan, Muhammad Mushtaq
   Ahmad, Mehboob
TI RETRACTED: The relationship between foreign direct investment and
   pro-poor growth policies in Pakistan: The new interface (Retracted
   article. See vol. 45, pg. 278, 2015)
SO ECONOMIC MODELLING
LA English
DT Article; Retracted Publication
DE Foreign direct investment; Consumer Price Index; Poverty; Exchange rate;
   Pro-poor investment index; Pakistan
ID INCOME INEQUALITY; POVERTY
AB The lack of asset accumulation may be one of the major reasons for poverty; consequently, the poor have not been able to sustain growth. Investment in the assets of the poor will play an essential role for formulating pro-poor growth policies. The aim of this study is to investigate the potential impact of FDI on the poor in Pakistan over the period 1985-2011. The regression model encompassing the impact of FDI on poverty reflects that if there is one percent increase in FDI is likely to reduce poverty by 0.47% at urban, 0.44% at rural and 0.46% at national levels respectively. The result concludes that although, there is a positive impact of FDI on poverty, this positive impact is not sufficient enough to conclude that investment is pro-poor in Pakistan, because, an intensity of income inequality is more than the FDI's poverty reduction at rural, urban and national levels. Pakistan's investment, poverty and inequality statistics were studied for the first time in terms of pro-poor growth scenario. Pro-poor investment index (PPII) and poverty equivalent investment rate (PEIR) reveal that investment is pro-poor in Pakistan from 1985-1986 to 2002-2005, however, the subsequent years from 2005 to 2011 demonstrated pro-rich investment scenario in Pakistan. If the investment still remains anti-poor in the subsequent years as reflected in the years 2005 to 2011, there is a likelihood that investment may not trickle down to the poor but instead to the non-poor in Pakistan. Thus checking vulnerability would offer wide option for the policy makers to settle the issue of the severity of poverty in the future. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Zaman, Khalid; Khan, Muhammad Mushtaq] COMSATS Inst Informat Technol, Dept Management Sci, Abbottabad, Pakistan.
   [Ahmad, Mehboob] Bahria Univ, Dept Management Sci, Islamabad, Pakistan.
RP Zaman, K (reprint author), COMSATS Inst Informat Technol, Dept Management Sci, Abbottabad, Pakistan.
EM khalidzaman@ciit.net.pk; khanmm@ciit.net.pk; mmehboobahmad@ciit.net.pk
CR Aaron C., 1998, CONTRIBUTION FDI POV
   Acosta P, 2008, WORLD DEV, V36, P89, DOI 10.1016/j.worlddev.2007.02.016
   Adelman Irma, 1973, EC GROWTH SOCIAL EQU
   Ali M., 2010, 25 ANN GEN M C PSDE
   Amjad R., 1997, Pakistan Development Review, V36, P39
   ANAND S, 1993, J DEV ECON, V41, P19, DOI 10.1016/0304-3878(93)90035-L
   Anwar Talat, 2006, CHANGES INEQUALITY C
   Aslam N., 1987, PAKISTAN DEV REV, V26, P787
   Bosworth BP, 1999, BROOKINGS PAP ECO AC, P143
   Carvalho S., 1996, IMPLEMENTING PROJECT
   Chenely H.B., 1966, AM ECON REV, V56, P179
   Chenery, 1975, PATTERNS DEV 1950 19
   Deininger K, 1996, WORLD BANK ECON REV, V10, P565, DOI 10.1093/wber/10.3.565
   Dollar D, 2002, J ECON GROWTH, V7, P195, DOI 10.1023/A:1020139631000
   ECLAC, 2004, FOR INV LAT AM CAR F
   Foster J., 2001, 453 INT DEV BANK
   GOP, 2011, EC SURV PAK 2010 11
   GOP, 2010, EC SURV PAK 2009 10
   Gujarati D. N, 2003, BASIC ECONOMETRICS
   Gwin C., 2002, IDAS PARTNERSHIP POV
   HIES, HOUS INT EC SURV
   Jalilian H., 2001, ASEAN EC B, V19, P231
   KAKWANI N, 1993, REV INCOME WEALTH, P121
   Kakwani N., 2004, PAKISTAN DEV REV, V42, P417
   Kakwani Nanak, 2000, ASIAN DEV REV, V18, P1
   Kappel R., 2004, MISSING LINKS UGANDA
   KAWAI H, 1994, DEV ECON, V32, P373, DOI 10.1111/j.1746-1049.1994.tb01046.x
   Khan A.H., 1999, EDRC REPORT SERIES
   Klasen S., 2003, P ABCDE EUR WASH D C
   Klein M., 2001, FOREIGN DIRECT INVES
   Knowles S., 2001, WIDER C GROWTH POV W
   KRUGMAN P, 1991, Q J ECON, V106, P651, DOI 10.2307/2937950
   Kuznets S, 1955, AM ECON REV, V45, P1
   Markusen JR, 1999, EUR ECON REV, V43, P335, DOI 10.1016/S0014-2921(98)00048-8
   MATSUYAMA K, 1991, Q J ECON, V106, P617, DOI 10.2307/2937949
   Nunnenkamp P., 2004, KIEL WORKING PAPER S
   Ravallion M, 2001, MEASURING PROPOOR GR
   Saboor A., 2004, THESIS U AGR FAISALA
   Shabbir T., 1992, PAKISTAN DEV REV, V31, P831
   Shahbaz M., 2008, INT RES J FINANCE EC, V21, P7
   Siddiqui R., 2002, REMITTANCES TRADE LI
   Siddiqui R., 2006, PAKISTAN I DEV EC WO
   Son H.H., 2006, PUBLIC FINANC REV, V34, P1
   SON HH, 2006, J ECON INEQUAL, V4, P181
   Son HH, 2008, WORLD DEV, V36, P1048, DOI 10.1016/j.worlddev.2007.10.002
   Tambunan T., 2005, FOR DIR INV POL CHAN, P1
   Tridico P., 2010, TRANSITION STUDY REV, V16, P979
   Tsai PL, 2007, WORLD DEV, V35, P1858, DOI 10.1016/j.worlddev.2006.11.013
   WDI, 2011, WORLD DEV IND
   Zaman K., 2011, J EC SOCIAL DEV, V13, P110
   Zaman K., 2012, S ASIAN J GLOBAL BUS, V1, P79
   Zaman K., 2009, INT J RURAL MANAGEME, V5, P217
   Zaman K., 2011, J YASAR U, V21, P3523
   Zaman K., 2010, INT RES J FINANCE EC, V3, P32
   Zaman K., 2010, INDIAN J EC 3, VXIC, P561
   Zaman K., 2010, J HUMANITIES SOCIAL, VXVIII, P109
   Zaman K., 2009, PAKISTAN J SOCIAL SC, V29, P211
   Zaman K., 2008, INT J RURAL MANAGEME, V4, P201
   Zaman K., 2012, INT J EC BUSINESS RE, V4, P485
   Zaman K, 2010, J ENVIRON PLANN MAN, V53, P977, DOI 10.1080/09640568.2010.495537
NR 60
TC 13
Z9 13
U1 1
U2 30
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0264-9993
EI 1873-6122
J9 ECON MODEL
JI Econ. Model.
PD JUL
PY 2012
VL 29
IS 4
BP 1220
EP 1227
DI 10.1016/j.econmod.2012.04.020
PG 8
WC Economics
SC Business & Economics
GA 972SJ
UT WOS:000306299900028
DA 2018-12-27
ER

PT J
AU Wei, YD
   Wang, X
   Zhang, SY
   Hou, L
   Wang, Y
   Xu, YW
   Sun, Q
   Zhao, HB
AF Wei, Yidong
   Wang, Xian
   Zhang, Shouyan
   Hou, Lei
   Wang, Yong
   Xu, Yawei
   Sun, Qi
   Zhao, Huaibing
TI RETRACTED: Transcatheter closure of perimembranous ventricular septal
   defects (VSD) with VSD occluder: early and mid-term results (Retracted
   article. See vol. 29, pg. 427, 2014)
SO HEART AND VESSELS
LA English
DT Article; Retracted Publication
DE Perimembranous ventricular septal defect; Transcatheter; Closure;
   Ventricular septal defect occluder
ID PATENT DUCTUS-ARTERIOSUS; PRELIMINARY EXPERIENCE; PERCUTANEOUS CLOSURE;
   DEVICE CLOSURE; FOLLOW-UP; COMPLICATIONS; IMMEDIATE; OCCLUSION;
   REGISTRY; CHILDREN
AB Results of perimembranous ventricular septal defects (pmVSD) transcatheter closure have been reported in the literature, mostly with the Amplatzer VSD device (muscular or eccentric) (AGA Medical Corp., Golden Valley, MN, USA). However, the data of percutaneous closure of pmVSD with VSD occluder (VSD-O) made in China are still limited. We sought to analyze the safety, efficacy, and follow-up results of percutaneous closure of pmVSD with VSD-O made in China. Seventy-eight patients underwent percutaneous closure of pmVSD at our institution between February 2005 and June 2007. A VSD device made in china (Huayishengjie Medical Corp., Beijing, China) was used in all subjects. The mean age at closure was 11 years (range 2.5-44 years). The attempt to place the device was successful in 74 patients (94.9%). The median device size used was 8 mm (range 5-16 mm). No deaths occurred. Total occlusion rate was 62.8% at completion of the procedure, rising to 87.2% at discharge and 99% during the follow-up. A total of eight early complications occurred (10.3%), but in all subjects these were transient. The median follow-up was 32 months. The most significant complication was complete atrioventricular block (cAVB) in the early phase (five subjects, 6.4%) and during the follow-up (one subject, 1.3%), and there was no need for pacemaker implantation in six subjects. Logistic regression analysis showed that the only variable significantly associated with the occurrence of this complication was age at the time of the procedure (p = 0.025; OR 0.22). All subjects experiencing this problem were < 5 years old. Percutaneous pmVSD closure used VSD-O made in China is associated with excellent success and closure rates, no mortality, and low morbidity. Nowadays, pmVSD percutaneous closure is a valuable alternative to surgery. Longer follow-up data and improvements in device characteristics are needed to reduce the risk of cAVB.
C1 [Wei, Yidong; Hou, Lei; Wang, Yong; Xu, Yawei] Tongji Univ, Dept Cardiol, Shanghai Peoples Hosp 10, Shanghai 200072, Peoples R China.
   [Wang, Xian; Zhang, Shouyan; Sun, Qi; Zhao, Huaibing] Beijing Army Gen Hosp, Dept Cardiol, Beijing 100700, Peoples R China.
RP Wei, YD (reprint author), Tongji Univ, Dept Cardiol, Shanghai Peoples Hosp 10, 301 Yanchang Rd, Shanghai 200072, Peoples R China.
EM weiyidong@yahoo.com
CR Arora Ramesh, 2003, J Interv Cardiol, V16, P83, DOI 10.1046/j.1540-8183.2003.08006.x
   Bass JL, 2003, CATHETER CARDIO INTE, V58, P238, DOI 10.1002/ccd.10406
   Butera G, 2006, AM HEART J, V151, P228, DOI 10.1016/j.ahj.2005.02.051
   Butera G, 2007, J AM COLL CARDIOL, V50, P1189, DOI 10.1016/j.jacc.2007.03.068
   Carminati M, 2005, AM J CARDIOL, V96, p52L, DOI 10.1016/j.amjcard.2005.09.068
   Chessa M, 2002, J AM COLL CARDIOL, V39, P1061, DOI 10.1016/S0735-1097(02)01711-4
   Fu YC, 2006, J AM COLL CARDIOL, V47, P319, DOI 10.1016/j.jacc.2005.09.028
   Hijazi ZM, 2003, CATHETER CARDIO INTE, V60, P107, DOI 10.1002/ccd.10567
   Hijazi ZM, 2002, CATHETER CARDIO INTE, V56, P508, DOI 10.1002/ccd.10292
   Holzer R, 2004, J AM COLL CARDIOL, V43, P1257, DOI 10.1016/j.jacc.2003.10.047
   Holzer R, 2006, CATHETER CARDIO INTE, V68, P620, DOI 10.1002/ccd.20659
   Huang TC, 2008, HEART VESSELS, V23, P187, DOI 10.1007/s00380-007-1028-3
   KIDD L, 1993, CIRCULATION, V87, P38
   Masura J, 2005, PEDIATR CARDIOL, V26, P216, DOI 10.1007/s00246-005-1003-7
   Pass RH, 2004, J AM COLL CARDIOL, V44, P513, DOI 10.1016/j.jacc.2004.03.074
   Pedra CAC, 2004, CATHETER CARDIO INTE, V61, P403, DOI 10.1002/ccd.10797
   Pinto RJ, 2006, CATHETER CARDIO INTE, V68, P145, DOI 10.1002/ccd.20813
   Thanopoulos BD, 2003, HEART, V89, P918, DOI 10.1136/heart.89.8.918
   Walsh MA, 2006, HEART, V92, P1295, DOI 10.1136/hrt.2005.084988
   Yip WCL, 2005, CATHETER CARDIO INTE, V66, P436, DOI 10.1002/ccd.20512
   Yu ML, 2009, HEART VESSELS, V24, P440, DOI 10.1007/s00380-009-1150-5
NR 21
TC 12
Z9 18
U1 2
U2 11
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0910-8327
EI 1615-2573
J9 HEART VESSELS
JI Heart Vessels
PD JUL
PY 2012
VL 27
IS 4
BP 398
EP 404
DI 10.1007/s00380-011-0153-1
PG 7
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 974IS
UT WOS:000306428000009
PM 21618026
DA 2018-12-27
ER

PT J
AU Wetherby, AE
   Mucha, NT
   Waterman, R
AF Wetherby, Anthony E.
   Mucha, Neil T.
   Waterman, Rory
TI RETRACTED: High Activity and Selectivity for Silane Dehydrocoupling by
   an Iridium Catalyst (Retracted article. See vol. 5, pg. 1736, 2015)
SO ACS CATALYSIS
LA English
DT Article; Retracted Publication
DE dehydrocoupling; iridium; pincer; silane; polysilane
ID MOLECULAR-WEIGHT POLYAMINOBORANES; TRANSITION-METAL-COMPLEXES; BOND
   METATHESIS MECHANISM; ELEMENT-ELEMENT BONDS; MAIN-GROUP ELEMENTS;
   WILKINSONS CATALYST; TERTIARY SILANES; SI-H; DEHYDROPOLYMERIZATION;
   DEHYDROGENATION
AB Iridium complexes bearing a bis(phosphinite) pincer ligand are,highly active for the dehydrocoupling of phenylsilane, comparable to other catalysts for this reaction. Interestingly, this catalysis produces primarily a single product, the decasilane ring cyclo-(PhSiH)(10) in what is unusually high selectivity for a single product in silane dehydrocoupling.
C1 [Wetherby, Anthony E.; Mucha, Neil T.; Waterman, Rory] Univ Vermont, Dept Chem, Burlington, VT 05405 USA.
RP Waterman, R (reprint author), Univ Vermont, Dept Chem, Burlington, VT 05405 USA.
EM rory.waterman@uvm.edu
FU U.S. National Science Foundation [CHE-0747612]
FX This work was supported by the U.S. National Science Foundation
   (CHE-0747612).
CR Braunstein P, 2000, CHEM REV, V100, P3541, DOI 10.1021/cr000444d
   BROWNWENSLEY KA, 1987, ORGANOMETALLICS, V6, P1590, DOI 10.1021/om00150a040
   CHANG LS, 1989, ORGANOMETALLICS, V8, P1885, DOI 10.1021/om00110a010
   Chauhan BPS, 1997, CHEM LETT, P785, DOI 10.1246/cl.1997.785
   Choi J, 2011, CHEM REV, V111, P1761, DOI 10.1021/cr1003503
   Clark TJ, 2006, CHEM-EUR J, V12, P8634, DOI 10.1002/chem.200600981
   Corey JY, 2011, CHEM REV, V111, P863, DOI 10.1021/cr900359c
   Corey JY, 1999, CHEM REV, V99, P175, DOI 10.1021/cr9701086
   Corey JY, 2004, ADV ORGANOMET CHEM, V51, P1, DOI 10.1016/S0065-3055(03)51001-2
   Denney MC, 2006, J AM CHEM SOC, V128, P12048, DOI 10.1021/ja062419g
   Dietrich BL, 2008, INORG CHEM, V47, P8583, DOI 10.1021/ic801161g
   Dioumaev VK, 1996, J ORGANOMET CHEM, V521, P133, DOI 10.1016/0022-328X(96)06357-7
   Dioumaev VK, 1999, ORGANOMETALLICS, V18, P2249, DOI 10.1021/om980816x
   Diversi P, 2000, J ORGANOMET CHEM, V593, P154, DOI 10.1016/S0022-328X(99)00469-6
   Fontaine FG, 2004, J AM CHEM SOC, V126, P8786, DOI 10.1021/ja048911m
   Fontaine FG, 2002, ORGANOMETALLICS, V21, P401, DOI 10.1021/om010757e
   Fontaine FG, 1998, CHEM COMMUN, P1253, DOI 10.1039/a802428f
   FRYZUK MD, 1994, INORG CHIM ACTA, V222, P345, DOI 10.1016/0020-1693(94)03927-5
   Gauvin F, 1998, ADV ORGANOMET CHEM, V42, P363, DOI 10.1016/S0065-3055(08)60546-8
   Gottker-Schnetmann I, 2004, ORGANOMETALLICS, V23, P1766, DOI 10.1021/om030670o
   Gottker-Schnetmann I, 2004, J AM CHEM SOC, V126, P1804, DOI 10.1021/ja0385235
   HARROD JF, 1991, POLYHEDRON, V10, P1239, DOI 10.1016/S0277-5387(00)86101-X
   Hill MS, 2010, STRUCT BOND, V136, P189, DOI 10.1007/978-3-642-05243-9_6
   Ihara E, 1998, J AM CHEM SOC, V120, P8277, DOI 10.1021/ja9817444
   IMORI T, 1994, POLYHEDRON, V13, P2231, DOI 10.1016/S0277-5387(00)88130-9
   Itazaki M, 2009, ANGEW CHEM INT EDIT, V48, P3313, DOI 10.1002/anie.200805112
   Jackson SM, 2011, EUR J INORG CHEM, P327, DOI 10.1002/ejic.201001165
   Jaska C. A., 2005, INORGANIC CHEM FOCUS, P53
   Jaska CA, 2004, PHOSPHORUS SULFUR, V179, P685, DOI 10.1080/10426500490426403
   Korkin SD, 2003, J ORGANOMET CHEM, V686, P313, DOI 10.1016/S0022-328X(03)00721-6
   Lambert JB, 2001, J PHYS ORG CHEM, V14, P370, DOI 10.1002/poc.377
   Lubben AT, 2008, ORGANOMETALLICS, V27, P3303, DOI 10.1021/om800164e
   MILLER RD, 1989, CHEM REV, V89, P1359, DOI 10.1021/cr00096a006
   OJIMA I, 1973, J ORGANOMET CHEM, V55, pC7, DOI 10.1016/S0022-328X(00)84018-8
   Park S, 2012, ACS CATAL, V2, P307, DOI 10.1021/cs200629t
   Roering AJ, 2010, ORGANOMETALLICS, V29, P2557, DOI 10.1021/om100216f
   Rosenberg L, 2003, J ORGANOMET CHEM, V685, P107, DOI 10.1016/S0022-328X(03)00712-5
   Rosenberg L, 2001, J AM CHEM SOC, V123, P5120, DOI 10.1021/ja015697i
   Smith EE, 2010, ORGANOMETALLICS, V29, P6527, DOI 10.1021/om100887v
   Stanier C., 2001, CHEM SCI SOC SUMM CS
   Staubitz A, 2008, ANGEW CHEM INT EDIT, V47, P6212, DOI 10.1002/anie.200801197
   Staubitz A, 2010, J AM CHEM SOC, V132, P13332, DOI 10.1021/ja104607y
   Tilley T. D., 1990, COMMENTS INORG CHEM, V10, P37
   TILLEY TD, 1993, ACCOUNTS CHEM RES, V26, P22, DOI 10.1021/ar00025a004
   Waterman R, 2008, CURR ORG CHEM, V12, P1322, DOI 10.2174/138527208785909592
   Waterman R, 2009, DALTON T, P18, DOI 10.1039/b813332h
   WOO HG, 1992, J AM CHEM SOC, V114, P7047, DOI 10.1021/ja00044a015
NR 47
TC 8
Z9 8
U1 6
U2 54
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 2155-5435
J9 ACS CATAL
JI ACS Catal.
PD JUL
PY 2012
VL 2
IS 7
BP 1404
EP 1407
DI 10.1021/cs300186v
PG 4
WC Chemistry, Physical
SC Chemistry
GA 972RP
UT WOS:000306297900013
DA 2018-12-27
ER

PT J
AU Waimann, CA
   Dal Pra, FM
   Marengo, MF
   Schneeberger, EE
   Gagliardi, S
   Cocco, JAM
   Sanchez, M
   Garone, A
   del Moral, REC
   Rillo, OL
   Salcedo, M
   Rosa, JE
   Ceballos, F
   Soriano, ER
   Citera, G
AF Waimann, Christian A.
   Dal Pra, Fernando M.
   Marengo, Maria F.
   Schneeberger, Emilce E.
   Gagliardi, Susana
   Maldonado Cocco, Jose A.
   Sanchez, Monica
   Garone, A.
   Chaparro del Moral, Rafael E.
   Rillo, Oscar L.
   Salcedo, Mariana
   Rosa, Javier E.
   Ceballos, F.
   Soriano, Enrique R.
   Citera, Gustavo
TI RETRACTED: Quality of life of patients with rheumatoid arthritis in
   Argentina: reliability, validity, and sensitivity to change of a Spanish
   version of the Rheumatoid Arthritis Quality of Life
   questionnaire(Retracted article. See vol. 32, pg. 1833, 2013)
SO CLINICAL RHEUMATOLOGY
LA English
DT Article; Retracted Publication
DE Argentina; Quality of life; Rheumatoid arthritis; Self-questionnaire;
   Spanish version; Validation
ID INDIRECT UTILITY MEASURES; CONSTRUCT-VALIDITY; RAQOL; ADAPTATION;
   VALIDATION; INSTRUMENTS; SCALE; EQ-5D; HAQ; RESPONSIVENESS
AB The Rheumatoid Arthritis Quality of Life (RAQoL) questionnaire is the first needs-based instrument specifically designed to measure quality of life (QoL) of patients with rheumatoid arthritis (RA). The aims of our study were to develop an Argentinean version of the RAQoL and to determine its reproducibility, validity, and sensitivity to change in patients with RA. Translation process was performed according to internationally accepted methodology. Internal consistency and test-retest reliability were calculated. Criterion and construct validity were assessed by comparing the RAQoL with parameters of disease activity, the Health Assessment Questionnaire (HAQ), and the Medical Outcomes Study 36-item health survey (SF-36) questionnaire. Sensitivity to change was measured at 6-12 months using standardized response mean (SRM). The minimal important change was defined as a change of 1 or 1.96 times the standard error of measurement. A total of 97 patients with RA were included. Cronbach's alpha was 0.93, and test-retest reliability was 0.95. The RAQoL showed moderate to strong correlation with parameters of disease activity, the HAQ, and the SF-36. Functional status was the main determinant of patients' level of QoL. The SRM of the RAQoL was 0.24. Agreement between 20 % improvement in RAQoL and ACR20 response was moderate. Minimal important change was 2.2 (1 SEM) or 4.3 (1.96 SEM). The Argentinean version of the RAQoL is the first Spanish translation of this questionnaire. Our findings show it to be valid, reliable, and sensitive to changes in RA clinical status.
C1 [Citera, Gustavo] IREP, Chief Sect Rheumatol, RA-1428 Buenos Aires, DF, Argentina.
   [Rosa, Javier E.; Ceballos, F.; Soriano, Enrique R.] Hosp Italiano Buenos Aires, Buenos Aires, DF, Argentina.
   [Garone, A.; Chaparro del Moral, Rafael E.; Rillo, Oscar L.; Salcedo, Mariana] Hosp Gen Agudos Dr E Tornu, Buenos Aires, DF, Argentina.
   [Waimann, Christian A.; Dal Pra, Fernando M.; Marengo, Maria F.; Schneeberger, Emilce E.; Gagliardi, Susana; Maldonado Cocco, Jose A.; Sanchez, Monica; Salcedo, Mariana; Citera, Gustavo] Inst Rehabil Psicofis IREP Buenos Aires, Buenos Aires, DF, Argentina.
RP Citera, G (reprint author), IREP, Chief Sect Rheumatol, Echeverria 955, RA-1428 Buenos Aires, DF, Argentina.
EM gustavocitera@gmail.com
OI Soriano, Enrique/0000-0003-3143-1084
FU Wyeth-Pfizer, Argentina
FX This study was supported by an unrestricted grant from Wyeth-Pfizer,
   Argentina.
CR Augustovski FA, 2009, VALUE HEALTH, V12, P587, DOI 10.1111/j.1524-4733.2008.00468.x
   ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302
   Augustovski FA, 2008, J CLIN EPIDEMIOL, V61, P1279, DOI 10.1016/j.jclinepi.2008.05.004
   Bejia I, 2006, CLIN RHEUMATOL
   BERGNER M, 1976, MED CARE, V14, P57, DOI 10.1097/00005650-197601000-00006
   Citera G, 2004, JCR-J CLIN RHEUMATOL, V10, P110, DOI 10.1097/01.rhu.0000128732.58292.cd
   Cohen J, 1988, STAT POWER ANAL BEHA
   Cooper JK, 2001, INT J QUAL HEALTH C, V13, P9, DOI 10.1093/intqhc/13.1.9
   Cox SR, 2007, RHEUMATOL INT, V27, P661, DOI 10.1007/s00296-006-0287-0
   DeJong Z, 1997, BRIT J RHEUMATOL, V36, P878
   Eberhardt K, 2002, SCAND J RHEUMATOL, V31, P6, DOI 10.1080/030097402317255291
   Fransen J, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2745
   FUCHS HA, 1989, ARTHRITIS RHEUM, V32, P531, DOI 10.1002/anr.1780320504
   Hedin PJ, 2006, SCAND J RHEUMATOL, V35, P117, DOI 10.1080/03009740500311770
   Houssien DA, 1997, BRIT J RHEUMATOL, V36, P69
   Kaplan RM, 2007, AM J MANAG CARE, V13, pS252
   Kutlay S, 2003, RHEUMATOL INT, V23, P21, DOI 10.1007/s00296-002-0247-2
   LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310
   Liang MH, 2000, MED CARE, V38, P84, DOI 10.1097/00005650-200009002-00013
   Linde L, 2008, J RHEUMATOL, V35, P1528
   Marra CA, 2005, SOC SCI MED, V60, P1571, DOI 10.1016/j.socscimed.2004.08.034
   Marra CA, 2005, QUAL LIFE RES, V14, P1333, DOI 10.1007/s11136-004-6012-0
   MCHORNEY CA, 1995, QUAL LIFE RES, V4, P293, DOI 10.1007/BF01593882
   MCKENNA SP, 1992, HEALTH POLICY, V22, P321, DOI 10.1016/0168-8510(92)90005-V
   Neville C, 2001, J RHEUMATOL, V28, P1505
   Nunnally JC, 1994, PSYCHOMETRIC THEORY
   Pacheco-Tena C, 2011, REUMATOL CLIN, V7, P98, DOI 10.1016/j.reuma.2010.02.002
   Pincus T, 2000, J RHEUMATOL, V27, P2727
   Rasch G, 1993, PROBABILISTIC MODELS
   Streiner D.L, 2008, HLTH MEASUREMENT SCA
   Swaine-Verdier A, 2004, VALUE HEALTH, V7, P27
   Tammaru M, 2006, RHEUMATOL INT, V26, P655, DOI 10.1007/s00296-005-0038-7
   Tammaru Marika, 2004, Health Qual Life Outcomes, V2, P69, DOI 10.1186/1477-7525-2-69
   Thorsen H, 2001, SCAND J RHEUMATOL, V30, P103
   Tijhuis GJ, 2001, RHEUMATOLOGY, V40, P1112, DOI 10.1093/rheumatology/40.10.1112
   van der Heijde D, 2000, J RHEUMATOL, V27, P261
   Wells G, 1999, J RHEUMATOL, V26, P217
   Whalley D, 1997, BRIT J RHEUMATOL, V36, P884
   WHALLEY D, 2000, QUAL LIFE RES, V9, P342
   Wolfe F, 1994, RHEUMATOID ARTHRITIS
   Wyrwich KW, 1999, J CLIN EPIDEMIOL, V52, P861, DOI 10.1016/S0895-4356(99)00071-2
   Y Garip, 2010, RHEUMATOL INT
NR 42
TC 5
Z9 5
U1 2
U2 10
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0770-3198
EI 1434-9949
J9 CLIN RHEUMATOL
JI Clin. Rheumatol.
PD JUL
PY 2012
VL 31
IS 7
BP 1065
EP 1071
DI 10.1007/s10067-012-1976-6
PG 7
WC Rheumatology
SC Rheumatology
GA 969NR
UT WOS:000306062900007
PM 22476205
DA 2018-12-27
ER

PT J
AU Yonglitthipagon, P
   Pairojkul, C
   Bhudhisawasdi, V
   Mulvenna, J
   Loukas, A
   Sripa, B
AF Yonglitthipagon, Ponlapat
   Pairojkul, Chawalit
   Bhudhisawasdi, Vajarabhongsa
   Mulvenna, Jason
   Loukas, Alex
   Sripa, Banchob
TI RETRACTED: Proteomics-based identification of alpha-enolase as a
   potential prognostic marker in cholangiocarcinoma (Retracted article.
   See vol. 49, pg. 196, 2016)
SO CLINICAL BIOCHEMISTRY
LA English
DT Article; Retracted Publication
DE Cholangiocarcinoma; Proteomics; Prognostic marker; alpha-Enolase; ENO1
ID HEPATOCELLULAR-CARCINOMA; OPISTHORCHIS-VIVERRINI; LUNG-CANCER;
   CELL-LINES; EXPRESSION; THAILAND; TUMOR; METASTASIS; GLYCOLYSIS;
   PROTEINS
AB Objectives: To investigate the association of expression status of alpha-enolase (ENO1) and clinicopathological outcomes of CCA patients.
   Design and methods: Two-dimensional gel electrophoresis (2-DE) and mass spectrometry (MS) were used to compare differential expressed protein profiles of four human CCA cell lines and H69, a non-malignant biliary cell line, as a control. Immunohistochemical analysis was carried out in tissue-microarray of human CCA tissues (n=301).
   Results: We identified ENO1 in all CCA cell lines but not H69 by proteomics based. About 75% of patients with CCA showed over-expression of ENO1 in hyperplastic bile duct and the tumors compared with that in tumor-adjacent normal tissue counterparts. Moreover, over-expression of ENO1 is significantly associated with poor prognosis and tumor invasion of CCA patients.
   Conclusions: ENO1 may serve as a prognostic marker to monitor the disease progression of these patients. (C) 2012 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.
C1 [Yonglitthipagon, Ponlapat; Pairojkul, Chawalit; Sripa, Banchob] Khon Kaen Univ, Dept Pathol, Fac Med, Khon Kaen 40002, Thailand.
   [Bhudhisawasdi, Vajarabhongsa] Khon Kaen Univ, Fac Med, Dept Surg, Khon Kaen 40002, Thailand.
   [Pairojkul, Chawalit; Bhudhisawasdi, Vajarabhongsa; Sripa, Banchob] Khon Kaen Univ, Fac Med, Liver Fluke & Cholangiocarcinoma Res Ctr, Khon Kaen 40002, Thailand.
   [Yonglitthipagon, Ponlapat; Mulvenna, Jason; Loukas, Alex] James Cook Univ, Queensland Trop Hlth Alliance, Cairns, Qld 4878, Australia.
RP Sripa, B (reprint author), Khon Kaen Univ, Dept Pathol, Fac Med, Khon Kaen 40002, Thailand.
EM ponlagon@gmail.com
RI Mulvenna, Jason/H-7110-2014; Loukas, Alex/B-7355-2014
OI Mulvenna, Jason/0000-0003-3521-8061; Loukas, Alex/0000-0002-0896-8441
FU National Cancer Institute [R01CA155297];  [PHD/0194/2548]
FX We would like to thank Arpa Surapaitoon, Jenjira Somprakhon and Manop
   Sripa at Tropical Disease Research, Khon Kaen University for technical
   assistance, Suwit Balthaisong and Jitsakul Phuyao at Department of
   Pathology, Faculty of Medicine for their help in the histological
   preparation of the human CCA tissues. This research was supported by
   award number R01CA155297 from the National Cancer Institute. The content
   is solely the responsibility of the authors and does not necessarily
   represent the official views of the NCI or the NIH. Ponlapat
   Yonglitthipagon is a Royal Golden Jubilee PhD scholar (grant
   PHD/0194/2548) through the laboratory of Dr. Banchob Sripa.
CR Altenberg B, 2004, GENOMICS, V84, P1014, DOI 10.1016/j.ygeno.2004.08.010
   Bartholow TL, 2011, BMC CLIN PATHOL, V11, DOI 10.1186/1472-6890-11-1
   BISHOP JG, 1990, NUCLEIC ACIDS RES, V18, P191, DOI 10.1093/nar/18.1.191
   Blechacz B, 2008, HEPATOLOGY, V48, P308, DOI 10.1002/hep.22310
   Bouvard V, 2009, LANCET ONCOL, V10, P321, DOI 10.1016/S1470-2045(09)70096-8
   Chang GC, 2006, CLIN CANCER RES, V12, P5746, DOI 10.1158/1078-0432.CCR-06-0324
   Clary BM, 2007, J GASTROINTEST SURG, V11, P1496
   David CJ, 2010, NATURE, V463, P364, DOI 10.1038/nature08697
   Desmetz C, 2008, J PROTEOME RES, V7, P3830, DOI 10.1021/pr800130d
   Fedor HL, 2005, METH MOLEC MED, V103, P89
   GRUBMAN SA, 1994, AM J PHYSIOL, V266, pG1060
   Hamaguchi T, 2008, INT J ONCOL, V33, P725, DOI 10.3892/ijo_00000058
   HAY MM, 1988, AM TYPE CULTURE COLL
   Huang HY, 2010, ANN SURG ONCOL, V17, P3212, DOI 10.1245/s10434-010-1185-y
   Jiang BH, 1997, CANCER RES, V57, P5328
   Jolodar A, 2003, BBA-GENE STRUCT EXPR, V1627, P111, DOI 10.1016/S0167-4781(03)00083-6
   Jongsuksuntigul P, 2003, ACTA TROP, V88, P229, DOI 10.1016/j.actatropica.2003.01.002
   Nathan H, 2007, J GASTROINTEST SURG, V11, P1488, DOI 10.1007/s11605-007-0282-0
   OLIVA D, 1989, GENE, V79, P355, DOI 10.1016/0378-1119(89)90217-5
   Olnes MJ, 2004, ONCOLOGY-BASEL, V66, P167, DOI 10.1159/000077991
   Pak JH, 2009, J CELL BIOCHEM, V108, P1376, DOI 10.1002/jcb.22368
   Sousa LP, 2005, BIOCHEM BIOPH RES CO, V337, P1065, DOI 10.1016/j.bbrc.2005.09.154
   Sousa LP, 2005, FRONT BIOSCI, V10, P2534, DOI 10.2741/1718
   Sriamporn S, 2004, TROP MED INT HEALTH, V9, P588, DOI 10.1111/j.1365-3156.2004.01234.x
   Sriamporn Supannee, 2005, Asian Pac J Cancer Prev, V6, P295
   Sripa B, 2008, CURR OPIN GASTROEN, V24, P349, DOI 10.1097/MOG.0b013e3282fbf9b3
   Sripa B, 2007, PLOS MED, V4, P1148, DOI 10.1371/journal.pmed.0040201
   Sripa B, 2005, WORLD J GASTROENTERO, V11, P3392, DOI 10.3748/wjg.v11.i22.3392
   Srisomsap C, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/437143
   Tsai ST, 2010, EUR J CANCER, V46, P1712, DOI 10.1016/j.ejca.2010.03.018
   vanDiest PJ, 1997, J CLIN PATHOL, V50, P801, DOI 10.1136/jcp.50.10.801
   Wu WG, 2002, CLIN EXP METASTAS, V19, P319, DOI 10.1023/A:1015515119300
   Yonglitthipagon P, 2010, INT J PARASITOL, V40, P1203, DOI 10.1016/j.ijpara.2010.05.002
   ZHANG Ying, 2010, Zhongguo Fei Ai Za Zhi, V13, P1089, DOI 10.3779/j.issn.1009-3419.2010.12.02
   Zhong L, 2003, CANCER DETECT PREV, V27, P285, DOI 10.1016/S0361-090X(03)00097-7
   Zhuang PY, 2008, CANCER, V112, P2740, DOI 10.1002/cncr.23488
NR 36
TC 19
Z9 21
U1 2
U2 18
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-9120
EI 1873-2933
J9 CLIN BIOCHEM
JI Clin. Biochem.
PD JUL
PY 2012
VL 45
IS 10-11
BP 827
EP 834
DI 10.1016/j.clinbiochem.2012.04.004
PG 8
WC Medical Laboratory Technology
SC Medical Laboratory Technology
GA 967PD
UT WOS:000305919400023
PM 22552009
OA Green Accepted
DA 2018-12-27
ER

PT J
AU Sophocleous, M
AF Sophocleous, Marios
TI RETRACTED: On Understanding and Predicting Groundwater Response Time
   (Retracted article. See vol. 52, pg. 322, 2014)
SO GROUND WATER
LA English
DT Article; Retracted Publication
ID WATER-QUALITY RESPONSE; LAND-USE CHANGE; TRANSIT-TIME; DIRECT
   SIMULATION; RESERVOIR THEORY; CATCHMENT-SCALE; AGE; MANAGEMENT;
   DISTRIBUTIONS; RECHARGE
AB An aquifer system, when perturbed, has a tendency to evolve to a new equilibrium, a process that can take from just a few seconds to possibly millions of years. The time scale on which a system adjusts to a new equilibrium is often referred to as response time or lag time. Because groundwater response time affects the physical and economic viability of various management options in a basin, natural resource managers are increasingly interested in incorporating it into policy. However, the processes of how groundwater responds to land-use change are not well understood, making it difficult to predict the timing of groundwater response to such change. The difficulty in estimating groundwater response time is further compounded because the data needed to quantify this process are not usually readily available. This article synthesizes disparate pieces of information on aquifer response times into a relatively brief but hopefully comprehensive review that the community of water professionals can use to better assess the impact of aquifer response time in future groundwater management investigations. A brief exposition on dimensional/scaling analysis is presented first, followed by an overview of aquifer response time for simplified aquifer systems. The aquifer response time is considered first from a water-quantity viewpoint and later expanded to incorporate groundwater age and water-quality aspects. Monitoring programs today, as well as water policies and regulations, should address this issue of aquifer response time so that more realistic management expectations can be reached.
C1 Univ Kansas, Kansas Geol Survey, Lawrence, KS 66047 USA.
RP Sophocleous, M (reprint author), Univ Kansas, Kansas Geol Survey, 1930 Constant Ave, Lawrence, KS 66047 USA.
EM marios@kgs.ku.edu
CR ALLISON GB, 1990, J HYDROL, V119, P1, DOI 10.1016/0022-1694(90)90030-2
   Appelo C. A. J., 2005, GEOCHEMISTRY GROUNDW, P672
   Bethke CM, 2002, GEOLOGY, V30, P385, DOI 10.1130/0091-7613(2002)030<0386:POGAC>2.0.CO;2
   Bethke CM, 2008, ANNU REV EARTH PL SC, V36, P121, DOI 10.1146/annurev.earth.36.031207.124210
   Beverly C, 2009, 18TH WORLD IMACS CONGRESS AND MODSIM09 INTERNATIONAL CONGRESS ON MODELLING AND SIMULATION, P1830
   Bredehoeft J, 2009, GROUND WATER, V47, P506, DOI 10.1111/j.1745-6584.2008.00538.x
   Bredehoeft JD, 2011, GROUND WATER, V49, P808, DOI 10.1111/j.1745-6584.2011.00799.x
   Bredehoeft J, 2011, GROUND WATER, V49, P468, DOI 10.1111/j.1745-6584.2010.00762.x
   Castro MC, 2005, GROUND WATER, V43, P368, DOI 10.1111/j.1745-6584.2005.0046.x
   Chesnaux R, 2005, GROUND WATER, V43, P511, DOI 10.1111/j.1745-6584.2005.0056.x
   Chesnaux R, 2012, WATER ENVIRON J, V26, P30, DOI 10.1111/j.1747-6593.2011.00260.x
   Close M., 2010, R10113 ENV CANT REG, P46
   Cook P. G., 2003, Water resources perspectives: evaluation, management and policy, P319
   Cook P. G., 2001, 4501 CSIRO LAND WAT, VTechnical Report 45/01, P133
   Cook P. G., 2002, AD SA SCI ENV WAT RE, P49
   Cook P. G., 2004, 2504 CSIRO LAND WAT
   COOK PG, 1989, J HYDROL, V111, P195, DOI 10.1016/0022-1694(89)90260-6
   Cook PG, 2000, ENV TRACERS SUBSURFA, P1, DOI DOI 10.1007/978-1-4615-4557-6_1
   Cornaton F, 2006, ADV WATER RESOUR, V29, P1267, DOI 10.1016/j.advwatres.2005.10.009
   Crank J., 1975, MATH DIFFUSION, P414, DOI DOI 10.1016/0306-4549(77)90072-X
   Dawes W. R., 2004, 3604 CSIRO LAND WAT, P78
   Dawes WR, 2004, MATH COMPUT SIMULAT, V64, P3, DOI 10.1016/S0378-4754(03)00116-2
   Erskine AD, 1997, J HYDROL, V202, P373, DOI 10.1016/S0022-1694(97)00058-9
   Etcheverry D, 2000, HYDROGEOL J, V8, P200
   Fenton O, 2011, ENVIRON SCI POLICY, V14, P419, DOI 10.1016/j.envsci.2011.03.006
   GELHAR L W, 1974, Ground Water, V12, P399, DOI 10.1111/j.1745-6584.1974.tb03050.x
   Gilfedder M., 2003, 1903 SCIRO LAND WAT, P17
   Gilfedder M, 2009, ENVIRON MODELL SOFTW, V24, P262, DOI 10.1016/j.envsoft.2008.06.009
   Ginn TR, 2009, TRANSPORT POROUS MED, V79, P117, DOI 10.1007/s11242-009-9406-1
   Glover R. E., 1954, AM GEOPHYS UNION T, V35, P468
   Goode DJ, 1996, WATER RESOUR RES, V32, P289, DOI 10.1029/95WR03401
   Hickson RI, 2009, INT J HEAT MASS TRAN, V52, P5776, DOI 10.1016/j.ijheatmasstransfer.2009.08.013
   HOOKEY GR, 1987, J HYDROL, V94, P181, DOI 10.1016/0022-1694(87)90039-4
   Hvorslev M. J., B US ARMY
   Jolly I., 2002, Natural Resource Management, V5, P16
   JOLLY ID, 1989, J HYDROL, V111, P391, DOI 10.1016/0022-1694(89)90270-9
   KAUFFMAN LJ, 2001, 014117 US GEOL SURV
   Kazemi GA., 2006, GROUNDWATER AGE, P325
   Knight JH, 2005, J HYDROL, V303, P79, DOI 10.1016/j.jhydrol.2004.08.018
   Kooi H, 2003, NETH J GEOSCI, V82, P31, DOI 10.1017/S0016774600022770
   Kraijenhoff van de Leur D. A, 1958, INGENIEUR, V19, P87
   Landman K. A., 2000, J APPL MATH DECIS SC, V4, P125, DOI DOI 10.1155/S1173912600000092
   Lindsey B. D., 2003, 034035 US GEOL SURV, P201
   Manga M, 1999, J HYDROL, V219, P56, DOI 10.1016/S0022-1694(99)00044-X
   Meals DW, 2010, J ENVIRON QUAL, V39, P85, DOI 10.2134/jeq2009.0108
   Meals DW, 2001, WATER SCI TECHNOL, V43, P175
   Molenat J, 2002, HYDROL PROCESS, V16, P479, DOI 10.1002/hyp.328
   Monsen NE, 2002, LIMNOL OCEANOGR, V47, P1545, DOI 10.4319/lo.2002.47.5.1545
   Newbold J. D., 2008, RIPARIAN ECOSYSTEMS, P1
   Nixon SW, 1996, BIOGEOCHEMISTRY, V35, P141, DOI 10.1007/BF02179826
   Owens LB, 2008, J SOIL WATER CONSERV, V63, P292, DOI 10.2489/jswc.63.5.292
   OWENS LB, 1992, J ENVIRON QUAL, V21, P406, DOI 10.2134/jeq1992.00472425002100030018x
   POLLOCK DW, 1994, 94464 US GEOL SURV O
   Rancic A., 2009, CLIMATIC INFLUENCE S, P101
   Rao P.S.C., 1985, P SOIL CROP SCI SOC, V44, P1
   Rassam D., 2004, 3504 CSIRO LAND WAT
   Schwartz FW, 2010, GROUND WATER, V48, P366, DOI 10.1111/j.1745-6584.2009.00655.x
   Scientific and Technical Advisory Committee Chesapeake Bay Program, 2005, STAC PUBL
   Sophocleous M, 2005, HYDROGEOL J, V13, P351, DOI 10.1007/s10040-004-0385-6
   Therrien R., 2010, HYDROGEOSPH IN PRESS
   Tomer MD, 2003, J ENVIRON QUAL, V32, P2158, DOI 10.2134/jeq2003.2158
   Van Dijk A. I. J. M., 2004, CLW03 CSIRO LAND WAT, P63
   Varni M, 1998, WATER RESOUR RES, V34, P3271, DOI 10.1029/98WR02536
   Vogel J. C., 1967, VIENN S IS HYDR P IN, P355
   Walker G. R., 2005, 1405 CSIRO LAND WAT, P21
   Walker G. R., 2007, 1307 CSIRO LAND WAT, P67
   Walton WC, 2011, GROUND WATER, V49, P126, DOI 10.1111/j.1745-6584.2010.00770.x
   Weissmann G. S., 2002, WATER RESOUR RES, V38, P16
NR 68
TC 21
Z9 21
U1 2
U2 30
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0017-467X
EI 1745-6584
J9 GROUND WATER
JI Ground Water
PD JUL-AUG
PY 2012
VL 50
IS 4
BP 528
EP 540
DI 10.1111/j.1745-6584.2011.00876.x
PG 13
WC Geosciences, Multidisciplinary; Water Resources
SC Geology; Water Resources
GA 967KQ
UT WOS:000305906900009
PM 22023718
DA 2018-12-27
ER

PT J
AU Chen, J
   Xi, B
   Zhao, YR
   Yu, Y
   Zhang, J
   Wang, CY
AF Chen, Jie
   Xi, Bo
   Zhao, Yueran
   Yu, Yang
   Zhang, Jie
   Wang, Chunyu
TI RETRACTED: High-mobility group protein B1 (HMGB1) is a novel biomarker
   for human ovarian cancer (Retracted article. See vol. 138, pg. 764,
   2015)
SO GYNECOLOGIC ONCOLOGY
LA English
DT Article; Retracted Publication
DE HMGB1; Ovarian cancer; Proliferation; Migration; Invasion
ID GLYCATION END-PRODUCTS; CELL LUNG-CANCER; GROUP BOX 1; GASTRIC-CANCER;
   EXPRESSION; RAGE; PROGRESSION; RECEPTOR; GROWTH; INFLAMMATION
AB Background. High mobility group box I (HMGB1), a nuclear and extracellular protein, is implicated in some physiologic and pathologic conditions. In this study, we investigated the expression and function of HMGB1 in ovarian cancer.
   Methods. cDNA microarray analysis was performed to compare gene expression profiles of the highly invasive and the low invasive subclones derived from the SKOV3 human ovarian cancer cell line. Immunohistochemistry (IHC) staining was performed to investigate HMGB1 expression in a total of 100 ovarian tissue specimens. In functional assays, effects of HMGB1 knockdown on the biological behavior of ovarian cancer cells were investigated.
   Results. HMGB1 was overexpressed in the highly invasive subclone compared with the low invasive subclone. High HMGB1 expression was associated with poor clinicopathologic features. Knockdown of HMGB1 expression significantly suppressed ovarian cancer cell proliferation accompanied by decreased cyclin D1 and PCNA expression, and inhibited cell migration and invasion accompanied by decreased MMP2 and MMP9 activities.
   Conclusion. HMGB1 is a newly identified gene overexpressed in ovarian cancer and associated with poor clinicopathologic features. HMGB1 may serve as a new biomarker and a therapeutic target for ovarian cancer in the future. (c) 2012 Elsevier Inc. All rights reserved.
C1 [Zhao, Yueran; Zhang, Jie] Shandong Univ, Shandong Prov Hosp, Cent Lab, Jinan 250021, Peoples R China.
   [Chen, Jie; Xi, Bo] Shandong Univ, Sch Publ Hlth, Dept Maternal & Child Hlth Care, Jinan 250012, Peoples R China.
   [Yu, Yang] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA.
   [Wang, Chunyu] Univ Houston, Ctr Nucl Receptors & Cell Signaling, Houston, TX 77204 USA.
RP Zhang, J (reprint author), Shandong Univ, Shandong Prov Hosp, Cent Lab, Jinan 250021, Peoples R China.
EM zhangjie19630711@163.com; chunyuwang2000@gmail.com
FU Department of Science and Technology of Shandong Province [2007BS03025]
FX This study was supported by a grant-in-aid for scientific research
   (2007BS03025) from the Department of Science and Technology of Shandong
   Province.
CR Akaike H, 2007, ANTICANCER RES, V27, P449
   ALBINI A, 1987, CANCER RES, V47, P3239
   Bao GQ, 2010, WORLD J SURG ONCOL, V8, DOI 10.1186/1477-7819-8-52
   Bassi R, 2008, J NEURO-ONCOL, V87, P23, DOI 10.1007/s11060-007-9488-y
   Bast RC, 2009, NAT REV CANCER, V9, P415, DOI 10.1038/nrc2644
   BERNUES J, 1986, BIOCHIM BIOPHYS ACTA, V866, P242, DOI 10.1016/0167-4781(86)90049-7
   Brezniceanu ML, 2003, FASEB J, V17, P1295, DOI 10.1096/fj.02-0621fje
   Brun JL, 2000, GYNECOL ONCOL, V78, P21, DOI 10.1006/gyno.2000.5805
   Campana L, 2008, CURR OPIN IMMUNOL, V20, P518, DOI 10.1016/j.coi.2008.04.012
   Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543
   Chen J, 2009, J CANCER RES CLIN, V135, P909, DOI 10.1007/s00432-008-0526-8
   Cho KR, 2009, ANNU REV PATHOL-MECH, V4, P287, DOI 10.1146/annurev.pathol.4.110807.092246
   Chung HW, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-38
   Curtin JF, 2009, PLOS MED, V6, P83, DOI 10.1371/journal.pmed.1000010
   Dumitriu IE, 2005, J IMMUNOL, V174, P7506, DOI 10.4049/jimmunol.174.12.7506
   Ellerman JE, 2007, CLIN CANCER RES, V13, P2836, DOI 10.1158/1078-0432.CCR-06-1953
   Evankovich J, 2010, J BIOL CHEM, V285, P39888, DOI 10.1074/jbc.M110.128348
   GE H, 1994, J BIOL CHEM, V269, P17136
   Huang WC, 2010, CYTOKINE, V51, P119, DOI 10.1016/j.cyto.2010.02.021
   Ishiguro H, 2005, PROSTATE, V64, P92, DOI 10.1002/pros.20219
   Jemal A, 2010, CA-CANCER J CLIN, V60, P277, DOI [10.1002/caac.20073, 10.3322/caac.20073]
   Jiao Y, 2007, ACTA PHARMACOL SIN, V28, P1957, DOI 10.1111/j.1745-7254.2007.00669.x
   Krynetskaia N, 2008, MOL PHARMACOL, V73, P260
   Leclerc E, 2009, REV NEUROSCIENCE, V20, P95
   Liu PL, 2010, AM J RESP CELL MOL, V43, P530, DOI 10.1165/rcmb.2009-0269OC
   Lopez-Otin C, 2007, NAT REV CANCER, V7, P800, DOI 10.1038/nrc2228
   Ostberg T, 2010, ARTHRITIS RHEUM-US, V62, P2963, DOI 10.1002/art.27590
   Park S, 2011, FRONT BIOSCI-LANDMRK, V16, P486, DOI 10.2741/3700
   Shang GH, 2009, RESP MED, V103, P1949, DOI 10.1016/j.rmed.2009.05.019
   Shen XK, 2009, ONCOL REP, V22, P535, DOI 10.3892/or_00000468
   Sims GP, 2010, ANNU REV IMMUNOL, V28, P367, DOI 10.1146/annurev.immunol.021908.132603
   Song B, 2012, CELL BIOCHEM FUNCT, V30, P11, DOI 10.1002/cbf.1811
   Tafani M, 2011, CARCINOGENESIS, V32, P1167, DOI 10.1093/carcin/bgr101
   Taguchi A, 2000, NATURE, V405, P354
   Tang DL, 2008, CRIT CARE MED, V36, P291, DOI 10.1097/01.CCM.0000295316.86942.CE
   Tang DL, 2010, BBA-GENE REGUL MECH, V1799, P131, DOI 10.1016/j.bbagrm.2009.11.014
   WEN L, 1989, NUCLEIC ACIDS RES, V17, P1197, DOI 10.1093/nar/17.3.1197
   Wu D, 2008, J PATHOL, V216, P167, DOI 10.1002/path.2391
   Yang H, 2010, BBA-GENE REGUL MECH, V1799, P149, DOI [10.1016/j.bbagrm.2009.11.049, 10.1016/j.bbagrm.2009.11.019]
   Yang LC, 2012, LEUKEMIA LYMPHOMA, V53, P315, DOI 10.3109/10428194.2011.616962
   Yao XJ, 2010, J CANCER RES CLIN, V136, P677, DOI 10.1007/s00432-009-0706-1
NR 41
TC 29
Z9 40
U1 69
U2 84
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0090-8258
EI 1095-6859
J9 GYNECOL ONCOL
JI Gynecol. Oncol.
PD JUL
PY 2012
VL 126
IS 1
BP 109
EP 117
DI 10.1016/j.ygyno.2012.03.051
PG 9
WC Oncology; Obstetrics & Gynecology
SC Oncology; Obstetrics & Gynecology
GA 967AL
UT WOS:000305878400022
PM 22484401
DA 2018-12-27
ER

PT J
AU Guan, ZJ
   Guo, B
   Huo, YL
   Guan, ZP
   Dai, JK
   Wei, YH
AF Guan, Zheng-jun
   Guo, Bin
   Huo, Yan-lin
   Guan, Zheng-ping
   Dai, Jia-kun
   Wei, Ya-hui
TI RETRACTED: SHORT COMMUNICATION: Organogenesis and somatic embryogenesis
   in callus derived from HBsAg-transgenic tomato mutant (Retracted
   article. See vol. 98, pg. 516, 2018)
SO CANADIAN JOURNAL OF PLANT SCIENCE
LA English
DT Article; Retracted Publication
DE Organogenesis; somatic embryogenesis; callus; transgenic; cherry tomato;
   mutant
ID REGENERATION
AB Guan, Z.-j., Guo, B., Huo, Guan, Z.-p., Dai, J.-k. and Wei, Y.-h. 2012. SHORT COMMUNICATION: Organogenesis and somatic embryogenesis in callus derived from HBsAg-transgenic tomato mutant. Can. J. Plant Sci. 92: 747-756. In the process of hepatitis B surface antigen (HBsAg) gene transformation, a transgenic cherry tomato (Lycopersivon esculent urn Mill.) mutant N244 was occasionally obtained. Based on its obvious variation in ploidy and phenotypic characteristics, morphogenesis and development in the mutant in vitro were studied by cytological analysis and ultrastructural examination. The adventitious shoot primordia first emerged in the mutant N244 leaf explants after 14 d of culture, and the somatic embryo pathway developed after 35 d. Transmission electron microscopy and scanning electron microscopy further indicated that during the explant's development, there were significant changes in morphology and quantity of some organelles in N244 callus cells. On the 7th day of culture, there was little cytoplasm and few organelles, except for a large number of dense lipid bodies in the mutant callus cells. In the later stage, the changes in chloroplasts, Golgi bodies and mitochondria showed obvious difference between N244 callus cells and the control. In addition, changes in physiological indexes (growth rate, soluble protein content, and antioxidant enzyme activities) at different development stages further revealed morphogenic variation of organogenesis and somatic embryogenesis in N244 callus. The growth rate of the mutant N244 was less rapid than that of the control during its callus differentiation, and the soluble protein content of N244 callus decreased from the explant's cultivation stage until the 28th day of culture. The mutant N244 had distinct differences in variation tendency of superoxide dismutase, catalase and peroxidase activities compared with the control at every stage of callus development. These findings provide the first report of simultaneous shoot organogenesis and somatic embryogenesis of transgenic mutant and help us to understand the development mechanism of transgenic plant mutant in vitro.
C1 [Guan, Zheng-jun; Guo, Bin; Wei, Ya-hui] NW Univ Xian, Key Lab Resource Biol & Biotechnol Western China, Minist Educ, Xian 710069, Shannxi, Peoples R China.
   [Guan, Zheng-jun] Yuncheng Univ, Dept Life Sci, Yuncheng 044000, Shanxi, Peoples R China.
   [Huo, Yan-lin] Yuncheng Univ, Ctr Biol & Chem Exiperiment, Yuncheng 044000, Shanxi, Peoples R China.
   [Guan, Zheng-ping] Nanjing Agr Univ, Dept Anim Sci & Technol, Nanjing 210095, Jiangshu, Peoples R China.
   [Dai, Jia-kun] Acad Sci, Enzyme Engn Inst Shaanxi, Xian 710600, Shaanxi, Peoples R China.
RP Wei, YH (reprint author), NW Univ Xian, Key Lab Resource Biol & Biotechnol Western China, Minist Educ, Xian 710069, Shannxi, Peoples R China.
EM guanzj722822@126.com; weiyahui@nwu.edu.cn
FU National Natural Science Foundation of China [31000144]; Opening
   Foundation of Key Laboratory of Resource Biology and Biotechnology in
   Western China (Northwest University) [08JZ72]; Specialized Foundation of
   Department of Education of Shaanxi Province, China [09JK746];
   Northwestern university graduate self-innovation project [10YZZ36];
   Yuncheng University Doctor Scientific research project [YQ-2011042]
FX This work was financially supported by National Natural Science
   Foundation of China (No. 31000144); Opening Foundation of Key Laboratory
   of Resource Biology and Biotechnology in Western China (Northwest
   University) (08JZ72); Specialized Foundation of Department of Education
   of Shaanxi Province, China (09JK746); Northwestern university graduate
   self-innovation project (10YZZ36); Yuncheng University Doctor Scientific
   research project (YQ-2011042). We are grateful to Deng Jun-jun for
   providing the seeds of cherry tomato, and all members of the Key
   Laboratory of Resource Biology and Biotechnology in Western China for
   numerous valuable discussions and advice about physiological indexes.
CR Aebi H, 1974, METHOD ENZYMAT AN, P674, DOI DOI 10.1016/B978-0-12-091302-2.50032-3
   Aileni M, 2011, PLANT BIOTECHNOL REP, V5, P147, DOI 10.1007/s11816-011-0166-3
   Allan AC, 1997, PLANT CELL, V9, P1559, DOI 10.1105/tpc.9.9.1559
   Arnaldos TL, 2002, J PLANT PHYSIOL, V159, P429, DOI 10.1078/0176-1617-00613
   Basu S, 2010, PLANT GROWTH REGUL, V60, P51, DOI 10.1007/s10725-009-9418-4
   BRENNAN T, 1977, PLANT PHYSIOL, V59, P411, DOI 10.1104/pp.59.3.411
   Diaz-Vivancos P, 2011, PLANT GROWTH REGUL, V65, P119, DOI 10.1007/s10725-011-9581-2
   Eva C., 2004, PLANT SCI, V167, P551
   GIANNOPOLITIS CN, 1977, PLANT PHYSIOL, V59, P309, DOI 10.1104/pp.59.2.309
   GIBBONS IR, 1960, J BIOPHYS BIOCHEM CY, V7, P697, DOI 10.1083/jcb.7.4.697
   Guan ZJ, 2011, RUSS J GENET+, V47, P923, DOI 10.1134/S1022795411080072
   Li CY, 2011, CAN J PLANT SCI, V91, P57, DOI 10.4141/CJPS10039
   Li H.S., 2000, PRINCIPLE TECHNOLOGY
   MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x
   Ntui VO, 2009, SCI HORTIC-AMSTERDAM, V119, P397, DOI 10.1016/j.scienta.2008.08.031
   REYNOLDS ES, 1963, J CELL BIOL, V17, P208, DOI 10.1083/jcb.17.1.208
   Saxena S, 1999, PLANT CELL REP, V18, P438, DOI 10.1007/s002990050600
   Snjezana M., 2011, J PLANT PHYSL, V168, P1943
   Tian C. E., 1992, J HUBEI I NATL NAT S, V30, P51
   Tian J. L., 2009, J PLANT PHYSL MOL BI, V29, P409
   Van Breusegem F, 2001, PLANT SCI, V161, P405, DOI 10.1016/S0168-9452(01)00452-6
   VanCamp W, 1997, FREE RADICAL BIO MED, V23, P515, DOI 10.1016/S0891-5849(97)00112-3
   Woods S. H., 1995, SOMATIC EMBRYOGENESI, V2, P41
   Xiang TaiHe, 1997, Acta Agronomica Sinica, V23, P353
   Yang H. P., 1991, CHIN B BOT, V8, P1
   Yu Y, 2011, CAN J PLANT SCI, V91, P159, DOI 10.4141/CJPS10034
   Zeng X. B., 1999, J GUANGXI YOUJIANG H, V12, P77
   Zhang SG, 2010, PLANT CELL TISS ORG, V100, P21, DOI 10.1007/s11240-009-9612-0
   Zhang Z. L., 2001, GUIDANCE PLANT PHYSL
NR 29
TC 2
Z9 2
U1 4
U2 16
PU CANADIAN SCIENCE PUBLISHING, NRC RESEARCH PRESS
PI OTTAWA
PA 65 AURIGA DR, SUITE 203, OTTAWA, ON K2E 7W6, CANADA
SN 0008-4220
EI 1918-1833
J9 CAN J PLANT SCI
JI Can. J. Plant Sci.
PD JUL
PY 2012
VL 92
IS 4
BP 747
EP 756
DI 10.4141/CJPS2011-264
PG 10
WC Agronomy; Plant Sciences
SC Agriculture; Plant Sciences
GA 966DD
UT WOS:000305816900012
DA 2018-12-27
ER

PT J
AU du Plessis, H
   du Rand, G
AF du Plessis, Henrietta
   du Rand, Gerrie
TI RETRACTED: Food traceability in the context of Karoo lamb: supply chain
   and consumer perspectives (Retracted article. See vol. 37, pg. 585,
   2013)
SO INTERNATIONAL JOURNAL OF CONSUMER STUDIES
LA English
DT Article; Retracted Publication
DE Conjoint analysis; consumer decision making; traceability; Karoo lamb;
   place of origin
ID INDUSTRY
AB As food markets have become more globalized, consumers have become more concerned about the origin of the foods they eat as confidence in the quality and safety of foods produced outside their local region or country has decreased. Traceability systems address these concerns by accommodating the importance of establishing a link between the product, the producer and the place of production, and these are gaining momentum in the food industry. This paper describes the product attributes that could influence the decision-making process of consumers towards purchasing a specific type of meat, namely Karoo lamb. Karoo lamb is the product of specifically reared lambs in the Karoo region of South Africa and has a distinctive taste. The information used in this paper was obtained in the first phase of a research endeavour involving three focus groups. They were conducted to identify the product attributes that were critical in influencing the consumers' preferences and choices regarding Karoo lamb. In phase two, conjoint analysis was used to measure the importance that individual consumers attach to the various product attributes and their denominations, and the utility they then attach to it based on their valuation of the product as a whole. Price, as an extrinsic attribute, was identified as the most important factor in the decision-making process of consumers when purchasing lamb. Safety and quality were also relatively important, although, of the two, food safety was clearly the more important consideration. This is not surprising given the legacy of bovine spongiform encephalopathy, commonly known as mad-cow disease, and Escherichia coli outbreaks that, in the past, received considerable publicity, especially in the press. The attribute origin was rated as of the lowest importance. Traceability can be meaningful to consumers although in an indirect manner. The importance of traceability to consumers is mostly in terms of its benefits such as providing information on safety and quality, in relation to aspects that they think are important regarding food in general. In terms of meat especially, there is a need for fast and reliable traceability systems along the full supply chain. From origin to the user, the end consumer, provision of safe and high-quality food is imperative.
C1 [du Plessis, Henrietta; du Rand, Gerrie] Univ Pretoria, Dept Consumer Sci, ZA-0002 Pretoria, South Africa.
RP du Plessis, H (reprint author), Univ Pretoria, Dept Consumer Sci, X0002, ZA-0002 Pretoria, South Africa.
EM henrietta.duplessis@telkomsa.net; gerrie.durand@up.ac.za
CR Bertolini M, 2006, FOOD CONTROL, V17, P137, DOI 10.1016/j.foodcont.2004.09.013
   Bramley C., 2007, Agrekon, V46, P69
   Bramley Cerkia, 2009, EC INTELLECTUAL PROP, V109, P121
   Brijball S., 2003, S AFRICAN J IND PSYC, V29, P93
   Coff C, 2008, INT LIBR ENVIRON AGR, V15, P1
   Donnelly KAM, 2009, MEAT SCI, V83, P68, DOI 10.1016/j.meatsci.2009.04.006
   Grunert KG, 2006, MEAT SCI, V74, P149, DOI 10.1016/j.meatsci.2006.04.016
   Hobbs J.E., 2003, INT AGR TRADE RES CO, V3, P15
   Kirsten J., 2008, POTENTIAL KAROO LAMB
   Kuznesof S., 1997, British Food Journal, V99, P199, DOI 10.1108/00070709710181531
   Lichtenberg L., 2008, 12 C EUR ASS AGR EC
   Schiffman L., 2007, CONSUMER BEHAV
   Shackell GH, 2008, INT J FOOD SCI TECH, V43, P2134, DOI 10.1111/j.1365-2621.2008.01812.x
   Smith GC, 2005, MEAT SCI, V71, P174, DOI 10.1016/j.meatsci.2005.04.002
   Sofos JN, 2008, MEAT SCI, V78, P3, DOI 10.1016/j.meatsci.2007.07.027
   van Rijswijk W, 2008, FOOD QUAL PREFER, V19, P452, DOI 10.1016/j.foodqual.2008.02.001
   Verbeke W, 2001, OUTLOOK AGR, V30, P249, DOI 10.5367/000000001101293733
NR 17
TC 3
Z9 3
U1 2
U2 31
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1470-6423
EI 1470-6431
J9 INT J CONSUM STUD
JI Int. J. Consum. Stud.
PD JUL
PY 2012
VL 36
IS 4
SI SI
BP 401
EP 407
DI 10.1111/j.1470-6431.2011.01063.x
PG 7
WC Business
SC Business & Economics
GA 965HC
UT WOS:000305757200005
DA 2018-12-27
ER

PT J
AU Zolfaghari, M
   Mousavifar, SA
   Pedram, S
   Haghani, H
AF Zolfaghari, Mitra
   Mousavifar, Seyedeh A.
   Pedram, Shadan
   Haghani, Hamid
TI RETRACTED: The impact of nurse short message services and telephone
   follow-ups on diabetic adherence: which one is more effective?
   (Retracted article. See vol. 25, pg. 1781, 2016)
SO JOURNAL OF CLINICAL NURSING
LA English
DT Article; Retracted Publication
DE adherence; glycosylated haemoglobin; nurse follow-up; short message
   service; telephone calls; type 2 diabetes mellitus
ID MOBILE PHONE; GLYCEMIC CONTROL; GLUCOSE CONTROL; CELLULAR PHONE; TYPE-2;
   MANAGEMENT; INTERVENTION; SYSTEM; COMPLICATIONS; MELLITUS
AB Aim. To compare the effectiveness of two methods of follow-up: short message service and telephone follow-up on type 2 diabetes adherence for three months. Background. Using telemedicine approaches may preserve appropriate blood glucose levels and may improve adherence to diabetes control recommendations in diabetic patients. Design. A quasi-experimental, two-group, pretest and post-test design was used in this study to evaluate the effectiveness of nurses follow-up via cellular phones and telephones. Methods. The sample consisted of 77 patients with type 2 diabetes that randomly were assigned to two groups: telephone follow-up (n = 39) and short message service (n = 38). Telephone interventions were applied by a researcher for three months; twice a week for the first month and every week for the second and third month. For three successive months, the short message service group that received messages about adherence to therapeutic regimen was examined. The data gathering instrument included data sheets to record glycosylated haemoglobin and the questionnaire related to adherence therapeutic regimen. Data gathering was carried out at the beginning of the study and after three and six months. The data were analysed using descriptive and inferential statistic methods with SPSS version 11.5. Results. Results showed that both interventions had significant mean changes in glycosylated haemoglobin. For the telephone group (p < 0.001), a mean change of -0.93 and for the short message service group (p < 0.001), a mean change of -1.01. There was no significant difference in diet adherence (p = 0.000), physical exercise (p = 0.000) and medication taking (p = 0.000) adherence in either groups. Conclusion. Intervention using short message services of cellular phones and nurse-led-telephone follow-up improved HbA1c levels and adherence to diabetes therapeutic regimen for three months in type 2 diabetic patients. Relevance to clinical practice. Both of follow-up intervention uses in this study can decrease HbA1c levels and escalate adherence to diabetes control recommendations in people with type 2 diabetes for three months.
C1 [Zolfaghari, Mitra] Univ Tehran Med Sci, Nursing & Midwifery Care Res Ctr, Nursing & Midwifery Sch, Tehran, Iran.
   [Mousavifar, Seyedeh A.; Pedram, Shadan] Univ Tehran Med Sci, Tehran Sch Nursing & Midwifery, Tehran, Iran.
   [Haghani, Hamid] Iran Univ Med Sci, Coll Management & Med Informat, Tehran, Iran.
RP Zolfaghari, M (reprint author), Univ Tehran Med Sci, Nursing & Midwifery Care Res Ctr, Nursing & Midwifery Sch, St Tohid Sq,POB 1419733171, Tehran, Iran.
EM zolfaghm@tums.ac.ir
RI Emchi, Karma/Q-1952-2016
OI Zolfaghari, Mitra/0000-0003-3374-1115
FU Faculty of Nursing and Midwifery of Tehran University of Medical
   Sciences, Islamic Republic of Iran [7091-28-02-87]
FX This research was supported by a grant from the Faculty of Nursing and
   Midwifery of Tehran University of Medical Sciences, Islamic Republic of
   Iran (project number: 7091-28-02-87). We thank all the project partners
   for their support and we would like to express our deep appreciation to
   the colleagues of Iranian Diabetes Association.
CR *ADA, 1997, DIABETES CARE S1, V20, pS5
   Amini M, 2008, DIABETES RES CLIN PR, V8, P18
   Azar M, 2009, DIABETES RES CLIN PR, V8, P9
   Blake Holly, 2008, Br J Community Nurs, V13, P162
   Cho JH, 2009, J TELEMED TELECARE, V15, P77, DOI 10.1258/jtt.2008.080412
   da Costa TM, 2010, INT J MED INFORM, V79, P65, DOI 10.1016/j.ijmedinf.2009.09.001
   Duplaga M., 2006, INFORM TECHNOLOGY SO, P248
   Esteghamati A, 2008, DIABETES CARE, V31, P96, DOI 10.2337/dc07-0959
   Faridi Z, 2008, J EVAL CLIN PRACT, V14, P465, DOI 10.1111/j.1365-2753.2007.00881.x
   Ferrer-Roca O, 2004, J TELEMED TELECARE, V10, P282, DOI 10.1258/1357633042026341
   Fjeldsoe BS, 2009, AM J PREV MED, V36, P165, DOI 10.1016/j.amepre.2008.09.040
   Franc S, 2010, MED MALADIES METABOL, V4, P274
   Gavin JR, 1997, DIABETES CARE, V20, P1183
   Gentles Stephen James, 2010, J Med Internet Res, V12, pe22, DOI 10.2196/jmir.1390
   Halkoaho A., 2007, EURODIABETES NURSING, V4, P14
   Kim C, 2007, DIABETES CARE, V30, P2857, DOI 10.2337/dc06-2464
   Kim CJ, 2006, CIN-COMPUT INFORM NU, V24, P337, DOI 10.1097/00024665-200611000-00008
   Kim HS, 2007, J CLIN NURS, V16, P1082, DOI 10.1111/j.1365-2702.2006.01698.x
   Kim HS, 2007, J CLIN NURS, V16, P1361, DOI 10.1111/j.1365-2702.2005.01506.x
   Kim HS, 2006, J NURS CARE QUAL, V21, P266, DOI 10.1097/00001786-200607000-00012
   Kim HS, 2005, J NURS CARE QUAL, V20, P154, DOI 10.1097/00001786-200504000-00011
   Kim HS, 2003, J ADV NURS, V44, P256, DOI 10.1046/j.1365-2648.2003.02800.x
   Kim SI, 2008, INT J MED INFORM, V77, P399, DOI 10.1016/j.ijmedinf.2007.07.006
   Kollmann A, 2006, HEFT JAHRANG, V4, P121
   Krishna S, 2009, TELEMED J E-HEALTH, V15, P231, DOI 10.1089/tmj.2008.0099
   Kwon HS, 2004, DIABETES RES CLIN PR, V66, pS133, DOI 10.1016/j.diabres.2003.10.028
   Lester RT, 2010, LANCET, V376, P1838, DOI 10.1016/S0140-6736(10)61997-6
   Liang X, 2010, DIABETIC MED, V11, P1464
   Norris SL, 2002, AM J PREV MED, V22, P15, DOI 10.1016/S0749-3797(02)00423-3
   Patrick K, 2008, AM J PREV MED, V35, P177, DOI 10.1016/j.amepre.2008.05.001
   Perez-Ferre Natalia, 2010, Diabetes Res Clin Pract, V87, pe15, DOI 10.1016/j.diabres.2009.12.002
   SHAMOON H, 1993, NEW ENGL J MED, V329, P977
   Strandbygaard U, 2010, RESP MED, V104, P166, DOI 10.1016/j.rmed.2009.10.003
   Turner RC, 1998, LANCET, V352, P837
   Wong FKY, 2005, J ADV NURS, V50, P391, DOI 10.1111/j.1365-2648.2005.03404.x
   Wu L, 2010, DIABETIC MED, V27, P1217, DOI 10.1111/j.1464-5491.2010.03113.x
   Yoon KH, 2008, DIABETES RES CLIN PR, V79, P256, DOI 10.1016/j.diabres.2007.09.007
NR 37
TC 52
Z9 53
U1 4
U2 29
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0962-1067
EI 1365-2702
J9 J CLIN NURS
JI J. Clin. Nurs.
PD JUL
PY 2012
VL 21
IS 13-14
BP 1922
EP 1931
DI 10.1111/j.1365-2702.2011.03951.x
PG 10
WC Nursing
SC Nursing
GA 952VK
UT WOS:000304821100016
PM 22239205
DA 2018-12-27
ER

PT J
AU Anderson, DE
   Awh, E
AF Anderson, David E.
   Awh, Edward
TI RETRACTED: The plateau in mnemonic resolution across large set sizes
   indicates discrete resource limits in visual working memory (Retracted
   article. See vol. 77, pg. 2519, 2015)
SO ATTENTION PERCEPTION & PSYCHOPHYSICS
LA English
DT Article; Retracted Publication
DE Visual working memory; Short-term memory
ID SHORT-TERM-MEMORY; CAPACITY; REPRESENTATIONS; MECHANISMS; CORTEX;
   INTELLIGENCE; ATTENTION; OBJECTS; BRAIN; MIND
AB The precision of visual working memory (WM) representations declines monotonically with increasing storage load. Two distinct models of WM capacity predict different shapes for this precision-by-set-size function. Flexible-resource models, which assert a continuous allocation of resources across an unlimited number of items, predict a monotonic decline in precision across a large range of set sizes. Conversely, discrete-resource models, which assert a relatively small item limit for WM storage, predict that precision will plateau once this item limit is exceeded. Recent work has demonstrated such a plateau in mnemonic precision. Moreover, the set size at which mnemonic precision reached asymptote has been strongly predicted by estimated item limits in WM. In the present work, we extend this evidence in three ways. First, we show that this empirical pattern generalizes beyond orientation memory to color memory. Second, we rule out encoding limits as the source of discrete limits by demonstrating equivalent performance across simultaneous and sequential presentations of the memoranda. Finally, we demonstrate that the analytic approach commonly used to estimate precision yields flawed parameter estimates when the range of stimulus space is narrowed (e.g., a 180A(0) rather than a 360A(0) orientation space) and typical numbers of observations are collected. Such errors in parameter estimation reconcile an apparent conflict between our findings and others based on different stimuli. These findings provide further support for discrete-resource models of WM capacity.
C1 [Anderson, David E.; Awh, Edward] 1227 Univ Oregon, Dept Psychol, Eugene, OR 97403 USA.
RP Awh, E (reprint author), 1227 Univ Oregon, Dept Psychol, Eugene, OR 97403 USA.
EM awh@uoregon.edu
FU NIH [R01 MH077105-01A2]
FX Supported by NIH Grant R01 MH077105-01A2 to E. A. E. A. and D. E. A.
   conceived and designed the experiments, D. E. A. collected and analyzed
   data, and D. E. A. and E. A. wrote the manuscript. We are grateful to
   Tim Brady for his advice on the simulation work.
CR Anderson DE, 2011, J NEUROSCI, V31, P1128, DOI 10.1523/JNEUROSCI.4125-10.2011
   Awh E, 2001, TRENDS COGN SCI, V5, P119, DOI 10.1016/S1364-6613(00)01593-X
   Awh E, 2007, PSYCHOL SCI, V18, P622, DOI 10.1111/j.1467-9280.2007.01949.x
   Barton B, 2009, J EXP PSYCHOL HUMAN, V35, P1359, DOI 10.1037/a0015792
   Bays P. M., 2009, J VISION, V7, P1, DOI DOI 10.1167/9.10.7
   Bays PM, 2008, SCIENCE, V321, P851, DOI 10.1126/science.1158023
   Bays PM, 2011, J VISION, V11, DOI 10.1167/11.10.6
   Brady T. F., 2011, J NEUROSCIENCE
   Brainard DH, 1997, SPATIAL VISION, V10, P433, DOI 10.1163/156856897X00357
   Cowan N, 2001, BEHAV BRAIN SCI, V24, P87, DOI 10.1017/S0140525X01003922
   Cusack R, 2009, PSYCHON B REV, V16, P641, DOI 10.3758/PBR.16.4.641
   Engle RW, 2002, CURR DIR PSYCHOL SCI, V11, P19, DOI 10.1111/1467-8721.00160
   Ester E. E., 2012, COGNITIVE NEUROSCIEN, P99
   Ester EF, 2009, J NEUROSCI, V29, P15258, DOI 10.1523/JNEUROSCI.4388-09.2009
   Fukuda F., 2009, J NEUROSCI, V29, P8726
   Fukuda K, 2010, PSYCHON B REV, V17, P673, DOI 10.3758/17.5.673
   GLANZER M, 1966, J VERB LEARN VERB BE, V5, P351, DOI 10.1016/S0022-5371(66)80044-0
   Gorgoraptis N, 2011, J NEUROSCI, V31, P8502, DOI 10.1523/JNEUROSCI.0208-11.2011
   Harrison SA, 2009, NATURE, V458, P632, DOI 10.1038/nature07832
   Jonides J, 2005, CURR DIR PSYCHOL SCI, V14, P2, DOI 10.1111/j.0963-7214.2005.00323.x
   Ma W. J., 2010, J VISION, V10, p728a, DOI [10.1167/10.7.728, DOI 10.1167/10.7.728]
   McCollough AW, 2007, CORTEX, V43, P77, DOI 10.1016/S0010-9452(08)70447-7
   Pelli DG, 1997, SPATIAL VISION, V10, P437, DOI 10.1163/156856897X00366
   Postle BR, 2006, NEUROSCIENCE, V139, P23, DOI 10.1016/j.neuroscience.2005.06.005
   Rademaker R. L., 2010, J VISION, V10, p726a, DOI [10.1167/4.12.11, DOI 10.1167/4.12.11]
   Serences JT, 2009, PSYCHOL SCI, V20, P207, DOI 10.1111/j.1467-9280.2009.02276.x
   Todd JJ, 2004, NATURE, V428, P751, DOI 10.1038/nature02466
   Vogel EK, 2004, NATURE, V428, P748, DOI 10.1038/nature02447
   Wilken P, 2004, J VISION, V4, P1120, DOI 10.1167/4.12.11
   Xu YD, 2006, NATURE, V440, P91, DOI 10.1038/nature04262
   Zhang WW, 2008, NATURE, V453, P233, DOI 10.1038/nature06860
NR 31
TC 26
Z9 26
U1 2
U2 17
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1943-3921
EI 1943-393X
J9 ATTEN PERCEPT PSYCHO
JI Atten. Percept. Psychophys.
PD JUL
PY 2012
VL 74
IS 5
BP 891
EP 910
DI 10.3758/s13414-012-0292-1
PG 20
WC Psychology; Psychology, Experimental
SC Psychology
GA 962PV
UT WOS:000305558300011
PM 22477058
OA Bronze, Green Accepted
DA 2018-12-27
ER

PT J
AU Nakajima, H
   Yoshioka, R
   Ezaki, Y
   Nagai, T
   Imokawa, G
AF Nakajima, Hiroaki
   Yoshioka, Ryosuke
   Ezaki, Yoshiyuki
   Nagai, Tomoyashu
   Imokawa, Genji
TI RETRACTED: Paracrine cytokine interaction between UVB-exposed epidermal
   keratinocytes and dermal fibroblasts in stimulating expression of skin
   fibroblast-derived elastase (Retracted article. See vol. 62, pg. 454,
   2013)
SO CYTOKINE
LA English
DT Article; Retracted Publication
DE Ultraviolet light; Elastase; Wrinkling; Skin fibroblasts; Neutral
   endopeptidase
ID INDUCED WRINKLE FORMATION; HAIRLESS MOUSE SKIN; MORPHOMETRIC ANALYSIS;
   SELECTIVE-INHIBITION; ELASTOLYTIC ACTIVITY; ULTRAVIOLET; DEGRADATION;
   IRRADIATION; MECHANISMS; FIBERS
AB Background: We recently reported that over-expression of skin fibroblast-derived elastase (SFE) plays a pivotal role in the mechanism of UVB-induced skin wrinkling. Since UVB penetrates only modestly to the dermis, we hypothesized that factors secreted by UVB-exposed keratinocytes in the epidermis trigger fibroblasts in the dermis to increase their expression of SFE which then degrades the elastic fibers.
   Objective: In this study, we characterized the paracrine interaction between human keratinocytes (HK) and human fibroblasts (HF) which leads to increased expression of SFE.
   Methods and results: Medium conditioned by UVB-exposed HK contained increased levels of IL-1 alpha, GM-CSF, IL-6, TNF alpha and IL-8. While HF cultured with those conditioned medium slightly down-regulated the gene expression of collagen and elastin, they significantly increased their expression of SFE at the transcriptional, translational and enzymatic levels. Neutralizing antibodies to IL-1 alpha or GM-CSF significantly abolished the increased expression of SFE at the translational and/or enzymatic levels in HF cultured with those conditioned medium, while neutralizing antibodies to IL-6, IL-8 or TNF alpha had no such effect. The addition of IL-1 alpha or GM-CSF, but not TNF alpha, IL-6 or IL-8, at concentrations ranging from 1 to 10 nm, significantly stimulated the enzymatic levels of SFE in HF.
   Conclusions: The sum of these findings suggests that IL-1 alpha and GM-CSF are intrinsic cytokines secreted by UVB-exposed HK that stimulate expression of SFE by HF, leading to UVB-induced wrinkle formation. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Nakajima, Hiroaki; Yoshioka, Ryosuke; Ezaki, Yoshiyuki; Nagai, Tomoyashu; Imokawa, Genji] Tokyo Univ Technol, Sch Biosci & Biotechnol, Hachioji, Tokyo 1920982, Japan.
RP Imokawa, G (reprint author), Tokyo Univ Technol, Sch Biosci & Biotechnol, 1404-1 Katakura, Hachioji, Tokyo 1920982, Japan.
EM imokawag@dream.ocn.ne.jp
CR Akazaki S, 2002, BRIT J DERMATOL, V147, P689, DOI 10.1046/j.1365-2133.2002.04874.x
   Akazaki S, 2001, J DERMATOL SCI, V27, pS5
   BOUDIER C, 1991, AM J RESP CELL MOL, V4, P497, DOI 10.1165/ajrcmb/4.6.497
   Brennan M, 2003, PHOTOCHEM PHOTOBIOL, V78, P43, DOI 10.1562/0031-8655(2003)078<0043:MMITMC>2.0.CO;2
   BRULS WAG, 1984, PHOTOCHEM PHOTOBIOL, V40, P485, DOI 10.1111/j.1751-1097.1984.tb04622.x
   CAMPBELL EJ, 1988, J CELL BIOL, V106, P667, DOI 10.1083/jcb.106.3.667
   CROUTE F, 1991, BRIT J DERMATOL, V124, P538, DOI 10.1111/j.1365-2133.1991.tb04946.x
   Fisher GJ, 1996, NATURE, V379, P335, DOI 10.1038/379335a0
   FULCHER IS, 1982, BIOCHEM J, V203, P519, DOI 10.1042/bj2030519
   GODEAU G, 1988, PATHOL BIOL, V36, P1133
   HOMSY R, 1988, J INVEST DERMATOL, V91, P472, DOI 10.1111/1523-1747.ep12476608
   Imayama Shuhei, 1994, Journal of Dermatological Science, V7, P32, DOI 10.1016/0923-1811(94)90019-1
   IMOKAWA G, 1992, J BIOL CHEM, V267, P24675
   IMOKAWA G, 1995, J INVEST DERMATOL, V105, P254, DOI 10.1111/1523-1747.ep12317607
   Imokawa G, 2009, J INVEST DERM SYMP P, V14, P36, DOI 10.1038/jidsymp.2009.11
   Irnokawa G, 2008, ARCH DERMATOL RES, V300, pS7, DOI 10.1007/s00403-007-0798-x
   KAO RC, 1988, J CLIN INVEST, V82, P1963, DOI 10.1172/JCI113816
   Mecham RP, 1997, J BIOL CHEM, V272, P18071, DOI 10.1074/jbc.272.29.18071
   Morisaki N, 2010, J BIOL CHEM, V285, P39819, DOI 10.1074/jbc.M110.161547
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   Nakagawa K, 1987, SKIN RES, V29, P793
   Rabe JH, 2006, J AM ACAD DERMATOL, V55, P1, DOI 10.1016/j.jaad.2005.05.010
   SCHWARTZ E, 1988, J INVEST DERMATOL, V91, P158, DOI 10.1111/1523-1747.ep12464405
   SENIOR RM, 1991, J BIOL CHEM, V266, P7870
   Shipley JM, 1996, J BIOL CHEM, V271, P4335
   Suganuma K, 2010, J DERMATOL SCI, V58, P136, DOI 10.1016/j.jdermsci.2010.02.009
   Takema Y, 1998, DERMATOLOGY, V196, P397, DOI 10.1159/000017931
   Tsuji N, 2001, PHOTOCHEM PHOTOBIOL, V74, P283, DOI 10.1562/0031-8655(2001)074<0283:TROESB>2.0.CO;2
   Tsukahara K, 2006, INT J DERMATOL, V45, P460, DOI 10.1111/j.1365-4632.2006.02557.x
   Tsukahara K, 2004, BRIT J DERMATOL, V151, P984, DOI 10.1111/j.1365-2133.2004.06203.x
   Tsukahara K., 2000, International Journal of Cosmetic Science, V22, P247, DOI 10.1046/j.1467-2494.2000.00033.x
   Tsukahara K, 2001, J INVEST DERMATOL, V117, P671, DOI 10.1046/j.0022-202x.2001.01450.x
   Tsukahara K., 2004, JICHI MED SCH J, V27, P19
   ZHENG PS, 1993, J INVEST DERMATOL, V100, P194, DOI 10.1111/1523-1747.ep12462807
NR 34
TC 3
Z9 4
U1 3
U2 15
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1043-4666
EI 1096-0023
J9 CYTOKINE
JI Cytokine
PD JUL
PY 2012
VL 59
IS 1
BP 166
EP 175
DI 10.1016/j.cyto.2012.03.008
PG 10
WC Biochemistry & Molecular Biology; Cell Biology; Immunology
SC Biochemistry & Molecular Biology; Cell Biology; Immunology
GA 962ZU
UT WOS:000305590700027
PM 22507381
DA 2018-12-27
ER

PT J
AU Theivanthiran, B
   Batra, S
   Balamayooran, G
   Cai, SS
   Kobayashi, K
   Flavell, RA
   Jeyaseelan, S
AF Theivanthiran, Balamayooran
   Batra, Sanjay
   Balamayooran, Gayathriy
   Cai, Shanshan
   Kobayashi, Koichi
   Flavell, Richard A.
   Jeyaseelan, Samithamby
TI RETRACTED: NOD2 Signaling Contributes to Host Defense in the Lungs
   against Escherichia coli Infection (Retracted article. See vol. 83, pg.
   2199, 2015)
SO INFECTION AND IMMUNITY
LA English
DT Article; Retracted Publication
ID CONTAINING ADAPTER PROTEIN; HUMAN ENDOTHELIAL-CELLS; NF-KAPPA-B;
   NEUTROPHIL RECRUITMENT; STAPHYLOCOCCUS-AUREUS; INNATE IMMUNITY;
   LEGIONELLA-PNEUMOPHILA; KLEBSIELLA-PNEUMONIAE; DIAMINOPIMELIC ACID;
   CROHNS-DISEASE
AB Bacterial pneumonia remains a significant cause of mortality in the United States. The innate immune response is the first line of defense against invading bacteria. Neutrophil recruitment to the lungs is the first step in a multistep sequence leading to bacterial clearance. Ligand interaction with pattern-recognizing receptors (PRRs) leads to chemokine production, which drives neutrophils to the site of infection. Although we demonstrated that RIP2 is important for host defense in the lungs against Escherichia coli, the individual roles of NODI and NOD2(-/-) in pulmonary defense have not been addressed. Here, we explored the role of NOD2 in neutrophil-mediated host defense against an extracellular pathogen, E. coli. We found enhanced bacterial burden and reduced neutrophil and cytokine/chemokine levels in the lungs of NOD2(-/-) mice following E. coli infection. Furthermore, we observed reduced activation of NF-kappa B and mitogen-activated protein kinases (MAPKs) in the lungs of NOD2(-/-) mice upon E. coli challenge. Moreover, NOD2(-/-) neutrophils show impaired intracellular bacterial killing. Using NOD2/RIP2(-/-) mice, we observed bacterial burden and neutrophil accumulation in the lungs similar to those seen with NOD2(-/-) mice. In addition, bone marrow-derived macrophages obtained from NOD2/RIP2(-/-) mice demonstrate a reduction in activation of NF-kappa B and MAPKs similar to that seen with NOD2(-/-) mice in response to E. coli. These findings unveil a previously unrecognized role of the NOD2-RIP2 axis for host defense against extracellular Gram-negative bacteria. This pathway may represent a novel target for the treatment of lung infection/inflammation.
C1 [Theivanthiran, Balamayooran; Batra, Sanjay; Balamayooran, Gayathriy; Cai, Shanshan; Jeyaseelan, Samithamby] Harvard Univ, Sch Med, Dept Pathobiol Sci, Lab Lung Biol, Boston, MA 02114 USA.
   [Theivanthiran, Balamayooran; Batra, Sanjay; Balamayooran, Gayathriy; Cai, Shanshan; Jeyaseelan, Samithamby] Harvard Univ, Sch Med, Ctr Expt Infect Dis Res, Boston, MA USA.
   [Kobayashi, Koichi] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
   [Flavell, Richard A.] Yale Univ, Sch Med, Howard Hughes Med Inst, Dept Immunobiol, New Haven, CT 06510 USA.
   [Jeyaseelan, Samithamby] LSU Hlth Sci Ctr, Dept Med, Sect Pulm & Crit Care Med, New Orleans, LA USA.
RP Jeyaseelan, S (reprint author), Harvard Univ, Sch Med, Dept Pathobiol Sci, Lab Lung Biol, Boston, MA 02114 USA.
EM jey@lsu.edu
FU Flight Attendant Medical Research Institute [YCSA-062466]; NIH [R01
   HL-091958, R01 HL-091958S1]
FX This work was supported by a Scientist Award from the Flight Attendant
   Medical Research Institute (YCSA-062466) and grants from the NIH (R01
   HL-091958 and R01 HL-091958S1 via ARRA) to S.J.
CR Abraham E, 2003, CRIT CARE MED, V31, pS195, DOI 10.1097/01.CCM.0000057843.47705.E8
   Balamayooran G, 2011, INFECT IMMUN, V79, P2567, DOI 10.1128/IAI.00067-11
   Balamayooran G, 2010, AM J RESP CELL MOL, V43, P5, DOI 10.1165/rcmb.2009-0047TR
   Balamayooran T, 2011, INFECT IMMUN, V79, P4588, DOI 10.1128/IAI.05641-11
   Batra S, 2012, J IMMUNOL, V188, P3458, DOI 10.4049/jimmunol.1101985
   Batra S, 2011, ARCH IMMUNOL THER EX, V59, P335, DOI 10.1007/s00005-011-0136-z
   Benko S, 2008, CYTOKINE, V43, P368, DOI 10.1016/j.cyto.2008.07.013
   Berrington WR, 2010, EUR J IMMUNOL, V40, P3519, DOI 10.1002/eji.201040518
   Beutz MA, 2005, CLIN CHEST MED, V26, P19, DOI 10.1016/j.ccm.2004.10.015
   Cai SS, 2010, J IMMUNOL, V185, P6214, DOI 10.4049/jimmunol.0903843
   Cai S, 2009, AM J RESP CELL MOL, V40, P701, DOI 10.1165/rcmb.2008-0152OC
   Chamaillard M, 2003, NAT IMMUNOL, V4, P702, DOI 10.1038/ni945
   Chen G, 2009, ANNU REV PATHOL-MECH, V4, P365, DOI 10.1146/annurev.pathol.4.110807.092239
   Correa-de-Santana E, 2009, J ENDOCRINOL, V203, P111, DOI 10.1677/JOE-09-0113
   Cowburn AS, 2008, CHEST, V134, P606, DOI 10.1378/chest.08-0422
   Craig A, 2009, INFECT IMMUN, V77, P568, DOI 10.1128/IAI.00832-08
   Deshmukh HS, 2009, INFECT IMMUN, V77, P1376, DOI 10.1128/IAI.00940-08
   Divangahi M, 2008, J IMMUNOL, V181, P7157, DOI 10.4049/jimmunol.181.10.7157
   DREVETS DA, 1992, J LEUKOCYTE BIOL, V52, P70
   Ferwerda G, 2005, PLOS PATHOG, V1, P279, DOI 10.1371/journal.ppat.0010034
   Frutuoso MS, 2010, MICROBES INFECT, V12, P819, DOI 10.1016/j.micinf.2010.05.006
   Gandotra S, 2007, INFECT IMMUN, V75, P5127, DOI 10.1128/IAI.00458-07
   Girardin SE, 2003, J BIOL CHEM, V278, P8869, DOI 10.1074/jbc.C200651200
   Griffith B, 2009, ANTIOXID REDOX SIGN, V11, P2505, DOI [10.1089/ars.2009.2599, 10.1089/ARS.2009.2599]
   Hirche TO, 2005, J IMMUNOL, V174, P1557, DOI 10.4049/jimmunol.174.3.1557
   Hruz P, 2009, P NATL ACAD SCI USA, V106, P12873, DOI 10.1073/pnas.0904958106
   Jeyaseelan S, 2005, J IMMUNOL, V175, P7484, DOI 10.4049/jimmunol.175.11.7484
   Jeyaseelan S, 2006, J IMMUNOL, V177, P538, DOI 10.4049/jimmunol.177.1.538
   Kanneganti TD, 2007, IMMUNITY, V27, P549, DOI 10.1016/j.immuni.2007.10.002
   Kapetanovic R, 2010, MICROBES INFECT, V12, P759, DOI 10.1016/j.micinf.2010.05.003
   Kim JY, 2008, J BIOL CHEM, V283, P137, DOI 10.1074/jbc.M704746200
   Kobayashi K, 2002, NATURE, V416, P194, DOI 10.1038/416194a
   Kobayashi KS, 2005, SCIENCE, V307, P731, DOI 10.1126/science.1104911
   Kumar P, 2010, BEHAV PHARMACOL, V21, P217, DOI 10.1097/FBP.0b013e32833a5bf4
   Lecine P, 2007, J BIOL CHEM, V282, P15197, DOI 10.1074/jbc.M606242200
   Lee MS, 2010, TOXINS, V2, P1515, DOI 10.3390/toxins2061515
   Maccarrone M, 2000, J BIOL CHEM, V275, P13484, DOI 10.1074/jbc.275.18.13484
   Maccarrone M, 2002, BLOOD, V100, P4040, DOI 10.1182/blood-2002-05-1444
   Magalhaes JG, 2011, CURR OPIN IMMUNOL, V23, P29, DOI 10.1016/j.coi.2010.12.003
   Marriott HM, 2007, EXP LUNG RES, V33, P493, DOI 10.1080/01902140701756562
   Marriott HM, 2008, AM J RESP CRIT CARE, V177, P887, DOI 10.1164/rccm.200707-990OC
   Matute JD, 2009, BLOOD, V114, P3309, DOI 10.1182/blood-2009-07-231498
   Meinzer U, 2005, LANCET, V365, P1752, DOI 10.1016/S0140-6736(05)66562-2
   Miao EA, 2006, NAT IMMUNOL, V7, P569, DOI 10.1038/ni1344
   Mizgerd JP, 2008, NEW ENGL J MED, V358, P716, DOI 10.1056/NEJMra074111
   Mizgerd JP, 2006, PLOS MED, V3, P155, DOI 10.1371/journal.pmed.0030076
   Mizgerd JP, 2002, SEMIN IMMUNOL, V14, P123, DOI 10.1006/smim.2001.0349
   Mohanty JG, 1997, J IMMUNOL METHODS, V202, P133, DOI 10.1016/S0022-1759(96)00244-X
   Murch O, 2008, SHOCK, V29, P388, DOI 10.1097/shk.0b013c3181453c59
   Netea MG, 2005, P NATL ACAD SCI USA, V102, P16309, DOI 10.1073/pnas.0508237102
   Netea MG, 2005, J IMMUNOL, V174, P6518, DOI 10.4049/jimmunol.174.10.6518
   Ong ES, 2003, AM J PHYSIOL-LUNG C, V285, pL879, DOI 10.1152/ajplung.00134.2003
   Pandey AK, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000500
   Peeters H, 2007, INT J IMMUNOGENET, V34, P181, DOI 10.1111/j.1744-313X.2007.00670.x
   Perez LH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010915
   Philpott DJ, 2010, CURR OPIN IMMUNOL, V22, P428, DOI 10.1016/j.coi.2010.04.010
   Quinton LJ, 2011, CELL TISSUE RES, V343, P153, DOI 10.1007/s00441-010-1044-y
   Rosenzweig HL, 2009, INVEST OPHTH VIS SCI, V50, P1739, DOI 10.1167/iovs.08-2756
   Sandvig K, 2002, FEBS LETT, V529, P49, DOI 10.1016/S0014-5793(02)03182-4
   Seger RA, 2010, NETH J MED, V68, P334
   Shimada K, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000379
   Uehara A, 2005, CELL MICROBIOL, V7, P53, DOI 10.1111/j.1462-5822.2004.00433.x
   Watanabe T, 2004, NAT IMMUNOL, V5, P800, DOI 10.1038/ni1092
   Young RE, 2007, BRIT J PHARMACOL, V151, P628, DOI 10.1038/sj.bjp.0707267
NR 64
TC 21
Z9 22
U1 2
U2 10
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0019-9567
EI 1098-5522
J9 INFECT IMMUN
JI Infect. Immun.
PD JUL
PY 2012
VL 80
IS 7
BP 2558
EP 2569
DI 10.1128/IAI.06230-11
PG 12
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 963DD
UT WOS:000305599400032
PM 22547547
OA Bronze, Green Published
DA 2018-12-27
ER

PT J
AU Koneswaran, M
   Narayanaswamy, R
AF Koneswaran, Masilamany
   Narayanaswamy, Ramaier
TI RETRACTED: CdS/ZnS core-shell quantum dots capped with mercaptoacetic
   acid as fluorescent probes for Hg(II) ions (Retracted article. See vol.
   183, pg. 1519, 2016)
SO MICROCHIMICA ACTA
LA English
DT Article; Retracted Publication
DE Quantum dots; Core-shell; CdS/ZnS; Probe; Mercury; Fluorescence
ID AQUEOUS-SOLUTION; ENERGY-TRANSFER; CDSE; NANOCRYSTALS;
   PHOTOLUMINESCENCE; NANOPARTICLES; PHOTOSTABILITY; NANOCLUSTERS;
   MERCURY(II); EMISSION
AB We have synthesised water soluble CdS/ZnS core-shell quantum dots (QDs) capped with mercaptoacetic acid (MAA). They were characterised by UV-vis absorption spectroscopy, fluorescence spectroscopy, FT-IR and transmission electron microscopy. Such QDs can be used as fluorescent probes for the determination of metal ions because they quench the fluorescence of the QDs. The QDs exhibit absorption and emission bands at 345 nm and 475 nm respectively, which is more longer wavelength compared to MAA-capped CdS QDs and obviously is the result of the larger particle size. The fluorescence intensity of CdS-based QDs is strongly enhanced by coating them with a shell of ZnS. In addition, such functionalised QDs are more sensitive to Hg(II) ions. Parameters such as pH, temperature and concentration of the QDs have been optimised. A high selectivity and sensitivity toward Hg(II) ions is obtained at pH 7.4 and a concentration of 12.0 mg of QDs per L. Under optimum conditions, the fluorescence intensity of CdS/ZnS QDs is linearly proportional to the concentration of Hg(II) in the range from 2.5 to 280 nM, with a detection limit of 2.2 nM. The effect of potentially interfering cations was examined and confirmed the high selectivity of this material.
C1 [Koneswaran, Masilamany] Sri Lanka Inst Nanotechnol SLINTEC, Colombo, Sri Lanka.
   [Koneswaran, Masilamany; Narayanaswamy, Ramaier] Univ Manchester, Sch Chem Engn & Analyt Sci, Ctr Instrumentat & Analyt Sci, Manchester M60 1QD, Lancs, England.
RP Koneswaran, M (reprint author), Sri Lanka Inst Nanotechnol SLINTEC, Colombo, Sri Lanka.
EM konesh26@yahoo.com
FU School of Chemical Engineering and Analytical Science of the University
   of Manchester
FX We are grateful for the support from the School of Chemical Engineering
   and Analytical Science of the University of Manchester to carry out this
   research.
CR Aldana J, 2001, J AM CHEM SOC, V123, P8844, DOI 10.1021/ja016424q
   Alivisatos AP, 1996, J PHYS CHEM-US, V100, P13226, DOI 10.1021/jp9535506
   Cai ZX, 2006, ANAL CHIM ACTA, V559, P234, DOI 10.1016/j.aca.2005.11.061
   Caruthers SD, 2007, CURR OPIN BIOTECH, V18, P26, DOI 10.1016/j.copbio.2007.01.006
   Chan WCW, 2002, CURR OPIN BIOTECH, V13, P40, DOI 10.1016/S0958-1669(02)00282-3
   Chen CC, 1999, LANGMUIR, V15, P6845, DOI 10.1021/la990165p
   Chen JL, 2006, ANAL CHIM ACTA, V577, P77, DOI 10.1016/j.aca.2006.06.039
   Chen YF, 2002, ANAL CHEM, V74, P5132, DOI 10.1021/ac0258251
   Chowdhury S, 2005, NUCL INSTRUM METH B, V240, P690, DOI 10.1016/j.nimb.2005.04.127
   Clapp AR, 2005, J AM CHEM SOC, V127, P18212, DOI 10.1021/ja054630i
   Dabbousi BO, 1997, J PHYS CHEM B, V101, P9463, DOI 10.1021/jp971091y
   Dong F, 2009, MICROCHIM ACTA, V165, P195, DOI 10.1007/s00604-008-0120-4
   Duong HD, 2007, TALANTA, V73, P899, DOI 10.1016/j.talanta.2007.05.011
   Gao MY, 1998, J PHYS CHEM B, V102, P8360, DOI 10.1021/jp9823603
   Gerion D, 2001, J PHYS CHEM B, V105, P8861, DOI 10.1021/jp0105488
   Goldman ER, 2002, J AM CHEM SOC, V124, P6378, DOI 10.1021/ja0125570
   Koneswaran M, 2009, SENSOR ACTUAT B-CHEM, V139, P91, DOI 10.1016/j.snb.2008.09.011
   Koneswaran M, 2009, SENSOR ACTUAT B-CHEM, V139, P104, DOI 10.1016/j.snb.2008.09.028
   Kuang R, 2010, MICROCHIM ACTA, V169, P109, DOI 10.1007/s00604-010-0323-3
   Landes C, 2001, J PHYS CHEM B, V105, P2981, DOI 10.1021/jp0041050
   Li H, 2007, IND ENG CHEM RES, V46, P2013, DOI 10.1021/ie060963s
   Liang JG, 2006, TALANTA, V69, P126, DOI 10.1016/j.talanta.2005.09.004
   Liang JG, 2004, ANALYST, V129, P619, DOI 10.1039/b317044f
   Lin CI, 2004, BIOSENS BIOELECTRON, V20, P127, DOI 10.1016/j.bios.2003.10.017
   Liu SM, 2000, PHYSICA E, V8, P174, DOI 10.1016/S1386-9477(99)00260-X
   Micic OI, 2000, J PHYS CHEM B, V104, P12149, DOI 10.1021/jp0021502
   MURRAY CB, 1993, J AM CHEM SOC, V115, P8706, DOI 10.1021/ja00072a025
   Myung N, 2003, NANO LETT, V3, P747, DOI 10.1021/nl034165s
   Peng H, 2007, J LUMIN, V127, P721, DOI 10.1016/j.jlumin.2007.04.007
   Peng XG, 1997, J AM CHEM SOC, V119, P7019, DOI 10.1021/ja970754m
   Rosi NL, 2005, CHEM REV, V105, P1547, DOI 10.1021/cr030067f
   Sandor M, 1999, ANAL CHIM ACTA, V388, P19, DOI 10.1016/S0003-2670(99)00096-3
   Smith AM, 2004, ANALYST, V129, P672, DOI 10.1039/b404498n
   Song KK, 2001, CURR APPL PHYS, V1, P169, DOI 10.1016/S1567-1739(01)00012-8
   Steckel JS, 2004, ANGEW CHEM INT EDIT, V43, P2154, DOI 10.1002/anie.200453728
   Tian YC, 1996, J PHYS CHEM-US, V100, P8927, DOI 10.1021/jp951965l
   Young S, 2007, SPECTROCHIM ACTA A, V68, P705, DOI 10.1016/j.saa.2006.12.049
   Zhang LJ, 2009, MICROCHIM ACTA, V166, P61, DOI 10.1007/s00604-009-0164-0
   Zhu CQ, 2005, CHEM LETT, V34, P898, DOI 10.1246/cl.2005.898
NR 39
TC 27
Z9 29
U1 4
U2 73
PU SPRINGER WIEN
PI WIEN
PA SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA
SN 0026-3672
EI 1436-5073
J9 MICROCHIM ACTA
JI Microchim. Acta
PD JUL
PY 2012
VL 178
IS 1-2
BP 171
EP 178
DI 10.1007/s00604-012-0819-0
PG 8
WC Chemistry, Analytical
SC Chemistry
GA 962EW
UT WOS:000305524800020
DA 2018-12-27
ER

PT J
AU Tseng, CP
   Chang, ML
   Chen, CW
AF Tseng, Chun-Pin
   Chang, Min-Li
   Chen, Cheng-Wu
TI RETRACTED: Human factors of knowledge sharing intention among taiwanese
   enterprises: a preliminary study (Retracted article. See vol. 26, pg.
   295, 2016)
SO HUMAN FACTORS AND ERGONOMICS IN MANUFACTURING & SERVICE INDUSTRIES
LA English
DT Article; Retracted Publication
DE Knowledge management; Knowledge sharing; Human factor; Taiwanese
   enterprises; Small and medium enterprises
ID ORGANIZATIONAL-CLIMATE; MANAGEMENT-SYSTEMS; INFORMATION; OPPORTUNITY;
   MOTIVATION; ABILITY; COMMUNITIES; PERFORMANCE; FIRM; STICKINESS
AB Knowledge management (KM) is very important in the business world of today. The Taiwanese government has recognized the importance of KM in helping small and medium enterprises (SMEs) to innovate through both their internal core competencies and external resources. They have the KM promotion project to combine resources from the information service industry and the academic sector in order to assist SMEs, and have been attempting to introduce the process of KM since 1993. The motivation, opportunity, and ability (MOA) framework has been applied to study how this MOA availability drives knowledge sharing in large enterprises. This study investigates the factors or barriers that influence the intention of knowledge sharing in Taiwanese SMEs through the MOA framework. It should help business managers identify the motivational elements that can encourage investment in it, and then propose pragmatic suggestions for introducing KM initiatives in order to reinvigorate the numbers of KM-implementing SMEs in Taiwan. (c) 2012 Wiley Periodicals, Inc.
C1 [Chen, Cheng-Wu] Natl Kaohsiung Marine Univ, Inst Maritime Informat & Technol, Kaohsiung 80543, Taiwan.
   [Tseng, Chun-Pin] Armaments Bur, Chung Shan Inst Sci & Technol, Tao Yuan, Taiwan.
   [Chang, Min-Li] Univ Maryland, Univ Coll, College Pk, MD 20742 USA.
   [Chen, Cheng-Wu] Natl Cheng Kung Univ, Global Earth Observat & Data Anal Ctr, Tainan 701, Taiwan.
RP Chen, CW (reprint author), Natl Kaohsiung Marine Univ, Inst Maritime Informat & Technol, Kaohsiung 80543, Taiwan.
EM chengwu@mail.nkmu.edu.tw
FU National Science Council of Taiwan, R.O.C. [NSC 100-2221-E-022-013-MY2,
   NSC 100-2628-E-022-002-MY2, NSC 98-2221-E-366-006-MY2]
FX The authors acknowledge the financial support from the National Science
   Council of Taiwan, R.O.C., under project numbers NSC
   100-2221-E-022-013-MY2 and NSC 100-2628-E-022-002-MY2, and NSC
   98-2221-E-366-006-MY2. The authors are also most grateful for the kind
   assistance of Waldemar Karwowski, Editor of Human Factors and Ergonomics
   in Manufacturing & Service Industries, and the constructive suggestions
   of the anonymous reviewers, all of which has led to the making of
   several corrections and suggestions that have greatly aided us in the
   presentation of this paper.
CR Adler PS, 2002, ACAD MANAGE REV, V27, P17, DOI 10.2307/4134367
   Al-Alawi A.I., 2007, J KNOWLEDGE MANAGEME, V11, P22, DOI DOI 10.1108/13673270710738898
   Alavi M, 2001, MIS QUART, V25, P107, DOI 10.2307/3250961
   Alazmi M, 2003, TOTAL QUAL MANAG BUS, V14, P199, DOI 10.1080/1478336032000051386
   Anantatmula V., 2006, Journal of Knowledge Management, V10, P25, DOI 10.1108/13673270610679345
   Anantatmula Vittal S, 2008, VINE, V38, P445, DOI 10.1108/03055720810917705
   Anantatmula Vittal S, 2007, VINE, V37, P133, DOI 10.1108/03055720710759928
   APEC Committee on Trade and Investment, 2004, APEC SURV SMALL MED
   Ardichvili A., 2003, Journal of Knowledge Management, V7, P64, DOI 10.1108/13673270310463626
   Argote L, 2003, MANAGE SCI, V49, P571, DOI 10.1287/mnsc.49.4.571.14424
   Barua A, 1997, J INFORM SCI, V23, P239, DOI 10.1177/0165551974231786
   BATRA R, 1986, J CONSUM RES, V12, P432, DOI 10.1086/208528
   Bock GW, 2005, MIS QUART, V29, P87
   BOHN RE, 1994, SLOAN MANAGE REV, V36, P61
   BOLAND RJ, 1995, ORGAN SCI, V6, P350, DOI 10.1287/orsc.6.4.350
   Borgatti SP, 2003, MANAGE SCI, V49, P432, DOI 10.1287/mnsc.49.4.432.14428
   Boudreau J., 2003, Manufacturing & Service Operations Management, V5, P179, DOI 10.1287/msom.5.3.179.16032
   Bowman BJ, 2002, INFORM SYST MANAGE, V19, P32, DOI 10.1201/1078/43201.19.3.20020601/37168.5
   Brooking A, 1997, LONG RANGE PLANN, V30, P364, DOI 10.1016/S0024-6301(97)80911-9
   Burgess D., 2005, Journal of Business Communication, V42, P324, DOI 10.1177/0021943605279485
   Burt RS, 1997, ADMIN SCI QUART, V42, P339, DOI 10.2307/2393923
   Butler JK, 1999, GROUP ORGAN MANAGE, V24, P217, DOI 10.1177/1059601199242005
   Cabrera A, 2002, ORGAN STUD, V23, P687, DOI 10.1177/0170840602235001
   Chan I., 2006, KNOWLEDGE MANAGEMENT, V9, P8
   Chauvel D., 2002, Journal of Knowledge Management, V6, P207, DOI 10.1108/13673270210434322
   Chen W. J., 2004, THESIS MING CHI U TE
   Choi B, 2003, INFORM MANAGE-AMSTER, V40, P403, DOI 10.1016/S0378-7206(02)00060-5
   Choi SY, 2008, J INF SCI, V34, P742, DOI 10.1177/0165551507087710
   Clark BH, 2005, J STRATEG MARK, V13, P241, DOI 10.1080/09652540500338014
   Coakes E, 2006, LEARN ORGAN, V13, P579, DOI 10.1108/09696470610705460
   Connelly EC, 2003, LEADERSHIP ORG DEV J, V24, P294, DOI DOI 10.1108/01437730310485815
   DAVENPORT T. H, 1998, WORKING KNOWLEDGE
   Davenport TH, 1998, SLOAN MANAGE REV, V39, P43
   Desouza K. C., 2006, Journal of Knowledge Management, V10, P32, DOI 10.1108/13673270610650085
   DeVellis R.F, 1998, SCALE DEV THEORY APP
   Duffy J., 2000, Information Management Journal, V34, P64
   Dyer JH, 2000, STRATEGIC MANAGE J, V21, P345, DOI 10.1002/(SICI)1097-0266(200003)21:3<345::AID-SMJ96>3.3.CO;2-E
   Gee Woo Bock, 2002, Information Resources Management Journal, V15, P14, DOI 10.4018/irmj.2002040102
   GRANT RM, 1991, CALIF MANAGE REV, V33, P114, DOI 10.2307/41166664
   Grant RM, 1996, STRATEGIC MANAGE J, V17, P109, DOI 10.1002/smj.4250171110
   Gupta AK, 2000, SLOAN MANAGE REV, V42, P71
   Gupta KS, 2008, KNOWL PROCESS MANAG, V15, P186, DOI 10.1002/kpm.309
   Hallahan K, 2000, PUBLIC RELAT REV, V26, P463, DOI 10.1016/S0363-8111(00)00059-X
   Hendriks Paul, 1999, KNOWLEDGE PROCESS MA, V6, P91, DOI [DOI 10.1002/(SICI)1099-1441(199906)6:2<LESS, DOI 10.1002/(SICI)1099-1441(199906)6:2<91::AID-KPM54>3.0.CO;2-M]
   HERZBERG F, 1987, HARVARD BUS REV, V65, P109
   Hsiu-Fen Lin, 2006, Management Decision, V44, P74, DOI 10.1108/00251740610641472
   Hsu LL, 2006, J COMPUT INFORM SYST, V46, P8
   Hsueh Y. L., 2005, THESIS NATL CHANGHUA
   Huysman M, 2006, J INF TECHNOL, V21, P40, DOI 10.1057/palgrave.jit.2000053
   Jones S., 2002, EMPLOYEE RESPONSIBIL, V14, P69
   Kearns GS, 2007, IEEE T ENG MANAGE, V54, P628, DOI 10.1109/TEM.2007.906848
   Kuan Yew Wong, 2005, Journal of Knowledge Management, V9, P64, DOI 10.1108/13673270510602773
   Kuo L. C., 2005, THESIS NATL PINTUNG
   Lee C. C., 2003, THESIS PROVIDENCE U
   Lee JH, 2006, INF RESOUR MANAG J, V19, P48
   Lesser EL, 2001, IBM SYST J, V40, P831, DOI 10.1147/sj.404.0831
   Liebowitz J., 1999, KNOWLEDGE PROCESS MA, V6, P37, DOI DOI 10.1002/(SICI)1099-1441(199903)6:1<37::AID-KPM40>3.0.CO;2-M
   Lu C. T., 1997, THESIS NATL SUN YAT
   MACINNIS DJ, 1991, J MARKETING, V55, P32, DOI 10.2307/1251955
   Masrek Mohamad Noorman, 2008, Information Management & Computer Security, V16, P89, DOI 10.1108/09685220810879591
   McDermott R., 2001, J KNOWLEDGE MANAGEME, V5, P76, DOI DOI 10.1108/13673270110384428
   Migdadi M, 2009, IND MANAGE DATA SYST, V109, P840, DOI 10.1108/02635570910968072
   Nahapiet J, 1998, ACAD MANAGE REV, V23, P242, DOI 10.2307/259373
   NONAKA I, 1994, ORGAN SCI, V5, P14, DOI 10.1287/orsc.5.1.14
   Nonaka I, 1996, INT J TECHNOL MANAGE, V11, P833
   O'Dell C, 1998, CALIF MANAGE REV, V40, P154, DOI 10.2307/41165948
   Politis J. D., 2003, Journal of Knowledge Management, V7, P55, DOI 10.1108/13673270310505386
   Probst G., 2000, MANAGING KNOWLEDGE B
   Reid F., 2003, EMPLOYMENT RELATIONS, V30, P43, DOI DOI 10.1002/ERT.10097
   Roth A. V., 1994, PLANNING REV, V22, P26
   Rothschild ML, 1999, J MARKETING, V63, P24, DOI 10.2307/1251972
   Ruggles R, 1998, CALIF MANAGE REV, V40, P80, DOI 10.2307/41165944
   Ruppel CP, 2001, IEEE T PROF COMMUN, V44, P37, DOI 10.1109/47.911131
   Saunders M., 2007, RES METHODS BUSINESS
   Schepers P, 2007, J BUS PSYCHOL, V21, P407, DOI 10.1007/s10869-006-9035-4
   Siemsen E, 2008, J OPER MANAG, V26, P426, DOI 10.1016/j.jom.2007.09.001
   Siemsen E, 2007, MANAGE SCI, V53, P1533, DOI 10.1287/mnsc.1070.0714
   Spender JC, 1996, STRATEGIC MANAGE J, V17, P5, DOI 10.1002/smj.4250171103
   Srivastava A., 2002, J LEADERSH ORG STUD, V9, P64, DOI [10.1177/107179190200900105, DOI 10.1177/107179190200900105]
   Staples DS, 2008, INFORM SYST J, V18, P617, DOI 10.1111/j.1365-2575.2007.00244.x
   Su C.-J., 2007, J GLOBAL BUSINESS TE, V3, P1
   Sung-Ho Yu, 2007, Journal of Knowledge Management, V11, P39, DOI 10.1108/13673270710832154
   Szulanski G, 1996, STRATEGIC MANAGE J, V17, P27, DOI 10.1002/smj.4250171105
   Szulanski G, 2000, ORGAN BEHAV HUM DEC, V82, P9, DOI 10.1006/obhd.2000.2884
   Szulanski G, 2004, ORGAN SCI, V15, P600, DOI 10.1287/orsc.1040.0096
   Teece DJ, 1997, STRATEGIC MANAGE J, V18, P509, DOI 10.1002/(SICI)1097-0266(199708)18:7<509::AID-SMJ882>3.0.CO;2-Z
   TYMON WG, 2003, CAREER DEV INT, V8, P12, DOI DOI 10.1108/13620430310459478
   Walker G, 1997, ORGAN SCI, V8, P109, DOI 10.1287/orsc.8.2.109
   Wasko MM, 2005, MIS QUART, V29, P35
   Wasko MM, 2000, J STRATEGIC INF SYST, V9, P155
   Widen-Wulff G, 2007, INF RESOUR MANAG J, V20, P46, DOI 10.4018/irmj.2007010104
   Wong KY, 2005, IND MANAGE DATA SYST, V105, P261, DOI 10.1108/02635570510590101
   Wu Z. W., 2005, THESIS HSIH HSIN U
   Xie S. Y., 2004, THESIS NATL CHENGCHI
NR 94
TC 17
Z9 17
U1 2
U2 50
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1090-8471
EI 1520-6564
J9 HUM FACTOR ERGON MAN
JI Hum. Factors Ergonom. Manuf. Serv. Ind.
PD JUL-AUG
PY 2012
VL 22
IS 4
BP 328
EP 339
DI 10.1002/hfm.20507
PG 12
WC Engineering, Manufacturing; Ergonomics
SC Engineering
GA 956IH
UT WOS:000305082800005
DA 2018-12-27
ER

PT J
AU Chen, CW
   Chang, ML
   Tseng, CP
AF Chen, Cheng-Wu
   Chang, Min-Li
   Tseng, Chun-Pin
TI RETRACTED: Human factors of knowledge-sharing intention among taiwanese
   enterprises: A model of hypotheses (Retracted article. See vol. 26, pg.
   287, 2016)
SO HUMAN FACTORS AND ERGONOMICS IN MANUFACTURING & SERVICE INDUSTRIES
LA English
DT Article; Retracted Publication
DE Knowledge management; Knowledge sharing; Human factor; Taiwanese
   Enterprises; Small and medium enterprises
ID MANAGEMENT-SYSTEMS; OPPORTUNITY; COMMUNITIES; MOTIVATION; ABILITY;
   PERFORMANCE; INFORMATION; STICKINESS; FRAMEWORK; NETWORKS
AB Knowledge management (KM) is very important in the business world of today. The Taiwanese government has recognized the importance of KM in helping small and medium enterprises (SMEs) to innovate through both their internal core competencies and external resources. This study combines the concept of social capital and motivationopportunityability models by both social and technological dimensions to investigate the human factors that characterize knowledge sharing and the motivational elements that can encourage investment in it. In addition, this study also proposes some possible perspective suggestions for implementing KM initiatives to reinvigorate Taiwanese SMEs. (c) 2012 Wiley Periodicals, Inc.
C1 [Chen, Cheng-Wu] Natl Kaohsiung Marine Univ, Inst Maritime Informat & Technol, Kaohsiung 80543, Taiwan.
   [Chang, Min-Li] Univ Maryland, Univ Coll, College Pk, MD 20742 USA.
   [Tseng, Chun-Pin] Armaments Bur, Chung Shan Inst Sci & Technol, Tao Yuan, Taiwan.
   [Chen, Cheng-Wu] Natl Cheng Kung Univ, Global Earth Observat & Data Anal Ctr, Tainan 701, Taiwan.
RP Chen, CW (reprint author), Natl Kaohsiung Marine Univ, Inst Maritime Informat & Technol, Kaohsiung 80543, Taiwan.
EM chengwu@mail.nkmu.edu.tw
FU National Science Council of Taiwan, R.O.C. [NSC 98-2221-E-366-006-MY2,
   NSC 100-2221-E-022-013-MY2, NSC 100-2628-E-022-002-MY2]
FX The authors acknowledge financial support from the National Science
   Council of Taiwan, R.O.C., under project number NSC
   98-2221-E-366-006-MY2, NSC 100-2221-E-022-013-MY2 and NSC
   100-2628-E-022-002-MY2. The authors are also most grateful for the kind
   assistance of Prof. Waldemar Karwowski, Editor of Human Factors and
   Ergonomics in Manufacturing & Service Industries, and the constructive
   suggestions of the anonymous reviewers, all of which has led to the
   making of several corrections and suggestions that have greatly aided us
   in the presentation of this paper.
CR Adler PS, 2002, ACAD MANAGE REV, V27, P17, DOI 10.2307/4134367
   Alavi M, 2001, MIS QUART, V25, P107, DOI 10.2307/3250961
   Ardichvili A., 2003, Journal of Knowledge Management, V7, P64, DOI 10.1108/13673270310463626
   Argote L, 2003, MANAGE SCI, V49, P571, DOI 10.1287/mnsc.49.4.571.14424
   BATRA R, 1986, J CONSUM RES, V12, P432, DOI 10.1086/208528
   BOLAND RJ, 1995, ORGAN SCI, V6, P350, DOI 10.1287/orsc.6.4.350
   Borgatti SP, 2003, MANAGE SCI, V49, P432, DOI 10.1287/mnsc.49.4.432.14428
   Boudreau J., 2003, Manufacturing & Service Operations Management, V5, P179, DOI 10.1287/msom.5.3.179.16032
   Bowman BJ, 2002, INFORM SYST MANAGE, V19, P32, DOI 10.1201/1078/43201.19.3.20020601/37168.5
   Cabrera A, 2002, ORGAN STUD, V23, P687, DOI 10.1177/0170840602235001
   Chan I., 2006, KNOWLEDGE MANAGEMENT, V9, P8
   Chen W. J., 2004, THESIS MING CHI U TE
   Choi B, 2003, INFORM MANAGE-AMSTER, V40, P403, DOI 10.1016/S0378-7206(02)00060-5
   Clark BH, 2005, J STRATEG MARK, V13, P241, DOI 10.1080/09652540500338014
   DAVENPORT T. H, 1998, WORKING KNOWLEDGE
   Davenport TH, 1998, SLOAN MANAGE REV, V39, P43
   Desouza K. C., 2006, Journal of Knowledge Management, V10, P32, DOI 10.1108/13673270610650085
   Grant RM, 1996, STRATEGIC MANAGE J, V17, P109, DOI 10.1002/smj.4250171110
   Gupta AK, 2000, SLOAN MANAGE REV, V42, P71
   Gupta KS, 2008, KNOWL PROCESS MANAG, V15, P186, DOI 10.1002/kpm.309
   Hallahan K, 2000, PUBLIC RELAT REV, V26, P463, DOI 10.1016/S0363-8111(00)00059-X
   Hendriks Paul, 1999, KNOWLEDGE PROCESS MA, V6, P91, DOI [DOI 10.1002/(SICI)1099-1441(199906)6:2<LESS, DOI 10.1002/(SICI)1099-1441(199906)6:2<91::AID-KPM54>3.0.CO;2-M]
   HERZBERG F, 1987, HARVARD BUS REV, V65, P109
   Hsueh Y. L., 2005, THESIS NATL CHANGHUA
   Huysman M, 2006, J INF TECHNOL, V21, P40, DOI 10.1057/palgrave.jit.2000053
   Kuan Yew Wong, 2005, Journal of Knowledge Management, V9, P64, DOI 10.1108/13673270510602773
   Kuo L. C., 2005, THESIS NATL PINTUNG
   Lee C. C., 2003, THESIS PROVIDENCE U
   Lesser EL, 2001, IBM SYST J, V40, P831, DOI 10.1147/sj.404.0831
   Lu C. T., 1997, THESIS NATL SUN YAT
   MACINNIS DJ, 1991, J MARKETING, V55, P32, DOI 10.2307/1251955
   Migdadi M, 2009, IND MANAGE DATA SYST, V109, P840, DOI 10.1108/02635570910968072
   Nahapiet J, 1998, ACAD MANAGE REV, V23, P242, DOI 10.2307/259373
   Nonaka I, 2000, LONG RANGE PLANN, V33, P5, DOI 10.1016/S0024-6301(99)00115-6
   Nonaka I., 1995, KNOWLEDGE CREATING C
   O'Dell C, 1998, CALIF MANAGE REV, V40, P154, DOI 10.2307/41165948
   Politis J. D., 2003, Journal of Knowledge Management, V7, P55, DOI 10.1108/13673270310505386
   Roth A. V., 1994, PLANNING REV, V22, P26
   Rothschild ML, 1999, J MARKETING, V63, P24, DOI 10.2307/1251972
   Siemsen E, 2008, J OPER MANAG, V26, P426, DOI 10.1016/j.jom.2007.09.001
   Siemsen E, 2007, MANAGE SCI, V53, P1533, DOI 10.1287/mnsc.1070.0714
   Srivastava A., 2002, J LEADERSH ORG STUD, V9, P64, DOI [10.1177/107179190200900105, DOI 10.1177/107179190200900105]
   Su C.-J., 2007, J GLOBAL BUSINESS TE, V3, P1
   Szulanski G, 1996, STRATEGIC MANAGE J, V17, P27, DOI 10.1002/smj.4250171105
   Szulanski G, 2000, ORGAN BEHAV HUM DEC, V82, P9, DOI 10.1006/obhd.2000.2884
   Walker G, 1997, ORGAN SCI, V8, P109, DOI 10.1287/orsc.8.2.109
   Wasko MM, 2005, MIS QUART, V29, P35
   Wasko MM, 2000, J STRATEGIC INF SYST, V9, P155
   Widen-Wulff G, 2007, INF RESOUR MANAG J, V20, P46, DOI 10.4018/irmj.2007010104
   Wong KY, 2005, IND MANAGE DATA SYST, V105, P261, DOI 10.1108/02635570510590101
   Xie S. Y., 2004, THESIS NATL CHENGCHI
NR 51
TC 48
Z9 50
U1 1
U2 77
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1090-8471
EI 1520-6564
J9 HUM FACTOR ERGON MAN
JI Hum. Factors Ergonom. Manuf. Serv. Ind.
PD JUL-AUG
PY 2012
VL 22
IS 4
BP 362
EP 371
DI 10.1002/hfm.20286
PG 10
WC Engineering, Manufacturing; Ergonomics
SC Engineering
GA 956IH
UT WOS:000305082800008
DA 2018-12-27
ER

PT J
AU Guo, JJ
   Zhang, LH
   Wang, HT
   Feng, GQ
AF Guo, Jingjing
   Zhang, Liehui
   Wang, Haitao
   Feng, Guoqing
TI RETRACTED: Pressure Transient Analysis for Multi-stage Fractured
   Horizontal Wells in Shale Gas Reservoirs (Retracted article. See vol.
   108, pg. 731, 2015)
SO TRANSPORT IN POROUS MEDIA
LA English
DT Article; Retracted Publication
DE Shale gas; Multi-stage fractured horizontal well; Desorption; Diffusion;
   Mathematical model
ID FLOW
AB This article presents the PTA on the multi-stage fractured horizontal well in shale gas reservoirs incorporating desorption and diffusive flow in the matrix. Currently, most PTA models are simply based on Darcy flow both in natural fractures and matrix without considering the mechanisms of desorption and diffusion in shale matrix. Source function and Laplace transform with the numerical discrete method are employed to solve the mathematical model. The solution is presented in the Laplace domain so that the wellbore storage effect and skin factor can be easily incorporated by convolution. Type curves are plotted with Stehfest algorithm and different flow regimes are identified. The presented model could be used to interpret pressure signals more accurately for shale gas reservoirs.
C1 [Guo, Jingjing; Zhang, Liehui; Wang, Haitao; Feng, Guoqing] SW Petr Univ, State Key Lab Oil & Gas Reservoir Geol & Exploita, Chengdu 610500, Peoples R China.
RP Zhang, LH (reprint author), SW Petr Univ, State Key Lab Oil & Gas Reservoir Geol & Exploita, 8 Xindu Ave, Chengdu 610500, Peoples R China.
EM zhangliehui@vip.163.com
FU National Science Fund for Distinguished Young Scholars of China
   [51125019]; National Program on Key fundamental Research Project (973
   Program) [2011CB201005]
FX This study was supported by National Science Fund for Distinguished
   Young Scholars of China (Grant No. 51125019) and the National Program on
   Key fundamental Research Project (973 Program, Grant No. 2011CB201005).
CR ALKOBAISI M, 2006, SPE RESERV EVAL ENG, V24, P345, DOI DOI 10.2118/92040-PA
   Brown M. L, 2009, SPE ANN TECHN C EXH, DOI [10.2118/125043-MS, DOI 10.2118/125043-MS]
   Cheng Y., 2011, SPE E REG M COL OH 1, DOI [10.2118/149311-MS, DOI 10.2118/149311-MS]
   Freeman C.M., 2009, SPE ANN TECHN C EXH, DOI [10.2118/124961-MS, DOI 10.2118/124961-MS]
   Hasan A.A., 2010, SPE UNC GAS C PITTSB, DOI [10.2118/130370-MS, DOI 10.2118/130370-MS]
   Hill D.G., 2000, GAS TIPS, V6, P4
   Javadpour F, 2007, J CAN PETROL TECHNOL, V46, P55, DOI 10.2118/07-10-06
   Javadpour F, 2009, J CAN PETROL TECHNOL, V48, P16, DOI 10.2118/09-08-16-DA
   Larsen L., 1994, SPE ANN TECHN C EXH, DOI [10.2118/28389-MS, DOI 10.2118/28389-MS]
   Larsen L., 1991, INT ARCT TECHN C ANC, DOI DOI 10.2118/22076-MS
   mad B, 2011, SPE W N AM REG M ANC, DOI [10.2118/144057-MS, DOI 10.2118/144057-MS]
   Medeiros F, 2008, SPE RESERV EVAL ENG, V11, P902, DOI 10.2118/108110-PA
   Ozkan E, 2011, SPE RESERV EVAL ENG, V14, P248, DOI 10.2118/121290-PA
   Ozkan E., 2010, SPE ANN TECHN C EXH, P19, DOI [10.2118/134830-MS, DOI 10.2118/134830-MS]
   Raghavan R.S., 1997, SPE J, V2, P235, DOI DOI 10.2118/27652-PA
   STEHFEST H, 1970, COMMUN ACM, V13, P47, DOI 10.1145/361953.361969
NR 16
TC 43
Z9 57
U1 5
U2 44
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0169-3913
EI 1573-1634
J9 TRANSPORT POROUS MED
JI Transp. Porous Media
PD JUL
PY 2012
VL 93
IS 3
BP 635
EP 653
DI 10.1007/s11242-012-9973-4
PG 19
WC Engineering, Chemical
SC Engineering
GA 958GW
UT WOS:000305225500017
DA 2018-12-27
ER

PT J
AU Amsterdam, A
   Raanan, C
   Schreiber, L
   Freyhan, O
   Fabrikant, Y
   Melzer, E
AF Amsterdam, Abraham
   Raanan, Calanit
   Schreiber, Letizia
   Freyhan, Ora
   Fabrikant, Yakov
   Melzer, Ehud
TI RETRACTED: Use of multiple biomarkers for the localization and
   characterization of colon cancer stem cells by indirect
   immunocytochemistry (Retracted article. See vol. 41, pg. 1888, 2012)
SO INTERNATIONAL JOURNAL OF ONCOLOGY
LA English
DT Article; Retracted Publication
DE colon cancer stem cells; G protein-coupled receptor 5; gamma-synuclein;
   p53; KRAS; epiregulin
ID PROTEIN-COUPLED RECEPTOR; SELF-RENEWAL; COLORECTAL-CANCER;
   SMALL-INTESTINE; OVARIAN-CANCER; MARKER; GENES; GPR49; OVEREXPRESSION;
   IDENTIFICATION
AB In this study, we used LGR5, gamma-synuclein, p53, KRAS and epiregulin antibodies to localize stem cells by indirect immunocytochemistry in paraffin sections of normal and cancerous colon tissues. In the normal colon tissue, no staining of cells with LGR5, gamma-synuclein, p53 and KRAS antibodies was observed, apart from a few scattered cells in between the colon villi that were faintly stained with antibodies to LGR5. Staining of highly differentiated cancer tissue with LGR5 antibodies revealed single cells or clusters of up to 4 cells in the interior space of the carcinoma cell layers. Staining of poorly differentiated cancer tissues (stage I-IV) revealed 9-81 clustered stem cells. The number of clustered stem cells increased significantly with the tumor stage, when comparing stage II to stage IV (p<00048). Occasionally, the clustered stem cells appeared in the interphase between the colon stroma and the tumor tissue. Surprisingly, antibodies to p53 clearly stained the clusters of stem cells both in the nuclei and the cytoplasm. The staining of the nuclei of other cells in the undifferentiated tumors was in general weaker, and no staining was found in the cytoplasm. Antibodies to gamma-synuclein heavily stained the endothelial cells of the blood vessels and some other scattered cells in the highly differentiated tumors. Antibodies to gamma-synuclein heavily stained the stem cells in both the cytoplasm and the nuclei of poorly differentiated tumors. Antibodies to KRAS stained the cytoplasm and the nuclei of stem cells in poorly differentiated tumors and also stained the cytoplasm of some scattered cells. Antibodies to epiregulin stained the cytoplasm of normal colon tissue cells in the crypt-villus axis. The antibodies weakly stained the highly differentiated tumor cells and moderately stained the moderately differentiated tumor cells. Of note, the antibodies intensively stained the clustered stem cells of the poorly differentiated tumor cells. These antibodies also clearly stained the clustered stem cells of poorly differentiated tumors but were not specific as they clearly stained cells in the crypt-villus axis of the normal colon wall. Our results show that LGR5 antibodies can serve as a reliable marker for colon cancer stem cells. Once the colon stem cells are identified, the targeting of specific drugs to kill these cells should be attempted in the future in order to cure this disease. Moreover, the fact that we did not find any stained cells with antibodies to LGR5 in normal tissues apart from a few scattered cells, suggests that the normal colon stem cells differ from the tumor stem cells at least as regards the expression of this protein. In addition, antibodies to gamma-synuclein, p53 and KRAS only stained the tumor stem cells and not the normal tissue. Thus, they can serve as multiple biomarkers for the localization of colon cancer stem cells by indirect immunofluorescence.
C1 [Amsterdam, Abraham; Freyhan, Ora] Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.
   [Raanan, Calanit] Weizmann Inst Sci, Biol Serv, IL-76100 Rehovot, Israel.
   [Schreiber, Letizia] Wolfson Govt Hosp, IL-58100 Holon, Israel.
   [Fabrikant, Yakov; Melzer, Ehud] Kaplan Med Ctr, IL-76100 Rehovot, Israel.
RP Amsterdam, A (reprint author), Weizmann Inst Sci, Dept Mol Cell Biol, 234 Herzl St, IL-76100 Rehovot, Israel.
EM abraham.amsterdam@weizmann.ac.il
CR Amsterdam A, 2012, INT J ONCOL, V40, P782, DOI 10.3892/ijo.2011.1268
   Amsterdam A, 2011, INT J ONCOL, V39, P1165, DOI 10.3892/ijo.2011.1123
   Amsterdam A, 2011, INT J ONCOL, V39, P649, DOI 10.3892/ijo.2011.1090
   Balschun K, 2011, EXPERT REV MOL DIAGN, V11, P799, DOI [10.1586/ERM.11.75, 10.1586/erm.11.75]
   Barker N, 2008, COLD SH Q B, V73, P351, DOI 10.1101/sqb.2008.72.003
   Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196
   Boman BM, 2008, J CLIN ONCOL, V26, P2828, DOI 10.1200/JCO.2008.17.6941
   Boman BM, 2008, CANCER RES, V68, P3304, DOI 10.1158/0008-5472.CAN-07-2061
   Burgess AW, 2011, EXP CELL RES, V317, P2748, DOI 10.1016/j.yexcr.2011.08.010
   Dhawan P, 2011, CURR TOP MED CHEM, V11, P1592
   Early DS, 2008, TRANSL RES, V151, P10, DOI 10.1016/j.trsl.2007.09.002
   Fan XS, 2010, INT J COLORECTAL DIS, V25, P583, DOI 10.1007/s00384-010-0903-z
   Goh AM, 2011, J PATHOL, V223, P116, DOI 10.1002/path.2784
   Golubovskaya VM, 2010, FRONT BIOSCI-LANDMRK, V15, P901, DOI 10.2741/3653
   Li HC, 2006, WORLD J GASTROENTERO, V12, P363, DOI 10.3748/wjg.v12.i3.363
   Haramis APG, 2004, SCIENCE, V303, P1684, DOI 10.1126/science.1093587
   He XC, 2004, NAT GENET, V36, P1117, DOI 10.1038/ng1430
   Hirose K, 2011, GENE EXPR PATTERNS, V11, P378, DOI 10.1016/j.gep.2011.04.002
   Hsu SY, 1998, MOL ENDOCRINOL, V12, P1830, DOI 10.1210/me.12.12.1830
   Huang Q, 2007, INT J SURG PATHOL, V15, P38, DOI 10.1177/1066896906295998
   Kawamura K, 2005, ANN NY ACAD SCI, V1041, P1, DOI 10.1196/annals.1282.001
   Korinek V, 1998, NAT GENET, V19, P379
   Liu CY, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-359
   Lobo NA, 2007, ANNU REV CELL DEV BI, V23, P675, DOI 10.1146/annurev.cellbio.22.010305.104154
   Maitland NJ, 2008, J CLIN ONCOL, V26, P2862, DOI 10.1200/JCO.2007.15.1472
   McClanahan T, 2006, CANCER BIOL THER, V5, P419, DOI 10.4161/cbt.5.4.2521
   Montgomery RK, 2008, J ANAT, V213, P52, DOI 10.1111/j.1469-7580.2008.00925.x
   Morita H, 2004, MOL CELL BIOL, V24, P9736, DOI 10.1128/MCB.24.22.9736-9743.2004
   National Toxicology Program, 2010, REP CARCINOG BACKGR, pi512
   Nicolis SK, 2007, NEUROBIOL DIS, V25, P217, DOI 10.1016/j.nbd.2006.08.022
   Normanno N, 2001, FRONT BIOSCI, V6, pD685, DOI 10.2741/Normano
   Park JI, 2005, ENDOCRINE, V26, P267, DOI 10.1385/ENDO:26:3:267
   Pierce G B, 1977, Adv Pathobiol, P141
   Radtke F, 2005, SCIENCE, V307, P1904, DOI 10.1126/science.1104815
   Rot S, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-429
   Tanese K, 2008, AM J PATHOL, V173, P835, DOI 10.2353/ajpath.2008.071091
   Timmons JA, 2005, BMC BIOL, V3, DOI 10.1186/1741-7007-3-19
   van der Flier LG, 2009, ANNU REV PHYSIOL, V71, P241, DOI 10.1146/annurev.physiol.010908.163145
   van Es JH, 2005, NATURE, V435, P959, DOI 10.1038/nature03659
   Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499
   Yamamoto Y, 2003, HEPATOLOGY, V37, P528, DOI 10.1053/jhep.2003.50029
   Yokota T, ANTICANCER IN PRESS
NR 42
TC 3
Z9 5
U1 1
U2 12
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1019-6439
EI 1791-2423
J9 INT J ONCOL
JI Int. J. Oncol.
PD JUL
PY 2012
VL 41
IS 1
BP 285
EP 291
DI 10.3892/ijo.2012.1430
PG 7
WC Oncology
SC Oncology
GA 949LX
UT WOS:000304578800035
PM 22504585
OA Bronze
DA 2018-12-27
ER

PT J
AU Panigrahi, JK
   Amirapu, S
AF Panigrahi, Jitendra K.
   Amirapu, Susruta
TI RETRACTED: An assessment of EIA system in India (Retracted article. See
   vol. 70, pg. 81, 2018)
SO ENVIRONMENTAL IMPACT ASSESSMENT REVIEW
LA English
DT Article; Retracted Publication
DE EIA system in India; Environmental clearance
ID ENVIRONMENTAL-IMPACT ASSESSMENT
AB Environmental impact assessment (EIA) was first introduced in India based on the Environmental Protection Act (EPA), 1986. But formally it came in to effect, when Ministry of Environment and Forest (MoEF) has passed a major legislative measure under EPA in January 1994 for Environmental Clearance (EC) known as EIA Notification, 1994. Subsequently, EIA processes have been strengthened by MoEF by a series of amendments. The current practice is adhering to EIA Notification, 2006 and its amendments. The pieces of evidence collected and analysis in the present assessment suggest that, despite a sound legislative, administrative and procedural set-up EIA has not yet evolved satisfactorily in India. An appraisal of the EIA system against systematic evaluation criteria, based on discussions with various stakeholders, EIA expert committee members, approval authorities, project proponents. NGOs and consulting professionals, reveals various drawbacks of the EIA system. These mainly include: inadequate capacity of EIA approval authorities, deficiencies in screening and scoping, poor quality EIA reports, inadequate public participation and weak monitoring. Overall, EIA is used presently as a project justification tool rather than as a project planning tool to contribute to achieving sustainable development. While shortcomings are challenging, Government of India is showing a high degree of commitment. The EIA system in the country is undergoing progressive refinements by steadily removing the constraints. The paper identifies opportunities for taking advantage of the current circumstances for strengthening the EIA process. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Panigrahi, Jitendra K.] Berhampur Univ, Dept Marine Sci, Berhampur 760007, Orissa, India.
   [Amirapu, Susruta] L&T RAMBOLL, EIA Dept, Hyderabad 500029, Andhra Pradesh, India.
RP Panigrahi, JK (reprint author), Berhampur Univ, Dept Marine Sci, Berhampur 760007, Orissa, India.
EM Jitu@scientist.com; susrutaa@gmail.com
CR Ahmad B., 2002, ENVIRON IMPACT ASSES, P213, DOI DOI 10.1016/S0195-9255(02)00004-5
   Aschemann R, 2007, ENV ASSESSMENT LECT
   Banerjee S, 2003, POLLUTION SMALL SCAL
   Bartlett RV, 1989, POLICY IMPACT ASSESS, P143
   Bhatta R, 2003, SEZS ENV EC POLI MAY
   Biswas D, 1996, TECH MONITOR, V13, P16
   BOYLE J, 1998, ENVIRON IMPACT ASSES, V18, P95
   Briffett Clive, 1999, P143
   CHEN WM, 1999, ENVIRON IMPACT ASSES, V19, P457
   Clark B., 1984, PERSPECTIVES ENV IMP
   Clark Brian D., 1999, P35
   Dubey S, 2004, WEAKENING ENVIROCLEA
   El-Fadl K, 2004, ENVIRON IMPACT ASSES, V24, P553, DOI 10.1016/j.eiar.2004.01.004
   Elliott M, 2009, ENVIRON IMPACT ASSES, P279
   EU, 2005, ENV ASS
   Fearnside Philip M., 1994, IMPACT ASSESSMENT, V12, P21, DOI DOI 10.1080/07349165.1994.9725849
   Fuller J., 1999, HDB ENV IMPACT ASSES, V2, P55
   Glasson J, 1999, INTRO ENV IMPACT ASS
   Glasson JR, 2005, INTRO ENV IMPACT ASS
   Greenpeace, 1999, 059 U EX DEP BIOL SC
   Hirji R., 1991, International Journal of Water Resources Development, V7, P154, DOI 10.1080/07900629108722508
   Joseph K, 1998, MONOGRAPH ENV IMPACT
   Kohli K, 2005, ENV CLEARANCES PLUG, P91
   Lisle S, 2010, STRUCTURE ENV GOVERN, Vxlv
   Lohani B. N, 1997, ENV IMPACT ASSESSMEN
   Menon M, 2009, EC POLITICAL WEEKLY, VXLIV
   Menon M, 2008, EC POLITICAL WEE JUN
   Menon M, 2007, EC POLITICAL WE 0630, P2490
   MoEF, 2006, ENV IMP ASS NOT S O
   MoEF, 2003, REP FORM RE IN PRESS
   MoEF, 1994, ENV IMP ASS NOT S O
   MoEF, 1997, ENV PROT ACT NOT REG
   [MoEF Impact assessment division], 2001, ENV IMP ASS MAN
   MoEF, 1994, MOEF ANN REP
   Momtaz S., 2002, ENVIRON IMPACT ASSES, V22, P163, DOI DOI 10.1016/S0195-9255(01)00106-8
   Murthy A, 2005, ENV IMPACT ASSESSMEN
   Nadeem O, 2008, ENVIRON IMPACT ASSES, V28, P562, DOI 10.1016/j.eiar.2008.02.003
   Paliwal R, 2006, ENVIRON IMPACT ASSES, V26, P492, DOI 10.1016/j.eiar.2006.01.004
   Rajaram T, 2008, FUTURES, V40, P56, DOI 10.1016/j.futures.2007.06.002
   Rajaram T, 2011, J ENVIRON MANAGE, V92, P140, DOI 10.1016/j.jenvman.2010.08.024
   Rajaram T, 2006, IMPACT ASSESS PROJ A, V24, P115
   Rao CVC, 1997, TECH MONITOR, V14, P40
   Rao DB, 2008, EC POLITICAL WEE DEC
   Rosencranz A, 2009, EC POLITICAL WEE AUG, VXLIV
   Sadler B, 1996, ENV ASSESSMENT CHANG
   Sahoo P, 2008, DISCUSSION PAPER SER
   Saldanha LF, 2007, GREEN TAPISM REV ENV
   Sinclair A.J., 2000, IMPACT ASSESSMENT PR, V18, P63
   Sridhar Aarthi, 2009, ENV GOVERNANCE REFOR
   WANG Y, 2003, ENVIRON IMPACT ASSES, V23, P543, DOI DOI 10.1016/S0195-9255(03)00071-4
   WERNER G, 1992, ENVIRONMENTAL IMPACT ASSESSMENT FOR DEVELOPING COUNTRIES, P16
   Wood C., 1995, ENV IMPACT ASSESSMEN
   Wood CM, 2003, ENVIRON IMPACT ASSES, P12
   Zubair L., 2001, ENVIRON IMPACT ASSES, V21, P469, DOI DOI 10.1016/S0195-9255(01)00081-6
NR 54
TC 21
Z9 24
U1 2
U2 24
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0195-9255
EI 1873-6432
J9 ENVIRON IMPACT ASSES
JI Environ. Impact Assess. Rev.
PD JUL
PY 2012
VL 35
BP 23
EP 36
DI 10.1016/j.eiar.2012.01.005
PG 14
WC Environmental Studies
SC Environmental Sciences & Ecology
GA 944PX
UT WOS:000304217400003
DA 2018-12-27
ER

PT J
AU Peyghan, E
   Tayebi, A
   Ahmadi, A
AF Peyghan, E.
   Tayebi, A.
   Ahmadi, A.
TI RETRACTED: Complex Bogoslovsky Finsler metrics (Retracted article. See
   vol. 398, pg. 456, 2013)
SO JOURNAL OF MATHEMATICAL ANALYSIS AND APPLICATIONS
LA English
DT Article; Retracted Publication
DE Bogoslovsky metric; Complex Berwald space; Generalized Berwald space
ID SPACES; CONNECTION
AB In this paper, we introduce a new class of complex Finsler metrics called complex Bogoslovsky metrics. We find conditions under which a complex Bogoslovsky metric be Kahlerian, strongly Kahlerian, weakly Kahlerian, Hermitian and generalized Berwaldian. (c) 2012 Published by Elsevier Inc.
C1 [Peyghan, E.; Ahmadi, A.] Arak Univ, Dept Math, Fac Sci, Arak 3815688349, Iran.
   [Tayebi, A.] Univ Qom, Fac Sci, Dept Math, Qom, Iran.
RP Peyghan, E (reprint author), Arak Univ, Dept Math, Fac Sci, Arak 3815688349, Iran.
EM epeyghan@gmail.com; akbar.tayebi@gmail.com
CR Abate M., 1994, LECT NOTES MATH
   Aikou T, 1998, ILLINOIS J MATH, V42, P481
   Aikou T, 2003, PUBL MATH-DEBRECEN, V63, P343
   Aikou T., 1996, CONT MATH, P109
   Aikou T., 2005, FINSLER GEOMETRY, P1
   Aldea N, 2012, J GEOM PHYS, V62, P368, DOI 10.1016/j.geomphys.2011.10.010
   Aldea N, 2009, J KOREAN MATH SOC, V46, P949, DOI 10.4134/JKMS.2009.46.5.949
   Bogoslovsky G.Yu., 1992, CLASSICAL QUANTUM GR, V9, P569
   Chen B, 2009, CHINESE ANN MATH B, V30, P173, DOI 10.1007/s11401-008-0092-z
   Munteanu G., 2004, FUNDAM THEOR PHYS, V141
   Nishikawa S, 2004, PROG NONLIN, V59, P113
   Peyghan E, 2011, IRAN J SCI TECHNOL A, V35, P89
   Peyghan E, 2010, NONLINEAR ANAL-REAL, V11, P3021, DOI 10.1016/j.nonrwa.2009.10.022
   Peyghan E, 2010, J MATH PHYS, V51, DOI 10.1063/1.3293760
NR 14
TC 3
Z9 3
U1 1
U2 7
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0022-247X
J9 J MATH ANAL APPL
JI J. Math. Anal. Appl.
PD JUL 1
PY 2012
VL 391
IS 1
BP 159
EP 169
DI 10.1016/j.jmaa.2012.02.020
PG 11
WC Mathematics, Applied; Mathematics
SC Mathematics
GA 910XN
UT WOS:000301682000014
OA Bronze
DA 2018-12-27
ER

PT J
AU Bernasconi, R
   Galli, C
   Noack, J
   Bianchi, S
   de Haan, CAM
   Reggiori, F
   Molinari, M
AF Bernasconi, Riccardo
   Galli, Carmela
   Noack, Julia
   Bianchi, Siro
   de Haan, Cornelis A. M.
   Reggiori, Fulvio
   Molinari, Maurizio
TI RETRACTED: Role of the SEL1L:LC3-I Complex as an ERAD Tuning Receptor in
   the Mammalian ER (Retracted article. See vol. 56, pg. 819, 2014)
SO MOLECULAR CELL
LA English
DT Article; Retracted Publication
ID RETICULUM-ASSOCIATED DEGRADATION; UBIQUITIN-LIGASE COMPLEX;
   ENDOPLASMIC-RETICULUM; QUALITY-CONTROL; MISFOLDED GLYCOPROTEINS;
   MANNOSIDASE-I; PROTEIN; DISPOSAL; PATHWAY; EDEM1
AB Several regulators of endoplasmic reticulum (ER)associated degradation (ERAD) have a shorter half-life compared to conventional ER chaperones. At steady state, they are selectively removed from the ER by poorly defined events collectively referred to as ERAD tuning. Here we identify the complex comprising the type-I transmembrane protein SEL1L and the cytosolic protein LC3-I as an ERAD tuning receptor regulating the COPII-independent, vesicle-mediated removal of the lumenal ERAD regulators EDEM1 and OS-9 from the ER. Expression of folding-defective polypeptides enhances the lumenal content of EDEM1 and OS-9 by inhibiting their SEL1L:LC3-I-mediated segregation. This raises ERAD activity in the absence of UPR-induction. The mouse hepatitis virus (MHV) subverts ERAD tuning for replication. Consistently, SEL1L or LC3 silencing impair the MHV life cycle. Collectively, our data provide new molecular information about the ERAD tuning mechanisms that regulate ERAD in mammalian cells at the post translational level and how these mechanisms are hijacked by a pathogen.
C1 [Bernasconi, Riccardo; Galli, Carmela; Noack, Julia; Bianchi, Siro; Molinari, Maurizio] Inst Res Biomed, CH-6500 Bellinzona, Switzerland.
   [de Haan, Cornelis A. M.] Univ Utrecht, Fac Vet Med, Dept Infect Dis & Immunol, Div Virol, NL-3508 TC Utrecht, Netherlands.
   [Reggiori, Fulvio] Univ Med Ctr Utrecht, Dept Cell Biol, Utrecht, Netherlands.
   [Molinari, Maurizio] Ecole Polytech Fed Lausanne, Sch Life Sci, CH-1015 Lausanne, Switzerland.
RP Molinari, M (reprint author), Inst Res Biomed, CH-6500 Bellinzona, Switzerland.
EM maurizio.molinari@irb.usi.ch
OI Reggiori, Fulvio/0000-0003-2652-2686
FU Foundation for Research on Neurodegenerative Diseases; Fondazione San
   Salvatore; Swiss National Science Foundation; Association Francaise
   contre les Myopathies; Novartis Stiftung fur medizinisch-biologische
   Forschung; Gabriele Foundation; Netherlands Organization for Scientific
   Research (NWO-ALW); Netherlands Organization for Scientific Research
   (Chemical Sciences, ECHO) [700.59.003, 821.02.017, DN82-303]
FX We would like to thank M. Aebi, E. Fasana, R. Gauss, A. Helenius, D.
   Hebert, L. Ruddock, and R. Sitia for insightful comments and
   discussions; L. Ruddock, K. Yamamoto, N. Mizushima, T. Nakajima, H.L.
   Ploegh, and S. Tolchinsky for providing various reagents; Iryna
   Monastyrska, M. Thelen, and E. Montani for the assistance during
   microscope imaging, and M. Hunziker. M.M. is supported by grants from
   the Foundation for Research on Neurodegenerative Diseases, the
   Fondazione San Salvatore, the Swiss National Science Foundation, the
   Association Francaise contre les Myopathies, the Novartis Stiftung fur
   medizinisch-biologische Forschung and the Gabriele Foundation.
   C.A.M.d.H. was supported by a grant from the Netherlands Organization
   for Scientific Research (NWO-ALW). F.R. is supported by the Netherlands
   Organization for Scientific Research (Chemical Sciences, ECHO
   grant-700.59.003; Earth and Life Sciences, Open Program
   grant-821.02.017; Cooperation Germany-DN82-303).
CR Aebi M, 2010, TRENDS BIOCHEM SCI, V35, P74, DOI 10.1016/j.tibs.2009.10.001
   Ballar P, 2010, INT J BIOCHEM CELL B, V42, P167, DOI 10.1016/j.biocel.2009.10.005
   Bernasconi R, 2008, J BIOL CHEM, V283, P16446, DOI 10.1074/jbc.M802272200
   Bernasconi R, 2011, CURR OPIN CELL BIOL, V23, P176, DOI 10.1016/j.ceb.2010.10.002
   Bernasconi R, 2010, J CELL BIOL, V188, P223, DOI 10.1083/jcb.200910042
   Cali T, 2008, BIOCHEM BIOPH RES CO, V371, P405, DOI 10.1016/i.bbrc.2008.04.098
   Chen X, 2011, J CELL BIOL, V192, P825, DOI 10.1083/jcb.201008090
   Christianson JC, 2008, NAT CELL BIOL, V10, P272, DOI 10.1038/ncb1689
   Christianson JC, 2012, NAT CELL BIOL, V14, P93, DOI 10.1038/ncb2383
   Cormier JH, 2009, MOL CELL, V34, P627, DOI 10.1016/j.molcel.2009.05.018
   de Haan CAM, 2005, J VIROL, V79, P14451, DOI 10.1128/JVI.79.22.14451-14456.2005
   de Haan CAM, 2010, AUTOPHAGY, V6, P994, DOI 10.4161/auto.6.7.13309
   Durcan TM, 2012, J BIOL CHEM, V287, P531, DOI 10.1074/jbc.M111.288449
   Hanna J, 2012, J BIOL CHEM, V287, P8633, DOI 10.1074/jbc.M111.317644
   Hebert DN, 2010, SEMIN CELL DEV BIOL, V21, P526, DOI 10.1016/j.semcdb.2009.12.007
   HELENIUS A, 1994, MOL BIOL CELL, V5, P253
   Hori O, 2004, GENES CELLS, V9, P457, DOI 10.1111/j.1365-9597.2004.00735.x
   Joshi B, 2010, J BIOL CHEM, V285, P8830, DOI 10.1074/jbc.M109.074344
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Laney J. D., 2002, CURR PROTOC PROTEIN, V14, P5
   Le Fourn V, 2009, CELL MOL LIFE SCI, V66, P1434, DOI 10.1007/s00018-009-9038-1
   Lederkremer GZ, 2009, CURR OPIN STRUC BIOL, V19, P515, DOI 10.1016/j.sbi.2009.06.004
   Liang JS, 2003, J BIOL CHEM, V278, P23984, DOI 10.1074/jbc.M302683200
   Miura H, 2010, GENES CELLS, V15, P843, DOI 10.1111/j.1365-2443.2010.01422.x
   Molinari M, 2003, SCIENCE, V299, P1397, DOI 10.1126/science.1079474
   Molinari M, 2007, NAT CHEM BIOL, V3, P313, DOI 10.1038/nchembio880
   Mueller B, 2006, J CELL BIOL, V175, P261, DOI 10.1083/jcb.200605196
   Nunziante M, 2011, J BIOL CHEM, V286, P33942, DOI 10.1074/jbc.M111.272617
   Olivari S, 2006, BIOCHEM BIOPH RES CO, V349, P1278, DOI 10.1016/j.bbrc.2006.08.186
   Reggiori F, 2010, CELL HOST MICROBE, V7, P500, DOI 10.1016/j.chom.2010.05.013
   Saeed M, 2011, J BIOL CHEM, V286, P37264, DOI 10.1074/jbc.M111.259085
   Satoh T, 2010, MOL CELL, V40, P905, DOI 10.1016/j.molcel.2010.11.017
   Shmueli A, 2009, BIOCHEM BIOPH RES CO, V390, P758, DOI 10.1016/j.bbrc.2009.10.045
   Smith MH, 2011, SCIENCE, V334, P1086, DOI 10.1126/science.1209235
   Stagg HR, 2009, J CELL BIOL, V186, P685, DOI 10.1083/jcb.200906110
   Tamura T, 2010, MOL MEMBR BIOL, V27, P412, DOI 10.3109/09687688.2010.495354
   Termine DJ, 2009, J CELL SCI, V122, P976, DOI 10.1242/jcs.037291
   Tortorella D, 2000, ANNU REV IMMUNOL, V18, P861, DOI 10.1146/annurev.immunol.18.1.861
   Tsai YC, 2007, NAT MED, V13, P1504, DOI 10.1038/nm1686
   Vembar SS, 2008, NAT REV MOL CELL BIO, V9, P944, DOI 10.1038/nrm2546
   Walter P, 2011, SCIENCE, V334, P1081, DOI 10.1126/science.1209038
   Wang F, 2011, J BIOL CHEM, V286, P43454, DOI 10.1074/jbc.M111.274332
   Wang F, 2012, J BIOL CHEM, V287, P10482, DOI 10.1074/jbc.M111.312223
   Wu Y, 2003, P NATL ACAD SCI USA, V100, P8229, DOI 10.1073/pnas.1430537100
   Wu Y, 2007, J BIOL CHEM, V282, P4841, DOI 10.1074/jbc.M607156200
   Yamasaki S, 2005, ARTHRITIS RES THER, V7, P181, DOI 10.1186/ar1808
   Younger JM, 2006, CELL, V126, P571, DOI 10.1016/j.cell.2006.06.041
   Zuber C, 2007, P NATL ACAD SCI USA, V104, P4407, DOI 10.1073/pnas.0700154104
NR 48
TC 30
Z9 30
U1 2
U2 17
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 1097-2765
EI 1097-4164
J9 MOL CELL
JI Mol. Cell
PD JUN 29
PY 2012
VL 46
IS 6
BP 809
EP 819
DI 10.1016/j.molcel.2012.04.017
PG 11
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 969ZD
UT WOS:000306097000011
PM 22633958
OA Bronze
DA 2018-12-27
ER

PT J
AU Ali, S
   Ahmad, A
   Aboukameel, A
   Bao, B
   Padhye, S
   Philip, PA
   Sarkar, FH
AF Ali, Shadan
   Ahmad, Aamir
   Aboukameel, Amro
   Bao, Bin
   Padhye, Subhash
   Philip, Philip A.
   Sarkar, Fazlul H.
TI RETRACTED: Increased Ras GTPase activity is regulated by miRNAs that can
   be attenuated by CDF treatment in pancreatic cancer cells (Retracted
   article. See vol. 414, pg. 313, 2018)
SO CANCER LETTERS
LA English
DT Article; Retracted Publication
DE Ras GTPase activity; K-Ras; miRNAs; CDF; Xenograft mouse model
ID LET-7 MICRORNA-BINDING; POTENTIAL TUMOR-SUPPRESSOR; GROWTH-FACTOR
   RECEPTOR; ONCOGENIC K-RAS; 3'-UNTRANSLATED REGION; MIR-21 EXPRESSION;
   SITE POLYMORPHISM; KRAS; PROLIFERATION; CYCLOOXYGENASE-2
AB Ras gene is frequently mutated, and also associated with increased Ras expression and its GTPase activity (activity) in pancreatic cancer (PC), which could in part be due to deregulated expression of microRNAs (miRNAs) contributing to tumor aggressiveness. Here we report, for the first time, that Ras expression and its activity were significantly higher in MIAPaCa-2 cells compared to COLO-357 and BxPC-3 cell lines, which was correlated with loss of let-7 family and miR-143 expression in MIAPaCa-2 cells compared to COLO-357 and BxPC-3 cells. Whereas the expression of miR-21, a frequently up-regulated miRNA in solid tumors was up-regulated in MIAPaCa-2 cells and it was correlated with increased Ras expression and its activity. The miRNAs, let-7i and miR-143 was found to target Ras, and forced re-expression of let-7i and miR-143 inhibited Ras activity, cell proliferation and colony formation in vitro. We also found that the treatment of cells in vitro or treatment of MIAPaCa-2 induced tumors in vivo with CDF, a novel synthetic analog of curcumin, led to the re-expression of let-7 and miR-143, and down-regulated miR-21 expression, which was consistent with attenuation of Ras expression and its activity. Moreover, re-expression of let-7i in vivo resulted in decreased tumor growth and Ras activity. These results suggest that the loss of expression of let-7 and miR-143, and increased expression of miR-21 leads to increased expression of Ras and its GTPase activity, which could be attenuated by CDF treatment and, thus CDF could become a novel therapeutic agent for the treatment of PC. (C) 2012 Elsevier Ireland Ltd. All rights reserved.
C1 [Sarkar, Fazlul H.] Wayne State Univ, Dept Pathol, Karmanos Canc Inst, Sch Med,Hudson Webber Canc Res Ctr 740, Detroit, MI 48201 USA.
   [Ali, Shadan; Aboukameel, Amro; Philip, Philip A.; Sarkar, Fazlul H.] Wayne State Univ, Dept Oncol, Karmanos Canc Inst, Sch Med, Detroit, MI 48201 USA.
   [Padhye, Subhash] Abeda Inamdar Senior Coll, Interdisciplinary Sci & Technol Res Acad, Pune 411001, Maharashtra, India.
RP Sarkar, FH (reprint author), Wayne State Univ, Dept Pathol, Karmanos Canc Inst, Sch Med,Hudson Webber Canc Res Ctr 740, 4100 John R St, Detroit, MI 48201 USA.
EM fsarkar@med.wayne.edu
FU National Cancer Institute, NIH [5R01CA131151, 3R01CA131151-02S109,
   1R01CA154321, 1R01CA132794]
FX This work was funded by grants from the National Cancer Institute, NIH
   5R01CA131151, 3R01CA131151-02S109, 1R01CA154321, and 1R01CA132794
   awarded to FHS. We also thank Puschelberg and Guido foundations for
   their generous contribution.
CR Ali S, 2005, MOL CANCER THER, V4, P1943, DOI 10.1158/1535-7163.MCT-05-0065
   Ali S, 2011, AM J TRANSL RES, V3, P28
   Ali S, 2010, CANCER RES, V70, P3606, DOI 10.1158/0008-5472.CAN-09-4598
   Ali S, 2010, J CELL BIOCHEM, V110, P171, DOI 10.1002/jcb.22523
   Arvanitakis M, 2004, ENDOSCOPY, V36, P535, DOI 10.1055/s-2004-814401
   Bao B, 2011, J CELL BIOCHEM, V112, P2296, DOI 10.1002/jcb.23150
   Bao B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017850
   Caulin C, 2004, CANCER RES, V64, P5054, DOI 10.1158/0008-5472.CAN-04-1488
   Chin LJ, 2008, CANCER RES, V68, P8535, DOI 10.1158/0008-5472.CAN-08-2129
   Christensen BC, 2009, CARCINOGENESIS, V30, P1003, DOI 10.1093/carcin/bgp099
   Diederichs S, 2006, CANCER RES, V66, P6097, DOI 10.1158/0008-5472.CAN-06-0537
   Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840
   Friday BB, 2005, BBA-REV CANCER, V1756, P127, DOI 10.1016/j.bbcan.2005.08.001
   Graziano F, 2010, PHARMACOGENOMICS J, V10, P458, DOI 10.1038/tpj.2010.9
   He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552
   Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001
   Jeong SH, 2009, EXP MOL MED, V41, P912, DOI 10.3858/emm.2009.41.12.097
   Johnson CD, 2007, CANCER RES, V67, P7713, DOI 10.1158/0008-5472.CAN-07-1083
   Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014
   Kent OA, 2010, GENE DEV, V24, P2754, DOI 10.1101/gad.1950610
   Lee EJ, 2007, INT J CANCER, V120, P1046, DOI 10.1002/ijc.22394
   Lee YS, 2007, GENE DEV, V21, P1025, DOI 10.1101/gad.1540407
   Li YW, 2009, CANCER RES, V69, P6704, DOI 10.1158/0008-5472.CAN-09-1298
   Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702
   Morris JP, 2005, SCI STKE, V2005, ppe41
   Nakajima Go, 2006, Cancer Genomics & Proteomics, V3, P317
   Oh JS, 2010, INT J RADIAT ONCOL, V76, P5, DOI 10.1016/j.ijrobp.2009.08.028
   PADHYE S, 2009, PHARM RES
   Padhye S, 2009, PHARM RES-DORDR, V26, P1874, DOI 10.1007/s11095-009-9900-8
   Pramanik D, 2011, MOL CANCER THER, V10, P1470, DOI 10.1158/1535-7163.MCT-11-0152
   Smits K.M., 2011, CLIN CANC RES
   Takagi T, 2009, ONCOLOGY-BASEL, V77, P12, DOI 10.1159/000218166
   Talotta F, 2009, ONCOGENE, V28, P73, DOI 10.1038/onc.2008.370
   Torrisani J, 2009, HUM GENE THER, V20, P831, DOI 10.1089/hum.2008.134
   Tsang WP, 2009, CARCINOGENESIS, V30, P953, DOI 10.1093/carcin/bgp094
   Wang ZW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020537
   Watanabe S, 2009, AM J PATHOL, V174, P854, DOI 10.2353/ajpath.2009.080523
   Wickramasinghe NS, 2009, NUCLEIC ACIDS RES, V37, P2584, DOI 10.1093/nar/gkp117
   Yan LX, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2803
   Yang Y, 2010, MOL BIOSYST, V6, P1873, DOI 10.1039/c004401f
   Zhang W, 2011, ANN ONCOL, V22, P104, DOI 10.1093/annonc/mdq315
   Zhang YQ, 2009, WORLD J SURG, V33, P698, DOI 10.1007/s00268-008-9833-0
   Zhao WG, 2010, CARCINOGENESIS, V31, P1726, DOI 10.1093/carcin/bgq160
NR 43
TC 43
Z9 45
U1 2
U2 10
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3835
EI 1872-7980
J9 CANCER LETT
JI Cancer Lett.
PD JUN 28
PY 2012
VL 319
IS 2
BP 173
EP 181
DI 10.1016/j.canlet.2012.01.013
PG 9
WC Oncology
SC Oncology
GA 934ZV
UT WOS:000303487500007
PM 22261338
OA Green Accepted
DA 2018-12-27
ER

PT J
AU Moussavi-Najarkola, SA
   Khavanin, A
   Mirzaei, R
   Salehnia, M
   Akbari, M
AF Moussavi-Najarkola, Seyyed-Ali
   Khavanin, Ali
   Mirzaei, Ramazan
   Salehnia, Mojdeh
   Akbari, Mehdi
TI RETRACTED: Assessment of the influence of whole body vibration on
   Cochlear function(Retracted article. See vol.12, Artn no. 17, 2017)
SO JOURNAL OF OCCUPATIONAL MEDICINE AND TOXICOLOGY
LA English
DT Article; Retracted Publication
DE Cochlear function; Whole body vibration; Distortion product otoacoustic
   emissions; Rabbit's hearing; DPOAEs
ID PRODUCT OTOACOUSTIC EMISSIONS; ACOUSTIC DISTORTION PRODUCTS; IMPULSE
   NOISE; HEARING-LOSS; INNER-EAR; EXPOSURES; AMPLITUDE; RABBITS; LESIONS
AB Background: Whole body vibration (WBV) is a potentially harmful consequence resulting from the dissipation of energy by industrial machineries. The result of WBV exposure on the auditory system remains unknown. The objective of the present research was to evaluate the influence of WBV on cochlear function, in particular outer hair cell function. It is hypothesized that WBV impairs cochlear function resulting in decreased Distortion Product Otoacoustic Emission (DPOAE) levels (L-dp) in rabbits subjected to WBV.
   Methods: Twelve rabbits were equally divided into vibration and control groups. Animals in vibration group were exposed to 1.0 ms(-2) r.m.s vertical WBV at 4-8 Hz for 8 h/day during 5 consecutive days. Outer hair cell function was assessed by comparing repeated-measurements of DPOAE levels (L-dp) across a range of f(2) frequencies in rabbits both exposed and unexposed to WBV. DPOAE level shifts (LSdp) were compared across ears, frequencies, groups, and times.
   Results: No differences were seen over time in DPOAE levels in the non-exposed rabbits (p = 0.082). Post-exposure L-dp in rabbits exposed to WBV were significantly increased at all test frequencies in both ears compared to baseline measures (p = 0.021). The greatest increase in L-dp following exposure was seen at 5888.5 Hz (mean shift = 13.25 dB). Post-exposure L-dp in rabbits exposed to WBV were not significantly different between the right and left ears (p = 0.083).
   Conclusion: WBV impairs cochlear function resulting in increased DPOAE responses in rabbits exposed to WBV. DPOAE level shifts occurred over a wide range of frequencies following prolonged WBV in rabbits.
C1 [Moussavi-Najarkola, Seyyed-Ali; Khavanin, Ali] TMU, Sch Med Sci, Dept Occupat Hlth, Tehran, Iran.
   [Mirzaei, Ramazan] ZUMS, Hlth Promot Res Ctr, Dept Occupat Hlth, Zahedan, Iran.
   [Salehnia, Mojdeh] TMU, Sch Med Sci, Dept Anat Sci, Tehran, Iran.
   [Akbari, Mehdi] IUMS, Sch Rehabil, Dept Audiol, Tehran, Iran.
RP Khavanin, A (reprint author), TMU, Sch Med Sci, Dept Occupat Hlth, Tehran, Iran.
EM khavanin@modares.ac.ir
OI mirzaei, ramazan/0000-0003-1468-8910
FU Tarbiat Modares University
FX We would like to specially thank Professor Roger P. Hamernik for
   sincerely and friendly critical comments and technical support. We
   gratefully thank Professor Richard D. Kopke for helpful comments in
   early steps of starting this project. This study was supported by the
   Tarbiat Modares University.
CR Anderson SD, ARCH OTOLARYNGOL, V224, P47
   Bochnia M, 2005, EUR ARCH OTO-RHINO-L, V262, P307, DOI 10.1007/s00405-004-0799-8
   BROWN AM, 1987, HEARING RES, V31, P25, DOI 10.1016/0378-5955(87)90211-5
   Budak B, 2009, AURIS NASUS LARYNX, V36, P255, DOI 10.1016/j.anl.2008.04.011
   Budak GG, 2009, INT J PEDIATR OTORHI, V73, P1143, DOI 10.1016/j.ijporl.2009.04.020
   Cohn ES, 1999, PEDIATRICS, V103, P546, DOI 10.1542/peds.103.3.546
   Engdahl B, 1996, J ACOUST SOC AM, V99, P1573, DOI 10.1121/1.414733
   HAMERNIK RP, 1989, J ACOUST SOC AM, V86, P2129, DOI 10.1121/1.398473
   HAMERNIK RP, 1980, J ACOUST SOC AM, V67, P928, DOI 10.1121/1.383942
   HAMERNIK RP, 1981, AUDIOLOGY, V20, P259
   HARRIS FP, 1992, ACTA OTO-LARYNGOL, V112, P36, DOI 10.3109/00016489209100780
   Janssen Thomas, 2008, V30, P421
   JAUHIAINEN T, 1969, LARYNGOSCOPE, V79, P1950, DOI 10.1288/00005537-196911000-00007
   Kakigi A, 1998, AUDIOL NEURO-OTOL, V3, P361, DOI 10.1159/000013806
   Katbamna B, 1999, EAR HEARING, V20, P393, DOI 10.1097/00003446-199910000-00002
   Kaul DK, 2000, J CLIN INVEST, V106, P411, DOI 10.1172/JCI9225
   Kemp David T., 2008, V30, P1
   KEMP DT, 1986, HEARING RES, V22, P95, DOI 10.1016/0378-5955(86)90087-0
   LONSBURYMARTIN BL, 1987, HEARING RES, V28, P173, DOI 10.1016/0378-5955(87)90048-7
   MARTIN GK, 1987, HEARING RES, V28, P191, DOI 10.1016/0378-5955(87)90049-9
   MARTIN GK, 1977, J ACOUST SOC AM, V62, pS88, DOI 10.1121/1.2016432
   OKADA A, 1972, J ACOUST SOC AM, V51, P1240, DOI 10.1121/1.1912967
   Pyykko I, 1987, ARCH OCCUP ENV HLTH, V38, P439
   Raveh E, 1998, J OTOLARYNGOL, V27, P354
   SAKASHITA T, 1991, ACTA OTO-LARYNGOL, P66
   SATO H, 1991, ACTA OTO-LARYNGOL, V111, P1037, DOI 10.3109/00016489109138447
   SEIDEL H, 1988, INT ARCH OCC ENV HEA, V61, P95, DOI 10.1007/BF00381613
   Seo S, 1955, FUKUOKA ACTA MED, V46, P943
   Sininger YS, 2004, SCIENCE, V305, P1581, DOI 10.1126/science.1100646
   Soliman S., 2003, INT C SER, V1240, P209
   South T, 2004, MANAGING NOISE VIBRA, P149
   STARCK J, 1988, SCAND J WORK ENV HEA, V14, P265, DOI 10.5271/sjweh.1922
   STOVER L, 1993, J ACOUST SOC AM, V94, P2670, DOI 10.1121/1.407351
   SUZUKI M, 1995, ANN OTO RHINOL LARYN, V104, P69, DOI 10.1177/000348949510400111
   TELISCHI FF, 1995, LARYNGOSCOPE, V105, P675, DOI 10.1288/00005537-199507000-00002
   Uchida Y, 2006, AURIS NASUS LARYNX, V33, P397, DOI 10.1016/j.anl.2006.03.002
   van den Brink G, 1970, FREQUENCY ANAL PERIO, P362
   Williams PL, 2000, PRINCIPLES TOXICOLOG
   YOKOYAMA T, 1974, ACTA OTO-LARYNGOL, V78, P207, DOI 10.3109/00016487409126346
   ZOROWKA P, 1993, INT J PEDIATR OTORHI, V27, P245, DOI 10.1016/0165-5876(93)90230-Z
NR 40
TC 2
Z9 2
U1 2
U2 9
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1745-6673
J9 J OCCUP MED TOXICOL
JI J. Occup. Med. Toxicol.
PD JUN 21
PY 2012
VL 7
AR 12
DI 10.1186/1745-6673-7-12
PG 7
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 072VV
UT WOS:000313702400001
PM 22720724
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Kasahara, Y
   Takeuchi, Y
   Iwasa, Y
AF Kasahara, Yuichi
   Takeuchi, Yuki
   Iwasa, Yoshihiro
TI RETRACTED: Bulk superconductivity and fully gapped superconducting state
   in Ba-doped phenanthrene (Retracted article. See vol. 87, 179902, 2013)
SO PHYSICAL REVIEW B
LA English
DT Article; Retracted Publication
ID FULLERIDES; DEPENDENCE; TRANSITION; TEMPERATURE; HEAT
AB The superconducting state of Ba-intercalated phenanthrene, Ba(1.5)phenanthrene, has been investigated by specific-heat measurements down to 0.4 K. A clear anomaly associated with the superconducting transition at T-c = 4.7 K indicates the bulk nature of the superconductivity. The temperature and the magnetic-field dependence of the electronic specific heat are consistent with a fully gapped superconducting order parameter. The electron-phonon coupling constant estimated from the specific-heat jump is 0.55 to 1.06, suggesting that the superconductivity of Ba1.5phenanthrene can be explained within the BCS approach with intermediate coupling mediated by phonons of approximately 100 cm(-1) in frequency, which is assigned as intercalant phonons or intermolecular phonon modes.
C1 [Kasahara, Yuichi; Takeuchi, Yuki; Iwasa, Yoshihiro] Univ Tokyo, QPEC, Tokyo 1138656, Japan.
   [Kasahara, Yuichi; Takeuchi, Yuki; Iwasa, Yoshihiro] Univ Tokyo, Dept Appl Phys, Tokyo 1138656, Japan.
   [Iwasa, Yoshihiro] RIKEN ASI, CERG, Wako, Saitama 3510198, Japan.
RP Kasahara, Y (reprint author), Univ Tokyo, QPEC, Tokyo 1138656, Japan.
EM kasahara@ap.t.u-tokyo.ac.jp; iwasa@ap.t.u-tokyo.ac.jp
RI Kasahara, Yuichi/N-8436-2013; Iwasa, Yoshihiro/C-1719-2009
FU JSPS [21224009, 2474022]; Strategic International Collaborative Research
   Program (SICORP) from JST; Murata Science Foundation, Japan
FX The authors would like to thank W. F. Wang and X. H. Chen for providing
   the sample. This work was supported in part by Grants-in-Aid for
   Scientific Research (S) (No. 21224009) and for Young Scientists (B) (No.
   2474022), the "Funding Program for World-Leading Innovative R&D on
   Science and Technology (FIRST Program)" from JSPS, the Strategic
   International Collaborative Research Program (SICORP) from JST, and the
   Murata Science Foundation, Japan.
CR Capone M, 2009, REV MOD PHYS, V81, P943, DOI 10.1103/RevModPhys.81.943
   Casula M, 2011, PHYS REV LETT, V107, DOI 10.1103/PhysRevLett.107.137006
   de Andres PL, 2011, PHYS REV B, V83, DOI 10.1103/PhysRevB.83.245113
   Ganin AY, 2010, NATURE, V466, P221, DOI 10.1038/nature09120
   Gauzzi A, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.067002
   Giovannetti G, 2011, PHYS REV B, V83, DOI 10.1103/PhysRevB.83.134508
   Gunnarsson O, 1997, REV MOD PHYS, V69, P575, DOI 10.1103/RevModPhys.69.575
   Iwasa Y, 2003, J PHYS-CONDENS MAT, V15, pR495, DOI 10.1088/0953-8984/15/13/202
   Kanoda K, 1997, PHYSICA C, V282, P299, DOI 10.1016/S0921-4534(97)00266-9
   Kato T, 2011, PHYS REV LETT, V107, DOI 10.1103/PhysRevLett.107.077001
   Kim JS, 2006, PHYS REV B, V74, DOI 10.1103/PhysRevB.74.214513
   Kim JS, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.027001
   Kim M, 2011, PHYS REV B, V83, DOI 10.1103/PhysRevB.83.214510
   Kosugi T, 2011, PHYS REV B, V84, DOI 10.1103/PhysRevB.84.214506
   MARSIGLIO F, 1986, PHYS REV B, V33, P6141, DOI 10.1103/PhysRevB.33.6141
   MCMILLAN WL, 1968, PHYS REV, V167, P331, DOI 10.1103/PhysRev.167.331
   Mitsuhashi R, 2010, NATURE, V464, P76, DOI 10.1038/nature08859
   MOLER KA, 1994, PHYS REV LETT, V73, P2744, DOI 10.1103/PhysRevLett.73.2744
   MUHLSCHLEGEL B, 1959, Z PHYS, V155, P313, DOI 10.1007/BF01332932
   PADAMSEE H, 1973, J LOW TEMP PHYS, V12, P387, DOI 10.1007/BF00654872
   SPARN G, 1991, SCIENCE, V252, P1829, DOI 10.1126/science.252.5014.1829
   Subedi A, 2011, PHYS REV B, V84, DOI 10.1103/PhysRevB.84.020508
   Takabayashi Y, 2009, SCIENCE, V323, P1585, DOI 10.1126/science.1169163
   Wang XF, 2011, PHYS REV B, V84, DOI 10.1103/PhysRevB.84.214523
   Wang XF, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1513
   Wanka S, 1998, PHYS REV B, V57, P3084, DOI 10.1103/PhysRevB.57.3084
   WERTHAME.NR, 1966, PHYS REV, V147, P295, DOI 10.1103/PhysRev.147.295
   Xue MQ, 2012, SCI REP-UK, V2, DOI 10.1038/srep00389
   Zhang LJ, 2006, PHYS REV B, V74, DOI 10.1103/PhysRevB.74.184519
NR 29
TC 7
Z9 7
U1 3
U2 40
PU AMER PHYSICAL SOC
PI COLLEGE PK
PA ONE PHYSICS ELLIPSE, COLLEGE PK, MD 20740-3844 USA
SN 1098-0121
J9 PHYS REV B
JI Phys. Rev. B
PD JUN 20
PY 2012
VL 85
IS 21
AR 214520
DI 10.1103/PhysRevB.85.214520
PG 5
WC Materials Science, Multidisciplinary; Physics, Applied; Physics,
   Condensed Matter
SC Materials Science; Physics
GA 962GM
UT WOS:000305530300009
DA 2018-12-27
ER

PT J
AU Kim, H
   Cho, OM
   Cho, HI
   Kim, JY
AF Kim, Hwasoon
   Cho, Ok Min
   Cho, Hyo Im
   Kim, Ju Yeun
TI RETRACTED: Risk Factors and Features of Critically Ill Patients with
   Deep Vein Thrombosis in Lower Extremities (Retracted article. See vol.
   45, pg. 157, 2015)
SO JOURNAL OF KOREAN ACADEMY OF NURSING
LA Korean
DT Article; Retracted Publication
DE Critical illness; Venous thrombosis; Risk factors
ID INTENSIVE-CARE-UNIT; VENOUS THROMBOEMBOLISM; BRAIN-INJURY; PREVALENCE;
   PREVENTION
AB Purpose: The purpose of this study was to identify the features, risk scores and risk factors for deep vein thrombosis in critically ill patients who developed deep vein thrombosis in their lower extremities. Methods: The participants in this prospective descriptive study were 175 adult patients who did not receive any prophylactic medication or mechanical therapy during their admission in the intensive care unit. Results: The mean age was 62.24 (+/- 17.28) years. Men made up 54.9% of the participating patients. There were significant differences in age, body mass index, and leg swelling between patients who developed deep vein thrombosis and those who did not have deep vein thrombosis. The mean risk score was 6.71(+/- 2.94) and they had on average 4.01(+/- 1.35) risk factors. In the multiple logistic regression, body mass index (odds ratio=1.14) and leg swelling (odds ratio=6.05) were significant predictors of deep vein thrombosis. Conclusion: Most critically ill patients are in the potentially high risk group for deep vein thrombosis. However, patients who are elderly, obese or have leg edema should be closely assessed and more than one type of active prophylactic intervention should be provided.
C1 [Kim, Hwasoon; Cho, Ok Min; Cho, Hyo Im; Kim, Ju Yeun] Inha Univ, Inchon 402751, South Korea.
RP Kim, H (reprint author), Inha Univ, 253 Yonghyun Dong, Inchon 402751, South Korea.
EM khs0618@inha.ac.kr
CR Bang SM, 2010, J KOREAN MED SCI, V25, P1553, DOI 10.3346/jkms.2010.25.11.1553
   Beck Diana M, 2006, Medsurg Nurs, V15, P282
   Caprini JA, 2005, DM-DIS MON, V51, P70, DOI 10.1016/j.disamonth.2005.02.003
   Choi D., 2011, J KOREAN CRITICAL CA, V4, P75
   Cook D, 2005, CRIT CARE MED, V33, P1565, DOI 10.1097/01.CCM.0000171207.95319.B2
   Cook D, 2010, CRIT CARE MED, V38, pE138, DOI 10.1097/CCM.0b013e3181cbaff4
   Crowther MA, 2005, J CRIT CARE, V20, P334, DOI 10.1016/j.jcrc.2005.09.011
   Geerts W, 2003, CHEST, V124, p357S, DOI 10.1378/chest.124.6_suppl.357S
   Geerts W, 2002, J CRIT CARE, V17, P95, DOI 10.1053/jcrc.2002.33941
   Goldhaber SZ, 1997, JAMA-J AM MED ASSOC, V277, P642, DOI 10.1001/jama.277.8.642
   John A., 2003, CLIN CHEST MED, V24, P1
   Keenan CR, 2007, CURR OPIN PULM MED, V13, P377, DOI 10.1097/MCP.0b013e3281eb8ef0
   Kim IG, 2004, J KOREAN SOC VASC SU, V20, P237
   Kim JS, 2009, J KOREAN ACAD NURS, V39, P288, DOI 10.4040/jkan.2009.39.2.288
   Kim KI, 2011, J ARTHROPLASTY, V26, P1112, DOI 10.1016/j.arth.2011.02.021
   Kim KS, 2009, NEUROCRIT CARE, V11, P28, DOI 10.1007/s12028-009-9201-4
   Korean Society on Thrombosis and Hemostasis, 2009, JAP GUID PREV VEN TH
   Muscedere JG, 2007, J CRIT CARE, V22, P285, DOI 10.1016/j.jcrc.2007.02.003
   Park HS, 2008, OBES REV, V9, P104, DOI 10.1111/j.1467-789X.2007.00421.x
   Phillips L., 2004, J INTEGRATED CARE PA, V8, P55
   Schuerer DJE, 2005, J TRAUMA, V58, P731, DOI 10.1097/01.TA.0000158247.77198.AD
   Taniguchi S, 2009, HEART VESSELS, V24, P425, DOI 10.1007/s00380-008-1135-9
   Wilasrusmee C, 2009, ASIAN J SURG, V32, P85, DOI 10.1016/S1015-9584(09)60016-6
   Xu Xiao-feng, 2008, Zhonghua Liu Xing Bing Xue Za Zhi, V29, P1034
   Yablon SA, 2004, NEUROLOGY, V63, P485, DOI 10.1212/01.WNL.0000133009.24727.9F
   Yim S. J., 2007, J KOREAN KNEE SOC, V19, P135
   주석규, 2006, Hip and Pelvis, V18, P61
NR 27
TC 0
Z9 0
U1 2
U2 9
PU KOREAN SOC NURSING SCIENCE
PI SEOUL
PA KOREA SCIENCE & TECHNOL CTR, 635-4 YEOKSAM-DONG, KANGNAM-GU,, SEOUL,
   135-703, SOUTH KOREA
SN 2005-3673
EI 2093-758X
J9 J KOREAN ACAD NURS
JI J. Korean Acad. Nurs.
PD JUN
PY 2012
VL 42
IS 3
BP 396
EP 404
DI 10.4040/jkan.2012.42.3.396
PG 9
WC Nursing
SC Nursing
GA 979LE
UT WOS:000306820700010
PM 22854552
OA Bronze
DA 2018-12-27
ER

PT J
AU Curti, S
   Hoge, G
   Nagy, JI
   Pereda, AE
AF Curti, Sebastian
   Hoge, Gregory
   Nagy, James I.
   Pereda, Alberto E.
TI RETRACTED: Electrical Transmission between Mammalian Neurons is
   Supported by a Small Fraction of Gap Junction Channels (Retracted
   article. See vol. 247, pg. 753, 2014)
SO JOURNAL OF MEMBRANE BIOLOGY
LA English
DT Article; Retracted Publication
DE Connexin36; Electrical coupling; Electrical transmission; Gap junction
ID TRIGEMINAL MESENCEPHALIC NUCLEUS; ZONULA OCCLUDENS-1 ZO-1; GOLDFISH
   MAUTHNER CELL; MOUSE-BRAIN; CLUB ENDINGS; RAT; SYNAPSES; CONNEXIN36;
   SYNCHRONIZATION; COMMUNICATION
AB Electrical synapses formed by gap junctions between neurons create networks of electrically coupled neurons in the mammalian brain, where these networks have been found to play important functional roles. In most cases, interneuronal gap junctions occur at remote dendro-dendritic contacts, making difficult accurate characterization of their physiological properties and correlation of these properties with their anatomical and morphological features of the gap junctions. In the mesencephalic trigeminal (MesV) nucleus where neurons are readily accessible for paired electrophysiological recordings in brain stem slices, our recent data indicate that electrical transmission between MesV neurons is mediated by connexin36 (Cx36)-containing gap junctions located at somato-somatic contacts. We here review evidence indicating that electrical transmission between these neurons is supported by a very small fraction of the gap junction channels present at cell-cell contacts. Acquisition of this evidence was enabled by the unprecedented experimental access of electrical synapses between MesV neurons, which allowed estimation of the average number of open channels mediating electrical coupling in relation to the average number of gap junction channels present at these contacts. Our results indicate that only a small proportion of channels (similar to 0.1 %) appear to be conductive. On the basis of similarities with other preparations, we postulate that this phenomenon might constitute a general property of vertebrate electrical synapses, reflecting essential aspects of gap junction function and maintenance.
C1 [Curti, Sebastian] Univ Republica, Fac Med, Dept Fisiol, Lab Neurofisiol Celular, Montevideo 11800, Uruguay.
   [Hoge, Gregory; Pereda, Alberto E.] Albert Einstein Coll Med, Dominick P Purpura Dept Neurosci, Bronx, NY 10461 USA.
   [Nagy, James I.] Univ Manitoba, Dept Physiol, Winnipeg, MB R3E OJ9, Canada.
RP Curti, S (reprint author), Univ Republica, Fac Med, Dept Fisiol, Lab Neurofisiol Celular, Gral Flores 2125, Montevideo 11800, Uruguay.
EM scurti@fmed.edu.uy; alberto.pereda@einstein.yu.edu
OI Nagy, James Imre/0000-0003-2753-091X
FU Comision Sectorial de Investigacion Cientifica; National Institutes of
   Health (NIH) [DC03186, NS0552827, NS44395]; Canadian Institutes of
   Health Research
FX Supported in part by Comision Sectorial de Investigacion Cientifica (to
   S.C.), National Institutes of Health (NIH) Grants DC03186 and NS0552827
   (to A.E.P.), and NIH Grant NS44395 and Canadian Institutes of Health
   Research (to J.I.N). Also supported by the program "Vinculacion con
   cientificos y tecnologos uruguayos residentes en el exterior'' of
   Agencia Nacional de Investigacion e Innovacion, Uruguay.
CR BAKER R, 1971, J PHYSIOL-LONDON, V212, P45, DOI 10.1113/jphysiol.1971.sp009309
   Beardslee MA, 1998, CIRC RES, V83, P629, DOI 10.1161/01.RES.83.6.629
   Bennett MVL, 2006, BRAIN CELL BIOL, V35, P5, DOI 10.1007/s11068-006-9004-x
   Bennett MVL, 1997, J NEUROCYTOL, V26, P349, DOI 10.1023/A:1018560803261
   Bennett MVL, 2004, NEURON, V41, P495, DOI 10.1016/S0896-6273(04)00043-1
   Condorelli DF, 1998, EUR J NEUROSCI, V10, P1202, DOI 10.1046/j.1460-9568.1998.00163.x
   Connors BW, 2004, ANNU REV NEUROSCI, V27, P393, DOI 10.1146/annurev.neuro.26.041002.131128
   Curti S, 2012, J NEUROSCI, V32, P4341, DOI 10.1523/JNEUROSCI.6216-11.2012
   Flores CE, 2012, P NATL ACAD SCI USA, V109, pE573, DOI 10.1073/pnas.1121557109
   Herve JC, 2007, J MEMBRANE BIOL, V217, P21, DOI 10.1007/s00232-007-9054-8
   HINRICHSEN CF, 1970, AM J ANAT, V127, P303, DOI 10.1002/aja.1001270306
   HINRICHSEN CF, 1970, J DENT RES, V49, P1369, DOI 10.1177/00220345700490063701
   Hormuzdi SG, 2004, BBA-BIOMEMBRANES, V1662, P113, DOI 10.1016/j.bbamem.2003.10.023
   Kamasawa N, 2006, NEUROSCIENCE, V142, P1093, DOI 10.1016/j.neuroscience.2006.08.020
   Kruger O, 2000, DEVELOPMENT, V127, P4179
   Li X, 2004, NEUROSCIENCE, V126, P611, DOI 10.1016/j.neuroscience.2004.03.063
   Li X, 2001, AM J PHYSIOL-HEART C, V281, pH1890
   Li XB, 2004, EUR J NEUROSCI, V19, P2132, DOI 10.1111/j.1460-9568.2004.03283.x
   LIN JW, 1988, J NEUROSCI, V8, P1302
   Llinas R, 1975, P GOLG CENT S, P379
   Meier Carola, 2006, V43, P99, DOI 10.1007/013
   Nagy JI, 2004, BRAIN RES REV, V47, P191, DOI 10.1016/j.brainresrev.2004.05.005
   Pedroarena CM, 1999, J NEUROPHYSIOL, V82, P1465
   PEINADO A, 1993, CEREB CORTEX, V3, P488, DOI 10.1093/cercor/3.5.488
   Penes MC, 2005, EUR J NEUROSCI, V22, P404, DOI 10.1111/j.1460-9568.2005.04225.x
   Pereda AE, 2004, BRAIN RES REV, V47, P227, DOI 10.1016/j.brainresrev.2004.06.010
   Sohl G, 1998, FEBS LETT, V428, P27, DOI 10.1016/S0014-5793(98)00479-7
   Srinivas M, 1999, J PHYSIOL-LONDON, V517, P673, DOI 10.1111/j.1469-7793.1999.0673s.x
   Srinivas M, 1999, J NEUROSCI, V19, P9848
   Teubner B, 2000, J MEMBRANE BIOL, V176, P246
   TUTTLE R, 1986, J COMP NEUROL, V246, P202, DOI 10.1002/cne.902460206
NR 31
TC 10
Z9 10
U1 2
U2 10
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0022-2631
EI 1432-1424
J9 J MEMBRANE BIOL
JI J. Membr. Biol.
PD JUN
PY 2012
VL 245
IS 5-6
SI SI
BP 283
EP 290
DI 10.1007/s00232-012-9449-z
PN 1
PG 8
WC Biochemistry & Molecular Biology; Cell Biology; Physiology
SC Biochemistry & Molecular Biology; Cell Biology; Physiology
GA 978HM
UT WOS:000306731400008
PM 22729690
DA 2018-12-27
ER

PT J
AU Lach, A
   Grzybek, M
   Heger, E
   Korycka, J
   Wolny, M
   Kubiak, J
   Kolondra, A
   Boguslawska, DM
   Augoff, K
   Majkowski, M
   Podkalicka, J
   Kaczor, J
   Stefanko, A
   Kuliczkowski, K
   Sikorski, AF
AF Lach, Agnieszka
   Grzybek, Michal
   Heger, Elzbieta
   Korycka, Justyna
   Wolny, Marcin
   Kubiak, Jakub
   Kolondra, Adam
   Boguslawska, Dzamila M.
   Augoff, Katarzyna
   Majkowski, Michal
   Podkalicka, Joanna
   Kaczor, Jakub
   Stefanko, Adam
   Kuliczkowski, Kazimierz
   Sikorski, Aleksander F.
TI RETRACTED: Palmitoylation of MPP1 (Membrane-palmitoylated Protein 1)/p55
   Is Crucial for Lateral Membrane Organization in Erythroid Cells
   (Retracted article. See vol. 293, pg. 2786, 2018)
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article; Retracted Publication
ID DETERGENT-RESISTANT MEMBRANES; GPI-ANCHORED PROTEINS; LIPID RAFTS;
   PLASMA-MEMBRANE; CORTICAL ACTIN; GLYCOPHORIN-C; T-CELLS; CHOLESTEROL;
   ASSOCIATION; IDENTIFICATION
AB S-Acylation of proteins is a ubiquitous post-translational modification and a common signal for membrane association. The major palmitoylated protein in erythrocytes is MPP1, a member of the MAGUK family and an important component of the ternary complex that attaches the spectrin-based skeleton to the plasma membrane. Here we show that DHHC17 is the only acyltransferase present in red blood cells (RBC). Moreover, we give evidence that protein palmitoylation is essential for membrane organization and is crucial for proper RBC morphology, and that the effect is specific for MPP1. Our observations are based on the clinical cases of two related patients whose RBC had no palmitoylation activity, caused by a lack of DHHC17 in the membrane, which resulted in a strong decrease of the amount of detergent-resistant membrane (DRM) material. We confirmed that this loss of detergent-resistant membrane was due to the lack of palmitoylation by treatment of healthy RBC with 2-bromopalmitic acid (2-BrP, common palmitoylation inhibitor). Concomitantly, fluorescence lifetime imaging microscopy (FLIM) analyses of an order-sensing dye revealed a reduction of membrane order after chemical inhibition of palmitoylation in erythrocytes. These data point to a pathophysiological relationship between the loss of MPP1-directed palmitoylation activity and perturbed lateral membrane organization.
C1 [Lach, Agnieszka; Korycka, Justyna; Wolny, Marcin; Kubiak, Jakub; Kolondra, Adam; Majkowski, Michal; Podkalicka, Joanna; Kaczor, Jakub; Stefanko, Adam; Sikorski, Aleksander F.] Univ Wroclaw, Biotechnol Fac, Lab Cytobiochem, PL-51148 Wroclaw, Poland.
   [Grzybek, Michal] Max Planck Inst Mol Biol & Genet, D-01307 Dresden, Germany.
   [Heger, Elzbieta; Boguslawska, Dzamila M.] Univ Zielona Gora, Dept Mol Biol, PL-65565 Zielona Gora, Poland.
   [Augoff, Katarzyna] Med Acad Wroclaw, Dept Gastrointestinal & Gen Surg, PL-50417 Wroclaw, Poland.
   [Kuliczkowski, Kazimierz] Med Acad Wroclaw, Dept Hematol, PL-50367 Wroclaw, Poland.
RP Sikorski, AF (reprint author), Univ Wroclaw, Biotechnol Fac, Lab Cytobiochem, Przybyszewskiego 63-77, PL-51148 Wroclaw, Poland.
EM afsbc@ibmb.uni.wroc.pl
OI Grzybek, Michal/0000-0003-2083-0506; Wolny, Marcin/0000-0003-1030-7607
FU DNA Sequencing and Oligonucleotide Synthesis Service of the Institute of
   Biochemistry and Biophysics, Warsaw, Poland; European Union Social Fund
   [POKL.04.01.01-00-054/10-00]; European Social Fund; Ethics Committee of
   the Medical University of Wroclaw [494/2007]; Polish Ministry of Science
   and Higher Education [NN3011611435]
FX This work was supported in part by Grant NN3011611435 from the Polish
   Ministry of Science and Higher Education and a sequencing grant from the
   DNA Sequencing and Oligonucleotide Synthesis Service of the Institute of
   Biochemistry and Biophysics, Warsaw, Poland.; Recipient of Grant
   POKL.04.01.01-00-054/10-00 from the European Union Social Fund.; Scholar
   within Sub-measure 8.2.2 Regional Innovation Strategies, Measure 8.2,
   Priority VIII: Regional human resources for the economy Human Capital
   Operational Programme co-financed by the European Social Fund and state
   budget.; We thank Unal Coskun and Ilya Levental (both Max Planck
   Institute, Dresden) and Daniel Lingwood (NIH, Vaccine Research Centre,
   Washington) for discussions and help; the HA patients and their sister
   for voluntary participation in this study are particularly acknowledged.
   The patient study was performed according to permission from the Ethics
   Committee of the Medical University of Wroclaw: project No. 494/2007.
   The help of Dr. Jan Korzeniewski from the Medical University of Wroclaw
   on the work with umbilical cord blood is greatly appreciated.
CR Arcaro A, 2001, J EXP MED, V194, P1485, DOI 10.1084/jem.194.10.1485
   Arni S, 1998, J BIOL CHEM, V273, P28478, DOI 10.1074/jbc.273.43.28478
   Balamuth F, 2004, J IMMUNOL, V172, P5887, DOI 10.4049/jimmunol.172.10.5887
   Charollais J, 2009, MOL MEMBR BIOL, V26, P55, DOI 10.1080/09687680802620369
   Chishti AH, 1996, BLOOD, V87, P3462
   Chorzalska A, 2010, CELL MOL BIOL LETT, V15, P406, DOI 10.2478/s11658-010-0012-6
   Ciana A, 2005, J BIOSCIENCES, V30, P317, DOI 10.1007/BF02703669
   Drenan RM, 2005, J CELL BIOL, V169, P623, DOI 10.1083/jcb.200502007
   El-Husseini AE, 2002, CELL, V108, P849, DOI 10.1016/S0092-8674(02)00683-9
   Fragoso R, 2003, J IMMUNOL, V170, P913, DOI 10.4049/jimmunol.170.2.913
   Goswami D, 2008, CELL, V135, P1085, DOI 10.1016/j.cell.2008.11.032
   Grzybek M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005053
   Guzzi F, 2001, BIOCHEM J, V355, P323, DOI 10.1042/0264-6021:3550323
   Hancock JF, 2006, NAT REV MOL CELL BIO, V7, P456, DOI 10.1038/nrm1925
   Hayot C, 2006, TOXICOL APPL PHARM, V211, P30, DOI 10.1016/j.taap.2005.06.006
   HEMMING NJ, 1995, J BIOL CHEM, V270, P5360, DOI 10.1074/jbc.270.10.5360
   Huber TB, 2006, P NATL ACAD SCI USA, V103, P17079, DOI 10.1073/pnas.0607465103
   Hummel I, 2011, MOL PHARMACOL, V79, P229, DOI 10.1124/mol.110.069013
   Kakhniashvili DG, 2004, MOL CELL PROTEOMICS, V3, P501, DOI 10.1074/mcp.M300132-MCP200
   Kamata K, 2008, AM J HEMATOL, V83, P371, DOI 10.1002/ajh.21126
   Kanaani J, 2002, J CELL BIOL, V158, P1229, DOI 10.1083/jcb.200205053
   Korycka J, 2012, EUR J CELL BIOL, V91, P107, DOI 10.1016/j.ejcb.2011.09.013
   Koshino I, 2009, EXP PARASITOL, V123, P381, DOI 10.1016/j.exppara.2009.08.019
   Kusumi A, 2011, TRENDS BIOCHEM SCI, V36, P604, DOI 10.1016/j.tibs.2011.08.001
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Levental I, 2010, P NATL ACAD SCI USA, V107, P22050, DOI 10.1073/pnas.1016184107
   Levental I, 2010, BIOCHEMISTRY-US, V49, P6305, DOI 10.1021/bi100882y
   Levitan I, 2011, J LIPIDS, DOI 10.1155/2011/730209
   Lingwood D, 2007, NAT PROTOC, V2, P2159, DOI 10.1038/nprot.2007.294
   Loubery S, 2008, TRAFFIC, V9, P492, DOI 10.1111/j.1600-0854.2008.00704.x
   Ludwig A, 2010, J CELL BIOL, V191, P771, DOI 10.1083/jcb.201005140
   Machnicka B, 2012, CELL MOL LIFE SCI, V69, P191, DOI 10.1007/s00018-011-0804-5
   MARETZKI D, 1990, FEBS LETT, V259, P305, DOI 10.1016/0014-5793(90)80033-F
   Marfatia SM, 1997, J BIOL CHEM, V272, P24191, DOI 10.1074/jbc.272.39.24191
   Masuda M, 2011, J ONCOL, DOI 10.1155/2011/540148
   Mitchell DA, 2006, J LIPID RES, V47, P1118, DOI 10.1194/jlr.R600007-JLR200
   Moffett S, 2000, J BIOL CHEM, V275, P2191, DOI 10.1074/jbc.275.3.2191
   Nada S, 2003, J BIOL CHEM, V278, P47610, DOI 10.1074/jbc.M303873200
   Niemela PS, 2009, BBA-BIOMEMBRANES, V1788, P122, DOI 10.1016/j.bbamem.2008.08.018
   NOBLE NA, 1989, BLOOD, V74, P475
   Owen DM, 2006, BIOPHYS J, V90, pL80, DOI 10.1529/biophysj.106.084673
   Owen DM, 2007, SEMIN CELL DEV BIOL, V18, P591, DOI 10.1016/j.semcdb.2007.07.011
   Owen DM, 2010, MOL MEMBR BIOL, V27, P178, DOI 10.3109/09687688.2010.495353
   Parton RG, 2004, TRENDS CELL BIOL, V14, P141, DOI 10.1016/j.tcb.2004.02.001
   Pasini EM, 2010, J PROTEOMICS, V73, P421, DOI 10.1016/j.jprot.2009.07.004
   Pike LJ, 2006, J LIPID RES, V47, P1597, DOI 10.1194/jlr.E600002-JLR200
   Robinson P, 2010, CELL CALCIUM, V48, P183, DOI 10.1016/j.ceca.2010.08.006
   Rocks O, 2010, CELL, V141, P458, DOI 10.1016/j.cell.2010.04.007
   Samuel BU, 2001, J BIOL CHEM, V276, P29319, DOI 10.1074/jbc.M101268200
   SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463
   Schengrund CL, 2010, BRAIN RES BULL, V82, P7, DOI 10.1016/j.brainresbull.2010.02.013
   Seo PS, 2009, EXP BIOL MED, V234, P255, DOI 10.3181/0809-RM-275
   Sharma P, 2004, CELL, V116, P577, DOI 10.1016/S0092-8674(04)00167-9
   Shogomori H, 2005, J BIOL CHEM, V280, P18931, DOI 10.1074/jbc.M500247200
   Sim DS, 2007, ARTERIOSCL THROM VAS, V27, P1478, DOI 10.1161/ATVBAHA.106.139287
   Simons K, 2010, NAT REV MOL CELL BIO, V11, P688, DOI 10.1038/nrm2977
   TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350
   Uittenbogaard A, 2000, J BIOL CHEM, V275, P25595, DOI 10.1074/jbc.M003401200
   Webb Y, 2000, J BIOL CHEM, V275, P261, DOI 10.1074/jbc.275.1.261
   Yanagisawa K, 2011, J NEUROCHEM, V116, P806, DOI 10.1111/j.1471-4159.2010.07006.x
   Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8
NR 61
TC 22
Z9 24
U1 0
U2 13
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JUN 1
PY 2012
VL 287
IS 23
BP 18974
EP 18984
DI 10.1074/jbc.M111.332981
PG 11
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 974EF
UT WOS:000306411900009
PM 22496366
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Ban, SH
   Li, XY
AF Ban, Shu-Hao
   Li, Xiao-Yan
TI RETRACTED: Effects of boundary slippage on thin-film lubrication between
   two nonparallel plane plates (Retracted article. See vol. 28, pg. 1509,
   2012)
SO ACTA MECHANICA SINICA
LA English
DT Article; Retracted Publication
DE Bearing capacity; Boundary slippage; Dimensionless slipping size factor;
   Friction coefficient; Hydrodynamic lubrication; Negative pressure
ID ELASTOHYDRODYNAMIC LUBRICATION; SURFACES; CONTACTS; LIQUID; EHL
AB Hydrodynamic lubrications between two plane plates with an intersection angle theta have been investigated using the boundary slippage theory, and relations are obtained between dimensionless pressures and coordinate x, between bearing capacity, friction force, friction coefficient and dimensionless slipping size factor. The results show that bearing capacity of two plane plates without boundary slippage significantly increases with increasing intersection angle theta when 0 < theta < 1A degrees, whereas decreases with increasing intersection angle theta when theta > 1A degrees. The results also show that negative pressure occurs in fluid entrance region and bearing capacity decreases, and friction force and friction coefficient increase with the increase of dimensionless slipping size factor.
C1 [Ban, Shu-Hao; Li, Xiao-Yan] Changzhou Univ, Coll Mech & Energy Engn, Changzhou 213016, Peoples R China.
RP Ban, SH (reprint author), Changzhou Univ, Coll Mech & Energy Engn, Changzhou 213016, Peoples R China.
EM banshuhao@tsinghua.org.cn
CR Cieplak M, 2001, PHYS REV LETT, V86, P803, DOI 10.1103/PhysRevLett.86.803
   Ehret P, 1998, P ROY SOC A-MATH PHY, V454, P763, DOI 10.1098/rspa.1998.0185
   JACOBSON BO, 1984, J TRIBOL-T ASME, V106, P275, DOI 10.1115/1.3260901
   Kaneta M, 1996, J TRIBOL-T ASME, V118, P886, DOI 10.1115/1.2831624
   SHIEH JA, 1991, J TRIBOL-T ASME, V113, P372, DOI 10.1115/1.2920631
   Thompson PA, 1997, NATURE, V389, P360, DOI 10.1038/38686
   Zhang Y, 2004, IND LUBR TRIBOL, V56, P88, DOI 10.1108/00368790410524047
   [张勇斌 ZHANG Yongbin], 2008, [应用数学和力学, Applied Mathematics and Mechanics], V29, P1048
   Zhu YX, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.096105
NR 9
TC 1
Z9 1
U1 4
U2 14
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0567-7718
EI 1614-3116
J9 ACTA MECH SINICA-PRC
JI Acta Mech. Sin.
PD JUN
PY 2012
VL 28
IS 3
BP 625
EP 630
DI 10.1007/s10409-012-0086-7
PG 6
WC Engineering, Mechanical; Mechanics
SC Engineering; Mechanics
GA 971OS
UT WOS:000306214300007
DA 2018-12-27
ER

PT J
AU Mokhtari, B
   Pourabdollah, K
AF Mokhtari, Bahram
   Pourabdollah, Kobra
TI RETRACTED: Extraction of s-block metals by nano-baskets of
   calix[4]crown-3 (Retracted article. See vol. 92, pg. 267, 2014)
SO CANADIAN JOURNAL OF CHEMISTRY-REVUE CANADIENNE DE CHIMIE
LA English
DT Article; Retracted Publication
DE nano-baskets; competitive extraction; calix[4]crown-3; s-block metals
ID DIFFERENTIAL-PULSE VOLTAMMETRY; COMPETITIVE SOLVENT-EXTRACTION;
   ALKALINE-EARTH METALS; CALIXARENE; CALIXCROWNS; SIZE
AB Three kinds of nano-baskets including 1,2-alternate and cone conformers of di-ionizable p-tert-butylcalix[4]arene-1,2-crown-3 and the cone conformer of p-tert-butylcalix[4]arene-1,2-thiacrown-3 were synthesized and the competitive solvent extractions of alkali and alkaline earth metal cations were studied. The novelty of this study is including three binding units of the calixarene's bowl, the crown ether's ring, and electron-donor ionizable moieties in a unique scaffold, in which their sizes were selected based upon their complexation ability to show equal binding tendency towards the cations. The objective of this work is to assess the extraction efficiency, selectivity, and pH(1/2) of such complexes. The results of solvent extraction experiments indicated that these compounds were effective extractants of alkali and alkaline earth metal cations. Their selectivities were greatly influenced by the acidity of the solution and the conformations of the calixcrown. One conformer was highly selective to Na+ and the other to Ba2+ in acidic and basic solutions, respectively.
C1 [Mokhtari, Bahram; Pourabdollah, Kobra] Islamic Azad Univ, Razi Chem Res Ctr RCRC, Shahreza Branch, Shahreza, Iran.
RP Pourabdollah, K (reprint author), Islamic Azad Univ, Razi Chem Res Ctr RCRC, Shahreza Branch, Shahreza, Iran.
EM pourabdollah@iaush.ac.ir
FU Islamic Azad University (Shahreza branch); Iran Nanotechnology
   Initiative Council
FX This work was supported by Islamic Azad University (Shahreza branch) and
   the Iran Nanotechnology Initiative Council.
CR Arena G., 2002, J SUPRAMOL CHEM, V2, P521, DOI DOI 10.1016/S1472-7862(02)00022-9
   Kim JS, 2009, J INCL PHENOM MACRO, V63, P189, DOI 10.1007/s10847-008-9503-8
   Lamare V, 1998, EUR J ORG CHEM, P1559
   Lynch J. A., 2001, J SUPRAMOL CHEM, V1, P139, DOI DOI 10.1016/S1472-7862(02)00005-9
   Mokhtari B, 2013, DRUG CHEM TOXICOL, V36, P119, DOI 10.3109/01480545.2011.653490
   Mokhtari B, 2012, J INCL PHENOM MACRO, V74, P183, DOI 10.1007/s10847-011-0099-z
   Mokhtari B, 2012, J INCL PHENOM MACRO, V73, P1, DOI 10.1007/s10847-011-0062-z
   Mokhtari B, 2012, ELECTROANAL, V24, P219, DOI 10.1002/elan.201100584
   Mokhtari B, 2011, J COORD CHEM, V64, P4079, DOI 10.1080/00958972.2011.636040
   Mokhtari B, 2011, J COORD CHEM, V64, P4029, DOI 10.1080/00958972.2011.635790
   Mokhtari B, 2012, J ELECTROCHEM SOC, V159, pK61, DOI 10.1149/2.048203jes
   Mokhtari B, 2011, J COORD CHEM, V64, P3081, DOI 10.1080/00958972.2011.613462
   Mokhtari B, 2011, J COORD CHEM, V64, P3189, DOI 10.1080/00958972.2011.616930
   Mokhtari B, 2012, J THERM ANAL CALORIM, V110, P1043, DOI 10.1007/s10973-011-2014-7
   Mokhtari B, 2012, J INCL PHENOM MACRO, V73, P269, DOI 10.1007/s10847-011-0052-1
   Mokhtari B, 2011, SUPRAMOL CHEM, V23, P696, DOI 10.1080/10610278.2011.605452
   Mokhtari B, 2011, B KOREAN CHEM SOC, V32, P3979, DOI 10.5012/bkcs.2011.32.11.3979
   Mokhtari B, 2011, B KOREAN CHEM SOC, V32, P3855, DOI 10.5012/bkcs.2011.32.11.3855
   Mokhtari B, 2011, ASIAN J CHEM, V23, P4717
   Mokhtari B, 2011, CHROMATOGRAPHIA, V73, P829, DOI 10.1007/s10337-011-1954-1
   Mokhtari B, 2011, J RADIOANAL NUCL CH, V287, P921, DOI 10.1007/s10967-010-0881-1
   Mokhtari B, 2011, J COORD CHEM, V64, P743, DOI 10.1080/00958972.2011.555538
   Mokhtari B, 2011, J INCL PHENOM MACRO, V69, P1, DOI 10.1007/s10847-010-9848-7
   Salorinne K, 2008, J INCL PHENOM MACRO, V61, P11, DOI 10.1007/s10847-008-9411-y
   Ungaro R., 1984, J INCLUSION PHENOM, V2, P199, DOI DOI 10.1007/BF00663257
   Yang YF, 2010, J INCL PHENOM MACRO, V66, P163, DOI 10.1007/s10847-009-9675-x
NR 26
TC 15
Z9 16
U1 3
U2 12
PU CANADIAN SCIENCE PUBLISHING, NRC RESEARCH PRESS
PI OTTAWA
PA 65 AURIGA DR, SUITE 203, OTTAWA, ON K2E 7W6, CANADA
SN 0008-4042
EI 1480-3291
J9 CAN J CHEM
JI Can. J. Chem.-Rev. Can. Chim.
PD JUN
PY 2012
VL 90
IS 6
BP 560
EP 566
DI 10.1139/V2012-020
PG 7
WC Chemistry, Multidisciplinary
SC Chemistry
GA 969ZI
UT WOS:000306097500010
DA 2018-12-27
ER

PT J
AU Ma, L
   Zhang, HF
   Han, CR
   Tong, DN
   Zhang, MY
   Yao, YA
   Luo, Y
   Liu, XB
AF Ma, Lan
   Zhang, Haifeng
   Han, Carrie
   Tong, Danian
   Zhang, Meiyan
   Yao, Yi'an
   Luo, Yu
   Liu, Xuebo
TI RETRACTED: Fibroblast Growth Factor Receptor 4 Polymorphisms and
   Susceptibility to Coronary Artery Disease (Retracted article. See vol.
   35, pg. 107, 2016)
SO DNA AND CELL BIOLOGY
LA English
DT Article; Retracted Publication
ID SMOOTH-MUSCLE-CELLS; FGF RECEPTOR; CANCER; PROMOTES; OSTEOSARCOMA;
   ANGIOGENESIS; EXPRESSION; HEPARIN; BREAST; RISK
AB Fibroblast growth factors (FGFs) and their receptors (FGFRs) play crucial roles in vascular smooth muscle cell proliferation and atherosclerosis and, therefore, may potentially affect the development of coronary artery disease (CAD). FGFR4 rs351855 (Gly388Arg) polymorphism has shown to be a risk factor for many diseases. The aim of this study was to investigate the association between FGFR4 polymorphisms and the susceptibility to CAD in the Chinese population. Two polymorphisms, rs351855 (Gly388Arg) and rs641101, were detected by polymerase chain reaction-restriction fragment length polymorphism and direct sequencing in 687 CAD cases and 732 age-matched controls. Data were analyzed using the chi-square test. Results showed that frequencies of GA genotype, AA genotype, and A allele in rs351855 (Gly388Arg) polymorphism were significantly lower in CAD patients than in controls (odds ratio (OR) = 0.78, 95% confidence intervals (CIs): 0.62-0.98, p = 0.034; OR = 0.58, 95% CI: 0.42-0.80, p = 0.001; and OR = 0.77, 95% CI: 0.66-0.90, p = 0.001, respectively). The rs641101 polymorphism did not show any correlation with CAD. Haplotype analysis revealed that rs351855 and rs641101 AG haplotype also had lower frequency in CAD patients (OR = 0.79, 95% CI: 0.67-0.92, p = 0.002). Our data suggested that the FGFR4 rs351855 (Gly388Arg) polymorphism and AG haplotype (rs351855 and rs641101) could act as protective factors against CAD in the Chinese population and indicated that a single gene polymorphism could have diverse functions in different diseases.
C1 [Ma, Lan; Yao, Yi'an; Luo, Yu; Liu, Xuebo] Tongji Univ, Dept Cardiol, Shanghai E Hosp, Shanghai 200120, Peoples R China.
   [Zhang, Haifeng] Gen Hosp Shenyang Mil Reg, Dept Neurosurg, Shenyang, Peoples R China.
   [Han, Carrie] Univ Toronto, Div Clin Sci, Toronto, ON, Canada.
   [Tong, Danian] Shanghai Jiao Tong Univ, Peoples Hosp 3, Dept Surg, Shanghai 200030, Peoples R China.
   [Zhang, Meiyan] Tongji Univ, Emergency Ctr, Shanghai E Hosp, Shanghai 200120, Peoples R China.
RP Liu, XB (reprint author), Tongji Univ, Dept Cardiol, Shanghai E Hosp, 150 Jimo Rd, Shanghai 200120, Peoples R China.
EM xueboliu70@hotmail.com
FU Key Disciplines Group Construction Project of Pudong Health Bureau of
   Shanghai [pkzxkq2010-01]
FX This research was funded by Key Disciplines Group Construction Project
   of Pudong Health Bureau of Shanghai (Grant No. pkzxkq2010-01).
CR BAIRD A, 1985, BIOCHEM BIOPH RES CO, V126, P358, DOI 10.1016/0006-291X(85)90614-X
   BJORNSSON TD, 1991, P NATL ACAD SCI USA, V88, P8651, DOI 10.1073/pnas.88.19.8651
   CASSCELLS W, 1992, P NATL ACAD SCI USA, V89, P7159, DOI 10.1073/pnas.89.15.7159
   CHAMPIONARNAUD P, 1991, ONCOGENE, V6, P979
   CUEVAS P, 1991, CIRC RES, V69, P360, DOI 10.1161/01.RES.69.2.360
   EISEMANN A, 1991, ONCOGENE, V6, P1195
   Eswarakumar VP, 2005, CYTOKINE GROWTH F R, V16, P139, DOI 10.1016/j.cytogfr.2005.01.001
   FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664
   Frullanti E, 2011, EUR J CANCER PREV, V20, P340, DOI 10.1097/CEJ.0b013e3283457274
   Gaziano TA, 2010, CURR PROB CARDIOLOGY, V35, P72, DOI [10.1016/j.cpcardio1.2009.10.002, 10.1016/j.cpcardiol.2009.10.002]
   HUGHES SE, 1993, CARDIOVASC RES, V27, P1214, DOI 10.1093/cvr/27.7.1214
   JAAKKOLA S, 1993, INT J CANCER, V54, P378, DOI 10.1002/ijc.2910540305
   JACKSON CL, 1993, AM J PATHOL, V143, P1024
   LEHTOLA L, 1992, INT J CANCER, V50, P598, DOI 10.1002/ijc.2910500419
   LEUNG HY, 1994, INT J CANCER, V59, P667, DOI 10.1002/ijc.2910590515
   LINDNER V, 1991, CIRC RES, V68, P106, DOI 10.1161/01.RES.68.1.106
   Liu Y, 2011, DNA CELL BIOL, V30, P1051, DOI 10.1089/dna.2011.1269
   Ma L, 2011, DNA CELL BIOL, V30, P1033, DOI 10.1089/dna.2011.1261
   MatsumotoYoshitomi S, 1997, INT J CANCER, V71, P442
   MIKAWA T, 1995, ANN NY ACAD SCI, V752, P506, DOI 10.1111/j.1749-6632.1995.tb17459.x
   NABEL EG, 1993, NATURE, V362, P844, DOI 10.1038/362844a0
   REIDY MA, 1991, ANN NY ACAD SCI, V638, P290, DOI 10.1111/j.1749-6632.1991.tb49039.x
   SCHWEIGERER L, 1987, NATURE, V325, P257, DOI 10.1038/325257a0
   Shi YY, 2005, CELL RES, V15, P97, DOI 10.1038/sj.cr.7290272
   Takahashi A, 1999, BIOCHEM BIOPH RES CO, V257, P855, DOI 10.1006/bbrc.1999.0465
   TAN EML, 1989, BIOCHEM BIOPH RES CO, V163, P84, DOI 10.1016/0006-291X(89)92102-5
   TEMPLETON TJ, 1992, DEV BIOL, V154, P169, DOI 10.1016/0012-1606(92)90057-N
   Wang JH, 2008, NEOPLASIA, V10, P847, DOI 10.1593/neo.08450
   Wang W, 2011, DNA CELL BIOL, V30, P925, DOI 10.1089/dna.2011.1211
   WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82
   WINKLES JA, 1987, P NATL ACAD SCI USA, V84, P7124, DOI 10.1073/pnas.84.20.7124
   Xu W, 2010, EUR J CANCER, V46, P3332, DOI 10.1016/j.ejca.2010.06.017
   Yang Y, 2012, MOL CARCINOGEN, V51, P515, DOI 10.1002/mc.20805
NR 33
TC 5
Z9 5
U1 2
U2 5
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1044-5498
EI 1557-7430
J9 DNA CELL BIOL
JI DNA Cell Biol.
PD JUN
PY 2012
VL 31
IS 6
BP 1064
EP 1069
DI 10.1089/dna.2011.1552
PG 6
WC Biochemistry & Molecular Biology; Cell Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Cell Biology; Genetics & Heredity
GA 966XY
UT WOS:000305871900023
PM 22313031
OA Green Published
DA 2018-12-27
ER

PT J
AU Oh, CS
   Han, CS
AF Oh, Chang-Sup
   Han, Chang-Suk
TI RETRACTED: Precipitation behavior of Al-Ti-Ag alloy system (Retracted
   article. See vol. 21, pg. 614, 2015)
SO METALS AND MATERIALS INTERNATIONAL
LA English
DT Article; Retracted Publication
DE alloys; aging; mechanical properties; transmission electron microscopy
   (TEM); precipitates
ID INTERMETALLICS; TEMPERATURE; PHASE; DEFORMATION; FRACTURE; CRYSTAL;
   AL3TI; CR
AB Transmission electron microscopy (TEM) examinations of Al3Ti with an L1(2)-ordered structure have revealed the precipitation of D0(23)-Al11Ti5 and L1(0)-TiAl upon aging after quenching from higher temperatures. TEM observations revealed that fine uniform precipitation of Al2Ti occurs when the supersaturation is sufficiently high, and, a preferential precipitation at the antiphase boundaries can be observed in alloy with a low supersaturation. When L1(2)-Al3Ti is supersaturated with DO22-Al3Ti, DO23-Al11Ti5 with a multidomain structure is formed during aging. On the other hand, plate-like L1(0)-TiAl precipitates lie on the {001} planes of (Al,Ag)(3)Ti matrix in the short aging period and the habit plane changed from {001} to {hhl} after a long period aging or higher temperature aging and finally to {225} of the matrix lattice. The Ll(2) phase field in the Al-Ti-Ag system is severely skewed with respect to the temperature axis and is restricted into a much smaller field at lower temperatures. Appreciable hardening and overage softening during aging can be explained in terms of microstructural variations.
C1 [Han, Chang-Suk] Hoseo Univ, Dept Def Sci & Technol, Asan 336795, South Korea.
   [Oh, Chang-Sup] Korea Inst Sci & Technol Informat, Reseat Program, Taejon 305806, South Korea.
RP Han, CS (reprint author), Hoseo Univ, Dept Def Sci & Technol, Asan 336795, South Korea.
EM hancs@hoseo.edu
CR Ashby M. F., 1963, PHILOS MAG, V8, P1647
   ASHBY MF, 1963, PHILOS MAG, V8, P1083, DOI 10.1080/14786436308207338
   Bevington JP, 2007, HYPERFINE INTERACT, V177, P15, DOI 10.1007/s10751-008-9615-y
   CLIFF G, 1975, J MICROSC-OXFORD, V103, P203, DOI 10.1111/j.1365-2818.1975.tb03895.x
   Hata S, 2005, PHIL MAG LETT, V85, P175, DOI 10.1080/09500830500157462
   Kainuma R, 2000, INTERMETALLICS, V8, P869, DOI 10.1016/S0966-9795(00)00016-9
   Lee DB, 2000, MAT SCI ENG A-STRUCT, V290, P1, DOI 10.1016/S0921-5093(00)00956-4
   Lee DB, 2008, MET MATER-INT, V14, P335, DOI 10.3365/met.mat.2008.06.335
   Lin JG, 2001, T NONFERR METAL SOC, V11, P266
   Mabuchi H, 1996, INTERMETALLICS, V4, pS193, DOI 10.1016/0966-9795(96)00005-2
   Mabuchi H., 1991, B JPN I MET, V30, P24
   Mabuchi H., 1999, JAP I LIGHT METALS, V49, P38
   Nakano T, 2005, PHILOS MAG, V85, P2527, DOI 10.1080/14786430500079728
   NAKAYAMA Y, 1993, INTERMETALLICS, V1, P41, DOI 10.1016/0966-9795(93)90020-V
   RAMAN A, 1965, Z METALLKD, V56, P44
   SCHUSTER JC, 1990, Z METALLKD, V81, P389
   TURNER CD, 1989, ACTA METALL MATER, V37, P2635, DOI 10.1016/0001-6160(89)90296-4
   Watanabe M, 1996, ULTRAMICROSCOPY, V65, P187, DOI 10.1016/S0304-3991(96)00070-8
   Watanabe Y, 2005, MET MATER-INT, V11, P391, DOI 10.1007/BF03027510
   WU ZL, 1990, SCRIPTA METALL MATER, V24, P2187, DOI 10.1016/0956-716X(90)90508-E
   Zhu H, 2005, PHIL MAG LETT, V85, P377, DOI 10.1080/09500830500251786
NR 21
TC 3
Z9 3
U1 2
U2 10
PU KOREAN INST METALS MATERIALS
PI SEOUL
PA KIM BLDG 6TH FLOOR, SEOCHO-DAERO 56 GIL 38, SEOCHO-GU, SEOUL 137-881,
   SOUTH KOREA
SN 1598-9623
EI 2005-4149
J9 MET MATER INT
JI Met. Mater.-Int.
PD JUN
PY 2012
VL 18
IS 3
BP 397
EP 404
DI 10.1007/s12540-012-3003-5
PG 8
WC Materials Science, Multidisciplinary; Metallurgy & Metallurgical
   Engineering
SC Materials Science; Metallurgy & Metallurgical Engineering
GA 964JJ
UT WOS:000305689900003
DA 2018-12-27
ER

PT J
AU Barnett, RLE
AF Barnett, R. -L. Etienne
TI RETRACTED: Abscence and Modiano subterfuge (Retracted article. See vol.
   42, pg. 359, 2015)
SO NEOHELICON
LA French
DT Article; Retracted Publication
AB In the textualized universe of Modiano, the creative impulse is inextricably linked to the unstable framework in which such matter is cast. Utterances of language translate the power of transgression. The text is birthed as an object of inquiry, ultimately to be dismantled: the work is no less elliptical than it is auto-reflexive. As a self-fixed interrogator focused upon the residual matter that it is and which it only can be, it is no longer subservient to the references it struggles to invoke, much less to signify. Writing, then, is an unending auto-reflexive process of annihilation and reification, and subsists, as such, to the sole extent that it disassociates from all conventional voices of articulation. More obtusely, to "poeticize" is to re-transcribe-otherly and with abruptness-the withered sputtering(s) of the artistic imperative. Writing, like photography, aims and frames, slices the world into sequences and images-partial, scattered, at once undone so as to be resuscitated, briefly, again. The extant is eschewed. At stake and at center-stage : a propelled form of motivity, speed, accelerations and dead-stops, an aleatory array of unremitting shifts, "instantan,es"aEuro"obstinately un-emblematic. Raging or controlled, the poem or the photo can only be a non-representational sliver, the transitory residue of an infinite combinatorics of possibles. Hence, arbitrary breaches, clamoring interruptions, ludic contortions of incompleteness. A curious dynamic.
C1 [Barnett, R. -L. Etienne] Off Univ Provost, Atlanta, GA 30360 USA.
   [Barnett, R. -L. Etienne] Univ Atlanta, Atlanta, GA 30360 USA.
   [Barnett, R. -L. Etienne] CNRS, F-75005 Paris, France.
RP Barnett, RLE (reprint author), Off Univ Provost, Atlanta, GA 30360 USA.
EM RL_Barnett@msn.com
CR Avni O, 1997, DUN PASSE AUTRE AUX
   Barnett R. -L. E, 2012, EXEGESE ETUDES TEXTU, V57, P68
   Barnett R.-L.E., 2011, LITTERATURES, V67, P77
   Bersani J, 1977, NOUVELLE REV FRANCAI, V298, P78
   Brisset A, 1982, TEXTE REV CRITIQUE T, V1, P143
   Dallenbach Lucien, 1977, RECIT SPECULAIRE ESS
   Eco U, 1966, POETICHE JOYCE
   Guicharnaud J, 1989, DILEMMES ROMAN ESSAY, P341
   Hallyn F, 1980, ROMANICA GRANDESIA, P183
   Hutcheon Linda, 1984, NARCISSISTIC NARRATI
   Josselin J.-F, 1988, NOUV OBSERVATEUR, V1209, P61
   Kerbat-Orecchioni C, 2001, ACTES LANGAGE DISCOU
   Laurent Th, 1997, OEUVRE PATRICK MODIA
   Modiano P, 1989, VESTIAIRE ENFANCE
   Modiano P, 1984, RONDE NUIT
   Modiano P, 1990, PARIS MATCH, V2137, P21
   Modiano P, 1990, VOYAGE NOCES NRF
   Modiano P, 1975, PLACE ETAILE
   Montalbetti J, 1969, MAGAZINE LIT, V34, P42
   Nettelbeck C. W, 1986, ARCH LETT MODERNES, V220, P3
   Olsen L., 1987, ELLIPSE UNCERTAINTY
   Parrochia D., 1996, ONTOLOGIE FANTOME ES
   Paterson J. M, 1982, TEXTE REV CRITIQUE T, V1, P177
   RICARDOU Jean, 1978, NOUVEAUX PROBLEMES R
   Vitoux F, 1989, NOUV OBSERVATEUR, V1266, P75
NR 25
TC 1
Z9 1
U1 0
U2 2
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0324-4652
EI 1588-2810
J9 NEOHELICON
JI Neohelicon
PD JUN
PY 2012
VL 39
IS 1
BP 73
EP 87
DI 10.1007/s11059-012-0120-6
PG 15
WC Literature
SC Literature
GA 958IP
UT WOS:000305230300006
DA 2018-12-27
ER

PT J
AU Sun, YL
   Chang, YS
   Lin, YS
   Yen, CH
AF Sun, Yu-ling
   Chang, Yuo-sheng
   Lin, Yin-shen
   Yen, Chon-ho
TI RETRACTED: Pilot production of recombinant human clotting factor IX from
   transgenic sow milk (Retracted article. See vol. 926, pg. 108, 2013)
SO JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL
   AND LIFE SCIENCES
LA English
DT Article; Retracted Publication
DE Factor IX; Transgenic sow; Milk; Purification
ID HUMAN PROTEIN-C; PURITY FACTOR-IX; MANUFACTURING PROCESS;
   GAMMA-CARBOXYLATION; BLOOD-COAGULATION; MOLECULAR-BASIS; MAMMARY-GLAND;
   EXPRESSION; PURIFICATION; PIGS
AB Valuable pharmaceutical proteins produced from the mammary glands of transgenic livestock have potential use in the biomedical industry. In this study, recombinant human clotting factor IX (rhFIX) produced from transgenic sow milk for preclinical animal studies have been established. The transgenic sow milk was skimmed and treated with sodium phosphate buffer to remove abundant casein protein. Then, the gamma-carboxylated rhFIX fraction was segregated through the Q Sepharose chromatography from uncarboxylated one. For safety issue, the process included virus inactivation by solvent/detergent (S/D) treatment. Subsequently, the S/D treated sample was loaded into the Heparin Sepharose column to recover the rhFIX fraction, which was then reapplied to the Heparin Sepharose column to enhance rhFIX purity and lower the ratio of activated form rhFIX (rhFIXa) easily. This was possible due to the higher affinity of the Heparin affinity sorbent for rhFIXa than for the rhFIX zymogen. Furthermore, an IgA removal column was used to eliminate porcine IgA in purified rhFIX. Finally, nanofiltration was performed for viral clearance. Consequently, a high-quality rhFIX product was produced (approximately 700 mg per batch). Other values for final rhFIX preparation were as follows: purity, >99%; average specific activity, 415.6 +/- 57.7 IU/mL and total milk impurity, <0.5 ng/mg. This is the first report that described the whole process and stable production of bioactive rhFIX from transgenic sow milk. The overall manufacturing process presented here has the potential for industrial production of rhFIX for treatment of hemophilia B patients. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Sun, Yu-ling; Chang, Yuo-sheng; Lin, Yin-shen; Yen, Chon-ho] Anim Technol Inst Taiwan, Div Biotechnol, Chunan 350, Miaoli, Taiwan.
RP Yen, CH (reprint author), Anim Technol Inst Taiwan, Div Biotechnol, POB 23, Chunan 350, Miaoli, Taiwan.
EM chy01@mail.atit.org.tw
FU Ministry of Economic Affairs of Executive Yuan, Taiwan, R.O.C.
   [96-EC-17-A-17-R7-0454]
FX This work was supported by the grant of 96-EC-17-A-17-R7-0454 from the
   Ministry of Economic Affairs of Executive Yuan, Taiwan, R.O.C. The
   authors gratefully thank to Dr. Shih-Rong Wang for the technical
   operation of viral reduction factor at Biosafety Test Laboratory and
   persons who have participated in the execution of this production
   process of the Animal Technology Institute Taiwan.
CR ANDERSSON LO, 1975, THROMB RES, V7, P451, DOI 10.1016/0049-3848(75)90039-0
   ANSON DS, 1985, NATURE, V315, P683, DOI 10.1038/315683a0
   Blostein M, 2008, HAEMOPHILIA, V14, P1063, DOI 10.1111/j.1365-2516.2008.01828.x
   BUSBY S, 1985, NATURE, V316, P271, DOI 10.1038/316271a0
   Chang CH, 2008, IN VIVO, V22, P693
   Chang JT, 2010, JPN J VET RES, V58, P179
   Chang LC, 2011, MOL PHARMACEUT, V8, P1767, DOI 10.1021/mp200133s
   Chowdary P, 2001, HAEMOPHILIA, V7, P140, DOI 10.1046/j.1365-2516.2001.00494.x
   CLARK AJ, 1989, BIO-TECHNOL, V7, P487, DOI 10.1038/nbt0589-487
   Clark AJ, 1998, J MAMMARY GLAND BIOL, V3, P337, DOI 10.1023/A:1018723712996
   DELASALLE H, 1985, NATURE, V316, P268, DOI 10.1038/316268a0
   DENMAN J, 1991, BIO-TECHNOL, V9, P839, DOI 10.1038/nbt0991-839
   DISCIPIO RG, 1978, J CLIN INVEST, V61, P1528, DOI 10.1172/JCI109073
   FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3
   FURIE B, 1990, BLOOD, V75, P1753
   Furie B, 1999, BLOOD, V93, P1798
   Gailani D, 2000, TRENDS CARDIOVAS MED, V10, P198, DOI 10.1016/S1050-1738(00)00070-0
   Gillis S, 1997, PROTEIN SCI, V6, P185
   Harrison S, 1998, SEMIN HEMATOL, V35, P4
   HUGHES HC, 1986, LAB ANIM SCI, V36, P348
   JALLAT S, 1990, EMBO J, V9, P3295, DOI 10.1002/j.1460-2075.1990.tb07529.x
   Johnston A, 2000, BIOLOGICALS, V28, P129, DOI 10.1006/biol.1999.0242
   KAUFMAN RJ, 1986, J BIOL CHEM, V261, P9622
   Kim WH, 2009, J BIOTECHNOL, V142, P275, DOI 10.1016/j.jbiotec.2009.06.001
   Lee HG, 2009, J REPROD DEVELOP, V55, P484, DOI 10.1262/jrd.20212
   Lindsay M, 2004, J CHROMATOGR A, V1026, P149, DOI 10.1016/j.chroma.2003.11.006
   Morcol T, 2001, BIOTECHNOL PROGR, V17, P577, DOI 10.1021/bp010023x
   Paleyanda RK, 1997, NAT BIOTECHNOL, V15, P971, DOI 10.1038/nbt1097-971
   Roberts PL, 2003, VOX SANG, V84, P170, DOI 10.1046/j.1423-0410.2003.00275.x
   Rohlena J., 2004, THESIS
   Shapiro AD, 2005, BLOOD, V105, P518, DOI 10.1182/blood-2004-06-2283
   Van Cott KE, 1999, GENET ANAL-BIOMOL E, V15, P155, DOI 10.1016/S1050-3862(99)00020-0
   Van Cott KE, 2001, TRANSGENIC RES, V10, P43, DOI 10.1023/A:1008963817646
   Velander W.H., 2002, US Patent, Patent No. [6,344,596, 6344596]
   VELANDER WH, 1992, P NATL ACAD SCI USA, V89, P12003, DOI 10.1073/pnas.89.24.12003
   Wajih N, 2005, J BIOL CHEM, V280, P31603, DOI 10.1074/jbc.M505373200
   Wojcik EGC, 1998, BBA-PROTEIN STRUCT M, V1382, P91, DOI 10.1016/S0167-4838(97)00149-0
   WU SC, 2006, Patent No. 7087808
   Yang LK, 2002, J BIOL CHEM, V277, P50756, DOI 10.1074/jbc.M208485200
   Yen C.H., 2011, U.S. Patent, Patent No. [7,943,739, 7943739]
   YEN CH, 2007, Patent No. 7214319
NR 41
TC 7
Z9 7
U1 3
U2 24
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1570-0232
EI 1873-376X
J9 J CHROMATOGR B
JI J. Chromatogr. B
PD JUN 1
PY 2012
VL 898
BP 78
EP 89
DI 10.1016/j.jchromb.2012.04.022
PG 12
WC Biochemical Research Methods; Chemistry, Analytical
SC Biochemistry & Molecular Biology; Chemistry
GA 956NZ
UT WOS:000305097700010
PM 22578515
DA 2018-12-27
ER

PT J
AU Khoza, S
   Barner, JC
   Bohman, TM
   Rascati, K
   Lawson, K
   Wilson, JP
AF Khoza, Star
   Barner, Jamie C.
   Bohman, Thomas M.
   Rascati, Karen
   Lawson, Kenneth
   Wilson, James P.
TI RETRACTED: Use of antidepressants and the risk of type 2 diabetes
   mellitus: a nested case-control study (Retracted article. See vol. 34,
   pg. 795, 2012)
SO INTERNATIONAL JOURNAL OF CLINICAL PHARMACY
LA English
DT Article; Retracted Publication
DE Antidepressants; Diabetes; Diabetes type-2; Medicaid; Nested
   case-control study; Prescriptions claim database; Texas; United States
ID CENTRAL TEXAS VETERANS; PREVENTION PROGRAM; MEDICINE USE; WEIGHT-GAIN;
   HOSPITALIZATIONS; ASSOCIATION; POPULATION; DEPRESSION; DISORDERS;
   REGIMENS
AB Background Recent evidence from case reports, observational studies, and randomized trials suggests that long-term use of antidepressants increases the risk of developing diabetes. However, the nature of the relationship between antidepressants and diabetes remains unclear. Objective To determine whether there is an association between antidepressant use and the risk of developing type 2 diabetes mellitus. Methods A nested case-control study using the Texas Medicaid prescription claims database was conducted. Data were extracted for new users of either antidepressant agents (exposed) or benzodiazepines (unexposed) from January 1, 2002 through December 31, 2009. Patients aged 18-64 years without a history of diabetes were included in the cohort. The adjusted odds ratio (OR) and 95% confidence interval (CI) for the risk of diabetes associated with antidepressant exposure was computed using conditional logistic regression, controlling for demographic and clinical covariates. Main outcome measure Development of type 2 diabetes mellitus Results Among the total sample (N = 44,715), the majority were in the exposed (N = 35,552) vs. the unexposed (N = 9,163) group. A total of 2,943 cases of type 2 diabetes mellitus and 11,748 matched controls (1:4) were identified using risk-set sampling. Cases and controls were matched using age and gender. Antidepressant use was associated with an increase in the risk of (type-2) diabetes when compared to benzodiazepine use [Adjusted Odds Ratio (OR) = 1.512; 95% CI 1.345-1.700]. The association was observed with serotonin-norepinephrine reuptake inhibitors (OR = 1.742; 95% CI 1.472-2.060), tricyclic antidepressants (OR = 1.533; 95% CI 1.295-1.814), selective serotonin reuptake inhibitors (OR = 1.457; 95% CI 1.279-1.659), "Other" antidepressants (OR = 1.318; 95% CI 1.129-1.540). Conclusions Antidepressant use was associated with an increased risk of (type-2) diabetes. This association was observed for tricyclic antidepressants, serotonin-reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, and other antidepressants.
C1 [Khoza, Star] Univ Zimbabwe, Dept Clin Pharmacol, Coll Hlth Sci, Harare, Zimbabwe.
   [Barner, Jamie C.; Rascati, Karen; Lawson, Kenneth; Wilson, James P.] Univ Texas Austin, Coll Pharm, Austin, TX 78712 USA.
   [Bohman, Thomas M.] Univ Texas Austin, Sch Social Work, Austin, TX 78712 USA.
RP Khoza, S (reprint author), Univ Zimbabwe, Dept Clin Pharmacol, Coll Hlth Sci, POB A 178, Harare, Zimbabwe.
EM skhoza53@gmail.com
CR Andersohn F, 2009, AM J PSYCHIAT, V166, P591, DOI 10.1176/appi.ajp.2008.08071065
   Anderson Robert N, 2003, Natl Vital Stat Rep, V52, P1
   Atlantis E, 2010, INT J GERIATR PSYCH, V25, P688, DOI 10.1002/gps.2409
   Barner JC, 2004, PHARMACOTHERAPY, V24, P1529, DOI 10.1592/phco.24.16.1529.50952
   Brown LC, 2008, DIABETES RES CLIN PR, V79, P61, DOI 10.1016/j.diabres.2007.07.009
   Centers for disease control and prevention, 2009, DIAB FACT SHEET 2007
   Dailey G, 2001, CLIN THER, V23, P1311, DOI 10.1016/S0149-2918(01)80110-7
   Derijks HJ, 2008, EUR J CLIN PHARMACOL, V64, P531, DOI 10.1007/s00228-007-0441-y
   Etminan M, 2003, PHARMACOTHERAPY, V23, P1411, DOI 10.1592/phco.23.14.1411.31939
   Henderson DC, 2000, AM J PSYCHIAT, V157, P975, DOI 10.1176/appi.ajp.157.6.975
   Kivimaki M, 2010, DIABETES CARE, V33, P2611, DOI 10.2337/dc10.1187
   Kivimaki M, 2010, DIABETES CARE, V33, P1471, DOI 10.2337/dc09-2359
   Knol MJ, 2007, INT CLIN PSYCHOPHARM, V22, P382, DOI 10.1097/YIC.0b013e3282202c0e
   Luna B, 2001, JAMA-J AM MED ASSOC, V286, P1945, DOI 10.1001/jama.286.16.1945
   Mojtabai R, 2008, J CLIN PSYCHIAT, V69, P1064, DOI 10.4088/JCP.v69n0704
   NIHCM Foundation, 2001, PRESCR DRUG EXP 2001
   Opolka JL, 2004, PSYCHIAT SERV, V55, P151, DOI 10.1176/appi.ps.55.2.151
   PANDIT MK, 1993, ANN INTERN MED, V118, P529, DOI 10.7326/0003-4819-118-7-199304010-00008
   Patel NC, 2005, J AM ACAD CHILD PSY, V44, P548, DOI 10.1097/01.chi.0000157543.74509.c8
   Raeder MB, 2006, J CLIN PSYCHIAT, V67, P1974, DOI 10.4088/JCP.v67n1219
   Rascati KL, 2005, CLIN THER, V27, P346, DOI 10.1016/j.clinthera.2005.03.005
   Rubin RR, 2008, DIABETES CARE, V31, P420, DOI 10.2337/dc07-182T
   Rubin RR, 2010, DIABETES CARE, V33, P2549, DOI [10.2337/dc10-1033, 10.2337/dc10.1033]
   SCLAR DA, 1991, CLIN THER, V13, P489
   Smith MJ, 2004, ANN ALLERG ASTHMA IM, V92, P40, DOI 10.1016/S1081-1206(10)61708-5
   Texas health and human services, 2009, TEX MED CHIP PERSP
   VONKORFF M, 1992, J CLIN EPIDEMIOL, V45, P197, DOI 10.1016/0895-4356(92)90016-G
   Winer N, 2004, J CLIN PHARMACOL, V44, P397, DOI 10.1177/0091270004263017
   Yang M, 2007, CLIN THER, V29, P1214, DOI 10.1016/j.clinthera.2007.06.013
NR 29
TC 4
Z9 4
U1 2
U2 15
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 2210-7703
EI 2210-7711
J9 INT J CLIN PHARM-NET
JI Int. J. Clin. Phar,.
PD JUN
PY 2012
VL 34
IS 3
BP 432
EP 438
DI 10.1007/s11096-012-9608-4
PG 7
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 953PG
UT WOS:000304882000006
PM 22249783
DA 2018-12-27
ER

PT J
AU Clement-Schatlo, V
   Marino, D
   Burkhardt, K
   Teta, P
   Leyvraz, F
   Schatlo, B
   Frank, S
   Schaller, K
   Castella, V
   Radovanovic, I
AF Clement-Schatlo, Virginie
   Marino, Denis
   Burkhardt, Karim
   Teta, Patrick
   Leyvraz, Fabienne
   Schatlo, Bawarjan
   Frank, Stephan
   Schaller, Karl
   Castella, Vincent
   Radovanovic, Ivan
TI RETRACTED: Quantification, self-renewal, and genetic tracing of FL1(+)
   tumor-initiating cells in a large cohort of human gliomas (Retracted
   article. See vol. 16, pg. 889, 2014)
SO NEURO-ONCOLOGY
LA English
DT Article; Retracted Publication
DE cancer-initiating cells; epilepsia; genetic; mouse model; stemness
ID CANCER STEM-CELLS; CENTRAL-NERVOUS-SYSTEM; NEURAL PRECURSORS;
   BRAIN-TUMORS; GLIOBLASTOMA; IDENTIFICATION; HETEROGENEITY; NEUROGENESIS;
   MUTATIONS; PHENOTYPE
AB Evidence has emerged that the initiation and growth of gliomas is sustained by a subpopulation of cancer-initiating cells (CICs). Because of the difficulty of using markers to tag CICs in gliomas, we have previously exploited more robust phenotypic characteristics, including a specific morphology and intrincic autofluorescence, to identify and isolate a subpopulation of glioma CICs, called F1(+). The objective of this study was to further validate our method in a large cohort of human glioma and a mouse model of glioma. Seventy-four human gliomas of all grades and the GFAP-V(12)HA-ras B8 mouse model were analyzed for in vitro self-renewal capacity and their content of FL1(+). Nonneoplastic brain tissue and embryonic mouse brain were used as control. Genetic traceability along passages was assessed with microsatellite analysis. We found that FL1(+) cells from low-grade gliomas and from control nonneoplasic brain tissue show a lower level of autofluorescence and undergo a restricted number of cell divisions before dying in culture. In contrast, we found that FL1(+) cells derived from many but not all high-grade gliomas acquire high levels of autofluorescence and can be propagated in long-term cultures. Moreover, FL1(+) cells show a remarkable traceability over time in vitro and in vivo. Our results show that FL1(+) cells can be found in all specimens of a large cohort of human gliomas of different grades and in a model of genetically induced mouse glioma as well as nonneoplastic brain. However, their self-renewal capacity is variable and seems to be dependent on the tumor grade.
C1 [Clement-Schatlo, Virginie] Univ Geneva, Dept Clin Neurosci, Neurosurg Serv, CH-1211 Geneva, Switzerland.
   [Burkhardt, Karim] Univ Geneva, Div Surg Pathol, CH-1211 Geneva, Switzerland.
   [Teta, Patrick; Leyvraz, Fabienne; Castella, Vincent] Univ Ctr Legal Med, Forens Genet Unit, Geneva, Switzerland.
   [Teta, Patrick; Leyvraz, Fabienne; Castella, Vincent] Univ Ctr Legal Med, Forens Genet Unit, Lausanne, Switzerland.
   [Teta, Patrick; Schatlo, Bawarjan; Schaller, Karl; Radovanovic, Ivan] Univ Hosp Geneva, Neurosurg Serv, Dept Clin Neurosci, Geneva, Switzerland.
   [Frank, Stephan] Univ Basel Hosp, Inst Pathol, Div Neuropathol, CH-4031 Basel, Switzerland.
RP Clement-Schatlo, V (reprint author), Univ Geneva, Dept Clin Neurosci, Neurosurg Serv, Rue Gabrielle Perret Gentil 4, CH-1211 Geneva, Switzerland.
EM virginie.clement@unige.ch
OI Schatlo, Bawarjan/0000-0002-9221-0843
FU foundation "Anita et Werner Damm-Etienne"; foundation "Ernest and Lucie
   Schmidheiny"
FX This work was supported by the foundation "Anita et Werner Damm-Etienne"
   and the foundation "Ernest and Lucie Schmidheiny."
CR Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236
   Beier D, 2007, CANCER RES, V67, P4010, DOI 10.1158/0008-5472.CAN-06-4180
   Bell DW, 2010, J PATHOL, V220, P231, DOI 10.1002/path.2645
   Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730
   Chen RH, 2010, CANCER CELL, V17, P362, DOI 10.1016/j.ccr.2009.12.049
   Clement V, 2007, CURR BIOL, V17, P165, DOI 10.1016/j.cub.2006.11.033
   Clement V, 2010, NAT METHODS, V7, P224, DOI [10.1038/NMETH.1430, 10.1038/nmeth.1430]
   Clement V, 2009, INT J CANCER, V125, P244, DOI 10.1002/ijc.24352
   Danzer SC, 2008, NEUROSCIENTIST, V14, P446, DOI 10.1177/1073858408317008
   DeCarvalho AC, 2010, STEM CELLS, V28, P181, DOI 10.1002/stem.264
   Deleyrolle LP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015844
   Ding H, 2001, CANCER RES, V61, P3826
   Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433
   Galli R, 2004, CANCER RES, V64, P7011, DOI 10.1158/0008-5472.CAN-04-1364
   Galmozzi E, 2006, CURR MED CHEM, V13, P603, DOI 10.2174/092986706776055661
   Gomori E, 2002, J NEUROPATH EXP NEUR, V61, P396
   Gunther HS, 2007, ONCOGENE, V36
   Hemmati HD, 2003, P NATL ACAD SCI USA, V100, P15178, DOI 10.1073/pnas.2036535100
   Jenkins RB, 2011, CANCER GENET-NY, V204, P13, DOI 10.1016/j.cancergencyto.2010.10.002
   Kim KJ, 2011, NEUROPATHOLOGY, V31, P494, DOI 10.1111/j.1440-1789.2010.01194.x
   Klein CA, 1999, P NATL ACAD SCI USA, V96, P4494, DOI 10.1073/pnas.96.8.4494
   Kondo T, 2006, EUR J CANCER, V42, P1237, DOI 10.1016/j.ejca.2006.01.038
   Kroonen J, 2008, Rev Med Liege, V63, P251
   Mlynarik C, 2011, NMR BIOMED, V15, P506
   NAGEL S, 1995, CANCER RES, V55, P2866
   Pardal R, 2003, NAT REV CANCER, V3, P895, DOI 10.1038/nrc1232
   Persson AI, 2010, CANCER CELL, V18, P669, DOI 10.1016/j.ccr.2010.10.033
   Pfenninger CV, 2007, CANCER RES, V67, P5727, DOI 10.1158/0008-5472.CAN-07-0183
   PIERCE GB, 1983, AM J PATHOL, V113, P115
   Prestegarden L, 2010, CANCER RES, V70, P8255, DOI 10.1158/0008-5472.CAN-10-1592
   Prestegarden L, 2010, CANCER RES, V70, P4274, DOI 10.1158/0008-5472.CAN-09-3904
   Rebetz J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001936
   Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167
   Salk JJ, 2010, ANNU REV PATHOL-MECH, V5, P51, DOI 10.1146/annurev-pathol-121808-102113
   Siebzehnrubl FA, 2011, GLIA, V59, P1135, DOI 10.1002/glia.21143
   Siebzehnrubl FA, 2008, EPILEPSIA, V49, P55, DOI 10.1111/j.1528-1167.2008.01638.x
   Siebzehnrubl FA, 2009, BRAIN PATHOL, V19, P399, DOI 10.1111/j.1750-3639.2008.00189.x
   Singh SK, 2004, ONCOGENE, V23, P7267, DOI 10.1038/sj.onc.1207946
   Singh SK, 2003, CANCER RES, V63, P5821
   Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128
   Temple S, 2001, NATURE, V414, P112, DOI 10.1038/35102174
   Thang NNT, 2010, CANCER RES, V70, P4829, DOI 10.1158/0008-5472.CAN-09-3074
   Thon N, 2010, MOL CELL NEUROSCI, V43, P51, DOI 10.1016/j.mcn.2008.07.022
   Tsao JL, 1998, AM J PATHOL, V153, P1189, DOI 10.1016/S0002-9440(10)65663-5
   Uchida N, 2000, P NATL ACAD SCI USA, V97, P14720, DOI 10.1073/pnas.97.26.14720
   Yuan XP, 2004, ONCOGENE, V23, P9392, DOI 10.1038/sj.onc.1208311
   Zhou S, 2001, NAT MED, V7, P1028, DOI 10.1038/nm0901-1028
NR 47
TC 1
Z9 1
U1 2
U2 10
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1522-8517
EI 1523-5866
J9 NEURO-ONCOLOGY
JI Neuro-Oncology
PD JUN
PY 2012
VL 14
IS 6
BP 720
EP 735
DI 10.1093/neuonc/nos084
PG 16
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA 955PB
UT WOS:000305031900008
PM 22584872
OA Bronze, Green Published
DA 2018-12-27
ER

PT J
AU Lin, CK
   Chao, TK
   Lai, HC
   Lee, HS
AF Lin, Chih-kung
   Chao, Tai-Kuang
   Lai, Hung-Cheng
   Lee, Herng-Sheng
TI RETRACTED: LMX1A as a Prognostic Marker in Ovarian Mucinous
   Cystadenocarcinoma (Retracted article. See vol. 138, pg. 167, 2012)
SO AMERICAN JOURNAL OF CLINICAL PATHOLOGY
LA English
DT Article; Retracted Publication
DE LMX1A; Osteopontin; Immunostaining score
ID CANCER STATISTICS; OSTEOPONTIN; CELLS; IDENTIFICATION; TARGET; ROLES
AB This study aimed to evaluate the relationship of LMX1A and osteopontin (OPN) expression with clinicopathologic parameters for the 4 most common ovarian surface epithelial carcinomas. Both biomarkers were investigated immunohistochemically using tissue microarrays of 249 specimens including 91 serous cystadenocarcinomas, 56 mucinous cystadenocarcinomas, 64 endometrioid adenocarcinomas, 26 clear cell carcinomas, and 12 normal ovarian tissues. All 4 carcinomas showed significant expression of LMX1A and OPN. In addition, higher immunostaining scores and percentage of cells stained for LMX1A in mucinous cystadenocarcinomas correlated with T stage, American Joint Committee on Cancer clinical stage, poorer tumor differentiation, and poorer survival rate. In serous cystadenocarcinoma, higher percentage of staining for OPN and higher intensity or immunostaining scores for LMX1A correlated with poorer tumor differentiation. Thus, the expression of LMX1A may be an independent prognostic risk factor in mucinous cystadenocarcinoma and a helpful marker in evaluating this tumor's aggressiveness.
C1 [Lin, Chih-kung; Chao, Tai-Kuang; Lee, Herng-Sheng] Tri Serv Gen Hosp, Dept Pathol, Natl Def Med Ctr, Taipei, Taiwan.
   [Lai, Hung-Cheng] Tri Serv Gen Hosp, Dept Gynecol & Obstet, Natl Def Med Ctr, Taipei, Taiwan.
RP Lee, HS (reprint author), Tri Serv Gen Hosp, Dept Pathol, Natl Def Med Ctr, 325,Sect 2,Cheng Gong Rd, Taipei, Taiwan.
EM doc31795@yahoo.com.tw
FU Tri-Service General Hospital, Taipei, Taiwan [TSGH-C100-110]
FX Supported by grant TSGH-C100-110 from Tri-Service General Hospital,
   Taipei, Taiwan.
CR Cai JL, 2009, STEM CELLS, V27, P220, DOI 10.1634/stemcells.2008-0734
   CANNISTRA SA, 1993, NEW ENGL J MED, V329, P1550, DOI 10.1056/NEJM199311183292108
   Chakraborty G, 2006, CURR MOL MED, V6, P819, DOI 10.2174/156652406779010803
   Chizhikov VV, 2010, P NATL ACAD SCI USA, V107, P10725, DOI 10.1073/pnas.0910786107
   Dawid IB, 1998, TRENDS GENET, V14, P156, DOI 10.1016/S0168-9525(98)01424-3
   Denhardt DT, 1998, J CELL BIOCHEM, P92, DOI 10.1002/(SICI)1097-4644(1998)72:30/31+<92::AID-JCB13>3.0.CO;2-A
   Furger Kara A., 2001, Current Molecular Medicine (Hilversum), V1, P621, DOI 10.2174/1566524013363339
   Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15
   Hobert O, 2000, TRENDS GENET, V16, P75, DOI 10.1016/S0168-9525(99)01883-1
   Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106
   Lai HC, 2008, INT J CANCER, V123, P161, DOI 10.1002/ijc.23519
   Liu CY, 2009, J PATHOL, V219, P222, DOI 10.1002/path.2589
   Matsuura M, 2010, CANCER SCI, V101, P1828, DOI 10.1111/j.1349-7006.2010.01615.x
   Menon U, 2007, NAT CLIN PRACT ONCOL, V4, P498, DOI 10.1038/ncponc0906
   PARTIN AW, 1989, P NATL ACAD SCI USA, V86, P1254, DOI 10.1073/pnas.86.4.1254
   Schorge JO, 2004, CLIN CANCER RES, V10, P3474, DOI 10.1158/1078-0432.CCR-03-0365
   Toy H, 2009, PATHOL ONCOL RES, V15, P203, DOI 10.1007/s12253-008-9130-0
   Tuck AB, 2000, J CELL BIOCHEM, V78, P465, DOI 10.1002/1097-4644(20000901)78:3<465::AID-JCB11>3.0.CO;2-C
   Tuck AB, 2001, J MAMMARY GLAND BIOL, V6, P419, DOI 10.1023/A:1014734930781
   Visintin I, 2008, CLIN CANCER RES, V14, P1065, DOI 10.1158/1078-0432.CCR-07-1569
   Weber GF, 2001, BBA-REV CANCER, V1552, P61, DOI 10.1016/S0304-419X(01)00037-3
   Wong KK, 2001, BIOTECHNIQUES, V30, P670, DOI 10.2144/01303dd05
NR 22
TC 7
Z9 7
U1 2
U2 12
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0002-9173
EI 1943-7722
J9 AM J CLIN PATHOL
JI Am. J. Clin. Pathol.
PD JUN
PY 2012
VL 137
IS 6
BP 971
EP 977
DI 10.1309/AJCPIX0RUO5PGLXD
PG 7
WC Pathology
SC Pathology
GA 949KS
UT WOS:000304575700015
PM 22586057
OA Bronze
DA 2018-12-27
ER

PT J
AU Benyoucef, S
   Amrani, M
AF Benyoucef, Salah
   Amrani, Moussa
TI RETRACTED: Adsorptive removal of phosphate from aqueous solution by
   chemically modified biosorbent (Retracted article. See vol. 57, 2016)
SO DESALINATION AND WATER TREATMENT
LA English
DT Article; Retracted Publication
DE Sawdust; Biosorbent; Low cost; Phosphate removal; Adsorption isotherms;
   Kinetics; Thermodynamics
ID PHOSPHORUS REMOVAL; WASTE-WATER; EFFLUENTS; ISOTHERM; ULTRAFILTRATION;
   EQUILIBRIUM; KINETICS; REACTOR; CR(VI); LIGNIN
AB In the present study, chemically modified biosorbent (Pinus halepensis Miller) was used for removal of phosphate from water. Biosorbent preparation process included size fractionation, extraction for surface activation, acid prehydrolysis, and treatment with urea. Sorption of phosphate ions onto biosorbent was studied using the batch technique. The effect of different parameters such as contact time, adsorbate concentration, and temperature was investigated. The adsorption kinetics data were best described by the pseudo-second-order rate equation, and equilibrium was achieved after 40 min. The Langmuir and Freundlich equations for describing adsorption equilibrium were applied to data. The constants and correlation coefficients of these isotherm models were calculated and compared. The adsorption isotherms obey the Freundlich equation. The thermodynamic parameters like free energy, enthalpy and entropy changes for the adsorption of phosphate ions have been evaluated and it has been found that the reaction was spontaneous and endothermic in nature. The low value of activated energy of adsorption, 3.088 kJ mol(-1) indicates that the phosphate ions are easily adsorbed on the sawdust. Results suggest that the prepared chemically modified Aleppo pine sawdust has potential in remediation of contaminated waters by phosphate.
C1 [Benyoucef, Salah; Amrani, Moussa] MHamed Bougara Univ, Fac Sci, Lab Soft Technol Recovering & Sustainable Dev, Boumerdes, Algeria.
RP Amrani, M (reprint author), MHamed Bougara Univ, Fac Sci, Lab Soft Technol Recovering & Sustainable Dev, Boumerdes, Algeria.
EM moussaamrani@yahoo.fr
CR Abd El-Latif M.M., 2009, DESALIN WATER TREAT, V6, P252, DOI DOI 10.5004/DWT.2009.501
   Abolonskay A.V., 1965, HDB PRACTICAL WORK C
   Aksu Z, 2001, SEP PURIF TECHNOL, V21, P285, DOI 10.1016/S1383-5866(00)00212-4
   Anirudhan TS, 2009, DESALIN WATER TREAT, V12, P3, DOI 10.5004/dwt.2009.997
   Ayoub GM, 2001, WATER ENVIRON RES, V73, P478, DOI 10.2175/106143001X139533
   Babu BV, 2008, ADSORPTION, V14, P85, DOI 10.1007/s10450-007-9057-x
   Basso MC, 2002, IND ENG CHEM RES, V41, P3580, DOI 10.1021/ie020023h
   Behrendt H, 1997, ARCH NAT CONSERV LAN, V35, P329
   Bhattacharya AK, 2008, CHEM ENG J, V137, P529, DOI 10.1016/j.cej.2007.05.021
   Borgnino L, 2009, COLLOID SURFACE A, V341, P46, DOI 10.1016/j.colsurfa.2009.03.037
   Valero MAC, 2009, DESALIN WATER TREAT, V4, P122, DOI 10.5004/dwt.2009.366
   Camarillo R, 2009, DESALIN WATER TREAT, V6, P211, DOI 10.5004/dwt.2009.640
   Chitrakar R, 2006, J COLLOID INTERF SCI, V297, P426, DOI 10.1016/j.jcis.2005.11.011
   Del Bubba M, 2003, WATER RES, V37, P3390, DOI 10.1016/S0043-1354(03)00231-8
   EGGERS E, 1991, Water Science and Technology, V24, P333
   Gieseke A, 2002, WATER RES, V36, P501, DOI 10.1016/S0043-1354(01)00232-9
   GILES CH, 1974, J COLLOID INTERF SCI, V47, P755, DOI 10.1016/0021-9797(74)90252-5
   Guo XY, 2008, J HAZARD MATER, V151, P134, DOI 10.1016/j.jhazmat.2007.05.065
   Hane J.S., 2003, 6 INT REG C ENV WAT
   Ho YS, 2006, WATER RES, V40, P119, DOI 10.1016/j.watres.2005.10.040
   Kannan N, 2001, DYES PIGMENTS, V51, P25, DOI 10.1016/S0143-7208(01)00056-0
   Khan MA, 2004, INT J ADHES ADHES, V24, P485, DOI 10.1016/j.ijadhadh.2004.01.003
   Krishnan KA, 2008, COLLOID SURFACE A, V317, P344, DOI 10.1016/j.colsurfa.2007.11.002
   Lyubchik S.I., 2004, COLLOID SURF A, V242, P51
   Mortula M, 2007, J ENVIRON ENG SCI, V6, P157, DOI 10.1139/S06-042
   Naiya TK, 2009, CHEM ENG J, V148, P68, DOI 10.1016/j.cej.2008.08.002
   Nir T, 2009, DESALIN WATER TREAT, V8, P24, DOI 10.5004/dwt.2009.686
   Peleka EN, 2009, DESALINATION, V245, P357, DOI 10.1016/j.desal.2008.04.050
   Penetra RG, 1999, WATER SCI TECHNOL, V40, P137, DOI 10.1016/S0273-1223(99)00619-8
   PUCKETT LJ, 1995, ENVIRON SCI TECHNOL, V29, pA408, DOI 10.1021/es00009a001
   Rana AK, 1997, J APPL POLYM SCI, V64, P1517, DOI 10.1002/(SICI)1097-4628(19970523)64:8<1517::AID-APP9>3.0.CO;2-K
   Rehman H., 2006, J CHIN CHEM SOC-TAIP, V53, P1045
   Ruan HD, 2000, J ENVIRON QUAL, V29, P1875, DOI 10.2134/jeq2000.00472425002900060021x
   SIDIRAS DK, 1989, BIOMASS, V19, P289, DOI 10.1016/0144-4565(89)90073-5
   Weber W J, 1963, J SANITARY ENGINEERI, V89, P31, DOI DOI 10.1016/J.DESAL.2010.08.036
   Yan LG, 2010, J HAZARD MATER, V179, P244, DOI 10.1016/j.jhazmat.2010.02.086
NR 36
TC 5
Z9 5
U1 2
U2 26
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1944-3994
EI 1944-3986
J9 DESALIN WATER TREAT
JI Desalin. Water Treat.
PD JUN
PY 2012
VL 44
IS 1-3
BP 306
EP 313
DI 10.5004/dwt.2012.2244
PG 8
WC Engineering, Chemical; Water Resources
SC Engineering; Water Resources
GA 949PX
UT WOS:000304589200038
DA 2018-12-27
ER

PT J
AU Xu, XC
   Liu, TT
   Zhang, AM
   Huo, XX
   Luo, QL
   Chen, ZW
   Yu, L
   Li, Q
   Liu, LL
   Lun, ZR
   Shen, LL
AF Xu, Xiucai
   Liu, Tingting
   Zhang, Aimei
   Huo, Xingxing
   Luo, Qingli
   Chen, Zhaowu
   Yu, Li
   Li, Qing
   Liu, Lili
   Lun, Zhao-rong
   Shen, Jilong
TI RETRACTED: Reactive Oxygen Species-Triggered Trophoblast Apoptosis Is
   Initiated by Endoplasmic Reticulum Stress via Activation of Caspase-12,
   CHOP, and the JNK Pathway in Toxoplasma gondii Infection in Mice
   (Retracted article. See vol. 83, pg. 1735, 2015)
SO INFECTION AND IMMUNITY
LA English
DT Article; Retracted Publication
ID NF-KAPPA-B; OXIDATIVE STRESS; MEDIATED APOPTOSIS; INTERFERON-GAMMA; TH1
   CYTOKINES; CELL-DEATH; IFN-GAMMA; ER STRESS; LIPOPOLYSACCHARIDE;
   GLYCOSYLPHOSPHATIDYLINOSITOLS
AB Toxoplasma gondii infection in pregnant women may result in abortion or in fetal teratogenesis; however, the underlying mechanisms are still unclear. In this paper, based on a murine model, we showed that maternal infection with RH strain T. gondii tachyzoites induced elevated production of reactive oxygen species (ROS), local oxidative stress, and subsequent apoptosis of placental trophoblasts. PCR array analysis of 84 oxidative stress-related genes demonstrated that 27 genes were upregulated at least 2-fold and that 9 genes were downregulated at least 2-fold in the T. gondii infection group compared with levels in the control group. The expression of NADPH oxidase 1 (Nox1) and glutathione peroxidase 6 (Gpx6) increased significantly, about 25-fold. The levels of malondialdehyde (MDA) and 8-hydroxydeoxyguanosine (8-OHdG) increased significantly with T. gondii infection, and levels of glutathione (GSH) decreased rapidly. T. gondii infection increased the early expression of endoplasmic reticulum stress (ERS) markers, followed by cleavage of caspase-12, activation of ASK1/JNK, and increased apoptosis of trophoblasts, both in vivo and in vitro. The apoptosis of trophoblasts, the activation of caspase-12 and the ASK1/JNK pathway, and the production of peroxides were dramatically inhibited by pretreatment with N-acetylcysteine (NAC). The upregulation of Nox1 was contact dependent and preceded the increase in levels of ERS markers and the activation of the proapoptosis cascade. Thus, we concluded that apoptosis in placental trophoblasts was initiated predominantly by ROS-mediated ERS via activation of caspase-12, CHOP, and the JNK pathway in acute T. gondii infection. Elevated ROS production is the central event in T. gondii-induced apoptosis of placental trophoblasts.
C1 [Xu, Xiucai; Liu, Tingting; Zhang, Aimei; Huo, Xingxing; Luo, Qingli; Chen, Zhaowu; Yu, Li; Liu, Lili; Shen, Jilong] Anhui Med Univ, Dept Microbiol & Parasitol, Anhui Prov Labs Pathogen Biol & Zoonoses, Hefei, Peoples R China.
   [Xu, Xiucai; Zhang, Aimei; Li, Qing] Anhui Med Univ, Cent Lab, Affiliated Prov Hosp, Hefei, Peoples R China.
   [Liu, Lili] Anhui Med Univ, Affiliated Hosp 4, Dept Lab Diag, Hefei, Peoples R China.
   [Lun, Zhao-rong] Sun Yat Sen Univ, Ctr Parasit Organisms, State Key Lab Biocontrol, Sch Life Sci, Guangzhou 510275, Guangdong, Peoples R China.
   [Lun, Zhao-rong] Sun Yat Sen Univ, Key Lab Trop Dis & Control, Minist Educ, Zhongshan Med Sch, Guangzhou 510275, Guangdong, Peoples R China.
RP Shen, LL (reprint author), Anhui Med Univ, Dept Microbiol & Parasitol, Anhui Prov Labs Pathogen Biol & Zoonoses, Hefei, Peoples R China.
EM shenjilong53@126.com
FU Natural Basic Research Program of China [2010CB530001]; National Natural
   Science Foundation of China [81171605]; Education Department Research
   Program of Anhui, China [KJ2011Z200]
FX This work was funded by the Natural Basic Research Program of China
   (grant 2010CB530001), by the National Natural Science Foundation of
   China (grant 81171605), and by the Education Department Research Program
   of Anhui, China (grant KJ2011Z200).
CR Abbasi M, 2003, J INFECT DIS, V188, P608, DOI 10.1086/377132
   Amarante-Paffaro A, 2004, REPRODUCTION, V128, P207, DOI 10.1530/rep.1.00214
   Barber EM, 2005, INFECT IMMUN, V73, P6322, DOI 10.1128/IAI.73.10.6322-6331.2005
   Biagioli M, 2008, CELL CALCIUM, V43, P184, DOI 10.1016/j.ceca.2007.05.003
   Burton GJ, 2009, PLACENTA, V30, pS43, DOI 10.1016/j.placenta.2008.11.003
   Campos MA, 2001, J IMMUNOL, V167, P416, DOI 10.4049/jimmunol.167.1.416
   Carey LC, 2003, BIRTH DEFECTS RES A, V67, P240, DOI 10.1002/bdra.10035
   da Cunha AA, 2011, INT IMMUNOPHARMACOL, V11, P706, DOI 10.1016/j.intimp.2011.01.016
   Debierre-Grockiego F, 2003, J BIOL CHEM, V278, P32987, DOI 10.1074/jbc.M304791200
   Debierre-Grockiego F, 2007, J IMMUNOL, V179, P1129, DOI 10.4049/jimmunol.179.2.1129
   Ding SZ, 2007, INFECT IMMUN, V75, P4030, DOI 10.1128/IAI.00172-07
   Elsheikha Hany M., 2009, JOURNAL OF THE EGYPTIAN SOCIETY OF PARASITOLOGY, V39, P421
   Endo M, 2005, J BIOCHEM, V138, P501, DOI 10.1093/mvi143
   Fang YJ, 2010, J LEUKOCYTE BIOL, V87, P1019, DOI 10.1189/jlb.0509352
   Gavrilescu LC, 2001, J IMMUNOL, V167, P902, DOI 10.4049/jimmunol.167.2.902
   Geva E, 2002, J CLIN ENDOCR METAB, V87, P4213, DOI 10.1210/jc.2002-020195
   Heussler VT, 2001, INT J PARASITOL, V31, P1166, DOI 10.1016/S0020-7519(01)00271-5
   Hoshida MS, 2007, PLACENTA, V28, P1059, DOI 10.1016/j.placenta.2007.03.009
   Huppertz B, 2006, AM J OBSTET GYNECOL, V195, P29, DOI 10.1016/j.ajog.2005.07.039
   Jauniaux E, 2000, AM J PATHOL, V157, P2111, DOI 10.1016/S0002-9440(10)64849-3
   Kaneto H, 2005, J MOL MED-JMM, V83, P429, DOI 10.1007/s00109-005-0640-x
   Kim I, 2008, NAT REV DRUG DISCOV, V7, P1013, DOI 10.1038/nrd2755
   Kim WH, 2010, KOREAN J PARASITOL, V48, P325, DOI 10.3347/kjp.2010.48.4.325
   Kitamura M, 2010, BIOMETALS, V23, P941, DOI 10.1007/s10534-010-9296-2
   Krishnegowda G, 2005, J BIOL CHEM, V280, P8606, DOI 10.1074/jbc.M413541200
   Kubota K, 2005, J BIOL CHEM, V280, P23194, DOI 10.1074/jbc.M503288200
   Mordue DG, 2001, J IMMUNOL, V167, P4574, DOI 10.4049/jimmunol.167.8.4574
   Myatt L, 2004, HISTOCHEM CELL BIOL, V122, P369, DOI 10.1007/s00418-004-0677-x
   Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513
   Nakka VP, 2010, NEUROTOX RES, V17, P189, DOI 10.1007/s12640-009-9110-5
   Nishikawa Y, 2007, PARASITE IMMUNOL, V29, P375, DOI 10.1111/j.1365-3024.2007.00956.x
   Oyadomari S, 2002, APOPTOSIS, V7, P335, DOI 10.1023/A:1016175429877
   Park HS, 2004, J IMMUNOL, V173, P3589, DOI 10.4049/jimmunol.173.6.3589
   Payne TM, 2003, J CELL SCI, V116, P4345, DOI 10.1242/jcs.00756
   Pfaff AW, 2007, PARASITOLOGY, V134, P1895, DOI 10.1017/S0031182007000200
   Pollard AM, 2008, INFECT IMMUN, V76, P103, DOI 10.1128/IAI.01170-07
   Redman CW, 2005, SCIENCE, V308, P1592, DOI 10.1126/science.1111726
   Ronnberg E, 2010, INFECT IMMUN, V78, P854, DOI 10.1128/IAI.01004-09
   Senegas A, 2009, INT J PARASITOL, V39, P481, DOI 10.1016/j.ijpara.2008.08.009
   Sener G, 2006, J PINEAL RES, V41, P220, DOI 10.1111/j.1600-079X.2006.00357.x
   Siemieniuk E, 2008, TOXICOL MECH METHOD, V18, P519, DOI 10.1080/15376510701624001
   Tenter AM, 2000, INT J PARASITOL, V30, P1217, DOI 10.1016/S0020-7519(00)00124-7
   Valenca SS, 2008, ENVIRON RES, V108, P199, DOI 10.1016/j.envres.2008.07.001
   Wang H, 2003, BIOL REPROD, V69, P1957, DOI 10.1095/biolreprod.103.019620
   Watson D, 2009, BRIT J BIOMED SCI, V66, P208
   Wells PG, 2009, TOXICOL SCI, V108, P4, DOI 10.1093/toxsci/kfn263
   Whitaker SM, 2008, INFECT IMMUN, V76, P2149, DOI 10.1128/IAI.01528-07
   Yang PX, 2008, AM J OBSTET GYNECOL, V198, DOI 10.1016/j.ajog.2007.06.070
   Yavuz E, 2006, PLACENTA, V27, P780, DOI 10.1016/j.placenta.2005.07.002
   Zhao L, 2008, TOXICOL SCI, V103, P149, DOI 10.1093/toxsci/kfn027
   Zhu JH, 2011, BIOCHEM BIOPH RES CO, V404, P559, DOI 10.1016/j.bbrc.2010.12.025
   Zou W, 2010, TOXICOLOGY, V272, P32, DOI 10.1016/j.tox.2010.03.015
NR 52
TC 42
Z9 54
U1 2
U2 25
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0019-9567
EI 1098-5522
J9 INFECT IMMUN
JI Infect. Immun.
PD JUN
PY 2012
VL 80
IS 6
BP 2121
EP 2132
DI 10.1128/IAI.06295-11
PG 12
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 946WH
UT WOS:000304387700018
PM 22473610
OA Bronze, Green Published
DA 2018-12-27
ER

PT J
AU Liu, J
   Smeesters, D
   Trampe, D
AF Liu, Jia (Elke)
   Smeesters, Dirk
   Trampe, Debra
TI RETRACTED: Effects of Messiness on Preferences for Simplicity (Retracted
   article. See vol. 39, pg. NIL_257, 2012)
SO JOURNAL OF CONSUMER RESEARCH
LA English
DT Article; Retracted Publication
ID MORTALITY SALIENCE; LIMITED-RESOURCE; SELF-ESTEEM; MEDIATION;
   INFORMATION; CHOICE; CONSUMPTION; PERSUASION; LIBERALS; CONTEXTS
AB This research examines the effect of experiencing messiness, induced by a messy environment or by priming the concept of messiness, on consumers. We propose that messiness is an aversive state and that consumers are motivated to attenuate this state by seeking simplicity in their cognitions, preferences, and choices. Six experiments support our theorizing. Experiments 1A-1C (conducted in the laboratory) and experiment 2 (conducted in the field) demonstrate that when messiness is salient, consumers form simpler product categorizations, are willing to pay more for a T-shirt with a simple picture, and seek less variety in their choices. Experiment 3 brings additional evidence for the underlying role of the need for simplicity by showing that when the need for simplicity is satiated, the effects of messiness disappear. A final experiment shows a boundary condition of the messiness effect: political conservatives are more susceptible to messiness primes compared to liberals.
C1 [Liu, Jia (Elke); Trampe, Debra] Univ Groningen, NL-9700 AV Groningen, Netherlands.
   [Smeesters, Dirk] Erasmus Univ, Rotterdam Sch Management, NL-3000 DR Rotterdam, Netherlands.
RP Liu, J (reprint author), Univ Groningen, POB 800, NL-9700 AV Groningen, Netherlands.
EM Jia.Liu@rug.nl; DSmeesters@rsm.nl; D.Trampe@rug.nl
CR Argo JJ, 2008, J MARKETING RES, V45, P690, DOI 10.1509/jmkr.45.6.690
   Argo JJ, 2005, J CONSUM RES, V32, P207, DOI 10.1086/432230
   Baumeister RF, 1998, J PERS SOC PSYCHOL, V74, P1252, DOI 10.1037//0022-3514.74.5.1252
   Belk Russell W., 2007, CONSUMP MARK CULT, V10, P133, DOI DOI 10.1080/10253860701256208
   Carney DR, 2008, POLIT PSYCHOL, V29, P807, DOI 10.1111/j.1467-9221.2008.00668.x
   CHAIKEN S, 1980, J PERS SOC PSYCHOL, V39, P752, DOI 10.1037/0022-3514.39.5.752
   Chanceaux Myriam, 2009, J VISION, V9, P1
   Dijksterhuis A, 2001, ADV EXP SOC PSYCHOL, V33, P1, DOI 10.1016/S0065-2601(01)80003-4
   Elias N., 2000, CIVILIZING PROCESS S
   Evans GW, 1991, NEW DIRECTIONS HLTH, P127
   Fennis BM, 2009, J CONSUM RES, V35, P906, DOI 10.1086/593291
   Ferraro R, 2005, J CONSUM RES, V32, P65, DOI 10.1086/429601
   FISKE ST, 1990, ADV EXP SOC PSYCHOL, V23, P1, DOI 10.1016/S0065-2601(08)60317-2
   Fitzsimons GM, 2008, J CONSUM RES, V35, P21, DOI 10.1086/527269
   Freedman David H., 2008, PERFECT MESS HIDDEN
   Gino F, 2010, PSYCHOL SCI, V21, P712, DOI 10.1177/0956797610366545
   Gosling SD, 2002, J PERS SOC PSYCHOL, V82, P379, DOI 10.1037//0022-3514.82.3.379
   Goukens C, 2007, J CONSUM RES, V34, P386, DOI 10.1086/518542
   Jost JT, 2006, AM PSYCHOL, V61, P651, DOI 10.1037/0003-066X.61.7.651
   Jost JT, 2003, PSYCHOL BULL, V129, P339, DOI 10.1037/0033-2909.129.3.339
   Kahn BE., 1995, J RETAIL CONSUM SERV, V2, P139, DOI DOI 10.1016/0969-6989(95)00038-0
   Kay AC, 2008, J PERS SOC PSYCHOL, V95, P18, DOI 10.1037/0022-3514.95.1.18
   Keizer K, 2008, SCIENCE, V322, P1681, DOI 10.1126/science.1161405
   Knight K., 1999, MEASURES POLITICAL A, P59
   Levav J, 2009, J CONSUM RES, V36, P600, DOI 10.1086/599556
   Liljenquist K, 2010, PSYCHOL SCI, V21, P381, DOI 10.1177/0956797610361426
   LINVILLE PW, 1982, J PERS SOC PSYCHOL, V42, P193, DOI 10.1037/0022-3514.42.2.193
   Liu J, 2010, J MARKETING RES, V47, P251, DOI 10.1509/jmkr.47.2.251
   Loken B, 2006, ANNU REV PSYCHOL, V57, P453, DOI 10.1146/annurev.psych.57.102904.190136
   Mandel N, 2002, J CONSUM RES, V29, P235, DOI 10.1086/341573
   Mandel N, 2008, J CONSUM RES, V35, P309, DOI 10.1086/587626
   MATHENY AP, 1995, J APPL DEV PSYCHOL, V16, P429, DOI 10.1016/0193-3973(95)90028-4
   McConnell AR, 2010, J EXP SOC PSYCHOL, V46, P361, DOI 10.1016/j.jesp.2009.10.019
   Meyers-Levy J, 2007, J CONSUM RES, V34, P174, DOI 10.1086/519146
   Muller D, 2005, J PERS SOC PSYCHOL, V89, P852, DOI 10.1037/0022-3514.89.6.852
   Napier JL, 2008, PSYCHOL SCI, V19, P565, DOI 10.1111/j.1467-9280.2008.02124.x
   NEUBERG SL, 1993, J PERS SOC PSYCHOL, V65, P113, DOI 10.1037/0022-3514.65.1.113
   Noftle EE, 2007, J PERS SOC PSYCHOL, V93, P116, DOI 10.1037/0022-3514.93.1.116
   Petty R. E, 1981, ATTITUDES PERSUASION
   Preacher KJ, 2004, BEHAV RES METH INS C, V36, P717, DOI 10.3758/BF03206553
   Preacher KJ, 2007, MULTIVAR BEHAV RES, V42, P185, DOI 10.1080/00273170701341316
   Rucker DD, 2008, J CONSUM RES, V35, P257, DOI 10.1086/588569
   SCOTT WA, 1969, J PERS SOC PSYCHOL, V12, P261, DOI 10.1037/h0027734
   Simon H A, 1962, P AM PHILOS SOC, V106, P467, DOI DOI 10.2307/985254
   SRULL TK, 1979, J PERS SOC PSYCHOL, V37, P1660, DOI 10.1037//0022-3514.37.10.1660
   Stapel DA, 2011, SCIENCE, V332, P251, DOI 10.1126/science.1201068
   Stifter CA, 1999, CHILD DEV, V70, P21, DOI 10.1111/1467-8624.00003
   Tice DM, 2001, J PERS SOC PSYCHOL, V80, P53, DOI 10.1037//0022-3514.80.1.53
   TVERSKY A, 1974, SCIENCE, V185, P1124, DOI 10.1126/science.185.4157.1124
   TVERSKY A, 1972, PSYCHOL REV, V79, P281, DOI 10.1037/h0032955
   WATSON D, 1988, J PERS SOC PSYCHOL, V54, P1063, DOI 10.1037/0022-3514.54.6.1063
   West S. G, 1991, MULTIPLE REGRESSION
   Williams LE, 2008, PSYCHOL SCI, V19, P302, DOI 10.1111/j.1467-9280.2008.02084.x
   Zhao XS, 2010, J CONSUM RES, V37, P197, DOI 10.1086/651257
NR 54
TC 3
Z9 3
U1 2
U2 39
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0093-5301
EI 1537-5277
J9 J CONSUM RES
JI J. Consum. Res.
PD JUN
PY 2012
VL 39
IS 1
BP 199
EP 214
DI 10.1086/662139
PG 16
WC Business
SC Business & Economics
GA 946SW
UT WOS:000304376200014
DA 2018-12-27
ER

PT J
AU Vareille, M
   Kieninger, E
   Alves, MP
   Kopf, BS
   Moller, A
   Geiser, T
   Johnston, SL
   Edwards, MR
   Regamey, N
AF Vareille, Marjolaine
   Kieninger, Elisabeth
   Alves, Marco P.
   Kopf, Brigitte S.
   Moeller, Alexander
   Geiser, Thomas
   Johnston, Sebastian L.
   Edwards, Michael R.
   Regamey, Nicolas
TI RETRACTED: Impaired type I and type III interferon induction and
   rhinovirus control in human cystic fibrosis airway epithelial cells
   (Retracted article. See vol. 68, pg. 886, 2013)
SO THORAX
LA English
DT Article; Retracted Publication
ID RESPIRATORY VIRAL-INFECTIONS; INFLAMMATORY RESPONSE;
   PSEUDOMONAS-AERUGINOSA; VIRUS-INFECTIONS; SYNCYTIAL VIRUS;
   YOUNG-CHILDREN; ASTHMA; EXPRESSION; INNATE; EXACERBATIONS
AB Background Rhinoviruses are important triggers of pulmonary exacerbations and possible contributors to long-term respiratory morbidity in cystic fibrosis (CF), but mechanisms leading to rhinovirus-induced CF exacerbations are poorly understood. It is hypothesised that there is a deficient innate immune response of the airway epithelium towards rhinovirus infection in CF.
   Methods Early innate immune responses towards rhinoviruses (RV-16, major-type and RV-1B, minor-type) in CF and non-CF bronchial epithelial cell lines and primary nasal and bronchial epithelial cells from patients with CF (n=13) and healthy controls (n=24) were studied.
   Results Rhinovirus RNA expression and virus release into supernatants was increased more than tenfold in CF cells compared with controls. CF cells expressed up to 1000 times less interferon (IFN) type I (beta) and type III (lambda) mRNA and produced less than half of IFN-beta and IFN-lambda protein compared with controls. In contrast, interleukin 8 production was not impaired, indicating a selective deficiency in the innate antiviral defence system. Deficient IFN production was paralleled by lower expression of IFN-stimulated genes including myxovirus resistance A, 2',5'-oligoadenylate synthetase, viperin and nitric oxide synthase 2. Addition of exogenous type I and III IFNs, particularly IFN-beta, restored antiviral pathways and virus control in CF cells, underscoring the crucial role of these molecules.
   Conclusions This study describes a novel mechanism to explain the increased susceptibility of patients with CF to rhinovirus infections. A profound impairment of the antiviral early innate response in CF airway epithelial cells was identified, suggesting a potential use of IFNs in the treatment of rhinovirus-induced CF exacerbations.
C1 [Vareille, Marjolaine; Kieninger, Elisabeth; Alves, Marco P.; Kopf, Brigitte S.; Regamey, Nicolas] Inselspital Bern, Univ Childrens Hosp Bern, Div Resp Med, Dept Paediat, CH-3010 Bern, Switzerland.
   [Vareille, Marjolaine; Kieninger, Elisabeth; Alves, Marco P.; Kopf, Brigitte S.; Regamey, Nicolas] Univ Bern, Dept Clin Res, Bern, Switzerland.
   [Vareille, Marjolaine] Univ Bern, Inst Infect Dis, Bern, Switzerland.
   [Vareille, Marjolaine] Fac Med & Pharm, Immunol Lab, Clermont Ferrand, France.
   [Moeller, Alexander] Univ Childrens Hosp, Dept Resp Med, Zurich, Switzerland.
   [Geiser, Thomas] Univ Bern, Inselspital, Div Resp Med, Univ Hosp Bern, CH-3010 Bern, Switzerland.
   [Johnston, Sebastian L.; Edwards, Michael R.] Univ London Imperial Coll Sci Technol & Med, Natl Heart Lung Inst, Dept Resp Med, Wright Fleming Inst Infect & Immun, London, England.
   [Johnston, Sebastian L.; Edwards, Michael R.] Univ London Imperial Coll Sci Technol & Med, MRC & Asthma UK Ctr Allerg Mech Asthma, London, England.
RP Regamey, N (reprint author), Inselspital Bern, Univ Childrens Hosp Bern, Div Resp Med, Dept Paediat, CH-3010 Bern, Switzerland.
EM nicolas.regamey@insel.ch
RI Johnston, Sebastian/I-2423-2012; Kummer, Juerg/B-3322-2011
OI Edwards, Michael Robert/0000-0001-6837-0532
FU Division of Anaesthesiology, University of Bern; Swiss National Science
   Foundation [PP00P3_123453/1]; ERS; Fondazione Ettore e Valeria Rossi;
   Austrian, German and Swiss Paediatric Respiratory Society; Medical
   Research Council [G1000758, G1000758B]; National Institute for Health
   Research [NF-SI-0508-10212]
FX The authors thank all study participants and their families for
   participating in the study; Kathrin Muhlemann and Susanne Aebi from the
   Department of Infectious Diseases, University of Bern, Amiq Gazdhar,
   Patrizia Castiglioni and Fabian Blank from the Division of Respiratory
   Medicine, University of Bern, Philipp Latzin, Aline Schoegler and
   Nathalie Vielle from the Division of Respiratory Medicine, Department of
   Paediatrics, University Children's Hospital of Bern and Monika Stutz
   from the Department of Clinical Research, University of Bern for their
   technical and scientific support; and the staff of the Division of
   Anaesthesiology, University of Bern for their support.; This work was
   supported by the Swiss National Science Foundation (PP00P3_123453/1)
   (NR), the ERS/Marie Curie Joint Research Fellowship (short-time
   fellowship) (MV), the Fondazione Ettore e Valeria Rossi (long-time
   fellowship) (EK) and the Austrian, German and Swiss Paediatric
   Respiratory Society (short-time fellowship) (EK).
CR ABMAN SH, 1988, J PEDIATR-US, V113, P826, DOI 10.1016/S0022-3476(88)80008-8
   Aldallal N, 2002, AM J RESP CRIT CARE, V166, P1248, DOI 10.1164/rccm.200206-627OC
   Bruscia E, 2002, GENE THER, V9, P683, DOI 10.1038/sj.gt.3301741
   Chattoraj SS, 2011, INFECT IMMUN, V79, P4131, DOI 10.1128/IAI.05120-11
   Collinson J, 1996, THORAX, V51, P1115, DOI 10.1136/thx.51.11.1115
   Contoli M, 2006, NAT MED, V12, P1023, DOI 10.1038/nm1462
   COZENS AL, 1994, AM J RESP CELL MOL, V10, P38, DOI 10.1165/ajrcmb.10.1.7507342
   FLOTTE TR, 1992, AM J RESP CELL MOL, V7, P349, DOI 10.1165/ajrcmb/7.3.349
   Fulcher ML, 2009, AM J PHYSIOL-LUNG C, V296, pL82, DOI 10.1152/ajplung.90314.2008
   Giebels K, 2008, PEDIATR PULM, V43, P169, DOI 10.1002/ppul.20751
   Gielen V, 2010, EUR RESPIR J, V36, P646, DOI 10.1183/09031936.00095809
   He JQ, 2008, EUR RESPIR J, V32, P755, DOI 10.1183/09031936.00129107
   JOHANSEN HK, 1992, THORAX, V47, P109, DOI 10.1136/thx.47.2.109
   JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225
   Khaitov MR, 2009, ALLERGY, V64, P375, DOI 10.1111/j.1398-9995.2008.01826.x
   Kieninger E, 2012, EUR RESPIR J, V39, P297, DOI 10.1183/09031936.00054511
   Kluijver JC, 2003, AM J RESP CRIT CARE, V168, P1174, DOI 10.1164/rccm/200212-1520OC
   Kotenko SV, 2003, NAT IMMUNOL, V4, P69, DOI 10.1038/ni875
   Kuiken T, 2008, VACCINE, V26, pD59, DOI 10.1016/j.vaccine.2008.07.025
   Li K, 2010, AM J RESP CRIT CARE, V181
   Luciani A, 2010, NAT CELL BIOL, V12, P863, DOI 10.1038/ncb2090
   Malfroot Anne, 2005, J Cyst Fibros, V4, P77, DOI 10.1016/j.jcf.2004.10.003
   Mallia P, 2011, AM J RESP CRIT CARE, V183, P734, DOI 10.1164/rccm.201006-0833OC
   Message SD, 2008, P NATL ACAD SCI USA, V105, P13562, DOI 10.1073/pnas.0804181105
   Moss RB, 2005, PEDIATR PULM, V39, P209, DOI 10.1002/ppul.20152
   Papi A, 1999, J BIOL CHEM, V274, P9707, DOI 10.1074/jbc.274.14.9707
   Schoenborn JR, 2007, ADV IMMUNOL, V96, P41, DOI 10.1016/S0065-2776(07)96002-2
   Simon HU, 2003, ALLERGY, V58, P1250, DOI 10.1046/j.1398-9995.2003.00424.x
   Slater L, 2011, PLOS PATHOG, V6
   SMYTH AR, 1995, ARCH DIS CHILD, V73, P117, DOI 10.1136/adc.73.2.117
   Sutanto E, 2011, EUR RESPIR J, V38, p[S259, A1449]
   Sutanto EN, 2011, AM J RESP CELL MOL, V44, P761, DOI 10.1165/rcmb.2010-0368OC
   Takaoka A, 2003, NATURE, V424, P516, DOI 10.1038/nature01850
   van Ewijk Bart E, 2005, J Cyst Fibros, V4 Suppl 2, P31, DOI 10.1016/j.jcf.2005.05.011
   van Ewijk BE, 2008, PEDIATRICS, V122, P1171, DOI 10.1542/peds.2007-3139
   Vareille M, 2011, CLIN MICROBIOL REV, V24, P210, DOI 10.1128/CMR.00014-10
   WANG EEL, 1984, NEW ENGL J MED, V311, P1653, DOI 10.1056/NEJM198412273112602
   Wang Q, 2009, J IMMUNOL, V183, P6989, DOI 10.4049/jimmunol.0901386
   Wark PAB, 2005, J EXP MED, V201, P937, DOI 10.1084/jem.20041901
   Wark PAB, 2009, RESPIROLOGY, V14, P180, DOI 10.1111/j.1440-1843.2009.01480.x
   Wat D, 2008, J CYST FIBROS, V7, P320, DOI 10.1016/j.jcf.2007.12.002
   Wedzicha Jadwiga A, 2004, Proc Am Thorac Soc, V1, P115, DOI 10.1513/pats.2306030
   Xatzipsalti M, 2008, CLIN EXP ALLERGY, V38, P466, DOI 10.1111/j.1365-2222.2007.02906.x
   Xu WL, 2006, J INTERF CYTOK RES, V26, P609, DOI 10.1089/jir.2006.26.609
   Zheng S, 2004, AM J PHYSIOL-LUNG C, V287, pL374, DOI 10.1152/ajplung.00039.2004
   Zheng S, 2003, IMMUNITY, V18, P619, DOI 10.1016/S1074-7613(03)00114-6
NR 46
TC 27
Z9 27
U1 2
U2 15
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0040-6376
EI 1468-3296
J9 THORAX
JI Thorax
PD JUN
PY 2012
VL 67
IS 6
BP 517
EP 525
DI 10.1136/thoraxjnl-2011-200405
PG 9
WC Respiratory System
SC Respiratory System
GA 946KU
UT WOS:000304351300010
PM 22213737
OA Bronze
DA 2018-12-27
ER

PT J
AU Watkins, SK
   Zhu, ZQ
   Watkins, KE
   Hurwitz, AA
AF Watkins, Stephanie K.
   Zhu, Ziqiang
   Watkins, Keith E.
   Hurwitz, Arthur A.
TI RETRACTED: Isolation of Immune Cells from Primary Tumors (Retracted
   article. See 2016)
SO JOVE-JOURNAL OF VISUALIZED EXPERIMENTS
LA English
DT Article; Retracted Publication
DE Cancer Biology; Issue 64; Immunology; Prostate; tumor; immune cell
   isolation; mouse; TRAMP; B16 melanoma; leukocyte; dendritic cell; T cell
AB Tumors create a unique immunosuppressive microenvironment (tumor microenvironment, TME) whereby leukocytes are recruited into the tumor by various chemokines and growth factors (1,2). However, once in the TME, these cells lose the ability to promote anti-tumor immunity and begin to support tumor growth and down-regulate anti-tumor immune responses (3-4). Studies on tumor-associated leukocytes have mainly focused on cells isolated from tumor-draining lymph nodes or spleen due to the inherent difficulties in obtaining sufficient cell numbers and purity from the primary tumor. While identifying the mechanisms of cell activation and trafficking through the lymphatic system of tumor bearing mice is important and may give insight to the kinetics of immune responses to cancer, in our experience, many leukocytes, including dendritic cells (DCs), in tumor-draining lymph nodes have a different phenotype than those that infiltrate tumors (5,6). Furthermore, we have previously demonstrated that adoptively-transferred T cells isolated from the tumor-draining lymph nodes are not tolerized and are capable of responding to secondary stimulation in vitro unlike T cells isolated from the TME, which are tolerized and incapable of proliferation or cytokine production (7,8). Interestingly, we have shown that changing the tumor microenvironment, such as providing CD4(+) T helper cells via adoptive transfer, promotes CD8(+) T cells to maintain pro-inflammatory effector functions (5). The results from each of the previously mentioned studies demonstrate the importance of measuring cellular responses from TME-infiltrating immune cells as opposed to cells that remain in the periphery. To study the function of immune cells which infiltrate tumors using the Miltenyi Biotech isolation system(9), we have modified and optimized this antibody-based isolation procedure to obtain highly enriched populations of antigen presenting cells and tumor antigen-specific cytotoxic T lymphocytes. The protocol includes a detailed dissection of murine prostate tissue from a spontaneous prostate tumor model (TRansgenic Adenocarcinoma of the Mouse Prostate -TRAMP) (10) and a subcutaneous melanoma (B16) tumor model followed by subsequent purification of various leukocyte populations.
C1 [Watkins, Stephanie K.; Zhu, Ziqiang; Hurwitz, Arthur A.] Natl Canc Inst Frederick, Tumor Immun & Tolerance Sect, Mol Immunoregulat Lab, Canc & Inflammat Program, Frederick, MD 21702 USA.
   [Watkins, Keith E.] KEWB Prod, Frederick, MD USA.
RP Hurwitz, AA (reprint author), Natl Canc Inst Frederick, Tumor Immun & Tolerance Sect, Mol Immunoregulat Lab, Canc & Inflammat Program, Frederick, MD 21702 USA.
EM hurwitza@mail.nih.gov
FU NIH, NCI
FX The authors would like to thank Dr. Scott Durham for review of the
   manuscript and video. This work is supported in-part by the intramural
   research program of the NIH, NCI.
CR Anderson MJ, 2007, J IMMUNOL, V178, P1268, DOI 10.4049/jimmunol.178.3.1268
   Ganss R, 1998, CANCER RES, V58, P4673
   HURWITZ AA, 2001, CURR PROTOC IMMUNOL, pCH20, DOI DOI 10.1002/0471142735.IM2005S45
   Lewis CE, 2006, CANCER RES, V66, P605, DOI 10.1158/0008-5472.CAN-05-4005
   Matheu M.P., 2007, JOVE-J VIS EXP, pe409, DOI [10.3791/409, DOI 10.3791/409]
   Shafer-Weaver K.A., 2009, TUMOR SPECIFIC CD8 T
   Shafer-Weaver KA, 2009, CANCER RES, V69, P6256, DOI 10.1158/0008-5472.CAN-08-4516
   Shurin MR, 2006, CANCER METAST REV, V25, P333, DOI 10.1007/s10555-006-9010-6
   Singh V, 2009, J IMMUNOTHER, V32, P129, DOI 10.1097/CJI.0b013e31819144d7
   Watkins S.K., 2011, J CLIN INVEST, V121
NR 10
TC 8
Z9 8
U1 0
U2 0
PU JOURNAL OF VISUALIZED EXPERIMENTS
PI CAMBRIDGE
PA 1 ALEWIFE CENTER, STE 200, CAMBRIDGE, MA 02140 USA
SN 1940-087X
J9 JOVE-J VIS EXP
JI J. Vis. Exp.
PD JUN
PY 2012
IS 64
AR e3952
DI 10.3791/3952
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA V36PI
UT WOS:000209223100031
PM 22733225
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Yin, ZQ
   Zhang, WM
   Song, GX
   Luo, D
AF Yin, Zhi Qiang
   Zhang, Wei Ming
   Song, Guo Xin
   Luo, Dan
TI RETRACTED: Meta-analysis on the comparison between two topical
   calcineurin inhibitors in atopic dermatitis (Retracted article. See vol.
   40, pg. 418, 2013)
SO JOURNAL OF DERMATOLOGY
LA English
DT Article; Retracted Publication
DE atopic dermatitis; calcineurin inhibitor; meta-analysis; pimecrolimus;
   tacrolimus
ID TACROLIMUS OINTMENT; PIMECROLIMUS CREAM; PEDIATRIC-PATIENTS; MODERATE;
   SAFETY
AB Topical calcineurin inhibitors have proved to be suitable for the treatment of AD. We conducted a meta-analysis comparing efficacy and tolerance of tacrolimus with pimecrolimus in treatment of AD. According to our meta-analysis, tacrolimus 0.1% was more effective than pimecrolimus 1% in adult patients (week 3: risk ratio [RR] 0.55, 95% confidence interval [CI] 0.420.73), and tacrolimus (a combination of 0.03% and 0.1%) was also more effective than pimecrolimus 1% in pediatric patients (week 6/end of study: RR 0.76, 95% CI 0.630.92). Regardless of age or illness severity, tacrolimus 0.1% had higher efficacy than pimecrolimus 1% in the treatment of AD (week 3: RR 0.55, 95% CI 0.420.72). In adult patients, tacrolimus 0.1% had more adverse events than pimecrolimus 1% (RR 1.30, 95% CI 1.021.66), but the incidence of adverse events between tacrolimus 0.1% (or 0.03%) and pimecrolimus 1% was not significantly different in pediatric patients. No matter whether the patients were adult or pediatric, more pimecrolimus-treated patients withdrew from the trials because of a lack of efficacy. Regardless of age and illness severity, more pimecrolimus 1%-treated patients withdrew from the trials because of a lack of efficacy, compared with tacrolimus 0.1% (or 0.03%)-treated patients. More pimecrolimus-treated pediatric patients withdrew from the trials because of adverse events (RR 0.26, 95% CI 0.10.68). More pimecrolimus 1%-treated patients withdrew from the trials because of adverse events, compared with tacrolimus 0.03%-treated patients, regardless of age (RR 0.1, 95% CI 0.020.53). In conclusion, tacrolimus ointment has higher efficacy and better tolerance than pimecrolimus cream in treatment of AD.
C1 [Yin, Zhi Qiang; Luo, Dan] Nanjing Med Univ, Affiliated Hosp 1, Dept Dermatol, Nanjing 210029, Jiangsu, Peoples R China.
   [Zhang, Wei Ming; Song, Guo Xin] Nanjing Med Univ, Affiliated Hosp 1, Dept Pathol, Nanjing, Jiangsu, Peoples R China.
RP Luo, D (reprint author), Nanjing Med Univ, Affiliated Hosp 1, Dept Dermatol, 300 Guangzhou Rd, Nanjing 210029, Jiangsu, Peoples R China.
EM daniluo2005@sina.com
CR Abramovits William, 2008, J Drugs Dermatol, V7, P1153
   Charman CR, 2000, BRIT J DERMATOL, V142, P931, DOI 10.1046/j.1365-2133.2000.03473.x
   Chen SL, 2010, J DERMATOL TREAT, V21, P144, DOI 10.3109/09546630903401470
   Fleischer AB, 2007, J DERMATOL TREAT, V18, P151, DOI 10.1080/09546630701287332
   Kempers S, 2004, J AM ACAD DERMATOL, V51, P515, DOI 10.1016/j.jaad.2004.01.051
   Kirsner RS, 2010, ACTA DERM-VENEREOL, V90, P58, DOI 10.2340/00015555-0748
   LIGHT RJ, 1984, SUMMING UP SCI REVIE
   Maged M, 2009, J DERMATOL SCI, V54, P76, DOI 10.1016/j.jdermsci.2009.02.002
   Paller AS, 2005, J AM ACAD DERMATOL, V52, P810, DOI 10.1016/j.jaad.2004.12.038
   Taneja C, 2010, J DRUGS DERMATOL, V9, P372
NR 10
TC 8
Z9 9
U1 3
U2 13
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0385-2407
J9 J DERMATOL
JI J. Dermatol.
PD JUN
PY 2012
VL 39
IS 6
BP 520
EP 526
DI 10.1111/j.1346-8138.2012.01529.x
PG 7
WC Dermatology
SC Dermatology
GA 939JM
UT WOS:000303805900003
PM 22409418
DA 2018-12-27
ER

PT J
AU Calvo-Guirado, JL
   Delgado-Ruiz, RA
   Ramirez-Fernandez, MP
   Mate-Sanchez, JE
   Ortiz-Ruiz, A
   Marcus, A
AF Calvo-Guirado, J. L.
   Delgado-Ruiz, R. A.
   Ramirez-Fernandez, M. P.
   Mate-Sanchez, J. E.
   Ortiz-Ruiz, A.
   Marcus, Abboud
TI RETRACTED: Histomorphometric and mineral degradation study of Ossceram
   (R): a novel biphasic B-tricalcium phosphate, in critical size defects
   in rabbits (Retracted article. See vol. 29, pg. 669, 2018)
SO CLINICAL ORAL IMPLANTS RESEARCH
LA English
DT Article; Retracted Publication
DE bone regeneration; bone substitute; critical size defects; EDX; element
   mapping; hydroxyapatite; tricalcium phosphate
ID ANORGANIC BOVINE BONE; CALCIUM-PHOSPHATE; IN-VITRO; SUBSTITUTES;
   CERAMICS; HYDROXYAPATITE; REGENERATION; RESORPTION; CELLS;
   DIFFERENTIATION
AB Objective: To carry out a histomorphometric analysis of a new highly porous (95%) biphasic calcium phosphate (hydroxyapatite 60%/B-tricalcium phosphate 40%), used to fill critical size defects in rabbit tibiae, supplementing histomorphometric findings with radiographic thermal imaging, EDX analysis and Ca/P ratio mapping at different time stages. Materials and methods: Two critical size defects of 6 mm diameter were created in both tibiae of 21 New Zealand rabbits, test group (Ossceram (R)) and control group. Histomorphometric, radiographic thermal imaging, EDX and element mapping analysis were performed at 15, 30 and 60 days after graft insertion. Results: Histomorphometric analysis at 30 days showed more new bone formation in defects filled with Ossceram (R) 4.41 +/- 0.23 mm than the test group 1.94 +/- 0. 28 mm (P<0.05). Element analysis revealed higher percentages of Ca (42.33 +/- 2.8%) and P (1.3 +/- 0.8%) in the test group than in the control group (P<0.05). Element mapping showed that Ca and P were concentrated in medullar and cortical zones in the test group but were concentrated only in cortical zones in the control group. Test group histomorphometry at 60 days showed complete closure of the cortical defect 5.37 +/- 0.32 mm more than the control group 2.3 +/- 0.54 mm. There was no cortical defect closure or medullar bone formation in the control group (P<0.05). Element analysis revealed higher percentages of Ca (32.26 +/- 21.7%) and P (1.5 +/- 0.3%) in the test group than in the control group (P<0.05). Conclusion: Defects of a critical size in a rabbit tibia model can be sealed using a highly porous biphasic calcium phosphate; this supports new bone formation, creates a bridge between borders and facilitates bone ingrowth. Furthermore, this study observed partial dissolution of the mineral phase of the graft material and its incorporation into the surrounding bone. Radiographic thermal imaging may be used to supplement histological and chemical analyses.
C1 [Calvo-Guirado, J. L.; Delgado-Ruiz, R. A.; Ramirez-Fernandez, M. P.; Mate-Sanchez, J. E.; Ortiz-Ruiz, A.] Univ Murcia, Fac Med & Dent, Murcia, Spain.
   [Marcus, Abboud] SUNY Stony Brook, Fac Med, Dept Prosthodont, Stony Brook, NY 11794 USA.
RP Calvo-Guirado, JL (reprint author), Univ Murcia, Fac Med & Dent, Murcia, Spain.
EM joseluis.calvo@um.es
RI Ortiz Ruiz, Antonio/M-2458-2018; Mate Sanchez de Va, Jose
   Eduardo/R-9750-2018
OI Ortiz Ruiz, Antonio/0000-0001-9113-8416; Mate Sanchez de Va, Jose
   Eduardo/0000-0002-4216-421X; RAMIREZ FERNANDEZ, MARIA
   PIEDAD/0000-0003-1913-9902
FU Department of General Dentistry (COIA); Faculty of Medicine and
   Dentistry, University of Murcia, Spain
FX Calvo-Guirado J. L., Delgado-Ruiz R. A., Ramirez-Fernandez M. P.,
   Mate-Sanchez J. E., Ortiz-Ruiz A. and, Marcus Abboud declare that they
   have no conflict of interests. The study was initiated and self-funded
   by the Department of General Dentistry (COIA) and Master of Implant
   Dentistry (Prof. Dr J. L. Calvo-Guirado), Faculty of Medicine and
   Dentistry, University of Murcia, Spain. The study materials and biopsies
   were kindly provided by Bredent Medical GmbH & Co. KG. The authors
   gratefully acknowledge the assistance of Nuria Garcia Carrillo
   (Veterinary, University of Murcia, Spain).
CR Boix D, 2004, J PERIODONTOL, V75, P663, DOI 10.1902/jop.2004.75.5.663
   Bouler JM, 1996, J BIOMED MATER RES, V32, P603, DOI 10.1002/(SICI)1097-4636(199612)32:4<603::AID-JBM13>3.0.CO;2-E
   Bucholz RW, 2002, CLIN ORTHOP RELAT R, P44
   Cavagna R, 1999, J LONG-TERM EFF MED, V9, P403
   Chang BS, 2000, BIOMATERIALS, V21, P1291, DOI 10.1016/S0142-9612(00)00030-2
   Chazono M, 2004, J BIOMED MATER RES A, V70A, P542, DOI 10.1002/jbm.a.30094
   CONNOLLY JF, 1991, CLIN ORTHOP RELAT R, P259
   COSTANTINO PD, 1994, OTOLARYNG CLIN N AM, V27, P1037
   De Oliveira JF, 2003, ARTIF ORGANS, V27, P406
   EGGLI PS, 1988, CLIN ORTHOP RELAT R, P127
   Fan HS, 2007, J NANOSCI NANOTECHNO, V7, P808, DOI 10.1166/jnn.2007.501
   Gauthier O, 1998, BIOMATERIALS, V19, P133, DOI 10.1016/S0142-9612(97)00180-4
   GAZDAG AR, 1995, J AM ACAD ORTHOP SUR, V3, P1, DOI DOI 10.5435/00124635-199501000-00001
   Geiger F, 2005, J BONE MINER RES, V20, P2028, DOI 10.1359/JBMR.050701
   Geiger M, 2003, ADV DRUG DELIVER REV, V55, P1613, DOI 10.1016/j.addr.2003.08.010
   Giannoudis PV, 2005, INJURY, V36, P20, DOI 10.1016/j.injury.2005.07.029
   Haga M, 2009, ANAT REC, V292, P38, DOI 10.1002/ar.20748
   Jensen S S, 1996, Int J Oral Maxillofac Implants, V11, P55
   Jensen SS, 2006, CLIN ORAL IMPLAN RES, V17, P237, DOI 10.1111/j.1600-0501.2005.01257.x
   Karageorgiou V, 2005, BIOMATERIALS, V26, P5474, DOI 10.1016/j.biomaterials.2005.02.002
   Keller JC, 1997, DENT MATER, V13, P62, DOI 10.1016/S0109-5641(97)80010-3
   Kim BS, 2000, WORLD J UROL, V18, P2, DOI 10.1007/s003450050002
   Kojima T, 2007, J BONE MINER METAB, V25, P361, DOI 10.1007/s00774-007-0763-y
   Kondo N, 2005, BIOMATERIALS, V26, P5600, DOI 10.1016/j.biomaterials.2005.02.026
   LANE JM, 1999, CLIN ORTHOP RELAT R, V361, P216
   Lazary A, 2007, BIOMATERIALS, V28, P393, DOI 10.1016/j.biomaterials.2006.09.002
   Le Guehennec L, 2005, J BIOMED MATER RES B, V72B, P69, DOI 10.1002/jbm.b.30118
   Legeros RZ, 2003, J MATER SCI-MATER M, V14, P201, DOI 10.1023/A:1022872421333
   LeGeros RZ, 2002, CLIN ORTHOP RELAT R, P81
   Lindgren C, 2010, CLIN ORAL IMPLAN RES, V21, P924, DOI 10.1111/j.1600-0501.2010.01933.x
   Lu JX, 1999, J MATER SCI-MATER M, V10, P111, DOI 10.1023/A:1008973120918
   Mankani MH, 2001, BIOTECHNOL BIOENG, V72, P96, DOI 10.1002/1097-0290(20010105)72:1<96::AID-BIT13>3.0.CO;2-A
   Navarro M, 2004, BIOMATERIALS, V25, P4233, DOI 10.1016/j.biomaterials.2003.11.012
   Ogose A, 2006, BIOMATERIALS, V27, P1542, DOI 10.1016/j.biomaterials.2005.08.034
   OZAWA M, 1995, J JPN SOC BIOMATER, V13, P17
   RAWLINGS CE, 1993, NEUROSURGERY, V33, P935
   Rohanizadeh R, 1998, J BIOMED MATER RES, V42, P530, DOI 10.1002/(SICI)1097-4636(19981215)42:4<530::AID-JBM8>3.0.CO;2-6
   Schmitz JP, 1999, J ORAL MAXIL SURG, V57, P1122, DOI 10.1016/S0278-2391(99)90338-5
   Slater N, 2008, CLIN ORAL IMPLAN RES, V19, P814, DOI 10.1111/j.1600-0501.2008.01550.x
   SPECTOR M, 1994, CLIN PLAST SURG, V21, P437
   Wahl DA, 2006, EUR CELLS MATER, V11, P43, DOI 10.22203/eCM.v011a06
   Walsh WR, 2008, BIOMATERIALS, V29, P266, DOI 10.1016/j.biomaterials.2007.09.035
   Wiltfang F, 2003, CLIN ORAL IMPLAN RES, V14, P213, DOI 10.1034/j.1600-0501.2003.140212.x
   Yamada S, 1997, J BIOMED MATER RES, V37, P346, DOI 10.1002/(SICI)1097-4636(19971205)37:3<346::AID-JBM5>3.0.CO;2-L
   Yuasa T, 2005, DENT MATER J, V24, P207, DOI 10.4012/dmj.24.207
   Zou C, 2005, BIOMATERIALS, V26, P5276, DOI 10.1016/j.biomaterials.2005.01.064
NR 46
TC 30
Z9 31
U1 1
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0905-7161
EI 1600-0501
J9 CLIN ORAL IMPLAN RES
JI Clin. Oral Implant. Res.
PD JUN
PY 2012
VL 23
IS 6
BP 667
EP 675
DI 10.1111/j.1600-0501.2011.02193.x
PG 9
WC Dentistry, Oral Surgery & Medicine; Engineering, Biomedical
SC Dentistry, Oral Surgery & Medicine; Engineering
GA 930EC
UT WOS:000303119000003
PM 21492238
DA 2018-12-27
ER

PT J
AU Ying, JJ
   Wang, XF
   Yan, YJ
   Xiang, ZJ
   Luo, XG
   Sun, Z
   Chen, XH
AF Ying, Jianjun
   Wang, Xiangfeng
   Yan, Yajun
   Xiang, Ziji
   Luo, Xigang
   Sun, Zhe
   Chen, Xianhui
TI RETRACTED: s-wave superconductivity in barium-doped phenanthrene as
   revealed by specific-heat measurements (Retracted article. See vol. 87,
   179901, 2013)
SO PHYSICAL REVIEW B
LA English
DT Article; Retracted Publication
ID SPIN; TEMPERATURE; COEXISTENCE; HYDROCARBON; CONDUCTORS; VORTEX; STATES
AB We report specific-heat studies on high-quality Ba-doped phenanthrene, one of the organic superconductors with fused benzene rings, with 100% shielding fraction. The specific-heat data indicate that Ba-doped phenanthrene is a single-gap s-wave superconductor with moderate coupling, and this sets constraints on theoretical models for the understanding of superconductivity in these hydrocarbon superconductors.
C1 [Ying, Jianjun; Wang, Xiangfeng; Yan, Yajun; Xiang, Ziji; Luo, Xigang; Chen, Xianhui] Univ Sci & Technol China, Hefei Natl Lab Phys Sci Microscale, Hefei 230026, Anhui, Peoples R China.
   [Ying, Jianjun; Wang, Xiangfeng; Yan, Yajun; Xiang, Ziji; Luo, Xigang; Chen, Xianhui] Univ Sci & Technol China, Dept Phys, Hefei 230026, Anhui, Peoples R China.
   [Sun, Zhe] Univ Sci & Technol China, Natl Synchrotron Radiat Lab, Hefei 230029, Anhui, Peoples R China.
RP Chen, XH (reprint author), Univ Sci & Technol China, Hefei Natl Lab Phys Sci Microscale, Hefei 230026, Anhui, Peoples R China.
EM chenxh@ustc.edu.cn
OI Wamg, Xiangfeng/0000-0001-9845-1659
FU National Natural Science Foundation of China [11190021, 51021091];
   National Basic Research Program of China (973 Program) [2012CB922002,
   2011CB00101]; Chinese Academy of Sciences
FX This work is supported by National Natural Science Foundation of China
   (Grants No. 11190021 and No. 51021091), the National Basic Research
   Program of China (973 Program, Grants No. 2012CB922002 and No.
   2011CB00101), and the Chinese Academy of Sciences.
CR Bouquet F, 2001, EUROPHYS LETT, V56, P856, DOI 10.1209/epl/i2001-00598-7
   Brossard L, 1998, EUR PHYS J B, V1, P439, DOI 10.1007/s100510050207
   CAROLI C, 1964, PHYS LETT, V9, P307, DOI 10.1016/0031-9163(64)90375-0
   Chen H, 2009, EPL-EUROPHYS LETT, V85, DOI 10.1209/0295-5075/85/17006
   Drew AJ, 2009, NAT MATER, V8, P310, DOI [10.1038/NMAT2396, 10.1038/nmat2396]
   Elsinger H, 2000, PHYS REV LETT, V84, P6098, DOI 10.1103/PhysRevLett.84.6098
   Ishiguro T., 1997, ORGANIC SUPERCONDUCT
   Kato T, 2011, PHYS REV LETT, V107, DOI 10.1103/PhysRevLett.107.077001
   Kim JS, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.217002
   Kobayashi H, 1996, J AM CHEM SOC, V118, P368, DOI 10.1021/ja9523350
   Lee PA, 2006, REV MOD PHYS, V78, P17, DOI 10.1103/RevModPhys.78.17
   Mathur ND, 1998, NATURE, V394, P39
   Mitsuhashi R, 2010, NATURE, V464, P76, DOI 10.1038/nature08859
   PADAMSEE H, 1973, J LOW TEMP PHYS, V12, P387, DOI 10.1007/BF00654872
   Rosseinsky MJ, 2010, NATURE, V464, P39, DOI 10.1038/464039a
   Singleton J, 2000, REP PROG PHYS, V63, P1111, DOI 10.1088/0034-4885/63/8/201
   Sun CP, 2004, PHYS REV B, V70, DOI 10.1103/PhysRevB.70.054519
   Taguchi Y, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.217002
   Taylor OJ, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.057001
   VOLOVIK GE, 1993, JETP LETT+, V58, P469
   Wang XF, 2011, PHYS REV B, V84, DOI 10.1103/PhysRevB.84.214523
   Wang XF, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1513
   WERTHAME.NR, 1966, PHYS REV, V147, P295, DOI 10.1103/PhysRev.147.295
   Xue MQ, 2012, SCI REP-UK, V2, DOI 10.1038/srep00389
NR 24
TC 6
Z9 6
U1 3
U2 35
PU AMER PHYSICAL SOC
PI COLLEGE PK
PA ONE PHYSICS ELLIPSE, COLLEGE PK, MD 20740-3844 USA
SN 2469-9950
EI 2469-9969
J9 PHYS REV B
JI Phys. Rev. B
PD MAY 31
PY 2012
VL 85
IS 18
AR 180511
DI 10.1103/PhysRevB.85.180511
PG 5
WC Materials Science, Multidisciplinary; Physics, Applied; Physics,
   Condensed Matter
SC Materials Science; Physics
GA 950KR
UT WOS:000304648600001
DA 2018-12-27
ER

PT J
AU Vadla, GP
   Vellaichamy, E
AF Vadla, Gangadhara Prasadachari
   Vellaichamy, Elangovan
TI RETRACTED: Anti-fibrotic cardio protective efficacy of aminoguanidine
   against streptozotocin induced cardiac fibrosis and high glucose induced
   collagen up regulation in cardiac fibroblasts (Retracted article. See
   vol. 223, pg. 150, 2014)
SO CHEMICO-BIOLOGICAL INTERACTIONS
LA English
DT Article; Retracted Publication
DE Aminoguanidine; Streptozotocin; Cardiac fibrosis; Cardiac fibroblasts;
   Matrix metalloproteinases; Collagen
ID MATRIX METALLOPROTEINASES; ADVANCED GLYCATION; CEREBRAL-ISCHEMIA;
   ANGIOTENSIN-II; EXPRESSION; RATS; INHIBITION; HEART; DYSFUNCTION; CELLS
AB This study mainly focuses on cardio protective anti-fibrotic activity of aminoguanidine against streptozotocin induced cardiac fibrosis and high glucose induced collagen accumulation in cardiac fibroblasts. Dysregulation of matrix metalloproteinase especially 2 and 9 were considered to be responsible for the abnormal collagen deposition, which resulting improper cardiac contractile function in diabetic mice. Mice received a single dose of streptozotocin (100 mg/kg) through tail vein to induce diabetes. Normal and diabetic mice received aminoguanidine orally (100 mg/kg/day) throughout the study period of 8 weeks. Cardiac fibroblasts cultured and exposed to high glucose, aminoguanidine and both for 48 h. Collagen quantitatively estimated in both in vivo and in vitro models. Altered structural changes were studied using the Masson tri-chrome staining. TEM images of cardiac sections. Increased collagen and metalloproteinase activities were confirmed using gelatin zymography, western blotting and gene expression studies. The exact mechanism responsible for high glucose induced collagen up regulation in diabetic heart was incompletely understood. From this above in vivo and in vitro results, we conclude that, the cardio protective anti fibrotic activity of amino guanidine was mainly attributed by exhibiting the inhibitory efficacy against streptozotocin and high glucose induced collagen accumulation probably by inhibiting high glucose altered metalloproteinase-2 and -9 activities. (C) 2012 Elsevier Ireland Ltd. All rights reserved.
C1 [Vadla, Gangadhara Prasadachari; Vellaichamy, Elangovan] Univ Madras, Dept Biochem, Madras 600025, Tamil Nadu, India.
RP Vellaichamy, E (reprint author), Univ Madras, Dept Biochem, Guindy Campus, Madras 600025, Tamil Nadu, India.
EM ganm.u.research@gmail.com
CR Arai T, 1996, VET RES COMMUN, V20, P215, DOI 10.1007/BF00366919
   Asbun J, 2005, AM J PHYSIOL-HEART C, V288, pH227, DOI 10.1152/ajpheart.00340.2004
   AVIOLI LV, 1967, J CLIN INVEST, V46, P217, DOI 10.1172/JCI105524
   Bayraktutan U, 2002, DIABETES OBES METAB, V4, P224, DOI 10.1046/j.1463-1326.2002.00184.x
   Biernacka A, 2011, AGING DIS, V2, P158
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Cash D, 2001, BRAIN RES, V905, P91, DOI 10.1016/S0006-8993(01)02508-2
   Chakraborti S, 2003, MOL CELL BIOCHEM, V253, P269, DOI 10.1023/A:1026028303196
   Chang KC, 2006, BRIT J PHARMACOL, V147, P944, DOI 10.1038/sj.bjp.0706684
   Cockroft KM, 1996, STROKE, V27, P1393, DOI 10.1161/01.STR.27.8.1393
   de Souza RR, 2002, BIOGERONTOLOGY, V3, P325, DOI 10.1023/A:1021312027486
   Gao CQ, 2003, CARDIOVASC RES, V57, P426
   Gonzalez A, 2004, MED CLIN N AM, V88, P83, DOI 10.1016/S0025-7125(03)00125-1
   Heymans S, 2005, CIRCULATION, V112, P1136, DOI 10.1161/CIRCULATIONAHA.104.516963
   Ho FM, 2007, J CELL BIOCHEM, V101, P442, DOI 10.1002/jcb.21192
   Jesmin S, 2003, ARTERIOSCL THROM VAS, V23, P2021, DOI 10.1161/01.ATV.0000094235.78783.D1
   Jun JH, 2011, BRIT J ANAESTH, V106, P650, DOI 10.1093/bja/aer006
   Keira Sidney Mamoru, 2004, Acta Cir. Bras., V19, P17, DOI 10.1590/S0102-86502004000700005
   Kwak HB, 2011, FASEB J, V25, P1106, DOI 10.1096/fj.10-172924
   Lam S, 2003, KIDNEY INT, V63, P878, DOI 10.1046/j.1523-1755.2003.00824.x
   Li H, 2000, CARDIOVASC RES, V46, P298, DOI 10.1016/S0008-6363(00)00028-6
   Liu XJ, 2007, BMC CELL BIOL, V8, DOI 10.1186/1471-2121-8-1
   Loffek S, 2011, EUR RESPIR J, V38, P191, DOI 10.1183/09031936.00146510
   Lorenzl S, 2003, STROKE, V34, pE37, DOI 10.1161/01.STR.0000075563.45920.24
   McCartney-Francis NL, 2001, J IMMUNOL, V166, P2734, DOI 10.4049/jimmunol.166.4.2734
   McLennan SV, 2002, DIABETOLOGIA, V45, P268, DOI 10.1007/s00125-001-0730-4
   Merchan JR, 2003, J NATL CANCER I, V95, P388, DOI 10.1093/jnci/95.5.388
   NEUMAN RE, 1950, J BIOL CHEM, V184, P299
   Nwogu JI, 2001, CIRCULATION, V104, P2216, DOI 10.1161/hc4301.097193
   Parks WC, 2004, NAT REV IMMUNOL, V4, P617, DOI 10.1038/nri1418
   Parlakpinar H, 2005, MOL CELL BIOCHEM, V277, P137, DOI 10.1007/s11010-005-5779-9
   PELOUCH V, 1993, MOL CELL BIOCHEM, V129, P101, DOI 10.1007/BF00926359
   Portik-Dobos V, 2002, DIABETES, V51, P3063, DOI 10.2337/diabetes.51.10.3063
   Prasadachari V. Gangadhar, 2011, INT J RES PHARM SCI, V2, P421
   Prasadachari V. Gangadhar, 2011, J PHARM RES, V4, P2806
   Ratnikov BI, 2002, LAB INVEST, V82, P1583, DOI 10.1097/01.LAB.0000038555.67772.DB
   Shamhart PE, 2009, AM J PHYSIOL-ENDOC M, V297, pE1147, DOI 10.1152/ajpendo.00327.2009
   Singh R, 2001, DIABETOLOGIA, V44, P129, DOI 10.1007/s001250051591
   Takizaw S, 2007, BRAIN RES, V1183, P124, DOI 10.1016/j.brainres.2007.07.006
   Tripathi BK, 2006, MED SCI MONITOR, V12, pRA130
   Verma RP, 2007, BIOORGAN MED CHEM, V15, P2223, DOI 10.1016/j.bmc.2007.01.011
   Wang MY, 2003, HYPERTENSION, V41, P1308, DOI 10.1161/01.HYP.0000073843.56046.45
   Wang XX, 2007, AM J HYPERTENS, V20, P629, DOI 10.1016/j.amjhyper.2006.12.003
   Westermann D, 2007, DIABETES, V56, P641, DOI 10.2337/db06-1163
   Xiao H., 2011, CARDIOVASC RES, V87, P04
   Zhang FY, 1998, BRAIN RES, V802, P104, DOI 10.1016/S0006-8993(98)00557-5
NR 46
TC 10
Z9 10
U1 2
U2 13
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0009-2797
EI 1872-7786
J9 CHEM-BIOL INTERACT
JI Chem.-Biol. Interact.
PD MAY 30
PY 2012
VL 197
IS 2-3
BP 119
EP 128
DI 10.1016/j.cbi.2012.04.005
PG 10
WC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology
GA 956PL
UT WOS:000305101500007
PM 22543014
DA 2018-12-27
ER

PT J
AU Tomita, M
   Takizawa, Y
   Kanbayashi, A
   Murata, H
   Tanaka, A
   Nakaike, M
   Hatanaka, M
   Kai, T
   Hayashi, M
AF Tomita, Mikio
   Takizawa, Yusuke
   Kanbayashi, Atsushi
   Murata, Hiroyuki
   Tanaka, Ayako
   Nakaike, Mariko
   Hatanaka, Megumi
   Kai, Tomomi
   Hayashi, Masahiro
TI RETRACTED: Suppression of efflux transporters in the intestines of
   endotoxin-treated rats (Retracted article. See vol. 465, pg. 479, 2014)
SO INTERNATIONAL JOURNAL OF PHARMACEUTICS
LA English
DT Article; Retracted Publication
DE Lipopolysaccharide; mdr; mrp2; Rhodamine123; 5-CFDA; Ileum
ID P-GLYCOPROTEIN EXPRESSION; PREGNANE X RECEPTOR; MULTIDRUG-RESISTANCE;
   INFLAMMATORY CYTOKINES; ACTIVATED RECEPTOR; LIVER; ISCHEMIA/REPERFUSION;
   LIPOPOLYSACCHARIDE; RHODAMINE123; EXCRETION
AB Infection and inflammation suppress the expression and activity of several drug transporters in the liver. In the intestine, P-glycoprotein (PGP/mdr1) and the multidrug resistance-associated protein 2 (MRP2) are important barriers to the absorption of many clinically important drugs. The protein expression and activity of these transporters were examined during inflammation induced by lipopolysaccharide (LPS). The transport of rhodamine123 (Rho123) and 5-carboxyfluorescein (5-CF) was determined in isolated ileal segments from endotoxin-treated or control rats in the presence or absence of inhibitors. The reverse transcription-polymerase chain reaction was used to measure mRNA levels. Compared with the controls, the mRNA levels of mdr1a and mrp2 were significantly decreased by approximately 50% in the ilea of the LPS-treated rats. Corresponding reductions in the basolateral-apical efflux of Rho123 and 5-CF were observed, resulting in significant increases in the apical-basolateral absorption of these compounds. Neither the permeability of fluorescein isothiocyanate labeled dextran 4000 (FD-4), a paracellular marker, nor membrane resistance was altered. These results indicate that endotoxin-induced inflammation reduces the intestinal expression and activity of PGP and MRP2 in rats, which eliciting corresponding changes in the intestinal transport of their substrates. Hence, infection and inflammatory diseases may induce variability in drug bioavailability through alterations in the intestinal expression and activity of drug transporters. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Tomita, Mikio; Takizawa, Yusuke; Kanbayashi, Atsushi; Murata, Hiroyuki; Tanaka, Ayako; Nakaike, Mariko; Hatanaka, Megumi; Kai, Tomomi; Hayashi, Masahiro] Tokyo Univ Pharm & Life Sci, Sch Pharm, Dept Drug Absorpt & Pharmacokinet, Hachioji, Tokyo 1920392, Japan.
RP Takizawa, Y (reprint author), Sch Pharm & Life Sci, Dept Drug Absorpt & Pharmacokinet, 1432-1 Horinouchi, Hachioji, Tokyo 1920392, Japan.
EM takizawa@toyaku.ac.jp
CR Geick A, 2001, J BIOL CHEM, V276, P14581, DOI 10.1074/jbc.M010173200
   Goralski KB, 2003, BRIT J PHARMACOL, V139, P35, DOI 10.1038/sj.bjp.0705227
   Hartmann G, 2003, CLIN PHARMACOL THER, V73, pP60, DOI 10.1016/S0009-9236(03)90578-9
   Hartmann G, 2002, J PHARMACOL EXP THER, V303, P273, DOI 10.1124/jpet.102.039404
   Hartmann G, 2001, INT IMMUNOPHARMACOL, V1, P189, DOI 10.1016/S0162-3109(00)00271-X
   Iida Aiko, 2005, Drug Metab Pharmacokinet, V20, P100, DOI 10.2133/dmpk.20.100
   Kalitsky-Szirtes J, 2004, DRUG METAB DISPOS, V32, P20, DOI 10.1124/dmd.32.1.20
   Kast HR, 2002, J BIOL CHEM, V277, P2908, DOI 10.1074/jbc.M109326200
   Lee G, 2001, CAN J PHYSIOL PHARM, V79, P876, DOI 10.1139/cjpp-79-10-876
   MOLMENTI EP, 1993, J BIOL CHEM, V268, P14116
   Moriguchi J, 2007, EUR J PHARMACOL, V565, P220, DOI 10.1016/j.ejphar.2007.02.058
   Nagira M, 2006, DRUG METAB PHARMACOK, V21, P230, DOI 10.2133/dmpk.21.230
   Pascussi JM, 2000, BIOCHEM BIOPH RES CO, V274, P707, DOI 10.1006/bbrc.2000.3219
   Payen L, 2002, CELL BIOL TOXICOL, V18, P221, DOI 10.1023/A:1016020626941
   Piquette-Miller M, 1998, PHARMACEUT RES, V15, P706, DOI 10.1023/A:1011962818051
   Salphati L, 1998, BIOCHEM PHARMACOL, V55, P387, DOI 10.1016/S0006-2952(97)00436-X
   Slaviero KA, 2003, LANCET ONCOL, V4, P224, DOI 10.1016/S1470-2045(03)01034-9
   Staudinger JL, 2001, P NATL ACAD SCI USA, V98, P3369, DOI 10.1073/pnas.051551698
   Stephens RH, 2002, BRIT J PHARMACOL, V135, P2038, DOI 10.1038/sj.bjp.0704668
   Synold TW, 2001, NAT MED, V7, P584, DOI 10.1038/87912
   Tang Wendy, 2000, Molecular Cell Biology Research Communications, V4, P90, DOI 10.1006/mcbr.2000.0264
   Tomita Mikio, 2004, Drug Metab Pharmacokinet, V19, P33, DOI 10.2133/dmpk.19.33
   Tomita M, 2010, INT J PHARMACEUT, V392, P35, DOI 10.1016/j.ijpharm.2010.03.019
   Tomita M, 2010, INT J PHARMACEUT, V387, P1, DOI 10.1016/j.ijpharm.2009.10.042
   Tomita M, 2009, DRUG METAB PHARMACOK, V24, P428, DOI 10.2133/dmpk.24.428
NR 25
TC 6
Z9 8
U1 2
U2 16
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-5173
EI 1873-3476
J9 INT J PHARMACEUT
JI Int. J. Pharm.
PD MAY 30
PY 2012
VL 428
IS 1-2
BP 33
EP 38
DI 10.1016/j.ijpharm.2012.02.027
PG 6
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 919XD
UT WOS:000302364600005
PM 22387888
DA 2018-12-27
ER

PT J
AU Tian, Y
   Huang, TX
   Li, GC
   Liu, J
   Wang, XN
   Feng, HP
   Wang, JF
AF Tian, Yuan
   Huang, Tuxiong
   Li, Guangchao
   Liu, Ji
   Wang, Xiaoning
   Feng, Hanping
   Wang, Jufang
TI RETRACTED: Apoptosis of CT26 colorectal cancer cells induced by
   Clostridium difficile toxin A stimulates potent anti-tumor immunity
   (Retracted article. See vol. 425, pg. 119, 2012)
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article; Retracted Publication
DE Anti-tumor immunity; Apoptosis; Colorectal cancer cell; CT26;
   Clostridium difficile; Toxin A
ID DENDRITIC CELLS; TUMOR-CELLS; CALRETICULIN EXPOSURE; IMMUNOGENICITY;
   DISEASE; DEATH; INDUCTION; MECHANISM; PROTEINS; BETA
AB Clostridium difficile toxin A (TcdA) is one of the main pathogenic factors released by C. difficile. Due to its potent cytotoxic and proinflammatory activities, we investigated the anti-tumor activity of TcdA. CT26 colorectal cancer cells were challenged with recombinant TcdA, and it was found that TcdA could induce apoptosis of CT26 cells. Calreticulin (CRT) exposure to the cell surface during TcdA-induced apoptosis suggested that this apoptosis may correlate with immunogenicity. Moreover, TcdA-treated apoptotic CT26 cells were highly immunogenic since they could stimulate DC activation, T-cell activation, and anti-tumor activity. Furthermore, the anti-tumor immune response generated was specific and long-term. In summary, these studies demonstrate that C difficile toxin A can induce apoptotic death of CT26 colorectal cancer cells and stimulate potent anti-tumor immunity. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Tian, Yuan; Huang, Tuxiong; Li, Guangchao; Liu, Ji; Wang, Jufang] S China Univ Technol, Sch Biosci & Bioengn, Guangzhou 510006, Guangdong, Peoples R China.
   [Wang, Xiaoning] Geneml Hosp Peoples Liberat Army, Inst Life Sci, Beijing, Peoples R China.
   [Feng, Hanping] Univ Maryland, Sch Dent, Dept Microbial Pathogenesis, Baltimore, MD 21201 USA.
RP Wang, JF (reprint author), S China Univ Technol, Sch Biosci & Bioengn, Guangzhou 510006, Guangdong, Peoples R China.
EM jufwang@scut.edu.cn
FU National High-tech R&D Program of China (863 Program) [2007AA021702];
   Scientific and Technological Specialized Project for the National New
   Medicine Formulation [2011ZX09506-001]; Planned Science and Technology
   Project of Guangdong Province, China [2011B050400016]; Ministry of
   Education of China [NCET-10-0399]
FX This work was supported by Grants from National High-tech R&D Program of
   China (863 Program) (2007AA021702), the Scientific and Technological
   Specialized Project for the National New Medicine Formulation
   (2011ZX09506-001), the Planned Science and Technology Project of
   Guangdong Province, China (2011B050400016) and Program for New Century
   Excellent Talents in University of Ministry of Education of China
   (NCET-10-0399).
CR Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767
   BOON T, 1994, ANNU REV IMMUNOL, V12, P337, DOI 10.1146/annurev.immunol.12.1.337
   Brito GAC, 2002, J INFECT DIS, V186, P1438, DOI 10.1086/344729
   Casares N, 2005, J EXP MED, V202, P1691, DOI 10.1084/jem.20050915
   Castagliuolo I, 1998, J IMMUNOL, V160, P6039
   D HE, 2000, GASTROENTEROLOGY, V119, P139, DOI 10.1053/gast.2000.8526
   Fadeel B, 2005, J INTERN MED, V258, P479, DOI 10.1111/j.1365-2796.2005.01570.x
   Fadok VA, 1998, J CLIN INVEST, V101, P890, DOI 10.1172/JCI1112
   Feng HP, 2001, BLOOD, V97, P3505, DOI 10.1182/blood.V97.11.3505
   Feng HP, 2002, BLOOD, V100, P4108, DOI 10.1182/blood-2002-05-1389
   Feng HP, 2005, J IMMUNOL, V175, P421, DOI 10.4049/jimmunol.175.1.421
   Feng HP, 2003, BLOOD, V101, P245, DOI 10.1182/blood-2002-05-1580
   He D, 2002, GASTROENTEROLOGY, V122, P1048, DOI 10.1053/gast.2002.32386
   Kim H, 2005, GASTROENTEROLOGY, V129, P1875, DOI 10.1053/j.gastro.2005.09.011
   Kroemer G, 2005, NAT MED, V11, P725, DOI 10.1038/nm1263
   Kroemer G, 2005, CELL DEATH DIFFER, V12, P1463, DOI 10.1038/sj.cdd.4401724
   Michalak M, 1998, BIOCHEM CELL BIOL, V76, P779, DOI 10.1139/bcb-76-5-779
   Obeid M, 2007, CELL DEATH DIFFER, V14, P1848, DOI 10.1038/sj.cdd.4402201
   Obeid M, 2007, NAT MED, V13, P54, DOI 10.1038/nm1523
   Poelmann RE, 2000, CELL TISSUE RES, V301, P43, DOI 10.1007/s004410000227
   Pothoulakis C, 1996, EUR J GASTROEN HEPAT, V8, P1041, DOI 10.1097/00042737-199611000-00003
   Poxton IR, 2001, CLIN MICROBIOL INFEC, V7, P421, DOI 10.1046/j.1198-743x.2001.00287.x
   Rathmell JC, 2002, CELL, V109, pS97, DOI 10.1016/S0092-8674(02)00704-3
   Steinman RM, 2000, J EXP MED, V191, P411, DOI 10.1084/jem.191.3.411
   Sun XM, 2010, TOXINS, V2, P1848, DOI 10.3390/toxins2071848
   Voll RE, 1997, NATURE, V390, P350, DOI 10.1038/37022
   Voth DE, 2005, CLIN MICROBIOL REV, V18, P247, DOI 10.1128/CMR.18.2.247-263.2005
NR 27
TC 1
Z9 2
U1 3
U2 16
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD MAY 25
PY 2012
VL 422
IS 1
BP 15
EP 21
DI 10.1016/j.bbrc.2012.04.068
PG 7
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 955UK
UT WOS:000305046200004
PM 22548800
DA 2018-12-27
ER

PT J
AU Liu, WT
   Tian, FF
   Kurata, T
   Morimoto, N
   Abe, K
AF Liu, Wentao
   Tian, Fengfeng
   Kurata, Tomoko
   Morimoto, Nobutoshi
   Abe, Koji
TI RETRACTED: Dynamic changes of mitochondrial fission proteins after
   transient cerebral ischemia in mice (Retracted article. See vol. 1507,
   pg. 155, 2013)
SO BRAIN RESEARCH
LA English
DT Article; Retracted Publication
DE Mitochondria; Fission; Fis1; Peri-infract regions; tMCAO
ID FOREBRAIN ISCHEMIA; BRAIN ISCHEMIA; CELL-DEATH; MORPHOLOGY; EXPRESSION;
   GENE; DNA
AB With fusion or fission, mitochondria alter their morphology in response to various physiological and pathological stimuli resulting in either elongated, tubular, interconnected or fragmented form. Immunohistochemistry and Western blot analyses were performed at 2, 7, 14 and 28 d after 90 min of transient middle cerebral artery occlusion (tMCAO) in mice. The present study showed that mitochondrial fission protein fission 1 (Fisl) and phosphorylated dynamin-related protein 1 (P-Drpl) both progressively increased with the peak at 14 d after tMCAO. Double immunofluorescent analysis showed the number of double positive cells with Fish/ Drpl reduced between 2 and 28 d after 90 min of tMCAO, and also showed some double positive cells with Fis1/terrninal deoxynucleotidyl transferase-mediated dUTP-digoxigenin nick end labeling (TUNEL) in the peri-infract regions at 2 d after the reperfusion. The present study suggests a progressive activation of mitochondrial fission proteins Fisl and P-Drpl in relation to apoptotic process in neural cells of the peri-infract regions after tMCAO. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Liu, Wentao; Tian, Fengfeng; Kurata, Tomoko; Morimoto, Nobutoshi; Abe, Koji] Okayama Univ, Dept Neurol, Grad Sch Med Dent & Pharmaceut Sci, Okayama 7008558, Japan.
RP Abe, K (reprint author), Okayama Univ, Dept Neurol, Grad Sch Med Dent & Pharmaceut Sci, 2-5-1 Shikatacho, Okayama 7008558, Japan.
EM gmd422020@s.okayama-u.ac.jp
FU Ministry of Health, Labour and Welfare of Japan;  [21390267]; 
   [22659260]
FX This work was partly supported by Grant-in-Aid for Scientific Research
   (B) 21390267 and Challenging Research 22659260, and by Grants-in-Aid
   from the Research Committees (Mizusawa H, Hakano I, Nishizawa M, Sasaki
   H, and Sobue G) from the Ministry of Health, Labour and Welfare of
   Japan.
CR ABE K, 1995, STROKE, V26, P1478, DOI 10.1161/01.STR.26.8.1478
   Abe K, 1998, CELL MOL NEUROBIOL, V18, P709, DOI 10.1023/A:1020230220971
   Abe K, 1996, ADV NEUROL, V71, P485
   ABE K, 1993, J CEREBR BLOOD F MET, V13, P773, DOI 10.1038/jcbfm.1993.98
   Andrew B., 2008, NATURE, V9, P505
   ASTRUP J, 1977, STROKE, V8, P51, DOI 10.1161/01.STR.8.1.51
   Bevers MB, 2008, J CEREBR BLOOD F MET, V28, P655, DOI 10.1038/sj.jcbfm.9600595
   Chan DC, 2006, ANNU REV CELL DEV BI, V22, P79, DOI 10.1146/annurev.cellbio.22.010305.104638
   Chan DC, 2006, CELL, V125, P1241, DOI 10.1016/j.cell.2006.06.010
   Chen H, 2009, HUM MOL GENET, V18, P169
   Han XJ, 2008, J CELL BIOL, V182, P573, DOI 10.1083/jcb.200802164
   Hausenloy DJ, 2007, CLIN PHARMACOL THER, V82, P370, DOI 10.1038/sj.clpt.2007.6100352
   Henze K, 2003, NATURE, V426, P127, DOI 10.1038/426127a
   Hoppins S, 2007, ANNU REV BIOCHEM, V76, P75
   Horbinski C, 2005, FREE RADICAL BIO MED, V38, P2, DOI 10.1016/j.freeradbiomed.2004.09.030
   Lees KR, 2006, NEW ENGL J MED, V354, P588, DOI 10.1056/NEJMoa052980
   Lipton P, 1999, PHYSIOL REV, V79, P1431
   Okamoto K, 2005, ANNU REV GENET, V39, P503, DOI 10.1146/annurev.genet.38.072902.093019
   PETER S, 2009, STROKE, V40, P3149
   Soane L, 2007, J NEUROSCI RES, V85, P3407, DOI 10.1002/jnr.21498
   Su B, 2010, BBA-MOL BASIS DIS, V1802, P135, DOI 10.1016/j.bbadis.2009.09.013
   TIAN F, 2010, AUTOPHAGY, V8, P1107
   Tian FF, 2011, AUTOPHAGY, V7, P985, DOI 10.4161/auto.7.9.16012
   Zhang XM, 2010, BRAIN RES, V1343, P143, DOI 10.1016/j.brainres.2010.04.027
   Zhang Y, 2007, FEBS LETT, V581, P2168, DOI 10.1016/j.febslet.2007.01.095
NR 25
TC 13
Z9 14
U1 4
U2 12
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0006-8993
J9 BRAIN RES
JI Brain Res.
PD MAY 25
PY 2012
VL 1456
BP 94
EP 99
DI 10.1016/j.brainres.2012.03.038
PG 6
WC Neurosciences
SC Neurosciences & Neurology
GA 950EU
UT WOS:000304633200009
PM 22498177
DA 2018-12-27
ER

PT J
AU Kellom, M
   Basselin, M
   Keleshian, VL
   Chen, M
   Rapoport, SI
   Rao, JS
AF Kellom, Matthew
   Basselin, Mireille
   Keleshian, Vasken L.
   Chen, Mei
   Rapoport, Stanley I.
   Rao, Jagadeesh S.
TI RETRACTED: Dose-dependent changes in neuroinflammatory and arachidonic
   acid cascade markers with synaptic marker loss in rat lipopolysaccharide
   infusion model of neuroinflammation(Retracted article. See vol. 18, pg.
   Artn no.40, 2017)
SO BMC NEUROSCIENCE
LA English
DT Article; Retracted Publication
DE Arachidonic acid; Cytokine; Synapse; Drebrin; Lipopolysaccharide;
   Synaptophysin; Phospholipase A(2); Neuroinflammation; NF-kappa B
ID ACTIVATED PROTEIN-KINASE; NF-KAPPA-B; NITRIC-OXIDE SYNTHASE;
   ALZHEIMERS-DISEASE; GENE-EXPRESSION; PHOSPHOLIPASE A(2);
   BINDING-PROTEIN; INTRACEREBROVENTRICULAR INFUSION; DOCOSAHEXAENOIC ACID;
   EXCITATORY SYNAPSES
AB Background: Neuroinflammation, caused by six days of intracerebroventricular infusion of bacterial lipopolysaccharide (LPS), stimulates rat brain arachidonic acid (AA) metabolism. The molecular changes associated with increased AA metabolism are not clear. We examined effects of a six-day infusion of a low-dose (0.5 ng/h) and a high-dose (250 ng/h) of LPS on neuroinflammatory, AA cascade, and pre- and post-synaptic markers in rat brain. We used artificial cerebrospinal fluid-infused brains as controls.
   Results: Infusion of low- or high-dose LPS increased brain protein levels of TNF alpha, and iNOS, without significantly changing GFAP. High-dose LPS infusion upregulated brain protein and mRNA levels of AA cascade markers (cytosolic cPLA(2)-IVA, secretory sPLA(2)-V, cyclooxygenase-2 and 5-lipoxygenase), and of transcription factor NF-kappa B p50 DNA binding activity. Both LPS doses increased cPLA(2) and p38 mitogen-activated protein kinase levels, while reducing protein levels of the pre- synaptic marker, synaptophysin. Post-synaptic markers drebrin and PSD95 protein levels were decreased with high-but not low-dose LPS.
   Conclusions: Chronic LPS infusion has differential effects, depending on dose, on inflammatory, AA and synaptic markers in rat brain. Neuroinflammation associated with upregulated brain AA metabolism can lead to synaptic dysfunction.
C1 [Kellom, Matthew; Basselin, Mireille; Keleshian, Vasken L.; Chen, Mei; Rapoport, Stanley I.; Rao, Jagadeesh S.] NIA, Brain Physiol & Metab Sect, NIH, Bethesda, MD 20892 USA.
RP Rao, JS (reprint author), NIA, Brain Physiol & Metab Sect, NIH, 9000 Rockville Pike,Bldg 9,1S-126, Bethesda, MD 20892 USA.
EM jrao@mail.nih.gov
FU National Institute on Aging, National Institutes of Health
FX This research was supported entirely by the Intramural Research Program
   of the National Institute on Aging, National Institutes of Health. We
   thank the NIH Fellow Editorial Board for assistance.
CR Abelev BI, 2006, PHYS REV LETT, V97, P1
   Anthony IC, 2008, INT REV PSYCHIATR, V20, P15, DOI 10.1080/09540260701862037
   Antonio V, 2002, BIOCHEM J, V368, P415, DOI 10.1042/BJ20020658
   Aoki C, 2005, J COMP NEUROL, V483, P383, DOI 10.1002/cne.20449
   Balsinde J, 1999, J BIOL CHEM, V274, P25967, DOI 10.1074/jbc.274.37.25967
   Basselin M, 2007, J NEUROCHEM, V102, P761, DOI 10.1111/j.1471-4159.2007.04593.x
   Basselin M, 2011, NEUROCHEM RES, V36, P139, DOI 10.1007/s11064-010-0282-4
   Basselin M, 2010, J LIPID RES, V51, P1049, DOI 10.1194/jlr.M002469
   Bhat NR, 2002, BRAIN RES, V948, P93, DOI 10.1016/S0006-8993(02)02953-0
   Block ML, 2005, PROG NEUROBIOL, V76, P77, DOI 10.1016/j.pneurobio.2005.06.004
   Campbell J, 2004, J IMMUNOL, V173, P6928, DOI 10.4049/jimmunol.173.11.6928
   Cole GM, 2010, J NUTR, V140, P869, DOI 10.3945/jn.109.113910
   Coulon L, 2003, FREE RADICAL BIO MED, V35, P616, DOI 10.1016/S0891-5849(03)00386-1
   Czapski GA, 2010, BRAIN RES, V1356, P85, DOI 10.1016/j.brainres.2010.07.096
   DeMar JC, 2006, BBA-MOL CELL BIOL L, V1761, P1050, DOI 10.1016/j.bbalip.2006.06.006
   DOZA YN, 1995, FEBS LETT, V364, P223, DOI 10.1016/0014-5793(95)00346-B
   El-Hussein AE, 2000, SCIENCE, V290, P1364
   Esposito G, 2008, J NUCL MED, V49, P1414, DOI 10.2967/jnumed.107.049619
   Evans GJO, 2005, BIOCHEM SOC T, V33, P1350, DOI 10.1042/BST0331350
   Fiebich BL, 2001, J NEUROCHEM, V79, P950, DOI 10.1046/j.1471-4159.2001.00652.x
   FORD AL, 1995, J IMMUNOL, V154, P4309
   Goralski KB, 2005, AM J PHYSIOL-GASTR L, V289, pG434, DOI 10.1152/ajgpi.00562.2004
   GRIFFIN DE, 1994, ANN NEUROL, V35, P592, DOI 10.1002/ana.410350513
   Hanisch UK, 2002, GLIA, V40, P140, DOI 10.1002/glia.10161
   Harigaya Y, 1996, J NEUROSCI RES, V43, P87, DOI 10.1002/jnr.490430111
   Hatanpaa K, 1999, J NEUROPATH EXP NEUR, V58, P637, DOI 10.1097/00005072-199906000-00008
   Hauss-Wegrzyniak B, 1999, BRAIN RES, V815, P36, DOI 10.1016/S0006-8993(98)01081-6
   Hauss-Wegrzyniak B, 1998, BRAIN RES, V794, P211, DOI 10.1016/S0006-8993(98)00227-3
   Hauss-Wegrzyniak B, 1998, BRAIN RES, V780, P294, DOI 10.1016/S0006-8993(97)01215-8
   Hauss-Wegrzyniak B, 2002, NEUROSCI LETT, V322, P75, DOI 10.1016/S0304-3940(02)00087-3
   Hernandez M, 2002, CIRC RES, V90, P38, DOI 10.1161/hh0102.102978
   Ito D, 1998, MOL BRAIN RES, V57, P1, DOI 10.1016/S0169-328X(98)00040-0
   Ivanov A, 2009, J CELL SCI, V122, P524, DOI 10.1242/jcs.033464
   Kellom M, 2011, FASEB J, V25, P1
   Kim HW, 2010, NEUROBIOL DIS, V37, P596, DOI 10.1016/j.nbd.2009.11.010
   Kleinert H, 2003, BIOL CHEM, V384, P1343, DOI 10.1515/BC.2003.152
   Kojima N, 1988, Brain Res, V464, P207
   Lahiri DK, 1998, MOL BRAIN RES, V58, P112, DOI 10.1016/S0169-328X(98)00115-6
   Lehnardt S, 2002, J NEUROSCI, V22, P2478, DOI 10.1523/JNEUROSCI.22-07-02478.2002
   Li YK, 2003, J NEUROSCI, V23, P1605
   Lietz M, 2003, EUR J BIOCHEM, V270, P2, DOI 10.1046/j.1432-1033.2003.03360.x
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Maezawa I, 2006, FASEB J, V20, P797, DOI 10.1096/fj.05-5423fje
   Maitra U, 2011, J IMMUNOL, V186, P4467, DOI 10.4049/jimmunol.1003300
   Marriott LK, 2007, ENDOCRINE, V32, P317, DOI 10.1007/s12020-008-9038-1
   MORII H, 1994, BIOCHEM BIOPH RES CO, V205, P6, DOI 10.1006/bbrc.1994.2621
   Munoz L, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-21
   Nakajima K, 2004, NEUROCHEM INT, V44, P205, DOI 10.1016/S0197-0186(03)00163-3
   Niederberger E, 2007, EUR J PHARMACOL, V559, P55, DOI 10.1016/j.ejphar.2006.11.074
   Nimmo Alan J, 2009, Recent Pat CNS Drug Discov, V4, P86
   Ooe N, 2004, MOL CELL BIOL, V24, P608, DOI 10.1128/MCB.24.2.608-616.2004
   Pereira SG, 2008, INT J BIOCHEM CELL B, V40, P1425, DOI 10.1016/j.biocel.2007.05.004
   Perera PY, 2001, J IMMUNOL, V166, P574, DOI 10.4049/jimmunol.166.1.574
   Possel H, 2000, GLIA, V32, P51, DOI 10.1002/1098-1136(200010)32:1<51::AID-GLIA50>3.0.CO;2-4
   Rao JS, 2010, MOL PSYCHIATR, V15, P384, DOI 10.1038/mp.2009.47
   Rapoport SI, 2008, PROSTAG LEUKOTR ESS, V79, P153, DOI 10.1016/j.plefa.2008.09.010
   Richardson RL, 2005, BEHAV PHARMACOL, V16, P531, DOI 10.1097/01.fbp.0000179278.03868.96
   Rosenberger TA, 2004, J NEUROCHEM, V88, P1168, DOI 10.1046/j.1471-4159.2003.02246.x
   Rosenberger TA, 2010, NEUROCHEM INT, V56, P501, DOI 10.1016/j.neuint.2009.12.010
   Sa MJ, 2004, ACTA NEUROPATHOL, V107, P97, DOI 10.1007/s00401-003-0781-3
   Sawada M, 1999, J NEUROCHEM, V72, P1466, DOI 10.1046/j.1471-4159.1999.721466.x
   Serio KJ, 2005, AM J PHYSIOL-CELL PH, V288, pC1125, DOI 10.1152/ajpcell.00296.2004
   Strokin M, 2003, BRIT J PHARMACOL, V139, P1014, DOI 10.1038/sj.bjp.0705326
   Tanabe T, 2002, PROSTAG OTH LIPID M, V68-9, P95, DOI 10.1016/S0090-6980(02)00024-2
   Vervoordeldonk MJBM, 1996, FEBS LETT, V397, P108, DOI 10.1016/S0014-5793(96)01148-9
   Waetzig V, 2005, GLIA, V50, P235, DOI 10.1002/glia.20173
   WESSELINGH SL, 1994, ADV NEUROIMMUNOL, V4, P199, DOI 10.1016/S0960-5428(06)80258-5
   Willard LB, 2000, EXP BRAIN RES, V134, P58, DOI 10.1007/s002210000446
   WRIGHT SD, 1986, J EXP MED, V164, P1876, DOI 10.1084/jem.164.6.1876
NR 69
TC 17
Z9 20
U1 2
U2 5
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2202
J9 BMC NEUROSCI
JI BMC Neurosci.
PD MAY 23
PY 2012
VL 13
AR 50
DI 10.1186/1471-2202-13-50
PG 11
WC Neurosciences
SC Neurosciences & Neurology
GA 015XS
UT WOS:000309480300001
PM 22621398
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Alcinyi, MV
   Dandara, C
   Garnieldien, J
   Heckmann, JM
AF Alcinyi, M. V.
   Dandara, C.
   Garnieldien, J.
   Heckmann, J. M.
TI RETRACTED: Association of transforming growth factor beta-1 (TGFB1)
   regulatory region polymorphisms with myasthenia gravis-related
   ophthalmoparesis (Retracted article. See vol. 271, pg. 69, 2014)
SO JOURNAL OF NEUROIMMUNOLOGY
LA English
DT Article; Retracted Publication
DE Myasthenia gravis; Ophthalmoplegia; Extraocular muscles; Single
   nucleotide polymorphisms; Transforming growth factor beta-1; African
ID EXTRAOCULAR-MUSCLE; CELLS; FIBROGENESIS; EXPRESSION; UNIQUE; SMAD3; SNP
AB We investigated the association of an ophthalmoplegic complication developing in African myasthenia gravis (MG) subjects with polymorphisms in the regulatory region of TGFB1. We found significant associations with several putative functional single nucleotide polymorphisms (SNPs) (including two novel SNPs) that potentially alter transcription factor binding. Our data support a hypothesis that altered TGFB1 regulation may predispose individuals who harbour these SNPs to developing ophthalmoplegia as a result of increased TGF-beta 1 driven myofibrosis as a consequence to complement-mediated damage. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Alcinyi, M. V.; Heckmann, J. M.] Groote Schuur Hosp, Dept Med, Neurol Res Grp, ZA-7925 Cape Town, South Africa.
   [Dandara, C.] Univ Cape Town, Fac Hlth Sci, Div Human Genet Clin & Lab Sci, ZA-7925 Cape Town, South Africa.
   [Garnieldien, J.] Univ Western Cape, S African Natl Bioinformat Inst, Bellville, South Africa.
RP Heckmann, JM (reprint author), Groote Schuur Hosp, Dept Med, Neurol Res Grp, ZA-7925 Cape Town, South Africa.
EM Jeanine.heckmann@uct.ac.za
RI Dandara, Collet/D-1978-2009
OI Dandara, Collet/0000-0002-5925-4895
FU University of Cape Town
FX The authors wish to thank Ms. Henriette Uwimphuwe and Mr. Mpho Madiba
   for assisting with sequencing. This study was supported by a University
   of Cape Town research grant.
CR Bateman KJ, 2007, SAMJ S AFR MED J, V97, P959
   Bonniaud P, 2005, J IMMUNOL, V175, P5390, DOI 10.4049/jimmunol.175.8.5390
   Carlson ME, 2008, NATURE, V454, P528, DOI 10.1038/nature07034
   FENICHEL G, 1966, ANN NY ACAD SCI, V135, P60, DOI 10.1111/j.1749-6632.1966.tb45463.x
   Gauldie J, 2007, BIOCHEM SOC T, V35, P661, DOI 10.1042/BST0350661
   Healy J, 2009, INT J CANCER, V125, P1483, DOI 10.1002/ijc.24526
   Heckmann JM, 2007, NEUROMUSCULAR DISORD, V17, P929, DOI 10.1016/j.nmd.2007.07.002
   Heckmann JM, 2010, GENES IMMUN, V11, P1, DOI 10.1038/gene.2009.61
   Heckmann J.M., S AFR MED J IN PRESS
   HU ED, 1995, P NATL ACAD SCI USA, V92, P9856, DOI 10.1073/pnas.92.21.9856
   Kusner LL, 2010, INVEST OPHTH VIS SCI, V51, P192, DOI 10.1167/iovs.08-2857
   Lepper C, 2009, NATURE, V460, P627, DOI 10.1038/nature08209
   Li Y, 2004, AM J PATHOL, V164, P1007, DOI 10.1016/S0002-9440(10)63188-4
   Ma JJ, 2002, MUSCLE NERVE, V26, P804, DOI 10.1002/mus.10272
   Pacheco-Pinedo EC, 2009, PHYSIOL GENOMICS, V37, P35, DOI 10.1152/physiolgenomics.00051.2008
   Porter JD, 2006, PHYSIOL GENOMICS, V24, P264, DOI 10.1152/physiolgenomics.00234.2004
   Shah R, 2006, HUM GENET, V119, P61, DOI 10.1007/s00439-005-0112-y
   Soltys J, 2008, ANN NY ACAD SCI, V1132, P220, DOI 10.1196/annals.1405.037
   Yuan HY, 2006, NUCLEIC ACIDS RES, V34, pW635, DOI 10.1093/nar/gkl236
   Zeiger U, 2010, PHYSIOL GENOMICS, V41, P289, DOI 10.1152/physiolgenomics.00169.2009
NR 20
TC 0
Z9 0
U1 1
U2 7
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0165-5728
EI 1872-8421
J9 J NEUROIMMUNOL
JI J. Neuroimmunol.
PD MAY 15
PY 2012
VL 246
IS 1-2
BP 96
EP 99
DI 10.1016/j.jneuroim.2012.03.002
PG 4
WC Immunology; Neurosciences
SC Immunology; Neurosciences & Neurology
GA 942FA
UT WOS:000304026900014
DA 2018-12-27
ER

PT J
AU Huijgen, R
   Boekholdt, SM
   Arsenault, BJ
   Bao, WH
   Davaine, JM
   Tabet, F
   Petrides, F
   Rye, KA
   DeMicco, DA
   Barter, PJ
   Kastelein, JJP
   Lambert, G
AF Huijgen, Roeland
   Boekholdt, S. Matthijs
   Arsenault, Benoit J.
   Bao, Weihang
   Davaine, Jean-Michel
   Tabet, Fatiha
   Petrides, Francine
   Rye, Kerry-Anne
   DeMicco, David A.
   Barter, Philip J.
   Kastelein, John J. P.
   Lambert, Gilles
TI RETRACTED: Plasma PCSK9 Levels and Clinical Outcomes in the TNT
   (Treating to New Targets) Trial (Retracted article. See vol. 61, pg.
   1751, 2013)
SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
LA English
DT Article; Retracted Publication
DE biomarker; CHD; LDL; PCSK9; statin
ID DENSITY-LIPOPROTEIN CHOLESTEROL; LDL CHOLESTEROL; STATIN THERAPY;
   FAMILIAL HYPERCHOLESTEROLEMIA; NONHUMAN-PRIMATES; ATORVASTATIN;
   METAANALYSIS; GENE; PROPROTEIN-CONVERTASE-SUBTILISIN/KEXIN-TYPE-9;
   CORRELATE
AB Objectives The purpose of this study was to investigate whether high levels of circulating proprotein convertase subtilisin kexin type 9 (PCSK9) would increase cardiovascular risk in statin-treated patients.
   Background Statins activate low-density lipoprotein (LDL) receptor gene expression, thus lowering plasma LDL levels. But statins also activate the expression of PCSK9, a secreted inhibitor of the LDL receptor, thereby limiting their beneficial effects.
   Methods We have measured the plasma PCSK9 levels of 1,613 patients with stable coronary heart disease enrolled in the Treating to New Targets study, a randomized trial that compared the efficacy of high-versus low-dose atorvastatin. After a run-in period with atorvastatin 10 mg daily, patients were randomized to either continue with 10 mg or be up-titrated to 80 mg of atorvastatin, and followed during 5 years for major cardiovascular events (MCVEs).
   Results Circulating PCSK9 levels measured at randomization were predictive of clinical outcomes in the group randomized to remain on atorvastatin 10 mg (p = 0.039), but not in the group that intensified atorvastatin treatment to 80 mg (p = 0.24). Further, PCSK9 levels measured 1 year post-randomization did not change upon increase of the statin dose.
   Conclusions PCSK9 levels predict cardiovascular events in patients treated with low-dose atorvastatin. (A Study to Determine the Degree of Additional Reduction in CV Risk in Lowering LDL Below Minimum Target Levels [TNT]; NCT00327691) (J Am Coll Cardiol 2012;59:1778-84) (C) 2012 by the American College of Cardiology Foundation
C1 [Huijgen, Roeland; Boekholdt, S. Matthijs; Arsenault, Benoit J.; Kastelein, John J. P.] Univ Amsterdam, Acad Med Ctr, Dept Vasc Med, NL-1105 AZ Amsterdam, Netherlands.
   [Boekholdt, S. Matthijs] Univ Amsterdam, Acad Med Ctr, Dept Cardiol, NL-1105 AZ Amsterdam, Netherlands.
   [Bao, Weihang; DeMicco, David A.] Pfizer Inc, New York, NY USA.
   [Davaine, Jean-Michel; Lambert, Gilles] Univ Nantes, Lab Inserm U957, Fac Med, Nantes, France.
   [Tabet, Fatiha; Petrides, Francine; Rye, Kerry-Anne; Barter, Philip J.; Lambert, Gilles] Heart Res Inst, Sydney, NSW, Australia.
   [Rye, Kerry-Anne; Barter, Philip J.] Univ Sydney, Fac Med, Sydney, NSW 2006, Australia.
RP Lambert, G (reprint author), INSERM, U957, Fac Med, 1 Rue Gaston Veil, F-44035 Nantes, France.
EM gilles.lambert@univ-nantes.fr
RI Boekholdt, Matthijs/G-7562-2014
OI Lambert, Gilles/0000-0001-5632-0685
FU Pfizer Inc.; Fonds de la recherche en sante du Quebec; Dutch Heart
   Foundation [2010T082]; National Health and Medical Research Council of
   Australia [1010867]; Pfizer
FX The TNT study and the analyses described in this paper were funded by
   Pfizer Inc. Dr. Arsenault is supported by a post-doctoral fellowship
   from the Fonds de la recherche en sante du Quebec. Dr. Kastelein is a
   recipient of the lifetime achievement award of the Dutch Heart
   Foundation, 2010T082. Dr. Lambert is a recipient of the project grant
   1010867 from the National Health and Medical Research Council of
   Australia. Dr. DeMicco is an employee of Pfizer. Dr. Barter has received
   honraria for lectures from and is on the advisory board for Pfizer. Dr.
   Kastelein has received consultancy fees from Pfizer. All other authors
   have reported that they have no relationships relevant to the contents
   to this paper to disclose.
CR Alborn WE, 2007, CLIN CHEM, V53, P1814, DOI 10.1373/clinchem.2007.091280
   Arsenault Benoit J, 2011, J Am Coll Cardiol, V57, P63, DOI 10.1016/j.jacc.2010.06.052
   Baigent C, 2005, LANCET, V366, P1267, DOI 10.1016/S0140-6736(05)67394-1
   Berge KE, 2006, ARTERIOSCL THROM VAS, V26, P1094, DOI 10.1161/01.ATV.0000204337.81286.1c
   Cannon CP, 2006, J AM COLL CARDIOL, V48, P438, DOI 10.1016/j.jacc.2006.04.070
   Careskey HE, 2008, J LIPID RES, V49, P394, DOI 10.1194/jlr.M700437-JLR200
   Chan JCY, 2009, P NATL ACAD SCI USA, V106, P9820, DOI 10.1073/pnas.0903849106
   Dong B, 2010, INT J MOL MED, V27, P103
   Dubuc G, 2004, ARTERIOSCL THROM VAS, V24, P1454, DOI 10.1161/01.ATV.0000134621.14315.43
   Dubuc G, 2009, J LIPID RES, V51, P140
   Duff CJ, 2009, BIOCHEM J, V419, P577, DOI 10.1042/BJ20082407
   Frank-Kamenetsky M, 2008, P NATL ACAD SCI USA, V105, P11915, DOI 10.1073/pnas.0805434105
   Grundy Scott M, 2004, J Am Coll Cardiol, V44, P720, DOI 10.1016/j.jacc.2004.07.001
   Homer VM, 2008, ATHEROSCLEROSIS, V196, P659, DOI 10.1016/j.atherosclerosis.2007.07.022
   Jeong HJ, 2008, J LIPID RES, V49, P399, DOI 10.1194/jlr.M700443-JLR200
   Lakoski SG, 2009, J CLIN ENDOCR METAB, V94, P2537, DOI 10.1210/jc.2009-0141
   Lambert G, 2008, CLIN CHEM, V54, P1038, DOI 10.1373/clinchem.2007.099747
   Lambert G, 2007, CURR OPIN LIPIDOL, V18, P304, DOI 10.1097/MOL.0b013e3281338531
   Lambert G, 2009, ATHEROSCLEROSIS, V203, P1, DOI 10.1016/j.atherosclerosis.2008.06.010
   LaRosa JC, 2005, NEW ENGL J MED, V352, P1425, DOI 10.1056/NEJMoa050461
   Law MR, 2003, BRIT MED J, V326, P1423, DOI 10.1136/bmj.326.7404.1423
   Mayne J, 2007, BIOCHEM BIOPH RES CO, V361, P451, DOI 10.1016/j.bbrc.2007.07.029
   Ni YG, 2010, J BIOL CHEM, V285, P12882, DOI 10.1074/jbc.M110.113035
   Poirier S, 2009, J BIOL CHEM, V284, P28856, DOI 10.1074/jbc.M109.037085
   Rashid S, 2005, P NATL ACAD SCI USA, V102, P5374, DOI 10.1073/pnas.0501652102
   Scotti E, 2011, MOL CELL BIOL, V31, P1885, DOI 10.1128/MCB.01469-10
   Steinberg D, 2009, P NATL ACAD SCI USA, V106, P9546, DOI 10.1073/pnas.0904560106
   Thompson JF, 2009, CIRC-CARDIOVASC GENE, V2, P173, DOI 10.1161/CIRCGENETICS.108.818062
   Waters DD, 2004, AM J CARDIOL, V93, P154, DOI 10.1016/j.amjcard.2003.09.031
   Welder G, 2010, J LIPID RES, V51, P2714, DOI 10.1194/jlr.M008144
   Zelcer N, 2009, SCIENCE, V325, P100, DOI 10.1126/science.1168974
NR 31
TC 44
Z9 47
U1 1
U2 17
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0735-1097
J9 J AM COLL CARDIOL
JI J. Am. Coll. Cardiol.
PD MAY 15
PY 2012
VL 59
IS 20
BP 1778
EP 1784
DI 10.1016/j.jacc.2011.12.043
PG 7
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 941YY
UT WOS:000304007000007
PM 22575316
OA Bronze
DA 2018-12-27
ER

PT J
AU Herranz, N
   Dave, N
   Millanes-Romero, A
   Morey, L
   Diaz, VM
   Lorenz-Fonfria, V
   Gutierrez-Gallego, R
   Jeronimo, C
   Di Croce, L
   de Herreros, AG
   Peiro, S
AF Herranz, Nicolas
   Dave, Natalia
   Millanes-Romero, Alba
   Morey, Lluis
   Diaz, Victor M.
   Lorenz-Fonfria, Victor
   Gutierrez-Gallego, Ricardo
   Jeronimo, Celia
   Di Croce, Luciano
   Garcia de Herreros, Antonio
   Peiro, Sandra
TI RETRACTED: Lysyl Oxidase-like 2 Deaminates Lysine 4 in Histone H3
   (Retracted article. See vol. 63, pg. 180, 2016)
SO MOLECULAR CELL
LA English
DT Article; Retracted Publication
ID COMPLEX; DEMETHYLATION; METHYLATION; CHROMATIN; ENZYME; TRANSCRIPTION;
   DEACETYLASE; MECHANISMS; COMPONENT; SUBUNITS
AB Methylation of lysine 4 (K4) within histone H3 has been linked to active transcription and is removed by LSD1 and the JmjC domain-containing proteins by amino-oxidation or hydroxylation, respectively. Here, we describe the deamination catalyzed by Lysyl oxidase-like 2 protein (LOXL2) as an unconventional chemical mechanism for H3K4 modification. Infrared spectroscopy and mass spectrometry analyses demonstrated that recombinant LOXL2 specifically deaminates trimethylated H3K4. Moreover, LOXL2 activity is linked with the transcriptional control of CDH1 gene by regulating H3K4me3 deamination. These results reveal another H3 modification and provide a different mechanism for H3K4 modification.
C1 [Herranz, Nicolas; Dave, Natalia; Millanes-Romero, Alba; Diaz, Victor M.; Gutierrez-Gallego, Ricardo; Garcia de Herreros, Antonio; Peiro, Sandra] IMIM Hosp Mar, Programa Recerca Canc, Barcelona 08003, Spain.
   [Herranz, Nicolas; Millanes-Romero, Alba; Diaz, Victor M.; Gutierrez-Gallego, Ricardo; Garcia de Herreros, Antonio] Univ Pompeu Fabra, Dept Ciencies Expt & Salut, Barcelona 08003, Spain.
   [Jeronimo, Celia; Di Croce, Luciano] Ctr Regulacio Genom, Barcelona 08003, Spain.
   [Lorenz-Fonfria, Victor] Univ Autonoma Barcelona, Dept Bioquim & Biol Mol, Unitat Biofis, Barcelona 08003, Spain.
   [Di Croce, Luciano] ICREA, Barcelona 08003, Spain.
RP Peiro, S (reprint author), IMIM Hosp Mar, Programa Recerca Canc, Barcelona 08003, Spain.
EM speiro@imim.es
RI Lorenz Fonfria, Victor/B-3754-2018; Diaz, Victor Manuel/F-5013-2016; Di
   Croce, Luciano/E-7759-2015; Garcia de Herreros, A/H-3104-2014
OI Lorenz Fonfria, Victor/0000-0002-8859-8347; Diaz, Victor
   Manuel/0000-0001-8561-7576; Di Croce, Luciano/0000-0003-3488-6228;
   Garcia de Herreros, A/0000-0001-5270-0808; Gutierrez Gallego,
   Ricardo/0000-0001-9639-2181
FU FIS [PS09/00258, CP08/00223]; MEC [SAF2006-00339, SAF2010-16089];
   Fundacion Cientifica de la Asociacion Espanola contra el Cancer (AECC);
   Instituto Carlos III [RD06/0020/0040]; Generalitat de Catalunya
   [2009SGR867]; AECC; EMBO; CIHR; ICREA
FX We are grateful to A. Riquel and R. Pena for technical assistance, and
   to R. Vinas-Castells for helpful comments. We greatly thank L. Espinosa
   for the H3 construct. We also thank E. Dunach (Universite de Nice) for
   advice on the reaction mechanism, E. Padros and the Unitat de Biofisica
   (UAB) for support in the infrared experiments, and J. Valle and D.
   Andreu and the UPF Peptide Facility for the synthesis of the peptides.
   This work was supported by FIS (PS09/00258; CP08/00223), MEC
   (SAF2006-00339 and SAF2010-16089), Fundacion Cientifica de la Asociacion
   Espanola contra el Cancer (AECC), Instituto Carlos III/FEDER
   (RD06/0020/0040), and Generalitat de Catalunya (2009SGR867). S.P. was
   recipient of a Miguel Servet contract (FIS); N.H. was supported by a
   predoctoral fellowship from MEC; N.D. was supported by AECC fellowship,
   and C.J. was supported by EMBO and CIHR fellowships.
CR Cloos PAC, 2008, GENE DEV, V22, P1115, DOI 10.1101/gad.1652908
   Gansner JM, 2007, DEV BIOL, V307, P202, DOI 10.1016/j.ydbio.2007.04.029
   Herranz N, 2008, MOL CELL BIOL, V28, P4772, DOI 10.1128/MCB.00323-08
   Jeronimo C, 2007, MOL CELL, V27, P262, DOI 10.1016/j.molcel.2007.06.027
   KAUFMAN PD, 1995, CELL, V81, P1105, DOI 10.1016/S0092-8674(05)80015-7
   Kuzmichev A, 2002, GENE DEV, V16, P2893, DOI 10.1101/gad.1035902
   Li B, 2007, CELL, V128, P707, DOI 10.1016/j.cell.2007.01.015
   Li HT, 2006, NATURE, V442, P91, DOI 10.1038/nature04802
   Lucero HA, 2006, CELL MOL LIFE SCI, V63, P2304, DOI 10.1007/s00018-006-6149-9
   Mosammaparast N, 2010, ANNU REV BIOCHEM, V79, P155, DOI 10.1146/annurev.biochem.78.070907.103946
   Ng SS, 2007, NATURE, V448, P87, DOI 10.1038/nature05971
   Payne SL, 2007, J CELL BIOCHEM, V101, P1338, DOI 10.1002/jcb.21371
   Peinado H, 2005, EMBO J, V24, P3446, DOI 10.1038/sj.emboj.7600781
   Schneider J, 2006, ACS CHEM BIOL, V1, P75, DOI 10.1021/cb600030b
   Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012
   Shilatifard A, 2008, CURR OPIN CELL BIOL, V20, P341, DOI 10.1016/j.ceb.2008.03.019
   Smith E, 2010, MOL CELL, V40, P689, DOI 10.1016/j.molcel.2010.11.031
   Smith-Mungo LI, 1998, MATRIX BIOL, V16, P387, DOI 10.1016/S0945-053X(98)90012-9
   Socrates G., 2001, INFRARED RAMAN CHARA
   Tsukada Y, 2006, NATURE, V439, P811, DOI 10.1038/nature04433
   Verreault A, 1996, CELL, V87, P95, DOI 10.1016/S0092-8674(00)81326-4
   Wang SX, 1996, SCIENCE, V273, P1078, DOI 10.1126/science.273.5278.1078
   Wu M, 2008, MOL CELL BIOL, V28, P7337, DOI 10.1128/MCB.00976-08
   Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924
   Zhang Y, 1998, CELL, V95, P279, DOI 10.1016/S0092-8674(00)81758-4
NR 25
TC 54
Z9 60
U1 6
U2 19
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1097-2765
EI 1097-4164
J9 MOL CELL
JI Mol. Cell
PD MAY 11
PY 2012
VL 46
IS 3
BP 369
EP 376
DI 10.1016/j.molcel.2012.03.002
PG 8
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 942SZ
UT WOS:000304071100014
PM 22483618
OA Bronze
DA 2018-12-27
ER

PT J
AU Jia, P
   Li, YF
   Wang, J
   Zhang, FX
   Liu, K
   Wang, ZH
AF Jia, Peng
   Li, Yanfang
   Wang, Jue
   Zhang, Fengxiao
   Liu, Kun
   Wang, Zhaohui
TI RETRACTED: The effect of alendronate on the expression of osteopontin
   and osteoprotegerin in calcified aortic tissue of the rat (Retracted
   article. See vol. 719, pg. 128, 2013)
SO EUROPEAN JOURNAL OF PHARMACOLOGY
LA English
DT Article; Retracted Publication
DE Alendronate; Osteopontin; Osteoprotegerin; Vascular calcification;
   Osteoporosis
ID SMOOTH-MUSCLE-CELLS; VASCULAR CALCIFICATION; DEFICIENT MICE;
   CLINICAL-IMPLICATIONS; ARTERY CALCIFICATION; BONE LOSS; IN-VITRO;
   MECHANISMS; INACTIVATION; OSTEOPOROSIS
AB Vascular calcification is a pathobiological process which leads to high morbidity and mortality in cardiovascular disease. The association between vascular calcification and osteoporosis has been reported widely, and there are close relationships among vascular calcification, related cardiovascular disease and osteoporosis, but the biochemical mechanism of vascular calcification is presently unclear. For exploring the possible mechanism of artery calcification we established aorta calcification in an animal model with vitamin D-3 and warfarin and tested the effect of alendronate on the expression of osteopontin and osteoprotegerin in calcified aorta tissue of the rat through measuring gene and protein expression of osteopontin and osteoprotegerin respectively. The results indicated compared with control group, the aortic calcium content of calcification group was obviously increased, osteopontin mRNA and osteoprotegerin mRNA were significantly reduced, and osteoprotegerin and osteopontin protein expressions were reduced. Compared with calcification group, the aortic calcium content of alendronate group was obviously reduced, osteopontin mRNA and osteoprotegerin mRNA were significantly increased, and osteopontin and osteoprotegerin protein expression were increased. We conclude that artery calcification may reduce the expression of osteopontin and osteoprotegerin. Alendronate may inhibit rat aorta calcification by up-regulating osteopontin and osteoprotegerin expression. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Jia, Peng; Li, Yanfang; Zhang, Fengxiao; Liu, Kun; Wang, Zhaohui] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Inst Cardiovasc Dis,Dept Cardiol, Wuhan 430074, Peoples R China.
   [Wang, Jue] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Inst Cardiovasc Dis,Dept Hematol, Wuhan 430074, Peoples R China.
RP Liu, K (reprint author), Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Inst Cardiovasc Dis,Dept Cardiol, 1277 Jiefangdadao, Wuhan 430074, Peoples R China.
EM liukun@mail.hust.edu.cn; zhwprof@163.com
FU Key Scientific and Technological Projects in Wuhan China [201051299454]
FX This research was supported by Key Scientific and Technological Projects
   in Wuhan China (no. 201051299454).
CR Ahmed S, 2001, AM J KIDNEY DIS, V37, P1267, DOI 10.1053/ajkd.2001.24533
   Bagger YZ, 2006, J INTERN MED, V259, P598, DOI 10.1111/j.1365-2796.2006.01640.x
   Bennett BJ, 2006, ARTERIOSCL THROM VAS, V26, P2117, DOI 10.1161/01.ATV.0000236428.91125.e6
   Body JJ, 2003, CANCER-AM CANCER SOC, V97, P887, DOI 10.1002/cncr.11138
   Bucay N, 1998, GENE DEV, V12, P1260, DOI 10.1101/gad.12.9.1260
   Collin-Osdoby P, 2004, CIRC RES, V95, P1046, DOI 10.1161/01.RES.0000149165.99974.12
   Cundy T, 2002, HUM MOL GENET, V11, P2119, DOI 10.1093/hmg/11.18.2119
   Davies MR, 2001, KIDNEY INT, V60, P472, DOI 10.1046/j.1523-1755.2001.060002472.x
   Giachelli CM, 2005, CIRC RES, V96, P717, DOI 10.1161/01.RES.0000161997.24797.c0
   Hofbauer LC, 2004, JAMA-J AM MED ASSOC, V292, P490, DOI 10.1001/jama.292.4.490
   Johnson RC, 2006, CIRC RES, V99, P1044, DOI 10.1161/01.RES.0000249379.55535.21
   Jono S, 2000, J BIOL CHEM, V275, P20197, DOI 10.1074/jbc.M909174199
   Kiel DP, 2001, CALCIFIED TISSUE INT, V68, P271, DOI 10.1007/BF02390833
   Lomashvili KA, 2004, J AM SOC NEPHROL, V15, P1392, DOI 10.1097/01.ASN.0000128955.83129.9C
   Min H, 2000, J EXP MED, V192, P463, DOI 10.1084/jem.192.4.463
   Mori K, 1998, FEBS LETT, V433, P19, DOI 10.1016/S0014-5793(98)00870-9
   Price PA, 2001, ARTERIOSCL THROM VAS, V21, P817, DOI 10.1161/01.ATV.21.5.817
   Price PA, 2000, ARTERIOSCL THROM VAS, V20, P317, DOI 10.1161/01.ATV.20.2.317
   Qi YF, 2003, PEPTIDES, V24, P287, DOI 10.1016/S0196-9781(03)00036-6
   Shanahan CM, 1999, CIRCULATION, V100, P2168, DOI 10.1161/01.CIR.100.21.2168
   Shao JS, 2006, ARTERIOSCL THROM VAS, V26, P1423, DOI 10.1161/01.ATV.0000220441.42041.20
   Speer MY, 2002, J EXP MED, V196, P1047, DOI 10.1084/jem.20020911
   Theoleyre S, 2004, CYTOKINE GROWTH F R, V15, P457, DOI 10.1016/j.cytogfr.2004.06.004
   Towler DA, 1998, J BIOL CHEM, V273, P30427, DOI 10.1074/jbc.273.46.30427
   Vattikuti R, 2004, AM J PHYSIOL-ENDOC M, V286, pE686, DOI 10.1152/ajpendo.00552.2003
   Wada T, 1999, CIRC RES, V84, P166, DOI 10.1161/01.RES.84.2.166
   Wu SY, 2003, PEPTIDES, V24, P1149, DOI 10.1016/j.peptides.2003.07.008
NR 27
TC 8
Z9 9
U1 5
U2 18
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0014-2999
EI 1879-0712
J9 EUR J PHARMACOL
JI Eur. J. Pharmacol.
PD MAY 5
PY 2012
VL 682
IS 1-3
BP 126
EP 130
DI 10.1016/j.ejphar.2012.02.023
PG 5
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 928KU
UT WOS:000302982400017
PM 22387856
DA 2018-12-27
ER

PT J
AU Pudukudy, M
   Yaakob, Z
   Narayanan, B
   Ramakrishnan, R
   Viswanathan, S
AF Pudukudy, Manoj
   Yaakob, Zahira
   Narayanan, Binitha
   Ramakrishnan, Resmi
   Viswanathan, Suraja
TI RETRACTED: Hydrogen production from sea water using waste aluminium and
   calcium oxide (Retracted article. See vol. 37, pg. 19268, 2012)
SO INTERNATIONAL JOURNAL OF HYDROGEN ENERGY
LA English
DT Article; Retracted Publication
DE Alternative fuel; Hydrogen; Aluminium; Calcium oxide
ID HYDROLYSIS; METAL; CYCLE
AB There are several reports currently on the hydrogen production from water employing aluminium powders, alloys and waste aluminium materials. However, mostly it is done in the presence of corrosive sodium hydroxide. Present study reports the production of hydrogen from sea water, which is the most dominant source of crude water. Instead of sodium hydroxide, cheap calcium oxide is employed with waste aluminium for the production of hydrogen and it is found that the minerals present in sea water and the use of NaCl as an additive enhances the rate of hydrogen production. It is also observed that change in the reaction conditions has a marked effect on the induction period for H-2 evolution. Additionally, the solid obtained after completion of H-2 production shows good efficiency in water splitting reaction. Copyright (C) 2012, Hydrogen Energy Publications, LLC. Published by Elsevier Ltd. All rights reserved.
C1 [Pudukudy, Manoj; Narayanan, Binitha; Ramakrishnan, Resmi] Sree Neelakanta Govt Sanskrit Coll, Dept Chem, Palakkad 679306, Kerala, India.
   [Pudukudy, Manoj; Yaakob, Zahira; Viswanathan, Suraja] Univ Kebangsaan Malaysia, Dept Chem & Proc Engn, Ukm Bangi 43600, Selangor, Malaysia.
   [Yaakob, Zahira] Univ Kebangsaan Malaysia, Fuel Cell Inst, Ukm Bangi 43600, Selangor, Malaysia.
RP Narayanan, B (reprint author), Sree Neelakanta Govt Sanskrit Coll, Dept Chem, Palakkad 679306, Kerala, India.
EM binithann@yahoo.co.in
OI Pudukudy, Manoj/0000-0003-3370-4752; Narayanan,
   Binitha/0000-0003-4658-3910
FU Universiti Kebangsaan Malaysia [UKM-AP-TK-05-2009]
FX The authors gratefully acknowledge the financial support given for this
   work by the Universiti Kebangsaan Malaysia under the Arus Perdana Grant
   Number of UKM-AP-TK-05-2009. STIC, CUSAT, Kochi, India is acknowledge
   for XRD and FTIR analysis.
CR Cho CY, 2005, MATER TRANS, V46, P2704, DOI 10.2320/matertrans.46.2704
   Christopher TH, 2002, SENSOR ACTUAT B-CHEM, V87, P414
   Granovskii M, 2007, J POWER SOURCES, V167, P461, DOI 10.1016/j.jpowsour.2007.02.031
   Grosjean MH, 2006, J ALLOY COMPD, V416, P296, DOI 10.1016/j.jallcom.2005.09.008
   Grosjean MH, 2006, INT J HYDROGEN ENERG, V31, P109, DOI 10.1016/j.ijhydene.2005.01.001
   Hoffmann P., 2002, TOMORROWS ENERGY HYD
   Kravchenko OV, 2005, J ALLOY COMPD, V397, P58, DOI 10.1016/j.jallcom.2004.11.065
   Lavalley JC, 1996, CATAL TODAY, V27, P377, DOI 10.1016/0920-5861(95)00161-1
   LUTZ HD, 1994, J MOL STRUCT, V328, P121, DOI 10.1016/0022-2860(94)08355-X
   Martinez SS, 2005, SOL ENERG MAT SOL C, V88, P237, DOI 10.1016/j.solmat.2004.09.022
   Rundong L, 2011, INT C COMP DISTR CON
   Sakintuna B, 2007, INT J HYDROGEN ENERG, V32, P1121, DOI 10.1016/j.ijhydene.2006.11.022
   Soler L, 2006, INT J HYDROGEN ENERG, V31, P129, DOI 10.1016/j.ijhydene.2004.11.001
   Uan JY, 2007, INT J HYDROGEN ENERG, V32, P2337, DOI 10.1016/j.ijhydene.2007.03.014
   Vishnevetsky I, 2007, INT J HYDROGEN ENERG, V32, P2791, DOI [10.1016/j.ijhydene.2007.04.004, 10.1016/j.ijhydeile.2007.04.004]
   Visser T., 2003, VIBRATIONAL SPECTR, V33, P223
   Wegner K, 2006, INT J HYDROGEN ENERG, V31, P55, DOI 10.1016/j.ijhydene.2005.03.006
NR 17
TC 10
Z9 10
U1 2
U2 34
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0360-3199
J9 INT J HYDROGEN ENERG
JI Int. J. Hydrog. Energy
PD MAY
PY 2012
VL 37
IS 9
BP 7451
EP 7456
DI 10.1016/j.ijhydene.2012.01.106
PG 6
WC Chemistry, Physical; Electrochemistry; Energy & Fuels
SC Chemistry; Electrochemistry; Energy & Fuels
GA 955SC
UT WOS:000305040200014
DA 2018-12-27
ER

PT J
AU Das, DK
   Rahman, A
AF Das, D. K.
   Rahman, A.
TI RETRACTED: Expression of a rice chitinase gene enhances antifungal
   response in transgenic litchi (cv. Bedana)(Retracted article. See
   vol.128,pg.247,2017)
SO PLANT CELL TISSUE AND ORGAN CULTURE
LA English
DT Article; Retracted Publication
DE Agrobacterium tumefaciens; Blight; Die back and leaf spots; Phomopsis
   sp.; Somatic embryogenesis; Transformation
ID TUMEFACIENS-MEDIATED TRANSFORMATION; POLYACRYLAMIDE-GEL ELECTROPHORESIS;
   SOMATIC EMBRYOGENESIS; CONSTITUTIVE EXPRESSION; RHIZOCTONIA-SOLANI;
   PLANT-REGENERATION; FUNGAL PATHOGENS; RESISTANCE; PROTOPLASTS; L.
AB To enhance the antifungal response of litchi (Litchi chinensis Sonn.), transgenic plants were generated by transferring rice chitinase gene driven by a maizeubiquitin promoter along with its first intron into the zygotic embryos via Agrobacterium tumefaciens-mediated transformation. After co-cultivation for 2 days, zygotic embryos were transferred onto Murashige and Skoog (MS) modified media supplemented with 25 mgl(-1) hygromycin and 400 mgl(-1) cefotaxime. Consequently embryos were selected and the antibiotic resistant transgenic plantlets were regenerated. The culture time from zygotic embryo to transgenic plants was 14 months. The integration of the transgene was confirmed by PCR, RT-PCR, Southern and western blot analyses. The transgenic plants exhibited higher chitinase activity than the non-transformed plants. The chitinase activity when examined using the native polyacrylamide in-gel assay, indicated that the foreign gene expression resulting in the protein of expected molecular weight that showed chitinase activity. The transgenic plants showed delayed onset of the disease and smaller lesions following in vitro inoculation of die-back, leaf spots and blight pathogen (Phomopsis sp.). The transgenic plants were adapted to the greenhouse and did not show any phenotypic alterations.
C1 [Das, D. K.; Rahman, A.] TM Bhagalpur Univ, Post Grad Dept Biotechnol, Bhagalpur 812007, India.
RP Das, DK (reprint author), TM Bhagalpur Univ, Post Grad Dept Biotechnol, Bhagalpur 812007, India.
EM dilipdas1@live.com
FU University Grants Commission, Govt. of India, New Delhi
FX Authors are grateful to the University Grants Commission, Govt. of
   India, New Delhi for providing financial assistance. We are highly
   thankful to Dr. M. V. Razam, Department of Genetics, South Campus,
   University of Delhi, New Delhi, India, for providing rice chitinase 11
   cDNA and antibody, Mr. S. C. B. Sharma, Advanced Instrumentation
   Research Facility, JNU, New Delhi for providing Electron micrography and
   Dr. Shiva Prakash, Senior Scientist, Monsanto company, Bangalore, India
   for manuscript updating.
CR ASAO H, 1997, PLANT BIOTECHNOL-NAR, V14, P145
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   BROGLIE K, 1991, SCIENCE, V254, P1194, DOI 10.1126/science.254.5035.1194
   Chen A, 2010, PLANT CELL TISS ORG, V100, P49
   Chen WP, 1998, THEOR APPL GENET, V97, P1296, DOI 10.1007/s001220051022
   Chhikara S, 2012, PLANT CELL TISS ORG, V108, P83, DOI 10.1007/s11240-011-0015-7
   Das DK, 2002, PLANT CELL REP, V20, P999, DOI 10.1007/s00299-002-0441-4
   Das DK, 2010, CURR TRENDS BIOTENOL, V41, P820
   Das DK, 1996, IN VITRO CELL DEV, V32, p63A
   Emani C, 2003, PLANT BIOTECHNOL J, V1, P321, DOI 10.1046/j.1467-7652.2003.00029.x
   FREARSON EM, 1973, DEV BIOL, V33, P130, DOI 10.1016/0012-1606(73)90169-3
   Fu L. F., 1983, Acta Genetica Sinica, V10, P369
   GAMBORG OL, 1968, EXP CELL RES, V50, P151, DOI 10.1016/0014-4827(68)90403-5
   Girhepuje PV, 2011, PLANT CELL TISS ORG, V105, P243, DOI 10.1007/s11240-010-9859-5
   HAHLBROCK K, 1989, ANNU REV PLANT PHYS, V40, P347, DOI 10.1146/annurev.pp.40.060189.002023
   He XL, 2008, PLANT CELL REP, V27, P903, DOI 10.1007/s00299-008-0519-8
   Hoagland DR, 1950, CALIF AGR EXP STN B
   Jayaraj J, 2007, PLANT CELL REP, V26, P1539, DOI 10.1007/s00299-007-0368-x
   Jayraj J, 2004, FUNGAL DIS RESISTANC, P139
   Jonathan HC, 1997, P FLA STATE HORT SOC, V110, P149
   KAO KN, 1975, PLANTA, V126, P105, DOI 10.1007/BF00380613
   Konieczny R, 2009, PLANT CELL TISS ORG, V11, P36
   Kumar SM, 2004, PLANT BREEDING, V123, P485, DOI 10.1111/j.1439-0523.2004.01028.x
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   LAGRIMINI LM, 1991, PLANT PHYSIOL, V96, P577, DOI 10.1104/pp.96.2.577
   LEGRAND M, 1987, P NATL ACAD SCI USA, V84, P6750, DOI 10.1073/pnas.84.19.6750
   Li MR, 2010, PLANT CELL TISS ORG, V102, P321, DOI 10.1007/s11240-010-9736-2
   LIN W, 1995, BIO-TECHNOL, V13, P686, DOI 10.1038/nbt0795-686
   Lloyd G, 1981, COMB P INT PLANT PRO, V30, P421
   Lodhi M. A., 1994, Plant Molecular Biology Reporter, V12, P6, DOI 10.1007/BF02668658
   Manju Y, 2010, PLANT CELL TISS ORG, V103, P377
   Menzel CM, 2005, LITCHI AND LONGAN: BOTANY, PRODUCTION AND USES, P59, DOI 10.1079/9780851996967.0059
   MILLER GL, 1959, ANAL CHEM, V31, P426, DOI 10.1021/ac60147a030
   Morton J., 1987, FRUITS WARM CLIMATES, P249
   MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x
   Nishizawa Y, 1999, THEOR APPL GENET, V99, P383, DOI 10.1007/s001220051248
   NISHIZAWA Y, 1991, PLANT SCI, V76, P211, DOI 10.1016/0168-9452(91)90143-V
   Pena-Ramirez YJ, 2011, PLANT CELL TISS ORG, V105, P203, DOI 10.1007/s11240-010-9853-y
   Puchooa D., 2004, Journal of Applied Horticulture (Lucknow), V6, P11
   Punja ZK, 2006, CAN J PLANT PATHOL, V28, pS298, DOI 10.1080/07060660609507387
   Rangan P, 2010, PLANT CELL TISS ORG, V16, P1
   Rolle RS, 2004, APO SEM RED POSTH LO
   SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0
   Sridevi G, 2003, J PLANT BIOCHEM BIOT, V12, P93, DOI 10.1007/BF03263168
   Stehpan JW, 1990, J MICROBIAL METHODS, V12, P197
   Tanveer K, 2010, PLANT CELL TISS ORG, V101, P323
   Thiago S, 2009, PLANT CELL TISS ORG, V99, P281
   TRUDEL J, 1989, ANAL BIOCHEM, V178, P362, DOI 10.1016/0003-2697(89)90653-2
   TRUDEL J, 1990, ANAL BIOCHEM, V189, P249, DOI 10.1016/0003-2697(90)90116-Q
   Yamamoto T, 2000, PLANT CELL REP, V19, P639, DOI 10.1007/s002999900174
   Yu CH, 2000, PLANT CELL TISS ORG, V61, P51, DOI 10.1023/A:1006446506041
   Zhou LN, 1993, GUANGDONG AGR SCI, V5, P14
NR 52
TC 8
Z9 9
U1 3
U2 27
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0167-6857
EI 1573-5044
J9 PLANT CELL TISS ORG
JI Plant Cell Tissue Organ Cult.
PD MAY
PY 2012
VL 109
IS 2
BP 315
EP 325
DI 10.1007/s11240-011-0097-2
PG 11
WC Biotechnology & Applied Microbiology; Plant Sciences
SC Biotechnology & Applied Microbiology; Plant Sciences
GA 950QD
UT WOS:000304662900012
DA 2018-12-27
ER

PT J
AU Kriz, J
   Eich, HT
   Mucke, R
   Buntzel, J
   Muller, RP
   Bruns, F
   Seegenschmiedt, MH
   Gosheger, G
   Micke, O
AF Kriz, Jan
   Eich, Hans Theodor
   Muecke, Ralph
   Buentzel, Jens
   Mueller, Rolf-Peter
   Bruns, Frank
   Seegenschmiedt, M. Heinrich
   Gosheger, Georg
   Micke, Oliver
TI RETRACTED: Radiotherapy for Giant Cell Tumors of the Bone: A Safe and
   Effective Treatment Modality (Retracted article. See vol. 32, pg. 3593,
   2012)
SO ANTICANCER RESEARCH
LA English
DT Article; Retracted Publication
DE Rare neoplasm; radiation therapy; giant cell tumor of the bone; benign
   disorders
ID MANAGEMENT
AB Background: Giant cell tumor of the bone (GCTB) is a benign or sometimes semi-malignant neoplasm accounting for 5% of all primary bone tumors. This type of tumor has been historically considered as radioresistant, but nowadays radiotherapy (RT) is used in unresectable, recurrent or incompletely resected cases. Since the value of RT is not well defined, a national cohort study was conducted. Patients and Methods: Six German institutions collected data from 35 patients treated during the last 35 years and analyzed them. Results: From 1975-2010 16 male and 19 female patients with 39 lesions were irradiated for GCTB. The median age was 30 years and the median follow-up 65 months. Nineteen patients had undergone RT for recurrent or unresectable disease and 16 patients for non-in-sano resection. The actuarial 5-year overall and disease-free survival rates were 90% and 59%, respectively. Conclusion: RT is an easy, safe and effective method for the treatment of GCTB. It may provide an attractive alternative to mutilating surgery.
C1 [Micke, Oliver] Franziskus Hosp, Klin Strahlentherapie & Radioonkol, Dept Radiotherapy & Radiat Oncol, D-33615 Bielefeld, Germany.
   [Kriz, Jan; Mueller, Rolf-Peter] Univ Cologne, Dept Radiat Oncol, D-50931 Cologne, Germany.
   [Kriz, Jan; Eich, Hans Theodor] Univ Hosp Muenster, Dept Radiat Oncol, Munster, Germany.
   [Muecke, Ralph] Lippe Hosp, Dept Radiotherapy, Lemgo, Germany.
   [Buentzel, Jens] Sudharz Hosp, Dept Otolaryngol, Nordhausen, Germany.
   [Bruns, Frank] Hannover Med Sch, Dept Radiotherapy & Special Oncol, D-3000 Hannover, Germany.
   [Seegenschmiedt, M. Heinrich] Ctr Radiat Oncol, Hamburg, Germany.
   [Gosheger, Georg] Univ Hosp Muenster, Dept Orthoped, Munster, Germany.
RP Micke, O (reprint author), Franziskus Hosp, Klin Strahlentherapie & Radioonkol, Dept Radiotherapy & Radiat Oncol, Kiskerstr 26, D-33615 Bielefeld, Germany.
EM strahlenklinik@web.de
CR BINI SA, 1995, CLIN ORTHOP RELAT R, V321, P245
   CAMPANACCI M, 1987, J BONE JOINT SURG AM, V69A, P106, DOI 10.2106/00004623-198769010-00018
   Caudell JJ, 2003, INT J RADIAT ONCOL, V57, P158, DOI 10.1016/S0360-3016(03)00416-4
   Chakravarti A, 1999, J BONE JOINT SURG AM, V81A, P1566, DOI 10.2106/00004623-199911000-00008
   Cooper A, 1818, SURG ESSAYS
   DAHLIN DC, 1970, CANCER, V25, P1061, DOI 10.1002/1097-0142(197005)25:5<1061::AID-CNCR2820250509>3.0.CO;2-E
   Feigenberg SJ, 2003, CLIN ORTHOP RELAT R, P207, DOI 10.1097/01.blo.0000069890.31220.b4
   GOLDENBERG RR, 1970, J BONE JOINT SURG AM, VA 52, P619, DOI 10.2106/00004623-197052040-00001
   Jaffe HL, 1940, ARCH PATHOL, V30, P993
   Macrove RC, 1978, CANCER, V41, P957
   Malawer MM, 1999, CLIN ORTHOP RELAT R, P176
   MANKIN HJ, 1982, CANCER-AM CANCER SOC, V50, P613, DOI 10.1002/1097-0142(19820815)50:4<613::AID-CNCR2820500402>3.0.CO;2-L
   Mc Donald DJ, 1986, J BONE JOINT SURG AM, V46, P63
   Mendenhall WM, 2006, AM J CLIN ONCOL-CANC, V29, P96, DOI 10.1097/01.coc.0000195089.11620.b7
   Oritz-Cruz EJ, 1993, CLIN ORTHOP RELAT R, V291, P215
   Roeder F, 2010, RADIAT ONCOL, V5, DOI 10.1186/1748-717X-5-18
   Ruka W, 2003, INT J RADIAT ONCOL, V78, P494
   Suit H, 1999, SEMIN RADIAT ONCOL, V9, P171, DOI 10.1016/S1053-4296(99)80007-1
   TURCOTTE RE, 1993, CLIN ORTHOP RELAT R, P215
   TURCOTTE RE, 2002, CLIN ORTHOP RELAT R, V397, P248
   Ward WG, 2002, CLIN ORTHOP RELAT R, P259
NR 21
TC 5
Z9 6
U1 0
U2 9
PU INT INST ANTICANCER RESEARCH
PI ATHENS
PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22,
   ATHENS 19014, GREECE
SN 0250-7005
EI 1791-7530
J9 ANTICANCER RES
JI Anticancer Res.
PD MAY
PY 2012
VL 32
IS 5
BP 2069
EP 2073
PG 5
WC Oncology
SC Oncology
GA 947LQ
UT WOS:000304431900236
PM 22593490
DA 2018-12-27
ER

PT J
AU Batista, RD
   Rosetti, EP
   Zandonade, E
   Roelke, LH
   Vettore, MV
   Oliveira, AE
AF Batista, Rafaela das Merces
   Rosetti, Elizabeth Pimentel
   Zandonade, Eliana
   Roelke, Leonard Hermann
   Vettore, Mario Vianna
   Oliveira, Adauto Emmerich
TI RETRACTED: Association between periodontal disease and subclinical
   atherosclerosis: the ELSA-Brasil study (Retracted article. See vol. 28,
   pg. 1613, 2012)
SO CADERNOS DE SAUDE PUBLICA
LA English
DT Article; Retracted Publication
DE Atherosclerosis; Carotid Artery Diseases; Periodontics
ID INTIMA-MEDIA THICKNESS; LOW-BIRTH-WEIGHT; CORONARY-HEART-DISEASE;
   CHRONIC KIDNEY-DISEASE; CARDIOVASCULAR-DISEASE; VASCULAR-DISEASE;
   CAROTID-ARTERY; ORAL INFECTIONS; RISK; EXPOSURE
AB The aim of this study was to investigate the relationship between periodontal disease and increased thickness of the carotid artery intimamedia complex. A cross-sectional study was conducted with 220 adults (age >= 35 years) among participants in the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). Carotid artery ultrasound and periodontal clinical examinations were conducted and included visible plaque index, gingival bleeding on probing index, probing pocket depth (PPD), and clinical attachment level (CAL). Individuals with increased carotid artery thickness showed fewer teeth and higher frequency of CAL >= 3mm, CAL >= 4mm, CAL >= 5mm, and CAL >= 6mm and PPD >= 4mm (p < 0.05). Despite the use of 18 definitions for periodontal disease, only one confirmed the hypothesis of an association between periodontal disease and subclinical atherosclerosis. Individuals with 10% or more sites with CAL >= 4mm were more likely to present carotid thickening.
C1 [Batista, Rafaela das Merces; Rosetti, Elizabeth Pimentel; Roelke, Leonard Hermann; Oliveira, Adauto Emmerich] Univ Fed Espirito Santo, Ctr Ciencias Saude, Vitoria, Brazil.
   [Zandonade, Eliana] Ctr Univ Vila Velha, Vila Velha, Brazil.
   [Vettore, Mario Vianna] Univ Fed Rio de Janeiro, Inst Estudos Saude Colet, Rio De Janeiro, Brazil.
RP Batista, RD (reprint author), Univ Fed Espirito Santo, Programa Posgrad Saude Colet, Ctr Ciencias Saude, Av Resplendor 563,Sala 305, BR-29101500 Vila Velha, ES, Brazil.
EM rafinhambatista@hotmail.com
CR AINAMO J, 1975, INT DENT J, V25, P229
   Beck JD, 2005, CIRCULATION, V112, P19, DOI 10.1161/CIRCULATIONAHA.104.511998
   Beck JD, 2001, ARTERIOSCL THROM VAS, V21, P1816, DOI 10.1161/hq1101.097803
   Burt Brian, 2005, J Periodontol, V76, P1406
   Cairo F, 2008, J CLIN PERIODONTOL, V35, P465, DOI 10.1111/j.1600-051X.2008.01228.x
   Demmer RT, 2008, COMMUNITY DENT ORAL, V36, P493, DOI 10.1111/j.1600-0528.2008.00435.x
   Departamento de Analise de Situacao em Saude Secretaria de Vigilancia em Saude Ministerio da Saude, 2007, EST INF SAUD G
   Desvarieux M, 2005, CIRCULATION, V111, P576, DOI 10.1161/01.CIR.0000154582.37101.15
   Desvarieux M, 2003, STROKE, V34, P2120, DOI 10.1161/01.STR.0000085086.50957.22
   Fisher MA, 2010, CURR OPIN NEPHROL HY, V19, P519, DOI 10.1097/MNH.0b013e32833eda38
   Franek E, 2006, J NEPHROL, V19, P346
   Geerts SO, 2004, J PERIODONTOL, V75, P1274, DOI 10.1902/jop.2004.75.9.1274
   Genctoy G, 2007, INT J CLIN PRACT, V61, P577, DOI 10.1111/j.1742-1241.2007.01283.x
   Greenland P, 2003, JAMA-J AM MED ASSOC, V290, P891, DOI 10.1001/jama.290.7.891
   Lopez NJ, 2002, J PERIODONTOL, V73, P911, DOI 10.1902/jop.2002.73.8.911
   Lotufo RFM, 2005, GLOSSARIO SOC BRASIL
   Lunardelli AN, 2005, J CLIN PERIODONTOL, V32, P938, DOI 10.1111/j.1600-051X.2005.00759.x
   Marin C, 2005, J CLIN PERIODONTOL, V32, P299, DOI 10.1111/j.1600-051X.2005.00661.x
   Ministerio da Saude, 2008, OR COL AN DAD ANTR S
   Mochari H, 2008, AM J CARDIOL, V102, P1509, DOI 10.1016/j.amjcard.2008.07.047
   Moliterno LFM, 2005, J CLIN PERIODONTOL, V32, P886, DOI 10.1111/j.1600-051X.2005.00781.x
   Moore S, 2004, BRIT DENT J, V197, P251, DOI 10.1038/sj.bdj.4811620
   Mustapha IZ, 2007, J PERIODONTOL, V78, P2289, DOI 10.1902/jop.2007.070140
   Offenbacher S, 2001, Ann Periodontol, V6, P164, DOI 10.1902/annals.2001.6.1.164
   Offenbacher S, 1996, J PERIODONTOL, V67, P1103, DOI 10.1902/jop.1996.67.10s.1103
   Piconi S, 2009, FASEB J, V23, P1196, DOI 10.1096/fj.08-119578
   Radnai M, 2004, J CLIN PERIODONTOL, V31, P736, DOI 10.1111/j.1600-051X.2004.00564.x
   Rajapakse PS, 2005, J DENT RES, V84, P274, DOI 10.1177/154405910508400313
   Scannapieco Frank A, 2003, Ann Periodontol, V8, P38, DOI 10.1902/annals.2003.8.1.38
   Soder PO, 2009, J PERIODONTAL RES, V44, P452, DOI 10.1111/j.1600-0765.2008.01145.x
   Stein JH, 2008, J AM SOC ECHOCARDIOG, V21, P93, DOI 10.1016/j.echo.2007.11.011
   Tzorbatzoglou ID, 2010, INT ANGIOL, V29, P27
   Van Dyke TE, 2008, J PERIODONTOL, V79, P1501, DOI 10.1902/jop.2008.080279
   Xiang XM, 2010, J PERIODONTOL, V81, P186, DOI 10.1902/jop.2009.090419
NR 34
TC 2
Z9 2
U1 2
U2 13
PU CADERNOS SAUDE PUBLICA
PI RIO DE JANIERO
PA RUA LEOPOLDO BUHOES 1480, RIO DE JANIERO, RJ 210410210, BRAZIL
SN 0102-311X
EI 1678-4464
J9 CAD SAUDE PUBLICA
JI Cad. Saude Publica
PD MAY
PY 2012
VL 28
IS 5
BP 965
EP 976
PG 12
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 948ZY
UT WOS:000304545300015
PM 22641519
OA DOAJ Gold
DA 2018-12-27
ER

PT J
AU Heidari, A
   Vedad, S
   Heidari, N
   Ghorbani, M
AF Heidari, Alireza
   Vedad, Seyedali
   Heidari, Niloofar
   Ghorbani, Mohammadali
TI RETRACTED: Flux Dynamics in Y358 Superconductors (Retracted article. See
   vol. 5, pg. 2816, 2012)
SO MATERIALS
LA English
DT Article; Retracted Publication
DE high-T-c superconductor; thermally activated flux motion; transition
   temperature
ID HIGH-TEMPERATURE SUPERCONDUCTORS; RESISTIVE TRANSITION
AB Thermally activated flux motion and specific electric resistance in Y358 were studied under different magnetic fields ranging from 0 to 15 kOe. Through investigating the broadening of normal-superconducting transition, we found that the thermally-activated-flux-motion model can describe the electronic effect near the superconducting transition temperature. By modifying this model, specific electric resistance at different magnetic fields was calculated.
C1 [Heidari, Alireza; Vedad, Seyedali; Heidari, Niloofar; Ghorbani, Mohammadali] Inst Adv Studies, Tehran 1445663543, Iran.
RP Ghorbani, M (reprint author), Inst Adv Studies, Tehran 1445663543, Iran.
EM prof.alireza.heidari@instituteforadvancedstudies.us;
   seyedali.vedad@yahoo.com; heidarinilufar@yahoo.com;
   mohammadalighorbani1983@yahoo.com
FU Institute for Advanced Studies of Iran
FX The work described in this paper was fully supported by grants from the
   Institute for Advanced Studies of Iran. The authors would like to
   express genuine and sincere thanks and appreciation and their gratitude
   to the Institute for Advanced Studies of Iran.
CR Aliabadi A, 2009, PHYSICA C, V469, P2012, DOI 10.1016/j.physc.2009.09.003
   AMBEGAOKAR V, 1969, PHYS REV LETT, V22, P1364, DOI 10.1103/PhysRevLett.22.1364
   BORDET P, 1988, NATURE, V334, P596, DOI 10.1038/334596a0
   DEUTSCHER G, 1987, PHYS REV LETT, V59, P1745, DOI 10.1103/PhysRevLett.59.1745
   Ekicibil A, 2011, SOLID STATE SCI, V13, P1954, DOI 10.1016/j.solidstatesciences.2011.08.024
   GAMCHI HS, 1994, PHYS REV B, V50, P12950, DOI 10.1103/PhysRevB.50.12950
   GROSS R, 1990, PHYS REV LETT, V64, P228, DOI 10.1103/PhysRevLett.64.228
   MARSH P, 1988, NATURE, V334, P141, DOI 10.1038/334141a0
   PALSTRA TTM, 1991, PHYS REV B, V43, P3756, DOI 10.1103/PhysRevB.43.3756
   Pradhan AK, 2001, PHYS REV B, V64, DOI 10.1103/PhysRevLett.87.212509
   Sujinnapram S., 2001, B MATER SCI, V34, P1053
   TINKHAM M, 1988, PHYS REV LETT, V61, P1658, DOI 10.1103/PhysRevLett.61.1658
   Topal U, 2011, J SUPERCOND NOV MAGN, V24, P2099, DOI 10.1007/s10948-011-1176-7
   Topal U, 2011, J SUPERCOND NOV MAGN, V24, P1815, DOI 10.1007/s10948-011-1129-1
   Udomsamuthirun P, 2010, J SUPERCOND NOV MAGN, V23, P1377, DOI 10.1007/s10948-010-0786-9
   WU MK, 1987, PHYS REV LETT, V58, P908, DOI 10.1103/PhysRevLett.58.908
NR 16
TC 2
Z9 2
U1 2
U2 16
PU MDPI AG
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 1996-1944
J9 MATERIALS
JI Materials
PD MAY
PY 2012
VL 5
IS 5
BP 882
EP 888
DI 10.3390/ma5050882
PG 7
WC Materials Science, Multidisciplinary
SC Materials Science
GA 947UP
UT WOS:000304457700009
PM 28817014
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Kim, H
   Kim, DH
   Park, SB
   Ko, YG
   Kim, SW
   Do, YJ
   Park, JH
   Yang, BS
AF Kim, Hyun
   Kim, Dong Hun
   Park, Soo Bong
   Ko, Yeoung-Gyu
   Kim, Sung-woo
   Do, Yoon Jun
   Park, Jae-Hong
   Yang, Boh-Suk
TI RETRACTED: Induction of Ski Protein Expression upon Luteinization in Rat
   Granulosa Cells (Retracted article. See vol. 29, pg. 157, 2016)
SO ASIAN-AUSTRALASIAN JOURNAL OF ANIMAL SCIENCES
LA English
DT Article; Retracted Publication
DE Arkadia; Granulosa Cells; Luteinization; Ski
ID MACROPHAGES ENHANCE PROLACTIN; OVARIAN-FOLLICLE DEVELOPMENT;
   CORPUS-LUTEUM; C-SKI; TGF-BETA; CELLULAR COMPOSITION; PREGNANT RAT;
   IN-VITRO; GROWTH; DIFFERENTIATION
AB Ski protein is implicated in proliferation/differentiation in a variety of cells. We had previously reported that Ski protein is present in granulosa cells of atretic follicles, but not in preovulatory follicles, suggesting that Ski has a role in apoptosis of granulosa cells. The alternative fate of granulosa cells other than apoptosis is to differentiate to luteal cells; however, it is unknown whether Ski is expressed and has a role in granulosa cells undergoing luteinization. Thus, the aim of the present study was to locate Ski protein in the rat ovary during luteinizationto predict the possible role of Ski. In order to examine the expression pattern of Ski protein along with the progress of luteinization, follicular growth was induced by administration of equine chorionic gonadtropin to immature female rats, and luteinization was induced by human chorionic gonadtropin treatment to mimic luteinizing hormone (LH) surge. While no Ski-positive granulosa cells were present in preovulatory follicle, Ski protein expression was induced in response to LH surge, and was maintained after the formation of the corpus luteum (CL). Though Ski protein is absent in granulosa cells of preovulatory follicle, its rriRNA (c-Ski) was expressed and the level was unchanged even after LH surge. Taken together, these results demonstrated that Ski protein expression is induced in granulosa cells upon luteinization, and suggests that its expression is regulated post-transcriptionally.
C1 [Kim, Hyun] Univ Tokyo, Grad Sch Agr & Life Sci, Dept Vet Physiol, Bunkyo Ku, Tokyo 1138657, Japan.
   [Kim, Hyun; Kim, Dong Hun; Park, Soo Bong; Ko, Yeoung-Gyu; Kim, Sung-woo; Do, Yoon Jun; Park, Jae-Hong] RDA, Natl Inst Anim Sci, Anim Genet Resources Stn, Namwon 590832, South Korea.
   [Yang, Boh-Suk] RDA, Natl Inst Anim Sci, Korean Native Cattle Expt Stn, Pyeongchang 232952, South Korea.
RP Kim, H (reprint author), Univ Tokyo, Grad Sch Agr & Life Sci, Dept Vet Physiol, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1138657, Japan.
EM kimhyun7268@yahoo.co.kr
FU National Institute of Animal Science, Rural Development Adminstration,
   Republic of Korean [PJ008240022012]
FX This work was supported by 2011 PostDoctoral Fellowship Program
   (PJ008240022012) of National Institute of Animal Science, Rural
   Development Adminstration, Republic of Korean.
CR AMBROSE MR, 1995, DNA CELL BIOL, V14, P701, DOI 10.1089/dna.1995.14.701
   Bell E. T., 1968, J EXP PHYSL COGN MED, V53, P129
   BRANNSTROM M, 1994, BIOL REPROD, V50, P1161, DOI 10.1095/biolreprod50.5.1161
   Drummond AE, 2002, ENDOCRINOLOGY, V143, P1423, DOI 10.1210/en.143.4.1423
   Ebisawa T, 2001, J BIOL CHEM, V276, P12477, DOI 10.1074/jbc.C100008200
   ENDERS AC, 1962, J CELL BIOL, V12, P101, DOI 10.1083/jcb.12.1.101
   Episkopou V, 2001, NATURE, V410, P825, DOI 10.1038/35071095
   Erickson Gregory F, 2003, Reprod Biol Endocrinol, V1, P9, DOI 10.1186/1477-7827-1-9
   Espey LL, 2002, BIOL REPROD, V67, P1662, DOI 10.1095/biolreprod.102.005173
   GRIMES HL, 1993, ONCOGENE, V8, P2863
   Hanyu A, 2001, J CELL BIOL, V155, P1017, DOI 10.1083/jcb.200106023
   Juengel JL, 2005, HUM REPROD UPDATE, V11, P144, DOI 10.1093/humupd/dmh061
   Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9
   Kim H, 2006, J REPROD DEVELOP, V52, P715, DOI 10.1262/jrd.18051
   Knight PG, 2006, REPRODUCTION, V132, P191, DOI 10.1530/rep.1.01074
   LI Y, 1986, J VIROL, V57, P1065
   Liu XD, 2001, CYTOKINE GROWTH F R, V12, P1, DOI 10.1016/S1359-6101(00)00031-9
   Luo KX, 2004, CURR OPIN GENET DEV, V14, P65, DOI 10.1016/j.gde.2003.11.003
   Luo KX, 2003, J BONE JOINT SURG AM, V85A, P39, DOI 10.2106/00004623-200300003-00008
   MATSUYAMA S, 1992, ENDOCRINOL JAPON, V39, P51
   MATSUYAMA S, 1995, ENDOCR J, V42, P203, DOI 10.1507/endocrj.42.203
   McNatty KP, 2005, REPRODUCTION, V129, P481, DOI 10.1530/rep.1.00517
   MEYER GT, 1980, ANAT REC, V197, P369, DOI 10.1002/ar.1091970311
   Nagano Y, 2007, J BIOL CHEM, V282, P20492, DOI 10.1074/jbc.M701294200
   Nagano Y, 2010, J BIOCHEM, V147, P545, DOI 10.1093/jb/mvp202
   NELSON SE, 1992, ENDOCRINOLOGY, V130, P954, DOI 10.1210/en.130.2.954
   Nilsson EE, 2002, BIOL REPROD, V67, P1018, DOI 10.1095/biolreprod.101.002527
   Nilsson EE, 2003, BIOL REPROD, V69, P1265, DOI 10.1095/biolreprod.103.018671
   NOMURA N, 1989, NUCLEIC ACIDS RES, V17, P5489, DOI 10.1093/nar/17.14.5489
   Nothnick WB, 1996, ENDOCRINOLOGY, V137, P3784, DOI 10.1210/en.137.9.3784
   OSHEA JD, 1989, J REPROD FERTIL, V85, P483
   Pehlivan T, 2001, J ENDOCRINOL, V170, P639, DOI 10.1677/joe.0.1700639
   Richards JS, 2005, BIOL REPROD, V72, P1241, DOI 10.1095/biolreprod.104.038083
   RODGERS RJ, 1984, J ANAT, V138, P757
   ROY SK, 1994, BIOL REPROD, V51, P821, DOI 10.1095/biolreprod51.5.821
   SMITH MF, 1994, J ANIM SCI, V72, P1857, DOI 10.2527/1994.7271857x
   STAVNEZER E, 1989, MOL CELL BIOL, V9, P4038, DOI 10.1128/MCB.9.9.4038
   STAVNEZER E, 1986, J VIROL, V57, P1073
   SUTRAVE P, 1989, MOL CELL BIOL, V9, P4046, DOI 10.1128/MCB.9.9.4046
   Ueki N, 2008, ONCOGENE, V27, P300, DOI 10.1038/sj.onc.1210654
   XIAO S, 1992, ENDOCRINOLOGY, V131, P2365, DOI 10.1210/en.131.5.2365
   XIAO S, 1992, ENDOCRINOLOGY, V131, P1009, DOI 10.1210/en.131.3.1009
   Xu J, 2002, BIOL REPROD, V66, P1571, DOI 10.1095/biolreprod66.6.1571
   YAMANOUCHI K, 1992, BIOL REPROD, V46, P1109, DOI 10.1095/biolreprod46.6.1109
   Zhao J, 2001, BIOL REPROD, V65, P967, DOI 10.1095/biolreprod65.3.967
NR 45
TC 1
Z9 1
U1 2
U2 10
PU ASIAN-AUSTRALASIAN ASSOC ANIMAL PRODUCTION SOC
PI SEOUL
PA ROOM 708 SAMMO SPOREX, 1638-32, SEOWON-DONG, GWANAK-GU, SEOUL 151-730,
   SOUTH KOREA
SN 1011-2367
EI 1976-5517
J9 ASIAN AUSTRAL J ANIM
JI Asian Australas. J. Anim. Sci.
PD MAY
PY 2012
VL 25
IS 5
BP 635
EP 641
DI 10.5713/ajas.2011.11336
PG 7
WC Agriculture, Dairy & Animal Science
SC Agriculture
GA 940PL
UT WOS:000303905400006
PM 25049607
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Palenik, CJ
AF Palenik, Charles John
TI RETRACTED: The effect of long-term disinfection on clinical contact
   surfaces (Retracted article. See vol. 143, pg. 968, 2012)
SO JOURNAL OF THE AMERICAN DENTAL ASSOCIATION
LA English
DT Article; Retracted Publication
DE Disinfection; environmental asepsis; surface cleaning; surface integrity
ID RESISTANT STAPHYLOCOCCUS-AUREUS; CONTAMINATION
AB Background. The author measured the effect long-term disinfection had on common types of dental office environmental surfaces.
   Methods. The author tested nine common dental surfaces and six spray disinfectants, as well as a tap water control. The author used the "spray-wipe-spray" method with paper towels to disinfect the surfaces. Each surface was disinfected 1,920 times, which was an estimate of the number of cleanings per year. After every 100 disinfections, the author conducted blood removal testing of the surface, which monitored residual blood and disinfectant cleaning ability.
   Results. The surface that was most difficult to clean was textured vinyl, followed by smooth vinyl, enameled metal, service line rubber hosing and brushed aluminum. Diluted bleach affected surfaces the most, which resulted in higher blood removal scores.
   Conclusions. When compared with the control, Birex SE had equal or better cleaning scores across time, which might indicate that its use caused little change in the integrity of the surfaces. The results for the other disinfectants varied.
   Clinical Implications. Disinfectants should have good antimicrobial activity and minimal negative impact on the integrity of the surfaces being disinfected. Effective disinfection is highly dependent on efficient cleaning (removal of the bioburden present).
C1 [Palenik, Charles John] Indiana Univ, Sch Dent, Dept Oral Biol, Infect Control Res & Serv, Indianapolis, IN USA.
RP Palenik, CJ (reprint author), 5868 E 71st St, Indianapolis, IN 46220 USA.
EM cpalenik@osap.org
FU Biotrol (Earth City, Mo.)
FX Biotrol (Earth City, Mo.) provided funding for this study that included
   travel to meetings and author compensation.; Biotrol (Earth City, Mo.)
   provided financial support for and the Birex and Opti-Cide<SUP>3</SUP>
   products used in this study.
CR Biotrol, SURF DIS CLEAN
   Kohn William G, 2003, MMWR Recomm Rep, V52, P1
   Dancer SJ, 2008, LANCET INFECT DIS, V8, P101, DOI 10.1016/S1473-3099(07)70241-4
   Ghaznavi-Rad E, 2010, INFECT CONT HOSP EP, V31, P1302, DOI 10.1086/657587
   Klevens RM, 2007, PUBLIC HEALTH REP, V122, P160, DOI 10.1177/003335490712200205
   Miller CH, 2010, INFECT CONTROL MANAG, P171
   Molinari JA, 2004, COMPEND CONTIN ED DE, V25, P36
   Molinari JA, 2004, COMPEND CONTIN ED DE, V25, P32
   Molinari John A, 2004, Compend Contin Educ Dent, V25, P32
   Organization for Safety Asepsis and Prevention, OSAP PROV SURF DIS R
   Palenik Charles John, 2005, Dent Today, V24, P124
   Palmero, STRAIGHT TALK DISINF
   Rutala WA, 2008, GUIDELINE DISINFECTI
   Spaulding EH, 1968, DISINFECTION STERILI, P517
   Stiefel U, 2011, INFECT CONT HOSP EP, V32, P185, DOI 10.1086/657944
   TotalCare, CAVICIDE CAVIWIPES
   Weber DJ, 2010, AM J INFECT CONTROL, V38, pS25, DOI 10.1016/j.ajic.2010.04.196
NR 17
TC 2
Z9 4
U1 2
U2 23
PU AMER DENTAL ASSOC
PI CHICAGO
PA 211 E CHICAGO AVE, CHICAGO, IL 60611 USA
SN 0002-8177
EI 1943-4723
J9 J AM DENT ASSOC
JI J. Am. Dent. Assoc.
PD MAY
PY 2012
VL 143
IS 5
BP 472
EP 477
DI 10.14219/jada.archive.2012.0207
PG 6
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA 944FS
UT WOS:000304185300012
PM 22547718
DA 2018-12-27
ER

PT J
AU Buroni, S
   Pasca, MR
   Ribeiro, ALDL
   Degiacomi, G
   Molteni, E
   Riccardi, G
AF Buroni, Silvia
   Pasca, Maria Rosalia
   Ribeiro, Ana Luisa de Jesus Lopes
   Degiacomi, Giulia
   Molteni, Elisabetta
   Riccardi, Giovanna
TI RETRACTED: Antituberculars which target
   decaprenylphosphoryl-beta-D-ribofuranose 2 '-oxidase DprE1: state of art
   (Retracted article. See vol. 95, pg. 1369, 2012)
SO APPLIED MICROBIOLOGY AND BIOTECHNOLOGY
LA English
DT Review; Retracted Publication
DE Tuberculosis; Mycobacteria; Vaccines; DprE1; Drug target
ID D-RIBOSE 2'-EPIMERASE; MYCOBACTERIUM-TUBERCULOSIS; PUBLISHED LITERATURE;
   LATENT TUBERCULOSIS; D-ARABINOSE; BENZOTHIAZINONES; RESISTANCE; VACCINE;
   METAANALYSIS; PERSISTENCE
AB Multidrug resistance is a major barrier in the battle against tuberculosis and still a leading cause of death worldwide. In order to fight this pathogen, two routes are practicable: vaccination or drug treatment. Vaccination against Mycobacterium tuberculosis with the current vaccine Mycobacterium bovis Bacillus Calmette-Guerin is partially successful, being its efficacy variable. A few new tuberculosis vaccines are now in various phases of clinical trials. The emergence of multidrug-resistant strains of M. tuberculosis gave the impulse to discover new effective antitubercular drugs, a few of which are in clinical development. Here we focus on three different classes of very promising antitubercular drugs recently discovered (benzothiazinones, dinitrobenzamides, and benzoquinoxalines) that share the same cellular target: a subunit of the heteromeric decaprenylphosphoryl-beta-d-ribose 2'-epimerase, encoded by the dprE1 (or Rv3790) gene. This enzyme is involved in the biosynthesis of d-arabinose which is crucial for the synthesis of the mycobacterial cell wall and essential for the pathogen's survival.
C1 [Buroni, Silvia; Pasca, Maria Rosalia; Ribeiro, Ana Luisa de Jesus Lopes; Degiacomi, Giulia; Molteni, Elisabetta; Riccardi, Giovanna] Univ Pavia, Dipartimento Biol & Biotecnol Lazzaro Spallanzani, I-27100 Pavia, Italy.
   [Degiacomi, Giulia] Comenius Univ, Dept Biochem Mlynska Dolina, Bratislava 84215, Slovakia.
RP Riccardi, G (reprint author), Univ Pavia, Dipartimento Biol & Biotecnol Lazzaro Spallanzani, Via Ferrata 9, I-27100 Pavia, Italy.
EM silvia.buroni@unipv.it; mariarosalia.pasca@unipv.it;
   analuisa.dejesuslopesribeiro@unipv.it; degiacomi@fns.uniba.sk;
   elisabetta.molteni@dottorandi.iusspavia.it; giovanna.riccardi@unipv.it
RI riccardi, gabriele/A-9269-2012
OI Buroni, Silvia/0000-0002-6979-2275; PASCA, Maria
   Rosalia/0000-0002-8906-4937
FU European Commission [LSHP-CT 2005-018923, 260872]
FX We thank the European Commission for support (VI Framework, contract no.
   LSHP-CT 2005-018923 and VII Framework, contract no. 260872).
CR Aagaard C, 2011, NAT MED, V17, P189, DOI 10.1038/nm.2285
   Andersen P, 2005, NAT REV MICROBIOL, V3, P656, DOI 10.1038/nrmicro1211
   Andersen P, 2007, TRENDS MOL MED, V13, P175, DOI 10.1016/j.molmed.2007.03.004
   Andersson DI, 2006, CURR OPIN MICROBIOL, V9, P461, DOI 10.1016/j.mib.2006.07.002
   Berry MPR, 2010, NATURE, V466, P973, DOI 10.1038/nature09247
   Callan HE, 2009, CHEM RES TOXICOL, V22, P937, DOI 10.1021/tx900034r
   Carroll P, 2011, APPL ENVIRON MICROB, V77, P5040, DOI 10.1128/AEM.02880-10
   Cegielski JP, 2010, CLIN INFECT DIS, V50, pS195, DOI 10.1086/651491
   Christophe T, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000645
   COLDITZ GA, 1995, PEDIATRICS, V96, P29
   COLDITZ GA, 1994, JAMA-J AM MED ASSOC, V271, P698, DOI 10.1001/jama.271.9.698
   Cole ST, 2011, CURR OPIN MICROBIOL, V14, P570, DOI 10.1016/j.mib.2011.07.022
   Crellin PK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016869
   Dietrich J, 2009, APMIS, V117, P440, DOI 10.1111/j.1600-0463.2009.02458.x
   Roldan M, 2008, FEMS MICROBIOL REV, V32, P474, DOI 10.1111/j.1574-6976.2008.00107.x
   Donald PR, 2007, PAEDIATR RESPIR REV, V8, P134, DOI 10.1016/j.prrv.2007.04.001
   Dye C, 2006, LANCET, V367, P938, DOI 10.1016/S0140-6736(06)68384-0
   Dye C, 2008, J R SOC INTERFACE, V5, P653, DOI 10.1098/rsif.2007.1138
   ELLIS MK, 1992, CHEM-BIOL INTERACT, V82, P151, DOI 10.1016/0009-2797(92)90107-V
   Gandhi NR, 2006, LANCET, V368, P1575, DOI 10.1016/S0140-6736(06)69573-1
   Girardi E, 2000, AIDS, V14, pS47
   Kochi A, 2001, B WORLD HEALTH ORGAN, V79, P71
   Maertzdorf J, 2011, GENES IMMUN, V12, P15, DOI 10.1038/gene.2010.51
   Magnet S, 2010, TUBERCULOSIS, V90, P354, DOI 10.1016/j.tube.2010.09.001
   Makarov V, 2006, J ANTIMICROB CHEMOTH, V57, P1134, DOI 10.1093/jac/dk1095
   Makarov V, 2009, SCIENCE, V324, P801, DOI 10.1126/science.1171583
   Manabe YC, 2000, NAT MED, V6, P1327, DOI 10.1038/82139
   Manina G, 2010, CURR MED CHEM, V17, P3099, DOI 10.2174/092986710791959693
   Manina G, 2010, MOL MICROBIOL, V77, P1172, DOI 10.1111/j.1365-2958.2010.07277.x
   Meniche X, 2008, MICROBIOL-SGM, V154, P2315, DOI 10.1099/mic.0.2008/016378-0
   Mikusova K, 2005, J BACTERIOL, V187, P8020, DOI 10.1128/JB.187.23.8020-8025.2005
   Miller JR, 2009, P NATL ACAD SCI USA, V106, P1737, DOI 10.1073/pnas.0811275106
   Morrison J, 2008, LANCET INFECT DIS, V8, P359, DOI 10.1016/S1473-3099(08)70071-9
   Pasca MR, 2010, ANTIMICROB AGENTS CH, V54, P1616, DOI 10.1128/AAC.01676-09
   Rappuoli R, 2011, NATURE, V26, P463
   Reeve IT, 2002, CHEM RES TOXICOL, V15, P361, DOI 10.1021/tx0155552
   Ribeiro ALDL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026675
   Riccardi G, 2009, FUTURE MICROBIOL, V4, P597, DOI 10.2217/FMB.09.20
   Rowland K, 2012, NATURE, DOI [10.1038/nature.2012.9797, DOI 10.1038/NATURE.2012.9797]
   Sassetti CM, 2003, P NATL ACAD SCI USA, V100, P12989, DOI 10.1073/pnas.2134250100
   SELWYN PA, 1989, AM J PUBLIC HEALTH, V79, P1358, DOI 10.2105/AJPH.79.10.1358
   SPAIN JC, 1995, ANNU REV MICROBIOL, V49, P523, DOI 10.1146/annurev.mi.49.100195.002515
   Stewart GR, 2003, NAT REV MICROBIOL, V1, P97, DOI 10.1038/nrmicro749
   Trefzer C, 2012, J AM CHEM SOC, V134, P912, DOI 10.1021/ja211042r
   Trefzer C, 2010, J AM CHEM SOC, V132, P13663, DOI 10.1021/ja106357w
   Triola G, 2009, BIOORGAN MED CHEM, V17, P1079, DOI 10.1016/j.bmc.2008.02.046
   Wolucka BA, 2008, FEBS J, V275, P2691, DOI 10.1111/j.1742-4658.2008.06395.x
NR 47
TC 3
Z9 3
U1 3
U2 15
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0175-7598
J9 APPL MICROBIOL BIOT
JI Appl. Microbiol. Biotechnol.
PD MAY
PY 2012
VL 94
IS 4
BP 907
EP 916
DI 10.1007/s00253-012-4013-4
PG 10
WC Biotechnology & Applied Microbiology
SC Biotechnology & Applied Microbiology
GA 935TQ
UT WOS:000303544400005
PM 22526781
DA 2018-12-27
ER

PT J
AU Phadke, M
   Lokeshwar, MR
   Bhutada, S
   Tampi, C
   Saxena, R
   Kohli, S
   Shah, KN
AF Phadke, Meghana
   Lokeshwar, M. R.
   Bhutada, Shraddha
   Tampi, Chandralekha
   Saxena, Renu
   Kohli, Sudha
   Shah, K. N.
TI RETRACTED: Kearns Sayre Syndrome-Case Report with Review of Literature
   (Retracted article. See vol. 80, pg. 982, 2013)
SO INDIAN JOURNAL OF PEDIATRICS
LA English
DT Article; Retracted Publication
DE Kearns-Sayre's syndrome; CPEO (Chronic progressive external
   ophthalmoplegia with myopathy); Chronic progressive external
   ophthalmoplegia with ragged red fibers; Oculo cranio somatic
   neuromuscular disease with ragged red fibers
ID MITOCHONDRIAL-DNA; HEART BLOCK; OPHTHALMOPLEGIA; DELETION
AB Kearns-Sayre Syndrome is form of rare mitochondrial cytopathy, first described by Thomas P. Kearns and George Pomeroy Sayre in 1958 and is characterized by progressive external opthalmoplegia, cardiac conduction block, pigmentary retinal degeneration, variable number of red ragged fibers on muscle biopsy. It presents before the child reaches the age of twenty. Kearns-Sayre syndrome may affect many organ systems and additional features may include myopathy, dystonia, bulbar symptoms in the form of dysarthria and nasal regurgitation and bilateral facial weakness. Endocrine abnormalities (e.g., diabetes, growth retardation/short stature, and hypoparathyroidism), bilateral sensorineural deafness, dementia, cataracts, and proximal renal tubular acidosis, skeletal muscle weakness (proximal more than distal) and exercise intolerance are additional features. Kearns Sayre Syndrome occurs as a result of large-scale single deletions (or rearrangements) of mitochondrial DNA (mtDNA), which is usually not inherited but occurs spontaneously, probably at the germ-cell level or very early in embryonic development. No disease-modifying therapy is available for Kearns-Sayre syndrome (KSS). Management is supportive vigilance for detection of associated problems. In the future, potential treatment in patients with Kearns-Sayre syndrome may attempt to inhibit mutant mtDNA replication or encourage replication of wild-type mtDNA.
C1 [Phadke, Meghana; Lokeshwar, M. R.; Bhutada, Shraddha; Shah, K. N.] Lilavati Hosp & Res Ctr, Dept Pediat, Mumbai, Maharashtra, India.
   [Saxena, Renu; Kohli, Sudha] Sir Gangaram Hosp, Ctr Med Genet, New Delhi, India.
   [Tampi, Chandralekha] Lilavati Hosp & Res Ctr, Dept Pathol, Mumbai, Maharashtra, India.
RP Lokeshwar, MR (reprint author), 19A Shree Dattaguru Soc, Mumbai 400088, Maharashtra, India.
EM mrlokeshwar@gmail.com
OI saxena, renu/0000-0002-1344-2831
CR Barragan-Campos Hector Manuel, 1999, Archivos del Instituto de Cardiologia de Mexico, V69, P559
   BERENBERG RA, 1977, ANN NEUROL, V1, P37, DOI 10.1002/ana.410010104
   BERKOVIC SF, 1989, BRAIN, V112, P1231, DOI 10.1093/brain/112.5.1231
   Carod-Artal FJ, 2006, NEUROLOGIA, V21, P357
   Chu BC, 1999, NEURORADIOLOGY, V41, P759, DOI 10.1007/s002340050838
   DIMAURO S, 1993, ARCH NEUROL-CHICAGO, V50, P1197, DOI 10.1001/archneur.1993.00540110075008
   FISCHELGHODSIAN N, 1992, PEDIATR RES, V31, P557, DOI 10.1203/00006450-199206000-00004
   Franco E, 1999, NEUROLOGIA, V9, P463
   Gregoratos Gabriel, 2002, Circulation, V106, P2145, DOI 10.1161/01.CIR.0000035996.46455.09
   HARVEY JN, 1992, CLIN ENDOCRINOL, V37, P97, DOI 10.1111/j.1365-2265.1992.tb02289.x
   JAGER BV, 1960, AM J MED, V29, P888, DOI 10.1016/0002-9343(60)90122-4
   Katsanos KH, 2001, AM J NEPHROL, V21, P150, DOI 10.1159/000046239
   KEARNS THOMAS P., 1965, TRANS AMER OPHTHALMOL SOC, V63, P559
   KEARNS TP, 1958, ARCH OPHTHALMOL-CHIC, V60, P280, DOI 10.1001/archopht.1958.00940080296016
   Lee K T, 2001, Kaohsiung J Med Sci, V17, P336
   Lertrit P, 1999, HUM GENET, V105, P127, DOI 10.1007/s004390051074
   LESTIENNE P, 1988, LANCET, V1, P885
   Mehndiratta MM, 2002, NEUROL INDIA, V50, P162
   OGASAHARA S, 1985, NEUROLOGY, V35, P372, DOI 10.1212/WNL.35.3.372
   Rajakannan, 2000, Indian J Ophthalmol, V48, P54
   Seneca S, 2001, ARCH NEUROL-CHICAGO, V58, P1113, DOI 10.1001/archneur.58.7.1113
   Usui M, 2002, Kyobu Geka, V55, P1112
   ZEVIANI M, 1988, NEUROLOGY, V38, P1339
NR 23
TC 10
Z9 10
U1 1
U2 15
PU SPRINGER INDIA
PI NEW DELHI
PA 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001,
   INDIA
SN 0019-5456
EI 0973-7693
J9 INDIAN J PEDIATR
JI Indian J. Pediatr.
PD MAY
PY 2012
VL 79
IS 5
BP 650
EP 654
DI 10.1007/s12098-011-0618-3
PG 5
WC Pediatrics
SC Pediatrics
GA 934XX
UT WOS:000303481200009
PM 22231766
DA 2018-12-27
ER

PT J
AU Wong, IKY
   Andriessen, A
   Lee, DTF
   Thompson, D
   Wong, LY
   Chao, DVK
   So, WKW
   Abel, M
AF Wong, Irene K. Y.
   Andriessen, Anneke
   Lee, Diana T. F.
   Thompson, David
   Wong, Lau Yun
   Chao, David V. K.
   So, Winnie K. W.
   Abel, M.
TI RETRACTED: Randomized controlled trial comparing treatment outcome of
   two compression bandaging systems and standard care without compression
   in patients with venous leg ulcers (Retracted article. See vol. 56, pg.
   1830, 2012)
SO JOURNAL OF VASCULAR SURGERY
LA English
DT Article; Retracted Publication
ID QUALITY-OF-LIFE; ELASTIC BANDAGES; LOWER-LIMB; ULCERATION; STIFFNESS;
   PRESSURE; 4-LAYER
AB Background: Compression therapy is not common for venous leg ulcer patients in Hong Kong.
   Methods: This randomized controlled trial compared the clinical effectiveness of compression bandaging using four-layer bandaging (4LB) or short-stretch bandaging (SSB) and usual care (moist wound healing dressing without compression). The 24-week study looked at venous leg ulcer patients aged >60 years in a community setting. The primary parameter was time to ulcer healing. Secondary parameters were ulcer area and pain reduction comparing week 0 (start) vs week 24 (end), measuring results per group and between groups. Intention-to-treat analysis involved descriptive statistics, survival analysis, and repeated measures analysis of variance. The log-rank test was used for univariable analysis. All withdrawn patients had a negative outcome score over the whole study duration.
   Results: Of 321 patients who received randomized treatment, 45 (14%) did not complete the 24-week study period. At 24 weeks, Kaplan-Meier analysis on healing time was statistically significant (P < .001) in favor of the compression groups. The mean (SD) healing time in the SSB group (9.9 [0.77]) was shorter than that of the 4LB group (10.4 [0.80]) and the usual care group (18.3 [0.86]). Pain reduction was significant (P < .001) for the compression-treated groups only.
   Conclusions: Compression bandaging was more effective than usual care without compression. Both compression systems were safe and feasible for venous ulcer patients in a community setting in Hong Kong. (J Vasc Surg 2012;55:1376-85.)
C1 [Andriessen, Anneke] Andriessen Consultants, NL-6581 RK Malden, Netherlands.
   [Andriessen, Anneke] Radboud Univ Nijmegen Med Ctr, Nijmegen, Netherlands.
   [Wong, Irene K. Y.] Hong Kong Sanat & Hosp, Sch Nursing, Hong Kong, Hong Kong, Peoples R China.
   [Lee, Diana T. F.] Chinese Univ Hong Kong, Nethersole Sch Nursing, Hong Kong, Hong Kong, Peoples R China.
   [Thompson, David] Univ Leicester, Dept Hlth Sci, Dept Cardiovasc Sci, Leicester, Leics, England.
   [Wong, Lau Yun] Hosp Author, Prince Wales Hosp, Dept Surg, Hong Kong, Hong Kong, Peoples R China.
   [Chao, David V. K.] Hosp Author, Kowloon E Cent Cluster, Hong Kong, Hong Kong, Peoples R China.
   [So, Winnie K. W.] Chinese Univ Hong Kong, Sch Nursing, Hong Kong, Hong Kong, Peoples R China.
   [Abel, M.] Lohmann & Rauscher, Rengsdorf, Germany.
RP Andriessen, A (reprint author), Andriessen Consultants, Zwenkgras 25, NL-6581 RK Malden, Netherlands.
EM anneke.a@tiscali.nl
RI Thompson, David/C-6320-2009; Thompson, David/E-2431-2018; Lee,
   Diana/O-7364-2015; So, Winnie/A-3994-2015
OI Thompson, David/0000-0001-8518-6307; Lee, Diana/0000-0001-7227-5204; So,
   Winnie/0000-0001-9243-2924
FU Health, Welfare and Food Bureau of Hong Kong; Lohmann & Rauscher GmbH,
   Rengsdorf, Germany
FX This study was funded by the Health, Welfare and Food Bureau of Hong
   Kong and was supported by Lohmann & Rauscher GmbH, Rengsdorf, Germany,
   who provided the study products and a limited educational grant for
   educating the involved clinicians on compression bandaging and the
   basics of moist wound healing. This was done to ensure correct
   application of the bandages and dressings. At the time, compression
   bandaging to treat venous leg ulcers had not been introduced in the
   community or in the hospital in Hong Kong.
CR Bergan JJ, 2006, NEW ENGL J MED, V355, P488, DOI 10.1056/NEJMra055289
   BROWSE NL, 1982, LANCET, V2, P243
   Charles H, 2001, Prof Nurse, V17, P123
   CONSORT, CONSORT TRANSP REP T
   Cullum N, 2009, COCHRANE DB SYST REV, V1
   FALANGA V, 1993, LANCET, V341, P1006, DOI 10.1016/0140-6736(93)91085-Z
   Gupta A K, 2000, J Cutan Med Surg, V4, P8
   HIGLEY HR, 1995, BRIT J DERMATOL, V132, P79, DOI 10.1111/j.1365-2133.1995.tb08629.x
   KIKTA MJ, 1988, J VASC SURG, V7, P478, DOI 10.1067/mva.1988.avs0070478
   Lam CLK, 2002, QUAL LIFE RES, V11, P668
   LINDHOLM C, 1993, ACTA DERM-VENEREOL, V73, P440
   Milic DJ, 2010, J VASC SURG, V51, P655, DOI 10.1016/j.jvs.2009.10.042
   Moffatt CJ, 2010, BRIT J DERMATOL, V162, P51, DOI 10.1111/j.1365-2133.2009.09397.x
   Moffatt CJ, 2003, WOUND REPAIR REGEN, V11, P166, DOI 10.1046/j.1524-475X.2003.11303.x
   Moffatt CJ, 2001, INT ANGIOL S1, V20, P291
   Morrell CJ, 1998, BRIT MED J, V316, P1487, DOI 10.1136/bmj.316.7143.1487
   Mosti G, 2008, PHLEBOLOGY, V23, P287, DOI 10.1258/phleb.2008.008009
   Mosti G, 2008, DERMATOL SURG, V34, P631, DOI 10.1111/j.1524-4725.2007.34119.x
   Mosti G, 2010, J VASC SURG, V52, P925, DOI 10.1016/j.jvs.2010.04.081
   O'Meara S, 2009, BRIT MED J, V338, DOI 10.1136/bmj.b1344
   Partsch H, 2005, EUR J VASC ENDOVASC, V30, P415, DOI 10.1016/j.ejvs.2005.06.002
   Partsch H, 2005, DERMATOL SURG, V31, P625, DOI 10.1097/00042728-200506000-00002
   Partsch H, 1999, DERMATOL SURG, V25, P695, DOI 10.1046/j.1524-4725.1999.98040.x
   Partsch H, 2001, VASA-J VASCULAR DIS, V30, P108, DOI 10.1024/0301-1526.30.2.108
   Partsch H., 2005, LEG ULCERS DIAGNOSIS, P109
   PHILLIPS T, 1994, J AM ACAD DERMATOL, V31, P49, DOI 10.1016/S0190-9622(94)70134-2
   Rabe E, 2008, EUR J VASC ENDOVASC, V35, P494, DOI 10.1016/j.ejvs.2007.08.006
   Williams C, 2000, Br J Nurs, V9, P237
   Williams Clare, 2002, Br J Nurs, V11, P398
   Wong I, 2005, J CLIN NURS, V14, P118, DOI 10.1111/j.1365-2702.2004.00947.x
   Wong I, 2003, J Wound Care, V12, P17
   Wong IKY, 2006, J CLIN NURS, V15, P356, DOI 10.1111/j.1365-2702.2006.01307.x
NR 32
TC 6
Z9 7
U1 1
U2 18
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0741-5214
J9 J VASC SURG
JI J. Vasc. Surg.
PD MAY
PY 2012
VL 55
IS 5
BP 1376
EP 1385
DI 10.1016/j.jvs.2011.12.019
PG 10
WC Surgery; Peripheral Vascular Disease
SC Surgery; Cardiovascular System & Cardiology
GA 934LV
UT WOS:000303446700020
PM 22429451
OA Bronze
DA 2018-12-27
ER

PT J
AU Lee, WI
   Shih, BY
   Chen, CY
AF Lee, Wan-I
   Shih, Bih-Yaw
   Chen, Chen-Yuan
TI RETRACTED: A hybrid artificial intelligence sales-forecasting system in
   the convenience store industry (Retracted article. See vol. 26, pg. 285,
   2016)
SO HUMAN FACTORS AND ERGONOMICS IN MANUFACTURING & SERVICE INDUSTRIES
LA English
DT Article; Retracted Publication
DE Radial basis function neural network; Artificial intelligence;
   Intelligent robot; Self-organizing map; Sales forecasting; Convenience
   stores
ID NONLINEAR STRUCTURAL SYSTEMS; NEURAL-NETWORKS; MODEL; SATISFACTION;
   PERFORMANCE; QUALITY; GAP
AB Recently, there has been increasing interest in computer-aided ergonomics and its applications, such as in the fields of intelligent robots, intelligent mobiles, intelligent stores, and so on. The operation of convenience stores (CVS) in Taiwan is facing a crossover revolution by providing multiple services, including daily fresh foods, a cafe, ticketing, and a grocery. Therefore, forecasting the daily sales of fresh foods is getting more and more complex due to the influence of both internal and external factors. Eventually, a reliable sales-forecasting system will play an important role in improving business strategies and increasing competitive advantages. The purpose of this study is the development of an enhanced hybrid sales-forecasting model of fresh foods, called ECFM (Enhanced Cluster and Forecast Model), for CVSs by combining a self-organization map (SOM) neural network and radial basis function (RBF) neural networks. The model is evaluated for a six-month sales data set of daily fresh foods at a chained CVS in Taiwan. Meanwhile, the performance of the proposed model is compared with that of fuzzy neural network (FNN) and cluster and forecast model (CFM). The result reveals that the proposed model is not only amenable but can also promise the fresh food sales forecasting for CVSs. (C) 2011 Wiley Periodicals, Inc.
C1 [Lee, Wan-I] Natl Kaohsiung First Univ Sci & Technol, Dept Mkt & Distribut Management, Kaohsiung, Taiwan.
   [Shih, Bih-Yaw; Chen, Chen-Yuan] Natl Pingtung Univ Educ, Dept & Grad Sch Comp Sci, Pingtung 90003, Taiwan.
   [Chen, Chen-Yuan] Natl Kaohsiung First Univ Sci & Technol, Doctoral Program Management, Kaohsiung, Taiwan.
RP Chen, CY (reprint author), 4-18 Minsheng Rd, Pingtung City 90003, Pingtung County, Taiwan.
EM cyc@mail.npue.edu.tw
FU National Science Council, Republic of China [NSC 97-2221-E-327-024, NSC
   98-2221-E-153-004, NSC 99-2628-E-153-001, NSC 100-2628-E-153-001]
FX We are appreciative of the financial support in the form of research
   grants from the National Science Council, Republic of China (grant nos.
   NSC 97-2221-E-327-024, NSC 98-2221-E-153-004, NSC 99-2628-E-153-001, and
   NSC 100-2628-E-153-001. Also, we are most grateful for the constructive
   suggestions of the anonymous reviewers all of which have led to the
   making of several corrections and suggestions that have greatly aided us
   in the presentation of this article.
CR ARMSTRONG JS, 1988, INT J FORECASTING, V4, P449
   Barnes Reports, 2010, CONV STOR, P4
   Bih-Yaw Shih, 2008, International Journal of Electronic Business Management, V6, P227
   Campbell D, 2009, ACCOUNT REV, V84, P1749, DOI 10.2308/accr.2009.84.6.1749
   Chase C. W., 1993, J BUSINESS FORECASTI, V12, P15
   Chen CY, 2011, J VIB CONTROL, V17, P1798, DOI 10.1177/1077546310381101
   Chen CW, 2007, ENG COMPUTATION, V24, P116, DOI 10.1108/02644400710729536
   Chen CW, 2010, J VIB CONTROL, V16, P1651, DOI 10.1177/1077546309104185
   Chen CW, 2009, EXPERT SYST APPL, V36, P4765, DOI 10.1016/j.eswa.2008.06.062
   DEROECK R, 1991, INT J FORECASTING, V7, P1, DOI 10.1016/0169-2070(91)90027-S
   Frees EW, 2004, INT J FORECASTING, V20, P99, DOI 10.1016/S0169-2070(03)00005-0
   Han HG, 2010, NEURAL COMPUT APPL, V19, P667, DOI 10.1007/s00521-009-0323-6
   Haykin S., 1999, NEURAL NETWORKS COMP
   Kalteh AM, 2008, ENVIRON MODELL SOFTW, V23, P835, DOI 10.1016/j.envsoft.2007.10.001
   Karayiannis NB, 1997, IEEE T NEURAL NETWOR, V8, P1492, DOI 10.1109/72.641471
   Kasabov NK, 1996, FDN NEURAL NETWORKS
   Kohonen T., 2001, SELF ORG MAPS
   Lee WI, 2011, AFR J BUS MANAGE, V5, P722
   Lee WI, 2010, IRAN J PUBLIC HEALTH, V39, P15
   Lee WI, 2010, J VIB CONTROL, V16, P1977, DOI 10.1177/1077546309349849
   Lee WI, 2010, AFR J BUS MANAGE, V4, P448
   Lee WI, 2010, INT J INNOV COMPUT I, V6, P1805
   Loukas YL, 2000, ANAL CHIM ACTA, V417, P221, DOI 10.1016/S0003-2670(00)00934-X
   LUSK EJ, 1981, FUZZY SET SYST, V5, P149, DOI 10.1016/0165-0114(81)90013-0
   MAHMOUD E, 1992, INT J FORECASTING, V8, P251, DOI 10.1016/0169-2070(92)90123-Q
   Makridakis S., 1989, FORECASTING METHODS
   McCarthy TM, 2006, J FORECASTING, V25, P303, DOI 10.1002/for.989
   Platt J, 1991, NEURAL COMPUT, V3, P213, DOI 10.1162/neco.1991.3.2.213
   Rojas I, 2002, NEUROCOMPUTING, V42, P267, DOI 10.1016/S0925-2312(01)00338-1
   Salmeron M, 2002, LECT NOTES COMPUT SC, V2415, P589
   TANG ZY, 1991, SIMULATION, V57, P303, DOI 10.1177/003754979105700508
   Thomassey S, 2007, APPL SOFT COMPUT, V7, P1177, DOI 10.1016/j.asoc.2006.01.005
   Venkatesan R, 2004, MARKET SCI, V23, P451, DOI 10.1287/mksc.1040.0056
   Weigend A. S., 1991, ADV NEURAL INFORMATI, V3, P875
   Winklhofer H, 2003, INT J FORECASTING, V19, P271, DOI 10.1016/S0169-2070(01)00146-7
NR 35
TC 20
Z9 20
U1 6
U2 36
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1090-8471
EI 1520-6564
J9 HUM FACTOR ERGON MAN
JI Hum. Factors Ergonom. Manuf. Serv. Ind.
PD MAY-JUN
PY 2012
VL 22
IS 3
BP 188
EP 196
DI 10.1002/hfm.20272
PG 9
WC Engineering, Manufacturing; Ergonomics
SC Engineering
GA 931DI
UT WOS:000303194700002
DA 2018-12-27
ER

PT J
AU Orr, WS
   Denbo, JW
   Saab, KR
   Myers, AL
   Ng, CY
   Zhou, JF
   Morton, CL
   Pfeffer, LM
   Davidoff, AM
AF Orr, Wayne S.
   Denbo, Jason W.
   Saab, Karim R.
   Myers, Adrianne L.
   Ng, Catherine Y.
   Zhou, Junfang
   Morton, Christopher L.
   Pfeffer, Lawrence M.
   Davidoff, Andrew M.
TI RETRACTED: Liposome-encapsulated curcumin suppresses neuroblastoma
   growth through nuclear factor-kappa B inhibition (Retracted article. See
   vol. 159, pg. 674, 2016)
SO SURGERY
LA English
DT Article; Retracted Publication
ID TRANSCRIPTION FACTOR; TUMOR-GROWTH; ACTIVATION; CELLS; APOPTOSIS;
   PROLIFERATION; RADIATION; PATHWAYS; ALPHA; MODEL
AB Background. Nuclear factor-kappa B (NF-kappa B) has been implicated in tumor cell proliferation and survival and in tumor angiogenesis. We sought to evaluate the effects of curcumin, an inhibitor of NF-kappa B, on a xenograft model of disseminated neuroblastoma.
   Methods. For in vitro studies, neuroblastoma cell lines NB1691, CHLA-20, and SK-N-AS were treated with various doses of liposomal curcumin. Disseminated neuroblastoma was established in vivo by tail vein injection of NB1691-luc cells into SCID mice, which were then treated with 50 mg/kg/day of liposomal cureumin 5 days/week intraperitoneally.
   Results. Curcumin suppressed NF-kappa B activation and proliferation of all neuroblastoma cell lines in vitro. In vivo, curcumin treatment resulted in a significant decrease in disseminated tumor burden. Curcumin-treated tumors had decreased NF-kappa B activity and an associated significant decrease in tumor cell proliferation and an increase in tumor cell apoptosis, as well as a decrease in tumor vascular endothelial growth factor levels and microvessel density.
   Conclusion. Liposomal curcumin suppressed neuroblastoma growth, with treated tumors showing a decrease in NF-kappa B activity. Our results suggest that liposomal curcumin may be a viable option for the treatment of neuroblastoma that works via inhibiting the NF-kappa B pathway. (Surgery 2012;151:736-44.)
C1 [Orr, Wayne S.; Denbo, Jason W.; Saab, Karim R.; Myers, Adrianne L.; Ng, Catherine Y.; Zhou, Junfang; Morton, Christopher L.; Davidoff, Andrew M.] St Jude Childrens Res Hosp, Dept Surg, Memphis, TN 38105 USA.
   [Orr, Wayne S.; Denbo, Jason W.; Myers, Adrianne L.; Davidoff, Andrew M.] Univ Tennessee, Hlth Sci Ctr, Dept Surg, Memphis, TN USA.
   [Pfeffer, Lawrence M.] Univ Tennessee, Hlth Sci Ctr, Dept Pathol, Memphis, TN USA.
RP Davidoff, AM (reprint author), St Jude Childrens Res Hosp, Dept Surg, 262 Danny Thomas Pl, Memphis, TN 38105 USA.
EM Andrew.davidoff@stjude.org
OI Pfeffer, Lawrence/0000-0003-2809-1234
FU Assisi Foundation of Memphis; U.S. Public Health Service [CA23099];
   National Cancer Institute [21766, CA133322]; American Lebanese Syrian
   Associated Charities (ALSAC)
FX Supported by the Assisi Foundation of Memphis, the U.S. Public Health
   Service Childhood Solid Tumor Program Project Grant No. CA23099, the
   Cancer Center Support Grant No. 21766 from the National Cancer
   Institute, Grant No. CA133322 from National Cancer Institute, and by the
   American Lebanese Syrian Associated Charities (ALSAC).
CR Aggarwal BB, 2005, CANC TREAT, V126, P103, DOI 10.1007/0-387-24361-5_5
   Aggarwal BB, 2005, CLIN CANCER RES, V11, P7490, DOI 10.1158/1078-0432.CCR-05-1192
   Aggarwal BB, 2007, EXPERT OPIN THER TAR, V11, P109, DOI 10.1517/14728222.11.2.109
   Aravindan N, 2008, CANCER BIOL THER, V7, P569, DOI 10.4161/cbt.7.4.5534
   Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649
   Bednarski BK, 2008, MOL CANCER THER, V7, P1827, DOI 10.1158/1535-7163.MCT-08-0321
   Bonizzi G, 2004, TRENDS IMMUNOL, V25, P280, DOI 10.1016/j.it.2004.03.008
   Campbell KJ, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-101
   Dent P, 2003, RADIAT RES, V159, P283, DOI 10.1667/0033-7587(2003)159[0283:SARIAO]2.0.CO;2
   Dickson PV, 2007, J PEDIATR SURG, V42, P1172, DOI 10.1016/j.jpedsurg.2007.02.027
   Gilmore TD, 1997, SEMIN CANCER BIOL, V8, P61, DOI 10.1006/scbi.1997.0056
   Li L, 2005, CANCER-AM CANCER SOC, V104, P1322, DOI 10.1002/cncr.21300
   Maris JM, 2010, NEW ENGL J MED, V362, P2202, DOI 10.1056/NEJMra0804577
   Shishodia S, 2005, BIOCHEM PHARMACOL, V70, P700, DOI 10.1016/j.bcp.2005.04.043
   Shishodia S, 2003, CARCINOGENESIS, V24, P1269, DOI 10.1093/carcin/bgg078
   Shishodia Shishir, 2004, Cancer Treat Res, V119, P139
   Sims TL, 2010, MOL CANCER THER, V9, P761, DOI 10.1158/1535-7163.MCT-09-0800
   Spurbeck WW, 2002, BLOOD, V100, P3361, DOI 10.1182/blood.V100.9.3361
NR 18
TC 17
Z9 18
U1 2
U2 11
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0039-6060
J9 SURGERY
JI Surgery
PD MAY
PY 2012
VL 151
IS 5
BP 736
EP 744
DI 10.1016/j.surg.2011.12.014
PG 9
WC Surgery
SC Surgery
GA 932QK
UT WOS:000303305400014
PM 22284765
OA Green Accepted
DA 2018-12-27
ER

PT J
AU Pillania, RK
AF Pillania, Rajesh K.
TI RETRACTED: Innovation research in India: A multidisciplinary literature
   review (Retracted article. See vol. 80, pg. 1446, 2013)
SO TECHNOLOGICAL FORECASTING AND SOCIAL CHANGE
LA English
DT Review; Retracted Publication
DE Innovations; India; Multidisciplinary; Bibliometric analysis; Literature
   review
ID RESEARCH-AND-DEVELOPMENT; COUNTRIES
AB The purpose of this research work is to study the progress of research on innovations in India and to outline and identify the key disciplines, journals, articles and authors. For this, the author studied the existing literature from the various fields in which innovations in Indian research work has been published using ISI Web of Knowledge database. This paper finds that there is an increasing amount of research work on innovations in India and the bibliographical search resulted in three-hundred-ninety-eight documents and eight-hundred-eighty-eight authors: and were published in three-hundred-four different sources and classified in ninety-one multiple disciplines. The seven major disciplines and their underlying journals are business and economics, agriculture, public administration, education and educational research, psychology, plant sciences and social sciences other topics account for the majority of publications. The most prolific journals measured by the number of research papers published are Economic and Political Weekly, World Development, Harvard Business Review. Technology Forecasting and Social Change and Indian journal of Agricultural Economics. (C) 2012 Elsevier Inc. All rights reserved.
C1 Management Dev Inst, Sukhrali 122001, Gurgaon, India.
RP Pillania, RK (reprint author), Management Dev Inst, Sukhrali 122001, Gurgaon, India.
EM rajesh@pillania.org
CR Acedo FJ, 2005, INT BUS REV, V14, P619, DOI 10.1016/j.ibusrev.2005.05.003
   Altenburg T, 2008, WORLD DEV, V36, P325, DOI 10.1016/j.worlddev.2007.06.011
   Arnott DC, 2007, EUR J MARKETING, V41, P1203, DOI 10.1108/03090560710773408
   BORGMAN CL, 2000, WEB KNOWLEDGE, P143
   CHRISTENSEN CM, 2006, HARVARD BUS REV, V84, P41
   D'Costa AP, 2003, WORLD DEV, V31, P211, DOI 10.1016/S0305-750X(02)00182-1
   Feinberg SE, 2001, J INT BUS STUD, V32, P421, DOI 10.1057/palgrave.jibs.8490975
   Glanzel W, 1996, SCIENTOMETRICS, V35, P291, DOI 10.1007/BF02016902
   Karmarkar U, 2004, HARVARD BUS REV, V82, P100
   KIM J, 2008, J ADVERT, V37, P99
   Kim WC, 2004, HARVARD BUS REV, V82, P76
   Pal A, 2005, IEEE T INF TECHNOL B, V9, P59, DOI 10.1109/TITB.2004.842410
   Pasadeos Y., 1999, J PUBLIC RELAT RES, V11, P29, DOI DOI 10.1207/S1532754XJPRR1101_
   Patibandla M, 2002, WORLD DEV, V30, P1561, DOI 10.1016/S0305-750X(02)00060-8
   Peters DH, 2003, HEALTH POLICY PLANN, V18, P249, DOI 10.1093/heapol/czg031
   Pillania R.K., 2008, MANAGE DECIS, V46, pi
   Pillania R. K., 2005, GLOB BUS REV, V6, P31
   Pillania RK, 2009, MULTINATL BUS REV, V17, P1, DOI 10.1108/1525383X200900007
   PILLANIA RK, 2006, GLOB J FLEX SYST MAN, V6, P21
   PRAHALAD CK, 1997, RETHINKING FUTURE, P60
   PRICE DJD, 1976, J AM SOC INFORM SCI, V27, P292, DOI 10.1002/asi.4630270505
   Raut LK, 1995, J DEV ECON, V48, P1, DOI 10.1016/0304-3878(95)00028-3
   Reddy P, 1997, WORLD DEV, V25, P1821, DOI 10.1016/S0305-750X(97)00079-X
   REEVES B, 1983, HUM COMMUN RES, V10, P119, DOI 10.1111/j.1468-2958.1983.tb00007.x
   SACHS G, 2007, BRICS
   Sachs Goldman, 2003, DREAMING BRICS PATH
   SCHUBERT A, 1989, SCIENTOMETRICS, V16, P3, DOI 10.1007/BF02093234
   Van Raan Anthony F.J., 2003, TECHNIKFOLGENABSCHAT, V1, P20
   WHITE HD, 1989, ANNU REV INFORM SCI, V24, P119
   Wiberley SE, 2003, LIBR QUART, V73, P121, DOI 10.1086/603393
   Zhao MY, 2006, MANAGE SCI, V52, P1185, DOI 10.1287/mnsc.1060.0516
NR 31
TC 4
Z9 4
U1 1
U2 32
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0040-1625
EI 1873-5509
J9 TECHNOL FORECAST SOC
JI Technol. Forecast. Soc. Chang.
PD MAY
PY 2012
VL 79
IS 4
BP 716
EP 720
DI 10.1016/j.techfore.2012.02.003
PG 5
WC Business; Planning & Development
SC Business & Economics; Public Administration
GA 929TD
UT WOS:000303087700011
DA 2018-12-27
ER

PT J
AU Mondal, NC
   Sarwade, DV
   Singh, VS
AF Mondal, N. C.
   Sarwade, D. V.
   Singh, V. S.
TI RETRACTED: Development prospects of groundwater resources in an
   elliptical shape island, Union Territory of Lakshadweep, India
   (Retracted article. See vol. 71, pg. 2481, 2014)
SO ENVIRONMENTAL EARTH SCIENCES
LA English
DT Article; Retracted Publication
DE Island aquifer; Groundwater resources; Seawater intrusion; Lakshadweep;
   India
ID LARGE-DIAMETER WELLS
AB A major problem of the islanders is the availability of fresh water for drinking purpose. Groundwater is the only source of fresh water for the islanders. The demand for groundwater is increasing very year due to growing population and urbanization. A proper understanding of the groundwater condition is important in order to meet this increasing demand and to formulate future development and management strategies. It is in this context, principal hydrogeologic units; water table fluctuation pattern, general groundwater potential, existing groundwater withdrawal structures and draft, water quality, etc. have been studied in an elliptical shape Andrott Island of Union Territory of Lakshadweep, India, through field investigation and secondary data collection. Groundwater occurs under phreatic condition and seawater is in hydraulic continuity with the groundwater as evidenced by the tidal influence in almost all the wells. Groundwater level fluctuation due to seasonal variation varies from 0 to 0.542 m depending on the distance of the well from the coast. Depth to groundwater level varies from less than 1.234 to 3.520 m depending on the topography. Groundwater level fluctuation is due to the combination of factors like rainfall, tidal activities, sub-surface runoff, and draft. Large diameter dug wells are the main groundwater extraction structures in this island. There are 2,143 dug wells with almost each family having its own well and the density of the dug wells is about 437/km(2). The stage of groundwater development is estimated as 37% and hence "Safe" for further groundwater development in this island. However, considering the very limited fresh-water resources and also the growing demand for groundwater, various management strategies such as rainwater harvesting, artificial recharge of groundwater, public participation in water conservation and wise use of groundwater, etc., have been suggested.
C1 [Mondal, N. C.; Singh, V. S.] CSIR, Natl Geophys Res Inst, Hyderabad 500606, Andhra Pradesh, India.
   [Mondal, N. C.] Texas A&M Univ, Dept Biol & Agr Engn, College Stn, TX 77843 USA.
   [Sarwade, D. V.] Cent Soil & Mat Res Stn, New Delhi 110016, India.
RP Mondal, NC (reprint author), CSIR, Natl Geophys Res Inst, Uppal Rd, Hyderabad 500606, Andhra Pradesh, India.
EM ncmngri@yahoo.co.in
RI Mondal, Nepal/C-5087-2009; Singh, Vijay/F-9162-2013
OI Mondal, Nepal/0000-0002-6173-7458; Singh, Vijay/0000-0002-8455-585X
FU DST (Govt. of India), New Delhi, under BOYSCAST [SR/BY/A-05/2008]
FX The officials of PWD and DST, Lakshadweep, had been helpful in carrying
   out various studies at Andrott Island. The study had been financed
   partially by DST (Govt. of India), New Delhi, under BOYSCAST Programme
   (SR/BY/A-05/2008, Dt. 16-19th January 2009). The Director of NGRI,
   Hyderabad, had given permission to publish this paper. The two anonymous
   reviewers had suggested their constructive comments to improve the
   article. The authors are thankful to them.
CR Ajaykumar VR, 1995, INDIAN J EARTH SCI, V22, P165
   AJAYKUMAR VR, 1996, J ASS EXPLORATION GE, V17, P11
   American Public Health Association (APHA), 1985, STAND METH EX WAT WA
   Banerjee P, 2008, ENVIRON GEOL, V55, P901, DOI 10.1007/s00254-007-1041-y
   Central Ground Water Board (CGWB), 1995, GROUNDW RES MAN UN 2
   Central Ground Water Board (CGWB), 1997, GROUNDW EST METH 199
   Domenico PA, 1990, PHYS CHEM HYDROGEOLO
   GUPTA CP, 1988, J HYDROL, V103, P209, DOI 10.1016/0022-1694(88)90134-5
   Hem J.D., 1970, 1473 USGS
   Indian Standard Institution (ISI), 1983, ISI PUB
   JAYAKUMAR M, 1988, AGR FOREST METEOROL, V43, P235, DOI 10.1016/0168-1923(88)90051-2
   Karanth KR, 1987, GROUNDWATER ASSESSME
   LLOYD JW, 1980, WATER RESOUR BULL, V16, P646
   Mallik TK, 2001, J GEOL SURV INDIA SP, V56, P1
   Mandel S, 1980, GROUNDWATER RESOURCE
   Muralidharan MP, 2001, J GEOL SURV INDIA SP, V56, P9
   NAZEEB KM, 1995, GROUNDWATER RESOUR 2
   Orellana E, 1966, MASTER TABLES CURVES, P193
   Piper AM, 1944, EOS T AM GEOPHYS UN, V25, P914
   Prasad NBN, 2003, INT C WAT ENV WE 200, P122
   Prasada Rao GSLHV, 1994, P NAT SEM WAT MAN PL, P65
   Revichandran D, 2001, J GEOL SURV INDIA SP, V56, P221
   Rushton K.R., 1979, SEEPAGE GROUNDWATER
   Sarwade DV, 2007, ENVIRON GEOL, V52, P1475, DOI 10.1007/s00254-006-0592-7
   Singh VS, 1999, HYDROLOG SCI J, V44, P173, DOI 10.1080/02626669909492216
   Singh VS, 1999, ENVIRON GEOL, V38, P168, DOI 10.1007/s002540050412
   Todd DK, 1980, GROUNDWATER HYDROLOG
   TRIVEDY RK, 1984, CHEM BIOL METHODS WA
   VELPEN BPA, 1988, ITC J, V4
   Wagle BG, 1993, INDIAN J MAR SCI, V22, P203
   Yusuf M., 1993, ADV COCONUT RES DEV, P337
NR 31
TC 2
Z9 3
U1 3
U2 9
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1866-6280
EI 1866-6299
J9 ENVIRON EARTH SCI
JI Environ. Earth Sci.
PD MAY
PY 2012
VL 66
IS 1
BP 17
EP 29
DI 10.1007/s12665-011-1199-1
PG 13
WC Environmental Sciences; Geosciences, Multidisciplinary; Water Resources
SC Environmental Sciences & Ecology; Geology; Water Resources
GA 925ER
UT WOS:000302744100002
DA 2018-12-27
ER

PT J
AU Deo, RC
AF Deo, Ravinesh C.
TI RETRACTED: A review and modelling results of the simulated response of
   deforestation on climate extremes in eastern Australia (Retracted
   article. See vol. 120, pg. 356, 2013)
SO ATMOSPHERIC RESEARCH
LA English
DT Review; Retracted Publication
DE Deforestation; Physics of land surface processes; Bootstrapping
   procedure; Australian droughts
ID LAND-COVER CHANGE; GENERAL-CIRCULATION MODELS; PREDICTABILITY
   EXPERIMENTS; AMAZON DEFORESTATION; NET-RADIATION; HEAT-FLUX; SURFACE;
   IMPACT; VARIABILITY; RAINFALL
AB The native vegetation cover in Australia has been modified extensively since the advent of European population. This was paralleled by increases in mean surface temperatures, decreases in mean rainfall and persistence of long-lasting and severe droughts, especially in eastern Australia. The purpose of this article is twofold: (1) to review the simulated response of deforestation on Australian droughts in light of the physics of land-surface processes, (2) to provide further analysis of the modelling results from the CSIRO Mark 3 Atmospheric Global Climate Model (AGCM) to quantify the changes in Australian droughts from the pre-European to modern-day land cover conditions. The simulated response for the austral summer for the modern-day period showed (1) a shift in the tails of the probability distribution functions of rainfall and temperature towards drier and warmer conditions, (2) a decrease in average rainfall between similar to 4-12%, (3) a reduction in average soil moisture by similar to 40%, (4) an increase dry spells by similar to 3-4 days, (5) a decrease in cumulative wet day rainfall between 10 and 25 mm day(-1), (6) an increases in drought duration by similar to 6-12 consecutive days and an increase in drought severity by similar to 4-8%, (7) an average warming of similar to 0.4-3.6 degrees C, and an increase in dry spells by similar to 6-9 days for the 1982/83 El Nino event. These changes were statistically significant at the 95% confidence level using the non-parametric bootstrapping procedure. The simulated changes in atmospheric variables indicate that deforestation has been a contributing factor to the observed increases in drought severity and duration in eastern Australia. (C) 2012 Elsevier B.V. All rights reserved.
C1 Univ So Queensland, Fac Sci, Dept Math & Comp, Toowoomba, Qld 4300, Australia.
RP Deo, RC (reprint author), Univ So Queensland, Fac Sci, Dept Math & Comp, Springfield Campus, Toowoomba, Qld 4300, Australia.
EM physrcd@yahoo.com
FU Land and Water, Australia Innovation Call Grant [UQL29]
FX It is acknowledged that a condensed version of this article was
   published in the Proceedings of Modelling and Simulation Conference
   (18th World IMACS/MODSIM Congress). This research was funded by Land and
   Water, Australia Innovation Call Grant, UQL29 and project was undertaken
   at the University of Queensland and Queensland Department of Environment
   and Resource Management in collaboration with Dr C. McAlpine and Mr J.
   Syktus. We thank all three reviewers whose comments have improved an
   earlier xversion of this research article.
CR Alexander LV, 2009, INT J CLIMATOL, V29, P417, DOI 10.1002/joc.1730
   [Anonymous], 2009, NATURE, V458, P1081, DOI [10.1038/4581081d, DOI 10.1038/4581081D]
   Barnett TP, 1997, J CLIMATE, V10, P2321, DOI 10.1175/1520-0442(1997)010<2321:PPAAIO>2.0.CO;2
   Barson MM, 2000, LAND COVER CHANGE AU
   Bengtsson L, 1996, CLIM DYNAM, V12, P261, DOI 10.1007/BF00219500
   Cai W, 2008, GEOPHYS RES LETT, V35, DOI 10.1029/2008GL033727
   Cai WJ, 2003, MON WEATHER REV, V131, P1189, DOI 10.1175/1520-0493(2003)131<1189:SEVAAS>2.0.CO;2
   Chambers SD, 2005, J GEOPHYS RES-ATMOS, V110, DOI 10.1029/2004JD005299
   CLOTHIER BE, 1986, AGR FOREST METEOROL, V37, P319, DOI 10.1016/0168-1923(86)90069-9
   Deo RC, 2007, MODSIM 2007: INTERNATIONAL CONGRESS ON MODELLING AND SIMULATION, P626
   Deo RC, 2009, GEOPHYS RES LETT, V36, DOI 10.1029/2009GL037666
   Deo R.C., 2009, 18 WORLD IMACS C MOD
   Deo RC, 2011, WEATHER, V66, P64, DOI 10.1002/wea.659
   DiCiccio TJ, 1996, STAT SCI, V11, P189
   DUDEWICZ EJ, 1988, MODERN MATH STAT
   Dunn PK, 2001, INT J CLIMATOL, V21, P89, DOI 10.1002/joc.596
   Durieux L, 2003, REMOTE SENS ENVIRON, V86, P132, DOI 10.1016/S0034-4257(03)00095-6
   Efron B., 1993, INTRO BOOTSTRAP
   Foley JA, 2003, FRONT ECOL ENVIRON, V1, P38, DOI 10.2307/3867963
   Forster P, 2007, CLIMATE CHANGE 2007: THE PHYSICAL SCIENCE BASIS, P129
   Francois C, 1997, INT J REMOTE SENS, V18, P2587, DOI 10.1080/014311697217495
   Frich P, 2002, CLIMATE RES, V19, P193, DOI 10.3354/cr019193
   Fu R, 2004, THEOR APPL CLIMATOL, V78, P97, DOI 10.1007/s00704-004-0046-7
   FUCHS M, 1966, AGRON J, V58, P597, DOI 10.2134/agronj1966.00021962005800060014x
   Gallant AJE, 2007, AUST METEOROL MAG, V56, P223
   Garratt J. R, 1992, ATMOSPHERIC BOUNDARY
   Gibbs W.J., 1967, BUREAU METEOROLOGY B, V48
   Gordon H. B., 2002, 60 CSIRO
   Hansen J, 1997, J GEOPHYS RES-ATMOS, V102, P6831, DOI 10.1029/96JD03436
   Henderson-Sellers A., 1993, CLIM DYNAM, V15, P319
   Jacobs JM, 2002, J HYDROL, V266, P53, DOI 10.1016/S0022-1694(02)00117-8
   Jin ML, 2006, J CLIMATE, V19, P2867, DOI 10.1175/JCLI3720.1
   Kershaw P, 2003, FRESHWATER BIOL, V48, P1274, DOI 10.1046/j.1365-2427.2003.01085.x
   KIMES DS, 1985, REMOTE SENS ENVIRON, V18, P205, DOI 10.1016/0034-4257(85)90058-6
   Kirkpatrick J., 1999, CONTINENT TRANSFORME
   Knutti R, 2002, NATURE, V416, P719, DOI 10.1038/416719a
   Kumar A, 1997, J CLIMATE, V10, P83, DOI 10.1175/1520-0442(1997)010<0083:IAIOTO>2.0.CO;2
   Kysely J, 2008, J APPL METEOROL CLIM, V47, P3236, DOI 10.1175/2008JAMC1763.1
   Lambin E. F., 2006, LAND USE LAND COVER
   Latif M, 2001, CLIM DYNAM, V18, P255, DOI 10.1007/s003820100174
   Lawrence P., 2004, THESIS U QUEENSLAND
   LIVEZEY RE, 1983, MON WEATHER REV, V111, P46, DOI 10.1175/1520-0493(1983)111<0046:SFSAID>2.0.CO;2
   Los SO, 2006, GEOPHYS RES LETT, V33, DOI 10.1029/2006GL027065
   Loveland TR, 2000, INT J REMOTE SENS, V21, P1303, DOI 10.1080/014311600210191
   LYONS TJ, 1993, B AM METEOROL SOC, V74, P1327, DOI 10.1175/1520-0477(1993)074<1327:LIIASR>2.0.CO;2
   Mahmood R, 2010, B AM METEOROL SOC, V91, P37, DOI 10.1175/2009BAMS2769.1
   Marengo J. A., 2001, BIOGEOCHEMISTRY AMAZ, P17
   Maynard K, 2004, CLIM DYNAM, V22, P343, DOI 10.1007/s00382-003-0371-z
   McAlpine CA, 2007, GEOPHYS RES LETT, V34, DOI 10.1029/2007GL031524
   Mcalpine CA, 2009, GLOBAL CHANGE BIOL, V15, P2206, DOI 10.1111/j.1365-2486.2009.01939.x
   MEARNS LO, 1984, J CLIM APPL METEOROL, V23, P1601, DOI 10.1175/1520-0450(1984)023<1601:EHTECI>2.0.CO;2
   MEHERHOMJI VM, 1991, CLIMATIC CHANGE, V19, P163, DOI 10.1007/BF00142223
   Misra V, 2008, J CLIMATE, V21, P5852, DOI 10.1175/2008JCLI2205.1
   Molders N, 2007, ATMOS RES, V84, P142, DOI 10.1016/j.atmosres.2006.06.004
   Nair US, 2007, J GEOPHYS RES-ATMOS, V112, DOI 10.1029/2006JD007505
   Narisma GT, 2006, EARTH INTERACT, V10
   Narisma GT, 2003, J HYDROMETEOROL, V4, P424, DOI 10.1175/1525-7541(2003)4<424:TIOYOL>2.0.CO;2
   Nicholls N, 2004, CLIMATIC CHANGE, V63, P323, DOI 10.1023/B:CLIM.0000018515.46344.6d
   Nicholls N., 2006, ENERGY ENV, V17, P1, DOI DOI 10.1260/095830506776318804
   Nicholls N, 2006, AUST METEOROL MAG, V55, P199
   NOBRE CA, 1991, J CLIMATE, V4, P957, DOI 10.1175/1520-0442(1991)004<0957:ADARCC>2.0.CO;2
   NOILHAN J, 1989, MON WEATHER REV, V117, P536, DOI 10.1175/1520-0493(1989)117<0536:ASPOLS>2.0.CO;2
   OYAMA MD, 2004, REV BRAS METEOROL, V19, P203
   Peixoto J. P., 1992, PHYS CLIMATE, P520
   Pielke RA, 2002, PHILOS T ROY SOC A, V360, P1705, DOI 10.1098/rsta.2002.1027
   Pitman AJ, 2007, QUATERNARY SCI REV, V26, P189, DOI 10.1016/j.quascirev.2006.06.014
   Pitman AJ, 2009, GEOPHYS RES LETT, V36, DOI 10.1029/2009GL039076
   PITMAN AJ, 1995, ATMOS RES, V37, P229, DOI 10.1016/0169-8095(94)00079-S
   Pitman AJ, 2004, J GEOPHYS RES-ATMOS, V109, DOI 10.1029/2003JD004347
   Power SB, 2007, GEOPHYS RES LETT, V34, DOI 10.1029/2007GL030854
   Ray DK, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2002JD002654
   Reiczigel J, 2005, AM STAT, V59, P156, DOI 10.1198/000313005X23526
   Rowell D.P., 1998, J CLIMATE, V11, P112
   Roy SB, 2002, J GEOPHYS RES-ATMOS, V107, DOI 10.1029/2000JD000266
   Scaife AA, 2009, CLIM DYNAM, V33, P603, DOI 10.1007/s00382-008-0451-1
   Schwerdtfeger P., 1993, RABBIT FENCE SURPRIS
   SELLERS PJ, 1986, J ATMOS SCI, V43, P505, DOI 10.1175/1520-0469(1986)043<0505:ASBMFU>2.0.CO;2
   SHUKLA J, 1990, SCIENCE, V247, P1322, DOI 10.1126/science.247.4948.1322
   SHUTTLEWORTH WJ, 1991, REV GEOPHYS, V29, P585, DOI 10.1029/91RG01815
   Smith I, 2004, AUST METEOROL MAG, V53, P163
   Solomon S, 2007, CLIMATE CHANGE 2007: THE PHYSICAL SCIENCE BASIS, P19
   Su Z, 2002, HYDROL EARTH SYST SC, V6, P85, DOI 10.5194/hess-6-85-2002
   Syktus J., 2003, SCI DROUGHT, P160
   Syktus J.I., 2007, INT C MOD SIM MODSIM, P611
   Timbal B, 2006, GEOPHYS RES LETT, V33, DOI 10.1029/2005GL025361
   VANDEGRIEND AA, 1993, INT J REMOTE SENS, V14, P1119, DOI 10.1080/01431169308904400
   Vendrasco EP, 2009, ATMOS RES, V94, P409, DOI 10.1016/j.atmosres.2009.06.016
   Voldoire A, 2004, CLIM DYNAM, V22, P857, DOI 10.1007/s00382-004-0423-z
   Watterson IG, 2007, CLIM DYNAM, V28, P703, DOI 10.1007/s00382-006-0206-9
   Werth D, 2002, J GEOPHYS RES-ATMOS, V107, DOI 10.1029/2001JD000717
   WIGLEY TML, 1990, J GEOPHYS RES-ATMOS, V95, P851, DOI 10.1029/JD095iD01p00851
   Zahira S, 2009, REMOTE SENS-BASEL, V1, P795, DOI 10.3390/rs1040795
   Zhao M, 2001, CLIM DYNAM, V17, P467, DOI 10.1007/PL00013740
   Zwiers F. W, 1999, STAT ANAL CLIMATE RE
   Zwiers FW, 1996, CLIM DYNAM, V12, P825, DOI 10.1007/s003820050146
NR 95
TC 1
Z9 1
U1 3
U2 42
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0169-8095
EI 1873-2895
J9 ATMOS RES
JI Atmos. Res.
PD MAY
PY 2012
VL 108
BP 19
EP 38
DI 10.1016/j.atmosres.2012.01.007
PG 20
WC Meteorology & Atmospheric Sciences
SC Meteorology & Atmospheric Sciences
GA 921XE
UT WOS:000302510600003
DA 2018-12-27
ER

PT J
AU Lee, TW
   Montgomery, JM
   Birch, NP
AF Lee, Tet Woo
   Montgomery, Johana M.
   Birch, Nigel P.
TI RETRACTED: The serine protease inhibitor neuroserpin regulates the
   growth and maturation of hippocampal neurons through a non-inhibitory
   mechanism (Retracted article. See vol. 125, pg. 637, 2012)
SO JOURNAL OF NEUROCHEMISTRY
LA English
DT Article; Retracted Publication
DE axon growth; dendritic branching; schizophrenia; serpin
ID TISSUE-PLASMINOGEN ACTIVATOR; RECEPTOR-RELATED PROTEIN; NERVOUS-SYSTEM;
   SERPIN SUPERFAMILY; VISUAL-CORTEX; DENSITY; CELLS; EXPRESSION; CULTURE;
   FAMILY
AB Neuroserpin is a brain-specific serine protease inhibitor that is expressed in the developing and adult nervous system. Its expression profile led to suggestions that it played roles in neuronal growth and connectivity. In this study, we provide direct evidence to support a role for neuroserpin in axon and dendritic growth. We report that axon growth is enhanced while axon and dendrite diameter are reduced following neuroserpin treatment of hippocampal neurons. More complex effects are seen on dendritic growth and branching with neuroserpin-stimulating dendritic growth and branching in young neurons but switching to an inhibitory response in older neurons. The protease inhibitory activity of neuroserpin is not required to activate changes in neuronal morphology and a proportion of responses are modulated by an antagonist to the LRP1 receptor. Collectively, these findings support a key role for neuroserpin as a regulator of neuronal development through a non-inhibitory mechanism and suggest a basis for neuroserpins effects on complex emotional behaviours and recent link to schizophrenia.
C1 [Lee, Tet Woo; Birch, Nigel P.] Univ Auckland, Sch Biol Sci, Auckland 1010, New Zealand.
   [Lee, Tet Woo; Montgomery, Johana M.; Birch, Nigel P.] Univ Auckland, Ctr Brain Res, Auckland 1010, New Zealand.
   [Montgomery, Johana M.] Univ Auckland, Dept Physiol, Auckland 1010, New Zealand.
RP Birch, NP (reprint author), Univ Auckland, Sch Biol Sci, Thomas Bldg,3A Symonds St,Private Bag 92019, Auckland 1010, New Zealand.
EM n.birch@auckland.ac.nz
RI Birch, Nigel/H-2498-2011; Lee, Tet Woo/E-3833-2012
OI Birch, Nigel/0000-0002-8417-3587; Lee, Tet Woo/0000-0002-2744-1784
FU Tertiary Education Commission; Health Research Council of New Zealand;
   Royal Society of New Zealand
FX We would like to acknowledge Angela van Diepen for help with the
   immunoprecipitations and western blotting, Leigh Coates for preparation
   of recombinant RAP and Boehringer Ingelheim (N.Z.) Ltd. for providing
   Actilyse (R). We would like to thank David Christie for critical reading
   of the manuscript. This research was supported through a Bright Future
   Top Achiever Doctoral Scholarship from the Tertiary Education Commission
   (to TWL) and the Health Research Council of New Zealand and the Royal
   Society of New Zealand Marsden Fund. The authors declare no conflicts of
   interest.
CR BANKER GA, 1977, BRAIN RES, V126, P397, DOI 10.1016/0006-8993(77)90594-7
   Barker-Carlson K, 2002, J BIOL CHEM, V277, P46852, DOI 10.1074/jbc.M207740200
   Borges VM, 2010, J NEUROSCI RES, V88, P2610, DOI 10.1002/jnr.22428
   Brennand KJ, 2011, NATURE, V473, P221, DOI 10.1038/nature09915
   Brown MD, 1997, BRAIN RES, V747, P313, DOI 10.1016/S0006-8993(96)01321-2
   DOTTI CG, 1988, J NEUROSCI, V8, P1454
   Hastings GA, 1997, J BIOL CHEM, V272, P33062, DOI 10.1074/jbc.272.52.33062
   Herz J, 2002, ANNU REV BIOCHEM, V71, P405, DOI 10.1146/annurev.biochem.71.110601.135342
   HERZ J, 1991, J BIOL CHEM, V266, P21232
   Hill RM, 2000, BIOCHEM J, V345, P595, DOI 10.1042/0264-6021:3450595
   Hill RM, 2001, PROTEIN EXPRES PURIF, V22, P406, DOI 10.1006/prep.2001.1463
   Jaaro-Peled H, 2010, SCHIZOPHRENIA BULL, V36, P301, DOI 10.1093/schbul/sbp133
   Ji YY, 2010, NAT NEUROSCI, V13, P302, DOI 10.1038/nn.2505
   Kennedy SA, 2007, THROMB HAEMOSTASIS, V97, P394, DOI 10.1160/TH06-09-0543
   Krueger SR, 1997, J NEUROSCI, V17, P8984
   Law RHP, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-5-216
   Lee TW, 2008, J NEUROSCI RES, V86, P1243, DOI 10.1002/jnr.21592
   Littell R.C, 2006, SAS MIXED MODELS
   Madani R, 2003, MOL CELL NEUROSCI, V23, P473, DOI 10.1016/S1044-7431(03)00077-0
   Makarova A, 2003, J BIOL CHEM, V278, P50250, DOI 10.1074/jbc.M309150200
   Malladi R, 1996, IEEE T IMAGE PROCESS, V5, P1554, DOI 10.1109/83.541425
   Mataga N, 2004, NEURON, V44, P1031, DOI 10.1016/j.neuron.2004.11.028
   Miranda E, 2006, CELL MOL LIFE SCI, V63, P709, DOI 10.1007/s00018-005-5077-4
   Olson ST, 2011, PROG MOL BIOL TRANSL, V99, P185, DOI 10.1016/S1877-1173(11)99005-X
   Osterwalder T, 1998, J BIOL CHEM, V273, P2312, DOI 10.1074/jbc.273.4.2312
   Osterwalder T, 1996, EMBO J, V15, P2944, DOI 10.1002/j.1460-2075.1996.tb00657.x
   Parmar PK, 2002, J NEUROCHEM, V82, P1406, DOI 10.1046/j.1471-4159.2002.01100.x
   QIAN Z, 1993, NATURE, V361, P453, DOI 10.1038/361453a0
   Ranganathan S, 2011, J NEUROSCI, V31, P10836, DOI 10.1523/JNEUROSCI.5065-10.2011
   Rasband W.S., 1997, IMAGEJ
   Ricagno S, 2009, J MOL BIOL, V388, P109, DOI 10.1016/j.jmb.2009.02.056
   Selemon LD, 1999, BIOL PSYCHIAT, V45, P17, DOI 10.1016/S0006-3223(98)00281-9
   Shi Y, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000188
   SHOLL DA, 1953, J ANAT, V87, P387
   Silverman GA, 2010, J BIOL CHEM, V285, P24299, DOI 10.1074/jbc.R110.112771
   STOECKLI ET, 1989, EUR J BIOCHEM, V180, P249, DOI 10.1111/j.1432-1033.1989.tb14640.x
   Strickland DK, 2002, TRENDS ENDOCRIN MET, V13, P66, DOI 10.1016/S1043-2760(01)00526-4
   Tan ZJ, 2010, P NATL ACAD SCI USA, V107, P9873, DOI 10.1073/pnas.1003480107
   Teesalu T, 2004, THROMB HAEMOSTASIS, V92, P358
   TSIRKA SE, 1995, NATURE, V377, P340, DOI 10.1038/377340a0
   Wannier-Morino P, 2003, EUR J NEUROSCI, V17, P1853, DOI 10.1046/j.1460-9568.2003.02628.x
   Whisstock JC, 2010, J BIOL CHEM, V285, P24307, DOI 10.1074/jbc.R110.141408
   Yepes M, 2000, BLOOD, V96, P569
NR 43
TC 13
Z9 13
U1 2
U2 17
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3042
EI 1471-4159
J9 J NEUROCHEM
JI J. Neurochem.
PD MAY
PY 2012
VL 121
IS 4
BP 561
EP 574
DI 10.1111/j.1471-4159.2011.07639.x
PG 14
WC Biochemistry & Molecular Biology; Neurosciences
SC Biochemistry & Molecular Biology; Neurosciences & Neurology
GA 924WG
UT WOS:000302721400007
PM 22191421
OA Bronze
DA 2018-12-27
ER

PT J
AU Hedayati, A
   Safahieh, A
AF Hedayati, Aliakbar
   Safahieh, Alireza
TI RETRACTED: Serum hormone and biochemical activity as biomarkers of
   mercury toxicity in the yellowfin seabream Acanthopagrus latus(Retracted
   article. See vol. 33, pg. NP2-NP2, 2017)
SO TOXICOLOGY AND INDUSTRIAL HEALTH
LA English
DT Article; Retracted Publication
DE Fish; marine environment; mercury; toxicity; serum
ID PHYSIOLOGICAL-RESPONSE; CYPRINUS-CARPIO; STRESS-RESPONSE; FISH; LIVER;
   RIVER; RECEPTORS; SEDIMENTS; EXPOSURE; CATFISH
AB This study was undertaken in two separate environmental and experimental conditions. The environmental test was carried out at creeks in the Persian Gulf and the experimental test was undertaken in seawater re-circulatory tanks. Mercury concentrations were determined using a standard cold vapour atomic absorption method. Serum enzymes were determined with Diagnostics Infinity reagent kit. Serum glucose and total protein were measured photometrically. Serum hormones were assayed using diagnostic ELISA kits. Results of the present investigation indicated that the sub-acute and chronic mercury concentrations tested may cause several changes in the biochemical and hormone parameters of the studied fish and we can use these changes as biomarkers for mercury detection. The range of mercury concentrations found in the creek water and specially sediments along the Mahshahr coast was higher than the other marine environment. It was declared that between enzymatic indices serum acid phosphatase (ACP) amount and ACP activity, between hormonal indices testosterone, T3 and T3/T4 and between metabolite index total protein can be considered as suitable and effective biomarkers of mercury pollution in yellowfin seabream.
C1 [Hedayati, Aliakbar] Gorgan Univ Agr Sci & Nat Resources, Dept Fisheries, Gorgan, Iran.
   [Safahieh, Alireza] Univ Marine Sci & Technol, Dept Marine Biol, Khorramshahr, Iran.
RP Hedayati, A (reprint author), Gorgan Univ Agr Sci & Nat Resources, Dept Fisheries, Gorgan, Iran.
EM Marinebiology1@gmail.com
RI Hedayati, Aliakbar/R-1734-2016
OI Hedayati, Aliakbar/0000-0001-7658-5314; Safahieh,
   Alireza/0000-0003-3721-0258
FU Iranian National Science Foundation (INSF) [88000678]
FX This work was supported by the Iranian National Science Foundation
   (INSF; grant number 88000678).
CR Abdel-Tawwab M, 2007, AQUACULTURE, V272, P335, DOI 10.1016/j.aquaculture.2007.09.004
   [Anonymous], 2005, STAND METH EX WAT WA
   Arnold SF, 1996, SCIENCE, V272, P1489, DOI 10.1126/science.272.5267.1489
   BANAUCH D, 1975, Z KLIN CHEM KLIN BIO, V13, P101
   Bonga SEW, 1997, PHYSIOL REV, V77, P591, DOI 10.1152/physrev.1997.77.3.591
   Brown SB, 2004, ENVIRON TOXICOL CHEM, V23, P1680, DOI 10.1897/03-242
   Cajaraville MP, 2000, SCI TOTAL ENVIRON, V247, P295, DOI 10.1016/S0048-9697(99)00499-4
   Canli Mustafa, 1996, Turkish Journal of Zoology, V20, P161
   Carletta MA, 2002, MAR ENVIRON RES, V54, P601, DOI 10.1016/S0141-1136(02)00133-2
   Chaurasia SS, 1996, B ENVIRON CONTAM TOX, V56, P649, DOI 10.1007/s001289900095
   David M, 2004, CHEMOSPHERE, V56, P347, DOI 10.1016/j.chemosphere.2004.02.024
   Deane EE, 2001, COMP BIOCHEM PHYS B, V129, P687, DOI 10.1016/S1096-4959(01)00369-4
   Di Giulio RT, 2008, TOXICOLOGY FISHES, P1101
   DIGIULIO RT, 1993, AQUAT TOXICOL, V26, P1, DOI 10.1016/0166-445X(93)90002-I
   Dytham C., 1999, CHOOSING USING STAT
   El-Demerdash FM, 1999, INT J ENVIRON HEAL R, V9, P89
   EPA(U.S. Environmental Protection Agency), 1992, QUAL CRIT WAT 1992
   Gad SC, 2007, ANIMAL MODELS TOXICO, V950
   Gupta P, 1997, FRESEN ENVIRON BULL, V6, P355
   Haschek WM, 2010, FUNDAMENTALS OF TOXICOLOGIC PATHOLOGY, 2ND EDITION, P1
   Hecker M, 2002, ENVIRON SCI TECHNOL, V36, P2311, DOI 10.1021/es010186h
   Hedayati A., 2010, WORLD J FISH MARINE, V2, P86
   Hedayati Aliakbar, 2010, World Journal of Fish and Marine Sciences, V2, P186
   Hontela A, 1996, AQUAT TOXICOL, V35, P171, DOI 10.1016/0166-445X(96)00012-4
   Iwama GK, 1999, AM ZOOL, V39, P901
   Jessica D, 2007, SCI TOTAL ENVIRON, V372, P497, DOI 10.1016/j.scitotenv.2006.08.020
   Lawrence A, 2003, EFFECTS POLLUTION FI, P362
   LOVETT DL, 1994, COMP BIOCHEM PHYS B, V109, P163, DOI 10.1016/0305-0491(94)90153-8
   Lucas A, 1996, BIOENERGETICS AQUATI
   Matthiessen P, 2003, PURE APPL CHEM, V75, P2249, DOI 10.1351/pac200375112249
   Mazorra MT, 2002, COMP BIOCHEM PHYS B, V131, P241, DOI 10.1016/S1096-4959(01)00502-4
   Moopam, 1999, MAN OC OBS POLL AN M
   Neff JM, 1997, ENVIRON TOXICOL CHEM, V16, P917, DOI 10.1897/1551-5028(1997)016<0917:EOAITM>2.3.CO;2
   NELSON D. L., 2005, LEHNINGER PRINCIPLES, P1013
   Oruc EO, 1999, ENVIRON POLLUT, V105, P267, DOI 10.1016/S0269-7491(98)00206-1
   PELGROM SMGJ, 1995, AQUAT TOXICOL, V32, P303, DOI 10.1016/0166-445X(95)00004-N
   Poleksic V, 1999, ECOTOX ENVIRON SAFE, V43, P213, DOI 10.1006/eesa.1999.1790
   Prasath PMD, 2008, IRAN J ENVIRON HEALT, V5, P109
   Reid SG, 1998, COMP BIOCHEM PHYS C, V120, P1, DOI 10.1016/S0742-8413(98)00037-1
   REITMAN S, 1957, AM J CLIN PATHOL, V28, P56
   Saera-Vila A, 2009, COMP BIOCHEM PHYS A, V154, P197, DOI 10.1016/j.cbpa.2009.06.004
   Safahieh Alireza, 2010, American-Eurasian Journal of Toxicological Sciences, V2, P162
   Savari Ahmad, 2010, World Journal of Fish and Marine Sciences, V2, P475
   Schlenk D, 2001, TARGET ORGAN TOXICIT, V2, P225
   Scott GR, 2004, AQUAT TOXICOL, V68, P369, DOI 10.1016/j.aquatox.2004.03.016
   Shakoori A.R., 1994, J ECOTOXICOL ENV MON, V4, P81
   Shi JB, 2005, ENVIRON INT, V31, P357, DOI 10.1016/j.envint.2004.08.008
   Sperry TS, 1999, ENDOCRINOLOGY, V140, P1602, DOI 10.1210/en.140.4.1602
   THOMAS P, 1989, MAR ENVIRON RES, V28, P499, DOI 10.1016/0141-1136(89)90291-2
   Webb MAH, 2006, ARCH ENVIRON CON TOX, V50, P443, DOI 10.1007/s00244-004-0159-0
NR 50
TC 4
Z9 4
U1 2
U2 14
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0748-2337
EI 1477-0393
J9 TOXICOL IND HEALTH
JI Toxicol. Ind. Health
PD MAY
PY 2012
VL 28
IS 4
BP 306
EP 319
DI 10.1177/0748233711410916
PG 14
WC Public, Environmental & Occupational Health; Toxicology
SC Public, Environmental & Occupational Health; Toxicology
GA 923OM
UT WOS:000302628600003
PM 21911425
DA 2018-12-27
ER

PT J
AU Jahanbin, K
   Hedayati, A
   Moini, S
   Gohari, AR
   Emam-Djomeh, Z
   Esposito, A
   Bagheri, T
AF Jahanbin, Kambiz
   Hedayati, Aliakbar
   Moini, Sohrab
   Gohari, Ahmad Reza
   Emam-Djomeh, Zahra
   Esposito, Antonio
   Bagheri, Tahere
TI RETRACTED: The first application of a new polysaccharide from
   Acanthophyllum bracteatum for the health improvement of Atlantic salmon
   exposed to mercury chloride(Retracted article. See vol. 33, pg. NP1-NP1,
   2017)
SO TOXICOLOGY AND INDUSTRIAL HEALTH
LA English
DT Article; Retracted Publication
DE Atlantic salmon; fish health; polysaccharide; probiotic; mercury
ID RAINBOW-TROUT; HEMATOLOGICAL PARAMETERS; TOXICITY; DIETARY; GROWTH;
   FISH; CADMIUM; STRESS; RESISTANCE; APOPTOSIS
AB Polysaccharides are biopolymers that play key roles as therapeutic agents. The current study examined the efficiency of a polysaccharide newly derived from a plant resource for detection of sub-acute mercury (Hg) exposure on blood characteristics of Atlantic salmon. The polysaccharide was extracted from the roots of Acanthophyllum bracteatum, and the Atlantic salmon were divided into three groups and placed in fiberglass tanks: one with no Hg as a control, one filled with 60 mu g l(-1) of Hg solution, and one with 60 mu g l(-1) Hg solution plus 1% weight/weight (w/w) of polysaccharide, which had been added 24 hours before the addition of Hg solution. Serum hematological and biochemical parameters were analysed. Results of the study showed that the blood factors were significantly adjusted in the group that had been exposed to the polysaccharide and Hg compared to the group that had been exposed only to Hg. The polysaccharide had an adjustment effect on lymphocytes, granulocytes, red blood cells (RBCs), Hemoglobin (Hb), mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), alanine aminotransferase (ALT), aspartate aminotransferase (AST), protein, chlorine (Cl), sodium (Na), and glucose. It did not have a significant effect on hematocrit (Ht), mean corpuscular hemoglobin concentration (MCHC), potassium (K), and monocytes. Finally, the results confirmed that the new polysaccharide has useful effects on the host, possibly acting as a probiotic by selectively motivating the activity of some useful bacteria, which can improve the host health. This is the first report on application of this polysaccharide for the health improvement of Atlantic salmon exposed to mercury chloride.
C1 [Hedayati, Aliakbar; Bagheri, Tahere] Univ Agr Sci & Nat Resources, Dept Fishery, Gorgan, Iran.
   [Jahanbin, Kambiz] Shahrood Univ Technol, Sch Agr Engn, Fac Agr, Shahrood, Iran.
   [Moini, Sohrab; Emam-Djomeh, Zahra] Univ Tehran, Dept Food Sci & Engn, Karaj, Iran.
   [Gohari, Ahmad Reza] Univ Tehran Med Sci, Med Plants Res Ctr, Tehran, Iran.
   [Esposito, Antonio] Ist Zooprofilatt Sperimentale Mezzogiorno, Lab Patol Organismi Acquat, Rome, Italy.
RP Hedayati, A (reprint author), Univ Agr Sci & Nat Resources, Dept Fishery, Gorgan, Iran.
EM marinebiology1@gmail.com
RI Hedayati, Aliakbar/R-1734-2016; Emam-Djomeh, zahra/D-2277-2016
OI Hedayati, Aliakbar/0000-0001-7658-5314; Emam-Djomeh,
   zahra/0000-0002-1690-1968; Jahanbin, Kambiz/0000-0002-5772-2501
FU Istituto Zooprofilattico Sperimentale del Mezzogiorno, Roma, Italy
FX The authors are deeply grateful to the Istituto Zooprofilattico
   Sperimentale del Mezzogiorno, Roma, Italy, for financial support and
   providing necessary facilities for the experiment, and for their support
   during the tenure of this project.
CR Abdel-Tawwab M, 2007, AQUACULTURE, V264, P236, DOI 10.1016/j.aquaculture.2006.12.020
   Amarowicz R, 2000, J AGR FOOD CHEM, V48, P2755, DOI 10.1021/jf9911601
   Arifkhodzhaev AO, 2003, CHEM NAT COMPD, V39, P111
   Arifkhodzhaev AO, 1997, CHEM NAT COMPD, V33, P693
   Arifkhodzhaev AO, 1999, CHEM NAT COMPD, V35, P169
   Baskin DS, 2003, TOXICOL SCI, V74, P361, DOI 10.1093/toxsci/kfg126
   Beutler E, 2001, TURKISH J ZOOLOGY, V20, P161
   Bonga SEW, 1997, PHYSIOL REV, V77, P591, DOI 10.1152/physrev.1997.77.3.591
   Chowdhury MJ, 2004, AQUAT TOXICOL, V69, P149, DOI 10.1016/j.aquatox.2004.05.002
   Fange R, 1992, FISH PHYSIOL BIOCHEM, V12B, P376
   Gaidi G, 2004, J NAT PROD, V67, P1114, DOI 10.1021/np040001v
   Ghaffari SM, 2004, BIOLOGIA, V59, P53
   Ghorpade N, 2002, ECOTOX ENVIRON SAFE, V53, P255, DOI 10.1006/eesa.2002.2212
   Gibson G. R., 2003, Gut flora, nutrition, immunity and health, P52
   GIBSON GR, 1995, J NUTR, V125, P1401
   GOLDENFARB PB, 1971, AM J CLIN PATHOL, V56, P35
   Hedayati A., 2010, WORLD J FISH MARINE, V2, P86
   Houston AH, 1997, T AM FISH SOC, V126, P879, DOI 10.1577/1548-8659(1997)126<0879:RATCHV>2.3.CO;2
   Jimenez-Medina E, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-78
   Kim SG, 2008, B ENVIRON CONTAM TOX, V81, P470, DOI 10.1007/s00128-008-9499-1
   Kim SH, 2005, IMMUNOPHARM IMMUNOT, V27, P123, DOI 10.1081/IPH-200051757
   Komarov VL, 1970, FLORA USSR, V6, P594
   Kumar M, 2005, J HEALTH SCI, V51, P424, DOI 10.1248/jhs.51.424
   Kurbanova AD, 2003, CHEM NAT COMPD, V39, P361
   LACAILLEDUBOIS MA, 1993, PHYTOCHEMISTRY, V34, P489, DOI 10.1016/0031-9422(93)80036-R
   LEE RG, 1998, WINTROBES CLIN HEMAT
   Leonard J, 1986, JARDIN BOTANIQUE NAT, V6, P10
   Lim C, 2000, AQUACULTURE, V185, P313, DOI 10.1016/S0044-8486(99)00352-X
   Liu F, 1997, LIFE SCI, V60, P763, DOI 10.1016/S0024-3205(97)00004-0
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   MACINNES JR, 1977, FISH B-NOAA, V75, P199
   Merrifield DL, 2010, AQUACULTURE, V302, P1, DOI 10.1016/j.aquaculture.2010.02.007
   Olivieri G, 2000, J NEUROCHEM, V74, P231, DOI 10.1046/j.1471-4159.2000.0740231.x
   Ooi VEC, 2000, CURR MED CHEM, V7, P715
   Palackova J., 1994, SUBLETHAL CHRONIC EF, P53
   Parsa A, 1951, FLORE IRAN, V1, P1043
   Petri D, 2006, AQUAT TOXICOL, V80, P207, DOI 10.1016/j.aquatox.2006.07.019
   Prasath PMD, 2008, IRAN J ENVIRON HEALT, V5, P109
   Rechinger KH, 1988, FLORA IRANICA FLORA, P253
   REDDY PS, 1994, ECOTOX ENVIRON SAFE, V29, P255, DOI 10.1016/0147-6513(94)90002-7
   REITMAN S, 1957, AM J CLIN PATHOL, V28, P56
   Ribeiro CAO, 2006, ENVIRON RES, V101, P74, DOI 10.1016/j.envres.2005.11.005
   Rodriguez-Estrada U, 2009, AQUACULT SCI, V57, P609
   Rossi AD, 1997, CELL DEATH DIFFER, V4, P317, DOI 10.1038/sj.cdd.4400244
   Sancho E, 2000, ECOTOX ENVIRON SAFE, V46, P81, DOI 10.1006/eesa.1999.1888
   SANDNES K, 1988, J FISH BIOL, V32, P129, DOI 10.1111/j.1095-8649.1988.tb05341.x
   Schiman-Czeika H, 1988, FLORA IRANICA
   Sealey WM, 2007, N AM J AQUACULT, V69, P400, DOI 10.1577/A06-080.1
   Sevag MG, 1934, BIOCHEM Z, V419, P273
   Staykov Y, 2007, AQUACULT INT, V15, P153, DOI 10.1007/s10499-007-9096-z
   Torre D, 2005, CHEMOSPHERE, V59, P577
   Trinder P., 1969, ANNALS CLINICAL BIOC, V6, P24, DOI DOI 10.1177/000456326900600108
   Yen GC, 1996, MUTAGENESIS, V11, P37, DOI 10.1093/mutage/11.1.37
NR 53
TC 5
Z9 5
U1 1
U2 14
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0748-2337
EI 1477-0393
J9 TOXICOL IND HEALTH
JI Toxicol. Ind. Health
PD MAY
PY 2012
VL 28
IS 4
BP 377
EP 384
DI 10.1177/0748233711413797
PG 8
WC Public, Environmental & Occupational Health; Toxicology
SC Public, Environmental & Occupational Health; Toxicology
GA 923OM
UT WOS:000302628600011
PM 21911428
DA 2018-12-27
ER

PT J
AU Wu, GW
   Chen, XZ
   Peng, J
   Cai, QY
   Ye, JX
   Xu, HF
   Zheng, CS
   Li, XH
   Ye, HZ
   Liu, XX
AF Wu, Guangwen
   Chen, Xuzheng
   Peng, Jun
   Cai, Qiaoyan
   Ye, Jinxia
   Xu, Huifeng
   Zheng, Chunsong
   Li, Xihai
   Ye, Hongzhi
   Liu, Xianxiang
TI RETRACTED: Millimeter wave treatment induces apoptosis via activation of
   the mitochondrial-dependent pathway in human osteosarcoma cells
   (Retracted article. See vol. 44, pg. 629, 2014)
SO INTERNATIONAL JOURNAL OF ONCOLOGY
LA English
DT Article; Retracted Publication
DE osteosarcoma cell; millimeter wave; apoptosis; mitochondria
ID CHANNEL-FORMING ACTIVITY; BCL-2 PROTEIN FAMILY; CYTOCHROME-C;
   GENE-EXPRESSION; DEATH; BAX; MEMBRANE; RELEASE; CHONDROCYTES; CANCER
AB Millimeter wave (MW) is an electromagnetic wave with a wavelength between 1 and 10 mm and a frequency of 30-300 GHz that causes multiple biological effects and has been used as a major component in physiotherapies for the clinical treatment of various types of diseases including cancers. However, the precise molecular mechanism of the anticancer activity of rnillimeter wave remains to be elucidated. In the present study, we investigated the cellular effects of the MW in the U-2OS human osteosarcoma cell line. Our results showed that MW induced cell morphological changes and reduced cell viability in a dose- and time-dependent manner suggesting that MW inhibited the growth of U-2OS cells as demonstrated. Hoechst 33258 staining and Annexin V/propidium iodide double staining exhibited the typical nuclear features of apoptosis and increased the proportion of apoptotic Annexin V-positive cells in a dose-dependent manner, respectively. In addition, MW treatment caused loss or plasma membrane asymmetry, release of cytochrome c, collapse of mitochondria! membrane potential, activation of caspase-9 and -3, and increase of the ratio of proapoptotic Bax to anti-apoptotic Bcl-2. Taken together, the results indicate that the U-2OS cell growth inhibitory activity of MW was due to mitochondrial-mediated apoptosis, which may partly explain the anticancer activity of millimeter wave treatment.
C1 [Peng, Jun; Cai, Qiaoyan; Ye, Jinxia; Liu, Xianxiang] Fujian Univ Tradit Chinese Med, Acad Integrat Med, Biomed Res Ctr, Fuzhou 350108, Peoples R China.
   [Xu, Huifeng] Fujian Univ Tradit Chinese Med, Fujian Key Lab Integrat Med Geriatr, Fuzhou 350108, Peoples R China.
RP Liu, XX (reprint author), Fujian Univ Tradit Chinese Med, Acad Integrat Med, Biomed Res Ctr, 1 Huatuo Rd, Fuzhou 350108, Peoples R China.
EM liuxianxiang@163.com
FU Developmental Fund of Chen Keji Integrative Medicine [CKJ2010023]
FX This work was supported by the Developmental Fund of Chen Keji
   Integrative Medicine (CKJ2010023).
CR Adams JM, 2007, ONCOGENE, V26, P1324, DOI 10.1038/sj.onc.1210220
   Adams JM, 2001, TRENDS BIOCHEM SCI, V26, P61, DOI 10.1016/S0968-0004(00)01740-0
   Antonsson B, 2000, BIOCHEM J, V345, P271, DOI 10.1042/0264-6021:3450271
   Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370
   Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305
   Bancroft MI, 2003, PHYSIOTHERAPY, V89, P729
   Boos G, 2000, TOXICOL LETT, V116, P7, DOI 10.1016/S0378-4274(00)00192-2
   Brown GC, 1999, BIOCHEM SOC SYMP, V66, P17, DOI 10.1042/bss0660017
   Chen JL, 2009, INT J INFECT DIS S1, V13, pS62
   Chou AJ, 2006, EXPERT REV ANTICANC, V6, P1075, DOI 10.1586/14737140.6.7.1075
   Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883
   COSSARIZZA A, 1993, BIOCHEM BIOPH RES CO, V197, P40, DOI 10.1006/bbrc.1993.2438
   Dorey G, 2000, PHYSIOTHERAPY, V86, P413
   Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000
   Federman N, 2009, CURR TREAT OPTION ON, V10, P82, DOI 10.1007/s11864-009-0087-3
   Fujio Y, 2000, CIRCULATION, V101, P660, DOI 10.1161/01.CIR.101.6.660
   Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899
   Kager L, 2003, J CLIN ONCOL, V21, P2011, DOI 10.1200/JCO.2003.08.132
   Kim SJ, 2004, CLIN IMAG, V28, P291, DOI 10.1016/S0899-7071(03)00206-7
   Kitada S, 2002, ONCOGENE, V21, P3459, DOI 10.1038/sj/onc/1205327
   Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132
   Korper S, 2003, EXP HEMATOL, V31, P815, DOI 10.1016/S0301-472X(03)00199-1
   Lauridsen MC, 2005, ACTA ONCOL, V44, P449, DOI 10.1080/02841860510029905
   Li XH, 2010, INT J MOL MED, V25, P393, DOI 10.3892/ijmm_00000357
   Longhi A, 2006, CANCER TREAT REV, V32, P423, DOI 10.1016/j.ctrv.2006.05.005
   Mantymaa P, 2000, BRIT J HAEMATOL, V108, P574, DOI 10.1046/j.1365-2141.2000.01852.x
   Millenbaugh NJ, 2008, RADIAT RES, V169, P288, DOI 10.1667/RR1121.1
   MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471
   Opferman JT, 2003, NATURE, V426, P671, DOI 10.1038/nature02067
   SMILEY ST, 1991, P NATL ACAD SCI USA, V88, P3671, DOI 10.1073/pnas.88.9.3671
   Somerhausen ND, 1999, EUR J SURG ONCOL, V25, P215, DOI 10.1053/ejso.1998.0630
   Thomenius MJ, 2003, J BIOL CHEM, V278, P6243, DOI 10.1074/jbc.M208878200
   Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312
   Usichenko TI, 2008, EUR J PAIN, V12, P617, DOI 10.1016/j.ejpain.2007.10.004
   Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4
   VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M
   Wang YP, 2001, J INFRARED MILLIM W, V20, P283
   Wei MC, 2000, GENE DEV, V14, P2060
   Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281
   Wu GW, 2009, INT J MOL MED, V23, P461, DOI 10.3892/ijmm_00000152
   Wu GW, 2011, MOL MED REP, V4, P1001, DOI 10.3892/mmr.2011.522
   Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129
   Yip KW, 2008, ONCOGENE, V27, P6398, DOI 10.1038/onc.2008.307
   Youle RJ, 2008, NAT REV MOL CELL BIO, V9, P47, DOI 10.1038/nrm2308
   Zhadobov M, 2007, BIOELECTROMAGNETICS, V28, P188, DOI 10.1002/bem.20285
   Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549
NR 46
TC 2
Z9 3
U1 3
U2 23
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1019-6439
EI 1791-2423
J9 INT J ONCOL
JI Int. J. Oncol.
PD MAY
PY 2012
VL 40
IS 5
BP 1543
EP 1552
DI 10.3892/ijo.2012.1330
PG 10
WC Oncology
SC Oncology
GA 918TG
UT WOS:000302273400025
PM 22246399
OA Bronze
DA 2018-12-27
ER

PT J
AU Anderson, DE
   Bell, TA
   Awh, E
AF Anderson, David E.
   Bell, Theodore A.
   Awh, Edward
TI RETRACTED: Polymorphisms in the 5-HTTLPR Gene Mediate Storage Capacity
   of Visual Working Memory (Retracted Article)
SO JOURNAL OF COGNITIVE NEUROSCIENCE
LA English
DT Article; Retracted Publication
ID SEROTONIN TRANSPORTER GENE; SHORT-TERM-MEMORY;
   CATECHOL-O-METHYLTRANSFERASE; 5-HT1A RECEPTOR-BINDING;
   INDIVIDUAL-DIFFERENCES; PROMOTER POLYMORPHISM; PREFRONTAL CORTEX; BIASED
   ATTENTION; COGNITIVE PERFORMANCE; FLUID INTELLIGENCE
AB Working memory (WM) is a limited capacity system that permeates nearly all levels of cognition, ranging from perceptual awareness to intelligence. Through behavioral, electrophysiological, and neuroimaging work, substantial gains have been made in understanding this capacity-limited system. In the current work, we examined genetic contributions to the storage capacity of WM. Multiple studies have demonstrated a link between the serotonin transporter-linked polymorphic region (5-HTTLPR) and cognition, where better performance is observed in individuals possessing a copy of the short (s) variant of the polymorphism compared with individuals homozygous for the long (l) variant. We predicted the same profile in WM performance, such that estimated capacities of l/l carriers should be smaller than s/s and s/l carriers. To measure WM capacity, we implemented a change detection task, which requires observers to actively maintain the color and spatial location of briefly presented squares over a short retention interval. In line with our prediction, we observed similar WM performance between s/s and s/l groups, and these individuals performed better than the l/l group. We then discuss the distribution of the serotonin transporter system and parallels between WM and attention to provide insight into how variation in the 5-HTT polymorphism could lead to individual differences in the storage capacity of WM.
C1 [Anderson, David E.; Bell, Theodore A.; Awh, Edward] Univ Oregon, Eugene, OR 97403 USA.
RP Anderson, DE (reprint author), 1227 Univ Oregon, Dept Psychol, Eugene, OR 97403 USA.
EM danders3@uoregon.edu; awh@uoregon.edu
FU  [NIH-R01MH077105]
FX This study was supported by NIH-R01MH077105 to E. A. E. A. conceived and
   designed the experiment, D. E. A. collected and analyzed data, D. E. A.,
   T. A. B., and E. A. wrote the report.
CR Althaus M, 2009, CLIN NEUROPHYSIOL, V120, P93, DOI 10.1016/j.clinph.2008.10.012
   Awh E, 2006, NEUROSCIENCE, V139, P201, DOI 10.1016/j.neuroscience.2005.08.023
   Awh E, 2001, TRENDS COGN SCI, V5, P119, DOI 10.1016/S1364-6613(00)01593-X
   Beevers CG, 2007, J ABNORM PSYCHOL, V116, P208, DOI 10.1037/0021-843X.116.1.208
   Beevers CG, 2009, J ABNORM PSYCHOL, V118, P670, DOI 10.1037/a0016198
   Bennett AJ, 2002, MOL PSYCHIATR, V7, P118, DOI 10.1038/sj/mp/4000949
   Bleckley MK, 2003, PSYCHON B REV, V10, P884, DOI 10.3758/BF03196548
   Borg J, 2009, INT J NEUROPSYCHOPH, V12, P783, DOI 10.1017/S1461145708009759
   Brainard DH, 1997, SPATIAL VISION, V10, P433, DOI 10.1163/156856897X00357
   Buschman TJ, 2011, P NATL ACAD SCI USA, V108, P11252, DOI 10.1073/pnas.1104666108
   Canli T, 2005, P NATL ACAD SCI USA, V102, P12224, DOI 10.1073/pnas.0503880102
   Canli T, 2007, NAT NEUROSCI, V10, P1103, DOI 10.1038/nn1964
   Chun MM, 2011, NEUROPSYCHOLOGIA, V49, P1407, DOI 10.1016/j.neuropsychologia.2011.01.029
   Cowan N, 2005, COGNITIVE PSYCHOL, V51, P42, DOI 10.1016/j.cogpsych.2004.12.001
   Cowan N, 2001, BEHAV BRAIN SCI, V24, P154
   Crisan LG, 2009, SOC COGN AFFECT NEUR, V4, P399, DOI 10.1093/scan/nsp019
   Curtis CE, 2003, TRENDS COGN SCI, V7, P415, DOI 10.1016/S1364-6613(03)00197-9
   D'Esposito M, 1999, BRAIN COGNITION, V41, P66, DOI 10.1006/brcg.1999.1096
   David SP, 2005, J NEUROSCI, V25, P2586, DOI 10.1523/JNEUROSCI.3769-04.2005
   Deckert J, 1997, PSYCHIATR GENET, V7, P45, DOI 10.1097/00041444-199700710-00008
   Enge S, 2011, NEUROPSYCHOLOGIA, V49, P3776, DOI 10.1016/j.neuropsychologia.2011.09.038
   Enge S, 2011, BEHAV BRAIN RES, V216, P122, DOI 10.1016/j.bbr.2010.07.021
   Engle RW, 1999, J EXP PSYCHOL GEN, V128, P309, DOI 10.1037//0096-3445.128.3.309
   Engle RW, 2002, CURR DIR PSYCHOL SCI, V11, P19, DOI 10.1111/1467-8721.00160
   Fallgatter AJ, 2004, NEUROPSYCHOPHARMACOL, V29, P1506, DOI 10.1038/sj.npp.1300409
   Fallgatter AJ, 1999, INT J NEUROPSYCHOP, V2, P115, DOI 10.1017/S1461145799001455
   Flint J, 1999, BRAIN, V122, P2015, DOI 10.1093/brain/122.11.2015
   Fox E, 2009, P R SOC B, V276, P1747, DOI 10.1098/rspb.2008.1788
   Fukuda K, 2011, PSYCHOL SCI, V22, P361, DOI 10.1177/0956797611398493
   Fukuda K, 2010, PSYCHON B REV, V17, P673, DOI 10.3758/17.5.673
   Fukuda K, 2010, CURR OPIN NEUROBIOL, V20, P177, DOI 10.1016/j.conb.2010.03.005
   Fukuda K, 2009, J NEUROSCI, V29, P8726, DOI 10.1523/JNEUROSCI.2145-09.2009
   FUNAHASHI S, 1989, J NEUROPHYSIOL, V61, P331
   Gibb BE, 2009, J CLIN CHILD ADOLESC, V38, P415, DOI 10.1080/15374410902851705
   Glatz K, 2003, J NEUROCHEM, V86, P1072, DOI 10.1046/j.1471-4159.2003.01944.x
   Gurevich EV, 1996, NEUROPSYCHOPHARMACOL, V14, P309, DOI 10.1016/0893-133X(95)00139-5
   Hariri AR, 2002, SCIENCE, V297, P400, DOI 10.1126/science.1071829
   Heinz A, 2005, NAT NEUROSCI, V8, P20, DOI 10.1038/nn1366
   Homberg JR, 2011, BIOL PSYCHIAT, V69, P513, DOI 10.1016/j.biopsych.2010.09.024
   Jedema HP, 2010, MOL PSYCHIATR, V15, P512, DOI 10.1038/mp.2009.90
   Kane MJ, 2001, J EXP PSYCHOL GEN, V130, P169, DOI 10.1037/0096-3445.130.2.169
   Koechlin E, 2003, SCIENCE, V302, P1181, DOI 10.1126/science.1088545
   Lesch KP, 1996, SCIENCE, V274, P1527, DOI 10.1126/science.274.5292.1527
   Li Q, 2000, J NEUROSCI, V20, P7888
   Lira A, 2003, BIOL PSYCHIAT, V54, P960, DOI 10.1016/S0006-3223(03)00696-6
   Liu S, 2010, J PHYSIOL SCI, V60, pS201
   Luck SJ, 1997, NATURE, V390, P279, DOI 10.1038/36846
   Madsen K, 2011, PSYCHOPHARMACOLOGY, V213, P573, DOI 10.1007/s00213-010-1926-4
   McCann UD, 2008, PSYCHOPHARMACOLOGY, V200, P439, DOI 10.1007/s00213-008-1218-4
   McCollough AW, 2007, CORTEX, V43, P77, DOI 10.1016/S0010-9452(08)70447-7
   Mcnab F, 2008, NAT NEUROSCI, V11, P103, DOI 10.1038/nn2024
   Morley KI, 2001, BEHAV GENET, V31, P511, DOI 10.1023/A:1013337209957
   Osinsky R, 2008, EMOTION, V8, P584, DOI 10.1037/a0012826
   Paaver M, 2007, PSYCHOPHARMACOLOGY, V194, P545, DOI 10.1007/s00213-007-0867-z
   Palva JM, 2010, P NATL ACAD SCI USA, V107, P7580, DOI 10.1073/pnas.0913113107
   Papale LA, 2010, J BIOL CHEM, V285, P16553, DOI 10.1074/jbc.M109.090084
   Papassotiropoulos A, 2011, MOL PSYCHIATR, V16, P184, DOI 10.1038/mp.2009.133
   PASHLER H, 1988, PERCEPT PSYCHOPHYS, V44, P369, DOI 10.3758/BF03210419
   Pelli DG, 1997, SPATIAL VISION, V10, P437, DOI 10.1163/156856897X00366
   Pezawas L, 2005, NAT NEUROSCI, V8, P828, DOI 10.1038/nn1463
   Roiser JP, 2007, INT J NEUROPSYCHOPH, V10, P449, DOI 10.1017/S146114570600705X
   Roiser JP, 2006, PSYCHOPHARMACOLOGY, V188, P213, DOI 10.1007/s00213-006-0495-z
   Sakai K, 2002, NAT NEUROSCI, V5, P479, DOI 10.1038/nn846
   Savitz J, 2006, GENES BRAIN BEHAV, V5, P311, DOI 10.1111/j.1601-183X.2005.00163.x
   Sen S, 2004, AM J MED GENET B, V127B, P85, DOI 10.1002/ajmg.b.20158
   Soderqvist S, 2010, BIOL PSYCHIAT, V68, P1120, DOI 10.1016/j.biopsych.2010.07.036
   Strobel A, 2007, J COGNITIVE NEUROSCI, V19, P1923, DOI 10.1162/jocn.2007.19.12.1923
   Tan HY, 2007, J NEUROSCI, V27, P13393, DOI 10.1523/JNEUROSC.4041-07.2007
   Tan HY, 2007, P NATL ACAD SCI USA, V104, P12536, DOI 10.1073/pnas.0610125104
   Thomason ME, 2010, BIOL PSYCHOL, V85, P38, DOI 10.1016/j.biopsycho.2010.04.009
   Todd JJ, 2004, NATURE, V428, P751, DOI 10.1038/nature02466
   Unsworth N, 2005, MEM COGNITION, V33, P213, DOI 10.3758/BF03195310
   Vogel EK, 2005, NATURE, V438, P500, DOI 10.1038/nature04171
   Vogel EK, 2004, NATURE, V428, P748, DOI 10.1038/nature02447
   Vogel EK, 2000, PSYCHOPHYSIOLOGY, V37, P190, DOI 10.1111/1469-8986.3720190
   Vogel EK, 2001, J EXP PSYCHOL HUMAN, V27, P92, DOI 10.1037/0096-1523.27.1.92
   Williams LM, 2009, NEUROIMAGE, V47, P804, DOI 10.1016/j.neuroimage.2009.05.009
   Xu YD, 2006, NATURE, V440, P91, DOI 10.1038/nature04262
NR 78
TC 23
Z9 23
U1 2
U2 24
PU MIT PRESS
PI CAMBRIDGE
PA ONE ROGERS ST, CAMBRIDGE, MA 02142-1209 USA
SN 0898-929X
EI 1530-8898
J9 J COGNITIVE NEUROSCI
JI J. Cogn. Neurosci.
PD MAY
PY 2012
VL 24
IS 5
BP 1069
EP 1076
DI 10.1162/jocn_a_00207
PG 8
WC Neurosciences; Psychology, Experimental
SC Neurosciences & Neurology; Psychology
GA 918NI
UT WOS:000302256300003
PM 22332803
OA Green Accepted, Green Published
DA 2018-12-27
ER

PT J
AU Zhang, J
   Zhu, JS
   Zhou, Z
   Chen, WX
   Chen, NW
AF Zhang, Jing
   Zhu, Jin-Shui
   Zhou, Zhou
   Chen, Wei-Xiong
   Chen, Ni-Wei
TI RETRACTED: Inhibitory effects of ethyl pyruvate administration on human
   gastric cancer growth via regulation of the HMGB1-RAGE and Akt pathways
   in vitro and in vivo (Retracted article. See vol. 36, pg. 3716, 2016)
SO ONCOLOGY REPORTS
LA English
DT Article; Retracted Publication
DE ethyl pyruvate; high mobility group box-B1; receptor for advanced
   glycation end-products; growth; gastric cancer
ID GLYCATION END-PRODUCTS; MOBILITY GROUP BOX-1; TUMOR-GROWTH;
   GENE-EXPRESSION; LUNG-CANCER; P53 PATHWAY; CELLS; RAGE; APOPTOSIS;
   RECEPTOR
AB The high mobility group box-Bl (HMGB1)-receptor for advanced glycation end-products (RAGE) and the protein kinase B (Akt) pathways play a crucial role in tumorigenesis and development of many malignant tumors. Ethyl pyruvate (EP), a potent inhibitor of HMGB1 release, can exert antitumor effects on the growth of gastric cancer. Therefore, it is necessary to observe the effects of EP on gastric cancer growth in vitro and in vivo. Human gastric adenocarcinoma tissues of different grades (N=45) were collected. The expression of HMGB1 and RAGE was evaluated immunohistochemically in biopsy samples. After SGC-7901 gastric cancer cells were treated with EP, the expression of HMGB1, RAGE, Akt, phosphorylated Akt (p-Akt) and some transcription factors was identified and the effects of EP on cell proliferation, invasion, cell cycle distribution and apoptosis were assessed. A subcutaneous xenograft tumor model was established, validating the effects of EP on tumor growth in vivo. The expression of HMGB1 and RAGE was respectively observed in 73.3 and 68.9% of the gastric adenocarcinoma tissues. The frequency of positive expression increased with the ascending grade of the tumor malignancy. EP decreased the expression of HMGB I, RAGE, Akt, p-Akt, Ki-67 and matrix metallopeptidase-9 (MMP-9), and increased the expression of p53. Moreover, EP could inhibit tumor cell proliferation and invasion, induce cell cycle arrest and apoptosis and slow the growth of xenograft tumors. In conclusion, HMGB1 and RAGE were strongly expressed in gastric adenocarcinoma, and EP administration inhibited gastric cancer growth via regulation of the HMGB1-RAGE and Akt pathways. EP may play a critical role in the treatment of cancer in conjunction with other therapeutic agents.
C1 [Zhang, Jing; Zhu, Jin-Shui; Zhou, Zhou; Chen, Wei-Xiong; Chen, Ni-Wei] Shanghai Jiao Tong Univ, Dept Gastroenterol, Shanghai Peoples Hosp 6, Shanghai 200233, Peoples R China.
RP Zhu, JS (reprint author), Shanghai Jiao Tong Univ, Dept Gastroenterol, Peoples Hosp 6, 600 Yishan Rd, Shanghai 200233, Peoples R China.
EM zhujs1803@hotmail.com
FU Science and Technology Commission Animal Experiment Foundation of
   Shanghai, China [10140902500]
FX This study was supported by the Science and Technology Commission Animal
   Experiment Foundation of Shanghai, China (grant no. 10140902500). We
   thank the members of the Chinese Academy of Sciences (Shanghai) for
   providing their technical assistance.
CR Akaike H, 2007, ANTICANCER RES, V27, P449
   Arumugam T, 2006, J NATL CANCER I, V98, P1806, DOI 10.1093/jnci/djj498
   Bennett-Guerrero E, 2009, J CARDIOTHOR VASC AN, V23, P324, DOI 10.1053/j.jvca.2008.08.005
   Cawston TE, 2006, BEST PRACT RES CL RH, V20, P983, DOI 10.1016/j.berh.2006.06.007
   Chung KY, 2008, TRANSPL P, V40, P2136, DOI 10.1016/j.transproceed.2008.06.040
   Czyzewska J, 2004, Rocz Akad Med Bialymst, V49 Suppl 1, P64
   Dave SH, 2009, J LEUKOCYTE BIOL, V86, P633, DOI 10.1189/jlb.1008662
   Fu YC, 2009, INT J ONCOL, V35, P583, DOI 10.3892/ijo_00000369
   Gnanasekar M, 2009, INT J ONCOL, V34, P425, DOI 10.3892/ijo_00000166
   Gupta S. K., 2000, Indian Journal of Physiology and Pharmacology, V44, P101
   Han Z, 2006, J EXP CLIN CANC RES, V25, P601
   Han Z, 2008, DIGEST DIS SCI, V53, P1801, DOI 10.1007/s10620-007-9824-2
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/j.cell.2011.02.013
   Hanford LE, 2004, J BIOL CHEM, V279, P50019, DOI 10.1074/jbc.M409782200
   Huttunen HJ, 2004, J INTERN MED, V255, P351, DOI 10.1111/j.1365-2796.2003.01301.x
   Iiizumi M, 2008, BBA-REV CANCER, V1786, P87, DOI 10.1016/j.bbcan.2008.07.002
   Ishiguro H, 2005, PROSTATE, V64, P92, DOI 10.1002/pros.20219
   Jiao Y, 2007, ACTA PHARMACOL SIN, V28, P1957, DOI 10.1111/j.1745-7254.2007.00669.x
   Jing RR, 2010, GENET TEST MOL BIOMA, V14, P355, DOI 10.1089/gtmb.2009.0064
   Kang R, 2010, CELL DEATH DIFFER, V17, P666, DOI 10.1038/cdd.2009.149
   Kawahara KI, 2008, INT J MOL MED, V22, P639, DOI 10.3892/ijmm_00000066
   Kim SY, 2010, CANCER LETT, V295, P236, DOI 10.1016/j.canlet.2010.03.006
   Kim S, 2009, NATURE, V457, P102, DOI 10.1038/nature07623
   Kostova N, 2010, MOL CELL BIOCHEM, V337, P251, DOI 10.1007/s11010-009-0305-0
   Kountouras J, 2005, HEPATO-GASTROENTEROL, V52, P1305
   Kuniyasu H, 2002, J PATHOL, V196, P163, DOI 10.1002/path.1031
   Liang XY, 2009, J LEUKOCYTE BIOL, V86, P599, DOI 10.1189/jlb.0908578
   Lim SC, 2007, INT J MOL MED, V20, P187
   Liu PL, 2010, AM J RESP CELL MOL, V43, P530, DOI 10.1165/rcmb.2009-0269OC
   Liu XH, 2006, BRAIN RES, V1070, P24, DOI 10.1016/j.brainres.2005.11.041
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009
   Mizutani A, 2010, PULM PHARMACOL THER, V23, P308, DOI 10.1016/j.pupt.2010.03.002
   Nakamura JL, 2005, J NEURO-ONCOL, V71, P215, DOI 10.1007/s11060-004-1718-y
   Nam SY, 2003, APMIS, V111, P1105, DOI 10.1111/j.1600-0463.2003.apm1111205.x
   Neugut AI, 1996, SEMIN ONCOL, V23, P281
   Park JS, 2003, AM J PHYSIOL-CELL PH, V284, pC870, DOI 10.1152/ajpcell.00322.2002
   Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74
   Sasahira T, 2005, VIRCHOWS ARCH, V446, P411, DOI 10.1007/s00428-005-1210-x
   Schlegel J, 2000, CANCER LETT, V158, P103, DOI 10.1016/S0304-3835(00)00515-2
   Taguchi A, 2000, NATURE, V405, P354
   Tajima Y, 2006, CLIN CANCER RES, V12, P6469, DOI 10.1158/1078-0432.CCR-06-1339
   Tang DL, 2010, BBA-GENE REGUL MECH, V1799, P131, DOI 10.1016/j.bbagrm.2009.11.014
   Turovskaya O, 2008, CARCINOGENESIS, V29, P2035, DOI 10.1093/carcin/bgn188
   Ulloa L, 2002, P NATL ACAD SCI USA, V99, P12351, DOI 10.1073/pnas.192222999
   Vakkila J, 2004, NAT REV IMMUNOL, V4, P641, DOI [10.1038/nri1415, 10.1038/bri1415]
   Vaseva AV, 2009, BBA-BIOENERGETICS, V1787, P414, DOI 10.1016/j.bbabio.2008.10.005
   Vazquez A, 2008, NAT REV DRUG DISCOV, V7, P979, DOI 10.1038/nrd2656
   Volp K, 2006, GUT, V55, P234, DOI 10.1136/gut.2004.062729
   Zhang J, 2009, TECHNOL CANCER RES T, V8, P467, DOI 10.1177/153303460900800608
   Zhang Peng, 2009, Zhonghua Yi Xue Za Zhi, V89, P3156
NR 51
TC 25
Z9 34
U1 2
U2 22
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1021-335X
EI 1791-2431
J9 ONCOL REP
JI Oncol. Rep.
PD MAY
PY 2012
VL 27
IS 5
BP 1511
EP 1519
DI 10.3892/or.2012.1623
PG 9
WC Oncology
SC Oncology
GA 917TX
UT WOS:000302202600032
PM 22246223
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Parthibavarman, M
   Vallalperuman, K
   Sekar, C
   Rajarajan, G
   Logeswaran, T
AF Parthibavarman, Mathivanan
   Vallalperuman, Kaliyan
   Sekar, Chinnathambi
   Rajarajan, Gopal
   Logeswaran, Thanagaraju
TI RETRACTED: Microwave synthesis, characterization and humidity sensing
   properties of single crystalline Zn2SnO4 nanorods (Retracted article.
   See vol. 95, pg. 76, 2013)
SO VACUUM
LA English
DT Article; Retracted Publication
DE ZTO; Optical materials; X-ray diffraction; Electron microscopy;
   Luminescence; Humidity sensor
ID PHOTOLUMINESCENCE PROPERTIES; TIN OXIDE; NANOWIRES; NANOPARTICLES;
   NANOBELTS
AB The single crystalline Zn2SnO4 (ZTO) nanorods are synthesized by a simple microwave irradiation method. The nanorods are characterized by different techniques and the characterization results are shows single phase from XRD and the select area electron diffraction (SAED) pattern indicates that the ZTO nanorod growth direction of [(1) over bar3 (3) over bar]. The optical properties were analyzed by using UV-VIS diffuse reflectance spectroscopy. The band gap energy of as-synthesized ZTO nanorods is 3.26 eV. This is in good agreement with the reported values of 3.25 eV. In addition, the room temperature photoluminescence spectrum (PL) of the ZTO nanorods results indicates a broad blue-green emission with a maximum center at 490 nm and 520 nm. The strong PL emission of the nanorods suggests its possible potential applications in nano-scale optoelectronic devices. The ZTO nanorods show good sensitivity towards the relative humidity. The calculated response and recovery time were found to be 23s and 28s respectively. These results indicate promising applications of ZTO nanorods in high performance gas sensors and humidity controlled electronic device. Moreover the Method is simple, fast, less time and cost effective when compared to other methods. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Parthibavarman, Mathivanan; Vallalperuman, Kaliyan; Rajarajan, Gopal] Mahendra Engn Coll, Dept Phys, Tiruchengode 637503, Tamil Nadu, India.
   [Sekar, Chinnathambi] Periyar Univ, Dept Phys, Ctr Nanosci & Technol, Salem 636011, Tamil Nadu, India.
   [Sekar, Chinnathambi] Alagappa Univ, Dept Bioelect & Biosensors, Karaikkudi 630003, Tamil Nadu, India.
   [Logeswaran, Thanagaraju] Sri Ramakrishna Mission Vidyalaya Coll Arts & Sci, Dept Phys, Nanotechnol Lab, Coimbatore 641020, Tamil Nadu, India.
RP Parthibavarman, M (reprint author), Mahendra Engn Coll, Dept Phys, Tiruchengode 637503, Tamil Nadu, India.
EM varmanphysics85@gmail.com
RI Gopal, Dr Rajarajan/D-7731-2016
OI Gopal, Dr Rajarajan/0000-0002-2082-9807
CR Ai ZH, 2010, J HAZARD MATER, V179, P141, DOI 10.1016/j.jhazmat.2010.02.071
   Barsan N, 2010, J ELECTROCERAM, V5, P143
   Cheng G, 2007, J CRYST GROWTH, V309, P53, DOI 10.1016/j.jcrysgro.2007.09.007
   Henrich V. A., 1994, SURFACE SCI METAL OX, P312
   Hu JQ, 2003, ADV MATER, V15, P1000, DOI 10.1002/adma.200304825
   Krishnakumar T, 2008, MATER LETT, V62, P3437, DOI 10.1016/j.matlet.2008.02.062
   Krishnakumar T, 2009, MATER LETT, V63, P896, DOI 10.1016/j.matlet.2009.01.032
   Lei M, 2010, J NANOSCI NANOTECHNO, V10, P8432, DOI 10.1166/jnn.2010.3025
   Li Y, 2005, PHYS STATUS SOLIDI A, V202, P435, DOI 10.1002/pssa.200406924
   Lou XD, 2006, MAT SCI ENG A-STRUCT, V432, P221, DOI 10.1016/j.msea.2006.06.010
   Nikolic N, 2001, J EUR CERAM SOC, V21, P20714
   Parthibavarman M, 2010, J OPTOELECTRON ADV M, V12, P1894
   Parthibavarman M, 2011, MAT SCI ENG C, V319, P840
   Parthibavarman M, 2011, J ALLOY COMPD, V509, P4788
   Sedghi SM, 2010, SENSOR ACTUAT B-CHEM, V145, P7, DOI 10.1016/j.snb.2009.11.002
   Sergiu ST, 2005, SENSOR ACTUAT B-CHEM, V107, P379
   Wang JX, 2008, CRYST GROWTH DES, V8, P707, DOI 10.1021/cg060779+
   Wang JX, 2004, SOLID STATE COMMUN, V131, P435, DOI 10.1016/j.ssc.2004.06.009
   Wang LS, 2005, NANOTECHNOLOGY, V16, P2928, DOI 10.1088/0957-4484/16/12/034
   Wang SM, 2007, MATER LETT, V61, P3005, DOI 10.1016/j.matlet.2006.07.197
   Yan HQ, 2003, ADV MATER, V15, P402, DOI 10.1002/adma.200390091
   Yawale SP, 2007, SENSOR ACTUAT A-PHYS, V135, P388, DOI 10.1016/j.sna.2006.08.001
NR 22
TC 6
Z9 7
U1 4
U2 39
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0042-207X
J9 VACUUM
JI Vacuum
PD APR 27
PY 2012
VL 86
IS 10
BP 1488
EP 1493
DI 10.1016/j.vacuum.2012.02.018
PG 6
WC Materials Science, Multidisciplinary; Physics, Applied
SC Materials Science; Physics
GA 973WH
UT WOS:000306390200014
DA 2018-12-27
ER

PT J
AU Kolodkin-Gal, I
   Cao, SG
   Chai, L
   Bottcher, T
   Kolter, R
   Clardy, J
   Losick, R
AF Kolodkin-Gal, Ilana
   Cao, Shugeng
   Chai, Liraz
   Boettcher, Thomas
   Kolter, Roberto
   Clardy, Jon
   Losick, Richard
TI RETRACTED: A Self-Produced Trigger for Biofilm Disassembly that Targets
   Exopolysaccharide (Retracted article. See vol. 161, pg. 946, 2015)
SO CELL
LA English
DT Article; Retracted Publication
ID D-AMINO ACIDS; BACILLUS-SUBTILIS BIOFILMS; STAPHYLOCOCCUS-AUREUS;
   BACTERIAL BIOFILMS; VIBRIO-CHOLERAE; AMYLOID FIBERS; MATRIX; SUBSTANCES
AB Biofilms are structured communities of bacteria that are held together by an extracellular matrix consisting of protein and exopolysaccharide. Biofilms often have a limited lifespan, disassembling as nutrients become exhausted and waste products accumulate. D-amino acids were previously identified as a self-produced factor that mediates biofilm disassembly by causing the release of the protein component of the matrix in Bacillus subtilis. Here we report that B. subtilis produces an additional biofilm-disassembly factor, norspermidine. Dynamic light scattering and scanning electron microscopy experiments indicated that norspermidine interacts directly and specifically with exopolysaccharide. D-amino acids and norspermidine acted together to break down existing biofilms and mutants blocked in the production of both factors formed long-lived biofilms. Norspermidine, but not closely related polyamines, prevented biofilm formation by B. subtilis, Escherichia coli, and Staphylococcus aureus.
C1 [Cao, Shugeng; Boettcher, Thomas; Clardy, Jon] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.
   [Kolodkin-Gal, Ilana; Losick, Richard] Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA.
   [Chai, Liraz; Kolter, Roberto] Harvard Univ, Sch Med, Dept Microbiol & Immunobiol, Boston, MA 02115 USA.
RP Clardy, J (reprint author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.
EM jon_clardy@hms.harvard.edu; losick@mcb.harvard.edu
FU German Academy of Sciences Leopoldina [LPDS 2009-45]; National
   Institutes of Health [GM18568, GM58213, GM82137, GM086258, AI057159];
   BASF Advanced Research Initiative at Harvard University
FX We thank T. Kodger for help with dynamic light scattering, C. Marks and
   A. Grahame for their help with sample preparation for electron
   microscopy imaging, and the Harvard Center for Nanoscale Systems for use
   of its Imaging Facility. I. K.-G. is a fellow of the Human Fronteir
   Science Program. T. B. was supported by German Academy of Sciences
   Leopoldina (LPDS 2009-45), Leopoldina Research Fellowship. This work was
   supported by National Institutes of Health grants GM18568 to R. L.,
   GM58213 and GM82137 to R. K., GM086258 and AI057159 to J.C. and by the
   BASF Advanced Research Initiative at Harvard University to R. L. and R.
   K. Harvard University has filed a patent application based on this work.
CR Aguilar C, 2007, CURR OPIN MICROBIOL, V10, P638, DOI 10.1016/j.mib.2007.09.006
   Berne B. J, 1976, DYNAMIC LIGHT SCATTE
   Branda SS, 2006, MOL MICROBIOL, V59, P1229, DOI 10.1111/j.1365-2958.2005.05020.x
   Branda SS, 2005, TRENDS MICROBIOL, V13, P20, DOI 10.1016/j.tim.2004.11.006
   Branda SS, 2004, J BACTERIOL, V186, P3970, DOI 10.1128/JB.186.12.3970-3979.2004
   Branda SS, 2001, P NATL ACAD SCI USA, V98, P11621, DOI 10.1073/pnas.191384198
   Bryers JD, 2008, BIOTECHNOL BIOENG, V100, P1, DOI 10.1002/bit.21838
   Cava F, 2011, EMBO J, V30, P3442, DOI 10.1038/emboj.2011.246
   Costerton JW, 1999, SCIENCE, V284, P1318, DOI 10.1126/science.284.5418.1318
   Danese PN, 2000, J BACTERIOL, V182, P3593, DOI 10.1128/JB.182.12.3593-3596.2000
   Hochbaum AI, 2011, J BACTERIOL, V193, P5616, DOI 10.1128/JB.05534-11
   Karatan E, 2005, J BACTERIOL, V187, P7434, DOI 10.1128/JB.187.21.7434-7443.2005
   Karatan E, 2009, MICROBIOL MOL BIOL R, V73, P310, DOI 10.1128/MMBR.00041-08
   Kolodkin-Gal I, 2010, SCIENCE, V328, P627, DOI 10.1126/science.1188628
   Kropec A, 2005, INFECT IMMUN, V73, P6868, DOI 10.1128/IAI.73.10.6868-6876.2005
   Lee J, 2009, J BIOL CHEM, V284, P9899, DOI 10.1074/jbc.M900110200
   Lopez D, 2009, FEMS MICROBIOL REV, V33, P152, DOI 10.1111/j.1574-6976.2008.00148.x
   McSwain BS, 2005, APPL ENVIRON MICROB, V71, P1051, DOI 10.1128/AEM.71.2.1051-1057.2005
   Molnar-Perl I, 2003, J CHROMATOGR A, V987, P291, DOI 10.1016/S0021-9673(02)01537-6
   Nagorska K, 2007, ACTA BIOCHIM POL, V54, P495
   O'Toole G, 2000, ANNU REV MICROBIOL, V54, P49, DOI 10.1146/annurev.micro.54.1.49
   O'Toole GA, 1998, MOL MICROBIOL, V30, P295, DOI 10.1046/j.1365-2958.1998.01062.x
   Orgad O, 2011, BIOFOULING, V27, P787, DOI 10.1080/08927014.2011.603145
   Otto M, 2008, CURR TOP MICROBIOL, V322, P207
   Price NL, 2009, J BACTERIOL, V191, P1798, DOI 10.1128/JB.00798-08
   Romero D, 2011, TRENDS MICROBIOL, V19, P304, DOI 10.1016/j.tim.2011.03.003
   Romero D, 2011, MOL MICROBIOL, V80, P1155, DOI 10.1111/j.1365-2958.2011.07653.x
   Romero D, 2010, P NATL ACAD SCI USA, V107, P2230, DOI 10.1073/pnas.0910560107
   Sutherland IW, 2001, MICROBIOL-UK, V147, P3, DOI 10.1099/00221287-147-1-3
   Vinayahan T, 2010, BIOMACROMOLECULES, V11, P3367, DOI 10.1021/bm100486p
   Vlamakis H, 2008, GENE DEV, V22, P945, DOI 10.1101/gad.1645008
NR 31
TC 93
Z9 103
U1 2
U2 107
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0092-8674
EI 1097-4172
J9 CELL
JI Cell
PD APR 27
PY 2012
VL 149
IS 3
BP 684
EP 692
DI 10.1016/j.cell.2012.02.055
PG 9
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 934KN
UT WOS:000303443100018
PM 22541437
OA Bronze, Green Accepted
DA 2018-12-27
ER

PT J
AU Wang, DS
   Chu, PC
   Yang, CN
   Yan, RB
   Chuang, YC
   Kulp, SK
   Chen, CS
AF Wang, Dasheng
   Chu, Po-Chen
   Yang, Chia-Ning
   Yan, Ribai
   Chuang, Yu-Chung
   Kulp, Samuel K.
   Chen, Ching-Shih
TI RETRACTED: Development of a Novel Class of Glucose Transporter
   Inhibitors (Retracted article. See vol. 61, pg. 5056, 2018)
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article; Retracted Publication
ID GENE-EXPRESSION; CANCER-CELLS; PHARMACOLOGICAL EXPLOITATION; MEDICINAL
   CHEMISTRY; BREAST-CANCER; GLUT1; CARCINOMA; METABOLISM; MECHANISM;
   FLUORINE
AB On the basis of our finding that the antitumor effect of 5-{4-[(1-methylcyclohexyl)methoxy]benzyl}thiazolidine-2,4-dione, a thiazolidinedione peroxisome proliferator-activated receptor (PPAR)gamma agonist, was, in part, attributable to its ability to block glucose uptake independently of PPAR gamma, we used its PPAR gamma-inactive analogue to develop a novel class of glucose transporter (GLUT) inhibitors. This lead optimization led to compound 30 {5-(4-hydroxy-3-trifluoromethylbenzylidene)-3[4,4,4-trifluoro-2-methyl-2-(2,2,2-trifluoroethyl)butyl]thiazolidine-2,4- dione} as the optimal agent, which exhibited high antitumor potency through the suppression of glucose uptake (IC50, 2.5 mu M), while not cytotoxic to prostate and mammary epithelial cells. This glucose uptake inhibition was associated with the inhibition of GLUT1 (IC50, 2 mu M). Moreover, the mechanism of antitumor action of compound 30 was validated by its effect on a series of energy restriction-associated cellular responses. Homology modeling analysis suggests that the inhibitory effect of compound 30 on glucose entry was attributable to its ability to bind to the GLUT1 channel at a site distinct from that of glucose.
C1 [Wang, Dasheng; Chu, Po-Chen; Yan, Ribai; Kulp, Samuel K.; Chen, Ching-Shih] Ohio State Univ, Coll Pharm, Div Med Chem, Columbus, OH 43210 USA.
   [Yang, Chia-Ning; Chuang, Yu-Chung] Natl Kaohsiung Univ, Inst Biotechnol, Kaohsiung 811, Taiwan.
   [Chen, Ching-Shih] Natl Cheng Kung Univ, Inst Basic Med Sci, Tainan 70101, Taiwan.
RP Chen, CS (reprint author), Ohio State Univ, Coll Pharm, Div Med Chem, 500 W 12th Ave, Columbus, OH 43210 USA.
EM chen.844@osu.edu
FU National Institutes of Health [CA112250]; Department of Defense
   [W81XWH-09-0198]; Ministry of Economic Affairs (Taiwan)
   [99-EC-17-A-17-S1-152]
FX This work was supported by National Institutes of Health Grant CA112250
   and Department of Defense Prostate Cancer Research Program Grant
   W81XWH-09-0198 (to C.-S.C.) and by Ministry of Economic Affairs (Taiwan)
   Grant 99-EC-17-A-17-S1-152 (to C.-N.Y.).
CR Airley RE, 2007, CHEMOTHERAPY, V53, P233, DOI 10.1159/000104457
   Baer SC, 1997, J AM ACAD DERMATOL, V37, P575, DOI 10.1016/S0190-9622(97)70174-9
   Calvo MB, 2010, INT J ENDOCRINOL, DOI 10.1155/2010/205357
   BROWN RS, 1993, CANCER, V72, P2979, DOI 10.1002/1097-0142(19931115)72:10<2979::AID-CNCR2820721020>3.0.CO;2-X
   Cantuaria G, 2001, CANCER-AM CANCER SOC, V92, P1144, DOI 10.1002/1097-0142(20010901)92:5<1144::AID-CNCR1432>3.0.CO;2-T
   Cao XH, 2007, CANCER CHEMOTH PHARM, V59, P495, DOI 10.1007/s00280-006-0291-9
   Chan DA, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002394
   Chen CH, 2011, J BIOL CHEM, V286, P9968, DOI 10.1074/jbc.M110.203240
   Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478
   Haber RS, 1998, CANCER, V83, P34, DOI 10.1002/(SICI)1097-0142(19980701)83:1<34::AID-CNCR5>3.0.CO;2-E
   Haber RS, 1997, THYROID, V7, P363, DOI 10.1089/thy.1997.7.363
   Hagmann WK, 2008, J MED CHEM, V51, P4359, DOI 10.1021/jm800219f
   Harmon AW, 2004, BREAST CANCER RES TR, V85, P103, DOI 10.1023/B:BREA.0000025397.56192.e2
   Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809
   Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2
   Joost HG, 2001, MOL MEMBR BIOL, V18, P247, DOI 10.1080/09687680110090456
   Kelloff G, 2005, CLIN CANCER RES, V11, P2785, DOI 10.1158/1078-0432.CCR-04-2626
   Kim JW, 2006, CANCER RES, V66, P8927, DOI 10.1158/0008-5472.CAN-06-1501
   Kroemer G, 2008, CANCER CELL, V13, P472, DOI 10.1016/j.ccr.2008.05.005
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Macheda ML, 2005, J CELL PHYSIOL, V202, P654, DOI 10.1002/jcp.20166
   Muller K, 2007, SCIENCE, V317, P1881, DOI 10.1126/science.1131943
   NAGASE Y, 1995, J UROLOGY, V153, P798, DOI 10.1016/S0022-5347(01)67725-5
   NISHIOKA T, 1992, CANCER RES, V52, P3972
   Park JB, 2001, J NAT PROD, V64, P381, DOI 10.1021/np000411t
   Purser S, 2008, CHEM SOC REV, V37, P320, DOI 10.1039/b610213c
   Rudlowski C, 2003, AM J CLIN PATHOL, V120, P691, DOI 10.1309/4KYNQM5862JW2GD7
   Salas-Burgos A, 2004, BIOPHYS J, V87, P2990, DOI 10.1529/biophysj.104.047886
   Schwartzenberg-Bar-Yoseph F, 2004, CANCER RES, V64, P2627, DOI 10.1158/0008-5472.CAN-03-0846
   Shanmugam M, 2009, J BIOL CHEM, V284, P26816, DOI 10.1074/jbc.M109.000646
   Stewart GD, 2008, ONCOL REP, V20, P1561, DOI 10.3892/or_00000180
   Vander Heiden MG, 2011, NAT REV DRUG DISCOV, V10, P671, DOI 10.1038/nrd3504
   WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309
   Wei SO, 2010, J BIOL CHEM, V285, P9780, DOI 10.1074/jbc.M109.065466
   Wei S, 2009, MOL PHARMACOL, V76, P47, DOI 10.1124/mol.109.055376
   Wood TE, 2008, MOL CANCER THER, V7, P3546, DOI 10.1158/1535-7163.MCT-08-0569
   Yang CC, 2007, CANCER RES, V67, P3229, DOI 10.1158/0008-5472.CAN-06-2759
   Yang J, 2008, J MED CHEM, V51, P2100, DOI 10.1021/jm701212m
   Younes M, 1995, ANTICANCER RES, V15, P2895
   Younes M, 1997, CANCER, V80, P1046, DOI 10.1002/(SICI)1097-0142(19970915)80:6<1046::AID-CNCR6>3.0.CO;2-7
   Young CD, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1852
NR 41
TC 32
Z9 32
U1 0
U2 9
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
EI 1520-4804
J9 J MED CHEM
JI J. Med. Chem.
PD APR 26
PY 2012
VL 55
IS 8
BP 3827
EP 3836
DI 10.1021/jm300015m
PG 10
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 930VV
UT WOS:000303173600017
PM 22468970
OA Green Accepted
DA 2018-12-27
ER

PT J
AU Chalkias, A
   Xanthos, T
AF Chalkias, Athanasios
   Xanthos, Theodoros
TI RETRACTED: Post-cardiac arrest brain injury: Pathophysiology and
   treatment (Retracted article. See vol. 4, 2016)
SO JOURNAL OF THE NEUROLOGICAL SCIENCES
LA English
DT Review; Retracted Publication
DE Brain injury; Cardiac arrest; Neuroprotection; Pathophysiology;
   Post-resuscitation period; Treatment
ID MILD THERAPEUTIC HYPOTHERMIA; RESUSCITATION COUNCIL GUIDELINES;
   CEREBRAL-BLOOD-FLOW; EMERGENCY CARDIOVASCULAR CARE; CRITICALLY-ILL
   PATIENTS; CARDIOPULMONARY-RESUSCITATION; COMATOSE SURVIVORS; GLUCOSE
   CONTROL; VENTRICULAR-FIBRILLATION; MYOCARDIAL DYSFUNCTION
AB Cardiac arrest is a leading cause of death that affects more than a million individuals worldwide every year. Despite the recent advancement in the field of cardiac arrest and resuscitation, the management and prognosis of post-cardiac arrest brain injury remain suboptimal. The pathophysiology of post-cardiac arrest brain injury involves a complex cascade of molecular events, most of which remain unknown. Considering that a potentially broad therapeutic window for neuroprotective drug therapy is offered in most successfully resuscitated patient after cardiac arrest, the need for further research is imperative. The aim of this article is to present the major pathophysiological disturbances leading to post-cardiac arrest brain injury, as well as to review the available pharmacological therapies. (C) 2011 Elsevier B.V. All rights reserved.
C1 [Chalkias, Athanasios; Xanthos, Theodoros] Univ Athens, Sch Med, Dept Anat, Athens 11527, Greece.
RP Chalkias, A (reprint author), Univ Athens, Sch Med, Dept Anat, 75 Mikras Asias St, Athens 11527, Greece.
EM thanoschalkias@yahoo.gr
CR Arrich J, 2007, CRIT CARE MED, V35, P1041, DOI 10.1097/01.CCM.0000259383.48324.35
   Assandri R, 1999, J PHYSIOL-LONDON, V516, P343, DOI 10.1111/j.1469-7793.1999.0343v.x
   BECK T, 1995, STROKE, V26, P1107, DOI 10.1161/01.STR.26.6.1107
   Bernard SA, 1997, ANN EMERG MED, V30, P146, DOI 10.1016/S0196-0644(97)70133-1
   Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289
   Bernard SA, 2010, CIRCULATION, V122, P737, DOI 10.1161/CIRCULATIONAHA.109.906859
   *BRAIN RES CLIN TR, 1986, NEW ENGL J MED, V314, P397
   Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526
   Bro-Jeppesen J, 2009, RESUSCITATION, V80, P171, DOI 10.1016/j.resuscitation.2008.09.009
   Busch M, 2006, ACTA ANAESTH SCAND, V50, P1277, DOI 10.1111/j.1399-6576.2006.01147.x
   Castejon OJ, 2009, ULTRASTRUCT PATHOL, V33, P102, DOI 10.1080/01913120902787076
   Chakraborty M, 1998, BIOCHEM MED METAB B, V40, P8
   Chalkias A, 2012, HEART FAIL REV, V17, P117, DOI 10.1007/s10741-011-9255-1
   Chong ZZ, 2002, J CEREBR BLOOD F MET, V22, P503, DOI 10.1097/00004647-200205000-00001
   Deakin CD, 2010, RESUSCITATION, V81, P1305, DOI 10.1016/j.resuscitation.2010.08.017
   DeVries HE, 1997, PHARMACOL REV, V49, P143
   Digicaylioglu M, 2001, NATURE, V412, P641, DOI 10.1038/35088074
   Don CW, 2009, CRIT CARE MED, V37, P3062, DOI 10.1097/CCM.0b013e3181b7f59c
   EIMERL S, 1994, J NEUROCHEM, V62, P1223
   El-Menyar AA, 2005, CHEST, V128, P2835, DOI 10.1378/chest.128.4.2835
   Feng ZC, 1998, RESUSCITATION, V37, P33, DOI 10.1016/S0300-9572(98)00031-8
   Finfer S, 2009, NEW ENGL J MED, V360, P1283, DOI 10.1056/NEJMoa0810625
   Fiskum G, 2008, ANN NY ACAD SCI, V1147, P129, DOI 10.1196/annals.1427.026
   Friberg H, 2002, BIOCHIMIE, V84, P241, DOI 10.1016/S0300-9084(02)01381-0
   Froehler MT, 2007, J NEUROL SCI, V261, P118, DOI 10.1016/j.jns.2007.04.042
   Gazmuri RJ, 1997, CHEST, V111, P712, DOI 10.1378/chest.111.3.712
   Goldhaber JI, 2000, ANTIOXID REDOX SIGN, V2, P55, DOI 10.1089/ars.2000.2.1-55
   Griesdale DEG, 2009, CAN MED ASSOC J, V180, P821, DOI 10.1503/cmaj.090206
   Gunn A J, 2006, NeuroRx, V3, P154, DOI 10.1016/j.nurx.2006.01.007
   Heyndrickx GR, 2006, SEMIN CARDIOTHORAC V, V10, P236, DOI 10.1177/1089253206291137
   HIRANO A, 1994, MICROSC RES TECHNIQ, V27, P543, DOI 10.1002/jemt.1070270609
   Holzer M, 2002, NEW ENGL J MED, V346, P549
   Holzer M, 2006, STROKE, V37, P1792, DOI 10.1161/01.STR.0000227265.52763.16
   Hossmann KA, 2001, ACTA NEUROPATHOL, V101, P101
   Hossmann KA, 1997, SHOCK, V8, P95, DOI 10.1097/00024382-199708000-00004
   Huet O, 2011, CRIT CARE MED, V39, P1712, DOI 10.1097/CCM.0b013e3182186d42
   INGVAR M, 1986, ANN NY ACAD SCI, V462, P194, DOI 10.1111/j.1749-6632.1986.tb51254.x
   Kawata M, 2006, J THORAC CARDIOV SUR, V131, P1331, DOI 10.1016/j.jtcvs.2005.10.035
   Koster RW, 2010, RESUSCITATION, V81, P1277, DOI 10.1016/j.resuscitation.2010.08.009
   Laurent I, 2002, J AM COLL CARDIOL, V40, P2110, DOI 10.1016/S0735-1097(02)02594-9
   Laver S, 2004, INTENS CARE MED, V30, P2126, DOI 10.1007/s00134-004-2425-z
   Lefer AM, 1996, CARDIOVASC RES, V32, P743, DOI 10.1016/0008-6363(96)00073-9
   Lindner KH, 1996, HEART, V75, P145, DOI 10.1136/hrt.75.2.145
   Lipinski CA, 1999, RESUSCITATION, V42, P221, DOI 10.1016/S0300-9572(99)00083-0
   Longstreth WT, 2002, NEUROLOGY, V59, P506, DOI 10.1212/WNL.59.4.506
   Maiese K, 2004, TRENDS PHARMACOL SCI, V25, P577, DOI 10.1016/j.tips.2004.09.006
   Maiese K, 2008, CYTOKINE GROWTH F R, V19, P145, DOI 10.1016/j.cytogfr.2008.01.004
   Maiese K, 2010, EXP GERONTOL, V45, P217, DOI 10.1016/j.exger.2010.01.004
   Martin E, 2005, J NEUROSCI RES, V79, P240, DOI 10.1002/jnr.20293
   MICKEL HS, 1987, STROKE, V18, P426, DOI 10.1161/01.STR.18.2.426
   Muresanu DF, 2010, ANN NY ACAD SCI, V1199, P15, DOI 10.1111/j.1749-6632.2009.05328.x
   Niemann JT, 2004, CRIT CARE MED, V32, P1753, DOI 10.1097/01.CCM.0000132899.15242.D3
   Noguchi CT, 2007, CRIT REV ONCOL HEMAT, V64, P159, DOI 10.1016/j.critrevonc.2007.03.001
   Nolan JP, 2010, RESUSCITATION, V81, P1219, DOI 10.1016/j.resuscitation.2010.08.021
   Nolan JP, 2010, CURR OPIN CRIT CARE, V16, P216, DOI 10.1097/MCC.0b013e3283383dca
   Nolan JP, 2008, RESUSCITATION, V79, P350, DOI 10.1016/j.resuscitation.2008.09.017
   Oddo M, 2006, CRIT CARE MED, V34, P1865, DOI 10.1097/01.CCM.0000221922.08878.49
   Oksanen T, 2007, INTENS CARE MED, V33, P2093, DOI 10.1007/s00134-007-0876-8
   Peberdy MA, 2010, CIRCULATION, V122, pS768, DOI 10.1161/CIRCULATIONAHA.110.971002
   Polderman KH, 2009, CRIT CARE MED, V37, P1101, DOI 10.1097/CCM.0b013e3181962ad5
   Preiser JC, 2009, INTENS CARE MED, V35, P1738, DOI 10.1007/s00134-009-1585-2
   Ribatti D, 1999, BLOOD, V93, P2627
   Ristagno G, 2009, CRIT CARE MED, V37, P1408, DOI 10.1097/CCM.0b013e31819cedc9
   RUBERTSSON S, 1995, CRIT CARE MED, V23, P715, DOI 10.1097/00003246-199504000-00021
   Sharma AB, 2007, AM J PHYSIOL-HEART C, V292, pH198, DOI 10.1152/ajpheart.00698.2006
   Sharma HS, 2011, J NEURAL TRANSM, V118, P87, DOI 10.1007/s00702-010-0486-4
   SIMS NR, 1995, METAB BRAIN DIS, V10, P191, DOI 10.1007/BF02081026
   Wiener RS, 2008, JAMA-J AM MED ASSOC, V300, P933, DOI 10.1001/jama.300.8.933
   Springborg JB, 2002, BRIT J PHARMACOL, V135, P823, DOI 10.1038/sj.bjp.0704521
   STAHL GL, 1995, CIRC RES, V76, P575, DOI 10.1161/01.RES.76.4.575
   Storm C, 2008, CRIT CARE, V12, DOI 10.1186/cc6925
   Tang MK, 2010, J CEREBR BLOOD F MET, V30, P119, DOI 10.1038/jcbfm.2009.194
   Vasileiou I, 2009, EUR J PHARMACOL, V605, P1, DOI 10.1016/j.ejphar.2009.01.007
   Villa P, 2003, J EXP MED, V198, P971, DOI 10.1084/jem.20021067
   Xanthos T, 2011, CURR PHARM DESIGN, V17, P1517, DOI 10.2174/138161211796197115
   Xu K, 2010, BRAIN RES, V1328, P181, DOI 10.1016/j.brainres.2010.02.080
   ZWEMER CF, 1994, RESUSCITATION, V27, P159, DOI 10.1016/0300-9572(94)90009-4
NR 77
TC 41
Z9 44
U1 2
U2 8
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0022-510X
EI 1878-5883
J9 J NEUROL SCI
JI J. Neurol. Sci.
PD APR 15
PY 2012
VL 315
IS 1-2
BP 1
EP 8
DI 10.1016/j.jns.2011.12.007
PG 8
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 920YQ
UT WOS:000302445600001
PM 22251931
DA 2018-12-27
ER

PT J
AU Patrick, BA
   Jaiswal, AK
AF Patrick, Brad A.
   Jaiswal, Anil K.
TI RETRACTED: Stress-induced NQO1 controls stability of C/EBP alpha against
   20S proteasomal degradation to regulate p63 expression with implications
   in protection against chemical-induced skin cancer(Retracted article.
   See vol. 36, pg. 2920, 2017)
SO CANCER RESEARCH
LA English
DT Meeting Abstract; Retracted Publication
C1 [Patrick, Brad A.; Jaiswal, Anil K.] Univ Maryland, Sch Med, Baltimore, MD 21201 USA.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2012
VL 72
SU 8
MA 2217
DI 10.1158/1538-7445.AM2012-2217
PG 1
WC Oncology
SC Oncology
GA V43SR
UT WOS:000209701606248
DA 2018-12-27
ER

PT J
AU Dhonukshe, P
   Weits, DA
   Cruz-Ramirez, A
   Deinum, EE
   Tindemans, SH
   Kakar, K
   Prasad, K
   Mahonen, AP
   Ambrose, C
   Sasabe, M
   Wachsmann, G
   Luijten, M
   Bennett, T
   Machida, Y
   Heidstra, R
   Wasteneys, G
   Mulder, BM
   Scheres, S
AF Dhonukshe, Pankaj
   Weits, Daan A.
   Cruz-Ramirez, Alfredo
   Deinum, Eva E.
   Tindemans, Simon H.
   Kakar, Klementina
   Prasad, Kalika
   Mahonen, Ari Pekka
   Ambrose, Chris
   Sasabe, Michiko
   Wachsmann, Guy
   Luijten, Marijn
   Bennett, Tom
   Machida, Yasunori
   Heidstra, Renze
   Wasteneys, Geoffrey
   Mulder, Bela M.
   Scheres, Ben
TI RETRACTED: A PLETHORA-Auxin Transcription Module Controls Cell Division
   Plane Rotation through MAP65 and CLASP(Retracted article. See vol. 155,
   pg. 1189, 2013)
SO CELL
LA English
DT Article; Retracted Publication
ID MICROTUBULE-ASSOCIATED PROTEINS; ARABIDOPSIS-THALIANA ROOT; CORTICAL
   MICROTUBULES; SELF-ORGANIZATION; AXIS FORMATION; GENE ENCODES; PATTERNS;
   GROWTH; RECEPTOR; DIFFERENTIATION
AB Despite their pivotal role in plant development, control mechanisms for oriented cell divisions have remained elusive. Here, we describe how a precisely regulated cell division orientation switch in an Arabidopsis stem cell is controlled by upstream patterning factors. We show that the stem cell regulatory PLETHORA transcription factors induce division plane reorientation by local activation of auxin signaling, culminating in enhanced expression of the microtubule-associated MAP65 proteins. MAP65 upregulation is sufficient to reorient the cortical microtubular array through a CLASP microtubule-cell cortex interaction mediator-dependent mechanism. CLASP differentially localizes to cell faces in a microtubule- and MAP65-dependent manner. Computational simulations clarify how precise 90 degrees switches in cell division planes can follow self-organizing properties of the microtubule array in combination with biases in CLASP localization. Our work demonstrates how transcription factor-mediated processes regulate the cellular machinery to control orientation of formative cell divisions in plants.
C1 [Dhonukshe, Pankaj; Weits, Daan A.; Cruz-Ramirez, Alfredo; Kakar, Klementina; Prasad, Kalika; Mahonen, Ari Pekka; Wachsmann, Guy; Luijten, Marijn; Bennett, Tom; Heidstra, Renze; Scheres, Ben] Univ Utrecht, Dept Biol, NL-3584 CH Utrecht, Netherlands.
   [Deinum, Eva E.; Tindemans, Simon H.; Mulder, Bela M.] FOM Inst AMOLF, NL-1098 XG Amsterdam, Netherlands.
   [Ambrose, Chris; Wasteneys, Geoffrey] Univ British Columbia, Dept Bot, Vancouver, BC V6T 1Z4, Canada.
   [Sasabe, Michiko; Machida, Yasunori] Nagoya Univ, Grad Sch Sci, Div Biol Sci, Nagoya, Aichi 4648602, Japan.
   [Mulder, Bela M.] Wageningen Univ, Lab Plant Cell Biol, NL-6708 PB Wageningen, Netherlands.
RP Dhonukshe, P (reprint author), Univ Utrecht, Dept Biol, Padualaan 8, NL-3584 CH Utrecht, Netherlands.
EM p.b.dhonukshe@uu.nl; b.scheres@uu.nl
OI Wasteneys, Geoffrey/0000-0002-8746-7994; Bennett,
   Tom/0000-0003-1612-4019; Cruz-Ramirez, Luis Alfredo/0000-0001-9973-5784;
   Scheres, Ben/0000-0001-5400-9578; Mulder, Bela/0000-0002-8620-5749;
   Mahonen, Ari Pekka/0000-0001-6051-866X
FU Netherlands Scientific Organization's (NWO's)-VENI; Utrecht University;
   European Research Council; HFSP; EMBO; Netherlands Genomics Initiative
   (NGI); NWO-Horizon; Natural Sciences and Engineering Research Council of
   Canada; Netherlands Consortium for System Biology; Foundation for
   Fundamental Research on Matter (FOM)-NWO
FX We thank Mark Estelle, Kenichiro Hayashi, Martine Pastuglia, Marcus
   Heisler, and Takashi Hashimoto for sharing published materials; Anirban
   Baral for help with experiments; and Frits Kindt and Ronald Leito for
   photography and image processing. This work was supported by:
   Netherlands Scientific Organization's (NWO's)-VENI Grant (P. D.),
   Utrecht University Independent Investigator Grant (P. D.), European
   Research Council Advanced Investigator Grant (B. S.), HFSP fellowship
   (A. P. M.), EMBO fellowship (K. P.), Netherlands Genomics Initiative
   (NGI) and NWO-Horizon grants (M. L. and R. H.), Natural Sciences and
   Engineering Research Council of Canada Grant (G. W. and C. A.),
   Netherlands Consortium for System Biology's grant (B. S. and E. E. D.),
   and Foundation for Fundamental Research on Matter (FOM)-NWO (B.M.M.).
CR Aida M, 2004, CELL, V119, P109, DOI 10.1016/j.cell.2004.09.018
   Allard JF, 2010, MOL BIOL CELL, V21, P278, DOI 10.1091/mbc.E09-07-0579
   Ambrose C, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1444
   Ambrose JC, 2008, MOL BIOL CELL, V19, P4730, DOI 10.1091/mbc.E08-06-0665
   Ambrose JC, 2007, PLANT CELL, V19, P2763, DOI 10.1105/tpc.107.053777
   Baena-Lopez LA, 2005, CURR BIOL, V15, P1640, DOI 10.1016/j.cub.2005.07.062
   Bennett T, 2010, PLANT CELL, V22, P640, DOI 10.1105/tpc.109.072272
   Blilou I, 2005, NATURE, V433, P39, DOI 10.1038/nature03184
   Brady SM, 2007, SCIENCE, V318, P801, DOI 10.1126/science.1146265
   Camilleri C, 2002, PLANT CELL, V14, P833, DOI 10.1105/tpc.010402
   Campilho A, 2006, PLANT J, V48, P619, DOI 10.1111/j.1365-313X.2006.02892.x
   Chan J, 1999, P NATL ACAD SCI USA, V96, P14931, DOI 10.1073/pnas.96.26.14931
   De Smet I, 2008, SCIENCE, V322, P594, DOI 10.1126/science.1160158
   De Smet I, 2011, NAT REV MOL CELL BIO, V12, P177, DOI 10.1038/nrm3064
   De Smet I, 2010, P NATL ACAD SCI USA, V107, P2705, DOI 10.1073/pnas.0915001107
   Dharmasiri N, 2005, DEV CELL, V9, P109, DOI 10.1016/j.devcel.2005.05.014
   Dharmasiri N, 2005, NATURE, V435, P441, DOI 10.1038/nature03543
   Dhonukshe P, 2006, DEV CELL, V10, P137, DOI 10.1016/j.devcel.2005.11.015
   Dhonukshe P, 2005, BMC BIOL, V3, DOI 10.1186/1741-7007-3-11
   Dhonukshe P, 2008, NATURE, V456, P962, DOI 10.1038/nature07409
   DiLaurenzio L, 1996, CELL, V86, P423, DOI 10.1016/S0092-8674(00)80115-4
   DOLAN L, 1993, DEVELOPMENT, V119, P71
   Eren EC, 2010, MOL BIOL CELL, V21, P2674, DOI 10.1091/mbc.E10-02-0136
   Fache V, 2010, PLANT CELL, V22, P3804, DOI 10.1105/tpc.110.080606
   Gaillard J, 2008, MOL BIOL CELL, V19, P4534, DOI 10.1091/mbc.E08-04-0341
   Galinha C, 2007, NATURE, V449, P1053, DOI 10.1038/nature06206
   Granger CL, 2001, PROTOPLASMA, V216, P201, DOI 10.1007/BF02673872
   Grieneisen VA, 2007, NATURE, V449, P1008, DOI 10.1038/nature06215
   Guilfoyle TJ, 2007, CURR OPIN PLANT BIOL, V10, P453, DOI 10.1016/j.pbi.2007.08.014
   GUNNING BES, 1978, PLANTA, V143, P121, DOI 10.1007/BF00387786
   Hamann T, 1999, DEVELOPMENT, V126, P1387
   Hardtke CS, 1998, EMBO J, V17, P1405, DOI 10.1093/emboj/17.5.1405
   Hayashi K, 2008, P NATL ACAD SCI USA, V105, P5632, DOI 10.1073/pnas.0711146105
   Heidstra R, 2004, GENE DEV, V18, P1964, DOI 10.1101/gad.305504
   Heisler MG, 2005, CURR BIOL, V15, P1899, DOI 10.1016/j.cub.2005.09.052
   Helariutta Y, 2000, CELL, V101, P555, DOI 10.1016/S0092-8674(00)80865-X
   JURGENS G, 1995, CELL, V81, P467, DOI 10.1016/0092-8674(95)90065-9
   KARES C, 1990, PLANT MOL BIOL, V15, P225, DOI 10.1007/BF00036909
   Kepinski S, 2005, NATURE, V435, P446, DOI 10.1038/nature03542
   Kirik V, 2007, J CELL SCI, V120, P4416, DOI 10.1242/jcs.024950
   Lau S, 2011, NAT CELL BIOL, V13, P611, DOI 10.1038/ncb2212
   Li H, 2009, PLANT MOL BIOL, V69, P313, DOI 10.1007/s11103-008-9426-1
   Lucas JR, 2011, PLANT CELL, V23, P1889, DOI 10.1105/tpc.111.084970
   MANDERS EMM, 1992, J CELL SCI, V103, P857
   Muller S, 2009, TRENDS CELL BIOL, V19, P180, DOI 10.1016/j.tcb.2009.02.002
   Nakajima K, 2001, NATURE, V413, P307, DOI 10.1038/35095061
   Peret B, 2009, TRENDS PLANT SCI, V14, P399, DOI 10.1016/j.tplants.2009.05.002
   Petersson SV, 2009, PLANT CELL, V21, P1659, DOI 10.1105/tpc.109.066480
   Petricka JJ, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a000497
   PICKETTHEAPS JD, 1966, J CELL SCI, V1, P109
   Rasmussen CG, 2011, ANNU REV PLANT BIOL, V62, P387, DOI 10.1146/annurev-arplant-042110-103802
   Rasmussen CG, 2011, J CELL SCI, V124, P270, DOI 10.1242/jcs.073676
   Sabatini S, 1999, CELL, V99, P463, DOI 10.1016/S0092-8674(00)81535-4
   Smertenko A, 2000, NAT CELL BIOL, V2, P750, DOI 10.1038/35036390
   Smertenko AP, 2008, PLANT CELL, V20, P3346, DOI 10.1105/tpc.108.063362
   Smith LG, 2001, NAT REV MOL CELL BIO, V2, P33, DOI 10.1038/35048050
   Staswick PE, 2005, PLANT CELL, V17, P616, DOI 10.1105/tpc.104.026690
   Ten Hove CA, 2010, CURR BIOL, V20, P452, DOI 10.1016/j.cub.2010.01.018
   TORRESRUIZ RA, 1994, DEVELOPMENT, V120, P2967
   TRAAS J, 1995, NATURE, V375, P676, DOI 10.1038/375676a0
   Tromas A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006648
   Ueda K, 1999, PROTOPLASMA, V206, P201, DOI 10.1007/BF01279267
   Van Damme D, 2004, PLANT PHYSIOL, V136, P3956, DOI 10.1104/pp.104.051623
   Wasteneys GO, 2009, TRENDS CELL BIOL, V19, P62, DOI 10.1016/j.tcb.2008.11.004
   Willemsen V, 2008, DEV CELL, V15, P913, DOI 10.1016/j.devcel.2008.09.019
   Xu J, 2006, SCIENCE, V311, P385, DOI 10.1126/science.1121790
NR 66
TC 36
Z9 39
U1 1
U2 68
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0092-8674
EI 1097-4172
J9 CELL
JI Cell
PD APR 13
PY 2012
VL 149
IS 2
BP 383
EP 396
DI 10.1016/j.cell.2012.02.051
PG 14
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 926BF
UT WOS:000302805600017
PM 22500804
OA Bronze
DA 2018-12-27
ER

PT J
AU Akila, P
   Prashant, V
   Suma, MN
   Prashant, SN
   Chaitra, TR
AF Akila, P.
   Prashant, V.
   Suma, M. N.
   Prashant, S. N.
   Chaitra, T. R.
TI RETRACTED: CD163 and its expanding functional repertoire (Retracted
   article. See vol. 487, pg. 377, 2018)
SO CLINICA CHIMICA ACTA
LA English
DT Review; Retracted Publication
DE CD163; Hemoglobin scavenger receptor; Scavenger receptor cysteine-rich
   superfamily; Inflammation; Hemoglobin-haptoglobin complexes
ID SCAVENGER RECEPTOR CD163; SOLUBLE CD163; DIFFERENTIATION ANTIGEN;
   MACROPHAGE RECEPTORS; DENDRITIC CELLS; HUMAN MONOCYTES; CROSS-LINKING;
   HEMOGLOBIN; EXPRESSION; PROTEIN
AB Macrophages are key players of the immune system and express a variety of surface receptors. CD163 is one such receptor which belongs to the scavenger receptor cysteine-rich super family (SRCR-SF) class B. It has four isoforms which differ in the structure of their cytoplasmic domains and putative phosphorylation sites. Expression of CD163 is tightly regulated with a general tendency of anti-inflammatory signals to induce its synthesis, while pro-inflammatory signals downregulate its expression. Previously the molecule has been shown to act as a receptor for hemoglobin-haptoglobin complexes. However, it also plays a crucial role in the control of inflammatory processes by induction of anti-inflammatory pathways. Soluble CD163, which is generated via ectodomain shedding, serves as a potential diagnostic tool in a variety of disease states, such as inflammation, atherosclerosis, transplant rejection and carcinoma. Recently, CD163 has been identified as a promising target for cell directed therapy. In this review we aim to summarize the current knowledge of CD163. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Akila, P.; Prashant, V.; Suma, M. N.; Chaitra, T. R.] JSS Univ, Dept Biochem, JSS Med Coll, Mysore, Karnataka, India.
   [Prashant, S. N.] JSS Univ, Dept Pediat, JSS Med Coll, Mysore, Karnataka, India.
RP Akila, P (reprint author), JSS Univ, Dept Biochem, JSS Med Coll, Mysore, Karnataka, India.
EM akila.prashant@gmail.com
FU Indian Council of Medical Research (ICMR), New Delhi [2008-00740]
FX The authors are grateful to the Indian Council of Medical Research
   (ICMR), New Delhi for funding the Project with IRIS ID: 2008-00740 which
   has led to writing this review article.
CR Areschoug T, 2009, CELL MICROBIOL, V11, P1160, DOI 10.1111/j.1462-5822.2009.01326.x
   Bachli EB, 2006, J LEUKOCYTE BIOL, V79, P312, DOI 10.1189/jlb.0605309
   Baeten D, 2004, ARTHRITIS RHEUM, V50, P1611, DOI 10.1002/art.20174
   Bover LC, 2007, J IMMUNOL, V178, P8183, DOI 10.4049/jimmunol.178.12.8183
   Buechler C, 2000, J LEUKOCYTE BIOL, V67, P97
   Bunn HF, 2003, HARRISONS PRINCIPLES, P681
   Chasis JA, 2006, CURR OPIN HEMATOL, V13, P137, DOI 10.1097/01.moh.0000219657.57915.30
   Davis BH, 2005, CYTOM PART B-CLIN CY, V63B, P16, DOI 10.1002/cyto.b.20031
   DIJKSTRA CD, 1985, IMMUNOLOGY, V54, P589
   DjemadjiOudjiel N, 1996, ARCH DERMATOL RES, V288, P757, DOI 10.1007/s004030050137
   Droste A, 1999, BIOCHEM BIOPH RES CO, V256, P110, DOI 10.1006/bbrc.1999.0294
   Fabriek BO, 2007, J NEUROIMMUNOL, V187, P179, DOI 10.1016/j.jneuroim.2007.04.016
   Fabriek BO, 2007, BLOOD, V109, P5223, DOI 10.1182/blood-2006-08-036467
   Fabriek BO, 2009, BLOOD, V113, P887, DOI 10.1182/blood-2008-07-167064
   FREEMAN M, 1990, P NATL ACAD SCI USA, V87, P8810, DOI 10.1073/pnas.87.22.8810
   GORDON S, 1995, CURR OPIN IMMUNOL, V7, P24, DOI 10.1016/0952-7915(95)80025-5
   Graversen JH, 2002, INT J BIOCHEM CELL B, V34, P309, DOI 10.1016/S1357-2725(01)00144-3
   Guetta J, 2007, ATHEROSCLEROSIS, V191, P48, DOI 10.1016/j.atherosclerosis.2006.04.032
   Hintz KA, 2002, J LEUKOCYTE BIOL, V72, P711
   Hiraoka A, 2005, PATHOL RES PRACT, V201, P379, DOI 10.1016/j.prp.2004.10.006
   Hohenester E, 1999, NAT STRUCT BIOL, V6, P228, DOI 10.1038/6669
   Kaplan MJ, 2002, J IMMUNOL, V169, P6020, DOI 10.4049/jimmunol.169.10.6020
   Kishimoto T, 1997, BLOOD, V89, P3502
   Kristiansen M, 2001, NATURE, V409, P198, DOI 10.1038/35051594
   Kusi KA, 2008, CLIN VACCINE IMMUNOL, V15, P1456, DOI 10.1128/CVI.00506-07
   Langlois MR, 1996, CLIN CHEM, V42, P1589
   LAW SKA, 1993, EUR J IMMUNOL, V23, P2320, DOI 10.1002/eji.1830230940
   Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9
   Madsen M, 2004, J BIOL CHEM, V279, P51561, DOI 10.1074/jbc.M409629200
   Maniecki MB, 2006, IMMUNOBIOLOGY, V211, P407, DOI 10.1016/j.imbio.2006.05.019
   Marsters SA, 1998, CURR BIOL, V8, P525, DOI 10.1016/S0960-9822(98)70204-0
   Matsushita N, 2002, CLIN EXP IMMUNOL, V130, P156, DOI 10.1046/j.1365-2249.2002.01963.x
   Moller HJ, 2004, EUR J HAEMATOL, V72, P135, DOI 10.1046/j.0902-4441.2003.00193.x
   Moller HJ, 2002, SCAND J CLIN LAB INV, V62, P29, DOI 10.1080/003655102762377466
   Moller HJ, 2002, BLOOD, V99, P378, DOI 10.1182/blood.V99.1.378
   Nielsen MJ, 2006, J LEUKOCYTE BIOL, V79, P837, DOI 10.1189/jlb.1005602
   Onofre Gabriela, 2009, Acta Medica (Hradec Kralove), V52, P57, DOI 10.14712/18059694.2016.105
   Otterbein LE, 2000, NAT MED, V6, P422
   Polek TC, 2003, J BIOL CHEM, V278, P32317, DOI 10.1074/jbc.M302518200
   Polfliet MMJ, 2006, IMMUNOBIOLOGY, V211, P419, DOI 10.1016/j.imbio.2006.05.015
   Ritter M, 1999, PATHOBIOLOGY, V67, P257, DOI 10.1159/000028105
   Ritter M, 2001, EUR J IMMUNOL, V31, P999, DOI 10.1002/1521-4141(200104)31:4<999::AID-IMMU999>3.0.CO;2-R
   Ritter M, 1999, BIOCHEM BIOPH RES CO, V260, P466, DOI 10.1006/bbrc.1999.0866
   Sanchez C, 1999, J IMMUNOL, V162, P5230
   Sarrias MR, 2004, CRIT REV IMMUNOL, V24, P1
   Schaer DJ, 2006, BLOOD, V107, P373, DOI 10.1182/blood-2005-03-1014
   Schaer DJ, 2001, IMMUNOGENETICS, V53, P170, DOI 10.1007/s002510100304
   Schaer DJ, 2005, EUR J HAEMATOL, V74, P6, DOI 10.1111/j.1600-0609.2004.00318.x
   Sulahian TH, 2000, CYTOKINE, V12, P1312, DOI 10.1006/cyto.2000.0720
   Sulahian TH, 2004, J LEUKOCYTE BIOL, V76, P271, DOI 10.1189/jlb.1003523
   Sulahian TH, 2001, J IMMUNOL METHODS, V252, P25, DOI 10.1016/S0022-1759(01)00328-3
   Taylor PR, 2005, ANNU REV IMMUNOL, V23, P901, DOI 10.1146/annurev.immunol.23.021704.115816
   Timmermann M, 2005, FREE RADICAL BIO MED, V39, P98, DOI 10.1016/j.freeadbiomed.2005.02.031
   Van den Heuvel MM, 1999, J LEUKOCYTE BIOL, V66, P858
   Van Gorp H, 2010, MOL IMMUNOL, V47, P1650, DOI 10.1016/j.molimm.2010.02.008
   VERSCHURE PJ, 1989, SCAND J IMMUNOL, V29, P371, DOI 10.1111/j.1365-3083.1989.tb01136.x
   Wagener FADTG, 2003, PHARMACOL REV, V55, P551, DOI 10.1124/pr.55.3.5
   WEINSTEIN MB, 1984, BIOCHEM BIOPH RES CO, V123, P489, DOI 10.1016/0006-291X(84)90257-2
   Wiley SR, 2001, IMMUNITY, V15, P837, DOI 10.1016/S1074-7613(01)00232-1
   Williams L, 2002, J LEUKOCYTE BIOL, V72, P800
   ZWADLO G, 1987, EXP CELL BIOL, V55, P295
NR 61
TC 37
Z9 41
U1 0
U2 18
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0009-8981
EI 1873-3492
J9 CLIN CHIM ACTA
JI Clin. Chim. Acta
PD APR 11
PY 2012
VL 413
IS 7-8
BP 669
EP 674
DI 10.1016/j.cca.2012.01.028
PG 6
WC Medical Laboratory Technology
SC Medical Laboratory Technology
GA 913WL
UT WOS:000301908000004
PM 22309681
DA 2018-12-27
ER

PT J
AU Garedew, A
   Andreassi, C
   Moncada, S
AF Garedew, Assegid
   Andreassi, Catia
   Moncada, Salvador
TI RETRACTED: Mitochondrial Dynamics, Biogenesis, and Function Are
   Coordinated with the Cell Cycle by APC/C-CDH1 (Retracted article. See
   vol. 16, pg. 284, 2012)
SO CELL METABOLISM
LA English
DT Article; Retracted Publication
ID OXIDATIVE-PHOSPHORYLATION; AEROBIC GLYCOLYSIS; CYTOCHROME-C; S PHASE;
   MTDNA; PROLIFERATION; METABOLISM; RESPIRATION; DYSFUNCTION; PROGRESSION
AB Cell proliferation is associated with a high rate of aerobic glycolysis, which has been widely interpreted as a compensatory mechanism for suppressed mitochondrial function, despite reports of high respiration rates. The molecular mechanisms that link cell proliferation with mitochondrial metabolism, dynamics, and biogenesis remain obscure. Here, we show that proliferation is associated with an increase in both glycolysis and respiration, in conjunction with mitochondrial fusion and biogenesis. Changes in mitochondrial morphology and mass are due to accumulation of OPA1, MFN1, and TFAM, silencing any of which hinders cell proliferation. Moreover, the levels of OPA1, MFN1, and TFAM are regulated by the ubiquitin ligase APC/C-CDH1, which also controls proteasomal degradation of key glycolytic, glutaminolytic, and cell-cycle proteins. Thus, we have identified an important component of the molecular mechanism that coordinates cell proliferation with activation of the mitochondrial metabolic machinery that provides the necessary energy and biosynthetic substrates.
C1 [Garedew, Assegid; Moncada, Salvador] UCL, Wolfson Inst Biomed Res, London WC1E 6BT, England.
   [Andreassi, Catia] UCL, MRC Lab Mol Cell Biol, London WC1E 6BT, England.
   [Andreassi, Catia] UCL, Dept Neurosci Physiol & Pharmacol, London WC1E 6BT, England.
RP Garedew, A (reprint author), UCL, Wolfson Inst Biomed Res, Mortimer St, London WC1E 6BT, England.
EM a.garedew@ucl.ac.uk; s.moncada@ucl.ac.uk
FU British Heart Foundation [PG/10/72/28449]; MAC [G1001704]; Medical
   Research Council [G1001704]
FX We are grateful to Annie Higgs for reading the manuscript and for very
   useful comments and suggestions. We thank Drs. Y. Kubo, N.G. Larsson, A.
   Nott, and S. Geley for kindly providing us with plasmids and Dr. A
   Saiardi for generously providing MEF cells. We would like to thank
   Istvan Kovacs and Nanci Frakich for technical help and Carolina Maestre
   for the help with immunoprecipitation. The work was supported by the
   British Heart Foundation Grant PG/10/72/28449 and MAC Grant G1001704 to
   S.M. and A.G.
CR Aguilar V, 2010, EMBO MOL MED, V2, P338, DOI 10.1002/emmm.201000089
   Almeida A, 2010, P NATL ACAD SCI USA, V107, P738, DOI 10.1073/pnas.0913668107
   Arakaki N, 2006, BIOL PHARM BULL, V29, P1962, DOI 10.1248/bpb.29.1962
   Arnoult D, 2005, J BIOL CHEM, V280, P35742, DOI 10.1074/jbc.M505970200
   Bauer DE, 2004, FASEB J, V18, P1303, DOI 10.1096/fj.03-1001fje
   Bergmeyer H.U., 1974, METHOD ENZYMAT AN, V1, P443
   Brand KA, 1997, FASEB J, V11, P388
   Chen HC, 2005, J BIOL CHEM, V280, P26185, DOI 10.1074/jbc.M503062200
   Chen HC, 2010, CELL, V141, P280, DOI 10.1016/j.cell.2010.02.026
   Colombo SL, 2010, P NATL ACAD SCI USA, V107, P18868, DOI 10.1073/pnas.1012362107
   Cormio A, 2009, BIOCHEM BIOPH RES CO, V390, P1182, DOI 10.1016/j.bbrc.2009.10.114
   D'Souza AD, 2007, MITOCHONDRION, V7, P374, DOI 10.1016/j.mito.2007.08.001
   DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002
   Detmer SA, 2007, NAT REV MOL CELL BIO, V8, P870, DOI 10.1038/nrm2275
   DiGregorio PJ, 2001, J BIOL CHEM, V276, P1930, DOI 10.1074/jbc.M003911200
   Ekstrand MI, 2004, HUM MOL GENET, V13, P935, DOI 10.1093/hmg/ddh109
   Garedew A, 2008, J CELL SCI, V121, P3468, DOI 10.1242/jcs.034660
   Gattermann N, 2004, NUCLEOS NUCLEOT NUCL, V23, P1275, DOI 10.1081/NCN-200027545
   Gomes LC, 2011, NAT CELL BIOL, V13, P589, DOI 10.1038/ncb2220
   GUPPY M, 1993, EUR J BIOCHEM, V212, P95, DOI 10.1111/j.1432-1033.1993.tb17637.x
   HACKENBROCK CR, 1971, J CELL BIOL, V51, P123, DOI 10.1083/jcb.51.1.123
   Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809
   Herzig RP, 2000, J BIOL CHEM, V275, P13134, DOI 10.1074/jbc.275.17.13134
   Horn SR, 2011, MOL BIOL CELL, V22, P1207, DOI 10.1091/mbc.E10-07-0567
   Kashatus DF, 2011, NAT CELL BIOL, V13, P1108, DOI 10.1038/ncb2310
   KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477
   Koppenol WH, 2011, NAT REV CANCER, V11, P325, DOI 10.1038/nrc3038
   Lai YP, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007766
   Lee CH, 2011, AM J PATHOL, V178, P2066, DOI 10.1016/j.ajpath.2011.01.056
   Lee S, 2007, BIOCHEM BIOPH RES CO, V357, P111, DOI 10.1016/j.bbrc.2007.03.091
   Li F, 2005, MOL CELL BIOL, V25, P6225, DOI 10.1128/MCB.25.14.6255-6234.2005
   Mitra K, 2009, P NATL ACAD SCI USA, V106, P11960, DOI 10.1073/pnas.0904875106
   Neutzner A, 2005, J BIOL CHEM, V280, P18598, DOI 10.1074/jbc.M500807200
   ROBBINS E, 1969, J CELL BIOL, V43, P629, DOI 10.1083/jcb.43.3.629
   Saraste M, 1999, SCIENCE, V283, P1488, DOI 10.1126/science.283.5407.1488
   Schieke SM, 2008, CELL CYCLE, V7, P1782, DOI 10.4161/cc.7.12.6067
   Taguchi N, 2007, J BIOL CHEM, V282, P11521, DOI 10.1074/jbc.M607279200
   Tudzarova S, 2011, P NATL ACAD SCI USA, V108, P5278, DOI 10.1073/pnas.1102247108
   VANDENBOGERT C, 1988, EXP CELL RES, V178, P143, DOI 10.1016/0014-4827(88)90385-0
   WEINHOUSE S, 1976, Z KREBSFORSCH KLIN O, V87, P115
NR 40
TC 17
Z9 18
U1 2
U2 20
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 1550-4131
EI 1932-7420
J9 CELL METAB
JI Cell Metab.
PD APR 4
PY 2012
VL 15
IS 4
BP 466
EP 479
DI 10.1016/j.cmet.2012.03.003
PG 14
WC Cell Biology; Endocrinology & Metabolism
SC Cell Biology; Endocrinology & Metabolism
GA 922CC
UT WOS:000302523400009
PM 22482729
OA Bronze
DA 2018-12-27
ER

PT J
AU Lukianova-Hleb, EY
   Ren, XY
   Constantinou, PE
   Danysh, BP
   Shenefelt, DL
   Carson, DD
   Farach-Carson, MC
   Kulchitsky, VA
   Wu, XW
   Wagner, DS
   Lapotko, DO
AF Lukianova-Hleb, Ekaterina Y.
   Ren, Xiaoyang
   Constantinou, Pamela E.
   Danysh, Brian P.
   Shenefelt, Derek L.
   Carson, Daniel D.
   Farach-Carson, Mary C.
   Kulchitsky, Vladimir A.
   Wu, Xiangwei
   Wagner, Daniel S.
   Lapotko, Dmitri O.
TI RETRACTED: Improved Cellular Specificity of Plasmonic Nanobubbles versus
   Nanoparticles in Heterogeneous Cell Systems (Retracted article. See vol.
   12, art no E0187820, 2017)
SO PLOS ONE
LA English
DT Article; Retracted Publication
ID SCATTERING SUBMICROSCOPIC PARTICLES; HIGHLY FLUORESCENT ANALOGS; GOLD
   NANOPARTICLES; DRUG-DELIVERY; PHOTOTHERMAL BUBBLES; BIOLOGICAL
   APPLICATIONS; OPTICAL-SCATTERING; NANO-THERMOLYSIS; LEUKEMIA-CELLS;
   TRACER LABELS
AB The limited specificity of nanoparticle (NP) uptake by target cells associated with a disease is one of the principal challenges of nanomedicine. Using the threshold mechanism of plasmonic nanobubble (PNB) generation and enhanced accumulation and clustering of gold nanoparticles in target cells, we increased the specificity of PNB generation and detection in target versus non-target cells by more than one order of magnitude compared to the specificity of NP uptake by the same cells. This improved cellular specificity of PNBs was demonstrated in six different cell models representing diverse molecular targets such as epidermal growth factor receptor, CD3 receptor, prostate specific membrane antigen and mucin molecule MUC1. Thus PNBs may be a universal method and nano-agent that overcome the problem of non-specific uptake of NPs by non-target cells and improve the specificity of NP-based diagnostics, therapeutics and theranostics at the cell level.
C1 [Lukianova-Hleb, Ekaterina Y.; Constantinou, Pamela E.; Danysh, Brian P.; Shenefelt, Derek L.; Carson, Daniel D.; Farach-Carson, Mary C.; Wagner, Daniel S.; Lapotko, Dmitri O.] Rice Univ, Dept Biochem & Cell Biol, Houston, TX 77251 USA.
   [Ren, Xiaoyang; Wu, Xiangwei] Univ Texas MD Anderson Canc Ctr, Dept Clin Canc Prevent, Houston, TX 77030 USA.
   [Kulchitsky, Vladimir A.] Natl Acad Sci Belarus, Inst Physiol, Minsk, BELARUS.
   [Lapotko, Dmitri O.] Rice Univ, Dept Phys & Astron, Houston, TX USA.
RP Lukianova-Hleb, EY (reprint author), Rice Univ, Dept Biochem & Cell Biol, POB 1892, Houston, TX 77251 USA.
EM dl5@rice.edu
RI Wagner, Daniel/C-9379-2009; ren, xianyan/J-3165-2018
OI Wagner, Daniel/0000-0002-0595-2436; 
FU National Institutes of Health [R01GM094816, P01 CA098912, S10RR026399
   01]; MD Anderson Gynecologic Specialized Programs of Research Excellence
   (SPORE) in Uterine Cancer [2P50CA098258-06]
FX This work was supported by National Institutes of Health Grant
   R01GM094816 (DOL), P01 CA098912 (MCFC), MD Anderson Gynecologic
   Specialized Programs of Research Excellence (SPORE) in Uterine Cancer,
   Pilot Project Award 2P50CA098258-06 (DDC). Confocal microscopy was
   performed on equipment obtained through a Shared Instrumentation Grant
   from the National Institutes of Health (S10RR026399 01). The funders had
   no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Adamson A. W., 1997, PHYS CHEM SURFACES
   Anderson LJE, 2010, J CONTROL RELEASE, V144, P151, DOI 10.1016/j.jconrel.2010.02.012
   ANDERSON RR, 1983, SCIENCE, V220, P524, DOI 10.1126/science.6836297
   Bernardi RJ, 2008, J NEURO-ONCOL, V86, P165, DOI 10.1007/s11060-007-9467-3
   Bohren CF, 1998, ABSORPTION SCATTERIN
   Boisselier E, 2009, CHEM SOC REV, V38, P1759, DOI 10.1039/b806051g
   Braun GB, 2009, ACS NANO, V3, P2007, DOI 10.1021/nn900469q
   Cai WB, 2008, NANOTECHNOL SCI APPL, V1, P17, DOI 10.2147/NSA.S3788
   Chen WX, 2010, MOL CANCER THER, V9, P1028, DOI 10.1158/1535-7163.MCT-09-0829
   Chithrani BD, 2007, NANO LETT, V7, P1542, DOI 10.1021/nl070363y
   Chithrani BD, 2006, NANO LETT, V6, P662, DOI 10.1021/nl052396o
   Cho KJ, 2008, CLIN CANCER RES, V14, P1310, DOI 10.1158/1078-0432.CCR-07-1441
   de Gennes PGF, 2004, CAPILLARY WETTING PH
   DEAN J. A, 1999, LANGES HDB CHEM
   El-Sayed IH, 2005, NANO LETT, V5, P829, DOI 10.1021/nl050074e
   Francois L, 2001, PHYS CHEM CHEM PHYS, V3, P4965, DOI 10.1039/b106690k
   Gregor PD, 2005, INT J CANCER, V116, P415, DOI 10.1002/ijc.21014
   HAIGLER HT, 1979, J CELL BIOL, V81, P382, DOI 10.1083/jcb.81.2.382
   Hauck TS, 2008, ADV MATER, V20, P3832, DOI 10.1002/adma.200800921
   Hleb EY, 2008, NANOTECHNOLOGY, V19, DOI 10.1088/0957-4484/19/35/355702
   Hleb EY, 2008, NANOMEDICINE-UK, V3, P647, DOI 10.2217/17435889.3.5.647
   Hleb EY, 2008, NANOMEDICINE-UK, V3, P797, DOI 10.2217/17435889.3.6.797
   Hu M, 2006, CHEM SOC REV, V35, P1084, DOI 10.1039/b517615h
   Huang XH, 2006, J AM CHEM SOC, V128, P2115, DOI 10.1021/ja057254a
   Huschka R, 2010, NANO LETT, V10, P4117, DOI 10.1021/nl102293b
   Hutson MS, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.158104
   Jain PK, 2008, ACCOUNTS CHEM RES, V41, P1578, DOI 10.1021/ar7002804
   Khlebtsov NG, 2004, NATO SCI SER II MATH, V161, P265
   Khlebtsov NG, 2000, COLLOID J+, V62, P765, DOI 10.1023/A:1026643111821
   Kim B, 2010, NAT NANOTECHNOL, V5, P465, DOI [10.1038/NNANO.2010.58, 10.1038/nnano.2010.58]
   Kohli V, 2005, BIOTECHNOL BIOENG, V92, P889, DOI 10.1002/bit.20689
   Kumar S, 2007, NANO LETT, V7, P1338, DOI 10.1021/nl070365i
   Lapotko D, 2005, PRO BIOMED OPT IMAG, V5697, P82, DOI 10.1117/12.596372
   Lapotko D, 2002, PHOTOCHEM PHOTOBIOL, V75, P519, DOI 10.1562/0031-8655(2002)075<0519:PMORSO>2.0.CO;2
   Lapotko D, 2006, CANCER LETT, V239, P36, DOI 10.1016/j.canlet.2005.07.031
   Lapotko Dmitri, 2011, Cancers (Basel), V3, P802, DOI 10.3390/cancers3010802
   Lapotko D, 2009, OPT EXPRESS, V17, P2538, DOI 10.1364/OE.17.002538
   Lapotko D, 2009, INT J HEAT MASS TRAN, V52, P1540, DOI 10.1016/j.ijheatmasstransfer.2008.08.010
   Lapotko DO, 2007, NANOMEDICINE-UK, V2, P241, DOI 10.2217/17435889.2.2.241
   Lapotko DO, 2006, LASER SURG MED, V38, P631, DOI 10.1002/lsm.20359
   Lewinski N, 2008, SMALL, V4, P26, DOI 10.1002/smll.200700595
   Li JL, 2009, CANCER LETT, V274, P319, DOI 10.1016/j.canlet.2008.09.024
   Liang XJ, 2010, P NATL ACAD SCI USA, V107, P7449, DOI 10.1073/pnas.0909707107
   Lin CP, 1998, APPL PHYS LETT, V72, P2800, DOI 10.1063/1.121462
   Loo C, 2005, NANO LETT, V5, P709, DOI 10.1021/nl050127s
   Lukianova-Hleb EY, 2010, NANOTECHNOLOGY, V21, DOI 10.1088/0957-4484/21/8/085102
   Lukianova-Hleb E, 2010, ACS NANO, V4, P2109, DOI 10.1021/nn1000222
   Lukianova-Hleb EY, 2012, ADV MATER, V24, P3831, DOI 10.1002/adma.201103550
   Lukianova-Hleb EY, 2012, LANGMUIR, V28, P4858, DOI 10.1021/la205132x
   Lukianova-Hleb EY, 2012, BIOMATERIALS, V33, P1821, DOI 10.1016/j.biomaterials.2011.11.015
   Lukianova-Hleb EY, 2011, THERANOSTICS, V1, P3, DOI 10.7150/thno/v01p0003
   Lukianova-Hleb EY, 2011, J CONTROL RELEASE, V152, P286, DOI 10.1016/j.jconrel.2011.02.006
   Lukianova-Hleb EY, 2011, J SURG RES, V166, pE3, DOI 10.1016/j.jss.2010.10.039
   Lukianova-Hleb EY, 2009, NANO LETT, V9, P2160, DOI 10.1021/nl9007425
   Lukianova-Hleb E, 2009, LASER SURG MED, V41, P240, DOI 10.1002/lsm.20749
   Lukianova-Hleb EY, 2011, J NANOMED NANOTECH, V2, P104
   Mallidi S, 2009, NANO LETT, V9, P2825, DOI 10.1021/nl802929u
   Mandal D, 2009, J MATER SCI-MATER M, V20, P347, DOI 10.1007/s10856-008-3588-x
   Meng HA, 2010, ACS NANO, V4, P4539, DOI 10.1021/nn100690m
   Mie G, 1908, ANN PHYS-BERLIN, V25, P377
   Neumann J, 2007, J APPL PHYS, V101, DOI 10.1063/1.2740348
   O'Neal DP, 2004, CANCER LETT, V209, P171, DOI 10.1016/j.canlet.2004.02.004
   Oberdoester G, 2005, ENV HLTH PERSPECT, V118, pA380
   Paasonen L, 2007, J CONTROL RELEASE, V122, P86, DOI 10.1016/j.jconrel.2007.06.009
   Paasonen L, 2010, J CONTROL RELEASE, V147, P136, DOI 10.1016/j.jconrel.2010.07.095
   Peer D, 2007, NAT NANOTECHNOL, V2, P751, DOI 10.1038/nnano.2007.387
   Pissuwan D, 2011, J CONTROL RELEASE, V149, P65, DOI 10.1016/j.jconrel.2009.12.006
   Pitsillides CM, 2003, BIOPHYS J, V84, P4023, DOI 10.1016/S0006-3495(03)75128-5
   Prentice P, 2005, NAT PHYS, V1, P107, DOI 10.1038/nphys148
   Prigodich AE, 2009, ACS NANO, V3, P2147, DOI 10.1021/nn9003814
   Qin GT, 2011, NANOTECHNOLOGY, V22, DOI 10.1088/0957-4484/22/15/155605
   Sajja Hari Krishna, 2009, Curr Drug Discov Technol, V6, P43
   Salmaso S, 2009, J MATER CHEM, V19, P1608, DOI 10.1039/b816603j
   Shukla R, 2005, LANGMUIR, V21, P10644, DOI 10.1021/la0513712
   Sokolov I, 2007, SMALL, V3, P419, DOI 10.1002/smll.200600319
   Sokolov K, 2003, CANCER RES, V63, P1999
   Stevenson D, 2006, OPT EXPRESS, V14, P7125, DOI 10.1364/OE.14.007125
   Tong L, 2009, NANOMEDICINE-UK, V4, P265, DOI 10.2217/NNM.09.4
   Vigderman L, 2012, ANGEW CHEM INT EDIT, V51, P636, DOI 10.1002/anie.201107304
   Vogel A, 2005, APPL PHYS B-LASERS O, V81, P1015, DOI 10.1007/s00340-005-2036-6
   Vogel A, 2008, PHYS REV LETT, V100, DOI 10.1103/PhysRevLett.100.038102
   Wagner DS, 2010, BIOMATERIALS, V31, P7567, DOI 10.1016/j.biomaterials.2010.06.031
   Wang F, 2011, ACS NANO, V5, P3679, DOI 10.1021/nn200007z
   Wang LH, 2011, NAT PHOTONICS, V5, P183, DOI 10.1038/nphoton.2011.24
   West JL, 2003, ANNU REV BIOMED ENG, V5, P285, DOI 10.1146/annurev.bioeng.5.011303.120723
   Wu GH, 2009, METHOD ENZYMOL, V464, P279, DOI 10.1016/S0076-6879(09)64014-3
   Yang LL, 2008, J BIOMED NANOTECHNOL, V4, P439, DOI 10.1166/jbn.2008.007
   Yao CP, 2005, J BIOMED OPT, V10, DOI 10.1117/1.2137321
   Yao CP, 2009, J BIOMED OPT, V14, DOI 10.1117/1.3253320
   Yguerabide J, 1998, ANAL BIOCHEM, V262, P137, DOI 10.1006/abio.1998.2759
   Yguerabide J, 1998, ANAL BIOCHEM, V262, P157, DOI 10.1006/abio.1998.2760
NR 91
TC 27
Z9 27
U1 2
U2 31
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 3
PY 2012
VL 7
IS 4
AR e34537
DI 10.1371/journal.pone.0034537
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 952PZ
UT WOS:000304805900044
PM 22509318
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Lichtenthaler, U
   Muethel, M
AF Lichtenthaler, Ulrich
   Muethel, Miriam
TI RETRACTED: The role of deliberate and experiential learning in
   developing capabilities: Insights from technology licensing (Retracted
   article. See vol. 33, pg. 243, 2014)
SO JOURNAL OF ENGINEERING AND TECHNOLOGY MANAGEMENT
LA English
DT Article; Retracted Publication
DE Dynamic capabilities; Organizational learning; Path dependence;
   Technology licensing; Technology transfer
ID RESEARCH-AND-DEVELOPMENT; UNDERSTANDING DYNAMIC CAPABILITIES;
   INTERNATIONAL JOINT VENTURES; RESOURCE-BASED VIEW; ABSORPTIVE-CAPACITY;
   OPEN INNOVATION; ORGANIZATIONAL AMBIDEXTERITY; STRATEGIC ALLIANCES;
   KNOWLEDGE TRANSFER; MULTIDIMENSIONAL CONCEPTUALIZATION
AB We discuss the interdependencies between deliberate and experiential learning in developing a dynamic technology licensing capability, which was termed 'desorptive capacity' in earlier conceptual work. We use new three-year lagged data from two surveys of 79 firms to examine the role of dedicated licensing employees and prior licensing experience in developing firms' sensing, seizing, and transforming capacities in technology out-licensing. The findings emphasize capabilities' multidimensionality and critical trade-offs due to interdependencies between deliberate and experiential learning in developing capabilities. Besides interdependencies with experiential learning, deliberate learning strengthens sensing and seizing capacity, but it negatively affects transforming capacity based on inertia. (C) 2011 Elsevier B.V. All rights reserved.
C1 [Lichtenthaler, Ulrich] Univ Mannheim Schloss, Chair Management & Org, D-68131 Mannheim, Germany.
   [Muethel, Miriam] WHU Otto Beisheim Sch Management, Chair Leadership & Human Resource Management, D-56179 Vallendar, Germany.
RP Lichtenthaler, U (reprint author), Univ Mannheim Schloss, Chair Management & Org, D-68131 Mannheim, Germany.
EM lichtenthaler@uni-mannheim.de; miriam.muethel@whu.edu
CR Abell P, 2008, MANAG DECIS ECON, V29, P489, DOI 10.1002/mde.1413
   Agarwal R, 2009, ORGAN SCI, V20, P281, DOI 10.1287/orsc.1090.0423
   Agrawal A, 2006, STRATEGIC MANAGE J, V27, P63, DOI 10.1002/smj.508
   Alexy O, 2009, MIT SLOAN MANAGE REV, V51, P71
   Argote L., 1999, ORG LEARNING CREATIN
   Arora A, 2010, IND CORP CHANGE, V19, P775, DOI 10.1093/icc/dtq022
   Barkema HG, 2008, J MANAGE, V34, P594, DOI 10.1177/0149206308316968
   Barkema HG, 1997, ACAD MANAGE J, V40, P426, DOI 10.2307/256889
   Barreto I, 2010, J MANAGE, V36, P256, DOI 10.1177/0149206309350776
   Bierly PE, 2009, J MANAGE STUD, V46, P481, DOI 10.1111/j.1467-6486.2009.00829.x
   Bingham CB, 2007, STRATEG ENTREP J, V1, P27, DOI 10.1002/sej.1
   Birkinshaw J, 2008, ACAD MANAGE REV, V33, P825
   Capron L, 2009, ORGAN SCI, V20, P294, DOI 10.1287/orsc.1070.0328
   Chen CL, 2009, J ENG TECHNOL MANAGE, V26, P247, DOI 10.1016/j.jengtecman.2009.10.002
   Chesbrough H., 2006, OPEN BUSINESS MODELS
   Chesbrough HW, 2009, HARVARD BUS REV, V87, P68
   COHEN A, 2004, IP LAW BUSINESS, V4, P31
   Cohen J., 2003, APPL MULTIPLE REGRES
   COHEN WM, 1990, ADMIN SCI QUART, V35, P128, DOI 10.2307/2393553
   Collins JD, 2006, J ENG TECHNOL MANAGE, V23, P147, DOI 10.1016/j.jengtecman.2006.06.007
   Cummings JL, 2003, J ENG TECHNOL MANAGE, V20, P39, DOI 10.1016/S0923-4748(03)00004-3
   Danneels E, 2008, STRATEGIC MANAGE J, V29, P519, DOI 10.1002/smj.684
   Danneels E, 2007, STRATEGIC MANAGE J, V28, P511, DOI 10.1002/smj.598
   DAVIS JL, 2001, EDISON BOARDROOM LEA
   Delios A, 2003, STRATEGIC MANAGE J, V24, P1153, DOI 10.1002/smj.355
   Delios A, 2001, ACAD MANAGE J, V44, P1028, DOI 10.2307/3069446
   Di Minin A, 2010, CALIF MANAGE REV, V52, P132, DOI 10.1525/cmr.2010.52.3.132
   Dutta S, 2005, STRATEGIC MANAGE J, V26, P277, DOI 10.1002/smj.442
   Eisenhardt KM, 2000, STRATEGIC MANAGE J, V21, P1105, DOI 10.1002/1097-0266(200010/11)21:10/11<1105::AID-SMJ133>3.0.CO;2-E
   Faems D, 2008, ACAD MANAGE J, V51, P1053, DOI 10.5465/AMJ.2008.35732527
   Faraj S, 2000, MANAGE SCI, V46, P1554, DOI 10.1287/mnsc.46.12.1554.12072
   Floyd SW, 2000, ACAD MANAGE REV, V25, P154, DOI 10.2307/259268
   Ford JD, 2008, ACAD MANAGE REV, V33, P362, DOI 10.5465/AMR.2008.31193235
   Fosfuri A, 2006, STRATEGIC MANAGE J, V27, P1141, DOI 10.1002/smj.562
   Fosfuri A, 2010, IND CORP CHANGE, V19, P767, DOI 10.1093/icc/dtq025
   Foss NJ, 2007, ORGAN STUD, V28, P749, DOI 10.1177/0170840607072546
   Gambardella A, 2001, MARKETS TECHNOLOGY E
   Gambardella A, 2007, RES POLICY, V36, P1163, DOI 10.1016/j.respol.2007.07.006
   Gans JS, 2008, MANAGE SCI, V54, P982, DOI 10.1287/mnsc.1070.0814
   Gavetti G, 2005, ORGAN SCI, V16, P599, DOI 10.1287/orsc.1050.0140
   George G, 2005, IND CORP CHANGE, V14, P119, DOI 10.1093/icc/dth046
   Grant RM, 2004, J MANAGE STUD, V41, P61, DOI 10.1111/j.1467-6486.2004.00421.x
   Grindley PC, 1997, CALIF MANAGE REV, V39, P8, DOI 10.2307/41165885
   Gupta AK, 2006, ACAD MANAGE J, V49, P693, DOI 10.2307/20159793
   Hair J., 2006, MULTIVARIATE DATA AN
   Hall BH, 2005, RAND J ECON, V36, P16
   Harreld JB, 2007, CALIF MANAGE REV, V49, P21, DOI 10.2307/41166404
   Harrison DA, 2007, ACAD MANAGE REV, V32, P1199
   Heimeriks KH, 2007, STRATEG ORGAN, V5, P373, DOI 10.1177/1476127007083347
   Heimeriks KH, 2007, J MANAGE STUD, V44, P25, DOI 10.1111/j.1467-6486.2006.00639.x
   Helfat C. E., 2007, DYNAMIC CAPABILITIES
   Helfat CE, 2009, STRATEG ORGAN, V7, P91, DOI 10.1177/1476127008100133
   Hoang H, 2010, STRATEGIC MANAGE J, V31, P734, DOI 10.1002/smj.834
   IANSITI M, 1994, IND CORP CHANGE, V3, P557
   Jacobides MG, 2005, STRATEGIC MANAGE J, V26, P395, DOI 10.1002/smj.460
   JAWORSKI BJ, 1993, J MARKETING, V57, P53, DOI 10.2307/1251854
   Kale P, 2007, STRATEG MANAGE J, V28, P981, DOI 10.1002/smj.616
   Kaplan S, 2008, ACAD MANAGE J, V51, P672
   Keil T, 2008, J MANAGE STUD, V45, P1475, DOI 10.1111/j.1467-6486.2008.00806.x
   Kim Y, 2009, J ENG TECHNOL MANAGE, V26, P57, DOI 10.1016/j.jengtecman.2009.03.003
   King DR, 2003, J ENG TECHNOL MANAGE, V20, P303, DOI 10.1016/j.jengtecman.2003.08.007
   Kleinsmann M, 2010, J ENG TECHNOL MANAGE, V27, P20, DOI 10.1016/j.jengtecman.2010.03.003
   KOGUT B, 1992, ORGAN SCI, V3, P383, DOI 10.1287/orsc.3.3.383
   Lai HC, 2010, J ENG TECHNOL MANAGE, V27, P183, DOI 10.1016/j.jengtecman.2010.06.005
   Lane PJ, 2006, ACAD MANAGE REV, V31, P833, DOI 10.5465/AMR.2006.22527456
   Lange D, 2008, ACAD MANAGE REV, V33, P710
   LEVINTHAL DA, 1993, STRATEGIC MANAGE J, V14, P95, DOI 10.1002/smj.4250141009
   Li JT, 2005, ACAD MANAGE J, V48, P794, DOI 10.5465/AMJ.2005.18803923
   Lichtenthaler U, 2008, J ENG TECHNOL MANAGE, V25, P200, DOI 10.1016/j.jengtecman.2008.07.001
   Lichtenthaler U, 2010, CALIF MANAGE REV, V53, P154, DOI 10.1525/cmr.2010.53.1.154
   Lichtenthaler U, 2010, ORGAN SCI, V21, P1054, DOI 10.1287/orsc.1090.0499
   Lichtenthaler U, 2009, J MANAGE STUD, V46, P1315, DOI 10.1111/j.1467-6486.2009.00854.x
   Malik OR, 2009, J MANAGE STUD, V46, P421, DOI 10.1111/j.1467-6486.2008.00817.x
   March JG, 1991, ORGAN SCI, V2, P71, DOI 10.1287/orsc.2.1.71
   Markman GD, 2009, J MANAGE STUD, V46, P625, DOI 10.1111/j.1467-6486.2009.00835.x
   Marsh SJ, 2006, J PROD INNOVAT MANAG, V23, P422, DOI 10.1111/j.1540-5885.2006.00214.x
   McCarthy IP, 2006, J PROD INNOVAT MANAG, V23, P437, DOI 10.1111/j.1540-5885.2006.00215.x
   McCarthy IP, 2011, R&D MANAGE, V41, P240, DOI 10.1111/j.1467-9310.2011.00642.x
   McCarthy IP, 2010, ACAD MANAGE REV, V35, P604, DOI 10.5465/AMR.2010.53503029
   Muthusamy SK, 2005, ORGAN STUD, V26, P415, DOI 10.1177/0170840605050874
   Narula R, 2002, RES POLICY, V31, P795, DOI 10.1016/S0048-7333(01)00148-2
   O'Reilly CA, 2008, RES ORGAN BEHAV, V28, P185, DOI 10.1016/j.riob.2008.06.002
   O'Reilly CA, 2009, CALIF MANAGE REV, V51, P75, DOI 10.2307/41166506
   Oerlemans LAG, 2010, J ENG TECHNOL MANAGE, V27, P33, DOI 10.1016/j.jengtecman.2010.03.002
   Piderit SK, 2000, ACAD MANAGE REV, V25, P783, DOI 10.2307/259206
   Podsakoff PM, 2003, J APPL PSYCHOL, V88, P879, DOI 10.1037/0021-9101.88.5.879
   Raisch S, 2009, ORGAN SCI, V20, P685, DOI 10.1287/orsc.1090.0428
   Reagans R, 2005, MANAGE SCI, V51, P869, DOI 10.1287/mnsc.1050.0366
   Reuer JJ, 2002, J MANAGE, V28, P47, DOI 10.1177/014920630202800104
   Rivette K, 2000, REMBRANDTS ATTIC UNL
   Romme AGL, 2010, IND CORP CHANGE, V19, P1271, DOI 10.1093/icc/dtq031
   Rothaermel FT, 2007, ORGAN SCI, V18, P898, DOI 10.1287/orsc.1070.0291
   Rothaermel FT, 2009, ORGAN SCI, V20, P759, DOI 10.1287/orsc.1080.0404
   Rothaermel FT, 2004, STRATEGIC MANAGE J, V25, P201, DOI 10.1002/smj.376
   Sakkab NY, 2002, RES TECHNOL MANAGE, V45, P38
   Salvato C, 2009, ORGAN SCI, V20, P284
   Schreyogg G, 2007, STRATEG MANAGE J, V28, P913, DOI 10.1002/smj.613
   Schweizer L, 2005, J ENG TECHNOL MANAGE, V22, P315, DOI 10.1016/j.jengtecman.2005.09.004
   Siegel DS, 2004, J ENG TECHNOL MANAGE, V21, P115, DOI 10.1016/j.jengtecman.2003.12.006
   Silverman BS, 1999, MANAGE SCI, V45, P1109, DOI 10.1287/mnsc.45.8.1109
   Simsek Z, 2009, J MANAGE STUD, V46, P864, DOI 10.1111/j.1467-6486.2009.00841.x
   Simsek Z, 2009, J MANAGE STUD, V46, P597, DOI 10.1111/j.1467-6486.2009.00828.x
   Sirmon DG, 2009, STRATEGIC MANAGE J, V30, P1375, DOI 10.1002/smj.791
   Sydow J, 2009, ACAD MANAGE REV, V34, P689, DOI 10.5465/AMR.2009.44885978
   Teece DJ, 2007, STRATEG MANAGE J, V28, P1319, DOI 10.1002/smj.640
   Teece DJ, 1997, STRATEGIC MANAGE J, V18, P509, DOI 10.1002/(SICI)1097-0266(199708)18:7<509::AID-SMJ882>3.0.CO;2-Z
   Tripsas M, 2009, ORGAN SCI, V20, P441, DOI 10.1287/orsc.1080.0419
   Tsai KH, 2008, J BUS VENTURING, V23, P91, DOI 10.1016/j.jbusvent.2005.07.002
   Tushman ML, 1996, CALIF MANAGE REV, V38, P8, DOI 10.2307/41165852
   Vergne JP, 2010, J MANAGE STUD, V47, P736, DOI 10.1111/j.1467-6486.2009.00913.x
   Verona G, 2003, IND CORP CHANGE, V12, P577, DOI 10.1093/icc/12.3.577
   Winter SG, 2003, STRATEGIC MANAGE J, V24, P991, DOI 10.1002/smj.318
   Zahra SA, 2002, ACAD MANAGE REV, V27, P185, DOI 10.5465/AMR.2002.6587995
   Zahra SA, 2006, J MANAGE STUD, V43, P917, DOI 10.1111/j.1467-6486.2006.00616.x
   Zhao Z, 2005, J MANAGE STUD, V42, P127, DOI 10.1111/j.1467-6486.2005.00491.x
   Zollo M, 2004, STRATEGIC MANAGE J, V25, P1233, DOI 10.1002/smj.426
   Zollo M, 2002, ORGAN SCI, V13, P339, DOI 10.1287/orsc.13.3.339.2780
NR 117
TC 13
Z9 13
U1 2
U2 77
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0923-4748
EI 1879-1719
J9 J ENG TECHNOL MANAGE
JI J. Eng. Technol. Manage.
PD APR-JUN
PY 2012
VL 29
IS 2
BP 187
EP 209
DI 10.1016/j.jengtecman.2011.10.001
PG 23
WC Business; Engineering, Industrial; Management
SC Business & Economics; Engineering
GA 966OY
UT WOS:000305848500001
DA 2018-12-27
ER

PT J
AU Athar, M
   Awan, AU
   Fetecau, C
AF Athar, M.
   Awan, A. U.
   Fetecau, Corina
TI RETRACTED: A note on the unsteady flow of a fractional Maxwell fluid
   through a circular cylinder (Retracted article. See vol. 28, pg. 1510,
   2012)
SO ACTA MECHANICA SINICA
LA English
DT Article; Retracted Publication
DE Fractional Maxwell fluid; Velocity field; Shear stress; Exact solutions
ID CONSTANTLY ACCELERATING PLATE; GENERALIZED 2ND-GRADE FLUID; OLDROYD-B
   FLUID; VISCOELASTIC FLUID; ROTATIONAL FLOW; SIDE WALLS; MODEL; MOTION;
   PIPE
AB In this note the velocity field and the adequate shear stress corresponding to the unsteady flow of a fractional Maxwell fluid due to a constantly accelerating circular cylinder have been determined by means of the Laplace and finite Hankel transforms. The obtained solutions satisfy all imposed initial and boundary conditions. They can easily be reduced to give similar solutions for ordinary Maxwell and Newtonian fluids. Finally, the influence of pertinent parameters on the fluid motion, as well as a comparison between models, is underlined by graphical illustrations.
C1 [Athar, M.; Awan, A. U.; Fetecau, Corina] GC Univ Lahore, Abdus Salam Sch Math Sci, Lahore, Pakistan.
RP Athar, M (reprint author), GC Univ Lahore, Abdus Salam Sch Math Sci, 68-B New Muslim Town Lahore, Lahore, Pakistan.
EM athar_sms@yahoo.com
FU Abdus Salam School of Mathematical Sciences, GC University, Lahore,
   Pakistan; Higher Education Commission of Pakistan
FX The authors would like to express their gratitude to reviewers for their
   careful assessment and very fruitful observations and recommendations.
   They are also extremely grateful and thankful to the Abdus Salam School
   of Mathematical Sciences, GC University, Lahore, Pakistan and Higher
   Education Commission of Pakistan for supporting and facilitating this
   research work.
CR Akhtar W, 2008, B MATH SOC SCI MATH, V51, P93
   Akhtar W, 2009, Z ANGEW MATH PHYS, V60, P498, DOI 10.1007/s00033-008-7129-8
   Debnath L, 2007, INTEGRAL TRANSFORMS
   Fetecau C, 2007, ACTA MECH, V189, P53, DOI 10.1007/s00707-006-0407-7
   Fetecau C, 2007, APPL MATH MODEL, V31, P647, DOI 10.1016/j.apm.2005.11.032
   Fetecau C, 2005, Z ANGEW MATH PHYS, V56, P1098, DOI 10.1007/S00033-005-4034-2
   Fetecau C, 2003, INT J NONLIN MECH, V38, P423, DOI 10.1016/S0020-7462(01)00062-2
   Qi HT, 2006, ACTA MECH SINICA, V22, P301, DOI 10.1007/s10409-006-0013-x
   Hayat T, 2008, NONLINEAR ANAL-REAL, V9, P2288, DOI 10.1016/j.nonrwa.2007.08.005
   Hayat T, 2006, PHYS LETT A, V358, P396, DOI 10.1016/j.physleta.2006.04.117
   Hayat T, 2004, APPL MATH COMPUT, V151, P153, DOI 10.1016/S0096-3003(03)00329-1
   Hayat T, 2004, APPL MATH COMPUT, V151, P105, DOI 10.1016/S0096-3003(03)00326-6
   Jamil M, 2010, NONLINEAR ANAL-REAL, V11, P4302, DOI 10.1016/j.nonrwa.2010.05.016
   Lorenzo C. F., 1999, NASATP1999209424
   Mahmood A, 2008, ARCH MECH, V60, P385
   Mahmood A, 2010, ACTA MECH SINICA-PRC, V26, P541, DOI 10.1007/s10409-010-0353-4
   MAKRIS N, 1993, J ENG MECH-ASCE, V119, P1663, DOI 10.1061/(ASCE)0733-9399(1993)119:8(1663)
   Podlubny I., 1999, FRACTIONAL DIFFERENT
   Qi HT, 2007, MECH RES COMMUN, V34, P210, DOI 10.1016/j.mechrescom.2006.09.003
   Sneddon IN, 1951, FOURIER TRANSFORMS
   Tan WC, 2002, ACTA MECH SINICA-PRC, V18, P342
   Tan WC, 2003, INT J NONLINEAR MECH, V38, P645
   Tong DK, 2005, INT J ENG SCI, V43, P281, DOI 10.1016/j.ijengsci.2004.09.007
   Vieru D, 2008, APPL MATH COMPUT, V200, P459, DOI 10.1016/j.amc.2007.11.017
   Vieru D, 2007, MECCANICA, V42, P573, DOI 10.1007/s11012-007-9081-7
   Wang SW, 2009, NONLINEAR ANAL-REAL, V10, P1087, DOI 10.1016/j.nonrwa.2007.11.027
   Yang D, 2010, COMPUT MATH APPL, V60, P2231, DOI 10.1016/j.camwa.2010.08.013
NR 27
TC 3
Z9 3
U1 3
U2 12
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0567-7718
EI 1614-3116
J9 ACTA MECH SINICA-PRC
JI Acta Mech. Sin.
PD APR
PY 2012
VL 28
IS 2
BP 308
EP 314
DI 10.1007/s10409-012-0004-z
PG 7
WC Engineering, Mechanical; Mechanics
SC Engineering; Mechanics
GA 939ZY
UT WOS:000303861000008
DA 2018-12-27
ER

PT J
AU Meyl, K
AF Meyl, Konstantin
TI RETRACTED: DNA and Cell Resonance: Magnetic Waves Enable Cell
   Communication (Retracted article. See vol. 32, pg. 138, 2013)
SO DNA AND CELL BIOLOGY
LA English
DT Article; Retracted Publication
AB DNA generates a longitudinal wave that propagates in the direction of the magnetic field vector. Computed frequencies from the structure of DNA agree with those of the predicted biophoton radiation. The optimization of efficiency by minimizing the conduction losses leads to the double-helix structure of DNA. The vortex model of the magnetic scalar wave not only covers many observed structures within the nucleus perfectly, but also explains the hyperboloid channels in the matrix when two cells communicate with each other. Potential vortexes are an essential component of a scalar waves, as discovered in 1990. The basic approach for an extended field theory was confirmed in 2009 with the discovery of magnetic monopoles. For the first time, this provides the opportunity to explain the physical basis of life not only from the biological discipline. Nature covers the whole spectrum of known scientific fields of research, and interdisciplinary understanding is required to explain its complex relationships. The characteristics of the potential vortex are significant. With its concentration effect, it provides for miniaturization down to a few nanometers, which allows enormously high information density in the nucleus. With this first introduction of the magnetic scalar wave, it becomes clear that such a wave is suitable to use genetic code chemically stored in the base pairs of the genes and electrically modulate them, so as to "piggyback" information from the cell nucleus to another cell. At the receiving end, the reverse process takes place and the transported information is converted back into a chemical structure. The necessary energy required to power the chemical process is provided by the magnetic scalar wave itself.
C1 First Transfer Ctr Scalar Wave Technol 1st TZS, D-78048 Villingen Schwenningen, Germany.
RP Meyl, K (reprint author), First Transfer Ctr Scalar Wave Technol 1st TZS, Technol Pk,Erikaweg 32, D-78048 Villingen Schwenningen, Germany.
EM prof@meyl.eu
CR Adrian L, 2000, NATURE, V408, P580, DOI 10.1038/35046063
   Alberts B., 1994, MOL BIOL CELL, P343
   Engels J. W, 2011, P 2 WORLD DNA GEN DA, P64
   Fredholm L, 2003, SCIENCE
   Heine H, 1997, LEHRBUCH BIOL MED GR, P56
   Jaenicke L., 1998, MOLEKULARBIOLOGIE ZE, P109
   Karp G, 2005, CELL MOL BIOL
   Lewin B, 1990, GENES 4, P421
   Meyl K., 2010, SELF CONSISTENT ELEC
   Meyl K, 2011, P 2 WORLD DNA DAY CH, P101
   Meyl K, 2011, DNA CELL RESONANCE C
   Popp A. F, 1987, NEUE HORIZONTE MED
   Sheldrake Rupert, 1995, 7 EXPT THAT COULD CH
   Sinden R. R., 1994, DNA STRUCTURE FUNCTI, P398
   Zhang L, 2011, P 2 WORLD DNA GEN DA, P110
NR 15
TC 5
Z9 5
U1 3
U2 23
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1044-5498
EI 1557-7430
J9 DNA CELL BIOL
JI DNA Cell Biol.
PD APR
PY 2012
VL 31
IS 4
BP 422
EP 426
DI 10.1089/dna.2011.1415
PG 5
WC Biochemistry & Molecular Biology; Cell Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Cell Biology; Genetics & Heredity
GA 926TH
UT WOS:000302854200003
PM 22011216
DA 2018-12-27
ER

PT J
AU Auten, RL
   Gilmour, MI
   Krantz, QT
   Potts, EN
   Mason, SN
   Foster, WM
AF Auten, Richard L.
   Gilmour, M. Ian
   Krantz, Q. Todd
   Potts, Erin N.
   Mason, S. Nicholas
   Foster, W. Michael
TI RETRACTED: Maternal Diesel Inhalation Increases Airway Hyperreactivity
   in Ozone-Exposed Offspring (Retracted article. See vol. 52, pg. 523,
   2012)
SO AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY
LA English
DT Article; Retracted Publication
DE diesel; fetal inflammation; ozone; airway hyperreactivity
ID EARLY POSTNATAL-DEVELOPMENT; INFLAMMATORY LUNG INJURY; NEWBORN RATS;
   ALVEOLAR DEVELOPMENT; MICE; HYPEROXIA; EXHAUST; ASTHMA; PARTICLES;
   RESPONSES
AB Air pollutant exposure is linked with childhood asthma incidence and exacerbations, and maternal exposure to airborne pollutants during pregnancy increases airway hyperreactivity (AHR) in offspring. To determine if exposure to diesel exhaust (DE) during pregnancy worsened postnatal ozone-induced AHR, timed pregnant C57BL/6 mice were exposed to DE (0.5 or 2.0 mg/m(3)) 4 hours daily from Gestation Day 9-17, or received twice-weekly oropharyngeal aspirations of the collected DE particles (DEPs). Placentas and fetal lungs were harvested on Gestation Day 18 for cytokine analysis. In other litters, pups born to dams exposed to air or DE, or to dams treated with aspirated diesel particles, were exposed to filtered air or 1 ppm ozone beginning the day after birth, for 3 hours per day, 3 days per week for 4 weeks. Additional pups were monitored after a 4-week recovery period. Diesel inhalation or aspiration during pregnancy increased levels of placental and fetal lung cytokines. There were no significant effects on airway leukocytes, but prenatal diesel augmented ozone-induced elevations of bronchoalveolar lavage cytokines at 4 weeks. Mice born to the high-concentration diesel-exposed dams had worse ozone-induced AHR, which persisted in the 4-week recovery animals. Prenatal diesel exposure combined with postnatal ozone exposure also worsened secondary alveolar crest development. We conclude that maternal inhalation of DE in pregnancy provokes a fetal inflammatory response that, combined with postnatal ozone exposure, impairs alveolar development, and causes a more severe and long-lasting AHR to ozone exposure.
C1 [Auten, Richard L.; Mason, S. Nicholas] Duke Univ, Dept Pediat Neonatal Med, Durham, NC 27710 USA.
   [Potts, Erin N.; Foster, W. Michael] Duke Univ, Dept Med Pulm Crit Care Med, Durham, NC 27710 USA.
   [Gilmour, M. Ian; Krantz, Q. Todd] US EPA, Natl Hlth & Environm Effects Res Lab, Environm Publ Hlth Div, Res Triangle Pk, NC 27711 USA.
RP Auten, RL (reprint author), Duke Univ, Dept Pediat Neonatal Med, DUMC Box 3373, Durham, NC 27710 USA.
EM auten@duke.edu
FU U.S. Environmental Protection Agency Children's Environmental Health
   Center [RD 83329301]; National Institutes of Health [ES-016347]
FX This work was supported by U.S. Environmental Protection Agency
   Children's Environmental Health Center Award RD 83329301, and by
   National Institutes of Health grant ES-016347.
CR Auten RL, 2007, AM J RESP CRIT CARE, V176, P291, DOI 10.1164/rccm.200605-6620C
   Auten RL, 2009, AM J RESP CRIT CARE, V180, P1218, DOI 10.1164/rccm.200901-0116OC
   Auten RL, 2006, AM J PHYSIOL-LUNG C, V290, pL32, DOI 10.1152/ajplung.00133.2005
   Auten RL, 2001, AM J PHYSIOL-LUNG C, V281, pL336
   Auten RL, 2009, MATERNAL DIESEL EXHA
   Bozanich EM, 2005, J APPL PHYSIOL, V99, P108, DOI 10.1152/japplphysiol.01111.2004
   Bry K, 2010, SEMIN PERINATOL, V34, P211, DOI [10.1053/j.sempen.2010.02.006, 10.1053/j.semperi.2010.02.006]
   DIAZSANCHEZ D, 1994, J CLIN INVEST, V94, P1417, DOI 10.1172/JCI117478
   Fedulov AV, 2008, AM J RESP CELL MOL, V38, P57, DOI 10.1165/rcmb.2007-0124OC
   Fedulov AV, 2008, J IMMUNOTOXICOL, V5, P445, DOI 10.1080/15476910802481765
   Fedulov AV, 2010, AM J RESP CELL MOL B, V43, P750
   Foster WM, 2001, J APPL PHYSIOL, V90, P1111
   Fujimoto A, 2005, ENVIRON TOXICOL, V20, P431, DOI 10.1002/tox.20129
   Ghio AJ, 2001, AM J RESP CRIT CARE, V164, P704, DOI 10.1164/ajrccm.164.4.2011089
   Gowdy K, 2008, TOXICOL APPL PHARM, V229, P310, DOI 10.1016/j.taap.2008.01.040
   Hertz-Picciotto I, 2008, BASIC CLIN PHARMACOL, V102, P146, DOI 10.1111/j.1742-7843.2007.00190.x
   Hollingsworth JW, 2008, J CLIN INVEST, V118, P3462, DOI 10.1172/JCI34378
   Hunter DD, 2010, AM J RESP CELL MOL, V43, P750, DOI 10.1165/rcmb.2009-0191OC
   Irvin Charles G, 2009, Proc Am Thorac Soc, V6, P306, DOI 10.1513/pats.200808-091RM
   Jobe Alan H, 2005, J Perinatol, V25 Suppl 2, pS31, DOI 10.1038/sj.jp.7211317
   Johnston CJ, 2000, INHAL TOXICOL, V12, P205
   Koppelman GH, 2011, CURR OPIN ALLERGY CL, V11, P414, DOI 10.1097/ACI.0b013e32834a9573
   Kramer BW, 2009, SEMIN FETAL NEONAT M, V14, P2, DOI 10.1016/j.siny.2008.08.011
   Kuhn C, 2000, AM J RESP CELL MOL, V22, P289, DOI 10.1165/ajrcmb.22.3.3690
   Lim RH, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004660
   Margolis HG, 2009, INT J ENVIRON HEAL R, V19, P139, DOI 10.1080/09603120802415792
   McConnell R, 2010, ENVIRON HEALTH PERSP, V118, P1021, DOI 10.1289/ehp.0901232
   Midoro-Horiuti T, 2010, ENVIRON HEALTH PERSP, V118, P273, DOI 10.1289/ehp.0901259
   Perera FP, 2008, ENVIRON HEALTH PERSP, V116, P987, DOI 10.1289/ehp.11173
   Reliene R, 2005, MUTAT RES-FUND MOL M, V570, P245, DOI 10.1016/j.mrfmmm.2004.11.010
   Schultz ED, 2015, PEDIATR RES, V77, P606, DOI [10.1203/PDR.0b013e3181e0cd97, 10.1203/00006450-201011001-00134, 10.1038/pr.2015.18]
   Sharkhuu T, 2010, TOXICOL LETT, V196, P12, DOI 10.1016/j.toxlet.2010.03.017
   Tadesse S, 2011, REPROD SCI, V18, P713, DOI 10.1177/1933719110396722
   Tang JR, 2010, AM J PHYSIOL-LUNG C, V299, pL735, DOI 10.1152/ajplung.00153.2010
   United States Environmental Protection Agency, 2002, HLTH ASS DOC DIS ENG, P669
   Vancza EM, 2009, TOXICOL SCI, V107, P535, DOI 10.1093/toxsci/kfn253
   Veres TZ, 2007, AM J RESP CELL MOL, V37, P553, DOI 10.1165/rcmb.2007-00870C
   Veres TZ, 2009, AM J PATHOL, V174, P808, DOI 10.2353/ajpath.2009.080800
   Wang Lei, 2007, Birth Defects Research, V81, P144, DOI 10.1002/bdrc.20097
   Yi M, 2004, AM J RESP CRIT CARE, V170, P1188, DOI 10.1164/rccm.200402-215OC
   Yost BL, 2005, AM J PHYSIOL-LUNG C, V289, pL627, DOI 10.1152/ajplung.00377.2004
   Zielinska Barbara, 2010, Res Rep Health Eff Inst, P5
NR 42
TC 24
Z9 26
U1 4
U2 11
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1044-1549
EI 1535-4989
J9 AM J RESP CELL MOL
JI Am. J. Respir. Cell Mol. Biol.
PD APR
PY 2012
VL 46
IS 4
BP 454
EP 460
DI 10.1165/rcmb.2011-0256OC
PG 7
WC Biochemistry & Molecular Biology; Cell Biology; Respiratory System
SC Biochemistry & Molecular Biology; Cell Biology; Respiratory System
GA 924LC
UT WOS:000302691900006
PM 22052876
OA Green Published
DA 2018-12-27
ER

PT J
AU Mandal, A
   Meda, V
   Zhang, WJ
   Dalai, AK
AF Mandal, A.
   Meda, V.
   Zhang, W. J.
   Dalai, A. K.
TI RETRACTED: Spectroscopic investigation of collagen scaffolds impregnated
   with AgNPs coated by PEG/TX-100 mixed systems (Retracted article. See
   vol. 52, pg. 20, 2013)
SO INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
LA English
DT Article; Retracted Publication
DE Silver nanoparticles; Polyethylene glycol; Triton X-100; Collagen; FTIR;
   FT-Raman
ID CHEMICAL-REDUCTION METHOD; SODIUM DODECYL-SULFATE; SILVER NANOPARTICLES;
   VIBRATIONAL SPECTROSCOPY; BIOMEDICAL APPLICATIONS; ANTIBACTERIAL
   ACTIVITY; POLY(ETHYLENE GLYCOL); SECONDARY STRUCTURE; SILICA PARTICLES;
   RAMAN-SCATTERING
AB Silver nanoparticles have received attention as novel antimicrobial agents due to their high surface area to volume ratio and the unique chemical and physical properties. In order to study the effects of capping agents on silver nanoparticles (AgNPs), the nanoparticles were synthesized via chemical reduction method using different concentrations (0.3 mM, 0.6 mM and 0.9 mM) of polyethylene glycol (PEG) and Triton X-100 (TX). Also, AgNPs capped by the combinations of both PEG and TX were synthesized. These coated AgNPs were incorporated into collagen, lyophilized to form scaffolds and characterized by FTIR and FT-Raman spectroscopy. Results on mechanical property of all the scaffolds displayed no significant difference in the percentage elongation at break. However, the maximum percentage of 46.67% was observed with the combinations (0.9 mM PEG + 0.9 mM TX). This implies that the combinations of surfactants increase the elasticity, which is useful for biomedical applications, e.g., Heart-valve preparations. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Mandal, A.; Meda, V.; Zhang, W. J.] Univ Saskatchewan, Div Biomed Engn, Saskatoon, SK S7N 5A4, Canada.
   [Meda, V.; Dalai, A. K.] Univ Saskatchewan, Dept Chem & Biol Engn, Saskatoon, SK S7N 5A4, Canada.
RP Meda, V (reprint author), Univ Saskatchewan, Div Biomed Engn, 51 Campus Dr, Saskatoon, SK S7N 5A4, Canada.
EM venkatesh.meda@usask.ca
FU SHRF (Saskatchewan Health Research Foundation)
FX The involvement of W.J. Zhang in this work is partially supported by
   SHRF (Saskatchewan Health Research Foundation) Phase I project
   'BioNEMS'.
CR Agarwal M, 1998, BIOTECHNOL PROGR, V14, P517, DOI 10.1021/bp980015p
   Albornoz C, 2006, J MAGN MAGN MATER, V305, P12, DOI 10.1016/j.jmmm.2005.11.021
   Alexeev VL, 1996, LANGMUIR, V12, P2392, DOI 10.1021/la950707c
   ALIX AJP, 1988, J MOL STRUCT, V174, P159, DOI 10.1016/0022-2860(88)80151-0
   Bremmell KE, 1999, COLLOID SURFACE A, V146, P75, DOI 10.1016/S0927-7757(98)00802-4
   Buzzaccaro S., 2007, PHYS REV LETT, V99
   CLAESSON PM, 1986, J CHEM SOC FARAD T 1, V82, P2735, DOI 10.1039/f19868202735
   CLSI/NCCLS, 2006, METH DIL ANT SUSC TE
   da Silva EC, 2008, J NANOPART RES, V10, P201, DOI 10.1007/s11051-008-9483-z
   Fathima N.N., 2008, IND J SCI TECHNOL, V1, P3
   Fonseca MJ, 1996, BBA-BIOMEMBRANES, V1279, P259
   Geetha B, 1996, J CHEM PHYS, V105, P9649, DOI 10.1063/1.472809
   GEORGE A, 1991, BIOCHEMISTRY-US, V30, P2372, DOI 10.1021/bi00223a011
   Hoa L.T.M., 2009, PHYS C SER, V187
   Horikoshi K., 1990, J MOL STRUCT, V33, P239
   Hough D.B., 1987, SURFACTANT SCI SER, V23
   IWAMOTO R, 1968, J POLYM SCI A2, V6, P1509, DOI 10.1002/pol.1968.160060808
   Jodar-Reyes AB, 2006, J COLLOID INTERF SCI, V298, P248, DOI 10.1016/j.jcis.2005.12.035
   KALYANASUNDARAM K, 1976, J PHYS CHEM-US, V80, P1462, DOI 10.1021/j100554a015
   Khanna PK, 2005, MATER CHEM PHYS, V93, P117, DOI 10.1016/j.matchemphys.2005.02.029
   Kheybari S, 2010, DARU, V18, P168
   Kline SR, 1996, LANGMUIR, V12, P2402, DOI 10.1021/la950716l
   Koehler RD, 1997, LANGMUIR, V13, P2463, DOI 10.1021/la960552o
   Krafft C, 2006, SPECTROSC-INT J, V20, P195, DOI 10.1155/2006/738186
   Kramb RC, 2008, LANGMUIR, V24, P7565, DOI 10.1021/la800021h
   KRIMM S, 1986, ADV PROTEIN CHEM, V38, P181, DOI 10.1016/S0065-3233(08)60528-8
   Kumar R, 2011, J MOL STRUCT, V994, P117, DOI 10.1016/j.molstruc.2011.03.005
   Lee CH, 2001, INT J PHARMACEUT, V221, P1, DOI 10.1016/S0378-5173(01)00691-3
   Liu QT, 2007, LANGMUIR, V23, P8217, DOI 10.1021/la700364t
   Luo CC, 2005, J COLLOID INTERF SCI, V288, P444, DOI 10.1016/j.jcis.2005.03.005
   Maeda M, 1999, J CONTROL RELEASE, V62, P313, DOI 10.1016/S0168-3659(99)00156-X
   Mandal A., 2010, BIOL ENG, V2, P63
   MANDAL AB, 1987, EUR J BIOCHEM, V169, P617, DOI 10.1111/j.1432-1033.1987.tb13653.x
   MANDAL AB, 1980, INDIAN J CHEM A, V19, P620
   MANDAL AB, 1988, LANGMUIR, V4, P736, DOI 10.1021/la00081a041
   MANDAL AB, 1980, J PHYS CHEM-US, V84, P856, DOI 10.1021/j100445a012
   Mansur HS, 2004, POLYMER, V45, P7193, DOI 10.1016/j.polymer.2004.08.036
   Maroto JA, 1998, COLLOID SURFACE A, V145, P271, DOI 10.1016/S0927-7757(98)00683-9
   MATEJKA P, 1992, J PHYS CHEM-US, V96, P1361, DOI 10.1021/j100182a063
   McPherson J.M., 1986, BIOMED MAT RES, V20, P93
   Morones JR, 2005, NANOTECHNOLOGY, V16, P2346, DOI 10.1088/0957-4484/16/10/059
   NAPPER DH, 1983, POLYM STABILIZATION
   Nayeri M., 2010, COLLOID SURF A, V38, P84
   OTTEWILL RH, 1968, KOLLOID Z Z POLYM, V227, P108, DOI 10.1007/BF02085284
   Overman SA, 1998, BIOCHEMISTRY-US, V37, P5654, DOI 10.1021/bi972339c
   Pachence JM, 1996, J BIOMED MATER RES, V33, P35, DOI 10.1002/(SICI)1097-4636(199621)33:1<35::AID-JBM6>3.0.CO;2-N
   PACHENCE JM, 1987, MED DEVICE DIAGN IND, V9, P49
   Palla BJ, 2002, J COLLOID INTERF SCI, V256, P143, DOI 10.1006/jcis.2002.8648
   Panacek A, 2006, J PHYS CHEM B, V110, P16248, DOI 10.1021/jp063826h
   Pelton JT, 2000, ANAL BIOCHEM, V277, P167, DOI 10.1006/abio.1999.4320
   Reddy GK, 1996, CLIN BIOCHEM, V29, P225, DOI 10.1016/0009-9120(96)00003-6
   Rose C, 1996, INT J BIOL MACROMOL, V18, P41, DOI 10.1016/0141-8130(95)01054-8
   Schweitzer-Stenner R, 2006, VIB SPECTROSC, V42, P98, DOI 10.1016/j.vibspec.2006.01.004
   Shameli K, 2010, INT J NANOMED, V5, P573
   Sharma KP, 2009, J PHYS CHEM B, V113, P3423, DOI 10.1021/jp810769g
   Silver S, 1996, ANNU REV MICROBIOL, V50, P753, DOI 10.1146/annurev.micro.50.1.753
   SLAWSON RM, 1992, PLASMID, V27, P72, DOI 10.1016/0147-619X(92)90008-X
   Sripriya R, 2003, J APPL POLYM SCI, V87, P2186, DOI 10.1002/app.11651
   Sun YJ, 2008, NANOTECHNOLOGY, V19, DOI 10.1088/0957-4484/19/11/115604
   Sun YJ, 2008, J CHEM PHYS, V128, DOI 10.1063/1.2832322
   Tanaka H, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.168303
   Touati D, 2000, ARCH BIOCHEM BIOPHYS, V373, P1, DOI 10.1006/abbi.1999.1518
   Tran N, 2010, INT J NANOMED, V5, P277
   Tu A.T, 1982, RAMAN SPECTROSCOPY B, P65
   Vladislav B., 2006, J BIOL CHEM, V281, P15208
   Von Rybinski W., 1987, SURFACTANT SCI SER, V23
   WOESSNER JF, 1961, ARCH BIOCHEM BIOPHYS, V93, P440, DOI 10.1016/0003-9861(61)90291-0
   WONG K, 1989, LANGMUIR, V5, P1346, DOI 10.1021/la00090a014
   YOUNES H, 1988, EUR POLYM J, V24, P765, DOI 10.1016/0014-3057(88)90013-4
   Zhang Y, 2002, BIOMATERIALS, V23, P1553, DOI 10.1016/S0142-9612(01)00267-8
NR 70
TC 6
Z9 6
U1 2
U2 21
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0141-8130
J9 INT J BIOL MACROMOL
JI Int. J. Biol. Macromol.
PD APR 1
PY 2012
VL 50
IS 3
BP 603
EP 612
DI 10.1016/j.ijbiomac.2012.01.001
PG 10
WC Biochemistry & Molecular Biology; Chemistry, Applied; Polymer Science
SC Biochemistry & Molecular Biology; Chemistry; Polymer Science
GA 924BF
UT WOS:000302664900022
PM 22260903
DA 2018-12-27
ER

PT J
AU Guarino, A
   Wudy, A
   Basile, F
   Ruberto, E
   Buccigrossi, V
AF Guarino, Alfredo
   Wudy, Anna
   Basile, Francesca
   Ruberto, Eliana
   Buccigrossi, Vittoria
TI RETRACTED: Composition and roles of intestinal microbiota in children
   (Retracted article. See vol. 27, pg. 973, 2014)
SO JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE
LA English
DT Article; Proceedings Paper; Retracted Publication
CT 5th EURAIBI-Europe Against Infant Brain InjuryInternational Meeting
CY APR 19-21, 2011
CL Siena, ITALY
DE 16S rDNA; gut microbial enterotypes; microbiome; molecular microflora
   evaluation; newborn infant
ID GUT MICROBIOTA; PEDIATRIC-PATIENTS; DISEASE; BACTERIA; FLORA;
   ENTEROTYPES; DIETARY; HEALTH; AGE
AB Objective: To provide an update of the advantages of new-generation molecular diagnostics to study the diversity of intestinal microflora and to evaluate its alteration in human diseases. Methods: We review recent advances in understanding the complex ecosystem of gut microbiota based on a dynamic and mutual interaction with the host. Results: In vaginal delivery, the contact with the mother's vaginal and intestinal flora is an important source of Lactobacillus, Prevotella and other Bifidobacterium. On the opposite, in cesarean delivery, direct contact of the mouth of the newborn with vaginal and intestinal microbiota is replaced by exogenous non-maternally derived bacteria colonizing the infants' intestine producing a less diverse flora. The original microbiome settings evolve during the growth converging to three main clusters defined "enterotypes" in the adult age. Conclusions: The key role in human health could depend on the balance between beneficial and harmful microbial species populating the gut, therefore the intestinal microflora can been considered as a potential biomarker and/or therapeutic target in intestinal and extra-intestinal diseases.
C1 [Guarino, Alfredo; Wudy, Anna; Basile, Francesca; Ruberto, Eliana; Buccigrossi, Vittoria] Univ Naples Federico II, Dept Pediat, Naples, Italy.
RP Guarino, A (reprint author), Univ Naples Federico II, Dept Pediat, Via S Pansini 5, I-80131 Naples, Italy.
EM alfguari@unina.it
CR Arumugam M, 2011, NATURE, V473, P174, DOI 10.1038/nature09944
   Azcarate-Peril M Andrea, 2011, Gut Microbes, V2, P234, DOI 10.4161/gmic.2.4.16332
   Bercik P, 2011, GASTROENTEROLOGY, V141, P599, DOI 10.1053/j.gastro.2011.04.052
   Bruzzese E, 2007, CLIN NUTR, V26, P322, DOI 10.1016/j.clnu.2007.01.004
   Cowan D, 2005, TRENDS BIOTECHNOL, V23, P321, DOI 10.1016/j.tibtech.2005.04.001
   De Filippo C, 2010, P NATL ACAD SCI USA, V107, P14691, DOI 10.1073/pnas.1005963107
   De Palma G, 2010, BMC MICROBIOL, V10, DOI 10.1186/1471-2180-10-63
   Festi D, 2011, DIGEST DIS, V29, P518, DOI 10.1159/000332975
   Gibson GR, 1999, COLONIC MICROBIOTA N, P1
   Guarino A, 2011, CURR OPIN GASTROEN, V27, P24, DOI 10.1097/MOG.0b013e3283413750
   Hopkins MJ, 2005, FEMS MICROBIOL ECOL, V54, P77, DOI 10.1016/j.femsec.2005.03.001
   Karlsson CLJ, 2011, PEDIATR RES, V70, P282, DOI 10.1203/PDR.0b013e318225f765
   Luoto R, 2011, J PEDIATR GASTR NUTR, V52, P90, DOI 10.1097/MPG.0b013e3181f3457f
   Mackie RI, 1999, AM J CLIN NUTR, V69, p1035S, DOI 10.1093/ajcn/69.5.1035s
   Mai V, 2004, J NUTR, V134, P459
   Mshvildadze M, 2010, J PEDIATR-US, V156, P20, DOI 10.1016/j.jpeds.2009.06.063
   O'Hara AM, 2006, EMBO REP, V7, P688, DOI 10.1038/sj.embor.7400731
   Palmer C, 2007, PLOS BIOL, V5, P1556, DOI 10.1371/journal.pbio.0050177
   Rhee SH, 2009, NAT REV GASTRO HEPAT, V6, P306, DOI 10.1038/nrgastro.2009.35
   Roberfroid M, 2010, BRIT J NUTR, V104, pS1, DOI 10.1017/S0007114510003363
   Roudiere L, 2009, J MICROBIOL METH, V79, P156, DOI 10.1016/j.mimet.2009.08.005
   Saulnier DM, 2011, GASTROENTEROLOGY, V141, P1782, DOI 10.1053/j.gastro.2011.06.072
   Schippa S, 2010, BMC MICROBIOL, V10, DOI 10.1186/1471-2180-10-175
   Schwiertz A, 2010, J PEDIATR-US, V157, P240, DOI 10.1016/j.jpeds.2010.02.046
   Su C, 2012, APPL MICROBIOL BIOT, V93, P993, DOI 10.1007/s00253-011-3800-7
   Swidsinski A, 2009, J PHYSIOL PHARMACOL, V60, P61
   Torrazza RM, 2011, J PERINATOL, V31, pS29, DOI 10.1038/jp.2010.172
   Tringe SG, 2005, SCIENCE, V308, P554, DOI 10.1126/science.1107851
   Wang RF, 2004, MOL CELL PROBE, V18, P223, DOI 10.1016/j.mcp.2004.03.002
   Wu GD, 2011, SCIENCE, V334, P105, DOI 10.1126/science.1208344
NR 30
TC 20
Z9 22
U1 3
U2 48
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1476-7058
EI 1476-4954
J9 J MATERN-FETAL NEO M
JI J. Matern.-Fetal Neonatal Med.
PD APR
PY 2012
VL 25
SU 1
BP 63
EP 66
DI 10.3109/14767058.2012.663231
PG 4
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 919JO
UT WOS:000302321100018
PM 22348506
DA 2018-12-27
ER

PT J
AU Williams, B
   Brown, D
AF Williams, Bethan
   Brown, David
TI RETRACTED: Direct to consumer Internet advertising of statins: an
   assessment of safety (Retracted article. See vol. 21, pg. 909, 2012)
SO PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
LA English
DT Article; Retracted Publication
DE statin; Internet; advertising; direct to consumer
ID HEALTH INFORMATION; GUIDELINES; DEMENTIA; BENEFITS; QUALITY; DRUGS;
   HARMS; WANT; CARE; WEB
AB Purpose To evaluate a sample of Internet sites advertising statins for sale to the general public. Methods A simulated customer search and evaluation of retrieved sites using evaluation tools focussing on quality (Q) and safe medicine use (SMU). Sites retrieved on 17 November 2010 were systematically analysed from 19 November to 23 December 2010. Results One hundred eighty-four sites met the inclusion criteria: 40 each for atorvastatin, pravastatin, rosuvastatin, and simvastatin and 24 for fluvastatin. Sites originated from 17 different countries. Most sites scored less than half the maximum Q score (26; range 5-17). Mean total SMU scores for each statin group were lower than 50% of the maximum (45; range of 0-28). There were no statistically significant differences between statins. General contraindications were absent in 92.4% of sites and contraindicated medicines in 47.3%. Key warnings on the appearance of symptoms associated with myopathy, liver disease, hypersensitivity, and pancreatitis were absent in 37, 48.4, 91.3, and 96.2% of sites, respectively. Most websites presented a chaotic and incomplete list of known side effects; just 13 (7.1%) presented a list compatible with current prescribing information. Only two-thirds (65.8%) attempted to describe any in lay language. Conclusions A potential purchaser of statins is likely to encounter websites from a wide geographical base and of generally poor quality. This has potentially serious implications for the safety of purchasers who may not be aware of the problems associated with ordering medicines online or the actual medication, which they receive. Direct to consumer advertising websites need tighter controls. Copyright (C) 2012 John Wiley & Sons, Ltd.
C1 [Williams, Bethan; Brown, David] Univ Portsmouth, Sch Pharm & Biomed Sci, Portsmouth PO1 2DT, Hants, England.
RP Brown, D (reprint author), Univ Portsmouth, Sch Pharm & Biomed Sci, St Michaels Bldg,White Swan Rd, Portsmouth PO1 2DT, Hants, England.
EM david.brown@port.ac.uk
CR Abramson J, 2007, LANCET, V369, P168, DOI 10.1016/S0140-6736(07)60084-1
   Almasi EA, 2006, PLOS MED, V3, P284, DOI 10.1371/journal.pmed.0030145
   Aulton F, 2006, EC AFF, V26, P24
   Berry DC, 1997, PSYCHOL HEALTH, V12, P467, DOI 10.1080/08870449708406723
   Berry DC, 2003, DRUG SAFETY, V26, P1, DOI 10.2165/00002018-200326010-00001
   Bradford WD, 2006, CLIN THER, V28, P2105, DOI 10.1016/j.clinthera.2006.12.015
   Cramer C, 2008, NEUROLOGY, V71, P344, DOI 10.1212/01.wnl.0000319647.15752.7b
   Dickinson D, 2003, BRIT MED J, V327, P861, DOI 10.1136/bmj.327.7419.861-a
   Eysenbach G, 2002, BRIT MED J, V324, P573, DOI 10.1136/bmj.324.7337.573
   Fox N, 2005, SOC SCI MED, V61, P1474, DOI 10.1016/j.socscimed.2005.03.011
   Gibson L, 2004, BRIT MED J, V328, P1221, DOI 10.1136/bmj.328.7450.1221-b
   Gilbody S, 2005, QUAL SAF HEALTH CARE, V14, P246, DOI 10.1136/qshc.2004.012781
   Gongeau MJ, 2005, PHARMACOTHERAPY, V25, P228
   HealthWatch, 2002, POS PAP DIR CONS ADV
   Huh J, 2004, J HEALTH COMMUN, V9, P529, DOI 10.1080/10810730490882667
   Lecky B., 2008, BMJ-BRIT MED J, V337, P1159
   Lexchin J, 2002, J PUBLIC POLICY MARK, V21, P194, DOI 10.1509/jppm.21.2.194.17595
   Liang BA, 2008, WAKE FOREST INTELL P, V8, P301
   Mackey TK, 2011, J PHARM SCI-US, V100, P4571, DOI 10.1002/jps.22679
   Mansfield PR, 2005, BRIT MED J, V330, P5, DOI 10.1136/bmj.330.7481.5
   McKenney JM, 2006, AM J CARDIOL, V97, p89C, DOI 10.1016/j.amjcard.2006.02.030
   Medicines and Healthcare Regulatory Agency, 2005, GUID COMM RISKS BEN
   Mintzes B, 2003, CAN MED ASSOC J, V169, P405
   Mintzes B, 2002, BRIT MED J, V324, P908, DOI 10.1136/bmj.324.7342.908
   Murray E, 2004, J AM BOARD FAM PRACT, V17, P6, DOI 10.3122/jabfm.17.1.6
   National Institute for Health and Clinical Excellence, 2008, NICE IMPL UPT REP ST
   New Zealand Medicines and Medical Devices Safety Authority, 2001, GUID ADV PRESCR MED
   Rains SA, 2009, COMPUT HUM BEHAV, V25, P544, DOI 10.1016/j.chb.2008.11.005
   Savoie I, 2002, J CLIN EPIDEMIOL, V55, P95, DOI 10.1016/S0895-4356(01)00436-X
   Schwartz LM, 2009, ANN INTERN MED, V150, P516, DOI 10.7326/0003-4819-150-8-200904210-00106
   Shepperd S, 1993, DISCERN QUALITY CRIT
   Silberg WM, 1997, JAMA-J AM MED ASSOC, V277, P1244, DOI 10.1001/jama.277.15.1244
   Silva MA, 2006, CLIN THER, V28, P26, DOI 10.1016/j.clinthera.2006.01.005
   Sumpradit N, 2004, CLIN THER, V26, P135, DOI 10.1016/S0149-2918(04)90014-8
   Toop L, 2003, N Z MED J, V116, P1180
   Vitry A, 2004, AUSTR PRESCRIBER, V27, P4
   Wang YL, 2007, INT J MED INFORM, V76, P575, DOI 10.1016/j.ijmedinf.2006.04.001
   Wolozin B, 2004, CURR OPIN LIPIDOL, V15, P667, DOI 10.1097/00041433-200412000-00007
   World Health Organization, 1988, ETH CRIT MED DRUG PR
   Wu TY, 2010, J ROY SOC MED, V103, P239, DOI 10.1258/jrsm.2010.100113
NR 40
TC 4
Z9 4
U1 3
U2 25
PU WILEY PERIODICALS, INC
PI SAN FRANCISCO
PA ONE MONTGOMERY ST, SUITE 1200, SAN FRANCISCO, CA 94104 USA
SN 1053-8569
J9 PHARMACOEPIDEM DR S
JI Pharmacoepidemiol. Drug Saf.
PD APR
PY 2012
VL 21
IS 4
BP 352
EP 365
DI 10.1002/pds.3208
PG 14
WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy
SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy
GA 923NR
UT WOS:000302626500002
PM 22298504
OA Bronze
DA 2018-12-27
ER

PT J
AU Iwamoto, J
   Takeda, T
   Matsumoto, H
AF Iwamoto, J.
   Takeda, T.
   Matsumoto, H.
TI RETRACTED: Sunlight exposure is important for preventing hip fractures
   in patients with Alzheimer's disease, Parkinson's disease, or stroke
   (Retracted article. See vol. 137, pg. 630, 2018)
SO ACTA NEUROLOGICA SCANDINAVICA
LA English
DT Article; Retracted Publication
DE sunlight; vitamin D; hip fracture; Alzheimer's disease; Parkinson's
   disease; stroke
ID RANDOMIZED CONTROLLED-TRIAL; VITAMIN-D; NEUROLOGICAL DISEASES;
   HYPOVITAMINOSIS-D; ELDERLY-WOMEN; FALLS; METAANALYSIS; RISK;
   OSTEOPOROSIS; EFFICACY
AB Objectives - Hypovitaminosis D as a result of malnutrition or sunlight deprivation, increased bone resorption, low bone mineral density (BMD), or an increased risk of falls may contribute to an increased risk of hip fractures in patients with neurological diseases, including Alzheimer's disease, Parkinson's disease, and stroke. The purpose of this study was to clarify the efficacy of sunlight exposure for reducing the risk of hip fractures in patients with such neurological diseases. Methods - The English literature was searched using PubMed, and randomized controlled trials evaluating the efficacy of sunlight exposure for reducing the risk of hip fractures in patients with Alzheimer's disease, Parkinson's disease, and stroke were identified. The relative risk and the 95% confidence interval were calculated for individual randomized controlled trials, and a pooled data analysis (meta-analysis) was performed. Results - Three randomized controlled trials were identified. Sunlight exposure improved hypovitaminosis D and increased the BMD. The relative risk (95% confidence interval) of hip fractures was 0.22 (0.05, 1.01) for Alzheimer's disease, 0.27 (0.08, 0.96) for Parkinson's disease, and 0.17 (0.02, 1.36) for stroke. The relative risk (95% confidence interval) calculated for the pooled data analysis was 0.23 (0.10, 0.56) (P = 0.0012), suggesting a significant risk reduction rate of 77%. Conclusions - The present meta-analysis added additional evidence indicating the efficacy of sunlight exposure for reducing the risk of hip fractures in patients with Alzheimer's disease, Parkinson's disease, and stroke.
C1 [Iwamoto, J.] Keio Univ, Inst Integrated Sports Med, Sch Med, Shinjuku Ku, Tokyo 1608582, Japan.
RP Iwamoto, J (reprint author), Keio Univ, Inst Integrated Sports Med, Sch Med, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.
EM jiwamoto@a8.keio.jp
RI Matsumoto, Hideo/A-2304-2014
CR Baker NL, 2011, AGE AGEING, V40, P49, DOI 10.1093/ageing/afq146
   BEADLE PC, 1977, BRIT J DERMATOL, V97, P585
   Bischoff HA, 2001, HISTOCHEM J, V33, P19, DOI 10.1023/A:1017535728844
   Bischoff-Ferrari HA, 2004, JAMA-J AM MED ASSOC, V291, P1999, DOI 10.1001/jama.291.16.1999
   Bischoff-Ferrari HA, 2005, JAMA-J AM MED ASSOC, V293, P2257, DOI 10.1001/jama.293.18.2257
   BUCHNER DM, 1987, JAMA-J AM MED ASSOC, V257, P1492, DOI 10.1001/jama.257.11.1492
   Deeks JJ, 2005, J CLIN EPIDEMIOL, V58, P882, DOI 10.1016/j.jclinepi.2005.01.016
   Epstein S, 2000, AGING CLIN EXP RES, V12, P330, DOI 10.1007/BF03339858
   Epstein S, 2007, BONE, V41, pS3, DOI 10.1016/j.bone.2007.03.006
   GRISSO JA, 1991, NEW ENGL J MED, V324, P1326, DOI 10.1056/NEJM199105093241905
   Harada A, 2001, OSTEOPOROSIS INT, V12, P215, DOI 10.1007/s001980170132
   Iwamoto J, 2009, OSTEOPOROSIS INT, V20, P1233, DOI 10.1007/s00198-008-0794-9
   Iwamoto J, 2008, CURR MED RES OPIN, V24, P1379, DOI 10.1185/030079908X297321 
   Iwamoto Jun, 2009, Ther Clin Risk Manag, V5, P773
   Iwamoto J, 2008, CLIN INTERV AGING, V3, P483, DOI 10.2147/CIA.S3177
   Iwamoto J, 2009, CLIN DRUG INVEST, V29, P471, DOI 10.2165/00044011-200929070-00005
   Kang JH, 2011, STROKE, V42, P336, DOI 10.1161/STROKEAHA.110.595538
   LESTER E, 1980, SCAND J CLIN LAB INV, V40, P145, DOI 10.3109/00365518009093017
   Melton LJ, 2006, MOVEMENT DISORD, V21, P1361, DOI 10.1002/mds.20946
   Nurmi I, 2003, ARCH ORTHOP TRAUM SU, V123, P551, DOI 10.1007/s00402-003-0583-z
   Runge M., 2006, Journal of Musculoskeletal & Neuronal Interactions, V6, P167
   Sato Y, 2005, J BONE MINER RES, V20, P1327, DOI 10.1359/JBMR.050402
   Sato Y, 2005, CEREBROVASC DIS, V20, P187, DOI 10.1159/000087203
   Sato Y, 2003, NEUROLOGY, V61, P338, DOI 10.1212/01.WNL.0000078892.24356.90
   Sato Y, 2002, BONE, V30, P325, DOI 10.1016/S8756-3282(01)00645-7
   Sato Y, 2011, PARKINSONISM RELAT D, V17, P22, DOI 10.1016/j.parkreldis.2010.10.008
   Sato Y, 2011, J STROKE CEREBROVASC, V20, P41, DOI 10.1016/j.jstrokecerebrovasdis.2009.10.007
   van Schoor NM, 2003, JAMA-J AM MED ASSOC, V289, P1957, DOI 10.1001/jama.289.15.1957
   Weller I, 2004, ANN EPIDEMIOL, V14, P319, DOI 10.1016/j.annepidem.2003.08.005
NR 29
TC 13
Z9 13
U1 1
U2 11
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0001-6314
EI 1600-0404
J9 ACTA NEUROL SCAND
JI Acta Neurol. Scand.
PD APR
PY 2012
VL 125
IS 4
BP 279
EP 284
DI 10.1111/j.1600-0404.2011.01555.x
PG 6
WC Clinical Neurology
SC Neurosciences & Neurology
GA 904UJ
UT WOS:000301223100012
PM 21682695
DA 2018-12-27
ER

PT J
AU Garner, R
AF Garner, Richard
TI RETRACTED: Understanding the Small Object Argument (Retracted article.
   See vol. 22, pg. 683, 2014)
SO APPLIED CATEGORICAL STRUCTURES
LA English
DT Article; Retracted Publication
DE Weak factorisation system; Small object argument
ID CATEGORIES
AB The small object argument is a transfinite construction which, starting from a set of maps in a category, generates a weak factorisation system on that category. As useful as it is, the small object argument has some problematic aspects: it possesses no universal property; it does not converge; and it does not seem to be related to other transfinite constructions occurring in categorical algebra. In this paper, we give an "algebraic" refinement of the small object argument, cast in terms of Grandis and Tholen's natural weak factorisation systems, which rectifies each of these three deficiencies.
C1 Uppsala Univ, Dept Math, S-75106 Uppsala, Sweden.
RP Garner, R (reprint author), Uppsala Univ, Dept Math, Box 480, S-75106 Uppsala, Sweden.
EM rhgg2@cam.ac.uk
OI Garner, Richard/0000-0003-4475-8721
FU St John's College, Cambridge; Marie Curie Intra-European Fellowship
   [040802]
FX Supported by a Research Fellowship of St John's College, Cambridge and a
   Marie Curie Intra-European Fellowship, Project No. 040802.
CR Adamek J., 2002, CAH TOPOL GEOM DIFFE, VXLIII, P83
   Applegate H., 1966, SEM TRIPL CAT HOM TH, P156
   Balteanu C, 2003, ADV MATH, V176, P277, DOI 10.1016/S0001-8708(03)00065-3
   Beck J., 1966, SEM TRIPL CAT HOM TH, P119
   BLACKWELL R, 1989, J PURE APPL ALGEBRA, V59, P1, DOI 10.1016/0022-4049(89)90160-6
   Bousfield Aldridge K., 1977, J PURE APPL ALGEBRA, V9, P207, DOI 10.1016/0022-4049(77)90067-6
   Dubuc E., 1970, LECT NOTES MATH, V145
   Forcey S., 2004, ALGEBR GEOM TOPOL, V4, P95
   FREYD PJ, 1972, J PURE APPL ALGEBRA, V2, P169
   Gabriel P., 1971, LECT NOTES MATH, V221
   Garner R., 07111761 ARXIV
   Gordon R., 1995, MEM AM MATH SOC, V117
   Grandis M, 2006, ARCH MATH-BRNO, V42, P397
   Gurski N., 2006, THESIS U CHICAGO
   Hovey M, 1999, MATH SURVEYS MONOGRA, V63
   JOYAL A, 1993, ADV MATH, V102, P20, DOI 10.1006/aima.1993.1055
   Kelly G. M., 1980, B AUSTRAL MATH SOC, V22, P1, DOI DOI 10.1017/S0004972700006353
   Lack S, 2002, K-THEORY, V26, P171, DOI 10.1023/A:1020305604826
   Lamarche Francois, 2007, THEORY APPL CATEG, V18, P473
   Quillen DG, 1967, LECT NOTES MATH, V43
NR 20
TC 2
Z9 2
U1 3
U2 9
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0927-2852
EI 1572-9095
J9 APPL CATEGOR STRUCT
JI Appl. Categ. Struct.
PD APR
PY 2012
VL 20
IS 2
BP 103
EP 141
DI 10.1007/s10485-008-9126-7
PG 39
WC Mathematics
SC Mathematics
GA 915NA
UT WOS:000302032900001
DA 2018-12-27
ER

PT J
AU Bonomi, FG
   De Nardi, M
   Fappani, A
   Zani, V
   Banfi, G
AF Bonomi, Felice Giulio
   De Nardi, Massimo
   Fappani, Aldo
   Zani, Viviana
   Banfi, Giuseppe
TI RETRACTED: Impact of Different Treatment of Whole-Body Cryotherapy on
   Circulatory Parameters (Retracted article. See vol. 60, pg. 401, 2012)
SO ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS
LA English
DT Article; Retracted Publication
DE Whole-body cryotherapy; Cryochamber; Cryosauna; Blood pressure; Heart
   rate
ID COLD-AIR -110-DEGREES-C; BLOOD-PRESSURE; WOMEN; MEN; CRYOSTIMULATION;
   EXPOSURES; RESPONSES; CAPACITY; HUMANS
AB Cryotherapy is commonly used as a procedure to relieve pain symptoms, particularly in inflammatory diseases, injuries and overuse symptoms. A peculiar form of cold therapy or stimulation was proposed 30 years ago for the treatment of rheumatic diseases. The therapy consists in the exposure to very cold air in special cryochambers. The air is maintained at temperatures between -110 and -160 degrees C. The treatment was named whole-body cryotherapy (WBC). It consists in a brief exposure to extreme cold in a temperature-controlled chamber. It is applied to relieve pain and inflammatory symptoms caused by numerous disorders, particularly those associated with rheumatic conditions, and it is recommended for the treatment of arthritis, fibromyalgia and ankylosing spondylitis. The aim of this study was to investigate the effects of different treatment of WBC on blood pressure (BP) and heart rate (HR) parameters in adult subjects characterized from non-pathological values of BP. Eighty subjects (36 females, 44 males, age range 19-80 years) submitted to 4-17 WBC applications for a total of 816 treatments were recruited. Immediately before and after each WBC application systolic and diastolic BP and HR were measured and recorded. We did not find significant differences in BP and HR (p > 0.05). WBC seems to be safe with respect to unwanted BP and HR alterations for adult patients. An individual monitoring of subjects is recommended over the treatment, but pathological changes of circulatory parameters can be considered rare and occasional.
C1 [De Nardi, Massimo; Banfi, Giuseppe] Univ Milan, Sch Med, Milan, Italy.
   [Bonomi, Felice Giulio; Fappani, Aldo; Zani, Viviana] Poliambulatorio BonGi, Orzinuovi, Italy.
   [Banfi, Giuseppe] IRCCS Galeazzi, Milan, Italy.
RP De Nardi, M (reprint author), Univ Milan, Sch Med, Milan, Italy.
EM massimodenardi@alice.it
OI Banfi, Giuseppe/0000-0001-9578-5338
CR ANTONY I, 1994, HYPERTENSION, V24, P212, DOI 10.1161/01.HYP.24.2.212
   Banfi G, 2010, SPORTS MED, V40, P509, DOI 10.2165/11531940-000000000-00000
   BRENNAN PJ, 1982, BMJ-BRIT MED J, V285, P919, DOI 10.1136/bmj.285.6346.919
   Buemi M, 1997, HYPERTENSION, V30, P845, DOI 10.1161/01.HYP.30.4.845
   DiCarli MF, 1997, NEW ENGL J MED, V336, P1208, DOI 10.1056/NEJM199704243361703
   Dugue B, 2005, SCAND J CLIN LAB INV, V65, P395, DOI 10.1080/00365510510025728
   Fricke R, 1989, Z PHYS MED BALN MED, V18, P1
   Jansky L, 2006, PHYSIOL RES, V55, P543
   Jansky L, 1996, EUR J APPL PHYSIOL O, V72, P445, DOI 10.1007/BF00242274
   Leppaluoto J, 2008, SCAND J CLIN LAB INV, V68, P145, DOI 10.1080/00365510701516350
   LEPPALUOTO J, 1991, ARCTIC, V44, P139
   Lubkowska A, 2011, J THERM BIOL, V36, P264, DOI 10.1016/j.jtherbio.2011.03.011
   Lubkowska A, 2010, INT J OCCUP MED ENV, V23, P367, DOI 10.2478/v10001-010-0037-0
   Missmann M, 2007, PHYS REHAB KUR MED, V17, P286
   Papenfuss W., 2006, 2 AUSTR S WBCT FEBR
   Smolander J, 2006, CLIN PHYSIOL FUNCT I, V26, P232, DOI 10.1111/j.1475-097X.2006.00675.x
   Taghawinejad M, 1989, Z PHYS MED BALN MED, V18, P31
   TAGHAWINEJAD M, 1989, Z PHYS MED BALN MED, V18, P23
   VICTOR RG, 1987, HYPERTENSION, V9, P429, DOI 10.1161/01.HYP.9.5.429
   WENDT T, 1983, Z KARDIOL, V72, P24
   Westerlund T, 2006, J THERM BIOL, V31, P342, DOI 10.1016/j.jtherbio.2006.01.004
   Westerlund T, 2004, J THERM BIOL, V29, P285, DOI 10.1016/j.jtherbio.2004.05.004
   Yamauchi T, 1986, Z PHYS MED BALNEOL M, V15, P31
NR 23
TC 11
Z9 11
U1 2
U2 11
PU SPRINGER BASEL AG
PI BASEL
PA PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND
SN 0004-069X
J9 ARCH IMMUNOL THER EX
JI Arch. Immunol. Ther. Exp.
PD APR
PY 2012
VL 60
IS 2
BP 145
EP 150
DI 10.1007/s00005-012-0163-4
PG 6
WC Immunology
SC Immunology
GA 918TD
UT WOS:000302273100006
PM 22310979
DA 2018-12-27
ER

PT J
AU Zhang, P
   Wan, T
   Zhang, G
AF Zhang, P.
   Wan, T.
   Zhang, G.
TI RETRACTED: Enhancement of bio-sludge gravitational thickening with weak
   ultrasound (Retracted article. See vol. 9, pg. 759, 2012)
SO INTERNATIONAL JOURNAL OF ENVIRONMENTAL SCIENCE AND TECHNOLOGY
LA English
DT Article; Retracted Publication
DE Activated sludge; Dry weight; Extracellular polymeric substances;
   Polyelectrolyte; Settleability; Sonication
ID WASTE-ACTIVATED-SLUDGE; SEWAGE-SLUDGE; DISINTEGRATION; DEWATERABILITY;
   BIODEGRADATION; SEPARATION; LIQUID
AB Gravitational thickening is the prevailing method to reduce bio-sludge volume though the process is slow and usually requires addition of polyelectrolyte(s). This paper investigated the potential benefits of sonication on enhancing the bio-sludge gravitational thickening with very low energy dose, thereby called "weak ultrasound". Results showed that weak sonication significantly changed the bio-sludge settleability and the main mechanism was release of the loosely bound extracellular polymeric substances. The changes were strongly influenced by power density and sonication duration. Low frequency was better but the difference was insignificant. Weak sonication (< 680 kJ/kg DS) improved the sludge gravitational thickening while high ultrasonic energy deteriorated the process. Considering both the sludge thickening efficiency and energy consumption, the optimum conditions were 0.15 W/ml, 7 s and 25 kHz. Under such conditions, the energy dose was only 155 kJ/kg DS, much lower than literature reports and the sludge settling time shortened from the original 24 to 12 h. Weak sonication could substitute expensive polyelectrolyte coagulant for bio-sludge thickening. Combination of weak sonication and polyelectrolyte could further reduce the settling time to 6 h. The final water content of the thickened bio-sludge was not changed after sonication or polyelectrolyte addition.
C1 [Wan, T.; Zhang, G.] Harbin Inst Technol, State Key Lab Urban Water Resource & Environm, Harbin 150090, Peoples R China.
   [Zhang, P.] Beijing Forestry Univ, Sch Environm Sci & Engn, Beijing 100083, Peoples R China.
RP Zhang, G (reprint author), Harbin Inst Technol, State Key Lab Urban Water Resource & Environm, 73 Huanghe Rd, Harbin 150090, Peoples R China.
EM zgm200@126.com
FU Chinese Ministry of Science Technology [2009ZX07424-005]; State Key Lab
   of Urban Water Resource and Environment [QA200903]
FX The authors thank financial supports from Chinese Ministry of Science &
   Technology (2009ZX07424-005) and the State Key Lab of Urban Water
   Resource and Environment (QA200903).
CR Andrew DE, 1998, STANDARDS METHODS EX
   Bien J, 1997, WATER SCI TECHNOL, V36, P101, DOI 10.1016/S0273-1223(97)00675-6
   Bougrier C, 2006, CHEM ENG PROCESS, V45, P711, DOI 10.1016/j.cep.2006.02.005
   Chen YG, 2001, WATER RES, V35, P2615, DOI 10.1016/S0043-1354(00)00565-0
   Chu CP, 2001, WATER RES, V35, P1038, DOI 10.1016/S0043-1354(00)00338-9
   de Sarabia ERF, 2000, ULTRASONICS, V38, P642
   Dewil R, 2006, CHINESE J CHEM ENG, V14, P105, DOI 10.1016/S1004-9541(06)60045-1
   Emir E, 2006, WATER SCI TECHNOL, V53, P121, DOI 10.2166/wst.2006.215
   Feng X, 2009, BIORESOURCE TECHNOL, V100, P1074, DOI 10.1016/j.biortech.2008.07.055
   Gonze E, 2003, CHEM ENG PROCESS, V42, P965, DOI 10.1016/S0255-2701(03)00003-5
   Hua I, 1997, ENVIRON SCI TECHNOL, V31, P2237, DOI 10.1021/es960717f
   Keiding K, 1997, WATER RES, V31, P1665, DOI 10.1016/S0043-1354(97)00011-0
   Kim YU, 2003, JPN J APPL PHYS 1, V42, P5898, DOI 10.1143/JJAP.42.5898
   Kopp J, 2000, WATER SCI TECHNOL, V42, P141
   Li H, 2009, J HAZARD MATER, V161, P1421, DOI 10.1016/j.jhazmat.2008.04.113
   Mikkelsen LH, 2001, COLLOID SURFACE A, V182, P1, DOI 10.1016/S0927-7757(00)00772-X
   Na S, 2007, ULTRASON SONOCHEM, V14, P281, DOI 10.1016/j.ultsonch.2006.06.004
   Nickel K, 2007, ULTRASON SONOCHEM, V14, P450, DOI 10.1016/j.ultsonch.2006.10.012
   Schlafer O, 2002, ULTRASONICS, V40, P25, DOI 10.1016/S0041-624X(02)00086-0
   SUSLICK KS, 1990, SCIENCE, V247, P1439, DOI 10.1126/science.247.4949.1439
   Tiehm A, 2001, WATER RES, V35, P2003, DOI 10.1016/S0043-1354(00)00468-1
   Wang F, 2006, ULTRASON SONOCHEM, V13, P334, DOI 10.1016/j.ultsonch.2005.04.008
   Wang F, 2005, J HAZARD MATER, V123, P145, DOI 10.1016/j.jhazmat.2005.03.033
   Wang F, 2006, THESIS TIANJIN U CHI
   Yasuhiko W, 1999, WATER RES, V33, P3245
   Yin X, 2004, ULTRASON SONOCHEM, V11, P337, DOI 10.1016/j.ultsonch.2004.02.005
   Yin X, 2006, ULTRASONICS, V44, pE397, DOI 10.1016/j.ultras.2006.05.187
   Zhang PY, 2007, BIORESOURCE TECHNOL, V98, P207, DOI 10.1016/j.biortech.2005.12.002
NR 28
TC 4
Z9 4
U1 4
U2 23
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1735-1472
EI 1735-2630
J9 INT J ENVIRON SCI TE
JI Int. J. Environ. Sci. Technol.
PD APR
PY 2012
VL 9
IS 2
BP 287
EP 296
DI 10.1007/s13762-012-0023-0
PG 10
WC Environmental Sciences
SC Environmental Sciences & Ecology
GA 918KT
UT WOS:000302249100010
DA 2018-12-27
ER

PT J
AU Ugurlu, N
   Bayar, B
   Bayar, K
   Goktas, A
   Karakaya, IC
   Polat, H
AF Ugurlu, Nezihe
   Bayar, Banu
   Bayar, Kilichan
   Goktas, Atilla
   Karakaya, Ilkim Citak
   Polat, Hatice
TI RETRACTED: Development, validity and reliability of the Turkish version
   of the Hung Postpartum Stress Scale (Retracted article. See vol. 38, pg.
   1274, 2012)
SO JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH
LA English
DT Article; Retracted Publication
DE postpartum stress; postpartum stress scale; reliability; validity
ID SOCIAL SUPPORT; DEPRESSION
AB Aim: The aim of the current study was to translate the Hung Postpartum Stress Scale into Turkish and test the reliability and validity of the Turkish version of the scale.
   Methods: The translation process of the Hung Postpartum Stress Scale into Turkish and the testing of reliability and validity of the newly developed scale on postpartum stress in women are described. The questionnaire was translated using a back-translation technique. Expert review of internal consistency reliability, content validity, factor analysis of construct validity and criterion-related validity were examined.
   Results: Cronbach's alpha for the Turkish version of the Hung Postpartum Stress Scale was 0.931, indicating very good reliability. Factor analyses resulted in a two factor scale structure: maternal concerns and acceptability of the newborn by the family. Analyses also indicated good test-re-test reliability for the Turkish version of the Hung Postpartum Stress Scale (P < 0.01).
   Conclusions: The present study describes the design of a Turkish version of the Hung Postpartum Stress Scale. The newly developed scale proved to be reliable and valid and will be a valuable instrument for women's healthcare professionals.
C1 [Ugurlu, Nezihe] Mugla Univ, Mugla Sch Hlth Sci, Dept Nursing, TR-48170 Mugla, Turkey.
   [Bayar, Banu; Bayar, Kilichan; Karakaya, Ilkim Citak] Mugla Univ, Mugla Sch Hlth Sci, Dept Physiotherapy & Rehabil, TR-48170 Mugla, Turkey.
   [Goktas, Atilla] Mugla Univ, Dept Stat, Fac Arts & Sci, TR-48170 Mugla, Turkey.
   [Polat, Hatice] Mugla State Hosp, Mugla, Turkey.
RP Ugurlu, N (reprint author), Mugla Univ, Mugla Sch Hlth Sci, Dept Nursing, TR-48170 Mugla, Turkey.
EM nugurlu@mu.edu.tr
CR Akdolun N., 2002, J CUMHURIYET U SCH N, V6, P42
   Andresen EM, 2000, ARCH PHYS MED REHAB, V81, pS15, DOI 10.1053/apmr.2000.20619
   Arslantas H., 2009, J ADNAN MENDERES U M, V10, P13
   Ayers S, 2001, J PSYCHOSOM OBST GYN, V22, P13, DOI 10.3109/01674820109049947
   Ayvaz S, 2006, TURK PSIKIYATR DERG, V17, P243
   Bahadoran P, 2008, IJNMR, V13, P110
   Baser M., 2005, J HEALTH SCI, V14, P54
   Beydag K., 2007, TAF PREVENTIVE MED B, V6, P479
   Bland JM, 1999, STAT METHODS MED RES, V8, P135, DOI 10.1177/096228029900800204
   Cheng CY, 2009, RES NURS HEALTH, V32, P582, DOI 10.1002/nur.20356
   Duman NB, 2009, TAF PREV MED B, V8, P73
   Efe SY, 2009, J TURK-GER GYNECOL A, V10, P14
   Egri G, 2007, TSK KORUYUCU HEKIMLI, V6, P313
   Fishbein E G, 1998, J Obstet Gynecol Neonatal Nurs, V27, P142, DOI 10.1111/j.1552-6909.1998.tb02604.x
   Groer MW, 2002, JOGNN-J OBST GYN NEO, V31, P411, DOI 10.1111/j.1552-6909.2002.tb00063.x
   Gulseren L, 1999, TURK PSIKIYATR DERG, V10, P58
   Horowitz J A, 1999, J Obstet Gynecol Neonatal Nurs, V28, P595, DOI 10.1111/j.1552-6909.1999.tb02168.x
   Hung CH, 2006, J CLIN NURS, V15, P718, DOI 10.1111/j.1365-2702.2006.01350.x
   Hung CH, 2005, J ADV NURS, V50, P417, DOI 10.1111/j.1365-2648.2005.03407.x
   Hung CH, 2001, J ADV NURS, V36, P676, DOI 10.1046/j.1365-2648.2001.02032.x
   Hung Chich-Hsiu, 2006, Kaohsiung Journal of Medical Sciences, V22, P500
   Hung CH, 2007, COMMUNITY MENT HLT J, V43, P1, DOI 10.1007/s10597-006-9066-3
   Hung CH, 2007, J NURS SCHOLARSHIP, V39, P71, DOI 10.1111/j.1547-5069.2007.00146.x
   KAISER HF, 1974, PSYCHOMETRIKA, V39, P31, DOI 10.1007/BF02291575
   Leung Sharron K S, 2005, Health Care Women Int, V26, P212, DOI 10.1080/07399330590917771
   Miller RL, 2006, BMC PSYCHIATRY, V6, DOI 10.1186/1471-244X-6-12
   Ngai FW, 2010, NURS RES, V59, P185, DOI 10.1097/NNR.0b013e3181dbb9ee
   Nur N, 2004, J FACULTY MED CUMHUR, V26, P55
   Pinar G., 2009, DICLE MED J, V36, P184
   Polit D. F., 1999, NURSING RES PRINCIPL
   Reece S M, 1993, Matern Child Nurs J, V21, P91
   Senses M, 2002, COCUK FORUMU, V5, P44
   Sharma S., 1996, APPL MULTIVARIATE TE
   Shaws M, 1967, SCALES MEASUREMENT A
   Smith M P, 1989, Midwifery, V5, P182, DOI 10.1016/S0266-6138(89)80005-1
   STEMP PS, 1986, J MARRIAGE FAM, V48, P271, DOI 10.2307/352394
   Surkan PJ, 2006, MATERN CHILD HLTH J, V10, P375, DOI 10.1007/s10995-005-0056-9
NR 37
TC 1
Z9 1
U1 3
U2 22
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1341-8076
EI 1447-0756
J9 J OBSTET GYNAECOL RE
JI J. Obstet. Gynaecol. Res.
PD APR
PY 2012
VL 38
IS 4
BP 705
EP 713
DI 10.1111/j.1447-0756.2011.01754.x
PG 9
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 914CK
UT WOS:000301926100013
PM 22381128
DA 2018-12-27
ER

PT J
AU Chen, ZY
   Wu, YJ
   Di, LJ
   Wang, GD
   Shen, YF
AF Chen, Zhiyuan
   Wu, Yongjun
   Di, Lijun
   Wang, Guodong
   Shen, Yufang
TI RETRACTED: The AtCCX1 transporter mediates salinity tolerance in both
   Arabidopsis and yeast (Retracted article. See vol. 110, pg. 317, 2012)
SO PLANT CELL TISSUE AND ORGAN CULTURE
LA English
DT Article; Retracted Publication
DE AtCCX1; Na+/K+ exchanger; Cation calcium exchangers; CCXs
ID SALT TOLERANCE; SACCHAROMYCES-CEREVISIAE; CATION TRANSPORTER; ANTIPORTER
   CAX1; ION HOMEOSTASIS; NA+ UPTAKE; EXPRESSION; STRESS; THALIANA; SODIUM
AB Maintaining high cytosolic K+/Na+ ratio and detoxicity of Na+ is important for plant cell metabolism and resistance to salt stress. Cation calcium exchangers, CCXs, are a novel family of genes that have recently been separated from the family of cation exchangers, CAXs, and these are likely to be correlated with Na+ transport. In this study, an Arabidopsis CCX putative gene, AtCCX1, has been cloned, and second structure model is constructed. Moreover, expression patterns in various tissues of Arabidopsis have been investigated along with heterologous expression of AtCCX1 in yeast. The gene AtCCX1 contains 1713 nucleotides, with a short N-terminal hydrophilic domain that does not support an N-terminal autoinhibitory domain. Expression of AtCCX1 in Arabidopsis is higher under salt stress and drought stress when compared to wild-type, but when plants are exposed to either cold stress or abscisic acid treatment, no differences in expression levels are observed. Yeast lines expressing AtCCX1 are more tolerant to low pH medium and have displayed higher level of tolerance to sodium salt stress compared to wild-type lines. Inductively coupled plasma atomic emission spectroscopy analysis has revealed that following overexpression of AtCCX1 in yeast, accumulation of Na+ is increased, while accumulation of K+ and Cu2+ is decreased. These findings support the fact that AtCCX1 is critical for Na+ tolerance and may serve as a Na+/K+ exchanger, similar to AtCCX3.
C1 [Chen, Zhiyuan; Wu, Yongjun] NW A&F Univ, Coll Life Sci, Yangling 712100, Shaanxi, Peoples R China.
   [Chen, Zhiyuan; Di, Lijun; Wang, Guodong] NW A&F Univ, Coll Sci, Yangling 712100, Shaanxi, Peoples R China.
   [Shen, Yufang] Chinese Acad Sci, Inst Soil & Water Conservat, Yangling 712100, Shaanxi, Peoples R China.
   [Shen, Yufang] Minist Water Resources, Yangling 712100, Shaanxi, Peoples R China.
RP Wu, YJ (reprint author), NW A&F Univ, Coll Life Sci, Yangling 712100, Shaanxi, Peoples R China.
EM nwsuafdrought@yahoo.com.cn
FU National Natural Scientific Foundation of China [30600384, 50809068];
   Young Outstanding Scholar Foundation of Northwest AF University
FX We thank two anonymous reviewer's comments and two editor's advices,
   especially Schuyler S. Korban's cirtical reading and very useful
   revision advices. We thank Toshiro Shigaki for providing Yeast strains
   K667. We thank National Natural Scientific Foundation of China (Grant
   30600384 and 50809068) and Young Outstanding Scholar Foundation of
   Northwest A&F University for providing the study funds.
CR Amoroso S, 2007, PHARM RES, V56, P556
   Amoroso S, 2007, CELL CALCIUM, V41, P221
   Amtmann A, 1999, ADV BOT RES, V29, P75
   Baek D, 2011, PLANT CELL PHYSIOL, V52, P149, DOI 10.1093/pcp/pcq182
   Blumwald E, 2000, CURR OPIN CELL BIOL, V12, P431, DOI 10.1016/S0955-0674(00)00112-5
   Cai XJ, 2004, MOL BIOL EVOL, V21, P1692, DOI 10.1093/molbev/msh177
   Cheng NH, 2005, PLANT PHYSIOL, V138, P2048, DOI 10.1104/pp.105.061218
   Darley CP, 2000, BIOCHEM J, V351, P241, DOI 10.1042/0264-6021:3510241
   Dubcovsky J, 1996, THEOR APPL GENET, V92, P448, DOI 10.1007/BF00223692
   Eide DJ, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-9-r77
   Fliegel L, 2008, J MOL CELL CARDIOL, V44, P228, DOI 10.1016/j.yjmcc.2007.11.016
   Fukuda A, 2011, PLANTA, V233, P175, DOI 10.1007/s00425-010-1289-4
   Gaxiola RA, 1999, P NATL ACAD SCI USA, V96, P1480, DOI 10.1073/pnas.96.4.1480
   Guan B, 2010, PLANT CELL TISS ORG, V103, P343, DOI 10.1007/s11240-010-9787-4
   Hanana M, 2009, BOTANY, V87, P1023, DOI 10.1139/B09-073
   Hasthanasombut S, 2011, PLANT CELL TISS ORG, V104, P79, DOI 10.1007/s11240-010-9807-4
   Hauser F, 2010, PLANT CELL ENVIRON, V33, P552, DOI 10.1111/j.1365-3040.2009.02056.x
   Hirschi KD, 2008, PLANT PHYSIOL, V148, P1474
   HORIE TS, 2005, PLANT J, V44, P928, DOI DOI 10.1111/J.1365-313X.2005.02595.X
   Ikegami K, 2009, J PLANT RES, V122, P235, DOI 10.1007/s10265-008-0201-9
   Jin TC, 2010, PLANT CELL TISS ORG, V100, P219, DOI 10.1007/s11240-009-9628-5
   Kinclova O, 2003, YEAST, V20, pS231
   Laurie S, 2002, PLANT J, V32, P139, DOI 10.1046/j.1365-313X.2002.01410.x
   Leidi EO, 2010, PLANT J, V61, P495, DOI 10.1111/j.1365-313X.2009.04073.x
   Li JP, 2007, ENDOCRINOLOGY, V148, P2116, DOI 10.1210/en.2006-1321
   Li TX, 2010, CHINESE SCI BULL, V55, P1127, DOI 10.1007/s11434-010-0092-8
   Maser P, 2001, PLANT PHYSIOL, V126, P1646, DOI 10.1104/pp.126.4.1646
   Mason MG, 2010, PLANT J, V64, P753, DOI 10.1111/j.1365-313X.2010.04366.x
   Morris J, 2008, PLANT PHYSIOL, V148, P1474, DOI 10.1104/pp.108.118810
   Munns R, 2005, NEW PHYTOL, V167, P645, DOI 10.1111/j.1469-8137.2005.01487.x
   Paul S, 2011, PLANT CELL TISS ORG, V105, P233, DOI 10.1007/s11240-010-9857-7
   Piqueras A, 1996, PLANT CELL TISS ORG, V45, P53, DOI 10.1007/BF00043428
   Pittman JK, 2004, PLANT MOL BIOL, V56, P959, DOI 10.1007/s11103-004-6446-3
   Pittman JK, 2002, J BIOL CHEM, V277, P26452, DOI 10.1074/jbc.M202563200
   Pittman JK, 2002, PLANT PHYSIOL, V130, P1054, DOI 10.1104/pp.008193
   Pittman JK, 2001, PLANT PHYSIOL, V127, P1020, DOI 10.1104/pp.127.3.1020
   Plett D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012571
   Ren ZH, 2005, NAT GENET, V37, P1141, DOI 10.1038/ng1643
   Roslyakova TV, 2009, COMP BIOCHEM PHYS A, V153A, pS190, DOI 10.1016/j.cbpa.2009.04.421
   Sher AA, 2008, PROG BIOPHYS MOL BIO, V96, P377, DOI 10.1016/j.pbiomolbio.2007.07.018
   Shi HZ, 2003, NAT BIOTECHNOL, V21, P81, DOI 10.1038/nbt766
   Shigaki T, 2006, J MOL EVOL, V63, P815, DOI 10.1007/s00239-006-0048-4
   Shigaki T, 2003, J BIOL CHEM, V278, P6610, DOI 10.1074/jbc.M209952200
   Shigaki T, 2001, J BIOL CHEM, V276, P43152, DOI 10.1074/jbc.M106637200
   Shigekawa M, 1999, J BIOL CHEM, V274, P23094
   Shinozaki K, 2000, CURR OPIN PLANT BIOL, V3, P217, DOI 10.1016/S1369-5266(00)00067-4
   Silva-Ortega CO, 2008, PLANT PHYSIOL BIOCH, V46, P82, DOI 10.1016/j.plaphy.2007.10.011
   Somboonwatthanaku I, 2010, PLANT CELL TISS ORG, V103, P369, DOI 10.1007/s11240-010-9790-9
   Subramanyam K, 2011, PLANT CELL TISS ORG, V105, P181, DOI 10.1007/s11240-010-9850-1
   Tian N, 2011, S AFR J BOT, V77, P160, DOI 10.1016/j.sajb.2010.07.010
   Uozumi N, 2000, PLANT PHYSIOL, V122, P1249, DOI 10.1104/pp.122.4.1249
   Wei Q, 2011, PLANT CELL TISS ORG, V105, P309, DOI 10.1007/s11240-010-9869-3
   Wu SJ, 1996, PLANT CELL, V8, P617, DOI 10.1105/tpc.8.4.617
   Xia GM, 2007, J PLANT PHYSL, V164, P1377
   Xu K, 2009, J PLANT BIOL, V52, P453, DOI 10.1007/s12374-009-9058-2
   Xuan N, 2011, PLANT CELL TISS ORG, V107, P101, DOI 10.1007/s11240-011-9962-2
   Yokoi S, 2002, PLANT J, V30, P529, DOI 10.1046/j.1365-313X.2002.01309.x
   Zhang XH, 2011, PLANT CELL TISS ORG, V107, P1, DOI 10.1007/s11240-011-9950-6
   Zhu JK, 2003, CURR OPIN PLANT BIOL, V6, P441, DOI 10.1016/S1369-5266(03)00085-2
   Zhu JK, 1998, PLANT CELL, V10, P1181
   Zhu JK, 2001, TRENDS PLANT SCI, V6, P66, DOI 10.1016/S1360-1385(00)01838-0
NR 61
TC 4
Z9 5
U1 2
U2 16
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0167-6857
EI 1573-5044
J9 PLANT CELL TISS ORG
JI Plant Cell Tissue Organ Cult.
PD APR
PY 2012
VL 109
IS 1
BP 91
EP 99
DI 10.1007/s11240-011-0077-6
PG 9
WC Biotechnology & Applied Microbiology; Plant Sciences
SC Biotechnology & Applied Microbiology; Plant Sciences
GA 909XG
UT WOS:000301599800010
DA 2018-12-27
ER

PT J
AU Cole, LA
AF Cole, Laurence A.
TI RETRACTED: Minimally-aggressive gestational trophoblastic neoplasms
   (Retracted article. See vol. 130, pg. 254, 2013)
SO GYNECOLOGIC ONCOLOGY
LA English
DT Article; Retracted Publication
DE HCG; Choriocarcinoma; GTD; Persistent hydatidiform mole;
   Hyperglycosylated hCG
ID HUMAN CHORIONIC-GONADOTROPIN; FREE BETA-SUBUNIT; HYPERGLYCOSYLATED HCG;
   CELL-PROLIFERATION; CANCER; EXPRESSION; CHORIOCARCINOMA; APOPTOSIS;
   TUMOR; VACCINE
AB Introduction. We have previously defined a new syndrome "Minimally-aggressive gestational trophoblastic neoplasms" in which choriocarcinoma or persistent hydatidiform mole has a minimal growth rate and becomes chemorefractory. Previously we described a new treatment protocol, waiting for hCG rise to >3000 mIU/ml and disease becomes more advanced, then using combination chemotherapy. Initially we found this treatment successful in 8 of 8 cases, here we find this protocol appropriate in a further 16 cases. Initially we used hyperglycosylated hCG, a limited availability test, to identify this syndrome. Here we propose also using hCG doubling rate to detect this syndrome.
   Methods. Minimally aggressive gestational trophoblastic disease can be detected by chemotherapy resistance or low hyperglycosylated hCG, <40% of total hCG. It can also be identified by hCG doubling rate, with doubling time greater than 2 weeks.
   Results. Nineteen new cases were identified as having minimally aggressive gestational trophoblastic disease by hyperglycosylated hCG and by hCG doubling test. All were recommended to hold off further chemotherapy until hCG >3000 mIU/ml. One case died prior to the start of the study, one case withdrew because of a lung nodule and one withdrew refusing the suggested combination chemotherapy. The remaining 16 women were all successfully treated.
   Discussion. A total of 8 plus 16 or 24 of 24 women were successfully treated using the proposed protocol, holding back on chemotherapy until hCG >3000 mIU/ml. (C) 2011 Elsevier Inc. All rights reserved.
C1 [Cole, Laurence A.] USA hCG Reference Serv, Albuquerque, NM 87109 USA.
RP Cole, LA (reprint author), USA hCG Reference Serv, 2412 Calle Panza NW, Albuquerque, NM 87104 USA.
CR ACEVEDO HF, 1992, CANCER, V69, P1818, DOI 10.1002/1097-0142(19920401)69:7<1818::AID-CNCR2820690726>3.0.CO;2-7
   Bellet D, 1997, CANCER RES, V57, P516
   Boffa JJ, 2003, J AM SOC NEPHROL, V14, P1132, DOI 10.1097/01.ASN.0000060574.38107.3B
   Butler SA, 2000, BRIT J CANCER, V82, P1553
   Butler SA, 2003, CLIN CANCER RES, V9, P4666
   Butler SA, 2010, HUMAN CHORIONIC GONADOTROPIN (HCG), P153, DOI 10.1016/B978-0-12-384907-6.00014-1
   Carter WB, 2006, BREAST CANCER RES TR, V100, pS243
   Cole LA, 2007, PLACENTA, V28, P977, DOI 10.1016/j.placenta.2007.01.011
   COLE LA, 1987, J CLIN ENDOCR METAB, V65, P811, DOI 10.1210/jcem-65-4-811
   COLE LA, 1983, ENDOCRINOLOGY, V113, P1176, DOI 10.1210/endo-113-3-1176
   Cole LA, 2011, MOL CELL ENDOCRINOL
   Cole LA, 2006, J REPROD MED, V51, P919
   Cole LA, 2006, GYNECOL ONCOL, V102, P145, DOI 10.1016/j.ygyno.2005.12.047
   Cole LA, 2006, GYNECOL ONCOL, V102, P151, DOI 10.1016/j.ygyno.2005.12.045
   Cole LA, 2010, HUMAN CHORIONIC GONADOTROPIN (HCG), P145, DOI 10.1016/B978-0-12-384907-6.00013-X
   Cole LA, 2010, HUMAN CHORIONIC GONADOTROPIN (HCG), P343, DOI 10.1016/B978-0-12-384907-6.00032-3
   Cole LA, 2010, GYNECOL ONCOL, V116, P3, DOI 10.1016/j.ygyno.2009.09.028
   COSGROVE DE, 1989, BIOCHIM BIOPHYS ACTA, V1007, P44, DOI 10.1016/0167-4781(89)90128-0
   Delves PJ, 2007, MOL CELL ENDOCRINOL, V260, P276, DOI 10.1016/j.mce.2006.02.018
   EDWARDS DR, 1987, EMBO J, V6, P1899, DOI 10.1002/j.1460-2075.1987.tb02449.x
   Gillott DJ, 1996, BRIT J CANCER, V73, P323, DOI 10.1038/bjc.1996.56
   Hamada AL, 2005, J CLIN ENDOCR METAB, V90, P4873, DOI 10.1210/jc.2004-2458
   Harvey RA, 2008, J REPROD MED, V53, P643
   He LZ, 2004, CLIN CANCER RES, V10, P1920, DOI 10.1158/1078-0432.CCR-03-0264
   Iles RK, 2007, MOL CELL ENDOCRINOL, V260, P264, DOI 10.1016/j.mce.2006.02.019
   Iversen PL, 2003, CURR OPIN MOL THER, V5, P156
   Kiyoto S, 2009, JPN J CANC CHEMOTHER, V36, P2623
   Kohorn EI, 2010, GYNECOL ONCOL, V117, P505, DOI 10.1016/j.ygyno.2010.01.030
   Kwak HJ, 2006, MOL CANCER RES, V4, P209, DOI 10.1158/1541-7786.MCR-05-0140
   LAPTHORN AJ, 1994, NATURE, V369, P455, DOI 10.1038/369455a0
   Laub M, 2003, MATERIALWISS WERKST, V34, P1113, DOI 10.1002/mawe.200300715
   LEHNERT SA, 1988, DEVELOPMENT, V104, P263
   LI MC, 1956, P SOC EXP BIOL MED, V93, P361
   McKnight JA, 2003, CLIN TECH SMALL AN P, V18, P67, DOI 10.1053/svms.2003.36617
   Morse MA, 2011, CLIN CANCER RES, V17, P4844, DOI 10.1158/1078-0432.CCR-11-0891
   Moulton HM, 2002, CLIN CANCER RES, V8, P2044
   Onitake Y, 2009, J PEDIATR SURG, V44, P2258, DOI 10.1016/j.jpedsurg.2009.07.046
   REGELSON W, 1995, CANCER, V76, P1299, DOI 10.1002/1097-0142(19951015)76:8<1299::AID-CNCR2820760802>3.0.CO;2-L
   Seckl MJ, 2010, GYNECOL ONCOL, V117, P505, DOI 10.1016/j.ygyno.2010.01.016
   Soloni P, 2010, J PEDIATR SURG, V45, pE1, DOI 10.1016/j.jpedsurg.2010.02.045
   Staun-Ram E, 2005, REPROD BIOL ENDOCRIN, V3, DOI 10.1186/1477-7827-93-56
   Sun LM, 2008, MOL CANCER RES, V6, P10, DOI 10.1158/1541-7786.MCR-07-0208
   Triozzi PL, 1999, ONCOL REP, V6, P7
   Wikipedia, CHEM
NR 44
TC 2
Z9 2
U1 0
U2 5
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0090-8258
EI 1095-6859
J9 GYNECOL ONCOL
JI Gynecol. Oncol.
PD APR
PY 2012
VL 125
IS 1
BP 145
EP 150
DI 10.1016/j.ygyno.2011.12.441
PG 6
WC Oncology; Obstetrics & Gynecology
SC Oncology; Obstetrics & Gynecology
GA 913LO
UT WOS:000301879600027
PM 22198244
DA 2018-12-27
ER

PT J
AU Li, CM
   Jiang, WL
   Zhu, HB
   Hou, J
AF Li, Chunmei
   Jiang, Wanglin
   Zhu, Haibo
   Hou, Jian
TI RETRACTED: Antifibrotic effects of protocatechuic aldehyde on
   experimental liver fibrosis (Retracted article. See vol. 51, pg. 675,
   2013)
SO PHARMACEUTICAL BIOLOGY
LA English
DT Article; Retracted Publication
DE Liver fibrosis; protocatechuic aldehyde; transforming growth factor-beta
   1; connective transforming growth factor
ID TISSUE GROWTH-FACTOR; HEPATIC-FIBROSIS; IN-VITRO; EXPRESSION; RATS;
   CELLS; BETA; HYALURONAN; CIRRHOSIS; MARKERS
AB Background: Recent studies have demonstrated that transforming growth factor-beta 1 (TGF-beta 1) and connective transforming growth factor (CTGF) are associated with the pathophysiology of liver fibrosis. We isolated protocatechuic aldehyde, the major degradation of phenolic acids.
   Objective: This study was carried out to investigate the potential antifibrotic effect of Protocatechuic aldehyde (PA) on experimental liver fibrosis in vitro and in vivo, and to explore its possible mechanism.
   Materials and methods: Cell proliferation was determined. Type I collagen, type III collagen, transforming growth factor-beta 1 (TGF-beta 1) and connective transforming growth factor (CTGF) were measured by ELISA kits in TNF-alpha stimulated HSCs. In the carbon tetrachloride (CCL4)-induced rat liver fibrosis model, liver fibrosis grade and histopathological changes were evaluated, and biochemical indicators were determined. Furthermore, immunostaining and Western blot analysis were used to detect hepatic TGF-beta 1 and CTGF expression in liver tissue.
   Results: Overall, our results indicated that PA inhibits HSCs proliferation, inhibits the levels of TGF-beta 1, CTGF, type I collagen and type III collagen in TNF-alpha stimulated HSCs. Treatment of PA causes a significant reduction in fibrosis grade, ameliorates biochemical indicators and histopathological morphology, and reduces liver TGF-beta 1 and CTGF expression in rat model of CCL4 -induced liver fibrosis.
   Conclusion: These findings suggest that PA has potentially conferring antifibrogenic effects.
C1 [Li, Chunmei; Jiang, Wanglin] Yantai Univ, Sch Pharm, Laishan Dist 264003, Yantai, Peoples R China.
   [Jiang, Wanglin; Zhu, Haibo; Hou, Jian] Luye Pharma Grp Ltd, State Key Lab Long acting & Targeting Drug Delive, Yantai, Peoples R China.
RP Jiang, WL (reprint author), Yantai Univ, Sch Pharm, 32 Qingquan Rd, Laishan Dist 264003, Yantai, Peoples R China.
EM davidjiangwl@163.com
FU State Key Laboratory of Long-acting and Targeting Drug Delivery
   Technologies (Luye Pharma Group Ltd.)
FX The study was financially supported by State Key Laboratory of
   Long-acting and Targeting Drug Delivery Technologies (Luye Pharma Group
   Ltd.).
CR Bataller R, 2005, J CLIN INVEST, V115, P209, DOI 10.1172/JCI200524282
   Blom IE, 2002, MATRIX BIOL, V21, P473, DOI 10.1016/S0945-053X(02)00055-0
   Bosetti C, 2007, J HEPATOL, V46, P827, DOI 10.1016/j.jhep.2007.01.025
   China Medical Association Infectious Branch, 1995, ZHONGHUA CHUANRANBIN, V13, P241
   George J, 2007, GENE THER, V14, P790, DOI 10.1038/sj.gt.3302929
   Gressner AM, 2003, J HEPATOL, V39, P856, DOI 10.1016/S0168-8278(03)00432-X
   Gressner AM, 2002, FRONT BIOSCI, V7, pD793, DOI 10.2741/gressner
   Gressner OA, 2008, J HEPATOL, V49, P758, DOI 10.1016/j.jhep.2008.03.029
   Gressner OA, 2008, LIVER INT, V28, P1065, DOI 10.1111/j.1478-3231.2008.01826.x
   Griffiths Clare, 2005, Health Stat Q, P6
   Han Chun-jie, 2007, Zhong Yao Cai, V30, P1541
   Hayasaka A, 1998, DIGESTION, V59, P381, DOI 10.1159/000007493
   Kim KJ, 2008, ARCH PHARM RES, V31, P1572, DOI 10.1007/s12272-001-2153-7
   Kim YS, 2007, EUR J PHARMACOL, V569, P171, DOI 10.1016/j.ejphar.2007.05.054
   Korner T, 1996, J HEPATOL, V25, P684, DOI 10.1016/S0168-8278(96)80239-X
   Lee MK, 2008, PHYTOMEDICINE, V15, P775, DOI 10.1016/j.phymed.2007.10.004
   Li GM, 2008, J GENE MED, V10, P1039, DOI 10.1002/jgm.1223
   Li GM, 2006, J GENE MED, V8, P889, DOI 10.1002/jgm.894
   Li GS, 2010, PHYTOMEDICINE, V17, P282, DOI 10.1016/j.phymed.2009.05.002
   Liu XJ, 2006, LIVER INT, V26, P8, DOI 10.1111/j.1478-3231.2005.01192.x
   Lv T, 2006, WORLD J GASTROENTERO, V12, P2195, DOI 10.3748/wjg.v12.i14.2195
   Murawaki Y, 1996, J GASTROEN HEPATOL, V11, P459, DOI 10.1111/j.1440-1746.1996.tb00291.x
   Paradis V, 2002, LAB INVEST, V82, P767, DOI 10.1097/01.LAB.0000017365.18894.D3
   Shigeki TA, 2006, CLIN CHIM ACTA, V364, P33, DOI 10.1016/j.cca.2005.06.014
   Uchio K, 2004, WOUND REPAIR REGEN, V12, P60, DOI 10.1111/j.1067-1927.2004.012112.x-1
   Zhou Z, 2005, EUR J PHARMACOL, V513, P1, DOI 10.1016/j.ejphar.2005.01.059
   Zhou Z, 2007, ANTIVIR RES, V74, P59, DOI 10.1016/j.antiviral.2006.12.005
NR 27
TC 14
Z9 14
U1 2
U2 14
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1388-0209
EI 1744-5116
J9 PHARM BIOL
JI Pharm. Biol.
PD APR
PY 2012
VL 50
IS 4
BP 413
EP 419
DI 10.3109/13880209.2011.608193
PG 7
WC Plant Sciences; Medical Laboratory Technology; Pharmacology & Pharmacy
SC Plant Sciences; Medical Laboratory Technology; Pharmacology & Pharmacy
GA 905VL
UT WOS:000301304100003
PM 22129045
DA 2018-12-27
ER

PT J
AU Liu, J
   Smeesters, D
   Vohs, KD
AF Liu, Jia (Elke)
   Smeesters, Dirk
   Vohs, Kathleen D.
TI RETRACTED: Reminders of Money Elicit Feelings of Threat and Reactance in
   Response to Social Influence (Retracted article. See vol. 41, pg. 236,
   2014)
SO JOURNAL OF CONSUMER RESEARCH
LA English
DT Article; Retracted Publication
ID WORD-OF-MOUTH; INTERPERSONAL CLOSENESS; PSYCHOLOGICAL REACTANCE;
   BEHAVIOR; ACCESSIBILITY; POWER; INFORMATION; PERCEPTIONS; PERSONALITY;
   PERSUASION
AB When consumers are reminded of money, do they conform, shrug off, or react against others' attempts to influence them? Prior research on reminders of money suggests that either of the last two outcomes is probable. The current research proposed that the self-sufficient motivation induced by money reminders causes consumers to perceive social influences as threats to their autonomy. We predicted that consumers reminded of money would deviate from social influence, an effect that would be caused by feeling threatened. Across three experiments, money-primed participants behaved opposite to the source of influence, displaying reactance stemming from heightened feelings of threat. However, this reactance response was eliminated when money-primed participants were not personally invested in a decision; consequently, they showed indifference in the face of social influence. Hence, reminders of money boost the motivation to be autonomous and sensitize consumers to potential constraints on their personal decision-making freedom.
C1 [Liu, Jia (Elke)] Univ Groningen, NL-9700 AV Groningen, Netherlands.
   [Smeesters, Dirk] Erasmus Univ, Rotterdam Sch Management, NL-3000 DR Rotterdam, Netherlands.
   [Vohs, Kathleen D.] Univ Minnesota, Carlson Sch Management, Minneapolis, MN 55455 USA.
RP Liu, J (reprint author), Univ Groningen, POB 800, NL-9700 AV Groningen, Netherlands.
EM Jia.Liu@rug.nl; DSmeesters@rsm.nl; vohsx005@umn.edu
CR Ackerman JM, 2008, PERS SOC PSYCHOL REV, V12, P118, DOI 10.1177/1088868308315700
   Almond R, 2004, PSYCHOANAL PSYCHOL, V21, P371, DOI 10.1037/0736-9735.21.3.371
   Alperin RM, 2001, PSYCHOANAL PSYCHOL, V18, P137, DOI 10.1037//0736-9735.18.1.137
   ARON A, 1992, J PERS SOC PSYCHOL, V63, P596, DOI 10.1037/0022-3514.63.4.596
   Bargh J. A, 2000, HDB RES METHODS SOCI, P253
   Baumeister RF, 2011, ANNU REV PSYCHOL, V62, P331, DOI 10.1146/annurev.psych.093008.131126
   Baumeister Roy F., 2011, THERES NO YOU UNPUB
   Bergman Marilyn M., 1991, NEUROPSYCHOLOGY, V5, P17
   BLASS T, 1991, J PERS SOC PSYCHOL, V60, P398, DOI 10.1037//0022-3514.60.3.398
   Brehm J. W., 1966, THEORY PSYCHOL REACT
   BROWN JJ, 1987, J CONSUM RES, V14, P350, DOI 10.1086/209118
   Campbell MC, 2000, J CONSUM RES, V27, P69, DOI 10.1086/314309
   Chartrand TL, 2007, J EXP SOC PSYCHOL, V43, P719, DOI 10.1016/j.jesp.2006.08.003
   Cialdini R, 2009, INFLUENCE SCI PRACTI
   Cialdini RB, 2004, ANNU REV PSYCHOL, V55, P591, DOI 10.1146/annurev.psych.55.090902.142015
   CLEE MA, 1980, J CONSUM RES, V6, P389, DOI 10.1086/208782
   Conway LG, 2005, J PERS SOC PSYCHOL, V89, P311, DOI 10.1037/0022-3514.89.3.311
   DeMarree KG, 2005, J PERS SOC PSYCHOL, V89, P657, DOI 10.1037/0022-3514.89.5.657
   FISKE AP, 1992, PSYCHOL REV, V99, P689, DOI 10.1037/0033-295X.99.4.689
   Fitzsimons GJ, 2004, MARKET SCI, V23, P82, DOI 10.1287/mksc.1030.0033
   Fuegen K, 2004, RESISTANCE AND PERSUASION, P39
   Galinsky AD, 2006, PSYCHOL SCI, V17, P1068, DOI 10.1111/j.1467-9280.2006.01824.x
   Goldstein NJ, 2008, J CONSUM RES, V35, P472, DOI 10.1086/586910
   HERR PM, 1991, J CONSUM RES, V17, P454, DOI 10.1086/208570
   Holland RW, 2004, PSYCHOL SCI, V15, P237, DOI 10.1111/j.0956-7976.2004.00658.x
   Hong SM, 1996, EDUC PSYCHOL MEAS, V56, P173, DOI 10.1177/0013164496056001014
   Kardes F. R., 2002, CONSUMER BEHAV MANAG
   Kay AC, 2008, J EXP SOC PSYCHOL, V44, P275, DOI 10.1016/j.jesp.2007.05.005
   Keltner D, 1997, PERS SOC PSYCHOL B, V23, P1066, DOI 10.1177/01461672972310007
   Kivetz R, 2005, J CONSUM RES, V31, P725, DOI 10.1086/426606
   Laran J, 2010, J CONSUM RES, V37, P304, DOI 10.1086/652193
   Lea SEG, 2006, BEHAV BRAIN SCI, V29, P161
   Milgram S., 1974, OBEDIENCE AUTHORITY
   Mogilner C, 2010, PSYCHOL SCI, V21, P1348, DOI 10.1177/0956797610380696
   Muller D, 2005, J PERS SOC PSYCHOL, V89, P852, DOI 10.1037/0022-3514.89.6.852
   Nolan JM, 2008, PERS SOC PSYCHOL B, V34, P913, DOI 10.1177/0146167208316691
   Pfeffer J, 2009, J ECON PSYCHOL, V30, P500, DOI 10.1016/j.joep.2008.08.006
   Preacher KJ, 2007, MULTIVAR BEHAV RES, V42, P185, DOI 10.1080/00273170701341316
   Quoidbach J, 2010, PSYCHOL SCI, V21, P759, DOI 10.1177/0956797610371963
   RASKIN R, 1988, J PERS SOC PSYCHOL, V54, P890, DOI 10.1037/0022-3514.54.5.890
   Smeesters D, 2009, J PERS SOC PSYCHOL, V96, P395, DOI 10.1037/a0012959
   SNYDER M, 1974, J PERS SOC PSYCHOL, V30, P526, DOI 10.1037/h0037039
   SRULL TK, 1979, J PERS SOC PSYCHOL, V37, P1660, DOI 10.1037//0022-3514.37.10.1660
   Stapel DA, 2006, J PERS SOC PSYCHOL, V90, P258, DOI 10.1037/0022-3514.90.2.258
   Tanner RJ, 2008, J CONSUM RES, V34, P754, DOI 10.1086/522322
   TETLOCK PE, 1992, ADV EXP SOC PSYCHOL, V25, P331, DOI 10.1016/S0065-2601(08)60287-7
   Tetlock PE, 1999, DUAL-PROCESS THEORIES IN SOCIAL PSYCHOLOGY, P571
   Vohs KD, 2008, CURR DIR PSYCHOL SCI, V17, P208, DOI 10.1111/j.1467-8721.2008.00576.x
   Vohs KD, 2006, SCIENCE, V314, P1154, DOI 10.1126/science.1132491
   Vohs Kathleen D., PSYCHOL SCI IN PRESS
   Vohs Kathleen D., 2011, PEOPLE REMINDE UNPUB
   WATSON D, 1988, J PERS SOC PSYCHOL, V54, P1063, DOI 10.1037/0022-3514.54.6.1063
   Weatherford Jack, 1998, HIST MONEY
   Wicklund R. A., 1974, FREEDOM REACTANCE
   Wiggins J. S., 1979, J PERS SOC PSYCHOL, V37, P295
   Wooten DB, 2004, J CONSUM RES, V31, P551, DOI 10.1086/425089
   Zhou XY, 2009, PSYCHOL SCI, V20, P700, DOI 10.1111/j.1467-9280.2009.02353.x
NR 57
TC 16
Z9 19
U1 4
U2 64
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0093-5301
EI 1537-5277
J9 J CONSUM RES
JI J. Consum. Res.
PD APR
PY 2012
VL 38
IS 6
BP 1030
EP 1046
DI 10.1086/661553
PG 17
WC Business
SC Business & Economics
GA 906OW
UT WOS:000301356900006
DA 2018-12-27
ER

PT J
AU Korkut, T
   Hancerliogullari, A
AF Korkut, Turgay
   Hancerliogullari, Aybaba
TI RETRACTED: The Evaluation of Reactor Performance by using Flibe and
   Flinabe Molten Salts in the APEX Hybrid Reactor (Retracted article. See
   vol. 31, pg. 304, 2012)
SO JOURNAL OF FUSION ENERGY
LA English
DT Article; Retracted Publication
DE APEX; MCNP; Flibe; Flinabe; Hybrid; Blanket
ID RADIATION-DAMAGE; FUSION BREEDER
AB The modeling of APEX hybrid reactor, produced by using ARIES-RS hybrid reactor technology, has been performed by using the MCNP-4B computer code and ENDF/B-V-VI nuclear data. Around the fusion chamber, molten salts Flibe (Li2BeF4) and Flinabe (LiNaBeF4) were used as cooling materials. APEX reactor was modeled in the torus form by adding nuclear materials of low significance in the specified percentages between percent 0-12 to the molten salts. The result of the study indicated that fissile material production, UF4 and ThF4 heavy metal salt increased nearly at the same percentage and it was observed that the percentage of it was practically the same in both materials. In order for the hybrid reactor to work itself in terms of tritium, TBR (tritium breeding ratio) should be lower than 1.05. When flibe molten salt was utilized in the APEX hybrid reactor, TBR was calculated as > 1, 22 and when flinabe molten salt was used, TBR was calculated as > 1.06.
C1 [Korkut, Turgay] Ibrahim Cecen Univ Agri, Fac Sci & Art, Dept Phys, TR-04100 Agri, Turkey.
   [Hancerliogullari, Aybaba] Kastamonu Univ, Fac Sci & Art, Dept Phys, TR-37100 Kastamonu, Turkey.
RP Korkut, T (reprint author), Ibrahim Cecen Univ Agri, Fac Sci & Art, Dept Phys, TR-04100 Agri, Turkey.
EM turgaykorkut@hotmail.com
OI Hancerliogullari, Aybaba/0000-0001-7008-480X
CR Abdou MA, 2001, FUSION ENG DES, V54, P181, DOI 10.1016/S0920-3796(00)00433-6
   Abdou MA, 1999, FUSION ENG DES, V45, P145, DOI 10.1016/S0920-3796(99)00018-6
   Bremister J., 1993, MCNP 4A GEN MONTE CA
   Liu XP, 2005, FUSION ENG DES, V75-79, P1275, DOI 10.1016/j.fusengdes.2005.06.236
   McCarthy KA, 2000, FUSION ENG DES, V51-52, P549, DOI 10.1016/S0920-3796(00)00217-9
   Moir RW, 1997, NUCL FUSION, V37, P557, DOI 10.1088/0029-5515/37/4/I13
   Sahin HM, 2007, ANN NUCL ENERGY, V34, P861, DOI 10.1016/j.anucene.2007.04.011
   Sahin S, 2004, ENERG CONVERS MANAGE, V45, P1497, DOI 10.1016/j.enconman.2003.09.014
   Sarer B, 2007, FUSION SCI TECHNOL, V52, P107
   Sarer B., 2005, GU J SCI, V18, P17
   Ubeyli M, 2007, J FUSION ENERG, V26, P317, DOI 10.1007/s10894-007-9079-0
NR 11
TC 1
Z9 1
U1 3
U2 17
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0164-0313
EI 1572-9591
J9 J FUSION ENERG
JI J. Fusion Energy
PD APR
PY 2012
VL 31
IS 2
BP 151
EP 159
DI 10.1007/s10894-011-9441-0
PG 9
WC Nuclear Science & Technology
SC Nuclear Science & Technology
GA 899AG
UT WOS:000300783000009
DA 2018-12-27
ER

PT J
AU Amarnath, K
   Kumar, J
   Reddy, T
   Mahesh, V
   Ayyappan, SR
   Nellore, J
AF Amarnath, Kanchana
   Kumar, Jayanthi
   Reddy, Tejesh
   Mahesh, Vakka
   Ayyappan, Senniyanallur Rathakrishnan
   Nellore, Jayshree
TI RETRACTED: Synthesis and characterization of chitosan and grape
   polyphenols stabilized palladium nanoparticles and their antibacterial
   activity (Retracted article. See vol. 111, pg. 769, 2013)
SO COLLOIDS AND SURFACES B-BIOINTERFACES
LA English
DT Article; Retracted Publication
DE Palladium nanoparticles; Chitosan; Antibacterial activity; Grape
   polyphenols; Green synthesis
ID GOLD NANOPARTICLES; SILVER NANOPARTICLES; ANTIMICROBIAL MECHANISM;
   MEDIATED SYNTHESIS; ESCHERICHIA-COLI; LEAF EXTRACT; SIZE;
   NANOCOMPOSITES; IRRADIATION; MICROSCOPY
AB Based on enhanced effectiveness, the new age drugs are nanoparticles of polymers, metals or ceramics, which can combat conditions like cancer and fight human pathogens like bacteria. In this present study we aimed for a green approach to synthesize palladium nanoparticles by reducing palladium chloride salts with nontoxic and biodegradable polymeric chitosan and grape polyphenols and confirmed by FTIR, TEM, SEM and UV-spectroscopy. We also extended our study to show the efficacy of the grape and chitosan impregnated palladium nanoparticles as an antibacterial agent against Escherichia coli. Antibacterial assays were carried out with a representative gram-negative bacterium. E. coli and a gram-positive bacterium, Staphylococcus aureus. Commendable efforts have been made to explore this property using electron microscopy, which has revealed size dependent interaction of palladium nanoparticles conjugates with bacteria by disrupting cell membranes and the leakage of cytoplasm. Therefore, the observed results imply that grape and chitosan-based nano palladium conjugates prepared in our present system are promising candidates for a wide range of biomedical and general applications. (C) 2011 Elsevier BM. All rights reserved.
C1 [Amarnath, Kanchana] Sathyabama Univ, Dent Coll & Hosp, Dept Med Biochem, Madras 600119, Tamil Nadu, India.
   [Kumar, Jayanthi; Reddy, Tejesh; Mahesh, Vakka; Nellore, Jayshree] Sathyabama Univ, Dept Biotechnol, Madras 600119, Tamil Nadu, India.
   [Ayyappan, Senniyanallur Rathakrishnan] Sathyabama Univ, Dent Coll & Hosp, Dept Microbiol, Madras 600119, Tamil Nadu, India.
RP Amarnath, K (reprint author), Sathyabama Univ, Dent Coll & Hosp, Dept Med Biochem, Madras 600119, Tamil Nadu, India.
EM kanchibms@yahoo.co.in
CR Amro NA, 2000, LANGMUIR, V16, P2789, DOI 10.1021/la991013x
   Bhattacharya D, 2005, CRIT REV BIOTECHNOL, V25, P199, DOI 10.1080/07388550500361994
   Bong K. Choi, 2001, INT J ANTIMICROB AG, V18, P553
   Burt S, 2004, INT J FOOD MICROBIOL, V94, P223, DOI 10.1016/j.ijfoodmicro.2004.03.022
   Chen W, 2001, MATER LETT, V50, P53, DOI 10.1016/S0167-577X(00)00411-0
   DONGWEI W, 2009, CARBOHYD RES, V344, P2375
   Dudhani AR, 2010, CARBOHYD POLYM, V81, P243, DOI 10.1016/j.carbpol.2010.02.026
   Esumi K, 2003, COLLOID SURFACE B, V32, P117, DOI 10.1016/S0927-7765(03)00151-6
   Fritsch D, 2003, CATAL TODAY, V82, P105, DOI 10.1016/S0920-5861(03)00208-6
   Gulcan O., 2004, J FOOD SCI AGR, V84, P1807
   Hamouda T, 2000, J APPL MICROBIOL, V89, P397, DOI 10.1046/j.1365-2672.2000.01127.x
   Hamouda T, 1999, J INFECT DIS, V180, P1939, DOI 10.1086/315124
   Harris DM, 2005, EXP BIOL MED, V230, P558, DOI 10.1177/153537020523000807
   Holt KB, 2005, BIOCHEMISTRY-US, V44, P13214, DOI 10.1021/bi0508542
   Huang HZ, 2004, CARBOHYD RES, V339, P2627, DOI 10.1016/j.carres.2004.08.005
   Huang HZ, 2004, COLLOID SURFACE B, V39, P31, DOI 10.1016/j.colsurfb.2004.08.014
   Huang HZ, 2003, COLLOID SURFACE A, V226, P77, DOI 10.1016/S0927-7757(03)00382-0
   Huang HZ, 2004, BIOMACROMOLECULES, V5, P2340, DOI 10.1021/bm0497116
   Huang L, 2007, J COLLOID INTERF SCI, V316, P398, DOI 10.1016/j.jcis.2007.07.039
   Jayakumar R, 2010, CARBOHYD POLYM, V82, P227, DOI 10.1016/j.carbpol.2010.04.074
   Jayaprakasha GK, 2003, FOOD RES INT, V36, P117, DOI 10.1016/S0963-9969(02)00116-3
   Kanchana A, 2010, NANO-MICRO LETT, V2, P169, DOI 10.5101/nml.v2i3.p169-176
   Kim JY, 2008, WATER RES, V42, P356, DOI 10.1016/j.watres.2007.07.024
   Kim KJ, 2008, J MICROBIOL BIOTECHN, V18, P1482
   Klabunde K.J., 1996, PHYS CHEM, V12, P142
   Klinge CM, 2003, J AGR FOOD CHEM, V51, P1850, DOI 10.1021/jf0259821
   Korovchenko P., 2005, CATAL TODAY, V133, P102
   Kosaraju SL, 2006, CARBOHYD POLYM, V64, P163, DOI 10.1016/j.carbpol.2005.11.027
   Long DW, 2007, RADIAT PHYS CHEM, V76, P1126, DOI 10.1016/j.radphyschem.2006.11.001
   Luo CC, 2005, J MOL CATAL A-CHEM, V229, P7, DOI 10.1016/j.molcata.2004.10.039
   Mallikarjuna N., 2008, GREEN CHEM, V10, P859, DOI DOI 10.1039/B804703K
   Mikes O, 2008, CZECH J FOOD SCI, V26, P182, DOI 10.17221/1591-CJFS
   Mulvaney P, 1996, LANGMUIR, V12, P788, DOI 10.1021/la9502711
   MUZZARELLI R, 1990, ANTIMICROB AGENTS CH, V34, P2019, DOI 10.1128/AAC.34.10.2019
   Nemamcha A, 2009, PHYSCS PROC, V2, P713, DOI 10.1016/j.phpro.2009.11.015
   Nitin C.M., 2010, INDIAN J DENT RES, V21, P380
   Parashar V, 2009, DIG J NANOMATER BIOS, V4, P45
   Pastrana-Bonilla E, 2003, J AGR FOOD CHEM, V51, P5497, DOI 10.1021/jf030113c
   Pillai ZS, 2004, J PHYS CHEM B, V108, P945, DOI 10.1021/jp037018r
   Prathap S.C., 2006, BIOTECHNOL PROGR, V22, P577, DOI DOI 10.1021/BP0501423
   Qi LF, 2004, CARBOHYD RES, V339, P2693, DOI 10.1016/j.carres.2004.09.007
   Roller S, 1999, INT J FOOD MICROBIOL, V47, P67, DOI 10.1016/S0168-1605(99)00006-9
   Sanoj R., 2010, INT J BIOL MACROMOL, V7, P37
   Sathishkumar M, 2009, J HAZARD MATER, V171, P400, DOI 10.1016/j.jhazmat.2009.06.014
   Shankar S., 2003, BIOTECHNOL PROGR, V19, P6
   Shankar SS, 2004, J COLLOID INTERF SCI, V275, P496, DOI 10.1016/j.jcis.2004.03.003
   Shi ZL, 2006, BIOMATERIALS, V27, P2440, DOI 10.1016/j.biomaterials.2005.11.036
   Shi ZL, 2005, BIOMATERIALS, V26, P501, DOI 10.1016/j.biomaterials.2004.02.060
   Shim H, 2002, APPL CATAL A-GEN, V237, P41, DOI 10.1016/S0926-860X(02)00299-5
   Stoimenov PK, 2002, LANGMUIR, V18, P6679, DOI 10.1021/la0202374
   Sugunan A, 2005, SCI TECHNOL ADV MAT, V6, P335, DOI 10.1016/j.stam.2005.03.007
   Sun LP, 2006, POLYMER, V47, P1796, DOI 10.1016/j.polymer.2006.01.073
   Sun XP, 2005, MATER LETT, V59, P4048, DOI 10.1016/j.matlet.2005.07.060
   Wei DW, 2008, CARBOHYD RES, V343, P512, DOI 10.1016/j.carres.2007.10.031
   Wei DW, 2006, J NANOSCI NANOTECHNO, V6, P2508, DOI 10.1166/jnn.2006.530
   Wu Y., 2001, MAT RES B, V253, P193
   Zhang X., 2003, BIOMATERIALS, V24, P2871
NR 57
TC 33
Z9 34
U1 4
U2 60
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0927-7765
EI 1873-4367
J9 COLLOID SURFACE B
JI Colloid Surf. B-Biointerfaces
PD APR 1
PY 2012
VL 92
BP 254
EP 261
DI 10.1016/j.colsurfb.2011.11.049
PG 8
WC Biophysics; Chemistry, Physical; Materials Science, Biomaterials
SC Biophysics; Chemistry; Materials Science
GA 900AM
UT WOS:000300859000036
PM 22225943
DA 2018-12-27
ER

PT J
AU Khan, J
   Khan, S
   Attaullah, S
   Ali, I
   Khan, SN
AF Khan, Jabbar
   Khan, Sanaullah
   Attaullah, Sobia
   Ali, Ijaz
   Khan, Shahid Niaz
TI RETRACTED: Aurora kinase-C-T191D is constitutively active mutant
   (Retracted article. See vol. 13, 17, 2012)
SO BMC CELL BIOLOGY
LA English
DT Article; Retracted Publication
DE Aurora-C; Oncogene; Centrosome; Multinucleation; Tumour
ID CHROMOSOMAL PASSENGER PROTEIN; C KINASE; MITOTIC KINASE; HUMAN CANCER;
   MEIOSIS I; OVEREXPRESSION; EXPRESSION; LOCALIZATION; MUTATION; CELLS
AB Background: Aurora kinases (Aurora-A, B and C) belong to a family of conserved serine/threonine kinases which are key regulators of cell cycle progression. Aurora-A and Aurora-B are expressed in somatic cells and involved in cell cycle regulation while aurora-C is meiotic chromosome passenger protein. As Aurora kinase C is rarely expressed in normal somatic cells and has been found over expressed in many cancer lines. It is suggested that Aurora-C-T191D is not hyperactive mutant.
   Result: Aurora-C-T191D variant form was investigated and compared with wild type. The overexpression of Aurora-C-T191D was observed that it behaves like Aurora-C wild type (aurC-WT). Both Aurora-C-T191D and aurC-WT induce abnormal cell division resulting in centrosome amplification and multinucleation in transiently transfected cells as well as in stable cell lines. Similarly, Aurora-C-T191D and aurC-WT formed foci of colonies when grown on soft agar, indicating that a gain of Aurora-C activity is sufficient to transform cells. Furthermore, we reported that NIH-3 T3 stable cell lines overexpressing Aurora-C-T191D and its wild type partner induced tumour formation when injected into nude mice, demonstrating the oncogenic activity of enzymatically active Aurora kinase C. Interestingly enough tumour aggressiveness was positively correlated with the rate of kinase activity, making Aurora-C a potential anti-cancer therapeutic target.
   Conclusion: These findings proved that Aurora C-T191D is not hyperactive but is constitutively active mutant.
C1 [Khan, Sanaullah; Khan, Shahid Niaz] Kohat Univ Sci & Technol, Dept Zool, Kohat, Pakistan.
   [Khan, Jabbar] Gomal Univ Dera Ismail Khan, Dept Biol Sci, Dera Ismail Khan, Pakistan.
   [Khan, Jabbar] Univ Rennes 1, Inst Genet & Dev, Rennes 1, France.
   [Attaullah, Sobia] Islamia Coll Peshawar, Dept Zool, Peshawar 25120, Khyber Pakhtunk, Pakistan.
   [Ali, Ijaz] Khyber Pakhtunkhwa Univ Agr Peshawar, Inst Biotechnol & Genet Engn, Khyber Pakhtunkhwa, Pakistan.
RP Khan, S (reprint author), Kohat Univ Sci & Technol, Dept Zool, Kohat, Pakistan.
EM sanaullahkust@gmail.com
RI Khan, Sanaullah/J-2880-2015
OI Ali, Imran/0000-0001-6511-8374
CR Bernard M, 1998, GENOMICS, V53, P406, DOI 10.1006/geno.1998.5522
   Carroll PE, 1999, ONCOGENE, V18, P1935, DOI 10.1038/sj.onc.1202515
   Dieterich K, 2007, NAT GENET, V39, P661, DOI 10.1038/ng2027
   Dieterich K, 2009, HUM MOL GENET, V18, P1301, DOI 10.1093/hmg/ddp029
   Dutertre S, 2005, CELL CYCLE, V4, P1783, DOI 10.4161/cc.4.12.2172
   Fu JY, 2007, MOL CANCER RES, V5, P1, DOI 10.1158/1541-7786.MCR-06-0208
   Gautschi O, 2008, CLIN CANCER RES, V14, P1639, DOI 10.1158/1078-0432.CCR-07-2179
   Jiang Y, 2003, ONCOGENE, V22, P8293, DOI 10.1038/sj.onc.1206873
   Kanda A, 2005, ONCOGENE, V24, P7266, DOI 10.1038/sj.onc.1208884
   Katayama H, 1999, J NATL CANCER I, V91, P1160, DOI 10.1093/jnci/91.13.1160
   Kimura M, 1999, J BIOL CHEM, V274, P7334, DOI 10.1074/jbc.274.11.7334
   Li XY, 2004, J BIOL CHEM, V279, P47201, DOI 10.1074/jbc.M403029200
   Lin YS, 2006, GENE EXPRESSION, V13, P15, DOI 10.3727/000000006783991962
   Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483
   Nguyen HG, 2005, MOL CELL BIOL, V25, P4977, DOI 10.1128/MCB.25.12.4977-4992.2005
   Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096
   Pihan GA, 1998, CANCER RES, V58, P3974
   Price DM, 2009, ENDOCRINOLOGY, V150, P2334, DOI 10.1210/en.2008-1507
   Rannou Y, 2008, CELL CYCLE, V7, P3012, DOI 10.4161/cc.7.19.6718
   Sasai K, 2004, CELL MOTIL CYTOSKEL, V59, P249, DOI 10.1002/cm.20039
   Slattery SD, 2009, CELL CYCLE, V8, P2984
   Spengler D, 2007, CELL CYCLE, V6, P2579, DOI 10.4161/cc.6.20.4781
   Tanaka K, 2005, NATURE, V434, P987, DOI 10.1038/nature03483
   Tang CJC, 2006, DEV BIOL, V290, P398, DOI 10.1016/j.ydbio.2005.11.036
   Tatsuka M, 1998, CANCER RES, V58, P4811
   Tseng TC, 1998, DNA CELL BIOL, V17, P823, DOI 10.1089/dna.1998.17.823
   Uzbekova S, 2008, BIOL REPROD, V78, P218, DOI 10.1095/biolreprod.107.061036
   Yang KT, 2010, MOL BIOL CELL, V21, P2371, DOI 10.1091/mbc.E10-02-0170
NR 28
TC 1
Z9 1
U1 2
U2 8
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2121
J9 BMC CELL BIOL
JI BMC Cell Biol.
PD MAR 26
PY 2012
VL 13
AR 8
DI 10.1186/1471-2121-13-8
PG 9
WC Cell Biology
SC Cell Biology
GA 924TO
UT WOS:000302714400001
PM 22443468
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Azakir, BA
   Di Fulvio, S
   Kinter, J
   Sinnreich, M
AF Azakir, Bilal A.
   Di Fulvio, Sabrina
   Kinter, Jochen
   Sinnreich, Michael
TI RETRACTED: Proteasomal Inhibition Restores Biological Function of
   Mis-sense Mutated Dysferlin in Patient-derived Muscle Cells (Retracted
   article. See vol. 292, pg. 12542, 2017)
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article; Retracted Publication
ID GIRDLE MUSCULAR-DYSTROPHY; IN-VITRO; MULTIPLE-MYELOMA; GENE;
   DEGRADATION; EXPRESSION; MUTATIONS; MEMBRANE; MYOPATHY; DEFICIENCY
AB Dysferlin is a transmembrane protein implicated in surface membrane repair of muscle cells. Mutations in dysferlin cause the progressive muscular dystrophies Miyoshi myopathy, limb girdle muscular dystrophy 2B, and distal anterior compartment myopathy. Dysferlinopathies are inherited in an autosomal recessive manner, and many patients with this disease harbor mis-sense mutations in at least one of their two pathogenic DYSF alleles. These patients have significantly reduced or absent dysferlin levels in skeletal muscle, suggesting that dysferlin encoded by mis-sense alleles is rapidly degraded by the cellular quality control system. We reasoned that mis-sense mutated dysferlin, if salvaged from degradation, might be biologically functional. We used a dysferlin-deficient human myoblast culture harboring the common R555W mis-sense allele and a DYSF-null allele, as well as control human myoblast cultures harboring either two wild-type or two null alleles. We measured dysferlin protein and mRNA levels, resealing kinetics of laser-induced plasmalemmal wounds, myotube formation, and cellular viability after treatment of the human myoblast cultures with the proteasome inhibitors lactacystin or bortezomib (Velcade). We show that endogenous R555W mis-sense mutated dysferlin is degraded by the proteasomal system. Inhibition of the proteasome by lactacystin or Velcade increases the levels of R555W mis-sense mutated dysferlin. This salvaged protein is functional as it restores plasma membrane resealing in patient-derived myoblasts and reverses their deficit in myotube formation. Bortezomib and lactacystin did not cause cellular toxicity at the regimen used. Our results raise the possibility that inhibition of the degradation pathway of mis-sense mutated dysferlin could be used as a therapeutic strategy for patients harboring certain dysferlin mis-sense mutations.
C1 [Sinnreich, Michael] Univ Basel Hosp, Neuromuscular Res Grp, Dept Neurol, CH-4031 Basel, Switzerland.
   [Sinnreich, Michael] Univ Basel Hosp, Neuromuscular Res Grp, Dept Biomed, CH-4031 Basel, Switzerland.
   Univ Basel, CH-4031 Basel, Switzerland.
RP Sinnreich, M (reprint author), Univ Basel Hosp, Neuromuscular Res Grp, Dept Neurol, Petersgraben 4, CH-4031 Basel, Switzerland.
EM msinnreich@uhbs.ch
RI Kinter, Jochen/C-4515-2008
FU Myosuisse; Association Francaise contre les Myopathies; Muscular
   Dystrophy Association Canada-Amyotrophic Lateral Sclerosis Society
   Canada-Canadian Institutes of Health Research (MDAC-ALS-CIHR); Swiss
   National Science Foundation; German Ministry of Education and Research
   (BMBF, Bonn, Germany)
FX This work was supported by Myosuisse, Association Francaise contre les
   Myopathies, Muscular Dystrophy Association Canada-Amyotrophic Lateral
   Sclerosis Society Canada-Canadian Institutes of Health Research
   (MDAC-ALS-CIHR) Partnership, and the Swiss National Science Foundation.;
   We thank Muscle Tissue Culture Collection for providing the myoblast
   samples used in this study. The Muscle Tissue Culture Collection is part
   of the German network on muscular dystrophies (MD-NET, service structure
   S1, 01GM0601) funded by the German Ministry of Education and Research
   (BMBF, Bonn, Germany). The Muscle Tissue Culture Collection is a partner
   of EuroBio-Bank and TREAT-NMD. We thank Dr. E. Shoubridge and Timothy
   Johns for help with the E6E7 retroviral infection of the human myoblast
   cultures; Dr. K. Bushby, Newcastle, for the GFP-cDNA; Beat Erne and
   Steven Salomon for technical assistance; and Drs. M. Filipowicz, J.
   Sinnreich, M. Ruegg, and J. Halter for helpful discussions.
CR Aartsma-Rus A, 2010, EUR J HUM GENET, V18, P889, DOI 10.1038/ejhg.2010.4
   Adams J, 2004, CANCER INVEST, V22, P304, DOI 10.1081/CNV-120030218
   Azakir BA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010122
   Bansal D, 2003, NATURE, V423, P168, DOI 10.1038/nature01573
   Bashir R, 1998, NAT GENET, V20, P37
   Belanto JJ, 2010, NEUROMUSCULAR DISORD, V20, P111, DOI 10.1016/j.nmd.2009.12.003
   Bittner RE, 1999, NAT GENET, V23, P141, DOI 10.1038/13770
   Bonuccelli G, 2007, CELL CYCLE, V6, P1242, DOI 10.4161/cc.6.10.4182
   Bross PF, 2004, CLIN CANCER RES, V10, P3954, DOI 10.1158/1078-0432.CCR-03-0781
   Chaudhuri TK, 2006, FEBS J, V273, P1331, DOI 10.1111/j.1742-4658.2006.05181.x
   de Luna N, 2006, J BIOL CHEM, V281, P17092, DOI 10.1074/jbc.M601885200
   De Luna N, 2004, J NEUROPATH EXP NEUR, V63, P1104, DOI 10.1093/jnen/63.10.1104
   Diaz-Manera J, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.35
   Galbiati F, 2000, J BIOL CHEM, V275, P37702, DOI 10.1074/jbc.M006657200
   GARD DL, 1980, CELL, V19, P263, DOI 10.1016/0092-8674(80)90408-0
   Gazzerro E, 2010, AM J PATHOL, V176, P1863, DOI 10.2353/ajpath.2010.090468
   Hideshima T, 2001, CANCER RES, V61, P3071
   Ho M, 2004, HUM MOL GENET, V13, P1999, DOI 10.1093/hmg/ddh212
   Illa I, 2001, ANN NEUROL, V49, P130, DOI 10.1002/1531-8249(200101)49:1<130::AID-ANA22>3.3.CO;2-S
   Kinali M, 2009, LANCET NEUROL, V8, P918, DOI 10.1016/S1474-4422(09)70211-X
   Krahn M, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000951
   Krahn M, 2009, HUM MUTAT, V30, pE345, DOI 10.1002/humu.20910
   Liewluck T, 2009, CLIN NEUROL NEUROSUR, V111, P613, DOI 10.1016/j.clineuro.2009.05.001
   Liu J, 1998, NAT GENET, V20, P31
   Lochmuller H, 1999, EXP CELL RES, V248, P186, DOI 10.1006/excr.1999.4407
   Lostal W, 2010, HUM MOL GENET, V19, P1897, DOI 10.1093/hmg/ddq065
   Nguyen K, 2007, ARCH NEUROL-CHICAGO, V64, P1176, DOI 10.1001/archneur.64.8.1176
   Nguyen Karine, 2005, Hum Mutat, V26, P165, DOI 10.1002/humu.9355
   Pedemonte N, 2005, J CLIN INVEST, V115, P2564, DOI 10.1172/JCI24898
   Sinnreich M, 2006, NEUROLOGY, V66, P1114, DOI 10.1212/01.wnl.0000204358.89303.81
   Sterz J, 2008, EXPERT OPIN INV DRUG, V17, P879, DOI [10.1517/13543784.17.6.879 , 10.1517/13543780802122163]
   Therrien C, 2006, J NEUROL SCI, V250, P71, DOI 10.1016/j.jns.2006.07.004
   van Deutekom JC, 2007, NEW ENGL J MED, V357, P2677, DOI 10.1056/NEJMoa073108
   Wang BJ, 2010, J APPL PHYSIOL, V109, P901, DOI 10.1152/japplphysiol.01366.2009
   WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6
   Wein N, 2010, HUM MUTAT, V31, P136, DOI 10.1002/humu.21160
NR 36
TC 29
Z9 29
U1 1
U2 6
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD MAR 23
PY 2012
VL 287
IS 13
BP 10344
EP 10354
DI 10.1074/jbc.M111.329078
PG 11
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 917IN
UT WOS:000302167200062
PM 22318734
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Zhang, AH
   Sun, H
   Yang, B
   Wang, XJ
AF Zhang, Aihua
   Sun, Hui
   Yang, Bo
   Wang, Xijun
TI RETRACTED: Predicting new molecular targets for rhein using network
   pharmacology(Retracted article. See vol. 8, 105, 2014)
SO BMC SYSTEMS BIOLOGY
LA English
DT Article; Retracted Publication
ID METABOLIC NETWORK; DRUG DISCOVERY; DISSECTION; CYTOSCAPE; MODEL
AB Background: Drugs can influence the whole biological system by targeting interaction reactions. The existence of interactions between drugs and network reactions suggests a potential way to discover targets. The in silico prediction of potential interactions between drugs and target proteins is of core importance for the identification of new drugs or novel targets for existing drugs. However, only a tiny portion of drug-targets in current datasets are validated interactions. This motivates the need for developing computational methods that predict true interaction pairs with high accuracy. Currently, network pharmacology has used in identifying potential drug targets to predicting the spread of drug activity and greatly contributed toward the analysis of biological systems on a much larger scale than ever before.
   Methods: In this article, we present a computational method to predict targets for rhein by exploring drug-reaction interactions. We have implemented a computational platform that integrates pathway, protein-protein interaction, differentially expressed genome and literature mining data to result in comprehensive networks for drug-target interaction. We used Cytoscape software for prediction rhein-target interactions, to facilitate the drug discovery pipeline.
   Results: Results showed that 3 differentially expressed genes confirmed by Cytoscape as the central nodes of the complicated interaction network (99 nodes, 153 edges). Of note, we further observed that the identified targets were found to encompass a variety of biological processes related to immunity, cellular apoptosis, transport, signal transduction, cell growth and proliferation and metabolism.
   Conclusions: Our findings demonstrate that network pharmacology can not only speed the wide identification of drug targets but also find new applications for the existing drugs. It also implies the significant contribution of network pharmacology to predict drug targets.
C1 [Zhang, Aihua; Sun, Hui; Yang, Bo; Wang, Xijun] Heilongjiang Univ Chinese Med, Natl TCM Key Lab Serum Pharmacochem, Harbin 150040, Peoples R China.
   [Zhang, Aihua; Sun, Hui; Yang, Bo; Wang, Xijun] Key Pharmacometab Platform Chinese Med, Harbin 150040, Peoples R China.
RP Wang, XJ (reprint author), Heilongjiang Univ Chinese Med, Natl TCM Key Lab Serum Pharmacochem, Heping Rd 24, Harbin 150040, Peoples R China.
EM xijunwangls@126.com
FU Natural Science Foundation of State [90709019]; National Specific
   Program on the Subject of Public Welfare [200807014]; National Key
   Subject of Drug Innovation [2009ZX09502-005]; National Program on Key
   Basic Research Project of China [2005CB523406]
FX This work was supported by grants from the Key Program of Natural
   Science Foundation of State (Grant No. 90709019), the National Specific
   Program on the Subject of Public Welfare (Grant No. 200807014), National
   Key Subject of Drug Innovation (Grant No. 2009ZX09502-005), and National
   Program on Key Basic Research Project of China (Grant No. 2005CB523406).
CR Burga A, 2011, NATURE, V480, P250, DOI 10.1038/nature10665
   Chang CL, 2012, EVID-BASED COMPL ALT, P1, DOI 10.1155/2012/125247
   Cline MS, 2007, NAT PROTOC, V2, P2366, DOI 10.1038/nprot.2007.324
   Collins SR, 2007, NATURE, V446, P806, DOI 10.1038/nature05649
   Fang KC, 2011, BMC SYST BIOL, V5, DOI 10.1186/1752-0509-5-83
   Gilchrist M, 2006, NATURE, V441, P173, DOI 10.1038/nature04768
   Gu J, 2010, BMC SYST BIOL, V4, DOI 10.1186/1752-0509-4-47
   Hopkins AL, 2008, NAT CHEM BIOL, V4, P682, DOI 10.1038/nchembio.118
   Huthmacher C, 2010, BMC SYST BIOL, V4, DOI 10.1186/1752-0509-4-120
   Janga SC, 2009, MOL BIOSYST, V5, P1536, DOI [10.1039/B908147j, 10.1039/b908147j]
   Kim HU, 2012, BIOTECHNOL J, V7, P330, DOI 10.1002/biot.201100159
   Li S, 2011, BMC SYST BIOL, V5, DOI 10.1186/1752-0509-5-S1-S10
   McEachin RC, 2010, BMC SYST BIOL, V4, DOI 10.1186/1752-0509-4-158
   Morrow John Kenneth, 2010, Critical Reviews in Biomedical Engineering, V38, P143
   Morse DL, 2010, BIOCHEM PHARMACOL, V80, P731, DOI 10.1016/j.bcp.2010.04.011
   Overton IM, 2011, BMC SYST BIOL, V5, DOI 10.1186/1752-0509-5-68
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Shen CY, 2011, BMC SYST BIOL, V5, DOI 10.1186/1752-0509-5-67
   van Laarhoven T, 2011, BIOINFORMATICS, V27, P3036, DOI 10.1093/bioinformatics/btr500
   Wang L, 2008, P NATL ACAD SCI USA, V105, P4826, DOI 10.1073/pnas.0712365105
   Wang XJ, 2012, J PROTEOMICS, V75, P1411, DOI 10.1016/j.jprot.2011.11.011
   Xia Z, 2010, BMC SYST BIOL, V4, DOI 10.1186/1752-0509-4-S2-S6
   Yao X, 2011, BMC SYST BIOL, V5, DOI 10.1186/1752-0509-5-79
   Zhao SW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011764
NR 24
TC 27
Z9 33
U1 5
U2 34
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1752-0509
J9 BMC SYST BIOL
JI BMC Syst. Biol.
PD MAR 21
PY 2012
VL 6
AR 20
DI 10.1186/1752-0509-6-20
PG 8
WC Mathematical & Computational Biology
SC Mathematical & Computational Biology
GA 933DP
UT WOS:000303339900001
PM 22433437
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Peyghan, E
   Tayebi, A
AF Peyghan, E.
   Tayebi, A.
TI RETRACTED: Sasaki-Randers metric in Finsler geometry (Retracted article.
   See vol. 398, pg. 455, 2012)
SO JOURNAL OF MATHEMATICAL ANALYSIS AND APPLICATIONS
LA English
DT Article; Retracted Publication
DE Foliation; Paracontact structure; Totally geodesic distribution
AB In this paper, we consider the Randers metric F = alpha + beta on a smooth manifold M and by using it define Sasaki-Randers metric G on the slit tangent bundle TMo. We introduce natural foliations on (TMo, G) and study totally geodesic and bundle-likeness properties of them. Then, we construct a framed f(3, - 1)-structure on TMo and show that it reduces to an almost paracontact structure on the indicatrix bundle. (C) 2011 Elsevier Inc. All rights reserved.
C1 [Peyghan, E.] Arak Univ, Dept Math, Fac Sci, Arak 3815688349, Iran.
   [Tayebi, A.] Qom Univ, Fac Sci, Dept Math, Qom, Iran.
RP Peyghan, E (reprint author), Arak Univ, Dept Math, Fac Sci, Arak 3815688349, Iran.
EM epeyghan@gmail.com; akbar.tayebi@gmail.com
CR Antonelli P. L., 1993, THEORY SPRAYS FINSLE
   Asanov G. S., 1985, FINSLER GEOMETRY REL
   Bao D., 2000, INTRO RIEMANNIAN FIN
   Bao D., 2004, J DIFFER GEOM, V66, P391
   Bejancu A, 2006, FOLIATIONS GEOMETRIC
   Bejancu A, 2006, REP MATH PHYS, V58, P131, DOI 10.1016/S0034-4877(06)80044-3
   Ingarden R.S., 1957, TRAV SOC SCI LETT B, V45, P1
   Matsumoto M., 1974, J MATH KYOTO U, V14, P477
   Mihai I., 1996, PADGE, V2
   Randers G., 1941, NATURE, V59, P195
   Tayebi A, 2010, B IRAN MATH SOC, V36, P57
   Tayebi A, 2010, J GEOM PHYS, V60, P1665, DOI 10.1016/j.geomphys.2010.05.016
   Tayebi A., 2008, NATURE, V72, P1
   Yasuda H., 1977, Reports on Mathematical Physics, V11, P347, DOI 10.1016/0034-4877(77)90075-1
NR 14
TC 1
Z9 1
U1 1
U2 10
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0022-247X
EI 1096-0813
J9 J MATH ANAL APPL
JI J. Math. Anal. Appl.
PD MAR 15
PY 2012
VL 387
IS 2
BP 1137
EP 1145
DI 10.1016/j.jmaa.2011.10.021
PG 9
WC Mathematics, Applied; Mathematics
SC Mathematics
GA 850WI
UT WOS:000297229900055
OA Bronze
DA 2018-12-27
ER

PT J
AU Badylak, SF
   Weiss, DJ
   Caplan, A
   Macchiarini, P
AF Badylak, Stephen F.
   Weiss, Daniel J.
   Caplan, Arthur
   Macchiarini, Paolo
TI RETRACTED: Engineered whole organs and complex tissues (Retracted
   article. See vol. 392, pg. 11, 2018)
SO LANCET
LA English
DT Article; Retracted Publication
ID EXTRACELLULAR-MATRIX SCAFFOLDS; REGENERATIVE MEDICINE APPROACH;
   SMALL-INTESTINAL SUBMUCOSA; MESENCHYMAL STEM-CELLS; PROGENITOR CELLS;
   LUNG-TISSUE; 3-DIMENSIONAL CULTURE; CLINICAL-APPLICATION; BIOLOGIC
   SCAFFOLD; GENE-EXPRESSION
AB End-stage organ failure is a key challenge for the medical community because of the ageing population and the severe shortage of suitable donor organs available. Equally, injuries to or congenital absence of complex tissues such as the trachea, oesophagus, or skeletal muscle have few therapeutic options. A new approach to treatment involves the use of three-dimensional biological scaffolds made of allogeneic or xenogeneic extracellular matrix derived from non-autologous sources. These scaffolds can act as an inductive template for functional tissue and organ reconstruction after recellularisation with autologous stem cells or differentiated cells. Such an approach has been used successfully for the repair and reconstruction of several complex tissues such as trachea, oesophagus, and skeletal muscle in animal models and human beings, and, guided by appropriate scientific and ethical oversight, could serve as a platform for the engineering of whole organs and other tissues.
C1 [Badylak, Stephen F.] Univ Pittsburgh, Dept Surg, McGowan Inst Regenerat Med, Pittsburgh, PA USA.
   [Weiss, Daniel J.] Univ Vermont, Coll Med, Vermont Lung Ctr, Burlington, VT USA.
   [Caplan, Arthur] Univ Penn, Sch Med, Ctr Bioeth, Philadelphia, PA 19104 USA.
   [Macchiarini, Paolo] Adv Ctr Translat Regenerat Med, Stockholm, Sweden.
RP Macchiarini, P (reprint author), Karolinska Inst, Adv Ctr Translat Regenerat Med ACTREM, Div Ear Nose & Throat, Dept Clin Sci Intervent & Technol CLINTEC, Alfred Nobel Alle 8, S-14186 Stockholm, Sweden.
EM paolo.macchiarini@ki.se
RI Macchiarini, Paolo/E-6878-2013; Phatak, Sai/C-5725-2012
OI Badylak, Stephen/0000-0003-3555-0689
FU Wallenberg Institute for Regenerative Medicine; Karolinska
   Institutet/SLL (Stockholm, Sweden); US National Institutes of Health
   [RC4HL106625]; National Heart, Lung, and Blood Institute [R21HL094611]
FX This review was supported by the Wallenberg Institute for Regenerative
   Medicine and Karolinska Institutet/SLL grants (Stockholm, Sweden) and
   grants from the US National Institutes of Health (RC4HL106625) and
   National Heart, Lung, and Blood Institute (R21HL094611). We thank Eve A
   Simpson, Philipp Jungebluth, and Silvia Baiguera for their excellent
   technical assistance with this report.
CR Agrawal V, 2011, TISSUE ENG PT A, V17, P2435, DOI [10.1089/ten.tea.2011.0036, 10.1089/ten.TEA.2011.0036]
   Agrawal V, 2010, P NATL ACAD SCI USA, V107, P3351, DOI 10.1073/pnas.0905851106
   Andrade CF, 2007, AM J PHYSIOL-LUNG C, V292, pL510, DOI 10.1152/ajplung.00175.2006
   Antunes MB, 2007, BIOTECHNIQUES, V43, P195, DOI 10.2144/000112493
   Asnaghi MA, 2009, BIOMATERIALS, V30, P5260, DOI 10.1016/j.biomaterials.2009.07.018
   Atala A, 2006, LANCET, V367, P1241, DOI 10.1016/S0140-6736(06)68438-9
   Auger FA, 2009, SKIN PHARMACOL PHYS, V22, P94, DOI 10.1159/000178868
   Bader A, 1998, EUR J CARDIO-THORAC, V14, P279, DOI 10.1016/S1010-7940(98)00171-7
   Badylak SF, 2007, BIOMATERIALS, V28, P3587, DOI 10.1016/j.biomaterials.2007.04.043
   Badylak SF, 2011, TISSUE ENG PT A, V17, P1643, DOI [10.1089/ten.TEA.2010.0739, 10.1089/ten.tea.2010.0739]
   Baiguera S, BIOMATERIAL IN PRESS
   Baiguera S, 2011, BIOMATERIALS, V32, P4433, DOI 10.1016/j.biomaterials.2011.02.055
   Baiguera S, 2010, BIOMATERIALS, V31, P8931, DOI 10.1016/j.biomaterials.2010.08.005
   Barkan D, 2010, EUR J CANCER, V46, P1181, DOI 10.1016/j.ejca.2010.02.027
   Beattie AJ, 2009, TISSUE ENG PT A, V15, P1119, DOI 10.1089/ten.tea.2008.0162
   Biancosino C, 2006, CYTOTHERAPY, V8, P178, DOI 10.1080/14653240600621166
   BISSELL MJ, 1982, J THEOR BIOL, V99, P31, DOI 10.1016/0022-5193(82)90388-5
   Borschel GH, 2004, PLAST RECONSTR SURG, V113, P595, DOI 10.1097/01.PRS.0000101064.62289.2F
   BOUDREAU N, 1995, TRENDS CELL BIOL, V5, P1, DOI 10.1016/S0962-8924(00)88924-2
   Brewer MB, 2011, HERNIA, V15, P141, DOI 10.1007/s10029-010-0748-y
   Brown BN, 2009, BIOMATERIALS, V30, P1482, DOI 10.1016/j.biomaterials.2008.11.040
   Brown D. W., 2008, Morbidity and Mortality Weekly Report, V57, P1229
   Calve S, 2010, DEV BIOL, V344, P259, DOI 10.1016/j.ydbio.2010.05.007
   Caplan A, 2004, AM J BIOETHICS, V4, P18, DOI 10.1080/15265160490496930
   Caplan A, 2010, AM J BIOETHICS, V10, P24, DOI 10.1080/15265161.2010.481980
   Cebotari S, 2006, CIRCULATION, V114, pI132, DOI 10.1161/CIRCULATIONAHA.105.001065
   Chen F, 1999, UROLOGY, V54, P407, DOI 10.1016/S0090-4295(99)00179-X
   Choe MM, 2006, AM J RESP CELL MOL, V35, P306, DOI 10.1165/rcmb.2005-0443OC
   Cortiella J, 2006, TISSUE ENG, V12, P1213, DOI 10.1089/ten.2006.12.1213
   Cortiella J, 2010, TISSUE ENG PT A, V16, P2565, DOI 10.1089/ten.tea.2009.0730
   Crapo PM, 2011, BIOMATERIALS, V32, P3233, DOI 10.1016/j.biomaterials.2011.01.057
   Curcio E, 2010, BIOMATERIALS, V31, P5131, DOI 10.1016/j.biomaterials.2010.03.013
   Dahl SLM, 2003, CELL TRANSPLANT, V12, P659, DOI 10.3727/000000003108747136
   Daly AB, 2012, TISSUE ENG PT A, V18, P1, DOI [10.1089/ten.tea.2011.0301, 10.1089/ten.TEA.2011.0301]
   Daly KA, 2009, TISSUE ENG PT A, V15, P3877, DOI [10.1089/ten.tea.2009.0089, 10.1089/ten.TEA.2009.0089]
   Draheim KM, 2011, METHODS MOL BIOL, V750, P261, DOI 10.1007/978-1-61779-145-1_18
   Eiraku M, 2008, CELL STEM CELL, V3, P519, DOI 10.1016/j.stem.2008.09.002
   Eiraku M, 2011, NATURE, V472, P51, DOI 10.1038/nature09941
   El Nahas AM, 2005, LANCET, V365, P331, DOI 10.1016/S0140-6736(05)17789-7
   EXPOSITO JY, 1992, J BIOL CHEM, V267, P15559
   Gassmann P, 2004, ONKOLOGIE, V27, P577, DOI 10.1159/000081343
   Gilbert TW, 2007, J BONE JOINT SURG AM, V89A, P621, DOI 10.2106/JBJS.F.00742
   Grillo HC, 2002, ANN THORAC SURG, V73, P1995, DOI 10.1016/S0003-4975(02)03564-6
   Guenou H, 2009, LANCET, V374, P1745, DOI 10.1016/S0140-6736(09)61496-3
   Heron Melonie, 2009, Natl Vital Stat Rep, V57, P1
   Hodde J P, 2005, J Wound Care, V14, P23
   Hoppo T, 2011, GASTROENTEROLOGY, V140, P656, DOI 10.1053/j.gastro.2010.11.006
   Houghton AM, 2006, CANCER RES, V66, P6149, DOI 10.1158/0008-5472.CAN-04-0297
   Huh D, 2010, SCIENCE, V328, P1662, DOI 10.1126/science.1188302
   Jungebluth P, 2011, LANCET, V378, P1997, DOI 10.1016/S0140-6736(11)61715-7
   Laurance J, 2010, BRIT MED J, V340, DOI 10.1136/bmj.c1633
   Lin YM, 2006, J BIOMATER APPL, V21, P109, DOI 10.1177/0885328206057952
   Lineen E, 2008, J CRANIOFAC SURG, V19, P923, DOI 10.1097/SCS.0b013e318175b5ab
   Liu MY, 2000, J APPL PHYSIOL, V89, P2078
   Macchiarini P, 2008, LANCET, V372, P2023, DOI 10.1016/S0140-6736(08)61598-6
   Mase Vincent J Jr, 2010, Orthopedics, V33, P511, DOI 10.3928/01477447-20100526-24
   Mondrinos MJ, 2007, AM J PHYSIOL-LUNG C, V293, pL639, DOI 10.1152/ajplung.00403.2006
   Morigi M, 2008, STEM CELLS, V26, P2075, DOI 10.1634/stemcells.2007-0795
   Morigi M, 2010, STEM CELLS, V28, P513, DOI 10.1002/stem.293
   Murry CE, 2008, CELL, V132, P661, DOI 10.1016/j.cell.2008.02.008
   Nakayama KH, 2010, TISSUE ENG PT A, V16, P2207, DOI [10.1089/ten.tea.2009.0602, 10.1089/ten.TEA.2009.0602]
   Nelson CM, 2005, SEMIN CANCER BIOL, V15, P342, DOI 10.1016/j.semcancer.2005.05.001
   Nieponice A, 2006, ANN THORAC SURG, V82, P2050, DOI 10.1016/j.athoracsur.2006.06.036
   Omori K, 2008, ANN OTO RHINOL LARYN, V117, P673, DOI 10.1177/000348940811700908
   OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6
   Orens Jonathan B, 2009, Proc Am Thorac Soc, V6, P13, DOI 10.1513/pats.200807-072GO
   Ott HC, 2008, NAT MED, V14, P213, DOI 10.1038/nm1684
   Ott HC, 2010, NAT MED, V16, P927, DOI 10.1038/nm.2193
   Ott HC, 2005, CIRCULATION, V112, pU105
   Petersen TH, 2010, SCIENCE, V329, P538, DOI 10.1126/science.1189345
   Price AP, 2010, TISSUE ENG PT A, V16, P2581, DOI [10.1089/ten.tea.2009.0659, 10.1089/ten.TEA.2009.0659]
   Priya SG, 2008, TISSUE ENG PART B-RE, V14, P105, DOI 10.1089/teb.2007.0318
   Reynolds Teri A, 2008, Ann Emerg Med, V52, P561, DOI 10.1016/j.annemergmed.2008.09.013
   Roomans Godfried M, 2010, Eur Cell Mater, V19, P284
   Ross EA, 2009, J AM SOC NEPHROL, V20, P2338, DOI 10.1681/ASN.2008111196
   Roy M, 2009, J CELL BIOCHEM, V106, P200, DOI 10.1002/jcb.22005
   Sellaro TL, 2010, TISSUE ENG PT A, V16, P1075, DOI 10.1089/ten.TEA.2008.0587
   Shigemura N, 2006, AM J RESP CRIT CARE, V174, P1199, DOI 10.1164/rccm.200603-406OC
   Shin'oka T, 2001, NEW ENGL J MED, V344, P532, DOI 10.1056/NEJM200102153440717
   Soto-Gutierrez A, 2011, TISSUE ENG PART C-ME, V17, P677, DOI 10.1089/ten.tec.2010.0698
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Tottey S, 2011, TISSUE ENG PT A, V17, P37, DOI [10.1089/ten.tea.2010.0188, 10.1089/ten.TEA.2010.0188]
   United States Renal Data System (USRDS), 2009, REN DIS DAT
   Uygun BE, 2010, NAT MED, V16, P814, DOI 10.1038/nm.2170
   Valentin JE, 2010, BIOMATERIALS, V31, P7475, DOI 10.1016/j.biomaterials.2010.06.039
   Valentin JE, 2009, TISSUE ENG PT A, V15, P1687, DOI 10.1089/ten.tea.2008.0419
   Vlodavsky I, 2002, SEMIN CANCER BIOL, V12, P121, DOI 10.1006/scbi.2001.0420
   VRACKO R, 1974, AM J PATHOL, V77, P314
   Wilson JM, 2009, SCIENCE, V324, P727, DOI 10.1126/science.1174935
   Zehr KJ, 2005, J THORAC CARDIOV SUR, V130, P1010, DOI 10.1016/j.jtcvs.2005.03.044
NR 90
TC 269
Z9 282
U1 11
U2 150
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0140-6736
EI 1474-547X
J9 LANCET
JI Lancet
PD MAR 10
PY 2012
VL 379
IS 9819
BP 943
EP 952
DI 10.1016/S0140-6736(12)60073-7
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA 906NY
UT WOS:000301353700035
PM 22405797
DA 2018-12-27
ER

PT J
AU Wang, J
   Sun, SG
   Cao, XB
   Deng, XJ
   Zhang, YJ
   Zhu, Q
AF Wang, Jing
   Sun, Shenggang
   Cao, Xuebing
   Deng, Xuejun
   Zhang, Yunjian
   Zhu, Qing
TI RETRACTED: Overexpression of alpha CP2, a translational repressor of
   GAP-43, inhibited axon outgrowth during development in Xenopus laevis
   (Retracted article. See vol. 421, pg. 634, 2012)
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article; Retracted Publication
DE GAP-43; alpha CP2; 3 '-UTR; Translational repressor; mRNA stability;
   Axon outgrowth
ID RECEPTOR MESSENGER-RNA; POSTTRANSCRIPTIONAL REGULATION; 3'-UNTRANSLATED
   REGION; 3-UNTRANSLATED REGION; GENE-EXPRESSION; DOMAIN PROTEINS;
   HNRNP-K; BINDING; CELLS; IDENTIFICATION
AB The 3'-untranslated regions (3'-UTRs) of growth-associated protein 43 (GAP-43), which is crucial for neural development and axonal regeneration, are highly conserved among vertebrates. Previous studies in mammals have identified one U-rich cis element within GAP-43 3'-UTR and several trans factors that regulate its mRNA stability. However, much less is known in lower vertebrates. The Xenopus GAP-43 3'-UTR, despite its high similarity with those in higher vertebrates, contains unique CU-rich sequences, suggesting the existence of novel cis elements and trans factors. In current study, we isolated four proteins bound to GAP-43 3'-UTR from juvenile frog brain using affinity purification. Mass spectrometry identified Hu antigen D (HuD) and poly(C) binding protein 2 (alpha CP2) as the proteins forming 48- and 44-kDa ribonucleoprotein complexes, respectively. We validated the association between alpha CP2 and GAP-43 3'-UTR in vivo. After confirming the post-transcriptional effects of alpha CP2 on GAP-43 expression, we demonstrated that alpha CP2 directly inhibited the translation of GAP-43 gene, without affecting its mRNA stability. alpha CP2 overexpression led to decreased level of GAP-43 protein and significantly inhibited axonal outgrowth in primarily cultured neurons. Our study therefore provided insights on novel functions of alpha CP2 in vertebrate nervous system during development and new mechanisms of post-transcriptional regulation for GAP-43 gene. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Sun, Shenggang; Cao, Xuebing; Deng, Xuejun; Zhang, Yunjian; Zhu, Qing] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Neurol, Wuhan 430022, Hubei, Peoples R China.
   [Wang, Jing] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Radiol, Wuhan 430022, Hubei, Peoples R China.
RP Zhu, Q (reprint author), Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Neurol, Wuhan 430022, Hubei, Peoples R China.
EM whqz666@gmail.com
FU Hubei provincial Science and Technology Department [2007ABA278]
FX We thank Mrs. Ning Yin (Union Hospital, Tongji Medical College) for help
   raising and preparing Xenopus tissues. This work was supported by a
   grant from Hubei provincial Science and Technology Department
   (2007ABA278).
CR Anderson KD, 2001, EXP NEUROL, V168, P250, DOI 10.1006/exnr.2000.7599
   Becker T, 1998, J NEUROSCI, V18, P5789
   Benowitz LI, 1997, TRENDS NEUROSCI, V20, P84, DOI 10.1016/S0166-2236(96)10072-2
   Blaxall BC, 2000, J BIOL CHEM, V275, P4290, DOI 10.1074/jbc.275.6.4290
   Chung SM, 1997, J BIOL CHEM, V272, P6593, DOI 10.1074/jbc.272.10.6593
   GOOD PJ, 1995, P NATL ACAD SCI USA, V92, P4557, DOI 10.1073/pnas.92.10.4557
   Gravina P, 2002, GENE, V290, P193, DOI 10.1016/S0378-1119(02)00561-9
   Holcik M, 1997, P NATL ACAD SCI USA, V94, P2410, DOI 10.1073/pnas.94.6.2410
   Irwin N, 1997, NUCLEIC ACIDS RES, V25, P1281, DOI 10.1093/nar/25.6.1281
   Keene JD, 2006, NAT PROTOC, V1, P302, DOI 10.1038/nprot.2006.47
   Liu YY, 2008, DEVELOPMENT, V135, P3125, DOI [10.1242/dev.066993, 10.1242/dev.022236]
   Meberg PJ, 1995, MOL BRAIN RES, V34, P343, DOI 10.1016/0169-328X(95)00206-8
   Namgung U, 2000, EUR J NEUROSCI, V12, P3124, DOI 10.1046/j.1460-9568.2000.00196.x
   NEDIVI E, 1992, J NEUROSCI, V12, P691
   Ostareck-Lederer A, 2004, BIOL CELL, V96, P407, DOI 10.1016/j.biolcel.2004.03.010
   PERRONEBIZZOZERO NI, 1993, J CELL BIOL, V120, P1263, DOI 10.1083/jcb.120.5.1263
   Perrotti D, 2002, NAT GENET, V30, P48, DOI 10.1038/ng791
   SCHADEN H, 1994, J NEUROBIOL, V25, P1570, DOI 10.1002/neu.480251209
   Schrama LH, 1997, NEUROSCIENCE, V76, P635, DOI 10.1016/S0306-4522(96)00400-9
   SKENE JHP, 1989, ANNU REV NEUROSCI, V12, P127, DOI 10.1146/annurev.ne.12.030189.001015
   STRITTMATTER SM, 1995, CELL, V80, P445, DOI 10.1016/0092-8674(95)90495-6
   Thisted T, 2001, J BIOL CHEM, V276, P17484, DOI 10.1074/jbc.M010594200
   Thyagarajan A, 2004, J BIOL CHEM, V279, P49680, DOI 10.1074/jbc.M408915200
   Wang XM, 1996, EMBO J, V15, P5040, DOI 10.1002/j.1460-2075.1996.tb00884.x
   Yeap BB, 2002, J BIOL CHEM, V277, P27183, DOI 10.1074/jbc.M202883200
NR 25
TC 1
Z9 1
U1 3
U2 13
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD MAR 9
PY 2012
VL 419
IS 2
BP 262
EP 267
DI 10.1016/j.bbrc.2012.02.006
PG 6
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 913XP
UT WOS:000301911000023
PM 22342981
DA 2018-12-27
ER

PT J
AU Bolla, K
   Ashforth, EJ
AF Bolla, Krishna
   Ashforth, Elizabeth Jane
TI RETRACTED: Cryptomycota: the missing link (Retracted article. See vol.
   5, pg. 883, 2014)
SO PROTEIN & CELL
LA English
DT News Item; Retracted Publication
ID CHITIN SYNTHESIS; ROZELLA; FUNGI
C1 [Bolla, Krishna; Ashforth, Elizabeth Jane] Chinese Acad Sci, Inst Microbiol, Key Lab Pathogen Microbiol & Immunol, Beijing 100190, Peoples R China.
RP Bolla, K (reprint author), Chinese Acad Sci, Inst Microbiol, Key Lab Pathogen Microbiol & Immunol, Beijing 100190, Peoples R China.
EM bollakrishna@gmail.com
CR Bowman SM, 2006, BIOESSAYS, V28, P799, DOI 10.1002/bies.20441
   BULAWA CE, 1993, ANNU REV MICROBIOL, V47, P505, DOI 10.1146/annurev.micro.47.1.505
   HELD AA, 1981, BOT REV, V47, P451, DOI 10.1007/BF02860539
   HELD AA, 1980, CAN J BOT, V58, P959, DOI 10.1139/b80-119
   James TY, 2012, BIOESSAYS, V34, P94, DOI 10.1002/bies.201100110
   Jones MDM, 2011, NATURE, V474, P200, DOI 10.1038/nature09984
   Lara E, 2010, PROTIST, V161, P116, DOI 10.1016/j.protis.2009.06.005
   Munro CA, 2001, MED MYCOL, V39, P41, DOI 10.1080/714030998
   Not F, 2002, AQUAT MICROB ECOL, V28, P157, DOI 10.3354/ame028157
   POWELL MJ, 1984, MYCOLOGIA, V76, P1039, DOI 10.2307/3793019
   Ruiz-Herrera Jose, 2002, FEMS Yeast Research, V1, P247, DOI 10.1016/S1567-1356(01)00049-6
   van Hannen EJ, 1999, APPL ENVIRON MICROB, V65, P2478
NR 12
TC 1
Z9 1
U1 5
U2 27
PU HIGHER EDUCATION PRESS
PI BEIJING
PA NO 4 DEWAI DAJIE, BEIJING 100120, PEOPLES R CHINA
SN 1674-800X
EI 1674-8018
J9 PROTEIN CELL
JI Protein Cell
PD MAR
PY 2012
VL 3
IS 3
BP 161
EP 162
DI 10.1007/s13238-012-2013-x
PG 2
WC Cell Biology
SC Cell Biology
GA 029WE
UT WOS:000310526900001
PM 22528810
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Guo, PM
   Huang, FH
   Huang, QD
   Zheng, C
AF Guo, Pingmei
   Huang, Fenghong
   Huang, Qingde
   Zheng, Chang
TI RETRACTED: Optimization of Biodiesel Production Using a Magnetically
   Stabilized Fluidized Bed Reactor (Retracted article. See vol. 55, pg.
   561, 2013)
SO JOURNAL OF THE AMERICAN OIL CHEMISTS SOCIETY
LA English
DT Article; Retracted Publication
DE Biodiesel; Nanometer magnetic solid catalyst; Magnetically stabilized
   fluidized bed reactor; Transesterification
ID OIL; TRANSESTERIFICATION; FERMENTATION; BIOREACTOR
AB A biodiesel production process using magnetically stabilized fluidized bed reactor (MSFBR) has been developed based on the refined cottonseed oil. The reactant flow rate and magnetic field intensity effects on the nanometer magnetic catalyst behavior in the column were investigated. Orthogonal experiments (L-4(2)(3)) were applied to optimize the best transesterification reaction conditions. Reaction temperature, methanol to oil molar ratio, and reactant flow rate were the main factors to influence transesterification conversion efficiency. These three factors chosen for the present investigation were based on the results of single-factor tests. The optimum transesterification reaction conditions of cottonseed oil were determined in MSFBR as follows: methanol to oil molar ratio 8: 1, 40 cm(3) min(-1) reactant flow rate, 225 Oe magnetic field intensity and reaction temperature of 65 degrees C, the conversion efficiency reached 97% in 100 min. The cold filter plugging point and kinematic viscosity of cottonseed oil biodiesel were higher than that described by Chinese specifications of biodiesel because of the special fatty acid profiles of cottonseed oil. The activity stability of the nanometer magnetic solid catalyst in MSFBR was much better than that in the autoclave stirred reactor (ASR).
C1 [Guo, Pingmei; Huang, Fenghong; Huang, Qingde; Zheng, Chang] Hubei Energy Res Ctr Oil Crops & Biodiesel, Wuhan 430062, Peoples R China.
   [Guo, Pingmei; Huang, Fenghong; Huang, Qingde; Zheng, Chang] Chinese Acad Agr Sci, Oil Crops Res Inst, Wuhan 430062, Peoples R China.
RP Huang, FH (reprint author), Hubei Energy Res Ctr Oil Crops & Biodiesel, Wuhan 430062, Peoples R China.
EM pmguo06@sina.com; huangfh@oilcrops.cn
FU High Technology R&D Program (863 project) [2009AA 05Z437]; National
   Science and Technology Support Program [2009BADB1B10]; Oil Crops
   Research Institute [1610172011014]
FX We are grateful for the financial support given by High Technology R&D
   Program (863 project) (No. 2009AA 05Z437), National Science and
   Technology Support Program (No. 2009BADB1B10), Director Fund of Oil
   Crops Research Institute (No. 1610172011014).
CR Albuquerque MCG, 2009, RENEW ENERG, V34, P857, DOI 10.1016/j.renene.2008.07.006
   Alcantara R, 2000, BIOMASS BIOENERG, V18, P515, DOI 10.1016/S0961-9534(00)00014-3
   Brady D, 1996, BIOTECHNOL LETT, V18, P1213, DOI 10.1007/BF00128595
   Candeia RA, 2009, FUEL, V88, P738, DOI 10.1016/j.fuel.2008.10.015
   [陈文伟 Chen Wenwei], 2007, [太阳能学报, Acta Energiae Solaris Sinica], V28, P324
   [戴玲妹 DAI Lingmei], 2009, [中国油脂, China Oils and Fats], V34, P53
   DAVISON BH, 1988, APPL BIOCHEM BIOTECH, V18, P19, DOI 10.1007/BF02930815
   dos Santos ICF, 2008, BIORESOURCE TECHNOL, V99, P6545, DOI 10.1016/j.biortech.2007.11.048
   FREEDMAN B, 1984, J AM OIL CHEM SOC, V61, P1638, DOI 10.1007/BF02541649
   GILSON CD, 1993, BIOTECHNOL TECH, V7, P397, DOI 10.1007/BF00152548
   Guo PM, 2008, INT C BIOM EN TECHN, V3-5, P286
   Knothe G, 2005, FUEL PROCESS TECHNOL, V86, P1059, DOI 10.1016/j.fuproc.2004.11.002
   Liu C, 2010, RENEW ENERG, V35, P1531, DOI 10.1016/j.renene.2009.10.009
   Liu CZ, 2009, BIORESOURCE TECHNOL, V100, P878, DOI 10.1016/j.biortech.2008.07.016
   Liu CS, 2007, 12 INT RAP C, P350
   Granados ML, 2007, APPL CATAL B-ENVIRON, V73, P317, DOI 10.1016/j.apcatb.2006.12.017
   Meher LC, 2006, RENEW SUST ENERG REV, V10, P248, DOI 10.1016/j.rser.2004.09.002
   Meher LC, 2006, BIORESOURCE TECHNOL, V97, P1392, DOI 10.1016/j.biortech.2005.07.003
   Muniyappa PR, 1996, IMPROVED CONVERSION, P23
   Nabi MN, 2009, APPL THERM ENG, V29, P2265, DOI 10.1016/j.applthermaleng.2008.11.009
   Qian JF, 2008, BIORESOURCE TECHNOL, V99, P9009, DOI 10.1016/j.biortech.2008.04.059
   Rashid U, 2008, FUEL, V87, P265, DOI 10.1016/j.fuel.2007.05.003
   Riley MR, 1996, BIOTECHNOL BIOENG, V49, P223, DOI 10.1002/bit.260490202
   ROSENSWEIG RE, 1979, SCIENCE, V204, P57, DOI 10.1126/science.204.4388.57
   Sarin R, 2009, BIORESOURCE TECHNOL, V100, P4187, DOI 10.1016/j.biortech.2009.03.072
   Sharma YC, 2008, FUEL, V87, P2355, DOI 10.1016/j.fuel.2008.01.014
   TERRANOVA BE, 1991, BIOTECHNOL BIOENG, V37, P110, DOI 10.1002/bit.260370204
   Vasudevan PT, 2008, J IND MICROBIOL BIOT, V35, P421, DOI 10.1007/s10295-008-0312-2
   Webb C, 1996, CHEM ENG J BIOCH ENG, V61, P241, DOI 10.1016/0923-0467(95)03043-3
   Zhang ChunHua, 2010, Transactions of the Chinese Society of Agricultural Engineering, V26, P298
NR 30
TC 3
Z9 3
U1 4
U2 23
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0003-021X
EI 1558-9331
J9 J AM OIL CHEM SOC
JI J. Am. Oil Chem. Soc.
PD MAR
PY 2012
VL 89
IS 3
BP 497
EP 504
DI 10.1007/s11746-011-1924-7
PG 8
WC Chemistry, Applied; Food Science & Technology
SC Chemistry; Food Science & Technology
GA 959DK
UT WOS:000305291600015
DA 2018-12-27
ER

PT J
AU Mahmoudi, M
   Saidi, A
   Nassab, SAG
   Hashemipour, MA
AF Mahmoudi, Mojtaba
   Saidi, Alireza
   Nassab, Saied Abdolreza Gandjalikhan
   Hashemipour, Maryam Alsadat
TI RETRACTED: A three-dimensional finite element analysis of the effects of
   restorative materials and post geometry on stress distribution in
   mandibular molar tooth restored with post-core crown (Retracted article.
   See vol. 33, pg. 147, 2014)
SO DENTAL MATERIALS JOURNAL
LA English
DT Article; Retracted Publication
DE Finite element analysis; Stress; Molar teeth; Post-core crown
ID COMPOSITE RESIN; TEETH; ROOT; RESISTANCE; STRENGTH; PREMOLAR; BEHAVIOR;
   SYSTEMS; INLAYS
AB This study investigated the effects of crown material, post material, and post geometry on stress distribution in molar tooth restored with post-core crown. A three-dimensional solid model consisting of the mandibular second molar tooth, periodontal ligament, cortical bone, and spongy bone was generated. Finite element analysis results showed that prefabricated posts with a composite resin core increased stress concentration at the cementoenamel junction (CEJ), while cast posts induced high stress at post-dentin interface. Increase in the elastic modulus of crown material also increased the stress concentration, especially at CEJ.
C1 [Hashemipour, Maryam Alsadat] Kerman Oral & Dent Dis Res Ctr, Fac Dent, Dept Oral Med, Kerman, Iran.
   [Mahmoudi, Mojtaba; Saidi, Alireza; Nassab, Saied Abdolreza Gandjalikhan] Shahid Bahonar Univ, Sch Engn, Dept Mech Engn, Kerman, Iran.
RP Hashemipour, MA (reprint author), Kerman Oral & Dent Dis Res Ctr, Fac Dent, Dept Oral Med, Blvd Jomhorieslami,Shafa St, Kerman, Iran.
EM m_s_hashemipour@yahoo.com
OI Saidi, Ali Reza/0000-0002-7359-0860; Hashemipour, Maryam
   Alsadat/0000-0002-1075-4020
FU Kerman Oral and Dental Diseases Research Center for Biomaterials and
   Biomechanics;  [T/88/144]
FX This study was supported in part by a Faculty Development Grant from the
   Chancellor of Research, Kerman Oral and Dental Diseases Research Center
   for Biomaterials and Biomechanics, and by Grant T/88/144.
CR Asmussen E, 2005, J PROSTHET DENT, V94, P321, DOI 10.1016/j.prosdent.2005.07.003
   Ausiello P, 2001, J BIOMECH, V34, P1269, DOI 10.1016/S0021-9290(01)00098-7
   Dejak B, 2008, J PROSTHET DENT, V99, P131, DOI 10.1016/S0022-3913(08)60029-3
   Eskitascioglu G, 2002, J ENDODONT, V28, P629, DOI 10.1097/00004770-200209000-00001
   Fu G, 2010, DENT TRAUMATOL, V26, P64, DOI 10.1111/j.1600-9657.2009.00829.x
   Genovese K, 2005, J BIOMECH, V38, P2375, DOI 10.1016/j.jbiomech.2004.10.009
   Ichim I, 2006, INT ENDOD J, V39, P443, DOI 10.1111/j.1365-2591.2006.01085.x
   Jiang W, 2010, J PROSTHET DENT, V103, P6, DOI 10.1016/S0022-3913(09)60206-7
   Kayabasi O, 2006, ADV ENG SOFTW, V37, P649, DOI 10.1016/j.advengsoft.2006.02.004
   Lin CL, 1999, COMPUT METH PROG BIO, V59, P187, DOI 10.1016/S0169-2607(99)00004-8
   Maceri F, 2007, J BIOMECH, V40, P2386, DOI 10.1016/j.jbiomech.2006.11.018
   Miura J, 2009, DENT MATER, V25, P67, DOI 10.1016/j.dental.2008.04.015
   Natali AN, 2004, DENT MATER, V20, P623, DOI 10.1016/j.dental.2003.08.003
   Okada D, 2008, DENT MATER J, V27, P605, DOI 10.4012/dmj.27.605
   Pegoretti A, 2002, BIOMATERIALS, V23, P2667, DOI 10.1016/S0142-9612(01)00407-0
   Pierrisnard L, 2002, J PROSTHET DENT, V88, P442, DOI 10.1067/mpr.2002.128376
   Poiate IAVP, 2008, J BIOSCI BIOENG, V106, P606, DOI 10.1263/jbb.106.606
   Rodrigues FP, 2009, DENT MATER, V25, pE47, DOI 10.1016/j.dental.2009.02.007
   Salameh Z, 2008, J DENT, V36, P513, DOI 10.1016/j.jdent.2008.03.014
   Uddanwadiker RV, 2007, J BIOSCI BIOENG, V104, P363, DOI 10.1263/jbb.104.363
   Wakabayashi N, 2008, J DENT, V36, P463, DOI 10.1016/j.jdent.2008.03.010
   Zarone F, 2006, DENT MATER, V22, P1035, DOI 10.1016/j.dental.2005.11.034
NR 22
TC 7
Z9 10
U1 3
U2 18
PU JAPANESE SOC DENTAL MATERIALS DEVICES
PI TOKYO
PA C/O KOKU HOKEN KYOKAI, 1-43-9 KOMAGOME TS BDG, KOMAGOME, TOSHIMA-KU,
   TOKYO, 170-0003, JAPAN
SN 0287-4547
J9 DENT MATER J
JI Dent. Mater. J.
PD MAR
PY 2012
VL 31
IS 2
BP 171
EP 179
DI 10.4012/dmj.2011-138
PG 9
WC Dentistry, Oral Surgery & Medicine; Materials Science, Biomaterials
SC Dentistry, Oral Surgery & Medicine; Materials Science
GA 952KA
UT WOS:000304790200001
PM 22447049
OA Bronze
DA 2018-12-27
ER

PT J
AU Avcu, S
   Ozcan, HN
   Izmirli, M
   Lemmerling, M
AF Avcu, S.
   Ozcan, H. N.
   Izmirli, M.
   Lemmerling, M.
TI RETRACTED: CT and MR findings in a neuroforaminal extraskeletal Ewing
   sarcoma mimicking benign nerve sheath tumor (Retracted article. See vol.
   182, pg. 749, 2013)
SO IRISH JOURNAL OF MEDICAL SCIENCE
LA English
DT Article; Retracted Publication
DE Extraskeletal Ewing sarcoma; Neural foramen; Spine; CT; MRI
AB Introduction We report the CT and MR findings in a 30-year-old man with extraskeletal Ewing sarcoma (EES) involving the left neural foramen at L5-S1 level.
   Materials and methods The patient was evaluated with preoperative lumbosacral CT and MR imaging and postoperative lumbosacral MR imaging.
   Results The lesion was hyperdense on CT, isointense on T1- and T2-weighted MR images, and enhanced homogeneously after intravenous gadolinium injection. With these CT and MR findings, surgery was performed with a presumptive diagnosis of nerve sheath tumor, but the histopathological examination revealed EES. Chemotherapy and radiotherapy were planned postoperatively.
   Conclusion This case illustrates that even in benign looking lesions in a neuroforamen one can never exclude malignancy, and this is even more true in a population of young adults.
C1 [Avcu, S.] Yuzuncu Yil Univ, Fac Med, Dept Radiol, TR-65100 Van, Turkey.
   [Avcu, S.; Ozcan, H. N.; Lemmerling, M.] AZ Sint Lucas Hosp, Dept Radiol, Ghent, Belgium.
   [Izmirli, M.] AZ Sint Lucas Hosp, Dept Radiat Oncol, Ghent, Belgium.
RP Avcu, S (reprint author), Yuzuncu Yil Univ, Fac Med, Dept Radiol, Kazim Karabekir Cad, TR-65100 Van, Turkey.
EM serhatavcu@hotmail.com
CR BENMEIR P, 1991, SPINE, V16, P224, DOI 10.1097/00007632-199102000-00025
   HIGGINS JC, 1994, PEDIATR CARDIOL, V15, P207, DOI 10.1007/BF00800678
   Isefuku S, 2006, TOHOKU J EXP MED, V209, P369, DOI 10.1620/tjem.209.369
   KASPERS GJJL, 1991, CANCER-AM CANCER SOC, V68, P648, DOI 10.1002/1097-0142(19910801)68:3<648::AID-CNCR2820680335>3.0.CO;2-Q
   LONGWAY SR, 1986, ARCH PATHOL LAB MED, V110, P1058
   PAVLIDIS NA, 1991, EUR J SURG ONCOL, V17, P308
   Shin JH, 2001, AM J NEURORADIOL, V22, P795
   STUARTHARRIS R, 1986, EUR J CANCER CLIN ON, V22, P393, DOI 10.1016/0277-5379(86)90104-5
   Toh KL, 1999, J UROLOGY, V162, P159, DOI 10.1097/00005392-199907000-00041
NR 9
TC 2
Z9 4
U1 3
U2 15
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0021-1265
EI 1863-4362
J9 IRISH J MED SCI
JI Irish J. Med. Sci.
PD MAR
PY 2012
VL 181
IS 1
BP 123
EP 125
DI 10.1007/s11845-010-0534-y
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA 935SK
UT WOS:000303540500024
PM 20676795
DA 2018-12-27
ER

PT J
AU Zhou, TZ
   Li, J
   Gao, LS
AF Zhou Tie-Zhong
   Li Jing
   Gao Lian-Shan
TI RETRACTED: Cavity design and optimization for a passive hydrogen maser
   (Retracted Article)
SO ACTA PHYSICA SINICA
LA Chinese
DT Article; Retracted Publication
DE passive hydrogen maser; microwave cavity; unload Q value; filling factor
AB According to the theory of electromagnetism, we establish the equation of resonance frequency for simplified model of cavity of passive hydrogen maser. We find the optimal dimension of the cavity, which makes the product of the Q value and the filling factor reach a maximal value. The experimental results indicate that the so designed cavity can be utilized undoubtedly for the passive hydrogen maser, and achieve the Q value of 9800 and the filling factor of 1.2. Furthermore, the resulting capacity of storage volume is the biggest is ever reported cavities of passive hydrogen maser.
C1 [Zhou Tie-Zhong] Beijing Univ Aeronaut & Astronaut, Beijing 100191, Peoples R China.
   [Zhou Tie-Zhong; Li Jing; Gao Lian-Shan] Beijing Inst Radio Metrol & Measurement, Beijing 100854, Peoples R China.
RP Zhou, TZ (reprint author), Beijing Univ Aeronaut & Astronaut, Beijing 100191, Peoples R China.
EM zhoutiezhong_7869@hotmail.com
CR Berthoud P, 2003, P IEEE INT FREQ CONT, P90
   Chen HB, 2009, C P NAT TIM FREQ CHE, P96
   Collins GB, 1948, MICROWAVE MAGNETRONS, P82
   Guan SJ, 2001, ANN SHANGHAI OBSERV, V22, P136
   Howe DA, 1979, IEEE 33 INT FREQ CON, P554
   [雒向东 LUO Xiang-dong], 2010, [宇航计测技术, Journal of Astronautic Metrology and Measurement], V30, P71
   Opie DB, 1991, IEEE 45 INT FREQ CON, P467
   Peter HE, 1978, IEEE 32 INT FREQ CON, P469
   Serebryannikov AE, 2005, IEEE T PLASMA SCI, V33, P1019, DOI 10.1109/TPS.2005.848606
   Waller P, 2008, P 40 ANN PREC TIM TI, P69
   Wang HM, 1979, IEEE 33 INT FREQ CON, P543
   Wang QH, 2000, IEEE T ULTRASON FERR, V47, P197, DOI 10.1109/58.818762
   Wang YQ, 1986, QUANTUM PHYS ATOMIC, P403
   Zhang DJ, 1992, 23 PTTI 1992, V1992, P277
   [周铁中 Zhou Tiezhong], 2010, [计量学报, Acta Metrologica Sinica], V31, P359
   Zhou TZ, 2011, IEEE INT C EL MEAS I, P7
NR 16
TC 0
Z9 0
U1 4
U2 6
PU CHINESE PHYSICAL SOC
PI BEIJING
PA P O BOX 603, BEIJING 100080, PEOPLES R CHINA
SN 1000-3290
J9 ACTA PHYS SIN-CH ED
JI Acta Phys. Sin.
PD MAR
PY 2012
VL 61
IS 5
AR 050601
PG 7
WC Physics, Multidisciplinary
SC Physics
GA 930VT
UT WOS:000303170800012
DA 2018-12-27
ER

PT J
AU Qiu, HJ
   Zou, FX
AF Qiu, Huajun
   Zou, Feixue
TI RETRACTED: Nanoporous PtCo Surface Alloy Architecture with Enhanced
   Properties for Methanol Electrooxidation (Retracted article. See vol. 5,
   pg. 6775, 2013)
SO ACS APPLIED MATERIALS & INTERFACES
LA English
DT Article; Retracted Publication
DE dealloying; structure stability; bimetallic catalysts; fuel cell
ID OXYGEN REDUCTION REACTION; FUEL-CELLS; ELECTROCATALYTIC OXIDATION;
   ELECTRONIC-STRUCTURE; CARBON-MONOXIDE; BULK ALLOY; CATALYSTS; CO; GOLD;
   PERFORMANCE
AB By selectively dealloying a PtCoAl ternary alloy, a novel nanoporous PtCo (np-PtCo) alloy with a three-dimensional bicontinuous pore-ligament structure is successfully fabricated. X-ray diffraction and electron microscopic characterizations demonstrate the single-crystal nature of the alloy ligament with a ligament size down to similar to 3 nm. After a mild electrochemical dealloying process, a nanoporous near-surface alloy structure with a Pt-rich surface and a PtCo alloy core is obtained. Electrochemical measurements show that the np-PtCo surface alloy has greatly enhanced catalytic activity and durability toward methanol electrooxidation compared with a state-of-the-art Pt/C catalyst. The peak current density of methanol electrooxidation on a np-PtCo surface alloy is more than 5 times of that on Pt/C. More importantly, continuous potential cycling from 0.6 to 0.9 V (vs RHE) in a 0.5 M H2SO4 aqueous solution demonstrates that a np-PtCo surface alloy has excellent structure stability, with more than 90% of the initial electrochemical active surface area (EASA) retained after 5000 potential cycles. Under the same conditions, the EASA of Pt/C drops to similar to 170%. With evident advantages of facile preparation as well as enhanced electrocatalytic activity and durability, a np-PtCo surface alloy nanomaterial holds great potential as an anode catalyst in direct methanol fuel cells.
C1 [Qiu, Huajun; Zou, Feixue] Shandong Univ, Sch Chem & Chem Engn, Jinan 250100, Peoples R China.
   [Qiu, Huajun] Nanyang Technol Univ, Sch Chem & Biomed Engn, Singapore 637457, Singapore.
RP Qiu, HJ (reprint author), Shandong Univ, Sch Chem & Chem Engn, Jinan 250100, Peoples R China.
EM qiuhuajun@gmail.com
FU Nanyang Technological University; Shandong University
FX This work was supported by Nanyang Technological University and Shandong
   University. H.Q, thanks the two reviewers for their insightful advice.
CR Borup R, 2007, CHEM REV, V107, P3904, DOI 10.1021/cr050182l
   Chen AC, 2010, CHEM REV, V110, P3767, DOI 10.1021/cr9003902
   Chen LY, 2009, ADV FUNCT MATER, V19, P1221, DOI 10.1002/adfm.200801239
   Chen ZW, 2007, ANGEW CHEM INT EDIT, V46, P4060, DOI 10.1002/anie.200700894
   Ding Y, 2004, ADV MATER, V16, P1897, DOI 10.1002/adma.200400792
   Du C., 2010, ACS APPL MATER INTER, V3, P105
   Erlebacher J, 2004, J ELECTROCHEM SOC, V151, pC614, DOI 10.1149/1.1784820
   Erlebacher J, 2001, NATURE, V410, P450, DOI 10.1038/35068529
   Fujita T, 2008, PHYS REV LETT, V101, DOI 10.1103/PhysRevLett.101.166601
   Gasteiger HA, 2005, APPL CATAL B-ENVIRON, V56, P9, DOI 10.1016/j.apcatb.2004.06.021
   Gojkovic SL, 2003, J SERB CHEM SOC, V68, P859, DOI 10.2298/JSC0311859G
   Guo JW, 2005, ELECTROCHIM ACTA, V51, P754, DOI 10.1016/j.electacta.2005.05.056
   Guo SJ, 2011, J AM CHEM SOC, V133, P15354, DOI 10.1021/ja207308b
   Hernandez-Fernandez P, 2010, J POWER SOURCES, V195, P7959, DOI 10.1016/j.jpowsour.2010.06.009
   Hsieh CT, 2009, J POWER SOURCES, V188, P347, DOI 10.1016/j.jpowsour.2008.12.031
   Kabbabi A, 1998, J ELECTROANAL CHEM, V444, P41, DOI 10.1016/S0022-0728(97)00558-5
   Knudsen J, 2007, J AM CHEM SOC, V129, P6485, DOI 10.1021/ja0700855
   Koenigsmann C, 2011, ACS NANO, V5, P7471, DOI 10.1021/nn202434r
   Koenigsmann C, 2011, J AM CHEM SOC, V133, P9783, DOI 10.1021/ja111130t
   Koenigsmann C, 2010, NANO LETT, V10, P2806, DOI 10.1021/nl100718k
   Koh S, 2007, J AM CHEM SOC, V129, P12624, DOI 10.1021/ja0742784
   Koh S, 2007, J PHYS CHEM C, V111, P3744, DOI 10.1021/jp067269a
   Komatsu T, 2008, J CATAL, V258, P306, DOI 10.1016/j.jcat.2008.06.030
   Kowal A, 2009, NAT MATER, V8, P325, DOI [10.1038/NMAT2359, 10.1038/nmat2359]
   Kuo PL, 2011, ACS APPL MATER INTER, V3, P115, DOI 10.1021/am1010089
   Li WZ, 2006, J PHYS CHEM B, V110, P15353, DOI 10.1021/jp0623443
   Liang HW, 2011, ADV MATER, V23, P1467, DOI 10.1002/adma.201004377
   Liu J, 2011, ACS APPL MATER INTER, V3, P3552, DOI 10.1021/am200782x
   Liu LF, 2010, J MATER CHEM, V20, P5621, DOI 10.1039/c0jm00113a
   Liu LF, 2009, NANO LETT, V9, P4352, DOI 10.1021/nl902619q
   Liu ZL, 2011, ACS APPL MATER INTER, V3, P3824, DOI 10.1021/am2010515
   Liu ZN, 2009, ELECTROCHIM ACTA, V54, P7286, DOI 10.1016/j.electacta.2009.07.049
   Mani P, 2011, J POWER SOURCES, V196, P666, DOI 10.1016/j.jpowsour.2010.07.047
   Okaya K, 2010, ACS APPL MATER INTER, V2, P888, DOI 10.1021/am9008693
   Prabhuram J, 2006, J PHYS CHEM B, V110, P5245, DOI 10.1021/jp0567063
   Qian LH, 2007, APPL PHYS LETT, V91, DOI 10.1063/1.2773757
   Qiu HJ, 2008, J PHYS CHEM C, V112, P14781, DOI 10.1021/jp805600k
   Qiu HJ, 2011, CHEMPHYSCHEM, V12, P2118, DOI 10.1002/cphc.201100205
   Qiu HJ, 2009, J PHYS CHEM C, V113, P2521, DOI 10.1021/jp8090304
   Salgado JRC, 2005, APPL CATAL B-ENVIRON, V57, P283, DOI 10.1016/j.apcatb.2004.11.009
   Shui JI, 2011, ADV FUNCT MATER, V21, P3357, DOI 10.1002/adfm.201100723
   SIERADZKI K, 1993, J ELECTROCHEM SOC, V140, P2868, DOI 10.1149/1.2220924
   Simmonds MC, 1998, CORROS SCI, V40, P43, DOI 10.1016/S0010-938X(97)00109-1
   Stamenkovic V, 2006, ANGEW CHEM INT EDIT, V45, P2897, DOI 10.1002/anie.200504386
   Stamenkovic VR, 2007, NAT MATER, V6, P241, DOI 10.1038/nmat1840
   Stamenkovic VR, 2006, J AM CHEM SOC, V128, P8813, DOI 10.1021/ja0600476
   Stephens IEL, 2011, J AM CHEM SOC, V133, P5485, DOI 10.1021/ja111690g
   Strasser P, 2010, NAT CHEM, V2, P454, DOI [10.1038/NCHEM.623, 10.1038/nchem.623]
   Su FB, 2005, CHEM MATER, V17, P3960, DOI 10.1021/cm0502222
   Sun SH, 2011, ANGEW CHEM INT EDIT, V50, P422, DOI 10.1002/anie.201004631
   Van Petegem S, 2009, NANO LETT, V9, P1158, DOI 10.1021/nl803799q
   Wang C, 2009, J PHYS CHEM C, V113, P19365, DOI 10.1021/jp908203p
   Wang DS, 2011, SCI REP-UK, V1, DOI 10.1038/srep00037
   Wang JX, 2011, J AM CHEM SOC, V133, P13551, DOI 10.1021/ja204518x
   Wang ZB, 2006, ELECTROCHIM ACTA, V51, P5691, DOI 10.1016/j.electacta.2006.03.002
   WIECKOWSKI A, 1995, J ELECTROANAL CHEM, V382, P97, DOI 10.1016/0022-0728(94)03672-P
   Xu CX, 2011, ACS APPL MATER INTER, V3, P4626, DOI 10.1021/am201057t
   Zeng JH, 2007, INT J HYDROGEN ENERG, V32, P4389, DOI 10.1016/j.ijhydene.2007.03.012
   Zhang ZH, 2011, NANOSCALE, V3, P1663, DOI 10.1039/c0nr00830c
   Zhang ZH, 2009, J PHYS CHEM C, V113, P12629, DOI 10.1021/jp811445a
   Zhou WP, 2011, ELECTROCHIM ACTA, V56, P9824, DOI 10.1016/j.electacta.2011.08.055
   Zielasek V, 2006, ANGEW CHEM INT EDIT, V45, P8241, DOI 10.1002/anie.200602484
NR 62
TC 45
Z9 46
U1 2
U2 84
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1944-8244
J9 ACS APPL MATER INTER
JI ACS Appl. Mater. Interfaces
PD MAR
PY 2012
VL 4
IS 3
BP 1404
EP 1410
DI 10.1021/am201659n
PG 7
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
SC Science & Technology - Other Topics; Materials Science
GA 914RD
UT WOS:000301968400037
PM 22364172
DA 2018-12-27
ER

PT J
AU Merighi, S
   Gessi, S
   Varani, K
   Simioni, C
   Fazzi, D
   Mirandola, P
   Borea, PA
AF Merighi, Stefania
   Gessi, Stefania
   Varani, Katia
   Simioni, Carolina
   Fazzi, Debora
   Mirandola, Prisco
   Borea, Pier Andrea
TI RETRACTED: Cannabinoid CB2 receptors modulate ERK-1/2 kinase signalling
   and NO release in microglial cells stimulated with bacterial
   lipopolysaccharide (Retracted article. See vol. 174, pg. 2609, 2017)
SO BRITISH JOURNAL OF PHARMACOLOGY
LA English
DT Article; Retracted Publication
DE cannabinoids; CB2 receptors; signalling pathways; ERK-1/2; NO; microglia
ID NITRIC-OXIDE SYNTHASE; ACTIVATED PROTEIN-KINASES; ENDOTHELIAL
   GROWTH-FACTOR; NECROSIS-FACTOR-ALPHA; HUMAN-MELANOMA CELLS; NF-KAPPA-B;
   INTERLEUKIN-8 EXPRESSION; INTERNATIONAL UNION; IL-12P40 PRODUCTION;
   ASTROCYTE CULTURES
AB BACKGROUND AND PURPOSE
   Cannabinoid (CB) receptor agonists have potential utility as anti-inflammatory drugs in chronic immune inflammatory diseases. In the present study, we characterized the signal transduction pathways affected by CB2 receptors in quiescent and lipopolysaccharide (LPS)-stimulated murine microglia.
   EXPERIMENTAL APPROACH
   We examined the effects of the synthetic CB2 receptor ligand, JWH-015, on phosphorylation of MAPKs and NO production.
   KEY RESULTS
   Stimulation of CB2 receptors by JWH-015 activated JNK-1/2 and ERK-1/2 in quiescent murine microglial cells. Furthermore, CB2 receptor activation increased p-ERK-1/2 at 15 min in LPS-stimulated microglia. Surprisingly, this was reduced after 30 min in the presence of both LPS and JWH-015. The NOS inhibitor L-NAME blocked the ability of JWH-015 to down-regulate the LPS-induced p-ERK increase, indicating that activation of CB2 receptors reduced effects of LPS on ERK-1/2 phosphorylation through NO. JWH-015 increased LPS-induced NO release at 30 min, while at 4 h CB2 receptor stimulation had an inhibitory effect. All the effects of JWH-015 were significantly blocked by the CB2 receptor antagonist AM 630 and, as the inhibition of CB2 receptor expression by siRNA abolished the effects of JWH-015, were shown to be mediated specifically by activation of CB2 receptors.
   CONCLUSIONS AND IMPLICATIONS
   Our results demonstrate that CB2 receptor stimulation activated the MAPK pathway, but the presence of a second stimulus blocked MAPK signal transduction, inhibiting pro-inflammatory LPS-induced production of NO. Therefore, CB2 receptor agonists may promote anti-inflammatory therapeutic responses in activated microglia.
C1 [Merighi, Stefania; Gessi, Stefania; Varani, Katia; Simioni, Carolina; Fazzi, Debora; Borea, Pier Andrea] Univ Ferrara, Pharmacol Sect, Dept Clin & Expt Med, I-44100 Ferrara, Italy.
   [Merighi, Stefania; Gessi, Stefania; Varani, Katia; Simioni, Carolina; Fazzi, Debora; Borea, Pier Andrea] Univ Ferrara, Interdisciplinary Ctr Study Inflammat, I-44100 Ferrara, Italy.
   [Mirandola, Prisco] Univ Parma, Osped Maggiore, Inst Normal Human Anat, Dept Human Anat Pharmacol & Forens Med, I-43100 Parma, Italy.
RP Borea, PA (reprint author), Univ Ferrara, Pharmacol Sect, Dept Clin & Expt Med, Via Fossato di Mortara 17-19, I-44100 Ferrara, Italy.
EM bpa@unife.it
RI Mirandola, Prisco/L-3137-2015
OI Mirandola, Prisco/0000-0002-5058-3924; Simioni,
   Carolina/0000-0003-0801-7811
FU 'Fondazione Cassa di Risparmio' of Ferrara
FX This work was supported by 'Fondazione Cassa di Risparmio' of Ferrara.
CR Alexander SPH, 2011, BRIT J PHARMACOL, V164, pS1, DOI 10.1111/j.1476-5381.2011.01649_1.x
   Aloisi F, 2001, GLIA, V36, P165, DOI 10.1002/glia.1106
   Atwood BK, 2010, BRIT J PHARMACOL, V160, P467, DOI 10.1111/j.1476-5381.2010.00729.x
   Benito C, 2008, BRIT J PHARMACOL, V153, P277, DOI 10.1038/sj.bjp.0707505
   Bhat NR, 1998, J NEUROSCI, V18, P1633
   Bodles AM, 2005, NEUROBIOL AGING, V26, P9, DOI 10.1016/j.neurobiolaging.2004.02.022
   Bosier B, 2010, BIOCHEM PHARMACOL, V80, P1, DOI 10.1016/j.bcp.2010.02.013
   Cabral GA, 2008, BRIT J PHARMACOL, V153, P240, DOI 10.1038/sj.bjp.0707584
   CORRADIN SB, 1993, GLIA, V7, P255, DOI 10.1002/glia.440070309
   Correa F, 2005, BRIT J PHARMACOL, V145, P441, DOI 10.1038/sj.bjp.0706215
   Correa F, 2008, BIOCHEM J, V409, P761, DOI 10.1042/BJ20071329
   Correa F, 2011, BRAIN BEHAV IMMUN, V25, P736, DOI 10.1016/j.bbi.2011.01.020
   Correa F, 2010, GLIA, V58, P135, DOI 10.1002/glia.20907
   Correa F, 2009, BIOCHEM PHARMACOL, V77, P86, DOI 10.1016/j.bcp.2008.09.014
   Ehrhart J, 2005, J NEUROINFLAMM, V12, P2
   Eljaschewitsch E, 2006, NEURON, V49, P67, DOI 10.1016/j.neuron.205.11.027
   Facchinetti F, 2003, GLIA, V41, P161, DOI 10.1002/glia.10177
   Fernandez-Ruiz J, 2007, TRENDS PHARMACOL SCI, V28, P39, DOI 10.1016/j.tips.2006.11.001
   Fernandez-Ruiz J, 2009, BRIT J PHARMACOL, V156, P1029, DOI 10.1111/j.1476-5381.2008.00088.x
   Gertsch J, 2008, P NATL ACAD SCI USA, V105, P9099, DOI 10.1073/pnas.0803601105
   Gobbi G, 2003, BRIT J HAEMATOL, V121, P892, DOI 10.1046/j.1365-2141.2003.04369.x
   Gonzalez-Scarano F, 1999, ANNU REV NEUROSCI, V22, P219, DOI 10.1146/annurev.neuro.22.1.219
   GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X
   Hanisch UK, 2007, NAT NEUROSCI, V10, P1387, DOI 10.1038/nn1997
   Hillard CJ, 1999, FEBS LETT, V459, P277, DOI 10.1016/S0014-5793(99)01253-3
   Horvath RJ, 2008, J NEUROCHEM, V107, P557, DOI 10.1111/j.1471-4159.2008.05633.x
   Howlett AC, 2002, PHARMACOL REV, V54, P161, DOI 10.1124/pr.54.2.161
   Howlett AC, 2005, HANDB EXP PHARMACOL, V168, P53
   Hsieh GC, 2011, BRIT J PHARMACOL, V162, P428, DOI 10.1111/j.1476-5381.2010.01046.x
   Jeon YJ, 1996, MOL PHARMACOL, V50, P334
   Jung WK, 2010, BRIT J PHARMACOL, V159, P1274, DOI 10.1111/j.1476-5381.2009.00615.x
   Klegeris A, 2003, BRIT J PHARMACOL, V139, P775, DOI 10.1038/sj.bjp.0705304
   Klein TW, 2007, ADV EXP MED BIOL, V601, P395
   Kreitzer FR, 2009, PHARMACOL THERAPEUT, V122, P83, DOI 10.1016/j.pharmthera.2009.01.005
   Lehnardt S, 2002, J NEUROSCI, V22, P2478, DOI 10.1523/JNEUROSCI.22-07-02478.2002
   Lourbopoulos A, 2011, BRAIN RES, V1390, P126, DOI 10.1016/j.brainres.2011.03.020
   Marrs WR, 2010, NAT NEUROSCI, V13, P951, DOI 10.1038/nn.2601
   Merighi S, 2005, J BIOL CHEM, V280, P19516, DOI 10.1074/jbc.M413772200
   Merighi S, 2007, MOL PHARMACOL, V72, P395, DOI 10.1124/mol.106.032920
   Merighi S, 2010, BIOCHEM PHARMACOL, V79, P471, DOI 10.1016/j.bcp.2009.09.009
   Merighi S, 2009, NEOPLASIA, V11, P1064, DOI 10.1593/neo.09768
   Molina-Holgado F, 2002, J NEUROSCI RES, V67, P829, DOI 10.1002/jnr.10165
   Mukhopadhyay S, 2006, J NEUROIMMUNOL, V181, P82, DOI 10.1016/j.jneuroim.2006.08.002
   Murphy S, 2000, GLIA, V29, P1, DOI 10.1002/(SICI)1098-1136(20000101)29:1<1::AID-GLIA1>3.0.CO;2-N
   Oh YT, 2010, NEUROSCI LETT, V474, P148, DOI 10.1016/j.neulet.2010.03.026
   Ortega-Gutierrez S, 2005, GLIA, V52, P163, DOI 10.1002/glia.20229
   Pertwee RG, 2010, PHARMACOL REV, V62, P588, DOI 10.1124/pr.110.003004
   Pietr M, 2009, FEBS LETT, V583, P2071, DOI 10.1016/j.febslet.2009.05.028
   Romero-Sandoval EA, 2009, MOL PAIN, V5, DOI 10.1186/1744-8069-5-25
   Ross RA, 2000, EUR J PHARMACOL, V401, P121, DOI 10.1016/S0014-2999(00)00437-4
   Sheng WS, 2005, GLIA, V49, P211, DOI 10.1002/glia.2010S
   Stefano GB, 1996, J BIOL CHEM, V271, P19238, DOI 10.1074/jbc.271.32.19238
   Stella N, 2010, GLIA, V58, P1017, DOI 10.1002/glia.20983
   Waksman Y, 1999, J PHARMACOL EXP THER, V288, P1357
   Walter L, 2003, J NEUROSCI, V23, P1398
   Wang MJ, 2006, J NEUROCHEM, V97, P857, DOI 10.1111/j.1471-4159.2006.03776.x
NR 56
TC 28
Z9 29
U1 2
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0007-1188
EI 1476-5381
J9 BRIT J PHARMACOL
JI Br. J. Pharmacol.
PD MAR
PY 2012
VL 165
IS 6
SI SI
BP 1773
EP 1788
DI 10.1111/j.1476-5381.2011.01673.x
PG 16
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 897WC
UT WOS:000300689800014
PM 21951063
OA Green Published
DA 2018-12-27
ER

PT J
AU Panthee, DR
   Foolad, MR
AF Panthee, Dilip R.
   Foolad, Majid R.
TI RETRACTED: A reexamination of molecular markers for use in
   marker-assisted breeding in tomato (Retracted article. See vol. 194, pg.
   149, 2013)
SO EUPHYTICA
LA English
DT Article; Retracted Publication
DE Disease resistance; Marker validation; Molecular breeding; Molecular
   markers; Solanum lycopersicum
ID SPOTTED-WILT-VIRUS; NEMATODE-RESISTANCE GENE; BACTERIAL WILT;
   FUSARIUM-WILT; SCAR MARKERS; LATE BLIGHT; LYCOPERSICON-PERUVIANUM;
   PHYTOPHTHORA-INFESTANS; DISEASE RESISTANCE; TSWV RESISTANCE
AB Molecular markers have been used for identification and mapping of genes and QTLs for numerous agriculturally important traits in tomato, including resistance/tolerance to biotic and abiotic stresses and fruit- and flower-related characteristics. However, the extent to which markers have been utilized in tomato breeding programs has not been clearly determined. A review of the literature indicated that the utility of most markers for use in tomato breeding programs have not been verified. Many markers are not validated across tomato genotypes or are not polymorphic within tomato breeding populations. In this study, we examined the utility of available markers for several major disease resistance traits in tomato by testing them in a number of breeding lines and commercial cultivars with known resistance/susceptibility responses. While several markers were validated, others needed PCR optimization for successful amplifications or were not informative in the genotypes used. Specifically, of the 37 markers examined 19 (similar to 51%) were informative, including markers for resistance to Fusarium wilt, late blight, bacterial wilt, tomato mosaic virus, tomato spotted wilt virus, and root knot nematodes. It appears that many of the available markers may need to be further refined or examined for trait association and presence of polymorphism in breeding lines and populations. However, with recent advances in tomato sequencing, it is becoming increasingly possible to develop more informative markers to accelerate the use of MAS in tomato breeding.
C1 [Foolad, Majid R.] Penn State Univ, Dept Hort, University Pk, PA 16802 USA.
   [Foolad, Majid R.] Penn State Univ, Intercoll Grad Degree Programs Plant Biol & Ge, University Pk, PA 16802 USA.
   [Panthee, Dilip R.] N Carolina State Univ, Dept Hort Sci, Mt Hort Crops Res & Extens Ctr, Mills River, NC 28759 USA.
RP Foolad, MR (reprint author), Penn State Univ, Dept Hort, University Pk, PA 16802 USA.
EM mrf5@psu.edu
CR Agrios G. N, 2004, PLANT PATHOLOGY
   Ammiraju JSS, 2003, THEOR APPL GENET, V106, P478, DOI 10.1007/s00122-002-1106-y
   Arens P, 2010, THEOR APPL GENET, V120, P655, DOI 10.1007/s00122-009-1183-2
   Barillas AC, 2008, REP TOMATO GENET COO, V58, P11
   BERNATZKY R, 1986, GENETICS, V112, P887
   Black L. L., 1996, Phytopathology, V86, pS24
   Chague V, 1996, THEOR APPL GENET, V92, P1045, DOI 10.1007/BF00224047
   Chunwongse J, 2002, J HORTIC SCI BIOTECH, V77, P281, DOI 10.1080/14620316.2002.11511493
   CIRULLI M, 1969, PHYTOPATHOLOGY, V59, P1287
   DANESH D, 1994, MOL PLANT MICROBE IN, V7, P464, DOI 10.1094/MPMI-7-0464
   Dax E, 1998, EUPHYTICA, V101, P73, DOI 10.1023/A:1018307326636
   DAX E, 1994, EUPHYTICA, V74, P159, DOI 10.1007/BF00033782
   Devran Z, 2008, RUSS J NEMATOL, V16, P143
   Dianese EC, 2010, MOL BREEDING, V25, P133, DOI 10.1007/s11032-009-9313-8
   El Mohtar CA, 2007, PLANT DIS, V91, P758, DOI 10.1094/PDIS-91-6-0758
   *FAOSTAT, 2008, FAO STAT DAT
   Filho HPM, 1980, ACTA HORTIC, V100, P383
   FINLAY KW, 1953, AUST J BIOL SCI, V6, P153, DOI 10.1071/BI9530153
   Foolad Majid R, 2007, Int J Plant Genomics, V2007, P64358, DOI 10.1155/2007/64358
   Foolad MR, 2008, CRIT REV PLANT SCI, V27, P75, DOI 10.1080/07352680802147353
   FULTON TM, 1995, PLANT MOL BIOL REP, V13, P207, DOI 10.1007/BF02670897
   Fulton TM, 2002, PLANT CELL, V14, P1457, DOI 10.1105/tpc.010479
   Gardner RG, 2010, HORTSCIENCE, V45, P824
   Garland S, 2005, AUST J AGR RES, V56, P285, DOI 10.1071/AR04140
   GOODWIN SB, 1995, PLANT DIS, V79, P1181, DOI 10.1094/PD-79-1181
   GRIMAULT V, 1995, J PHYTOPATHOL, V143, P349, DOI 10.1111/j.1439-0434.1995.tb00274.x
   Hanson PM, 1998, PLANT DIS, V82, P74, DOI 10.1094/PDIS.1998.82.1.74
   Hemming MN, 2004, THEOR APPL GENET, V109, P409, DOI 10.1007/s00122-004-1646-4
   Jablonska B, 2007, PLANT PHYSIOL, V143, P1044, DOI 10.1104/pp.106.089615
   Kiewnick S, 2009, J NEMATOL, V41, P134
   Lanfermeijer FC, 2005, J EXP BOT, V56, P2925, DOI 10.1093/jxb/eri288
   Langella R, 2004, J HORTIC SCI BIOTECH, V79, P806, DOI 10.1080/14620316.2004.11511846
   Lim GTT, 2006, AUSTRALAS PLANT PATH, V35, P671, DOI 10.1071/AP06073
   Lim G, 2008, THEOR APPL GENET, V118, P57, DOI 10.1007/s00122-008-0876-2
   Mangin B, 1999, GENETICS, V151, P1165
   Mejia L., 2009, RPT TOMATO GENETIC C, V59, P32
   Merk HL, 2011, PLANT BREED IN PRESS
   Miao LX, 2009, MOL BIOL REP, V36, P479, DOI 10.1007/s11033-007-9204-1
   Moon H, 2007, CROP SCI, V47, P1887, DOI 10.2135/cropsci2007.01.0002
   Moreau P, 1998, MOL PLANT MICROBE IN, V11, P259, DOI 10.1094/MPMI.1998.11.4.259
   Mutlu N, 2008, THEOR APPL GENET, V117, P1303, DOI 10.1007/s00122-008-0864-6
   Ohmori T, 1996, THEOR APPL GENET, V92, P151, DOI 10.1007/BF00223369
   Ori N, 1997, PLANT CELL, V9, P521
   Panthee DR, 2010, HORTSCIENCE, V45, P1547
   Peirce L. C, 1971, REP TOMATO GENET COO, V21, P30
   Pillen K, 1996, GENOME MAPPING PLANT, P281
   Robbins MD, 2010, HORTSCIENCE, V45, P1424
   Rosello S, 2001, EUPHYTICA, V119, P357, DOI 10.1023/A:1017506213974
   Saidi M, 2008, CZECH J GENET PLANT, V44, P83, DOI 10.17221/47/2008-CJGPB
   Scott JW, 2008, ACTA HORTIC, V789, P21
   Scott J. W., 1988, Proceedings of the Florida State Horticultural Society, V101, P390
   Scott JW, 2004, J AM SOC HORTIC SCI, V129, P394
   SCOTT JW, 2005, P 1 INT S TOM DIS, V695, P161
   Scott JW, 2007, GENETIC IMPROVEMENT, V2, P457
   SEAH S, 2007, REPORT TOMATO GENETI, V57, P37
   Sela-Buurlage MB, 2001, MOL GENET GENOMICS, V265, P1104, DOI 10.1007/s004380100509
   Smiech M, 2000, ACTA PHYSIOL PLANT, V22, P299, DOI 10.1007/s11738-000-0039-9
   Sobir Ohmori T, 2000, THEOR APPL GENET, V101, P64
   STEVENS MR, 1995, THEOR APPL GENET, V90, P451, DOI 10.1007/BF00221989
   STEVENS MR, 1992, EUPHYTICA, V59, P9
   TANKSLEY SD, 1992, GENETICS, V132, P1141
   TANKSLEY SD, 1983, PLANT MOL BIOL REP, V1, P3, DOI DOI 10.1007/BF02680255
   Thoquet P, 1996, MOL PLANT MICROBE IN, V9, P837, DOI 10.1094/MPMI-9-0837
   USDA-NASS, 2008, AGR STAT
   Wang JF, 2000, MOL PLANT MICROBE IN, V13, P6, DOI 10.1094/MPMI.2000.13.1.6
   Williamson VM, 1998, ANNU REV PHYTOPATHOL, V36, P277, DOI 10.1146/annurev.phyto.36.1.277
   WILLIAMSON VM, 1994, THEOR APPL GENET, V87, P757, DOI 10.1007/BF00221126
   Yaghoobi J, 2005, MOL GENET GENOMICS, V274, P60, DOI 10.1007/s00438-005-1149-2
   Yang W., 2007, GENETIC IMPROVEMENT, V2, P379
   YOUNG ND, 1988, GENETICS, V120, P579
   Zaccardelli M, 2008, ACTA HORTIC, V789, P147
NR 71
TC 10
Z9 11
U1 3
U2 74
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0014-2336
EI 1573-5060
J9 EUPHYTICA
JI Euphytica
PD MAR
PY 2012
VL 184
IS 2
BP 165
EP 179
DI 10.1007/s10681-011-0544-5
PG 15
WC Agronomy; Plant Sciences; Horticulture
SC Agriculture; Plant Sciences
GA 912GP
UT WOS:000301783700002
DA 2018-12-27
ER

PT J
AU Muramatsu, T
   Matsushita, K
   Yamashita, K
   Kondo, T
   Maeda, K
   Shintani, S
   Ichimiya, S
   Ohno, M
   Sone, T
   Ikeda, N
   Watarai, M
   Murohara, T
AF Muramatsu, Takashi
   Matsushita, Kunihiro
   Yamashita, Kentaro
   Kondo, Takahisa
   Maeda, Kengo
   Shintani, Satoshi
   Ichimiya, Satoshi
   Ohno, Miyoshi
   Sone, Takahito
   Ikeda, Nobuo
   Watarai, Masato
   Murohara, Toyoaki
CA NAGOYA HEART Study Investigators
TI RETRACTED: Comparison Between Valsartan and Amlodipine Regarding
   Cardiovascular Morbidity and Mortality in Hypertensive Patients With
   Glucose Intolerance NAGOYA HEART Study (Retracted article. See vol. 72,
   pg. E37, 2018)
SO HYPERTENSION
LA English
DT Article; Retracted Publication
DE angiotensin II type 1 receptor blocker; calcium channel blocker;
   cardiovascular disease; diabetes mellitus; hypertension; impaired
   glucose tolerance
ID ANTIHYPERTENSIVE SURVIVAL EVALUATION; ANGIOTENSIN-ALDOSTERONE SYSTEM;
   DIABETES-MELLITUS; RANDOMIZED-TRIAL; CLINICAL EVENTS; BLOOD-PRESSURE;
   DISEASE; RISK; OUTCOMES; NEPHROPATHY
AB It has not been fully examined whether angiotensin II receptor blocker is superior to calcium channel blocker to reduce cardiovascular events in hypertensive patients with glucose intolerance. A prospective, open-labeled, randomized, controlled trial was conducted for Japanese hypertensive patients with type 2 diabetes mellitus or impaired glucose tolerance. A total of 1150 patients (women: 34%; mean age: 63 years; diabetes mellitus: 82%) were randomly assigned to receive either valsartan-or amlodipine-based antihypertensive treatment. Primary outcome was a composite of acute myocardial infarction, stroke, coronary revascularization, admission attributed to heart failure, or sudden cardiac death. Blood pressure was 145/82 and 144/81 mm Hg, and glycosylated hemoglobin was 7.0% and 6.9% at baseline in the valsartan group and the amlodipine group, respectively. Both of them were equally controlled between the 2 groups during the study. The median follow-up period was 3.2 years, and primary outcome had occurred in 54 patients in the valsartan group and 56 in the amlodipine group (hazard ratio: 0.97 [95% CI: 0.66-1.40]; P=0 .85). Patients in the valsartan group had a significantly lower incidence of heart failure than in the amlodipine group (hazard ratio: 0.20 [95% CI: 0.06-0.69]; P=0.01). Other components and all-cause mortality were not significantly different between the 2 groups. Composite cardiovascular outcomes were comparable between the valsartan-and amlodipine-based treatments in Japanese hypertensive patients with glucose intolerance. Admission because of heart failure was significantly less in the valsartan group. (Hypertension. 2012; 59: 580-586.). Online Data Supplement
C1 [Muramatsu, Takashi; Matsushita, Kunihiro; Yamashita, Kentaro; Kondo, Takahisa; Maeda, Kengo; Shintani, Satoshi; Murohara, Toyoaki] Nagoya Univ, Grad Sch Med, Dept Cardiol, Showa Ku, Nagoya, Aichi 4668550, Japan.
   [Ichimiya, Satoshi] Yokkaichi Municipal Hosp, Yokaichi, Japan.
   [Ohno, Miyoshi] Japanese Red Cross Nagoya First Hosp, Nagoya, Aichi, Japan.
   [Sone, Takahito] Ogaki Municipal Hosp, Ogaki, Japan.
   [Ikeda, Nobuo] Chunichi Hosp, Nagoya, Aichi, Japan.
   [Watarai, Masato] Anjo Kosei Hosp, Anjo, Japan.
RP Murohara, T (reprint author), Nagoya Univ, Grad Sch Med, Dept Cardiol, Showa Ku, 65 Tsurumai, Nagoya, Aichi 4668550, Japan.
EM murohara@med.nagoya-u.ac.jp
RI Murohara, Toyoaki/M-4958-2014; Matsushita, Kunihiro/B-1021-2018;
   Hirashiki, Akihiro/M-4855-2014; Kondo, Takahisa/M-4918-2014
OI Matsushita, Kunihiro/0000-0002-7179-718X; Hirashiki,
   Akihiro/0000-0002-3234-3177; Takeshita, Kyosuke/0000-0002-8283-3799
FU Nagoya University, Graduate School of Medicine; Actelion; Astellas;
   Bayer; Boehringer Ingelheim; Chugai; Daiichi Sankyo; Dainippon Sumitomo;
   Eisai; Fuji Film RI; Kaken; Kowa; Kureha; Medtronic; Mitsubishi Tanabe;
   Mochida; MSD; Novartis; Pfizer; Sanofi-Aventis; Schering-Plough; Takeda;
   Novartis Pharma
FX The NAGOYA HEART Study was funded by Nagoya University Graduate School
   of Medicine. The Department of Cardiology, Nagoya University Graduate
   School of Medicine, reported receiving research promotion grants
   (Shougaku Kifukin) from Actelion, Astellas, Bayer, Boehringer Ingelheim,
   Chugai, Daiichi Sankyo, Dainippon Sumitomo, Eisai, Fuji Film RI, Kaken,
   Kowa, Kureha, Medtronic, Mitsubishi Tanabe, Mochida, MSD, Novartis,
   Pfizer, Sanofi-Aventis, Schering-Plough, and Takeda. However, the
   research topics of these donation grants are not restricted.; To.M.
   received lecturer's fees from Daiichi Sankyo, Novartis Pharma, Pfizer,
   and Takeda.
CR Afridi I, 2003, J HYPERTENS, V21, P1983, DOI 10.1097/01.hjh.0000084751-37215.d2
   American Diabetes Association, 2004, Diabetes Care, V27 Suppl 1, pS15
   Arauz-Pacheco Carlos, 2004, Diabetes Care, V27 Suppl 1, pS65
   Balkau B, 2007, CIRCULATION, V116, P1942, DOI 10.1161/CIRCULATIONAHA.106.676379
   Berl T, 2003, ANN INTERN MED, V138, P542, DOI 10.7326/0003-4819-138-7-200304010-00010
   Bhatt DL, 2010, JAMA-J AM MED ASSOC, V304, P1350, DOI 10.1001/jama.2010.1322
   Borch-Johnsen K, 2001, ARCH INTERN MED, V161, P397
   Brenner BM, 2001, NEW ENGL J MED, V345, P861, DOI 10.1056/NEJMoa011161
   Burnier M, 2006, J HYPERTENS, V24, P11, DOI 10.1097/01.hjh.0000191244.91314.9d
   Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2
   Cooper ME, 2001, AM J HYPERTENS, V14, P475, DOI 10.1016/S0895-7061(00)01323-6
   Curb JD, 1996, JAMA-J AM MED ASSOC, V276, P1886, DOI 10.1001/jama.276.23.1886
   Estacio RO, 1998, NEW ENGL J MED, V338, P645, DOI 10.1056/NEJM199803053381003
   Gerstein HC, 2000, LANCET, V355, P253
   Hansson L, 1992, Blood Press, V1, P113, DOI 10.3109/08037059209077502
   Japan Diabetes Society, 2007, TREATM GUID DIAB 200
   Julius S, 2004, LANCET, V363, P2022, DOI 10.1016/S0140-6736(04)16451-9
   Kubo M, 2003, STROKE, V34, P2349, DOI 10.1161/01.STR.0000090348.52943.A2
   Kurokawa Kiyoshi, 2006, Clin Exp Nephrol, V10, P193, DOI 10.1007/s10157-006-0427-6
   Leenen FHH, 2006, HYPERTENSION, V48, P374, DOI 10.1161/01.HYP.0000231662.77359.de
   Lewis EJ, 2001, NEW ENGL J MED, V345, P851, DOI 10.1056/NEJMoa011303
   Mancia G, 2007, EUR HEART J, V28, P1462, DOI 10.1093/eurheartj/ehm236
   Matsushita K, 2010, J CARDIOL, V56, P111, DOI 10.1016/j.jjcc.2010.03.004
   McMurray JJ, 2010, NEW ENGL J MED, V362, P1477, DOI 10.1056/NEJMoa1001121
   Mochizuki S, 2007, LANCET, V369, P1431, DOI 10.1016/S0140-6736(07)60669-2
   Nakao K, 2010, HYPERTENS RES, V33, P600, DOI 10.1038/hr.2010.38
   Ogihara T, 2008, HYPERTENSION, V51, P393, DOI 10.1161/HYPERTENSIONAHA.107.098475
   Ogihara T, 2009, HYPERTENS RES, V32, P3, DOI 10.1038/hr.2008.15
   Perkins JM, 2008, CURR OPIN ENDOCRINOL, V15, P147, DOI 10.1097/MED.0b013e3282f7026f
   Sawada T, 2009, EUR HEART J, V30, P2461, DOI 10.1093/eurheartj/ehp363
   Tatti P, 1998, DIABETES CARE, V21, P597, DOI 10.2337/diacare.21.4.597
   Tominaga M, 1999, DIABETES CARE, V22, P920, DOI 10.2337/diacare.22.6.920
   Turnbull F, 2005, ARCH INTERN MED, V165, P1410
   Turnbull F, 2003, LANCET, V362, P1527
   Turner RC, 1998, BMJ-BRIT MED J, V316, P823, DOI 10.1136/bmj.316.7134.823
   Ueshima H, 2007, J ATHEROSCLER THROMB, V14, P278, DOI 10.5551/jat.E529
   Volpe M, 2009, J HYPERTENS, V27, P941, DOI 10.1097/HJH.0b013e32832961ed
   Weber MA, 2004, LANCET, V363, P2049, DOI 10.1016/S0140-6736(04)16456-8
   Yusuf S, 2001, JAMA-J AM MED ASSOC, V286, P1882, DOI 10.1001/jama.286.15.1882
NR 39
TC 34
Z9 37
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0194-911X
EI 1524-4563
J9 HYPERTENSION
JI Hypertension
PD MAR
PY 2012
VL 59
IS 3
BP 580
EP U126
DI 10.1161/HYPERTENSIONAHA.111.184226
PG 12
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 911KF
UT WOS:000301715000020
PM 22232134
OA Bronze
DA 2018-12-27
ER

PT J
AU Valastyan, S
AF Valastyan, Scott
TI RETRACTED: Roles of MicroRNAs and Other Non-coding RNAs in Breast Cancer
   Metastasis (Retracted article. See vol. 21, pg. 151, 2016)
SO JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA
LA English
DT Article; Retracted Publication
DE MicroRNA; Metastasis; Breast cancer; Cancer stem cells;
   Epithelial-mesenchymal transition; miR-31; miR-200
ID MESENCHYMAL TRANSITION; TUMOR-METASTASIS; MIR-200 FAMILY; IN-VIVO;
   INVASION; CELLS; SUPPRESSION; EXPRESSION; MODEL; TUMORIGENICITY
AB Despite the fact that metastases are responsible for the overwhelming majority of human cancer deaths, our comprehension of the molecular events that drive metastatic progression remains woefully incomplete. Excitingly, the recent appreciation that various species of non-coding RNAs-including microRNAs-play pivotal roles in dictating the malignant behaviors of breast carcinoma cells promises to afford new insights into the molecular circuitry that determines metastatic propensity. Here, I summarize our current knowledge regarding these still-emerging functions for non-coding RNAs in the pathogenesis of breast cancer metastasis, with an emphasis placed upon the roles played by microRNAs in these processes. Additionally, I discuss the potential translational opportunities afforded by these research findings for the diagnosis and treatment of human breast tumors. When assessed collectively, it is apparent that although this field of research is still in its infancy, comprehension of the biological actions of microRNAs and other non-coding RNAs will hold important consequences for our understanding of the etiology of metastatic disease, as well as its clinical management and treatment.
C1 Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.
RP Valastyan, S (reprint author), Harvard Univ, Sch Med, Dept Cell Biol, 200 Longwood Ave, Boston, MA 02115 USA.
EM scott_valastyan@hms.harvard.edu
RI Xie, Huangming/B-2260-2012
FU NIH; U.S. Department of Defense; Damon Runyon Cancer Research Foundation
FX The author's research is supported by the NIH, U.S. Department of
   Defense, and Damon Runyon Cancer Research Foundation. S. V. is the Harry
   Kriegel Fellow of the Damon Runyon Cancer Research Foundation. S. V. is
   an inventor on patent applications based in part on findings pertaining
   to miR-31 detailed in this manuscript.
CR Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871
   American Cancer Society, 2009, CANC FACTS FIG 2009
   Asangani IA, 2008, ONCOGENE, V27, P2128, DOI 10.1038/sj.onc.1210856
   Baffa R, 2009, J PATHOL, V219, P214, DOI 10.1002/path.2586
   Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002
   Calin GA, 2007, CANCER CELL, V12, P215, DOI 10.1016/j.ccr.2007.07.027
   Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997
   Carmeliet P, 2011, NAT REV DRUG DISCOV, V10, P417, DOI 10.1038/nrd3455
   Cimmino A, 2005, P NATL ACAD SCI USA, V102, P13944, DOI 10.1073/pnas.0506654102
   Clevers H, 2011, NAT MED, V17, P313, DOI 10.1038/nm.2304
   Dykxhoorn DM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007181
   Elmen J, 2008, NATURE, V452, P896, DOI 10.1038/nature06783
   Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840
   Fang JH, 2011, HEPATOLOGY, V54, P1729, DOI 10.1002/hep.24577
   Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098
   Foekens JA, 2008, P NATL ACAD SCI USA, V105, P13021, DOI 10.1073/pnas.0803304105
   Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075
   Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722
   Griffiths-Jones S, 2008, NUCLEIC ACIDS RES, V36, pD154, DOI 10.1093/nar/gkm952
   Gupta RA, 2010, NATURE, V464, P1071, DOI 10.1038/nature08975
   He L, 2007, NAT REV CANCER, V7, P819, DOI 10.1038/nrc2232
   Huang QH, 2008, NAT CELL BIOL, V10, P202, DOI 10.1038/ncb1681
   Karreth FA, 2011, CELL, V147, P382, DOI 10.1016/j.cell.2011.09.032
   Kasinski AL, 2011, NAT REV CANCER, V11, P849, DOI 10.1038/nrc3166
   Korpal M, 2008, RNA BIOL, V5, P115, DOI 10.4161/rna.5.3.6558
   Korpal M, 2011, NAT MED, V17, P1101, DOI 10.1038/nm.2401
   Kota J, 2009, CELL, V137, P1005, DOI 10.1016/j.cell.2009.04.021
   Krutzfeldt J, 2005, NATURE, V438, P685, DOI 10.1038/nature04303
   Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702
   Lujambio A, 2008, P NATL ACAD SCI USA, V105, P13556, DOI 10.1073/pnas.0803055105
   Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174
   Ma L, 2010, NAT BIOTECHNOL, V28, P341, DOI 10.1038/nbt.1618
   Ma L, 2010, NAT CELL BIOL, V12, P247, DOI 10.1038/ncb2024
   Martello G, 2010, CELL, V141, P1195, DOI 10.1016/j.cell.2010.05.017
   Pantel K, 2008, NAT REV CANCER, V8, P329, DOI 10.1038/nrc2375
   Penna E, 2011, EMBO J, V30, P1990, DOI 10.1038/emboj.2011.102
   Png KJ, 2012, NATURE, V481, P190, DOI 10.1038/nature10661
   Prensner JR, 2011, CANCER DISCOV, V1, P391, DOI 10.1158/2159-8290.CD-11-0209
   Salmena L, 2011, CELL, V146, P353, DOI 10.1016/j.cell.2011.07.014
   Shimono Y, 2009, CELL, V138, P592, DOI 10.1016/j.cell.2009.07.011
   Song B, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-29
   Sotiropoulou G, 2009, RNA, V15, P1443, DOI 10.1261/rna.1534709
   Takeshita F, 2010, MOL THER, V18, P181, DOI 10.1038/mt.2009.207
   Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487
   Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007
   Tili E, 2009, INT REV IMMUNOL, V28, P264, DOI 10.1080/08830180903093796
   Trang P, 2010, ONCOGENE, V29, P1580, DOI 10.1038/onc.2009.445
   Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024
   Valastyan S, 2011, GENE DEV, V25, P646, DOI 10.1101/gad.2004211
   Valastyan S, 2009, CELL CYCLE, V8, P3506, DOI 10.4161/cc.8.21.9802
   Valastyan S, 2009, GENE DEV, V23, P2592, DOI 10.1101/gad.1832709
   Valastyan S, 2009, CELL, V137, P1032, DOI 10.1016/j.cell.2009.03.047
   Ventura A, 2009, CELL, V136, P586, DOI 10.1016/j.cell.2009.02.005
   Webster RJ, 2009, J BIOL CHEM, V284, P5731, DOI 10.1074/jbc.M804280200
   Wellner U, 2009, NAT CELL BIOL, V11, P1487, DOI 10.1038/ncb1998
   Wiggins JF, 2010, CANCER RES, V70, P5923, DOI 10.1158/0008-5472.CAN-10-0655
   Wu HL, 2009, CELL RES, V19, P439, DOI 10.1038/cr.2009.18
   Yu F, 2007, CELL, V131, P1109, DOI 10.1016/j.cell.2007.10.054
NR 58
TC 16
Z9 18
U1 2
U2 8
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1083-3021
EI 1573-7039
J9 J MAMMARY GLAND BIOL
JI J. Mammary Gland Biol. Neoplasia
PD MAR
PY 2012
VL 17
IS 1
BP 23
EP 32
DI 10.1007/s10911-012-9241-9
PG 10
WC Oncology; Endocrinology & Metabolism; Physiology
SC Oncology; Endocrinology & Metabolism; Physiology
GA 913AZ
UT WOS:000301845000004
PM 22293951
DA 2018-12-27
ER

PT J
AU Duval, BD
   Blankinship, JC
   Dijkstra, P
   Hungate, BA
AF Duval, Benjamin D.
   Blankinship, Joseph C.
   Dijkstra, Paul
   Hungate, Bruce A.
TI RETRACTED: CO2 effects on plant nutrient concentration depend on plant
   functional group and available nitrogen: a meta-analysis (Retracted
   article. See vol. 216, pg. 1675, 2015)
SO PLANT ECOLOGY
LA English
DT Article; Retracted Publication
DE Elevated CO2; Meta-analysis; Nitrogen status; Nutrients; Plant nutrition
ID ELEVATED ATMOSPHERIC CO2; CARBON-DIOXIDE ENRICHMENT; SCRUB-OAK
   ECOSYSTEM; GRAIN QUALITY; ELEMENT INTERACTIONS; SOIL CARBON; STRUCTURAL
   CHARACTERISTICS; MINERAL CONCENTRATION; PHOSPHORUS-NUTRITION;
   CHEMICAL-COMPOSITION
AB Elevated CO2 is expected to lower plant nutrient concentrations via carbohydrate dilution and increased nutrient use efficiency. Elevated CO2 consistently lowers plant foliar nitrogen, but there is no consensus on CO2 effects across the range of plant nutrients. We used meta-analysis to quantify elevated CO2 effects on leaf, stem, root, and seed concentrations of B, Ca, Cu, Fe, K, Mg, Mn, P, S, and Zn among four plant functional groups and two levels of N fertilization. CO2 effects on plant nutrient concentration depended on the nutrient, plant group, tissue, and N status. CO2 reduced B, Cu, Fe, and Mg, but increased Mn concentration in the leaves of N-2 fixers. Elevated CO2 increased Cu, Fe, and Zn, but lowered Mn concentration in grass leaves. Tree leaf responses were strongly related to N status: CO2 significantly decreased Cu, Fe, Mg, and S at high N, but only Fe at low N. Elevated CO2 decreased Mg and Zn in crop leaves grown with high N, and Mn at low N. Nutrient concentrations in crop roots were not affected by CO2 enrichment, but CO2 decreased Ca, K, Mg and P in tree roots. Crop seeds had lower S under elevated CO2. We also tested the validity of a "dilution model." CO2 reduced the concentration of plant nutrients 6.6% across nutrients and plant groups, but the reduction is less than expected (18.4%) from carbohydrate accumulation alone. We found that elevated CO2 impacts plant nutrient status differently among the nutrient elements, plant functional groups, and among plant tissues. Our synthesis suggests that differences between plant groups and plant organs, N status, and differences in nutrient chemistry in soils preclude a universal hypothesis strictly related to carbohydrate dilution regarding plant nutrient response to elevated CO2.
C1 [Duval, Benjamin D.; Dijkstra, Paul; Hungate, Bruce A.] Univ Arizona, Dept Biol Sci, Flagstaff, AZ 86011 USA.
   [Duval, Benjamin D.; Dijkstra, Paul; Hungate, Bruce A.] Merriam Powell Ctr Environm Res, Flagstaff, AZ 86011 USA.
   [Blankinship, Joseph C.] Univ Calif Merced, Sch Nat Sci, Merced, CA 95343 USA.
RP Duval, BD (reprint author), Univ Illinois, Energy Biosci Inst, Urbana, IL 61801 USA.
EM bdduval@illinois.edu
RI Hungate, Bruce/F-8991-2011
OI Hungate, Bruce/0000-0002-7337-1887
FU National Science Foundation-IGERT
FX The authors sincerely thank Drs. Irakli Loladze, Andreas Fangmeier,
   Nicole Geissler, and their colleagues for sharing data. Dr. George Koch
   and Christina Bentrup provided enlightening conversations that clarified
   the interpretation of our results, and Dr. Walter G. Whitford provided
   valuable comments on an earlier manuscript. Dr. Craig Osenberg helped in
   clarifying variance calculations in the use of meta-analysis. J.
   Bradford McArtor contributed valuable infrastructure to B.D.D. A
   National Science Foundation-IGERT Fellowship supported B.D.D. during the
   preparation of the manuscript.
CR Adriano D. C, 2001, TRACE ELEMENTS TERRE
   Almeida JPF, 1999, PLANT SOIL, V210, P159, DOI 10.1023/A:1004625801141
   BARNES JD, 1992, NEW PHYTOL, V121, P403, DOI 10.1111/j.1469-8137.1992.tb02940.x
   Baxter R, 1997, J EXP BOT, V48, P1477, DOI 10.1093/jxb/48.7.1477
   BAXTER R, 1994, J EXP BOT, V45, P1267, DOI 10.1093/jxb/45.9.1267
   BAZZAZ FA, 1990, ANNU REV ECOL SYST, V21, P167, DOI 10.1146/annurev.es.21.110190.001123
   Blank RR, 2006, INT J WILDLAND FIRE, V15, P227, DOI 10.1071/WF05055
   Blank RR, 2004, PLANT SOIL, V262, P159, DOI 10.1023/B:PLSO.0000037032.43098.5c
   Bloom AJ, 2010, SCIENCE, V328, P899, DOI 10.1126/science.1186440
   Brady N. C, 2002, NATURE PROPERTIES SO
   Campbell CD, 2002, PLANT CELL ENVIRON, V25, P1051, DOI 10.1046/j.1365-3040.2002.00883.x
   Cao WX, 1997, J PLANT NUTR, V20, P871, DOI 10.1080/01904169709365302
   Carney KM, 2007, P NATL ACAD SCI USA, V104, P4990, DOI 10.1073/pnas.0610045104
   Cheng WG, 2009, AGR FOREST METEOROL, V149, P51, DOI 10.1016/j.agrformet.2008.07.006
   Cheng WX, 1998, PLANT SOIL, V202, P167, DOI 10.1023/A:1004315321332
   Cotrufo MF, 1998, GLOB CHANGE BIOL, V4, P43, DOI 10.1046/j.1365-2486.1998.00101.x
   de Graaff MA, 2006, GLOBAL CHANGE BIOL, V12, P2077, DOI 10.1111/j.1365-2486.2006.01240.x
   De la Puente LS, 2000, AGROCHIMICA, V44, P221
   Drake BG, 1997, ANNU REV PLANT PHYS, V48, P609, DOI 10.1146/annurev.arplant.48.1.609
   Duval BD, 2011, ENVIRON SCI TECHNOL, V45, P2570, DOI 10.1021/es102250u
   Ebersberger D, 2003, SOIL BIOL BIOCHEM, V35, P965, DOI 10.1016/S0038-0717(03)00156-1
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Fangmeier A, 1997, ENVIRON POLLUT, V96, P43, DOI 10.1016/S0269-7491(97)00013-4
   Fangmeier A, 2002, EUR J AGRON, V17, P353, DOI 10.1016/S1161-0301(02)00071-0
   Fangmeier A, 1999, EUR J AGRON, V10, P215, DOI 10.1016/S1161-0301(99)00012-X
   Farrar JF, 2000, NEW PHYTOL, V147, P43, DOI 10.1046/j.1469-8137.2000.00688.x
   Finzi AC, 2001, ECOLOGY, V82, P470, DOI 10.1890/0012-9658(2001)082[0470:FLPCAD]2.0.CO;2
   Finzi AC, 2007, P NATL ACAD SCI USA, V104, P14014, DOI 10.1073/pnas.0706518104
   Fuhrer J, 2003, AGR ECOSYST ENVIRON, V97, P1, DOI 10.1016/S0167-8809(03)00125-7
   Geissler N, 2009, J EXP BOT, V60, P137, DOI 10.1093/jxb/ern271
   Goldberg S, 1996, SOIL SCI SOC AM J, V60, P425, DOI 10.2136/sssaj1996.03615995006000020013x
   HEAGLE AS, 1993, NEW PHYTOL, V123, P751, DOI 10.1111/j.1469-8137.1993.tb03786.x
   Hedges LV, 1999, ECOLOGY, V80, P1150, DOI 10.1890/0012-9658(1999)080[1150:TMAORR]2.0.CO;2
   Hogy P, 2009, EUR J AGRON, V30, P85, DOI 10.1016/j.eja.2008.07.006
   Hogy P, 2008, J CEREAL SCI, V48, P580, DOI 10.1016/j.jcs.2008.01.006
   HULUKA G, 1994, AGR FOREST METEOROL, V70, P141, DOI 10.1016/0168-1923(94)90053-1
   Hungate BA, 2003, SCOPE SER, V61, P47
   Hungate BA, 2004, SCIENCE, V304, P1291, DOI 10.1126/science.1095549
   Hungate BA, 1999, GLOBAL CHANGE BIOL, V5, P1
   HUNT R, 1995, ANN BOT-LONDON, V75, P207, DOI 10.1006/anbo.1995.1014
   Intergovernmental Panel on Climate Change, 2007, AR4 INT PAN CLIM CHA
   Jain V, 2007, BIOL PLANTARUM, V51, P559, DOI 10.1007/s10535-007-0122-9
   Jenny H, 1980, SOIL RESOURCE ECOLOG, V37
   Johnson DW, 2004, BIOGEOCHEMISTRY, V69, P379, DOI 10.1023/B:BIOG.0000031054.19158.7c
   Johnson DW, 2003, ECOL APPL, V13, P1388, DOI 10.1890/02-5139
   Kabata-Pendias A., 2001, TRACE ELEMENTS SOILS
   Keutgen N, 2001, J PLANT PHYSIOL, V158, P1307, DOI 10.1078/0176-1617-00564
   KNECHT GN, 1983, J PLANT NUTR, V6, P301, DOI 10.1080/01904168309363091
   Koch KE, 1996, ANNU REV PLANT PHYS, V47, P509, DOI 10.1146/annurev.arplant.47.1.509
   Langley JA, 2009, SOIL BIOL BIOCHEM, V41, P54, DOI 10.1016/j.soilbio.2008.09.016
   LETHIEC D, 1995, TREES-STRUCT FUNCT, V10, P55, DOI 10.1007/BF00192184
   Li J, 2007, PEDOSPHERE, V17, P343, DOI 10.1016/S1002-0160(07)60041-1
   Li ZY, 2010, J HAZARD MATER, V177, P352, DOI 10.1016/j.jhazmat.2009.12.039
   Loladze I, 2002, TRENDS ECOL EVOL, V17, P457, DOI 10.1016/S0169-5347(02)02587-9
   Luo Y, 2004, BIOSCIENCE, V54, P731, DOI 10.1641/0006-3568(2004)054[0731:PNLOER]2.0.CO;2
   Luomala EM, 2005, PLANT CELL ENVIRON, V28, P733, DOI 10.1111/j.1365-3040.2005.01319.x
   Lynch JP, 2001, PLANT SOIL, V237, P225, DOI 10.1023/A:1013324727040
   Ma HL, 2007, PLANT SOIL, V294, P137, DOI 10.1007/s11104-007-9241-5
   MANDERSCHEID R, 1995, AGR ECOSYST ENVIRON, V54, P175, DOI 10.1016/0167-8809(95)00602-O
   Melillo JM, 2003, SCOPE SER, V61, P1
   MORGAN JA, 1994, PLANT SOIL, V165, P139, DOI 10.1007/BF00009970
   Natali SM, 2009, ECOSYSTEMS, V12, P715, DOI 10.1007/s10021-009-9251-7
   NEWBERY RM, 1995, NEW PHYTOL, V130, P565, DOI 10.1111/j.1469-8137.1995.tb04333.x
   Niinemets U, 1999, GLOBAL CHANGE BIOL, V5, P455, DOI 10.1046/j.1365-2486.1999.00241.x
   NORBY RJ, 1986, PLANT PHYSIOL, V82, P83, DOI 10.1104/pp.82.1.83
   Norby RJ, 2005, P NATL ACAD SCI USA, V102, P18052, DOI 10.1073/pnas.0509478102
   Oh NH, 2004, GLOBAL CHANGE BIOL, V10, P1936, DOI 10.1111/j.1365-2486.2004.00864.x
   Oksanen E, 2005, GLOBAL CHANGE BIOL, V11, P732, DOI 10.1111/j.1365-2486.2005.00938.x
   ONEILL EG, 1987, PLANT SOIL, V104, P3, DOI 10.1007/BF02370618
   OVERDIECK D, 1993, VEGETATIO, V104, P403, DOI 10.1007/BF00048169
   Pal M, 2004, AGR ECOSYST ENVIRON, V101, P31, DOI 10.1016/S0167-8809(03)00202-0
   Pal M, 2003, BIOL PLANTARUM, V47, P227
   PEET MM, 1986, PLANT PHYSIOL, V80, P63, DOI 10.1104/pp.80.1.63
   Penuelas J, 2001, GLOBAL CHANGE BIOL, V7, P291, DOI 10.1046/j.1365-2486.2001.00409.x
   Penuelas J, 1997, NEW PHYTOL, V135, P439, DOI 10.1046/j.1469-8137.1997.00676.x
   Pfirrmann T, 1996, NEW PHYTOL, V134, P267, DOI 10.1111/j.1469-8137.1996.tb04631.x
   Piikki K, 2007, AGR ECOSYST ENVIRON, V118, P55, DOI 10.1016/j.agee.2006.04.012
   Polley HW, 2011, PLANT ECOL, V212, P945, DOI 10.1007/s11258-010-9874-y
   Poorter H, 2003, NEW PHYTOL, V157, P175, DOI 10.1046/j.1469-8137.2003.00680.x
   PORTER MA, 1984, PLANT PHYSIOL, V74, P413, DOI 10.1104/pp.74.2.413
   Prior SA, 1998, J PLANT NUTR, V21, P1407, DOI 10.1080/01904169809365492
   Prior SA, 2008, J PLANT NUTR, V31, P758, DOI 10.1080/01904160801928364
   Reich PB, 2006, NATURE, V440, P922, DOI 10.1038/nature04486
   Roberntz P, 1998, TREE PHYSIOL, V18, P233
   Rodenkirchen H, 2009, EUR J FOREST RES, V128, P117, DOI 10.1007/s10342-008-0221-y
   Rosenberg MS, 2000, META WIN VERSION 2 1
   RUBIO F, 1995, SCIENCE, V270, P1660, DOI 10.1126/science.270.5242.1660
   Schlesinger W. H, 1997, BIOGEOCHEMISTRY ANAL
   Seiler TJ, 2009, GLOBAL CHANGE BIOL, V15, P356, DOI 10.1111/j.1365-2486.2008.01740.x
   Seneweera SP, 1997, SOIL SCI PLANT NUTR, V43, P1131
   Shinano T, 2007, TREE PHYSIOL, V27, P97, DOI 10.1093/treephys/27.1.97
   SHIPLEY B, 1992, WATER AIR SOIL POLL, V64, P585, DOI 10.1007/BF00483368
   SILVESTER WB, 1989, SOIL BIOL BIOCHEM, V21, P283, DOI 10.1016/0038-0717(89)90106-5
   Sterner R. W., 2002, ECOLOGICAL STOICHIOM
   Stitt M, 1999, PLANT CELL ENVIRON, V22, P583, DOI 10.1046/j.1365-3040.1999.00386.x
   Suter D, 2002, NEW PHYTOL, V154, P65, DOI 10.1046/j.1469-8137.2002.00368.x
   TAIZ L., 2002, PLANT PHYSL
   Taub DR, 2008, J INTEGR PLANT BIOL, V50, P1365, DOI 10.1111/j.1744-7909.2008.00754.x
   THOMAS RB, 1991, OECOLOGIA, V88, P415, DOI 10.1007/BF00317587
   TREMBLAY N, 1988, J PLANT NUTR, V11, P37, DOI 10.1080/01904168809363783
   Utriainen J, 2000, TREES-STRUCT FUNCT, V14, P475, DOI 10.1007/s004680000062
   van Groenigen KJ, 2006, P NATL ACAD SCI USA, V103, P6571, DOI 10.1073/pnas.0509038103
   VITOUSEK PM, 1991, BIOGEOCHEMISTRY, V13, P87
   Williams RJP, 2002, BIOCHEM BIOPH RES CO, V292, P293, DOI 10.1006/bbrc.2002.6518
   WOODIN S, 1992, NEW PHYTOL, V122, P635
   Woodward FI, 2002, CURR OPIN PLANT BIOL, V5, P207, DOI 10.1016/S1369-5266(02)00253-4
   Wu DX, 2004, AGR ECOSYST ENVIRON, V104, P493, DOI 10.1016/j.agee.2004.01.018
   Yamakawa Y, 2004, PLANT SOIL, V259, P367, DOI 10.1023/B:PLSO.0000020988.18365.b5
NR 108
TC 36
Z9 40
U1 8
U2 164
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1385-0237
EI 1573-5052
J9 PLANT ECOL
JI Plant Ecol.
PD MAR
PY 2012
VL 213
IS 3
BP 505
EP 521
DI 10.1007/s11258-011-9998-8
PG 17
WC Plant Sciences; Ecology; Forestry
SC Plant Sciences; Environmental Sciences & Ecology; Forestry
GA 909VC
UT WOS:000301592600013
DA 2018-12-27
ER

PT J
AU Malik, P
   Kadam, RS
   Cheruvu, NPS
   Kompella, UB
AF Malik, Pradip
   Kadam, Rajendra S.
   Cheruvu, Narayan P. S.
   Kompella, Uday B.
TI RETRACTED: Hydrophilic Prodrug Approach for Reduced Pigment Binding and
   Enhanced Transscleral Retinal Delivery of Celecoxib (Retracted article.
   See vol. 12, pg. 2558, 2015)
SO MOLECULAR PHARMACEUTICS
LA English
DT Article; Retracted Publication
DE celecoxib; prodrugs; transscleral; melanin binding; retinal delivery
ID DIABETIC MACULAR EDEMA; DRUG-DELIVERY; CYCLOOXYGENASE-2 INHIBITOR;
   SELECTIVE INHIBITOR; POSTERIOR SEGMENT; VASCULAR LEAKAGE; GROWTH-FACTOR;
   RAT MODEL; RETINOPATHY; LIPOPHILICITY
AB Transscleral retinal delivery of celecoxib, an anti-inflammatory and anti-VEGF agent, is restricted by its poor solubility and binding to the melanin pigment in choroid-RPE. The purpose of this study was to develop soluble prodrugs of celecoxib with reduced pigment binding and enhanced retinal delivery. Three hydrophilic amide prodrugs of celecoxib, celecoxib succinamidic acid (CSA), celecoxib maleamidic acid (CMA), and celecoxib acetamide (CAA) were synthesized and characterized for solubility and lipophilicity. In vitro melanin binding to natural melanin (Sepia officinalis) was estimated for all three prodrugs. In vitro transport studies across isolated bovine sclera and sclera-choroid-RPE (SCRPE) were performed. Prodrug with the highest permeability across SCRPE was characterized for metabolism and cytotoxicity and its in vivo transscleral delivery in pigmented rats. Aqueous solubilities of CSA, CMA, and CAA were 300-, 182-, and 76-fold higher, respectively, than celecoxib. Melanin binding affinity and capacity were significantly lower than for celecoxib for all three prodrugs. Rank order for the % in vitro transport across bovine sclera and SCRPE was CSA > CMA similar to CAA similar to celecoxib, with the transport being 8-fold higher for CSA than celecoxib. CSA was further assessed for its metabolic stability and in vivo delivery. CSA showed optimum metabolic stability in all eye tissues with only 10-20% conversion to parent celecoxib in 30 min. Metabolic enzymes responsible for bioconversion included amidases, esterase, and cytochrome P-450. In vivo delivery in pigmented BN rats showed that CSA had 4.7-, 1.4-, 3.3-, 6.0-, and 4.5-fold higher delivery to sclera, choroid-RPE, retina, vitreous, and lens than celecoxib. CSA has no cytotoxicity in ARPE-19 cells in the concentration range of 0.1 to 1000 mu M. Celecoxib succinamidic acid, a soluble prodrug of celecoxib with reduced melanin binding, enhances transscleral retinal delivery of celecoxib.
C1 [Kompella, Uday B.] Univ Colorado, Dept Pharmaceut Sci, Aurora, CO 80045 USA.
   [Malik, Pradip; Cheruvu, Narayan P. S.; Kompella, Uday B.] Univ Nebraska Med Ctr, Omaha, NE 68198 USA.
RP Kompella, UB (reprint author), Univ Colorado, Dept Pharmaceut Sci, Anschutz Med Campus,12850 E Montview Blvd, Aurora, CO 80045 USA.
EM uday.kompella@ucdenver.edu
FU NIH [EY018940, EY017533]
FX This work was supported by NIH Grants EY018940 and EY017533. The authors
   also thank Dr. Sunil Vooturi and Ashish Thakur for their help in CSA
   synthesis.
CR Amrite AC, 2006, INVEST OPHTH VIS SCI, V47, P1149, DOI 10.1167/iovs.05-0531
   Amrite A, 2010, EXPERT OPIN DRUG DEL, V7, P631, DOI 10.1517/17425241003663236
   Amrite AC, 2008, J PHARMACOL EXP THER, V324, P749, DOI 10.1124/jpet.107.128918
   Ayalasomayajula SP, 2005, EUR J PHARMACOL, V511, P191, DOI 10.1016/j.ejphar.2005.02.019
   Ayalasomayajula SP, 2004, PHARM RES-DORDR, V21, P1797, DOI 10.1023/B:PHAM.0000045231.51924.e8
   Ayalasomayajula SP, 2003, EUR J PHARMACOL, V458, P283, DOI 10.1016/S0014-2999(02)02793-0
   Benezra D., 1999, OCULAR INFLAMMATION, pxiv
   Blumenkranz MS, 2010, EYE, V24, P428, DOI 10.1038/eye.2009.335
   Callanan D, 2008, CLIN OPHTHALMOL, V2, P689
   Cheruvu NPS, 2008, INVEST OPHTH VIS SCI, V49, P333, DOI 10.1167/iovs.07-0214
   Cheruvu NPS, 2006, INVEST OPHTH VIS SCI, V47, P4513, DOI 10.1167/iovs.06-0404
   Chew Emily Y, 2010, Retina, V30, P459, DOI 10.1097/IAE.0b013e3181bcf1a0
   Clemett D, 2000, DRUGS, V59, P957, DOI 10.2165/00003495-200059040-00017
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Higuchi T., 1975, PRODRUGS NOVEL DRUG, pix
   Kadam RS, 2011, DRUG METAB DISPOS, V39, P1529, DOI 10.1124/dmd.111.040055
   Kadam RS, 2011, INVEST OPHTH VIS SCI, V52, P5387, DOI 10.1167/iovs.10-6233
   Kadam RS, 2010, J PHARMACOL EXP THER, V332, P1107, DOI 10.1124/jpet.109.161570
   Kompella UB, 2003, INVEST OPHTH VIS SCI, V44, P1192, DOI 10.1167/iovs.02-0791
   Kompella UB, 2010, THER DELIV, V1, P435, DOI 10.4155/TDE.10.40
   Lamango NS, 2005, J BIOCHEM MOL TOXIC, V19, P347, DOI 10.1002/jbt.20100
   Lamoureux EL, 2004, ARCH OPHTHALMOL-CHIC, V122, P84, DOI 10.1001/archopht.122.1.84
   Leblanc B, 1998, REGUL TOXICOL PHARM, V28, P124, DOI 10.1006/rtph.1998.1243
   Lee TWY, 2004, J OCUL PHARMACOL TH, V20, P43, DOI 10.1089/108076804772745455
   Mamidi RNVS, 2002, BIOPHARM DRUG DISPOS, V23, P273, DOI 10.1002/bdd.319
   Maurice DM, 2002, SURV OPHTHALMOL, V47, pS41, DOI 10.1016/S0039-6257(02)00326-0
   MAURICE DM, 1978, JPN J OPHTHALMOL, V22, P95
   Miyata N, 2001, BRIT J PHARMACOL, V133, P325, DOI 10.1038/sj.bjp.0704101
   Mohamed Q, 2007, JAMA-J AM MED ASSOC, V298, P902, DOI 10.1001/jama.298.8.902
   MORGAN PH, 1977, J IMMUNOL, V119, P19
   Pasinetti GM, 1998, J NEUROSCI RES, V54, P1
   PENG HM, 1995, ARCH BIOCHEM BIOPHYS, V318, P333, DOI 10.1006/abbi.1995.1237
   Penning TD, 1997, J MED CHEM, V40, P1347, DOI 10.1021/jm960803q
   Qandil AM, 2011, INT J PHARMACEUT, V416, P85, DOI 10.1016/j.ijpharm.2011.06.013
   Rao VR, 2010, INVEST OPHTH VIS SCI, V51, P5198, DOI 10.1167/iovs.09-5144
   Sarich TC, 1999, J PHARMACOL EXP THER, V289, P695
   Sennlaub F, 2003, CIRCULATION, V108, P198, DOI 10.1161/01.CIR.0000080735.93327.00
   Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603
   Stella VJ, 2007, BIOTECHNOL PHARM ASP, V5, P3
   Subbaramaiah K, 1997, P SOC EXP BIOL MED, V216, P201
   Talley JJ, 2000, J MED CHEM, V43, P1661, DOI 10.1021/jm000069h
   Thakur A, 2011, DRUG METAB DISPOS, V39, P771, DOI 10.1124/dmd.110.037408
   Wen H, 2010, PHARM RES-DORDR, V27, P2446, DOI 10.1007/s11095-010-0237-0
   Wilkinson-Berka JL, 2004, CURR PHARM DESIGN, V10, P3331, DOI 10.2174/1381612043383142
   ZANE PA, 1990, PHARMACEUT RES, V7, P935, DOI 10.1023/A:1015997823755
NR 45
TC 5
Z9 5
U1 3
U2 17
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1543-8384
J9 MOL PHARMACEUT
JI Mol. Pharm.
PD MAR
PY 2012
VL 9
IS 3
BP 605
EP 614
DI 10.1021/mp2005164
PG 10
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA 902DG
UT WOS:000301018200026
PM 22256989
OA Green Accepted
DA 2018-12-27
ER

PT J
AU Murdoch, BE
   Kuruvilla, MS
   Goozee, JV
AF Murdoch, Bruce E.
   Kuruvilla, Mili S.
   Goozee, Justine V.
TI RETRACTED: Effect of speech rate manipulations on articulatory dynamics
   in severe traumatic brain injury: An EMA and EPG study (Retracted
   article. See vol. 30, pg. 1041, 2016)
SO BRAIN INJURY
LA English
DT Article; Retracted Publication
DE Traumatic brain injury; articulatory kinematics; speech rate
   manipulations; electromagnetic articulatography; electropalatography
ID DIFFERENT SPEAKING CONDITIONS; ORAL DIADOCHOKINESIS; MUSCLE-ACTIVITY;
   DYSARTHRIA; MOVEMENTS; TASK; CONSONANTS; DISORDERS; STABILITY; VELOCITY
AB Background: Manipulation of speech rate forms an integral part of the treatment of dysarthria and the effects of changes in speech rate on articulatory dynamics in persons with traumatic brain injury (TBI) is poorly documented.
   Objective: To determine the effects of manipulations of speech rate (habitual vs fast) on lingual kinematics and tongue-to-palate contacts in adult speakers with severe TBI and matched normal controls.
   Materials and methods: Six adults with severe TBI and five matched non-neurologically impaired controls underwent testing of their articulatory function using electromagnetic articulography (EMA) and electropalatography (EPG).
   Results: The results demonstrated that the TBI and control groups selected different strategies for increasing speech rate, with the TBI group showing an increase in articulatory effort estimated from an increase in maximum velocity and maximum acceleration/deceleration of tongue movement when speaking at the fast rate. The control group demonstrated no effects of a fast speech rate on articulatory kinematics for sentence productions.
   Conclusions: When speaking at a fast rate, individuals with severe TBI appear to use greater articulatory effort, possibly to preserve the distinctiveness of phonetic segments in order to avoid articulatory undershoot. In contrast, control subjects show a greater economy of effort when speaking at a fast rate, possibly to preserve articulatory precision.
C1 [Murdoch, Bruce E.; Goozee, Justine V.] Univ Queensland, Ctr Neurogen Commun Disorders Res, St Lucia, Qld, Australia.
   [Kuruvilla, Mili S.] Munroe Meyer Inst Genet & Rehabil, Neurogenet Commun Disorders Ctr, Omaha, NE USA.
RP Murdoch, BE (reprint author), Third Mil Med Univ, Dept Neurobiol, Coll Basic Med Sci, Chongqing Key Lab Neurobiol, Chongqing 400038, Peoples R China.
EM b.murdoch@uq.edu.au
RI Murdoch, Bruce/C-1397-2012
OI Kuruvilla-Dugdale, Mili/0000-0001-7900-2364
FU Motor Accident Insurance Commission of Queensland, Australia
FX This work was supported by a research grant from the Motor Accident
   Insurance Commission of Queensland, Australia. The authors report no
   conflicts of interest. The authors alone are responsible for the content
   and writing of the paper.
CR ACKERMANN H, 1995, FOLIA PHONIATR LOGO, V47, P15, DOI 10.1159/000266338
   BLUMBERGER J, 1995, BRAIN INJURY, V9, P797, DOI 10.3109/02699059509008235
   BROOKS VB, 1986, NEURAL BASIS MOTOR C
   CAMPBELL TF, 1995, J SPEECH HEAR RES, V38, P864, DOI 10.1044/jshr.3804.864
   DENIL LF, 1991, J ACOUST SOC AM, V89, P845, DOI 10.1121/1.1894645
   Dromey C, 1998, J SPEECH LANG HEAR R, V41, P1003, DOI 10.1044/jslhr.4105.1003
   Ewing-Cobbs L, 1990, TRAUMATIC BRAIN INJU, P107
   FLEGE JE, 1988, J ACOUST SOC AM, V84, P901, DOI 10.1121/1.396659
   GAY T, 1973, PHONETICA, V27, P44, DOI 10.1159/000259425
   GAY T, 1981, PHONETICA, V38, P148, DOI 10.1159/000260020
   GIBBON F, 1990, BRIT J DISORD COMMUN, V25, P329
   Goozee JV, 2003, CLIN LINGUIST PHONET, V17, P375, DOI 10.1080/0269920031000079967
   Goozee JV, 2000, THESIS U QUEENSLAND
   Hall KD, 1997, INT CONGR SER, V1146, P547
   HARDCASTLE WJ, 1991, BRIT J DISORD COMMUN, V26, P41
   Jaeger M, 2000, FOLIA PHONIATR LOGO, V52, P187, DOI 10.1159/000021533
   Kent RD, 2000, FOLIA PHONIATR LOGO, V52, P48, DOI 10.1159/000021512
   KENT RD, 1972, J SPEECH HEAR RES, V15, P453, DOI 10.1044/jshr.1503.453
   Kleinow J, 2001, J SPEECH LANG HEAR R, V44, P1041, DOI 10.1044/1092-4388(2001/082)
   Kuehn D. P, 1976, J PHONETICS, V4, P303
   LINDBLOM B, 1963, J ACOUST SOC AM, V35, P1773, DOI 10.1121/1.1918816
   Lindblom B, 1988, C LANG CHANG BIOL EV
   McClean MD, 2003, J SPEECH LANG HEAR R, V46, P1387, DOI 10.1044/1092-4388(2003-108)
   MCHENRY M, 1994, BRAIN INJURY, V8, P363, DOI 10.3109/02699059409150987
   Murdoch B. E., 1987, AUSTR J HUMAN COMMUN, V15, P15
   NELSON WL, 1983, BIOL CYBERN, V46, P135, DOI 10.1007/BF00339982
   OSTRY DJ, 1985, J ACOUST SOC AM, V77, P640, DOI 10.1121/1.391882
   Perkell JS, 2002, J ACOUST SOC AM, V112, P1642, DOI 10.1121/1.1506368
   Perkell JS, 2002, J ACOUST SOC AM, V112, P1627, DOI 10.1121/1.1506369
   Scott D, 2002, EPGLAB MANUAL UNPUB
   Smith A, 2000, J SPEECH LANG HEAR R, V43, P521, DOI 10.1044/jslhr.4302.521
   SMITH A, 1995, EXP BRAIN RES, V104, P493
   Sonoda Y, 1986, J ACOUSTICAL SOC JAP, V7, P51
   Tasko SM, 2004, J SPEECH LANG HEAR R, V47, P85, DOI 10.1044/1092-4388(2004/008)
   Theodoros DG, 2001, TRAUMATIC BRAIN INJU, P155
   Wang YT, 2005, J COMMUN DISORD, V38, P231, DOI 10.1016/j.jcomdis.2004.12.001
   Wang YT, 2004, CLIN LINGUIST PHONET, V18, P57, DOI 10.1080/02699200310001596160
   Weismer G, 2000, FOLIA PHONIATR LOGO, V52, P201, DOI 10.1159/000021536
   Westbury J. R., 1993, ANN B RES I LOGOPEDI, V27, P13
   Wohlert AB, 2000, J SPEECH LANG HEAR R, V43, P1229, DOI 10.1044/jslhr.4305.1229
   Yorkston KM, 1991, CLIN MANAGEMENT DYSA
   ZIEGLER W, 1993, J SPEECH HEAR RES, V36, P683, DOI 10.1044/jshr.3604.683
   Ziegler W, 2002, BRAIN LANG, V80, P556, DOI 10.1006/brln.2001.2614
NR 43
TC 3
Z9 4
U1 3
U2 19
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0269-9052
EI 1362-301X
J9 BRAIN INJURY
JI Brain Inj.
PD MAR
PY 2012
VL 26
IS 3
BP 241
EP 260
DI 10.3109/02699052.2011.650664
PG 20
WC Neurosciences; Rehabilitation
SC Neurosciences & Neurology; Rehabilitation
GA 899XD
UT WOS:000300849100005
PM 22372412
DA 2018-12-27
ER

PT J
AU Gao, M
   Wu, WH
   Wu, FC
AF Gao, Ming
   Wu, Weihong
   Wu, Fachao
TI RETRACTED: Thermal degradation and flame retardance of epoxy resins
   containing a microencapsulated flame retardant (Retracted article. See
   vol. 18, pg. 267, 2012)
SO JOURNAL OF VINYL & ADDITIVE TECHNOLOGY
LA English
DT Article; Retracted Publication
ID POLYPROPYLENE; AGENT; FIRE
AB Two steps were used in the synthesis of a microencapsulated intumescent flame retardant (MIFR). First bis (1-oxo-2,6,7-trioxa-l-phosphabicyclo[2.2.2]octane-4-methylol) phosphate melaminium salt (Melabis) was synthesized. Then the Melabis was encapsulated with melamine resin to obtain the MIFR. Its structure was characterized by XPS, SEM, and elemental analysis, and the factors affecting microencapsulation were identified and discussed. Epoxy resins (EP) were modified with the MIFR to prepare flame-retardant EP, whose flammability and burning behavior were characterized by UL 94 and limiting oxygen index (LOI) tests. The microcapsules (20% by weight) were added to EP in order to achieve an LOI of 29.5% and a UL 94 rating of V-0. The thermal properties of epoxy resins containing the MIFR were investigated by thermogravimetry (TG) and differential thermogravimetry (DTG). The FR decreased by weight loss, Rmax (the maximum weight loss rate), and the thermal stability of EP while promoting the formation of an effective charring layer. The char structures were studied by SEM. J. VINYL ADDIT. TECHNOL., 2012. (c) 2012 Society of Plastics Engineers
C1 [Gao, Ming; Wu, Fachao] N China Inst Sci & Technol, Dept Environm Engn, Beijing 101601, Peoples R China.
   [Gao, Ming] China Univ Min & Technol, Sch Chem & Environm Engn, Beijing 100083, Peoples R China.
   [Wu, Weihong] Agr Univ Hebei, Coll Sci, Baoding 071000, Peoples R China.
RP Gao, M (reprint author), N China Inst Sci & Technol, Dept Environm Engn, Beijing 101601, Peoples R China.
EM gmscy@hotmail.com
FU Post-doctoral Science of China [2011M500446]; Hebei Province Natural
   Science of China [E2011508001]
FX Contract grant sponsor: Post-doctoral Science of China; contract grant
   number: 2011M500446; contract grant sponsor: Hebei Province Natural
   Science of China; contract grant number: E2011508001.
CR Fontaine G, 2008, POLYM DEGRAD STABIL, V93, P68, DOI 10.1016/j.polymdegradstab.2007.10.019
   Gao F, 2006, POLYM DEGRAD STABIL, V91, P1295, DOI 10.1016/j.polymdegradstab.2005.08.013
   Gao M, 2009, J THERM ANAL CALORIM, V95, P605, DOI 10.1007/s10973-008-9766-8
   Gao M, 2006, J FIRE SCI, V24, P499, DOI 10.1177/0734904106061522
   Gao M, 2010, COMBUST SCI TECHNOL, V182, P1446, DOI 10.1080/00102200903490228
   Gao M, 2010, J APPL POLYM SCI, V115, P2346, DOI 10.1002/app.29483
   Halpern Y., 1984, U. S. Patent, Patent No. [4,478,998, 4478998]
   Liu YL, 2001, POLYMER, V42, P3445, DOI 10.1016/S0032-3861(00)00717-5
   Ma ZL, 2006, J APPL POLYM SCI, V101, P739, DOI 10.1002/app.23973
   Pecht M, 2006, MICROELECTRON RELIAB, V46, P53, DOI 10.1016/j.microrel.2005.09.001
   Scandurra A, 2004, APPL SURF SCI, V235, P65, DOI 10.1016/j.apsusc.2004.05.139
   Shieh JY, 2001, POLYMER, V42, P7617, DOI 10.1016/S0032-3861(01)00257-9
   Wang CS, 1999, J POLYM SCI POL CHEM, V37, P3903, DOI 10.1002/(SICI)1099-0518(19991101)37:21<3903::AID-POLA4>3.0.CO;2-X
   Wu CS, 2002, POLYM DEGRAD STABIL, V78, P41, DOI 10.1016/S0141-3910(02)00117-9
   Wu FC, 2011, ADV MATER RES-SWITZ, V197-198, P1346, DOI 10.4028/www.scientific.net/AMR.197-198.1346
   Wu K, 2008, POLYM ADVAN TECHNOL, V19, P1118, DOI 10.1002/pat.1095
   Xing WY, 2009, POLYM ADVAN TECHNOL, V20, P696, DOI 10.1002/pat.1335
NR 17
TC 8
Z9 8
U1 3
U2 39
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1083-5601
EI 1548-0585
J9 J VINYL ADDIT TECHN
JI J. Vinyl Addit. Technol.
PD MAR
PY 2012
VL 18
IS 1
BP 40
EP 45
DI 10.1002/vnl.20301
PG 6
WC Chemistry, Applied; Materials Science, Textiles; Polymer Science
SC Chemistry; Materials Science; Polymer Science
GA 897RJ
UT WOS:000300672500005
DA 2018-12-27
ER

PT J
AU Gathmann, B
   Binder, N
   Ehl, S
   Kindle, G
AF Gathmann, B.
   Binder, N.
   Ehl, S.
   Kindle, G.
CA ESID Registry Working Party
TI RETRACTED: The European internet-based patient and research database for
   primary immunodeficiencies: update 2011 (Retracted article. See vol.
   169, pg. 70, 2012)
SO CLINICAL AND EXPERIMENTAL IMMUNOLOGY
LA English
DT Article; Retracted Publication
DE epidemiology; ESID; online database; primary immunodeficiency; registry
ID DISEASES; REGISTRY
AB In order to build a common data pool and estimate the disease burden of primary immunodeficiencies (PID) in Europe, the European Society for Immunodeficiencies (ESID) has developed an internet-based database for clinical and research data on patients with PID. This database is a platform for epidemiological analyses as well as the development of new diagnostic and therapeutic strategies and the identification of novel disease-associated genes. Since its start in 2004, 13 708 patients from 41 countries have been documented in the ESID database. Common variable immunodeficiency (CVID) represents the most common entity with 2880 patients or 21% of all entries, followed by selective immunoglobulin A (sIgA) deficiency (1424 patients, 10.4%). The total documented prevalence of PID is highest in France, with five patients per 100 000 inhabitants. The highest documented prevalence for a single disease is 1.3 per 100 000 inhabitants for sIgA deficiency in Hungary. The highest reported incidence of PID per 100 000 live births was 16.2 for the period 1999-2002 in France. The highest reported incidence rate for a single disease was 6.7 for sIgA deficiency in Spain for the period 1999-2002. The genetic cause was known in 36.2% of all registered patients. Consanguinity was reported in 8.8%, and 18.5% of patients were reported to be familial cases; 27.9% of patients were diagnosed after the age of 16. We did not observe a significant decrease in the diagnostic delay for most diseases between 1987 and 2010. The most frequently reported long-term medication is immunoglobulin replacement.
C1 [Gathmann, B.; Ehl, S.; Kindle, G.] Univ Med Ctr Freiburg, CCI, D-79106 Freiburg, Germany.
   [Binder, N.] Univ Med Ctr Freiburg, Inst Med Biometry & Med Informat, D-79106 Freiburg, Germany.
   Univ Freiburg, D-79106 Freiburg, Germany.
RP Gathmann, B (reprint author), Univ Med Ctr Freiburg, CCI, Breisacher Str 116, D-79106 Freiburg, Germany.
EM benjamin.gathmann@uniklinik-freiburg.de
OI Pignata, Claudio/0000-0003-1568-9843; Litzman, Jiri/0000-0002-1926-5426;
   Farmaki, Evangelia/0000-0002-5132-8255; Seidel, Markus
   G/0000-0003-0981-8661; Richter, Darko/0000-0002-6559-9056; Binder,
   Nadine/0000-0002-1919-4154; Bernatowska, Ewa/0000-0002-0125-266X
FU EU [HEALTH-F2-2008-201549]; German BMBF [01GM0896]; PPTA Europe; Federal
   Ministry of Education and Research (BMBF) [01 EO 0803]
FX We are most grateful to all the staff at all medical centres and
   national registries participating in the database project for their
   continuous contribution. The complete list of documenting centres is
   available at http://www.esid.org/centers.php. This work was supported by
   EU grant no. HEALTH-F2-2008-201549 (EURO-PADnet), German BMBF grant
   01GM0896 (PID-NET) as well as by PPTA Europe (http://www.pptaglobal.org)
   sponsorship of ESID. This study was supported by the Federal Ministry of
   Education and Research (BMBF 01 EO 0803). The authors are responsible
   for the contents of this publication.
CR Al-Herz W, 2008, J CLIN IMMUNOL, V28, P186, DOI 10.1007/s10875-007-9144-5
   Albert MH, 2010, BLOOD, V115, P3231, DOI 10.1182/blood-2009-09-239087
   Beaute J, 2010, CLIN IMMUNOL, V135, P264, DOI 10.1016/j.clim.2010.02.021
   Bewick Viv, 2004, Crit Care, V8, P196, DOI 10.1186/cc2857
   Boyle JM, 2007, J CLIN IMMUNOL, V27, P497, DOI 10.1007/s10875-007-9103-1
   Eades-Perner AM, 2007, CLIN EXP IMMUNOL, V147, P306, DOI 10.1111/j.1365-2249.2006.03292.x
   Gathmann B, 2009, CLIN EXP IMMUNOL, V157, P3, DOI 10.1111/j.1365-2249.2009.03954.x
   Geha RS, 2007, J ALLERGY CLIN IMMUN, V120, P776, DOI 10.1016/j.jaci.2007.08.053
   Gennery AR, 2010, J ALLERGY CLIN IMMUN, V126, P602, DOI 10.1016/j.jaci.2010.06.015
   Gennery AR, 2010, J ALLERGY CLIN IMMUN, V126, pe1
   Gliklich RE, 2007, AHRQ PUBLICATION
   Guzman D, 2007, BIOINFORMATICS, V23, P654, DOI 10.1093/bioinformatics/btl675
   Hammarstrom L, 2000, CLIN EXP IMMUNOL, V120, P225, DOI 10.1046/j.1365-2249.2000.01131.x
   Joshi AY, 2009, MAYO CLIN PROC, V84, P16, DOI 10.1016/S0025-6196(11)60802-1
   Kirkpatrick P, 2007, J CLIN IMMUNOL, V27, P517, DOI 10.1007/s10875-007-9105-z
   Lainka E, 2011, RHEUMATOLOGY, V50, P237, DOI 10.1093/rheumatology/keq270
   Micol R, 2011, J ALLERGY CLIN IMMUN, V128, P382, DOI 10.1016/j.jaci.2011.03.052
   Neven B, 2011, BLOOD, V118, P4798, DOI 10.1182/blood-2011-04-347641
   Ozen S, 2011, EUR J PEDIATR, V170, P445, DOI 10.1007/s00431-011-1411-z
   Rosenberg PS, 2006, BLOOD, V107, P4628, DOI 10.1182/blood-2005-11-4370
   Tunis SR, 2010, STAT MED, V29, P1963, DOI 10.1002/sim.3818
NR 21
TC 67
Z9 72
U1 3
U2 19
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0009-9104
J9 CLIN EXP IMMUNOL
JI Clin. Exp. Immunol.
PD MAR
PY 2012
VL 167
IS 3
BP 479
EP 491
DI 10.1111/j.1365-2249.2011.04542.x
PG 13
WC Immunology
SC Immunology
GA 883EU
UT WOS:000299617700012
PM 22288591
OA Bronze, Green Published
DA 2018-12-27
ER

PT J
AU Amsterdam, A
   Shezen, E
   Raanan, C
   Schreiber, L
   Slilat, Y
   Fabrikant, Y
   Melzer, E
   Seger, R
AF Amsterdam, Abraham
   Shezen, Elias
   Raanan, Calanit
   Schreiber, Letizia
   Slilat, Yasmin
   Fabrikant, Yakov
   Melzer, Ehud
   Seger, Rony
TI RETRACTED: Two initiation sites of early detection of colon cancer,
   revealed by localization of pERK1/2 in the nuclei or in aggregates at
   the perinuclear region of tumor cells (Retracted article. See vol. 41,
   pg. 1887, 2012)
SO INTERNATIONAL JOURNAL OF ONCOLOGY
LA English
DT Article; Retracted Publication
DE colon cancer; MAPK; pERK1/2; cancer stem cells; p53; KRAS; epiregulin
ID COLORECTAL-CANCER; EPIREGULIN EXPRESSION; STEM-CELLS; LOW-GRADE;
   AMPHIREGULIN; METASTASIS; CETUXIMAB; TUMORIGENESIS; TRANSLOCATION;
   CARCINOMAS
AB We have used human specimens and antibodies to pERK1/2 to detect early development of colon cancer, using indirect immunocytochemistry. Two distinct sites were stained; one at the tip of the colon villi and the other in the stromal tissue, associated with the colon tissue. These foci represent early stages of colon cancer initiation, as established by enhanced KRAS, and lack of p53 staining. It should be noted, however, that the enhanced KRAS coincides with the initiation of tumor growth revealed by pERK1/2 only in the tip of the colon villi but not in the stromal initiation site of the colon tumors. Interestingly, foci of pERK1/2 staining were also detected within 50% of stromal tissue and tips of colon villi, that were classified as normal tissues, distal from the malignant one according to general morphology. The staining of pERK1/2 at the stromal foci of this apparently non-malignant tissue appeared as aggregates at the perinuclear region, while at the colon epithelium, it appeared at the cell nuclei. At low-grade of colon cancer, that was still free of induced mutated p53, staining of pERK1/2 was prominent at the cell nuclei both at the stroma tissue and the tip of the colon villi. In intermediate stage, that exhibited a significant p53 staining, only a fraction of p53-free tumor cells was labeled with pERK1/2 antibody, while in high-grade tumors, all cells of tumors were labeled with antibodies to p53, but not with pERK1/2. We also found that the cytoplasm of low-grade tumors was positive for epiregulin, while this labeling decreased in high-grade tumors. Interestingly, we found that the tumors initiating from the stroma demonstrated poor structural differentiation, while the tumors initiating from the epithelial cells of the colon demonstrated high structural differentiation. It is concluded that pERK1/2 is a sensitive early marker of colon cancer, which disappears at later stages of cancer development. Moreover, pERK1/2 staining can distinguish between tumor cells originated from the tip of the colon villi and those originated in the stroma, associated with the colon tissue, and thus can assist in selecting the appropriate therapy.
C1 [Amsterdam, Abraham; Slilat, Yasmin] Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.
   [Shezen, Elias] Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel.
   [Raanan, Calanit] Weizmann Inst Sci, Dept Biol Serv, IL-76100 Rehovot, Israel.
   [Seger, Rony] Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel.
   [Schreiber, Letizia] Wolfson Govt Hosp, IL-58100 Holon, Israel.
   [Fabrikant, Yakov; Melzer, Ehud] Kaplan Med Ctr, IL-76100 Rehovot, Israel.
   [Fabrikant, Yakov; Melzer, Ehud] Hebrew Univ Jerusalem, Jerusalem, Israel.
RP Amsterdam, A (reprint author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.
EM abraham.amsterdam@weizmann.ac.il
CR Baba I, 2000, CANCER RES, V60, P6886
   Bae JH, 2010, MOL CELLS, V29, P443, DOI 10.1007/s10059-010-0080-5
   Baselga J, 2001, EUR J CANCER, V37, pS16
   Bokemeyer C, 2008, J CLIN ONCOL, V26, DOI 10.1200/jco.2008.26.15_suppl.4000
   Chuderland D, 2008, MOL CELL, V31, P850, DOI 10.1016/j.molcel.2008.08.007
   Derdak Z, 2006, CARCINOGENESIS, V27, P956, DOI 10.1093/carcin/bgi335
   FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I
   Figueras J, 2001, BRIT J SURG, V88, P980, DOI 10.1046/j.0007-1323.2001.01821.x
   Ginath S, 2001, INT J ONCOL, V18, P1133
   HIGGINS GA, 1975, ANN SURG, V181, P624, DOI 10.1097/00000658-197505000-00017
   Hurwitz HI, 2009, ONCOLOGIST, V14, P22, DOI 10.1634/theoncologist.2008-0213
   Jaaro H, 1997, P NATL ACAD SCI USA, V94, P3742, DOI 10.1073/pnas.94.8.3742
   Jacobs B, 2009, J CLIN ONCOL, V27, P5068, DOI 10.1200/JCO.2008.21.3744
   Jonker DJ, 2007, NEW ENGL J MED, V357, P2040, DOI 10.1056/NEJMoa071834
   Keshet Y, 2010, METHODS MOL BIOL, V661, P3, DOI 10.1007/978-1-60761-795-2_1
   Khambata-Ford S, 2007, J CLIN ONCOL, V25, P3230, DOI 10.1200/JCO.2006.10.5437
   Klump B, 2004, INT J COLORECTAL DIS, V19, P23, DOI 10.1007/s00384-003-0499-7
   Kosakowska EA, 2010, FOLIA HISTOCHEM CYTO, V48, P597, DOI 10.2478/v10042-010-0078-z
   Li XD, 2010, ONKOLOGIE, V33, P353, DOI 10.1159/000315380
   Liu CY, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-359
   Liu HY, 2005, CANCER RES, V65, P7635, DOI 10.1158/0008-5472.CAN-05-1089
   Matsuda T, 2009, WORLD J GASTROENTERO, V15, P2708, DOI 10.3748/wjg.15.2708
   Matsumoto M, 2011, BMC GASTROENTEROL, V11, DOI 10.1186/1471-230X-11-59
   Mayhew TM, 2008, HISTOCHEM CELL BIOL, V130, P299, DOI 10.1007/s00418-008-0451-6
   Medema JP, 2011, NATURE, V474, P318, DOI 10.1038/nature10212
   Nakajima T, 2007, DIS COLON RECTUM, V50, P677, DOI 10.1007/s10350-006-0843-4
   Nishimura T, 2008, ONCOL REP, V19, P105
   O'Neill CJ, 2005, AM J SURG PATHOL, V29, P1034
   Plotnikov A, 2011, BBA-MOL CELL RES, V1813, P1619, DOI 10.1016/j.bbamcr.2010.12.012
   Rembacken BJ, 2000, LANCET, V355, P1211, DOI 10.1016/S0140-6736(00)02086-9
   Shaikh AJ, 2009, ASIAN PAC J CANCER P, V10, P361
   SHIMODA T, 1989, CANCER, V64, P1138, DOI 10.1002/1097-0142(19890901)64:5<1138::AID-CNCR2820640529>3.0.CO;2-A
   Singer G, 2005, AM J SURG PATHOL, V29, P218, DOI 10.1097/01.pas.0000146025.91953.8d
   Ueda K, 2003, ONCOGENE, V22, P5586, DOI 10.1038/sj.onc.1206845
   Vermeulen L, 2008, CELL DEATH DIFFER, V15, P947, DOI 10.1038/cdd.2008.20
   Vermeulen L, 2010, NAT CELL BIOL, V12, P468, DOI 10.1038/ncb2048
   VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901
   WINAWER SJ, 1993, NEW ENGL J MED, V329, P1977, DOI 10.1056/NEJM199312303292701
   Wu WKK, 2009, ANTICANCER RES, V29, P229
   Yao Z, 2009, BIOFACTORS, V35, P407, DOI 10.1002/biof.52
   Zeren T, 2008, ACTA HISTOCHEM, V110, P256, DOI 10.1016/j.acthis.2007.08.007
NR 41
TC 4
Z9 4
U1 2
U2 11
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1019-6439
EI 1791-2423
J9 INT J ONCOL
JI Int. J. Oncol.
PD MAR
PY 2012
VL 40
IS 3
BP 782
EP 788
DI 10.3892/ijo.2011.1268
PG 7
WC Oncology
SC Oncology
GA 890AT
UT WOS:000300118200020
PM 22108866
OA Bronze
DA 2018-12-27
ER

PT J
AU Nocito, MJ
   Luna, PC
   Contardi, ML
   Mazzini, MA
AF Nocito, Mabel J.
   Luna, Paula C.
   Contardi, Maria L.
   Mazzini, Miguel A.
TI RETRACTED: Delleman syndrome: Report of a case in an adolescent
   boy(Retracted article. See vol. 83, pg. 145, 2017)
SO INDIAN JOURNAL OF DERMATOLOGY VENEREOLOGY & LEPROLOGY
LA English
DT Letter; Retracted Publication
C1 [Nocito, Mabel J.; Luna, Paula C.; Mazzini, Miguel A.] Hosp Churruca, Dept Dermatol, Buenos Aires, DF, Argentina.
   [Contardi, Maria L.] Hosp Churruca, Dept Ophtalmol, Buenos Aires, DF, Argentina.
EM jimenanocito@gmail.com
CR ALGAZALI LI, 1988, J MED GENET, V25, P773, DOI 10.1136/jmg.25.11.773
   Arora V, 2009, INDIAN J OPHTHALMOL, V57, P387, DOI 10.4103/0301-4738.55074
   Brugger PC, 2007, PRENATAL DIAG, V27, P356, DOI 10.1002/pd.1676
   Patil SJ, 2006, INDIAN PEDIATR, V43, P173
   Sadhasivam S, 1998, ANESTH ANALG, V87, P553, DOI 10.1097/00000539-199809000-00009
NR 5
TC 2
Z9 2
U1 2
U2 3
PU MEDKNOW PUBLICATIONS & MEDIA PVT LTD
PI MUMBAI
PA B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075,
   INDIA
SN 0378-6323
EI 0973-3922
J9 INDIAN J DERMATOL VE
JI Indian J. Dermatol. Venereol. Leprol.
PD MAR-APR
PY 2012
VL 78
IS 2
DI 10.4103/0378-6323.93662
PG 3
WC Dermatology
SC Dermatology
GA 913EW
UT WOS:000301858600037
PM 22421675
OA DOAJ Gold
DA 2018-12-27
ER

PT J
AU Turkyilmazoglu, M
AF Turkyilmazoglu, Mustafa
TI RETRACTED: MHD fluid flow and heat transfer with varying Prandtl numbers
   due to a rotating disk subject to a uniform radial electric field
   (Retracted article. See vol. 140, pg. 830. 2018)
SO APPLIED THERMAL ENGINEERING
LA English
DT Article; Retracted Publication
DE Electric potential; Radial electric; MHD flow; Rotating disk; Heat
   transfer
ID BOUNDARY-LAYER; MAGNETIC-FIELD; ABSOLUTE INSTABILITY; INJECTION;
   LAMINAR; SUCTION
AB The flow and heat transfer of an incompressible electrically conducting fluid over a rotating infinite disk are studied in the present paper. The disk finds itself subjected to a uniform normal magnetic field. The particular interest lies in searching for the effects of an imposed radial electric field on the behavior of the physical flow. The gradient of an electric potential generated on the disk penetrates through the fluid and greatly influences the boundary layer formation. The presented model representing the fluid motion is a general case since it reduces to the traditional Karman's viscous pump when the electric potential is ignored. The governing Navier-Stokes and Maxwell equations of the constructed model together with the energy equation are converted into self-similar forms using suitable similarity transformations. The flow and thermal boundary layers are shown to be much affected by the presence of a uniform radial electric parameter. Some parameters of fundamental physical significance such as the surface shear stresses in the radial and tangential directions and the heat transfer rate are numerically evaluated. The effects of electric conductivity of the disk and Prandtl number of the fluid on the flow and forced convection heat transfer are further discussed. (C) 2011 Elsevier Ltd. All rights reserved.
C1 Hacettepe Univ, Dept Math, TR-06532 Ankara, Turkey.
RP Turkyilmazoglu, M (reprint author), Hacettepe Univ, Dept Math, TR-06532 Ankara, Turkey.
EM turkyilm@hacettepe.edu.tr
CR Ariel PD, 2002, Z ANGEW MATH MECH, V82, P235, DOI 10.1002/1521-4001(200204)82:4<235::AID-ZAMM235>3.0.CO;2-L
   Attia HA, 2001, APPL MATH MODEL, V25, P1089, DOI 10.1016/S0307-904X(01)00033-6
   AWAD MM, 2008, T ASME J HEAT TRANSF, V130
   BANKS WHH, 1976, ACTA MECH, V24, P273, DOI 10.1007/BF01190376
   BENTON ER, 1966, J FLUID MECH, V24, P781, DOI 10.1017/S0022112066001009
   Cochran WG, 1934, P CAMB PHILOS SOC, V30, P365
   Evans HL, 1968, LAMINAR BOUNDARY LAY
   Hossain MA, 2001, INT J THERM SCI, V40, P11, DOI 10.1016/S1290-0729(00)01183-2
   Jasmine HA, 2005, J ENG MATH, V52, P337, DOI 10.1007/s10665-005-2732-6
   KUMAR SK, 1988, COMPUT FLUIDS, V16, P183, DOI 10.1016/0045-7930(88)90005-9
   LINGWOOD RJ, 1995, J FLUID MECH, V299, P17, DOI 10.1017/S0022112095003405
   MILLSAPS K, 1952, J AERONAUT SCI, V19, P120
   Owen J. M, 1995, ROTATING CAVITIES, V2
   OWEN JM, 1989, ROTOR STATOR SYSTEMS, V1
   PAO HP, 1968, AIAA J, V6, P1285, DOI 10.2514/3.4735
   RILEY N, 1964, Q J MECH APPL MATH, V17, P331, DOI 10.1093/qjmam/17.3.331
   Shevchuk IV, 2009, HEAT MASS TRANSFER, V45, P1313, DOI 10.1007/s00231-009-0505-x
   Shevchuk IV, 2009, LECT NOTES APPL COMP, V45, P1, DOI 10.1007/978-3-642-00718-7
   Sparrow E. M., 1962, J APPL MECH, V29, P181, DOI DOI 10.1016/0045-7930(88)90005-9
   SPARROW EM, 1959, ASME, V81, P249
   Turkyilmazoglu M, 2007, J ENG MATH, V59, P337, DOI 10.1007/s10665-007-9137-7
   TURKYILMAZOGLU M, 2009, T ASME J HEAT TRANSF, V131
   TURKYILMAZOGLU M, 1998, THESIS U MANCHESTER
   von Karman T, 1921, Z ANGEW MATH MECH, V1, P233
NR 24
TC 7
Z9 7
U1 3
U2 11
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1359-4311
J9 APPL THERM ENG
JI Appl. Therm. Eng.
PD MAR
PY 2012
VL 35
BP 127
EP 133
DI 10.1016/j.applthermaleng.2011.10.014
PG 7
WC Thermodynamics; Energy & Fuels; Engineering, Mechanical; Mechanics
SC Thermodynamics; Energy & Fuels; Engineering; Mechanics
GA 868JK
UT WOS:000298519400013
DA 2018-12-27
ER

PT J
AU Li, J
   Zhu, HF
   Wang, SH
   Ye, P
   Liu, CG
   Wu, J
   Xia, JH
AF Li, Jun
   Zhu, Hongfei
   Wang, Sihua
   Ye, Ping
   Liu, Chenggui
   Wu, Jie
   Xia, Jiahong
TI RETRACTED: Blockade of NKG2D Synergized With CTLA4-Ig in Promoting
   Long-Term Graft Survival in Murine Models of Cardiac Transplantation
   (Retracted article. See vol. 96, pg. E20, 2014)
SO TRANSPLANTATION
LA English
DT Article; Retracted Publication
DE NKG2D; IL-17; gamma delta T Cell; Cardiac transplantation
ID ISCHEMIA-REPERFUSION INJURY; NATURAL-KILLER-CELLS; ALLOGRAFT-REJECTION;
   INTERFERON-GAMMA; T-CELLS; IN-VIVO; NK CELLS; ORGAN-TRANSPLANTATION;
   IMMUNE-RESPONSE; MICE
AB Background. Blockade of B7-CD28 interaction with CTLA4-Ig could prolong allograft survival in cardiac transplantation. NKG2D is an activating or coactivating receptor on NK cells, gamma delta T, and CD8(+) T cells and played an important role in transplant immunity.
   Methods. C57BL/6 (wild type and gamma delta(-/-) or interleukin (IL)-17(-/-)) mice were transplanted with allogeneic BALB/c hearts and treated with CTLA4-Ig alone or in combination with anti-NKG2D monoclonal antibodies. The survival of grafts was monitored daily by abdominal palpation until the complete cessation of cardiac contractility.
   Results. We found that wild type recipient treated with anti-NKG2D monoclonal antibodies plus CTLA4-Ig showed significantly prolonged survival cardiac allograft (> 90 days, P < 0.001). These in vivo results in combined therapy group correlated with low expression of interferon-gamma whereas increased expression of IL-4 and alternatively activated macrophage markers. Furthermore, with blockade of NKG2D, the number of IL-17-producing gamma delta T cells was significantly reduced, which was demonstrated as the main source of IL-17 production. And in our gamma delta(-/-) and IL-17(-/-) murine cardiac transplantation models, we found that gamma delta or IL-17 deficiency could significantly prolong cardiac allograft survival.
   Conclusion. Blockade of NKG2D is effective in synergizing with CTLA4-Ig to promote long-term cardiac allograft survival in mice, and this effect is associated with decreased infiltration of IL-17-producing gamma delta T cells.
C1 [Li, Jun; Wang, Sihua; Ye, Ping; Liu, Chenggui; Wu, Jie; Xia, Jiahong] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Cardiovasc Surg, Wuhan 430074, Peoples R China.
   [Zhu, Hongfei] Wuhan Univ, Sch Stomatol, Minist Educ, Dept Anesthesiol, Wuhan 430072, Peoples R China.
   [Zhu, Hongfei] Wuhan Univ, Sch Stomatol, Minist Educ, Key Lab Oral Biomed, Wuhan 430072, Peoples R China.
RP Li, J (reprint author), Wuhan Jiefang Rd 1277, Wuhan 430022, Peoples R China.
EM lijun00207@163.com; profxjh@163.com
FU National Natural Science Foundation of China [81070205]; State Key
   Development Program of Basic Research of China [2010CB535012]
FX This work was supported in part by National Natural Science Foundation
   of China grants 81070205 and by State Key Development Program of Basic
   Research of China grant 2010CB535012.
CR Bouhlel MA, 2007, CELL METAB, V6, P137, DOI 10.1016/j.cmet.2007.06.010
   Burrell BE, 2008, J IMMUNOL, V181, P3906, DOI 10.4049/jimmunol.181.6.3906
   Cerwenka A, 2000, IMMUNITY, V12, P721, DOI 10.1016/S1074-7613(00)80222-8
   CORRY RJ, 1973, TRANSPLANTATION, V16, P343, DOI 10.1097/00007890-197310000-00010
   Dehmel S, 2010, EUR J IMMUNOL, V40, P267, DOI 10.1002/eji.200939652
   Delfs MW, 2001, TRANSPLANTATION, V71, P606, DOI 10.1097/00007890-200103150-00005
   Dong C, 2006, NAT REV IMMUNOL, V6, P329, DOI 10.1038/nri1807
   Feng L, 2006, TRANSPLANT P, V38, P2195, DOI 10.1016/j.transproceed.2006.06.013
   Fernandez NC, 1999, NAT MED, V5, P405
   FERRICK DA, 1995, NATURE, V373, P255, DOI 10.1038/373255a0
   Fischbein MP, 2000, J IMMUNOL, V165, P7316, DOI 10.4049/jimmunol.165.12.7316
   Geldhof AB, 2002, BLOOD, V100, P4049, DOI 10.1182/blood-2001-11-0106
   Gorbacheva V, 2010, AM J PATHOL, V177, P1265, DOI 10.2353/ajpath.2010.091106
   Ito Y, 2008, AM J PHYSIOL-GASTR L, V294, pG199, DOI 10.1152/ajpgi.00286.2007
   Itoh S, 2010, J CLIN IMMUNOL, V30, P235, DOI 10.1007/s10875-009-9366-9
   Kim J, 2007, J IMMUNOL, V179, P6416, DOI 10.4049/jimmunol.179.10.6416
   Kjellev S, 2007, EUR J IMMUNOL, V37, P1397, DOI 10.1002/eji.200636473
   Larsen CP, 1996, NATURE, V381, P434, DOI 10.1038/381434a0
   Li J, 2011, J IMMUNOL, V186, P3753, DOI 10.4049/jimmunol.1002143
   Lin WS, 2005, J CELL BIOL, V169, P603, DOI 10.1083/jcb.200502086
   Lopez-Larrea C, 2008, TRENDS MOL MED, V14, P179, DOI 10.1016/j.molmed.2008.02.004
   Mahalingam S, 2001, P NATL ACAD SCI USA, V98, P6812, DOI 10.1073/pnas.111151098
   Martinez FO, 2009, ANNU REV IMMUNOL, V27, P451, DOI 10.1146/annurev.immunol.021908.132532
   Molet S, 2001, J ALLERGY CLIN IMMUN, V108, P430, DOI 10.1067/mai.2001.117929
   Nagano H, 1997, J CLIN INVEST, V100, P550, DOI 10.1172/JCI119564
   Nagata T, 2008, J IMMUNOL, V181, P7473, DOI 10.4049/jimmunol.181.11.7473
   Ogasawara K, 2004, IMMUNITY, V20, P757, DOI 10.1016/j.immuni.2004.05.008
   PEARSON TC, 1994, TRANSPLANTATION, V57, P1701, DOI 10.1097/00007890-199406270-00002
   Pende D, 2001, EUR J IMMUNOL, V31, P1076, DOI 10.1002/1521-4141(200104)31:4<1076::AID-IMMU1076>3.3.CO;2-P
   Raulet DH, 2004, NAT IMMUNOL, V5, P996, DOI 10.1038/ni1114
   Raulet DH, 2003, NAT REV IMMUNOL, V3, P781, DOI 10.1038/nri1199
   Rincon-Orozco B, 2005, J IMMUNOL, V175, P2144, DOI 10.4049/jimmunol.175.4.2144
   Saiura A, 2001, TRANSPLANTATION, V72, P320, DOI 10.1097/00007890-200107270-00027
   SAYEGH MH, 1995, J EXP MED, V181, P1869, DOI 10.1084/jem.181.5.1869
   Schnickel GT, 2008, J IMMUNOL, V180, P4714, DOI 10.4049/jimmunol.180.7.4714
   Suarez-Alvarez B, 2007, AM J TRANSPLANT, V7, P1842, DOI 10.1111/j.1600-6143.2007.01838.x
   Suarez-Alvarez B, 2009, AM J TRANSPLANT, V9, P251, DOI 10.1111/j.1600-6143.2008.02526.x
   Tajima M, 2008, J EXP MED, V205, P1019, DOI 10.1084/jem.20071133
   Tellides G, 2000, NATURE, V403, P207, DOI 10.1038/35003221
   TURKA LA, 1992, P NATL ACAD SCI USA, V89, P11102, DOI 10.1073/pnas.89.22.11102
   Tzachanis D, 2002, BLOOD, V99, P1465, DOI 10.1182/blood.V99.4.1465
   van der Touw W, 2010, AM J TRANSPLANT, V10, P1354, DOI 10.1111/j.1600-6143.2010.03086.x
   Weis M, 1997, CIRCULATION, V96, P2069, DOI 10.1161/01.CIR.96.6.2069
   Wynn TA, 2004, NAT REV IMMUNOL, V4, P583, DOI 10.1038/nri1412
   Yuan XL, 2008, J EXP MED, V205, P3133, DOI 10.1084/jem.20081937
   Zhang ZX, 2008, J IMMUNOL, V181, P7489, DOI 10.4049/jimmunol.181.11.7489
   Zou YZ, 2007, NEW ENGL J MED, V357, P1293, DOI 10.1056/NEJMoa067160
   Zou YZ, 2002, HUM IMMUNOL, V63, P30, DOI 10.1016/S0198-8859(01)00349-4
   Zwirner NW, 2000, HUM IMMUNOL, V61, P917, DOI 10.1016/S0198-8859(00)00162-2
NR 49
TC 12
Z9 13
U1 3
U2 15
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0041-1337
EI 1534-6080
J9 TRANSPLANTATION
JI Transplantation
PD FEB 27
PY 2012
VL 93
IS 4
BP 356
EP 363
DI 10.1097/TP.0b013e31823ffce7
PG 8
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 894GT
UT WOS:000300415800009
PM 22179404
DA 2018-12-27
ER

PT J
AU Ndiath, MO
   Sougoufara, S
   Gaye, A
   Mazenot, C
   Konate, L
   Faye, O
   Sokhna, C
   Trape, JF
AF Ndiath, Mamadou O.
   Sougoufara, Seynabou
   Gaye, Abdoulaye
   Mazenot, Catherine
   Konate, Lassana
   Faye, Oumar
   Sokhna, Cheikh
   Trape, Jean-Francois
TI RETRACTED: Resistance to DDT and Pyrethroids and Increased kdr Mutation
   Frequency in An. gambiae after the Implementation of Permethrin-Treated
   Nets in Senegal (Retracted article. See vol. 11, e0156195, 2016)
SO PLOS ONE
LA English
DT Article; Retracted Publication
ID ANOPHELES-GAMBIAE; INSECTICIDE RESISTANCE; MALARIA TRANSMISSION;
   WEST-AFRICA; DIPTERA-CULICIDAE; HOLOENDEMIC AREA; MOLECULAR-FORMS;
   SUSCEPTIBILITY; BENIN; IDENTIFICATION
AB Introduction: The aim of this study was to evaluate the susceptibility to insecticides of An. gambiae mosquitoes sampled in Dielmo (Senegal), in 2010, 2 years after the implementation of Long Lasting Insecticide-treated Nets (LLINs) and to report the evolution of kdr mutation frequency from 2006 to 2010.
   Methods: WHO bioassay susceptibility tests to 6 insecticides were performed on adults F0, issuing from immature stages of An. gambiae s.l., sampled in August 2010. Species and molecular forms as well as the presence of L1014F and L1014S kdr mutations were assessed by PCR. Longitudinal study of kdr mutations was performed on adult mosquitoes sampled monthly by night landing catches from 2006 to 2010.
   Findings: No specimen studied presented the L1014S mutation. During the longitudinal study, L1014F allelic frequency rose from 2.4% in year before the implementation of LLINs to 4.6% 0-12 months after and 18.7% 13-30 months after. In 2010, An. gambiae were resistant to DDT, Lambda-cyhalothrin, Deltamethrin and Permethrin (mortality rates ranging from 46 to 63%) but highly susceptible to Fenitrothion and Bendiocarb (100% mortality). There was significantly more RR genotype among An. gambiae surviving exposure to DDT or Pyrethroids. An. arabiensis represented 3.7% of the sampled mosquitoes (11/300) with no kdr resistance allele detected. An. gambiae molecular form M represented 29.7% of the mosquitoes with, among them, kdr genotypes SR (18%) and SS (82%). An. gambiae molecular form S represented 66% of the population with, among them, kdr genotype SS (33.3%), SR (55.6%) and RR (11.1%). Only 2 MS hybrid mosquitoes were sampled and presented SS kdr genotype.
   Conclusion: Biological evidence of resistance to DDT and pyrethroids was detected among An. gambiae mosquitoes in Dielmo (Senegal) within 24 months of community use of LLINs. Molecular identification of L1014F mutation indicated that target site resistance increased after the implementation of LLINs.
C1 [Ndiath, Mamadou O.; Sougoufara, Seynabou; Gaye, Abdoulaye; Mazenot, Catherine; Sokhna, Cheikh; Trape, Jean-Francois] Inst Rech Dev, URMITE, UMR 198, Dakar, Senegal.
   [Konate, Lassana; Faye, Oumar] UCAD, Lab Ecol Vectorielle & Parasitaire, Fann Dakar, Senegal.
RP Ndiath, MO (reprint author), Inst Rech Dev, URMITE, UMR 198, Campus Commun UCAD IRD Hann,BP 1386,CP 18524, Dakar, Senegal.
EM cheikh.sokhna@ird.fr
FU French Ministry of Research; Department Support and Formation of the
   south communities of the Research Institute for the Development (IRD)
FX This work was supported by the French Ministry of Research and the
   Department Support and Formation of the south communities of the
   Research Institute for the Development (IRD). The funders had no role in
   study design, data collocation and analysis, decision to publish, or
   preparation of the manuscript.
CR Abate A, 2011, TROP MED INT HEALTH, V16, P486, DOI 10.1111/j.1365-3156.2011.02728.x
   [Anonymous], FOC SEN PROGR IMP SE
   [Anonymous], 2008, WORLD MAL REP 2008
   Antonio-Nkondjio C, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-154
   Balkew M, 2010, PARASITE VECTOR, V3, DOI 10.1186/1756-3305-3-40
   Betson M, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-187
   Ceesay SJ, 2008, LANCET, V372, P1545, DOI 10.1016/S0140-6736(08)61654-2
   Chandre F, 1999, J AM MOSQUITO CONTR, V15, P53
   Czeher C, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-189
   Diabate A, 2002, AM J TROP MED HYG, V67, P617, DOI 10.4269/ajtmh.2002.67.617
   Diop A, 2010, RAPPORTS ANNUELS PRO
   Diop A, 2008, RAPPORTS ANNUELS PRO
   Djegbe I, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-261
   Donnelly MJ, 2009, TRENDS PARASITOL, V25, P213, DOI 10.1016/j.pt.2009.02.007
   Fanello C, 2002, MED VET ENTOMOL, V16, P461, DOI 10.1046/j.1365-2915.2002.00393.x
   Fontenille D, 1997, AM J TROP MED HYG, V56, P247, DOI 10.4269/ajtmh.1997.56.247
   Gillies MT, 1968, PUBLICATIONS S AFRIC
   Hargreaves K, 2000, MED VET ENTOMOL, V14, P181, DOI 10.1046/j.1365-2915.2000.00234.x
   Hunt RH, 2011, PARASITE VECTOR, V4, DOI 10.1186/1756-3305-4-107
   Kelly-Hope L, 2008, LANCET INFECT DIS, V8, P387, DOI 10.1016/S1473-3099(08)70045-8
   Koekemoer LL, 2011, VECTOR-BORNE ZOONOT, V11, P1193, DOI 10.1089/vbz.2010.0192
   Martinez-Torres D, 1998, INSECT MOL BIOL, V7, P179, DOI 10.1046/j.1365-2583.1998.72062.x
   Matowo J, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-193
   [Ministere de la Sante et de la Prevention Programme National de Lutte contre le Paludisme], 2010, PROGR NAT LUTT PAL
   N'Guessan R, 2007, EMERG INFECT DIS, V13, P199, DOI 10.3201/eid1302.060631
   O'Meara WP, 2008, LANCET, V372, P1555, DOI 10.1016/S0140-6736(08)61655-4
   Pages F, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-178
   Ranson H, 2000, INSECT MOL BIOL, V9, P491, DOI 10.1046/j.1365-2583.2000.00209.x
   Ranson H, 2011, TRENDS PARASITOL, V27, P91, DOI 10.1016/j.pt.2010.08.004
   Santolamazza F, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-74
   Stump AD, 2004, AM J TROP MED HYG, V70, P591, DOI 10.4269/ajtmh.2004.70.591
   Thwing JI, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-86
   Trape JF, 2011, LANCET INFECT DIS, V11, P925, DOI 10.1016/S1473-3099(11)70194-3
   TRAPE JF, 1994, AM J TROP MED HYG, V51, P123, DOI 10.4269/ajtmh.1994.51.123
   Trape JF, 2012, J INFECT DI IN PRESS
   Vezenegho SB, 2009, MED VET ENTOMOL, V23, P326, DOI 10.1111/j.1365-2915.2009.00840.x
   Vulule JM, 1999, MED VET ENTOMOL, V13, P239, DOI 10.1046/j.1365-2915.1999.00177.x
   VULULE JM, 1994, MED VET ENTOMOL, V8, P71, DOI 10.1111/j.1365-2915.1994.tb00389.x
   *WHO, 1998, TEST PROC INS RES MO
   WHO, 2006, PEST THEIR APPL CONT
   WHO, 2007, INS TREAT NETS WHO P
   Yadouleton AW, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-83
   Zaim M, 2000, MED VET ENTOMOL, V14, P1, DOI 10.1046/j.1365-2915.2000.00211.x
NR 43
TC 32
Z9 33
U1 1
U2 21
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 22
PY 2012
VL 7
IS 2
AR e31943
DI 10.1371/journal.pone.0031943
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 926ZZ
UT WOS:000302875500055
PM 22384107
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Chen, YL
   Liu, C
   Xu, XD
   Zhang, XJ
   Shen, WB
AF Chen, Yalin
   Liu, Chang
   Xu, Xiaodong
   Zhang, Xiaojiang
   Shen, Wangbing
TI RETRACTED: Simple mental arithmetic is not so simple: An ERP study of
   the split and odd-even effects in mental arithmetic (Retracted article.
   See vol. 528, pg. 92, 2012)
SO NEUROSCIENCE LETTERS
LA English
DT Article; Retracted Publication
DE Strategy selection in mental arithmetic; Split effect; Parity/odd-even
   effect; Non-retrieval; Event-related potential/ERP
ID DIGIT ADDITION; PROBLEM SIZE; RETRIEVAL; PARITY; FACTS; RULE;
   MULTIPLICATION; VERIFICATION; POTENTIALS; ACTIVATION
AB This study aimed to investigate the effects of split size (small vs. large splits) and odd-even congruency (parity congruency vs. parity incongruency) of answers on arithmetical equation processing. Event-related potentials were recorded from 18 students in a first-answer-then-equation presentation mode. The ERP results showed that the odd-even congruency had a significant effect on the late positive wave in the small, but not the large split, with a late positive slow wave elicited by the small-split and the odd-even congruent conditions. This result suggests that the split effect has priority over parity congruency when both split and parity are at play simultaneously. Specifically, in non-retrieval arithmetic verification tasks, parity is modulated in cases where a direct judgment cannot be reached simply by depending on the split information. Crown Copyright (C) 2012 Published by Elsevier Ireland Ltd. All rights reserved.
C1 [Chen, Yalin; Liu, Chang; Xu, Xiaodong; Zhang, Xiaojiang; Shen, Wangbing] Nanjing Normal Univ, Cognit Neurosci Lab, Nanjing 210097, Jiangsu, Peoples R China.
   [Chen, Yalin; Liu, Chang; Xu, Xiaodong; Zhang, Xiaojiang; Shen, Wangbing] Nanjing Normal Univ, Sch Educ Sci, Nanjing 210097, Jiangsu, Peoples R China.
   [Xu, Xiaodong] Nanjing Normal Univ, Sch Foreign Languages & Cultures, Nanjing 210097, Jiangsu, Peoples R China.
RP Liu, C (reprint author), Nanjing Normal Univ, Cognit Neurosci Lab, 122 Ninghai Rd, Nanjing 210097, Jiangsu, Peoples R China.
EM liuchang@njnu.edu.cn
FU National Natural Science Foundation of China [30200082]; Foundation for
   the Author of National Excellent Doctoral Dissertation of PR China
   [200006]
FX The work described in this study was supported by grants obtained from
   the National Natural Science Foundation of China (30200082) and the
   Foundation for the Author of National Excellent Doctoral Dissertation of
   PR China (200006).
CR Butterworth B, 2001, Q J EXP PSYCHOL-A, V54, P1005, DOI 10.1080/02724980143000064
   Dehaene S, 2003, COGN NEUROPSYCHOL, V20, P487, DOI 10.1080/02643290244000239
   Didierjean A, 2007, BRIT J PSYCHOL, V98, P529, DOI 10.1348/000712606X161947
   El Yagoubi R, 2003, NEUROPSYCHOLOGIA, V41, P855, DOI 10.1016/S0028-3932(02)00180-X
   Jost K, 2004, PSYCHOPHYSIOLOGY, V41, P46, DOI 10.1111/1469-8986.00119
   Kazui H, 2000, PSYCHIAT CLIN NEUROS, V54, P479, DOI 10.1046/j.1440-1819.2000.00739.x
   Klein E, 2009, BRAIN COGNITION, V69, P369, DOI 10.1016/j.bandc.2008.08.031
   Kong H, 2005, COGNITIVE BRAIN RES, V22, P397, DOI 10.1016/j.cogbrainres.2004.09.011
   KRUEGER LE, 1984, MEM COGNITION, V12, P171, DOI 10.3758/BF03198431
   Lemaire P, 1999, MEM COGNITION, V27, P364, DOI 10.3758/BF03211420
   Lochy A, 2000, MEM COGNITION, V28, P358, DOI 10.3758/BF03198551
   Niedeggen M, 1999, PSYCHOL SCI, V10, P271, DOI 10.1111/1467-9280.00149
   Nunez-Pena MI, 2007, INT J PSYCHOPHYSIOL, V64, P165, DOI 10.1016/j.ijpsycho.2007.01.007
   Nunez-Pena MI, 2006, NEUROREPORT, V17, P357
   Nunez-Pena MI, 2005, NEUROSCI LETT, V373, P21, DOI 10.1016/j.neulet.2004.09.053
   Nunez-Pena MI, 2004, COGNITIVE BRAIN RES, V18, P130, DOI 10.1016/j.cogbrainres.2003.09.010
   Robert ND, 2008, EUR J COGN PSYCHOL, V20, P123, DOI 10.1080/09541440701275823
   Vandorpe S, 2005, EXP PSYCHOL, V52, P47, DOI 10.1027/1618-3169.52.1.47
   Zhou XL, 2006, NEUROPSYCHOLOGIA, V44, P2500, DOI 10.1016/j.neuropsychologia.2006.04.003
NR 19
TC 3
Z9 3
U1 3
U2 14
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3940
EI 1872-7972
J9 NEUROSCI LETT
JI Neurosci. Lett.
PD FEB 21
PY 2012
VL 510
IS 1
BP 62
EP 66
DI 10.1016/j.neulet.2012.01.005
PG 5
WC Neurosciences
SC Neurosciences & Neurology
GA 907CR
UT WOS:000301395900014
PM 22266238
DA 2018-12-27
ER

EF